﻿   Table of Contents
Title Page
Introduction
About This Book
BASIC SCIENCE
Cancer prevention: The forgotten stepchild of cancer research? David Gorski
The complexity of cancer: A science-based view. David Gorski.
Cancer research: Going for the bunt versus swinging for the fences. David Gorski.
Skepticism versus nihilism about cancer and science-based medicine. David Gorski.
Worshiping at the altar of the Cult of the Brave Maverick Doctor | D Gorski
Why haven’t we cured cancer yet? David Gorski.
Why haven’t we cured cancer yet? (Revisited): Personalized medicine versus evolution | D Gorski
The Cancer Moonshot: Hype versus reality | D Gorski
Everything Causes Cancer | S Novella
Everything we eat causes cancer…sort of | D Gorski
Is U.S. cancer care “in crisis,” as the Institute of Medicine proclaims? | D Gorski
Cancer Deaths Continue to Decline | S Novella
Cancer Death Rate Continues to Decline | S Novella
Contrary to what we are frequently told, we are not “losing the war on cancer” | D Gorski
Contrary to what we are frequently told, we are not “losing the war on cancer” (2020 edition) | D Gorski
We are not “losing the war on cancer” (belated 2021 edition) | D Gorski
Applying evolutionary principles to cancer treatment. David Gorski.
Genetics and evolution in cancer | D Gorski
Recent Developments and Recurring Dilemmas in Cancer Screening: Colon, Lung, Thyroid | H Hall
Is cancer due mostly to “bad luck”? | D Gorski
WHO Systematic Review of RF and Cancer | S Novella
Radiation from medical imaging and cancer risk. David Gorski
Cancer disparities: It’s money that matters (along with a lot of other things) | D Gorski
Expectations versus reality in science-based oncology | D Gorski
Chemotherapy doesn’t work? Not so fast… (A lesson from history) | D Gorski
Does chemotherapy cause cancer to spread? | D Gorski
Meet the new drugs, same as the old drugs? | D Gorski
Cancer care in the U.S. versus Europe: Is more necessarily better? | D Gorski
A Universal Anti-Cancer Drug? | S Novella
The future of cancer therapy? | D Gorski
This Book Won’t Cure Your Cancer, But It Will Help You Think More Clearly About It | H Hall
The Natural Cancer Cure Narrative | S Novella
Natural versus “natural” in CAM world. David Gorski 
On the nature of “alternative” medicine cancer cure testimonials. David Gorski 
Chemotherapy doesn’t work? Not so fast… David Gorski 
How reproducible is basic lab research in cancer biology? | D Gorski
Surgeon General Alcohol Warning | D Gorski
Aspartame and Cancer | S Novella
Vitamin D and the relationship to colon cancer | S Gavura
Another antivaccine zombie meme: polio vaccine and SV40 and cancer, oh, my! | D Gorski
Dr. William Makis and “turbo cancer”: Falsely blaming COVID-19 vaccines for cancer D. Gorski
Here we go again: Another study is being misrepresented as evidence that COVID vaccines cause cancer | D Gorski
Should We Avoid Dairy Out of Fear of Cancer? | H Hall
There is no evidence that COVID-19 vaccines are causing cancers associated with “accelerated aging” | D Gorski
Peddling Misinformation About Diet and Cancer | S Novella
Supplements and cancer prevention | D Gorski
Vitamins and Cancer Risk | S Novella
How can we counter misinformation from “chemo truthers”? | D Gorski
When science- and evidence-based guidelines conflict with patient wishes: What’s a doc to do? | D Gorski
Mouse “avatars”: New predictors of response to chemotherapy? | D Gorski
Will Your Tattoo Give You Cancer: Probably Not…but Maybe? | C Jones
Infectious Diseases and Cancer | M Crislip
Sharks Get Cancer, Mole Rats Don’t: Clues to Understanding Cancer | H Hall
A brief note on killing cancer cells in a dish | D Gorski
Confusing overdiagnosis for an “epidemic” of thyroid cancer in Japan after Fukushima | D Gorski
Reclassifying thyroid cancer and the willful misunderstanding of overdiagnosis | D Gorski
Diet and exercise versus cancer: A science-based view | D Gorski
Obesity, cancer, and chemotherapy | D Gorski
Guess who pioneered chemoprevention through diet? | J Bellamy
Liver cancer, naturally | S Gavura
2023 Cancer Statistics Report | S Novella
Colonoscopy and Other Colorectal Cancer Screening Options: An Update | H Hall
Questioning Whether Psychotherapy and Support Groups Extend the Lives of Cancer Patients | J Coyne
Don’t Blame the Patient | S Novella
Using Viruses to Treat Cancer | S Novella
“Liquid biopsies” for cancer screening: Life-saving tests, or overdiagnosis and overtreatment taken to a new level? | D Gorski
The Role of Liquid Biopsies in Oncology | H Hall
CRISPR Treatment for Cancer | S Novella
Redefining cancer | D Gorski
The Science Behind the Roundup Lawsuit | S Novella
Update on Glyphosate | S Novella
Glyphosate Remains Controversial | S Novella
Electromagnetic Fields at Work Show No Brain Tumor Risk | S Novella
Do Sunscreens Cause Cancer? | H Hall
Dental X-rays and Brain Tumors — Oh My! | S Hendry
Cancer, vitamin supplements, and unexpected consequences | S Gavura
Newborn Phototherapy and Cancer: Cutting Edge Research or “Big Data” Failure? | C Jones
The ROCA Screening Test for Ovarian Cancer: Not Ready for Prime Time | H Hall
Prostate Cancer Dilemmas: To Test or Not to Test, To Cut or Not to Cut | H Hall
Once more into the screening breach: The New York Times did not kill your patient | D Gorski
PSA Screening for Prostate Cancer | S Gavura
Myeloproliferative neoplasms – an overview and my experiences | J Luke
Answering Cancer Quackery: The Sophisticated Approach to True Believers | H Hall
Quoth Myrna Mantaring: “US government data” confirms a “143,233% increase in cancer cases due to COVID vaccination”? I answer with a plea for math-based reality checks. | D Gorski
Another Misguided Cancer Testimonial | H Hall
Kudos to a Journalist | H Hall
Cunnilingus, Michael Douglas’s Cancer, and the HPV Vaccine | H Hall
CLINICAL TRIALS
Myths integrative medicine sells us: “We never advocate alternative medicine without conventional medicine” | D Gorski
Clinical equipoise versus scientific rigor in cancer clinical trials. David Gorski.
100% Cure Rate Is Hard to Believe | H Hall
Double standards in hematology for integrative and complementary medicine: a case study | J Luke
A miracle cancer prevention and treatment? Not necessarily as the analysis of 26 articles by legendary Hans Eysenck shows. | T Witkowski
Kidney Cancer and Incidentalomas | H Hall
GONZALEZ REGIMEN
The Ethics of “CAM” Trials. Gonzo (Part I). Kimball Atwood
The Ethics of “CAM” Trials. Gonzo (Part II). Kimball Atwood
The Ethics of “CAM” Trials. Gonzo (Part III). Kimball Atwood 
The Ethics of “CAM” Trials. Gonzo (Part IV). Kimball Atwood
The Ethics of “CAM” Trials. Gonzo (Part V). Kimball Atwood
The Ethics of “CAM” Trials. Gonzo (Part V). Kimball Atwood
The “Gonzalez Trial” for Pancreatic Cancer: Outcome Revealed. Kimball Atwood
“Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part I: Results). Kimball Atwood
“Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part II: Loose Ends). Kimball Atwood.
Evidence-Based Medicine, Human Studies Ethics, and the ‘Gonzalez Regimen’: a Disappointing Editorial in the Journal of Clinical Oncology Part 1. Kimball Atwood.
Evidence-Based Medicine, Human Studies Ethics, and the ‘Gonzalez Regimen’: a Disappointing Editorial in the Journal of Clinical Oncology Part 2. Kimball Atwood.
'ALTERNATIVE' TREATMENTS
Abraham Cherrix is alive and well because of science-based medicine | D Gorski
CAM use and chemotherapy: A negative correlation | D Gorski
Complementary and Alternative Medicines and Cancer | S Gavura
Cancer Treatment Centers of America: Revisiting the epitome of “integrative” cancer care | Science-Based Medicine
Cancer Treatment Centers of America and “naturopathic oncology”. David Gorski.
“Integrative oncology”: The Trojan horse that is quackademic medicine infiltrates ASCO | D Gorski
The false dichotomies of CAM and “integrative medicine” | D Gorski
Announcement: “Integrative oncology” – Really the best of both worlds? | D Gorski
Selling “integrative oncology” as a monograph in JNCI | D Gorski
Revisiting “integrative oncology”: The battle to integrate quackery with oncology continues | D Gorski
Two integrative oncologists delude themselves that their specialty is science-based | D Gorski
What is “integrative oncology”? Even the Society for Integrative Oncology doesn’t seem to know for sure | D Gorski
The integration of mysticism and pseudoscience with oncology continues apace in NCI-designated comprehensive cancer centers | D Gorski
Why cancer patients choose “integrative oncology” and what they get: Perception vs. reality | D Gorski
“Atavistic oncology”: Another dubious cancer therapy to be avoided | D Gorski
“Atavistic oncology” revisited: Dr. Frank Arguello responds | D Gorski
“Alternative” cancer cures in 1979: How little things have changed | D Gorski
CAM and cancer: Who uses CAM, and why? | S Gavura
A horrifying survey of “pediatric naturopathic oncology” practice | D Gorski
High dose vitamin C and cancer: Has Linus Pauling been vindicated? David Gorski
Vitamin C strikes (out) again. David Gorski
The return of the revenge of high dose vitamin C for cancer | D Gorski
The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatment. David Gorski.
Why we don’t prescribe bark for cancer. David J Kroll
Eric Merola and Ralph Moss try to exhume the rotting corpse of Laetrile in a new movie | D Gorski
Avemar: Wheat Germ for Cancer | H Hall
The NORI protocol: An unproven fruit-based nutritional treatment for cancer sold by a self-proclaimed “expert” | D Gorski
Ketogenic diet does not “beat chemo for almost all cancers” | D Gorski
Biologie Totale and other bastard offspring of Ryke Geerd Hamer’s German New Medicine. David Gorski.
The “Iron Rule of Cancer”: The dangerous cancer quackery that is the “German New Medicine”. David Gorski.
The (Not-So-)Beautiful (Un)Truth about the Gerson protocol and cancer quackery. David Gorski
The Gerson protocol, cancer, and the death of Jess Ainscough, a.k.a. “The Wellness Warrior” | D Gorski
The Hidden Cancer Cure. Steven Novella.
“The Truth About Cancer” Series Is Untruthful About Cancer | H Hall
The Hippocrates Health Institute: Cancer quackery finally under the spotlight, but will it matter? | Science-Based Medicine
Florida tells Brian Clement to stop practicing medicine | J Bellamy
Naturopathic Cancer Quackery | S Novella
Be careful what you wish for… | D Gorski
Herbal Products and Cancer Treatment | S Novella
Escharotic Treatment for Cervical Dysplasia: A New Incarnation of Black Salve? | H Hall
Cowabunga! Can Cow Therapy Cure Cancer? | H Hall
Cantron: A tale of false hope for cancer | D Gorski
“Eliminating cancer” with Traditional Chinese Medicine and other state-sanctioned quackery | J Bellamy
Presidential candidate Ben Carson: Shilling for Mannatech with his very own alternative cancer cure testimonial? | D Gorski
Supplement vendors make unfounded cancer treatment claims | S Gavura
Do dietary supplements affect the survival of cancer patients? | S Gavura
Medical marijuana as the new herbalism, part 2: Cannabis does not cure cancer | D Gorski
Medical marijuana as the new herbalism, part 3: A “cannabis cures cancer” testimonial | D Gorski
Hash Oil for Gliomas? What Would You Do? Harriet Hall.
CBD Oil Fails to Improve Symptom Control in Advanced Cancer | S Gavura
CAM Use by Brain Tumor Patients. Steven Novella.
Steve Jobs’ cancer and pushing the limits of science-based medicine. David Gorski
Steve Jobs’ medical reality distortion field. David Gorski 
“And one more thing” about Steve Jobs’ battle with cancer. David Gorski
Is shameless self-promotion of your science a good idea? | D Gorski
NIH funds training in behavioral intervention to slow progression of cancer by improving the immune system | J Coyne
The Mind in Cancer: Low Quality Evidence from a High-Impact Journal | J Coyne
Fenbendazole is fast becoming the laetrile of the 2020s | D. Gorski
No turbo cancer at ASCO: William Makis vs. Scott Adams and A Midwestern Doctor instead? | D Gorsii
Tess Lawrie: Ivermectin isn’t just for COVID-19 but cures cancer too! | D Gorski
COVID-19 antivax quacks are now “repurposing” ivermectin for cancer | D Gorski
Mark Sircus and “natural allopathic medicine”? Now I’ve heard everything from quacks | D. Gorski
Clínica 0-19: False hope in Monterrey for DIPG patients (part 1) | D Gorski
Clínica 0-19: False hope in Monterrey for brain cancer patients (part 2) | D Gorski
Clínica 0-19: False hope in Monterrey for brain cancer patients (part 3) | D Gorski
Clínica 0-19: False hope in Monterrey for brain cancer patients (part 4) | D Gorski
Clínica 0-19: False hope in Monterrey for DIPG patients (Part 5, A dubious poster is presented) | D Gorski
German alternative cancer clinics: Combining experimental therapeutics with rank quackery and charging big bucks for it | D Gorski
Cancer quackery from Germany to Australia | D Gorski
Cancer Centers and Advertising Practices | H Hall
Rigvir: Another unproven and dubious cancer therapy to be avoided | D Gorski
Ty Bollinger’s “The Truth About Cancer” and the unethical marketing of the unproven cancer virotherapy Rigvir | D Gorski
Rigvir strikes back, or: A conversation with a Rigvir flack | D Gorski
“Chemotherapy is for losers”: A tragic tale of cancer, naturopathic quackery, and murder | D Gorski
Did cannabis oil save Deryn Blackwell, the “boy in seven billion,” when his bone marrow transplant for two cancers was failing? | D Gorski
The return of marketing hype for “whole body scans”…now with AI! | D Gorski
FitScript™: Functional health quackery and a misleading alternative cancer cure testimonial | D Gorski
So-Called Alternative Medicine for Cancer | H Hall
The Cancer Cure Anecdote | S Novella
Paul Marik: Disparaging chemotherapy in order to sell cancer quackery | D Gorski
FDA blacklists cesium chloride, ineffective and dangerous naturopathic cancer treatment | J Bellamy
Yes, Chris beat cancer, but it wasn’t quackery that cured him | D Gorski
Chris Beat Cancer: A Comprehensive Guide to Making a Killing | B MacBeth
3-Bromopyruvate: The latest cancer cure “they” don’t want you to know about | D Gorski
Beetroots Don’t Cure Cancer | S Novella
Can Ivermectin and Mebendazole Treat Cancer? | D Weinberg
A shoddy, ethically-challenged cancer study gets published… for now. | D Weinberg
Is An Israeli Company About to Cure Cancer? | S Novella
CAM Promotion in Adolescent and Young Adult Cancer Programs | J Luke
Cold Caps Combat Hair Loss from Chemotherapy | H Hall
IBM’s Watson versus cancer: Hype meets reality | D Gorski
CELL PHONES AND CANCER
New Data on Cell Phones and Cancer. Steven Novella 
Critique of “Risk of Brain Tumors from Wireless Phone Use” Lorne Trottier
Are Cell Phones a Possible Carcinogen? An Update on the IARC Report | L Trotter
Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer! David Gorski
Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer! (revisited). David Gorski.
No, a rat study with marginal results does not prove that cell phones cause cancer, no matter what Mother Jones and Consumer Reports say | D Gorski
About that Cell Phone and Cancer Study | S Novella
Cell phones and cancer: random chance in clinical trials | C Labos
The Nation indulges in fear mongering about cell phones and cancer | D Gorski
No, carrying your cell phone in your bra will not cause breast cancer, no matter what Dr. Oz says | D Gorski
One more time: No, wearing a bra does not cause breast cancer | D Gorski
BREAST CANCER
The mammography wars heat up again. David Gorski.
The mammography wars heat up again (2012 edition) | D Gorski
A holiday round in the mammography debate | D Gorski
The Canadian National Breast Screening Study ignites a new round in the mammography wars | D Gorski
In which Dr. Gorski is taken to task by an eminent radiologist for his posts on mammography | D Gorski
Screening for disease in people without symptoms: The reality | G Gorski
The USPSTF recommendations for breast cancer screening: Not the final word. David Gorski
Another wrinkle to the USPSTF mammogram guidelines kerfuffle: What about African-American women? David Gorski
The early detection of cancer and improved survival: More complicated than most people think . David Gorski
The uncertainty surrounding mammography continues | D Gorski
The American Cancer Society’s new mammography guidelines: Déjà vu all over again | D Gorski
Mammography and overdiagnosis, revisited | D Gorski
Early detection of cancer, part 2. Breast cancer and MRI, David Gorski
The cancer screening kerfuffle erupts again: “Rethinking” screening for breast and prostate cancer. David Gorski 
Do over one in five breast cancers detected by mammography alone really spontaneously regress? David Gorski
Mammography and the acute discomfort of change | D Gorski
Is watchful waiting for ductal carcinoma in situ (DCIS) safe? Preliminary results of the COMET trial | D Gorski
How should we treat DCIS? | D Gorski
Mandatory breast density reporting legislation: The law outpaces science, and not in a good way | D Gorski
Thermography is Not Approved for Breast Cancer Screening in Canada | B Nilson
Are one in three breast cancers really overdiagnosed and overtreated? David Gorski.
You’ve been diagnosed with breast cancer. How soon do you need treatment? | D Gorski
Oprah’s buddy Dr. Christiane Northrup and breast thermography: The opportunistic promotion of quackery. David Gorski.
Avastin and metastatic breast cancer: When science-based medicine collides with FDA regulation. David Gorski.
Molecular breast imaging (MBI): A promising technology oversold in a TED Talk? David Gorski.
Breast implants and anaplastic large cell lymphoma (ALCL): Is there a link? David Gorski 
Abortion and breast cancer: The manufactroversy that won’t die. David Gorski
Alternative medicine use and breast cancer. David Gorski
Alternative medicine use and breast cancer (2012 update) | D Gorski
Aromatase inhibitors and acupuncture in breast cancer: Spinning a negative study, four years later | D Gorski
An all-too-common breast cancer testimonial for “alternative medicine” David Gorski 
Why do some women refuse treatments for their breast cancer? | D Gorski
Just in Case | J Storey
Psychological support and breast cancer – again Wallace Sampson
More Breast Cancer Awareness Month pseudoscience from (who else?) Joe Mercola. David Gorski 
Angelina Jolie, radical strategies for cancer prevention, and genetics denialism | Science-Based Medicine
Angelina Jolie, surgical strategies for cancer prevention, and genetics denialism (revisited) | D Gorski
Angelina Jolie’s surgeon peddles misinformation about…breast cancer! | D Gorski
A formal request for retraction of a Cancer article | J Coyne
Frightening Breast Cancer Patients with Bad Science | J Coyne
Breast cancer myths: No, antiperspirants do not cause breast cancer | D Gorski
Blaming breast cancer on autism | D Gorski
ASCO endorses the integration of quackery into breast cancer care | D Gorski
Using alternative medicine to treat cancer, even alongside conventional therapies, is still a bad idea | D Gorski
MEDIA, REGULATION, LAW AND EDUCATION
The North Carolina Board of Medical Examiners, Dr. Rashid Buttar, and protecting the public from practitioners of non-science-based medicine. David Gorski
STANISLAW BURZYNZSKI
Stanislaw Burzynski: The Early Years, part 1 | D Gorski
Stanislaw Burzynski: Bad medicine, a bad movie, and bad P.R. | D Gorski
Dr. Stanislaw Burzynski’s “personalized gene-targeted cancer therapy”: Can he do what he claims for cancer? | D Gorski
The compassion gambit | D Gorski
Dr. Stanislaw Burzynski’s antineoplastons versus patients | D Gorski
False balance about Stanislaw Burzynski and his disproven cancer therapy, courtesy of STAT News | D Gorski
My Cancer Free Life: A reality series designed to promote Stanislaw Burzynski’s quackery | D Gorski
Dr. Stanislaw Burzynski’s cancer “success” stories | D Gorski
Dr. Stanislaw Burzynski’s cancer “success” stories update: Why is the release of the Burzynski sequel being delayed? | D Gorski
Three myths about Stanislaw Burzynski and The Skeptics | Science-Based Medicine
Now that Burzynski has gotten off in 2012, Burzynski The Movie will spawn a sequel in 2013 | D Gorski
Burzynski: Cancer Is A Serious Business, Part 2: Like the first Burzynski movie, only more so? | Science-Based Medicine
Eric Merola’s conspiracy-mongering and more of Dr. Stanislaw Burzynski’s cancer “success” stories | D Gorski
Revealed by the FDA: The results of the most recent inspection of the Burzynski Clinic | D Gorski
USA Today versus Stanislaw Burzynski | D Gorski
The Burzynski Empire strikes back | D Gorski
The Skeptics for the Protection of Cancer Patients need your help | D Gorski
Stanislaw Burzynski: Using 1990s techniques to battle the FDA today | D Gorski
Stanislaw Burzynski and Robert O. Young: How two quacks of a feather illustrate how poorly states regulate medical practice | D Gorski
The Texas Medical Board vs. Stanislaw Burzynski, 2014 edition | D Gorski
The Center for Inquiry weighs in on the FDA’s mishandling of Stanislaw Burzynski’s clinical trials | D Gorski
Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA caves | Science-Based Medicine
Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA really caves | Science-Based Medicine
Stanislaw Burzynski: A deceptive propaganda movie versus an upcoming news report | D Gorski
BBC Panorama investigates Stanislaw Burzynski | D Gorski
The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine | D Gorski
Cancer quack Stanislaw Burzynski continues to prey on cancer patients in 2023 | D Gorski
MAHA: Everything old is new again, except this time antiscience cranks (like Stanislaw Burzynski) are in charge | D Gorski
Cancer quackery: Under MAHA, everything old is new again | D Gorski
pH Miracle Living “Dr.” Robert O. Young is finally arrested, but will it stop him? | Science-Based Medicine
“Integrative” oncology: Trojan horse, quackademic medicine, or both? David Gorski.
“Patient-Centered Care” and the Society for Integrative Oncology. Kimball Atwood
Tom Harkin, NCCAM, health care reform, and a cancer treatment that is worse than useless. David Gorski.
The FDA’s accelerated drug approval program is failing to protect cancer patients | D Gorski
FDA issues warning letter to “holistic” practitioner offering thermography for breast cancer detection | J Bellamy
Cancer quack Colleen Huber sues Britt Hermes over criticism | J Bellamy
Suzanne Somers’ Knockout: Dangerous misinformation about cancer (part 1) David Gorski 
Bill Maher endorses cancer quackery. David Gorski
Mike Adams on Dr. Mehmet Oz’s colon polyps: “Spontaneous” disease? David Gorski.
ASCO endorses “integrative oncology” quackery for cancer pain | Science-Based Medicine
Monsanto gets injunction against California’s mandated cancer warning for glyphosate | J Bellamy
How Google listings are used by alternative cancer clinics to lure in desperate patients | D Gorski
Facebook, Google, and social media vs. medical misinformation: An update | D Gorski
Bad Documentary Review: Cancer Can Be Killed | B MacBeth
Crowdfunding: The fuel for cancer quackery | D Gorski
Crowdfunding: The fuel for cancer quackery (part 2) | D Gorski
More, please! A victim of cancer quack Robert O. Young wins a $105 million settlement | D Gorski
A whole issue of JACM devoted to “integrative oncology” propaganda? Oh, goody. | D Gorski
Dana-Farber Cancer Center’s Integrative Medicine Expansion | D Gorski
The Integrative Oncology Scholars Program: Indoctrinating the next generation of “integrative oncology” believers | D Gorski
Apple Cider Vinegar | S Novella
The metastasis hoax? | D Gorski
WHAT IS THE HARM?
The price of cancer quackery. David Gorski 
Rejecting cancer treatment: What are the consequences? | S Gavura
Alternative medicine kills cancer patients | D Gorski
Risks of CAM Treatments for Cancer | S Novella
Naturopathy vs. patients: Patients lose | D Gorski
Alternative cancer clinics, distrust of medicine, and MAHA | D Gorski
The deadly false hope of German alternative cancer clinics | D Gorski
How not to win friends and influence people. David Gorski
The Orange Man. David Gorski
When urgency to cure beats research ethics, bad things happen | D Gorski
The sad saga of an Amish girl with a curable cancer whose parents are refusing chemotherapy in favor of “natural healing” | D Gorski
Flipping the Script In Action: The Nick Gundersen Case | B MacBeth
Ontario fails to protect the life of a First Nations girl with cancer | D Gorski
An aboriginal girl dies of leukemia: Parental “rights” versus the right of a child to medical care | D Gorski
An update on the case of Sarah Hershberger: Parental rights trump the right of a child with cancer to live | Science-Based Medicine
Death by “alternative” medicine: Who’s to blame? David Gorski 
Death by “alternative” medicine: Who’s to blame? (Revisited) David Gorski
Death from Cancer Quackery – Black Salve Edition | S Novella
The sad but unexpectedly hopeful cancer saga of Cassandra Callender | D Gorski
Another cancer tragedy in the making | D Gorski
The case of chemotherapy refusenik Daniel Hauser. David Gorski.
Natural History | M Crislip
A Review of Flipping The Script: Parents Fight Back | B MacBeth
Chemotherapy versus death from cancer. David Gorski.
Complementary and alternative medicine in hospice care. Brennen McKenzie 
   
Science-Based Medicine Cancer and CAM
A Critical Guide for the Health Practitioner and Consumer
2025 Edition


Executive Editor Steven Novella MD
Managing Editor David Gorski MD PhD
Series Editor Mark Crislip MD

   Introduction
Steven Novella
The world of health care is becoming an increasingly complex and challenging place. The internet is changing the way we generate and access information, and health information is one of the most popular uses of the internet. It represents an unprecedented democratization of information and opinion. 
While there are many advantages and benefits to such information access, there are also many challenges to health professionals, regulators, academics, and consumers. There is a proliferation of health related products and services, with many provocative health claims. Regulations are generally not keeping up, and often have been watered down, in the face of this onslaught of claims and products. 
The consumer is left with an overwhelming array of health claims, many of which challenge and even directly oppose the traditional experts and institutions. 
The mission of Science-Based Medicine (SBM) is to be a source of reliable information and analysis to help navigate the wild west of health information on the internet and elsewhere. The authors who contribute to this series of e-books are all physicians and other health care professionals who have a great deal of experience educating the public about complex medical issues. We especially take on controversial issues and try to expose pseudoscience and fraud wherever possible.
The Philosophy of Science-Based Medicine
The philosophy of SBM, at its core, is simple: Safe and effective health care is critical to everyone’s quality of life; so much so that it is generally considered a basic human right. Therefore, health care products and services that work and are safe are better than those that do not work or are unsafe. 
The best method for determining which interventions and health products are safe and effective is, without question, good science. Therefore it is in everyone’s best interest for health care to be systematically evaluated by the best science available.
Too often the nature of science itself is misunderstood or misrepresented to the public. Science is not an arcane and privileged discipline. By its very nature it is meant to be transparent and public. Science is nothing more than a systematic and careful use of evidence and logic to evaluate factual claims. And good science possesses certain virtues that are not unique to science but generic to all intellectual endeavors: fairly accounting for all available evidence, using valid and internally consistent logic, using unambiguous concepts and language, proper use of statistics, being quantitatively precise and accurate, and above all being honest.
And yet there are numerous and powerful influences in society that strongly appose the scientific basis of medicine. Driven by some combination of ideology or the desire for profit they wish to eliminate standards of science in health care, or (often under the guise of “health care freedom”) create a double standard in which unscientific methods and products can thrive unchecked. Others simply lack the training or knowledge to achieve minimal standards of quality for scientific medicine. And even the best traditions of scientific medicine can benefit from more critical analysis.
Recognition of the need for careful scientific analysis in medicine partly stems from a recognition that it is very difficult (almost impossible) to reliably assess treatments anecdotally. Human perception, memory, and cognition are prone to a host of flaws, weaknesses, and biases that will tend to mislead us, especially towards conclusions that we wish to be true. Placebo effects, confirmation bias, and simple statistics can make any intervention seem effective, even when they are worthless or harmful. 
Science-Based Medicine vs Evidence-Based Medicine
Within the practice of medicine there is already a recognition of the need to raise the standards of evidence and the availability of the best evidence to the practitioner and the consumer – formalized in the movement known as evidence-based medicine (EBM). 
EBM is a vital and positive influence on the practice of medicine, but it has its limitations. EBM tends to focus on clinical trial results to the exclusion of scientific plausibility. The focus on trial results (which, in the EBM lexicon, is what is meant by “evidence”) has its utility, but fails to properly deal with medical modalities that are highly implausible, or seem to defy well-established findings in science.
All of science describes the same reality, and therefore it must (if it is functioning properly) all be mutually compatible. Collectively, science builds one cumulative model of the natural world. This means we can make rational judgments about what is likely to be true based upon what is already well established. This does not necessarily equate to rejecting new ideas out-of-hand, but rather to adjusting the threshold of evidence required to establish a new claim based upon the prior scientific plausibility of the new claim. Failure to do so leads to conclusions and recommendations that are not reliable, and therefore medical practices that are probably not safe and effective.
The SBM Series
This is why the authors of this series strongly advocate for science based medicine – the use of the best scientific evidence available, in the light of our cumulative scientific knowledge from all relevant disciplines, in evaluating health claims, practices, and products. 
Some of the articles here will analyze individual studies, and explore the strengths and weaknesses of their methods, separating what the study really tells us from how it may be represented in the media. Other articles will summarize what many studies tell us about a specific medical question. 
We will also explore health information on the internet, separating out which information is reliable from that which is misleading, erroneous, or possibly even fraudulent. Likewise we will critique mainstream media coverage of health topics, giving the reader specific tools for to critically analyze health information for themselves.
Other articles will explore topics related to health regulation and academia. Regulations have struggled to keep up with the rapidly changing health care market place, with critical gaps that leave the health care consumer responsible for their own protection. Academic institutions themselves, long the defenders of high standards of scholarship in all fields, including medicine, have been infiltrated by promoters of pseudoscientific belief systems. The result is that there is no longer any single reliable guarantee of scientific integrity. 
The SBM series of e-books is organized by topic, such as acupuncture, chiropractic, homeopathy, and many others. The books are collections of essays, not intended to be a systematic reference, but rather to explore the various scientific issues related to each topic. The goal is to give the reader critical thinking skills and a deeper understanding of, not just the current findings of science, but the process of science, specifically how it relates to health care and the topic of each book. 
Science-based medicine can serve as your pocket guide through the wilderness of health information.

As of 2025, there are over 5000 essays on the Science Based Medicine website. I do no know about you, but I find it difficult to find any post I wrote, much less one written by another contributor.
The volumes in the series are
CAM Concepts Chiropractic COVID Critical Thinking Diet and Nutrition Ethics and CAM Herbs, Supplements, and Diet Homeopathy Infections and Immunity Law and CAM Media and Internet Medicine, Public Health, Dentistry and Pediatrics Miscellaneous CAM Naturopathy Neurology and Psychiatry Placebo Quackademic Medicine Regulation. FDA and FTC SBM or EBM Stem Cells, Genetics, AI and Gender Supplements, Vitamins and Herbs Vaccine & Anivax Vaccines and Autism Vaccines and Preventable Infections
The articles are roughly organized by publication date and topic. Many articles will be in multiple volumes as an essay of, for example, chiropractic and law will be found in both the chiropractic volume and the law volume.
You may find the organization a bit odd. I do. But 5000 plus articles are difficult to organize and I have more to do in my retirement than work of these volumes.
Still, if you find I have missed a nentry or some glaring error, drop me a note and I will fix it for the next edition.
About the authors Steven P. Novella, MD – Founder and Executive Editor Science Based Medicine. Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD. David H. Gorski, MD, PhD – Managing Editor. Science Based Medicine. Mark A. Crislip, MD. Editor, Science Based Medicine Guides. He did he editing of all the volumes so is to blame for any mistakes. As to all the other contributors, if you are interested click on the ‘Link’ at top of each essay to go the SBM site, where further information about each author can be found. A Note On References
The chapters in this book were originally blog entries at ScienceBasedMedicine.org. Blog and web pages lend themselves to hyperlinks to sources and references that are tedious to translate into footnotes for this ebook. Under the title of each essay is a hyperlink, cleverly titled ‘Link’, to the original blog entry with all the hyperlinks and references, as well as the comments to the blogs, which often have interesting and thoughtful insights by our readers, as well as some curious comments by the not so thoughtful. Graphs, tables and links to videos are not in included these essays due to issues of copyright and permission. However, thanks to the ‘Link’, the graphics are a click away. Thanks for reading the site. Mark Crislip


   Basic Science

   Cancer prevention: The forgotten stepchild of cancer research?
David Gorski
Link
The New York Times has been periodically running a series about the “40 years’ war” on cancer, with most articles by Gina Kolata. I’ve touched on this series before, liking some parts of it, while others not so much. In particular, I criticized an article one article that I thought to be so misguided about how the NIH grant system leads researchers to “play it safe” and how we could cure cancer if we could just fund “riskier” research that I had to write an extended screed about the misconceptions in the article. The latest installment, Medicines to Deter Some Cancers Are Not Taken, also by Kolata, is much better in that it discusses a problem at the heart of cancer, namely that we have developed drugs that can decrease the risk of specific cancers but they are not as widely used as they could be.
The first part of the article contrasts a seeming incongruity:
Many Americans do not think twice about taking medicines to prevent heart disease and stroke. But cancer is different. Much of what Americans do in the name of warding off cancer has not been shown to matter, and some things are actually harmful. Yet the few medicines proved to deter cancer are widely ignored.
Take prostate cancer, the second-most commonly diagnosed cancer in the United States, surpassed only by easily treated skin cancers. More than 192,000 cases of it will be diagnosed this year, and more than 27,000 men will die from it.
And, it turns out, there is a way to prevent many cases of prostate cancer. A large and rigorous study found that a generic drug, finasteride, costing about $2 a day, could prevent as many as 50,000 cases each year. Another study found that finasteride’s close cousin, dutasteride, about $3.50 a day, has the same effect.
This is indeed a contrast. Think about it. Millions of Americans take statins, for instance, to lower their cholesterol and thereby try to prevent the complications of elevated cholesterol, such as heart disease, vascular disease, and strokes. Yet, for at least two common cancers, there are proven effective drugs that will lower the risk of cancer considerably with a side effect profile at least as favorable as that of statins.
Of course, preventing cancer is not like preventing heart disease. “Cancer” is not a disease, but many diseases arising from many different organs with many different biological behaviors. There is no drug that can prevent “cancer.” There are, however, specific drugs that can lower the risk of specific cancers. So right there you have a big difference that could partially explain the reticence. Which cancers should be prevented? How many different drugs are you willing to take to prevent how many different cancers?
One thing that the article points out that is quite true and has been quite disappointing to cancer researchers, and that’s that diet does not have nearly as large an effect as we had hoped. Kolata correctly points out that if we could eliminate smoking cancer deaths would decrease by about a third. Lung cancer is quite rare in nonsmokers. Indeed, back in the early part of the 20th century, lung cancer was so rare that there are reports describing how, when a patient died of it, medical students would be told that they had to go to see the autopsy because they might not ever see another case in their careers. Now lung cancer is the single largest cause of cancer deaths in both men and women, causing 30% of cancer deaths in men and 26% of cancer deaths in women, and it’s all due to smoking:
No other preventative intervention could conceivably even come close in terms of effect as cutting smoking to zero. Obviously, such a thing will not come to pass in my lifetime, but as a cancer surgeon I can always hope, can’t I? Also as a human being, too. After all, I’ve already lost an aunt to smoking-induced lung cancer in 2008, and I have several relatives who smoke who, I fear, might well join her.
After that, Kolata suggests that avoiding hormone replacement therapy containing estrogen and progestin after menopause would be a good preventative, which may be true, but since the Women’s Health Initiative study reported in 2002 that showed an increased risk of breast cancer from such HRT, few women take them any more anyway.
What’s more interesting is how Kolata correctly points out just how little diet and other lifestyle factors seem to matter compared to our hopes. If anyone wants to counter the claims of woo-meisters that we evil “allopathic” doctors don’t pay attention to diet and lifestyle, one only needs to look at just how much money has been spent on studies of diet and exercise and how they impact cancer and heart disease. There have been many studies. Of course, it’s incredibly difficult to do a randomized study, particularly a double-blinded one, of diet and exercise; so most of them end up being observational. The problem with such studies is, as with all such cohort studies, controlling for confounders. It’s hard enough to control for confounders that the investigators know about, but there are often many confounders that they don’t know about and may not identify until after the study is over. In any case, suffice it to say that studies of diet as a means of preventing cancer have been disappointing of late, as Kolata points out:
For example, public health experts for years recommended eating five servings of fruits and vegetables a day to prevent cancer, but the evidence is conflicting, at best suggestive, and far from definitive.
Low-fat diets were long thought to prevent breast cancer. But a large federal study randomizing women to a low-fat or normal diet and looking for an effect in breast cancer found nothing, said its director, Ross L. Prentice of the Fred Hutchinson Cancer Research Center in Seattle.
Fiber, found in fruits, vegetables and grains, is often thought to prevent colon cancer, even though two large studies found no effect.
“We thought we would show relationships that were strong and true,” said Dr. Tim Byers, professor of epidemiology at the Colorado School of Public Health, “particularly for dietary choices and food and vegetable intake. Now we have settled into thinking they are important but it’s not like saying you can cut your risk in half or three-quarters.” Others wonder whether even such qualified support is misplaced.
There has to be a reason the research disappointed, said Colin B. Begg, chairman of the department of epidemiology and biostatistics at Memorial Sloan-Kettering Cancer Center. Perhaps the crucial time to intervene is early in life.
“That’s one possibility,” Dr. Begg said. “The other is that it’s all sort of nonsense to begin with.”
One potential reason for these results is that the effect of diet or other environmental exposures may have a “window of vulnerability” that occurs in youth or childhood. Certainly, in the breast cancer field, we are starting to think that and actively research the possibility. The problem is, if that’s true, then dietary interventions during adulthood may have little or no effect on ultimate cancer risk.
Which brings us to drugs and supplements.
Kolata mentions the cautionary tales of beta-carotene and selenium, the former of which was thought to prevent cancer and the latter to prevent prostate cancer. However, when a large study of beta carotene was done, not only did the supplement not prevent cancer but it appeared to increase the risk of lung cancer in smokers. Selenium and vitamin E similarly were found to have no protective impact on prostate cancer risk and, in fact, the trial studying the question was halted because there was a hint of actually increased risk. Even so, as Kolata points out, ads for such supplements continue to imply, with the Quack Miranda warning, that such supplements “improve prostate health,” whatever that means, although the implication is that they decrease the risk of prostate cancer.
Now here’s where the drugs come in. Because I’m a breast cancer surgeon, I’m going to focus mainly on strategies to prevent breast cancer. It turns out that tamoxifen can decrease the risk of breast cancer by 50% in high risk women. Tamoxifen is a selective estrogen receptor modulator (SERM) that antagonizes estrogen action in breast tissues but has partial agonist activity in bone and endometrium. Indeed, raloxifene, another SERM, is used primarily to prevent and treat bone loss in women with osteoporosis. A $110 million clinical trial showed that its ability to prevent breast cancer is not statistically significantly different than that of tamoxifen, with the advantage that, unlike tamoxifen, raloxifene does not increase the risk of uterine cancer and does not increase the risk of blood clots as much as tamoxifen does.
So, with such overwhelming evidence that in women at high risk for breast cancer, why is it that so few are offered the option of tamoxifen or raloxifene? Kolata explains:
“Those were your tax dollars and mine,” he [Dr. Victor Vogel] added. “You can’t do too many $110 million studies.”
He cannot understand why no one cares, but some doctors say they see a number of problems. It is usually not the cost; tamoxifen is about 30 cents a day and raloxifene $3.30 a day. It is doctors’ practices and women’s concerns.
Most doctors, said Dr. Therese B. Bevers, medical director of the Cancer Prevention Center at M. D. Anderson, do not take the first step — calculating a woman’s lifetime risk of getting breast cancer — in part because that can lead to the next step, spending an hour or so discussing cancer risk and drug risks and benefits.
Dr. Bevers suggests the drugs for women whose lifetime odds exceeds 20 percent. That could include, for example, a 55-year-old woman who began menstruating early (increasing the risk), had her first child late (again increasing the risk), and whose mother and sister got breast cancer. About half the time, though, women with that kind of risk turn down the drugs, Dr. Bevers said. “The No. 1 reason I hear is, ‘Oh, I just don’t like to take medications,’ ” she added.
Yet the same women will happily down supplements that woo-meisters like Dr. Mercola or Mike Adams will suggest to them as cancer preventing. Some will down many supplements a day without thinking twice about it, even though there is no good evidence that they do anything other than enrich the supplement manufacturers who make them and they often cost far more than the paltry 30 cents a day that tamoxifen costs. Moreover, in general for prevention the usual course of tamoxifen or raloxifene is five years, in marked contrast to supplements, where the woo-meisters recommend them for the rest of one’s life.
Of course, never having worked anywhere else other than NCI-designated comprehensive cancer centers, I am probably spoiled in this respect. Such centers always have genetic counseling and prevention clinics. I can simply refer suitable patients there, where our trusty and excellent genetic counselors will calculate patients’ lifetime risk of breast cancer, construct family trees, decide if testing for cancer susceptibility genes is appropriate, and then make science-based recommendations for risk prevention strategies and/or screening strategies tailored to the individual patient. (Who says “allopathic medicine” doesn’t individualize therapy?) In any case, I can see why primary care doctors don’t bring these issues up more often, but with the advent of genetic counseling clinics I am puzzled why more patients aren’t referred to a specialist for these conversations.
One problem mentioned in the article is that there aren’t any particularly good biomarkers for increased risk for cancer, especially ones that fall in response to preventative interventions, the way, for example, cholesterol does for heart disease. Another is what I mentioned earlier, namely that cancer is not one disease, meaning that it is likely that many drugs would be needed to prevent various cancers. True, for the really common cancers, like prostate, breast, and colon, it might be worth it to develop such drugs, but neither the risk-benefit profile nor the number of patients who would benefit would be likely to lead to such drugs for less common cancers. And, as has been pointed out, our risk assessment tools are currently crude at best. In fact, even with better biomarkers I’m not so sure that interest would improve because biomarkers have their own problems and many people have a tendency to fear pharmaceuticals more than they fear a hypothetical increased risk of cancer. In the case of drugs that prevent breast cancer, nearly all of them have anti-estrogen activities and thus produce side effects of estrogen deprivation, such as hot flashes and other menopausal symptoms. It’s a very high bar to meet to produce effective drugs that people will actually take, given that it’s hard enough to persuade patients to comply with drugs designed to treat actual diseases and conditions.
The end result of all of this is that drug companies, once interested in developing cancer preventing drugs, are now floundering. As Kolata notes:
But risk assessment is not easy, and biomarkers are still more of a dream than a reality. There are other problems, too. If each cancer requires a different drug for prevention, how many drugs can a person take? For now, Dr. Curt said, the very idea of cancer prevention is daunting. And since cancer can take decades to develop, by the time a study concludes, a drug’s patent life may be over.
It is not a pretty picture, Dr. Vogel said.
“You have to think that in boardrooms they are saying, Man, did we learn a lesson,” he said. “We will stay as far away as possible from cancer prevention.”
Sadly, supplement manufacturers are not faced with such problems because they don’t actually have to demonstrate that their supplements have the health effects that they claim they have. The war against cancer goes on, but one weapon is not being developed.

   The complexity of cancer: A science-based view
David Gorski
Link
Last week I participated in a panel discussion at NECSS with John Snyder, Kimball Atwood, and Steve Novella, who reported on the conference last Monday. What I mentioned to some of the attendees is that I had managed to combine NECSS with a yearly ritual that I seldom miss, namely the yearly meeting of the American Association for Cancer Research (AACR) meeting. There are two huge cancer meetings every year, AACR and the annual meeting of the American Society for Clinical Oncology (ASCO). AACR is the meeting dedicated to basic and translational research; ASCO, as the word “clinical” in its name implies, is devoted mainly to clinical research. Personally, being a translational researcher myself and a surgeon, I tend to prefer the AACR meeting over ASCO, not because ASCO isn’t valuable, but mainly because ASCO tends to be devoted mostly to medical oncology and chemotherapy, which are not what I do as a surgeon. Each meeting draws between 10,000 to 15,000 or even more clinicians and researchers dedicated to the eradication of cancer.
Having taken the Acela train from the NECSS meeting in New York straight to Washington, DC for the AACR meeting, I couldn’t help but think a bit about the juxtaposition of our discussion of the infiltration of quackademic medicine into medical academia with the hard core science being discussed at AACR. One session in particular at AACR highlighted what is one of the most significant differences between science-based medicine and the various forms of “alternative” medicine that we discuss here on SBM on such a regular basis. That difference, quite simply put, is the difference between the simple and the complex. “Alternative” medicine supporters often scoff at practitioners of science-based oncology, asking why we don’t have a “cure for cancer” yet—as if cancer were a single disease!—or why we haven’t made much more progress since President Richard Nixon declared “war on cancer” back in 1971. One part of the answer is that cancer is incredibly complicated. Not only is it not a single disease, but each variety of cancer is in and of itself incredibly complicated as well. To steal from Douglas Adams, cancer is complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think algebra is complicated, but that’s just peanuts to cancer.
On Tuesday morning, I attended a session that hammered home that cancer is complex. The session was called, appropriately enough, The Complexity of Cancer. It was chaired by Dr. Joan S. Brugge, professor of Cell Biology at Harvard Medical School and featured as speakers cancer stem cell expert Dr. Sean J. Morrison of the University of Michigan, as well as two faculty from UCSF, Dr. Lisa M. Coussens and Dr. Allan Balmain. Dr. Brugge spoke about mechanisms that control tumor cell anchorage, as well as the interface between genetics and metabolism in cancer; Dr. Morrison discussed cancer stem cells and how some tumors appear to follow the stem cell model while others didn’t; Dr. Coussens discussed how chronic inflammation can lead to cancer; and Dr. Balmain discussed genetic network analysis as a means of determining the susceptibility to cancer of various cells.
Right from the beginning, Dr. Brugge invoked Nixon’s war on cancer with a particularly appropriate observation, namely that the war has been far more difficult than anyone could possibly have ever envisioned in 1971. Back in 1971, in the wake of the discovery of the first oncogene, src, most scientists studied almost exclusively cancer cells, not appreciating the role of the surrounding matrix of normal cells and connective tissue in both preventing and modulating tumors. It’s true that, even back in 1971, scientists understood that the immune system has an important role in controlling cancer, but we lacked the tools to study this system in great detail. Since 1971, the list of discoveries about cancer has been long. Some examples include the discovery of many more oncogenes; tumor suppressor genes; the role of tumor angiogenesis in cancer; cancer stem cells; the rediscovery of the Warburg effect and metabolic derangements in cancer cells; and an enormous number of discoveries in tumor immunology. Each discovery helped us understand better how normal cells become tumors and how tumors grow, invade, and metastasize. But each discovery also led to additional complexities and more questions.
One characteristic that virtually defines a malignant cell in solid organs (as opposed to blood-derived tumors) is its ability to survive when not attached to other cells in its normal surrounding matrix of collagen and other connective tissues. This characteristic of tumor cells has long been recognized, having been first described back in the 1960s. Normal cells, when not attached to the proteins to which they normally cling, rapidly undergo programmed cell death (apoptosis). Apoptosis due to becoming detached is known as anoikis. Dr. Brugge started out discussing her interest in anoikis and understanding how breast epithelial cells survive detachment. Her talk ended up encompassing intracellular signaling pathways, metabolic derangements, and genetics. One observation that is likely underappreciated is that cells that undergo detachment develop metabolic deficiencies that lead to decreased ATP deproduction, decreased cellular energy (real energy, not the fake “energy” — or qi — that alt-med proponents often invoke), and ultimately programmed cell death. One of the more provocative observations is that antioxidants can actually help save these cells by neutralizing reactive oxygen species (ROS) and thereby rescuing fatty acid oxidation. For purposes of this discussion, the details aren’t important (although they are very important for cancer biology). What is important is that antioxidants are not a universal good when it comes to cancer; in the case of the models of breast cancer discussed by Dr. Brugge, antioxidants actually promote the survival of transformed cells because part of the mechanism by which these cells undergo programmed death is through the production of ROS. Does this result mean that antioxidants don’t prevent cancer? Of course not. It does however, when taken in context with other studies, suggest a great deal of complexity, where in some cases antioxidants prevent cancer and others may promote cancer.
Contrast this to the frequent alt-med claim that antioxidants prevent cancer and are virtually always good.
Dr. Morrison’s talk touched upon one of the most contentious issues in cancer today, namely the cancer stem cell hypothesis. This hypothesis goes something like this. There exist within cancer a population of cells that behave like stem cells. They are self-regenerating and each is capable of dividing indefinitely and recapitulating a tumor, while the vast majority of tumor cells have only limited replicative potential. The population of cells that can actually produce new tumors may be very small, much less than 1% of the cells in any given tumor. This concept has been most validated in leukemias, although there is good evidence that breast and a variety of other cancers may follow a stem cell-like model.
Cancer stem cell
Under the stem cell model of cancer, these stem cells are highly resistant to chemotherapy, which wipes out all the non-stem tumor cells but leaves a few tumor stem cells, which can rapidly grow and then recreate the tumor, even from a single cell. In essence, the stem cell model postulates a hierarchy among tumor cells, as contrasted to the previous model, which was a more stochastic model in which any tumor cell could produce a tumor. To boil the concept down, in the stochastic model, any given cell in a tumor could be viewed as having, for example, a 1% chance of being able to form a new tumor if transplanted, while in the stem cell model only 1% of the cells of a given tumor can form new tumors, but they do so with very high efficiency. Moreover, these cancer stem cells have various protein and genetic markers that distinguish them from other cells in the same cancer.
The concept of the cancer stem cell is rather controversial. Personally, although the evidence has persuaded me that there is such a thing as what is commonly called a “cancer stem cell,” from my perspective I view the term as a poor descriptor of this cell mainly for semantic reasons. The term “stem cell” implies unlimited ability to produce different tissue types, which is not what this model is about at all. It’s long been known that tumors are made up of different populations of cells with different characteristics, and it’s not such a stretch to accept that many tumors might have a subpopulation of cells that are most responsible for tumor growth, with most of the other cells remaining quiescent or only slowly dividing. What Dr. Morrison argued is that some cancers follow a more “stem cell” model, while others follow a more stochastic model. He used the example of melanoma to illustrate this point: over 30% of the cells in a given melanoma studied can produce new tumors. While this observation might be consistent with the existence of a melanoma stem cell that makes up 30% of a typical melanoma, Dr. Morrison was unable to find any markers to distinguish the cells that could form tumors from those that could not, and he checked over 50 markers. While this does not entirely rule out a stem cell model (it’s possible that he hasn’t yet found the right marker), it is more consistent with a stochastic model, in which each cell in the melanoma has a 30% chance of being able to form a tumor when transplanted.
Why is this important? It’s important because it has great relevance to treatment. If a tumor is driven by stem cells, then to eradicate the tumor it is necessary to eliminate the stem cells. If it is driven by a more stochastic mechanism, a non-stem cell mechanism, then a “kill ‘em all” approach is more likely to succeed. Of course, it wouldn’t surprise me if it turns out that most tumors actually fall somewhere on a continuum between being stem cell-driven and being stochastic. Cancer is just that complex. The term “either-or” rarely, if ever, applies to it.
Dr. Coussens’ talk is fascinating for what it revealed about the immune system and cancer. How many times have you heard “alternative medicine” believers and promoters brag that this nostrum or that potion “boosts the immune system”? As we’ve said before here, it’s a meaningless claim, because sometimes boosting the immune system is bad, as in autoimmune diseases. In cancer, it’s long been known that inflammation, particularly chronic inflammation, can lead to cancer. One of the most classic examples of this phenomenon is how gastroesophageal reflux disease (GERD) can lead to inflammation in the lower esophagus, which can lead to a change in the cells there known as Barrett’s esophagus, which can ultimately lead to esophageal cancer. Inflammation is a function of the immune system; consequently, when you take anti-inflammatories, you are suppressing part of the immune system on purpose in order to decrease inflammation. In any case, Dr. Coussens discussed how activation of certain parts of the immune system can suppress cancer development, while activation of other parts can promote tumor progression. This slide, taken on my iPhone, demonstrates the concept:
Dr. Balmain echoed this message but came at it from a different angle, namely from the complexity of changes in gene expression in cancer, and how a highly complex interaction between inflammation, stromal cells, the immune response, metabolism, and changes in gene expression in a tissue, specifically skin, can influence susceptibility to cancer. One of the big disappointments in cancer research is that relatively few cancers have easily identifiable genes driving them, even though many tumors have a strong heritable component. The reason may well be due to the inheritance of multiple susceptibility genes of low penetrance, meaning that they don’t individually have a strong effect on the characteristics of a cell. Cancer actually involves changes in the expression levels of hundreds, if not thousands, of different genes. In fact, the way we now look at cancer is through network analysis of the levels of thousands of genes in the cell. We’ve gone from looking at single genes to looking at thousands upon thousands of genes. As Dr. Balmain concluded, cancer susceptibility and progression depend upon the emergent properties of many genes, each of which individually has a small effect, and these genetic variants affect the tumor cell, the microenvironment surrounding the tumor cell, or both. Moreover, depending upon the tumor type and situation, inflammatory networks can play opposite roles, either promoting or inhibiting tumor susceptibility and progression.
Is that complicated enough for you yet?
Then let’s move on beyond this talk. On Friday, a bunch of us on our floor on the cancer institute got together to discuss interesting stuff we saw and learned at AACR this year. One topic that came up is the Cancer Genome Atlas, or TCGA (you gene geeks out there may find the initials amusing, but they explain why the word “the” was included). The idea behind the project is to sequence the genomes of many, many cancers. You might wonder why it’s necessary to sequence so many cancer genomes, and it’s not an unreasonable question. The reason is that so many cancers are driven by different mutations that it’s unlikely that any two tumors have the same set of mutations driving them. Consequently, TCGA seeks to sequence at least 500 cancers for each cancer type studied. It started with a pilot project and has since been expanded to 20 different tumors. By sequencing lots and lots of tumors, or so the idea goes, we can identify commonly occurring mutations and sets of mutated genes, perhaps even across cancers, that can be targeted for therapy. At the very least, it is thought that we will be able to develop a greater understanding of the complexity of cancer.
I must admit that when I first heard of TCGA, I was skeptical. To me, it struck me as perhaps the largest fishing expedition in the history of cancer research. Moreover, even this massive undertaking is only part of the picture. As I alluded to earlier, the metabolism of cancer cells is often hugely abnormal, and a “chicken or the egg” argument continues to some extent even now about whether it is the metabolic abnormalities that drive mutations or the mutations that produce metabolic abnormalities. More likely, it’s a little of both, the exact proportion of which depending upon the tumor cell. None of this even considers influences outside of the genome (epigenetic influences) or differences in how proteins are made. Part of our discussion also pointed out that so many mutations have been associated with cancer and that they are often so different in different tumors, even from the same tissue, that trying to figure out which mutations found in TCGA are even relevant to cancer and which ones are actually driving the development, progression, and spread of cancer will be a daunting task, every bit as challenging as the Manhattan Project or sending a man to the moon in less than a decade. In fact, when you consider how vastly, hugely, mind-bogglingly complicated cancer is, it’s amazing that we do as well as we do now and that we’ve made as much progress as we have, arguments over whether we are too conservative or whether pursuing riskier research strategies will bear fruit faster notwithstanding.
Compare this to the view of many practitioners of unscientific medicine. My favorite example of a vastly, hugely, mind-bogglingly simple pseudo-explanation for cancer is that of the late Hulda Clark, who claimed to be able to cure all cancers (not just all cancers, but all disease) but who died of multiple myeloma herself. Her idea was that all cancer is caused by a liver fluke, which she would claim to be able to kill (and thus cure the cancer) with device she called her “Zapper,” a cheap little electrical gadget that looked as though it were assembled from spare parts at Radio Shack.
Another quack, Nicholas Gonzalez, claims that all cancer is due to a deficiency in pancreatic enzymes, for which he prescribes pancreatic enzyme replacement, up to 150 supplement pills a day, a “nutritional” regimen consisting of various vegetable and fruit juices , and a “detoxification” regimen including coffee enemas. He made a name for himself with a cherry-picked case series of his own patients that appeared to have survived pancreatic cancer far longer than is generally anticipated based on historical controls. This lead to a highly unethical clinical trial that ultimately showed that Gonzalez’s patients did considerably worse than conventional therapy, as poor as conventional science-based therapy does against pancreatic cancer.
These are not the only ones, of course. Still another quack, Robert O. Young, ascribes all cancer to “acidity” in the blood, and his treatment is always diet and bicarbonate to try to “alkalinize” the blood:
Young even goes so far as to describe cancer as a “poisonous acidic liquid,” states that “there is no such thing as a cancer cell” and that cancer cells are cells that have been “spoiled by acid.” To him, the tumor is the “body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.” Young’s ideas have sucked in unwitting cancer patients, including one named Kim Tinkham, who even appeared on Oprah’s show a couple of years ago. (In addition, Young also doesn’t believe that sepsis is caused by bacterial infection.) On a related note, another quack named Tullio Simoncini espouses a variant of Robert Young’s ideas in that he believes that all cancer is a fungus. The similarity is that he prescribes “alkalinization” for the fungus, some of which can involve injecting sodium bicarbonate directly into tumors.
If there’s one difference between science-based medicine and quackery when it comes to cancer, it’s that science-based medicine appreciates the sheer complexity of tumors, while quacks often go for risibly simplistic pseudo-explanations of cancer. The complexity of cancer as a set of related diseases is incredible. Indeed, one has to respect it and even stand in awe at its ability to grow, evolve, and ultimately develop resistance to almost any treatment we can come up with. That’s not to say that the situation is hopeless, but it is an explanation as to why, nearly 40 years after Nixon’s war on cancer commenced, our progress against this foe has been incremental. Despite this record, I remain nonetheless optimistic and expect this situation to change within my lifetime. The reason is that we are finally developing the tools, both scientific and technological, along with the computational power to analyze the data, that hold out hope of an understanding of different cancers deep enough to make real progress in reducing the incidence, morbidity, and mortality from cancer. This isn’t any comfort to patients suffering from cancer now or to those who have (as I have) lost loved ones to cancer, but it does give me hope that, should I be one of the unlucky ones who develop cancer, my chances of survival will be better than at any time in history.
No quack can even come close to giving me that sort of hope.

   Cancer research: Going for the bunt versus swinging for the fences
David Gorski
Link
A couple of weeks ago, our resident skeptical medical student Tim Kreider wrote an excellent article about an op-ed in NEWSWEEK by science correspondent Sharon Begley, in which he pointed out many misconceptions she had regarding basic science versus translational research, journal impact factors, and how journals actually determine what they will publish. Basically, her thesis rested on little more than a few anecdotes by scientists who didn’t get funded or published in journals with as high an impact factor as they thought they deserved, with no data, science, or statistics to tell us whether the scientists featured in her article were in fact representative of the general situation. Begley’s article caught flak from others, including Mike the Mad Biologist and our very own Steve Novella. Naturally, as the resident cancer surgeon and researcher, I had thought of weighing in, but other issues interested me more at the time.
In retrospect, I rather regret it, given that this issue crops up time and time again. In essence, it’s a variant of the lament that pops up in the press periodically, when science journalists look at survival rates for various cancers and ask why, after nearly 40 years, we haven’t yet won the war on cancer. Because of his youth, Tim probably hasn’t seen this issue crop up before, but, trust me, every couple of years or so it does. Begley’s article and the NYT article strike me as simply “Why are we losing the war on cancer?” 2009 edition.
Now the New York Times has given me an excuse both to revisit Begley’s article and discuss yesterday’s front page article in the NYT Grant System Leads Cancer Researchers to Play It Safe. Basically, they are variants of the same complaints I’ve heard time and time again. Now, don’t get me wrong. By no means am I saying that the current system that the NIH uses to determine which scientists get funded. Those who complain that the system is often too conservative have a point. The problem, all too often, however, is that the proposals for how to fix the problem are usually either never spelled out or rest on dubious assumptions about the nature of cancer research themselves.
Sharon Begley’s lament: Those nasty scientists hinder translational research
Earlier this month, Begley produced an article that, quite frankly, annoyed the crap out of me, called From Bench To Bedside: Academia slows the search for cures. It never ceases to amaze me how some pundits can take an enormously flawed idea as to why a problem exists and run right off the cliff with it.
Begley begins by pointing out that President Obama has not yet appointed a Director of the NIH. That’s a fair enough criticism. Personally, I’m not happy that there’s no permanent NIH Director yet. I’d like to think, as Begley hopes, that it’s because Obama realizes how important this pick is and wants to get it right. But that’s about all I agree with Begley on. After that introduction, she runs straight off the cliff:
NIH has its work cut out for it, for the forces within academic medicine that (inadvertently) conspire to impede research aimed at a clinical payoff show little sign of abating. One reason is the profit motive, which is supposed to induce pharma and biotech to invest in the decades-long process of discovering, developing and testing new compounds. It often does. But when a promising discovery has the profit potential of Pets.com, patients can lose out. A stark example is the work of Donald Stein, now at Emory University, who in the 1960s noticed that female rats recovered from head and brain injuries more quickly and completely than male rats. He hypothesized that the pregnancy hormone progesterone might be the reason. But progesterone is not easily patentable. Nature already owns the patent, as it were, so industry took a pass. “Pharma didn’t see a profit potential, so our only hope was to get NIH to fund the large-scale clinical trials,” says Stein. Unfortunately, he had little luck getting NIH support for his work (more on that later) until 2001, when he received $2.2 million for early human research, and in October a large trial testing progesterone on thousands of patients with brain injuries will be launched at 17 medical centers. For those of you keeping score at home, that would be 40 years after Stein made his serendipitous discovery.
Whenever I see a story like this, I always wonder exactly why it took so long to move an idea from concept to clinical trial to clinical use. Indeed, recently John Ioannidis (who is most famous for an article a couple of years ago entitled Why Most Published Research Findings Are False, which Steve blogged about at the time it was first published) published a study that showed that it takes between 14 and 44 years for an idea to make it “from bench to bedside.” In any case, when in doubt, do a PubMed search to see what the person describing his research has published. So I did just that for Dr. Stein. He has a healthy publication record (162 publications), as well as a number of publications from the late 1960s on brain injury in rodent models. Clearly, Dr. Stein has been a successful and well-funded rsearcher. However, when I searched his name and “progesterone,” I didn’t find a single publication until 2006. So I dug a little deeper, and the first paper I could find by him postulating a sex difference in healing after head injuries was published in 1987. In 1986, he coauthored a review in Nature on the pharmacological attenuation of brain injury after trauma, and didn’t once mention progesterone. The point here is not to cast doubt on Dr. Stein’s contention that he first noticed this finding in the 1960s, but rather to point out that it’s hard for me not to wonder whether this particular line of research was a high priority in his career, because he doesn’t appear to have published on it for 20 years and didn’t really start doing a lot of work on it until the last few years, with a flurry of interesting publications since 2006.
The other point is, as I have said time and time again, that a scientist can’t just go to human studies (unless, of course, one believes animal rights activists who deny that animal research contributes anything to medical advancements). There has to be solid preclinical evidence. In other words, there has to be a lot of cell culture, biochemical, and animal work that all support your hypothesis, and it can take a minimum of several years to develop that evidence. Medical ethics and the Helsinki Accord demand it. Moreover, the sort of preclinical work that would have been needed to lay the groundwork for clinical trials of progesterone as a neuroprotective agent in trauma is exactly the sort of research that the NIH has funded all these years. One wonders why Dr. Stein, who clearly has a well-funded lab, didn’t divert a bit of that funding earlier to do some pilot experiments to use to pursue NIH funding. Maybe he didn’t have enough extra funds lying around or couldn’t find a way to relate the project to one of his existing projects sufficiently to justify doing so. In any case, at the risk of sounding too harsh, I will say that the whole big pharma thing struck me as very self-serving. Whatever the case was, I strongly suspect that the full story is far more complicated than the “big pharma won’t fund it because it can’t patent it” hyperbole that Begley is laying down (and that sounds very much like the same sorts of excuses purveyors of “natural” therapies use to justify why they don’t do any research to show that their “cures” work).
But that’s not what irritated me the most about Begley’s article. This is:
The desire for academic advancement, perversely, can also impede bench-to-bedside research. “In order to get promoted, a scientist must publish in prestigious journals,” notes Bruce Bloom, president of Partnership for Cures, a philanthropy that supports research. “The incentive is to publish and secure grants instead of to create better treatments and cures.” And what do top journals want? “Fascinating new scientific knowledge, [not] mundane treatment discoveries,” he says. Case in point: in research supported by Partnership for Cures, scientists led by David Teachey of Children’s Hospital of Philadelphia discovered that rapamycin, an immune-suppressing drug, can vanquish the symptoms of a rare and sometimes fatal children’s disease called ALPS, which causes the body to attack its own blood cells. When Teachey developed a mouse model to test the treatment, he published it in the top hematology journal, Bloodin 2006.
A brief aside: Wow. Surgeon that I am, I didn’t know that Blood was such a top tier journal. The reason I’m amazed is that I published in Blood last year. If Blood will take one of my manuscripts, it can’t be that awesome, can it? (Cue false modesty.) Now, back to Begley:
But the 2009 discovery that rapamycin can cure kids with ALPS? In the 13th-ranked journal. The hard-core science was already known, so top journals weren’t interested in something as trivial as curing kids. “It would be nice if this sort of work were more valued in academia and top journals,” Teachey says. Berish Rubin of Fordham University couldn’t agree more. He discovered a treatment for a rare, often fatal genetic disease, familial dysautonomia. Given the choice of publishing in a top journal, which would have taken months, or in a lesser one immediately, he went with the latter. “Do I regret it?” Rubin asks. “Part of me does, because I’m used to publishing in more highly ranked journals, and it’s hurt me in getting NIH grants. But we had to weigh that against getting the information out and saving children’s lives.”
Let’s boil down Begley’s thesis here. The cool basic science stuff appeared in the top hematology journal, but the first report of the application of that basic science to treat patients appeared in only in the 13th-ranked journal. Obviously journals value basic science over clinical science! Those bastards! They don’t care about curing children! To them curing kids is “trivial.”
Begley seems blissfully ignorant of two things: How journal rankings work and the fact that different scientific journals fill different niches. Ranking of scientific and medical journals are in general based on something called the “impact factor” (IF). The IF is often used as a proxy for the importance of a journal in its field, with the higher the IF number the better. Although the algorithm that determines the IF is proprietary, it is calculated based on a two-year period and is based on the average number of citations in a year given to papers in a journal published during the two preceding years. In general, higher IF journals are viewed as more desirable to publish in. Thus, what makes the IF a proxy for a journal’s importance is the presumption that more citations of its articles equates to more interesting science and novel findings that more scientists cite. This may or may not be a valid assumption. Finally, one aspect of the IF is that journals designed for a more general readership tend to have higher IFs than subspecialty journals. In other words, Cell, Nature, and Science have high IFs. Within a field, Cancer Research or Clinical Cancer Research has a higher IF than Breast Cancer Treatment and Research.
Here’s where niches come in. Different journals have different niches. For example, the example mentioned by Begley, Blood, is not primarily a clinical journal. True, it does publish some clinical trial results, but its main emphasis is clearly on basic and translational research. It’s simply silly to get all worked up because Blood didn’t publish a small pilot study with six patients and conclude that journals don’t value clinical research. They do, just not journals that are primarily basic and translational science journals. Publishing clinical trials is not their raîson d’être. However, I think I know why Teachey’s second study was not viewed as being interesting as his first study. A mouse model that provided proof of principle that rapamycin can treat a rare blood condition, complete with scientific mechanism is indeed interesting for a wide range of researchers, basic science, translational, and clinical. A small pilot study tends to be less so.
Let’s look at Teachey’s BJH article. It’s a nice study, but clearly a very preliminary pilot study. Such pilot studies do not generally make it into the top tier journals, no matter how interesting the science is, because, well, they’re so preliminary and small (and thus could be wrong). Begley seems to think that not considering such studies as being top tier is akin to considering curing children of deadly diseases to be “trivial.” She also seems to think that not placing such a study in a top tier journal will fatally delay the application of such cures. However, no treatment is going to be approved on the basis of such a small pilot study; at a minimum, a larger phase II study would still have to be done, and that is the study that would be likely to show up in the higher tier journals, particularly if it was well-designed to include some cool correlative science studies that confirmed the mechanism in humans. In either case, Begley doesn’t make a good case that Teachey’s study’s not being published in Blood has somehow delayed the fruits of his research from reaching sick children. Much work still needs to be done before Teachey’s discovery becomes common practice.
Begley is closer to the mark (albeit still exaggerating) when she discusses how the importance of IFs can distort how and where scientists decide to publish. In brief, scientists tend to want to publish in the highest impact journals because articles in such journals are viewed as being more meaningful than in lesser journals. Where she goes off the mark is her assumption that it is those horrible basic scientists, with their insistence on knowing molecular mechanisms that keep clinical research in the ghetto of lower tier journals, are somehow keeping teh curez from teh sick babiez!!!! (Sorry. I’ll try to restrain myself from using LOL Cat-speak.) For instance, after lionizing Berish Rubin for having chosen to publish in the lesser journal rather than keep teh curez from teh babiez (oops, I did it again), she castigates an unnamed scientist:
Not all scientists put career second. One researcher recently discovered a genetic mutation common in European Jews. He has enough to publish in a lower-tier journal but is holding out for a top one, which means identifying the physiological pathway by which the mutation leads to disease. Result: at least two more years before genetic counselors know about the mutation and can test would-be parents and fetuses for it.
This is so vague as to be useless. “A genetic mutation common in European Jews”? What mutation? What is the significance of this mutation in carriers? To what disease or defect does it predispose? Begley doesn’t say. I realize she’s probably doing so in order not to give a huge clue as to who this evil careerist scientist who doesn’t care about patients may be, but without that information I have no idea whether this discovery is so potentially important to patients that delaying its publication until he figures out how this mutation does its dirty work is unconscionable. Clearly Begley seems to think so, but there’s nowhere near enough information in her column for me to hazard even a wild guess. Validating a new genetic mutation as a risk factor to the point of developing a reliable screening test for it is an incredibly difficult task, requiring epidemiology and clinical trials to confirm the basic science. The process of FDA approval for a new genetic test is not trivial. In any case, all we’re left with is a bunch of self-serving anecdotes to support her dislike of basic science.
There’s a deeper problem, though, with Begley’s essay. Having both an MD and a PhD and doing translational research myself, I think I have some perspective on this. The problem is that Begley seems to buy into the Magic Bullet model of scientific progress, a.k.a. the “big breakthrough.” While it’s true that big breakthroughs so sometimes occur (think Gleevec, for instance), the vast majority of science and scientific medicine is incremental, each new advance being built upon prior advances. It’s also very frequently full of false starts, dead ends, and research that looks promising at first and then peters out. If a big breakthrough could be conjured by willpower and risky research, we’d have the cure for cancer by now. These disease processes are incredibly complex, and sometimes the research to understand and treat them are even more complex.
But it’s more than that. Begley may have a point when she mentions that clinical researchers are often stymied when their their grants are reviewed by basic scientists, but I can tell you that this goes both ways. If you’re a basic scientist and want to get funded by the NIH, your project had better have a practical application to human disease. Just studying an interesting biochemical reaction or a fascinating gene because it is fascinating science is not enough. If you can’t show how it will result in progress towards a treatment for a disease, it is incredibly unlikely that your grant will be funded by the NIH.
Discoveries can’t be mandated or dictated, no matter how much Begley seems to think that just changing the emphasis of the NIH to more translational research or funding riskier projects would do it. Again, don’t get me wrong; there’s no doubt that the NIH has often been far too conservative in what grants it funds, and that risk averseness becomes worse the tighter its budget gets and the tighter the paylines it can fund. However, the NIH is also the steward of taxpayer money. Fund too many risky projects, and it is likely that nothing will come of the vast majority of them. As in everything, there needs to be balance. Ideally there should be a portfolio of research that is balanced between the solid, but not radical, science that is likely to reliably lead to incremental progress and riskier projects with a higher potential payoff but a much higher risk of producing nothing.
This is a perfect point to segue to yesterday’s NYT article, which takes a different perspective on the same old complaint but still manages to fail to avoid many of the same pitfalls.
The New York Times: Are researchers “playing it too safe”?
The NYT article, written by Gina Kolata, comes at the question of how the NIH funds research and what research is done in our academic medical centers from a different viewpoint than Begley. Kolata argues that the system is broken but sees the answer not in the sort of clinical research and comparative effectiveness research beloved by Begley, which in her ideal world would rapidly translate basic science findings into treatments and new tests, but in another mantra that seems to be going around, namely “high impact” research, which, we’re told piously and solemnly, we are not doing nearly enough of because the NIH doesn’t encourage it or fund it. Indeed, whenever I see an article entitled something like Grant System Leads Cancer Researchers to Play It Safe, I know exactly how it’s going to start, and this article follows the playbook almost exactly:
Among the recent research grants awarded by the National Cancer Institute is one for a study asking whether people who are especially responsive to good-tasting food have the most difficulty staying on a diet. Another study will assess a Web-based program that encourages families to choose more healthful foods.
Many other grants involve biological research unlikely to break new ground. For example, one project asks whether a laboratory discovery involving colon cancer also applies to breast cancer. But even if it does apply, there is no treatment yet that exploits it.
The cancer institute has spent $105 billion since President Richard M. Nixon declared war on the disease in 1971. The American Cancer Society, the largest private financer of cancer research, has spent about $3.4 billion on research grants since 1946.
Yet the fight against cancer is going slower than most had hoped, with only small changes in the death rate in the almost 40 years since it began.
Again, I’m not saying that it’s ridiculous to question why all that money and all these breakthroughs have not made a greater impact on cancer mortality than they have. On the other hand, there is a false premise in the whole question. Specifically, there is an unspoken assumption that “riskier” research is inherently more likely to result in “breakthroughs” than the more incremental model of building on previous results. The expectation is that all of that money should have produced “blockbusters” that make huge dents in cancer mortality. Unfortunately, science and biology are hard. They conspire to frustrate even the most ambitious wishes for cures, whether they come from scientists, politicians, or journalists reworking a tired old script yet another time. It also disturbs me to see the clearly derogatory tone directed at the study of diet and health, which, quite frankly, seems at odds with the argument that the NIH doesn’t spend enough on research into diet, exercise, and prevention, which by its very nature tends to consist of studies of this sort which are highly unlikely to produce anything other than incremental results leading to incremental improvements to our knowledge of how to use diet as a tool to prevent disease. Quite frankly, research of this nature isn’t viewed as being as “sexy” as the sort of research Kolata thinks we should be doing more of. After all, it doesn’t involve new genes, new proteins, or novel science, but rather deals with the application of what we have known for decades.
Let’s get to the crux of the article:
“These grants are not silly, but they are only likely to produce incremental progress,” said Dr. Robert C. Young, chancellor at Fox Chase Cancer Center in Philadelphia and chairman of the Board of Scientific Advisors, an independent group that makes recommendations to the cancer institute.
Again, note the contempt for such projects. “These grants are not silly”? Talk about damning with faint praise! But I digress. Let’s get back on track:
The institute’s reviewers choose such projects because, with too little money to finance most proposals, they are timid about taking chances on ones that might not succeed. The problem, Dr. Young and others say, is that projects that could make a major difference in cancer prevention and treatment are all too often crowded out because they are too uncertain. In fact, it has become lore among cancer researchers that some game-changing discoveries involved projects deemed too unlikely to succeed and were therefore denied federal grants, forcing researchers to struggle mightily to continue.
Here we go again. Everything old is new again. This is the very same complaint that pops up periodically. Again, I’m not saying that it doesn’t have merit, only that it tends to be made in the absence of any hard evidence that (1) innovative ideas don’t eventually get funded and (2) that funding “riskier” ideas will inevitably lead to more home runs (more on this later). Also, very conveniently, this sort of complaint always seems to pop up the most in lean times. Indeed, I remember back when I was a graduate student in the early 1990s (when Tim was in grade school). That is the last time the funding situation got as bad as it has been at the NIH for the last few years, and I remember reading articles very similar to this one. Inevitably, tight fiscal times appear to lead to a sort of funding conservatism for exactly the reason above: The NIH doesn’t want to risk precious grant funds on projects that are too risky.
As evidence of this problem, does Kolata dig into the grants system and try to put together data showing that conservative funding policies are leading to the shutting out of game-changing research? What do you think? Of course not! Instead she relies, just as Begley did, on anecdotes from scientists who produced great work but were not funded initially. First up in the anecdote parade is Dennis Slamon. Personally, I admire Dr. Slamon’s work greatly. Through science and determination, he truly did change breast cancer therapy, and for the better. Specifically, he is the person who developed trastuzumab (trade name: Herceptin); i.e., a humanized monoclonal antibody against the HER-2/neu oncoprotein, which was discovered by Robert Weinberg’s group in 1984. HER-2 in general portends poorer prognosis and is generally a marker for more aggressive cancers with lower survival rates with conventional therapy. The reason is that HER-2 encodes a cell surface receptor that is a member of the epidermal growth factor receptor family. When it is amplified, as it is in approximately 22% of human breast cancers, its activity can result in increased cell proliferation, cell motility, tumor invasiveness, a higher likelihood of regional and distant metastases, accelerated angiogenesis, and reduced apoptosis. All of these are bad things. Consistent with this biological effect, HER-2 amplification, the presence of HER-2 amplification correlates with nastier appearing tumors on histology, decreased disease-free survival, increased metastasis, and decreased overall survival. Indeed, for overall survival and disease-free survival, the relative risk of death for women with HER-2-positive cancer versus HER-2-negative cancer is in the 1.8 to 2.7 range. In other words, women with HER-2-positive breast cancer are more than two times more likely to recur and die of their disaease.
It is also true that the addition of Herceptin, which blocks the HER-2 receptor, to standard chemotherapy of HER-2-containing cancers improves the prognosis in women with such cancers, although Kolata overstates how much it does so. For all its usefulness, Herceptin is not a magic bullet; it is not a cure. Indeed, the original phase III trial reported in the New England Journal of Medicine in 2001 found that in patients with HER-2-postive metastatic breast cancer, the addition of trastuzumab to conventional chemotherapy resulted in a longer time to disease progression (median, 7.4 versus 4.6 months; p < .001), a higher response rate (50% versus 32%; p < .001), a longer duration of response (median, 9.1 versus 6.1 months; p < .001), and an increase in median survival from 20.3 months to 25.1 months (p=0.008). Consistent with this, the addition of Herceptin resulted in a 20% lower risk for death. These are all very good things, but not a cure.
In Kolata’s article, Slamon complains that he had difficulty getting the NIH to fund his studies and that it took a grant from Revlon for him to continue his research. His story is a bit too convenient, as a perusal of the Internet using my mad Google skillz found that the story is a bit more complex than what Kolata tells. Indeed, a made-for-TV movie about Slamon and Herceptin aired on Lifetime in 2008 called Living Proof, which was based on a book by Robert Bazell called HER-2: The Making of Herceptin, A Revolutionary Treatment for Breast Cancer, tells a more complex story than just the NIH’s not funding his research. For example, this passage from a review of Bazell’s book is illuminating:
Then, another stroke of dumb luck occurred in 1986. Ullrich accidentally met Dennis Slamon in a Denver airport. Slamon, a practicing oncologist at UCLA’s Jonsson Cancer Center, is a dogged and devoted cancer researcher. Throughout the next 2 years, Slamon and Ullrich pursued the hypothesis that HER-2 neu played a role in the growth of breast and ovarian cancers. By 1987, they published their results, which suggested that cancers overexpressing HER-2 are more likely to recur and spread more quickly.
But could their work be reproduced and their conclusion be confirmed? More delays ensued as their colleagues failed to reproduce their experiment. These delays were dumb bad luck. Two long years later, Slamon and Ullrich proved that the failure to reproduce their work was due to the “use of contaminated chemicals, faulty techniques, and idiotic mistakes by the laboratories conducting the experiments.”
By 1988, Slamon and Ullrich looked to Genentech for support to take their promising experiment to the next level of development. Support was not forthcoming. Genentech was no longer focused on cancer drug development. Their oncology staff had been disbanded following the unsuccessful interferon-alfa trials.
Herceptin’s development languished until more dumb luck occurred. In late 1989, the mother of a senior Genentech vice president was diagnosed with breast cancer. “Just like that, one man flipped the switch on HER-2″ and convinced his colleagues that HER-2 was worth Genentech’s investment. Again, and not for the last time, an unexpected player would rescue Herceptin.
It’s just sloppy reporting not mention this background and simply buy into the image of the “brave maverick doctor” whose work wasn’t appreciated by the NIH. Why did the NIH decide not to fund Slamon’s work? Without seeing the pink sheets (the summary statement that all applicants for a grant receive containing reviewers’ evaluations of the grant appplication), it’s impossible to know for sure. In the absence of having read Bazell’s book, however, I can still speculate a bit, at the risk of looking foolish. If, for example, Slamon and Ullrich (the latter of which was a Genentech scientist) had submitted their HER-2 grants around the time other researchers were having difficulty duplicating their results, the reviewers at the NIH study section responsible for reviewing Slamon’s grants would almost certainly have known about it. Moreover, if a pharmaceutical company had been developing Herceptin, it is possible that reviewers would have been less enthusiastic about it, wondering quite reasonably why the NIH should fund the development of this drug if Genentech would no longer do so. As much as I love a story of a scientific maverick overcoming the hidebound system (why else would Judah Folkman be one of my scientific heroes?), I’m not sure that Slamon’s case represents as pure an example of such a scientist as this article would have you believe. (Maybe I should get a copy of Bazell’s book and read it.)
It’s also rather odd that Kolata would focus on Slamon first. It is true that Herceptin represents the first successful example of a molecularly targeted therapy for breast cancer. (Well, not quite. One could equally well argue that the anti-estrogen drug Tamoxifen, which blocks the proliferative effect of estrogen due to its binding with its receptor, were the first.) However, only 20% of women with breast cancer can be expected to benefit from it, and it is an incredibly expensive drug, and it is not without its toxicities, the worst of which is toxicity to the heart, which precludes its use in many women with heart disease. In any event, the high cost of Herceptin (several thousand dollars a month, with the usual duration of treatment for breast cancer being one year). Indeed, when research suggested a benefit for extending the use of Herceptin for adjuvant therapy against early stage tumors, in contrast to its initial uses in more advanced tumors, some European governments balked at the cost.
Two more anecdotes follow, which are more interesting but less convincing, namely because we don’t have the benefit of history to tell us that the investigator was definitely on to something, as we do with Dennis Slamon. Because one of the researchers whose anecdote is told didn’t even bother to try to apply to the NIH for funding because he figured it wouldn’t be fundable. Whether he’s right or wrong, who can tell? Instead, I’ll concentrate on the other anecdote, that of Eileen K. Jaffe of Fox Chase Cancer Center:
When Dr. Jaffe stumbled upon results that went against textbook explanations, suggesting that it might be possible to find an entirely new class of drugs that could disable proteins that fuel cancer cells. Now she wants to find chemicals that might be developed into such drugs.
But her grant proposal was rejected out of hand by the institutes of health, not even discussed by a review panel. She had no preliminary data showing that the idea was likely to work, something reviewers always want to see, and the idea was just too unprecedented.
And this is not the least bit unreasonable, if indeed her idea was that novel. Indeed, even Dr. Jaffe acknowledges this:
Dr. Jaffe is just conceiving her project; it is much to soon to know whether it will result in a revolutionary drug. And even if she does find potential new drugs, it is not clear that they will be effective. Most new ideas are difficult to prove, and most potential new drugs fail.
So Dr. Jaffe was not entirely surprised when her grant application to look for such cancer drugs was summarily rejected.
“They said I don’t have preliminary results,” she said. “Of course I don’t. I need the grant money to get them.”
Actually, that’s not quite true. It is, for example, close to true for the gold standard of NIH grants, the R01. These grants generally provide around $150,000 to $250,000 a year for three to five years to fund a project, and it is usually about these grants that most of the complaints are made. That’s because reviewers do tend to be pretty conservative about such grants. The reason is that these grants provide a lot of money for a lot of years and can be renewed at the end of each grant through a process known as competitive renewal, in which the investigator reports on the progress made in the previous grant period and proposes where he wants to go over the next five years. In other words, an R01 is a huge commitment, and, again not unreasonably, reviewers want to see a lot of preliminary data to suggest that the project is feasible and likely to produce results that improve our understanding of a disease and lead to strategies for therapy. It’s exactly the sort of grant mechanism designed to look at a question like this one described in the article:
In the study asking whether a molecular pathway that spurs the growth of colon cancer cells also encourages the growth of breast cancer cells, the principal investigator ultimately wants to find a safe drug to prevent breast cancer. She received a typical-size grant of a little more than $1 million for the five-year study.
The plan, said the investigator, Louise R. Howe, an associate research professor at Weill Cornell Medical College, is first to confirm her hypothesis about the pathway in breast cancer cells. But even if it is correct, the much harder research would lie ahead because no drugs exist to block the pathway, and even if they did, there are no assurances that they would be safe.
I actually agree to some extent with Kolata’s thesis, namely that much of the grant funding at the NIH is too conservative and that the NIH should find a way to fund more innovative and “risky” grants. Indeed, I tend to approve of various initiatives to fund innovative research, such as “pioneer awards,” which are designed to fund research examining “ideas that have the potential for high impact but may be too novel, span too diverse a range of disciplines or be at a stage too early to fare well in the traditional peer review process,” and the so-called “transformative R01 grants” for “proposing exceptionally innovative, high risk, original and/or unconventional research with the potential to create or overturn fundamental paradigms.”
One difference between me and those calling for reform of the NIH grant process is that I openly admit that I don’t have any data to support my bias that the current system is too conservative and that a way needs to be found to fund more innovative (or at least different) research. What bothers me is that neither Begley, Kolata, nor any of the scientists interviewed by both of them seem able to present any hard data or science to support their bias either. They believe that funding more risky projects will result in better payoffs than sticking with the slow march of incremental science. They have anecdotes of scientists whose ideas were later found to be validated and potentially game-changing who couldn’t get NIH funding, but how often does this really happen? The vast majority of “wild” ideas are considered “wild” precisely because they are new and there is no good support for them. Once evidence accumulates for them, they are no longer considered quite so “wild.” More importantly, we are looking through what we doctors like to call the “retrospectoscope,” which, as we say, always provides 20-20 vision. We know today that the scientists whose anecdotes of woe describing the depradations of the NIH were indeed onto something. How many more proposed ideas that seemed innovative at the time but ultimately went nowhere?
We don’t know.
We also don’t know exactly how the NIH would choose between so many “risky” projects. Sanjay Srivastava, writing about the NYT article, asks an excellent question:
The practical problem is that we would have to find some way to choose among high-risk studies. The problem everybody is pointing to is that in the current system, scientists have to present preliminary studies, stick to incremental variations on well-established paradigms, reassure grant panels that their proposal is going to pay off, etc. Suppose we move away from that… how would you choose amongst all the riskier proposals?
People like to point to historical breakthroughs that never would have been funded by a play-it-safe NCI. But it may be a mistake to believe those studies would have been funded by a take-a-risk NCI, because we have the benefit of hindsight and a great deal of forgetting. Before the research was carried out — i.e., at the time it would have been a grant proposal — every one of those would-be-breakthrough proposals would have looked just as promising as a dozen of their contemporaries that turned out to be dead-ends and are now lost to history. So it’s not at all clear that all of those breakthroughs would have been funded within a system that took bigger risks, because they would have been competing against an even larger pool of equally (un)promising high-risk ideas.
In other words, a lot of the current crop of criticisms of the way the NIH selects grants of the sort put forth by the NYT rest on a large measure of selective memory and confirmation bias. Science that is successful is remembered; proposals that go nowhere are lost to the mists of time. Scientists whose work was later validated after the NIH didn’t fund it are remembered and make good press copy. The many more scientists whose work wasn’t funded and went nowhere aren’t.
Moreover, it’s easy to make grand claims that all that nasty preliminary data isn’t necessary, that we should fund “plausible” studies that sound promising. However, it is the preliminary data supporting them that turn studies from speculative to plausible. Without that data, the possibilities are virtually endless, with little to distinguish truly plausible proposals from interesting but implausible ideas.
Of course, given that the conservatism of the NIH grant process always tends to be more of a complaint when funding is tight, I could envision a way of testing the hypothesis that funding more “risky” research results in more breakthroughs. It would be imperfect, but it might provide enough evidence to justify further exploration of this idea. Specifically, I’m referring to the period from fiscal year 1998 to 2003, during which the NIH budget, thanks to bipartisan support, doubled. The NIH could look at funding data from that period and ask some questions:
     1.  Were more “risky” grants funded?
     2.  What was the result of those grants?
     3.  Were “riskier” grants more or less likely to result in new treatments that impacted the survival of cancer patients?
I realize that it would be difficult to come up with measurements to answer such questions that would be truly objective, but even imperfect data on this score would be better than what we have now, which is in essence no data. Or, at least if there is such data, I couldn’t find it. Perhaps that’s because the assumption that more “innovative” research must be needed because we haven’t impacted cancer survival rates as much as we think we should have during the last 37 years, which means we need more innovative research. Circular reasoning at its finest, at least without some hard data. Given that what happened in response to the doubling of the NIH budget was in essence a spending spree that attracted more applications than ever to the NIH and spurred more building of research facilities by universities, I rather suspect that such a study would not show what proponents of altering how the NIH decides what research to fund would want it to show.
The symptom or the disease?
Blogger Mike the Mad Biologist has asked on two occasions, first in response to the NEWSWEEK article and then in response to this NYT article: Are these critics mistaking the symptom for the disease? As Mike points out, the problem goes beyond funding levels. Rather, it is incentives. It is where the money goes and what is funded. On that score, the NIH is profoundly schizophrenic these days. The sorts of promising high risk proposals do not in general come from large, multi-institutional, collaborative groups. There are too many interests, and such groups tend to have too much at stake to take many risks. The very sort of researcher who will propose the risky projects that all these reformers is the small, independent researcher funded by an R01. Yet, what has the NIH been shifting its funds to lately??
Big science. Large projects. Walter Boron put it well in a commentary in Physiology three years ago:
But there is still one more piece to the pay-line puzzle: the allocation of NIH dollars, sometimes mandated by Congress, and often following the advice of committees of independent investigators. The fraction of the NIH budget devoted to research by independent investigators (Table 1) steadily fell from 1998 to 2003. Conversely, spending for other programs including “big science”—the sequencing of genomes, clinical trials, and other costly and lengthy projects—steadily rose. Where does one draw the line between shifting funds to big science and yet maintaining a healthy portfolio of independent-investigator research? When the NIH is afloat in money (e.g., pay lines 25th percentile for research by independent investigators), such a shift may make sense. An example is the sequencing of the human genome, which has been invaluable. But what about sequencing the squid genome, which I personally would love to see? Before addressing this question, let us examine the value of investigator-initiated research and the dangers of interrupting it for even a couple of years.
The scientific engine that drives translational research—and that drives big science as well—is the independent investigator. It is the independent investigator who trains the next generation of researchers. Moreover, discoveries almost always come about when bright independent investigators stumble over unexpected findings and then sort them out. Such stumbling is unpredictable. The bigger the discovery, the more unpredictable. As unnerving as it may seem, the best way to invest in discovery is to fund the best independent investigators and turn them loose to stumble.
Of course, Dr. Boron doesn’t really have any data to support his thesis, either, but he does illustrate the conflict between “big science” and the innovation that NIH reformers are pushing for. Also, if anecdotal evidence counts, then let me place my own personal anecdote on the table. One of the two projects I’m working on now came about from a completely serendipitous discovery on the part of my collaborator, who pursued a completely unexpected observation. Based on that discovery, the NIH has funded two R01s, and the ASCO Foundation has funded me. Based on my anecdote, the NIH must fund risky and innovative research.
Yes, two can play at the anecdote game.
All snarkiness aside, though. One problem is that the public has a rather distorted view of how science works. Science generally does result in incremental progress. Sometimes, there are even periods of stagnation, during which, or so it seems, very little is discovered and few advances made. Breakthroughs, such as the discovery of HER-2 are much less common than the gradual accumulation of knowledge and understanding that builds on what has been done before. Indeed, even a breakthrough like HER-2 was built on what came before, as Dennis Slamon’s work could not have occurred were it not for Robert Weinberg, who discovered HER-2 in the first place.
I think that the issue is better put by Wafik el-Deiry, the physician-scientist who discovered p21WAF1/CIP1 a very important cell cycle regulator whose expression p53 activates. What I consider to be cool about Dr. el-Deiry is that he’s on Twitter, where he Tweeted in response to the NYT article:
The major advances in cancer research have come from basic research without expectations of immediate impact on patients’ lives
And followed up with this Tweet:
Yes, I worry about change that may set us back by putting less value on basic science & more on hi risk pie in the sky
I agree and share Dr. el-Deiry’s concern. Oncogenes, tumor suppressor genes, HER-2, intracellular signaling molecules, all of these and more were discovered by basic scientists working because they simply wanted to know how cells work and what goes wrong to turn them cancerous. What I worry about is that, in the rush to fund more “innovative” and “translational” research, basic science will be left out. Why this worries me is that, without basic science, there can be no translational science. Translational research depends upon a constant flow of new observations and new discoveries in basic science.
More importantly, it can’t be predicted where those new discoveries will come from. Sometimes they come right out of left field, like the aforementioned project I’m working on now, which resulted from a serendipitous discovery by my collaborator and has the potential to result in a great new treatment for not just breast cancer but melanoma as well. It was not the sort of discovery that could have been foretold, and it may never have been noticed if it hadn’t been for a basic scientist following curiosity where it led. In any case, those who advocate for funding more “risky” research must have a lot of faith in current scientists who serve on NIH study sections to identify what proposals are truly innovative. I’m not sure I share that faith. In fact, I’m sure that I don’t. At the risk of belaboring the point, I will repeat that many breakthroughs could not have been identified in a research proposal beforehand. Moreover, it can’t be emphasized enough that translational research depends upon a steady stream of interesting science from the laboratories of basic scientists. Dry up that stream, and translational research will slow to a crawl.
That’s why, going back to the baseball-inspired title of this post, I would argue that no radical overhaul of how the NIH distributes grants is necessary. Rather, the portfolio of research funded by the NIH needs to be better balanced than it is now. Just like a good hitting lineup, the NIH research portfolio needs the right mix of “hitters,” including the high average hitters who tend to hit nearly all base hits (“safer science” proposals); the clever utility hitters, who make things happen by putting the ball in play a lot by various methods, such as bunting, little bloopers, line drives (the more eclectic proposals who can span multiple disciplines); and the sluggers who can hit the ball out of the park but tend to strike out a lot (high risk, high payoff proposals). Finding the right mix is difficult, and there will naturally be disagreement over what the “sweet spot” is. Indeed, what constitutes that “sweet spot” could very well change over time. Right now, it’s probably true that the NIH has a lineup that’s too full of bunters and base hit hitters, although we shouldn’t forget that a lineup full of such hitters can still score a lot of runs. It’s just that a slugger or two who can hit the occasional grand slam can result in even more runs, if placed in the correct place in the lineup. The risk is that the NIH has to be careful not to end up with a lineup of home run hitters who strike out a lot without getting anyone on.
I fear that’s what we’ll end up with, though. I also have to wonder whether, if critics got their way and the NIH were to put a lot more money into funding “high risk studies,” there would be so many failures that the press would suddenly start saying, as Sanjay put it, “Grant System Funds Too Many Dead Ends.” And, no doubt, Sharon Begley would still be be complaining about the NIH not funding enough clinical research and that it’s still devaluing clinical research.
ADDENDUM:
An excellent discussion of the NYT article can be found here (and is well worth reading in its entirety). In it, Jim Hu did something I should have done, namely check the CRISP database in addition to PubMed. A couple of key points follow about the examples cited in the NYT article.
Regarding Dennis Slamon:
I hate to criticize Dennis Slamon, because the HER2 to Herceptin story is a great one. But the image one gets of his research program being saved by a friend from Revlon while the NCI ignored him isn’t consistent with what you get when you search for his grants in the CRISP database. Slamon got an NCI grant in 1984 to work on “oncogenes in physiologic and pathologic states”. Two NCI grants are cited in the 1987 Science paper showing HER-2 amplification in breast cancer (one was probably for the collaborator’s lab), and he’s been pretty continuously funded by NCI since then. So I’d love to know what this story applies to.
Me too. Regarding Ellen Jaffe:
Eileen Jaffe has studied the enzymology of porphobilinogen synthase under a 20-year multiply renewed grant from the National Institutes for Environmental and Health Sciences. Recently, she’s been working on an idea called morpheeins, which she’s patented as the basis for drug discovery. I have no idea what was in the grant, but what I see doesn’t scream “missed opportunity to cure cancer” at me.
Which was my thought, too, looking at her publication record. Finally, regarding Louise R. Howe’s studies on signaling and cancer:
The plan, said the investigator, Louise R. Howe, an associate research professor at Weill Cornell Medical College, is first to confirm her hypothesis about the pathway in breast cancer cells. But even if it is correct, the much harder research would lie ahead because no drugs exist to block the pathway, and even if they did, there are no assurances that they would be safe.
I have no idea what Kolata has against Dr. Howe’s project. The same could have been said about HER2 in 1987.
Or about any number of oncogenes and targeted therapies. Yikes! The same could be said about what I’m working on. Oh, no, that must mean I’m not sufficiently innovative for Kolata’s taste…

   Skepticism versus nihilism about cancer and science-based medicine
David Gorski
Link
Last Friday, Mark Crislip posted an excellent deconstruction of a very disappointing article that appeared in the most recent issue of Skeptical Inquirer, the flagship publication of the Committee for Skeptical Inquiry (CSI). I say “disappointing,” because I was disappointed to see SI (Skeptical Inquirer, not Sports Illustrated) publish such a biased, poorly thought out article, apparently for the sake of controversy. I’m a subscriber myself, and in general enjoy reading the magazine, although of late I must admit that I don’t always read each issue cover to cover the way I used to do. Between work, grant writing, blogging, and other activities, my outside reading, even of publications I like, has declined. Perhaps SI will soon find itself off my reading list. Be that as it may, I couldn’t miss the article that so irritated Mark, because it irritated me as well. There it was, emblazoned prominently on the cover of the March/April 2011 issue: Seven Deadly Medical Hypotheses. I flipped through the issue to the article to find out that this little gem was written by someone named Reynold Spector, MD. A tinge of familiarity going through my brain, I tried to think where I had heard that name before.
And then I remembered.
Dr. Spector, it turns out, first got on my nerves about a year ago, when he wrote an article for the January/February 2010 issue of SI entitled The War on Cancer: A Progress Report for Skeptics. I remember at that time being irritated by the article and wanting to pen a discussion of the points raised but don’t recall why I never actually did. It was probably a combination of the fact that SI doesn’t publish its articles online until some months have passed after the paper version has been released and perhaps my laziness about having to manually transcribe with my own fingers any passages of text that I might want to cite. By the time the article was available online, I forgot about it and never came back to it–until now. I should therefore, right here, right now, publicly thank Mark (and, of course, Dr. Spector) for providing me the opportunity to revisit that article in the context of piling on, so to speak, Dr. Spector’s most recent article. After all, Deadly Hypothesis Seven (as Dr. Spector so cheesily put it) is:
From a cancer patient population and public health perspective, cancer chemotherapy (chemo) has been a major medical advance.
Dr. Spector then takes this opportunity to cite copiously from his 2010 article, sprinkling “(Spector, 2010)” throughout the text like powdered sugar on a cupcake. There’s the opening I needed to justify revisiting an article that’s more than a year old! And what fantastic timing, too, hot on the heals of my post from a couple of weeks ago entitled Why haven’t we cured cancer yet?
Back to the future, before visiting the past
Before I leap back more than a year, first let me just point out that I agree with Mark 100% when he castigated Dr. Spector for his opening volley. Although thought had never occurred to me at the time, in retrospect I even agree with Crislip’s likening Dr. Spector’s tirade to a Mike Adams screed, at least in dogmatic certainty and tone. Sadly, for entertainment value at least, Dr. Spector lacks the looney hyperbole of Mike Adams. Also, unlike Adams, Dr. Spector is a real scientist, but damn if, references omitted, this first sentence couldn’t have come right out of a Mike Adams special:
A chronic scandal plagues the medical and nutritional literature (Spector and Vessell, 2006; Spector, 2009): much of what is published is erroneous, pseudoscientific, or worse.
Like Mark, I’m a John Ioannidis convert, and I accept that there is a lot of medical literature that is erroneous. (Just search for Dr. Ioannidis’ last name on this blog, and you’ll find copious posts praising him and discussing his work.) In fact, as I’ve pointed out, most medical researchers instinctively know that most new scientific findings will not hold up to scrutiny, which is why we rarely accept the results of a single study, except in unusual circumstances, as being enough to change practice. I also have pointed out many times that this is not necessarily a bad thing. Replication is key to verification of scientific findings, and more often than not provocative scientific findings are not replicated. Does that mean they shouldn’t be published?
As for pseudoscience, I’m half tempted to agree with Dr. Spector, but just not in the way he thinks. Unfortunately, over the last 20 years or so, there has been an increasing amount of pseudoscience in the medical literature in the form of “complementary and alternative medicine” (CAM) studies of highly improbable remedies or even virtually impossible ones (i.e., homeopathy). However, that does not appear to be what Dr. Spector is talking about, which is why I looked up his references. The second reference is to an SI article from 2009 entitled Science and Pseudoscience in Adult Nutrition Research and Practice. There, and only there, did I find out just what it is that Dr. Spector apparently means by “pseudoscience”:
By pseudoscience, I mean the use of inappropriate methods that frequently yield wrong or misleading answers for the type of question asked. In nutrition research, such methods also often misuse statistical evaluations.
Ah, now I get it! Dr. Spector doesn’t really know the difference between inadequately rigorous science and pseudoscience! Now, don’t get me wrong. I know that it’s not always easy to distinguish science from pseudoscience, especially at the fringes, but in general bad science has to go a lot further than Dr. Spector thinks to merit the the term “pseudoscience.” It is clear (to me, at least) from his articles that Dr. Spector throws around the term “pseudoscience” around rather more loosely than he should, using it as a pejorative for any clinical science less rigorous than a randomized, double-blind, placebo-controlled trial that meets FDA standards for approval of a drug (his pharma background coming to the fore, no doubt). Pseudoscience, Dr. Spector. You keep using that word. I do not think it means what you think it means. Indeed, I almost get the impression from his articles that Dr. Spector views any study that doesn’t reach FDA-level standards for drug approval to be pseudoscience. He also piles on nutritional science (that is, after all, his area of specialty), and there is no doubt that here is a lot of pseudoscience there; however the vast majority of it is not in the scientific literature. Rather, it’s snake oil salesmen selling diets and supplements based on less rigorous science, the willful twisting and misinterpretation of acceptable science, and making up claims out of whole cloth.
Here’s the deal. Medical science, when it works well, tends to progress from basic science, to small pilot studies, to larger randomized studies, and then–only then–to those big, rigorous, insanely expensive randomized, double-blind, placebo-controlled trials. Dr. Spector mentions hierarchies of evidence, but he seems to fall into a false dichotomy, namely that if it’s not Level I evidence, it’s crap. The problem is, as Mark pointed out, in medicine we often don’t have Level I evidence for many questions. Indeed, for some questions, we will never have Level I evidence. Clinical medicine involves making decisions in the midst of uncertainty, sometimes extreme uncertainty. One example is hormone replacement therapy for menopause before the results of the Women’s Health Initiative study were reported. Indeed, Dr. Spector makes much hay out of the widespread use of hormone replacement therapy (HRT) back in the 1980s and 1990s, as an example of what happens when we don’t adhere to proper clinical trial design, labeling Deadly Hypothesis Two as:
The hypothesis was that if women replace these hormones postmenopausally with HRT, they will remain “youthful” and not suffer from heart disease, dementia, vaginal dryness, hot flashes, and fractured bones.
Dr. Spector then proceeds to paint a picture of reckless physicians proceeding on crappy studies to pump women full of hormones. Actually, it was more than a bit more complicated on than that. That was the time when I was in my medical training, and I remember the discussions we had regarding the strength (or lack thereof) of the epidemiological data and the lack of good RCTs looking at HRT. I also remember that nothing works as well to relieve menopausal symptoms as HRT, an observation we have been reminded of again since 2003, which is the year when the first big study came out implicating HRT in increasing the risk of breast cancer (more later). It’s also hard not to point out that, these days, it’s not physicians promoting HRT. Rather, it’s women like Suzanne Somers promoting “bioidentical hormones” and telling postmenopausal women that they should strive for the estrogen levels that they had when they were 25. Be that as it may, I found a rather fascinating editorial in the New England Journal of Medicine from more than 20 years ago that discussed the state of the evidence back then with regard to estrogen and breast cancer:
Evidence that estrogen increases the risk of breast cancer has been surprisingly difficult to obtain. Clinical and epidemiologic studies and studies in animals strongly suggest that endogenous estrogen plays a part in causing breast cancer. If so, exogenous estrogen should be a potent promoter of breast cancer. Although more than 20 case–control and prospective studies of the relation of breast cancer and noncontraceptive estrogen use have failed to demonstrate the expected association, relatively few women in these studies used estrogen for extended periods. Studies of the use of diethylstilbestrol and oral contraceptives suggest that a long exposure or latency may be necessary to show any association between hormone use and breast cancer. In the Swedish study, only six years of follow-up was needed to demonstrate an increased risk of breast cancer with the postmenopausal use of estradiol. It should be noted, however, that half the women in the subgroup that provided detailed data on the duration of hormone use had taken estrogen for many years before their base-line prescription status was defined. The duration of estrogen exposure in these women before the diagnosis of breast cancer was probably seriously underestimated; a short latency cannot be attributed to estradiol on the basis of these data. Other recent studies of the use of noncontraceptive estrogen suggest a slightly increased risk of breast cancer after 15 to 20 years’ use.
One notes that, even now, the evidence is conflicting regarding HRT and breast cancer, with the preponderance of evidence suggesting that mixed HRT (estrogen and progestin) significantly increases the risk of breast cancer, while estrogen-alone HRT very well might not increase the risk of breast cancer at all or (more likely) only very little. Indeed, I was just at a conference all day Saturday where data demonstrating this very point were discussed by one of the speakers. None of this stops Dr. Spector from categorically labeling estrogen as a “carcinogen that causes breast cancers that kill women.” Maybe. Maybe not. It’s actually not that clear. The problem, of course, is that, consistent with the first primary reports of WHI results, the preponderance of evidence finding health risks due to HRT have indicted the combined progestin/estrogen combinations as unsafe. Even at this late time, we do not truly know whether estrogen-alone HRT carries significant risks (there are even some studies, a subgroup of the WHI included, that hint at a slightly protective effect of estrogen against breast cancer), but we do have a pretty good idea that estrogen-alone HRT is almost certainly safer than estrogen-progestin HRT, at least with respect to breast cancer. Unfortunately, there is good evidence that estrogen-only HRT increases the risk of uterine cancer. Either way, Dr. Spector’s dogmatic and unnuanced discussion of the issue suggests an axe to grind more than an interest in providing an accurate picture. Indeed, he even goes so far as to slip this sentence in there: “In legal challenges the U.S. Supreme Court has upheld the notion that HRT causes breast cancer.”
What? Who cares what the Supreme Court says about medical causation? That’s a legal standard, not a scientific standard! There’s no reason to throw such a sentence into a serious medical article.
The rest of the “Seven Deadly Medical Hypotheses” remain just as questionable, particularly the way Dr. Spector castigates the idea that screening populations for breast and prostate cancer saves lives. In all fairness, Dr. Spector’s skepticism towards screening is actually the least unreasonable part of his most recent article, given recent evidence. He even concludes that mammography has a small benefit. Therein lies a contradiction. If mammography, for instance, is beneficial, even if only slightly, then how can it be part of a “deadly medical hypothesis”? Calling screening a “deadly” medical hypothesis is, as is the case with much of this article, way over the top. A “disappointing” medical hypothesis would be a far better description. In any case, for a far more nuanced discussion of cancer screening, I will blow my own horn and suggest that you go to read these posts:
Posts by yours truly:
The early detection of cancer and improved survival: More complicated than most people think
Early detection of cancer, part 2: Breast cancer and MRI
Do over one in five breast cancers detected by mammography alone really spontaneously regress?
Are one in three breast cancers really overdiagnosed and overtreated?
The cancer screening kerfuffle erupts again: “Rethinking” screening for breast and prostate cancer
The USPSTF recommendations for breast cancer screening: Not the final word
The mammography wars heat up again
Molecular breast imaging (MBI): A promising technology oversold in a TED Talk?
Posts by Harriet Hall:
Screening Tests – Cumulative Incidence of False Positives
Overdiagnosis
By Val Jones:
The Mammogram Post-Mortem
Read them now, or read them later. They are far more informative and nuanced than anything Dr. Spector has written on these topics for SI. For example, you won’t find the word “deadly” in there anywhere. In the meantime, let’s move on to the article that irritated me so over a year ago. Oddly enough, it was a bit more balanced and less dogmatic than the current article.
“We’re losing the war on cancer”?
The beginning of The War on Cancer A Progress Report for Skeptics, while not as over-the-top as the beginning of Seven Deadly Medical Hypotheses, is still pretty negative:
In 1971, President Nixon and Congress declared war on cancer. Since then, the federal government has spent well over $105 billion on the effort (Kolata 2009b). What have we gained from that huge investment? David Nathan, a well-known professor and administrator, maintains in his book The Cancer Treatment Revolution (2007) that we have made substantial progress. However, he greatly overestimates the potential of the newer so-called “smart drugs.” Re searchers Psyrri and De Vita (2008) also claim important progress. However, they cherry-pick the cancers with which there has been some progress and do not discuss the failures. Moreover, they only discuss the last decade rather than a more balanced view of 1950 or 1975 to the present.
On the other hand, Gina Kolata pointed out in The New York Times that the cancer death rate, adjusted for the size and age of the population, has decreased by only 5 percent since 1950 (Kolata 2009a). She argues that there has been very little overall progress in the war on cancer.
I find it rather amusing how Dr. Spector accuses investigators like Dr. Vincent DeVita (who is a coauthor of one of the widely used textbooks of oncology there is, a copy of which sits on my shelf in my office) of “cherry picking” cancers for for which progress has been made and focusing primarily on the last decade while at the same time stating that he is going to focus on adult solid cancers, where less progress has been made. One might argue that this is a correct way to do it, and far be it from me to claim that the war on cancer has been an overwhelming success. As I pointed out a couple of weeks ago, however, there is a reason (many reasons, actually) why progress has been so elusive. There is also at least one other reason. However, it’s quite obvious in both articles that Dr. Spector has himself concentrated on data that he can use to make the situation look as dismal as possible; i.e., to support his apparently preconceived conclusions that the war on cancer has been a miserable failure and that chemotherapy doesn’t work (that is, except when it does work very well). Indeed, in his most recent article, Dr. Spector uses terminology that is even more negative about chemotherapy than in his previous article. For example in the current article, Dr. Spector writes:
The hypothesis behind current chemotherapy is deeply flawed. How can we expect these drugs, most of which are nonspecific cellular poisons, to kill only wiley cancer cells and not normal cells? In fact, cacner chemotherapy routinely kills bone marro and the cell lining of the gastrointestinal tract, with very distressing (indeed sometimes fatal) side effects.
It rather shocks me that a pharmacologist like Dr. Spector would write something like this without mentioning that the reason chemotherapy can work in some tumors is because it is more toxic to the cancer cell than it is to (most of) the surrounding normal tissue. The same thing is true of radiation. This is not a trivial point. Dr. Spector makes it sound as though chemotherapy poisons everything equally and that it’s a miracle that it ever works at all. He then writes:
However, it cannot be denied that there are a few populations for which chemotherapy is marvelously effective, as noted above, and must be used.
No kidding! For example, many leukemias and lymphomas, testicular cancer, and anal cancer (which is treated primarily with the Nigro protocol, which consists of chemotherapy and radiation), among others!
Dr. Spector correctly points out that smoking tobacco products is a major cause of lung cancer, which causes most cancer deaths these days in both men and women. He even shows several very nice graphs that demonstrate that lung cancer death rates began to skyrocket about twenty years after cigarette consumption began to skyrocket (Figure 3) and that lung cancer death rates have been declining (in men at least; they appear to be peaking in women, Figures 4 and 5), approximately 25 years after cigarette consumption began to decline. All of these results are very much in accord with what we know about cigarette smoke as a carcinogen. One thing is clear: If we could eliminate cigarette smoking completely, approximately 20 years later, declines in lung cancer deaths would drive major declines in overall cancer deaths. There’s little doubt of that. However, such an observation is very much a “Well, duh!” conclusion. It’s not as though public health authorities in the U.S are unaware of such statistics or that dramatic gains or haven’t been working to try to discourage smoking. Changing behavior is very, very hard. In fact, I would argue that decreasing cancer mortality by 5% since 1950 is actually pretty darned good, given that lung cancer mortality tripled among men between 1950 and 1990 and more than doubled among women from 1970 to 2000. If you don’t believe me, take a look at these graphs from the SEER Database of cancer death rates from the various major forms of cancer, in particular Figure 4 and Figure 5. Then there is this graph in Figure 2:
This demonstrates that, although cancer incidence rates are leveling off, cancer death rates are decreasing. Sure, it’s not as good as we need to do, but notice that the curves are separating. Indeed, if you look at Figure 7, you’ll see an estimate of how high cancer mortality would be if cancer mortality rates had remained the same over the last 20 years:
The American Cancer Society attributes the decreases in cancer mortality to this:
The decrease in lung cancer death rates among men is due to a reduction in tobacco use over the past 50 years, whereas the decrease in death rates for female breast, colorectal, and prostate cancer largely reflects improvements in early detection and/or treatment. Between 1990–1991 and 2006, death rates increased for liver cancer in both men and women, esophageal cancer and melanoma in men, and lung and pancreatic cancer in women. Figure 7 shows the total number of cancer deaths avoided since death rates began to decrease in 1991 in men and in 1992 in women. Approximately 767,000 cancer deaths (561,400 in men and 205,700 in women) were averted between 1991–1992 and 2006.
Death rates from all cancer are a rather crude measure of how the war on cancer is going, anyway, being an aggregate number that is only likely to be affected very late as a result of improvements in cancer therapy. Our population is aging, which means that more people are living long enough to develop cancer, particularly given that we’ve made such dramatic progress in decreasing death rates from cardiovascular disease. People who live longer because they don’t die of cardiovascular disease have to die of something, and cancer, being number two (although not for long), is the next most likely cause. In any case, let me provide an example of what I find wrong with Dr. Spector’s thesis. In his “war on cancer” article a year ago, Dr. Spector wrote:
The FDA has approved bevacizumab for the cancers listed in table 5 (Physicians Desk Reference [PDR] 2009; Health Agencies Update 2009). Since the median survival of colorectal cancer is eighteen months, bevacizumab therapy would cost about $144,000 (in such a patient) for four months prolongation of survival (Keim 2008). In the other cancers in table 4, there is no prolongation of survival. Moreover, bevacizumab can have terrible side effects, including gastrointestinal perforations, serious bleeding, severe hypertension, clot formation, and delayed wound healing (PDR 2009). By the criteria in table 4, bevacizumab is at best a marginal drug. It only slightly prolongs life, demonstrable only in colorectal cancer, has serious side effects, and is very expensive.
Here’s a more provocative and somewhat more optimistic assessment of the progress we’ve made in treating metastatic colorectal cancer in graph form (click to make bigger):
Untreated metastatic colorectal cancer has about a four to six month median survival. Our old chemotherapy regimens increased the medical survival in metastatic colorectal cancer to around 12 months. Newer regimens boosted that to around 16 or 17 months. Adding bevacizumab then increased the survival to around 21 months. All of this has occurred since the mid-1990s. Is it enough? Of course not! But as a clinician I would argue that quadrupling the life expectance of someone with metastatic colorectal cancer is nothing to sneeze at. Indeed, I even have personal experience with this. The father of a good friend died last summer of metastatic colorectal cancer after having lasted over six years. A combination of surgeries, chemotherapy, and other treatments kept him going. He played golf until a week before his health declined precipitously and unexpectedly, and he died. Yes, he was certainly an outlier, but if the median survival of a group of cancer patients is pushed longer and longer, there will be more and more outliers like my friend’s father. True, we would much prefer a cure (or at least a reasonable chance of a cure), but ask the cancer patient what that extra year or several months means to him or her. Also true, as a society, we have to decide how much we are willing to pay for that additional survival, but that is a societal question more than anyone else. It’s also rather disappointing that Dr. Spector would describe bevacizumab as a “nonspecific toxin” that interferes with blood vessel growth throughout the body. That’s not quite true. Bevacizumab does interfere with angiogenesis, but it tends to be much more specific for tumor blood vessels and other abnormal blood vessels than for normal blood vessels. Indeed, the most recent concepts regarding bevacizumab is that it actually “normalizes” tumor blood vessels, allowing chemotherapy to get to the tumor better. This observation explains a paradoxical observation that I made in the 1990s that radiation and antiangiogenic therapy with anti-VEGF antibody produced greater than additive anti-tumor effects.
Be that as it may, suppose I’ll be accused of “cherry picking” this example, but I don’t care that much. I choose it because I want to point out that the situation is not always as grim as Dr. Spector claims and that we have made enormous progress in treating some cancers over the last 40 years. I would also point out that the $105 billion we have spent on the war on cancer since 1970 breaks down to only around $2.6 billion a year. In recent years, the yearly budget for the National Cancer Institute has hovered in the $4.7 to $5.2 billion range. This may sound like a lot of money, but in reality it is only 0.1% of the $3.8 trillion federal budget this year. Let’s just put it this way, the entire yearly budget for the NCI would fund the war in Afghanistan for approximately 16 or 17 days. That is not a lot of money in the grand scheme of things; certainly it isn’t enough money to pay for a real “war” on cancer.
Where do we go from here?
Let me just begin my conclusion by conceding that Dr. Spector does make a few good points, albeit in insufficient detail in some cases. For example, his discussion of lead time bias is superficial and doesn’t even use the proper term for the concept, and he leaves out the concept of length bias in screening altogether. More irritating, though, is that there’s clearly a relentless effort on his part in both articles to paint as grim a view of the situation as before. Yes, Dr. Spector is correct that, if we could only decrease smoking to nothing we could decrease the death rate from lung cancer dramatically over the next 20-30 years. He’s also correct that decreasing use of HRT will help decrease the death rate from breast cancer, but in reality we’ve already done that. HRT use has declined precipitously after 2002; there isn’t much room to decrease it further. He also recommends vaccines to prevent HPV infection and thereby decrease the risk of cervical cancer, but that is really a pretty small contribution to the overall cancer death rate. Even so, let’s say we do all these things that Dr. Spector suggests because they are good things to do and will have an effect. Ignore for the moment how difficult it is to get people to stop smoking to prevent lung cancer, to stop drinking to prevent head and neck, esophageal, and liver cancers, and to lose weight to decrease the incidence of obesity-related cancers. Let’s say we can do it. What then? We will still have lots of people who will develop cancer and die from it if we don’t come up with better therapies. How do we do that? On that score, Dr. Spector is profoundly self-contradictory. I’ll show you what I mean.
At one point, Dr. Spector opines:
In my view the principal problem is that we just do not understand the causes of most cancers. We don’t even know if the problem is genetic or epigenetic or something totally unknown. In theory, problems 2 through 6 in table 6 are all correctable with political and scientific will and more knowledge. Even though we know cancer of the lung is caused by cigarette smoking, we do not know the mechanism, and (except for surgery) we do not know how to meaningfully intervene (see table 2). The pharmaceutical industry cannot make real progress until we understand the mechanisms and molecular causes of cancer so that industrial, academic, and governmental scientists have rational targets for intervention. We will make no progress if there are five hundred or more genetic abnormalities in a single cancer cell. Where would one begin?
And:
Moreover, with better mechanistic understanding of cancer, we could make truly “smart” drugs, as has been done in recent years for atherosclerosis (heart attacks), hypertension (strokes), gastrointestinal diseases (ulcers), and AIDS—with truly remarkable results. Let us hope cancer is next.
I can’t argue with that. Indeed, I’m very much about trying to understand the biology of cancer much better, so that we can design treatments that will be much more effective, “truly smart drugs,” as Dr. Spector puts it. That’s the direction, in fact, that I’m trying to move my research effort, with the help of a very good systems biologist. Here’s the problem. In his most recent article, Dr. Spector dismisses as useless and deadly the very techniques that we will require in order to generate the hypotheses that could lead to that better understanding of cancer upon which Dr. Spector’s proposed next generation of “smart drugs” would be based. Yet Dr. Spector poo-poos genome-wide association studies (GWAS), using them as an example of Deadly Hypothesis One. He lambastes the concept of personalized medicine and the genetic studies that will be necessary to achieve it as Deadly Hypothesis Six. He praises the methods used by the FDA, but, as explained by Mark Crislip, the rigor demanded by the FDA is the final step in a long process that begins with basic science, progresses through epidemiology and pilot studies, and then finally concludes with large, phase III randomized trials. Moreover, the final studies leading to FDA approval really are the “safest” part of the process, based on scads of data from all those earlier studies.
In other words, Dr. Spector, while claiming we need new and innovative hypotheses and ways to understand biology is in reality advocating very safe science indeed.
Dr. Spector makes a point that we need a better understanding of cancer, but he clearly has little idea about how to bring that about from a basic science perspective. So boxed into his clinical trial and pharma perspective is he that he castigates the very means of developing new hypotheses to test that we need. While Dr. Spector is correct that GWAS and gene expression profiling studies have been disappointing thus far, one needs to remember that the technology to do these studies has been in existence only a relatively few years and that these studies generate huge masses of data that strain even the best computers to analyze. In other words, we are early into these processes, but, as the cancer genome anatomy project demonstrates, we are learning.
That’s why I conclude that the worst aspect of Dr. Spector’s most recent article and his whole attitude in general is how he labels as Deadly Hypothesis One the concept that either “the investigator does not need a specific hypothesis and/or can use an inadequate method to test the hypothesis.” Yes, failing to use a specific hypothesis is not a good idea later in the process of drug development, but if we are to understand the biology of cancer sufficiently to design the next generation of “smart drugs,” we need new hypotheses, and these come from pilot studies. We sometimes call these studies “fishing expeditions” or, less pejoratively, “hypothesis generating experiments.” Come to think of it, one wonders whether Dr. Spector approved of the Human Genome Project. After all, there was no hypothesis to test there; scientists were simply trying sequence the entire human genome, and they learned a lot. More importantly, the results of the HGP generated many new hypotheses to test, many of which are being tested now, along with a revolution in genomic technology. The problem with Dr. Spector’s point of view is that he strikes me as seeing everything through the lens of pharma and the FDA. Scientific rigor is a good thing before approving drugs and treatments; in fact, it’s absolutely essential. However, the discovery process often begins by looking around and seeing if there’s anything interesting to see. Without that discovery process, all those rigorous trials meeting FDA requirements would never come to fruition because there would be no basic science pipeline to supply the translational research pipeline that eventually results in new drugs. Many–the vast majority, actually–of these hypotheses will never pan out, but they are just as essential to science-based medicine as the studies Dr. Spector loves.
Can we do better in the “war on cancer”? Of course we can–and must. However, it must be remembered that the “war on cancer,” like most wars, is not World War II. There is not, nor will there be, a total victory, an atomic bomb-like magic bullet that destroys all cancer. There will, as with most wars, be equivocal results, wins and losses, and pyrrhic victories. But we won’t get even that far if we embrace scientific nihilism over healthy skepticism.

Worshiping at the altar of the Cult of the Brave Maverick Doctor
David Gorski on December 14, 2015
Link

One of my favorite television shows right now is The Knick, as I described before in a post about medical history. To give you an idea of how much I’m into The Knick, I’ll tell you that I signed up for Cinemax for three months just for that one show. (After its second season finale airs next Friday, I’ll drop Cinemax until next fall.) The reason why I’m bringing up The Knick (besides I love the show and need to bring it up at least once a year) is because an article by Malcolm Gladwell in The New Yorker entitled “Tough Medicine“, which is a commentary based on a new book on cancer by a veritable god of cancer research, Vincent T. DeVita, Jr., immediately resonated with a storyline in this season of The Knick. I haven’t yet read The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable–and How We Can Get There by Vincent T. DeVita and Elizabeth DeVita-Raeburn, but I want to. I can tell, though, that there will be parts of the book I find annoying just from Gladwell’s take on it, which approvingly describes DeVita as railing against the cautiousness and incremental nature of today’s cancer research. To give you an idea of where Gladwell’s coming from, I note that his article shows up in the title bar of my web browser not as “Tough Medicine” but rather “How To Cure Cancer”, even as the title on the web page itself remains “Tough Medicine”. On the other hand, the article does conclude with Gladwell demonstrating a better understanding of the disadvantages of what DeVita is proposing than it seems that he will in the beginning. In fact, it is Gladwell who is more reasonable than his subject, although he does appear share DeVita’s apparent assumption that potentially all cancer patients are savable if only we try hard enough.

The Brave Maverick Doctor versus the clinician-scientist
Here’s where my reference to The Knick comes in. (Because it seems mandatory these days, I’ll issue a spoiler alert right now. Skip to the next section if you don’t want to be exposed to major plot points from the show.) The Knick is a show set in the fictional Knickerbocker Hospital in lower Manhattan and takes place more than a century ago, the first season in 1900, the second in 1901. Its main character, Dr. John Thackery (brilliantly portrayed by Clive Owen) is a surgeon clearly patterned on one of the veritable gods of American surgery, William Stewart Halsted, whose contributions to surgery, including blood transfusions, sterile surgical gloves, local anesthesia, an emphasis on the delicate handling of tissue, cancer surgery, and the surgical residency program, are legendary. He was also a cocaine and morphine addict, but managed to function well in spite of his addictions. Thackery is also an addict, but doesn’t function nearly as well.
The fictional Dr. Thackery is a type of doctor to whom I’ve referred as the Maverick Doctor, or Brave Maverick Doctor when I’m in a sarcastic mood. Such doctors can be bold, reckless even. They believe in their own rightness, thinking that their training as physicians should be enough for society to trust their judgment to do what they believe to be right and bristle at anything they view as constraining their freedom of medical judgment in any way, such as evidence-based treatment guidelines. When they’re right, as, for example, William Halsted and Vincent DeVita frequently were, they can push the envelope of medicine faster than anyone. There’s a very good reason why, for example, DeVita is one of editors of the main textbook of oncology owned by most oncologists, myself included. Unfortunately, when Brave Maverick Doctors are wrong (the far more frequent situation), as, for example, Stanislaw Burzynski is wrong, they are frequently very, very wrong and can do great harm. Not surprisingly, there is a disturbingly high percentage of quacks among Brave Maverick Doctors. Think Mark Geier. Think Rashid Buttar. Think Andrew Wakefield. You get the idea. Indeed, there is a whole medical organization dedicated to Brave Maverick Doctors, the American Association of Physicians and Surgeons (AAPS).
Relevant to DeVita’s book and Gladwell’s article, one of the central themes of The Knick is the conflict between the innovation of Brave Maverick Doctors and its inherent risk. This conflict is embodied in the character of Thackery, who is often bold to the point of recklessness in his pursuit of curing disease. On the other side, the slow, methodical accumulation of scientific knowledge is represented by Dr. Levi Zinberg at Mt. Sinai Hospital. Thackery is all about trying new things, almost regardless of the cost or risk, while Zinberg is all about collaboration and the careful, incremental, scientific advancement of medicine. In the first season, for example, Thackery comes to view Zinberg as a competitor, even going so far as to become obsessed with identifying different blood types before Zinberg does, after having been informed that that’s what Zinberg was working on. Zinberg, for his part, offers collaboration and even shares his laboratory notes with one of Thackery’s junior surgeons, Bertram Chickering, Jr., to show his good faith, telling Chickering to feel free to share his notes with Thackery.
In the second season, this conflict is even more prominent. In episode 3 this season, “The Best with the Best to Get the Best“, for personal reasons Chickering decides to leave the Knick and take a position at Mt. Sinai working for Zinberg. There, his experience with Thackery comes into immediate conflict with the way things are done at Mt. Sinai, and he is disappointed when Zinberg assigns him a laboratory project working with a new gland extract (adrenaline) instead of letting him operate right away. When Chickering suggests accelerating the testing of the new gland extract in animals from mice to larger animals or even humans, he is told in no uncertain terms,”Dr. Zinberg is very specific about his protocols. Start on mice. Present our findings. Then on to rats, then guinea pigs, then cats, dogs, and pigs, and only then to humans.”
This conflict comes to a head when Chickering’s mother is diagnosed with inoperable laryngeal cancer. He tells Zinberg of his mother’s condition and that he is determined to seek out new experimental procedures to save her life, to which Zinberg replies by cautioning him not to let his emotions get the better of him. This leads him to seek out Dr. Algernon Edwards, a brilliant African-American surgeon hired early in the first season by the Knick’s board of directors over Thackery’s objections (which were based on racism, of course) who had ultimately won Thackery’s respect. Edwards tells Chickering of a paper by Pierre Curie, and says he can translate it from French if Bertie locates a copy, which he does. The procedure involves injecting the tumor with mercury and zinc and then zapping it with electricity. This leads to an episode entitled, appropriately enough, “There Are Rules“, where Chickering persuades Edwards to help him, saying, “I don’t have the luxury of two years of study.” It is about as succinct an expression of the inherent conflict in medical research between risk and careful scientific study as you’ll ever see.
And help him Edwards does. The two operate on Chickering’s mother at Mt. Sinai in secret, with Chickering’s father in the room, unable to watch. Not surprisingly, the surgery does not go well. The tumor does not soften as predicted, and the two get into bleeding and do damage to Mrs. Chickering’s airway while trying to separate the tumor from surrounding structures. They are also discovered by a janitor, who leaves to inform Zinberg, who bursts in a few minutes later demanding to know what is going on. To his credit, when Zinberg sees what’s going on, he stops scolding and leaps in to help as much as he can. Unfortunately, they can’t save Mrs. Chickering, who dies on the table. Thus ends Chickering’s tenure at Mt. Sinai. He resigns before Zinberg can fire him; not surprisingly he winds up back at the Knick with Thackery, who has actually become slightly less reckless.
This fundamental conflict between careful, slow scientific progress and the need to do something for patients who are suffering now and going to die soon is a theme Gladwell revisits in his article. Of course, most clinical researchers are not a Dr. Thackery or a Dr. Zinberg, who really are archetypes more than anything else. Most physician-scientists and clinical researchers fall somewhere in between these extremes. What seems to bother Gladwell and Dr. DeVita is that over the last three decades the balance in medicine has clearly moved away from the Thackerys and towards the Zinbergs, which leads DeVita to make the same sorts of misguided arguments that I’d discussed being made for right-to-try laws, the Saatchi bill, and the 21st Century Cures Act, all of which seek to remove patient protections in the name of letting Maverick Doctors “innovate” more.
Brave Maverick Oncologists and the wild, wild West of the 1960s
When I referred to Vincent DeVita as a “god” of oncology, I was only exaggerating slightly. If you don’t believe me, go back and read a post I wrote two years ago that uses one of DeVita’s review articles as a jumping off point to discuss how chemotherapy went from a near-fringe idea to being validated as a successful treatment for a number of cancers. It’s a good overview of the history of chemotherapy, a history that DeVita lived right in the middle of and whose success he was very much a part of. Now 80 years old, DeVita uses his book to look back at the history of cancer chemotherapy, and the anecdote that Gladwell chooses to start his article is very telling:
In the fall of 1963, not long after Vincent T. DeVita, Jr., joined the National Cancer Institute as a clinical associate, he and his wife were invited to a co-worker’s party. At the door, one of the institute’s most brilliant researchers, Emil Freireich, presented them with overflowing Martinis. The head of the medical branch, Tom Frei, strode across the room with a lab technician flung over his shoulder, legs kicking and her skirt over her head. DeVita, shocked, tried to hide in a corner. But some time later the N.C.I.’s clinical director, Nathaniel Berlin, frantically waved him over. Freireich, six feet four and built like a lineman, had passed out in the bathtub. Berlin needed help moving him. “Together, we pulled him up, threw his arms over our shoulders, and dragged him out through the party,” DeVita writes, in his memoir, “The Death of Cancer” (Sarah Crichton Books). “Out front, Freireich’s wife, Deanie, sat behind the wheel of their car. We tossed Freireich in the backseat and slammed the door.”
Half a century ago, the N.C.I. was a very different place. It was dingy and underfunded—a fraction of its current size—and home to a raw and unruly medical staff. The orthodoxy of the time was that cancer was a death sentence: the tumor could be treated with surgery or radiation, in order to buy some time, and the patient’s inevitable decline could be eased through medicine, and that was it. At the N.C.I., however, an insurgent group led by Frei and Freireich believed that if cancer drugs were used in extremely large doses, and in multiple combinations and repeated cycles, the cancer could be beaten. “I wasn’t sure if these scientists were maniacs or geniuses,” DeVita writes. But, as he worked with Freireich on the N.C.I.’s childhood-leukemia ward—and saw the fruits of the first experiments using combination chemotherapy—he became a convert.
You get the idea. Back in 1963, men were men, women were women, and the sheep ran scared. Or something. Maybe it was Mad Men, but with oncologists and cancer researchers instead of advertising executives. Or maybe the NCI was the wild, wild West, populated by nothing but Maverick Doctors. As I will discuss, the wild frontier turns out to be a very good metaphor for cancer research as practiced 50 years ago, at least in terms of the attitudes of the physicians at the forefront back then compared to the way things are done now.
Having established the wild West, Maverick doctor bona fides of the era, Gladwell next relates anecdotes from DeVita’s book in which a Maverick doctor shows those cautious, pointy-headed professors how curing cancer is done, starting with one of DeVita’s own accomplishments when he decided to try to replicate Frei and Freirich’s success with childhood leukemia in an adult malignancy. Back in the early 1960s, Hodgkin’s disease, too, was also a virtual death sentence, with very little that doctors could do to save the lives of patients diagnosed with the disease. Over a few beers one night, DeVita and a colleague named Jack Moxley mapped out a protocol based on what Frei and Freireich were doing with leukemia. Because of the ability of cancer cells to mutate and develop resistance under the selective pressure of chemotherapy, they estimated that they needed four drugs, each working through a different mechanism, so that the cells that survived one wave would be killed by the next. They then plotted how often the drugs could be given and how high the doses would need to be. Obviously, the doses needed to be high enough to kill the cancer cells but not so high that the patient died. Ultimately they settled on a regimen called MOMP: three eleven-day rounds of nitrogen mustard, Oncovin (a brand of vincristine), methotrexate, and prednisone, interspersed with ten-day recovery cycles.
This story is the very essence of science-based medicine combined with “maverick-y-ness. Here, two oncology fellows carefully examined the medical literature regarding chemotherapy drugs and what was known about the biology of Hodgkins’ lymphoma at the time and came up with what seemed to be a reasonable combination of drugs. It’s not something that could be done today in the same way, but as I will explain, contrary to what DeVita and Gladwell seem to think, that’s not a bad thing. In the meantime, let’s look at what happened:
“The side effects were almost immediate,” DeVita writes:
The sound of vomiting could be heard along the hallway. Night after night, Moxley and I paced outside the rooms of our patients, fearful of what might happen. Over the weeks that followed, they lost weight and grew listless, and their platelet counts sank lower and lower to dangerous levels.Then came the surprise. Twelve of the fourteen patients in the initial trial went into remission—and nine stayed there as the months passed. In most cases, the tumors disappeared entirely, something that had never before been seen in the treatment of solid tumors. In the spring of 1965, DeVita went to Philadelphia to present the results to the annual meeting of the American Association for Cancer Research. He stood up before the crowd and ran triumphantly through the data: ” ‘Our patients were, therefore,’ I said, savoring the dramatic conclusion, ‘in complete remission.’ “
What happened? An illustrious cancer expert named David Karnofsky made a narrow point about the appropriateness of the term “complete remission.” After that, nothing: “There were a few perfunctory questions about the severity of the side effects. But that was it.” History had been made in the world of cancer treatment, and no one seemed to care.
Why did DeVita’s work receive such a lukewarm reception? It’s hard to say. It could well have been the natural reticence and skepticism that scientists exercise upon hearing radical new results. It could well have been that the audience thought the data too good to be true. Whatever the reason, Gladwell next discusses the next stage of DeVita’s career, when after finishing his fellowship at the NCI he went to Yale to do another year of residency before coming back to the NCI. A stronger echo of Dr. Chickering’s experience leaving the Knick and taking a position at Mt. Sinai would be hard to imagine:
When his first go-round as a clinical associate at the N.C.I. was up, DeVita took a post as a resident at Yale. At what was supposed to be a world-class hospital, he discovered that the standard of care for many cancers was woefully backward. Freireich had taught DeVita to treat Pseudomonas meningitis in leukemia patients by injecting an antibiotic directly into the spinal column—even though the drug’s label warned against that method of administration. That was the only way, Freireich believed, to get the drug past the blood-brain barrier. At Yale, DeVita writes, “you just didn’t do that kind of thing. As a result, I watched leukemic patients die.” Leukemia patients also sometimes came down with lobar pneumonia. Conventional wisdom held that that ought to be treated with antibiotics. But N.C.I. researchers had figured out that the disease was actually a fungal infection, and had to be treated with a different class of drug. “When I saw this condition in patients with leukemia and pointed it out to the chief of infectious diseases at Yale, he didn’t believe me—even when the lab tests proved my point,” DeVita continues. More patients died. Leukemia patients on chemotherapy needed platelets for blood transfusions. But DeVita’s superiors at Yale insisted there was no evidence that transfusions made a difference, despite the fact that Freireich had already proved that they did. “Ergo, at Yale,” DeVita says, “I watched patients bleed to death.”
Elsewhere, DeVita relates [PDF] how he had originally wanted to do a fellowship at Yale too but decided to come back to the NCI after a year because of his experiences at the school.
It’s hard to judge this story without knowing a bit more, but notice how DeVita said that Freirich had taught him to treat Pseudomonas meningitis with intrathecal antibiotics. Had he yet published a convincing clinical study showing that intrathecal antibiotics worked better? I searched for Freireich’s publications on Pseudomonas infections from the 1960s; all I could find was an analysis of 54 episodes of multiple organism sepsis in leukemia patients from 1965, which isn’t applicable to the problem. A search for Freirich’s name and just “meningitis” only revealed this case report from 1968 on Listeria monocytogenes meningitis. In other words, as far as I can ascertain, Freireich had apparently not published his experience with the use of intrathecal antibiotics for meningitis in leukemia patients at the time DeVita was at Yale. Similarly, I was not able to find papers by Freireich on fungal infections before 1968. So why on earth would the doctors at Yale believe DeVita? Why should they have? If it’s not published, then why would they do it? On the other hand, Freireich had published several papers on the effectiveness of transfusions by the late 1960s, one in the New England Journal of Medicine in 1959.
Whether or not he was off base criticizing his colleagues at Yale in the late 1960s, DeVita does note something that I’ve noted myself, as have many others, namely that new ideas are often resisted and that clinical practice doesn’t always change. He noted that he couldn’t do a combination-chemotherapy trial in the US because it went against the grain at the time, necessitating doing it overseas. He also cites the example of Bernie Fisher, who had shown that there was no difference in survival in breast cancer between radical mastectomy and much less invasive breast-conserving surgery followed by radiation therapy, and how he had had difficulty enrolling patients to his studies because of resistance from surgeons.
What DeVita neglects to note is that eventually data did win out, and our practice changed. Indeed, I myself have never even done a radical mastectomy because the procedure had been obsolete years before I did my surgical residency. Heck, my practice has changed radically, in response to clinical trials, just since I first became an attending in 1999. As I like to point out, change in science-based medicine is messy. It often takes more time than we think it should, particularly in retrospect. But eventually we do change practice in response to data and science. At the heart of this change, the question is always: How much new evidence is required before a critical mass of physicians are convinced to change practice? Not all conservatism in medicine is bad. One need only point to the debacle that resulted from the much-too-rapid adoption of high dose chemotherapy and bone marrow transplantation for advanced breast cancer that became popular in the 1990s, only to be shown to do no good and cause a lot of harm when decent randomized clinical trials were done.
Innovation versus practice guidelines
A second key anecdote from DeVita’s book related by Gladwell involves DeVita’s experience with how a new regimen that he developed was altered as it spread from the NCI to other cancer centers, in this case Memorial Sloan-Kettering Cancer Center (MSKCC). Basically, over the next few years, DeVita and colleagues refined the MOMP regimen, which became MOPP: two full doses of nitrogen mustard and vincristine on the first and the eighth days, and daily doses of procarbazine and prednisone for fourteen days, followed by two weeks of rest. The results of a second trial, published in 1970, showed MOPP to be superior to MOMP.
What puzzled DeVita was how tepid the response was at MSKCC when he presented his work there. Indeed, oncologist after oncologist there told him MOPP “didn’t work.” Why was that? Ironically enough, it was the product of the very same sort of tinkering that DeVita had used seven years earlier to develop MOMP:
Baffled, he asked one of the hospital’s leading oncologists, Barney Clarkson, to explain exactly how he was administering the MOPP protocol. Clarkson answered that he and his colleagues had decided to swap the nitrogen mustard in DeVita’s formula for a drug called thiotepa. This was a compound they had developed in-house at Memorial Sloan Kettering and felt partial to. So MOPP was now TOPP. DeVita writes:
They’d also cut the dose of procarbazine in half, because it made patients nauseous. And they’d reduced the dose of vincristine drastically because of the risk of nerve damage. They’d also added, at a minimum, an extra two weeks between cycles so that patients would have fully recovered from the toxic effects of the prior dose before they got the next. They gave no thought to the fact that the tumor would have been back on its feet by then, too, apparently.
These alterations had not been tested or formally compared with DeVita’s original formula. They were simply what the oncologists at Memorial Sloan Kettering felt made more sense. After an hour, DeVita had had enough:
“Why in God’s name have you done this?” he asked.
A voice piped up from the audience. “Well, Vince, most of our patients come to us on the subway, and we don’t want them to vomit on the way home.”
Here were physicians at one of the world’s greatest cancer hospitals denying their patients a potentially life-saving treatment because their way felt better.
So basically, the doctors at MSKCC had altered the protocol, and the resultant protocol, TOPP, didn’t work. What would have been appropriate, if the oncologists at MSKCC really thought their protocol was an improvement, would have been to do a clinical trial comparing MOPP to TOPP head to head, but they didn’t do that. They just changed DeVita’s protocol as they saw fit and started using it. For them to conclude that TOPP didn’t work, it must have been very obviously different from the results reported by DeVita with MOPP, because there was no control group and no clinical trial. Worse, if DeVita’s account is to be believed, the oncologists at MSKCC didn’t even differentiate their new protocol from DeVita’s original protocol or figure out that the reason that their protocol didn’t work was because of their alterations.
One might think that this sort of experimentation would indicate that perhaps there should be some clinical guidelines that made sure that MOPP, which had been validated as effective in clinical trials, should be administered the same way, but that’s exactly the opposite of what DeVita argues, according to Gladwell:
But here “The Death of Cancer” takes an unexpected turn. DeVita doesn’t think his experience with the stubborn physicians at Memorial Sloan Kettering or at Yale justifies greater standardization. He is wary of too many scripts and guidelines. What made the extraordinary progress against cancer at the N.C.I. during the nineteen-sixties and seventies possible, in his view, was the absence of rules.
And:
Clinical progress against a disease as wily and dimly understood as cancer, DeVita argues, happens when doctors have the freedom to try unorthodox things—and he worries that we have lost sight of that fact.
Where have we heard these arguments before? Oh, yes. I remember. They’re the same arguments made by proponents of the Saatchi Bill and the misguided 21st Century Cures Act. The central idea behind all of these policy ideas is that we somehow have to “free” doctors and researchers to “innovate,” rather than “shackling” them. The impetus for these ideas is, in essence, worshiping at the altar of the cult of the Brave Maverick Doctor. It is the Great Man (or Woman) theory of the history of medicine, in which breakthroughs come not so much because of the gradual accretion of knowledge, with each new scientific finding building on what has been discovered before, but because of singular individuals with the vision and the bravery to see what needs to be done and the cleverness, intelligence, and will to do it.
DeVita vs the FDA
Gladwell notes that the angriest part of DeVita’s book is his chapter about the FDA, where he argues that the FDA has somehow fundamentally misunderstood innovation. I rather suspect a lot of DeVita’s hostility comes from two experiences he had in his life. First, he describes a prolonged battle to save his friend Lee, who developed advanced prostate cancer. DeVita kept pushing to get him into clinical trial after clinical trial, to get experimental therapies off protocol, and basically to try anything that could be tried, ending when he couldn’t get Lee an experimental drug called abiraterone and died. He later learned that abiraterone was so effective that the clinical trial was halted early and now clearly believes that he could have saved him, even though there is no cure for advanced prostate cancer. (Abiraterone significantly prolongs life, but is not a cure.) Another incident is that DeVita, ironically enough, was the father of the Ted DeVita, the “boy in the bubble,” who developed aplastic anemia and lived well over eight years in a plastic bubble before succumbing.
Specifically, he objects to the FDA’s mandate to require that all new approved drugs be safe and efficacious, pointing out that this “gatekeeping” function of the FDA can hinder progress. I’ll have to wait to read the book to see if DeVita’s argument is more compelling than how Gladwell represents it, but I was underwhelmed, as not a single example of how “progress” had been hindered was provided, only hypothetical examples. In one, he suggests that cancer is like a door with three locks, each with a different key. If a drug “opens the first lock,” it would be a breakthrough but wouldn’t cure the cancer by itself. So DeVita asks:
So how do you get it through a trial that requires proof of efficacy—especially if you don’t yet know what the right keys for the two remaining locks are? Since cancer comes in a dizzying variety of types and subtypes, each with its own molecular profile, we want researchers to be free to experiment with different combinations of keys.
The problem with this analogy is that it is disappointingly simplistic given who is making it and that the time to work out the preliminary answer to this question is in preclinical research leading to the development of this drug and others, not in human beings. Moreover, as represented by Gladwell, this argument completely ignores the incredible genetic heterogeneity of even a single cancer, where different cells, even in the same tumor, might have different combinations of these locks. He also criticizes the FDA for approving drugs for very specific indications, including specific cancers and even specific stages of cancers, complaining, “The vital insight gained by using an approved drug in a different way for a different tumor has been lost.” No, it has not. In this age of precision medicine based on genomics, if anything, we’re becoming more open to trying drugs designed for one tumor in another tumor based on the genetic abnormality it targets rather than the tissue of origin of the tumor. The FDA is struggling, as we all are, with the question of how to target therapy to the individual characteristics of the tumor. New forms of clinical trials are being tested. New regulatory frameworks are being developed.
To his credit, Gladwell points out exactly what’s wrong with DeVita’s argument for more freedom to tinker, specifically the paradox at the heart of it. First, he notes that the breakthroughs at the NCI in the 1960s and 1970s were the product of a freewheeling intellectual climate and a relative lack of rules over what could and could not be done in clinical trials. Indeed, it’s quite true that no one could do now what DeVita did 52 years ago. At the same time, it was that very same climate that allowed the oncologists at MSKCC muck up DeVita’s effective chemotherapy regimen by turning MOPP into TOPP. The problem with such a freewheeling atmosphere without rules is that, for it to be a net benefit, there have to be more doctors like Emil Freireich and Vincent DeVita than there are like Barney Clarkson, as Gladwell notes. Personally, having been in medicine in one form or another for 30 years now, I am not nearly so confident that there aren’t a lot more Barney Clarksons than Vincent DeVitas. In fact, I’m quite sure that there are and that, contrary to DeVita’s claims that an extra 100,000 more patients a year could be cured if we just used all the wonderful drugs out there to their fullest potential, opening medical practice and research to the sort of “innovation” DeVita proposes would end up harming far more patients than it would ever help.
Let’s just put it this way. By DeVita’s definition, Stanislaw Burzynski is “innovating” with his “make it up as you go along” form of “personalized gene-targeted” cancer therapy combined with his antineoplastons. After all, it is very difficult to identify, except in retrospect, after we know what works and what doesn’t, who is a Stanislaw Burzynski-style maverick and who is a Vincent DeVita-style maverick.
The problem with mavericks and nostalgia
‘Cause the good ole days weren’tAlways goodAnd tomorrow ain’t as bad as it seems
– Billy Joel
DeVita’s complaints about medicine are not uncommon. I tend to hear complaints like his from (mostly) an older generation of physicians who came of age in terms of their medical career during times when physician autonomy was perceived to be much closer to absolute and constraints on doing research less onerous, in other words, in a more freewheeling “wild West” sort of atmosphere. Given that, I can’t help but think that there is more than a little nostalgia, a pining for the “good old days,” in DeVita’s book. I also can’t help but wonder if Gladwell was rather selective in his quoting of DeVita, given that in an NPR interview just one month ago promoting his book, DeVita said very little that was so critical of the state of cancer research.
Be that as it may, I tend to view new fields of medical research as being rather like the American frontier. The first ones in are the hardiest and bravest, the ones willing to take the most risk, such as trappers and mountain men. They clear the way for the next wave, and as new arrivals keep coming, civilization intrudes. There are more and more laws and rules, and there is no longer absolute freedom. Eventually, what was once frontier is now little different from the states where all the settlers came from, and the original trailblazers have either moved on or struggle to fit in. Cancer research is rather like that. Back in its “wild West” period, because so little was known about cancer and so few effective treatments existed outside of surgery for certain specific cancers, there was an “anything goes” culture because, or so it was perceived, there was much to gain and very little to lose by trying almost anything. So men like DeVita (and, yes, unfortunately it was almost all men back then) did. Also, the less that’s known, the more variability in care is acceptable, because we don’t know what the best existing treatment is. The more we learn, the greater the risk in practicing outside of evidence-based guidelines because doing so becomes more likely to harm than help.
We are all products of our time and experiences, and DeVita is no different. He became a cancer researcher in a specific time and place, and his life experiences, particularly with his son with aplastic anemia and his friend with prostate cancer shaped his views. Think of it this way: DeVita, as brilliant as he is and as deserving as he is of all the respect he gets, was nonetheless very fortunate very early in his career. After all, his first attempt at innovation through tinkering happened to be a smashing success. There was no guarantee at the time that this would be the case. Indeed, it’s not hard to imagine an alternative history, in which his first attempt at multimodality chemotherapy was so toxic that it killed most of his patients before their cancers could or was simply ineffective and toxic. Would DeVita view giving physicians unfettered freedom to “tinker” so favorably if that had been the case? After all, in other hands, such tinkering resulted in an ineffective treatment combination.
One thing I like about The Knick is that it shows that one maverick can easily produce both possible outcomes. In other words, it’s a mistake to separate mavericks into Freireich-style mavericks and Clarkson-style mavericks. Any single maverick, for any given bit of “tinkering,” can produce Freireich or DeVita results or he can produce Clarkson-style results. Indeed, when Brave Maverick Surgeon John Thackery does his “tinkering,” sometimes, he’s successful, as when he successfully separates a pair of conjoined twins this season. More often, he fails miserably. Two of the more dramatic failures occurred when Thackery outright killed a girl transfusing her with his own blood based on his incorrect hypothesis of what blood types are near the end of the first season and in the second season when, while trying to treat a man’s addiction by ablating part of his brain, he inadvertently damaged part of the brain that resulted in a locked in patient. (If you don’t know what locked in syndrome is, read this or watch The Diving Bell and the Butterfly. It’s arguably a fate worse than death.) This season, when Chickering, following the lead of his mentor, tries an experimental treatment on his mother, disaster ensues. The converse can also happen, as in the first season when Dr. Zinberg develops the “illuminating intrascope,” which allows doctors to look inside their patients without making large incisions. (Basically, it was a precursor to what we use today as the laparoscope.) This conflict appears poised to come to a head in the season finale on Friday, as the synopsis includes this: “Thackery eschews Zinberg’s (Michael Nathanson) advice at Mt. Sinai and opts for a dramatic, and risky, alternative course of action.”
Same as it ever was.
Unlike 50 (or 115) years ago, medicine today is, for better or worse, largely a “team sport.” This is particularly true when it comes to serious diseases like cancer. For instance, in my specialty, breast cancer surgery, it’s uncommon that I am the only physician involved in the care of my patients with breast disease. It happens for patients undergoing a biopsy and for patients with ductal carcinoma in situ whose tumors are hormone receptor negative and who are thus not going to benefit from estrogen-blocking therapy. Even in both of these cases, at the very least a pathologist is also involved. The care of the rest of my patients involves a combination of surgery, radiation oncology, and medical oncology.
The collaborative nature of cancer care today can be frustrating to some doctors. In addition, there is a certain type of personality that views evidence-based guidelines as “being told what to do.” It’s not hard to find these doctors; indeed, just peruse the feed for Kevin, MD, and it won’t take more than a few days for you see them, and if you peruse the AAPS Twitter feed, you’ll see them in spades. Truly, the appeal of the cult of the Brave Maverick Doctor is strong. It’s just disappointing to see a physician as eminent as Vincent DeVita worshiping at the altar of the cult of the Brave Maverick Doctor.
Few physicians are as brilliant as Dr. DeVita or Dr. Freireich, and even brilliant maverick doctors “tinkering” the way DeVita did tend to be wrong far more often than they are correct. That’s why, as The Knick puts it, there are rules. Reasonable people can disagree over how strict those rules need to be, but there have to be rules.

   Why haven’t we cured cancer yet?
David Gorski
Link
Why haven’t we cured cancer yet?
If we can put a man on the moon, why can’t we cure cancer?
If we can harness the atom, why can’t we cure cancer?
How many times have you heard these questions, or variants thereof? How many times have you asked this question yourself? Sometimes, I even ask this question myself. Saturday was the two year anniversary of the death of my mother-in-law from a particularly nasty form of breast cancer, and, even though I am a breast cancer surgeon, I still wonder why there was nothing in the armamentarium of science-based medicine that could save her from a several month decline followed by an unpleasant death. That’s why, to me at least, the timing of the publication of a study examining the genome of prostate cancer that was published in Nature and summarized in this Science Daily news story was particularly apt. Performed as part of the National Cancer Institute’s Cancer Genome Project, the study undertook complete genome sequencing of seven advanced and aggressive prostate cancers. The results, as ERV put it, revealed what can be describe as a “train wreck.”
Personally, I’d describe it as looking as though someone threw a miniature grenade into the nucleus of a prostate epithelial cell. You’ll see what I mean shortly.
Of course, although that image does give you an idea of the chromosomal chaos in the heart of prostate cancer cells, it is inaccurate in that it implies a sudden explosion, after which the damage is done, and if there’s one thing we know about cancer it’s that in most cases it takes many years for a normal cell to progress to a cancer cell fully capable of metastasizing and killing its host. I’ve written in detail about the complexity of cancer before, of course, and have even pointed out before that when President Nixon launched the “war on cancer” 40 years ago scientists had no idea how difficult it would be. Indeed, before I discuss the current study, it’s probably useful to reiterate a bit why, in order to put the study in context.
Cancer is not a single disease, and cancers are different
I’m sure that it probably becomes tiresome for readers to read this time and time again, and, believe me, sometimes I find it tiresome to keep repeating it, but it must be said: Cancer is not a single disease. It’s hundreds of diseases. Although there are many common themes in cancer, such as loss of responsiveness to growth signals with a resultant ability to grow unchecked. Other common capabilities of cancer cells include evasion of programmed cell death (apoptosis), inducing the surrounding tissue to provide a blood supply (angiogenesis), evading the immune system, and invading the blood or lymphatic systems to travel elsewhere in the body and take up shop in other organs, such as liver, lung, or bone. Although there are, again, common molecular themes by which cancers do this, individual cancers acquire these necessary (to the cancer) abilities by many different ways.
Even cancers arising from the same cell type can be quite different. For instance, the breast cancer that killed my mother-in-law was a rare spindle cell variant, which is quite different from the much more common invasive ductal carcinoma that is estrogen and progesterone receptor positive. Indeed, even within individual cancers, different populations of cells can be quite different. In many solid tumors, there are cells now referred to as “stem cells.” Personally, I consider this term a bit of a misnomer that I really don’t like because these cells are not really pluripotent, and the cell types into which they can differentiate are rather limited. Moreover, this nomenclature has also made the concept of the cancer stem cell more controversial scientifically than it really needs to be. What we are really talking about are a relatively small population of cells in many tumors that are endlessly self-renewing and, in general, resistant to chemotherapy. In mice, these are the only cells that can actually form a new tumor when transplanted into a new mouse, and these are the cells that appear to be responsible for relapse after chemotherapy and radiation therapy. Indeed, cancer progression can be viewed as being due to a case of evolution in which the tumor cells that survive selection to continue to grow are the ones that become best at doing all the things that tumor cells need to do to evade the body’s defenses and overcome its growth control signals.
One of my favorite examples of how cancer progression can be understood using evolutionary principles was a study of esophageal cancer by Carlo Maley, PhD, a researcher at The Wistar Institute, that was published nearly five years ago. In essence, Maley applied population biology principles, specifically the Shannon Diversity Index, to predict which cases of Barrett’s esophagus (a precancerous condition in which the cells lining the lower esophagus are changed by chronic inflammation such that they look more like the cells that line the inside of the stomach) are most likely to progress to invasive esophageal cancer.
Not only is cancer not a single disease, but individual cancers are made up of multiple different clones of cancer cells under selective pressure to become ever more invasive and deadly. Looking at it this way, it’s a wonder we don’t all die of cancer. We do, however, virtually all have small foci of cancer within us, as I’ve pointed out before. Yet most of us do not develop cancer, and fewer of us end up dying of cancer, even though cancer is currently duking it out with heart disease as the number one cause of death in industrialized societies. Fortunately, the steps required for cancer to become deadly are difficult and numerous, and the body’s defenses against cancer are formidable.
Mechanisms of carcinogenesis are not simple
Let’s take a trip in a time machine back to 40 years ago, around the time that Nixon signed the National Cancer Act of 1971. I was a child, and molecular biology was in its infancy. Few of the fancy tools that scientists take for granted these days when it comes to studying genes, proteins, and how they interact even existed. Heck, polymerase chain reaction (PCR)—at least, as we know it now—wasn’t even invented for another 12 years and didn’t become widespread until the late 1980s and early 1990s. (Nearly 20 years later, I still chuckle at the memory of the monster of a PCR machine, the only one in our department, that I occasionally tried to use in graduate school. The thing took up the better part of a benchtop.) In 1971, the very first oncogene discovered, src, had only been reported the previous year, and it hadn’t even been demonstrated that oncogenes were defective protooncogenes; i.e., genes involved in cell growth that were mutated in cancers. That discovery would not come until 1976. Tumor suppressor genes were not discovered until nearly 10 years later, when the retinoblastoma (Rb) gene was characterized in 1986. An even more famous tumor suppressor gene, p53 (or TP53), had been discovered in 1979 by Lionel Crawford, David P. Lane, Arnold Levine, and Lloyd Old, but had initially been thought to be an oncogene. Burt Vogelstein demonstrated its function as a tumor suppressor gene in 1989, and ultimately it was demonstrated to be a critical gene for responding to DNA damage. How that ten-year voyage from oncogene to tumor suppressor played out is described in detail here. It makes interesting reading how a scientific concept can change as new evidence comes in.
Thus, over the first 25 years or so after the National Cancer Act of 1971, it was all about the genes and mutations. The picture that began to emerge was that oncogenes drove tumor growth along with loss of tumor suppressor gene activity. This seemed to fit in nicely with Alfred G. Knudson’s “two-hit” hypothesis, which stated that not only were “hits” required in oncogenes to cause cancer but in tumor suppressors as well. Later, Burt Vogelstein developed a model of multi-stage carcinogenesis that required at least six mutations:
As you can see, things were getting pretty complicated. Even so, based on what we know now, even Vogelstein’s increasingly sophisticated models in retrospect turn out to have been fairly simplistic. We discovered this over the last decade or so, because, with the advent of expression array profiling (a.k.a. “gene chips” or “cDNA microarrays”) in the late 1990s, it became possible to measure the level of expression of thousands of genes at the same time. Before then, we did not have the computational power or the technology necessary to do this, but over the last decade or so, it’s become more apparent than ever before that it is not primarily individual genes that determine cancer, or even a handful of genes, but hundreds or even thousands of genes that form complex networks of interactions. Also, around 1998 it was discovered that there is a whole new class of RNA, known as microRNAs (miRNAs), which regulate gene expression. More recent evidence suggests that miRNA expression patterns might actually tell us more about how cancer develops than whole genome expression array profiling because individual miRNAs often regulate the expression of hundreds of genes.
And I’m not even getting into deep sequencing of whole genomes in cancer yet, or the metabolic derangements that characterize cancers and allow them to grow where normal cells cannot, derangements that are probably just as critical to the process of carcinogenesis as genetic alterations.
So, putting it all together as we understand it in 2011, cancer cells not only have mutations that result in dysregulated expression of oncogenes and tumor suppressors, but these changes result in the alteration of expression of hundreds of genes, and in different types of cancer it will be different batteries of genes and miRNAs that are messed up in different ways. In fact, in individual tumors, there will be different populations of cells with different sets of genes and miRNAs messed up in different ways. Even worse, as a tumor progresses, it tends to become more heterogeneous, meaning that the number of different populations of cells tends to increase. Looking at it this way, it’s amazing that we have been able to do as well as we have with various forms of “targeted” therapy directed at specific single molecular targets or a class of molecular targets in cancer cells. Gleevec®, for instance, has been amazingly successful as a targeted agent directed against several members of a class of enzyme known as a tyrosine kinases, and by that mechanism it has been phenomenally successful as a treatment for gastrointestinal stromal tumors and certain types of leukemia. Even hoary old Tamoxifen is a targeted therapy directed at the estrogen receptor, and it still remains a mainstay of treatment for estrogen receptor-positive cancers to this day, along with a newer class of drugs known as aromatase inhibitors.
Unfortunately, in the grand scheme of things relatively few tumors are responsive to the targeting of single agents.
The prostate cancer genome
So what does this study tell us? Basically, scientists working at the Broad Institute, Weill Cornell Medical College, the Weizmann Institute of Science, Yale University, and Harvard University completely sequenced the entire genome of seven different prostate cancers and catalogued the abnormalities found by comparing the genome in prostate cancer with that found in the white blood cells of each patient, which were used as the normal control. Of course, this is what’s known as a “hypothesis-generating” study (a.k.a. a “fishing expedition” to those more inclined to disparagement). Personally, I have no problems with “fishing expeditions,” because without them we would have a serious lack of hypotheses to test. Moreover, this sort of fishing expedition is one where, almost no matter what scientists found, they would learn something useful about prostate cancer. True, it may not be the sort of knowledge that can be translated into therapy quickly. In fact, going in I would have predicted that it almost certainly would not be the sort of understanding that would lead to rapid improvement in prostate cancer treatment, and the results of this study show that it is not. What it does show is just how messed up the genome of cancer cells tends to be.
So what did the investigators find? Rearrangements and translocations. Lots and lots of intrachromosomal rearrangements and interchromosomal translocations. In fact, they found a median of 90 rearrangements and translocations per cancer genome (range: 43–213). They even included a pretty picture to represent the rearrangements. Known as a Circos plot, this graph shows the genomic location in the outer ring and chromosomal copy number in the inner ring (red, copy gain; blue, copy loss). Interchromosomal translocations and intrachromosomal rearrangements are shown in purple and green, respectively. (click on the picture to go to the Nature website and see the full size version):
These rearrangements were, as noted above, both within chromosomes (intrachromosomal) and between chromosomes (interchromosomal). These are represented in the following figure (again, click on the figure to see the full-size version):
Panel a shows an idealized picture of how these translocations work, with chromosomal breaks and rejoining with pieces of other chromosomes. It’s not necessary for me to go into the details other than to point out that in panels b an c we see that the break points have a disturbing propensity to be located right smack dab in the middle of important genes, like tumor suppressors. For instance, in PR-2832, break points appear in the middle of TP53 and ABL1. In other tumors, investigators found recurrent rearrangements that involved CADM2 and PTEN. PTEN is a known tumor suppressor gene, but CADM2 (cell adhesion molecule 2). This result appears to be confirmatory of recent results implicating CADM2 as a tumor suppressor gene in prostate cancer. Overall, scientists observed some new rearrangements, and ones that had been detected before.
Or, to put it even more simply, as William Phelps, program director for Translational and Preclinical Cancer Research at the American Cancer Society, put it:
Here’s one way to conceptualize the alteration, Phelps said: “If the genome was a book, instead of just looking for out-of-place letters or misspelled words, whole genome sequencing looks for whole paragraphs that are in the wrong place.
“Because [the researchers] sequenced everything, they were able to map not only individual base changes but also how whole genes or segments of the chromosomes had moved around,” Phelps said. “By sequencing everything and comparing the normal DNA (in white blood cells), they could see that not only were there individual base changes in the genes, but the genes themselves had been reshuffled in the tumor as part of the process of becoming cancer,” he explained.
“If we could use those changes as a diagnostic tool that would be tremendously valuable,” he added.
Whole genome sequencing also enables scientists to look not only at “coding” genes, but also “noncoding” DNA around the genes that was once thought to be “junk” but is now known to play an important regulatory role within cells, Phelps said.
I’ll admit that when it was announced, I was skeptical of the utility of the cancer genome project. I still am, actually. Basically, it’s one massive fishing expedition. However, as the years have gone by, I’ve become less skeptical, although I can’t say that I’ve exactly embraced it. This study leads me to consider that perhaps I was wrong in my original assessment.
More interesting than whether I screwed up five years ago when I first heard of this project, these sorts of rearrangements have long been appreciated as being important in leukemias and lymphomas, but in solid tumors they had not—until relatively recently. One thing that is important to keep in mind is that these scientists focused on aggressive, advanced pancreatic cancer. Consequently, they were selecting for most “messed up” genomes. As more and more cancer genomes are sequenced, scientists will be able to make comparisons between aggressive and indolent tumors. It is possible that one day doctors will be able to sequence a patient’s tumor and use what is learned from this to tell whether the tumor is aggressive or not—or potentially whether it even needs treatment or not. I’ve written extensively about the problem of overtreatment and even about spontaneous regression. Wouldn’t it be great if we could identify patterns of rearrangements and mutations (or lack thereof) that are associated with slow growing, indolent tumors compared to patterns associated with fast-growing, deadly tumors like the one that killed my mother-in-law, and then be able to use that information to target therapy or to decide that a cancer patient can be safely treated with watchful waiting? Until the last few years, we really didn’t have the technology and computing power to make such a dream a possibility, but now we do.
So why haven’t we cured cancer, anyway?
I close with the same question with which I opened. Why haven’t we cured cancer yet, anyway? Yes, I know it’s a bit of a misleading question, given that we can actually cure quite a few cancers, including several leukemias and lymphomas, which are curable with chemotherapy and radiation, and solid tumors like breast and colorectal cancer which are curable with a combination of surgery, chemotherapy, and radiation. Unfortunately, although we do fairly well (and in some cases very well) against early stage cancer, we don’t do so well against stage IV metastatic disease, particularly solid tumors. The vast majority of these are not curable, and, very likely, the vast majority are much like the prostate cancer specimens studied by these researchers, full of chromosomal rearrangements and mutations leading to abnormalities in many different signaling pathways.
Last year, the tenth anniversary of the announcement of the results of the Human Genome Project provoked a veritable flood of “Why haven’t we cured cancer yet?” or “Why haven’t we cured this disease yet?” For example, Nicholas Wade wrote a painfully simplistic article last June entitled A Decade Later, Genetic Map Yields Few New Cures. It’s an article I should have blogged about; perhaps even eight months later it would be worth doing, although you could always read this perspective instead. Let’s put it this way: The technology, techniques, and knowledge developed during the Human Genome Project laid the groundwork that has made it possible to sequence the entire genome of prostate cancer tumors and compare them this way. Come to think of it, I’m really dreading December 23, 2011. That will mark the 40th anniversary of Richard Nixon’s signing of the National Cancer Act of 1971. I just know that the month of December will be filled with stories lamenting, “Why haven’t we cured cancer yet?” or proclaiming the “war on cancer” to have been a failure. Some will be from the mainstream media, and even more will come from places like NaturalNews.com and Dr. Mercola’s website. That’s one prediction you don’t have to be a psychic to make. I also predict a whole bunch of articles and blog posts trying to claim that we’d be able to cure cancer “if only,” as in “if only” we’d be less conservative in our research approach (never mind that there are lots of high-risk approaches, and the ones that work only appear obvious in hindsight), “if only” we’d educate our kids in science better, “if only” we’d get rid of the FDA (yes, this guy was serious, as silly as his argument is), or “if only” doctors didn’t make so much money treating cancer with drugs and wouldn’t make any money treating it with “natural” therapies.
In preparation for this landmark event, I’ll begin with a pre-emptive answer (which I’ll no doubt have to repeat in December). Why haven’t scientists cured cancer yet? Leaving aside the trite answer of “Which cancer?” I can say this: Because it’s hard. It’s very, very hard. It’s harder than going to the moon; it’s harder than building the nuclear bomb; it’s harder than wiping out smallpox. All of those were, of course, also very, very hard too, but cancer is a harder nut to crack still. It’s hundreds, perhaps thousands, of diseases. Each type of cancer can be many, even dozens, of different diseases in itself. Each tumor can be many diseases that are constantly evolving, both in response to the environment in which the cancer cells grow and to treatments that are thrown at them.
And most cancer cell genomes probably look like the prostate cancer genomes analyzed in this paper. There’s a less thorough study that suggests that the breast cancer genome does.
Does that mean I have no hope? Of course not! Otherwise, I wouldn’t keep doing what I’m doing. I am simply expressing humility in the face of a protean foe that has thus far withstood our best efforts to eradicate it. That does not mean that it will continue to do so. After all, never before have we had the tools that we have now to probe deeply into the biology of cancer at the whole genome level as we do today.
Still, it will be hard.

Why haven’t we cured cancer yet? (Revisited): Personalized medicine versus evolution
David Gorski on April 9, 2012
Link
About a year ago, I addressed what might seem to the average reader to be a very simple question: Why haven’t we cured cancer yet? As I pointed out at the time, it’s a question that I sometimes even ask myself, particularly given that cancer has touched my life. Three years ago, my mother-in-law died of a particularly nasty form of breast cancer. Even though I am a breast cancer surgeon, I still wonder why there was nothing that could save her (and there still is nothing that could have saved her, if it existed then) from a decline over several months followed by an unpleasant death. Yet, as a cancer researcher, I do understand somewhat. A couple of years ago, I wrote in depth about the complexity of cancer from a science-based viewpoint, as compared, of course, to the incredibly simplistic view that many purveyors of alternative medicine quackery promote as being The One True Cause of Cancer. As I put it at the time, shamelessly stealing from Douglas Adams: Cancer is complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think algebra is complicated, but that’s just peanuts to cancer.
I saw more evidence of that at the American Association for Cancer Research meeting last week. In fact, if there’s anything I’ve learned, it’s that developing personalized therapy for cancer is going to be a hell of a lot more difficult than we had ever suspected. Actually, it wasn’t just the AACR meeting that taught me this, but it’s as good a pretext as any to discuss some cool new science. I only wish it was science that pointed an obvious path forward to the development of personalized therapy. On the other hand, if it were easy then anyone could do the “personalized therapy for dummies” approach that, for example, Stanislaw Burzynski takes. Then there’s the even more ridiculously simplistic approach that certain practitioners of “complementary and alternative medicine” (CAM) take.
So why haven’t we cured cancer yet? Again? One reason that I discussed last time I covered this topic concerns a study that used the latest next generation sequencing (NGS) techniques to sequence seven aggressive and advanced prostate cancers. I described the results as these genomes looking like someone threw a miniature grenade into the nucleus of a prostate epithelial cell. In other words, these are some really messed up genomes. (I wanted to use another word to describe it, but this is a family blog—sort of, anyway.) I used this example to explain once again that cancer is not a single disease. It’s hundreds of diseases. Although there are common themes in how cells become cancerous, such as loss of responsiveness to growth signals with a resultant ability to grow unchecked, evasion of programmed cell death (apoptosis), inducing the surrounding tissue to provide a blood supply (angiogenesis), evading the immune system, and invading the blood or lymphatic systems to travel elsewhere in the body and take up shop in other organs, such as liver, lung, or bone, individual cancers acquire these necessary (to the cancer) abilities through many different mechanisms. For this reason, it’s completely ridiculous to speak of a “cure for cancer.”
It’s also the reason I expressed skepticism when Steve Novella discussed a potential universal anti-cancer drug. Ditto when the press breathlessly reports studies suggesting a “universal cancer vaccine.” While these sorts of research findings are promising, they need to be put into perspective. We’ve seen their like many times before, and various cancers are still deadly diseases. In fact, my career intersected with this sort of hype back in the 1990s, when I studied combining angiogenesis inhibitors with radiation therapy in experimental models of cancer in mice. For a period of time in the late 1990s, I lived the hype. Then reality, as it always does, brought us all down to earth. Now, 15 years later, we know that angiogenesis inhibitors, although useful, are not any sort of “magic bullet” cure for all solid tumors. Like many advances before, they have now taken their place in the armamentarium of anticancer drugs, more important than some but not as important as others.
It’s even more complicated than that.
The challenge
It turns out that cancer is an even more difficult foe than my original introduction of the topic indicates, which was designed to bring readers up to speed on the issue. Ever since the genomics revolution began in the 1990s and accelerated in the 2000s, the dream has been to use the gene expression profiling information and the genome sequences of individual cancers derived from next generation sequencing technology and the latest analytic techniques. It seemed like a perfectly reasonable dream early in the genomics revolution, so much so that the Cancer Genome Project, which has been sequencing cancer genomes furiously, seemed like the right way to lay the groundwork for personalized cancer therapy. Couple that with the rapid advances in sequencing technology that have allowed us to sequence both a genome and every single RNA produced by that genome, both coding and noncoding, with a rapidity previously thought completely impossible, and the rapid decline in price of sequencing a genome that might well bring the cost below $1,000 before too long, and it’s easy to understand why scientists are sequencing every tumor in sight, and more of them.
For example, a year ago a paper describing NGS sequencing of seven prostate cancers was hot news. These days, such a study would probably only make into a middle-tier journal. As of last week, one has to sequence 104 triple negative breast cancers. This was a study that was mentioned by several speakers at the AACR meeting but wasn’t published in Nature until the day after the meeting ended. This one’s so hot off the presses that it doesn’t even show up in PubMed yet. It comes from Samuel Aparicio at the University of British Columbia, plus other groups from UCSF, Cambridge, the University of Alberta, and Simon Fraser University and is entitled The clonal and mutational evolution spectrum of primary triple-negative breast cancers. A news report describes the finding thusly:
The journal Nature has just published the team’s findings online.
The study is the largest genetic analysis of what were thought to be triple negative breast cancer tumours.
The 59 scientists involved in this study expected to see similar gene profiles when they mapped on computer the genomes of 100 tumours.
But to their amazement they found no two genomes were similar, never mind the same. “Seeing these tumours at a molecular level has taught us we’re dealing with a continuum of different types of breast cancer here, not just one,” explains Steven Jones, co-author of this study.
Triple-negative breast cancer (TNBC) is a form of breast cancer that is characterized in the clinic by its lack of hormone receptors—i.e., estrogen receptor (ER) and progesterone receptor (PR)—and its lack of amplification of HER2/neu, an oncogene that can be targeted with Herceptin (trastuzumab). In general, most (but not all) TNBCs belong to a category of breast cancer established 10 years ago by early gene expression profiling techniques known as basal-like. Worse, TNBC tends to be more aggressive than ER-positive cancers, metastasizing earlier and recurring earlier. Because TNBC doesn’t express receptors that confer sensitivity to agents targeted against the estrogen receptor or HER2, the only systemic therapy that is currently effective against TNBC is cytotoxic chemotherapy, which is very effective initially. Unfortunately, that efficacy doesn’t translate into better survival. TNBC, although making up only around 15% of breast cancer, accounts for a disproportionate share of breast cancer deaths. This study, which looked at newly diagnosed TNBC before any treatment was initiated, suggests one reason why. In this study of 104 TNBCs, which is the largest series of tumors subjected to NGS analyses to date, no two tumors were the same, and they were heterogeneous even before any treatment was initiated.
That reason is that TNBC is not a single disease. In fact, even an individual TNBC tumor is not a single disease. Tumor cells undergo evolution as they grow, so that the cells in them are genetically heterogeneous. The cells growing in one area of a tumor can and often do have markedly different genetic mutations from the cells growing in another part of the tumor. Arapicio’s group found evidence that this is going on in TNBC in spades. One finding in the study was that groups of mutations within individual cases have different clonal frequencies, indicative of distinct clonal genotypes. What this means is that analysis of the NGS data found evidence of different clones of cells with different frequencies of groups of mutations, suggesting that there are a number of different clones of cells with different genetic makeups in each tumor. They also found that p53 was the most frequently mutated gene and that tumors harboring p53 mutations tended to have the greatest number of overall mutations, consistent with the role of p53 as “guardian of the genome.” Moreover, tumors varied wildly from each other in the number of mutations, with some tumors harboring just a handful of somatic mutations and others harboring hundreds. Finally, only around 36% of these mutations were expressed, which is consistent with other studies. Overall, this study shows:
The team found that each tumor displayed multiple “clonal genotypes,” suggesting that the cancer would have to be treated as multiple diseases, rather than a single entity.
“Triple negative breast cancer is not just one uniform subtype of breast cancer,” Sam Aparicio, professor of pathology and lab medicine at UBC and senior author of the study, said in a statement. “It’s actually extremely complex, with each cancer at a different stage in the evolutionary process at the time of diagnosis.” This finding could “help explain why patient responses to treatment differ greatly,” he added.
If there’s a place where evolution will inform medicine at least as much as it does in infectious disease and the development of antibiotic resistance in microorganisms, it’s in cancer. The knowledge that tumors are heterogeneous and that they undergo evolution based on the selective pressures from the host, including characteristics of the organ and its microenvironment and other factors, is not new. Neither is the knowledge that cancer cells undergo evolution under the selection pressure of various therapies, thus developing resistance to those therapies. Indeed, it is the tumors that are less heterogeneous because they are driven by a single mutation, that tend to be actually curable or best controlled with single-agent targeted therapies. Just like the case in whole organisms undergoing evolution in response to selective pressures, genetic variability in cancer cells provides the raw material upon which evolutionary selection pressures can operate. The result is that tumors with more genetic heterogeneity tend to develop resistance to therapy sooner.
Personalized therapy versus cancer cell heterogeneity
Less than a month before the AACR meeting, yet another study was published that threw cold water on the idea that NGS sequencing of tumors will lead to personalized therapy of cancer any time soon. This study by Charles Swanton and colleagues published in the New England Journal of Medicine, is yet more evidence at how heterogeneous cancer is and how it evolves as it progresses and metastasizes. Basically, what Swanton’s group did was to examine four patients with metastatic renal cell carcinoma, but to analyze different locations within the primary tumor and metastases, subjecting the tissue from these various locations to NGS techniques and mutational analysis.
Data derived from the first patient is probably the best example to discuss. This is a patient who had a type of renal cell carcinoma known as clear cell carcinoma, with lung and chest wall metastases. He was treated for six weeks with everolimus and then underwent nephrectomy. He was started on everolimus again for six weeks and then underwent resection of his chest wall metastases. In both cases, the tumors did not shrink in response to the targeted treatment. Investigators then did the following:
For Patient 1, we performed exon-capture multiregion sequencing on DNA from pretreatment biopsy samples of the primary tumor (PreP) and chest-wall metastasis (PreM), nine primary-tumor regions of the nephrectomy specimen (R1 to R9), a metastasis in the perinephric fat of the nephrectomy specimen (M1), two regions of the excised chest-wall metastasis (M2a and M2b), and germline DNA19 (Figure 2A). This sequencing resulted in a median coverage of 74 reads (Table 1 in the Supplementary Appendix). Nonsynonymous somatic point mutations and insertions and deletions (indels) that change the protein amino acid sequence were filtered and manually reviewed to remove sequencing and alignment errors and to determine the regional distribution of mutations. Regions R6 and R7 were excluded from analyses since only one nonsynonymous variant passed filtering. We identified 101 nonsynonymous point mutations and 32 indels (Table 2 in the Supplementary Appendix) and mapped their regional distributions across the tumor (Figure 2B). Sanger sequencing was used to validate 42 mutations. Of these mutations, 37 (88%) were specifically validated in regions in which they were initially identified (Figure 2B, and Fig. 1 in the Supplementary Appendix), documenting genetic intratumor heterogeneity.
Don’t worry so much about the gobbledygook. The point is that the investigators sequenced nine areas in the primary tumor, two regions of the chest wall metastasis, a metastasis in the fat around the kidney, and the patient’s germline DNA for comparison. What they found was a pattern of mutations in the tumor regions consistent with branching evolution:
We inferred ancestral relationships and constructed a phylogenetic tree of the tumor regions by clonal ordering, as described by Merlo et al.20 (Figure 2C), which revealed branching rather than linear tumor evolution. One branch evolved into the clones present in metastatic sites, and the other diversified into primary tumor regions. R4 shared some, but not all, primary-tumor and metastatic mutations, which suggested the presence of at least two clonal populations in this region that arose from progenitor cells of the metastases and of other primary tumor sites.
And, since a picture is worth a thousand words, here is Figure 2:
Another key finding is that it really matters which part of a tumor a biopsy is taken from. It matters a lot. For instance, in this same tumor, a single biopsy only contained approximately 55% of all the mutations detected in the tumor and only 34% of all mutations that were detected by multiregion sequencing in the nephrectomy specimen were present in all regions. To me, it’s a classic scientific-ese understatement when the authors state that these results indicate “that a single biopsy was not representative of the mutational landscape of the entire tumor bulk.”
This heterogeneity means something, too. More and more, oncologists are using tests that are gene expression signatures in order to guide therapy. In breast cancer, for instance, we use the Oncotype DX assay a lot in order to decide whether patients with ER-positive breast cancers and no lymph node metastases will benefit from chemotherapy. In renal cell carcinoma, apparently there is a 110-gene signature profile that is used to classify clear cell carcinoma. Swanton looked specifically at this profile in Patient #1:
We determined the intratumoral expression of a 110-gene signature shown to classify clear-cell carcinoma into two molecular subgroups: clear-cell A (associated with a good prognosis) and clear-cell B (associated with a poor prognosis).24 Consistent with the phylogenetic analysis, metastatic sites and the primary-tumor site R4 segregated together, enriched for genes in the clear-cell A subgroup, in contrast to the remaining tumor regions that were enriched for the clear-cell B subgroup (Figure 3C). Thus, prognostic gene-expression signatures may not correctly predict outcomes if they are assessed from a single region of a heterogeneous tumor.
To give you a visual picture, take a look at Figure 3C. You don’t need to know how to interpret the gene signatures, other than that red means the gene is expressed at a higher level and blue means it’s expressed at a lower level. Just look at the patterns in the different areas of the tumor assayed. Notice how different they are? That’s what the authors are talking about. Once again, a picture is worth the proverbial thousand words (not that that stops me from writing a thousand words anyway).
Given the difficulty we often have in obtaining anything more than a needle biopsy of tumors, one biopsy from one area of a tumor is almost always what oncologists base their treatment decisions on. At least in breast cancer, we usually have the whole primary tumor, but even so only a small portion is used to do the actual Oncotype DX test. What are the consequences of this tumor heterogeneity? Evolution rules. For instance, a few months ago, researchers at Washington University did NGS analyses on the genomes of primary and relapsed tumors in eight patients with acute myeloid leukemia (AML) and found two main patterns in the relapsed tumors:
In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.
Inside Darwin’s tumor, indeed. The tumor cells that survived chemotherapy acquired new mutations that allowed them to regrow even faster. The parallels between cancer biology and antibiotic resistance are both sobering and humbling, the attempts of evolution denialists to paint evolution as irrelevant to medicine notwithstanding.
Meanwhile, at the AACR meeting, there were a number of other abstracts and talks that were variations on the same theme. There is a large degree of inter-tumor variability in genetic makeup and a large degree of intra-tumor variability as well. One of these studies, which looked at tumors from the ACOSOG Z1031 trial comparing different aromatase inhibitors in ER-positive breast cancer, found that the complexity of genomic changes correlated with lack of response to therapy. Moreover, as was discussed in at least a couple of talks at the AACR meeting, an evolution-based analysis of tumors using the latest NGS techniques indicates that for most solid tumors the time from founder mutation to clinically apparent metastasis is between 20 and 30 years. For example, for pancreatic cancer it’s a median of around 21 years, and for colon cancer it’s around 30 years. That’s decades of evolution that can occur in the tumor to result in heterogeneity. Worse, it means that, by the time we see a tumor clinically, it’s already very late in the process. This is not new news, of course. We’ve always known that it’s at least several years from initiation of cancer to clinical presentation, with the part of the process from detection of the tumor to death making up a relatively small part of the timeline of the history of a cancer. All that the new NGS sequencing techniques have shown us is that the process of carcinogenesis starts earlier than we had previously thought and results in more branches in the evolutionary tree of a tumor than we had previously thought, resulting in even more tumor heterogeneity than we had thought.
So what the new genomic analytical techniques have re-emphasized to us in a quantitative manner that we couldn’t use before is that not only is cancer not a single disease but that cancer types are not single diseases. Breast cancers, for instance, have been shown to harbor at least 1,700 different mutations, but only three of them showed up in at least 10% of patients, with the great majority of them being unique to each patient. The most recent study in Nature discussed above shows that even a single subtype of breast cancer that is generally treated clinically more or less the same, TNBC, varies wildly (and almost continuously) in the genomic changes and mutations each tumor has. Not only that, but each TNBC is in essence several diseases, because each TNBC is made up of many different clones that have evolved as the tumor itself grew, progressed, and evolved. All of this occurs even before the tumor has been subjected to any treatment at all. As if that’s not bad enough, it would appear that tumors are a mosaic of groups of many different tumor cell types that develop through branching evolution such that metastases can be very different from the primary tumor and even different regions of the primary tumor can be very different from each other, so much so that finding a “favorable prognosis signature” on a core biopsy means only that that one area biopsied has that gene signature. Large areas elsewhere in the tumor could have the unfavorable prognosis signature.
In an accompanying editorial in the NEJM, Dan DeLongo sums it up thusly, puncturing the optimism at the heart of visions of personalized medicine for cancer using targeting agents:
This modicum of success (since none of the new agents produce cures in advanced cancers, although curative combinations may yet emerge) has led to a certain level of overoptimism in the field. A new world has been anticipated in which patients will undergo a needle biopsy of a tumor in the outpatient clinic, and a little while later, an active treatment will be devised for each patient on the basis of the distinctive genetic characteristics of the tumor. The path to that new world is already being cleared, with several companies now marketing genetic tests that measure the genetic signature of a tumor, with the expectation that this signature will direct the choice of treatment and predict treatment outcome.
However, as Albert Einstein noted, “things should be made as simple as possible, but not simpler.” A serious flaw in the imagined future of oncology is its underestimation of tumor heterogeneity — not just heterogeneity between tumors, which is a central feature of the new image of personalized medicine, but heterogeneity within an individual tumor.
Derek Lowe put it quite well in the title of a recent post, Personalized Medicine for Cancer? Try Every Cell. He’s right. We’re at the point where it is now possible to do NGS on single cells. If the rate of progress continues apace, a year or two from now such sequencing studies will become fairly routine. At least at the big genomics centers, it’s becoming more common. As these studies go from sequencing 100 cells to sequencing 1,000 cells or 10,000 cells, or a million cells, it’s likely that it will be discovered that intratumor heterogeneity is even greater than found in these two studies.
The future of personalized medicine
Does all of this mean that personalized cancer therapy is a pipe dream? If I thought that, I wouldn’t be moving towards genomics in my research. It is, however, becoming clear that developing personalized therapies for cancer is going to be a lot more difficult than we had thought before. I asked the rhetorical question, “Why haven’t we cured cancer yet?” The answer is, of course, that curing a single cancer, much less many cancers, is really, really hard. Scientists not only have to contend with basically a continuous spectrum of mutations between individual cancers that renders the concept of even single cancer subtypes horribly naive, but with a near continuous spectrum of mutations between groups of cells in a single tumor.
There is reason for hope, however. As was discussed at AACR, the vast majority of cancer-causing driver mutations can be divided into 12 key molecular signaling pathways, and, as was found in the NEJM paper, mutations at the “trunk” of the divergent branching evolution tend to remain as divergent evolution occurs, and targeting them is likely to be more effective than targeting mutations further out on the branches. It might be possible to hone in on these different pathways. In the meantime, as the cost of sequencing continues to fall, it might become feasible to sequence several parts of a tumor and its metastases and map out treatments that cover all of them. Personalized medicine is thus possible and still holds promise. It’s just not going to be as simple as getting a biopsy of a tumor and picking a targeted agent or two to blast the tumor into oblivion. The point is not that personalized medicine is impossible or that it’s impossible to develop cures for various cancers. The point is that biology is always way more complicated than we ever thought it was, and evolution almost always wins out. Or, as a character named Dr. Ian Malcolm in the movie Jurassic Park, observes:
If there is one thing the history of evolution has taught us it’s that life will not be contained. Life breaks free, expands to new territories, and crashes through barriers, painfully, maybe even dangerously, but, ah, well, there it is.
Unfortunately, paraphrase a later quote from Dr. Malcolm, cancer always finds a way. Well, pretty darned close to always, anyway. If I believed that cancer always finds a way, then I would also believe that cancer research and personalized therapy are futile endeavors. I do not believe that.
Even so, the reason we haven’t cured cancer yet is because we haven’t figured out how to overcome the power of evolution. Until we figure out a way to do that, we will continue to make only incremental progress.

The Cancer Moonshot: Hype versus reality
The Cancer Moonshot has been promoted as a strategy to break the logjam that seems to be holding up new, much more effective treatments for cancer. The key word is “seems,” because in reality the Cancer Moonshot is more hype than promise.
David Gorski on September 12, 2016
Link


The Cancer Moonshot. It’s a topic that I’ve been meaning to address ever since President Barack Obama announced it in his State of the Union address this year and tasked Vice President Joe Biden to head up the initiative. Biden, you’ll recall, lost his son to a brain tumor. Yet here it is, nearly eight months later, and somehow I still haven’t gotten around to it. The goal of the initiative is to “eliminate cancer as we know it,” and to that end, with $195 million invested immediately in new cancer activities at the National Institutes of Health and $755 million proposed for FY 2017. My first thought at the time was that that wasn’t nearly enough money to achieve the ambitious goals set out by the President. That has now become particularly clear now that the National Cancer Institute has released the report from the initiative’s blue ribbon panel suggesting ten ways to speed up progress against cancer. 
Initial thoughts on the Cancer Moonshot
When I first saw the President announce the Cancer Moonshot initiative several months ago, I couldn’t help but think that, although a very catchy title that would grab attention, calling the initiative the Cancer Moonshot was profoundly deceptive, probably unintentionally so but deceptive nonetheless. Why? The analogy between finding cures for cancer and going to the moon in the 1960s is profoundly flawed. The latter was primarily an engineering problem. The science, in particular the physics, necessary to achieve a moon landing was already adequately understood. What was needed was the technology to achieve the ambitious goal and the resources to develop that technology. In the Cold War era of the 1960s, in which the original moonshot was part of the geopolitical competition between the U.S. and the Soviet Union, it didn’t take much to direct resources to this end, resulting in a moon landing less than a decade after President John F. Kennedy, Jr. announced it.
The other reason that the analogy is deceptive is that the original moonshot was a much simpler problem to solve than cancer is. That’s not to say the original moonshot wasn’t a very difficult initiative, but cancer is orders of magnitude more difficult. As I’ve pointed out many times before, cancer is not just one disease. It’s hundreds. Even individual cancers are incredibly complex. Thanks to the power of evolution, tumors evolve into masses of heterogenous cells with different genetic makeups, such that tumor cells from a metastasis might well be resistant to treatments to which the primary tumor is sensitive. Breast cancers, for example, have been shown to harbor at least 1,700 different mutations, but only three of them showed up in at least 10% of patients, with the great majority of them being unique to each patient. Back in 2011, which was the 40th anniversary of President Nixon’s War on Cancer initiative, there was a spate of “Why haven’t we cured cancer yet” articles. I explained why. Cancer is not a single disease, and cancers are different. The mechanisms of carcinogenesis are not simple. Cancers evolve rapidly because of their genetic instability, leading to tumor heterogeneity. There are many more reasons, but those are the top three. Although, thanks to rapid advancements in gene sequencing and computer technology since the 1990s, the last two decades have produced massive quantities of data on the sequences of individual cancers, which genes are mutated and where, and how intracellular signaling pathways controlling proliferation, migration, and invasion are altered in cancer, at least thus far the effect on patient care has been far more modest.
None of this is to say that the Cancer Moonshot itself is a bad thing, only that, as has been the case for so many initiatives to “cure cancer” before, what it is likely to achieve is actually far more modest than what is being promised.
The Blue Ribbon panel’s report
When the news stories started coming out last week about the Cancer Moonshot, I naturally gravitated over to the National Cancer Institute website to get the details. The first thing I did was to look at who was on the blue ribbon panel. There’s no doubt that there are heavy hitters on the panel, whose names I immediately recognized, but there are also a fair number whom I had never heard of before. Be that as it may, the process is described thusly:
The BRP members were announced on April 4, 2016, and the first (virtual) meeting took place on April 11. At this meeting the members agreed to establish seven working groups to focus on major topic areas. The working group members were announced on May 2, and the groups met frequently until mid-July. In addition, the BRP met several more times—in person on April 18 and July 20, and virtually on July 13.
The working groups began with broad discussions of the state of the field for their respective topics and considered ideas from the members and the community at large. The panel considered more than 1,600 ideas submitted by the broader cancer community through a dedicated website, email, and other routes. Some working groups created subgroups with focused expertise in particular areas to carefully craft their recommendations. As the working groups narrowed in on their specific recommendations, the chairs of multiple groups also met to discuss cross-cutting themes and to merge similar topics into joint recommendations.
The BRP reviewed the working groups’ draft recommendations at its June 13 meeting and reviewed their final recommendations at its July 20 (in-person) meeting.
In other words, it sounds like a typical process for producing a white paper or set of evidence-based recommendations. The result was a 100+ page report, Research Opportunities for the Vice President’s Cancer “Moonshot“. I didn’t read the entire thing, given how long it was, but did hit some of the highlights, such as the Tumor Evolution and Progression Working Group Report. Each working group report is divided into nice bite-sized sections, including
    • What is the recommendation?
    • Where are we now?
    • Where do we need to be (in 1-5 years)? (with priorities listed)
    • Strategy: What will it take to get there?
    • What does success look like?
The panel’s recommendations are also summarized in a short version and long version of the report, as well as in a video:
The recommendations include:
     1.  Establish a network for direct patient involvement
     2.  Create a clinical trials network devoted exclusively to immunotherapy
     3.  Develop ways to overcome resistance to therapy
     4.  Build a national cancer data ecosystem
     5.  Intensify research on the major drivers of childhood cancers
     6.  Minimize cancer treatment’s debilitating side effects
     7.  Expand use of proven prevention and early detection strategies
     8.  Mine past patient data to predict future patient outcomes
     9.  Develop a 3D cancer atlas
     10.  Develop new cancer technologies
Some of these recommendations are pretty uncontroversial. For instance, although more detail is given, who on earth would be against developing new cancer technologies? The rub, of course, is which new cancer technologies. Similarly, who would be against minimizing the debilitating effects of chemotherapy and other treatments? Or expanding the use of proven prevention techniques? For instance, tobacco use is the single largest cause of preventable deaths, and those deaths aren’t just due to tobacco-associated cancers like lung cancer. If smoking could be eliminated, as I’ve pointed out before, deaths from cancer would plummet because by far the most common cause of preventable cancer is tobacco, causing an estimated 86% of cases of lung cancer, 65% of cases of esophageal cancer and cancers of the oropharynx and head and neck, 37% of cases of bladder cancer, and 29% of cases of pancreatic cancer.
Uncontroversial recommendations aside, most of the recommendations are pretty measured and well thought out, although at least one appears to be a result of a current scientific bandwagon effect. Let’s take a look.
Selected Cancer Moonshot recommendations: Immunotherapy
The first thing I noticed when I read the Cancer Moonshot Blue Ribbon Panel report, is that there wasn’t anything particularly bold about it, the effusive praise heaped on it by the American Society of Clinical Oncology (ASCO) notwithstanding. Personally, if this weren’t called the Cancer Moonshot, I wouldn’t think that was a bad thing, but rather a good thing. In actuality, the report is a synthesis of where cancer research is right now and where it is going rather than any sort of bold vision of where it should go. Again, that’s not a bad thing. Martial rhetoric, exaggerated promises, and analogies to massive scientific efforts of the past have always been at odds with the evolutionary and incremental nature of cancer research; so a report that proposes, in essence, to take the technology and science we have today and to build on it is the best that is likely to be expected, even if it’s a bit boring. In retrospect, I wish I hadn’t skipped this year’s ASCO meeting because I could have seen Vice President Biden give his pitch for the initiative.
The first recommendation that leapt out at me was definitely the recommendation for a clinical trials network devoted exclusively to immunotherapy. Yes, that’s the one that’s clearly based on a current scientific fad. My guess is that, if the Cancer Moonshot Blue Ribbon Panel had been convened in the 1990s it would have included an initiative to investigate antiangiogenic therapy (therapy that targets blood vessel development). Is immunotherapy a big enough deal to rate one of the ten major recommendations of the panel and a recommendation for a national clinical trials network devoted solely to immunotherapy? Maybe, but over the years I’ve become a lot more skeptical, remembering all the hype and promise of antiangiogenic treatments in the 1990s and the previous wave of immunotherapy hype in the 1980s. (That’s what happens when you get to be a bit of an old fart.) Those memories temper my enthusiasm.
On the other hand, there’s no doubt that a new class of drugs, immune checkpoint inhibitors, is a big deal. There are lots of other forms of immunotherapy that have been developed. For example, there are humanized monoclonal antibodies against specific cancer targets (like Herceptin). There are cell-based therapies, some of which I saw when I was a resident in the late 1980s and early 1990s. There are dendritic cell therapies. There are also cancer vaccines, which have had pretty mixed results and are mostly still experimental. There are vaccines to prevent cancer, the most successful of which is, obviously, HPV vaccines such as Gardasil and Cervarix, which prevent cervical cancer by preventing infection by the most common HPV types. To be honest, though, my assessment of these other forms of immunotherapy is that they’ve had fairly limited success over the last 30 years, other than Gardasil and Herceptin, and I consider Herceptin to be targeted therapy more than immunotherapy. Immune checkpoint inhibitors are different, though. These days, when a cancer researcher (and, truth be told, the Cancer Moonshot Blue Ribbon Panel) say “immunotherapy”, what they really mean are mainly immune checkpoint inhibitors.
One of the most critical components of the immune system is the ability to distinguish between what is “foreign” and “self.” The main job of the immune system is to leave self alone and to attack foreign invaders, such as bacteria. Obviously it’s a lot more complicated than that, because we have trillions of bacteria that live on our bodies in relative harmony with us, but for purposes of this discussion it’s not necessary to go into that more deeply. The problem with cancer, of course, has always been that cancer at least starts out as “self.” It is our own cells. When they become cancerous, some tumor cells are indeed recognized as no longer being self, but some cancers are very good at evading the immune system, often by tricking these immune checkpoints. Immune checkpoint inhibitors target proteins controlling these checkpoints, such as PD-1, which normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body. Immune checkpoint inhibitors are one of the most promising classes of new drugs in the pipeline.
The report states:
The success rates of first-generation cancer immunotherapies, such as checkpoint inhibitors, genetically engineered T cells, and new immune activators have improved remarkably over the last 10 years, resulting in durable, long-term survival—and, in some cases cures—for a subset of patients with advanced cancers such as melanoma, blood, and lung cancers. However, only 10-20% of patients with these cancers have long-term responses to current immunotherapies. We must learn why some patients who have melanoma (such as President Carter) or lung cancer respond to checkpoint blockade immunotherapy, whereas patients with many other types of adult cancers, including ovarian, breast, pancreatic, brain, and prostate cancer—as well as most pediatric cancers—have brief responses or do not respond at all.
Same as it ever was. One could say the same thing about many targeted therapies. I’m not sure I would have devoted a whole national clinical trials network to just immunotherapy. I would have thought bigger and included all targeted therapies, as I tend to agree with cancer researcher Vinay Prasad:
Immunotherapy refers to promising new drugs that harness the body’s immune system to fight cancer, and indeed these have generated impressive outcomes for some patients. But with dozens of immunotherapy studies underway, that rocket has already lifted off, and it’s unclear what Biden’s moonshot can add. And, unfortunately, the bitter reality is that despite immunotherapy’s promise, its benefits will probably remain confined to a minority of patients with certain types of cancer. Immunotherapy is unlikely to be a panacea.
In other words, there is nothing about immunotherapy that is likely to be the “magic bullet” that some portray it as.
Selected Cancer Moonshot recommendations: Clinical trials
I was heartened to see in the panel’s recommendations establishing a network for direct patient involvement, building a national cancer data ecosystem, and mining past data to learn to predict patient outcomes. One of the most pressing problems confronting cancer research is recruiting patients to clinical trials to test new therapies. Thus, I like hearing things like:
This recommendation calls for cancer patients to join a new national network that, with appropriate privacy safeguards, will provide them with a genetic profile of their own cancer and let them “pre-register” for clinical trials, so they can be contacted when a trial for which they may be eligible opens. Researchers will be able to access patient outcomes reported in the network database to conduct studies on what treatments work, in whom, and in which types of cancer.
And creating an ecosystem to facilitate cancer research:
Technology has enabled the collection of a massive amount of patient data. But these data are often stored in proprietary databases or accessible only to a select group of people, limiting their usefulness as a research resource. A national ecosystem that links many of the nation’s largest data repositories would enable one-stop, free access for researchers, doctors, and patients to share data on cancer and fuel faster progress.
Smaller countries, with national health care systems, already have such outcomes data that researchers can mine. The fragmentation of the US health system and a lack of will to make such a database a priority have long been an issue. Also, such a database and encouragement to patients to empower them to be more involved in their own care by having access to their genetic profile could increase patient enthusiasm for research.
Similarly, what about mining past data for the purpose of hypothesis-generation?
Understanding why some patients with the same type and stage of cancer, and same treatment may end up with different outcomes continues to be a research challenge. Analysis of existing tumor tissue from patients who received standard-of-care treatment, stored at biobanks around the country, may enable discovery of genetic and other factors that distinguish which individuals would bene t from standard care versus experimental treatment in a clinical trial.
We have an enormous resource in the form of existing patient samples. It just hasn’t been adequately mined. However, I can’t help but echo cancer researcher Vinay Prasad’s skepticism when the Cancer Moonshot initiative was first announced:
Another oft-mentioned proposal is harnessing the power of big data. One such idea is to closely examine what therapies have worked for individuals and which unique genetic traits allowed those therapies to work, and then extend these findings to other patients. Unfortunately, such an approach is fraught with limits. My colleague Andrae Vandross and I recently reviewed the published reports of patients who have had an exceptional response to a cancer drug. In many instances, we found that these patients responded unusually well not only to the studied drug but also to older ones. In several cases, these people had already survived far longer than the typical patient by the time they received the lauded medication. It is hard, then, to conclude which patients have great outcomes because of a drug and which simply have slow-growing cancers — a phenomenon doctors have recognized for years. But this distinction is the very crux of the big-data approach. Observational data — no matter how “big” — will have difficulty overcoming this challenge.
The other trouble with big data is that if we agree that the outcomes we have now are mediocre (and I think we can agree on that), studying these outcomes in greater detail is unlikely to result in truly transformative approaches. It would be like NASA scientists studying old nautical voyages to figure out how to reach the moon.
I’m not as pessimistic about big data approaches a Prasad is, but I do share some of his skepticism. We’ve been trying big data approaches using genomic data for over 15 years now, and thus far we haven’t found anything truly transformational. Again, to me that’s not a criticism of using big data approaches. Such computational approaches are and will be very useful in cancer research. It’s just that they are and will be very useful in an incremental fashion, and they are prone to pitfalls that have plagued cancer research since cancer research began. In cancer, we frequently point out that biology is king. If you’re lucky enough to get a “good” cancer, chances are that you will tend to do well no matter what treatment is used. (Most alternative cancer cure testimonials consist of patients with “good” cancers.) If you’re unlucky enough to get a nasty cancer, chances are that you will do poorly regardless of treatment. I don’t see anything in the “big data” proposals that will overcome that. However, I also don’t think that better tools for hypothesis generation and to improve patient participation are a bad thing. They’re just not transformational.
The overall problem
I don’t see much reason to go into a lot of detail about the other recommendations. As I said before, most are not particularly controversial. Certainly none of them are transformational, including developing strategies to overcome resistance to anticancer therapies (a research priority that’s been a priority ever since anticancer therapies entered the field), minimizing side effects (a long-neglected priority that has come to the fore already in the last five or ten years, no “moonshot” required), expanding the use of prevention and early screening (the latter, of course, is not without risks, such as overdiagnosis and overtreatment), intensifying research into the drivers of childhood cancers (which basically says right there that it’s just ramping up what we’re already doing), or developing new technologies to fight cancer (which is something cancer researchers have been doing since time immemorial).
I will admit that I found the proposal to develop a 3D and 4D cancer atlas to be kind of cool:
Oncologists today rely on past experience, consultation with multidisciplinary teams, published studies, and other sources to make diagnosis and treatment decisions. Providing a web-based catalog of the genetic lesions and cellular interactions in tumor, immune, and other cells in the tumor microenvironment that maps the evolution of tumors—from development to metastasis—will enable researchers to develop predictive models of tumor progression and response to treatment that will ultimately help oncologists make informed treatment decisions for each patient.
The “4D” aspect, discussed in the more detailed report, involves rerecording the same data over time for individual patients. The problem with such an atlas, however, is the same problem with all of “precision medicine,” namely that we don’t yet know what to do with all the mountains of information gathered for them when it comes to applying all that data to individual patients. That leads me to wonder if the effort and expense necessary to build such a tool will pay off.
I realize that to persuade politicians to fund an effort it’s often necessary to sex it up and make it appealing. I also know that slow and steady incremental advancement is far less sexy than a “moonshot”-style effort, as in a massive surge of resources and effort directed at a single focused goal. Unfortunately, the whole concept of a “moonshot,” while well-suited for focused engineering problems such as landing a human being on the Moon, is poorly suited to a problem like “eliminating cancer as we know it,” which, by the way, is a poorly defined goal. You might remember the then-director of the NCI, Andrew Von Eschenbach, making the goal of the NCI to “eliminate suffering and death” from cancer by 2015. Well, it’s now 2016, and there’s still plenty of suffering and death from cancer in the US. Indeed, I remember attending a meeting of the American Association for Cancer Research in 2003 or 2004, where I attended a talk by Von Eschenbach and thought, “What is this guy smoking?” That was pretty much the reaction of every researcher with whom I spoke about his talk. The point is that making promises like that, framing cancer research as a “war” (which implies someday winning), or selling the idea that a concentrated “moonshot”-style effort can eliminate cancer is the wrong message.
Cancer is not a focused problem. It’s many hundreds, if not thousands, of problems, many interrelated, some not, that require many different solutions. Progress in cancer research, like science, will always be incremental, resistant to surrendering to victorious scientists and physicians the way Germany and Japan surrendered to the Allies in 1945, resistant to promises to eliminate it in 12 years, and certainly resistant to focused “moonshot” efforts to solve it. That doesn’t mean that there aren’t some good ideas worth implementing in the Cancer Moonshot, nor does it mean that it wouldn’t be worth increasing cancer research funding significantly, given the decrease in real purchasing power of the NIH and NCI budgets since 2004. Invested wisely, such funding could certainly contribute to real advances. The problem is, as with all science, it’s very difficult to predict where, when, or how such advances will manifest themselves or even what they’ll be. All we do know is that they’ll come about through incremental progress based on prior research. Unfortunately, that message is not one that’s as appealing as that of the Cancer Moonshot.

Everything Causes Cancer
Steven Novella on September 11, 2013
Link
It’s likely you know someone who has bought into the notion that nutrition is everything, the source of all health and the cause of all illness. Nutrition is very important, to be sure, but it is only one of many possible causes of disease, and if you live in a Western industrialized nation you probably have adequate nutrition. The notion, however, that food can heal is powerfully alluring, and it makes great headlines. The result is that people who read the headlines for the latest food to avoid, or the latest ingredient that will make them live longer or stave off disease, seem to have an association for everything. Eating around them is to be constantly told that food X is good for you and will prevent Y, or that some other food should be avoided because it causes Z.
Red peppers will help prevent cancer and help you lose weight. Garlic will help prevent heart disease and aids in iron metabolism. Cayenne pepper prevents strokes. Peaches prevent heart disease and cancer. In fact- think of any food at random and type “random food health benefits” into Google and chances are you will be rewarded with a list of the amazing health benefits of whatever food you wish.
My usual response when offered such advice is – you know, food is healthy for you. I recommend you eat food every day. Food is full of nutrition, essential vitamins and minerals, and will give you energy. If you don’t eat food, your health with dramatically suffer. But don’t eat too much food – that’s not healthful.
It is helpful to have published evidence and statistics to back up my casual observation – that nearly all foods are touted as having health benefits or risks. Earlier this year Schoenfeld and Ioannidis did just that. They selected 50 common ingredients at random out of cookbooks, then scoured the literature looking for studies showing an association (positive or negative) with cancer. They found that 80% of the ingredients had such published studies:
Forty ingredients (80%) had articles reporting on their cancer risk. Of 264 single-study assessments, 191 (72%) concluded that the tested food was associated with an increased (n = 103) or a decreased (n = 88) risk; 75% of the risk estimates had weak (0.05 > P ≥ 0.001) or no statistical (P > 0.05) significance. Statistically significant results were more likely than nonsignificant findings to be published in the study abstract than in only the full text (P < 0.0001). Meta-analyses (n = 36) presented more conservative results; only 13 (26%) reported an increased (n = 4) or a decreased (n = 9) risk (6 had more than weak statistical support). The median RRs (IQRs) for studies that concluded an increased or a decreased risk were 2.20 (1.60, 3.44) and 0.52 (0.39, 0.66), respectively. The RRs from the meta-analyses were on average null (median: 0.96; IQR: 0.85, 1.10).
These results mean a few things. First – about 60% of all food ingredients will either increase or decrease your cancer risk, if you believe the studies included in this review. That is a lot of ingredients to keep track of – imagine designing your diet around this information, and this is only for cancer specifically. However, meta-analysis decreased that number by about 2/3, to about 20%. That’s a bit more manageable, but still quite a large number of ingredients.
Fortunately (well, depending on your perspective) you can probably ignore most of this data. Most of the studies were one-off studies, and 2/3 of those that were replicated did not fare well according to the meta-analysis. Further, study replication tended to diminish the magnitude of the relative risk (either increase or decrease).
This is a pattern that has been found generally in the literature, including by Ioannidis himself. Preliminary studies tend to have a large effect size which diminishes throughout replication and with more rigorous studies. Often that effect size declines to zero. This phenomenon is called “the decline effect”, and is at least in part due to publication bias.
Generally speaking, preliminary studies tend to have a positive bias, caused by both a researcher bias and a publication bias. With replication and more rigorous studies, most of these preliminary (and positive) results are discovered to be wrong (Ioannidis again).
Those effects that survive replication tend to diminish in magnitude (the decline effect). The simplest explanation for this is regression to the mean – the tendency for any extreme result (which is likely to get published) to return to a more statistically average result. Further, practitioners are probably adopting interventions too early, before they have finished declining in the research, and are subject to later reversals with more rigorous data.
In this current study on food and cancer, we are seeing all of these same effects, just applied to the relative risk of cancer associated with specific foods and ingredients. There is a large volume of preliminary and low grade evidence, most of it shows a positive result (an association), and most of that does not survive later replication.
Also reassuring is that when you look at the relative risk of various foods and cancer as revealed in the meta-analysis, they all average out. As the authors say – “The RRs from the meta-analyses were on average null.”
This can mean one of two things (or both): either there is some risk or benefit to certain foods, but all these effects average out to zero, or we are just seeing a scatter of random results in the literature that average out to zero – meaning the results themselves may not be real.
Either way it seems to me that these results suggest it is probably a waste of time to obsess over the health risks and benefit of every food and ingredient.
The more research we do on the health effects of food the more the aggregate of this research supports the following simple rule: eat a variety of food, don’t eat anything to excess, and like your mother said, make sure you eat your vegetables.

Everything we eat causes cancer…sort of
David Gorski on January 7, 2013
Link
Red meat causes cancer. No, processed meat causes cancer. OK, it’s both red meat and processed meat. Wait, genetically modified grain causes cancer (well, not really). No, aspartame causes cancer. No, this food coloring or that one causes cancer.
Clearly, everything you eat causes cancer!
That means you can avoid cancer by avoiding processed meats, red meat, GMO-associated food (no, probably not), aspartame, food colorings, or anything “unnatural.” Or so it would seem from reading the popular literature and sometimes even the scientific literature. As I like to say to my medical students, life is a sexually transmitted fatal disease that gets us all eventually, but most of us would like to delay the inevitable as long as possible and remain as healthy as possible for as long as possible. One of the most obvious ways to do accomplish these twin aims is through diet. While the parameters of what constitutes a reasonably healthy diet have been known for decades, diet still ranks high on the risk of concerns regarding actions we take on a daily basis that can increase our risk of various diseases. Since cancer is disease (or, I should say, cancers are diseases) that many, if not most, people consider to be the scariest, naturally we worry about whether certain foods or food ingredients increase our risk of cancer.
Thus was born the field of nutritional epidemiology, a prolific field with thousands of publications annually. Seemingly, each and every one of these thousands of publications gets a news story associated with it, because the media love a good “food X causes cancer” or “food Y causes heart disease” story, particularly before the holidays. As a consequence, consumers are bombarded with what I like to call the latest health risk of the week, in which, in turn, various foods, food ingredients, or environmental “toxins” are blamed and exonerated for a panoply of health problems, ranging from the minor to the big three, cardiovascular disease, diabetes, and cancer. It’s no wonder that consumers are confused, reacting either with serial alarm at each new “revelatory” study or with a shrug of the shoulders as each new alarm joins other alarms to produce a tinnitus-like background drone. Unfortunately, this cacophony of alarm also provides lots of ammunition to quacks, cranks, and crackpots to tout their many and varied diets that, they promise, will cut your risk of diseases like cancer and heart disease to near zero—but only if adhered to with monk-like determination and self-denial. (Yes, I’m talking about you, Dean Ornish, among others.)
All of this is why I really wanted to write about an article I saw popping up in the queue of articles published online ahead of print about a month ago. Somehow, other topics intervened, as did my vacation and then the holidays, and somehow I missed it last week, even though a link to the study sits in my folder named “Blog fodder.” Fortunately, it just saw print this week in its final version, giving me an excuse to make up for my oversight. It’s a study by one of our heroes (despite his occasional misstep) here on the SBM blog, John Ioannidis. It comes in the form of a study by Jonathan D. Schoenfeld and John Ioannidis in the American Journal of Clinical Nutrition entitled, brilliantly, Is everything we eat associated with cancer? A systematic cookbook review.
Now, when John Ioannidis says a “systematic cookbook review,” he really means “a systematic cookbook review.” Basically, he and Schoenfeld went through The Boston Cooking School Cookbook and tested whether various ingredients described and used in the recipes in the cookbook had been tested for an association with cancer and what was found. What I love about John Ioannidis is embodied in the methodology of this study:
We selected ingredients from random recipes included in The Boston Cooking-School Cook Book (28), available online at http://archive.org/details/bostoncookingsch00farmrich. A copy of the book was obtained in portable document format and viewed by using Skim version 1.3.17 (http://skim-app.sourceforge. net). The recipes (see Supplementary Table 1 under “Supplemental data” in the online issue) were selected at random by generating random numbers corresponding to cookbook page numbers using Microsoft Excel (Microsoft Corporation). The first recipe on each page selected was used; the page was passed over if there was no recipe. All unique ingredients within selected recipes were chosen for analysis. This process was repeated until 50 unique ingredients were selected.
We performed literature searches using PubMed (http://www. ncbi.nlm.nih.gov/pubmed/) for studies investigating the relation of the selected ingredients to cancer risk using the following search terms: “risk factors”[MeSH Terms] AND “cancer”[sb] AND the singular and/or plural forms of the selected ingredient restricted to the title or abstract. Titles and abstracts of retrieved articles were then reviewed to select the 10 most recently published cohort or case-control studies investigating the relation between the ingredients and cancer risk. Ingredient derivatives and components (eg, orange juice) and ingredients analyzed as part of a broader diet specifically mentioned as a component of that diet were considered. Whenever ,10 studies were retrieved for a given article, an attempt was made to obtain additional studies by searching for ingredient synonyms (eg, mutton for lamb, thymol for thyme), using articles explicitly referred to by the previously retrieved material, and broadening the original searches (searching simply by ingredient name AND “cancer”).
How can you not love this guy?
His results were also not that surprising. First, he noted that for 80% of the ingredients his methodology identified there was at least one study examining its cancer risk. That’s forty ingredients, which he helpfully lists: veal, salt, pepper spice, flour, egg, bread, pork, butter, tomato, lemon, duck, onion, celery, carrot, parsley, mace, sherry, olive, mushroom, tripe, milk, cheese, coffee, bacon, sugar, lobster, potato, beef, lamb, mustard, nuts, wine, peas, corn, cinnamon, cayenne, orange, tea, rum, and raisin. He also notes that these ingredients represent many of the most common sources of vitamins and nutrients in a typical US diet. In contrast, the ten ingredients for which no study was identified tended to be less common: bay leaf, cloves, thyme, vanilla, hickory, molasses, almonds, baking soda, ginger, and terrapin. One wonders how almonds aren’t considered under nuts, but that’s just me being pedantic.
One also wonders whether “Dr.” Robert O. Young, alkalinization quack extraordinaire, who claims that cancer is due to too much acid and that alkalinization is the answer, has heard about no studies for baking soda, which to him, along with a vegan-based diet that is allegedly “alkalinizing,” is part of the “alkaline cure” for everything from cancer to sepsis to heart disease. Now, if you type “baking soda cancer” into the PubMed search box, you’ll actually pull of over 350 articles. However, none of them appear to be epidemiological studies. This reminds me. I need to look into that literature and do a post about it again. But I digress.
Let’s get back to the meat of the study itself. (Sorry, I couldn’t resist.)
Having identified the studies and meta-analyses, Schoenfeld and Ioannidis next extracted the data from the studies, looked at the quality of the studies, the size and significance of the effects reported, how specific they were, and whether there were indications of bias in any of them. The results they found were all over the map, with about the same number of studies finding increased compared to decreased risks of malignancy, and, as before, Schoenfeld and Ioannidis provide a helpful list:
Author conclusions reported in the abstract and manuscript text and relevant effect estimates are summarized in Table 1. Thirty-nine percent of studies concluded that the studied ingredient conferred an increased risk of malignancy; 33% concluded that there was a decreased risk, 5% concluded that there was a borderline statistically significant effect, and 23% concluded that there was no evidence of a clearly increased or decreased risk. Thirty-six of the 40 ingredients for which at least one study was identified had at least one study concluding increased or decreased risk of malignancy: veal, salt, pepper spice, egg, bread, pork, butter, tomato, lemon, duck, onion, celery, carrot, parsley, mace, olive, mushroom, tripe, milk, cheese, coffee, bacon, sugar, lobster, potato, beef, lamb, mustard, nuts, wine, peas, corn, cayenne, orange, tea, and rum.
The statistical support of the effects was weak (0.001 # P , 0.05) or even nonnominally significant (P . 0.05) in 80% of the studies. It was also weak or nonnominally significant, even in 75% of the studies that claimed an increased risk and in 76% of the studies that claimed a decreased risk (Table 1).
To boil it all down, what we have here are a bunch of studies that report an association between a food or food ingredient and either increased or decreased risk of various cancers, but the vast majority of them have very weak effect sizes and/or nominal statistical significance. Next, Schoenfeld and Ioannidis looked at ingredients for which meta-analyses existed and found 36 relevant effect size estimates based on meta-analyses. Many of these meta-analyses combined studies using different exposure contrasts, such as highest quartile/lowest quartile versus another measure, such as the highest versus lowest consumption. Only 13 meta-analyses were done by combining data on the same exact contrast across all studies. As one would expect when one pools diverse studies, meta-analyses tended to find smaller effects than individual studies, as shown in the following table from the paper (click to embiggen):
As I said, these findings are all over the map. Now, if you really want to see how chaotic the literature examined by Schoenfeld and Ioannidis is, take a look at the effect sizes found for ingredients for which there have been more than ten studies:
As you can see, it’s quite complex and all over the map, although there are a few ingredients for which the studies do appear to be fairly consistent, such as bacon being associated consistently with a higher risk of cancer. Bummer. Or is it? Let’s continue with Schoenfeld and Ioannidis’ analysis. What they found is rather disturbing. First, they report that although 80% of the studies they examined reported positive findings (i.e., a positive association between the food or ingredient studied and some form of cancer):
…the vast majority of these claims were based on weak statistical evidence. Many statistically insignificant “negative” and weak results were relegated to the full text rather than to the study abstract. Individual studies reported larger effect sizes than did the meta-analyses. There was no standardized, consistent selection of exposure contrasts for the reported risks. A minority of associations had more than weak support in meta-analyses, and summary effects in meta-analyses were consistent with a null average and relatively limited variance.
In other words, there are lots of studies out there that claim to find a link, either for increased risk or a protective effect, between this food or that ingredient and cancer, but very few of them actually provide convincing support for their hypothesis. Worse, there appear to be a lot of manuscript-writing shenanigans going on, with the abstract (which usually means, I note, the press release) touting a strong association while the true weakness of the association is buried in the fine print in the results or discussion sections of the paper. Given that most scientists tend not to read each and every word of a paper unless they’re very interested in it or it’s highly relevant to their research, this deceptive practice can leave a false impression that the reported association is stronger than it really is. Yes, I realize that we as scientists should probably be more careful, but a combination of time pressures and the enormous volume of literature out there make it difficult to do so. Moreover, as Schoenfeld and Ioannidis note in their discussion, although they didn’t cover the entire nutritional epidemiology literature for all these ingredients (which would be virtually impossible), their search strategy was “representative of the studies that might be encountered by a researcher, physician, patient, or consumer embarking on a review of this literature.” In other words, they tried to search the literature in a way that would bring up the most commonly cited recent studies.
The effect is likely to be even worse for the lay public, who get information filtered through press releases that tend to amplify the same problem (lack of proper caveats and discussion of how nominal or marginal the association actually is when examined critically). After all, university press offices are not generally known for their nuance, and reporters tend to want to cover stories they deem interesting. Marginal studies are less interesting than a study with a strong, robust result. So studies all too often tend to be presented as though they have a strong, robust result, even when they don’t. This is facilitated by another problem observed by Ioannidis, namely the wide variety and inconsistency in definitions and exposure contrasts. This, argue Schoenfeld and Ioannidis, make it easier for reporting biases to creep into the literature.
There’s also the issue of reporting bias, which could easily be more acute in nutritional epidemiology. The reason is that there is, understandably, a huge public interest in what sorts of foods might either be protective against or cause cancer. In an accompanying editorial, Michelle M. Bohan Brown, Andrew W Brown, and David B Allison, while noting that Schoenfeld and Ioannidis’ work does indeed suggest that everything we eat is associated with cancer in some way, also note that their study reports evidence of publication bias:
They [Schoenfeld and Ioannidis] found that almost three-fourths of the articles they reviewed concluded that there was an increased or decreased risk of cancer attributed to various foods, with most evidence being at least nominally significant. It appears, then, that according to the published literature almost everything we eat is, in fact, associated with cancer. However, Schoenfeld and Ioannidis proceeded to show that biases exist in the nutrient-cancer literature. The fidelity of research findings between nutrients and cancer may have been compromised in several ways. They identified an overstating of weak results (most associations were only weakly supported), a lack of consistent comparisons (inconsistent definitions of exposure and outcomes), and possible suppression of null findings (a bimodal distribution of outcomes, with a noticeable lack of null findings).
Brown et al note that the sources of these sorts of biases have been well known for a long time and can lead to self-deception. The types of bias most responsible for positive findings appear to include what is known as “white hat bias” (“bias leading to distortion of research-based information in the service of what may be perceived as ‘righteous ends’”), confirmation bias (in which overstated results match preconceived views, so that the authors overstating the results don’t adequately consider the weaknesses of their work), and, of course, publication bias. These biased results are then disseminated to the public through the lay media. As Brown et al note:
The implications of Schoenfeld and Ioannidis’ analysis may be important for nutritional epidemiology even more broadly. Numerous food ingredients are thought to have medicinal properties that are not sufficiently supported by current knowledge—for example, coffee “curing” diabetes (11). These distortions can also be used to demonize foods, as shown by the longstanding presumption that dietary cholesterol in eggs contributes to heart disease (12). Causative relations between various foods and diseases likely do exist, but the evidence for many relations is weak, although conclusions about these relations are stated with the certainty one would expect only from the most strongly supported evidence.
Indeed. Another implication, not noted by either Schoenfeld and Ioannidis or Brown et al, is that weak research findings suggesting a link between this food or that food and cancer, not only lead to the inappropriate demonization of some foods but to quackery. Anyone who has been a regular reader of this blog or one of the other blogs of the contributors to SBM, or who has followed the “alternative medicine” online underground will immediately note that quacks frequently tout various “superfoods” or supplements chock full of various food ingredients believed to have protective effects against various diseases as the cure for what ails you, be it cancer, heart disease, diabetes, or whatever. Publishing studies with weak associations tarted up to look stronger than they really are only provides fuel for these quacks. Indeed, there is one site run by a Sayer Ji that devotes much of its news section to publishing stories and abstracts describing such studies. I’m referring to GreenMedInfo, which routinely publishes posts with titles like Avocado: The Fat So Good It Makes Hamburger Less Bad; Black Seed – ‘The Remedy For Everything But Death’; and 5 Food-Medicines That Could Quite Possibly Save Your Life. And that’s just one example. Mike Adams, for instance, does the same sort of thing, just yesterday posting articles claiming that various foods can “lower blood pressure fast” and that the “Paleo diet” combined with vitamin D and avoiding food additives can reverse multiple sclerosis. Not surprisingly, the same sorts of hyperbole can regularly be found on The Huffington Post, and touted by supplement sellers. Even mainstream media outlets like MSNBC get into the act.
Of course, in all fairness, in science, most studies should just be published and let the chips fall where they may. It’s unfair to blame the authors of nutritional epidemiology studies for how their studies are used and abused. It is not unfair to blame them if they use poor methodology or the strength and significance of their findings in the abstract and hide their weakness by burying it deep in the verbiage of the results or discussion sections. If Schoenfeld and Ioannidis are correct, this happens all too often. Obviously, their sample is a fairly small slice of the nutritional epidemiological literature and as such might not be representative, but given the methods used to choose the studies examined I doubt that if Schoenfeld and Ioannidis had gone up to 100 foods they would have found anything much different.
Unfortunately, in almost the mirror image to the nutrition alarmists, one also sees a disturbing temptation on the part of those who represent themselves as scientific to go too far in the other direction and point to Schoenfeld and Ioannidis’ study as a convenient excuse to summarily dismiss nutritional epidemiological findings linking various foods or types of foods with cancer or other disease. For example, the American Council on Science and Health (ACSH) did just that in response to this study, gloating that it proves that its dismissal of food health scares are insignificant. Well, actually, many scares are insignificant, but surely not all of them are. The ACSH also almost goes into conspiracy theories when it further claims that the mainstream media except for a couple of UK newspapers, such as The Guardian, ignored the study. Although arguably this particular study didn’t get huge coverage, it’s going a bit far to claim that the mainstream media ignored it. It didn’t; the study was featured on Boing-Boing, The Washington Post, Reason, Cancer Research UK, and others. Of course, one can’t help but note that the ACSH is the same organization that has referred to advocating organic foods as “elitist”, likes to disparagingly refer to questions about links between environment and cancer as “chemophobia,” and been very quick to dismiss the possibilities that various chemicals might be linked to cancer, as so famously parodied on The Daily Show. a few years ago. We must resist the temptation to go too far in the opposite direction and reflexively dismiss even the possibility of such risks as the ACSH is wont to do, most famously with pesticides and other chemicals.
Indeed, as was pointed out at Cancer Research UK, the real issue is that individual studies taken in isolation can be profoundly misleading. There’s so much noise and so many confounders to account for that any single study can easily miss the mark, either overestimating or underestimating associations. Given publication bias and the tendency to believe that some foods or environmental factors must cause cancer, it’s not too surprising that studies tend to overestimate effect sizes more often then they underestimate them. Looking through all the noise and trying to find the true signals, there are at least a few foods that are reliably linked to cancer. For instance, alcohol consumption is positively linked with several cancers, including pancreatic, esophageal, and head and neck cancers, among others. There’s evidence that eating lots of fruit and vegetables compared to meat can have protective effects against colorectal cancer and others, although the links are not strong, and processed meats like bacon have been linked to various cancers, although, again, the elevated risk is not huge. When you boil it all down, it’s probably far less important what individual foods one eats than that one eats a varied diet that is relatively low in red meat and high in vegetables and fruits and that one is not obese.
So what can be done? It would be a good thing indeed if the sorts of observations that Ioannidis has made lead to reform. Between Schoenfeld and Ioannidis’ study and the accompanying editorial several remedies have been proposed that are not unlike steps that have been imposed on clinical trials of therapies and drugs: increased use and improvement of clinical trial and observational study registries; making raw data publicly available; making supporting documentation such as protocols, consent forms, and analytic plans publicly available; and mandating the publication of results from human (or animal) research supported by taxpayer funds. I must admit that the last of these is already a requirement, as is registration of all taxpayer-supported clinical trials at ClinicalTrials.gov, but the other proposals could also help.
Finally, I’ll finish with a quote from the editorial by Brown et al:
As Schoenfeld and Ioannidis (6) highlighted, comprehensive approaches to improve reporting of nutrient-disease outcomes could go a long way toward decreasing repeated sensational reports of the effects of foods on health. However, none of these debiasing solutions address the fundamental human need to perceive control over feared events. Although scientists may have ulterior motives for looking for nutrient-disease associations, the public is always the final audience. It is therefore imperative that we spend less time repeating weak correlations and invest the resources to vigorously investigate nutrient-cancer and other disease associations with stronger methodology, so that we give the public lightning rods instead of sending them up the bell tower.
That last remark refers to Ben Franklin’s lightning rod and how churches used to think that ringing bells would protect against lightning strikes when in fact ringing bells only put the bell ringers in danger from lightning, which often struck bell towers because bell towers were usually the highest buildings in most towns. It’s a metaphor that fits, because the superstition about lightning before the lightning rod could divert devastating lightning strikes from bell towers is not unlike the irrational beliefs about food-cancer links that all too often predominate even today. The answer is more rigorous science and less publicizing of weak science.

Is U.S. cancer care “in crisis,” as the Institute of Medicine proclaims?
David Gorski on September 16, 2013
Link
Americans love to fight, traditionally. All real Americans love the sting and clash of battle…When you, here, everyone of you, were kids, you all admired the champion marble player, the fastest runner, the toughest boxer, the big league ball players, and the All-American football players. Americans love a winner. Americans will not tolerate a loser.
– General George S. Patton, Jr., June 5, 1944
General George S. Patton, Jr. was famous for his flamboyance and aggressiveness going on the attack, among other things. He was also known for a number of pithy quotes made throughout his lifetime, particularly during World War II, such as the one above in which he declared how much Americans love to fight. I sometimes wonder whether he was more correct in that assessment than he knew in that we seem to view almost everything through the lens of war and a crisis that calls for a war. In medicine, for instance, we have the “war on cancer” and the “war on obesity.” We have a propensity for likening problems and their solutions to war, where the goal is to destroy the enemy.
Similarly, but less dramatic (although only slightly so), we have various crises. Indeed, Americans seem to love to compare problems to crises as much as they love to compare them to war. Of course, the two are closely related, as a crisis of some sort is a necessary prelude to a war. We can argue about the definition of a “crisis,” but one thing is certain. No matter how one defines it the word “crisis” implies an urgent problem and further implies that something must be done now—or at least very soon—to prevent the catastrophic consequences of that problem, which usually involve a breakdown of a current system. It was with these thoughts in mind that I approached the Institute of Medicine (IOM) consensus report released last week, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis. It’s a behemoth of a report, weighing in at 360 pages, and it does indeed paint a picture of some very serious problems in cancer care that should be addressed. It is subdued in that it doesn’t engage in that oh-so-American tendency to declare “war” on every problem, but is cancer care “in crisis”? Of that, I’m not so sure, but it’s definitely got problems. But, as I’ve said, the system’s had problems for a long time, as the IOM itself documented in its 1999 report Ensuring Quality of Cancer Care, which concluded that “for many Americans with cancer, there is a wide gulf between what could be construed as the ideal and the reality of their experience with cancer care.” The report also recommended steps to improve cancer care and the evidence base for cancer care, and to overcome barriers of access to high-quality cancer care. As the introduction to the current report states:
These recommendations led to a number of efforts targeted at improving the delivery of cancer care. The Secretary of the U.S. Department of Health and Human Services (HHS) established the Quality of Cancer Care Committee to work on issues identified in the report. A number of organizations used the report to develop core indicators of quality of cancer care and recommendations for improving the quality of cancer care, including the Agency for Healthcare Research and Quality (AHRQ), the National Quality Forum (NQF), and the National Dialogue on Cancer (a collaboration organized by former President George H.W. Bush and Senator Dianne Feinstein, now known as C-Change). In response to the report, the American Society of Clinical Oncology (ASCO) undertook a national study of the quality of care delivered by oncologists, called the National Initiative on Quality Cancer Care (ASCO, 2013). In addition, the Cancer Quality Alliance, a diverse group of stakeholders committed to advocating for improvements in the quality of cancer care, used this report and several other IOM reports to develop five cancer case studies depicting a vision for high-quality cancer care and a blueprint for action to realize that vision (Rose et al., 2008). The report provided major input into quality of cancer care legislation drafted by the Senate Health, Education, Labor, and Pension Committee
Not to blow my own horn (too much, anyway), I happen to be involved with two major quality improvement initiatives, one national through the American College of Surgeons Committee on Cancer and another statewide initiative seeking to improve the quality of breast cancer care throughout the state, not just at the two NCI-designated comprehensive cancer centers in the state and the several large health systems but at community hospitals as well. After all, most cancer care in this country does not occur at the 41 NCI-designated comprehensive cancer centers. It is clear to me that, since 1999, there has been a sea change in the attitudes of physicians regarding outcomes tracking to improve quality and adherence to evidence-based guidelines for the better. Physicians in the past were all too frequently wedded to a view in which a physician’s autonomy and every decision was unquestioned (and the choice of the word “his” was intentional, given how male-dominated the profession was) and they viewed attempts to persuade them to adopt evidence-based guidelines as intolerable infringements on their god-like autonomy. Today, they are much more receptive to following the guidelines, particularly in oncology. (Unfortunately, when it comes to the CDC’s recommended vaccine schedule we’ve seen an example of a physician who still follows the old-school, haughtily dismissing the recommended schedule because he thinks his clinical experience trumps expert, evidence-based guidelines. But I digress.)
Here’s a typical example of how the report is being discussed in the press:
Cancer treatment has grown so complex, many U.S. doctors can’t keep up with new information and are offering incorrect treatment, failing to explain options and leaving patients to coordinate their own care, according to a report released on Tuesday by the Institute of Medicine, part of the National Academy of Sciences.
The 315-page report, “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,” identifies a long list of reasons for the crisis, including a growing demand for cancer care as more people receive a diagnosis and a shrinking oncology workforce.
“Probably on average the quality of care is not bad, but we know there are people who are not getting the (highest) standard of care,” said Dr Patricia Ganz, who chaired the institute’s panel that wrote the report and is a professor at the Schools of Medicine and Public Health, University of California, Los Angeles. “Patients need to be asking, Is my doctor giving me appropriate treatment?”
On its web page for the report, the IOM even includes a video designed to zero in on the issues discussed in the report:
The first thing I noticed about this video is that it does indeed touch on a number of prominent problems with the cancer care system, but that most of the problems discussed are in reality problems with the entire health care system that tend to be magnified in cancer care. The IOM identifies six items that it used as a conceptual framework on which to drape its solutions:
     1.  Engaged patients
     2.  Adequately staffed, trained, and coordinated workforce
     3.  Evidence-based cancer care
     4.  A learning health care IT system for cancer
     5.  Translation of evidence into clinical practice, quality measurement, and performance improvement
     6.  Accessible, affordable health care
The IOM also articulates ten goals for its recommendations:
     1.  Provide patients and their families with understandable information about cancer prognosis, treatment benefits and harms, palliative care, psychosocial support, and costs.
     2.  Provide patients with end-of-life care that meets their needs, values, and preferences.
     3.  Ensure coordinated and comprehensive patient-centered care.
     4.  Ensure that all individuals caring for cancer patients have appropriate core competencies.
     5.  Expand the breadth of data collected in cancer research for older adults and patients with multiple comorbid conditions.
     6.  Expand the depth of data collected in cancer research through a common set of data elements that capture patient-reported outcomes, relevant patient characteristics, and health behaviors.
     7.  Develop a learning health care information technology system for cancer that enables real-time analysis of data from cancer patients in a variety of care settings.
     8.  Develop a national quality reporting program for cancer care as part of a learning health care system.
     9.  Implement a national strategy to reduce disparities in access to cancer care for underserved populations by leveraging community interventions.
     10.  Improve the affordability of cancer care by leveraging existing efforts to reform payment and eliminate waste.
I don’t think I’ll be able to address all the issues, because each of the six items in the conceptual framework and goals have several recommendations to achieve them and the discussion would quickly balloon beyond the already prodigious verbiage of a typical one of these posts. (Also, I’m trying to make like Harriet and keep my posts a bit brief, at least under 4,000 words for a change.) So I’ll basically pick and choose, since a lot of these principles and recommendations are related. Let’s start with the issues that are basically the same issues that plague all of medicine, for instance an adequately staffed and trained workforce, a better IT system, and accessible, affordable care. All three of these are clearly interrelated, and tend to boil down to money, perverse incentives in the reimbursement system, and systemic inefficiencies. For example, if we want an adequately staffed, trained, and coordinated workforce, it’s going to require cash. From somewhere.
Fortunately, there are some actions that can be taken legislatively, and recommendations to change the system so that reimbursement for team-based care is more favorable are appreciated. Of course, recommendations for a shift to team-based care will conflict with recommendations to improve the number of trained providers, because team-based care can be quite inefficient. Multidisciplinary tumor care groups often see far fewer patients in a day because each patient is seen by all the specialties on the same day. For example, such systems can make it hard for surgeons to see enough patients to generate enough cases to generate enough revenue be financially viable. As long as surgeons are paid by the procedure, this will be a problem. Also, multidisciplinary teams require a significant infrastructure to maintain, and that doesn’t come cheap. Come to think of it, two of these goals (better IT, an adequately staffed and trained workforce) will likely conflict with making cancer care more affordable. True, it’s argued that this won’t be the case because better coordination of care, better cancer IT, and better staffing will reduce costs, but the evidence is rather thin to support these assertions.
In the case of IT and a better electronic medical record (EMR), certainly there would be benefits, as described in the report and greatly touted in the video, where one of the patients complained that lack of coordination between her doctors led to her being overdosed with an antihypertensive medication. The problem with coordinating care in the US is that there is no single unified health system, nor is there a single, unified medical record. Large health systems have common medical records, but that only helps if a patient is receiving all of his or her care in a single health care system. EMRs from different health care systems often don’t talk to each other. Transferring data from EMRs can be a nightmare. Worse, many of the existing EMRs are not exactly what one would call “user friendly.” Indeed, the EMR I’m stuck using can best be described as “user hostile.” After five years, I can honestly say that I still don’t fully understand much of it, and I’m not exactly computer illiterate. In fairness, I will point out that I haven’t put the time in to learn all the ins and outs of the system, but that brings up another point, namely that the up-front costs, in terms of money and time to implement an EMR, are enormous. Between lost productivity and the costs of implementation and maintenance, many private practices can’t afford it. Worse:
To make matters tougher on physicians, today’s EHRs are not really designed to “optimize speed of throughput for the clinician,” Haughton says. In many instances, a quick handwritten note in a patient’s chart is all that’s needed to record the encounter. Today’s EHRs, however, with their quality reporting and meaningful use integrations, make it challenging for doctors to complete their notes swiftly. They must enter, and often re-enter again and again, patient data that are not immediately germane to the medical issue at hand. Thus, it can take physicians a significantly longer time to input their notes into an electronic record than it took with their old paper processes—thereby increasing practice costs after EHR implementation.
Moreover, the advantages of adopting a health IT, for cancer or any other disease, are blunted if the systems can’t communicate with each other. Politically, it might never be possible to have a single EMR as there is an inherent distrust of the government having too much of our health information, something that would be facilitated by a single, unified EMR.
Of course, the EMR is only part of the better health IT so I don’t want to dwell on it too long. The overall recommendation was to have a “learning IT,” but I think that my brief discussion of EMRs is quite relevant, because this is what the IOM’s vision for a “learning health care system” includes:
Science and Informatics
    • Real-time access to knowledge – A learning health care system continuously and reliably captures, curates, and delivers the best available evidence to guide, support, tailor, and improve clinical decision making and care safety and quality.
    • Digital capture of the care experience – A learning health care system captures the care experience on digital platforms for real-time generation and application of knowledge for care improvement.
“Digital capture of the care experience” is, basically, the EMR. However, the IOM goes beyond that in wanting this digital capture to be able to be fed into a system that can track outcomes and be used for “real time” care improvement and improved clinical decision-making. This is a very tall order that would require considerable allotment of resources. The IOM states that many of the elements necessary are already in place, but if they are I can’t see them, and I’m involved in quality initiatives in my own institution, with the American College of Surgeons, and with our statewide collaborative. Data are not entered into our databases in anything resembling “real time,” despite our best efforts. I’d love to see such a system, although I’m perhaps a bit more skeptical of the claimed benefits for it; indeed, it would be highly useful to have such a system for all of medicine, not just cancer. Also in fairness, the IOM does recognize the difficulties and challenges involved in
Of most interest to me are the IOM recommendations regarding evidence-based oncology. Ironically, it’s hard not to point out that the evidence base for a lot of the health IT recommendations being able to do what they are claimed to be able to do is currently thin to nonexistent, but in terms of actual treatment there has been a major initiative over the last 14 years to improve the adherence to evidence-based guidelines in treating cancer patients. Although this has largely been fairly successful, the IOM points out that there are areas where current oncology practices fall short, particularly in the elderly, for whom the evidence base supporting some common treatments is disappointingly thin.
However, the IOM does make a good point that cancer care has become more complex in the last 14 years. That is arguably true, with the proliferation of genomic tests for various cancers, the attempts to administer “personalized” cancer treatment (or, at it’s now more often called “precision oncology“). Few diseases, or classes of diseases (which is what cancer really is, a large class of diseases) require as many specialties to treat it. Nearly every patient with a solid tumor (as opposed to hematologic malignancies) can expect to be treated—or at least seen—by a minimum of two specialties (medical oncology and surgical oncology) and most see a third specialist as well (radiation oncology).
Once the province of surgeons and local-regional therapies, cancer treatment has evolved rapidly in recent decades. Systemic treatments emerged in the 1950s and 1960s, initially as relatively nonspecific chemotherapies with limited efficacy in some human cancers. Empiricism dominated oncology drug development in this era, rather than an understanding of tumor biology. In recent years, researchers have developed treatments targeting specific molecular aberrations (e.g., imatinib for chronic myelogenous leukemia, trastuzumab for breast cancer). Molecularly targeted treatments have pervaded Food and Drug Administration (FDA) approvals in oncology in the past decade and have improved patient outcomes for many cancers. These agents commonly require a test to assess the drug target in the patient’s tumor. As such, companion diagnostic testing (e.g., estrogen receptor [ER] and human epidermal growth factor receptor-2 [HER2] in breast cancer, anaplastic lymphoma kinase [ALK] and epidermal growth factor receptor [EGFR] in non small-cell lung cancer) has increased in importance. The sheer number of targeted agents has increased the educational burden for cancer care clinicians and the financial burden for the healthcare system. In the near future, the implementation of genome-based diagnostics will likely alter both our ability to deliver precision medicine and the complexity of cancer treatment (IOM, 2010, 2012b; NRC, 2011).
Indeed, even the surgical treatment of breast cancer has become more complex. When we do a sentinel lymph node biopsy, for instance, what findings lead us to go back and take the rest of the lymph nodes? Should we do breast-conserving surgery or a mastectomy? When should neoadjuvant chemotherapy be given to shrink the tumor, and how do we predict the likelihood of success?
In any case, the recommendations of the IOM are on more solid ground here, and include requiring researchers evaluating the role of standard and novel interventions and technologies used in cancer care to include a plan to study a population that mirrors the age distribution and health risk profile of patients with the disease, as well as recommending that the National Cancer Institute should build on ongoing efforts and work with other federal agencies, the Patient Centered Outcomes Research Institute, clinical and health services researchers, clinicians, and patients to develop a common set of data elements that captures patient-reported outcomes, relevant patient characteristics, and health behaviors that researchers should collect from randomized clinical trials and observational studies. And, of course, the IOM is big on comparative effectiveness research (CER), which basically involves doing research that compares the effectiveness of two existing treatments. One problem with CER, however, as I’ve pointed out before, is that it sometimes takes so long to do clinical trials that by the time the results of CER studies are published their results might very well no longer be relevant to cancer care because the standard of care has moved to something different than the treatments being compared. So, yes, I like CER, too. However, I don’t know that its power is as great as its adherents claim.
I’m also very impressed with the IOM’s recommendations for improved palliative care and increased emphasis on palliative care. Five years ago, my mother-in-law was diagnosed with a recurrence of a particularly nasty form of breast cancer. This recurrence was in the form of widespread metastatic disease, clearly incurable. If there’s one thing that resonates with me it’s the deficiencies in palliative care in this country, particularly with respect to home care and home hospice. Once my mother-in-law was in inpatient hospice, the care she received was excellent, but while she was still at home the burden fell nearly entirely on my wife and her sister, with very little guidance. If there’s a gap in US cancer care, it’s there. I learned more than I ever had before about the “real world” during those months.
Finally, one very important part of the IOM report is its emphasis on patient-centered care. I’ve written about patient-centered care on multiple occasions before (for example, here), and I definitely believe that we do not always study the patient outcomes that matter to patients. The video above featured a woman who saw a “famous” oncologist about her cancer who recommended a very aggressive course of therapy even though she had stage IV (and therefore incurable) disease, and a man with stage I prostate cancer whose first doctor recommended very aggressive surgery. Neither, we’re told, were asked what they wanted or what they valued. Although I like to think that this sort of paternalism and “go for cure no matter what” attitude is becoming less prevalent, it still exists in a lot of oncology. That’s why it’s hard not to agree that patient-centered care is important. However, I always raise one caveat. The decisions and the trade-offs patients decide to accept should be informed by the science. The options presented to the patient, and their cost in terms of potential complications and impact on the patient’s ability to go about his daily activities and in essence live his life, must be based on science. The key is that we, as clinicians, must make sure that the patient has accurate, up-to-date, science-based information upon which to base his or her choice.
Let me just finish by pointing out that, my skepticism towards parts of this report notwithstanding, the IOM has demonstrated once again the difference between science- and evidence-based medicine and CAM. SBM rigorously questions everything about how it does everything and is continually trying to improve. Nothing is off the table, and we discuss our deficiencies and failures openly. I can’t help but contrast that to certain other areas of “medicine” frequently discussed on this blog. Even if I don’t agree with everything in the IOM report and suspect that the use of the word “crisis” was a means of getting attention more than an accurate description of the situation, the IOM itself deserves plaudits for its work in this area.

Cancer Deaths Continue to Decline
Overall cancer incidence has been stable in women and declining steadily in men. Changes in specific cancers reflect known risk factors and the effect of screening methods. What is not seen in this data is any mysterious increase in any specific cancer or cancers overall. 
Steven Novella on January 10, 2018
Link

Cancer remains the number 2 killer in the US, causing 22% of all deaths, just behind heart disease at 23%. The American Cancer Society carefully tracks all cancer statistics as a way of gauging how we are doing in all aspects of the fight to reduce the cancer burden in the population. The latest statistics are available for 2015 and they show that recent trends have continued:

There is a lot to unpack in these numbers, and they are interesting for science-based medicine beyond just telling us how we are doing in the war on cancer. It is also interesting what the numbers do not show, but we will get to that below.
Cancer incidence
Here are the main findings of these latest statistics:
Over the past decade of data, the cancer incidence rate (2005-2014) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2006-2015) declined by about 1.5% annually in both men and women. The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Let’s look first at cancer incidence – how many new cases of cancer are diagnosed each year. First we have to recognize that “cancer” is not one disease but a category of diseases, or a disease type. There are many different kinds of cancer, and the data does track them individually, so we will delve down a little into specific cancers as well.
Overall the incidence of all cancers was stable in women, and declined by 2% in men. For both sexes colorectal cancers have been steadily declining. This is likely not due to changes in risk factors, but mainly to increased screening. More people over 50 are getting colonoscopies (up from 22% to 60%), and more cancers are being prevented by removing precancerous polyps.
Lung cancer rates are also dropping, reflecting decreased tobacco use, and are dropping faster in men than in women.
These dropping rates are offset in women by small increases in breast, uterine, thyroid, and melanoma cancers. These increases are mostly in minority populations, and stable in non-Hispanic white women.
The decline in male cancer overall is largely driven by decreases in prostate cancer. This is probably entirely an artifact of screen procedures for prostate cancer. In the mid-1990s prostate specific antigen (PSA) testing started to be used extensively, finding many early prostate cancers. However, tracking these cases showed that many early prostate cancers would never cause problems, and we were probably overtreating these early cases. This led to a later decline in the use of PSA for routine screening.
Liver cancers have been increasing a bit, which is thought to be due to increases in hepatitis C, which in turn has been increasing partly due to the opioid epidemic.
So overall cancer incidence has been stable in women and declining steadily in men. Changes in specific cancers reflect known risk factors and the effect of screening methods. What is not seen in this data is any mysterious increase in any specific cancer or cancers overall.
This data does not fit the fearmongering narrative that we often confront on SBM, that the toxic bogeyman de jour is making us sick. There is no increase due to GMOs, vaccines, pesticides, or toxins in food. Cancer rates are driven by smoking and other tobacco use, hepatitis C, UV light, and other known risk factors.
The numbers also break the common “alternative medicine” narrative that mainstream medicine does not focus on prevention and wants to keep us sick – nonsense! When available, preventive measures like colonoscopy are reducing cancer incidence. Mainstream medicine has been engaged in a campaign to reduce real cancer risk factors like smoking for decades. Now we are confronting the hepatitis C increase and pushing for greater screening and early treatment to prevent liver cancer.
Deaths from cancer
There are two main ways to look statistically at deaths from cancer – the overall death rate from cancer, and the death (or survival, if we want to be positive) rate for those diagnosed with cancer.
The overall death rate from cancer has been steadily declining by 1.5% per year since 1991. This has resulted in a cumulative decrease in the cancer death rate by 26% (32% in men and 23% in women). This data is interesting because it is not affected directly by cancer screening or diagnostic artifacts. If you are going to die from your cancer, you are going to die, no matter when we diagnose it or how we categorize it.
The reduction in cancer deaths has two components: a reduction in cancer incidence (discussed above) and increased survival of those with cancer. The main challenge in determining cancer survival is what is called the lead-time bias. If we diagnose cancers earlier, then people will survive longer after their diagnosis, even if we did not extend their survival with treatment. We can, however, compensate for lead-time bias by tracking survival based upon the stage of the cancer (a measure of how advanced the cancer is).
Even when we look at the data accounting for stage at diagnosis, overall cancer survival has been steadily increasing. In 1975 the overall 5-year survival rate for cancer was 50%. In 2007 it was 68%. The data also shows a slow improvement in survival of cancer over this time, and this trend continues.
There are stark differences by cancer type, however. Some cancers are much harder to treat than others:
Progress has been especially rapid for hematopoietic and lymphoid malignancies due to improvements in treatment protocols, including the discovery of targeted therapies. For example, the 5-year relative survival rate for chronic myeloid leukemia increased from 22% for patients diagnosed in the mid-1970s to 68% for those diagnosed during 2007 through 2013. Based on a review of clinical trial data, most patients with chronic myeloid leukemia who are treated with tyrosine kinase inhibitors experience near normal life expectancy, particularly those diagnosed before age 65 years.
Cancer survival has increased at all stages, so this does not just reflect lead-time bias. However, early stages have benefited more than late stages.
By contrast improvement in lung and pancreatic cancer survival has been slow, which partly reflects the fact that these cancers tend to be diagnosed at more advanced stages.
The future
There are still some risk factors driving cancer rates that have significant room for improvement. The biggest is clearly smoking. While tobacco use has declined from 42% in the 1960s to about 17% now, this still is the largest preventable cause of death. Smoking correlates highly with less education and lower socioeconomic status. It is, essentially, a social problem, and can be addressed through education.
We also need more screening and early treatment for hepatitis C, and we need to address the underlying opioid epidemic that is driving hepatitis C rates.
There is actually a vaccine that can prevent some types of cancer – specifically the human papillomavirus (HPV) vaccine. This can prevent cervical and some oral cancers. Uptake of the vaccine has been limited by political and ideological opposition to this health measure, however.
In addition our ability to treat various forms of cancer has been steadily improving and will likely continue to improve. There will not be any sudden “cure for cancer.” It is too diverse and complex a disease for any one cure. Advances are likely to be incremental, but they add up over time. That is what has been happening, and is overwhelmingly likely to continue to happen. Cancer survival will slowly steadily improve, and each decade we will see significant improvements.
This also, of course, breaks the common alternative medicine narrative that mainstream cancer treatments are ineffective, even counterproductive. This claim is nothing but a cynical attack on effective medicine in order to sell snake oil to desperate patients with serious disease. It is difficult to overstate how malicious such behavior is. Dr. Gorski reported in August on a Yale study that found that patients who delay standard treatment in order to pursue alternative cancer treatments have a lower survival rate.
The alternative medicine fad is demonstrably eating into our improvements in cancer treatment by selling a harmful narrative that scares patients away from effective treatment or lures them with worthless ones. That is why it is so important to push back.
But numbers don’t lie, so we will continue to monitor and publish cancer statistics in order to tell the real story.

Cancer Death Rate Continues to Decline
The new data are in – cancer deaths continue to decline at a steady rate.
Steven Novella on January 9, 2019
Link
The title of this post is similar to my post from one year ago – because the death rate from cancer is, in fact, continuing to decline, as it was a year ago. This is good news, reflecting several trends. It also is in direct contradiction to the typical alternative medicine, pseudoscience, everything-is-killing-you narrative spread by promoters of dubious treatments.
Here is an overview of the results:
Over the past decade of data, the cancer incidence rate (2006‐2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007‐2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.
This represents an almost exact continuation of the trends from last year. Cancer deaths peaked in 1991, attributed to an aging population and greater detection. Since then cancer deaths have steadily decreased, as you can see by the graph. The downward lines are now fairly consistent. But let’s look a little bit deeper into the data.
First, we have to separate cancer incidence (the number of new cases of cancer) from cancer deaths (the number of people who die from cancer) and cancer survival rates (how long people live once they have been diagnosed with cancer). Cancer incidence is a result of several factors affecting risk and detection. The risk of cancer increases with age, and our aging population therefore will tend to increase the overall incidence. Other specific cancers have specific risk factors, and they will have a significant effect on the incidence. The biggest one here is smoking and lung cancer.
As we get better at detection this will also increase the numbers, but this is an artifact, not the detection of a real increase in new cases of cancer. There is generally better and earlier detection over time, but the biggest blip here is still prostate cancer. The use of PSA screening, a blood test for prostate cancer, dramatically increased the numbers. This practice was stopped because of overdiagnosis, however, and the number of detected cases dropped just as dramatically. Again – this is completely an artifact of medical practice, not reflecting real disease rates.
Overall cancer incidence, as indicated above, has been stable. There is a small decrease in men, due to the prostate issue, but if we take this out, cancer incidence has been pretty flat. Again – this breaks the “cancer epidemic” narrative that is dredged up to stoke false fears about vaccines, cell phones, GMOs, or whatever boogeyman you want to attack. Some specific cancers have been declining, however. The biggest one here is lung cancer in men, reflecting decreased smoking rates. Lung cancer is declining more slowly in women, reflecting the fact that women overall are slower to quit smoking.
This is a good example of how a public health campaign can have a real and dramatic effect on health. Smoking is a clear risk factor for lung cancer, which is the number one cancer killer for men and women (it is number two in incidence for both, behind prostate in men and breast in women). Lung cancer should be rare – it is only smoking that makes it as common as it is. In a sense, smoking is the number one cause of cancer deaths, and it is completely avoidable. We need to keep this message prominent, and keep up pressure to reduce smoking rates and prevent young people from taking up smoking.
Colorectal cancer is also on the decline. This is partly due to screening (get your scheduled colonoscopies), but screening cannot completely explain the decline.
Three cancer types, though small as a percentage of all cancers, are increasing a bit. Liver cancer is increasing, and this is thought to be primarily due to increased incidence of hepatitis C, which is a major risk factor. Alcoholism is also a risk factor, and that may be playing a role as well. Melanoma is also increasing, the major risk factor for which is sun exposure.
Thyroid cancer is also on the rise. This primarily due to increased detection of smaller cancers (many of which would never have posed a problem), but there is debate as to whether increased detection can explain all of the rise in incidence.
So overall what the incidence data tells us is – quit smoking, use sunscreen, and get your colonoscopy. It does not, however, contain any signal of increased risk for cancer due to some unknown environmental agent.
Let’s turn now to cancer death rate, which is a combination of the cancer incidence and survival. Overall incidence is stable, so this does not explain the steady decline in deaths. What does is mostly increased cancer survival. If you look at people who have cancer, at all ages and for most types of cancer, survival is increasing. This reflects improved treatment. It also reflects improved detection. If we are better at detecting cancer, we will find it earlier, which creates increased “lead time”. Survival will seem to increase simply because we knew about the cancer earlier. However, this is easy to control for in the statistics.
If we control for increased lead time, survival is still improving, reflecting better treatment. Treatment is also more effective if you start it earlier, so improved detection and treatment are related in this way. Improved treatment reflects continuing research in cancer. There are new treatments coming on line all the time. Recently we have moved into an era of immunotherapy for cancer, for example. Each time a new potential treatment is discovered it is overhyped as a potential “cure” but in reality each discovery contributes incrementally to overall progress.
The cumulative effect of all of these small but substantial advances is a steady increase in cancer survival. This is similar to other technologies dealing with complex multifactorial challenges. Battery and solar technology come to mind. In the exact same way, the press talks constantly of “breakthroughs” but in reality we are making steady incremental improvements that lead to a slow but steady (about 1% per year) increase in battery life and solar efficiency. Over the decades, these incremental improvements add up.
In a similar way, there will never be a “cure for cancer”. Cancer is many diseases, and it is complex. But each advance moves the needle a little bit, and over the last 25 years we have decreased cancer deaths by 27% – again, about 1% per year on average. The tortoise definitely wins this race.
Meanwhile, alternative cancer treatments have made no progress. They have nothing to show for all their conspiracy theories and overhyped claims – except an increase in the risk of death. People who use alternative cancer treatments, either in addition to or instead of mainstream treatments, die more quickly from their cancer. This effect will only get greater as survival with mainstream treatments steadily improves.
While this data are a bit complicated to unpack, there are some clear signals. Cancer detection and treatment are overall steadily improving. Public health campaigns to reduce risk factors and improve screening are also effective.

Contrary to what we are frequently told, we are not “losing the war on cancer”
A common narrative about cancer is that we are making no progress in our fight against it. Fortunately, the actual data do not agree. Yes, too many people still die of cancer and progress is slow, but it’s not correct to claim that we are losing the war on cancer.
David Gorski on April 3, 2017
Link

If you were to rely on much of what you see in the mainstream media and on social media, you probably have the impression that we are not doing very well against cancer. Indeed, a common trope I see in a lot of articles is that we are somehow “losing” the war on cancer. Just for yuks, I Googled the term “losing the war on cancer,” and it didn’t take long to find a lot of articles, both in the mainstream press and, more predictably, on alternative medicine-friendly websites making just that argument. Indeed, in 2011, which was the 40th anniversary of President Nixon’s declaration of “war on cancer,” I noted that, so common were articles on that event questioning progress against cancer, I fully expected to be fielding similar articles in 2021 for the 50th anniversary of Nixon’s “war on cancer”; that is, if I’m still blogging then. (I wasn’t blogging in 2001; so I missed the 30th anniversary round of self-flagellation by oncologists.)
To demonstrate what I’m talking about, I picked an article from 2004. The key argument of this sort of article goes something like this: 
But it’s not. Hope and optimism, so essential to this fight, have masked some very real systemic problems that have made this complex, elusive, relentless foe even harder to defeat. The result is that while there have been substantial achievements since the crusade began with the National Cancer Act in 1971, we are far from winning the war. So far away, in fact, that it looks like losing.
Just count the bodies on the battlefield. In 2004, cancer will claim some 563,700 of your family, friends, co-workers, and countrymen. More Americans will die of cancer in the next 14 months than have perished in every war the nation has ever fought … combined. Even as research and treatment efforts have intensified over the past three decades and funding has soared dramatically, the annual death toll has risen 73%—over one and a half times as fast as the growth of the U.S. population.
And, six years later in 2010, this:
In 1971, President Nixon and Congress declared war on cancer. Since then, the federal government has spent well over $105 billion on the effort (Kolata 2009b). What have we gained from that huge investment? David Nathan, a well-known professor and administrator, maintains in his book The Cancer Treatment Revolution (2007) that we have made substantial progress. However, he greatly overestimates the potential of the newer so-called “smart drugs.” Researchers Psyrri and De Vita (2008) also claim important progress. However, they cherry-pick the cancers with which there has been some progress and do not discuss the failures. Moreover, they only discuss the last decade rather than a more balanced view of 1950 or 1975 to the present.
I note that this article appeared in Skeptical Inquirer and was written by Reynold Spector, MD. I discussed it in depth before and am merely citing this passage as an example of the sort of argument that I’m talking about. You can read my original deconstruction if you want the details. I also note that what is often forgotten in the media is that cancer is not a single disease, but rather hundreds of diseases, and that it’s rather simplistic to discuss “cancer” as though it were a single disease. Yet we do it all the time.
The reason I decided to address this issue is because it turns out that we aren’t doing as poorly against cancer as commonly portrayed. I was reminded of this by news accounts of a new report that was recently published in the Journal of the National Cancer Institute (JNCI), which reinforced the findings of the 2017 yearly report on cancer published by the American Cancer Society in January, which I had meant to write about but somehow never did. (Now I have my chance to atone for that.) As you will see, together, these reports show slow but steady progress in bringing down the death rates for most cancers. Also, it shows that the overall picture is complicated, such that referring to “losing” or “winning” the war on cancer is a poor way to describe progress on this front.
Cancer mortality: Declining for most cancers
The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) all collaborate to compile data on cancer incidence and mortality. Periodically, they publish reports on trends in cancer incidence, survival, and mortality in the US. That’s where the primary data for the JNCI report came from, including the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program. The data for the ACS article came primarily from the National Center for Health Statistics and the SEER Program since 1973 and by the Centers for Disease Control and Prevention’s (CDC’s) National Program of Cancer Registries (NPCR) since 1995. Given the overlap in the data sources used, the outcomes examined, and even a couple of the authors, I found it most convenient to use both articles as the basis for my post, noting that, despite the overlap, each study examined somewhat different questions.
Perusing the two studies, I find that the ACS study is a bit more useful because it examines mortality trends over a much longer period of time, whereas the JNCI study emphasizes five year survival more than mortality, and, as I’ve explained before, five year survival rates can be influenced by overdiagnosis and lead time bias, while mortality rates are not. An excellent explanation of lead time bias can be found here (and, if I do say so myself, here), but the basic concept is that if you detect a cancer earlier but your treatments have no effect on the overall biological progress of the cancer, survival will appear to be better even though the patient dies at the same time he would have died of the cancer anyway.
However, the JNCI study notes in the introduction its rationale for examining changes in survival rates:
In addition to death and incidence rates, survival is an important measure for assessing progress in efforts to improve cancer outcomes (19). As with most disease surveillance measures, the interpretation of survival trends is complicated by changes in screening and detection practices (19,20). In particular, screening may lead to the detection of cases that would not have been detected through clinical manifestation in a lifetime (overdiagnosis) or the detection of cancers that are inherently slow growing (length bias). Screening may also result in earlier diagnosis without changing the date of death, generating apparent improvements in survival without changing the actual course of disease (lead time bias) (21). In this report, we examine temporal changes in overall and stage-specific survival for all races/ethnicities combined and in overall survival by race, and contemporary overall survival by race and ethnicity and state of residence. We interpret these survival statistics in the context of changes in screening, early detection, and treatment.
In terms of overall mortality from cancer, the JNCI found that from 2000 to 2014 mortality has been decreasing at 1.8% per year for men and 1.4% per year for women. This is shown in Figure 1 from the paper:
The authors then looked at mortality rates due to various common cancers in men and women and found that mortality has been steadily decreasing for nearly all cancers:
As you can see, death rates during this period decreased significantly for 11 of the 16 cancers in men, with big yearly decreases in lung cancer mortality, attributable mainly to the decline in smoking. In contrast death rates increased for cancers of the liver and, to a lesser extent, of the pancreas and brain, while rates stabilized for bladder and oral cavity cancers. In addition, in women, death rates declined for 13 of the 18 most common cancer types. For example, breast cancer mortality declined by 1.6% per year, consistent with other studies that I’ve seen. The exceptions included cancers of the uterus and of the liver cancer, for which death rates increased, and for pancreas, brain, and myeloma, for which death rates remained stable. By comparison, during the same period, cancer incidence rates among women remained stable, while declining among men.
How do these results compare to the 2017 edition of the ACS yearly study that’s released every January? Well, let’s go to the “money figure,” as I like to call it:
As you can see, its results are consistent with what the JNCI study reports, at least in terms of mortality. Mortality from cancer has been falling steadily since the early 1990s, more in men (who still have higher mortality) than in women. You’ll note that the curves go farther back in time for this graph than they do in the JNCI study. You might also wonder what that peak in male cancer incidence in early 1990s might represent. Wonder no more. Here is the incidence graph, broken down by cancer type:
Yes, the increase in cancer incidence that spiked in the early 1990s was due to a surge in the detection of asymptomatic tumors as a result of the introduction of widespread use of the prostate-specific antigen (PSA) test as a screening modality. Notice the further drop after 2010 after the U.S. Preventative Services Task Force (USPSTF) recommended against the routine use of PSA screening because of growing concerns about overdiagnosis and overtreatment of prostate cancer due to the test.
But what about mortality? The ACS answers the question:
These graphs are informative in that they trace mortality rates all the way back to 1930. If there’s a story to tell here, it’s the story of the orange line, which represents lung cancer, a disease that went from causing few deaths in 1930 to the number one cause of cancer death by the 1950s for men and by the 1990s for women. As you can see, the death rate from lung cancer peaked around 1990 for men and 2000 for women, after which it began a steady decline. All of this is tracks with the prevalence of smoking, with a roughly quarter century delay. It’s also consistent with how men took up smoking in large numbers before women did, hence the 10 year delay between men and women in terms of peak lung cancer mortality.
Not surprisingly, the ACS data also show that the exceptions to the rule of declining mortality are liver cancer and uterine cancer, with little change in the death rate from pancreatic cancer.
What about survival?
I’ve discussed before how cancer mortality is a better measure of success in combatting cancer than five year survival is. The reason, of course, is that five year survival can be affected by screening in terms of overdiagnosis and lead time bias. However, that is not to say that five year and ten year survivals are not useful measures of progress against cancer. Five year survival rates for cancers which we don’t routinely screen, for instance, are far less likely to be affected by such factors. As I noted before, the cancers for which the US has better five year survival rates than European countries are virtually all cancers for which the U.S. screens intensively, such as prostate and breast cancer. Also examining stage-specific survival rates can help mitigate the likelihood that lead time bias is the explanation for an increase in five year survival rather than an actual improvement in treatment.
In the JNCI paper, changes in five year survival were compared between the periods of 1975-1977 and 2006-2012, both for all stages lumped together and among cancers diagnosed as local disease, regional disease, and distant metastasis (spread). The all-stage data were reported in the paper and the data broken out by stage were reported in a very unwieldy table in the supplemental material. Over that time, changes in five year survival for various cancers overall ranges from a relative change of -4% (absolute percentage: -3.5%) for uterine cancer to 428% (absolute percentage 14.6% or from 3.4 to 18.1%) for cancer of the liver and intrahepatic bile ducts. In other words, even though five year survival for liver cancer has gone from utterly dismal to just dismal in 40+ years, more people are dying of liver cancer because its incidence is increasing. In any event, five year survival has indeed increased for breast and prostate cancer, as we would expect for screen-detected cancers subject to the potential overdiagnosis, but the five year survivals for a number of cancers for which we do not screen have increased markedly, such as: non-Hodgkin’s lymphoma (from 46.5% to 72.6%); melanoma (from 81.9% to 93.2%); leukemia (from 34.2% to 62.7%); and multiple myeloma (from 24.6% to 50.2%). For all sites, adjusted by case mix, five year survival has increased from 50.3% to 66.4%.
For more advanced disease, it’s not surprising that increases in survival have been less impressive but real. For instance, for metastatic breast cancer, five year survival has increased from 18.7% in 1977 to 33.6% in 2012, which is nearly a doubling in survival. Gains have been even more impressive in head and neck cancer, with an increase from 18.5% five year survival to 39.8%. Unfortunately, some of these doublings in five year survival are not so great in absolute terms. For instance, in lung cancer, five year survival for metastatic lung cancer has more than doubled, but that represents going from 1.8% to 4.2%, a result that no one would consider a major advance, particularly patients and their families. Ditto metastatic pancreatic cancer, for which survival has only increased from 0.9% to 3.3%. The problem, of course, is that even though survival for localized pancreatic cancer has increased from 7% to 32.1%, the vast majority of pancreatic cancer is not found when it’s still localized to the organ.
Finally, there remain some real disparities in cancer outcomes based on race and region. For example, this figure compares five year survival statistics for Caucasians versus African-Americans for localized, regional, and metastatic cancers:
As you can see, African-Americans with nearly every cancer do significantly worse, particularly for localized and regional cancers, where treatment makes the most difference. Unfortunately, not everyone is sharing equally in the improvements in survival and declines in mortality due to cancer.
Are we winning or losing the war on cancer?
So we circle back to the original question that inspired this post: Are we winning or losing the war on cancer? I know, I know, it’s a simplistic question, and I myself pointed out how cancer is not one disease near the beginning of this exploration. I also routinely point out the same thing whenever someone asks the question, “Why haven’t we cured cancer yet?” (Mainly because it’s complicated as hell.) What the evidence shows clearly is that death rates from cancer are slowly falling, driven by declines in death rates from most of the common cancers. Meanwhile, five year survival rates are climbing for most cancers, even for more advanced disease. Unfortunately, the answer to my question is, like many Facebook relationship statuses, complicated.
Any strategy to combat cancer rests on three legs: Prevention, diagnosis, and treatment. Changes in diagnostic modalities can increase the apparent incidence of cancer through overdiagnosis, as well as the five year survival through lead-time bias, but they can also result in a decrease in mortality due to the cancer being screened for. There are many tradeoffs.
There is also little doubt that improvements in treatment have likely played a significant role in the declines in mortality from some cancers and improved five year survivals. Some of this can be seemingly mundane, even though it really isn’t, such as improvements in surgery. Indeed, the authors also note that, for cancers for which the primary treatment is surgery that has a significant mortality rate, such as cancers of the stomach, lung, pancreas, and esophagus, decreasing the acute mortality from surgery will improve the five year survival. Indeed, they note that lower surgical mortality may have been achieved through improvements in anesthesia and supportive care, institution of quality improvement programs, and regionalization of high-risk surgeries. Again, it’s complicated.
Improvements in chemotherapy, targeted therapy, and other treatments also likely played a role in the declines in cancer mortality:
The survival improvements over time highlighted in this report also reflect major advances in systemic therapies for some cancers, including imatinib mesylate for chronic myelogenous leukemia in the early 1990s (79), rituximab for B-cell non-Hodgkin lymphoma in the 1990s (80), and combination of chemotherapies for childhood cancers beginning in the 1960s (81,82). In particular, the continued statistically significant improvements in five-year survival rates for most cancers occurring in children—with over 80% of children surviving five years during recent diagnosis years—have been attributed to the systematic conduct of clinical trials assessing the efficacy of multimodal approaches involving combination chemotherapy, radiotherapy, and/or surgery with increased expertise in supportive care in specialized cancer centers (83). Member institutions of the Children’s Oncology Group, a National Cancer Institute supported trials group, care for 90% of children diagnosed with cancer in the United States (61,84).
In this era of increasingly personalized cancer therapy, it is hoped that dramatic progress in treatment and survival will be observed for other cancer types as well. It may not be possible in this analysis to detect the impact of very recent therapeutic improvements on population survival due to the time lag for case reporting and follow-up in cancer registry data; examples include protein kinase inhibitors for non–small cell lung cancer, colorectal cancer, and chronic myeloid leukemia; anti-angiogenics (which inhibit blood vessel growth) for colorectal and ovarian cancers; and immunotherapy for melanoma and non–small cell lung cancer (85). Such improvements may also be difficult to discern in population-based registry data for therapies that apply only to subsets of patients for a cancer site.
However, as good as our tests and treatments can be, we can’t forget that tobacco remains the single largest cause of preventable cancer in existence, and the main cancer it causes, lung cancer, is among the most deadly. As noted in the ACS paper from January:
The decline in cancer mortality over the past 2 decades is the result of steady reductions in smoking and advances in early detection and treatment, reflected in considerable decreases for the 4 major cancers (lung, breast, prostate, and colorectum) (Fig. 7). Specifically, the death rate dropped 38% from 1989 to 2014 for female breast cancer, 51% from 1993 to 2014 for prostate cancer, and 51% from 1976 to 2014 for colorectal cancer. Lung cancer death rates declined 43% from 1990 to 2014 among males and 17% from 2002 to 2014 among females due to reduced tobacco use because of increased awareness of the health hazards of smoking and the implementation of comprehensive tobacco control.[41] Tobacco control efforts adopted in the wake of the first Surgeon General’s report on smoking and health in 1964 have resulted in an estimated 8 million fewer premature smoking-related deaths, one-third of which are due to cancer.[42, 43] Despite this progress, in much of the Southern United States, 40% of cancer deaths in men in 2014 were caused by smoking.[44]
The JNCI paper agrees and notes:
In particular, cigarette smoking prevalence among adults over the past 50 years decreased by more than 50% because of public health policies against tobacco and increased awareness about the health hazards of smoking (42). However, there are still about 40 million adult smokers (43), and smoking remains the leading cause of cancer death (42,44–46). These facts underscore the need for expansions of federal and state tobacco control programs and the development of new strategies, such as pricing strategies and plain tobacco packaging to accelerate the reduction in tobacco use (47).
Indeed, a significant fraction of the overall decrease in cancer mortality is being driven by declines in lung cancer mortality due to the decline in smoking over the last 50 years. However, it’s not all just smoking. I note that breast cancer is a cancer whose incidence is not strongly influenced by smoking history, but mortality from this cancer has declined over 30% since 1990. Mortality from several other cancers is declining at similar rates. It would seem that we are slowly winning the war on cancer, but, again, it’s complicated, and there are warning flags on the horizon.
One such warning flag is the obesity epidemic. My cancer center recently hosted Otis Brawley, the medical director of the American Cancer Society. He noted that, as smoking-related cancers are in decline due to the decline in smoking, obesity-related cancers are on the rise, thanks to the huge increases in obesity since the 1980s. Indeed, the obesity epidemic is likely responsible in part for the increase in mortality from liver cancer:
In contrast, the continued increase in liver cancer incidence rates is likely due to the high prevalence of chronic hepatitis C virus infection resulting from intravenous drug use by baby boomers during the 1960s to 1980s, as well as the obesity epidemic beginning in the 1980s (18). The obesity epidemic also may have contributed in part to the increases in endometrial, pancreas, and kidney cancer incidence rates (14) because obesity is estimated to account for 49%, 28%, and 24% of the total cases, respectively, in the United States (57).
Indeed, the obesity epidemic has yet to show its full effects on cancer incidence and mortality, given that obesity has been linked to at least 13 types of cancer, including a very strong association with uterine cancer and adenocarcinoma of the esophagus and a significant association with liver, pancreas, and gastric cancer. Dr. Brawley noted that it likely won’t be long before obesity-associated cancers surpass tobacco-associated cancers as the main causes of preventable cancer mortality. Again, it’s complicated, and that’s without even going more deeply into the disparities in cancer incidence and survival based on race and region. Cancer is multifactorial.
So, are we winning or losing the war on cancer? I would argue that, contrary to the common perception, we are not losing it. Mortality is declining and survival is increasing for most cancers. It’s just that progress is slow. It might have been hubris to think that progress would be anything other than slow, or it might have been overpromising in order to secure research funding. It was probably both. Whatever the case, conquering all cancers is a project that will take more than decades. It will take generations.

Contrary to what we are frequently told, we are not “losing the war on cancer” (2020 edition)
The narrative we hear from the media (and, of course, from alternative medicine mavens) is that we are “losing the war on cancer.” It’s actually not true. As the latest statistics from the American Cancer Society show, the mortality rate from cancer has been declining for decades.
David Gorski on January 13, 2020
Link

One of the most common narratives I observe coming from those promoting “alternative medicine” (i.e., quackery) is that we are “losing the war on cancer”. (Just Google the phrase if you don’t believe me, and it’s not just alternative medicine mavens who are repeating the meme.) Usually, these sorts of stories come up during anniversaries of President Nixon’s declaration of “war on cancer” (particularly decade anniversaries like the 40th anniversary in December 2011, leaving us less than two years away from the next big round of stories). Of course, I’ve always objected to the use of the metaphor of “war” for progress against the disease and even more so how this particular metaphor lumps a large group of very different diseases into one term, “cancer”, as though it were all one disease. Even so, it is a useful exercise from time to time to determine how science-based medicine is doing against the large group of diseases known collectively as “cancer” and, in particular, how it is doing against the most common cancers that afflict humanity. Fortunately, the American Cancer Society (ACS) does just that every year in January, when it publishes its yearly update to its cancer statistics, thus providing a snapshot of where we are in terms of cancer.
Where we are is actually not bad. This year, the ACS reported the single largest one-year decline in cancer mortality and the continuation of 25 years of continuous decline in death rates due to cancer:
The death rate from cancer in the US declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop ever recorded, according to annual statistics reporting from the American Cancer Society. The decline in deaths from lung cancer drove the record drop. Deaths fell from about 3% per year from 2008 – 2013 to 5% from 2013 – 2017 in men and from 2% to almost 4% in women. However, lung cancer is still the leading cause of cancer death.
The decline in the death rate over the past 26 years has been steady. Overall cancer death rates dropped by an average of 1.5% per year between 2008 and 2017. This translates to more than 2.9 million deaths avoided since 1991, when rates were at their highest. A total of 1,806,590 new cancer cases and 606,520 deaths are expected in the US in 2020, which is about 4,950 new cases and more than 1,600 deaths each day.
The numbers are reported in “Cancer Statistics, 2020,” published in the American Cancer Society’s peer-reviewed journal CA: A Cancer Journal for Clinicians.
Again, cancer is not all one disease; so it’s necessary to unpack these figures and go into more detail. The news is mostly, but not all, good. I also realize that, to those who have lost loved ones to cancer or who are facing imminent death from cancer, these figures might well represent cold comfort. Cancer does, after all, still remain the number two cause of death in the US, close behind heart disease, at least for now. (Cancer is expected to surpass heart disease as the number one cause of death soon and has already done so in some countries.) That means, for all the progress that’s been made in terms of declining cancer mortality, a lot of people—far too many—still die of a form of cancer and that that will continue for the foreseeable future.
The good news and bad news
Whenever discussing cancer statistics, I like to use a few key figures from the yearly ACS report on cancer statistics. First, there’s this one, which shows the estimated numbers of new cases and cancer deaths for cancers in males and females:
As you can see, lung cancer remains by far the biggest cancer killer for both men and women, and the vast majority of lung cancer cases are attributable to smoking tobacco. In terms of incidence, gender-specific cancers (prostate in men and breast in women) are the most common, and each is the second most common cause of death. Pancreatic cancer is a particularly deadly cancer, making up only 3% of cancers but 8% of cancer deaths.
Here are the highlights of the positive findings:
    • Lung cancer death rates declined by 51% from 1990 to 2017 among men and 26% from 2002 to 2017 among women. From 2013 to 2017, the rates of new lung cancer cases dropped by 5% per year in men and 4% per year in women. The differences reflect historical patterns in tobacco use, where women began smoking in large numbers many years later than men and were slower to quit. However, smoking patterns do not appear to explain the higher lung cancer rates being reported in women compared with men born around the 1960s.
    • Breast cancer death rates declined 40% from 1989 to 2017 among women.
    • Prostate cancer death rates declined 52% from 1993 to 2017 among men.
    • Colorectal cancer death rates declined 53% from 1980 to 2017 among men and by 57% from 1969 to 2017 among women.
These are amazing numbers and reflect real progress. Yes, declines in smoking are enough to drive a fraction of the decline in the overall death rate from cancer, but tobacco use alone doesn’t explain the striking declines in mortality from breast, prostate, and colorectal cancer.
Personally, I always find it interesting, from a historical perspective, to examine the incidence curves that are always included by the ACS every year, first for cancer overall:
And individual cancers in men and women:
As you can see, although cancer incidence has been declining rapidly in men and the slow increase in women has mostly leveled off. People who see these curves for the first time often ask about the spike in cancer incidence for men in the early 1990s. That increase was driven by widespread prostate‐specific antigen (PSA) testing among previously unscreened men and the subsequent overdiagnosis of a lot of asymptomatic prostate cancer that likely didn’t need treatment. The overall decline in cancer rates for men between 2007 and 2014 was driven primarily by the decline in lung cancer incidence due to a decrease in the number of people smoking, but the decline leveled off after that. The authors attribute that leveling off to slowing declines for colorectal cancer (CRC) and stabilizing rates for prostate cancer. The overall incidence of cancer in females has remained fairly stable for the last quarter century or so. The authors note that the decline in lung cancer rates has “been offset by a tapering decline for CRC and increasing or stable rates for other common cancers”.
In terms of incidence, there are some interesting observations, some of which are likely due to the increasing prevalence of obesity, which is a strong risk factor for some cancers. For instance, breast cancer incidence has increased by 0.3% per year since 2004, and the authors suggest that this increase could well be due to increasing obesity and declines in the fertility rate. Some of the first things they teach you about breast cancer in medical school are its risk factors, which include nulliparity (having no children, and actually, having more children correlates with a lower risk of breast cancer, as does breast feeding), early age at menarche (first menstrual period), and late menopause. Obesity, unsurprisingly, is also a risk factor for breast cancer. Of course, the gradual rise in breast cancer rates makes the dramatic decline in mortality from breast cancer (40% in 30 years) even more remarkable.
In addition:
The slight rise in breast cancer incidence rates (by approximately 0.3% per year) since 2004 has been attributed at least in part to continued declines in the fertility rate as well as increased obesity,36 factors that may also contribute to the continued increase in incidence for uterine corpus cancer (1.3% per year from 2007‐2016).37 However, a recent study indicated that the rise in uterine cancer is driven by nonendometrioid subtypes, which are less strongly associated with obesity than endometrioid carcinoma.38 Thyroid cancer incidence has stabilized after the implementation of more conservative diagnostic practices in response to the sharp uptick in the diagnosis of largely indolent tumors in recent decades.39, 40
I’ve written about overdiagnosis of thyroid cancer, thanks to ultrasound screening, and how that has led to consideration of reclassifying an indolent variant of thyroid cancer as not cancerous. The increase in incidence of uterine cancer is a bit of an oddity, and more research will be needed to determine what might be causing it.
And there’s more:
Incidence also continues to increase for cancers of the kidney, pancreas, liver, and oral cavity and pharynx (among non‐Hispanic whites) and melanoma of the skin, although melanoma has begun to decline in recent birth cohorts.28, 44 Liver cancer is increasing most rapidly, by 2% to 3% annually during 2007 through 2016, although the pace has slowed from previous years.8 The majority of these cases (71%) are potentially preventable because most liver cancer risk factors are modifiable (eg, obesity, excess alcohol consumption, cigarette smoking, and hepatitis B and C viruses).45 Chronic hepatitis C virus (HCV) infection, the most common chronic blood‐borne infection in the United States, confers the largest relative risk and accounts for 1 in 4 cases.46 Although well‐tolerated antiviral therapies achieve cure rates of >90% and could potentially avert much of the future burden of HCV‐associated disease,47 most infected individuals are undiagnosed, and thus untreated. Only 14% of the more than 76 million individuals born during 1945 through 1965 (baby boomers) had received the recommended one‐time HCV test in 2015.48 Compounding the challenge is a greater than 3‐fold spike in acute HCV infections reported to the CDC between 2010 and 2017 as a consequence of the opioid epidemic, of which 75% to 85% of cases will progress to chronic infection.49
We’ve also noted the increase in liver cancer incidence before. Sadly, it looks as though the opioid addiction epidemic will in future decades claim more victims due to liver cancer.
Contrary to what you might read, there doesn’t seem to be a signal indicating increased cancer incidence due to an as yet undiscovered environmental exposure or toxin. Cancers for which obesity is a risk actor are, unsurprisingly, on the rise, and cancers for which tobacco is a major risk factor are on the decline, while cancers associated with hepatitis B and C infections are on the rise. As Steve Novella has said many times, the best advice for minimizing your chances of being diagnosed with cancer are don’t smoke, exercise, eat a healthy diet, maintain a healthy weight, get your colonoscopy (which actually has decreased the incidence of colorectal cancer), and use sunscreen. Also, be vaccinated against hepatitis B to prevent liver cancer and against HPV to prevent cervical and other HPV-associated cancers and screened for hepatitis C if you’re in the appropriate age range.
Declining cancer mortality
There’s one more figure that I like to show from this yearly report, and that’s a more detailed breakdown of cancer mortality going all the way back to 1930:
As you can see, cancer mortality for men climbed continuously from 1930 and peaked around 1990. Unsurprisingly, that increasing mortality was mostly driven by smoking, as the generation of men with the highest usage of tobacco reached the age and number of years spent smoking when lung cancer is most likely to strike. Mortality began to decline, delayed by a number of years of course, as smoking rates began to decline after 1972.
Getting into the weeds a bit:
The progress against cancer reflects large declines in mortality for the 4 major cancers (lung, breast, prostate, and colorectum) (Fig. 7). Specifically, as of 2017, the death rate has dropped from its peak for lung cancer by 51% among males (since 1990) and by 26% among females (since 2002); for female breast cancer by 40% (since 1989); for prostate cancer by 52% (since 1993); and for CRC by 53% among males (since 1980) and by 57% among females (since 1969). The CRC death rate in women was declining prior to 1969, but that is the first year for which data exclusive of the small intestine are available. Two decades of steep (4% per year on average) declines for prostate cancer are attributed to an earlier stage at diagnosis through PSA testing, as well as advances in treatments.61, 62 However, prostate cancer death rates stabilized in recent years (Table 5), possibly related to declines in PSA testing and an uptick in the diagnosis of distant stage disease.32 Declines in mortality have also slowed for female breast and CRC. In contrast, declines in lung cancer mortality have accelerated, from approximately 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women.
In other words, a lot of progress has been made, but, again, lung cancer is primarily driving the bus here, along with the other most common cancers. Some of this progress is from screening. Some of it comes from better treatments. In particular, there is one success story based on improved treatment, namely melanoma, for which the mortality decline has been truly dramatic:
Recent mortality declines are even more rapid for melanoma of the skin, most likely reflecting improved survival in the wake of promising new treatments for metastatic disease. In 2011, the US Food and Drug Administration approved ipilimumab, the first immune checkpoint inhibitor approved for cancer therapy,63 and vemurafenib, a BRAF inhibitor, for the treatment of advanced melanoma.64 Subsequently, the 1‐year relative survival rate for metastatic melanoma escalated from 42% for patients diagnosed during 2008 through 2010 to 55% for those diagnosed during 2013 through 2015.65 Likewise, the overall melanoma mortality rate dropped by 7% annually during 2013 through 2017 in men and women aged 20 to 64 years compared with declines during 2006 through 2010 of approximately 1% annually among individuals aged 50 to 64 years and 2% to 3% among those aged 20 to 49 years (Fig. 8). The impact was even more striking for individuals aged 65 years and older, among whom rates were increasing prior to 2013 but are now declining by 5% to 6% per year.
Yes, melanoma is a nasty one. Traditionally, when I was in training, there was basically little or no systemic therapy. There was interferon, but that didn’t improve survival much, and it had a number of side effects that made patients feel terrible while they were using it. Other than surgical advances, mainly in the form of less radical surgery such as sentinel lymph node sampling supplanting radical lymphadenectomy (removal of all the lymph nodes in a nodal basin), there just wasn’t much else to offer melanoma patients. Given that melanoma responded, albeit weakly, to immunotherapy with interferon, it’s not entirely unexpected that it would respond even better to the new generation of immunotherapy agents, such as immune checkpoint inhibitors.
Unfortunately, not all the news is good. Mortality rates have risen over the last decade for pancreatic cancer in males and uterine cancer in females, as well as for some less common cancers, such as cancers of the liver, small intestine, anus, penis, brain and nervous system, eye and orbit, and oral cavity and throat. Increases in liver cancer mortality are, however, slowing in women and stabilizing in men
Also, there are large disparities in cancer mortality and incidence, and the largest disparities exist for cancers that are, theoretically at least, the most preventable, such as lung cancer, cervical cancer, and melanoma of the skin. For example, lung cancer mortality and incidence rates are three- to -fourfold higher in Kentucky than they are in Utah, and that’s all based on smoking prevalence.
For cervical cancer:
Similarly, cervical cancer incidence and mortality currently vary by 2‐fold to 3‐fold between states, with incidence rates ranging from <5 per 100,000 population in Vermont and New Hampshire to 10 per 100,000 population in Arkansas (Table 10). Ironically, advances in cancer control often exacerbate disparities, and state gaps for cervical and other HPV‐associated cancers may widen in the wake of unequal uptake of the HPV vaccine, which has already shown efficacy in reducing the burden of cervical intraepithelial neoplasia of grade 2 or higher.81 In 2018, up‐to‐date HPV vaccination among adolescents (those aged 13‐17 years) ranged from 38% in Kansas and Mississippi to >70% in North Dakota and Rhode Island among girls and from 27% in Mississippi to >70% in Massachusetts and Rhode Island among boys.75
Basically, states that make it a priority to vaccinate against HPV will likely ultimately benefit through decreased incidence of and mortality from cervical cancer.
There are also disparities in cancer survival between African-Americans and whites, with the five year survival for all cancers combined being 67% overall, 68% for whites, and 62% for African-Americans. After adjusting for age, sex, and stage at diagnosis, the relative risk of death after a cancer diagnosis is 33% higher in black patients than in white patients, and this disparity is even larger for American Indians/Alaska Natives, among whom the risk of cancer death is 51% higher than it is for whites.
Finally, the incidence of childhood cancers has been slowly increasing by about 0.7% per year since 1975 for reasons that have not been worked out. However, death rates from childhood cancers continue to decline. The overall mortality from childhood cancer declined from 6.3 (per 100,000 population) in children and 7.1 in adolescents in 1970 to 2.0 and 2.7, respectively, in 2017, for overall cancer mortality reductions of 68% in children and 63% in adolescents. During that same time period, mortality from leukemia has declined by 83% in children and by 68% in adolescents; from lymphoma by 80% and 82%, respectively. The five year relative survival rate has improved from 58% for all cancers combined in the 1970s to 84% in the early 2010s for children.
We are not losing the war on cancer
Critics of oncology and some quacks, not infrequently argue that we’re “losing the war on cancer.” (Again, just Google the phrase “losing the war on cancer”.) Arguably, we’re slowly winning, at least if you insist on using that metaphor. Mortality from cancer is declining, and for some cancers the decline has been quite dramatic just within my lifetime. For breast cancer, it’s been incredibly dramatic within my professional lifetime. I graduated from medical school over 30 years ago, and in that time mortality from breast cancer has declined by 40%. That is, quite simply, incredible to me.
Of course, it’s a painfully simplistic question, as is another question I keep hearing, “Why haven’t we cured cancer yet?” (Mainly because it’s complicated as hell.) What the evidence has shown clearly (and based on the ACS report is continuing to show) is that overall death rates from cancer are steadily falling, driven by declines in death rates from most of the common cancers. Meanwhile, five year survival rates are climbing for most cancers, even for more advanced disease.
Of course, as tobacco-caused cancers decline, unfortunately the incidence of cancers linked to obesity is climbing. So is the incidence of liver cancer, which is linked to hepatitis B and C, which are in turn increasingly linked to the opioid addiction epidemic. It will be decades before we know the full effect on cancer incidence and mortality of the obesity and opioid epidemics, and it is possible that some of the progress made thus far in reducing cancer mortality will be reversed. We also have a long way to go in terms of making sure that race and socioeconomic status do not impact one’s risk of dying from cancer.
Still, even if you insist on using the metaphor of a war, I would argue that, contrary to the common perception, we are not losing the “war on cancer”. Mortality is declining and survival is increasing for most cancers. It’s just that progress is slow, and results are mixed. I’ve always thought that it was hubris to think that progress would be anything other than slow against such a deadly, complex, multifactorial set of diseases that go under the label of cancer. Conquering all cancers is a project that will take more than decades. It will take generations. I also understand that the dramatic progress made is cold comfort to those who’ve lost loved ones to cancer or who are facing imminent death themselves from cancer. After all, I lost my mother-in-law to breast cancer 11 years ago, and by then the decline in breast cancer mortality since my youth had already reached dramatic levels.
Even if you think that progress against cancer has been too slow, the latest ACS data demonstrate conclusively that the narrative regular SBM readers hear from various proponents of “alternative cancer cures”, that cancer is killing more than ever, that big pharma doesn’t want to cure cancer, is not only incorrect but detached from reality.

We are not “losing the war on cancer” (belated 2021 edition)
The narrative we hear time and time again is that we are “losing the war on cancer”. The latest cancer statistics show that this narrative is not true.
David Gorski on July 19, 2021
Link

If you’ve perused the alternative medicine (i.e., quack) cancer literature as long as I have, you’ll recall seeing certain key narratives recurring. One such narrative, of course, is that “conventional” cancer treatments (often characterized as “cut, burn, poison”) do more harm than good. Another such narrative is that you can almost completely prevent cancer if only you eat the right foods, use the right supplements, and live the right lifestyle. There are others, of course, often based on a germ of truth exaggerated and weaponized to spread fear and suspicion of science-based cancer treatments. For example, it is true that “conventional” treatments of surgery, chemotherapy, and radiation are associated with unpleasant side effects and occasionally life-threatening risks, and diet and lifestyle can reduce your risk of cancer, but not by nearly as much as these narratives claim. (Contrary to one favorite narrative, vegans, for instance, can still get cancer.)
One other key narrative about cancer that is common not just in “alternative” cancer social media, discourse, and publications but also all too often spills over into mainstream media is that we are “losing the war on cancer”, more specifically, that we have not significantly decreased the mortality and suffering from cancer, despite a now nearly 50 year “war on cancer”, This is, of course, a narrative that has been discussed and mostly contested on SBM multiple times, including in 2017, 2018, and 2020 (before the pandemic hit, of course). It’s such a perennial topic that I expected to write a post about it in January, which is when the American Cancer Society traditionally publishes the latest US cancer statistics, but the tsunami of COVID-19 misinformation got in the way. Fortunately, recently the American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries issued their Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. Before that, in January the American Cancer Society published its 2021 cancer statistics. As in the past, the picture painted, although not simple, is far more optimistic than the narrative of “losing the war on cancer” tends to suggest, although I do expect that, as we get closer to December 23, 2021, the 50th anniversary of President Richard Nixon’s signing the National Cancer Act of 1971, we will start to see “losing the war on cancer” articles appear, as they did ten years ago, and ten years before that.
Let’s dig into the current numbers, though, shall we?
Cancer 2021, by the numbers
The annual report on cancer published recently looked at incidence data for all cancers from 2001 through 2017 and survival data for melanoma cases diagnosed during 2001-2014 and followed up through 2016 using data obtained from the Centers for Disease Control and Prevention- and National Cancer Institute-funded population-based cancer registry programs compiled by the North American Association of Central Cancer Registries. In addition, cancer mortality data for the years 2001 through 2018 were obtained from the National Center for Health Statistics’ National Vital Statistics System. Using this data, trends in age-standardized incidence and death rates, and 2-year relative survival were estimated, and trends in incidence and mortality were expressed as average annual percent change (AAPC) during the most recent 5 years (2013-2017 for incidence and 2014-2018 for mortality).
I’ll start with the summary of the results from the abstract, and then look at some key points:
Overall cancer incidence rates (per 100,000 population) for all ages during 2013–2017 were 487.4 among males and 422.4 among females. During this period, incidence rates remained stable among males but slightly increased in females (AAPC = 0.2%; 95% confidence interval [CI] = 0.1% to 0.2%). Overall cancer death rates (per 100,000 population) during 2014–2018 were 185.5 among males and 133.5 among females. During this period, overall death rates decreased in both males (AAPC = −2.2%; 95% CI =−2.5% to − 1.9%) and females (AAPC = −1.7%; 95% CI = −2.1% to − 1.4%); death rates decreased for 11 of the 19 most common cancers among males and for 14 of the 20 most common cancers among females, but increased for 5 cancers in each sex. During 2014–2018, the declines in death rates accelerated for lung cancer and melanoma, slowed down for colorectal and female breast cancers, and leveled off for prostate cancer. Among children younger than age 15 years and adolescents and young adults aged 15–39 years, cancer death rates continued to decrease in contrast to the increasing incidence rates. Two-year relative survival for distant-stage skin melanoma was stable for those diagnosed during 2001–2009 but increased by 3.1% (95% CI = 2.8% to 3.5%) per year for those diagnosed during 2009–2014, with comparable trends among males and females.
This being the age of the pandemic, I can’t help but interject a brief comparison here. COVID-19 killed approximately 375,000 in the US in 2020. That translates to a death rate of approximately 114 per 100,000, which is disturbingly in the same ballpark as cancer deaths among females in the study described above, and the COVID-19 pandemic didn’t really hit the US in a big way until March 2020.
But let’s get back to cancer. As I write every time I discuss cancer survival and mortality statistics, cancer is not one disease. It’s literally dozens, if not hundreds, of diseases. So it’s necessary to unpack these figures and go into more detail. The news is mostly good. I also realize that, to those who have lost loved ones to cancer or who are facing imminent death from cancer, these figures might well represent cold comfort. Cancer does, after all, still remain the number two cause of death in the US, close behind heart disease, at least for now. (Cancer is expected to surpass heart disease as the number one cause of death soon and has already done so in some countries.) That means, for all the progress that’s been made in terms of declining cancer mortality, a lot of people—far too many—still die of a form of cancer and that that will continue for the foreseeable future.
That being said, what are the key takeaway points from this review of US cancer statistics? First, and most importantly, consistent with previous reports, cancer death rates are continuing to decrease. In this overview, overall they decreased 2.2% per year (on average) among males and 1.7% per year (on average) among females. During the same time period, incidence rates among men were stable during 2001-2007, decreased an average of 2.2% per year during 2007-2013, and became stable again during 2013-2017. Among females, overall cancer incidence rates were stable during 2001-2003 and increased slightly during 2003-2017 (APC = 0.2%; 95% CI = 0.1% to 0.2%). What is interesting to me in the curves (below) is how cancer incidence rates for males and females appear to be converging, with men’s cancer incidence declining to be closer to that of women, while women’s incidence rates remain mostly stable. Meanwhile, the downward trend in mortality during that same time period is unmistakable:
I note that these data are pretty consistent with the ACS publication in January, from which these charts were obtained. I include them because the data presented therein goes back much further, to 1975:
As you can see, cancer incidence and mortality peaked around 1990 in both men and women, with mortality having been on a steady downward trend since around the same time. This observation is likely due primarily to the effect of tobacco, which causes one of the deadliest cancers, lung cancer. Given that there is about a two decade lag between changes in smoking behavior and differences in lung cancer incidence and mortality, it makes sense that we would start to see the effects of the smoking cessation campaigns and declines in tobacco use that began in the 1960s and 1970s start to be reflected at this time.
More recently, though, declines in lung cancer mortality reflect improvements in treatment as well. As stated in the Annual Report to the Nation on the Status of Cancer:
Historical declines in cigarette smoking have been followed by declines in incidence and death rates for several smoking-related cancers, including lung, bladder, and larynx. Moreover, as reported in previous studies (27, 28) and observed in this study, lung cancer death rates have declined at a faster pace compared to declines in incidence rates since the mid-2000s, and the difference in the pace of decline has become greater in more recent years. This pattern corresponds to the timing of approval of targeted therapies and other advances in care for the most common subtype of lung cancer, non-small-cell lung cancer (NSCLC), which have resulted in increases in survival and accelerated declines in death rates for this subtype (28). In contrast, declines for small-cell lung cancer, with no approved novel treatments during our study period (29), have been similar to declines in incidence rates, with no improvement in survival rates for this subtype (28).
The first targeted therapy for NSCLC was approved by the FDA in 2003 (30), followed by the approval of several other targeted treatments, recommendations for genetic mutation testing of all individuals with non-squamous NSCLC for relevant genetic targets in 2012 (28), and the approval of 3 immune checkpoint inhibitors for NSCLC in 2015-2016 (31). Increases in the proportion of individuals with NSCLC who receive definitive therapy (32), better understanding of treatment options for older persons with NSCLC (33-35), other recent advances in care for NSCLC, such as adjuvant therapy (36) and maintenance therapy (37), and increased access to care through the Medicaid expansion (38) may also have contributed to the acceleration in declines in lung cancer death rates. Any contribution of earlier detection through lung cancer screening (39) to declines in lung cancer death rates is likely to be modest, given low utilization of screening (4.4% of eligible individuals in 2015) (40). Despite substantial declines in death rates, lung cancer is still the leading cause of cancer death in both sexes, accounting for more than 22% of all cancer deaths in the United States (27), underscoring the need for broader implementation of tobacco control interventions.
In other words, as much as the percentage of the population who smoke and use tobacco products has declined markedly in this country over the last 50 years, tobacco is still the number one cause of cancer deaths. That’s how deadly tobacco addiction is.
While the news about the modifiable cancer risk factor of smoking coupled with more effective treatments of the main cancer caused by smoking is generally good it’s not as good for others. Unfortunately, as you might imagine, obesity-related cancers are on the rise:
In contrast to the rapid decline in incidence rates of smoking-related cancers, incidence rates continued to increase for several cancers, particularly those associated with excess body weight (41), such as cancers of the female breast, corpus uteri, pancreas, kidney, and myeloma (rates rising among females only). The staggering rise of obesity (42, 43) and total sitting time (44) continues among both adults and youth. A parallel rise in death rates occurred for pancreatic and uterine cancers, and the earlier declines in death rates slowed for female breast and colorectal cancers, suggesting that for these cancers, increases in incidence rates are of sufficient magnitude to outweigh improvements in survival. Importantly, a recent study of trends by 5-year age groups showed steeper increases in incidence rates among progressively younger ages and successively younger generations for cancers of the corpus uteri, pancreas, kidney, colorectum, and multiple myeloma (18), foreboding of future burden of these cancers in the decades to come.
Besides all the other adverse health consequences of obesity, there is cancer as well. The obesity epidemic does not bode well for future cancer incidence and mortality.
Overall, though, cancer mortality is declining for most cancers:
I also can’t help but mention my clinical specialty, breast cancer, and cite what the report says about it:
Female breast cancer is the most commonly diagnosed cancer among women and among AYA [adolescents and young adults], and the second leading cause of cancer death among women. The increase of breast cancer incidence is largely driven by hormone-receptor positive cancer (50, 51), which may in part reflect continuing reduction of parity rates (52, 53), advanced age at first birth (53), the obesity epidemic (postmenopausal breast cancer) (52), high levels of physical inactivity, and increase of alcohol consumption (54, 55). As noted in the last year’s report (56), the decline of breast cancer death rates overall has slowed since 2007, and even more so since 2014, and rates have stabilized among young women since 2010, halting the progress achieved through early detection and improved treatments. Moreover, substantial racial disparities persist, as death rates are 40% higher among Black women than White women despite similar incidence rates.
At the risk of blowing my own horn too much, the cancer center where I am faculty, it turns out, is a leader in studying racial disparities in cancer incidence, treatment, and mortality. So I am acutely aware of the racial disparities that exist for breast cancer. (I should do a post about it in the future.). The conclusions in the report above are similar to those reported by the ACS report in January:
Overall cancer incidence in women has ticked up slightly in recent years after stable rates over the past couple of decades.46 This partly reflects a slowing decline for CRC coupled with increasing rates for breast and uterine corpus cancers (Fig. 3). Breast cancer incidence rates continue to increase by about 0.5% per year, which is attributed at least in part to continued declines in the fertility rate and increased body weight.47 These factors may also contribute to the continued increase in uterine corpus cancer incidence of about 1% per year,48 although a recent study indicated that this trend is driven by nonendometrioid subtypes, which are not as strongly associated with obesity as endometrioid carcinoma.49
When it comes to other cancers:
Cancer survival has improved since the mid-1970s for all of the most common cancers except uterine cervix and uterine corpus,64 largely reflecting the absence of major treatment advances for these cancers.65, 66 For cervical cancer, it may also reflect an increasing proportion of adenocarcinoma over time because of widespread cytology screening, which mostly detects squamous precancerous lesions and invasive squamous cell carcinomas.67 Screening also hinders the utility of tracking trends in survival to measure progress against breast and prostate cancers because of lead-time bias and the detection of indolent cancers.68 Gains in survival have been especially rapid for hematopoietic and lymphoid malignancies due to improvements in treatment protocols, including the development of targeted therapies. For example, the 5-year relative survival rate for chronic myeloid leukemia increased from 22% in the mid-1970s to 72% for those diagnosed during 2010 through 2016,6 and most patients treated with tyrosine kinase inhibitors experience near-normal life expectancy.69
I’ve discussed (as have others) many times the issue of overdiagnosis of indolent cancers by screening mammography programs and how difficult it is to demonstrate a definite improvement in breast cancer mortality due to mammography. The same confounding issue is generally true to varying degrees for other cancers for which we screen (especially prostate cancer), namely that it is hard to determine how much of an increase in survival is due to better treatment versus lead-time and length biases of screening, which preferentially picks up slower growing tumors and artificially inflate survival (but not mortality) rates. That is why cancer mortality is generally a better metric than survival rates for diagnosed cancers, at least for cancers for which we screen that are subject to overdiagnosis. For cancers for which we do not screen, such as hematological malignancies, however, increases in survival are generally driven mostly by improvements in treatment.
Another example of this is melanoma:
As noted in the last two annual reports and in other studies, death rates for cutaneous melanoma have declined rapidly in recent years following introduction of new therapies, including targeted and immune checkpoint inhibitors, the first of which was approved by the FDA in early 2011 (15, 56, 91, 92). In this year’s report, we present trends in stage-specific survival from 28 states and find increases in 2-year relative survival beginning in 2009 for distant-stage disease (3.1% per year). An increase in survival for distant-stage melanoma has also been documented in the CONCORD-3 study, in which 1-year net survival for cases diagnosed during 2001-2010 in the United States was stable at 43%, but it started to increase from 2010, reaching 56.6% for cases diagnosed in 2013 (93). The increase in late-stage melanoma survival in the United States slightly preceded the FDA approval of new therapies, likely because of the administration of these therapies through clinical trials and the FDA expanded access programs prior to the approval (93).
Again, melanoma is a cancer type that is not routinely screened for, at least not in the systematic way that breast, prostate, and, increasingly, lung cancer are screened for. In any event, I remember well when I was a resident in the 1990s. Although localized melanoma had a very good prognosis, metastatic melanoma was in essence a death sentence. It laughed at chemotherapy, and the only immune therapies were drugs like interferon, often at high doses that were quite toxic and didn’t have a lot of effect. However, melanoma death rates started a significant decline in 2013 among males (5.7% per year) and in 2012 among females (4.4% per year) after a period of stable trends. Finally, after decades of not a lot of progress in melanoma, science-based medicine is starting to come through. Interferon is still an important component, but newer immunotherapy drugs and targeted drugs are making a difference.
Another observation in the annual report is that cancer death rates decreased an average of 0.9% per year among adolescents and young adults (AYA), and an average of 1.4% per year among children between 2014 and 2018. I like to say that childhood cancer is an excellent example of what science-based medicine can do. Back in the 1950s and 1960s, childhood cancer was generally a death sentence. Since then, survival rates for most childhood cancers have reached the 80% range and higher.
We are not losing the war on cancer
Any strategy to combat cancer rests on three legs: Prevention, diagnosis, and treatment. Changes in diagnostic modalities can increase the apparent incidence of cancer through overdiagnosis, as well as the five year survival through lead-time bias, but they can also result in a decrease in mortality due to the cancer being screened for. As I have pointed out on a number of occasions before, there are many tradeoffs.
There is also little doubt that improvements in treatment have likely played a significant role in the declines in mortality from some cancers and improved five year survivals, but, although the overall arc is towards declining mortality and improved survival, progress is uneven. Indeed, the report concludes:
Cancer death rates in the United States continue to decline overall and for many cancer types. Furthermore, declines in death rates have accelerated for lung cancer and melanoma, likely owing to advances in treatment. However, earlier progress has slowed for several common cancers, death rates are increasing for several other cancers, and incidence rates are increasing slightly among females and in younger ages. These results inform ongoing and future efforts in prevention, early detection, and treatment and broad implementation of effective interventions, especially among under-resourced populations.
Critics of oncology and some quacks, not infrequently argue that we’re “losing the war on cancer”. (Again, just Google the phrase “losing the war on cancer”.) Arguably, we’re slowly winning, at least if you insist on using that metaphor. Mortality from cancer is declining, and for some cancers the decline has been quite dramatic just within my lifetime. For breast cancer, it’s been incredibly dramatic within my professional lifetime. I graduated from medical school over 30 years ago, and in that time mortality from breast cancer has declined by 40%, as shown in the ACS report from January. That is, quite simply, incredible to me.
Of course, it’s a painfully simplistic question, as is another question I keep hearing and have written about at least a couple of times, “Why haven’t we cured cancer yet?” (Mainly because it’s complicated.) What the evidence has shown clearly (and based on the cancer report is continuing to show) is that overall death rates from cancer are steadily falling, driven by declines in death rates from most of the common cancers. Meanwhile, five year survival rates are climbing for most cancers, even for more advanced disease.
I’ve always thought that it was hubris to think that progress would be anything other than slow against such a deadly, complex, multifactorial set of diseases that go under the label of cancer. Conquering all cancers is a project that will take more than decades. It will take generations. I also understand that the dramatic progress made is cold comfort to those who’ve lost loved ones to cancer or who are facing imminent death themselves from cancer. After all, I lost my mother-in-law to breast cancer 13 years ago, and by then the decline in breast cancer mortality since my youth had already reached dramatic levels. My wife lost her aunt to it in January, after the decline in breast cancer mortality had become truly impressive.
Even if you think that progress against cancer has been too slow, the latest cancer statistics data demonstrate conclusively that the narrative regular SBM readers hear from various proponents of “alternative cancer cures”, that cancer is killing more than ever, that big pharma doesn’t want to cure cancer, is not only incorrect but detached from reality. The actual situation is far more optimistic, albeit not universally so.

   Applying evolutionary principles to cancer treatment
David Gorski
Link
A couple of weeks ago, there was a lot of hype about a study that hadn’t been released yet. Indeed, there was a story in Wired entitled To Survive Cancer, Live With It and an editorial by the study’s lead author in Nature entitled A change in strategy in the war on cancer. Not bad for a study that hadn’t been released yet. Intrepid medical and science blogger that I am, I waited until the actual study was published a week ago the June 1 episode of Cancer Research. It’s a clever study, but the hype over it was a bit overblown. For example:
For all the weapons deployed in the war on cancer, from chemicals to radiation to nanotechnology, the underlying strategy has remained the same: Detect and destroy, with no compromise given to the killer. But Robert Gatenby wants to strike a peace.
A mathematical oncologist at the Moffitt Cancer Center, Gatenby is part of a new generation of researchers who conceive of cancer as a dynamic, evolutionary system. According to his models, trying to wipe cancer out altogether actually makes it stronger by helping drug-resistant cells flourish. Rather than fighting cancer by trying to eradicate its every last cell, he suggests doctors might fare better by intentionally keeping tumors in a long-term stalemate.
Maybe I’m being a bit picky, but what annoys me about the news reports on this study is that the concept of turning cancer into a manageable chronic disease like diabetes or hypertension is not by any means a new idea. Remember, one of my major research interests is the inhibition of tumor angiogenesis. Consequently, I know that the late, great Judah Folkman first proposed the concept of using antiangiogenic therapy to turn cancer into a chronic disease at least as early as the mid-1990′s. The only difference is the strategy that he proposed. The idea had also been floating around for quite a while before that, although I honestly do not know who first came up with it.
But let’s see what Dr. Gatenby proposes. What makes it interesting is that his study actually looks at how scientists have applied evolutionary principles to cancer until recently, argues that we’ve been doing it wrong. He then proposes a way to use the evolutionary dynamics of applied ecology. He may well be on to something. First, here’s the problem:
The German Nobel laureate Paul Ehrlich introduced the concept of ‘magic bullets’ more than 100 years ago: compounds that could be engineered to selectively target and kill tumour cells or disease-causing organisms without affecting the normal cells in the body. The success of antibiotics 50 years later seemed to be a strong validation of Ehrlich’s idea. Indeed, so influential and enduring was medicine’s triumph over bacteria that the ‘war on cancer’ continues to be driven by the implicit assumption that magic bullets will one day be found for the disease.
Yet lessons learned in dealing with exotic species, combined with recent mathematical models of the evolutionary dynamics of tumours, indicate that eradicating most disseminated cancers may be impossible. And, more importantly, trying to do so could make the problem worse.
Traditionally, cytotoxic chemotherapy has been given in either as fixed doses close to the maximum tolerated dose or, as has been common more recently, a regimen known as “dose dense.” Basically, the fixed dose schedules involve giving as much chemotherapy as the patient can tolerate up to what is known as the “maximum tolerated” dose and giving it over as short a period of time as possible, while “dose-dense” therapies try to target chemotherapy doses to the time of maximal tumor growth, when tumors are maximally sensitive to chemotherapy. This strategy is based on what is called the Norton-Simon model. One key assumption behind such therapies is that chemotherapy fails because of the evolution of resistant cells after chemotherapy has begun. The idea behind this strategy is to hit the tumor cells as hard as possible as fast as possible to kill as many cells as possible and minimize the opportunity to develop resistance. Dose-dense chemotherapy has definitely resulted in improvements in survival in multiple tumors but rarely results in cure, at least in the common “solid” malignancies that kill so many, such as breast, prostate, lung, and colon cancer. However, that improvement sometimes comes at a price: Increased toxicity and side effects.
Based on Judah Folkman’s work, around the turn of the century (the 21st century, not the 20th century) Robert Kerbel proposed a new regimen known as metronomic chemotherapy. Metronomic therapy involves giving chemotherapy either continuously or at frequent dosing but at a much lower dose, the idea being that, because blood vessels are lined by genetically stable endothelial cells, they do not evolve resistance, and chemotherapy can be antiangiogenic. The idea was to deliver the same total dose of chemotherapy but without all the toxicity, meanwhile keeping the tumor in check or shrinking it by the effect the chemotherapy has on the tumor blood vessels. The drawback is that long periods of therapy may be required and the cumulative doses may end up being actually higher than more standard therapies. On the other hand, this latter aspect may not be a drawback because metronomic chemotherapy may allow a greater cumulative dose, with a concurrent greater cumulative effect. Metronomic chemotherapy is a promising concept, but thus far clinical trials in humans have been fairly disappointing.
One aspect that is shared among both of these therapy modalities is that they generally both involve fixed schedules and fixed doses. What Dr. Gatenby proposes to get around this is to apply what he calls “adaptive therapy.” This therapy is based on population ecology and the observation that the development of resistance does not come free. Indeed, resistant cells need to expend energy in order to do what cells do to overcome chemotherapy; for exmple, to repair DNA faster, pump the chemotherapy out of the cell, bypass intracellular signaling pathways blocked by new targeted therapies, or crank out enough peptides that induce the ingrowth of new blood vessels in order to overcome therapies that block these factors. In other words resistant cells tend to have a lower fitness under normal conditions. It is only the selective pressure of chemotherapy that allows resistant cells to proliferate faster than normal cells, and, indeed, resistant cells tend to lose their resistance when the selective pressure is removed.
Given this concept, Gatenby likens adaptive therapy to controling invasive species:
Gatenby: How people treat invasive species can provide an analogy for thinking about cancer therapy. In treating a field for a pest, for example, you might treat three-quarters of it with a pesticide, and leave the other quarter untreated. Pesticide-sensitive pests remain there, and they spread out into the field after treatment, preventing pesticide resistance from becoming dominant.
Using pesticides on an entire field is like what we’re doing with cancer now. And we all agree that we’d rather get rid of the pests altogether, but if you can’t do it, if every time you have an infestation you treat it and get resistance, then you try a different strategy. The alternative is to try to reduce the pest population so that it doesn’t damage your crop, and accept the fact that they’re going to be there. That’s what I’m talking about with cancer.
Wired.com: What type of treatment would that involve?
Gatenby: Instead of fixing the dose of the drugs, you fix the size of the tumor. Your whole goal is to keep the tumor stable. You continuously alter the drug, the dose, the timing of the dose, with that goal in mind.
And:
Our models show that in the absence of therapy, cancer cells that haven’t evolved resistance will proliferate at the expense of the less-fit resistant ones. And, when a large number of the sensitive cells are killed, for instance by aggressive therapies, the resistant types are able to proliferate unconstrained. This means that high doses of chemotherapy might actually increase the likelihood of a tumour becoming unresponsive to further therapy.
So, just as the judicious use of pesticides can be used to successfully control invasive species, a therapeutic strategy explicitly designed to maintain a stable, tolerable tumour volume could increase a patient’s survival by allowing sensitive cells to suppress the growth of resistant ones.
It’s a fascinating concept. The idea is to keep from killing off too many of the sensitive cancer cells, so that they can grow to a certain point and keep the resistant cells in check. But can it work?
The Cancer Research paper published a week ago presents evidence that, at least in mouse models, it might be able to. I will admit that a lot of the mathematics in the paper are beyond me. There was a time when I was in college and taking all sorts of calculus and differential equations when these equations wouldn’t make my brain hurt to look at them, but if you don’t use it you lose it, and lost it I have (mostly). Suffice it to say that the model takes into account estimates of variability of fitness in tumor cells making up the population, dosing, differential uptake with tumor size, and other critical parameters. The concept of adaptive therapy requires that chemotherapy doses be adjusted to maintain constant tumor volume, increasing dosage if the tumor grows and decreasing it if the tumor shrinks. First, the mathematical model:
The graphs above represent modeling of dose dense/maximum tolerated dose (MTD) therapy, adaptive therapy, adaptive therapy (ADAP), and three varieties of metrnomic therapy, continuous infusion, high frequency, and low frequency. Four combinations of mixed cell populations were tested, including:
     1.  FR with high free-field fitness and high sensitivity to therapy
     2.  R with lower fitness and low sensitivity to therapy
     3.  S with low fitness and high sensitivity
     4.  ER with high intrinsic sensitivity and fitness but in an environment that restricts proliferation and response.
Combinations that were modeled included: (a) ”FS and R,” (b) ”S and FR,” (c) ”FS and R and ER,” and (d) ”FS and ER.” Strikingly, by day 1,500 of tumor growth (1,100 days after therapy was started), the tumor treated using the MTD strategy had grown to be the largest whereas those treated with metronomic therapy were smallest. When the simulations were run out to many thousands more days, until the tumor burden achieved the lethal threshold, all patients in the MTD and metronomic therapies eventually succumbed to their disease. In this model the tumors treated with adaptive therapy remained stable even after a period exceeding 10,000 days. In other words, tumors treated with MTD had the best initial response rate to therapy but tended to develop resistance rapidly, while tumors treated with metronomic chemotherapy remained stable and did not grow appreciably for much longer but nonetheless eventually developed resistance to the point where the tumor escaped therapy and killed the host. In contrast, tumors treated with adaptive therapy remained stable for a very long time.
Mathematical models are all well and good, but does adaptive chemotherapy work for real? To test that, Gatenby designed an adaptive therapy protocol for a mouse model of ovarian cancer. It was a tricky experiment to do, as his group had to measure the tumor burden every three days and then adjust the chemotherapy dose according to their behavior, decreasing the dose for each mouse if its tumor shrank and increasing the dose if it grew. All of this was done fore each and every mouse, meaning that there could be as many doses of chemotherapy as there were mice in the adaptive therapy group. Here’s the method:
The adaptive group received an initial dose of 50 mg/kg and thereafter the tumors were evaluated every 3 days and the dose was adjusted to maintain a stable tumor volume. The algorithm for dosing basically represented “a shot in the dark” because no prior experience was available to parameterize the models. Drug doses were established in increments of 10 mg/kg starting at the starting dose of 50 mg/kg. A treatment decision was made at the time of each measurement. If the tumor remained stable (defined as the no more than a 10% change from the prior volume using caliper measurements), no drug would be administered. If the tumor diminished in size or remained stable for two or more measurements, the next dose would be decreased by one 10 mg/kg decrement. If the tumor increased in size greater than 10%, the same dose of drug would be administered. If the tumor again increased in size, the dose would be increased to the next higher level.
As you can see, this is a pretty labor intensive regimen. No doubt Gatenby will be able to refine his method and develop a protocol that isn’t in essence a reasonable guess, but for now there isn’t a lot to guide scientists in developing such adaptive protocols.
Here’s the result:
In the mice, the adaptive regimen using carboplatin clearly worked better than the standard carboplatin regimen, suggesting that adaptive therapy can work. As Gatenby puts it:
Our analysis shows that, in the absence of therapy, the fitter, chemosensitive cells actually suppress the growth of the less fit but resistant population. Therapies designed to kill maximum numbers of cancer cells produce an environment in which the resistant cells both survive and are unopposed by the fitter, chemosensitive populations. This permits rapid regrowth of a therapy-resistant cancer. Alternatively, if therapy is limited to allow a significant number of chemosensitive cells to survive, they will, in turn, suppress the growth of the resistant population. We hypothesized that under these circumstances, adaptive therapy should be designed to maintain a normal cohort of surviving sensitive cells.
Another interesting aspect of this study is that it’s been known for some time that using metronomic chemotherapy allows a larger total dose of chemotherapy given over a longer period of time with lower toxicity. It works well in mice, but unfortunately is less stunningly effective in humans (much like antiangiogenic therapy, alas). The larger total dose of chemotherapy that can be delivered is one reason that has been postulated as an explanation for why metronomic chemotherapy can be more effective than dose dense chemotherapy. There’s no reason to think that adaptive chemotherapy wouldn’t behave similarly and allow for a larger total dose. But, in this model at least, it went beyond that. The adaptive chemotherapy group the dose required to maintain tumor stability decreased with time from 50 mg/kg to 10 mg/kg. In the experiment I showed, the individtual doses were 50, 40, 40, 30, 30, 20, 20, 10, 10, 10, 10, 10, 10, 10, 10, 10 mg/kg. This observation is consistent with a stabilization of the tumor cell population consistent with the evolutionary and ecological model used to test the study hypothesis.
The power of evolutionary principles is that they apply to more than just populations of organisms. They can equally apply to populations of cells within an organism, like cancer. In other words, evolution acts at both the organism level and the cellular leve. Tumors, given their genetic instability, enormous heterogeneity, and subpopulations of cells with different fitness and sensitivity to selective pressures are a perfect system to apply the principles of evolutionary ecology to. What’s fascinating about this study is that it appears that using evolutionary principles in a savvier way than we have in the past can work. In theory and in at least one animal model, it can produce more effective chemotherapeutic regimens. Indeed, one fascinating observation is that, the longer the tumors were treated with adaptive therapy, the less chemotherapy was required and the longer the intervals between doses that were needed to maintain a constant volume. Like the concept of antiangiogenic therapy proposed by Judah Folkman, however, applying evolution to cancer may require a rethinking of how we deal with cancer.
Unfortunately, I don’t see an obvious or immediate application of adaptive chemtherapy in humans. The reason is that it would be very cumbersome, labor-intensive, and expensive. Tumor measurements far more frequent than what we routinely do now would be required, as would frequent adjustments in chemotherapy dosing. As a strictly practical matter, it would be very hard to implement. Indeed, this model was very simplistic in that it tested adaptive chemotherapy using one drug. In reality, very few chemotherapy regimens in common use involve only one drug, and any truly adaptive therapy would have to adjust multiple drugs, with a concomitant exponential increase in complexity administrating it. Also, from a strictly clinical standpoint, tumors that are large or advanced would need to be shrunk because their size causes serious symptoms. How that would be integrated into an adaptive regimen remains to be seen.
Another potential problem is one that has been seen by scientists trying to use a similar approach to control HIV infection: compensatory mutations. In antibacterial therapy, the long term removal of antibiotics has not thus far resulted in the disappearance of resistant strains, and this is due to compensatory mutations that can restore the fitness of these strains. This phenomenon has only been described in viruses and bacteria, but it would not be surprising if they also occurred in cancer cells.
Even so, there is one potential use that I can envision for this sort of ecological approach to produce adaptive chemotherapy. This would be as a means of treating tumors that have well-validated serum tumor markers that correlate well with tumor burden in individual patients; for example, colorectal cancer (tumor marker: carcinoembryonic antigen, or CEA) or prostate cancer (tumor marker: prostate-specific antigen, or PSA). One can imagine an implantable pump that could measure the levels of these tumor markers and then, according to algorithms developed based on ecological and evolutionary principles, continuously adjust the dose of metronomic chemotherapy to keep a patient’s tumors in check.
Finally, as Gatenby himself points out, these sorts of approaches will not render the search for cures unnecessary. After all, consider other chronic diseases. Diabetes, for instance, can be managed quite well on a chronic basis, but what patient with type I diabetes wouldn’t want to be cured and thus able to throw away his insulin syringes? In the case of cancer, cures remain preferable, but, like the case of diabetes, sometimes settling for chronic management is the best we can do.
REFERENCE:
Gatenby, R., Silva, A., Gillies, R., & Frieden, B. (2009). Adaptive Therapy Cancer Research, 69 (11), 4894-4903 DOI: 10.1158/0008-5472.CAN-08-3658

Genetics and evolution in cancer
Several new studies were published earlier this month describing the sequencing of over 2,600 cancer genomes. What the results show include what sorts of mutations drive cancer development and how evolution makes cancers so difficult to treat.
David Gorski on February 17, 2020
Link

Why haven’t we cured cancer yet? How many times have I heard that question before, and how many times have I tried to answer it? I don’t know. I do know that I’ve pointed out many times that cancer is not one disease, but hundreds and that the genomes of cancers are messed up, real messed up, and that trying to cure any single cancer is fighting against the power of evolution that makes cancer more resistant to treatment the longer it’s exposed to a given treatment. Still, every so often a study comes out that leads me to revisit the question in light of the new data published. This time around, it’s a study published earlier this month in Nature by the Pan-Cancer Analysis of Whole Genomes Consortium (PCAWG) of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) examining the evolutionary history of over 2,600 cancers representing 38 different kinds of cancer, each of whose whole genome was sequenced and analyzed. The conclusions of the study, the work of a more than a thousand scientists in 37 countries on four continents taking place over more than a decade, are fascinating and very much consistent with cancer being primarily a disease caused by mutations in a relatively small set of genes. Actually, it’s a series of papers based on the same massive study. Before we dig in, let’s consider just how massive this undertaking was:
The project involved an interdisciplinary group of scientists from 4 continents, with 744 affiliations between them, who had to overcome major technical, legal and ethical challenges to carry out distributed analyses while protecting patient data. Researchers were divided into 16 working groups, each focused on distinct facets of cancer genomics — assessing the recurrence of mutations, for instance, or inferring tumour evolution.
Altogether, the consortium performed integrative analyses of 38 tumour types. The group sequenced 2,658 whole-cancer genomes (Fig. 1), alongside matched samples of non-cancerous cells from the same individuals. These data were complemented by 1,188 transcriptomes — the sequences and abundances of RNA transcripts in a tumour.
These efforts involved extensive quality control and coordinated data processing, as well as massive, systematic experimental validation of the computational pipelines used to detect mutations. Many computational algorithms and pipelines were used and compared in concert. This required hundreds of terabytes of data, spread across multiple data centres, and probably millions of processing hours — all facilitated by cloud computing. Notably, the PCAWG efforts provide a prime example of how cloud computing can make international collaboration possible and help to advance data-intensive fields.
These sorts of projects just weren’t possible not too long ago. Neither the computational power nor the techniques needed to sequence an entire genome in a short period of time existed. The results of this project were published in six papers:
     1.  Pan-cancer analysis of whole genomes
     2.  Analyses of non-coding somatic drivers in 2,658 cancer whole genome
     3.  The repertoire of mutational signatures in human cancer
     4.  Patterns of somatic structural variation in human cancer genomes
     5.  The evolutionary history of 2,658 cancers
     6.  Genomic basis for RNA alterations in cancer
In addition to these papers, a number of companion papers were published in other Nature Publishing Group journals, so many that I must confess that I haven’t had a chance to read them all yet. That’s why I’ll mainly focus on the core six listed above, mainly (but not exclusively) the first and fifth papers, because the effect of evolution on cancer development has always been an interest of mine.
Personally, I like how the first paper mentions that “cancer” is not a single disease, that it’s an incredibly diverse collection of diseases:
‘Cancer’ is a catch-all term used to denote a set of diseases characterized by autonomous expansion and spread of a somatic clone. To achieve this behaviour, the cancer clone must co-opt multiple cellular pathways that enable it to disregard the normal constraints on cell growth, modify the local microenvironment to favour its own proliferation, invade through tissue barriers, spread to other organs and evade immune surveillance21. No single cellular program directs these behaviours. Rather, there is a large pool of potential pathogenic abnormalities from which individual cancers draw their own combinations: the commonalities of macroscopic features across tumours belie a vastly heterogeneous landscape of cellular abnormalities.
This heterogeneity arises from the stochastic nature of Darwinian evolution. There are three preconditions for Darwinian evolution: characteristics must vary within a population; this variation must be heritable from parent to offspring; and there must be competition for survival within the population. In the context of somatic cells, heritable variation arises from mutations acquired stochastically throughout life, notwithstanding additional contributions from germline and epigenetic variation. A subset of these mutations alter the cellular phenotype, and a small subset of those variants confer an advantage on clones during the competition to escape the tight physiological controls wired into somatic cells. Mutations that provide a selective advantage to the clone are termed driver mutations, as opposed to selectively neutral passenger mutations.
The fifth paper also points out how important evolution and selective pressures are on the development of any given cancer:
Similar to the evolution in species, the approximately 1014 cells in the human body are subject to the forces of mutation and selection1. This process of somatic evolution begins in the zygote and only comes to rest at death, as cells are constantly exposed to mutagenic stresses, introducing 1–10 mutations per cell division2. These mutagenic forces lead to a gradual accumulation of point mutations throughout life, observed in a range of healthy tissues5,6,7,8,9,10,11 and cancers12. Although these mutations are predominantly selectively neutral passenger mutations, some are proliferatively advantageous driver mutations13. The types of mutation in cancer genomes are well studied, but little is known about the times when these lesions arise during somatic evolution and where the boundary between normal evolution and cancer progression should be drawn.
I’ve discussed the heterogeneity of cancer before based on much smaller studies from several years ago. Basically, because of mutations and different selective pressures on a given cancer, the cells in one part of a cancer are often quite different than the cells in another part, and the cells in metastases are, again, often quite different from the cells in the primary tumor mass. One time when I described the results of a study sequencing cancer genomes, I described these genomes as looking like someone threw a miniature grenade into the nucleus of the cell from which the cancer originated. In other words, these are some really messed up genomes. (I wanted to use another word to describe it, but this is a family blog—sort of, anyway.) I used this example to explain once again that cancer is not a single disease. It’s hundreds of diseases. Although there are common themes in how cells become cancerous, such as loss of responsiveness to growth signals with a resultant ability to grow unchecked, evasion of programmed cell death (apoptosis), inducing the surrounding tissue to provide a blood supply (angiogenesis), evading the immune system, and invading the blood or lymphatic systems to travel elsewhere in the body and take up shop in other organs, such as liver, lung, or bone, individual cancers acquire these necessary (to the cancer) abilities through many different mechanisms. The current set of studies helps describe the sorts of genomic changes in cancer cells that allow them to do these things.
The first key finding, reported in the first paper, is that on average each cancer genome contains four or five driver mutations, which provide the cells with a selective advantage. The authors’ initial analysis found nearly 10% of cancers did not have an identifiable driver mutation. When they went back and accounted for technical issues (some normal matched samples had significant contamination with DNA from cancerous samples) and other factors that could hamper identification of driver mutations, they still were unable to identify a driver mutation in 5.3% of the cancer genomes studied, which tells us that we have not yet identified all the mutations that can drive cancer.
The authors also looked at the types of mutational events observed in the cancers. In particular they looked at the sorts of mutations that can generate multiple mutations in a single catastrophic event: (1) chromoplexy, in which repair of co-occurring double-stranded DNA breaks—usually on different chromosomes—results in shuffled chains of rearrangements; (2) kataegis, a focal hypermutation process that leads to locally clustered nucleotide substitutions, biased towards a single DNA strand; and (3) chromothripsis, in which tens to hundreds of DNA breaks occur simultaneously, clustered on one or a few chromosomes, with near-random stitching together of the resulting fragments. Chromoplexy and translocations were found in 18% of samples and were particularly prominent in prostate adenocarcinoma, lymphoid malignancies, and, unexpectedly, thyroid adenocarcinoma. Kataegis events were found in 60.5% of all cancers, with particularly high abundance in lung squamous cell carcinoma, bladder cancer, acral melanoma and sarcomas. Finally, chromothripsis was observed in 22.3% of the samples, most frequently among sarcoma, glioblastoma, lung squamous cell carcinoma, melanoma and breast adenocarcinoma.
At least as important as the types of mutations observed in cancer is the timing of such mutations, which is what the fifth paper is all about. It turns out that you can reconstruct part of the evolutionary history of a cancer through whole genome sequencing:
The genome of a cancer cell is shaped by the cumulative somatic aberrations that have arisen during its evolutionary past, and part of this history can be reconstructed from whole-genome sequencing data3 (Fig. 1a). Initially, each point mutation occurs on a single chromosome in a single cell, which gives rise to a lineage of cells bearing the same mutation. If that chromosomal locus is subsequently duplicated, any point mutation on this allele preceding the gain will subsequently be present on the two resulting allelic copies, unlike mutations succeeding the gain, or mutations on the other allele. As sequencing data enable the measurement of the number of allelic copies, one can define categories of early and late clonal variants, preceding or succeeding copy number gains, as well as unspecified clonal variants, which are common to all cancer cells, but cannot be timed further. Lastly, we identify subclonal mutations, which are present in only a subset of cells and have occurred after the most recent common ancestor (MRCA) of all cancer cells in the tumour sample (Supplementary Information).
The ratio of duplicated to non-duplicated mutations within a gained region can be used to estimate the time point when the gain happened during clonal evolution, referred to here as molecular time, which measures the time of occurrence relative to the total number of (clonal) mutations. For example, there would be few, if any, co-amplified early clonal mutations if the gain had occurred right after fertilization, whereas a gain that happened towards the end of clonal tumour evolution would contain many duplicated mutations14 (Fig. 1a, Methods).
The following figure from the paper gives you an idea of the principles involved, in particular panel A.
The results of this particular analysis shows that, unsurprisingly, driver mutations that most commonly occur in a given cancer also tend to occur the earliest in the development of that cancer. In a similar vein, if a certain cancer type is characterized by copy number gains, these copy number amplifications tend to occur early as well. One example discussed is clear cell cancer of the kidney, which frequently has a copy number gain of part of chromosome 5, which tends to arise early in the evolution of this particular cancer. In addition, the authors found that mutational signatures change over time in at least 40% of tumors and tend to reflect an increase in the frequency and severity of DNA repair defects.
Perhaps the most important finding of this study is its finding that driver mutations can occur years before cancer is diagnosed. Figure 6 (below) shows the order of mutations for four common cancers, colorectal cancer, lung cancer, ovarian cancer, and pancreatic cancer:
Another key finding of these analyses, reported in the second paper, is that it’s not just mutations on coding regions (i.e., regions of DNA that contain genes that produce proteins) that can drive cancer. Although a lot less common than driver mutations in coding regions, driver mutations in noncoding regions do occur. Usually, these are mutations in regulatory regions of the genome that result in the overexpression of a protein. This sort of analysis is much harder because it is a lot more difficult to accurately detect mutations in noncoding regions than in coding regions, or to assess their recurrence, which is one reason why, although it has been known that such mutations exist, their prevalence in cancer has not been well characterized. Great care had to be taken to exclude artefacts and find such mutations. In this study, the authors report finding relatively frequent mutations in non-coding regions of the telomerase gene TERT that result in overexpression of the telomerase enzyme (which can allow tumor cells to divide uncontrollably by eliminating the limit on the number of times a given cell can divide), that is similar to the high prevalence of telomerase mutations found in a previous pan-cancer study of more-advanced (metastatic) tumors, namely 12%. Although the study could not conclusively rule out the existence of other non-coding drivers, it did show that driver mutations in noncoding parts of the genome are not nearly as common as such mutations in coding regions.
At this point, you might note that this is all well and good, but what can be done with this information? An accompanying editorial in Nature lets us know what must come next if any of this is to benefit patients. After noting that when cancer genome sequencing projects were first launched the hope was that they would result in a catalog of mutations that can give rise to a cancer and that this core mission has now been achieved, the editorial notes:
Cancer genomes have been sequenced for more than a decade, but now researchers and the funders who support them must tackle the next challenge. The goal has always been to improve the lives of those affected by cancer, and the reams of data amassed by sequencing projects have helped. They are used by researchers to find new drug targets, and to generate new markers that can be used to match patients with the treatment most likely to help.
But most of the data so far have been limited in one crucial respect: clinical details of the sample donors are often missing. The first samples collected for the Cancer Genome Atlas, a sequencing project that ran from 2006 to 2018, co-funded by the US National Cancer Institute and the National Human Genome Research Institute, typically came with little more than the donor’s gender, diagnosis and age at diagnosis. Rarely would there be a record of that person’s family or medical history, what therapy they had received and how they had responded — all crucial information if genome sequences are to be put to work to help patients.
Yes, we have all this information now, but what we also know is that, as I like to describe while channeling Douglas Adams, cancer is complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think your income tax return is complicated, but that’s just peanuts compared to cancer.
In any event, to reiterate things I’ve written about in the past, the vast majority of cancer-causing driver mutations can be divided into a relatively few key molecular signaling pathways. As these most recent papers found, confirming previous findings, mutations at the “trunk” of the divergent branching evolution tend to remain as divergent evolution occurs, which is why targeting them is more likely to be effective than targeting mutations further out on the “branches.” Unfortunately, what this study also shows is that, thanks to evolution, curing a given cancer is just not going to be as simple as getting a biopsy of a tumor and picking a targeted agent or two to blast the tumor into oblivion. Not only is cancer not one disease, even a given cancer is in a given patient is arguably not just one disease but many as evolution leads its cells to become more and more heterogeneous. This doesn’t mean that true “personalized medicine” or “precision medicine” is impossible or that it’s impossible to develop cures for various cancers. The point is just that, as this study shows us yet again, that biology is always way more complicated than we ever thought it was, and evolution almost always wins out in the end.

Recent Developments and Recurring Dilemmas in Cancer Screening: Colon, Lung, Thyroid
Harriet Hall on November 18, 2014
Link

A new stool DNA test was recently approved by the FDA for colon cancer screening. My first reaction was “Yay! I hope it’s good enough to replace all those unpleasant, expensive screening colonoscopies.” But of course, things are never that simple. I wanted to explain the new test for our readers; but before I could start writing, some other issues in cancer screening barged in and demanded to be included. They exemplify the dilemmas we face with every screening test. We have covered these issues before, but mainly in reference to mammography and prostate (PSA) screening. My article morphed into a CLT sandwich: colon, lung, and thyroid cancer screening.
The current issue of American Family Physician has a great article on cancer screening. It uses lucid graphics to illustrate lead time bias, length time bias, and overdiagnosis bias, as well the effect of varying tumor growth rates on screening success rates, all concepts that have been covered by Dr. Gorski here. Briefly, screening may do more harm than good if:
     1.  It detects cancerous cells that never would have developed into invasive cancers or harmed the patient in any way;
     2.  Early diagnosis and treatment decrease quality of life without reducing death rates; or
     3.  The test falsely indicates cancer in patients who don’t have it or fails to indicate cancer in some who do.
Colon cancer
Current recommendations advise screening after age 50 by any of three methods: colonoscopy every 10 years, flexible sigmoidoscopy every 5 years, or fecal occult blood (FOBT) testing every year. Sigmoidoscopy and FOBT screening have been shown to reduce the number of deaths from colorectal cancer, but colonoscopy has not; studies are in progress. There is as yet no good evidence that any colon cancer screening test reduces overall mortality. Colonoscopy is considered the gold standard because polyps and cancers can be directly visualized and biopsied, but as yet there is no good evidence from controlled studies to confirm our reasonable assumption that it ought to be the best screening test to reduce deaths from colon cancer. It is generally considered the preferred screening option; but it is invasive, requires an unpleasant bowel prep, is unacceptable to many patients, is expensive, requires sedation, carries risks, and consumes a lot of specialist time and resources.
Colonoscopy identifies cancers directly; other tests use indirect methods. Blood in the stool can be a sign of colon cancer, and fecal occult blood testing (FOBT) uses guaiac to detect blood in the stool that isn’t obvious to the naked eye. It requires three stool samples and avoidance of foods that could cause a false positive test. Fecal immunochemical testing (FIT or iFOBT) requires only a single sample with no dietary restrictions, and it is less likely than guaiac testing to confuse bleeding from the upper digestive tract with bleeding from the colon.
The new DNA test (Cologuard) also requires only a single specimen and no dietary restrictions. It looks for DNA markers associated with colorectal cancers as well as for blood. It detects more polyps and more cancers than previous fecal tests, but has more false positive results.
According to The Medical Letter, the new DNA stool test “detected 92% of cases of colorectal cancer in asymptomatic average-risk persons, but it detected less than half of advanced precancerous lesions and produced a substantial number of false-positive results.” The appropriate interval for screening has not been established; Medicare has approved reimbursement for testing every 3 years with a preliminary pricing decision at $502. A positive screening test must be followed by colonoscopy. So this test is promising but it is no panacea, and questions remain. We’ll have to wait for controlled studies to tell us whether it can replace colonoscopy screening or reduce all-cause mortality. Until we have that data, it is a reasonable option for patients who refuse colonoscopy.
Lung cancer
Lung cancer is responsible for 27% of all cancer deaths in the US, and 33% of deaths in smokers. We used to do annual chest x-rays, but they missed small cancers and the larger ones they detected were often untreatable. We stopped doing them once we realized they didn’t improve survival. With computed tomography (CT) there is a better chance to detect small cancers that have not yet metastasized. If we did annual CTs on everyone, we would get way too many false positives and expose people to radiation for no benefit, so screening is directed at high-risk individuals. Since 1999 several studies have evaluated low-dose CT to screen smokers for lung cancer. Screening reduces all-cause mortality by 6.7%. To detect one case of cancer, 320 smokers have to be screened for 5 years.
There are some problems:
    • Patients at lower risk are unlikely to benefit.
    • Radiation is involved; and even at low dose, the cumulative exposure over a lifetime of screening could be harmful.
    • It leads to over-diagnosis and unnecessary invasive surgeries.
    • It’s expensive.
    • It’s a technological Band-Aid for a lifestyle problem that would be better addressed by getting patients to stop smoking.
The United States Preventive Services Task Force currently recommends annual screening for lung cancer with low-dose CT in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should stop when the person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. The American Academy of Family Physicians adds that it should only be done in conjunction with smoking cessation interventions.
Thyroid cancer
Korea is in the midst of an apparent thyroid cancer epidemic: between 1993 and 2011, the incidence rose by a factor of 15. More than 40,000 Koreans were diagnosed with thyroid cancer in 2011. The rate of diagnosis has skyrocketed, but the death rate has not changed; the number of deaths from thyroid cancer has remained stable, between 300 and 400 deaths a year. This isn’t a true epidemic; it’s a consequence of over-diagnosis from injudicious screening.
Korea has national health insurance. In 1999 it implemented a free national screening program for cancers of the breast, cervix, colon, stomach, and liver. Ultrasound screening for thyroid cancer was offered as an add-on for a small copayment. Many people who opted for ultrasound screening were found to have small cancers. We have long known that at least one third of adults have small thyroid cancers; most of these never produce symptoms and are only found at autopsy after people die of something else. Guidelines recommend against surgery for tumors smaller than 0.5 cm, but the guidelines are frequently disregarded. Most patients are treated: 2/3 with radical thyroidectomy, 1/3 with subtotal thyroidectomy. Most of them require lifelong thyroid replacement therapy, 11% develop hypothyroidism, and there are surgical complications including a 2% risk of vocal cord paralysis and even a small risk of death.
The incidence of thyroid cancer diagnoses has also more than doubled in the US and several other countries. Ultrasound has a role in diagnosis, but indiscriminate ultrasound screening for thyroid cancer clearly does more harm than good, and can’t be recommended.
Conclusion
You might think we should always screen everyone for all kinds of cancer because early detection saves lives. We shouldn’t always, because sometimes it doesn’t. This is a hard message to get across to the public and even to some doctors.
Technological advances will continue to improve screening tests; but we will always face difficult decisions about who to screen and when.
Addendum
This article originally said Cologuard does not test for blood, but a company representative contacted me with a clarification: it does test for blood along with DNA markers. I also said Medicare was considering coverage, but Medicare has now made a decision. I have updated the text accordingly.

Is cancer due mostly to “bad luck”?
David Gorski on January 5, 2015
Link

One of the more difficult conversations to have with a patient as a cancer doctor occurs when a patient, recently informed of her diagnosis of, for example, breast cancer, asks me, “Why did I get this? What caused it?” What almost inevitably follows is an uncomfortable conversation in which explanations of the multiple known causes of breast cancer do not satisfy the patient. The reason, of course, is because when a patient asks, “What caused it?” she doesn’t mean what causes breast cancer in general or in statistical terms. Rather, she means, what caused my breast cancer? It’s a question that can only occasionally be answered. For instance, if it’s lung cancer and the patient is a smoker, then it was almost certainly smoking that caused the cancer, because lung cancer is a relatively rare cancer in the absence of smoking. In the case of breast cancer, contrary to the prevailing belief that leads women with breast cancer to be puzzled about how they could get it when there’s “no cancer” in their families, only around 5-10% of cases have a familial or genetic component. That means that around 90% of breast cancers are what we call “sporadic,” which means that we can’t identify a specific cause. Or, as I like to say, “We just don’t know.” Worse, in the case of breast cancer, the environmental factors we know about appear to contribute modestly at best to the risk of cancer. (More on this later.)
Understandably, patients hate hearing “We just don’t know,” some vague handwaving about genes, and that there is nothing that we know of that they did that caused their cancer. People—including oncologists—really don’t like the concept of “sporadic” cancer, mainly because humans crave explanation. The default assumption is that everything must happen for a reason and there must be a cause for every disease or cancer. Perhaps the most ridiculously emphatic statement of this that I’ve encountered thus far comes from (who else?) über-quack Mike Adams when he heaped contempt on the idea of sporadic disease as “spontaneous disease.” He did this in the context of a story describing how, after Dr. Mehmet Oz had followed recommended care and undergone screening colonoscopy to look for polyps, he was shocked that he actually had some. This led Adams, in his usual inimitable fashion, to construct a straw man so massive that it could be seen from space when he set it on fire, declaring that “colon polyps, in other words, appear without any cause!” and that “mainstream medicine…believes in the theory of ‘spontaneous disease’ that ‘strikes’ people at random.”
Not exactly.
On the other hand, there is a lot of randomness in disease, not just cancer, as hard as it is for Mike Adams, or anyone to accept. Just because there is a varying amount of randomness in who gets a disease does not mean that mainstream medicine claims there is no cause to these diseases. Rather, for diseases like cancer, it’s a stochastic process, meaning that chance can play a role—sometimes a big role—in determining who gets sick. Indeed, just last week there was more evidence supporting this idea published in Science. Unfortunately, much of the mainstream press coverage presented the message of the paper a bit too simplistically. Even more unfortunately, it was the authors who encouraged this, as did the Johns Hopkins University press release about the study, which was entitled “Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows“. Yes, I groaned when I read this title.
Other headlines followed Hopkins’ lead:
     1.  Math Suggests Most Cancers Are Caused By “Bad Luck”
     2.  Two-thirds of cancers caused by bad luck, not heredity & environment
     3.  Besides Lifestyle and Inherited Genes, Cancer Risk Also Tied to Bad Luck
     4.  Biological bad luck blamed in two-thirds of cancer cases
I groaned. Then it was once more unto the breach.
Is cancer mostly “bad luck”?
The paper itself, by Cristian Tomasetti, a biostatistician interested in cancer evolution, genomics, and stem cell dynamics, and Bert Vogelstein, the latter of whom is a giant in cancer research, the man who pioneered the concept of tumor suppressor genes, validated p53 (TP53) as a tumor suppressor gene, discovered (with collaborators) the APC tumor suppressor gene, and whose team developed a major model explaining the progression of colorectal cancer from normal epithelium to polyp to dysplastic polyp to in situ cancer to cancer, is entitled “Variation in cancer risk among tissues can be explained by the number of stem cell divisions“. This, of course, is a different message than what is being promoted in the Hopkins press release and all the news stories that flowed from that. It is, however, a fascinating paper, although certainly not without issues, and it does support the idea that a large percentage of cancers tend to be due to mutations that occur during DNA replication during cell division.
The authors start out by noting:
Extreme variation in cancer incidence across different tissues is well known; for example, the lifetime risk of being diagnosed with cancer is 6.9% for lung, 1.08% for thyroid, 0.6% for brain and the rest of the nervous system, 0.003% for pelvic bone and 0.00072% for laryngeal cartilage (1–3). Some of these differences are associated with well-known risk factors such as smoking, alcohol use, ultraviolet light, or human papilloma virus (HPV) (4, 5), but this applies only to specific populations exposed to potent mutagens or viruses. And such exposures cannot explain why cancer risk in tissues within the alimentary tract can differ by as much as a factor of 24 [esophagus (0.51%), large intestine (4.82%), small intestine (0.20%), and stomach (0.86%)] (3). Moreover, cancers of the small intestinal epithelium are three times less common than brain tumors (3), even though small intestinal epithelial cells are exposed to much higher levels of environmental mutagens than are cells within the brain, which are protected by the blood-brain barrier.
Another well-studied contributor to cancer is inherited genetic variation. However, only 5 to 10% of cancers have a heritable component (6–8), and even when hereditary factors in predisposed individuals can be identified, the way in which these factors contribute to differences in cancer incidences among different organs is obscure.
So this is what we know about cancer. Its incidence varies tremendously among tissues in a way that can’t be explained by environmental exposure or heredity. I might quibble with the authors’ not discussing lung cancer more as a major exception to this tendency, given that nearly all lung cancer is caused by tobacco smoking, but overall for most other cancers this is basically accurate. Given the inadequacy of environmental factors and inherited genetic mutations as explanations for how cancers arise, the authors then tell the reader how this led them to look at what they call a “third factor”: the stochastic effects associated with the lifetime number of stem cell divisions within each tissue. The first thing that struck me as I read this paper is that this is not a new or radical idea. Far from it! It’s long been known that tissues with cell types that undergo rapid division over a lifetime tend to be more susceptible to developing cancer; e.g., the epithelial cells of the colon, which are prone to cancer, compared to cancers arising in the brain or in muscle, where cells divide much less. The reason, it’s been hypothesized, is that more rapid cell division leads to more errors in DNA replication, which leads to more mutations. However, there are glaring exceptions, such as the small intestine, whose epithelial cells replicate rapidly and continuously throughout the human lifespan – yet small bowel cancer is rare.
The question most readers have, probably, is why Tomasetti and Vogelstein wanted to concentrate on stem cells. The reason is simple and fairly obvious. Most cells are fully or partially differentiated, and a relatively small proportion of cells in most tissues and organs are responsible for the development and maintenance of the tissue and its architecture, as well as for replacing cells that are lost. As is pointed out in the paper, until recently, the nature, number, and hierarchical division patterns of various stem cells were not well characterized. In any case, the hypothesis being tested in this paper relies on three key concepts: (1) that cancer is mostly the result of acquired genetic and epigenetic changes; (2) genetic changes occur primarily by chance during DNA replication; and (3) that the endogenous mutation rate of all human cell types appears to be very similar. These concepts, taken together, predict that the number of cell divisions among stem cells in each organ during a lifetime should correlate strongly with the lifetime risk of cancer in that organ. To test this prediction, Tomasetti and Vogelstein set out to estimate the lifetime number of stem cell divisions in each organ and determine if it correlates with cancer risk in that organ.
So Tomasetti and Vogelstein reviewed the current literature, identifying 31 tissue types in which stem cells had been quantitatively assessed. They then plotted the total number of stem cell divisions during the average human lifespan on the X-axis and the lifetime risk for cancer as recorded in the Surveillance, Epidemiology, and End Results (SEER) database in that organ on the Y-axis. Here’s the end result in Figure 1:
As you can see, there is a striking, highly-positive correlation on a log-scale graph. As noted by the authors, this correlation extended across five orders of magnitude and encompassed cancers with tremendous differences in prevalence. The authors note:
No other environmental or inherited factors are known to be correlated in this way across tumor types. Moreover, these correlations were extremely robust; when the parameters used to construct Fig. 1 were varied over a broad range of plausible values, the tight correlation remained intact…
A linear correlation equal to 0.804 suggests that 65% (39% to 81%; 95% CI) of the differences in cancer risk among different tissues can be explained by the total number of stem cell divisions in those tissues. Thus, the stochastic effects of DNA replication appear to be the major contributor to cancer in humans.
It seems pretty bullet-proof, right? Well, maybe. Maybe not. As was pointed out by Paul Knoepfler, the single most difficult issue in this analysis is how to accurately and consistently calculate reliable estimates of the number of lifetime stem cell divisions in a series of diverse tissues. This is far from a trivial matter, or, as Dr. Knoepfler describes it, “extremely difficult and it’s not difficult to imagine such calculations being off by one or more orders of magnitude.” For instance, take a look at this description in the supplemental data of how stem cell divisions were calculated for adenocarcinomas and squamous cell carcinomas of the esophagus (which I’ll quote because I realize that most of you don’t have access to the paper itself):
The lifetime incidence of cancer of the esophagus is ~0.51% (3). The vast majority of these cancers are either adenocarcinomas or squamous cell carcinomas, and the ratio of these two types has changed considerably in the last few decades. Currently, ~38% of esophageal cancers are squamous cell carcinomas (66, 67). The lifetime incidence of esophageal squamous cell carcinoma is therefore 0.0051•0.38 = 0.001938. The esophagus is 18 to 26 cm long and 2 to 3 cm in diameter (68), resulting in an average surface area of ~172.79 cm2. The area of a squamous cell in the basal layer is ~80μm2 (69). The fraction of stem cells in the basal layer has been estimated to be 0.4% of the total basal layer cells (70), so there are a total of ~2.16•108 basal cells and 8.64•105 stem cells in the basal layer. As the normal mucosal epithelium is ~10-20 layers thick, the total number of epithelial cells in the esophagus is estimated to be ~2.16•108 •15= 3.24•109. Cells have been estimated to turn over ~ every 21 days (71, 72).
As you can see, multiple assumptions had to be made for each parameter, and then these parameters are multiplied together to estimate the total lifetime number of stem cell divisions. To be fair, one thing Knoepfler didn’t mention is that there was a statistical analysis done to test the robustness of the correlation in which the estimates of total stem cell divisions was allowed to vary by 100-fold in either direction, but even so, there are a number of other issues. For instance, not all cancers originate with stem cells, and some organs have more than one type of stem cell population. Yet the paper seemed to treat stem cells as one population for each organ. Still, as a first approximation, it’s not unreasonable to do it this way.
In addition, to try to tease out which tissues are more prone to cancer than their stem cell replication totals would suggest, Tomasetti and Vogelstein calculated what they call an “extra risk score” (ERS), defining it as the product of the lifetime risk and the total number of stem cell divisions (in log10). Machine learning methods were then used to classify tumors based only on this score. The details are a bit much, even for me, but the bottom line is that the ERS is meant to be a measure of how well that particular tumor type “fits the model.” More specifically:
If the ERS for a tissue type is high—that is, if there is a high cancer risk of that tissue type relative to its number of stem cell divisions—then one would expect that environmental or inherited factors would play a relatively more important role in that cancer’s risk (see the supplementary materials for a detailed explanation). It was therefore notable that the tumors with relatively high ERS were those with known links to specific environmental or hereditary risk factors.
The authors referred to tumors with high ERS values as “D-tumors” (for “deterministic,” meaning deterministic factors such as environmental mutagens or hereditary predispositions strongly affect their risk) and tumors with low ERS values as “R-tumors” (for “replicative”) in which stochastic factors, most likely errors during DNA replication as stem cells divide, most strongly affect risk. Not surprisingly, cancers that came up as D-tumors with high ERS scores included colorectal cancer related to familial adenomatous polyposis (FAP), which is due to a mutation in a tumor suppressor gene (APC) and whose most severe form results in a 90+% risk of colorectal cancer by age 50, and to Lynch syndrome (HNPCC or hereditary nonpolyposis colorectal cancer), which is due to an autosomal dominant inherited mutation that produces a high risk of colorectal cancer, as well as cancers of the endometrium, ovaries, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin. Lynch syndrome is due to defects in DNA mismatch repair, which lead to—you guessed it—more mistakes during DNA replication, leading to more mutations. People with Lynch syndrome have an 80% lifetime risk of colorectal cancer. Indeed, in general, so high is the risk of colorectal cancer in people with FAP or HNPCC that close monitoring with regular colonoscopies is always recommended, and prophylactic surgery to reduce the risk of cancer by eliminating the tissue at risk is frequently recommended. The recommended operation is usually total proctocolectomy (removal of the entire colon and rectum) as young adults, although because there are less aggressive variants of FAP sometimes close monitoring is considered more appropriate.
One little nit I have to pick with this graph is that the lung cancer cases are divided into smokers and non-smokers. Again, lung cancer, which is such a leading cause of preventable cancer (with the authors noting that smoking increases lung cancer risk 23-fold in men and 13-fold in women, for an overall 18-fold increase in risk), is a special case, but that doesn’t justify dividing the cases of lung cancer into those related to smoking and those unrelated to smoking. Doing so smacks of trying to downplay one case of environmental factors being very important. After all, there are other cancers whose incidence is very much influenced by smoking, including esophageal cancer, head and neck squamous cell cancers, and pancreatic cancer, but no such effort was made to divide these tumors into smoking-induced and not smoking-induced. This lapse is curious and not explained in the paper at all. Either all the strongly smoking-induced cancers or none of them should have been divided into groups based on smoking.
Another issue is that most of the “D-tumors,” the ones known to have definite genetic or environmental causes that fell out were tumors caused by genetics. Of tumors known to have a strong environmental component, only smoking-induced lung cancer, basal cell carcinoma (due to sun exposure), and thyroid cancer (follicular or papillary types, known to be significantly due to radiation exposure) showed up in the D-tumors group. This made me wonder if Tomasetti and Vogelstein’s model was sensitive enough to pick up tumors that have a significant environmental component, given that environmental influences tend not to produce cancer risks as high as those seen in people harboring genes for inherited cancers, for which mutant gene carriers can have up to a 90% lifetime risk of cancer when they have a particularly nasty genetic predisposition.
There are other problems. The first is a rather glaring anomaly. Oddly, malignant melanoma, which is known to be strongly associated with sun exposure, showed up as an “R-tumor,” and no discussion was offered to explain why this might have happened. Again, this brings into question the sensitivity of the model. Next, two major cancers, breast and prostate cancer, were not included in the analysis because Tomasetti and Vogelstein could not find good estimates in the literature for stem cell proliferation rates for these cancers. Given that these are two of the “big three” cancers with the highest incidence in the US (breast, prostate, and lung cancers), this omission presents a problem for generalizability. Overall, I wonder why Tomasetti and Vogelstein didn’t just show the first graph, which pretty much gives us all the information we need. The second analysis involved a transformation of the data whose rationale is not clear and even questionable, and that is not particularly informative. I understand why they did it, but I think it weakens the paper.
As has been pointed out elsewhere by Bob O’Hara and Grrlscientist, what is being represented as “bad luck” might or might not be that. What Tomasetti and Vogelstein’s calculations show is that, in their model, 65% of the variability in cancer incidence between tissues is attributable to variability in stem cell proliferation in those tissues, which, they argue, is not the same thing as what proportion of cancer is due to “bad luck.” What they are, in fact, describing is the stochastic component related to differences in stem cell proliferation, but “bad luck” is pithier and easier to understand. Therein, I suspect, lays their problem. It would have been a lot less interesting to the press to say that 65% of the variation in incidence between 31 cancers is explained by variations in lifetime stem cell proliferation in those tissues.
Perhaps the most reassuring thing about this paper, oddly enough, is that even after their having estimated the variability in incidence explained by stem cell proliferation and determined that 65% of tumors risk is correlated with stem cell proliferation and thus the accumulation of errors in replication, Tomasetti and Vogelstein’s estimate isn’t too far off from what we already know, as you will see. That’s part of the reason why I tend consider objections to the paper by bloggers like Bob O’Hara and GrrlScientist and The Stats Guy to be at least partially missing the point, at least from my perspective as a cancer biologist and clinician, in that they tend to focus on semantics (namely the use of the term “bad luck”) and purely statistical issues rather than considering these findings in context of what we already know about cancer biology. PZ Myers noted this problem before I did (damn this publication schedule in which I had to wait until Monday to post this!), but, for example, one of O’Hara and GrrlScientist’s key objections is:
So, what proportion of cancers are due to bad luck? Unfortunately it’s difficult to tell from the paper. The figure from the paper is on the log scale, and if we extrapolate the model to zero (no cell divisions), we’d see it assumes there is no risk of cancer.
To which PZ replied:
That’s what we’d expect if the magnitude of Mystery Factor X was 0, and the baseline rate of somatic errors leading to cancer was set by the replication error rate.
I’ll also add that this is not at all an unreasonable assumption as a first approximation for such a model. After all, without cell division there can’t be cancer, regardless of the source of cancer-causing mutations, which are random during DNA replication, epigenetic changes, or other sources. If the cells don’t divide, even mutations caused by something other than errors in DNA replication won’t be passed on and can’t accumulate to result in carcinogenesis. In any case, what Tomasetti and Vogelstein were correlating was the variability in cancer incidence that could be attributed to variations in stem cell proliferation. That’s it. Absolute cancer risk for each tissue isn’t the issue, but rather variability in cancer risk and what contributes to it.
In the ballpark
Let’s try to put Tomasetti and Vogelstein’s finding in context with respect to what we already know about cancer biology and epidemiology.
Any cancer biologist (like me), oncologist, or oncologic surgeon (like me) should know that we already have copious data for a large number of tumors that provide us with estimates of the relative effects of lifestyle and environment versus genetics versus randomness on the risk of developing cancer. Part of what bothered me about this paper is that this was not adequately discussed. (Actually, it was hardly discussed at all, but then, it is a Science paper, and Science imposes ridiculously tight word limits on most articles.) While it is not really possible to prevent most inherited cancers short of relatively radical or invasive interventions (chemopreventative drugs like Tamoxifen for familial breast cancer, which reduces the relative risk by only around 50%, or surgery to remove the organ before cancer can develop, as is done to prevent familial breast and colorectal cancer), it is theoretically possible to prevent a lot of cancer. I say “theoretically” because actually implementing the interventions designed to prevent these cancers would often be incredibly difficult as a practical matter. Just consider how difficult it has been to get people to quit smoking and lose weight if you don’t believe me.
Perhaps my favorite quick and dirty (not to mention, reliable) reference guide to estimates of what percentage of different cancers are potentially preventable is published on the Cancer Research UK website. On a page entitled Statistics on preventable cancers, you can peruse the estimated relative contribution to various factors, such as smoking, alcohol consumption, diet, sunlight, radiation, and others, to a wide array of different human cancers. Not surprisingly, by far the most common cause of preventable cancer is tobacco, causing an estimated 86% of cases of lung cancer, 65% of cases of esophageal cancer and cancers of the oropharynx and head and neck, 37% of cases of bladder cancer, and 29% of cases of pancreatic cancer. Diet is estimated to contribute to 31% of bowel cancers, 46% of esophageal cancer, 51% of stomach cancers, and 56% of head and neck cancers. Alcohol contributes to several cancers, including breast, bowel, esophageal, oral, and liver cancers, but the effects are much more modest. Sunlight contributes to 86% of cases of malignant melanoma, which, again, makes it very curious that melanoma showed up as an “R-tumor” in Tomasetti and Vogelstein’s analysis.
Overall, if you look at CRUK’s estimates of the percentage of cancers that are potentially preventable, you’ll find that, not surprisingly, it’s very high for smoking-related cancers like lung cancer (89%), esophageal cancer (75%), oral cancers (91%), pancreatic cancer (37%), and bladder cancer (42%). In contrast, it’s very low for cancers like non-Hodgkin’s lymphoma, prostate cancer, brain cancers, and myeloma. For the rest, it’s somewhere in between. Also included in the list are cancers caused by viral infections, such as cervical cancer, which can be prevented by preventing HPV infection.
One problem with much of the reporting of the study seems to be a misinterpretation of what the authors were getting at, which is stated near the end of the paper:
In formal terms, our analyses show only that there is some stochastic factor related to stem cell division that seems to play a major role in cancer risk. This situation is analogous to that of the classic studies of Nordling and of Armitage and Doll (10, 29). These investigators showed that the relationship between age and the incidence of cancer was exponential, suggesting that many cellular changes, or stages, were required for carcinogenesis. On the basis of research since that time, these events are now interpreted as somatic mutations. Similarly, we interpret the stochastic factor underlying the importance of stem cell divisions to be somatic mutations. This interpretation is buttressed by the large number of somatic mutations known to exist in cancer cells (14–16, 30).
In other words, even if taken at face value as reported in the media, Tomasetti and Vogelstein haven’t really demonstrated anything new. We’ve known for a long time that there is a strong stochastic (probabilistic) component to cancer development. The risk for some cancers appears to be mostly stochastic; the risk for other cancers is more strongly influenced by heredity; and the risk of other cancers, such as lung cancer, is more strongly influenced by environment. Some are influenced significantly by all three. These observations are, quite frankly, trivial. What Tomasetti and Vogelstein have done that’s different is to recast the stochastic component of cancer risk as not being due to just any old mutations in the cells in a tissue but rather to the accumulated mutations in stem cells, which is proportional to the total number of cell divisions. They then tried to estimate what percentage of cancers are primarily related to these stochastic factors and estimated that it’s around two thirds.
Now here’s the funny thing. If you interpret Vogelstein’s estimate the way it’s been represented in the press and by Vogelstein, as representing the percentage of cancers that are due primarily to “chance” and thus not related to environment and not potentially preventable (a not unreasonable interpretation, by the way), it turns out not to be such a bad first approximation at all. It’s actually not far off from what has been a fairly accepted estimate for quite a few years now, namely that between one third and one half of cancers are potentially preventable, implying that they are due to environmental causes that can be altered, such as smoking or diet. Given the level of uncertainty inherent in such estimates, even if you interpret Vogelstein and Tomasetti’s conclusion that two thirds of cancers are due to “bad luck,” their estimate of the percentage of cancers that are probably not preventable is definitely in the ballpark of commonly-accepted estimates, albeit at the lower end. Does that mean they’re on to something in concluding that stem cell replication over one’s lifetime primarily determines the “stochastic” component of cancer risk for each organ? That remains to be seen, but their preliminary finding makes sense, both from the perspective of producing a result that’s in the ballpark of what we already know based on epidemiology and being biologically plausible based on basic cancer biology.
There are two things that were probably responsible for the objections to this article. First was its being presented as concluding that two thirds of cancers are due to “bad luck.” While I understand that Vogelstein probably wanted to simply things so that they would be comprehensible to everyone, he might have simplified them a bit too much in search of the pithy, memorable phrase. (He certainly succeeded at getting the study noticed!) Lost in the shuffle was a more nuanced discussion of what Vogelstein was getting at when he said:
“All cancers are caused by a combination of bad luck, the environment and heredity, and we’ve created a model that may help quantify how much of these three factors contribute to cancer development,” says Bert Vogelstein, M.D., the Clayton Professor of Oncology at the Johns Hopkins University School of Medicine, co-director of the Ludwig Center at Johns Hopkins and an investigator at the Howard Hughes Medical Institute.
“Cancer-free longevity in people exposed to cancer-causing agents, such as tobacco, is often attributed to their ‘good genes,’ but the truth is that most of them simply had good luck,” adds Vogelstein, who cautions that poor lifestyles can add to the bad luck factor in the development of cancer.
That cancer is due to a combination of random probabilistic processes, environmental exposures, and heredity, is a non-controversial statement. What is controversial are estimates of the relative contribution of environment, given that the percentage of cancers due to inherited cancer-causing mutations is known and low. Take the example of breast cancer, which is a cancer for which environmental and lifestyle contributions are not particularly high, with perhaps 27% of breast cancers being due primarily to environment (which includes diet and exercise, as well as hormone replacement therapy). The vast majority of those environmental contributions come from obesity and alcohol consumption, neither of which reaches the double digits, percentage-wise. Yet there are organizations that promote the idea that “chemicals” in our environment are a major cause of breast cancer. Unfortunately, about 5-10% of breast cancer is inherited (which can only be prevented by aggressive means, such as chemoprevention or prophylactic surgery), while perhaps up to 27% has a strong environmental component. That leaves around 60% of breast cancer (or, even using higher estimates, at least 50%) as falling into the “we don’t know” or “stochastic” category, with, sadly, nothing that we know of right now that can be done to prevent these cases.
In other words, some of the objections to this paper seem to flow from a belief in inflated estimates of just what proportion of cancer is due to “environment” and is therefore potentially preventable. It’s been suggested that cancer biologists might be too fast to blame unknown causes on “randomness,” the assumption being that not knowing something means that we will know it in the future and more prevention will be possible. The problem is that not knowing something doesn’t mean that there’s a realistic way of obtaining that missing knowledge or that even if we obtained that knowledge that we’d be able to do anything with it. Also, from a biology standpoint, we already know a lot about the stochastic nature of cancer formation, and within this framework Tomasetti and Vogelstein’s study “makes sense,” although it might have under- or over-estimated the actual component due to errors in DNA replication in stem cells. Clearly the model needs refinement.
In any case, this sort of mindset showed up when, after Knoepfler’s analysis, a commenter named Catherine Danielson asked:
I have got to say that one question came to my mind instantly: who funded this cancer study? Sorry to be cynical, but when a study comes out that essentially clears all environmental factors from blame, I start to wonder if any of the funding came from, say, Monsanto. Whose interests might this study serve? Might we learn anything more if we follow the money? Maybe these questions have nothing to do with anything, but I think that they should be at least asked. We’ll certainly never find out the answers otherwise.
According to the acknowledgments, the work going into this paper, by the way, was supported by The Virginia and D. K. Ludwig Fund for Cancer Research, The Lustgarten Foundation for Pancreatic Cancer Research, The Sol Goldman Center for Pancreatic Cancer Research, and NIH grants P30-CA006973, R37-CA43460, RO1-CA57345, and P50-CA62924. No corporate funding there. It’s also a misstatement of the findings of the paper to say that it “essentially clears all environmental factors from blame”. You can argue whether it overestimates what percentage of cancer is related to variability in stem cell proliferation on some good statistical grounds, but a key finding of the paper is that at least one third of cancer incidence is not explained by this.
Unfortunately, Tomasetti and Vogelstein, did fall for another trap. Faced with their results, they demonstrated that they probably do not understand the concept of overdiagnosis and overtreatment:
The implications of their model range from altering public perception about cancer risk factors to the funding of cancer research, they say. “If two-thirds of cancer incidence across tissues is explained by random DNA mutations that occur when stem cells divide, then changing our lifestyle and habits will be a huge help in preventing certain cancers, but this may not be as effective for a variety of others,” says biomathematician Cristian Tomasetti, Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. “We should focus more resources on finding ways to detect such cancers at early, curable stages,” he adds.
Unfortunately, as I and others have documented here time and time again, early diagnosis is a lot more complicated an issue than even most physicians—even oncologists and radiologists—realize. Overdiagnosis and overtreatment are real phenomena because detecting cancers at ever-earlier stages and ever-smaller sizes picks up cancers that would never threaten the life of the patient, but we have to treat them as though they would because we can’t (yet) predict which ones are safe to watch and which ones will progress. Early diagnosis does not lead inevitably to improved survival. We’ve discussed this issue again and again here with respect to mammography, PSA testing for prostate cancer, screening for cancer in general, and screening for other diseases. More screening is not necessarily better.
In actuality, if Tomasetti and Vogelstein are correct, the proper conclusion would be to try to reduce environmental exposures for cancers known to have a large environmental contribution. For tumors that are largely driven by accumulated errors in DNA replication in stem cells we need to work on understanding the pathways that drive their growth and progression in order to develop better-targeted therapies, and to develop better surgical techniques to remove tumors for which extirpation is curative. Don’t get me wrong – early detection can be useful, but it is very cancer-type-specific and depends upon a tumor that progresses predictably from early pre-malignant stages and for which early intervention either prevents progression (as in removing polyps from the colon) or results in a better outcome (which is true of several cancers, but not to the extent that we like to think, being confounded by lead time and length biases). Finally, because screening sensitivity and specificity depend strongly on the prevalence of the cancer being screened for, screening only makes sense for the most prevalent cancers, like breast, prostate, lung, and colorectal.
It’s understandable that humans crave explanation, particularly when it comes to causes of a group of diseases as frightening, deadly, and devastating as cancer. In fact, both PZ Myers and David Colquhoun have expressed puzzlement over why there is so much resistance is to the concept that random chance plays a major role in cancer development, with Colquhoun going so far as to liken it to ” the attitude of creationists to evolution.” Their puzzlement most likely derives from the fact that they are not clinicians and don’t have to deal with patients, particularly given that, presumably, they do have a pretty good idea why creationists object to attributing evolution to random chance acted on by natural selection and other forces.
Clinicians could easily have predicted that a finding consistent with the conclusion that, as a whole, probably significantly less than half of human cancers are due to environmental causes that can be altered in order to prevent them would not be a popular message. Human beings don’t want to hear that cancer is an unfortunately unavoidable consequence of being made of cells that replicate their DNA imperfectly over the course of our entire lives. There’s an inherent hostility to any results that conclude anything other than that we can prevent most, if not all, cancers if only we understood enough about cancer and tried hard enough. Worse, in the alternative medicine world there’s a concept that we can basically prevent or cure anything through various means (particularly cancer), most recently through the manipulation of epigenetics. Unfortunately, although risk can be reduced for many cancers in which environmental influences can increase the error rate in DNA replication significantly, the risk of cancer can never be completely eliminated. Fortunately, we have actually been making progress against cancer, with cancer death rates having fallen 22% since 1991, due to combined efforts involving smoking cessation (prevention), better detection, and better treatment. Better understanding the contribution of stochastic processes and stem cell biology to carcinogenesis could potentially help us do even better.

WHO Systematic Review of RF and Cancer
Steven Novella on September 4, 2024
Link

In our increasingly technological we are constantly exposed to radio frequency electromagnetic waves (RF-EMF). It would certainly be inconvenient, to say the least, if this ubiquitous and essential technology had negative health effects. But of course we would need to know if this were the case so that steps could be taken to fix it.
Fortunately, a recent systematic review conducted by the World Health Organization (WHO) has found that there is no association between the use of cell phones (and resulting exposure to RF) and an increased risk of brain cancer. This is true of adult users, pediatric users, and workplace exposure. While reassuring, these results are not surprising, as we have discussed here many times before.
Before we dissect the study, let’s go over some background. The notion that RF from cell phones can increase the risk of brain cancer was never very plausible. EMF in the RF range is what is called “non-ionizing radiation”, which means it is too low energy to break chemical bonds. Ionizing radiation, which does break chemical bonds, can damage DNA and proteins, causing mutations and cellular damage. At most non-ionizing radiation can heat up tissue slightly.
So there really isn’t much of a plausible mechanism by which exposure to RF, even in close proximity and for long periods of time (such as common cell phone use), would cause cancer. This has not stopped almost constant fearmongering about RF going back decades. This even predates cellphones, with the fear that just living near power lines could increase the risk of leukemia (it doesn’t).
All of this has not stopped a cottage industry of sensationalism and snake oil devices to “protect” cell phone users from scary RF radiation. There has been a long line of bad reporting on this topic, it seems simply because the narrative that big industry is hiding the true risks of using their products is a compelling narrative that makes for click-worthy headlines.
There is also no shortage of devices that shield you from the RF of your cellphone. To the extent that these devices actually work (meaning that they block RF, not that they protect your health) they would prevent the cell phone from functioning. Most such devices are useless. Plus, if you truly wanted your cellphone to not put out RF when you don’t need it – put it in Airplane mode. That’s what it’s for.
Despite this, it is worth asking and investigating whether or not there could be any risk from a new technology that suddenly everyone is using. But researching risk is complicated, and certain to generate a lot of data noise that is tricky to parse through. This is why we need experts to carefully evaluate the evidence and tell us what it means.
One approach is to assess the potential hazard of an exposure – does it even theoretically cause biological harm? This is usually done with in-vitro studies or animal studies, and published in “toxicology” journals. This is useful research, but easily misinterpreted. The idea is to push biological systems to their breaking point, to see where that breaking point is, in order to estimate hazard. For example, rats can be given ridiculously high exposure rates to see what it would take to cause harm. This does not mean there is a risk to humans in real-life exposure settings.
With regard to RF, the animal data has been mostly negative but a little mixed. The research is divided into two categories – non-thermal exposure (exposure that does not significantly raise tissue temperature) and thermal levels of RF exposure. The non-thermal exposure literature is negative. The thermal exposure literature is mostly negative, but a little mixed. This is consistent with there being no hazard, but also with there being a small hazard at thermal levels of exposure that cannot be ruled out. This is the kind of technical science speak that often gets misinterpreted in the media, or by motivated snake oil peddlers.
Hazard, however, is just about the potential to cause injury. Risk is what we really want to know – what is the increase in risk for a negative outcome in various exposure scenarios? To assess risk we need human data. Unfortunately, for risk studies we cannot do randomized trials – you cannot randomize a study subject to be exposed to a potential hazard to see if it harms them. It’s not ethical. So we need to rely on observational studies.
We can ask the simple question – since the widespread adoption of cell phones in the 1990s, has the incidence of brain cancer (in general or of any specific type) increased? As you might expect, the answer is complicated, but it’s basically no. There is no clear increase in brain cancer over the last three decades. This is very reassuring. But there are many confounding factors to this kind of data, so by itself it’s not enough to demonstrate not risk. It’s possible, for example, that an increased risk from cell phones is being masked by a decrease due to other public health reasons. It’s also possible that an apparent increase is due to better diagnostic techniques or more thorough screening.
What is considered the most direct evidence is population or cohort based correlational studies – is there any correlation between the risk of getting brain cancer and exposure intensity or duration? It is these kinds of studies that are the focus of the recent WHO systematic review. The looked at 63 studies between 1994 and 2022, in 22 countries, making 119 different exposure comparisons. They found:
“There was no observable increase in mRRs (meta-relative risk) for the most investigated neoplasms (glioma, meningioma, and acoustic neuroma) with increasing time since start (TSS) use of mobile phones, cumulative call time (CCT), or cumulative number of calls (CNC).” 
They found no increased risk in children or adults, regardless of the intensity or duration of exposure. This, again, is very reassuring. It should, in fact, put the question to bed, but when it comes to risk reassuring data never does.
Part of the problem is that you can never scientifically prove zero risk. You can only set upper limits statistically on the potential risk. This is why such studies often conclude things like – we did not detect any significant risk, but we cannot rule out a small risk below the detection threshold of the study.
Also – there is the question of the duration of the study. If you follow people for 10 years, that does not rule out a risk that only becomes significant after 20 years of exposure. So you can always ask for longer duration studies. This is why this review is helpful, because now we have data over 30 years.
However, some will then argue that the risk only became significant with the adoption of 5G technology. So research using 3G or older generation cell phones is not relevant. This creates a forever moving target. Once we show 5G is safe, 6G will be rolled out and the process will start all over again.
These caveats are semi-reasonable, in that it is true, shorter duration studies do not rule out a risk to longer durations, and studies with lower frequency technology may not perfectly predict the risks of higher frequency technology. The problem is, using this logic to dismiss decades of reassuring research about both hazard and risk, and setting an unrealistic and impractical threshold for evidence of lack of risk.
In life, there is no zero risk. There are no absolute guarantees of safety. This is not an excuse – this is reality. We always have to think about relative risk and the magnitude of risk, and not demand an impossible goal of zero risk.
Looking at the big picture, what we can say at this time is that – non ionizing radiation (especially non thermal) has no plausible mechanism of causing biological harm. A hazard from a currently unknown mechanism is always impossible to rule out, but is not very plausible here. Further, the observational data has not demonstrated any actual risk of exposure to RF through cell phone use or otherwise.
For me, the bottom line is, any remaining potential risk is too small to worry about. It is down in the background noise of life. You have more risk driving to work, eating food, and engaging in just about any recreational activity. In fact, worrying unnecessarily about the risks of RF from cell phones itself is likely a higher risk to you than the RF exposure. It can cause anxiety, make you vulnerable to wasting money and resources on anti-RF scams, and perhaps limit your use of a technology that might just save you one day. Even if you think these are small risks, the point is, the potential remaining risk of RF from cell phones is so small it is likely even less.
The WHO report is good news, and in the full context of the question of the risks of RF, is not surprising. Take it for the good news it is.

   Radiation from medical imaging and cancer risk
David Gorski
Link
Science-based medicine consists of a balancing of risks and benefits for various interventions. This is sometimes a difficult topic for the lay public to understand, and sometimes physicians even forget it. My anecdotal experience suggests that probably surgeons are usually more aware of this basic fact because our interventions generally involve taking sharp objects to people’s bodies and using steel to remove or rearrange parts of people’s anatomy for (hopefully) therapeutic effect. Ditto oncologists, who prescribe highly toxic substances to treat cancer, the idea being that these substances are more toxic to the cancer than they are to the patient. Often they are only marginally more toxic to the cancer than to the patient. However, if there’s one area where even physicians tend to forget that there is potential risk involved, it’s the area of diagnostic tests, in particular radiological diagnostic tests, such as X-rays, fluoroscopy, computed tomography (CT) scans, and the variety of ever more powerful diagnostic studies that have proliferated over since CT scans first entered medical practice in the 1970s. Since then, the crude images that the first CT scans produced have evolved, thanks to technology and ever greater computing power, to breathtaking three dimensional-views of the internal organs. Indeed, just since I finished medical school back in the late 1980s, I’m continually amazed at what these new imaging modalities can accomplish.
The downside of these imaging modalities is that most of them require the use of X-rays to produce their images. True, over the last 15 years or so MRI, which uses very strong magnetic fields and radiofrequency radiation rather than ionizing radiation to produce its images, has become increasingly prevalent. MRI is great because it produces more contrast between different kinds of soft tissue than CT scans do. However, CT tends to be superior for examining calcified organs, such as bone. (The breast surgeon in me notes that breast MRI is pretty much useless for detecting microcalcifications, an important possible indicator for cancer.) Also, MRI scans require a prolonged period of laying still in a very tight tube, which is a problem for patients with any degree of claustrophobia, although “open” MRIs are becoming increasingly available. More importantly for the quality of images, because they require a patient to lie more still than a CT, MRIs tend to be prone to more motion artifacts, which is perhaps why CT is more frequently used to image the abdomen other than large solid organs such as the liver. The point is that, although MRI is becoming more prevalent, CT scans aren’t going away any time soon. They have different strengths and weaknesses as imaging modalities and are therefore best suited for different, albeit overlapping, sets of indications.
Even so, it’s pretty amazing to consider how much these imaging modalities have changed medical practice in the last three decades. Before CT, surgeons often did exploratory surgery to diagnose a problem, often not knowing what they would find. They had to be ready for almost anything, and there were frequent surprises. (Some older surgeons lament that this has taken some of the excitement out of surgery, but there’s little doubt it’s better for the patients.) Another area where surgery used to be done routinely was in the staging of Hodgkin’s lymphoma. Patients underwent staging laparotomy, where the surgeon in essence carefully explored the abdomen, removed the spleen, and took biopsies of multiple areas in order to define precisely the extent of intraabdominal disease. Based on the results, the stage would be determined and therapy chosen. However, over the last 25 years or so, fewer and fewer of these have been done, thanks to better CT imaging and evolving practice in which more and more Hodgkin’s lymphoma patients receive chemotherapy. Indeed, during my residency I can only recall doing one or two staging laparotomies.
While CT imaging has revolutionized surgery and medicine, it is not entirely benign. Often, it requires the injection of intravenous contrast agents that can damage the kidneys and cause allergic reactions, occasionally life-threatening. Pretty much every physician is aware of these risks. Less acknowledged is the risk from the ionizing radiation from such tests, and physicians tend to downplay the risks from radiation. One exception is pediatrics, because it’s long been known that children are more sensitive to the effects of radiation than adults are, and they have much more time left in their lives for potential radiation-induced cancers to make themselves known. That is why pediatricians tend to be more judicious about the use of CT scans. In any case, by and large, CT scans require far more radiation than other imaging modalities. This concern was again brought to the fore last week by two studies recently published in the Archives of Internal Medicine, along with an accompanying editorial1,2,3. Together, these studies suggest that far more radiation is used in some CTs than is necessary and that there may be far more radiation-induced cancers due to medical tests than we would like to acknowledge. Taken together with another review article in the New England Journal of Medicine from a couple of years ago, they should make us as physicians think more carefully about how we use diagnostic imaging studies.
The NEJM review4 is useful because it gives the background in terms of typical doses of radiation for various imaging studies:
And for the huge increase in the number of CT scans being done in the U.S. every year:
That’s over 60 million CT scans performed in the U.S. in 2006. More recent data shows that 70 million scans were performed in 20072. and, for example, a typical CT scan of the chest results in an absorbed radiation dose 100-fold higher than a typical two-view PA and lateral chest X-ray. Moreover, as Smith-Bindman et al2 point out:
Exposure to ionizing radiation is of concern because evidence has linked exposure to low-level ionizing radiation at doses used in medical imaging to the development of cancer. The National Academy of Sciences’ National Research Council comprehensively reviewed biological and epidemiological data related to health risks from exposure to ionizing radiation, recently published as the Biological Effects of Ionizing Radiation (BEIR) VII Phase 2 report.7 The epidemiologic data described atomic bomb survivors, populations who lived near nuclear facilities during accidental releases of radioactive materials such as Chernobyl, workers with occupational exposures, and populations who received exposures from diagnostic and therapeutic medical studies. Radiation doses associated with commonly used CT examinations resemble doses received by individuals in whom an increased risk of cancer was documented. For example, an increased risk of cancer has been identified among long-term survivors of the Hiroshima and Nagasaki atomic bombs, who received exposures of 10 to 100 milli-sieverts (mSv).8-11 A single CT scan can deliver an equivalent radiation exposure,12 and patients may receive multiple CT scans over time.13
They then observe that few studies have tried to quantify rigorously the typical real-world doses of radiation received in hospitals due to CT scanning. Most studies, other than for CT coronary angiography, have used phantoms rather than patients. So Smith-Bindman et al2 looked at imaging studies in four San Francisco-area hospitals, one of which was at UCSF, and used a method called the “effective dose” to quantify radiation exposure in consecutive studies. What was most shocking is what they found regarding the variability in radiation exposures both within and between institutions even for the same test. Indeed, they noted a mean 13-fold variation between the highest and lowest radiation dose for each study type:
This particular plot type, known as box-and-whiskers, shows the 25th to 75th percentile range in the boxes, while the bars show the range between the highest and lowest values, with the median value being represented by the dots. The investigators then estimated the increased excess risk of cancer for these radiation doses and concluded:
Among 40-year-old women, 1 cancer would occur among 8105 patients who underwent a routine head CT scan (IQR, 1 in 6110 to 1 in 9500). For a 60-year-old woman, the risks were substantially lower and varied from approximately 1 in 420 examinations for CT coronary angiography (IQR, 1 in 370 to 1 in 640) to 1 in 12 250 examinations for a routine head CT scan (IQR, 1 in 9230 to 1 in 14 360). For a 20-year-old woman, the risks were substantially higher and varied from approximately 1 in 150 examinations for CT coronary angiography (IQR, 1 in 130 to 1 in 230) to 1 in 4360 examinations for a routine head CT scan (IQR, 1 in 3290 to 1 in 5110).
These are not insignificant risks. It should be noted, however, that this study has several weaknesses. The biggest weakness is that the cohort studied (1,119 patients) was not large enough to identify possible reasons why the dose of radiation varied so much for even the same tests, including experience of the technologist, physician availability to check the studies and determine the need for additional imaging, geographic variation, imaging algorithms available or used, and patient factors (such as weight). The authors point out that far more standardization is required and that studies are needed to figure out why there may be such variation in radiation dose.
The second study drives home the point that radiation from CT scans can increase cancer risk by using different methodology. Berrington et al1 started with risk models based on National Research Council’s “Biological Effects of Ionizing Radiation” report and organ-specific radiation doses derived from a national survey were used to estimate age-specific cancer risks for each scan type and then combined these models with age- and sex-specific scan frequencies obtained from insurance claims data and surveys. Using a Monte Carlo simulation, they then estimated the number of excess cancers due to radiation from CT scanning. Their conclusions:
Overall, we estimated that approximately 29,000 (95% UL, 15 000-45 000) future cancers could be related to CT scans performed in the US in 2007. The largest contributions were from scans of the abdomen and pelvis (n = 14,000) (95% UL, 6,900-25,000), chest (n = 4100) (95% UL, 1,900-8,100), and head (n = 4000) (95% UL, 1,100-8,700), as well as from chest CT angiography (n = 2,700) (95% UL, 1,300-5,000). One-third of the projected cancers were due to scans performed at the ages of 35 to 54 years compared with 15% due to scans performed at ages younger than 18 years, and 66% were in females.
This graph tells the tale:
The black bars are for men; the white for women. Women tend to have a higher sensitivity to the effects of radiation in cancer production.
One thing that is very important is to put these figures in perspective. 29,000 is a huge number, but compared to the number of new cancer cases every year (estimated to be 1.5 million in 2009, down from earlier years). Indeed, Berrington et al1 estimate that their study suggests that approximately 1% to 3% of cancers in any given year can be attributed to past CT use. Another thing that is very important is that these results are due to a simulation, which is very dependent on the values inputted and the assumptions made in constructing the simulation. The estimates of the number of CT scans. For example, for solid tumors the assumption was a five-year lag period and a linear dose-response model. I’m not sure how valid that assumption for lag time is, given that there are quite a few tumors with longer lag periods after radiation exposure. Still, overall, this study likely represents a fairly good estimate of how many additional cancers there are due to CT scanning, but it is just that, an estimate. It also does not provide any information to tell us which cancers were actually caused by radiation from a CT scan. Neither of these studies do; they’re both population-based and look at aggregate statistics. Even so, the possibility that as many as 3% of adult cancers might be due to radiation from medical imaging studies is a problem that should sober even the most gung ho advocate of using such studies, particularly considering that the risk tends to be higher in younger people.
All of this brings us back to what I started this post with: All of medicine is a balancing of risks versus benefits. One reason I was so disturbed by the proliferation of whole-body imaging studies being marketed by unscrupulous companies on a cash basis is because, in an asymptomatic patient, the risks from radiation from such studies on average probably outweigh any conceivable benefit, especially if we take the risks of false positives leading to invasive tests such as biopsies into account. Still, there is no doubt that CT scans are highly beneficial when it comes to diagnosing disease and, these days, to guiding physicians in doing less invasive needle biopsies for diagnosis where before a surgical biopsy might have been required. That leaves the question: What to do with these results?
One approach to reducing radiation exposure from medical imaging would be to be to try to standardize imaging studies more, so that the dose of radiation for each one varies less, and, even more importantly, to find ways to decrease the dose of radiation for each test without sacrificing image quality or diagnostic sensitivity or specificity. The authors of both studies agreed on these tactics. However, far more difficult will be tactics designed to change physician behavior.
Clearly, the first thing we as a profession should do is to make ourselves very aware that a CT scan (or any scan involving a significant radiation dose) is not an entirely benign thing. We sometimes do treat them that way, and this must stop. There are several strategies to reduce the risk from these imaging studies. One obvious one, of course, is to order fewer studies and to stop ordering them for questionable indications. Critical to this approach would be better data and studies that help us clearly define when such tests are appropriate and indicated; i.e., a more rigorous application of science-based medicine to medical imaging. Sadly, this is not as much the case now as it should be, as the author of the accompanying editorial3, Dr. Rita Redberg, points out:
In addition, it is certain that a significant number of CT scans are not appropriate. A recent Government Accountability Office report on medical imaging, for example, found an 8-fold variation between states on expenditures for in-office medical imaging; given the lack of data indicating that patients do better in states with more imaging and given the highly profitable nature of diagnostic imaging, the wide variation suggests that there may be significant overuse in parts of the country.4 For example, a pilot study found that only 66% of nuclear scans were appropriate using American College of Cardiology criteria—the remainder were inappropriate or uncertain.5
Indeed, medical imaging is highly profitable. Moreover, sometimes laziness rules. It is easier just to order a CT scan than to use more mundane methods of trying to figure out what’s wrong with a patient, and the current malpractice climate often leads to physicians practicing “defensive” medicine, part of which may involve, for example, ordering a CT scan for a patient with abdominal pain “just in case” even when it’s known that the diagnostic yield is likely to be very low. At the risk of getting myself in trouble, I’ll point out that patients, too, bear some of the blame, just as they do for the overuse of antibiotics that leads to resistant organisms. Some just won’t be reassured without an imaging study; although they might be if they were more carefully informed of the increased risk of cancer from medical imaging studies. In any case, all of these factors combine to drive the explosion in CT imaging, which has increased faster than evidence of its benefit.
Finally, it is critical to remember that, for individual patients, the risk of any single imaging study is pretty low, and the potential benefit, when the study is ordered appropriately according to science- and evidence-based guidelines, will almost certainly far outweigh the slightly increased risk of cancer. For example, if you’re in the emergency room with severe chest pain, the last thing you should be worrying about is the radiation you’ll receive from a cardiac catheterization and angioplasty. Even if your chance of developing cancer from the radiation is increased by 1 in 100, that pales in comparison to your chance of dying now if your blocked coronary artery isn’t identified and opened up. If you’ve been in a car crash and might have a lacerated spleen or liver that needs repair or might have a subdural hematoma that could squish your brain against the inside of your skull, the risk from the radiation due to the CT scans that would diagnose these problems is nothing compared to your risk of death or serious disability now.
The problem is that the indications for CT scans have expanded to the point where they are often done even when they don’t provide information that will change the course of management for a patient. For instance, it used to be that general surgeons (of which I still count myself one) could diagnose acute appendicitis in a young male (who doesn’t have female reproductive organs, disorders of which can be confused with appendicitis) by history and physical exam alone and be highly accurate doing so. Yet these days, even young men with right lower abdominal pain get a CT scan that tells the surgeon that, yes, they have acute appendicitis before going to the OR. Many patients with acute peritonitis don’t need a CT scan for a surgeon to know that they need an operation. A very ill-appearing febrile patient lying perfectly still because the slightest movement causes him intense abdominal pain doesn’t need a CT scan; most of the time, he needs a trip to the OR as soon as possible to fix whatever intraabdominal catastrophe is going on. (This reminds me of a surgical aphorism that some attendings used to use to tweak residents examining a patient with peritonitis, which went, “What are you waiting for? Even the janitor can see that this patient needs an operation!”) Unfortunately, these days it seems that virtually all patients presenting to the ER with abdominal pain get a CT scan. As Dr. Redberg points out, “more and more often patients go directly from the emergency department to the CT scanner even before they are seen by a physician or brought to their hospital room.” This approach is all too easy and seductive, and all too often even general surgeons have allowed it to become the rule rather than the exception because it’s far easier to wait for the CT scan than to get out of bed to determine if a patient really needs a CT scan. Indeed, back when I still did general surgery call and chastised an ER doc for ordering a CT scan that I didn’t consider indicated, the response was that all the surgeons there wanted a CT before he even called them about a patient with abdominal pain and would get irate if he didn’t have one. This happened over ten years ago.
The bottom line is that, when the test is indicated based on guidelines constructed using science and evidence, the benefits of doing a CT scan or other medical imaging procedures requiring similar amounts of radiation outweigh the risks. The problem is that all too often these scans are not ordered using science-based guidelines and in all too many cases the evidence is not clear that doing a CT scan will improve patient outcomes. Clearly, we require more and better studies that define when the benefit of doing a CT scan outweighs the risk from the radiation. In the meantime, physicians and patients need to be aware of data like these regarding the risk of cancer due to radiation from CT scans, and physicians need to exercise some restraint and–dare I say?–clinical judgment when deciding to order these tests.
MORE INFORMATION:
The NCI Factsheet on Computed Tomography: Questions and Answers
REFERENCES:
1. Berrington de Gonzalez, A., Mahesh, M., Kim, K., Bhargavan, M., Lewis, R., Mettler, F., & Land, C. (2009). Projected Cancer Risks From Computed Tomographic Scans Performed in the United States in 2007 Archives of Internal Medicine, 169 (22), 2071-2077 DOI: 10.1001/archinternmed.2009.440
2. Smith-Bindman, R., Lipson, J., Marcus, R., Kim, K., Mahesh, M., Gould, R., Berrington de Gonzalez, A., & Miglioretti, D. (2009). Radiation Dose Associated With Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer Archives of Internal Medicine, 169 (22), 2078-2086 DOI: 10.1001/archinternmed.2009.427
3. Redberg RF (2009). Cancer risks and radiation exposure from computed tomographic scans: how can we be sure that the benefits outweigh the risks? Archives of internal medicine, 169 (22), 2049-50 PMID: 20008685
4. Brenner DJ, & Hall EJ (2007). Computed tomography–an increasing source of radiation exposure. The New England journal of medicine, 357 (22), 2277-84 PMID: 18046031

Cancer disparities: It’s money that matters (along with a lot of other things)
Cancer is a complex set of diseases. I commonly discuss complexities in its biology and treatment. However, there’s another layer of complexity that leads to marked disparities in cancer incidence and death rates. One major factor associated with such disparities is socioeconomic status.
David Gorski on October 8, 2018
Link

As I’ve written more times than I can remember, cancer is complicated. Really complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think balancing your checkbook is complicated, but that’s just peanuts to cancer. (Apologies to Douglas Adams.) First of all, contrary to the way alternative medicine mavens (and all too many people in general) portray it, cancer isn’t just one disease; it’s hundreds. Even cancer arising from the same organ might not be one disease. For instance, one study of a particularly aggressive subtype of breast cancer found that no two cancer genomes were the same, and, thanks to the power of evolution, the genetically unstable cancer cells lead to increasingly heterogeneous tumors as they grow, such that one part of a cancer might be significantly different from another part and metastases can be even more different. Phylogenetic trees can even be constructed. Cancer often involves many more cell types than just the cancer cell as well, not to mention the contribution of the immune system and metabolism in addition to the various genetic derangements in the cancer cells themselves.
One area of cancer research where this complexity becomes apparent is cancer disparities. I’ve discussed how lifestyle and diet can increase or reduce one’s risk, but there’s a whole other layer to the question of environmental effects on cancer risk and mortality. For instance, where you live matters. Your race or ethnicity can matter. Your socioeconomic status can matter. As the National Cancer Institute notes:
Cancer disparities (sometimes called cancer health disparities) are differences in cancer measures such as:
    • incidence (new cases)
    • prevalence (all existing cases)
    • mortality (deaths)
    • morbidity (cancer-related health complications)
    • survivorship, including quality of life after cancer treatment
    • burden of cancer or related health conditions
    • screening rates
    • stage at diagnosis
Cancer disparities can also be seen when outcomes are improving overall but the improvements are delayed in some groups relative to other groups.
Although disparities are often considered in the context of race/ethnicity, other population groups may experience cancer disparities. These include groups defined by disability, gender/sexual identity, geographic location, income, education, and other characteristics.
And here’s a video primer:
The one disparity that interests me as a breast cancer surgeon is the increased prevalence of triple negative breast cancer, a particularly nasty subtype, in premenopausal African American women, because our cancer center is in an area where half of our patients are African-American.
Basically, cancer disparities are where the rubber hits the road in a practical manner, as genetics, environment, lifestyle, and access to care can all impact who dies from cancer and who survives. So, for a change of pace (and because it interested me), I thought I’d look at a study of cancer disparities just published in JAMA Network Open on Friday that attempts to quantify cancer disparities. Its investigators include researchers from Yale and the University of Chicago, who report rather striking disparities in cancer death rates by county in in the US related to socioeconomic status.
The authors note:
Advances in cancer prevention, diagnosis, and treatment have led to rapid reductions in cancer mortality in the United States, with cancer death rates decreasing from 240 per 100,000 person-years in 1980 to 192 per 100 000 person-years in 2014.1-3 Reductions in cancer mortality, however, are not synonymous with reductions in cancer disparities—perhaps in part because of variation in access to advances in care. Indeed, cancer disparities remain substantial in the United States by geographic area and by socioeconomic status.4-6 The socioeconomic cancer disparities are notable in particular because they may worsen over time owing to the soaring costs of cancer diagnosis and treatment. Thus, there are major concerns about US socioeconomic disparities in cancer deaths.
To estimate cancer disparities, the investigators carried out a cross-sectional study assessing cancer disparities by county. They included all counties with cancer death rates available from 2014 in a database published by the Institute for Health Metrics and Evaluation. The database is based on data from the National Center for Health Statistics death record data and curated to eliminate “garbage codes, which are implausible or nonspecific causes of death.” The authors also linked the cancer death rate of each county to the median household income from 2012 in order to allow a two year lag prior to the primary outcome measure in 2014. The use of MHI is justified because it’s widely used and a readily available marker of socioeconomic status and because the authors expected it to have the most relevance to cancer death rates because of the financial toxicity of cancer.
So the primary outcome of this study was the age-adjusted cancer death rate per 100,000 person-years. Then:
To identify the factors that may serve as mediators of the association between the exposure and the outcome at the county level, we used time-lagged variables from the Robert Wood Johnson Foundation County Health Rankings conceptual model (eTable 1 in the Supplement). This model systematically evaluates and ranks counties according to a series of health risk factors that are selected on the basis of their validity and their importance in public health.17,18 It then groups these health factors into domains: health risk behaviors, clinical care factors, socioeconomic factors, and physical environment factors.18 We added a fifth domain to include cancer-relevant health policies—for example, the number of state-level mandates for insurance coverage of cancer care. Last, we added other factors, such as the presence of a comprehensive cancer center nearby, that were not included in the County Health Rankings model but were expected to be relevant to cancer outcomes.19,20 We obtained factors from multiple sources, including the Centers for Disease Control and Prevention, the American Lung Association, the National Cancer Institute, and the American Society of Clinical Oncology (eTable 1 in the Supplement).21-26
Counties were stratified into quartiles: low- (lowest quartile), medium- (middle quartiles), and high-income (highest quartile) groups. Regression models were used to identify multiple factors associated with the disparities found and to test the hypothesis that the various factors chosen above may serve as mediators of disparities between counties. The authors also used the sums of the values of the possible mediators to calculate a standardized risk score that they called the disparity risk index.
Not surprisingly, there were significant differences in cancer mortality found. A total of 3,135 counties were examined, with a median household incomes ranging from $22,126 to $121,250 per year. There were also striking differences in cancer death rates, which varied widely across counties, from 70.7 to 503.5 deaths per 100,000 person-years, the mean being 206.4. As one might predict, low income counties (median income $33,445) had a higher proportion of residents who were non-Hispanic black, lived in rural areas, or reported poor or fair health compared to high income counties (median income $55,780). The mean (SD) cancer death rate was 185.9 (24.4) per 100 000 person-years in high-income counties, compared with 204.9 (26.3) and 229.7 (32.9) per 100,000 person-years in medium- and low-income counties, respectively. There were also significant variations in cancer death rates by income group, with a mean death rate ± standard deviation of 229.7 ± 32.9 deaths per 100,000 person-years in the counties in the lowest quartile counties versus 204.9 ± 26.3 deaths per 100,000 person-years in the middle quartile counties and 185.9 ± 24.4 deaths per person-years in the highest quartile counties. The authors found that the geographic clusters, or hot spots, with the highest cancer death rates were in the South, including the Mississippi River Delta, in addition to Appalachia (n = 507 counties in hot spots at a threshold of P <  .05, Figure 2). There were many overlaps between these hot spots and low-income counties, as shown below in Figure 2 from the paper.
The authors tested various factors for whether they could be mediators of the observed disparities. A total of 38 factors were tested in a single-mediator model, which led 19 factors to meet the criteria for being included in a multi-mediator model. Of these, eight retained significance in the fully adjusted mediation model, suggesting that at least these eight county-level factors could be serving as mediators of the observed county-level socioeconomic cancer disparities. The authors note that these factors are important because they correlate with county-level MHI and because they could well fit into relevant pathways known to affect cancer risk and outcome. Of these, three factors were health risk behaviors (rates of obesity, smoking, and physical inactivity); two were health policies (smoke-free laws and the state Medicaid fee index, which is a state-level ratio of provider payments from Medicaid vs Medicare); and one was a health environment factor (food insecurity, defined as the percentage of the population that lacks a reliable source of food). The effects are shown on the graph below, specifically what percentage of the disparity observed is explained by each factor:

As you can see by eyeballing the graph, much of the disparity can be explained by these factors, Indeed, the authors calculated that, in aggregate, these factors explained more than four-fifths (81.25%, to be precise) of the association between county-level median incomes and cancer death rates. As should be done, the statisticians did various sensitivity analyses, to see if the method choosing the variables affected the results. It didn’t. Different methods of variable selection led to similar models. So, basically, the final multivariable model “seemed to provide an accurate and robust estimate of the degree to which the factors may explain the disparities”, at least for this dataset and these variables.
Of course, this is an epidemiological study. Since it uses aggregated data and doesn’t look at individual-level date (e.g., MHI of individuals), it’s prone to the ecological fallacy (making inferences about the nature of individuals based on inference from the group to which they belong, most commonly deducing correlation between individual variables from the correlation of the variables collected for the group). Also, these are aggregated cancer death rates; they’re not broken out by cancer type. This means that large differences between the incidences of different cancers by county could confound results, although such confounding would provide interesting fodder for further research. In any event, this study is more hypothesis-generating for some correlations, although certainly finding that smoking, obesity, and physical inactivity are the strongest possible mediators of the cancer disparities is confirmatory of a lot of what we know already.
Two other major findings of this study included the finding that food insecurity and access to quality medical care are associated with higher cancer death rates. The authors note:
There are multiple ways in which these 2 factors may account for disparities in cancer deaths. For example, low-quality clinical care may lead to delays in the diagnosis and treatment of cancer, and food insecurity may increase the incidence of certain cancers in populations due to poor nutrition, even if obesity rates are similar. Efforts to target nonbehavioral mediators might be useful in light of evidence that addressing health risk behaviors is necessary but not sufficient if the ultimate goal is to eliminate health disparities.46,47 In addition, the issue of regular access to healthy foods, or food security, might warrant further consideration in future studies of cancer disparities. This is because studies suggest that food insecurity is correlated with poor health,48 high costs,49 and obesity—a key risk factor for cancer.10 In addition, because obesity is a risk factor for diabetes and cardiovascular disease, efforts to address it might lead to substantial gains in population-level health outcomes.
There’s also this:
Finally, to address disparities, it may be critical to maintain policies that are associated with better outcomes in low-income communities. For example, efforts to limit the expansion of Medicaid may undermine efforts to lessen socioeconomic cancer disparities, in part because the states with vs without Medicaid expansions have had larger improvements in screenings for and early detections of cancer.50,51 Our study adds to these findings by suggesting that limited access to affordable care is a mediator of cancer disparities, at the same time as many of the low-income counties with the highest mortality rates are in the states that eschewed the expansion.
I realize that people don’t like it when we get political here, even if it’s a little bit political, but the fact that the US, alone among developed nations, does not have a system of universal health insurance for its citizens virtually guarantees major disparities. At the very minimum, it means that existing disparities are not ameliorated. Disparities research is a reminder that it’s impossible to separate politics from medicine, because science-based public health care policies will inevitably mean making choices in law and regulation. Those choices are inherently political. Also, money and income matter. They matter a lot.
Ameliorating disparities in cancer outcome and incidence is also very difficult, because so many factors affect them. There are biological differences among populations, socioeconomic differences, differences in environmental exposures, differences in health behaviors, differences in so many things, that it’s hard to tell how much of which disparity is likely to be caused or mediated by what factor. Thus designing and implementing strategies to reduce these disparities are among the most difficult challenges cancer professionals face.

Expectations versus reality in science-based oncology
David Gorski on July 1, 2013
Link
Well, the latest round of grant applications and pre-applications is finally over, which gave me time this weekend to peruse the stack of journals that’s been accumulating on my desk. Oddly enough, despite my being about as plugged in as you can be at my age, I’m still old-fashioned enough to enjoy the physical sensation and the overall experience of picking up the most recent issue of a journal and randomly flipping through it. There’s something about the feel of the paper, the smell of the coating and print, as well as the sheer undirectedness of it all. It’s how I find articles that I probably would never find if I relied just on perusing the table of contents of an electronic edition.
Sadly, that’s not how I found this week’s topic. The study that I’m going to discuss this week is an E-pub ahead of print that I became aware of through a Reuters story, late last week when I still didn’t have time to deal with it. As is my usual practice, I saved the link for later in Safari’s Reading List, and this time I actually managed to come back to it. The story is entitled “Many cancer patients expect palliative care to cure“, and it’s about a recent publication out of the Dana-Farber Cancer Institute published online in the Journal of Clinical Oncology (JCO) entitled “Expectations About the Effectiveness of Radiation Therapy Among Patients With Incurable Lung Cancer“. It caught my eye, even a week ago, because managing expectations in patients with advanced cancer. It then led me to do a search for related articles, which brought me to a similar study from last fall in the New England Journal of Medicine, entitled “Patients’ Expectations about Effects of Chemotherapy for Advanced Cancer“, also from the same group at the Dana-Farber. This latter study looked at patients’ expectations regarding chemotherapy, and I even remember having encountered it when it was first published and wanted to blog about it then. I don’t recall why I didn’t, but here’s my chance to revisit it.
There is not a cancer clinician out there whom I’ve ever met who hasn’t thought that he’s given a patient with incurable cancer an accurate, science-based assessment of his prognosis, only to find that the patient still expects to be cured. Even as a breast surgeon, I occasionally encounter the issue even though the vast majority of my patients are early stage and therefore potentially curable by surgery, supplemented with a combination consisting of one or more of the common breast cancer treatment modalities of chemotherapy, hormonal therapy, and radiation. In my practice, it’s usually when I’m referred a patient who has stage IV disease that has either been stable for a while, leading to the question of whether removing the primary tumor will prolong life. There is evidence that it will, but, given that the data supporting this contention are all largely retrospective and no large randomized trials have been published yet, many of us suspect that there is a large component of selection bias in the existing data supporting removing the primary tumor in patients with metastatic disease.
The other example is the occasional patient with metastatic disease whose primary tumor is large and on the verge of ulcerating. Disease that gets to this point is known as en cuirasse disease. It’s nasty in the extreme, leaving a woman with a bleeding, stinking, necrotic mass on her chest wall that can’t be removed without major surgery that involves removing huge swaths of skin, soft tissue, and chest wall. Such surgery is rarely, if ever, done, because it’s too major to be proposed for palliation of a patient who likely only has months to live. If you want an example of just how horrible a death comes from en cuirasse disease, I described one at the end of my post on German New Medicine, specifically the example of Michaela Jakubczyk-Eckert. (Warning: That link is not for the squeamish.) Surgery is often worth it to prevent such a complication of advanced breast cancer, even if it won’t save the patient’s life. I try to be very clear—blunt, even—about this whenever I see the occasional patient referred for consideration of palliative mastectomy, but, even so, although I can’t give a percentage a significant number of patients appear to believe that having a mastectomy might actually save their lives.
So it is with patients with metastatic lung cancer and colorectal cancer receiving chemotherapy, as illustrated in the NEJM article. In both studies, which are based on the same national, prospective, observational cohort study, the Cancer Care Outcomes Research and Surveillance (CanCORS) study, a large multi-center consortium study funded by the National Cancer Institute whose aims are to:
     1.  assess the quality of care received by cancer patients and survivors;
     2.  explore the relationship between quality of care and patient health outcomes; and
     3.  evaluate how characteristics of patients, providers, caregivers, and delivery systems affect quality of care and outcomes.
Specific questions to be answered include:
    • Are there racial, ethnic, and socioeconomic differences in use of effective therapies for colorectal cancer and lung cancer?
    • Are there racial, ethnic, and socioeconomic differences in patients’ assessments of the quality of cancer care?
    • How do patients and physicians decide about therapies for colorectal cancer and lung cancer?
    • Why do outcomes of lung cancer surgery and colorectal cancer surgery vary by hospital and surgeon volume?
    • What factors explain participation in clinical trials for lung cancer and colorectal cancer?
    • Are patients’ symptoms recognized and treated effectively at different stages of illness?
Obviously, these two papers report on the results of asking about how patients and physicians decide on therapy for colorectal cancer and lung cancer and racial differences in patients’ assessments of the quality of their cancer care. Specifically, the part of the study that I’m going to discuss involved assessing patients with newly diagnosed metastatic lung or colorectal cancer (stage IV) who were alive four months after diagnosis and had received chemotherapy (the NEJM study) or who had newly diagnosed lung cancer, stage IV or stage IIIB with malignant pleural effusion, who had received, or were scheduled to receive, palliative radiation therapy. There were 1,193 patients in the NEJM study and 384 in the JCO study, both respectable-sized cohorts. The questions asked were adapted from the Los Angeles Women’s health study and were worded:
After talking with your doctors about chemotherapy, how likely did you think it was that chemotherapy (in the case of the NEJM study) or radiation therapy (in the case of the JCO study) would:
    • help you live longer?
    • cure your cancer?
    • help you with problems you were having because of your cancer?
Response options were “very likely,” “somewhat likely,” “a little likely,” “not at all likely,” and “don’t know.” Refusal to respond was also recorded. Patient demographics were, of course, recorded and correlated with the likelihood of various responses.
In the part of the study reported in the NEJM, I think it’s easiest just to present the “money graph.” There are three panels: A. Cure; B. Life extension; and C. Symptom relief. The results are:
The authors described the results thusly:
The proportion of patients with inaccurate expectations about the likelihood that chemotherapy might cure their cancer according to patients’ characteristics is shown in Table 1. Overall, 69% of patients with lung cancer and 81% of those with colorectal cancer gave answers that were not consistent with understanding that chemotherapy was very unlikely to cure their cancer.
This is a huge number, and the authors reported that the likelihood of misunderstanding correlated with a diagnosis of colorectal cancer as opposed to lung cancer, nonwhite patients or ethnic group (specifically Latino and Hispanic patients) as compared to white race (odds ratio, 2.82, confidence interval 1.51 to 5.27), African-American race (odds ratio 2.93), and Asian or Pacific Islander patients (odds ratio, an amazing 4.32). No other factors, including education, functional status, and the patient’s role in decision making, correlated with a higher likelihood of an inaccurate response about the curative potential of chemotherapy.
But what about radiation therapy? The JCO study reported depressingly similar results. Here is the equivalent graph to the one above for patient understanding about the curative potential of radiation therapy. Note that, for reasons unclear to me, the order of the questions are reversed: A. Symptom relief; B Life extension; and C. Cure. I don’t know why. The authors just chose to do it that way.
Depressingly as well, the authors’ conclusion about radiation therapy is very similar to their conclusion about chemotherapy, except that slightly different factors appear to be correlated with an inaccurate understanding of the palliative nature of the proposed treatment:
The proportion of patients who did not accurately understand that palliative RT was “not at all likely” to cure their cancer was 64%. Table 2 shows the unadjusted and adjusted analyses of factors associated with inaccurate beliefs about cure from RT. On multivariable analysis, older patients were more likely to have inaccurate beliefs (with age younger than 55 years as the reference, odds ratio [OR] was 1.44 for ages 55 to 64 years, 1.78 for ages 65 to 74 years, and 2.45 for ages older than 74 years; overall P =.02) as were patients of nonwhite race (African American OR, 1.48; other nonwhites OR, 3.32; overall P =.009), and patients whose surveys were completed by surrogates because they were too sick were less likely to have inaccurate beliefs (OR, 0.54; P = .04). Likelihood of inaccurate beliefs also varied by PDCR site (overall P .04).
Then, combining the results about radiation therapy with the results concerning chemotherapy previously reported in the NEJM, the authors report this not-so-surprising result:
Among 285 patients in our cohort who also completed survey items on their expectations about chemotherapy, we found that patients with inaccurate beliefs about RT were significantly more likely to also have inaccurate beliefs about chemotherapy (P. 002 by McNemar’s test); 92% of patients with inaccurate beliefs about RT also had inaccurate beliefs about chemotherapy (Table 3).
So, basically, we have a problem in oncology. There are a lot of patients with advanced cancer who don’t understand the true nature of their prognosis. The strength of these two studies is that they looked prospectively at robust sample sizes of patients, but they both share one big inherent weakness, and that’s that neither of them can tell us why there is this huge disconnect between the patients’ perception of their prognosis and the likelihood that chemotherapy or radiation therapy could potentially cure their cancer or help them live significantly longer versus the actual prognosis. We’re missing a critical piece of information, and that’s that we don’t know what these patients were told by their oncologists and radiation oncologists regarding their actual prognosis. In both studies, the authors point out that there is a lot of evidence that physicians are often uncomfortable talking to their patients about terminal cancer and death. Although on one level, this is not surprising (after all, physicians are human beings and don’t like contemplating mortality any more than the average person—less even, perhaps, because there is the whole issue of wanting to be able to cure patients and facing a profound rebuke to their professional abilities when faced with a patient they know they can’t cure), normally one would hope that physicians would be trained to address these issues honestly, openly, and with dignity. As in everything in medicine, things tend to be messier and more complicated than that.
Of course, this goes both ways. A physician’s discomfort facing a terminally ill patient is minor compared to the anguish of that terminally ill patient himself. No one wants to face the end of his existence. No one wants to contemplate what sorts of pain, suffering, and loss of autonomy he will have to endure before the end comes. Everyone reacts with at least some denial when faced with such horrible news. Pretty much everyone wants to grasp at any straw that is within reach when faced with a terminal diagnosis. Add the patients’ tendency to deny they are dying with physician discomfort over telling them that they are, in fact, dying and that the goals of the chemotherapy and radiation therapy being proposed are strictly palliative (i.e., to address symptoms and possibly prolong life somewhat), and it is probably not so surprising that so many patients with terminal cancer misunderstand their prognosis and the likelihood that their therapy will help them in the most important way that matters to them, prolongation of life or cure of their cancer. Or, it is not so surprising that they might respond to surveys in a way that suggests that they don’t understand the direness of their prognosis, which is a different thing than necessarily misunderstanding their prognosis. Either way, it is a significant problem. As Drs. Thomas J. Smith and Dan L. Longo point out in an accompanying editorial to the NEJM study, entitled “Talking to patients about dying“, patients “also choose not to believe.” Indeed, when patients are given their actual prognosis, many will still not admit that treatment will not cure them.
As the study authors point out in both articles, an honest, accurate discussion about patient prognosis is absolutely essential. Without it, patients do not have true informed consent and can feel driven to continue toxic treatments that can reduce the quality of their remaining life without significantly increasing the likelihood that they will live longer. There is always a fine, fuzzy, grey line between continuing chemotherapy and/or radiation for palliative purposes and feeling driven to continue it at all costs because it comes to be perceived as the only hope left. In the NEJM paper, the authors write:
Should we be concerned that the majority of patients with these diseases provide responses suggesting that they do not understand that there is essentially no chance that the chemotherapy they are receiving will cure them? Chemotherapy may offer palliation and some prolongation of life, so it represents a reasonable treatment choice for some patients. However, an argument can be made that patients without a sustained understanding that chemotherapy cannot cure their cancer have not met the standard for true ongoing informed consent to their treatment.28 Furthermore, previous studies have shown that patients with advanced cancer would accept toxic treatment for even a 1% chance of cure but would be unwilling to accept the same treatment for a substantial increase in life expectancy without cure.29,30 This finding suggests that patients who do not know whether a treatment offers any possibility of cure may be compromised in their ability to make informed treatment decisions that are consonant with their preferences.29,30 Finally, and perhaps most worrisome, this misunderstanding could represent an obstacle to optimal end-of-life planning and care.
In the JCO paper, they write:
Poor understanding of treatment goals and prognosis are problematic for both medical and policy reasons. Patients cannot make well-informed decisions about their end-of-life care, taking into account risks and benefits of treatment, if they hold inaccurate beliefs about the goals of care. Studies have shown that patients with advanced cancer who do not understand and overestimate their prognosis are more likely to pursue intensive therapies near the end of life.14,28 These therapies may reduce quality of remaining life and incur substantial costs for patients with limited life expectancy. In particular, palliative RT requires daily visits for treatment, which can be burdensome for patients and families. It is possible that patients who understand that RT is not at all likely to result in cure might choose to forgo RT or pursue shorter courses of treatment. Although randomized studies suggest that short courses of RT are equally effective in many patients with poor prognosis,29 lengthier courses are more commonly given.8
In other words, this disconnect between the science-based goals of treatment and what patients perceive the goals of treatment to be, matters. It matters a lot. We exhaust a lot of money and, at least as important, precious time that terminally ill patients don’t have very much of, to administer toxic treatments that will not cure them. That does not mean that such treatments don’t palliate. When used appropriately in the correct clinical situations, radiation therapy and chemotherapy produce excellent palliation and are thus appropriate for quite a few patients with terminal cancer. However, that palliation generally means symptom reduction and maybe a slight increase in survival time.
Finally, there was an incredibly intriguing and paradoxical observation (at least to me) reported in the NEJM paper. It’s an observation that to me is relevant not just to science-based cancer care, but to the cancer quacks about which I write so often. Specifically, the authors report that patients were “less likely to provide inaccurate responses” if they reported lower scores for physician communication. That’s right, lower scores for physician communication correlate with a greater likelihood that the patient understands his prognosis and the goals of palliative chemotherapy. Specifically, in the scoring system used for patients to rate communication with their doctors, a score of 100 represents a perfect score. Using patients who scored their communication with their doctors under 80 as the baseline, the investigators calculated the odds ratio of a patient having an incorrect understanding of his prognosis to be 1.90 among those who gave a perfect score of 100 in physician communication. For patients who scored their physician’s communication between 80-99, the odds ratio was 1.32 compared to baseline. In other words, there was an inverse correlation between a patient’s rating of the communication with his physician and the likelihood that he had a correct understanding of the seriousness of his prognosis. In other words, high communication scores correlating with less understanding. Interestingly, this same correlation was not observed in the radiation therapy study reported in the JCO. In any case, the authors note:
In an era of greater measurement and accountability in health care, we need to recognize that oncologists who communicate honestly with their patients, a marker of a high quality of care, may be at risk for lower patient ratings. Our results suggest the need for targeted education to help all physicians learn to communicate honestly while also maintaining patients’ trust and regard. Efforts to incorporate earlier and more effective end-of-life care must address honestly and unambiguously patients’ unrealistic expectations about the outcomes of chemotherapy.
I think you can see the two directions where I’m going with this. First of all, as I’ve pointed out before, quality of care does not correlate with patient satisfaction scores. Companies that compile customer satisfaction ratings, like Press-Ganey, try to convince hospitals and patients that if patients are satisfied with a hospital it must mean that hospital is providing high quality care. The inherent assumption is that if patients are satisfied then the hospital and health care providers must be doing a good job. But, as I pointed out before, it’s just not that simple, and this could well be an example of that. I sometimes say that, as physicians and health care providers, there are times when we have to be “cruel to be kind in the right measure” (to steal a line from Nick Lowe). Giving a terminally ill patient a realistic assessment of his prognosis could well mean that the patient will think less highly of that physician’s communication skills—or even of that physician, period. Yet, giving the patient that assessment is the right thing to do. Sure, it’s also more complicated than that in that there are right and wrong times to deliver the news. Deliver it at the wrong time, and the patient will be less likely to accept it. Recognizing the right time to deliver such news is a physician skill that is what we call the “art” rather than the science of medicine. But sooner or later the news must be delivered.
The second direction I’m going, of course, is toward quacks and dubious cancer doctors. Almost invariably, such doctors are lionized by their patients, even the ones for whom treatment isn’t working (which is almost always nearly all of them—we are talking about quackery and non-science-based treatments here). They achieve this by giving the patient an unrealistic expectation that they can be saved, glossing over every setback as either being expected or indicative that, despite all appearances, the treatment is working after all (“the tumor will swell before it disappears” or “cyst formation means that the tumor is dying inside“). These practitioners will inevitably claim that they “never promised a cure,” and perhaps that is true if you look at what they say written on paper, but, in reality, when you take the totality of their interactions with patients into account, they do more or less promise a cure. Some even do so quite literally.
As hard as it is for many physicians and even patients to believe, patients generally welcome truthful and accurate conversations about prognosis, which do not usually increase anxiety or depression. Common reasons that physicians avoid such conversations include a number of misconceptions, some shared by patients and physicians, for which there is no evidence or for which there is actually disconfirming evidence, such as beliefs that palliative therapy will hasten the end or that it will rob the patient of hope. There’s no doubt that talking to patients about their prognosis is hard. Quite honestly, there’s a reason I’m a breast cancer surgeon instead of an oncologist, and that’s that the vast majority of my patients are potentially curable, many very curable. Yet, it’s part of our jobs. Even though I don’t come across a lot of patients with terminal disease in my practice, I want to be better at communicating with the ones I do encounter. Our patients deserve no less.

Chemotherapy doesn’t work? Not so fast… (A lesson from history)
David Gorski on October 28, 2013
Link
If there’s one medical treatment that proponents of “alternative medicine” love to hate, it’s chemotherapy. Rants against “poisoning” are a regular staple on “alternative health” websites, usually coupled with insinuations or outright accusations that the only reason oncologists administer chemotherapy is because of the “cancer industrial complex” in which big pharma profits massively from selling chemotherapeutic agents and oncologists and hospitals profit massively from administering them. Indeed, I’ve lost track of the number of such rants I’ve deconstructed over the years. Usually, they boil down to two claims: (1) that chemotherapy doesn’t work against cancer (or, as I’ve called it before, the “2% gambit“) and (2) that the only reason it’s given is because doctors are brainwashed in medical school or because of the profit motive or, of course, because of a combination of the two. Of course, the 2% gambit is based on a fallacious cherry picking of data and confusing primary versus adjuvant chemotherapy, and chemotherapy does actually work rather well for many malignancies, but none of this stops the flow of misinformation.
Misinformation and demonization aside, it is also important to realize that the term “chemotherapy,” which was originally coined by German chemist Paul Ehrlich, was originally intended to mean the use of chemicals to treat disease. By this definition, virtually any drug is “chemotherapy,” including antibiotics. Indeed, one could argue that by this expansive definition, even the herbal remedies that some alternative medicine practitioners like to use to treat cancer would be chemotherapy for the simple reason that they contain chemicals and are being used to treat disease. Granted, the expansive definition evolved over the years, and these days the term “chemotherapy” is rarely used to describe anything other than the cytotoxic chemotherapy of cancer that in the popular mind causes so many horrific side effects. But in reality virtually any drug used to treat cancer is chemotherapy, which is why I like to point out to fans of Stanislaw Burzynski that his antineoplastons, if they actually worked against cancer, would be rightly considered chemotherapy, every bit as much as cyclophosphamide, 5-fluorouracil, and other common chemotherapeutics.
Chemotherapy, not surprisingly, is easy to demonize. There are few treatments that cause such odious side effects, and when taken to its fullest extreme, such as complete ablation of a cancer patient’s bone marrow in preparation for a bone marrow transplant, chemotherapy can be brutal. It’s also true that for advanced solid malignancies, it only tends to produce palliation or a prolongation in survival, not a cure, and people with cancer want a cure. Palliation just isn’t that appealing, for obvious reasons. When people think of chemotherapy, they think of hair falling out, nausea and vomiting, fatigue, and death. Since chemotherapy is often given for more advanced malignancies, it’s sometimes hard to tell how many of these symptoms (other than the hair loss) are due to the cancer and how much they are due to side effects of the chemotherapy, and many people incorrectly blame chemotherapy for the deaths of their loved ones with cancer. Also, because, like radiation therapy, chemotherapy is often given in the adjuvant setting (i.e., in addition to curative surgery in order to decrease the risk of recurrence and death), it’s very easy to produce stories in which people with cancer refuse chemotherapy and/or radiation therapy after surgery and attribute their survival not to the conventional therapy (surgery) but to whatever quackery they chose to use. When used in early stage cancer, although its relative efficacy can seem large, for example a 30% decrease in the risk of dying, if the risk of dying of cancer is only 10% to begin with, that’s only a 3% survival benefit on an absolute basis.
I’ve made it a habit of discussing many of these alternative cancer cure anecdotes, such as one about Chris Wark that I did just a couple of weeks ago. It’s a theme of mine that goes back to the very beginning of this blog. Sometimes little or no quackery is involved, but rather patients are pushed away from chemotherapy by major news outlets publishing irresponsible news stories that offer misguided justifications for refusing chemotherapy, making treatment sound as though it will irrevocably destroy lives. In reality, the use of alternative medicine instead of effective treatment for cancer is, where it’s been studied, is always associated much poorer survival, even in pancreatic cancer, for which conventional treatments don’t do so well. Still, among the treatments in the “cut, poison, burn” terminology that believers in alternative medicine like to use to describe conventional cancer therapy, it is the “poison” that causes the most fear and is most viciously demonized in the alt-med “literature.”
It’s for those reasons that I thought that now would be a good time to do a post on the history of chemotherapy by Vincent DeVita (one of the pioneers of chemotherapy) and Edward Chu. It’s also a good time because I came across an article from about five years ago that describes this history quite well. There’s much to be learned there, and this history also explains some of the quotes of scientists often trotted out in an effort to attack chemotherapy.
The early days
For centuries, for solid tumors like breast cancer and colon cancer at least, the only “cure” was surgery. Moreover, because there was no adjuvant therapy, these surgical cures were often radical, because if the tumor recurred after surgery there was close to zero chance of salvaging the patient’s life. In addition, because there were no screening tests, most cancers were not discovered until they were relatively advanced; it was rare back then to find a breast cancer less than 2 cm in diameter. One example that I like to point to is that of William Stewart Halsted, the American surgeon who now stands as almost a god of surgery. In the late 1800s, Halsted developed the radical mastectomy, a procedure that involved taking not only the breast, but the underlying pectoralis major muscle, as well as all the axillary lymph nodes (under the arm). This procedure produced survival rates considerably higher than what were previously achieved at the time, and it relatively rapidly became the standard of care for around 80 years. (Unfortunately, that was probably about 20-30 years longer than it should have.) DeVita describes it thusly:
Surgery and radiotherapy dominated the field of cancer therapy into the 1960s until it became clear that cure rates after ever more radical local treatments had plateaued at about 33% due to the presence of heretofore-unappreciated micrometastases and new data showed that combination chemotherapy could cure patients with various advanced cancers. The latter observation opened up the opportunity to apply drugs in conjunction with surgery and/or radiation treatments to deal with the issue of micrometastases, initially in breast cancer patients, and the field of adjuvant chemotherapy was born. Combined modality treatment, the tailoring of each of the three modalities so their antitumor effect could be maximized with minimal toxicity to normal tissues, then became standard clinical practice.
As the 20th century dawned (and for quite some time thereafter), there really was no effective treatment for cancer except for surgery, which limited cancer treatments to tumors that could be excised and left people with hematological malignancies (leukemias and lymphomas) pretty much out of luck. Leukemias and lymphomas were treated mainly with arsenic, which didn’t actually work very well, if at all; they were thus generally considered to be chronic, incurable diseases.
The first major advance that helped with the development of chemotherapy as we know it today occurred in the 1910s, when George Clowes of the Roswell Park Memorial Institute developed the first transplantable rodent tumor systems. This advance allowed the testing of compounds in animal models before trying them in humans. At the time, tissue culture techniques were in their infancy, having only just been described a few years before, and would not become commonplace in laboratories for another three or four decades. Early systems included sarcomas and Erlich’s ascites tumor. These were all induced by carcinogens in mice and could be transplanted from mouse to mouse.
Decades passed, and the development of chemotherapy didn’t really go anywhere until the 1930s, when, as DeVita describes:
It was Murray Shear, at the Office of Cancer Investigations of the USPHS, a program that was later combined in 1937 with the NIH Laboratory of Pharmacology to become the National Cancer Institute (NCI), who in 1935 set up the most organized program that would became a model for cancer drug screening ( 7). Shear’s program was the first to test a broad array of compounds, including natural products, and had both interinstitutional and international collaborations. He ultimately screened over 3,000 compounds using the murine S37 as his model system. However, because only two drugs ever made it to clinical trials and were eventually dropped because of unacceptable toxicity, the program was dissolved in 1953 just as discussions began about establishing an organized national effort in drug screening. This failure was in part due to the antipathy toward the testing of drugs to treat cancer but also to a lack of information and experience on how to test potentially toxic chemicals in humans.
The failure of this drug screening initiative is part of what contributed to the pessimism with respect to chemotherapy and cancer that developed in the 1950s. Prior, in the 1940s, there had been a great deal of enthusiasm for chemotherapy based on the breakthroughs of Alfred Gilman and Louis Goodman, who tested the effects of nitrogen mustards on lymphoma based on observations that an accidental spill of sulfur mustards on troops from a bombed ship in Bari Harbor, Italy, in WWII had led to the observation that the bone marrow and lymph nodes were markedly depleted in men exposed to the mustard gas. Experiments in mice bearing a transplanted lymphoid tumor with nitrogen mustard resulted in marked regression, which led Goodman and Gilman ask Gustaf Lindskog, a thoracic surgeon, to administer nitrogen mustard to a patient with non–Hodgkin’s lymphoma and severe airway obstruction. The tumor regressed, and the same results were seen in several other patients treated this way. Publication of these results in 1946 led to widespread enthusiasm for the use of drugs related to the chemicals in nitrogen mustard, such as chlorambucil and cyclophosphamide, the latter of which is still commonly used for breast cancer and several other cancers today.
Here’s where the optimism turned sour:
The use of nitrogen mustard for lymphomas spread rapidly throughout the United States after the publication of the Lindskog article in 1946. If one reads the literature of the time, there was a real sense of excitement that perhaps drugs could cure patients with cancer ( 19). Unfortunately, remissions turned out to be brief and incomplete, and this realization then created an air of pessimism that pervaded the subsequent literature of the 1950s. A cadre of academic physicians, led by the famous hematologist William Dameshek, who having seen apparent success turn to failure could never again be persuaded that cancer was curable by drugs (20), became harsh critics of a national drug development program and the effort to prove that drugs could cure advanced cancers.
And it is here where many of the anti-chemotherapy quotes by reputable scientists and physicians originate, albeit often in exaggerated forms. For instance, one of the most famous of these statements is from a man named Hardin Jones, who is quoted as saying, “My studies have proved conclusively that untreated cancer victims actually live up to four times longer than treated individuals.” (Indeed, if you Google Hardin Jones’ name and this statement—or just his name—you will find this quote cited in many different contexts. Frequently articles quoting Jones on these issues will claim that he published these statistics in his article in Transactions, New York Academy of Science, series 2, v. 18, n.3, p.322. As our frequent commenter Peter Moran has pointed out, however, this particular study dates back to 1956 and says no such thing.
There’s no doubt, however, that Jones had a dim view of cancer treatments of his day, but he was not alone. Five or six decades ago, after the hope of the late 1940s that using alkylating agents would cure many cancers had been crushed and improvements in survival from cancer had been shown to be frustratingly elusive, there were a lot of cancer doctors who were despairing that cancer could ever be cured with chemotherapy. Interestingly, Jones used his data to build a statistical model proposing that “…the death rate for all kinds of cancer remains nearly fixed from the moment when cancer is identified…” That sounds a lot like lead time bias. Jones was, however, somewhat prescient in proposing that the biology of the tumor is arguably the prime determinant of survival, even with treatment. In any case, I tend to agree with Dr. Moran that Jones’ pessimistic view was a product of his times.
This pessimism continued into the 1960s. Indeed, one of the more interesting aspects of DeVita’s article is a series of anecdotes about how dimly the medical profession viewed chemotherapy in the 1960s and how skeptical most doctors were that any cancer would ever be cured with chemotherapy. At the time, there was no specialty known as medical oncology, and doctors who administered chemotherapy at hospitals were viewed as “underachievers, at best.” As DeVita describes, very respected physicians and chairs of departments viewed chemotherapists as the “lunatic fringe.” Louis K. Alpert, who had published one of the earliest reports using nitrogen mustards to treat lymphoma was routinely referred to by the house staff and the faculty as “Louis the Hawk and his poisons.” Here is more evidence of the low esteem with which doctors administering chemotherapy for cancer were viewed at the time:
At Yale, the first institution to test chemotherapy in humans in the modern era, the chemotherapist Paul Calabresi, a distinguished professor and founding father in the field, was forced to leave because he was involved in too much early testing of new anticancer drugs, an exercise as unpopular with the faculty and house staff at Yale as it was at Columbia.
At the Clinical Center of the NCI, where so many of the early breakthroughs with chemotherapy occurred, the well-known hematologist George Brecher, who read all the bone marrow slides of the leukemic patients, routinely referred to the Leukemia Service as the “butcher shop” at rounds.
And these are only the stories that can be told. It took plain old courage to be a chemotherapist in the 1960s and certainly the courage of the conviction that cancer would eventually succumb to drugs. Clearly, proof was necessary, and that proof would come in the form of the cure of patients with childhood acute leukemia and in adults with advanced Hodgkin’s disease.
It took the success of studies like the ones described in detail by DeVita to start to change the tide. For instance, new protocols for Hodgkin’s lymphoma increased the complete remission rate from near zero to 80%, with 60% of patients with advanced Hodgkin’s disease who attained a complete remission never relapsing. Follow-up is now well-beyond 40 years. By 1970, Hodgkin’s disease went from a death sentence to being viewed as largely curable with drugs, the first adult malignancy cured by chemotherapy. Add to this the amazing progress being made in childhood cancers at the time, and the tide was turning. Successes in hematological malignancies piled on successes, and the principle that some cancers could be cured with drugs became accepted. What amazes me is that this acceptance didn’t really take hold widely until the mid-1970s, which in the scheme of things is really not that long ago. It is also ironic to me that the attitude towards chemotherapy exhibited by believers in alternative medicine is very much akin to the attitude towards chemotherapy exhibited by mainstream science 50-60 years ago. The difference is that science has evolved; chemotherapy critics in the antiscience fringe have not.
Adjuvant chemotherapy
Hematological malignancies (such as leukemias and lymphomas) are much less common in adults than solid malignancies (e.g., breast, colon, lung, and other “solid” organ cancers). Many of these solid malignancies are treated primarily with surgery and have been for many decades. Breast and colon cancer are the most prominent (and among the most common) examples. From the 1970s on, the primary rise in the use of chemotherapy has been as adjuvant therapy; i.e., as therapy added to the curative therapy (surgery) to decrease the rate of recurrence and death. Ironically, using chemotherapy for adjuvant treatment met almost the same level of resistance as the use of chemotherapy to try to cure advanced hematological malignancies. In this, Bernie Fisher at the University of Pittsburgh was a pioneer, and DeVita tells us why:
The main problem was where to test these treatment regimens as adjuvants to surgery. Despite the excitement over the new chemotherapy data, most surgeons in the United States were still reluctant to participate in clinical trials testing its use postoperatively. The courageous Bernard Fisher was the first choice (Fig. 8). He and his group, the National Surgical Adjuvant Breast Project (NSABP), had done an early adjuvant study, sponsored by the CCNSC, testing the use of the alkylating agent thiotepa postoperatively to kill cancer cells dislodged at surgery (81). They were also in the process of challenging the status quo, questioning the need for radical mastectomy and postoperative radiotherapy, and were in position to test chemotherapy. The late Paul Carbone of NCI contacted Bernard Fisher, and he agreed to test L-PAM in a randomized controlled trial. But still no person or institution in the United States was prepared to test combination chemotherapy as an adjunct to surgery in breast cancer. Paul Carbone then contacted Gianni Bonadonna of the Istituto Nazionale Tumori, in Milan, Italy, about doing the study. Under its director, the surgical pioneer Umberto Veronesi, the Istituto was treating a large number of breast cancer patients and, like Fisher, was exploring the use of lesser operations than the radical mastectomy. Bonadonna came to the NIH Clinical Center to review the results of the CMF protocol, which had not yet been published and agreed along with Veronesi to conduct a randomized controlled trial of a slightly dose-reduced version of CMF versus no therapy. The U.S. NCI Chemotherapy program, under Zubrod, paid for the study through a contract with the Istituto Tumori. This contract also provided for costs of a permanent statistical center and was the beginning of long time collaboration between the two National Cancer Centers.
In other words, the National Cancer Institute had to look outside of the U.S. to find an investigator willing to do a trial of adjuvant chemotherapy with a regimen containing more than one drug. Both of these studies were positive and set off a flurry of studies trying to see if the addition of adjuvant chemotherapy could decrease recurrence and prolong survival after curative surgery for cancer. It was also around this time that Lawrence Einhorn developed a chemotherapy regimen that resulted in the cure rate of metastatic testicular cancer going from 10% to 60%. By 1981, Dr. Norman D. Nigro, a colorectal surgeon at my home institution, developed the protocol named after him to treat anal cancer in many cases without having to do an abdominoperineal resection (APR). This was considered a major advance, because an APR basically involves removing the rectum and anus, sewing the hole shut, and leaving the patient with a permanent colostomy.
Chemotherapy and breast cancer
There’s one study that I like to cite to people who claim that chemotherapy doesn’t work, and this post seems as good a place to do it as any. It’s a large meta-analysis from two years ago. Funded by Cancer Research UK, the British Heart Foundation and the UK Medical Research Council, this study was carried out by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) at the Clinical Trial Service Unit at the University of Oxford, United Kingdom and entitled “Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.”
It’s really quite an incredible effort to collate patient-level data for so many women in so many clinical trials. I sometimes say about meta-analyses the prototypical complaint about meta-analyses, namely that the quality of the output is critically dependent on the quality of the input. In other words, “garbage in, garbage out.” However, the inclusion criteria for the EBCTCG are actually pretty stringent. More importantly, the EBCTCG has access to unpublished data and patient-level information, as is explained here. The EBCTCG also goes to great lengths to try to include data from every randomized trial ever published, or an unbiased subset of them, in order to try to minimize selection bias that all-too-often results from too-rigid selection criteria used for meta-analyses. All in all, it’s an enormous effort.
Overall, this meta-analysis involved over 100,000 patients involved in 123 randomized trials over 40 years, and the authors made these comparisons: (1) taxane-based versus non-taxane-based regimens (data for 33 trials, begun in 1994-2003); (2) any anthracycline-based regimen versus standard or near-standard (cyclophosphamide/methotrexate/5-fluorouracil (CMF, 20 trials, begun in 1978-97); (3) higher versus lower anthracycline dosage (six trials, begun in 1985-94); and (4) polychemotherapy versus no adjuvant chemotherapy (64 trials, begun in 1973-96, including 22 of various anthracycline-based regimens and 12 of standard or near-standard CMF). Several meta-analyses were performed, which produced five main findings:
     1.  Standard CMF and standard 4AC (ACT without the “T,” which is an older chemotherapy regimen used before taxanes were developed) were roughly equivalent in efficacy. Both of them roughly halved two-year recurrence rates and resulted in a proportional decrease in recurrence over the next eight years by approximately one-third. Overall, breast cancer mortality rates were reduced proportionally by 20-25%.
     2.  Regimens with lower chemotherapy doses per cycle were less effective.
     3.  Regimens with a lot more chemotherapy than the old standard 4AC (but not so nasty that they required stem-cell rescue) were somewhat more effective. They further decreased breast cancer mortality by 15-20%. The most prominent of these regimens is 4AC plus four cycles of “T” (a taxane), which became the standard of care for node-positive breast cancer after taxanes were developed.
     4.  In all chemotherapy comparisons, the ten year overall mortality was reduced because there was not very much excess mortality due to causes other than breast cancer during the first year.
     5.  In all meta-analyses looking at taxane-based regimens or anthracycline-based regimens (doxorubicin is an anthracycline), the proportional reductions in early recurrence, any recurrence, and breast cancer mortality were more or less independent of age, nodal status, tumor size, or even estrogen receptor status.
The authors conclude:
While awaiting the results of these new trials, it appears that ER status, differentiation, and the other tumour characteristics available for the present meta-analyses had little effect on the proportional risk reductions with taxane-based or anthracycline-based regimens. The more effective of these regimens offer on average a one-third reduction in 10-year breast cancer mortality, roughly independently of the available characteristics. The absolute gain from a one-third breast cancer mortality reduction depends, however, on the absolute risks without chemotherapy (which, for ER-positive disease, are the risks remaining with appropriate endocrine therapy). Although nodal status and tumour diameter and differentiation are of little relevance to the proportional risk reductions produced by such chemotherapy (and by tamoxifen therapy), they can help in treatment decisions as they are strongly predictive of the absolute risk without chemotherapy, and hence of the absolute benefit that would be obtained by a one-third reduction in that risk.
The bottom line is that, contrary to what you will hear from cranks and alt-med supporters who believe in “alternative” cancer cures, in the case of early stage breast cancer, chemotherapy saves lives. In women with breast cancer, it decreases the risk of their dying from breast cancer by approximately one-third. This is nothing to sneeze at, as it means thousands upon thousands of women who would have died but did not, thanks to chemotherapy. This study simply represents yet another in a long line of studies, another strand in the web of evidence that support the efficacy of chemotherapy in prolonging the lives of women with breast cancer. It’s not perfect, and it has a lot of potential complications, but it works. This is but one example.
Indeed, as DeVita points out, besides its well-demonstrated role in treating hematological malignancies, chemotherapy now has a role in the primary treatment of advanced malignancies such as bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, nasopharyngeal cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer. It’s also used to prolong survival in the adjuvant setting for breast cancer, colorectal cancer, cervical cancer, gastric cancer, head and neck cancer, pancreas cancer, melanoma, non-small cell lung cancer, osteogenic sarcoma, and ovarian cancer. I must admit, though, I’m a bit surprised that other soft tissue sarcomas weren’t included on the list.
Chemotherapy and cancer
I’m no Pollyanna, as I’m sure regular readers realize. You just have to read my posts over the years about screening for cancer or how little better newer drugs seem to be than old drugs used to treat cancer to see that. I realize that chemotherapy is imperfect and doesn’t work well for a lot of cancers. Many of the drugs cause bad side effects, and, as I’ve explained before, in the adjuvant setting you have to treat a lot of patients to benefit relatively few. I also realize that chemotherapy is sometimes oversold. At the same time, I also know that now is the best time there has ever been for treating cancer with drugs. Targeted agents allow us to attack more precisely the molecular derangements driving cancer growth with lower toxicity. Molecular profiling is paving the way for precision medicine, in which someday (or so we hope) we will be able to target treatments to the specific abnormalities in a specific patient’s tumor. Certainly, I have no illusion of how difficult this is to accomplish, but I do believe that over time we will find ways to do it.
It’s helpful to look at the scope of advances over the last 100 years or so, as provided in these helpful diagrams in DeVita’s article:
As slow as it seems to those of us living it, cancer research has produced a lot of breakthroughs. Those who wonder why we haven’t cured “cancer” yet should read earlier posts I’ve written on the topic. Cancer is hard. Real hard. It is also hundreds of diseases, not some monolithic disease, just as chemotherapy is dozens of drugs and hundreds of drug combinations, not some monolithic mythical “chemotherapy.” It is not reasonable to expect that a span of a mere few decades or even a century is enough to cure all cancer. We have, however, brought the cure of several cancers within reach and do actually cure many cancers. Also, contrary to popular belief, the death rate from cancer is decreasing. In the US, it’s been decreasing for nearly the last 25 years, as shown in this graph from the most recent American Cancer Society statistics:
Note that this is happening even as the age-adjusted incidence of cancer is remaining steady or slightly increasing. Fewer and fewer people with cancer die of their disease. I realize that this is no consolation to anyone who has lost loved ones to the disease (as I have), but it does give hope for the future.
And, yes, promoters of alternative cancer cures can deny it all they like, but chemotherapy is indeed a major part of the reason for better outcomes and more hope in cancer. “Cut, poison, burn”? Well, yes. Unfortunately, that’s what works, including the “poison” part. Until we find something that works without as much morbidity, “cut, poison, burn” will have to do.
That reminds me. I really need to review the movie of the same title.

Does chemotherapy cause cancer to spread?
Earlier this month, a study was published in Science Translational Medicine that showed how chemotherapy before surgery can stimulate breast cancer invasiveness and invasion under certain circumstances. Not surprisingly, alternative cancer cure mavens everywhere are spinning the study as “proof” that chemotherapy has no benefit and causes only harm (and so you should buy their nostrums instead). Unsurprisingly, the actual results are far more nuanced. They do not demonstrate that chemotherapy is ineffective but rather point the way forward to improving chemotherapy regimens.
David Gorski on July 17, 2017
Link

Over the last week or two, you might have noticed a disturbance in the alternative medicine force. Unlike disturbances in the Force in Star Wars movies (which usually result from horrors like the obliteration of millions of lives on Alderaan), this was a joyous disturbance in the mystical nonexistent energy fields in which promoters of alternative medicine cancer cures and haters of chemotherapy and “conventional” cancer treatment (the two almost always go together) thought that a major study in a reputable journal had put yet another “final nail in the coffin” of chemotherapy. Or at least they could spin the study as an indication that chemotherapy is nothing more than an expensive toxic brew foisted on an unsuspecting public by the nefarious shadowy forces of Big Pharma in order to extract maximal resources from third party payers, which, to them, is almost as good. Of course, they do this with any study that suggests chemotherapy isn’t as effective as people would like, but this study seemed on the surface like powerful ammunition. It’s not. It’s an interesting preclinical study showing a mechanism by which chemotherapy given before surgery (neoadjuvant chemotherapy) might promote the spread of some cancers. Whether the findings are clinically important remains to be seen.
“Alternative cancer cure” advocates and salesmen rejoice
Although it’s an interesting study with somewhat of a cautionary note, it’s far less of a “black eye” to chemotherapy (as Jeffrey Jaxen put it over at that repository of science misinterpreted to promote alternative or “natural” medicine, Sayer Ji‘s GreenMedInfo), than advertised. Meanwhile, Chris Wark of “Chris Beat Cancer” (hint: surgery, not the quackery he pursued, took care of his colon cancer) practically exults that “chemo may spread breast cancer and trigger more aggressive tumors.” Of course, the real gloating comes from—who else?—Mike Adams, who proclaims the study a “Medical BOMBSHELL” showing that chemotherapy has been found to spread cancer. He also can’t help but throw in the lies he’s been peddling about me:
The cancer industry is a corrupt, criminally-operated branch of modern medicine, run by felony criminals and hucksters like Dr. Farid Fata who is currently serving prison time for falsely diagnosing people with cancer so he could profit from chemotherapy treatments they didn’t need. His colleague, Dr. David Gorski of the Karmanos Cancer Center in Detroit, is not yet in prison but has been reported to the FBI for investigation. He remains one of the sickest and most sociopathic abusers of women in the history of cancer surgery, earning him the nickname “Gorski the Nipple Ripper.” He has also been accused of promoting cancer-causing medical interventions, possibly as a means to further his own profit interests at the expense of the health of innocent women. Dr. David Gorski has also been linked to “skeptics” kingpin James Randi, who was caught on tape soliciting sex acts from a young male.
Yawn. I guess I can expect another paragraph like this inserted into pretty much any rant against chemotherapy that Adams writes. It’s my badge of honor, I guess. Oh, well. Word to Mikey: I used to be upset by your smear campaign against me—about a year ago. These days, however, I’m laughing at you, not with you, because your lies are so transparently over the top that no one but your hardcore followers would even have a chance of believing them. I was never a “colleague” of Dr. Fata, who never worked at my cancer center, and that “nipple ripper” name came from Patrick “Tim” Bolen, a man who used to be cancer quack Hulda Clark’s most vigorous defender. I also note that it was Adams himself who claimed to have reported me to the FBI (something conveniently not mentioned). That was well over a year ago. Neither I nor anyone I know has been contacted by the FBI or my state attorney general (where Adams also claims to have filed a complaint). I suspect his “criminal complaints,” if they were ever filed at all, ended up in the “crank file,” where they belong.
Sorry for that diversion. It seemed…necessary. Let’s get back to what less insane-sounding (but equally mistaken) alternative cancer cure advocates are saying, after which then I’ll delve into the study itself and show you why, although it is a reason for some concern, it’s not evidence that chemotherapy doesn’t work, and, in fact, if validated by further studies, points the way to overcoming what might be a significant problem in cancer chemotherapy. In discussing this study, Jaxen, for instance, lists all the usual suspects of studies trotted out by the anti-chemotherapy brigade every time they feel a rant coming on. For example, he invokes what I like to call the “2% gambit,” citing, as all who use this gambit do, a single Australian study from around 16 years ago that left out a lot of chemotherapy-sensitive tumors and willfully confused adjuvant chemotherapy with chemotherapy delivered as primary treatment for curative intent. Basically, he sees the study as “more evidence” of this:
By now, many are beginning to understand that one of the problems with chemotherapy is that it doesn’t address the underlying cause(s) of cancer. Chemotherapy originated from an idea and consciousness that was far from idealistic. The whole generation of chemotherapeutic drugs that are being used today, and there are over one hundred of them, developed from poisonous nerve gas created for warfare. As reported in 2012 by Green Med Info, cancer is the second leading cause of death in the developed world, and yet much of the medical and research communities are still in the dark ages when it comes to treating and understanding it. However, in the age of information, great strides are being made by doctors and researchers who are going against the grain of the failed convention ‘wisdom’ in cancer treatment. In addition, individuals are beginning to take responsibility by educating themselves.
Of course, for all their claims of “addressing the underlying cause” of cancer, alternative medicine cancer cure mavens always fail to show how their favored nostrums do any better on that score, much less that they are actually more effective than conventional treatments—or even that they’re effective at all.
Chris Wark chimes in with the same propaganda:
As I’ve said many times, chemotherapy is often only a short-term solution to a long-term problem.
The new study presents evidence that chemotherapy can switch on a repair mechanism in the body which ultimately allows tumours to grow back stronger. It also increases the number of ‘doorways’ on blood vessels which allow cancer to spread throughout the body.
At least Wark admits that chemotherapy can sometimes be at least a “short term solution” to cancer. Again, nothing Wark discusses shows how his preferred methods do anything to “address the underlying cause” of the long term problem of cancer. We know that diet and certain environmental exposures can modulate cancer risk for certain cancers, but once the cancer is already established it’s too late for that.
So now that we’ve seen ideology in action, let’s look at science in action.
How chemotherapy is used to treat cancer
Before I get to the study, in order to help readers not familiar with how chemotherapy is used to treat cancer, I feel obligated to provide a brief primer. There are four main ways that chemotherapy is used to treat cancer:
Curative: Chemotherapy can be the primary (and sometimes only) treatment for cancer. This is common in hematological malignancies, like leukemia and lymphomas, where it’s usually some combination of chemotherapy ± radiation therapy that is curative. Surgery is rarely indicated. The intent here is to use chemotherapy to eliminate cancer from the body.
Adjuvant chemotherapy: After definitive surgical treatment of the primary cancer, chemotherapy is administered to decrease the chance of recurrence. This is a very common use of chemotherapy, particularly in breast cancer and colorectal cancer. Indeed, the use of adjuvant chemotherapy for breast cancer since the 1980s, among other factors, has contributed to a decline in breast cancer mortality of around 30% since 1990.
Neoadjuvant chemotherapy: Neoadjuvant chemotherapy is administered before surgery. In general, there are two main reasons to administer neoadjuvant chemotherapy: (1) to shrink a tumor to make a non-operable tumor (e.g., one stuck to major structures) operable for cure; and (2) to make organ-sparing surgery possible. This latter use is common in breast cancer in order to shrink a tumor so that a mastectomy is not required to remove it and breast-conserving surgery is possible. Moreover, in breast cancer, it is known from numerous studies that neoadjuvant chemotherapy results in equivalent results as adjuvant chemotherapy. Overall survival and disease-free survival and time to locoreginal recurrence are the same, whether chemotherapy is administered before or after surgery. The same idea is used in the surgical treatment of low rectal cancer requiring an abdominoperineal resection (APR) to remove. An APR involves removing the anal sphincter and leaving the patient with a permanent colostomy. With neoadjuvant chemotherapy, it is often possible to shrink the tumor enough to make sphincter-sparing surgery possible, something very desirable to patients, the vast majority of whom understandably recoil at the idea of requiring a permanent colostomy.
Palliative chemotherapy: In stage IV disease, chemotherapy is often used to palliate symptoms from growing tumors and can prolong life, although not result in long term survival. This is also a common use of chemotherapy.
The study that the likes of Mike Adams and Chris Wark are crowing over examines neoadjuvant chemotherapy. That’s an important point. It does not apply to other uses of chemotherapy. Think of it this way. Adjuvant chemotherapy is quite different from neoadjuvant chemotherapy in one way. The primary tumor is not present when adjuvant chemotherapy is administered. All that’s left are microscopic tumor deposits that could turn into metastases. Those are what adjuvant chemotherapy targets, because chemotherapy is much better at wiping out microscopic tumor deposits than macroscopic tumors. Contrast that to neoadjuvant chemotherapy, which targets both those same microscopic tumor deposits and also targets the main tumor, which is usually large. (Remember the reasons why neoadjuvant chemotherapy is administered.)
Comparatively speaking, there are many orders of magnitude more cancer cells in the neoadjuvant setting than in the adjuvant setting. If spread of tumor due to neoadjuvant chemotherapy were a major factor clinically, we’d expect survival using neoadjuvant chemotherapy before surgery to be worse than using it after surgery. That we don’t see that is a good reason to be at least a little skeptical of how clinically relevant the results of this study will turn out to be. Indeed, I’ve never ceased to be amazed that, in breast cancer and most cancers for which neoadjuvant chemotherapy is used, the survival benefit provided by chemotherapy (adjusted for tumor stage and other relevant characteristics, of course) is the same regardless of whether the chemotherapy is administered before or after surgery. Even better, neoadjuvant chemotherapy can give an indication of how “nasty” (i.e., resistant to chemotherapy) a tumor is, based on how much (or how little) it shrinks in response to chemotherapy. Moreover, pathologic complete response (that is, a response so dramatic that the tumor not only disappears clinically but the pathologist can’t find any viable tumor cells in the resected specimen) is an excellent prognostic factor predicting favorable outcomes.
Keep these things in mind as I discuss the study.
Does neoadjuvant chemotherapy “spread” cancer?
So let’s take a look at the study itself (Karagiannis et al, “Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism“), which was published in a Science journal, Science Translational Medicine by a group at the Albert Einstein College of Medicine. Reading the abstract, I quickly realized—surprise! surprise!—that the findings were considerably more nuanced and interesting than Adams, Wark, and Jaxen presented. I also quickly realized that the purpose of the study was to identify potential problems with how neoadjuvant works in order to find strategies to make it work better. Of course, doing research to make existing therapies better is complex, and the authors noted that increasing tumor cell dissemination could “diminish the clinical benefit” of neoadjuvant chemotherapy. Note the distinction. It is known—sorry, couldn’t resist a Game of Thrones reference given that as I write this the season seven premiere is only a few hours away—from numerous studies that neoadjuvant chemotherapy produces a survival advantage for breast cancer patients in addition to the advantages it produces in making inoperable tumors operable or making it possible for women who would otherwise lose their breast to preserve it. Tumor cell dissemination as a result of chemotherapy reduces, not eliminates, that benefit, and it certainly does not “make cancer spread” in such a way that neoadjuvant chemotherapy is worse than no chemotherapy. Yet that’s what the cancer quacks strongly imply.
So what is the mechanism being examined here? Previous work has demonstrated one mechanism by which breast cancer cells can gain access to blood vessels and spread. In this mechanism, breast cancer tumor cell spread occurs at microscopic structures dubbed tumor microenvironment of metastasis (TMEM). Each TMEM is composed of three cell types, all in direct physical contact with each other: a tumor cell making a protein that regulates a structural protein (actin) known as Mammalian-enabled (MENA), a perivascular macrophage (an immune cell near the blood vessel), and an endothelial cell (the cell type that lines blood vessels). Vascular permeability due to TMEM has been shown to be localized and mediated by vascular endothelial growth factor–A (VEGF-A) release from the TMEM-bound macrophages, which express the angiopoietin receptor TIE2. Now, I used to do a lot of work with VEGF-A back in the 1990s, when I studied tumor angiogenesis, the process by which tumors interact with their environment to stimulate the ingrowth of new blood vessels. Basically, the macrophages associated with TMEM secrete this factor, which increases vascular permeability, making “holes” through which tumor cells can gain entry to the blood vessel and spread via blood. However, only tumor cells expressing high levels of MENA can take advantage of this. (Note that there are different isoforms—variants—of Mena that are pro-invasion and anti-invasion; when we refer to MENA here, we’re mostly referring to the MENAINV.) Tumors with a high TMEM “score” in animal models have a higher likelihood of metastasis compared to tumors with low TMEM scores.
The authors hypothesized that preoperative chemotherapy could increase the density and activity of TMEM sites in breast cancer, as well as an increase in invasion-promoting MENA isoforms, and thereby increase the number of tumor cells spreading. They based their hypothesis on the observation that one chemotherapy agent, paclitaxel (a.k.a. Taxol), induces an influx of macrophages into the primary tumor and that macrophages are required for TMEM assembly. The hypothesis was tested using a transgenic mammary tumor model in which mouse mammary tumor virus–polyoma middle T antigen was introduced to produce a mouse strain that spontaneously develops mammary tumors at a high rate, patient-derived xenografts (PDXs, which are tumors derived from patients that can grow in mice with defective immune systems), and pre- and post-neoadjuvant breast cancer tissue samples from human patients. There are also all sorts of pretty images from intravital imaging (IVI, which allows imaging of living animals at a cellular level) that a researcher needs if he wants to publish in a journal like Cell, Science, or Science Translational Medicine. I don’t mean that so much as a knock on the authors given that the paper is actually good, but rather as a sarcastic aside at what it takes these days to be published in top-tier journals. Besides, several of the authors have an extensive background in imaging research; so I can’t really fault them for using it. It is, after all, so much cooler to look at these complexes in living mice than to do what they had to do in humans and test fixed tissue from biopsies and surgical specimens.
The authors addressed their hypothesis using multiple tumor models, including the MMTV-PyMT mice, another mouse strain bearing tumors transplanted from the MMTV-PyMT mice, and two PDX models, (HT17 and HT33, for anyone who’s interested). Animals were treated with various chemotherapeutics and compared to controls, with the tumors imaged, levels of various RNAs and proteins compared, and tumors assessed. Key findings were as follows:
    • Paclitaxel at the dose used delayed tumor growth (as expected) but increased TMEM assembly by as much as three-fold.
    • Paclitaxel increased the infiltration of perivascular macrophages in the primary breast cancer microenvironment.
    • Paclitaxel induced TMEM-dependent vascular permeability in breast tumors.
    • Paclitaxel increased metastatic dissemination of breast tumors (roughly a two-fold difference, although the result wasn’t statistically significant for one tumor model—Figure 3I). This was confirmed by examining the lungs of the mice, where investigators found an increase in both microscopic metastases in the paclitaxel-treated mice and single-cell metastases (two-fold increase).
    • Paclitaxel promotes the expression of invasive isoforms of Mena in breast tumors, and dissemination required Mena.
    • Levels of circulating tumor cells in the bloodstream increased in response to chemotherapy.
    • Treating mice with doxorubicin and cyclophosphamide (two other drugs commonly used in standard-of-care breast cancer treatment) produced similar changes in the primary tumors and their surrounding microenvironment.
Finally, when the investigators tested human breast cancer tissue before and after neoadjuvant chemotherapy with paclitaxel followed by combined doxorubicin/cyclophosphamide, they found this:
Areas staining positive for MENA also increased. Pretty striking, I’ll agree. However, remember what I said above. Neoadjuvant chemotherapy is still quite effective.
More importantly, consider this final result. In the same mouse models, blocking the TIE2 receptor with rebastinib decreased the number of perivascular macrophages and blocked the increase in circulating tumor cells to the level of controls without affecting TMEM assembly. This means that TIE2 inhibition blocks the function of TMEM sites but not their assembly. Fortunately, in these mouse models, that was enough. More importantly, it also suggests a strategy for making neoadjuvant chemotherapy work better in patients, as illustrated here:
Note that there are multiple points that can be attacked to overcome the stimulation of more invasiveness by chemotherapy.
Putting it all together
If there’s one thing that distinguishes science-based medicine (SBM) from the sort of medicine advocated by those promoting alternative cancer cures, it’s that SBM is always trying to make things better. When it is observed that, for instance, neoadjuvant chemotherapy might not be having as strong an effect on tumors as it could, scientists look for the reason why. If that reason why happens to be that some forms of chemotherapy might increase the ability of cells from the primary tumor to spread, decreasing the benefit of neoadjuvant chemotherapy, they look for the molecular and cellular mechanisms responsible for that problem and then try to find ways to exploit those mechanisms to overcome the problem. That’s exactly what Karagiannis et al did. So when quack-loving entrepreneurs like Mike Adams, Chris Wark, and Jeffrey Jaxen tell you this study “proves” that chemotherapy does more harm than good, they’re either ignorant or intentionally misrepresenting the results, because the study doesn’t show that at all.
It’s not just the quacks, though. Articles in mainstream news sources reported this study with headlines like “Chemotherapy could cause cancer to SPREAD and grow back even more aggressive, new study claims.” OK, that’s The Daily Mail, which is to science as The Weekly World News is to, well, news. But other stories had headlines like “Chemotherapy could spread cancer cells and lead to more advanced tumours, says study” and “Chemotherapy before breast cancer surgery might fuel metastasis.” Far better is a headline like “Neoadjuvant Chemotherapy Treatment May Increase Risk Of Breast Cancer Spreading In Some Patients“, which more accurately assesses the results of the study. In fairness, I know that editors, not reporters, determine headlines and most of the mainstream articles I mentioned did point out some of the caveats that I discussed, but the impression most people take away comes from the headline, and that impression was only marginally less scary than the headlines coming from Sayer Ji’s and Mike Adams’ websites.
More importantly, if you’re a woman considering neoadjuvant chemotherapy to treat breast cancer, don’t let the spin on this study frighten you out of it. The benefits of neoadjuvant chemotherapy include not only improved survival but the possibility of breast conserving surgery, and, as I mentioned before, there is no detectable difference in overall survival whether chemotherapy is administered before or after surgery.
As for the future, research like this could lead the way to better neoadjuvant chemotherapy. For example, a woman undergoing neoadjuvant chemotherapy might some day have biopsies done part way through the chemotherapy. If her tumor’s TMEM score has increased markedly, then I could envision the addition of a TIE2 inhibitor or other inhibitor of TMEM function being added to her chemotherapy to block the increased level of circulating tumor cells and reverse whatever increased risk of metastasis that might be attributable to neoadjuvant chemotherapy in order to produce better outcomes. That’s how SBM improves, in contrast to alternative medicine, in which no therapies are abandoned when demonstrated to be ineffective and/or dangerous and no therapies are ever improved upon.

Meet the new drugs, same as the old drugs?
David Gorski on July 23, 2012
Link
“Targeted therapy.” It’s the holy grail of cancer research these days. If you listen to its most vocal proponents, it’s the path towards “personalized medicine” that improves survival with much lower toxicity. With the advent of the revolution in genomics that has transformed cancer research over the last decade, including the petabytes of sequence and gene expression data that pour out of universities and research institutes, the promise of one day being able to a patient’s tumor, determining the specific derangements in genome and gene expression that drive its uncontrolled proliferation, and finding drugs to target these abnormalities seems more tantalizingly close than ever. Indeed, it seems so close that even dubious practitioners, such as Stanislaw Burzynski, have jumped on the bandwagon, co-opting the terms used by real oncologists and real cancer researchers to sell “personalized gene-targeted cancer therapy,” which in their hands are really no more than a parody of efforts to synthesize the enormous quantity of genomic data each patient’s tumor possesses and figure out how best to take advantage of it, a “personalized genomic therapy for dummies,” if you will.
That’s not to say that there aren’t roadblocks to realizing this vision. The problems to be overcome are substantial, and I’ve discussed them multiple times before. For example, just a couple of weeks ago I discussed an example of just what it takes to apply these new genomic techniques to an individual patient. The resources required are staggering, and, more problematic, there often aren’t any single “magic bullet” molecular pathways identified that can be targeted with existing drugs. The case I discussed was a fortunate man indeed in that such a pathway was identified, but most tumors are driven by many derangements in growth control, metabolism, migration, and the other hallmarks of malignancy described by Robert Weinberg. Worse, in many cases we don’t even have drugs that can attack many of the abnormalities that drive cancer progression. Then there’s the issue of tumor heterogeneity, which comes about because cancer is as good example of a disease as I can think of in which evolution due to natural selection results in incredible differences in the cancer cells in one part of the tumor compared to other parts of the tumor or in the tumor metastases. A “targeted” therapy that targets the genetic abnormalities in one part of the cancer might well fail to target the genetic abnormalities driving another part of the tumor.
These, and many other reasons, are why we haven’t “cured cancer” yet.
Of course, the main promise of the new targeted therapies, besides more precisely targeting the actual genetic abnormalities that drive the growth of specific tumors, is decreased toxicity. Whereas cytotoxic chemotherapy is like a blunderbuss that pummels and poisons cells, both normal and cancerous (it just poisons cancer cells more, which is why it works), “targeted” agents are frequently portrayed as “smart bombs” that attack only the cancer cells and produce little, if any, collateral damage. But is that true? If a new study just published online in the Journal of Clinical Oncology by a group at the Princess Margaret Hospital and University in Toronto, the answer is “probably not.” The study’s title pretty much sums up the findings: The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs. However, as you will see, the way the results of the study (Niraula et al) are being reported are not exactly in line with what the study found. In other words, this study finds something that seems unexpected, part of which is a bit unexpected, most of which is not.
A bit of background is in order, and the introduction of the paper is a good place to start:
Although virtually all new drugs are tested in early-phase clinical trials designed to evaluate toxicity and tolerance, these trials are small and can detect only common toxicities. Most large RCTs are primarily not designed to detect differences in quality of life or toxicity of treatment between the study arms and are usually inadequately powered to do so. Furthermore, some anticancer drugs are approved on the basis of smaller, nonrandomized, unblinded clinical trials5 in which detection of toxicity can be severely impaired. Rare but potentially serious toxicities may not be detected in RCTs owing to a selection of patients with high performance status and minimal comorbidity or because of relatively short follow-up. The quality of reporting toxicity in RCTs has been criticized following evidence that some toxicities may be detected but inadequately reported.3,6 Increased treatment-related mortality associatedwith bevacizumab,7 increased cardiovascular morbidity of aromatase inhibitors,8,9 and increased risk of cardiopulmonary arrest with cetuximab10 were all either undetected or unreported at the time of drug approval but were described postmarketing. Therefore, efforts to monitor for toxicities after completing pivotal phase III RCTs are essential.11 The US Food and Drug Administration has encouraged a systematic approach to the collection and reporting of toxicity.12 Until such measures are implemented, there will continue to be concerns about failure of detection and reporting of serious and fatal toxicities.
In essence, the approval process for cancer drugs suffer from the same limitations as the approval process for all drugs does. The phase III studies used to support approval, although large, are not large enough to identify uncommon complications and toxicities or to do a fine analysis of differences in quality of life. Unfortunately, these sorts of issues are often not identified until approved drugs go into wide usage. Post marketing surveillance studies are useful for this purpose, but it’s a bit hit or miss whether such studies are done. Because anticancer agents, even targeted therapies, are directed at critical signaling pathways that control cell replication, death, mobility, and other key processes common in all cells, even targeted therapies are likely to produce at least some toxicity. Basically, all drug approval is a delicate balancing act between doing enough studies with enough patients to ensure that the drug tested is safe and effective versus cost and the time it takes to do the necessary studies.
What the authors hypothesized is that the experimental arms of studies used to support the approval of new agents would be associated with a higher rate of significant toxicity. The specific toxicities studied included treatment-related deaths, any toxicity severe enough that treatment had to be halted, and grade 3 and 4 adverse events (AEs). Grade 3 AEs include “symptoms causing inability to perform usual social and functional activities,” while grade 4 AEs are potentially life-threatening and result in “symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death.” To test their hypothesis, the authors identified 38 RCTs used to support approval of a drug for a cancer indication between January 2000 and December 2010, specifically the phase III randomized clinical trials used to support FDA approval of these drugs. A meta-analysis was performed, and correlations were made between the odds ratios for the three primary endpoints (treatment-related deaths, AEs resulting in treatment discontinuation, and grade 3/4 AEs) associated with the new drug and hazard ratios for overall survival (OS) and progression-free survival (PFS) associated with these drugs.
What the authors found can be boiled down fairly easily. Compared with control groups, the odds ratio (OR) for treatment-associated toxic deaths was elevated (OR, 1.40; 95% CI, 1.15 to 1.70; P peripheral neuropathy is a common complication of taxanes, so much so that many women I’ve operated on who underwent such therapy complain about numbness in their fingers, and one of the main drugs included in the meta-analysis was docetaxel (trade name Taxotere); so I’m not terribly surprised that this toxicity would come to the fore.
There are a number of other issues that were brought up with respect to this trial as well. The results I’ve just described were the overall results. The authors had several pre-planned subgroup analyses, and the results were a mixture of the aforementioned surprising and unsurprising results. The first surprising result is that the authors compared ” targeted drugs directed against a specific molecular target (specifically, the target population to be treated was selected by presence of a biomarker) versus drugs that are less specific (unselected target population, not based on presence of a biomarker). In this classification, docetaxel would be less specific because it is a general microtubule inhibitor that interferes with cell division. Its use is thus not chosen on the basis of an existing biomarker. In contrast, drugs like Tamoxifen or aromatase inhibitors would be considered “targeted” because they target estrogen signaling and are therefore only used in women whose cancers make the estrogen receptor. Similarly Herceptin would be considered a targeted agent because it targets HER2 and is only used in women whose cancers make this particular oncogene protein product.
The findings were a bit unexpected in that, targeted therapies had a higher OR for the three end points than the “less targeted” agents. However, I have a bit of a problem with this. Here’s a table describing the OR of the various endpoints for these two groups, with the 95% confidence intervals (CIs) in parentheses below each OR:
Group	Toxic death	Treatment discontinuation	Grade 3/4 AEs
Specific targeted agents	1.54
(0.93 to 2.55)	1.00
(0.76 to 1.32)	2.20
(1.69 to 2.85)
Less specific agents	1.24
(0.96 to 1.60)	1.40
(1.22 to 1.60)	1.40
(1.18 to 1.66)
Notice that, for the specific targeted agents, the ORs are not statistically significantly different than 1.0 for toxic deaths and treatment discontinuation, but for the less specific agents, the ORs are statistically significantly greater than 1.0 for two out of the three endpoints. So, while it’s true that the risk of grade 3/4 AEs is higher for the targeted agents, the ORs for everything else are not. Personally, I’d call this a wash, or even potentially an indication that the less targeted therapies produce more AEs, as one would expect.
The next thing that the authors did that seemed to get lost in the news reports discussing this study. For instance:
The study showed the newer cancer drugs caused significantly more side effects, and more treatment-related deaths, than their older counterparts. “You’ve got to consider both efficacy and toxicity in the picture,” said Susan Ellenberg, who has studied drug side effects at the University of Pennsylvania’s Perelman School of Medicine in Philadelphia.
She said the analysis wasn’t so surprising, and isn’t “a big alarm.”
While it is correct that this isn’t a “big alarm,” reporting this study in a blanket fashion as showing these newer drugs as causing significantly more side effects is simplifying the results of this study way too much. The reason, I would posit, comes from another pre-planned subgroup analysis that the authors did:
Agents were classified into four subgroups: targeted agent alone versus placebo or best supportive care (subgroup A); targeted agent alone versus nontargeted systemic anticancer therapy (subgroup B); targeted agent combined with nontargeted systemic anticancer therapy versus nontargeted systemic anticancer therapy alone (subgroup C); and chemotherapeutic agents (subgroup D). We compared the rates of treatment-related death, treatment discontinuation, and grade 3/4 AEs in each of these subgroups. In a separate analysis, we pooled the odds of hematologic and nonhematologic toxicities in each of the subgroups.
Overall, the finding of this subgroup analysis for the three endpoints of the study was described in the discussion thusly by the authors:
Our analysis shows that most newly approved anticancer drugs are associated with increased odds of toxic death, treatment discontinuation, and severe AEs compared with the standard treatment received by controls. There was an overall increase in the odds of toxic death, treatment discontinuation, and grade 3/4 AEs with the use of new agents versus the control groups except when targeted agents alone were compared with chemotherapy in the control arm. When individual toxicities were evaluated independently, the odds were increased to a greater extent for nonhematologic than for hematologic toxicities with the use of experimental agents compared with the controls.
In other words, when these new agents go head-to-head with existing cancer therapies, the OR for serious AEs is not elevated in the experimental group, while in groups for which the new agent was either tested versus placebo or best supportive care or combined with nontargeted anticancer therapies or with cancer chemotherapy the addition of the new drugs increased the chance of significant toxicity. This is about as expected a result as I can think of. Of course a new agent is likely to produce more toxicity than placebo; that is, if it’s an active drug. Of course adding a new agent to existing agents, be they traditional chemotherapy or other nontargeted agents will increase toxicity! It’s a general principle that an active drug will be more toxic than placebo and that adding another drug to an existing mix of drugs is likely to produce more toxicity! In fact, I’d be surprised if the investigators didn’t find that.
That‘s the message that’s being lost in how this particular study is being reported. Now don’t get me wrong here. This study, admittedly, is disappointing. However, it’s disappointing not because it shows that the newer drugs are so much “more toxic,” but rather because it suggests that, contrary to the hope and the hype, the newer drugs are probably not less toxic than existing drugs. Actually, the study doesn’t exactly show that. The numbers of studies looking at head-to-head comparisons of new drugs with established treatment regimens was too small. It does, however, strongly suggest that newer agents at the very least are not that much less toxic than existing drugs and might be more. It also confirms the long-known dictum in pharmacology that the more drugs you give at the same time the higher the chance of interactions and toxicity. Newer, “targeted” drugs are not immune to that basic principle of pharmacology.
Another finding that seems surprising on the surface but really isn’t is that the observed toxicity of newly approved drugs did not correlate with how much they were able to increase OS or PFS. There is a misconception common even among doctors that the price we pay for more effective anticancer drugs is more toxicity, but that’s not necessarily true, and this study is simply more evidence to that effect. Another implication of this observation is simply to reinforce the point that we have to weigh toxicities very carefully versus incremental improvements in OS and PFS that result from adding new drugs to our cancer treatment regimens. There often comes a point where patients judge that the additional toxicity is not worth it for the amount of potential benefit that such drugs provide. In any case, it should not be surprising that toxicity and efficacy are largely independent properties of such drugs. As the authors themselves point out, efficacy is determined by the sensistivity of tumor cells and their microenvironment to the drug, while toxicity is more dependent on drug metabolism and clearance, as well as comorbidities, organ function, and concurrent medications, among other things.
What needs to be remembered about the new generation of more targeted therapies is that, unless they are used in patients whose tumors have the intended molecular target and are thus likely to be sensitive to the medication, the chances of benefit decline while the chances of toxicity increase. That is why, for instance, we do not give Herceptin to patients whose tumors do not make HER2 and do not use Tamoxifen or aromatase inhibitors in patients whose breast cancer is ER(-). For us to realize the maximum benefit at the lowest cost in terms of toxicity from these new medications, in addition to biomarkers that predict response (such as the aforementioned ER and HER2 markers) but biomarkers that also predict toxicity.
Finally, it’s important to note that, as incredible and copious as it is, all this genomic data doesn’t help us that much—yet. The reason is that we don’t yet know what to do with this “firehose” of a data stream, how to apply the data contained therein to guiding patient care in order to cure more patients and prolong the survival more of those who cannot be cured. I actually believe that one day we will have the tools and knowledge to do that, such that I envision a day when we will use tumor biopsies and blood to construct comprehensive genomic, transcriptomic, and proteomic profiles of individual patient tumors and use them to target the molecular derangements that drive them. However, I am under no illusion that reaching that day will be easy, cheap, or without other cost. Studies like Niraula et al keep us humble.

Cancer care in the U.S. versus Europe: Is more necessarily better?
David Gorski on April 16, 2012
Link
The U.S. is widely known to have the highest health care expenditures per capita in the world, and not just by a little, but by a lot. I’m not going to go into the reasons for this so much, other than to point out that how to rein in these costs has long been a flashpoint for debate. Indeed, most of the resistance to the Patient Protection and Affordable Care Act (PPACA), otherwise known in popular parlance as “Obamacare,” has been fueled by two things: (1) resistance to the mandate that everyone has to buy health insurance, and (2) the parts of the law designed to control the rise in health care costs. This later aspect of the PPACA has inspired cries of “Rationing!” and “Death panels!” Whenever science-based recommendations are made that suggest ways to decrease costs by reevaluating screening tests or decreasing various tests and interventions in situations where their use is not supported by scientific and clinical evidence, whether by the government or professional societies, you can count on it not being long before these cries go up, often from doctors themselves.
My perspective on this issue is that we already “ration” care. It’s just that government-controlled single payer plans and hybrid private-public universal health care plans use different criteria to ration care than our current system does. In the case of government-run health care systems, what will and will not be reimbursed is generally chosen based on evidence, politics, and cost, while in a system like the U.S. system what will and will not be reimbursed tends to be decided by insurance companies based on evidence leavened heavily with business considerations that involve appealing to the largest number of employers (who, let’s face it, are the primary customers of health insurance companies, not individuals insured by their health insurance plans). So what the debate is really about is, when boiled down to its essence, how to ration care and by how much, not whether care will be rationed. Ideally, how funding allocations are decided would be based on the best scientific evidence in a transparent fashion.
The study I’m about to discuss is anything but the best scientific evidence.
Last week, I noticed articles and posts on blogs I follow about a study released in the April 2012 issue of Health Affairs that looked at cancer outcomes in the U.S. compared to cancer care in Europe and announced American Cancer Patients Live Longer Than Those in Europe; Higher-Priced Cancer Treatments in US Offer Better Survival:
The United States spends more on cancer care than European countries, but a new study published in Health Affairs suggests that investment also generates a greater “value” for US patients, who typically live nearly two years longer than their European counterparts.
Tomas Philipson, the Daniel Levin Chair in Public Policy at the University of Chicago, and his coauthors found that the cost of cancer treatment in the United States was higher than such care in ten European countries from 1983 to 1999. However, they also found that for most cancer types investigated, US cancer patients lived longer than their European counterparts. Cancer patients diagnosed during 1995-99, on average, lived 11.1 years after diagnosis in the United States, compared to just 9.3 years from diagnosis in Europe.
As Steve Novella put it, a single study doesn’t necessarily mean anything. More importantly, this is a classic example of a study whose conclusions do not follow from the evidence and the methods. So let’s dig in, shall we? We’ll start by taking a look at the actual study itself, which, unfortunately, is behind a paywall; so I’ll try to cite as much of it as I think relevant. The article is by a group led by Tomas Philipson, the chair in public policy at the University of Chicago and is entitled An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is ‘Worth It’ In The Case Of Cancer.
Here’s the abstract:
The United States spends more on health care than other developed countries, but some argue that US patients do not derive sufficient benefit from this extra spending. We studied whether higher US cancer care costs, compared with those of ten European countries, were “worth it” by looking at the survival differences for cancer patients in these countries compared to the relative costs of cancer care. We found that US cancer patients experienced greater survival gains than their European counterparts; even after considering higher US costs, this investment generated $598 billion of additional value for US patients who were diagnosed with cancer between 1983 and 1999. The value of that additional survival gain was highest for prostate cancer patients ($627 billion) and breast cancer patients ($173 billion). These findings do not appear to have been driven solely by earlier diagnosis. Our study suggests that the higher-cost US system of cancer care delivery may be worth it, although further research is required to determine what specific tools or treatments are driving improved cancer survival in the United States.
Before I discuss the article, I’m going to pause here for a moment to ask you, our readers, whether you can figure out just from this abstract what the fatal flaw of this paper is most likely to be. It should be mind-numbingly obvious to longtime readers who’ve read some of my previous posts on cancer screening, and, in fact, the authors try to preemptively address this criticism. They fail, but they do mention it.
Now, if I were to tell you that most of the difference in survival between U.S. and European cancer patients reported in the study was driven by breast and prostate cancer, do you know what I’m trying to hint at? Sadly, health bloggers who should know better didn’t pick up on this flaw. Not surprisingly, this study’s findings are being touted in some circles as evidence that the U.S. does better treating cancer and, by extension, that our current system is better than any sort of government-run system.
There’s just one problem with this study. That problem is embodied in three words: Lead time bias. Remember lead time bias? I’ve written about it enough times before, particularly in the context of discussing overdiagnosis and overtreatment. Basically, using the time from diagnosis to the time of death is not the correct way to analyze data like this. To explain why, a picture is worth a thousand words (not that it’ll stop me from writing a thousand words, as is my wont, because to me a picture plus a thousand words is equal to two thousand words). So here’s a picture I’ve used before to illustrate lead time bias:
In this illustration, we see how early detection, when a cancer is in its preclinical phase (i.e., before it can be detected by symptoms or clinical examination), screening can make survival after diagnosis seem longer even if the treatments used have no effect at all. Unless the rate of progression from the point of a screen-detected abnormality to a clinically detected abnormality is known, it is thus very difficult to figure out whether a treatment of the screen-detected tumor is actually improving survival when compared to tumors detected later. If investigators are to do so, the lead time needs to be known and subtracted from the group with the test-based diagnoses. Moreover, this lead time is usually stochastic. It will be different for different patients, with some progressing rapidly and some progressing slowly. This variability, as I have discussed before, is responsible for a second type of bias, known as length bias, which is illustrated thusly:
Basically, what this graph illustrates is how screening programs preferentially pick up tumors that are growing slowly and more likely to portend a good prognosis (or represent overdiagnosis), rather than tumors that are rapidly growing and likely to portend a worse prognosis. This problem is at the heart of the issue of overdiagnosis. Basically, overdiagnosis, as I’ve discussed before, refers to disease detected by a screening test that, even if not treated, would never threaten the life or seriously threaten the quality of life of a patient. In the case of cancer, for instance, I’ve pointed out how frequently such disease is found in autopsy specimens. For instance, although the prevalence of clinically apparent prostate cancer in men aged 60 to 70 was only around 1% 20 years ago, at the time it was known that 40% of men in their 40s have histologic evidence of the disease. Thyroid cancer has a prevalence of around 0.1% of clinically apparent disease in adults aged 50 to 70, but autopsy studies looking at thyroids very finely find at least one papillary thyroid cancer in at 36% of adults. As I’ve pointed out elsewhere before as well, if breast tissue is looked at closely enough in an autopsy series of women between 40 and 50, foci of breast cancer can be found 39% of the time. In other words, aggressive screening can lead to more patients having a diagnosis of cancer for a longer period of time even without any real improvement in survival.
What all this means is that looking at population-level survival rates as a surrogate for how well a country is doing against cancer is fraught with confounders, in particular lead time bias. In a country where there is a lot of screening for cancer, lead time bias will be a bigger issue. There will also be more overdiagnosis, which will inflate the apparent survival time after a cancer diagnosis in the population. In such a case, we would anticipate that some of the largest gains in apparent survival would be in cancers for which major screening programs were undertaken, cancers like breast and prostate cancer, which is exactly what the authors observed. Now consider the time period that the authors chose to examine: 1983 to 1999. That is exactly the time period when large screening programs for breast and prostate cancer were being implemented, both in the U.S. and Europe. For example, in the U.S., breast cancer screening has traditionally been much more aggressive: Every year instead of every two to three years, as is common in many European countries and Canada, and beginning at age 40 rather than age 50, which is why these two graphs from the paper are not at all surprising. Here’s “Exhibit 1.” I have no idea why it’s called that instead of “Figure 1,” but it’s annoying and perhaps emblematic of how such a paper could have been accepted for publication in the first place. It’s as though the Philipson et al view their paper as a set of legal, rather than scientific, arguments:
Notice in the first one how the survival rate curves are almost perfectly parallel. This sort of a graph is exactly what I would expect if lead time bias were largely responsible for the difference in survival between the European Union and the U.S. Sure, that might not be the entire explanation, but seeing a graph like this sends up huge red flags, as does this figure:
This latter “exhibit” suggests that the vast majority of the detected survival advantage in the U.S. was due mainly to breast and prostate cancer, exactly the two cancers for which screening programs were ramped up beginning in the late 1970s through the 1980s.
Given the common knowledge of how lead time bias affects comparisons of the sort Philipson et al did, I really wanted to know why Philipson et al chose to look at survival statistics from time of diagnosis, rather than cancer death rates or another measurement:
The term survival gains refers to increases in years of life expectancy from cancer diagnosis seen over time. We decided to focus on examining survival gains over time because doing so provides insight into the progress that countries have made relative to their own baselines. An analysis that focuses instead on levels of survival is more likely to be influenced by intrinsic population characteristics, such as genetic predisposition to cancer, and might not reflect the impact of different health care systems.
This, of course, utterly misses the point of why looking at survival as a surrogate, at least aggregate survival rates for cancer, is generally easily confounded by lead time bias and other factors, in particular overdiagnosis. That’s why mortality rates are a better measure for how well we are doing against cancer. They aren’t affected by lead time bias, overdiagnosis, or length bias. One of the best explanations of why mortality rates are a better measure on a population level for how we are doing against cancer than survival rates was provided by Aaron Carroll:
Let’s say there’s a new cancer of the thumb killing people. From the time the first cancer cell appears, you have nine years to live, with chemo. From the time you can feel a lump, you have four years to live, with chemo. Let’s say we have no way to detect the disease until you feel a lump. The five year survival rate for this cancer is about 0, because within five years of detection, everyone dies, even on therapy.
Now I invent a new scanner that can detect thumb cancer when only one cell is there. Because it’s the United States, we invest heavily in those scanners. Early detection is everything, right? We have protests and lawsuits and now everyone is getting scanned like crazy. Not only that, but people are getting chemo earlier and earlier for the cancer. Sure, the side effects are terrible, but we want to live.
We made no improvements to the treatment. Everyone is still dying four years after they feel the lump. But since we are making the diagnosis five years earlier, our five year survival rate is now approaching 100%! Everyone is living nine years with the disease. Meanwhile, in England, they say that the scanner doesn’t extend life and won’t pay for it. Rationing! That’s why their five year survival rate is still 0%.
None of this is to say that screening for cancer is useless. I’ve never said that, nor do I believe it. I have, however, explained that demonstrating real increases in survival due to screening is devilishly difficult, far more difficult than “common sense” would lead the average person (or even physician) unschooled in the intricacies involved would think, hence the controversy over prostate and breast cancer screening and, in particular the UPSTF recommendations from two and a half years ago regarding screening mammography.
Aaron Carroll also did me a favor and saved me a lot of work by compiling mortality rates for various cancers in G8 countries as another way to illustrate what is almost certainly closer to the real situation. The fact that he did it for years much more recent than the time period Philipson et al. did was rather curious, of course, but maybe not so much so given that more recent statistics show that most European countries have results much closer to those in the U.S. than 20 years ago. Be that as it may, Carroll points out that the U.S. is among the best in the world when it comes to breast cancer but not actually the best. Japan appears to be doing much better than the U.S. As a cancer surgeon, I will point out that breast cancer in Japan might be different, possibly due to lifestyle differences. In terms of other cancers, Carroll concludes that for cervical cancer, we’re in the middle of the pack; for colorectal cancer, we’re unequivocally doing the best; and for prostate cancer we’re in the high end of the middle of the pack. The most interesting observation is that for lung cancer we are doing abysmally. The obvious excuse for that is tobacco smoking, but it turns out that the U.S. has one of the lowest rates of tobacco use of these countries; so that doesn’t explain it. As Aaron’s last cancer graph shows graph when it comes to overall mortality from cancer, compared to the G8 countries, the U.S. is doing well but is not the best. As Aaron sums it up:
Not nearly where you’d like to see us. Because we don’t do as well with some of the more prevalent cancers, we wind up doing much worse overall when it comes to cancer mortality than you’d think. This is why, when some point to us having the “best” health care system, they focus on colon cancer or breast cancer, not on lung cancer. Overall, though, we’re not.
I can’t help but notice, too, that if you really want to compare countries with universal health care systems to the U.S. (and, let’s face it, that’s what this is really all about, trying to show that “socialized medicine” leads to “death panels,” health care rationing, and lower survival rates for deadly diseases like cancer), you really should include Japan in the mix. The problem, of course, is that Japan does a lot better than the U.S. in many areas. My point, however, is not to denigrate the U.S. healthcare system. It does quite well in some areas, not so well in others, and overall it’s very good but not spectacular, at least when we look at cancer mortality. The real problem is not that the U.S. system doesn’t deliver quality cancer care. Rather, the problem is that delivering that care in the U.S. is spectacularly expensive for the results it gets compared to other countries that spend considerably less.
Surprisingly (to me at least), there’s been some really good reporting that punctures the claims of this particular study. First, there’s this one, in which Steven Reinberg interviews Dr. Otis Brawley, the chief medical officer and executive vice president at the American Cancer Society. Dr. Brawley points out that, yes, overdiagnosis is likely the fatal confounder not accounted for by Philipson et al.
More impressive is Reuters article by Sharon Begley, in which she explains very well why this study doesn’t show what Philipson et al conclude that it shows. Also, unlike the case in some other posts and articles that I’ve seen dealing with this study, Begley doesn’t suggest that Philipson et al completely ignored lead time bias. In all fairness, before finishing, I have to state unequivocally they didn’t. The problem with their analysis is that they made a highly unconvincing argument using mortality statistics for why they don’t think lead time bias was a major confounder of their results. In fact, they did some rather amazing contortions to try to justify their approach of focusing on survival statistics instead of mortality rates, even to the point that they included an online supplement in which they examined mortality rates in the various countries included in their study. Here’s the problem with that argument, which is summed up very well in Begley’s article:
The Philipson team acknowledges that survival data can be misleading. They justify their approach, however, by saying that because deaths from cancer as a percentage of a country’s population fell faster in the United States than in 10 countries in Europe from 1982 to 2005, the higher U.S. survival “suggests that lead-time bias did not confound our results.”
Some experts in cancer statistics were not convinced.
“Why do the authors use the wrong metric – survival – in the analysis and then argue that the right measure – mortality – provides corroborating evidence?” asked Welch. “As long as your calculation is based on survival gains, it is fundamentally misleading.”
Indeed. I found that very curious myself, particularly how the justification was buried in an online supplement, rather than described in the text of the paper itself. It makes me wonder if it was something the authors cooked up to justify themselves after peer reviewers started hammering them on the issue of lead time bias. It wouldn’t surprise me in the least if that were the case, although, again in all fairness, it might not be. Similarly, their lame argument that they chose increases in survival as their metric because it would allow them to compare each country to its baseline made me laugh. Do they seriously believe that following mortality trends over time wouldn’t allow them to compare each country to its baseline? Is it just me? Am I alone in finding such an argument … unconvincing?
In reality, there are two ways to study how well different countries are doing in terms of cancer care. One way is, as mentioned several times in this post, to focus on cancer mortality. Another way is much more difficult in that it involves comparing stage-specific survival rates, and, for cancers for which there are screening programs, survival rates for screen-detected cancers and survival rates for all cancers. The latter is an analysis that is very difficult to carry out, given that not all countries have good registries that have cases properly stratified by stage and that it wouldn’t be able to compare how countries are doing against all cancers overall, only individual cancers. Also, stage definitions change over time, and carrying out such an analysis would involve taking such changes into account—not an easy adjustment. Yet, Philipson et al. chose to do neither of these things; indeed, they picked the very metric for which confounding factors, such as lead time bias and overdiagnosis, tend to be the most problematic.
I wonder why.
More importantly, I wonder how this study ever passed peer review. One would think that Health Affairs would have at its disposal a cancer epidemiologist who understands overdiagnosis, lead time bias, and length bias to tap as a peer reviewer. I guess not.

A Universal Anti-Cancer Drug?
Steven Novella on March 28, 2012
Link
We frequently deal with fraud and quackery on this blog, because part of our mission is to inform the public about such things, and also they are great examples for explaining the difference between legitimate and dubious medical claims. It is always our goal not just to give a pronouncement about this or that therapy, but to work through the logic and evidence so that or readers will learn how to analyze claims for themselves, or at least know when to be skeptical.
One skepticism-inducing red flag is any treatment that claims to treat a wide range of ailments, especially if those ailments are known to have difference causes and pathophysiologies. Even claiming that one treatment might be effective against all cancer is dubious, because cancer is not one disease, but a category of disease. We are fond of pointing out that there are many types and stages of cancer, and each one requires individualized treatments. As an aside, it is ironic that CAM proponents often simultaneously tout how individualized their treatment approach is, but then claim that one product or treatment can cure all cancer. Meanwhile they criticize the alleged cookie-cutter approach of mainstream medicine, which is actually producing a more and more individualized (and evidence-based) approach to such things as cancer.
In any case – my immediate response to any article or website claiming to treat most or all cancer is to be highly skeptical, but I reserve final judgment until after I read through the details. What kinds of evidence are being presented to support the claims, and what are the alleged mechanisms of action? Are those making the claims being cautious like a scientist should, or are they being promotional like a used-car salesman?
A recent study claiming a potential treatment for many types of cancer has been making the rounds. The title of the article being circulated is, One Drug to Shrink All Tumors. What made me take immediate interest in this article was that it was not on a dubious website, sensational tabloid, or even mainstream news outlet, but on the news section of the American Academy for the Advancement of Science (AAAS) website. This is a report of serious medical research. The title, I suspect, is perhaps a bit more sensational than it otherwise would have been because of a geeky nod to the “one ring to bind them all” Lord of the Rings quote. Regardless of the source and the headline – what is the science here?
What scientists have discovered over the last decade is that some blood cancer cells (leukemia and lymphoma) express on their surface a protein called CD47. This protein acts as a signal to the immune system and prevents it from attacking the cancer cells. The same CD47 protein is expressed on normal blood cells and keeps them safe from the immune system as they circulate around the body. It makes sense that those neoplastic cells that by chance express CD47 are the ones that will survive and develop into a cancer. Those that do not express the protein are probably weeded out by the immune system. Cancer cells are therefore the Darwinian survivors, although not beneficial for the host.
The AAAS is now reporting on a new finding of Dr. Irving Weissman, who made the original CD47 discovery:
“What we’ve shown is that CD47 isn’t just important on leukemias and lymphomas,” says Weissman. “It’s on every single human primary tumor that we tested.” Moreover, Weissman’s lab found that cancer cells always had higher levels of CD47 than did healthy cells. How much CD47 a tumor made could predict the survival odds of a patient.
Not exactly all tumors, but every one tested so far. Still, this is an amazing discovery. It seems that expression of CD47 is a universal or near universal property of all cancer cells, perhaps required for their ability to evade the immune system long enough to become clinically detectable. Weissman and his team then took the next logical step, they created anti-CD47 antibodies and then tested their activity against tumors. They transplanted “human breast, ovary, colon, bladder, brain, liver, and prostate tumors” into mice, and then compared untreated mice to those treated with anti-CD47 antibodies. What they found is that those mice that were treated generally experienced shrinkage of their tumor and a marked decrease in the risk of the tumor spreading. This is not the same thing as a cure, but any treatment that shrinks tumor and prevents metastasis is a useful treatment against cancer and is likely to prolong survival, decrease recurrence, and increase the probability of a cure.
Our experience with past treatments that show similar promise is that they turned out not to be outright cures, but those that worked became useful additional treatments that improve outcome in some cancers. If anti-CD47 antibodies pan out as an effective treatment, it is likely that they too will be added to the anti-cancer armamentarium, but will not be cures by themselves.
So far, so good – we have what sounds like a very plausible mechanism, and reasonable animal data. Further, the scientists express the proper degree of caution and skepticism toward their own research. They point out that anti-CD47 antibodies also allow the immune system to attack healthy blood cells, causing anemia. The decrease in blood counts was short-lived in the mice, but obviously this will be something to watch carefully in human trials. The also report:
“The microenvironment of a real tumor is quite a bit more complicated than the microenvironment of a transplanted tumor,” he notes, “and it’s possible that a real tumor has additional immune suppressing effects.”
Another important question, Jacks says, is how CD47 antibodies would complement existing treatments. “In what ways might they work together and in what ways might they be antagonistic?” Using anti-CD47 in addition to chemotherapy, for example, could be counterproductive if the stress from chemotherapy causes normal cells to produce more CD47 than usual.
Exactly – animal models are great preludes to human studies, but they are not the same as human data. Biological systems are complex, and we cannot predict what factors may affect the response of a native human tumor to this treatment based upon evidence from transplanted tumors. Further, there are other factors that may impact the net effect of this treatment in humans with cancer, such as interactions with chemotherapy or other host responses.
Therefore, there is no substitute for controlled human trials. We cannot and should not base claims of efficacy, or even safety, on a plausible mechanism and encouraging animal data. What we have so far is sufficient justification for phase I clinical trials in humans, and nothing more.
This is a point worth emphasizing, as it is very common for dubious treatments and products to base clinical claims on preliminary basic science or animal data, often backed up by nothing but anecdotes. Together this kind of evidence can make a compelling story to the non-scientist, and that’s what the marketers are counting on. It is helpful to see how real scientists approach the evidence, and the process that is necessary before we can know that a treatment is safe and effective.
Anti-CD47 antibodies are definitely a promising discovery and a treatment to watch. I hope the research pans out and we can add this to our available treatments for cancer. It is possible, even probable, that (if the treatment proves safe and effective) in the future we may test cancers for the presence of CD47, and then then give the treatment only to those who express this protein – further individualizing cancer treatment. Human studies are likely to take 5-10 years, however, and that’s if everything goes well.

The future of cancer therapy?
David Gorski on July 9, 2012
Link
I was contemplating writing a post along the same lines as Harriet’s post about evolutionary medicine last week, but then on Sunday morning I saw an article that piqued my interest. Sorry, Harriet, my response, if I get to it, might have to wait until next week, although we could always discuss the usefulness (versus the lack thereof) of evolutionary medicine over a beer or two at The Amazing Meeting in a few days. In the meantime, this week’s topic will revisit a topic near and dear to my heart, a topic that I tend to view (sort of) in a similar way as Harriet views evolutionary medicine, namely personalized medicine or the “individualization” of treatments. It’s a topic I’ve written about at least twice before and that Brennen McKenzie wrote about just last week. In essence, we both pointed out that when it comes to “complementary and alternative medicine” (CAM) or “integrative medicine” treatments for various conditions and diseases, what CAM practitioners claim to be able to do with respect to “individualized care” is nonsense based on fantasy. Science-based medicine already provides individualized care, but it’s individualized care based on science and clinical trials, not tooth fairy science.
Serendipitously, this point was driven home over the weekend in an article by Gina Kolata in the New York Times entitled In Treatment for Leukemia, Glimpses of the Future. While the story is basically one long anecdote that shows what can be done when new genomic technologies are applied to cancer, it also shows why we are a very long way from the true “individualization” of cancer care. It also turns out that I’ve discussed the same basic story before, but here I’ll try to discuss it in a bit more detail.
As hard as it is to believe, it’s been nine months since Steve Jobs succumbed to a metastatic neuroendocrine cancer of the pancreas. Last November, the authorized biography of Steve Jobs, written by Walter Isaacson, revealed that after his cancer recurred for the second (and final) time Jobs became one of the first twenty people in the world to have all the genes of his cancer and his normal tissues sequenced, which was done by a collaboration of research teams at Stanford, Johns Hopkins, and the Broad Institute. At the time (2010-2011), it cost $100,000 to do. Scientists and oncologists looked at this information and used it to choose various targeted therapies for Jobs throughout the remainder of his life, and Jobs met with all his doctors and researchers from the three institutions working on the DNA from his cancer at the Four Seasons Hotel in Palo Alto to discuss the genetic signatures found in Jobs’ cancer and how best to target them. Jobs’ case, as we now know, was, alas, a failure. However much Jobs’ team tried to stay one step ahead of his cancer, the cancer caught up and passed whatever they could do.
Kolata’s story, in contrast, appears to be that of a success. It is the story of Dr. Lukas Wartman, a recent graduate of the Washington University hematology-oncology fellowship who is now an Instructor in the Division of Oncology:
Genetics researchers at Washington University, one of the world’s leading centers for work on the human genome, were devastated. Dr. Lukas Wartman, a young, talented and beloved colleague, had the very cancer he had devoted his career to studying. He was deteriorating fast. No known treatment could save him. And no one, to their knowledge, had ever investigated the complete genetic makeup of a cancer like his.
So one day last July, Dr. Timothy Ley, associate director of the university’s genome institute, summoned his team. Why not throw everything we have at seeing if we can find a rogue gene spurring Dr. Wartman’s cancer, adult acute lymphoblastic leukemia, he asked? “It’s now or never,” he recalled telling them. “We will only get one shot.”
We learn later in the article that Dr. Wartman had first been diagnosed with acute lymphoblastic leukemia in 2002, when he was a fourth year medical student ready to finish up and move on to residency. During trip out to California for a job interview, he began to experience overwhelming fatigue. Upon his return, he found he couldn’t run anymore and started having night sweats. At first he thought it was mono, but then he started having bone pain. He finally went to an urgent care center, where at first it was thought that he might be suffering from depression, but it was also noticed that he had a low white blood cell count.
The rest of his story can be summarized in a manner that is still too common among leukemia patients. He underwent nine months of intensive chemotherapy, which was followed by 15 months of maintenance chemotherapy. Five years later, his leukemia recurred, and he underwent a bone marrow transplantation, which is the usual treatment for recurrent ALL. Thus far, he had beaten the odds, having not realized how bad they are for recurrent ALL:
Seven months after the transplant, feeling much stronger, he went to a major cancer meeting and sat in on a session on his type of leukemia. The speaker, a renowned researcher, reported that only 4 or 5 percent of those who relapsed survived.
“My stomach turned,” Dr. Wartman said. “I will never forget the shock of hearing that number.”
In the vast majority of cases, a patient like Dr. Wartman would be dead. As is pointed out in Kolata’s article, we are not even sure of the expected survival rate of someone who has relapsed twice with ALL, other than that the odds are clearly very, very low. However, Dr. Wartman was very fortunate to have friends who had access to technologies to which few have access. Because he is a researcher at the Washington University and knew Dr. Timothy Ley, a world-renowned leukemia researcher and Associate Director for Cancer Genomics for the The Genome Institute at Washington University and because he was apparently well-liked there, Dr. Ley offered to do what was described in the introduction of Kolata’s article. It was a massive undertaking, as well:
Dr. Ley’s team tried a type of analysis that they had never done before. They fully sequenced the genes of both his cancer cells and healthy cells for comparison, and at the same time analyzed his RNA, a close chemical cousin to DNA, for clues to what his genes were doing.
The researchers on the project put other work aside for weeks, running one of the university’s 26 sequencing machines and supercomputer around the clock. And they found a culprit — a normal gene that was in overdrive, churning out huge amounts of a protein that appeared to be spurring the cancer’s growth.
Even better, there was a promising new drug that might shut down the malfunctioning gene — a drug that had been tested and approved only for advanced kidney cancer. Dr. Wartman became the first person ever to take it for leukemia.
And now, against all odds, his cancer is in remission and has been since last fall.
As is often the case when I’m reading an article in the lay press, I sometimes have to read a bit between the lines and make an educated guess as to what exactly it was that Dr. Ley’s team did. The first analysis appears to be a next generation sequencing (NGS) analysis of both the leukemic cells and normal cells. NGS techniques allow the sequencing of complete genomes in a matter of weeks. In “old-fashioned” automated sequencing using Sanger techniques, the rate-limiting step in the sequencing process was the need to separate reaction products on a polyacrylamide gel in order for the sequence to be read. Next generation sequencing (NGS) techniques overcome this limitation by arraying DNA molecules on solid surfaces by anchoring and copying single DNA molecules on glass slides or or array of beads. Going into the details of these new sequencing techniques is beyond the scope of this particular post (maybe some day), but for interested readers who know a bit about sequencing and PCR, there is a decent general description here. The long and the short of it is that NGS techniques allow the massively parallel sequencing of a genome such that 30 gigabases of DNA sequence, which is the equivalent of approximately 10 haploid human genomes, can be obtained in a week at a cost of approximately $15,000. By way of comparison, the draft human genome reference that was reported in 2001 to six-fold redundancy took five years of sequencing by several laboratories and cost billions of dollars. That is how much technology has advanced in a single decade. It’s truly astonishing.
The second analysis that was performed is almost certainly another NGS techique known as RNAseq, which is the common name for whole genome shotgun sequencing (WTSS). Again, the details of the technique are beyond the scope of this post. However, RNAseq overcomes the major limitation of cDNA microarrays, which is that it is only possible to measure the mRNAs whose sequences are known and therefore have been placed on the gene chip. Consequently, cDNA microarrays can’t discover previously unknown transcript and in general do not cover noncoding RNAs, such as microRNAs and long noncoding RNAs (lncRNAs). RNAseq does. As a result, using RNAseq it is possible to identify every sequence of every mRNA transcript, coding and noncoding, being made by the cell and how much. Of course, cDNA microarray techniques are by no means dead yet, the primary reason being that RNAseq is a lot more expensive than cDNA microarray techniques, at least ten-fold more, and cDNA microarray experiments can be completed a lot faster.
Taking the results of the sequencing of the entire genome and RNAseq data and analyzing them allows scientists to probe the genome and transcriptome of cancers in a way that was never before possible. It produces an enormous amount of data, too, terabytes from a single experiment. At cancer meetings I’ve been to, investigators frequently refer to a “firehose” of data, petabytes in magnitude. Indeed, the sheer quantity of data from these experiments challenges the bandwidth of universities doing them, and, in fact, it’s not at all uncommon for the preferred means of sending experimental data to be to load up a hard drive with the data and send it by the quaint but effective method of overnight mail to other investigators because it’s faster and more reliable that way. Not surprisingly, serious computing power and major advancements in computer algorithms have been necessary to develop the methods of analyzing data from these experiments.
What I’m trying to convey is that what WUSTL did for Dr. Wartman was not a little deal. It was a big deal that took a lot of resources and effort and likely cost well over $100,000. Apparently it was paid for through research grants, and Dr. Ley claims that no patients were neglected while all that sequencing and computing firepower were transferred to sequencing Dr. Wartman’s cancer genome and transcriptome, having done the same thing for a previous patient. That might well be true, but does anyone believe that Dr. Wartman would have had access to so much genomics goodness if he hadn’t been a researcher at The Genome Institute? Be that as it may, Dr. Wartman’s luck didn’t end at having friends willing to go to such great lengths for him. Here’s what happened when all that sequencing was done and analyzed:
The cancer’s DNA had, as expected, many mutations, but there was nothing to be done about them. There were no drugs to attack them.
But the other analysis, of the cancer’s RNA, was different. There was something there, something unexpected.
The RNA sequencing showed that a normal gene, FLT3, was wildly active in the leukemia cells. Its normal role is to make cells grow and proliferate. An overactive FLT3 gene might be making Dr. Wartman’s cancer cells multiply so quickly.
Even better, there was a drug, sunitinib or Sutent, approved for treating advanced kidney cancer, that inhibits FLT3.
In brief, for whatever reason, Dr. Wartman’s leukemia cells appeared not to have any mutations in the FLT3 gene, which would have been found in the DNA sequencing, but for some reason (probably a mutation in a regulatory region) was making lots and lots of the kinase coded for by FLT3. FLT3 has also been implicated as a molecular target in acute myeloid leukemia (AML). Indeed, this is the very reason why sequencing the genome and transcriptome both are frequently needed to understand what is driving the cancer. Of course, as I’ve discussed before, the genome of your typical cancer cell is so messed up that it’s impossible to identify a single gene that is primarily responsible for the cancer, but in this case Dr. Wartman was again incredibly lucky. His recurrent ALL was being driven primarily by FLT3, a single gene, and there exists a good drug to target that oncogene. Even better, as predicted by the biology, treating Dr. Wartman with sunitinib worked! His blood cell counts started to normalize within days, and he rapidly went into remission.
There was a hitch, however. Sunitinib is very, expensive ($330 per day), and Dr. Wartman’s insurance company wouldn’t pay for it, given that it was being used off-label. Basically, Dr. Wartman scraped together enough money to buy a week’s worth of the drug, and that’s what demonstrated such remarkable effects. Later, the doctors in his division pitched in to buy him more drug. After a few weeks, Dr. Wartman was in complete remission. Fantastic news, but it presented a dilemma: Should Dr. Wartman keep taking the drug, or should he undergo another bone marrow transplant? Ultimately, the decision was made to do another bone marrow transplant because of fear that the leukemia would soon evolve resistance. When evolution meets modern medicine, evolution nearly always wins. In another stroke of luck, Pfizer decided to supply Dr. Wartman with the drug free of charge until he underwent a bone marrow transplant. As of the running of the story, Dr. Wartman remains, as far as the best tools of modern medicine can tell, free of cancer, although he is suffering from graft versus host disease due to his transplant.
There’s no doubt that “individualized” medicine will become increasingly a part of modern medical care, with the individualization based on sequencing the genomes and transcriptomes of patients. In just a few years, the price of a complete genome sequence has fallen from hundreds of thousands of dollars to around $15,000. True, that doesn’t count all the analysis and that’s $15,000 per genome, which means at least $30,000 to sequence a normal and cancerous genome. There are, however, lots of things we do in medicine that cost $15,000. The price doesn’t have to come down much more before whole genome sequencing starts to look doable for individual patients. After all, gene tests like the OncoType DX cost on the order of $3,000 to $4,000, and we now order this test fairly routinely for patients with estrogen receptor-positive, node-negative breast cancer because in the end it saves a lot of patients from unnecessary chemotherapy.
The problem with the individualization of care based on genomics are well-illustrated in this article, which, let’s not forget, is nothing more than anecdote. The question of its generalizability remains to be determined. Using genomics to individualize treatment worked in Dr. Wartman’s case. What his odds of long-term survival are now, no one really knows, but we do know this much. There’s little doubt that, without the discovery that sunitinib would be an appropriate drug to treat his cancer, he would almost certainly be dead by now. Unfortunately, his example can be countered with that of Steve Jobs, whom sequencing his tumor ultimately didn’t help, and Christopher Hitchens, who according to this article also had his cancer sequenced.
How many will have results like Dr. Wartman’s and how many will have results like those of Steve Jobs or Christopher Hitchens? Most cancers are not driven by just one gene that can be targeted, nor are most other diseases and conditions that we might wish to use genome and transcriptome sequencing as a guide to therapy. We’re drowning in genomic data right now, and we just don’t know how to use it yet. Nor will we know until a lot more research is done. The problem is that, with a relatively few exceptions like the case of Dr. Wartman, we don’t know enough yet to translate genome and transcriptome sequences into therapies. We also don’t have drugs for anywhere near all the potential molecular targets that can be identified this way, and the targeted drugs that we do have tend to be enormously expensive. For all the promise it shows and for the now occasional success story like that of Dr. Wartman, the genomics revolution will, like most revolutions, be messy.

This Book Won’t Cure Your Cancer, But It Will Help You Think More Clearly About It
Harriet Hall on November 10, 2015
Link

Gideon Burrows has an inoperable brain cancer that is slow growing but is inevitably going to kill him. He has written a remarkable book about his experience, This Book Won’t Cure Your Cancer. A professional wordsmith, he is able to describe his experience of illness so vividly that the reader enters into his life, feels what he feels, and shares his suspense about what the next scan or doctor’s visit will reveal. Along with him, we suffer through the panic and fear, the chaos, the agonies of delays and uncertainty, the unpleasant hospital environment, and specialists with poor bedside manners. We follow him through difficult decisions about how to share the bad news with friends, relatives, and his young children; and we understand why this engenders guilt feelings. The story is as engaging as a detective story; we can hardly wait to see what the next scan will show and how the story of his illness will play out. It puts a human face on the cancer experience, and it would be valuable for that alone, but it is much more. The gradually unfolding episodes of his personal story are interwoven with what amounts to a primer on how to think critically about science-based medicine vs. alternative treatments. I can’t recommend this book highly enough.
Untrustworthy information
When people are diagnosed with cancer, they are vulnerable and desperate. They look for information and are likely to find cookbooks, miracle stories, alternative medicine, and “forbidden cancer cures.” Their friends bombard them with advice. Most of those sources “offer hope to people when they need it most, but have earned no right to do so.”
Burrows reads “the biggest cancer book of all time,” Anticancer: A New Way of Life, by Servan-Schreiber, and is bitterly disappointed. It offers a plan to keep cancer at bay through mental balance and diet, but he realizes that Servan-Schreiber is making unwarranted extrapolations from single scientific studies and anecdotes, and he is blaming the victim by trying to establish a lifestyle cause for a kind of tumor for which science has found no cause and which is likely due only to bad luck. Servan-Schreiber thought he had beaten cancer, but it returned with a vengeance. Then he wrote a second book. Instead of acknowledging that his methods hadn’t worked, he rationalized that he hadn’t followed his own advice carefully enough. He hadn’t done enough to control stress. Maybe he hadn’t eaten properly. He died shortly after the second book was published. People are still reading his books and following his advice; many of them don’t realize he is dead.
The cancer culture
Burrows describes the prevailing cancer culture that depicts it as a battle, calls patients brave warriors, and celebrates the victorious survivors. He says:
Cancer is not a brave battle to fight, it is a terrible disease to run away from. It is a puzzle to try to solve, something to try to keep at bay using the very best tools we have…I’m not brave. I’m just getting on. Making the most of what I’ve got. Crying, and laughing, and forgetting, and remembering, and plodding and pedaling on. Like we all do, cancer or not.
When to stop looking for other opinions
Three different specialists give him the same prognosis. His cancer is inoperable. It will inevitably progress and need treatment, but for now all that is needed is to monitor it with scans and to control his seizures with medication. Friends suggested he keep looking for a surgeon who would be willing to operate. What if he searched the world and found five doctors who wouldn’t operate and a sixth who would? Would it be rational to trust the sixth doctor’s opinion more than that of the other five? Of course not. He should trust him less. Unfortunately, many patients play this game, spend enormous amounts of money, and end up worse or no better than they would have been.
He talks about the false promises of unconventional cancer doctors like Burzynski, and the impetus to “try anything.” He says it is not reasonable to “try anything” if there is no evidence that “anything” works. People say it’s worth trying because there is no evidence that it doesn’t work. He spots the fallacy in that reasoning:
There are many millions of things that have not been proven to not cure cancer, but mostly because many millions of things have never been tried. That does not mean they are a potential cure, nor that they are sensible to pursue.
What if he proposed that blowing up 100 red balloons would cure cancer? Is that really any more ridiculous than coffee enemas? When does anything become something we should try, and who gets to decide what is too ridiculous to try? Even alternative practitioners disagree with each other. Where do you draw the line? If a treatment has not been proven to work, is not biologically plausible, has not been tested in animals, and is not backed by the majority of scientific experts, shouldn’t it fall on the same side of the line as the red balloons?
He doesn’t blame people who go off in pursuit of a promised miracle cure. He understands their desperation and the comfort of having a hope to cling to. Rather, he blames those who offer that anything without a fair, accurate, and accountable foundation. The power and responsibility to advise about cancer treatment “should only be earned by results, proof, and accountability.”
What constitutes proof?
He describes how people ignore reality to cling to their beliefs. When alternative medicine proponent Chris Woollams’ daughter survived for longer than average, he credited her alternative treatments; when her tumor recurred and killed her, he blamed her for not following his regime properly. When Wellness Warrior Jessica Ainscough died, her followers claimed it was because she didn’t do Gerson therapy correctly. Those who get both conventional and alternative treatment and survive often refuse to give credit to the conventional treatment.
…it doesn’t matter what you think cured you or made you feel better. Opinion doesn’t come into it, only the biology and science.
Testimonials abound. “It worked for me” is a kind of “social proof” but in reality is no evidence at all. In fact, personal testimonies are the enemy of proof. We hear about successes, but we don’t hear about the failures because no records are kept (until the internet anyway). To be taken seriously, a theory has to be falsifiable. Excusing failures by saying the treatment wasn’t properly followed leaves no way to determine whether it actually works. Controlled scientific studies can test whether it works; they are based on falsifiability. Proponents of alternative medicine often reject the scientific approach; they argue that their treatments are not amenable to randomized controlled trials, and that they might still work for an individual even when studies show they didn’t work for the people in the studies.
He faults alternative providers for not carrying out even the most basic scientific controls. If they have a treatment that works, they should want to inform the world. It would be simple to publish honest, even independently audited lists of all treated patients with data on all the successes and failures. The argument that there isn’t money to test alternative medicine is a red herring; even small businesses monitor their performance indicators.
Diet
Diet advice and cancer cookbooks and abound, but:
The most science has shown is that having a generally healthy diet and exercising regularly lowers our risk of getting cancer. It does not prevent cancer. It does not cure it.
The media
The media report real new developments in scientific cancer treatment right along with sensationalist stories about unreliable pseudoscientific claims. They strive for “balance” and give alternative treatments more credit than they deserve. This is wrong-headed; it’s not a matter of two politicians presenting opposing views, it’s a matter of scientific fact and expert opinion versus speculation and uninformed opinions of non-experts (and sometimes even of charlatans). The news serves to confuse rather than to inform.
Confronting rubbish
Is it rude or cruel to confront people who talk rubbish about cancer? If we don’t, are we allowing potentially more damage to be done just to avoid a personal feeling of discomfort? “How far does our reluctance to criticise mean that energy, passion and grief is channeled away from cancer cure research, not towards it?”
Ancient wisdom
Ancient practice is not always ancient wisdom…That something was being done in the earliest days of civilisation to cure illnesses should make us more wary of those treatments, not keener to try them for ourselves…progress means replacement of the old and ineffective, the unproven and dangerous, by the new and better, the proven and safer.
Religion
People ask, “What about God?” As an atheist, the question never arose for him, even though he holds a degree in theology. He explains why prayer is only likely to make those who pray feel like they are acting virtuously, and why it is logically indefensible as an attempt to improve health outcomes.
Cancer is natural
“Cancer doesn’t care about you.” It isn’t something gone wrong; it is DNA doing what DNA is supposed to do. Without DNA mutation, there would be no evolution, no us. Cancer is a natural consequence of the same mechanisms that make our hair grow and our wounds heal. There are many cancers, and half of us will get one eventually. Cancers are not always a death sentence. We can cure some of them and live with others.
Doctor-bashing
Proponents of alternative medicine love to criticize doctors, and it’s undeniable that there is a lot wrong with conventional medicine. The system is flawed. Individual doctors are not perfect; they miss diagnoses and make mistakes.
But if we exercise scepticism and doubt about medically trained doctors, oncology and conventional medicine, then we should subject alternative medicine to at least the same level of doubt and scrutiny. In fact, I would argue alternative medicine deserves far more doubt because it self-consciously puts itself outside conventional medicine that has been proven by time and experience to, mostly but not always, get it right.
Big Pharma and conspiracy theories
Big Pharma deserves blame for many sins, but it is ridiculous to say it doesn’t want to find a cure for cancer or already has a cure and is keeping it secret. He explains why those conspiracy theories are completely wrong-headed. The idea that there’s no money in natural products is easily refuted by the success of bottled water and natural health food stores.
Who is an expert?
Self-declared “experts” write books. But it only takes two minutes on the Internet to demonstrate that there are experts in that field who question or disagree with them. Failure to reveal the controversy should make readers question whether anything else in the book is true.
Burrows put his life in the hands of real experts who know far more about his tumor than any patient or self-proclaimed cancer guru. He can make choices about his care, but:
They set the boundaries between which I can make decisions. That’s the rational way to behave, and I understand that they know best.
Some major issues for society
Aysha King was a five-year-old boy whose parents refused conventional treatment in the UK and took him to Spain for a treatment that his doctors knew was not appropriate for his condition. Burrows uses Aysha’s case as a springboard to discuss some of the major issues our society is failing to deal with:
    • The idea that parents know what’s best for their child
    • The false claim that treatments are rejected simply on the basis of cost
    • A breakdown in communications
    • The role played by the newspapers, fueled by lack of information
    • The strong emotions that are evoked by the plight of a sick child
Conventional medicine and alternative medicine operate in two separate universes that don’t communicate with each other. Alternative providers fail to understand the scientific realities of modern cancer treatment. Conventional providers often fail to appreciate their patients’ fears and misunderstandings. Patients are left in limbo.
As a society, we need to have a sensible conversation about dying, and not just keep patients with cancer alive longer at all costs. We should learn when to let go. A recent study found that hospice patients with an end-of-life plan not only had a better quality of life than those who insisted on every possible intervention, but they actually lived longer.
Hope
At the end of the book, his condition is stable and he is far from devoid of hope; but his hope is centered in realism and rationalism. He hopes for the possible, not for the impossible: perhaps a change in medication will better control his seizures, perhaps he will survive long enough for science to find an effective cure for his cancer. He believes that reality and science are always better than lies and belief in magic. He thinks it is a shame that patients turn to alternative medicine and make themselves ineligible for clinical trials that offer real hope for contributing to the greater good.
He predicts that believers in alternative medicine will demonize him for writing this book, but he makes them this promise:
If you can show me firm, peer-reviewed scientific evidence that your cancer prevention therapy or cure works, I will no longer call it alternative medicine. I’ll call it medicine. And if proven to work for my particular brain tumour, I’ll be first in line for a dose.
Encouraging a sharper critical eye
Burrows’ message is that we often act irrationally around cancer. He wrote his book not to advise patients about cancer treatment but to encourage people to look at the information they are given (from both conventional and unconventional sources) with a sharper critical eye. This book beautifully complements Siddhartha Mukherjee’s Pulitzer Prize-winning The Emperor of All Maladies: A Biography of Cancer. Reading both of them will help you understand pretty much everything worth knowing about cancer and the people who suffer from it.

The Natural Cancer Cure Narrative
Julie Reason and her husband are producing a documentary about her cancer, and efforts to cure it. Based on their comments, they are drawing upon an established and false narrative about the causes and cures of cancer, one that can be dangerous to her, and all other cancer patients.
Steven Novella on May 24, 2017
Link

Julie Reason, 39, unfortunately has stage IV breast cancer, which means that is has spread and is probably incurable. In her desperation, which is completely understandable, she is turning to “holistic, natural” treatments thinking that they offer hope. The scientific evidence tells us they don’t offer hope, only a false but compelling narrative optimized to ensnare desperate people.
It is also unfortunate that Julie and her husband Christian have decided to make a feature length film in order to spread that narrative, which can only serve to ensnare other people into this false hope.
The Narrative
As is often discussed in skeptical writing, people like stories. We learn and communicate through stories, and we intuitively understand them. A good story will therefore tend to take on a life of its own, even when completely disconnected from reality. We call deeply rooted elaborate narratives – culture.
The so-called “alternative medicine” phenomenon is largely based on a narrative, one that has been successfully marketed. Proponents collectively took treatments and health claims that 40 years ago were considered health fraud and flipped the narrative – these treatments were not rejected because they lacked scientific backing, but because of a systematic bias in the medical-industrial complex. Health care con-artists were no longer the villains, they were the heroes trying to bring natural cures to the public and opposed by a cabal of science-based thugs. It amazes me still how well this narrative worked.
They are also trying to flip the narrative on what constitutes good science. While mainstream medicine is going through a period of self-reflection where it is generally agreed that we need to increase the rigor of science (more replication, less p-hacking, etc.), the parallel CAM movement is trying to weaken the rigor of medical science. They are not succeeding for medical science in general, but are successfully carving out a double standard for themselves. For regular medicine, we need rigorous science. For “alternative” medicine we can get by with pathetically low standards of science that will say whatever we want it to, and still get to label our treatments “evidence based.” It is an incredible scam.
In order to claim that treatments which are clearly useless or have already been shown not to work are still valid, the narrative needs to include a conspiracy theory to explain away any inconvenient evidence. That is the purpose of a conspiracy theory – it is a magic wand that dismisses any negative evidence, and explains away the lack of any positive evidence. Conspiracy theories can be made up as needed, and invoked at will without the burden of showing evidence for the conspiracy itself.
I don’t blame patients facing terminal illness for embracing this narrative. Would you rather live in a world where you have an incurable and terminal illness, or one in which there is a hidden cure out there, but the forces of evil are trying to hide it from you? All you need is to be plucky enough to pursue the cure and your problems will be solved.
The narrative also incorporates the ubiquitous appeal to nature fallacy – anything natural is good, and anything “chemical” is bad. Cancer is caused by exposure to chemicals, so all you have to do to cure it is purge yourself of chemicals and consume only all-natural foods and pure water. Oh yeah, and a bunch of supplements you will have to mortgage your house to pay for.
That is the narrative that has victimized Julie Reason. She says:
The diet is very strict, basically just fruit and veg while I can only drink water. I also take between 60 and 70 supplements a day with some of them as expensive as £90, while I also take cannabis oil which helps.
Promoting the film she and her husband are trying to fund, he says:
The feature-length documentary will look at how the chemicals used in agriculture and food, as well as our general everyday environment, affect our bodies’ immune system. Against All Odds will bring a better understanding to the problem we face as consumers, where large multinational companies are putting profits before the health of the people, and will look at the influences corporations have on government. The film will bring you some inspiring stories from people who have turned their lives around and are beating cancer after being labelled as stage four terminally ill.
Yep, that’s the narrative in a nutshell.
This is also a common approach to promoting dubious treatments, using anecdotal evidence. You cannot know if an individual has “beaten cancer” because of a specific treatment. That is because cancer is a complex category of many diseases, and has a variable natural history. You cannot know what would have happened in any individual if they had chosen different treatment options or no treatment. It is also very common for those facing cancer to combine multiple treatments, standard and dubious. There is a tendency to credit the dubious treatment, partly because that justifies the decision to pursue such treatment in the first place.
There is also a well-known phenomenon called “survivor bias.” If 100 people have cancer with 98% fatality, and then you talk to the 2 people who survive you might be tempted to conclude that whatever they were doing was responsible for their survival. However, they may just be lucky. This is like asking lotto winners how they pick their numbers.
This is the problem with anecdotal evidence – it doesn’t really tell you anything (except what you want to conclude in the first place). We need high quality scientific evidence to sort through all the complexity.
What the science shows (as nicely reviewed by David Gorski) is that a good diet and regular exercise are associated with an overall decreased risk of developing cancer. However, once you develop cancer it is too late to prevent it. The relationship between diet and cancer outcomes is more complex.
The bottom line is that you cannot cure your cancer with diet. Good nutrition is important to good outcomes, but they don’t treat the cancer itself. Cancer is both a genetic and metabolic disease, and is complex. No simplistic approach is likely going to work, and there is no reason to think that eating fruits and vegetables is going to alter the genetic mutations that make cells cancerous. The usual justification for the diet approach is that a good diet “boosts the immune system.” This is based on the false premise that a healthy immune system can beat all cancers all the time. But this is simply not true.
I wish the best for Julie Reason, but the film she plans with her husband is misguided. It is based on a false and simple narrative, divorced from science, and is nothing more than a conspiracy theory. It is especially pernicious to frame the narrative as providing hope for the terminal. False hope can lead people to do desperate and self-destructive things, and to distrust the very people who are likely to be giving the best advice.

   Natural versus “natural” in CAM world.
David Gorski 
Link
“When I use a word,” Humpty Dumpty said in rather a scornful tone, “it means just what I choose it to mean — neither more nor less.”
“The question is,” said Alice, “whether you can make words mean so many different things.”
“The question is,” said Humpty Dumpty, “which is to be master— that’s all.”
From: Through the Looking Glass, and What Alice Found There by Lewis Carroll
“How can I help seeing what is in front of my eyes? Two and two are four.”
“Sometimes, Winston. Sometimes they are five. Sometimes they are three. Sometimes they are all of them at once. You must try harder. It is not easy to become sane.”
From: Nineteen Eighty-Four by George Orwell
One of the most powerful weapons in the armamentarium of advocates of the unscientific and implausible medical practices that fall under the rubric of “complementary and alternative medicine” (CAM) or, even worse, “integrative medicine” (IM), both of which seek to seamlessly “integrate” pseudoscience with science to the point that people start to be unable to tell which is which in order to “complement” effective medicine with placebo-based medicine, is their skill manupulating language. Wally Sampson has harped on this time and time again on this blog, particularly in his masterful fictional (but all too true-sounding) response to the question, “Why would medical schools associate with quackery?” Kimball Atwood has even turned the–shall we say?–”plasticity” with which CAM/IM advocates manipulate language to their advantage into humorous and all-too-infrequently recurring Friday feature. All of us have complained about how CAM/IM advocates have coopted diet and exercise as being somehow “alternative” and are now using that as the “foot in the door” to introduce pseudoscientific quackery like reiki and homeopathy into not just medical schools but to try to persuade the incoming Obama Administration to fund quackery on equal terms with scientific medicine as part of a “reform” designed to “promote health.”
Much of the success, both previous and current, of CAM/IM advocates depends upon language. Just like Humpty-Dumpty, to ideologues like Deepak Chopra, words mean just what they choose them to mean, and, just like the view forced on Winston Smith at the Ministry of Love, two plus two are sometimes five, no matter how much we know they are four. All it takes is viewing science as “just another narrative,” as postmodernist supporters of CAM/IM would like. Once that happens, there is nothing to stop one from viewing CAM/IM as being a “narrative” just as valid as that of science-based medicine. It’s the way “quackery” has been transformed into “unconventional,” later into “alternative,” and most recently “integrative” medicine. It’s all designed to play on the natural American desire to be “fair” and the media’s desire for “balance,” even though it is not fair to give pseudoscience a patina of scientific respectability that it does not deserve or use “balance” to present quackery as though it has equal standing with scientific medicine.
If there is one word that has been corrupted by the CAM/IM movement more than any other, my vote would go the world “natural.” Of course, it’s not just the CAM/IM movement that has molded this word to mean whatever meaning is required for whatever purpose is desired. For decades, the advertising industry has done the same. However, the CAM/IM movement takes it to a new level, or “kicks it up a notch,” as a certain TV chef likes to say.
I came across a perfect example of this in the form of a man named Tony Isaacs.
Tony Isaacs happened to have written an article for one of the biggest repositories of quackery on the Internet, Mike Adams’ (who likes to call himself the “Health Ranger“) NaturalNews.com. The article, entitled Patrick Swayze’s Misguided Faith in Mainstream Medicine, was a smug broadside at Patrick Swayze. Swayze, as you may recall, was diagnosed with stage IV pancreatic cancer in early 2008. Last week, Swayze did something that really angered a lot of CAM/IM advocates. He gave an interview to Barbara Walters. No, it wasn’t giving an interview to Barbara Walters that annoyed CAM/IM purveyors. What angered them was what he actually said in that interview with Barbara Walters, which was relayed to me by one of my co-bloggers, as well as Majikthise. This is what Swayze said:
If anybody had that cure out there, like so many people swear they do, you’d be two things. You’d be very rich, and you’d be very famous. Otherwise, shut up.
He’s also fairly realistic about his chances:
“Five years is pretty wishful thinking,” the ‘Dirty Dancing’ star told Walters, who had been pressing the heavy question. “Two years seems likely if you’re going to believe statistics.”
Here we have a man facing death, a man who is highly unlikely to survive much longer than a year, in essence telling the CAM/IM crowd to stick it where the sun don’t shine. If ever there were a situation where the temptation to try something–anything–different, even the rankest forms of quackery, Swayze’s situation is it. After all, other celebrities facing death from cancer have succumbed to the temptation to try quackery, celebrities such as Steve McQueen, Coretta Scott King, and possibly even Michael Landon. That Swayze hasn’t followed that siren song shows that he not only realizes CAM/IM has nothing that will save his live but also that his best hope for palliation and possible extension of the time he has left rests with science- and evidence-based medicine, as small and weak as that hope may currently seem.
Tony Isaacs was displeased:
The mainstream medicine group that has failed to conquer cancer for half a century has clearly gotten into Swayze’s head. These are the same MD’s and oncologist who will more often than not advise a person to not take antioxidants when having chemo, though there have been no reliable studies to support such advice and many which dispute it. The mainstream chemo theory is to weaken and destroy the cancer cells with chemical poison which also weakens and destroys the rest of the body’s cells and organs in the often misplaced hope that the symptoms of cancer (tumors and cancer cell masses) will somehow be eliminated before the treatment itself kills the patient. It is a desperate gamble that fails more often than not. Even when most or all of the symptoms are eliminated by chemo (or radiation), the damage to the body’s natural immune system, major organs and overall health is so great that the way is paved for the return and unabated growth of cancer in a body whose natural defenses have been rendered virtually useless.
So far, nothing different than the usual tropes. Yes, differential toxicity towards cancer cells compared to normal cells is how chemotherapy works. However, the immune system is far more resiliant than woo-philes like Isaacs can conceive. They seem to think that the immune system can’t ever recover from the insult of chemotherapy. It can. It is also true that chemotherapy can increase the risk of secondary malignancies, as can radiation. However, the benefits of chemotherapy and radiation usually outweigh the risks of secondary malignancies. Indeed, if a cancer patient lives long enough to get a secondary malignancy, usually many years, isn’t that better than dying within months of the first cancer? Moreover, it’s not as though “conventional” doctors are not aware of this problem and researchers aren’t trying to find treatments that either don’t produce this complication or have a lower chance of producing it. Here, however, is where we see how the word “natural” means something different in CAM-speak than it does everywhere else:
While addressing the underlying causes of cancer is the ultimate key to long term cancer survival, one cannot ignore the symptoms of cancer which may well kill you in the short term before you are able to restore you body and immune system to optimum health. Here too, the right herbs and supplements can play a vital role in attacking tumors and cancer cells to arrest their growth and eliminate them to give the body the time it often needs to become restored and keep cancer at bay in the future. Though pancreatic cancer is a very aggressive and difficult cancer to beat, two natural items featured here at Natural News have been particularly successful against pancreatic cancer: oleander and black cumin seed oil.
Elsewhere, Isaacs drives his point home:
In contrast to at least 6000 years of the practice of natural medicine, Western medicine treats the body as a collection of parts instead of as a synergistic organism. When it comes to treating broken bones and injured body parts, mainstream Western medicine is unequaled. When this same approach is used to treat illness and disease – fixing or repairing the parts where the symptoms of underlying illnesses manifest themselves, modern medicine fails miserably
In the instance of cancer, instead of addressing the causes of cancer – toxins, pathogens and a weakened immune system – we see instead treatments that either slash, burn or poison away the tumors and cancer cells, which further weakens an immune system cancer has already defeated and only worsens the conditions that led to cancer to begin with.
[...]
And so, when we go to an oncologist and are diagnosed with cancer what is the prescribed treatment? Does it incorporate ANY of the above elements? No, sadly it does not. Our doctor prescribes what he or she has been taught: cut out, radiate or poison the symptom and do nothing to address the underlying causes and natural imbalances that led to the symptom.
As a result, the way is paved for the return of the cancer or the introduction of another cancer or serious condition. Even worse, the road to further illness is often made easier due to the damage to the immune system and major organs caused by the treatment of the symptom.
Nature, on the other hand, enables us to address virtually every area of knowledge and concern. In a future installment, we will take a look at a suggested protocol based on what nature has to offer.
This is nonsense on many, many levels. Science-based physicians have been studying nature for centuries trying to find the cause of and cure for cancer. Indeed, science has also been studying natural compounds for centuries, and many of our most potent drugs against cancer. Examples include the class of drugs known as taxanes or the class of drugs known as the vinca alcaloids, which were originally isolated and/or modified from plants. Indeed, existing happily within science- and evidence-based medicine is a discipline dedicated to finding natural products that can treat or cure disease. It’s called pharmacognosy, and is the area of study that our occasional coblogger David Kroll specializes in. What Isaacs is presenting is a false dichotomy: Either accept his pseudoscientific representations of what herbs, supplements, and “natural products” can do or die from cancer.
Isaacs is not even consistent, either. He refers to chemotherapy as “poison,” but he sells oleander plant extracts and an “oleander soup” as a treatment for various cancers and other diseases. In some places, he likes to brag about how the UT-M.D. Anderson Cancer Center is supposedly studying oleander as a treatment for cancer. However, the M.D. Anderson website itself describes just how toxic oleander is:
Side Effects and Warnings:
Common oleander contains a strychnine-like toxin and a heart-active cardiac glycoside substance (similar to the prescription drug digoxin) that may cause the heart to beat rapidly or abnormally, or to stop beating. Common oleander has been used as rat poison, insecticide and fish poison and is toxic to mammals including humans. Animals (sheep) have died after eating as little as two to three leaves of Nerium oleander (common oleander). Children may die after eating a single leaf of common oleander. Eating the leaves, flowers or bark of common oleander may cause nausea, vomiting, stomach cramps, pain, fatigue, drowsiness, unsteadiness, bloody diarrhea, abnormal heart rhythms, seizures, liver or kidney damage or unconsciousness. Death may occur within one day. Reports of toxicity and deaths in children and adults have been reported for decades in Australia, India, Sri Lanka and the United States.
Fruits of Thevetin peruviana (yellow oleander) are thought to be even more toxic to mammals, including humans. Based on human studies of intentional overdose (suicide attempts), eating eight or more seeds of yellow oleander may be fatal. Additional side effects of oleander ingestion include irritation and redness of lips, gums and tongue, nausea, vomiting, depression, irritability, fast breathing, sweating, stomach pain, diarrhea, headache, confusion, visual disturbances and constricted pupils. Abnormal blood tests, including tests of liver and kidney function (potassium, bilirubin, creatinine and blood urea), have been reported in humans. It is possible that plants grown in the same soil as oleander plants or in soil exposed to oleander may contain trace amounts of oleander.
That’s some seriously toxic stuff, isn’t it? In fact, it sounds a lot like…chemotherapy. Yes, that’s exactly what it sounds like. Actually, it sounds like some of the most toxic chemotherapy currently used–maybe even more toxic. Worse, unlike many chemotherapeutic agents, it’s unclear if oleander extracts have any actual benefit against pancreatic cancer–or any other cancer, for that matter. It’s possible that they might, as might any natural product with biologically active agents with the appropriate chemical activity, but the evidence isn’t there in the form of randomized trials showing a definite benefit. Such evidence may be found someday, but it is not there yet. Certainly Isaacs’ anecdotes do not qualify as any sort of convincing evidence. Indeed, he brags about pancreatic cancer patients living five months using a specific oleander extract called Anvirzel, but in retort I point out that Patrick Swayze has lived nearly a year since his diagnosis using science-based medical therapies. Of course, the example of Patrick Swayze tells us no more than the example of patients taking Anvirzel. One year survival rates for patients with advanced pancreatic cancer range from 20-30%. That’s why randomized clinical trials are needed. Moreover, even if oleander is effective against pancreatic cancer, it is clear that it is unlikely to be much more effective than current chemotherapy, if it is even as effective.
So what makes chemotherapy “unnatural” and oleander “natural”? In fact, Isaacs’ hypocrisy goes beyond that, because the oleander extract he is touting is not any sort of raw plant extract. It’s a natural product isolated by–horror of horrors!–an actual biotech startup company! It’s a pharmaceutical company, and it’s not studying these extracts because of any commitment to “natural” therapies. It’s studying them because its scientists hope that they will form the basis of effective chemotherapy against various cancers and, above all else, to make money. That’s what companies exist for, to make money for their investors and shareholders. In other words, it’s just like the big pharmaceutical giants Merck and Bristol-Myers-Squibb except that it’s not that big. But it hopes to be someday.
Also, apparently one of the clinical trials using oleander is for another experimental agent dubbed testing an agent dubbed PBI-05204. It is a phase I trial, which means that it is not testing efficacy, but rather maximum tolerated dose and pharmacokinetics. In any case, get a load of what Isaacs said about it:
I realize that oleander in raw form is highly toxic – but not so when processed into the medicine and supplement form (which is itself now made by a pharmaceutical manufacturing company to exact standards) and the FDA phase I trials found no doseage limit for toxicity, but rather stopped because the dose reached a size that was impractical to exceed.
As a point of interest, the very latest oleander medicine that has entered phase I FDA testing at MD Anderson clinic has no name yet, but is known simply as PBI-05204 (the PBI stands for Phoenix Biotechnology Inc).
Taking raw plant compounds and then processing them and modifying them to make them less toxic and (hopefully) more effective is exactly what the science-based medical science of pharmacognosy has been doing for centuries and, yes, those evil pharmaceutical companies have been doing for many decades, if not over a century. More than that, PBI-05204 is a drug. Not only is it a drug, but it’s a drug made by a pharmaceutical company, a startup biotechnology company that’s raising cash from investors just like any other biotech company and, presumably, hopes someday to make a tidy profit and grow into something much bigger. Moreover, the oleander product PBI-05204 is a purified (and possibly modified) natural product, just like lots of other experimental compounds isolated, purified, chemically modified, and manufactured by pharmaceutical companies, both large and small. The only difference is that this particular patented natural product is derived from a plant something that Isaacs likes, extracts of which promotes in the form of oleander soup.
Now do you understand what I am talking about? As was the case with Humpty Dumpty, to Isaacs, “natural” means exactly what he chooses it to mean, neither more nor less. The list of cancer chemotherapeutics derived from natural products is long: taxol (derived from the bark of the Pacific yew tree), vincristine and vinblastine (derived from Catharanthus roseus, commonly known as the Madagascar periwinkle), campothecin and irinotecan (discovered in the barks of the Chinese camptotheca tree and the Asian nothapodytes tree), anthracycline chemotherapy agents such as doxorubicin (derived from the bacteria Streptomyces peucetius), and etoposide (derived from the mayapple), among others. To Isaacs and other advocates of so-called “natural” therapies, these chemotherapeutic agents are purest evil, the tool of the Devil himself, given that they are used by oncologists to “poison” cancer. In contrast, it doesn’t matter to him that the oleander plant is extremely toxic and that extracts from it can similarly be very toxic. To Isaacs, it’s “natural.” That means it must be good; it must be holy; it must be right. It must cure cancer, HIV, and other diseases.
Here’s another example. On Tony Isaacs’ website, a man named Chris Beckett writes:
The human body is self-preserving, self-maintaining, and self-healing. All that is required from us is to remove the causes of the problem, rest (go to bed) and preferably stop eating (fast), since the body will use the energy saved from not having to digest food, for the incredibly powerful healing & cleansing processes of the body to be initiated.
Yet on his very website, he is selling colloidal gold, all manner of supplements, various “oxygen-saturated” gels (trust me, you don’t need extra oxygen on your skin, even if the oxygen doesn’t diffuse away almost as soon as the gel is applied), and even collodal silver! Never mind that colloidal silver is no more “natural” than metallic silver forged into a ring or other jewelry. It has to be isolated, synthesized, and made into a colloidal suspension. It’s also funny how Isaacs fails to mention that chronic usage of colloidal silver can produce what I’ve occasionally termed the “Smurf syndrome,” a.k.a. agyria.
Come to think of it, there’s one other therapy that is frequently touted as “natural,” and that’s “detoxification” therapies, such as the regimens popularized by Max Gerson or Nicholas Gonzalez. After all, the colon is a finely tuned organ that naturally eliminates waste and does it quite effectively. Yet, if we are to believe “alternative” medicine practioners, the colon can’t do its job and needs to be “cleansed.” In fact, I find it hard to imagine anything more unnatural than the “colon cleansing” therapies, variants of which have been espoused and popularized by Gerson, Kelly, and Gonzalez. After all, they involve pumping large quantities of fluids into one’s rectum to fill the colon and flush out the feces and supposedly somehow “detoxify” the liver, coupled with the ingestion of all sorts of supplements and juices to the point where the carrot juice can turn patients orange. What’s so “natural” about shooting coffee (or anything other liquid) up your butt and taking up to 100 supplement pills a day? Yet, what do we find on Tony Isaac’s page?
That’s right, all sorts of “intestinal detox” and colon cleansing products that the human body does not need and that may even be harmful. In fact, the body does quite a good job of “cleansing” itself of “toxins” without all these unnatural interventions. Apparently, these advocates of “natural hygiene” don’t trust the body’s natural ability to detoxify itself. I realize that they claim that the “modern world” is so full of “toxins” that the body supposedly never evolved to eliminate, but in reality much about our world is actually cleaner than it was, say, 100 years ago. More importantly, these toxins are always unnamed or their identities only vaguely alluded to; there is never any compelling evidence presented that they cause the chronic health problems attributed to them; and there is never any evidence from basic science or clinical studies to show that these “detox regimens” actually “detoxify” anything, much less cure the diseases or relieve the symptoms for which they are advocated.
The bottom line is that the belief that “natural” is better than the products of big pharma is far more akin to religion than to science, and it is this belief that drives so much of the “alternative” medicine movement. Mr. Isaacs himself epitomizes this double standard through his hawking of various oleander extracts, even though oleander is extremely toxic, and his ability to see no conflict at all between his support of using purified components from oleander made by a profit-driven startup biotech company and his disparaging of chemotherapy and “mainstream” medicine as not being “natural.” Those of us advocating science-based oncology, in contrast, perceive no difference. Oleander extracts, if they end up being shown to be effective against cancer, will be correctly considered chemotherapy. Oncologists will happily add them to their armamentarium of chemotherapy and use them based solely on their ratio of efficacy to toxicity.
Just like any other new cancer therapy that is shown to be effective.
Also, these oleander extracts are being tested and marketed by institutions that are firmly part of the “conventional” biomedical industrial complex, with clinical trials being done at a major cancer center. Actually that’s not entirely correct. There is one difference between Isaac’s oleander and chemotherapy. Specifically, there has to be hard scientific evidence that chemotherapy is effectve against various cancers before it can be marketed. Oleander extracts have not yet passed that hurdle. They may, but they have not yet. Yet that doesn’t stop Isaacs from making unsupported claims for their efficacy, especially given that there is no evidence that I can find that oleander extracts are any more effective against, for example, pancreatic cancer than currently used chemotherapy regimens. Certainly there is no evidence that Isaacs can present of any miraculous-seeming “cures” that would make his bold admonition that Patrick Swayze would do much better with “natural” therapies like oleander than he is currently doing using the fruits scientific oncology to fight his cancer.
Co-blogger Mark Crislip once characterized CAM/IM in a frighteningly accurate way, one that I will likely appropriate when I have the opportunity:
Much of alternative medicine where it overlaps with real medicine is the art of making therapeutic mountains out of clinical molehills.
That’s exactly what Isaacs is doing here. He takes the results of cell culture studies and preliminary phase I clinical trials for various oleander extracts and, because he perceives them as being more “natural” than chemotherapy, ignores just how toxic oleander is, and arrogantly argues that his “natural” therapies are so much better than conventional chemotherapy that poor Patrick Swayze is hopelessly deluded to choose science-based medicine instead of his so-called “natural” cures.
Two and two equal three or five indeed depending the need, and words mean exactly what CAM/IM advocates choose them to mean, neither more nor less. Especially the word “natural.”

   On the nature of “alternative” medicine cancer cure testimonials
David Gorski 
Link
No doubt you’ve come across them before, either on the Internet, printed advertisements, or radio and TV ads: Alternative medicine cancer “testimonials.” They are the primary means by which “alternative” therapies for cancer (or just about any other disease) are promoted and the primary “evidence” that is used to “prove” the efficacy of non-evidence-based therapies. There’s no doubt that they sure can sound convincing. Typically, what you will see or hear is a chipper-looking and -sounding person who claims that this treatment “cured” his or her cancer. These testimonials almost always include many or all of these elements: First, the cancer patient receives the diagnosis, after which she is lost and suffering at the hands of “conventional” doctors, who either cannot or do not wish to understand and who cannot do anything for her. Often, this will take the form of the classic alt-med cliche that the patient was “sent home to die.” Then, when all hope seems lost, the patient discovers an alternative medicine “healer” or treatment. It is not infrequently described in quasireligious terms, like a revelation or something that brings the patient out of the darkness and into the light. Naturally, there is resistance from the patient’s doctors, family, and/or friends, who warn against it, with doctors warning of dire consequences if the patient abandons conventional medicine. But the patient, convinced by dubious practitioners, friends, and, of course, previous testimonials, “sees” that the treatment “works” in a way that medical science cannot and survives. Infused with fervor, the patient now wants to spread the word. Often, the patient is now selling the remedy. Perhaps you’ve seen such testimonials or heard them on the radio and thought: “Gee, this sounds great. I wonder if it works.”
The answer is: Almost certainly not.
Let’s face it. Cancer is definitely scary. In fact, a cancer diagnosis is very, very scary thing for anyone to face, even when it is a cancer that is treatable and potentially curable. One reason is that it’s such a common type of disease that, by the time we reach a certain age, almost all of us have seen at least one friend or loved one die of it. All too often, that death is horrific, and even when it is not the wasting and weakness that are often seen before the end provokes a visceral reaction produced by few diseases. Worse, the treatments of cancer can be toxic. For solid tumors, surgery, sometimes disfiguring, is often required. Radiation therapy may be needed, or, most feared of all, chemotherapy. Contrary to what is said on many websites dedicated to “alternative” medicine, doctors do not “cut,” “burn,” and “poison” cancer patients (as proponents of unscientific treatments for cancer often characterize cancer treatments) because we enjoy it or because of failure of imagination. We use them because they are the best treatments that we currently have, and, for several common malignancies, they are quite effective. Even so, this cartoon remains a common misconception of what cancer therapies are.
Given the fear of cancer and treatments for cancer, it is not surprising that nonscientific “cures” flourish and many people, unfortunately, fall prey to them. Of course, it is not science that drives these sorts of therapies, although they are often dressed up in “science-y” sounding terminology in order to obscure what to an oncologist or cancer investigator would obviously be the extreme biological or even physical implausibility of the remedy. These treatments do not rely on randomized clinical trials or basic science to support their efficacy, either. Rather, they rely on testimonials, one of the most visible and highly abused methods of selling dubious therapies. Because it is my specialty, I will concentrate on breast cancer testimonials as a prototypical example, although many of the same principles apply to any “alternative medicine” testimonial.
Before I can explain why testimonials are generally unconvincing to anyone who knows a bit about cancer, a little terminology is in order. The treatment of breast cancer is divided into two phases, locoregional control (treatment of the disease in the breast and the axillary lymph nodes) and systemic control (prevention of distant metastases). Surgery and radiation therapy are modalities used for local control; chemotherapy and hormonal therapy, for systemic control. Adjuvant therapy is one of these modalities administered after surgery. Adjuvant radiation therapy will improve local control and lower the rate of recurrence in the breast. Adjuvant chemotherapy and hormonal therapy will improve systemic control and decrease the rate of development of metastases, which are usually what kill patients. Such adjuvant therapies are what I like to call “icing on the cake” of surgery.
The reason breast cancer testimonials sound so convincing is that most lay people don’t know a lot about the disease, particularly that surgery alone “cures” many breast cancers. Early stage cancers are cured by surgery alone more often than not, and a significant minority of patients with even large tumors and multiple positive lymph nodes still have a not insignificant chance of long term survival with surgery alone. I’ll start with a very common example. In the case of a lumpectomy, the local recurrence rate in the breast can be as high 30-40%. Radiation can reduce it to less than 10%. That means that women who forgo radiation are still more likely than not to avoid local recurrence in their breast, particularly if their tumor is small. In terms of distant metastases, which is what kills in the case of breast cancer and virtually all solid malignancies, chemotherapy and hormonal therapy improve survival. The improvement is small on an absolute basis in patients with early stage cancers but becomes more impressive with more advanced operable tumors. Because many breast cancer patients will do well with surgery alone, clinical trials with large numbers of patients are needed to find true treatment effects due to adjuvant therapies. Indeed, one of the hottest areas of cancer research is to determine molecular characteristics of tumors that will allow oncologists to differentiate women with low risk disease, who could forego chemotherapy safely, from those with high risk disease, who would be far more likely to benefit. As it is now, we give chemotherapy to the many in order to benefit the few simply because we do not know which specific women will benefit.
These facts help to explain breast cancer survivors who have undergone surgery but decided to forego chemotherapy and/or radiation therapy in favor of “alternative” medicine (Suzanne Somers, for instance). When such patients have a tumor with a good prognosis, where recurrence is uncommon or have a more advanced tumor but are lucky enough not to recur, they attribute their survival not to the primary surgery, but rather to whatever alternative therapy they have decided to take, even though it almost certainly had nothing to do with their survival. To them, it was the alternative medicine that “saved” them, not good old-fashioned surgery. In contrast, women who opt for alternative therapy and then recur obviously don’t provide good testimonials to sell alternative medicine, which is why you almost never hear about them. They’re bad for business.
Some might ask: Why do patients fall for this? It is not a matter of intelligence. In my experience, women who pursue alternative therapy are, more often than not, intelligent and/or highly educated. Instead, they do not possess sufficient scientific knowledge and/or critical thinking skills to separate truth from nonsense in medicine. Cancer and most other diseases are not something about whose therapy one can self-teach with much hope of success. However, because we all have to deal with health issues at one time or another, we all have opinions about them and, in a democratic delusion, tend to think that we can teach ourselves enough about the science of a disease to become “experts.” We don’t do this so much about, say quantum physics. Few would think that they could self-educate about particle physics enough to argue against well-supported science when it comes to particle physics, but many will do so with medicine. Unfortunately, we as physicians all too often encourage such thinking by being dismissive or not listening closely enough to the complaints of our patients.
It also seems to be a question of human nature. The diagnosis of breast cancer can be emotionally devastating. Formerly self-assured women feel themselves losing control of their lives. Unfortunately, our system of medicine reinforces this feeling of loss of control, as it is all too often impersonal and even disrespectful of patients. Patients find themselves going to multiple doctor’s visits, where all too often they have to wait for hours in crowded waiting rooms to see their doctors, who then, thanks to the demands of managed care, only spend 5 or 10 minutes with them discussing a life-threatening disease. They deal with voicemail hell trying to reach their doctor when they are having problems and endure many other indignities. They often conclude from this that the system does not respect their time or them (which it often doesn’t) and that they are considered nothing more than a number, a disease, an insurance number, or money. In contrast, “alternative” practitioners often provide the human touch that is too often missing from modern medicine. They take the time to listen to the patient and make her feel good about herself and her decision, all too often giving erroneous information about chemotherapy and radiation therapy. When a woman makes a decision to choose alternative therapy, she often sees herself as “taking control” of her treatment from uncaring doctors whose treatments, she is told, do not treat the root cause of her disease. Understandably, she may feel liberated from the tyranny of HMOs, cancer centers, clinics, and hospitals and back in control of her own destiny. In addition, many testimonials have religious overtones as well, where lost, suffering women misguided by conventional doctors and without hope find a savior (their “healer”) and/or enlightenment (the “alternative” therapy) that leads her out of the darkness and into the light of good health again. Her ignoring the reportedly dire warnings of doctors (unbelievers, apostates, infidels) is validated by her apparently excellent outcome.
That religion and spirituality should play such a large role in alternative medicine testimonials should not be surprising, given how much of alt-med is infused with New Age “spirituality” about living “energy flows” and connections with the earth. Consider, for instance, the concepts behind traditional Chinese medicine (TCM). These concepts are mostly based on a non-Christian religion (Taoism) particularly the emphasis of TCM on the need to correct “imbalances” between different kinds of spiritual “energies” in order to restore health. These concepts powerfully influence more of alt-med than just TCM. Sometimes, fundamentalist Christians, who would normally be very suspicious of such non-Christian concepts, manage find a way to infuse their brand of alt-med with their Christian religion (particularly faith-healing, which fits in well with alt-med spirituality) or to downplay inconvenient Eastern or pagan spirituality that underlies much of alt-med. (For examples of what I’m talking about check this and this out.)
Even doctors, who are trained to have the knowledge and critical thinking skills to know better, are not immune to falling under this spell. Case in point, Dr. Lorraine Day was Associate Professor of Orthopedic Surgery at UCSF and Chief of Orthopedic Surgery at San Francisco General Hospital in the 1980′s. She made a name for herself through dire warnings of AIDS spreading through aerosolized blood during trauma surgery (although, as far as I can tell from PubMed, she never published any studies in peer-reviewed journals to support her claims other than this interview). In the early 1990′s, Dr. Day developed breast cancer. Her website and this annotated transcript of one of her informercials tell her tale. In brief, in 1993 Dr. Day underwent an excisional biopsy that showed a ~2 cm breast cancer, with tumor extending to the margins. She then underwent what sounds like a re-excision lumpectomy, refusing the addition of axillary dissection, the standard of care at the time. (Axillary dissection has since been supplanted, for most breast cancer patients, by sentinel lymph node biopsy.) Dr. Day then started an alternative medicine regimen of diet manipulations and prayer. Nine months later, she developed a small “bump” near her previous site, which (she claims) grew to the size of a grapefruit in only three weeks. She even posted a picture. (I have to point out that I’ve never seen a breast cancer–recurrent or primary–even a really nasty one, that looked like this or that grew that fast. Invasive breast cancers usually start ulcerating through the skin long before they stick out and stretch the skin the way that Dr. Day’s lesion did.) The mass was, according to her, partially removed surgically, after which she was “sent home to die.”
Of course, this is not how her story ended. According to her testimonial, she “cured” herself with a regimen that included the same sorts of dietary manipulations and prayer as before. Dr. Barrett has posted a very good analysis of Dr. Day’s story and a deconstruction of her infomercial, concluding that the second operation most likely cured her and that the grapefruit-sized mass was most likely not recurrent cancer. Given that Dr. Day has refused to release the pathology report for her last operation after having released her first pathology report and only part of her second report (it’s a cancer staging form without the actual pathology report and leaves out the part that tells whether the residual cancer had been completely excised with clear margins at her second operation), I tend to agree with Dr. Barrett’s assessment. Very likely the last pathology report shows no breast cancer (in which case the second operation cured her) or a recurrent cancer that was completely excised (in which case the third operation cured her). Of course, Dr. Day could easily prove doubters wrong by releasing the the complete second report or the last pathology report, but she does not.
I mention this case to demonstrate that even highly trained and educated doctors, who should be able to evaluate alternative medicine therapies dispassionately, can become their biggest boosters. Even if Dr. Day could prove that she cured herself exactly as described on her website, I would still ask her why she never did a clinical trial to see if her result could be generalized to others, instead of using her story to sell a product called Barley Green and her books and videos. I would ask her why she didn’t hook up with basic scientists to study the constituents of Barley Green. That would be what a real academic surgeon would do. If her recovery was as miraculous as she claims, it would not take very many patients or very long at all to show the efficacy of her regimen. Unfortunately, Dr. Day appears to take a dim view of even honest criticism and is not above threatening her critics with the wrath of God. Ironically, recently Dr. Day announced that she will no longer sell Barley Green because the company that previously manufactured it was taken over by a Japanese company, which is going to supplant it with a barley product that uses “energized water.” Oddly enough, Dr. Day can believe that Barley Green and prayer saved her life, but is very skeptical about anything that even has a whiff of New Age about it.
Another aspect of testimonials is denial. There is a need to believe that the chosen “alternative” therapy is working, even when the evidence shows that it is not. One example of such a testimonial is a woman by the name of Kim Tinkham. If you read her story, it contains many of the same elements that Dr. Day’s did. There is the diagnosis, the shock, and then the seemingly brave decision to go against what three doctors recommended for her stage III breast cancer, namely a lumpectomy and axillary lymph node dissection, followed by chemotherapy and radiation, a very reasonable recommendation with a decent chance of saving her life. What’s missing are two things. First, Tinkham didn’t undergo a surgical excision of her tumor. Instead, she fell under the influence of a practitioner named Robert O. Young, who believes that in essence all disease, including cancer, is due to excess acidity and treats it all by trying to “alkalinize the blood.” Second, she spared us the cliche of her doctors “sending her home to die.” Here is one part of her testimonial, that really stands out:
She can still feel the tumor just underneath the surface of her skin, where it will probably remain for a while.
But she knows it’s harmless. Now, it’s simply her badge of honor – the reminder that she, Kim Tinkham, defeated cancer without any surgery, invasive procedures, radiation or chemotherapy.
Note that Tinkam tells us that the tumor is still there! Note also that no mention is made of whether the tumor has grown or shrunk. What is most likely going on is that Tinkham is fortunate enough to have a relatively indolent, nonaggressive tumor. It is probably slowly growing; so that in the ten months or so since her diagnosis it may not be obvious that it’s grown unless she regularly undergoes ultrasounds, mammograms, or MRIs, which would give an objective measurement of its size. So, if the tumor is still there and is not obviously shrinking, how on earth can Young tell Tinkham that her tumor is gone? Here’s how:
A recent blood test proved that the stage three breast cancer diagnosed in February is absent from her body. But she really didn’t need a blood test to tell her that. Just hours after she had her blood taken for the test, and days before she knew the results, she was confident that her new lifestyle had allowed her body to fight the cancer.
I want to emphasize right here that there is no blood test that can tell a woman that she is breast cancer free. None. Unlike PSA for prostate cancer and CEA for colorectal cancer, tumor markers for breast cancer are notoriously unreliable. Moreover, even if she did have a blood test that told her she is tumor free, if the tumor is still there, she should pay attention to the tumor, not to any dubious “blood test” that a dubious practitioner represents to her as having any validity whatsoever in determining the status of her tumor. One of the aspects of unscientific practitioners is that they often have unscientific and unvalidated blood tests or other tests that “monitor” the tumor. They then tell patients that their tumor is getting better on the basis of these tests alone, even as the evidence is that it is not. They tell the patient she is getting better (or even “cancer-free”) right up until she becomes moribund.
This testimonial also demonstrates the religious or spiritual element that is often behind so much of “alternative” medicine. I did a search on her name, and it became clear in accounts of how Oprah Winfrey had Tinkham on her show to discuss her decision to treat her breast cancer with “natural” methods that Tinkham believes in The Secret. The same sort of wishful thinking that led her to fall for nonsense such as the “Law of Attraction” has led her to fall for the science-free nonsense that Young is telling her about her cancer. The bottom line is that, to those with little knowledge of medicine, testimonials can sound convincing. However, behind them there is usually a Secret-like element of really, really wanting to believe. Moreover, even someone without much medical knowledge but with halfway decent critical thinking skills and some skepticism should be able to come up with the right question, namely: How on earth can Tinkham claim that she is cancer-free on the basis of a blood test alone when her tumor is still there? Such a person will see this testimonial for what it obviously is, and that person won’t necessarily have to be highly educated to do it.
Never forget that alternative medicine testimonials exist largely for one purpose: To sell a product. Most of them are advertisements, nothing more. They are no more “unbiased” than pharmaceutical advertisements for their latest, greatest drug. In fact, they are worse, because at least the pharmaceutical companies have to be able to back up their claims with science and disclose potential adverse reactions in their ads. No such requirements exist for most alternative medical treatments, mainly because most of them claim to be supplements rather than medicines. The other problem with testimonials is that they don’t rise even to the lowest level of medical evidence, the anecdotal report. Anecdotal reports in medicine require a careful documentation of symptoms, lab tests, diagnoses, exact courses of treatment, and a patient’s response to treatment. Testimonials almost never present these elements in sufficient detail to judge whether the treatment actually did anything. There’s just no way of telling truth from exaggeration or fiction. Boiled down to the essence, these testimonials usually appear convincing for one of these reasons:
     1.  The patient never had cancer to begin with. It was either an erroneous diagnosis by a legitimate doctor or a diagnosis based on an unscientific and unvalidated test used by the alt-med practitioner. This is more common than one might think (one example is pancreatic cancer), and I may do a post on this issue in the future.
     2.  The patient underwent partial conventional therapy before abandoning it for alt-med (for example, an excision but no radiation or chemotherapy, like Suzanne Somers or Lorraine Day).
     3.  The patient still has cancer but, like Kim Tinkham, has been told by her practitioner that she is “cancer-free.” If the tumor is slow-growing, this may be convincing for many months or even a few years.
In conclusion, be very skeptical of alt-med testimonials. If you look at them closely, you will often find that the patient did have significant conventional treatment; that the story is vague (often omitting, for example, the stage or histology of cancer or even whether the cancer was biopsy-proven); that there is no objective data, just references to other testimonials; or that the data mentioned either comes from alt-med websites selling a product rather than peer-reviewed medical journals or is a non sequitur about studies in peer-reviewed sources. They also have an afterlife, and it is not uncommon for cancer testimonials from patients who have died of their cancer to continue to circulate on the Internet long after the patient’s death, much like the undead. Finally, remember that conventional medicine is not above misusing testimonials in advertisements. Treat them with the same degree of skepticism. Look for the scientific and clinical evidence, not stories of great cures, regardless of the type of testimonial. If there is one principle I hope to impart here, it is that the claims of conventional medicine and alternative medicine should be treated the same and that they should be held to the same standard of both basic scientific and clinical evidence. I do not differentiate between the two when considering evidence, nor should you.

   Chemotherapy doesn’t work? Not so fast…
David Gorski 
Link
“CHEMOTHERAPY DOESN’T WORK!!!!!”
“CHEMOTHERAPY IS POISON!!!!”
“CHEMOTHERAPY WILL KILL YOU!!!!”
I’ve lost count of how many times I’ve come across statements like the ones above, often in all caps, quite frequently with more than one exclamation point, on the websites of “natural healers,” purveyors of “alternative medicine.” In fact, if you Google “chemotherapy doesn’t work,” “chemotherapy is poison,” or “chemotherapy kills,” you’ll get thousands upon thousands of hits. In the case of “chemotherapy kills,” Google will even start autofilling it to read “chemotherapy kills more than it saves.” The vast majority of the hits from these searches usually come from websites hostile to science-based medicine. Examples include Mercola.com, the website of “alternative medicine entrepreneur” Dr. Joe Mercola and NaturalNews.com, the website of Mike Adams, where you will find cartoons like this one, which likens the administration of chemotherapy to a Nazi death camp: Link
Here’s another example, entitled The truth about chemotherapy and the cancer industry: Link
Note how Adams portrays screening for cancer and chemotherapy as a deadly scam designed solely to enrich the “cancer industry” as it kills patients.
As my final example, there’s this cartoon: Link
An article by Mike Adams entitled Chemotherapy Stickup that accompanies the cartoon above makes this astounding claim:
There is not a single cancer patient that has ever been cured by chemotherapy. Zero. They don’t exist. Not a single documented case in the history of western medicine.
And why is that? Because conventional medicine operates from the false belief that there is no cure for cancer! Thus, anyone offering a cure (or assisting in the body’s own natural reversal of the disease) is immediately dismissed as a quack. Meanwhile, the real quackery is found in the pushing of toxic chemotherapy chemicals that are injected into the bodies of patients and called “treatment” when they should really be called “torture.” (Nancy Pelosi, by the way, was never briefed on the fact that chemotherapy is torture…)
When I first encountered that cartoon a few years ago, I was a bit surprised that even Mike Adams would go so far as to make such an absolutist statement that not a single person has ever been cured of cancer by chemotherapy in the entire history of “western medicine.” All it would take is a single example to prove him wrong, like—oh, you know—Lance Armstrong, the patients cared for by my pediatric oncology colleagues, or the patients I saw during my training cured of anal cancer by the Nigro protocol. The Nigro protocol, by the way, consists of combined chemotherapy and radiation and is still the standard of care for anal cancer. That doesn’t even count all the patients with leukemia or lymphoma cured primarily by chemotherapy.
Unfortunately, this attitude isn’t just limited to cranks. There are legitimate scientists, even those who have published in magazines devoted to skepticism, who make very similar statements, although perhaps not quite as absolutist. Not quite, but close. For example, there’s Reynold Spector, whom Mark Crislip and I took to task for his article earlier this year in Skeptical Inquirer entitled Seven Deadly Medical Hypotheses. One of his “seven deadly medical hypotheses” read thusly:
From a cancer patient population and public health perspective, cancer chemotherapy (chemo) has been a major medical advance.
In other words, to Dr. Spector, the very idea that chemotherapy is a notable advance in the treatment of cancer is a “deadly medical hypothesis.” Of course, his statement is not a hypothesis at all, deadly or otherwise, as what one means by a “major medical advance” is very subjective (Dr. Spector really needs to get himself hence to a medical dictionary) and the weasel words of “from a patient population and public health perspective” give Dr. Spector wiggle room, but it’s very clear what his intent is. He doesn’t think chemotherapy works very well, if at all, even as he admits:
However, it cannot be denied that there are a few populations for which chemotherapy is marvelously effective, as noted above, and must be used.
So which is it?
In previous posts, such as Why haven’t we cured cancer yet? and Skepticism versus nihilism about cancer in science-based medicine, I explored some of these questions. In the former article, I pointed out just how complex the problem is, with cancer being hundreds of different diseases and using the example of just how messed up the prostate cancer genome is to provide an idea of the magnitude of the problem. In the second article, I pointed out an example of a specific cancer for which advances in chemotherapy have made a meaningful difference in both survival and quality of life outcomes. What I haven’t yet done is to look at the arguments cancer cranks use to try to convince people that chemotherapy doesn’t work.
Attacking chemotherapy
Any rational assessment of the efficacy of chemotherapy must be forced to include an admission that chemotherapy is only rarely curative in solid malignancies, particularly advanced solid malignancies. Notable exceptions include testicular cancer (which is what Lance Armstrong was cured of) and anal cancer. In contrast, for hematological malignancies, such as leukemia and lymphoma, chemotherapy is usually the mainstay of therapy. However, not being curative doesn’t mean that chemotherapy is useless anymore than the fact that beta blockers don’t cure hypertension and metformin doesn’t cure diabetes makes them “useless” drugs. Before we take a rational look at what chemotherapy can and can’t do, let me just point out that there are three studies that are frequently used by cranks to try to argue that chemotherapy is useless.
The first one is easily dismissed, but you’ll see it a lot anyway. It’s frequently cited in articles with titles like 75% of MDs Refuse Chemotherapy Themselves and the claim will go something like this:
Several full-time scientists at the McGill Cancer Center sent to 118 doctors, all experts on lung cancer, a questionnaire to determine the level of trust they had in the therapies they were applying; they were asked to imagine that they themselves had contracted the disease and which of the six current experimental therapies they would choose. 79 doctors answered, 64 of them said that they would not consent to undergo any treatment containing cis-platinum – one of the common chemotherapy drugs they used – while 58 out of 79 believed that all the experimental therapies above were not accepted because of the ineffectiveness and the elevated level of toxicity of chemotherapy. (Source: Philip Day, “Cancer: Why we’re still dying to know the truth”, Credence Publications, 2000)
Wow! This sounds really damning, doesn’t it? What hypocrites those oncologists are! Right?
Wrong.
It turns out that this survey is over 25 years old and was about a specific kind of chemotherapy, cisplatin for non-small cell lung cancer, which was a new therapy at the time and didn’t have a lot of evidence for it. As Anaximperator describes, a followup survey was conducted in 1997 at a session on the National Comprehensive Cancer Network (NCCN) clinical practice guidelines. Participants were asked to respond to the same question regarding chemotherapy:
You are a 60-year-old oncologist with non-small-cell lung cancer, one liver metastasis, and bone metastases.
Your performance status is 1. Would you take chemotherapy? Yes or no?
The results? Let Anaximperator tell the tale:
The overall results of the 1997 follow-up survey show that 64.5% would now take chemotherapy – which is almost a doubling from 34% to 64.5% of those willing to have chemotherapy and radiotherapy and a quadrupling from 17% to 64.5% of those who would take chemotherapy alone.
Anaximperator adds:
The study from 1991, “Oncologists vary in their willingness to undertake anti-cancer therapies,” pertains to many kinds of cancer and cancer stages, from early stage to terminal, as well as to experimental therapies. It shows percentages as high as 98% of doctors willing to undergo chemotherapy, while the remaining 2 % were uncertain, and none answered “definitely no” or “probably no” to chemotherapy.
Should another survey be conducted today, there’s a good chance the results would be even higher in favour of chemotherapy, given that over the years chemotherapy has shown enhanced clinical benefit and less side effects.
Indeed. One should also note that this question was constructed such that the clinical presentation of the cancer was incurable. Participants were presented with a scenario in which they are diagnosed with stage IV metastatic disease, a situation where opting for palliative care rather than aggressive treatment often makes sense, which makes the results even more striking. Also, I know from personal experience that it is not true that oncologists tend to turn down chemotherapy, even for advanced disease. having known oncologists who developed various cancers and underwent standard-of-care chemotherapy. Indeed, just this week, I was saddened to learn that an oncologist I used to know at my old job recently developed cancer and is currently undergoing chemotherapy. He’s also lost all his hair, just like many of his patients. In the end, this particular ploy serves two purposes. First, it implies that oncologists are hypocrites who don’t believe that the treatments they are giving patients are worthwhile. Second, it feeds into the conspiracy theories beloved of quacks with the implication that oncologists are hiding something about chemotherapy effectiveness. They’re not.
My favorite example of the use of the next study beloved of anti-chemotherapy cranks is by Andreas Moritz, who describes himself as “a medical intuitive; a practitioner of Ayurveda, iridology, shiatsu, and vibrational medicine; a writer; and an artist.” The article is entitled Can you trust chemotherapy to cure your cancer? and in it Moritz cites a study from Australia published in 2004:
An investigation by the Department of Radiation Oncology, Northern Sydney Cancer Centre, Australia, into the contribution of chemotherapy to 5-year survival in 22 major adult malignancies, showed startling results: The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.” [Royal North Shore Hospital Clin Oncol (R Coll Radiol) 2005 Jun;17(4):294.]
The research covered data from the Cancer Registry in Australia and the Surveillance Epidemiology and End Results in the USA for the year 1998. The current 5-year relative adult survival rate for cancer in Australia is over 60%, and no less than that in the USA. By comparison, a mere 2.3% contribution of chemotherapy to cancer survival does not justify the massive expense involved and the tremendous suffering patients experience because of severe, toxic side effects resulting from this treatment. With a meager success rate of 2.3%, selling chemotherapy as a medical treatment (instead of a scam), is one of the greatest fraudulent acts ever committed. The average chemotherapy earns the medical establishment a whopping $300,000 to $1,000,000 each year, and has so far earned those who promote this pseudo-medication (poison) over 1 trillion dollars. It’s no surprise that the medical establishment tries to keep this scam alive for as long as possible.
Here is the study to which Moritz refers and which is the origin of the claim that “chemotherapy only provides 2% benefit,” a favorite talking point used by cancer quacks. I’ve seen it on websites ranging from Moritz’s website to NaturalNews.com, to Mercola.com, to Whale.to (my favorite), to I forget how many others. Always it’s the same thing, a variant of a statement claiming that chemotherapy only contributes 2% to five year survival in adult malignancies, followed by conspiracy-mongering of the sort above in which chemotherapy is portrayed as a huge scam designed to enrich big pharma. Indeed, so common is this particular favorite that I proclaim it “The 2% Gambit.” It turns out that this is not such an impressive study. Indeed, it appears almost intentionally designed to have left out the very types of cancers for which chemotherapy provides the most benefit, and it uses 5 year survival exclusively, completely neglecting that in some common cancers (such as breast cancer) chemotherapy can prevent late relapses. There were also a lot of inconsistencies and omissions in that leukemias were not included, while leukemia is one type of cancer against which chemotherapy is most efficacious. Indeed, the very technique of lumping all newly diagnosed adult cancers together is guaranteed to obscure benefits of chemotherapy among subgroups by lumping in patients for whom chemotherapy is not even indicated. A letter to the editor listed these problems and several really egregious errors and omissions, too:
The authors omitted leukaemias, which they curiously justify in part by citing the fact that it is usually treated by clinical haematologists rather than medical oncologists. They also wrongly state that only intermediate and high-grade non-Hodgkin’s lymphoma of large-B cell type can be cured with chemotherapy, and ignore T-cell lymphomas and the highly curable Burkitt’s lymphoma. They neglect to mention the significant survival benefit achievable with high-dose chemotherapy and autologous stem-cell transplantation to treat newly-diagnosed multiple myeloma [4]. In ovarian cancer, they quote a survival benefit from chemotherapy of 11% at 5 years, based on a single randomised-controlled trial (RCT), in which chemotherapy was given in both arms [5]; however, subsequent trials have reported higher 5-year survival rates. In cancers such as myeloma and ovarian cancer, in which chemotherapy has been used long before our current era of well-designed RCTs, the lack of RCT comparing chemotherapy to best supportive care should not be misconstrued to dismiss or minimise any survival benefit. In head and neck cancer, the authors erroneously claim the benefit from chemotherapy given concomitantly with radiotherapy in a meta-analysis to be 4%, when 8% was in fact reported [6].
The authors do not address the important benefits from chemotherapy to treat advanced cancer. Many patients with cancers such as lung and colon present or relapse with advanced incurable disease. For these conditions, chemotherapy significantly improves median survival rates, and may also improve quality of life by reducing symptoms and complications of cancer.
Of course, those using this particular gambit almost invariably never include the criticism of this particular article. Another aspect of this particular study that always bothered me is that it appeared to lump patients undergoing adjuvant chemotherapy in with those undergoing chemotherapy for cure or palliation. Adjuvant chemotherapy is given after surgery in order to decrease the rate of recurrence, but the truly curative modality is the surgery itself. In early stage cancer, the absolute benefit of chemotherapy in terms of prolonging survival tends to be modest, often single digit percentages. Lumping adjuvant therapy in with other uses of chemotherapy again appears custom-designed to minimize the survival benefit due to chemotherapy observed.
The second study frequently cited by cancer quacks as evidence that “chemotherapy doesn’t work” is, not surprisingly, also cited by Moritz:
In 1990, the highly respected German epidemiologist, Dr. Ulrich Abel from the Tumor Clinic of the University of Heidelberg, conducted the most comprehensive investigation of every major clinical study on chemotherapy drugs ever done. Abel contacted 350 medical centers and asked them to send him anything they had ever published on chemotherapy. He also reviewed and analyzed thousands of scientific articles published in the most prestigious medical journals. It took Abel several years to collect and evaluate the data. Abel’s epidemiological study, which was published on August 10, 1991 in The Lancet, should have alerted every doctor and cancer patient about the risks of one of the most common treatments used for cancer and other diseases. In his paper, Abel came to the conclusion that the overall success rate of chemotherapy was “appalling.” According to this report, there was no scientific evidence available in any existing study to show that chemotherapy can “extend in any appreciable way the lives of patients suffering from the most common organic cancers.”
I looked for this study. In fact, I went to The Lancet’s website and looked up the August 10, 1991 issue. I could find no study by Ulrich Abel or anything about chemotherapy other than this study on stroke after chemotherapy for testicular cancer. So I went to PubMed and searched on Ulrich Abel’s name for 1991. All I could find were two articles, one on common infections in chemotherapy patients and another on Crohn’s disease. Nor was I the only blogger who couldn’t find this ethereal Lancet paper by Dr. Abel. So I started searching other years, and then I found what appears to be the paper to which Moritz referred, only it wasn’t published in 1991 but rather in 1992 and it wasn’t published in The Lancet but rather in Biomedicine & Pharmacotherapy, a much lower tier journal. Somehow, through the magic of playing “telephone” over the Internet, this article has morphed from being in a lower tier journal to having been in The Lancet—even published on a specific date!
It turns out that the Dr. Abel’s article is rather odd. It’s not really a study, and it’s definitely not a meta-analysis. Nor is it really a particularly good systematic review, given that the methodology of selecting papers isn’t exactly transparent, and the larger “review” to which he refers readers appears to be in German and not readily available on the web, as far as I can tell. In the abstract, Dr. Abel states that “as a result of the analysis and the comments received from hundreds of oncologists in reply to a request for information, the following facts can be noted.” More importantly, Dr. Abel was addressing a fairly limited situation that excludes two of the most effective uses of chemotherapy, as described in this English translation of a Der Spiegel article describing his work:
    • Abel’s verdict against the medicinal treatment of cancer is emphatically untrue for various kinds of lymph cancer, Hodgkin’s disease, leukemias, sarcomas, and testicular cancers in the male. These kinds of malignancies can be cured by chemotherapy with a high degree of probability, especially in children — an undisputed success. But these are, in any case, only a very small part of the new cases of cancer diagnosed every year.
    • Abel’s doubts are not directed against chemotherapy when it is used in support of a curative operation, in order to shrink the tumor beforehand; nor do they apply to chemotherapy used prophylactically after an operation, to prevent a relapse (as an adjuvant).
These are, of course, the two most effective uses of chemotherapy that there are. I’ll grant critics that the types of tumors that can be cured with chemotherapy with a high degree of probability are a minority of tumors, but, contrary to what is implied in many uses of Dr. Abel’s work, they are not insignificant. For example, leukemias and lymphomas (Hodgkins and non-Hodgkins) add up to almost 10% of newly diagnosed cancers every year, and they are cured primarily with chemotherapy. Sarcomas and testicular cancers are much less common, but add them in and the total exceeds 10%. A distinct minority, yes, but the fact that many of these cancers can be cured with chemotherapy puts the lie to statements like the one by Mike Adams quoted above, which, not surprisingly, is parroted in Andreas Moritz’s little screed.
The second indication left out of Dr. Abel’s analysis, adjuvant chemotherapy, can, depending on the circumstance and tumor, be highly effective. Admittedly in early stage breast cancer adjuvant chemotherapy adds on an absolute basis only low single digit percentages to five and ten year survivals, but in more locally advanced breast cancer, particularly so-called “triple negative” breast cancer, the benefit is much more substantial. For instance, using Adjuvant Online, it’s possible to use the latest literature to estimate the benefit of chemotherapy in specific clinical situations. Here’s an example of a hypothetical 40 year old woman with an estrogen receptor negative tumor measuring between 3 and 5 cm with 1-3 axillary lymph nodes positive for metastatic disease: Link
Note that standard chemotherapy increases this woman’s chance of survival by 18% on an absolute basis and by 35% on a relative basis. Either way, the survival benefit is substantial. These are women who otherwise would have died but did not, thanks to chemotherapy. These women could be your mother, your wife, your sister, or even your daughter. The bottom line is that, even though I wasn’t particularly impressed with his methodology, Dr. Abel was actually reasonably nuanced in his discussion in that he discussed overdiagnosis and stage migration as confounders that can make a treatment seem more effective than it is, as I myself have discussed many times on this blog, starting with this post.
Besides, few oncologists would disagree with this statement at the end of Dr. Abel’s abstract, “With few exceptions, there is no good scientific basis for the application of chemotherapy in symptom-free patients with advanced epithelial malignancy.” And, indeed, most oncologists do not recommend chemotherapy for patients with stage IV epithelial malignancies who are asymptomatic, because at that point all treatment is palliative, and you can’t palliate symptoms that don’t exist. That’s why chemotherapy is, in most cases, reserved for when tumor progression leads to symptoms. Moreover, this study only examined epithelial malignancies. These are cancers for which surgery can be curative if the tumor has not metastasized. Since 1991, also, we have made significant advances in improving survival using chemotherapy. I’ve used the example of colorectal cancer before, where, thanks to newer and better chemotherapy regimens developed over the last couple of decades that have improved survival in patients with liver metastases from 6 months to close to two years.
I also note that since 1992, Dr. Abel has been co-author on a number of studies involving chemotherapy, for instance, a trial in nephroblastoma and a clinical trial of high dose chemotherapy in aggressive lymphoma. As recently as 2009, Dr. Abel was co-author on a randomized multicenter study comparing two different chemotherapy regimens in pancreatic cancer. Yes, pancreatic cancer, that most intractable of cancer problems with a five-year survival rate of only around 20% in the most favorable cases; i.e., the ones that can be completely resected surgically. Clearly, Dr. Abel buys into the evil big pharma propaganda that chemotherapy can cure at least some forms of cancer and, as far as I can tell, has never written a followup to his 1992 paper.
The bottom line is that the “evidence” used by cranks and quacks to prove that “chemotherapy doesn’t work” is most often based on intellectually dishonest tactics. They either misrepresent studies, as they frequently do with the McGill study claiming that oncologists won’t use chemotherapy. True, thanks to the way these studies have been misrepresented over the years, many of these quacks probably honestly think they’re accurately representing them, but that just goes to show how lazy they are about going back to the primary sources to back up their claims. As for the rest, the Australian study was custom-designed to minimize the apparent utility of chemotherapy, while Dr. Abel’s study intentionally left out the types of situations where chemotherapy is most useful and looked at primarily advanced malignancies. In this latter case, there’s nothing wrong with that approach; the problem comes when the quacks either intentionally or unintentionally fail to disclose that qualification, lose any hint at nuance, and use the results to imply that chemotherapy doesn’t work for anything.
Framing the question
Considering the question of whether chemotherapy “works” or not is very similar to asking the question, “Why haven’t we cured cancer yet?” The reason is that it’s a question that’s so vague as to be almost meaningless. Cancer is, as I have pointed out, hundreds of diseases, each driven by a plethora of different combinations of disruptions in cell growth control mechanisms. A more appropriate question is whether we’ve cured this cancer or that cancer, not whether we’ve cured cancer. Similarly, asking the question of whether chemotherapy “works” is similarly vague and meaningless. The real questions are (1) whether this specific chemotherapy regimen “works” for this cancer, although there are some examples that in aggregate we can make some conclusions about and (2) whether specific chemotherapy regimens can cure specific cancers. As noted above, even some “skeptics” of chemotherapy admit that chemotherapy can be “marvelously effective” for some cancers; the argument that usually follows is that the cancers for which chemotherapy is effective are so few as not to matter. The other issue is that few cancers are treated only with chemotherapy. Multidisciplinary and multimodality therapy are more the rule than the exception, particularly for solid malignancies and includes chemotherapy, radiation therapy, surgery, hormonal therapy, and a variety of other less common therapies.
What needs to be understood is that chemotherapy is very good for some things. For instance, it’s very good for treating and curing leukemias and lymphomas. For certain cancers, it’s also very good at decreasing the chance of relapse after curative surgery. When given before curative surgery, chemotherapy can also make organ-preserving surgery possible. Prominent examples include using neoadjuvant chemotherapy (chemotherapy before surgery) to shrink breast cancers so that they can be removed without mastectomy and shrinking rectal cancers so that sphincter-sparing surgery is possible (i.e., surgery that leaves the anal sphincter intact and thereby spares the patient having to have a permanent colostomy). For specific tumors, chemotherapy has also contributed to significant increases in survival, but it is not a panacea. For example, chemotherapy usually does very little for pancreatic cancer, and metastatic melanoma laughs at most chemotherapy (although there are newer agents that provide hope that this will no longer be the case). For all its uses and advantages, chemotherapy alone is not very good at prolonging survival in advanced epithelial malignancies, and it’s not at all unreasonable to ask whether it is overused in such patients, who are, for the most part, currently incurable.
This reasonable skepticism devolves into nihilism or crankery, however, when tactics such as those used by Mike Adams, Andreas Moritz, or, yes, even the esteemed Reynold Spector are used to “prove” that chemotherapy is “useless.” Moreover, such “skepticism” completely dismisses as worthless survival benefits of a few months, which certainly aren’t “worthless” to many patients. Such briefly lengthened survival times can mean the difference between seeing a child graduate from college or not, seeing a child get married or not, or seeing the birth of a grandchild or not. It must also be remembered that the measured improvements in survival due to chemotherapy are usually medians. Not uncommonly, buried in that median are “outliers” who derive a huge survival benefit from the chemotherapy and survive many more months than expected, sometimes many more years than expected. Moreover, it does patients no favor to try to use the observation that chemotherapy has at best relatively modest benefits in patients with advanced epithelial malignancies to try to imply that chemotherapy doesn’t work for all patients. In particular, patients have to remember that just because chemotherapy doesn’t do that well against advanced malignancies does not, as the quacks would have you believe, imply that “alternative medicine” can do better.

How reproducible is basic lab research in cancer biology?
Last week, a review of the reproducibility of several highly cited cancer biology papers was published. The results were mixed and demonstrate how difficult reproducing published results can be at times—and how scientists need to do better.
David Gorski on January 23, 2017
Link

When deciding what to write about this week, I had thought about expounding on, for instance, my concerns regarding vaccine policy given the new administration, but I think I’ve done enough of that for the moment at my not-so-super-secret other blog. Besides, there will be plenty of time and many opportunities to return to my concerns in that area over the next four years. Also, on Thursday I happened to see a number of stories about a study and project that demonstrates a key difference between science and pseudoscience. They had titles like, “Rigorous replication effort succeeds for just two of five cancer papers” (Science), “Cancer reproducibility project releases first results: An open-science effort to replicate dozens of cancer-biology studies is off to a confusing start” (Nature), and “What Does It Mean When Cancer Findings Can’t Be Reproduced?” (NPR). Basically, these stories all reference a review of the initial results of the Reproducibility Project in Cancer Biology. The studies are summed up in an overview by Brian A. Nosek and Timothy M. Errington (“Making sense of replications“) and an editorial published by eLife, the open-access journal reporting the results of various reproducibility projects (“Reproducibility in cancer biology: The challenges of replication“). After all the politically-charged topics I’ve been dealing with the last week, a post purely about science is just the break I need. So let’s dig in, starting with some background, noting that only two of the five papers could be rigorously replicated.
Reproducibility: One cornerstone of science
Reproducibility is key to science. If science is the best method that we have of figuring out how nature works, if our hypotheses and theories are to have any basis in reality, then the observations upon which those hypotheses and theories are based must be reproducible. To the average lay person without a background in science, this doesn’t sound like a particularly difficult issue. After an interesting scientific paper is published, why can’t other scientists just do what the scientists publishing the paper did? However, as any scientist knows, particularly biological scientists, it’s nowhere near that simple. First, there is little or no reward for just reproducing the work of other scientists. Certainly, a scientist is not going to get a grant to reproduce those results, and publications reporting reproduced results will not be published in high impact journals. As the Reproducibility Project: Cancer Biology puts it:
Despite being a defining feature of science, reproducibility is more an assumption than a practice in the present scientific ecosystem (Collins, 1985; Schmidt, 2009). Incentives for scientific achievement prioritize innovation over replication (Alberts et al., 2014; Nosek, et al., 2012). Peer review tends to favor manuscripts that contain new findings over those that improve our understanding of a previously published finding. Moreover, careers are made by producing exciting new results at the frontiers of knowledge, not by verifying prior discoveries.
Which is, of course, true. Scientists go into science in the first place to make new discoveries, and translational scientists go into cancer research to discover new understandings of what causes cancer and how to use those new understandings to find new and innovative treatments for cancer.
Usually, one of the only times it’s deemed worthwhile to reproduce another scientist’s results is as the first step to trying to expand on the observations of that scientist, and that in fact is probably how most scientific research is replicated when it is replicated. Basically, you have to know that you’re doing things the same way and getting the same results using the same materials and methods before you can build on those results. Even so, such replications are usually not direct or complete replications; usually scientists only replicate as little as they need to assure themselves they’re on the right track. Complete sets of experiments are rarely replicated, the more expensive and time-consuming the experiment the less frequently replicated.
Another aspect of reproducibility is how well scientists record their methods in scientific papers; i.e., the transparency of science. The standard should be to record the methods in sufficient detail that a scientist knowledgeable in the field could replicate the experiments using the published description alone, but that standard is rarely met. If you read a number of scientific papers, you will find that there is huge variability in the amount of detail provided in the Methods sections of scientific papers. For some journals, like Cell, the amount of detail is pretty high, although often still not high enough to easily reproduce an experiment. For other journals (like, ironically enough, very high impact journals like Science and Nature), the level of detail can be frustratingly low. For most journals, it’s somewhere in between. I, like any other scientist, know from personal experience, particularly during graduate school and my PhD studies, just how difficult it can be to look at the Methods section of a paper and figure out how to replicate an experiment as the first step towards asking additional experiments . Not uncommonly, it was necessary to contact the lab that published the work I was trying to replicate. Sometimes we needed their reagents, such as plasmids or other recombinant DNA constructs. Sometimes we needed help troubleshooting when we didn’t get the same results.
Again, as the Reproducibility Project: Cancer Biology puts it:
Reproducing prior results is challenging because of insufficient, incomplete, or inaccurate reporting of methodologies (Hess, 2011; Prinz et al., 2011; Steward et al., 2012; Hackam and Redelmeier, 2006; Landis et al., 2011). Further, a lack of information about research resources makes it difficult or impossible to determine what was used in a published study (Vasilevsky et al., 2013). These challenges are compounded by the lack of funding support available from agencies and foundations to support replication research. When replications are performed, they are rarely published (Collins, 1985; Schmidt, 2009). A literature review in psychological science, for example, estimated that 0.15% of the published results were direct replications of prior published results (Makel et al., 2012). Finally, reproducing analyses with prior data is difficult because researchers are often reluctant to share data, even when required by funding bodies or scientific societies (Wicherts et al., 2006), and because data loss increases rapidly with time after publication (Vines et al., 2014).
Finally, although not really discussed that much, there are intangible reasons—or seemingly intangible reasons—why it can be difficult to reproduce research. Some experimental techniques, for example, require considerable skill to produce meaningful measurements. Immunofluorescence, for instance, is one, particularly when using multiple antibodies to label different proteins with different fluorescent colors. Techniques that depend on surgical skill on small animals (e.g., mice and other rodents) are another. I’ve known a few scientists over the years who suddenly had trouble reproducing their own work when a skilled technician or postdoc left the lab. The explanation was not fraud but rather because the remaining personnel didn’t know all the ins and outs of the experimental technique. It’s not uncommon for a lot of time to be wasted due to loss of skilled personnel as those left behind troubleshoot and figure out subtleties of an experimental technique that aren’t recorded in their lab protocol books, no matter how detailed. Basically, the “institutional” memory of a laboratory is difficult to maintain, given that, other than the principal investigator and (sometimes) a permanent technician and/or lab manager, most personnel in labs are only there for at most a few years to get their PhD or do a postdoctoral fellowship. Turnover is high by design. Often there are little “tricks” or nuances to various experimental techniques to get them to work well that are lost when someone leaves a lab. That’s why maintaining protocol notebooks is so important, but few labs do this as rigorously as they should, and even detailed protocol books aren’t always enough.
Is there a “reproducibility crisis”?
Part of the impetus to form the Reproducibility Project, a collaboration between Science Exchange and the Center for Open Science, was based on the perception that there is a “crisis” in reproducibility. Although I know there were papers and commentaries dating long before that, the first commentary that brought this topic to the public consciousness in a big way was written by C. Glenn Begley, a consultant for Amgen, and Lee M. Ellis, a cancer surgeon at the University of Texas M.D. Anderson Cancer Center, that concluded that 47 out of 53 “landmark” preclinical studies in cancer (i.e., basic science studies in cancer) couldn’t be replicated by Amgen sufficiently rigorously to proceed with using the results to design drugs to target the interventions. As I pointed out at the time, that was a very high bar for any finding in science, given that not all discoveries of molecular targets or mechanisms would necessarily be druggable or suitable for therapy. I also noted that the papers were from high impact journals which are known for publishing only the most “cutting edge” science, which tends to be the kind of science whose findings are most often later overturned or found to be incorrect.
Of course, there are other studies and other indications. Just last year, Nature published a survey that found that more than 70% of scientists have failed reproduce another scientist’s experiment and that 50% had even failed to reproduce their own. Some 52% of the scientists surveyed thought that there was a reproducibility “crisis.” I agreed that there was a problem, but I don’t believe it is a “crisis.”
Reproducibility: A personal anecdote
To illustrate the complexities of “reproducibility,” I often recount an incident from my early scientific career as a surgical oncology fellow working in a radiation oncology laboratory in the late 1990s. At the time, Dr. Judah Folkman had recently published papers describing the angiogenesis inhibitors angiostatin and endostatin and how strikingly they shrank tumors down to the point where they became dormant as a small clump of cells that didn’t grow. There were a lot of exaggerated headlines at the time along the line of “Is this the cure for cancer?” (I shudder to think what reporting would have been like if Facebook, Twitter, and the like had existed at the time,) Angiogenesis inhibitors block the formation of blood vessels by blocking the action of factors secreted by the tumor to induce the growth of new blood vessels to feed its growth and thereby hijack the normal physiologic process of angiogenesis. Our laboratory wanted to combine angiostatin and radiation therapy in an animal model to see if the effects were additive or synergistic.
Our results were ultimately published in Nature, the only Nature paper on my CV, but the path to these results was not straight. It was widely known through the grapevine at the time that other laboratories were having difficulty reproducing Folkman’s striking results. In our case, we were not observing nearly as potent an antitumor effect as Folkman had described with angiostatin in our angiostatin alone group, which we wanted to compare with a group of mice treated with both angiostatin and radiation therapy. We wondered if it was something to do with the angiostatin itself, which was being made in bacteria from a plasmid by our collaborators. Given that Folkman was one of the best scientists I ever met, none of us doubted his results and assumed that it must be something we were doing.
It actually was. We contacted Folkman, who provided reagents, protocols, and advice, as well as some angiostatin made in his laboratory. It turns out that the peptide we were making was easily denatured (unfolded), which was why it was not as potent as Folkman had reported. Now here’s why I say we couldn’t replicate his results. It’s because we couldn’t fully replicate his results. Our angiostatin inhibited the growth of a wide variety of tumors, but, even after applying the tweaks to our angiostatin production suggested by Folkman, in our hands angiostatin never inhibited tumor growth as potently as Folkman had reported. So in other words, there could easily have been something else going on that we never figured out. Be that as it may, Folkman had the best attitude I’ve ever seen in a scientist regarding reproducibility, as we learned later when we heard of how he had done the same thing for several other labs, even to the point of dispatching one of his postdocs to help other investigators to get angiostatin and endostatin to work. Still, few investigators could ever quite replicate Folkman’s initial results, although many, including our lab, demonstrated that angiostatin and endostatin were potent angiogenesis inhibitors.
So why do I repeat this anecdote almost every time discussions of scientific reproducibility come up? Simple. It’s to illustrate that reproducibility falls on a spectrum. Did we fail to reproduce Folkman’s results? Yes and no. Yes, we reproduced the key result that angiostatin inhibits tumor growth by blocking angiogenesis, but, no, we didn’t reproduce the same very powerful effect size reported by Folkman. The point is that replication of any given scientific finding can range from total failure to replicate (e.g., if we had failed to show any antitumor effect of angiostatin at all) to partial failure to replicate (e.g., what actually happened) to success at replication (e.g., we had shown angiostatin to block tumor growth in the angiostatin along group as powerfully as Folkman had). It all becomes even more confusing when we consider that there is no standard definition of or clear consensus over what does and doesn’t constitute scientific reproducibility.
One of the strengths of the initial results of the Reproducibility Project: Cancer Biology, is that this messiness is appreciated and explained.
Reproducibility in Cancer Biology Research: The setup
Before I discuss the results, I should explain a bit more about what the Reproducibility Project: Cancer Biology is and does. In brief, the Reproducibility Project: Cancer Biology, which was founded in 2014, established a core team to design, prepare, and monitor project operations dedicated to testing the reproducibility of results reported in 50 high-impact papers published between 2010 and 2012. The plan was to replicate a subset of experimental results from each article. For each chosen paper a Registered Report detailing the proposed experimental designs and protocols for each subset of experiments to be replicated was to be peer reviewed and published prior to data collection. Following completion of data collection, results were to be published as a Replication Study. The report that made the news last week represents the results of Replication Studies for the first five papers chosen.
Here are the five papers, with links to the Registered Report and the Replication Study for each:
     1.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc (Registered Report; Replication Study).
     2.  Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs (Registered Report; Replication Study).
     3.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data (Registered Report; Replication Study).
     4.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (Registered Report; Replication Study).
     5.  Melanoma genome sequencing reveals frequent PREX2 mutations (Registered Report; Replication Study).
There’s your reading assignment. No, just kidding. I only provide the links to make it easier for interested readers to check out the studies and replication studies if they are so inclined. Also, it’s easier to refer to each study by number. But how were these studies chosen? That’s a fair question.
The sampling frame was defined as the 400 most cited papers from both Scopus and Web of Science using the search terms (cancer, onco*, tumor*, metasta*, neoplas*, malignan*, carcino*) for 2010, 2011, and 2012. Citations were counted from all sources, which include primary research articles and reviews. This produced an initial sample of 501 articles from 2010, 444 from 2011, and 438 from 2012. Altmetrics scores from Mendeley and Altmetric.com were collected for the entire dataset and used to create a final impact score for each paper. Citation rates and altmetric scores were each standardized by dividing each metric by the highest in the dataset to give each paper a normalized metric score between 0 and 1, which was summed to create an aggregate impact score. Within each year, articles were reviewed for inclusion eligibility starting with the highest aggregate impact article. Articles were removed if they were clinical trials, case studies, reviews, or if they required specialized samples, techniques, or equipment that would be difficult or impossible to obtain. Also, articles reporting sequencing results, such as publications from The Cancer Genome Atlas project, were excluded. However, if sequencing or proteomic experiments were only part of an article, the other experiments in those papers could still be eligible. Review of articles continued until a total of 50 articles, about one-third from each year, were identified as eligible. The final set included 17 papers from 2010, 17 from 2011, and 16 from 2012. From each paper, a subset of experiments were identified for replication, prioritizing those that support the main conclusions of the paper while also attending to feasibility and resource constraints.
So what we are seeing is just one-tenth of the original plan. Actually, it’s more than that, because in late 2015, the Reproducibility Project: Cancer Biology announced that it had to cut back its ambitions and now plans to do only 37 papers, largely because of budgetary constraints. As a bit of a reality check for reproducibility efforts, I note that the project had originally budgeted around $25,000 to $35,000 for each experiment, but this figure turned out to be too low. Thanks to time-consuming peer-reviews, material transfer agreements, and expensive animal experiments, the team came up with a new estimated cost of $40,000 per experiment on average. This is, of course, one reason why replications are not done nearly as often as they should be. In fact, only 29 will now be done thanks to both budgetary problems and the difficulties investigators had obtaining information and materials.
I also note an inherent bias in the choice of papers. Highly cited reports, or “high impact” reports, tend to be the most novel, interesting, or even controversial (i.e., again, “cutting edge”), which also means that, again, they are “frontier science,” whose results are more frequently overturned.
Before I discuss the actual results, here’s another wrinkle, thrown in to emphasize the complexity involved in these replication studies. I can’t help but briefly quote Nosek and Errington themselves:
There is no such thing as exact replication because there are always differences between the original study and the replication. These differences could be obvious (like the date, the location of the experiment, or the experimenters) or they could be more subtle (like small differences in reagents or the execution of experimental protocols). As a consequence, repeating the methodology does not mean an exact replication, but rather the repetition of what is presumed to matter for obtaining the original result.
Direct replication is defined as attempting to reproduce a previously observed result with a procedure that provides no a priori reason to expect a different outcome (Open Science Collaboration, 2015; Schmidt, 2009). In a direct replication, protocols from the original study are followed with different samples of the same or similar materials: as such, a direct replication reflects the current beliefs about what is needed to produce a finding. Conducting a direct replication tests those beliefs empirically. In a conceptual replication, on the other hand, a different methodology (such as a different experimental technique or a different model of a disease) is used to test the same hypothesis: as such, by employing multiple methodologies conceptual replications can provide evidence that enables researchers to converge on an explanation for a finding that is not dependent on any one methodology.
Most replication in science is conceptual replication.
Reproducibility in cancer research: The results
So here is how Nosek and Errington describe the results of the first five replication papers:
The first five Replication Studies have now been published. Two of the studies reproduced important parts of the original papers (Kandela et al., 2017; Aird et al., 2017), and one did not (Mantis et al., 2017). The other two Replication Studies were uninterpretable because the control tumors grew too quickly or too slowly (or exhibited spontaneous regressions) to reliably measure whether the experimental intervention had the predicted effect (Horrigan et al., 2017a; Horrigan et al., 2017b): however, in one of these two cases the original paper (Willingham et al., 2012) has led to clinical trials for anti-CD47 antibody therapy that will provide extensive additional data on the effectiveness of this approach. Three of the Replication Studies are also accompanied by Insight articles (Dang, 2017; Davis, 2017; Sun and Gao, 2017).
First, let’s look at the clear failure to replicate (#2). The original paper reported the effects of a tumor-penetrating peptide (short protein), iRGD peptide, which in the paper increased cellular uptake of the chemotherapy agent doxorubicin in a xenograft model of prostate cancer. A xenograft model involves injecting human tumor cells into immunosuppressed mice and measuring their growth and the ability of the intervention tested to inhibit or reverse that growth. Basically, the Replication Study failed to find statistically significant differences in the penetrance of doxorubicin into the tumor cells, the tumor weight for mice treated with DOX and iRGD compared to DOX alone, or a measure of programmed cell death (apoptosis).
Neither of the two studies reported to be replicated (#1 and #3) was exactly a resounding replication, either. For example, in #3, the results were mixed, as described in an accompanying commentary. In the original paper, for example, the authors noted that cimetidine induced the death of human lung cancer cell line A549. So they tested three doses of the drug against A549 tumor xenografts (tumor cells implanted in mice) and noticed that cimetidine decreased the growth rate of these cells, an affect that was statistically significant, an effect that was close to as strong as that of low dose doxorubicin, a chemotherapy agent. In the replication study, it was found that cimetidine still reduced in decreases in tumor sizes, but they were not statistically significant when a Bonferroni correction for multiple comparisons was applied. However, a statistically significant effect was observed when the dataset from the Replication Study was combined with that from the original paper in a meta-analysis. What stood out to me was that the doxorubicin also failed to produce a statistically significant result in the Replication Study. Doxorubicin is a powerful chemotherapeutic agent; so I have to ask what was going on in the Replication Study. Be that as it may, as noted in the commentary, there can be many factors that influence the robustness of the xenograft models used in these experiments, including “batch effects on the efficacy of the drugs used; changes in the properties of cell lines over time; the strains of the mice used, and also their sex; factors related to microbiome and chow; circadian effects; temperature; and the antimicrobials that might be used in certain facilities.”
The second study (#1) was also somewhat mixed. As noted in an accompanying commentary, the treatment tested in mice did work in decreasing the level of c-Myc (the gene targeted) in multiple myeloma cell lines and did increase the overall survival of the mice in the tumor model used, but the results as measured by bioluminescence were not statistically significant. It is speculated that it was because many of the control mice had to be euthanized early before their pre-specified endpoint because of disease progression and high tumor burden.
In fact, anyone who’s ever done tumor xenograft experiments in mice has encountered the problem of tumors either growing so fast that the mice have to be euthanized prior to the planned end of the experiment or not growing at all. Certainly I have. Indeed, that is the reason that the other two studies uninterpretable. In #4, several tumors exhibited spontaneous regression, and in one Replication Study (#5) melanoma xenografts in the control group grew much faster than they did in the original study, which made the detection of the accelerated tumor growth due to mutations in the PREX 2 gene very difficult to detect compared to the original study. Even the author of the accompanying commentary seemed puzzled:
This Replication Study represents a cautionary tale concerning the impact of biological variability on experimental design. While strenuous efforts were made to precisely copy the experimental conditions employed in the original study, the xenografts in the Replication Study behaved in a fundamentally different way to those in the original study. The mechanistic basis for the observed differences is unclear. Presumably, there was a difference in the melanoma cells and/or the mice. Although the cells were obtained from the same source, small differences in culture conditions or passage history could have contributed to differences between the studies. Similarly, although the mice were obtained from the same source, housing the animals in a different facility may have contributed to differences between the studies.
My guess as someone who’s done quite a few xenograft experiments in a career dating back to the 1990s is that, for whatever reason, in the Replication Study, the number of tumor cells injected was too high for the mice and conditions, for whatever reason. There is a lot of biological variability in the behavior of tumors and a lot of factors that can affect their growth that might not be obvious. That’s why, if you’re doing experiments in a different institution, doing preliminary dose-response experiments to determine the optimal number of cells to inject is highly advisable. Also, what all of the Replication Studies suggest, whether they replicated key parts of the original studies or not, is that many of the animal experiments reported in the literature are underpowered to test the hypotheses under consideration.
Scientists react
Unsurprisingly, some scientists are not exactly fans of the Reproducibility Project. For example, Robert Weinberg, one of whose studies is a Reproducibility Project currently on hold, isn’t thrilled, having said, “It’s a naÏveté that by simply embracing this ethic, which sounds eminently reasonable, that one can clean out the Augean stables of science.” Maybe, but he doesn’t exactly say exactly what’s wrong with this ethic either.
Other scientists react this way:
This past January, the cancer reproducibility project published its protocol for replicating the experiments, and the waiting began for [Richard] Young to see whether his work will hold up in their hands. He says that if the project does match his results, it will be unsurprising —the paper’s findings have already been reproduced. If it doesn’t, a lack of expertise in the replicating lab may be responsible. Either way, the project seems a waste of time, Young says. “I am a huge fan of reproducibility. But this mechanism is not the way to test it.”
Others say:
Almost every scientist targeted by the project who spoke with Science agrees that studies in cancer biology, as in many other fields, too often turn out to be irreproducible, for reasons such as problematic reagents and the fickleness of biological systems. But few feel comfortable with this particular effort, which plans to announce its findings in coming months. Their reactions range from annoyance to anxiety to outrage. “It’s an admirable, ambitious effort. I like the concept,” says cancer geneticist Todd Golub of the Broad Institute in Cambridge, who has a paper on the group’s list. But he is “concerned about a single group using scientists without deep expertise to reproduce decades of complicated, nuanced experiments.”
This is not an unreasonable concern. Nor is that of Erkki Ruoslahti, author of the one study that clearly failed to replicate:
Ruoslahti, a cancer biologist at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, disputes the verdict on his research. After all, at least ten laboratories in the United States, Europe, China, South Korea and Japan have validated the 2010 paper1 in which he first reported the value of the drug, a peptide designed to penetrate tumours and enhance the cancer-killing power of other chemotherapy agents. “Have three generations of postdocs in my lab fooled themselves, and all these other people done the same? I have a hard time believing that,” he says.
This is, of course, an argument in favor of conceptual replication. Yes, it is self-serving, but that doesn’t mean it’s not a valid argument.
Is there a crisis in cancer biology research reproducibility?
Traditionally, the way science is replicated is not usually through the direct replication of key experiments in papers, as the Reproducibility Project: Cancer Biology is doing. It is usually through other laboratories doing what Ruoslahti says and testing the same hypothesis using different methods and taking the next steps. Unsurprisingly, Ruoslahti is concerned that the recently published report will harm his ability to raise capital for DrugCendR, a company in La Jolla that he founded to develop his therapy. Is that fair? It might not be if his results have indeed been replicated by other groups. On the other hand, to me all science is fair game for attempts at replication.
Tim Errington, manager of the Reproducibility Project, emphasizes that a single failure to replicate is not proof that the initial findings were wrong and shouldn’t put a stain on individual papers, but surely he must know that scientists will interpret a failure to replicate in just that manner. After all, scientists have pride and ego as well. Not surprisingly, many are alarmed and defensive when informed that another scientist failed to replicate their findings. I’m sure even Judah Folkman was disturbed by the news that scientists were having a hard time replicating his results with angiostatin and endostatin. That’s where scientists need to strive to be more like Folkman. Most at least try to be, but far too many have a hard time separating their ego from their work.
Overall, I tend to look as the results of these five Replication Studies as two out of three being replicated, with the other two not counting because of flukes that introduced problems not seen in the original paper, meaning:
Such conflicts mean that the replication efforts are not very informative, says Levi Garraway, a cancer biologist at the Dana-Farber Cancer Institute in Boston, Massachusetts. “You can’t distinguish between a trivial reason for a result versus a profound result,” he says. In his study, which identified mutations that accelerate cancer formation, cells that did not carry the mutations grew much faster in the replication effort — perhaps because of changes in cell culture. This meant that the replication couldn’t be compared to the original.
Even so, the optimistic interpretation is that more than 33% of studies are likely to be difficult to replicate and the more conventional interpretation that 60% of the studies were not replicated, with the remaining 40% having some problems, I’d conclude that there is definitely a problem. However, one of the greatest strengths of science (and science-based medicine) is that it is self-correcting. The process is, of course, messy and slow, but it is ongoing. Also remember that this is a small sample, only five studies, all of which of the type that were considered “cutting edge” and therefore less “safe” than the average study. I look at research like the Reproducibility Project as the means to identify the problem. What we next need to do is to figure out what causes the problem and to focus on solutions. I’m not convinced that replicability problems in preclinical research are the major reason why so many drugs that make it to clinical trials fail to be approved by the FDA, given how much conceptual replication goes on before a drug ever makes it to clinical trials in the first place, but certainly it couldn’t hurt.
The NIH agrees. It’s recently released guidelines meant to improve the reproducibility of cancer research and recommend that journals ask for more thorough methods sections and more sharing of data, and the Reproducibility Project have produced a wiki describing how they went about their work and describing the changes they would like to see. Change is coming, and it appears to be for the better.

Surgeon General Alcohol Warning
Steven Novella on January 8, 2025
Link
In 1964 the US Surgeon General released its first report on the health risks of smoking and tobacco use. This turned out to be a landmark move, paving the way for the following decades of progressively more restrictive regulation of public tobacco use and marketing. In 1964 smoking was at its peak in the US, when 42% of Americans smoked. Today the number is down to 11.5%. It’s likely that were it not for the Surgeon General’s warning about tobacco products most Americans would not even know the Surgeon General existed.
Recently the Surgeon General, Vivek Murthy, released a new advisory warning of the links between alcohol use and cancer. It remains to be seen what effect this advisory will have on the culture of alcohol use in the US, and it’s hard to imagine it will be anything like the effects on tobacco use, but it will likely increase public awareness of the true risks of excessive alcohol use. In the announcement the HHS reports:
“Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States – greater than the 13,500 alcohol-associated traffic crash fatalities per year in the U.S. – yet the majority of Americans are unaware of this risk,” said U.S. Surgeon General Dr. Vivek Murthy. “This Advisory lays out steps we can all take to increase awareness of alcohol’s cancer risk and minimize harm.”
Regular alcohol consumption has been linked to cancer of the breast, colorectum, esophagus, liver, mouth, pharynx, and larynx. Alcohol is estimated to cause about 3.5% of all cancers. The amount of alcohol consumption relates directly to cancer risk, but even modest consumption, such as one drink per day, may be enough to increase risk.
The advisory makes several specific recommendations – to change the required labeling of alcoholic beverages to include the warning about cancer risk (much like the mandatory warning on cigarette packages), to increase public awareness of the risk, and to change recommendations for safe amounts of alcohol consumption to include data on cancer risk.
Moderating alcohol consumption can also have other benefits as well. It is estimated that in the US there were 178,000 premature deaths due to alcohol use. The WHO estimates this figure is 2.6 million world wide, or about 5% of deaths. On average this reduces lifespan by 24 years. The causes of death from alcohol include cancer, direct alcohol poisoning, car accidents, heart failure, and liver damage. This is greater, by the way, than all other recreational drugs combined. At the peak of the opioid epidemic in the US in 2022, deaths from opioids were 84 thousand.
There is also a lot of death and social harm from the effects of alcohol use. It is estimated that about 40% of violent crimes in the US are committed while under the influence of alcohol. About 48% of homicides were committed while under the influence. Obviously alcohol use is difficult to disentangle from complex social factors with which it is associated. But at the very least it can be an accelerant to violence.
It is also likely that the negative health effects of alcohol are underestimated by the mortality numbers above. Excessive alcohol use has dramatic negative effects on overall health, often contributing to death from other causes but not listed as a “cause of death”. People with alcohol use disorder have a life expectancy 24-28 years shorter than the general population.
Will the Surgeon General’s advisory have any effect? It is also hard to predict the effect of public health measures. Just giving people information tends to have a modest effect on their behavior. But even modest effects can reduce premature deaths, healthcare costs, and costs to society. There definitely appears to be a knowledge gap.
According to a recent Gallup poll, only 45% of Americans agreed that 1-2 drinks per day (enough to increase cancer risk) is bad for one’s health, while 43% said it made no difference, and 8% said it was good for health. As recently at 2016 these numbers were 26%, 51%, and 19% respectively, so there has been a recent cultural shift. This shift also appears to be generational, with younger populations having a more negative image of regular alcohol use.
As the history with tobacco shows, the US Surgeon General does have a unique position in terms of shaping public perception of health risks. Unlike with tobacco, where there is no safe level of use, just moderating one’s use of alcohol may have significant health benefits. The key seems to be avoiding daily use or binge drinking. This may be the beginning of a cultural shift that reduces overall alcohol consumption, and thereby reducing alcohol related deaths. People should at least know all the risks before they make personal decisions about their own use.


Aspartame and Cancer
Despite the leaked new classification as a “possible” carcinogen, the evidence still shows aspartame is safe.
Steven Novella on July 5, 2023
Link

It was recently leaked that the World Health Organization (WHO) is about to change their classification of the artificial sweetener, aspartame, to category 2b – possibly carcinogenic to humans. This has caused some confusion, and has fed existing conspiracy theories about the sweetener. For some reason, even before the web, there was a viral campaign to spread fear and misinformation about aspartame. This took on a life of its own, and could not be quelled by something as pedestrian as evidence.
There must be something about the narrative that resonates – aspartame seems too good to be true. It is 200 times sweeter than sugar, and so can give the foods we love a sweet taste without the calories. Something in our “Simpsons” programmed sensibilities and baseline cynical nature says – it must be unhealthy. Also, the appeal-to-nature crowd that demonizes anything they arbitrarily deem not natural found a convenient target to sow fear and mistrust in mainstream institutions.
Meanwhile, there have literally been thousands of studies, and over 60 scientific and regulatory bodies around the world have reviewed the evidence and found aspartame to be safe for human consumption. There are also many reviews of the evidence in the published literature, generally finding no clear evidence of any link between aspartame consumption and any disease. It always needs to be noted that the one exception is people with phenylketonuria, who should not consume aspartame.
But researching risk is complex and the evidence is often misunderstood and misrepresented. One type of such research is pre-clinical, basic toxicology research. This focuses on whether the chemical in question does stuff to cells or biochemistry. How is it metabolized, what are the breakdown products, does it increase or decrease inflammation or oxidative stress, is it a potential mutagen, and many other assays. This kind of research just tells us if a substance is a potential hazard, but not whether it will confer a health risk.
The difference between hazard and risk is important to understand in terms of this research. A good analogy I often go to is – a shark in a tank is a hazard, meaning that it can potentially cause harm in the right circumstance. But as long as you don’t swim in the tank with the shark, the risk is zero. Something happening chemically may be a hazard, but we need to know how the substance is metabolized, will it get to the target tissue and in what dose, and what compensatory mechanisms are there? A potential hazard can be of zero risk depending on exposure.
Then we get to animal research, which more directly assesses risk. But in animal research the goal is often to “Mythbuster” the question – stress the system until it breaks, meaning increasing the exposure to a potential hazard to see where it starts to become a risk. Sometimes this is explicitly done in what is called the LD50 test – what is the dose that kills half of test animals? Toxicity is all about dose, and so this research is used to know where the threshold dose of toxicity is. Typically, regulations then build in 1-2 orders of magnitude of a safety buffer.
Finally there is clinical and ecological research – is there any actual increase in a negative outcome (such as disease incidence) from controlled or real-world use? This is the definitive evidence about risk. It doesn’t matter if a substance changes a chemical in a petri dish, or kills rats when given in massive doses. What matters is if there is any net health risk when used by humans in the usual dose.
With aspartame, as with anything that gets studied enough, there is a lot of noise in terms of things that happen at a petri dish level, or in animal research, but there is no apparent risk of any disease when consumed by humans in normal amounts. Actual risk may come into play with levels of consumption that are inhuman – on the order of 60 liters of aspartame-sweetened drinks per day every day.
With this as context, how do we make sense of the new WHO classification? We need a bit of further context. The WHO classification system is based on hazard, not risk. They are not determining that something actually causes cancer, only whether or not it is a carcinogen. Further, the classification system is based upon the strength of the evidence, not the magnitude of the effect. Classification 1 is for substances known to be carcinogenic to humans. This means the evidence is clear, but it says nothing about the effect size – we could be really confident in a tiny effect size. Classification 2A is probable, and 2B (the apparent new classification for aspartame) is possible. Category 3 is unclassifiable as a carcinogen, and class 4 is probably not carcinogenic.
A lot of things that we consume every day are in category 2B. Drinking hot beverages is in category 2A, above that of aspartame. Here is a full list of 2B.
But even the categorization of 2B is likely to be controversial. Here is the latest review of the question in the published literature, from 2022, which concludes:
Taken together, available evidence supports that aspartame consumption is not carcinogenic in humans and that the inconsistent findings of the RI studies may be explained by flaws in study design and conduct (despite additional analyses to address study limitations), as acknowledged by authoritative bodies.
Even if we can quibble about the evidence and whether or not there is the possibility of a carcinogenic effect from aspartame, it is not controversial that exposure levels would have to be much higher than what most people consume to confer any risk. At the end of the day the evidence still supports the conclusion that aspartame is safe at human levels of consumption.

Vitamin D and the relationship to colon cancer
Colorectal cancer is common. A new study examines the relationship with vitamin D levels.
Scott Gavura on June 28, 2018
Tweet

Almost every week there a new story about vitamin D and its relationship with some health outcome. There is a long list of observational studies have linked low vitamin D levels to a range of illnesses. This has driven widespread interest in supplementation, as well as the interest in testing vitamin D levels in the blood, in the hopes that apparent “deficiencies” can be identified and treated. Back in 2016 I summarized a narrative review that looked at vitamin D use for multiple health outcomes. It concluded that the evidence for supplementation was unconvincing for most uses. In that post, I noted that there was little evidence to show supplementation had any meaningful effect in cancer, but better quality evidence was needed. Recently a new paper was published that examined the relationship between vitamin D levels and colorectal cancer risk. Colorectal cancer is a very common cancer (your lifetime risk is about 4.2%) and any intervention to reduce the overall incidence of cancer would offer significant public health benefits. I took a closer look at the new paper to determine if my 2016 assessment required revision. Key questions include (1) the relationship between blood levels of vitamin D and colon cancer incidence, and (2) whether or not vitamin D supplementation has any relationship with colon cancer. As you’ll see these are two very different questions.
The evidence thus far
Vitamin D has for some time been associated with colorectal cancer, in the belief that it can lower colorectal cancer risk via antiproliferative, pro-apoptotic, and anti-angiogenic properties
Back in 2016 I referenced a meta-analysis of existing randomized controlled trials of vitamin D supplements, with or without calcium, which looked at an range of outcomes, including cancer. It looked at seven trials for cancer, involving over 48,000 patients and noted that supplementation “lay within the futility boundary, indicating that vitamin D supplementation does not alter the relative risk of any of these endpoints by 15% or more.” The authors’ conclusion was that “Future trials with similar designs are unlikely to alter these conclusions.” I had also noted that the Cochrane Review had also concluded that there was a lack of evidence to support vitamin D supplementation:
There is currently no firm evidence that vitamin D supplementation decreases or increases cancer occurrence in predominantly elderly community-dwelling women. Vitamin D₃ supplementation decreased cancer mortality and vitamin D supplementation decreased all-cause mortality, but these estimates are at risk of type I errors due to the fact that too few participants were examined, and to risks of attrition bias originating from substantial dropout of participants. Combined vitamin D₃ and calcium supplements increased nephrolithiasis, whereas it remains unclear from the included trials whether vitamin D₃, calcium, or both were responsible for this effect. We need more trials on vitamin D supplementation, assessing the benefits and harms among younger participants, men, and people with low vitamin D status, and assessing longer duration of treatments as well as higher dosages of vitamin D. Follow-up of all participants is necessary to reduce attrition bias.
The new study
This new study, entitled “Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts ” is an analysis of 17 studies that looked at the relationship between circulating vitamin D levels in the blood, and the relationship with colorectal cancer. It was funded by the National Heart, Blood, and Lung Institute and the National Cancer Institute. This was not a study that looked at supplementation. The authors combined data sets to give a final count of 5,706 patients that had developed colorectal cancer, and 7,107 patients that had not. All of the studies had collected blood samples pre-diagnosis, and all tested for 25(OH)D or 25-hydroxyvitamin D in a consistent manner (which allowed pooling) as all were part of the international Circulating Biomarkers and Breast and Colorectal Cancer Consortium. (25(OH)D is the commonly-accepted measure for vitamin D levels in the body.) Those with cancer were matched according to main characteristics (gender, age, etc.) The authors then estimated the risk of cancer by the absolute (pre-cancer) blood concentration of 25(OH)D.
There was voluminous statistical analysis done, and I will leave it to methodologists to appraise. The population studied was mainly white (83.9%), fairly evenly split male/female, and the median age at blood draw was 60 years. The median time from blood draw to cancer diagnosis was 5.5 years. The authors created quintiles of 25(OH)D measurements, using the 3rd quintile as the reference. In a logistical regression model, participants in the lowest quintile had a 23% greater risk of colorectal cancer, and those in the highest quintile had a 21% lower risk of colorectal cancer. This trend was observed even after adjusting for exercise, body mass index (BMI), recognized non-dietary colorectal cancer risk factors, and alcohol consumption. They also adjusted for seasonal variation in vitamin D levels. Figure 1 shows the key observation well, showing risk decreasing as levels are higher. You can also see that the association was stronger in women than in men.

The authors found that colorectal cancer risk decreased steadily and significantly with increasing pre-diagnosis 25(OH)D levels, up to 100 nmol/L. Circulating 25(OH)D at levels below 30 nmol/L (considered “deficient” by the IOM) was associated with a 31% greater risk of colorectal cancer compared with 50 to <62.5 nmol/L, the lower range of 25(OH)D considered sufficient for bone health. Interestingly, colorectal cancer risk was lower at 25(OH)D concentrations that are higher than those currently considered sufficient for bone health. What this study doesn’t answer, and can’t answer, is whether or not people with higher vitamin D levels (and lower rates of colorectal cancer) differed in some unobserved way from those with lower levels. This could mean that vitamin D isn’t the causative factor at all.
The bottom line
The evidence for supplementation with vitamin D is not that convincing. However, given the modest benefit, low cost, and relative lack of side effects, vitamin D supplementation at modest doses is safe and is not likely to cause harm. This newest study does not show that there is a benefit to supplementation, however it does show a positive association with higher levels. How those levels may have become higher (diet vs. supplementation vs. sun exposure) was not explored in this study. While this new study shows what appears to be a relationship between vitamin D levels and colorectal cancer, it doesn’t tell us anything about supplementation itself. At this time, there is little support in treatment guidelines for vitamin D supplementation to prevent colon cancer. However, it adds to the body of evidence about vitamin D and cancer. It would seem the safest things to do to avoid colorectal cancer would be to ensure that you’re getting adequate vitamin D in your diet, and, perhaps more importantly, you’re addressing the biggest factors for colorectal cancer prevention. Until better evidence emerges, continuing to take a cautious approach to vitamin D supplementation seems the most reasonable approach.

Another antivaccine zombie meme: polio vaccine and SV40 and cancer, oh, my!
David Gorski on September 9, 2013
Link
The Internet has produced a revolution with respect to information. Now, people anywhere, any time, can find almost any information that they want, as long as they have a connection to the global network and aren’t unfortunate enough to live in a country that heavily censors the Internet connections coming in. In addition, anyone any time can put his or her opinion out on the Internet and it might be read by people on the other side of the planet. For example, it continually amazes me that my blatherings here are read by people in Australia and New Zealand, as well as Europe and pretty much every other continent. Before the Internet, there was no way I would ever have achieved my current measure of minor celebrity status (and I do mean minor). Now, with enough good (I hope) writing and some links from some popular sources, and I can make my opinion known worldwide.
The dark side of this is that cranks can also make their opinions known worldwide, and, all too frequently, they are much better at it than skeptics are. For example, this very blog used a generic, vanilla WordPress template for the longest time, only updating it a few months ago. Meanwhile crank websites like NaturalNews.com are decked out in the latest, greatest web accoutrements, complete with video. One other problem with the democratization of information is that there now exist what I like to call “zombie memes.” In the world of quackery and pseudoscience, these are pseudoscientific claims on the Internet that never die, no matter how often they are refuted. Generally, such memes/claims pop up, make a fuss, are refuted, and then disappear. Then a few months (or even a year or two) later, something will happen to resurrect them. Maybe it’s a clueless mortician cremating the remains of such a zombie meme during a rainstorm and letting whatever it is that resurrected the dead meme in the first place permeate the soil of a graveyard of dead memes. Maybe it involved injecting a glowing fluid into the corpse of the meme. Who knows? Who cares that much? All I know is that these zombie memes keep popping up again and again as though they were new.
Now that the World Wide Web (at least as we know it, in its graphically browsable form) is approaching its twentieth birthday, we now have enough perspective to see these things. Steve Novella pointed out one zombie meme just the other day about the MMR, as did a certain person well known to this blog. Just yesterday I noticed another of these zombie memes arising from the dead yet again to feast on the brains of the living and thus make them cranks too. (At least, that is the goal of their continual resurrection.) This one popped up at that online repository of all things quackery, NaturalNews.com, in a post by Mike Adams himself entitled Merck vaccine developer admits vaccines routinely contain hidden cancer viruses derived from diseased monkeys. Other versions of this meme pop up from time to time with titles like CDC Admits 98 Million Americans Received Polio Vaccine In An 8-Year Span When It Was Contaminated With Cancer Virus.
Let’s dive in, shall we?
Maurice R. Hilleman is a little-known giant in the history of vaccines in the 20th century, having developed 36 vaccines, more than any other scientist in history, of which eight are still used today. So successful was he that he has been credited with saving more lives than any other medical scientist of the 20th century. Consequently, it’s rather strange to see his name be such a critical part of the first antivaccine zombie meme I’m going to discuss, which Mike Adams promoted just yesterday. As a companion piece on NaturalNewsTV, he has a video, with text superimposed that says, “All vaccines contain foreign DNA, RNA, and proteins that may prompt allergies and autoimmune diseases from bacteria, fungi, yeast, bovine fetal serum, monkey kidney tissues, toxic metals, mercury, and aluminum, MSG, and corpse preservatives formaldehyde and formalin.” One can’t help but chuckle and note that formalin is formaldehyde in a neutral buffered solution. They’re basically the same thing.
Be that as it may, let’s see what Adams claims, along with many other cranks:
If you haven’t yet realized the truth about how vaccines contain hidden cancer viruses, prepare yourself to be shocked by the admission you’re about to hear. Decades ago, one of the most prominent vaccine scientists in the history of the vaccine industry — a Merck scientist — made a recording where he openly admitted that vaccines given to Americans were contaminated with leukemia and cancer viruses.
In hearing this admission, his colleagues (who are also recorded here) break into laughter and seem to think it’s hilarious. They then suggest that because these vaccines are first tested in Russia, their side effects will help the U.S. win the Olympics because the Russian athletes will all be “loaded down with tumors.”
For the record, this is the same vaccine that was given to tens of millions of Americans and promoted by the government. To this day, people still carry these hidden cancer viruses which have proven to be a boon to the cancer industry.
One notes that this most recent article by Adams is close to a verbatim republication of an article from two years ago by Adams. It regurgitates a claim that SV40 that contaminated some early batches of the polio vaccine in the late 1950s were the cause of the “cancer epidemic.” Other variants of this claim are that the polio vaccine was responsible for creating AIDS. The first is a distortion and exaggeration; the second is even worse.
Before I discuss the actual content of the interview, I must note that it was apparently found by a man named Leonard Horowitz, who is quoted on Whale.to as having said, “The greatest lie ever told is that vaccines are safe and effective.” On a Whale.to page devoted to Horowitz, we learn that Horowitz is a world class conspiracy theorist who has written articles like Big Pharma/Lancet Scam: Vaccine-Autism Link Denied (coauthored with Mike Adams himself!), Watchdog Groups Say Death Toll From Vaccines Amounts to “Genocide” Surgeon General’s Letter in USA Today Assailed, and Emerging Viruses: AIDS & Ebola. Nature, Accident or Intentional? (a credulous interview with Gary Null). His website, Tetrahedron Publishing Group, is replete with similar articles and hawks colloidal silver as well, while his own website bills him as a “Humanitarian, Clinician, Prophet, Scholar and Natural Healer Advances Global Healing.” On his other website, American Red Double Cross, Horowitz attacks the Red Cross and bills himself thusly:
Dr. Len Horowitz, internationally known authority in public health and emerging diseases, and the nationally syndicated radio talk show host of “The Insight Hour,” delves into the darkest side of drug-based medicine, including the mass killing and poisoning of people for profit and politics.
This led me to The Insight Hour with Dr. Leonard Horowitz and Stacy Kane and an effort by him called LOVE528, which he represents as central to the “musical mathematical matrix of creation.” Horowitz even has a hallowed entry in the Encyclopedia of American Loons, which describes the full breadth of his woo, as does his Wikipedia entry. He’s also known for publishing an article in Medical Hypotheses entitled Polio, hepatitis B and AIDS: an integrative theory on a possible vaccine induced pandemic.
First of all, it would help to know when this interview was done. Obviously, it had to be before 2005, because that’s the year Hilleman died at the age of 85. I did a bit of Googling, and this footage is allegedly footage cut from a production by medical historian Dr. Edward Shorter done for PBS WGBH in Boston. I can’t find the video online, but there is a book by Shorter entitled The Health Century: A Companion to the PBS Television Series, which was published in 1987. So presumably this interview with Hilleman likely took place sometime in the year or two before that, which is informative in that it tells us that the conspiracy theory that the polio vaccine was the origin of AIDS is at least 25 years old. No wonder it keeps popping up again and again. The jokes about cancer causation by the vaccine indicate that, similarly, the idea that the early batches of polio vaccines were contaminated with SV40 were around in the 1980s. In any case, this found footage was taken by Horowitz and woven into a conspiracy magnum opus of a film entitled In Lies We Trust: The CIA, Hollywood and Bioterrorism. (The complete segment begins just after the 2 hour mark.)
In any case, this appears to be the “money quote” that the antivaccine movement likes to cite:
Dr Edward Shorter: Tell me how you found SV40 and the polio vaccine.
Dr Maurice Hilleman: Well, that was at Merck. Yeah, I came to Merck. And uh, I was going to develop vaccines. And we had wild viruses in those days. You remember the wild monkey kidney viruses and so forth? And I finally after 6 months gave up and said that you cannot develop vaccines with these damn monkeys, we’re finished and if I can’t do something I’m going to quit, I’m not going to try it. So I went down to see Bill Mann at the zoo in Washington DC and I told Bill Mann, I said “look, I got a problem and I don’t know what the hell to do.” Bill Mann is a real bright guy. I said that these lousy monkeys are picking it up while being stored in the airports in transit, loading, offloading. He said, very simply, you go ahead and get your monkeys out of West Africa and get the African Green, bring them into Madrid unload them there, there is no other traffic there for animals, fly them into Philadelphia and pick them up. Or fly them into New York and pick them up, right off the airplane. So we brought African Greens in and I didn’t know we were importing the AIDS virus at the time.
Miscellaneous background voices:…(laughter)… it was you who introduced the AIDS virus into the country. Now we know! (laughter) This is the real story! (laughter) What Merck won’t do to develop a vaccine! (laughter).
If you listen to the actual interview (at around 2:15 in), you’ll see that it’s very clear that Hilleman, obviously aware of the conspiracy theories claiming that the AIDS virus derived from the virus used to make the early polio vaccine, was making a joke and that the people in the room during the interview realized it was a joke. That’s why they laughed. They were laughing at the conspiracy theorists. Those claims were clearly floating around in the mid-1980s, right at the height of the AIDS epidemic, before there was much in the way of effective treatment. So this part of the interview was cut from the show. One wonders how much else was cut from the show, given that generally only fractions of total footage make it into any documentary. (Remember Dr. Jay Gordon whining about how his extensive interview had been cut altogether from the PBS documentary The Vaccine War?) In any case, Shorter, hardly “hiding” the footage, deposited it all in the National Library of Medicine, where it is available to all. That’s how Horowitz found it and decided that Hilleman making jokes was “evidence” that he really did “bring the AIDS virus to the US,” as this post claims.
So what’s the real story? It is indeed true that back in the late 1950s, batches of polio vaccine were contaminated with a monkey virus known as SV40, which stands for “Simian Vacuolating Virus 40” (hence Hilleman’s mention of that “damn vaculating agent that we have”) or “Simian Virus 40.” It was the 40th simian virus that Hilleman had discovered, hence the name. The polio vaccines developed by Jonas Salk and Albert Sabin in the 1950s were made by growing the polio virus in kidney cells derived from Asian rhesus monkeys (hence the reference to monkey kidney cells). Salk’s polio vaccine was a killed vaccine, in which the viral particles were inactivated with formaldehyde and the killed virus injected to produce an antibody response against the polio virus that could prevent infection with live polio virus. It contained very little SV40, because the formaldehyde also inactivated SV40. Sabin’s virus, on the other hand, was a live virus vaccine and was more heavily contaminated with SV40.
In 1959, a researcher at the National Institutes of Health named Bernice Eddy noticed that monkey kidney cells were dying without obvious cause. (Note that she was also a critical player in the Cutter incident, in which she discovered that the vaccines manufactured by Cutter Laboratories had live polio virus in them.) She made extracts of the cells and injected them under the skin of 23 newborn hamsters; within nine months 20 of them developed large tumors. Meanwhile, Hilleman and his collaborator Ben Sweet isolated the virus responsible and found SV40 was found in both the Sabin and Salk vaccines. It didn’t help that Eddy had brought her findings to Dr. Joseph Smadel, chief of the NIH’s biologics division, who made a huge mistake and dismissed the tumors as harmless “lumps.”
By 1961, there was significant concern among U.S. Public Health Service officials, as it has been found that as many as one-third of polio vaccines were tainted. As a result, although there was no evidence at the time that SV40 was harmful to humans, it was ordered that manufacturers find a way to eliminate SV40 from all future vaccines, which they promptly did. New procedures were developed to neutralize any SV40 and SV40-free African green monkeys were then used to produce the bulk of the vaccine instead of rhesus monkeys (hence Hilleman’s reference to green monkeys in his interview). Showing that no good deed goes unpunished, conspiracy theorists latched on to the African green monkeys as the vector through which the AIDS virus was brought into the U.S. via the new polio vaccines (hence Hilleman’s joke about “importing the AIDS virus”). These actions were all well and good, but the government didn’t recall the contaminated vaccine stocks and did not notify the public, because, as Hilleman later recounted, government officials were worried about a panic that might jeopardize the vaccine program. In any case, by 1963, SV40 had been eliminated from the nation’s polio vaccine stock. However, millions of people had received the vaccine.
But does SV40 cause cancer in humans? In a word, as far as we can tell, no.
Even early on, there were indications that this was unlikely. First of all, followup studies demonstrated that while injecting SV40 would produce tumors, ingesting it did not. Other studies showed that children receiving Sabin’s oral polio vaccine did not develop antibodies to SV40, as one would expect if they were being exposed. SV40 apparently passed through children’s GI tracts without ever causing an SV40 infection.
As the years went by, there were studies that reported finding SV40 in human tumor samples, which was obviously worrisome. The most prominent of these studies were by Michael Carbone at the NIH. In the late 1980s, he tested 48 human mesotheliomas and found SV40 by PCR in 28 of them. In 1990s, PCR “unleashed a wave of SV40” discoveries, including a variety of bone, brain, and hematopoietic malignancies, so much so that in 1997 the National Cancer Institute set up an SV40 working group, as described by ERV. The report stated:
In order to resolve why some laboratories detect traces of SV40 in mesothelioma while others do not, an International SV40 Working Group, which included the majority of laboratories studying SV40 in human tissues, was formed in 1997. Nine laboratories from the working group agreed to participate in a study, funded and organized by the National Cancer Institute (NCI). Each group was given 25 paired-duplicate samples of human mesotheliomas, a single set of 25 normal lung tissue samples, and positive and negative control samples. All the samples were blinded (labeled so that the human tumors and controls could not be distinguished) and each laboratory used its particular assay for detecting SV40, many of which had been used to detect SV40 previously. The results, published in the May 2001 issue of Cancer Epidemiology, Biomarkers and Prevention (36), showed that none of the mesothelioma specimens was consistently positive for SV40.
That would be this paper.
For example, after Carbone had presented his evidence linking SV40 to mesothelioma, Howard Strickler, an epidemiologist at the NCI, and Joseph Fraumeni, director of NCI’s Division on Cancer Epidemiology and Genetics presented other evidence. For instance, PCR on 50 mesotheliomas from Armed Forces hospitals across the country found no SV40. Another study compared cancer rates in people born between 1947 and 1963, who were likely to have been exposed to contaminated polio vaccine, to people born after 1963, who were highly unlikely to have been exposed. There was no difference in cancer rates. This is a result that has held up, as studies performed eight years, fifteen years, and thirty years after SV40-contaminated vaccines had been given to children found that they had the same cancer incidence as groups not exposed to contaminated vaccine (for example, this study, this study, this study, and this study).
This story reminds me a bit of the Andrew Wakefield story in that these false positive results were most likely due to contamination with plasmid sequence. The SV40 and CMV promoters are very commonly used as a strong promoter to drive the expression of genes by plasmids, while the SV40 large T-antigen is commonly used to immortalize cell lines. Pretty much any molecular biology laboratory is likely to be swimming in contamination with SV40 and CMV sequences, much as the laboratory that was used to test Andrew Wakefield’s gut biopsy samples from autistic children was swimming in measles sequences. So very rigorous measures need to be taken if you’re going to look for these sequences to make sure the controls are all appropriate. As those of us who’ve ever done extensive PCR work know as well, even that isn’t always enough. Even the most careful scientist can occasionally be fooled by contamination problems when using PCR.
But what about the claim that the polio vaccine provided us not only with cancer-causing SV40 but with AIDS? This one is a lot easier to deal with because, unlike the SV40 fear mongering, which was built on a grain of truth, this particular myth is, as we say, right out:
In the 1990s, certain critics began to blame the testing of a live, weakened polio vaccine in Africa in the 1950s for the spread of acquired immune deficiency syndrome (AIDS). Those behind the accusation argued that chimpanzee cells were used to create the vaccine, and that those cells had been contaminated with a virus that sometimes affects chimps: simian immunodeficiency virus, or SIV. When the vaccine was given to children in Africa, they argued, SIV mutated to become human immunodeficiency virus, or HIV, which causes AIDS.
The accusations, however, were demonstrably false for a variety of reasons. Most notably, the weakened polio vaccine was not made with chimpanzee cells, but with monkey cells. The vaccine was later tested using a technique that can detect viral DNA (the PCR technique, or polymerase chain reaction); it did not contain SIV or HIV.
Researchers at the University of Birmingham in Alabama demonstrated in 2006 that while HIV was in fact a derivative of SIV, chimpanzees in Cameroon that had been infected with SIV in the 1930s were the most likely source of the AIDS epidemic—decades before the weakened polio vaccine was tested in Africa.
So wait a minute. Was it the switch to green monkeys in wake of the SV40 contamination problem or was it the testing of live attenuated polio virus in Africa that created the AIDS virus? I just can’t keep the stories straight.
Whatever the case, the SV40 conspiracy theory can easily be looked at as a case of no good deed going unpunished. After all, for all the castigation of the “sloppy science” that led to the polio vaccine by quacks and cranks, scientists back then used the best tools they had at the time, and quacks tend to fall into the trap of looking at those times through the lens of the scientific techniques that are available to us today. Scientists didn’t have PCR to look for sequences of contaminating viruses; that technique didn’t become widely available until more than 25 years later. Think of it this way: Watson and Crick’s original paper demonstrating the double helical structure of DNA was only published in 1953, which is around the time the polio vaccine was being developed, and Marshall Nirenberg didn’t publish his paper in which he “cracked the genetic code” until 1961. (I used the paper as part of a journal club-style class I taught for graduate students. It’s a really clever paper.)
In a way, it’s astounding to me that scientists could accomplish what they did then, that Eddy could detect the contaminating virus in 1959, and that Hilleman could identify it as a distinct virus in 1960. Even if the SV40 contaminating the Salk and Sabin polio vaccines really did cause cancer (and the evidence thus far is that it did not), the government moved pretty quickly to fix the problem. Sure, you can criticize the NCI for not taking Eddy’s results as seriously as they deserved or officials responsible for the vaccine program for not recalling the contaminated vaccines. Those are legitimate criticisms, but, even in spite of those missteps, in less than two years the contaminated polio vaccines were gone, which is a pretty impressive accomplishment. Then, over the next few decades, scientists did periodic studies to try to determine whether there had been any ill effects from the SV40 contamination, particularly in terms of an increased incidence of cancer in people who had received the contaminated vaccine. They failed to find any.
It’s time to move on, but we all know that the antivaccine cranks and quacks won’t, except temporarily. Once zombie memes are established, be they about vaccines, quackery, 9/11 conspiracy theories, pseudoscience, or involving other demonstrably bogus assertions, they are nigh-impossible to kill once and for all. Indeed, maybe “zombie” is the wrong word for them. After all, even in The Return of the Living Dead (in which they were the most indestructible), zombies could still be destroyed by reducing them to fine ash using a crematorium. (At least in The Walking Dead, all it takes to kill a zombie is a good head shot.) I rather suspect that antivaccine zombie memes would only be made stronger and more widely dispersed by such utter destruction. On second thought, that is a lot like the zombies in The Return of the Living Dead.
In any event, I fully expect that this particular meme will continue for the rest of my life, with the same few articles evolving only slightly, showing up periodically, being Tweeted all over the Internet, and spread all over Facebook, being refuted, and disappearing for a while, only to show up again later. Zombie memes never die. They always rise again. If readers of this post share it in response to seeing this particular zombie meme, perhaps this post can become a zombie meme too, but as a force for good. And I promise you that I will never, ever eat your brains.
Unless I’m really hungry, that is.
“Mooore braaains!”

Dr. William Makis and “turbo cancer”: Falsely blaming COVID-19 vaccines for cancer
A prominent oncologist and cancer biologist, Wafik El-Deiry, recently amplified claims that COVID-19 vaccines cause “turbo cancer,” wanting a “civil discourse about science and actual answers that are missing.” Unfortunately, calls for “civil discourse” by an eminent oncologist about unfounded claims only lends undeserved credibility to them. So, once more into the fray…
David Gorski on October 2, 2023
Link
There’s a line from a movie that I like to quote sometimes when I feel obligated to blog once more about a previously covered topic that I’ve become tired of. It comes from The Godfather, Part III and features aging mafia don Michael Corleone (played by Al Pacino) expressing frustration over being pulled back into the family “business” that he thought he had finished, all with an immortal line, “Just when I thought I was out…they pull me back in.” As I sit and type this, I’m feeling that same energy about claims that COVID-19 vaccines cause “turbo cancer.” Heck, I had even had an idea for a post today that had nothing to do with COVID-19 or vaccines, but, again, I’m feeling the energy of this video right now, and I go once more into the fray, particularly given that the person who pulled me back in is someone whom I never would have predicted even a few months ago, an eminent oncologist and cancer biologist whose research greatly influenced me (and whose work I used to cite a lot) when I was in graduate school in the 1990s, Prof. Wafik El-Deiry.
Before I get into the latest “turbo cancer” claims, I will note that the last time I published a post on this blog about the claim that COVID-19 vaccines somehow cause fast-growing “turbo” cancers and/or stimulate the “turbo-charged” growth of cancers in remission was late last year; so, in fairness, I guess that it is not unreasonable to write an update, even if I did do a couple of other posts over at my not-so-secret other blog in the interim. The claim has, as all dubious antivax claims do, mutated and metastasized. (What can I say? I’m a cancer surgeon and cancer biologist. I sometimes can’t resist borrowing terms from cancer to describe dubious claims, misinformation, and disinformation.) When last I discussed the concept of “turbo cancer” nine months ago, I could not ascertain when the term had been invented and who had invented it, but I did know who was promoting it, doctors like a family doctor named James Hoffe:
Dr Charles Hoffe ~ “As a family doctor a small percentage of cancer patients would be diagnosed with stage 4, now 2/3rds of my cancer patients are diagnosed with stage 4The tumours are bigger than ever they grow aggressively,spread very aggressively & are resistant to treatment” pic.twitter.com/tWw3rwf74f
— Janey (@_Janey_Jay) November 14, 2022
A physician who more recently started promoting the idea of “turbo cancer” is Dr. William Makis, a nuclear medicine radiologist who frequently misrepresents himself as an “oncologist.” I noted on his X (Twitter) feed that he appears to have taken up the “turbo cancer” banner sometime around February or March, for example:
NEWS: Canadian doctor Dr.Anil Kapoor has died suddenly on Feb.28, 2023 after a "short and courageous battle with an acute illness"
He battled with an aggressive (turbo) cancer for a month before passing away#turbocancer#diedsuddenly#cdnpoli #ableghttps://t.co/7ekxIGmAso pic.twitter.com/7qWdvuwMot
— William Makis MD (@MakisMD) March 3, 2023
Since then he’s been relentless in promoting the idea of “turbo cancer” supposedly caused by COVID-19 vaccines, for example, a few weeks ago he was claiming that “turbo cancers” were “decimating” teachers who had been forced to be vaccinated.
My uncle had the vaccine and he got run over by a turbo truck 😔
— Joel Ramirez (@JoelRam97490484) September 6, 2023
Indeed, here is a post from Dr. Makis published while I was still writing this SBM post:
It is promoting a recent article on his Substack (because of course he has a monetized Substack) entitled TURBO CANCER – Hepatobiliary System (Part 3) – Stage 4 COLON Cancer – Why are COVID-19 mRNA Vaccinated getting these types of Turbo Cancers? – 30 recent tragic cases. Unfortunately, it’s paywalled, meaning that I can’t go through it in detail. However, fortunately I have other sources to see what Makis is claiming. Unfortunately, the source that “pulled me back in,” so to speak was one that I really wish hadn’t, namely the aforementioned Dr. El-Deiry, who Tweeted/posted this over the weekend:
I watched this interview that speaks of persecution of scientists and physicians who are reporting cancers or looking into mechanisms in the setting of COVID vaccines. The concerns are about repeated boosters that ultimately dampen the very immune system they are boosting.…
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 30, 2023
Because Dr. El-Deiry has a blue check and the whole post won’t embed, I will cite it in its entirety, for the benefit of those of you who don’t have (or no longer have) an X/Twitter account:
I watched this interview that speaks of persecution of scientists and physicians who are reporting cancers or looking into mechanisms in the setting of COVID vaccines. The concerns are about repeated boosters that ultimately dampen the very immune system they are boosting. Description of turbo cancers sound a lot like hyperprogression and sounds awfully similar to p53 with the range of tumors among young people.
Should this be ignored or should it be investigated as part of the risk:benefit ratio for different age groups who are getting 5th and 6th booster shots 3 years into the COVID pandemic.
IS THE COVID VACCINE CAUSING TURBO CANCERS?
William @MakisMD MD a Canadian oncologist gives a 30 minute interview describing that clinical oncologists are seeing more cancers among younger people in certain professions with mandated vaccines. Breast, colon, brain, lung cancers, lymphoma and leukemia cancers. Also rare cancers such as angioimmunoblastic lymphoma, or infiltrating basiloid carcinoma. Canadian doctors, teachers, etc. He mentions a surge in go fund me pages with younger people with cancer “that we haven’t seen before.” He talks about other side effects such as sudden death or heart attacks or people too sick to work. He mentions turbo-cancers in pregnant women and young kids as young as 12. He says turbo cancers including among young people will be a long-term effect of COVID vaccination and that they are rising. He says the cancers are treatment resistant and that more research into their mechanisms would be helpful. A rise in all cause mortality among 18-24 worldwide is mentioned. It is mentioned that only 5-6% of Canadians have taken boosters in the last 6 months.
He describes in detail several possible mechanisms that could lead to cancer in susceptible individuals.1- He says the liposomal nanoparticles or LNP go systemic in the body.2- Pseudouridine modification of the mRNA vaccine which stabilizes the RNA suppresses innate immune surveillance by dampening activity of toll-like receptors.3- DNA fragments might integrate thereby disrupting tumor suppressor genes.4- Plasmid DNA may be taken up by the microbiome which can amplify it. 5- Repeated shots cause shift to IgG4 which is associated with tolerance and seems associated with more flu or repeated COVID infection.“The more doses the more damage to the immune system”The interview includes mention of@P_J_Buckhaults @Kevin_McKernan Angus Dalgleish among others.Doctors being persecuted for causing vaccine hesitancy.
It’s a sad day for science if scientists can’t ask scientific questions and are not supported to investigate them. This is not about anti-vaxx. It’s about risks among certain groups that may be more susceptible to adverse events plus general information. Are they fear-mongering or providing discussion and insight into molecular mechanisms in the tradition of science and medicine? I believe more research is needed on those whose cancers are growing faster or on material from those who die in temporal association to vaccine boosters. These may be rare events but they need to be talked about, understood and known better as potential risks. This should be done in a safe environment as part of science and medicine with no politics.
I was gobsmacked when I read this.
When an eminent scientist is a bit too trusting…
I must admit that it is very disturbing to me to see someone as eminent as Dr. El-Deiry lending his reputation built up over more than three decades actually posting a video by antivax conspiracy theorist Del Bigtree. And make no mistake, Del Bigtree has been a major antivax conspiracy theorist and misinformation spreader since at least 2016 when he produced the antivax conspiracy film VAXXED, with the godfather of the modern antivaccine movement Andrew Wakefield, who made his directorial debut with the film. His video podcast The Highwire has since served as an outlet for a relentless promotion of antivax misinformation of the worst sort. Let’s put it this way. If you appear on The Highwire with Del Bigtree, at least one of two things are true about you. You are almost certainly antivax or, as sometimes happens, you’ve made a huge mistake.
Let me also make three brief observations before I discuss Dr. Makis’s claims in more depth. First, it is, as Dr. El-Deiry observes, good to be open minded. It is not, however, good to be so open-minded that your brains fall out. His belief that scientific “truth” will always drive out the lies is painfully naive, and I would have thought that a cancer biologist who has been studying tumor suppressor genes for over three decades would recognize the dodginess of the claims being made. Apparently I was wrong. Second, the reaction to physicians and scientists who have started to spread misinform has nothing to do with “persecution.” Rather, as I like to say, it’s about quality control, not censorship. and Dr. El-Deiry’s apparent affinity for the universal narrative of conspiracy theorists, that they are being “persecuted” by nefarious forces who want to cover up some great evil, is disturbing. Finally, the video itself mentions a veritable host of doctors spreading misinformation about COVID-19 who have been on The Highwire before—whom, hilariously, Bigtree describes as “some of the greatest scientists and doctors in the world”—such as Dr. Peter McCullough, Dr. Paul Marik, and Dr. Robert “inventor of mRNA vaccines” Malone, all of whom are antivax conspiracy theorists. Dr. McCullough, for example, has been promoting the “died suddenly” conspiracy theory about vaccines and sells unproven supplements to treat “COVID-19 vaccine injury.” Dr. Marik is one of the founders of the Frontline COVID-19 Critical Care Alliance (FLCCC), a group of now antivax doctors who have been selling dubious cures for COVID-19 since 2020, and Dr. Malone has become one of the most prolific spreaders of misinformation and conspiracy theories about COVID-19 vaccines since the mRNA vaccines were first announced, even before they were ever approved.
Unsurprisingly, Bigtree introduces Dr. Makis as an oncologist, a claim that Dr. El-Deiry took at face value. He’s not. He’s a nuclear medicine physician, a radiologist. His ResearchGate profile even still says that, as does this legal decision. There’s nothing wrong with that, of course. The problem is that he misrepresents himself as an oncologist. Moreover, he lost his medical license. I also note that Bigtree seems to claim that Dr. Makis invented the term “turbo cancer.” He clearly did not. As I pointed out before, it was a term being used in 2022, but Dr. Makis doesn’t seem to have glommed onto it until February or March of 2023, at least if his X/Twitter feed is any indication. I also can’t help but note that one of the studies apparently cited (there are no direct citations) showing an increase in cancer incidence among younger people ran from 1990-2019; in other words, the rise in cancer incidence predates the pandemic, but antivaxxers are misrepresenting the study as support for “turbo cancer”:
Even more hilarious, antivaxxers don't even bother to read the study, which only covers the years 1990 to 2019.😂 https://t.co/cuejD08RXl
— David Gorski, MD, PhD (@gorskon) September 6, 2023
Dr. Makis and “turbo cancer”
Right at the beginning of the interview, Dr. Makis relates an anecdote about a 12-year-old boy who, according to him, developed stage IV brain cancer four weeks after a single dose of the Moderna vaccine. Of course, 12-year-olds have, alas, developed horrible brain cancers since, basically, forever. Indeed, I discussed more cases of children with brain cancer than I care to remember in debunking the treatments offered by cancer quack Dr. Stanislaw Burzynski. This anecdote tells us nothing other than that Dr. Makis is prone to the post hoc ergo propter hoc fallacy. Dr. Makis claims that he had never seen anything like this before, despite having diagnosed 20,000 cancers in his career, which makes me wonder: He’s diagnosed so many tumors but never a brain cancer in a child? Perhaps he wasn’t a pediatric doc. Various forms of brain cancer are, unfortunately, sometimes pediatric tumors. It is also true that the incidence of childhood and adolescent brain tumors has been increasing, but the increase dates to long before the pandemic and has been relatively slow and there is no evidence of a large spike since COVID-19 vaccines were recommended for children.
In any event, Dr. Makis starts out claiming that there has been an epidemic of what he calls “turbo cancer” since the COVID-19 vaccines came out, adding that oncologists “don’t know how to treat” these cancers and that after such tumors are surgically excised doctors discover that the tumor has already spread. My reaction to claims like this is that there’s a phenomenon common among antivaxxers and COVID-19 conspiracy theorists since the pandemic hit, specifically their tendency to discover a phenomenon that they hadn’t known about before and then claiming that it’s something never seen (or only very rarely seen) before the vaccines rolled out. One good example is sudden cardiac death in young people, a sad phenomenon that was identified as a syndrome 50 years ago and has long been so known that we have identified gene mutations and anatomic abnormalities that predispose to sudden cardiac death. It’s the very reason why schools require sports physicals before children and adolescents can participate in strenuous and contact sports. As I like to say: Just because it’s new to you doesn’t mean it’s new, and I repeat that to Dr. Makis, who opines about advanced breast cancers in women in their 20s and 30s, which I saw before the pandemic, most likely because I’m in a tertiary care cancer center. (Years ago, one of my colleagues, now retired, saw breast cancer in a 14 year old, which is rare.)
In addition, there is no evidence that an unusual number of people are dying of cancer since the vaccines rolled out, as a friend of the blog pointed out:
Makis is an ghoul who torments and harasses families who have lost loved ones to falsely blame their deaths on vaccines.
He is the personification of pure evil.
And you promote him on your Twitter page? Shameful.
Turbo cancer is a made up term by people like Makis to grift… pic.twitter.com/kFiBbeCBap
— The Real Truther (@thereal_truther) September 30, 2023
Next up, instead of looking at the actual medical literature, Dr. Makis looked at GoFundMe pages for young people raising funds with cancer. Shockingly, Bigtree actually noted something semi-reasonable, namely that there is no way to know how many of these people were vaccinated against COVID-19, saying that we just “assume” that. Too bad he didn’t also point out that the number of GoFundMe pages for young people raising money for treatment of advanced cancers could also correlate with a lot of other things other than actual cancer incidence (such as lack of insurance that becomes more prevalent during economic downturns, belief in alternative medicine cures (lots of Burzynski patients use GoFundMe to try to pay for his quackery), and the like. Instead, Bigtree asked rhetorical questions like, “When do we remember this many young people getting cancer at the same time?” and “When do we remember this many athletes collapsing with heart attacks?” It’s an interesting question, but more like one of selective memory. After all, there is a veritable industry of misinformation promoting these stories; so of course we “remember” them more! Dr. Makis, for his part, blames this nonexistent epidemic of “turbo cancer” on vaccines, claiming to have observed it in doctors and other professions for whom vaccines were mandated. Again, he presents no evidence other than anecdotal evidence.
This brings us to Bigtree asking about potential “mechanisms” by which mRNA vaccines could supposedly cause cancer. First up, as listed in Dr. El-Deiry’s post above as #2, Dr. Makis blames the pseudouridine base used in the vaccines. Of course, pseudouridine is used because native, unmodified mRNA has a very short half-life—minutes to hours, generally, and I know, having studied mRNA half-life for a gene that I first identified in the 1990s—which is too short to produce sufficient spike protein to result in a useful immune response. Of course, antivaxxers will exaggerate the other way and claim that the modified mRNA never goes away and keeps pumping out spike protein almost indefinitely, but that is nowhere near true. In any event, Dr. Makis cites work that pseudouridine-containing RNA can decrease the activity of proteins known as Toll-like receptors, which is in part how these modified mRNAs escape degradation by the immune system. Dr. Makis, of course, claims without evidence that the mRNA vaccines damage cancer surveillance. It’s all hand-waving, of course, based on papers that did find this but have shown no link to cancer. In brief, there is no evidence that modified mRNA “dampens the immune response” to cancer, including the 2005 paper by Kariko et al that found that the modified mRNA did dampen the immune response to…RNA!
Next up, Dr. Makis leans into the claim that the mRNA from the vaccine can be “reverse-transcribed” into the genome or that the “DNA contamination” of plasmid fragments can somehow integrate into the genome and cause insertional mutagenesis and cancer. I’ve dealt with both of these claims in detail before; so I won’t reinvent the wheel (much). For the latter claim, Bigtree plays a brief snippet of a video that I recently debunked elsewhere in which Dr. Philip Buckhaults promotes an unpublished study that hasn’t been peer-reviewed to fear monger about “contamination” of the vaccines with residual plasmid DNA from the manufacturing process. Unfortunately, last month Prof. El-Deiry found that testimony convincing as well:
For the record, Wafik is not anti-vaccine and never has been. Vaccines save lives and the COVID vaccines given to millions of people around the world have saved countless lives. As a physician, I happily received my first COVID vaccine by December of 2020. There are questions 3…
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 23, 2023
As for the claim that the mRNA can be “reverse-transcribed” into DNA—the dreaded cDNA coding for the evil spike protein, no less!—that “integrates” into the genome, that is a claim made a long time ago that was based on a very bad scientific study that has never been replicated. It was a very artificial system used in vitro, anyway, and it’s not as though DNA in the bloodstream hasn’t been extensively studied for a long time.
Another claim made by Dr. Makis is that this contaminating DNA can be picked up by our “gut bacteria” and alter the microbiome of those bacteria, to unknown effect. What Dr. Makis, even as he cites Philip Buckhaults and Kevin McKernan’s fear mongering about DNA “contamination,” fails to mention is that even Buckhaults’s and McKernan’s work, if you take it at face value (which, obviously, I do not), shows that the fragments of DNA in the vaccine are nearly all very small, averaging in the 100 bp range. They don’t code for anything, they can’t induce bacteria or other cells to code for anything. There is no good biological mechanism described by which they could get into the nucleus and insert themselves into the genome, and even if they could mutational mutagenesis events from such a process that could give rise to cancer would be very rare, as they would have to specifically inactivate a tumor suppressor gene or activate an oncogene. Indeed, given the multiple-hit hypothesis of cancer, it’s unlikely that just affecting one tumor suppressor or one oncogene would be enough. Multiple cancer-promoting integrations would have to happen in the same cell.
Predictably, next Dr. Makis fear mongers about the lipid nanoparticles that are used to hold the mRNA molecules and that fuse to cells in order to introduce the mRNA into them, so that their transcriptional machinery can start using the mRNA as a template to make spike protein. His concern is that the lipid nanoparticles are “unmodified” (whatever that means) and that they “go systemic.” I’ve discussed the biodistribution studies for the lipid nanoparticles (LNPs) before. You might recall that very soon after the vaccines were introduced antivaxxers began fear mongering about “sterility” and female fertility on the basis of a Japanese biodistribution study of the LNPs used in the Pfizer vaccine that found that the lipid nanoparticles did lodge in the ovaries. As I pointed out at the time, the study used a huge dose of LNPs injected intravenously, not intramuscularly (the way vaccines are injected) and then measured where in the body they ended up. Peak accumulation in the ovaries was 0.095% (or less than 1:1,000 of the total dose of lipid nanoparticle. Unsurprisingly, Dr. Makis is unable to produce any evidence even tenuously linking these LNPs to an increased risk of cancer—or even to mechanistic studies in vitro or in mice that would suggest they could cause cancer. (And, no, this study wouldn’t have counted even if Dr. Makis had mentioned it.)
Finally, Dr. Makis handwaves about “antibody shift” in which the immune system shifts to a different kind of antibody (IgG4) after repeated exposures to an antigen promoting immune tolerance for that antigen. His claim is that this “antibody shift” happens after repeated COVID-19 boosters and then predisposes to cancer, as well as to infection with a number of other pathogens. As I like to say, I am not an immunologist, but I do know that this is pure nonsense, thanks to a number of social media scientists and doctors who do know what they are talking about and have taken the time to address this claim:
Makis' trolling on IgG4 is immunologically illiterate + been addressed to death.
Evidence of harmful immunosuppression is not therehttps://t.co/63fHR5khbzhttps://t.co/FgTwS15HXrhttps://t.co/CcwZPC5NrKhttps://t.co/6bCPEp74Y6https://t.co/BQTe7NBX1xhttps://t.co/kaDGj0wu6o pic.twitter.com/i4qDmOapPQ
— Atomsk's Sanakan (@AtomsksSanakan) September 30, 2023
Let’s just say that the question of antibody switching and COVID-19 vaccines is far more nuanced than what Dr. Makis suggests and that there is no good evidence to support his fear mongering. Nor is there good evidence that the vaccines can cause autoimmunity:
It's just Makis + Hart disinforming again.
It's telling watching the non-expert contrarians abusing terminology like "IgG4" that they were willfully ignorant on before the pandemic.https://t.co/kcFmevlkpVhttps://t.co/CcwZPC5NrKhttps://t.co/oXd8CaGQ3ehttps://t.co/Im6E7qH4Ep pic.twitter.com/0irIlKYNY9
— Atomsk's Sanakan (@AtomsksSanakan) June 5, 2023
Finally, Dr. Makis dons the mantle of the persecuted brave maverick scientist—and not just about COVID-19. He claims to have treated many patients with radioisotopes as a nuclear medicine doctor. In fairness, it is true that some cancers are treated by nuclear medicine doctors with radioisotopes, Thyroid cancer, for instance, is treated with radioactive iodine, which preferentially goes to the thyroid gland. However, it’s a huge stretch to make the claim that Dr. Makis is an oncologist. Again, he is a radiologist who specializes in nuclear medicine imaging, and there’s nothing wrong with that. It’s an important specialty in oncology. What is wrong with Dr. Makis is the claim that he makes that he was “curing” 80-85% of his stage IV neuroendocrine cancer patients, but that the Canadian government shut him down for some reason because they “didn’t like the program.” He further claims that the government, after shutting him down and taking away his license, is rebuilding his program, but under government control. Somehow, given Dr. Makis’ history, I’d be more prone to believe that the government had a very good reason for shutting down his operation and stripping him of his license.
You should probably look into people before you platform them https://t.co/zpCzMWgkgi pic.twitter.com/WB4diSVHEd
— Jonathan Laxton MD, FRCPC 🐈🐱🐈‍⬛ (@dr_jon_l) April 12, 2023
Bigtree, of course, calls this “socialism,” in which the government “stole” Dr. Makis’ technology. But have no fear! His loss of license has freed him to “speak out” against “turbo cancer” and all manner of horrific “vaccine injuries”! He even claims to have found leukemias that can kill in a manner of days or even hours.
Bigtree also cites a paper co-authored by Peter McCullough (whom, as we showed before, is pure antivax conspiracy theorist) and Stephanie Seneff, who prepandemic had claimed that by 2025 GMOs and vaccines would result in all children being autistic, which, if you know the background of these claims, should be all you need to see to know that Brandolini’s law is in full effect.
For Prof. El-Deiry, this is Brandolini's law. My corrollary to Brandolini's law is that Brandolini was an optimist. It takes at least two to three orders of magnitude more energy to refute bullshit than it does to produce it. pic.twitter.com/75lzggvPwr
— David Gorski, MD, PhD (@gorskon) October 1, 2023
It is not about “free speech” or “persecution”
I am not saying that every scientifically reasonable concern about vaccines that have been distributed to billions of people now should not be the subject of scientific investigation. What I differ about is what constitutes a scientifically reasonable concern. To know what concerns are and are not scientifically reasonable, you have to know a few things. First, you need to know the science and potential mechanisms. Dr. Makis, unsurprisingly, claims that we are not studying these “mechanisms,” when his own discussion indicates that we have. . Second, you need to know the specific misrepresentations of science used by antivaxxers to promote fear, uncertainty, and doubt about vaccines. Finally, contrary to Dr. El-Deiry’s claims, who is making these claims matters. I know he’s been on NIH study sections before. When grant applications are discussed, the criteria used to rank it include the qualifications and track record of the investigators, as well as the overall environment in which they work. He wouldn’t question that that should be considered for NIH applications. So why does he react so strongly to criticizing quacks and cranks like Dr. Makis based on their long track record of spreading misinformation about COVID-29 and vaccines?
Nor is it about “free speech,” as Prof. El-Deiry claims:
Are you an advocate for suppression of free speech? It’s been stated repeatedly this is not anti-vaccine and so I’ll point this out as you list pro-vax in your profile. If you are able to debate about facts, mechanisms and concerns then that would be positive. The reason the post…
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 30, 2023
Full quote:
Are you an advocate for suppression of free speech? It’s been stated repeatedly this is not anti-vaccine and so I’ll point this out as you list pro-vax in your profile. If you are able to debate about facts, mechanisms and concerns then that would be positive. The reason the post was made was exactly about the intimidation and persecution you’re promulgating and claims of misinformation. Personal attacks on scientists or anyone else is not constructive at all. A scientific conversation is not possible with someone with your attitude.
Nor is it about “censorship” or “repression,” as Dr. El-Deiry claims:
Is that your tactic when you disagree with someone? Just try to discredit and censor conversation?
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 30, 2023
Again, Dr. El-Deiry’s attitude is either willfully or just painfully naive. He is either utterly unaware of the well-funded networks that exist to spread misinformation and/or he is sympathetic to the misinformation being spread. I am having a hard time envisioning another possibility. I like to cite the famous adage from Spider-Man, “With great power comes great responsibility.” In science, I like to rephrase that somewhat to say something like, “With great scientific reputation comes great responsibility.” The bottom line is that Dr. El-Deiry has a 30-year career studying cancer, tumor suppressor genes, and, more recently, tumor immunology. He is the director of a new cancer center. I’ll just reiterate that his work in the 1990s was work that I cited often as a graduate student and researcher. When he platforms cranks—and, Dr. El-Deiry’s call for “civility” and disdain for “attacking” such “scientists” as Dr. Makis and others notwithstanding, these are cranks whose views he is platforming and presenting not as the fear mongering they are but as scientifically credible concerns that demand urgent investigation—it matters. A lot. Moreover, criticizing the views and behaviors of the likes of Dr. Makis, removing their licenses to practice, and other sanctions are not “persecution,” defamation, or “censorship” of scientific debate. They are desperately needed quality control.
I hope that Dr. El-Deiry will eventually understand that.

Here we go again: Another study is being misrepresented as evidence that COVID vaccines cause cancer
An eminent oncologist, cancer researcher, and cancer center director is promoting a study that seems to show—but, when critically examined, doesn’t—that COVID vaccines are associated with increased cancer risk.
David Gorski on September 29, 2025
Link
When I was thinking about what to write for today, I had a number of ideas, and, unfortunately, they all had to do with the utter nightmare that federal medical, public health, and biomedical research programs are becoming under the current administration, overseen by Secretary of Health and Human Services Robert F. Kennedy, Jr., who, in return for being given free rein to “go crazy on health” (i.e. eliminate vaccines) has signed on to the dismantling of public health. Then, life intervened, and, uncharacteristically, I didn’t have time to write anything until last night, which led me to think that maybe I should do a reverse Commando (it’s the opening joke from last week’s post—look it up if you don’t remember) and do a simpler post about something else. True, it’s about vaccines, but it’s also about looking at a study that is being circulated widely and misrepresented as being good evidence that COVID-19 vaccines cause cancer. Yes, we’re back at “turbo cancer.”
Here’s what brought this study to my attention:
Censorship shows up on @LinkedIn once again for peer-reviewed literature. This time the Korean study with data on 8.4 million people is labeled as misinformation. Sad to see. @RetsefL @RWMaloneMD @RobertKennedyJr @KUPERWASSERLAB https://t.co/LEw1cs2OPF pic.twitter.com/AJXr4uxDkh
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 28, 2025
Sadly, it’s Prof. Wafik El-Deiry again, someone who featured prominently in last week’s post, and he’s at it again, whining about “censorship” again because LinkedIn moderated his post and snitch-tagging RFK Jr. and antivaxxers turned members of the CDC Advisory Committee on Immunization Practices (ACIP), Robert “Inventor of mRNA Vaccines (not)” Malone and Levi Retsef. Last week, you’ll remember, as a member of the ACIP COVID-19 working group Prof. El-Deiry gave an error- and misinformation-filled presentation to ACIP that fear mongered about the dreaded “DNA contamination” of vaccines and contained false claims that there was good evidence that COVID-19 vaccines are associated with an increased risk of cancer.
As I described last week, we have met Prof. El-Deiry before in the context of his having demonstrated too little skepticism of work claiming that contaminating DNA from mRNA-based COVID-19 vaccines could integrate into genomic DNA and cause “turbo cancers,” to overinterpreting and overextrapolating results that his lab published linking binding of the spike protein to p53 (the granddaddy of tumor suppressor genes) to possible cancer development, to being willing to let his good name as a respected cancer researcher and director of a major cancer center be weaponized against vaccines by being interviewed by an antivax “journalist.” I’ve expressed my disappointment in Dr. El-Deiry on a number of occasions, as well as my admiration for his pre-COVID vaccine work, especially his groundbreaking work from the 1990s on another tumor suppressor, p21, which I cited often in my graduate work. Then, as now, Prof. El-Deiry was quite…defensive…when criticized:
A typical response to Prof. El-Deiry when called out.
Also, he retreats to what I like to call appeal to impact factor:
I understand the journal IF is 11 and they publish after peer review. Not only is science politicized but it is also censored.
— Wafik S. El-Deiry, MD, PhD, FACP (@weldeiry) September 28, 2025
An impact factor of 11 is quite respectable, but that doesn’t mean the journal can’t publish crap. Let me remind you that The Lancet once published a fraudulent case series by a certain British gastroenterologist that falsely linked the MMR vaccine to autism, and The Lancet has a much higher impact factor. Moreover, Dr. Young above made some very valid criticisms, as you’ll see. No, I’m not saying that this study is fraudulent. Rather, I’m saying it’s not very good and very likely suffers from significant biases that render its findings of associations between COVID-19 vaccines and cancer suspect.
So let’s take a look at the paper, published online last Friday: 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea, by Hong Jin Kim, Min-Ho Kim, Myeong Geun Choi & Eun Mi Chun. Two of the authors are faculty at Department of Internal Medicine, Ewha Womans University Mokdong Hospital, one from Ewha Womans University Seoul Hospital, and the last from based at Kyung-in Regional Military Manpower Administration.
Let’s start with the title, which should be a red flag for problems with this paper: One year risks. As I’ve emphasized time after time after time after time, cancer takes a long time to develop, usually years, sometimes decades. I routinely cite a study done examining survivors of the nuclear bombings of Hiroshima and Nagasaki, which found that the increased risk of cancer attributable to the ionizing radiation dosages victims survived, well, let me just quote a summary of the findings again:
What do these data show? First, the risk of developing a radiation-induced cancer is dose-related—the higher the dose, the greater the probability a cancer in an A-bomb survivor was caused by radiation exposure. Second, the A-bomb data allow us to determine the briefest interval from radiation exposure to cancer diagnosis. For leukemias, this is about 2 years, and for solid cancers, about 10 years. These increased risks, especially those for solid cancers, were most easily detected after 30 years and remain over a person’s lifetime.
Remember, ionizing radiation is a very powerful carcinogen. It’s incredibly unlikely that, even if COVID-19 vaccines contributed to cancer development (a hypothesis for which there is no good evidence), the effect would not be as dramatic as for ionizing radiation. Remember, the intervals described above (two years for hematologic malignancies and ten years for solid cancers) are the briefest interval observed between radiation exposure to cancer diagnosis. Put that into context by considering that December will mark the five year anniversary of the first doses of the Pfizer mRNA-based COVID-19 vaccine rolling out to the public, starting with healthcare workers, who were prioritized. That’s how I got my first dose in December 2020.
In fairness, more recent studies show shorter minimum latency periods. For example, the CDC World Trade Center Health Program defines minimum latency periods for these cancers as:
The Administrator of the WTC Health Program has determined minimum latencies for the following five types or categories of cancer eligible for coverage in the WTC Health Program:
(1) Mesothelioma — 11 years, based on direct observation after exposure to mixed forms of asbestos in case series;
(2) All solid cancers (other than mesothelioma, lymphoproliferative, thyroid, and childhood cancers) — 4 years, based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies;
(3) Lymphoproliferative and hematopoietic cancers (including all types of leukemia and lymphoma) — 0.4 years (equivalent to 146 days), based on low estimates used for lifetime risk modeling of low-level ionizing radiation studies;
(4) Thyroid cancer — 2.5 years, based on low estimates used for lifetime risk modeling of low- level ionizing radiation studies; and
(5) Childhood cancers (other than lymphoproliferative and hematopoietic cancers) — 1 year, based on the National Academy of Sciences findings.
Again, remember that these are minimum latencies, and they are generously low estimates, as a fair reading of the whole document, which cites longer estimates in its discussion, will indicate.
In brief, I, as several others on X, the hellsite formerly known as Twitter, as well as other social media observed, an increased one-year risk almost certainly represents detection bias of some sort, in which those in the vaccinated group are more likely than those in the unvaccinated group to have their cancers detected. Again, more on that later.
Now consider the findings:
The oncogenic potential of SARS-CoV-2 has been hypothetically proposed, but real-world data on COVID-19 infection and vaccination are insufficient. Therefore, this large-scale population-based retrospective study in Seoul, South Korea, aimed to estimate the cumulative incidences and subsequent risks of overall cancers 1 year after COVID-19 vaccination. Data from 8,407,849 individuals between 2021 and 2023 were obtained from the Korean National Health Insurance database. The participants were categorized into two groups based on their COVID-19 vaccination status. The risks for overall cancer were assessed using multivariable Cox proportional hazards models, and data were expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). The HRs of thyroid (HR, 1.351; 95% CI, 1.206–1.514), gastric (HR, 1.335; 95% CI, 1.130–1.576), colorectal (HR, 1.283; 95% CI, 1.122–1.468), lung (HR, 1.533; 95% CI, 1.254–1.874), breast (HR, 1.197; 95% CI, 1.069–1.340), and prostate (HR, 1.687; 95% CI, 1.348–2.111) cancers significantly increased at 1 year post-vaccination. In terms of vaccine type, cDNA vaccines were associated with the increased risks of thyroid, gastric, colorectal, lung, and prostate cancers; mRNA vaccines were linked to the increased risks of thyroid, colorectal, lung, and breast cancers; and heterologous vaccination was related to the increased risks of thyroid and breast cancers. Given the observed associations between COVID-19 vaccination and cancer incidence by age, sex, and vaccine type, further research is needed to determine whether specific vaccination strategies may be optimal for populations in need of COVID-19 vaccination.
Here is the graph:
Looking at this result and study, I had a number of questions, but one thing stood out, something I noticed immediately, even leaving aside for the moment, specific questions about the methodology used to do the multivariate analysis. (For example, I see no mention of specific very important confounders. More on that later.) Look at the specific cancers that have an increased one-year risk in the vaccinated:
Thyroid cancer
Gastric Cancer
Colorectal cancer
Lung cancer
Breast cancer
Prostate cancer
What do these cancers have in common? It helps if you remember that this is a South Korean study. Why? Most readers know that in the US we routinely screen for breast, prostate, and colorectal cancer in the US, with high risk populations (e.g., smokers) also screened for lung cancer (although uptake of that screening is low). So what about gastric and thyroid cancer. First, gastric cancer is more common in Asian populations, which is why Japan and Korea both have active screening programs for gastric cancer. In the past barium studies were used, but now it’s endoscopy. So, unlike the case in the US, in South Korea gastric cancer is a screen-detected cancer.
Thyroid cancer is another interesting cancer to have been detected in this study. We don’t routinely screen for thyroid cancer in the US, but in South Korea—you guessed it!—they do. Moreover, South Korea has the highest incidence of thyroid cancer in the world, which has been called an “epidemic.” There is now good evidence that the large increase in the incidence of thyroid cancer in South Korea is almost certainly the result of overdiagnosis from the ultrasound screening program. Overdiagnosis, if you’ll recall, is the detection of real disease by screening that is very early and/or indolent and would likely, if untreated, never cause the patient harm. If you want to review in detail the concepts of overdiagnosis and lead time bias, both of which can increase the apparent incidence of cancers screened for as well as the apparent five-year survivals, I refer you to previous posts (linked in this paragraph) of mine on the topic.
I’ve discussed overdiagnosis a number of times on this blog for a number of cancers, including breast cancer and, yes, thyroid cancer. You might remember that, after the March 2011 meltdowns at the Fukushima Daiichi Nuclear Power Plant in Japan as a result of damage sustained from a tsunami that hit Japan, there was concern about an “epidemic” of thyroid cancer in Japan. After the disaster, Japan started an ultrasound screening program for thyroid cancer, resulting in an “epidemic” of thyroid cancer diagnoses that were later shown to be almost certainly nearly all due to overdiagnosis.
So what does this all have to do with the study linking the six cancers above to COVID-19 vaccines? I think you probably can figure out where I’m going with this. First of all, there is no good detailed description of how standard confounders were treated, such as age, smoking history, sex, family history, obesity, alcohol use, etc. Don’t get me wrong. There was some stratification for age and sex, but:
Meanwhile, vaccinated males were more vulnerable to gastric and lung cancers, whereas vaccinated females were more susceptible to thyroid and colorectal cancers. In terms of age stratification, the relatively younger population (individuals under 65 years) was more vulnerable to thyroid and breast cancers; by comparison, the older population (75 years and older) was more susceptible to prostate cancer (Additional File 3). Booster doses substantially affected the risk of three cancer types in the vaccinated population: gastric and pancreatic cancers (Table 1). Our findings highlighted various cancer risks associated with different COVID-19 vaccine types.
Prostate cancer is a disease of old men. Autopsy series, for instance, show that more than half of men over 80 have foci of cancer in their prostates, and the median age at diagnosis is late 60s. As for that finding that boosters are associated with increased risk of gastric and pancreatic cancers at one year, I looked at that result and, again, strongly suspected some form of detection bias. After all, pancreatic cancer takes years to develop. It’s rare for this cancer to go from nothing to cancer within a year. Indeed, the WTC Health Program cites studies showing that it takes 18 years from the time of the first cancer-causing mutations in the pancreas to clinically evident pancreatic cancer.
What this study screams to me is healthy vaccinee bias, specifically a side effect of healthy vaccinee bias known as healthy user bias. You might recall that healthy vaccinee bias is a type of confounding in observational studies (like this one, a retrospective observational study) where healthier, more health-conscious individuals are more likely to get vaccinated. This bias can lead to the overestimate of vaccine efficacy, which is obviously not an issue in this study, which didn’t even try to estimate vaccine efficacy. That wasn’t its purpose. Healthy user bias, which is related, is the likelihood that people engaging in one health behavior (e.g., getting vaccinated against COVID-19) will be more likely also to engage in other health interventions, such as cancer screening. What I think we’re very likely seeing in this study is nothing more than a failure to correct for screening intensity, along with other potential confounders, so that the likelihood that people who were vaccinated and boosted were more likely to undergo screening, leading to an apparent increased incidence of the six screen-detected cancers described within a year, or to seek medical care for lesser symptoms, leading to, for instance, an earlier diagnosis of pancreatic cancer, a cancer that is not routinely screened for. Add to that lots of evidence that has failed to find a post-vaccination surge in cancer cases, either in the US or worldwide, and this paper looks fatally flawed, at least to me.
Moreover, at the end of the study:
The data that support the findings of this study are available from National Health Insurance Service in South Korea but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of National Health Insurance Service, South Korea.
One hopes that there will be independent researchers who will request and receive the data.
All of this brings me back to Prof. El-Deiry. He’s an eminent cancer researcher and has been for 30 years. He was rumored to be a contender to head the National Cancer Institute (likely because of his receptiveness to nonsense about “turbo cancer” due to COVID-19 vaccines). Fortunately (and highly unusual for this administration), it appears that someone actually qualified to run NCI will be appointed. He really should know better. He really should have been able to see the glaring problems with this study that make its conclusions linking COVID-19 vaccines both highly implausible from a biological and clinical standpoint based on what we know about carcinogenesis and cancer latency and very suspicious for specific obvious biases. Seriously, the finding that only cancers routinely screened for came up in the analysis other than the secondary analysis for “boosters” should have been a huge red flag for detection bias in the context of what we know about how long cancer latency is.
Sadly, if there’s one thing I’ve learned during the pandemic, it’s that no one is entirely immune to misinformation. Indeed, people whom you wouldn’t expect fall prey to misinformation in topics in which they have expertise. Apparently, that includes eminent oncologists and cancer researchers.



Should We Avoid Dairy Out of Fear of Cancer?
A doctor is adamant about avoiding dairy because IGF-1 allows cancer cells to multiply. I think he’s relying on speculation and an over-abundance of caution.
Harriet Hall on June 9, 2020
Link

A neighbor told me, “one of my doctors was very adamant about not consuming dairy because the growth factor creates the right environment for cancer cells to multiply.” My reaction was “Whaaaat!??” From what I’ve been reading, dairy products decrease the risk of bowel cancer, may increase the risk of prostate cancer, and there is no strong evidence linking dairy to any other cancers. My neighbor is a woman, so prostate cancer is not an issue. I checked out various health, cancer, and vegan websites, and they pretty much confirmed what I thought. Did I miss something? Is there some new evidence that I haven’t heard about yet? Or did her doctor over-react? I decided to look again.
IGF-1 is insulin-like growth factor-1. Cows have been bred to produce more IGF-1, plus they are treated with hormones. Cow’s milk contains IGF-1, and blood levels may be higher in milk drinkers. PubMed lists numerous studies suggesting an association of higher blood levels of IGF-1 with various cancers, but the evidence doesn’t show that milk drinkers are actually more likely to develop those cancers. IGF-1 is produced in the human liver in considerably larger amounts than anyone is likely to get from dairy foods.
An article on Healthline says, “IGF-1 has been linked with an increased risk of prostate cancer. However, this may be a consequence of cancer rather than a cause… Keep in mind that most of the available evidence is based on observational studies, which provide suggestive evidence but not definite proof.” References are provided from what they consider to be trustworthy sources. Remember the difference between correlation and causation.
A new study published in February 2020 in the International Journal of Epidemiology found an association between high dairy intake and breast cancer. It found that women who drank the most cow’s milk per day had 50% increased risk for breast cancer compared with women who drank the least.
Medscape reported it in an article titled “New Study Suggests Milk Could Increase Breast Cancer Risk.” Note the careful language “suggests” and “could”. The new study was based on data from a long-running study of Seventh Day Adventists, whose other health practices might act as confounders and skew the data. An independent cancer scientist characterized the study as “provocative, but not enough to warrant a change in guidelines”. He pointed out that it was an observational study that can’t prove that cow’s milk causes breast cancer, and noted that the results were significant only for postmenopausal women and not for premenopausal women, and we know the incidence of breast cancer rises with age. Also, the associations were significant only for hormone receptor-positive cancers. He said the data must not be overinflated, and called for the study to be replicated. The Medscape article added that “Dairy has even been tied to decreased risk for breast cancer, according to the World Cancer Research Fund.”
The Medscape article referred to a review in The New England Journal of Medicine by Willett and Ludwig that I covered in my recent SBM post about the evidence on milk and health. That review essentially said the guidelines on milk consumption are not based on good evidence. Medscape interviewed Willett and quotes extensively from him and other scientists who agree with him. He does not say everyone should abstain from dairy because IGF causes cancer.
Conclusion: I’m not convinced
The observational studies looking for a correlation between cancer and consumption of dairy foods are far from definitive, and their conclusions are often conflicting. While there is legitimate concern about IGF-1, the evidence has not shown that fear of cancer is a good reason to avoid consuming dairy products. I think my neighbor’s doctor went way beyond the actual evidence and relied on speculation and an over-abundance of caution. The precautionary principle may sound like the safest approach, but often it isn’t: it can lead to unanticipated harms.
Disclaimer: I don’t drink milk because I don’t enjoy the taste, but I love cheese and yogurt and butter, and I don’t intend to reduce my consumption any time soon. If my doctor told me what my neighbor’s doctor told her, I would change doctors.

There is no evidence that COVID-19 vaccines are causing cancers associated with “accelerated aging”
A recent presentation at AACR found a link between markers of accelerated aging and an increased risk of cancer. Then antivaxxers got a hold of it to blame COVID-19 vaccines not just for cancer, but for “accelerated aging” causing it.
David GorskionApril 15, 2024
Link

Those who follow me on X, the hellsite formerly known as Twitter, know that I just spent the last few days in Orlando (unfortunately) to attend the annual meeting of the American Society of Breast Surgeons. You might also know that I stirred the pot a bit on social media by posting my objection to the keynote speaker citing what I like to call a zombie statistic, namely that long-debunked claim that medical errors are the third leading cause of death in the US, accounting for over 250,000 deaths annually. Unfortunately, the stirring didn’t take, but if you want to know why this zombie statistic is bogus but nonetheless won’t die and, worse, seemingly has become part of accepted wisdom, a statistic thrown out at the beginning of so many medical talks as though it were accurate, read this. Moreover, the real number is likely 5- to 20-fold lower. I even thought about writing an update looking at the latest evidence regarding the death toll from medical errors, but decided that that was a project that would require more time than I had last weekend, between travel, meetings, and the like. File it away for later, in favor of something that I can handle fairly quickly but still caught my interest.
I’ve now written more times than I can remember why the antivax claim that COVID-19 vaccines are causing a wave of “turbo cancers” is utter nonsense. Briefly, the idea is that somehow the evil humors in the vaccine are more powerful than the most powerful known carcinogen (ionizing radiation) and have caused a wave of highly aggressive cancers in only three years since the vaccines were even widely administered. Never mind that most cancers take more like 10 years to show up after exposure to a carcinogen and that the ones being reported (mostly solid tumors like breast, colon, etc.) do not match the few cancers types that can appear less than three years after exposure to a carcinogen, like leukemias. I thought I had seen every twist on the “turbo cancer” myth; that is, until this weekend.
You see, another meeting was going on last week, overlapping the breast surgery meeting. It’s a meeting that I used to go to every year but, since the pandemic, have not attended. I’m referring to the American Association for Cancer Research (AACR). This year, I had to choose, and unfortunately it made more sense to choose a clinical meeting. In any event, there was a talk presented at the meeting that found that the incidence of “accelerated aging”—I’ll explain how that was defined in a moment, when I get into the weeds of the study that I could find, even though it hasn’t been published in a peer-reviewed journal yet—has increased in younger cohorts of adults. If confirmed, it would be a very interesting finding, something worthy or further research to determine why this might be happening. It might also potentially be an explanation for why the incidence of cancer has been increasing in younger people over the last 25 years.
Quote antivaxxers: It’s got to be the vaccines that done it!
Of course, that’s not how antivaxxers saw it, and the news reports in even conventional media didn’t help. Before I get to the abstract itself, let’s look at the AACR press release, entitled, blandly enough, Accelerated Aging May Increase the Risk of Early-onset Cancers in Younger Generations. Basically, the finding was that accelerated aging was more common in recent birth cohorts and was associated with increased incidence of early-onset solid tumors. SciTech Daily’s headline tacked onto the press release was a little more provocative but not particularly alarming, Unraveling the Rapid Aging Mystery Behind Early-Onset Cancers. ASCO Post reported, Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations, while CNN added, Accelerated aging linked to cancer risk in younger adults, research shows. You can probably see where I’m going with this and how antivaxxers decided to spin the study, which, again, hasn’t even been formally published yet.
First, there was the NY Post headline, Cancer rates rising in young people due to ‘accelerated aging,’ according to ‘highly troubling’ new study. Note the “highly troubling” part added. Also note that this article was actually by Melissa Rudy of Fox News. It also, for no apparent reason other than to fear monger, quotes Dr. Brett Osborn, portrayed as an “expert in longevity.” Never having heard of Dr. Osborn before, naturally I just had to Google him. Unsurprisingly, this is what I found near the top of the search results:
Yeah, Dr. Osborn is a body builder and ripped. My question: Natty or not? (I vote for not.)
Why don’t I have a professional photographer shoot me looking all studly like this?
And:
To Brett Osborn, DO, FAANS, CSCS, most ailments of modern-day society can be prevented. The West Palm Beach neurosurgeon, author, and founder of Senolytix views good health as a privilege to be earned.
“Patients should not expect their doctors to keep them in good health,” he says. “Most patients could solve their problems by taking simple steps, like losing weight, exercising more, and eating better.”
Dr. Osborn founded Senolytix to help put patients on a path to extend the number of years of optimal body and mental health. From comprehensive assessments of a patient’s condition, he develops a plan built around better nutrition, proper exercise, and medications that may include hormone replacement therapy, supplements, and improved sleep.
On his website, he makes it even more explicit:
The following are the most important:- Health is a privilege, NOT a right.- There are no “diets,” or secret exercise regimens which will grant one health or a particular body type. Proper manipulation of one’s biochemistry through the above modalities (i.e., turning on the right genes through strength training) will grant one health and longevity.- Health is a lifelong endeavor. There are no races. It is a lifestyle. We must constantly strive to better ourselves (through daily physical and mental challenges) in order to delay the aging process.- Keep bodily inflammation at a minimum (through strength training, nutrition and supplementation, proper sleep and stress reduction techniques). This maintains nearly all disease processes in check.
Good health is a “privilege to be earned”? Seriously? This is the sort of attitude that is everything that is wrong with “alternative health.” What about people who are not sufficiently privileged to be able to adhere to a program like the ones that Dr. Osborn promotes? What about people with genetic predisposition to disease that they inherited through no fault of their own? No one is saying that lifestyle changes, such as a healthier diet and getting more exercise and better sleep, can’t be very beneficial to health, but these people seem to engage in a combination of magical thinking that people have complete control over their health and whether they get sick or not. (“This maintains nearly all disease processes in check”? At least he said “almost.”) Unsurprisingly, like most medical “entrepreneurs,” Dr. Osborn has a YouTube channel, a Twitter feed, and other social media where he hawks his company Senolytix, which offers all sorts of tests and “longevity” medicine interventions. Oh, and his father, whom he cites as an inspiration, was a chiropractor.
My point is simply that he is clearly not a real expert on the science that was reported at AACR. Being boarded by the American Academy of Anti-Aging Medicine is not a qualification of which I’d be proud. If you don’t believe me, just search for this organization on this blog.
I don’t want to dwell too much on Dr. Osborn’s take, though. Rather, I mention it mainly to show how a mainstream news organization quoting an anti-aging entrepreneurial neurosurgeon with an agenda, someone who dogmatically states:
NO ONE is too old for strength training. NO ONE is exempt from exercise. Numerous studies have demonstrated that one’s ability to combat disease is resident within our muscles. Muscles are the protein depots from which our immune system indirectly generates antibodies. Stronger individuals live longer, period. This HAS been proven.
Actually, there is indeed such research, but that same research shows that there are other factors associated with longevity. As we say, it’s complicated.
In any case, it’s a spin on the findings like that of Dr. Osborn that really is just a short hop, skip, and a jump to someone like Mike Adams in a story like Government comes up with another new excuse for the genocide they’ve unleashed upon the planet: ‘accelerated aging’ among the young is causing all of these ‘turbo cancers’, complete with an image like:
Subtle, Mike isn’t.
Let’s see how he spins these findings. After that, I’ll go through the study to tell you what the investigators really found, so that you can see how quacks cherry pick unpublished studies from meeting proceedings and spin them into, well, something like this.
Hilariously, this isn’t even original Mike Adams. He’s republishing an article by someone named Stefan Stanford republished at AllNewsPipeline.com, with an added tagline, “Eugenicists Covering Up Genocide To Avoid Being Executed For Crimes Upon Humanity.” Nice.
Behold:
The latest mind-boggling story over at the NY Post on Tuesday proving just how full of ‘s’ our ‘globalist overlords’ and the mainstream media are in 2024 is titled “Cancer rates rising in young people due to ‘accelerated aging,’ according to ‘highly troubling’ new study.”
Reporting that new research presented this week at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California has found that ‘the young’ are now aging much more rapidly than they have in the past and thus, they are being struck much more frequently with problems that had normally been mainly associated with ‘the elderly,’ take note that once again, these globalist scum are trying to come up with an excuse for the genocide they’re carrying out that should, in any kind of ‘just’ society, leave them all executed and buried 6′ under for their crimes upon humanity.
Reporting that ‘accelerated aging,’ when someone’s biological age is greater than their chronological age, is increasing the risk of deadly cancer tumors in ‘the young,’ we warned just days ago in this story on ANP that so-called ‘turbo cancers’ were exploding among younger generations, with Dr. William Makis MD warning us he had never seen anything like this before.
And while the globalists continue to come up with one excuse after another for this ‘explosion‘, such as ‘global warming‘ or ‘bacteria in the gut linked to processed foods,’ Dr. Makis ties the huge spike in these cases of rapidly spreading cancers in the young directly to the ‘COVID vax.‘
One more time, Dr. Makis is an antivax quack, and “turbo cancer” is not a thing. Moreover, let’s just say that the above take is a…highly exaggerated…version of what the study found, as you will see. Elsewhere, there are articles on quack antivax websites with headlines like, WEF-Linked Study Blames ‘Accelerated Aging’ for Spike in Turbo Cancers Among Young People. I note that the study said nothing about “turbo cancers.”
Meanwhile, on social media:
ACCELERATED AGING!!!What could it be??? Harmful mRNA???💀💉 https://t.co/C0cQd9Vsyi
— Cyberpunk Sense 👑 (@napoleon21st) April 9, 2024
Just wait until they start giving this to all the c19 v@xxed people with the screwed up metabolism and accelerated aging. Oh, what fun.
— Joanie J. 🇺🇸 (@joaniej0243) April 13, 2024
Government comes up with another new excuse for the genocide they’ve unleashed: ‘accelerated aging’ among the young is causing all of these ‘turbo cancers’ – NOT THE KILLER CLOT SHOT.https://t.co/RR5lwOz7s0
— Bob March (@BobMarch273045) April 13, 2024
💥WEF trying to claim "accelerated aging" responsible for turbo cancers in young people. Some are dying within one week of diagnosis. Doctors point to clear evidence that cancers are appearing only in young people having received mRNA vaccines. https://t.co/PQ6G7u2IXZ
— Linda Britton-Fairchild (@FairchildL3853) April 14, 2024
In fairness, there is another contingent blaming the “accelerated aging” on COVID-19, which is more plausible, but still overblown, given that such trends do not happen over a time period as short as the four years since COVID-19 hit.
But what did the study actually show?
“Accelerated aging”?
I almost hesitated to write this post because (1) I didn’t attend AACR and therefore didn’t attend the talk. Thus, all I have are the abstract, press releases, and news reports of interviews with the first author, Ruiyi Tian, MPH, a graduate student at Washington University in St. Louis, and her PhD thesis advisor in whose lab she did the work, Dr. Yin Cao, an associate professor of surgery and senior author of the new research; and (2) I don’t have the figures or detailed methods. I thought about it, though, and then figured that I do have enough to discuss that it should quickly become obvious that antivaxxers are just making stuff up about this research. Also, I’m sure it’s likely disconcerting to Ms. Tian and Dr. Cao; so if either of you see this post and want to chime in or ask for advice on what to do with antivaxxers swarming, let’s just say my email is [email protected].
So here’s the abstract:
The first thing to note is that this study took advantage of the UK Biobank. As I was unfamiliar with this particular database, I took a look at the UK Biobank website, to see that it is an impressive piece of work:
UK Biobank participants have generously provided a very wide range of information about their health and well-being since recruitment began in 2006. This has been added to in the following ways:
    • Imaging: Brain, heart and full body MR imaging, plus full body DEXA scan of the bones and joints and an ultrasound of the carotid arteries. The goal is to image 100,000 participants, and to invite participants back for a repeat scan some years later. 
    • Genetics: Whole genome sequencing for all 500,000 participants, whole exome sequencing for 470,000 participants, genotyping (800,000 genome-wide variants and imputation to 90 million variants).
    • Health linkages: Linkage to a wide range of electronic health-related records, including death, cancer, hospital admissions and primary care records. 
    • Biomarkers: Data on more than 30 key biochemistry markers from all participants, taken from samples collected at recruitment and the first repeat assessment. 
    • Activity monitor: Physical activity data over a 7-day period collected via a wrist-worn activity monitor for 100,000 participants plus a seasonal follow-up on a subset.
    • Online questionnaires: Data on a range of exposures and health outcomes that are difficult to assess via routine health records, including diet, food preferences, work history, pain, cognitive function, digestive health and mental health. 
    • Repeat baseline assessments: A full baseline assessment is undertaken during the imaging assessment of 100,000 participants.
    • Samples: Blood & urine was collected from all participants, and saliva for 100,000.
That’s a heck of a lot of data to mine. I can see why this database was attractive to Tian and Cao. One shortcoming of the study, though, is immediately apparent (and mentioned in a number of places). This is a UK-only study. Whether its results are generalizable to other populations is an open question. I also did some searches and found that there was a study by a different group using the UK Biobank published a year ago that showed correlation between a different set of biomarkers related to aging and the risk of developing cancer. What this study does that’s different is to try to quantify the risk of early onset cancers in people with elevated biological age as assessed by the nine biomarkers included in the PhenoAge calculator.
Next up, how was “accelerated aging” defined? Here’s how:
Biological age was assessed using the PhenoAge algorithm based on nine blood chemistry markers collected at baseline, including albumin, alkaline phosphatase, creatinine, C-reactive protein, glucose, mean corpuscular volume, red cell distribution width, white blood cell count, and lymphocyte proportion. AA was quantified by standardizing the residuals of biological age after regression against chronological age. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). In secondary analyses, we compared the associations with late-onset cancers (diagnosed after age 55).
To put it more simply, nine biomarkers were examined, and an algorithm used to calculate each person’s “biological age” as indicated by these markers and compare it with their chronological age. CNN Health actually gives a good explanation of the relevance of each of these markers:
They homed in on nine blood-based markers that have been shown to correlate with biological age:
    • albumin: a protein made by the liver that declines with age
    • creatinine: a waste product in blood produced by protein digestion and the breakdown of muscle tissue; a measure of kidney function. Lower levels correlate with better longevity.
    • glucose: With age, blood sugar stays higher for longer after meals.
    • c-reactive protein: made by the liver in response to inflammation; relatively higher levels correspond to faster aging
    • lymphocyte percent: The concentration of these white blood cells related to immune function tends to decrease with age.
    • mean cell volume: a measure of the average size of red blood cells, which increases with age
    • red cell distribution width: the difference between the size of a person’s smallest and largest red blood cells, which tends to increase with age
    • alkaline phosphatase: an enzyme produced mainly by the liver and bones that tends to increase with age
    • white blood cell counts: Numbers of white cells in the high end of the normal range in the blood may correspond with greater aging.
I do, however, feel obligated to point out one thing. PhenoAge is just one algorithm. It purports to measure “biologic age,” but does it? Does it really? That, too, is a weakness of the study. There is, of course, evidence that PhenoAge is better predictive of age-related health outcomes, such as all-cause mortality, cancers, healthspan, physical functioning, and Alzheimer’s disease, than other measures. It would have been nice to look at other potential measures of biologic age besides a single algorithm. One also can’t help but note that it would be a lot less sexy to say that a panel of biomarkers predicts your risk of early onset cancer than it was to say that “accelerated aging” does.
Moving on, CNN actually summarized the findings of the study pretty well:
They then checked cancer registries to see how many in the group had been diagnosed with early cancers, which the researchers defined as cancers appearing before age 55. There were nearly such 3,200 cancers diagnosed.
The researchers found that people born in 1965 or later were 17% more likely to show accelerated aging than those born from 1950 through 1954.
Basically, people who are currently younger than 59 have a 17% higher chance of showing signs in this panel of accelerated aging than those aged 70-74. This has consequences. Overall, for all cancers, people with accelerated aging have an of developing cancer with a hazard ratio (HR) of 1.08, but this was driven primarily by a few cancers, such as lung cancer (HR 1.42), gastrointestinal (HR 1.22), and uterine cancer (HR 1.36). Moreover, those with the highest degree of accelerated aging had the highest risk of early onset cancer, as high as two-fold (lung cancer).
So what does this all mean? One thing that it doesn’t mean is that COVID-19 vaccines are causing an epidemic of “accelerated aging” that is in turn causing an epidemic of early onset “turbo cancers.” These sorts of changes in biomarkers don’t happen overnight in a population, and a little over three years since the start of the mass vaccination campaign against COVID-19 is basically overnight. Also, again, it must be emphasized that cancers in response to carcinogens don’t pop up overnight, as the whole “turbo cancer” narrative claims. They take several years, usually a decade or more. Only some of the hematological malignancies take a timeframe under three years, and even then, even if COVID-19 vaccines were as cancer-causing as someone like Dr. Makis claims, we would only just now be starting to see an uptick in a small number of specific hematologic malignancies.
What is interesting about this study, if its results are replicated and bear out, is that they suggest a potential set of blood tests that could identify people at a higher risk for lung, GI, and uterine cancers, as well as a less dramatically elevated risk of other cancers. In other words, testing for accelerated aging could be a way of identifying people who are at higher risk, so that targeted interventions can be developed and implemented to decrease their risk.
What might explain these results and why these specific cancers seemed to be the most influenced by accelerated aging? One possible explanation:
The study wasn’t designed to answer questions about why these cancer types seemed to have the strongest ties to accelerated aging, but Ruiyi Tian, the graduate student who led the research, has some theories.
Tian said it’s possible that lungs are more vulnerable to aging than other types of tissues because the lung has a limited ability to regenerate. Stomach and intestinal cancers, she says, have been linked to inflammation, which increases with aging.
Not vaccines.
As an oncologist says:
Dr. Anne Blaes, who studies the impact of biological aging in cancer survivors at the University of Minnesota, said the study results are exciting because they could point to a better way to find people who are at higher risk of getting cancer when they’re young. Right now, young adults who don’t have a family history or other risk factor aren’t regularly screened for most kind of cancer.
“We’re seeing more and more cancers, especially GI cancers and breast cancers, in younger individuals. And if we had a way of identifying who’s at higher risk for those, then really, you can imagine we’d be recommending screening at a different time,” said Blaes, a professor and director of the Division of Hematology and Oncology at UM medical school. She was not involved in the new research.
Blaes said that if you can find people who are at higher risk because their cells are aging faster, you can target lifestyle interventions too: things like nutrition, exercise and sleep.
“There are medications that also look like they can slow down accelerated aging,” said Blaes, who is testing two of them in cancer survivors. Cancer survivors often show greater biological aging, perhaps because of the after effects of therapies like chemotherapy and radiation.
The medications belong to a class called senolytics, drugs thought to target and get rid of damaged and aging cells.
Of course, this reminds me of Dr. Osborn, whose company is called Senolytix, but let’s just say that, just perusing his website, I am less impressed with his dedication to rigorous science, although his website is quite slick and he does conveniently have three different levels of patient access, Express (meet the nurse practitioner, not Dr. Osborn), Essential, and Elite VIP (“our most extensive, full-service, VIP Concierge membership,” complete with full access to Dr. Osborn, “dependent on Dr. Osborn’s capacity & Neurosurgery call schedule,” of course). I note that the Elite VIP membership offers what many dubious anti-aging clinics that I’ve seen over the years have offered
That and his fear mongering in the NYP article didn’t impress me with his dedication to science:
“Our nation’s health – let alone Britain’s – is imperiled, and unless radical measures are taken, this trend will likely worsen before it gets better,” he warned.
“The younger population will be stricken with lethal diseases at an earlier age.”
Maybe, but what does he mean by “radical measures”? Never mind. I don’t care, for purposes of this discussion. He fits in mainly because of how Fox News used him as a dubious “expert” who promotes infrared saunas as longevity tools in order put an alarming spin on the story. From there, disinformation merchants picked up on it. Of course, antivaxxers and others promoting quackery have long been skilled at distorting and misappropriating legitimate research in order to promote a narrative supporting antivaccine views and quackery. This was just a particularly egregious one. It doesn’t matter that there’s zero evidence, either in this study or anywhere else, to support the false claim that COVID-19 vaccines are responsible for the phenomenon observed in the study so badly distorted by Mike Adams and his ilk.

Peddling Misinformation About Diet and Cancer
Selling dubious nutrition products often involve attacking, and suing, your critics.
Steven Novella on March 22, 2023
Link

Many people in the SBM community have expressed concern about a lawsuit currently happening in Australia. Dr. Adam Smith, a Melbourne GP, is being sued for defamation by naturopathy, Farrah Agustin-Bunch. It my opinion this looks like a classic case of using legal thuggery to silence and intimidate legitimate commentary. Smith says he was concerned by the extreme claims being made by Agustin-Bunch and wanted to “do a good deed” by providing some scientific response. Looking at Agustin-Bunch’s website it looks like she has a history of responding to such criticism by going on the attack, trying to turn the tables on her critics and, at least in this case, suing them.
Unfortunately for Smith, the laws in Australia are are defamation friendly. Sydney has been called the defamation capital of the world. He is reportedly already out of pocket $600,000 dollars in legal fees, and will likely spend two million before things are done. But to his credit he is not backing down.
To get the flavor of Agustin-Bunch’s strategy, I found a 2018 Quackwatch article about her, and her response. Quackwatch is a consumer protection website focuses on bogus medical claims and treatments, founded by Stephen Barrett and now run by CFI. Smith and Barrett take exception to the fact that Agustin-Bunch is promoting the typical range of dietary solutions to all problems, selling her “pixie dust” magnesium supplement and Boston-C supplements for many things, including cancer. On the package the Boston-C supplement claims it “supports immune system function” and “natural detoxification and cleansing”. We have heard these claims before. The Philippines FDA, where her clinic is, has shut down her clinic and cited her for selling products that are not approved.
To fight back against Barrett she quotes the following criticism:
“The Quackbusters, founded by the disgraced, unlicensed psychiatrist, Stephen Barrett, are a ubiquitous shadow network in the world of health and medicine with a unique talent.
Now that is defamation. Stephen Barrett is only “unlicensed” because he is retired. He was fully licensed when practicing. He is not “disgraced” by any objective measure, and she cites no cause or justification for this claim. (He had no complaints against his license, which was in good standing when he retired.) She tries to diminish Dr. Barrett by saying he has no “reported medical training since 1961”. That was the year he completed his residency. He was in practice until 1993, which means he had to keep up with his continuing medical education requirements, so her statement is false.
There is more, but actually that is likely the point – keep her critics defending themselves from her own baseless accusations rather than discussing the dubious nature of her medical advice. She is setting up a battle of authority (rather than evidence) and then relentless attacks her critics. I want to focus, rather, on one claim she makes as part of her push back against Quackwatch. She quotes Barrett as writing:
“I recommend steering clear of: Anyone who suggests that most diseases are caused by faulty nutrition. Although some diseases are diet-related, most are not.”
She takes this out of context then takes a number of other quotes from medical sources out of context to create a false impression. She writes:
“Increasing cancer rates also cannot be attributed to genetic factors, which are directly implicated in, at most, 5 – 10 percent of all cancers. I firmly believe that upwards of 90 – 95 percent of cancer incidence originates from lifestyle and environmental factors, with diet being far and away the primary causal component in cancer incidence today.”
For support she does not have definitive references in the medical literature, but misleading quotes. Here is just one representative example:
The National Academy of Sciences contradicts Stephen Barrett.
“In most Western countries, including the United States, diet-related chronic diseases represent the single largest cause of morbidity and mortality.”
She is conflating diet and nutrition. In the West, in developed nations, the contribution of diet to disease is largely not from malnutrition – not something that can be fixed with supplements – but from obesity and consuming too much of certain things, like meat, sugar, and fat. She uses conclusions that are really about obesity to justify prescribing supplements for cancer.
Let’s look at the actual evidence. A 2019 study looking at 80,000 new cancer cases in the US found that only 5.2% were attributable to diet. That is what Dr. Barrett is talking about, and directly contradicts Agustin-Bunch’s narrative. A 2020 review of diet and cancer published in BMJ made very direct conclusions from the data.
“High dose vitamin or mineral supplements have not reduced cancer risk in well nourished populations and might increase risk; for example, high dose β carotene might increase the risk of lung cancer. Vitamin and mineral supplements should not be used for cancer prevention, although they can be important for other aspects of health, such as folic acid supplements for women before conception.
What about eating fruits and vegetables, rather than supplements?
“In the 2018 World Cancer Research Fund report neither fruits nor vegetables were considered to be convincingly or probably associated with the risk of any cancer.”
They leave the door open for a small effect for some cancers, most notable colon cancer, which makes sense. About 10% of cancers likely result from genetics. This does not mean the rest is environmental and lifestyle factors, as Agustin-Bunch false concludes. The evidence, in fact, suggests that as much as 65% of cancers are just due to bad luck. The rest are due to known significant causes, like smoking and obesity. There is some controversy over how exactly to interpret the data on “bad luck” as a cause for cancer, but either way it is still a major cause.
But that doesn’t sell supplements. Supplement sellers need to create the narrative that most health issues are cause by poor nutrition and that their special products are the best way to treat that – but the evidence is just not on their side. When called out on their misleading claims, it is common for them to go on the attack. They claim there is a conspiracy, scientists don’t actually know what they are talking about, they attack specific critics, they claim that they have some special knowledge, and when they can, they use legal thuggery.
What they can’t use is legitimate science, because it does not support their marketing narrative.

Supplements and cancer prevention
David Gorski on April 30, 2012
Link
The bloggers here have been very critical of a law passed nearly 20 years ago, commonly referred to as the DSHEA of 1994. The abbreviation DSHEA stands for about as Orwellian a name for a law as I can imagine: the Dietary Supplement Health and Education Act. Of course, as we’ve pointed out time and time again, the DSHEA is not about health, and it’s certainly not about education. Indeed, perhaps my favorite description of this law comes from our very own Peter Lipson, who refers to it as a “travesty of a mockery of a sham.” Rather, it’s about allowing supplement manufacturers and promoters of so-called “complementary and alternative medicine” (CAM, with or without a preceding “s,” depending on your taste) who do not want pesky things like government laws and regulations to interfere with their selling of pseudoscience to market various compounds as “dietary supplements” with near-impunity. As Harriet Hall put it so accurately, the DSHEA is “a stealth weapon that allows the sale of unproven medicines just as long as you pretend they are not medicines.”
The DSHEA accomplishes this by making a seemingly reasonable distinction between food and medicine and twisting it in such a way that allows manufacturers to label all sorts of botanicals and various other compounds, many of which have substances in them with pharmacological activity, and sell them as “supplements” without prior approval by the FDA before marketing. As long as the manufacturer is careful enough not to make health claims that are too specific, namely that the supplement can diagnose or treat any specific disease, and sticks to “structure-function” statements (“it boosts the immune system!”), almost anything goes, particularly if a Quack Miranda Warning is included.
Not surprisingly, given what a big business supplements have become in this country largely due to the DSHEA, manufacturers and CAM advocates fight tooth and nail against any attempt to update the DSHEA to correct some of its more unfortunate consequences. Led by Utah Senator Orrin Hatch and Iowa Senator Tom Harkin, who together make up a bipartisan tag-team in defense of the supplement industry and do their best to block any effort to increase its regulation by the FDA. We saw that most recently when Arizona Senator John McCain, of all people, introduced a bill in 2010 to try to tighten up the DSHEA and was thoroughly slapped down by Orrin Hatch. More recently, not satisfied with how good things are for the supplement industry, another Utah Representative Jason Chaffetz reached across the aisle to Jared Polis, teaming up to introduce the Free Speech About Science Act, which basically seeks to allow the supplement industry to make more liberal claims about its products. All it will need is a “peer-reviewed” paper to support it (Mark and David Geier would do!), and you can claim almost anything. Anything to grow the supplement industry, which is currently around $30 billion a year.
That’s why it’s critical, from time to time, to look at actual evidence, and just last week Maria Elena Martinez, PhD, of the University of California San Diego, and co-authors did in a commentary published online in the Journal of the National Cancer Institute entitled Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms.\
As several of us have pointed out before, there are science-based roles for supplementation. For instance, in the case of nutritional deficiencies, and Martinez et al point out the very same thing:
Clearly, dietary supplements are useful for the treatment of nutrient deficiencies; however, with the exception of select subgroups (2,3), such deficiencies are relatively uncommon in the United States and most industrialized countries today.
Of course, if you listen to CAM promoters and supplement manufacturers, you’d think that supplements are absolutely essential to preventing cancer. While it is true that there is increasing evidence that diet has a significant effect on our risk for various cancers, this evidence is nothing new. We’ve simply concentrated on it more in recent years, and a new generation of “natural health” advocates, such as Dean Ornish, have attributed near magical powers to diet as a tool for preventing cancer. As a byproduct of increasing evidence that cancer risk is influenced by lifestyle choices, it is understandably tempting to think that we could somehow “bottle” what’s in various foods as supplements that could reverse or ameliorate diet-associated cancer risks. Ironically, although CAM advocates would never concede it, this sort of thinking is the sort of thinking they themselves decry in conventional medicine when they make the exaggerated charge that all doctors do (or want to do) is to prescribe a pill to deal with health issues. Think about it: Even is supplement did what is claimed for them, is there any real difference between just prescribing a supplement to decrease cancer risk rather than recommending much harder lifestyle interventions and prescribing a statin to prevent heart disease rather than recommending much harder lifestyle interventions?
Martinez et al then go on to summarize the state of evidence as it currently exists for the use of supplements to prevent cancer. They conclude that there is precious little evidence for efficacy and existing evidence for harm. Their assessment of the evidence for antioxidants is particularly withering:
Several early observational studies (10–13) found that diets high in fruit and vegetables were associated with diminished risk of several cancers, including respiratory and gastrointestinal cancers. The importance of β-carotene and other carotenoids was suggested by both retrospective and prospective studies showing that low levels of β-carotene in the serum were associated with higher subsequent risk for lung cancer (14). At one point, research focused on retinoid supplementation, in light of the finding that β-carotene is converted to retinol (13). It was hypothesized that the lower risk associated with consumption of these foods, and with β-carotene, α-tocopherol, and vitamin C intake, might be attributable to the activity of antioxidants. In vitro and in vivo studies suggested that these compounds encourage growth of normal tissue and block growth of abnormal tissue (2). However, human experimental studies have uncovered the following: β-carotene does not prevent non-melanoma skin cancer recurrence (15); β-carotene and α-tocopherol with vitamin C do not protect against adenoma recurrence (16); β-carotene and vitamin A do not protect against lung cancer incidence (17); α-tocopherol and β-carotene do not prevent lung cancer (18); β-carotene does not prevent lung cancer (19); vitamins C and E do not protect against total cancer incidence (20); and α-tocopherol, vitamin C, and β-carotene do not protect against total cancer or cancer mortality (21). Based on a review of trial data, a Cochrane report (22) concluded that there was no convincing evidence that β-carotene, vitamin A, vitamin C, or vitamin E supplements, given singly or in combination, prevent gastrointestinal cancers.
That’s not all, though. An article such as this can’t go without mentioning the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which was resoundingly negative. Selenium and vitamin E showed no evidence of decreasing the risk of prostate cancer, leading to the trial being halted after approximately 5.5 years of followup. Consistent with the results of SELECT, a Southwest Oncology Group (SWOG) trial showed that selenium supplementation in men with a premalignant precursor of prostate cancer showed no benefit, and another trial showed that selenized yeast does not prevent recurrence of stage I non-small cell lung cancer. As Martinez et al put it, “organic selenium appears to provide no cancer prevention benefit.”
Not every trial was negative. One exception noted by Martinez et al is a 20 year old prevention trial in China consisting of 30,000 subjects. This study showed a 13% reduction in cancer mortality, including a 21% reduction in gastric cancer mortality, compared to placebo controls in a randomized trial testing a combination of β-carotene, vitamin E, and selenium. This is, at best, a modest effect. However, similar studies looking at such cocktails were even less convincing, including a companion study of 3,000 subjects examining a supplement that contained 14 vitamins and 12 minerals, including β-carotene, vitamin E, and selenium. No statistically significant effect on cancer incidence was observed.
The counterweight to the weight of existing high quality evidence looking at antioxidants and cancer, which suggests no benefit in the vast majority of cancers studied this far and equivocal evidence even in the handful of studies that suggest a benefit is a cohort of studies that suggests the real possibility of harm due to antioxidant use:
Several antioxidant trials (17,18,30,31) have actually reported increased risks with supplementation. The most prominent example, β-carotene and lung cancer, was tested in two RCTs (17,18) in high-risk populations of heavy smokers and asbestos-exposed individuals. Individuals randomly assigned to β-carotene in the Beta-Carotene and Retinol Efficacy Trial (CARET) trial had a 39% increase in lung cancer incidence compared with those in the placebo arm (17); the ATBC trial found a 16% increase in risk of lung cancer associated with β-carotene (18). With prolonged follow-up, NPC investigators found that selenium supplementation statistically significantly increased the risk of squamous cell skin cancer by 25% and total non-melanoma skin cancer by 17% (30). The increased risk was particularly marked among individuals in the highest tertile of circulating selenium levels just before the start of the trial. The most recent illustration of the possibility that pharmacological doses of antioxidants may not have the intended effect comes from the extended follow-up in the SELECT trial, which reported that α-tocopherol increased risk of prostate cancer by a statistically significant 17%; these results led the authors to conclude that consumers should be skeptical of health claims related to unregulated over-the-counter products (31).
The authors then looked at folate supplementation. The state of the evidence for whether folate can prevent cancer is similarly disappointing. In fact, it can be described as largely negative. Worse, like the case with antioxidants, contrary to the hypothesized benefit of folic acid supplementation, there is evidence that it can contribute to some cancers. For instance, there is one trial that showed that long-term supplementation with folic acid increases the risk of advanced colorectal adenomas (relative risk = 1.67) and the risk of developing three or more such adenomas (RR = 2.32). An elevated risk of prostate cancer was also observed. These results are consistent with preclinical studies in animals suggesting that folic acid can increase the risk of cancer, as well as observational studies that have linked higher dietary intake with an increased risk of prostate and breast cancer. Ironically, in the U.S. and other countries, the government has mandated folic-acid fortification of the food supply, which makes the question of whether folic acid supplementation is doing more harm than good particularly pertinent. True, there’s strong evidence that folic acid supplementation of the diet in pregnant women can decrease the risk of birth defects, particularly neural tube defects, but that is short term supplementation compared to long term supplementation. The question, then, is, as always: Is the balance of benefit versus risk due to folate supplementation favorable? There’s enough evidence out there to be concerned that the answer to that question might very well be no, except for pregnant women.
Finally, Martinez et al take on the case of vitamin D and calcium. Anyone who’s been reading CAM-friendly websites these days probably knows that vitamin D is currently viewed by many in the alternative medicine world as some sort of panacea that prevents all cancer. Heck, to listen to some CAM advocates tell it, vitamin D is supposedly so awesome that it prevents influenza more effectively than the influenza vaccine. Of course, as has been discussed on this very blog, the picture is, as is usually the case, more complicated than that, and Martinez et al try to communicate that complexity, referencing the Institute of Medicine’s recent recommendations for vitamin D and calcium intake published in 2011, in which the IOM concluded that there is insufficient evidence to conclude that there is a causal association between low vitamin D intake or low blood 25 hydroxy (OH) vitamin D [25(OH)D] levels and cancer. Martinez et al sum up this data thusly:
There have been many epidemiological investigations of blood 25 hydroxy (OH) vitamin D [25(OH)D] concentrations and cancer-related endpoints (45–49), and meta-analyses of these have shown statistically significant inverse associations between serum 25(OH)D and colorectal adenoma (46,49) and colorectal cancer (45), whereas the results for prostate cancer have largely been null (45,48). For breast cancer, the relationship with serum 25(OH)D levels varies by study design; case-control studies generally demonstrate inverse associations, and prospective studies have been null (45,47,50); because blood levels are collected after the onset of cancer in case-control studies, the potential for bias in these studies must be considered (47,50). Clearly, clinical trials are needed to elucidate any preventive effect of vitamin D (51,52). To date, three short-term RCTs of vitamin D and cancer endpoints (52–55) have been completed; one showed no direct effect of vitamin D supplementation on cancer mortality (53), the second showed no reduction in breast or colorectal cancer incidence by a vitamin D/calcium combination (54,55), and the third showed a reduction in total cancer incidence by a calcium/vitamin D combination vs placebo (56). As concluded in a recent meta-analysis, because of the potential confounding inherent in observational studies and the limited data from clinical trials, evidence is currently insufficient to draw conclusions about the efficacy of vitamin D supplementation for cancer prevention (57).
As far as cancer is concerned, there just isn’t a whole lot of data from well-designed randomized clinical trials testing the effect of vitamin D supplementation on cancer risk to hang one’s hat on. The same is true of calcium supplementation, only more so. Observational studies have, as Martinez et al almost drolly characterize it, “yielded diverse results.” In any case some of the diverse results with respect to vitamin D suggest a correlation between high vitamin D concentrations and pancreatic cancer, while a recent meta-analysis suggests a reduction in risk. In the case of prostate cancer, however, a recently published study suggests a statistically significantly increased risk of prostate cancer (RR = 1.56 for men in the highest quintile) among men who have the highest levels of 25(OH)D, a finding that was more striking for aggressive disease, leading the authors of the study to advise caution in recommending vitamin D for cancer prevention. Puzzlingly, these results are in contrast to a lot of basic science research that supports a beneficial role for vitamin D compounds in prostate cell proliferation and differentiation, prostate cancer cell growth and invasion, and tumorigenesis.
To say that the state of evidence in support of the use of various dietary supplements as cancer preventatives is unsettled is a gross understatement. Martinez et al discussed supplements that have been studied the most and, let’s be frank, that involve the purest supplements, most of which contain only a single ingredient, and they found little evidence of efficacy in preventing cancer but some evidence of potential harm. That’s not even counting the near innumerable supplements now being sold that are not pure substances but some form of extract from plant, fungi, yeast, or even animal origin. As I’ve said before time and time again, supplements that “work” (i.e., have some sort of biological effect) are drugs. They’re impure, adulterated drugs with highly variable potency because of their highly variable content of active ingredient. Obviously, supplements that don’t have such a biological effect are worthless (except for lining the pockets of supplement manufacturers). That’s why supplement manufacturers very much want consumers to believe that their supplements have a whole range of beneficial biological effects, and the DSHEA allows them to imply that, as long as they don’t do it too explicitly.
Martinez et al put the blame squarely where it belongs: On the DSHEA and another law. They also explain how supplement manufacturers get around even the weak prohibitions in the DSHEA:
Even without such direct statements, anticancer effects can be implied. For example, even though the manufacturers of Pill X cannot openly advertise that it prevents prostate cancer, they can create an advertisement that states that prostate cancer is a major health problem, that Pill X has a role to “support prostate health,” and that a particular study found that the compounds in Pill X reduced the growth of prostate cells in culture. Their website can then be accompanied by advertisements for Pill X and can contain links to testimonials that are free to expound the benefits of Pill X as experienced by real people. The absence of credible scientific evidence that taking Pill X confers anti-prostate cancer properties in men can be easily obscured by this constellation of claims that collectively suggest anticancer effects. As a result of limited regulatory authority, manufacturers who cannot overtly claim anticancer benefits of supplements without scientific proof are nonetheless free to imply those benefits in ways that make it difficult for the consumer to discern innuendo from scientific fact (82).
Indeed. Another recent review concluded that, with the possible exceptions of vitamin D and omega-3 fatty acids, there are no data to support the widespread use of dietary supplements in Westernized populations and that such supplements can even be harmful. Another recent study finds no effect from supplements on all-cause mortality and even found a negative effect from folic acid supplementation, consistent with yet another study. The bottom line is that, at present, it is quite probable that most supplements probably do more harm than good.
So why do so many people take supplements? Martinez et al also quite correctly point out:
Undoubtedly, use is driven by a common belief that supplements can improve health and protect against disease, and that at worst, they are harmless. However, the assumption that any dietary supplement is safe under all circumstances and in all quantities is no longer empirically reasonable. Believers in supplements are sometimes quick to discredit caution over supplement use, as they suggest that the tendency of mainstream science to ignore nonconventional evidence is tainted or that mainstream science is somehow corrupted by its link to a medical–industrial complex that seeks to protect profits rather than prevent disease.
Right on cue, our favorite quack apologist and supplement hawker, Joe Mercola, chimed in with an article entitled Over 60 Billion Doses a Year and Not ONE Death, But Still Not Safe? In it, Mercola in his usual frothing-at-the-mouth style (although not nearly as frothy as another favorite quack apologist Mike Adams) rants that a recent survey from the American Association of Poison Control Centers’ National Poison Data System reveals, there were zero deaths linked to nutritional supplements in 2010, amusingly citing the Orthomolecular Medicine News Service as its source. Orthomolecular medicine, you might recall, is a form of supplement quackery originally embraced by Linus Pauling when he concluded that high dose vitamin C was the cure for the common cold and cancer.
Never let it be said that Mercola isn’t good at intentionally confusing short term toxicity with long term effects in his eagerness to attack a straw man. He seems to think that when scientists point out that supplements can be hazardous that they are claiming that supplements will kill you fast when in reality most potential problems with supplements are long term health effects, although, I would point out, certain supplements can certainly cause serious problems more acutely. In any case, when Mercola asks, “Where are the bodies?” I’d answer that if a supplement increases the risk of a common cancer by 25%, that’s a lot of potential bodies. They just won’t be directly linked to supplements. Particularly amusing is Mercola’s outrage that the FDA is trying to impose the same limits on supplements as on aspartame, monosodium glutamate, and sodium nitrate.
What is infuriating Mercola and the supplement industry are draft guidelines from the FDA designed to assess new ingredients in supplements using safety standards similar to what are required for the approval of new food additives, as described in this recent New England Journal of Medicine commentary:
The proposed guidance clarifies the level of evidence the FDA would use to assess safety. Specifically, the safety of supplements would be evaluated according to three key factors: documented history of use (e.g., in foods or in supplements or herbal medicines sold outside the United States), formulation and proposed daily dose (e.g., more or less than was formerly consumed), and the recommended duration of use (e.g., intermittent or long-term). The FDA’s guidance provides a thoughtful framework for evaluating the safety of new ingredients (see table Required Safety Testing for New Dietary Ingredients Labeled for Intermittent Use.), and if implemented it would lead to substantial improvement in safety. For example, the FDA would require in vitro, animal, and tolerability testing for products that would be marketed for consumption at doses greater than those historically ingested.
In actuality, however, even these draft guidelines do not go far enough, and the supplement industry is vigorously opposing them, even though they strike me as an eminently reasonable strategy for trying to address at least one of the shortcomings of the DSHEA. After all, don’t supplement manufacturers themselves claim that their supplements are food, not medicine? Then why not require that new supplement ingredients without documented historical usage be subject to the same requirements for safety as any other food additive?
It’s important to remember that, in the end, supplements that have biological activity are functioning as drugs. As Martinez et al and a number of other studies strongly suggest, there is very little, if any, evidence that supplements improve health, at least in an already well-fed population, with a precious few possible exceptions that are far more narrow than anything CAM advocates or supplement manufacturers claim. Worse, at least as it stands right now, for most supplements, it is disturbingly likely that the harms probably outweigh the benefits for most people. This is one area where we probably do need more studies, but they need to be “strategically designed” studies, as Martinez et al put it, set up in light of existing evidence from previous studies that have been largely negative.

Vitamins and Cancer Risk
Vitamins have been promoted as a general panacea, as well as a means of preventing cancer. In reality, high doses of vitamins may even cause cancer.
Steven Novella on May 6, 2015
Link
One of the greatest triumphs of marketing over evidence was the incredible rise of vitamin supplement use in the 20th century. Supplement makers successfully created a “health halo” around vitamins, and taking your vitamins became a virtue, something mothers told their children to do. The evidence, however, does not tell such a simple story.
In recent years it has become increasingly apparent that there are unintended consequences to taking vitamin supplements, and in fact there may be a net negative health effect. This is especially true for those who are healthy and don’t need vitamins, and for those who exceed the recommend dosages.
A recent review of the last 20 years of literature on the subject, presented at the American Association for Cancer Research 2015 meeting, found an overall increased risk of cancer among vitamin users. Dr. Tim Byers presented the study, which echoes the result of a 2012 review that he and others published. He specifically refers to two famous studies showing an increased risk of cancer from vitamins.
The 2011 SELECT trial found an overall increased risk of prostate cancer among men taking vitamin E. 
It has also been shown, first in a 1994 NEJM study, that high doses of beta carotene increase the risk of lung cancer in smokers and those exposed to asbestos.
In fact, antioxidants in general lack evidence for an overall health benefit and in high doses may increase cancer and overall mortality.
Folic acid and cancer risk is a more complex topic. There is evidence that taking folate reduces the risk of breast and possibly colon cancer. There is a “U” shaped relationship between dose and cancer risk, however:
Women with daily dietary folate intake between 153 and 400 μg showed a significant reduced breast cancer risk compared with those <153 μg, but not for those >400 μg.
There is preliminary evidence that higher doses of folate may increase cancer risk.
There are several possible mechanisms by which excess vitamin intake may promote cancer. Cancer cells are metabolically very active. Taking more vitamins than is necessary for healthy cells may only serve to feed cancerous cells, promoting their growth. Elevated levels of vitamins, exceeding what the body need for normal metabolism, may also result in the creation of alternate downstream metabolites that have negative health consequences. Further, taking megadoses of a vitamin may alter the body’s natural homeostasis with negative consequence. This is likely true with antioxidants – oxidative compounds are used by the immune system and act as signals for the creation of protective proteins. There is a balance between oxidants and anti-oxidants, and shifting that balance is not beneficial.
There are also possible unintended consequences. The evidence is fairly clear that having a healthful and well-rounded diet has health benefits. Taking vitamins does not replace having a good diet. However, taking vitamins may lead to a false sense of security, justifying a less healthful diet with net negative health consequences.
Conclusion
Dr. Byers gave a reasonable summation of the evidence:
This is not to say that people need to be afraid of taking vitamins and minerals. If taken at the correct dosage multivitamins can be good for you. But there is no substitute for good food.
My reading of the evidence leads to several specific recommendations:
    • Do not use vitamins as a substitute for an overall healthful diet. Try to get your vitamins and minerals through a well-rounded diet with sufficient fruits and vegetables.
    • Routine supplementation in healthy individuals is unnecessary.
    • Do not take megadoses or even exceed recommended doses of vitamins or minerals. The evidence suggests this can be harmful.
    • Targeted supplementation of specific vitamins at correct doses in specific individuals or populations can be beneficial.
    • For targeted supplementation (such as folic acid in women of child-bearing age) follow accepted guidelines, or the advice of your physician. Often physicians will directly measure the blood level of specific vitamins and supplement accordingly.
Perhaps the greatest harm of the supplement industry over the last half-century has been the cultivation of the idea that vitamin and mineral supplements are harmless, that if some is good then more is better, and that the public can determine their own supplement needs based on industry marketing and magazine articles (and now websites).
It turns out that none of these assumptions are true. There is a risk to excess vitamin use. Determining who should receive what dose of which vitamin is also a bit complex and nuanced, and perhaps a little professional guidance is in order. It’s quite possible that vitamin supplement use, in addition to costing billions of dollar per year, has been a net health negative. We can save money and ensure that it is a net health positive with more rational and evidence-based supplementation.

How can we counter misinformation from “chemo truthers”?
Denial of the benefits of chemotherapy is very prevalent in “natural health” movements. This denial is based on fear mongering, pseudoscience, and conspiracy theories and thus shares many similarities with the antivaccine movement. How can the misinformation spread by “chemo truthers” be countered on social media?
David Gorski on January 27, 2020
Link
I frequently write about the misinformation and disinformation about cancer, chemotherapy, and other modalities used to treat cancer spread by believers in alternative medicine and, in particular, in alternative cancer cures. If there’s one thing that characterizes the disinformation about chemotherapy promoted by cancer quacks, it’s an extreme demonization of chemotherapy as ineffective poison. Of course, chemotherapy is indeed toxic, although lost in the fear mongering is that the toxicity of chemotherapy depends a lot on the specific chemotherapeutic agents used. In other words, some chemotherapy drugs are not that toxic, while others are very toxic, with others ranging somewhere between the two extremes. Yet, to those promoting alternative cancer cures, “chemotherapy” is to describe all chemotherapy, which is always described in the most horrific terms. Recently, I came across an article by Kelsey Osgood entitled “Chemotherapy Truthers Are the New Anti-Vaxxers“.
I actually like the term “chemotherapy Truther” (or “chemo Truthers”). It’s a great term that captures the disinformation, conspiracy theories, and pseudoscience behind chemotherapy denial (another term I like to describe this phenomenon). I was going to quibble that chemotherapy denial is not a new thing (I’ve been encountering it for decades) any more than antivaccine pseudoscience is new, but then I saw that the article compares the rise of misinformation about chemotherapy on social media to that of antivaccine pseudoscience and asks what Facebook, Twitter, and other platforms are doing about it. Of course, I’ve long argued that antivaccine misinformation and disinformation are not the only “fake news” whose spread social media has greatly facilitated. I saw antivaccine misinformation as a good starting point in terms of figuring out how to clean up the cesspit of that is Facebook, Twitter, Instagram, and, increasingly, Tik Tok. (Yes, antivaxxers have discovered Tik Tok, and it’s as cringeworthy as you might expect. If you have a Tik Tok account just do a search for “vaccine injury” or “vaccine side effects” and you’ll see what I mean.)
“Chemo Truth”
Osgood focuses primarily on two purveyors of cancer quackery who are well known to SBM readers, Chris Wark and Ty Bollinger, noting at the beginning of her article how she had first encountered Wark:
In 2017, a family member of mine was diagnosed with colon cancer. The sad announcement was sent via email, after which my (enormous) extended family sent a flurry of follow-ups. One detail stuck out: My family member had decided to forego chemotherapy after discovering the website of Chris Wark, a self-described health coach, blogger, and public speaker.
According to Wark’s site, in December 2003, when he was 26, he was diagnosed with Stage 3C colon cancer (meaning the cancer had grown into or through the outermost layer of the colon or rectum and may have spread to four or more lymph nodes). Wark had surgery to remove part of his colon, but when an oncologist told him he’d need up to a year of chemotherapy, he refused. Instead, he adopted a raw vegan diet, subsisting on juices, salad, and smoothies for months.
Today, he says he has a clean bill of health, which he attributes to his “radical” diet and lifestyle changes. He’s also part of a vocal community of holistic health advocates who decry traditional cancer treatments as ineffective at best and harmful by design at worst. Their enemy number one: chemotherapy.
I’ve written about Chris Wark before, particularly the name of his website, Chris Beat Cancer. Of course, as I explained, yes, Chris did beat colon cancer, but it wasn’t all the dietary interventions and quackery that he used. It was the extirpation of his cancer by a skilled surgeon. As I explained at the time based on Wark’s public description of his cancer, in the case of colon cancer, surgery is the primary treatment. Chemotherapy is adjuvant therapy, designed to reduce the risk of cancer recurrence as metastatic disease, and, depending on the cancer, chemotherapy can be very effective at that.
The conflation of adjuvant therapy after surgical extirpation of a cancer and chemotherapy as the primary therapy for such cancers is a common theme in alternative cancer cure testimonials. These testimonials are persuasive to the average person because most non-physicians (and even some physicians who don’t take care of cancer patients regularly) do not understand the difference. I estimated that Wark had stage III disease. I estimated that, by refusing chemotherapy, Wark decreased his chances of surviving his cancer by between 12-25%, and that he had a 30-64% chance of surviving with surgery alone. (I didn’t have full staging information, hence the uncertainty in estimates.) Of course, Wark couldn’t accept that, even going so far as to claim that surgery alone doesn’t cure stage III colon cancer, which is utter rubbish. Surgery can and does, but surgery plus adjuvant chemotherapy have a significantly better chance of curing that cancer. As I observed at the time, those odds (30-64% chance of long term survival) aren’t good enough. Why should we settle for such odds using surgery alone, when we can improve them significantly with chemotherapy?
After noting how effective chemotherapy can be, Osgood observes:
Still, a group of online cancer truthers have zeroed in on chemotherapy as the ultimate example of the hubris and greed of Western medicine and Big Pharma. They claim chemotherapy is ineffective, that it weakens the immune system, and even that it causes cancer. They say the only reason it’s the frontline treatment for cancer is because American physicians are beholden to pharmaceutical giants, incentivizing them to resort to drugs at the expense of prevention and general wellness education.
Part of the reason this message might be compelling to vulnerable people is because not all of it is outlandish. Drug companies do behave unethically: Federal prosecutors in Brooklyn are currently investigating pharmaceutical giants, including Johnson & Johnson and Teva, to determine whether they ignored distribution regulations to increase sales of addictive opioids. And primary care is seriously undervalued, which leaves some consumers suspicious that the health care establishment is less interested in preventative care than more lucrative, specialist-driven therapies.
If there’s a common theme in the denial of various science-based medical treatments, it’s tarring them with the ethical lapses and profit-driven activities of big pharma and the failings of our medical system. Antivaxxers certainly do this; it’s one of their primary tools, in particular falsely accusing anyone who has the temerity to defend vaccines against their disinformation of being on the payroll of big pharma, a trope I like to refer to as the “pharma shill gambit.” Of course, frequently, such attacks are projection, ignoring the fact that so many influencers in this realm (such as Joe Mercola) profit handsomely selling alternative medicine. In fact, Chris Wark himself recently released a book on how to “beat” cancer and has long sold web series, health coaching, and the like pushing the same message.
Osgood further observes:
Anti-chemo advocates have other commonalities: They often distrust government organizations, particularly the U.S. Centers for Disease Control and Prevention (CDC), they have rigid ideas about diet, and they are often Christian or lean heavily on New Thought ideology. If you spend time in their spaces, you see the same dubious, universally unproven “miracle” cures promoted on loop: the ketogenic diet, high-dose vitamin C drips, essential oils, coffee enemas, ozone treatment, all the herbs, detox regimens like Gerson therapy, and prayer.
One of the most prolific outfits in this universe is The Truth About Cancer, often abbreviated as TTAC, run by former bodybuilder and accountant Ty Bollinger and his wife, Charlene. Founded in 2014 after numerous members of Ty’s family died of cancer, TTAC’s website is a vast library of articles with titles like “30+ Natural Alternatives to Consider Before Chemotherapy” or “The Truth About Chemotherapy — Toxic Poison or Cancer Cure?”
Sound familiar? It should. Antivaxxers share many of these commonality as well, particularly distrust of the CDC. Ty Bollinger has been peddling cancer quackery for as long as I can remember. (I started blogging 15 years ago, and I don’t remember the first time I encountered him. It was at least several years ago.) His online video series, The Truth About Cancer is packed full of misinformation, pseudoscience, and promotion of ineffective quack cancer cures, including the promotion of a bogus “virotherapy” known as Rigvir.
Osgood also notes that there is increasingly an alliance between the antivaccine movement and the “chemo truth” movement. This alliance is nothing new, of course. If you go to “natural health” events or read “natural health” propaganda, you’ll quickly note that there is considerable overlap between the group of people believing in cancer quackery and those with antivaccine views, and that vaccines and chemotherapy are demonized using similar terms.
A recent example of this confluence between the two movements occurred in October:
In October of this year, the Bollingers staged a conference in Anaheim, California, called The Truth About Cancer Live. Three of the headline speakers featured are primarily known for their anti-vaccine views: Del Bigtree, producer of the widely criticized documentary Vaxxed; Robert F. Kennedy Jr., environmental lawyer turned anti-vaccine campaigner; and Andrew Wakefield, the author of the Lancet study that proposed a link between the MMR vaccine and autism. (Wakefield’s study was debunked and the Lancet retracted it; he’s since been stripped of his medical license.)
Footage from the 2019 TTAC Live event is no longer accessible online (unless you want to pay a minimum of $199 to access it) but I managed to catch speeches by Kennedy and Bigtree during the live broadcast. Kennedy’s focused on how the HPV vaccine Gardasil increases risk of cervical cancer. (The CDC maintains Gardasil is safe.) Bigtree’s speech was entirely about vaccines: He never mentioned cancer, except once, obliquely, when he gesticulated at a graph about vaccines projected onto a screen and burst out, “This is why we’re sick!”
It is of course, utterly untrue that Gardasil increases the risk of cervical cancer (quite the opposite, in fact), but this event does show how antivaxxers and chemotherapy truthers are natural allies. They both share an overblown belief that “natural” is always better, that humans have a near-total ability to keep themselves healthy through lifestyle and diet (and certain supplements, of course), and that pharmaceutical drugs cure almost nothing.
Ty Bollinger strikes back
Unsurprisingly, cancer quacks Ty and Charlene Bollinger were unhappy about Osgood’s article and published a response. Predictably and amusingly, Ty Bollinger’s response to Osgood’s article goes a long way to unintentionally amplify her points about the Bollingers. Bollinger begins by expressing faux outrage that Osgood published her article on the same day that his father would have turned 76 if he were still alive, implying that she did it on purpose. Somehow I doubt that Osgood even knew when Bollinger’s father’s birthday was, but such a framing is useful to Bollinger to frame the issue as though Osgood’s article was a personal attack on him. He also seems to think that the term “cancer truther” was a reference to him and his wife. It might have been, but if the shoe fits…
Bollinger’s responses are very predictable, consisting mostly of “cancer truther” or “chemo truther” tropes that I’ve deconstructed more times than I can remember:
According to a 2004 report by Morgan, Ward, and Barton (Department of Radiation Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, NSW, Australia): “The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. … survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.”
In another study published in the February 2017 issue of JAMA Internal Medicine, researchers Rupp and Zuckerman looked at 18 FDA approved chemo drugs, and found that NONE of them actually helped cancer patients live longer.
Longtime readers will recognize that study and recognize the first claim by Bollinger as what I’ve dubbed the “2% gambit” about chemotherapy. I’ve deconstructed why it’s a deceptive gambit based on a crappy study before. The long version of the debunking can be found here, and the short version goes something like this: This is not an impressive study and actually appears almost intentionally designed to have left out the very types of cancers for which chemotherapy provides the most benefit. It uses 5 year survival exclusively, completely neglecting that for some common cancers (such as breast cancer) chemotherapy can prevent late relapses, and there were also a lot of inconsistencies and omissions in that leukemias were not included, while leukemia is one type of cancer against which chemotherapy is most efficacious. As I noted at the time, the very technique of lumping all newly diagnosed adult cancers together is guaranteed to obscure benefits of chemotherapy among subgroups by lumping in patients for whom chemotherapy is not even indicated.
Bollinger’s invocation of the second article is even more deceptive. The article is not about all chemotherapy. It is only discussing newer chemotherapy drugs that underwent fast track approval based on surrogate endpoints; i.e., endpoints other than overall survival. It is about 18 drugs approved between 2008 and 2012, and it is a criticism that the FDA is approving new cancer drugs too rapidly. It’s a criticism that I myself echoed just last year. What Bollinger likely knows but deceptively leaves out is that standard-of-care chemotherapy for various cancers is standard-of-care because it has been shown to prolong overall survival in appropriate randomized clinical trials.
Bollinger also neglects to note that cancer mortality has been falling for 30 years and that the most recent report from the American Cancer Society showed the largest single year drop in cancer mortality ever observed. In fact, chemotherapy is effective when used appropriately. Yes, many chemotherapy agents are toxic, but most patients consider the toxicity worth it in order to survive their cancer.
For some reason, Bollinger also notes that chemotherapy can weaken the immune system. I don’t recall seeing Osgood actually write anything other than that cancer truthers make that claim, much less try to refute it. So he cites BreastCancer.org and the American Cancer Society stating that chemotherapy can temporarily weaken the immune system. No legitimate medical group says otherwise. It’s basically a straw man argument. I can see why Bollinger made it, though. It’s the only thing he can say in reply that’s clearly factual; so he had to find a way to shoehorn it into his response.
Next up:
Every oncologist knows that chemotherapy has “collateral damage” (aka side effects). It’s not a matter of “if” but “how much” collateral damage will be caused by the chemo. Just like when the USA strikes another country or terrorist cell, the decision is frequently based on deciding how much collateral damage to “civilian” populations is deemed acceptable.
Have you heard of tamoxifen? It’s a breast cancer drug. Did you know that it’s classified by the World Health Organization and the American Cancer Society as a human carcinogen?
According to the Report on Carcinogens, Fourteenth Edition, which is published on the NIH website,
Tamoxifen is known to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in humans. … Data from epidemiological studies and clinical trials indicate a causal relationship between exposure to tamoxifen and cancer of the uterus (endometrial type). … In rats, it promoted the development of … liver tumors in several studies and kidney tumors in one study.”
In light of the above facts, does chemotherapy really make sense? Even if tamoxifen was effective (which increasingly it is not), does it really matter if it “cures” breast cancer only to cause endometrial or liver or kidney cancer as a direct result of the treatment?
This argument is deceptive in that tamoxifen is not generally considered chemotherapy, at least not in the same sense that cytotoxic drugs are. It’s a pill, one of the earliest routinely used targeted therapies. It’s an endocrine therapy that is directed against the estrogen receptor, whose activity fuels the growth of roughly 70% of breast cancers. It is true that on an absolute basis tamoxifen slightly increases the risk of uterine cancer. That’s been known for decades, but that slight increased risk of uterine cancer is very much outweighed by the benefits of tamoxifen in preventing breast cancer recurrence. As BreastCancer.org says (given that Bollinger likes to quote that website): “The breast cancer treatment tamoxifen (sometimes called by its brand name, Nolvadex) increases the risk of developing endometrial cancer, but not nearly enough to outweigh its benefits against breast cancer in most women”.
Bollinger also notes:
Additionally, in a 2009 study published on Science Direct, researchers Yan, Lu, and Yao demonstrated that chemotherapy not only enriches but also induces cancer stem cells. And a 2012 study from China indicates that chemotherapy can induce a phenomena [sic] called “stemness,” which occurs when the cells begin to express genes (such as p21 and p53) that are vital for maintaining stem cell functions. This, in turn, can drive the recurrence and speed the metastasis of cancer.
Amusingly, the first article was published in Bioscience Hypotheses, a journal discontinued in 2010. It’s not a study per se. It’s more like a commentary. The second study appears to be only a cell culture study. I can’t say for sure, though, because it is no longer available at the journal website online. Let’s just say that Bollinger did some mighty fine cherry picking. Of course, there is some evidence that chemotherapy can in some cases facilitate the spread of certain cancers (I even discussed one such study three years ago), but guess what? The benefits shown in clinical trials clearly outweigh harm from that possibility.
Here’s another amusing response by Bollinger:
KO asserts: Anti-chemo warriors have, perhaps unsurprisingly, joined forces with anti-vaccine advocates, whose crusading efforts have led to the resurgence of numerous preventable diseases like measles.
TB response: Despite the fact that neither Charlene nor I would take chemotherapy, we are not “anti-chemo” (and we’re not “anti-vaxx” either, FYI). We are for freedom to CHOOSE. That’s all. I think that’s where folks like Kelsey and others don’t really get it. And speaking of the measles … were you aware that it was a fully vaccinated 22-year-old theater employee in New York City who developed the measles in 2011 and was released without hospitalization or quarantine? Ultimately, she transmitted the measles to four other people, according to a May 2014 report in Clinical Infectious Diseases that tracked symptoms in the 88 people with whom “Measles Mary” interacted while she was sick.
There have been other measles “outbreaks” that occurred in fully (or almost fully) vaccinated populations, but the point is that if the measles vaccine (MMR) was effective, then there should NEVER be an outbreak in a fully vaccinated population.
Notice how Bollinger’s response basically makes Osgood’s point for her. Antivaxxers frequently say, “I’m not antivaccine. I’m pro-freedom” or “pro-parental rights.” Bollinger says the same thing, just substituting chemotherapy, “I’m not anti-chemo. I’m just pro-freedom to choose.” Then he pivots to a particularly brain dead antivaccine talking point. Later, he cherry picks a single table that suggests that the risk of cervical cancer with Gardasil is higher, ignoring utterly all the other high quality data (summarized by a friend of the blog here) showing that Gardasil and Cervarix (the other HPV vaccine) are very effective in preventing cervical intraepithelia neoplasia, the precursor to cervical cancer. He even repeats the claim that that Maurice Hilleman “admitted” that polio vaccines tainted with SV40 used until the early 1960s caused an epidemic of cancer. Sorry, Mr. Bollinger, but the evidence shows that they didn’t. He even trots out the antivaccine lie that Wakefield’s paper, although retracted, has never been debunked. (I rather think that Brian Deer would have something to say about that, given how fraudulent Wakefield’s study was.) He even echoes the Alex Jones wannabe Mike Adams about thimerosal in one of the remaining thimerosal-containing flu vaccines. (I laughed out loud when I read that.) Thanks, Mr. Bollinger, for making Osgood’s point for her again about the confluence between the antivaccine movement and the cancer/chemo truth movement!
Social media versus cancer misinformation
What can social media do about this spread of misinformation? I discussed this issue a couple of times last year, specifically what Google and the various social media platforms are doing to try to rein in the worst of the medical misinformation, starting with antivaccine misinformation. It’s an unenviable task, but one that the social media companies brought upon themselves by being so resistant in the past to any sort of content moderation. The let the problem fester for so long that it’s out of control now.
Noting that such companies have made efforts to rein this in, Osgood also notes, quoting yours truly and others:
But the system remains imperfect. In October, when BuzzFeed alerted Facebook and YouTube about groups promoting “black salve,” a tissue-eating paste hawked as a treatment for skin and breast cancer, YouTube removed the content, but Facebook declined to. (The Bollingers hyped the benefits of black salve on a recent live Q&A.) And when I loaded The Truth About Cancer and Chris Wark’s page on Facebook in early December, neither had a disclaimer about possible health misinformation.
“It’s hard to stay on top of the keywords and phrases that they’re using,” says Renée DiResta, the 2019 Mozilla fellow in media, misinformation, and trust. “Sometimes when new narratives emerge, they kind of get a bump until the platform reacts.”
Gorski is skeptical that algorithms alone can handle the monumental amount of misinformation online, or be able to reliably distinguish between valid and invalid material. “Even huge companies like Facebook don’t have the resources to hire the hordes of moderators it would require to do it with humans,” he says. “Their tools are kind of blunt.”
It is, as noted in the article, and arms race, and I remain skeptical that algorithm-based methods alone can ever rein in such health misinformation, for this reason:
When I look up Erin Elizabeth on Twitter, the algorithm suggests I follow Del Bigtree, The Truth About Cancer, and numerous anti-vaccine advocacy groups. This is one of the tech giants’ blind spots: They can dissuade you from entering the echo chamber in the first place, but once you land on one of these pages, you’ll still be directed to others with similar views. I also noticed that some anti-vaccine activists and cancer truthers have started avoiding certain flag-worthy terms or intentionally misspelling them — such as replacing the c’s in “vaccines” with apostrophes — which the human and digital monitors haven’t caught on to yet. As Gorski says, “It’s an arms race.”
Erin Elizabeth, you might know, is Joe Mercola’s longtime girlfriend. Those who follow me on Twitter might also know that she’s really, really unhappy with me right now.
In any event, it is an arms race. One thing I’ve learned is that antivaxxers forming new Facebook groups are very careful not to mention vaccines in the title and instead use terms like “medical freedom” or “parental rights” or other antivaccine dog whistles. Algorithms are dumb. They do what they’re programmed to do and can thus be gamed for a while before their creators realize they’re being gamed and tweak the algorithm to account for the gaming. There will always be a need for human moderators, and even Google realizes this, but none of the tech companies appear to care enough to hire enough moderators or to pay them enough to retain quality people. Maybe someday artificial intelligence will be the answer, but I wouldn’t put too much faith in computer-only solutions.
In the end, “Cancer Truth” or “Chemo Truth” are just another kind of misinformation and disinformation based on conspiracy theories and, as such, highly resemble antivaccine misinformation. All of these fear-mongering conspiracy theories based on pseudoscience and misinformation can cause significant harm, the antivaccine movement to public health and the “cancer truth” movement to cancer patients with cancer who are misled into pursuing ineffective treatments, thus lessening their chances of surviving their disease. Dealing with this sort of misinformation in medicine will be the primary challenge of science communicators for the foreseeable future.

When science- and evidence-based guidelines conflict with patient wishes: What’s a doc to do?
We use the term “science-based medicine” (SBM) because medicine isn’t a science. The best medicine, however, is based in science. Patient values are also important, but what is a science-based doctor to do when SBM conflicts with what a patient or family wants?
David Gorski on October 3, 2016
Link

There’s a misconception that I frequently hear about evidence-based medicine (EBM), which can equally apply to science-based medicine (SBM). Actually, there are several, but they are related. These misconceptions include the idea that EBM/SBM guidelines are a straightjacket, that they are “cookbook medicine,” and that EBM/SBM should be the be-all and end-all of how to practice clinical medicine. New readers might not be familiar with the difference between EBM and SBM, and here is not the place to explain the difference in detail because this post isn’t primarily about that difference. However, for interested readers, a fuller explanation can be found here, here, here, and here. The CliffsNote version is that EBM fetishizes the randomized clinical trial above all other forms of medical investigation, a system that makes sense if the treatments being tested in RCTs have a reasonably high prior probability of translating to human therapies based on basic science mechanisms, experimental evidence in cell culture, and animal experiments. Using Bayesian considerations, when the prior probability is very low (as is the case for, for example, homeopathy), there will be a lot of false positive trials. Such is how EBM was blindsided by the pseudoscience of “complementary and alternative medicine” (CAM) or, as it is called now, “integrative medicine.”
However, for purposes of this post, SBM and EBM can be considered more or less equivalent, because we are not going to be discussing CAM, but rather widely accepted treatment guidelines based on science, both basic and clinical trial science. I merely mention this difference for completeness and for new readers who might not be familiar with the topics routinely discussed here. For purposes of this post, I’m talking evidence-based guidelines from major medical societies. More specifically, I want to address the disconnect between what patients often want and what our current guidelines state. It’s not just patients either, but doctors; however, for purposes of this post I’m going to focus more on patients. It’s a topic I’ve addressed before, in particular when it comes to breast cancer, where I’ve discussed changes in the mammography screening guidelines and Choosing Wisely guidelines for breast cancer. There are many other examples that I haven’t discussed.
What got me thinking about this again was an article by Don S. Dizon, MD, FACP, Associate Professor of Gynecologic Oncology at Harvard Medical School, appearing in the ASCO Post entitled “Evidence Should Inform Guidelines, Not Be Used as a Mandate.” While I agree with a lot of what Dr. Dizon writes, I also have a couple of nits to pick as well, but first let’s see what he wrote.
Early detection of cancer recurrence: Evidence versus patient wishes
While cancer patients are understandably overjoyed when their treatment successfully puts them into remission, they are equally understandably frightened as well. What terrifies them, of course, is the fear that their cancer will recur to claim their lives. It’s not an unreasonable fear, either, because even for early stage invasive breast cancer, which is highly successfully treated, long term survival is well over 90%, which means that 5-10% will still recur in their lifetimes despite the best efforts and maximal therapy. For higher stages of breast cancer and other cancers, the risk is higher. As the years go by and patients pass the five year mark, that fear will tend to recede, but it never goes away, particularly for hormone receptor-positive breast cancer (for example), which is notorious for recurring late, sometimes as late as 20 years later. Here’s where patient wishes frequently clash with EBM/SBM. Patients naturally want to be monitored frequently and aggressively for recurrence. However, for many cancers oncologists know that, paradoxically, early detection of recurrence does not impact survival.
This is true, for example, for ovarian cancer, and Dr. Dizon, being a gynecologic oncologist, begins with one of his patients, whom he calls “Jody.” Jody was treated two years ago for a rare form of ovarian cancer. At surgery, fortunately it was confined to the pelvis and had not spread to the abdomen. She then underwent chemotherapy, and her CA-125 levels fell with each cycle until her CA-125 was within the normal range. CA-125 is a tumor marker frequently elevated in ovarian cancer and useful for following response to therapy. If therapy doesn’t drop CA-125 to normal, chances are that there’s residual disease. Also, frequently, a rising CA-125 level is the first indication of recurrence, which made it very attractive for oncologists to follow CA-125 levels after successful treatment of ovarian cancer.
With that background in place, Dr. Dizon continues:
At her first post-chemotherapy visit, I relayed the results of her CA-125 and CT. “Based on both, you are now in remission.”
“Wow,” she said. “I am so relieved this is over. What comes next, though?”
At that point I discussed her follow-up. “Your risk of recurring will be greatest in the next 3 years,” I said. “As such, I’d like you to be seen here every 3 months for a physical exam that will include a pelvic. I really wouldn’t recommend anything more.”
“Wait—no blood tests? What about imaging?” she asked.
These are, of course, perfectly reasonable questions, questions that virtually every cancer patient asks when confronted with a post-therapy screening regimen that strikes them as insufficiently aggressive. After all, intuitively, it seems “obvious” to most people that early detection of a recurrence should lead to better outcomes, just as it is intuitively “obvious” to most people that early detection of cancer in a healthy population should lead to better survival and better outcomes. Yet, as any longtime reader of SBM knows, that is often not the case. Thanks to overdiagnosis (the diagnosis of subclinical disease that would never progress to harm the patient), lead time bias (how screening can give the false appearance of prolonging life even in the absence of effective treatment), and length bias (the bias in screening towards picking up indolent, slowly progressing disease), the relationship between early detection and prognosis is not nearly as clear as “intuition” leads us to believe. In other words, more is not necessarily better, the assumption of even doctors that failure to screen kills their patients. The reality is that screening for cancer (or any disease) in asymptomatic people can help, but it can also harm. Most patients (and, unfortunately, a lot of doctors) don’t understand that.
Many of these considerations come into play in screening a cancer patient for recurrence after she has been successfully treated to bring her cancer into remission, although the difference is that the incidence of recurrence will be much higher in such patients than the incidence of the disease is in asymptomic patients never before diagnosed with cancer. It’s also why, for most cancers, evidence-based guidelines no longer recommend intensive screening for recurrence after successful treatment, as is the case for ovarian cancer, which Dr. Dizon tried to explain to his patient:
“Well,” I answered, “the data suggest that nothing else will be very helpful. I know we measured your CA-125 during treatment, but it was to help me guide the impact of chemotherapy. After treatment, a large randomized trial done in the United Kingdom showed that routinely measuring CA-125 isn’t helpful. In that trial, women entering remission agreed to have their CA-125 levels checked but the results were masked. If their CA-125 rose above twice the upper limit of normal, patients were randomly assigned to one group who were told their CA-125 and asked to start chemotherapy as soon as possible (called the “early” chemotherapy group) or to another group who were not told their CA-125 and only started chemotherapy when clinical or symptomatic relapse was diagnosed (called the “delayed” chemotherapy group). The upshot is that overall survival was no different between either group. The only impact was that women in the early chemotherapy group experienced worsening of their perceived health sooner than those treated in the delayed group.”
“Therefore,” I concluded, “on the basis of pretty good data, it would be very reasonable not to follow your CA-125 if you are feeling well. However, if you develop any symptoms at all, or if you are worried at some point, we could certainly check it. As for imaging, I wouldn’t subject you to CT scans at regular intervals if you feel well. If we do a scan, it should be because there’s a question or a concern.”
This is the study to which Dr. Dizon was referring. There were 1,442 patients in the study, and its conclusions were about as unequivocal as one can get in a study:
Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone, and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
To repeat: The only effect of screening CA-125 and treating early based on a biochemical increase in the level of the tumor marker was more treatment with chemotherapy and a longer period of time with a recurrence before death.
Ovarian cancer is not alone
It’s not just ovarian cancer for which intensive screening is not recommended after curative treatment has successfully resulted in cancer remission. In fact, after a period of time a couple of decades ago when we were routinely screening patients for recurrence, we’ve learned again that more is not necessarily better and that less can be more. Consider Choosing Wisely, a program initiated by the American Board of Internal Medicine (ABIM) Foundation that challenged medical professional societies to identify and publicize medical practices that are not evidence-based but nonetheless common. (Given my tendencies, I can’t help but contrast Choosing Wisely to how practitioners of CAM pretty much never urge their members to abandon practices that aren’t evidence-based, but I digress, if only slightly.) Among these first five guidelines was this:
Don’t perform surveillance testing (biomarkers) or imaging (PET, CT, and radionuclide bone scans) for asymptomatic individuals who have been treated for breast cancer with curative intent.
Surveillance testing with serum tumor markers or imaging has been shown to have clinical value for certain cancers (e.g., colorectal). However for breast cancer that has been treated with curative intent, several studies have shown there is no benefit from routine imaging or serial measurement of serum tumor markers in asymptomatic patients.
False-positive tests can lead to harm through unnecessary invasive procedures, over-treatment, unnecessary radiation exposure, and misdiagnosis.
That was 2012. What about now? Well, ASCO has doubled down, recently extending the recommendation to basically all cancers, at least as far as advanced imaging, such as CT and PET scans go:
Avoid using PET or PET-CT scanning as part of routine follow-up care to monitor for a cancer recurrence in asymptomatic patients who have finished initial treatment to eliminate the cancer unless there is high-level evidence that such imaging will change the outcome.
PET and PET-CT are used to diagnose, stage and monitor how well treatment is working. Available evidence from clinical studies suggests that using these tests to monitor for recurrence does not improve outcomes and therefore generally is not recommended for this purpose.
False positive tests can lead to unnecessary and invasive procedures, overtreatment, unnecessary radiation exposure and incorrect diagnoses.
Until high level evidence demonstrates that routine surveillance with PET or PET-CT scans helps prolong life or promote well-being after treatment for a specific type of cancer, this practice should not be done.
There are exceptions, one of which, at least, leads to some disagreement with the ASCO Choosing Wisely guideline above. For example, for colorectal cancer, for high risk patients with colorectal cancer (stage II or III) treated with curative intent, there is high level evidence that intensive surveillance can be beneficial for high risk patients (stages II and III) treated for cure with normal CEA levels and no evidence of disease on scans—although that even has its caveats. For example, the authors of the guidelines for surveillance after treatment of colorectal cancer caution:
Seven meta-analyses have addressed the relationship between intensive surveillance and survival following re- section of colorectal cancer2,23–28 (table 2) including an updated Cochrane analyses.28 All meta-analyses report increased curative resections and improved survival in patients undergoing more intensive surveillance. One meta-analysis,2 which included the largest number of cases (n = 2923), reported that more intense follow-up was associated with increased curative resection rate (24.3% vs 9.9%) and improved survival (78.2% vs 74.3%). In the most recent Cochrane analysis, improved chance of curative surgery for recurrence was associated with higher intensity of surveillance (OR, 2.41; 95% Ci, 1.64–3.54).28 however, there are difficulties with evaluating these studies because testing modalities and the definitions of “intense follow-up” vary. When evaluating the RCT and meta-analyses data in total, it appears that curative resection for recurrence uniformly increases with increased surveillance, whereas the survival advantage is more variable, and likely modest at best.
Another exception: Surveillance colonoscopy is recommended every year for five years for patients with colorectal cancer treated with curative resection.
I could go on with multiple other examples, but the point remains. For the vast majority of cancers, intensive screening after curative treatment does not result in prolong survival, and, even when there is evidence that it does, such as in colorectal cancer, the survival benefit reported is variable and at best very modest. That means that the overall message to oncologists for most cancers is: Don’t be ordering CT scans every six months or following tumor markers every three months. It’s a viewpoint that oncologists have resisted but are finally coming around to. It’s also a viewpoint that is not popular with patients, as you will see.
Dr. Dizon’s patient reacts
Consistent with what I’ve been saying, Dr. Dizon’s patient was not—shall we say?—enthusiastic about his recommendation:
She had looked at me then, not quite sure what to make of this. “Okay, but if I want my CA-125 checked every 3 months you’d do it?”
“Yes, I would,” I said. “I just wanted to make sure you had all the information you needed to make that decision.”
“Fine,” she continued. “I would really prefer we checked my CA-125 when I came in for my exams. It just doesn’t make sense to me that it wouldn’t be helpful.”
See what I mean by these new data being counterintuitive? Most patients react that way, and it often requires a fair amount of explaining and cajoling to reassure the patient that doing a bunch of expensive tests (or even a relatively inexpensive blood test many times) will not benefit the patient, at least not in terms of overall survival, and is likely to negatively impact her quality of life. On the other hand, anxiety is a powerful motivator, and, if it is intense enough, can rub off on even the most experienced clinician armed with piles of evidence from well-designed clinical trials to support his recommendations.
Here’s what happened next at a later visit by the patient for followup after her having persuaded Dr. Dizon to do regular CA-125 levels:
Unfortunately, her CA-125 result came back markedly elevated. I called her and gave her the results, recommending that we get a CT scan. She agreed.
Jody returned to my office the following week. Her CT showed new growth in her abdomen, consistent with peritoneal disease. I started to review options for treatment, but she stopped me. “I just need you to know that I am angry,” she said. “Thank God I asked to have my CA-125 followed—it’s how we picked up this disease. I can’t even imagine where I’d be had I taken your advice and didn’t do bloodwork and just waited for symptoms. Who on earth would follow such advice? It’s like you had asked me to put my head in the sand and ignore what was going on around me. I’m sorry, but I could never do that—and it turns out, I was right.”
I wasn’t prepared for her anger, especially about a conversation we had had years earlier, but I also knew that rehashing the data would serve no purpose. So, instead of going through the data once more, I did what I thought was best. I apologized:
“Jody, I am sorry that you had felt like I was imposing a recommendation on you. It was not my intent. I had hoped to let you know of your options, so that, together, we could choose a surveillance strategy that made sense to you. To do it, I wanted to make sure you knew that there was data available. If it came across any other way, then I take responsibility.”
Whether this was the right course of action or not, I’m not sure. One could certainly argue that that visit wasn’t the right time for Dr. Dizon to point out that he had done nothing wrong and in fact did everything right. As physicians, it is our job to present the best evidence-based treatment recommendations that we can, personalizing them to the patient. Indeed, my main quibble with him is that, at least as he told the story, Dr. Dizon gave in too easily to agreeing to do something that he himself knew not to be purely evidence-based. Personally, although I agree in general with Dr. Dizon’s conclusion, I wasn’t sure, as I read his article, whether Jody was the best example to use to illustrate the principle:
But Jody reminded me once more that evidence has its place­, but it’s not gospel. In the end, the data need to be interpreted by our patients, in the context of their own preferences and values, and each person will reach a different conclusion. In the end, evidence should inform our guidance, but it should not be used to enforce mandates.
On the other hand, if the survival outcome is the same regardless of whether one checks CA-125 levels every three months after curative treatment of ovarian cancer or not, one can argue that there wouldn’t be a lot of harm in acceding to the wishes of patients like Jody. Going against that conclusion is evidence that diagnostic tests with a low pretest probability of disease to rule out conditions and reassure the patient actually do little to reassure patients or decrease their anxiety. Indeed, there is actually evidence that more testing increases patient anxiety and certainly leads to higher costs.
Be that as it may, I myself have not infrequently said that a patient’s values matter, using this example. Some patients want to do everything; others value quality of life over quantity. Our job is to give the best evidence-based recommendation that will fit in with the patient’s values. However, in this age where we cannot just ignore cost, a very uncomfortable question always rears its ugly head: How much more are we willing to pay to deviate from evidence-based guidelines to accommodate a patient’s values? If physicians and patients together don’t answer that question, we can be sure that third party payers will.

Mouse “avatars”: New predictors of response to chemotherapy?
David Gorski on October 1, 2012
Link
Over the years, I’ve written a lot about “personalized medicine, mainly in the context of how the breakthroughs in genomic medicine and data pouring in from the Cancer Genome Atlas is providing the raw information necessary for developing truly personalized cancer therapy. The problem, of course, is analyzing it and figuring out how to apply it. Another problem, of course, is developing the necessary targeted drugs to attack the pathways that are identified as being dysregulated in cancer cells. Oh, and there’s that pesky evolution of resistance to antitumor therapies. Indeed, most recently, the Cancer Genome Atlas is bearing fruit in breast cancer (a study that I’ve been meaning to blog about).
One problem with modeling the pathways based on next generation sequencing data and expression profiling is testing whether therapies predicted to work from these analyses actually do work without actually testing potentially toxic drugs on patients. Cell culture is notoriously unreliable as a predictor. However, there is another way that’s intriguing. Unfortunately, as intriguing as it is, it has numerous problems, and, unfortunately, it’s being prematurely marketed to patients. Although I had heard of this technique as a research tool before, I learned about its marketing to patients when I came across an article by Andrew Pollack in the New York Times entitled Seeking Cures, Patients Enlist Mice Stand-Ins. Basically, it’s about a trend in science and among patients to use custom, “personalized’ mouse xenograft models in order to do “personalized” therapy:
Megan Sykes, a medical researcher, has a mouse with a human immune system — her own. She calls it “Mini-Me.”
There are also mice containing a part of 9-year-old Michael Feeney — a cancerous tumor extracted from his lungs. Researchers have tested various drugs on the mice, hoping to find the treatment that would work best for Michael.
In what could be the ultimate in personalized medicine, animals bearing your disease, or part of your anatomy, can serve as your personal guinea pig, so to speak. Some researchers call them avatars, like the virtual characters in movies and online games.
“The mice allow you the opportunity to test drugs to find out which ones will be efficacious without exposing the patient to toxicity,” said Colin Collins, a professor at the University of British Columbia.
Well, yes and no.
My first reaction to this story was a massive yawn. Scientists have been removing bits of patient’s tumors and implanting them into immunosuppressed mice for decades. As I pointed out, I had heard of implanting bits of patient tumors into mice a long time ago. I’ve even known investigators who did such work. Certainly, such models have their uses and can be moderately predictive of at least initial human response (namely, tumor shrinkage), but they have been less successful at being predictive of what therapies will actually prolong human life or cure disease. It’s been fairly hit or miss. So what’s different about these mouse models in this story? Two things. First, instead of using a cancer cell line, these tumors are derived from a patient’s own tumor. In essence, they are chunks of the patient’s tumor implanted under the skin of the appropriate mouse strain; i.e., the strain with the “human” immune system.
As “un-novel” as this all is, what was novel (and to me somewhat alarming) is that companies are apparently already marketing these sorts of animal models to patients. It might very well be that combining the use of genomics to identify specific genetic abnormalities in cancer cells, matching them with targeted drugs, and then testing these drugs in mouse models of the patient’s very own tumor could revolutionize cancer therapy. After all, one problem with using just genomics is that the first test of whether the prediction is right is in patients, and using cell culture models has been quite unreliable to predict whether a given patient’s tumor will be sensitive to a given drug. On the other hand, it’s incredibly labor-intensive and expensive. In other words, avatars are an interesting research tool that could become very useful over time when combined with the genomics revolution. One example is the Breast Cancer Genome Guided Therapy Study (BEAUTY) project (which has the most god-awful contrived acronym I’ve seen in a very long time), which is being carried out at the Mayo Clinic’s Center for Individualized Medicine.
There’s more on this study here:
And here. It’s a fascinating, systematic study that is likely to provide very useful information. Basically, the investigators will not only do next generation sequencing (NGS) on patient’s tumors before and after chemotherapy, but they will keep the patient’s tumor cells alive and grow them in mice to test the predictions that these NGS techniques lead to. The whole thing is likely to be hideously expensive; although the cost of NGS sequencing techniques is plummeting, the cost of keeping a large colony of mice is skyrocketing. That’s why, right now, this sort of combination of techniques is (and should probably only be) limited to cutting edge research laboratories. It’s not something that just anyone can do, nor has it been validated yet in clinical trials.
Out of curiosity, I wandered over to the website of the company mentioned in the NYT article, Champions Oncology, which markets its test under the name Personalized Champions TumorGrafts™ as “empowering patients and physicians using an in vivo mouse avatar-based diagnostic model that has shown to be predictive of a patients’ clinical response to anticancer therapies.” TumorGrafts are further described thusly:
A piece of the patient’s living tumor is removed during surgery or biopsy and is implanted in mice. By implanting the tumor together with it’s microenvironment, TumorGrafts continue to very closely resemble the patient’s tumor with 94% genetic correlation to the tumor in the patient. Our TumorGrafts successfully grow over 80% of all tumors implanted.
And:
Our scientists work closely with treating physicians to determine which drugs to test on the patient’s TumorGrafts. Our labs will administer these treatments to the TumorGrafted mice and measure the living tumor’s response to each drug regimen. Physicians receive a robust report on the effectiveness of each tested therapy on the TumorGrafts. With this information in hand, physicians can personalize each patient’s cancer treatment.
It sound suspiciously to me like making educated guesses and throwing them at the mouse tumor models. In the article, a boy named Michael Feeney is described. Michael has Ewing’s sarcoma, and his parents paid over $25,000 to have a bit of his tumor sent to Champions Oncology for its TumorGraft test. The results came back suggesting gemcitabine, docetaxel, Avastin and Afinitor as a combination of drugs to use, which is described by Michael’s oncologist as “not something oncologists would typically choose.” It’s probably for the same reason that the combinations that Stanislaw Burzynski chooses based on a gene test that he uses are not combinations that oncologists would typically choose because of the potential for synergistic toxicity. In any case, I have to wonder how Champions Oncology came up with the idea of testing that combination in the first place. At least with NGS, there is the guidance of specific mutations uncovered through sequencing. In the case of the BEAUTY study, those mutations will guide testing in mouse avatars. In the case of the TumorGraft test, there are a practically uncountable number of potential drug combinations that can be tested, each taking a certain number of mice. How does one prioritize? I’m surprised it only cost the Feeneys $25,000!
This made me wonder what the evidence base for this test was. I was disturbed by what I found. What I would normally expect to find would be well-designed basic science, animal studies, and clinical trials supporting the hypothesis that using TumorGraft-guided therapy improves response rates or, better yet, survival rates. That is the minimum that I would expect. What I found were preliminary studies, some of which weren’t even based on the company’s test, and then, under a section called Our Experience was nothing of the sort. What I found was a single case report of a man with pancreatic cancer who survived over five years with pancreatic cancer. Unfortunatley, one case study does not adequate evidence make, and I note that this particular patient also had his tumor genome sequenced, as described in this case report. In other words, this case report is much like the BEAUTY trial than it is like what is described on the company website for what it does. In other words, it’s not exactly a fair comparison. Champions narrowed down its choices of therapies to try based on sequencing of the patient’s cancer cells, not the way that the test is described. If the company is routinely sequencing patient tumors and then testing combinations in its TumorGraft test, that would be less questionable to me, although I would still consider it way premature to offer such a test to patients. Way premature.
Nor do testimonials, which are the other main type of evidence on the Champions Oncology website. I can’t help but notice in these testimonials that there doesn’t seem to be any testimonials stating that the results of the TumorGraft test has actually saved a life that wouldn’t have been saved using conventional methods. There are, however, testimonials like this:
A combination of world-class advice and the data from the mice is ensuring that my oncologist has far more information about the potential effectiveness of various treatments than would normally be the case. I feel more in control and not a passive victim of my condition.
Or
Working with Champions’ experts has provided my physician, my family and me with a hopeful path to treat my disease… using Champions TumorGrafts™, [they] identified a novel drug combination that has provided promising results and an improved quality of life.
Oh, sure, there are scientific studies listed. They’re all fairly small and definitely preliminary. One was carried out by Bayer Schering Pharma AG, which didn’t really demonstrate that TumorGraft or TumorGraft-like tests improve patient outcomes. There was, as I pointed out, the aforementioned case report of the man with pancreatic cancer who had a prolonged remission. I’m not saying that the technique of sequencing a patient’s tumor and then testing targeted therapies identified by that sequencing doesn’t have promise; I am saying that it’s not ready for prime time and that offering it to patients before it’s been validated (and charging patients for it) is the same thing as charging patients for an experimental test or therapy, which is what TumorGraft is. Even if it turns out to be the be-all and end-all of personalized cancer therapy, charging patients for it right now is in my opinion at best highly dubious and at worst completely wrong. In other words, count me as one of the critics:
Critics are numerous and have a lot to say. The total length of the procedure is long and patients have died waiting for their mice to be done growing their tumors. Sometimes the tumors do not grow at all. Mice can die during the transplant or when undergoing treatment. The tumor may not behave the same in mice. Treatments that are effective in mice may not have the same effect in humans. Critics are unsure whether it will prolong patients’ lives and the process is very financially draining; it can cost upwards of tens of thousands of dollars, which insurance does not cover. Skeptics say that a randomized trial would need to occur in order to prove that people with avatars would do better than more traditional methods.
Exactly. Although I now count myself as a critic, I’m a hopeful critic, though. There are studies, for instance, that suggest that the use of these animal models in which patients’ own tumors are grown in mice do correlate pretty closely with patient response to the chemotherapy tested. For instance, this study, which is the main study touted by Champions Oncology, involved testing 63 drugs in 232 treatment regimens, and only a few of the tumors were subjected to gene expression profiling. Interestingly, in the conclusion the authors write something that I completely agree with:
The limitations to this approach certainly challenge the broad clinical application of the process and will need to be resolved before this can be first tested in a randomized clinical trial. The process requires large amounts of fresh tumor material and intense resources to generate the tumorgraft. Even in the best conditions, 25 to 30% of implants fail, and those that engraft require 6 to 8 months of additional propagation to be useful for treatment.
This paper was published in 2011 and was done in collaboration with scientists associated with Champions Biotechnology. One wonders why a year later Champions thinks that it’s OK to charge patients for this test. Believe it or not, I do think that sequencing cancer genomes and doing expression profiling, then using mouse models like this, could hold considerable promise for predicting individual patient response to different regimens. I just don’t think the contention that this approach does has been documented. I also view this as a test that will not be helpful to a lot of cancer patients because it just takes too long and is way more expensive than most insurance plans and governments would be willing to pay for without slam dunk evidence that it does a lot better than what we’re doing now. In the NYT article, Dr. Ronnie Morris, the president of Champions, noted that the company has had about 160 patients so far and has tested drugs on mice for 60 of them. However, the other patients “either died too soon, or the tumor did not grow in the mice, or the patients are too new to have reached the drug testing stage.”
So in the end, what we have here is an animal model that very well might be predictive of human response in a way that is more direct and individualized. Unfortunately, it’s not ready for prime time, and might never be. Personally, I tend to view this sort of test as a better research tool than actual diagnostic and predictive test, given its expense, how labor intensive it is, and how long it takes. It could, however, be potentially quite useful in testing whether findings in NGS and/or expression profiling data are predictive of response to specific targeted therapies and, in turn, whether response in the mice is predictive of response in humans. In its current form, however, avatars seem far too cumbersome, labor-intensive, and expensive for routine use, even if it’s limited only to patients with advanced tumors.
NOTE: I’m in Chicago right now attending the American College of Surgeons annual meeting, and didn’t have time to produce a new post up to the usual high standards we demand here at SBM. Since several of you requested a discussion of this study, I figured I’d retool a post that I did over at my not-so-super-secret other blog. I’ll be back next week with a new magnum opus.

Will Your Tattoo Give You Cancer: Probably Not…but Maybe?
Do tattoos cause lymphoma? A new study that says “maybe?” is making the rounds but I wouldn’t worry too much.
Clay Jones on June 21, 2024
Link

That didn’t take long. A bit over a month ago I discussed, for the 2nd time, the relationship between tattoos and your immune system. The claim being made by pretty much just the one guy is that tattoos might improve immune function and reduce risk of illness. It was, and continues to be, a ridiculous notion with extremely low plausibility based on a poor understanding of how the immune system works and a few comically bad studies.
So why are we here again talking about tattoos and the immune system? Thanks for asking. Since my previous post on the subject, a study out of Sweden was published in eClinicalMedicine, an open access clinical journal from The Lancet, that has been discussed widely on various forms of media, both social and…anti-social? The sexy headline, often not followed by the appropriate full context, is that tattoos increase your risk of malignant lymphoma by 21%. Sounds scary. But do they? Do they really?
The authors of the study paint a compelling picture, or at least they discuss why there is enough plausibility for there to reasonably be some concern and to justify their investigation, which is the first of its kind:
Tattoo inks are cocktails of organic and inorganic colour pigments, together with precursors and byproducts from the pigment synthesis, and additives. Coloured inks may contain primary aromatic amines (PAA), black inks often contain polycyclic aromatic hydrocarbons (PAH), and metals (i.e., arsenic, chromium, cobalt, lead, and nickel) are found in ink of all colours. A significant and concerning number of chemicals in tattoo ink are classified as carcinogenic by the International Agency for Research on Cancer.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00228-1/fulltext
The IARC, an intergovernmental agency that forms part of the World Health Organization, doesn’t have a perfect track record when it comes to these things. For what it’s worth, they have weighed in on the issue of tattoos and long term risks, particularly cancer. They have this to say in regards to tattoos and their potential carcinogeneity:
Neither tattooing as a lifestyle behaviour nor specific tattoo inks have yet been evaluated by the IARC Monographs programme. However, several substances classified as carcinogenic (Group 1), probably carcinogenic (Group 2A), or possibly carcinogenic (Group 2B) to humans have been identified in tattoo inks; these classifications were based on studies that did not specifically consider the intradermal exposure scenario as seen with tattooing. Although some of these classified substances, particularly metals, were once used as colour pigments, the carcinogens present in tattoo inks today are generally contaminants due to impure raw materials or contamination during the production process.
https://tattoo.iarc.who.int/faq/
As the authors in the Swedish study point out, there is some evidence that these potential carcinogens do not simply stay in the skin where they impress friends, family members, and future employers. Research has found that pigments and metals from the tattooing process end up in regional lymph nodes, and lymph nodes are made up of often rapidly proliferating tissue that is believed to be sensitive to carcinogenic chemicals and the development of DNA mutations. They mention that exposures to “solvents, flame retardants, pesticides, and hair dyes” are increasingly believed to be involved in the development of malignant lymphoma, so why not chemicals found in tattoo inks?
As discussed in the many news articles written about this paper, the authors did indeed find that tattoo exposure was associated with a 21% increase in the diagnosis of malignant lymphomas. But we need to look closer at the study methodology before getting too worked up. First off, this was a case-control study that set out to compare all the people in Sweden aged 20-60 years who were diagnosed with malignant lymphoma between 2007 and 2017 to a bunch of random age- and sex-matched controls who weren’t. They then retrospectively determined who had tattoos and who didn’t, along with a number of tattoo exposure variables, and used multivariable logistic regression to determine the incidence of rate ratio of lymphoma in people with tattoos. Huzzah!
Of the nearly 12,000 potential study subjects, a little over half of those with lymphoma (1,398) and just under half of the controls (4,193) responded. 21% of subjects with lymphoma had tattoo exposure compared to 18% of those with none, resulting in an incidence rate ratio of 1.21, which is where the 21% relative risk increase comes from. Yes, we are talking about relative risk. And malignant lymphoma is not a particularly common cancer, with a lifetime cumulative non-Hodgkin lymphoma (about 85-90% of lymphoma cases) risk of 0.72% in men and 0.35% in women worldwide. Lymphoma rates vary from country to country, with some having higher incidence than others, but compare that to colon cancer’s lifetime risk of 4.4% in men and 4.1% in women.
There are many known and suspected risk factors for lymphoma. Family history, medications, autoimmune disorders, and infections with certain viruses, like Epstein-Barr virus, are just a few examples. It is exceedingly difficult to tease out many of these potential variables in a retrospective study, meaning that it is entirely possible that the study finding is just statistical noise. It is perhaps even likely that it is. And a confidence interval (0.99-1.48) that includes 1 does not inspire…trust?
There were a few other tidbits from the study that are worth noting, though they should also be taken with a grain of salt. In fact, they probably make the overall finding more suspicious. Risk of lymphoma was higher when tattoo exposure occurred less than two years before a cancer diagnosis, which strikes me as odd, but also when a first tattoo was at least 11 years old, which makes more sense. Cumulative and higher exposure to mutagens should increase risk, but there was not any apparent increase in risk from having a larger total tattooed body surface area. Finally, some lymphomas appeared to be more common than others in subjects with tattoos compared to those without.
I can’t help but worry that this is all just an example of the Texas Sharpshooter fallacy, the most famous example of which (to me) being the uproar over power lines causing leukemia in Swedish children. To be fair, the authors of the study are aware of the many limitations and attempt to address them. Many of these assumptions are a stretch, in my humble opinion. Ultimately, I think we can all agree that it is impossible to put too much stock in an observational and retrospective study like this one.
More and better research is needed to come close to answering the question of whether or not tattoos play a role in the development of lymphoma or any health problems. According to an interview of the lead researcher, the team is also looking into any link between tattoos and skin cancer as well as autoimmune disease. They really seem to hate these cans…I mean tattoos. The IARC is working on a prospective cohort study that is better designed to shed some light, but we won’t have results for many years.
What should people do in the meantime? Eat a healthy diet. Exercise regularly. And put down those cigarettes and that yard of ale. I honestly wouldn’t lose much sleep over the risk of cancer from a tattoo, but different people may have less comfort with uncertainty. If you do get some ink, just make sure that they use a clean needle.

Infectious Diseases and Cancer
Mark Crislip on September 30, 2016
Link


With apologies to my colleagues, but infectious diseases really is the most interesting specialty in medicine. There are innumerable interesting associations and interactions of infectious diseases in medicine, history, art, science, and, well, life, the universe and everything. ID is so 42.
A recent email led me to wander the numerous interactions between infections and cancer.
There are the cancers that are caused by infection. HPV and cervical and throat cancer. EBV and lymphoma. HHV8 and Kaposi’s Sarcoma. I certainly hope I am not reincarnated as a Tasmanian Devil.
There are the less clear cut causations/ associations, like toxigenic Bacteroides fragilis and bowel cancer or a scar carcinoma in tuberculosis. It is an interesting area of research but still unsettled.
Cancers and infections
Some cancers lead to infections. Bowel cancer makes a matrix not made by normal cells that allows the preferential adherence of Streptococcus gallolyticus, then bacteremia and endocarditis. If you see a patient dying of Clostridium septicum sepsis, they likely have an underlying bowel cancer.
And on and on. ID is all about knowing these odd associations.
But it gets odder.
Infections and cancers
There has long been a peculiar association between having an acute infection and having cancer going into remission. There are numerous case reports of cancer regression after bacterial, fungal, viral, and protozoal infections.
Why? Maybe some tumors are temperature sensitive and die at higher temperature:
Preclinical and clinical studies have shown for decades that tumor cells demonstrate significantly enhanced sensitivity to “fever range” hyperthermia (increasing the intratumoral temperature to 42–45°C) than normal cells, although it is unknown why cancer cells exhibit this distinctive susceptibility.
Fever is mediated in part by the cytokine TNF, aka tumor necrosis factor.
It is a curiosity that was recognized for centuries but first used clinically in the late 1800s by Dr. William Coley, who actually injected live Streptococci and other bacterial products into patients and saw a regression of primarily bone and soft tissue tumors. Infection of live bacteria into patients is not such a great idea, especially in the pre-antibiotic era, so he used killed Streptococci and Serratia with similar results.
Use of toxins and bacteria has become passé for the treatment of cancer, but hyperthermia is still an area of active research in cancer treatment, as is using bacteria to kill tumors. GMO Clostrida spp for example, have been infected into animal tumors with good results.
It is an intervention prone to hype and some curious practices. What a surprise.
Infectious disease (thankfully) isn’t brain surgery
A pair of neurosurgeons at UC Davis had to quit after they infected brain tumor patients with bowel bacteria, one of whom died of sepsis. They used Enterobacter aerogenes, a reasonably hard organism to kill, and reinforces why saying something isn’t brain surgery is, from an internist’s perspective, not really saying it is all that difficult. Neurosurgeons operate on brains but it doesn’t follow that theirs is particularly high functioning.
And there is a case that I remember but cannot find (false memory?) of a lab tech who tried to cure his own cancer (lymphoma?) by injecting E. coli (?) into his bloodstream. It did not affect the cancer but he did get septic and almost died. I probably should delete the prior sentence but I am hoping one of my readers with better Google-Fu than I can find the reference.
Of course the pseudo-medicine world takes advantage of this curiosity by offering saunas and other forms of heat as cancer treatment, assuming that all cancers are susceptible to increased temperature. Often heat is combined with other pseudo-medicines with the expected results. From what I can tell from the web, it is promulgated more in Europe that in the US as a cancer cure.
Most of the cancer patients I see have fevers, often from infection, and neither the infection nor the fever is all that salubrious. For some cancers fever is a presenting sign, such as the classic Pel-Ebstein fever of lymphoma, doing the malignancy little if any harm. Fever as a cancer treatment is interesting phenomena but not the be all and end all of cancer therapy.
Cancer, childhood infections, and disease
And then there is the literature that suggests childhood infections, especially the vaccine preventable infections, prevent adult cancers.
It is a most unimpressive literature fraught with methodological bias, the most important being relying on memory and questionnaires for past infections.
One study notes:
A history of common colds or gastroenteric influenza prior to the interview was found to be associated with a decreased cancer risk…There was no apparent relationship between childhood infections or other diseases reported in the earlier history, and cancer risk.
To which I say, what the hell is gastroenteric influenza?
“Febrile infectious childhood diseases in the history of cancer patients and matched controls,” published in Medical Hypotheses, found in patients in an Anthroposophic medical practice, a decrease in cancers associated with measles, mumps, rubella, pertussis, scarlet-fever and chickenpox as a child. Another study suggests an association between measles and a decreased risk of lymphoma.
There are variable results when looking for an association:
In this pre-vaccination cohort, childhood infection with measles and influenza were associated with a reduced risk of death from cancer in adulthood, while pertussis was associated with an increased risk.
Others find no, or worse associations:
We could not confirm the results of former studies which assumed a preventive effect of childhood diseases and fever on the cancer risk. On the contrary, on the basis of this investigation one might postulate a 2- to 3-fold rise of the cancer risk by mumps or whooping cough.
Or:
These results offer little support for either a protective effect of enhanced immune surveillance or a harmful effect from antigenic stimulation in relation to risk for acute leukemia in adults
Although doing phone interviews may have increased the risk of brain tumor (sarcasm).
It is a curious literature but nowhere near robust enough to draw a conclusion. You know the old skeptical saw, association is not causation. And one would have to wonder how these infections, each involving different pathophysiologies in the primary disease, could have an effect on so many different tumors of such radically different origins so many years later.
From a causal perspective and the wide variations in effect it seems more noise than real. As one author noted:
However, the associations between cancer risk and childhood infectious diseases are intriguing.
But has I have learned in the last 35 years, most intriguing ideas are not valid upon further testing.
As an excuse to avoid childhood vaccinations, the literature is not convincing. The known mortality and morbidity of vaccine-preventable illnesses far outweigh the maybe of cancer prevention.
And if worried about future cancer, I would assume the HPV vaccine would be high on such a todo list.

Sharks Get Cancer, Mole Rats Don’t: Clues to Understanding Cancer
Harriet Hall on May 3, 2016
Link
We think of cancer as caused by mutations. Mutations are necessary, but not sufficient, to cause cancer. New research indicates that it’s the body’s response to mutant cells that determines whether cancer will develop. James S. Welsh, MD, a radiation oncologist and researcher, has written a book on the immunology of cancer, Sharks Get Cancer, Mole Rats Don’t: How Animals Could Hold the Key to Unlocking Cancer Immunity in Humans. In it, he pieces together clues from animals, pregnancy, Ebola virus, infections, organ transplantation, parasites, and human cancer patients, weaving a web of insights that point to a better understanding of cancer biology and treatment.
Sharks do get cancer

The first book claiming that sharks don’t get cancer came out in 1992. It persuaded so many people to take shark cartilage that the world market exceeded $30 million and shark populations decreased by as much as 80%. Sharks do get cancer, as you can see in this picture.
Ironically, sharks can even get cancer of the cartilage! And of course shark cartilage supplements don’t prevent cancer in humans. Welsh explains how that myth got started. It was magical thinking based on extrapolation from a legitimate scientific study on angiogenesis where tumor growth in lab animals was suppressed by placing rabbit cartilage next to the tumors.
Mole rats don’t
The naked mole rat (which is neither a mole nor a rat) may be the world’s ugliest animal. It has been compared to a miniature pink walrus, a saber-toothed sausage, and a bratwurst with teeth.
Naked mole rats have a number of unusual features: low oxygen consumption, an ability to slow their metabolism, a variable body temperature, and skin insensitivity to pain. And they are immune to cancer. If only we could understand how they accomplish that, we might be able to apply the knowledge to prevent cancers in humans. There are some clues. They have massive hyaluronan molecules that physically space their cells apart, they have a p16-mediated aversion to cellular crowding, and their biochemical protein synthesis mechanisms are unusually error-free. Their cells are also resistant to death by apoptosis and are more likely to undergo necrotic cell death.

Cancer immunity is also found in specially bred lab mice that overexpress a cancer-fighting gene called PAR4. Gene expression of PAR4 can be stimulated in other animals by a secretagogue. There is also a natural mutant “mighty-mouse” that passes on cancer resistance by autosomal dominant inheritance. These mice rarely get cancer, and if they do, it spontaneously regresses. And when white blood cells from mighty-mice were injected into mice with advanced cancers, it cured them! We can’t give mouse blood to humans, but understanding what is happening here could eventually lead to human treatments.
Abscopal effects
Welsh tells us about two of his own patients whose terminal cancer was treated with local radiation for palliative purposes only. He was amazed to see all evidence of cancer vanish from the entire body, a rare phenomenon known as the abscopal effect. Abscopal means “away from the target,” where local treatment causes a systemic response. Spontaneous remissions can occur even in the most advanced metastatic cancer. If only we could understand what is happening in those cases and harness it!
Cancer is not contagious
Scientists have always maintained that cancer is not contagious. You can’t catch it like you catch a cold. But it turns out you can catch it if you are a Tasmanian devil. The population of Tasmanian devils has been decimated by devil facial tumor disease (DFTD) a cancer that is passed from animal to animal through bites. The tumor is a bizarre new life form that has achieved immortality by passing itself on from individual to individual like some alien parasite. No other cancer is contagious in this sense; but as many as 15% of cancers are caused by viruses that are contagious, like HPV and hepatitis B.
Dogs get a contagious cancer called canine transmissible venereal tumor (CTCT). It is sexually transmitted and affects the penis. It accounts for up to 29% of all dog tumors in places like India where neutering is not common. Interestingly, it often undergoes spontaneous and permanent remission. In healthy adult dogs it typically progresses for 2-6 months, is stable for a while, and then regresses. In immunosuppressed dogs, it continues to grow and it metastasizes. It is exquisitely sensitive to radiation, and a radiation cure leaves the dog permanently immune to this type of cancer. It can pass to other species including coyotes, foxes, and jackals, which is really weird because of the barriers posed by the major histocompatibility (MHC) system. It has been suggested that the MHC system might have evolved to prevent tumors from being transplanted and that without it, contagious tumors might be more common.
Don’t blame cancer on modern lifestyle
Cancer is not a disease of civilization or of modern lifestyles. It’s a fact of nature. It’s been around at least since the Cretaceous: dinosaurs got it. It has been demonstrated in the remains of early humans. 50% of domestic dogs get cancer by the age of 10. Clams get cancer. Tapeworms get cancer (and that cancer has been known to spread throughout the body of their human host). Plants get cancer, although their rigid cell walls prevent metastasis.
Lessons from parasites
Cancer can be thought of as a sort of unsuccessful parasite that dies when it kills its host. The cancer in Tasmanian devils has found a way out. Perhaps we can find clues in the behavior of other parasites. The Ebola virus escaped from a natural reservoir to infect human hosts, where it is very successful at propagating itself. It first silences the immune cells intended to detect and destroy it. It lulls them into inaction until it is too late; then when they finally wise up, they overreact with a cytokine storm that does more harm than good. Those in the 15-45 age group, the group with the strongest immune systems, are the most likely to die.
Clues from organ transplants
Sometimes cancers are inadvertently transplanted along with organs. If the immunosuppressive treatment is stopped, the cancer ought to be rejected along with the transplanted organ. But it isn’t. It seems to have developed a cloak of invisibility. In one case, a man died of ovarian cancer after a transplant from a woman.
In another case, a kidney donor had been treated for melanoma 32 years earlier and was considered cured, but melanoma was transplanted along with the kidney; apparently he had been sheltering a few malignant cells in his kidneys all those years.
There is an increased risk of cancer with transplantation and lifelong immunosuppression. Squamous cell skin cancers in transplant patients behave differently: they metastasize and are very aggressive.
These are tantalizing clues to something, but what?
Coley’s toxins: sometimes they worked!
After severe infections, tumors sometimes regress. In the 1890s, William Coley experimented with injecting streptococcal organisms into patients with advanced cancers. His patients usually developed a severe infection with high fevers, and many of them died; but a few survived and became cancer-free. “Coley’s toxins” were discredited and abandoned, but the possible mechanisms for his inconsistent successes are being looked at again.
Is cancer a disease of aging?
It’s logical that the older you get, the more likely you are to develop cancer, because you have had more time to develop mutations; but what if the association of cancer with aging is due to a waning of immunity with age? What if we are constantly developing cancer cells that are being suppressed by our immune systems? Perhaps some are being eliminated and some are merely being kept under control so we can live with them without harm.
Are we asking the wrong questions? Instead of asking why smokers are more likely to develop lung cancer, maybe we should ask why most smokers don’t get it, and why Uncle Joe remained in good health to the age of 102 despite smoking, drinking, eating junk food, and being exposed to toxins. Why are some people resistant to cancer? There is an autosomal-recessive hereditary condition called Laron dwarfism where the affected people never get cancer. What’s more, they don’t develop diabetes despite being obese.
Pregnancy
In pregnancy, a fetus must escape immune surveillance and not be recognized as “foreign.” The mechanism is not well understood, but it seems that the placenta acts as an immune regulatory organ to protect the embryo. There is a rare condition called a hydatidiform mole where an “empty” ovum is fertilized by sperm. 15-20% of these become malignant. But they have no maternal DNA; they are entirely foreign male tissue. Why are they not rejected by the immune system? Molecules are being discovered that are common to both fetal protection and cancer protection. In the microenvironment of the cancer, the immune system acts to protect the cancer just as the placenta protects the fetus.
Conclusion: A great book about a terrible scourge
This is an outstanding book. It combines a fun trip to the zoo with an introductory course in cancer immunology. It’s full of weird facts that you can repeat as trivia to impress your friends. I could only sample its riches here. There is much more in the book, with details and copious references. The subject is endlessly fascinating, and the writing style is clear, appealing, and accessible, broken into 36 short, easily-digested chapters. This is cutting edge hypothesis-generating science pointing to exciting discoveries sure to come in the near future.
As Dr. Welsh concludes:
Years of skepticism about cancer immunotherapy are finally fading… The revolution is on!

A brief note on killing cancer cells in a dish
David Gorski on May 27, 2013
Link

I am taking the Memorial Day holiday off. I will return next week (or even earlier if something comes up that I can’t resist blogging about). In the meantime, here’s a general principle that needs to be remembered in cancer research:
I would also add to that list: So does bleach. So does acid. So does alkali. So does pouring the media out of the dish and letting the cells dry out. So do a variety of lethal poisons. So does heat. So does cold. The list goes on.
The point, of course, is that it’s very easy to kill cells in a cancer dish. What is difficult is selectively killing cancer cells in the human body while not harming normal cells.
See you all next week!

Confusing overdiagnosis for an “epidemic” of thyroid cancer in Japan after Fukushima
David Gorski on March 14, 2016
Link


One of my favorite topics to blog about for SBM is the topic of overdiagnosis and overtreatment. These are two interrelated phenomena that most people are blissfully unaware of. Unfortunately, I’d also say that the majority of physicians are only marginally more aware than the public about these confounders of screening programs, if even that.
Overdiagnosis has long been appreciated to be a major impediment to translating programs to screen for disease into better outcomes in a number of diseases but has only recently really seeped into the public consciousness, beginning in particular in 2009 when the United States Preventative Services Task Force (USPSTF) issued mammography recommendations that pushed back the recommended age to start screening to 50. Certainly, the concept of overdiagnosis is counterintuitive. After all, why do we screen for disease in asymptomatic people? The reason is simple—and maddeningly intuitive. We screen for disease based on the belief that catching potentially deadly diseases like cancer early, before they produce clinical symptoms, will allow earlier intervention and save lives. It seems blindingly obvious that this should be the case, doesn’t it? Unfortunately, real life biology and pathophysiology aren’t quite so neat and tidy, and the relationship between early detection and improved survival is muddied by phenomena such as lead time bias and the Will Rogers effect, in addition to overdiagnosis.
What is overdiagnosis? In brief, it is the detection of pathology or disease that, if left untreated, would never endanger the life of a patient or even harm him. Note that overdiagnosis is not the same thing as a false positive. A false positive occurs when a test detects disease that isn’t really there; in contrast with overdiagnosis there is definite pathology. The disease being screened for is there, at least in an early form. It’s just that, at the very early stage detected, it’s either not progressive or so indolent that the patient will grow old and die of something else before it would ever cause a problem. Indeed, it’s been estimated that as many as one in three breast cancers detected by mammography in asymptomatic women might be overdiagnosed and that one in five might spontaneously regress. However, because we don’t know which ones are unlikely to cause harm and haven’t worked out a safe method of observing them and intervening if they look as though they are progressing, we are obligated to treat them all when discovered. The problem of overdiagnosis has led to multiple alterations in what once were considered definitive recommendations for screening mammography, first by the USPSTF and most recently by the American Cancer Society.
You can see how this might be the case if you consider two examples I discussed in an old post. First, in autopsy series, foci of prostate cancer can be found in at least 75% of men over the age of 80; yet the vast majority of men who die after age 80 die of something other than prostate cancer. Second, in autopsy series, thyroid cancer can easily be found in 36% of adults, and investigators have estimated that if the slices were made thinly enough for microscopic examination they could have “found” thyroid cancer in close to 100% of adults between 50-70, even though clinically apparent thyroid cancer receiving treatment only had a prevalence in the population studied of around 0.1%.
Overdiagnosis has become such an important topic that it’s been written about extensively on SBM, mostly by Harriet Hall and myself, with respect to diseases like prostate cancer, breast cancer, and thyroid cancer.
Speaking of thyroid cancer…
Fukushima and the “epidemic” of thyroid cancer in children
If there were ever a better example of the adage, oft-stated by yours truly, that the more intensively you look for a disease the more of it you will find, it’s hard to find a better example of this than the aftermath of the March 2011 meltdowns at the Fukushima Daiichi Nuclear Power Plant in Japan as a result of damage sustained a tsunami that hit Japan. It was the largest nuclear disaster since Chernobyl in 1986, and its effects are still being felt.
Now here’s where overdiagnosis is illustrated. An article in Science from earlier this month reported:
Months after the disaster, Fukushima Prefecture set about examining the thyroids of hundreds of thousands of children and teens for signs of radiation-related cancers. The screening effort was unprecedented, and no one knew what to expect. So when the first round of exams started turning up thyroid abnormalities in nearly half of the kids, of whom more than 100 were later diagnosed with thyroid cancer, a firestorm erupted.
Does this sound familiar? First, consider that the amount of radiation emitted by the Fukushima reactors was one-tenth that emitted by Chernobyl and that, as reported in this article, the World Health Organization (WHO) estimated that the 12 to 25 mSv of exposure in the first year after the accident in the hardest hit areas might result in tiny increases in cancer incidence. By way of comparison, people receive around 2.4 mSv of background radiation per year and a chest X-ray delivers around 0.1 mSv (here is a a handy visual comparison from xkcd). So why did the Fukushima Prefecture undertake this screening program? Here’s why:
Memories of Chernobyl got Japanese authorities worrying about thyroid cancer. The fallout from that April 1986 accident included radioactive iodine, which settled across swathes of Belarus, Russia, and Ukraine, contaminating pastures grazed by dairy cows. Children who drank the tainted milk accumulated the radioactive iodine in their thyroids. (Adult thyroids absorb less iodine.) A 2006 World Health Organization (WHO) study found that in the most contaminated areas, there had been about 5000 thyroid cancer cases among those who were under 18 at the time of the accident, though the report noted that more cases could emerge over time. The United Nations in 2006 attributed 15 childhood thyroid cancer deaths to Chernobyl. Caught early, the cancer is almost always cured by removal of the thyroid gland.
The WHO had also estimated that the thyroid-equivalent doses in 2011 were between 100 and 200 mSv in the worst-hit areas and 10-100 mSv elsewhere in the Fukushima Prefecture as delivered by inhalation, external exposure from groundshine (radiation emitted from isotopes that land on the ground), and ingestion. So it was not unreasonable that there might be an increase in thyroid cancer among people who were under 18 at the time of the disaster. However, the WHO also noted in 2013 that intensive screening for thyroid cancer was likely to increase the prevalence of thyroid cancer solely through a screening effect, which is basically another term for overdiagnosis.
The results of the screening program thus far were reported in an October 2015 article published in Epidemiology by an environmental epidemiologist at Okayama University named Toshihide Tsuda, entitled “Thyroid Cancer Detection by Ultrasound Among Residents Ages 18 Years and Younger in Fukushima, Japan: 2011 to 2014.” In it, Tsuda et al examined data from the screening program. Basically, all residents 18 years old and younger in March 2011 were screened by ultrasound during the 2011-2013 fiscal years according to the nearest area first, in 2011; the “middle area” second in 2012; and the “least contaminated area” in 2013. “Nearest area” denotes the area closest to the plant which was the most contaminated, while “middle area” and “least contaminated” area denote the areas further away with decreasing levels of contamination. A second round of screening began in April 2014 and is scheduled to be completed this month.
Positive findings were handled thusly:
Subjects with positive findings received a secondary examination, and if necessary, underwent fine needle aspiration. When cancer cells were detected, the patient was followed and operated on at an appropriate time. The excised thyroid tissue was examined histologically. Explanations about medical decisions, such as timing of fine needle aspiration and surgery, were not made publicly available by the prefecture. In addition to the progressive course of the disease, a patient’s school schedule was also considered in the timing of procedures because of the need for hospitalization. Based on information from Fukushima Prefecture, most fine needle aspirations and surgeries were performed by doctors from Fukushima Medical University.
Overall, of 367,687 residents were screened in 2011, 298,577 (81%) underwent the first round screening by the end of December 2014, with the proportion of residents of the respective areas who had undergone screening being 88% in 2011; 87% in 2012; and 74% in 2013. Basically, Tsuda et al found between 0 and 605 cases per million in the various areas
Further results:
Among 2,251 ultrasound screen-positive cases by the end of December 2014, 2,067 cases were examined in secondary examinations, which detected 110 thyroid cancer cases, as indicated by the presence of cancer cells by cytology after fine needle aspiration. Among the 110 cases, 87 cases were operated by the end of December 2014: 86 cases were histologically confirmed (83 papillary carcinomas and three poorly differentiated carcinomas), and one case was diagnosed as a benign tumor.
Overall, according to Tsuda et al, this finding represents an approximately 30-fold increase in the number of thyroid cancer cases among children and adolescents in the Fukushima Prefecture. Not surprisingly, there was considerable alarm after the publication of these results that still persists until today. Just last month, for instance, The Telegraph published the alarming headline “Fukushima disaster: Children cancer rates rise with 16 new cases.” Back around the time this study was first published online, it wasn’t uncommon to see articles and posts with titles like ‘Fukushima: “Alarming” Rise in Child Thyroid Cancer Rates‘ and “Researcher: Children’s cancer linked to Fukushima radiation.” Even the occasional medical site fell for the hype.
There is almost certainly no “thyroid cancer epidemic” in Fukushima
This study is, not surprisingly, being held up as evidence that there is a radiation-induced “epidemic” of thyroid cancer in Fukushima Prefecture, all due to the meltdown of the nuclear reactor. But is there? The authors of the study itself acknowledge that at least some of the increase could be due to the “screening effect” (or, as I call it, overdiagnosis) detecting silent thyroid cancers in children but blithely dismiss this possibility as unlikely “magnitude of the IRRs was too large to be explained only by this bias.” This, of course, leads to the question, “How could Tsuda know this?” The answer to that question is obviously, “He can’t.” First, he doesn’t compare his results to the known prevalence of small, subclinical thyroid cancer in children, which, admittedly, is difficult to know because autopsy series of children are hard to carry out. Second, he doesn’t know that the apparent prevalence of a disease can’t be increased by 30-fold by vigorous screening. We know, for instance, that the prevalence of ductal carcinoma in situ has increased at least 16-fold since mammographic screening began in the 1980s, all due to mammographic screening, as I have discussed on several occasions before.
Perhaps his strongest argument is that 40 of 54 cases operated on in the Fukushima Prefecture had positive lymph nodes. However, looking at the report cited by Tsuda and using a bit of the old Google Translate (the document is in Japanese), I see that 52 of the 54 cases showed papillary carcinoma, which is the most common (and least aggressive) form, and it’s not clear to me, due to the limitations of Google Translate, exactly what was found in all these cases. On the other hand, it strains credulity to believe that the relatively small dose of radiation to which the children of these areas were exposed could result in thyroid cancers, including node-positive thyroid cancers, in such a short period of time. Remember, these are primarily the results of the first screening, some of which occurred less than a year after the meltdowns. In cancer biology, that’s a short period of time.
It turns out that the reaction to Tsuda’s paper among epidemiologists wasn’t so favorable, though. For example:
Scientists emphatically disagree. “The evidence suggests that the great majority and perhaps all of the cases so far discovered are not due to radiation,” says Dillwyn Williams, a thyroid cancer specialist at University of Cambridge in the United Kingdom. In journal papers and in a series of letters published last month in Epidemiology, scientists have attacked the alarmist interpretations. Many acknowledge that baseline data from noncontaminated areas were needed from the outset and that the public should have been better educated to understand results and, perhaps, to accept watchful waiting as an alternative to immediate surgery. But most also say the findings hint at a medical puzzle: Why are thyroid abnormalities so common in children? The “surprising” results of the screening, Williams says, show that “many more thyroid carcinomas than were previously realized must originate in early life.”
Indeed, at the time Tsuda’s report was published, there was even an accompanying editorial by Scott Davis, who noted:
As stated at the beginning, this commentary is intended to broaden the context or perspective from which the report by Tsuda and colleagues can be evaluated. I have highlighted some of the major challenges faced in a large-scale disaster of the kind experienced in Fukushima, particularly regarding the collection of data from individuals. In this respect, it was not possible to collect the detailed data needed to estimate an individual radiation dose. Therefore, the findings cannot contribute to the two most urgent scientific questions: the characteristics of the dose response curve at low doses, and the details of the role of other factors that might modify the risk of thyroid cancer associated with radiation exposure. Similarly, these findings do not add anything new regarding radiation-induced (or related) thyroid cancer.
Davis further noted that, “given the preliminary geographic dose estimates, any excess of cases due to radiation from the Fukushima plant would be too small to detect using epidemiologic methods,” and that the primary usefulness of Tsuda’s work is to help the Japanese government decide how to allocate health care resources for the victims of Fukushima.
The letters received by Epidemiology from radiation biologists, physicists, and epidemiologists were scathing. For instance, it was noted that the authors used an unvalidated method to estimate IRRs, that the study design was not clearly labeled as an ecological study (for more on ecological studies and the ecological fallacy that vastly overestimates correlations, go here), and, of course, that there could indeed be a massive increase in prevalence due solely to a screening effect, as Richard Wakeford and colleagues point out:
Thyroid disease screening with ultrasound can have a dramatic effect on the detection of thyroid nodules. A 15-fold increase in the incidence of thyroid cancer occurred in South Korea after the introduction of a national cancer screening program in 1999, with the incidence rate in regions increasing in direct proportion to the proportion of screened people. Consequently, it is inappropriate to compare the data from the Fukushima screening program with cancer registry data from the rest of Japan where there is, in general, no such large-scale screening. The proper comparison is between different screened areas within Fukushima Prefecture, since significant radioactive contamination from the accident was confined to a relatively small part of the prefecture.
There is no statistically discernible difference in thyroid cancer prevalence between the low, intermediate and high contamination areas of Fukushima Prefecture. The prevalence ratio (PR) for the highest to lowest contamination areas was 1.08 (95% CI: 0.60, 1.96), and the highest prevalence was seen in the area with an intermediate level of contamination (PR= 1.21 (95% CI: 0.80, 1.82)). Further, the measured levels of radioactivity in thyroids in Fukushima Prefecture were far lower4 than would be needed to elevate cancer rates as much as Tsuda et al.1 claim.
But here’s the letter that really demonstrates that Tsuda’s study does not identify that there is any sort of thyroid cancer “epidemic.” It’s by Noboru Takamura at the Department of Global Health, Medicine and Welfare, Atomic Bomb Disease Institute, Nagasaki University:
We recently conducted thyroid ultrasound screening, using the same procedures as the Fukushima Health Management Survey, in 4,365 children aged 3–18 years from three Japanese prefectures, and confirmed one patient with papillary thyroid cancer (prevalence, 230 per million). Furthermore, we recently reviewed findings of thyroid ultrasound screening conducted in Japan.3 In one survey, 9,988 students underwent thyroid screening and four students (including one foreign student) were subsequently diagnosed with thyroid cancer (prevalence, 300 per million). In another study at Okayama University that examined 2,307 students, three patients with thyroid cancer were found (prevalence, 1,300 per million), while at Keio High School, of 2,868 female students examined, one was found to have thyroid cancer (prevalence, 350 per million). These results show that the prevalence of thyroid cancer detected by advanced ultrasound techniques in other areas of Japan does not differ meaningfully from that in Fukushima Prefecture.
In other words, putting it all together, when advanced ultrasound techniques are used to screen for thyroid cancer in children in Japan, there is no detectable difference between the prevalence of thyroid cancer in children in the three areas Tsuda et al surveyed, and there is no detectable difference between the prevalence of thyroid cancer detected this way in the Fukushima Prefecture and that observed in other studies examining students in other parts of Japan. Tsuda’s study is not good evidence that radiation from Fukushima has created an “epidemic” of thyroid cancer.
Overdiagnosis again
The health authorities in the Fukushima Prefecture were well-intentioned, and, in reality, I can’t really fault them for wanting to determine whether the nuclear accident at Fukushima would result in a detectable increase in thyroid cancer in children, given that there is good evidence that radiation to the neck during childhood can increase the risk of this particular cancer. However, it’s clear that many of the doctors involved, although they recognized the issue of overdiagnosis as a potential confounder, didn’t understand just how much overdiagnosis (or, if you prefer, the screening effect) can increase the apparent prevalence of the disease being screened for. If you don’t go into such a massive population screening effort with your eyes wide open, you can easily be fooled into thinking a disease has become a lot more common when in fact all that’s happened is that you’re finding more of it because you’re looking for it a lot harder.
Unfortunately, such findings can cause harm. Besides the anxiety finding such lesions causes patients and their families, virtually all of the children in whom small cancers were found underwent total thyroidectomy, some with removal of the lymph nodes in their central neck. Thyroidectomy is a safe operation, but nonetheless carries the risk of damage to the recurrent laryngeal nerve, which can cause hoarseness due to paralysis of one of the vocal cords, or to the superior thyroid nerve, which can cause permanent changes to the voice. There is also a risk of damage to the parathyroids and permanent hypoparathyroidism. These risks are small but real. Finally, a guaranteed outcome of a total thyroidectomy is the life-long need to take thyroid hormone supplements. Given how uncommon thyroid cancer is throughout life, it’s highly likely that the vast majority of these children did not need to have their thyroids removed.
Dillwyn Williams is quoted near the end of the article as saying that the “surprising” result of Tsuda’s study is that “many more thyroid carcinomas than were previously realized must originate in early life.” I’m not sure why Williams considers that finding so surprising. I suppose it could be considered a surprise that so many more children have small cancers in their thyroid glands than expected, but it shouldn’t be as big a surprise as Tsuda, Williams, and many others view it. When you look for disease carefully and aggressively, you will always find a lot more of it. Then you’re confronted with the dilemma of what to do with it, given that it is subclinical and you don’t know if it will ever progress to cause harm to the patient.
None of this is to say that screening programs don’t save lives. Clearly they do. It’s just that it’s rarely as many lives saved as people assume, because the relationship between early detection and saving lives is nowhere near as clear as people view it. The thyroid screening program launched in the wake of the Fukushima disaster illustrates that very starkly.

Reclassifying thyroid cancer and the willful misunderstanding of overdiagnosis
David Gorski on April 25, 2016
Link


If there’s one lesson that we here at Science-Based Medicine like to emphasize, it’s that practicing medicine and surgery is complicated. Part of the reason that it’s complicated is that for many diseases our understanding is incomplete, meaning that physicians have to apply existing science to their treatment as well as they can. The biology of cancer, in particular, can be vexing. Some cancers appear to progress relentlessly, meaning that it’s obvious that all of them must be treated. Others, particularly when detected in their very early stages through screening tests, have a variable and therefore difficult to predict clinical course if left untreated. Unfortunately, some people, such as Sayer Ji, don’t understand that. They like their medicine black and white, and if physicians ever change guidelines in order to align them more closely with scientific understanding, they write blisteringly ignorant articles like “‘Oops… It Wasn’t Cancer After All,’ Admits The National Cancer Institute/JAMA.”
Not exactly. An expert panel recommended reclassifying a specific thyroid lesion as not cancerous based on recent science. It’s called medicine correcting itself. Admittedly, this reclassification was probably long overdue, but what would Mr. Ji rather have? Medicine not correcting itself in this situation? In any case, when last I met Mr. Ji, he was happily abusing the science of genetics to argue that Angelina Jolie and other carriers of deleterious cancer-causing mutations don’t need prophylactic surgery because lifestyle interventions will save them through epigenetics, which to “natural health” enthusiasts like Mr. Ji seems to mean the magical ability to prevent any disease. Most recently, he has appeared on the deeply dishonest “documentary” about alternative medicine cancer cures, The Truth About Cancer, to expound on how chemotherapy is evil. His rant about the reclassification of a non-encapsulated follicular variant of papillary thyroid cancer as not cancer is more of the same, as you will see.
Overdiagnosis and the question of what is and isn’t “cancer”?
The sort of issue mangled by Mr. Ji in his article is one that those of us who treat breast cancer have been dealing with for a long time now. For example, as a breast cancer surgeon, I deal all the time with a disease entity known as ductal carcinoma in situ (DCIS). Basically, it’s a condition in which cancerous-appearing cells are found in the milk ducts of the breast but have not crossed the basement membrane, which surrounds the milk ducts. Generally, we consider DCIS to be stage 0 breast cancer, specifically cancer that hasn’t invaded through the basement membrane into the breast yet. Of course, as I’ve written before many times, it’s not as simple as that. Many—probably most—DCIS lesions never progress to cancer in the patient’s lifetime, particularly the so-called low grade lesions, which are called low grade because their cells resemble normal milk duct cells. On the other hand, higher grade lesions, which look more like frank cancer, likely progress to cancer at a much higher rate. However, because we have no reliable means of predicting which DCIS lesions will progress to invasive cancer and which will not, we end up treating them all in basically the same way: surgical excision plus or minus (usually plus) radiation plus or minus an estrogen-blocking drug.
Confusing the question of treatment of very early stage breast cancer is the apparent massive increase in incidence of DCIS over the last 40 years. Basically, as I’ve described multiple times before, the incidence of DCIS has increased 16-fold since 1975. Given that it’s highly implausible and unlikely that the “true” incidence of DCIS has increased so markedly in such a short time (and three or four decades is a short time for a change this massive), the likely explanation is the institution of widespread mammographic screening programs beginning in the early 1980s, leading to overdiagnosis.
Overdiagnosis is a phenomenon that’s been discussed here many times, both by myself and Harriet Hall. Basically, it is the detection of disease that would never go on to harm or kill the person harboring it. If there’s one thing that the mass screening of large asymptomatic populations for diseases has taught us, it’s that there’s a lot more preclinical disease out there in healthy people than we had previously suspected, or, as I put it, if you look very hard for a condition you will find more of it. Always. Indeed, thanks to a mass thyroid screening program after the Fukushima nuclear disaster, we recently learned that even children have way more preclinical thyroid cancer than we had previously thought. As I’ve discussed before, in autopsy studies half of men over 65 and three-quarters of men over 80 have tiny foci of cancer in their prostates; thyroid cancer can be found in 36% of adults, and the study’s investigators estimated that if the slices had been made thinly enough for microscopic examination they could have “found” thyroid cancer in close to 100% of adults between 50-70, even though clinically apparent thyroid cancer requiring treatment only has a prevalence in the population studied of around 0.1%. In breast cancer, it has been estimated that as many as one in three mammographically detected cancers in otherwise asymptomatic women might be overdiagnosed, although other estimates are around 10%. The reason the estimates vary so much is that we can’t do a study in which mammographically detected small invasive breast cancers are not treated is because, even if these estimates are correct, most of them do appear to progress. We’re thus forced to rely on inferences from epidemiological studies. Whatever the true number is, given that there are 240,000 new cases of breast cancer diagnosed every year, overdiagnosis is a huge problem, no matter how much some physicians would try to claim otherwise.
Once we acknowledge the existence of overdiagnosis, the questions then become:
    • Does the disease found at such an early, asymptomatic stage need to be treated?
    • Will treating the disease earlier, before it becomes symptomatic, lead to improved outcomes in terms of survival and/or morbidity?
    • Are these early lesions actually cancer?
The answers to these questions are not straightforward in the least, particularly given how difficult it is to show a survival benefit due to early intervention, thanks to lead time bias and length bias. It is this accumulation of evidence of overdiagnosis that has led to a rethinking of cancer screening and changes in recommended screening guidelines. They’re also leading scientists and physicians to reexamine the classification of cancerous-appearing lesions formerly classified as cancer:
In fact, said Dr. Otis Brawley, chief medical officer at the American Cancer Society, the name changes that occurred went in the opposite direction, scientific evidence to the contrary. Premalignant tiny lumps in the breast became known as stage zero cancer. Small and early-stage prostate lesions were called cancerous tumors. Meanwhile, imaging with ultrasound, M.R.I.’s and C.T. scans find more and more of these tiny “cancers,” especially thyroid nodules.
“If it’s not a cancer, let’s not call it a cancer,” said Dr. John C. Morris, president-elect of the American Thyroid Association and a professor of medicine at the Mayo Clinic. Dr. Morris was not a member of the renaming panel.
Dr. Barnett S. Kramer, director of the division of cancer prevention at the National Cancer Institute, said, “There’s a growing concern that many of the terms we use don’t match our understanding of the biology of cancer.” Calling lesions cancer when they are not leads to unnecessary and harmful treatment, he said.
Exactly. It is entirely rational and scientific to adjust medical nomenclature to reflect more recent science and understanding of disease. Again, doing so is anything but simple, as there will always be disagreements, and, yes, turf wars and fears among some physicians who treat these early lesions of losing business, but just because the renaming process is messy and contentious doesn’t mean there is nefarious intent to it or that there was nefarious intent in the nomenclature being replaced.
Reclassifying thyroid cancer
Mr. Ji, of course, is not interested in any of the complexities briefly touched on above. Rather, he is interested in vilifying “conventional” medicine:
Back in 2012, The National Cancer Institute convened an expert panel to evaluate the problem of cancer’s misclassification and subsequent overdiagnosis and overtreatment, determining that millions may have been wrongly diagnosed with “cancer” of the breast, prostate, thyroid, and lung, when in fact their conditions were likely harmless, and should have been termed “indolent or benign growths of epithelial origin.” No apology was issued. No major media coverage occurred. And more importantly, no radical change occurred in the conventional practice of cancer diagnosis, prevention, or treatment.
No major media coverage? Seriously? Besides Medscape, The Wall Street Journal covered it. So did The New York Times. I remember several stories about it in the national media, including television, at the time. Since then, there’s been a lot of coverage of the scientific controversy about overdiagnosis, particularly due to mammographic screening, in the national and international press. Perhaps Mr. Ji’s memory is faulty.
In any case, the summary to which Mr. Ji refers in his introductory rant is this article published in JAMA in 2013 by Laura Esserman (a breast surgeon whose work I admire) and colleagues. It summarized the NCI panel’s recommendations thusly:
     1.  Physicians, patients, and the general public must recognize that overdiagnosis is common and occurs more frequently with cancer screening.
     2.  Change cancer terminology based on companion diagnostics.
     3.  Create observational registries for low malignant potential lesions.
     4.  Mitigate overdiagnosis.
     5.  Expand the concept of how to approach cancer progression.
Esserman et al concluded:
The original intent of screening was to detect cancer at the earliest stages to improve outcomes; however, detection of cancers with better biology contributes to better outcomes. Screening always results in identifying more indolent disease. Although no physician has the intention to overtreat or overdiagnose cancer, screening and patient awareness have increased the chance of identifying a spectrum of cancers, some of which are not life threatening. Policies that prevent or reduce the chance of overdiagnosis and avoid overtreatment are needed, while maintaining those gains by which early detection is a major contributor to decreasing mortality and locally advanced disease. The recommendations of the task force are intended as initial approaches. Physicians and patients should engage in open discussion about these complex issues. The media should better understand and communicate the message so that as a community the approach to screening can be improved.
In this light, it is easy to see how utterly silly Mr. Ji’s rant is. The task forces’ recommendations were meant as a starting point for discussion, not a pronouncement. Moreover, one could very much view the reclassification of a variant of thyroid cancer as not being malignant as addressing recommendations #2, 4, and 5. Indeed, this is the first time a lesion that had been classified as a cancer has been reclassified as not cancer.
Let’s take a look at the actual study.
When is thyroid cancer not cancer?
The relevant study, whose first author is Yuri E. Nikiforov, vice chairman of the pathology department at the University of Pittsburgh, basically tells you what you need to know: “Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.” There it is right there in the title: This study is addressing recommendations #2 and 4 (at minimum) from the NCI workshop. In fact, it says right in the introduction that that was the purpose of this study! In essence, this paper lays out the case for changing the nomenclature of “encapsulated follicular variant of papillary thyroid carcinoma” (EFVPTC), which is generally treated like thyroid cancer now, to call these lesions “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” (NIFTP). As I’ve discussed before, with the widespread use of thyroid ultrasound, overdiagnosis of indolent thyroid cancers has become a major problem, with large increases in the incidence of these lesions being reported, including noninvasive EFVPTC.
What the authors did was an international, multidisciplinary, retrospective study of patients with thyroid nodules diagnosed as EFVPTC, including 109 patients with noninvasive EFVPTC observed for 10 to 26 years and 101 patients with invasive EFVPTC observed for 1 to 18 years. Noninvasive EFVPTC included EFVPTC that had not invaded through its capsule. Twenty-four pathologists making up the Endocrine Pathology Society working group developed consensus criteria for the diagnosis of EFVPTC, and these were applied to the pathology slides. Molecular analysis of the tumors was also carried out using using ThyroSeq v2, which looks at a panel of 14 oncogenes for mutations.
The authors observed that none of the patients with noninvasive EFVPTC died of their disease in the follow-up period, while five of the patients with EFVPTC developed metastatic disease and two died. Genetic analysis of the lesions showed that noninvasive EFVPTC was predominately driven by mutations in the RAS oncogene, which are associated with follicular thyroid cancer, as opposed to the mutations in invasive EFVPTC, which were driven by BRAF and RET rearrangements, which have classically been associated with papillary thyroid cancer. On the basis of these observations and a review of the literature the authors recommended their proposed name change and listed rigorous, reproducible diagnostic criteria they propose for differentiating EFVPTC from NIFTP. Because approximately 20% of thyroid cancer is EFVPTC, this name change could affect up to 45,000 patients worldwide per year.
The authors conclude:
The results of this study, together with previously reported observations, suggest that when the diagnosis of NIFTP is made on the basis of careful histopathological examination, the tumor will have a low recurrence rate, likely less than 1% within the first 15 years. Of note, most differentiated thyroid carcinomas relapse within the first decade after initial therapy, although late recurrences and distant spread are documented. Importantly, a large proportion of patients with tumors diagnosed as NIFTP in the present study underwent lobectomy only and none received RAI [radioiodine] ablation. This suggests that clinical management of patients with NIFTP can be deescalated because they are unlikely to benefit from immediate completion thyroidectomy and RAI therapy. Staging would be unnecessary. In addition to eliminating the psychological impact of the diagnosis of cancer, this would reduce complications of total thyroidectomy, risk of secondary tumors following RAI therapy, and the overall cost of health care. Avoidance of RAI treatment alone would save between $5000 and $8500 per patient (based on US cost). Decreased long-term surveillance would account for another substantial proportion of cost reduction.
In other words, for this lesion, taking the involved thyroid lobe (or even perhaps just excising the lesion) is probably enough treatment. No completion total thyroidectomy would be necessary, nor would radioactive iodine or follow-up tests to screen for recurrence. The need for lifelong thyroid hormone supplementation would be eliminated in most patients because they would not require a total thyroidectomy.
Where do we go from here?
As hard as it is to come to a science-based agreement on a set of diagnostic guidelines and a reclassification of a disease entity, where the rubber hits the road will be how these recommendations will be viewed by practicing physicians. It’s reassuring to learn that eight leading professional societies have signed on to the new classification and the new name. That will definitely help with the adoption of the new classification and nomenclature, but it won’t be enough. As I’ve pointed out before, change in medicine is slower than we would like in some areas. We’ve learned that lesson from the Choosing Wisely program, and as the co-director of a statewide quality consortium I’ve learned that implementing change is complex and difficult, and that the wrong kind of change is often too easy to implement.
Practice is also changing to reflect these new realities. For example, men with low grade prostate cancers now often undergo “watchful waiting,” with no intervention unless the tumors progress. (Indeed, I know someone whose treatment involved just that. Unfortunately, he ultimately required radiation therapy, but that was because his tumor progressed.) In breast cancer treatment, recommendations are now less aggressive. For instance, in women over 70 with well-differentiated hormone receptor-positive cancers, radiation is now no longer routinely recommended. Our treatments have become more targeted, as well. For another example, there is the OncoType assay that measures the expression of 21 genes to predict whether women with hormone receptor-positive breast cancers with negative lymph nodes require chemotherapy, resulting in less chemotherapy being given; and this is only one of several such assays.
Indeed, it’s funny how Mr. Ji fails to note that, in this case, Dr. Nikiforov is basically going back to do what Mr. Ji thinks he should do: Let the patients previously treated as though they had cancer know that they didn’t. From a New York Times story on the change:
Dr. Nikiforov says he owes it to patients with reclassified tumors to tell them they never had cancer after all. At the University of Pittsburgh Medical Center, he and others are going to start reviewing medical records and pathology reports to identify previous patients and contact them. He estimates there have been about 50 to 100 each year at the medical center. They no longer have to go back for checkups. They lose the shadow of cancer that the diagnosis hung over their lives.
Informing these patients, Dr. Nikiforov said, “is a moral obligation of doctors.”
Indeed it is. In fact, this reclassification of EFVPTC as NIFTP is arguably the first fruit of the NCI recommendations that Mr. Ji keeps pointing to that actually involved renaming a disease entity. It’s not the first fruit of those recommendations, however. The ACS recommendations for mammographic screening are another. However, renaming disease entities is more difficult in other cancers because the delineation is not so clear-cut. There is no doubt that DCIS can progress to cancer at a substantial rate; the same is true for a lot of other early lesions classified as cancer that might be candidates for a name change, such as prostate cancer. Indeed, when doctors proposed doing just what the NCI proposed for early prostate cancers, there was a great deal of push-back—and not just from physicians. Great care and weighing a huge body of evidence, some of it contradictory, will be required, and it is taking years, as anyone who knew anything about the issues involved in 2012, when the NCI conference occurred, knew it would.
Of course, Mr. Ji isn’t about the careful weighing of evidence. He is about attacking “conventional” medicine and using the “science was wrong before” trope to try to claim that he was right all along and, by implication, he must be right about the “natural” treatments for cancer that he promotes on his website. Even then, he doesn’t understand:
Another topic I have been trying to spread awareness about is thyroid cancer overdiagnosis and overtreatment. When I first reported on this two years ago in my article, Thyroid Cancer Epidemic Caused by Misinformation, Not Cancer, a series of compelling studies from around the world revealed that the rapid increase in diagnoses in thyroid cancer reflected their misclassification and misdiagnosis. As was the case with screening detected breast and prostate “cancers,” and even many ovarian “cancers,” the standard of care often required the removal of the organ, as well as irradiation and chemotherapy — two known cancer promoting interventions.
Actually, overdiagnosis does not involve misdiagnosis. A breast cancer picked up on screening mammography is a breast cancer. Its cells look just as malignant as cells from cancers picked up when a lump forms. The same is true for prostate cancer and, yes, most thyroid cancers. Remember, it’s not just the cancers being reclassified here that are being overdiagnosed by the widespread use of thyroid ultrasound. The real issue is that over the last decade we are learning that many of these cancers are indolent and would never harm the patient if left alone; the problem, of course, is figuring out which are dangerous and which can be either be safely watched or be adequately treated by excision alone. Dr. Nikiforov’s team’s work addresses exactly that question: Which cancers don’t need aggressive treatment? A side benefit of his work is that he identified a variant of thyroid cancer that is so indolent that it basically never metastasizes and therefore shouldn’t be called cancer.
It is useful in these situations to compare alternative medicine to science-based medicine. Those of us advocating for SBM realize its shortcomings better than most, and at least as well as Mr. Ji. We also actively work to change areas where conventional medical care is not adequately science-based. Indeed, this proposed reclassification of a type of thyroid cancer came about because a physician looked at medical practice and saw something not science-based:
The reclassification drive began two years ago when Dr. Yuri E. Nikiforov, vice chairman of the pathology department at the University of Pittsburgh, was asked his opinion about a small thyroid tumor in a 19-year-old woman. It was completely encased in a capsule and the lobe of her thyroid containing it had been removed to establish a diagnosis.
Over the last decade, Dr. Nikiforov had watched as pathologists began classifying noninvasive tumors as cancers and attributed the change to rare cases in which patients had a tumor that had broken out of its capsule, did not receive aggressive treatment and died of thyroid cancer. Worried doctors began treating all tumors composed of cells with nuclei that looked like cancer nuclei as if they were cancers. But this young woman’s story drove Dr. Nikiforov over the edge.
“I told the surgeon, who was a good friend, ‘This is a very low grade tumor. You do not have to do anything else.’ ” But the surgeon replied that according to practice guidelines, she had to remove the woman’s entire thyroid gland and treat her with radioactive iodine. And the woman had to have regular checkups for the rest of her life.
“I said, ‘That’s enough. Someone has to take responsibility and stop this madness,’ ” Dr. Nikiforov said.
It’s doctors like Dr. Nikiforov who see a medical practice that is not adequately science-based and fix it, not quacks like Mr. Ji, whose main interests in cancer seem to be to convince you that chemotherapy kills and causes far more harm than untreated cancer (wrong), that patients with cancer-causing gene mutations don’t need surgery (wrong), and that natural lifestyle changes and whatever supplements he likes can prevent cancer through the magic of epigenetics (wrong again). He latches on to examples like the reclassification of thyroid cancer of SBM correcting itself as evidence that conventional medicine is hopelessly flawed not because he wants to improve medical practice, but because he wants to substitute pseudoscience for science and non-evidence-based “alternative” treatments for validated science-based treatments. Doctors, like Dr. Nikiforov, who promote evidence-based practice are not a validation of Mr. Ji’s profoundly misguided beliefs.

Diet and exercise versus cancer: A science-based view
Yes, diet and exercise can be useful to prevent some cancers. Unfortunately, they don’t prevent all cancers, and the effect size is more modest than often represented. That’s not to say that eating right and exercise aren’t good. They are, for so many other reasons than cancer. Just don’t view them as a panacea for preventing cancer.
David Gorski on September 19, 2016
Link

One of the most effective spin techniques used by advocates of “integrative medicine” (also sometimes called “complementary and alternative medicine,” or CAM for short) to legitimize quackery has been to claim basically all non-pharmacologic, non-surgical interventions as “integrative,” “complementary,” or “alternative.” Thus, science-based interventions such as diet changes to treat and/or prevent disease, exercise, and other lifestyle alterations are portrayed as somehow so special that they need their own specialty, “integrative medicine,” even though they are simply part of medicine. I pointed this out a mere two weeks ago when I discussed the National Center for Complementary and Integrative Health (NCCIH) review of non-pharmacological treatments for pain. It was a systematic review that was essentially negative but spun as positive for some interventions and lacked some key analyses that a good systematic review includes, such as assessment of the quality of the studies included and evaluating them for bias.
Such were my thoughts over the weekend as I got into a Twitter exchange with an advocate of integrative medicine who was touting the benefits of diet as a cancer preventative and how a course in nutrition “opened her eyes.” That in and of itself wasn’t particularly annoying, although I strongly suspect that the nutrition course she took was not given by actual registered dietitians or other experts in science-based nutrition (she wouldn’t say when questioned). What was annoying is that she trotted out some tropes beloved by integrative medicine proponents, such as the claim that most doctors don’t do prevention because they get paid to treat. She was called out for it:
.@DrKristieLeong "Not all docs emphasize prevention because they get paid to treat it." How else to interpret that? pic.twitter.com/5mMmpxGDKC
— Doc Bastard (@DocBastard) September 17, 2016
Oddly enough, on the same day a post from the American Society of Clinical Oncology (ASCO) came up in e-mail lists that discussed the actual evidence for the utility of diet and exercise for cancer prevention. It’s almost as though Twitter were telling me it was time for me to discuss this issue from a science-based perspective. So I will attempt to do so.
Diet and exercise versus cancer: The evidence
As I was in the middle of this Twitter exchange, which was much longer than most that I indulge in mainly because my wife was away for the day, I saw in my e-mail in box this article, Impact of Adherence to Cancer Prevention Guidelines on Diet, Physical Activity on Cancer Risk and Mortality (PDF). My first thought when reading this summary was that this is cool, something I need to read. My second thought was, given my recent Twitter exchange now would be a good time to blog about it. My third thought, which came as I went searching for the actual study, is why it took ASCO two months to feature the story, given that the actual study by Lindsay N. Kohler, MPH and co-authors had been published in July in Cancer Epidemiology, Biomarkers & Prevention. I also noted that it came from the University of Arizona, which did raise red flags for me given that that is the home of the godfather of “integrative medicine,” Andrew Weil, but fortunately the systematic review came out of the Department of Nutritional Sciences and the Mel and Enid Zuckerman College of Public Health. That’s not to say that I wasn’t concerned somewhat, given that the Zuckerman College of Public Health made a deal last year with Southwest College of Naturopathic Medicine to offer a dual-degree program for a naturopathic medical degree (ND) and a master’s degree in public health (MPH), slated to begin this term.
Still, I decided to take a look at the review on its merits. It begins with a discussion of existing dietary and exercise guidelines for health and cancer prevention developed by the U.S. Department of Health and Human Services along with health organizations such as the American Cancer Society and the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). These cancer prevention and health promotion guidelines focus on specific lifestyle recommendations to
    • Achieve and maintain a healthy weight throughout life
    • Adopt a physically active lifestyle
    • Consume a healthy diet with an emphasis on plant-based foods
    • Limit alcohol consumption
Looking at the detailed ACS guidelines (lay version here) originally published in 2012 and the WCRF/AICR guidelines, I realize that I’m probably not doing so great. Granted, I recently started a concerted effort to alter my diet and lose about 20-25 lbs, which would bring me back to a pretty healthy weight, and to exercise by bicycling several miles five or more times a week, taking more brisk walks, and taking the stairs instead of the elevator more often, but I still am sedentary a lot and really have a hard time sticking to the more plant-based diet. In this, I rather suspect that I’m not unlike a lot of middle-aged guys whose jobs don’t involve physical labor.
My own personal difficulties grappling with trying to adopt a healthier lifestyle aside, Kohler et al sought to determine whether adherence to the ACS guidelines is associated with a decreased risk of cancer. In other words, do the guidelines work? To this end, they undertook a systematic review of the epidemiology literature, focusing only on prospective cohort studies. That means that the investigators followed the subjects in their cohorts only after they were enrolled in the study. Prospective studies are generally considered a higher level of evidence than retrospective studies (studies that look at patients in the past) because recall bias can be decreased, objective measurements can be taken in a standardized fashion, and the effect of confounders can be decreased. Here’s how the studies were chosen:
Only prospective cohort studies were eligible for inclusion, as the focus was to ascertain cancer incidence and cancer mortality. Minimally, studies must have collected data for physical activity and diet, generated an adherence score on the basis of either ACS or WCRF/AICR cancer prevention guidelines (2, 12), and reported cancer outcomes of incidence and/or mortality to be deemed eligible for this review. Overall cancer incidence and cancer mortality were the primary outcomes of interest. However, site-specific cancer risks were also considered when data were available from at least two studies meeting the eligibility criteria. Commentaries and summary documents were excluded unless they presented additional data.
Resulting in the following studies being chosen from the database databases the current recommendations of Preferred Reporting Items for Systematic Reviews and Meta-analysis Approach (PRISMA):
A total of 2,033 potentially relevant studies were reviewed; after removal of duplicates and exclusion on the basis of title or abstract, 25 full articles on nutrition and physical activity cancer prevention guideline adherence were retained for in-depth consideration. The selection process for the articles is shown in Fig. 1. We identified 12 articles that met the a priori criteria for inclusion (Table 1). These studies represented analyses of data from 10 cohorts including the Cancer Prevention Study-II (CPS-II) nutrition cohort (13), the Women’s Health Initiative (WHI) cohort (14), the NIH-American Association of Retired Persons (NIH-AARP) Diet and Health Study cohort (15), the Framingham Offspring (FOS) cohort (16), the Vitamins and Lifestyle (VITAL) Study cohort (17), the Canadian National Breast Screening Study (CNBSS; ref. 18), the Swedish Mammography Cohort (SMC; ref. 19), the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (20, 21), the Southern Community Cohort Study (SCCS; ref. 22), and the Iowa Women’s Health Study (IWHS) cohort (23).
Reviewing the 12 studies, Kohler et al found that high adherence to established nutrition and exercise guidelines was associated with decreases of 10% to 61% overall cancer incidence and mortality. The study finding the greatest reduction in risk was the analysis of the VITAL study by Hastert and colleagues, which found that meeting at least five recommendations from the WCRF/AICR guidelines compared with meeting none demonstrated a 61% reduction in cancer-specific mortality over 7.7 years of follow-up (HR, 0.39; 95% CI, 0.24–0.62). The study that showed the lowest decrease was a study utilizing the ACS guidelines including nearly a half a million men and women aged 50-71 years in the NIH-AARP Diet and Health Study. Basically, Kabat and colleagues reported a statistically significant decrease in cancer incidence over the 10.5 years of follow-up for both highly adherent men (HR, 0.90; 95% CI, 0.87–0.93) and women (HR, 0.81; 95% CI, 0.77–0.84). A statistically significant reduction in cancer mortality was also reported during the 12.6 years of follow-up for both highly adherent men (HR, 0.75; 95% CI, 0.70–0.80) and women (HR, 0.76; 95% CI, 0.70–0.83; ref. 27). In fact, here’s a table summarizing the studies (click to embiggen, if necessary):

Yes, the figures are all over the place, but there is a consistent association with adherence to the ACS or WCRF/AICR dietary guidelines with decreased overall incidence of and mortality from cancer. The variability can likely be explained by the differences in the cohorts (for instance, the NIH-AARP cohort consisted only of people over 50, an age when people enter the most cancer-prone period in their lives), how adherence scores were defined, and the like. But what about the effect of diet and exercise on individual cancers?
Diet and exercise versus individual cancers
The authors also looked at the effect of adherence to these diet and exercise recommendations on the incidence and risk of mortality from individual cancers, primarily breast, colorectal, lung, and endometrial cancer, because these are the cancers for which the most studies were available.
For breast cancer, there were eight studies reporting results for breast cancer. Kohler et al note that there were consistent reductions in breast cancer incidence reported in the WHI, NIH-AARP, and EPIC cohorts for high adherence to nutrition and physical activity cancer prevention guidelines versus low adherence, for a reduction in risk. Also, meeting at least five WCRF/AICR recommendations compared with meeting none was associated with a 60% reduction in breast cancer incidence. Overall, the reduction in risk associated with high adherence to guidelines compared to low adherence ranged from 19%–60%, although one of the studies did not reach statistical significance.
Results were similar, although there were fewer studies, for colorectal cancer and endometrial cancer. Basically four of these studies reported results for colorectal cancer specifically, with decreased risk of this disease found in the WHI cohort and the NIH-AARP cohort, as well as the EPIC cohort. The FOS cohort showed a trend towards decreased risk of colorectal cancer that did not reach statistical significance. Taken together, the four studies suggested a reduction in risk associated with adherence to diet and exercise guidelines ranging from 27%–52%. In the case of endometrial cancer, there were three studies that examined this cancer as an endpoint. Both the NIH-AARP and EPIC cohorts both found decreased risk associated with higher adherence to guidelines, and, again, there was one cohort (WHI) with a finding of decreased risk that did not reach statistical significance; the overall decrease in risk reported was 23%–60%.
Finally, the authors examined lung cancer. Of course, lung cancer is unique in that it is a cancer for which the main lifestyle cause is unequivocally known: smoking tobacco products. Although Kohler et al characterize the effect of adherence to diet and exercise guidelines on lung cancer risk as “equivocal,” my reading of the studies they report leads me to believe that adherence to the diet and exercise probably has little or no effect on the risk of lung cancer. This is not particularly surprising given how powerful the effect of smoking is on lung cancer risk and how uncommon lung cancer not associated with smoking is.
What did surprise me is that there was no association with prostate cancer incidence noted utilizing the ACS guidelines in the NIH-AARP cohort or the WCRF/AICR guidelines in the EPIC or FOS cohorts given that prostate cancer is one cancer commonly invoked as being preventable by diet. On the other hand, the diets touted for preventing prostate cancer are more extreme than those encompassed by the ACS and WCRF/AICR guidelines because they are usually vegan. The authors also found no reduction in risk associated with high adherence to diet and exercise guidelines versus low adherence for ovarian cancer.
Diet and exercise versus cancer: Putting it all together
Physicians have sought to identify modifiable risk factors for cancer for a very long time now, possibly as far back as Hippocrates. Of course, two such factors that rapidly rise to the top of any list for just about any disease must be diet and exercise, and, contrary to the frequent criticism of “conventional” medicine by those advocating “integrative” approaches, a great deal of research has been done examining the effects of various diets, exercise, and the like on the risk of cancer in general and of specific cancers. Unlike the case of drug therapies and other discrete treatments, it’s a lot harder to tease out the effects of diet and exercise on cancer risk because such studies take a lot of subjects (one of those cohorts has half a million subjects) and, because the most common cancers are generally diseases of aging, a long period of time. Moreover, while it’s possible to do a randomized controlled trial for many interventions, the complexities of diet make studying the effects of nutrition in such a manner very difficult. That’s not to say that it can’t be done. Indeed, it is being done, but the same problem exists: Lots of patients and lots of time are still required, which has led some to question whether RCTs are superior to prospective cohort studies for such interventions. The point, of course, is that physicians and scientists, contrary to the stereotype, have not been “ignoring” the role of diet in diseases like cancer. Quite the contrary.
This particular systematic review is touted as the first to examine dietary and physical activity cancer prevention guidelines and aggregate the effects on cancer outcomes reported by the existing scientific literature. As such, the authors note its strengths and weaknesses, which are worth quoting at length:
Strengths of this systematic review include strict inclusion criteria to include only prospective studies that constructed adherence scores to the established cancer prevention guidelines by ACS or WCRF/AICR. All of the studies contained sizeable cohorts with multiple years of follow-up leading to sufficient sample sizes, ample power to detect associations, and sufficient number of outcomes, enabling them to evaluate associations for some site-specific cancers. However, there are also some limitations that must be considered. First, all studies generated their own adherence scores on the basis of recommendations from either the ACS or WCRF/AICR. Most studies assigned points for meeting or partially meeting recommendations, whereas others categorized adherence as “met” or “did not meet” recommendations. Including multiple levels of exposure may better capture the degree of adherence to the guidelines. Although ACS and WCRF/AICR guidelines are very similar, interpretations of how to measure the recommendations varied. Notably, physical activity was assessed several ways including in metabolic equivalents, times per week, and even a physical activity index. Furthermore, studies utilized frequency questionnaires to capture diet and physical activity data. These self-reported measures are well-known sources of measurement error, which may bias findings toward the null, lending to conservative findings in this review. Components of the adherence score were measured singularly at baseline and used to assess cancer risk over time. Repeated measurements of diet and physical activity may have provided an improved exposure assessment of long-term behavior and risk over time. Follow-up times ranged from 7.7 to 14 years, which may not be sufficient for assessing the protective role of adherence to nutrition and physical activity cancer prevention guidelines. In addition, although the studies evaluated large cohorts, there was limited population heterogeneity with regard to race or ethnicity, with the exception of the WHI and SCCS studies. Furthermore, analyses varied somewhat among the studies. All studies evaluating associations with ACS guideline adherence made comparisons of high versus low adherence. One study used WCRF/AICR guidelines to compare “met” versus “did not meet” recommendations (29), whereas a single study evaluated adherence to WCRF/AICR guidelines on the basis of point increments of the overall score (36). Finally, the potential for publication bias is always of concern. Studies with significant findings are more likely to be published than those with null or unimportant findings. Grey literature was included in the search via Google Scholar in an attempt to capture any work that hasn’t been formally published (abstracts, conference proceedings, etc.). Even though the studies differed in some measurements of individual score components, construction of the adherence score, specifics of the set of guidelines used, and analytic methods, it is important to note that studies generally demonstrated agreement in their findings even across countries with varying diet and physical activity patterns.
You get the idea. The studies chosen were generally of high quality, but their methodologies for assessing adherence to the ACS and WCRF/AICR guidelines varied considerably. In actuality, to me the very fact that studies of such disparate groups using differing methods of assessment are all finding more or less the same thing tells me that the assessment by Kohler et al is likely pretty robust.
Another thing that has to be considered. This is a systematic review of a very specific question: Does adherence to the ACS and/or WCRF/AICR guidelines for diet and exercise (which, when you come down to it, are strongly similar) decrease the risk of being diagnosed with cancer and ultimately dying of cancer? The answer is yes, and we know at least some of the cancers affected: breast, colorectal, and endometrial cancers. We also know cancers for which adherence to these guidelines probably has little effect: lung, prostate, and ovarian cancers. Of course, this is a very limited number of the cancers that afflict human beings. It’s quite likely that diet and exercise impact the risk of many other cancers. However, this review doesn’t really address the effects of specific dietary and exercise interventions. It doesn’t, for instance, tell us if this food or that food, this nutrient or that nutrient, is associated with increased or decreased cancer risk. Those are different questions, and they are actually questions better suited to RCTs than the question that Kohler et al examined.
The reason proponents of integrative medicine claim so many non-surgical, non-pharmacological interventions is because, although inflated claims are often made for them, they can actually work, in contrast to the pseudoscientific treatments also “integrated” into medicine, such as acupuncture, traditional Chinese medicine (TCM), and the like. There’s a reason why we at SBM have at various times referred to diet, exercise, and other science-based lifestyle interventions co-opted by integrative medicine as a “Trojan horse,” particularly in academia. Once academia brings the nice, shiny “horse” of “non-pharmacological interventions” into its citadel, out jump the Greeks of quackery.None of this, however, means that diet and exercise aren’t powerful tools to promote health. Rather, it’s that they are and should remain part of science-based medicine, rather than being tainted by association with the quackery of integrative medicine. And there is a lot of science out there to support the important role of diet as a modulator of cancer risk.
Unfortunately, taking all the evidence together for individual foods, nutrients, exercise, and diet becomes devilishly complicated and contradictory, too. For example, do you remember John Ioannidis’ systematic review of existing scientific evidence associating specific foods with cancer? I do, as Steve Novella and I both blogged about it. Basically, Ioannidis examined 50 common ingredients at random out of cookbooks. He then scoured the literature looking for studies showing an association (positive or negative) with cancer and found that 80% of the ingredients had such studies, often with studies linking them to cancer and others showing a protective effect. As I said at the time, that’s why it’s important to aggregate data. Whenever it comes to studies of diet and virtually any health outcome, there is always a lot of noise.
There is a lot of noise in Kohler’s study, too, but the results are consistent. You can reduce your risk of cancer by staying active and exercising, eating a healthy diet with a lot of plant-based foods and minimizing intake of processed meats, limiting alcohol consumption (although I think the WCRF/AICR guidelines go a bit too far in saying that you shouldn’t drink at all if possible), and maintaining a healthy weight. (Of course, if you stay active and eat a healthy diet, maintaining a healthy weight will probably not be a problem.) Conceptually, it’s easy to do. In practice, as I’m discovering, it’s anything but easy.

Obesity, cancer, and chemotherapy
David Gorski on September 23, 2013
Link
In medicine, particularly oncology, it’s often the little things that matter. Sometimes, however, the “little things” aren’t actually little; they just seem that way. I was reminded of this by a story that was circulating late last week in the national media, often under titles like “Obese cancer patients often shorted on chemo doses”, ”Are obese people with cancer getting chemotherapy doses too small for them?”, and “Obese Cancer Patients Not Getting Full Doses of Chemotherapy Drugs”. It’s also interesting to me because it stands in marked contrast to something I’ve written about a lot on this blog: The overtreatment of cancer. In this case, this story is about the undertreatment of cancer in patients who are obese, and it’s a problem that has definite adverse effects on an obese person’s odds of surviving cancer.
I’ve been aware of this issue for some time and had been thinking of blogging about it for at least three years. The reason is that the oncologist who is best known for sounding the alarm on this issue is Jennifer Griggs at the University of Michigan and, being local and all, I’ve seen her speak on the topic several times at local breast cancer conferences. Now that I work with a statewide breast cancer care quality improvement initiative, I’m becoming more aware of her work. Indeed, I was rather puzzled why this issue bubbled up enough to be reported widely on the national news last week when the Nature Clinical Oncology paper by Gary H. Lyman and Alex Sparreboom that drew attention to the issue was published in August, and the original American Society of Clinical Oncology (ASCO) guidelines were published last year. Whatever the reason this issue has been getting more attention, it’s a good thing.
Although the issue is simple in concept, namely that obese patients are not always getting full weight-based doses of adjuvant chemotherapy after cancer therapy, it’s not so simple to change attitudes. In chemotherapy dosing, most doses are calculated based on body weight or body surface area (BSA), which depends upon the weight. However, which “weight” to use in the BSA calculation has been a matter of controversy. When the actual body weight (ABW) is used, the BSA calculated can be huge, making it understandable why some oncologists might balk at the doses that they calculate, which can look staggering and provoke a reaction of “Holy crap, I can’t give anyone that much chemotherapy!” (Of course, the word used is usually not “crap.”) As a result, many oncologists “cap” chemotherapy doses, regardless of how large the patient is and how much chemotherapy the patient’s weight mandates, or use various forms of “adjusted” body weights in the BSA calculation, such as the ideal body weight.
The issue is summed up nicely in an AP story by Marilynn Marchione:
Obese people are less likely to survive cancer, and one reason may be a surprising inequality: The overweight are undertreated.
Doctors often short them on chemotherapy by not basing the dose on size, as they should. They use ideal weight or cap the dose out of fear about how much treatment an obese patient can bear. Yet research shows that bigger people handle chemo better than smaller people do.
Even a little less chemo can mean worse odds of survival, and studies suggest that as many as 40 percent of obese cancer patients have been getting less than 85 percent of the right dose for their size.
Now, the largest organization of doctors who treat cancer, the American Society of Clinical Oncology, aims to change that. The group has adopted guidelines urging full, weight-based doses for the obese.
Being reluctant to give full doses in such patients is not entirely unreasonable on the surface. For instance, in breast cancer, one of the most commonly used drugs is Adriamycin (generic name: doxorubicin), and one of its most serious potential complications is cardiac toxicity that in extreme cases can lead to congestive heart failure. Also, given the association of diseases like type II diabetes with obesity, many oncologists will see multiple comorbidities in their obese patients and decide that the better part of valor is to dial back the doses a bit in order to avoid doing more harm than good. Recent evidence, however, is suggesting that these concerns are overblown. Worse, recent evidence is also suggesting that there is a very real potential for doing harm by not giving full, weight-based chemotherapy doses, hence the recent ASCO guidelines and the article by Dr. Lyman in Nature Clinical Oncology.
The derivation of these guidelines is actually interesting in that it shows how tricky and complex it is to derive science- and evidence-based guidelines for oncology. Because there has never been a randomized clinical trial comparing full, weight-based dosing of chemotherapy versus dose-capped regimens, what we are left with are observational and retrospective studies, which have a variety of shortcomings that can be hard to overcome, particularly confounding by other factors. However it is certainly plausible, from both a basic science and clinical perspective, that the common practice of underdosing the obese could potentially lead to poorer outcomes. Moreover, there is now good evidence that not only is obesity itself is a risk factor for various cancers (e.g., breast) but that it is a negative prognostic factor for patients who do develop cancer, meaning that such patients are more likely to die of their disease. Indeed, a recent meta-analysis concluded that obesity very likely contributes significantly to the risk of death due to breast, prostate, and colorectal cancer.
In terms of the association of obesity to various cancers, there is now robust evidence linking obesity to an increased risk of cancer. Indeed, in 2002 the International Agency for Research on Cancer (IARC), using obesity prevalence data from Europe and relative risks from a meta-analysis of published studies, concluded that obesity was a cause of 11% of colon cancer cases, 9% of postmenopausal breast cancer cases, 39% of endometrial cancer cases, 25% of kidney cancer cases, and 37% of esophageal cancer cases. Meanwhile, data from the American Cancer Society suggested that obesity was related to mortality from liver cancer, pancreatic cancer, non-Hodgkin’s lymphoma, and myeloma. This effect on mortality reflects both the excess incidence and excess mortality among those with cancer. Overall, it has been estimated that obesity causes approximately 20% of all cancer cases. Over 32 years ago, Sir Richard Doll estimated that “overnutrition” (i.e., being overweight or obese) caused a combined 35% of all cancer cases. For the cancer to which I’ve devoted my professional life, breast cancer, as pointed out by Lyman and Sparreboom it’s been known for over 40 years that in animal models a reduction in chemotherapy dose by as little as 20% can reduce complete remission and cure rates by up to 50%. It has also been known for at least 20 years that breast cancer recurrence and survival are negatively impacted by obesity. The dose-response curve for chemotherapy can be steep in many tumors.
Why it is the case that obesity is both a risk factor for the development of cancer, particularly more aggressive forms of the cancers for which it is a risk factor, as well as a risk factor for mortality from cancer is not fully understood yet. Various molecular mechanisms have been proposed, including insulin resistance common in the very obese and in people with type II diabetes, altered levels of insulin-like growth factors, oxidative stresses, adipokines (growth factors secreted by adipose—fat—tissue), and obesity-related inflammatory markers. Whatever the biological mechanisms behind the increased risk related to obesity for developing cancer and for any cancers that develop to be more aggressive subtypes, it is certainly plausible from a basic and clinical scientific standpoint that undertreating such cancers could potentially lead to higher rates of recurrence.
In obese patients, this appears to happen a lot. Back in 2005, Dr. Griggs published a paper in JAMA Internal Medicine looking at how often such dose reductions occurred. She found that dose reductions on the first dose (usually called “cycle”) of chemotherapy, which would eliminate dose reductions due to toxicity, were instituted in 9% of the healthy weight, 11% of the overweight, 20% of the obese, and 37% of the severely obese women. She also found that first cycle dose reductions were independently associated with being overweight (P = .03), obese (P< .001), severely obese (P<.001), older than 60 years (P<.001), and having a serious comorbid condition (P = .03). Interestingly, she also found that severe obesity was actually associated with a lower likelihood of being admitted for febrile neutropenia (fever with a low white blood cell count, indicating potential infection in an immunosuppressed patient), was actually less common (odds ratio, 0.61; 95% confidence interval, 0.38-0.97) in the severely obese even in patients who received full dose, and there was a trend towards less admissions for febrile neutropenia associated with increasing body mass index that only became statistically significant at a BMI ≥ 35.
More importantly, it’s been known since the 1990s that decreased chemotherapy dose delivered is associated with significant increases in recurrence and decreases in survival. For instance, in 1996, in a retrospective analysis of a randomized trial of women with lymph-node-positive early stage breast cancer, Rosner et al. found that obese women receiving adjuvant chemotherapy experienced no greater toxicity or poorer outcomes than similarly treated healthy weight patients, and overweight women receiving full dose chemotherapy experienced better failure-free survival than those receiving reduced doses. More recent studies, such as this meta-analysis by Hourdequin et al., show that obese patients receiving chemotherapy based on the use of their actual body weight experienced the same or fewer chemotherapy-related complications as compared to the non-obese when they received the full ABW-based dose of chemotherapy, and survival outcomes did not differ between the obese and non-obese who received their full dosage of chemotherapy. Couple that with studies linking decreased dose to poorer outcomes, and the likelihood that obese patients not receiving their full doses are at significantly increased risk of dying of their cancers. As ASCO put it in their guidelines:
Recommendation 1.1: The Panel recommends that actual body weight be used when selecting cytotoxic chemotherapy doses regardless of obesity status. There is no evidence that short- or long-term toxicity is increased among obese patients receiving full weight–based chemotherapy doses. Most data indicate that myelosuppression is the same or less pronounced among the obese than the non-obese administered full weight–based doses.
However:
Recommendation 1.2: The Panel recommends full weight–based chemotherapy dosing for morbidly obese patients with cancer, subject to appropriate consideration of other comorbid conditions. Data are extremely limited regarding optimal dose selection among the morbidly obese and other special subgroups. More studies are needed to evaluate optimal agents and agent combinations for obese and morbidly obese patients with cancer; however, based on available information, it seems likely that the same principles regarding dose selection for obese patients apply to the morbidly obese.
And finally:
The Panel recommends that full weight–based chemotherapy doses (IV and oral) be used in the treatment of the obese patient with cancer, particularly when the goal of treatment is cure. Selecting reduced doses in this setting may result in poorer disease-free and overall survival rates. There are compelling data in patients with breast cancer that reduced dose-intensity chemotherapy is associated with increased disease recurrence and mortality. Although data in other malignancies are more limited, based on improved survival observed with chemotherapy compared with controls, a dose-response relationship exists for many responsive malignancies. Therefore, although data are not available to address this question for all cancer types, in the absence of data demonstrating sustained efficacy for reduced dose chemotherapy, the Panel believes that the prudent approach is to provide full weight–based chemotherapy dosing to obese patients with cancer, especially those receiving treatment with curative intent. Most of the data in support of full weight–based dosing come from the treatment of early-stage disease. Data supporting the use of full weight– based doses in the advanced disease setting are limited.
At this point, it is worth reiterating that medicine is rarely black and white (one notable exception is the case of something like homeopathy, which violates multiple laws of physics and chemistry and is, without a doubt, total quackery). It exists in shades of gray, which is where these recommendations come from. The panel examined evidence from multiple sources, including preclinical evidence from cell culture and animal models that dose reduction of chemotherapy can compromise “cure” rates, coupled it with evidence from humans that obese patients are more prone to cancer and more likely to die of cancer if they get it, noted that obese patients frequently don’t receive the full recommended dose of chemotherapy and that decreased dose of chemotherapy is associated with increased risk of cancer recurrence and death. From these data, they made the connection that quite likely at least part of the increased mortality due to cancer in the obese is because many of them don’t receive their full dose of chemotherapy based on a BSA calculated from their ABW. They also noted that obese patients are no more likely—and, in fact, may be less likely—to suffer chemotherapy-related complications than the non-obese when they receive full chemotherapy doses. Putting it all together, the panel was quite reasonable to recommend that chemotherapy dosing based on BSA be calculated using ABW, not the various other “capped” dosing methods or methods using adjusted body weights.
At the same time, weaknesses and uncertainties were acknowledged. For instance, as has been pointed out before, there has never been a randomized controlled clinical study comparing full, ABW-based dosing to capped doses and/or doses based on various adjusted weights. Given the confluence of evidence above, such a trial would likely fail the ethical test of clinical equipoise and therefore never be approved by an institutional review board. As I’ve said many times before, the reason we call it “science-based” medicine rather than science is because ethical and practical considerations limit how rigorous we can be. Moreover, we don’t know enough about the pharmacokinetics of chemotherapy drugs in the morbidly obese to determine whether a different strategy for calculating their doses would result in decreased recurrences and decreased toxicity.
Mark Crislip likes to quote a certain not-so-popular former defense secretary, “As you know, you go to war with the army you have, not the army you might want or wish to have at a later time.” It was one of the rare bits of actual near-wisdom that ever came out of the mouth of Donald Rumsfeld. Patients need to be treated now and clinicians can only use the tools they have at the time. Right now weight-based dosing is the tool that we have. Maybe someday there will be “personalized” (or “precision”) dosing based on expression levels of various proteins that metabolize the drug, weight, and who-knows-what other personal factors. That doesn’t help patients today; so we go with what we have, especially since the evidence that we have strongly supports not reducing chemotherapy dose in the obese just because they are obese. As Gary Lyman put it, while more research is clearly needed in this important area, it is essential that the science that we do have is applied appropriately and effectively in the optimal treatment of patients with cancer.
Finally, it’s a mistake to refer to this problem as “discrimination” against the obese, as Melissa Ford at BlogHer did:
We’ve seen a lot of discrimination towards obese individuals in various areas of health care not to mention a wide-range of businesses from airlines to restaurants. Yet in this case, we’re talking about a person’s survival. For 40% of obese cancer patients, before they’ve taken their first dosage of chemotherapy, the odds are stacked against them — not by science or fate, but by the doctor treating them.
While there is certainly discrimination against obese people because they are obese, dose reduction of chemotherapy in the obese is not an example of it. Rather, this practice derives from a concern that did not seem unreasonable in the past but that we now know to be almost certainly misplaced; that dosing obese patients the same way we dose non-obese patients will harm them. As Dr. Lyman says:
Don’t call it supersizing; it’s right-sizing cancer care, said Dr. Gary Lyman, a Duke University oncologist who led the panel that wrote the advice.
“There’s little doubt that some degree of undertreatment is contributing to the higher mortality and recurrence rates in obese patients,” he said.
Finally, there’s another lesson to be had here. Based on these data, there is a growing consensus to link the receiving of adequate chemotherapy doses to quality metrics in oncology care. Most people, including physicians, think that it’s all about saving money when they see evidence-based guidelines. Sometimes it is, particularly with initiatives like Choosing Wisely, which is designed to discourage the use of unnecessary tests and procedures. In this case, though, it isn’t. Treating with the full dose of chemotherapy is likely to cost more in the short term. Whether the amount by which it will decrease recurrences will be such that there will be a net savings because of fewer relapsed cancer patients is currently unknown. It might not be. In this case, higher quality care is likely to cost more. Such is likely to be the cost of “right-sizing cancer care.”

Guess who pioneered chemoprevention through diet?
Jann Bellamy on December 24, 2015
Tweet


This is an expansion of a post I did over on the Society for Science-Based Medicine blog about this time last year. The original post, which got far more traffic than is usual for the SFSBM, is a good example of how science works and the good that it can do. The hard work of real science illustrated here serves as a striking counterpoint to the slap-dash system of pseudoscience, which churns out fake diseases, causes, and cures by the dozen based on a fuzzy understanding of real science fueled by a healthy dose of imagination.
Naturopaths and “functional medicine” practitioners would have the public believe that they are the true experts on nutrition and health. Even though their nutritional advice contains a large serving of hooey and a big helping of dietary supplements, which they are happy to sell to patients.
So it was with great interest that I read the obituary of Dr. Lee Wattenberg in the New York Times.
Dr. Wattenberg published a landmark paper in the journal Cancer Research that reviewed 36 years of animal studies on the effects that certain compounds had on the development of cancer. The paper laid the framework for understanding how these compounds work. . . .
He showed that cabbage, brussel sprouts, cauliflower and broccoli inhibit the development of carcinogens. He isolated a compound in garlic that decreased “by a factor of three” the chances that animals injected with cancer agents would develop that cancer. He found two chemicals in coffee that neutralize free radicals, which are harmful chemicals commonly implicated in the onset of cancer.
Who was Lee Wattenberg?
Was he a naturopath? A functional medicine practitioner? No, Wattenberg was a medical doctor and his pioneering paper was published in 1966, almost 50 years ago. Long before functional medicine appeared on the scene, Wattenberg was researching the effect of diet on cancer prevention.
So was Wattenberg assailed by his colleagues as an apostate, a renegade who might destroy the medical profession’s alleged lucrative devotion to treating cancer with the tools of Big Pharma and surgery? Not at all. He was, according to the American Association for Cancer Research, “revered by his colleagues in the cancer field as a self-effacing leader.”
Wattenberg served on the Board and as president of that organization, where he was elected a Fellow. He received a number of awards from organizations devoted to fighting cancer and cancer research. For 60 years, Wattenberg was a faculty member at the University of Minnesota medical school and published many papers in the medical literature.
According to the obituary,
His interest was in helping to prevent cancer, and in a statement after his death, the American Association for Cancer Research called him the “father of chemoprevention.” . . .
“About two-thirds of all cancers are preventable,” Margaret Foti, the association’s current chief executive, said in the statement. “Because of Lee Wattenberg’s dedication to and belief in the promise of cancer prevention, the field has taken its rightful place as one of the most important areas of cancer research.”
Isn’t that something? The CEO of a respected medical research organization is talking about prevention, right there in the Times. Prevention through diet, no less. And saying it is an important area of cancer research! Doesn’t look like the stereotypical picture of medicine the pseudoscientific diet wizards try to sell. Doesn’t appear that medicine is solely interested in treating the disease rather than the “whole person,” as integrative medicine proponents would have us believe. Frankly, it appears to be – dare I say it? – positively “holistic” to me.
However, as is always true in scientific inquiry, not all of his hypotheses panned out.
Dr. Wattenberg and others once hoped that beta carotene, a substance found in carrots, squash and other vegetables, would help prevent cancer. But in clinical trials, beta carotene was found to increase the risk of lung cancer. Similarly, vitamin E, a substance once thought to lower the risk of prostate cancer, may actually raise the risk.
According to his daughter, these setbacks never discouraged her dad. He was “always eager to try the next thing.” Of course, when the next thing didn’t work, he didn’t keep advocating for its inclusion in clinical practice in spite of the evidence. He moved on.
Let’s briefly compare this approach to that of naturopaths, who wield their claimed expertise in nutrition like a truncheon, and Mark Hyman, MD, functional medicine guru.
Diet as disease prevention and treatment: naturopathic version
Guided by a “food is medicine” philosophy that relies heavily on the philosophy part, evidence be damned, the naturopath’s approach seems to dictate an endless trial-and-error elimination of this, adding that, until some positive result is achieved. This result is then attributed to the naturopath’s expertise in dietary advice, whether actual causation was involved or not.
Britt Hermes, herself a former naturopath and guest blogger on SBM, describes her own experience with naturopathic dietary advice on her own blog, Naturopathic Diaries. While anecdotal, it is a fair exemplar of standard naturopathic practice, as her “treatment” took place in a clinic run by Bastyr, where she received her naturopathic education and training. She later incorporated this dietary philosophy into her own naturopathic practice. As she describes it:
When my naturopath suggested severe dietary restrictions [for psoriasis and acne], I embraced them wholeheartedly and cultivated them into my own nutritional monster.
She was told to avoid all dairy, eat more protein, and eliminate refined sugars. Her naturopath explained the fictional gut-skin connection, reinforced when she learned about the “leaky gut” syndrome at Bastyr. For this, she was prescribed dietary supplements and herbs. She got IV “detoxification” treatments at Bastyr. Unnecessary weight loss was encouraged. She was given bogus IgG food intolerance tests. She was told not to eat any food that was the “root cause” of her acne and that she was “addicted to sugar.”
At her naturopath’s prompting, she detailed every bowel movement and her symptoms of bloating, pain and constipation. Instead of properly diagnosing these as a result of her pseudoscientific treatments, they were chalked up to “food reactions,” as were her irritability and depression, which were actually caused by hunger and malnutrition. Hermes instituted her own regimen of unproven dietary measures prompted by her faith in naturopathy and vetted in discussions with other Bastyr students and her naturopath.
As she notes:
Even by critics, naturopaths are often acknowledged for having training in nutrition . . . However, the nutritional training is wrapped up in pseudoscience, which makes it difficult to tease apart what is real and what is fake. For example, naturopaths often make dietary recommendations based on applied kinesiology tests, unvalidated blood tests, or far-fetched medical explanations. A commonly prescribed, but unproven, naturopathic diet theory is the elimination of nightshades to reduce the symptoms of inflammatory diseases, especially arthritis.
This is but one example of how naturopaths’ claim of special expertise in health and disease prevention through diet crumbles under closer examination, a subject we’ve examined on SBM a number of times in posts addressing dubious naturopathic dietary advice and diabetes, autism, infertility, allergies, and hypertension.
Diet as disease prevention and treatment: functional medicine version
The medical profession has its own “food as medicine” gurus, characterized by their splashy diet books and money-making diet schemes. Notable among these is Mark Hyman, MD, a family practice doctor and the main public face of “functional medicine.”
What is functional medicine? Good question. Here’s David Gorski’s take:
Functional medicine is pure pseudoscience, as Wally Sampson has explained. It postulates “imbalances” in hormones and neurotransmitters, oxidation-reduction, detoxification and biotransformation, immune function, inflammation, and cell structure. It’s all so vague that these “imbalances” could mean almost anything, and when practitioners of “functional medicine” refer to them, they usually do.
And that of the late, great Wally Sampson, who wrote a classic series on functional medicine (Functional Medicine (FM): What Is It?; Functional Medicine II; Functional Medicine III; Functional Medicine IV):
After extensive searching and examination, my answer is still – only the originators of “FM” know. Or, at least one must assume they know, because so far as I can see, I certainly see nothing that distinguishes “FM” from other descriptions of sectarian and “Complementary/Alternative Medicine” practices. A difference may lie in the advocates’ assumptions to have found some “imbalance” of body chemistry or physiology before applying one or more unproved methods or substances. From what I could determine, the “imbalance” or dysfunction is usually either imaginary or at least presumptive. And the general principles are so poorly defined as to allow practioners vast leeway to apply a host of unproven methods.
Hyman has adopted the naturopathic mantra that “conventional” medicine treats only symptoms by reaching for the prescription pad, while “functional medicine” gets at the “root cause” of disease. In fact, Hyman’s articles on the treatment of psoriasis and acne sound remarkably like the naturopathic regimens prescribed for Britt Hermes.
Hyman’s outfit sells proprietary programs online, including dietary supplements prescribed by these programs. According to his website, he has authored journal articles on the subject, but, according to PubMed, all of them have appeared in one journal of dubious scientific rigor, Alternative Therapies in Health and Medicine.
Unfortunately, the “Institute for Functional Medicine,” where Hyman serves as board chair, is an approved provider of continuing medical education credit, where its courses are chock full of quackery, aided by lectures from not only the supposedly science-based professions, like medicine and dentistry, but a fair helping of naturopaths and chiropractors.
Hyman’s poor understanding of the diseases about which he pontificates have been the subject of several take downs in the science blogosphere: autism, dementia, and, relevant to our subject here, cancer. He regularly holds forth on the Huffington Post, free from the restraints of science and evidence.
As Steve Novella opined, practitioners like Hyman:
seem to search for any tenuous evidence to support their philosophy or marketing strategy and then make huge hand-waving extrapolations from the evidence to their practice.
Jerome Groopman, MD, chronicled Hyman’s extrapolations versus actual evidence more recently in a New Yorker article, where several experts disagreed with Hyman’s conclusions. Even in the face of this, according to Groopman:
Mark Hyman holds fast to his view. “Inflammation is the final common pathway for pretty much all chronic diseases,” he told me. His recommended solution is an “anti-inflammatory diet”—omitting sugar, caffeine, beans, dairy, gluten, and processed foods, as well as taking a variety of supplements, including probiotics, fish oil, Vitamins C and D, and curcumin, a key molecule in turmeric.
Although, Groopman added, Hyman, “at times, acknowledges the possible limits of his paradigm” and that it is hard to “connect the dots.” This reads more like another act of hubris on Hyman’s part rather than an actual admission that he might be wrong. “Possible” limits?
Note the contrast here between Dr. Wattenberg’s work and that of functional medicine practitioners and naturopaths. Dr. Wattenberg reviewed the research before developing his theories. He published his work in well-regarded peer-reviewed journals. And he was willing to move on when the evidence wasn’t there. No clinging to a “philosophy” or pet ideas despite the evidence. Just a lot of hard work and devotion to the scientific method. Dr. Wattenberg was “revered” by other scientists. No one would ever say that about Hyman or naturopaths.
Happy Holidays, everyone! See you in January.

Liver cancer, naturally
Aristolochic acid, a highly toxic substance naturally found in some traditional herbal medicines, may be a significant cause of liver cancer.
Scott Gavura on November 2, 2017
Link
Not all cancers affect all populations equally. Liver cancer is the fifth-most common cancer worldwide, but the prevalence varies widely. Liver cancer cases skew heavily to less developed regions of the world, where 83% of cases are found – it’s over six times more common there than in Northern Europe, for example. In Asia, the high rates of liver cancer have been linked to hepatitis B and C, which is widespread, and a proven cause of cancer. And liver cancer continues to strike Asian American and Pacific Islanders more than any other American ethnic group as well, where hepatitis continues to circulate in the population. Now there’s new evidence to suggest that a substance found in some traditional Chinese medicines may also be causing liver cancer. They’re called aristolochic acids, and they illustrate, with a substantial body count, that what’s natural isn’t necessarily healthy or good.
What are Aristolochic acids?
In the early 1990’s a strange cluster of acute, end-stage renal disease appeared in women in Belgium. It was determined that all had been exposed to the chemical aristolochic acid (AA) at a weight loss clinic, due to the consumption of Chinese herbs which contained natural AA. Approximately one third of the more than 300 cases have subsequently required a kidney transplant, and cancers of the urothelial tract in this group have also been widespread. In the Balkans, low level exposure to AA via flour consumption that contains seeds from Aristolochia clematitis is believed to be responsible for what is now called Balkan-endemic nephropathy. Subsequent study that was initiated after the Belgian case identified that that AA is responsible for tumour development and for activating destructive fibrotic changes in the kidney. For over a decade now it has been well established that AA is a nephrotoxin and a powerful carcinogen with a short “latency period”, in that it causes permanently damage, quickly. What’s remarkable is that none of this was known until the 1990s despite “thousands of years” of use as a traditional medicine. As Steven Novella noted in a past post on aristolochic acid and urinary tract cancer:
This example just highlights the fact that widespread use of an herbal product, or any treatment, is not sufficient to ensure that it is safe, or even that it is effective. Common use may be enough to detect immediate or obvious effects, but not increased risk of developing disease over time. That requires careful epidemiology or specific clinical studies. We know about the risks of prescription drugs only because they are studied, and then tracked once they are on the market. Without similar study and tracking there is simply no way to know about the risks of herbal products. Relying upon “generally recognized as safe” is folly.
While herbal remedies that contain AA are now banned in many countries, AA-induced kidney damage and related cancers continues to appear worldwide. As AA’s cancer-causing effects have now been widely studied, the distinct way that they damage cells has been described as a sort of “signature” that is easily identifiable in tumour samples. This brings us to this new study of liver cancers attributed to AA, which have been less closely associated with AA. This study used that unique “signature” to look for AA exposure.
Aristolochic acids and liver cancers
There is good evidence to show that the consumption of AA-containing products in Taiwan has been widespread through the use of prescribed herbal medicines. The paper is entitled “Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia” and it’s from Alvin Ng and associates, published in Science Translational Medicine in October, 2017. This was a retrospective analysis of hepatocellular carcinomas (HCC, liver cancer in lay terms) and patients were included if they (1) had true HCC (2) there was sufficient DNA available from a sample of the tumour. 98 HCCs from Taiwan hospitals were studied based on whole-exome sequencing and mutation identification. They looked for the distinctive way in which AA causes mutations. The researchers subsequently examined 1,400 HCCs from other regions in the world. The final analysis was as follows:
    • Taiwan: 78% of tumours had evidence of AA exposure
    • China: 47% of tumours had evidence of AA exposure
    • Southeast Asia: 29% of tumours had evidence of AA exposure
    • Korea: 13% of tumours had evidence of AA exposure
    • Japan: 2.7% of tumours had evidence of AA exposure
    • North America: 4.8% of tumours (in one hospital, 22% of 87 patients, all of Asian ancestry, had evidence of AA exposure)
    • Europe: 1.7% of tumours had evidence of AA exposure
Here is the global breakdown, with the red portion illustrating the proportion of tumours that were linked to AA exposure:

Reducing your risk of kidney and liver cancer
Herbal remedies are popular worldwide. In China and other countries in Asia, there is strong support for, and belief in “traditional” Chinese medicine despite the fact that it is neither truly traditional (as it is now promoted), nor particularly effective. This new analysis shows that the use of (or exposure to) AA is widespread in some parts of the world, and appears to be be a cause in a substantial numbers of liver cancers. The authors noted that the presence of AA-associated cancer does not appear to be declining in Taiwan, despite the banning of some AA-containing herbs in 2003. This may be due to a lag effect (like cancer and smoking) but may also be due to continued exposure to, or consumption of, AA-containing products.
If you’re a user of traditional Chinese medicine, avoiding AA is easier said than done, unless you have impeccable knowledge of herbs, their origins, and the supply chains you’re getting your products from. I’ve blogged before about TCM, noting that contamination is common. Mislabelling of products also appears to be widespread, suggesting that rigorous and credible testing of final products may be the only way consumers can be assured they’re avoiding AA in the products they buy. The linkage of AA to kidney damage, and the evolving story of its cancer-causing potential illustrates that even widespread use of a product for hundreds (or thousands) of years give no automatic assurance of safety. If it were not for the Belgian weight loss clinic kidney failure cluster, the widespread toxicity of AA may not even be known today.

2023 Cancer Statistics Report
Cancer deaths continue to decline at a steady rate.
Steven Novella on January 18, 2023
Link

Each year the American Cancer Society publishes cancer statistics for the US. This is a massive set of data capturing the incidence of every type of cancer and deaths from cancer. This is an important window into how medical interventions for preventing, detecting, and treating cancer are doing. There are some important trends in the 2023 report worth highlighting.
The top line observation is that cancer deaths continued to decline:
Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted.
This is all observational data, so we can only infer cause and effect. But epidemiologists have been following and examining this data for decades, so we can make some fairly high-confidence conclusions. Cancer mortality can be reduced in three major ways. The first is by preventing cancer from occurring in the first place, through preventive measure. The second is through improved treatment for cancer when it occurs. The third is by changes in diagnosis of cancer – anything that might cause someone to die from cancer without being recorded as a cancer death. If anything our ability to properly diagnose cancer and cancer screening and surveillance has increased, so this factor would likely artificially increase the measured cancer death numbers. Also, failure to screen properly can increase cancer death by delaying treatment.
Just looking at total cancer deaths captures all of these factors. The big picture is that there has been a steady decline in cancer deaths of a little more than 1% each year for decades, adding up to 33% since 1991. This has mainly been accomplished through improved prevention and treatment. There has been a steady increase in available treatments, with newer technologies constantly coming online. Each one provides and incremental improvement in cancer survival with a steady cumulative effect.
For example, in 1997 the first monoclonal antibody drug to treat cancer was approved (Rituximab). In 2004 the FDA approved the first antiangiogenesis drug, drugs that reduce the growth of blood vessels to feed solid tumors. In 2017 the first car-t cell therapy, that uses the patient’s own immune cells to fight their cancer, was approved. And there are new technologies in the pipeline – such as using CRISPR to engineer tumor cells to kill the tumors themselves and function as a vaccine against cancer recurrence. There have been countless other advances over this time, but these are some of the exciting new technologies that have come into use.
The bottom line is that the steady improvement in cancer survival and reduction in cancer deaths is largely due to advances in science and medical technology. This is necessary because cancer is a difficult enemy. It is also not one disease, but a category containing many diseases. Cancer cells evolve to evade our treatments. This is SBM so I have to emphasize that these improvement are the result of science. Meanwhile, so-called “alternative medicine” approaches that try to avoid, deny, or change the rules of science are associated with increased death from cancer.
Preventive measures also made a huge impact on these numbers. Under this category, the biggest story is the success of the HPV vaccine. From 2012 to 2019 there was a 65% drop in cervical cancer incidence. The incidence had already been dropping due to increased screening and treatment of precancerous lesions, but this is now the first cohort of women who received the vaccine and they show a significant increase in the rate of decline.
HPV causes almost all cases of cervical cancer, and also increases the risk of cancer of the vulva, vagina, penis, anus, and oropharynx. The HPV vaccine is extremely effective at preventing HPV infection.
Other US studies have shown “surprisingly large” herd immunity, the study authors said. Sexually active females age 14 to 24 who were vaccinated showed a 90% reduction in infections with HPV-16 or HPV-18, and even those who had not been vaccinated had a 74% reduction in infections.
This is an opportunity to virtually eliminate cervical cancer, and significantly reduce the others listed above. The only thing that stands in the way is vaccine hesitancy. The authors also report:
In 2020, only 32% of boys and girls ages 13 to 17 in Mississippi were up to date with HPV vaccination and only 43% in West Virginia. States with high proportions of vaccinated teens include Massachusetts (73%), Hawaii (74%), and Rhode Island (83%). In the coming years, these differences will become apparent in incidence rates for cervical and other HPV-associated cancers.
We have the technology to eliminate a type of cancer with a safe and effective preventive measure. We now have data that the HPV vaccine not only works to prevent HPV infection but also cervical cancer. We need sustained efforts to make the public aware of these facts so as not to lose out on the potential benefits of this technology.
The other interesting result of this latest cancer data is that the story of screening for prostate cancer continues. The issue is using prostate specific antigen (PSA) levels in the blood to screen for early prostate cancer. This screening works, but does tend to have a lot of false positives, which can lead to unnecessary biopsy and surgery. For that reason in 2008 the US Preventive Services Task Force (USPSTF) changed their recommendation, to not use PSA for routine screening in men 75 and older, and then later for all men.
This change resulted in a decrease in prostate cancer diagnoses – but this was not a real decrease, just an artifact of decreased screening. Now we are seeing the downside to this decision – for the first time in 20 years, death from prostate cancer has increased in the US. Further, the proportion of prostate cancer that is diagnosed in a later stage when the cancer is harder to treat has doubled in the last 10 years.
This is all a balancing act between optimal screening of at risk populations while minimizing false positives and the negative effects that come from it. The same debate was had with regard to mammograms and breast cancer. More screening is not always better.
The recommendations on using PSA to screen for prostate cancer have therefore again shifted. Now the recommendation is for men 50 and older to have a conversation with their primary doctor about the risks and benefits of PSA screening, and to make an informed individual decision. The problem can also be mitigated by newer technology, using markers and imaging to stage prostate cancer. The PSA story is a good example of how cancer statistics are used to tweak medical practice and recommendations.
There is more in the full report, but these were the highlights. Overall the report is good news. Cancer treatment, starting with prevention, continues to improve. The reports estimates that 3.8 million cancer deaths have been averted since 1991. Cancer is still a scary diagnosis, but it is decidedly less scary than it was 30 years ago.

Colonoscopy and Other Colorectal Cancer Screening Options: An Update
Harriet Hall on November 12, 2013
Link
When I wrote about colonoscopy in 2010, colonoscopy was thought to be the best screening test for colorectal cancer because it could visualize the entire colon and could remove adenomas that were precursors of cancer. But only fecal occult blood testing (FOBT) and sigmoidoscopy had been proven to decrease colorectal cancer incidence and mortality (by 16% and 28%, respectively). Observational evidence suggested that colonoscopy would reduce the incidence and the number of deaths from colorectal cancer, but there were no randomized controlled trials, and the reduction in incidence of cancer after colonoscopy screening seemed to be restricted to left-sided colon cancers, which didn’t make sense.
We still don’t have any randomized controlled trials of colonoscopy, but a 2013 case-control study from Germany compared patients with and without colorectal cancer and found that those who reported having had a colonoscopy were less likely to develop colon cancer for up to 10 years after the procedure. And now two studies published in the New England Journal of Medicine in September 2013 have shed more light on the subject.
Sigmoidoscopy or colonoscopy vs. no screening
A large cohort study by Nishihara et al. looked at data from the Nurses’ Health Study and the Health Professionals Follow-up Study with a total of 88,902 subjects followed for 22 years. During that time, 1,815 colorectal cancers developed, and 474 subjects died from colorectal cancer. Those who had sigmoidoscopy or colonoscopy were much less likely to develop colon cancer than those who did not.
COLORECTAL CANCER	Hazard ratio compared to no endoscopy
After polypectomy	.57
After negative sigmoidoscopy	.60
After negative colonoscopy	.44
In right colon after negative colonoscopy	.73
	
DEATH FROM COLORECTAL CANCER	
After sigmoidoscopy	.59
After colonoscopy	.32
From right colon cancer after colonoscopy	.47
From right colon cancer after sigmoidoscopy	No reduction
This is very encouraging. Colonoscopy cuts the incidence of colon cancer and of death from colon cancer by more than half. And it’s clearly superior to sigmoidoscopy in detecting cancers in the right side of the colon (proximal colon).
Usual care vs. fecal occult blood testing
The second study, by Shaukat et al. was a randomized controlled trial comparing usual care to annual or biennial screening with fecal occult blood testing (FOBT). It followed 33,020 subjects age 50-80 for 30 years. Annual screening reduced colorectal cancer mortality to a relative risk of .68; biennial screening to a relative risk of .78. All-cause mortality was not reduced. There was no benefit of screening below the age of 60 in women, although there was for men.
10% of participants had a positive FOBT at each screening, and 83% of those were further evaluated by colonoscopy, with polypectomy if polyps were detected. Long-term reduction of risk of death from colon cancer was consistent with the effect of removing adenomas that would have progressed to cancer and death.
It would not be appropriate to draw conclusions about the relative efficacy of FOBT vs. colonoscopy from these very different trials. There is still no evidence from randomized controlled trials directly comparing FOBT with colonoscopy, but such trials are in progress.
The recently introduced fecal immunochemical test (FIT) is more sensitive than the traditional guaiac test for FOBT, so it is likely that the results of fecal testing will improve. What we can say is that both types of screening are effective, and that the studies support current screening recommendations of FOBT annually, sigmoidoscopy every 5 years, or colonoscopy every 10 years from age 50 to 75. Patients can choose any of these after considering cost, complications, convenience, and other factors. Two other possible options are screening with barium enemas and virtual colonoscopy. Virtual colonoscopy (with CT) requires the same bowel prep as colonoscopy and if an abnormality is found, regular colonoscopy is still required for follow-up. Barium enemas miss about 50% of the cancers that can be found with colonoscopy. Both of those involve considerable exposure to radiation.
My colonoscopy experience (anecdote alert!)
I thought I would share my own colonoscopy experience for interested readers who want to hear a personal story about what it involves and what it’s like. If you’re not interested, just skip to the next heading. After reviewing the evidence and the pros and cons of each option, and considering my personal feelings about colonoscopy, I elected annual FOBT screening, and this year one of the three FOBT tests was positive for occult blood, so I had to bite the bullet and have a colonoscopy. It didn’t cost me anything, since as a military retiree I’m covered under Tri-Care for Life, but it was time-consuming. It involved 3 separate appointments on different dates: (1) with my primary provider to get a referral to the GI clinic; (2) in the GI clinic for pre-procedure history and physical and for education for informed consent (both by a physician assistant), and for instructions about the prep (by a nurse); and (3) for the procedure itself, which also required a time commitment from my husband who was required to be in the waiting room throughout the procedure and drive me home afterwards, since I couldn’t drive after IV sedation.
The thing I dreaded most was the bowel prep, and most people agree that’s the worst part of the procedure. I got a new and improved split-prep regimen. For 3 days before the colonoscopy I had to avoid high-fiber foods like popcorn, beans, seeds, multigrain bread, nuts, salad/vegetables, and fruit, which made meal planning a bit problematic. The day before colonoscopy, I was only allowed clear liquids, and was told to drink 8 ounces every hour, to include water, apple or white grape juice, broth, coffee or tea (without milk or cream), clear carbonated beverages, Kool-Aid (not red or blue), Jell-O (not red or blue), popsicles (not red or blue). They gave me a huge plastic jug with bowel prep powder with instructions to fill with water, mix, and keep refrigerated. Late in the afternoon on the day before colonoscopy, I had to start drinking an 8 oz glass of the bowel prep every 15-20 minutes until the level was down to a mark they had made on the jug. I was also instructed to continue hourly clear liquids up until midnight to prevent dehydration. On the morning of the colonoscopy I was instructed to skip my usual medications and drink the remaining solution, 8 oz. every 15-20 minutes, finishing 3 hours before leaving for my appointment. The solution didn’t taste very good, and it was difficult to force so much down in such a short time and the frequent intervals required watching the clock carefully or setting an alarm. I didn’t get nauseated, but I felt bloated and uncomfortable, and of course I spent quite a lot of time on the john including throughout the night (didn’t get much sleep). No cramps, just a lot of liquid, and it became hard to tell when I needed to get to the bathroom. By morning only clear liquid was coming out.
The procedure itself was a breeze. I was admitted with a patient wristband, given a hospital gown and an IV was started. There was a long wait, and eventually my gurney was rolled into the procedure room, where I was asked to lie on my side and given a sedative through the IV. The next thing I knew, I was waking up in the recovery area. They told me they had removed one small polyp, and the pathology results would be available in three weeks. I had no pain afterwards, didn’t even pass a lot of gas as they had warned I might. Went home and slept for several hours. My abdomen felt vaguely uncomfortable for about 3 days afterwards.
The polyp was a 4 mm adenoma, and they recommended a repeat colonoscopy in 5 years rather than the usual 10 year screening interval. I dreaded having to go through the bowel prep again, and in 10 years I would be past the upper age limit for screening. I discussed this with a gastroenterologist I knew, and he agreed with me that in my case my personal risk factors for colon cancer were so low that it would be reasonable to wait longer than 5 years, so with any luck I will never have another one. I sure hope I don’t. The whole rigmarole was unpleasant and complicated. I sure hope science and technology will come up with a better screening test sometime soon. There has to be a better way!
I certainly don’t regret getting it. I considered it medically necessary because of the positive FOBT, and I no longer have to wonder whether all is well in my colon. They got a good look throughout and removed the one small benign polyp. That’s very reassuring.
Pros and cons of colonoscopy
Colonoscopy is undoubtedly the best option for examining the entire colon and removing polyps that might develop into cancer. But there are risks: perforation of the bowel (in less than 0.2% of patients), bleeding, anesthesia complications, dehydration from the laxatives, rupture of the spleen (rare), infection, nausea, vomiting, allergic reactions, and even death (in 0.003-0.03% of patients). There is a substantial time commitment and an average cost of over $1,185 in the US. The total cost to insurance companies and the government must be staggering. There is inconvenience, time lost from work, and an arduous bowel prep. There are not enough colonoscopists to screen the entire population as recommended. A gastroenterologist can spend a huge chunk of his time doing these routine screening procedures. According to a British report, clinicians did up to 448 a year, with an average of 205. I’d think a gastroenterology subspecialist would get bored and feel frustrated that after his 14 to 15 years of education after high school, he was spending so much time on such a routine procedure. As the population ages and the demand for colonoscopies increases, I wonder whether it wouldn’t make more sense to train PAs (physician assistants) to do the job. It’s basically a matter of manual skills, coordination, and practice, and I think PA’s could be taught to do it as competently and safely as MDs, and doctors could be on standby to assist in managing any complications that developed. It would save money and leave the gastroenterologists free to exercise the clinical expertise that they have trained so long to attain.
Conclusion
New evidence supports the current recommendations for colorectal cancer screening. Screening by either FOBT, sigmoidoscopy, or colonoscopy significantly reduces the incidence of colorectal cancer and the death rate from colorectal cancer. We still don’t have evidence to directly compare the effectiveness of the different options or to show a decrease in all-cause mortality. Trials are in progress that should provide that evidence. Meanwhile, if you are approaching the age of 50, you have a decision to make: not whether to be screened, but which screening test to choose.

Questioning Whether Psychotherapy and Support Groups Extend the Lives of Cancer Patients
James Coyne on August 31, 2012
Link
What a wonderful world it would be if cancer patients could extend their survival time by mobilizing their immune systems by eating the right foods, practicing yoga, and venting their emotions in a support group. The idea that patients can enlist their immune systems to fight the progression of cancer is deeply entrenched in psychosomatic medicine and the imagination of the lay public, and evidence to the contrary has been sometimes bitterly resisted. Of course, cancer patients can use psychological techniques to relieve stress or find emotional relief in support groups and thereby improve the quality of their lives. But the prospect of being able to improve the quality of life pales in comparison to the promise of being able actually to extend life.
The hope that psychosocial intervention extends lives attracts philanthropic contributions to cancer centers and justifies research programs to determine just how psychological processes affect cancer. It is a lot easier to obtain funding if we promise to slow progression of cancer than if we merely claim to offer patients solace and support or to be study ways to reduce stress and improve emotional well-being.
No mechanism by which the mind can alter the course of cancer has been convincingly demonstrated. But the jury was still out until the late 2000s, when well-resourced, carefully designed trials — with survival as the primary endpoint — repeatedly failed to show that psychological interventions were effective. My colleagues and I asked at the 2006 European Health Psychology Conference whether we could “Bury the Idea…” that psychotherapy could extend lives of cancer patients, and this was followed by our systematic review of the available data, “The Conflict Between Hope and Evidence.” Investigators who had undertaken ambitious, well-designed trials to test the efficacy of psychosocial interventions echoed with “Letting Go of Hope” and “Time to Move on.” For some of us, to make claims in earshot of cancer patients that we could extend their lives with psychotherapy was perpetuating a cruel hoax.
Then in 2010, a study was published that claimed that a package of dietary advice and stress reduction techniques could hold off recurrence and extend the lives of women with early breast cancer. We published a detailed analysis showing the intervention was essentially inert and that the authors were “Finding What Was Not There.” However in 2012, that trial was counted as positive in a nonsystematic and highly selective review in Psycho Oncology, “Mind Matters In Cancer Survival,” which concluded:
The majority show a survival advantage for patients randomized to psychologically effective interventions for individuals with a variety of cancers, including breast, melanoma, gastrointestinal, lymphoma, and lung cancers. Importantly, for breast and other cancers, when aggressive anti-tumor treatments are less effective, supportive approaches appear to become more useful.
So,this article argued, psychological interventions are particularly indicated to extend the lives of patients with cancers that are less responsive to aggressive biomedical treatments. Yet, the review failed to cite any of the seeming unanimous contrary assessments now being reached by others, nor even some highly relevant randomized trials with null findings. The first question I had to ask was “How did this article get through peer review?” My suspicions that it had not were confirmed when I saw that the journal indicated that had been received on February 16, 2012 and accepted on February 24, 2012. I wrote to the editor:
I was quite surprised to see [the] article on psychosocial interventions and survival in Psycho Oncology with such selective and distorted attention to literature and lack of attention to criticisms of this work. To me it appears like a breakdown in peer review … Is there any explanation for it?
She replied
Professor David Spiegel submitted this paper as a non-peer reviewed editorial as the Recipient of the IPOS Sutherland Award.
This privilege is offered to all who receive the Sutherland Lifetime Achievement Award.
The process of deciding who receives the Sutherland Award goes through a committee and external peer review process.
Invited Editorials in this category are read by the 2 co-editors to ensure nothing that might infringe copyright or lead to legal proceedings is written.
While some may not agree with Professor Spiegel’s opinions this would not be a basis for dis-allowing an invited editorial. Editorials may be opinion-based.
Yet, a “peer review” of whether to invite someone to author an article is a far cry from peer review of the article itself. And nowhere did the article state that it was an invited editorial or that the normal peer review had not occurred. The was an example of the unacknowledged privileged opportunities to publish articles espousing particular positions about which I have been complaining for awhile.
I will bypass the strict deadlines and word limits set by Psycho Oncology for a Letter to the Editor and will instead provide a critique here, drawing heavily on peer-reviewed commentaries that my colleagues and I have published.
The content of “Mind Matters in Cancer Survival” in Psycho Oncology overlaps considerably with an identically entitled commentary in JAMA by the same author, and the longer Psycho Oncology article shares nine of the 10 citations of the JAMA article. I do not know whether the JAMA article was thoroughly peer reviewed, but I can attest that a number of authors who actually conducted clinical trials with survival as the outcome wrote critical responses to JAMA that were summarily rejected without comment. So much for post-publication peer review, but freedom from criticism is one benefit of privileged access publication. Articles showing up in the literature without acknowledgment that they have evaded peer review, either prepublication or post, is confusing and slows the progress of science. An article protected from criticism escapes the kinds of influences that serve to move scientific discussion forward. Science should be about reconciling ideas with embarrassing data.
The shorter JAMA article framed the issue of how mind matters in cancer survival much the same as the Psycho Oncology article, but did so in a more dramatic and disconfirmable fashion. For instance, the JAMA article more boldly cites as evidence of psychological control over disease progression that
Individuals tend to die after rather than before their birthdays and major holidays, suggesting some ability to postpone death for a short period to reach a meaningful goal.
This idea was the basis of the movie Black Swan but has been thoroughly debunked. A systematic review concluded
Research over the past three decades has failed to provide convincing evidence that psychological phenomenon such as ‘giving up’ or ‘holding on’ can influence the timing of death.
Keeping this myth alive, of dying persons controlling the time of their death, burdens cancer patients and their caregivers with unrealistic hopes that patients can, if they try hard enough, keep themselves alive for important family events. Conversely, if patients are nonetheless dying at times that are inopportune for family members, they can be accused of not trying hard enough or simply not being made of the right stuff. Even worse, the myth encourages family members to exhort dying patients to hang in there and endure excruciating pain to be alive for family events, rather than graciously accepting the end or whatever fits their personal preferences.
The JAMA “Mind Matters in Cancer Survival” also interprets in more decisive terms a recent palliative care trialwith non-small cell lung cancer patient . The trial had found that patients who given four opportunities to discuss resuscitation preferences, pain control, and the aggressiveness of treatment received less aggressive treatment, were less depressed, had higher quality of life, and lived longer with a median survival advantage of 2.25 months.
The JAMA article imposed this interpretation
This apparently counterintuitive finding suggested emotional support is not only psychologically beneficial but also medically efficacious. Moreover, the palliative care intervention also improves the quality of life by reducing depression.
Perhaps, but maybe more aggressive treatment at the end of life might not only decreases quality of life but actually shorten life. There is no indication in the original article that the investigators’ primary motive was to extend life, certainly not at the cost of other considerations. And with the intervention group receiving less aggressive treatment, the most parsimonious explanation of results is that life was shortened in the control group because of more aggressive treatment. We don’t know if the treatment received in the control group was less medically appropriate, but we certainly don’t have a basis to jumping to the conclusion that provision of emotional support to the intervention group was the key mechanism for the longer survival of the intervention group.
The Psycho Oncology article counts this trial as the eighth of a series of trials providing positive evidence for the efficacy of psychotherapy in promoting survival of cancer patients. (Whoops! When did this become a trial of psychotherapy?)
enlargeFew of the other “positive trials” listed in Table 1had survival as their primary endpoint. Most were not shown to improve survival in appropriate analyses. Among those that came even close, none were construed by their investigators as testing psychotherapy. I will review the widely misunderstood 1989 Spiegel Lancet study in a future blog post, but here I will concentrate on why the other trials the Psycho Oncology article claims to have shown “survival benefits from psychotherapy” did not do so. I will also call attention to some relevant trials that the article missed altogether, and then point to some strengths of the trials conceded in the article to be negative.
Richardson JL, Shelton DR, Krailo M, et al: The effect of compliance with treatment on survival among patients with hematologic malignancies. Journal of Clinical Oncology 8:356-364, 1990
This trial evaluated 3 different interventions training low income patients with hematologic malignancies and their caregivers in the monitoring of side effects and complications, how they could communicate better with medical personnel, and the need for them to recognize and get prompt attention for fever, bleeding, and other medical problems. One of the three interventions involved home visits and leaving poster reminders of what needed to be done. The investigators’ description of their interventions does not sound like psychotherapy. To remove any doubt, I wrote to the first author and I published her reply:
“I would agree that our study was not psychotherapy. Our study was very behavioral in concept and delivery – teaching people how to manage the disease, the treatment and the health care system. I think you can go a long way with basic patient education, family education, and health care system manipulation strategies.”
An earlier report of this trial does designate survival as a primary endpoint. With no more than 25 patients assigned to the control group or any of the three interventions, the trial would have been grossly underpowered to test effects on survival of any one of the different interventions. Post hoc survival analyses combined the three different intervention groups into one. Simple univariate analyses revealed a survival benefit for patients getting one of the interventions.
The authors state
It is also possible that the programs, by training the patients to be responsible for their own care, allowed them a sense of greater control and resulted in less fear and anxiety (p. 363).
This quotation has been cited elsewhere as the basis for counting this study as evidence that psychotherapy improves survival. Yet, the intervention did not focus on reducing fear and anxiety, and a related paper from the project reports no changes in depression across the intervention period.
The most parsimonious explanation of this trial is that after discharge from the hospital, low income and nonEnglish-speaking cancer patients benefit from education and home visits for them and their families, but it seems quite a stretch to invoke some unmeasured psychological processes as the mechanism.
Fawzy FI, Fawzy NW, Hyun CS, et al: Malignant-melanoma – effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Archives of General Psychiatry 50:681-689, 1993
This small study of stress management and health education for postsurgical malignant melanoma patients did not have survival as a primary endpoint and did not have even a provision for long term follow-up. Nonetheless, inspired by the Spiegel 1989 Lancet study, the authors undertook a post hoc examination of survival at 5-6 and 10 years post treatment and declared
When controlling for other risk factors, at 5- to 6-year follow-up, participation in the intervention lowered the risk of recurrence by more than 2 1/2 fold (RR = 2.66), and decreased the risk of death approximately 7-fold (RR = 6.89). At the 10-year follow-up, a decrease in risk of recurrence was no longer significant, and the risk of death was 3-fold lower (RR = 2.87) for those who participated in the intervention.
Largely as a result of this claim, the study received widespread attention and for a long time, little critical scrutiny. Yet, when it was entered as evidence in the Great Debate (Resolved: Psychosocial Interventions Can Improve Clinical Outcomes in Organic Disease) held at the American Psychosomatic Society in 2001, it was savaged by Arnold Relman, former editor of the New England Journal of Medicine as being
…fatally flawed because the analysis is not by the intent-to-treat method, which should be standard epidemiologic practice. The authors did not report the results on all their randomized subjects, which would have been the proper, “intent-to-treat” procedure. The number of exclusions and losses to follow-up after randomization could easily have affected the outcome critically since their groups were relatively small and they report a relatively small number of deaths or recurrences. So, I believe that any critical and experienced epidemiologist would consider that study invalid. You have to analyze by intent to treat, and there were enough cases lost to have totally changed the results and the conclusions, depending on their outcome. You simply cannot find out what happened to a lot of missing patients in this study, so you cannot have much confidence in the conclusions.
Wally Sampson, editor emeritus of science-based medicine caught some strangeness in the control group of this study. The 5-year survival of Stage I melanoma in the time after the trial was approximately 92%, yet the 5-year follow up survival for patients from the control group retained for analysis was only about 72%. Sampson calculated that the probability of a representative sample of 34 persons with Stage I melanoma having a 5-year survival rate this low is about 0.001.
Our detailed review of both the 5-6 and 10 year follow-up articles confirmed:
    • Main analyses were biased by selectively excluding patients after randomization. Of the 40 patients assigned to the intervention group, one patient was excluded due to death, one due to incomplete baseline data, and a third due to the presence of Major Depressive Disorder.
    • In contrast, of the 40 patients assigned to the control condition, only 28 completed baseline and 6-month assessments, but survival data were included for those in the control condition regardless of the completeness of their data.
    • Fewer patients randomized to intervention and retained for analysis had died at 5-6 year follow-up than control patients (p = .03), but this difference would become non-significant with the reclassification of one patient or reversal of any of the many post hoc decisions about selectively including or excluding patients.
    • The impressive claims about a sevenfold difference in survival at 5-6 years and threefold at 10 years represent an abuse of statistics. First, a simple log-rank test was not significant for differences in the distributions of survival for the two groups. Second, the authors apparently confused odds ratios with relative risks. Odds ratios are useful in observational studies, but they are likely to overestimate the benefits of offering an intervention in clinical practice when applied to results of randomized trials. Third, these odds ratios arise only in inappropriate multivariate analyses. The authors selected possible covariates from preliminary analyses that allowed inspection of almost as many covariates as the number of deaths to be explained (20) at the 5 to 6 year follow-up. Even the small pool of covariates retained for subsequent analyses violated the usual rule of having at least 10 to 15 events (in this case deaths) to be explained per covariate.
The Psycho Oncology article does not mention that in 2007 a Danish group reported results of a large, well designed controlled trial attempted to replicate the Fawzy study. Fawzy’s co-author/wife served as a consultant. No effect for survival or time to recurrence was found.
Kuchler, T., B. Bestmann, et al. (2007). “Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. JCO,25(19): 2702-8.
This study was covered in my inaugural blog post and claimed that 222 minutes of psychotherapy produced a 10-year survival benefit among a mixed group of patients with gastrointestinal cancer. The Psycho Oncology article interprets this as another demonstration of the power of mind in cancer survival, but a simpler explanation is more reasonable. Namely, therapist took an active role in medical care and spent about as much time interacting with the rest of the medical team as with the patients. Compared to the control group, the intervention group received a lot more postoperative chemotherapy, radiotherapy, and time in intensive care. This difference in medical care cannot readily be dismissed.
McCorkle R, Strumpf NE, Nuamah IF, et al: A specialized home care intervention improves survival among older post-surgical cancer patients. Journal of the American Geriatrics Society 48:1707-1713, 2000
This nursing intervention for postsurgical cancer patients emphasized both physical and psychosocial support and the monitoring of physical status and an offsetting of potentially lethal complications of surgery. The article identified as the intervention’s key focus the monitoring of physical status and heading off potentially complications of surgery. A later meta analysis evaluating whether psychological interventions increased survival excluded the trial because
The result may… reflect an effect of combined optimized medical treatment and psychosocial intervention
The authors seemed intent on distinguishing their trial from a psychosocial intervention, stating
…this is the first [trial] to examine the impact of…nursing interventions on survival in cancer patients. Other studies have focused on patient’s psychosocial status, including depressive symptoms, function, and the effects of support groups.
To settle any doubt about the authors’ aims, I asked the first author directly and published her reply
We did what we did really because of the physical care. The deaths were related to major complications, sepsis, pulmonary embolus, etc. The nurses picked these things up and prevented the crisis” (R. McCorkle, personal communication, August 3, 2004).
Spiegel D, Butler LD, Giese-Davis J, et al: Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer – A randomized prospective trial. Cancer 110:1130-1138, 2007
This study attempted replication of the original Spiegel 1989 Lancet study with a somewhat larger sample of 67 women with confirm metastatic or locally recurrent breast cancer and a control group[ in which 61 women received only educational materials. The text of the Psycho Oncology article notes that the trial had no overall effect on survival, but counted it in the table as a positive finding based on post hoc subgroup analyses in which women with negative estrogen receptor status (n = 25) in the intervention group live longer when exposed to the intervention. This would not have been hypothesized. If anything, given psychoneuroimmunological speculations about psychological factors in breast cancer, an effect of psychological intervention restricted to positive estrogen receptor status women would have been predicted.
Regardless, an argument is being made on the basis of post hoc subgroup analyses involving only 25 patients. The Psycho Oncology article also fails to note that another study of supportive expressive therapy failed to replicate this finding in similar post hoc analyses.
Andersen BL, Yang HC, Farrar WB, et al: Psychologic Intervention Improves Survival for Breast Cancer Patients A Randomized Clinical Trial. Cancer 113:3450-3458, 2008
The study has been interpreted as a challenge to the conclusions of my colleagues and me that no trial psychosocial intervention has ever achieved a positive effect with survival designated as a primary outcome and in which there was no medical co-intervention confound. The intervention involved providing women with strategies to reduce stress and improve mood and diet in ways believed to influence the likelihood of recurrence. The study has been widely hyped and now NCI is even offering free training and delivering this intervention, an issue I will address in a future blog. My colleagues and I examined this trial carefully and concluded in a published critique that survival was not in a primary outcome and there was a lack of evidence that an effect on survival had been achieved.
We noted that the article reporting survival inexplicably did not provide the usual unadjusted outcomes for survival, such as a Kaplan-Meier estimate, which would allow independent evaluation of claims of an effect on survival. Also, the number of women experiencing a cancer recurrence did not differ significantly between the intervention (25.4%) and control conditions (29.2%). Odds Ratio = 0.83, CI = 0.46 – 1.48, P = .525. The difference in median time to recurrence was small –six months– with the range of time to event approximately 11.8 years in the control group and 10.9 years in the intervention group. There was no difference in the proportion of women who died in the intervention group (21.1%) versus the control condition (26.5%), Odds Ratio = 0.74, CI = 0.40 – 1.36, P = .332, with a similar lack of results when we examined only those deaths due to breast cancer. Finally, the differences in recurrence (n=4) and survival (n=6) between the 2 groups was less than impressive.
This was about as far as we could go in re-analyzing the data available in their article. When we submitted our critical commentary to Cancer, Professor Anderson attempted to have it suppressed and when she did not succeed, she refused to offer a reply. She has since also refused to answer journalists’ questions concerning our commentary.
The Trials Considered Negative in the Psycho Oncology Article
My colleagues and I reviewed the trials considered negative in the Psycho Oncology article. Of the seven trials counted as negative, three (1, 2, 3) were large, well conducted and transparently reported trials with survival as an a priori outcome. A fourth smaller trial also had survival as an a priori primary outcome and included more patients who were actually exposed to the intervention than the original Spiegel Lancet study.
A fifth study achieved modest, but unsustained improvement on mood measures and no effects on survival, but there is no evidence that survival was an a priori primary outcome.
A sixth study explicitly rejected survival as an outcome for a sample of patients with stage IV cancer included on the basis of clinician judgment that they had less than 12 but more than three months to live. These patients were chosen on the assumption that being so close to death, “advanced intervention [of any kind] has relatively little impact on survival” and so psychotherapy focused on improving “the quality but not the length of survival”.
A final study by Ilnyckyj and colleagues excluded patients who were judged to need psychotherapy, but nonetheless provided psychotherapy in groups led by professionals who “were not instructed any specific techniques” and who lacked the guidance of any treatment manual. There was a breakdown randomization of the study, and no differences were found for psychological outcomes. The trial remained unpublished until a medical fellow who was not involved in the original study was inspired by publication of Spiegel’s Lancet article to undertake a 11 year follow-up. The study would have remained in obscurity because it in was published in a soon defunct journal (Annals of the Royal College of Physicians and Surgeons of Canada) and was not referenced in either PubMed nor ISI Web of Science, but it was included in a review by David Spiegel.
enlargeRelevant Trials Unmentioned in the Psycho Oncology Article
As I have noted, the Psycho Oncology article failed to note either a well-designed intervention study that failed to replicate Fawzy’s results or another study that failed to replicate subgroup analyses for Spiegel’s 2007 findings of differences associated with estrogen receptor status. Another study that was ignored was a large, well designed and well controlled study of a home intervention providing support and information to cancer patients and had null findings. Finally, a study of cognitive behavioral symptom management intervention for patients with solid tumors appeared too late to be included in the Psycho Oncology article, but meets the criteria by which other trials were included. Post hoc analyses revealed no effect on survival.
Boxscores are for Baseball, not the Evaluation of Clinical Trials
We can beconfident that the boxscores newspapers reported for the major leagues include the valid scores of all the relevant games with no games included that should not have been. For a variety of reasons, these conditions do not hold for boxscores of clinical trials, and most authorities reject and even ridicule reliance on boxscores for the evaluation of interventions has evidence-based.
The Psycho Oncology article gives an 8-7 boxscore for positive versus negative trials evaluating psychosocial interventions promoting survival of cancer patients. But the flaws in how this score was calculated highlight why most authorities negatively view boxscores. The trials counted as positive include three for which authors of the original study denied were tests of psychotherapy and another in which the group assigned to psychotherapy also received considerably more medical intervention. A fifth study had not even declared survival as a primary outcome, and classification of it as positive depends on secondary subgroup analyses. A sixth study also did not have survival as a primary outcome, used different rules for retaining intervention versus control patients, and relied on voodoo statistics to support claims of an effect on survival. A seventh study claimed to have obtained an extension of life for early breast cancer patients, but this claim depends on voodoo statistics, and the author has refused to respond to published criticisms.
The final trial classified as positive, Spiegel’s original Lancet study, will be discussed in detail in my next post, but it suffices to say here that it too was not designed with survival as the primary outcome.
Boxscore evaluations of clinical trials disregard the quality and even the aims of studies. None of the studies classified as positive had both survival a primary outcome a priori and had equivalent medical treatment delivered to intervention and control groups. In contrast, a number of negative studies designated had survival has an a priori outcome and some negative trials were simply not included in the Psycho Oncology evaluation.
We cannot quantify publication bias in the literature concerning whether psychosocial interventions affect survival, but we can establish that there it’s substantial. First, published trials that are accepted as relevant are a small subset of the many trials conducted to evaluate effects of interventions on psychological outcomes without survival as a primary outcome. There has been little interest in going to each of these studies to conduct post hoc follow-up survival analyses, particularly when the mechanism by which psychological intervention could influence survival is so undocumented. If someone were to attempt such a follow-up analysis and obtained negative findings, a report would probably not be published. The rationale for rejection was that the trial was not intended to test an effect on survival. On the other hand, finding an effect on survival in post hoc analyses would be a “man bites dog story” considered worthy of publication.
There is evidence of publication bias even for well-designed studies that designated survival as a primary outcome. Journal of Clinical Oncology published an extremely flawed study claiming positive results. Yet, when I contacted authors of well-designed studies with null findings, they reported that their manuscripts were rejected at Journal of Clinical Oncology. Confirmation bias is high, especially for the publication of studies with attention-getting hypotheses, even if they are implausible.
The hypothesis that psychotherapy can improve survival concerns a basic biomedical outcome, and yet evaluations of it have not adhered to the basic rules by which biomedical interventions are evaluated. I doubt whether the hypothesis would have kept in circulation if was evaluated by those rules. “Evidence” is summarily rejected in the biomedical literature when it has small samples with post hoc re-designations of primary outcomes, reliance on subgroup analyses and analyses that are not intent to treat, and ignoring of powerful confounds. Why should it be any different for psychosocial interventions that allegedly affected the same important biomedical outcome, death?
Claims that psychotherapy promotes survival of cancer patients represent the same woo science that is used for other complementary and alternative interventions. These false claims can confuse patients making difficult choices about accepting disfiguring and painful medical procedures with established efficacy. Moreover, particularly at the end of life, the false hope of psychotherapeutic intervention extending patients lives can distract them from putting their lives in order and planning for a good death, unburdened by anyone’s expectation that they need to fight on.
I renew my offer to publicly debate the hypothesis that psychotherapy promotes survival. I’m sure we could sell a lot of tickets and I would donate my proceeds to a charitable cause offering psychosocial interventions to improve the quality of life of under-served cancer patients and their caregivers.

Don’t Blame the Patient
Steven Novella on April 24, 2024
Link

When patients are diagnosed with cancer, or a terminal illness of any kind, they report that there are a couple of near universal reactions by the people around them. First, everyone has advice for them. Everyone thinks they know what caused their illness and what will cure it. The floodgates of free advice and misinformation open.
Everyone also wants them to stay positive. A positive attitude will get them through their illness. Many patients internalize this advice, as in this patient discussing her diagnosis of brain cancer:
“It hasn’t been sunshine and rainbows since getting my diagnosis, but I still believe in the law of attraction. I believe that if I think more positive thoughts, I will attract more of the positive things I want in life. I can’t do this 100% of the time, but in my experience, thinking this way as much as possible has yielded positive results.”
But when the diagnosis of cancer was confirmed she also had this reaction:
“At first, it was hard to believe that our positive intentions hadn’t worked. I even blamed myself for not being positive enough.”
It is easy to see the attraction of believing in a positive attitude, for patients and for everyone around them. It’s uncomfortable and difficult to deal with a serious and potentially fatal diagnosis. People struggle to find something positive to say, to take some of the emotional sting out of the situation. Patient’s themselves want to believe they have some degree of control over their situation. Belief in the power of positive thinking does the trick, so people reach for this.
There is also an entire cottage industry of alternative medicine gurus who are essentially selling the snake oil of positive thinking. Throw in a little dietary and lifestyle advice, maybe some magic energy, and you have the whole package. Anything, it may seem, is better than the stark reality of biology. Patients with serious diagnoses like cancer are extremely vulnerable, and make easy targets for selling false hope.
But most people advising positive thinking mean well, and they may really believe it. It’s one of those fold wisdoms that many people believe but happen to be wrong. There is a legitimate scientific question here – is there any measurable effect from having a positive attitude in terms of survival or perhaps quality of life? It’s not entirely implausible that there would be. Attitude may affect compliance with treatment, a better appetite and therefore nutrition, and improved sleep. More speculatively it’s possible that increased emotional stress releases corticosteroids that suppress immune function.
But this question has been asked and answered years ago. Here is one review from 2010:
“Claims about these areas of research routinely made in the positive psychology literature do not fit with available evidence.”
Perhaps the definitive study involved over 1000 patient with head and neck cancer, and found:
“No statistically significant univariate or multivariate effects were observed for emotional well-being, and there were no effects limited to subgroups. These results stand in sharp contrast to the prognostic value of a variety of demographic and clinical variables.”
The study was able to see the effects of demographics and clinical variables, but not attitude or emotional outlook. Some studies, however, show a positive effect on quality of life, but this, of course, is more subjective. It’s also a bit circular – people who are happier seem to be happier.
But the pressure to be positive can also have a profoundly negative effect on patients. They feel guilty when not being positive, and they blame themselves when things go poorly because they were not positive enough.
Sometimes a positive attitude is formulated as a specific intervention. But these don’t work either. As the American Cancer Society summarizes:
“Research has not shown that techniques like guided imagery, relaxation, or meditation can control cancer growth.”
Further, what I find when looking through the literature for the last decade is that researchers have essentially stopped looking at the question – meaning the effects of attitude on survival or disease course. All of the studies are of subjective outcomes, like anxiety, symptom management, or some measure of quality of life. Even there the results are mixed and modest.
Given this reality, it is arguably important not to burden patients with what has been termed “the tyranny of positive thinking”. This is just a setup for false hope, disappointment, and self-blame. It’s also a setup for exploitation, which can sap people and their loved-ones of limited time and resources.
This is not to say there is no value in counseling or helping people with terminal diagnoses to make the best of the time they have. But I would further argue that having a realistic view of the medical reality, whatever that is, is helpful. It helps people accept their situation and make the best of it, or react in whatever way they want. Belief in magic is counterproductive, and leads to poor decision-making and often self-blame.
Patients do not need you to tell them everything will be alright, that they can beat their cancer if they stay positive, and they don’t need you to tell them how to respond to their diagnosis. They just need your love and support. You don’t have to offer a solution, especially a false one.

Using Viruses to Treat Cancer
Engineering viruses to target cancer cells is an emerging and promising avenue for cancer treatment.
Steven Novella on September 28, 2022
Link

Cancer remains a severe and challenging health problem. It remains the number two killer in developed nations, after heart disease. It is also a complex category of diseases that are very difficult to treat. Despite that, progress has been steady, with cancer survival increasing by about 1% per year over the last few decades. This adds up – with cancer survival increasing by 32% from its peak in 1991 to 2019. There is no single reason for this increase, it is the cumulative effect of multiple new treatments and advances.
This is important to keep in mind when interpreting news reports of new cancer treatments. There will likely never be (at least not anytime in the foreseeable future) a “cure for cancer”. Rather, there will be a series of incremental treatments. New treatments always sound incredibly promising, and sound as if, in theory, they should eradicate all cancers. Then in clinical trials it turns out they are an effective treatment, but far from a cure. Yet they add to the total set of tools we have to fight cancer, chipping away at the problem and contributing to the increase in survival.
We also have to recognize the time it takes to develop these ideas into safe and effective treatments. Often there is a 20-30 year delay from original concept to making a significant impact in the clinic. At the beginning of my career in the 1990s I remember hearing about monoclonal antibodies and how powerful they were. Already they were an important tool for research. But it is really only in the last decade that monoclonal antibody therapies have taken off, and now it appears there is a monoclonal therapy for almost everything.
Viruses
The use of viruses as a tool for treatment also has a long history. The first virus was discovered in 1892, and soon after it was observed that viral infections could be associated with tumor regression. Deliberate viral infections were used to treat cancer, but they did not work very well and the viruses also causes significant morbidity in healthy tissues. There was a resurgence of research in the 1950s and 1960s, but ultimately this went nowhere. Now we are in the middle of another resurgence of anti-tumor (“oncolytic”) viral therapy spawned by increasing technology in genetic manipulation, where we can engineer viruses to be more specific and more deadly to cancer cells.
The new study
A recent study illustrates where the research is. The researchers are using an enhanced herpes simplex virus (the virus that causes cold sores) called RP2 which they have modified in two ways. The first is to add a GM-CSF (granulocyte macrophage colony-stimulating factor), a fusogenic protein. Fusogenic proteins allow cells to fuse together. They also have effects on immune activity, and may both stimulate and repress tumor growth. So the effects are complex, but in this study the researchers were hoping that this protein would help target cancer cells, activate the immune system against them, and be directly oncolytic – killing cancer cells by causing them to fuse with neighboring cells.
They also added anti-CTLA-4 antibody-like molecules, which are a type of checkpoint inhibitor. This is another relatively new cancer treatment. Checkpoints (discovered in 1995) are proteins that keep immune T-cells from killing other cells, as a way of protecting host cells from auto-immune damage. Cancers often evolve these checkpoint proteins in order to protect themselves from the immune system. Checkpoint inhibitors are designed to inactivate these proteins selectively on cancer cells, allowing T-cells to target and kill them.
The RP2 virus, therefore, should target cancer cells, directly killing them and activating the immune system against them. Sounds promising. For some patients they also combined this therapy with a proven monoclonal antibody therapy – nivolumab (nivo), to see if there is a synergistic effect. Here are the results:
Objective responses with RP2 monotherapy were observed in 3 out of 9 pts including 1 CR for ≥15 months in mucoepidermoid carcinoma, 1 PR for ≥18 months in esophageal cancer with liver metastases, 1 PR in uveal melanoma with liver metastases that progressed at 15 months. Objective responses with RP2 + nivo treatment were 44.4% in cutaneous melanoma (4/9), 25% in uveal melanoma (2/8), and 33% in SCCHN (1/3) pts. All seven responding patients had previously failed anti-PD-1 therapy, with all but one response durable to date for >425 days.
Again, not a total cure, but these are promising results for such an early-stage study mostly designed to evaluate safety. Anti-PD-1 therapy is another checkpoint inhibitor. So these patients have already failed standard therapy, including similar advanced therapies. Any response is therefore likely incremental, meaning it can contribute to overall cancer survival.
Obviously a lot more research has to be done, and it may be another 10-15 years before these treatments become standard. So far it seems that the RP2 virus is well tolerated, but there is a lot of concern with safety when deliberately infecting patients with viruses. In this case the virus is directly injected into tumors, which does help with targeting, but viruses reproduce and spread so there is always concern they can cause harm to the host beyond the targeted tumor.
Conclusion: The hope and the hype of cancer treatments
Advances like this need to be looked at in two ways simultaneously. First, we need to be realistic about how long it takes to develop such treatments, and the ultimate impact they will have on cancer survival. They take a long time and generally have incremental effects. On the other hand, we are living in a science-fiction future from the perspective of just a few decades ago. We are using advanced genetic engineering and monoclonal antibodies to target proteins we didn’t even know existed in previous decades, and enhancing immune function in highly specific ways. It is imperfect and messy, but powerful. Improvements in cancer survival times are not only steadily increasing, they are accelerating.
This is what real science looks like, and it is far better then chasing our tails looking for magical or “alternative” therapies.

“Liquid biopsies” for cancer screening: Life-saving tests, or overdiagnosis and overtreatment taken to a new level?
David Gorski on September 28, 2015
Link

I’ve written many times about how the relationship between the early detection of cancer and decreased mortality from cancer is not nearly as straightforward as the average person—even the average doctor—thinks, the first time being in the very first year of this blog’s existence. Since then, the complexities and overpromising of various screening modalities designed to detect disease at an early, asymptomatic phase have become a relatively frequent topic on this blog. Before that, on my not-so-super-secret other blog, I noted that screening MRI for breast cancer and whole body CT scans intended to detect other cancers early were not scientifically supported and thus were far more likely to cause harm than good. That was well over ten years ago. Now we have a company offering what it refers to as a “liquid biopsy” for the early detection of cancer. I fear that this is the recipe for the ultimate in overdiagnosis. I will explain.
The problem, of course, is that disease progression, including cancer progression, is not always a linear process, in which the disease progresses relentlessly through its preclinical, asymptomatic phase to symptoms to complications to (depending on the disease) death. There is such a thing as disease that remains asymptomatic and never progresses (at which point it’s hard to justify actually calling it a disease). As I pointed out in my first SBM post on the topic, at least three-quarters of men over 80 have evidence of prostate cancer in autopsy series. Yet nowhere near three-quarters of men in their 80s die of prostate cancer—or ever manifest symptoms from it. This is what is meant by overdiagnosis, the diagnosis of disease that doesn’t need to be treated, that would never cause a patient problems.
When teaching medical students and residents, I frequently emphasize that overdiagnosis is different from a false positive because overdiagnosis does diagnose an actual abnormality or disease. For example, ductal carcinoma in situ (DCIS) diagnosed by mammography leading to a biopsy is a real pathological abnormality; it is not a false positive. We just do not know which cases of DCIS will progress to cancer and which will not, leading to a question of how DCIS should be treated or at the very least whether we should treat it as aggressively as we do now, particularly given that the apparent incidence of DCIS has increased 16-fold since the 1970s, all of it due to mammographic screening programs and the increased diagnosis of DCIS and early stage breast cancer has not resulted in nearly as much of a decrease in the diagnosis of advanced stage breast cancer as one would expect if early diagnosis were having an impact in reducing the diagnosis of late stage disease.
Overdiagnosis would not be such an issue if it didn’t inevitably lead to overtreatment. DCIS, for instance, is treated with surgery, radiation, and anti-estrogen drugs. Early stage prostate cancer used to be treated with radical prostatectomy, but now more frequently with radiation. Many of these men and women didn’t actually need treatment. We just don’t know which ones. This is why over the last six or seven years a significant rethinking of screening for breast and prostate cancer has occurred. There has been a backlash, of course, but the rethinking seems to have taken hold.
Not everywhere, of course.
A “liquid biopsy” for cancer
The concept of a blood test that can diagnose cancer is, of course, not a new idea. Indeed, prostate-specific antigen (PSA) screening for prostate cancer has been around for decades and is arguably just that: A diagnostic test used to diagnose or follow the progression or treatment of cancer. Ditto carcinoembryonic antigen (CEA) for colorectal cancer, CA19-9 for pancreatic cancer, and CA125 for ovarian cancer. Indeed, there are a wide variety of tumor markers, some useful, some not-so-useful, some worthless, that can be measured in the blood. Usually these are proteins or other chemicals produced more by specific cancers than by normal tissue that can be detected at elevated levels in patients with those cancers and often rise and fall with progression or response to therapy. For instance, for colon cancers associated with elevated CEA, CEA levels should fall to very low or undetectable levels after effective treatment and rising levels can indicate cancer recurrence.
These tests, as reliable or unreliable as they are, depending on the test, are associated with specific cancers. Even so, one question that always comes up whenever tumor marker levels rise is whether the recurrence—if recurrence there is—is a local recurrence where the tumor was resected or a distant (metastatic) recurrence. Local recurrences are often treatable for cure, albeit at much lower success rates than for a primary cancer, while metastatic recurrences usually indicate incurable disease. Another problem is that rising levels of tumor markers often precede detectable recurrence, resulting in a diagnostic challenge: Where is the recurrence? In the case of CEA, for instance, this problem has resulted in various clever strategies to label antibodies against CEA with radiotracers and then using intraoperative probes to seek where the antibodies bind. Even so, demonstrating improved survival targeting very early recurrences using such methods has been problematic. Indeed, it has been very difficult to demonstrate that finding very early asymptomatic cancer recurrences in general, regardless of the method used to detect them, improves survival. That is why we no longer do nearly as many routine scans after seemingly successful cancer treatment as we have in the past. In the vast majority of cases, it doesn’t improve survival, but it does cause all sorts of problems.
Enter CancerIntercept™ by Pathway Genomics
With that background in mind, how does a cancer clinician approach the recent press release by Pathway Genomics, which announced that “Pathway Genomics Launches First Liquid Biopsy Test To Detect Cancer-Associated Mutations In High-Risk Patients“? Here are some of the claims:
Pathway Genomics, a global precision medical diagnostics company, announced the launch of CancerIntercept™, its first liquid biopsy, a non-invasive screening test designed for early cancer detection and monitoring, for as low as $299.
The test detects mutations that are commonly associated with lung, breast, ovarian, colorectal cancers and melanoma, as well as mutations that occur less frequently in other cancer types (such as pancreatic, head and neck, thyroid, gastric and prostate cancers). View an animation of how CancerIntercept works here.
The test is offered for two general populations: CancerIntercept™ Detect is the first liquid biopsy designed to detect tumor DNA in high-risk but otherwise healthy patients; CancerIntercept™ Monitor monitors patients with active or previously diagnosed cancer. Both programs use advanced DNA analysis to identify small DNA fragments that are shed from cancer cells and released into the bloodstream. The tests analyze the presence of 96 frequently occurring DNA mutations in nine cancer genes.
“Early detection is the single most important factor in ensuring successful treatments and improved survival rates,” said Jim Plante, CEO and founder of Pathway Genomics. “Cancer patients and those at risk for the disease can take proactive steps to safeguard their health and fight back against some of the most virulent forms of the disease.”
In addition, with CancerIntercept Monitor, physicians are able to supplement more invasive tissue biopsies and scans with liquid biopsies to monitor cancer treatment efficacy, disease progression and recurrence. CancerIntercept Monitor can also be ordered with personalized Clinical Trial Matching for later stage cancer patients.
“Rising levels of tumor DNA may indicate progression of the cancer before there is clinical or imaging evidence of tumor growth” said Dr. Glenn Braunstein, MD and Chief Medical Officer of Pathway Genomics. “Our liquid biopsy tests may also detect new mutations that occur over time and signal that the patient is becoming resistant to current therapy.”
Naturally, Pathway Genomics has produced a very sophisticated animated video to tout the benefits of its new product:
In the press release, Pathway Genomics states that the test can be either ordered through a patient’s own physician or, helpfully, it has an “online physician referral network,” presumably of physicians willing to order the test if the patient’s physician is not. Of note, the $299 price is for patients receiving the test on a “subscription” service, with repeat tests done at quarterly intervals. For just one test, the price is $699; annual, $499, semi-annual, $399. In other words, the company is incentivizing patients to be tested more frequently by accepting a smaller profit margin in return for more frequent testing. As we will see, that there is a severe lack of compelling scientific evidence that quarterly testing with CancerIntercept™ Detect benefits patients more than semi-annual or yearly testing matters not at all. As we will also see, that there is an even more disturbing lack of compelling evidence presented that testing with CancerIntercept™ Detect decreases mortality rates from cancer even in high risk patients matters not at all.
A “cancer stethoscope,” dissected
Featured prominently in the promotional video, press release, and company website is a reference to CancerIntercept™ Detect and CancerIntercept™ Monitor as a “stethoscope” for cancer. It sounds like an awesome marketing simile, at least if you don’t think about it too closely. After all, CancerIntercept™ Detect is first a “yes-no” test: Is there DNA containing a cancer-specific mutation in the blood or is there not? Then it is—if you accept the company’s advertising materials—a diagnostic test. Which cancer-associated mutation(s) is there in the blood and at what level? A stethoscope, on the other hand, simply amplifies what can be heard without it. Before stethoscopes existed, doctors could simply put their ear to a patient’s chest or back. Moreover, interpreting heart sounds and breath sounds is a skill that requires a great deal of practice to master. It’s an essential skill for primary care physicians and many other specialties. Of course, it’s quite clever of Pathway Genomics to liken its test to this essential physician tool, but it’s a very imperfect analogy.
Be that as it may, let’s look at some of the specific claims made by Pathway Genomics. Which claims have merit? From my perspective, only one of the claims might have merit, while the rest are highly questionable at best. To understand which one, you must first know what, exactly, these tests do. Cancer cells release small fragments of DNA into the bloodstream, known as cell-free DNA or cfDNA. For CancerIntercept™ Detect, cfDNA in the blood is tested for the presence of circulating tumor DNA (ctDNA) by screening for specific cancer-associated mutations using polymerase chain reaction (PCR) to amplify both the mutant and wild type DNA, followed by a “specific enrichment of the mutant and simultaneous removal of the wild type DNA by using a proprietary technology,” after which the “mutant DNA is sequenced on Illumina’s next-generation sequencing platform.” Pathway Genetics claims that the test can detect two mutant copies of DNA per 5 ml blood sample. I always get a bit worried when I hear of a “proprietary” method to enrich mutant DNA compared to wild type (i.e., “normal”) DNA, because I can’t evaluate whether it’s an accurate and reliable method or not.
So what does this test detect? The test examines 96 mutation “hotspots” among nine cancer “driver” genes (i.e., genes that, when mutated, can cause cancer or contribute to cancer progression). The genes tested for are involved primarily in melanoma, breast, ovarian, lung, and colorectal cancers, and for those of you with the knowledge and inclination to evaluate them, these specific mutations in the following genes: BRAF, CTNNB1, EGFR, FOXL2, GNAS, KRAS, NRAS, PIK3CA and TP53. You don’t have to know all these genes for purposes of this discussion, but I list them for those who might be interested. Basically, to me it sounds like a shotgun approach to a bunch of mutations without anything resembling adequate clinical validation to justify its recommended use.
For whom is CancerIntercept™ Detect intended?
Helpfully, Pathway Genetics includes a “white paper” that enumerates what its tests do and what, according to the company, the supporting evidence is for their indications. Unfortunately, it’s mighty thin gruel. According to the white paper, CancerIntercept™ Detect can be used thusly:
For preventative surveillance of high-risk populations in order to screen for mutations that could indicate early disease. Examples of high risk populations include, but are not limited to:
    • Significant family history of one of the cancers that are known to harbor the mutations in the genes within the screen.
    • Known genetic predisposition for one of the screened cancer types.
    • Personal history of smoking, or prolonged exposure to second-hand smoke.
    • Exposure to known carcinogens, like radon.
    • Prolonged radiation or UV light exposure.
    • History of hormone use (fertility drugs, progestogen-containing hormone replacement therapy).
    • Certain reproductive and dietary factors.
    • History of certain infectious diseases or chronic health conditions.
(Cancer types included in the screen: breast, colorectal, lung, melanoma, and ovarian cancers).
In a FAQ, Pathway Genomics states that CancerIntercept™ Detect should be considered for basically the same sorts of patients and includes a link to its clinical questionnaire. As a questionnaire to determine the appropriateness of a screening test, it is quite risible. For instance, the very first question is “How would you rate your risk of cancer?” followed by a 1 to 10 scale, with 10 being the highest risk. If there’s one thing that most people don’t have a good handle on, it’s their actual risk for cancer; those at high risk tend to underestimate their risk while those at low risk tend to overestimate their risk. For purposes of a screening test—and, let’s face it, that’s how Pathway Genomics is marketing this test, as a screening test—what the patient thinks his or her risk of cancer is really doesn’t matter, except perhaps as a marketing tool for a test like this. What really matters are the parts of the clinical history that are predictive risk factors.
In fairness, the rest of the questionnaire does ask about family history, previous hereditary cancer tests, health conditions associated with a higher risk of cancer, and various environmental exposures, some common (alcohol, smoking), some less so (asbestos, nickel, chromium, silica dust, etc.). The problem is that nowhere on the form or in Pathway Genomics’ online literature is there an indication of a risk level as assessed by the test where CancerIntercept™ Detect wouldn’t be appropriate. If, for instance, a prospective patient were to check no relevant exposures, no family history of cancer, no diseases associated with increased risk, and that he or she was a teetotaler who never touched alcohol or tobacco, would the company refuse to run the test, even though that person has at most average risk for cancer but probably actually has lower than average risk? Somehow, I tend to doubt it. That is unlike, for instance, the OncoType DX test for breast cancer. If the patient is inappropriate for the test (her tumor is estrogen receptor negative or HER2-positive, for instance), the company will not run the test. Worse, in the white paper, there is no direct clinical trial evidence cited showing that this particular test decreases mortality for cancer or even results in earlier diagnosis. As is frequently the case with various alternative medicine modalities, there are lots of references cited; it’s just that many of them are not directly relevant, nor do they support many of the claims being made, particularly for CancerIntercept™ Detect.
For whom is CancerIntercept™ Monitor intended?
CancerIntercept™ Monitor is a similar test but intended for patients who have already been diagnosed with cancer. With this test the company is on a bit more solid ground than it is with CancerIntercept™ Detect, but still, in my estimation, makes a number of claims that are not fully supported by the evidence. According to the same Pathway Genetics white paper, CancerIntercept™ Monitor can be used thusly:
    • Monitor residual disease in patients with known mutations in the primary tumor.
    • Monitor treatment efficacy in patients.
    • Monitor disease progression and tumor evolution (i.e. development of tumor resistance).
    • Help the physician explore other options of treatment when the patient is resistant to current therapies.
    • Provide an alternative method for biopsy when tissue is difficult to obtain or not available, or when the primary site of metastatic disease is unknown.
    • Provide an alternative method for biopsy when the quantity of tissue obtained in a biopsy sample is limited and traditional molecular genotyping is requested.
    • Provide prognostic information for some patients.
I can see the potential utility of genomic tests applied to “liquid biopsies” of tumors. So can a lot of other investigators. It is true that, if a primary tumor has already been diagnosed, monitoring the mutation-containing DNA fragments in the blood might well be useful for identifying potential driver mutations and following response to therapy via a blood test rather than other more difficult tests. That’s why liquid biopsies are being tested in clinical trials. Indeed, Pathway Genomics lists a number of such clinical trials examining the prognostic value of various mutations screened for by the CancerIntercept™ Monitor and Detect tests in terms of recurrence, survival, and response to treatment, as well as correlation with the actual presence or absence of the mutation in the tumor itself. These tests could potentially be used to support the utility of a test like CancerIntercept™ Monitor in identifying specific mutations in patients with an already diagnosed cancer of a type that often harbors mutations tested for by the test.
My concern, however, is the lack of specific evidence that this specific test does what the company claims it does and is useful for the indications in patients with cancer that the company lists. Again, given that the enrichment process is proprietary, it’s impossible for me—and any other scientist with a molecular biology background—to satisfy ourselves that the methodology is sound, at least not without seeing some rather specific evidence from each step in the assay to show that it does what is claimed for a large number of samples and doesn’t over- or under-enrich for ctDNA.
The FDA steps in
Not surprisingly, the Food and Drug Administration (FDA) took an interest in Pathway Genomics’ claims after the splash it made with its announcement earlier this month, so much so that it sent a letter last week to Pathway Genomics Founder and CEO Jim Plante. Its letter doesn’t mention CancerIntercept™ Monitor, likely for the reasons I mentioned above. After all, there is an argument to be made that, if the test works as described, it is only combining tests for known cancer-associated mutations in ctDNA, although it must be pointed out that such a test is still only useful in the context of a clinical trial. In any case, that’s probably not a hill the FDA wanted to die on, at least not first, which is probably why instead the FDA does express a considerable amount of concern regarding CancerIntercept™ Detect. Specifically, in its letter the FDA expresses the very same concerns that I did:
We have conducted a review of our files and have been unable to identify any Food and Drug Administration (FDA) records reflecting the approval, clearance, or listing of these devices. We have also examined published literature and have not found any published evidence that this test or any similar test has been clinically validated as a screening tool for early detection of cancer in high risk individuals. We have reviewed the information presented on your website in the white paper, entitled “Liquid Biopsy for the Detection and Monitoring of Cancer: Analysis of 96 Hotspot Mutations via Plasma Derived Circulating Tumor DNA,” dated September 2015. It is unclear how the literature that you cited, addressing the presence of circulating tumor DNA (ctDNA) in already-diagnosed patients, is adequate to support the expansive claims of screening for early cancer detection using ctDNA in undiagnosed patients for up to 10 different cancers with the CancerInterceptTM Detect.
I agree. The literature cited by Pathways Genomics is in no way adequate to support the claims made for CancerIntercept™ Detect. I’d also add that the literature cited would not be adequate (to me, at least) to support the claims made for CancerIntercept™ Monitor, either, although for CancerIntercept™ Monitor the disconnect is much less egregious. Be that as it may, screening an asymptomatic population is a very different thing from monitoring a tumor marker in an already-diagnosed patient with cancer.
There are a number of perils and pitfalls in using tumor markers to follow cancer patients for response to treatment and recurrence. It’s not as though we don’t have considerable experience with them. Indeed, the scientific literature surrounding CEA and PSA, which have often been used for this purpose, is replete with the difficulties and complexities of following just a single molecule for a single cancer known to produce it. What does a rising level of a ctDNA with one or more of the mutations tracked by CancerIntercept™ Monitor mean? What should a clinician do? How sensitive is the test for detecting recurrences of the cancers covered by the test? How specific? How do you use the information to guide treatment, or do you use it at all? After all the hype, precision medicine is in its infancy and a recent clinical study (SHIVA) published in The Lancet Oncology failed to find a survival benefit using genomic profiling and targeted treatment in patients with advanced cancer, leading the authors to specifically recommend against using targeted therapies off-label for cancers for which they are not indicated based on the presence of mutations targeted by the drugs (perhaps a topic for another post).
As for monitoring for recurrence in a patient successfully treated for cancer, perhaps Pathway Genetics should consider that, of the original “Choosing Wisely” guidelines from the American Society of Clinical Oncology, one of the guidelines against scientifically unsupported treatment stated, “For individuals who have completed curative breast cancer treatment and have no physical symptoms of cancer recurrence, routine blood tests for biomarkers and advanced imaging tests should not be used to screen for cancer recurrences”—exactly the indication Pathway Genomics proposes for CancerIntercept™ Monitor, particularly given that in 2013 ASCO widened the recommendation to avoid advanced imaging as routine follow-up for pretty much all cancers unless there is high level evidence supporting it.
These issues are complicated enough when monitoring a patient known to have cancer and whose ctDNA mutation profile might agree with the mutation profile of his or her cancer, but start screening an asymptomatic population, even a “high risk” population, for ten cancers using a test like CancerIntercept™ Detect, and the issues and complexity skyrocket.
We know that our bodies are always producing cells with various mutations that could grow into cancer. Usually, these cells either die or the body eliminates them. Often, these tiny cancers never progress beyond a tiny cancer because they don’t acquire the ability to induce the body to provide them with a blood supply. Without a blood supply, they remain limited by how far oxygen will diffuse in plasma (less than 1 mm) and never grow larger. As I described a long time ago, most men over 80 have tiny prostate cancers. Thyroid cancer is an uncommon cancer, but a Finnish study found evidence of papillary thyroid cancer in 36% of adults in an autopsy series. We’re constantly producing tiny cancers that either don’t progress beyond microscopic size or regress. How often does CancerIntercept™ Detect identify these tiny cancers in normal people?
More importantly, what do we do if these ctDNA fragments with cancer-associated mutations are found in an asymptomatic patient who just got the test because the company’s marketing made it sound as though he should? These mutations are not cancer type-specific. They’re found in many kinds of cancer. A clinician would have little idea where to look, particularly for the more “promiscuous” mutations found in many types of cancer. Will clinicians do PET scans, whole body CT scans, and/or MRIs in a frantic search for a tumor that might never harm the patient? Would finding tumors, be they from breast, prostate, the GI tract, ovaries, or elsewhere result in lower mortality from those cancers, or would we see a massive wave of overdiagnosis, with subsequent overtreatment, based on these findings? I don’t know for sure, but my prediction is the latter. Think of it this way. We have significant overdiagnosis and overtreatment from far less sophisticated and sensitive tests, like mammography and PSA. Imagine how much more we would be likely to see from a test like CancerIntercept™ Detect.
Think of it this way: If a patient had an abnormal CancerIntercept™ Detect test, he would almost certainly be imaged up, down, left, and right, undergo blood tests and possibly invasive tests like colonoscopy (for GI cancer-associated mutations). Then, if all of those were negative, there would be pressure to “do something,” possibly even administer targeted agents or chemotherapy, because watchful waiting is not something most physicians and patients are comfortable with for an unknown cancer.
Pathway Genomics just doesn’t “get it”
Does Pathway Genomics “get” these issues? If its response to the FDA is any indication, the answer is a resounding no:
We are carefully considering the concerns of the FDA as stated in their letter, and we will be responding to that letter. We assure that there is physician involvement in the ordering, review and follow-up of CancerIntercept™ testing. We believe that CancerIntercept™ Detect is a laboratory developed test and, as a CLIA and CAP certified clinical laboratory, we are offering it as such. While Pathway Genomics is involved in educating and marketing the tests to physicians and consumers, we do not believe this is a direct-to-consumer model. We believe we have performed appropriate validation of the test as a laboratory developed test, and we are in the process of performing additional studies.
Now you know why Pathway Genetics has its own network of physicians for this test, to avoid the “direct-to-consumer” model while still being able to do the test for pretty much any consumer who wants it. Moreover, while Pathway Genomics might believe that it has “validated” its test sufficiently as a “laboratory-developed test” (LDT), in my opinion it hasn’t validated its test anywhere near adequately as a screening test for the general population, “high risk” or not.
Why is Pathway Genetics emphasizing that it considers its test a “laboratory-developed test” in a CLIA- and CAP-certified clinical laboratory? Dr. J. Leonard Lichtenfeld, Deputy Chief Medical Officer for the American Cancer Society, describes in a blog post that echoes many of the concerns I have about these tests:
The test in question is only done by this one company, measuring over 90 genetic abnormalities in the blood sample. And, since this is a proprietary laboratory test it can be offered directly to the public and the company can make whatever claims it chooses to consumers and health professionals–who may not even be aware there is no oversight by the Food and Drug Administration to verify the claims made for the test. (The Centers for Medicare and Medicaid services oversees the general quality of the laboratories offering these tests, but does not do specific review of a test in these situations).
This is basically the situation right now, but the FDA’s policy towards these tests could well be changing, as its regulations are from an era before tests like CancerIntercept™ Detect and CancerIntercept™ Monitor (Jann Bellamy has discussed the changing role of the FDA in lab-developed tests before). As the FDA described on its website, the FDA “does not consider diagnostic devices to be LDTs if they are designed or manufactured completely, or partly, outside of the laboratory that offers and uses them,” explaining, “While the uses of an LDT [laboratory developed test] are often the same as the uses of FDA-cleared or approved in vitro-diagnostic tests, some labs may choose to offer their own test. For example, a hospital lab may run its own vitamin D assay, even though there is an FDA-cleared test for vitamin D currently on the market.”
In other words, back in the day, LDTs were generally simple tests, such as for vitamin D levels, electrolyte levels, or other commonly measured parameters. They were not complex genomic tests involving enrichment of plasma for specific types of DNA and then next generation sequencing of the resulting fraction. As a result, the FDA has provided draft guidance for the development of a regulatory framework for LDTs, invited public comment, and held a public workshop earlier this year for public input.
Tests used to diagnose or guide treatment of a disease, particularly cancer, should have strong scientific evidence supporting their indications, accuracy, and efficacy. Barring that, results from tests like the ones marketed by Pathway Genomics can confuse far more than illuminate our decisions on how to treat patients. As Dr. Lichtenstein puts it, “Take an abnormal result from this test to your doctor and the real possibility exists they will have no clue what to do with it.” Exactly so.
He also notes, as I’ve noted before, that there will be testimonials that this test saved people’s lives. Of course, as I’ve described so many times before, just because a patient believes a test (such as thermography for breast cancer) or a treatment (such as Stanislaw Burzynski’s antineoplastons) saved her life, that does not make it so.
Tests like CancerIntercept™ Detect demonstrate just how urgent the need is for the FDA to modernize its regulation of laboratory-developed tests. Maybe Pathway Genetics is the perfect test case. Liquid biopsies will very likely be validated as a means of guiding therapy in cancer patients, but it’s way, way too early to consider using them as screening tests for cancer in asymptomatic patients. Our experience with much simpler screening tests like mammography and PSA screening should tell us that much. The potential of genomic tests is huge, but such tests need to be validated by science before being offered to patients on a large scale.
And Pathway Genomics is far from alone in this field.

The Role of Liquid Biopsies in Oncology
Liquid biopsies can be used to reduce the amount of chemotherapy used for patients with stage II colon cancer.
Harriet Hall on June 28, 2022
Link

When a patient has cancer, cell-free tumor DNA circulates in the blood and can be detected in a peripheral blood sample. This is known as a “liquid biopsy,” and it has become a routine practice in oncology, greatly facilitating detection of residual disease. A recent study published in The New England Journal of Medicine demonstrates its value for decisions about chemotherapy.
The study, by Tie et al., is titled “Circulating Tumor DNA [ctDNA] Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer”. As the accompanying editorial points out, “Colon cancer is the third most common cancer worldwide and the second leading cause of cancer-related death”. Patients with stage II colon cancer who have had surgery intended to cure it are 18 times as likely to have a relapse if ctDNA is detectable. Similar results have been seen in other types of cancer. The test has high specificity and sensitivity.
Surgery is curative for 80% of patients with stage II colon cancer. Guidelines recommend adjuvant chemotherapy for high-risk patients based on clinical features. The benefit of adjuvant chemotherapy for these patients is unclear. It benefits fewer than 5% and exposes many other patients to the toxic effects of an unnecessary treatment. Before liquid biopsies, there was no satisfactory way to predict which patients were likely to benefit.
The new study was large, prospective, randomized, and well-designed. It set out to answer two questions:
     1.  Is ctDNA-guided management noninferior to standard management guided by clinical risk factors? The primary endpoint was 2-year recurrence-free survival.
     2.  Would less chemotherapy be used with the ctDNA-guided approach?
The answers to both questions were a resounding “YES.”
Results
The recurrence-free survival was 93.5% with ctDNA-guided management and 92.4% with standard management. Chemotherapy use was indicated for 15% of patients in the ctDNA-guided group and 28% in the standard-management group. As the editorial authors put it: “biology outperforms anatomy.”
Conclusion: Liquid biopsies are an invaluable tool for oncologists
They can detect residual disease in cancer patients who were thought to have been cured by surgery. And they can guide appropriate individualized decisions about chemotherapy, providing it where needed but sparing those patients who would not benefit. There are still many questions about the details and about other types of cancer, but this trial was an excellent start, and further research will be ongoing. A great example of science in action.

CRISPR Treatment for Cancer
CRISPR-Cas9 combined with a new delivery system shows promise in treating some of the most deadly cancers.
Steven Novella on November 25, 2020
Link

I first wrote about CRISPR here in 2017. We are used to medical hyperbole and hype failing to materialize, but at the time I characterized CRISPR as having legitimate promise as a game-changing medical intervention. It’s still early days in this technology, but advances are moving fast. A recent study looking at CRISPR in the treatment of cancer gives a good indication of how useful this technology can be.
For a quick overview, CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. They are a technology borrowed from certain bacteria that use the technique as part of their immune response to viruses. Researchers realized that we could use CRISPR for genetic engineering – to cut or insert DNA in a targeted location in the genome. The Cas9 enzyme is what cuts the DNA, while the CRISPR portion contains a targeting sequence that binds to the desired location on the DNA and also includes the sequence that you want inserted. This is referred to as the CRISPR-Cas9 system. I will note that there are other enzymes that can be used also, but for now Cas9 is the most common.
The applications of this technology are many, the most obvious being in genetics research and genetic engineering. The CRISPR-Cas9 system is fast, easy, and cheap, which allows many research labs to use it, promising to accelerate the pace of genetics research.
What still remains unknown is how this technology will translate to direct medical applications. Perhaps the most obvious such application is in fixing genetic errors, but there are a couple of limiting factors. One is the issue of off-target changes. How often does CRISPR target the wrong part of the DNA? This is a concern, but researchers are quickly figuring out how to minimize off-target effects, and how to trade speed for accuracy.
Another limiting factor is getting CRISPR-Cas9 into live cells, but only the cells you want. This was the problem that the current study sought to overcome, and that is really the new technology they are introducing. If we could get CRISPR into only cancer cells, for example, we could use it to kill those cancer cells while leaving healthy cells alone. Existing targeting systems used to deliver chemotherapy to cancer cells cannot handle the large size of the CRISPR-Cas9, and have limited penetrance – they don’t get into enough of the target cancer cells.
Their solution was to use lipid nanoparticles. They write:
Lipid nanoparticles (LNPs) are clinically approved nonviral nucleic acid delivery systems capable of delivering potentially such large payloads. Cationic ionizable lipids are the key component of LNPs that enables efficient nucleic acid encapsulation, cellular delivery, and endosomal release.
They had to modify the LNPs to deliver a larger molecule and to be able to deliver the payload into many different tissue types. The CRISPR itself is targeted at tumor survival genes. Disrupting these genes should cause the cancer cell to at least stop replicating and also hopefully die and undergo apoptosis. To study their new LNP delivery system with CRISPR-Cas9 targeting tumor survival genes, they studies glioblastoma and ovarian cancer in mice. What they found was extremely encouraging.
Glioblastoma is the most aggressive form of brain cancer, with a mean survival of about 15 months. This cancer has proven very resistant to treatments with chemotherapy and radiation and are not resectable because of the way they invade throughout the brain. The researchers deliberately targeted glioblastoma for this reason. They performed a single injection of the LNPs with the CRISPR-Cas9 payload into the brains of mice with glioblastoma. The found:
…up to ~70% gene editing in vivo, which caused tumor cell apoptosis, inhibited tumor growth by 50%, and improved survival by 30%.
If that translates to humans, it is an impressive result. It is not a cure, which is true of all new anti-cancer treatments, but this would contribute significantly to the steadily-increasing survival of cancer patients.
They also studied ovarian cancer and found:
Intraperitoneal injections of EGFR-targeted sgPLK1-cLNPs caused their selective uptake into disseminated ovarian tumors, enabled up to ~80% gene editing in vivo, inhibited tumor growth, and increased survival by 80%.
That is even more impressive. Of course I have to emphasize that this was a study in mice, not people. It is also a first study of this technology and has to be replicated and expanded. But it is difficult to overhype how significant these results are. They show the potential of the combination of LNPs to deliver CRISPR-Cas9 to targeted cells. They plan next to test this approach in blood borne cancer. Hopefully they will be able to continue to tweak the technology to get further uptake in the target cells.
The study also found that the LNP system was safe and did not provoke a host immune response. Further, because the treatment itself is not chemotherapy, overall the side effects were minimal, and there is no expectation that the tumor will be able to develop resistance. Evolving resistance to each round of chemotherapy is one of the greatest limiting factors in targeted chemotherapy – but there is no resistance to having your DNA sliced up.
The researchers also emphasize that this system of LNPs delivering CRISPR-Cas9 is not specific to cancer type or to cancer itself. Once the basic technology is perfected, it can be applied to other cells types. It could be used, for example, to target infectious organisms. I can imagine that bacterial sepsis (blood infection) would be a likely application.
In short, this is an incredibly promising new approach to treating cancer, including the worst types of solid tumors that currently have a poor prognosis. To balance the hype, however, we need to keep in mind that there is a lot of clinical research between this potential treatment and use on actual patients in the clinic. It will be years before these treatments get approval, and that is if everything goes well.
But I do think the strong probability is that this or something like this will eventually be used to treat cancer. It represents a new treatment paradigm that will be complementary to existing treatments, and has the potential to significantly improve cancer survival in many types of cancer.

Redefining cancer
David Gorski on October 21, 2013
Link
Blogging is a rather immediate endeavor. Over the last nine years (nearly), I’ve lost track of how many times I saw something that I wanted to blog about but by the time I got around to it, it was no longer topical. Usually what happens is that my Dug the Dog tendencies take over, as I’m distracted by yet another squirrel, although sometimes there are just too many targets topics and too little time. Fortunately, however, sometimes the issue is resurrected, sometimes in a really dumb way, such that I have an excuse to correct my previous oversight. This is just such a time, and the manner in which the topic has been resurrected is every bit as dumb as the rant by the Food Babe that Mark Crislip so delightfully deconstructed last Friday. Unfortunately, for purposes of snark, I’m not Mark Crislip—but, then, who is?—but fortunately I am known elsewhere (and sometimes here) for being a bit “insolent.” So let’s dig in. We’ll start with the idiocy and then use that as a “teachable moment” about cancer biology. Funny how I manage to do that sort of thing so often.
Abuse of cancer science for political purposes
I realize that we at SBM are supposed to stay, for the most part, apolitical, but the idiocy that’s leading me to revisit a topic is unavoidably political because it involves using a profound misunderstanding of science for political ends. Specifically, I’m referring to the misuse of a legitimate scientific debate about cancer screening and diagnosis for purely political ends. First, however, for those not living in the US or my fellow citizens who might be blissfully unaware (in this case) of recent events, during the first half of October, our nation underwent what can only be described as a self-inflicted crisis that could have caused worldwide economic turmoil if it hadn’t been (sort of) resolved at the last minute. The reason for the crisis boiled down to the extreme resistance of some of our more radically conservative Representatives to the Patient Protection and Affordable Care Act, usually referred to as just the Affordable Care Act (ACA) or, colloquially, Obamacare. Normally when we write about Obamacare here on SBM, it’s to complain about how advocates of unscientific medicine and outright quackery have tried to piggyback their advocacy on the ACA in order to have health insurance plans sold through government exchanges cover modalities like naturopathy, chiropractic, and other so-called “complementary and alternative medicine” (CAM) or “integrative medicine.” In related posts, I’ve examined the evidence with respect to the relationship between health insurance and mortality and whether attacks on Medicaid as not improving the health of patients insured by it have any validity. (Let’s just say they are oversimplifications and distortions.)
The claims I’m about to address come from a place every bit as brain dead as the Food Babe in its own way and seem to have originated from an article on Forbes by someone named Paul Hsieh, who claims to “cover health care and economics from a free-market perspective.” Imagine my relief, because he sure doesn’t seem able to cover them from a science-based prospective. Behold his op-ed, Why The Federal Government Wants To Redefine The Word ‘Cancer’. The insinuation (although Hsieh is quick to deny that that’s what he’s really saying) is that the government wants to redefine cancer so that fewer patients will be diagnosed with cancer and qualify for treatment under Obamacare:
With respect to the definition of “cancer,” downgrading some conditions as no longer being “cancer” can and will used to justify reducing “unnecessary” screening tests (e.g., mammograms for women between ages 40-49). Mammograms can now detect the condition known as “ductal carcinoma in situ” (DCIS), which would no longer be called a cancer under the new proposal.
And, later:
I don’t believe the individual scientists arguing for a redefinition of cancer are driven by inappropriate political motives. But government will soon account for 66% of health spending and is aggressively seeking to limit health expenditures. Hence, the government may have a vested interest in definitions that err towards undertreatment, rather than overtreatment. We must remain vigilant against any attempts by the government to use language as a tool of covert rationing.
Imagine my further relief that Hsieh doesn’t think those of us who are interested in reducing overtreatment are twirling our moustaches and rubbing our hands with glee as we plot on “death panels” how to deny mom and grandma her mammograms to save money, all in the service of Obamacare. Not that I actually believe him. Or maybe he doesn’t believe that, but knows that the rubes who read his column do.
What Hsieh is referring to is an article published online in JAMA in July, and in the dead tree edition, by Laura J. Esserman, Ian M. Thompson, Jr., and Brian Reed entitled Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement, a viewpoint report that was reported fairly widely in the media in Medscape, the New York Times, and NPR. The article, as I will discuss shortly, should not have been a surprise to anyone who regularly reads this blog or my writings at my not-so-super-secret other blog about overdiagnosis and overtreatment of cancer and the complexities of screening asymptomatic populations for cancers. As I’ve said time and time again, the relationship between early diagnosis and improvements in survival is complex and not nearly as clear-cut as most people, even most physicians, think. What Esserman et al. discussed as part of their summary of recommendations of a working group at the National Cancer Institute was simply the next logical step, recommending possible strategies to reign in overdiagnosis without compromising treatment of potentially life-threatening cancers. Their recommendations are reasonable and science-based, although likely to be at least somewhat controversial. Near the end of his piece, Hsieh quotes Dr. Milton Wolf, who says something that is so wrong on so many levels that one wishes it were possible to strip doctors of their medical licenses for spreading medical misinformation:
Health care rationing takes many insidious forms but perhaps the most immoral is for the government to wage a public relations campaign designed specifically to dissuade patients and doctors from seeking available cures for cancer. They scheme to rename cancer, not to cure it, but to deny it exists. These government rationers have calculated that rather than actually treat patients with cancer, it’s cheaper to simply keep them as calm as Hindu cows right up to the very end.
I’ve noticed that radiologists (for example, Dr. Daniel Kopans) seem to be the ones most opposed to any recommendation that involves decreasing screening intensity or frequency. One notes that Wolf is also a conservative Republican running for the Senate in Kansas who is in favor of defunding or repealing Obamacare. Ironically, he is also Barack Obama’s second cousin, who proudly proclaims, “I may not be the first doctor to oppose ObamaCare, but I am the first doctor from Barack Obama’s own family to oppose ObamaCare” and has even written an e-book entitled First, Do No Harm: The President’s Cousin Explains Why His Hippocratic Oath Requires Him to Oppose ObamaCare (Voices of the Tea Party). He’s also written articles with titles like The FDA’s one-man death panel and Tyranny in our time, criticizing his cousin and Obamacare. You get the idea.
Well, maybe you don’t. Hsieh and Dr. Wolf are downright reasonable in comparison to how the right wing blogosphere ran with this story. Here’s a sampling:
    • “It is plain and simply rationing of health care. And, at some point, rationing becomes a death sentence. So, in the opinion of your humble observer of the asylum we all have to live in, the House Republicans should go back to their original proposal to defund ObamaCare and each time the Senate sends the bill back to the House, they should just change the date and return it to the Senate. Keeping the government in partial shut-down may be a godsend.” – Asylum Watch.
    • “And why would the Obama administration want to re-define cancer? Because starting tomorrow, Obamacare will begin subsidizing millions of Americans’ health insurance, and cancer tests and treatments are expensive. This is nothing more than a back-door, roundabout form of rationing. It has nothing to do with improving health care or saving lives and everything to do with bureaucrats picking and choosing who gets what tests and treatments.” – Poor Richard’s News.
    • “Aren’t we glad that crazy Sarah Palin lady with her death panel rants didn’t get elected. And instead we live with a wise and sane government that fights new wars while renaming them as interventions and cures cancer by renaming it and denying coverage? Hope. Change. Death.” – Daniel Greenfield, Frontpage Mag.
    • “Cancer tests and treatment are expensive, and the government doesn’t want to foot the chemotherapy bill for lesions that don’t have a ‘reasonable likelihood of killing the patient.’ This redefining of the word cancer has absolutely nothing to do with improving healthcare, with saving lives, or with saving patients unnecessary anxiety; it is no more than an underhanded and surreptitious attempt at rationing. It is a cloak-and-dagger attempt to restrict who can benefit from healthcare system overpromised to us by Obama himself.’ – Crissy Brown, Thoughts on Liberty.
    • “One of the great problems in allowing the government– especially one proven to be untrustworthy by a number of recent high-profile scandals– to run health care and judiciously dole treatments with an idea toward cost-saving, is that the truth becomes completely lost. Any sort of trust that is supposed to exist between patient and doctor is lost as doctors are required to redefine, to the point of untruth, diagnoses, treatment options, and future prognosis due to the federal legal requirements. It’s Orwellian and wrong. And it’s guaranteed by ObamaCare.” – Yukio Ngaby at the very much misnamed Critical Narrative.
    • “The government wants to redefine the word “cancer” in order to have fewer conditions that can be classified as actual cancer. I’m going to go out on a limb here and ask…..do they really believe changing a couple of definitions is really going to help lessen the lives taken by cancer? I mean, if you paint a coconut pink it is still a coconut isn’t it?” – The Black Sheep Conservative.
I’m going to go out on a limb here (actually, no I’m not) and say bluntly that all of these criticisms demonstrate an astronomical level of ignorance about cancer that at its heart boils down to a conspiracy-minded belief that the government (via the NCI) wants to redefine cancer in order to not have to treat people with cancer and save money, no matter how many lives this costs. Of course, it never occurred to them that, given by definition overdiagnosis and overtreatment mean diagnosing cancer that will never threaten the life of the patient and treating such cancers unnecessarily, reducing overdiagnosis and overtreatment is a desirable goal, both from the standpoint of improving patient care (overtreatment is all risk, no benefit, after all) and decreasing costs. This is the problem with science-based guidelines rooted in new understandings of cancer biology. Reasonable recommendations about how to decrease the rate of overdiagnosis and overtreatment are immediately seized upon by activists. Unfortunately, as can be seen from Dr. Wolf’s likening of such recommendations to slaughtering cattle, a lot of physicians share in this ignorance. With that in mind, let’s look at what Esserman et al. actually wrote and recommended.
Redefining cancer: What it really means
I’ve discussed ductal carcinoma in situ (DCIS) before on multiple occasions. To recap, DCIS is a condition in which malignant-appearing ductal cells are observed in the milk ducts of the breast but have not yet invaded through the membrane surrounding the duct to get into the tissue outside of the duct. To put it simply, that’s basically what “in situ” means, that the cancerous cells have not yet invaded the basement membrane. There are quite a few epithelial cancers that have a carcinoma in situ stage: breast, colon, bladder, prostate, and others. In the breast, DCIS is generally considered “stage 0” cancer, and treatment has a very high success rate. The reason for this success is likely because a lot of DCIS, possibly even most DCIS, never progresses to invasive cancer or progresses so slowly that the women who have it die of something else (such as old age) before it ever causes a problem. Indeed, it is estimated that low grade DCIS, if it progresses, does so within a time frame of 5 to 40 years and possibly in only 20% of DCIS cases, while high grade DCIS is more likely to progress. The same sort of behavior occurs with a lot of early stage prostate cancer in men. Since I’m a breast cancer surgeon, most of my examples will come from breast cancer. In other words, premalignant lesions are not one disease, and many of them will never cause harm within the remaining lifetime of the person harboring them.
The fact is that before the advent of widespread mammographic screening, DCIS was a relatively uncommon diagnosis. Now, thirty years or so after mass mammographic screening programs became widespread, DCIS is common. Indeed, approximately 40% of breast cancer diagnoses are in fact DCIS. A recent study found that DCIS incidence rose from 1.87 per 100,000 in the mid-1970s to 32.5 in 2004. That’s a more than 16-fold increase over 30 years, and it’s pretty much all due to the introduction of mammographic screening of asymptomatic women. One potential reason is that by the time DCIS progresses to the point of being detectable by means other than mammography (such as feeling a breast mass), it has usually progressed to invasive ductal cancer. Another potential reason is that much of the DCIS we detect by mammography doesn’t progress to become symptomatic and threaten the life of the woman. Probably both mechanisms are in play. Either way, we don’t know for sure what percentage of DCIS lesions progress to cancer, and, in fact, we don’t know for sure whether the progression from normal ductal cells to cancer necessarily goes through DCIS. (Yes, I am a co-author on this paper and helped with much of the clinical discussion.) Indeed, there are currently three main models, all of which might contribute in different specific cases of DCIS, for how infiltrating ductal cancer (IDC) arises:
Supporting the hypothesis that something more than just a straight linear model of breast cancer progression is most in line with how breast cancer develops is the observation that, although the diagnosis of breast cancer has very much slanted much more towards DCIS and early stage (stage I and II) cancers over the last 30 years, detecting and treating these cancers aggressively has not resulted in a proportionate decrease in metastatic and locally advanced cancers. This was reported in the New England Journal of Medicine last December and is in line with other studies that I’ve mentioned finding that one in three breast cancers diagnosed by mammographic screening could be overdiagnosed and that one in five might spontaneously regress without treatment. Indeed, it’s becoming increasingly apparent that even a subset of frankly invasive cancers either don’t progress, progress so slowly that they won’t cause harm, or even regress. Treating these lesions provides no benefit to women, but does produce risk. In other words, these lesions (in this case, DCIS) that we refer to as “cancer” might better be considered something else, as many of them might not behave like cancer at all, at least not if defined as if untreated, inevitably progressing into a cancer that will threaten a woman’s life within her natural lifespan. Some are likely to be very indolent; some might even regress.
Who wouldn’t want to reduce the number of patients who are overtreated, and who wouldn’t want to name these premalignant, possibly malignant, conditions more accurately? Although part of this debate does have something to do with decreasing costs, contrary to what the fractally wrong quotes above more than insinuate, the primary reason is to decrease the number of patients subjected to potentially toxic therapies like radiation, surgery, and even chemotherapy for lesions that would cause no harm in their lifetime. The problem, as I’ve pointed out time and time again, is that we don’t yet know how to distinguish the in situ and early invasive cancers that are harmless from the ones that will progress. Until we can do that, we as physicians feel obligated to treat all of them aggressively.
With this background in mind, the recommendations by Esserman et al. seem downright reasonable, mainly because they are downright reasonable, beginning with the introduction:
Over the past 30 years, awareness and screening have led to an emphasis on early diagnosis of cancer. Although the goals of these efforts were to reduce the rate of late-stage disease and decrease cancer mortality, secular trends and clinical trials suggest that these goals have not been met; national data demonstrate significant increases in early-stage disease, without a proportional decline in later-stage disease. What has emerged has been an appreciation of the complexity of the pathologic condition called cancer. The word “cancer” often invokes the specter of an inexorably lethal process; however, cancers are heterogeneous and can follow multiple paths, not all of which progress to metastases and death, and include indolent disease that causes no harm during the patient’s lifetime. Better biology alone can explain better outcomes. Although this complexity complicates the goal of early diagnosis, its recognition provides an opportunity to adapt cancer screening with a focus on identifying and treating those conditions most likely associated with morbidity and mortality.
Changes in cancer incidence and mortality reveal three patterns that emerged after inception of screening (Table). Screening for breast cancer and prostate cancer appears to detect more cancers that are potentially clinically insignificant. Lung cancer may follow this pattern if high-risk screening is adopted. Barrett esophagus and ductal carcinoma of the breast are examples for which the detection and removal of lesions considered precancerous have not led to lower incidence of invasive cancer. In contrast, colon and cervical cancer are examples of effective screening programs in which early detection and removal of precancerous lesions have reduced incidence as well as late-stage disease. Thyroid cancers and melanoma are examples for which screening has expanded and, along with it, the detection of indolent disease.
All of which is basically what I’ve been saying, with the addition of the examples of cervical and colorectal cancer, which do appear to behave in a manner consistent with a more linear progression model, which means that removing early stage disease does effectively prevent the appearance of late stage disease. Based on these observations, here is what the NCI recommends, with my comment afterward
    • Physicians, patients, and the general public must recognize that overdiagnosis is common and occurs more frequently with cancer screening. [Note: This is nothing that I haven’t been saying for at least four years now, ever since I started to appreciate the complexities of screening for cancer.]
    • Change cancer terminology based on companion diagnostics. Use of the term “cancer” should be reserved for describing lesions with a reasonable likelihood of lethal progression if left untreated. There are two opportunities for change. First, premalignant conditions (eg, ductal carcinoma in situ or high-grade prostatic intraepithelial neoplasia) should not be labeled as cancers or neoplasia, nor should the word “cancer” be in the name. Second, molecular diagnostic tools that identify indolent or low-risk lesions need to be adopted and validated. Another step is to reclassify such cancers as IDLE (indolent lesions of epithelial origin) conditions. [Note: Again, if you understand the more recent data with respect to screening certain cancers, none of this is an attempt by the evil government to withhold vital care from cancer patients. It is actually an attempt to improve the care of cancer patients by decreasing overdiagnosis and more carefully “personalizing”—if you’ll excuse the use of this overused term—care to the patient’s tumor.]
    • Create observational registries for low malignant potential lesions. Providing patients and clinicians with pathologic diagnosis and information related to disease prognosis is crucial to informed decision making, including comfort with alternate treatment strategies such as active surveillance. [Note: Again, if we are truly going to “personalize” the treatment of lesions of low malignant potential, we need better information about what percentage of them progress into life-threatening malignancy and over what time frame they do so in order to facilitate shared decision-making between physician and patient. Again, this is not withholding treatment; this is empowering patients based on scientific findings to make decisions regarding their care with which they are comfortable.]
    • Mitigate overdiagnosis. Strategies to reduce detection of indolent disease include reducing low-yield diagnostic evaluations appropriately, reducing frequency of screening examinations, focusing screening on high-risk populations, raising thresholds for recall and biopsy, and testing the safety and efficacy of risk-based screening approaches to improve selection of patients for cancer screening. [Note: Again, this is nothing that I haven’t discussed in depth many times, beginning with the USPSTF recommendations for mammography. Unfortunately, any attempt to decrease screening inevitably runs into criticism that we’ll be “killing patients,” because the idea that premalignant diseases inevitably progress to life-threatening cancer is deeply embedded not only in the popular concept of cancer, but in the medical profession itself. Indeed, physicians even go so far as to erroneously blame the New York Times for killing patients by publicizing the problems with screening tests for cancer, like PSA testing.]
    • Expand the concept of how to approach cancer progression. Future research should include controlling the environment in which precancerous and cancerous conditions arise, as an alternative to surgical excision. [Note: I must admit that this one left me scratching my head a bit. What, specifically, does this mean in practice? I must admit that I don’t know.]
Esserman et al. conclude by pointing out that much of this is an issue of communication as much as it is of science. After all, for the last 30-40 years, the medical profession and public health officials have been drumming it into our heads that we have to catch cancer early and that screening tests are the best way to do it, without also pointing out that every medical tests have risks and benefits. Yes, catching cancer early tends to be better in many ways. Treatment is more likely to be successful (or at least appear so) and, in the case of many cancers, can be achieved with much less aggressive and disfiguring surgeries. In my field, the example of doing a lumpectomy compared to being forced to do a mastectomy comes to mind. However, much more difficult is explaining how much of that improved survival is due to lead time bias and how much is due to treatment and early detection (as I’ve discussed here, here, here, and here). It’s also hard to include in such discussions the concept of length bias, in which most cancer screening tests are biased towards detecting slower-growing, more indolent disease. As I’ve discussed before as well, to avert one death from breast cancer with mammographic screening for women between the ages of 50-70, 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of DCIS. The additional price of this was estimated to be 90 biopsies and 535 recalls for additional imaging, as well as many cancers treated as if they were life threatening when they are not. To prevent one death from prostate cancer, 1,410 men need to be screened over 9 years, for a total of 2,397 screening visits and 48 cancers detected. In other words, screening takes a lot of effort for, on an absolute basis, not as many lives saved as most people, even doctors, believe.
When taken in this context, all Esserman et al. are saying is that we need to screen smarter, not more, and that we need to adjust our terminology and treatments to be more in line with our more recent understanding of biology. As Dr. Otis Brawley, chief medical officer of the American Cancer Society, put it so aptly, “We need a 21st-century definition of cancer instead of a 19th-century definition of cancer, which is what we’ve been using.” He’s right. Most of our definitions of carcinoma, carcinoma in situ, and premalignant conditions date back over 100 years and were based largely on what could be observed about tumors under the microscope. In 2013, we now have the tools to probe the molecular pathways that define and drive the progression of cancer.
Conclusions: Cancer is scary
There is actually one point that the cranks attacking the recommendations of the NCI panel make that has some validity, just not in the way that they think it does. That point is that words have power, and the word “cancer” has particular power. Of course, the cranks think that the reason the NCI is suggesting ceasing to use the word “cancer” to describe conditions that appear cancerous using old criteria but are not likely to harm patients who have them, is to deceive patients and doctors into accepting less care in order to save money. In reality, it is a plea to bring language more into line with new science, based on concern among doctors that “hundreds of thousands of men and women are undergoing needless and sometimes disfiguring and harmful treatments for premalignant and cancerous lesions that are so slow growing they are unlikely to ever cause harm.” At the same time, we do not want to go too far in the opposite direction and err on the side of undertreatment.
Frequently referenced in discussions of the NCI recommendations is another study that I had meant to blog about when it first came out but got distracted by my Dug the Dog tendencies. (It came out about the same time the NCI recommendations saw print.) This study by Omer et al. examined the effect of how DCIS is described on the treatment choices of women. In the study, 394 women without a history of breast cancer were presented with three scenarios that described ductal carcinoma in situ (DCIS) as noninvasive breast cancer, breast lesion, or abnormal cells. They were then asked to choose among three treatment options: surgery, medication, or active surveillance. When DCIS was described as noninvasive cancer, 53% favored nonsurgical options. However, 63% chose nonsurgical options when the term used was breast lesion, a number that rose to 69% when the term used was abnormal cells. The authors concluded:
We conclude that the terminology used to describe DCIS has a significant and important impact on patients’ perceptions of treatment alternatives. Health care providers who use ‘cancer’ to describe DCIS must be particularly assiduous in ensuring that patients understand the important distinctions between DCIS and invasive cancer.
Or, as Ian Thompson put it:
“That is the real world of this when you include the word ‘cancer,’” Dr. Thompson said. “Because the word ‘cancer’ has a connotation that is profoundly bad.” The word “precancerous” has that same connotation. “That means the shoe is going to drop sometime down the road and that you are irresponsible if you don’t do anything about it,” he continued.
The consequences of the use of the word “cancer” to describe conditions that are only somewhat likely to progress can be seen all around us. For instance, the NPR article on the NCI recommendations tells the story of a 42-year-old woman who was diagnosed with DCIS and decided that she wanted a double mastectomy. In fact, I was shocked to learn that 6% of women with DCIS opt to undergo double mastectomy, which is massive overkill for such lesions that will not decrease the risk of dying of breast cancer. The consequences are found in women with DCIS being pressured by well-meaning doctors to have surgery right away, as if DCIS will turn into cancer overnight if they don’t act. It won’t.
In the end, dealing with premalignant lesions comes down to three things. First, we desperately need more accurate methods of risk assessment that allow us to accurately predict the likelihood that a given lesion will progress into cancer. Second, we have to get rid of the mindset that all precancerous lesions will inevitably “turn into” cancer. They won’t, and which ones are dangerous depends on the cancer type, observable characteristics such as nuclear grade, and molecular characteristics that we haven’t dissected yet. Finally, it’s a matter of communication. Telling people that finding cancer early is always better, that precancerous lesions found by screening will inevitably kill them if they don’t act, is based on an understanding of cancer progression that is decades old and no longer appropriate given the knowledge accumulated over the last two decades. It might be a cliché, but we need to screen smarter, not more, and we need to be able to explain that not all premalignant lesions require aggressive treatment.
It’s not going to be easy to change this culture and mindset, though, not the least of which because cynical pundits like Paul Hsieh and Mark Wolf are trying to convince people for their own political purposes that any effort to decrease screening, or more accurately describe premalignant lesions that are unlikely to cause harm, is somehow wanting to let cancer patients die in order to save money.

The Science Behind the Roundup Lawsuit
A jury has awarded a man $289 million for allegedly contracting cancer from exposure to Roundup, but the science is not on their side.
Steven Novella on August 15, 2018
Link

On August 10th a California jury awarded Dewayne Johnson $289 million dollars in damages against the company Monsanto (now owned by Bayer). The decision was based on the claim that Johnson (a greenskeeper) developed non-Hodgkins lymphoma because of his exposure to Roundup, an herbicide that contains the active ingredient glyphosate that was developed by Monsanto.
The decision will almost certainly be appealed, and is being widely criticized because it is not in line with the science. There is a long history of juries awarded damages based on flimsy science. Dow Corning famously filed for bankruptcy following class action law suits for alleged damages due to silicone breast implants, while the science was still preliminary. The claim was that the breast implants were causing auto-immune disease, which the manufacturer denied. Juries found the women sympathetic, however, and companies rarely appear sympathetic in such trials. But in 2000 a meta-analysis found:
On the basis of our meta-analyses, there was no evidence of an association between breast implants in general, or silicone-gel-filled breast implants specifically, and any of the individual connective-tissue diseases, all definite connective-tissue diseases combined, or other autoimmune or rheumatic conditions. From a public health perspective, breast implants appear to have a minimal effect on the number of women in whom connective-tissue diseases develop, and the elimination of implants would not be likely to reduce the incidence of connective-tissue diseases.
It seems we have a similar situation with Roundup and cancer, except the meta-analysis was published before the huge jury award, rather than after. The wrinkle here is that this and other lawsuits were likely sparked in part by the WHO decision in 2015 to classify glyphosate as a “probable carcinogen”. That decision was an outlier, however, and was immediately criticized. Several independent reviews of the WHO decision concluded that the decision was in error, and that the totality of evidence does not support the conclusion that there is any link between glyphosate and non-Hodgkins lymphoma specifically, or any cancer. I review the evidence and the expert panel reviews here.
An interesting 2017 review explored why the European Union (which concluded glyphosate was safe) came to a different conclusion than the WHO:
Use of different data sets, particularly on long-term toxicity/carcinogenicity in rodents, could partially explain the divergent views; but methodological differences in the evaluation of the available evidence have been identified. The EU assessment did not identify a carcinogenicity hazard, revised the toxicological profile proposing new toxicological reference values, and conducted a risk assessment for some representatives uses.
Essentially they used different data and methods. There is also this:
In a Special Report published on June 14, 2017, investigators at Reuters uncovered the shocking fact that an American scientist, Dr. Aaron Blair, the Chairman of the International Agency for Research on Cancer’s (IARC) Monograph 112 on glyphosate, suppressed critically important science.
The hidden science in question is recent data from the Agricultural Health Study (AHS), the largest and most comprehensive study ever conducted on pesticide exposure in humans. Evidence shows that Dr. Blair withheld updated data from the study which evaluates the pesticide exposure of more than 50,000 farmers and their families. The updated data reinforces the study’s original conclusion in 2005 that there is no evidence linking glyphosate exposure to cancer incidence.
So the best data we have shows no link between glyphosate and cancer, but that data was ignored by Dr. Blair. Further, Blair was involved with this study, and so definitely knew this data existed. Also, under oath Dr. Blair admitted: “[the] data would have altered IARC’s analysis.”
We are now, in part, seeing the fallout from this bad decision by the IARC.
According to reports of the case, Johnson’s attorney had to overcome the actual science showing glyphosate is safe and not associated with cancer. He did this by claiming that Roundup as a whole may cause cancer, even though glyphosate alone does not. While not impossible, this is an implausible claim that is still lacking in evidence. This was an act of simply moving the goalpost to avoid the more definitive scientific evidence. The ploy worked.
Johnson is also claiming that he had two accidental exposed to Roundup, so he was exposed to far more than would be the case with normal use. However, the time between exposure and his development of NHL was probably far too short for a causal relationship – a fact apparently not considered compelling by the jury.
Why should we all care about this? I of course have sympathy for Mr. Johnson, just as I have sympathy for all of those women who developed autoimmune diseases after getting silicone breast implants. I also think it is extremely important to hold corporations accountable if they cause harm due to their products. But justice in these cases will only prevail if the science prevails.
Further, glyphosate is demonstrably far less toxic than the alternative herbicides. If glyphosate is banned, or rendered unusable because of unfair lawsuits and unscientific jury verdicts, an important agricultural option will be eliminated – not because of science or because it’s the right thing, but out of fear and ignorance.
Reasonable people can argue and disagree about the optimal role of glyphosate and other herbicides in agriculture, and that is not the point of this article. But agricultural decisions should be based on a consensus view of the science, not the emotions of 12 jurors who clearly wanted to punish Monsanto regardless of what the science says.
This and other decisions also point to a flaw in our legal system. This is a much longer discussion outside the scope of this article, but the rules on the admissibility and role of scientific evidence in the courtroom still leave much to be desired in my opinion. Ultimately this case turned on an evaluation of a scientific claim, and I don’t see why such scientific questions should be decided by non-expert jurors.

Update on Glyphosate
A legal decision against the makers of glyphosate is not supported by the science.
Steven Novella on April 3, 2019
Link

Glyphosate has been in the new recently because of the recent court case in which a jury awarded DeWayne Johnson $289 million dollars from Monsanto for glyphosate allegedly causing his lymphoma. This, of course, is used as support for those who claim that glyphosate is unsafe, and also for anti-GMO rhetoric as some GMOs are engineered to be tolerant of glyphosate to facilitate its use as an herbicide.
I wrote about this case last year, but now it is back as Johnson prevailed in appeal. I also wrote about the science behind glyphosate in 2014. There have been some significant studies since then, so in light of the recent attention the herbicide is getting, an update is warranted.
There are two basic safety issues with glyphosate – exposure in the general population, mostly from consuming food that was grown using glyphosate, and agricultural exposure. The first question is easier to answer.
A 2017 review found:
Two complementary exposure assessments, human-biomonitoring and food-residues-monitoring, suggests that actual exposure levels are below these reference values and do not represent a public concern.
This has been the consistent finding of studies for decades. The level of exposure for the general public, even with the increased agricultural use in the last 20 years, is well below safety limits. Why, then, did the IARC designate glyphosate as a probable carcinogen? They famously left out the most updated data to which they had access. Also, their designation is an outlier. Other reviewers did not reach the same conclusion.
The data that was excluded from the WHO’s assessment is the 2018 Agricultural Health Study. This study, which included 50,000 people, found:
In this large, prospective cohort study, no association was apparent between glyphosate and any solid tumors or lymphoid malignancies overall, including NHL and its subtypes. There was some evidence of increased risk of AML among the highest exposed group that requires confirmation.
This large and fairly definitive study, especially when put in the context of all the other studies, puts to bed the notion that there is any significant risk from general exposure to glyphosate. As we always point out – there is no such thing as zero risk. But we can use evidence to set probable limits on how large a remaining risk might be. The health risk of general exposure to glyphosate is anywhere from nothing to negligible – it has vanished into the background risk of just being alive.
But this study also brings us to the second consideration – the risk of agricultural workers who might be exposed to much higher levels than the general population. Toxicity is always about dose, and so it is plausible while there is no risk to the general population, there is a risk from much higher exposure.
As an aside, this is why the frequent challenge to those simply pointing out the science on the safety of glyphosate to drink a glass of the stuff, “if you think it’s so safe,” is absurd. There are countless things that we consume and are exposed to all the time that I would not drink an entire glass of. That is not the threshold for safety.
There have been studies that show a small association between agricultural exposure to glyphosate and NHL (Non-Hodgkin Lymphoma). This association shows up in a recent meta-analysis, but only for the highest exposure group. They found a relative risk increase of 41%, but this translates to an absolute risk increase of 8 per 100,000 or 0.008.
This study has also been criticized for the methods of meta-analysis used. For example, they had to determine how to combine very different data that uses different definitions of exposure. Some scientists have argued that the data does not support the conclusions.
A recent study not included in that meta-analysis, however, which was a large analysis looking at many pesticides and lymphoma outcomes, found:
During follow-up, 2430 NHL cases were diagnosed in 316 270 farmers accruing 3 574 815 person-years under risk. Most meta-HRs suggested no association. Moderately elevated meta-HRs were seen for: NHL and ever use of terbufos (meta-HR = 1.18, 95% CI: 1.00-1.39); chronic lymphocytic leukaemia/small lymphocytic lymphoma and deltamethrin (1.48, 1.06-2.07); and diffuse large B-cell lymphoma and glyphosate (1.36, 1.00-1.85); as well as inverse associations of NHL with the broader groups of organochlorine insecticides (0.86, 0.74-0.99) and phenoxy herbicides (0.81, 0.67-0.98), but not with active ingredients within these groups, after adjusting for exposure to other pesticides.
This evidence is fairly weak. The confidence interval for glyphosate includes 1.00. Also, there was only a risk found for B-cell lymphoma, not NHL. Inconsistencies like that suggest the association may not be real.
At present from all existing evidence I think the best conclusion is that there may be a small correlation between the highest levels of agricultural exposure of glyphosate and some types of lymphoma, but the existing evidence is not of sufficient quality and consistency for a final determination. It does warrant further study, but also indicates that any potential risk is likely small. In the meantime it certainly makes sense for agricultural workers who deal with pesticides of any type to practice good safety – using protection suits and breathing masks, for example.
There is another element of the DeWayne Johnson case that should be mentioned. The delay between his exposure and diagnosis was too short, it is argued, to have been that actual cause of his NHL. The legal case itself is complex, and I do not intend to comment on the legal issues here. My only intent is to the put the science into context.

Glyphosate Remains Controversial
Steven Novella on February 25, 2026
Link

Glyphosate is the most used herbicide in the world, with farmer applying about 750 million kg per year. The US is the heaviest user, responsible for 19% of global use. The chemical is popular among industrial farmers because it is safe and effective, and yet it also remains highly controversial. It is also back in the news, and so an update on the science of the safety of glyphosate is in order.
Glyphosate is a non-specific herbicide, meaning it kills most plants. It works by blocking the shikimic acid pathway, which is necessary for the production of important proteins in plants and some microorganisms. It does not affect animals, which is part of the reason it is considered safe for crops. It is currently approved, and has been reapproved, by regulatory agencies in the US, Canada, Europe and Australia.
It is also safer, and this is important, than any other viable alternative herbicide. Its widespread use has arguable reduced human exposure to other chemicals which do not have as good a safety profile. However, there are other alternatives, specifically farming without the use of herbicides, and the use of organic herbicides. However, manually pulling weeds is not practical on industrial scales.
Organic herbicides are considered safer by some because they break down more quickly and do not persist in the environment. But this also means they need to be applied more frequently and at higher doses. So they are considered to have more acute but less chronic toxicity, however, they are not as well studied. Often the “appeal to nature” fallacy is invoked to argue for their safety, but this is not a valid point.
Currently, therefore, there is no perfect solution, which is why glyphosate remains highly used. It remains controversial for several reasons. First, it was originally produced by Monsanto (now owned by Bayer), which is itself a controversial company. Monsanto marketed “Roundup ready” GMO crops, which could tolerate glyphosate and increased its use, so the herbicide became wrapped up in the anti-GMO messaging.
But there is also a legitimate scientific controversy fueling the public controversy, and it mainly revolves around how best to approach the question of toxicity. As I have discussed previously, we can frame this as a difference between hazard and risk. Hazard is the potential to cause harm, while risk is the actual chance of harm at a given level of exposure. There is no question glyphosate is a potential hazard. It has the potential to be carcinogenic and to be an endocrine disruptor. There is also some potential that, because it affects some microorganisms, it can affect the gut flora of humans and other animals. But is it a risk at actual levels of exposure?
This difference is why the International Agency for Research on Cancer (IARC) designated glyphosate a “probable carcinogen” – using their hazard-based approach. But regulatory agencies, using a risk-based approach, have repeated found glyphosate to be safe.
Regarding risk, there are two populations to consider – farm workers with potentially heavy exposure to glyphosate, and everyone else exposed only through crops that have been treated with glyphosate. Here is some recent evidence since the last time I wrote about it.
A 2022 systematic review of glyphosate and neurological outcomes found no association. Here is a good recent summary of how the regulatory agencies determine safety levels. The EPA, for example, determines a maximum daily exposure “based on amounts that are 1/100th (for sensitive populations) to 1/1,000th (for children) the no observed adverse effects level (NOAEL) identified through a comprehensive battery of animal toxicology studies.”
Research on actual level of glyphosate in crops and livestock are variable, by country and crop, are mixed. Many crops have no residue or slight residue below regulatory limits, but some due exceed those limits. However, because of the two orders of magnitude margin of safety, none exceed safety limits even if they exceed the regulatory limits. But you can focus on different parts of this information to either make a case for or against the safety of glyphosate.
The bottom line for consumers has not changed – while there is a potential hazard, consumer exposure levels remain far below a level that plausibly causes any risk. Where the scientific controversy remains heated is over the question of an association with non-Hodgkin’s lymphoma, especially for workers with the highest exposure.
These two reviews come to the conclusion that there is a persistent signal in the research for an association between high levels of glyphosate exposure and non-Hodgkin’s lymphoma (NHL). However, this 2023 review aligns more with the opinion of regulatory agencies. It finds that most of the epidemiological studies looking at this question are highly flawed, mainly because they do not control for exposure to other pesticides. Meanwhile, the best epidemiological study found no association between glyphosate exposure, even at the highest levels, and NHL.
While I personally find the evidence overall supports the safety of glyphosate (I feel a risk-based approach is better than a hazard-based approach, there is a wide margin of safety levels, and the best evidence is negative), there is a lot of data that legitimately can be seen as concerning. There is also the question of industry influence in the research. A study from 2000 showing glyphosate is safe was recently retracted because of undisclosed industry funding. It is therefore no wonder that the public remains confused and divided on the safety of glyphosate.
As it stands I think the regulatory agencies are correct is continuing to approve glyphosate. It is likely safe and better than all the alternatives. However, more and better research is always welcome. This is definitely an area where we would benefit from highly rigorous large consensus studies designed to resolve continued scientific disagreement.
    • 

Electromagnetic Fields at Work Show No Brain Tumor Risk
A new study finds no significant correlation between workplace exposure to radio frequency (RF) or intermediate frequency (IF) electromagnetic waves and the most common brain tumors. This is more reassuring evidence that non-ionizing EMFs are probably safe.
Steven Novella on August 1, 2018
Link 
Our civilization is increasingly bathed in electromagnetic fields, including radio frequency waves, microwaves, and higher frequencies. It is understandable that people would worry if this sudden increase in exposure poses any health risk. Fortunately, the evidence so far is reassuring.
Despite the negative evidence to date, in 2011, the International Agency for Research on Cancer classified EMF as a “possible” carcinogen. They have a low threshold for this category, which is rather long. It requires limited evidence of carcinogenic potential in humans and inadequate evidence in animals. This is the, “Probably should do more research just to be sure, but basically don’t worry about it,” category.
EMF and cancer
A new study takes a close look at occupational exposure or electromagnetic fields (EMF), specifically radiofrequency (RF) and intermediate frequency (IF) EMF, and also show no association. The researchers individually rated workers by their exposure to radio frequency and intermediate frequency EMF, and compared 4,000 cases of either meningioma or glioma (the two most common types of brain tumor) and 5,000 controls. They found:
Overall, around 10% of study participants were exposed to RF while only 1% were exposed to IF-EMF. There was no clear evidence for a positive association between RF or IF-EMF and the brain tumors studied, with most results showing either no association or odds ratios (ORs) below 1.0. The largest adjusted ORs were obtained for cumulative exposure to RF magnetic fields (as A/m-years) in the highest exposed category (≥90th percentile) for the most recent exposure time window (1–4 years before the diagnosis or reference date) for both glioma, OR = 1.62 (95% confidence interval (CI): 0.86, 3.01) and meningioma (OR = 1.52, 95% CI: 0.65, 3.55).
Essentially, this is a negative study. The possible correlation between the highest and most recent exposure with brain tumors was not statistically significant. The authors conclude that this possible association deserves further research, which is what authors always say, but this needs to be put into context.
When looking for so many possible correlations, there is going to be a lot of statistical noise. In this study, some of the groups had risks less than one, which if taken literally means that the EMF had a protective effect. No one would conclude this, however. This is just the random noise in the data. Even statistical significance does not necessarily mean an effect is real, but it is a minimum threshold for the data being interesting. In these kinds of studies, and generally, a non-statistical trend should just be treated as negative.
But this also highlights an important aspect of research that is looking for risks – such studies can never prove a risk of zero. There is no such thing as zero risk in science, because that would require complete evidence, which is impractical. So unless you study every human being on the planet, you cannot conclude zero risk, and even then you can just conclude that the risk is less than one in 7.5 billion.
Studies looking for correlations to determine potential risk can only make statistical statements about the probability of risk of a certain magnitude. So in this case the study failed to find a risk from occupational exposure to EMF big enough to be detected by the power of this study, but a smaller risk cannot be ruled out. In other words, any remaining risk must be too small for this study to have detected.
This potentially means that we are never fully done looking for potential risks – we can keep looking for smaller and smaller risks from some exposure. When is the possible remaining risk small enough that we can treat it as no risk? That is a judgement call, but generally we use the background risk as a guide. Once any possible risk is so small that it gets lost in the background risk of just being alive, then it is probably not worth worrying about at that point.
Is EMF there? That’s the question. I think we are close, if we are not already there, and this study brings us closer.
But there is another type of evidence that can be used to address this question also – plausibility. Is there a known mechanism for causing cancer or some other harm, and would we predict based on basic mechanisms that the exposure should convey some risk?
For EMF in the RF and IF range and risk of cancer the answer is that there is no proven plausible mechanism for causing cancer. High frequency EMF carries enough energy that it can break chemical bonds, and therefore cause damage to proteins and DNA. This is a known cancer risk.
Low and intermediate frequency EMF, however, are too low-energy to break bonds. Some have concluded from this that we can eliminate any potential risk on theoretical grounds alone, but I would not go that far. The history of science teaches humility in this regard – even low frequency EMF is a real detectable thing, and carries energy that could potentially have an effect on living tissue, short of breaking chemical bonds.
So I would consider the plausibility of harm as low, but non-zero. Still, this is also reassuring. When we combine low plausibility, with reassuring observational evidence of a lack of correlation, then we are starting to get to the point that we can stop worrying about low frequency EMF.
Unfortunately, I don’t think we are at the point where there is yet enough of a consensus that research will stop. There is still a lot of statistical noise in the research, like in this study, and those who fear a link between EMF and cancer point to that noise as showing a possible risk and demanding more research.
As cell phone use continues to increase, and with each new wave of technology (now with 5G coming), fears of cell phones causing brain cancer continue. I suspect that for years, and probably decades, there will be continuing fear of Wi-Fi, cell phones, and similar technologies causing adverse health effects. Researchers will continue to search for possible links, and the data will probably continue to look like it does now – overall negative, but with the unavoidable randomness that will continue to stoke fears and prompt yet more research.
For now I think it is reasonable to continue to use cell phones and Wi-Fi, reassured that if there is any risk, existing research says it is probably too small to worry about.

Do Sunscreens Cause Cancer?
Elizabeth Plourde thinks sunscreens cause cancer rather than preventing it. She blames sunscreens for everything from coral reef die-offs to autism. Neither her evidence nor her reasoning stand up to scrutiny.
Harriet Hall on June 12, 2018
Link


A reader asked me to look into the claims that sunscreens cause cancer, especially the claims made by Elizabeth Plourde. When our own Scott Gavura evaluated sunscreens, he concluded:
The data on sunscreen use and cancer risk are complex, but on balance suggest that the short-term and long-terms benefits of sunscreens significantly outweigh their risks when used during periods of unavoidable exposure.
Elizabeth Plourde thinks otherwise. She says sunscreens don’t work to protect from skin cancer; in fact, they cause cancer (not just skin cancers, but breast, prostate, and other cancers). Her book Sunscreens Biohazard: Treat as Hazardous Waste accuses sunscreens of all manner of evils, everything from causing infertility to destroying coral reefs. She even implicates sunscreens as a cause of autism. She is not the only one to raise these issues, but she has written the most comprehensive critique of sunscreens, with over 500 references. I wanted to give her a fair hearing, and the book was not available through my library or even through inter-library loan, so I bit the bullet and sacrificed $9.98 of my hard-earned money for the Kindle version and read it. I learned a few things, but I didn’t find her evidence or her reasoning convincing.
An epiphany based on a false observation and a single study
She starts by describing the epiphany that led to her investigations. She had read that coral reefs were dying due to global warming; but when she went swimming in Hawaii, she thought the water felt colder than ever before in her 40 years’ experience of swimming there. She didn’t question the validity of her subjective impression; if she had, she might have learned that sea temperatures in Hawaii are actually rising. Anyway, she assumed global warming couldn’t be the cause of coral die-off, and she quickly found another explanation: an article “unequivocally demonstrating” that coral die from exposure to sunscreen chemicals. She says she “immediately” knew she had to write a book warning the world that sunscreens were threatening not only coral reefs but the whole marine habitat. Seems like a bit of a leap to me! As she combed the scientific literature in search of confirmation, she found that birds, mammals, and humans were also under threat.
I looked up the article that had impressed her so much. It was not the unequivocal proof she thinks it was. The researchers added varying amounts of sunscreen to plastic bags of seawater containing nubbins of coral organisms. The concentration of sunscreen they used was higher than most reported environmental levels, and the bleaching they found was not dose-dependent. The mechanism? Sunscreen apparently promoted a lytic cycle in viruses latent in the coral. They estimated that up to 10% of the world’s reefs are potentially threatened by sunscreen-induced coral bleaching. I don’t think that conclusion is warranted by their data. And it’s only a single laboratory study that has not been replicated.
Why she thinks sunscreens don’t work
She argues that if sunscreens really worked, the incidence of skin cancer would have dropped by now, as the use of sunscreens has become ubiquitous. She reports that studies have shown both increases and decreases in the incidence of skin cancer, but then she claims that there has been “a tremendous and consistent rise.” Her citation for this says nothing of the sort. It does say the results of studies are controversial, with some showing a protective effect of sunscreen and others suggesting a significant risk.
Even if the incidence of skin cancers has risen, that’s not evidence that sunscreens don’t work, or that they cause skin cancer. There could be other reasons, confounding factors, to explain the rise. It might be that people are spending more time in the sun because sunscreens give them a false sense of security; it might be that they are not using sunscreens properly or reapplying them when needed; it might be that they are using older UVB sunscreens that don’t protect from UVA; it might be due to other factors like depletion of the ozone layer, longer lifespans, increased popularity of outdoor activities, exposed skin due to clothing style, use of tanning beds, earlier detection of skin cancer, etc. Plourde’s reasoning is faulty and is unworthy of a scientist.
One of her references says:
Whereas chronic sun exposure is the main cause of NMSC [non-melanoma skin cancer], the development of melanoma appears to be related to intense, intermittent sun exposure. Ozone depletion has contributed to rising incidence rates of both NMSC and melanoma. In contrast to NMSC, there is not a direct relationship between ultraviolet radiation and melanoma.
Nowhere does Plourde even mention ozone depletion. Her review of the literature seems to be aimed at finding justification for her pre-conceived ideas, not at searching out the truth.
Sunscreens not associated with melanoma
She thinks sunscreens cause melanomas. The article she incorrectly cited for incidence found that the data “do not suggest a causative association between sunscreen use and melanoma.” Meta-analyses like this one have confirmed that there is no association between sunscreen use and melanoma.
The various types of sunscreen
Plourde does a good job of describing the various sunscreen ingredients and the difference between UVA and UVB protection. She provides a comprehensive list of existing sunscreens and explains that newer sunscreens are safer and more effective for blocking both UVA and UVB. She mentions that other sunscreens are being developed; but she discourages early adoption, since she says it has taken 30 years to identify the harms from older products.
Sunscreens were originally marketed to prevent sunburn, not cancer. In Europe, they are regulated as cosmetics, while in the US they are considered drugs. They are rated by SPF (sun protection factor) but this only applies to UVB; there is no good way to rate UVA sunscreens.
The American Academy of Dermatology recommends everyone use a sunscreen that provides:
    • Broad-spectrum protection (protects against UVA and UVB rays)
    • SPF 30 or higher
    • Water resistance
Endocrine disruptors?
She says sunscreens contain endocrine disrupting chemicals that can have estrogenic, androgenic, anti-estrogenic, and anti-androgenic effects. She provides plentiful evidence for these effects in laboratory rats, but no evidence for significant effects in humans. She provides evidence for endocrine effects in fish in the lab, but then she assumes that intersex fish and other reproductive anomalies found in nature are a result of the minuscule amounts of sunscreen chemicals that have been detected in our oceans and streams. She cites changing statistics for male infertility, cryptorchidism, hypospadias, testicular cancer, breast reduction surgeries in men, and the timing of puberty. She suggests that all of these could be caused by sunscreens, but there is no evidence that they are.
Other concerns
She speculates that sunscreens could be contributing to other health problems like breast cancer, thyroid disorders, and obesity. She sees “connections” between the rise in autism and the rise in sunscreen use. She says those connections make it imperative to do more research to find out if sunscreens cause autism. She repeatedly talks about correlations as if they meant more than they do. The incidence of autism has risen in perfect correlation to the sales of organic food. She does not recommend more research to determine if organic food causes autism.
She worries about nanoparticles. She cites all kinds of laboratory evidence suggesting “possible” harm from nanoparticles, but no actual evidence of harm to humans from nanoparticles in sunscreens.
She is worried that sunscreens reduce levels of vitamin D, even though some research shows they don’t. She goes to great lengths to explain all of the possible harms from decreased vitamin D.
Coral reefs
She thinks it has been definitively established that sunscreen chemicals can result in coral death. She bases that opinion on lab studies and correlations (the tourism boom in Belize coincided with coral bleaching). A report by the Australian Government’s Great Barrier Reef Marine Park Authority doesn’t even mention sunscreens among the threats to the reef.
The ubiquity of sunscreen chemicals
She shows evidence that sunscreen chemicals are found not only in our water, but in household dust, breast milk, and pretty much everywhere. But in what amounts? The detection of minute amounts is a tribute to the incredible precision of modern laboratory methods, but it says nothing about whether those tiny amounts cause any significant harm to humans. Lab analysis can detect the tiniest amounts of all kinds of other chemicals. The human body is constantly coping with minuscule amounts of all those other chemicals, with no evidence of harm. We can’t avoid all of them, but we needn’t worry about all of them. The poison is in the dose.
Alternatives to sunscreens
She recommends “Mother Nature’s sunscreen:” an antioxidant UV protection diet that she says will strengthen the immune system and protect from cancer. She also recommends organic food, aloe vera, and a longlist of amino acids (including histidine, which she spells histadine) and other nutrients that are photoprotective, even caffeine and goji berries (juice found to reduce sunburn in mice). After sun exposure, she recommends putting olive oil and tea on the skin. Of course, there is no evidence that her “natural” measures are anywhere near as effective as sunscreens. She gives sensible advice about reducing sun exposure and wearing protective clothing. But she recommends avoiding all sunscreens because there is no sunscreen on the market that doesn’t contain harmful chemicals.
The precautionary principle
She says:
Indeed, studies examining sunscreens and their effectiveness or potential harmful consequences demonstrate conflicting results that researchers, themselves, state are difficult to explain. The major reasons for these inconsistencies are due to the fact that the human body and the interactions of the ecosystems are so complex it is difficult to design studies that can control all the individual and environmental variables in order to discern definitive answers.
She’s certainly right about that. But then she seems to assume that not knowing if there are harmful consequences equates to reasonable certainty that there probably are harmful consequences. And she is arguing that science can never rule out harmful consequences. Where does that leave us? She seems to think that if there is even a whisper of a suggestion of a possibility of harm, we should act to avoid that possibility. I disagree, because the precautionary principle fixates only on harms and disregards the benefits; and precautionary actions have often led to unforeseen consequences that were even worse.
Putting risks in perspective
Scott Gavura’s approach (see above) is much more reasonable. As a recent review concluded, “Given the established benefits of UV protection, the use of sunscreens remains an important part of an overall photoprotective strategy.”
Conclusion: Not good science
Plourde’s book is a cherry-picked, poorly reasoned diatribe, not a fair assessment of the scientific evidence. The bottom line: no, sunscreens don’t cause cancer; they protect against it. There are some legitimate concerns about possible adverse effects and environmental impacts, and we can continue to study possible risks and to look for newer, more effective, safer sunscreens. Meanwhile, we can continue to use existing UVA/UVB sunscreens judiciously, cover up, and avoid unnecessary sun exposure.

Dental X-rays and Brain Tumors — Oh My!
Steve Hendry on May 11, 2012
Link
Fear sells, and the media loves it. If it’s scary, no matter how tenuous the link or inconclusive the study, you are going to see it on the news. How many times over the years have you heard that your cell phone might give you brain cancer, even though it never turns out to be true? Once such a claim is made, however, it becomes lodged into the public’s psyche and is accepted as true, even after refutations and retractions are published (see Wakefield, Andrew).
And so it is with x-rays. The latest scare du jour, a recent study out of Yale that claims to show a correlation between dental x-rays and intracranial meningioma — the most common brain tumor and usually benign — has been enjoying widespread attention in newspapers and on the evening news. We don’t know if it will be on Dr. Oz, because we can’t bring ourselves to watch that show, but we feel the chances are good. Other alt-medders will no doubt have collective woogasms over the story and will further incite fear and mistrust into the doctor-patient relationship. In fact, the Mercola website wasted no time in weighing in:
While this study does not necessarily establish causation between dental X-rays and tumors, previous research has also implicated dental X-rays in the development of thyroid cancer, and research clearly shows this type of radiation is not harmless…
Typical alarmist fear-mongering. When has any health care professional claimed that radiation is harmless? This is not cutting edge research; Wilhelm Röntgen, the discoverer of x-rays in 1895 and winner of the Nobel Prize in 1901 for his research in the field, advocated the use of lead aprons for protection from the ionizing radiation way back when. Further, trying to lump one study linking dental x-rays to meningioma to another study linking them to thyroid cancer is taking quite the kitchen sink approach. But if there are multiple alleged possible potential theoretical adverse effects from our dental death rays, it must be true, right?
Well, not so fast. We’re dentists, and unlike many knee-jerkers, we’ve actually read the study and would like to offer a little bit of insight into this before everyone panics. In fact, with respect to Letterman, we’d like to offer our Top Three Reasons Not To Panic:
1. The data is primarily anecdotal. The study authors reasoned that since actual data about people’s radiographic histories is hard to compile (people typically see multiple dentists over their lifetimes, and there is no central repository of radiographs taken), it would be acceptable for epidemiological purposes to simply interview people and ask them to recall what dental x-rays they’d had taken over the years since childhood. Claus et al. claim that people show accurate and unbiased recall of their x-ray histories suitable for drawing inferences decades later, but we have news for you. It is standard procedure for us, as dentists, to ask new patients what sorts of radiographs they’ve had in the last fews years (we will ask your previous dentist for copies to avoid taking them needlessly) and you people are terrible at remembering this sort of thing. Except for people who haven’t seen a dentist at all in years, it’s actually a bit unusual for a patient to accurately tell us what and when their last dentist took, even in the previous couple of years — we usually have to call your previous office to find out. Based on our daily reality, the idea that patients can recall what radiographs they’d had since childhood with epidemiologically useful accuracy seems implausibly optimistic, especially when considering that the sample population ranged from 20 years to 79 years old. This would require an accurate memory and reporting of radiographs taken as far back as the 1940’s and 1950’s in many cases, which we submit is not a valid assumption. In fact, the authors, to their credit, state:
Limitations of this study include the possibility of either under-reporting or over-reporting of dental x-rays by study participants. This is a difficult problem in epidemiology, because, unlike medical care, which (at least within cohorts of patients drawn from health maintenance organizations or similar entities) may be confirmed by a review of centralized medical records, dental care generally is obtained (even for a single individual) from numerous dentists, all of which are outside of a health maintenance organization or hospital-based setting, providing little opportunity for researchers to validate dental reports in a timely or cost-efficient manner. No national database of dental treatment exists within the United States; hence, researchers must rely on patient self-report, despite the potential for bias.
Let’s play a fun game. We’ll ask you, the astute and intelligent reader of the Science Based Medicine Blog, to recall your dental x-ray history for your entire life. Can you recall the exact dates when a full series of radiographs were taken? What about a panelipse? Corrected tomograms? Cone beam films? Individual films called periapicals? What about bitewing x-rays?
How did you do?
Not very well, did you? Well, don’t feel badly; we’re dentists and we wouldn’t be able to recall our own radiographic history from memory even if threatened with homeopathic hemlock! Asking meningioma patients if they remember having x-rays, and comparing with the memories of people not preoccupied with having brain tumors, is not only inaccurate, but also raises the obvious possibility of reporting bias by the study participants.
We are also concerned that the authors apparently did not survey for other potential confounding factors, such as tobacco history, diet, occupational exposures, etc., or if so, they were not disclosed in the paper. It might even be that having had dental x-rays is correlated with going to the dentist regularly, and that those people are also more likely to see a physician regularly and have a timely diagnosis of medical conditions like meningioma. Or perhaps people who live healthy lifestyles and thus have healthier teeth and gums require fewer dental x-rays over their lifetime. In this scenario, quantitative measurements of dental x-rays are an indirect indication of systemic health, and thus meningioma risk. Who knows, but the point is that there are a myriad of risk factors not considered in this study, and the one variable they attempted to measure was vague and nebulous.
2. The results defy dose response expectations The Yale study reports that meningioma patients are twice as likely than controls subjects to remember ever having had a bitewing x-ray (the most common film used in dentistry), and that more frequent bitewings were associated with increased risk. So far so good. But they found no significant correlation with full mouth series radiographs — a set of 16-20 dental x-rays. Please note that a full series of dental radiographs includes 2-4 bitewings, then adds 14-18 more! The take home message, if this were valid, is that a couple of cavity detecting x-rays may give you a brain tumor, but if your dentist takes an extra dozen or so films instead, you’ll be fine. Dr. Alan Lurie, president of the American Academy of Oral and Maxillofacial Radiology, said “That inconsistency is impossible to understand to me”, and he has a good point. “I think it is a very flawed study,” Dr. Lurie went on to say. As reported in the ADA News:
He (Lurie) characterized at least one outcome of the study—reflected in a table that related meningioma risk to types of dental X-ray examination—as “radio-biologically impossible.”
Said Dr. Lurie, “They have a table, Table 2, in which they ask the question, ‘Ever had a bitewing,’ and the odds ratio risk from a bitewing ranges from 1.2 to 2.0, depending on the age group. Then they asked ‘Ever had full mouth’ series, and the odds ratio risk from a full mouth series ranged from 1.0 to 1.2.
“That is biologically not possible because the full mouth series has two to four bitewings plus another 10 to 16 periapicals. A full mouth series, just to round things off, is 20 intraoral X-rays of which two to four are bitewings. They are showing that one bitewing has 50 to 100 percent greater risk than a full mouth series that has multiple bitewings plus a bunch of other films.”Explaining this gross internal discrepancy is difficult, as the epidemiologic and statistical methods are widely accepted, Dr. Lurie said. He attributes the perceived discrepancy in the data to possible recall bias in the patients involved in the study.
The study also found no correlation with cone-beam CT scans, increasingly used in dental implant treatment and providing the highest x-ray dose of any dental radiograph.
3. Lost in the background. Claus et al. point out that dental x-rays are the most common source artificial source of ionizing radiation, which is true, but omit the fact that they are among the least significant quantitatively. Data published in 2009 in the journal Radiology, puts this nicely in perspective:
Estimated collected effective dose from various sources, U.S. 2005 (thousand person-sieverts)
Natural background	720.0
Medical radiography	899.0
Nuclear medicine	231.0
Dental radiography	2.5
Nuclear power	0.1
Consumer products and misc.	39.0
Take note: in the race to blast the most radiation through your brain, nature is falling a bit behind your hospital, but your dentist can’t get within 2 orders of magnitude of it. That’s why you never see a Superhero (or a Godzilla) mutating out of a dental office to save (or destroy) the world. While hospitals and Mother Nature have veritable radiation bazookas at their disposal, we have but pea shooters.
The reason your dentist is actually such a poor choice for suicide by brain tumor is related not to frequency (what the authors of the study focused on) but to dose. Particularly with current trends toward digital x-ray equipment (which exposes patients to significantly less radiation than film x-rays), the actual radiation dose in a dental x-ray might surprise you (data from the Health Physics Society and from Randall Munroe’s superb infographic):
Dose in microsieverts
Dental bitewing	5
Dental Panorex	10
Daily background radiation	10
Airplane flight NY-LA	40
Chest x-ray	100
Lumbar spine	1500
Intravenous pyelogram	3000
Whole-body CT scan	10,000
Coronary angiogram	20,000
We hope this will help you understand why we roll our eyes when a physician reporter on NBC tells the audience that they should be really be refusing x-rays at the dentist. This is dangerous advice coming from someone outside of their field of expertise.
Medical radiation aside, an important question remains: when we all get several hundred μSv of background ionizing radiation through our bodies and brains per year — every year- it seems a bit odd that an extra 10 μSv, even once in your life, would significantly raise your risk of anything to the degree that the Yale study claims.
And One More Thing. We are really getting a bit tired of hearing everyone who publishes or pontificates about x-rays opine sagely that x-rays should only be used where necessary, as if they have invented the concept of radiation hygiene. This implies that physicians and dentists routinely take unnecessary x-rays. But this is not a new idea. Keeping radiation exposure As Low As Reasonably Achievable is a cornerstone of diagnostic radiography, and has been for decades. It’s called the ALARA Principle, and it has been taught to everyone who uses x-rays in Medicine and Dentistry for ages. If you go to your dentist (or your physician) and announce that you don’t want any unnecessary x-rays he or she is NOT going to say “no problem — we never really needed the ones we used to take!”. If he or she is any good, chances are that radiographs are prescribed (and that really is the correct term) because the diagnostic benefits of the bitewing or the angiogram vastly outweigh the risks. It’s good to discuss this with your healthcare provider, but bear in mind that doing many invasive procedures without the benefit of adequate diagnostic radiographs is often regarded as malpractice, and for good reason.
And One More One More Thing. We have devoted most of this blog post pointing out some of the flaws of this study and how it may have adverse effects upon your dental health. We would be remiss, however, if we didn’t point out that the fallout from studies such as these rests squarely upon the shoulders of irresponsible reporting by the media. In a desperate battle for viewers/listeners/readers, these stories are belched to the public uncritically, with fear being the primary angle. Rarely is equal time given to rational responses, and sadly, the personalities who spout the loudest are often physicians contracted with the news networks. This is unfortunate for many reasons; among them being that 1) as doctors, they should know better; they should read the article themselves and be able to interpret it correctly, and 2) their opinion is held in high regard by the public, making our job of discussing it with our patients that much more difficult. We can’t tell you how often we have heard from our colleagues the fallout we’ve received when the Great and Powerful Oz (a cardio-vascular surgeon) informed his disciples that one can effectively whiten one’s teeth with raisins and lemons. Not only is that patently false; it’s harmful to teeth, as putting something almost as corrosive as battery acid on one’s teeth is generally frowned upon in the dental community.. Stories such as these can often create a wedge in the relationship we dentists try so hard to establish with our patients.
Finally, dentistry is by necessity somewhat more reliant on routine radiographs than other health professions because we deal primarily with hard tissues subject to diseases that are often invisible without some radiographs. Keep in mind that tooth decay and periodontal disease are among the most prevalent diseases of the human race, and early detection and treatment are critical to good oral and systemic health. Without radiographs, we often cannot see decay until it reaches the nerve and kills your tooth, or the impacted wisdom tooth until it has damaged the tooth next door, or the asymptomatic abscess until it puts you in the hospital. Occasionally, we discover pathological processes, including the rare case of oral cancer long before they would manifest clinically. A timely x-ray, even in someone with no symptoms, could save a life. We as a profession readily accept the radiation burden in a bitewing or full mouth exam because of the obvious benefits for the well being of our patients. When we order any X-ray exam, we have made the determination that the benefit outweighs the risk and the risk of such exams are much less than those risks we commonly accept in daily life. We do not take this responsibility lightly.
So, do dental x-rays cause meningiomas? We have criticized the original article and the reporting thereof, but the fact remains that we don’t know. They might, of course, but unfortunately the article only gives us a smattering of data that may or may not be relevant. The signal to noise ratio contained in this study was too low to be of much use, and it’s hard to understand how higher-dose x-ray exams could be safer than the lower dosed single bitewings, or why far higher doses from other sources would not contribute to the same problem. Hopefully a more thorough study will be done to add to our body of knowledge and either confirm or refute the findings of the original article.
We do hope this has helped pull at least some of you back from the brink of a total freakout about your next dental visit. If you still need more dental fear, stay tuned — we hope to tell you soon about another dire threat from your dentist: silver amalgam fillings.
Dr. Grant Ritchey received his Bachelor’s degree in Human Biology from the University of Kansas in 1982, and his Doctor of Dental Surgery degree from the University of Oklahoma in 1986. He lives in Kansas City, is married, and has two grown daughters. Since 1986, he has maintained a general dental practice in Tonganoxie, Kansas, and was awarded a Fellowship in the Academy of General Dentistry in 1998. Currently, he is working toward his Masters in Education Degree from the University at Buffalo in the Science and the Public program, with an emphasis on the prevalence of alternative medical practices in dentistry.
Dr. Steve Hendry, BSc DDS FAGD, completed an honours degree in Genetics at the University of Western Ontario before deciding to be a dentist when he grew up. He spent summers working in a corn cytogenetics research lab through dental school. Since graduating in 1981, he’s maintained a general dental practice. Steve has always been fascinated and appalled at the scarcity of critical thinking skills in society and, increasingly in his own profession. He is particularly proud of having attained the status of “closed minded” in the eyes of some of his woo-friendly peers.

Cancer, vitamin supplements, and unexpected consequences
Not only do B-vitamin supplements not protect you from lung cancer, they may significantly raise your risk of cancer.
Scott Gavura on September 7, 2017
Link


Vitamin supplements have been successfully marketed for decades, despite the lack of good evidence that they are necessary or beneficial for the vast majority of people that take them. While frank deficiencies of vitamins are generally rare (you don’t see scurvy much anymore), dietary restrictions, pregnancy, and even socio-economic status may increase the possibility of a deficiency and an evidence-based recommendation to supplement. It’s more of an open question if supplementation in the absence of any clear medical need is advisable or necessary. As a pharmacist I’ve spent a lot of time over the years speaking with patients about vitamin supplementation. Many seem to take the view of vitamins as a reasonable “insurance policy” for their diet, and a net positive thing they can do to support healthy living. Early in my career, I viewed vitamin supplementation without any clear medical clear need as producing “expensive urine” for the user, but unlikely to cause much harm. But over the past 25 years, evidence has emerged to change my view. I am much more skeptical now of the net benefit of vitamin supplementation. That position is based on the results of multiple studies that have shown that vitamin supplementation is not always harmless – in some cases it appears to be harmful, and should be discouraged. 
Many of the problems with vitamin supplementation have emerged when we have assumed that isolated vitamins are an appropriate or equivalent substitute for foods that contain those same vitamins. Compound this with the equally bad idea that more=better, and you have supplement doses much higher than would be consumed in diet alone. Antioxidants are the most representative example. The idea for antioxidants emerged from observations about oxidative stress and their contribution to illness and aging, and the hypothesis that antioxidant supplements could minimize these effects. Yet trials have failed to show that antioxidant supplements have the same effects as antioxidant-rich foods. Over time it became clear that beta-carotene supplements could raise your risk of cancer. Vitamin E supplements also appears to raise, rather than lower, prostate cancer risk. Steven Novella’s post from 2015 summarizes the evidence on vitamins and cancer risk, and provides the backdrop to the study I want to review today that illustrates the cautious, deliberate approach we should take to supplementation.
Studying the effect of B-vitamin supplementation
Any pharmacy that you walk through will likely have several shelves of different combinations of vitamins all touted with specific purposes. “Stresstabs” are a popular vitamin brand sold around the world that are essentially a multivitamin with added B vitamins. Presumably created based on some idea that stress depleted B-vitamins, or could be relieved with B-vitamins, Stresstabs were very popular in the local pharmacy where I worked where patients thought they could get a “quick fix” from the stress in their lives. There’s also B12 supplements which continue to be marketed as some kind of energy panacea despite the lack of any evidence they do anything useful if you’re not deficient.
This new study from Brasky and colleagues is entitled “Long-Term, Supplemental, One-Carbon Metabolism–Related Vitamin B Use in Relation to Lung Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort” and was published in the Journal of Clinical Oncology. This is a focused analysis of the B-vitamins (B6, B9 (folate), and B12) on lung cancer risk. The paper is behind a paywall, so regrettably the detail may not be easily accessible to you.
The authors start out by noting that the results from previous studies of B-vitamins and lung cancer have been unclear, yet there have been hints of the risk of harm. The authors hypothesized that doses of B-vitamins in excess of the Recommended Daily Allowance (RDA) might be cancer-promoting through effects on the cellular environment. This analysis draws on data collected from the VITamins And Lifestyle cohort study, initiated in 2000 to study the association of vitamin supplements with cancer risk. Over 77,000 men and women aged 50-76 years living in Washington state were enrolled, with the objective of tracking cancer and deaths. As part of the study, participants reported their regular consumption of vitamins (individual products and multivitamins) over the prior 10 years. The 10-year average daily dose of vitamins B6, B9, and B12 were calculated, and participants were stratified by doses consumed, ranging from multivitamin-level-doses (small) to what would be considered high doses.
In addition to supplementation habits, dietary habits were assessed using standardized questionnaires, and multiple health-related risk factors (e.g., smoking history) were also collected.
Patients were followed for the incidence of lung cancer from baseline (2000-2002) through December 31, 2007. The incidence of cancer was determined through linkage to the SEER cancer registry. 808 cases of invasive lung cancer were identified in the cohort.
The statistical analysis is complex and used models to estimate hazard ratios and confidence intervals for the association between doses of B-vitamins and the risk of lung cancer. They tried to identify and control for as many confounders as possible (e.g., adjusting for smoking rates, or adjusting B-vitamin intake based on caloric intake).
The findings were pretty striking. Based on information collected when participants enrolled in the study, former use of individual supplements of vitamin B6 or B12 was associated with an increase in lung cancer risk in men, but not women. Compared to no supplementation, vitamin B6 increased the risk of lung cancer by 84%, and vitamin B12 was observed to more than double risk. Looking at the 10-year average daily dose, the increase in cancer risk was associated with the highest levels of supplementation: more that 20mg/day of B6 and more than 55mcg/day of B12. No association was found between folate (folic acid) and lung cancer risk. The trend was most significant in smokers. There were no beneficial effects of supplementation seen in any group.
Implications
This study gives fairly compelling evidence that consumption of high doses of vitamins B6 and B12 are associated with an increased lung cancer risk. This association was found in men only, and was stronger in smokers. No association was found in women, and no association was found with the consumption of B-vitamins in the low doses contained in multivitamins. The authors suggest that doses of B6 and B12 that are taken in excess of dietary requirements may be causing pro-cancer effects.
Key considerations
Perhaps not surprisingly, industry advocates have moved quickly to question or dismiss the findings (“Statistical chance” says one) and criticizing the coverage of the trial. But what’s arguably just as important as the elevated risk of lung cancer observed is the fact that there was no evidence found to suggest that B-vitamin supplementation offers any meaningful benefit, either.
Despite that marketing that vitamin-or-supplement-de-jour can prevent cancer or help you live longer/better, there is actually little evidence that any vitamin or mineral supplement has any meaningful or beneficial effects in the absence of a true deficiency. Vitamin supplementation remains exceptionally popular, and this new study should be considered in the context of other studies that have raised concerns that these products may be causing harm. Vitamin supplementation can be medically appropriate, but we should not view indiscriminate supplementation as a panacea or as harmless insurance against dietary deficiencies. And if we elect to take a vitamin supplement, isolated vitamin supplements may deliver the higher doses that appear to be associated with more risk. Probably the best advice that can come from studies like this is that we don’t fully understand the consequences of our vitamin supplement habit. Focusing on a healthy, balanced diet to meet our vitamin needs is the approach that appears to offer the best benefits and the fewest risks.

Newborn Phototherapy and Cancer: Cutting Edge Research or “Big Data” Failure?
Clay Jones on June 3, 2016
Link
While social media and news outlets were reacting, or in some cases overreacting, to a new rodent-based medical study on the unlikely link between cell phone use and brain cancer last month, two studies and an accompanying commentary were quietly published in Pediatrics that raised similar concerns. Rather than cell phone use, the proposed potential cause of pediatric cancer in these newly published papers was phototherapy, a common treatment for newborn jaundice that I use regularly and have written about before. My previous post has a full review of jaundice in the newborn, how it can potentially cause permanent brain damage, and why phototherapy is a safe and effective treatment in most cases.
But is phototherapy truly safe? Can exposure to a narrow spectrum of blue light increase the risk of cancer in young children? And if so, what type or types of cancer? This is exactly what the study authors set out to investigate using the power of “Big Data.” Time will eventually tell us if the authors’ conclusions are justified or if they will end up only serving as excellent future examples of the Texas Sharpshooter Fallacy.
But I am perhaps getting ahead of myself.
Phototherapy and cancer: Is it probable?
A proposed link between phototherapy and cancer isn’t new. The phototherapy used in hospitals and at home to treat severe jaundice in babies consists of blue light between 430 and 490 nm in length. It isn’t ultraviolet, but it’s close. Ultraviolet light is not ionizing radiation, like x-rays, but it does have both positive and negative health effects. Most well-known is the link between ultraviolet light, in the form of excessive sun or tanning bed exposure, and skin cancer, but we also rely on it for vitamin D production. In fact, ultraviolet light is the only carcinogen with known health benefits.
So phototherapy is close to ultraviolet light on the electromagnetic spectrum. I would love to be able to brush this off, but there is in vitro research going back to the 1970s showing that DNA damage does occur in peripheral blood cells such as circulating lymphocytes, and in vivo data more recently has supported this. Again, sunlight has been shown to do the same thing, although there is considerably greater evidence in support of its impact on skin cells and the related increase in the risk of skin cancer. Any link between sun exposure and non-skin cancer is highly controversial at best.
The most recent paper on the subject of phototherapy-induced DNA damage, published in January of this year, again showed that phototherapy alone, rather than the elevated levels of bilirubin causing jaundice, damages DNA in blood cells. It appears that the longer the exposure to the light the greater the evidence of damage, regardless of the intensity of the phototherapy. This is a real effect, so unlike cell phones and brain cancer there is some plausibility to an association between phototherapy and cancer. But our much more advanced epidemiological understanding of the health effects of sun exposure serves as a glaring counterbalance to the concerns raised in these new studies.
Investigations into a link between phototherapy and cancer in children have so far been a mixed bag. Epidemiological studies, likely because of the data on DNA damage in peripheral blood cells such as lymphocytes and monocytes, have primarily focused on the risk of leukemia. I personally think it’s a stretch knowing what we do about sun exposure as explained above. Some of these studies have shown no association whatsoever. Others have shown possible increased risk of leukemia, but not always the same types. No studies have been able to conclusively answer the question.
The new studies
In the first paper, researchers set out to look for an association between newborn phototherapy and the diagnosis of any cancer during the study period, rather than just leukemia. It is a retrospective cohort study that looked at nearly half a million children born in Northern California hospitals from 1995 to 2011. They weeded out significantly premature infants and babies that died prior to discharge home from the hospital, and follow-up began after 60 days of life. Using electronic records, they gathered data on phototherapy use, cancer diagnoses, and numerous other variables such as gender, race and ethnicity, maternal age, birth weight, blood levels of bilirubin, and diagnosis of a genetic disorder or congenital anomaly.
Of the 499,621 study subjects, 39,403 of which had undergone phototherapy, 711 were ultimately diagnosed with cancer at some point after 60 days of life. 60 of these children with cancer had been exposed to phototherapy, which works out to 25 cases of cancer per 100,000 person-years compared to 18/100,000 in the unexposed group. Prior to adjusting for potential confounding variables, they found statistically significant but tiny increased risk for any cancer, any leukemia, myelocytic leukemia specifically, other leukemia, and liver cancer. After adjustment, the apparent increased risk disappeared.
The authors downplay the likelihood that chance or bias, rather than confounding alone, played any significant role in their initial findings of a crude association. I wasn’t impressed with their logic. They also go to great lengths to explain that they are not ruling out the possibility that there truly is a risk associated with phototherapy, despite the negative results, particularly for myelogenous leukemia, but they admit that it would be low.
After pointing out the low risk of negative outcomes in most babies with jaundice, and implying that treatment guidelines are too aggressive, they call for providers to avoid unnecessary phototherapy. Infants with Down syndrome, who have a much higher baseline risk of leukemia, are singled out as a potentially vulnerable population. Newborns with Down syndrome are also at increased risk for severe jaundice, so this presents a conundrum if one were to incorporate the authors’ conclusions into daily practice. Much more likely is that genetic abnormalities such as Down syndrome increase the risk of both jaundice and leukemia regardless of phototherapy exposure. As we say repeatedly, correlation does not necessarily equal causation.
In the second paper, a historical cohort study, the same authors looked at an order of magnitude more children, around 5 million born from 1998 to 2007, whose data was culled from the California Office of Statewide Health Planning and Development. Although it’s a lot more babies, use of this deidentified data set requires many more assumptions of accuracy than in the previous study and it only goes out to one year of age. They did not include the significantly premature or infants who died within 60 days of birth, and attempted to gather data on the same potential confounding variables as in the previous study.
Of the 5,144,849 included study subjects, 1,100 were diagnosed with cancer in the first year of life, which yields a population incidence of 21.4/100,000. Of the 178,017 subjects who received phototherapy, 58 were diagnosed with cancer, resulting in an incidence in the exposed of 32.6/100,000. That is an unadjusted relative risk (RR) of 1.6 with a CI that nudges up against 1. It’s statistically significant, but I question how clinically meaningful it is. There were similar small unadjusted risk differences found with myeloid leukemia, kidney cancer, and “other cancers.”
After adjusting for potentially confounding variables, these findings persisted but were overall a bit less significant. They came up with a number needed to harm, by causing an additional case of any cancer, of 10,638. For children with Down syndrome, only 0.2% of the overall cohort, they settled on a number needed to harm of 7,812. Keep in mind that although this study included many more subjects, it was significantly limited by a lack of access to the same potential confounding variables as in the previous study. This may explain why the concerning findings didn’t melt away after adjustment.
They also found that jaundice itself was an independent risk factor for cancer, albeit a small one with an RR of 1.3, but this raises some serious concerns in my opinion. Increased risk of cancer caused by jaundice alone is not something that has been reported. In fact, studies (including one I linked to above) looking into the mutagenic properties of phototherapy have shown that bilirubin doesn’t even cause DNA damage.
We know that bilirubin is neurotoxic, hence the brain damage with sustained high levels in the blood, but it would be very unlikely to cause cancer. In this study, they found similar risk of various cancers in infants who got phototherapy as in those who were simply jaundiced. It’s all likely just statistical noise as this association wasn’t found in the first study, which had access to actual serum levels rather than just a diagnosis code.
In this study, the authors again call for caution when recommending phototherapy. They again point out that most children with even severe jaundice don’t suffer permanent disability, and call for providers to avoid phototherapy unless indicated based on treatment guidelines. The potential risk of cancer, it is implied, should enter into our risk/benefit assessments.
Of note in both studies was the finding that the percentage of infants undergoing phototherapy increased significantly during the study periods. In particular in the first study, which included more recent data from 2011, the use of phototherapy increased from roughly 3% of subjects to nearly 16%. In the second study, use only increased from 3% to a little over 4%. That’s a big difference and I’m not sure why there was such a large discrepancy. I can’t find recent data on this question, but the lower figures are much more consistent with my own personal experience.
It is very likely that there has been an increase in the use of phototherapy considering that updated AAP guidelines in 2004 standardized our approach to universally screening all infants prior to discharge from the newborn nursery and tightened up recommendations for post-discharge follow-up. Universal screening of babies will find more cases of jaundice that is less clinically apparent and more likely to be near or just at the threshold for initiating phototherapy. But what we have not seen is an increase in cancer in children, which speaks against a causal link with phototherapy.
Some perspective
Accompanying the above two studies in Pediatrics last month was a commentary, “Can Big Data Shed Light on the Origins of Pediatric Cancer?“, the primary author of which is a pediatric oncologist at the Dana-Farber Cancer Institute here in Boston. It both supports the ultimate conclusions of the two studies, which really just boil down to “follow the treatment guidelines for newborn jaundice,” and attempts to put their findings into perspective. She begins, however, by lamenting the difficulty in searching for environmental causes of pediatric cancer and the difficulty in performing helpful epidemiological studies on such rare diagnoses.
She writes about how the authors had to develop a scoring system to help take into account all the potential confounding variables that might increase the risk of cancer and the need for phototherapy. She presents this as a necessary aspect of studying such uncommon outcomes. While I don’t question this, I do wonder how many researcher degrees of freedom went into its use. Could this have played a role in why the second study found an association with cancer even after adjustment was performed?
Frazier goes on to point out, rightfully so, how few actual cases of cancer were observed in these studies. It’s great that pediatric cancer is so rare, but it should give pause to anyone making strong claims based on three cases of liver cancer and ten cases of myelogenous leukemia in a phototherapy exposed group of over 175,000 babies. And considering the deidentified nature of the larger study data set, it is possible that some of these were inappropriately labeled as having undergone phototherapy. It wouldn’t take very many errors of that nature to completely change the statistical results.
Any conclusions of a causal relationship between phototherapy and cancer in children, according to Frazier, are a “judgement call.” She lists and then attempts to jibe these findings with Hill’s criteria for causation, first stating that the exposure in this case is plausible. I disagree. The plausibility is perhaps greater than homeopathy but it is extremely low in my opinion.
She claims that “most of the case-control studies have suggested an association between phototherapy and childhood cancer, principally acute myelogenous leukemia.” Again, I disagree. Some have, some haven’t. It’s mixed, which is what would be expected with preliminary studies looking at rare outcomes when no true relationship exists. The best of these smaller studies, which looked at 55,000 Danish children, showed no association.
She mentions an analogy with UV light and its proven ability to cause skin cancer, although the far-UV found in sunlight reaching us through the atmosphere isn’t ionizing radiation as she implies. But as I discussed earlier, this doesn’t support a link to cancers of the blood or solid organs and doesn’t meet Hill’s criteria in my opinion. Again, sun exposure causes skin cancer only, and risk is generally felt to be primarily associated with the number of episodes where severe sunburn has occurred. Babies are not burned by phototherapy in any way.
Frazier points out a dose-related increased risk of myelogenous leukemia seen in the first study I discussed. But this is based on only two cases in children who were exposed to higher doses of phototherapy. And again, after adjusting for potentially confounding variables, any association between cancer and phototherapy disappeared.
She then points out the fact that rates of cancer in children are not increasing, even the cancers that the study authors are most concerned about. In her final statement, Frazier recognizes “that the information is imperfect” and that front line providers face a dilemma. Phototherapy, she writes, might not be harmless and we should weigh the risks and benefits before placing orders.
Phototherapy vs cancer vs jaundice
Despite the fact that I think these two studies are largely nonsense, and I do not agree with any recommendations to discuss the risk of cancer with parents of children who require phototherapy as part of the informed consent process, I agree with their overall conclusions that we shouldn’t start phototherapy on kids who don’t meet treatment criteria. Phototherapy may not cause cancer in my opinion, but it is not risk free. No medical intervention ever is.
When an infant is placed under the lights, it means they are not in their mother or father’s arms. It usually means that they must stay in the hospital or be readmitted and hospitalization is not a benign intervention. It exposes patients to hospital bugs and medicalizing babies has the potential for establishing a false parental impression of vulnerability.
Phototherapy can thus potentially interfere with bonding. It can also interfere with early breastfeeding attempts and potentially lead to failure. This isn’t likely, particularly if the mother is supported in her efforts by a team that includes evidence-based lactation consultants. It is also helpful, once bilirubin levels are clearly responding to treatment, to relax the strict protocols about time allowed out from under the lights for feeding and snuggling.
Weighing risks and benefits of any intervention is paramount in the practice of medicine. In the context of newborn jaundice, we must consider the risk of untreated jaundice and the potential for permanent injury to a child’s brain. It is rare but it is considered a “never event” in pediatrics. Thus the gain on our approach to starting treatment is already cranked up pretty high and we don’t need to push it even further without good reason, such as a very rapid rate of rise in bilirubin in a child with a pathologic etiology of their jaundice.
How did the media handle the story?
At Science-Based Medicine, we frequently discuss the mishandling of nuanced medical findings by the media and institutional press releases that seem more interested in drumming up interest than in the accuracy of their reporting. I have to say that in this case, it wasn’t that bad – although I must add that this story was largely ignored, which I found a bit surprising considering it is the perfect set up for overreaction. Baby cancer! But cell phones are sexier I guess.
As expected, The Daily Mail botched their coverage of the studies, calling phototherapy a “leukemia and kidney cancer risk” right out of the gates. They right the ship towards the end, but the damage is already done. A United Press International article is better, but includes a terrible quote from epidemiologist and study author Thomas Newman that implies phototherapy may cause cancer in 1 out of every 1,000 treated babies. The two press releases on the publications are also fairly bland, although the one from UCSF focuses on children with Down syndrome and, I believe, isn’t clear enough that it is likely a case of correlation rather than causation.
Conclusion: Phototherapy is still safer than jaundice
Pediatric cancer is rare, so determining what potential environmental factors if any may play a role is exceedingly difficulty. I certainly understand the drive to make use of our increasing access to “Big Data” in order to attempt to tease them out. That being said, I don’t think that this approach was very helpful in building a case against newborn phototherapy.
There is no reason to differentiate any risk of negative health effects related to phototherapy from that of sun exposure, which is not associated with non-skin cancers. Plausibility of phototherapy causing leukemia is there but it is extremely low, and even lower for solid organ cancers such as in the kidney or liver. These studies do not justify changing the medical approach to science-based jaundice management. And I worry now about parents refusing phototherapy or avoiding recommended newborn follow-up care because of unfounded fears of cancer..

The ROCA Screening Test for Ovarian Cancer: Not Ready for Prime Time
Harriet Hall on June 21, 2016
Link


Ovarian cancer is relatively rare but deadly. The lifetime risk of ovarian cancer is 1.5% compared to 12% for breast cancer, but it is the 5th most common cause of cancer death for women. Since the ovaries are hidden deep in the pelvis and the symptoms of ovarian cancer are non-specific, the cancer is often advanced by the time it is diagnosed and survival rates are low. Early detection by screening would be expected to improve outcomes. Two screening methods have been proposed: the cancer antigen CA-125 blood test, and pelvic ultrasound. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) found that screening with CA-125 and ultrasound did not reduce ovarian cancer mortality. The USPSTF recommends against screening for ovarian cancer because it does not reduce mortality and carries important potential harms from false positives and unnecessary surgeries.
Ovarian cancer screening is being re-considered in the light of a recent study, the UKCTOCS trial, published in The Lancet in December 2015. On the basis of that study, a test called ROCA is being offered directly to the public for $295. It’s important to understand what the study actually found, and why experts have questioned the wisdom of offering this test to the public at this time.
The UKCTOCS study
The letters stand for United Kingdom Collaborative Trial of Ovarian Cancer Screening. It was a randomized controlled trial with over 200,000 postmenopausal subjects. Half got no screening; a quarter got annual pelvic ultrasound; and a quarter got annual multimodal screening (MMS). In multimodal screening, changes in CA-125 levels were interpreted with an algorithm to assess ovarian cancer risk. Women found to be at high risk were further evaluated with repeat CA-125 tests and/or ultrasound. There was a trend to reduced mortality from ovarian cancer (15% in the MMS group and 11% in the ultrasound group), but the trend did not reach statistical significance. MMS was more sensitive than simply measuring CA-125 with a cut-off value, as had been done in previous studies; there were fewer unnecessary surgeries. The reduction in mortality appeared only after 7-10 years of screening. There was a stage shift: more cases were diagnosed at an early stage with MMS. The authors found their results encouraging, but they pointed out that:
Further follow-up is needed to assess the extent of the mortality reduction before firm conclusions can be reached on the long-term efficacy and cost-effectiveness of ovarian cancer screening.
The reaction of experts
In February 2016 a panel of experts convened at the Banbury Center, Cold Spring Harbor Laboratory, to discuss the implications of the study’s findings. They concluded that it was premature to recommend MMS at this time. They said:
Although women and health care professionals may look to these findings as finally providing a strategy for successful screening for ovarian cancer, the study investigators and participants at this meeting believe that screening policy requires a sound scientific foundation, which we currently do not have.
In June 2016, American Family Physician published an excellent review article on the diagnosis and management of ovarian cancer. They recommended that women at average risk should not be screened, and that women at high risk because of family history should be referred for genetic counseling. Additionally they recommended against routine screening pelvic examinations in asymptomatic women.
Accompanying that article were two editorials. One was signed by all the Banbury participants. They concluded:
The ROCA, a component of the MMS strategy evaluated in the UKCTOCS trial, is already commercially available. Although no organization recommends ovarian cancer screening in average-risk women, some women may wish to undergo periodic screening for ovarian cancer with CA 125 testing; therefore, health care professionals must advise women regarding the potential benefits and risks as we understand them now. Given the gaps in the evidence, the majority of Banbury participants were uncomfortable with direct-to-consumer advertising of an ovarian cancer screening test at this time.
The other editorial, by AFP editor Jay Siwek, was more forceful, saying that the ROCA protocol used in the study had been commercialized and promoted to the public in an unqualified way. He pointed out these shortcomings:
     1.  The reduction in ovarian cancer mortality was not statistically significant.
     2.  The reduction was not constant over time.
     3.  Only one-fourth of the patients were followed long enough to begin to see a possible benefit.
     4.  The effect of screening on all-cause mortality was not reported.
     5.  The ROCA is a proprietary algorithm patented by the investigators.
And he concluded:
In keeping with the principles of the Choosing Wisely campaign, physicians and patients would do well to avoid the pitfalls of overscreening and wait for results that promise more hope than hype.
Conclusion
The ROCA protocol looks promising, but the evidence is preliminary. It’s not yet ready for prime time.

Prostate Cancer Dilemmas: To Test or Not to Test, To Cut or Not to Cut
Diagnosing prostate cancer based on the prostate-specific antigen (PSA) test is a tricky proposition. The cancer itself can be slow-growing, and the treatment harmful. Medicine is complicated, particularly when it comes to cancer screening.
Harriet Hall on August 21, 2012
Link
The issue of PSA screening has been in the news lately. For instance, an article in USA Today reported the latest recommendations of the US Preventive Services Task Force (USPSTF): doctors should no longer offer the PSA screening test to healthy men, because the associated risks are greater than the benefits. The story was accurate and explained the reasons for that recommendation. The comments on the article were almost uniformly negative. Readers rejected the scientific evidence and recounted stories of how PSA screening saved their lives.
It’s not surprising that the public fails to understand the issue. It’s complicated and it’s counterintuitive. We know screening detects cancers in an early stage when they are more amenable to treatment. Common sense tells us if there is a cancer present, it’s good to know about it and treat it. Unfortunately, common sense is wrong. Large numbers of men are being harmed by over-diagnosis and unnecessary treatment, and surgery may not offer any advantage over watchful waiting.
The natural course of the disease
The natural course of prostate cancer is different from that of most cancers. It can be aggressive with early metastasis and death; but more often it is small, slow growing, and non-invasive. In the latter case, the patient dies of something else before the prostate cancer ever causes any harm. Autopsy studies of men who died of other causes found a prevalence of prostate cancer that increased with age and was as high as 80%. Obviously those 80% of men would not have benefited from pre-mortem diagnosis or treatment of their cancers. But prostate cancer does kill. Death rates per 100,000 population vary by race and ethnicity from around 10 for Asians to around 50 for blacks. It would be nice if we could clearly differentiate those cancers likely to kill from those that are harmless. We can’t. So we have felt compelled to treat every cancer we diagnose.
PSA levels
The PSA test doesn’t give simple yes/no answers. Using a cut-off of 4.0 ng/mL, only about 25% of men who have biopsies for elevated PSA levels are found to have cancer. And 15% of biopsies in men with lower levels of PSA also detect cancer. PSA levels can be elevated for non-cancer reasons like an enlarged prostate (benign prostatic hypertrophy or BPH), inflammation of the prostate, urinary retention, a recent rectal exam, a recent biopsy, or even recent ejaculation. Most doctors look at repeated tests, the degree of elevation, and increases over time before deciding to biopsy.
Making a diagnosis
If PSA results are worrisome, the next step is a needle biopsy, usually done through the rectum with ultrasound guidance. Biopsies are not yes/no tests either. Typically 12 areas are sampled. This leaves 99% of the prostate unexamined, so a cancer could easily be missed. The more sites biopsied, the more likely a cancer will be diagnosed and the less likely that the cancer will be one of those likely to kill the patient, so it’s difficult to decide how many biopsies are optimal. When initial biopsy results are negative, repeat biopsies are positive in 25-30% of cases. When cancers are detected, they are assigned a Gleason score based on their microscopic appearance. Gleason scores range from 2 to 10, with 10 having the worst prognosis.
Treatment
For the typical newly diagnosed patient the treatment options are surgery or radiation. There are other treatment options for advanced or metastatic cancer, including hormones and chemotherapy. New treatments being studied include cryosurgery and focused ultrasound.
Radiation can cause impotence, urinary problems, and an increased risk of other cancers. Surgery can cause impotence, incontinence of urine and stool, and for some unknown reason the penis may be 1-2 cm shorter after radical prostatectomy. Despite pre-operative counseling, men tend to be surprised and disappointed when they develop impotence and incontinence. A new study in the Journal of Urology found that / a year after surgery, 46% reported that incontinence was worse than they had expected and 44% said sexual function was worse than expected.
The no-treatment option
A recent randomized controlled study in The New England Journal of Medicine followed a group of men with localized prostate cancer for 12 years and compared the outcomes from radical prostatectomy versus observation alone. They found that overall, surgery did not significantly reduce deaths from prostate cancer or all-cause mortality, although for a subgroup of men with a very high PSA level (over 10 ng/ml) there was a clear benefit from surgery. The study also collected data on the side effects of surgery. Within 30 days of surgery, 1/5 of patients had serious complications including deaths. Two years after surgery, 17% were incontinent, 81% had erectile dysfunction, and 12% had bowel dysfunction.
The USPSTF recommendations
I won’t review the studies the USPSTF based their recommendations on. They did a thorough review of the literature and explained their findings in detail. They acknowledged that the evidence was conflicting but concluded that PSA screening detects more cases of prostate cancer but results in small to no reduction in mortality while resulting in substantial harm to many men. They recommended against PSA screening.
Not everyone agrees. Catalona et al. wrote about “What the U.S. Preventive Services Missed in Its Prostate Cancer Screening Recommendations” in the Annals of Internal Medicine. The American Urological Association has also spoken out. Urologists and family physicians may have different perspectives because they see a different patient population.
A new article in The New England Journal of Medicine, “Quality-of-Life Effects of Prostate-Specific Antigen Screening,” revisits a large European study that showed a 29% reduction in prostate cancer deaths in men who underwent PSA screening. They used quality-adjusted life-years to measure both harms and benefits. Their findings indicate that the net effect of prostate-cancer screening could be a loss or a gain, depending on patients’ feelings about the downstream consequences of screening (such as the long-term consequences of impotence and incontinence from treatments that may have been unnecessary). Their findings support a shared decision-making process.
Current practice
Most medical groups have accepted the USPSTF recommendations. If patients request testing, they recommend discussing the pros and cons and jointly making individual decisions based on risk factors and patient preferences. (Risk factors include age, ethnicity, family history, obesity, diet, and possibly smoking.) There are no simple answers, and we wouldn’t want to miss men with PSA levels above 10 ng/mL where treatment would make a difference.
Conclusion
Medicine is complicated.

Once more into the screening breach: The New York Times did not kill your patient
Dr. George Lombardi thinks that he could have saved a patient from dying of prostate cancer if a prostate specific antigen test had been done. Is he right? Probably not.
David Gorski on March 25, 2013
Link
One of the more depressing things about getting much more interested in the debate over how we should screen for common cancers, particularly breast and prostate cancer, is my increasing realization of just how little physicians themselves understand about the complexities involved in weighing the value of such tests. It’s become increasingly apparent to me that most physicians believe that early detection is always good and that it always saves lives, having little or no conception of lead time or length bias. Sadly, just last week, I saw another example of just this phenomenon in the form of an article written by Dr. George Lombardi entitled My Patient, Killed By The New York Times. The depth of Dr. Lombardi’s misunderstanding of screening tests permeates the entire article, which begins with his recounting a story about a patient of his, whose death he blames on The New York Times. After describing the funeral of this 73-year-old man who died of prostate cancer, Dr. Lombardi then makes an accusation:
This one filled me with a special discomfort as I knew a secret: He didn’t have to die. I knew it and he had known it. Had he told?
About 5 years ago he had just retired and had a lot more time on his hands. He was a careful man, lived alone, considered himself well informed. He got into the habit of clipping articles on medical issues and either mailing them to me or bringing them in. They came from a variety of sources and were on a variety of topics. He wasn’t trying to show me up. He was genuinely curious. I kidded him that maybe he’d like to go to medical school in his retirement. ‘No’ he laughed, ‘I just like to be in the know.’
When he came in for his physical in 2008 he told me he’d agree to the DRE but not the PSA (his medical sophistication extended to the use of acronyms: DRE stands for digital rectal exam where I feel the prostate with my gloved finger for any abnormality and PSA for prostatic [sic] specific antigen which is a blood protein unique to the prostate and often elevated in prostate cancer). He had read that the use of PSA as a screening test was controversial. This was the year that the United States Preventive Services Task Force, a government panel that issues screening guidelines, recommended against routine PSA screens for older men. It was often a false positive (the PSA was elevated but there was no cancer), led to unnecessary biopsies, and besides most prostate cancers at his age were indolent and didn’t need to be treated. I countered that prostate cancer was the second leading cause of cancer deaths in men and that it was better to know than not to know. This way it would be our decision. The patient with his doctor deciding what was best. But no, he wanted to stick to his guns and since the DRE was normal no PSA blood test was sent.
After describing a conversation with the man’s daughter, who said, “My father was killed by The New York Times,” Dr. Lombardi then goes on to anecdotal evidence and a cherry-picked publication to support his view, quoting an oncologist who says he’s “seeing more men presenting with advanced prostate cancer” and then referring to a single paper in the current Annals of Internal Medicine about PSA screening. Before I look at the article and a recently published paper on screening mammography that made the news, I can’t help but point out that I (mostly) agree with Dr. Lombardi when he says:
Public health doctors, policy experts and journalists tend to look at the population as a whole. It is a better story if it is one story. It makes a better headline. Their statistics are people I sit across from everyday trying to figure out what the future holds. We each have our job to do.
The problem is, of course, that Dr. Lombardi takes that observation and draws the wrong conclusion, namely that his patient died because of lack of screening. He attacks a straw man, sidestepping the true argument, namely that evidence shows that PSA screening probably causes more harm than good for men at average risk of prostate cancer. Unfortunately, Dr. Lombardi obviously does not understand some very basic concepts behind cancer screening, nor does he apparently recognize that doctors who deal with the population-level data that we have regarding screening tests and try to apply them to individual patients are actually looking in a very systematic way about what the benefits of screening are to the individual patient. More on that later. In the meantime, although I wouldn’t go quite as far as Dr. John Schumann did in criticizing Dr. Lombardi, I do view his lament as a jumping off point to look at some recent data on screening for the two most common cancers, breast and prostate.
The problem with screening (yet again for the umpteenth time)
Before I get to my updates on cancer screening, to set the stage I think it’s critical to revisit these two key concepts that you must understand to understand a bit about the difficulties involved in using a screening test to decrease cancer mortality. I’ve explained them both in depth before, so I don’t feel the need to resurrect a detailed explanation again other than to boil them down to two points, with relevant links and illustrative graphs that illustrate the concept. Those who want the more characteristically (for me) verbose versions can follow the links.
First, let’s briefly recap lead time bias, which tells us that earlier detection does not necessarily result in improvements in survival and more successful treatment. In fact, even if earlier treatment has no effect whatsoever on the natural history of a cancer, earlier detection will still give the appearance of an increase in media survival. That increase is simply the “lead time” that comes from detecting the tumor earlier (hence the term “lead time bias”), before it becomes clinically apparent on its own. This concept is illustrated below in these two graphs, first a simpler one:
And a slightly more complex one:
I have explained the concept of lead time bias in more depth here and here, but I do like that graph for illustrating the concept, as well as this one, which demonstrates the effect of lead time bias on a survival curve:
Perhaps my favorite simple and clever explanation of how lead time bias can result in apparently increased survival rates even if treatment has no effect whatsoever on a cancer’s progression comes from Aaron Carroll. It’s well worth reading.
Now let’s briefly move on to length bias. It turns out that most cancer screening tests have an inherent bias towards detecting more indolent, less deadly cancers because of length time bias. Aggressive, fast-growing tumors tend to go from undetectable to clinically apparent due to symptoms, often already having progressed to an advanced stage, in a shorter time than the time interval between screening tests. These tumors thus do not count as having been detected by the screening test because they go from undetectable to symptomatic between, for example, mammography scans. The slower-growing a tumor is, the longer the length of time between its reaching the minimal detectable size of the screening test and becoming symptomatic, the longer the time there is for a screening test to detect it, as illustrated by these two graphs, beginning with this one:
The length of the arrows above represents the length of the detectable preclinical phase, from the time of detectability by the test to clinical detectability. Of six cases of rapidly progressive disease, testing at any single point in time in this hypothetical example would only detect 2/6 tumors, whereas in the case of the slowly progressive tumors 4/6 would be detected. Worse, the effect of length bias increases as the detection threshold of the test is lowered and disease spectrum is broadened to include the cases that are progressing the most slowly, as shown below:
The other problem with length bias is that the more sensitive the test, the more likely it is to detect indolent tumors that are so slow-growing that within the lifetime of the patient they wouldn’t progress to the point where they would endanger the patient’s life. Some, particularly screen-detected cancers, even spontaneously regress. Such indolent or self-limited cancers do not require treatment, but are frequently diagnosed by screening, a phenomenon known as overdiagnosis. The problem, of course, is that our ability to detect such cancers far surpasses our knowledge of how to predict which ones will regress or remain indolent. So we err on the side of aggressive treatment because we quite reasonably view the consequences of guessing wrong as being so much worse for individual patients than overtreating other patients who don’t require treatment. However, for the average patient, the odds of being helped by a screening test are rather small. For instance, to avert one death from breast cancer with mammographic screening for women between the ages of 50-70, 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of DCIS. The additional price of this was estimated to be 90 biopsies and 535 recalls for additional imaging, as well as many cancers treated as if they were life threatening when they are not. For prostate, to prevent one death from cancer, 1,410 men need to be screened over 9 years, for a total of 2,397 screening visits and 48 cancers detected. In other words, screening takes a lot of effort for, on an absolute basis, not as many lives saved as we had hoped. Moreover, in the case of breast cancer, on an absolute scale, the reduction in the risk of dying from cancer is small, as I’ve discussed, and the risks of overtreatment are high.
PSA Screening: Smarter, not harder?
Given that Dr. Lombardi cited it, I thought I’d look at the recent Annals article first. The article comes from a group at the Fred Hutchinson Cancer Center at the University of Washington and is entitled Comparative Effectiveness of Alternative Prostate-Specific Antigen-Based Prostate Cancer Screening Strategies: Model Estimates of Potential Benefits and Harms.
I can’t help but notice, first off, that this is a modeling paper. In other words, the investigators did what the hated U.S. Preventative Services Task Force (USPSTF) did in changing its recommendations for mammographic screening for breast cancer and PSA screening for prostate cancer. They took existing data and ran a bunch of computer simulations in order to model the effects of different screening regimens, noting that they were looking for ways to “screen smarter.” Of course, Dr. Lombardi’s argument is basically a straw man in that no one is saying that PSA screening is necessarily completely useless. What is being said is that there is a significant risk of overdiagnosis, overtreatment, and harm that must be balanced against the relatively small benefit of most of the recommended screening regimens. Back when radical prostatectomy was the preferred treatment for early stage prostate cancer, the risk of harm from overtreatment was significant, up to and including death, but more frequently including complications from surgery, such as incontinence, erectile dysfunction, and other less specific risks of major pelvic surgery, such as injury to the colon, bladder, and other bowel. Later, as radiation therapy supplanted surgery as the preferred treatment for very early stage prostate cancer, the potential complications, such as radiation proctitis. Dr. Schumann described these complications dramatically in his rebuttal to Dr. Lombardi’s article.
In other words, a “one size fits all” approach will not do; we need a more “personalized” approach, if you’ll excuse the term in the wake of its corruption by people like Stanislaw Burzynski. That’s exactly what the investigators on this paper (Gulati et al) tried to do.
What Gulati et al did was to model an large number of screening strategies, thirty-five in all, and then estimate the benefits and harms of each compared to the reference screening strategy of annual screening for patients aged 50 to 74 years with a PSA threshold of 4.0 g/L for biopsy referral. They also tried to validate the models when possible by seeing if it predicts incidence beyond the years of calibration (1975-2000) and to perform sensitivity analyses. Gulati et al summarize their results thusly:
Our results yield several important conclusions. First, we find that aggressive screening strategies, particularly those that lower the PSA threshold for biopsy, do reduce prostate cancer mortality relative to the reference strategy. However, the harms of unnecessary biopsies, diagnoses, and treatments may be unacceptable. Quantifying the magnitude of these harms relative to potential gains in lives saved is critical for determining whether the projected harms are acceptable.
Second, we find substantial improvements in the harm/benefit tradeoff of PSA screening with less frequent testing and more conservative criteria for biopsy referral in older men. These approaches preserve the survival effect and markedly reduce screening harms compared with the reference strategy. In particular, using age-specific PSA thresholds for biopsy referral (strategy 20) reduces false-positive results by a relative 25% and overdiagnoses by 30% while preserving 87% of lives saved under the reference strategy. Alternatively, using longer screening intervals for men with low PSA levels (strategy 22) reduces false-positive results by a relative 50% and overdiagnoses by 27% while preserving 83% of lives saved under the reference strategy. These adaptive, personalized strategies represent prototypes for a smarter approach to screening.
It should also be noted that the decrease in risk of dying of prostate cancer, even under the most optimistic scenarios in the models, was on the orders of a fraction of a percent in absolute terms. Under the models studied by Gulati et al, the risk of death due to prostate cancer without screening was 2.86% but could be reduced to between 2.02% and 2.43%, depending on the model. That’s at most a 0.84% absolute risk reduction, although on a relative scale, a decrease in risk of dying from 2.86% to 2.20% is 29%. The overall conclusion from the modeling study was that it is possible to “screen smarter” if the PSA threshold to refer for biopsy is higher, screening for men with low PSA values is decreased in frequency, and older men, who tend to have elevated PSA anyway, are screened less aggressively. All of these are not unreasonable ideas, and they illustrate the tradeoffs involved in any sort of screening program. They are also far removed from Dr. Lombardi’s straw man characterization of arguments that PSA screening can result in more harm than good as “ignorance is bliss when it comes to PSA screening.”
But what about mammography?
We also screen for breast cancer in women. The preferred test, of course, is mammography, and there is no doubt that regular mammography in women between the ages of 50 and 74 definitely reduces mortality from breast cancer. Of that much, we can be certain, although the risks of overtreatment are not insignificant. Over the last decade or so, the recommendations that screening should begin at age 40, that it should be done annually, and that it should continue for the rest of a woman’s life became the basis of public health policy with respect to breast cancer, as well as breast cancer awareness campaigns by advocacy groups. Then, in 2009, the USPSTF dropped its bombshell, in which it suggested that this screening campaign was too aggressive, resulted in too much overdiagnosis and overtreatment, and should be scaled back. Its recommendation was to begin screening for asymptomatic women at average risk (and this must be emphasized: we’re not referring to women at high risk or women who notice a lump in their breast or other symptoms) at age 50 and to perform it every two years instead of every year. I discussed this when the recommendations caused a stir three years ago, and I stand by what I wrote then.
Interestingly, a recent study from the Breast Cancer Surveillance Consortium published in JAMA Internal Medicine a week ago (Outcomes of Screening Mammography by Frequency, Breast Density, and Postmenopausal Hormone Therapy) seems to support the findings of the USPSTF in 2009. It’s a prospective cohort study examining outcomes of women screened at mammography facilities in community practice that participate in the Breast Cancer Surveillance Consortium (BCSC) mammography registries, and the question to be answered was whether there was a difference in outcomes between women screened on a yearly basis with mammography and women who underwent screening on a biennial basis. Data were collected prospectively on 11,474 women with breast cancer and 922,624 without breast cancer who underwent mammography at BCSC facilities, so this is a large study. The study’s findings are summarized thusly:
Mammography biennially vs annually for women aged 50 to 74 years does not increase risk of tumors with advanced stage or large size regardless of women’s breast density or HT use. Among women aged 40 to 49 years with extremely dense breasts, biennial mammography vs annual is associated with increased risk of advanced-stage cancer (odds ratio [OR], 1.89; 95% CI, 1.06-3.39) and large tumors (OR, 2.39; 95% CI, 1.37-4.18). Cumulative probability of a false-positive mammography result was high among women undergoing annual mammography with extremely dense breasts who were either aged 40 to 49 years (65.5%) or used estrogen plus progestogen (65.8%) and was lower among women aged 50 to 74 years who underwent biennial or triennial mammography with scattered fibroglandular densities (30.7% and 21.9%, respectively) or fatty breasts (17.4% and 12.1%, respectively).
Leading the authors to conclude:
Women aged 50 to 74 years, even those with high breast density or HT use, who undergo biennial screening mammography have similar risk of advanced-stage disease and lower cumulative risk of false-positive results than those who undergo annual mammography. When deciding whether to undergo mammography, women aged 40 to 49 years who have extremely dense breasts should be informed that annual mammography may minimize their risk of advanced-stage disease but the cumulative risk of false-positive results is high.
In other words, in terms of reducing their risk of being diagnosed with an advanced stage tumor or a large sized tumor, it appears not to matter whether women between 50 and 74 undergo mammography every year or every other year. This is not the case when it comes to women between 40 and 49, where less frequent screening is associated with a statistically significant increased risk of being diagnosed with advanced disease. However, one has to balance that with the increased risk of false positive mammography and the absolute risk of dying of breast cancer in this age range, which is only in the range of 0.3%. This is a number that increases with age, but it is still small. For instance, Esserman et al characterized it thusly for a 60 year old woman:
Essentially, mammography reduces the odds of a 60-year-old woman dying of breast cancer in the next decade by 30%. Sounds impressive, until you look at her absolute risk: by getting her annual mammogram, her chances of dying from breast cancer are whittled from 0.9% to 0.6%. Overall, for every 1,000 women in their 60s screened for breast cancer in the next 10 years, mammograms will save the lives of 3 people but 6 others will still die. (The numbers edge up or down in lockstep with a woman’s age.)
As is often the case, this study illustrates the difficulty in balancing the risks and benefits of screening for breast cancer. Remember, the idea behind screening for a cancer — any cancer — is that detecting it early will allow early treatment, better prognosis, and a decrease in the number of people who are diagnosed with later stage cancer, which is more likely to be fatal. As a study that I discussed a few months ago showed, mammography has not reduced the number of breast cancer cases diagnosed at an advanced stage as much as one would expect, meaning that there is significant overdiagnosis. Welch’s study estimated overdiagnosis to range from 22% to 31%. From my reading of the literature, this is only a little bit higher than the rate of overdiagnosis of screen-detected breast cancers that has been estimated, namely around 20%.
The bottom line
Does this mean that we should throw up our hands and stop screening for breast and prostate cancer? Of course not! However, we have to balance the risks versus the benefits in a way that doctors like Dr. Lombardi are seemingly unable to do. Dr. Lombardi clearly views screening as an unalloyed good and believes that his unfortunate patient could have been saved if only he hadn’t listened to the NYT, which described the controversy over PSA screening for prostate cancer, and decided that it wasn’t for him. Never mind those pointy-headed docs in the USPSTF who say that PSA screening for men over 75 can’t be recommended and that balance between the benefits and the drawbacks of prostate cancer screening in men younger than age 75 years cannot be assessed, because the available evidence is insufficient. The American Cancer Society emphasizes that the decision to be screened should involve the man being screened. In any case, the danger of relying on anecdotal information, as Dr. Lombardi apparently does, is that there is no good evidence that PSA screening would have saved his patient’s life. Earlier detection could just as easily have ended up with an apparent increase in survival time that was entirely due to lead time bias. Similarly, those of us who take care of breast cancer patients have to be careful not to be seduced by the idea that mammography is some sort of panacea that will give us power over this dread disease.
The idea that finding cancer earlier almost always saves lives is a seductive one. It gives us, the physicians, the idea that we have power over cancer in contrast to how we frequently feel as though we lack such power. While there is no doubt that screening can decrease mortality from cancer, the devil is in the details. Effect sizes and absolute risk reductions are usually very small, even though they might be fairly impressive as relative values. Screening programs are resource intensive. Most importantly, nothing is free. The benefits of screening do not come without a significant cost in terms of money, overdiagnosis and overtreatment, and psychic anguish. It is entirely appropriate to openly discuss these issues, as it is not possible to have true informed consent on the part of the patient if he or she doesn’t understand the potential risks of screening, so that these risks can be balanced against the not-inconsequential benefits that screening could bring.
I’d like to conclude by putting on my scientist cap. I was once a bit like Dr. Lombardi in that I didn’t think much about screening for cancer and assumed that finding disease early is almost always a good thing. I’ve since come to appreciate that, like many things in medicine, it’s not that simple. Medicine is hard and complicated. Real hard and complicated. It’s very rare that any test or treatment is an unalloyed good or ill. Every test or treatment demands a balance between benefits and risks. Screening is no different. If admitting that to our patients and honestly discussing it with them causes us problems as a physician, then it will just have to cause us problems.
To me, the best solution will come from basic research. The shortcomings of screening, including overdiagnosis, overtreatment, lead time bias, and length bias, are not reasons to give up on screening. They are reasons to learn how to screen smarter. They are also reasons that we desperately need to understand the pathophysiology of the diseases for which we screen. After all, after finding a cancer or ductal carcinoma in situ by mammography, it would be so much better to be able to analyze, for example, its gene expression profile, and to predict whether it’s a cancer that will remain indolent or whether it’s one that’s going to progress rapidly. Prediction based on biology, be it biology as determined by genomic profiling, proteomic profiling, metabolomic profiling, or whatever combination of tests it takes, will allow us to usher in the era of true personalized medicine, in which patients receive treatment as aggressive as their disease’s biology requires or no treatment at all, if their disease’s biology tells us that it’s highly unlikely to end their lives or cause serious disability. I only hope I live to see that day.
In the meantime, we muddle through, balancing benefits and risks as best we can and, hopefully, explaining adequately to patients why we do what we do.

PSA Screening for Prostate Cancer
PSA testing is controversial. A new study finds that PSA screening for prostate cancer offers no survival benefits.
Scott Gavura on March 22, 2018
Tweet

It may sound obvious that detecting cancer is a good thing. The ideal screening test for cancer will identify people without symptoms, yet find aggressive cancers before they have metastasized (spread). Under these circumstances, a test will not only reduce the risk of death from the cancer being screened for, but it will lead to a longer life overall. But not all screening tests are equally effective, and not all cancers necessarily require treatment if they are detected by screening. When you combine an imprecise test with a cancer that can be slow-growing and may not even cause harm, there is the significant risk of overdiagnosis and overtreatment. That’s the current controversy in the screening and treatment of prostate cancer, and the value of the prostate specific antigen (PSA) blood test. Prostate cancer is a major cancer killer in men. Yet far more men die with prostate cancer than of prostate cancer, as prostate cancer can be slow-growing, non-invasive, and never cause any harm. Now there is new data to inform decision-making about whether men who are free of symptoms and over the age of 50 should have their PSA tested.
The PSA controversy
PSA testing is controversial. The prostate specific antigen is a protein produced by the prostate. It became accepted as a screening test in the 1990s, before there was good evidence that it effectively reduced mortality from prostate cancer, or mortality overall. This blood test, along with a prostate digital examination, is one of the ways that prostate cancer can be detected, as PSA can be elevated years before prostate cancer causes symptoms. However, the results of PSA testing are imprecise, and high levels do not necessarily signal that one has cancer, as this infographic explains:

Benign prostatic hypertrophy and prostatitis are other conditions that can raise PSA in the absence of cancer. The positive predictive value for a PSA level that exceeds 4 (the usual threshold) is estimated at about 30%, meaning that less than one in three with a “high” PSA will actually have cancer revealed after a biopsy. Harriet Hall described back in 2012 that when it comes to prostate cancer, large numbers of men are being harmed by over-diagnosis and subsequent over-treatment, with surgery that can leave men incontinent and impotent, and no evidence that this approach offers any advantage over “watchful waiting” for most men.
A very brief review of the PSA screening literature
There are two papers commonly cited when it comes to PSA screening. The first is from Andriole and colleagues, and is titled “Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up,” more commonly called the PLCO trial. The PLCO trial randomized men to annual PSA testing and digital rectal exam (DRE), or to “usual care” which sometimes included prostate screening and sometimes did not. The PLCO trial found, not surprisingly, an increase in prostate cancer detected in the treatment arm. However, there were low mortality rates in both groups and there was no significant difference in deaths due to prostate cancer, even after 15 years of follow-up. Notably, the trial has been criticized for “contamination”, in that most men in the control arm had at least one PSA test over the course of the study. So it’s argued that PLCO is actually an evaluation of more versus less PSA testing, rather than an evaluation of PSA testing itself.
The other major study is from Schröder and colleagues, and it’s entitled “Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up” which we will refer to as the ERSPC trial. This was a multi-country European trial that evaluated PSA testing and it found that PSA testing did result in an absolute risk reduction of 0.11 per 1,000 person-years, or 1 prostate cancer death averted per 781 men invited for screening. This is about a 20% relative risk reduction. Another way to state the results is that 48 additional patients need to be diagnosed with prostate cancer to prevent one prostate cancer death.
The PLCO study and the ERSPC study had different findings, except for the most important outcome. While ERSPC was the only trial that found a prostate cancer survival benefit, neither study found any overall survival benefit. The best we could conclude from these two trials was that PSA testing may reduce death from prostate cancer.
The new study
This new study addresses one of the criticisms of the PLCO trial. If the PLCO trial was “contaminated” by testing in the control arm, then a better study would evaluate PSA versus no testing at all. That’s exactly what this study did. It’s from Martin and colleagues and is called “Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality” (the CAP trial). It included over 400,000 British men aged 50-69. Men were randomized into an RN appointment, where they were offered information on a PSA test, and if they chose, the test. The other group didn’t invite men for testing. After a 10 year period, the study found that there were more prostate cancers detected from this one-time testing. However, this group was no less likely to die from prostate cancer. Here’s the key finding – no difference in mortality between the two groups:
The one-off PSA test detects cancers, but doesn’t save lives from prostate cancer. Vinay Prasad pointed out on Twitter out that prostate cancer mortality was small in the study, compared to overall (all-cause) mortality:
This infographic from Cancer Research UK summarizes the implications of PSA screening, and draws on data from the Cochrane Review:

To PSA screen or not?
Prostate cancer is a major killer of men and it is admittedly frustrating that the PSA test is largely ineffective as a screening tool. Given there is still no effective way to identify the prostate cancers that really need to be treated, the PSA as a screening tool is leading to overdiagnosis and overtreatment, with the resulting harms. What this evidence means for men is that if you lack any symptoms of prostate cancer, PSA testing has significant risks. It is important to understand the overall risks and the small (if any) benefits. Whether you have prostate cancer detected or not, there is an equal chance of you being alive in 10 years. For health professionals, PSA testing mandates a detailed discussion with patients on the risks of screening. Screening and dialogue tools may be helpful in translating the findings of the accumulated research, ideally leading to shared decision-making. While it’s important that there is continued research into better screening and treatment tools for prostate cancer, we must also use the evidence we already have on PSA screening to reduce practices that harm men and offer no clear benefits.

Myeloproliferative neoplasms – an overview and my experiences
In 2014 I was diagnosed with a type of myeloproliferative neoplasm. Since that time I have sought many treatments, and experienced many setbacks. Science-based medicine has kept me alive to write this post. Here I pass along some of my knowledge and experience regarding these rare cancers.
Jesse Luke on August 18, 2017
Link

Author’s note: I have received messages informing me about errors that were made in haste during the writing of this article. I have corrected them and the specific changes made can be found in the Erratum. In addition, I have also received quite a few questions asking where more can be learned about MPNs. I have included a short list of resources for both the lay-person and the professional. I thank all readers for pointing out true factual error. It helps all of us.

Most people will be familiar with the more common blood cancers like leukemias and lymphomas, but there is a rarer group that still causes considerable suffering. Cancers in this group are in many ways harder to treat, and due to their rarity they receive little research funding and even less recognition. These cancers are called myeloproliferative neoplasms (MPNs). This post will deal with what are called “classical” (or “typical”) Ph-negative MPNs. Ph stands for the Philadelphia chromosome, a translocation that is the defining feature of chronic myeloid leukemia (CML). Its absence is part of the diagnostic criteria for the Ph negative MPNs. I have a vested interest in these cancers as I have a rare MPN myself, which I will discuss later.
Basic hematology and MPN fundamentals
All blood cells form in the bone marrow from pluripotent stem cells and then further differentiate into two types of blasts; myeloid blasts and lymphoid blasts. Myeloid blasts become red cells, platelets, and all white cells except lymphocytes. Lymphoid blasts become lymphocytes, B-cells, T-cells, and plasma B cells.

MPNs originate in the myeloid line from various mutations and affect the bloodlines in varying ways. It is best to consider these cancers as occupying a spectrum rather than being discrete entities. MPNs don’t have stages per se, but phases. They have the propensity to evolve into more severe classifications, then finally into acute myeloid leukemia (AML), a form that is notorious for its resistance to treatment. This is sometimes called “MPN Blast Phase”. The incidence of transformation varies between MPNs as well as the average life expectancy of those diagnosed. The following are the “typical” MPNs and my own.
    • Essential thrombocythemia (ET): The most indolent of MPNs, causes an increase in the platelet count that sometimes cross >1,000 x 109/L (the average is about 150-450 x 109/L). The main concern is thrombosis (and paradoxically, also bleeding at platelet levels above 1500 x 10^9/L). Life expectancy varies between studies, but is on par with to slightly below the average population. The prevalence is 38-57 cases per 100,000 persons.
    • Polycythemia vera (PV): This primarily causes an increase in red blood cells but is often accompanied by increases in platelets and white cells. These significantly increase the risk of major bleeding and clotting problems. Median survival based a recent large-scale study is 11-28 years. The prevalence is 44-57 cases per 100,000 persons.
    • Myelofibrosis (MF, including post-PV and post-ET as well): Causes the tissues of the bone marrow to scar and become incapable of producing new blood cells. This often results in cytopenias (low blood counts) that can lead to lethal infections and an enlargement of the spleen (sometimes requiring removal) and liver through a process known as “extramedullary hematopoiesis”, which means that the creation of blood switches partially to other organs, like the liver and spleen, to make up for the loss of marrow production. Median survival is roughly six years. The prevalence is 4-6 cases per 100,000 persons.
    • Myeloproliferative neoplasm/Myelodysplastic syndrome, unclassified (MPN/MDS-U): Acts like both an MPN and MDS (where the bone marrow does not produce enough of some blood cell types). MPN/MDS-U may present in varying ways, showing features of just a few or many distinct classifications. (I show features of both PV and MDS-U.) It is essentially a catch-all when no more specific diagnosis can be provided. It is too rare for an incidence, prevalence, or prognosis to be estimated.
In addition to the risks of death from bleeding, thrombosis, infections, and evolution to other classifications and AML, all MPNs carry a high symptom burden, with many patients experiencing symptoms of severe fatigue, inactivity, night sweats, bone pain, and difficulty concentrating (among others). To make matters worse, treatment options are limited.
Current treatment options
In the world of MPNs there are few treatment options, remissions are extremely rare, and this group of cancers is often considered incurable. Depending on the type, there are several options for management; most have been around since the 1950s. The oldest of these is therapeutic phlebotomy for PV; this is medical lingo for actual bloodletting. The process is exactly the same as giving blood, with a goal of bringing the hematocrit level below 45% for men and 42% for women. The frequency of this action varies from patient to patient; some a few times a year, some a few times a month. Another mainstay is simple aspirin therapy to help prevent blood clots. If these first-line treatments fail (most often intolerance) or a patient is in a worse prognostic group (often due to a previous clot) then pharmaceutical cytoreductive therapy is initiated.
This is essentially chemotherapy, the most common being a drug called hydroxyurea/hydroxycarbamide. It is thought to act through RNA inhibition and reduces the blood counts. Busulfan or similar drugs (alkylating agents) may sometimes be used, but this is rare after it was discovered that it may actually speed up the evolution to AML and is typically only recommended in older patients. Other drugs occasionally used include anagrelide for platelet reduction and radioactive phosphorus (P32) which reduces all types of blood cells. None of these are ideal, however, as they have severe adverse effects including the possible speeding of progression.
As a last-ditch effort, sometimes an allogenic stem cell transplant (allo-SCT) is undertaken. It is often viewed as the only potentially curative option for MPNs. The risk of death is often uncomfortably high (> 50% in some cases); in addition, the patient’s age and other comorbidities may be contraindications. There is no guarantee of long-term survival, as MPN patients are at a greater risk for secondary malignancies and there is always a risk of relapse.
In the future
It is, however, not all doom and gloom for MPN patients. Even with limited research funding, there is a small but highly dedicated group of doctors and researchers that have been developing and testing new options. Most recently this has led to the approval of ruxolitinib (trade name Jakafi), the first drug approved for both MF and PV. It works through targeting the pathways affiliated with a mutation common in MPNs called JAK2 (V617F) by inhibiting JAK1 and JAK2 enzymes. It has been shown to be effective in reducing constitutional symptoms in patients with both diseases, as well as reducing the phlebotomy requirement for PV patients.
Another drug showing promise that is currently off-label but in late phase trials is peglyated interferon. It has the advantage of being a non-chemotherapeutic agent and works through modulating the immune system. It has even been shown to induce hematologic remission in some patients (though this is not the same as a cure). The drug is often the first choice for young, high-risk patients, but long-term adherence is sometimes hindered by adverse effects, including flu-like symptoms and suicidal ideations.
Newer drugs are following the path of targeted therapies such Jakafi. There are several other JAK inhibitors in trials at multiple centers worldwide. Another possible route is telomerase inhibitors, such as imetelstat. Telomerase in a chemical in the body that basically helps prevent premature degradation of our telomeres which cap the ends of chromosomes (and a frequent target of quackery). However, in cancer this is obviously not a good thing. And with the advent of CRISPR-CAS9 gene editing there seems to hope to go beyond merely controlling the disease and actually arriving at a cure, but I must say that such options are sadly many years away from being a realistic possibility.
My experience with myeloproliferative neoplasms
I was initially diagnosed with an MPN-U, later revised to an MPN/MDS-U in the autumn of 2014. It took approximately six months to reach this diagnosis from a visit to my GP for headache and fatigue. After my initial tests, I was met with innocuous diagnoses of a mild infection and a kidney cyst. Deeper testing revealed rarer results that led me to being referred to pretty much every type of clinical specialist out there, along with meeting a substantial population of New York City’s hematologists. I was screened and tested for various cancers including brain, lung, colon, stomach, thyroid, kidney, liver, pretty much all of them. It wasn’t until I landed at Memorial Sloan Kettering’s leukemia service that the idea of my actual diagnosis was entertained. It was during the 2nd or 3rd visit that it was confirmed and I was immediately started on cytoreductive therapy. Prior to that I was averaging 2-3 phlebotomies a week (that’s a liter and a half of blood a week).
The fun didn’t end there, it was discovered that I quickly became resistant to the chemo after just a few months. Over the past few years I have been on three different agents and I am now at the point where I have reached the maximum possible dose on the last line therapy. I have been seen at Dana-Farber, Fred Hutch, and had my case reviewed by every expert my doctor and I could think of. There aren’t any easy solutions.
I experience multiple symptoms daily, both from the cancer itself and my medications. I have severe fatigue, nausea, headaches, night sweats, muscle aches, and trouble concentrating. Not three weeks ago I had a transient ischemic attack (TIA or “mini stroke”). As I result I now take an increased dose of aspirin and a statin in addition to my 10 other medications. I don’t know if they will help me, but I feel it is the safest option.
Right now, we are looking for other medications that have cytoreductive effects with minimum side effects; however, the issue is that most chemotherapeutic drugs are not intended to be used constantly for years at a time. I have also been evaluated for an allo-SCT, but that carries all the risks I mentioned above, and most transplant hematologists are hesitant to do it, as am I.
I don’t ask readers for pity though: I ask that you keep MPNs in mind along with other rare cancers. It is not simply lung or breast cancer patients that need attention, but all those with cancer. It has been shown that roughly 20% of all cancers diagnosed are actually rare cancers. Even eight years after the reclassification of MPNs as a type of cancer, the American Cancer Society does not recognize them on their website or support services.
I also would like to say that if it wasn’t for the strict attention to science that hematology is intertwined with today, I wouldn’t be alive to write this today. Science-based medicine can and does save lives. I’m not sure what the cure for MPNs or me is, but I’m sure it’s not in a turmeric smoothie or the hands of a reiki master.
Patient resources
    • http://www.mpnresearchfoundation.org/
    • http://www.cancerresearchuk.org/about-cancer/other-conditions/myeloproliferative-neoplasms
    • http://www.lls.org/myeloproliferative-neoplasms
    • https://www.cancer.gov/types/myeloproliferative
A few technical resources I like
    • Williams Hematology, 9E by Kenneth Kaushansky Dr. MD
    • Wintrobe’s Clinical Hematology, Thirteenth Edition by John P. Greer MD
    • Hematology: Basic Principles and Practice, 6th by Ronald Hoffman. (new edition comes out in a few days, I think it’s well worth it. Hoffman is a great hematologist and a great MPN expert)
    • www.bloodjournal.org
    • www.nejm.org
    • http://www.haematologica.org/
    • www.readbyqxmd.com (program that allows you link with all your journals or by keyword and automatically receive new articles to your devices with an option to download full pdf)
    • https://www.uptodate.com/home
    • http://www.dynamed.com/home/
Erratum
    • Corrected an error in the listing of MPNs that had caused confusion and made unclear whether prevelance or incidence was being discussed.
    • Corrected blood value measurements because of error in essential thrombocythemia.
    • Modified ET to include paradoxical bleeding.
    • Clarified the mechanism of action of Jakafi.

Answering Cancer Quackery: The Sophisticated Approach to True Believers
Harriet Hall on June 30, 2015
Link

I got an e-mail with a link to a video featuring “Dr.” Leonard Coldwell, a naturopath who has been characterized on RationalWiki as a scammer and all-round mountebank. Here are just a few examples of his claims in that video:
    • Every cancer can be cured in 2-16 weeks.
    • The second you are alkaline, the cancer already stops. A pH of 7.36 is ideal; 7.5 is best during the healing phase. [We are all alkaline. Normal pH is 7.35-7.45.]
    • IV vitamin C makes tumors disappear in a couple of days.
    • Very often table salt is 1/3 glass, 1/3 sand, and 1/3 salt. The glass and sand scratch the lining of the arteries, they bleed, and cholesterol is deposited there to stop the bleeding.
    • Patients in burn units get 20-25 hard-boiled eggs a day because only cholesterol can rebuild healthy cells; 87% of a cell is built on cholesterol.
    • Medical doctors have the shortest lifespan: 56. [Actually they live longer than average.]
My correspondent recognized that this video was dangerous charlatanism that could lead to harm for vulnerable patients. He called it a “train wreck, with fantasy piled upon idiocy.” His question was about the best way to convince someone that it was insane. He said, “If you could rely on someone to follow and understand basic information about the relevant claims, it would be a gimme. But to the casual disinterested observer, who can interpret the whole video as ‘Well, he just wants people to eat right,’ pointing out the individual bits of lunacy just looks like so much negativity.”
He asked, “How do I best represent what’s happening to someone who is either a) emotionally invested in this and/or b) casually approving of it? … I just want to be patient, not shout anyone down, not make anyone defensive, and then win. Very surprised I don’t already know how. But I feel like I don’t. What is the psychologically sophisticated approach to this?”
Here’s how I answered him
You can’t change someone else’s mind; they have to change their own mind. The sophisticated approach is to ask them questions that lead them to doubt, and gently lead them to discover the truth for themselves. That is something Socrates was very good at; I’m not. But I can suggest some questions to ask. Maybe start with some kind of validation: Wow, that really sounds good; I can see why you’re impressed, but there are some things I’m wondering about…
If alkalinization works so well to eliminate cancer, why do you suppose he bothers to recommend a lot of other ways to cure cancer, with vitamin C, oxygen, a vegan diet, etc? Why do you suppose oncologists don’t offer any of those treatments to their patients? How likely is it that this one man is right and the entire scientific medical community is wrong about everything from salt to vitamins to cholesterol? How do you think he arrived at those conclusions? Have you ever seen a video that you knew was wrong about anything? How could you go about finding out if anything in this one was inaccurate? Have you read what other doctors have had to say about the alkaline diet? Is there a way you could verify his claims through other sources? Would it be worthwhile to look for the scientific evidence he cites? If you think “he just wants people to eat right,” don’t you think all those people who disagree with him also want people to eat right? If you get cancer and try the alkaline diet and it hasn’t eliminated the cancer as promised in two days, what will you think? What will you do?
Do you believe that “very often, table salt is one-third glass, one-third sand, and one-third salt”? Did you know that the FDA requires that all US table salt be at least 97.5% pure sodium chloride, and it is usually much purer? We can find out for ourselves. Let’s do a little experiment. Glass and sand don’t dissolve in water. Put some table salt in a glass of water. The salt will dissolve and any impurities will sink to the bottom and form a visible sediment. Do you see a residue of sand and glass particles in the bottom?
How could sand and glass in the diet get into the arteries and scratch them? Aren’t insoluble materials indigestible? Don’t they pass through the digestive system and end up in the toilet?
My “SkepDoc’s Rule” is before you accept a claim, try to find out who disagrees with it and why. There are almost always two sides, and it quickly becomes obvious which side is supported by the best evidence and reasoning. If your interlocutor refuses to even look at any contradictory evidence, there is no point in continuing the discussion.
Don’t expect to “win.” True believers are impervious to evidence and reason. The best you can hope to do is plant a seed. Sometimes it takes many seeds of doubt, planted and watered by many different sources over the years, to finally have an effect.
Further thoughts
Since I wrote that, I’ve learned more about how to talk to true believers, and I’ve been persuaded that the task is not as hopeless as I thought. I heard philosopher and educator Peter Boghossian speak at a conference and was intrigued enough to seek out and read his book, A Manual for Creating Atheists, where he describes a method to engage the faithful in conversations that will help them question how certain they can be about the truth of beliefs that are based on faith alone, to help them value reason and evidence over faith, superstition, and irrationality. Instead of discussing specific beliefs, he tries to get people to analyze how they arrive at beliefs in general. It occurred to me that most of what he says applies to true believers in CAM as well as to true believers in religion. Not everyone wants to create atheists, but I hope we all want to create critical thinkers.
Questioning epistemology, not specific beliefs
Rather than questioning specific beliefs, Boghossian questions epistemology: the study of knowledge, how we come to know what we know, how we decide whether to accept a belief as true. His approach is based on the Socratic method of asking questions that get his interlocutors to think more clearly. You can see Boghossian’s methods in action in a series of YouTube videos by Anthony Magnabosco. He does “street epistemology,” asking random people how they arrived at their God belief, and if they are using a possibly unreliable method to arrive there, trying to help them discover that.
How do we know what we know? In the Tuyuca language spoken by a tribe in the Amazon rain forest, to say that someone is chopping trees requires that one also specify how one knows this.1 If you hear that someone is chopping trees, then you say: Kiti-gï tii gí where gí serves to indicate that this is something you hear. But if you actually see him chopping trees, then you say Kiti-gï tii-í where the í indicates your having seen rather than heard it. If you have not actually perceived him chopping trees but have reason to suppose that he is doing so, then the sentence is Kiti-gí tii-hXi;2 if your source of information about the tree chopping is hearsay, then this requires a special marker: Kiti-gï tii-yigï. It would be helpful if English specified the source of knowledge; our grammar doesn’t do it, but we can specify it using other words.
Boghossian gives five reasons why people embrace absurd propositions:
     1.  They have a history of not formulating their beliefs on the basis of evidence.
     2.  They formulate their beliefs on what they thought was reliable evidence but wasn’t.
     3.  They have never been exposed to competing epistemologies and beliefs.
     4.  They yield to social pressures.
     5.  They devalue truth or are relativists.
All of these are applicable to CAM.
True believers do change their minds. Plenty of people have converted from one religion to another or rejected religious beliefs entirely; plenty of believers in CAM have come to reject it in favor of science. Swift said, “You do not reason a man out of something he was not reasoned into.” But people have been reasoned out of religious beliefs, including many ex-preachers. How can we best assist that process?
The Socratic method
The Socratic method has five stages:
     1.  Wonder (I wonder if there is intelligent life on other planets)
     2.  Hypothesis (There must be, since the Universe is so large)
     3.  Elenchus (Q&A) – facilitator generates ideas about what might make the hypothesis untrue. (What if we’re the first? Or the last?)
     4.  Accept or revise hypothesis (There probably is, but maybe not)
     5.  Act accordingly (Stop saying you are certain there must be.)
For a CAM belief:
     1.  I wonder if tea tree oil will cure my toenail fungus
     2.  I know it will work, because it worked for my cousin
     3.  But what if it would have cleared up on its own without treatment? What if your cousin didn’t actually have a fungus? What if a controlled study had shown tea tree oil wasn’t effective?
     4.  I can’t know for sure whether it works, but I’m going to try it.
     5.  If your toenail clears up, don’t tell people you have proved that it works.
Implementing the Socratic method for CAM
It helps to establish a friendly, trusting relationship with your interlocutor. Try to establish some things you have in common. Show an interest in his beliefs; try to understand exactly what it is that he believes and how he arrived at the beliefs. Say, “Tell me more about that.” Validate his experience. Don’t assume he is wrong. Assume he might be right, and show that you are willing to change your own beliefs if provided sufficient evidence. This should not be an adversarial relationship. Remember that you can learn from anyone; everyone you meet knows something you don’t know.
Don’t talk about facts. If the person didn’t form his belief because of facts, he won’t change his mind because of facts. The idea is not to change beliefs, but to change the way people form beliefs. Try to avoid arguing about the belief itself and concentrate on how the belief was arrived at and how one can best arrive at beliefs that are true. Do other people ever arrive at beliefs that are wrong? How does that happen? Ask your interlocutor to think of examples of false beliefs that other people hold, and talk about where they went wrong. Ask him to rate on a numerical scale how confident he is that his beliefs are true. Magnabosco uses a scale of 1-100 where 100 is absolute certainty.
If you can think of a claim that contradicts the believer’s claim, ask how you could go about determining which of two claims is correct. If two believers believe equally strongly in two different religions, they can’t both be right; how could you go about determining which one is right? If one CAM claims that all disease is due to subluxations and another claims that all disease is due to disturbances of qi in the meridians, point out that they can’t both be true.
If they claim to have evidence, you might ask, “For all evidence-based beliefs, it’s possible that there could be additional evidence that comes along that could make one change one’s beliefs. What evidence would you need to make you change your mind?”
If your interlocutor bases his belief on something he “felt,” ask how could we differentiate between that kind of feeling and a delusion? (It’s much less likely to be a delusion if the believer is willing to revise the belief.)
Boghossian uses this series of questions in the classroom:
     1.  Is it possible that some people misconstrue reality?
     2.  Do some people misconstrue reality?
     3.  If one wants to know reality, is one process just as good as any other? (Flipping a coin? Interpreting a dream? Doing a scientific experiment?)
     4.  So then are some processes worse and some better?
     5.  Is there a way we can figure out which processes are good and which are not?
Most students quickly figure out that processes that rely on reason and evidence are more reliable than other processes.
Understand that some people are epistemological victims who have never encountered competing ways of understanding reality. Some religious believers have been deliberately isolated and protected from exposure to any information outside their religious tradition. For CAM, even some doctors and scientists fail to truly understand how the scientific method works and how important it is. CAM advocates seek out like-minded people. Internet “filter bubbles” deliver customized information so people are not likely to find contradictory or disconfirming information by googling.
Surely it is worthwhile trying to help people think more clearly. Think of it as an intervention, like deprogramming a cult member. These are people who need your help. Certainty is the enemy of truth. It removes curiosity and stifles investigation. Susan Jacoby said “I think of the first atheist as someone who, while grieving over the death of a child in ancient times, refused to say, ‘It’s the will of the gods,’ and instead began searching for a natural rather than a supernatural explanation.” If everyone had believed homeopathy was the cure for all disease, antibiotics would never have been discovered. Reality is always a better guide to life than fantasy and error.
Boghossian cites another author who calls religion a kind of virus that infects people, spreads to others, programs the host to replicate the virus, creates antibodies or defenses against other viruses, takes over certain mental and physical functions and hides itself within the individual in such a way that it is not detectable by the individual. In that sense, belief in CAM is also a virus.
It’s cruel to take away people’s cherished beliefs without offering a replacement that offers hope for a better life. Boghossian has proposals for helping religious believers who have given up their belief but are devastated by the loss of their community and need a new source of support. For CAM, we can offer a truly effective way of determining whether a treatment works, the scientific method; and we can direct them to credible sources of information and empower them to tell for themselves whether something is science and pseudoscience. As Bill Nye says, “Science rules!” It doesn’t always provide certainty, but isn’t uncertainty preferable to false certainty? Science is fascinating and exciting and full of wonders and it has the added advantage of being true.
If you fail
If you think your intervention has been a failure, you may be wrong. If believers get angry or seem to become even more entrenched in their beliefs, it may be that they are already experiencing doubts. They may have become more self-aware. Boghossian says, “They may have said things or taken positions to justify the beliefs to themselves.” You may have made a small dent in their certainty, and dents may set the stage for a later breakthrough.
The final comeback
True believers often end with these final arguments:
     1.  “It’s true for me.”
     2.  Even if it isn’t true, it helps people (by providing hope, motivation, etc.)
At this point, you can ask if people are really helped by forming false beliefs.
Another skeptic’s approach to a true believer
Benjamin Radford’s recent article in Skeptical Inquirer3 also offers some very constructive advice. He describes his response to a woman who believes she has been cursed and asks him how to remove the curse. He sympathizes with her and assures her that he is concerned about her welfare. He validates her experience that “something” is going on. He plants a seed of doubt and offers an alternate, non-threatening explanation for what she experienced. He demonstrates open-mindedness. He gives her accurate information about psychic scams. He establishes his bona fides as an expert on the subject, focusing on the psychology of curse beliefs. He explains that all curses are fundamentally the same. He empowers her: he advises her to stop going to psychics, to remember that everyone has some of the same troubles she is attributing to the curse, and to not focus on the negative things but on positive things she can do to help herself.
A final word
I can’t claim that there are any controlled studies to show that this method works to persuade true believers to change their minds or that it is better than any other method. But other methods have few success stories, and in my opinion this sounds like it might be worth trying. It certainly isn’t easy. I recently tried to apply Boghossian’s methods in an e-mail exchange with a woman who holds all kinds of weird beliefs, and I failed miserably. In my experience of many similar discussions, the true believer always eventually makes new claims that are so outrageous that I lose self-control and simply can’t restrain myself from throwing facts at them to show them how wrong they are, and that ends any chance of a productive discussion. I’ll keep trying. I would appreciate hearing from others who have had successes or failures in discussions with true believers.
At any rate, the purpose of SBM is not to convince true believers but to provide accurate information so people whose minds are not irrevocably made up can make informed health decisions. And we have had considerable success doing that.

Notes
     1.  The Power of Babel, by James McWhorter. New York: Henry Holt and Company, 2002. P. 180. Return to text.
     2.  The X stands for a linguistic symbol I was unable to reproduce. Return to text.
     3.  Radford, B. “A skeptic’s guide to ethical and effective curse removal.” Skeptical Inquirer 39:4, p. 26-8. July/August 2015 Return to text.
        ◦ 

Quoth Myrna Mantaring: “US government data” confirms a “143,233% increase in cancer cases due to COVID vaccination”? I answer with a plea for math-based reality checks.
Myrna Mattaring, a retired scientist who worked in diagnostic labs, claims that COVID-19 vaccines caused a 1432% increase in cancer cases, a clearly impossible claim. Here I make a plea for examining such claims, including a much more famous and accepted one, with basic math.
David Gorski on September 3, 2024
Link

If there’s a lesson that I’ve learned about the claims of cranks, quacks, and pseudoscientists, it’s that too much is never enough in terms of their hyperbolic claims. For example, with respect to COVID-19 vaccines and cancer, it wasn’t enough just to falsely claim that COVID-19 vaccines cause cancer. Oh, no. They had to cause “turbo cancers,” cancers so much nastier, fatal, and prone to appearing in younger people than regular boring, run-of-the-mill cancers. Nor is it enough to say that the vaccines have caused the incidence of cancer merely to have doubled or tripled—or even quadrupled—any of which, if true and provable with statistics and epidemiology linking vaccination to cancers, would be alarming enough. That’s not enough for cranks. Oh, no. Behold the latest claim from Myrna Mantaring, MT, MCI, MS, MBA, CLSp MB (ASCP), who “has more than 50 years of experience in the fields of Diagnostic and Research Laboratory Technology, Microbiology, Immunology, and Molecular Biology” (but apparently none in epidemiology), who has appeared with antivaxxer Polly Tommey (buddy of Andrew Wakefield) on CHD.TV to claim that there has been a “143,233% increase in cancers due to COVID vaccination” in the US:
"The increase in cancer, according to the latest report, the US government data confirms [a] 143,233% increase in cancer cases due to COVID vaccination. That's unreal. But it's true."Myrna Mantaring, MT, MCI, MS, MBA, CLSp MB (ASCP), who has more than 50 years of experience in… pic.twitter.com/kzDcuHDb9c
— Sense Receptor (@SenseReceptor) August 18, 2024
“US government data”? Which “US government data”?
Amusingly, even some antivaxxers are responding with “WTF?”:
I don't think the increase is that high.
— My Dog Is Fat (Fat Dog Acceptance Movement) (@CypressXMX) August 18, 2024
“I don’t think the increase is that high” is a hilarious understatement.
Interestingly enough, the video of Polly Tommey interviewing Myrna Mantaring was first posted on CHD.TV on August 14 under The People’s Study but it didn’t appear to start gaining much traction until last week, when The Lioness of Judah posted a link to the video on their popular conspiracy Substack, Exposing the Darkness, having shown up on—where else?—Rumble.
The money quote that all the sources amplifying this video cite is this:
The increase in cancer, according to the latest report, the US government data confirms [a] 143,233% increase in cancer cases due to COVID vaccination. That’s unreal. But it’s true.
Big, if true.
Actually, Mantaring was right the first time, when she categorized it as “unreal.” But who, pray tell, is Myrna Mantaring? Her history, as described as follows. From 2005 to 2015 she served as a military hospital’s health science administrator and research-technology laboratory manager. (Note that the hospital is not named.) From 2015 until her retirement in 2021, she also worked as a clinical-diagnostic laboratory manager for the same hospital’s department of nephrology. Again, these are not really qualifications that I would associate with the ability to be able to parse and analyze “US government data” regarding COVID-19 vaccination and cancer, much less to conclude that COVID vaccines had caused a 1,423.33-fold increase in cancer cases when even a quack like William “turbo cancer” Makis doesn’t make such a claim.
So why write about a fringe claim that is clearly absolute bollocks (as my British friends would put it)? I would argue that it’s worth my attention for the same reason that writing about Dr. Marty Makary’s bogus “estimate” that medical errors are the third leading cause of death in the US, namely to examine such factoids under the lens of critical thinking and basic mathematical literacy. The main difference between the two is that Makary’s estimate became so widely believed that I keep seeing it pop up, mentioned as an accepted factoid, even in ostensibly evidence- and science-based sources, like John Oliver’s This Week Tonight. It doesn’t even matter that, like Mantaring’s estimate, it doesn’t even pass the “smell test” in terms of being plausible from a strictly mathematical standpoint, although, admittedly, it is more plausible than Mantaring by a lot.
Here’s what I mean.
Makary’s estimate in 2016 was that that over 251,000 people a year were dying in hospitals as a result of medical errors. According to the CDC, in 2010 only 715,000 of US deaths occurred in hospitals, implying that, if Makary’s estimate were accurate, then 35% of inpatient deaths are due to medical errors. It was worse than that, though, because Makary’s upper estimate was 400,000 inpatient deaths due to medical error. That was 56%—yes, 56%—of all inpatient deaths! As I said at the time It wasn’t anywhere near plausible that somewhere between one-third to over one-half of all inpatient deaths in the US were due to medical error. It just wasn’t, unless you’re a conspiracy theorist of the type who believes that hospitals were intentionally killing COVID-19 patients through their protocols. Of course, Makary’s estimate, based as it was on unjustified extrapolation from small studies that used an overly broad definition of death by medical error, was just low enough to seem plausible if you didn’t look too closely at the numbers and didn’t compare them to known statistics.
Now, let’s do the same thing with Myrna Mantaring’s estimates. To do that, I head over to the CDC’s website and look at the incidence of new cancer cases by year:
There are a couple of things right here that we can look at. First, note that the trend in new cancer cases per 100,000 population is actually slowly declining. Now, let’s look at the numbers for the year 2020, given that COVID-19 vaccines didn’t receive emergency use authorization (EUA) until December of that year and mass vaccination didn’t really take off until early 2021. According to the accompanying data table, the models rate in 2021 (which I use because the actual rate was lower due to disruptions in screening and patient care due to the pandemic in 2020) was 447.5 per 100,000. Now, if Mantaring were correct and the incidence of new cancer cases increased 143,233% due to COVID-19 vaccines, it’s a simple matter to see what that would look like by multiplying 447.5 by the 1,432.33-fold increase claimed by Mantaring. If you do that, you’ll quickly come up with an estimate for incidence of new cancer diagnoses per year of 640, 968 per 100,000, or more than 6.4 times what is possible. That Mantaring didn’t do that sort of basic plausibility check on her number tells me all I need to know about her.
Moreover, even if you accept the idea of “turbo cancer,” in which COVID-19 vaccines are supposedly so carcinogenic that they can cause cancer faster than ionizing radiation (two to ten years, depending on the specific malignancy), you would expect to have started seeing the trend in the numbers by 2022 at least, and the trend couldn’t be the least bit subtle if we were going to achieve the mass death from cancer estimated by Mantaring by this year. Basically, like Makary’s estimate, Mantaring’s estimate doesn’t pass the basic smell test, but even more obviously. Truly, mathematical literacy is not a characteristic of cranks, although at least Makary didn’t produce a number higher than was physically even possible.
Watching the video, I looked for an explanation for how Mantaring came up with her estimate. I was amused by her introduction. Tommey wanted to talk about Mantaring’s sister, but Mantaring wanted to list her credentials, none of which were particularly relevant to her overarching claim regarding cancer. She also pointedly mentioned that when the pandemic hit in March 2020 she was considered an “essential employee” and came to work every day, which is also fairly irrelevant given that it would be expected that laboratory personnel responsible for doing lab tests in a hospital can’t do their jobs remotely. But she did start “following all news, seminars, symposia, and investigations related to the pandemic, the early treatment, the development and approval of the gene-based vaccine, as well as the CDC reporting system.” Impressive, if true, given that the sheer volume of “news, seminars, symposia, and investigations” described would have been beyond the ability of one person to follow them all while doing her job, which more and more sounds like more of a laboratory technician than an investigative scientist.
Of course, because Mantaring performed PCR diagnostics of viral diseases, she claims that she was immediately able to “recognize the government’s continuing fraud and deception in their COVID-19 testing and vaccine policies,” which she characterized as “crimes against humanity” and part of the “World Economic Forum’s diabolical new world agenda.” She also mentions how “fetal cell lines” were used in the manufacture of the vaccines, a longstanding antivax trope that seeks to weaponize religious objections about abortion to sow disgust about vaccines, while going on about the “limited safety data” and supposedly rushed testing—and this all in the first three minutes of the video!
I wasn’t really interested in going over the same old, same old antivax tropes about COVID-19 vaccines, nearly all of which Mantaring hit at one time or another, along with “early treatment protocols” about hydroxychloroquine and ivermectin, which she urged her family and friends not to take the vaccine but to use these repurposed drugs, which do not work. Unsurprisingly, she states that the reason she retired in 2021 was to avoid mandatory COVID-19 vaccination at her job. That is why I basically listened to the video in the background, waiting for something—anything—describing how she had come up with her ridiculously implausible estimate for such a massive increase in cancer incidence being linked to the COVID-19 vaccines.
I did learn, however, that Mantaring’s sister in Toronto was diagnosed with sarcomatoid urothelial carcinoma, a rare and aggressive cancer of the bladder, “after being fully vaccinated and boostered as mandated by the vaccine passport per the Trudeau government.” Sadly, she couldn’t tolerate the preoperative chemotherapy and was scheduled for surgery in April 2022, at which point it had invaded the uterus and surrounding bowel, requiring more extensive surgery. Eventually it spread to the liver, and her sister died from her disease, seven months from diagnosis. While this is a tragic story, it is not unusual for a cancer like this one, which is aggressive. After this, Mantaring claims that her sister’s story confirmed for her what she had been hearing from people in her circle about cancer in vaccinated people, leading her to go on and on about how spike protein supposedly causes cancer, facilitated by its also causing “vaccine-acquired immune deficiency,” a nonexistent syndrome that antivaxxers like to call VAIDS.
So I listened to the video, wondering if there was any more than the quotes about cancer from COVID vaccines that had been highlighted by The Lioness of Judah and various antivaxxers on X, the hellsite formerly known as Twitter, and other social media, other than this in response to a question about Tommey why the public “fell in line with” and “obeyed” government vaccine mandates “without thinking” (of course—sheeple!):
Because they trusted the government. They would not think that the government will lie to them. And it’s also a belief that a sophisticated form of medicine from big pharma, no less, big names—Pfizer, AstraZeneca, J&J—you would think, they would have no second thoughts. But what triggered my suspicion was, coming from an immunology background and working in an immunization clinic, we don’t do this. We don’t push out a vaccine with less than a year of trials.
Actually, in a pandemic, we do, and the testing was adequate. Elsewhere, she asks:
How can a government people trust lie to them?
Good question, but few are the people who trust the government never to lie, particularly in our current political climate.
At this point, I was getting tired; so I’m just going to come around to the punchline. Myrna Mantaring doesn’t present any evidence to support her claim that as a result of COVID-19 vaccination cancer cases have increased by 143,233%, other than referring to unnamed and undescribed US government data. Her entire argument on this point boils down to basically, “Trust me, bro.” No, seriously. She doesn’t even show graphs or charts. Even cranks as cranky as William Makis show graphs and charts. They might be poorly conceived, designed, and analyzed graphs and charts, but they are at least an attempt to show evidence. From Mantaring, we get nothing.
It’s worse than that. With a little help from a reader, I was made aware of the origin of the “143,233% increase” in cancer claim, and it’s about what you might have predicted. First, it’s not a new figure. In fact, it’s older than even I had suspected. It comes from a conspiracy website called The Exposé, started in 2020 by a British welder named Jonathan Allen-Walker, and an article published there in August 2022 entitled U.S. Government data confirms a 143,233% increase in Cancer cases due to COVID Vaccination. The analysis involved the Vaccine Adverse Events Reporting System (VAERS), because of course it did. Basically, the anonymous author of the article examined cancer-related reports to VAERS related to flu vaccines administered from 2008 to 2020 and COVID-19 vaccines administered between December 2020 and August 2022, and came up with this graph:
I’ve explained more times than I can remember why VAERS is not reliable when it comes to estimating population prevalence of a given condition or for linking that condition to vaccines, given the base rate fallacy and thus don’t know the base rate of the given condition to compare the VAERS data to. Moreover, after the release of COVID-19 vaccines, for the first time ever, the CDC publicized VAERS and encouraged reporting adverse events to it, which, to the surprise of no one familiar with VAERS, led to a huge spike in reports of adverse events related to COVID-19 vaccines. Again, this number fails a basic plausibility test, and only the mathematically illiterate would take such an estimate seriously.
As I reach the end, again one might wonder: Why did I bother? Myrna Mantaring is so obviously off the deep end that it seems pointless to discuss a clearly and obviously fantastical estimate for how much COVID-19 vaccines supposedly increase the number of cancer diagnoses. I bothered because, for one thing, to most people it’s not obvious that her estimate is so obviously off the deep end and mathematically impossible. To know that takes background knowledge. For example, just look at some of the responses in The Lioness of Judah’s comments after one commenter suggests that there’s no way the increase is this high, even though that commenter seems clearly to believe that COVID-19 vaccines contribute to cancer:
You get the idea.
In the end, I wrote about this as a basic plea to do a reality check whenever you see a figure that seems implausible or inflated. With Mantaring’s estimate, it’s really easy, which is why I chose it, much the same way that I like to use homeopathy as an example of extreme implausibility. All you have to do is to look up cancer incidence statistics and then see if what she is claiming is even possible. (It isn’t.) For a claim like Marty Makary’s “third leading cause of death” claim about medical errors, it’s trickier. First, you have to parse his claim a bit and realize that it’s only about in-hospital deaths, not all deaths. Then you have to look up the statistics for how many people die in hospitals in the US every year, so that you have something to compare to. Doing that, you will see that, while Makary’s estimate of 250K to 400K deaths due to medical errors in hospitals is possible, it is incredibly implausible that such a high percentage of deaths in hospitals are due to medical errors. If you want to go further, you can then compare Makary’s number to total deaths in the US every year. If you do so, you’ll find that it’s also pretty darned implausible there too, given that at the time there were estimated to be 2.6 million deaths per year in the US; Makary’s estimate would imply that medical errors cause between 10% and 15% of all deaths every year. Even that comparison tells you how implausible Makary’s numbers were; yet almost no one pointed this out, and his “third leading cause of death” factoid became so ubiquitous that even other ostensibly reason-based sources routinely cite it.
Skepticism and critical thinking are your friends, and I hope that this little exercise, even carried out on an estimate from an obvious crank whose argument boils down to “trust me, bro” inspires you to apply such methods to any numbers-based claim that doesn’t sound plausible or correct. Now, if only the press and many of my medical colleagues who still parrot Makary’s figure would do the same thing.

Another Misguided Cancer Testimonial
Mike Shedlock wrote a post about how he beat prostate cancer. In doing so, he provides a typical example of how difficult the medical literature can be for a layperson to read, and where they can get things wrong.
Harriet Hall on January 27, 2015
Link


An economic analyst, Mike “Mish” Shedlock, wrote a blog post to describe how he beat prostate cancer. When laymen and patients write about cancer, they are likely to get some things wrong. Mish’s story is full of typical misunderstandings and misinterpretations.
He interpreted his experience in his own way and did his own research into the medical literature, something he was not qualified to do. Prostate cancer is a very complex subject, and understanding the implications of published studies for treating patients can be difficult even for experts. In typical Dunning-Kruger fashion, he rejected the advice of his doctors, thinking he could do better.
What his tests showed
Mish had been getting prostate-specific antigen (PSA) tests every couple of years. He believes this is a routine test recommended for men as they get older. It’s not that simple: the PSA test has its uses, but when used as a routine-screening test on the entire population of older males, it is likely to do more harm than good. The U.S. Preventive Services Task Force (USPSTF) says there is insufficient evidence to recommend routine screening. I’ve written before about the prostate screening controversy.
He thinks any reading under 3.0 (or 4.0 or 2.5) is normal. It’s not that simple: there are no defined normal levels for PSA. Low levels can be seen in patients with cancer, and high levels can be a sign of a number of other things, like inflammation or the benign prostate enlargement (BPH) that men frequently develop as they get older. Whatever the level, what is most significant is not the level itself, but a rise over time. After two readings in the 1-2 range, Mish had a reading of 6.65 followed by a reading of 7.13, and his doctor recommended a biopsy.
The biopsy showed cancer. Actually, out of 12 biopsy samples only one showed cancer, and that was only in 10% of that sample. The Gleason score was 6. That score is intermediate, between low-grade, well-differentiated tumors that are less likely to progress and high-grade, poorly-differentiated cancers that are more aggressive. With a Gleason score of 6 and a PSA of 7, his cancer would be considered Stage 1, the earliest stage.
Treatment options
For Stage 1 cancer, there are three treatment options: surgery, radiation, and active surveillance. Many of these cancers are so slow growing that the patient will die of something else before the cancer ever causes symptoms or metastasizes. The prevalence of prostate cancer detectable on autopsies rises with age to eventually become almost universal; men are far more likely to die with prostate cancer than of prostate cancer. And the surgery has a high rate of complications, such as incontinence and impotence. The wisest course in many cases is not to treat but to monitor the patient, with the understanding that treatment may be indicated at a later time if there are signs of progression.
Mish’s surgeon strongly recommended surgery, with an estimated price tag of $20,000. His regular doctor recommended radiation therapy, which can be even more expensive and also has a high risk of complications. Mish says he did his own research and found a third option: wait and see. Most doctors would have explained all three options and let the patient participate in the decision. It doesn’t sound like Mish was given the information he needed to give informed consent.
He chose the surveillance option, but he wasn’t content to just sit back and wait. After 60 hours of research, he settled on a cocktail of the ten “most promising things” that he thought would help fight his cancer. His doctor was against the idea but agreed to go along as long as he continued PSA monitoring. He told the oncologist he was going to have a PSA test every month; the oncologist tried to dissuade him, arguing that every six months would be often enough. More frequent monitoring would just detect more meaningless fluctuations. Unfortunately he expressed that by telling Mish the test “wasn’t that reliable,” and Mish misunderstood. He assumed “the more unreliable a test is, the more tests one should take to weed out erroneous outlier results.” But then he got an outlier result and he didn’t weed it out. A scant month later, his score had skyrocketed to 17.65. The oncologist would not have repeated the test that soon, since PSA levels are known to go up after biopsy. A month after that, it had dropped to 2.39, well below the pre-biopsy level and well within the “normal” range. And it stayed down. Eight months after that one high reading, it was down to 1.94. The surgeon wanted another biopsy because of the one high reading. Mish was worried that despite the now low-normal readings, his cancer might have progressed without showing on the test because his cocktail of alternative treatments might have artificially lowered the PSA readings. So he agreed to another biopsy, and this one showed no evidence of cancer.
Mish’s cocktail
Here’s what he took:
     1.  Resveratrol: 250 mg twice daily
     2.  Indole-3-Carbinol: 200mg twice daily
     3.  Bromelain: 500mg twice daily
     4.  Querceten: 300mg twice daily
     5.  Turmeric extract: 300 mg twice daily
     6.  Vitamin D3: 5,000 IU twice daily
     7.  Vitamin K2: 100mcg twice daily
     8.  Vitamin B12: 100mcg twice daily
     9.  Selenium: 50mcg twice daily
     10.  Sodium bicarbonate orally: One half teaspoon twice daily – one hour in the morning right after waking, and again in the evening right before bed – empty stomach
I’ll review these in reverse order:
    • Number 10 clearly contributed nothing; it is foolishness based on Robert O. Young’s nonsensical “pH Miracle” myth.
    • Number 9 may have been counterproductive. There are studies indicating that selenium supplements increase the risk of prostate cancer.
    • Numbers 6-8 are indicated for people with a deficiency of those vitamins, but it is preferable to get them through diet rather than through pills.
    • Number 5, turmeric, has shown promise in preclinical studies, but the concentration needed for its anticancer effects may not be achievable in the human body with supplements.
    • For numbers 2 and 4, indole-3-carbinol and quercetin, a search of PubMed found some rat and lab studies, but no evidence of clinical benefit for human prostate cancer.
    • For number 3, bromelain, PubMed listed no studies about prostate cancer at all.
    • For number 1, resveratrol, there are indeed some studies, but they are far from convincing.
Mish attributes his success mainly to the first four. He particularly has confidence in resveratrol based on some positive studies he found, but he is cherry-picking to find what he wants to believe. It’s easy to find positive studies to support almost anything. If you look for negative studies you can find those too, for instance this one that showed decreased survival with resveratrol. I wonder if his research also dug up the fact that many of the positive resveratrol studies by the most prolific resveratrol researcher were deliberately falsified. He was found guilty of outright fabrication of data, and he was charged with fraud and fired. I consulted PubMed and found two systematic reviews of resveratrol and other phytochemicals. The first concluded:
[it is] impossible to make definite statements or conclusions on the clinical efficacy in cancer patients because of the great variability and differences of the study designs, small patient numbers, short treatment duration and lack of a standardised drug formulation. Although some results from these clinical studies seem encouraging, reliable or long-term data on tumor recurrence, disease progression and survival are unknown. At present, there is no convincing clinical proof or evidence that the cited phytochemicals might be used in an attempt to cure cancer of the prostate.
The other review concluded:
…at present there is no clinical evidence that phytochemicals might have a therapeutic use in prostate cancer in relation to reduction of tumor progression or improved survival. The question about an improved immune function or quality of life remains open. Potentially the use of phytochemicals could play a role in a preventive setting.
And pharmacokinetic studies of doses up to 5 grams per day have demonstratedpoor bioavailability of resveratrol.
In my opinion, Mish’s “research” only demonstrates his incompetence to do research. He went in with an agenda, looking for anything that “might” help and ignoring evidence that it might not. Without a medical or scientific background, he has no way to put the studies he finds into context or to evaluate their credibility, so his judgment is flawed.
What may really have happened
It’s possible to put an entirely different interpretation on the facts Mish provides. Here’s a devil’s advocate version of his story:
There was no need to do PSA screening tests in the first place. The initial elevated readings that led to the biopsy were not signs of cancer; he had a transient rise due to some other, unimportant, cause. The 17.65 reading was an outlier, probably caused by the recent biopsy. The biopsy was not necessary, and the one sample that showed 10% cancer may have only reflected a small focus of disease that would never have caused him any problems. His cocktail of supplements had no effect. In fact, it’s possible that some elements of the cocktail might have been harmful in some way.
Mish (along with a lot of other men) might have been better off if he had never been screened with PSA tests.
Conclusion: Mish probably didn’t cure his cancer
Mish thinks he “beat cancer” with his cocktail of diet supplements; we can’t rule out that possibility, but I think it is highly unlikely. I don’t think his cocktail made a bit of difference. I think he fooled himself. The cocktail fed him false hope, gave him a false sense of control, and provided the virtuous feeling that he was “doing something” rather than passively waiting for what the future would bring.
Fortunately he is still under the care of his regular doctor, who tolerated his experimentation and continued to monitor his condition. The negative biopsy doesn’t mean that his cancer is gone. If it isn’t, we can hope that it won’t progress; and we can hope that if it does, he will get the appropriate treatment.

Note: the original title of this post and the accompanying picture were interpreted by readers as mocking the patient and making fun of him, which was not the author’s intention. The title has been changed and the picture removed in response.

Kudos to a Journalist
Harriet Hall on February 26, 2013
Link
Many SBM readers will remember the late, great Barry Beyerstein, a luminary of the skeptical movement and author of a classic article that has been cited many times on SBM, an explanation of why bogus therapies seem to work.
One of his greatest personal accomplishments is not as well known: he produced an exceptional daughter, Lindsay Beyerstein, a freelance writer, philosopher, and polymath who stepped into her father’s shoes as a faculty member of the annual Skeptic’s Toolbox workshop after his death and has done a truly admirable job there.
Among Lindsay’s many other activities, she works for the Sidney Hillman Foundation, a nonprofit that honors excellence in socially conscious journalism. One of her goals has been to reward excellence in science journalism. Bob Ortega has just received a Sidney Award for his exposé of a widely used HPV (human papillomavirus) test that is not FDA approved and has an unacceptably high rate of false negative results. Her interview with him was published on the Hillman Foundation website. On SBM, we frequently criticize journalists who get the science wrong. For a change, I’d like to congratulate Mr. Ortega for not only getting the science right, but for accomplishing something that could potentially save lives.

As with so many discoveries in science and journalism, this one started with a chance observation. A senior reporter at the Arizona Republic, Ortega was working on an unrelated story when a pathologist happened to mention a patient who had been diagnosed with cervical cancer after getting two negative SurePath tests in a row. He mentioned that the test in question was not even FDA approved. Ortega could have overlooked that as irrelevant to the story he was investigating, but he was astute enough to recognize the germ of another story and to pursue it diligently.
Screening for cervical cancer today involves two tests: the long-familiar Pap smear and the newer HPV test. The Pap test identifies abnormal cells that may develop into cancer if not treated. The HPV test identifies the presence of DNA or RNA from HPV virus types that are associated with high risk of cancer. The results of both tests affect clinical decisions about further diagnostic procedures and the timing of repeat screening tests.
Typical procedure is for doctors to collect a single sample that the lab can use for both Pap and HPV tests. The Pap test is usually done right away but the HPV test may not be done until a later date. A common practice has been to await the Pap results before instructing the lab to run the HPV test on the same sample (because depending on the Pap results, the HPV test might not add anything that would affect management).
BD SurePath is a preservative used in test kits. It is FDA approved for Pap tests, but not for HPV tests. SurePath was submitted for FDA approval for HPV testing 3 times in the last 10 years. Each time the application was withdrawn; we don’t know why. There is a competing product, ThinPrep, that is FDA approved for both. Doctors usually don’t know what product their lab is using or whether it is FDA-approved.
Withdrawal of the FDA applications means the in-house data were not made public, but Ortega’s sources indicated that the SurePath test had a false-negative rate as high as 50%, compared to 10% for FDA-approved brands. In other words, as many as 50% of women who had high-risk HPV infections were being falsely reassured that they did not. The company claims that false-negatives aren’t a problem unless testing is delayed for 8 weeks. But Ortega found 17 independent medical studies, most of which showed that the samples began to degrade after a few days or even within 24 hours. He learned that the manufacturer and the FDA were aware of the problem long before any action was taken. And the action that was finally taken didn’t amount to much.
On June 8, 2012, the manufacturer, in collaboration with the FDA, sent a bulletin to laboratory customers stating SurePath is not FDA-approved for use with the most common HPV test, hybrid-capture II. “Use of the SurePath sample may under certain conditions produce false-negative results … (that) could lead to inappropriate patient management and potentially compromise patient safety,” the bulletin stated.
The warning was only sent to labs; not to doctors or patients. Ortega interviewed numerous gynecologists 5 months later; none of them were aware of the warning.
SurePath has a 30% share of the market, selling 3 million test packs a year. Why do so many labs choose SurePath? One possible explanation is that it costs $1-2 less than the FDA-approved tests. And using the test off-label is perfectly legal, as long as the individual lab does the required in-house validation studies to convince itself that it is getting good results.
This highlights not only the problems with this one test, but also the deficiencies in FDA oversight and notification procedures in general. The test is still in wide use, and FDA procedures have not changed, but at least the information Mr. Ortega dug up is now available to doctors and patients.
Ms. Beyerstein says:
Ortega engaged deeply with the peer-reviewed literature, interviewed numerous experts, and delved into complex medical and regulatory issues to report this story. He eschews sensationalism and innuendo and focuses on the facts, which are damning.
An MD blogger characterized Ortega’s story as:
some of the best health reporting I have ever seen. His article not only gives me almost everything I need to know on this issue as a clinician, but includes information on how the article was complied, and excellent info for patients wondering what to do themselves with this information.
So kudos to Bob Ortega, and thanks for an outstanding piece of science journalism that can serve as an example to his colleagues everywhere. And thanks to Lindsay Beyerstein for publicizing his accomplishments.

Cunnilingus, Michael Douglas’s Cancer, and the HPV Vaccine
Harriet Hall on August 6, 2013
Link

Conservative Christians are calling for banning oral and anal sex between consenting adults, claiming that the practices allow for the spread of disease. Radio host Brian Fischer says that a rise in head, neck and throat cancers “among millennials” is a direct result of the influence of “Bill Clinton and Monica Lewinsky.” He compares oral sex and homosexual sex to drug trafficking, pedophilia and bestiality. He hasn’t decided how offenders should be punished but he suggests either issuing summonses like parking tickets or putting them into programs akin to drug rehab. He says Liz Cheney (the daughter of former Vice President Cheney) is “not a patriot” because she may support gay marriage.
Those of us who want the government to stay the hell out of our bedrooms will gladly ignore such rants, but the health risks of sexual practices are real. Michael Douglas recently shocked the world by announcing that cunnilingus could have caused his throat cancer. He was right, it could have.
HPV causes several kinds of cancer
Most head and neck cancers are caused by tobacco and alcohol, but researchers believe that up to 80% of oropharyngeal cancers are due to HPV (human papilloma virus) infection. The cause can be confirmed by testing biopsy samples for HPV DNA. The incidence of throat cancer caused by HPV is rising rapidly (a 225% increase from 1988 to 2004) and has been attributed to an increase in oral sex. It is estimated that by 2020 HPV will cause more oropharyngeal cancers than cervical cancers in the US.
Approximately 15 types of HPV cause virtually all cases of cervical cancer; types 16 and 18 account for 70% of cases. Type 16 causes 85% of anal cancers. Types 16 and 18 cause close to half of vaginal, vulvar, and penile cancers. More than half of cancers diagnosed in the oropharynx are linked to Type 16. In addition, people infected with HPV may be three times as likely to develop esophageal cancer. DNA tests for HPV are accurate, but there are as yet no FDA-approved tests for detecting HPV virus in men.
HPV vaccines
One of the Holy Grails of medical research is a vaccine to prevent cancer. Now we have 2 of them, Gardasil and Cervarix. Both vaccines are highly protective against HPV types 16 and 18, and Gardasil also protects against type 6 and 11. They have not specifically been approved for prevention of oropharyngeal cancer, but we can expect that they will accomplish that as well.
Only half of US girls age 13-17 have received a dose of the HPV vaccine, and only a third have received the full recommended series of three. Other countries have higher vaccination rates; the rate in Rwanda is 80%. Despite the poor uptake in the US, HPV infections in teens have fallen by half since the vaccines became available, suggesting that some degree of herd immunity is occurring. By one estimate, if the vaccination rate in the US equaled Rwanda’s, 50,000 lifetime cases of cervical cancer could be prevented.
The vaccines are most effective if given before sexual activity starts. A series of three injections two months apart is recommended at age 11-12 for both girls and boys. The cost in the US is a total of $450, not always covered by insurance; but the manufacturers have cut their prices to the world’s poorest countries to below $5 a dose. In poor countries, Pap tests are impractical, treatment of cancer is not readily available, and cervical cancer kills an estimated 275,000 women a year.
Two factors are responsible for the low vaccination rate in the U.S.: doctors are not pushing the vaccine and malicious rumors are frightening parents.
Irresponsible fear-mongering
Myth: The HPV vaccine has killed at least 21 girls (Mercola says 122).Reality: Deaths have occurred after the vaccine; deaths have occurred in girls who were not vaccinated; not one single death has ever been attributed to the vaccine.
Myth: The vaccine has caused 9749 adverse reactions.Reality: No serious adverse reactions have been attributed to the vaccine.
Myth: It has caused 10 miscarriages.Reality: It has not been linked to miscarriages. Sure, 10 individuals may have had miscarriages after getting the vaccine, but the baseline rate of miscarriage is higher than that in women who have not been vaccinated.
Note: these 3 claims were based on reports to VAERS (the Vaccine Adverse Event Reporting System). VAERS only lists things that happened after vaccination; it doesn’t mean they were caused by vaccination. Relying on VAERS data is a post hoc ergo propter hoc error in reasoning. 57,000,000 doses of the vaccine have been administered, yet no deaths or serious adverse reactions have been linked to the vaccine.
Myth: It hasn’t been properly tested.Reality: It was tested in thousands of girls before marketing, and the after-market experience with 57,000,000 doses constitutes a further test.
Myth: It hasn’t been shown to reduce the rate of cervical cancer.Reality: It takes a couple of decades for those cancers to appear. Meanwhile, it has reduced the rate of the infections that cause those cancers, so it would be amazing if it had no impact.
Myth: It only covers a few strains of the virus.Reality: Yes, but those are the ones that matter.
Myth: It will lead to promiscuity.Reality: More than one study has shown that it doesn’t.
Myth: Mike Adams, the “Health Ranger,” says the FDA knew as early as 2003 that the HPV virus was not linked to cervical cancer.Reality: What is he smoking? The entire scientific community accepts the strong evidence of a link.
Conclusion: A vaccine to prevent cancer!
We have a vaccine for cancer! A very safe vaccine that reduces the rate of HPV infections and therefore will reduce the rate of cervical cancer and several other types of cancer. If Michael Douglas had had the option of being vaccinated as a teen, it’s possible that it could have prevented his throat cancer. I don’t see any valid reason to refuse the vaccine other than perhaps its cost. My daughters were both vaccinated, and if I had a teenage son, I would make sure he got the vaccine too. And before anyone has a chance to suggest it, let me say that I do not receive any pay from Big Pharma nor do I own any stock in the companies that make the vaccines.

   Clinical Trials

Myths integrative medicine sells us: “We never advocate alternative medicine without conventional medicine”
“Integrative medicine” (IM) effectively integrates quackery with real medicine. The main talking point by advocates of IM meant to deflect this criticism is that IM practitioners always use alternative medicine with conventional medicine and never advocate the use of alternative medicine alone. A new book by a prominent advocate of IM suggests that this talking point is at best self-delusion among academics who have embraced IM.
David Gorski on January 8, 2017
Link


If there’s one thing that proponents of “integrative medicine” (or, as it’s been called in the past, “complementary and alternative medicine,” or CAM) take great pains to emphasize whenever defending their integration of prescientific and pseudoscientific medicine into medicine, it’s that they do not recommend using “alternative medicine” instead of real medicine but in addition to real medicine. Indeed, the “gods” of integrative medicine, such as Barrie Cassileth at Memorial Sloan-Kettering Cancer Center, not only emphasize that ad nauseam but actually often take umbrage when it is suggested that integrative medicine advocates ever suggest that alternative medicine should be used instead of science- and evidence-based medicine. She’s even written articles attacking cancer quackery, seemingly oblivious to the fact that many of modalities that fall under the rubric of integrative medicine are based on the same mystical or pseudoscientific ideas that the quackery she decries is.
Certainly, that’s what I once thought about Glenn Sabin. Longtime readers might remember Glenn Sabin because he’s been featured right here on this very blog at least a couple of times and even more on my not-so-super-secret other blog. For instance, Sabin’s admission that integration medicine is a “brand, not a specialty,” served as the basis for my discussion of the evolution of integrative medicine as a concept. Sabin has also declared that CAM is dead and that “evidence-based, personalized integrative medicine continues its ascent,” and still more recently he wrote a book listing what he considers to be the 125 milestones in the development of integrative medicine. Through it all, if there’s one unerring talking point that proponents of integrative medicine never abandon, it’s that message that the woo is supposed to complement real medicine, to be “integrated with real medicine” and not to be used in place of it. Sabin used to promote this message himself, and, in fairness, he has advocated that newly diagnosed cancer patients should, if possible, go to an NCI-designated comprehensive cancer center (NCI-CCC) for a second opinion. (Also, in the cause of full disclosure, I’ve spent my entire career working at two NCI-CCCs and my entire training was at institutions with affiliate NCI-CCCs.)
Unfortunately, now Sabin’s gone one step beyond with his new book. In it, he has co-opted “N-of-1” trials to promote his message, using them not as an experimental method whose usefulness is not yet sure but rather as a slogan for integrating quackery with medicine. He also seems more enamored of an NCI-CCC like Dana Farber Cancer Institute more as a means of making sure that his disease course is “chronicled through the Harvard medical system” than anything else, as you’ll see. He also helps demonstrate why lie number one about “integrative medicine” is the claim that the woo is never used alone. As you will see, several luminaries in the world of integrative oncology who really should know better were quite impressed with this alternative cancer cure testimonial and appear quite unconcerned about the message Sabin’s book promotes.
Glenn Sabin’s alternative medicine cancer cure testimonial
I was actually surprised—but perhaps shouldn’t have been—when I discovered that Sabin has what is in essence his very own alternative cancer cure testimonial. I really don’t know (and am a little embarrassed by) how it could be that I didn’t know this before. But now I do, thanks to his new book. That book is entitled N-of-1: One man’s Harvard-documented remission of incurable cancer using only natural methods. I recognized immediately that this is not a book about an “N-of-1” clinical trial (an interesting topic for another day), but rather a book describing an alternative medicine cancer cure testimonial co-opting a hot new area of clinical trial research.
Given the number of such stories that I’ve deconstructed in the past, I couldn’t let this one pass without examining it more closely, particularly given that it features quotes by Lee M. Nadler, MD, on how he has “witnessed an extraordinary patient who achieved a clinical response through non-conventional treatment approaches” and by David Rosenthal, MD on how Sabin “understands the importance of the mind and body in reducing stress and improving overall clinical outcomes in cancer” and how we “are pleased to be able to work with him.” Both, of course, are Harvard faculty. I even took advantage of the ability to download an excerpt from the book.
Here’s the blurb on Sabin’s website:
In 1991, Glenn Sabin was a 28-year-old newlywed diagnosed with chronic lymphocytic leukemia (CLL)–a disease doctors called “uniformly fatal.” Treatments could buy him some time and eventually ease his discomfort, but there was no conventional cure. Glenn’s prognosis was clear: he was going to die.
Although Glenn and his wife, Linda, continued to consult with doctors, cancer specialists and top oncologists, Glenn made a monumental decision: he would become his own health advocate. While he continued to “watch and wait,” Glenn would figure out how to stay alive.
No one could predict when a large-scale clinical trial would discover a cure for CLL, so Glenn began his own, medically monitored and carefully researched lifestyle changes. He would conduct his own, single patient clinical trial.
He would become an “n of 1.”
Today, Glenn is not only alive, but a 2012 biopsy at Harvard confirmed that his bone marrow contains no leukemic cells. His case is now part of the medical literature.
I note right now that whatever it is that Glenn Sabin has documented, it is not an “N-of-1 trial.” (More on that later.) I was nonetheless glad to see that this case was part of the medical literature in the form of this case report now, because it gave me a far better account than I usually get upon which to base my discussion. So I headed straight to the source to check out this case report and was actually a bit surprised to notice that one of the authors is someone with whom I was acquainted, albeit not well. I also noticed that the authors included Jeffery White, Director, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute. (That’s OCCAM, an office that has a budget approximately as large as that of the NCCIH.) The first author is someone named Dawn Lemanne, who is affiliated with Oregon Integrative Oncology and Memorial Sloan-Kettering Cancer Center. Let’s just say that hers does not appear to be a particularly evidence-based practice.
So what does Sabin claim? Basically, he claims that his “natural therapies” resulted in (or at least contributed greatly to) his remission from CLL, not once, but twice. In 1991, Sabin was diagnosed with CLL and underwent a splenectomy because they lymphocytes had infiltrated his spleen. It was noted that, after his splenectomy, from 1992 to 2003, Sabin remained asymptomatic, but serial bone marrow biopsies revealed increasing lymphocytic infiltration. During this period, the peripheral white blood cell count fluctuated between 5.3 and 14.8 g/dL. Also, in 1993, Sabin did this:
Meanwhile, in 1993, at age 30, the patient began a self-directed health regimen. This included a near-vegetarian diet with occasional seafood, filtered water, over-the-counter nutritional supplements, and exercise (mainly resistance training with some aerobic activity consisting of power walking). He avoided processed foods and obtained organic or unsprayed produce whenever possible.
So, while Sabin was undergoing this self-directed health regimen, his numbers were getting worse. This is not particularly good evidence supporting the efficacy of diet and exercise for curing CLL. In fact, in 2003, Sabin developed fever, malaise, night sweats, and fatigue. Basically, he developed a relapse of his CLL and treatment with steroids, rituximab, and cytotoxic drugs was recommended. He declined, and amended his supplement regimen to include conjugated linoleic acid, whey protein with lactoferrin, and the botanical extract artemisinin. This is how the testimonial goes after that:
Despite feeling poor, he walked and swam daily. By October 2003, a few months after the episode began, the hemoglobin had risen to a normal value of 13.4 g/dL. The constitutional symptoms abated, and the patient made a complete clinical recovery.
In May 2006, when the patient was 42, a bone marrow examination showed lymphocytic replacement of 30%. This was decreased compared to the 2003 examination during the hemolytic anemia episode when lymphoid aggregates had replaced 90% to 100% of the marrow.
So, over three years, he got better, but not completely better. Three years later, in 2009:
In December 2009, the white blood cell count rose to 17,500/µL, with a lymphocytosis of 63%. Hemoglobin was 13.6 g/dL, and platelets measured 293,000/µL. The patient, now age 46 and asymptomatic, consulted author KB.
Based on early-phase clinical trials showing the efficacy of epigallocatechin-3 gallate in chronic lymphocytic leukemia, author KB prescribed a supplement formula containing reishi mushroom (Ganoderma lucidum), chaga mushroom (Inonotus obliquus), and green tea (Camellia sinensis) [2]. This formulation was chosen because the green tea fraction provided approximately 1200 mg daily of epigallocatechin-3-gallate.
In addition to this directed anticancer treatment, the patient’s constitutional resistance to cancer progression was assessed via detailed testing of inflammation and glucose metabolism. High-normal fibrinogen levels and modest elevations in D-dimer and C-reactive protein were interpreted as signifying hypercoagulability and mild generalized inflammation. Although levels of insulin, blood glucose, and fructosamine were normal, C-peptide was above ideal at 5.3 ng/mL, suggestive of aberrant glucose metabolism. In addition, 25-hydroxy vitamin D was 46.7 ng/mL, slightly below the optimum range of 50 to 70 ng/mL.
To address these issues, the patient was placed on high-dose fish oil containing eicosapentaenoic acid (10.8 g) and docosahexaenoic acid (2.4 g daily), curcumin (4 g daily), vitamin D3, Scutellaria baicalensis, and probiotics. Calcium and magnesium were added to address a reported decrease in lumbar vertebral bone density.
Despite this approach, by October 2010, the white blood cell count had reached 47,800/µL, with lymphocytes at 81.6%. At this time, author BRK detected an immunoglobulin variable region heavy chain (IgVH) mutation in the peripheral blood by PCR.
So basically what is clear is that the woo wasn’t working. Sabin was slowly getting worse. At least, his laboratory values were slowly deteriorating. His CLL was still active. Then this happened:
In December 2010, author KB increased the dose of epigallocatechin-3-gallate to 4 g daily, basing the dose on that used in a clinical trial at Mayo Clinic [2].
In February 2011, two months after the patient began the higher dose of epigallocatechin-3-gallate, the white blood cell count peaked at 50,600/µL, with 84% lymphocytes. Fibrinogen, D-dimer, C-reactive protein, and C-peptide levels had dropped to low-optimal ranges. The vitamin D level had reached a supranormal level of 110 ng/dL, and the dose of supplemental vitamin D was decreased.
In March 2011, the white blood cell count had dropped, measuring 30,600/µL. By August 2011, the white blood cell count was 6800/µL, with a lymphocyte fraction of 49%.
In January 2012, when the patient was 48, a marrow examination at the Dana-Farber Cancer Institute demonstrated slightly elevated cellularity at 60%. However, lymphocytes represented only 5% to 10% of the cellularity. Flow cytometry of the aspirate also showed no evidence of a lymphoproliferative disorder. These findings were interpreted as being inconsistent with a lymphoproliferative disorder.
In September 2014, when the patient was 51, the marrow was hypercellular at 80%. However, lymphocytes again comprised only 5% to 10% of the cellular component. Of particular note, these lymphocytes were specifically tested and found to be predominantly CD3 positive T cells, whereas B cells would have been consistent with chronic lymphocytic leukemia. For a second time, flow cytometry of the aspirate showed no molecular evidence of a lymphoproliferative disorder. IgVH mutation was no longer detected on PCR. The entire study was interpreted as being without evidence of a lymphoproliferative disorder.
Sounds convincing, right? At least, it does to those without medical training. Unfortunately, it also seems to have convinced others who should know better. Let’s take a closer look.
Deconstructing Glenn Sabin’s alternative cancer cure testimonial
When I looked at Sabin’s alternative medicine cancer cure testimonial in more detail, as is almost always the case for such testimonials, reality appeared much less impressive than what was being sold. For instance, I noticed that his white blood cell count kept increasing after Dr. Block increased the dose of epigallocatechin-3-gallate. It kept increasing for two full months and peaked at a pretty impressively high level. Then it decreased some and took a total of eight months after the dose change to decrease to a level within normal parameters. A year later, he appeared to be in remission, but even more than three years later, although there didn’t seem to be molecular evidence of a lymphoproliferative disorder, Sabin’s lab results can’t be said to be exactly normal. Yes, in 2015, three years after his last flare-up followed by a seeming remission, Sabin is doing well. I hope he continues to do well.
Unfortunately, this testimonial is thin gruel to attribute Sabin’s good fortune to any sort of “natural” regimen that he undertook. After all, the first time around in 1992, he did a radical lifestyle alteration, but it clearly didn’t impact the course of his disease over more than a decade. Similarly, his later experiences don’t demonstrate that epigallocatechin-3-gallate or any of the other woo that Sabin undertook is the cause of his remission, no matter how much Sabin and the authors of the article describing his case report want to make it so. Correlation does not equal causation. It can indicate causation, but quite frequently it does not. Basically, this whole case report is singularly unconvincing.
Why?
I learned right away why I should be skeptical of this testimonial right from the very beginning of the case report:
Clinical remission of chronic lymphocytic leukemia without conventional therapy is a rare event, estimated to occur at the rate of 1% per year among cases of CLL [1]. Moreover, most such remissions are incomplete; a recent review of 21 such cases found persistent monoclonal B lymphocytosis in 67%, with only 33% regressing to a molecularly normal phenotype
So right away, we know that approximately 1% of patients per year with CLL will undergo spontaneous remission and that around 33% of those patients will completely regress to the point where molecular techniques can’t find any cancer cells. We also know that one publication has listed 21 such cases, of which seven were complete molecular remission. In other words, if these figures are accurate a grand total of around 0.3% of patients with CLL (all comers) per year will undergo a complete molecular remission. That’s 3 out of 1,000. Admittedly, that’s a low number, but I wouldn’t call it so low as to be so out of the ordinary that the most likely explanation for why Sabin has done well over the last quarter century must be the woo that he indulged in, even taking into account the observation that, as a young man, Sabin was less likely to undergo remission than as the more typical CLL patient, who is elderly. A more likely explanation is that he was one of the three in a thousand (or one in a thousand or even one in ten thousand if you think his chances of a spontaneous remission were much lower because his young age and splenic involvement with CLL, which usually portends a more dire prognosis). None of this is to say that the epigallocatechin-3-gallate couldn’t have had an effect. Clearly, it might have, although this single anecdote is not good evidence that it did. What I am saying is that Sabin is far too confident that his use of alternative medicine and integrative therapies were the cause of the remission of his cancer, particularly given that, according to the case report, Sabin remained asymptomatic throughout his entire course over 25 years, with the exception of the times he had his two relapses.
So one has to ask oneself when confronting a testimonial like this: What is more likely, that Sabin cured himself with lifestyle changes, green tea extract, high-dose fish oil, curcumin, vitamin D3, Scutellaria baicalensis, and probiotics, or that he was one of the handful of CLL patients who are fortunate enough to have a complete remission with no molecular signs of the tumor? While it is possible that Sabin’s interventions might have impacted his cancer in a positive manner, this testimonial isn’t particularly strong evidence of that. The timing isn’t as compelling as it’s sold, which is this way in the introduction to Sabin’s book:
When I was diagnosed with chronic lymphocytic leukemia in 1991, most doctors would have said that modern medicine had no cure.
Most doctors believed then, that finding effective cancer treatments required huge sums of money to be spent on randomized controlled trials, in which expensive pharmaceuticals, many with harsh side effects are tested on numerous human subjects over many years. Such undertakings require the concerted efforts of exquisitely trained, well-funded, and very persistent scientists.
Most doctors believed then that nothing I could do for myself would help me survive leukemia. Although diet, supplements, and exercise—the pursuit of good health—might make my body stronger, my lifestyle choices would have no effect on the leukemia, and would therefore be a waste of time and money.
In 1991, most doctors would have said that there was no way I could successfully treat my own cancer, at home.
It is now 2016, and I am alive. And although I am well, very well indeed, many physicians still say that a patient cannot successfully treat cancer at home. However, perhaps it can be done. Perhaps I have done it. I don’t know. This book is my story, and it is above all the story of an experiment. As an experimenter I have catalogued my failures as well as my successes, in hopes that interested readers might find some instruction in both.
I note in fairness that I can’t fully evaluate Sabin’s cataloguing of his successes and failures for the simple reason that the book excerpt I got from his website was only the first few chapters that described his initial diagnosis. It’s compelling reading, the story of a young man recently married who was diagnosed with a chronic disease expected to be lethal, but it doesn’t really provide any details. I also note this case report of a spontaneous remission of CLL, in which there was no apparent triggering event and the authors noted that “even after the complete spontaneous clinical and laboratory regression of the disease, there were still occult CLL cells in the remaining microenvironmental niches of the bone marrow that could be detected by molecular techniques.” Again, I hope Sabin continues to do well. I really do. However, there’s a good chance he still has leukemic cells lurking at a level that is currently undetectable.
An alternative cancer cure testimonial is not an “N-of-1” trial
I discussed Sabin’s case for a simple reason. Along with John Weeks, Sabin is one of the leading lay popularizers of “integrative medicine,” thanks to his consulting business FON Consulting, which advertises itself as “positioning integrative health organizations for long term growth while advancing evidence-based integrative medicine as the standard of care” using business models “driven by innovative marketing, clear messaging and customer engagement via branded storytelling.” As a result, Sabin is tight with many leading integrative medicine physicians, as evidenced by the blurbs they provided for his book. Some of the luminaries of integrative medicine and oncology who provided Sabin with blurbs include Drs. Jun Mao, Debu Tripathy, Mark Hyman, David Rosenthal, Lorenzo Cohen, Moshe Frenkel (who’s affiliated with M.D. Anderson and into homeopathy and co-authored a study testing homeopathic remedies on breast cancer cells), and others.
Even though it is clear from what I’ve read of his book and about his book, Sabin clearly he believes that alternative medicine probably cured him of a fatal disease, and even though Sabin has sold his alternative cancer cure testimonial as an “N-of-1” trial, these oncologists and physicians are not alarmed. Instead, they provide words of praise. While I expect such nonsense from Mark Hyman and a “naturopathic oncologist” like Lise Alschuler (whose Arizona clinic advertises quackery galore and who also provided a blurb), I do not expect it from Lorenzo Cohen, Jun Mao, or Debu Tripathy. In reality, his “N-of-1” is not a clinical trial, Sabin’s use of the term notwithstanding. There was no predetermined protocol, and his story shows none of the hallmarks of a real N-of-1 trial. Basically, Sabin’s story is nothing more than, at best, a case report, but, as told on his website, an alternative cancer cure testimonial masquerading as an “N-of-1” trial.
In this, he is little different from Suzanne Somers, Chris Wark, a Stanislaw Burzynski patient, or any number of believers in medical pseudoscience who use their testimonial of survival as evidence that quackery works. Sure, Sabin is less quacky than Somers or Wark, and—who knows?—maybe green tea extract, curcumin, and fish oil have effects against CLL, but, whatever denials he might make otherwise, his book is selling the message that you don’t necessarily need conventional medicine to treat cancer, that you can treat your cancer on your own with “natural” methods. That’s a message that’s bound to lead to preventable deaths. It’s also counter to the number one talking point of integrative medicine in general and integrative oncology in particular: That alternative medicine should be used with medicine and not as an alternative to medicine. It’s a premise that is belied by the embrace of naturopathy by integrative medicine, given how naturopaths frequently substitute quackery for real medicine.
Finally, you can see the way “integrative oncology” is going by this description of Sabin’s co-author, Dawn Lemanne, MD, MPH:
Dr. Dawn Lemanne is a practicing oncologist and integrative medicine authority. One of a small but growing number of oncologists integrating conventional and complementary therapies to treat cancer, Dr. Lemanne approaches each patient as an n of 1. Her practice draws patients from around the globe.
Dr. Lemanne is a proponent of rigorous single-subject research design development and is active in the quantified self movement. The first medical oncologist to serve on the faculty of New York’s Memorial Sloan Kettering Cancer Center’s integrative medicine service, she currently teaches physicians in the University of Arizona’s flagship integrative medicine fellowship. She is the author of peer-reviewed scientific articles, textbook chapters, and works for the popular press. Dr. Lemanne speaks by invitation domestically and internationally.
After earning the MD degree at the University of California, San Francisco, Dr. Lemanne trained in medical oncology at Stanford University and in integrative medicine at the University of Arizona. She also holds advanced degrees from UC Berkeley and Johns Hopkins University.
Rigorous? I’d hardly call the case report on Glenn Sabin that I just examined rigorous.
Clearly, since most integrative medicine modalities fail in rigorous randomized clinical trials, this is the way the specialty is going, both because “N-of-1” trials can be sold as evidence that the woo being integrated into medicine works without the need for all those pesky expensive rigorous randomized trials and because N-of-1 trials cater to the very core beliefs of CAM and integrative medicine. After all, integrative medicine is based, above all, on catering to “special snowflakes.” Its proponents claim to treat each patient as an “individual” and to treat the “whole” person, and N-of-1 trials make it all about the individual patient. This moves medicine away from rigorous science and back towards pre-clinical trial medicine, in which anecdotes and case reports ruled. It’s all of a piece with how integrative medicine “turns back the clock” on medicine. Yes, there is a role for “N-of-1” trials in conventional science-based medicine, but it’s still controversial how useful and rigorous they can be, when and under what circumstances they should be used, and how they should be designed. Unfortunately, Glenn Sabin is showing integrative medicine the way to put the cart before the horse and make “N-of-1” the slogan for integrative medicine. In it, he is also showing the claims by integrative oncology that the woo should never, ever be trusted without conventional medicine as well to be, if not an outright lie, self-delusion.

   Clinical equipoise versus scientific rigor in cancer clinical trials
David Gorski 
Link
A critical aspect of both evidence-based medicine (EBM) and science-based medicine (SBM) is the randomized clinical trial. Ideally, particularly for conditions with a large subjective component in symptomatology, the trial should be randomized, double-blind, and placebo-controlled. As Kimball Atwood pointed out just last week, in EBM, scientific prior probability tends to be discounted while in SBM it is not, particularly for therapies that are wildly improbable strictly on the basis of basic science, but for both the randomized clinical trial remains, in essence, where the “rubber hits the road,” so to speak. Indeed, when the prior probability of a therapy working based on preclinical basic science investigations appears high, EBM and SBM should be (and are, for the most part) more or less indistinguishable.
The ethics of clinical trials, however, demand a characteristic known as clinical equipoise. Stated briefly, for purposes of clinical trials, clinical equipoise demands that at the time a clinical trial is being carried out there be a state of genuine scientific uncertainty in the medical community over which of the drugs or treatments being tested is more efficacious and safer. One reason (among many) why the Gonzalez trial was completely unethical was a lack of clinical equipose. (Lack of adequate informed consent was another.) Lack of clinical equipoise is also the reason why a prospective randomized, double-blind, placebo-controlled clinical trial testing an unvaccinated group versus a vaccinated control group to determine whether vaccines cause autism would be completely unethical. Such a trial would egregiously violate the principle of clinical equipoise because the unvaccinated group would be left unprotected against potentially life-threatening vaccine-preventable diseases, and that is completely unacceptable from an ethical perspective. Consequently, we have had to rely on on the accumulation of data from less rigorous trial designs to demonstrate that there is no correlation between vaccines and autism. Even so, the accumulated weight of such evidence is enough, and for some questions that is the best we can do because scientific rigor sometimes conflicts with human subjects research ethics. This is an extreme example of lack of clinical equipoise, but it illustrates the point. If we know (or have good scientific reason to suspect) that one treatment is better than another, it is unethical to randomize patients to the arm that receives what is, based on what is known at the time of the trial, likely to be an inferior treatment.
Sometimes, however, the question of whether clinical equipoise exists in a clinical trial is not so obvious as it is for trials proposed by cranks. This situation sometimes crops up in clinical trials for cancer. I was reminded of this issue by a front page story in the New York Times yesterday, New Drugs Stir Debate on Basic Rules of Clinical Trials. In it, reporter Amy Harmon uses a classic human interest story to highlight the issue of clinical equipoise in a clinical trial for a new drug for melanoma that shows great promise. In brief, it is the story of two cousins, one of whom is receiving the new “wonder drug” (whether it is truly a wonder drug or not remains to be seen) in a clinical trial and one of whom is receiving the current standard of care for stage IV melanoma, which, to put it bluntly, sucks in that it has very little effect in prolonging life:
And when, last year, each learned that a lethal skin cancer called melanoma was spreading rapidly through his body, the young men found themselves with the shared chance of benefiting from a recent medical breakthrough.
Only months before, a new drug had shown that it could safely slow the cancer’s progress in certain patients. Both cousins had the type of tumor almost sure to respond to it. And major cancer centers, including the University of California, Los Angeles, were enrolling patients for the last, crucial test that regulators required to consider approving it for sale.
“Dude, you have to get on these superpills,” Thomas McLaughlin, then 24, whose melanoma was diagnosed first, urged his cousin, Brandon Ryan. Mr. McLaughlin’s tumors had stopped growing after two months of taking the pills.
But when Mr. Ryan, 22, was admitted to the trial in May, he was assigned by a computer lottery to what is known as the control arm. Instead of the pills, he was to get infusions of the chemotherapy drug that has been the notoriously ineffective recourse in treating melanoma for 30 years.
Even if it became clear that the chemotherapy could not hold back the tumors advancing into his lungs, liver and, most painfully, his spine, he would not be allowed to switch, lest it muddy the trial’s results.
The melanoma drug in question, PLX4032 (RG7204) was developed by U.S.-based biotechnology firm Plexxikon, which partnered with Swiss pharmaceutical firm Roche to bring the drug to market. The drug targets a specific (but common) mutation in the BRAF proto-oncogene (pronounced “b-raf,” not “braf”) found in melanoma. Interestingly enough, I’ve actually participated in research with a collaborator who is a melanoma surgeon to develop PCR-based methods to detct this very mutation (which was at the time erroneously referred to as the V599E mutation) that results in activation of the BRAF protooncogene, but it’s been five years since I have done any work in this area. In any case, it is gratifying to see that others have developed drugs that target these activating mutations.
Melanoma, for those unfamiliar with the disease, is a cancer that develops in melanocytes, the pigmented cells in the skin. It is highly curable when it is caught early, because surgical excision and sampling of the regional lymph node basins is highly effective. It can even occasionally be controlled in the metastatic setting, resulting in long term survival, if the metastasis can be completely excised surgically. However, once melanoma is stage IV and metastatic to multiple sites or to a site (or sites) from which the tumor cannot be surgically resected, melanoma is incurable. Worse, it’s notoriously resistant to chemotherapy. The very best standard of care chemotherapy regimens include dacarbazine or temozolomide, the former of which is usually first line therapy and the latter of which is sometimes preferred because it can be given orally. Neither work very well.
So in melanoma basically what we have is a disease that is incurable and fatal when it reaches stage IV and for which, unlike the case with, for example, colorectal cancer, there is no good therapy that can markedly prolong survival. Enter PLX4032. PLX4032 is remarkable because it is a targeted agent directed at the V600E BRAF mutation that, in phase I trials, demonstrated significant activity against melanomas harboring that mutation. Since V600E is a common mutation in melanoma, being present in around 50-60% of tumors, that means more than half of patients with metastatic melanoma could potentially benefit from the drug. What do I mean by “significant” activity? In a multicenter dose-escalation phase I trial whose results were recently reported in the New England Journal of Medicine and the press, 81% of patients with V600E mutations showed tumor shrinkage of at least 30%. Moreover, side effects were not prohibitive, with cutaneous (skin) side effects, fatigue, and arthralgias (joint pain) predominating. The worst potential side effect was squamous cell carcinoma of the skin.
These results are quite impressive for a phase I study. Remember that phase I trials are not designed to detect efficacy; they are safety studies. The idea is to increase the dose in humans until dose-limiting toxicities are encountered. If tumor responses are seen, so much the better. Typically, less than 25% of subjects in a phase I trial will demonstrate measurable tumor shrinkage, making 81% very impressive indeed. Moreover, among subjects receiving the drug, the estimated median progression-free survival (PFS) has been 7 months, compared to historical controls of around 2 months. The duration of these responses was on the order of 8 months, which means that the tumors did nearly all start growing again, but, even so, this is far better than the standard of care chemotherapy for metastatic melanoma, dacarbazine, which only slowed tumor growth in 15 percent of patients for an average of two months. Of course, the results of this phase I trial are no guarantee that the apparent increase in PFS (which may or may not be real, given that there is no control arm in a phase I trial) will translate into an increase in overall survival (OS) — remember Avastin — but it is very promising, which is why this new clinical trial was begun. Indeed, I view PLX4032 as a prime example of SBM at work, starting with a basic science observation (many melanomas harbor BRAF mutations that drive their growth) and using that basic science to develop a therapy, ultimately bringing that therapy to clinic.
So here’s the question. Given the result of this phase I trial, is there truly clinical equipoise regarding PLX4032 in melanoma that has the V600E BRAF mutation? It’s not an easy question, and some physicians come down on either side of the issue, as discussed in the NYT article. First, the side arguing that drugs like PLX4032 are challenging our current cancer clinical trial paradigm:
But critics of the trials argue that the new science behind the drugs has eclipsed the old rules — and ethics — of testing them. They say that in some cases, drugs under development, PLX4032 among them, may be so much more effective than their predecessors that putting half the potential beneficiaries into a control group, and delaying access to the drug to thousands of other patients, causes needless suffering.
“With chemotherapy, you’re subjecting patients to a toxic treatment, and the response rates are much lower, so it’s important to answer ‘Are you really helping the patient?’ ” said Dr. Charles L. Sawyers, chairman of human oncology at Sloan-Kettering. “But with these drugs that have minimal side effects and dramatic response rates, where we understand the biology, I wonder, why do we have to be so rigorous? This could be one of those defining cases that says, ‘Look, our system has to change.’”
But does it? On the other side:
Defenders of controlled trials say they are crucial in determining whether a drug really does extend life more than competing treatments. Without the hard proof the trials can provide, doctors are left to prescribe unsubstantiated hope — and an overstretched health care system is left to pay for it. In melanoma, in particular, no drug that looked promising in early trials had ever turned out to prolong lives.
PLX4032 shrinks tumors in the right patients, for a limited time. But would those who took it live longer? No one knew for sure.
“I think we have to prove it,” said Dr. Paul B. Chapman, a medical oncologist at Memorial Sloan-Kettering Cancer Center who is leading the trial. “I think we have to show that we’re actually helping people in the long run.”
Both are powerful arguments. On the one hand, if drugs like PLX4032 really are far and away more effective than previous generations of experimental drugs in the pipeline to market, then rigidly sticking to the old system has the potential to result in the loss of potentially savable lives and in increased suffering that could potentially have been ameliorated. However, we have been fooled before. Drugs that look highly promising in preliminary studies have ultimately fizzled, and increases in response rates and even increases in PFS have not always translated into increases in OS. Again, remember Avastin. Then, as was suitably mentioned in the NYT article, there is the cautionary example of bone marrow transplantation for advanced breast cancer, which during the 1990s was thought to prolong survival. As a result, both physicians and patient advocacy groups lobbied, using their political muscle to persuade health insurance companies to pay for bone marrow transplants for breast cancer. However, when the careful clinical trials were done, it was found that bone marrow transplantation was no more efficacious than high dose chemotherapy and that it caused death in some cases. The history of cancer research is littered with drugs that appeared efficacious in early clinical trials and then failed when subjected to more rigorous testing. How do we know that PLX4032 isn’t one of those drugs?
We don’t. Clinical trials are how we figure out the answer to that question:
“My goal,” Dr. Chapman shot back, “is to find out as quickly as possible in as few patients as possible whether this works. If we never know, then we’re never going to be able to build on anything.”
One of the melanoma field’s senior clinicians, Dr. Chapman had lived through trial after trial of drugs that failed to live up to early promise. Almost every oncologist knew, too, of a case nearly 20 years earlier when bone marrow transplants appeared so effective that breast cancer patients demanded their immediate approval, only to learn through a controlled trial that the transplants were less effective than chemotherapy and in some cases caused death.
“Making patients’ tumors go away is gratifying,” Dr. Chapman told critics. “But that’s not the business I’m in. I’m in the business of making people live longer. That’s what I want to do.”
Which brings us back to the whole debate on whether PFS in the absence of OS is reason enough to approve a new anticancer drug, the very same question faced for Avastin. Again, we have no idea that PLX4032 even prolongs OS compared to the standard of care, although we do have an indication that it does prolong PFS. On the other hand, PLX4032 has considerably less toxicity than dacarbazine, meaning that the potential to cause harm would seem to be less, at least from what we know now. All of this leads to a critical question: Is a phase I trial with stellar results enough to claim that there is not equipoise between PLX4032 and the standard of care? Add to that information in the NYT article that describes the “Lazarus” effect observed in some patients who were clearly weeks or even days from death could get off of oxygen and out of bed after placed on PLX4032, sometimes even for months. Is this all enough information to destroy clinical equipoise for this drug and make performing a randomized trial against standard of care unethical?
One thing that puzzled me initially is why the design for this trial was chosen. It’s a straightforward open label randomized trial comparing PLX4032 against dacarbazine that does not allow patients in the dacarbazine arm to cross over if they are receiving no benefit. Originally, the principal investigator of the current trial wanted to do a test of PLX4032 versus standard of care in only the sickest patients. If, reasoned Dr. Paul Chapman, the drug did indeed show this “Lazarus effect” in some patients, it would be justification to get it approved as rapidly as possible, even before evidence of improvements in OS were shown. On the other hand, it appears that the drug company (Roche) feared that such a trial would only provide justification for approval for PLX4032 only in that small group of the sickest patients. It wanted approval for the widest indications possible, which requires a large, phase III randomized clinical trial.
In other words, economics appears to have trumped science and ethics. The best design from an ethical standpoint, one that would also be scientifically strong, would have been to do a randomized trial of dacarbazine plus or minus PLX4032. One group would receive dacarbazine plus placebo; the other dacarbazine plus PLX4032. Both groups would be receiving the standard of care, and there would still be genuine uncertainty whether the combination is better than dacarbazine alone. This is how clinical trials testing many new anticancer drugs are performed these days. Because clinical equipoise would tell us that testing a new anticancer drug versus placebo would be unethical in most cases, the two choices left are to test a new drug either against standard of care or added to standard of care. In addition, for trials in which clinical equipoise is not as clear as it should be, in general there is a built-in planned interim analysis of PFS and OS, wherein the trial is stopped if one group is doing significantly more poorly than the other group to the point where the results are so clear-cut that statistically there is no way that the addition of the remaining patients could change the results. In addition, often patients are allowed to cross over to the other group if after a certain period of time they are receiving no benefits. This can go both ways, either control crossing over to experimental drug or those receiving experimental drug crossing over to the control group. Such a design makes the analysis of the data harder to do, but it does mitigate some of the ethical concerns. Unfortunately, in this case, the investigators chose clarity rather than allowing patients to cross over.
Interestingly enough, it is the basic scientists who are most in favor of the contention that this drug should be more widely available:
Some of the strongest criticism came from laboratory researchers who study the biology of the disease and see the drug as fundamentally different from its predecessors. The previous red herrings, they argued, never had such a high response rate. Few other drugs had shrunk tumors in as high a percentage of patients with melanoma or any other solid tumor as PLX4032 had in its first human trial.
“Many of my colleagues who are outstanding clinical investigators have been able to convince themselves that this is a fair thing to do,” Dr. David E. Fisher, a leading melanoma biologist at Massachusetts General, said of the controlled trial. “My personal view is it’s nuts. I don’t know anyone who hasn’t shuddered at the concept that we can’t let patients on the control arm cross over because we need them to die earlier to prove this point.”
Quite frankly, even though I am a staunch advocate of science-based medicine, I, too, shudder at this design. On the other hand, the basic scientists seem rather cavalier to me in their belief that improvements in response and PFS will translate into improvements in OS. After all, even though the toxicities observed in the phase I trial were relatively mild, one of them was squamous cell carcinoma. As promising as PLX4032 is, there is still power to the argument that we can’t know for sure if it is superior unless we actually do the careful clinical trial, keeping the failures of promising treatments of the past in mind.
In oncology clinical trials, as in clinical trials for treatments of any life-threatening disease, there is always a tension between wanting the “cleanest” possible results versus doing the best for each individual patient. It is a balancing act that relies on the ethics of physicians and a combination of hope and altruism in the patients who become subjects in such trials. Both patients and physicians want the drugs being tested to work, but in some cases clinical trials are very much, to invoke my Star Trek geek tendencies, a case where the good of the many is weighed against the good of the few — or the one — with the balancing of these factors done using knowledge with huge gaps in it. How to maximize the good for as many patients as possible is the goal, but, as we have seen, this is a goal that is not so easily accomplished, just as clinical equipoise is a concept that is easily stated but not so easily applied. PLX4032 teaches us that.

100% Cure Rate Is Hard to Believe
Harriet Hall on July 12, 2022
Link

An experimental cancer drug made 100% of rectal cancers disappear in a small trial, allowing subjects to avoid the standard treatment of chemotherapy and surgery . “Some scientists say these kinds of results have never been seen in the history of cancer research.” 100% is hard to believe; the 95% confidence interval was 74 to 100. Whatever the true percentage, if this study is confirmed, it may represent a real game-changer, a revolution in cancer therapy at least for some patients.
Standard treatment
Locally advanced rectal cancer is typically managed with a combination of adjuvant chemotherapy and radiation followed by surgery. Only a quarter of patients have a complete response, and the side effects and complications can be devastating. A substantial percentage of patients develop bowel, urinary, and sexual dysfunction; infertility; and altered quality of life. Resection of the rectum often involves a permanent colostomy. Some patients have been unable to leave home for decades because of fecal incontinence and shame. A non-surgical treatment would be life-altering for these patients. The new trial appears to show that 100% of them can be cured without surgery. 
Mismatch repair deficiency
Up to 10% of rectal adenocarcinomas are mismatch-repair deficient and respond poorly to standard treatment regimens. They have mutations in genes that would normally correct mistakes made when DNA is copied in a cell. Immune checkpoint blockade has been shown to be a highly effective first-line treatment for cancers with mismatch repair deficiency. On the basis of benefits seen in metastatic disease, the authors of the new study hypothesized that single-agent programmed death1 (PD-1) blockade might be beneficial for patients with mismatch-repair-deficient locally advanced rectal cancer. They found that it was beneficial beyond their wildest dreams.
Study design and results
This was a small study published in The New England Journal of Medicine on June 23, 2022; the planned enrollment was 30 patients, but only 12 patients had completed the protocol at the time of publication. It was a small prospective single-group phase 2 study. Dostarlimab (brand name Jemperli) is a monoclonal antibody that was granted accelerated approval in April, 2021 for adults with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
Subjects were given IV doses of 500 mg dostarlimab every 3 weeks for 6 months. The plan was to follow this with radiation, chemotherapy, and surgery; but patients who had a complete clinical response did not require further treatment. Only a complete clinical response could be evaluated; evaluation of a complete pathological response was impossible without surgery. All of the subjects in the trial had a complete clinical response. There was no recurrence of disease during a median follow-up time of 12 months; surveillance is ongoing. Adverse events were common, but none were serious events classified as grade 3 or higher. Therapeutic responses were rapid; symptoms resolved within 9 weeks in 81% of patients.


It’s not cheap
The price of one dose is over $11,000. Still, considering the savings in human suffering and the financial costs of standard treatment, it might turn out to be a bargain.
Conclusion: very encouraging but will require more study 
I still find it hard to believe the reported cure rate of 100%. But I am cautiously optimistic and look forward to further studies. This is a new non-operative approach to treatment of a subgroup of rectal cancer patients, and it might be applicable to as many as 4-5% of all cancer patients. It may represent a real revolution in cancer treatment.


Double standards in hematology for integrative and complementary medicine: a case study
In this post I discuss several yoga studies that were presented to a gathering of some of the world’s best MPN researchers and clinicians. They illustrate an apparent double standard in hematological cancer research, which allows integrative and complementary treatments to skip over the normally high rigor and standards typical of the sub-specialty.
Jesse Luke on August 3, 2018
Link

The practice of integrative medicine, the use of alternative medicine along with evidenced-based medicine, has infiltrated patient care in many institutions in recent years. This is of major concern for many reasons, but the most important is that the vast majority of these “interventions” are not based on scientific evidence or thought, and some claims violate basic scientific laws of physics or chemistry. In addition, many components of evidenced-based medicine, such as the importance of diet and exercise, have been re-branded as integrative or complementary care. No specialty or clinical focus of medicine appears to be immune, and at a hematology conference (10th International Congress on Myeloproliferative Neoplasms and Chronic Myeloid Leukemia) last fall this was further impressed upon me by a presentation by Ruben Mesa, MD. It was strikingly obvious and disconcerting that the “complementary” approaches were excused from the strict scientific rigor and level of evidence typical of modern scholarship in hematology. 
Before delving into details, I wish to make clear that I do not consider Dr. Mesa, currently the director of UT Health Cancer Center San Antonio, to be a quack or health fraudster. He is in fact quite well respected in the myeloproliferative neoplasm (MPN) community and has helped contribute to collective medical knowledge, including work that helped lead to the approval of the first JAK2 (Janus Kinase) inhibitor, ruxlitonib. A good amount of his most recent work focuses on quality-of-life (QOL) issues; in MPNs these can be significant, as I know this first-hand. Long time readers may remember that I have been dealing with a MPN myself, a type of hematological cancer that (in very simple terms) results in excessive proliferation in red cells, platelets, and/or most white cells. Research into QOL issues is certainly a noble and respectful pursuit, but there is a downside – frequent exposure to patient suffering and the search for solutions can lead to desperation; this in turn often leads to credulity and thus sub-par research. The three “Non-pharmacological complimentary [sic] approaches” he presents are diet (nothing strange, not complementary); Acceptance and Commitment therapy (ACT), a third wave cognitive behavioral therapy drawing heavily from behaviorism, a bit strange but psychotherapy is not CAM either; and most specifically, yoga. I’ll examine yoga in detail for readers.
Yoga
Yoga refers to a wide range of mystical beliefs and practices (built on top of and with many others) that range from very old to very new that had goals ranging from gaining invincibility in warriors to attaining Moksha (exemption to reincarnation) by the priestly classes.1 The yoga of current popular thought and practice, which I will discuss today, is about 100-150 years old. It was brought to the West due to the efforts of a few advocates; esoteric groups like the Theosophical Society, proponents of New Thought and New Age practices that sought to merge with other metaphysical concepts of healing. I term this post-Esalen medicine, after the center that had a tremendous effect on disseminating New Age, traditional, and “spiritual” ideas about health to the public.
With that in mind, it is quite clear that Western yoga is not the ancient wisdom-filled panacea that proponents push as an almost essential tool on an individual’s journey to “wellness” through “self-care”. In reality, outside of biased narratives, the modern practice appears to be little more than appropriation of religious and cultural practices, modified and diluted in the name of profits or other self-serving interests, with no regard to the historic, societal, or scientific reality.
Once the spiritual trappings are removed it is simply a form of exercise, a very complicated stretching and breathing regimen, but still exercise (theologians can debate whether it’s still yoga). Exercise is a vital part of health and has always been a part of care in real medicine, there’s nothing strange about it once baseless metaphysical claims are removed. The danger is that it is not taught or promoted this way. I am not recommending against exercise, any physical activity is healthier than none, and, if you can separate the metaphysics from the exercise I will even go as far as saying yoga is fine. The question now is, why is it being treated differently from other exercise, and can it actually “treat” anything? Let’s evaluate the evidence.
There are only a few articles on yoga in MPNs but Dr. Mesa is listed on most I could find. These articles examine the use of “online-streamed yoga” for symptom management, one specifically for fatigue and general QOL. We’ll look at a single-arm and a subsequent controlled study.2, 3, 4, 5 There are a plethora of problems with these, so many in fact that I’m doubtful Blood or Haematologica would have even passed them to peer-review, let alone publish, if they were on a less trendy topic.
Patients were selected through the internet through methods that employed avenues like social media, forums, and patient groups. Though recruiting in this way is not inherently bad, it can lead to the recruitment of people interested in the popular “Indo-chic” practice of yoga out of a fascination with the Eastern exotic (the authors admit to this recruitment limitation). In what seems to be a result of this, the participants fit well into the most typical CAM user demographic: middle-aged married white women with an undergraduate degree or higher (this also implies more disposable income). So with the exotic fascination combined with the ideal demographic group it shouldn’t come as a surprise that in the single-arm study3 (n= 55, 38 or 69% completed 12-week intervention) there was significant improvement in symptoms including sleep, fatigue, anxiety, and anxiety (of note is the fact patients with diagnosed mood disorders like depression and anxiety were ineligible for the study). Yet despite this only 13 subjects said they would continue with the intervention and only an anemic 37% of subjects completed intervention as prescribed (this is self-reported so very likely lower; patients lie) which was defined as 60 minutes or greater a week, which works out to only 8.57 minutes a day. Most importantly, “There were no significant differences in outcomes between those that averaged = 60 min/week of yoga”. Despite the above results not justifying further resource expenditure for continued research, it was embarked upon anyway.
The controlled study2, 4 does not improve upon the single-arm in a significant way, it only further demonstrates the lack of usefulness and rigor. The recruitment method still focused on social media and patient groups, patients with mood disorders were still excluded, along with anyone that was already engaging in 150 minutes or more of physical activity a week (22 minutes per day). The subjective reporting of prescription adherence was shown to be lower than the objective measurement (but again, patients lie). Subjects were put into either the yoga group (n=27) or the control group (n=21), which was simply a wait-list. The intervention group, but not control group had blood work done at baseline and post study: a CBC (complete blood count), IL-6 (interleukin 6), and TNF-a (tumor necrosis factor alpha). The final two are inflammatory markers but to the best of my knowledge there is no proven causation that symptom burden is a direct result of their levels (the inclusion of these seems to be based off studies on inflammatory bowel disease).
The lack of testing in control subjects, the fact that the only significant change was in the levels of TNF-a with a result of -1.3 plus or minus 1.5, along with the uncertain meaning of these values seems to indicate a hollow attempt at presenting objective measures to increase credibility rather than the stated purpose of testing “blood draw feasibility”. The effect on symptom burden was reported from three online subjective self-report tools: the MPN symptom assessment form (MPN-SAF; 18 symptom questions on a 1-10 scale) as well as the MPN-SAF brief fatigue inventory (MPN-SAF fatigue; 9 fatigue related questions on a 1-10 scale), and the NIH PROMIS QOL (a single question out of 10 on the Global Health measure on QOL on a 5-1 scale). There were no significant differences at the end of the study in values of the more comprehensive surveys, the MPN-SAF and MPN-SAF fatigue. In fact, the only statistically significant result was from the NIH PROMIS scale – which is again only a single question from the 10 question global health scale. The study, as is typical in CAM or integrative medicine research, called for more research, justifying this with the QOL scale results and the reduction in TNF-a. The failure to demonstrate significant improvements was claimed to be due to not having enough subjects, specifically male subjects.The lack of willingness to entertain, let alone accept the null hypothesis in the studies examined above is obvious and disconcerting but unfortunately unsurprising. The fact that limited philanthropic funds were used to finance the studies is all the more disappointing in such a small and underfunded field.
Conclusion
For those that may think that I’m being too harsh, and that it is possible maybe Dr. Mesa was simply interested in the exercise component and his involvement in the rebranding of standard medical recommendations as integrative or complementary was accidental, I have an important counterpoint. This article in the European Medical Journal: “The SIMM study: survey of integrative medicine in myeloproliferative neoplasms”. The study touted how effective “integrative medicine interventions” were at reducing symptom burden and how many cancer patients used it, and it did show that some interventions listed were quite effective. The problem is that 7/10 of interventions, the ones that actually worked, were not alternative or integrative. The article classifies the following as integrative: aerobic activity, massage (considered supportive care in real medicine), yoga (just exercise as I already discussed), nutrition, strength training (anaerobic exercise), acupuncture, meditation, breathing exercise, “chiropractice” [sic], and support groups. Only three of these can be considered alternative or integrative: acupuncture, which is based on meta-physics and is useless beyond a placebo; chiropractic care, based on non-scientific vitalist ideas and is only of comparable efficacy to massage or paracetamol for lower back problems; and meditation, which can be alternative or not depending on how this highly variable term is used.
The rebranding of standard care and recommendations of science-based medicine is dangerous as it only serves to provide a veneer of legitimacy to the complete nonsense promoted like energy healing (violates laws of physics and was disproven by a 9 year old girl in 1998) and thereby attract new customers, because that’s all patients are to the proponents, a source of income and/or a source of undeserved praise. Once all items appropriated from genuine medical care are removed, the alternative and integrative medicine fields seem to be composed of nothing but health fraud, willful ignorance, and significant delusion, none of which belong in hematological cancer care, nor cancer care, nor medicine in general.
Citations
     1.  York M. Historical dictionary of New Age movements. Lanham, Md: Scarecrow Press; 2004.
     2.  Eckert R, Huberty J, Dueck A, Kosiorek H, Larkey L, Mesa RA. A Pilot Study of Online Yoga to Improve Fatigue and Quality of Life in Myeloproliferative Neoplasm Patients. Blood. 2017 Dec 7;130(Suppl 1):3443–3443.
     3.  Huberty J, Eckert R, Gowin K, Mitchell J, Dueck AC, Ginos BF, et al. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica. 2017 Oct 1;102(10):e384–8.
     4.  Eckert, R. Myeloproliferative Neoplasm Patients [Internet]. [cited 2018 Jul 11].
     5.  Huberty J, Eckert R, Gowin KL, Ginos B, Kosiorek HE, Dueck AC, et al. Online-Streamed Yoga As a Non-Pharmacologic Symptom Management Approach in Myeloproliferative Neoplasms. Blood. 2016 Dec 2;128(22):5478–5478.

A miracle cancer prevention and treatment? Not necessarily as the analysis of 26 articles by legendary Hans Eysenck shows.
A recent investigation at King’s College London has revealed major problems in the scientific career of one of psychology’s most published scientists, Hans Eysenck.
Tomasz Witkowski on January 31, 2020
Link

[Editor’s note: Though limitations in WordPress force us to attribute this article solely to returning author Tomasz Witkowski, it was written and submitted by both Dr. Witkowski and his colleague Maciej Zatonski, whose books have been favorably reviewed by Harriet. Welcome back!]
It is currently estimated that at least one in four readers of this article will die of cancer. This rather simple statistic leads rational readers to consider such cause of their death as quite likely. As a result, some of us will make conscious efforts to follow certain lifestyle that could potentially minimize the above risk. The fact is that we are not able to influence the vast majority of known factors that contribute to our individual risks of developing cancer, not mentioning the causes that still remain unknown. Despite the progress made in medical oncology in the last two decades, many of us will receive a death sentence long before it will be actually carried out. Unlucky diagnosis of certain malignancies, or other currently untreatable and unmanageable conditions, can constitute such a sentence for many of us. In such moments, support that we receive from those that surround us is of exceptional importance. Some of us consider doctors to be oracles, and we can often be inclined to perceive capabilities of physicians as superhuman; at the right moment, a nurse can transform into an angel of hope.
In such life and death circumstances, psychologists – as people thought to be able to soothe the souls of the afflicted and fuel their hearts with positivity – become the bearers of hope for the sick, as well as their families. Many psychologists have dedicated their entire careers to helping people diagnosed with cancer. They have even developed a new field of expertise that deals with topics such as the links between cancer progression and psychological factors. This emerging discipline is called “psycho-oncology”. It is defined as an interdisciplinary field at the intersection of physical, psychological, social, and behavioral aspects of the cancer experience. It researches emotional reactions of patients at various stages of cancer progression, including emotional impact on patients’ families and on the medical personnel engaged with them. Psycho-oncological “knowledge” is applied to help patients in an appropriate manner depending on the treatment phase and/or stage of the disease. The main forms of aid are: psycho-education, support, attitude changing, and “debunking” of myths associated with cancer. This is achieved using methods and techniques applied in psychotherapy.
Although many prominent scholars practice and research psycho-oncology, the field is contaminated with suspicious pseudo-scientific constructs, claims made by self-appointed gurus, and fraudulent (as recently proven) research results coming from the most distinguished scientists.
Enter Hans Eysenck and Ronald Grossarth-Maticek
In May 2019 a report from an internal enquiry conducted by the King’s College London (KCL) was released. This report diplomatically labels 26 articles published by Professor Hans Jürgen Eysenck as “unsafe” (the list attached to the report contains only 25 articles). Eysenck was one of the most renowned and influential psychologists of all time. When he died in 1997, he was the most cited living psychologist and the third-most cited of all time, just behind Sigmund Freud and Jean Piaget. In the global rating of most cited scholars across all social sciences Eysenck ranked third, following only Sigmund Freud and Karl Marx. Up to this very day it is difficult to find a ranking where Eysenck does not hold one of the podium places.
The report published by the KCL committee scrutinised only articles from peer-reviewed journals that Eysenck co-authored with Ronald Grossarth-Maticek, and analysed data relevant to personality and physical health outcomes in conditions like cancer, cardiovascular diseases, their causes and methods of treatment. All of reviewed research results were assessed as “unsafe”. In their publications both authors claimed no causal connection between tobacco smoking and development of cancer or coronary heart disease, and attributed those outcomes to personality factors, as described by James Coyne in Science Based Medicine. In one of their research projects conducted among more than 3,000 people, Eysneck and Grossarth-Maticek have claimed that people with a “cancer-prone personality” were 121 times more likely to die of the disease than patients without such a disposition (38.5% vs 0.3% ).
The authors have also contributed personality factors to the risk of developing coronary heart disease. Their publications stated that subjects who were “heart-disease prone” died 27 times more often than people without such temperament. The cancer-prone personality was described as generally passive in the face of stress from external sources. Those who were heart disease-prone were unable to leave from an unsatisfactory situation by themselves, which in turn made them increasingly violent and hostile. In contrast, a “healthy” personality was autonomous, with a positive outlook on life and its challenges.
Those completely improbable results were quickly adapted by the psychological community to justify interventions that are, in best-case scenarios, ineffective. In the world of clinical medicine, oncologists are rarely familiar with all tools used by psychologists. Doctors assume that supplementary psychological services, often well embedded in hospitals, use methods of similar quality tested with similar scrutiny as the therapies found in mainstream medicine.
The greatest hits in the album of suspicious publications are articles where the authors “demonstrated” that they can effectively “prevent cancer and coronary heart disease in disease-prone probands”. In one of their projects, 600 “disease-prone probands” received a leaflet explaining how to make more autonomous decisions and how to take control over their destinies. This simple intervention resulted in one of the most spectacular findings in the history of medicine, psychology, and probably in the entire scientific literature. After over 13 years of observation, the group of 600 patients randomly assigned to this “bibliotherapy” (as it was called by the authors) had an overall mortality of 32% when compared to 82% among the 600 people who were not lucky enough to receive the leaflets. Surely those findings, published in 1991, must have revolutionised medical oncology…or at least cause a significant consternation.
It is difficult even to estimate the real costs of services provided by “psycho-oncologists” that have no validity nor clinical justification. To make things more difficult, those interventions are often mixed into a wider offering that includes more validated methods (like CBT for anxiety related to diagnosis of cancer). It is easy however, to imagine how it might cause unnecessary suffering to people diagnosed with a terminal condition, especially when patients are told that the disease is the result of who they are or what they believe in. The impact might be exacerbated once patients realise how difficult it might be to do anything about it. Common sense suggests that assigning blame for being diagnosed with cancer to patients’ convictions or beliefs does not feel therapeutic. And after the KCL report, we know why it feels like that: it’s simply not true.
Why has this stood unchallenged for so long?
Why are those made up and improbable results repeated, quoted, and implemented in hospitals around the world? Because they claim extraordinary results at virtually no cost (apart from hefty prices of experts involved in giving away ineffective leaflets). There might be another reason – a dependency created between a psychologist and a vulnerable patient, which later fuels the need for further interactions: a self-sustaining loop of demand for services designed to solve only the problems it created. Significant sums of money often follow the newly created, yet unnecessary, needs. Are there better ways to spend limited healthcare budgets? We leave the answer to the readers. One thing we know for sure – Eysenck appeared to have quite robust business intuitions, as we will show in later in the article.
Eysenck’s uneven research history
The report published by the King’s College London fuelled yet another stormy debate among academics. We are not dealing here with a case of a junior academic at the starting line of his scientific career, as in the 2013 case of Diedrik Stapel’s frauds. This time we are talking about one of the founding fathers of psychology, someone whose contribution to the field can only be matched by less than a dozen of titans of social sciences. But similarly, as in all other announcements of scandalous frauds in psychology, the scientists confronted with new facts appear to be perplexed. Are there any foundations for their confusion?
Eysenck built his academic credentials primarily around a dimensional model of personality that he authored. The model was based on factor-analytic summaries rooted deeply in our biological predispositions. This model withstood the test of time, mostly due to multiple research findings that validated his model’s predictive validity. Generations of psychologists “diagnosed” their patients using Eysenck’s personality questionnaires. Nowadays the model has been updated, but its core elements still form the basis of the so-called Big Five (the name given to the world’s most popular concept of personality). Eysenck played a crucial role in establishing the field of clinical psychology in the United Kingdom, relentlessly promoting novel, much more efficacious behavioural therapies, as opposed to traditional psychoanalytical approaches.
Eysenck’s fame however was densely intertwined with controversies, such as his surprising defense of Sir Cyril Burt – a discredited psychologist who falsified or entirely made up the majority of his research results, including the names of his non-existing co-authors. Eysenck could have been blinded by his loyalty to Burt, the first knighted psychologist for his contributions to science. After all, it was Burt, who as Eysenck’s long-standing mentor, helped him to jump in the deep end of the pool of social sciences.
However, we can’t play the loyalty card when we try to explain Eysenck’s quite peculiar beliefs in parapsychology and astrology. His convictions can be only described as naïve, since the parapsychological experiments that he often quoted to prove the existence of the paranormal were always flawed with obvious methodological infractions, and none of them were ever replicated. James Randi – the stage magician and famous sceptical thinker – has accurately noted that Eysenck was supporting and backing deceitful clairvoyants and fortune tellers, promoting them as authentic and never criticising, or even mentioning, the deceitful methods that they use. In 1977 Eysenck started to write an article in support of the absurd and wildly nonsensical Mars effect proposed by a French psychologist and astrologer Michel Gauquelin. The article was devoted to a purported statistical correlation between athletic eminence of the positioning of the planet Mars relative to the horizon at the time and place of birth.
Eysenck’s set of beliefs was largely ignored, probably in the same way we tolerate certain eccentric quirks of the senior people that we respect. Unfortunately, not all of that crankiness was harmless. The Psychology of Politics turned out to be a very controversial book. Eysenck suggested that political behaviours may be analysed in terms of two separate and independent dimensions: traditional distinctions between the left and the right, and how “tenderminded” or “toughminded” a person is. The research that formed the foundation for his book was widely criticised on a number of grounds, including emphasising that his findings could not be extrapolated to the entire British middle class, because his sample was formed primarily from far younger and better educated people. Furthermore, supporters of various political parties were unreliably recruited in inconsistent ways: communists were enrolled through party branches, fascists in non-specified ways, and supporters of other parties through questionnaires distributed by Eysenck’s students to their friends. He has later compared the answers from 250 middle-class supporters of the Liberal Party with 27 answers from liberal working-class representatives. As a cherry on the top of this methodological blunder, he rounded up the scores in a way that would support his hypotheses. Other, similar controversies could fill another few paragraphs.
However, the most destructive and infamous of his achievements was the publication of the book entitled The Causes and Effects of Smoking in 1980, where he condemned the already established causal relationship between tobacco smoking and lung cancer. His later cooperation with Ronald Grossarth-Maticek resulted in the publication of numerous articles that were recently assessed as “unsafe”. The irregularities uncovered during preparation of the KCL’s report appalled and shocked the global scientific community.
The first methodological cavils in the works of Grossarth-Maticek were raised as early as 1985 by David Gilbert in his letter directed to Hans Eysenck. What is even more remarkable is that Gilbert worked for the R.J. Reynolds Tobacco Company at the time when he pointed out his concerns to Eysenck. It wasn’t until late 1980s before more serious allegations were formed against Eysenck-Grossarth duo. In 1991 the Psychological Inquiry devoted an entire issue to the works of the two authors. Leading authorities in psycho-oncology and medical statistics described their concerns, concentrated mainly around two issues. The first related to the accuracy of the data due to the recruitment strategies, reliability of measurements, and other errors in data collection. Second was the lack of credibility of the results, which often showed unprecedented outcomes, unseen in other similarly conducted experiments. Their results did not fit in any meaningful way into then-current clinical knowledge or to up-to-date achievements and advances in aetiology of cancers and other medical conditions.
Those concerns were collected and presented jointly one more time in 1993 by the psychiatrists Anthony Pelosi and Louise Appleby from Priory Hospital in Glasgow. A few attempts to replicate Eysenck and Grossarth-Maticek experiments were also undertaken in 1996 and 1997. The replication attempts did not confirm the original findings.
Curiously enough, the fact that escaped the majority’s attention was that Grossarth-Maticek claimed his affiliation to King’s College, while never having actually worked there. He was employed at the University of Heidelberg. The Institute of Psychiatry at KCL employed only Eysenck.
Following the money…to cancer
Let’s take a closer look at Eysenck’s already-mentioned “business” intuitions. Suspicions raised with regard to accuracy and honesty of the research conducted by Eysenck were flagged not only by the scientific community. In 1996, The Independent published an article uncovering payments made by a clandestine American tobacco fund and other the largest tobacco manufacturers to Eysenck in excess of £800,000 (worth approximately $1.3 million USD at 1996 exchange rates). The secretive fund, known as Special Account Number 4, released millions of dollars to mostly American scientists who were carefully chosen by tobacco industry lawyers because their research results could be used to protect tobacco companies from claims raised by victims of tobacco-related lung cancers.
In his response to those revelations, Eysenck stated that he has never heard of the Special Account Number 4. He could not also recall from where the millions of British pounds for his research came. When asked directly about his opinion about his engagement with the tobacco industry lawyers in the process of selecting and screening academics to lead research projects, he responded briefly: “As long as somebody pays for the research, I don’t care who it is”. He also stated that it is the quality of the research that matters, not the funding source and later added that he had never used the above-mentioned funds. The documents uncovered during court trials revealed that Eysenck was one of the key beneficiaries of tobacco industry in Great Britain and that Special Account Number 4 granted him an additional special financial award for so called “consultations”. The medical consequences caused by defending the tobacco industry and denying the link between smoking and lung cancer are yet difficult to estimate. Lung cancer killed at least 1.5 million people in 2012 alone. As this condition is predominantly related to tobacco smoking, and usually develops over decades, there is no reliable way to estimate how much damage could have been caused by delaying the introduction of antismoking policies by even one year. It is also easy to imagine that some individuals could delay (or even completely abandon) the idea of quitting smoking when shown with leaflet that postulated that they have no or low risk of developing lung cancer, because their “healthy” personality.
Despite all these controversies, nobody took any actions to retract the research articles published by the Eysenck-Grossarth-Maticek duo. Apparently, allegations as described above are not sufficient to warrant any decisive actions amongst the scientific community – at least not when dealing with a legend. And it probably wouldn’t have led to anything if it wasn’t for Anthony Pelosi, who published an article in the Journal of Health Psychology in February 2019 calling out Eysenck’s case “one of the worst scientific scandals of all time”. As it turns out, it was not easy to publish his article. Pelosi had written his paper three years earlier upon receiving an invitation to write an article for the Personality and Individual journal, established by…Eysenck himself. When Pelosi submitted his paper to the journal it was immediately rejected, taking him three years to find a publisher that would accept the manuscript.
Pelosi’s article was accompanied by an open letter to King’s College London written by David Marks, the editor-in-chief of the Journal of Health Psychology, where he appealed to the KCL and the British Psychological Society (BSP) to conduct an official investigation and requesting retracting, or at the very least correcting, 61 publications, including over 40 articles, 10 book chapters and 2 books – both issued three time.
Fabrications and investigations
Following the open, public requests KCL initiated an enquiry into only one-third of the publications requested to be reviewed by Marks. The reviewed papers were diplomatically described as “unsafe” in the report that was released upon the completion of the investigation. The enquiry was focused exclusively on the publications of authors who reported the Institute of Psychiatry as their affiliated employer at the time of publication. Since Eysenck has completed his collaboration with the Institute in 1983, all of his works published after that date were not included in the enquiry. The British Psychological Society has responded to the open letter and refused to conduct an independent enquiry, pushing the responsibility back to the universities.
When in the 1970s the fraudulent practices of Sir Cyril Burt, who was Eysenck’s mentor, were finally and incontrovertibly proven, it appeared to be an unprecedented case in the history of psychology. The scope and panache of Burt’s fabrications of research results, his bravado and arrogance (Burt would copy his made up numbers in subsequent publications with accuracy to 2 decimal places), and his sense of impunity (he made up non-existent co-authors of his articles), were so shocking that it seemed nobody would feel brave enough to repeat such manipulations and cover-ups in the future. Especially when we take into account the fact that Burt operated in times where verification of certain facts, which today takes no more than few hours, would then require many weeks of phone calls, letters, long journeys, repeated visits to archives, etc.
Unfortunately, we did not have to wait very long for another scandal. Apart from few minor psychological fraudsters who are being uncovered every few years, Burt was finally dethroned “nobbily” by a Dutch social psychologist Deidrik Stapel in 2013. At least 58 of his articles turned out to be falsified and subsequently retracted. Since then, frauds committed by Dirk Smeester and Lawrence Sanna were revealed. We’ve also learned of falsified research papers of yet another German psychologist working in Amsterdam – Jens Förster, and an American psychologist Brad Bushman. The scandals did not spare even the best universities in the world. Sandra Lozano was fabricating results of her research in the walls of Stanford University, while Marc Hauser was making up his numbers at the heart of Harvard. Last year the world was shocked when Philip Zimbardo’s forgeries of his famous Stanford prison experiment were exposed. This counting rhyme is obviously non-exhaustive and could be continued for much longer. Today we are focusing however only on frauds committed by one of the most notable, prominent and distinguished academics in the history of the psychology. Since the British Psychological Society refused to investigate the allegations of Pelosi and Marks that 61 publications must be retracted, we are unlikely to witness (at least not very soon) Hans Eysenk to drop from the list of most cited psychologists, despite him having high chances to dethrone the current King of Scientific Fraudsters Diederik Stapel with 58 publications retracted. When analysing this case, we must not forget that those particular accusations are aimed at only a fraction of Eysenck’s research activities. During his extremely fertile life he managed to publish over 900 scientific articles and have over 50 books translated later into numerous foreign languages. Shouldn’t those also be verified?
After humiliating degradation and after losing his job Diedrik Stapel published a particular memoir of a fraudster, where he described a rather accurate characteristics of the academia of psychologists. He emphasises virtually complete lack of any structure of control or self-correction: “Nobody ever checked my work. They trusted me.” They will continue to trust even more once the fraudster will secure a strong position in the academic hierarchy and seal it with titles, degrees, prizes, awards and honoris causa doctorates. They will continue to claim that science has self-correcting mechanisms built into it. And the price for such misperceived and ill-understood academic freedom will be paid by members of the general public when they make everyday decisions related to smoking or when deciding to improve on their personalities, fed by misconstrued beliefs related to the development of cancer, unnecessary suffering, and premature deaths. Those damages will never be assessed.

Kidney Cancer and Incidentalomas
Kidney cancer diagnoses are increasing but there has been no increase in mortality or rate of metastases. Kidney cancer is most often diagnosed as an incidental finding on a CT scan that was done for unrelated reasons. Treatment may not always be needed.
Harriet Hall on February 12, 2019
Link

In the February 1, 2019 issue of American Family Physician, there is an editorial by H. Gilbert Welch titled “Stumbling onto Cancer: Avoiding Overdiagnosis of Renal Cell Carcinoma.” He points out that the incidence of kidney cancer has more than doubled since 1975, but “This is not an epidemic of disease, this is an epidemic of diagnosis.” It is a side effect of increased use of imaging. The majority of kidney cancers today are detected as incidental findings on a CT scan ordered for a totally unrelated reason. Areas where more CT scans are done have a higher incidence of nephrectomies.
Diagnoses of kidney cancer are indeed on the rise. It is one of the top ten cancers in the US. According to the American Cancer Society, in 2019 we can expect 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women) and 14,770 deaths from the disease (9,820 in men and 4,950 in women). The lifetime risk of developing kidney cancer is 1 in 48 men and 1 in 93 women. It can present with bloody urine, flank pain and an abdominal mass, and 20% of patients present with paraneoplastic disease (hypertension, hypercalcemia, and polycythemia). But more than 50% of patients are asymptomatic at the time of diagnosis. And 30% of patients already have metastases when they are diagnosed. Treatment is usually surgical, but some patients can be followed with active surveillance.
CT can detect 90% of renal masses and can help identify benign masses that do not require further investigation and lesions that can be monitored with active surveillance. The 5-year survival rates are 93% for localized cancers and 12% if there are distant metastases, so early detection would be expected to save lives. Unfortunately, no screening test has been shown to reduce the risk of death, and screening tests for renal cell carcinoma are not recommended except in the case of certain inherited syndromes.
This graph from the editorial shows that while the incidence of kidney cancer has doubled, there has been no change in mortality or in the incidence of metastases. The 5-year survival rate is increasing, but this is an artifact of lead time bias and overdiagnosis bias.
Welch has long been a vocal critic of injudicious screening tests. He has written several books including Overdiagnosed: Making People Sick in the Pursuit of Health, which I reviewed in 2011. He says,
Imaging – and testing in general – has real downsides, such as stumbling onto things you wish you had not.
He illustrates with a typical case from his own practice. Mr. Baker’s presenting complaint was hoarseness for six weeks. An ENT specialist found a small tumor on the vocal cord and removed it, effecting a complete cure. Somewhere along the way a chest x-ray was done that was interpreted as abnormal. Further evaluation with a chest CT scan showed no abnormality in the chest but showed a 5-cm mass in the kidney compatible with renal carcinoma. The urologist recommended the kidney be surgically removed, but Dr. Welch and Mr. Baker made a shared decision to forgo surgery and follow with repeat CT scans. Sometimes the lesion enlarged a bit, sometimes it shrank. Ten years later he died of pneumonia with both kidneys intact. Autopsy showed he did indeed have a renal carcinoma, but it had remained asymptomatic for ten years and had never spread beyond the kidney.
His editorial ends with the admonition to test wisely, weigh the risks and benefits of testing, and remember that sometimes the right thing to do is nothing.
Thyroid cancer
There is another screening test that caused an epidemic, not of disease but of overdiagnosis. Screening for thyroid cancer is not recommended in the US, but it has been aggressively pursued in South Korea, where by 2011 the incidence of thyroid cancer diagnoses had risen to 15 times the level in 1993. David Gorski has written about overdiagnosis in Japan following the Fukushima disaster and about the willful misunderstanding of overdiagnosis.
Incidentalomas
An incidentaloma is an unexpected abnormality accidentally found on medical imaging studies done for an unrelated reason. Estimates vary, but incidental findings probably occur in at least half of imaging studies. In a TedX talk, radiologist Jill Wruble said she never saw a “normal” patient; she identifies 2-3 abnormalities on every scan. Researchers are trying to develop guidelines to help clinicians decide whether a given incidental finding requires further evaluation. Meanwhile, patients and doctors worry. Pursuing a diagnosis is likely to require invasive and expensive tests, including biopsies and surgery with all their possible harms and complications, up to and including death. In my SkepDoc column in Skeptic magazine I described how an incidentaloma on a routine (and not medically indicated) chest x-ray started a sequence of events that killed my father-in-law. Scans have detected incidentalomas in my own liver and kidney that my doctors agreed did not warrant any further investigation. I am not worried, but I can imagine how medically naïve patients might worry obsessively about what was lurking in their body, particularly if they distrust the medical profession.
Conclusion: Screening tests and imaging should be used judiciously
Screening tests can save lives, but not as many as most people think. They can also lead to unnecessary treatments or initiate a diagnostic wild goose chase that can harm or even kill patients. Imaging studies are important components of the diagnostic process but they routinely detect incidentalomas, most of which we would be better off not knowing about.
To repeat what I said in my SkepDoc column, “Technology is getting away from us like the broom in The Sorcerer’s Apprentice. We need to tame that broom.”

   The Gonzalez Regimen

   The Ethics of “CAM” Trials. Gonzo (Part I)
Kimball Atwood
Link
Introduction
On Feb. 25, 2008, the federal Office for Human Research Protections (OHRP) cited Columbia University Medical Center (CUMC) for violating Title 45, Part 46 of the Code of Federal Regulations: Protection of Human Subjects (45CFR§46). The violations involved Columbia’s administration of the NIH-sponsored trial of the bizarre “Gonzalez Regimen” for treating cancer of the pancreas.† The OHRP’s determination letter to Steven Shea, MD, the Director of the Division of General Medicine and Senior Vice-Dean at CUMC, cited ethical problems of a serious kind:
We determine that the informed consent for the 40 of 62 subjects referenced by CUMC was not documented prior to the start of research activities, nor was the requirement for documentation waived by the CUMC IRB for subjects in this study.
It was the second time that the OHRP had cited Columbia for its dubious management of the “Gonzalez” trial. The first occurred in Dec. 2002, after investigators had determined that the trial’s consent form “did not list the risk of death from coffee enemas.” The OHRP listed several other violations at that time, but “redacted” them from the letter that it made available to the public.
The “Gonzalez Regimen”
The full name of the trial, which began in 1999, is:
Prospective Cohort Study of Gemcitabine Versus Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support (Gonzalez Regimen) in Patients With Stage II, III, or IV Adenocarcinoma of the Pancreas
The trial ostensibly investigates a “detoxification” regimen advocated by Nicholas Gonzalez, a physician who has been found “guilty of negligence and incompetence on more than one occasion” and has been ordered to pay large, justified malpractice settlements on others. The regimen includes pancreatic enzymes taken by mouth—which, according to the National Cancer Institute (NCI) description, “may help kill cancer cells”—and the following:
Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
Writer Michael Specter described the regimen’s oral medications for an article in the New Yorker several years ago:
The list of supplements that Gonzalez hands out to most patients with solid tumors runs to four single-spaced pages. It includes, in part, sixty freeze-dried, porcine-pancreatic enzyme pills (swallowed in six batches, all of which must be taken with water, and none of which may be taken with food or within an hour of a meal). During breakfast and dinner, each patient must swallow capsules of adrenal medulla, amino acids, bone marrow, selenium 50, thyroid, Vitamin A 10,000, and Vitamin E succinate.
There are separate pills for the lymph, liver, and kidney–all to help balance deficiencies caused by lack of enzymes, or because the body is overwhelmed fighting cancer. During lunch, each patient must take a pill with twenty-five thousand units of beta carotene, as well as pills with copper gluconate, manganese glycerophosphate, potassium citrate, and Vitamin D. Twice each day, whenever it’s convenient, patients must dilute a mixture of black-walnut formula in water and drink it. Patients who suffer from metal toxicity also need to take nine pills of sodium alginate.
In all there are about 150 pills per day. The regimen is “alternative,” not “integrative.”
An “Eccentric” Dentist
Gonzalez inherited most of this regimen and his ideas about cancer from a dentist in Texas. He frequently recounts his experience, beginning as a medical student at Cornell, interviewing
…my mentor, Dr. William Kelley, the eccentric and controversial dentist who, over a 20-year period, developed a very intensive way of treating cancer using diet, supplements, large doses of pancreatic enzymes, the controversial detoxification routines, such as coffee enemas.
[...]
I learned about Dr. Kelley in 1981, after my second year of medical school at Cornell. I was fortunate at the time that I was already kind of being taken under the wing of Robert Good, who, at that time, was president of Sloan-Kettering Cancer Institute.
[...]
I had met Kelley in the summer of 1981. Again, the details of which aren’t important for this session. At that time, he was very controversial. He was just coming off of that Steve McQueen fiasco. Steve McQueen, the actor who did Kelley’s program.
Kelley was desperate to have his work tested. This is 1981, before the NCI had an Office of Alternative Medicine, before there was a National Center for Alternative Medicine, before any of those things were up and running.
It was a very controversial time to be treating cancer patients with nutrition, particularly if you were a dentist and not a physician, so there were all kinds of legal issues involved.
When I met Kelley, he expressed one interest and one intention. Whatever’s said about him or isn’t said about him, whatever people may think or not think about him today in 2000, in 1981 he had one intention. He wanted his work properly evaluated by the orthodox medical community.
He believed he was doing something of value. He also said in our first session that if he was doing something of value it needed to be tested properly so it could be mainstreamed into orthodox medicine where any big therapy belongs. I thought that was a very noble and honorable intention, and he maintained that intent through the next 5 years.
Under Dr. Good’s direction, initially, as a medical student, but subsequently as an immunology fellow in his research group which, at that point, eventually moved to the University of South Florida, I completed an intensive investigation of Kelley’s work.
[...]
We were confronted with an alternative practitioner in 1981, who had treated literally over 10,000 patients using this nutritional program over a 20-year period. It was a mass of information.
One of the first things Kelley did for which I respect him to this day enormously, is he opened all his records to me. There were no secrets. His successes, his failures, the people that loved him, the people that wrote him hate letters, all that stuff was opened to me from the time I first started investigating his work. There were no secrets.
We were confronted with a mass of records. Half of them were in Dallas, where we had an office, half of them were in Washington state; some of them went back 25 years. At one point, he had had a fire in his house, some of his records were destroyed. And I was confronted with this enormous project that Dr. Good was encouraging me to do without the slightest idea how to do it.
[...]
It took eventually 5 years to do that. Of course, I began the study while I was a medical student, continued it extensively while I was a fourth-year medical student. I had a 4-month block of time to really get involved with this. Then during my 2-year immunology fellowship this is primarily what I did.
To the day I die, will be grateful to Dr. Good that he allowed me to do this while I was doing my immunology training. I eventually went through 10,000 of Kelley’s records, evaluated over 1,000 very intensively. By intensive evaluation, I mean, we got complete medical records. I interview all his patients, over 1,000. Of this group, we were able to select 455 that we felt at least met the initial criteria for the second part of the research study. Terrible prognosis, biopsy-proven, radiographic studies either ──── survival or tumor regression. We eventually selected that down to 50 patients that we evaluated — that I evaluated extensively. Some of these patients I interviewed 6, 8, 10 times. Some of them I actually went to their home. We got complete medical records.
I apologize for that voluminous and tedious quotation, but it amounts to a small fraction of a recurrent litany of name-dropping, euphemism, false modesty, other acts of pseudo-self-deprecation, and unfalsifiable claims.
According to Dr. Gonzalez, the result of his 5-year investigation of Kelley’s practice was a 500-page manuscript that he never published: “One Man Alone: An Investigation of Nutrition, Cancer, and William Donald Kelley.” It consisted of detailed case reports of the above-mentioned 50 patients. That manuscript, however, was examined in detail by six physician reviewers for the Congressional Office of Technology Assessment (OTA), as reported in 1990. The OTA reviewers found that
In all cases,…documentation presented in the manuscript was inadequate to confirm critical details of the narrative, and in many cases, it appeared that critical pieces of information did not exist in the medical record at all (e.g., confirmation of metastatic disease), mainly because the patients had not been followed up with tests and scans to determine the status of their disease.
The OTA’s assessment of both Kelley’s regimen and the similar regimen of Max Gerson did not suggest real evidence of efficacy.
Dr. Gonzalez’s CV reveals that he spent much of his 4th year of medical school pursuing his interest in Kelley, and that his postgraduate clinical training consisted solely of an internship (1 year) in internal medicine at Vanderbilt. Above, he admits to having spent most of his ”2-year immunology fellowship” poring over Kelley’s records and writing his manuscript. Thus Dr. Gonzalez’s implicit claims to clinical expertise in general, to specific expertise in oncology, and to expertise in conducting clinical trials are unwarranted.
Or maybe just a Garden-Variety Quack
It is instructive to compare Dr. Gonzalez’s statements about Kelley to statements written by two veteran and savvy health fraud investigators, Stephen Barrett, MD, the acerbic founder and editor of Quackwatch, and his frequent co-author, the late hematologist and nutritionist Victor Herbert, MD, JD:
In the 1960s, William Donald Kelley, D.D.S., developed a program for cancer patients that involved dietary measures, vitamin and enzyme supplements, and computerized “metabolic typing.” Kelley classified people as “sympathetic dominant,” “parasympathetic dominant,” or metabolically “balanced” and made dietary recommendations for each type. He claimed that his “Protein Metabolism Evaluation Index” could diagnose cancer before it was clinically apparent and that his “Kelley Malignancy Index could detect “the presence or absence of cancer, the growth rate of the tumor, the location of the tumor mass, prognosis of the treatment, age of the tumor and the regulation of medication for treatment.”
In 1970, Kelley was convicted of practicing medicine without a license after witnesses testified that he had diagnosed lung cancer on the basis of blood from a patient’s finger and prescribed dietary supplements, enzymes, and a diet as treatment. In 1976, following court appeals, his dental license was suspended for five years. However, he continued to promote his methods until the mid-1980s through his Dallas-based International Health Institute. Under the institute’s umbrella, licensed professionals and “certified metabolic technicians” throughout the United States would administer a 3,200-item questionnaire and send the answers to Dallas. The resultant computer printout provided a lengthy report on “metabolic status” plus detailed instructions covering foods, supplements (typically 100 to 200 pills per day), “detoxification” techniques, and lifestyle changes.
Basic Science: Implausible
As is true for Gonzalez, Kelley also did not concoct the ideas that were the bases for his treatments, but borrowed them from fanciful notions that had begun early in the 20th century. The history is recounted in Mr. Specter’s New Yorker article and in the NCI’s “PDQ Summary,” but is best explained in an article by the late Sloan-Kettering biochemist Saul Green. Green’s essay dismantles each component of the “Kelley/Gonzalez” claim and exposes its most fundamental defect: it fails to acknowledge that cancer is a genetic disease; thus the “daughters” of cancer cells are themselves cancer cells.
What that means is that the Kelley/Gonzalez “detoxification” regimen, even if it were what its name implies (it isn’t), even if it were capable of removing carcinogens (it is not), and even if its several other tenets were valid (they are not), would already be too late once cancer has begun. From the standpoint of basic science, several unanimously unlikely sub-claims add up to a vanishingly unlikely whole.
Empirical Evidence: Implausible
But what about empirical evidence? It is the claim of clinical successes, after all, that constitutes the formal rationale for the study. In public, it seems, Gonzalez is careful not to offer quantitative rates of cure or survival times for patients on his regimen. In numerous places, however, he implies miracle cures of patients who had been on death’s door when he (or Kelly, before him) met them. Such statements can be found on his website, in the New Yorker article, and in lectures. According to a 1998 article by Victor Herbert, moreover, information discovered in the course of a successful $2.65 million malpractice case against Gonzalez suggests that what he tells patients is different from what he tells the press.¹ Dr. Herbert had been one of the plaintiff’s expert witnesses, and thus had access to the evidence:
Gonzalez’s own tape and his subpoenaed office records showed that he stated to [the plaintiff] that he cured 75% of all cancers with his ‘detoxification’ therapy.
He said that the only people he could not cure were those whose ability to be detoxified was destroyed by chemotherapy and/or radiation. He talked her out of the regime, which was scheduled pelvic irradiation to destroy residual endometrial cancer following hysterectomy. Gonzalez represented to her that hair analysis showed that she was full of cancer and cancer toxins, and he would detoxify her by prescribing daily about 150 supplements plus 6 coffee enemas and by doing monthly hair analysis to show her progression to cure.
Subpoena revealed that Gonzalez’s hair analyses for non-existent cancer toxins were carried out on a word processor, not on a hair analyzer. He said her ‘cancer indicators’ were falling, without naming any toxin or indicator…¹
There has been one previous “study,” reported by Dr. Gonzalez himself, purporting to demonstrate a favorable effect of the “Gonzalez regimen” on cancer of the pancreas. According to the NCI,
…a prospective nonconsecutive case series conducted by the developer and an associate, included 11 patients diagnosed with adenocarcinoma of the pancreas (stage II or stage IV). None of the patients had received chemotherapy or radiation therapy, and none had undergone surgical resection with curative intent. All the patients had pancreatic tumors that were either unresected or partially resected. Survival from the time of diagnosis was the only study endpoint, and all 11 patients (including one who left the study) were included in this survival analysis.
The investigators reported a median survival time of 17 months and a mean survival time of 25.2 months for these patients. Nine patients (82%) survived 1 year, five patients (45%) survived 2 years, and four patients (36%) survived 3 years. At the time the study was reported, two patients were alive: one who had survived 3 years, and one who had survived 4 years. The researchers concluded that the 1-year and 2-year survival percentages for this group of patients were superior to those observed for other U.S. patients diagnosed with adenocarcinoma of the pancreas (1-year survival, all stages = 25%; 2-year survival, all stages = 10%).
The key phrase in that summary is “nonconsecutive case series,” which means that Dr. Gonzalez and his associate did not enroll every patient with pancreatic cancer who came along, but selected among them. According to the abstract of his case series, the 11 subjects were accrued over 3 years, between January 1993 and April 1996. Although we don’t know how many potential subjects there were during that time, Gonzalez reported in 1999:
I have followed thousands of patients over the years who have done coffee enemas in some cases for decades: virtually all patients report an increase sense of well being. I have done them myself daily since first learning about them in 1981.
Since he didn’t begin to follow others “doing coffee enemas” until 1987, he must have averaged nearly 200 or more “coffee enema” patients/year over 12 years. They may not all have had cancer of the pancreas, but there may have been many more than 200/yr, and it seems likely that patients with untreatable cancers would have been preferentially attracted by Gonzalez’s claims. Of the four most common malignant tumors—those of colon, lung, breast, and pancreas—that of the pancreas is the least likely to be treatable at the time of its discovery. By these criteria, Dr. Gonzalez may have seen as many as several hundred patients per year with pancreatic cancer, but probably no fewer than 50/yr.
Elsewhere, however, Dr. Gonzalez disputes this, and seems to contradict his previous assertion about “coffee enemas”:
Over the years, I have repeatedly heard the claim that Dr. Isaacs and I must be processing and treating thousands and thousands of new cancer patients each year to obtain the results illustrated by these case reports. In fact, a good friend of mine recently remarked that I must be seeing “350-450” new cases of pancreatic cancer yearly, because we are well known for our success with this particular illness. This is simply not the case. In reality, we see no more than 3-5 new cases a year.
Maybe yes, maybe no. It matters, of course, because the 11-subject case series is meaningless without a denominator, i.e., the total number of patients from which the 11 were culled. I’ve known plenty of patients who lived with cancer of the pancreas for more than one year, a few who lived 2 years, and one who lived 4 years, and I’m not even a cancer specialist. None of those patients “did” the “Gonzalez regimen,” but if they had it would have been a simple matter to compile their case histories in such a way as to cast a favorable light on it. We’ve mentioned such “selective reporting” previously on SBM.
In an article in 1995, philosopher Douglas Stalker argued that such reporting of “best” cancer cases is inevitably misleading:
It is almost axiomatic that if a therapy has been in use for a period of time, some patients will have received the therapy and will also have experienced a positive outcome of their medical problem. The therapy may have caused the positive outcome, or it may not have. A positive case does not tell us about cause and does not distinguish the true from the false therapy hypothesis; positive cases alone do not change the prior probability of a hypothesis.
Stalker showed that the NCI had no idea how to respond to positive case reports, including those involving Laetrile and the first 3 that Gonzalez himself had offered in the early 1990s. Stalker demonstrated the fallacy of the NCI’s “Best Case Series Program” to evaluate “alternative” cancer claims, which began in 1991. It is still in force and does not require that the cases be “consecutive” or that a denominator be reported. He predicted, correctly, that the program was likely to result in the NIH awarding grants for trials of methods for which the evidence was less favorable than that for many plausible chemotherapy regimens that had been automatically dismissed after failing the standard uncontrolled screening test of the day, the Gehan two-stage trial.
How could the NIH have ever allocated $1.5 million of taxpayers’ money for a trial of the “Gonzalez regimen”?
Reference
[1] Herbert V. The Continuing Case of Nicholas Gonzalez. Scientific Review of Alternative Medicine 1998;2(2):43-44

   The Ethics of “CAM” Trials. Gonzo (Part II)
Kimball Atwood
Link
Laetrile and the Politics of NIH-Sponsored trials of “Alternative Cancer Treatments”
Part I of this blog ended by asking how, in light of the implausible and arduous nature of the “Gonzalez regimen” for cancer of the pancreas, and the unconvincing “best case series,” the NIH could ever have decided to fund a trial of it.† This entry will begin to answer that question. In so doing it may seem to veer from the original subject, but hold on to your seats: what you’ll find here is a piece of the treasure map that leads to the Mother Lode of Fool’s Gold that is government-sponsored “CAM” research.
All historical accounts of the encroachment of implausible claims into the research agenda of the NIH must begin with Laetrile. By that is meant all implausible claims, not merely those having to do with cancer. Elsewhere we have traced the history of “chelation therapy” for coronary artery disease, and have shown that its origins as a political movement, eventually leading to an unethical, $30 million, 2000 subject NIH trial, were intimately associated with people and organizations advocating Laetrile—the most lucrative health fraud ever perpetrated in the United States. In that essay we offer evidence that the creation of the NCCAM itself was at least partly attributable to the history of Laetrile and its advocates. Several good histories or partial histories of the Laetrile debacle are available online, including here, here, here, here, here, and here. The best,¹ but one that does not seem to be available online, is by the recently deceased dean of historians of American quackery, James Harvey Young.
If Young were still alive, I suspect that he would agree that the NCI’s decision in the late 1970s to fund a trial of Laetrile to settle the matter “once and for all,” in the words of Director Arthur Upton,¹ was a mistake. The initial attempt to solicit case reports from Laetrile-prescribing physicians yielded only a tiny fraction of the cases that the NCI had expected. Nevertheless, the sum of information thus generated, together with what was already known about Laetrile, should have convinced the NCI to go no further. The NCI, however, arrived at the opposite conclusion, in part because it had no idea how to evaluate such cases, as Douglas Stalker explained in his 1995 article cited in Part I of this blog. The eventual prospective trial, an uncontrolled but well-performed case series, was headed by the Mayo Clinic cancer researcher Charles Moertel, who had been the first to call for a Laetrile study. It showed, beyond any reasonable doubt, that Laetrile was both dangerous and a complete failure.
Hard-core Laetrile advocates rejected that finding, as expected after Laetrile kingpin Robert Bradford had brought an unsuccessful lawsuit attempting to block the study before it was completed, and after disparaging statements made by other advocates before it had begun.¹ ² Upon publication of Moertel’s report in 1982, Bradford opined:
The whole thing is a put-up deal to discredit Laetrile. It was a phony test, and I’m not surprised at the results.¹
That was the opinion of Laetrile advocates in general and, although stated with less vehemence, of a few apologists in academia. Even Linus Pauling, who had become a crank in his old age, wrote an opposing letter to the New England Journal of Medicine.² Notwithstanding those opinions, some think that the Moertel study was the prototype for demonstrating the social value of trials of implausible medical claims (IMC). The late NCCAM Director Stephen Straus, for example, in attempting to refute our fellow blogger Wally Sampson’s arguments against the NCCAM’s agenda, claimed in 2001 that the demand for Laetrile had “abated markedly only after competent studies showed it to be ineffective.”
The Early Courtship of an Odd Couple: Quackery and EBM
In fact, the demand (or at least the supply, and hence the public health menace) had abated markedly in 1979, after the Supreme Court’s decision in the Rutherford case had upheld the FDA’s decision to regulate Laetrile as a “new drug.” That ruling, for practical purposes, made Laetrile illegal.¹ ² In the history of Laetrile, however, we can detect both roots of the political “CAM” movement—in the virulent, paranoid, but well-organized and well-funded Laetrile advocacy organizations, virtually every one of whose principals was a member of the arch-right-wing John Birch Society—and the more subtle harbingers of what would become Evidence-Based Medicine’s (EBM) self-imposed, if unwitting failure to reckon with implausible claims. Those harbingers can be found, for instance, beginning on p. 16 of FDA Commissioner Donald Kennedy’s Decision in 1977 to declare Laetrile a “new drug”:
1. Objective Evidence of Effectiveness
The courts have thus determined that, as a matter of law, no ‘general recognition’ of a drug’s effectiveness can exist absent adequate and well-controlled clinical investigations…. There are no clinical investigations of Laetrile’s effectiveness, published or otherwise…
There is…an apparent lack of public understanding of what the required studies consist of and why they are required. The Commissioner will thus include in this opinion a discussion of what adequate and well-controlled studies are and why they are needed.
That language must have seemed utterly reasonable at the time, particularly in the context of a much larger statement that included overwhelming evidence against Laetrile. It is now clear, however, that IMC advocates eventually came to view access to taxpayer-sponsored trials of their pet claims as a right of citizenship—not as a decision rightfully based on scientific promise. In this era of EBM and its tunnel-vision for controlled clinical trials to the near-exclusion of all other evidence, the words of the Commissioner, of Moertel , and of a few other scientists at the time could be interpreted as an invitation to such folly.
If that sounds farfetched, consider the Authors’ Conclusions in the abstract of the 2006 Cochrane Review of “Laetrile Treatment for Cancer”:
The claim that Laetrile has beneficial effects for cancer patients is not supported by data from controlled clinical trials. This systematic review has clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment.
That astonishing statement is due to the singular blind spot in EBM’s “evidence” calculus, as originally discussed here and here. The abstract of the Cochrane Review for Laetrile, without any apparent sense of irony, also offers this:
OBJECTIVES: The aim of this review was to assess the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment.
SELECTION CRITERIA: Randomized clinical trials (RCTs) and non randomized controlled clinical trials (non-RCTs).
MAIN RESULTS: No RCTs or non-RCTs were found, so no abstraction of outcome data could be performed in this systematic review.
The absurdity of the marriage of EBM and IMC is again exposed. It seems plain—but not, apparently, to the Cochrane authors and like-minded EBM puppets. Can they really believe that absent “RCTs or non-RCTs” there is no basis upon which to judge “the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment?” Laetrile is one of the most well-considered quack claims in history. The evidence against it, even without considering Moertel’s study—its extreme biological implausibility, its persistence having been an obvious matter of lucrative health fraud, its advocates having been sociopathic criminals, its “miraculous” cures having been revealed as illusory, its ineffectiveness and risk of cyanide toxicity having been demonstrated in prospective animal studies performed by real scientists and by numerous unfortunate cases of desperate cancer sufferers—is overwhelming.
One of the authors of the Cochrane Laetrile review was Edzard Ernst, whose enigmatic views are illustrated by that review and by his previously quoted, perfectly fallacious dismissal of “a priori plausibility,” which stand in sharp contrast to his considerable insight into the process of IMC advocacy:
A[n]…important point relates to a repetitive pattern in the scientific investigation of “bogus” therapies. Proponents first manage to mobilize supporters to campaign in their favor. This brings financial gain. When skeptics ask about the evidence, the burden of proof is swiftly put on their shoulders, and the lack of evidence is made to look like a “conspiracy” of orthodoxy against the alternative. If scientists then decide to rigorously test the method, its proponents would celebrate this as a breakthrough for their method. Again, this amounts to financial gain. Subsequently, a study may prove that the method is ineffective. Proponents now claim that the research was flawed, did not adhere to their protocol, or was wrongly analyzed. The press coverage yet again brings financial gain. This pattern repeats itself with depressing regularity, e.g., when Laetrile or Di Bella’s cancer cure were promoted.
Ernst is absolutely correct about that “repetitive pattern.” Then how can he ignore its obvious conclusions? One is that scientists should NOT “decide to rigorously test [a 'bogus'] method” other than for the same reason that they propose to test any other method: that there is genuine scientific promise. In particular, noisy, obnoxious, and even well-funded and politically-connected advocacy is, in the absence of scientific promise, a terrible reason to decide to rigorously test a method. That lesson is the legacy of the NCI’s Laetrile trial and why we can now judge it to have been a mistake. Another obvious conclusion is that emotional advocacy—by scientifically-naive individuals who, for various reasons not relevant to natural processes, believe in the IMC in question—must count against the prior probability of the claim being valid. Douglas Stalker called that a “source reason for prior probability ranking” and gave several examples.
The Odd Couple Ties the Knot
I cannot, in this entry or even in several, present a comprehensive history to convince you, dear readers, of my assertion about Laetrile and government-sponsored IMC research in the U.S. It is my hope that someone with more time and historical savvy than I have, perhaps the scholarly heir to James Harvey Young, will eventually do that. Instead I’ll offer a few more clues next week—no, more than clues: compelling, albeit incomplete pieces of evidence. I’ll present them not according to chronology, but in such a way as to induce each to help explain the next to be discussed, and so on. Forgive me if that doesn’t work.
References
1. Young JH. Laetrile in Historical Perspective. In: Young JH. American Health Quackery. Princeton, Princeton Univ. Press 1992, pp. 205-55
2. Bross IDJ; Pauling L; Culbert ML. Laetrile. NEJM 1982;307(2):118-19

   The Ethics of “CAM” Trials. Gonzo (Part III)
Kimball Atwood 
Link
A Reminder (Mainly to Myself): this Blog will Eventually get back to Discussing the NIH Trial of the “Gonzalez Regimen” for Treating Cancer of the Pancreas†
Which, if you’ll recall, is an arduous dietary and “detox” regimen that includes 150 pills per day, many of which contain pancreatic enzymes, two “coffee enemas” per day, ”a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest,” and more. In Part II I ventured off on a tangent about Laetrile and government sponsorship of trials of implausible cancer “cures.” That became more involved than I had planned (but also more enlightening, or so I hope), and Part III continues on that tangent.
The Politics of “Alternative Cancer Treatments”: the Lamentable Legacy of Laetrile (cont.)
The whole tide is beginning to turn toward metabolic therapy for degenerative disease and preventive medicine. Laetrile…has been the battering ram that is dragging right along with it…B-15,…acupuncture, kinesiology, …homeopathy and chiropractic…And we’ve done it all by making Laetrile a political issue.”
-Michael Culbert, editor of The Choice, the newsletter of the Committee for Freedom of Choice in Medicine. Quoted in 1979.¹
The Next Step: IAT Spawns the OTA Report on “Unconventional Cancer Treatments”…
In 1985, not long after the demise of Laetrile, pushers of implausible cancer treatments were in the news again. This time the treatment was the “immuno-augmentative therapy” (IAT) of Lawrence Burton. According to the 1990 Congressional Office of Technology Assessment (OTA) Report on Unconventional Cancer Treatments,
Treatment consists of daily self-injections of processed blood products, continuing for the life of the patient.
…
At least four IAT products may be prescribed to treat human cancer patients. The IAT brochure states that some of these are manufactured from the pooled blood of cancer patients and others from the pooled blood of human donors who do not have cancer.
The brochure describes IAT products as:
Deblocking Protein (DP) —an alpha 2 macroglobulin [etc.]
Tumor Antibody 1 (TA1) —a combination of alpha 2 macroglobulin, IgG, IgM, and IgA [etc.]
Tumor Antibody 2 (TA2) —differs from TA1 in potency and possibly composition of immunoglobulins [etc.]
Tumor Complement (TC)…Described as complement C3 that is uniquely active in activating TA1 and TA2. [etc.]
There is no record of Burton’s carrying out biochemical analyses of these materials to identify their components, and his patents describing their manufacture prescribe no tests for identity. Nor has independent analysis of IAT materials been reported from samples provided directly by Burton.
…
NCI analyzed IAT treatment materials provided by the family of a deceased IAT patient in 1984. According to the NCI analysis, all the treatment materials were dilute blood proteins, in which the major component was albumin, and all were reported to be devoid of the components described in the IRC brochure.
In 1985, according to the OTA report, Burton’s clinic in the Bahamas had been
closed by the Bahamian Government at the recommendation of the Pan American Health Organization (PAHO), after contamination of IAT treatment materials with hepatitis B and the AIDS virus was reported.
Shortly thereafter a group called the “IAT Patients Association” (IATPA) was founded by Frank Wiewel, “whose father-in-law was a patient of Burton,” and whose name would become better known within a few years. According to the OTA Report,
IATPA was founded in July 1985 with the single goal of re-opening the Immunology Researching Centre (IRC), a clinic in the Bahamas at which Lawrence Burton offers IAT…The leadership of IATPA also persuaded then-Congressman Guy Molinari to hold public hearings on IAT…
Since the reopening of the IAT clinic in March 1986, IATPA leaders and a member of Congressman Molinari’s staff, acting as principal members of the Coalition (and later the Alliance for Alternative Medicine), helped to rally congressional interest, culminating in the request for OTA’s case study of IAT.
Thus it was the closing of the Burton’s IAT clinic that led shortly to the congressional request that the OTA prepare a report on “Unconventional Cancer Treatments.” Molinari’s original request, signed by 40 other legislators, was only for the OTA to design a study of IAT. Representative John Dingell asked that it include “unconventional” cancer treatments in general. (see also here and here for explanations of the OTA Report). The OTA bent over backwards to please advocates, placing on its Advisory Panel 8 members (out of 18) who were “generally supportive of unconventional treatments.”
…Which Tweaks the National Cancer Institute (NCI)
The OTA Report made several recommendations about “Evaluating Unconventional Cancer Treatments.” Among these were criteria for “Best Case Reviews,” which were adopted by the NCI in 1991 and are still in force. The OTA also designed a trial for IAT, as had been its charge, and went out of its way to try to persuade Lawrence Burton to participate in the planning:
OTA enlisted the assistance of academically-based experts in clinical trials, an oncologist from NCI and one from FDA, and asked Burton for his participation. Burton appointed a resident patient who was active in the IATPA, to represent him on this “IAT Working Group.” Burton himself would not participate except at interim and final decision points. As is turned out, this was a significant handicap.
It went downhill from there. At the first meeting in the Bahamas,
Burton’s participation in the discussion was limited mainly to the first morning. At that time, he characterized the OTA draft as “childish and inane.”
There was never a trial of IAT. There was never a case series suggesting safety or efficacy. There were several looks at records and documents by outsiders, including our own Wally Sampson, suggesting ineffectiveness. There were also several cases of hepatitis associated with the treatment, an incidence of skin abscesses at injection sites of 4.5/100 between 1983 and 1984, and evidence that some of the “blood products” had been contaminated with HIV. (All discussed and referenced here)
John Birch Lives: Paranoid IMC Advocates Play the “Freedom Card”
So much for good-faith attempts by the “establishment” to give advocates of Implausible Medical Claims (IMC) their day in court. Once again, however, the good guys failed to learn that lesson. As had been the case with Laetrile, IAT supporters blamed the government and the OTA for Burton’s failings:
…an IATPA member indicated, “in the course of these events, we [IATPA] became convinced that a conspiracy exists which suppresses evaluation of unconventional treatments and have become more broadly politically active in response to this.”
Michael Culbert, the veteran of the Laetrile wars and the author of the quotation that opened this blog entry, was succinct in his assessment of the entire OTA Report:
The document refers several times to the interesting phrase, “scientific medicine,” and therein lies not only the fallacy of the document, but indeed, of the entire thought system of the American medical establishment. We wonder when medicine stopped being an art and became a science. Orthodoxy cannot escape its blind allopathic paradigm; one based on, essentially, discarded Newtonian mechanistic principles.
It cannot any more grasp the concept of individualized, integrated, total metabolic protocols in the management of cancer than it can abandon its obsession with animal tumor systems, cell lines, tumor types, etc.
As Americans drop like flies to the pandemic of cancer, it should be clear that what we need is a new paradigm; a multi-factorial view of cancer causation; a body-wide concept of its management, and an abandonment of the status quo which has ill-served the nation.
Nothing could be more obscene than the spectacle of dying Americans denied freedom of choice in therapy having to go underground, go abroad, or do without. Nothing is more disturbing than the spectacle of government power being used to arrest, harass, chasten, and destroy physicians and researchers who, by adopting so called alternative approaches, are only trying to help their patients.
The vicious system which, on the one hand says “we cannot cure you,” and on the other hand says, “but don’t try some unproven remedy” and warns you always not to sneak off to Tijuana, must come to an end. It is blatantly immoral. And along with it is the randomized, placebo controlled, double-blind study. I can’t think of anything more immoral than using that as a rational scientific exercise.
The solution to all this, of course, is not scientific. It is political. If people have to take to the streets to secure what should be their birthright, freedom of choice in medicine, against the tyrannical concentration of economic and vested interests, then they will.
“Medical writer” Ralph Moss also addressed the OTA. He stated that he had worked at Memorial Sloan-Kettering as “assistant director of public affairs” from 1974-77. He claimed that he had “[blown] the whistle on [Sloan-Kettering's] cover-up” of an animal study, performed by Dr. Kanematsu Sugiura, which found that “in the control animals 80% had lung metastases but only 20% had them in the treated animals.” Moss chastised the OTA for allegedly not having acknowledged the “cover-up”:
This report on “Unconventional Cancer Treatments” was supposed to investigate a coverup. Instead it has become part of that coverup. In its present form, it will set back the study of non-toxic cancer treatments for years to come.
…
People are dying of cancer in this country. You remind me of that Ron Cobb cartoon of a little child dying of malnutrition. There are 8 or 10 doctors standing around its crib, pointing and questioning and rubbing their chins, like “What’s going on? We have to get the medical reports on this.”
People are dying.
We cremated Ron Wolin this week. It’s a very interesting story. Ron was co-founder of the Patients’ Rights Legal Action Fund and a patient of Dr. Burzynski. He was lying on a couch in Dr. Burzynski’s office in Houston when the FDA came in and seized 220,000 documents from Burzynski’s office. They took 11 filing cabinets, loaded them onto a U-Haul and drove away. And the very same day, Dr. Burton’s clinic was shut down in the Bahamas, July 17, 1985.
Now, I know what’s going on here and I’m not fooled. And I’ll tell you something: repression breeds resistance. Ron Wolin watched those records go out the door, then he founded an organization which forced the government to a standstill in the courts. And the same day, by coincidence, Frank Wiewel was in Dr. Burton’s clinic. You know, just a guy, with his father-in-law. And he watched Burton’s clinic closed and look, here he is. He’s the head of two cancer organizations. And I was just a guy who happened to be in the right place at the right time.
So, I’m not afraid of you, and I’m not afraid of what you’re doing. You’ll continue with this? Fine. We’ll continue to fight you.
Compare Moss’s account of the Sloan-Kettering “cover-up” with the account given on p. 23 of FDA Commissioner Kennedy’s 1977 report.
Moss reported the opinion of another person whose views would be heard again:
Gar Hildenbrand, who was both an Advisory Panel member and an outspoken activist, called on supporters of the Gerson diet and cancer patients in general to practice civil disobedience outside the meeting.
“On March 9th,” he wrote, “hundreds of people with cancer, people recovering from cancer, and worried well people will walk into the streets. In the early morning, at the Office of Technology Assessment, cancer patients will lie down in front of the doors to tell Congress: ‘You allow this system to go unchallenged OVER MY DEAD BODY.’ “
Hildenbrand was, and is, a conspicuous proponent of Gerson Therapy, another “dietary” and “detoxification” scheme that relies heavily on coffee enemas. His own views (“As a medication, the coffee enema is in a class by itself”) and links to other such opinions can be found here.
The “Harkinites” are Born
Iowa Congressman Berkley Bedell was one of the signatories of Rep. Guy Molinari’s request to the OTA. The above-mentioned Frank Wiewel may have helped Bedell find “alternative” treatments after Bedell had found out that he had prostate cancer. Bedell was not quite as rabid in his views as were Wiewel, Hildebrand, and Moss, but was every bit as ignorant of biology and science. Those four—Bedell, Wiewel, Moss, and Hildebrand—would soon become known as the “Harkinites”: the “experts” hand-picked by Iowa Senator Tom Harkin to advise the Director of the NIH Office of Alternative Medicine, the brainchild of Harkin and Bedell.
References
1. Bruzelius N. The Merchants of Laetrile. New England (magazine section), Boston Sunday Globe, June 17, 1979. Quoted in: Young JH. Laetrile in Historical Perspective. In: Young JH. American Health Quackery. Princeton, Princeton Univ. Press 1992, p. 245.

   The Ethics of “CAM” Trials. Gonzo (Part IV)
Kimball Atwood
Links
A Review; then Back to the Gonzalez Regimen†
Part I of this blog introduced the topic of the “Gonzalez regimen” for treating cancer: “Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support” and “detoxification” with twice daily coffee enemas, daily “skin brushing,” “a complete liver flush and a clean sweep and purge on a rotating basis each month,” and more. The topic was occasioned by the federal Office for Human Research Protections having recently cited Columbia University, for the second time, for violations of human subject protections in its NIH-funded trial of Gonzalez’s method as a treatment for cancer of the pancreas.
Part I discussed the implausible and bizarre regimen and cited Gonzalez’s troubles with malpractice suits and with the New York medical board during the 1990s. It ended by wondering what could have induced the NIH to give a $1.5 million grant to Columbia University to study the method.
Parts II and III began to answer that question, tracing some of the key events and individuals from the Laetrile wars in the 1970s to the NCI-funded trial of Laetrile reported in 1982, to the ”immuno-augmentative therapy” (IAT) battles of the mid-’80s, to the Report on “Unconventional Cancer Treatments” by the Congressional Office of Technology Assessment (OTA) in 1990, which in turn led to the NCI adopting its “Best Case Series Program” in 1991.
The end of Part III hinted that the conspiracy mongering that had greeted every attempt by the government to explain its positions on implausible cancer treatments, from Laetrile to the OTA report, ultimately led to the creation of the Office of Alternative Medicine (OAM) at the NIH, also in 1991. There is plenty of evidence for that, both from the conspiracy mongers themselves and from more level-headed observers. Each time the government acted—to fund a trial of Laetrile, to solicit the OTA report and propose a study of IAT, to establish the NCI “Best Case Series” program, and to establish the OAM—it was not because of scientific or medical considerations, but because of political pressure. More on that from time to time, but now back to Dr. Gonzalez.
A Helping Hand from the OAM
In September, 1992, the nascent OAM convened a “Workshop on Alternative Medicine.” The resulting report, “Alternative Medicine: Expanding Medical Horizons,” has correctly been called “an uncritical catalog of virtually every dubious and unproven treatment method of the past 100 years.” Physicist Robert Park called it “surely the most credulous document ever offered in the name of medical science” (NY Times, 7/9/1995). The report referred to Gonzalez’s unpublished, 500 page manuscript describing cases culled from the records of his “mentor,” the Texas dentist William Donald Kelley (discussed in Part I of this blog):
This case series has been singled out by proponents as one of the most convincing in support of an unconventional cancer treatment.
No surprise, then, what happened next. According to Dr. Gonzalez,
In July of 1993, the National Cancer Institute (NCI) invited me to present case reports from my practice, detailing patients with appropriately diagnosed poor-prognosis cancer who had enjoyed tumor regression or unusual survival while following my therapy. Dr Isaacs and I put together 25 cases for the session, which was attended by a large group of NCI scientists and lasted 3 hours. After the meeting, I was asked to pursue as a next step a pilot study evaluating my approach in 10 patients diagnosed with advanced adenocarcinoma of the pancreas.
Curiously, although the OAM report was dated September 14-16, 1992, it also has this:
Gonzalez recently submitted to NCI a meticulously documented best case series (Friedman 1993).”
Suddenly, Dr. Gonzalez had become a minor celebrity. According to Victor Herbert, it happened just in time:
The New York State licensing agency attempted to revoke [Gonzalez's] license [in 1994]. Revocation was prevented by testimony from defenders, such as Harvard’s George Blackburn, MD, and American Health Foundation’s Ernst Wynder, PhD. Blackburn and Wynder testified that Gonzalez’s cancer therapy, particularly his oral pancreas-extract supplement, was promising as a cancer cure. The testimony and the licensing board ignored the 1990 Congressional Office of Technology Assessment (OTA) report to Congress that Gonzalez’s claims have no basis in fact.¹
Perusing the documents generated by the New York State Board for Professional Medical Conduct, in the matter of Dr. Gonzalez, is not for the faint of heart. The Findings of Fact reveal a practitioner who is beyond incompetent. In the cynical vernacular of medical shop talk, he is “007: licensed to kill.” That the eventual consent order let him off scot-free, for practical purposes, is a sad commentary on the capacity of the medical profession to regulate itself and to protect the public. Gonzalez himself learned nothing, as evidenced by his words at the White House Commission on Complementary and Alternative Medicine Policy in 2000:
…the very day I was in Switzerland presenting to Pierre Gastri’s [ph] group was the very day the medical board served my office with a subpoena announcing they were going to try and close my office down because to sum it up in non-legalese terms, I basically represented a subhuman pond scum that was, you know, taking money from unsuspecting cancer patients. All the time while I was trying to present my work and getting funding and doing clinical trials, the medical board relentlessly tried to basically close my office down. We eventually prevailed…
According to Victor Herbert, Columbia University opened its arms to Gonzalez at about the same time:
Gonzalez was subsequently hired by Fredi Kronenberg, PhD, director of Columbia University College of Physicians & Surgeons’ “alternative” medicine course. Gonzalez and other advocates of pseudoscience-based medicine were hired by Dr. Kronenberg to give one-hour lectures promoting their practices as legitimate. Kronenberg and Medical School dean Herbert Pardes refused requests to withdraw the invitation or to allow alumni Stephen Barrett or me to be present when Gonzalez spoke, for rebuttal.¹
The Pilot Study Considered Again
Dr. Gonzalez eventually reported his “pilot study” of cancer of the pancreas in 1999, as discussed in Part I. He claimed that his outcomes for 11 patients had been markedly better than those typically found for comparable patients who receive “conventional” treatments. His report is vulnerable to several objections, the most obvious of which is that he selected the “best cases” from a larger pool, possibly a much larger pool—as mentioned in Part I. Other objections have to do with the cases themselves. Intrepid reader Dr. Peter Moran (thank you for calling my attention to this, pmoran) examined Gonzalez’s report and observed:
Case H was almost certainly a bile duct cancer, which has a far better prognosis than cancer of the pancreas. . .
Case J had a Whipple’s procedure for an early pancreatic cancer. This case should not have been included, as the fact that the cancer was deemed operable indicates a more favourable prognosis…
Case K is not certainly pancreatic cancer. The diagnosis rests upon a surgeon’s opinion from palpation of an unbiopsied pancreatic mass…
Case L could well be a better prognosis duodenal or ampullary adenocarcinoma…
Some may regard these concerns as trivial, but those four cases happen to have the more prolonged survivals (37-47 months). The 10-29 month survival in the other seven patients is good but not overly convincing evidence of a treatment effect in a such a highly selected group.
Similar objections apply to cases that Dr. Gonzalez reported in Alternative Therapies in 2007. Six patients, designated “#26-#31,” were said to have presented with cancer of the pancreas. They were alive and well 15, 10, 10.5, 6, 5.5, and 24 years later, respectively. Patient #26, however, reportedly had a biopsy of a lung nodule but not of his pancreas; the presumption that his cancer had begun in the pancreas had been based on uncertain CT findings. Dr. Gonzalez gave no details about where this man’s diagnostic work-up had been done. Patient #27 also lacked a biopsy to prove cancer of the pancreas; the diagnosis was based on even flimsier radiologic evidence than in the previous case.
Patient #28 reportedly had a biopsy of a mass in the pancreas, but it was reported to be a rare “carcinoid-islet cell” tumor—a very different sort from the standard adenocarcinoma of the “exocrine” pancreas, and one that, according to the Washington Manual of Oncology, can have “long periods of disease stability.” Patient #30 had no biopsy of his pancreas, only radiologic evidence of a pancreatic mass. Prior to pursuing Dr. Gonzalez’s regimen he had completed 3 of the 4 cycles of chemotherapy that had been recommended to him, and a CT scan had shown “marked improvement” after only the second cycle. Patient #31 was a “24-year Kelley Survivor,” i.e., a case report that Gonzalez had taken from Kelley’s records. We can therefore assume that in the case of patient #31, “…documentation…was inadequate to confirm critical details of the narrative….”
Dr. Gonzalez Goes to Washington—Again
Representative Dan Burton (R-IN), the former chairman of the House Committee on Government Reform, has been one of the most virulent and influential proponents of implausible cancer treatments and other IMCs. Burton had fought to legalize Laetrile in his home state of Indiana during the 1970s, and later used his committee chairmanship for the advocacy of homeopathy for bioterrorism and other purposes, “detoxification” and “supporting the vital force” for cancer, the herbal mixture “PC-SPES” for prostate cancer (since found to be adulterated by prescription pharmaceuticals), acupuncture for “end of life” care, and “antineoplastons” for medulloblastoma.
Burton has also championed the cause of those who claim that vaccinations and mercury amalgams cause autism and ADHD, argued against FDA regulation of “dietary supplements,” including ephedra, and argued that the Department of Health and Human Services (HHS) should have an “Associate Secretary for Complementary or Alternative Medicine.” For his many hearings on these topics he has invited such expert witnesses as actress Jane Seymour, whose advocacy of homeopathy on the national stage followed her experience as Dr. Quinn, Medicine Woman.
“Dr.” Ralph Moss, introduced in Part III, is one of the original “Harkinites” (a term coined by Joseph Jacobs, the first full-time Director of the Office of Alternative Medicine). His degree is in classics, but he has styled himself as an expert in cancer—mainly “alternative” cancer treatments. Moss was a long-time member of the NCCAM’s Cancer Advisory Panel for Complementary and Alternative Medicine (CAPCAM). In 2004 he wrote a glowing eulogy for rabid Laetrile promoter Michael Culbert, who had been a vice-president of the Committee for Freedom of Choice in Medicine, the major Laetrile advocacy organization. Moss has recently written approvingly of Mexican cancer clinics that continue to peddle Laetrile, although he is careful to add that “there are no reliable ‘miracle cures’ for cancer in Tijuana or elsewhere.”
In 2000 Moss recounted, with considerable satisfaction, how the Director of the National Cancer Institute (NCI) had caved to political arm-twisting:
After stormy hearings of Rep. Dan Burton’s House Committee on Government Reform and Oversight, NCI Director Richard Klausner, MD, changed NCI’s direction and asked members of the CAM community to advise NCI on the evaluation of new therapies.
Elsewhere we find that one of those “stormy hearings” had apparently taken place in the relative privacy of Burton’s office:
In his campaign to win federal support, Gonzalez got a boost from Rep. Dan Burton (R-Ind.), the chairman of the House Government Reform and Oversight Committee and a longtime alternative medicine ally. Burton held a June 1998 meeting in his office that brought together Gonzalez and NCI Director Richard Klausner to discuss a study of the regimen.
Shortly thereafter, the NIH announced its grant of $1.4 million for a controlled trial of the “Gonzalez Regimen.” It was in trouble almost immediately, as will be discussed next week.
References
[1] Herbert V. The Continuing Case of Nicholas Gonzalez. Scientific Review of Alternative Medicine 1998;2(2):43-44

               The Ethics of “CAM” Trials. Gonzo (Part V)
Kimball Atwood
Link
Part IV of this blog ended by observing that the NIH-funded trial of the “Gonzalez regimen” for cancer of the pancreas,† to have begun in March, 1999, was in trouble almost as soon as it started. As originally designed, it was to have been a randomized, controlled trial comparing gemcitabine, the standard chemotherapy, to the “Gonzalez regimen” of pancreatic enzymes, “supplements,” twice-daily coffee enemas, and other purported methods of “detoxification.” By June, 1999, according to Dr. John Chabot, the Columbia University surgeon acting as Principal Investigator (PI) of the trial, only 3 of the first 50 potential subjects had agreed to be randomized, and none of the three met the eligibility criteria. By January, 2000 it had become clear that the trial would not accrue a sufficient number of subjects if it remained randomized, because almost all of the potential subjects were intent on being in the “nutritional,” ie, the Gonzalez arm.
Trouble with Randomizing
The investigators at Columbia therefore decided to change the protocol to a “single-armed, non-randomized case-cohort study where patients will only be enrolled in what was the nutritional arm.” Paradoxically, PI John Chabot had recently explained, at the 1999 Comprehensive Cancer Care Conference of James Gordon’s Center for Mind-Body Medicine, why this would not be a scientifically sound design:
Would it be possible to allow patients to choose what arm of the trial they want to be on?
Giving individualized treatment in a non-random fashion is more realistic than randomizing, but unfortunately, randomizing was necessary to maintain the validity and integrity of the study in the face of traditional criticism.
Language similar to Chabot’s gratuitous, final phrase has become a staple gesture used by academic researchers speaking to “CAM” audiences. It appears to answer the perpetual special pleading of IMC advocates by passing the buck to unnamed “traditional critics,” as if the issue were not really one of “validity and integrity.” Chabot himself later admitted to being one of those critics, at a 2001 meeting of the White House Commission on Complementary and Alternative Medicine Policy, chaired by Gordon:
The vast majority of people who call with interest are only interested in alternative medicine approaches. Patients who express interest in this protocol are generally healthier than the overall population of patients that I see in my practice with advanced pancreatic cancer. The way this protocol, and, I suspect, many are designed, the patients who meet the eligibility criteria are clearly healthier than the general population of advanced pancreatic cancer patients.
One has to be very careful coming to any conclusions comparing these patients with the general population of pancreatic cancer patients.
I will stop at my third observation. The effects of psychosocial support and delivering hope to these patients is not insignificant. In the absence of a blinded, randomized trial, separating these effects from the physiologic and pharmacologic effects will be a major challenge in trial design.
Trouble with Regulators
It was not long after the protocol was changed that the trial began to draw the attention of the federal Office of Human Research Protections (OHRP). In 2002, a determination letter from the OHRP to Columbia stated:
OHRP finds that the informed consent documents reviewed and approved by the Institutional Review Board (IRB) for this study did not list the risk of death from coffee enemas.
The 2002 OHRP letter listed 7 additional complaints, but each of these was “redacted” from the public copy. We would love to know what they were. In 2003 the OHRP sent another determination letter to Columbia, revealing problems that the agency itself likely did not recognize as being as worrisome as they were. Among them:
(1) Department of Health and Human Services (HHS) regulations at 45 CFR 46.110(b)(2) permit use of expedited procedures for review of minor changes to previously approved research during the period for which approval is authorized. OHRP finds that the CUHS institutional review board (IRB) employed expedited procedures to review changes that exceed this limitation. On January 20, 2000, the CUHS IRB received a request from the principal investigator to approve an amendment to the protocol that included eliminating the randomization and adding a patient questionnaire. It appears that approval of this amendment was done in an expedited manner.
…
(3) OHRP finds that the informed consent documents reviewed and approved by the CUHS IRB for this study failed to adequately address the following elements required by HHS regulations at 45 CFR 46.116(a)(1):
(a) An explanation of the purposes of the research. The IRB-approved protocol stated that “primary endpoint is survival….” However, the informed consent document stated that “the purpose of this research study is to determine whether enzyme-nutritional therapy is as effective as a drug called gemcitabine for treating pancreatic adenocarcinoma.”
(b) A complete description of the procedures to be followed, and identification of any procedures which are experimental.
(i) The protocol included an evaluation of nutritional status by a “subjective global assessment” questionnaire and a questionnaire regarding quality of life. These assessments were not mentioned in the informed consent document.
(ii) The informed consent document referred to the alternative regimen as “pancreatic proteolytic enzyme therapy” or “enzyme-nutritional therapy” and throughout referred to the study as involving “treatment” and “therapy.” The only treatment or therapy available on the protocol was gemcitabine; therefore it appears that the experimental procedures were not accurately described in the informed consent document.
Corrective Action: OHRP acknowledges that the informed consent document will be revised to state the purpose of the study more directly, to refer specifically to the questionnaires and assessments noted above, and replace the words “treatment” and “therapy” with the term “experimental regimen” or similar. OHRP finds that these corrective actions adequately address the above finding and are appropriate under the CUHS FWA.
(4) HHS regulations at 45 CFR 46.116 require that informed consent information be in language understandable to the subject or the subject’s legally authorized representative. OHRP finds that the informed consent document approved by the CUHS IRB for this study appeared to include complex language that would not be understandable to all subjects, such as alleviating, persist, emesis, anorexia, myalgias, arthralgias, transient intolerance, abdomen and pelvis.
…
A Troubling Case History
Readers who know something about both human studies ethics and the nature of the Gonzalez regimen will have sensed, while reading the charges quoted above, the pungent aroma of rat. This blog will discuss the ethics of the trial at length, but first it will summarize the experience of an unsuspecting artist in his 40s, the father of two boys, who was diagnosed in March of 2002 with cancer of the pancreas and made the mistake of submitting himself to the trial. The story can be told only because a friend of the patient, mathematician Susan Gurney, wrote and published it in the Scientific Review of Alternative Medicine:
My friend’s wife was a believer in homeopathic medicine. She and others in her community suggested that he look into a protocol run by Nicholas Gonzalez, MD….His protocol was being funded by the National Institutes of Health and the National Center for Complementary and Alternative Medicine and implemented at Columbia Presbyterian. My friend’s surgeon [Dr. Chabot] was one of the investigators.
…my friend decided that the Gonzalez protocol seemed to offer the most hope for survival…[he] arranged to meet with Dr. Gonzalez during the 2 weeks that followed his recovery from surgery to determine whether or not he was eligible for the trial. He was encouraged when he was found to be acceptable. Dr. Gonzalez told him that in order to meet the criteria one had to be still strong enough to follow an arduous regimen…
…
During this time I also investigated the Gonzalez protocol. I had obtained a copy of an article by Michael Specter in the February 5, 2001 issue of the New Yorker magazine. The article seemed to indicate that although this protocol had been funded by the NIH, there was some debate as to its value by physicians at Columbia Presbyterian. I was disturbed to read that Dr. Gonzalez had been successfully sued and that New York State had made attempts to remove his license…I placed a call to Dr. Chabot’s office. It was not returned.
…
Dr. Gonzalez advised my friend to have fillings from his teeth removed by a dentist in Connecticut, which he did on April 16. He had just begun the vitamin and enzyme protocol, which was very time-consuming…His wife was by that time already extremely busy obtaining all the pills and food that were required for the Gonzalez regimen.
That same day I called Karen Antman, MD, head of oncology at Columbia Presbyterian…she said that my friend had been offered many different treatment options, and had chosen the Gonzalez one. She encouraged me to do further research.
On April 17 I once again called Dr. Chabot’s office and spoke with his secretary, saying that I had some questions about the Gonzalez trial. I was informed that I should speak to Michelle Gabay, the nurse who was running the protocol…[but] she had no answers to my questions about Gonzalez protocol results.
…
My friend was determined to try as hard as he could to maintain the regimen, which is extremely difficult. He had been told that pain might be an indication that the tumors were being dissolved, and that he could expect weight loss as he was detoxifying his body. I saw him on April 26, when he told me that he was in more pain. It was obvious that he had lost a significant amount of weight. In the next few weeks he was to describe himself to his mother as looking like “a concentration camp victim from Auschwitz.”
He was having difficulty sleeping. Whether this was because of coffee enema stimulation or because he was experiencing ever-increasing pain and stress, I do not know…but [he] said that he was going to stick with this regimen until the next appointment, when he would get the results. He was determined to give it his utmost effort.
I told him that I was going to attend the annual conference of the American Society of Clinical Oncology (ASCO) and would report on other options to him. Once at ASCO, I learned quickly and definitively that the Gonzalez protocol was a fraud; no mainstream doctors believed it was anything else and they were surprised that anyone with education would be on it.
…
During the following month, my friend lost 30-40 pounds and became so weak that he could no longer walk his dog around the block. The pain was becoming unbearable, and he was eager to be evaluated and have another scan.
…
My friend was not scanned until Sunday, June 2, when he received bad news. The tumors had progressed. The Gonzalez regimen had not worked.
On Monday he made an appointment with Dr. Sherman, the oncologist at Columbia Presbyterian…
By this time my friend was extremely thin and weak. He was given prescriptions for pain medication and chemotherapy, and scheduled for additional intravenous therapy the following week.
….He felt better in June,…[but although he] started eating regular food and sipping concentrated food supplements, he was unable to gain weight and did not show an obvious early response to his 3 chemotherapy treatments…
Over the Fourth of July weekend…his lungs filled with fluid. He was rushed to [the] hospital….Over the course of that month he stabilized somewhat, but he continued to weaken. He went home on July 26, intending to talk to his doctor, who had been away that week. He did not live to have the conversation.
…
By Sunday, hospice care was called in and he died a few days later, in the early morning of August 1, 2002. That he died was not surprising, as pancreatic cancer is a terminal disease. That he died as quickly and brutally as he did, however, is tragic.
…
We had [had] many conversations about treatment options…but the Gonzalez protocol quickly overwhelmed him; first by being impossibly time-consuming and then by being so physically debilitating. Had he realized this in early April, he would have had a real chance to examine his options. But once the decision was made to begin the Gonzalez protocol, with the apparent support of those involved in his care at Columbia Presbyterian, he became committed to it.
By remaining neutral about the Gonzalez regimen, physicians at Columbia Presbyterian who place patients in this trial effectively preclude them from starting other options, because of the demands it places on patients and their families. If physicians believe they are truly being neutral by not fully explaining the Gonzalez protocol’s nature to cancer patients, it is they who are in denial.¹
Physicians may quibble slightly with Ms. Gurney’s assessment, noting that the course of her friend’s illness—the pain, weakness, insomnia, weight loss, and early death—was entirely consistent with that of untreated cancer of the pancreas alone. That is true, but it is still possible that his particular course was made worse by the arduous regimen. There is no denying that his pain could have been largely mitigated, that he would have had more useful time during his last few months if he hadn’t been on the Gonzalez regimen, and that he would have had a better chance of responding to standard treatment or to a rational nutritional regimen if these had begun earlier.
Troubles with Human Studies Ethics
“A Clinically Competent Medical Person”?
It is also clear that some of the medical practices reported by Ms. Gurney amounted to incompetent nonsense. An example was Gonzalez’s having instructed the patient to have his fillings removed, almost certainly to relieve presumed mercury poisoning from dental amalgams—a common “CAM” canard (was that part of the protocol?). Also included were Gonzalez’s having told the patient that “pain might be an indication that the tumors were being dissolved, and that he could expect weight loss as he was detoxifying his body.”
Such claims are similar to those that the New York State Board for Professional Medical Conduct had described in its Findings of Fact in 1994:
For all patients A through F, the Hearing Committee found that Respondent failed to correctly interpret signs and symptoms of disease progression…, in some cases attributing symptoms of cancer progression to non-compliance with his protocol.
…
The Hearing Committee…finds that Respondent’s treatment of Patients A through F was incompetent within the meaning of New York State Education Law Section 6530 (5) in that it demonstrated a lack of requisite skill and knowledge.
…
…the Hearing Committee sought both training appropriate for Respondent’s practice, the vast majority of whose patients have some form of cancer, and experience in a setting that would acquaint Respondent with the broader aspects of practice, including the entire cycle of death and available palliative aspects of treatment of the terminally ill.
The 1998 Consent Order agreed:
In the treatment of all the patients in this case, the Respondent demonstrated that he lacked the basic understanding of the disease from which all the patients were suffering. For example, in the case of Patient C, the Respondent describe the Patient as being stable, doing fine or in a rebuilding process, when the Patient was suffering increasing pain and showing other symptoms which demonstrated the marked progression of her disease. In the case of Patient F, the Patient showed symptoms such as progressive inflammation, crusting and weeping of the breast and increased pain, which were the result of metastatic disease, but which the Respondent attributed to toxicity and a repair and rebuilding process.
The Review Board sustains the Hearing Committee’s Determination ordering the Respondent to undergo retraining in oncology.
Relevant human studies treatises stipulate certain qualifications for investigator/practitioners. The Helsinki Declaration is explicit:
Medical research involving human subjects should be conducted only by scientifically qualified persons and under the supervision of a clinically competent medical person. The responsibility for the human subject must always rest with a medically qualified person and never rest on the subject of the research, even though the subject has given consent.
The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value. When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.
The Belmont Report requires that IRBs consider the practices of the pertinent physician, with the implication that those practices meet acceptable standards of care:
Research and practice may be carried on together when research is designed to evaluate the safety and efficacy of a therapy. This need not cause any confusion regarding whether or not the activity requires review; the general rule is that if there is any element of research in an activity, that activity should undergo review for the protection of human subjects.
The NIH also has certain requirements for investigator/practitioners, although these are more difficult to find. According to the 2001 Request for Applications (RFA) for another NCCAM-sponsored trial:
Biographical sketches for all key investigators must be provided. In addition, applications must name a Senior Investigator for each trial site in the consortium that will be responsible for on-site clinical and scientific implementation, direction and management of the trial protocol….Senior Investigators must have substantial experience in the treatment and management of CAD and in the design, implementation and evaluation of clinical trials.
If we change “CAD” to “cancer of the pancreas,” it seems likely that similar requirements should have applied to Gonzalez (the trial corresponding to the RFA quoted above is also in violation of those requirements, but that is another story).
The New York Board’s opinions quoted above should have been part of the deliberations of any committee—the scientific review group at the NIH or the Columbia Institutional Review Board (IRB), for example—charged with passing judgment on the trial. We can safely assume that either Gonzalez’s history was not made available to those committees or, if it was, that the committees reneged on their responsibilities.
Uninformed Consent, Inappropriate Subject Selection, and Lack of Clinical Equipoise
We have already seen, in the OHRP’s determination letters of 2002 and 2003, that until at least 2003 the Gonzalez trial’s consent information was woefully inadequate. I wonder if the new one is any better. In 2003, using the Gonzalez regimen as an example, I argued that the information offered to prospective subjects of trials of implausible claims is likely to be misleading:
Plausibility also figures in informed consent language and subject selection. How many subjects who are not wedded to “alternative medicine” would be likely to join a study that independent reviewers rate as unlikely to yield any useful results, or in which the risks are stated to outweigh the potential benefits? Are informed consents for such studies honest? In at least one case cited in the following paragraph, the answer is “no.” Nor may subjects who prefer “alternative” methods be preferentially chosen for such research even if they seek this, because “fair subject selection requires that the scientific goals of the study, not vulnerability, privilege, or other factors unrelated to the purposes of the research, be the primary basis for determining the groups and individuals that will be recruited and enrolled” (Emanuel et al. 2000).
The Office for Human Research Protections recently cited Columbia University for failure to describe serious risks on the consent form of its “Gonzalez” protocol for cancer of the pancreas, funded by the NCCAM (OHRP 2002). The study proposes to compare the arduous “Gonzalez” method, which is devoid of biological rationale, to gemcitabine, an agent acknowledged by the investigators to effect “a slight prolongation of life and a significant improvement in . . . quality of life.” Nevertheless, a letter from Columbia to prospective subjects states, “it is not known at the present time which treatment approach is best [sic] overall” (Chabot 1999). The claim of clinical equipoise, or uncertainty in the expert medical community over which treatment is superior–necessary to render a comparison trial ethical–is not supported by the facts (Freedman 1987).
Ms. Gurney’s article provides additional, compelling evidence that the Gonzalez protocol did not meet the standard of clinical equipoise:
…at ASCO, I learned quickly and definitively that the Gonzalez protocol was a fraud; no mainstream doctors believed it was anything else and they were surprised that anyone with education would be on it.
The “mainstream doctors” of the American Society of Clinical Oncology must be judged representatives of the pertinent “expert medical community.”
I am aware that “clinical equipoise,” as a prerequisite for a trial being judged ethical, has been challenged. Nevertheless, the challenges do not impinge upon the points made here, nor have they resulted in a consensus opinion that “clinical equipoise” no longer be considered a requirement for a trial.
There are many other reasons that the Gonzalez trial is unethical, but I will limit this discussion to three more: scientific reasons, the fallacy of popularity, and the need for independent review.
Science and Ethics
There is a consensus, among those who consider human studies ethics, that a study must be scientifically sound in order to be ethical. According to the Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS; Geneva, Switzerland:1993. Quoted here):
Scientifically unsound research on human subjects is ipso facto unethical in that it may expose subjects to risks or inconvenience to no purpose.
The Helsinki Declaration agrees:
Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation.
There is no body of basic science or animal experimentation that supports the claims of Gonzalez.
Emanuel and colleagues, writing in JAMA in 2000, asserted:
Examples of research that would not be socially or scientifically valuable include clinical research with…a trifling hypothesis…
I assert that highly implausible claims ought to be viewed as “trifling hypotheses.”
The Fallacy of Popularity
Virtually all of the research agenda of the NCCAM has been justified by the assertion that implausible claims that are popular require research, merely because people are using them. Referring to the opinions of the late NCCAM Director Stephen Straus, Science Magazine wrote in 2000:
Scientific rigor is sorely needed in this enormously popular but largely unscrutinized field….Most of these substances and treatments have not been tested for either safety or efficacy.
As surprising as it may be to some, however, a method’s popularity may not supercede the interests of individual trial subjects. According to the Helsinki Declaration:
In medical research on human subjects, considerations related to the well-being of the human subject should take precedence over the interests of science and society.
The Belmont Report agrees:
Risks and benefits of research may affect the individual subjects, the families of the individual subjects, and society at large (or special groups of subjects in society). Previous codes and Federal regulations have required that risks to subjects be outweighed by the sum of both the anticipated benefit to the subject, if any, and the anticipated benefit to society in the form of knowledge to be gained from the research. In balancing these different elements, the risks and benefits affecting the immediate research subject will normally carry special weight.
The U.S. Code of Federal Regulations is unequivocal:
The IRB should not consider possible long-range effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility. (CFR §46.111)
The Requirement for Independent Review
As explained by Emanuel and colleagues:
Investigators inherently have multiple, legitimate interests—interests to conduct high-quality research, complete the research expeditiously, protect research subjects, obtain funding, and advance their careers. These diverse interests can generate conflicts that may unwittingly distort the judgment of even well-intentioned investigators regarding the design, conduct, and analysis of research.
…[thus] for much of clinical research, review should be done by a full committee of individuals with a range of expertise who have the authority to approve, amend, or terminate a study.
Emanuel and colleagues suggested that it is IRBs that provide such independent reviews, but we have already shown that IRBs can only be expected to act according to the information made available to them by the investigators. We have shown, in addition, that the ”expert medical community” need be involved in such independent reviews. Individuals with the requisite expertise may or may not be members of the pertinent IRB.
Reference
1. Gurney S. Socially Harmful but Unapparent Effects of the NCCAM-Columbia University-Gonzalez Protocol. Sci Rev Alt Med 7 (2):74-77 (Fall/Winter 2003-4)

   The Ethics of “CAM” Trials. Gonzo (Part VI)
Kimball Atwood
Link
Part V of this Blog argued that the NCCAM-sponsored trial of the “Gonzalez regimen” for cancer of the pancreas is unethical by numerous criteria.† To provide an illustration, it quoted a case history of one of the trial’s subjects, who had died in 2002.¹ It had been written by the subject’s friend, mathematician Susan Gurney. A similar story was told on ABC 20/20 in 2000, albeit not about a trial subject. Each of these cases demonstrates the wide breadth of Gonzalez’s quackery, as did his brush with the New York medical board during the 1990s.
This entry addresses some aspects of how those in charge of the trial failed in their duty to protect human subjects. By implication, it suggests what is necessary to prevent similar travesties in the future. It also addresses, to the small extent that the information exists, what appear to be the final ethical violations: first, that the trial will never be completed, thus having “expose[d] subjects to risks or inconvenience to no purpose.” Second, that Columbia University and the responsible investigators have no intention of explaining why.
Science and Medical Need, not Politics, should Determine Human Studies Agenda
Recall that the impetus for the government to fund a trial of the Gonzalez regimen came not from the NIH itself or from any legitimate scientist, but from the office of an old Laetrile warrior, Indiana congressman Dan Burton. Burton is a well-known bully and shill for implausible medical claims. Stephen Barrett of Quackwatch has justifiably called him “quackery’s best friend in congress.” Burton is a sponsor of the annually-defeated “Access to Medical Treatment Act,” which is a euphemism for Freedom to Defraud You. To illustrate how cozy he is with the tiny world of politically-connected quacks, consider Burton’s glowing recommendation of Rashid Buttar, about whom Dr. Gorski wrote on Monday.
For years, Burton was the chairman of the powerful House Committee on Government Reform. Hearings of that committee, particularly during the 106th and 107th Congresses, were littered with pitches for implausible medical claims and diatribes against immunizations and other rational public health measures. Together with Senator Tom Harkin (D-IA), the creator of the NCCAM, Burton and a few other congressmen have managed to scare NIH scientists and administrators away from their proper concerns with scientific and ethical issues. Thus Richard Klausner, the former director of the National Cancer Institute, eventually caved to the pressure, as reported in Part IV of this blog. So did Claude Lenfant, the former director of the National Heart, Lung, and Blood Institute (bullied here by Burton; caved here).
Shortly after the late Stephen Straus was appointed the first director of the NCCAM in 2000, he revealed in an interview with Science Magazine that he, too, now viewed the scientific and ethical rules of human studies as optional:
Yet principles aside, Straus also has to follow the mandate of Congress–and some of its, well, less-than-scientific members. NCCAM is stuck funding a 5-year, $1.4 million trial of an unusual protocol designed to treat terminal pancreatic cancer by physician Nicolas Gonzalez. The so-called Gonzalez Protocol–a hodgepodge of pancreatic enzymes, coffee enemas, and up to 150 dietary supplements a day–caught the attention of Representative Dan Burton (R-IN), who in 1998 encouraged the National Cancer Institute (NCI) to study it. Even though Straus considers the evidence just an “aggregate of interesting anecdotes,” he defends the trial –albeit lukewarmly. “I’m more comfortable and find it easier to approach and fund things that already make a lot more sense to me,” he admits. “But the mandate here is … to be willing to take more risks for things that are novel.”
Except that Straus did not have to follow the mandate of Congress to its inevitable collision with human studies ethics. Political pressure, “mandates,” alleged popularity of a method, and even laws may not force biomedical scientists to expose human subjects to risks and discomforts that would not otherwise occur. The Helsinki Declaration, which is, in effect, the consensus of world opinion on the subject, addresses the issue explicitly:
Research Investigators should be aware of the ethical, legal and regulatory requirements for research on human subjects in their own countries as well as applicable international requirements. No national ethical, legal or regulatory requirement should be allowed to reduce or eliminate any of the protections for human subjects set forth in this Declaration.
Such language did not happen by accident. It was a purposeful response to the infamous excuse offered at the Nuremberg Trials. Did it occur to Dr. Straus that a very small number of ignorant Congressmen were attempting to require hapless, desperate human subjects, such as Ms. Gurney’s friend, to “be willing to take more risks?” In the US, any NIH scientist not wishing to violate human studies ethics may simply refuse to do so or, if necessary, resign his post. He needn’t worry about being shot.
In less public circumstances, Dr. Straus did not appear to have qualms about the ethics of the trial. At a meeting of the Cancer Advisory Panel for Complementary and Alternative Medicine in 2001,
A long discussion ensued about the Kelley/Gonzalez criteria and efficacy of study; and the potential dampening effect of a failure of this study. Dr. White noted that the eligibility criteria may be too strict. Although the study has been highly publicized, only about 10% of referrals qualify. Possible solutions were discussed without clear answers, since publicity has not been the problem. Dr. Straus noted that in the future, with best case series data, we can have other trials with easier recruitment of patients and less stringent criteria…. Dr. Straus said, “Our ability to reach out and be open-minded about alternative therapies is constantly impugned by traditional medicine and others. We must press on, because this is groundbreaking and important.”
The “it’s out of my hands” plea at the NIH was also apparent at Columbia. Michael Specter, author of the 2001 New Yorker article about Gonzalez, interviewed Karen Antman, who at the time was the chief of Columbia’s division of medical oncology and a past president of the American Society of Clinical Oncology:
I asked if it would be right to infer that she thought the trial wouldn’t work. She shook her head. I asked if she had an idea why it might work. She said no. Did she have any opinions at all about the potential of nutritional therapy or the Gonzalez regime? “I have lots of opinions,” she told me, “but none of them matter.”
Could any reader who imagines that a chief ought to be a chief, or who is aware of the concept of clinical equipoise (discussed last week) not shudder at such an abdication of professional and ethical responsibility? John Chabot, the principal investigator, suggested on several occasions that he was not happy with the trial (here and here, and contradicted his own claim of equipoise here) but proceeded anyway. Susan Gurney argued that the refusal of such authorities to come clean with their views had contributed to the suffering of her friend:
He was an artist—a painter and a sculptor—and he had little scientific knowledge. When Dr. Chabot was neutral about the Gonzalez protocol, and when Dr. Antman said nothing adverse about it, my friend assumed that they must genuinely believe that the treatment could work.¹
Ms. Gurney later wrote me about something she had not included in her article: that James Gordon, the chairman of the White House Commission on Complementary and Alternative Medicine Policy at the time, had “paid a personal visit to my friend’s house – and praised the Gonzalez protocol to him.” The poor subject was a victim of both government-sponsored experts and government appointed pseudo-experts. He could not have known the difference, of course.
The Non-Outcome of the Gonzalez Trial
In anticipation of this blog series I wrote Susan Gurney to ask if she had a copy of the consent form and if she had learned more about the trial over the past few years. I was surprised, but not terribly so, by her reply:
I do not have the Gonzalez consent form….Columbia Presbyterian has been completely consistent in refusing to come forward and publish the study results, or air any of this sad business. John Chabot, the principal investigator, is now head of the Pancreatic Center of Excellence, and in between ski trips I hear that he supposedly does perform skillful and agressive surgery on pancreatic cancer patients. Al Neugut, head of the Herbert Irving Cancer Center, shrugs and says it wasn’t his idea, and pointed the finger at Karen Antman, who I think is now Provost at BU Medical School, and thriving. Victor Grann is in charge of the data, and is helping cover it up and won’t talk. William Sherman, who initially warned me about the study, but in the end could do nothing to stop it and wasn’t willing to rock the boat over it, is still practicing oncology to the best of his rather admirable ability, but it is a sore point and when we speak – which is now infrequent- I do not mention it.
I have called four reporters, written to two, obtained partial records from the NIH, and even paid a lawyer who said he could get me a story – and I have failed completely to get this study reported to the public in any way.
I know from the web that Gonzalez is as active politically about the rights of free trade, vitamin business, etc. as ever – I can only imagine that he is also thriving.
I wondered whether Columbia “refusing to publish the study results” was nothing more than the usual, long delay between the end of subject accrual and the publication of the paper. Gonzalez himself, however, had provided the answer more than a year ago, in an interview for Alternative Therapies:
AT: Let’s talk about the NCI study on your work. Has that been completed?
Dr Gonzalez: I’ve been working on this for more than 7 years. In 1998, we got the first approval for the study, and I started the project in 1999. I thought the project was designed incorrectly from the beginning. The administrators of the study initially set it up as a randomized study in which patients would be randomized into our treatment or chemotherapy. The patients had no choice about treatment. The administrators insisted the study had to be designed this way.
I argued that no one’s going to agree to do that because patients who are interested in the study only want to get my therapy….They spent a year trying unsuccessfully to get it to work as a randomized study. No one wanted to enter, so eventually they had to change the format so patients could choose the therapy they wanted, either ours or chemo. We ran into many other problems, including the predictable bias from the oncology profession. Many patients were discouraged from considering this study by their original oncologists, and a number were discouraged from continuing even after they had entered.
There was a constant undercurrent of hostility toward the study that really had a deleterious effect. Right now, the project is on hold, and government officials are looking into the way the study was set up and run by the people at NCI and Columbia. I can’t go into the details at this point, but I certainly would have run it differently. Our input regarding the design was very often ignored, so there were design flaws in the study that I believed helped undermine the study.
AT: You’re not hopeful some of those issues will be resolved and you’ll be able to move forward with the study?
Dr Gonzalez: I don’t think so. Right now, as far as I’m concerned, it won’t happen. What the NCI or the National Institutes of Health will decide to do, I can’t say, but I’ll tell you, after spending 7 years trying to get the study to work and fighting at every step, I would not want to go through that again….If I really felt that the NCI was serious about looking into alternative therapies, I would reconsider. But after 7 years, I believe they’re just not interested if the treatment wasn’t developed by them or at a major academic institution…
AT: Is it politics or a particular bias?
Dr Gonzalez: I think it’s a question of research bias and experts who surprisingly can’t do anything outside of their particular area of expertise. Natural treatments like mine are not just another chemotherapy, and you can’t design clinical studies to test them as if they were. We don’t offer a chemo drug, where the patient shows up and gets to watch TV and eat ice cream while nurses inject the medication. In our case, the patient has to change his or her entire life, so compliance becomes a major issue. You’re held hostage by patient compliance… This was chemo vs Gonzalez, and the oncology profession by and large rallied against it…For this study to have worked, the NCI needed to rise to the occasion and deal with the pervasive bias within the oncology profession. But they never did. They never did anything. I don’t know whether it was indifference or that they just didn’t care. But they didn’t do what needed to be done, in my opinion.
AT: Is this a case of the methodologies not being appropriate for this type of research or these types of protocols?
Dr Gonzalez: That’s correct. The NCI operates on a drug model and wants natural products to fit into a drug model, and natural therapies don’t. With chemotherapy, patients need only show up. With our therapy, patients have to change their whole life. Should the NCI ever wish to test an alternative dietary or nutritional approach again, they must ensure that the bias of the oncology profession, which in our case influenced accrual and compliance of accepted patients, be effectively countered.
AT: Have you considered writing a book about your treatment plan?
Dr Gonzalez: We’ve just finished a book about the NIH clinical study because so many people wanted to know what happened after 7 years of work. I was asked by some of my congressional supporters to document all the mistakes that were made, and it turned into a book. And we think that should be published.
It is hard to imagine, reading Dr. Gonzalez’s words, that he and Susan Gurney were talking about the same trial. Yet they appear to agree that it has come to a dead end. Gonzalez seems to believe that the reason has to do with “the pervasive bias within the oncology profession” convincing subjects not to be compliant with his regimen. Ms. Gurney’s information suggests a different take: the academics at Columbia were at first altogether too willing to foist patients into the trial, but when it became clear that it was a horrible experience they had second thoughts. Possibly because they realized what a terrible mistake they had made, but almost certainly because the OHRP (Gonzalez’s “government officials,” apparently) came knocking for the third time, Columbia decided to circle the wagons:
…for the record, although Sherman warned me about the trial to begin with – in the end nobody would come forward. I will be happy to be quoted about the sad situation – I have spoken to Chabot in person, who will not come forward and say anything publicly ‘according to the advise of his lawyers’ -which from what I understand are the Columbia Institution lawyers. This is simply being covered up – and the data are not going to be released- publicly – is what I believe. As well, they think that Gonzalez has friends in Congress – so they claim that he would only make Columbia look bad again and they wouldn’t defeat him – only end up taking the blame.
‘Enlightened self-interest’ I believe is the term I heard used.
‘Spineless wonders’ is the phrase that I myself would use.
Epilogue
Gonzalez claimed that the “oncology profession” had influenced not only compliance, but accrual of subjects. The latest OHRP determination letter, however, suggests that there were at least 62 subjects and possibly more than 113—a range consistent with the originally planned goal of 90. So why will there, apparently, not be a report? We have suggested a possible reason above, but that does not deal with the fact that there still must have been outcomes. Even Gonzalez’s claim, that subjects were not compliant, does not excuse the investigators from reporting the results. An “intention to treat” analysis is all the more important for a method that is notoriously difficult for subjects to complete.
What if the outcomes were what most experts would expect, ie, that subjects on the Gonzalez regimen did no better that comparable patients with cancer of the pancreas who were untreated, and worse than those who received standard treatments? That would present an obvious, but embarrassing conclusion: that the New York Office of Profession Medical Conduct had been correct about Gonzalez all along. The only reasonable actions would now be for New York to strip him of his medical license, for the NIH and Columbia University to admit publicly that they had made a terrible mistake in making him responsible for experimental subjects in an NIH-funded trial, and to thereby expose fundamental ethical problems with human trials of implausible medical claims. If the responsible institutions find themselves at odds with Gonzalez’s “friends in Congress,” so be it. Let the debate go public.
It seems that Columbia and the NIH have backed themselves into a corner: the “potential dampening effect of a failure of this study.” Will we be hearing from them anytime soon?
1. Gurney S. Socially Harmful but Unapparent Effects of the NCCAM-Columbia University-Gonzalez Protocol. Sci Rev Alt Med 7 (2):74-77 (Fall/Winter 2003-4)

   The “Gonzalez Trial” for Pancreatic Cancer: Outcome Revealed
Kimball Atwood
Links
A Review
Dr. Lipson’s “detoxification” post on Thanksgiving Day and Dr. Gorski’s recent post about “Gerson Therapy” were timely, because last weekend I noticed something that I should have noticed months ago. Before delivering the punch line, let me remind you, Dear Reader, of the nature of the topic. The regimen advocated by Nicholas Gonzalez is a variation of a “detoxification” treatment for cancer that has been around, in one form or another, for more than 50 years (“Gerson Therapy” is another example).† Here is the National Cancer Institute’s (NCI) description:
Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
As unlikely as it may seem, in 1999 American taxpayers began paying for people with cancer of the pancreas to be subjected to that regimen, in a trial sponsored by the National Center for Complementary and Alternative Medicine (NCCAM) and the NCI, conducted under the auspices of Columbia University. Gonzalez provided the treatments. A few months ago I presented a multi-part treatise on the “Gonzalez regimen” and the trial. It demonstrated that all evidence, from basic science to clinical, including the case series that supposedly provided the justification for the trial, had failed to support any real promise (the case series had previously been considered by reader Dr. Peter Moran, who also found them wanting).
It showed that the impetus for the trial, as has been true for other regrettable trials of implausible health claims, can be traced not to science but to the reactionary politics of anti-intellectual populism: initially to Laetrile and to the “Harkinites,” and more recently to the Honorable Dan Burton (R-IN). It reported that there were major problems with the Gonzalez trial from the outset, and that for at least one subject the regimen was more torture than therapy. It reported that for unclear reasons the trial had come to a halt a couple of years ago, and that it appeared that there would never be a report of its findings.
Ethical Breaches
That series of posts also argued what was later summarized here: that, for clear-cut reasons, the New York State Board for Professional Medical Conduct had nearly revoked Dr. Gonzalez’s medical license during the 1990s—only to retreat from that position after two misguided academics testified that his regimen might benefit cancer patients.
The apparent “non-outcome” of the Gonzalez trial would be the final insult among its numerous, serious ethical violations. These were discussed, at some length, here and here. Several readers subsequently lamented that the results might never be made public: these included Drs. Moran and Gorski, and even an admirer of Nicholas Gonzalez, who identified himself as one of his patients.
The Outcome Revealed
The last post in that series occurred on May 2, 2008. One month later, the federal Office for Human Research Protections (OHRP) issued yet another determination letter regarding the Gonzalez trial. I gave it a cursory look in June, but I must have been distracted by other topics at the time; last weekend I hauled it out and couldn’t believe what I saw at point number “4″ (emphasis added):
The complainant alleged that a minimum of 72 subjects were to be enrolled under the IRB-approved protocol, but that the study was terminated with only 62 enrolled subjects, in violation of HHS regulations… CUMC [Columbia University Medical Center] reported that the Data Safety and Monitoring Committee (DSMC) for this protocol recommended that the study be terminated before it reached its full enrollment of 72 subjects. At its September 30, 2005 meeting, the DSMC recommended that the study be terminated due to predetermined stopping criteria. This information was submitted to the CUMC IRB on October 17, 2005, and the study termination was approved by the IRB. Termination of the study in response to the DSMC recommendation was appropriate.
Most of you will immediately recognize the significance of those words. For those who don’t, let me explain, with slight oversimplification. A human trial of an investigational treatment is “terminated due to predetermined stopping criteria” for only one of two possible reasons:
A. At some point during the trial the investigational treatment is found to be superior to the standard (control) treatment, to an extent sufficient to render the remainder of the planned trial incapable of refuting this finding. Thus the trial is halted because the favorable outcome is certain and it would now be unethical to withhold the investigational treatment from the control group. It would also be unethical not to make this information public as soon as is realistically possible.
B. At some point during the trial the investigational treatment is found to be inferior to the standard (control) treatment, to an extent sufficient to render the remainder of the planned trial incapable of refuting this finding. Thus the trial is halted because the unfavorable outcome is certain and it would now be unethical…you know the rest. “Inferior,” by the way, needn’t mean merely “not as effective.” More commonly, it means “more dangerous.”
At the risk of belaboring the obvious, I ask the reader to imagine which outcome applied to the Gonzalez trial. If ”A” had been the case, wouldn’t it have been splashed all over the front pages of newspapers everywhere, way back in 2005? Of course it would have. It is certain that ”B” was the explanation for the trial having been halted. This is not the least bit surprising, in light of what we already knew about the onerous regimen.
More Evidence
For the benefit of paranoiacs who believe that modern medicine is in cahoots with drug companies to deprive honest people of effective therapies, let’s consider more evidence that ”B” above must have been the trial’s outcome. In Part VI of my original series on the Gonzalez matter, I quoted from a 2007 interview published in Alternative Therapies:
AT: Let’s talk about the NCI study on your work. Has that been completed?
…
Dr Gonzalez: …We ran into many other problems, including the predictable bias from the oncology profession. Many patients were discouraged from considering this study by their original oncologists, and a number were discouraged from continuing even after they had entered.
There was a constant undercurrent of hostility toward the study that really had a deleterious effect. Right now, the project is on hold, and government officials are looking into the way the study was set up and run by the people at NCI and Columbia. I can’t go into the details at this point, but I certainly would have run it differently. Our input regarding the design was very often ignored, so there were design flaws in the study that I believed helped undermine the study.\
AT: You’re not hopeful some of those issues will be resolved and you’ll be able to move forward with the study?
Dr Gonzalez: I don’t think so. Right now, as far as I’m concerned, it won’t happen. What the NCI or the National Institutes of Health will decide to do, I can’t say, but I’ll tell you, after spending 7 years trying to get the study to work and fighting at every step, I would not want to go through that again…
…Natural treatments like mine are not just another chemotherapy, and you can’t design clinical studies to test them as if they were. We don’t offer a chemo drug, where the patient shows up and gets to watch TV and eat ice cream while nurses inject the medication. In our case, the patient has to change his or her entire life, so compliance becomes a major issue. You’re held hostage by patient compliance…
…With our therapy, patients have to change their whole life. Should the NCI ever wish to test an alternative dietary or nutritional approach again, they must ensure that the bias of the oncology profession, which in our case influenced accrual and compliance of accepted patients, be effectively countered.
AT: Have you considered writing a book about your treatment plan?
Dr Gonzalez: We’ve just finished a book about the NIH clinical study because so many people wanted to know what happened after 7 years of work. I was asked by some of my congressional supporters to document all the mistakes that were made, and it turned into a book. And we think that should be published.
Do those sound like the words of someone whose mavericky treatment has recently been exonerated?
The Complainant Probably Revealed
Within that quotation is a statement that is interesting for another reason:
…government officials are looking into the way the study was set up and run by the people at NCI and Columbia. I can’t go into the details at this point, but I certainly would have run it differently.
Dr. Gonzalez appears to have been referring to the OHRP’s investigation that eventually resulted in its determination letter of June 2, 2008, quoted above. Further evidence for this is the preliminary determination letter of Feb. 25, 2008, which was part of the same investigation. The June 2 letter, moreover, includes several “complainant allegations”—numbers 3-7—that, in summary, charge that Columbia University had enrolled subjects who were either too sick or too emotionally unstable to comply with the “Gonzalez Regimen,” and that the DSMC’s decision to stop the trial had been wrong. The OHRP found, however, that each of these allegations was without merit.
All of this suggests that the complainant in this case was not someone who recognized the trial as unethical for all the reasons discussed here months ago, but rather someone who knew that the results of the trial were not flattering to the “Gonzalez Regimen,” and was rather desperately trying to make that inconvenient fact go away. Someone, that is, such as Gonzalez himself, or a surrogate believing himself to be acting in Gonzalez’s interest.
Another relevant statement, previously quoted but now perhaps more revealing than it seemed then, is from mathematician Susan Gurney, who had written an account of one subject’s unfortunate experience in the trial:
…for the record, although Sherman warned me about the trial to begin with – in the end nobody would come forward. I will be happy to be quoted about the sad situation – I have spoken to Chabot in person, who will not come forward and say anything publicly ‘according to the advise of his lawyers’ -which from what I understand are the Columbia Institution lawyers. This is simply being covered up – and the data are not going to be released- publicly – is what I believe. As well, they think that Gonzalez has friends in Congress – so they claim that he would only make Columbia look bad again and they wouldn’t defeat him – only end up taking the blame.
‘Enlightened self-interest’ I believe is the term I heard used.
‘Spineless wonders’ is the phrase that I myself would use.
Finally, consider this excerpt from a comment by a reader calling himself “CAMCENTRAL.” It appeared in October, months after the final posting of my original series:
The reason there has been no data published is that the study was poorly managed by the NIH and Columbia. The principal investigator at Columbia has been found guilty by the Office of Human Subject Protections for among other things failing to follow federal guidelines on obtaining written informed consent from patients for a majority of the patients. Among the many problems that doomed this study were that the principal investigator, Dr. John Chabot, not Dr. Gonzalez was in complete charge of patient referral to the nutritional arm and repeatedly referred patients who did not fit within the protocol and who never fully participated in the treatment. The truth on this will one day come out, but the fault on this study lays clearly at the fit [sic] of the NIH staff responsible for managing this study and of the principal investigator Dr. John Chabot…that he continues to be allowed to be involved in clinical trials is a real travesty.
A New Epilogue
We now know considerably more than we did in May. The Gonzalez trial was stopped early, in 2005, after the DSMC found that the data convincingly demonstrated that the regimen was inferior to standard treatment for cancer of the pancreas. This information has been available to the public since June 2, 2008, but until now could be found only in the esoteric OHRP determination letter. The reason that the results of the trial have not been reported in the usual way, or otherwise made public by the relevant sponsoring and investigating institutions or individuals, appears to be that Gonzalez or someone close to him, likely with the aid of lawyers and “friends in Congress,” has managed to suppress them. Ironically, Gonzalez (or his surrogate) seems to have shot himself in the foot: the unsuccessful appeal to the OHRP to cast doubt on the trial results is the only reason we know that the trial was “terminated due to predetermined stopping criteria.”
Isn’t it odd that government websites, including the National Cancer Institute and ClinicalTrials.gov (“Last updated: October 18, 2008″), continue to portray the Gonzalez trial as ongoing? Time to come clean, fellas: your cover is blown. We the taxpayers, not Gonzalez or Burton or Columbia University or the NCI or the NCCAM, own this trial. We know the main outcome in spite of Gonzo and/or his friends attempting to silence it, and in spite of spineless wonders who seem all too willing to be silenced. Now we want the details.

   “Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part I: Results)
Kimball Atwood
Link
One of the more bizarre and unpleasant “CAM” claims, but one taken very seriously at the NIH, at Columbia University, and on Capitol Hill, is the cancer “detoxification” regimen advocated by Dr. Nicholas Gonzalez:
Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
Veteran SBM readers will recall that in the spring of 2008 I posted a series of essays* about this regimen and about the trial that compared it to standard treatment for subjects with cancer of the pancreas. The NIH had funded the trial, to be conducted under the auspices of Columbia, after arm-twisting by Rep. Dan Burton [R-IN], a powerful champion of quackery, and much to the delight of the “Harkinites.”
In the fall of 2008 I posted an addendum based on a little-known determination letter that the Office for Human Research Protections (OHRP) had sent to Columbia during the previous June. The letter revealed that the trial had been terminated in October, 2005, due to “pre-determined stopping criteria.” This demonstrated that Gonzalez’s regimen must have been found to be substantially worse than the current standard of care for cancer of the pancreas, as ineffective as that standard may be. I urge readers who require a review or an introduction to the topic to read that posting, which also considered why no formal report of the trial had yet been made available.
Now, finally, the formal report has been published online by the Journal of Clinical Oncology (JCO):
Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer
John A. Chabot, Wei-Yann Tsai, Robert L. Fine, Chunxia Chen, Carolyn K. Kumah, Karen A. Antman, and Victor R. Grann
JCO Early Release, published online ahead of print Aug. 17, 2009. Journal of Clinical Oncology, 10.1200/JCO.2009.22.8429
The Results of the Gonzalez Trial
The abstract can be read here. First, the punch line:
Conclusion: Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme [Gonzalez's] treatment.
According to the article proper,
Twelve months after enrollment, 56% of chemotherapy-group patients were alive; 16% of the enzyme-group patients were alive. The longest survivors were one chemotherapy-group patient who died at 39.5 months and one chemotherapy-group patient who was censored at 37.5 months (ie, the closing date of the data analysis) and, at the time of manuscript submission, was still alive at 40 months.
The Gonzalez regimen was not only much worse than standard treatment in this study; it was also substantially worse than the experience of more than 20,000 comparable patients in the US between 1988 and 2001, as reported by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. This is illustrated in a self-explanatory figure from the JCO paper:
The Columbia trial also looked at ’quality of life’:
In this study, patients in the enzyme-treatment and chemotherapy groups had similar scores in quality of life at enrollment, but the enzyme group fared much worse than the gemcitabine group in the subsequent year…Pain levels appeared to diverge during the initial 6 months of the study and were more severe among the enzyme group.
Discussion
This is a slam-dunk condemnation of the Gonzalez regimen. For more than 20 years, Gonzalez has claimed near-miraculous survival times—measured in years-to-decades, rather than in months—for patients with life-threatening cancer, including pancreatic cancer. His “case series,” upon which the NIH’s decision to fund a large trial was purportedly based, had included 11 patients. According to the National Cancer Institute (NCI):
The investigators reported a median survival time of 17 months and a mean survival time of 25.2 months for these patients. Nine patients (82%) survived 1 year, five patients (45%) survived 2 years, and four patients (36%) survived 3 years. At the time the study was reported, two patients were alive: one who had survived 3 years, and one who had survived 4 years. The researchers concluded that the 1-year and 2-year survival percentages for this group of patients were superior to those observed for other U.S. patients diagnosed with adenocarcinoma of the pancreas (1-year survival, all stages = 25%; 2-year survival, all stages = 10%).
I have previously explained (here and here), as has Dr. Peter Moran (here), why that case series was unreliable and was not a worthy basis for conducting a larger trial.
Dr. Gonzalez has also claimed that patients who use coffee enemas “report an increased sense of well being.” He reportedly told at least one subject in the Columbia trial
that pain might be an indication that the tumors were being dissolved, and that he could expect weight loss as he was detoxifying his body.
The JCO report soundly refutes Gonzalez’s claims. The treatment does not prolong the lives of patients with cancer of the pancreas; it substantially shortens their lives. It does not increase patients’ sense of well being; rather, it makes their quality of life “much worse.” The fate of the typical subject in the “enzyme” group appears to have been similar to that of a young man whose tragic story was told by his friend, Susan Gurney, and recounted here.
Is this the last word on the Gonzalez regimen? Are there weaknesses in the study that might save it, at least for now? I raise this question for completeness’ sake only, for in my opinion there was never a justification for performing the trial. Nevertheless, I’ll mention the only obvious methodologic flaw: As previously discussed, the trial was not randomized because at its outset too few prospective subjects were willing to take a chance on not being in the “Gonzalez” group. Thus allocation to that group was chosen by the subjects themselves. They were compared to a cohort of patients who chose standard treatment. Although not randomly allocated, the subjects in the two groups were reported to be well matched:
Fifty-ﬁve patients, 23 on the control arm and 32 on the experimental arm, enrolled on the study and were available for analysis… The patients in both the control and experimental arms were carefully enrolled according to identical entry criteria. There were no statistically signiﬁcant differences at the time of enrollment in age, sex, weight, ECOG performance status, stage of disease, pathology, quality of life, or CA19-9. Bilirubin and albumen were signiﬁcantly higher in the chemotherapy group, but all values were clinically within normal limits and met eligibility criteria.
All but two subjects in each group, moreover, were judged Grade 0 (“Fully active, able to carry on all pre-disease performance without restriction”) or Grade 1 (“Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work”) by the Eastern Cooperative Oncology Group (ECOG) Performance Status assessment. This is important because, as I reported last year, someone (probably Gonzalez or a surrogate) had complained to the OHRP that several subjects who would not be capable of adhering to the “enzyme” regimen had been enrolled in the trial (see points 5-7 in the OHRP letter).
The lack of randomization (and blinding), then, seems insufficient to cast doubt on such a definitive outcome. It is likely, moreover, that any bias resulting from self-selection of subjects to the Gonzalez group would have skewed the results in favor of that regimen—the opposite of what was ultimately found. Gonzalez himself seemed to realize this back in 2000, when the trial had barely begun:
DR. GONZALEZ: Interesting question. I didn’t have time to go into the details of how it was going. Initially, it was set up as a randomized trial about a year ago, and Jeff and I kind of struggled with that and I always knew there would be problems.
And—–going back to this gentleman’s question, I’m the first person on Earth to say that the belief system of the patient is really important in how they do. Randomized trial patients have no choice and the study was set up when my therapy was being compared to the best available chemotherapy for inoperable pancreatic adenocarcinoma.
Well, patients know in this day and age chemotherapy is a death sentence for inoperable pancreatic adenocarcinoma and our first study had already been published.
Over a period of several months, Columbia got 200 phone calls. A hundred and ninety-seven patients, who would have been perhaps appropriate for the study, refused to enter unless they could be guaranteed my arm of the study.
Now a randomized study is considered the gold standard and I felt we had to at least try. Dr. Klausner thought we had to try. Dr. White thought we had to try. After a year of trying that we all realized it wasn’t going to work that way, so we set it up as a case control where patients have choice. If they want chemo, they get chemo; if they want me, they get me.
Hopefully, their belief in chemo will be as strong as the patients’ belief in my therapy. We’re going to try and match them evenly.
Now in terms of technical methodology it’s maybe a little less rigorous than a randomized study, but it’s raised all kinds of issues about how you test an alternative therapy where belief is important and a patient who doesn’t care whether they get chemo or my therapy for pancreatic cancer is going to be a very unusual patient.
Patients who come to me usually believe in this. They would seek alternatives. By definition, they’re seeking something different.
At the same conference, Gonzalez opined that in order to validate his regimen, the trial would eventually need to demonstrate outcomes virtually the inverse of what have now been reported:
DR. GONZALEZ: It’s set up as a survival study. We’re looking at survival.
SPEAKER: Do you have an idea of what you’re looking for?
DR. GONZALEZ: Well, Jeff and I were just talking a couple weeks ago. You know, to get any kind of data that would be beyond criticism is—-always be criticism, but at least three times.
You would want in the successful group to be three times — the median to be three times out from the lesser successful groups.
So, for example, if the average survival with chemo, which we suspect will be 5 months, you would want my therapy to be at least — the median survival to be at least 15, 16, 17 months, as it was in the pilot study.
We’re looking for a median survival three times out from the chemo group to be significant.
To save you the trouble of scrolling upward, let me repeat the JCO report’s conclusion:
Among patients who have pancreatic cancer, those who chose gemcitabine-based chemotherapy survived more than three times as long (14.0 v 4.3 months) and had better quality of life than those who chose proteolytic enzyme treatment.
There is More to This Story
I am happy that the results of the Gonzalez trial, such as they are, have finally been made public. Nevertheless, the report is full of troubling information, both stated and unstated. There is substantial evidence of ethical breaches, including some that might elude readers who are not familiar with the topic. A compelling argument can even be made that the JCO should not have published the report—as paradoxical as that sounds. I’ve previously discussed several of these issues (also here), but the JCO report demands that they be revisited. I’ll do that next week.
REFERENCE:
John A. Chabot, Wei-Yann Tsai, Robert L. Fine, Chunxia Chen, Carolyn K. Kumah, Karen A. Antman, & Victor R. Grann (2009). Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer Journal of Clinical Oncology : 10.1200/JCO.2009.22.8429 (E-pub ahead of print)

   “Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part II: Loose Ends)
Kimball Atwood
Link
Last week I discussed the dismal results of the “Gonzalez Trial” for cancer of the pancreas,* as reported in an article recently posted on the website of the Journal of Clinical Oncology. I promised that this week I’d discuss “troubling information, both stated and unstated [in the report],” and also some ethical issues. More has come to light in the past few days, including Nicholas Gonzalez’s own voluminous, angry response to the JCO article. I’ll comment upon that below, but first a brief review.
The trial was begun in 1999 under the auspices of Columbia University, after Rep. Dan Burton had pressured NCI Director Richard Klausner to fund it. It was originally conceived as a randomized, controlled trial comparing the “Gonzalez Regimen” to standard chemotherapy for cancer of the pancreas. In the first year, however, only 2 subjects had been accrued, purportedly because those seeking Gonzalez’s treatment were not willing to risk random assignment to the chemotherapy arm. In 2000, the protocol was changed to a “prospective, cohort study” to allow potential subjects to choose which treatment they would follow. Gonzalez himself was to provide the ‘enzyme’ treatments.
After that there was little public information about the trial for several years, other than a few determination letters from the Office of Human Research Protections and a frightening account of the experience of one subject treated by Gonzalez. By 2006 or so, those of us who pay attention to creeping pseudomedicine in the academy were wondering what had become of it. About a year ago we found out: the trial had been quietly “terminated” in 2005 after it met “pre-determined stopping criteria.” As explained here, that meant that the Gonzalez group had not fared well.
Four years after the trial’s ‘termination,’ the report was finally published: The Gonzalez cohort had not only fared much worse than the cohort that received chemotherapy, but it had fared worse than a comparable group of historical controls. Here, again, is the survival graph from the JCO paper:
The Gonzalez group had also fared much worse in ‘quality of life’ scores, which included a measure of pain.
Now let’s read between the lines. Forgive me for taking shortcuts; I’m a little pressed for time.
Problems: Stated and Unstated
The Authors
The first, glaring omission from the paper is Gonzalez’s name among the authors. I’ll discuss that below, together with observations about his posted response to the publication of the report.
The “Introduction”
Here is the entire rationale offered for having performed a trial of the Gonzalez regimen:
The Scottish embryologist John Beard ﬁrst proposed pancreatic proteolytic enzyme treatment in 1906 and soon after published a monograph, entitled The Enzyme Therapy of Cancer. In 1981, Nicholas Gonzalez began to evaluate the use of proteolytic enzyme therapy. Twelve years later, in 1993, he was invited to present a series of cases at the National Cancer Institute (NCI), which led him to undertake a case series of alternative medical therapy that included proteolytic enzymes, diet, nutritional supplements, and detoxiﬁcation procedures. Among 11 patients with inoperable, biopsy-proven, stages II to IV pancreatic adenocarcinoma, he reported 81% survival at 1 year and 45% at 2 years. Four of the 11 patients survived for 3 years.
…
As a result of [the] bleak survival reports [of standard treatment] and the promise of proteolytic enzyme therapy, the NCI, in November 1998, funded a randomized, controlled, phase III trial.
What’s missing:
A discussion of Beard’s quaint proposal in light of current knowledge.
    • The common sense observation that a century ought to have been enough time for this ‘theory’ to declare itself one way or the other (it did, of course).
    • The NCI’s inviting Dr. Gonzalez to present his case series had been motivated not by scientific interest, but by political pressure that had been building since the demise of Laetrile, as explained here, here, and here.
    • There was no promise of proteolytic enzyme therapy. It was implausible to begin with, and Gonzalez’s case series was not valid, as explained here, here, and here.
    • Quotation marks around the word “detoxification.” Or better, an explanation.
    • The real reasons that the NCI funded the trial.
My opinion of what’s missing is not merely my opinion. According to the JCO “Information for Contributors” page:
At the 2008 ASCO Annual Meeting, Editor-in-Chief Dr. Daniel Haller spoke on “How to Write an Outstanding Manuscript.” In his lecture, Dr. Haller shared tips on how to write and submit your manuscript, an overview of the publication and review process, considerations for journal editors and contributors, and more. To view click here.
If you do that, here’s what you’ll find in Dr. Haller’s talk:
For Phase III clinical trials, follow CONSORT guidelines closely.
CONSORT stands for Consolidated Standards of Reporting Trials. Here is part of its statement regarding “The Introduction”:
Typically, the introduction consists of free-flowing text, without a structured format, in which authors explain the scientific background or context and the scientific rationale for their trial…Authors should report the evidence of the benefits of any active intervention included in a trial. They should also suggest a plausible explanation for how the intervention under investigation might work, especially if there is little or no previous experience with the intervention. The Helsinki Declaration states that biomedical research involving people should be based on a thorough knowledge of the scientific literature. That is, it is unethical to expose human subjects unnecessarily to the risks of research…
We’ll continue to reference the CONSORT statement as we look at…
The Methods
From CONSORT:
The study intervention: Authors should describe each intervention thoroughly, including control interventions…In some cases, description of who administered treatments is critical because it may form part of the intervention. For example, with surgical interventions, it may be necessary to describe the number, training, and experience of surgeons in addition to the surgical procedure itself. When relevant, authors should report details of the timing and duration of interventions, especially if multiple-component interventions were given.
From the report of the Gonzalez trial:
Proteolytic Enzyme Treatment
The enzyme treatment included orally ingested proteolytic enzymes, nutritional supplements, detoxiﬁcation, and an organic diet (unaltered from the pilot study). Patients received three pancreatic enzyme and two magnesium citrate capsules with each meal. The patients also took speciﬁed numbers of capsules with magnesium citrate and Papaya Plus every 4 hours on an empty stomach. The dose for patients with stage II disease was 69 enzyme capsules, and the dose for patients with stages III or IV was 81 capsules per day. After day 16, patients had a 5-day rest period and then resumed treatment on day 22. Treatment could be adjusted by the physician and could be increased for cancer progression. A diet that required at least 70% of the food to be raw or minimally cooked was required. All food was organic. Prescribed detoxiﬁcation procedures included coffee enemas twice each day; skin brushing and cleansing; salt and soda baths; and a liver ﬂush, clean sweep, and purging.
Questions:
    • Would the physician know how to adjust the treatment for cancer progression, when the treatment has never been studied in a systematic way?
    • How would the physician even know if there had been cancer progression, if he believes that “pain might be an indication that the tumors were being dissolved, and that [the patient] could expect weight loss as he was detoxifying his body”?
    • What is the meaning of “detoxification” in this context? How could a coffee enema be considered a detoxification procedure? How could skin brushing be considered detoxification? Where is the evidence that there are special toxins on the skin of people with cancer of the pancreas, or that removing them might have anything to do with its treatment?
    • What is a “liver flush”? What is a “clean sweep”? These are not coherent medical or scientific terms. In a scientific report, neologisms must be defined and their rationale explained.
    • What about advising subjects to have the fillings removed from their teeth? There is no mention of that in the methods, but we know that Dr. Gonzalez advised at least one subject to do that.
Another pertinent passage:
Patients in the experimental arm received proteolytic treatment under the care of a practitioner familiar with the regime…
That practitioner was Gonzalez himself. Wasn’t this important enough to mention in the report?
The Discussion
Pertinent excerpts:
Little is known about…the benefits or harms of alternative medicine used in place of conventional, evidence-based treatments [for cancer].
Oh really? Actually, quite a lot is known, and none of it is good.
This report may be among the first…to compare allopathic treatment to an alternative medicine program…
Ouch! The A-word is a dead give-away that the authors know little of their topic. And let’s hope that this is the last such report, for reasons introduced in this passage:
Despite the intent of all the investigators involved to complete the study as an initially planned (ie, a randomized, controlled trial), physicians and patients were strongly committed to their own beliefs. Unless physicians convey clinical equipoise and sincere uncertainty about which treatment is better, patients rarely submit to random assignment, especially in the setting of a lethal disease.
The problem is that there was not clinical equipoise, period. There was never a consensus among experts in cancer medicine or cancer biology that the Gonzalez Regimen was even remotely likely to be comparable to the best current treatment, even for a chemotherapy-resistant tumor such as cancer of the pancreas. Dr. Chabot, the Principal Investigator, stated as much when he first advertised the trial—without, apparently, realizing the implication. If either subject accrual or subject compliance in the trial was compromised by oncologists warning patients away from the Gonzalez regimen (as Gonzalez maintains happened), that meant only one thing: that the trial never should have begun, because it did not satisfy a fundamental ethical requirement.
That the authors failed to grasp that general truth is confirmed in this passage:
The ﬁndings in this study suggest that controlled studies of alternative medicine regimens are feasible…
Finally, this passage raises questions:
The unexpectedly long survival observed in the gemcitabine group also may have been due to the selection criteria and changes in supportive care (eg, better use of surgical procedures, antibiotics, pain medication, and noninvasive placement of biliary stents).
As I suggested in a comment last week, I believe that here the authors were comparing the survival curve of the gemcitabine group in this trial to survival outcomes in other chemotherapy trials—not to the survival curve of the Gonzalez group. Nevertheless, the passage raises the issue of possible differences in supportive care between the two groups in this trial. There almost certainly were such differences, as evidenced by the experience of Susan Gurney’s friend and as now claimed by Gonzalez himself:
For those subjects destined to receive chemotherapy, Dr. Fine had at his disposal the resources of Columbia, a team of expert senior physicians, researchers, fellows (oncologists in training), residents, highly skilled oncology nurses and other support personnel, and all the high tech facilities one could wish for. According to his own statements, he and his highly motivated team employ all the benefits of modern academic, hospital based medicine, sparing no intervention, withholding no aid to keep patients alive – even to the point of repeated surgeries, and paracentesis (removal of abdominal fluid) done 2-3 times a week, a procedure rarely in the past pursued so determinedly. Those under Dr. Fine’s charge could not ask for more intense or sophisticated care, from an enthusiastic, supportive staff at a major academic institution. Our patients, on the other hand, faced quite a different and often grim situation at the hands of local doctors at best indifferent and frequently hostile to our therapy.
…
Of all the nutrition patients, only one – who ultimately survived 3.5 years – received anywhere near the level of intensive supportive care and encouragement given the chemotherapy patients. In this unique situation, the local doctors coordinated their treatment with me, realizing full well that he was sustaining a most unusual response. In no other case did the local doctors encourage aggressive intervention to keep the patients alive and also on the nutritional therapy. The general physician attitude toward our patients could not be in sharper contrast to the enthusiastic team approach of Dr. Fine, whose talented staff appear to have one ultimate, determined goal with all their intensive care, to keep patients alive as long as possible and on treatment as long as possible.
I regard this complaint by Gonzalez, even if true, as disingenuous. If he felt that way at the time, he should have kicked and screamed it from the rooftops. Why didn’t he mention it in his complaint to the OHRP? We find nothing of the sort in either the two, pertinent determination letters (here and here) or in Gonzalez’s rebuttal to those letters. What we know about Gonzalez’s practice style is that his response to signs of complications or disease progression has been to deny, ignore, rationalize, or otherwise ‘treat’ them with his ‘regimen’ (look here under “A Clinically Competent Medical Person?”). I suspect that he thought of this complaint only after reading the JCO report.
Gonzalez’s sudden enlightenment notwithstanding, a parity in supportive care between the two groups would almost certainly not have changed the survival differences in any important way. It might have changed the ‘quality of life’ differences, however, particularly regarding pain. In any case, for both scientific and ethical reasons there should not have been such a disparity, and since many ‘supportive care’ interventions were not part of the formal protocol they should have been reported in the JCO article, as required by the CONSORT standards for reporting results:
Authors should report all departures from the protocol, including unplanned changes to interventions, examinations, data collection, and methods of analysis.
Gonzalez Answers More Questions
In his posted response to the JCO article, Gonzalez has answered several of the questions that we’ve posed over the last couple of years. He was, as we suspected, the author of the last complaint to the OHRP: the one that, ironically, resulted in our discovering what had happened to the trial. His identity as the complainant is made clear by his unhappy response to the OHRP’s findings, and also by a piece written in 2008 by his friend, ‘Harkinite’ Ralph Moss–which I hadn’t noticed until last week (thank you, Peter Moran).
Second, we have a pretty good idea why it took the Columbia team so long to publish the report. Gonzalez tacitly threatened the authors and Columbia with serious repercussions if they did so, and given his relations with powerful politicians Dan Burton and Tom Harkin, he may actually have been able to deliver on that threat (maybe he still can). In a 2006 letter to Lee Goldman, Dean of the Columbia University College of Physicians and Surgeons, Gonzalez warned that Burton and Harkin had already leaned on then-NIH Director Elias Zerhouni on his behalf. We are also told, in that letter, that a manuscript of the trial report had been submitted to the Journal of the American Medical Association (JAMA) at some time during 2006–unbeknownst to Gonzalez until he was phoned by the oncology editor. According to Gonzalez, who had not been listed as one of the authors, JAMA rejected the manuscript after that phone conversation.
This information, together with Susan Gurney’s having reported that PI Chabot would “not come forward and say anything publicly ‘according to the advise of his lawyers’ –which from what I understand are the Columbia Institution lawyers,” suggests that Columbia really was cowed, for a time, by Gonzalez’s threats. This is not a valid reason for having deprived desperate cancer patients of the results, of course. I wonder what changed recently?
Third, we have a damn good idea why Gonzalez wasn’t listed as an author, or even as the “participating alternative practitioner“: that he, or perhaps the Columbia Institution lawyers, had warned against it. Gonzalez, by the way, stumbles badly in his long complaint to Dean Goldman when he writes:
I had no knowledge of any “manuscript preparation” in progress, I was never invited to discuss the manuscript during its preparation, and I never heard from anyone about a manuscript until Dr. Pasche of JAMA called me on December 3, 2006. I was rather surprised, to say the least, to learn from Dr. Pasche that without my knowledge a paper had been written…
Hmmm. On the previous page, Gonzalez mentions a “research team meeting” in June, 2006, to which he had been invited but did not attend. One of the agenda items for that meeting was “Discussion of data analyses and the preparation of the study manuscript.” Afterward, Dr. Gonzalez received the minutes of the meeting “promptly.” In his own words,
The notes do indicate…that Dr. Chabot and the others intended to publish and publicize the data as if the study had legitimately been brought to conclusion.
Gonzalez: The “data, in my opinion, [are] largely meaningless, and the controversies surrounding my work still unresolved“
Is this true? Was the trial so flawed that its reported results are meaningless? Gonzalez cites a 2005 letter from Dr. Linda Engel, “the official spokesperson of the NIH,” to support his contention:
…it appears as if the current design and implementation of the study may have resulted in accrual into the two study arms of patient populations that are not comparable. As a consequence, it is very difficult (if not impossible) to ascertain treatment effect with any certainty.
…
…it is highly likely (if not certain) that reviewers of the data from this study will raise substantive and legitimate concerns about the comparability of the two populations. As a consequence, it is virtually certain that the controversy surrounding the study will not be settled by the data from it.
Gonzalez’s representation of Dr. Engel as “the official spokesperson of the NIH” is misleading. What she was, at the time of her letter, was Special Assistant to the Director of the NCCAM. The Director was the late Stephen Straus, who, in a 2001 meeting discussing the Gonzalez trial, had worried that
Our ability to reach out and be open-minded about alternative therapies is constantly impugned by traditional medicine and others. We must press on, because this is groundbreaking and important.
As is the norm for NCCAM functionaries, Dr. Engel’s views were politically, not scientifically based. More about this below.
Dr. Gonzalez’s arguments are many, his writing voluminous and redundant, his tone paranoid and conspiratorial. Some of what he writes may be true, and if so speaks to the ethics of the trial and to some of the inadequacies of the report: among these are charges of inadequate informed consent procedures and of undisclosed conflicts of interest among some of the authors. The only charge that could possibly render the data meaningless, however, is that the two cohorts were sufficiently different, in their degree of disease progression, to explain the difference in reported outcomes. This, in my opinion, is demonstrably untrue.
To simplify the exercise, let’s see what happens if we ignore the gemcitabine arm altogether. We needn’t concern ourselves with it, because its better-than-previously reported outcomes, so rankling to Gonzalez and to Dr. Engel, are beside the point. What interests us about this trial is that the Gonzalez group did so poorly: worse than the SEER data for comparably staged cancer of the pancreas, and much worse than Gonzalez’s previously reported, unsupervised case series. Gonzalez worries that PI Chabot saddled him with sicker patients than were allocated to the chemotherapy arm:
During one of the regularly scheduled group meetings held December 13, 2004 at Dr. Chabot’s Columbia office, at a time the clinical trial had been up and running for a full five years, Dr. Isaacs and I first became aware of a very significant difference in both the total number of patients entered into each arm, and the stage of their disease. By that time, 38 patients had been admitted for nutrition treatment, and of these, approximately 76% by our accounting had been initially diagnosed with the most advanced (stage IV) disease, the other 24% with earlier stage II or III. This pattern approximated, as did our pilot study, the usual distribution of newly diagnosed pancreatic cancer patients as reported in the literature.
…during that meeting, Dr. Chabot handed out a “data chart” which included the total numbers of patients admitted into each of the two groups, with the breakdown by stage. First, I was surprised that he had tabulated the numbers incorrectly for our group, which he reported incorrectly consisted of 35% at stage II and III and 64.7% at stage IV. But I was even more surprised to learn that the chemotherapy arm of the study, created under the direction of the Columbia oncologists, consisted of only 14 patients, 61.5% with earlier stage II and III disease, with only some 38% as advanced stage IV – a near reversal of the distribution in the nutrition group, and a reversal of the usual breakdown reported among patients diagnosed with pancreatic cancer.
Well, all right, for the sake of argument let’s assume that this happened. It would certainly have ethical implications, but what does it say about the efficacy of the Gonzalez regimen? In order to answer the question, consider another of Gonzalez’s statements from the same essay (emphasis added):
The literature reports only 5% or less of patients will be initially diagnosed with stage I tumors. Of the group categorized as “non-stage I” approximately 70-75% are classified at diagnosis as stage IV, the most advanced level, with 25-30% as stage II and III. In the Gemzar study from 1997, which excluded operable stage I patients, those entered into each arm fell into this range, with approximately 28% diagnosed as stage II and III, and 72% as stage IV. In our pilot study, which also disqualified those with operable disease, 8 of 11 patients, or 73%, presented initially with stage IV, and three as inoperable or locally advanced stage II, the numbers again conforming to the usual distribution of non-stage I subjects.
But the pilot study, which Gonzalez has just characterized as having a subject mix similar to the ‘enzyme’ group in the cohort trial, reported outcomes far better than those reported in the cohort trial. Forget about the chemotherapy arm in the current report: what’s interesting is the difference in outcomes of the ‘enzyme’ arm compared to the case series that had ostensibly justified the trial to begin with.
Gonzalez’s other, potentially data-damning charge is that the subjects allocated to his regimen were not capable of following it, for whatever reason: they couldn’t swallow, they had no one at home to help, etc. Again, to give him the benefit of the doubt, let’s look at the only statement in his rebuttal to offer a justified, quantitative estimate of the statistical damage that this may have caused. He argues that there ought to have been a “lead-in” provision, such that he could have given each prospective subject a 1-2 week trial period in order to determine if each was capable of following the regimen:
Had a lead-in been in play, even if only a week long as in the Gemzar study, we could have discounted, out of the total of 39 eventually admitted into the nutrition arm, 11 patients who never started the therapy or dropped out within the first seven days, all of whom died fairly quickly after their initial consultation with us.
Continuing to give Gonzalez the benefit of the doubt, let’s assume that those 11 were among the 32 eventually reported in the JCO. That leaves 21 who, by his estimation, would have graduated from the lead-in period into the study proper, of whom only 7 would have been alive at 10 months and 2 at 20 months (see the figure above). Not much better, that. Elsewhere, of course, Gonzalez writes that many more of his subjects were unsuitable:
Overall, we estimate that of the 39 patients Dr. Chabot ultimately approved for the nutrition arm, only 6-8 at most liberal analysis actually followed the regimen as prescribed to any significant degree.
Now we’re getting somewhere: if 21 could have begun the regimen, but only 6-8 could have continued it for any reasonable time after 1-2 weeks, then that’s really the point of an “intent to treat” analysis, isn’t it? Yet Gonzalez wants it both ways: “heads I win, tails you lose” is the way one commenter put it. The only thing about this special pleading that I find mildly interesting, although merely as a curiosity, is that it might explain how Gonzalez could be a true-believing crackpot rather than a charlatan. If he has, over the years, unwittingly used his arduous regimen as a survival test, it’s just possible that he actually believes it works—as mistaken as that is. I doubt this, because I don’t really believe the results of the case series, and in any event it’s irrelevant to the practical matter: the JCO report demonstrates that the Gonzalez regimen doesn’t work, and his objections do not change that.
More Problems
As suggested above, some of what Gonzalez has written, if true, is pertinent to the proper reporting of the trial and to its ethics, even if it does not negate the overwhelming conclusion. He writes that “39″ subjects were “eventually admitted into the nutrition arm,” but only 32 were reported in the JCO. What happened to the rest? Throughout Gonzalez’s rebuttal materials are other numbers that don’t match those in the JCO report. According to CONSORT,
…it may be difficult for readers to discern whether and why some participants did not receive the treatment as allocated, were lost to follow up, or were excluded from the analysis. This information is crucial for several reasons.
Gonzalez also writes that most of the ‘enzyme’ subjects were enrolled early in the 5 or so years that the trial was active, while most of the chemotherapy subjects were enrolled in the later years. This does nothing to change my opinion of the important outcome, for which I’m not considering the chemotherapy cohort at all, but it does trigger CONSORT objections.
There are probably more quibbles, but enough.
Ethics Redux: What is the Responsibility of Journals?
This essay has added several, relatively minor points—other than the delay in publication—to the ethical arguments that I made a year and a half ago, here and here. I urge readers who haven’t read those pieces to do so. The JCO report and Gonzalez’s response to it do not change any of those arguments: the trial was overwhelmingly and horribly unethical, and never should have been done. It answered no legitimate scientific or medical question, because that had long ago been answered. It subjected unwary human subjects to the whims of a dangerous quack whose license to practice medicine had been nearly revoked, and should have been, several years before. It somehow bamboozled otherwise respected academics into colluding in the systematic torture of those subjects. It is Exhibit #1 in the case against politicians bullying the NIH into accepting their pet projects, but it is equally disturbing in its exposure of the involved biomedical scientists and administrators as the “spineless wonders” that they were. (Exhibit #2 is here).
I promised last week that I’d address the paradoxical question of whether or not the JCO should have published the report. In today’s post are many examples of problems in the manuscript that should have been, and possibly were, noticed by reviewers, but apparently were allowed to remain. Might that have been because correcting them would have made the article too embarrassing, or have made it unpublishable on the basis of pseudoscience alone? Consider, for example, trying to justify “a liver flush [and] clean sweep.” I wonder what discussions occurred in the editorial boardroom.
Even these objections are not the crux of why the JCO ought to have considered, and possibly did consider, not publishing the article. The crux is this unambiguous sentence in the Declaration of Helsinki of the World Health Organization, to which most medical journals, including the JCO, claim allegiance:
Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.
Also see the American Society of Clinical Oncology Policy Statement: Oversight of Clinical Research, published by the JCO.
It may seem like an impossible dilemma, at first glance. I’ve already stated that I’m happy that the results of this trial were finally made public, and that is true. Nevertheless, the admonition in the Helsinki Declaration can have no teeth if it is so easily flouted in a case as flagrant as this. I suggest that there were alternatives to merely publishing the article in its current form. The NIH, which funded the study, could have published the results on its own website, ClinicalTrials.gov. The NCI and the NCCAM, the relevant sub-institutions, could have publicized the results on their own websites, in order to get the word out to cancer patients and to “alties,” respectively. As of last week, there was a resounding silence at those locations. It seems as though the responsible governmental sources are less than anxious to do the only thing that can give this sordid affair even the possibility of doing some good for future cancer patients. It’s funny how the NCCAM exuberantly trumpeted the once-in-a-blue-moon “landmark study” that it viewed as having supported an implausible method (in spite of it having done nothing of the kind), but is reticent to publicize the many failures.
Finally, the JCO might have–and I hope still will, in its hard-copy edition–include an accompanying editorial acknowledging the ethical problems with the trial and the dilemma involved in choosing to publish the report. Recall that it was at a meeting of the American Society of Clinical Oncologists (ASCO), the organization that publishes the JCO, that Susan Gurney first learned “quickly and definitively” what the responsible investigators at Columbia would not tell her:
that the Gonzalez protocol was a fraud; no mainstream doctors believed it was anything else and they were surprised that anyone with education would be on it.
Clinical equipoise, there was not.
What Should Happen Now?
In a nutshell:
The New York medical board should strip Gonzalez of his license, now that their only reason for not having done so years ago has vanished. The authors of the report should be scrutinized by the OHRP and the NIH. They should be banned from being investigators in any NIH-sponsored trial for some finite period, and their involvement in the Gonzalez trial should become a noticeable smear on their reputations. NIH scientists and administrators should ‘cowboy up’ and refuse to be bullied by politicians, no matter how influential. If they must resign to make the point, they should do so loudly and clearly. President Obama and the American people should be wary of Tom Harkin becoming the next NIH legislative czar, and should use this episode to explain why. The NCCAM should be abolished. IRBs should be alerted that every time a proposal to study a “CAM” claim is submitted, there is a high probability of mischief.
I’m sure you can think of more.

   Evidence-Based Medicine, Human Studies Ethics, and the ‘Gonzalez Regimen’: a Disappointing Editorial in the Journal of Clinical Oncology Part 1
Kimball Atwood
Link
Background: the distinction between EBM and SBM
An important theme on the Science-Based Medicine blog, and the very reason for its name, has been its emphasis on examining all the evidence—not merely the results of clinical trials—for various claims, particularly for those that are implausible. We’ve discussed the distinction between Science-Based Medicine (SBM) and the more limited Evidence-Based Medicine (EBM) several times, for example here (I began my own discussion here and added a bit of formality here, here, and here). Let me summarize by quoting John Ioannidis:
…the probability that a research finding is indeed true depends on the prior probability of it being true (before doing the study), the statistical power of the study, and the level of statistical significance.
EBM, in a nutshell, ignores prior probability† (unless there is no other available evidence) and falls for the “p-value fallacy”; SBM does not. Please don’t bicker about this if you haven’t read the links above and some of their own references, particularly the EBM Levels of Evidence scheme and two articles by Steven Goodman (here and here). Also, note that it is not necessary to agree with Ioannidis that “most published research findings are false” to agree with his assertion, quoted above, about what determines the probability that a research finding is true.
The distinction between SBM and EBM has important implications for medical practice ethics, research ethics, human subject protections, allocation of scarce resources, epistemology in health care, public perceptions of medical knowledge and of the health professions, and more. EBM, as practiced in the 20 years of its formal existence, is poorly equipped to evaluate implausible claims because it fails to acknowledge that even if scientific plausibility is not sufficient to establish the validity of a new treatment, it is necessary for doing so.
Thus, in their recent foray into applying the tools of EBM to implausible health claims, government and academic investigators have made at least two, serious mistakes: first, they have subjected unwary subjects to dangerous but unnecessary trials in a quest for “evidence,” failing to realize that definitive evidence already exists; second, they have been largely incapable of pronouncing ineffective methods ineffective. At best, even after conducting predictably disconfirming trials of vanishingly unlikely claims, they have declared such methods merely “unproven,” almost always urging “further research.” That may be the proper EBM response, but it is a far cry from the reality. As I opined a couple of years ago, the founders of the EBM movement apparently “never saw ‘CAM’ coming.”
The “Gonzalez” Trial
One such dangerous and unnecessary trial was “Evaluation of Intensive Pancreatic Proteolytic Enzyme Therapy with Ancillary Nutritional Support Versus Gemcitabine Chemotherapy in the Treatment of Inoperable Pancreatic Adenocarcinoma,” begun in 1999. It was funded by the National Cancer Institute (NCI) and the National Center for Complementary and Alternative Medicine (NCCAM), and was conducted by Nicholas Gonzalez and investigators at Columbia University. The ‘enzyme therapy’ part of the trial is more commonly known as the “Gonzalez Detoxification Regimen”:
Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
More than two years ago I wrote a series of posts* discussing Gonzalez, the regimen, the history leading to the funding of the trial, and aspects of the trial itself. In summary, Gonzalez appears to be a dangerous quack who should have had his medical license stripped by the state of New York during the 1990s, but was saved at the 11th hour by naïve “alternative medicine” enthusiasm; the regimen was highly implausible; there were no prior animal or clinical studies sufficient to warrant a human trial; its real impetus was the gathering political strength of the anti-intellectual “health freedom” movement in the aftermath of the Laetrile wars, culminating in Congressman Dan Burton’s bullying of NCI Director Richard Klausner; the NCI and Columbia subsequently justified the trial by citing a dubious case series provided by Gonzalez himself; the trial was unethical in numerous ways, amounting to torture-until-death for at least one hapless subject who, desperate for anything that might work, had stumbled into it because of his own scientific naïveté and because his consent was uninformed by existing knowledge—which, of course, the Columbia investigators should have provided him.
Shortly after my first series of posts it became clear that the Columbia investigators had found the Gonzalez regimen sufficiently inferior to the standard chemotherapy regimen to have stopped the trial early, in 2005. Finally, in August of 2009, the report of the trial, by John Chabot and colleagues (Gonzalez’s name was conspicuously missing from the report), was published by the Journal of Clinical Oncology (JCO): subjects in the Gonzalez arm had fared terribly, not only much worse than subjects in the chemotherapy arm, but also worse than 20,000 historical controls gleaned from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.
In my last post on the topic, I explained numerous problems with the formal report, contrasting it with the Consolidated Standards of Reporting Trials (CONSORT), which the JCO expects authors to honor. I explained that the results were nevertheless sufficient to disqualify the Gonzalez Regimen once and for all, Gonzalez’s own objections notwithstanding. I explained why Gonzalez’s name had not appeared in the article. I reiterated that the trial was unethical in the extreme, and lamented the JCO’s decision to publish the report—in direct violation of this statement in the Declaration of Helsinki, to which the JCO claims allegiance:
30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research… Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.
I mentioned ways in which the results of the trial could have been made public without violating that important statement. Since things had not turned out that way, I hoped that the JCO would eventually publish “an editorial acknowledging the ethical problems with the trial and the dilemma involved in choosing to publish the report.” I sent an email to an acquaintance who was a member of the JCO editorial board, asking that he or Editor-in-Chief Daniel Haller would recognize that the issue oughtn’t be ignored. I cited the pertinent SBM posts. I was ignored. When no editorial or other comment appeared in the JCO over the next few months, I stopped looking.
The Editorial
Only recently I noticed that the JCO had solicited an editorial after all; authored by Dr. Mark Levine of McMaster University, it appeared online in March, 2010. The title offered a bit of hope that the journal had finally “got it”:
Conventional and Complementary Therapies: A Tale of Two Research Standards?
Alas, ‘twas not to be. The first clue is found at the beginning of the essay:
In the early 1990s, I began to notice that some patients were choosing alternatives to the mainstream or conventional treatments. These so-called alternative therapies included a range of interventions, such as dietary and behavioral interventions, vitamin supplements and herbs, and traditional systems such as Chinese and homeopathic medicines. Most of these were not supported by sound scientific methods.
Notice the word “methods.” Dr. Levine didn’t write, “most of these were not supported by sound science.” This suggests that he was partially blinded by the EBM understanding of “evidence” and “scientific.” The next clue consists of the entire second paragraph, a series of bland restatements of proponents’ definitions (from the NCCAM, in this case) and ambiguous assertions about “CAM” that have come to be typical for medical academics who ought to know better. But I venture from the main point.
In the third paragraph, Dr. Levine verifies what we had suspected above:
I am fortunate to have spent my entire academic career at McMaster University (Hamilton, Ontario, Canada), the birthplace of evidence-based medicine, and to have had the privilege of learning from colleagues such as David Sackett, MD, and Gord Guyatt, MD.
Before proceeding, let me acknowledge—particularly for the benefit of Dr. Levine or any other EBM aficionados who may read this—that his essay is, in some ways, a good one. He was asked to comment on two reports of “CAM” treatments that had appeared in the JCO: the Gonzalez trial and a trial of acupuncture for hot flashes in women receiving anti-estrogen therapy for breast cancer. In each case he made valid criticisms of the methods and of the authors’ conclusions. He stressed that the authors hadn’t specified the questions that they were trying to answer. He wrote that “non-inferiority” studies require larger sample sizes than “superiority” studies, but that the authors of these reports hadn’t offered power calculations to justify their (small) sample sizes. He pointed out that the “control” intervention in the acupuncture trial, venlaxafine (Effexor), doesn’t work very well, thus implying that it may mean very little to judge a novel treatment similarly efficacious.
Nevertheless, in regard to the Gonzalez trial Dr. Levine faltered even as he applied what would usually be a solid EBM-style criticism:
The question addressed in the original randomized trial by Chabot et al was not specified. Was the hypothesis that chemotherapy is better than enzyme therapy, or was it that enzyme therapy is no worse than chemotherapy? My answer to this is, “I do not know.”
While this is technically correct, it misses the more important point, which can only be appreciated by looking beyond the trial itself: the interesting question, given the implausible nature of the method, is whether “enzyme therapy” for cancer of the pancreas is anything like what Gonzalez and his patrons had cracked it up to be prior to the trial. The most reasonable cohort to compare this group to, then, is not the chemotherapy arm reported in the JCO article, but Gonzalez’s case series that had ostensibly justified the trial in the first place:
As of 12 January 1999, of 11 patients entered into the study, 9 (81%) survived one year, 5 (45%) survived two years, and at this time, 4 have survived three years. Two patients are alive and doing well: one at three years and the other at four years.
Contrast those results with the 32 “enzyme-group” subjects reported in the JCO: 7 were alive at 10 months, 2 at 20 months, 1 at 30 months, and none at 40 months. Median survival was 4.3 months. We do not need formal statistics or a new, randomized trial with a larger sample size to justify dismissing the Gonzalez regimen.

   Evidence-Based Medicine, Human Studies Ethics, and the ‘Gonzalez Regimen’: a Disappointing Editorial in the Journal of Clinical Oncology Part 2
Kimball Atwood
Link
At the end of Part 1, I wrote:
We do not need formal statistics or a new, randomized trial with a larger sample size to justify dismissing the Gonzalez regimen.
In his editorial for the JCO, Mark Levine made a different argument:
Can it be concluded that [the] study proves that enzyme therapy is markedly inferior? On the basis of the study design, my answer is no. It is not possible to make a silk purse out of a sow’s ear.
That conclusion may be correct in the EBM sense, but it misses the crucial point of why the trial was (ostensibly) done: to determine, once and for all, whether there was anything to the near-miraculous claims that proponents had made for a highly implausible “detoxification” regimen for cancer of the pancreas. Gonzalez himself had admitted at the trial’s inception that nothing short of an outcome matching the hype would do:
DR. GONZALEZ: It’s set up as a survival study. We’re looking at survival.
SPEAKER: Do you have an idea of what you’re looking for?
DR. GONZALEZ: Well, Jeff [Jeffrey White, the director of the Office of Cancer Complementary and Alternative Medicine at the NCI—KA] and I were just talking a couple weeks ago. You know, to get any kind of data that would be beyond criticism is—-always be criticism, but at least three times.
You would want in the successful group to be three times — the median to be three times out from the lesser successful groups.
So, for example, if the average survival with chemo, which we suspect will be 5 months, you would want my therapy to be at least — the median survival to be at least 15, 16, 17 months, as it was in the pilot study.
We’re looking for a median survival three times out from the chemo group to be significant.
Recall that the median survival in the Gonzalez arm eventually turned out to be 4.3 months.
It would not surprise me if Dr. Levine, the author of the JCO editorial, were to take issue with what I’ve written so far. I would be remiss, for example, to leave readers with the impression that he called for another, larger trial, performed not as a cohort study but as a randomized, controlled trial, in order to prove whether (or not) “enzyme therapy is markedly inferior” to chemotherapy for cancer of the pancreas. He specifically did not make that recommendation; instead he argued, reasonably, “Given the scarcity of resources for cancer research, there are many more important questions to address.” I’ll come back to that statement, because although it hints that Dr. Levine has intuitively recognized the need for invoking prior probability when considering health research policy, he still appears confused by a strict, EBM perspective.
Human Studies Ethics: why Science Matters
Dr. Levine may also feel misrepresented by my emphases on the pseudoscientific nature of the Gonzalez regimen and the ethics of the trial. Near the beginning of his editorial, possibly to distance himself from those very issues, he wrote:
The goal of this discussion is not to debate the merits of conventional medicine versus CAM.
Let’s cut to the chase: “the merits of conventional medicine versus CAM,” at least insofar as the phrase refers to public perceptions or individual choices of patients or even physicians, are not the issues here. The overwhelming issues are ethical and scientific, and the two are not distinct: human studies ethics must be informed by science. I’ve explained this in some detail elsewhere in this long series. In summary, the Gonzalez trial repeatedly violated the Helsinki Declaration and other human studies treatises, including those established by the NIH itself and offered by NIH ethicists: it made Gonzalez, who is neither “a scientifically qualified person” nor “a clinically competent medical person,” responsible for human subjects; it did not minimize risks or enhance potential benefits, nor did “the potential benefits to individuals and knowledge gained for society … outweigh the risks” (it was a “trifling hypothesis”); it did not have “respect for enrolled subjects,” as evidenced by the horrible experience of at least one subject whose story was told by his friend, mathematician Susan Gurney; it did not “conform to generally accepted scientific principles…based on a thorough knowledge of the scientific literature, other relevant sources of information, and on adequate laboratory and, where appropriate, animal experimentation”; instead, it justified itself by citing a flawed, non-consecutive case series offered by Gonzalez himself, which both Dr. Peter Moran and I deconstructed with only a bit of effort (see also here), and by the “popularity” fallacy.
Perhaps most disturbing, even to people who aren’t familiar with the literature of human studies ethics, is that the trial investigators almost certainly failed to provide prospective subjects with the knowledge necessary for informed consent. Such knowledge would have consisted of the cancer biology known at the time, which overwhelmingly predicted that Gonzalez’s regimen would have no beneficial effect on cancer of the pancreas; of an accurate, honest assessment of his case series; and of his history of peddling pseudoscientific claims and providing incompetent care. I’ve written “almost certain” because I haven’t seen more than a short excerpt possibly from the trial’s consent form, although I’ve tried to do so (hint: if anyone reading this has a copy please send it on). I can’t imagine, however, that the consent form included comprehensive information because if it had, no competent IRB would have approved the study and very few subjects would have enrolled.
The history told by Susan Gurney about her friend, moreover, strongly suggests that he had not been adequately informed:
I told him that I was going to attend the annual conference of the American Society of Clinical Oncology (ASCO) and would report on other options to him. Once at ASCO, I learned quickly and definitively that the Gonzalez protocol was a fraud; no mainstream doctors believed it was anything else and they were surprised that anyone with education would be on it…
By remaining neutral about the Gonzalez regimen, physicians at Columbia Presbyterian who place patients in this trial effectively preclude them from starting other options, because of the demands it places on patients and their families. If physicians believe they are truly being neutral by not fully explaining the Gonzalez protocol’s nature to cancer patients, it is they who are in denial.
Michael Specter, who wrote about Gonzalez for the New Yorker in 2001, reported similar faux neutrality from Karen Antman, then the chief of Columbia’s division of medical oncology and a past president of the American Society of Clinical Oncology, who would be a co-author of the eventual JCO report. First, she showed him the excerpt that I mentioned above, which Mr. Specter characterized as “instructions that Columbia gives patients interested in the Gonzalez study”:
Many Americans who develop advanced cancer for which standard treatments have little to offer, turn to alternative or complementary therapies….There is no current conventional medical support for the theories and assumptions underlying the use of Nutritional Therapy. The Columbia College of Physicians and Surgeons does not support its use except as part of a properly conducted clinical trial.
If that bland statement was all prospective subjects were told about “conventional medical support” for the Gonzalez regimen, it hardly constituted a responsible explanation. Mr. Specter himself, who is not a physician or scientist, sensed that as well:
I asked if it would be right to infer that she thought the trial wouldn’t work. She shook her head. I asked if she had an idea why it might work. She said no. Did she have any opinions at all about the potential of nutritional therapy or the Gonzalez regime? “I have lots of opinions,” she told me, “but none of them matter.”
Except that such opinions do matter, as any human study investigator is expected to know. Susan Gurney explained why they would have mattered to her friend:
He was an artist—a painter and a sculptor—and he had little scientific knowledge. When Dr. Chabot was neutral about the Gonzalez protocol, and when Dr. Antman said nothing adverse about it, my friend assumed that they must genuinely believe that the treatment could work.
The trial’s Principal Investigator, John Chabot, was also reticent to offer subjects accurate information about the Gonzalez regimen, as evidenced by a 1999 “Dear Prospective Patient” letter. These findings—that oncologists in general thought that “the Gonzalez protocol was a fraud,” but that the Columbia investigators failed to disclose that fact, and the reasons for it, to subjects—exposes another ethical violation that I’ve previously discussed: the trial lacked clinical equipoise.
Finally, it is clear, as discussed here and elsewhere in this series, that the underlying impetus for the trial was political, not scientific. Shouldn’t that have also been included in the consent form?
EBM Gets it Wrong
Keeping all that in mind, let’s revisit the quotation from Dr. Levine explaining the goal of his editorial, this time putting it into the context of the entire paragraph:
I am fortunate to have spent my entire academic career at McMaster University (Hamilton, Ontario, Canada), the birthplace of evidence-based medicine, and to have had the privilege of learning from colleagues such as David Sackett, MD, and Gord Guyatt, MD. The goal of this discussion is not to debate the merits of conventional medicine versus CAM. Rather, the objectives are to consider whether these two paths of medicine should be held to the same standards of evidence in terms of clinical and policy decision making and to determine whether a model that historically has been based on weak evidence can be reconciled with the new paradigm of the requirement for high-quality evidence.
Yes! A thousand times yes! They should be held to the same standards of evidence. But that means that they should be required to meet the same preliminary standards before being accepted for high-quality human trials, and those standards are about scientific evidence: evidence from basic science, evidence from the biology of the disease in question, evidence from animal studies, and evidence from whatever preliminary human case reports or uncontrolled trials there may be. The Gonzalez regimen failed all of those requirements, and the trial was thus scientifically unjustified and unethical from the start.
Dr. Levine, however, is misled by the limited EBM understanding of “evidence,” as is suggested by the last line of the paragraph. Later, he leaves no doubt:
This is one of the most challenging editorials I have had to write. Wearing the hat of a clinical epidemiologist, it is difficult not to find fundamental flaws in both of these trials. Not too long ago, I would have dismissed them out of hand. However, as a clinician, I recognize that many of my patients seek CAM therapies, and many are using them and afraid to tell me. I am troubled by the lack of evidence for many of these therapies and the costs that patients incur in using them. In the past, there was a reluctance to subject CAM therapies to the same standards of evaluation as those for conventional therapies. Should CAM therapies undergo the same type of rigorous evaluation to which conventional therapies are subjected? Absolutely! When authors submit clinical trials to JCO, they are instructed to follow specific guidelines. These guidelines should be the same whether the intervention is chemotherapy, radiation, an herbal remedy, or a psychosocial intervention.
Yes, there are specific guidelines for publishing reports in the JCO, and in the case of the Gonzalez report, they were violated. I wonder why Dr. Levine didn’t mention CONSORT? Clearly, the “type of rigorous evaluation” to which he is referring is a clinical trial. Otherwise, there would be little trouble subjecting scientifically incoherent methods (not ‘CAM therapies,’ which begs the question) to the same standards of evaluation as those for scientifically coherent methods (not ‘conventional,’ which has irrelevant social connotations). The beginning of such an evaluation is to judge how plausible the method might be, and the way to do that is by considering scientific evidence. This, Dr. Levine, is evidence.
Similarly, there was not merely a “lack of evidence” for the Gonzalez regimen; there was abundant evidence against it. As suggested above, Dr. Levine must understand this at some level: although he argued, incorrectly and irrelevantly, that the trial had failed to prove that “enzyme therapy is markedly inferior” to gemcitabine, he nevertheless opined that “Given the scarcity of resources for cancer research, there are many more important questions to address.” How could he assign even a qualitative measure of “importance” without considering prior probability?
Yet again he retreats to the safe haven of EBM, failing to recognize the ethical mischief wrought by ignoring science:
Chabot et al should be congratulated on their persistence and determination to compare pancreatic enzymes versus [sic] chemotherapy.
No! A thousand times no! Compare Dr. Levine’s statement with my own:
The authors of the report should be scrutinized by the OHRP and the NIH. They should be banned from being investigators in any NIH-sponsored trial for some finite period, and their involvement in the Gonzalez trial should become a noticeable smear on their reputations.
Here is Dr. Levine’s final paragraph. Rather than comment further, I’ve provided pertinent hyperlinks:
Recently, there has been a shift from single CAM modalities for cancer management to a more comprehensive approach called integrative oncology, which is “an evolving, evidence-based specialty that uses CAM therapies in concert with biomedical cancer treatments to enhance its efficacy, improve symptom control, alleviate patient distress and reduce suffering.” I am encouraged that the leaders of the Society of Integrative Oncology (Dundas, Ontario, Canada) have developed evidentiary levels to gauge the strength of evidence for CAM therapies. It is not surprising that these levels are based on the foundational principles of evidence-based medicine established by Sackett et al. I look forward to future well-designed clinical trials that provide high-quality evidence on how CAM therapies can improve the quality of life of our patients.

   'Alternative' Treatments

Abraham Cherrix is alive and well because of science-based medicine
Although I haven’t discussed it here in depth, the case of Abraham Cherrix is an instructive example. Eleven years ago, he and his parents chose quackery over science-based medicine to treat his cancer. He’s alive now because he finally realized the error of his decision and underwent chemotherapy and a bone marrow transplant.
David Gorski on July 31, 2017
Link

One of the gratifying things about having been blogging so long—nearly 13 years now!—is that you start to see stories that you wrote about a long time ago resurface, allowing you to see the resolution. For instance, I’ve not infrequently written about people who, mistakenly believing the blandishments of alternative medicine practitioners that they could forego all that nasty chemotherapy and radiation and survive their cancer to live a happy, normal life, made the disastrous decision to eschew conventional medical therapy and pursue alternative medicine. My interest in this topic comes from the tendency of both alternative medicine practitioners and the patients themselves whom they’ve treated to tout their still being alive as ironclad proof that whatever quackery that was used works, that it can cure deadly cancers without all those unpleasant side effects and potential complications of our existing “cut, poison, burn” (in the quacks’ words) regimens. Sometimes, however, possibly more frequently than we suspect, such patients come to realize the error of their choices. Here, I’ll relate the story of one such young man named Abraham Cherrix, whom I’ve been writing about (elsewhere) intermittently since 2006 but hadn’t really thought about for a few years. Late last week, multiple readers sent me a news article about him, and I was very pleasantly surprised, for reasons that you’ll soon see. His story is very instructive.
The “alternative cancer cure testimonial”
Before I delve into Cherrix’s story, it seems appropriate to provide a little background for newcomers. If there’s anything I’ve hoped to convey it’s that these “alternative cancer cure” testimonials are seldom what they seem. Indeed, they’re almost never good evidence that whatever combination of coffee enema and eye of newt (I’m surprised I haven’t heard of eye of newt enemas yet) used by the cancer sufferer was what cured the disease. I don’t have the space (even with my tendency to logorrhea) to go into it in a lot of detail now (read this hoary classic if you want such a discussion), but very often the belief that the alternative cancer cure worked derives from a misunderstanding of the difference between curative chemotherapy used as primary therapy and adjuvant chemotherapy, which is usually administered after surgery in order to decrease the risk of recurrence. Quite often, if you delve into these stories, you’ll find that the patient actually underwent some form of surgical resection of their tumor, as was the case with, for example, Suzanne Somers or Chris Wark. People like this then eschew chemotherapy and proclaim that whatever “natural” treatment they used had cured their disease, even though it was the surgery that cured their disease and all they did by not accepting chemotherapy was to increase their chances of recurrence. (Indeed, when discussing these cases, I frequently use an online tool that estimates, based on clinical trial evidence, by what percentage chemotherapy decreases the chances of recurrence and increases long term survival.) Fortunately, because they survived they’re still around to proclaim themselves as having “naturally” cured their cancers by bucking the medical establishment and those dogmatic poison-pushing thralls of the pharmaceutical industry (as they frequently like to portray oncologists).
There are other reasons why patients with cancer who choose quackery over conventional medicine can appear to be survivors, adding plausibility to claims that they cured themselves, at least to those without training in oncology. They frequently misunderstand the highly variable course of some cancers. In the case of others, like patients treated by Stanslaw Burzynski, there is a small delayed cure rate due to conventional therapy, and the patients and families frequently misattribute the patient’s good fortune to the ineffective treatments the patient underwent after having undergone the definitive treatment. Indeed, in the case of brain tumors, there’s a phenomenon after radiation therapy known as “pseudoprogression,” where inflammation from the radiation causes the tumor to look as though it’s growing on imaging, after which it shrinks and, in a small percentage of cases, disappears entirely. (Guess when the shrinkage occurs. Yes, it often happens while the patient is being treated by Burzynski.) Some cancers have a low (but not so low as to be rare) rate of failing to progress or even spontaneously regressing. Some add less effective conventional medicine modalities to their battery of treatments that kept their disease at bay (which is what Cherrix did, as you will see).
The point is that rarely is there an “alternative cancer cure” testimonial in which the circumstances of treatment allow a cancer physician to attribute the patient’s excellent outcome to whatever alternative medicine was being used or where one can rule out some other cause for why the patient is doing well. Then there’s the whole issue of a form of selection bias. As I like to say, dead patients don’t give testimonials. A corollary to that adage is that alternative medicine mavens don’t like to hear testimonials from patients who tried alternative medicine, found it wasn’t working, and were saved by conventional medicine. As far as alternative cancer cure advocates see it, such patients might not be literally dead, but they are dead to the alternative medicine community, which quickly forgot that these patients had ever been promoted as poster children for cancer quackery.
Abraham Cherrix: The beginning
I first learned of Abraham Cherrix in 2006 through a news story:
NORFOLK – Fifteen-year-old Abraham Starchild Cherrix never intended to challenge the medical establishment when he refused chemotherapy earlier this year.
He simply believed the treatment was poisoning him, rather than saving him from Hodgkin’s disease. What he wanted was a more natural approach, which he sought through an alternative treatment clinic in Tijuana, Mexico.
That decision has led to a courtroom battle, accusations of parental neglect and the possibility of being removed from his Chincoteague home.
A judge earlier this week ordered Abraham to receive diagnostic tests to determine the status of his disease. On Friday, though, the tall, lanky boy refused to abide by the order. After showing up at Children’s Hospital of The King’s Daughters in a crisp white shirt and blue tie, he rejected the test.
“I think my body has taken enough, and it shouldn’t have to take any more,” he said.
Basically, four months before the story quoted above, Cherrix had finished induction chemotherapy for Hodgkin’s lymphoma, a very treatable cancer, particularly in children and teenagers, with a five year survival rate of approximately 85%. Unfortunately, his scans showed that he still had residual tumor, for which the treatment was additional chemotherapy and (possibly) ultimately a bone marrow transplant. It was at this point that he rebelled:
That’s when Abraham dug in his heels. He and his father did some research and decided to try a treatment in Tijuana that includes an organic diet and herbal supplements. Soon after, his case was reported to a child-abuse investigator at the Accomack County Department of Social Services, who asked a judge to order that the teen continue conventional treatment.
Abraham no longer uses the “Starchild” middle name, but, consistent with that name, his family was clearly prone to—shall we say?—alternative thinking. Instead of doing what good parents should do and making sure their son received proper treatment, they sought out “alternatives.” The alternative cancer treatment they picked out was a doozy, too. They decided to follow treatment recommendations from The Association for Research and Enlightenment, which just so happened to be based in Virginia Beach, which was about a two hour drive from the family’s home in Chincoteague. This Association was founded by a psychic healer named Edgar Cayce, who was known for falling into trances and giving readings on topics as varied as Hitler, astrology, the existence of Atlantis, ESP, ancient Egypt, and others. Through Cayce’s Association, Abraham and his father settled on the Hoxsey treatment.
Basically, the Hoxsey treatment consists of herbal concoctions popularized by Harry Hoxsey. Different varieties exist, including an “internal” treatment and external treatments with various pastes made up of some of the components of his treatment (usually used for skin cancers or tumors that can be palpated through the skin). Hoxsey claimed that the formula had been passed down from his grandfather John Hoxsey to his father to him, after his grandfather had mixed together grasses and flowering wild plants growing in a pasture where one of John Hoxsey’s horses grazed daily. The horse supposedly had a cancerous growth that went away, and Hoxsey thought that it was due to the plants upon which the horse grazed. He took plants from the pasture, mixed them together, added some ingredients for home remedies for cancer at the time, and–voilà!–he had what he thought was a cure for cancer. Many decades later, Hoxsey’s grandson described how this remedy supposedly worked thusly:
“It follows that if the constitution of body fluids can be normalized and the original chemical balance in the body restored, the environment again will become unfavorable for the survival and reproduction of these cells, they will cease to multiply and eventually they will die. Then if vital organs have not been too seriously damaged by the malignancy (or by surgery or irradiation) the entire organism will recover normal health.”
He [Hoxsey] also did not claim to know how or why his herbal cancer treatment worked, but he maintained that it “corrects the abnormal blood chemistry and normalizes cell metabolism” by “stimulat[ing] the elimination of toxins which are poisoning the system.”
There’s only one problem. There’s no good evidence that the Hoxsey treatment has any net anticancer activity whatsoever. Although some of the components have been reported to have mild antitumor activity in cell culture and animal systems, others have been reported to promote tumorigenesis. In any case, there is no evidence that the Hoxsey treatment as given has clinical efficacy against any human cancer. Indeed, the NCI investigated Hoxsey’s case series, and, as is frequently the case with such reports, concluded that there was inadequate information recorded to make any conclusions at all. The FDA investigated 400 cases whom Hoxsey claimed to cured and found not a single case of a bona fide cancer cure (Semin Oncol 1979;6(4):526-535). Indeed, in 1956, the FDA Commissioner ordered the posting of a “Public Beware!” warning against the Hoxsey treatment in U.S. Post Offices all over the country. And, as quacks frequently do, Hoxsey went to his grave claiming he was being “persecuted” by the “establishment.”
Until her death in 1999, Hoxsey’s longtime chief nurse Mildred Nelson continued Hoxsey’s legacy and administered his “treatment” in Tijuana, claiming an 80% success rate. Of note, Nelson believed that a “bad attitude” was usually responsible for her “20 percent failure rate” she reported for the Hoxsey treatment, with a patient’s strong belief that the treatment is going to lead to recovery being the best predictor of success. Convenient, isn’t it? Those pesky patients who have the temerity to die in spite of the Hoxsey treatment? Well, it was obviously their own fault! They didn’t believe hard enough!
Not surprisingly, Abraham Cherrix rapidly became a poster child for alternative medicine, with believers in alternative cancer cures castigating the courts for “medical fascism” and “medical kidnapping.” Like the case of Cassandra Callender, which I’ve discussed before, Cherrix was an appealing teen, with a loving family (his father owned a kayak business and his mother homeschooled five children). Unfortunately, even the Cherrixes couldn’t resist joining. His father was quoted at the time:
Jay Cherrix echoed that skepticism. He said that while his family would comply with the order of the court, he has trouble imagining a doctor violating his son’s wishes.
“I personally don’t think there is a Dr. Mengele in the United States who would pump this stuff into a 16-year-old who didn’t want that. I personally don’t think we’ve reached that point in our civilization,” he said.
In the meantime, Cherrix’s tumors continued to grow.

The court battle and aftermath
In July 2006, as discussed by bioethicist Art Caplan, the parents were charged with medical neglect and appeared before the Accomack Juvenile and Domestic Relations Court. The judge ruled that the parents should relinquish custody of Abraham, so that the state could make sure that he was treated with the recommended higher dose chemotherapy and radiation as soon as possible. However, right before the order was to take effect, the family obtained a stay from the Circuit Court of Accomack County and regained full custody, pending a new hearing. On August 16, 2006, Accomack Circuit Court Judge Glen Tyler cleared Abraham’s parents of all charges of medical neglect. He also announced that a settlement had been reached between the family and the Virginia Department of Social Services in which Abraham would be allowed to pursue the Hoxsey treatment as long as he was monitored by a board-certified oncologist in Mississippi with knowledge of alternative cancer treatments. The court stated it would “keep an eye on Abraham” to make sure that his treatment was reasonable.
Here’s the kicker. The doctor in Mississippi chosen by the Cherrixes (agreed to by the court) to oversee Cherrix’s care was not exactly what I’d refer to as a reputable oncologist Yes, 11 years ago, I did a little Googling and made a good guess. It turns out that doctor chosen was a radiation oncologist is: R. Arnold Smith, M.D.. Here is the tale:
Smith’s clinic employs immunotherapy, an innovative treatment that works to restore the immune system that age and cancer break down, helping the body fight back.
Combined with radiation therapy to debulk cancer, molecular targeted therapies to arrest host defenses, genomic assays, and chemotherapy when necessary, immunotherapy helps patients live a higher-quality, longer life, the oncologist says.
Today, after the short hearing, the judge looked at Abraham and said, “God bless you, Mr. Cherrix.”
Dr. Smith offered in his clinic the following treatments:
Dr. Arnold Smith was awarded a method patent for his application of Interleukin 2 to create a factory for natural killer cells. This treatment appears to be a significant innovation and advance. Interleukin 2, when injected subcutaneously, has been known for some time to produce a firm nodule often called an “injection site nodule.” These nodules, we believe, are composed of significant colonies of clonally-replicating natural killer cells.
Additional daily injections of Interleukin 2 are best exploited if they are given by injection just on the periphery of the nodule or plaque. Our current policy is to “grow” the initial nodule by progressive injections until a sizable plaque is created, measuring 8-10 cm in diameter. It becomes slightly inflamed, hot, swollen, sore, and red. The plaques are not very painful, but have occasionally contained areas of skin necrosis which have always healed completely.
It may be that use of Cimetidine, antioxidants, and replacement hormones facilitate the production of these plaques to a significant degree. We have seen several patients with lung cancer and colon cancer who have shown progressive decline in Carcinoembryonic Antigen after Interleukin 2. Belly Plaques were created and sustained.
I looked for articles in the peer-reviewed scientific literature published by Dr. Smith about this technique, but there was nothing in Medline more recent than the 1990s that I could find and none of it was about IL-2. However, Dr. Smith did list a number of publications on his CV on this technique in a journal I’ve never heard of before, Bulletin of Urgent and Recovery Medicine, a website for which I’ve been thus far unable to find. Looking at his CV and publication record, it appears that sometime around 1998 or so his publications stopped being mainstream and moved into this new “immunotherapy” and “anti-aging” medicine.
It is true that IL-2 has been used for melanoma and renal cell carcinoma. It can actually be fairly nasty stuff, with a lot of side effects, including capillary leak syndrome, hypotension, and acidosis. It’s also not all that effective, with perhaps a 20% response rate, but, unfortunately, for refractory tumors like melanoma and renal cell carcinoma, it and interferon are about the best we have. Sadly, no evidence is presented that Dr. Smith’s method does anything other than raise a really nasty looking wheal on the abdomen.
I also found it rather odd at the time that Abraham picked a therapy that is guaranteed to result in large painful welts on his abdomen using a cytokine that is not without side effects, all because he’s so adamant that he doesn’t want to suffer the side effects of chemotherapy again, but I’ve given up trying to understand his thought processes. At the time, I guessed that the settlement was about the best that could be hoped for, given Abraham’s age and tenacity. Basically, Dr. Smith let Cherrix go to the Tijuana clinic to receive the Hoxsey treatment and apparently treated him with his own special brand of “immunotherapy.”
Not surprisingly, less than a year later, these treatments didn’t stop his cancer. By January 2007, Cherrix was undergoing radiation therapy to shrink enlarged lymph nodes under his arms. By June 2007, he had relapsed again with a lesion on his lung. As I said at the time, treating this local tumor on the lung was very unlikely to cure Abraham’s cancer, because the cancer would just pop up somewhere else in his body. Dr. Smith and Abraham were in essence playing a game of Whac-A-Mole with his cancer. It turns out that this could (and did) go on for quite a while. It also turns out that without systemic therapy (i.e., chemotherapy) to kill the microscopic deposits of tumor that are responsible for new tumors popping up, the tumor would never be eradicated. I turned out to be correct, but that’s no big achievement. After all, I had a real oncologist (Dr. Craig Hildreth) to explain to me why what I thought was the case was actually the case and, more importantly, why zapping lymphoma tumors with radiation as they pop up is a strategy doomed to fail, referring to such a treatment as the “fallacy of moderation,” and concluding:
Thus, my final opinion: Abraham Cherrix should consider high-dose chemotherapy with stem cell support if he wants to cure his Hodgkin lymphoma. However, even this ultra-therapy has no guarantee of success, especially if one factors in his lung disease and his short duration of response to initial therapy.
Dr. Hildreth was correct, as you will now see.
Abraham Cherrix smolders along
Amazingly, Cherrix did fairly well for several years. He turned 18 in 2008 and seemed to be doing well. (Unfortunately, he was also giving talks at medical schools promoting pseudoscience and quackery using himself as a testimonial. Indeed, as I went back through old posts elsewhere while researching this post, I marveled that the last time I had written about him, other than in passing, was in 2013. Unfortunately, Cherrix was not doing that well. Indeed, he had a GoFundMe page asking for money for treatment:
Despite keeping positive and fighting for my life, I find myself in the same position yet again. I learned today that the cancer has returned to my left lung, explaining a long series of events leading up to it (coughing up blood, shortness of breath, difficulty sleeping, chest pains etc). Now that it’s more aggressive than before, I don’t feel like I have much time. I need to act fast and I’m limited with what I can do.
I have some treatment options that I could pursue and things I could do to improve my condition or even help cure me, but they’re expensive and not covered by my medical insurance (Medicaid/Medicare). I need supplements to boost my immune system, while seeking out doctors country-wide for different treatments and opinions. I need better food that I can’t afford, and I want to move out of my trailer and into a clean house. Most of these costs [sic] thousands of dollars alone… and I’m barely able to afford a ride into town for grocery supplies.
There are actually a few specific treatments I’d love to start with. Heated needle therapy is a good start, and something I’ve been curious about. Studies now are also showing the validity of Hemp Oil as a cure for cancer, so I’m trying to get into one of the research groups. However if I can’t get into these groups, the expense will be monumental and certainly not covered by my insurance.
After that, I hadn’t heard much of anything about Cherrix. I had no idea if he was still alive; that is, until last week.
Abraham Cherrix: Alive and well at 27, thanks to real medicine
The article several people sent to me was published on July 27 in the Virginia Pilot. After a recap of Cherrix’s 2006 court fight, we learn:
A lot has happened in the decade since then.
Cherrix, now 27, ended up accepting chemotherapy and also a stem cell transplant last year at the University of Virginia Cancer Center because tumors kept resurfacing.
“Honestly, if I had not done this, I would have died,” Cherrix said in a telephone interview.
Cherrix, who now lives in the southwestern Virginia town of Floyd, said he’s matured and feels humbled in his recognition of the value of scientifically based treatments.
“The other treatments didn’t have any hard evidence behind them,” he said. “There was no concrete evidence. I know what I am doing now is founded in reality, and I know it’s the best choice for me, and it’s scientifically based.”
Another rather odd thing we learn from the article is Dr. R. Arnold Smith, who treated Cherrix as part of the court agreement, was indicted in 2012:
Smith was charged with capital murder and conspiracy to commit murder in a murder-for-hire case that targeted a lawyer who represented Smith’s former wife in the couple’s divorce. Smith was found mentally unfit to stand trial and was committed to a state mental hospital in 2014. He was later released to private mental health treatment.
I didn’t learn anything in the article that I didn’t know, at least not up until 2013. So what most interested me was what brought Cherrix to the realization that he had to abandon the quackery and undergo real medical treatment if he wanted to have any hope of survival. The answer was there. He kept relapsing and undergoing radiation treatment. As predicted, eventually tumors started returning in areas that had been radiated before, meaning that he couldn’t receive radiation there again because radiation doses are cumulative over a person’s lifetime and the tissue damage they cause permanent. So by 2015, this was his situation. His parents had divorced, and he moved back in with his mother. Then:
In 2015, Cherrix hit a low point. He felt so tired, he was sleeping most of the day, he lost his appetite and began losing weight. A half a sandwich a day was all he could muster. His hair thinned and he felt feverish. He was also coughing up blood, and his back hurt. He went to oncologist Robert Rotche in Blacksburg, who ordered a biopsy and scans that showed a tumor pressing against his backbone.
The doctor began treatment with an antibody drug called brentuximab vedotin, which is used to treat relapsed Hodgkin’s. The medication reduced the tumors and symptoms and improved his blood counts. Rotche also referred him to the cancer center at the University of Virginia Health System in Charlottesville for a stem cell transplant.
In 2016, Cherrix underwent an autologous stem cell transplant. Before undergoing high dose chemotherapy and radiation, his stem cells had been harvested and stored, and they were reinfused on August 4, 2016. So far Cherrix has done well and is now taking brentuximab vedotin, which selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma, as consolidation therapy, and has been shown to improve survival.
Cherrix’s oncologist, naturally, is a bit vague on whether all the delay in treatment compromised Cherrix’s chances of survival. I have no doubt that these delays did, because they delayed his definitive treatment. Clearly Cherrix was very lucky, though. He had disease indolent enough that it did not “break out” and kill him, even during ten years of inadequate treatment with “pinpoint” radiation. Basically, it grew slowly enough and locally enough to allow his life to have been prolonged by nearly a decade using local therapy alone. I remain amazed (and happy) that his disease never blossomed all over his body during that time. If it had, all the “pinpoint” radiation in the world, “complemented” with bogus immunotherapy and the quackery known as Hoxsey therapy, wouldn’t have saved him. I’m just very happy that Cherrix’s disease was slow-growing enough that he lived long enough to come to realize what a disastrous decision he had made 11 years ago. I also realize that he’s not out of the woods yet, as his oncologist explains in the article that he’s got to hit the three year mark before he can be considered to be, in essence cured (or at least to have a very high chance of remaining cancer-free). I hope he makes it.
He hasn’t entirely disavowed his original decision, though:
Cherrix, while supporting evidence-based measures, said he still stands by his original stance of researching the treatment. His advice? “Question the world and how it works, but also be sensible.”
Which is not unreasonable, but I’d add to that: It’s good to be open-minded, but don’t be so open-minded that your brains fall out. Hoxsey therapy is one of those alternative medicine treatments that’s so obviously bogus that putting your life in the hands of a quack in a clinic in Tijuana administering that treatment falls under the category of being too open-minded.
Abraham Cherrix’s legacy
It’s not surprising that, once it became clear that Cherrix’s cancer wasn’t going away for very long, news of him in the sorts of websites and discussion boards where believers in alternative medicine tout the latest “miracle” cancer cures rapidly faded to nothing. Nor is it surprising that Cherrix is now a human interest “Where are they now?”-sort of story in a local newspaper. It’s true that one part of Cherrix’s legacy will be that, after a long flirtation with alternative medicine to treat his cancer, he finally came around to science and thus very likely saved his life. Unfortunately, that is not his only legacy. He left another, far more harmful, legacy:
Cherrix’s court case resulted in a Virginia law – known as Abraham’s law – that gives teenagers 14 or older and their parents the right to refuse medical treatments for ailments such as cancer. Teenagers and their parents can seek alternative treatments so long as they have considered all other medical options.
When I first heard about the law back in 2006, I thought of it as somewhat disturbing but probably another example of “placebo legislation,” a law that makes those passing it feel good but does little or nothing. In cases of a terminally ill child being treated with alternative medicine, the courts would still have had to examine the case and rule on whether or not the treatment, assuming it was carried out in what the parents believed to be the child’s best interest, constituted medical neglect. Also, in its original form, Abraham’s Law would have applied only to children with “terminal illnesses.” By the time it was passed and signed into law by the governor, the bill had broadened its reach to children with “life-threatening” condition and changes the definition of an “abused or neglected child” as follows:
Definition of abused or neglected child. Specifies that a decision by parents or another person with legal authority over a child to refuse a particular medical treatment for a child with a life-threatening condition shall not be deemed a refusal to provide necessary care if (i) such decision is made jointly by the parents or other person with legal authority for the child, and the child; (ii) the child has reached 14 years of age and is sufficiently mature to have an informed opinion on the subject of his medical treatment; (iii) the parents or other person with legal authority, and the child have considered alternative treatment options; and (iv) the parents or other person with legal authority, and the child believe in good faith that such decision is in the child’s best interest. Stipulates that this test shall not be construed to limit the provisions of §16.1-278.4 on children in need of services.
Worse, Virginia law now lists as an exclusion in the definition of an abused or neglected child:
However, no child who in good faith is under treatment solely by spiritual means through prayer in accordance with the tenets and practices of a recognized church or religious denomination shall for that reason alone be considered to be an abused or neglected child.
Basically, as a result of Abraham Cherrix’s battle, if you’re a child between the ages of 14-18, the State of Virginia no longer protects you from quackery or religious idiocy. Worse, it’s not just limited to children with “terminal” illnesses, where, it can be argued, nothing can save them and taking them away from their parents to have them obtain conventional therapy would cause them undue stress in the precious few remaining weeks or months of their lives. The law includes any child with a life-threatening condition. In other words, it now applies to all children in the State of Virginia with cancer, no matter how treatable the cancer is, because cancer is certainly a life-threatening condition.
Consider the practical import of this bill. Let’s say a 14-year-old is diagnosed with leukemia. Let’s further add that it’s an eminently treatable form of leukemia, with an expected remission and long term survival rate of over 90%, with the proper chemotherapy and targeted therapies which, thanks to science-based medicine, is not uncommon in pediatric cancers. Now, I’m not a lawyer, but under this law, it appears that parents can choose any quackery they wanted, be it the Hoxsey therapy, urine therapy, homeopathy, or whatever, as long as the decision to pursue this quackery was made “jointly with the child.” Now consider this: For a 14-year-old (or even for a 16-year-old or 17-year-old) living with his or her parents, how difficult do you think that it would be for the parents to get the child to agree with them, particularly if, as most believers in alternative cancer cures would do, they frame it as a choice between the horrors of chemotherapy (and, in the case of other tumors, surgery and radiation) versus a “natural” alternative that won’t cause them any pain or symptoms at all? Yes, saying it’s not neglect to use quackery to treat cancer in a child as long as the child agrees to it is the height of disingenuousness, and passing a law that codifies that statement is the height of irresponsibility.
But it’s worse than that.
Consider the case of a 14- to 17-year-old whose parents are Christian Scientists or other religions that claim that prayer alone can cure disease. Naturally, in the vast majority of cases, the child will have been raised in the same religion and will believe in its tenets, as his parents do. If that child gets cancer, it’s pretty likely that he would agree with his parents that prayer and whatever rituals demanded by the religion would be the proper treatment for the cancer and thus would agree with whatever woo the religion prescribes for treatment. As I like to say in cases like this, I support the right of any competent adult to choose whatever therapy for himself that he chooses—or no therapy at all. But children are different, even teenagers. We can argue about at what age a teen is competent to make life-or-death decisions like whether or not to take chemotherapy for a life-threatening cancer, and I did discuss my views on this topic while covering the case of Cassandra Callender, but clearly 14 years old is too young. So is 15.
Make no mistake. I’m very, very happy that I was so amazingly mistaken when I declared after the court ruling letting Cherrix pursue Hoxsey treatment and Dr. Smith’s bizarre combination of inadequate radiation therapy and bogus immunotherapy. However, he and his family served as the impetus for a law that basically eliminated the ability of its child welfare services to intervene in the case of 14- to 17-year-olds whose parents decide to pursue woo instead of effective medical treatment, not just for children with terminal illnesses, but for any child in that age range with a serious, life-threatening condition.
Unfortunately, that’s part of his legacy as well.

CAM use and chemotherapy: A negative correlation
“Complementary and alternative medicine” (CAM) is represented as safe because it is administered alongside conventional medicine, despite the fact that for the vast majority of CAM modalities there is little or no evidence for efficacy. However, as a new study shows, cancer patients who use CAM tend to be more likely to refuse conventional cancer treatment.
David Gorski on May 22, 2016
Link


So-called “alternative” medicine is made up of a hodge-podge of health care practices and treatments based on beliefs that are unscientific, pre-scientific, and pseudoscientific. These modalities include practices as diverse as homeopathy, traditional Chinese medicine, reflexology, reiki and other forms of “energy medicine” based on vitalism, chiropractic, and naturopathy, and that’s a short list of the quackery that falls under the rubric of the term “alternative medicine.” Unfortunately, this unscientific, pre-scientific, and pseudoscientific hodge-podge of treatments rooted in nonsense is rapidly being “integrated” into real medicine, thanks to an unfortunately influential movement in medicine whose members have been seduced into thinking that there might be something to them and view “integrating” them into medicine as means of practicing more “holistic” and “humanistic” medicine. This “integration” started out by being called “complementary and alternative medicine” (CAM) but now among believers the preferred term is usually “integrative medicine,” largely because it eliminates the word “alternative,” which implies (correctly) that the modality is not real medicine, and “complementary,” which implies a subsidiary status, a status of being nice to have but not essential.
Particularly harmful is the hostility towards conventional medicine that often strongly correlates with use of alternative medicine. Indeed, some people even choose to rely on alternative medicine instead of real medicine to treat cancer. Unsurprisingly, the results of such a decision are generally not very good. Actually, they are almost always terrible. Very, very terrible indeed. Not surprisingly, the use of alternative medicine is associated with bad outcomes. Cancer patients who might have survived die because of it. It’s not as though it hasn’t been studied either, although the main studies I’m aware of tend to look at the bad outcomes in patients who choose alternative medicine. There is another question, and it’s one that a new study published in JAMA Oncology last week seeks to answer. It’s a study that briefly made the news, producing headlines like:
    • “Users of complementary, alternative meds more likely to skip chemotherapy“
    • “Use of complementary, alternative medicine affects initiation of chemotherapy“
    • “Many breast cancer patients try alternative medicine first: Study“
The study itself is entitled “CAM Use and Chemotherapy Initiation Among Women With Invasive Non-Metastatic Breast Cancer.” Interestingly enough, the first author is someone we’ve met before, Heather Greenlee, a naturopath at Columbia University. She’s the one who wrote “evidence-based” guidelines for the Society for Integrative Oncology (SIO) regarding CAM use in breast cancer patients. This time around, she’s actually doing something useful: Looking at the correlation between CAM use and chemotherapy refusal with an oncologist named Dawn L. Hershman, MD.
Basically, this study examined a cohort of 685 women with nonmetastatic breast cancer recruited from multiple sites, including Columbia University Medical Center, Kaiser Permanente Northern California, and the Henry Ford Health System. The women were all under 70 years old and part of the Breast Cancer Quality of Care (BQUAL) study, a prospective cohort study. Of these women, 306 (45%) were clinically indicated to receive chemotherapy per National Comprehensive Cancer Network Guidelines. The investigators looked at factors that correlated with use or nonuse of chemotherapy in women for whom chemotherapy was indicated. Specifically, in baseline interviews they looked at the use of five different CAM types: vitamins and/or minerals; herbs and/or botanicals; other natural products; mind-body self practice; mind-body practitioner-based practice. From these interviews, each patient was defined as falling into one of three categories: any use, dietary supplement use, and mind-body use. Also, a CAM index score was developed to sum all five modalities.
When I first read the abstract, my first thought was: WTF? There’s a lot more to CAM than just vitamins, herbs, botanicals, and “mind-body” practices. It turns out, however, that the definitions were quite broad and in line with the National Center for Complementary and Integrative Health (NCCIH) definitions. For example, mind-body self practices included yoga and meditation, while practitioner-based mind-body practices included modalities as varied as acupuncture, reiki, and meditation. Special diets and multivitamins were excluded from the definition of CAM, because, according to the authors, these are commonly used and often not categorized as CAM. They justified the definition thusly in the introduction:
Studies often define CAM using a broad, nonspecific definition that includes any therapies or approaches that are a complement or alternative to conventional medical therapies. However, when defining clinical populations using CAM, it may be more useful to consider CAM using specific subcategories, such as dietary supplements and mind-body practices. Dietary supplements include vitamins, minerals, botanicals, and other natural products. Mind-body practices include practices such as yoga, meditation, qi gong, acupuncture, and massage. In the oncology setting, patients may use both dietary supplements and mind-body practices to relieve symptoms, for general health and wellness promotion and to increase their sense of hope and control, though the evidence base for mind-body practices is stronger than for dietary supplement use. Patient motivations and the benefits they hope to obtain may also differ between these 2 categories of CAM. It has been hypothesized that CAM use may be a risk factor for not initiating standard oncology treatments because patients may be exploring other alternative treatment approaches or because conventional oncology treatments are not congruent with patient belief systems. However, prior studies on CAM use among patients with breast cancer have not differentiated whether standard oncology treatments were indicated based on clinical characteristics of patients.
Fair enough, such as this definition is. CAM is basically vaguely defined anyway, and the number of subdivisions seems to be decreasing, so that pretty much everything that’s not dietary supplements, botanicals, or natural products falls into “mind and body” practices. If you’re going to study CAM, you have to choose a definition, and that’s not a straightforward task. Besides, when recognizing CAM, I sometimes have a hard time not invoking the old trope about pornography: I know it when I see it. In any case the authors did univariate and multivariate analyses looking for associations between current use of any CAM (yes/no), current dietary supplement use (yes/no), current mind-body use (yes/no), and number of CAM modalities currently used (range 0-5) and subsequent chemotherapy initiation. Demographic and clinical factors were tested as potential confounders. Here’s what they found:
    • Baseline CAM use was common and reported by 598 women (87%).
    • Chemotherapy was initiated by 272 women for whom chemotherapy was indicated (89%).
    • Among women for whom chemotherapy was indicated, dietary supplement use was associated with markedly less chemotherapy initiation (odds ratio: 0.16, meaning they were 84% less likely to accept chemotherapy).
    • For every one unit increase in the CAM score, the odds ratio for chemotherapy use was 0.64.
    • There was no association between mind-body practices and chemotherapy initiation.
    • There was no association between CAM use and chemotherapy use in women for whom the need for chemotherapy was judged to be discretionary.
The results are summarized below in this table:
TABLE
The authors note one surprising part of this result:
Women for whom chemotherapy is discretionary will likely have different reasons for chemotherapy initiation compared with women for whom chemotherapy is indicated. Here, we found that CAM use in the discretionary group was not associated with chemotherapy initiation. We hypothesized that CAM use would be associated with chemotherapy initiation among the discretionary group because there is more leeway in the decision making process, but we did not find that this was true. Instead, in the group with a clear clinical indication for chemotherapy, users of CAM were significantly overrepresented among the relatively small group that did not receive this indicated treatment.
That last sentence makes an important point. One of the weaknesses of this study is that the number of patients for whom chemotherapy was definitely indicated but who declined it was small, only 34 patients. It’s not clear how generalizable its results are. I, too, also found it odd that use of dietary supplement use negatively correlated with chemotherapy initiation while use of the more “woo-ey” therapies that fall under the category of mind-body treatments did not. Remember again: “Mind-body” doesn’t just encompass yoga, but also the purest quackery, such as reiki, acupuncture, other energy medicine, and the like. Unfortunately, the data aren’t granular enough to look at the use of specific “mind-body” modalities and their association with chemotherapy initiation. The same problem applies to the dietary supplement categories, because homeopathic remedies could easily be lumped under that category. With such small numbers, though, combining modalities into categories is unavoidable.
The authors do, however, speculate:
By nature, dietary supplement use differs from mind-body practices. Dietary supplements are ingested substances, whereas mind-body practices include behaviors and body-work. Presumably, patients with cancer who use either type of CAM hope to achieve a health-related benefit. In the general population, users of dietary supplements often use these products to improve or maintain overall health or for organ-specific health reasons (eg, heart, joint, skin). A population-based study of patients with cancer reported that patients with cancer took dietary supplements because “it was something they could do to help themselves” to boost immune function and to improve energy. In contrast, users of mind-body practices often do so for psychological benefits (eg, stress, anxiety, depression) and pain management. Distinguishing these motivations for use may explain our findings.
Perhaps. There might be something to this. It could also be that patients taking herbal remedies or dietary supplements are taking them instead of chemotherapy rather than in addition to chemotherapy. After all, herbal remedies, if they actually work to do anything, do so because they contain substances that act as drugs. Of course, there is also no good scientific evidence that any dietary supplement has an antitumor effect that decreases the risk of recurrence.
One area where this study is seriously lacking is hinted at. The authors mention that they didn’t look at genomic profiling tests that predict risk of recurrence, such as the OncoType, because such tests were not widely in use at the time subjects were being recruited for BQUAL. They wondered if perception of risk of recurrence affected the willingness of subjects to accept chemotherapy, which is not an unreasonable question. I note that the investigators had information on the single biggest determinant of risk of recurrence, stage at diagnosis, as well as other predictors, such as tumor markers. They could easily have estimated a ten year risk of recurrence based on those factors (or a range of recurrence risks, such as low, medium, or high) and then looked for a correlation, although I doubt they would have found one in this dataset because it’s too small.
I refer to this because risks versus benefits are a key consideration for any treatment. Chemotherapy is unpleasant and can result in serious side effects. If the benefit isn’t perceived as worth it, then a patient is much less likely to agree to use it. I’ve discussed adjuvant chemotherapy many times, often in the context of patients turning it down. In brief, adjuvant chemotherapy is administered after surgery in order to decrease the risk of recurrence. As is pointed out in the accompanying editorial by Robert Zachariae, adjuvant chemotherapy does decrease overall mortality and delays in chemotherapy decrease its effectiveness.
Of course, chemotherapy has different levels of benefit depending upon how high the risk of cancer recurrence is. That’s the reason why there are so many testimonials of patients who refused chemotherapy. They did, however, have primary surgery, which can be enough, particularly in earlier stage breast cancer. The motivation to undergo chemotherapy could be much less in a patient with stage I cancer, for whom the risk of recurrence might be less than 10% and the absolute benefit of chemotherapy on overall survival might only be 2-3% than it would be in a patient with stage III cancer for whom the risk of recurrence might be 50-60% or more, depending on the aggressiveness of the tumor, and the absolute survival benefit of 20% or even more, a much more convincing benefit.
Regardless if you buy the results of this study or not (and I’m not sure that I entirely do), Zachariae does use it to make an excellent point:
To provide the best evidence-based decision support regarding CAM use—including whether to use CAM as a complementary or alternative treatment to AC—oncologists need to be actively involved in discussing CAM use with their patients. Only by acknowledging that communication about CAM use is an important part of cancer care will oncologists be able to help patients to make sufficiently informed choices about CAM use. However, as shown in a systematic review of the available literature, a considerable proportion (20%-77%) of patients with cancer who use CAM do not disclose their CAM use, the main reasons for nondisclosure being the physician’s lack of inquiry; the patient’s anticipation of the physician’s disapproval, disinterest, or inability to help; and the patient’s perception that disclosure of CAM use is irrelevant to his or her conventional care.
Despite my strong opposition to CAM in general as unscientific, pre-scientific, and pseudoscientific, when it comes to CAM use in my own patients, I take a very pragmatic approach (believe it or not). I will not recommend, prescribe, or encourage CAM use, and, if asked, I am honest in my assessment of any given CAM modality, but I will not tell them not to use it either, unless I have a good reason to suspect that whatever it is they are doing could interfere with science-based treatment. Of course, for me to accomplish that, I need to know a lot about CAM, and I do. Unfortunately, the vast majority of oncologists do not. This study reiterates the need for oncologists to know enough to be able to address CAM use with their patients.
Their patients’ lives could depend on it.

Complementary and Alternative Medicines and Cancer
Does complementary and alternative medicine offer any meaningful benefits to cancer patients?
Scott Gavura on October 5, 2017
Link

If you are a cancer patient, you’re likely using complementary and alternative medicine (CAM), thinking about using it, or having CAM recommended to you by others. Surveys suggest that CAM use by cancer patients is fairly common. Whether you’re currently being treated for cancer or are a health professional who treats cancer patients, it’s important to understand the types of CAM, the impact of CAM on cancer, and how to make informed decisions about using CAM. Health professionals and cancer patients want the same thing: better cancer outcomes and better quality of life for cancer patients.
Last week I participated in the Canadian Association of Pharmacy in Oncology’s Fundamentals Day, where I had the opportunity to speak about CAM, pharmacy practice, and ethical, science-based patient care. What follows is a summary of that talk, which regular readers will see incorporates many familiar SBM topics. Rather than focusing on specific products (I only had 30 minutes), this talk looked at the phenomena of CAM, with the goal of equipping pharmacists to help patients make informed decisions about their cancer care.
What is CAM?
Depending on who you ask, you’ll get different definitions of what constitutes CAM. Some consider anything sufficiently “natural” is CAM. Others point to who sells it – CAM tends to be delivered by non-health-professionals, but some health professionals (and health organizations) offer CAM and conventional medicine side by side. David Gorski and others at this blog have written about the evolution of CAM, which started long ago as unconventional medicine, or quackery. These products came to be known as alternative medicine.
Alternative medicine sounds outside the mainstream (and it was), implying it’s an alternative to conventional medicine. Alternative medicine proponents didn’t like this, and so the term became “complementary and alternative medicine”, which retained the quackery, but added in utterly conventional treatments like dietary interventions and exercise.
But having “alternative” medicine in its name remained a problem for CAM proponents, so today the more common term you’ll see is “integrative”, reflecting the combined use of CAM and conventional medicine, where you can apparently have your chemotherapy, your acupuncture and your homeopathy, and they’re all “integrative”. But paraphrasing what Mark Crislip has said, when you integrate cow pie into apple pie, you do not make the apple pie better. You make it worse. And that’s the concern with CAM and cancer – does mixing in CAM with cancer treatment make patients better? Or worse?

So if we don’t even have a common definition to work from, is it possible to objectively assess it? CAM is mostly defined by what it is not, rather than by what it is. This is the definition from the National Center for Complementary and Integrative Health (formerly called the National Center for Complementary and Alternative Medicine, and before that, the Office of Alternative Medicine). (See what they did there?):
Use of products like herbs, vitamins, minerals, and probiotics, and medical practices (e.g., acupuncture) which are outside of the mainstream Western medicine.
    • ‘alternative’ when they are used in place of conventional medicine
    • ‘complementary’ when they are used together with conventional medicine
As a science-based health professional, it’s easier to think of CAM today as a continuum, ranging from science-backed interventions, used alongside cancer treatments, that may help quality-of-life and symptoms (e.g., supportive care), to implausible, unproven or disproven treatments, some of which may be claimed to actually treat the underlying cancer:

The easiest definition of CAM is attributed to Tim Minchin:
Do you know what they call alternative medicine that’s been proved to work? Medicine.
So how popular is CAM among cancer patients? It depends on what you consider CAM. Many people have spiritual beliefs, and based on some definitions, prayer could be considered CAM. Similarly for exercise – do you exercise when you have a cold? You could be using CAM, and not even know it.
Regardless of the definition, it’s fair to say that there is significant interest in CAM, and that prevalence is probably underestimated due to underreporting. A cancer diagnosis may motivate interest in CAM.
Why do cancer patients use CAM?
CAM is a cultural phenomenon, and not a product of science or evidence. As Steven Novella has noted previously, satisfaction with mainstream medicine is not an important factor in deciding to use CAM, and CAM users are generally satisfied with their mainstream care. CAM may be popular because its use aligns with a user’s personal philosophy, or simply to expand their options, perhaps because it is widely viewed as being natural and harmless. A 2013 systematic review in advanced cancer noted that use was felt to offer hope and even ambiguity about the future in these patients with a terminal cancer diagnosis. Patients who were younger, female, more educated, had a longer duration of disease, and had previously used CAM were more likely to use CAM. And a 2015 cross-sectional survey of patients at a academic cancer centre found that attitudes towards CAM predict CAM use. Patient age (<65 years), female gender and college education were associated with greater expected benefit from CAM.
The CAM lifecycle
Two or three decades ago, few randomized controlled trials of CAM therapies had been conducted, and the systematic review methodology was in its infancy. Since then there has been a significant increase in the evidence base for CAM, in terms of the number of trials and the quality of those trials. Parallel with this work has been improvements in the quality of systematic reviews across medicine, as well as the growth of the Cochrane Collaboration to support the development and dissemination of these systematic reviews. These evaluations have, on balance, demonstrated that most CAM therapies fail to provide objective benefits. But given CAM isn’t driven by evidence or even a rejection, necessarily, of conventional medicine, we shouldn’t expect the emergence of negative beliefs to cause a rejection of these therapies. Consequently, CAM has a predictable lifecycle:
    • CAM may start out being promoted by anecdotes, often by those with vested interests.
    • As interest builds, products undergo scientific scrutiny and possibly even clinical trials.
    • When research show treatments to be effective, they may be endorsed or supported by “conventional” medicine (e.g., mindfulness, ginger for nausea, etc.)
    • When trials show treatments are ineffective, a conspiracy is often blamed for suppressing and discrediting them (“Big Pharma!!!!”)
    • Scientifically discredited therapies continue to exist in the CAM universe. Treatments are never discarded because they’re ineffective.
A review by Edzard Ernst in 2011 asked “How much of CAM is based on research evidence? The answer is very little. Ernst looked at 685 treatment/condition pairings in the The Desktop Guide to Complementary and Alternative Medicine and examined the quantity, quality, and level of evidence. He calculated that only 7.4% of these pairings could be considered to be based on sound evidence, and suggested this might be a “gross over-estimate”.
Case Study: Laetrile, the unsinkable cancer quackery: You’ll find obituaries written about laetrile as a quack cancer remedy back as far as 1981. This compound is chemically related to amygdalin, a substance found naturally in the pits of apricots and various other fruits. It was touted as a cancer treatment in the 1960’s, subject to trials, and found to be completely ineffective. Yet today it still persists, despite an abundance of evidence that demonstrates it does not work. (Quackwatch has an excellent summary of laetrile.) Earlier this month, BMJ Case Reports featured a prostate cancer patient who was taking apricot kernel extract and gave himself cyanide poisoning. Amazingly after being told that he was poisoning himself the man apparently has restarted the supplement.
When alternative medicine is chosen in place of conventional cancer therapy, outcomes are worse
As David Gorski summarized in an extensive past SBM post, alternative medicine kills cancer patients. Skylar Johnson’s study of the US National Cancer Database examined breast, lung, prostate and colorectal cancer outcomes by studying 280 patients who did not receive “conventional” treatment and were noted to receive alternative medicine. Overall the hazard ratio for death was 2.5 greater for patients using CAM as their treatment, instead of conventional medicine. The survival curves tell the story here – the differences were significant for three of the four cancers, with the exception of prostate cancer, likely because the long natural course of the disease:

Johnson’s study is not the only paper that documents the relationship between alternative medicine use, and cancer. See, for example:
    • Chang, 2006: “Alternative therapies used as primary treatment for breast cancer are associated with increased recurrence and death”.
    • Han, 2011: “Alternative therapies used as primary treatment for breast cancer are associated with disease progression and increased risk of recurrence and death. Diminished outcomes are more profound in those delaying/omitting surgery.”
    • Saquib, 2012: “The risk for an additional breast cancer event and/or death was higher for those who did not receive any systemic treatments; the use of dietary supplements or CAM therapies did not change this risk. This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment.”
    • Joseph, 2012: “Women who declined primary standard treatment had significantly worse survival than those who received standard treatments.” “The majority of the patients (57%) in our series initially chose CAM as the primary treatment instead of surgery. Those who had chosen CAM had disease progression with particularly poor disease-specific survival when compared to those who received standard treatment.”
As I noted in a past post, no specific CAM intervention has shown any meaningful benefit in cancer. Probably the most comprehensive single review is a systematic review by Gerber et al, published in Breast Cancer Research and Treatment in 2006, which looked at CAM effectiveness for early breast cancer. It concludes:
There is no compelling evidence that any of the numerous complementary treatments available is sufficiently effective in breast cancer patients to justify its use. It should be the responsibility of those who claim efficacy for CAM to support these claims with acceptable evidence, rather than the responsibility of those who criticize CAM to prove its non-efficacy.
Does concurrent use of CAM with conventional cancer care affect survival or quality of life?
It’s possible that CAM, when used concurrently with conventional medicine, might offer some subjective benefits, particularly for side effects. However, given the potential for CAM-drug interactions (in the case of supplements and herbal remedies), survival benefits shouldn’t be assumed. A study of a Korean population by Yun and colleagues suggested that CAM had no effect on survival and worsened, rather than improved, quality-of-life. Similarly, so did a Malaysian study by Chui. Armstrong found no difference in QOL due to CAM in a study of patients with brain tumours. Risberg, studying a Norweigan population, also observed that concurrent CAM use predicted a shorter survival. However, the U.S. Health, Eating, Activity, and Lifestyle Study found no relationship between CAM use and breast cancer (or overall) survival. It’s unfortunate that this is such a poorly studied area, given the widespread interest in CAM by cancer patients. Overall, based on this limited evidence, it’s reasonable to conclude CAM may offer patients subjective benefits. However, there is no convincing evidence CAM use actually improves quality of life or has any beneficial effect on survival.
Promoting dialogue and informed decision-making is essential
Understanding CAM approaches and perspectives are essential to have meaningful conversations with patients about CAM use. While patients may elect to use unproven therapies, it is essential for health professionals to provide a professional evaluation of these therapies, using their knowledge, skills and abilities to support informed patient decision-making. Recognizing that many cancer patients may not understand the scientific process that underlies and informs cancer treatment, describing the lack of benefits of CAM use (and the potential risks, even when used concurrent with conventional care) are important. The Clinical Oncology Society of Australia’s position statement on CAM summarizes a reasonable approach for health professionals when talking to patients about CAM, which includes this suggested approach by Schofield:
     1.  Ask what patients understand about their illness.
     2.  Respect culture, values and beliefs.
     3.  Ask about use of CAM.
     4.  Explore reasons for CAM use, and the evidence base.
     5.  Address issues they want to resolve with CAM use.
     6.  Discuss concern you may have about their use of CAM.
     7.  Advise patients about CAM use based on an assessment of the evidence.
     8.  Summarize the discussion and check that they understand.
     9.  Document the discussion and inform others involved in that patient’s care
     10.  Monitor and follow-up at the next consultation.
If CAM works, it does so according to scientific principles – not alternative ones. There is no evidence that most of CAM has much to offer cancer patients, even when used alongside conventional care. Importantly, no treatments, even some forms of CAM, are without any risk. Given cancer patients may be more willing to accept the risks of CAM, it is important for health professionals to underscore what is known (and not known) about these treatments and approaches, in order to support informed patient decisions.

Cancer Treatment Centers of America: Revisiting the epitome of “integrative” cancer care
David Gorski on October 7, 2013
Link
Three weeks ago, I mentioned in a post that the week of October 7 to 14 was declared by our very own United States Senate to be Naturopathic Medicine Week, which I declared unilaterally through my power as managing editor of Science-Based Medicine (for what that’s worth) to be Quackery Week. One wonders where the Senate found the time to consider and vote for S.Res.221, which reads:
S.Res.221 – A resolution designating the week of October 7 through October 13, 2013, as “Naturopathic Medicine Week” to recognize the value of naturopathic medicine in providing safe, effective, and affordable health care.
I know, I know, it probably took all of five minutes to consider and vote for this, thanks to Sen. Barbara Mikulski (D-MD), who sponsored it. In any case, as October 7 approached, I thought about how I could keep my promise to blog about naturopathy this week, and I came up with a way to do it. It’s a bit roundabout, but I think it fits. The idea derives from a discussion I was having a while back about one of my “favorite” hospitals, namely the Cancer Treatment Centers of America, in which a colleague of mine questioned why there were so many CTCA ads on NPR and why CTCA is sponsoring shows on PBS such as the upcoming The Emperor of All Maladies by Ken Burns. Although I can’t wait to see this particular series, I am a bit worried that the infiltration of quackademic medicine will make an appearance, given that CTCA is a major sponsor.
Of course, PBS has come under fire here at SBM for doing more than airing acknowledgments from CTCA. There are several examples, such as its running of infomercials for Daniel Amen and Mark Hyman, as well as the local Colorado PBS station running, in essence, an infomercial for Stanislaw Burzynski, complete with Burzynski’s very own propagandist, Eric Merola. Let’s just say that, when it comes to medicine, PBS isn’t exactly as scientifically rigorous as it once was.
With this as my entry point, I noted that CTCA is very much into “naturopathic oncology” and that it’s been over three years since I’ve written about this. Given that this is Naturopathic Medicine Week 2013, this seemed like an excellent way to begin, with a recap and update on the nonsensical therapies that CTCA provides. In many ways, CTCA is the very epitome of “integrative medicine,” and I don’t mean that in a good way. (Actually, there is no good way to be the epitome of “integrative medicine,” which “integrates” pseudoscience and quackery with real medicine.) Then, late last year, it was revealed that Richard Stephenson, the founder of CTCA, is also one of the primary funding sources for Freedom Works, a right-wing Tea Party organization that was a major player in the 2012 elections. It was an interesting little tidbit in that it is yet another reminder that the tendency towards medical woo is not limited to the stereotypical crunchy granola-eating left wing fringe. Be that as it may, let’s take a look at what CTCA is offering these days. When I did this, I found a lot of the same ol’ same ol’, but one new development that echoes another frequent topic of this blog.
“Integrating” pseudoscience with science
The first thing I noticed when looking at the list of treatments that CTCA offers is that there is no segregation between the woo and the real medicine. Acupuncture, naturopathic medicine, “mind-body” medicine, and chiropractic are all “integrated” seamlessly into the list with chemotherapy, surgical oncology, and radiation oncology. The next thing I noticed is that the woo is also highly “integrated” into the national leadership of CTCA. For example, Katherine Anderson is the National Director, Naturopathic Medicine and Director, Naturopathic Medicine, Southwestern Regional Medical Center, while the Chief Information Officer is Timothy Birdsall, a naturopath who was Vice President, Integrative Medicine, and National Director of Naturopathic Medicine & Research from 2002 to 2012 and was named as the physician of the year by the American Association of Naturopathic Physicians (and who was also quite adept at spinning negative studies about his favorite supplements). Then there are James Rosenberg, National Director of Chiropractic Care; Carolyn Lammersfeld, Vice President of Integrative Medicine; Katherine Puckett, National Director of Mind-Body Medicine, and Director of the Department of Mind-Body Medicine; and Karen Gilbert, National Director of Oncology Rehabilitation, who also boasts of being certified in Lymphatic Drainage Therapy and Auriculotherapy. One notes that auriculotherapy is basically ear acupuncture based on the idea that the ear is a microsystem which reflects the entire brain represented on the auricle, the outer portion of the ear. Yes, it’s basically the same sort of quackery that Col. (Dr.) Richard Niemtzow offers our troops as “battlefield acupuncture.” What’s really depressing to see, however, is that a formerly well-respected surgical oncologist, Edgar Staren, is the President and CEO, Medicine and Science, and President and CEO, Western Regional Medical Center. I used to see him present from time to time at surgical meetings. In fact, I might even have met him in person back in the 1990s when I was looking for a job near the end of my fellowship and interviewed at Rush University Medical Center.
But what does CTCA offer in terms of “integrative” treatments these days? I wandered over to the section on integrative oncology services, and this is what I found. Naturally, I couldn’t resist heading first to the section on naturopathic medicine, particularly given that this is naturopathic medicine week. This is what CTCA touts, after declaring that naturopathic clinicians are “specialists in natural health care who use natural, non-toxic therapies to support the whole person and encourage the self-healing process”:
Throughout your treatment, your naturopathic clinician will recommend natural therapies to support your immune system and reduce any treatment-related side effects, including:
    • Herbal and botanical preparations, including herbal extracts and teas.
    • Dietary supplements, including vitamins, minerals and amino acids.
    • Homeopathic remedies, extremely low doses of plant extracts and minerals that gently strengthen the body’s healing and immune response.
    • Physical therapy and exercise therapy, including massage and other gentle techniques used on deep muscles and joints for therapeutic purposes.
    • Hydrotherapy, which prescribes water-based approaches like hot and cold wraps, and other therapies.
    • Lifestyle counseling. Many medical conditions can be treated with exercise, improved sleep, stress reduction techniques, as well as foods and nutritional supplements.
    • Acupuncture. Your naturopathic clinician may also recommend incorporating acupuncture into your treatment plan.
It’s rather amazing here how so many of the things that are wrong with “integrative oncology” are right there on a single page. Look at the list of therapies. They range from the purest quackery (homeopathy) to what should be science-based medicine (physical therapy and exercise therapy) and everything in between. I realize that most readers of SBM know what homeopathy is and why it is quackery, but in case there are new readers seeing this, I’ll briefly recap. Homeopathy postulates two main ideas, both of which have no basis in science: First that you relieve symptoms by using a substance that causes the symptom being treated, and, second, that diluting a substance makes it stronger. Of course, the substance must be diluted with strong shaking (known as “succussion” in homeopathy lingo) between each serial dilution step. Most homeopathic remedies are diluted so much that there is almost certainly nothing left of the original remedy. For example, Avogadro’s number (the number of molecules in a mole of a substance) is on the order of 6 x 1023. A typical homeopathic dilution is represented as “C,” where each “C” equals a 1:100 dilution. So, a 1C dilution is a 1:100 dilution; a 2C dilution is a 1:10,000 dilution (100 x 100); and so on. If you get to 12C, you’re talking a 1024 dilution, which is already greater than Avogadro’s number. That means that it’s unlikely that more than one molecule of the substance remains, and that assumes the homeopath started with a mole of the substance being diluted, which is rarely the case. Usually the homeopath starts with much less. Now consider that typical homeopathic dilutions are 30C (1060), more than 1036 orders of magnitude greater than Avogadro’s number, and just how quacky homeopathy is comes into focus. Sure, homeopaths will wave their hands about the “memory or water” or “nanoparticles,” but in reality homeopathy is nothing more than magical thinking. The same is largely true for acupuncture, which is nothing more than a theatrical placebo, and studies claiming otherwise are uniformly unconvincing.
Now let’s look at some of the other “integrative” treatments. They are a classic “rebranding” of science-based modalities as somehow being “alternative.” For example, physical therapy and exercise therapy have been well-accepted treatments for various musculoskeletal problems for a long time. There is nothing “alternative” or “integrative” about them. There is one caveat. Frequently, the “alternative” or “integrative” versions of these sorts of therapies get that way by “integrating” magical thinking into them. I can’t tell how much magical thinking has found its way into CTCA’s version of physical therapy and exercise therapy, but given who’s in charge of rehabilitation at CTCA (Karen Gilbert, certified in auriculotherapy and lymphatic drainage), I’m guessing that it’s probably a lot, particularly given the easy access to chiropractic and these recommendations for rehab:
Our massage therapists can help reduce your cancer-related pain and improve your quality of life during your cancer treatment. Some manual therapy options include:
    • Traditional massage
    • Stone therapy
    • Myofacial release
    • Soft tissue manipulation with passive stretching
    • Aromatherapy
    • Effleurage
    • Friction
    • Trigger point therapy
    • Acupressure
    • Reflexology
    • Chiropractic care
Chiropractic care
Our chiropractors treat bone, muscle or joint pain, without the use of drugs or surgery. Chiropractic care can also help to relieve symptoms such as neuropathy, nausea and headaches.
Auriculotherapy
This painless, non-invasive form of oncology rehabilitation, which involves stimulation of the auricle of the external ear, can help alleviate some of the side effects of cancer treatments, such as pain, nausea or fatigue.
Yes, indeed. It’s all there. Chiropractic, myofascial release, aromatherapy, acupressure, and, quackery of quackeries as quacky as homeopathy, reflexology.
Then there’s lifestyle counseling, which is a vague one. That can range in science-based practices, from practical advice on how to lose weight to exercising more and getting more sleep, but note how CTCA mentions nutritional supplements. It’s become increasingly apparent over the last several years that nutritional supplements are not necessary except in very specific (and relatively uncommon) cases of specific nutritional deficiencies, as long as the person eats a varied diet. Moreover, most studies of nutritional supplements for specific health conditions, with the possible exception of vitamin D, have been resoundingly negative.
One thing becomes clear as you peruse the treatment options offered at CTCA for virtually any cancer, and that’s that naturopathic treatments are deeply embedded (or “integrated”) into everything that is done at CTCA. Indeed, if you click on almost any cancer in this list, you’ll see three buttons. For instance, under the section on breast cancer, there are three buttons:
    • I’ve just been diagnosed
    • I’m searching for treatment options
    • I’m seeking integrative care
Also, take a look at this post on the CTCA blog about breast cancer awareness month. In it there’s a link to a page on naturopathic treatments for breast cancer, which recommends, in addition to the treatments in the list above, these treatments:
The following are additional ways naturopathic medicine can help combat side effects of breast cancer treatments:
    • Some hormone therapies for breast cancer can weaken the bones. Your naturopathic clinician may recommend vitamin D to protect the bones.
    • Chemotherapy for breast cancer may cause numbness or tingling in the hands and feet (peripheral neuropathy). Your naturopathic clinician can offer natural therapies to help treat this condition.
    • To help you fight nausea and vomiting, your breast cancer naturopathic medicine team may suggest ginger, peppermint oil, tea, sea bands, acupuncture and homeopathic remedies.
    • Some naturopathic remedies, such as green tea and melatonin, may help to decrease the risk of breast cancer recurrence.
    • Some endocrine treatments that are recommended for women with breast cancer are given for at least five years and have side effects that naturopathic medicine can help address. This allows you to tolerate these treatments and continue with important therapies to help decrease risk of recurrence.
Then there is this video that recommends supplements to combat cancer- and treatment-related fatigue. Vitamin D, of course, is not anything unique to naturopathy; when indicated it should be a part of standard treatment, not something recommended by a naturopath as an adjunct. Second, acupuncture and homeopathic remedies do nothing for nausea, and the evidence suggesting that green tea might decrease the risk of breast cancer recurrence is weak at best. So is the evidence that naturopathic treatments can significantly alleviate the symptoms of estrogen deprivation due to anti-estrogen drugs used to treat hormone-positive breast cancer.
There’s so much more, of course, but I’m trying to train myself not to be as verbose as perhaps you’ve become accustomed to (anything over 5,000 words is too much). The bottom line is that CTCA is indeed the epitome of “integrative” oncology in the way it truly does seamlessly “integrate” woo with science-based medicine such that it’s difficult for patients to distinguish what is science-based and what is not. Indeed, even physicians sometimes have difficulty telling where the SBM ends and the woo begins, even as otherwise excellent physicians and surgeons actually working at CTCA fall for the common trope that somehow taking care of the “whole patient” and being “holistic” means embracing pseudoscience, even touting it as what “sets CTCA apart.”
Disturbing echoes of another major topic of this blog
I’m going to leave the topic of naturopathic oncology for the moment, because, if there’s anything about CTCA that’s new, it’s not the naturopathy. Rather, it’s a new service CTCA offers that sounds a lot like a service I’ve been writing about for the last year and a half offered by our old “friend” Stanislaw Burzynski, specifically, his “personalized gene-targeted cancer therapy.” It’s basically using genomic testing to try to pick combinations of targeted therapies and chemotherapy that are likely to be most effective on any individual patient’s cancer. Go back and read that post. Now take a gander at CTCA’s webpage on Genomic Tumor Assessment, which boldly states:
Every cancer is different. Genomic testing helps our doctors understand a patient’s cancer at the molecular level. Information about genomic changes that are unique to your individual cancer will help us determine treatments most likely to work for you. It’s the promise of precision cancer treatment — a focus on the individual tumor in the individual patient.
Take a look at the video on that page. It’s very slick. It uses lots of 3D graphics showing DNA double helices and cells dividing. It sounds very convincing. However, much of it is, when you come right down to it, repackaging of things that conventional doctors already do. For instance, there’s a long section about colorectal cancer and how we know the proteins that drive the growth of colon cancer and, depending upon whether key genes are mutated, know which chemotherapies to choose. Ditto for breast cancer, where if the HER2 oncogene is turned up to 11, so to speak, we have a drug that targets it. In reality, this part of the video looks as though it’s just referring to these oncogenes that we already test for in colon cancer, non-small cell lung cancer, and breast cancer. There are already commercially-available tests for mutations in these genes, for example this one from Quest Diagnostics. None of this is particularly new, at least not anymore. CTCA even admits as much for non-small cell lung cancer and breast cancer, albeit in the small print, where it says that these tests have been done for several years as “part of the standard care.”
Here’s where CTCA claims to go beyond this:
If you and your oncologist decide you are a candidate for genomic testing, the following steps are taken:
    • CTCA collects a sample of your cancer tissue (if available) or a biopsy of your tumor and sends it to a respected genomic sequencing lab.
    • Sophisticated laboratory methods will capture genomic information in the tumor cells. Scientists at the sequencing lab extract the DNA from your tissue or tumor sample.
    • Genetic information is encoded as a sequence of nucleotides – guanine, adenine, thymine, and cytosine – which form the building blocks of DNA. Scientists at the lab then sequence the genes in your tissue or tumor sample to uncover the order of nucleotides.
    • Sequencing the tumor’s genetic profile produces a large amount of data. Scientists at the lab analyze this data to identify mutations that are critical to certain functions of the tumor.
Your oncologist will review the test results to determine if the information is helpful in the selection of a good treatment option for you.
All of this sounds to me a lot like what the Burzynski Clinic does. The question then becomes: Is CTCA any better at it than Burzynski is, the latter of whom, through the arrogance of ignorance, either thinks he “pioneered” this field twenty years ago (and that cancer centers like M.D. Anderson are only now following in the footsteps of his brilliance) or lies about his expertise in genomic testing and gene-targeted cancer therapy? The information is way too sketchy on the website to tell for sure, but it’s instructive to compare how CTCA sells “precision” medicine to how M.D. Anderson portrays it in the description of its Institute for Personalized Cancer Therapy:
Our strategic plan for the Institute is focused on the goal of defining the new standard of patient care – making personalized cancer therapy standard over the next 5 years, revolutionizing the way we manage patients. To accomplish this goal, we will:
     1.  Rapidly implement the expanded molecular pathology laboratories, technology, instrumentation, and infrastructure for personalized clinical trials;
     2.  Develop best practices for obtaining and managing patient biopsies and specimens to implement personalized cancer therapy;
     3.  Position MD Anderson to lead the way in therapeutic clinical trials based on the underlying genomic and molecular alterations in individual patient’s cancers;
     4.  Establish broad internal and external collaborations and partnerships to enhance our ability to rapidly transform discoveries into clinical practice and standard of care.
Note the emphasis on research and implementation. M.D. Anderson understands that “precision medicine” is not yet ready for prime time and that we don’t know yet whether or by how much the use of this genomic data for each patient’s tumor will impact patient care and outcomes. That’s why it has a research institute to develop the infrastructure and methodology for carrying out clinical trials to test “personalized” or “precision” medicine. Indeed, there has been some criticism of a “genomic gold rush,” in which cancer centers are seemingly competing to be the “firstest with the mostest” when it comes to genomic medicine. Even optimists point out that medicine is a long way from deriving useful information from routine tumor sequencing, much less improving patient outcomes.
I suppose that, in light of how the big cancer centers are going all-in, it’s not surprising that a for-profit hospital chain would want to emulate them. After all, don’t think that cancer centers aren’t using their new genomic institutes as marketing tools. However, there is a difference. The big cancer centers are building their genomic institutes in order to do the research necessary that will ultimately validate (or fail to validate) specific hypotheses regarding the use of routine genomic testing of patient tumor samples. There is enough uncertainty that, given the huge expenses involved and the massive effort this sort of research project takes, some are questioning the wisdom of setting these institutes up when the finances of medicine are so constrained right now and cost-containment is the order of the day. Even so, the goal, clearly, is to do the clinical trials that desperately need to be done.
In contrast, CTCA is selling genomic testing and personalized therapy as though it were already validated, as though it’s as routine and simple as sending off a piece of the patient’s tumor, either from a biopsy or a surgical resection, to the genomics lab to have it work its magic on the specimen, be it cDNA microarray analysis or the more recent advanced techniques like next generation sequencing, and then reading off the results. The implication is that we already know how to use the terrabytes of data that result from a typical sequencing of a single tumor to pick the best chemotherapy and targeted drugs for their individual cancer. Sure, there are disclaimers, but the overall message, complete with this spiffy infographic, is that this is cutting edge and that it will help cancer patients who come to CTCA. While there might be much to criticize when it comes to the “genomic gold rush,” the intent is to find out whether these techniques and the information they yield can greatly improve cancer outcomes. Now look at CTCA’s section on clinical trials. I don’t see any testing its Genomic Tumor Assessment to see if it provides information resulting in improved outcomes. Why is this? Indeed, look at this article on CTCA’s social media campaign for its “Real people. Real Discoveries.” campaign:
By launching the “Real People. Real Discoveries.” Social Media Campaign, CTCA places emphasis on key aspects of its core care delivery of genomic tumor assessment by emphasizing the importance of the individual’s genetic response and the potential it has for determining the best course of medicine and treatment. This focus inherently drives thoughts of “hope” without a specific reference to the word itself.
Notice that there isn’t any mention that this is still considered experimental. Rather, it is a media campaign designed to “drive thoughts of ‘hope'” without actually using the word itself.
Naturopathy and CTCA: Joined at the hip forever?
I’d like to finish by coming back to the topic of naturopathy, which might seem strange after discussing the use of genomic testing as a marketing tool. This is, after all, naturopathic medicine week, which is why I chose this topic in the first place. However, it is very clear that naturopathy is so completely embedded in CTCA that it taints the entire enterprise irredeemably. As I mentioned before, the impetus for founder of CTCA Richard J. Stephenson, was the death of his mother, Mary Brown Stephenson, from cancer and his frustration with the current system. Tragically, as so many before have done, in his grief and frustration, Stephenson confused “holistic” care with an openness to quackery like naturopathy and incorporated such quackery into CTCA right from the beginning, “integrating” it with standard, even state-of-the-art, conventional cancer care to the point where you can’t always tell where the science ends and the quackery begins. (Well, except for the homeopathy.) Sadly, a lot of otherwise-talented doctors bought into the idea and have—if you’ll excuse the term—completely “integrated” themselves into the CTCA system. In doing so, they have become complicit in the blurring of the line between science and pseudoscience in medicine while believing that they are doing good for the patient by giving them “holistic care.”

   Cancer Treatment Centers of America and “naturopathic oncology”
David Gorski 
Link
EDITOR’S NOTICE: NOTE THE DISCLAIMER.
On “wholistic” medicine
If there’s one aspect of so-called “alternative medicine” and “complementary and alternative medicine” (CAM) is that its practitioners tout as being a huge advantage over what they often refer to sneeringly as “conventional” or “scientific” medicine is that — or so its practitioners claim — alt-med treats the “whole patient,” that it’s “wholistic” in a way that the evil reductionist “Western” science-based medicine can’t be. Supposedly, we reductionistic, unimaginative physicians only focus on disease and ignore the “whole patient.” Of course, to me this claim is belied by the hectoring to which my own primary care physician has subjected me about my horrible diet and lack of exercise on pretty much every visit I’ve had with her, but then maybe she’s an anomaly, along with Dr. Lipson on this very blog and pretty much every other primary care doctor I’ve ever dealt with. Anecdotal experience, I know, but since alt-med mavens appear to value anecdotal evidence above pretty much all else I thought it appropriate to mention here. Also belying the claim of alt-med practitioners that they “individualize” treatments to their patients in a way that science-based medicine does not is the maddening tendency of various alt-med modalities to settle on just One True Cause of All Disease, be it liver flukes as the One True Cause of Cancer, heavy metal toxicity as the One True Cause of cancer, autism, and various other diseases, or “allergies,” acid, or obstruction of the flow of qi as the One True Cause of All Disease.
Given the claim of “wholism” that is such an advertising gimmick among many of the varieties of woo, I’m always interested when I see evidence that alt-med is imitating its envied and disliked reductionistic competition. True, this is nothing new, given how alt-med has tried to seek legitimacy by taking on the mantle of science-based medicine wherever it can. Examples include the National Center for Complementary and Alternative Medicine (NCCAM), various organizations that try to confer legitimacy to pseudoscience by providing “certification” in various flavors of woo, and moves to push state medical boards to go further than that and confer legally protected status to practitioners by actually licensing them. This latter tactic has been very successful in that many states now license acupuncturists, while some states even license naturopaths and “homeopathic physicians,” the latter of which I find quite amusing because the term perfectly encapsulates what must remain of such a physician’s medical training after being diluted to 30C with woo. The only difference is that, unlike what is claimed with homeopathy, diluting MD medical knowledge with woo does not make it stronger. In terms of naturopathy, though, one of the most alarming aspects of the infiltration of naturopaths into the health care system is that some states in the U.S. and provinces in Canada are seriously considering allowing them to prescribe real pharmaceutical medications, even though they lack the training and knowledge to use such drugs safely.
Imagine my combination of bemusement and alarm, then, when I learned of a new specialty of pseudoscience, namely the field of naturopathic oncology.
Be afraid. Be very afraid. (I know I was when I first encountered this specialty.)
Naturopathic oncology
It’s not surprising that I first discovered the “discipline” of naturopathic oncology at the Seattle Cancer Treatment and Wellness Center, which is affiliated with the Cancer Treatment Centers of America. As a science-based physician and surgeon I really detest CTCA because it is expert at combining state-of-the-art science-based medicine with pseudoscience like naturopathy, chiropractic, and acupuncture, as well as scientifically tested modalities known not to be particularly helpful in the clinical management of cancer, such as chemotherapy resistance testing (which could be the topic of an entire post). Suffice it to say that the last of these was prominently featured in Suzanne Somers’ cancer book last year. In any case, CTCA covers a continuum from the boringly “conventional” (traditional surgery, chemotherapy, and radiation) to the questionable (chemotherapy resistance testing), to pure pseudoscience (naturopathy, acupuncture, homeopathy) mixing them together to the point where it is impossible for the average consumer to know which is science-based and which is not.
We’ve written about naturopathy on multiple occasions here on SBM, but what is naturopathic oncology? Apparently it’s an “emerging field” within naturopathy concerned with applying naturopathy to cancer. I don’t know about you, but to be an “emerging field” within naturopathy is akin to being an emerging new paranormal phenomenon in the field of parapsychology. But, then, I’m just one of those nasty, reductionistic, skeptical, scientific physicians, so what do I know? On the other hand, Kimball Atwood characterized naturopathy as a “pseudoscientific cult“; so maybe I’m not that nasty, at least not in comparison. Be that as it may, let’s take a look at a couple of definitions, written by naturopaths themselves. First, there’s the Oncology Association of Naturopathic Physicians (OncANP) (yes, there is an Oncology Association of Naturopathic Physicians). This is how OncANP defines “naturopathic oncology“:
Naturopathic oncology is the application of the art and science of naturopathic medicine to the field of cancer care and treatment. Naturopathic oncologists work both in hospital oncology settings and in private practices bringing their wisdom, perspective and experience to aid oncology treatment teams that seek the best positive outcomes for their patients.
It all sounds relatively benign; that is, unless you know what naturopathy is. OncANP tries to justify the “need” for naturopathic oncology thusly:
Aware that modern medicine has made little advance in its War on Cancer, many people with cancer choose to also include complementary and alternative medicine in their fight against cancer. They reach out and employ a wide range of therapies including meditation, prayer, acupuncture, herbal, botanical, nutritional, homeopathic, dietary and other holistic practices seeking benefit.
Naturopathic doctors and physicians are trained in accredited naturopathic medical schools in modern scientific nature cure. They are trained in both modern science and natural medicine. They emerge from their training well versed in the use of botanical medicine, homeopathy, diet, fasting, nutritional supplementation, orthomolecular medicine, psycho-immunology and other complementary and alternative medical techniques; they serve as capable guides for patients interested in exploring alternative medicine.
Those naturopathic doctors who choose to specialize in naturopathic oncology understand both the standard treatments employed by medical oncologists and how best to work with them in a collaborative model of cancer co-treatment. They are well aware of the multitude of ‘alternative therapies’ promoted to cure cancer and can help patients understand which might be useful and why.
Note the common CAM claim that we have made “little advance” in the War on Cancer used as a justification for offering pseudoscience. Most of the “therapies” offered are fairly benign, such as meditation and prayer, although I can’t figure out why meditation and prayer are represented as “therapies” rather than manifestations of religion. Of course, much of what else falls under rubric of “naturopathic medicine” and “naturopathic oncology” is pure pseudoscience, in particular, orthomolecular medicine, a construct popularized by the late Nobel Prize winner gone woo Linus Pauling, is pure quackery, advocating as it does megadoses of various vitamins and supplements. Given how late in his life Pauling had come to believe that megadoses of vitamin C would cure cancer (they don’t, alas), it’s not surprising that Pauling was attracted to this particular form of quackery.
Then there’s acupuncture, the Jack of All Trades in CAM. It’s one of those modalities that, it seems, can do anything. Treat pain? Acupuncture. Improve the success rate of in vitro fertilization? Acupuncture. Reduce menopausal symptoms in women with breast cancer requiring anti-estrogen therapy. Acupuncture. Got migraines? Acupuncture. Asthma, allergies, bronchitis, sinusitis, sore throat, laryngitis, colds and flu? Acupuncture. Irritable bowel, colitis, constipation, diarrhea, gastritis, heartburn, food allergies, ulcers? Acupuncture. Cystitis, menstrual cramps, irregular or heavy periods, infertility, menopausal symptoms? Acupuncture.
I think you get the idea.
Naturopathic oncologists even have their own board certification, just like real oncologists. They even put the letters after their name, FABNO, which stands for “Fellow of the American Board of Naturopathic Oncology.” (Personally, I think it stands for “FAB? NO!”) Of course, given the panoply of dubious therapies, some of them contradictory to each other, that naturopaths use, I really wonder what the certifying test is like. When, for instance, do you choose megadoses of vitamin C over acupuncture or vice-versa? When do you choose live cell therapy over this supplement or that supplement? And what is the scientific evidence that any of it does cancer patients any good whatsoever? Especially homeopathy. (More on that in the next section.)
The mind boggles that this “specialty” has its own board certification. How long before naturopathic oncologists push for special privileges in the states that license naturopaths? It’s not even beyond my imagination to visualize them applying for, and getting, the prescribing power to administer chemotherapy along with their herbs, supplements, and other woo. Why would naturopathic oncologists even want this? Easy. For the same reason that naturopaths in general seem to be seeking prescribing power: Real drugs work, and if one mixes real drugs with naturopathy then patients will tend to attribute the success not to the evil pharmaceutical drug but rather to the naturopathic nostrum.
The Cancer Treatment Centers of America, naturopathic oncology, and other woo
I and other SBM bloggers have complained about the infiltration of what sometimes refer to as “quackademic medicine” into medical academia. Quackademic medicine, as you recall, is the term we use to describe how so many medical schools have taken to studying fairy dust treatments like reiki and acupuncture as though they are science-based, often justifying this study with the rationale that they are “ancient” treatments and that lots of people use them. Promoters of pseudoscience have even managed to carve out a whole center at that bastion of science-based medicine, the crown jewel of the biomedical research effort of the United States the National Institutes of Health. That center is the National Center for Complementary and Alternative Medicine (NCCAM).
While we’ve spent a lot of time on SBM lamenting and doing our part to combat the infiltration of pseudoscience into medical academia, we’ve spent comparatively little time on what is arguably an equally serious threat to science-based medicine. That is the infiltration of “integrative medicine” into private medical institutions that use integrative medicine as a marketing tool in order to distinguish themselves from the rest of the pack. Arguably, no hospital chain has been more successful at this than The Cancer Treatment Centers of America. Over more than 20 years, CTCA has built up a network of hospitals in suburban Chicago, Philadelphia, Tulsa, and suburban Phoenix, as well as a network of physician practice groups in Seattle and elsewhere. CTCA was founded in 1988 after its founder’s mother lost her battle with cancer, its mission being to “change the face of cancer.” Unfortunately, at least in its hospitals it is succeeding, and not in a good way. This is how CTCA describes its founder, Richard J. Stephenson’s, mission to find treatment for his mother:
After his mother’s diagnosis, Mr. Stephenson embarked on a mission to find the most advanced and effective cancer treatments available. He hoped his efforts would enable his mother to recover and remain an integral, irreplaceable part of his life and the lives of his children.
The Stephensons were sorely disappointed by what they found. What were regarded as world-renowned cancer treatment facilities were singularly focused on the clinical and technical aspects of cancer treatment, ignoring the individual needs of the patient and the multi-faceted nature of the disease. Tragically Mrs. Stephenson did not live to watch her grandchildren grow and mature.
To keep his mother’s memory and spirit alive, Richard vowed to change the face of cancer care. He selected a group of outstanding oncologists and challenged them to find a way to deliver whole-person cancer treatment in a compassionate, nurturing environment.
Death from cancer is tragic; it’s often painful and slow, and the sense of helplessness and loss that accompany watching the decline of a loved one to cancer is sometimes more than a person can bear. Mr. Stephenson might have done more good if he had dedicated his grief to founding truly science-based cancer hospitals that had ingrained in their culture caring and the “human touch.” Unfortunately, he appears to have confused compassion and the human touch with “integrating” pseudoscience into science-based medicine. Instead of producing an institution that could really transform cancer care by preventing the tendency of large institutions to become impersonal, he’s created a Frankenstein monster cobbled together using a lot of perfectly sound science-based treatments, including surgery, chemotherapy, and radiation with pure pseudoscience like naturopathy and traditional Chinese medicine bolted on like the head of the Frankenstein monster.
Let me show you what I mean. I happen to have a few quick-and-dirty rules of thumb that allow me to rapidly identify a practice that is full of woo. These are just my opinion, but I find them fairly useful, much like identifying the weasel words of woo can be for Dr. Atwood. One of these rules of thumb states that, if a CAM practitioner offers “detox foot baths” as one of his services, he’s a quack until proven otherwise (and he’s unlikely to be proven otherwise if he’s actually cynical enough or enough of a true believer to charge for quackery like “detox foot baths”). I haven’t seen a naturopathic oncologist, either at CTCA or elsewhere, offer detox foot baths (yet), but I have seen them offer homeopathy, and I’ve seen them advertise it at CTCA. In my opinion, homeopathy is rank quackery; there’s just no other way to put it. In fact, these are the treatments that the naturopaths at CTCA offer:
    • Nutritional supplements, including vitamins, minerals and amino acids
    • Botanical medicine (the use of herbs)
    • Homeopathic medicine
    • Hydrotherapy
I’m always irritated when I see nutrition co-opted this way. If you go to the nutrition page of CTCA, you’ll find a lot of verbiage that sounds perfectly reasonable and science-based (albeit with exaggerated claims that science-based physicians don’t pay any attention to nutrition). It’s also claimed that malnutrition is one of the main causes of cancer death, accounting for perhaps one third of them, which is one of those claims that is superficially true but also ignores the fact that many cancers cause cachexia (wasting syndrome) by mechanisms that are poorly understood. Cachexia can’t be reversed just by providing nutritional support, nor can it be so easily prevented. Worse, CTCA uses the term “superfoods,” which is a marketing term designed to make claims about various foods far beyond what science will support. Certainly, it’s not a medical or scientific term, and it’s particularly annoying when CTCA claims that “superfoods” actually “fortify the immune system,” as that’s the same trivially meaningless claim made by woo peddlers of all stripes. In any case, the claim that CTCA is any better than any other cancer center at nutrition falls apart when I see things like this on its website:
According to the National Cancer Institute, 20% to 40% of cancer patients die from causes related to malnutrition, not from the cancer itself. CTCA chef Kenny Wagnor suggests loading your diet with anti-oxidants, which are found in bright colored foods such as berries. Chef Wagnor prepares a blackberry strudel packed with tasty berries and pecans — a great combination of cancer fighting foods!
At the risk of annoying certain readers, I will point out the logical fallacy here: non sequitur. It does not follow from the observation that 20-40% of cancer deaths are related to malnutrition that eating lots of antioxidants will help you beat cancer. In fact, it’s controversial whether antioxidants help or hinder chemotherapy, as I’ve written about before. My pet peeve about how CAM practitioners abuse nutrition as being somehow “alternative” and not considered important by scientific medicine, note how CTCA naturopaths actually offer homeopathy to cancer patients. Yes, cancer patients are being given magic water in order to relieve the side effects of their cancer therapy.
The coopting of science-based modalities like nutrition at CTCA doesn’t end there. It’s everywhere. For instance, look at the CTCA webpage on Oncology Rehabilitation. In addition to standard physical and occupational therapy treatments, CTCA also offers:
    • Swedish Massage
    • Reflexology
    • Lymphedema Massage
    • Myofascial Release
I certainly don’t have any problem with Swedish massage. It’s not a “therapy” per se, but there’s little doubt that it makes patients feel better. Lymphedema massage, if done according to science-based principles and not according to some “alternative” medicine techniques, is a valid technique to try to reduce the lymphedema that can occur as a complication of lymph node dissections performed for breast cancer and melanoma. However, reflexology is pseudoscience, as is myofascial release. Once again, CTCA is “integrating” woo with science. This is not surprising, given that its entire website is permeated with what Dr. Atwood would call the Weasel Words of Woo. Here is an example from the Bone Cancer Treatment page:
Your body is designed to inherently establish, maintain, and restore health. The healing process is ordered and intelligent; nature heals through the response of the life force. The role of the naturopathic practitioner is to facilitate and augment this process, to identify and remove obstacles to your health and recovery, to help your body maintain its healthy equilibrium, and to support the creation of a healthy internal and external environment for you.
Note the vitalism inherent in this brief passage, in which nature heals through the “life force.” This is not science. It has no place in science-based medicine.
Naturopathic oncologists versus science-based medicine
Given the vitalism that permeates naturopathy, it’s not surprising that naturopathic oncologists, like naturopaths in general, are not too receptive to scientific testing of their “art.” Sure, they say they are, but when it comes right down to it, in contrast to science-based physicians, naturopaths can’t accept negative clinical trials. For example, take a look at what naturopath Timothy Birdsall, FABNO, who is Vice President of Integrative Medicine for CTCA, says about research finding that his favored therapies don’t work. In the American Association of Naturopathic Physicians’ blog, he wrote an essay earlier this month entitled The Problem With Research in response to clinical trial results showing that selenium doesn’t help patients with lung cancer. Here are some choice quotes:
To top it off, the reason I was out of the office last week was that I was attending the National Advisory Council for Complementary and Alternative Medicine, the advisory body to NIH’s NCCAM. On that council, we have talked about just this issue — why do therapies which seem to make biological and physiological sense, which have some epidemiologic data to support their use, and which naturopathic physicians (and other alternatively-minded practitioners) have been using for decades (or much longer), seem to fail in double blind, randomized clinical trials?
We science-based physicians ask ourselves the very same question time and time again. Many are the seemingly plausible therapies that, when tested in humans, failed to show benefit in cancer. Here’s the difference: when we see therapies, no matter how plausible, that fail in randomized clinical trials, we abandon them. True, it may take more time than we’d like. The process may be messier than we like, as some physicians who are wedded to these therapies are reluctant to give them up when science doesn’t support them. We then move on to try to figure out where our understanding of the biology went wrong. But abandon them we do. We don’t blame science and the randomized clinical trial (RCT), as Birdsall does. First, he trots out the favored canard of CAM practitioners everywhere and argues that RCTs “answer simple, straightforward questions” and (presumably) his woo isn’t simple. Of course, the question of whether selenium can, as he believes, be useful in treating lung cancer is actually a pretty simple, straightforward question not unlike the question of whether a certain chemotherapy can prolong survival or increase the cure rate of a cancer. Instead of realizing that, Birdsall attacks science:
And so I began to ponder the question, “What’s wrong with research?” A part of me becomes enraged at the reductionistic, allopathic, biomedical model, which breaks things down into components so small that all synergism, all interdependence is stripped away, and then declares those components to be ineffective. Another part argues that the wrong component was selected, or was a synthetic form (although in the lung cancer study, they used selenium yeast). But ultimately, I find myself becoming offended because I believe that these therapies work… Whoa! Believe? OK, but where is the role for evidence? I used to believe that stress caused gastric ulcers. And then along came Helicobacter pylori, and I had to change my belief to match the evidence.
Note the standard attack on “reductionism” and “allopathy” and the “biochemical model.” Then note the irony as Birdsall, while declaring that naturopathic oncologists must become science-based and train the next generation of naturopaths to be “great scientists” (I spit up my iced tea when I read that line), he proposes in essence destroying science in order to save it for naturopathy — or, more precisely, to use it to legitimize naturopathy:
Third, we should collaborate with other professions and institutions to craft the research models necessary to adequately perform “whole systems” naturopathic research. There are examples of this type of approach already existing in the health systems research literature which can be adapted to our needs. In the end, we must create and validate the tools to dethrone the randomized controlled trial as the gold standard, and construct new ways to validate clinical approaches to health issues. Much as the homeopaths of 2+ centuries ago created the proving as a way to better understand and utilize their remedies, we must refuse to be limited by the way conventional medicine views health and disease.
I would argue that invoking the magical techniques of people who believe that diluting a remedy makes it stronger and that water remembers all the good bits that have been in it but forgets all the urine and poo (as Tim Minchin so hilariously put it) is not the way to argue for science. Of course, the short version of this is: If RCTs don’t show that naturopathy works, we need to dethrone RCTs and make up our own research methods. Yes, I know RCTs have problems and limitations, but those problems and limitations don’t include not being able to answer the question of whether selenium and antioxidants can improve survival in lung cancer patients.
Sadly, it’s not just academia that is under siege by unscientific medical philosphies and treatment systems. True, academia sets the stage and promotes the spread of pseudoscience-based medicine because it is medical academia that does the research and trains the next generation of physicians. However, most medical care in this country is still provided by private physicians and private hospitals, and some private hospitals like CTCA have discovered that “integrating” pseudoscience-based medicine with science-based medicine can be a recipe for success. As “alternative” medicine infiltrates academia more and more, I fear that the stigma for offering these therapies will decrease more and more, leading to more hospitals and clinics like CTCA.

“Integrative oncology”: The Trojan horse that is quackademic medicine infiltrates ASCO
David Gorski on June 9, 2014
Link
You might have noticed that I didn’t produce a post last week, something that’s unusual for me, given how prolific I have been in the blogosphere. One reason was personal. The other reason was that last weekend I was attending the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago. I also must confess that, while I was there, I caused a bit of a stir on the meeting hashtag (#ASCO14) in the name of science-based medicine (SBM) on Twitter under my handle @gorskon. (What? You aren’t following me on Twitter? Get thee hence to my Twitter feed and add me. I’ll wait. Did you do it yet? Good. Now we can move on.) Of course, I know what you’re thinking: Cuddly, lovable me? Causing trouble? Making sure that I’ll almost certainly never be invited to be an official social media doc or to participate in panels on social media at ASCO, despite my extensive experience blogging, using Twitter, and just in general being a pain in the rear online to those who promote quackery and quackademic medicine? Perish the thought!
Of course, it was for just that reason that I was making a bit of a stir on Twitter. ASCO is one of the biggest (if not the biggest) and most organized oncology meetings out there, and there were several people considered “social media rock stars” in the world of oncology such as Mike Thompson, Deanna Attai, Matthew Katz, and Robert Miller live Tweeting the meeting, along with those viewed, correctly or incorrectly, as lesser lights, such as myself. In any case, on Sunday I noticed that a lot of people, including the official ASCO Twitter feed @ASCO, were Tweeting and re-Tweeting a link to this official story from ASCO, “Integrative Oncology Can Add Benefit to Traditional Cancer Treatments.” It was a description of a session that had been held on Saturday morning, Integrative Oncology: The Evidence Base, which, unfortunately, I had missed due to circumstances entirely beyond my control. Fortunately, however, ASCO is benevolent (not to mention that it also justifies the high cost of meeting registration) by providing immediate access to recordings of every major session, not to mention the slide sets used. If I couldn’t be there in person, at least I could cruise on over to the ASCO website and use my access to the 2014 virtual meeting to see what sort of quackademic medicine was being featured at ASCO.
There were three presenters and a panel discussion. Two of the presenters I was well familiar with, making me sad that I had missed the opportunity to be in the same room with them. First up, was Barrie Cassileth, PhD, whom we have met several times before and who is a big name in “integrative oncology,” as befits her position as the chief of the integrative medicine service and current holder of the Laurance S. Rockefeller Chair in Integrative Medicine at one of the greatest cancer centers in the world, Memorial Sloan-Kettering Cancer Center and her having founded the Society for Integrative Oncology (SIO), her topic being an introduction and overview, entitled, appropriately enough, “Integrative Oncology: Overview.” Next up was another big name whom we have met before, Lorenzo Cohen, PhD, who is basically Dr. Cassileth’s counterpart over at the other most famous cancer center in the US, the University of Texas M.D. Anderson Cancer Center, holding the titles of Professor and Director of the Integrative Medicine Program and having co-founded SIO with Dr. Cassileth. His topic was “Mind-Body Practices in Cancer.” Finally, to complete the trio, there was Michelle Harvie, PhD, with whom I am not familiar. She described on the website of the research institute where she works, the Manchester Breast Centre, as a research dietitian at the Genesis Breast Cancer Prevention Centre, University Hospital South Manchester Trust. She’s obviously nowhere near as big a name as Drs. Cohen and Cassileth, but she’s sure enough working on it.
Dr. Barrie Cassileth: “Integrative oncology isn’t quackery. Really, it isn’t!”
Dr. Cassileth seems to have a bit of a chip on her shoulder over “integrative oncology.” Clearly, she resents its being referred to as quackery, quackademic medicine, and not science-based. Indeed, of late, she has labored mightily to try to convince oncologists that “integrative” oncology isn’t cancer quackery, something I first noticed her doing with vehemence a couple of years ago in a review article that was, in part, a broadside against cancer quackery, such as Essiac, the German New Medicine, Entelev, shark cartilage, oxygen therapies, energy therapies, electrical devices (such as Hulda Clark’s “zapper,” prayer, and “healers” using therapeutic touch. That part of her article was something that anyone supporting SBM could appreciate. She also did, as I phrased it, question the “central dogma” of “complementary and alternative medicine” (CAM) or, as I like to call it, “wishing makes it so.” Unfortunately, some of that central dogma was evident in Dr. Cohen’s talk, as I will discuss in the next section. Much to my disappointment, there was no throwdown in the panel discussion between Dr. Cassileth and Dr. Cohen over this.
In any case, this same insistence that integrative medicine is evidence-based, in contrast to all that other cancer quackery, bubbled up again near the end of Dr. Cassileth’s talk in the form of a series of slides, one of which can be seen here, in which Dr. Cassileth, to her credit, emphasizes that alternative medicine is mostly quackery. In the accompanying article on the ASCO website, Cassileth says:
The first step in unraveling the beneficial from the detrimental may be a new understanding of the terminology used to describe these additive therapies, Barrie Cassileth, PhD, of the Memorial Sloan Kettering Cancer Center said during the session. Whereas complementary and adjunctive therapies may have beneficial therapeutic effects, it would be inappropriate to allow them to replace traditional interventions. The term ‘alternative treatments’ more aptly describes those modalities that proffer to replace medical or surgical intervention—although the word quackery may be even more fitting, Dr. Cassileth added.
To me, the “money slide” in the whole series was:
And that’s what bothers Dr. Cassileth the most. To her, quacks are “usurping” or co-opting the term “integrative oncology” in order to peddle cancer quackery. Of course, that’s not the way I saw it. The way I see it is that “integrative oncology” is integrating quackery into oncology. To paraphrase one of my Tweets at the meeting, the only thing “integrative” oncology adds to traditional cancer treatments is pseudoscience. To that, I now add that, if anyone is usurping or co-opting anything, it’s practitioners of “integrative oncology” and “integrative medicine.” They are co-opting perfectly science-based modalities, such as exercise and diet as somehow being “alternative” (word choice intentional, because something has to be “alternative” to fit into the paradigm of “integrating” non-standard therapies into conventional medicine) and then giving the appearance of “integrating them” into conventional medicine when they are already part of conventional medicine.
Indeed, it is not a coincidence that Dr. Cassileth broke down “integrative oncology” into six categories that the session would address:
     1.  Meditation and other “mind-body” therapies (Dr. Cohen)
     2.  Optimal nutrition, special diets, and supplements (Dr. Harvie)
     3.  Massage therapies
     4.  Music therapy
     5.  Acupuncture treatment
     6.  Exercise
Tellingly, Dr. Cassileth spent more effort discussing acupuncture, citing more studies, than she did for any other treatment listed above. It’s understandable that she didn’t discuss mind-body” treatments or nutrition, given that other speakers were going to address these, but, compared to acupuncture, she barely touched on massage and music therapy. She did discuss exercise a bit more, but, of course, from my perspective part of the reason she didn’t discuss exercise more is because it’s largely uncontroversial that at least mild-to-moderate exercise benefits cancer patients and that obesity is associated with a growing list of cancers. Again, there’s nothing “integrative,” “complementary,” or “alternative” about exercise. It’s science-based medicine. The same is true of nutrition. As for massage and music, I tend to agree with our co-editor and co-blogger Kimball Atwood, who simply says that he has no objection to massage, as long as there’s no medical contraindication, because it feels good, and what’s wrong with making patients feel better using something non-invasive? Back in the old days, we used to call such services “supportive” services, things done for patients to take their minds off being in the hospital and the sometimes painful and invasive treatments they require. The problem only comes when something like massage or music is “medicalized,” as in claiming that it treats specific diseases, or “woo-ified,” an all-too-common phenomenon for massage in particular in which massage becomes coupled or conflated with various forms of “energy healing.”
But what about the acupuncture studies? None of the studies presented by Dr. Cassileth provided any compelling evidence that acupuncture is anything more than what Steve Novella and David Colquhoun called it, a theatrical placebo. To this, I would add, given the claims that acupuncture can work to relieve symptoms or reverse virtually everything, be it infertility, nausea and vomiting from chemotherapy, pain, xerostomia, hot flashes, insomnia, lymphedema, and peripheral neuropathy due to certain chemotherapy drugs like taxol, chances are that means that it works for nothing. Dr. Cassileth’s presentation included the usual studies such as this study with no sham acupuncture control claiming that acupuncture relieved symptoms due to neck dissection. Indeed, in the discussion, Dr. Cassileth justifies this design thusly:
For our control arm, we opted for a pragmatic rather than a placebo control. A pragmatic control arm has the advantage of providing an estimate of effect size most consistent with the questions of greatest interest facing patients and clinicians. These questions include: What effects will an acupuncture referral have on a patient’s pain, and will the patient use less pain medication as a result? One disadvantage of a pragmatic comparison of acupuncture with usual care concerns lack of blinding and potential placebo effect.
Yup, which makes me ask: Why even bother doing this study? It shows nothing, Jon Snow. (Sorry. Game of Thrones is getting exciting as it nears the season finale.) She also cited a study indicating that acupuncture is helpful for post-surgery lymphedema in breast cancer patients, a conclusion that I characterized as: Keep those acupuncture needles away from my lymphedematous arm!
Other studies presented included a meta-analysis from 2005 that demonstrates the principle of GIGO as well as most acupuncture meta-analyses do with respect to relief of chemotherapy-induced nausea and vomiting. A more recent Cochrane meta-analysis, although still mildly positive, was a lot less so, concluding, “Overall, acupuncture-point stimulation of all methods combined reduced the incidence of acute vomiting (RR = 0.82; 95% confidence interval (CI) 0.69 to 0.99; P = 0.04), but not acute or delayed nausea severity compared to control.” That would be barely statistically significant, with the relative risk coming close to including 1.0. GIGO, indeed, plus theatrical placeboes!
If the studies she cited were the best that Dr. Cassileth could come up with for acupuncture, either she wasn’t trying very hard, or the evidence base stinks because acupuncture is nothing more than a theatrical placebo. Take your pick, but I pick the latter. In any case, there was nothing in Dr. Cassileth’s talk to change my opinion of either integrative oncology or acupuncture. “Rebranding” the others, such as diet and exercise, as being “additive,” “nonpharmacological,” or somehow “integrative” doesn’t change the fact that what Dr. Cassileth was doing was the same thing that “integrative practitioners” have been doing for a couple of decades now: Rebranding science-based modalities as somehow “integrative” or “alternative.” It is admirable that Dr. Cassileth can and does on occasion attack quackery in a way that would do SBM proud. Unfortunately, it is equally frustrating that she doesn’t seem to grasp that much of the “integrative” oncology she promotes, such as acupuncture, is based on the very same pre-scientific, vitalistic concepts as the cancer quackery she so rightly detests.
Dr. Lorenzo Cohen: Wishing makes it so!
Of all the modalities that Dr. Cassileth introduced in the first talk, the two that have traditionally been considered “alternative” were acupuncture, which she discussed, and various “mind-body” modalities, which Dr. Cohen discussed. I’ve discussed on multiple occasions how M.D. Anderson, sadly, has delved deeply into woo. Unfortunately, Dr. Cohen is the Delver-in-Chief, and he showed why in his talk. He’s definitely good. Sadly, what he’s good at is “integrating” pseudoscience into science-based medicine. He’s also good at “rebranding.”
One thing that has always bothered me about so-called “mind-body” modalities is the dualism inherent in the very name used to categorize these modalities. Think about it. The very term “mind-body” implies that the mind is somehow separate from the body. The assumption behind such modalities seems to be that training the “mind” to control what the “body” is doing will result in prolonged survival in cancer patients. It’s the very concept that Dr. James Coyne argued so eloquently against on this very blog a couple of years ago. To be honest, it’s also a concept that Dr. Cassileth herself argued against in the very same review article that got her into hot water with the “integrative medicine” crowd a couple of years ago as well. Let’s just cite some of her words:
Many of these ideas were promoted by a former Yale surgeon, a popular author who advocated special cancer patient support groups in his books. The importance of a positive attitude was stressed, as was the idea that disease could spring from unmet emotional needs. This belief anguished many cancer patients, who assumed responsibility for getting cancer because of an imperfect emotional status. Among alternative modalities, the mind/body approach has been especially persistent over time, possibly in part because it resonates with the American notion of rugged individualism.
To be fair, in the article Cassileth stated that there were “complementary” therapies that could improve quality of life, but she also stated that some promoters of “mind-body” treatments “overpromise,” by “suggesting that emotional stress or other emotional issues can cause diseases like cancer and that correction of these deficiencies through mind-body therapies can effectively treat major illnesses.”
That is exactly what Dr. Cohen suggested, albeit in a somewhat more subtle way than, say Ryke Geerd Hamer of German New Medicine fame, but, make no mistake, in his talk Dr. Cohen was arguing that mental states and stress contribute to cancer development and progression and that reversing those “bad” mental states can contribute to improved survival. Indeed, he started right out making that very argument, citing a study suggesting that depression is associated with decreased survival in cancer patients, an interesting but highly speculative eight year old review article on potential mechanisms by which stress can contribute to cancer (an article he kept coming back to again and again and again), a ten year old PNAS article contributed by Elizabeth Blackburn (a relatively newly converted proponent of “integrative medicine” whom we’ve met before) claiming that stress leads to shortened telomere length and thus diminished lifespan, and a study relating high social attachment to increased survival in ovarian cancer (which, ironically enough, also reported that “no significant association was found between access to instrumental social support and survival,” meaning that support groups weren’t correlated with increased survival). Why would he have mentioned these studies if he weren’t arguing that somehow the mind influences cancer mortality and that his “mind-body” interventions could potentially result in better survival?
I got the distinct feeling from Dr. Cohen’s talk that yoga is his big thing. He presented multiple studies of yoga in women with breast cancer. As I’ve said before, stripped of its spiritual elements, yoga is nothing more than a specific form of exercise involving stretching and various other body motions; so it’s not surprising that it would have potentially beneficial effects. Of course, that’s what Dr. Cohen noted, citing this recently published study from his group that compared women with breast cancer undergoing radiation therapy, dividing them into three groups: yoga, stretching exercises, and a wait list control. Of course, that means the study was not blinded, making it pretty much useless for saying much of anything about the effect of yoga, given that most of the measurements were subjective measurements of fatigue and health using self-reporting through survey tools. One change noted to be better in the yoga group was cortisol slope, which is a dubious measure, as Dr. Coyne and I have pointed out before. Cohen also cited another recent study that omitted the stretching control and was also similarly unblinded, that looked at inflammatory markers in the wait list control versus the yoga group. It reported much higher vitality and lower fatigue in the yoga group, along with a decrease in some inflammatory cytokines.
The list went on, including animal studies that related chronic stress to tumor progression, a progression that was reversed by beta blockers (drugs that block the effects of epinephrine signaling), an interesting finding, but one that hasn’t yet made it to the level that we recommend beta blockers for cancer patients. If this finding ends up being validated, it would then also become science-based medicine, and oncologists would start prescribing beta blockers to appropriate cancer patients, no woo needed.
Color me unimpressed. Also color me disappointed in that, yes, Dr. Cohen was arguing for exactly the sorts of contentions that Jim Coyne has refuted so well, both in the literature with his colleagues, and here on SBM.
Michelle Harvie: One of these things is not like the others
The last talk came from Dr. Michelle Harvie. To be honest, there’s really not a whole lot for me to say about it or to object to. Here are a couple of the key slides:
Her conclusions:
As I said, it’s hard for me to argue with most of this. It’s all pretty well evidence-based and unremarkable. She even showed data in which dietary interventions, including vegan diets, failed to arrest or slow the progress of prostate cancer, pointed out that the evidence that observational data regarding whether obesity and/or intentional weight loss has an effect on cancer progression is shaky at best (although it’s better for breast cancer and maybe prostate cancer), and cited a study that high fruit and vegetable intake appear not to affect the outcomes in breast cancer patients. She did point out, however, that a healthy diet can reduce overall mortality, but appears not to affect cancer-specific mortality much, if at all. That, of course, is not particularly surprising, given that healthy diets can definitely impact cardiovascular disease, diabetes, and other lifestyle-associated conditions. Basically, her overall message was that the data regarding diet and cancer survival are a lot less strong than we would like, although it is fairly clear that alcohol intake more than relatively low consumption, is associated with worse outcomes. She even cited an animal study in which nutraceuticals containing antioxidants decreased lifespan, pointed out that the evidence for ketogenic diets and cancer are inconclusive and that intermittent fasting probably has little effect on chemotherapy efficacy, and cited an abstract presented at ASCO that suggested that underweight patients with kidney cancer do worse than overweight patients.
In the end, Dr. Harvie’s talk was largely science-based medicine. Including it in a session on “integrative oncology” was nothing more than rebranding what should be a science-based modality, the effects of nutrition and diet on cancer treatment and survival, as being somehow “alternative” or “integrative.”
Yet another bit of “rebranding,” this time at ASCO
As is frequently the case in sessions like this at academic medical meetings, the last part of the session was a 20 minute panel discussion, in which members of the audience asked questions. What was incredibly disappointing to me was how little there was in the way of any sort of challenge to the assertions made by panel members in their talks or the assumptions underlying those talks. There were questions about green tea and whether it was beneficial, whether yoga has any benefit in relieving the symptoms of chemotherapy, leading to Dr. Cohen promoting a poster discussion he was going to present in a couple of days reporting the results of just such a study, and a question about how to keep “patients honest” about the supplements they’re taking. All of these warnings about dietary supplements not always mixing well with chemotherapy are useful, but it doesn’t really address whether integrative oncology is evidence-based, particularly given the bon mot delivered by Dr. Cohen that somehow it’s better to get antioxidants from foods than from supplements, even though, if antioxidants truly do interfere with chemotherapy action in some cases, chemically it would be the same and only the dose might be different. There was a question on juicing, which was generally not recommended.
I will point out that there was one hilarious question, in which an audience member asked how one can differentiate who is a good acupuncturist who will get the sorts of results claimed in the randomized clinical trials, from an acupuncturist who is a “charlatan.” Dr. Cassileth answered by saying that—of course!—MSKCC has six acupuncturists on staff, making her lucky that she can count on all of them as being highly skilled and doesn’t have to worry about “charlatan” acupuncturists. She also fried yet another of my irony meters when she declared quackery to be a huge problem in acupuncture, proclaiming that there are many acupuncturists who are not well-trained and who are not trained to work with cancer patients and that there’s a big difference between treating adults who might have some “aches and pains” and treating cancer patients. I, of course, agree, but not in the way that Dr. Cassileth meant her statements. There is indeed a big difference between treating benign aches and pains, which will almost always get better, and treating patients with serious disease, like cancer patients, for whom acupuncture is pretty much never appropriate. Come to think of it, acupuncture is pretty much never appropriate for anyone, because it doesn’t work.
And, of course, MSKCC offers a 21 hour Internet course for acupuncturists teaching how to use acupuncture for cancer patients! At only $495, it’s a total bargain! Helpfully, Dr. Cohen chimed in about how there’s a national credentialing board for acupuncturists, and you can look up acupuncturists online to see if they are trained and skilled. Yes, that’ll totally keep you away from quacks and charlatans! Oh, wait. Acupuncture is quackery; so maybe that won’t work so well. Sadly, none of this stopped Dr. Cassileth from suggesting acupuncture for postoperative pain right after this question.
Integrative oncology: Wanting to have it both ways
After having indulged myself in this session, I left very disappointed. On the one hand, I wished that I could have made it to the actual session instead of having to review it online, even though, given the credulity of the questions and the utter lack of challenge by anyone to the scientific basis of what was presented, I’m not sure I would have had the guts to get up there and say what needed to be said. On the other hand, it’s very clear that, for ASCO at least, the session was planned to scream as loudly as possible, “Pay no attention to the man behind the curtain (or prior plausibility or biology)! Integrative oncology is science!” To do that, the session focused pretty tightly on actual science-based modalities, such as diet and exercise, that could easily be “rebranded as somehow being “alternative” or “integrative,” while cherry picking data selling acupuncture as more than an elaborate placebo and implying that “mind” can control body and improve cancer survival based on animal studies and highly selective observational evidence. In essence, Drs. Cassileth and Cohen want to have it both ways, claiming for “integrative oncology” anything about diet, stress, and exercise that might be science- and evidence-based, “rebranding” them and lumping them together with the woo, like acupuncture, which, as mightily as they strive to make it appear evidence-based, remains prescientific, vitalistic nonsense.
ASCO, like many other medical professional societies—I’m talking to you, American Academy of Pediatrics—has a problem. Quackademic medicine is not only infiltrating oncology in the form of “integrative oncology,” but it’s becoming increasingly accepted. It’s not for nothing that we frequently refer to diet and exercise (rebranded as “integrative medicine,” of course!) as a Trojan horse that, once in the fortress of science-based medicine, opens up to disgorge pseudoscience. Sadly, oncology is not immune, as the increasing popularity of “integrative oncology” demonstrates. Unfortunately, “integrating” pseudoscience into science-based oncology does no good for cancer patients, the imprimatur of MSKCC, M.D. Anderson, and, yes, ASCO, notwithstanding.

The false dichotomies of CAM and “integrative medicine”
David Gorski on August 17, 2014
Link
A lot of medical specialties have throwaway newspapers/magazines that are supported by advertising and somehow mysteriously managed to show up for free in the mailboxes of practitioners. In my case, I’ve found myself on the subscription list for such papers about oncology, but also general surgery (I’m Board-certified as a general surgeon). When I have to recertify in about three years, it will be as a general surgeon, which was really fun to try to do last time after having specialized as a breast cancer surgeon, and will likely be even more fun next time, when I will be 10 years further out from my general surgery and surgical oncology training. In any case, that must be why, no matter where I end up working, sooner or later I end up receiving General Surgery News (GSN).
As throwaway professional newspapers go, GSN is not bad. However, occasionally it publishes op-ed articles that make me scratch my head or even tick me off with their obtuseness. Lately, apparently, it’s started some blogs. The one in particular that is the center of attention for this post is by Victoria Stern, is called “The Scope” and is billed as “exploring the lesser known sides of surgery.” Of course, it’s a bit odd that some of the first posts on this blog are about work hour restrictions and whether they leave new surgeons unprepared to practice surgery, the debate over breast screening, and what it takes to train expert surgeons, none of which are exactly “lesser known sides of surgery.” Work hour restrictions, in particular, have been discussed in surgery journals, at conferences, and among surgeons ad nauseam, particularly whether we are training a generation of surgeons unable to deal with the rigors of practicing surgery in the real world.
What caught my attention, though was a post from yesterday entitled “The Myth of Alternative Care, Growth of Complex Care“. Reading the title gave me a sinking feeling because whenever anyone mentions “complex care” in the context of alternative medicine, “complementary and alternative medicine” (CAM), “integrative medicine,” or whatever you want to call it, I know that a heapin’ helping of tropes and positive spin on pseudoscience is likely to be on its way. The reason, of course, is that CAM advocates love to argue that patient care is so complex that conventional medicine can’t adequately address it and needs some “help” from CAM. The article doesn’t “disappoint.”
Basically, Stern frames the post thusly. Alternative medicine is “bad.” No argument there. However, CAM is a different beast altogether. She starts with the standard CAM talking point that increasingly “patients are looking for answers outside of conventional medicine.” (Where have I heard that one before? Oh, yes. In pretty much every article and post spouting CAM apologia that I’ve ever read.) She then cites a 2006 study that has been blogged about before by someone near and dear to many SBM readers about the use of alternative medicine to treat breast cancer that pointed out the less than optimal (to put it kindly!) outcomes that result from such practices. She then quotes my good buddy and SBM fearless founder and leader Steve Novella, such that it becomes rapidly obvious that the post is set up to contrast “integrative medicine” with that nasty cancer quackery such that CAM/IM is a good thing:
“Alternative medicine is harmful,” said Steven Novella, MD, a neurologist and assistant professor at Yale University School of Medicine who is executive editor of the blog Science-Based Medicine. “If such alternatives were evidence-based at all, they would be considered medicine, not alternative medicine, and would be adopted into mainstream care.”
Complementary therapies, however, are a different ballgame altogether. Unlike alternative therapies, complementary interventions are not touted as cancer treatments. As the name implies, complementary modalities, such as vitamins and herbal supplements, massage, acupuncture, are meant to accompany mainstream care. The idea is to treat the entire patient, not just the disease.
Now there’s a total waste of a perfectly good Steve Novella quote.
Yes, there’s the granddaddy of CAM/IM tropes right there, the claim, either direct or implied, that CAM/IM, contrary to “conventional” science- and evidence-based medicine treats the “whole patient” (in this case the “entire patient”) and “not just the disease. This argument is, as I like to say, a pile of fetid dingo’s kidneys, because the implication is that you can’t treat the “entire” patient without embracing quackery such as acupuncture. A good primary care doctor using science-based medicine is a wholistic doctor who treats the “entire patient.” The same is true of a good oncologist practicing science-based oncology or a good surgeon practicing science-based surgery. The false dichotomy is plain: Either embrace the quackery that is CAM, or you are not treating the “whole” patient. Yes, it irritates the crap out of me, because I see it so much, and so few physicians directly question the assumption at the heart of a passage like the one above.
Let’s just put it this way. Whenever a CAM apologist says that she doesn’t practice that awful, nasty alternative medicine (which is quackery) and doesn’t recommend using it instead of conventional therapy, I respond, “That’s nice,” because that’s all it deserves. No one should be recommending foregoing effective science-based treatment in favor of magic and fairy dust. That is a bare minimum that we expect of physicians. However, when in the same paragraph (sometimes in the same sentence) I see advocates saying that it’s perfectly acceptable to add unproven therapies as an adjunct to conventional medicine (the “complementary” in CAM) or “integrating” them with science-based medicine, my teeth start to grind involuntarily. Bad reasoning has that effect on me. Think about it. A lot of the “respectable” CAM in integrative medicine derives from the very same pseudoscientific and prescientific ideas that are behind the quackery.
I like to use the idea of “energy healing” like reiki to illustrate the point. As I’ve written so many times before, reiki is finding its way more and more into academic medical centers as a “respectable” bit of integrative medicine. The key precept of reiki, as you will recall, is that reiki masters claim to be able to channel “healing energy” from what they call the “universal source.” Now, to drive the point home, let me suggest that you substitute the word “God” for “universal source.” See what I mean? Reiki is faith healing that substitutes Eastern mysticism for Christian beliefs. So, if faith healing is bad used alone, why is it suddenly “good” and “treating the whole patient” when used with standard treatment? The only reason I can think of is that at least the patient is getting standard treatment. That’s not enough. We shouldn’t be recommending the addition of ineffective treatments based on magical thinking to conventional treatment. Whether practitioners realize or admit it or not, acupuncture is based on similar prescientific ideas, given that qi (life energy) is supposed to be flowing through “meridians” (never mind that no anatomic structure has yet been discovered that corresponds to acupuncture meridians) and the needles are supposed to be “unblocking” or “redirecting” its flow for therapeutic effect. The same concept fits into chiropractic, as well, where removing subluxations is supposed to remove impediments to the action of “innate intelligence” healing the body. The list goes on and on and on of how vitalism is at the root of so many CAM treatments that are being “integrated” into medicine.
Unfortunately, Stern also incorporates another trope into her post:
In his surgical practice, Bruce Ramshaw, MD, FACS, chairman of the Halifax Health General Surgery Residency Program and co-director of the Advanced Hernia Solutions, Daytona Beach, Fla., takes a similar patient-centered approach to care. Dr. Ramshaw and his team, which includes a patient care manager, do not just treat hernias, they also try to understand their patients—what they really go through in their day-to-day lives as well as their fears and concerns about their health—offer potential solutions to diminish issues or anxieties, and involve family members in the process for added support.
In hernia repair and in medicine in general, there is no perfect way to treat each patient, said Dr. Ramshaw, but he hopes to come closer to an optimal treatment paradigm by applying this patient-focused approach to care. “Our goal is to form genuine relationships with patients,” Dr. Ramshaw said. (Read more about Dr. Ramshaw’s thoughts in his opinion piece, Love: Its Real Effect On Patient Care).
This kind of complex care that looks at the patient as a whole is becoming increasingly important not only for enhancing patients’ overall health, ensuring that they stay away from dangerous interventions and helping patients measure their expectations, but also as a way to create a true bond between physician and patient, an element of care that has been waning over the years. Although compassion and empathy won’t treat a person’s ailments, these traits can only help improve patient care and ultimately patient health.
Actually, there is little objectionable in Dr. Ramshaw’s article itself, other than its tendency towards a bit of “Patch Adams” sentimentality (although I note that he has written other things for GSN that I thought about blogging about before regarding “complexity theory” in medicine). So what is the problem? It’s not so much with Dr. Ramshaw as with what Stern does with his statements and articles. I think you can see it. Notice how CAM/IM is being conflated, without evidence, with measures that not only “treat the patient as a whole” but serve as a way to create a “true bond” between physician and patient. This is another massive false dichotomy. It is not necessary to embrace quackery to form a “true bond” between doctor and patient. Indeed, recommending treatments without good evidence behind them strikes me as potentially major impediment to forming such a “true bond,” at least if the patient ever finds out how thin the evidence base is for these treatments. In addition, what does it tell physicians practicing science-based medicine who can and do form “true bonds” with their patients without selling them fairy dust to tell them that such fairy dust is necessary to help them form such “bonds”?
Stern promises that her next blog will explore the “pros and cons of integrative medicine.” I can hardly wait.

Announcement: “Integrative oncology” – Really the best of both worlds?
David Gorski on September 19, 2014
Link

One of our goals here at SBM is to do more than just blog about the issues of science and pseudoscience in medicine that are our raison d’être. We also want to publish our science-based critiques in the peer-reviewed medical literature. Our first crack at this was an article by Steve Novella and myself published last month in Trends In Molecular Medicine entitled “Clinical trials of integrative medicine: testing whether magic works?” Even better, thanks to a press release and how the editors made the article free to all, it garnered more social media attention than any article previously published in TMM, and the editor has informed me that it “shot straight to the top of TMM’s ‘Most read’ article list and I anticipate it staying there for quite some time.” For this, Steve and I thank you, our readers, and those of you who spread the news. We’re hoping that this success garners more offers to write review and commentary articles for the peer-reviewed literature about topics near and dear to us.
Now, I’m happy to announce another commentary in the peer-reviewed literature. It’s an article I wrote for Nature Reviews Cancer that just appeared online yesterday entitled “Integrative oncology: Really the best of both worlds?” I must say, I’m quite proud of this one, and it is a big deal, hopefully to more people than just me. If you look up the impact factor for NRC, you’ll see it’s around 35, which is between The Lancet and JAMA.
Accessing this article is a little more difficult than accessing the previous one was, but not by that much. Normally, NRC articles are behind a paywall. In this case, my article is not behind a paywall, which is unusual, nor does it require a subscription to NRC or any Nature journal to be accessed. It does, however, require registration of a Nature.com login, which can be obtained for free, at, yes, Nature.com. Yes, I know it’s a bit of a pain and that many of you won’t want to register yet another login, but I assure you it will be worth it. Not only do you get access to my article, but there’s a lot of other cool science stuff at Nature even for free. That’s why I hope that a lot of you will do it and download the article. Read it, learn from it, and, hopefully, enjoy it. Let’s see if we can do it again and make this the most accessed article in NRC history.
Finally, consider this the comments section for the article. Therein lies another advantage of having access to a well-trafficked blog.

Selling “integrative oncology” as a monograph in JNCI
The Society of Integrative Oncology publishes its “evidence-based” guidelines for the supportive care of breast cancer patients, along with a whole lot of musings on integrating quackery with medicine. But are the guidelines science-based? I think you know the answer to that one.
David Gorski on December 1, 2014
Link


Sometimes, it’s hard not to get the feeling that my fellow bloggers at Science-Based Medicine and I are trying to hold back the tide in terms the infiltration of pseudoscience and quackery into conventional medicine, a term I like to refer to as quackademic medicine. In most cases, this infiltration occurs under the rubric of “complementary and alternative medicine” (CAM), which these days is increasingly referred to as “integrative medicine,” the better to banish any impression of inferior status implied by the name “CAM” and replace it with the implication of a happy, harmonious “integration” of the “best of both worlds.” (As I like to point out, analogies to another “best of both worlds” are hard to resist.) Of course, as my good buddy Mark Crislip has put it, the passionate protestations of CAM advocates otherwise notwithstanding, integrating cow pie with apple pie doesn’t make the cow pie better. Rather, it makes the apple pie worse.
In any case, over the last three months, Steve Novella and I published a solid commentary in Trends in Molecular Medicine decrying the testing in randomized clinical trials of, in essence, magic, while I managed to score a commentary in Nature Reviews Cancer criticizing “integrative oncology.” Pretty good, right? What do I see this month in the Journal of the National Cancer Institute (or JNCI, as we like to call it)? An entire monograph devoted to a the topic, “The Role of Integrative Oncology for Cancer Survivorship”, touting integrative oncology, of course. And where did I find out about this monograph? I found out about it from Josephine Briggs, the director of the National Center for Complementary and Alternative Medicine (NCCAM) herself, on the NCCAM blog in a post entitled “The Evidence Base for Integrative Approaches to Cancer Care“, in which she touts her perspective piece in the JNCI issue entitled “Building the Evidence Base for Integrative Approaches to Care of Cancer Survivors.” In an introductory article, Jun J. Mao and Lorenzo Cohen of the Department of Family Medicine and Community Health, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania and the University of Texas M.D. Anderson Cancer Center, respectively, line up this monograph thusly:
Cancer survivors, millions in number, often struggle to manage the physical as well as emotional, social, and spiritual consequences of their cancer and its necessary conventional treatments (1). Many individuals, like Josh Mailman (2), choose to incorporate complementary and integrative medicine therapies such as meditation, acupuncture, yoga, and diet into their cancer treatment with the goal of gaining a sense of control and being more active participants in their care. By doing so, they seek to improve their outcomes, including reducing the side effects of conventional cancer treatments and improving their quality of life and survival. More than ever before, cancer survivors desire the evidence-based integration of complementary and integrative medicine into conventional cancer care not only to treat their cancer but also to help in the healing of mind, body, and spirit.
Yes, it’s true. Thanks to the efficacy of real medicine, real oncology, there are now millions of people alive today who have survived cancer. This is a wonderful thing, unprecedented in medicine. It is also true that there are survivorship issues, both physical and psychological, that need to be tended to. These include a myriad of issues, including lasting sequelae of cancer and the treatments that eradicated it that impact quality of life, as well as psychological issues.
As is usual in such propaganda, the argument is made that patients are crying out for the “integration” of CAM into conventional care. This is, as many of us have pointed out over the years on SBM, at best an exaggeration that results from the co-opting of conventional, science-based interventions, such as diet and lifestyle changes, exercise, and pharmacognosy, as being somehow “alternative,” “complementary,” or “holistic” when they are nothing of the sort. Whether most CAM advocates realize it or not (and I doubt the authors of the articles making up this monograph and most prominent quackademics realize it), this co-optation serves the purpose of providing a sheen of respectability to the—shall we say?—less reputable, more pseudoscientific modalities that are routinely lumped in with CAM, such as reiki and other forms of “energy healing,” acupuncture and other traditional Chinese medicine, and naturopathy—even homeopathy. In any case, if you look at how prevalent the use of CAM is the numbers for hard-core alternative medicine, such as homeopathy, acupuncture, reiki, and the like remain very low (single digit percentages); the illusion of popularity is produced by lumping in supplements (pharmacognosy), diet and lifestyle interventions, and a vague “spirituality” into the mix. CAM/”integrative medicine” is not a scientific or medical construct, it’s an ideological construct, a marketing tool.
It is a brand, not a specialty, and it’s a brand that, as Mao and Cohen put it, they want to see “incorporated within the standard of care worldwide.”
Promoting the brand
Thumbing through this issue of JNCI (metaphorically speaking, obviously; I read it online), I was struck at just how much the monograph within was constructed to promote the concept of “integrative oncology” rather than to critically examine the concepts at the heart of integrative oncology, all gussied up in descriptions of “building the evidence base” (as Dr. Briggs put it). I suppose this is not the least bit surprising, but it is disappointing that the JNCI would devote a whole monograph to such an endeavor. Even more disappointing (but, again, not surprising) is the revelation of just how much the National Cancer Institute (NCI) supports CAM studies, as described in an article by Jeffrey D. White, MD, Office of Cancer Complementary and Alternative Medicine, NCI, entitled “National Cancer Institute’s Support of Research to Further Integrative Oncology Practice“. (Note the acronym, OCCAM, which, as I like to point out, is perhaps the world’s most inappropriate acronym for a government agency.) The amount of research support for CAM in oncology (or “integrative oncology”) through the OCCAM is laid out:
Both the absolute and proportional sizes of the National Cancer Institute’s (NCI’s) CAM research portfolio grew substantially in the early 2000s reaching a peak in FY2004 ($128.7 million; 2.7% of NCI’s appropriations). Over the intervening decade, NCI has annually supported over 300 intramural and extramural projects with some component of CAM research, with research costs totaling 80–120 million dollars annually (1). The great majority of these projects explore aspects of basic science or clinical cancer research; however, NCI also supports research to improve communication about CAM issues (2). The NCI’s Physician’s Data Query program also provides summaries of the literature about several CAM interventions with separate formats developed for healthcare practitioners and for patients (3).
I note that this is roughly the same size as NCCAM’s annual budget, with year-to-year fluctuations. Indeed, in 2004, OCCAM received more funding that NCCAM. Overall, if you add up all the CAM expenditures from all the institutes that make up the National Institutes of Health (NIH) in FY2013, you’ll find that it was nearly a half a billion dollars spent on the “integration” of pseudoscience with medicine by our federal government, half of that being administered by NCCAM and OCCAM. In any case, White’s article is, inadvertently no doubt, a perfect example of how a perfectly respectable specialty like natural products pharmacology (pharmacognosy) has been co-opted as somehow “alternative” or “complementary”:
NCI is the only institute at the National Institutes of Health with an office tasked with facilitating the growth of a CAM research portfolio and disseminating information on the topic. The Office of Cancer Complementary and Alternative Medicine (OCCAM), housed in the Division of Cancer Treatment and Diagnosis, works with various other components within NCI to accomplish these objectives. Among OCCAM’s activities is work done with laboratories in NCI’s Center for Cancer Research and the Natural Products Branch to establish collaborations with several international centers to screen novel natural products for anticancer activity and to train visiting postdoctoral fellows. This work is motivated by the recognition that traditional medical systems have been sources for identifying effective cancer therapeutics such as arsenic trioxide (5). OCCAM has also established unique opportunities for collaboration and dialog such as conferences about TCM and cancer and meetings to foster dialog and collaboration between CAM practitioners and cancer researchers.
Let’s just put it this way. Traditional Chinese medicine is a construct that was retconned by Mao’s regime to turn Chinese folk medicine that no educated Chinese wanted (because it was, by and large, quackery) into the “traditional Chinese medicine” to which academic medical centers such as M.D. Anderson and Memorial Sloan-Kettering Cancer Centers, not to mention the Cleveland Clinic, among others, devote considerable resources. It’s amazing how much things have changed in 30 years with respect to the government’s position on quackery.
Particularly troubling is how OCCAM is promoting “integrative oncology” beyond academic medical centers:
One major component of NCI’s clinical research activities is the work that takes place in the NCI Community Oncology Research Program (NCORP), formerly known as the Community Clinical Oncology Program. Approximately 30% of the clinical trials performed in this multicenter system for cancer prevention and symptom management studies are testing a CAM product (eg, ginger for chemotherapy induced nausea and vomiting) or other intervention (eg, acupuncture for cancer-associated fatigue) (4).
Let me repeat that: Nearly one-third of NCI-sponsored clinical trials through the NCORP are for “integrative oncology.” Comparing the evidence base for integrative oncology to conventional oncology, it boggles the mind that such a huge chunk of an important resource for testing is diverted in this way. Meanwhile, the NCI still administers its “best case” series, in which alternative medical practitioners present what they consider to be their most convincing single cases or case series to the NCI in order to try to entice the NCI into showing interest. It is this misguided program that led to the NCI working with Stanislaw Burzynski in the 1990s and Nicholas Gonzalez in the late 1990s and early 2000s, as well as to support high dose intravenous vitamin C treatment for cancer. OCCAM indeed.
It’s not just the government, of course. After all, the Society for Integrative Oncology is very much into promoting integrative oncology as well, as befits its name, as described in an article in the monograph by Susan Bauer-Wu, Suzanna Zick, Richard T. Lee, Lynda G. Balneaves and Heather Greenlee entitled “Advancing the Evidence Base and Transforming Cancer Care Through Interprofessional Collegiality: The Society for Integrative Oncology“:
As an interdisciplinary and interprofessional society, SIO is uniquely poised to lead the “bench to bedside” efforts in integrative cancer care. SIO members are comprised of a variety of professionals including, but not limited to, conventional cancer clinicians (ie, medical oncologists, radiation oncologists, and oncology nurses), family medicine providers, naturopathic doctors, traditional Chinese medicine practitioners, mind–body therapists, nutritionists, patient advocates, and basic scientists. This diverse membership facilitates true clinical integration of complementary modalities because such change requires breadth of expertise and different perspectives, to listen and learn from one another while challenging each other’s assumptions and existing paradigms.
OK, hold it right there. Any medical society that allows naturopaths to be members and touts “integrating” their “expertise” into medicine has automatically lost any claim to scientific legitimacy, given that naturopathy consists of a veritable cornucopia of pretty much every quackery known to humankind, including homeopathy (which is required study for naturopathy students and the knowledge of which is tested in the NPLEX, the naturopathic certification examination). Just peruse Scott Gavura’s Naturopathy vs. Science series, or any of a number of posts by myself or other SBM bloggers if you think I exaggerate. In particular, pay attention to what naturopaths say when they think no one’s listening. Ditto traditional Chinese medicine practitioners, as has been explained many times here before. This is the essence of quackademic medicine, elevating practitioners of pseudoscientific medicine, medicine based on prescientific concepts of how the body works and diseases develop, and outright quackery to be equals with practitioners of science-based medicine.
But it’s not just the SIO, unfortunately. In a commentary by Kevin D. Stein, Ted Gansler, Colleen Doyle, Rebecca Cowens-Alvarado, Virginia Krawiec, Carter Steger and Elvan C. Daniels entitled “Integrative Oncology and Wellness Considerations in Cancer Survivorship” the American Cancer Society has also weighed in. Yes, this is the same American Cancer Society that used to maintain a series on unproven methods in cancer treatment dedicated to examining cancer quackery—sadly abandoned over 20 years ago with the rise of CAM—but is now weighing in on “integrative oncology” and touting its research there. What the ACS writes is another perfect example of how “integrative oncology” has co-opted what should be science-based treatments, such as treatments involving exercise, nutrition, and life style modification:
The Society’s Nutrition and Physical Activity Guidelines for Cancer Survivors (2) are the foundation of communication, programmatic, and advocacy efforts designed to support survivors in their ability to make healthy lifestyle choices. Resources such as the What to Eat During Cancer Treatment cookbook, The Complete Guide to Nutrition For Cancer Survivors, and the online I Can Cope—Nutrition During Treatment help survivors manage nutrition-related side effects of treatment and maintain good nutritional status. The Society’s collaboration with the American College of Sports Medicine to create the Cancer Exercise Trainer certification helps survivors identify qualified exercise professionals to assist with setting and achieving physical activity goals, and our collaboration with the LiveSTRONG at the Y program provides local expertize to support survivors in being physically active.
No one would argue with these goals. There is nothing “alternative” or “integrative” about them. Now comes the quackery:
The ACS Extramural Grants department funds innovative research to advance the field of palliative care and symptom management, including integrative oncology. In addition to investigator-initiated mechanisms, the Society is also developing Requests For Applications to address how nutrition and physical activity influence survivors’ treatment, symptoms, weight, and QOL. Through Health Professional Training Grants, the Society funds clinicians and clinician-researchers working in the area of integrative oncology and has funded health professionals studying Reiki, mindfulness, acupuncture to treat hot flashes, and other integrative methods.
Reiki is, as I’ve discussed more times than I can remember, faith healing that substitutes Eastern mysticism for Christianity as its core belief system, and acupuncture is nothing more than a theatrical placebo, as has been discussed on this blog more times than I care to catalogue. Yet reiki, which does not belong in a medical center, except perhaps if one allows reiki masters into hospitals in the same way priests and ministers are allowed into hospitals (i.e., as chaplains there to comfort patients, with no claim of being able to treat anything), is now found in academic medical centers, such as the Cleveland Clinic, the University of Arizona, and many other academic medical centers, and the ACS is funding studies of it.
How far the ACS has fallen, allowing its admirable initiatives in promoting better care of cancer survivors to be co-opted by quackery. Unfortunately, it is a conscious strategy on the part of integrative oncology advocates to promote the use of CAM to treat cancer survivors, as described in an article by Julia H. Rowland and Ann O’Mara entitled “Survivorship Care Planning: Unique Opportunity to Champion Integrative Oncology?” What choice do CAM advocates have, given that CAM has not been shown to increase survival, but to shoehorn it into oncology as “integrative oncology” by emphasizing using placebo medicine to ease symptoms in survivors. None of this stops Rowland and O’Mara from trying to imply that CAM can increase survival in cancer patients:
Within the spectrum of treating the lingering and late effects of cancer, some promising interventions are emerging. For example, ginseng and yoga have shown promise in symptom management trials of fatigue and sleep disturbances respectively, both chronic problems reported frequently by cancer survivors (5,6). Given the documented positive association between quality of life and survival, there is arguably an important role for CAM use in recovery and life after cancer.
After co-opting pharmacognosy and exercise as somehow “alternative,” the next frontier for “integrative oncology” is to imply that it can somehow improve survival.
Bringing it all together
There were too many articles to cover them all in this post. In particular, there were a couple of clinical trials that demonstrate quite aptly the problems with integrative oncology as a concept. Perhaps, if nothing else grabs my attention before then, I will take a look at them next week, or perhaps I will discuss them on my not-so-super-secret other blog. What I wanted to finish with is what was clearly intended as the centerpiece of this monograph, a set of clinical guidelines by Heather Greenlee, Lynda G. Balneaves, Linda E. Carlson, Misha Cohen, Gary Deng, Dawn Hershman, Matthew Mumber, Jane Perlmutter, Dugald Seely, Ananda Sen, Suzanna M. Zick, Debu Tripathy, for the Society for Integrative Oncology Guidelines Working Group entitled “ Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer“. This is, after all, where the “rubber hits the road,” so to speak, in which the SIO ranks integrative oncology interventions based on what its guidelines working group considers to be the best existing evidence. The results, it turns out, are not surprising to someone rooted in science-based medicine. I’ll show you what I mean.
First of all, let’s look at how the guidelines were developed. First, SIO started with a working group, an expert panel, if you will, made up of members possessing expertise in medical oncology, radiation oncology, nursing, psychology, naturopathic medicine, traditional Chinese medicine, acupuncture, epidemiology, biostatistics, and patient advocacy. One wonders where the homeopaths and reiki masters were, although certainly naturopathy encompasses at least homeopathy, given how integral homeopathy is to naturopathy. In particular, one wonders why there doesn’t appear to be a chiropractor on the panel, given the popularity of chiropractic, which is at least as “respectable” as naturopathy or traditional Chinese medicine and has the added advantage that some musculoskeletal manipulation might actually provide some relief for low back pain. (Read Sam Homola’s excellent posts to learn what chiropractic, stripped of its vitalism, might be able to accomplish when strictly limited to musculoskeletal pain such as low back pain.) As I like to say, chiropractors are undertrained physical therapists with delusions of grandeur, but they are popular, and there’s no reason I can see for the SIO to leave them off the panel, at least not compared with TCM practitioners and naturopaths, as they did actually do a search for chiropractic, as shown in the supplemental data. (Spoiler alert: None of the chiropractic modalities were found to have sufficient evidence to make a recommendation.)
It is, however, telling to look at the list of excluded modalities:
Several interventions were excluded for the following reasons. Some have already been well summarized by other groups [eg, diet (22,23), physical activity (22–24)], while others already have a large evidence-base and are often no longer included in the definition of integrative or complementary interventions as they have become mainstream [eg, cognitive-behavioral therapy (25), psychoeducation (26), counseling (27), and support groups (26)]. Others were in early or pilot stages of research (eg, attention restoration therapy) or were not considered integrative interventions for the purposes of these guidelines (eg, prayer, spirituality).
Of course, once again I must emphasize that diet and physical activity were never “alternative” or “integrative,” nor was cognitive-behavioral therapy, counseling, or support groups, although all of these were oversold as improving cancer survival, as our occasional guest blogger James Coyne has described. As for the rest, prayer and spirituality are religion, not science. Overall, this list of excluded therapies is perfect as an illustration of the arbitrariness and falseness and of the very concept of “integrative medicine,” as is the manner in which the SIO defined these therapies itself:
Complementary and alternative therapies are generally defined as any medical system, practice, or product that is not part of conventional medical care (13,14). Examples include natural products (ie, vitamins, minerals, botanicals, and fish oil) and mind–body practices (ie, yoga, meditation, acupuncture, and massage). Complementary medicine is the use of a therapy in conjunction with conventional medicine (14). Alternative medicine is the use of a therapy in place of conventional medicine. Integrative medicine is the use of evidence-based complementary practices in coordination with evidence-based conventional care. Integrative oncology refers to the use of complementary and integrative therapies in collaboration with conventional oncology care.
Again, natural products are part of conventional medical care. For instance, digoxin is derived from the foxglove plant, although, as I like to say, there is a reason we don’t recommend that patients with heart failure or arrhythmias chew foxglove leaves to treat their heart condition. In terms of oncology, Taxol is derived from a substance in the bark of the Pacific Yew, and many chemotherapy agents were derived from natural products or the modification of natural products. The difference between using the “integrative oncology” version of natural products and the SBM version of natural products is that the “integrative” versions are crude, impure, and vary in activity from lot to lot.
Arbitrary and artificial definitions aside, the panel did an extensive literature search of nine databases (EMBASE, MEDLINE, PubMed, CINAHL, PsychINFO, Web of Science, SCOPUS, AMED, and Acutrial) from January 1, 1990 to December 31, 2013 and identified 4,900 articles, of which 203 were eligible for analysis because they were randomized controlled clinical trials of CAM interventions in breast cancer that met the inclusion criteria. It then ranked the interventions using the Jadad scoring scale and a modified scale adapted from the Delphi scoring scale to result in a score from A to I defined as follows (click to embiggen):
So what did the SIO find? Let’s put it this way. The results were most definitely…underwhelming. For example, the only grade A recommendations were for meditation, yoga, and relaxation with imagery for routine use for common conditions, including anxiety and mood disorders (Grade A). Notice that there are no grade A recommendations for anything having to do with pain, but only for symptoms with an even heavier subjective component, namely anxiety and mood. Of course, yoga is a form of exercise and therefore nothing out of the realm of conventional medicine, given the number of studies that have shown the benefits of exercise in cancer patients. Similarly, the only grade B recommendations included stress management, yoga, massage, music therapy, energy conservation, and meditation for stress reduction, anxiety, depression, fatigue, and quality of life. Interestingly, again, none of these, with the possible exception of meditation, can be considered in any way “alternative,” thus once again demonstrating how integrative oncology specifically and integrative medicine in general have co-opted treatments that should be considered conventional as somehow “alternative”. As for music therapy, massage, and the like, these represent modalities that I like to point to as examples of what we used to call supportive care that have been “medicalized” by CAM and turned into therapies when in reality they’re just activities and modalities that help patients feel a bit better or help pass the time, no specific effects intended. As for massage, it is rather disappointing that SIO lumped it together with “healing touch,” given that healing touch is a form of energy healing very much like reiki and thus total quackery, whereas massage at least has the benefit of feeling good to most patients.
As for the rest, surprisingly (given that this is an SIO document) but not surprisingly to anyone rooted in SBM, acupuncture does not appear as a modality in grade A or B, meaning that, at best, the SIO considers acupuncture for anything to be only worth recommending “selectively offering or providing this service to individual patients based on professional judgment and patient preferences” and deems that there “is at least moderate certainty that the net benefit is small.” Electroacupuncture (which is in reality TENS rebranded as acupuncture) and acupressure are given a grade B recommendation for nausea and vomiting, but that’s about the best, and as I’ve discussed before that evidence is a bit shaky.
The key observation was that the “majority of intervention/modality combinations (n = 138) did not have sufficient evidence to form specific recommendations (Grade I).” (Grade I means insufficient evidence.) I note that the supplemental document shows that homeopathy is one of those modalities, even though there is more than enough evidence on basic science considerations alone coupled with clinical trials that show no benefit above placebo to state that it is ineffective for basically everything. Ditto reflexology, which gets a grade I recommendation for most things, but a grade C recommendation for “improving quality of life among BC [breast cancer] patients.” Meanwhile healing touch is given a grade C recommendation for “improving mood in BC patients undergoing chemotherapy.” Once again, healing touch is energy medicine quackery, much like reiki. In other words, little, if anything, in these clinical guidelines gives support for real “alternative” treatments, although they do give mild support for a few potentially science-based modalities rebranded as CAM/”integrative oncology.”
Amusingly, however, these new guidelines are much weaker in their recommendations than a previous set of SIO guidelines discussed by Kimball Atwood six years ago. Particularly notable is how far down the ladder of recommendation strength acupuncture has fallen since then, and the SIO, at least for breast cancer survivors, no longer recommends considering consulting a “qualified expert in CAM modality, such as an Doctor of Naturopathy (ND) who is board certified in naturopathic oncology ” when conventional therapies fail, but I’m actually not sure the SIO did this, because these guidelines are for cancer survivors. Either way, it would seem as though the more studies are examined and performed, the weaker SIO’s recommendations become, which is not surprising given that most “integrative” oncology modalities are placebo.
Of course, the real reason for this monograph is not so much a critical analysis of integrative oncology, although some of the authors do appear to try to do this. The real purpose is to use an ostensibly critical analysis buying into the false dichotomy of “integrative oncology” in order to rebrand potentially science-based modalities as “alternative” or “integrative” and to provide ammunition for advocates of “integrative oncology” to start “integrating” quackery with science-based medicine. As Benjamin Kligler and Margaret Chesney state in their article in the monograph entitled “Academic Health Centers and the Growth of Integrative Medicine“, referring to the Consortium of Academic Health Centers for Integrative Medicine (which we’ve discussed before many times, for example, here and here):
Many barriers—including reimbursement challenges—still exist in the effort to make integrative approaches available as part of routine care. With the publication of this monograph though, we take an important step in removing one of the barriers to integration: the availability of high-quality research evidence on the appropriate role of integrative medicine in cancer care. We are proud to be part of this effort and look forward to the many ways in which the Consortium can provide support and momentum for researchers and clinicians in oncology as we move forward.
Except that this monograph doesn’t really do anything of the sort. If anything, it confuses matters. Unfortunately, integrative oncologists have been far too successful in promoting this false dichotomy listed in the same article unironically:
The Consortium of Academic Health Centers for Integrative Medicine—an organization comprised of 57 academic health centers and health systems in North America—defines integrative medicine as follows:
Integrative Medicine is the practice of medicine that reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, is informed by evidence, and makes use of all appropriate therapeutic approaches, healthcare professionals and disciplines to achieve optimal health and healing.
As this definition implies, although an openness to using therapies such as acupuncture or massage is a component of the integrative approach, integrative medicine goes far beyond simply combining the therapies previously described as “complementary/alternative medicine” with conventional care. It describes a change in philosophy, which expands our role beyond that of treating disease to reaffirm the commitment to treating the whole person. Almost more than anywhere else in medicine, the practice of oncology and the work of caring for a patient with cancer and their family clearly call for this approach and for a commitment to whole-person care. Lifestyle counseling, behavioral medicine interventions, and spiritual support all play critical roles in this integrative approach, alongside the use of other therapeutic strategies rooted in a rigorous evidence-based approach to the best conventional care. This is integrative medicine for cancer.
No, it is a false dichotomy. It is not necessary to “integrate” quackery like healing touch, naturopathy, or acupuncture with science-based conventional medicine in order to “reaffirm the commitment to treating the whole person” or expand a practitioner’s role “beyond that of treating disease.” A favorite saying of mine might be a bit of a cliché, but that’s OK. It’s a cliché that’s true. There is no such thing as “alternative,” “complementary,” or “integrative” medicine, nor should there be. Such medicine that is shown to be safe and effective scientifically ceases to be “alternative,” “complementary,” or “integrative” and becomes just medicine, and that is how it should be. Treatments that are truly effective and safe do not need the training wheels of a title like “alternative,” “complementary,” or “integrative.” They will stand on their own to scientific testing, no special protection required, and they shouldn’t be used until they have. Remember, as well meaning and sincere as its practitioners and champions are, “integrative oncology” is a Trojan horse that is depositing quackery right into the heart of academic medicine.

Revisiting “integrative oncology”: The battle to integrate quackery with oncology continues
Nature Reviews Cancer published a propaganda piece disguised as commentary promoting “integrative oncology,” or what I like to call “integrating” quackery with oncology.
David Gorski on August 19, 2024
Link

As a breast cancer surgeon, I’ve long been alarmed at the infiltration of non-evidence-based treatments that have steadily been infiltrating the specialty of oncology under the guise of “integrative oncology.” Indeed, I just realized that it’s been a full decade since I managed to publish a rather long opinion piece in Nature Reviews Cancer, in which I questioned whether integrative oncology is truly, as its proponents advertise, “the best of both worlds.” (Even if they haven’t actually read the article, regular readers will readily guess what my answer to that question was. Hint: Think Betteridge’s law of headlines.) It’s also been a decade since the primary “professional” organization representing “integrative oncology,” The Society for Integrative Oncology (SIO) published a monograph that supposedly presented “evidence-based” guidelines for the specialty. (Hint: They weren’t evidence-based.) Meanwhile, here at SBM I’ve written a number of posts discussing how, unlike the vision of its proponents of combining the “best of both worlds” (science-based medicine and “holistic”/alternative medicine) for the betterment of patient care, in reality what integrative oncology does, just as the more general “specialty” of “integrative medicine” under which it falls does, is to combine unproven and disproven treatments that include even outright quackery and mysticism with conventional, boring science-based oncology while simultaneously “rebranding” accepted evidence-based interventions involving diet and lifestyle as somehow being “alternative” or “integrative,” rather than just medicine.
I mention this background because last week, while perusing the journals that I like to peruse to see what’s new in cancer research and oncology, I came across a commentary published in Nature Reviews Cancer by three heavy hitters (if you can call them that) in integrative oncology, Gabriel Lopez, Santhosshi Narayanan, and Lorenzo Cohen, entitled Integrative medicine in oncology: redefining the standard of care. Oddly enough, it was about a decade ago when I attended a meeting of the American Society of Clinical Oncology (ASCO) in which Lorenzo Cohen PhD, a prominent proponent of integrative oncology at the University of Texas M.D. Anderson Cancer Center, promoted various “mind-body” woo as part of a panel talk, particularly yoga and a “wishing makes it so” idea more subtle than German New Medicine. He’s also featured in this blog a number of times before dating back to 2008 for overselling his acupuncture studies in cancer patients, for example. When I saw this article, I realized that, clearly, here was some blog fodder. Let’s dig in.
“Redefining the standard of care”?
The authors state their purpose right in the abstract:
Integrative medicine incorporated alongside cancer care, referred to as integrative oncology, is an evidence-informed field with established clinical guidelines. Although integrative oncology improves patient outcomes, it is inconsistently provided to patients. To align with best practices, it is necessary to increase awareness of integrative oncology, improve access to treatments, and provide consistent financial healthcare coverage.
I do like the careful choice of words here. Notice how the authors refer to integrative oncology as “evidence-informed,” rather than “evidence-based.” The wag in me can’t resist suggesting that evidence might “inform” integrative oncology, but that integrative oncology’s “integration” of quackery like acupuncture rather suggests to me that that “informing” was largely ignored in favor of ideology. I was also very interested in the assertion that integrative oncology improves patient outcomes, as I am unaware of any high quality scientific evidence that it does anything of the sort. The best that I’m aware of is that in the hands of practitioners who are less ideological, view themselves as more evidence-based, and try to act accordingly integrative oncology probably doesn’t harm patients. Probably. Of course, that’s in contrast with the more—shall we say?—avid proponents of integrative oncology who eagerly team up with naturopaths and practitioners of traditional Chinese medicine (TCM), deluding themselves that this improves patient care.
Notice, also, the framing. The authors view integrative oncology as an unalloyed good, a cutting edge concept that, because it’s so new, is “inconsistently provided to patients.” Because the authors view their specialty as an advancement over boring old conventional oncology, they view lack of access to modalities like TCM and acupuncture, reflexology, and the like as a health care disparity that must be urgently addressed. All cancer patients must have access to TCM, acupuncture, and all the other non-evidence-based treatments that integrative oncology has to offer! The authors even lament this disparity in more detail in the opening paragraph:
The goal of integrative oncology is to provide comprehensive support to individuals with cancer, their caregivers and their family across the cancer care continuum. According to the Journal of the National Cancer Institute expert consensus definition, integrative oncology is: “a patient centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment”1. In the USA, most National Cancer Institute (NCI)-designated Comprehensive Cancer Centers now have integrative oncology programs that enable access to this coordinated approach in conjunction with their oncology care plan. However, owing to inconsistent healthcare coverage, limited institutional funding, and lack of awareness for integrative oncology services, only a minority of patients have access to and/or utilize these treatments. Outside the USA, integrative oncology services are even more inconsistently provided to patients. This is equally true for high-, middle- and low-income countries. Yet some countries such as China, South Korea and Japan have integrative oncology often seamlessly integrated within the healthcare system.
I discussed the expert consensus definition of integrative oncology referred to above. In particular, I noted what the definition left out, namely just how quacky the modalities “integrated” into oncology in the specialty can be, including how the SIO admits naturopaths and even elects them as the organization’s president from time to time, never mind that all naturopaths are trained in The One Quackery To Rule Them All, homeopathy, and that the vast majority of naturopaths routinely prescribe homeopathic remedies, which, even the SIO concedes, are rooted in pseudoscience. It also leaves out how the SIO is fine with “integrating” quackery such as reflexology, reiki, and acupuncture into oncology and doesn’t object to even homeopathy at UC-Irvine and the Cleveland Clinic. At the University of Arizona Cancer Center, there was reiki, at least until a faculty member whose child developed cancer and was treated there made a stink. There’s also more energy medicine quackery, this time in the chemotherapy suite, at Georgetown University, as well as cupping, which is also pure quackery. There’s functional medicine at the Cleveland Clinic, George Washington University, University of Kansas, and, well, seemingly almost everywhere at any medical center with an integrative medicine program. If you want an idea of how bad functional medicine is, just check out this case report of functional medicine used for a patient with inflammatory breast cancer. This is what integrative oncology really involves.
As for why China, South Korea, and Japan have what the authors view as successful “integrative oncology,” one only has to understand the strong cultural affinity in such countries for the various forms of traditional Asian medicine, which is often “integrated” into the healthcare system. This is particularly true in China, where the government retconned the history of TCM and how it was promoted by Chairman Mao Zedong as both a substitute for “Western medicine” when he did not have enough physicians and as a cultural triumph of China to export to the world, the latter a message eagerly taken up by credulous journalists. In addition, China has used its influence with the World Health Organization (WHO) to “integrate” TCM diagnoses into the ICD-11 and promote TCM as “evidence-based,” even as it has actively promoted TCM as an industry whose products it exports to the world while requiring it in state hospitals, lowering the bar for its approval, passing laws to protect TCM against criticism—or what it calls “slandering” or “libeling” TCM—and even forcing its citizens to use TCM to treat COVID-19 early in the pandemic. Such is the largest of the systems that the authors admire because of its “seamless” integration of “traditional medicine” with medicine. Funny how the authors are unaware of this history or intentionally didn’t mention it.
But back to the touted “evidence base,” which is mentioned many times in the commentary, starting with the SIO guidelines, which are supposedly rooted in scientific and clinical evidence:
As the discipline of integrative oncology has expanded, there is a better understanding of how best to support patients using an integrative approach that may include counselling on different topics and various integrative oncology treatments. There is now an extensive research base that spans the methodology from observational studies using patient-reported outcomes to randomized clinical trials that assess symptom control and more objective outcomes. The field has matured to such an extent that there are now several organizations developing integrative oncology clinical practice guidelines.
There are also several organizations that represent naturopaths and acupuncturists. This is not a good argument. Also, as I’ve long discussed, generally most of the evidence for the therapies “integrated” into oncology (and medicine) are observational, and the relatively few randomized controlled clinical trials that exist are inevitably, when examined critically, negative, suffer from fatal methodological flaws, or tout minimal effects that are clinically irrelevant. (Advocates love to do this, in particular, for studies of acupuncture, such as this one.) Acupuncture, of course, is one of the most prominent “traditional” therapies that advocates like the authors love to “integrate” into oncology.
Unfortunately, the authors aren’t wrong when they note how totally embedded “integrative oncology” has become in mainstream oncology organizations:
The American Society of Clinical Oncology (ASCO) endorsed the SIO guidelines in 2018 and both organizations now have a formal partnership to co-develop multiple guidelines for the use of integrative oncology in cancer care including for pain management2, anxiety and depression2, and fatigue2 with sleep guidelines under development. Similarly, the National Comprehensive Cancer Network (NCCN) guidelines recommend using integrative therapies to treat several cancer- related and cancer treatment-associated symptoms. A summary of these recommendations is provided in Table 1. Integrative oncology contributes in substantial ways to symptom management in cancer care. Combinations of integrative oncology therapies may be considered to address several symptoms. Some integrative oncology therapies may be recommended despite the lower quality of evidence if there is some evidence for efficacy and a high safety profile. For example, patients living in a remote area may not have access to acupuncture but may be able to practice yoga for relief of aromatase inhibitor-induced arthralgia, although there is less evidence for yoga than for acupuncture.
I had to chuckle at that last sentence. “Less evidence for yoga than for acupuncture”? That would seem to imply that there is negative evidence for yoga, given that there is basically zero evidence for acupuncture against aromatase inhibitor-induced joint pain, as I discussed when deconstructing the study most commonly cited to support the use of acupuncture for this indication, including its update that tried—but failed—to provide evidence that acupuncture actually does work for aromatase-induced arthralgias.
As for Table 1, let’s take a look:
Reference 5 is a 2022 review article touting integrative oncology as a means to address global challenges of cancer treatment and prevention, and the table above is basically a rehash of that two-year-old table, which was basically a rehash of a previous 2021 article on supportive care in oncology. Let’s just say that none of the evidence for acupuncture for any of these indications is particularly strong;. Taken in totality, the evidence is actually most consistent with acupuncture being a theatrical placebo. Moreover, when you look critically at the studies touted by advocates, you will nearly always find that the RCTs at least are, in actuality, negative studies. Indeed, seeing acupuncture listed as having at least moderate quality evidence in the table makes me suspicious of everything else in the table. I won’t belabor the point too much, but, once again, I discussed the RCTs commonly cited for acupuncture for arthralgia and hot flashes in depth years ago. They were negative studies.
Amusingly, the authors (sort of) concede one of my big points about “integrative oncology,” namely that a lot of cancer centers are a bit more—shall we say?—expansive in their definition of what is “evidence-based”:
Some centres closely follow the clinical practice guidelines and avoid providing interventions that are not on the guidelines (such as Reiki), whereas others are more liberal with incorporating herbs or other modalities within their practice model. The more liberal approach can have downsides, including adverse events and the perception within the conventional oncology community that integrative oncology uses a different standard of evidence before incorporating a treatment as the standard of care outside of the research setting. This highlights the need for robust research efforts and more funding support for conducting integrative oncology clinical trials.
The “more liberal” approach? I laughed when I read this. After all, the whole idea of “integrative” oncology (or medicine) is to erase the boundaries between quackery and science-based medicine. Personally, of course, we at SBM have long argued for one standard of evidence, the science-based standard, to be applied to all medical interventions and tests. That’s why I was also amused at how unhappy the authors are about the perception that integrative oncology “uses a different standard of evidence.” It’s not just perception. As much as authors like Lorenzo Cohen like to try to shoehorn modalities like acupuncture into oncology as somehow being just as “evidence-based” as any other treatment in oncology, when you come right down to it, they are still just “integrating” quackery into oncology and throwing a patina of seeming EBM on top of it to hide the incredibly implausible nature of many of the “integrative” interventions touted, including in TCM. The standard of evidence for “integrative” therapies gets a much lower bar to clear than conventional, particularly pharmaceutical, treatments.
Putting the cart before the horse
As is nearly always the case with advocates for “integrating” unscientific treatments with science-based treatments, the authors cheerfully argue for putting the cart before the horse and pushing to “integrate” quackery with oncology, all in the name of…battling health disparities and disparities in access to care, which (of course) includes persuading third party payors to fund their woo:
As the evidence has grown in support of integrative oncology interventions, more healthcare insurers have begun to include these interventions as covered services. Yet, coverage is inconsistent. To mitigate growing healthcare disparities, it is crucial for all healthcare systems and insurers to align with the evidence and include integrative oncology treatments delineated in the clinical care guidelines within the standard of care. In addition, third-party payors need to be consistent across regions in terms of what is covered (for example, coverage of acupuncture should not depend on the state or province you live in but on medical evidence)
I’ll actually agree with that last sentence, although, unlike what the authors think, applying such a standard in my estimation would mean that third party payors should not cover acupuncture at all in their health insurance plans. I’d say the same thing for reflexology, TCM, and naturopathy (again, a prominent component of SIO to the point where two of the group’s past presidents have been naturopaths, even though the SIO downplays its relationship with naturopaths). In any event, just as those touting all forms of “integrative medicine” always do, the authors are putting the cart before the horse, advocating the adoption of prescientific and scientifically implausible theatrical placebos like acupuncture before there is strong evidence that they are efficacious for anything, all while claiming that “integrative oncology” has advance so much and become so evidence-based—excuse me, “evidence-informed”:
Integrative oncology as a field has advanced tremendously through the ever-expanding evidence-base. Although in many countries integrative oncology is provided in coordination with conventional oncology care to improve symptom control, quality of life, psychosocial wellbeing and clinical outcomes, there are many inconsistencies and most patients still lack access to these guideline-based, evidence-informed treatments. To improve patient outcomes, it is necessary to increase awareness of these treatments, provide more training of oncology and integrative clinicians on offering only evidence-informed services, and expand coverage for treatments by payors. In this way, integrative oncology will be more seamlessly incorporated within the standard of care.
I would question whether integrative oncology has advanced at all as a field in the decade since SIO first published its “guidelines.” How can it when the vast majorities of the modalities that it seeks to “integrate” are not science-based and the ones that can plausibly claim a basis in science and clinical evidence (e.g., nutrition) have been taken from medicine and “rebranded” as somehow “alternative” or “integrative”? As we at SBM have long argued, there really should be no such thing as “integrative” medicine, because medicine should be by default “integrative” in that it will integrate treatments that have been shown through science and rigorous clinical investigation to be safe and effective, to the point that “integrative” is an unnecessary addition to the word “medicine.”

Two integrative oncologists delude themselves that their specialty is science-based
Integrative oncology “integrates” quackery with oncology. Its practitioners, however, frequently delude themselves that their specialty is science-based. A recent review article by two integrative oncologists from Memorial Sloan-Kettering Cancer Center expresses that delusion perfectly.
David Gorski on January 14, 2019
Link

I write a lot about “integrative medicine,” particularly “integrative oncology.” The reason, of course, is because I (and we here at SBM) view integrative medicine as the integration of pseudoscience and quackery into medicine. It’s also label that “rebrands” perfectly good science-based lifestyle medicine, such as nutrition, exercise, and other lifestyle interventions, as somehow being “alternative” or “integrative”. It also uses them as a facade to cloak or disguise all the pseudoscience and quackery, like reiki, acupuncture, naturopathy, and the like. It’s not for nothing that one of our favorite metaphors for “integrative medicine” is the Trojan horse. Lifestyle medicine is the horse. Academic medical centers—and, increasingly, community hospitals—bring the horse in, and once it’s there the quackery leaps out to capture the fortress.
I was reminded yet again of this when Jann Bellamy sent me a link to a review article in the Journal of Oncology Practice, a clinical journal published by the American Society of Clinical Oncology. It comes from the integrative oncology group at one of the premier cancer hospitals of the world, the Memorial Sloan-Kettering Cancer Center. It’s by Shelly Latte-Naor, the Director of Mind-Body Medicine there—there exists such a title?—and Jun J. Mao, the Chief of the Integrative Medicine Service there and former president of the Society for Integrative Oncology, an organization I’ve written about quite a few times and one that, as I’m sure you can guess, doesn’t like me very much. In any event, the article is entitled “Putting Integrative Oncology Into Practice: Concepts and Approaches“, and it’s a blueprint for doing exactly that.
Let’s look at the rebranding right in the first sentence of the abstract:
Unmet symptom needs and a desire for holistic health approaches or even cure are among the motivations patients have for seeking out complementary and alternative medicine. Using complementary and alternative medicine instead of conventional cancer treatment can have a negative impact on clinical outcomes and survival. Integrative oncology is a patient-centered, evidence-informed field of comprehensive cancer care that uses mind-body practices, natural products, and lifestyle modifications from different traditions alongside conventional cancer treatments. It prioritizes safety and best available evidence to offer appropriate therapeutic interventions along with conventional care.
First, there’s the canard of “unmet medical needs,” which is a frequent justification used by integrative medicine advocates, that somehow conventional medicine is not meeting patient’s needs. Of course, no one claims that conventional medicine meets every patient needs or that there is no such thing as unmet medical needs. The canard is in the argument that to meet these unmet needs, you need to embrace pseudoscience and quackery. In any event, I should be grateful that Latte-Naor and Mao actually cited the recent study showing an association between CAM use and decreased survival in cancer patients. On the other hand, the authors try to use this as a justification for integrative medicine, ignoring completely the history of integrative medicine and how it is merely a rebranding of CAM. Of course, they said CAM use “instead” of conventional medicine, never mind that CAM use is by definition using alternative medicine alongside conventional medicine. It’s almost as though the authors are trying to “rebrand” CAM as just alternative medicine.
Here’s the main rebranding. “Complementary and alternative medicine” (i.e., CAM) is exactly the same thing as integrative medicine. There is no difference. Integrative medicine is just another term for CAM. Up until around the late 1990s or so, what we now know as integrative medicine was called CAM. Beginning around 20 years ago there was a conscious, concerted, and prolonged effort on the part of CAM advocates and practitioners to rename CAM “integrative medicine.” As I put it at the time, no longer were CAM practitioners content to have their favorite quackery be merely “complementary” to real medicine. After all, “complementary” implied a subsidiary position. Medicine was the cake, and their wares were just the icing. That wasn’t good enough. They craved respect. They wanted to be co-equals with physicians and science- and evidence-based medicine. The term “integrative medicine” (IM) served their purpose perfectly. No longer were their treatments merely “complementary” to real medicine. Now they were “integrating” their treatments with those of science- and evidence-based medicine! The implication, the very, very, very intentional implication, was that alternative medicine was co-equal to science- and evidence-based medicine, an equal partner in the “integrating”. The same process is going on today in that “integrative medicine” is falling out of favor as a name in favor of “integrative health”. The reason, I suspect, is that integrative medicine advocates want to sell their specialty as “wellness” too and that “medicine” is a less friendly word than “health”.
Next up, the “integrative medicine is science, ma-an” trope:
The practice of integrative oncology stands in contrast to the use of alternative medicine, which is often based on unsubstantiated claims and can involve rejection of conventional medical treatment. The use of alternative medicine in lieu of conventional treatment has been associated with decreased survival in the cancer setting.5 Integrative oncology prioritizes safety and best available evidence to offer appropriate therapeutic interventions along with conventional care. The commitment to rigorous scientific research and evidence-informed practice in cancer care was strongly emphasized by the foundation of the Society for Integrative Oncology (SIO) in 2003 and the release of the first set of general clinical practice guidelines in 2009, followed by two other cancer-specific guidelines thereafter.6-9 Most recently, ASCO endorsed SIO clinical guidelines for women with breast cancer.10
Yes, the authors are definitely doing some major language twisting, rebranding CAM to mean “alternative medicine” in one sentence while tacitly ignoring the way CAM had been rebranded and reborn as “integrative medicine”. In any event, integrative medicine specialists and advocates love to contrast all that quackery in alternative medicine with their supposedly science-based specialty. As for the clinical practice guidelines published by the SIO, I’ve deconstructed them before, as well as ASCO’s endorsement of them.
This, of course, is why the authors start out their list of integrative medicine with perfectly reasonable, science-based lifestyle interventions, such as exercise and physical activity, lifestyle modifications, diet, sleep, stress management, quitting smoking, not consuming too much alcohol or using illicit drugs. No one’s going to argue with those interventions as being useful. Indeed, those sorts of interventions are already part of conventional medicine and always have been. One can assert that these modalities have been underemphasized in medicine in favor of pharmaceuticals, and there is a reasonable debate to be had there. However, underutilization of lifestyle medicine in conventional medicine is a reason, but, I argue, not the primary justification for the existence of integrative medicine. The primary reason for including them in “integrative medicine” is to provide scientific cover for all the quackery that integrative medicine integrates with science-based medicine.
The next broad category of interventions listed includes “mind-body” interventions. That is, of course, a category name that I abhor, because embedded in it is an unjustified assumption of mind-body dualism. Here, the authors start listing the more dubious therapies, mixing them in with more reasonable therapies for which there is some evidence, such as massage, yoga (a form of exercise), and Tai Chi (another form of exercise.)
Here’s what they say about acupuncture:
Acupuncture is a therapy that originated from traditional Chinese medicine. It uses sterile thin needles that are inserted at specific points on the body and subsequently stimulated, either manually or electrically, to manage symptoms. Animal studies have found that acupuncture can stimulate the brain to release endogenous opioids, serotonin, and dopamine. Functional imaging studies in humans have also found that acupuncture can modulate multiple brain regions involved in cognition and emotion. The National Comprehensive Cancer Network Guidelines recommend the use of acupuncture for pain, fatigue, nausea, vomiting, and hot flashes, and in the setting of palliative care and survivorship.30 More than 80% of National Cancer Institute–designated comprehensive cancer centers recommend acupuncture for symptom management.31
Yes, that is unfortunate. Thus far, my cancer center doesn’t have an acupuncture program yet, but I live in fear of the “integrative medicine” bug biting someone in the leadership. Indeed, I’m amazed it hasn’t hit there yet. Elsewhere, however, quackery has infiltrated the vast majority of NCI-designated cancer centers, unfortunately. Of course, we’ve discussed acupuncture on this blog more times than I can remember, and it’s not for nothing that Steve Novella and David Colquhoun once referred to it as a “theatrical placebo.” That’s exactly what acupuncture is. Sure, advocates will trot out meta-analyses that claim to show that acupuncture works better than a placebo intervention, but they don’t really show that. The bottom line is that it doesn’t matter where you stick the needles. It doesn’t matter even if you stick the needles into the skin. Acupuncture “works” all the same. That’s why, as hard as they try to show that acupuncture “works”, whenever they do rigorous clinical trials, they fail.
Indeed, I like to point out that the embrace of acupuncture by integrative oncology disqualifies integrative oncologists from claiming that their specialty is in any way science-based. If it were truly science-based, it wouldn’t endorse acupuncture. None of that stops Latte-Naor and Mao from finishing with an invocation of the “it’s science, ma-an” gambit:
A key feature distinguishing integrative oncology from alternative medicine is its foundation of evidence-informed practice. Evidence-based medicine as a concept emerged in the 1980s and has since transformed medical education and clinical practice.60 It can be defined as the combined integration of the best available research evidence along with our clinical expertise while considering our patient’s values and circumstances (Fig 1B). As research begins to shed light on the safety and efficacy of complementary therapies, critical appraisal of the literature and ongoing learning is needed to incorporate these approaches into clinical practice. Using an evidence-informed approach allows clinicians to incorporate patients’ values and preferences along with their own clinical experience and current research evidence for therapeutic approaches (eg, medications or acupuncture for pain) to support a shared decision-making process for patients and families. Figure 2 shows a suggested algorithm of integrative therapy referral options that could help facilitate discussions on evidence-based approaches for patients with cancer.
Note that, other than acupuncture, the authors leave out the rank quackery in integrative medicine and oncology. Hospitals with integrative oncology and medicine programs all feature pseudoscience and quackery, such as the functional medicine, traditional Chinese medicine, and homeopathy at the Cleveland Clinic; reiki, “detox,” and chelation therapy at George Washington University; reiki and other quackery at the University of Arizona; The One Quackery To Rule Them All, homeopathy, at the University of California, Irvine; and acupuncture, reiki, and even homeopathy apologia at Georgetown.
Basically, what Shelly Latte-Naor and Jun Mao are presenting is their idealized version of integrative medicine that brooks no quackery (other than acupuncture, of course), where every intervention used is rigorously science-based. This is a typical portrait of integrative medicine painted by academics. They are science-based; so they can’t imagine that their specialty would not be, even as it embraces quackery. This version of integrative medicine and oncology leaves out the pseudoscience and quackery that the specialty really embraces. It’s even worse than that. The Society for Integrative Oncology allows naturopaths to join, which is embracing far more quackery than just acupuncture, given that naturopathy is a veritable cornucopia of quackery. Indeed, the organization has even elected two naturopaths as its president in the past, Heather Greenlee and Suzanna Zick!
Until the specialty of integrative oncology gets rid of naturopaths, acupuncturists, and all the other quackery that it tolerates, Latte-Naor and Mao are deluding themselves in trying to portray their specialty as science-based. If you take away the quackery from integrative medicine and oncology, all that’s left is just lifestyle medicine without a compelling rationale to be its own separate specialty. It is and always will be quackademic medicine.

What is “integrative oncology”? Even the Society for Integrative Oncology doesn’t seem to know for sure
Last week, the Society for Integrative Oncology published an article attempting to define what “integrative oncology” is. The definition, when it isn’t totally vague, ignores the pseudoscience at the heart of integrative oncology and medicine.
David Gorski on November 20, 2017
Link

Longtime readers of Science-Based Medicine and my not-so-secret other blog probably know that I’m not a fan of the specialty known as “integrative oncology.” My reasons are basically the same as the reasons why I detest “integrative medicine,” only subspecialized (like oncology), so to speak. Basically, “integrative medicine” integrates quackery with medicine, and integrative oncology integrates quackery into oncology. Given that I’m a cancer surgeon, I tend to take an even dimmer view of the latter than of the former, if only because it hits me where I live. For instance, when “integrative oncology” starts appearing at symposia at major cancer meetings, with nary a skeptical word showing up in the panel discussions afterwards, I despair. Unfortunately, the credulity that allows modalities like acupuncture, reiki, intravenous high dose vitamin C, and various other unproven and disproven treatments to find their way into academic medical centers has spawned a related phenomenon, quackademic medicine, or the study and acceptance of quackery in academic medical centers. The most prominent example of this latter phenomenon occurred in September, when the University of California at Irvine accepted a $200 million gift from Susan and Henry Samueli to build and staff a college devoted to integrating quackery into its component departments and promoting “integrative medicine.” Never mind the homeopathy.
Integrative oncology has become so established that it has its own professional society, the Society for Integrative Oncology (SIO). Not surprisingly, I’m not a fan of SIO, and SIO isn’t exactly a fan of me, either. I’ve related the story before, but let’s just say that the SIO was not pleased at my 2014 article in Nature Reviews Cancer discussing how integrative oncology is not evidence-based (to say the least), given its embrace of naturopathy. In brief, the SIO didn’t like how much verbiage I devoted to homeopathy in the article, pointing out that homeopathy is indeed not evidence-based and that no integrative oncologist worth his or her salt would ever use it. I pointed out that you can’t have naturopathy without homeopathy. After that, I asked how the SIO can reconcile its quite correct rejection of homeopathy with the fact that it admits naturopaths as members, that two of its recent past presidents have even been naturopaths, and that you can’t have naturopathy without homeopathy. It’s baked into the naturopathic curriculum, and it’s part of the naturopathic licensing exam. Moreover, one of the naturopaths who co-authored the SIO’s breast cancer clinical guidelines ran a clinical trial on homeopathy. That same naturopath, by the way, was a co-author on the update to those guidelines published just this year. The SIO never learns.
This time around, though, the reason the SIO caught my attention was this Tweet by Dr. Sheila Garland, re-Tweeted by Dr. Jun J. Mao, immediate past president of the SIO (but still president at the time he re-Tweeted this):
The beginning of a new era in evidence-informed integrative oncology research/practice that puts the person first #SIO2017 @Integrativeonc https://t.co/cmAMrCujjy
— Dr. Sheila Garland (@SNGarlandPhD) November 13, 2017
This Tweet touted what is now the “official” definition” of “integrative oncology” recently laid down by the SIO:
Official definition of Integrative Oncology! Spread the word! #SIO2017 We are research based! #cancerresearch pic.twitter.com/oeNsn9B1Jk
— Jodi MacLeod (@write4wellness) November 13, 2017
It turns out that this definition had just been published by Witt et al in the November issue of JNCI Monographs, just in time for the SIO annual meeting last week. When I saw it, my first reaction was to e-mail my fellow SBM bloggers with a link and this image:
So let’s take a look.
The process of defining “integrative oncology”
My first reaction (besides possessiveness) when I saw the article by Witt et al, A Comprehensive Definition for Integrative Oncology was: What? The organization has existed for nearly 15 years, and in all that time it hasn’t yet managed to define what it’s about until now? My second reaction was: What on earth does this definition actually mean? It is about as boring, generic, and—shall we say?—vague a definition of anything as I’ve ever seen. Take a look:
Integrative oncology is a patient-centered, evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments. Integrative oncology aims to optimize health, quality of life, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants before, during, and beyond cancer treatment.
In actuality, I was more interested in what was left out of this definition than what was in it, but I’ll get to that near the end of this post. First, I want to look at the process by which the authors developed this definition, as described in the article, which is open-access for those of you who want to read it yourselves. Before I get into the process, let’s look at some of the authors, who are big names in the world of integrative oncology. The lead author, Dr. Claudia Witt, is Professor and Chair of the Institute for Complementary and Integrative Medicine at the University of Zurich and University Hospital Zurich, as well as part-time Professor of Primary Care and Community Medicine at the Center for Integrative Medicine University of Maryland School of Medicine. Dr. Jun J. Mao is, of course, president of the SIO and Chief of the Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center. Dr. Lorenzo Cohen is someone whom we’ve met before, when he gave a talk at the American Society of Clinical Oncology (ASCO) meeting in 2014. He’s the Director of the Integrative Medicine Program at The University of Texas MD Anderson Cancer Center. Linda Balneaves is a nurse and the current president of SIO, having succeeded Dr. Mao at the SIO annual meeting last week. I also can’t help but note that one of the co-authors, Heather Greenlee, is a naturopath and has served as president of the SIO in the past as well.
In other words, these are indeed heavy hitters and the leadership of the SIO.
Let’s look at their justification for seeking this definition. After regurgitating the usual “complementary and alternative medicine” (CAM) blather about how patients are just “looking for “additional interventions that may help improve the efficacy of conventional cancer treatments, increase their chance of survival, and/or reduce their symptom burden associated with cancer or treatments” and “improve their quality of life during and following treatment,” Witt et al justify their search for a definition thusly:
With the integration of interventions such as acupuncture, mindfulness and yoga, and lifestyle counseling into major cancer centers in North America (eg, MD Anderson and Memorial Sloan Kettering Cancer Center), the term “integrative oncology” has become increasingly used. “Integrative” better represents the process of care that is provided in centers where patients are receiving these types of interventions in addition to their conventional cancer treatments. With the establishment in 2003 of the Society of Integrative Oncology (SIO), a nonprofit multidisciplinary professional organization, the term “integrative oncology” was further legitimized and began to be widely used. However, the term “integrative” is also used in other contexts. An example is the Berlin School of Integrative Oncology at the Charité Medical School in Berlin (2), which is an initiative of the German federal and state governments that aims to educate young scientists and physicians in oncology in an interdisciplinary, translational research context. Although the term “integrative oncology” is rarely used in such an educational context, having totally different meanings for the same term can generate confusion. Adding to this complexity is the growing attention to the notion of integrated care programs in oncology, in which numerous cancer specialties (eg, medical oncology, radiation oncology, surgical oncology, genetics, plastic surgery) work together to provide comprehensive patient care (3).
Furthermore, even in settings in which the term integrative oncology has been used to refer to the combination of complementary medicine therapies with conventional cancer treatments (4), the term has been defined in many different ways (5,6). Because of this lack of consensus, it has been difficult to communicate what is meant by “integrative oncology” to oncologists and other health professionals, as well as to key stakeholders, such as patients, administrators, and health policy makers. The aim of this project was to use a systematic approach to develop a comprehensive and acceptable definition for “integrative oncology.”
Actually, I’ve always rather suspected that this confusion is a feature, not a bug, related to the use of the word “integrative.” After all, integrative oncology, like integrative medicine, is a brand, not a specialty. It rebrands what should be considered perfectly fine science-based modalities, such as nutrition, lifestyle interventions, and the like, as somehow “alternative” or “integrative,” and then “integrates” quackery like acupuncture, reiki, functional medicine, and even homeopathy with them, to give the quackery the appearance of scientific legitimacy. No, I don’t think SIO is doing this intentionally; its leadership consists of true believers. But it is contributing to quackademic medicine and the integration of quackery into oncology. In any event, the word “integrative” is, as mentioned above, used to describe science-based endeavors, such as integrative biology. In this context, the word “integrative” connotes interdisciplinary study, a very different meaning than when the word “integrative” came to replace the term CAM to describe adding pseudoscience to medicine.
Indeed, use of the word “integrative” to describe medicine or the subspecialty of oncology connotes more than interdisciplinary patient care and research. It connotes the embrace of “alternative” treatment modalities as well. The term “CAM” still had the word “alternative” in it and the word “complementary” connoted that CAM was subsidiary to medicine, “complementary,” the icing on the cake, if you will. In other words, it’s not necessary, and science-based medicine is the real medicine. The adoption of the word “integrative” to rename CAM as “integrative medicine” was clearly intended to remove the implication that CAM was “complementary” and not as good as real medicine, in order to advance the narrative that integrative medicine is the “best of both worlds,” while also borrowing from the cachet of various “integrative” scientific disciplines as being multidisciplinary. Again, I don’t think SIO is out to deceive. Rather, the belief of the SIO leadership in the validity of integrative oncology has led them down this road, probably without even realizing it.
So how did Witt et al go about constructing their definition? Enter the mixed methods research design and Delphi method. This amused me, because it wasn’t so long ago that naturopathic oncologists used this very method to try to define priorities in naturopathic oncology. If you want the details of how the Delphi method works I discussed them in deconstructing the nonsense that naturopaths laid down about their quack specialty using the Delphi method. The CliffsNotes version is that the Delphi method entails a using a group of experts to answer a question. The experts anonymously reply to questionnaires and subsequently receive feedback in the form of the statistical representation of the group response, after which the process repeats itself until something resembling a consensus is arrived at. The way Witt et al did this is described:
A two-round Delphi process was then employed to further refine and gain consensus regarding the new definition. In the first round, the revised definition was distributed via an online survey (software SoSciSurvey [7]) to SIO board members as well as to a convenience sample of experts. The experts—oncologists, integrative oncology clinicians, and/or researchers from North America, Europe, and Asia—were contacted by the SIO board members. Based on first round feedback, the definition was revised and distributed again through an online survey to the full membership of SIO, with subsequent ratings and comments used to inform the final version of the definition. Data from both surveys were analyzed using descriptive statistics. Content analysis (8) was applied to the open-ended responses to identify any themes or concepts.
So, after this literature search and Delphi method, what did Witt et al find?
Defining “integrative oncology”
As a result of their literature search and two-round Delphi process, Witt et al found many definitions of “integrative medicine” and “integrative oncology” in the literature, which resulted in the following thematic suggestions:
    • evidence-based/evidence-informed/evidence-guided/using best available evidence (14 of 20);
    • accompanying conventional cancer treatment (18 of 20);
    • addressing outcomes such as well-being, body, and mind-spirit, as well as physical, psychological, and spiritual quality of life (seven of 20);
    • focused on health and not only on medicine (three of 20);
    • provided by a team of health care providers/multidisciplinary/interdisciplinary (four of 20);
    • patient-centered/personalized, individualized/whole person (two of 20).
The writing group, which consisted of “members with different professional/disciplinary backgrounds (ie, medical oncology, radiation oncology, surgical oncology, nursing, patient advocacy, psychology, psycho-oncology, epidemiology, integrative medicine, health policy),” added these additional suggestions:
    • type of interventions (mind-body therapies, natural products, lifestyle changes);
    • beyond provision of health care (information, translation of evidence, identification of beliefs, values and preferences, empowerment).
The initial definition of integrative oncology developed by the group thus read:
Integrative oncology is a patient-centered (theme 6), evidence-informed (theme 1) approach to health care (theme 4) that uses mind-body therapies, natural products, and lifestyle modification (theme 7) as adjunct to conventional cancer treatments (theme 2) and is ideally provided by a multidisciplinary team of care providers (theme 5). Integrative oncology aims to increase well-being of mind, body, and spirit (theme 3) and to provide patients with skills enabling them to help themselves during and beyond cancer treatment (theme 8).
After the two rounds of Delphi method, though, the group perceived that some changes were required:
Overall, the comments on the second Delphi survey were positive, but the suggestions were quite heterogeneous. Two-thirds of suggestions focused on what were perceived to be missing interventions, and it became clear that therapies such as acupuncture and massage were not well represented in the definition. As a consequence, the definition was revised using the umbrella term “mind and body practices,” which is used by the National Center for Complementary and Integrative Health in the United States. This term includes mind-based techniques such as meditation and hypnosis, as well as manual techniques such as acupuncture and massage (9). One respondent mentioned that “health care” encompassed a broader area than integrative oncology, and the decision was made to be more focused and to use the term “cancer care” in the revised version. Another respondent also suggested that the phrase “approach to cancer care” could be misleading and not specific enough as a field of care or medical specialty. Integrative oncology is more than just an approach to overall cancer care; it has been the focus of a professional organization for more than 10 years and is an established field in its own right. During the review process, it was noted that cancer prevention was not included in the definition. Because the ultimate goal of many integrative oncology behaviors is cancer prevention and control, the definition was modified to include prevention.
I’ve discussed before how quackery like the theatrical placebo known as acupuncture has mysteriously been subsumed into “mind and body practices”. Personally, I’ve always suspected that this was to hide the quackery of acupuncture with more benign modalities (such as massage) that, whether medically they can treat anything, generally do no harm, and can certainly feel good, thus improving quality of life. After all, given that the rationale in traditional Chinese medicine for acupuncture is that sticking the needles into specific “meridians” can redirect the flow of qi (life energy) for healing effect, acupuncture could easily be classified as a form of energy healing.
To the degree that integrative oncology sticks with science- and evidence-based tests and treatments, my main objection to it is that it’s not necessary. Nutrition, exercise, and other lifestyle-based interventions are already a part of science-based medicine. I like to cite, for instance, evidence-based recommendations for the treatment of hypertension and type II diabetes, both of which emphasize, except for severe cases, dietary modifications, exercise, and weight loss as the first interventions to attempt before placing the patient on medications.
To paraphrase Harriet Hall, what is good about integrative oncology (or medicine) is not unique to it. Continuing the paraphrase, unfortunately, what is unique to integrative oncology is not good, and the SIO definition obscures or neglects to mention these unique (and not good) aspects.
What the SIO left out
If you read the full article, it should become very apparent that its authors want desperately to convince the reader that integrative oncology is completely evidence-based. Sure, the SIO admits naturopaths and even elects them as the organization’s president from time to time, never mind that all naturopaths are trained in The One Quackery To Rule Them All, homeopathy, and that the vast majority of naturopaths routinely prescribe homeopathic remedies, which, even the SIO concedes, are rooted in pseudoscience.
I was reminded of this on—where else?—Twitter. I came across a post on the University of Pennsylvania’s OncoLink touting reiki in cancer care. Because the link was from 2011, I Tweeted a question to the OncoLink team. Here’s the response:
@gorskon, Reiki is a supportive therapy that can be used in conjunction with treatment. It is not promoted as an alternative to treatment
— OncoLink Team (@OncoLinkTeam) November 2, 2017
If there is a challenger to homeopathy’s title of The One Quackery To Rule Them All, reiki would be right up there. It is, as I have described many times before, a form of faith healing that substitutes Eastern religious beliefs for the Christian religious beliefs that usually undergird faith healing in the US.
But it’s not just Penn. The Dana Farber Cancer Institute has also gone all in for nonsense:
7 Ways Integrative Therapies Help Cancer Patients: https://t.co/bRHYbqhrcy pic.twitter.com/0kVQ4FKW0o
— Dana-Farber (@DanaFarber) August 26, 2017
The slideshow at the link above promotes reiki, reflexology, and acupuncture:



Of course, I’ve pointed out how oblivious the SIO is to the modalities that are really being “integrated” into oncology through integrative oncology just through the obliviousness of the SIO leadership to what naturopathy really is. As I’ve said before, if the SIO were really serious about being evidence-based, it would immediately purge itself of all naturopaths. It’s not, though. Its leadership up in the ivory towers of medical academia can delude themselves into thinking integrative oncology is totally evidence based, because they manage to ignore the quackery that is “integrated” along with the lifestyle-, exercise-, nutrition-, and meditation-based modalities to which they love to point.
I can’t help but point out a few more examples of the quackery that goes along with integrative oncology. At UC-Irvine and the Cleveland Clinic, there’s homeopathy. At the University of Arizona Cancer Center, there was reiki, at least until a faculty member whose child developed cancer and was treated there made a stink. There’s also more energy medicine quackery, this time in the chemotherapy suite, at Georgetown University, as well as cupping, which is also pure quackery. There’s functional medicine at the Cleveland Clinic, George Washington University, University of Kansas, and, well, seemingly almost everywhere at any medical center with an integrative medicine program. If you want an idea of how bad functional medicine is, just check out this case report of functional medicine used for a patient with inflammatory breast cancer. This is what integrative oncology really involves.
It is also this quackery that the SIO definition of “integrative oncology” does its best to obscure or ignore. If the SIO is truly serious about being science- and evidence-based, it needs to speak out strongly and now against naturopathy and the various forms of quackery that have found their way into academic medical centers, of which, I assure you, the above is but a small sampling. It won’t, though. The quackery is why integrative medicine and oncology exist in the first place. Without the quackery, CAM (or integrative medicine or oncology) becomes completely unnecessary as a field.

The integration of mysticism and pseudoscience with oncology continues apace in NCI-designated comprehensive cancer centers
Last week, I commented on the inability of the Society for Integrative Oncology to define what integrative oncology actually is. This week, I note the proliferation of the quackery of integrative oncology in places that should be rigorously science-based, namely NCI-designated comprehensive cancer centers.
David Gorski on November 27, 2017
Link

Last week, I took note of how what is now a major medical society devoted to integrative oncology, the Society for Integrative Oncology (SIO), revealed itself to be unable to define, other than in platitudes and vague feel-good verbiage, just what the heck “integrative oncology” even is when it published a monograph in JNCI. What I didn’t take note of last week was that the November issue in which the SIO’s monograph defining what integrative oncology is (or what the SIO thinks it is) didn’t contain just that one gem. In fact, like previous monographs published in years past, it’s chock full of SIO propaganda for integrative oncology. Indeed, there’s so much there that I could easily spend the next few weeks writing about each monograph in turn. I won’t do that today, although I do reserve the right to discuss one or two more over the next couple of months if the urge takes me. What I do want to do is to discuss one monograph in particular, “Growth of Integrative Medicine at Leading Cancer Centers Between 2009 and 2016: A Systematic Analysis of NCI-Designated Comprehensive Cancer Center Websites,” by Hyeongjun Yun, Lingyun Sun, and Jun J. Mao. I note that Dr. Mao is the immediate past president of SIO; this is coming from the top, so to speak.
I noted last week that I’m not a fan of the SIO, and it’s not a fan of me. I won’t repeat the story of my little discussion with them in which, in response to its umbrage taken in reaction to an article I published three years ago about integrative oncology, I tried to educate the leadership of the SIO that you can’t have naturopathy without homeopathy. Reread last week’s post if you want the details. My point is more that, as much as I don’t like what SIO stands for, it has, unfortunately, been effective, and this survey provides yet another metric suggesting its effectiveness, along with that of all the other groups promoting the integration of pseudoscience and mysticism into medicine.
“Unmet needs”? Why would one need pseudoscience?
Yun et al. justify this survey with the usual tired tropes used to justify “integrating” quackery with medicine, be it oncology or any other specialty. First, frame integrative oncology as an “unmet need”:
Patients’ unmet needs in managing these symptoms coupled with their desire to use natural approaches to improve their health have created a demand for integrative medicine (3,4). According to the National Center for Complementary and Integrative Health (NCCIH), integrative medicine differs from complementary and alternative medicine (CAM) because it brings together conventional and complementary treatments in a coordinated way (5). Neither rejecting conventional therapies nor relying on alternative medicine, integrative medicine adopts only those complementary modalities supported by the highest evidence of safety and effectiveness (6). Numerous studies have evaluated the efficacy of utilizing integrative medicine modalities to treat the side effects of conventional cancer therapies. For instance, there is growing evidence that acupuncture may be effective in managing cancer therapy–related adverse effects such as fatigue (7–10), postoperative pain (11,12), vasomotor symptoms (13–16), and nausea and vomiting (17). Likewise, research supports the use of modalities such as massage (18,19) and mind-body therapies for symptom management and spiritual transformation; the latter remains a largely unmet need in the current health care system, yet directly impacts patients’ quality of life (4,20–23).
I can’t help but wonder how one quantitatively evaluates “spiritual transformation” in rigorous clinical trials, but that’s just me. In any case, I can’t help but note that some of the citations are articles discussed here and elsewhere before. For instance, reference 5 has been addressed before as “integrative health” being a rebranding of “complementary and alternative medicine” (CAM), which was a rebranding of alternative medicine. Other references, for instance, the ones supporting acupuncture, cite the usual low quality studies or studies that rebrand transcutaneous nerve stimulation (TENS) as “electroacupuncture.” Then there’s the whole framing of integrative oncology as an “unmet need.” It’s a very common framing of integrative medicine, be it through taking advantage of the opioid crisis to sell pseudoscience by claiming that nonpharmacologic management of pain must include CAM or by arguing that addressing unmet needs in symptom management in cancer patients requires embracing pseudoscience. True, the latter argument isn’t stated in those words, but when you strip away the “integrative” and CAM gobbledygook, that’s the core of the argument you’re left with: A false dichotomy that posits that, to treat the “whole patient” and to address “unmet needs,” doctors must embrace the quackery in integrative medicine.
Next up, appeal to popularity:
The use of integrative medicine is extensive among cancer survivors. Globally, up to 43% of patients with cancer have used integrative medicine therapies during their treatment, and the overall prevalence of integrative medicine use has increased noticeably over the past years (24–26). In the United States, cancer survivors use integrative medicine even more than individuals without cancer (27). Cancer survivors are more likely to use integrative medicine modalities for wellness, pain, and improving their immune functions. Interestingly, most of them started using integrative medicine because their conventional health providers recommended it to them (28).
Of course, as we’ve discussed before, this percentage is inflated by the broad definition of “integrative medicine.” Basically, if you’ve ever had a massage or done art or music while being treated for cancer, by definition you’ve used integrative medicine. If you’ve ever meditated or prayed while being treated for cancer, you’ve used integrative medicine. If you’ve done Tai Chi, yoga, or Qi Gong (or even just exercise) while being treated for cancer, you’ve used “integrative medicine.” You get the idea. When you look at the “hard core” quackery, such as homeopathy, you’ll usually find that the number of patients using it is in low single digit percentages.
Integrative oncology and NCI-CCCs
The current survey is an update to a 2009 survey that found that 60% of National Cancer Institute (NCI)–designated comprehensive cancer centers (NCI-CCCs) provided information related to integrative therapies on their websites. Back in 2009, there were only 41 NCI-CCCs. Now there are 45. It’s worth looking at the old survey first, though, to see the sorts of modalities that were being offered at NCI-CCCs eight years ago and at what percentage of them:
Specific therapies listed did include some pure faith healing-related “energy medicine” quackery such as reiki (37% of websites), healing touch (29%). Not surprisingly, acupuncture showed up on 59% of websites, and dietary supplements, herbal medicine, and nutrition in one form or another showed up on between 42% and 56% of websites. To be honest, I was actually pleasantly surprised that only 60% of NCI-CCCs provided information on CAM. Indeed, it’s kind of amusing to note the reaction of the authors to the perceived deficiencies of various NCI-CCCs with respect to CAM:
Even with acknowledging these limitations, we still found that almost a third of leading U.S. cancer centers do not have functional websites related to CAM, and only a small proportion of the centers had websites independently judged to be excellent.
My reaction to that conclusion was: Gee, you say that as though it were a bad thing. I’m also happy that my cancer center’s website would almost certainly have been in that one-third of cancer centers without information on CAM. Indeed, one of the things I’ve always liked about my cancer center is the relative paucity of integrative oncology options offered compared to other cancer centers, but I always fear that, sooner or later, we’ll start to try to catch up.
So what’s the situation now? Table 1 in the new study tells the tale. Mentions of quite a few modalities increased sharply. For instance, mentions of acupuncture increased by 30%, from 59% of NCI-CCCs to 89%. That’s right. A whopping nine out of ten NCI-CCCs mention acupuncture credulously, and a full 73% offer it.
As a surrogate for just how much NCI-CCCs have abandoned science when it comes to integrative oncology, I like to examine the most implausible of treatments that fall under the mantle of “CAM” or integrative medicine. For example, mentions of healing touch, which is a form of “energy healing” (that doesn’t actually involve touching) in which the practitioner claims to be able to detect and manipulate a patient’s “life energy” field in order to heal and/or relieve symptoms, increased from 29% to 58%, a doubling of the number, and 29% of NCI-CCCs actually offer this magical, mystical, “healing” touch. Mentions of reiki, which, as I’ve described many times before, is nothing more than faith healing that substitutes Asian mystical religious beliefs for Judeo-Christian beliefs as the basis for healing (replace the “universal source” from which reiki masters claim to derive the healing energy with God or Jesus, and you’ll see what I mean), also increased markedly, from 37% of NCI-CCCs to more than half (53%) of NCI-CCCs, a more than 50% increase. Worse, 40% of NCI-CCCs actually offer reiki.
Not surprisingly, the “soft” parts of integrative medicine, the services that used to be offered for patient support and morale, such as art, music, massage, and various exercise programs but have, thanks to integrative medicine, become medicalized, appear on the vast majority of cancer center websites. One interesting finding is that, while exercise information is provided in 97.8% of cancer center websites, only 56% provide exercise/fitness services for their cancer patients. As much as it irks me that exercise and nutrition have been co-opted by integrative medicine and quacks like naturopaths, both can be science-based modalities for health promotion, particularly in cancer patients, although integrative medicine practitioners, particularly non-MD and non-dietician ones, often implement diet and exercise in non-evidence-based ways. (I’m talking to you, naturopaths, in particular.) Even so, we need to be doing better offering opportunities to help our patients exercise to improve their health and alleviate, for example, chemotherapy symptoms.
Overall, though, the authors are relatively happy with what they’ve found:
Despite these limitations, we found that there has been substantial growth in the presence of integrative medicine on the websites of NCI-designated comprehensive cancer centers since 2009. In addition, the majority of the centers provide integrative medicine services within the same academic health systems in which they are located. As these centers lead the way in cancer research and clinical innovation, we need to ensure that integrative medicine can be cohesively incorporated into the continuum of cancer treatment and survivorship care using a financially sustainable structure. In addition, evidence-informed integrative medicine needs to expand beyond the walls of academic medical centers into community cancer centers and clinics to benefit patients from diverse socio-economic backgrounds.
The SIO even includes plans for world domination (OK, I mean the promotion of integrative oncology) around the world.
What the SIO left out: Most of the quackery
It’s at this point that I can’t resist mentioning what the SIO clearly left out. Remember, as I’ve pointed out many times, the SIO admits naturopaths. So where is naturopathy in this survey? Isn’t naturopathy a part of “integrative oncology”? Certainly, the SIO seems to think so, given that it included presentations on naturopathic interventions in its recent annual meeting and even encourages naturopaths to join, listing them as equivalent to MDs. The SIO has even elevated two of them to the presidency of the organization! So why doesn’t the SIO include a survey of which NCI-CCCs mention and offer naturopathy to their patients? Are they embarrassed? Trying to hide something? One wonders what Suzanna Zick, who was SIO President from 2015-2016, or Heather Greenlee, who was president from 2014-2015, think of this omission? Both are naturopaths.
I really can’t help but suspect that, in its effort to persuade medical academia that integrative oncology is rigorously science- and evidence-based, whether intentionally or not, the SIO leadership is focusing all its attention on promoting the evidence-based modalities that have been “rebranded” as “integrative,” such as diet, exercise, and the like, and the patient support modalities that have been medicalized into “integrative medicine,” such as massage, art therapy, music therapy, and the like. Pay no attention to that quackery that integrative oncology and medicine lump together with the diet, exercise, and the like, the SIO seems to be saying by the absence of focus on naturopathy (and the homeopathy that nearly all naturopaths practice). Again, it can’t be emphasized enough that, wherever you find naturopaths practicing, you will find homeopathy being practiced.
True, there are a couple of exceptions. The SIO does mention reiki and therapeutic touch rather prominently in both surveys, both of which are obvious energy healing quackery. However, most people don’t realize that. Most people view reiki and healing touch as a form of massage or hands-on healing, even though healing touch usually doesn’t involve actually touching the patient. Either that, or they view them as some form of spirituality, which is actually not too far from the truth, but mystical claims such as what are made for reiki and healing touch do not belong in science- and evidence-based medicine. Yet there are NCI-CCCs that credulously promote energy healing. For instance, I’ve written about Georgetown University before. There’s an NCI-CCC there, the Georgetown Lombardi Comprehensive Cancer Center. I’ve described Georgetown as a bastion of quackademic medicine before because of its “pioneering” efforts to “integrate” the teaching of pseudoscience into its medical school curriculum. Relevant to cancer, though, Georgetown published an article in its official magazine about reiki in the chemotherapy suite:
For a long time Denise von Hengst had a secret she kept from friends and physicians alike. As she was undergoing treatment at Georgetown Lombardi Comprehensive Cancer Center for a particularly aggressive type of breast cancer—triple positive, HER2 positive—she was also regularly receiving Reiki, an ancient form of Japanese healing, to mitigate the debilitating anxiety and fear that accompanied her cancer diagnosis.
“At first I told no one about the Reiki,” says von Hengst. “Fear of the ‘woo-woo’ factor. People might think I’m nuts.”
No, I don’t think the patient is nuts. I think the cancer center is irresponsible for offering magic with its medicine, leavened with pseudo-skepticism:
However, skepticism remains, not only in the general population, but also within the medical field. Recently, several clinical trials have emerged attempting to prove, or disprove, the effectiveness of Reiki. Many of these studies have been criticized for the trial. design, number of participants and reporting mechanisms. Results of the trials are often inconclusive.
Yet as the anecdotal proof mounts and Reiki’s popularity increases, prestigious medical centers around the country are taking note and offering the treatment to patients at their facilities. Reiki can be found at hospitals and medical centers such as Boston Children’s Hospital, Dana Farber Cancer Institute, Stanford Health Care, Memorial Sloan Kettering Cancer Center, Duke University Health System and Cleveland Clinic, to name a few. Many academic medical centers such as Georgetown incorporate complementary therapies into their teaching curricula.
I have a question for the leadership of SIO: Is reiki evidence-based? Is it science-based? If it isn’t, then why are you supportive of NCI-CCCs offering it?
Here’s another example, the University of Arizona Cancer Center, which is an NCI-CCC. Take a look at its integrative medicine page. Look at what it offers: reiki (of course, even though a faculty member complained about it), reflexology (pure quackery that posits a nonexistent link between body parts and organs and specific areas on the soles of the feet and palms of the hands), craniosacral massage (which Mark Crislip drolly and correctly called a “SCAM of infinite jest“), healing touch (of course), and shiatsu (unproven).
Three years ago, the son of a professor in a humanities department at UA was treated for leukemia at the UA Cancer Center. He was appalled at all the quackery being offered to his son, including not just the above modalities, but distance healing, offered by a man named Frank Schuster:

After this professor complained, Shuster’s UA webpage was either removed or placed behind a login. However, I noticed something about UA’s list of offerings for integrative medicine. First, none of the practitioners were listed by their full names any more. It’s Jessica, Barb, Heidi, Michael, Denise, or Frank, the last of whom offers the reiki classes. Hmmm. I wonder if that’s Frank Schuster, still there, still practicing energy healing. I bet it is, but haven’t been able to verify it one way or the other.
I want to believe that the SIO wants to be scientifically rigorous. I really do. I’m guessing that most of the SIO physician and scientific leadership believes that they are being scientifically rigorous and trying to lay down a framework in science and clinical evidence for “integrative oncology,” even if they have a hard time defining what, exactly, integrative oncology is. It’s just that, for whatever reason, physicians who drink the Kool Aid of integrative medicine tend to develop massive blindspots about all the quackery that comes as a package with all the parts of integrative medicine that they like, such as the emphasis on lifestyle, diet, exercise, and the treatment of the “whole” person. These blindspots extend to naturopathy in particular, which is a veritable cornucopia of quackery, including homeopathy. Until the SIO can eliminate its blindspots over all the quackery that is included in “integrative medicine,” its claims of being scientifically rigorous are just so much self-delusion.

Why cancer patients choose “integrative oncology” and what they get: Perception vs. reality
Two recent studies, one from France and one from Taiwan, examine why patients seek “integrative” oncology and what they get. An undercover investigation shows how divorced from reality their perception is.
David Gorski on October 19, 2026
Link

A couple of weeks ago, I used the publication in The New York Times of an article describing how the journalist’s father had become ensnared by Envita, an “integrative oncology” clinic after he had been diagnosed with lung cancer, how the clinic milked him for all the cash it could, and how her father had died in a nearby ICU, far from home, friends, and most family, to discuss a more general phenomenon of these quack clinics and how they prey on desperate cancer patients. Although I’ve long thought about how these clinics advertise seemingly miraculous results—”cures,” even—on social media to lure patients with advanced cancers for which conventional science-based oncology can offer only palliative care, my anecdotal personal experience writing about this phenomenon doesn’t necessarily reflect reality, other than my perception of these clinics as profiting on quackery and misery. So it was that I became aware of a couple of recent studies, one from Taiwan and one from France, that examine the phenomenon from the perspective of who chooses these clinics.
The Taiwanese study looks at why women with breast cancer choose traditional Chinese medicine to treat their disease, while the French study is more general and asks why people choose integrative oncology. Both studies, as you will see, suffer from the problem of not being willing to label correctly the aspects of integrative oncology that are quackery, as well as from a bias towards academic integrative medical centers, which tend not to go nearly as far recommending unproven therapies and use “integrative” approaches only for symptom management, not to treat the cancer (although that is not always the case, given some examples of rank quackery I’ve found over the years at university-affiliated academic integrative oncology programs). Perhaps the greatest weakness is that neither considers many of the freestanding “integrative oncology” clinics and medical centers that are not only not constrained by evidence, but also unconstrained by affiliation with a university or academic medical center with a reputation to maintain. I was reminded by that of a post at ETP News examining what happened when an investigator actually went undercover posing as a patient with stage IV colon cancer to seek “integrative” oncology care.
Integrative oncology in France
I’ll start with the French study first. Entitled Integrative oncology consultation and patient referral to complementary therapies: results from the prospective study THERAC and published in the journal Supportive Care in Cancer, it comes from investigators at the Département Interdisciplinaire des Soins de Support en Oncologie (Interdisciplinary Department of Supportive Care in Oncology), Centre Léon Bérard in Lyon. Even though this is an observational study, its key strength is that data were collected prospectively, rather than retrospectively. Among its weaknesses is the size (it only examined 50 patients) and, from my perspective, this part of the rationale (IO=integrative oncology; CTh=Complementary and Alternative Medicine):
Currently, enthusiasm for IO is growing among patients and emergent framing needs and guidance increasingly recognized among medical professionals [5]. IO services at the National Cancer Institute (NCI)–designated comprehensive cancer centers have increased from about 50% in 2009 to 80% in 2016 [6]. American academic cancer centers (Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, etc.) have ongoing training programs including resources about integrative medicine [7]. In France, an increased number of initiatives are underway to improve IO implementation within conventional care structures [8] or in the associative field. In France, the University College of Integrative and Complementary Medicine (CUMIC) was created in 2017, and following the example of the Society for Integrative Oncology (SIO) founded in 2003, the French Society of Integrative Oncology (SFOI) was recently established in 2023 by oncologists and/or experts in integrative care.
However, the lack of scientific evidence is prejudicial and many healthcare professionals (physicians and healthcare teams) prefer to avoid discussion related to CTh [9], and referral to dedicated consultations or professional experts is still rare. Patients are also reluctant to spontaneously express their use of CTh with their oncologist [10]. The use of these therapies is therefore mainly decided on an isolated, individual basis. IO consultations have progressively emerged in France and worldwide, to overcome these difficulties, allow patient to express their needs, improve referral and individualized care pathway. IO consultations allow to better inform patients on CTh, CTh-associated risks and beyond the opportunity for better patient/physician relationship would contribute to improve patients’ quality of life.
“The lack of scientific evidence” for IO is “prejudicial”? They write that as though it were a bad thing! You don’t like the “prejudice” against “complementary and alternative medicine” (which we in the English-speaking world abbreviate as “CAM”)? Then produce some evidence that what you are doing is safe and effective. Basically, as is the case with most of these sorts of studies, this is more of a marketing exercise, specifically an analysis of the market, to identify ways to sell more product. That doesn’t mean that it doesn’t provide some useful insights, though.
The study producing the data is THERAC, which stands for “THERApies Complémentaires (Complementary Therapies):
The prospective, monocentric, exploratory, observational, descriptive study THERAC included all consecutive adult patients, treated at the Leon Berard Comprehensive Cancer Center (CLB) (Lyon, France), able to understand, read, and write in French, attending an IO consultation. The descriptive nature of the study was not supported by a priori hypotheses; the number of participants was set at 50 consecutive patients eligible to IO consultation in the next 6 to 12 months. All patients received dedicated information and provided informed consent. THERAC falls under the French regulation known as “Méthodologie de Référence MR-004.” This methodology was established by the French data protection authority (CNIL) to provide a legal framework for processing personal health data without requiring explicit patient consent, as long as certain strict conditions are met (here: data analysis projects where no active intervention or modification of patient care occurs). The institution (Leon Berard Cancer Center) certified that the study complied with the M004 rules. We ensure that Human Ethics and Consent to Participate declarations are available.
Basically, THERAC is a database of patients seeking integrative oncology services at the Léon Bérard Comprehensive Cancer Center in Lyon. The researchers used clinician-rated assessments at three fixed time points: First, at the moment of inclusion in the study; second, three months later; and finally, six months later. The idea was to capture the consultation process as it unfolds in routine clinical practice and obviate the possibility of poor memory and recall bias on the part of the subjects coloring their recollections. Subjects were recruited consecutively until the target accrual of 50 patients was reached. This, of course, is one of the weaknesses of the study; it only examines the experiences of 50 patients, and it took nearly a year (November 2021 to January 2023) to recruit them. As reported in the Results, the patients recruited were predominantly women (n = 45, 90%), with a median age of 52 (26–76) years, and a high socioeconomic status (Table 1). The latter characteristic is not surprising to me, given how much “integrative” medicine is targeted towards people with wealth. I was also not surprised that the cohort was predominantly made up of women, but I was surprised at how lopsided the distribution was. I would have predicted 60-70% women, not 90%. Given this distribution, it is not particularly surprising that more than half the patients (56%) were breast cancer patients. Moreover, most patients came from urban areas (80%), including 44% from wealthy metropolitan areas representing only 22% of the French population, with only 36% coming from what the authors describe as “precarious” population districts.
In other words, the population studied was not representative of the French population in general, but, again, that is not surprising given how much of the “integrative medicine” marketed by “respectable” academic medical centers pulls in the affluent. In fact, it’s easier just to show you a bar graph of the percentages of patients expressing specific expectations:
Results of the survey from THERAC regarding patients’ expectations for “integrative” oncology care.
These results should not be particularly surprising, as they do tend to align with previous data examining motivations of patients seeking “integrative” oncology care. Most such patients do tend to mistakenly conflate “holistic” care with “integrative” care. It is therefore not particularly surprising that, according to the investigators, patients “with follow-up completed were globally very satisfied with the IO consultation at 3 months (n = 27/29, 93%) and at 6 months (n = 11/11, 100%).” Interestingly, time spent with caregivers was a relatively minor expectation, which tends to conflict with the narrative that what “integrative” medicine patients seek are doctors and other caregivers who will spend more time with them.
I said that I was “less interested” in what was actually prescribed in the study, but that doesn’t mean that I was not interested at all. So here’s a graph showing what patients were offered:
I must admit that I was surprised at how much aromatherapy was offered and how little acupuncture and mindfulness were offered. However, if I knew more about the cancer center where this study was carried out, it wouldn’t have surprised me:
Aromatherapy is easily available within the Centre Léon Bérard through established protocols in both inpatient and outpatient settings, supported by the development of a dedicated clinical aromatherapy service in 2017 [26]. The relatively low cost and simplicity of administration of essential oils may also explain the widespread use of aromatherapy. The main indication in our study was anxiety management and sleep management, in consistence with current international IO recommendations [27].
In other words, aromatherapy and essential oils ruled this study because aromatherapy was the most easily offered CAM therapy at the cancer center where the study was being done. Convenient that. Of course, as I like to say, acupuncture is nothing more than a theatrical placebo, while reflexology is nothing more than a foot massage with delusions of grandeur. I was unfamiliar with sophrology, but it appears to be nothing more than a different form of meditation and mindfulness that is described as a “dynamic relaxation” method inspired by phenomenology, hypnosis, yoga, Tibetan Buddhist meditation, Japanese Zen meditation, progressive muscle relaxation, autogenic relaxation training, psychology, neurology.
Near the end of the Results and in the Discussion section, the authors give away the real game; i.e., the real purpose of the study:
Patients often resort to CTh on their own, without informing medical professionals, which isolates disciplines [32]. A collaborative organization involving different CTh professionals would instigate a synergy probably more relevant than strict superpositions of individual therapies [33] and would contribute to the development of an identified integrative care network at a national scale. Nurse coordinators and oncologists particularly concerned with CTh risks should be able to appraise patient understanding and feelings, and to detail CTh-related constraints and limitations, and appropriately refer patients to IO consultation. Medical professionals need to build confidence to convince patients to adequately protect themselves, through providing improved information regarding CTh-related potential risks. Lastly, medical professionals feared “patient unrealistic expectations” and patient perception of “hoping to get cured,” as previously reported [3], suggesting they may be challenged in addressing IO psychological impact.
And, finally:
IO consultations implementation in our French comprehensive cancer center constitutes an innovative approach which need to be further develop to better address patients’ needs and expectations, and contribute to patient healthcare satisfaction. Such initiatives need to be developed and encouraged to promote an advanced comprehensive care of cancer patients in a reassuring relational context.
My retort to this is the same retort that I always make whenever faced with the justification that quackery like acupuncture, reflexology, etc. needs to be “integrated” into cancer care: You don’t need to “integrate” quackery with medicine to “better address patients’ needs and expectations, and contribute to patient healthcare satisfaction.” Nor do you need to integrate quackery to provide true “holistic care.” While it is true that in the US, our primarily for-profit healthcare system puts time and resource constraints on practitioners that make it very difficult to address the “whole patient” in many cases, the answer to that is not to throw quackery into the gap between what patients want and what the healthcare system can achieve.
But what about Asia?
Now, on to Taiwan…
The next study to be considered here was published a couple of weeks ago in BMC Complementary Medicine and Therapies. Entitled Intentions, effects, and challenges associated with the use of traditional Chinese medicine for breast cancer: a qualitative study from TCM physicians, it looks at, unfortunately, physicians who use traditional Chinese medicine to treat cancer patients. Touted in what appears to be a press release as a “rare insider view of this dual-track care model, drawing on in-depth interviews with experienced TCM physicians who treat these patients every day,” this study examines the issue primarily from the perspective of TCM practitioners who are physicians, in particular the “challenges” of combining TCM with “Western medicine” (abbreviated, annoyingly, in this article as “WM”), as if such a combination is even desirable.
The design of the survey is described thusly:
To be eligible for participation in this study, TCM physicians were required to be currently assuming the position of an attending physician and to have treated patients with breast cancer–related conditions within the previous year. Purposive sampling interviews were conducted with TCM physicians from a municipal public hospital in northern Taiwan, who comprise the “TCM Cancer Special Clinic” and “Enhanced Daycare of TCM for Cancer Treatment.” Physicians who met the research criteria were included in this study and scheduled for in-depth interviews. During the initial recruitment phase, attending physicians with sufficient clinical experience were purposively approached. Subsequently, snowball sampling, base on the participants’ referrals, was conducted to explore the perspectives of TCM physicians across hospitals. Data collection was discontinued once saturation was reached; specifically, the recruitment of additional participants via snowball sampling ceased when no new factors emerged from the data. All interviewees provided written informed consent before their interviews.
Participants were asked the following questions (BCP=breast cancer patients):
Interview recordings were transcribed verbatim for further analysis. The interview guide comprised the following questions:
    • What is your experience with cancer treatment?
    • What do you think are the reasons for BCPs using TCM?
    • How do you think the stage of breast cancer affects the use of TCM by BCPs?
    • How effective is TCM in treating breast cancer?
    • If the patient is simultaneously seeking WM, how would you discuss TCM use or recommendations with the patient?
    • Do you think there are any limitations in the current use of TCM in breast cancer care? Do you have any suggestions for improvement?
Question #4 should be easy to answer: TCM is not effective at treating breast cancer. Question #5 should also be easy: Use conventional science-based medicine to treat your cancer. I tend not to recommend TCM to treat breast cancer, but if you insist, make sure that whatever TCM you choose doesn’t interfere with your treatment. My snarky answer to the last question would be: There aren’t nearly enough limitations in the current use of TCM to treat breast cancer. But that’s just me, and I’m not a TCM practitioner…obviously.
Indeed, as I like to say, TCM is a system of medicine based on a pre-scientific understanding of how the human body functions and becomes ill that has a lot in common with “Western” or European humoral theory, in which imbalances between the four “humors” (blood, yellow bile, black bile, and phlegm) determine health and disease. In TCM, this article actually lays it out. See the similarities:
In TCM, body constitution is interpreted as a reflection of individual health status, determined by differentiating the Yin-Yang balance of the five fundamental substances (essence, Qi, blood, body fluids, and spirit) as well as the five viscera (heart, liver, spleen, lung, and kidney). Because TCM considers disease to be caused by a Yin-Yang imbalance, such deviations in body constitution can influence a patient’s overall health and may affect the survival rate of cancer patients [26–28].
Whenever I see this description of TCM, I can’t help but add this little image:
I need to make a version of this meme for traditional Chinese medicine!
What was interesting about this study is that the TCM practitioners identified distress as a key motivator for women with breast cancer to seek TCM. The press release notes that in Taiwan’s health system, TCM is licensed, insured, and provided in dedicated hospitals and clinics, which means that patients don’t have to choose between science-based medicine and TCM, which is why many use both. The main finding of the study, though, is described thusly:
To the best of our knowledge, this is the first study to comprehensively explore the intentions, effects, and challenges associated with the use of TCM by BCPs from the perspective of TCM physicians. Our findings indicated that many BCPs tended to seek TCM care primarily to relieve the side effects of conventional treatment. According to TCM physicians, TCM care improves the body constitution of BCPs, potentially enabling the management of their tumors. However, certain challenges remain in TCM care. For example, some TCM physicians mentioned that TCM often encountered rejection from WM physicians. Nonetheless, the TCM physicians acknowledged that WM remains the primary treatment for breast cancer. They believed that TCM and WM can complement each other to improve health outcomes for BCPs. Medication use, health insurance, and policy restrictions of TCM emerged as key challenges in current breast cancer care.
Oh, dear. Some “WM physicians” reject TCM? What a shame. It should be nearly all. The claim that TCM care “improves the body constitution” of breast cancer patients is also mainly the perception of TCM practitioners, not anything for which any concrete evidence is presented. During the discussion, the authors state:
Depending on their culture and personal experiences, patients with cancer often consider TCM for their healthcare needs [21]. We previously reported that after receiving their diagnoses, BCPs often seek means to alleviate the side effects of conventional treatment, which becomes their primary intention for seeking TCM [15]. Similarly, a systematic review revealed that patients with cancer in Taiwan often seek TCM to address what WM cannot achieve—for example, eliminating the root of the disease [22]. These patients seek to improve their body constitution and well-being through TCM. Health insurance may influence how patients with cancer use TCM [22]. In the present study, some TCM physicians indicated that TCM care can address the limitations of conventional treatment and stabilize the condition of BCPs. The physicians also highlighted that combining WM with TCM can improve health-related outcomes and quality of life.
Again, nothing in this study actually supports the claim that combining “Western medicine” and TCM can “improve health-related outcomes and quality of life. The authors do cite a number of questionable studies suggesting that this is the case, as well as some systematic reviews that suggest that certain herbal medications have anti-tumor activity. This is, of course, nothing more than pharmacognosy, the branch of pharmacology that studies medicinal substances that can be isolated from plants and other natural products. You don’t need the rest of TCM to use pharmacognosy to improve the care of cancer patients, given that a large number of current cancer chemotherapeutics are either derived from natural products or are chemically altered components of natural products designed to give the medicine more desirable properties.
None of that stops the authors from arguing:
The present study revealed a gap between WM and TCM. Some TCM physicians mentioned that TCM and WM may be complementary. They highlighted the use of WM as the subjective treatment and TCM as an adjunct therapy as the best approach for breast cancer treatment. Therefore, further WM–TCM collaboration and additional evidence-based research into TCM are required to avoid potential health impairments and conflicts in the healthcare system [40, 47] and improve the health outcomes and quality of life of patients with cancer [48, 49]. A study reported that after completing a semester involving a TCM-based medicine curriculum, WM students could develop a better understanding of TCM and viewed TCM knowledge as beneficial to WM practice [50].
Sure. Indoctrination can work.
The bottom line from these two studies is that “integrative” oncology, whether it’s of the sort practiced in France based on its region-specific collection of unproven and pseudoscientific treatments to be added to conventional oncology or of the Chinese and Taiwanese variety, in which TCM is the collection of unproven and pseudoscientific treatments to be added to conventional oncology, does not really add anything desirable to conventional therapy that couldn’t be added by simply providing more resources and time to cancer doctors. It does, however, show that, whether in Europe or Asia, there are still large numbers of people who misperceive the addition of unproven and disproven therapies based on pre-scientific conceptions of how the body works to be a desirable thing.
Now here’s the problem. Both of these studies come from academic medical centers, where the more harmful aspects of “integrating” quackery with science-based medicine are usually under control. (Usually.) What happens when patients seek “integrative” care out in the wild? For that, we have oncologist Dr. Alex Morozov’s report at ETP News, entitled Selling Hope Chapter I: Going Undercover. (Full disclosure: I have been asked to be on the board of directors of ETP News and will likely soon be officially on the board.)
What is the reality? Probably more like Alex Morozov’s experience
We already established a couple of weeks ago that there are many “integrative” cancer clinics and medical centers, both in the US and, in particular, in countries like Mexico, where regulation of medicine is—shall we say?—somewhat more lax. We also discussed a recent NYT interview with Trisha Thadani, whose father was the subject of the NYT article on the quackery of “integrative oncology” clinics, and how bad actors entice desperate cancer patients. Here, Thadani was asked a question on this:
He couldn’t get a clear prognosis from his oncologist because every patient is different. That propelled him on a search for alternatives. What did he find?
My dad was inundated with ads for alternative cancer treatment clinics around the country and in Mexico. Clinics pay to target people who search for terms like “Stage 4 cancer survival rate” and “chemotherapy side effects.” He spoke to several other clinics — some of which I would later learn have troubled records — before picking one in Arizona.
What “reputable” integrative oncology clinics at academic medical centers (which are bad enough, given how their universities and reputations give quackery the appearance of legitimacy) frequently forget is that they are in competition with institutions whose dedication to evidence and science-based medicine is far below theirs, which leads patients to clinics like the one described in the NYT article, Envita. That last pitch is particularly bad, because, as the two studies I discussed above show, patients often seek “integrative” care because they are most concerned about the side effects of chemotherapy, radiation, surgery, and other therapies used to treat cancer.
This brings us to Dr. Morozov’s odyssey. The entire article is worth reading in full (as, I presume, subsequent parts of the story will be). In brief, Dr. Morozov posed as a stage IV colorectal cancer patient:
To see first-hand how and why these supplements are prescribed to patients, I went undercover, posing as a cancer patient myself. I prepared a fake colonoscopy report showing that I was diagnosed with colon cancer, a CT scan report showing liver metastases, and an imaginary oncologist’s note recommending chemotherapy.
I then saw a series of clinicians. I did not tell them that I am a physician myself. If they asked what I did for a living, I told them that I have an interest in AI and computers, which is true. My goal was to make sure that my experience would be similar to that of most patients, without any kind of special treatment.
Dr. Morozov also noted:
Undercover journalism has a long history, going back to pre-Civil-War America, when Northern reporters attended slave auctions in the South, posing as prospective buyers. Today’s Code of Ethics of the Society of Professional Journalists, of which I am a member, advises reporters to “avoid undercover or other surreptitious methods of gathering information unless traditional, open methods will not yield information vital to the public.” In my case, these conditions were clearly met. Even if I were to find cancer patients willing to tell me about their experiences, I would not be able to piece together their full stories from their recollections alone.
Fair enough. I buy this rationale. Certainly, I could never have pulled this off. I’m too bad an actor, and my poker face is not very convincing most of the time.
Again, I urge you to read the whole thing. Let’s just say that Dr. Morozov’s experiences were not unlike what I would have expected. He was offered a whole lot of expensive “functional medicine”-like blood tests, supplements, and other treatments, all at very high cost. Most incredible to me were the costs of his consultations. First, though, here’s how Dr. Morozov describes the beginning of his odyssey:
My first stop was Lubbock, Texas, to see Dr Ben Edwards. His company, Veritas Wellness, “started as a small functional medicine clinic and has now evolved into a worldwide online wellness and education platform,” according to a local business organization. Veritas sells its own line of branded supplements, which means that the bottle says “Veritas Wellness” on the label.
Edwards referred me to a former colleague, also in Texas, who follows a “metabolic approach to cancer”. I then went for a second, third, fourth and fifth opinion at other providers, always bringing my growing pile of prior records and recommendations. I saw a naturopathic doctor (ND) who serves as Clinical Professor at a major academic medical center; a senior board-certified medical oncologist at the same center; a functional medicine physician at another major academic center; a registered dietician at the same center; a board-certified medical oncologist at a third major academic center; and an AI bot on a wellness platform. More on each visit in the following chapters.
Ben Edwards has been featured on this blog before. He’s a profoundly antivax doc whose name has appeared for his use of quackery to treat measles patients during the West Texas measles outbreaks last year. His clinic, Veritas Wellness, appears to work primarily on a subscription model to provide ongoing services, starting at $29 a month (plus costs for labs and supplements, of course, as well as whatever video courses and books you might want to order). To give you an idea of how far down the rabbit hole of woo Edwards lures his marks, just note that he apparently believes in Masaru Emoto’s “magic water” that takes on the “intentions” directed at it, as well as Jacques Benveniste’s bogus experiments. Let’s just say that it all looks like homeopathy, without Edwards ever actually using the word homeopathy in his blog post about it, kind of like this post appears to be advocating the quackery known as live blood cell analysis without actually using the term. To give you an idea of his approach to evidence, I’m just going to drop a link to his blog post Theory vs. Truth. Wow. It’s like the creationist “just a theory” mischaracterization of evolution applied to all of medicine. Dr. Morozov further elaborates on Dr. Edwards’ journey from reputable family medicine doctor moving to an underserved part of Texas in 2009 to his current status as, in my not-so-humble opinion, an integrative quack and, now, cancer quack.
Just look at the email Dr. Edwards sent Dr. Morozov after his intake information was recorded:
I believe you are making a very wise decision to look into some complementary and alternative modalities for overcoming cancer. Here is exactly what I tell my patients who get a diagnosis of cancer…
Proceed with your oncologist to get the official diagnosis… Conventional medical techniques typically do really good with stage 1 (just cut it out basically). But, once it has spread at all, then in general the rates of survival with conventional techniques start to go down pretty fast. This is when I really, really encourage looking at adding in complementary and alternative things. SOMETIMES the conventional protocols do pretty good with SOME cancers that are stage 2, 3 and 4, but for the most part the more advanced stages/spread are not “curable”, and the conventional protocols just “extend life a little”… Consider asking some alternative clinics if they have data on their 5 year survival rates for your particular cancer.
Nice of him to admit that a lowly breast cancer surgeon like myself can actually help cancer patients, but only if they are stage I. In any event, this is standard cancer quack boilerplate about how “conventional oncology” can only treat local cancer, but you need them and their magic to treat anything more advanced.
The other thing that depressed me about that passage was that Dr. Morozov was referred to two oncologists, a functional medicine quack, and a naturopath, all spread out over three academic medical centers. I can sort of guess which centers these might have been, although they are not mentioned…yet. Perhaps my assessment that academic medical centers, especially university-affiliated centers, try to guard their reputation for being science-based was a bit too optimistic. In any event, the fact that these practitioners referred to “integrative oncology” practitioners at academic medical centers doesn’t improve my opinion of the practitioners and their cancer clinics. It diminishes my opinion of integrative cancer clinics associated with academic medical centers. I tried to guess which clinic was offering a “metabolic approach to cancer,” but using Google search, Gemini, and Claude, I discovered that there are just too many such clinics in Texas for me to hazard a strong guess, which depressed me even further.
Fortunately, Dr. Morozov had an excellent retort to his email:
Second, “asking” a for-profit “alternative cancer clinic” for their survival rates? From a consumer perspective, my advice to cancer patients would be the opposite: be very skeptical of outcome data self-reported by a for-profit cancer clinic. They are biased. They have a conflict of interest. They want your business. Look at each treatment individually and find studies done by independent researchers.
Third, trustworthiness aside, such numbers are hard to find. I searched and searched, but could not find an alternative cancer clinic with independently audited, cancer- and stage-specific five-year survival data demonstrating better outcomes than appropriately matched standard oncology care.
Indeed, a much less dodgy—but still dodgy—chain of “integrative” cancer centers, formerly known as the Cancer Treatment Centers of America, used to routinely exaggerate its survival statistics. The point is, you will never find accurate, reliable outcomes data from clinics like Envita or Veritas. If you do find such statistics, it’s advertising, not science.
In any case, as Dr. Morozov went to different practitioners recommended first by Edwards and then by subsequent practitioners whom he saw, this happened:
Over the course of my consultations, I was ordered 109 different blood tests (not counting repeats). Many tests had multiple measurements. For example, the complete blood count is one test that measures white cells, red cells, etc. My tests included a total of 230 different measurements.
I was charged enormous fees. Many were not covered by insurance at all. A two-hour zoom consultation cost me $3000. Supplements, about $1000/month. Blood, urine, stool and saliva tests, over $3000. Other visits could be covered by insurance, but I paid out of pocket. For a 7-minute discussion with an oncologist I was charged $1800. A one-hour consultation with a functional medicine doctor cost me $1400. I was simply informed of these prices and expected to pay. I was never asked about my financial situation or offered any financial assistance.
One provider was apologetic about the cost of supplements. He emphasized free shipping and discounts where possible. He made it sound like his recommendations were optional (“only if affordable,” he wrote in his clinical note). In my opinion, that’s not a good strategy when you are wearing a white coat and speaking with authority to a cancer patient. If the benefit is questionable, don’t ask the patient to spend the money. And if the benefit is clear, help them pay.
Indeed. And what can one do that’s worth $1,400 an hour—or, as was the case with the oncologist, over $15,000 per hour if seven minutes cost $1,800? As I like to say about these quacks, nice work if you can get it. Unfortunately, my sense of ethics would never allow me to go down this path.
Again, I encourage you to read Dr. Morozov’s Substack post in full. The main reason that I wrote this post is to emphasize how there is a massive disconnect between what “integrative” oncology practitioners in academic medical centers think that integrative medicine is and involves and what “integrative” oncology actually does involve on the ground level, where patients are brought in. Academic “integrative” oncology practitioners view their craft as somehow being the “best of both worlds,” in which alternative medicine is added to complement science-based oncology and relieve symptoms. The reality is far closer to what Dr. Morozov and Trisha Thadani have reported.

“Atavistic oncology”: Another dubious cancer therapy to be avoided
An idea promulgated by physicist Paul Davies that cancer is a reversion to a primordial cell type has been making the rounds. It’s even spawned a form of quackery, atavistic chemotherapy, promoted by Dr. Frank Arguello. Davies, in his hubris and his view of himself as an “outsider,” seems to think he’s the first scientist to have ever had this “brilliant insight,” when in fact the atavistic hypothesis of cancer hasn’t caught on is because it’s a hypothesis that is not new. It has been considered carefully by cancer biologists and found wanting based on biology and evolution. Unfortunately, it’s also a hypothesis that is easily co-opted for cancer quackery.
David Gorski on July 28, 2014
Link

EDITOR’S NOTE: Dr. Arguello has responded. See his response and my reply here.
Not infrequently, I’m asked why it is that I do what I do. Why do I spend so many hours of my free time, both here and at my not-so-super-secret other blog (NSSSOB), to write my detailed analyses of various forms of quackery, analyses of scientific studies, and expressions of my dismay at the infiltration of pseudoscience into medicine, particularly medical academia in a phenomenon I like to call “quackademic medicine”? One reason, of course, is because I passionately believe in what I am doing. Another reason is that I want information countering various forms of dubious medicine to be out there, and I have two well-trafficked blogs as a platform, although SBM long ago surpassed my NSSSOB in traffic and reach.
Over the last six years, there are some topics that I’ve written about many times, such as the antivaccine movement, Stanislaw Burzynski, cancer quackery, and common myths about cancer treatment. Surprisingly, there are some topics left that I should have written about a long time ago but haven’t, even though I had heard of them before. One such topic, atavistic oncology and chemotherapy, was brought to my attention a couple of weeks ago by a reader, who basically pointed me to a particular dubious bit of cancer treatment whose chief proponent, Dr. Frank Arguello, is apparently currently touring Canada to do conferences and meet with potential patients, placing ads in local newspapers in the cities in which he will be appearing. His meeting with patients in Canada seems particularly problematic, because his cancer practice is located in San Jose del Cabo, Baja California Sur, Mexico, a location that, given the nature of his practice and claims, struck me as remarkable only because it’s not Tijuana. In any case, Dr. Arguello just appeared in Saskatoon on Friday and is scheduled to appear in Regina on July 30, with appearances in Winnipeg, Vancouver, Calgary, Edmonton, and Toronto promised in the future, as well as U.S. appearances in San Francisco and Los Angeles. Specifically, after his appearance in Regina, advertised here:
“Helpfully,” Dr. Arguello points out that he will be staying in Regina on July 31 to “meet with patients,” no doubt to try to recruit them to come to his clinic in Mexico to be treated. One wonders if he could be nailed for practicing medicine without a Canadian license. Be that as it may, what, exactly, is Dr. Arguello’s “atavistic oncology”? It’s a post I’ve been meaning to do for probably years now; so now is as good a time as any. It’s also because the hypothesis that cancer represents an “atavism,” the reawakening of ancient genetic programs seen in our single-celled ancestors billions of years ago, pops up periodically and sounds plausible. Unfortunately, virtually every example of this hypothesis is riddled with misunderstandings of evolutionary biology that render the hypothesis at best highly implausible.
Warning signs of quackery in Dr. Arguello’s atavistic oncology
It is important to differentiate two aspects of “atavistic” oncology. First, there is the hypothesis that cancer represents “atavism,” a reversion to an ancient evolutionary pathway seen in single cell organisms and early multicellular organisms. As I will discuss later, this hypothesis is not well-supported by the evidence and, in fact, represents active misunderstanding of evolutionary biology. The second issue is, assuming it is an accurate hypothesis, what atavism implies for the actual treatment of cancer. In other words, even if atavism is true, would Dr. Arguello’s proposed treatment actually target it in such a manner as to result in better outcomes than existing treatments? In that area, Dr. Arguello fails even more astoundingly, as you will see.
The first thing I noticed when I perused Dr. Arguello’s website is that it demonstrates a number of the warning flags of quackery. For example, one notes a paucity of clinical trial data published in the peer-reviewed medical literature supporting the efficacy of his methods, but one does see a lot of testimonials. If one looks at Dr. Arguello’s CV and his LinkedIn page, you find a seemingly-impressive list of positions before he became the director of the Dr. Frank Arguello Cancer Clinic, Institute of Science and Genomic Medicine, including:
     1.  Assistant Professor of Pediatrics, Pediatric Hematology/Oncology Division University of Rochester School of Medicine and Dentistry (1990-1994)
     2.  Senior Investigator, Laboratory of Drug Discovery, Research and Development Division of Cancer Treatment, Developmental Therapeutics Program, National Cancer Institute- FCRDC (1994-2000)
     3.  Section Head of Preclinical Research & Development, Department of Drug Discovery Institute of Research Cesare Serono S.P.A ., The Ares-Serono Group (2000-2001)
An examination of Dr. Arguello’s CV and PubMed record rapidly reveals that his last peer-reviewed publication was in 2002, and that it was a review article. His scientific output, which had been pretty decent between 1988 and 2000. In academia, we sometimes see this sort of thing in doctors who decide to leave academia and go into private practice, but in the case of doctors like Dr. Arguello, who suddenly “discover” The One True Cause of Cancer and how to treat it, it’s a red flag suggesting unproven medicine at best and quackery at worst. In this case, it wasn’t until 2013 that he founded his clinic. In the meantime, he was busy starting a biotech business.
There’s even an offer to face a “public challenge” by conventional oncologists to demonstrate the efficacy of his methods by treating a patient with stage IV breast cancer, with the following criteria:
    • The challenge will be advertised publically by the hosting institution (challenger), and communicated to the press, who shall monitor the results over time.
    • The patient must have stage IV breast cancer. Other cases can be treated as long as a stage IV breast cancer patient is included in the challenge.
    • The patient must have a Karnofsky Performance Scale above 80%, and documented evidence that she has not been exposed to conventional chemotherapy and/or radiotherapy.
    • A neutral, non-biased review committee will review the protocol and publish the results.
    • The challenging institution must cover all expenses for the patient(s), studies, medical honorariums, travel, etc., and must make all legal and regulatory arrangements for the study. Confidentiality agreements, disclaimers, etc., will be established.
    • The challenging institution must have strong medical and scientific recognition to render a verdict that will affect the criteria of the medical and scientific community.
He even issued a press release for his challenge!
Of course, this is not the way things are done, and Dr. Arguello’s challenge is much like Jock Doubleday’s vaccine challenge in that it’s constructed in such a way that it’s unlikely that anyone will ever accept it, certainly not a reputable academic cancer center. This is not a clinical trial, much less a randomized clinical trial. No IRB worth its salt would ever approve such a “challenge,” because it is also totally unethical to offer an experimental therapy to a patient who hasn’t received standard-of-care treatment yet, given that there do currently exist effective treatments that at least palliate stage IV breast cancer. That’s particularly true given that Dr. Arguello doesn’t present any compelling preclinical evidence in cell culture or animal models to support his treatment. It’s even more of a problem, given that Dr. Arguello doesn’t even reveal the drugs and treatments he uses. Yes, you read that right. In a section of his patient brochure entitled “Drugs Employed & Their Use”, Dr. Arguello writes that he uses various FDA-approved drugs “off-label” to treat cancer:
The drugs used in combination have been selected based on the principles of “Atavistic Metamorphosis” published by Dr. Arguello in 2011, and after years of testing them in hopeless cancer patients. They fall in the pharmaceutical group of anti-bacterial (antibiotics), anti-fungal and anti-protozoal (anti-parasitic) drugs. Anti-viral drugs have also a place within the principles of Atavistic Chemotherapy because viruses preceded cells in their origin, and they were the precursors of the first cells on this planet. However, costs and toxicity of antiviral drugs have forced us to use them only when other approaches fail.
Because of delays in obtaining patents, the actual names of the medicines given in Atavistic Chemotherapy are not revealed to the patient. All of the drugs employed have expired patents since being in the market for decades. However, we are in the process of filing for patent protection for “New Use” or “New Formulation,” in order to protect the intellectual property and credit for this work. Although the drugs we use have been around for many years, Atavistic Chemotherapy and Immunotherapy is a new type of cancer treatment.
Another reason for not divulging the names of the medications is to prevent patients from self-medicating. It also prevents well-meaning caregivers from misusing drugs with which they are not familiar with in the treatment of cancer.
How humane. What rot! Sure, Dr. Arguello says that he’ll tell patients what the classes of drugs are that his patient receives and will offer them a hotline to find out exactly what the drugs are if they’re ever hospitalized and their doctors really need to know what they’re taking, but none of that helps scientists and oncologists to evaluate whether his treatments have any plausibility or likelihood of working. That’s the point. Of course, if any university were ever to accept a “challenge” from Dr. Arguello, he’d be forced to reveal exactly what his concoction is. Surely he knows this. In fact, in a way, Dr. Arguello is even worse than Stanislaw Burzynski. At least Burzynski apparently actually tried to do clinical trials before legitimate researchers decided they couldn’t work with him and he settled in 1997 on his model of using them to keep his clinic open and make money. Dr. Arguello doesn’t even seem to have done that.
But what is “atavastic oncology,” anyway?
Cancer as atavism: The resurrection of a very old idea
Perhaps the best way to explain what Dr. Arguello appears to mean when he describes “atavastic oncology” is to go to the source. Unfortunately (and not surprisingly), it’s a rather disjointed source, but it’s what Dr. Arguello claims; so we’re stuck with it. If you have time to go through it, there’s this 45 minute video:
On his website, there is this:
Cells in multicellular organisms have developed, over billions of years of evolution, complex and specialized cell functions according to their role in the body of multicellular organisms (skin cells, pancreatic cells, brain cells, etc.). We call these specialized cells “differentiated cells.” When differentiated cells lose their features of differentiation, they become “undifferentiated cells.”
We believe that when this happens, loss of differentiation features, cells reverse to their original, independent unicellular life form, and re-activate their basic functions of life: obtaining nourishment from the surrounding environment, reproducing themselves, migrating and spreading to ensure survival and perpetuation of life. This is what we call cancer. In other words, when a cell in a multicellular organism (animal or plant) reverts to its unicellular life form, cancer has developed. The resulting colony of reverted cancer cells will reproduce and spread inside the multicellular organism disrupting its functions and eventually causing its death.
And:
Atavistic metamorphosis proposes that cancer cells are cells that have reverted, evolutionarily, to their ancestral, independent status as unicellular organisms. It is from there that cancer only occurs in plants and animals/humans (multicellular organisms). This also explains why cancer does not occur nor can be induced experimentally in unicellular organisms such as bacteria, fungi and protozoa.
That last bit is about as silly as it gets. Of course, unicellular organisms can’t get cancer! Cancer, by its very definition as a set of diseases, requires a multicellular organism. Indeed, a seminal article from 2000 by Douglas Hanahan and Robert Weinberg described six hallmarks of cancer thusly:
     1.  sustaining proliferative signaling
     2.  evading growth suppressors
     3.  resisting cell death
     4.  enabling replicative immortality
     5.  inducing angiogenesis
     6.  activating invasion and metastasis
An update to this seminal work was published in 2011 and added additional hallmarks that had emerged over the last decade:
The point is that cancer is defined as a disease of multicellular organisms that results in a proliferating “organ” that doesn’t obey the rules that keep the rest of our cells growing when they’re supposed to grow, maintaining the structures they’re supposed to maintain, and staying in the parts of the body where they’re supposed to stay. Of course, unicellular organisms don’t get it!
It turns out that Dr. Arguello isn’t the only one promoting the atavistic hypothesis of cancer right now. In fact, two astrophysicists, Paul Davies and Charley Lineweaver, have been intermittently in the news for publishing a “unifying hypothesis” on the evolutionary origins of cancer. Back in 2011, for instance, Davies published an article in The Guardian entitled “Cancer: The beat of an ancient drum?” based on an article published by Davies and Lineweaver in Physical Biology entitled “Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors“. It turns out that the National Cancer Institute, in an effort to look at cancer in new ways, had recruited physical scientists to provide fresh insights. This was not a bad idea on its surface, but one consequence of bringing in people from unrelated disciplines is that they don’t know which hypotheses that have been considered before and rejected based on the evidence and therefore frequently act as though they were the first to have thought of a new hypothesis, as Davies does here:
With no prior knowledge of cancer, I started asking some very basic questions. What struck me from the outset is that something as pervasive and stubborn as cancer must be a deep part of the story of life itself. Sure enough, cancer is found in almost all multicellular organisms, suggesting its origins stretch back hundreds of millions of years.
Oncologists tend to think of cancer as a motley collection of cells gone berserk, but to me the way that tumours grow and spread to other organs indicates an organised and systematic strategy, designed to evade all that the body and the medical profession can throw at it. Such well-honed behaviour suggests they are the product of a long period of biological evolution.
I began wondering whether cancer might be an evolutionary throwback to the dawn of multicellular life, when single cells began cooperating and forming rudimentary aggregations.
And:
The reason that cancer deploys so many formidable survival traits in succession, is, we think, because the ancient genetic toolkit active in the earliest stages of embryogenesis gets switched back on, re-activating the Proterozoic developmental plan for building cell colonies. If you travelled in a time machine back one billion years, you would see many clumps of cells resembling modern cancer tumours.
The implications of our theory, if correct, are profound. Rather than cancers being rogue cells degenerating randomly into genetic chaos, they are better regarded as organised footsoldiers marching to the beat of an ancient drum, recapitulating a billion-year-old lifestyle. As cancer progresses in the body, so more and more of the ancestral core within the genetic toolkit is activated, replaying evolution’s story in reverse sequence. And each step confers a more malignant trait, making the oncologist’s job harder.
Note that this is merely a more “sophisticated”-sounding version of the same sorts of arguments that Dr. Arguello makes. Moreover, neither Lineweaver and Davies nor Arguello were the first to have thought of this idea. It’s a very old idea, indeed. Indeed, on Dr. Arguello’s site, there is a list of quotes from what he calls the “pioneers of atavistic metamorphosis,” including Rudolf Virchow, Herbert Snow, and Sir Henry Butlin, all of whom died at least over 84 years ago, with Virchow having made his name as the “father of modern pathology” back in the 19th century. In 2013, Darren Saunders pointed out that the idea that cancer represents some sort of devolutionary state dates at least as far back as Theodore Boveri, who 112 years ago published a fascinating article on the origin of cancer that, in part, discussed “interesting parallels” between malignant tumors and embryos produced by multiple divisions in the doubly fertilized sea urchin egg, as a suggestion of how tumors can resemble cells from early stages of embryogenesis. No wonder Saunders also likened the atavistic hypothesis of cancer from two astrophysicists to a doctor who reinvented calculus.
P.Z. Myers explained in depth why this line of reasoning was wrong, pointing out what any cancer biologist knows, namely that this “ancestral core of genes and processes deep in metazoan development” supposedly lurking, silenced, waiting to be switched on and to “turn the cell into a prehistoric monster” are not silent at all. They’re highly conserved (meaning that they’re so fundamental to cellular function that they developed very early in evolution and haven’t changed much) and active, controlling important developmental processes. They’re genes involved in cell division, adhesion, motility, and apoptosis (programmed cell death). As recognized by Hanahan and Weinberg’s hallmarks of cancer, they are the central controls that are disrupted in cancer and lose control over cell division. Moreover, Lineweaver and Davies, at least, totally misunderstand unicellular organisms when they argue that the ancient cellular program resurrected in cancer cells doesn’t “contain the genes that regulate cell proliferation.” Anyone who’s ever studied bacteriology would know that’s utter poppycock. Yes, even E. coli regulate their proliferation in response to a number of environmental factors, and there are bacteria that go completely dormant and form nonreplicating spores when environmental conditions are too harsh for replication.
The bottom line is that cancers are not most like single celled organisms. For one thing, they cannot survive outside of the body, leading Saunders to propose a test for the atavistic hypothesis: Drop tumor cells into the ocean and see if they live and grow, like ancient unicellular organisms could. In fact, most tumor cells can’t even survive for that long away from their fellow tumor cells in the body. The few that can are the ones that form metastases, but the vast majority of tumor cells that dislodge from the main tumor mass and get into the bloodstream die. Another limitation of the idea is the assumption that early metazoan organisms resemble tumor-like growths, which is simply not observed. As Saunders pointed out, cancers are dysfunctional by definition. I myself have written about how genetically messed up the genomes of cancer cells are on numerous occasions and how evolution drives the tumors to become more and more heterogeneous as they progress.
So what’s Arguello’s twist on atavism as the explanation for cancer? Well, I can’t read his book, although I could peruse a couple of chapters on Amazon. Well, his “reasoning, such as it is given that it’s based on an untenable hypothesis is this:
Atavistic oncology postulates that cancer cells are cells that have reactivated past evolutionary genetic information preserved in the genome (DNA). Thus cancer cells reacquire the abilities and behavior of their ancestral precursor cells, the primitive unicellular organisms. Therefore, malignant or pathogenic characteristics found in cancer cells such as unlimited replicative potential; capacity for invasion, migration, and metastases; abilities to evade the host’s immune system, and generate multidrug resistance; and abilities to live in hostile conditions are cellular traits reasserted from their hereditary past as primitive, independent single-celled organisms.
This does not imply that cancer cells are bacteria, or protozoa, or yeasts. It means that cancer cells express functions or behaviors similar to their ancestral parents, the unicellular organisms (such as bacteria-like and protist-like organisms) from which our cells originated.
If this is true, a combination of drugs that are effective to eradicate certain unicellular organisms should work in cancer treatment. Not only they should work, but this approach must be superior to any other approach used in the past to treat cancer. Because of the overwhelming results we have obtained and shown on our website, we prophesize that Atavistic Chemotherapy and Immunotherapy will become the way cancer is treated in the world.
So now we have the explanation for why Dr. Arguello uses anti-bacterial (antibiotics), anti-fungal, and anti-protozoal (anti-parasitic) drugs to treat cancer. It doesn’t explain why he uses antiviral drugs “when other approaches fail,” given that viruses are not considered to be unicellular organisms, given that they are not cells at all. Indeed, they are not even really considered to be alive, given that they cannot replicate by themselves and require a living host cell to do so. In fact, he even takes the idea that cancer cells are like metazoans and protozoans to the extreme that he thinks he can vaccinate against them by vaccinating against bacteria, while conceding, well:
Although unproven and totally speculative, we believe that the immune system can see and recognize molecular similarities on the surface among cancer cells, bacteria, protozoa and/or fungi. It is well known that vaccination for a given bacteria can indirectly protect the individual from other types of infections for different organisms not related to those in the vaccine. This is known as cross immune protection or resistance to phylogenetically unrelated organisms.
At least he admits this idea is totally unproven. But if that’s the case, then it’s even more unethical to use them as a basis of treatment without a lot more basic research and clinical trials. Would that he would admit the same for the rest of his ideas, but if you watched his video, you’d see that around 3:30 it’s claimed that Dr. Arguello can produce complete regressions of cancer.
Yes, cancer vaccines are a hot area of research right now. I happen to know researchers at my very own institution who are working on breast cancer vaccines, and I’ve served on the dissertation committee of a graduate student who was looking for ways to increase the efficacy of an experimental breast cancer vaccine. Vaccines are a promising area of research for some cancers. Here’s the problem. What Dr. Arguello is doing is not systematic or targeted, and my expressing my doubt is not, as he puts it, being skeptical about the idea that immunity against unicellular organisms or their toxins can crossreact against cancer cells and kill them. Rather, it’s against the idea that the reason this can happen is because tumor cells are atavistic, which is what Arguello argues. Indeed, it is striking how uncommon these observations appear to be (as demonstrated by the cherry picked papers included to bolster his point), other than the use of BCG as immunotherapy for bladder cancer, noted in a paper he misrepresents as having been published in Nature, when in fact it was published in a Nature journal, Mucosal Immunology.
What about the testimonials?
Leafing through the various testimonials included on Dr. Arguello’s website, I was struck at the resemblance of some of them to testimonials used by Dr. Burzynski. For instance, the case of Barb Juniper is an unfortunately typical case of a woman who developed melanoma, underwent successful surgical treatment, and then suffered a recurrence in the form of two brain metastases and a tiny deposit. These appear to have been surgically resected on January 24, although it’s not clear from the description (or the scans, for that matter), whether both or only one was resected. It’s also mentioned that an apparently-new frontal lobe metastasis was observed on March 4, but it’s also mentioned that an “abscess can’t be ruled out.”
The first thing I noticed is that many of these MRI slices are not at the same level and therefore not directly comparable. One of the lesions was clearly postsurgical change that resolved over the ensuing months. Another appeared to have shrunk in response to Avastin, although one can’t rule out atavistic chemotherapy having something to do with it. Of course, not knowing what drugs Dr. Arguello is giving, I don’t even know if his drugs cross the blood-brain barrier. I’m particularly shocked by this part of the testimonial:
He proposed to the patient a different approach in which for the first 30 days of the treatment the focus would be on reducing the blood flow and vascularity of the brain metastases to prevent bleeding during the actual atavistic chemotherapy and immunotherapy. This is called “Anti-Angiogenesis Treatment.” The patient accepted.
Dr. Arguello saw the patient on February 21, 2014, the same day she started the anti-angiogenesis treatment and continued until April 5, 2014 when the above treatment was discontinued and the atavistic chemotherapy and immunotherapy started.
One notes that we are not told which antiangiogenic therapy was used, but I can’t help but note that, paradoxically, bleeding is not an uncommon complication of certain antiangiogenic drugs. It’s all not particularly convincing.
Another case is that of a man with an indolent leiomyosarcoma of the leg that grew slowly over many years because he refused surgical intervention back in 2008 as the man sought “natural” (actually naturopathic) treatments. The series of photos (graphic!) to this surgeon show no obvious effect, and the patient abandoned treatment. There are several graphic series of photos of advanced breast cancer that might or might not have shown a treatment effect as opposed to the natural course of the tumor.
I like to think of it this way. If Dr. Arguello’s “atavistic” chemotherapy is as effective as he claims it is, it should be child’s play to demonstrate it in even a few relatively small clinical trials for different tumor types. He doesn’t. Instead, he cherry picks testimonials that might or might not show anything (it might be worth a separate post to analyze them individually) and issues nonsensical “challenges,” in essence, for others to do his own work for him. If he really did work as a pediatric oncologist at the University of Rochester and as a Senior Investigator in the Laboratory of Drug Discovery at the NCI, he knows these things. Yet he chooses not to do them. Instead, he does tours of Canada and the US looking for patients, doesn’t reveal what his protocols are, hiding behind a transparently deceptive excuse that he doesn’t want patients to “self-medicate” (and the more believable one that he doesn’t want other quacks to steal his ideas), and selling his cancer quackery at a clinic in Mexico.
There is a reason that atavistic oncology didn’t catch on among cancer researchers and physicians, and it’s not because of ideology and it’s not because of anyone “suppressing” the information. It’s because atavistic oncology is not consistent with well-established principles of biology and evolution based on 150 years of evidence. It’s because the hypothesis that cancer is an atavism provides no useful predictive power for treatment. Lineweaver and Davies might argue otherwise, claiming that atavism suggests treatments based on targeting the Warburg effect, DNA repair mechanisms, ABC transporters (which can function as drug efflux pumps), tumor-associated macrophages (TAMs), and immune interactions, a strategy they label as “target the weakness.” However, as a cancer researcher, I can tell you with knowledge that all of these “weaknesses” are already being investigated as potential therapeutic targets—and have been for at least the last decade—no appeal to atavism needed. Indeed, Lineweaver and Davies suggestion is downright insulting to cancer researchers who discovered the potential importance of these mechanisms in cancer and whose work Lineweaver and Davies seem to have inadvertently coopted as “just-so” stories that support their hypothesis.
Contrary to what Davies, Lineweaver, and Arguello seem to think, the reason the atavistic hypothesis of cancer hasn’t caught on is because it’s a hypothesis that is not new and has been considered and found wanting from a standpoint of biology and evolution. Unfortunately, it is a hypothesis that is easily co-opted for quackery, as Arguello has done.

“Atavistic oncology” revisited: Dr. Frank Arguello responds
Three weeks ago, I wrote about a cancer treatment promoted by Dr. Frank Arguello that I deemed to be quackery, launching into one of my usual discussions based in science (and with a touch of snark) regarding why. Dr. Arguello, it appears, is not very happy about what I wrote. So he responded. He also sent e-mails complaining to my cancer center director and chief medical officer, my department chair, the medical school dean, and at least one other dean of my medical school that I know of. Such is the price of criticizing pseudoscience. In any case, I thought I would share with you the exchange and let you judge for yourself.
David Gorski on August 18, 2014
Link

EDITOR’s NOTE: There are three Addendums after this post, containing the complete text of e-mails.
EDITOR’s NOTE #2 (8/19/14 4:51 PM): There is one more Addendum, as Dr. Arguello has sent me another e-mail.
EDITOR’s NOTE #3 (8/20/14 7:18 PM): There is yet another Addendum, as Dr. Arguello is now complaining to my place of work.
EDITOR’s NOTE #4 (8/21/14 5:30 PM): And the beat goes on. See Dr. Arguello’s next e-mail.
The following post will be of a type that I like to refer to as “taking care of business.” That’s not to say that it won’t be, as my posts usually are, informative and entertaining, but it does say that I’m doing it instead of what I had originally had in mind because something came up. That something is a rather unhappy e-mail from the doctor about whom I wrote three weeks ago. It’s just an indication that, although it’s a great thing that this blog is becoming more and more prominent, it’s also a two-edged sword. People actually notice it when I (or other SBM bloggers) criticize them for dubious medicine. We see this in how Dr. Edward Tobinick has launched what I (and many others) consider to be a frivolous lawsuit against SBM founder Steve Novella over a post from 2013 clearly designed to silence criticism. It’s legal thuggery, pure and simple. That’s the bad end of the spectrum. I’ve been at the receiving end of similar retaliation that could have just as bad an impact on me personally as far as my career goes when antivaccine activists tried to get me fired from my job four years ago.
The more common (and far less agita-inducing) end of the spectrum consists of e-mails or letters of complaint. Sometimes they come from eminent radiologists who don’t like my criticism of their attacks on mammography studies. (Actually, truth be told, it is rarely eminent radiologists—or eminent physicians and scholars—who complain.) More commonly, it’s practitioners who object to how their treatments have been described. This time around, it’s a man named Dr. Frank Arguello, whose “atavistic chemotherapy” I criticized in one of my typical long posts that also explained why. Last week, I received this e-mail from Dr. Arguello:
Dear Dr. Gorski,
I was recently referred to the online comments you wrote against my efforts to help people with cancer: Comments
I am 100% sure this approach will change the practice of oncology in the world. It will be a historical work, and you and your comments online, even if removed, will live in infamy. We had been previously informed that you contacted the Saskatchewan College of Physicians and Surgeons in an effort to stop me. Failed!I believe your actions online are a disservice to the community, particularly with your most recent comments about the science of atavistic oncology, not because you criticize questionable therapies around, but because you do not provide nor make any efforts to improve our current devastating results with conventional therapies.
I am starting to believe what is said about you, that you are a paid magnate from the pharmaceutical industry. You must be, because my clinical cases (not testimonials as you call them) are so compelling, that your actions can only be explained as coming from a person who does not understand clinical oncology and/or has an agenda to perpetuate our devastating oncological practices.
If you are not a paid magnate from the pharmaceutical industry, and you are genuinely interested in the science and treatment of cancer, are truly interested in helping people with cancer, and do not want to live forever in infamy, I challenge you to:
(1)Publish this letter next to your posting online and accept my public challenge posted on my website. I have a new patient from Hamilton, Ontario with disseminated melanoma. All medical records and CT-scan images are available from Prince Margaret Hospital in Toronto from as recently as last week. He had an inter-consultation with the Chair of the Melanoma Center at the Massachusetts General Hospital, Dr. Donald Lawrence, and we have his written opinion about that case.
You will not be responsible for expenses as stated in the original challenge on my website. But you will need to comply with all the public and medical scrutiny of the patient, treatment and results over time to be made known publically. I am meeting in Los Cabos with the patient this Saturday, August 16, 2014 to begin treatment. I could discuss this public challenge with him.
If you are in fact a paid agent from the pharmaceutical industry, or just a shameful character and enemy of science and medical progress, I propose the following:
(2)Put a link on the page of your comments, so that people can have a genuine scientific rebuttal to your comments. I would write and post this rebuttal online for this specific purpose.
I would like to clarify that my clinic was opened in Los Cabos in 2013, not 2002. You did not see publications from 2002, because I was working in medicine, but outside academia. Among other things, I was creating with my brothers a state-of-the-art, seven-floor high and now successful private Institute of Sciences and Genomic Medicine in Torreon, Mexico.(http://www.institutodeciencia.com/gallery/gallery.htm)
Our institute has been visited by many important scientists, most recently by Dr. Kary Mullis, the Nobel Prize winner in chemistry in 1993 for his invention of the polymerase chain reaction (PCR), a process which is hailed as one of the monumental scientific techniques of the twentieth century. (http://www.institutodeciencia.com/aboutus.htm)
Thank you for your kind consideration of my proposal.Respectfully,
Dr. Frank Arguello
P.S. I have recently compiled a number of articles from the early 1900s and late 1800s on survival times of patients with a variety of cancers. It appears that people live less now with our therapies (chemotherapy and radiation), when compared to untreated disease. Attached is a letter I just sent to an oncologist who contacted me several weeks ago to see if I could treat a patient with esophageal cancer. I rejected the case because it was terminal. In that recent letter, I question our practices, as I did with Dr. Lawrence, whom I mentioned above. I am planning to write an article regarding that, and if interested I could send you a draft prior to submission.
There was an attachment that led to a letter in PDF format from Dr. Arguello to Dr. Was Mansoor, a Consultant in Medical Oncology at the Christie Hospital in Manchester, England. I am not going to provide a direct link to the PDF because it mentions a patient’s name. I will, however, quote the letter dated August 11, expunging any patient-identifiable information:
Dear Dr. Mansoor,
I was contacted by XRX on July N, 2014, to let me know that her brother RXR had died. She mentioned that he died peacefully, but she still felt it was a bitter end to a valiant 18-month fight against the pain and his esophageal cancer. Unquestionably, it was an admirable effort from him as a cancer patient, and you as his oncologist.
In recent years, I have become concerned that patients “fights” against cancer are unfair, and destined to fail, because they are fighting with the wrong weapons. It is a fight where the outcome is already known before the “fight” starts, whether the patient maintains a positive attitude or not. The actual number of deaths due to a given cancer type can be predicted, even years in advance, regardless of our efforts. This trend will continue year after year if we do not change our way of thinking and our oncological practices. Obviously, all cancers are curable, and they have been curable for centuries, if removed completely with surgery before cancer cells have escaped to distant organs. The problem is for those patients in which cancer has escaped curability with surgery. Are we really treating and benefiting those patients with our current treatment approaches?
I have been studying the survival time of people with cancer who were never treated with our modern approaches of chemotherapy and radiation, not even surgery. Since it is extremely rare to find, today, cancer patients not exposed to some form of treatment, I collected papers from the 1800s and the first decades of the 1900s discussing survival time of untreated cancer patients. In the case of esophageal cancer, I found an article which reports the median survival time of 74 untreated patients with esophageal cancer seen at Middlesex Hospital, London, England, between 1883 and 1922. It reports an overall median survival time of 14.7 months (19.4 months for females and 12.1 months for males – with a range of months to several years) (Reference-1924). These are patients who did not receive any form of surgical treatment (medical treatments obviously did not exist at that time other than opium).
In a recent, 2014, study in the Netherlands involving 127 patients with inoperable or irresectable esophageal cancers, patients were divided into two groups – one group received chemotherapy and radiation and the other group radiation alone. The median survival time was 14 and 9 months, respectively (Reference-2014). There could be better survival times reported in the medical literature, but I selected this study because it is a large population of patients with inoperable esophageal cancers, and it emphases to toxicity inflicted in these patients with these forms of therapy.
Obviously, a treatment is of benefit only if it increases for a reasonable period of time the anticipated survival time without that treatment. In theory, we should be doing far better today in 2014 than 100 years ago, because aside from chemotherapy and radiation, we have potent antibiotics, blood transfusions, parenteral feeding, gastrostomies, stents, intensive care units, etc., which did not exist in the late 1800s and early 1900s. But this does not appear to be the case.
I am writing to you because I recently sent an e-mail to Dr. Donald Lawrence at the Massachusetts General Hospital (e-mail attached) with similar shocking findings with respect to our modern treatment for cutaneous and uveal melanomas (attached). I would like to extend the same invitation to you to reconsider what you are doing, what you could do, and invite you to help me to change our current oncological practices by taking my “Public Challenge” posted on my website. Although offered for breast cancer, we will take the challenge treating advanced esophageal cancer.
Respectfully,
Frank Arguello, MDAtavistic Oncology Clinicwww.AtavisticChemotherapy.comFormer Assistant Professor of Oncology,and Pediatrics, Hematology and Oncology,University of Rochester School of Medicine and Dentistry. Rochester, New York USA.Former Senior Scientist, Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health.Frederick, Maryland USA.
Dr. Gorski responds
I don’t know about you, but I find it quite odd that Dr. Arguello refers to himself on his official letters not by simply listing himself as the founder and director of the Atavistic Oncology Clinic, his current position, but by listing his previous positions, the most recent of which (his position at the NCI) he left 14 years ago. This is a signature, not a CV! Of course, the reason Dr. Arguello does this is obvious. It’s to assert to the world that he was once a real scientist and real oncologist, rather than an atavistic oncologist. How many people will mentally ignore the word “former” or even remember it? My immediate reaction upon seeing this was great amusement, and I’m sure that anyone who’s held an academic medical position will be similarly amused upon reading this.
Be that as it may, let’s take a look at the substance, such as it is, of the complaint. First, of all, I never contacted the Saskatchewan College of Physicians and Surgeons in an effort to stop Dr. Arguello. Perhaps someone else did, someone who was concerned about the spread of cancer quackery in Saskatchewan, but I assure Dr. Arguello that I did not. He can believe me or not. I don’t care, because, if someone really did try to stop him in Saskatchewan, I completely approve.
Next up, Dr. Arguello accuses me of not making any effort to improve existing therapies for cancer. This is, of course, utterly ridiculous, given that I have spent the last 15 years on the faculty of two different NCI-designated comprehensive cancer centers, where I’ve been funded at different times by private foundations, the NIH, and the Department of Defense to study ways to improve the treatment of breast cancer. Before that, I did laboratory research in what was then the cutting edge field of tumor angiogenesis. In addition, these days I also serve as one of the directors of a state-wide quality improvement initiative for breast cancer treatment. So it’s demonstrably wrong—and easily so!—to claim that I don’t do anything to improve cancer care with my career.
Of course, quality improvement through clinical trials and the mundane but necessary (and grueling) task of encouraging adherence to evidence-based guidelines is not what Dr. Arguello apparently considers to be “improving” cancer care. I’m just not going about it in the way that he approves of. He thinks I should be supporting him. What he doesn’t realize is that I would support him if he could provide evidence that his treatment works significantly better than the current standard of care. That’s the problem. He hasn’t provided such evidence and still doesn’t. Even worse, as I discussed last time, it’s not even clear what exactly he is giving his patients. He doesn’t tell them. He doesn’t provide detailed protocols. He’s so afraid that someone will steal his allegedly revolutionary idea that he doesn’t even tell his patients what they’re getting, except vaguely, unless there is a problem.
So instead Dr. Arguello resorts to the oldest form of ad hominem argument leveled against skeptics: The “pharma shill” gambit. I must admit, I chuckled when he referred to me as a “paid magnate from the pharmaceutical industry.” Normally, I wouldn’t make fun of a comment like that coming from someone who is not a native English speaker, but Dr. Arguello lived and worked in the US from 1987 to 2000 and writes reasonably well, if his letters are any indication. Thirteen years in the US ought to have been enough for him to learn the meaning of the word “magnate,” namely someone who has great power and wealth in a particular business or industry. Even if I were a “pharma shill,” I would most definitely not be a pharma magnate (I don’t even run my own company!), and if I really were a pharma magnate does Dr. Arguello honestly think that I’d bother with the likes of him? (Besides, personally, I prefer the term “shill” or “minion.”)
Ignoring the ad hominem, let’s move on to the two “challenges” Dr. Arguello makes. The first part of his challenge is easy. He wants me to publish his letter? I publish his letter! Part one done! I’ll even make sure there’s a link to this in the previous post, and in my response to Dr. Arguello I pointed out that no one is stopping him from diving into the comment section to make his case that I’m a nefarious pharma shill/minion/magnate out to destroy his great new discovery because it will bankrupt the pharmaceutical industry of which I am a magnate. I repeat that offer here. I promise, as editor, that his posts will be approved; that is, unless they become quite abusive. I will also e-mail him a link to this response.
The second part of his challenge is not so easy for a number of reasons, not the least of which are ethical. First, patient challenges like this are not how science is done. To me, they’re unethical, even if the patient gives permission. There’s also the rather major issue of patient confidentiality. I know HIPAA, the patient confidentiality laws in the US, but I don’t know what the equivalent to such laws is in Canada and Mexico. Regardless of what they are, following a patient like this that I’m not taking care of and who is not herself placing her scans and medical records in a publicly accessible repository (as Stanislaw Burzynski patients that I blog about do) makes me very uncomfortable—skeevy, even. So, no. I can’t do that.
I realize that Dr. Arguello thinks he’s making it easier for me by altering his original challenge that is on his website by not requiring me or my cancer center to pay for all patient expenses, but it’s a smokescreen. In this case, it’s one of his patients from Canada. In his original challenge, he expects the doctor (and institution) accepting the challenge to do all the work and bear all the expenses. This would be human subjects research, even if it’s only a single patient, because the treatment is very much nonstandard, even if a lot of what Dr. Arguello proposes is to use existing drugs off-label. Come to think of it, if I were a pharma magnate who happened to own a company that made some of the drugs or vaccines that Dr. Arguello uses for his “atavistic chemotherapy,” I might want to fund him, because if he really did have a treatment so much more effective than standard of care using my drugs off label, well, the profit potential would be fantastic! In any case, no institutional review board (IRB) worth its salt would approve a single patient experimental protocol using a drug protocol in which the drug identities, exact dosing and schedule, and duration of therapy aren’t spelled out in exquisite detail, and I know my IRB wouldn’t approve such a single patient study. Nor should it!
Of course, single case “challenges” are not in general particularly informative, especially for cancers like melanoma, which, as Dr. Arguello should know, can have variable courses, even when diagnosed as stage IV. Indeed, as Dr. Arguello should know, it is unclear whether the dominant driving force in melanoma long-term survivors is the host immune response against the tumor, inherent indolent disease biology, or response to therapy. So, even if Dr. Arguello’s patient were to be fortunate enough to turn out to be one of these long term survivors, it would not constitute compelling evidence that his treatment works. Those of us who’ve taken care of melanoma patients (as I have, albeit in relatively small numbers) or had a partner who takes care of a lot of melanoma patients (as I have) have seen outliers, patients with stage IV melanoma who have survived far longer than expected. The same is true of breast cancer (which, not coincidentally, was the main cancer in Dr. Arguello’s challenge before he made this one to me). That’s why we do clinical trials. A successful clinical trial would impress me far more than a single patient with a type of tumor that can produce long term survivor “outliers,” even in stage IV patients, as breast cancer and melanoma can. Dr. Arguello even seems to acknowledge that, as he turned down a case of esophageal cancer because it was “terminal.” Well, so is stage IV melanoma. Why does he accept stage IV melanoma and breast cancer cases and not esophageal cancer?
Now, I’ll take my lumps for getting one thing wrong. Dr. Arguello didn’t found his current clinic until 2013, and I will correct that in my original post. He does, however, have his El Instituto de Ciencia y Medicina Genómica (Institute of Sciences and Genomic Medicine) and his practice, founded in 2002. A perusal of the website using my rudimentary knowledge of Spanish plus Google Translate reveals that this is a “Mexico-British biotechnology company dedicated to scientific research in the field of gene and cell therapy. We also provide a diverse range of molecular and clinical laboratory analysis to other laboratories and hospitals around the country, as well as doctors and public in general.” Interestingly, I note that this company has contact with Kary Mullis, the Nobel Laureate who is best known for having in essence invented the modern day version of the polymerase chain reaction (PCR). One wonders what he thinks of atavistic chemotherapy. Or maybe one doesn’t. Mullis, as anyone who’s taken time to look into his history knows, has serious crank tendencies, not the least of which is HIV/AIDS denialism, a belief in astrology, anthropogenic climate change denialism, astral planes, and a belief in alien abduction. If I were Dr. Arguello, I don’t know that I’d be so anxious to advertise a connection with Kary Mullis, at least not if what I wanted was scientific respectability. In any case, what Dr. Arguello’s company appears to offer are molecular analyses for various purposes, including paternity, infectious diseases, genetic diseases, as well as cryopreservation of umbilical cord stem cells and of semen.
Of course, if I am a pharma magnate, Dr. Arguello wants me to “Put a link on the page of your comments, so that people can have a genuine scientific rebuttal to your comments. I would write and post this rebuttal online for this specific purpose.” As I’ve pointed out, though, there’s nothing stopping him from posting a comment after the original article, and there will be nothing stopping him from posting a comment and refuting me to his heart’s content after this post.
His final point rests on a publication from 1924 in which, or so he alleges, that the survival for esophageal cancer was actually better 100 years ago than it is now. To this end, he cites a paper from 1924 and compares it with a paper from 2014. Arguello notes that the median survival reported in 1924 was 19.4 months for females and 12.4 months for males. He then compares this to a series from 2014 examining patients with inoperable esophageal cancer, for whom median survival was 14 months with chemoradiation and 9 months for radiation alone. Does anyone see the problem with this comparison? I did, immediately.
First of all, the way esophageal cancer was diagnosed 100 years ago was very different than the way it is diagnosed now. During the time period when these cases were accumulated, endoscopy wasn’t routinely used. There weren’t even barium swallows. These days, flexible endoscopes with biopsy attachments are used to diagnose lesions of the esophagus. It’s also not a valid comparison to try to compare esophageal cancer in 2014 with 1924 and earlier, particularly cancer from 2014 that is inoperable. After all, what constituted “inoperable” 100 years ago was very different than what constitutes “inoperable” today. It’s a huge difference. Modern surgical technique allows us to remove tumors that no surgeon could have removed 100 years ago without killing the patient. Also, likely mixed in with the 1924 case series are benign tumors such as leiomyomas and tumors of less aggressiveness, given that there is no mention that there was verification by pathology in the paper. Finally, today cancer survival is calculated from time of diagnosis, not time of onset of symptoms. That means from the time that a biopsy is taken and cancer is demonstrated. I notice in the paper that “the natural duration of the disease in each case has been taken as that period which elapsed between the date of reputed onset as determined from the patient’s history and the date of death.” That alone could easily add several months—or even a year or more—to the survival times observed compared to now.
Round two and conclusion
After I responded to Dr. Arguello, he wrote back with a lengthy response. Given that it’s pretty much just repeating the same things again, I won’t be doing a blow-by-blow, but for completeness’ sake I have included it as an addendum to this post. What I will address are a couple of issues in the e-mail.
First, I note the same excuses we’ve heard from time immemorial that dubious practitioners trot out whenever they are challenged over why they don’t do clinical trials. After all, even Stanislaw Burzynski has done clinical trials! Dr. Arguello has done none, but he sure has a lot of excuses! Excuses aside, it is completely unethical to be administering this “atavistic chemotherapy” to patients under anything other than the auspices of a properly designed clinical trial with IRB approval (or approval from the equivalent ethics board in another country, if the trial is done elsewhere). It is even more unethical to charge patients for such a treatment outside of a clinical trial; there’s no excuse for that. (NOTE ADDED: See Addendum #2, where Dr. Arguello responds to this criticism.) I do find it interesting, however, that the Cancer Treatment Centers of American might consider such trials. All I can say is: When it comes to getting IRB approval, good luck with that. You’ll need it. Well, that, and, given the history of CTCA, I can’t think of a more “appropriate” partner for such an endeavor.
Finally, there’s his accusation that I did not read his book (which I didn’t, it’s true) and that I didn’t review the recent literature on cancer atavism. I didn’t need to read his book because (1) if what’s in his book is anything like what’s on his website then I know more than enough to know how incorrect it is and (2) I know it’s wrong because I did review the recent literature on atavism for my last post, including the article by Davies and Lineweaver in Physical Biology entitled “Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors.” Indeed, I specifically cited that paper and discussed it in my post, along with several others. That Dr. Arguello didn’t notice (or ignored) that fact does not speak well of his observational powers. If Dr. Arguello wants to send me a copy of his book (preferably as an e-book readable on my iPad), I might just read it and review it. Otherwise, I’m not paying for it. In fact, I learned there’s a new article fresh off the press making the same arguments by Lineweaver and colleagues. I might very well have to analyze that one too.
The bottom line is simple. The atavastic hypothesis of cancer, either as described by Lineweaver and Davies or by Dr. Arguello, is not a compelling hypothesis. It’s based on a misunderstanding of evolution and, as I discussed in detail last time, makes no good testable predictions about cancer and cancer treatment that are distinct from approaches that we are already taking in cancer research. Meanwhile, anecdotes demonstrate little or nothing, but it would appear that that’s all we’re going to get from Dr. Arguello. Note in that passage above that, Instead of publishing his results in a peer-reviewed journal, Dr. Arguello is basically declaring himself above it all (“I am not their peer”) and telling us that he will just publish another book. Guess what? I don’t care. It won’t impress me. If Dr. Arguello wants to prove he’s really on to something, the path forward is simple, but not easy: Do the work. Do the science, and do the clinical trials. Until then, don’t charge patients for an unproven treatment based on a dubious hypothesis.
And, as I have repeated before, Dr. Arguello is more than welcome to dive into the comments and demonstrate how mistaken I am—if he can.
ADDENDUM:
The following is the full text of the second e-mail that Dr. Arguello sent:
Dear Dr. Gorski:
I will numerate my comments, because each is a subject in itself:
(1) The Paid Magnate Agent. I was not aware of your existence until I was contacted by the Saskatchewan College of Physicians and Surgeons (SCPS). That is when I learned about online accusations made against you that you were a paid magnate from the pharmaceutical industry. Whether you are or not, it is totally irrelevant to me. You do not represent any organization dedicated to enforcing those types of rules, much less in another country. I personally condemn all forms of alternative treatments for cancer, in Tijuana or Germany, and I am starting to question all forms of conventional therapies (other than surgery) as well, but to be involved at a personal level and taking actions against the work of others by contacting agencies goes too far, and into malicious behavior, in my opinion.
(2) Questionable Fairness. Also, it is quite disturbing that you ignored the compelling evidences in my partial gallery of clinical cases on the website, which depict local recurrences of breast cancers after surgery and “prophylactic” chemotherapy and radiation; or progressions of cancers in conventional chemotherapy; or multiple metastases in the lungs, brain, liver, etc. disappearing following atavistic chemotherapy and immunotherapy. Most of them are cancer patients that were previously abandoned by their oncologists and hospitals in Canada, USA or Mexico. So, it would appear that you do not know or understand the evolution of patients in similar circumstances (the names of the hospitals involved, relevant pathological studies, etc., are described in each case). This is in fact a noble and unprecedented work in the history of cancer.
Could you show me any sequences of photos or radiological images of similar cancers (solid tumors) disappearing over time with any other therapy, after failing conventional chemotherapy and radiation? You could not even show me similar responses achieved in chemotherapy-naïve patients with any form of conventional chemotherapy. Radiation can do that but as a localized effect on individual tumors, not in a systemic fashion.
Our conventional therapies (except surgery) do not work for the vast majority of cancer patients. All common cancers are lethal today in 2014, just as it has been for centuries, if they escape curability with surgery. In this country alone, 1,605 men, women and children die every single day from cancer. Cancer is also the leading disease-related cause of death in children and adolescents between the ages of 1 and 19 in the USA. The mortality in cancer is increasing at an alarming rate, and I have started to believe that part of that is due to our conventional chemotherapies and radiation which trigger a non-return path to death in cancer patients because it generates resistant and aggressive cancers.
(3) Questionable Fairness #2. You say that “Because we at SBM always strive for accuracy, I will correct the date your clinic opened when I get a chance.” There are many inaccuracies in your comments. Hence my interest in a formal rebuttal, NOT a comment as you suggest, but a side by side discussion so that others may make their own judgments.
As is, it is a one-sided biased view of an important new approach in cancer. You did not provide any references to back up your statements as I do in my website. Your comments are totally your personal biased view of things, which is a completely unfair and improper way to discuss a scientific matter of the magnitude we are talking of here.
You did not even read my book, nor review recent literature on this topic after the publication of my book (see below). The science is there for you to review:
Article #1 Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer (2012)
Article #2 Cancer tumors as Metazoa 1.0: tapping genes of ancient Ancestors (2011)
(4) Why I Do Not Publish Your Clinical Trials. I would love to and I will publish these findings, of course. However, you need to take into consideration the following. I started to evaluate this therapy around September 2011 in Mexico basically as a “Proof-of-Concept Study,” which was approved by the Ethical Board of the School of Medicine and State University Hospital of Torreon, Mexico. The treatment has been evolving and improving with time, to the point that I felt confident of its effectiveness and superiority to any conventional approach by 2013. Still, the numbers of patients is small and the therapy is still changing.
In 2013 I contacted the Cancer Treatment Centers of America (CTCA), the NCI and the Georgia School of Medicine in Augusta (places where I had connections) to consider formal clinical trials. What do you think the response was? I must say, however, that a Dr. Niu from the CTCA in Arizona agreed to run a clinical trial for breast cancer patients. They have more than 10 trials going on, so it will take time.
Also note that I have patent applications filed for “new use” of existing medicines and “new formulations” of existing medicines to protect the credit of my work. Again, I would love to share all the information now, if a large institution agrees to do the work, compensate me for my patents, and put me in a leading position to continue with this work. I hate to keep traveling to Los Cabos.
But what type of review should I anticipate from peer-review journals when I am not their peer? I will publish under my terms. I am working on a large publication in the form of a book. This way, others can practice this new oncology and generate proof in their own practice. Count on it.
(5) “…what you propose strikes me as dubious, at best, from an ethical standpoint, even if the patient gives permission. More importantly, single case “challenges” are not in general particularly informative, especially for cancers like melanoma, which, as you know, can have variable courses, even when diagnosed as stage IV.”
I know two stage IV melanoma patients who have had their disease for years. I am well aware of them (10% of melanomas behave in that way). I do not believe it is the immune system, but the nature of those cancers. Otherwise people could experience fever or signs of inflammation in or around the tumors. Despite our insistence, the immune system cannot recognize cancer cells as foreign or antigenic organisms, unless a reason exists for that. Cancer cells, despite being destructive and independent beings, are not foreign to the body. Immune attacks against cancer cells may be mounted against cancer cells, not for being cancer cells as such, but rather because they may express antigens which can be recognized as foreign to the body. These are malignancies in which a virus is known or believed to be involved–some forms of leukemias, Burkitt and Hodgkin lymphomas, or when the cancer cells are antigenic to the host for the nature of the tissue involved. For example, the testicular seminoma and the gestational choriocarcinoma are highly antigenic tissues to the host. Seminal cells appear after birth and therefore aren’t recognized as one’s own during intrauterine development. In gestational choriocarcinoma, the cells are in part foreign (father’s antigens).
Curiously, the only malignancies curable today with conventional chemotherapy and radiation are those mentioned above (no more, no less). HOWEVER, non-testicular (ectopic) seminomas and non-gestational (ectopic) choriocarcinomas, as those arising from in the brain, lung, ovary/teratocarcinomas, etc., are not curable with those therapies (does this ring a bell?).
The old oncology sees groups of patients in clinical trials. This is a failure on their part. It also tries to fit cancer into our concepts of pathology and treatment. Cancer is unique and it does not fit in our criteria of pathology. Cancer is a cellular process and a biological being. Its nature fits perfectly in the criteria postulated by Robert Koch (Koch’s postulates) – it is an agent that is isolable, can be expanded in the lab, and when re-inoculated in a healthy individual the disease is generated. See also contagious cancers.
The new science of Atavistic Oncology recognizes and, it is my experience too, that EACH CANCER IS UNIQUE with respect to its ability to overcome treatments/cytotoxic drugs (note emphasis). In the same way that nature provides diversity among individuals to protect them from foreign cells (bacteria, protozoa and fungi), prevent them from perpetuating genetic defects, etc., that diversity is also reflected in the malignant form of those cells. This new atavistic oncology will eliminate not only our conventional cytotoxic drugs and radiation which are not anticancer agents, but cell poisons, but it will also eliminate the old-fashioned approach of prospective clinical trials and the current treatments of radiation and anticancer drugs. What drugs and combinations have proven helpful in individual cases and in what type of malignancies? Those will serve as a guide to determine prospective treatments on an individual basis. Treatment will be similar to severe bacterial, fungal and protozoa infections, and will consist of trial and error until THAT particular patient starts to respond.
The patient I mentioned to you yesterday is a 52-year-old from Hamilton, ON. He has had a very rapid progression in less than a year, from local recurrence on October 2013 soon after removal of the primary, to multiple surgeries which have disfigured his face (just as with Alice mentioned below), to now having multiple metastases in the lungs, liver and spleen (based on CT-scans). I am afraid they are also in the brain and bone if evaluated with an MRI and a bone scan/bone biopsy, respectively. In the last three months, from the CT-scan in March 2014 to the CT-scan of August 2014, the number and size of metastases doubled. Now there are two, possibly three large metastases in the liver, 20 or so in the lungs and two in the spleen. This is under Dacarbazine.
What ethical matters are you concerned about? The patient is going to die if he continues on conventional treatments. The ethical thing to do here is to abandon our current practices that are ineffective. One person with melanoma dies in the USA every 57 minutes under conventional chemotherapy/immunotherapy.
Please note that I have two other melanoma patients with rapidly progressive melanomas: Barbara without any therapy offered in BC, Canada because of large brain metastases and given three months of life–That was seven months ago and going (the case you conveniently ignored in the gallery. But those images are never seen with our conventional therapies), and Alice who exhausted all treatments offered in Toronto (Dacarbazine, Ipilimumab which destroyed her pituitary gland, IL-2 therapy). That was more than a year ago (also in the gallery).
Which ethical and privacy issues are you concerned about if we have written consent to cover all aspects related to treatment using off-label practices of FDA approved drugs?
Whether you accept the challenge or not, the patient needs to try to save or prolong his life. Treating them in the correct way (atavistic chemotherapy and immunotherapy) is the ethical thing to do here.
I have tried to cover all your concerns now because my trip to Los Cabos is tomorrow. I hope you are a serious person interested in reconsidering our devastating and totally useless oncological practices in benefit of our fellow humans. Please post either of my two e-mails to you on your site, so that you do not deprive people from the opportunity to be treated correctly. Accept my challenge and then, and only then, you can give whatever advice you want to people. Again, your preemptive attacks are totally improper and unjustified. Just because we can write things on the internet, does not mean we are free to speak our minds. Not on this important, potentially life-saving matter.
Respectfully,
Frank
ADDENDUM #2:
This is an e-mail sent by Dr. Arguello last night after learning my response would go live:
Dear David,
If you response is in regards to my two previous e-mails, you would need to post my two previous e-mails and allow me to respond to your final “response,” in order to be fair.
At this point we are even. You come from nowhere and list a number of personal views on cancer and on my work, I responded. You respondedl with another e-mail questioning many things, and calling it to be a dubious challenge. I responded to that e-mail. If you want to respond to that last e=mail I must have the opportunity to respond. Otherwise, there are three versions from you, and two mine.
I must add that perhaps you do not know that I never charged patients for this treatment until 2013 and I still do not charge a penny to people in less favored countries such as my patients in Mexico, Greece and Slovenia (name and contact info available). My charge to people in the USA and Canada is very reasonable and affordable –$1,500 USD /month -all included x 6 months to those with limited resources or 12 months to those who do not request facilities. If treatment takes longer than 12 months, the continuation of treatment is without cost.
Thank you!
Frank
PS. With regards to those hopeless cases of melanoma I have treated and reversed that. Please feel free to contact them:
NOTE: I will not publish patient names and have thus removed this part.
ADDENDUM #3:
And this is the e-mail sent to me earlier this morning, apparently after Dr. Arguello saw this post:
David,
I now know who you are. Your are not a magnate agent from the pharmaceutical industry. They could not hire such an incompetent person. They would hire a person with weight, with a scientific record to count. I believe you are simply a frustrated physician who has failed as a doctor and scientists and wants to create some name insulting and slandering others. You are not a magnate agent from any organization, other than a narcissist psychopath, a toxic/poisonous individual who defends HIS opinions.
I will discuss your case with a lawyer in your state because your comments cannot be seen as scientific opinions, but slanderous, personal comments which are creating financial damage in my practice. I hope you have some money or properties to recover part of the damages.
If you have knowledge in cancer, you have not shown it with your meager number of publications, where you are principal author in two or three obscure publications, a decade or two ago, and in a totally irrelevant subject to the problem of cancer.
I cannot give your more time. You have no experience in cancer research, nor clinical oncology, discussing the problem of cancer with you is equivalent to discuss it with a taxi driver. You only defend David’s opinion, you have absolutely no conception of the principles if honesty and fairness.
We will put a banner in our website with my second e-mail and this one, and I will categorically state that you are not qualified to discuss cancer research or clinical oncology. From your papers, I do not know if you are good in anything. I am telling you this with all honesty. I believe you are just alive in the field because of your slanderous work.
Frank
This was my response:
Dr. Arguello,
I have corrected the factual error I made in the first post, which was relatively minor and didn’t affect the overall discussion.
If there are any factual errors in this post, I am willing to correct them, if you would point them out. As a further demonstration of my good faith, I will now post your previous e-mail and this e-mail as well as a second addendum to the post.
The rest is my opinion, which is that I do not think your work has sufficient evidence to justify giving it to patients outside of a clinical trial. I have marshaled considerable literature and analysis to support that opinion. It is disappointing that you are unable to answer that opinion with science, but instead resort to ad hominem attacks (“pharma magnate” and “narcissist psychopath”) and legal threats. Very disappointing, indeed.
David
P.S. My publication record might not be awe-inspiring (as in hundreds of publications), but it is not insubstantial, either:
http://www.ncbi.nlm.nih.gov/pubmed/?term=gorski-dh
I note that I’m perfectly fine with Dr. Arguello posting links to his letters on his website as a rebuttal to my criticisms. I am fine with the free exchange of ideas, even harsh criticism of what I write. I would, however, caution Dr. Arguello. If he’s going to be thinking about suing for libel, he might want to be careful about what he retains in those letters. Calling me a narcissistic psychopath on his website could be considered libelous.
ADDENDUM #4:
Here is another e-mail from Dr. Arguello dated 8/19/2014 4:26 PM EDT:
Dr. Gorski,
For historical reasons, I have been replying in detail and respectfully to your defamatory statements in your original piece posted in your website. I really find it difficult to discuss the science and treatment of cancer with you, because I believe you do not understand the biology of cancer, but also you have the mentality of those inside the box. You never think outside the box, and cannot conceive concepts that are outside the box, and therefore alien to you.
(1) Your Old Thinking: You want to judge my work with YOUR way of thinking. The treatment and cure of cancer will be accomplished with a new scientific way of thinking and with drugs you have not conceived (outside the box), otherwise you or others would have found a cure for cancer decades ago.
Question: If one day we find a way to cure cancer medically (with medicines), do you think it will be with the same thinking and drugs we have been using for 70 years in the case of chemotherapy, or 100 years with radiation? Or will it be with a different way of thinking and drugs?
All the work that you and others are doing is totally useless and it has been useless for decades. All the genetic and metabolic abnormalities found in cancer cells are not the cause of cancer, they are a CONSEQUENCE of cancer (of atavistic transformation).
(2) Your Interpretation of Clinical Trials: It is very easy for you to throw around the word “clinical trials,” not only because you do not understand what a clinical trial conveys, but also because you don’t understand that the new science and correct treatment of cancer. Clinical trials, as you conceive them, are the result of our stupidity regarding study cancer treatments for the last 70 years. I already told you that my clinical proposal and consent form were reviewed and approved by the ethical committee of the hospital where it was initiated. These are called “Proof-of-Concept” study.
Eventually, clinical studies will be carried out, once the therapy is established as such. I already told you, this is an individualized therapy, and evolving therapy consisting of many drugs, and can only be compared with the natural course of the disease. The trial is does it prolog the life of this person when compared with no treatment at all based on historical controls? Current clinical trials are based on responses on the size of tumor or survival time as compared to other past intoxications. Ignoring that people could live longer and better without those treatments.
When Ether came into clinical use by Morton in the late 1840s (now we have ANESTHESIA), he did not conduct clinical trials to compare ether with the old method of intoxicating the patient with whiskey to see which was better.
When Lister introduced the use of carbolic acid in the 1880s for the prevention of infections of surgical wounds or injuries of war, and created ANTISEPSIA, he did not conduct clinical trials to compare carbolic acid with boiling oil applied to wounds as used to be done at that time.
When Sulfonamides and Penicillin were introduced in the late 1930 and early 1940s to treat infected wounds or systemic infections during war, they did not compare them with arsenic or mercury used before those discoveries. These moves created ANTIBIOTIC CHEMOTHERAPY.
ATAVISTIC CHEMOTHERAPY AND IMMUNOTHERAPY cannot be compared with conventional chemotherapy and radiation used today (equivalent to alcohol, boiling oil, and mercury mentioned above). It can only be compared with the natural history of the disease as such. I already told you that conventional chemotherapy and radiation appear to offer less survival time to patients with cancer as compared with the natural history of the disease. We have enough historical controls to prove that.
(3) Defamation (Slander and Libel): If you express your scientific or vernacular opinions on DCA, marijuana, ketogenic diets, the ugliness of frogs at night, the existence of ghosts, etc., there are no legal consequences for that in the country in which I am a citizen (USA), and the countries you specifically mentioned in your internet piece (Canada and Mexico).
But when you name a person, a business, a product, brand, a service, etc., you are entering a new terrain protected by laws in each country, and international laws. Although some journalists may be immune to them, because of lawful reasons, you are not. If your comments are made publicly (verbally or written), for example, that Justin Bieber is selfish and rude, and he should go back to Canada, there may be no consequence for that either. But if you express publicly (verbally or written) that Justin Bieber does not sing, but howls, and he should not be hired to sing at any event, then you will pay the consequences of that. Whether you are right or not about his singing, that is your personal opinion. You are potentially ruining his career, reputation, credibility, work, and the financial compensation of his work as a singer. In the case of Bieber, that could cost you millions for libel/defamation for damages in his countries of work.
When you publicly state in an international venue, such as the internet, that “Dr. Arguello’s treatment is dubious and it should be avoided,” that will cost you, too. Perhaps not millions as in the case of Bieber, but enough to compensate me for the potential damage caused to my practice now and in the future not only regarding my ability to make money, but for exposing me to hatred, contempt and ridicule.
Now, because you dislike Justin Bieber, you are not free to slander and advocate that he should not be hired. In the USA, Canada and Mexico we have “defamatory libel” and “blasphemous/malicious libel.” In Canada, both are crimes punishable by a maximum term of two years in prison. In the specific case of a “libel known to be false,” the prison term increases to a maximum of five years. A defamatory libel “is matter published, without lawful justification or excuse, that is likely to injure the reputation of any person by exposing him to hatred, contempt or ridicule, or that is designed to insult the person of or concerning whom it is published.” I am not interested in jail time, but in the economic damage I am already experiencing because of your posting.
I personally believe that all alternative and conventional cancer treatments are in their great majority scams to make money. Conventional chemotherapy is in reality an elegant scam to make money, too, by the industries that benefit from this commerce. Nobody is cured and their lifespans likely reduced. Eventually I will prove and publish this. There is no need to name people, but mistaken philosophies.
I had a short conversation with my lawyer concerning this matter, and it appears that you have been crossing the line and targeting people by name. I am wondering if I should join forces with others as a class suit, or do it alone. The question is how much can we get from you and your cronies?
(4) Final Thoughts: Please do not say that I am threatening you with legal action. I am not threatening; I am telling you what I am going to do. I am just tired of discussing this in a mature way with you. I personally feel you are a narcissist and sociopath, who does not help in the problem of cancer, but tries to perpetuate it. You are not qualified to judge this type of work. The real and sad part of this is this:
YOU DO NOT CARE ABOUT CANCER TREATMENTS AS SUCH; YOU DO NOT CARE ABOUT CANCER PATIENTS AND THEIR SUFFERING. YOU ONLY CARE ABOUT DAVID’S IDEAS AND OPINIONS ON HIS WEBSITE.
YOU DO NOT UNDERSTAND what is to do what I do, the great personal and economic sacrifices I have made to create a potential venue to help people with cancer. This is aside from sharing with them and their families their anxieties, uncertainties, pain, losses and sorrows. As the saying goes, “If you’re not part of the solution, you’re part of the problem.”
You need to provide solutions or get out of the way.
Frank
P.S. I know that these e-mails will become public someday, from there that I have not been using my French on you. Suffice to say that I am fluent in French when someone interferes, for no reason, in this important work. This is aside of slandering me.
—Frank Arguello, MDAtavistic Oncology Clinicwww.AtavisticChemotherapy.comFormer Assistant Professor of Oncology,and Pediatrics, Hematology and Oncology,University of Rochester School of Medicine and Dentistry.Rochester, New York USA.Former Senior Scientist,Division of Cancer Treatment & Diagnosis,National Cancer Institute, National Institutes of Health. Frederick, Maryland USA.
I do not see the point of responding further to Dr. Arguello other than to say that from now on I will be posting any threatening e-mails he sends me as additional addendums to this post and to say that Dr. Arguello apparently does not understand the First Amendment, free speech, and the difference between opinion and libel, not to mention the difference between criticizing his treatment and the lack of evidence for it compared to attacking him personally.
ADDENDUM #6:
Dr. Arguello complains to my place of work in an e-mail dated 8/20/2014 5:05 PM EDT:
Dear Drs. Weaver, Steffes and Yoo,
Respectfully, would like to call your attention to a number of disturbing experiences I have been subjected to by one of your staff members in your department of surgery, Dr. David Gorski.
I am a well-educated and respected oncologist-scientist, with academic trajectories at the University of Connecticut Health Center, The University of Rochester School of Medicine and Dentistry and its James P. Wilmot Cancer Center, where I was a James P. Wilmot Fellow for three years, and later Assistant Professor of Oncology, and Pediatric Hematology Oncology. Later, I joined the Department of Cancer Treatment and Diagnosis of the National Cancer Institute, National Institutes of Health. Few, but meaningful publications on the mechanisms of metastatic spread, skeletal metastases, spinal cord compression from vertebral metastases, as well as the trial of several experimental drugs resulted from that work: (www.atavisticchemotherapy.com//content/dr_frank_arguello_cv)
In my efforts to find a better way to understand and treat cancer, and after a year of reviewing the medical literature of other biological explanations as to the malignant behavior of cancer cells, I became aware of an old concept that originated with the father of pathology, Rudolf Virchow, in 1888. This concept has been brought into light several times over the last 100 years, but has not been pursued. I collected all this information and published a book entitled “Atavistic Metamorphosis: A New and Logical Explanation for the Origin and Biological Nature of Cancer Cells.” (Amazon.com). Briefly, this is a concept based on the evolution of life (cells) on this planet, which explains cancer as a de-evolution, a reversion of a differentiated cell to its ancestral, primitive, undifferentiated unicellular form from which all multicellular organisms originated from. The re-expression of ancient genes in a cell or organism is known in biology as “Atavism” (from Latin Atavus, ancestor or grandfather).
In 2011, I obtained approval from the Ethical Board Committee of a University Hospital in Torreon, Mexico to conduct a clinical trial to evaluate what I called “Atavistic Chemotherapy” on hopeless cancer patients. Torreon is my city of birth, although I have been living in the USA for almost 30 years; one of my brothers practices medicine there after receiving medical training in London.
The treatment consists of a combination of FDA-approved cytostatic and cytocidal drugs known to be effective against primitive unicellular organisms (protozoa, fungi and bacteria cells). Although the therapy is still evolving, the results in hopeless cancer patients are so compelling that speak for themselves. I invite you to see a partial gallery of clinical cases depicting images of cancers before and during treatment at: www.atavisticchemotherapy.com PLEASE NOTE: the results you will see in the sequence of images depicted in each case are without the use of conventional “anticancer drugs.”
Dr. Gorsik’s harassing stated when I prepared two conferences on this new interpretation and treatment of cancer in Saskatchewan, Canada. Soon after, I received a letter from Saskatchewan College of Physicians and Surgeons that Dr. Gorski had contacted them to warn them that I was not licensed to practice medicine in Saskatchewan. I have given presentations in the past at McGill University Department of Surgery in Montreal, where the head of the Sarcoma Team, Dr. Robert Turcotte, knows my work. I also co-authored, years ago, a book with Dr. William Orr, Head of Pathology at McMaster University in Hamilton, Ontario. So, Dr. Gorski was ignored once they learned about my qualifications.
Days later, Dr. Gorski posted online a number of defamatory statements about me, the atavistic nature of cancer cells which has been published by others before, and my treatment approach. Link:
www.sciencebasedmedicine.org/dr-frank-arguellos-atavistic-oncology-another-dubious-cancer-therapy-to-be-avoided/#begincomments
He believes that his website is a Medical Journal and that he is the Editor, but in reality this is just an unsophisticated venue for him to insult people and release his frustrations as a failed cancer researcher, because he does not have any ideas of his own. If he has some ideas on cancer or opposes the views of others for a better one, or if he has something to say against the science of atavistic oncology, my views or that of others published over the years starting with Virchow, he should do it through the existing venues we have as professional physicians to express our opinions, results, etc. – Medical Journals. But not by slandering people via a website.
I have contacted a law firm in Ohio which specializes in libel and slander via the internet. I just wanted to let you know that since he uses his affiliation with Wayne School of Medicine to boost his credibility, you could be also named in that suit. I perfectly understand that you do not support or review his writing on his website, but it is impossible for a lawyer not to see the direct connection between his defamatory work on that website and you in the same line of work.
Respectfully,
Frank Arguello, MDAtavistic Oncology Clinicwww.AtavisticChemotherapy.comFormer Assistant Professor of Oncology,and Pediatrics, Hematology and Oncology,University of Rochester School of Medicine and Dentistry.Rochester, New York USA.Former Senior Scientist,Division of Cancer Treatment & Diagnosis,National Cancer Institute, National Institutes of Health.Frederick, Maryland USA.
Note that Dr. Weaver is my departmental chair; Dr. Yoo is the chief medical officer at my hospital; and Dr. Steffes hasn’t worked at our hospital for four or five years.
ADDENDUM #5:
And the beat goes on, with another e-mail dated 8/21/2014 5:08 PM EDT:
Dr. Gorski,
I am kindly ask you to remove all your online postings regarding me and my work. The lawyer who is investigating this case has identified several reproductions in other websites that end with .org and suspect associated to you. He told me the names by phone, but I only remember the .org.
I am ready to send an e-mail to the Dean Dr. Parisi, and a large list of deans of your school. But I wanted to give you the opportunity to assure me you will remove that. I do not want to embarrass you more than you have embarrassed me, but I will have no mercy on you until you remove those defamatory statements. If I can recover money for damage I will certainly will do that if you persist.
If you want to talk about that subject of atavistic oncology, submit your paper to a peer-review medical journal.
Frank
—Frank Arguello, MDAtavistic Oncology Clinicwww.AtavisticChemotherapy.comFormer Assistant Professor of Oncology,and Pediatrics, Hematology and Oncology,University of Rochester School of Medicine and Dentistry.Rochester, New York USA.Former Senior Scientist,Division of Cancer Treatment & Diagnosis,National Cancer Institute, National Institutes of Health. Frederick, Maryland USA.
You know. I was worried before, but now I’m almost starting to feel sorry for this guy.

“Alternative” cancer cures in 1979: How little things have changed
When it comes to quackery, the decades and names change, but the song remains the same, as it has since the era of disco and earlier.
David Gorski on April 29, 2013
Link
Sometimes blogging topics arise from the strangest places. It’s true. For instance, although references to how tobacco causes cancer and the decades long denialist campaign by tobacco companies are not infrequently referenced in my blogging (particularly from supporters of highly dubious studies alleging a link between cell phone radiation and cancer and the ham-handed misuse of the analogy by antivaccinationists, who seem to think that vaccine companies engage in deceit on a scale similar to the deceptive practices of tobacco companies in “denying” that vaccines cause autism and all the other conditions, diseases, and horrors their fevered imaginations attribute to them), I’ve never really delved particularly deeply into one of the most useful repositories of documents on the topic that exists, namely the UCSF Legacy Tobacco Documents Library. Actually, the reason I started poking around there is not due to tobacco science, but because a fellow blogger mentioned to me that there were some articles and documents about Stanislaw Burzynski there dating back to the late 1970s. My curiosity was piqued.
As I explored, however, I learned that the documents there were not so much about Stanislaw Burzynski per se. In fact, they were more about the state of the underground “alternative cancer cures” industry in the late 1970s, which interested me greatly. The reason is that, when it comes to having delved so deeply into cancer quackery, I’m a relative newbie. Compared to, for example, Wally Sampson, Stephen Barrett, Peter Moran, or even Kimball Atwood, I’m inexperienced, having only noticed this phenomenon in a big way in the Usenet newsgroup misc.health.alternative back around 2001 or so, give or take a year. As a result, I don’t have the shared historical perspective that they do, mainly because I can only learn about that era from reading, studying, and talking to people who were active then. After all, in the late 1970s I was still in high school, and in the 1980s I was in college and medical school. There was no Internet (at least none that I had access to and that contained the wealth of easily accessible information to which we have become accustomed). In any case, in high school I had other interests, and throughout the 1980s I was too focused on getting an education and training to be a surgeon and researcher, a process that extended into the late 1990s. (Yes, it takes that long sometimes, particularly if you are masochistic enough to want to get a PhD, complete a general surgery residency, and do a fellowship in surgical oncology.)
The articles I came across were actually from a rather surprising source: Penthouse magazine. I suppose that, in retrospect, I should not be quite so surprised. Penthouse publisher Bob Guccione was apparently always into dubious cancer cures, later in 1995 having achieved some notoriety by promoting claims that hydrazine sulfate had cured his wife Kathy Keeton of metastatic breast cancer. Ultimately Keeton did go on to die of complications of surgery for upper intestinal obstruction, which sounds as though it was probably due to a recurrence of her cancer. Before her death, Keeton was a journalist and co-founder of Omni and Longevity magazines, the former of which, I’m ashamed to admit, I used to read rather frequently. In any case, she appears to have been a person who survived longer than expected while being treated with conventional therapy (Tamoxifen) and hydrazine sulfate, surviving two years after her diagnosis, which is certainly not outside the expected survival time for metastatic breast cancer in the 1990s, particularly if it was estrogen-receptor positive.
Be that as it may, back in the fall of 1979 I was in high school, and if I got my hands on a copy of Penthouse magazine, you can be sure that I probably wasn’t interested in the articles, with the possible exception of the Penthouse Forum. (What can I say? I was a typical teen in the late 1970s.) In any case, back at that time I would also never have heard of one of the co-authors of this trilogy of articles, namely Gary Null, who is still at it more than 33 years later. The articles appeared in the following issues of Penthouse (click on the cover to go to the direct link to scanned PDF of the article from the UCSF Legacy Tobacco Documents Library (fear not—what’s on the covers is tamer than what you can find in a typical Sports Illustrated swimsuit issue; it’s another way that times have changed over the last 33 years):
The Song Remains the Same, although the names do change
The first article in the trilogy, The Great Cancer Fraud by Gary Null and Robert Houston, is as good a place to start as any. It’s the longest of the three and the most comprehensive (if you can call it that) broadside against conventional cancer care that Gary Null can apparently muster. If you leave out a couple of the quackeries that I had never heard of, it’s also completely, utterly, and depressingly familiar to me, so much so that all Null would have to do would be to change some dates, update some figures, and add a couple of newer cancer quackeries, and it could very easily be published today on Null’s website, NaturalNews.com, or Whale.to. If you want evidence that the arguments made by promoters of “alternative cancer cures” are all variations on the same theme, a theme unchanged for decades, you really do need to read this article. It’s also amusing to look at the one ad left in for adult movies offering five Marilyn Chambers hardcore videos on sale for $366, marked down from $525. Who remembered porn was so expensive back in 1979? I just hope people who paid that much didn’t buy the Beta version. Oh, the horror of obsolescence!
But I digress. Sorry about that. I’m like Dug the Dog sometimes, and you never know what sort of thing will affect me like the word “squirrel” affected Dug.
Regular readers of SBM will likely find this article as utterly familiar as I did, with the possible exception of the last section of the article being taken up by touting Laetrile, which is rarely mentioned in SBM because in 2013 even cancer quacks don’t promote it much anymore, because even they seem to have accepted that it doesn’t work and can have nasty side effect of cyanide toxicity. (Whoops! Maybe I spoke too soon.) Indeed, if you read the Quackwatch article on Laetrile and compare it with the version of Laetrile discussed in Null’s article, you’ll wonder if the two are even on the same planet. Probably not. Either way, truly The Great Cancer Fraud is a blast from the past, except that when it was published, Gary Null was a young quackery supporter just building his reputation, and Laetrile was actually new news, having gained some traction in legislation thanks to the efforts of an incipient “health freedom” movement. (Remember, after all, that 1979 was the year that Led Zeppelin released its last album, In Through the Out Door, and The Cars released their second album, Candy-O.) Still, it’s worthwhile to look at some of the arguments and one or two of the “alternative cancer cures” that I hadn’t heard of.
Null began, as is his wont, by discussing what he saw as the skyrocketing incidence of cancer, which at the time was estimated to affect one in four people, meanwhile trotting out what are now tried-and-not-so-true gambits, lamenting the “failure” of the war on cancer (which was not even eight years old when this article was published), ranting about the “suppression” of real cures, and insinuating all sorts of dire conspiracies of the medical establishment and the media, which, to him, were all in collusion, along with the government to push only the “cut-poison-burn” approach to cancer. Actually, according to Null, the combination included the National Cancer Institute, the American Medical Association, “powerful chemical and drug industries,” the American Cancer Society, the Food and Drug Administration, and “many science writers who work for the national media.” This latter part of the conspiracy is particularly interesting to me, because my fellow bloggers and I have often lamented the fall of science writers and science/medical reporters in the “traditional” media. Remember that back then there was no Internet (at least the Internet at the time was restricted to relatively few academic, industrial, and military institutions), and there was no World Wide Web. Nor were there blogs and Twitter and Facebook. Science writers and science journalists were it for disseminating reliable scientific information to the masses in a form that people without scientific training could understand. No wonder Eric Merola, in his propaganda movie for Stanislaw Burzynski, so viciously goes after skeptical bloggers. He’s only doing exactly what Gary Null did 33 years ago when he attacked science and medical writers. As science journalism declined, science and medical blogging rushed in to fill the void as best as it could. So now we’re the new targets of people like Gary Null.
In fact, Null accused the American Cancer Society of, in essence, training journalists:
Let us look at how the cancer establishment influences these reporters — and then see how the reporters go into action to quash new cancer treatments.
The action begins every spring, when the American Cancer Society, one of the largest “charitable” organizations in the world, holds its national Science Writers’ Seminar at a resort locale. Here, selected health reporters from the leading media are soireed and surfeited in poolside luxury — a luxury that bespeaks the $126 million the ACS raised last year from the public — and slipped rah-rah cancer progress stories from acceptable researchers. The American Cancer Society seminars are essentially the spring fashion shows of cancer research, letting health and science reporters know where the big money’s going — although in actuality the expense has yielded almost complete failure at reducing the overall mortality level. There is always a “breakthrough” or two announced, and this right around contribution time, which nearly and coincidentally dovetails with the science writers’ conference.
Who knew the American Cancer Society was so powerful? Who knew it indoctrinated generations of health and science writers like that? What horrible things and dark secrets did the ACS inculcate into the science writers of the 1970s at these conferences? Well, it turns out that the UCSF archive actually has a summary of one of these seminars, the one held in 1975. Let’s take a look. According to the document, the seminar consists of daily morning and afternoon sessions in which noted cancer scientists give presentations followed by Q&A sessions, along with a general discussion after the end of each session. In 1975, there were sessions on genetics, the meaning of “high risk” when it comes to cancer, viruses in cancer (a hot topic even back in the 1970s), immunotherapy, hormones and breast cancer, and treatment advances in cancer. It all sounds so mundane and science-based. Of course, that’s the problem to someone like Null. Teaching journalists the latest in the science of cancer is generally considered a good thing, because journalists with a solid understanding of what they are reporting are more likely to get the science right, which is exactly what Null didn’t want and doesn’t want to this day. To him, it was all a conspiracy to indoctrinate science writers. Elsewhere in the article, Null lauds the rise of “self help” groups and writers as an antidote to that, the same way quacks laud the rise of alt-med bloggers today.
The more things change…
Does ACS still hold its Science Writers’ Seminar? I could see that the ACS was still doing them at least into the late 1990s, but I couldn’t find much after that. Maybe the ACS should resurrect the seminar series and include bloggers as well.
Null also touted a bunch of the usual quackery, such as the Gerson therapy, which is nonsense. One thing that piqued my interest was a treatment called Koch’s Glyoxylide. The reason that this caught my attention was the local connection. Dr. William F. Koch was a Detroit physician, and Null was particularly incensed at how the Wayne County Medical Society wrote a report in 1923 condemning Glyoxylide as worthless:
Koch’s work was judged and condemned to be worthless by the “Cancer Committee” of the Wayne County Medical Society in 1923 — a committee made up for the most part of surgeons and radium or X-ray “experts,” a class of people that assumed cancer to be curable only by these methods. As a result, both Koch and his cancer treatment were suppressed, and the oppression extended to the other doctors who attempted to use his methods in any kind of test.
Good going, Wayne County Medical Society! It apparently correctly identified the issue with glyoxylide, namely that it probably didn’t exist as a chemical and that his methods didn’t appear to do anything for cancer. The story of glyoxylide is actually rather fascinating, and perhaps I’ll revisit it sometime. For now, however, it suffices (to me at least) to say that it doesn’t work.
In that, glyoxylide was a lot like Lincoln’s Bacteriophage Method, which was promoted by Dr. Robert E. Lincoln:
Lincoln identified bacterial strains as contributing factors in hundreds of perplexing disease symptoms plaguing the human body, symptoms ranging from tiredness to leg cramps to mental depression to the common cold — and, ultimately, to cancer. In the late forties, Lincoln isolated two such strains of pathogens and with various diseases achieved a successful cure rate by using certain viruses (bacteriophages) against them. One cured cancer patient was the son of Sen. Charles Tobey, who spread the word about Lincoln’s therapy.
In 1952, after Lincoln was expelled from the Massachusetts Medical Society, Senator Tobey became so incensed that he presented the particulars to Congress: (1) in 1946 the Journal of the American Medical Association rejected Lincoln’s paper on clinical results with his ‘antibiotics”; (2) in 1948 the same paper was rejected by the New England Journal of Medicine; (3) in 1948 the director of a large Boston hospital was “unable to find the time” to review Lincoln’s work, after being invited to do so; and (4) Lincoln’s requests for assistance in publication were ignored by science editors.
So basically, Lincoln used bacteriophages (viruses that attack bacteria that today are commonly used to genetically engineer bacteria) to lyse Staphylococcus aureus. These lysates were either injected subcutaneously, applied intranasally, or administered orally or applied topically. The claim was that these lysates would somehow boost the “defensive mechanisms” of the body, particularly if “ubiquitous staph infection is a complication.” Unfortunately, the investigation of the Massachusetts Medical Society was quite thorough and concluded that there was no scientifically valid or convincing evidence presented that the phage lysates impacted the biology of cancer in any way. No wonder Null liked it.
Of course, the greatest evidence that the ACS was “suppressing” alternative “cancer cures” to Null was the existence of something that I really wish were still in existence today: The ACS list of unproven methods:
The unproven-methods list is in effect a blacklist of remedies that include some of the most promising methods for the control of cancer in the world today, among them many dietary and nutritional programs. Once a treatment gets on the list, it becomes virtually impossible for any of its proponents to continue their research. Grants dry up; doors to publications are closed. The unproven-methods list can be compared to the index of heresy in the Catholic Church in medieval times. It is a fast and efficient way of dealing with new remedies without the fuss and bother of “trials.”
Yes, indeed. Some tropes have been around forever, seemingly, and that applies to the “science is a religion” trope that is trotted out whenever professional societies try to uphold scientific standards against quackery. In fact, these days, the ACS appears not to maintain the dreaded list anymore and even has a “complementary and alternative medicine” section on its website. Maybe it’s a good idea not to segregate treatments into an entire category for “unproven” therapies and just list them in another way but say the same thing about therapies that are, in fact, unproven. I don’t know. But Null sure didn’t like it; so it couldn’t have been all bad.
Stanislaw Burzynski: The Early Years
Part II of the Null trilogy was written by Gary Null only and entitled The Suppression of Cancer Cures, lest you have any misconception where Null is coming from. Although other “brave maverick doctors” were mentioned in it, the article was primarily about Stanislaw Burzynski. In a way, I like to call this article, which is the shortest of the bunch, “Burzynski: The Early Years.” Although at the time the article was published Burzynski had isolated antineoplastons from urine, he hadn’t yet found a way to chemically synthesize them, mainly (apparently) because he hadn’t fully chemically characterized them yet. This meant that he actually was isolating them from gallons and gallons of human urine, all in order to do his experiments and, unfortunately, treat patients, which led to a hilarious analogy from Null:
Although antineoplastons are found in all normal body tissues and fluids, they are most easily extracted from urine. They appear to “normalize” cancer cells without inhibiting the growth of normal cells. Actually, urine therapy has been used as a folk remedy for cancer and other ailments for over 2,000 years. Even within the past 30 years, at least 45.000 injections of urine or urine extract were given in the United States and throughout Europe without any toxic side effects.
I’m guessing that Dr. Burzynski wasn’t too thrilled with that passage. To this day, he gets pretty irate when people refer to antineoplastons as coming from urine, being quick to correct them and tell them that he synthesizes them in a laboratory now. For an example, scroll down to question #3 in Eric Merola’s FAQ about Burzynski and Merola’s movie.
The real point of this article, however, is here:
The list of scientists who have been harassed includes names like Durovic, Ivy, Koch, Lincoln, Gerson—names that are, probably unknown to most people. But they can be compared with such innovators in science as Galileo, Pasteur, Semmelweis, and Jenner, all of whom were practically destroyed in their time by various powerful organizations, such as the Church and the medical establishment.
Today this kind of suppression is reserved not for astronomy, ecology, antisepsis, or vaccinations, but for the most steadily increasing and least understood disease of our time—cancer. The suppression of valuable treatments is the cancer blackout.
And so begins the narrative about Stanislaw Burzynski supposedly having a cure for cancer (or at least some cancers) that is being “suppressed” by mainstream oncology because…well, it’s never quite clear why: Because it interferes with profits; because it’s against the dogma of the time; because doctors and scientists apparently just can’t stand something that’s outside of the mainstream. The reasons why mainstream oncology would want to suppress these alleged cures are ever-morphing, seemingly into endless variants, depending upon the needs of the myth builder of the time spinning the yarn of a Great Man (or Woman) whose work is unappreciated by mere peons, who are either too unimaginative to understand or too threatened by the work ever to accept it. When you come right down to it, it’s not unlike Ayn Rand, and, in fact, reading this article by Null about Burzynski I couldn’t help but shake the image of Hank Rearden in Atlas Shrugged, a man who invented Rearden Metal, the best alloy in the world, and as a result had his competitors plotting against him and spreading lies about its danger. Or maybe he’s John Galt. Whatever. There is the attitude that somehow Stanislaw Burzynski is a Great Man being persecuted by fleas who fear his genius and want to mooch off of it. Null plays up this narrative.
For instance, Burzynski left Communist Poland in the late 1960s, as so many young Polish scientists did. The reason, it is implied, was because he was so much better than that, although it’s not particularly surprising that a man with few opportunities to pursue his dreams in Soviet-controlled Poland would yearn for the freedom of the West. In any case, Burzynski arrived in Houston and secured a job as a Research Associate at the Baylor College of Medicine, which is higher than a technician but not usually a faculty position. Generally, it’s the sort of position that PhDs who are either ineligible for a postdoctoral position or don’t qualify for a tenure-track position take doing research in someone else’s laboratory. He then managed to score an assistant professor position at Baylor, which is good. Clearly, he showed enough promise to compete for and obtain the position. He was even funded by the NCI from 1974 to 1977. According to this article, Burzynski got an NCI grant from 1974 to 1976 to fund his research involving gel filtration techniques to isolate peptides from urine and for testing their ability to inhibit in vitro growth of several types of cultured human cells. Ironically, as Null quotes Burzynski as saying, the NCI actually did fund Burzynski’s discovery of antineoplastons to some extent.
Unfortunately, when Burzynski applied to renew his grant in 1976, he apparently failed, although his funding continued until 1977. Not so coincidentally (to me, at least) 1977 was also the year that Burzynski left Baylor to form his own research institute. I can probably guess what happened. He failed to renew his grant; so he was probably told he would have to shut down his lab and either start seeing patients full time to support his position or find a job in someone else’s lab. Given that he had been there for five years, a common time after which medical researchers go up for tenure, he might have even failed to win tenure and been told to find another position. Whatever happened at Baylor, combine his failure to renew his grant with his being faculty in the Department of Anesthesiology, and what happened next doesn’t seem quite as conspiratorial as Null makes it sound:
Dr. Burzynski presented his startling results to the annual meeting of the Federation of the American Societies for Experimental Biology. When he met with enthusiastic responses, he knew then that it was time to begin human research.
However, soon after this Dr. Burzynski’s funding was decreased: then it was discontinued. His work was channeled into other areas of research, and his superiors discouraged his pursuit of cancer therapy. He couldn’t know at this time that this was only the beginning of his long battle with the medical establishment. Determined to continue, Dr. Burzynski struck out on his own and leased a 2,500-square-foot garage space in Houston, which he turned into an impressive private lab and office despite warnings that the medical establishment would challenge his activities.
Or, it could have been that Burzynski failed to renew his grant, and his Chair, being a Chair of a department of anesthesia and all, didn’t see the point in his continuing to do cancer research, which is more appropriately carried out in an oncology department, biochemistry department, or pharmacology department. Somehow, I doubt that there was any sort of grand conspiracy by The Man to keep Burzynski down. Whatever happened at Baylor, clearly there was some sort of a falling-out between Burzynski and the administration of the department of anesthesia, whether it was from his lack of grant funding or other conflicts. However, Burzynski used what happened to his advantage to construct the myth of the Great Man whose vision forced him to leave to pursue his scientific dream. Perhaps there was a grain of truth to that at the time he left, but over time in retrospect, now that we know what happened and how Burzynski turned out, it’s harder for an objective observer to accept that narrative. After all, why would a department of anesthesia support cancer chemotherapy research—which, let’s face it, Burzynski was doing—particularly if the investigator was losing his NIH funding? My guess, which could be wrong, is that Burzynski chewed through his startup funds between 1972 and 1974, parlaying them into an NIH grant, but was unable to keep the momentum going and renew that grant. Probably his department put up with him because he had achieved NIH funding and every department in a medical school loves an investigator with NIH funding, but was less enthusiastic about it when he lost that funding. In any case, the 1970s were a critical period in the development of the myth that is Burzynski. I’d love to know what really happened in the years leading up to 1977 that led to his leaving Baylor. All we get now are stories designed to make Burzynski look like a “brave maverick doctor” and a scientist on par with Galileo.
That myth-making and legend-building clearly had begun before Null wrote his article, the rest of which follows a script that was new back in 1979 but has become old and tiresome now. Any time anyone or any professional organization investigates Burzynski for unethical conduct, in this case administering his antineoplastons to patients even though (1) they were not approved drugs, (2) he hadn’t done any tests in animal tumor models yet, and (3) he wasn’t doing proper clinical trials, all of which were indications for an investigation, it couldn’t possibly have been because there were legitimate concerns about his activities. Oh, no. To Burzynski and his supporters like Null, it was (and still is) because the medical establishment was closing ranks to suppress a promising new cancer therapy.
Let’s compare and contrast to my situation. (Why not?) When I fail to get a grant or to renew one that I’ve had before, I view it as being because funding has tightened up (which it has), making what was good enough a few years ago no longer good enough, and/or because that time around I just didn’t do a good enough job convincing the reviewers. In other words, I view failure to be funded as being either my failing and/or due to circumstances not directed at me personally (e.g., the really crappy NIH funding situation right now). That wasn’t, however, how Burzynski thought. If he didn’t get a grant, it was obviously because the NCI was plotting against him. If his department discouraged him from pursuing antineoplaston research, it couldn’t possibly have been because Burzynski was losing his NIH funding and was not doing the sort of research that a department of anesthesia would generally take an interest in. Oh, no. It had to be because his department was trying to suppress his work as well, possibly because the government was putting pressure on it. When the AACR doesn’t accept my abstract for its annual meeting, I don’t blame the AACR; I ask myself what I could have done better and try again. Not Burzynski. If his abstract wasn’t accepted, it must have been part of a conspiracy by the “cancer establishment” to suppress his work, just as when Eric Merola recently related the story of Burzynski’s recent attempt to publish in The Lancet being rejected rapidly he not-so-subtly suggested that it must be either groupthink or a conspiracy among journal editors.
In this, Eric Merola is following a well-established script that was developed 30 years before his first movie. His “innovation” (if you can call it that) is to add The Skeptics™ as a new enemy keeping The Great Man down and trying to keep cancer patients from being cured of their cancers.
Plus ça change, plus c’est la même chose
The third installment of Gary Null’s 1979 trilogy of woo was co-written by Anne Pitrone and entitled Alternative Cancer Therapies. It was basically a tour of cancer quackery, circa 1979, combined with—you guessed it!—more conspiracy mongering about suppression of cancer cures and a lot of excuses, such as this:
Many of the clinics where we interviewed are understaffed or don’t have the funds to do important statistical analysis and follow-up of patients that would provide the general public, as well as the scientific community, with some idea of the results they’re getting. Many are so new that the statistics have limited meaning. Records of patient response are sometimes sketchy because of the nature of the treatment, which often involves the patient’s taking responsibility for a complete change of life-style as well as self-medication. Sometimes it is impossible for these clinics and doctors to get proper testing and/or cooperation with the medical community, although this has been changing dramatically as more positive research to support the alternative therapies has been discovered.
Part of the problem in analyzing statistics is that there is no single standard for measuring “positive results” in cancer. For example, when a doctor says he’s getting good results, does it mean that he’s getting objective (measurable) responses, such as tumor stabilization or regression? Or does he mean that he is getting subjective improvements, such as increased appetite, elimination of cachexia (wasting away), overall well-being, or elimination of pain? For some doctors “positive results” means simply that the patient dies in one month rather than in two weeks.
Regrettably, there is an element of vagueness in today’s alternative-therapy network not only because of the nature of the disease (cancer is not limited to one type, organ, or system) and the nature of the treatment (which is often self-administered), but also because there is a lack of long-term statistical observation. There are few doctors that have been able to keep statistically thorough records over a five- or ten-year period. Most clinics have at least some strong subjective results to report.
Null even conceded that, because of this lack of outcomes data, it would be “unwise” to “throw out conventional therapy altogether.”
More than 33 years later, nothing has changed. The same three self-excusing paragraphs could be written by Gary Null, Joe Mercola, Mike Adams, Julian Whitaker, Suzanne Somers, or any of the many apologists for and promoters of “alternative cancer cures” and published in a book or on a website today. Basically, there is no statistical evidence, because alternative cancer clinics are not about rigorous science and tracking of patient outcomes. They are about belief, standing against conventional cancer therapy, and magical thinking.
After that passage laying the groundwork for excuses as to why “alternative cancer clinics” can’t prove that what they do actually helps cancer patients or could do any better than what “conventional” cancer therapy could do at the time, Null then took Penthouse readers on a tour of cancer quackery: Gerson therapy, Linus Pauling’s high dose vitamin C, other high dose vitamin regimens, chelation therapy (yes, chelation therapy for cancer) and, of course Laetrile. The sad thing is, most of these treatments (if you can call them that) are still around and still being used by quacks, just in different combinations. For instance, I could easily find clinics for which a description like this would still apply:
“The main problem is that people wait until it’s too late, and then they want to take Laetrile and expect it to be a miracle for them,” said Dr. Robert Gibson of Ponca City, Okla. Basically using Laetrile in conjunction with a salt-free, high-fiber, and high-vegetable diet very similar to Dr. Gerson’s, Dr. Gibson also makes use of vitamins A, C, and E and enzymes. Formerly involved in a large general practice, Dr. Gibson has treated more than 2,000 cancer patients over the last three years, many of whom have “waited too long.” “For the very ill,” said Dr. Gibson, “we can relieve the pain with Laetrile and the diet and many times extend their lives beyond the expected survival; actually, the use of Laetrile is a little bit unpredictable. But if the medication does work, we’ve been getting very good responses with many different tumors. And with those patients that are in better shape than ‘terminal’ over the past three years, I’d say we’ve been getting about sixty-eight percent positive results.” Dr. Gibson points out that this is not really an adequate statistic, since most data on recovery require a “five-year survival time.”
Ah, yes. The old “If only the patient hadn’t waited too long to come to me” gambit.
Just for the heck of it, I tried to see how many of the clinics mentioned by Null 33 years ago are still around. As you might expect, many of these 1970s-era promoters of “alternative cancer cures,” like Dr. Dean Burk, have since died. (One notes that Dr. Burk was also an anti-fluoridation crackpot who was known for saying that “fluoridation is a form of public mass murder.”) Dr. Ray Evers, a promoter of chelation therapy for everything, including cancer, apparently died in 1990, and his fellow quacks paid tribute to him in 1991. Dr. R. Glen Green was apparently inducted into the Orthomolecular Medicine Hall of Fame in 2007 at age 84 but died in 2010. Nor is the Livingston Clinic still in operation, its not having been able to survive too many years after the death of its founder. In 2004, Dr. Jack Slingluff pled guilty to one count of introducing an unapproved new drug (Laetrile) into interstate commerce. The State Medical Board of Ohio suspended his medical license for a year and permanently revoked it in 2008, and he died in 2011. Similarly Dr. Emmanuel Revici died in the 1990s, but his clinic still exists and is still seeing patients.
In some cases, it’s not always clear whether the clinic is still in operation. For instance, it isn’t clear whether the Gibson Clinic still exists in Ponca City, OK; if it does it doesn’t have a web presence, although it’s listed in Whale.to. It does, however, turn out that one of these “brave maverick doctors” featured by Null is apparently still practicing. I’m referring to Dr. Michael Schachter, who runs the Schacter Center for Complementary Medicine, where he treats cancer using a combination of chelation therapy, various nutritional interventions, detoxification, intravenous H2O2 and/or vitamin C, and other woo. His center’s website even includes a Quack Miranda warning right here.
Oh, and Stanislaw Burzynski, as we all know, is still practicing.
Sadly, however, even though the unavoidable ravages of time have taken their toll on the “brave maverick doctors” profiled in Null’s article, each and every dubious and unproven therapy espoused by them is still being practiced today by someone somewhere. No matter how often the stake of science is driven into their heart (or, if you prefer The Walking Dead, the arrow or katana of science is driven into their brains), they always rise again. What taking this little step back into a time when I was still in high school has shown me is that, as the French say, plus ça change, plus c’est la même chose, or, as I like to say, there is nothing new under the sun, at least when it comes to “alternative cancer cures.” It’s kind of depressing to think that, not only has nothing really changed much in the last 33 years, but that, if anything, elements of what was once called quackery are more accepted than they were when Gary Null first published his trilogy of woo in Penthouse.

CAM and cancer: Who uses CAM, and why?
Many patients with cancer use complementary and alternative medicine, and it is important to understand why.
Scott Gavura on May 16, 2019
Link


How often is complementary and alternative medicine (CAM) used by cancer patients, and why do they use it? Cancer is among the most frightening of medical diagnoses, and it is not surprising to expect that cancer patients may wonder if non-standard or unconventional treatments might have any benefit. A new paper by Martin Keene and colleagues from the College of Medicine and Dentistry at James University in Australia sheds some new light on this this subject. But before we get to the study, we need to discuss the first problem the authors encountered – what exactly is CAM, anyway?
CAM in the eye of the beholder
Some consider anything sufficiently “natural” to be CAM. Others point to who sells it – CAM tends to be delivered by non-health-professionals, but some health professionals (and health organizations) offer CAM and conventional medicine side by side. David Gorski and others at this blog have written about the evolution of CAM, which was once called quackery. Rather than disappearing, these products came to be known as alternative medicine over time.
Alternative medicine sounds outside the mainstream (and it was), meaning it’s an alternative to conventional medicine. Alternative medicine proponents didn’t like this, and so the term became “complementary and alternative medicine”, which retained the quackery, but added in utterly conventional treatments like dietary interventions and exercise. Consequently, perfectly reasonable and even science-based interventions suddenly fell into the “CAM” category, alongside rank quackery and interventions that were unproven, disproven, or arguably harmful. So if we don’t even have a common definition to work from, is it possible to objectively assess its use? CAM is mostly defined by what it is not, rather than by what it is.
This image reflects my own thinking about CAM and cancer – a continuum ranging from science-backed interventions, used alongside cancer treatments, that may help quality-of-life and symptoms (e.g., supportive care), to implausible, unproven or disproven treatments, some of which may be claimed to actually treat the underlying cancer:
The CAM continuum, ranging from science-backed treatments to those that are unproven or even pseudoscience
Why is understanding CAM use in cancer important?
Widespread but undisclosed use of CAM has the potential to compromise cancer care. While few patients forsake science-based cancer care in favour of CAM, concurrent use is more common. Some CAM products can affect bleeding risk or may even compromise the effectiveness of chemotherapy. Notably, non-disclosure of CAM use to health professionals is common, with numbers in the literature suggesting 20%-77% of cancer patients never disclose CAM use.
This study for discussion today was a systematic review – a comprehensive search of the medical literature for all studies, which were then rolled up into a single analysis. Studies included had to be in the English language, developed with the intent of determining CAM use, had data with at least 100 subjects, in patients who were active cancer patients. Importantly, studies were excluded if they exclusively studied so-called “mind and body” interventions, like yoga or prayer. Data was extracted from each study in a standardized way and compiled for analysis.
The results
The paper is entitled “Complementary and alternative medicine use in cancer: A systematic review” and it was published in the journal Complementary Therapies in Clinical Practice.
The authors identified 61 relevant studies that included over 20,000 cancer patients in total. Breast cancer patients were the most common patient group studied, followed by hematologic (blood) cancers. Interestingly, this topic is under-researched in North America. The most common country among the 61 studies was Germany (9), followed by Turkey (6), Australia (5), and Malaysia (5). There were 4 from Italy and the USA, with several other countries represented by 3 or fewer studies. In most of the studies, self-completed questionnaires were the source of data.
Importantly, 53 of the 61 studies had a definition of CAM that included mind/body therapies. Only 5 studies looked solely at “biological therapies” such as herbal remedies or dietary supplements. Overall, the diversity of and generous definition of CAM serve to over-estimate the population of CAM users (if you feel, like I do, that broad definitions co-opt what arguably isn’t alternative medicine).
Prevalence – On average, 51% of cancer patients were using CAM, ranging from 16.5% to 93.4%. The authors attempted to break this down by cancer type, but statistical analysis showed no difference between groups, so I won’t show that data here. In addition, there were no statistically significant differences between different countries in terms of prevalence of use.
Demographics – 56 of the 61 studies looked at the demographics of users. The most common predictors of CAM use were:
    • female (even after controlling for the multiple studies in breast cancer)
    • higher education
    • younger
    • higher income
    • previous CAM use
Reasons for CAM use – The desire to treat or cure cancer was the most commonly cited reason for use, noted in 74% of studies. Other reasons given included intent to treat complications (e.g., side effects) (61%), influence general health (e.g., increase immunity) (57%), holistic treatment (57%), “Taking Control” or “Not wanting to miss a chance” (46%), and belief in CAM or dissatisfaction with conventional treatment (34%).
What does this study tell us?
This paper further confirms what we know about CAM and cancer. Importantly, CAM is a cultural phenomenon, and not a product of science or evidence. As Steven Novella has noted previously, satisfaction with mainstream medicine is not an important factor in deciding to use CAM, and CAM users are generally satisfied with their mainstream care. CAM may be popular because its use aligns with a user’s personal philosophy, or simply to expand their options, perhaps because it is widely viewed as being natural and harmless. A 2013 systematic review in advanced cancer noted that use was felt to offer hope and even ambiguity about the future in these patients with a terminal cancer diagnosis. That study, like this systematic review noted that patients who were younger, female, more educated, had a longer duration of disease, and had previously used CAM were more likely to use CAM. And a 2015 cross-sectional survey of patients at an academic cancer centre found that attitudes towards CAM predict CAM use. Patient age (<65 years), female gender and college education were associated with greater expected benefit from CAM.
Does concurrent use of CAM with conventional cancer care affect survival or quality of life?
It’s possible that CAM, when used concurrently with conventional medicine, might offer some subjective benefits, particularly for side effects. However, given the potential for CAM-drug interactions (in the case of supplements and herbal remedies), survival benefits shouldn’t be assumed. A study of a Korean population by Yun and colleagues suggested that CAM had no effect on survival and worsened, rather than improved, quality-of-life. Similarly, so did a Malaysian study by Chui. Armstrong found no difference in QOL due to CAM in a study of patients with brain tumours. Risberg, studying a Norwegian population, also observed that concurrent CAM use predicted a shorter survival. However, the U.S. Health, Eating, Activity, and Lifestyle Study found no relationship between CAM use and breast cancer (or overall) survival. Overall, based on this limited evidence, it’s reasonable to conclude CAM may offer cancer patients subjective benefits. However, there is no convincing evidence CAM use actually improves quality of life or has any beneficial effect on survival.
Conclusion: Little evidence to support CAM benefiting cancer patients
If CAM works, it does so according to scientific principles – not alternative ones. There is no evidence that most of CAM has much to offer cancer patients, even when used alongside conventional care. Importantly, no treatments, even some forms of CAM, are without any risk. However, cancer patients may be more willing to accept the risks of CAM given their diagnosis. This systematic review confirms that many to most people with cancer are using some form of CAM. Given the variety of approaches and therapies that now encompass CAM, cancer patients should be made to feel comfortable discussing CAM with their health care providers. Health professionals need to take a non-judgmental approach to understanding CAM use, while providing advice based on the best scientific information, with the goal of to supporting patient autonomy and safe, optimal cancer care.

A horrifying survey of “pediatric naturopathic oncology” practice
“Naturopathic oncology” is a specialty made up by naturopaths in order to justify using their quackery to treat cancer patients. A new survey takes it a step further and looks at using naturopathy to treat children with cancer, including the use of homeopathy, reiki, and restrictive diets.
David Gorski on October 7, 2019
Link

I’ve written a fair amount about the “medical specialty” known as naturopathic oncology. The reason, of course, is that I’m an oncologic surgeon; my entire career involves taking care of cancer patients and doing cancer research. As a result, I don’t like to see a “profession” as rife with pseudoscience and quackery as naturopathy attempt to create a “specialty” devoted to taking care of cancer patients. Of course, I don’t like to see naturopaths take care of any patients, but their taking care of cancer patients bothers me more. I first noticed that naturopaths were forming this subspecialty back in 2010, when I encountered naturopathic oncology in the context of the “integrative oncology” quackery being offered by the for-profit Cancer Treatment Centers of America. I even learned that naturopathic oncologists have their own board certification. Those who have this certification can be identified by the letters after their name, FABNO, which stands for “Fellow of the American Board of Naturopathic Oncology”. (Personally, I’ve always said that I think it should really stand for “FAB? NO!”) Of course, given the panoply of dubious therapies, some of them contradictory to each other, that naturopaths use, I really wonder what the certifying examination is like. When, for instance, do you choose megadoses of vitamin C over acupuncture or vice-versa? But I digress. Such are the questions that come up when quacks pretend that theirs is a real specialty while naturopathic oncologists use treatments like cesium chloride to treat cancer.
If there’s one area of oncology that deals with the most vulnerable of patients, it’s pediatric oncology. Fortunately, childhood cancer is uncommon, but it’s not that uncommon. Over 15,000 children a year are diagnosed with cancer (compared to 1.7 million adults). Also fortunately, thanks to advances in the multimodality therapy of childhood cancer, since the 1950s, when most childhood cancers were a death sentence, the survival has improved from 58% in the mid-1970s to well over 80% now. Of note, none of that improvement had anything to do with naturopaths, but rather science-based medicine and the very high level of participation of pediatric cancer sufferers in clinical trials. Unfortunately, even though they can’t define a science-based standard of care (how could they, given their specialty), apparently naturopaths nonetheless want a piece of the pediatric oncology pie. I discovered that when Jann Bellamy sent me a link to an article in Integrative Cancer Therapies, “Naturopathic Oncology Care for Pediatric Cancers: A Practice Survey“. The article is by Athanasios Psihogios, ND (Not-A-Doctor), Jullie K. Ennis, PhD, and Dugald Seely, ND (Not-A-Doctor), MSc, FABNO (FAB? NO!). We’ve met Dugald Seely before. Sadly, he seems to have some pull in the Society for Integrative Oncology, having co-authored SIO’s breast cancer care guidelines. He’s also managed to score some serious cash to do dubious clinical trials of naturopathic interventions in cancer ($7 million total between two grants).
So let’s see what Seely (who’s the corresponding author) and his colleagues have to say about naturopathic interventions in pediatric cancer. Naturally they can’t help but do what authors of nearly all articles about “integrative” medicine do, and appeal to popularity as a justification for their undertaking:
A recent survey of pediatric specialty outpatient clinics in Canada found that 61% of pediatric oncology patients use some form of complementary and alternative medicine (CAM).1 CAM use decisions by patients and their families are often self-directed and independent of the conventional oncology team. Furthermore, only 77% of CAM users informed their physician of this use and only 57% consulted a pharmacist.1 This may, in part, be due to the lack of mechanisms at the institutional level for conventional care providers to assist their patients in making informed decisions when it comes to CAM therapies and practitioners.2 While CAM use remains high, the literature indicates that significant gaps exist in research.3,4 The high prevalence of use, potential for harm, and lack of evidence and resources warrants further research in order to meet the evidentiary demand for CAM efficacy and safety.
This is the first survey to our knowledge that examines current practice in the naturopathic medical community regarding pediatric oncology. Naturopathic oncology, provided by licensed naturopathic doctors (NDs), aims to improve quality of life, manage side effects, facilitate recovery, prevent recurrence, and educate the patient regarding adopting a healthy lifestyle.5 Naturopathic oncology practice is not to be provided as an alternative form of medicine but ideally in conjunction and inclusive of conventional oncology care in a manner consistent with integrative oncology.6
How many times have I seen passages that read almost identically to the two paragraphs quoted above? I’ve lost count. The message is always the same: Patients are doing it, usually a majority of patients. Of course, that majority usually comes about by widening the definition of CAM to include so much that of course a majority of patients use CAM when defined that way! For instance, the study cited above looked at multivitamins, vitamin C, cold remedies, teething remedies, calcium, faith healing, massage, chiropractic, and relaxation, with by far the most commonly used “CAM” intervention being multivitamins and vitamin C. Having thus inflated the percentage of patients using “CAM”, CAM boosters then use that large number to argue that we should study these interventions.
Then, of course, the naturopaths claim that naturopathic oncology can do all these wonderful things, such as managing side effects and facilitating recovery, citing the OncANP description of naturopathic oncology. Of course, there’s little evidence that naturopathy can do anything to facilitate recovery, outside of perhaps recommending exercise and a healthy diet, and there’s certainly no credible evidence that adding naturopathy to conventional cancer care prevents cancer recurrence after successful initial treatment. That claim is, quite simply, nonsense. Similarly, the claim that naturopathic oncology should never be used instead of real medicine but alongside real medicine flies in the face of the numerous examples I’ve written about over the years of naturopaths doing exactly the opposite and treating cancer patients themselves without any conventional oncology, always with disastrous results.
So what do Seely and colleagues want to find out? The goals of their survey are:
This survey gathered information from NDs who see patients with cancer regarding: (1) practitioner demographics (education, clinical practice, etc), (2) natural health product (NHP) use (recommendations, dosing, reasons for use, and contraindications), (3) nutrition counselling, (4) physical medicine interventions, and (5) mental-emotional treatments.
The primary objectives of this survey are the following: (1) to identify and enumerate the most common therapeutic recommendations (among the 4 principal domains); (2) to identify the principal reasons for use of the primary NHPs recommended; (3) to identify contraindications reported by the respondents regarding NHPs recommended; and (4) to identify characteristics of NDs focused in oncology with regard to their care of pediatric patients with cancer. A secondary objective of the survey was to identify similarities and differences between oncology-focused NDs who do and do not treat children with regard to their pediatric cancer care recommendations.
The first thing I learned that’s disturbing is that, of the 99 naturopath practices surveyed that treat cancer, 47.5% also treat pediatric cancer. That’s right, nearly half of the naturopaths also ply their quackery on children with cancer. Even more depressing, when the authors asked those who don’t treat children why they don’t treat children, this was the answer:
The most frequent reason reported by respondents to explain why they do not treat pediatric cancer cases was an absence of public demand (ie, patients and families/caregivers not seeking the direct care of an ND; 45.1%). Overall, 59.7% of non-treater respondents reported a need for evidence-related resources (dosing, safety, clinical data/research), and 35.8% required educational resources (training, conferences, mentorship). Further details from the survey respondents as to reasons for not treating pediatric cancer cases and the resources that would be needed to better support a change in this practice are outlined in Tables 2 and 3, respectively.
Of note, the second most frequently cited reason these naturopaths don’t treat children is that the institution or clinic they work at doesn’t allow it. Less than 20% cited lack of comfort treating children with cancer and only 12% cited lack of training. In other words, if those factors were overcome, a lot more naturopaths would be willing to treat children with cancer, and one of the cited purposes of this survey was to identify factors that, if overcome, would make naturopathy available to more children with cancer. Some of the factors identified in the survey included more educational resources and clinical evidence. Of course, given that naturopathy is a specialty rooted in prescientific vitalism that fuses a wide variety of quackery to some science-based lifestyle advice, that evidence is unlikely to be forthcoming any time soon. On the other hand, the naturopathic standard of evidence to adopt a treatment is not exactly rigorous. After all, naturopaths are all trained in homeopathy.
So here’s where the rubber hits the road. What treatments do these “naturopathic oncologists” or naturopaths comfortable with treating pediatric cancer patients use to treat children? It is, as you would expect, the usual mixture of the potentially science-based (nutrition, exercise), the unproven, and quackery. For instance, here are the natural health products (NHP) that naturopaths reported using:
Eighty-four respondents provided complete information within the NHP domain (recommendations, reasons for use, reported contraindication, dosing, and administration). Eighteen NHPs were identified as primary recommendations (selected by >50% of those who do treat pediatric cancer cases): vitamin D (88.4%), fish-derived omega-3 (86.0%), probiotics (86.0%), vitamin C (79.1%), melatonin (76.7%), turmeric (Curcuma longa, curcumin extract; 74.4%), glutamine (72.1%), homeopathic Arnica (67.4%), Astragalus membranaceus (62.8%), magnesium (citrate, bisglycinate, etc; 62.8%), Coriolus versicolor (60.5%), zinc (58.1%), Boswellia serrata (frankincense; 53.5%), coenzyme Q10 (53.5%), ginger (Zingiber officinale; 53.5%), green tea (Camellia sinensis, epigallocatechin-3-gallate [EGCG]; 53.5%), reishi (Ganoderma lucidum; 53.5%), and vitamin B complex (53.5%; Table 4).
And why did they use these NHPs. Read, and weep:
Overall, 6 NHPs were primarily recommended for augmentation of the immune system (vitamin D, vitamin C, Astragalus membranaceus, Coriolus versicolor, Ganoderma lucidum, and zinc). Three NHPs were recommended primarily for anti-inflammatory effects (fish-derived omega-3, turmeric/curcumin, and Boswellia serrata). Two are primarily used for organ and tissue support (CoQ10 and homeopathic Arnica), which encompass endpoints such as postoperative recovery and cardiovascular support. Only one NHP was primarily recommended for antineoplastic activity (green tea/Camellia sinensis). All the remaining NHPs were primarily recommended for side effect–related endpoints; probiotics for gastrointestinal support (including diarrhea, constipation, and painful bowel movements), melatonin (insomnia and sleep quality), ginger (nausea/vomiting), magnesium for gastrointestinal support (including constipation and bowel movement regulation), and glutamine for general side effect management.
And what is the evidence that any of these NHPs do what naturopaths use them for? Slim to nonexistent, of course. Of course, homeopathic remedies are the purest quackery, given that homeopathy is The One Quackery To Rule Them All. I’ll (briefly, for me) explain why. Basically, homeopathy was invented by a German physician Samuel Hahnemann in 1796. Homeopathy is based on two “laws”. The first is the Law of Similars, which states that you treat a symptom using something that causes that symptom. Of course, there is no physiologic, biochemical, or medical basis for such a principle, and in fact what the first law of homeopathy resembles more than anything else is the principles of sympathetic magic, specifically Sir James George Frazer’s Law of Similarity as described in The Golden Bough (1922) as one of the implicit principles of sympathetic magic.
The second “law” of homeopathy, the Law of Infinitesimals, is even more ridiculous and pseudoscientific (or even mystical). This law states that homeopathic remedies become stronger with dilution. Indeed, the process of making a homeopathic remedy involves serial dilution, usually 1:100. The mother tincture (or original compound) is diluted 1:100 and then shaken vigorously (succussed), the succussion step being claimed to be necessary to “potentize” the remedy. After that, it’s diluted again in the same way. Each 1:100 dilution is designated by “C”, such that a 6C dilution equals six 1:100 dilutions. The problem comes with the higher dilutions. For instance, a 12C solution is on the order of a 10-24 dilution ((10-2)12 = 10-24). Many homeopathic remedies are on the order of 30C, which is a 10-60 dilution, or more than 1036-fold greater than Avogadro’s number. Some homeopathic remedies go up to 100C or more, or 10-200. Here’s a hint: The number of atoms in the known universe is estimated to be around 1078 to 1082. The math just doesn’t work, and remedies over around 12C are basically water. “Lesser” dilutions contain so little remedy that it’s highly unlikely that they have a pharmacological effect.
So what else besides NHPs do naturopaths use to treat children with cancer? Well, there’s nutrition. How can that be bad? Well, take a look:
Sixty-eight of the respondents selected nutrition recommendations that they would generally use in practice from a list provided. Primary nutrition recommendations (selected by >50% of all respondents) included the following: anti-inflammatory focused diet (77.9%), dairy restriction (66.2%), Mediterranean diet (66.2%), gluten restriction (61.8%), ketogenic diet (57.4%), and low glycemic diet (52.9%). No significant differences were found for any nutrition recommendation between treaters and non-treaters (Table 6).
When pediatric oncologists treat children with cancer, they have additional challenges other than just treating the cancer and managing side effects. They need to do everything they can to prevent the cancer and its treatment from adversely affecting the child’s growth and development. Needlessly putting children who are dealing with cancer and the toxic effects due to treatment on restrictive diets like the ketogenic diet (which is based on, in essence, starving the body to put it into ketosis), a gluten- and/or dairy-free diet, and the like is malpractice, as there is no evidence that these diets impact the course of cancer in children. There isn’t even particularly good evidence that the ketogenic diet, for instance, impacts the course of cancer in adults. Putting children with cancer on restrictive diets like the ketogenic diet is quackery and child abuse that worsen the child’s suffering by adding continual hunger to the mix while adding additional risk that the child will not meet growth and developmental milestones.
Next up, Seely and colleagues asked about physical interventions:
Sixty-eight respondents selected physical medicine interventions that they would generally recommend in practice from a list provided. Primary physical medicine recommendations (selected by >50% of all respondents) included the following: exercise (94.1%), acupuncture (77.9%), acupressure (72.1%), craniosacral therapy (69.1%), yoga (69.1%), hydrotherapy (67.6%), and massage therapy (66.2%). No significant differences were found for any physical medicine recommendation between treaters and non-treaters (Table 7).
Exercise is fine, if the child can do it given his disease. Yoga, hydrotherapy, and massage therapy are probably benign. (At least massage will make the child feel good, as long as it’s not too vigorous.) None of these will help the cancer, but are for the most part harmless. Acupuncture and acupressure are quackery, nothing but theatrical placebo, and sticking acupuncture needles into a child will traumatize that child for no good reason. Craniosacral therapy is alarming quackery.
Finally:
Sixty-eight respondents selected mental-emotional interventions that they would generally recommend from a list provided. Primary mental-emotional recommendations (selected by >50% of all respondents) included the following: meditation (79.4%), art therapy (77.9%), mindfulness-based stress reduction (70.6%), music therapy (70.6%), visualization (67.6%), cognitive-behavioral therapy (61.8%), progressive muscle relaxation (57.4%), diaphragmatic breathing (55.9%), psychotherapy (54.4%), and reiki (52.9%). No significant differences were found for any mental-emotional physical medicine recommendation between treaters and non-treaters (Table 8).
Art and music therapy are what we in the biz used to call patient support interventions. They weren’t designed to treat anything, but they were viewed as helpful in that they would help patients pass the time in the hospital or while being treated. Meditation and mindfulness probably don’t do any harm, although their benefits, if any, are frequently exaggerated by proponents and it would only be older children who could do them anyway. Reiki, of course, is nothing more than faith healing that substitutes Eastern mysticism for Judeo-Christian faiths.
Of course, there’s nothing in this survey that I couldn’t have predicted. Naturopathy, as we’ve discussed more times than I can easily determine on this blog, is a vitalism-based “specialty” in which there is no form of quackery that its practitioners won’t embrace. Even the science-based modalities embraced by naturopaths don’t survive unscathed. Naturopaths always find a way to inject pseudoscience into even those, such as their recommendations for restrictive diets for children with cancer.
Seely concludes, as you and I always knew he would, with a call for “more research”:
According to our survey, approximately half of NDs who treat cancer include pediatric cases within their practice. Those who do not treat pediatric cancer patients state that they primarily require more clinical information before they would treat this population. While recommendations varied between responders, there appears to be a few main interventions that are consistently most recommended among the majority of respondents, including both treaters and non-treaters. There is a need to evaluate the safety and efficacy of the recommendations identified in this survey. Relevant evidence syntheses in this area of pediatric integrative oncology will help develop a safe and evidence-informed hospital-based IPOP.
It’s a rallying cry of quacks the world over, even though we already have far more than enough evidence to conclude that a large number of the treatments (e.g., reiki, restrictive diets, craniosacral therapy, homeopathy) used by “naturopathic oncologists” treating children with cancer are ineffective and/or pure pseudoscience, while even the unproven treatments have a low probability of being found efficacious based on what we already know. This is the strategy: Argue that these treatments are popular and then urge “more research” regarding the CAM treatments used. Of course, if that “research” is done by naturopaths, it will be of poor quality but usable (by them) to justify and market their quackery. It’s just that, in this case, the naturopaths are arguing to subject children with cancer to quackery.

   High dose vitamin C and cancer: Has Linus Pauling been vindicated?
David Gorski
Link
THE ZOMBIE RISES AGAIN
Vitamin C as a treatment for cancer is back in the news again.
I’m not surprised. This is one therapy favored by advocates of “alternative” medicine that keeps popping up periodically (seemingly every couple of years or so). This latest bit of news has turned up almost right on time after the last time there was a push for rehabilitating vitamin C as a cancer cure a couple of years ago. Back in the spring of 2006, there were two studies published (more on them later) which were touted by the “complementary and alternative medicine” (CAM) crowd as evidence that Linus Pauling was supposedly vindicated. A little less than two weeks ago, an animal study was published suggesting that high dose intravenous vitamin C had antitumor activity in mouse models. A couple of weeks prior, there had also been published a phase I clinical trial that showed that megadoses of IV ascorbate were safe and well-tolerated in cancer patients if they were appropriately screened for renal disease. Given the latest studies of this particular modality against cancer, it seemed like an opportune time for me to examine this new evidence and ask the question: Has Linus Pauling been vindicated?
I’ll cut to the chase. The short answer is: Not really, with the qualification that it depends on what you mean by “vindicated.” The long answer follows.
THE NOBEL DISEASE
It’s been noted that there appears to be a tendency among Nobel Prize recipients in science to become enamored of strange ideas or even outright pseudoscience in their later years. Indeed, it’s happened often enough that some wags have dubbed this tendency the “Nobel disease.” Be it Linus Pauling and his obsession with vitamin C, Nikolaas Tinbergen and his adoption of the “refrigerator mother” hypothesis as the cause of autism (which has led one blogger going by the ‘nym Prometheus to quip that Tinbergen’s Nobel acceptance speech represented a “nearly unbeatable record for shortest time between receiving the Nobel Prize and saying something really stupid about a field in which the recipient had little experience”), or Louis J. Ignarro going from a Nobel Prize in Medicine for his work in figuring out nitric oxide signaling pathways to pushing his book on arginine supplementation as a cure-all for heart disease and becoming a shill for Herbalife, there’s something about becoming a Nobel Laureate that has a tendency to lead people to becoming cranks. Either that, or maybe it’s because mavericks who make Nobel-worthy discoveries have a tendency not always to recognize that not all of their ideas are as brilliant as the ones that garnered the Nobel Prize for them, although certainly another possibility is that winning the Nobel Prize tends to give some scientists an inflated sense of their own expertise in fields of science not related to the ones for which they won their Nobel Prize in the first place. Maybe it’s a bit of all of these.
LINUS PAULING’S DESCENT INTO PSEUDOSCIENCE
Be that as it may, the concept that megadoses of vitamin C can cure cancer has been around for decades now, ever since two-time Nobel Laureate Linus Pauling first proposed it. It began in 1972, when Ewan Cameron hypothesized that ascorbate could have anti-cancer action by inhibiting hyaluronidase and thereby preventing cancer spread after two-time Nobel Laureate Linus Pauling had first proposed that taking 1,000 mg of vitamin C daily can reduce the incidence of colds by 45% for most people. It wasn’t long before the two teamed up, and in 1976 Pauling and Dr. Ewan Cameron reported that a majority of 100 terminal cancer patients treated with 10,000 mg of vitamin C per day survived three to four times longer than patients who were not so treated.
Unfortunately, as experimental clinical protocols go, this study was a complete mess. Linus Pauling was not a clinician and had no experience in clinical trial design, and it really showed. Even as a restrospective analysis, the paper was a total embarrassment. There was no standardization, no good matching of controls by age, stage of cancer, or performance status; given the terrible design, there was clearly serious selection bias going on at a minimum. The study’s flaws, which were too numerous to mention, rendered its results essentially meaningless. If you want a quote from his original paper that shows this better than anything, here it is: “We believe that the ascorbate-treated patients represent a random selection of all the terminal patients in the hospital, even though no formal randomization process was used.” Suffice it to say that, in a clinical trial, it is not sufficient to “believe” that your groups were properly randomized and matched. You have to show it. Indeed, Dr. William D. DeWys, Chief of the Clinical Investigations Branch of the National Cancer Institute’s Cancer Therapy Program, pointed out that Pauling and Cameron failed at even a rudimentary effort to control for these variables:
Cameron’s patients began getting vitamin C when Cameron judged them “untreatable” and their subsequent survival was compared to that of the control patients from the time they had been labeled “untreatable.”
DeWys reasoned that if the two groups were comparable, the average time from the initial diagnosis to “untreatable” status should be similar for both groups. But they were not. He concluded that many of Cameron’s patients had been labeled untreatable earlier in the course of their disease and would therefore be expected to live longer. DeWys also noted that more than 20% of the patients in the control group had died within a few days of being labeled untreatable, whereas none of Cameron’s patients had died. This, too, suggested that Cameron’s patients had had less advanced disease when they were labeled untreatable.
The bottom line was that, for the above reasons and others, Pauling and Cameron’s study was shockingly bad. Undeterred, they published a followup study in 1978 that purported to confirm the findings of their 1976 study. It was little better. Pauling and Cameron used many of the same patients and selected a different control group, but the patients were still not matched for stage of cancer, age, or performance or nutritional status. It, too, was a shockingly poorly designed study, even for a retrospective study.
Three decades later, I have to wonder how these studies saw print. It turns out that they were originally published in the Proceedings of the National Academy of Sciences, which is not a clinical journal. Not surprisingly, given his Nobel Prizes, Linus Pauling was a member of the National Academy of Sciences. What is not really known much outside the scientific community is that thirty years ago members of the NAS could contribute papers to PNAS as they see fit and in essence pick their reviewers. Indeed, until recently, the only way that non-members could have papers published in PNAS was if a member of the Academy agreed to submit their manuscript for them (known as “communicating” it), and, in fact, members were supposed to take the responsibility for having such papers reviewed before “communicating them” to PNAS. Thus, in essence a member of the Academy could get nearly anything he or she wished published in PNAS, whether written by him or herself or a friend. Normally, this ability has not been such a big problem for quality, because getting into the NAS is so incredibly difficult and only the most prestigious scientists are invited to join. Consequently, PNAS is still a highly prestigious journal with a high impact factor, and most of its papers are of high quality. Scientists know, however, that sometimes Academy members use it as a journal of last resort to publish some of their leftover findings. They also know that on occasion, when rare members fall for dubious science, as Pauling did, they can “communicate” their questionable findings and get them published in PNAS unless they’re so outrageously ridiculous that even the deferential editorial board can’t stomach publishing them. All they have to do is to find a couple of sympathetic colleagues to review their manuscripts and then submit them. What keeps the overall quality of most of the journal’s articles high is primarily the desire of members of the Academy not to sully their names by communicating papers that they consider to be poor quality science. These days, submission requirements for PNAS are more rigorous, whether that manuscript is submitted by the member or “communicated” to the journal for another investigator. Even so, getting a paper published in PNAS is quite easy for an Academy member and incredibly difficult for a non-member who does not have the connections that allow him to line up an Academy member willing to act as referee and thus is forced to submit his manuscript directly to the journal. These observations largely explain how Linus Pauling could submit such shoddy studies to PNAS and have them published. (Thus endeth my chance for ever getting a manuscript of mine published in PNAS. Probably.)
Eventually, three different randomized trials of high dose vitamin C used to treat cancer were carried out by the Mayo Clinic. The first study was published in the New England Journal of Medicine in 1979, and Pauling was not pleased. He wrote a letter to the editor complaining that most patients had had extensive prior chemotherapy, which in his view meant that they wereimmunologically compromised. Given that his concept was that high dose vitamin C somehow boosted the immune system, he thought it was an unfair trial, even though his first trial had pointed out that the patients undergoing vitamin C treatment had received standard therapy, including surgery, radiation, and chemotherapy as appropriate. This was followed by two other randomized clinical trials, which when coupled with the first trial, involved 367 patients and failed to find a benefit from high dose oral vitamin C in cancer. Meanwhile, some studies were pointing out that high dose ascorbate was not without adverse reactions, including diarrhea, and even renal failure after high dose IV administration. Since then, among conventional oncologists at least, vitamin C as a therapy for cancer has been viewed as having no value.
It is highly doubtful that the concept that vitamin C might cure cancer and other diseases would ever have been taken as seriously as it was for as long as it has been had it not been championed by a scientific figure as towering as Linus Pauling. Unfortunately, in his zeal, Pauling popularized his ideas not primarily by publishing in scientific journals, but mostly by writing books, giving talks, and forming his own insitute to do experiments designed to prove his ideas. Another sure sign of a zealot, Pauling couldn’t tolerate data that contradicted his belief in vitamin C. Indeed, when data from the experiments of a colleague at his institute, Arthur Robinson, suggested that vitamin C at the doses advocated by Pauling might actually increase the rate of tumor growth in an experimental model in mice:
Robinson, a former student and long-time associate of Pauling, helped found the institute and became its first president. According to an investigative report by James Lowell, Ph.D., in Nutrition Forum newsletter, Robinson’s own research led him to conclude in 1978 that the high doses (5-10 grams per day) of vitamin C being recommended by Pauling might actually promote some types of cancer in mice [18]. Robinson told Lowell, for example, that animals fed quantities equivalent to Pauling’s recommendations contracted skin cancer almost twice as frequently as the control group and that only doses of vitamin C that were nearly lethal had any protective effect. Shortly after reporting this to Pauling, Robinson was asked to resign from the institute, his experimental animals were killed, his scientific data were impounded, and some of the previous research results were destroyed. Pauling also declared publicly that Robinson’s research was “amateurish” and inadequate. Robinson responded by suing the Institute and its trustees. In 1983, the suit was settled out of court for $575,000. In an interview quoted in Nature, Pauling said that the settlement “represented no more than compensation for loss of office and the cost of Robinson’s legal fees.” However, the court-approved agreement states that $425,000 of the settlement was for slander and libel.
In 1994, Robinson and two colleagues summarized the results of four mouse studies he had carried out while working at the Pauling Institute. Nearly all of the mice developed skin cancers (squamous cell carcinomas) following exposure to ultraviolet radiation. Altogether, 1,846 hairless mice received a total of 38 different diets. The researchers found that (a) the rate of onset and severity of tumors could be varied as much as 20-fold by just modifying dietary balance; (b) diets with the worst balance of nutrients had the greatest inhibitory effect on cancer growth; and (c) no cures or remissions were observed (although the researchers were not looking for this). In 1999, Robinson commented:
The results of these experiments caused an argument between Linus and me, which ended our 16-year period of work together. He was not willing to accept the experimentally proved fact that vitamin C in ordinary doses accelerated the growth rate of squamous cell carcinoma in these mice.
At the time, Linus was promoting his claim that “75% of all cancer can be prevented and cured by vitamin C alone.” This claim proved to be without experimental foundation and not true. . . . Vitamin C increased the rate of growth of cancer at human equivalents of 1 to 5 grams per day, but suppressed the cancer growth rate at doses on the order of 100 grams per day (near the lethal dose), as do other measures of malnutrition [21].
Of course, this could just be sour grapes after a falling out among old friends, or it could be only one side of a more nuanced story. It could also be that the acceleration of growth reported by Robinson may not be the behavior of all tumors or even most tumors in response to high dose vitamin C. However, if Robinson’s results as he reported later were correct, in the case of at least one tumor vitamin C appeared not to inhibit growth but rather to accelerate it. Pauling’s apparent willingness to suppress data that did not fit with his vitamin C hypothesis and to fire the man whose experiments yielded such data must be acknowledged, particularly given the libel settlement that resulted from legal action by Robinson. The representation of Pauling as a scientist unfairly vilified for his ideas that were outside the mainstream may have an element of truth to it, but just an element. The whole story is not nearly so flattering to Pauling, and he deserved more than a little of the vilification heaped upon him for his vitamin C advocacy and for his role in the promotion of orthomolecular medicine, which consisted mostly of recommending megadoses of vitamins and nutrients to treat disease.
Of course, falling from grace as Pauling did led to wishes for that most American of stories: His triumph and vindication, even if posthumous. At least, so Pauling’s admirers have been hoping for at least 20 years.
THE 21st CENTURY “VINDICATION” OF LINUS PAULING? (Take 1)
One aspect of dubious “alternative” therapies is that virtually no amount of evidence can persuade their adherents that their favored therapy really and truly does not work. However, in the case of vitamin C as a cancer therapy, one loophole in the clinical studies that did not show efficacy is that in all of well-designed randomized clinical trials, it was oral vitamin C that was studied. The evidence regarding high dose intravenous dosing was not as copious, and this oversight was exploited by all manner of CAM practitioners, some of whom promised near miraculous results with intravenous vitamin C, sometimes combined with various other supplements and minerals, while even as early as 2000 some “conventional” physicians and scientists suggested that a reevaluation was in order or that intravenous vitamin C could improve the quality of life for cancer patients.
It turns out that emerging data showed that ascorbate was differentially toxic to some tumor cell lines at concentration in the millimolar to tens of millimolar range. That’s an incredibly high concentration to have to achieve in blood and tissues. Indeed, if you told most pharmacologists that you had a new experimental compound for the treatment of cancer (or any other disease, for that matter) but that it required blood and tissue concentrations of 10 mM to be effective, nearly all of them would suggest that you give up in a hurry because of how difficult it is to reach concentrations that high in humans without toxicity. Even so, two and a half years ago, there came a study published in PNAS by Mark Levine and colleagues at the National Institute of Diabetes and Digestive and Kidney Diseases at the the National Institutes of Health. The PNAS study was simply an in vitro study using five tumor cell lines that showed selective toxicity due to ascorbate in tumor cells compared to normal cells at concentrations that are achievable with intravenous doses of ascorbate. It turns out that ascorbate was four- to twenty-fold more toxic to the tumor cells tested than to normal cells, and that cell killing depended upon hydrogen peroxide generation, as it was abrogated when cells were pretreated with peroxide scavengers. It’s a pretty straightforward paper. My only quibbles with it were that the concentrations of ascorbate used were very high, in the 2 to 20 mM range (hence the need for very high intravenous doses of vitamin C to achieve such levels in the blood) and that Levine only used monocytes, lymphocytes, fibroblasts, and breast epithelial cells as the “normal” cells. Also, he only exposed the cells to the ascorbate for one hour, even though the paper itself states that it can take several hours for a large intravenous dose of vitamin C to be eliminated from the body. At the time I thought that the paper represented an interesting in vitro observation, but, as they say, you can kill tumor cells in vitro with just about anything if you crank the concentration high enough. In vitro experiments can generate hypotheses, but they are inherently highly artificial systems. As clinicians, we want to know if this works in vivo. Many are the chemotherapeutic agents that appear to kill cancer cells selectively in vitro but fail in animal experiments. All in all, this study was hardly a stunning vindication of Pauling.
At around the same time, another study was published in the Canadian Medical Association Journal (CMAJ), also by Mark Levine and colleagues in collaboration with a group at McGill University. Based on the concept that only intravenous dosing can produce high enough blood levels of ascorbate and that that is the reason previous trials failed to show a benefit from high dose vitamin C, three cancer cases were reported, all of whom received high dose vitamin C and all of whom, it was claimed, showed much longer than expected survival. The problem is, there was a lot less there than has been reported, especially given that this study was of a type that I particularly detest (but that CAM advocates particularly love), the so-called “best case” series.
The first patient of the three reported, for instance, had renal cell carcinoma with putative lung metastases and received 65 g vitamin C intravenously twice a week for 10 months. The lung metastases were never biopsy-proven to be renal cell carcinoma, leaving some doubt about them. However, let’s accept that they probably were real lung metastases, even though none of them were ever biopsied. (We don’t always biopsy metastases to prove that they are metastases, particularly if the biopsy would be unduly risky. However, in oncology generally it is always better to have a tissue diagnosis than not.) The problem is that renal cell carcinoma is a tumor type that is one of the more common tumor types to be reported to undergo unexplained spontaneous remissions. It’s uncommon, but it has definitely been documented. Also, the patient received a number of other “alternative therapies,” including thymus protein extract, N-acetylcysteine, niacinamide, and whole thyroid extract. This led me to ask: If the authors believed that alternative therapies like high dose vitamin C can cure certain cancers, why did they automatically assume that it had to be the vitamin C? Why couldn’t it have just as plausibly been one of the other treatments or some combination of them? The fate of this patient was ultimately not good: “Unfortunately, the woman — a long-time smoker — was diagnosed four years later with small-cell lung cancer. She again opted for vitamin C treatment, but the second cancer did not respond.” Was there vitamin C resistance in the second tumor as opposed to the first, or did the first tumor just go into spontaneous remission, or was it something else? It’s impossible to say much of anything from this case.
The second case presented was of a man who had a primary bladder tumor with multiple satellite tumors. These were all resected with apparently clear margins transurethrally using a cystoscope. Rather than additional conventional therapy, the man chose intravenous vitamin C and was reported alive and well nine years later. Normally, this would be a pretty poor prognosis tumor without more therapy, but, as the accompanying commentary points out, long term survival has been reported with surgical therapy alone. Indeed, this case reminds me a lot of breast cancer patients who undergo excision of their primary tumor, forgo adjuvant therapy for alternative therapy, and then attribute their survival not to the conventional therapy (surgery) but rather to the alternative therapy. In addition, this patient also took a variety of other alternative therapies, leading to the question again: Why did the authors assume that it was the vitamin C? They may be correct, but there are too many confounding factors. It could just as plausibly been the surgery.
Finally, the third patient had a large paraspinous mass that turned out to be diffuse B-cell lymphoma. She agreed to radiation therapy but refused chemotherapy, opting instead for intravenous vitamin C. She, too, used a variety of other alternative therapies, including beta-carotene, bioflavonoids, chondroitin sulfate, coenzyme Q10, dehydroepiandrosterone, a multiple vitamin supplement, N-acetylcysteine, a botanical supplement, and bismuth tablets. It’s utterly ridiculous to include this case as “evidence” for the efficacy of vitamin C. Besides the confounding factor of using multiple alternative therapies, the patient reported only had, as far as can be told from the case report, a Stage I diffuse B cell lymphoma. Radiation therapy alone used to be a common treatment for such tumors and is well known to be able to produce long term survival in such cases. To try to show that this was something other than Stage I disease, the authors made much of the observation that the patient subsequently developed enlarged lymph nodes in numerous other nodal basins over ten years. However, nowhere did they report that any of these enlarged lymph nodes were ever biopsied to prove conclusively that they were recurrent lymphoma, and the only pathology result reported was from the biopsy of the paraspinous mass. One thing oncologists that I’ve worked with damned near always insist upon before diagnosing a recurrence of lymphoma is proof by tissue diagnosis, and it is very puzzling why such a simple procedure was not done at some point over the ten year case history reported. It would have been very easy to do biopsies of any of the superficial lymph nodes that were reported to have become enlarged. Another point I noticed was that, looking at the authors’ descriptions, only one of these nodes would I have even considered particularly suspicious (a 3 cm supraclavicular node). The majority of the nodes reported were merely described as merely “palpable” or as measuring 1.0 or 1.5 cm, which is within the normal range for lymph nodes in those basins.
This study is one reason why I really, really detest “best case” series. CAM advocates love such series, though, because they allow them to cherry pick patients. The problem is this: Even if these three cases do represent legitimate tumor responses to vitamin C, we have no idea what the denominator is. These cases were collected over many years, and it’s impossible to know how many thousands of patients underwent similar vitamin C regimens with no response at all. In fact, I find it hard not to point out that these were the very best cases the authors could come up with over a span of many years, and yet they are only marginally more convincing than the anecdotes. The bottom line: as of 2006, the evidence supporting the use of vitamin C in cancer, either intravenous or oral, was not compelling. Considering that even in theory very high ascorbate concentrations would be needed, meaning very high doses, for an effect that in vitro was fairly weak, made the whole thing seem like a long run for a short slide.
THE 21st CENTURY “VINDICATION” OF LINUS PAULING? (Take 2)
Fast forward to July and August 2008.
Two and a half years have passed, and Levine et al are back, this time with another study published in PNAS entitled Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. This time, they’ve done animal studies. Once again, these studies show mildly positive results. Once again, the whole obsession with using vitamin C to treat cancer, even if Levine’s results hold up as reported, strikes me as a long run for a short slide. Once again, I remain puzzled as to why there is such intense interest in what, even if it “works,” strikes me as a cumbersome and only mildly effective anticancer therapy.
How good is the study? Answer: It’s OK but it’s nothing special. In fact, it’s not particularly “meaty,” with only four figures, one of which is essentially a rehash from Levine’s previous PNAS paper with some extra cell lines added. Indeed, if this paper were not about a controversial and questionable therapy that had been thought to have been found wanting and instead been about a new cancer chemotherapeutic, my guess is that this result would have been viewed as mildly promising but nothing earthshaking. However, it’s not about some new chemotherapy agent; it’s about vitamin C. Consequently, it got a fair amount of attention in the press when it came out a couple of weeks ago.
Basically, this study reports the results of in vivo experiments in mouse tumor models using high dose vitamin C to treat tumors. In the introduction, Levine argues that the reason previous studies using high dose vitamin C to treat cancer failed to show an antitumor effect was because the drug was administered orally. The human body, he points out, keeps a pretty tight control over the allowable blood concentration of vitamin C, and it’s not possible to pump that concentration up above a certain level through oral dosing alone. If the blood level of ascorbate could be boosted far beyond the limit that can be achieved with oral dosing, Levine hypothesized, it might reach concentrations in the 10 mM range, which is the concentration range in which he has shown that ascorbate can kill tumor cells in vitro.
One very important thing to emphasize here, though, is that at these doses ascorbate is not acting as a nutrient. It is not a “nutritional” treatment for cancer, as some CAM advocates claim. Rather, it is acting as a drug, more specifically a prodrug that generates peroxide and ascorbate radicals. (It is not an uncommon for antioxidants to become prooxidants when administered at high doses.) Indeed, these are doses that are many, many, many times greater than what is required for good nutrition; they are true “megadoses.” To illustrate the point, I note that the doses used in mice by Levine et al were on the order of up to 4 g/kg twice daily. Translating that dose to the proverbial 70 kg man would mean a dose of up to 560 g per day, or nearly a pound and a quarter, administered intravenously. Of course, mice are not humans, and, as it turns out, it doesn’t take doses that high to reach blood concentrations in humans as high as those achieved in the mice using 4 g/kg ascorbate; it takes up to 1.5 g/kg (more on that later). Even so, we’re still talking huge doses of ascorbate just to get its blood and tissue concentrations into a theoretical potentially therapeutic range. Given that a typical orange contains approximately 45 mg of vitamin C, 1.5 g/kg administered to a 68 kg adult would translate into over 2,000 oranges’ worth of vitamin C. It’s also a ten-fold higher dose than was used by Pauling and Cameron.
After in essence recapping results presented in Figure 1 of their previous study for this study again and adding more cell lines to the panel to show that high concentrations of ascorbate are selectively toxic to tumor cells compared to normal cells, Levine gets to the meat of his results by testing his vitamin C regimen in three different mouse models of cancer in athymic nude mice: Ovcar5, a human ovarian cancer cell line; Pan02, a mouse pancreatic cancer cell line; and 9L, a rat glioblastoma cell line. Why he chose these particular cell lines is not really explained clearly. Personally, if I were doing this experiment I would have made sure to use nothing but human tumor cell lines; in this study only one of the xenograft models used was human. Be that as it may, tumors were allowed to grow to a volume of 50 ± 10 mm3, at which point treatment with either intraperitoneal injections of ascorbate or saline placebo were commenced. The results are below:
As you can see, the growth of the tumors was delayed, but there doesn’t appear to be any tumor shrinkage. It turns out that this is actually not a particularly uncommon result for a potential cancer chemotherapeutic drug (and, make no mistake, in this study ascorbate is being used as a chemotherapeutic agent). That’s why I don’t hold it against this study. I agree, based on the data presented, that against these three cell lines, at least, ascorbate at these doses does appear to exhibit some in vivo antitumor activity. However, it’s modest and it requires massive doses producing high concentrations of ascorbate in the blood to achieve, but it’s clearly there. At the end of the study, treated tumors were anywhere from 40-53% smaller than the untreated controls, and in the 9L cell line there was reportedly a major decrease in the frequency of detectable metastases. That’s fairly convincing. The rest of the study involved mainly measuring the levels of H2O2 in the tissues of treated animals. Amazingly, peak levels of as high as 30 mM were measured, and high concentrations of the oxidant ascorbate radical and H2O2 were measured.
The observation that such high ascorbate concentrations in the mice’s blood could be achieved led the authors to reference a phase I clinical trial of high dose intravenous vitamin C in advanced malignancy that had been published two weeks earlier and reported that it is possible to approach such high concentrations of ascorbate in humans with doses of 1.5 g/kg. Even though that’s not 4 g/kg, that dose is still a lot and still problematic, as the infusion of high volumes of high osmolarity solution did cause problems in this trial. Nonetheless, according to this phase I study, with appropriate screening for conditions that might predispose to adverse events, especially renal failure, the results of the phase I clinical trial suggest that high dose intravenous vitamin C is fairly well tolerated even at the highest dose range.
Based on the animal studies and the safety data from the phase I trial, Levine concludes that high dose intravenous ascorbate represents a promising new therapy that should be further investigated. If his were the only evidence I saw being presented, I’d agree that it’s mildly to moderately promising as an anticancer therapy. However, I find Levine’s results much less compelling in light of the history of the use of vitamin C in cancer and in light of my knowledge of cancer chemotherapeutics. More importantly, I know that the phase I clinical trial described above did not identify even a single patient with an objective response to therapy. In other words, not one patient’s tumor shrank. True, the lack of a single objective response in a phase I trial does not necessarily mean that a new cancer chemotherapy drug doesn’t work, but it certainly does dampen considerably any optimism that that the drug will work as a single agent. Taking the animal studies and the phase I trial together, I view the results with mild optimism that high dose vitamin C might have efficacy in human cancer and be useful in combination with other chemotherapy. However, putting these results in context with what has been reported before over 30 years decreases even that mild enthusiasm, especially when coupled with my observation of just how modest the responses were in the mice and by just how much ascorbate was required to result in even a mild antitumor effect. Indeed, the authors of the phase I trial even admitted:
In summary, this study shows that 1.5 g/kg ascorbic acid infused >90-120 min three times weekly is essentially free of risk and important side-effects when simple precautions are taken. In people with normal renal function, this dose achieves a plasma ascorbic acid concentration >10 mmol/l for several hours. No patient experienced an objective anticancer response, although two patients at the 0.6-g/kg dose received greater than six cycles of ascorbic acid with stable disease. Even though only six patients received the recommended phase II dose, our results suggest that the likelihood of an objective anticancer response to i.v. ascorbic acid alone is slight in unselected patients with multiply treated advanced cancer.
I do note the qualifiers in this admission: unselected patients and multiply treated advanced cancer. The latter qualification is in essence meaningless, because no one is going to use an agent like vitamin C as a first line therapy for any cancer if there is not strong clinical trial evidence showing that it works at least as well as current chemotherapeutics. To do otherwise would be highly unethical. On more solid ground is the former qualifier, as there conceivably might be a subpopulation that will respond to high dose vitamin C. Even if that is true, however, based on the results of this phase I trial and the animal studies, clearly vitamin C is not any sort of “miracle cure.”
LINUS PAULING: VINDICATED OR NOT?
All of this brings us back to the title of this post, to the question that just can’t be avoided: Do these two studies released in the last month vindicate Linus Pauling and all the alternative practitioners of high dose vitamin C therapy for malignancy? Again, it depends on what you mean by “vindicate,” but my answer is nonetheless: Not really, except perhaps in the weakest of ways.
Here’s why. Linus Pauling didn’t claim that vitamin C in combination with other chemotherapeutic drugs might provide an additional incremental benefit to patients, which is the very best that can be claimed for high dose ascorbate based on all the in vitro, in vivo, and clinical evidence thus far. That’s far too modest a claim. No, actually Pauling said that “75% of all cancer can be prevented and cured by vitamin C alone.” Similarly, boosters of vitamin C as a cancer therapy don’t claim that it provides a small additional benefit when administered with chemotherapy, either, which again is the very best that can be possibly claimed based on the experimental results described. Rather, they claim that high dose vitamin C cures cancer a high percentage of the time. Even the most optimistic appraisal of Levine’s results of Levine’s mouses study or the phase I clinical trial do not support any such claims. That much is brutally clear.
The bottom line from my perspective: Yes, vitamin C probably has some antitumor activity for some tumors, but as I contemplate the evidence for this effect the word “underwhelming” comes to mind, as does one of my favorite metaphors, namely the long run for a short slide. Apparently there are a lot of people who like getting their butts dirty sliding into base after a long run, though, because the attraction to vitamin C still lives on despite unimpressive evidence. Naturally, the authors of the phase I trial suggest using vitamin C in combination with chemotherapy, which is a perfectly reasonable approach for drugs that don’t show any objective evidence of activity as a single agent. However, this will not be easy, given that the sheer mass and volume of ascorbate that must be administered and the very high concentrations that are required even in the best case scenario could easily interfere with other chemotherapeutic agents.
One thing is fairly clear from the data reported thus far, even Mark Levine’s data and his calls to “revisit” the question of vitamin C and cancer with an “open mind”: If high dose intravenous ascorbate has antitumor activity in humans, that activity is almost certainly quite modest at best, and to achieve even such modest antitumor activity definitely requires incredibly high doses of ascorbate. Once again, I point out that any other experimental drug requiring such high plasma concentrations and high doses to achieve such a modest antitumor effect would probably garner very little interest from anyone, even if it were a potentially patentable product of big pharma. It’s possible that high dose IV ascorbate might ultimately find its way into the armamentarium of science-based oncology, but it’s very unlikely ever to become a mainstay of treatment for any malignancy. It’s just too wimpy.
REFERENCES:
1. Chen, Q., Espey, M.G., Sun, A.Y., Pooput, C., Kirk, K.L., Krishna, M.C., Khosh, D.B., Drisko, J., Levine, M. (2008). From the Cover: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proceedings of the National Academy of Sciences, 105(32), 11105-11109. DOI: 10.1073/pnas.0804226105
2. Hoffer, L.J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S.J., Rosadiuk, K., Rousseau, C., Robitaille, L., Miller, W.H. (2008). Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of Oncology DOI: 10.1093/annonc/mdn377

   Vitamin C strikes (out) again
David Gorski
Link
I didn’t think I’d be revisiting this topic again so soon. After all, I wrote one of my characteristic magnum opuses (opi?) less than two months ago, when I asked whether a recent animal study had vindicated Linus Pauling’s belief that high dose vitamin C is a highly effective cancer treatment. After that tsunami of verbiage that can only be exceeded by my fellow blogger Dr. Atwood when he’s on a roll doing a multipart deconstruction of some woo or other, I thought it would be best to give it a rest for a while. I guess less than two months will have to be enough.
The reason struck me as I was perusing the very latest issue of Cancer Research, hot off the presses October 1. As I did so, it didn’t take me long to come across an article from the Memorial-Sloan Kettering Cancer Center and the Herbert Irving Comprehensive Cancer Center at Columbia entitled Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs, whose first author is Dr. Mark Heaney.
Once more into the fray!
You may recall that, when last I discussed the topic of vitamin C as a “cancer cure,” I discussed a recent study out of Mark Levine’s laboratory at the Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, at the National Institutes of Health. At the time, Dr. Levine argued that the doses of vitamin C used in previous randomized, double-blind trials of vitamin C against cancer were oral and thus did not produce levels of ascorbate in the serum high enough to kill cancer cells because absorption of vitamin C is limited by the rate that the gastrointestinal tract can take it up. He argued that, to reach the very high doses found to be necessary in cell culture to kill lymphoma cells preferentially to normal cells,. We’re talking huge concentrations ranging from 2 to 20 mM, which are levels of active drug that are virtually unheard of for normal drugs. In mice, he showed that attaining such high blood concentrations was feasible in mice and that they demonstrated a mild antitumor effect in a three mouse models of cancer and differential toxicity to cancer cells over normal cells through, paradoxically, the induction of reactive oxidant species, as it turns out that this particular antioxidant can become a pro-oxidant at sufficiently high concentrations. Overall, I concluded that the available evidence suggests that, even if vitamin C does have an anti-tumor effect, it’s likely to be modest, making it a long run for a short slide; in other words, huge doses of vitamin C, such that they are difficult to get into the patient, for a pretty wimpy benefit.
Of course, as I pointed out before, every time there’s a study suggesting that “vitamin C might work after all,” the press go ga-ga all over it. Certainly that’s what happened for Dr. Levine’s cell culture study back in 2006 and his animal model study a couple of months ago. So, take a guess. What do you think the reaction to to the study I mentioned above published in the October 1 issue of Cancer Research?
Crickets chirping.
Yes, the silence was deafening. I wonder why? True, I did find articles in the Canadian press, in Medpage Today, and Medscape, but not much anywhere else. To find out why, let’s look at what the study found:
October 2, 2008 — Large supplemental doses of vitamin C could interfere with the therapeutic cytotoxic effects of a wide range of chemotherapy agents, suggests a new preclinical study. Although the finding comes from research conducted in cancer cell lines and mice, the authors say the conditions they created are similar to those found in the body, and speculate that the same mechanism might affect patient outcomes.
“It is possible that vitamin C supplementation may alter the effectiveness of commonly used chemotherapeutic agents and adversely influence treatment outcome,” the researchers write in the October 1 issue of Cancer Research.
So what did the researchers do? First, you have to understand that a common mechanism of action of many chemotherapeutic drugs is the generation of reactive oxygen species (some of which are known as oxygen free radicals), which the result in DNA damage. Consequently, one might reasonably hypothesize that vitamin C (ascorbate) might interfere with the action of some of these chemotherapeutic agents. On the other hand, if Dr. Levine is correct it could be argued that ascorbate might potentiate the activity of such chemotherapeutic agents.
Therefore, first, as scientists so often do, investigators tested combinations of different chemotherapeutic agents with increasing concentrations of vitamin C. One difference between this study and the previous two studies by Dr. Levine is that the range of ascorbate concentrations examined was from 0 to 0.5 mM, which is 10 to 20 times lower than the concentrations that Levine used. In any case, what he found was that treating two different leukemia and lymphoma cell lines with ascorbate at those concentrations before treating them with chemotherapeutic agents, including mechanistically dissimilar agents such as doxorubicin, which intercalates with DNA and causes DNA breaks; methotrexate, which inhibits folate metabolism; cisplatin, which crosslinks DNA; vincristine, which interferes with microtubule function; and imatinib mesylate (better known by its trade name of Gleevec), a selective inhibitor of the activity of a protein called bcr-abl, which is the oncogene that plays a central role in the development of chronic myelogenous leukemia (CML). The point is that these drugs all have very different mechanisms of action, and the finding was that vitamin C inhibited their effects. At the concentrations used, it didn’t inhibit or stimulate the growth of cells in and of itself. However, it did interfere with the actions of these drugs, decreasing their cytotoxicity to tumor cells by 30-70%.Next, they tested the effect of vitamin C and chemotherapy in mouse models of cancer using 250 mg/kg, again a much lower dose than what Dr. Levine used. Once again, vitamin C interfered with chemotherapy.
What was puzzling about these results is that not all of these drugs are thought to have as part of their mechanism of toxicity the generation of reaction oxygen species, and yet vitamin C interfered with them all. The question then became: Why? A series of additional experiments showed that it wasn’t because vitamin C made tumor cells better able to pump chemotherapeutic agents out. They then compared vitamin C to another chemical (N-acetylcysteine), which like vitamin C helps cells replenish their supply of free radical scavenging thiols such as glutathione, which neutralize reactive oxygen species. When cells were treated with N-acetylcysteine, it only protected them from one of the five chemotherapeutic agents, cisplatin, and vitamin C had minimal effects on intracellular reactive oxygen species. This result suggested that vitamin C works through a more general mechanism than simply an antioxidant mechanism. A further experiment showed that vitamin C was protective against mitochondrial damage caused by chemotherapeutic agents, a mechanism of action common to all five of the drugs. Dr. Heany speculates:
“Our study is a preclinical model that addresses only the situation when vitamin C is given in the setting of chemotherapy treatment,” Dr. Heaney emphasized. There have been no clinical studies of this topic so far, he said.
However, the finding could be of potential concern because “many people, cancer patients included, take supplemental vitamin C,” Dr. Heaney pointed out. Clinical studies of vitamin C supplementation in patients with advanced cancers have had mixed results. There are conflicting hypotheses, he explained. One theory is that vitamin C supplementation protects the cancer and is therefore detrimental to the patient. But there is also the opposite view, that vitamin C supplementation enhances the immune system or prevents indolent cancers from mutating more and becoming aggressive, which would be beneficial for the patient.
Asked to comment on this study, Len Lichtenfeld, MACP, deputy chief medical officer at the American Cancer Society said: “Vitamin C has a long history in cancer prevention and treatment. Although there is no evidence to demonstrate that vitamin C improves the outlook for patients with cancer, there are still reported observations that cancer patients continue to believe in the potential benefits of vitamin C. Although oncologists do not routinely recommend that patients with cancer take excessive doses of vitamin C, there are reports that cancer patients are being treated with vitamin C by alternative practitioners.”
Once again, it must be emphasized that this is a study in cell culture and a mouse model (in fact, much like the studies of Dr. Levine). It’s applicability to humans is not clear and requires testing. However, it does bring up an issue. Clinical trials are moving forward, spearheaded by Dr. Levine, of high dose intravenous vitamin C and cancer. Granted, the doses he is using are many times higher than what was used in the study showing vitamin C interference with chemotherapy. Also granted, Dr. Levine’s study implicates reactive oxygen species generated by vitamin C when it is present in very high concentrations, while Dr. Heaney’s study examined concentration ranges that are achievable with oral dosing. It’s not clear if the same results will apply. So what to do?
Dr. Heaney is cautious:
Lead author Mark Heaney, MD, PhD, from Memorial Sloan-Kettering Cancer Center, in New York, New York, told Medscape Oncology that he advises his cancer patients to avoid supplemental vitamin C during chemotherapy. “I recommend that my patients continue to eat a well-balanced diet that includes fruits and vegetables that contain vitamin C.”
“Such a diet could be expected to have moderate amounts of vitamin C as well as other important nutrients. There are no data to suggest that vitamin C obtained from fruits and vegetables is intrinsically different from vitamin C supplements. Given that our research was done in experimental model systems and was not a clinical trial, I am reluctant to predict a dose of supplemental vitamin C that could be extrapolated to our work. That said, oral vitamin C supplementation with doses as low as 250 mg over a 1-month period resulted in intracellular vitamin C concentrations in normal white blood cells that were close to those that we studied in white blood cell cancers,” Dr. Heaney said.
One thing that concerns me about this study is that any clinical trial that will be carried out with vitamin C and cancer will be chemotherapy plus vitamin C, not just vitamin C alone. After all, that’s the standard methodology for testing a putative chemotherapeutic agent: Add the experimental agent to standard of care chemotherapy. Based on Dr. Heaney’s result, a compelling case can be made that such a trial would be unethical, at least at the lower “megadoses” of vitamin C, because there is a plausible mechanism by which vitamin C might actually interfere with chemotherapy and thus do harm. At the the super high doses of vitamin C, such as the ones that Dr. Levine studied, we don’t know whether the vitamin C would interfere with chemotherapy based on a mechanism similar to that postulated in Dr. Heaney’s study or whether it might potentiate the activity of chemotherapy by generating reactive oxygen species, as the results of Dr. Levine’s studies might predict. However, I would argue that any study of super high dose vitamin C a la Dr. Levine plus chemotherapy would also be unethical, unless animal and cell culture data could be produced that would show that vitamin C as such high concentrations does not interfere with chemotherapy.
Another thing that bugs me about this study is that it’s another example of how the media reports anything having to do with Linus Pauling’s idea that megadoses of vitamin C can treat cancer. Whenever a study is reported that seems to be consistent with a use for vitamin C in treating cancer, almost inevitably it gets wide coverage. When a study is reported that suggests that high dose vitamin C has no use or–even worse–may be harmful, you hear nothing about it.
Same as it ever was.

The return of the revenge of high dose vitamin C for cancer
Vitamin C is back in the news as a cancer cure. Is it? No, no it is not.
David Gorski on February 10, 2014
Link

Somehow, I’ve a feeling we’re not in Kansas anymore—except that we are, as you will soon see.
Because I’m the resident cancer specialist on this blog, it usually falls on me to discuss the various bits of science, pseudoscience, and quackery that come up around the vast collection of diseases known collectively as “cancer.” I don’t mind, any more than my esteemed colleague Dr. Crislip minds discussing infectious diseases and, of course, vaccines, the most effective tool there is to prevent said infectious diseases. In any case, there are certain things that can happen during a week leading up to my Monday posting slot on SBM that are the equivalent of the Bat Signal. Call them the Cancer Signal, if you will. One of these happened last week, thus displacing that post I’ve been meaning to write on a particular topic once again. At this rate, I might just have to find a way to write an extra bonus post. But not this week.
In any case, this week’s Cancer Signal consisted of a series of articles and news reports with titles like:
    • Vitamin C shows promise as cancer therapy (FOX News).
    • Researchers establish benefits of high-dose vitamin C for ovarian cancer patients (Kansas University Medical Center press release).
    • Vitamin C injections ease ovarian-cancer treatments (Nature).
    • Vitamin C keeps cancer at bay, US research suggests (BBC).
    • Vitamin C May Help Cancer Treatment, Study Finds (NBC News).
    • IV Vitamin C Boosts Chemo’s Cancer-Fighting Power? (WebMD).
    • Vitamin C as cancer treatment? High doses boost chemotherapy in study (LA Times).
These stories, to varying degrees, miss the point. Unfortunately, I confess that I wasn’t able to help at least one of them. A reporter happened to leave me a message Tuesday morning, which is my operating room day, and I didn’t have time to read the paper and to get back to her before her deadline. That paper, by the way, appeared in Science Translational Medicine from Jeanne Drisko and Qi Chen from, yes, Kansas University Medical Center, and indicates to me that STM‘s standards are slipping. But then, STM did publish a rather credulous paper by our old friend Ted Kaptchuk on placebos; so maybe I expect too much. Clearly STM appears to be looking for more papers on “complementary and alternative medicine” (CAM) or “integrative medicine.”
Be that as it may, a typical story describes the recently published research thusly:
People with ovarian cancer who receive high-dose vitamin C injections are less likely to report toxic side effects from chemotherapy than people who had chemotherapy alone, according to the results of a small clinical trial.
The study, published today in Science Translational Medicine1, was too small to assess whether the combination of chemotherapy and vitamin C combats cancer better than chemotherapy alone. But accompanying work in mice suggests that the two treatments could be complementary.
The results are the latest salvo in long-running controversy over the use of vitamin C against cancer. Early studies championed by Nobel-prizewinning chemist Linus Pauling in the 1970s suggested that vitamin C could help to fight tumours2. But larger clinical trials failed to substantiate those claims3, 4.
With the spin, from another typical story, being:
One potential hurdle is that pharmaceutical companies are unlikely to fund trials of intravenous vitamin C because there is no ability to patent natural products.
“Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies,” said lead researcher Qi Chen.
“We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C.”
Yes, indeed. The same old tropes are there, from the claim that vitamin C has usefulness in treating cancer to the old ascorbate warriors’ lament that there’s no patent potential in vitamin C, which means that pharmaceutical companies don’t want to invest money into doing science and clinical trials on it because there’s no profit potential. Of course, I’ve written fairly extensively about vitamin C and cancer before, using it as an example of how even a two-time Nobel Prize winner like Linus Pauling could fall prey to bad science when he wandered outside of his area of expertise. Every so often these stories come up suggesting that Linus Pauling has somehow been vindicated and how vitamin C is the greatest thing for cancer patients since surgeons first discovered that some cancers could be cured by cutting them out. Inevitably, I have to throw cold water on such claims. No, Linus Pauling has not been vindicated, and, no, vitamin C for cancer is not all that great.
Also, no, contrary to what critics say, I’m not close-minded about vitamin C and cancer. Unlike so many “alternative” cancer treatments, it’s actually a chemical and, at the doses used by alternative cancer practitioners, a drug. There’s even a (very) weakly plausible mechanism by which it might work. However, in vitro, the concentrations required to provide even a whiff of a hint of antitumor activity are ridiculously high, and the same is true in animal models. Let’s just put it this way. Imagine a pharmaceutical company had developed a compound with properties identical to that of vitamin C and could thus own the complete patent on it as a drug. Given the ridiculously high concentrations and doses required in preclinical models to demonstrate a hint of antitumor activity, that pharmaceutical company would probably retire that compound before even the animal model stage because, as I like to put it, getting any useful anticancer activity out of it would be such a long run for a short slide. A good drug for cancer is, at the very minimum, active at low or reasonable concentrations against the cancer cells being targeted, and vitamin C fails miserably on that count. Worse, there are at least indications that in some cases vitamin C might interfere with chemotherapy.
Vitamin C in Kansas
So does this study change my opinion? Not really. It suggests there might be some utility for ascorbate (vitamin C) against ovarian cancer, but that ascorbate therapy for cancer still remains at best a long run for a very short slide right into the gloved ball of reality to be tagged for a third out. (OK, I’ll stop with the baseball analogies.)
The dubious reasoning begins right in the first paragraph, with the authors’ justification for “re-examining” ascorbate as a cancer therapy. Basically, they point out that the pharmacokinetics of oral ascorbate dosing is different from intravenous dosing, to the point where it is possible to obtain serum ascorbate concentrations of 10 mM (millimolar). To give those of you who aren’t chemists a rough comparison of just how high that concentration is, most cancer drugs have active concentrations in the nanomolar (nM) to micromolar (uM) range, in other words, a thousand-fold to a million-fold lower than 10 mM. For example, the IC50 (the concentration that leaves only 50% of cells alive) for paclitaxel is in the 2.5 to 7.5 nM nM range, depending upon the cell line, and 50 nM is considered a good, effective therapeutic concentration. You get the idea. You need a lot of ascorbate:
By contrast, when ascorbate is injected intravenously, tight control is bypassed and pharmacologic concentrations of ascorbate are established until excess ascorbate is excreted by kidney. Plasma concentrations greater than 10 mM are safely sustained in humans for ~4 hours (10–13). When patients have normal renal function and glucose-6-phosphate dehydrogenase (G6PD) activity, toxicity is minimal even with intravenous doses as high as 1.5 g/kg, equivalent to 105 g for a 70-kg person (2, 12). These data indicate that intravenous administration of pharmacologic ascorbate doses is safe and similar to drug administration. Therefore, the effect of ascorbate in cancer treatment is worth reexamining.
These are huge doses, consistent with previous experiments in mice with a xenograft from an ovarian cancer cell line (Ovcar5) in which 4 g/kg of ascorbate was administered twice daily for a total of 8 g/kg/day. The result was an inhibition of xenograft growth of around one-third after 30 days. Results for a pancreatic cancer cell line and a glioblastoma cell line were only marginally better.
The authors did several cell culture studies in which ovarian cancer cell lines were treated with ascorbate and various chemotherapeutic agents. The authors reported an IC50 of between 0.3 and 3.0 mM, which is still incredibly high for an anticancer drug. The authors blithely write that this is “easily achievable” with IV ascorbate. Maybe so, but given the quantities involved, if you’re going to use a drug that requires such high plasma concentrations to have activity, that activity had better be awesome. None of the activity shown in this paper can be characterized as being particularly impressive. Worse, the authors, despite testing several ovarian cancer cell lines, only tested one non-tumorigenic immortalized ovarian line, HIO-80, and, finding that the IC50 to kill HIO-80 cells was much higher than all but one of the other cell lines (SHIN3), proclaimed a high degree of specificity for cancer. Moreover, HIO-80 cells are hardly “normal.” They likely contain BRCA1 mutations. Finally, the authors only used one assay for proliferation, the MTT assay. This particular assay is very popular (I use it in my lab not infrequently) because it is faster and easier than counting viable cells and also allows for large experiments using 96-well plates. However, the MTT assay depends on the metabolism of cells to produce a dye that is detected. The amount of light absorbance due to the dye is assumed to be proportional to the number of viable cells. Usually, this assumption is reasonable accurate, but lots of things can interfere with this and render that assumption incorrect. For instance, one wonders if very high concentrations of ascorbate can interfere. I’d want to see a control demonstrating that the MTT results correspond to cell number.
In other words, if I were a reviewer for this paper, not so fast, I’d have said. I want to see the results for at least a couple of more non-tumorigenic cell lines and a control validating the MTT in the presence of so much ascorbate (even if just a reference) before I’ll let you conclude that the effects of ascorbate are highly specific for cancer over normal ovarian cells. At the very least, I wouldn’t have considered it unreasonable to ask for a couple more non-tumorigenic ovarian epithelial cell lines to be tested.
In any case, the authors also did some mechanistic studies, the results of which were consistent with the activity of ascorbate in cancer requiring the production of peroxide (H2O2), as H2O2 scavengers blocked the effect. They also did a series of experiments that indicated synergy between ascorbate and carboplatin, a common chemotherapy drug used in ovarian cancer. One area that, as a reviewer, I’d have gotten on the authors’ case was the series of xenograft experiments using ovarian cancer cell lines implanted under the skin of immunodeficient mice, specifically this part:
Two-tailed Student’s t test was performed for comparison of treated groups to control group in the cell and animal experiments, as well as for toxicity comparison between chemotherapy group and chemotherapy + ascorbate group.
No, no, no, no, no! This is some pretty basic stuff here. There are eight different experimental groups, and the authors didn’t control for multiple comparisons, as far as I am able to tell. Pair-wise two-tailed t-tests are not the correct statistical test for determining statistical significance in such a case; likely some form of ANOVA would be, given that the dataset consists of tumor weights and volumes of ascites, the latter being a common estimate of ovarian tumor burden in mouse models. Some form of ANOVA, likely factorial ANOVA, would have been the proper test, given that there are combinations of three drugs being used. Whatever the correct test is (and I’ll leave that to the statisticians out there), I know that Student’s t-test isn’t it, and that using Student’s t-test will often produce “false positives” that appear statistically significant but aren’t.
All of this, however, is the warm-up to the part of the study that got it noticed, namely the clinical trial. Without the clinical trial, this would have been yet another in vitro and animal study of high dose vitamin C that provokes a collective yawn throughout the scientific community. The clinical trial itself was a randomized prospective phase I/IIa clinical trial, which means that the trial was designed to combine an evaluation of toxicity with a pilot study to evaluate efficacy and safety. Its primary objective was to “determine the safety of high-dose intravenous ascorbate when combined with first-line chemotherapy paclitaxel and carboplatin in the treatment of advanced-stage ovarian cancer,” along with evaluation for toxicity. Consequently, the two groups were (1) standard carboplatin plus paclitaxel (Cp + Pax) and (2) carboplatin plus paclitaxel plus ascorbate (Cp + Pax + AA) according to this design:
Ascorbate dose for the Cp + Pax + AA arm was established via dose escalation initiated at 15 g per infusion titrated up to a therapeutic range of 75 or 100 g per infusion, with a target peak plasma concentration of 350 to 400 mg/dl (20 to 23 mM) (12, 13). The ascorbate infusion was given at a rate of 0.5 g/min, and 400 mg of magnesium chloride (Wellness Pharma) was supplemented into each infusion. Once the therapeutic dose was established, the Cp + Pax + AA group received ascorbate two times per week in conjunction with chemotherapy for 6 months, and injectable ascorbate was continued for another 6 months after chemotherapy completion.
In addition, the authors noted:
Two subjects voluntarily withdrew from the Cp + Pax arm before treatment commenced because they wanted intravenous vitamin C, and they were excluded from data analysis. Two subjects were removed from the Cp + Pax + AA arm because they were noncompliant with tobacco use, and one was removed from the Cp + Pax + AA arm after in vitro cytotoxic assays detected that her tumor cells were resistant to all chemotherapy. These three subjects received doses of chemotherapy and ascorbate, so their adverse events were counted, but they were excluded from the survival report (table S3). Double blinding was used at enrollment and randomization, but was not maintained during the treatment because no placebo control was used.
So what we have here is a small clinical trial with a 19% dropout rate that wasn’t even blinded. It reported zero difference in overall survival (both were, as one would expect for ovarian cancer at this stage, abysmal), and zero statistically significant difference in time to relapse/progression. In all fairness, there would have had to have been an enormous effect to produce a statistically significant effect on survival or progression in such a small study, but these are the two “hard” endpoints that would be least affected by the lack of blinding, although one notes that time to progression could be affected by lack of blinding when the definition depends on interpreting scans. It’s also hard not to note that the differences in toxicities are all in the mildest reported toxicities, grades 1 and 2 (out of a scale of 1 to 5, with a score of 1, which denotes mild toxicity that requires no intervention to 5, which is death). There were no statistically significant (or even close to statistically significant) differences in toxicities graded 3 or 4, which are the most troubling kind. Take a look at the graph:
Then, when the authors broke it down, this is what they found:
Notice the types of complaints with the biggest difference: gastrointestinal (which usually includes symptoms such as nausea, abdominal pain; dermatology, which usually includes itching and rashes of various types); pulmonary, which often includes symptoms of shortness of breath, cough, and the like, and renal/genitourinary, which is the only one that’s less objective. So, basically, what we have is a study that found no benefit in overall survival or time to progression (not unexpected for such a small study). More importantly, contrary to the way it was trumpeted to the press, the decrease in adverse events actually observed was limited to the least serious adverse events (grade 1 = minor, causing no limitation of activity, no intervention required; grade 2 = moderate, some limitation of activities, minimal intervention indicated) with the most potential to be subject to reporting bias, which in the context of a trial that is not blinded makes the difference reported probably meaningless. In other words, this was probably a negative study, a long run for a short slide, indeed. (Sorry, couldn’t resist.)
There’s no woo like Kansas woo
I thought it might be interesting to provide SBM readers with a bit of context about the institution from which this rather pointless study emerged. The reason that this particular study rose to the level that I thought I had to blog about it was not because a reporter contacted me about it. Rather, one of the key investigators on the study, Jeanne Drisko, recently appeared on a web chat, Can Alternative and Conventional Medicine Get Along?
This chat featured, in addition to Dr. Drisko, Dr. Josephine Briggs, the current director of the National Center for Complementary and Alternative Medicine (NCCAM) as well as an associate editor from Science Translational Medicine, Yevgeniya Nusinovich, M.D., Ph.D., who served as moderator. Dr. Jeanne Drisko’s titles include Director, KU Integrative Medicine and the Riordan Endowed Professor of Orthomolecular Medicine, and, consistent with her involvement in this study, KUMC offers its patients high dose vitamin C for cancer. The video itself was standard fair, discussed by a certain “friend,” where the Trial to Assess Chelation Therapy was incorrectly touted as a success warranting further study for chelation therapy for heart disease. However, what tweaked me to write this was Dr. Drisko’s mention at the end of her “hot off the presses” study of high dose vitamin C.
Personally, I found it instructive to take a look at the website for Dr. Drisko’s home department, the University of Kansas Medical Center Integrative Medicine Program. The first thing I noticed when I perused its website was this:
Nourishing the whole person — body, mind and spirit — and stimulating the body’s natural healing response, is our mission at KU Integrative Medicine. We combine the best therapies from conventional medicine with our integrative medicine approach, to form a comprehensive system of biomedical care.
From a patient’s very first visit with us, we attempt to uncover the underlying story that set the patient on their journey from wellness to disease. We listen. Based on our findings, we tailor a plan for each individual patient based on their lifestyle, their needs and their preferences. We consider the patient an integral part of the treatment team, and encourage patients to take control of their medical care.
Practitioners at KU Integrative Medicine include physicians, a naturopathic doctor, nurses, certified neurofeedback technicians and registered dietitians. We hope that you want to learn more about us, our services, and how we can help you forge a new path to healing and wellness.
Because Integrative Medicine attempts to dig deeper, very specialized lab work is often ordered. This also enables us to personalize your care and cater to your biochemical individuality.
Yes, it’s the same old tropes. KU claims to combine the “best of both worlds”. Unfortunately, whenever I hears that phrase, there’s another “best of both worlds” that I can’t help but think of, and it involves assimilation. Sadly, in this case the assimilation appears to involve science-based medicine being assimilated by quackery. After all, there’s a naturopath there, and naturopathy is nothing more than a cornucopia of pretty much every quackery imaginable under the sun, be it homeopathy, traditional Chinese medicine, “energy healing” modalities, and, of course “detoxification.”
However, it isn’t the fact that there’s a naturopath based at an academic medical center promising to “listen” and provide “individualized care.” That’s pretty much par for the course. In fact, it’s probably hard to find an “integrative medicine” program that doesn’t claim to “listen” and provide “personalized” or “individualized” care. Nor was I particularly surprised to see “healing foods” or neurofeedback. Nor was I even particularly surprised to see that KU offers detoxification. No, what caught my interest was the fact that KU offers “oral and intravenous vitamin and mineral therapies,” as in IV vitamin C being offered at a major academic medical center.
Orthomolecular medicine? Yes, Orthomolecular medicine, a form of quackery that posits that if the body needs some vitamins and minerals that more, more, more would be better. Indeed, it’s the quackery espoused by Linus Pauling that features, in particular, high dose vitamin C as one of its favored modalities. And guess what? The integrative medicine program at KU offers high dose intravenous vitamin C to its patients. It even has a FAQ about vitamin infusions on its site. What’s really scary, however, is this:
How do I know if the intravenous vitamin C therapy will work for my cancer?:
Each individual responds differently, and we can’t predict how different tumor types will react. A PET scan is usually a guidepost. If the PET is positive, the tumor usually responds to the vitamin C. If the PET is negative but there is active tumor present, the vitamin C is less effective in most cases. Vitamin C works best in the early stages of cancer when used in conjunction with chemotherapy or radiation. They will only consult patients who are also following along with a traditional oncologist.
It’s even said that there are “no contraindications to giving intravenous vitamin C with any chemotherapy when proper protocol is followed” and that the only chemotherapy that intravenous vitamin C doesn’t work with is methotrexate “because of urine pH requirements.” Upon what evidence is this based? Well, before it was minimal. One study examined on intravenous vitamin C. It was an in vitro and xenograft study (i.e., preclinical), and Dr. Drisko wasn’t even the corresponding author. Another study was a case series involving two patients. The third was a review article. None were particularly impressive. After this study, the evidence still remains unimpressive.
But that’s not all.
It turns out that Dr. Drisko has a rather dubious honor (dubious, at least to me; no doubt she doesn’t consider it so). I’m referring to her title of Chair of the Alliance for Natural Health USA. Yes, ANH-USA is one of the premier “health freedom” organizations in this country, “health freedom” in reality meaning advocating for freedom from pesky government regulation that might interfere with the selling of supplements. She’s also an advisory board member for the Institute for Functional Medicine. Functional medicine, a nebulously defined “specialty,” is pure pseudoscience, as has been described before. Perhaps the most famous practitioner of “functional medicine” is Dr. Mark Hyman, who promotes it under the title of “Ultrawellness.” In fact, the sad thing is this:
Dr Drisko teaches a fourth-year medical student elective in integrative medicine along with other teaching duties to 1st and 2nd year students, nursing students, and practicing physicians. A fellowship program in integrative medicine for primary care physicians began in 2008 under Dr Drisko’s leadership. She was nominated by the University of Kansas Medical Student Assembly to receive the Rainbow Award for Excellence in Teaching the Art of Medicine.
Dr Drisko serves the School of Medicine at KU Med by sitting on multiple committees, provides guidance for the State of Kansas on topics in integrative medicine, and participates at the national level on CAM initiatives. Dr Drisko is a member of the Kansas Cancer Research Institute and an advisory board member of the General Clinical Research Center at the University.
Meanwhile, the website for KUMC helpfully tells patients:
Will my insurance cover the costs of the vitamin C infusions?
They will not cover them in most cases. Alternative medicine doctors must use billing codes that are not usually accepted by insurance companies. And because vitamin C infusions are not FDA approved, insurance companies are not inclined to cover costs. Vitamin C infusions range in price from $125.00 to $160.00.
Good to know.
Yes, you read that right. An academic medical center is trying to facilitate patients going to alternative medicine practitioners who administer high dose vitamin C.
Depressingly, Dr. Drisko is intimately involved in the education of the next generation of doctors in Kansas and has started an “integrative medicine” program for primary care physicians, the better to “integrate” woo into real medicine. This latest highly unimpressive study being touted as evidence that high dose intravenous ascorbate/vitamin C therapy is anything other than a long run for a short slide (oops, there I go again!) is merely part of the campaign to insinuate quackademic medicine even more firmly into the mainstream than it has regrettably already succeeded in doing.

   The latest chapter in the seemingly never-ending saga of dichloroacetate as a cancer treatment
David Gorski
Link
The road from an idea to a useful drug is a long one, and in cancer it is often particularly long. One reason is that to be able to tell whether a given treatment is effective against cancer often takes several years at a minimum, in order to determine if patients receiving the new treatment are surviving their disease longer than those who are not. Surrogate endpoints are usually not enough. Tumor shrinkage in response to a drug often does not correlate with prolongation of survival, although the converse (i.e., lack of tumor shrinkage in response to a new drug) does strongly correlate with failure of a treatment to prolong survival. In other words, effects observed on surrogate endpoints are not enough to judge whether a cancer therapy is working or not.
Three years ago, predating the existence of this blog by nearly a year, I became aware of a story that involved many of the issues in bringing a compound from the laboratory to the clinic. The case was unusual in that is is very rare to see the scientific process by which new drugs progress through the stages of cancer research, from concept to testing in cell culture to testing in animals to testing in humans challenged so strongly by patients themselves. The reason that this normally doesn’t occur is that new cancer treatments are almost always the product of either university-conducted research, pharmaceutical company-conducted research, or partnerships between the two. This case was markedly different in that it involved a chemical that was not only easy to synthesize, but cheap and long out of patent. Even more intriguing, it targeted a metabolic abnormality found in many cancer cells, an abnormality first described nearly 80 years before by Otto Warburg in 1928. This latter aspect of the drug gave it every appearance of a “rediscovery” of old wisdom that big pharma had ignored for 80 years, and that only added to its mystique.
The chemical was dichloroacetate (DCA), and three years ago it created a world-wide sensation. Last week, it created a sensation again, as breathless news reports once again overhyped its promise. Since I’ve been following the story since early 2007, I appear to be in as good a position as anyone to tell the story thus far and put the new findings into context. To begin that process, let’s head back to January 2007.
“The cure for cancer big pharma doesn’t want you to know about”
The DCA saga began in January 2007, when I started noticing a bunch of posts by various bloggers as well as news stories that all had similar titles, such as Cheap, safe drug kills most cancers, Objectively pro-cancer, Gotta pay, When promising cures are ignored, and, my personal favorite, Potential cheap, safe cure for cancer: Will Big Pharma Allow It? These stories described some intriguing work by University of Alberta researcher Evangelos Michelakis regarding this old/new drug that showed great promise in cell culture and rodent models of cancer (more on that shortly) that was published in Cancer Cell. Typical quotes I saved at the time:
    • “Big Pharma won’t put up the dough to fund human research and enable this drug to come to market, there’s no money in it. In fact, it wouldn’t surprise me to discover that they had an interest in actively preventing the research so as to maintain demand for more expensive less effective drugs. This drug looks to be extremely promising, and I can’t imagine that it won’t get government funding for human trials, but that said, it doesn’t pay to underestimate the power of Big Pharma…” (unfortunately the original link is gone, but the text lives on)
    • “And here I thought the pharmaceutical companies had to charge such high prices because of all the research they were doing. Seems without the possibility of future revenue they can’t be bothered. Of course, a cheap cure for cancer would cut into profits in so many ways, wouldn’t it?” (From Digby, who really, really should have known better, but didn’t.)
    • “It seems to good to be true. A cheap, effective cancer cure that BigPharma doesn’t own. If further research proves effective in humans, it could be the answer to many peoples prayers. I’ve always thought something simple, rather than the current convoluted regimen of surgery, radiation and chemicals would be the cure for cancer. Again, if proven effective, will we ever see it in use in this country? Will patients have to take ‘DCA tours’ to Canada for treatment?” (Source: Randular’s diary.)
    • “Here’s the big catch. Pharmaceutical companies probably won’t invest in research into DCA because they won’t profit from it. It’s easy to make, unpatented and could be added to drinking water. Imagine, Gatorade with cancer control.” (Source; this particular editorial was truly overwrought.)
    • “My bet is that the dichloroacetate news will fade into the background very quickly. Because neither the US government, nor any major university, nor any private company (pharma or otherwise) will have the least bit of interest in funding further studies. There will be a small handful of tiny, underfunded studies, and that will be that. Indeed, already those with vested financial and personal prestige issues will be doing their best to put the brakes on anyone who takes this development seriously. Not because the megacomplex of big government and big business wants to kill people–it doesn’t, there are few if any mustache-twirling villains–but because of the age old factors of bureaucracy, personal pettiness, ego, and conflicts of interest.” (Source: Dean Esmay, scroll down for post.)
Note that there were two assumptions here three years ago. First, these bloggers and pundits assumed that the cell culture and animal work were definitive evidence that DCA might be a “cure” for cancer. Second, the assumption was that, because the drug was out of patent and very cheap to make, neither the government nor pharmaceutical companies would be interested in funding it, thus condemning thousands, maybe millions, of people to die of cancer unnecessarily. Unfortunately, the New Scientist article and articles in the Edmonton Sun featured headlines to that effect and quotes by the investigator Evangelos Michelakis lamenting how he had had difficulties finding funding to do the next step, clinical trials in cancer. As a result of these sensationalistic stories, unscrupulous “businessmen” sought to bring DCA to the masses.
DCA and the Warburg effect
DCA is a very simple molecule, deceptively simple. Basically, it is an analog of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. Interestingly, it is only one chlorine atom off from trichloroacetic acid (TCA), a chemical we routinely use in the laboratory to precipitate nucleic acids and proteins from solution. The structure of DCA is depicted below.
DCA has been around for a long time (which is why is it no longer under patent) and has primarily been used for inherited diseases of mitochondrial metabolism. Mitochondria are often (and correctly) referred to as the “powerhouses” or the “batteries” of the cell, because it is in the mitochondria that the main energy-containing molecule, ATP, is produced using byproducts of glycolysis and the Krebs citric acid cycle to generate a proton gradient across the mitochondrial membrane, which supplies the energy for the enzyme ATP synthase, which, true to its name, synthesizes ATP for use in the cell as a chemical source of energy. The key thing to remember about oxidative phophorylation is that it requires oxygen, whereas glycolysis does not. When there is insufficient oxygen, the end products of glycolysis end up being turned into lactic acid, which is one of the things that make muscles feel tired after a rapid workout that exceeds the capacity of the body to deliver oxygen to the tissues. The primary activity of DCA in cells is to inhibit the enzyme pyruvate dehydrogenase kinase. The result, to boil it down (and not to have to stress my knowledge of the basic biochemistry of glycolosis, the Krebs cycle, and oxidative phosphorylation too much) is to shift the metabolism of pyruvate from glycolysis towards oxidation in the mitochondria. To boil it down even further, DCA shifts the cell’s metabolism from anaerobic to aerobic metabolism.
The three components of glucose metabolism are shown below in simplified illustrations:
Why, then, would such an activity be useful as an anticancer therapy?
It all boils down to something known as the Warburg effect, which Otto Warburg first described way back in 1928 and reported in Science back in 1956. Over the last five years or so, cancer researchers have been increasingly coming to appreciate the role of abnormalities in metabolism, in particular the mitochondria, in cancer. To put it briefly, many cancers (approximately 60-90%) favor glycolysis, even in the presence of adequate oxygen for oxidative phosphorylation, leading to a voracious appetite for glucose. Indeed, it is this very avidity of cancer cells for glucose that is the basis of the PET scan, which detects the high uptake of a radiolabeled form of glucose by cancer cells relative to the surrounding normal cells.
Over the last few years, there has been a sort of “chicken or the egg” argument about what is more important and what is the first abnormality leading to cancer. The traditional view has long been that mutations in DNA lead to the activation of protooncogenes into cancer-initiating and causing oncogenes and to the shutdown of tumor suppressor genes. Under this model, mutations leading to cancer also lead to the observations of abnormalities in metabolism. In the wake of the DCA furor, there have been data reported suggesting that the metabolic derangements may actually occur first or simultaneously with the mutations. p53, for instance, the granddaddy of tumor suppressor genes, can trigger the Warburg effect when mutated. Whatever the case, it is now fairly clear that abnormalities in cancer cell metabolism are very important in driving cancer growth and could well represent targets for cancer therapy. AS a result of these new data, studying the metabolism of cancer cells has become a much hotter topic of research than it has been in the past. Everything old is new again, it seems. Why cancer cells might have an advantage due to the Warburg effect is a matter of debate, although, given how tumors frequently outgrow their blood supply, being able to maintain themselves in low oxygen situations would be advantageous.
This fascinating basic science met the public in January 2007, when Michelakis and his colleagues at the University of Alberta in Edmonton published a seminal paper in Cancer Cell. In the study, DCA was tested in multiple cell culture and rodent models of cancer. In rats, tumor weights in animals treated with DCA were approximately 60% lower than the tumors in the untreated control groups. The drug increased apoptosis, decreased proliferation, and inhibits tumor growth by acting on a critical enzyme that controls the switch between aerobic and anaerobic metabolism without harming non-cancerous cells. Even better, DCA had already been FDA-approved for mitochondrial disorders, meaning that using it in humans would be an “off-label” use of an already existing drug to test it in humans. Thus, the regulatory requirements were considerably easier to meet for early drug trials in cancer.
The “Pet DCA” phenomenon
The media coverage of the Michelakis study unleashed the proverbial perfect storm of conspiracy mongering about big pharma. Never before (at least that I can recall) had a chemical that was so cheap and so easy to synthesize, not to mention already used in patients for another indication, been reported as being a “cure” for cancer. This hype, of course, neglected what those of us who do cancer research as part of our living, namely that many are the candidate drugs that show a great deal of promise in animals but fail in humans and that at present there is no such thing as a “cure for cancer.” I like to think of the example of angiogenesis inhibitors, which I’ve been studying for 13 years now. Part of what attracted me to the study of these compounds were the amazing results of the late Dr. Judah Folkman in mice, which I’ve described on this blog before. However, the amazing results in mice did not translate to humans. That’s not to say that angiogenesis inhibitors don’t work, but in humans they did not produce anywhere near as dramatic results as they did in Dr. Folkman’s mouse experiments. That’s why, rather than being a “magic bullet” for cancer, angiogenesis inhibitors entered our armamentarium of anti-cancer drugs as a useful, but not miraculous, new addition. Avastin, for instance, has increased the five year survival rates in colorectal cancer metatastic to the liver and several other cancers, when added to the current standard of care, but it has not resulted in the cure of any metastatic cancer.
That being said, I can understand how cancer patients incurable with standard therapy would leap at this drug as their last hope. Unfortunately, there were unethical “entrepreneurs” who were more than eager to supply DCA to them. The most famous of these who appeared in the months following the publicity surrounding Michelakis’ study was a pesticide dealer named Jim Tassano, who leapt to create a website known as TheDCASite.com and BuyDCA.com (the latter of which appears to be unreachable at the moment). His way of getting around the FDA? To market his DCA as “Pet DCA,” to be sold for pets dying of cancer. It was as disingenuous an approach as could be imagined, because not only did Tassano openly admit that he knew that people were buying the drug for themselves but he blithely dismissed the possibility of serious side effects in adults. Although children could take the drug with few side effects, adults who took the drug often developed serious severe peripheral neuropathy. Since peripheral neuropathy is a side effect of some commonly used cancer chemotherapeutics, taking DCA with these cancer chemotherapies has the potential to do serious harm. Moreover, when asked about the source of DCA, the webmaster Heather Nordstrom replied:
In my opinion, it is not that difficult to get, but that may be because my step father has connections with manufacturers since we invent and sell tools for our family business. We know of a chemical company in China that makes DCA. It is pharmaceutical grade. More information on the quality and source will be posted on the website that sells it.
Naturally, I was…skeptical. Worse, scammers were hyping DCA as not being “chemotherapy,” when, if it works for cancer, that’s exactly what it is.
Meanwhile, cancer patients and their families flooded the discussion boards of TheDCASite.com to write about their self-experimentation. Here are a couple of posts that I saved (the DCASite.com purged many of its forums when it started to get into legal trouble):
My husband has been using DCA since early February. He has Glioblastoma, an aggressive brain cancer that DCA is proposed to target. The naDCA he is using was made in a private lab. We turned away from our medical community, realizing that we would not receive blessings from them, since they considered him a “dead man walking”. From what I have read here, my husband seems to be the earliest “labrat”. We obtained the DCA in early February, started at a 5% dose,(to test toxicity or side effects, I suppose) and after 4 days , he insisted on taking 25mg per kg. He takes a liquid dose twice a day( totaling 25mg per kg). He has been taking DCA since Feb 7, 2007, with full dose as of Feb 11. No side effects to report as yet. Though side effects of DCA(numbness in fingers and appendages) are also symptoms of his disease, there are none to report at this time. He is also taking 100mg per day of thiamine. He is also on CCNU, Heparin, and 16 mg steroid. So far, so good. I am taking weekly urine samples to check his billyrubin, ph , etc. He still sees an oncologist, and takes chemo( CCNU). His doctors do not know that he is taking DCA. I do not trust them, they have not been terribly compassionate through this, and I do not feel that they would be as knowledgable as those of us that are in these desparate situations. I pray for all of us that I can report great news in the weeks to come. I still can’t decide at this point if he should take THiamine or not? Any thoughts?
My thought at the time was that this woman’s husband was endangering his life by taking DCA along with his chemotherapy and not telling his doctors about it. Meanwhile, as time went on, someone on the DCASite actually questioned the anecdotes in May 2007:
Maybe I am crazy but it seems like every time I ask this question the admin removes it – if not then where is the question I asked last time?
I am asking this Question -
Do we want to know or not? is this a site for lies or truth? I have DCA and I also sent money in for the clinical trials as well as having my wife dealing with stage four lung cancer currently stable with antioxident regimens. Today we go in with DCA to see if her oncologist will support her using it.
Some news here would sure be great but NO ONE who has been CT scanned after using DCA for a couple months is talking or coming back except for squareb who gave us bad news. What is going on here? are we participating in a venting session where these folks are linked with those folks selling us DCA? what exactly is going on – our lives and our loved ones lives are on the line and not ONE CT SCAN in 4 months!!!! or the TRUTH is being removed from the site and people who had scans did post bad results so it was also removed like my questions are.
I am not happy about this admin – gee sorry I lost everything sorry – what? didn’t this happen last month on another persons testimony who DIED!! while using DCA. Something is definitely missing here and I am starting to think its THE TRUTH.
I believe in DCA but I am starting to think these admins are manipulating the information to suit them which is pretty typical for us trying to survive to run into. Sorry but these admins need to either post it ALL or explain why they are not allowing CT scan results to be listed on this site. Folks just think about it – Jan, Feb, March, April and now May – 4 months and nothing – come on folks lets get real here – do you really think its a coincidence?.
It is too bad that more people didn’t ask questions like this. squareb, by the way, was an early adopter of DCA whose tumor progressed on the drug.
Unfortunately, Jim Tassano wasn’t alone. For example, a family physician in Toronto named Dr. Humaira Khan, even though agreeing with the warnings not to use DCA outside the auspices of a clinical trial, decided to start selling DCA for $150 a week, using arguments of “health freedom” and wanting to “supervise” patients who would take the drug anyway. Dr. Khan’s webpage on DCA appears not to have been updated since 2008 but is claiming a high response rate. Odd, though, I haven’t seen this published anywhere in the peer-reviewed scientific literature, and a PubMed search turns up…nothing, at least nothing by Dr. Khan or anyone associated with her. Jim Tassano himself also tried to do a “clinical trial” of DCA that was basically nothing more than a questionnaire that–I kid you not–included questions like:
    • Do you think DCA is working for you? Why or why not? Scans? Examinations? Blood level testing? Here, I encourage you to freeform answer.
    • How do you rate your health compared to when you started DCA? 1. Much better; 2. Somewhat better; 3. About the same; 4. Somewhat worse; 5. Much worse
I trust that SBM readers will immediately recognize why such questions are worse than useless. Basically, they are doing nothing more than soliciting testimonials, and testimonials in cancer are often highly misleading, and that’s all TheDCASite has now. This is just as true for something like DCA as it is for any alternative medicine cancer therapies. Fortunately, in July 2007 the FDA finally acted to shut down TheDCASite.com, at least as far as selling DCA went. In response, Tassano shut down BuyDCA.com and morphed TheDCASite.com into an “informational” website. Much of what was on the forums there disappeared. Meanwhile, conspiracy theorists had a field day denouncing the FDA’s action.
Back to the future
Over the last couple of years, my biggest fear was that the activities of “entrepreneurs” like Jim Tassano would taint what is a scientifically fascinating and potentially very useful new cancer therapy with the indelible stain of quackery. DCA is most definitely not quackery. It is, however, unproven in humans and thus may not be effective, which is why self-treatment and treatment by doctors who have no clue what they are doing are not advisable. Fortunately, while ignorant businessmen like Tassano and opportunistic doctors were selling DCA to desperate cancer patients, a clinical trial was beginning by Michelakis and his team, and last week the results were reported in Science Translational Medicine entitled Metabolic Modulation of Glioblastoma with Dichloroacetate.
The first part of the study was something quite fascinating that I don’t recall ever having seen before in a clinical trial. Michelakis and colleagues studied 49 consecutive surgically excised glioblastomas. Glioblastoma is an aggressive form of brain cancer known to exhibit the Warburg effect and thus a good candidate for the first attempts at testing DCA in humans. These tumors were then tested in vitro with DCA. The excised tumors did demonstrate evidence of the Warburg effect, and treatment with DCA resulted in significant reversal of some of these features in the excised tumors, particularly mitochondrial hyperpolarization, while not having any effect on normal tissues excised with the cancers. The second part of the study is what most media and blog reports focused on. Michelakis treated five patients with neuroblastoma with oral DCA. However–and this needs to be emphasized–patients were also treated with temozolomide and radiation, with DCA added to the mix. The DCA dose started at 12.5 mg/kg orally twice a day for 1 month, and then the dose was increased to 25mg/kg orally twice a day. Michelakis then followed a dose de-escalation protocol, decreasing the dose by 50% when dose-limiting toxicity occurred. The patients were followed clinically for up to 15 months. In other words, this appeared to be a combined phase 0/phase I clinical trial.
For those not familiar with the various types of clinical trials, phase I clinical trials are not trials of efficacy. They are designed to determine two things: dose and dose-limiting side effects. They generally use a few patients (although five patients represent a rather small number, even for a phase I trial, which usually requires around 10 or 20), and it is not uncommon to perform a dose escalation. Researchers don’t expect necessarily to see tumor response in a phase I trial, as that is not the purpose of the trial, but it is heartening when tumor shrinkage is observed, for obvious reasons. Phase 0 trials similarly are not therapeutic trials but rather seek to determine if the drug is doing biochemically what it is expected to do based on preclinical studies. The usual design is to take a biopsy of the tumor, test it for biochemical markers in the laboratory, treat the patient with experimental drug, and then resect the tumor. The biochemical markers in the resected tumor are then compared with those measured in the pre-treatment biopsy. The idea is to see whether the drug can recapitulate biochemical changes in actual living tumors in human patients, the idea being that, if it can, then the drug is “hitting the target” (i.e., its molecular target) and therefore “working.” Whether its “working” actually shrinks tumors or results in prolonged patient survival is then the next question that has to be tested.
Michelakis went one further in that he isolated tumor cells from the pretreatment biopsies and produced glioblastoma cell lines. He could do this in three of the patients because he had tissue from their first debulking surgery, and these patients had recurrent glioblastoma that had failed additional chemotherapy (patients 1 through 3). All of them had had multiple rounds of different chemotherapy. Patients #1 and #2 showed signs of improvement or were at least stable for the full 15 months of the study, while patient #3 died three months after starting DCA therapy. Two other patients (patients #4 and #5) had new diagnoses, allowing initial tumor tissue from debulking surgery to be examined. Their treatment was somewhat different. After his first surgery, patient #4 underwent DCA therapy for three months followed by DCA and standard therapy. However, by the end of the third month, the patient showed evidence of progression requiring a second operation. Patient #5 underwent surgery followed by DCA and radiation with temozolomide for six months and then stayed on DCA for nine more months and is doing well.
The reason I mention this is because not only were there only five patients, but they were not all even treated the same way. They were treated with varying regimens of surgery, with drug therapies combining DCA and chemotherapy (mostly temozolomide), some with and some without radiation. Even so, the tissue from these tumors showed signs of metabolic reversion to an oxidative phosphorylation phenotype. The problem is, as both our very own David Kroll pointed out, we don’t know for sure if the DCA was responsible for this effect. As a cancer researcher, I can’t say whether the regressions observed were due to DCA, although the regression of paraventricular masses in patient #1 and the regression observed in patient #5 are certainly fairly suggestive (at least to me) of an anti-tumor effect due to DCA alone. The only side effect Michelakis reported was a reversible change in peripheral nerve function.
So what does this all mean?
I’m frequently asked why we shouldn’t just use DCA now–or even let people use it the way that they were using Jim Tassano’s homemade DCA? What’s the harm? That’s a rather difficult question, because there is always a conflict between wanting to do something now for suffering patients, damn the consequences, and following the scientific method to demonstrate efficacy and safety. Our nation has been at both extremes. Indeed, until 1906, pharmaceutical companies could make essentially any claims and sell essentially anything to the public as a drug without regulation. We all know how well that worked out. Early in the history of the FDA, as Dr Jerome Groopman points out, companies often tested new drugs by sending them to doctors to offer to their patients, asked for little information regarding side effects and complications, and had no standard criteria for efficacy. There was a reason we moved away from such a system.
I think Dr. J. Leonard Lichtenfeld, Deputy Chief Medical Officer for the national office of the American Cancer Society, put it well in writing about this latest DCA study on his blog, Dr. Len’s Cancer Blog:
This research still needs lots of work before we know whether it works or doesn’t work, and whether it is really safe or not when given to patients with cancer under a variety of circumstances.
If that sounds overly cautious, so be it. I have seen too many dashed hopes in my medical career which make me a bit cautious about reports like this. That’s not to say I don’t think it could work—it could, as I mentioned above—but I want to see evidence in well done trials that prove the point that DCA is effective in the treatment of which cancers under what circumstances.
Early in my cancer training there was a substance isolated by a researcher that was supposedly non-toxic and would cure leukemia. The research center where I was working was inundated from people around the globe who wanted this treatment, especially after the lead researcher injected himself on a nationwide morning show to demonstrate its apparent lack of toxicity.
Only grams of this medicine existed. Fortunes were offered in return for getting this miracle drug.
But the miracle drug—after reasonable clinical trials were done—didn’t work after all.
Many are the lists of new “miracle cures” that have met this same fate. The difference today is that the Internet has allowed news of these drugs to be disseminated to more people than ever before–and faster than every before. Moreover, it has linked patients and activists into mutually supportive disease-specific communities, who can inform and educate each other, as well as publicizing research about their disease and lobbying legislators. The dark side of this power, however, is that it can facilitate the spread of false hope and the demand for a drug after only cell culture and animal work, before it even makes it to human trials. Add unscrupulous “entrepreneurs” into the mix, and the potential for harm is great.
One has to remember that cancer is not just one disease. Not only that, but even a single type cancer is often not just one disease. As I have written extensively about before, cancer is incredibly complex. Because of that complexity, it’s incredibly unlikely that any one drug will be any sort of “magic bullet” to cure cancer. Worse, simply using a drug like DCA outside the auspices of well-designed clinical trials will virtually guarantee that we will never know for sure whether the drug actually works. Because of that, as frustrating as it is, as slow as it is, letting science take its course to determine if DCA works, how it works, and for what cancers it works, is the best method to make sure that the most patients are helped and the fewest are harmed. I don’t say this because I want DCA to fail; I say it because I would very much like to see DCA succeed.

   Why we don’t prescribe bark for cancer
David J Kroll
Link
My valued colleague, Dr. Antonio Baines, recently invited me to speak for his graduate course in Toxicology. Dr. Baines’ course is one of the most highly-regarded graduate classes at North Carolina Central University for M.S. students in Biology and Pharmaceutical Sciences. Antonio asked that I discuss the pharmacology and toxicology of herbal and non-botanical dietary supplements but pretty much gave me free reign as to the mechanism by which I would do so.
In the past, I have often introduced herbal supplements to students who already know a bit about drug and toxicant action by taking the example of the anticancer drug, taxol (Note: Little “t” taxol was the name originally given to this chemical by its co-discovers but the corporate sponsor used it as a registered trademark for the brand name, big “t” Taxol, and the USAN proposed the use of the cumbersome paclitaxel as the generic name.). As I noted in my previous post, taxol is an anticancer drug isolated from the bark of the Pacific yew tree, Taxus brevifolia, and was the first compound shown to kill cancer cells by promoting microtubule polymerization (and preventing depolymerization).
As a teaching tool in demonstrating how far we’ve come since Sertürner first isolated codeine and morphine from the opium poppy, I ask students to answer a rather simple, seemingly flippant, but highly informative question:
If taxol is an anticancer drug with known clinical activity against ovarian, lung, and breast cancer, why don’t we prescribe Taxus bark for cancer?
Similarly, why doesn’t the dietary supplement industry promote ground Taxus bark as an oral dosage form, herbal remedy to promote well-being for cancer patients?
These questions get to the heart of why we have come over 200 years from Sertürner’s day: to purify and concentrate pharmacologically-active constituents from natural products:
1. Drug metabolism and lack of oral bioavailability: Orally adminstered drugs are subject to first-pass metabolism when absorbed in the gut. The mesenteric blood supply collects into the hepatic portal vein and must get through the liver before being distributed to the rest of the body. The primary Phase I drug oxidizing enzymes and Phase II drug conjugating enzymes are in their highest concentrations in the liver and many compounds are metabolized to inactive compounds before they even reach the systemic circulation. (N.B., The intestinal mucosa also contains some cytochrome P450 isozymes, so metabolism starts even earlier than that.) As a result, many drugs, like taxol, must be given intravenously to preclude first-pass metabolism.
2. Influence of bark composition: Lignans and cellulosic compounds might interfere with the absorption of taxol by preventing its dissolution. In fact, any change in the amount or composition of inactive excipients in a prescription drug can dramatically influence dissolution and drug absorption. Other components of the bark might as as competitive inhibitors of taxol’s binding to tubulin or, in a broader sense, have some other adverse influence on drug pharmacodynamics. In addition, other components of the bark might enhance the metabolism of taxol. This leads us into:
3. What is the appropriate dose of bark?: This is a major stumbling point with herbal medicines. Indeed, botanical products may contain physiologically-active compounds, but these may be at concentrations too low to achieve relevant plasma concentrations. Taxus bark contains 0.05 to 0.005% taxol. Even if taxol were orally-active, the amount of bark one would have to ingest would be so large as to present a patient compliance issue (or at least severe gastrointestinal discomfort).
4. Reproducibility: If a tumor response was observed, how would one know how much bark to give the patient for the next dose? The environment (weather, soil composition, water, sun) in which the trees are grown can all influence the abundance of secondary metabolites present in crude plant material. Hence, there are significant lot-to-lot variations in the chemical composition of botanical products. Even if all of the above issues were circumvented, the reproducibility of subsequent doses might have unpredictable biological effects.
5. Toxicological issues: Again related to growth environment, many plants are bioaccumulators of heavy metals from the soil, especially cadmium. With many recent reports of heavy metal contamination of herbal remedies, companies are only now beginning to test their raw materials for heavy metals. Plant materials could also be contaminated with pesticides, insecticides, or harmful microorganisms that would also be removed if the active principle were purified. Moreover, there have been several cases of botanical products intentionally or accidentally adulterated with other prescription drugs (called ‘undeclared drugs’ by the US FDA) in the attempt to produce a biological effect that the plant medicine is incapable of having itself.
There are certainly more issues that readers are welcome to add in the comments. The point of this exercise was to demonstrate to students the distinctions between the safety and efficacy of crude plant products relative to pure drugs isolated from such natural sources. This discussion and list was compiled in a fraction of the time it took me to type it.
I wish to acknowledge the students of Dr. Antonio Baines’ BIOG 5140 – Toxicology class at North Carolina Central University for their individual contributions to this post:
Onize (Ony) Aiyede, Lavita Anderson, Chantal Bodkin-Clarke, Jamila Broadway, Shailendra Devota, Chang Hun Lee, and Roketa Sloan.

Eric Merola and Ralph Moss try to exhume the rotting corpse of Laetrile in a new movie
David Gorski on February 24, 2014
Link

Note: Some of you have probably seen a different version of this post fairly recently. I have a grant deadline this week and just didn’t have time to come up with fresh material up to the standards of SBM. This left me with two choices: Post a “rerun” of an old post, or recycle something. I decided to recycle something for reasons explained in the first paragraph of this post.
As I was deciding what to write about this week, I realized that, surprisingly, there is precious little on Science-Based Medicine about the granddaddy of modern cancer quackery, Laetrile. Given that the final nails were placed in the coffin of the quackery that was Laetrile more than 30 years ago in the form of a clinical trial that didn’t show a hint of a whiff of benefit in cancer patients, many of our younger readers might not even know what Laetrile is. But, as I explained when I wrote about Stanislaw Burzynski’s early years in the 1970s, which happened to be they heyday of Laetrile, in cancer quackery everything old is eventually new again, and Laetrile is apparently soon to be new again. True, it’s never really disappeared completely, because, again, no matter how discredited a cancer quackery is, someone somewhere will keep selling it and some poor cancer patient somewhere will be taken in. In any case, it occurred to me that we at SBM have discussed the politics of Laetrile. Indeed, Kimball Atwood once referred to it as the “the most lucrative health fraud ever perpetrated in the United States.” Moreover, Kimball makes a convincing case that the Laetrile controversy was an important precursor that laid the groundwork for advocates of “alternative medicine”—or, as it later became known, “complementary and alternative medicine” (CAM) or “integrative medicine—to successfully lobby for the founding at the National Institutes of Health of what later was named the National Center for Complementary and Alternative Medicine (NCCAM). However, there didn’t appear to be a post dedicated to discussing Laetrile itself, and something happened last week that allows me to rectify that situation.
So how is Laetrile about to become new again? Remember our old buddy Eric Merola? He’s the guy who made two—count ’em—two conspiracy-laden, misinformation-ridden, astonishingly bad bits of “great man” propaganda disguised as documentaries about a Houston cancer doctor peddling unproven cancer treatments and charging his patients tens and even hundreds of thousands of dollars for the privilege of being under his care while receiving this magic elixir, known as antineoplastons. Over the last several months, ever since he unleashed Burzynski: The Sequel on an unprepared and uninterested world, Merola has been hinting about his next project. Given Merola’s involvement in Zeitgeist: The Movie and his primary role in throwing together two hack propaganda pieces that were so blatantly worshipful of Burzynski that Leni Riefenstahl, were she still alive and able to see them, would have told Merola to cool it with the overheated hero worship and portrayal of his movie’s subject as a god-man a bit, I knew his next movie would be more of the same. I also knew it would not be about Burzynski.
What it would be about, specifically, remained a mystery, however, until about two months ago, when it was revealed that it would be about Ralph Moss, who, it turns out, is one of the foremost promoters of Laetrile and was intimately involved with putting pressure on Congress to push for clinical trials of Laetrile, even though there was nothing that would resemble convincing preclinical evidence to justify such a trial. It also turns out that he was one of the original “Harkinites,” described by Dr. Atwood thusly:
His degree is in classics, but he has styled himself as an expert in cancer—mainly “alternative” cancer treatments. Moss was a long-time member of the NCCAM’s Cancer Advisory Panel for Complementary and Alternative Medicine (CAPCAM). In 2004 he wrote a glowing eulogy for rabid Laetrile promoter Michael Culbert, who had been a vice-president of the Committee for Freedom of Choice in Medicine, the major Laetrile advocacy organization. Moss has recently written approvingly of Mexican cancer clinics that continue to peddle Laetrile, although he is careful to add that “there are no reliable ‘miracle cures’ for cancer in Tijuana or elsewhere.”
Somehow, I’m not surprised that this man is the topic of Eric Merola’s new movie. Apparently he’s found a new hero to worship other than Stanislaw Burzynski.
Last week, the YouTube channel for Merola’s movie, Second Opinion: Laetrile at Sloan-Kettering dropped four (!) trailers on an unsuspecting (and even more uninterested) world. My first reaction was: Did I read that right? Laetrile? I guess Merola must need a new conspiracy, his having so totally had his posterior handed to him over and over and over again over Stanislaw Burzynski. One wonders if Burzynski is about to lose his very own personal Leni Riefenstahl. (Hey, if Burzynski and Merola can Godwin the skeptics critical of Burzynski, I can return the favor, at least in jest.) Besides, the comparing Merola to Leni Riefenstahl does a profound disservice—to Leni Riefenstahl. After all, Leni Riefenstahl had serious talent, as vile as the cause to which she dedicated her talent was. Eric Merola? Not so much.
But let’s take a look at the trailers. I must admit, Merola’s production values are a bit better than they were. At least that robotic-sounding announcer doesn’t appear to be there anymore, although the cheesy music is, as are the annoyingly artificial, film school artsy camera angles, overcooked for straight documentary interviews, are still there. In the first one we see:
Of course, as I mentioned in the beginning of this post, Moss has been pushing Laetrile since the 1970s, complete with an obviously nonsensical conspiracy theory about how the leadership at Memorial Sloan-Kettering Cancer Center (MSKCC), where he worked as a medical writer, had suppressed evidence that it worked. Back then, Laetrile was the biggest cancer quackery going, way, way bigger than anything Stanislaw Burzynski had done, bigger than just about any bogus cancer therapy I can think of. You can see it from the NEWSWEEK cover from the period at the beginning of the clip, which proclaims that perhaps 70,000 Americans with cancer had crossed the border to Mexican quack clinics (well, it didn’t use that word, but it’s accurate) to get Laetrile. I must admit that I had never personally delved into some of the primary literature about Laetrile, but Merola’s movie gave me an excuse to do it. It’s quite revealing.
At least Merola got it right to describe Moss as a science writer at MSKCC. Depending on when he’s telling it, Moss has—shall we say?—inflated his credentials. For instance, in his book The Cancer Industry, Moss apparently represented himself as assistant director of public affairs, implying that an executive-level position made him privy to the innermost workings of MSKCC. Oddly enough, at least one contemporaneous account of the controversy also refers to him by that title. It turns out that he was nothing more than, as Merola reports, a science writer, being employed at MSKCC from 1974 to 1977 and receiving a “summary discharge.” (In other words, he was fired. In fact, he was fired the day after Second Opinion, who are discussed below, was trumpeted to the public, as this summary of the incident from 1977 published in Science describes.) His position was characterized as “ranked at the lower end of the pay scale.”
It strains credibility to believe that Moss could really have known much, if anything, about the high level machinations he claims to know about, even though a quote from the same account suggests that he did. Whatever the true case, other than Moss, the principals of the Sloan-Kettering incident are no longer alive and can’t confirm or deny Moss’ account. None of this stops Moss from spinning a tale of suppression of research by the powers-that-were at MSKCC to hide evidence that Laetrile was active against cancer, going so far as to say that all the leaders of MSKCC who stated that there was no evidence that Laetrile (or, to be more scientifically accurate, amygdalin) had significant anticancer activity were lying, accusing them of a cover-up. Why would MSKCC want to cover up evidence of a highly effective cancer treatment? As is the case with Burzynski, Merola, letting Moss tell his story unfiltered, never explains this convincingly.
In any case, Moss and a group of employees from MSKCC “leaked” documents which, or so they claimed, “proved” that Laetrile/amygdalin worked in animal models. This group, known as Second Opinion, wrote a report “blowing the whistle” about the cover-up. If these clips are to be judged, it’s going to be another hilarious bit of paranoid conspiracy mongering. Particularly amusing is this clip:
What was your reaction when you watched this? (Seriously. Watch it. It’s less than 2 minutes.) First, we have the unlikely tale of Moss meeting with all the top administrators of the Sloan-Kettering Institute to find out their views on Laetrile. Next, we’re treated to a bizarre story in which Moss claims to have met with Lloyd J. Old, MD, the vice-president of the Sloan-Kettering Institute at the time. Dr. Old is claimed to have said to Moss: “You want to know where we get all of our new ideas?” Old supposedly handed Moss a book, saying, “Here, this is the Bible.” That book, allegedly, was the American Cancer Society’s book, Unproven Methods of Cancer Management. (Sadly, it’s a book the American Cancer Society no longer publishes.) Basically, it was a list of cancer quackery, a compendium of brief articles the ACS published in its journal from the 1950s to the early 1990s describing modalities considered to be cancer quackery (although even then the ACS didn’t use that word), with brief explanations and reviews of the evidence showing why they were quackery.
My first thought was that Moss’s account was the proverbial pile of fetid dingoes’ kidneys. But then I wondered. Is it possible that Dr. Old might have been having a little fun with a clearly gullible young science writer who had probably by that time developed a reputation around MSKCC for believing in Laetrile, that he might have been pulling a credulous young writer’s leg, and messing with him a bit? I wonder. Certainly the story doesn’t sound particularly convincing, but if something like that did happen, I can totally picture Moss falling for a prank like that hook, line, and sinker. Who knows? As an aside, I happen to have collected quite a number of articles from the ACS Unproven Methods list. Some of this stuff I hadn’t heard of before. One of these days I’ll have to march through parts of the list. It’s perfect SBM material that can be done any time. In any case, I did find the last entry on Laetrile in the list, published in 1991, to be most helpful for this post.
Next up is another clip:
Now it’s not enough that Moss claims to have been buddies with the vice president of the Sloan-Kettering Institute. According to him, he was also buddies with Robert Good, MD, the president of the Institute himself. If Moss is to be believed, he was discussing writing a book with Dr. Good. Whether you believe this or not, Moss tells of an incident of scientific fraud that occurred that Dr. Good had to deal with, involving a researcher working for him named William Summerlin. This was a very famous case of scientific fraud in the 1970s, in which Summerlin convinced people that he could transplant skin from black mice onto white mice. If true, this would have been a major breakthrough because of the difficulty in getting transplants from genetically unrelated organisms to “take.” Supposedly, Summerlin accomplished this feat by culturing the skin in special solutions. In reality, he used black ink markers to darken the fur. It’s hard to believe anyone could get away with a trick that simple and obvious, but for a while Summerlin did, all while working for Dr. Good, who, impressed with his work, became his mentor and saw to his promotion. Ultimately Summerlin was found out, and the story made national news. (Indeed, an excerpt from a news report on the incident by Walter Cronkite himself is included in the clip above.) Moss says that this scandal broke the same day he learned he was getting a job at the Sloan-Kettering Institute. I suppose he tells this story to imply that Memorial Sloan-Kettering Cancer Center played fast and loose with science at the time. He denies it, and maybe Moss didn’t intend it that way, but you can be sure that Merola did.
So why, according to Merola, did Moss go on to become a Laetrile warrior and hardcore promoter of unproven “alternative” medicine? (Excuse me, that’s redundant.) Here is the blurb:
One of his first assignments was to write a biography about Dr. Kanematsu Sugiura, one of the Center’s oldest and leading research scientists as well as the original co-inventor of chemotherapy.
While meeting with this iconic scientist to pen a biography on his 60-year career at Sloan-Kettering, Moss discovered that Sugiura had been studying this “quack remedy” in laboratory mice, and with unexpectedly positive results. Shocked and bewildered, Moss reported back to his superiors what he had discovered, only to be met with backlash and denial from Sloan-Kettering’s leaders on what their own leading scientist had found.
Fueled by respect and admiration for Sugiura—Ralph W. Moss attempted to publicize the truth about Sugiura’s findings. And after all diplomatic approaches failed, Moss lived a double life, working as a loyal employee at Sloan-Kettering while also recruiting fellow employees to help anonymously leak this information to the American public—through a newly formed underground organization they called—“Second Opinion”.
There’s no doubt that Dr. Sugiura was a pioneer in chemotherapy research. (His obituary was published in Cancer Research, and, trust me, Cancer Research doesn’t do that for just any cancer researcher.) Were it not for his involvement in Laetrile research in the mid-1970s, people like Moss and Merola would revile him as one of the people who contributed to the “poisoning” of patients.
Here’s also where other sources were useful, because a lot of what’s on Merola’s website is the same old sorts of misinformation that he previously used in the service of Burzynski. The negative clinical trials were rigged not to work. He claims Laetrile “tested positively” in preclinical studies but that those results were covered up. Dr. Sugiura’s work was claimed to have been suppressed, causing Moss to form his “Second Opinion” group, which ultimately got him fired from Sloan-Kettering. At least, it sounds as though he were fired; it’s not clear. Whatever the case, it’s the same old conspiracy tropes that one finds swirling around Burzynski and his unproven cancer treatments. No wonder Merola was attracted to the topic. Of course, Laetrile was studied. It didn’t work.
So what about the “positive” results?
First, what is Laetrile, which is often interchangeably called amygdalin or “vitamin B-17,” even though it’s not a vitamin? Basically, “Laetrile” is the trade name for laevo-mandelonitrile-beta-glucuronoside, a substance allegedly synthesized by Ernst T. Krebs, Jr. in the 1920s. It’s chemically related to amygdalin, a substance found naturally in the pits of apricots and various other fruits. Again, most proponents of Laetrile for the treatment of cancer use the terms “Laetrile” and amygdalin interchangeably. Apparently amygdalin was tried as an anticancer agent as early as 1892, but was abandoned because it was ineffective and toxic, because it can break down into glucose, benzaldehyde, and hydrogen cyanide. (Yes, that cyanide.)
Like a lot of cancer quackery, the rationale for Laetrile has shifted over the decades. In the 1950s, Kreb claimed that cancer tissues are rich in an enzyme that causes amygdalin to release cyanide, which would destroy the cancer cells. Supposedly noncancerous tissues are protected by another enzyme. (Yeah, right.) Later, Krebs claimed that Laetrile/amygdalin is a vitamin (B17) and, of course, cancer is due to a deficiency in that particular vitamin. Other claims have shifted, from Laetrile being a cancer cure to being able to “control” cancer to being a cancer “preventative.” I see this in Merola’s website, where in one passage he claims that the reason the clinical trial in the 1980s showed no anti-cancer activity due to Laetrile is because it arrests cancer growth and shouldn’t be expected to work in advanced cancer. (Funny, the quacks in Tijuana never had any problem claiming Laetrile could cure advanced cancer.) I also note a great similarity with how evidence for antineoplastons is presented. For example, check out this story from the article on Laetrile on Quackwatch about Dr. Ernesto Contreras, one of the most—shall we say?—most active Laetrile doctors in history who ran a clinic in Tijuana in the 1970s:
By 1974, Dr. Contreras stated that he was seeing 100-120 new patients per month, with many more patients returning to obtain additional Laetrile. Patients typically were charged $150 for a month’s supply. Contreras acknowledged that few of his cancer patients were “controlled” with Laetrile. While admitting that 40% of the patients displayed no response, he claimed that 30% showed “most definite responses” to the drug. However, these statistics may not be reliable. In 1979, he claimed to have treated 26,000 cancer cases in 16 years. Yet when asked by the FDA to provide his most dramatic examples of success, Contreras submitted only 12 case histories. Six of the patients had died of cancer, one had used conventional cancer therapy, one had died of another disease after the cancer had been removed surgically, one still had cancer, and the other three could not be located [5].
Sound familiar?
The National Cancer Institute carried out a retrospective case review of case records of patients treated with Laetrile by practitioners all over the country in 1978. There were 67 case records submitted as “best cases.” Of these, the NCI could find evidence of a possible complete response in only two patients and of a partial response in four. Other reviews of case histories presented as the “best evidence” for Laetrile (such as this one) found no convincing evidence that it might have anticancer activity in humans.
The final nail in the coffin of Laetrile (unfortunately not the final nail in the coffins of Laetrile patients) was a clinical trial published in the New England Journal of Medicine in 1982, along with an accompanying editorial. Merola, not surprisingly, doesn’t like this trial and disingenuously criticizes it:
As explained in “Chapter 4″ of the “DVD Extras” of this project, the human clinical trials conducted were not designed based upon standard protocol by designing the human trials around the previous successful animal studies, which showed that Laetrile prevented cancer, stopped it’s [sic] ability to spread, and relieved pain. Instead, they chose patients who had exhausted all previous forms of therapy, and gave them Laetrile. The average survival time for these patients in the Laetrile studies was only 4.8 months.
They also did not conduct a randomized trial, instead they conducted a non-randomized Phase II study, with no basis for comparison to see how Laetrile fared against chemotherapy and/or radiation. Given that chemotherapy and radiation were unable to help these patients, it would be highly unlikely that Laetrile would have had any positive effect, since Laetrile was only proven in lab studies to prevent cancer and keep it from spreading, when administered in the early stages of cancer. Therefore, it would make sense that Laetrile would be ineffective within a group of late stage cancer patients.
Yes, this was a non-randomized phase II trial, but it was done that way because given the politics of the time it almost certainly couldn’t be done any other way, as the accompanying editorial noted that the trial had to “pick its way through a minefield of formidable obstacles.” It couldn’t be controlled, randomized, or blinded. As Dr. Arnold Relman described:
It avoided ethical objections by giving Laetrile to all patients (with fully informed consent, of course), but selecting as subjects only those for whom there was no known effective treatment or in whom standard treatments had already failed. On the other hand, it blunted the anticipated criticism from the Laetrilists by selecting patients only in good general condition and by including fully a third who had never received chemotherapy or radiotherapy and therefore might be considered particularly good candidates for Laetrile.
Yes, this was very much like trials of quackery like the Gonzalez Therapy, ten years before the founding of the office that would later become the National Center for Complementary and Alternative Medicine (NCCAM) and 20 years before the travesty of ethics and science known as the Gonzalez trial. In any case, 175 patients with advanced cancer were treated with Laetrile plus a “metabolic” therapy commonly used with Laetrile at the time. To blunt criticisms of the Laetrilists that the investigators weren’t using high enough doses, the investigators treated patients with a “standard” Laetrile dose and what they referred to as an “extremely high dose program.” The end results showed only one patient who met the criteria for a partial response to therapy, and that sounds as though it wasn’t real. The patient had stable tumor size for five weeks, then moved to another location, where his initial tumor measurements met the criteria for partial response. His tumor then progressed. Thus, this was a questionable, transient response. There was no evidence of prolongation of life based on historical controls and no evidence of tumor response, but there were several cases of cyanide toxicity. The bottom line was that there was not a hint of a whiff of any evidence that Laetrile had antitumor activity.
But what about the mouse studies by Dr. Sugiura? As our good friends at the American Cancer Society point out, at least a dozen sets of animal experiments were performed at seven institutions with a variety of transplantable tumors treated with Laetrile from different sources, including from the key organization at the time promoting Laetrile, the McNaughton Foundation. In all experiments that were properly blinded and used objective tumor measurements, there was no evidence of anti-tumor activity due to Laetrile. Then:
In 1975, Laetrile advocacy groups claimed that positive results had been obtained at Memorial Sloan-Kettering Cancer Institute. These experiments were not blinded and were based on visual estimation, rather than quantitative measurement, of metastatic growth. Further double-blind experiments that used an objective bioassay for metastatic growth were negative.
That would be this study, which concluded, “we do not have evidence to support taking amygdalin to clinical trial, although other considerations may require that one be conducted.” Those “other considerations” were lobbying and political pressure due to the activities of pro-Laetrile activists and pseudoscience-friendly legislators.
Science published a news/opinion article about Laetrile at MSKCC in 1977 that laid out the history of MSKCC’s testing of Laetrile. Some key passages:
Stock makes clear that he does not say Sugiura’s results are wrong. But he and Good believe that an important test for choosing between Sugiura’s results and his colleagues’ was a blind experiment in which the mice were injected by others and Sugiura, who did the pathology, was not told which mice were treated with laetrile and which were the controls. Although the system was the same as that of Sugiura’s first six experiments, in this case laetrile turned out to possess no anticancer activity.
If the inference is made that the results with the 14 tumor systems are more likely to be true, Sugiura’s results are an anomaly. No immediate explanation is available, but perhaps none is necessary: anomalies are a common feature of the scientific landscape and there is only time to resolve the most interesting.
This is very, very common. Even the best scientists forget that not just clinical trials need to be blinded. Animal experiments should, ideally, also be blinded, just as clinical trials are, particularly if measurements are being made that are the least bit subjective, such as a human being counting and estimating the volume of metastases. These days, we have much more objective systems, such as imaging systems that can calculate tumor volume based on volumetric estimates, which make blinding not always as critical. Still, many of these systems rely on humans to judge where the edges of the tumors are; so even then blinding is important. Here’s another telling passage, quoting the scientist whose records the Second Opinion Group managed to get a hold of:
Second Opinion charges that Sloan- Kettering has suppressed some results favorable to laetrile. The group has obtained certain data from the files of Elisabeth Stockert, a member of the Sloan- Kettering team, and claims that they show a positive anticancer effect for laetrile. Stock says he did not suppress the results, because he didn’t know about them, and would not have included them if he had because they are uninterpretable. Stockert agrees; the study, she says, was not a proper experiment but a preliminary investigation which had to be abandoned when she went to Paris for 5 months.
In other words, Second Opinion cherry picked some preliminary experiments that, according to the Science article, were “uninterpretable,” and ignored all the negative experiments.
The bottom line is that Eric Merola has once again yoked his horse to a scientific and medical loser, an even bigger loser than Burzynski has been. Laetrile was discredited a long time ago. His complaints about the lack of a randomized clinical trial are, as usual, whining. To get to a good randomized clinical trial, one needs convincing preclinical evidence in the form of cell culture and animal models, for which none existed for Laetrile, and a preliminary clinical trial. Well, the preliminary clinical trial was done, and it was negative. When that happens, in the normal course of drug development, the drug is abandoned; it is not taken to a larger randomized clinical trial. In fact, given the spectacular failure of Laetrile in animal studies and the NEJM clinical trial in 1982, it would be unethical to do another trial.
I do see one purpose to Merola’s resurrection of the rotting, apricot-scented corpse of Laetrile. Burzynski is currently trying to duplicate the political activism of the Laetrile supporters of the 1970s. Let’s hope he doesn’t succeed, because the Laetrile activists like Moss came the closest of anyone to persuading Congress to legalize cancer quackery—at least before Senator Tom Harkin persuaded Congress to create the NCCAM. It is, however, not surprising that Merola would be as attracted to Ralph Moss as he was to Stanislaw Burzynski, nor it is surprising that Burzynski is currently making similar arguments to the ones made by the Laetrilists in the 1970s.

Avemar: Wheat Germ for Cancer
Avemar is fermented wheat germ. It is claimed to be an effective addition to conventional cancer treatment. The evidence is lacking.
Harriet Hall on August 31, 2021
Link

The initials of the Australian organization Friends of Science in Medicine (FSM) happen to be the same as the Flying Spaghetti Monster but the two are diametrically opposed. The latter began as a satire on creationism and developed into a religion that makes unsupported and untestable claims; the former was established in 2011 to emphasize the importance of rigorous science in health care and to question unsubstantiated health claims. It focuses on Australia but has many members around the world, including most of the writers for Science-Based Medicine. Friends of Science in Medicine is currently challenging Australian regulations regarding “food as medicine”. They have found a marked discrepancy in consumer protection between the standards for therapeutic claims for medicines and therapeutic claims for foods. FSM’s current president, Ken Harvey, has written about Avemar, classified as a “Food for Special Medical Purposes for Cancer”, here. He mentions that the price of a month’s supply is $220 AUD.
Outrageous claims
Avemar is being promoted in the US with these outrageous claims:
Researchers have proved that Avemar is an effective cancer treatment that unlike other alternative cancer treatments does not treat a single type of cancer but works effectively in treatment of all types of cancer. It can therefore be used effectively in fighting breast cancer, cervical cancer as well as other cancers that have victimized our women for centuries.
Avemar also helps the immune system in identifying and killing the cancer cells. It strengthens the natural killer cells to spot and destroy the cancer cells as well as any other foreign body that may enhance the growth of the cancerous cells and cause more harm to the cancer patient. The cancer cell unfortunately may escape the natural killer cell by masking themselves in a special membrane that the natural killer cells cannot identify as foreign, Avemar helps in this situation as it inhibits the release of this special membrane thereby making it possible for the natural killer cells to spot the cancer cells and kill them.
What is it?
Avemar is a fermented wheat germ extract marketed as a medical food to supplement the diet of cancer patients undergoing standard cancer treatments including surgery, immunotherapy, chemotherapy, and radiation. It is said to improve quality of life.
What does the science say?
A 2018 systematic review found 16 studies suitable for analysis. All were on human cell lines cultivated in a lab; none of the studies evaluated clinical outcomes. They found some promising results, but concluded, “further in vitro and in vivo studies are necessary to prove its effectiveness and safety in humans.” An earlier systematic review in Australia had concluded “While the early evidence, particularly at the cellular level are promising, and of interest, the broader questions regarding Avemar as an adjunctive therapy in cancer treatment, and its clinical effectiveness have not been established to date”. So the claim that Avemar is an effective treatment for all types of cancer is not supported by the evidence.
I found a lot of studies of Avemar listed in PubMed, but they were mostly in vitro and animal studies. One clinical study of patients with rheumatoid arthritis found Avemar beneficial; but it was a small, uncontrolled open-label pilot study with only 15 patients. Another pilot study found that adding Avemar to a regimen of chemotherapy for high risk melanoma patients significantly improved survival. I found no rigorous research that compared clinically significant outcomes with Avemar to outcomes with placebo.
More questionable claims
On Amazon.com, Avemar is claimed to be an all-natural, holistic supplement that:
    • Supports the Immune System, Quality of Life, Mental Clarity, Physiological Cellular and Hormonal Immune Balance.
    • AVEMAR Supports Blood Sugar Levels and Glucose Metabolism. Supports White Blood Cells for Peak Performance.
These claims clearly go beyond the evidence. I couldn’t figure out what they were talking about when they said that cancer cells mask themselves in a special membrane that the natural killer cells can’t identify as foreign and that Avemar inhibits the release of that membrane.
Conclusion: Inadequate evidence
        ◦ The published evidence didn’t convince me that it doesn’t work, but I didn’t find convincing evidence that it does work. More and better research is needed. Wheat germ is food, but is Avemar a “food for special medical purposes” that warrants promoting this expensive product to vulnerable cancer patients? I’m skeptical.

The NORI protocol: An unproven fruit-based nutritional treatment for cancer sold by a self-proclaimed “expert”
Mark Simon is the founder of the Nutritional Oncology Research Institute. He doesn’t have an MD, DO, nor PhD. (He doesn’t even have an ND!) Yet he claims to have discovered a dietary protocol that can cure cancer. Can it? (I think you know the answer to this question.)
David Gorski on May 13, 2019
Link

I’ve been blogging for Science-Based Medicine for over eleven years now, and, before that, I had my personal blog, affectionately and sarcastically known here as my not-so-super-secret other blog (NSSSOB), which has been around more than fourteen years. So you’d think (or at least I do much of the time) that over all those years I’ve covered pretty much every form of dubious cancer treatment there is, either here on SBM or on my NSSSOB. Sadly, every so often reality disabuses me of this notion. Over the weekend, I was perusing what I like to call my Folder of Woo, basically a folder of links to potential blogging topics, when I noticed something called the NORI Protocol. I forgot when I had come across it the first time, but obviously I had meant to write about it sometime or another. After all, it was in my Folder of Woo! Given how much I write, though, I couldn’t remember if I had ever covered it. A quick search of both my blogs disabused me of this notion. There was one hit on my NSSSOB, but only because someone mentioned the NORI Protocol in the comments. Damn, I thought. How could I have failed to write about this one, given that it shows up all over the place?
So it’s time to take a more in-depth look at the NORI Protocol.
NORI Protocol: Red flags for quackery galore
So what is the NORI Protocol? Basically, it’s a high-fruit diet coupled with selenium supplementation. It helps to know what “NORI” stands for: the Nutritional Oncology Research Institute, home of the NORI Protocol. If you visit the website, the main page of NORI regales visitors with this description of the “institute”:
NORI is an independent research organization that has developed non-conventional methods for cancer treatment that do not rely on toxic drugs, surgery, or radiation. Cancer patients who choose to avoid conventional therapies or who have exhausted all other options may wish to explore this revolutionary and unique approach to cancer treatment and management offered exclusively by NORI. The NORI program is designed to be the most cost-effective alternative cancer treatment available. NORI represents the future in treating cancer in a safely and holistically, in the most health-promoting, effective, and scientifically sound manner possible.
So. Many. Red. Flags. And all of them right on the entry page. There’s the quack trope about cancer treatment that “does not rely on toxid drugs, surgery, or radiation.” There’s the statement about using this treatment instead of conventional therapies. There’s the claim that NORI is the “future of treating cancer in a safely and holistically, in the most health-promoting, effective, and scientifically sound manner possible,” whatever that means.
Then there’s this:
NORI is an organization focused on research and development of nutritionally based, nontoxic, drug-free cancer treatment methods. NORI has created a unique treatment protocol that may be utilized along with conventional therapies, or utilized alone for the treatment of nearly any form and stage of cancer. The NORI protocol is based on a specialized plant-based diet as a foundation while administering safe and effective natural compounds that selectively kill cancer cells. The NORI protocol has been proven effective for a wide array of cancers at all stages.
I love it when alternative medicine sellers claim that their treatment has been “proven effective for a wide array of cancers at all stages”. Whenever I see that, I ask: Where’s the beef? Where’s the science? Where are the randomized controlled clinical trials? As you will soon see, there is, to put it kindly, a paucity of these things supporting the NORI Protocol, although if you look at NORI’s page on its protocol, you’ll see lots of cherry picked studies, most in vitro, with only a phase I and phase II trial, the latter of which was not randomized. (Phase I trials by definition are not randomized.) You’ll also see lots of testimonials. I’ll discuss these later, with one exception – this testimonial from Amy H. in Los Angeles:
I was diagnosed with DCIS, stage 0, breast cancer in January of 2014. A surgeon wanted to give me a mastectomy and flap, and felt no other way would ensure my survival, or an attractive appearance. Shell shocked, I chose to treat it with a Naturopath, who guided me to healthier living on all levels. While I felt the results of that, I had developed a growth. I was told that it was a biopsy scar, but in late 2016 it grew significantly. I suspected it was not scar but tumor and started researching more about cancer, which made me doubt the effectiveness of what I was doing to heal. Sure enough, I went for an ultrasound and was told I had stage 4 breast cancer. Through a series of events I was told about the NORI Protocol and put into contact with Mark Simon. He presented what sounded to me like a very clear understanding of cancer and how to treat it. I had been facing unavailable doctors and practitioners, and he was available and supportive, and put me on a path that honored my instincts, calmed my fears, and made me feel like an active participant in my healing. While new to the protocol, I feel hopeful and aptly guided.
This testimonial is horrifying on so many levels, and I can’t believe that any hawker of an alternative dietary cure for cancer would include a testimonial like this. Those of you who’ve read SBM for a long time know that I’ve often questioned whether we overdiagnose and overtreat DCIS. However, that doesn’t mean that DCIS is benign, only that, because we don’t know which DCIS lesions will go on to turn into invasive cancer, we feel obligated to treat them all. However, as a breast surgeon, I can read between the lines here. If the surgeon seeing Amy H. recommended a mastectomy, that means that the DCIS took up so much of the breast that breast-conserving surgery was not possible. That’s high-risk DCIS. It’s therefore not surprising that Amy’s DCIS progressed to invasive cancer. As for having stage 4 cancer, it’s not clear to me how that could be diagnosed with just an ultrasound, unless maybe she had metastases in her liver that could be evaluated by ultrasound. Be that as it may, this testimonial shows a woman with high risk DCIS refusing standard-of-care treatment, seeing her cancer progress under the care of a naturopathic quack (even watching a mass grow and attributing it to scar tissue from her previous biopsy!), and then choosing another dubious treatment, with no outcome other than “hope” and being “aptly” guided being listed.
Time to discuss the NORI approach in more detail. First, let’s look at its creator, Mark Simon. Then we’ll look at the protocol itself, which involves a high fruit diet to “starve” cancer cells of the amino acid methionine, which, it is claims, sensitizes cells to selenium. Of course, it can’t be just any selenium. It has to be a special form of selenium. Nothing else will work.
Mark Simon: Developer of the NORI Protocol
Perhaps the best introduction I could find to Mark Simon is this 2015 interview with Chris Wark of Chris Beat Cancer fame. As I’ve described, Mr. Wark has the typical anecdote in which he misattributes his cure to the wrong treatment. Basically, he had stage 3 colon cancer, underwent surgery, but refused the recommended standard-of-care chemotherapy afterward. As is all too often the case, he sought out all manner of quackery, and when he did well he attributed his good outcome to the quackery, not to the surgery that removed his cancer. Now he runs a website and an alternative cancer cure Internet business in which he sells books and “coaching”, and uses all manner of dubious testimonials to hawk his wares. It’s a perfect match.
We learn from this interview that Mark Simon that he had been interested in alternative medicine for a long time, but details on his actual professional background are maddeningly vague. We’re told that he has a background in neuroscience and biomedical engineering, which is nice, but finding out what that background actually is wasn’t too easy. It took a fair amount of Googling to lead me to pages like this one, where I learned that Simon’s credentials include being a “health coach” and having a Clinical Nutrition Certificate from Natural Healing Institute. His LinkedIn profile only shows his positions at NORI dating back to 2011, when he founded NORI. Elsewhere, on Facebook Gene Fuss posted on The Truth About Cancer page that Simon “is trained in Neuroscience and Biomedical Engineering and nutrition, and has been a vegan for 32 years,” while attributing to him “DEEP knowledge about the biology of cancer tumors, more so than anybody I have encountered to date.”
If the claims made in the video above, and this video below about the NORI Protocol are any indication, I would be willing to contest the claim that Mark Simon has anything resembling “deep knowledge” about anything having to do with cancer or nutrition.
It doesn’t take too much knowledge to realize that the scientific claims in both videos and the NORI Protocol website are, at best, rather fishy and, at worst, downright quacky. As for Simon’s background, if he’s such an expert in neuroscience and biomedical engineering, why doesn’t he trumpet that background by including his degrees and what he did? He clearly doesn’t have an MD, PhD, or even an ND (the naturopath’s degree that I like to call “Not-a-Doctor”), and you know that if he had any of those degrees he’d include them, in his bio. Instead, he’s maddeningly vague. My guess is that he got an undergraduate or master’s degree in some science-related field and/or worked as a technician in a neuroscience and/or biomedical engineering lab somewhere. Simon can, of course, prove me wrong by listing his degrees and his pre-2011 employment history somewhere prominent.
On to Simon’s protocol!
NORI Protocol: Methionine deprivation and selenium cure cancer!
In both videos above, we learn that Mark Simon was inspired by the work of someone named Dr. Daniel Epner, a faculty member at Baylor College of Medicine, who published an article on methionine deprivation in 2001. It was this article that inspired Mark Simon to look into methionine restriction as a treatment for cancer. A PubMed search reveals 36 articles from Daniel E. Epner, 41 if you leave out his middle initial. The last article Dr. Epner wrote about methionine and cancer dates back to 2003. It’s a study that found that methionine restriction targets synthesis of thymidylate synthase, an enzyme that plays a crucial role in the early stages of DNA biosynthesis. His article is interesting, because it summarizes the studies in cell culture and animals showing that methionine restriction can have antitumor effects in a number of cancer cell lines and animal models. Of course, we all know how hard it is to translate such findings to humans, and Dr. Epner notes that a phase I trial had been carried out to show that methionine restriction plus chemotherapy was achievable and safe.
Interestingly, Dr. Epner does not practice medical oncology any more. He’s moved from Baylor to M.D. Anderson Cancer Center, whose website states:
Dr. Epner is a palliative care physician at MD Anderson Cancer Center who practiced medical oncology for several years before moving to the Department of Palliative Care in 2012. He began his faculty career at Baylor College of Medicine as principal investigator of a basic science lab, but he now focuses on psychosocial aspects of oncology. His primary academic interest is communication skills training for medical oncology fellows, palliative care fellows, and a variety of other providers.
Interesting career trajectory.
So, basically, with Mark Simon, we appear to have an overenthusiastic evangelist glomming on to one interesting finding with respect to cancer cells and running straight off the cliff with it, as you can see by the claims made by Simon for his NORI Protocol. Basically, these claims involve massive oversimplifications of the science and as yet unproven (and therefore unjustified) extrapolation from cell culture and animal studies to humans, with none of the valid research being done by Simon himself, just cherry-picked from the literature and based on nonsense like this:
There are two types of DNA in human cells, nuclear and mitochondrial. Cancer appears to be the result of damage to mitochondrial DNA while nuclear DNA damage is “after the fact”. Mitochondrial damage prevents the normal process called apoptosis or natural programmed cell death which shuts down the cell so that it does not continue to divide without end. Cancer is the same condition regardless of the site or organ of origin. Cancer is not 200 different diseases. It is a process defined by common metabolic abnormalities within malignant cells that can be effectively exploited without toxic drugs. It is generally the side effects of conventional therapies that take a cancer patient’s life, not cancer itself.
Whenever you see someone say that it is the toxicities of conventional therapies that kill most cancer patients, it’s 99.99% likely (at least) that you’re dealing with a quack. Also, yes, there is a metabolic component to cancer. Cancer cells, in addition to having their genomes messed up badly, also have messed up metabolic pathways. (I do so love using scientific terms.) That does not mean that cancer is all one disease, nor does it mean that the mutations driving cancer are unimportant.
Then the NORI website claims:
The key difference between the NORI approach and other nutritionally based cancer treatments is that NORI attempts to limit the availability of essential nutrients necessary to cancer cell survival while supplying adequate nutrients to healthy cells. The NORI approach to cancer nutrition is not designed to build or enhance the immune system. Cancer cells, like normal cells, have built-in means of defense against immune system attack, what separates conventional from most alternative cancer therapies is selectivity, meaning that conventional treatments destroy healthy cells while alternative therapies attempt to spare them.
Well, that’s a new one, an alternative therapy that doesn’t claim to “boost the immune system”!
The idea behind the NORI Protocol is this. Because many cancer cells are sensitive to methionine restriction, first you restrict methionine using a fruit-heavy diet. (Fruit doesn’t contain much methionine.) The length of time for this diet is “individualized”, of course. Also of course, he declines to discuss what criteria are used to determine the length of time recommended for each patient, just this:
Methionine restriction is individualized for each patient according to weight, nutritional status, disease progression and past dietary preferences. A methionine restricted diet may be continuous or cycled on and off depending on individual circumstances. Methionine restriction involves the elimination of many foods and a focus on mostly fruits. The natural sugars in fruits will not feed cancer cells or cause tumors to grow. It is a common misconception that fruit equals sugar and that fruits raise blood sugar. Fruit can be a problem if there is a high fat intake (greater than 10% of total caloric intake) which will cause insulin resistance.
That’s nice. Give me the protocol and the evidence base behind its specifics.
I’m particularly amused at how Simon gets past the “sugar feeds cancer” woo by claiming that the “natural” sugars in fruits don’t feed cancer unless you also eat a lot of fat and develop insulin resistance; so, yes, his NORI Protocol involves low fat diets as well. It’s also rather interesting that Simon focuses on fruits so much, given that vegetables are also low in methionine. Also problematic is the observation that normal cells need methionine too, as it’s an essential amino acid that the body can’t synthesize, which means that methionine can’t be eliminated from the diet entirely.
The next step after the methionine restriction, the patient can then eat a high methionine diet. The idea is that the methionine restriction will cause the cancer cells to stop growing, to arrest their cell cycle, and then adding methionine back, which supposedly causes them, to grow again and undergo apoptosis (programmed cell death). Layered on to this core idea is the claim that methionine restriction sensitizes the cancer cells to selenium, as well as the claim that the digestive enzymes in fruits also combat cancer.
If you look at the full NORI Protocol list of “chemotherapeutic agents,” you’ll find sodium selenite, selenomethionine, vitamin K3, shikonin (derived from the bark of the Gromwell root), vitamin E succinate, pine bark and grape seed extract, green tea extract, and a number of others. Basically, if you listen to Simon in his video above and read all the scientific claims on the NORI protocol website, what you’ll hear and see is what I like to refer to as “woo babble,” which is basically like Star Trek technobabble, only with woo.
But is there any evidence that methionine restriction combats cancer in actual humans? The answer is: Not a lot. If you look at recent review articles (e.g., this one, this one, and this one) about methionine restriction and cancer, you’ll find that, 18 years later, scientists are still working on it, and there is a huge paucity of clinical data supporting methionine restriction as a treatment for cancer. You’ll also learn that there’s evidence that methionine restriction could extend lifespan. You’ll also see authors recommending clinical trials, which appear not to have been done yet. You’ll also learn that there is a compound, methioninase, which breaks down methionine and can be used to restrict methionine. There’s evidence from patient-derived xenografts (tumors from humans clinical specimens grown in mice), but again little in the way of clinical evidence.
To Simon, however, the reason is obvious:
Why are alternative treatments like the NORI protocol not practiced by oncologists and researched through clinical trials? The answer is simple economics and excessive control by the pharmaceutical industry. Money and profits has become the primary driver in medical science in general. Medical science must serve all of us rather than the bottom line of multi-national corporations. NORI is a grassroots alternative cancer research institute that is carving out a path towards medical sanity within oncology.
It couldn’t possibly be because doing dietary studies of this sort of treatment is very difficult, could it? Oh, no! It has to be the big pharma conspiracy. So that’s why NORI sells a line of nutraceuticals, including—of course!—CBD oil. Not surprisingly, the protocol itself contains a disclaimer:
All statements regarding NORI nutraceuticals have not been evaluated by the United States Food and Drug Administration. NORI nutraceuticals are not intended to diagnose, treat, cure or prevent any disease. NORI nutraceuticals are provided as a component of a nutritional support program and are not intended as a substitute for conventional medical care.
Yep, it’s a quack Miranda warning! As is the case with so much cancer quackery, Simon has taken interesting scientific observations that aren’t ready for prime time yet and extrapolated mightily with them.
Testimonials galore!
So if all the science Mark Simon has is cherry picked science, does he have anything else? Like all good alternative cancer treatment advocates, he has testimonials! The most famous NORI protocol testimonial comes from Candice-Marie Fox, who claims to have cured her thyroid cancer using the NORI protocol:
We learn that Ms. Fox was diagnosed with thyroid cancer a few days before her 28th birthday in 2011. She claims it was stage III. Doing a bit of Googling reveals several things. First, she had papillary thyroid cancer, which is the most common and most treatable form of thyroid cancer. Indeed, there is controversy over whether papillary thyroid cancer always requires treatment given how much of it is overdiagnosed by ultrasound. (I doubt that applies here, because Ms. Fox states that she had a lump in her neck.) Also, there is no such thing as stage III papillary thyroid cancer in a 28 year old. If you look at the staging for this cancer, the highest stage a 28 year old can be is stage II, even with distant metastases. The survival rates are very high as well, with near 100% 5-year survival for localized and regional disease and 78% for even distant disease.
Also, Ms. Fox underwent standard-of-care surgery, a total thyroidectomy and what sounds like a central neck lymph node dissection, for the tumor. So at around the two minute mark, when she claimed that the cancer came back and had metastasized to her lungs, lymph nodes of the neck, and elsewhere. According to her, the doctors told her to come back in 6-9 months for more radiation and, if that doesn’t work, chemotherapy. That, too, caused my skeptical antennae to start twitching, because although radioactive iodine is used for metastatic papillary thyroid cancer, chemotherapy is not.
I’m not the only one who noticed holes in Ms. Fox’s story. Auma, a self-described “evil troll, Big Pharma employee and government spy,” noticed a lot of issues. Based on these articles and her own writing on Facebook, there are several impossible or misleading claims about her diagnosis and “natural cure”.
Having cancer spread to liver. After those pesky cancer surviving trolls started asking her questions on Facebook, she admitted liver tumors referenced in Daily Mail were benign.
Being stage IV. A few days back she claimed on FB that she had never called herself stage IV. How did the journalists get the idea of stage IV (in one article – grade IV) cancer then? Also, papillary thyroid cancer in people younger than 45 can only be stage I or II and 5 year survival is almost 100%.
Mark Simon being an oncologist instead of a quack nutritionist without a medical degree. This she also later admitted on FB and Daily Mail actually made a correction.
Rejecting chemo – in different sources Candice mentions having rejected radioactive therapy or chemotherapy. This sounds strange, because chemotherapy usually is not the first line of treatment for papillary thyroid cancer, but she makes it sound like she was certainly offered to do chemo and absolutely rejected it.
The biggest claim of them all is her terminal diagnosis and being given 5 years to live. I am not sure if she actually believes that herself or exaggerated her claims to get attention and embellish her money-earning cancer story. This is what I want to explore the most. Please keep in mind that I am not a doctor, just a patient myself who remembers the process of treatment well. If a medical specialist reads this, please add your perspective. Also, because I am not from an English speaking country, I constantly call thyroglobulin TGB, because that is how we abbreviate it. In English documentation it is usually abbreviated as Tg.
Auma also took a bunch of screenshots of Ms. Fox’s Facebook page contemporaneous with her actual treatments that show she left out a lot of stuff. It’s worth reading both posts, as long as they are, because of the level of detail. The bottom line is that Ms. Fox was cured by conventional therapy, not the NORI Protocol, but attributes her “cure” to her dietary intervention.
But what about the other testimonials? Most of them are similar in that it’s clear that the conventional treatment was what cured the cancer. There are patients with colorectal cancer who underwent surgery but turned down chemotherapy (like Chris Wark). There’s someone with recurrent Hodgkin’s lymphoma who underwent chemotherapy and the NORI protocol but attributes the good outcome to NORI. There are a couple of prostate cancer testimonials that aren’t particularly convincing because of the highly variable and often indolent courses that prostate cancer can take. There was another one of metastatic pancreatic cancer that regressed with the NORI protocol—and, of course, chemotherapy. Particularly distressing is that the man and his wife totally attribute the man’s good outcome to the NORI protocol. I wonder if they’ll blame it when the pancreatic cancer recurs, which it almost certainly will if it truly is pancreatic adenocarcinoma.
NORI Protocol: An idea oversold
If there’s one common theme in cancer quackery, it’s the co-optation of preclinical science (i.e., science that hasn’t been tested in clinical trials yet) or inadequately tested clinical science, and running with it. In other words, this sort of quackery involves taking the gray areas of science and unjustifiably eliminating the gray in order to sell a treatment. Will the NORI protocol hurt cancer patients? Probably not, but it’s hard to tell. Nutritional manipulations are not without risk. Will it treat their cancer? Based on my reading of the literature, who knows? It’s unproven, and the track record of translating cell culture and rodent studies into treatments is littered with the wreckage of promising-sounding ideas.
In this case, the gray area is methionine restriction as a treatment for cancer. It’s a dietary intervention that shows promise based on preclinical studies in cell culture and in rodent models but as yet has not been convincingly demonstrated to work in humans. Might methionine restriction have a role in treating human cancer? Possibly. One thing I can say for sure, though, is that, if methionine restriction is ever validated in randomized controlled clinical trials as an approach to improving the efficacy of chemotherapy, the science-derived protocol will almost certainly look little like what Mark Simon’s quackery-derived NORI protocol. Simon has both oversimplified the science (e.g., his claim that cancer is a single metabolic disease) while adding unnecessary complexity to the protocol (e.g., selenium and all the additional supplements, the mystical “individualization” of methionine restriction) to produce a protocol that is being massively oversold to desperate patients with cancer.
No wonder naturopaths love it so much.

Ketogenic diet does not “beat chemo for almost all cancers”
David Gorski on June 23, 2014
Link
One of the difficult things about science-based medicine is determining what is and isn’t quackery. While it is quite obvious that modalities such as homeopathy, acupuncture, reflexology, craniosacral therapy, Hulda Clark’s “zapper,” the Gerson therapy and Gonzalez protocol for cancer, and reiki (not to mention every other “energy healing” therapy) are the rankest quackery, there are lots of treatments that are harder to classify. Much of the time, these treatments that seemingly fall into a “gray area” are treatments that have shown promise in animals but have never been tested rigorously in humans or are based on scientific principles that sound reasonable but, again, have never been tested rigorously in humans. (Are you sensing a pattern here yet?) Often these therapies are promoted by true believers whose enthusiasm greatly outstrips the evidence base for their preferred treatment. Lately, I’ve been seeing just such a therapy being promoted around the usual social media sources, such as Facebook, Twitter, and the like. I’ve been meaning to write about it for a bit, but, as is so often the case with my Dug the Dog nature—squirrel!—other topics caught my attention.
I’m referring to a diet called the ketogenic diet, and an article that’s been making the rounds since last week entitled “Ketogenic diet beats chemo for almost all cancers, says Dr. Thomas Seyfried.” Of course, when I see a claim such as that, my first reaction is, “Show me the evidence.” My second reaction is, “Who is this guy?” Well, Dr. Seyfried is a professor of biology at Boston College, who’s pretty well published. He’s also working in a field that has gained new respectability over the last five to ten years, namely cancer metabolism, mainly thanks to a rediscovery of what Otto Warburg discovered over 80 years ago. What Warburg discovered was that many tumors rely on glycolysis for their energy even in environments with adequate oxygen for oxidative phosphorylation, which generates the bulk of the chemical energy used by cells. I described this phenomenon in more detail in a post I did four years ago about a drug that looks as though its anticancer properties come from its ability to reverse the Warburg effect.
What not to do if you want your hypothesis to be taken seriously
So on the surface, Dr. Seyfried’s argument that cancer is primarily a metabolic disease (an argument I’ll look at in more depth shortly) is well within the bounds of current oncologic science. Indeed, a few years ago it was all the rage, and I remember attending several sessions and lectures on the Warburg effect and cancer at the AACR meetings three or four years ago, although, oddly enough, I don’t recall as many the last couple of years. In any event, if that’s all I looked at, I probably would have shrugged my shoulders and moved on, as in, “Nothing to see here.” But there are quite a few red flags. The first red flag is a claim that a ketogenic diet can treat cancer better than chemotherapy. The second, even bigger, red flag is on Dr. Seyfried’s Boston College web page:
In addition, Dr. Seyfried has worked with noted alternative health advocate Dr. Mercola to provide a thought-provoking discussion on the benefits of a ketogenic diet. Dr. Mercola provides a thorough synopsis of the talk on his website, and also includes the original audio recording of their conversation.
Über-quack Dr. Mercola? Oh, dear. His evident pride at having been interviewed by Dr. Mercola does not reflect well on Dr. Seyfried’s critical thinking skills and knowledge of medicine. Dr. Mercola sells quackery. He has promoted antivaccine views, breast cancer pseudoscience, and the rankest cancer quackery, such as that of Tullio Simoncini, who believes that all cancer is a fungus and that baking soda is the way to treat it, and the Gerson therapy, which involves massive doses of supplements and, of course, twice-a-day coffee enemas. Seriously, this is not the sort of person a legitimate scientist wants to associate himself with—ever—if he wants to be taken seriously. I can see a naive researcher making a mistake and, not realizing who Dr. Mercola is, agreeing to an interview, but that’s the sort of thing that a reputable scientist would do his best to disavow and distance himself from.
Neither is the American College for Advancement in Medicine (ACAM), which bills itself as the “voice of integrative medicine,” where he’s given a major talk, the sort of organization a legitimate scientist wants to associate himself with if he wants to be taken seriously. Don’t believe me? Just peruse the ACAM website, where you will find lots of chelation therapy, including a program to “certify” in chelation therapy and detoxification, as well as other quackery. There’s a good reason that ACAM has appeared in many SBM posts throughout the years, and not in a favorable light. I emphasize again, this is not an organization with which a scientist who wishes to be taken seriously by oncologists associates himself.
Also, if a scientist wishes to be taken seriously, he shouldn’t say things like this:
The low-carb, high-fat ketogenic diet can replace chemotherapy and radiation for even the deadliest of cancers, said Dr. Thomas Seyfried, a leading cancer researcher and professor at Boston College.
In an exclusive interview, Dr. Seyfried discussed why the ketogenic diet has not been embraced by the medical community to treat cancer despite its proven track record both clinically and anecdotally.
“The reason why the ketogenic diet is not being prescribed to treat cancer is purely economical,” said Dr. Seyfried, author of Cancer as a Metabolic Disease. “Cancer is big business. There are more people making a living off cancer than there are dying of it.”
And don’t associate yourself with Ralph Moss, the number one promoter of laetrile quackery and make easily refuted claims such as the claim that “chemo and radiation do not cure cancer or extend life, although cancer physicians often make this claim” and that radiation “often does more harm than good to the patient.” Given that all Dr. Seyfried has is a couple of case studies as clinical support for his treatment (see below) and I can produce reams of studies over nearly 50 years demonstrating that chemotherapy can cure specific cancers and prolong life when used appropriately, the “2% gambit” notwithstanding, it’s not a winning proposition, and it sure doesn’t help your credibility to use the language of cancer quacks to promote your idea.
So, what, exactly is Dr. Seyfried’s hypothesis?
Cancer as a metabolic disease
Red flags or no red flags, it is, of course, possible that Dr. Seyfried is on to something and has let his enthusiasm overwhelm his judgment with respect to whom he associates with and the sorts of statements he makes, many of which sound as though they could have come from Stanislaw Burzynski, Ralph Moss, or Joe Mercola. In actuality, he isn’t totally wrong, but he isn’t totally right, either. As is typical of someone without a medical background, in particular an oncology background, he is, basically, putting the cart before the horse, as you will see.
In his talk, Dr. Seyfried begins with what he refers to as a “provocative question”: Is cancer a genetic or metabolic disease? Actually, whether he realizes it or not, his question is not quite as provocative as he thinks it is, nor is the answer anywhere near as clear-cut as he thinks it is or as he characterizes oncologists and cancer researchers as thinking it is. I’ll tell you what I think the answer to the question is after I’ve discussed Dr. Seyfried’s hypothesis. In the meantime, not surprisingly, his answer is that cancer is a metabolic disease, while everyone else’s answer—according to him, at least—is that it is a genetic disease, making him the brave maverick doctor, who says things like:
The current view now, without any question, is that cancer is a genetic disease. If you go on the National Cancer Institute website or you read any of the major articles published in Nature and Science, often the articles will start with, “Cancer is a genetic disease.” I think that this has become dogma.
Except that it really isn’t, at least not anymore. If you do a Pubmed search on “targeting cancer metabolism,” which is what Dr. Seyfried is talking about, you’ll find over 22,000 articles, with over 3,000 in 2013 alone, with a sharply increasing curve since 2000 that only now appears to be leveling off. A search on “cancer metabolism” brings up 369,000 references, with 28,000 in 2013 alone. Cancer metabolism is an incredibly important topic in cancer research and has been for several years now, and finding means of targeting the common metabolic abnormalities exhibited by cancer cells is currently a hot area of research. From my perspective, Dr. Seyfried is exaggerating how hostile the cancer research community is towards metabolism as an important, possibly critical, driver of cancer, although, to be fair, one prominent cancer researcher, Robert Weinberg, has been very skeptical. To me, Seyfried just appears unhappy that genetics is currently thought—for good reasons, I might add—to be the primary driver of most cancers. Note that I intentionally used such phrasing, because Dr. Seyfried, in my readings, appears all too often to speak of “cancer” as if it were a monolithic single disease. As I’ve pointed out many times before, it’s not. Indeed, only approximately 60-90% of cancers demonstrate the Warburg effect.
There are three components to glucose metabolism: glycolysis, which feeds the Krebs citric acid cycle, which in turn feeds oxidative phosphorylation. I show them below in simplified illustrations:
The issue with the Warburg effect is that it leads to a shift in metabolism that favors glycolysis. As a result of this shift, tumor cells tend to use a lot more glucose than normal cells because glycolysis is much less efficient at converting glucose into ATP molecules used for cellular energy than oxidative phosphorylation. One reason that this is thought to provide a growth advantage to cancer cells is because oxidative phosphorylation requires oxygen while glycolysis does not and cancers frequently outgrow their blood supply such that they often live and grow in tissue spaces where there is not much oxygen. In any case, the avidity of cancer cells for glucose has been known a long time and is the basis for positron emission tomography (PET) scanning, where a radiolabeled derivative of glucose is the most commonly used tracer for exactly that reason: Tumor cells take it up much more avidly than do normal cells, leading to ugly black blobs (old-fashioned PET scans alone) or pretty bright blobs (PET-CT) where there are tumor masses in the scans.
The idea behind ketogenic diets is very simple. If glucose is the primary fuel for cancer, then lower carbohydrate intake and replace carbohydrates with other sources of fuel, such as fats, in order to push the body’s metabolism into ketosis. It actually turns out that ketogenic diets are probably useful in the treatment of intractable epileptic seizures in children. Unfortunately, their mechanism of action in preventing seizures is unclear, although four potential mechanisms, including carbohydrate reduction, activation of ATP-sensitive potassium channels by mitochondrial metabolism, inhibition of the mammalian target of rapamycin (mTOR) pathway, or inhibition of glutamatergic synaptic transmission (glutamate as a neurotransmitter), have been proposed. Interestingly, the mTOR pathway is an important signaling pathway in many cancers that couples energy and nutrient abundance to the execution of cell growth and division, owing to the ability of TOR protein kinase to simultaneously sense energy, nutrients and stress and growth factors. It’s a commonly overactive signaling pathway in cancer.
It’s also interesting that the cancers used to produce the basic science cited by Dr. Seyfried are virtually all brain cancers and that virtually all the evidence comes from rodent tumor models. For one thing, if there is a tumor type that exhibits the Warburg effect and a high degree of metabolic derangement, it’s brain tumors. It’s no coincidence that dichloroacetate was first tested in brain tumors. In this study, VM/Dk mice were used, and a mouse histiocytoma cell line resembling human glioblastoma multiforme with macrophage/microglial properties derived from that same mouse strain (VM-M3) was implanted subcutaneously. This cell line has the property of metastasizing quickly and widely when implanted under the skin and allowed to grow, which actually makes it not very much like brain tumors, which seldom metastasize and usually kill through local invasion and taking up increasing volume in the closed space of the skull, something the brain most definitely does not like. The results showed that a ketogenic diet increased mean survival time by over 56%, while a combination of a ketogenic diet and hyperbaric oxygen therapy (HBOT) increased survival time 78%. The result is interesting, but it is a mouse tumor model, not a human tumor model, and that makes its applicability to humans tenuous, particularly given the nature of the murine tumor, but probably worth investigating further.
Another mouse study cited by Seyfried is one in which dietary restriction was reported to promote vessel maturation in a mouse astrocytoma model. Given that tumor angiogenesis is one of my scientific interests and I have a fair number of publications on the topic, I was interested. Unfortunately, I ended up being disappointed. This was another syngeneic model (i.e., a mouse tumor implanted in mice of the same strain from which the tumor was isolated as a cell line, like the one discussed above). Although it showed increased tumor vessel maturation (which is one mechanism by which inhibitors of angiogenesis work), I wasn’t quite convinced, because there was a distinct lack of quantification of the phenomenon, and the microscopy appears not to have been blinded, something that’s critical to avoid unconscious bias in the results. It’s not surprising that this result, which, if more convincing evidence had been obtained, could easily have appeared in Cancer Research, was published in a low tier journal. It’s an OK study, but not fantastic. Certainly it didn’t lead me to smacking myself in forehead and saying, “Of course!”
Throughout his talks, both here and elsewhere, Dr. Seyfried presents mouse studies that are interesting and suggestive that there might be something to this whole ketogenic diet thing, at least in brain tumors, such as this one. However, this is what we in the oncology biz would call pretty preliminary data, worthy of further investigation but not supporting the grandiose claims that Dr. Seyfried makes.
We need more beef. We need clinical studies. Unfortunately, they’re in short supply.
Clinical evidence for ketogenic diets as a cancer treatment
It’s not as though Dr. Seyfried doesn’t cite clinical evidence. It’s just that the evidence is so darned thin and unconvincing thus far. For instance, in this talk, the first study he presents is a very small case series (two patients, actually) performed in 1995 in which two girls with inoperable astrocytomas were placed on a ketogenic diet in order to “determine if a ketogenic state would decrease glucose availability to certain tumors, thereby potentially impairing tumor metabolism without adversely affecting the patient’s overall nutritional status.” Interestingly (to me, at least) these case reports came from University Hospitals of Cleveland, where I did my general surgery residency. In fact, I was still there in 1995. Unfortunately, I don’t have access to the journal back to 1995; so I’m stuck with just the abstract. However, the abstract is pretty clear:
Within 7 days of initiating the ketogenic diet, blood glucose levels declined to low-normal levels and blood ketones were elevated twenty to thirty fold. Results of PET scans indicated a 21.8% average decrease in glucose uptake at the tumor site in both subjects. One patient exhibited significant clinical improvements in mood and new skill development during the study. She continued the ketogenic diet for an additional twelve months, remaining free of disease progression.
One notes that the patient who didn’t survive 12 months wasn’t much mentioned; so I assume she didn’t demonstrate any clinical improvement. In any case, this study doesn’t really show anything, other than that a ketogenic diet might decrease glucose uptake in some brain tumors. It’s like a Burzynski case report, in which we have no idea whether the patient did better than expected because of the intervention or because she had less aggressive disease.
The next case report is from 2010. It describes the case of a 65-year-old woman who presented with progressive memory loss, chronic headaches, nausea, and a right hemisphere multi-centric tumor seen with magnetic resonance imaging (MRI). Following incomplete surgical resection, the patient was diagnosed with glioblastoma multiforme (GBM). Now here’s the kicker: The patient underwent standard therapy plus the ketogenic diet. A day after her surgery, she underwent a two-day fast, followed by a three day fast beginning a week after surgery, followed by a restricted ketogenic diet (only 600 Cal/day). Three weeks after her surgery (and two weeks after starting the ketogenic diet) she began standard of care treatment, concomitant radiation plus chemotherapy (temozolomide), “according to standard procedures,” which lasted six weeks. The patient also had a gene mutation in her tumor that produces increased sensitivity to temozolomide. The conclusion? Fortunately for the patient, she had what appears to have been a complete response, after which she went on a less restrictive ketogenic diet. Unfortunately, the patient recurred eight months later. By that point, the patient was off of the ketogenic diet. The authors’ conclusion? Because it was “unlikely” that the tumor would have responded this well on standard therapy alone, it must have been adding the ketogenic diet that done it. Worse, in the talk, Dr. Seyfried strongly implies that the tumor recurred because she had gone off the ketogenic diet two and a half months before her recurrence.
Irritatingly, during the same talk, Dr. Seyfried refers to having done a “biopsy” on the GBM when the case report clearly says that the patient underwent a partial excision of the temporal pole with incomplete debulking of the tumor, which is a different thing. When a surgeon tries to debulk a tumor, he is trying to remove as much of it as possible. When a surgeon biopsies a tumor, he is trying only to get enough tissue to make a diagnosis. He also heaps scorn on the hospital for insisting that the patient undergo standard of care therapy, clearly demonstrating that he has no understanding of clinical trial ethics. What most likely happened with this patient is that the debulking was significant, and the remaining tumor was small enough to be eliminated by the combined chemotherapy and radiation therapy—at least to the point of no longer being detectable on PET scan. Also, just because the diet appears to have decreased glucose uptake by the tumor doesn’t mean that the tumor was dying. In fact, it might have even made the PET scan less sensitive to whatever remaining viable tumor cells might still have been around, a possibility that I don’t see Dr. Seyfried as having considered.
There are other studies, but little or nothing in the way of randomized clinical trials. For instance, a recent retrospective study of 53 patients, of whom only six followed a ketogenic diet while being treated for GBM, concluded that the diet was safe, but no suggestion of efficacy was noted. More recently, a German group examined the effect of a ketogenic diet on 16 patients with advanced cancer of various types who had exhausted all therapeutic options. The treatment didn’t result in any serious side effects, although subjects found it very difficult to maintain the diet, particularly in the context of family life. Only five were able to complete the three month treatment period, and it was reported that these five didn’t have progression while on the diet. Of the remaining 11, two died early, one was unable to tolerate the diet and dropped out very quickly, two dropped out for personal reasons, one couldn’t continue the diet for more than a month and three had disease progression within less than 2 months of starting the diet and one dropped out to resume chemotherapy. As a whole, this study was well-nigh uninterpretable due to the different kinds of cancer, other than to conclude that less than 50% of patients with advanced cancer could adhere to the diet, and that those who could generally had no significant side effects. Of course, it’s unclear whether the diet helped the five who could adhere to it or whether those who adhered to it could do so because they had more indolent, less aggressive disease.
None of this stops Dr. Seyfried from concluding:
Preclinical and case report studies indicated that the restricted ketogenic diet (R-KD) can be an effective “metabolic therapy” for managing malignant brain cancer in children and adults.
The therapeutic effects of the R-KD against brain cancer can be enhanced when combined with drugs or HBOT that also target energy metabolism.
Uh, no. Not exactly. Preclinical experiments are intriguing but fairly limited in applicability, and the case reports demonstrate nothing of the sort. There’s more to Dr. Seyfried’s hypothesis, for example, his idea that metastatic cancer comes about because of alterations in glutamine metabolism, but unfortunately he appears to misunderstand the genetics of metastasis when he bases part of his conclusion on observations that metastatic cancers often have the same genetic derangements as the primary tumor. It’s been a longstanding question whether clones of tumor cells possess the ability to metastasize as an intrinsic part of the process of becoming cancer cells or whether they acquire it later. Given that evolution is a major force driving cancer cells to become more invasive and that tumors are very heterogeneous, full of lots of different clones with different sets of genetic mutations, Dr. Seyfried’s hypothesis is at best simplistic. Also disappointingly, the evidence for any diet as a treatment for cancer is weak at best.
Putting the cart before the horse
Clearly, ketogenic diets are not ready for prime time as a treatment for cancer, either alone or in combination with conventional therapy. Unfortunately, that hasn’t stopped it from being touted by all manner of alternative cancer practitioners (i.e., quacks) and others as a cancer cure that “they” don’t want you to know about or saying things like, “…it’s nothing short of medical malpractice and negligence to fail to integrate this type of dietary strategy into a patient’s cancer treatment plan,” as Joe Mercola did. Dr. Seyfried himself has contributed to the hyperbole quite a bit as well. For example:
These studies are all in combination with either radiation or chemotherapy. My preference is to start metabolic therapy with GBM (glioblastoma multiforme). This is a devastating type of brain cancer. Metabolic therapy with a restricted KD could be done with a few tumors where you know the conventional standard of care doesn’t work at all. You would choose those kinds of patients and do a clinical trial based on historical controls and see what the outcome would be and see if you could get some level of survival that would match or be better than the conventional standard of care.
Regular readers of SBM should know the problem with this sort of approach. No IRB worth its salt would approve such a trial because it would be ethically dubious, but, even worse, it would be ethically dubious and it wouldn’t really tell us anything unless those few patients either had near-miraculous responses or died very quickly. Anything else would simply tell us that the diet is probably doing no harm. More numbers would be needed, particularly if the comparison is to historical controls, to get even an inkling of whether there might be benefit. In that case, you might as well do a proper phase I/II clinical trial, which is what is happening. For instance:
Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma (ERGO2), a randomized clinical trial designed to evaluate whether a calorie-restricted, ketogenic diet and transient fasting can enhance the efficacy of reirradiation in patients with recurrent glioblastoma.
Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors (Ketones), a phase I pilot study in my neck of the woods (at least in my state) looking at the same sort of diet.
Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study, a small pilot study designed to examine the effect of a ketogenic diet in refractory GBM being treated with Avastin.
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma, a phase I/II trial designed to test whether a ketogenic diet enhances the efficacy of radiation and chemotherapy.
In other words, clinical data should be rolling in fairly soon, and that’s a good thing. In the meantime Dr. Seyfried and other advocates who so passionately believe that ketogenic diets will greatly help patients with brain cancer do no one any favors by claiming unequivocally that cancer is a metabolic disease and saying that ketogenic diets are more beneficial than chemotherapy for patients with brain tumors.
This brings me back to the question of whether cancer is a metabolic disease or a genetic disease, the answer to which I promised early on. The likely answer? It’s both! Indeed, a “chicken or the egg” argument continues about whether it is the metabolic abnormalities that cause the mutations observed in cancer cells or whether it is the mutations that produce the metabolic abnormalities. Most likely, it’s a little of both, the exact proportion of which depending upon the tumor cell, that combine in an unholy synergistic circle to drive cancer cells to be more and more abnormal and aggressive. Moreover, cancer is about far more than just the genomics or the metabolism of cancer cells. It’s also the immune system and the tumor microenvironment (the cells and connective tissue in which tumors arise and grow). As I’ve said time and time and time again, cancer is complicated, real complicated. The relative contributions of genetic mutations, metabolic derangements, immune cell dysfunction, and influences of the microenvironment are likely to vary depending upon the type of tumor and, as a consequence, require different treatments. In the end, as with many hyped cancer cures, the ketogenic diet might be helpful for some tumors and almost certainly won’t be helpful for others. Dr. Seyfried might be on to something, but he’s gone a bit off the deep end in apparently thinking that he’s found out something about cancer that no one else takes seriously—or has even thought of before.

   Biologie Totale and other bastard offspring of Ryke Geerd Hamer’s German New Medicine
David Gorski
Link
A few months ago, I wrote about a particularly nasty form of cancer quackery known as the “German New Medicine” or Die Germanische Neue Medizin in German. As you may recall, the German New Medicine is based on the nonsensical idea that cancer arises from an internal emotional conflict. This conflict then results in what is called the “Dirk Hamer Syndrome” (DHS) or “Dirk Hamer focus” in the brain, named after Dr. Ryke Geerd Hamer‘s son Dirk, who was tragically shot in his sleep by Vittorio Emanuel, the last crown prince of Italy. After a prolonged course requiring multiple operations, Dirk succumbed to his wounds and died. Three years later, Dr. Hamer developed testicular cancer, and, in a perfect case of post hoc ergo propter hoc, Hamer decided that it was the psychic shock of his son’s death that had caused his cancer. Thus was born Die Germanische Neue Medizin, which, according to Hamer, promises a 95% or more chance of curing any cancer, no matter how advanced. Never mind that Hamer apparently underwent a combination of surgery and other “conventional therapies for his testicular cancer. Also never mind that these “Dirk Hamer Focus” to which Hamer pointed on CT scans of the brain appeared, more than anything else, to be artifacts of the imaging process and nothing real.
As I described in my previous post in October, the German New Medicine is a seriously dangerous form of cancer quackery that is not only worthless but in many cases blames the patient for having developed cancer. Evidence can be found in this video, where a proponent of German New Medicine gives as examples of psychic stress a “cancer blow” that comes from menopause, in which loss of estrogen supposedly leads women to feel that they “aren’t the woman they used to be” and that that conflict is manifest in the bone or an athlete’s anger because of an injury that screws up his ability to perform leading to an osteosarcoma of extremity.
Unfortunately, cancer quackery frequently evolves under the selective pressure of competition with other cancer quackeries and based on the unique environments in which various forms of quackery come to land. Since I first wrote my post about Die Germanische Neue Medizin, I’ve been meaning to address one of its offshoots. The particular offshoot that I plan to address is, in essence, the French cousin of Die Germanische Neue Medizin, and it’s called Biologie Totale, or Total Biology (Claude Sabbah’s official site is here, but it’s all in French). I first became aware of Biologie Totale about a year and a half ago through this news story:
A new therapy that claims to cure cancer and other diseases but has been blamed for dozens of deaths in Europe is gaining popularity in Canada, according to a Radio-Canada investigation.
“Total biology” is a therapeutic approach that claims illness is caused by psychological conflicts in the brain.
The approach, also known as new medicine or bio-psycho-genealogy, professes to heal all disease, including AIDS and advanced forms of cancer.
The method is gaining traction in Quebec where patients are often told to ignore their cancer, or stop medical treatment altogether, according to an investigation by CBC’s French-language service.
The similarity of Biologie Totale to German New Medicine should be apparent just from the description above, but Biologie Totale, while resembling German New Medicine, appears to be on the way to “speciating,” so to speak from its precursor, except that Dr. Claude Sabbah appears to have been able to do something that I thought impossible: To make German New Medicine even more ridiculous. It always cracks me up to see such a name, too: Total Biology. Not New Biology (like German New Medicine). Total Biology. Apparently Sabbah thinks that he’s discovered a way of understanding the complete and total biology of the human organism. It would be nice if he did, but he doesn’t, as is demonstrated here:
The Total Biology of Living Beings is a concept that was developed by Claude Sabbah, the fruit of over 35 years of experience. In addition to his medical training (as a specialist in oncology, emergency medicine, sports and hyperbaric medicine and psychotherapy), Claude Sabbah is a researcher, NLP practitioner and a teacher and speaker of world renown. Total Biology integrates the knowledge drawn from several areas of medical specialization, recognized scientific research and various observations on the plant, animal and human realms. The concept sheds light and understanding on the normal functioning of a living creature, how it becomes ill and how it is possible for it to regain health and well being.
NLP, by the way, is neurolinguistic programming, a form of psychotherapy based on the concept that success can be achieved by simply modeling the language, behavior, and thought patterns of successful people. This concept in and of itself sounds very seductive and even fairly reasonable on the surface, but, as our fearless leader Steve Novella pointed out three years ago, research has shown it to be wrong. Steve used the example of an episode of Spongebob Squarepants in which Spongebob’s friend Patrick, envious because Spongebob has won lots of awards and he hasn’t, decides to mimick Spongebob’s every move. As Steve put it, Patrick is an affable loafer, lazy and not too bright, and he is no smarter or any less lazy due to simply mimicking Spongebob’s behavior. However, one can see how someone enamored of NLP might find Hamer’s concepts in German New Medicine to be seductive. Not surprisingly, Dr. Sabbah cites his inspiration as being from Dr. Hamer. Then he, like so many purveyors of pseudoscience, claims to have taken Dr. Hamer’s woo and gone much further:
Claude Sabbah has applied these findings from 1985. Since then, with his years of medical practice, his own findings, with the cooperation with many other researchers and scientists… Claude Sabbah has set the concept of Total Biology which integrates: Dr Hamer’s New Medicine, Modern Western and Asian Medicine, Observation of the Biological Laws of the Fauna & Flora, Biological Cellular Memorized Cycles, NLP, the concept of the mini-Maxi Schizophrenia, Biogenealogy, personal researches, and many more…
Is there any quackery Dr. Sabbah hasn’t mined for his Biologie Totale? More importantly, what, exactly, do Dr. Sabbah and his acolytes spreading like a–if you’ll excuse me–cancer throughout Quebec and Canada tell their patients to do to try to fix the results of these “psychic traumas”? In 2008 Radio Canada journaists went undercover to find out. It isn’t pretty. In fact, it’s an unholy combination of seemingly faith healing and German New Medicine:
He [Sabbah] teaches his approach in six-day seminars offered in France and Canada. He tells students that cancer and other diseases are formed in the brain first, and must be deprogrammed.
During the investigation, Radio-Canada journalists went undercover with hidden cameras seeking medical advice about fictitious diseases.
One of the journalists claimed to have breast cancer. She visited several total biology practitioners who told her that her life was not in danger, and the lump in her breast was the result of a maternal conflict.
She was recommended to stop chemotherapy altogether. During another visit a practitioner told her to drink champagne and relax.
Another undercover journalist who claimed he had prostate cancer was told his ailment was caused by a conflict between his parents at the time of his conception.
He was given orders to recite a prayer 15 times a day.
A CBC television news report can be viewed here. Oddly enough, it notes that Claude Sabbah had suffered a stroke and was recovering, which was why he missed a seminar in Quebec that he had been scheduled to do. Apparently Totale Biologie didn’t save him from that. In any case, the story of the woman with breast cancer sounds very familiar, doesn’t it? Do you remember a woman named Michaela Jakubczyk-Eckert? She had breast cancer, and she listened to Dr. Hamer. She ended up dying a horrible, painful death. It’s a good thing it was just reporters pretending to have breast cancer this time, as any real woman with breast cancer who listened to this nonsense risks suffering the same fate.
It’s also pretty amazing that anyone could think a malignant tumor is the result of a “maternal conflict.” But, as mentioned above, it’s not just this life we have to worry about. According to this quackery, a psychological conflict at conception can result in cancer later in life. But it goes even further than that. Indeed, Biologie Totale is a cornucopia of woo that goes into the past before conception and continues to differentiate into different flavors of Hamer’s concepts. I hadn’t had any idea, but after looking into it I found that it’s somehow become attached to a form of pseudoscience known as Memorized Biological Cellular Cycles and Biodecoding. If you want to get a load of how far this quackery goes by expanding on German New Medicine, read and be amazed at Psycho-biogenealogy & Transgenerational, which gets all lumped together with neurolinguqitic programming in a manner that is hard to believe. Even more amazing, it is now postulated that it’s not just this life we have to worry about. You can apparently have as close to a perfectly “conflict-free” life as there is, but if your parents or grandparents or ancestors even further back had “conflicts,” well, you’re out of luck. These can give you cancer:
Through Dr Hamer’s theories, we understand that diseases, emotional impacts associated with them and memories of traumas can be transmitted to future generations via genes. It seems logical that in some cases the primary programming cause of illness can be found on previous generations.
The modern face of the biogenealogy was mainly developed by Anne Ancelin-Schutzenberger, Doctor in psychology and researcher, who has conducted numerous research programs in Europe, Canada and the US. Her interest in spychogenealogy started when one day, she was concerned by a remark of her daughter who said : ” Do you realize, Mom, you are the elder of 2 children among which the second is dead. Dad is the elder of two children among which the second is dead. You know when uncle Jean-Paul died, I was afraid that my brother dies [...] ” Until the day the brother passed away…
Completed by Bert Hellinger’s works on the transgenerational and family constellations, biogenealogy explains the family dynamic and the way of transmission of ancestral memories of traumas. It brings a brand new understanding on how biological, behavioral and psychological patterns are transmitted, and offers amazing technics to deprogram them on the family alienation level. Working on those ancestral memories helps to free ourselves from them as well as the whole lineage from our ancestors to our descendants.
Cancer patients just can’t catch a break, can they? If their developing cancer isn’t their fault for thinking bad thoughts or being unable to overcome “psychic trauma” on their own, then it’s the fault of their family and previous generations! Never mind that there sort of idea is inconsistent with modern biology. In fact, it’s downright Lamarckian! I wonder if Dr. Sabbah is a creationist, too.
So what evidence does Dr. Sabbah and the panoply of other “blame-the-victim” quacks who draw inspiration from Hamer have to back up their claims that Biologie Totale or the many variants of the German New Medicine can cure cancer and pretty much every other disease just through psychotherapy to erase “psychic conflicts”? Do you even have to ask? It’s testimonials all the way down, of course, including these testimonials on various Biologie Totale websites. One testimonial in particular comes from a naturopath (of course) named Olivier Comoy, who claims that he’s seen many people recover from various illnesses but doesn’t specify the illnesses.I’m guessing, however, that Comoy didn’t see a single case of cancer or a non-self-limited disease that was cured by his ministrations. Either that, or he treated diseases with a waxing and waning course, saw the patient during the waning phase of his illness, declared a “cure,” and then sent the patient on his way, never to see the waxing phase return. Certainly there’s nothing like any sort of clinical trials, of even crappy quality, to support it. Unfortunately, there are more and more like him. Worse, it’s metastasizing to the United States, as these testimonials demonstrate.
There are few things I detest more than quacks like these believers in German New Medicine and Biologie Totale preying on the desperation of seriously ill patients. Not only can they not cure any patients, but they actively hurt them by telling them that the means to cure themselves is within them, not caring that the flip side of that message is that if they are not healed by tis quackery it must be their fault for not wanting it enough or not being able to work through some psychic trauma.
But why do people believe in this stuff?
Ever since I first discovered Hamer’s German New Medicine, Sabbah’s Biologie Totale, and the various flavors of this sort of quackery that have proliferated like cockroaches over the last decade, I’ve asked myself why people believe such obvious nonsense. As for a lot of cancer quackery, there is the desperation of patients who are faced with a life-threatening disease like cancer or AIDS or a debilitating chronic disease like multiple sclerosis. But that in and of itself doesn’t strike me as enough. I think part of the answer can be found in passages like this:
In the concept of Total Biology of Living Beings, dis-ease constitutes a perfect solution of the brain to ensure, in the short term, the survival of the organism. The dis-ease is a very precise transpose of an unresolved conflict, conscious or not, into the body.
Dis-eases, health problems and even behavioural problems appear when our conscious thought (our sixth sense) is unable to find a solution to a conflict which is either very intense or long-lasting and which, due to this, generates a stress which affects the whole body collectively. By means of these stresses, from minor to the more severe, the brain will direct the threatening stress to a particular body part or function of the body that is in correspondence with the conflict.
The conflict, once resolved, results in the absence of the dis-ease. However, if there is no solution, the brain will take charge to dispatch into the body and order a mutation of cells which will produce a state of dis-ease. This is the conversion into the biology of an unresolved stress affecting a precise area of the brain.
First, note how “disease” is spelled “dis-ease.” This is a common way of spelling the word on a wide variety of “alternative” medicine sites, and Hamerian woo fits very well into this thinking. For instance, at About.com’s Holistic Healing site, the reason for this spelling is explained thusly:
The term “dis-ease” is used as a substitute for the the word disease by individuals and healing communities who are aligned with wellness. In doing this it is their intent to place emphasis on the natural state of “ease” being imbalanced or disrupted, desiring not to give too much focus to a particular ailment.
Hamerian woo like German New Medicine and Biologie Totale go beyond even this by postulating that diseases afflicting humans aren’t really diseases at all, but rather the body behaving appropriately. But it goes even further by implicitly equating the word “ease” with emotional and psychological ease, with “dis-ease” being due to a buried psychological traumas. Moreover, German New Medicine and Biologie Totale are not unique in this respect of claiming that diseases like cancer and infections are not really diseases at all. Robert O. Young, for instance, postulates that cancer is not a disease as well. In fact, he claims that cancer is an acid liquid of “spoiled cells” and that cancerous tumors are nothing more than the body’s reaction to these “spoiled cells” to protect the rest of the body by encapsulating the cells. He claims the same thing about viruses, characterizing them as “molecular liquids or gases (venom) that can be created by chemical imbalances in humans.” Young even claims that sepsis is not caused by bacterial infection, terming it an “out-fection” which he characterizes as the “cell breaking down from the inside out from an emotional or physical stress or disturbance giving rise to increased acidity.” Amazing how so many of the various forms of woo circle around to blaming psychological trauma for physical diseases, isn’t it? Of course, Young takes an entirely different approach where alkalinization is his answer to everything, but there are echoes of Hamerian woo in a wide variety of “alternative” medicine.
Another example is a “healer” named Andreas Moritz. He’s been mentioned before on SBM for his book on “liver cleanses,” but his woo goes much farther than just that. Most recently, he was the subject of a bit of a blog storm for his having tried to shut down a blog critical of his quackery. What brought on the criticism was an article on his website entitled Cancer Is Not A Disease – It’s a Survival Mechanism. It’s all there: The claim that cancer is not really a disease but is in fact a normal response either to extreme “toxic” insult or to this:
After having seen thousands of cancer patients over a period of three decades, I began to recognize a certain pattern of thinking, believing and feeling that was common to most of them. To be more specific, I have yet to meet a cancer patient who does not feel burdened by some poor self-image, unresolved conflict and worries, or past emotional trauma that still lingers in his/her subconscious. Cancer, the physical disease, cannot occur unless there is a strong undercurrent of emotional uneasiness and deep-seated frustration.
Cancer patients typically suffer from lack of self-respect or worthiness, and often have what I call an “unfinished business” in their life. Cancer can actually be a way of revealing the source of such inner conflict. Furthermore, cancer can help them come to terms with such a conflict, and even heal it altogether. The way to take out weeds is to pull them out along with their roots. This is how we must treat cancer; otherwise, it may recur eventually.
“Poor self image”? Emotional traumas? Is that how mice and other animals develop cancer, too?
Basically, Moritz appears to take concepts from the quackery that is German New Medicine and Biologie Totale but doesn’t limit himself to them given that he clearly believes that exposure to large amounts of “toxic” carcinogens can lead to a collapse of the body’s defenses. More importantly, like Robert Young, he views cancer as a “survival mechanism.” In fact, Moritz calls cancer the “wisdom of the body.” Indeed, he goes so far as to rationalize how tumors can hijack normal physiological processes like angiogenesis (the ingrowth of new blood vessels) as “evidence” that the body doesn’t view cancer as a threat and actually goes out of its way to supply it with blood, oxygen, and nutrients. It never occurs to him that tumors actually trick the body into helping them grow.
Why does so much “alt-med” claim that cancer is actually not a disease but rather an example of the body’s “wisdom” or that cancer is due to unresolved psychological conflicts, past emotional trauma, or poor self-image? I’ve speculated multiple times about why there is this tendency to “blame the victim” in “alt-med,” an undercurrent of “The Secret“-like thought, sometimes implied sometimes explicity, that tells people that they have control over reality if they just want it badly enough. As far as Hamerian woo goes, I think there’s also an undercurrent of a view of nature and the human body that views nature as perfect, where disease (or “dis-ease”) is not because the body malfunctions but because it does what it is designed to do. While there is a germ of truth in this idea, as evidenced by our knowledge of how chronic inflammation can lead to cancer and vascular disease for example, Hamerian woo, like much of alt-med, takes this germ of a reasonable science-based idea and runs off the cliff with it to deny that bacteria can cause sepsis, that HIV can cause AIDS, or that viruses can cause disease.
But it goes even beyond that when it comes to cancer. Cancer is a set of diseases where the body’s own cells turn on it, ignoring the “ease” and “balance” so beloved of “alt-med” believers that normally control cellular proliferation. Cells grow out of control, damaging organs, hijacking the body’s own blood vessels, and parasitizing the body’s nutrient supply. How can that happen if the body is so perfect? There must be a secret “trauma” that leads the body to cause such a reaction to wall off the psychic trauma, of course! Or, if you don’t subscribe to Hamerian woo, then it must be external “toxins,” almost always unnatural human-made evil chemicals that disrupt the happy paradise of the body and must be purged. Come to think of it, it’s not unlike the story of Adam and Eve in the Garden of Eden, with science, including science-based medicine with its chemotherapy, surgery, and drugs playing the role of the fruit of the tree of knowledge of good and evil. Add a whole lot of wishful, magical thinking à la The Secret, creating a world in which either wishing makes it so or overcoming subconscious psychic truamas, and you have a recipe for a belief system that bears far more resemblence to religion than to science.

   The “Iron Rule of Cancer”: The dangerous cancer quackery that is the “German New Medicine”
David Gorski
Link
Given that I trained as a cancer surgeon, do laboratory and translational cancer research, and spend my clinical time taking care of breast cancer patients, not surprisingly one topic that gets me the most irritated and provokes a lot of my verbiage for SBM is cancer quackery. As I was perusing my list of posts the other day, it occurred to me that there’s one huge topic that in the more than a year and a half I’ve been blogging for SBM I’ve never covered. It’s a particularly pernicious and dangerous quackery. Indeed, it’s a quackery I mentioned during part of my talk at the Science-Based Medicine Conference, which Steve organized and where several SBM bloggers spoke the day before TAM7 started.
I’m referring to the dangerous and vile quackery known as the German New Medicine (Die Germanische Neue Medizin). Pioneered by Ryke Geerd Hamer, it is a quackery that claims lives. So what is this German New Medicine? Well, it appears to be a Theory of Everything Medical, and in particular everything having to do with cancer:
THE GERMAN NEW MEDICINE provides us with illuminating explanations about the origin, development and healing of both physical and mental disorders. In 1981, Dr. Hamer discovered that every DISEASE is caused by a shock experience that catches us completely off guard. He found that this shock not only occurs in the psyche but simultaneously in the brain and on the organ level. At the moment the unexpected trauma takes place the shock impacts a specific area in the brain causing a lesion that is clearly visible on a brain scan as a set of sharp concentric rings. With the impact the affected brain cells communicate the disturbance to the corresponding organ. Whether the organ responds with a tumor growth (cancer), with tissue degeneration, or with functional loss, is determined by the exact type of conflict shock. Based on the analysis of over 40,000 case studies Dr. Hamer is the first to provide scientific proof that cancer is not caused by a malfunctioning organism producing deadly cancer cells but is rather the result of an innate meaningful survival program that has been successfully practiced for millions of years. Since HEALING can only occur after the conflict has been resolved, the GNM-therapy focuses on identifying and resolving the original conflict. By understanding healing symptoms such as painful swelling, infections, fever, or inflammation in their psychological, biological and evolutionary context, we are able to liberate ourselves from the fear and panic that often come with the onset of an illness. Dr. Hamer’s findings offer a completely new understanding of so-called diseases. His scientific discoveries revolutionize entirely our view of medical conditions and their causes.
The German New Medicine presents a comprehensive system that allows us to understand what type of conflict causes the onset of a particular disease, how the disease manifests itself in the conflict active phase, what can be expected in the healing phase, and how all the developments are connected to the brain, verifiable with a brain scan.
The German New Medicine is a natural science, based on FIVE empirically disovered BIOLOGICAL LAWS that apply, in a strong scientific sense, to each and every case of disease of man and mammal.
The repository of quackery known as Mercola.com describes the “Five Biological Laws” of German New Medicine thusly:
GNM is based of five biological laws that apply scientifically to each and every case of disease. They include:
     1.  Every disease is caused by a conflict shock that catches an individual completely off guard.
     2.  Provided there is a resolution of the conflict, every disease proceeds in two phases, a conflict-active phase and a healing phase.
     3.  Ties the findings of the first two laws into the context of embryology and the evolution of man. It illustrates the biological correlation between the psyche, the brain, and the organ from an evolutionary point of view. (The Ontogenetic System of Tumors and Cancer-Equivalent Diseases.)
     4.  Addresses the role of microbes in the context of evolution and in relation to the three germ layers from which our organs originate. Microbes are indispensable to your survival.
     5.  Every so-called disease has to be understood as a “meaningful special biological program of nature” created to solve an unexpected biological conflict.
Further, Dr. Hamer believes that a person cannot die of cancer in and of itself.
If someone dies during the conflict-active phase of disease, he says, it’s because of energy loss, weight loss, sleep deprivation, and emotional and mental exhaustion. The stress of receiving a cancer diagnosis, or being given a negative prognosis, is often enough to deprive a person of their life-force. Conventional cancer treatments only accelerate the downward spiral.
Oooh, boy. So much woo in such a concentrated form. Oddly enough, it never occurs to Hamer that it might be–oh–the metastatic cancer that results in weight loss and the gradual decline of cancer patients. Also note how Hamer blames the doctors. If we tell a patient that that patient has a life-threatening cancer, it’s a “psychic shock” or a severe stress that actually “deprives the person of his life force.”
When I first heard of this particularly odious form of cancer quackery, my first question was: Why five BIOLOGICAL LAWS? (And in all capital letters, yet, as in “FIVE empirically disovered BIOLOGICAL LAWS”?) Why not four? Or six? It reminds me of the scene in Monty Python and the Holy Grail about the Holy Hand Grenade of Antioch, with a little change:
… And the Lord spake, saying, “First shalt thou take out the Unholy Conventional Medicine. Then, shalt thou come up with FIVE LAWS. No more, no less. FIVE shall be the number of laws thou shalt find, and the number of the laws shall be FIVE. Six shalt thou not find, neither find thou four, excepting that thou then proceed to FIVE. Seven is right out. Once the number FIVE, being the fifth number, be reached, then lobbest thou thy BIOLOGICAL LAWS towards cancer thy foe, who, being naughty in My sight, shall snuff it.” Amen.
Yes, I can see it now, except with German accents.
In case you’re curious, the creator of the German New Medicine, Dr. Ryke Geerd Hamer, named the DHS after his son, Dirk. You see, Dr. Hamer’s son was tragically shot in his sleep by Vittorio Emanuel, the last crown prince of Italy. After a prolonged course requiring multiple operations, his son unfortunately succumbed to his wounds, which undoubtedly caused Hamer immense emotional trauma, as the sudden loss of a child always does. Three years later, Hamer developed testicular cancer. So, in a perfect case of post hoc ergo propter hoc reasoning, Hamer decided that it must have been the psychic shock of his son’s death that caused his cancer. Forget about all that molecular biology. Forget about oncogenes and tumor suppressors. Forget about increased mutation rates. Forget about all that. Dr. Hamer is here to tell you that it’s “Hamer-time.” (Sorry, couldn’t resist.) In actuality, he’s here to tell you that everything that scientists think they know about the pathogenesis of cancer is wrong. Cancer is really due to a “psychic shock,” not genetic alterations in cells that lead to uncontrolled proliferation. What about cancer patients who have lived happy lives devoid of “highly acute, dramatic, and isolating shocks”? There’s no such person. If you search back far enough, you could probably find such a shock, and if that fails you could alway postulate some sort of birth trauma. I don’t mean to minimize the tragedy that Dr. Hamer must have suffered because of the shooting of his son and the fact that the killer got off with a slap on the wrist because of his title and wealth, nor am I claiming that mental stress doesn’t contribute to disease, but Hamer took his tragic personal experience and generalized it to a ridiculous extreme, even to the point of basing rather arrogantly-named “biological laws” on it. It’s as if the shock of losing his son unhinged his mind.
So what are these “laws” that Dr. Hamer so confidently postulated? Well, let’s look at the First Law, a.k.a. the Iron Rule of Cancer. Naturally, it’s subdivided into three criteria:
     1.  Every cancer or cancer-equivalent disease originates from a DHS (Dirk Hamer Syndrome), which is a serious, highly acute, dramatic and isolating shock that catches an individual completely off guard. The conflict shock occurs simultaneously in the psyche, the brain and the corresponding organ.
     2.  At the moment of the DHS, the content(s) of the conflict determine the location of the Hamer Focus in the brain and the location of the cancer or cancer-equivalent disease in the organ.
     3.  The development of the conflict determines the exact development of the Hamer Focus in the brain as well as the exact development of the cancer or cancer-equivalent disease in the organ.
The most ridiculous “law” at the heart of Hamer’s quackery is the Second Law, in which he claims that the origin of all cancer is in the brain. This, specifically, is what the “Hamer Focus” is:
By analyzing thousands of brain computer tomograms (CT) in relation to his patient’s histories, Dr. Hamer discovered that the moment a DHS occurs, the shock impacts a specific, pre- determined area in the brain, causing a “lesion” that is visible on a CT scan as a set of sharp concentric rings (In 1989, Siemens, the German CT scanner manufacturer, certified that these ring formations are not artifacts of the equipment). Upon impact, the affected brain cells communicate the shock to the corresponding organ, which in turn responds with a particular— predictable!—alteration. The reason why specific conflicts are indissolubly tied to specific brain areas is that during our historical evolution, each part of the brain was programmed to respond instantly to conflicts that could threaten our survival. While the “old brain” (brain stem and cerebellum) is programmed with basic survival issues that relate to breathing, eating, or reproduction, the “new brain” (cerebrum) is encoded with more advanced themes such as territorial conflicts, separation conflicts, identity conflicts, and self-devaluation conflicts.
Dr. Hamer’s medical research is firmly tied to the science of embryology, because whether the organ responds to a conflict by a tumor growth, by tissue meltdown, or by functional impairment is determined by the embryonic germ layer from which both the organ and corresponding brain tissue originate (Third Biological Law).
Here’s a video further describing Hamer’s bizarre ideas about cancer:
I find it particularly despicable how Dr. Holt, the narrator of this video, blames osteoporosis in a psychic conflict or blow that comes from menopause, in which loss of estrogen supposedly leads women to feel that they “aren’t the woman they used to be” and that that conflict is manifest in the bone. Equally despicable is the part where he talks about an athlete’s being angry because of an injury that screws up his ability to perform and that anger leading to an osteosarcoma of extremity. Here’s a further explanation:
The therapeutic focus of the New Medicine is to identify the original DHS and to find a solution to the conflict that is as real and as practical as possible. For example, a man who lost his business and suffers a territorial loss must find a new occupation; the shock from an unexpected early retirement could be resolved by establishing a new “domain”, such as by joining a club or taking up a neglected hobby. As soon as the conflict is resolved, healing runs its natural course.
Is Hamer really saying that, for example, if a new retiree was forced out of his job and then later develops colon cancer, his colon cancer could be cured just by finding him a hobby or other productive way to spend his time? How nice. I guess that would put us surgeons out of business, given that most colon cancer is cured primarily by surgery, with chemotherapy and, if it’s rectal cancer, radiation therapy decreasing the rates of post-surgical recurrence. More likely, if you tried to use that concept to treat GI malignancies it would give us more of the business that we really don’t like: malignant bowel obstructions that require urgent, rather than elective, surgery, with a resultant decrease in cure rates and increase in complications.
This is pseudoscience with an implausibility on par with that of homeopathy. Really. First, let’s take a look at the photo of a brain CT that, according to the “Second Law,” allegedly shows a “Dirk Hamer” focus (right). I’m not a radiologist, but this “Dirk Hamer focus” looks a lot to me like your basic CT scan artifact. One also has to wonder: If this were real, why has no other physician or investigator reported finding similar lesions in cancer patients? If all cancer really is due to the presence of the DHS lesions in the brain (which, according to Hamer, are due to whatever “psychic trauma” that supposedly caused the DHS and therefore caused the cancer), then why is it that no other oncologist or radiologist has ever reported them? After all, if every single cancer patient suffered some sort of psychic trauma resulting in DHS rings that in turn result in cancer, the correlation between such lesions and cancer should have been really easy to see, particularly with more modern CT scanners. Is Hamer so much more brilliant than everyone else? Whenever anyone claims that there is one cause for all cancers, run, don’t walk, from him! Hamer and his “DHS rings” are no different than Hulda Clark and her liver flukes, which Clark claims to be the cause of all cancer.
Here’s how Hamer views cancer, described in his Third Law, which he calls the “Ontogenetic System of Tumors’ Meaningful Special Biological Programs of Nature” (whatever that means):
In it, Hamer divides all tumors into two phases that he calls “sympatheticotonia” (conflict active phase) and vagotonia (conflict resolution phase). He explains how these phases work thusly:
GNM’s “Ontogenetic System of Tumors” illustrates that “old-brain”-controlled organs, which derive from the endoderm or the “old-brain”-mesoderm, like the lungs, liver, colon, prostate, uterus, corium skin, pleura, peritoneum, pericardium, breast glands, etc., always generate cell proliferation as soon as the corresponding conflict occurs. Tumors of these organs therefore develop exclusively during the conflict-active phase (initiated by the DHS).
Let’s take lung cancer, for example: The biological conflict linked to lung cancer is a “death-fright conflict”, because in biological terms the death panic is equated with being unable to breathe. With the shock of the death- fright the lung alveoli cells, which regulate breathing, instantly start to multiply, forming a lung tumor. Contrary to the conventional view, this multiplication of lung cells is not a pointless process but serves a very definite biological purpose, namely, to increase the capacity of the lungs and thereby optimize the organism’s chance of survival. Dr. Hamer’s brain scan analyses demonstrate that every person with lung cancer shows a distinct target ring configuration in the corresponding area in the brain stem, and that each patient had suffered an unexpected death panic prior to the onset of cancer. In the majority of cases the death scare was triggered by a cancer diagnosis shock that the person experienced as a “death sentence”. Given that smoking is on the decrease, this sheds new light on the enigmatic increase of lung cancer (“The #1 Killer”) and calls into question whether smoking is per se an actual cause of lung cancer.
That’s right. According to Hamer, smoking doesn’t cause lung cancer, so smoke ‘em if you’ve got ‘em!
He also blames breast cancer on either a “mother-child” or “partner worry” conflict. To him, these sorts of “conflicts” involve a child becoming ill or being seriously injured. According to the article above, Hamer’s “many case studies” show that women develop cancer of the breast from “obsessively worrying about the well-being of a loved one”, such as a child who is in trouble, a parent who is ill, or a dear friend who is a cause for concern. This concept is, of course, the purest poppycock, utter woo.
Of course, no good piece of cancer woo would be complete without its creator telling us “conventional” types that we have it all wrong about some key aspect of cancer. Not content to tell us that we have no idea what we’re talking about regarding the pathogenesis of cancer, like Hulda Clark, Hamer boldly tells us that we also have no clue about the real reason for cancer metastasis:
The standard metastasis theory suggests that cancer cells of a primary tumor travel via the blood stream or the lymph system to other parts of the body where they cause a cancerous growth at a new site (theoretically, this assumption would imply a potential risk of contracting cancer through a blood transfusion). The New Medicine does not dispute the fact of secondary and third cancers. However, according to the Five Biological Laws, second and third cancers are not the result of migrating cancer cells but of a second or third DHS, often triggered by a diagnosis or prognosis shock that puts the individual into total panic, causing a new conflict or even several new conflicts leading to additional cancers. For example, a cancer diagnosis shock can trigger a “death fright conflict” leading to the development of lung cancer.
Sorry, dude. If your cancer metastasizes, it’s not really the same tumor at all, but a new one. Moreover, obviously you’ve had some sort of other “psychic trauma” that caused the metastasis to pop up. It’s also pretty convenient that Hamer attributes metastasis to a “death fright conflict.” Pretty much each and every single cancer patient fears that his or her cancer will kill him. Thus, every cancer patient has a “death fright conflict.” Now that I think of it, though. If it is the case that most, if not all, cancer patients fear that their cancer will kill them, isn’t it true that most, if not all, cancer patients have a “death fright conflict”? If that’s the case, then why don’t all cancer patients develop metastases? Just a thought.
Let’s move on to the Fourth Biological Law, which supposedly addresses the role of microbes in disease and evolution, but for the life of me I can’t figure out exactly what the heck Dr. Hamer is saying about disease. Let’s whittle it down to two sections:
When our organs developed over the course of evolution, very specific types of microbes developed with them. The biological purpose of the billions of micro-organisms that inhabit our body is to maintain all the different tissues and keep them in a healthy state. Given the purposeful co-existence of man and microbes, the New Medicine identifies fungi, bacteria or viruses as loyal helpers that are indispensable for our survival.
It is the discovery of the New Medicine that microbes become without exception only active in the healing phase. In the phase of Normotonia as well as in the conflict active phase they are dormant and do not cause any infection. But at the moment of the conflict resolution, they receive a signal from the brain to start the work that was assigned to them. Pathogenic (active) microbes are totally harmless to all other organs.
And:
It is true that microbes are present in infectious diseases, but it is not the microbes that cause the disease. On the contrary, our organism uses the microbes to optimize the healing process. It is also true that microbes can be transmitted, but they stay inactive as long as we are not in the healing phase of the appropriate conflict.
Ah, so all of those pathogenic bacteria? Don’t worry about them. They only work for your good. So, if you have a big abscess, a gangrenous foot, pneumonia, AIDS, or hepatitis C, it’s just your body using bacteria or viruses to “optimize the healing process.” You don’t need antibiotics or antiviral drugs. If you die in the process, it just means that you weren’t able “resolve your inner conflict.”
Wrong. Especially this part about microbes:
Fungi and myco-bacteria (yellow group) are the oldest microbes. They exclusively work on organs and tissues that originate from the endoderm and are directed from the brain stem. Fungi like Candida or myco-bacteria like tubercular bacteria are the “destruction crew”. They decompose tumors such as colon tumors, lung tumors, kidney tumors, or liver tumor. During the healing phase they break down the extra cells that are no longer needed. Usually, this decomposing process is accompanied with fever and night sweats. What makes myco-bacteria remarkable is that they start to multiply immediately at the moment of the conflict shock. They multiply at a rate which parallels the growing tumor. The moment the conflict is resolved, the exact amount of tubercular bacteria is available that is necessary to decompose the tumor cells. If the microbes are absent because, for example, they were eradicated through vaccination, the tumor will be encapsulated in scar tissue and stays in place with no further cell augmentation. In this case the tumor will be viewed as “benign”.
Bacteria (orange group) inhabited the organs and tissues that derive from the mesoderm directed from the cerebellum (old brain mesoderm) or the cerebral medulla (new brain mesoderm). Bacteria are the “cleanup-workers. In old brain mesodermal tissue they decompose tumors such as glandular breast tumors or melanoma, and assist by clearing away the remnants. Bacteria also help to restore the tissue by forming abscesses that will be filled with scar tissue. In new brain mesodermal tissue, bacteria such as staphylococcus bacteria fill the gaps in the bone that were caused by the meltdown of callus cells and reconstruct the bone with granulating callus forming tissue. During the healing phase, bacteria also rebuild the cell loss (necrosis) of ovarian or testicular tissue.
Viruses (red group) are the youngest microbes. They exclusively work on tissue that derives from the ectoderm and is controlled from the cerebral cortex, e.g. the epidermis, the cervix, the intra-hepatic bile ducts, the mucous membrane of the stomach, the bronchia or the nose. Viruses are the “reconstruction workers”. They replenish the tissue that was lost during the preceding ulceration process. While old brain directed myco-bacteria start to multiply immediately with the onset of the conflict active phase, viruses start to divide and to become active only upon the resolution of the conflict. With viruses involved the healing phase is more dramatic, often accompanied with fever and inflammation. Examples for viruses at work are: pneumonia, hepatitis, herpes, or the “flu. If the necessary viruses are absent, healing still occurs but not to a biologically optimum degree.
Like tumor cells, microbes never cross the germ layer threshold (diagram). For example: pneumonia viruses only work on bronchial tissue which originates from the ectoderm and is controlled from the cerebral cortex, while tubercular bacteria are specialized to operate exclusively on lung alveoli tissue that originates from the endoderm and is directed from the brain stem. That is why we will never find tuberculosis in the bronchia.
Uh, no. Just one example: Tuberculosis can infect many organs and sites and not just ectodermally derived tissues, including lungs, kidneys, the meninges (lining of the brain), and bones and joints (which, happen to be derived from mesoderm, by the way). It is also not true that you don’t find tuberculosis in the bronchi.
But the bottom line for Hamer is the Fifth Biological Law, and, if you’ve been paying attention to alt-med concepts, you will realize that this “Law” echoes so much woo that you have to wonder if Dr. Hamer thought of it himself or simply synthesized many varieties of woo into a single concise statement that seems to sum up huge swaths of alternative medicine:
Every so-called disease has to be understood as a Meaningful Special Biological Program of Nature created to solve an unexpected biological conflict.
Every “so-called disease”? Yes, indeed. According to Dr. Hamer:
All so-called diseases have a special biological meaning … While we used to regard Mother Nature as fallible and had the audacity to believe that she constantly made mistakes and caused breakdowns (malignant, senseless, degenerative cancerous growths, etc.) we can now see, as the scales fall from our eyes, that it was our ignorance and pride that were and are the only foolishness in our cosmos. We could not understand such a ‘sewn up’ totality, and so brought upon ourselves this senseless, soulless and brutal medicine. Full of wonder, we can now understand for the first time that nature is orderly (we already knew that), and every occurrence in nature is meaningful, even in the framework of the whole, and that the events we called ‘diseases’ are not senseless disturbances to be repaired by sorcerers’ apprentices. We can see that nothing is meaningless, malignant or diseased.
Unfortunately, these ideas have power and resonance among cancer patients, and this attractiveness, coupled with the fear of science-based cancer therapy, particularly chemotherapy, has led all too many cancer patients to believe in Hamer’s quackery. For example, there was the case of Olivia Pilhar. Olivia was six years old in 1995 at the time she was diagnosed with a Wilm’s tumor, a highly treatable childhood malignancy, and her parents discovered Ryke Geerd Hamer. Her parents withheld conventional medical therapy and persued Hamer’s German New Medicine. In an echo of later cases in the United States of children whose parents decided to pursue “alternative medicine” rather than scientific medicine, such as Abraham Cherrix and Daniel Hauser, the Austrian government finally removed the parents’ rights of care and control, and they fled from Austria to Spain with Olivia. Despite Hamer’s “treatments,” Olivia’s tumor continued to grow. After negotiations including the intervention of the Austrian president, the parents were persuaded to return with the condition of no punishment. By then, Olivia’s tumor weighed several kilograms. The child was finally given emergency medical treatment, including chemotherapy and surgery, after a court order against the parents’ wishes. Olivia is still alive in 2009 and very lucky to be so. In the end, her chances at survival had been eroded, and she suffered far more than she needed to in order to treat her cancer. Her parents received an eight-month suspended jail sentence in Austria.
Another victim of Hamer’s quackery is Michaela Jakubczyk-Eckert (note: photos on this site not for the squeamish). This is the patient I spoke about at the Science-Based Medicine Conference in July. Michaela developed stage III breast cancer and initially underwent chemotherapy, with good response. If she had continued, likely she could have undergone surgery with curative intent. Unfortunately, she discovered Ryke Geerd Hamer, who persuaded her to give up chemotherapy and pursue German New Medicine. As a result, her cancer returned with a vengeance. She developed en cuirasse disease, which is cancer growing over a large portion of her chest wall. Her death in 2005 was unpleasant and very painful.
There’s another, equally unsavory aspect to Hamer, and it ties into another aspect of any serious cancer quackery, namely a foe that keeps The Truth from the people. Basically, Hamer is a raging anti-Semite. He has become convinced that the German New Medicine is being suppressed by the “International Jewish Conspiracy,” that Jewish scientists have stolen from him the idea of German New Medicine, and that they are hiding it from the world. Indeed, he further claims that the Jews use German New Medicine for themselves to cure their cancers but keep it from Gentiles, all the better to allow two billion people to die “needlessly” from cancer. In this, the German New Medicine shares with many other forms of quackery another essential ingredient: A conspiracy theory to explain why Hamer’s quackery isn’t more widely known, practiced, and above all appreciated for the “genius” that it is. In most cases of cancer quackery, it’s the pharmaceutical companies, governments, or some cabals made up of both who are said to be “suppressing” the latest cancer cure. In the case of Ryke Geerd Hamer, it’s…THE JEWS!!!!!!! (Cue scary music.)
If there’s one thing about the German New Medicine that feeds in to what I’ve thought for a long time now, it’s that many “alternative medicine” beliefs seem to demand some sort of “meaning” from disease. The cancer patient, when faced with the horror of his or her disease, will rail against the unfairness of it all. And indeed it isn’t fair. It isn’t fair at all. Cancer sucks. Regardless of the type of cancer, it’s a horrible, nasty disease, and some varieties are particularly deadly. But life itself isn’t fair. Sadly, bad things (like cancer or other life-threatening diseases) happen to good people. Personally, I don’t see much difference between Hamer’s quackery, in which all diseases are postulated to have a “special biological meaning” where the symptoms are the result of an inner mental conflict and the beliefs expressed by many religious people that bad things (like being afflicted with a horrible disease like cancer, whatever type) must be the result of a “higher purpose,” that they must serve a “greater good.” The only difference is that Hamer has replaced the appeal to an unknown and unknowable “meaning” dictated by God with an appeal to a greater “meaning” dictated by Nature. The hope that one’s suffering is all in the service of a greater good may well help many people deal with cancer or other life-threatening or debilitating diseases, but it’s not such a good idea as the basis of any sort of medicine, whether “New German” or otherwise.
The second, even worse thing, about the German New Medicine is that it feeds into another common strain in “alternative medicine” thought, namely to blame the victim. In the case of this particular form of cancer quackery, cancer isn’t a disease but rather a manifestation of something going on in the mind. If the cancer patient can’t overcome this “trauma” and thus dies, the implication is that it’s the cancer patient’s fault. If only he had believed more or done more to follow the particular woo that is supposed to save him, he would still be alive today.
That, I find to be the most despicable aspect of all when it comes to cancer quackery.

   The (Not-So-)Beautiful (Un)Truth about the Gerson protocol and cancer quackery
David Gorski
Link
Although this blog is about medicine, specifically the scientific basis of medicine and threats to the scientific basis of medicine regardless of the source, several of us also have an interest in other forms of pseudoscience and threats to other branches of science. One branch of science that is, not surprisingly, critical to medicine is the science of biology, and the organizing theory of biology is the theory of evolution, which was first reported by Charles Darwin and subsequently synthesized with the developing science of genetics in the early 20th century and then with our increasing knowledge of molecular biology, genomics, and proteonomics whose rise ushered us into the 21st century. However, the implications of evolution, namely that humans and apes both evolved from a common ancestor and that humans, for all their belief of being different and superior to animals, are in fact related to animals in the great chain of life going all the way back to single-celled organisms, does not go down well with certain religious fundamentalists, particularly Christian fundamentalists. Whereas I (and I daresay several of my cobloggers) find the interconnectedness of life, including humans, implied by Darwin’s theory to be beautiful and uplifting, many fundamentalists see it as a profound threat to their world view. Consequently, they have attacked the theory of evolution at every turn and tried to insert creationism, particularly the latest incarnation of creationism known as “intelligent design,” into science classes as an “alternative” to “Darwinism.” The manner in which they torture science, logic, and reason to try to cast doubt on a theory that is every bit as rock solid in terms of massive quantities of experimental and observational evidence to support it as any other theory in science, if not more so, is legendary and well documented at blogs such as The Panda’s Thumb and websites such as Talk Origins.
Although one day I plan on writing about how insights from evolutionary theory have led to deeper understandings of human disease and strategies to improve human health in the future, this time I want to concentrate on the similarities in techniques of spreading disinformation between creationists and purveyors of unscientific medical “treatments.” For background, first, you need to be aware of a movie that was released in April. The movie, Expelled!: No Intelligence Allowed was released. Starring Ben Stein at his most unctuous sporting a bullhorn and styling himself as a conservative, buttoned-down version of Angus Young through his choice of apparel in its promotional material, the movie’s main theme is that any academic who “questioned Darwinism” is “expelled” from academia. The basic idea is that “intelligent design” creationism is being “suppressed” by biologists who just can’t accept the thought of the existence of a “designer” (i.e., God). Indeed, the movie goes so far as to equate biologists and scientists who accept the theory of evolution as the best current explanation for the diversity of life to Hitler and the Nazis and their “suppression” of “alternatives” (word choice intentional) to “Darwinism” to Nazi and Stalinist persecution of dissidents and perceived threats to the regime. The movie even features a sequence where Ben Stein visits Dachau and Auschwitz, as though to imply that biologists are busy firing up the ovens for the Brave Maverick Scientists who “dissent from Darwin.”
These Brave Maverick Scientists are a lot like the Brave Maverick Doctors who champion unscientific medicine. After all, Kevin Trudeau has made a cottage industry and sold millions of books based on the claim that there are “natural cures” that “they” (as in doctors, pharmaceutical companies, and the government) don’t want you to know about and that as a consequence the full forces of these groups are being marshalled to “suppress” them and “persecute” the Brave Maverick Doctors who dare to question the “orthodoxy” of “allopathic medicine,” up to and including claims of “Nazi”-like suppression. (Just read those repositories of quackery NaturalNews.com and Whale.to if you don’t believe me.) For the “alternative medicine” movement, it’s all there, in websites, blogs, and books. But one thing that the movement pushing unscientific treatments has lacked, and that’s a movie to call its own, a movie to spread the same message.
That is, until now.
The (Not-So-)Beautiful (Un)Truth
A number of readers have e-mailed to me links and references to a new movie, which recently completed a run in New York City from November 14 through 20 and is scheduled to open on Wednesday in Los Angeles and show there through December 4. I’m referring to a movie entitled The Beautiful Truth. Before the e-mails started, I had had no inkling that this movie was being made or that its release was on the horizon. Maybe it’s because the movie is only showing in New York and Los Angeles and hasn’t made it out of the media enclaves of those cities out to the rest of us in flyover country, or maybe its release is so limited that I just hadn’t heard of it. Or maybe it’s because it didn’t have the multimillion dollar marketing push from religious fundamentalists, coupled with a famous face like that of Ben Stein fronting it. However, what this movie reminds me of, more than anything else, is Ben Stein’s pseudoscience- and lie-filled bit of “intelligent design” creationism propaganda Expelled!. The similarities are eerie, at least in terms of the message. The Beautiful Truth may not have the marketing muscle or celebrity behind it that Expelled! had (and still has behind its release as a DVD), but it does have slick website, not to mention a lot of trailers and clips from the movie on YouTube and elsewhere.
These trailers and clips make it quite obvious that The Beautiful Truth is nothing less than a credulous paean to cancer quackery in much the same way that Expelled! was a credulous paean to “intelligent design” creationism coupled with a conspiracy theory casting advocates of pseudoscience as brave “skeptics” of scientific orthodoxy. Specifically, it’s a paean to the quackery known as the Gerson therapy, mixed in with a veritable cornucopia of dubious and fraudulent cancer treatments. If the dozen or so clips on the website and YouTube are any indication, this movie is nothing less than a tour into the dark heart of American quackery led by a credulous guide who has drunk deeply from the Kool Aid on sites like Whale.to, NaturalNews.com, and Mercola.com. Just as Expelled! claims that academics are “suppressing” any criticism of “Darwinism” or research into “intelligent design,” The Beautiful Truth postulates a grand suppression of this “alternative” cure for cancer that “they” don’t want you to know about. The movie is described thusly:
Garrett is a 15-year old boy living in the Alaskan wilderness with a menagerie of orphaned animals. Growing up close with nature has given him a deep understanding of nutritional needs required by diet sensitive animals on the reserve. Unfortunately, the untimely and tragic death of his mother propelled him into a downward spiral and he risked flunking out of school. This led to his father’s decision to home-school Garrett. His first assignment was to study a controversial book written by Dr. Max Gerson.
Note the religious overtones to this plot device holding the movie together. Indeed, this is nothing less than a conversion story, of which we hear many from religious fundamentalists, the kind where after a tragedy a troubled youth falls into a pit of despair, complete with substance abuse, bad grades, and falling in with the “wrong” crowd. Either as a result of his fall or as the cause of his fall, the youth rejects Jesus. Then, in such stories, inevitably someone shows the troubled youth the Bible and tells him all about Jesus again, and eventually the youth “sees the light” and is saved from the darkness. This movie sounds exactly like this, except with “alternative” medicine being the savior and Max Gerson providing the “miracles” in the form of a “miraculous cure” for cancer. This is not surprising, because so much of “alternative” medicine is more like religion than anything else–and a cult religion at that, as has been argued by my cobloggers at various times. No amount of evidence or science deters its adherents from their belief. But, if you really, believe, the Messiah Max Gerson will cure you–yes, you!–of your cancer, no matter how advanced
The description of the movie continues:
Written over 50 years ago, Dr. Gerson found that diet could, and did, cure cancer. Controversial at the time (and even today), Garrett took on the challenge of researching this amazing therapy, which drew the interest of his neighbors in the small Alaskan community. With the help of Dr. Gerson’s daughter, Charlotte Gerson, and grandson, Howard Strauss, they gave him the ammunition needed to go in search for the truth – a truth that would affect not only him, but his entire Alaskan village – all of whom wanted to know if these claims were true. After a number of cancer patients, who were diagnosed as terminal, shared their stories and their medical records with Garrett, it became abundantly clear that, contrary to the disinformation campaign spear-headed by the multi-billion dollar medical and pharmaceutical industry, a cure for virtually all cancers and chronic diseases does exist – and has existed for over 80 years!
Of course it has. It always has–at least, if you listen to people like Mike Adams, that is. Indeed, I wonder if he had a hand in this movie. Alas for my speculation, according to the press kit, at least, he didn’t. In any case, if you believe purveyors of many, many forms of quackery, there is always a cure for cancer out there that big pharma and the government have been “suppressing” because–well, it’s never entirely clear exactly why they would keep such a cure a secret or, more incredibly, how they could possibly keep such a secret. Indeed, these cancer “cures” strike me as being either the world’s most well-kept conspiracies of all time (after all, I’m a cancer surgeon and researcher and I’ve never heard from my colleagues even a hint of such an amazing cure for cancer in general or any specific cancer) or the worst-kept (after all, filmmakers like Steve Kroschel, writer, producer, and director of The Beautiful Truth, seem to have very little difficulty finding out all about it). In actuality, whether the secret of these “natural cures” is well or poorly kept seems to vary with the needs of the advocate telling the story.
Moreover, none of these claims makes much sense on a strictly logical basis. Think about it this way: So many people die of cancer every year that virtually every person in developed countries, doctors and cancer researchers–and, yes, even big pharma executives–included, have known, know, or will know someone with cancer. Many have seen or will see someone they love die of cancer, sometimes in horrific ways. Certainly over the more than four decades of my existence, I have had multiple family members who have died of cancer. In fact, right now my wife and I are dealing with the heartbreak of a close family member recently diagnosed with widely metastatic breast cancer, and I’ve been trying to work every contact I know to get her to the best oncologist in order to provide her with the best possible palliation. Do the makers of this movie think that I or any other cancer researcher (or even big pharma executive) would withhold knowledge of such a “cure” or keep it from others if I knew of it? Indeed, because cancer kills so many people, many of these very same doctors and researchers will end up battling the disease at some point in their lives, and many of them will end up dying of it themselves. I might even end up dying of cancer someday. You might end up dying of cancer someday. Does it make any sort of sense logically that every single one of these doctors, executives, and bureaucrats would dismiss or conspire to suppress (or even blindly ignore the evidence for its existence because of dogma and “business as usual” of) such an amazingly effective cure, if it really existed? No, it does not. Someone would talk, probably a lot of people. I know I would. Again, given how cancer has recently touched our family, I assure you, if such a cure existed, I would make damned sure that family member got it, no matter what it was, and if it truly worked as advertised I would make sure everyone else knew about it too. You can be sure that quite a few of those supposedly nefarious cancer researchers, government bureaucrats, and big pharma executives would too.
So now, not surprisingly, the filmmaker (through Garrett) has a mission:
Garrett’s mission now is to tell the world.
Of course it is. It always is. Because he’s been converted and is now an evangelist.
The Gerson “Therapy”
Let’s review a bit about just what the Gerson therapy is. It’s a so-called “nutritional” therapy for cancer that involves consuming large quantities of fruit and vegetable juices, raw liver, coupled with a “detoxification” regime that involves frequent coffee enemas. It is described thusly on the movie’s website:
The Gerson Therapy is a powerful, natural treatment that boosts your body’s own immune system to heal cancer, arthritis, heart disease, allergies and many other degenerative diseases. One aspect of the Gerson Therapy that sets it apart from most other treatment methods is its all-encompassing nature. An abundance of nutrients from thirteen fresh, organic juices is consumed every day, providing your body with a super dose of enzymes, minerals and nutrients. These substances then break down diseased tissue in the body, while enemas aid in eliminating the lifelong buildup of toxins from the liver.
With its whole-body approach to healing, the Gerson Therapy naturally reactivates your bodys magnificent ability to heal itself with no damaging side-effects. Over 200 articles in respected medical literature and thousands of people cured of their incurable diseases document the Gerson Therapy’s effectiveness. The Gerson Therapy is one of the few treatments to have a 60 year history of success.
Although its philosophy of cleansing and reactivating the body is simple, the Gerson Therapy is a complex method of treatment requiring significant attention to detail. While many patients have made full recoveries practicing the Gerson Therapy on their own, for best results it is recommended to begin treatment at a Gerson Institute licensed treatment center. For more information, visit www.gerson.org.
All the usual buzz words are there, the “naturalness” of it (although I’ve never been able to figure out how advocates of these sorts of “natural detoxification” regimens can think that pumping coffee up one’s posterior is in any way “natural”); the vague and scientifically meaningless “boosting the immune system” claim; and, above all, the “detoxification” claim. Apparently believers in the Gerson therapy (not to mention many other forms of “alternative medicine,” believe that our bodies (and colons) are packed with hideous toxins that are making us ill. Once again, how shoving coffee up one’s posterior removes “toxins” I fail to understand, but then I’m thinking about this scientifically rather than religiously. Adherents who believe in detoxification appear to me to do so more out of a belief analogous to religion that they are “unclean” and need “purification,” much the same way that some fundamentalist Muslims engage in ritual self-flagellation or the manner in which in Christian religions Baptism is believed to cleanse the soul. The Gerson protocol provides that “purification,” just as a wide variety of “colon cleansers” and “liver flushes” beloved of “alternative medicine” mavens. Unfortunately, they do not work against cancer and can lead to delays in treatment and, even worse, can rob patients with fatal cancer of effective palliation when they usurp scientific medicine.
Actually, the Gerson protocol was a precursor to the now more commonly discussed and more (in)famous Gonzalez protocol, which my co-blogger Dr. Kimball Atwood IV deconstructed in such exquisite detail over the course of several posts right here on this very blog a while back (1, 2, 3, 4, 5, 6). Grafted onto the therapy by his daughter Charlotte since Max Gerson’s death have been other forms of woo, such as liver extract injections, ozone enemas, “live cell therapy,” thyroid tablets, castor oil enemas, clay packs, laetrile, and “vaccines” made from influenza virus and killed Staphylococcus aureus bacteria. Gerson’s “evidence” in the form of his case series was examined by the National Cancer Institute back in the 1950s, and this is what was found:
In 1947, the NCI reviewed ten cases selected by Dr. Gerson and found his report unconvincing. That same year, a committee appointed by the New York County Medical Society reviewed records of 86 patients, examined ten patients, and found no evidence that the Gerson method had value in treating cancer. An NCI analysis of Dr. Gerson’s book A Cancer Therapy: Results of Fifty Cases concluded in 1959 that most of the cases failed to meet the criteria (such as histologic verification of cancer) for proper evaluation of a cancer case [16]. A recent review of the Gerson treatment rationale concluded: (a) the “poisons” Gerson claimed to be present in processed foods have never been identified, (b) frequent coffee enemas have never been shown to mobilize and remove poisons from the liver and intestines of cancer patients, (c) there is no evidence that any such poisons are related to the onset of cancer, (d) there is no evidence that a “healing” inflammatory reaction exists that can seek out and kill cancer cells [17].
And:
Charlotte Gerson claims that treatment at the clinic has produced high cure rates for many cancers. In 1986, however, investigators learned that patients were not monitored after they left the facility [19]. Although clinic personnel later said they would follow their patients systematically, there is no published evidence that they have done so. A naturopath who visited the Gerson Clinic in 1983 was able to track 21 patients over a 5-year period (or until death) through annual letters or phone calls. At the 5-year mark, only one was still alive (but not cancer-free); the rest had succumbed to their cancer [20].
The cancer doctor in me knows that this is pretty much what would be expected if one were to follow 21 patients with advanced cancer who were being given no treatment. The exact timeframe for their deaths would vary depending upon the mix of cancers, but one could be pretty confident that very few, if any, of them would be alive after five years–or even two or three years. Moreover, because the Gerson regimen, like the Gonzalez regimen, is quite onerous and difficult to follow, only patients in relatively good shape to begin with can follow it, thus selecting for patients more likely to live longer with their metastatic cancer anyway.
But Back to the Quackery Propaganda…
If the clips posted to YouTube are any indication, this movie wastes no time in plunging down the rabbit hole of paranoid conspiracy-mongering. For example, here is its account of what happened to a reporter in the 1940s after reporting on Gerson’s claims:
And here is an interview with Gerson from 1957 in which he claims so many patients that “you” (meaning doctors) had “sent home to die” whom he “cured”:
In fact, as was the case for Expelled!, unacknowledged conspiracy or even outright dogma is at the heart of the movie. Be sure to check out this trailer for The Beautiful Truth as well. It’s got it all, including a leading question: “If your doctor knew of a cure for cancer that didn’t require expensive drugs, he would tell you, wouldn’t he?” In the typical “science has been wrong before” combined with “doctors will say anything if they’re paid enough” gambit, there are also the obligatory excerpts from cigarette ads from the 1940s and 1950s asking “What cigarette do you smoke, doctor?” Then there’s a woman who (I assume) is Charlotte Gerson ranting about how doctors can’t afford to let patients see “alternative” doctors because “alternative” medicine cures people when “conventional” medicine can’t and about how people have been “so brainwashed for so long.” In other words, it’s the same, tired old propaganda that so many quacks have been claiming for so long. It is propaganda that the esteemed director of this film seems perfectly predisposed to believe, as he appears not to have an ounce of skepticism in him, at least if his Director’s Statement is any indication:
I have worked with injured and orphaned wild animals and have been moved by the rcovery of wildlife from illness and disease by the nutritional therapies that I used. So when I was introduced to the work of Dr. Max Gerson on human nutrition by an associate, I wanted to investigate these amazing claims. I was startled by these discovereds, and, frankly, it has changed my life–especially when I was able to meet the people who should have been dead due to terminal cancer.
Since I am a filmmaker, I wanted to meet Dr. Gerson’s family and do a short film for charity. The fallout from that earlier work was so controversial, far-reaching, yet uplifting; I decided to make a feature length film.
I’ve spoken with hundreds of people about Gerson’s therapy and many people related their recovers, their skepticism and bias–most of which came from the medical community. But what I quickly found out that those who dismissed the therapy did not have conclusive evidence that it didn’t work. In doing more investigation, it quickly became evident that an almost criminal set of priorities has been in play when it comes to treating human disease.
In other words, Steve Kroschel is a credulous soul who hasn’t the slightest clue about how to evaluate scientific evidence relating to the efficacy of a cancer therapy (or any therapy, for that matter). He clearly has no idea how scientists and doctors determine whether any given therapy has any activity against cancer and assumes that they dismiss the Gerson therapy because of their bias against “unconventional” therapies. In other words, he’s a clueless wonder. In fact, he’s so credulous that the Gerson therapy and cancer aren’t enough for him. Here’s where the next similarity to Expelled! comes in, as Kroschel descends to the same level as Ben Stein did in Expelled! in an anti-fluoridation segment that’s replete with images of Hitler and his concentration camps, along with claims that Hitler wanted to use sodium fluoride as a technique for mass sterilization, presumably of the Jews:
Calling Mr. Godwin! Your presence is requested in the movie theater immediately!Kroschel also delves into dental amalgam quackery. The deconstruction of this particular form of “alt-med” is beyond the scope of this post, but Quackwatch and our very own Harriet Hall have provided excellent discussions for why the claims that the mercury in dental amalgams is some sort of horrific health threat is nonsense and why dentists and “alternative” practitioners who insist that people need to have their amalgam fillings removed in order to “detoxify” are almost invariably quacks. Suffice it to say that there is a widespread and paranoid belief that somehow the mercury in dental amalgams is causing all sorts of horrific health problems, much the same way that the mercury militia thinks that mercury in vaccines causes autism, and clearly Kroschel believes this pseudoscience as well:
Hilariously, there’s a segment in the video above of the dreaded “smoking tooth” video which in reality caught nothing more than water vapor. It’s one of the most amusingly silly bits of extravagant quackery that I’ve ever seen and always good for a hearty belly laugh (or a cry when I realize that there are a number of people who actually believe this sort of stuff) whenever I watch it. Unfortunately, Kroschel actually seems to think that this video is slam-dunk evidence of anything other than the video maker’s utter credulity. Now, like Harriet, I’m not saying that it isn’t possible that small amounts of mercury may escape from amalgams over many years, but no one has yet produced any remotely convincing evidence that (1) it is any more than trace amounts; (2) that any significant amount is actually absorbed at significant levels; or (3) that amalgams are linked with any health problems at all. In reality, the crowd that believes that dental amalgams cause all sorts of horrific chronic health problems is very much like the anti-vaccine crowd known as the “mercury militia,” which clings to the scientifically discredited belief that mercury in the thimerosal preservative that used to be common in childhood vaccines was a major cause of autism or people who try to link mercury from the smokestack emissions from power plants with autism. Both rely on misunderstandings, confuse correlation with causation, and a studied ignorance of the principle that the dose makes the poison. Yes, mercury is toxic, but not at all doses and not at the doses that were in vaccines and are in dental amalgams.As amusing (in a warped way) as I find the dreaded “smoking tooth” clip, my favorite segment is this next clip. Really, if you watch only one of the clips in this post, make this next clip the one. You won’t regret it. You really won’t. I swear. It has that sort of paranormal buzz about it that I find irresistable:
I don’t know about you, but I couldn’t stop laughing after I watched this clip. In it, two pictures are shown. One, we are told, is of a cooked baby carrot. The other, we are told, is of an uncooked baby carrot. The narrator proclaims, “The uncooked carrot has a startling line of strong energy” that–surprise, surprise!–the cooked carrot obviously lacks. Never mind that we have no idea what techniques were used to take these pictures or even what this “energy” is supposed to be. The conclusion? Pasteurized food is “dead, dead, DEAD” apparently just like the parrot in a certain famous Monty Python sketch and not unlike Steve Kroschel’s brain. Now, whatever negative nutritional changes cooking may induce in food, which may include the breakdown or degradation of some nutrients, this sort of nonsense is simply nothing more than superstitious vitalism, an ancient belief that there is a “life force” or “life energy” that animates life and is the difference between living matter and dead matter. It turns out that belief in vitalism is at the heart of many unscientific “alternative medicine” practices, for example, virtually any “energy healing” modality, such as reiki, therapeutic touch, acupuncture, or any other therapy that claims to manipulate qi. Those who believe in vitalism also often believe that it is somehow better to eat “live” food, as if we can somehow absorb its life force by eating it. It also looks no different than the hilarious quackery of “aura” cameras for humans or perhaps so-called “bioluminal” photography.Call me psychic if you want (or say I have delusions of being a psychic), but I’ll hazard a prediction here, not having seen the whole movie and noting the fact that there isn’t any information about all the cancer patients “cured” with Gerson therapy. My prediction? I predict that there will be the usual “testimonials” by people who say they were “sent home to die” by their oncologists, only to be “saved” by Gerson or his daughter. There will be Messianic overtones (with Gerson as the Messiah, of course) and a strong similarities to religious conversion stories in the testimonials, as I’ve pointed out before about such stories. Most importantly, though, in not a single one of the testimonials in the movie will there be sufficient detail or evidence presented to allow one to draw any reliable or convincing conclusions whatsoever regarding whether the Gerson therapy, in fact, cured the patient’s cancer. (There never is.) Key information will be missing from each and every such testimonial. (It always is.) I realize I’m going out on a limb here, but what’s the point of being a blogger if you don’t take outrageous risks from time to time? In any case, I’ve seen enough testimonials and observed how they are used to sell “alternative” medical therapies to know what to expect without even having to watch the movie.
Unfortunately, it’s too late for those of you in New York, as the film’s run there is over, but here’s one good thing about this movie for readers living in L.A. After some of the shows during the film’s L.A. run over the Thanksgiving weekend, there will be question-and-answer sessions featuring Howard Straus, Charlotte Gerson, and Polly Emery. This looks to me like an excellent opportunity for any enterprising medical skeptical doctors to try to put Gerson’s offsprings’ feet to the fire and try to get them to provide answers consisting of more than just the usual testimonials and claims that “they” are “suppressing” the “Truth.” Certainly, were I still living in New Jersey, I would have been highly tempted to make an appearance. On the other hand, it takes a hearty soul to do this sort of thing and plunge into the proverbial lions’ den. After all, people likely to make up the audience for such a movie want to believe, and likely the reaction to skeptical questions would be about the same as the reaction from the audience of the screening of Expelled! at which Richard Dawkins showed up. After all, on The Beautiful Truth blog, all I find are glowing “reviews” and posts about how popular and well-received the movie supposedly was in New York, not to mention a testimonial or two about “natural” cures.
The Beautiful Truth and Expelled!: The differences are only skin deep
The more I watch the clips from this movie, the more appropriate I think the comparison between The Beautiful Truth and Expelled! is. All the elements are there: Outrageous pseudoscience. Check. A scientific orthodoxy supposedly so blinded by greed and ideology that it can’t accept that Max Gerson “cured” cancer and therefore treats the Gerson protocol it as a challenge to its medical hegemony, just as in the eyes of ID creationists those evil “Darwinists” supposedly can’t stand challenges to “Darwinism” and treat them as a challenge to their scientific hegemony. Check. And, of course, there is at least one Godwin-worthy gratuitous comparison to Adolf Hitler and the Nazis. (Whether there are more or not, I can’t know without seeing the whole movie.) Check. From these clips and the descriptions of the movie on its website, it seems to me that all The Beautiful Truth lacks is Ben Stein in an Angus Young-style British schoolboy shorts walking up to oncologists and hospitals with a bullhorn and demanding why they don’t offer the Gerson therapy to their patients or, sans schoolboy pants, looking deeply contemplative and horrified at the ruins of Dachau or Auschwitz, and implying that doctors, the FDA, and the government are busy firing up the ovens for Dr. Gerson’s descendants, metaphorically speaking at least.
I suppose we can be grateful for that small mercy, at least. Ben stein looks ridiculous in a British schoolboy uniform.
Be that as it may, as a cancer surgeon, I find such promotion of the most obvious and blatant cancer quackery to be utterly despicable and fear that it will lead some patients to believe that the Gerson therapy really does cure cancer and to abandon effective cancer therapies. Also as distressing, the manner in which Kroschel uses his son Garrett as the vessel into which he pours his “alternative” medicine agenda and his defense of quackery is profoundly creepy. One hopes he is not damaged by the experience. Even better would be if in a year or two Garrett rebels against his father, as so many teen boys do, and decides to become an oncologist (or, better yet, a surgical oncologist) who rejects the Gerson protocol as the quackery it is and dedicates himself to using only the best science-based cancer therapy. The irony would be delicious.
Sadly, I realize that such an outcome is highly unlikely. After all, the apple usually doesn’t fall too far from the tree. But a science-based medicine boosting surgical oncologist can always dream, can’t he?

The Gerson protocol, cancer, and the death of Jess Ainscough, a.k.a. “The Wellness Warrior”
David Gorski on March 2, 2015
Link

Less than four days ago, a young Australian woman died of a very rare type of cancer. Most of my American and probably many of my European readers have never heard of her, but in Australia she had become quite famous over the last seven years as a major proponent of “natural health.” Her name was Jess Ainscough, but, like a certain American woman who has become famous for promoting dubious science, she was better known by her “brand” name. That brand name was The Wellness Warrior.
I first encountered Ms. Ainscough about a year and a half ago and have been intermittently following her career ever since. I’ve even blogged about her three or four times during that period over at my not-so-super-secret other blog. However, for whatever reason, even though it was my intent to write about her here on Science-Based Medicine, I never got around to it. Her death prodded me to write now, because her tale is a cautionary one important enough that I believe there should be something written here about it. Given that, those of you who follow my cubical other self will find some of this post repetitive. However, think of it as the first opportunity I’ve had to tell the story from beginning to end, along with a major deconstruction of the Gerson protocol. (Yes, unfortunately the Gerson protocol figures heavily in this story.) It’s a story that has led to the deaths of at least two people, and whose harm to others is impossible to quantify, given that the reach of The Wellness Warrior was long, at least in Australia.
The birth of The Wellness Warrior
Jess Ainscough’s “journey,” as she liked to call it, began in 2008, when she was 22 years old, as she relates in an article for DOLLY magazine from three years ago entitled “I’m healing myself from cancer naturally“:
I was living in Sydney at the time and working as the online editor for DOLLY magazine. I was living an ideal life for someone in their early twenties – burning the candle at both ends, paying no attention to how my actions could affect my health, but having a whole lot of fun while I was at it.
Everything was going exactly according to my life plan. Or so I thought.
On the 24th of April, 2008 I went to see my hand surgeon to have a cast removed, following an operation I had to biopsy some lumps that had been popping up all over my left hand and arm.
After taking the cast off, my doctor told me the news that would change my life in too many ways to predict. He said that I had cancer, and that the type of cancer I have is so rare that not many doctors know how to treat it.
Epithelioid sarcoma doesn’t respond to chemotherapy or radiation, and my only chance of prolonging my survival would be to have my arm amputated at the shoulder. But essentially, my condition was incurable.
This is the part of Ainscough’s story that has always puzzled me. It isn’t the part about her surgeon recommending an amputation. To me it sounds as though the operation that he recommended was either a shoulder disarticulation or, even more radical, a forequarter amputation, which involves removing not just the arm, but the shoulder joint and shoulder blade. Now here’s why this part of the story puzzled me. An operation as radical and disfiguring as shoulder disarticulation or forequarter amputation is usually not offered for palliative purposes. Let’s just put it this way. It’s an operation so uncommon that I’ve never done one; in fact, I’ve never even seen one done. Yet it is an operation that is occasionally necessary for sarcomas in the shoulder area, when attempts at limb-sparing surgery fail. If the surgeon was offering this operation to Ainscough, I strongly suspect that he didn’t think her cancer was “incurable.” Yet that word keeps popping up over and over again in Ainscough’s narratives. I suspect, but can never know one way or the other, that, because this cancer is so rare her doctors were pessimistic. Also, as we will see below, this type of sarcoma is prone to recur after excision.
Be that as it may, it would have been very difficult not to feel great sympathy for Ainscough in 2008. It’s hard to imagine facing the prospect of losing one’s arm at age 22 as the only chance at long term survival. Even as a middle-aged guy, I wonder if, faced with the same choice as Ainscough, I would be able to do it. Certainly at the very least, losing an arm would end my career as a surgeon. To be honest, I just don’t know. No one does, until she’s faced with such a decision.
So what is epithelioid sarcoma? A rare cancer with an incidence of around 0.3 to 0.4 per million (yes, million), epithelioid sarcoma is not among the most fast-growing of cancers. Indeed, it is slow-growing, but it is difficult to eradicate. Wide surgical excision is the recommended treatment because it’s the only thing that is known to prolong survival. The usefulness of other treatments remains unclear, because this cancer is so rare that there likely will never be a randomized, controlled clinical trial for adjuvant chemotherapy and/or radiation. In any case, epithelioid sarcoma frequently presents exactly as Ainscough described in her article, as firm or hard palpable masses, either in the deep soft tissue or the dermis (deep layer of the skin). The superficial lesions frequently ulcerate and are sometimes misdiagnosed as a poorly-healing wound. Unlike other sarcomas, epithelioid sarcomas tend to metastasize to lymph nodes.
As slow-growing as epithelioid sarcoma is, unfortunately, it’s also prone to recurrence after excision. It’s also prone to metastasize. However, if there’s one thing about Ainscough’s story, it’s that, even in her last blog post before the end, she emphasized that the tumor still hadn’t spread beyond her arm. (More on that later.) In general, radical excision, if feasible, is recommended to treat epithelioid sarcoma because less radical excisions result in recurrence rates as high as 77% in some studies. Also, regional lymph node metastases and local recurrence correlated with increased distant metastatic disease (such as lung or elsewhere) and decreased survival.
Even so, according to a review of the SEER database the ten-year survival for patients with epithelioid sarcoma is on the order of 61% (72% for patients between the ages of 17 and 30), and for patients with local disease and no evidence of lymph node or other metastases (i.e., patients like Ainscough) the five year survival rate can be as high as 75%. Of course, those survival rates assume treatment with successful surgery to widely excise the cancer; without surgery, five year survival is 35% and ten year survival is 33%. This implies that there is a subset of these cancers that is fairly indolent, as the vast majority of patients who are going to die of their disease do so within five years, with additional deaths after five years being relatively few. Granted, these are optimistic estimates. If Ainscough had more extensive regional tumor involvement, according to the SEER database, her expected ten-year survival would have been on the order of 49%. Still, that’s hardly “incurable,” and her story sounds as though her sarcoma probably had more favorable characteristics.
When I first encountered Ainscough, I noted that, although her sarcoma was very likely to result in her demise (which, sadly but not unexpectedly, it ultimately did), it might not happen for several more years. (Unfortunately, it was only a year and a half.) Worse, however, by refusing surgery, Ainscough decreased her chance of surviving 10 years by at least half. Just how much, it’s very, very hard to say. This particular tumor is so rare that there just aren’t a lot of data about how best to treat it other than with surgery. It’s unclear whether adding chemotherapy prolongs survival, although it is likely that postoperative radiation decreases the recurrence rate. What we can say is that a seven year survival after diagnosis without surgery is still well-within the expected range for patients with epithelioid carcinoma who do not undergo surgery. It is not out of the ordinary and thus gives no impression that whatever she did during her tenure as The Wellness Warrior had any effect whatsoever.
That being said, Ainscough relates that she was even ready to have the surgery, even to the point of having “signed the papers,” but “Baby Jesus, Buddha, Elvis – or whoever is up there – must have been looking out for me, because two days before I was due to have the operation, my medical team came to me with an alternative option.” That alternative was isolated limb perfusion. Basically, this is a technique sometimes used for soft tissue sarcomas of the extremity, or multifocal melanoma that can’t be resected without amputation, to try to destroy the tumor. As its name implies, isolated limb perfusion involves isolating the limb from the systemic circulation and infusing it with very (and I do mean very) high doses of chemotherapy. That’s what necessitates the isolation of the limb’s circulation; the concentration of chemotherapy is so high that if it leaked back into the rest of the circulation the consequences could be disastrous. Isolated limb perfusion can often cause seemingly near-miraculous results, even for melanoma and sarcoma, and apparently that was the case for Ainscough. Unfortunately, tumors tend to recur after isolated limb perfusion, and that’s exactly what happened to Ainscough about a year later, which led to the doctors recommending an amputation of her arm at the shoulder again as her only real chance of prolonging her survival.
So this is what Ainscough chose:
The way I saw it I had two choices. I could let them chase the disease around my body until there was nothing left of me to cut, zap or poison; or I could take responsibility for my illness and bring my body to optimum health so that it can heal itself. For me it was an easy decision.
I began looking at the different ways I may have contributed to the manifestation of my disease and then stopped doing them.
I swapped a lifestyle of late nights, cocktails and Lean Cuisines for carrot juice, coffee enemas and meditation and became an active participant in my treatment.
This research led me to Gerson Therapy which ensures you have a perfectly balanced diet for optimum health, assisting your body to flush out nasties whilst feeding it with all the goodness it needs to flourish.
The therapy involves drinking 13 fresh organic veggie juices per day (yes that’s one an hour, every hour of my waking day), five coffee enemas per day and a basic organic whole food plant-based diet with additional supplements.
For two years I devoted my entire life to healing, to the extent that I was effectively housebound.
I am ecstatic to report that it has worked for me. I have had no cancer spread, no more lumps pop up (they were popping up rapidly before) and I can actually see some of my tumours coming out through my skin and disappearing.
The Gerson therapy. Yes, Ainscough found one of the most ridiculous forms of quackery out there, and thus was born The Wellness Warrior. As of three years ago, she thought and taught that it had controlled her tumor, deluding herself into believing that just because tumors popped out of her skin and then disappeared it meant some sort of therapeutic effect had occurred. In actuality, it’s not at all uncommon for some cancers like epithelioid sarcoma to do just that. They grow to a certain size, erode through the skin, and then seem to disappear. As is the case with The Food Babe, Ainscough started blogging about her “journey.” Because she was pleasant, intelligent, and telegenic, she soon became more and more famous, to the point where she became a common fixture on Australian media and could book speaking tours that were well-attended. Her books sold, as did her other lines of products.
All the while, her cancer was slowly progressing.
The Gerson Protocol
I’ve written about the Gerson protocol before in the context of a medical propaganda movie, The Beautiful Truth, that promoted the Gerson treatment. In light of Ainscough’s death from cancer, however, it’s worth revisiting, as it’s been a few years since I discussed Max Gerson and his protocol.
Believe it or not, as recently as 25 years ago, the American Cancer Society published a regular series of articles in its journal, CA: A Cancer Journal for Clinicians, called at various times “Unproven methods of cancer management” or “Unproven methods of cancer treatment.” These brief (usually less than three page) articles discussed—you guessed it!—various forms of cancer quackery. Indeed, I systematically downloaded pretty much every one of these articles that I could find dating back to the early 1960s. One of these days, I’ll do a post about it, particularly since the ACS stopped publishing these articles around the time of the rise of “complementary and alternative medicine” in the 1990s. There’s some wild stuff there that even I hadn’t heard of. In the meantime, I refer to the last such article the ACS did on the Gerson method.
Basically, the Gerson method is considered the granddaddy of “metabolic therapy” for cancer, having been developed by Max Gerson, MD in the 1920s. Gerson wrote in the 1950s that “cancer is not a single cellular problem; it is an accumulation of numerous damaging factors combined in deteriorating the whole metabolism, after the liver has been progressively impaired in its functions.” To remedy this, Gerson developed a radical nutritional program combined with purges (particularly coffee enemas) that he believed would cure cancer and all degenerative diseases. Specifically Gerson:
…assumes that the weaker, “abnormal” cells that exist in every organism are first hurt and, in their anxiety to survive, change their metabolism from oxidative to fermentative. Thus, they leave the harmony of the normal cells and sustain themselves by destroying neighboring tissue with their toxic metabolic products, eventually killing the host body itself.
The Gerson treatment, it turns out, seeks to recreate a “near normal condition of the oxidizing system in the body, to which malignant cells with the fermentation system cannot adapt.” The ACS notes that promotional materials from the Gerson Institute state that the treatment is “able to achieve almost routine recovery—90% or better—from early to intermediate cancer” and, after cancer has metastasized to the liver or elsewhere, “about 50% recoveries can be achieved. Results are less certain if the patient has been poisoned by chemotherapy.” Looking at the Gerson Institute website now, I don’t see such clear-cut language, but I do see a lot of testimonials in its brochures. They seem to be of the usual variety. For instance, one woman had stage III melanoma and attributed her cure to Gerson, even though it’s not clear whether she had surgery or not. (Surgery alone cures melanomas that are curable, particularly in the 1990s.) There’s a man who sounds as though he was probably misdiagnosed with pancreatic cancer. Maybe I’ll do a separate post one day on the testimonials used to sell the Gerson therapy, as Max Gerson’s youngest daughter, Charlotte Gerson, who is almost 93, still runs the Gerson Institute in San Diego and (as noted by Jess Ainscough herself when she was there, quoting her as saying “Orthodox medicine has killed more people than Hitler and Stalin combined”) travels to the Gerson Clinic in Tijuana at least once a week.
In the meantime, I will take note that one thing heavily promoted by the Gerson Institute is Max Gerson’s original book A Cancer Therapy: Results of 50 Cases. In this book, 50 cases of cancer that Max Gerson supposedly cured with his treatment were discussed. Fortunately for me there’s no need for me to go through and analyze all 50 cases, because one of our readers, Peter Moran, already did just that a long time ago. Let’s just say that he was underwhelmed. There were lots of questionable diagnoses (e.g., no biopsy ever done), cancers already cured with surgery before the patient was treated with the Gerson protocol, and big holes in other stories. None of the cases appeared to be particularly convincing evidence for the efficacy of Gerson therapy.
In any event, even though a conversion to anaerobic (without oxygen) metabolism is a feature of many cancers (it’s known as the Warburg effect, something I’ve discussed before), there is no scientific reason to think that Gerson’s diet or “detoxification” would do anything to reverse that or to create a hostile environment in which anaerobic cancer cells couldn’t thrive. Let’s take a look at the summaries of the Gerson protocol that can be found on the Gerson Institute website and on Jess Ainscough’s blog. (Unfortunately, as I wrote this, I discovered that much of Ainscough’s blog has disappeared and that much of it is not in the Wayback Machine any more. Fortunately, I kept the complete text of at least a few of her posts.) Let’s start with the Gerson website, which describes the diet:
    • Thirteen glasses of fresh, raw carrot/apple and green-leaf juices prepared hourly from fresh, organic fruits and vegetables.
    • Three full plant-based meals, freshly prepared from organically grown fruits, vegetables and whole grains. A typical meal will include salad, cooked vegetables, baked potatoes, Hippocrates soup and juice.
    • Fresh fruit and vegetables available at all hours for snacking, in addition to the regular diet.
The Gerson therapy requires huge amounts of these fruits and vegetables to make these juices and meals, up to 20 lbs. per day or even more, as well as these supplements:
    • Potassium compound
    • Lugol’s solution
    • Vitamin B-12
    • Thyroid hormone
    • Pancreatic enzymes
Note that pancreatic enzymes come from, well, animal pancreases, and thyroid hormone comes from, well, animal thyroids, while Lugol’s solution is a solution of elemental iodine and potassium iodide in water, named after the French physician J.G.A. Lugol that was commonly used as a disinfectant. To top all this off (if you’ll excuse the term), the Gerson therapy involves coffee enemas, lots and lots and lots of coffee enemas, several a day. Meanwhile, variants of the Gerson therapy also include:
    • ozone treatment (given by enema or via infusion in autologous, heparinized blood or directly into patients’ blood vessels)
    • hydrogen peroxide (topically, rectally, or orally)
    • intravenous “GKI drip” (glucose, potassium, and insulin solutions)
    • “live cell therapy”
    • castor oil
    • clay packs
    • laetrile
Particularly amusing is a PDF on the Gerson Institute website entitled “Scientific Basis of Coffee Enemas“:
Coffee enemas are a vital part of the detoxification process of the Gerson Therapy. The purpose of the enemas is to remove toxins accumulated in the liver and to remove free radicals from the bloodstream. In the 1920s, two German professors tested the effects of infused caffeine on rats. They found that the caffeine travels via the hemorrhoidal vein and the portal system to the liver, opens up the bile ducts and allows the liver to release bile, which contains toxins. The theobromine, theophylline, and the caffeine in coffee dilate blood vessels and bile ducts, relax smooth muscles, and increase the bile flow.
This is, of course, utter nonsense. The liver needs no caffeine, theobromine, or theophylline to detoxify, nor does increased bile flow mean the liver is “detoxifying.” As our own Scott Gavura discussed, nor is it necessary to boost your liver’s glutathione production, certainly not by coffee enema given that the same effect, even if it were necessary, could be had by just drinking it. Indeed, the rationale for coffee enemas derives from the concept of “autointoxication,” which was actually a concept in mainstream medicine in the late 1800s and early 1900s but was dying out by the 1920s (when Gerson developed his therapy), mainly because our understanding of colon physiology had improved markedly and scientists realized that there was no basis for the concept. The idea was that we are “poisoning” ourselves through the colon and other organs and that we needed “detoxification,” such as enemas, purges, and other sorts of treatments. Indeed, sometimes this was taken to an extreme, with surgeons removing the entire colon to treat illnesses that had nothing to do with the colon, a particularly risky endeavor with a not-trivial mortality rate in the days before antibiotics. Like much of the Gerson protocol, the need for coffee enemas is based on an understanding of human cancer and physiology that was becoming outdated a century ago.
It was a very rigorous treatment as well, stretched out over two years. Jess Ainscough herself described a typical day. Because her content is rapidly becoming inaccessible, I’ll quote it in full:
I’ve had a couple of people ask me to write out a “day in the life” type post outlining a day of the Gerson Therapy. Oh how sorry you will be! Just kidding. I guess this will give you an idea of what the program entails on an hourly basis – even if you do nod off just reading about the sheer monotony of my days.
When I first got home from the Gerson clinic, it was extremely overwhelming. At the clinic we had everything done for us by the lovely Mexican doctors, nurses and kitchen staff. Here at home, it’s all up to my family and I. Saying that, I am incredibly lucky to have such an amazing family. Mum gave up work so that she could be my full-time carer. She does all the shopping, food preparation and some of the juices. I seriously don’t know how she does it. On weekends my dad and boyfriend are usually home so we have extra help.
7am: drag myself out of bed and meditate7.30am: first coffee enema for the day8am: breakfast (orange juice and oats with honey, banana, raisins and kiwi fruit)9am: green juice9.30am: carrot and apple juice10am: carrot and apple juice, work on blog and other writing bits and pieces11am: carrot juice, work on blog and other writing bits and pieces12pm: green juice, coffee enema #21pm: carrot and apple juice, lunch (soup, salad, veggies, potato), watch a bit of Oprah while we eat2pm: green juice, do more writing3pm: carrot juice, yoga4pm: carrot juice, take my dog for a walk5pm: carrot and apple juice, meditate6pm: carrot and apple juice, coffee enema #37pm: green juice, dinner (soup, salad, veggies, potato)8pm: watch a bit of TV or read in bed10pm: sleep
Every day is exactly the same as the one before, except on Tuesday and Thursday morning I take castor oil. Until recently I was doing five coffee enemas a day. I fit them in at 7.30am, 10.30am, 2pm, 6pm and 9pm. Pretty exciting stuff, huh. The one thing that is pushing me through the therapy is the thought of how amazing it will be once I finish. I doubt I will know what to do with myself. I don’t even remember what it’s like to be able to leave the house for more than an hour without worrying about juices or enemas. That day will be here before I know it though. It’s hard to believe I’m already three months in to the program. I’ve got 15 to go. Come on 15th October 2011!
She did this for two whole years, exulting over having consumed 8,760 glasses of juice, 2,920 coffee enemas, 1,460 baked potatoes, 1,460 bowls of Hippocrates soup, 33,580 supplements, and 174 shots of castor oil. In the process, she became an evangelist for Gerson, writing about the Gerson protocol and coffee enemas frequently on her blog and appearing in videos such as:
And:
And:
There are many more that were on her YouTube channel, but virtually all of her videos have since her death been marked private. You’ll note that the three I found above were on other YouTube channels. I also found this video, which I had thought lost but which is on HealthTalksTV and features Ainscough demonstrating how to prepare and administer a coffee enema (noting that you “can’t use instant” and have to use organic coffee—nor can you use just tap water):
Jess Ainscough did de-emphasize Gerson in the three years or so since she finished doing the Gerson protocol, but she never disavowed it. Instead, as The Wellness Warrior, she emphasized more the entire “natural” lifestyle, the smoothies, the vegan cooking, and some supplements. But the core of her transformation into a “natural health” celebrity was her original embrace of the Gerson protocol, as she said on more than one occasions that she was healing herself of cancer naturally, while all the while her cancer continued its slow, relentless progression.
Wishful thinking meets the reality of cancer biology
I said at the beginning that The Wellness Warrior’s delusions claimed not just her life, but another. This is the part of the story where I first encountered Jess Ainscough, the part of her story where her mother Sharyn died of breast cancer, as Jess related on her blog:
As many of you know, my Mum had breast cancer for the past few years. She was diagnosed about a year after I started Gerson Therapy, and seeing how much the therapy helped me, she went straight on it herself. However, unlike my journey, Mum’s was fraught with complications. She had been doing well and seemed to make it through her obstacles, however a few months ago it became clear that the cancer was getting ahead of her. She was in pain, lost a lot of weight, lost all energy, and her health quickly deteriorated. We explored lots of options however Mum choose to see out the final months of her life in a way that was exactly right for her.
Last Friday, after putting up the bravest fight I’ve ever witnessed, my mum passed away. She went peacefully and was comfortable with no drugs, which is what she always wanted. Her whole family was in the room, my dad and I were holding her hands and Edie was at the foot of her bed. She flickered her eyes, took one last gasp and then went off to sleep.
Here’s what Ainscough wrote when her mother was first diagnosed:
My family has been pretty much consumed by this disease for almost four years, so when my mum was diagnosed with breast cancer in April this year we knew exactly how to deal with it. Following her diagnosis, my mum refused any sort of conventional interference. She said no to a mammogram and a biopsy, told them that she wasn’t interested in going down the path of surgery, chemotherapy and radiation, and instead chose the same therapy as me.
As a result, her mother died, probably unnecessarily, about a year and a half ago after two and a half years, which is pretty close to the known The Wellness Warrior: Denial, Delusion, or Dishonesty?” and “How not to do transparency.” These included photos of Ainscough showing that her arm was looking worse, her hand was becoming contracted and developing open sores, and her body was becoming more hunched. I noted the same things over at my not-so-super-secret other blog.
A few months after the death of her mother, in response to criticism in the wake of her mother’s death and observations by critics that her arm was looking worse, Ainscough took to her blog to explain herself. Indeed, she even went so far as to say:
I’m not “in remission” or “cancer free”: I’m living and thriving with cancer, six years after diagnosis. And I’m going to continue to heal and thrive, with or without cancer, for as long as my personal journey on this planet dictates. I’ve never claimed to have cured myself (if you’ve seen this written online or in the media it’s because I have often been misquoted – these kinds of statements are false conclusions made by the author, not misleading information from me). However, I also don’t go around saying “I have cancer” because I don’t like to give power to the dis-ease. Whenever someone asks me about my health and how I’m feeling I say, “I’m awesome, I feel amazing!” because I am and I do. I live a very full, happy and healthy life – despite having cancer in my arm.
And:
I don’t claim that Gerson Therapy cured me: Gerson Therapy played a big part in my journey (it was two years of my life), but it’s certainly not my whole journey. It was what I needed at the time I went on it, in order to detoxify and nourish my body. There was a time when it appeared that everything I had been doing physically had stabilised my condition, but in recent months it has flared up again.
In counterpoint, Rosalie Hilleman documented several instances in which The Wellness Warrior had said just that, referring to herself as a “cancer survivor,” saying that she cured her own cancer, and appearing in interviews or articles where she’s referred to as having “beaten” cancer “naturally” with the Gerson protocol.
On September 26, 2014, Ainscough apologized on Facebook that she would not be able to speak at the Utopia Women’s Wellness event in Melbourne the following week. In her announcement, she cryptically wrote:
I had such a great time at the Sydney event, but the energy it required exerted me in a way I’m not yet ready for. As I mentioned in my talk that day, over the past year my condition has progressed from stable to aggressive. I’m on a healing roller coaster and I really need to listen to my body. This means that I will be continuing my hibernation a little longer to give myself my full undivided attention. Doing anything less would be a contradiction to the message I was planning on sharing with you at the event.
This “hibernation” is something that Ainscough undertook in June as a result of her declining health. By the time of her announcement in late September that she had to cancel her public appearances, it was clear that Ainscough could no longer hide that her health was deteriorating significantly. Indeed, from her last ever blog post in December, it was clear to me that she was likely not long for this world:
When I left you back in June to begin a period of self-care hibernation, my plan was to get my health back in tip top shape and then spend some time creating some awesome new stuff for you. The reality, however, is that I’ve spent the whole time focused on my health. For the last few months, I’ve been pretty much bedridden. Let me fill you in on what’s been going on with me …
This year absolutely brought me to my knees. I’ve been challenged, frightened, and cracked open in ways I never had before. After my mum died at the end of last year, my heart was shattered and it’s still in a million pieces. I had no idea how to function without her, and it turns out my body didn’t either. For the first time in my almost seven year journey with cancer, this year I’ve been really unwell. I’ve lived with cancer since 2008 and for most of those years my condition was totally stable. When my mum became really ill, my cancer started to become aggressive again. After she died, things really started flaring up.
I was truly saddened to hear this. The question that first came to my mind when I read this was this: What did she mean? How bad was it? It was pretty bad:
I’ve had scans to detect what’s going on in my body, and I can report that the disease is still contained to my left arm and shoulder, however I do have a big fungating tumour mass in that shoulder that’s causing me dramas. Over 10 months of non-stop bleeding from the armpit has rendered me really weak (and uncomfortable) and as a result I’ve had no choice but to stop absolutely everything and rest. Tallon [Jess’ fiance], my freaking hero, has had to step up and help me with everything from making food and juices, doing all of our housework and laundry to doing my hair.
So, in other words, Ainscough had the sarcoma equivalent of carcinoma en cuirasse, a tumor that has eroded through the skin and started to bleed. Apparently, she also started undergoing radiation therapy, although I have no independent confirmation of this other than from some commenters after this blog post. I have no idea what finally ended Jess Ainscough’s life. Given her description of frequent bleeding from her tumor mass to the point where she was anemic suggested to me that the tumor was fungating, eating through the skin. At the time, she said her scans indicated that the cancer hadn’t spread beyond the arm, but that didn’t mean it still couldn’t kill her. I suspect a combination of unrelenting chronic blood loss and perhaps a necrotic tumor becoming infected and leading to sepsis were the terminal events. If such sepsis was not recognized and treated promptly it could certainly have rapidly killed her in her weakened state. But this is all just speculation, an educated guess. I have no idea what the immediate cause of Jess Ainscough’s death was. It doesn’t really matter that much anyway. It’s enough just to say that her cancer finally killed her.
Cancer deaths like this always sadden me. Jess Ainscough had a shot, one good shot. That’s usually the case for most cancers; your first shot is your best shot, and we as cancer doctors need to make it count. She didn’t take her first shot. What saddens me even more is that I can understand why she didn’t take it, as, through a horrible quirk of fate, her one first, best shot involved incredibly disfiguring surgery and the loss of her arm. Still, I wish she had taken it and hadn’t instead decided to become an icon of “natural healing.” In her role as the Wellness Warrior, and in her promotion of Gerson quackery, Ainscough, with the noblest of motivations in the beginning, did harm and likely led some cancer patients down the path of quackery and preventable death. In this, Jess and Sharyn Ainscough were also just as much victims as any other cancer patient who chooses alternative medicine quackery. Unfortunately, she also promoted that same quackery, which made them complicit as well. Being simultaneously a victim and an enabler or promoter is frequently the case with believers in alt-med cancer “cures.”
All the more sad.
As outraged as we might have been over Ainscough’s promotion of the Gerson protocol in life, as we mourn, we should also remember that Jess Ainscough was also a victim of the very pseudoscience that she promoted. Now that she is gone, what I want to know is this: Who are the quacks who enabled her and egged her on? Who are the quacks who conned her into believing that Gerson therapy would save her life? They helped create the Wellness Warrior, and Jess Ainscough has finally paid the price.
The only thing that can be hoped for is that those promoting diet as a near panacea for everything will take a more critical look at their activities. I won’t hold my breath waiting, however. What I expect to find are excuses. I suspect they won’t be long in coming. After all, her social media accounts have disappeared, and her blog and website content are now inaccessible except through Google caches, which will disappear soon enough. They are no longer needed for their purpose.

   The Hidden Cancer Cure
Steven Novella
Link
Last week David Gorski wrote a excellent post about why we have not yet cured cancer. It turns out, cancer is a category of many individual diseases that are very challenging to treat. We have made steady progress, and many people with cancer can now be cured – but we have not discovered the one cure for all cancer. I personally am not convinced that we will discover a single cure for all cancer, at least not with any extrapolation of current technology. But if we continue to make progress as we are cancer will become an increasingly treatable and even curable type of disease.
This topic also brings up a meme that has been around for a long time – the notion that scientists have already cured cancer but the cure is being suppressed by the powers that be, to protect cancer as a source of income. In the comments to David’s article, Zuvrick writes:
So we can find a cure. It has probably happened multiple times. But nobody wants to cure cancer. Too many researchers earn a living seeking a cure by remaining inside a narrow, restricted channel of dogma. Their institutions get grant money and survive from the funding. Big Pharma makes big bucks selling chemotherapy drugs, surgeons remove tumors and various radiation devices employ radiologists and firms making these machines. MRI and CT scans would not be needed for cancer if Rife technology were available today.
I have heard or read some version of this claim since before I entered medical school. Superficially it may sound like profound wisdom (cynicism is a cheap way to sound wise) – but the idea collapses under the slightest bit of logical scrutiny.
First, as David thoroughly pointed out, the claim is implausible. Cancer is a complex set of diseases that defy sincere attempts at a cure. Those who promote the notion of the hidden cure often simultaneously promote wacky pseudoscientific treatments that they claim work – and Zuvrick is no exception. He believes that Royal Rife cured cancer 70 years ago. Rife was essentially a copycat of Albert Abrams who promoted his radio frequency devices. The concept is to use radio waves to alter the vibrations of cells in the body. This is pure nonsense. Here is a quick summary from Stephen Barret:
One of Abrams’s many imitators was Royal Raymond Rife (1888-1971), an American who claimed that cancer was caused by bacteria. During the 1920s, he claimed to have developed a powerful microscope that could detect living microbes by the color of auras emitted by their vibratory rates. His Rife Frequency Generator allegedly generates radio waves with precisely the same frequency, causing the offending bacteria to shatter in the same manner as a crystal glass breaks in response to the voice of an opera singer. The American Cancer Society has pointed out that although sound waves can produce vibrations that break glass, radio waves at the power level emitted a Rife generator do not have sufficient energy to destroy bacteria.
But let’s explore the logic of the hidden cure a bit further. Given that cancer is such a complex set of diseases, there is a vast and evolving science exploring the causes and behavior of cancers. This research takes place in numerous labs around the world. A cure for cancer would likely emerge from a collaboration among many researchers, in different labs and institutions, and even in different countries. Even if one lab made a significant breakthrough, it would be the capstone on top of a large body of research that was available to the entire community (and in fact the public). It would be impossible to keep other researchers from replicating the final steps that lead to a cure.
Often the hidden cure conspiracy idea is framed around the claim that a pharmaceutical company would hide such a cure to protect their profits from other cancer drugs. This claim fails not only for the reason above but for a separate practical reason. It would take about 100 millions dollars of research (if not more) to prove that a drug was actually a cure for one type of cancer (let alone all types of cancer). Why would a pharmaceutical company spend that kind of research money on a drug they know they have no intention of marketing, just so that they can suppress it? Also – where would they do such research? How could they get past all the regulatory hurdles to perform human research without revealing what they are doing?
Often those who claim that “they” are hiding a cure for cancer have only a vague notion of who “they” are. They generally have an image of the “medical establishment” as monolithic, but nothing could be further from the truth. The medical establishment is composed of universities, professional organizations, journals, regulatory agencies, researchers, funding agencies, and countless individuals – all with differing incentives and perspectives. The idea that they would all be in on a massive conspiracy to hide perhaps the greatest cure known to mankind is beyond absurd.
For those who think the profit motive is sufficient explanation, not all of the people and institutions named are for profit. And what about countries with socialized medicine who could dramatically reduce their health care costs if a cancer cure were found? Is Canada, the UK, all of the European Union, in fact, in on the conspiracy to protect American cancer treatment profits? It’s as if hidden cure conspiracy theorists forget that there are other countries in the world.
Hidden cancer cure conspiracies also are premised on a simplistic notion of how medicine and medical research progresses. The practice of medicine is constantly evolving in a process of creative destruction. New technologies render older ones obsolete. Resources ebb and flow to diseases as they emerge and are reduced or cured. There used to be entire hospitals dedicated to the chronic treatment of tuberculosis – and now, after antibiotics, those hospitals have been repurposed. Researchers, specialists, hospital space, and other resources shift over time to where they are needed.
If a cure for cancer were discovered it would not be as disruptive as is claimed by the conspiracy theorists. It would take years if not decades of research to explore how effective the treatment was for every type, grade, and stage of cancer. We could not assume that it cured all cancer even if it cured one type. And what about people who did not respond to the treatment, or could not tolerate it for some reason? (One might assume a 100% effective and side effect free cure for all cancer, but this gets progressively more unlikely.) Further, any real breakthrough cure would likely tell us something profound about the nature of cancer itself, and this would spawn entire research programs.
Research funding and researchers themselves would shift their focus where it was needed. Some might shift their skills to other diseases entirely, and perhaps fewer doctors and researchers would go into cancer research if a cure were already found. As with any other significant medical advance, the medical infrastructure would adapt.
Conspiracy theorists also tend to ignore the huge incentive to find a cure. For the researchers involved, it would mean fame, fortune, Nobel prizes and an enduring legacy within the halls of medicine. It is safe to say that it is every cancer researcher’s dream to be part of the team that finds the cure for cancer (or at least as big a breakthrough as is plausible).
The institution would also gain fame and prestige, which translates into more donations, better applicants, and also part ownership of any patents. A company that discovered the cure for cancer would make billions, even if it meant it would make existing drugs obsolete. Patents on drugs are finite, so companies are always looking for new drugs anyway. And imagine the public relations boon for the company that cured cancer – their name would forever be “Pharmaceutical Company – We Cured Cancer!” Even if the new treatment could not be patented, it would still be an enduring profit stream for the original company to market it – it would become their Tylenol, only bigger.
And of course the health care systems around the world would rejoice at the potential reduction in health care costs, which are now threatening to cripple the system. Doctors, hospitals, researchers – pretty much everyone, is making less money than they were a couple decades ago because of rising health care costs. The system is now being threatened by further cuts and restrictions to tame rising costs. A significant reduction in overall costs, by curing an expensive disease, would ease the pressure on the entire system, and free up resources for other diseases.
Finally, there is the human element. A hidden cure would require individual people to know that a cure for cancer is available but to deny this cure to dying patients in order to protect their or someone else’s profit. There may be people in the world who are that callous and evil, but think of all the people who would have to be that evil, over years or decades, to maintain a hidden cure. These are people who also have loved-ones who are likely to get cancer at some point in their lives, and who themselves are at risk for cancer. I would not casually assume that the medical establishment is full with such cartoonish maniacal villains.
Conclusion
The grand conspiracy of the hidden cancer cure is a meme that I wish would go away, but for some reason persists. It is like an urban legend – it appeals to some ill-formed fear or anxiety produced by the complexity of modern society. It gives a focus to these anxieties, and gives the illusion of control. No one wants to feel as if they are being deceived, and so assuming there is a conspiracy feels like a good way to avoid being duped. But ironically it is the conspiracy theorists who are being duped, or who are doing the deceiving.
The notion of a hidden cure is also dependent on seeing institutions with which one is not personally familiar as faceless and monolithic organizations, comprised of obedient drones. But these institutions are made of people – ordinary people with flaws and feelings and families just like everyone else. 

“The Truth About Cancer” Series Is Untruthful About Cancer
Ty Bollinger has produced a video series he calls The Truth About Cancer: A Global Quest. It’s about as huge a misnomer as can be imagined.
Harriet Hall on November 17, 2015
Link
The Truth About Cancer: A Global Quest is billed as “the documentary series the mainstream media refused to air.” It consists of eleven episodes and is produced by Ty Bollinger, an outspoken supporter of natural treatments for cancer. Episodes 1 and 2 are currently available online.
Ty Bollinger started his quest because several of his family members had died of cancer despite conventional cancer treatment. He believed they had died not of the cancer but of the cancer’s “so-called treatments” and “false treatments.” He doesn’t explain which cancers they had, what the treatments were, or why he calls them “false.” He was angry, and he wanted his relatives’ lives to matter; he thought he could give their deaths meaning by seeking out alternative treatments that would have saved them and could save others. He was an accountant and bodybuilder, untrained in science or medicine. He started out with the conviction that conventional cancer treatment was a fraud, and confirmation bias had a field day. Instead of learning about cancer from reliable sources, he avoided mainstream cancer experts and researchers and only interviewed alternative practitioners from all over the world who agreed with his premise. He eagerly swallowed everything they told him.
He says, “You are about to learn the best treatments and preventions to cancer, protocols that won’t harm your body, from the world leading doctors across the globe.” He promises to show viewers science and documented evidence. He promises to expose the lies of conventional cancer treatment. He thinks he has information that will eradicate cancer once and for all. He couldn’t be more wrong.
A hopelessly biased sample
The people Bollinger interviewed are not the world’s leading doctors, but infamous characters whose non-science-based views are notorious. I was only too familiar with many of the names: Matthias Rath, Mike “Health Ranger” Adams, Joseph Mercola, Jonathan Wright, Rashid Buttar, Russell Blaylock, Stanislaw Burzynski, and Tullio Simoncini. I will restrain myself and simply say these individuals are not reliable sources of health information. Others I was not familiar with, but they included “cancer conquerors” (patients with testimonials), journalists, chiropractors, naturopaths, integrative medicine practitioners, and operators of cancer clinics in Tijuana. He couldn’t have picked a more biased sample. He didn’t interview people like Siddhartha Mukherjee (the author of The Emperor of All Maladies), oncologists, or cancer researchers.
I have a rule, the SkepDoc’s Rule: before you believe a claim, make sure you understand who disagrees with it and why. Bollinger fails to do that. His mind is made up, and he is only willing to listen to people who agree with him. He asks questions like “Why would anyone prescribe poisons like chemotherapy?” but doesn’t consult the people who could answer and help him understand. He interviews patients who survived treatment with alternative medicine but doesn’t interview the families of patients who died.
False claims
He voices unsupported opinions and makes claims that can be easily refuted by a little research or even by common sense. Here are some of them:
    • The only thing that doctors are taught in medical school is how to prescribe drugs.
    • Professors are being paid by drug companies.
    • The Flexner Report, which reformed medical education in America, was a plot by Rockefeller and Carnegie to create a medical monopoly and eliminate all competition so they could sell more drugs.
    • “Anything coming from nature is excluded.”
    • The medical profession is a lap dog of the pharmaceutical industry.
    • Conventional medical has a monopoly on treatment: they make sure that insurance doesn’t cover CAM.
    • The number one goal of health care is to make money.
    • Saying they are making progress in any disease is only a propaganda war.
    • Business thrives on the continuation of existing diseases.
    • By 2020 more than half of cancers will be medically induced by drugs or radiation.
    • Nobody dies from the cancer, they die from consequences of the treatment.
    • Surgery spills cancer cells, radiation enhances them.
    • “It’s against the law in California for oncologists to recommend integrative.”
Lies about chemotherapy
He says chemo is incredibly ineffective and is such a hazardous material that nurses who administer it have to take precautions. If it’s hazardous to medical personnel, why give it to people who are sick? (There is a simple answer: because it has been proven to benefit those sick people.)
Chemo started with mustard gas. Yes, that’s true, but so what? The American Cancer Society explains the history of how observations of soldiers exposed to mustard gas led to an effective treatment for lymphoma.
He ask: “Why is modern medicine so drug-intensive?” My answer: because drugs have been proven to work. And because efforts to get patients to improve their health by lifestyle modifications are so often fruitless.
He claims that 97% of people who undergo chemo are dead in 5 years. That is absolutely not true. The study that claim is based on omitted all the types of cancer that chemo is most effective for, and it lumped chemo intended to cure with chemo used as an adjuvant or for palliation.
He perpetuates the lie that 90% of oncologists wouldn’t take chemotherapy themselves. That myth was based on another old study where oncologists were asked about an experimental chemotherapy regimen for one specific type of incurable lung cancer. The majority of them thought that the evidence available at that time showed that cisplatin and other experimental chemo drugs were ineffective and toxic. Keep in mind that lung cancer is not particularly amenable to chemo. A 1991 study in the British Journal of Cancer found that the majority of oncologists would take chemotherapy; for instance, 98% of oncologists would take their own medicine if they had stage IV Hodgkin’s disease, a cancer for which chemotherapy has been proven effective.
He claims that chemotherapy stimulates cancer stem cells. He interviews Blaylock, who seems to confuse embryonic stem cells with cancer stem cells. He says chemo has no effect on stem cells, only on daughter cells. After killing daughter cells it comes back “infinitely more aggressive.” When asked to explain, he says it’s complicated but has to do with chemistry and the micro-environment of the stem cell, producing cytokines that cause more DNA damage which makes the cancer more aggressive and more likely to metastasize. He can’t explain it because it isn’t true. Sayer Ji claims that chemo “enriches” cancer stem cells; there’s no evidence for that.
They claim that chemo harms every patient; it is referred to as “a suffering instead of a treatment.” They say that doctors who won’t prescribe it stand to lose their license. The tentacles of the medical cartel reach everywhere. Chemo causes side effects, which gives doctors a reason to prescribe more drugs and multiplies their business.
Matthias Rath says chemo is unethical and deceptive because it destroys the immune system and the immune system is needed to combat the cancer. He says doctors may not know better, but every scientist knows that chemo is a fraud, and if they say they don’t they should quit. (I know of doctors who think certain chemotherapies are sometimes used inappropriately, but I don’t know of a single reputable doctor or scientist who thinks chemo is “a fraud.”)
Breakthroughs in immunotherapy are misrepresented: immunologist and inventor A.J. Lanigan says “I don’t know that chemo has been successful at any level” except for making money. He sure doesn’t know much!
Rashid Buttar asks, “How is mandating chemo for children any different from Nazi Germany?” (Godwin’s Law strikes again!) It is trivially easy to answer that question, and it is grossly unfair of Bollinger not to interview anyone who knows the answer.
They say the FDA should be protecting us from chemotherapy drugs and other toxic substances but instead they are protecting the very industries that they were supposed to protect us from. FDA approval means proven safe and effective. Side effects discovered after marketing constitute fraud. (No, they constitute more information that becomes available when a drug is used by more people and people who are not as highly selected as the subjects in the clinical studies.)
The natural fallacy
Sayer Ji says studies show that turmeric, resveratrol, and green tea are superior to chemo. (Not true.) The drug companies supposedly ignore the evidence because they can’t patent a natural substance and prefer to make money by creating artificial ones. That’s just silly. The same companies that manufacture pharmaceuticals make plenty of money from vitamins and supplements. And they can take a natural medicine, isolate the active ingredient, improve on it, and patent their discovery; in fact, about half of our drugs were developed from plants through that process.
They cite problems with Big Pharma like ghost-written articles, studies where data were made up or manipulated, and corporate malfeasance of various sorts. These are things the medical establishment is well aware of and is trying to fix, with prominent projects like the All Trials campaign. But they go much further to demonize Big Pharma. Matthias Rath says Big Pharma companies were directly responsible for creating concentration camps and for the death of 60 million people. They wanted slave labor and put profits over lives. They created the system; later the Nazis decided to use it to kill Jews. Godwin’s Law again!
They say patent medicines do not belong in human bodies and that pharmaceutical medicine fails 97% of the time (demonstrably not true; every drug has to show evidence that it works before it can be marketed). Plant medicine is holistic, safer, more effective, and less expensive. Big Pharma can’t patent nature, so it tweaks molecule and it never works as well. “Can we, as mortal men, improve on nature?” (Emphatically YES, we can improve on nature, and we do. Their ignorance is appalling.)
War on nonconventional doctors?
Burzynski says the real war is being waged not on cancer but on unconventional doctors like him. He and Wright complain of being persecuted. They cite the Fitzgerald Report to congress in 1953 that supposedly revealed a conspiracy to close and destroy clinics, hospitals, and scientific research facilities that do not conform to the viewpoint of medical associations. It documented suppression of natural treatments, “and it’s in the Congressional Record!” Mercola claims information about laetrile was suppressed. It wasn’t. Laetrile was extensively investigated and shown not to work, so it was not approved by the FDA. This was no conspiracy: it was science in action, working to protect the public as the FDA is mandated to do.
They claim there is a conspiracy of the FDA, Big Pharma, and the AMA to suppress unconventional treatments. For instance, Royal Rife “knew there were microbes inside the cancer cells” and developed a machine that he claimed cured cancer by attacking the vibratory frequency of microbes. It wasn’t accepted by mainstream medicine (for very good reason!). Burzynski says there is merciless harassment of doctors who are inventors. He says he is saving people who would have died. He accuses the mainstream of obeying orders like Nazis. (Godwin’s law strikes yet again!) Buttar says it’s considered OK if patients die with chemo, but it’s not politically correct if they use CAM and survive. Tullio Simoncini says all new discoveries are shut down. “If you withhold treatment that can save someone’s life, isn’t that the same as murder?” Jonathan Wright claims a doctor in Alabama was treating cancer successfully with intravenous hydrochloric acid. He supposedly was visited by AMA and asked to sell his treatment and told if he didn’t he’d never be published again. He didn’t and he wasn’t. Harry Hoxsey’s cancer treatment allegedly worked. The AMA supposedly wanted to buy it and bury it. Hoxsey went to jail. Patients were loyal. The Hoxsey treatment is still available in Mexico. They use a formula that targets only the malignant cells, plus diet, vitamins, herbs, etc. The whole regimen takes one day.
The truth is that there is no conspiracy. The establishment would gladly accept any of those unconventional treatments if there were credible evidence that they did more good than harm.
Cancer survivor testimonials
Bollinger interviews a number of cancer survivors who have used alternative treatments. He doesn’t understand that the plural of anecdote is not data. He only looks at a few who survived; he doesn’t tell us about the many, many people who have died because they trusted unconventional treatments over proven treatments that would have saved their lives
For example, he interviews Chris Wark, “cancer conqueror.” David Gorski has put the record straight; Wark had curative surgery. He refused adjuvant chemotherapy that was not intended to cure but only as insurance to decrease the already small chance of recurrence; he was fortunate, and the cancer did not recur. He thinks he healed himself with diet and natural therapies. He didn’t.
The myths
Bollinger and the people he interviews subscribe to a number of unsubstantiated beliefs:
    • Natural is always best.
    • It is possible to prevent and cure cancer by lifestyle changes and natural remedies.
    • A healthy immune system can eliminate cancer.
    • Detoxification is necessary for health.
    • Conspiracy theories: the medical establishment is a totalitarian system that forces harmful treatment on its victims and is only interested in profits. “The so-called science, which is really just corporate driven fraudulent science, the so-called science-driven medicine is being forced on you in absolute violation of the AMA code of ethics, which says the patient must be informed and give consent.”
Episode 2
I started watching episode 2, about breast cancer and epigenetics, but I quit in disgust after only a few minutes. Angelina Jolie is criticized for letting “irrational fear” persuade her to get a prophylactic double mastectomy. She should have known that our genes do not control life. She could have deactivated her BRCA gene by diet and lifestyle. A chiropractor tells us that the BRCA genes actually prevent cancer and repair DNA damage, and they only mutate to cause cancer when people don’t live right. This amounts to denial of genetics and blaming the victim.
David Gorski is a breast cancer surgeon and researcher who knows far more about the subject than any chiropractor and he has explained the BRCA genes and Jolie’s case.
Dangerous misinformation
The Truth About Cancer is billed as a documentary series. It is not a documentary that tries to honestly present the facts, but a one-sided polemic, a vicious attack on conventional medicine based on misinformation, emotion, mistrust, and opinions that are not based on credible scientific evidence. It omits vital information, presents untruths and distorted partial truths, promotes natural treatments that have never been properly tested or have been tested and proven not to work, and it doesn’t give conventional medicine even the slightest chance to explain itself.
Conventional cancer treatment has cured some patients, prolonged the lives of others, and improved the quality of life for some of the ones who can’t be cured. It is ridiculous to talk about “cancer” as if it were one disease. There are many kinds of cancer, and the success rate varies. It is ridiculous to talk about chemotherapy without considering the type of cancer and the evidence for effectiveness, and without distinguishing between chemotherapies that are intended to cure and those that are prescribed as adjuvants, debulkers, or palliatives. We have seen incredible successes for many children’s cancers, and some adult cancers have been changed from a death sentences to a manageable chronic disease.
Bollinger doesn’t tell us about the patients who almost certainly could have been cured of cancer but who died because they rejected proven conventional treatments in favor of unproven natural treatments and outright quackery. He presents unconventional treatments as having been proven to work; they haven’t. If they had, they would be mainstream treatments and every oncologist would be using them.
Bollinger’s approach is as unfair as a trial where the prosecution is given carte blanche and no defense is allowed. This is a very unfortunate series, filled with misinformation but produced slickly, effectively appealing to emotion, and likely to mislead scientifically-naïve viewers and probably even some scientists who ought to know better. I predict that Bollinger will have blood on his hands: people will suffer and die unnecessarily because they believed this was “the truth about cancer” and were persuaded to reject lifesaving treatment.

The Hippocrates Health Institute: Cancer quackery finally under the spotlight, but will it matter?
David Gorski on February 23, 2015
Link


I first came across Brian Clement, the proprietor of the Hippocrates Health Institute in West Palm Beach, Florida, a little more than a year ago based on the story of Stephanie O’Halloran. Ms. O’Halloran was—word choice unfortunately intentional—a 23-year-old mother of an 18 month old child from Ireland who was diagnosed with stage IV breast cancer in 2013, with metastases to her lymph nodes, liver, lung, and leg. Unfortunately for her, she found Brian Clement at the Hippocrates Health Institute, who gave her false hope with his claims that a raw vegan diet and wheatgrass can treat just about everything. Unfortunately, but not unexpectedly, Ms. O’Halloran died in June 2014, less than nine months after having been diagnosed with metastatic breast cancer.
I didn’t write about Stephanie O’Halloran at the time (at least not here), but I did write about Brian Clement and the Hippocrates Health Institute (HHI) twice over the last several months in the context of the cases of two 11-year-old Aboriginal girls in Canada with cancer, specifically lymphoblastic leukemia. One was —word choice again unfortunately intentional—named Makayla Sault and the other is referred to as “JJ” in news reports to protect her privacy in her parents’ legal proceedings to assert their right to use traditional medicine to treat their daughter’s cancer rather than curative chemotherapy, which was estimated to have a 75% chance of curing Makayla Sault and an 85% to 90% chance of curing JJ. Unfortunately, both girls and their parents fell under the spell of Brian Clement and his cancer quackery. The result was one unnecessarily dead girl (Makayla Sault, who died last month) and one likely to be dead by the end of this year or not much longer (JJ). Such is the price of cancer quackery. In this case, even more puzzlingly, these girls’ parents seemed quite content to conflate the quackery of Brian Clement, a white man practicing in Florida, with “traditional Aboriginal medicine,” the sort of practices they were claiming to have a right to.
Brian Clement: Preying on desperate cancer patients for nearly three decades
Because I’ve adequately discussed the issues involving JJ and Makayla (that is, unless something new happens with respect to these girls’ stories), what I want to do now is to focus my attention more on Brian Clement himself and his practices. Over the last three years, I’ve spent considerable time and effort trying to pull the cover off of the machinations and abuse of clinical trial ethics by Stanislaw Burzynski. There’s been a growing thought in my mind that a similar effort should be directed at Brian Clement, because, although he doesn’t even make a pretense of doing clinical trials, he sells his cancer quackery the same way that Burzynski does: Through testimonials. Indeed, if there is one “good” thing that’s come out of the stories of Makayla Sault and JJ, it’s been increased scrutiny of Brian Clement and the HHI.
Most recently, this increased scrutiny has come in the form of news stories that have been appearing in the Canadian press, two just over this weekend:
    • “Florida health spa’s cancer claims under fire” and “Founder of Hippocrates Health Institute sued successfully twice“, Tim Alamenciak, The Toronto Star (February 21, 2015).
    • “Questions about Hippocrates: Complaint filed against clinic that treated First Nations girl pulled out of chemo“, Tom Blackwell, National Post (February 21, 2015).
    • “Contradicting cancer claims from Hippocrates Health Institute director“, Katie LaGrone, WPTV West Palm Beach (February 9, 2015).
After having spent so much verbiage last week criticizing the Star for its execrable “exposé” on Gardasil (an exposé that the editors of the Star finally saw fit to withdraw under a barrage of well-justified criticism, although they clearly still don’t get it), I feel that in fairness I have to note that Alamenciak goes part of the way towards redeeming the Star after that journalistic debacle by actually traveling down to West Palm Beach and interviewing Clement, although Clement wouldn’t say anything on camera for this report:
What Alamenciak was allowed to see included several classrooms, the wheatgrass juicing room, and a greenhouse. Pointedly, they weren’t allowed into the Vida Building, where many of the alternative treatments are administered. (I wonder why.) Even more pointedly, Alamenciak was accompanied everywhere by HHI’s lawyer and PR person, as well as Clement himself. As you’ll note, Alamenciak and crew do a good job of putting the lie to Clement’s claims that he doesn’t promise he can cure cancer, using, conveniently enough, clips from Clement’s own talks in which he—you guessed it—tells his audience his raw vegan diet and wheatgrass can cure cancer.
Similarly, Tom Blackwell’s story quotes Clement as saying in one of his videos:
The appeal is powerful. Though he often insists he does not “cure” or heal anyone, Mr. Clement has repeatedly claimed impressive results.
“We have … the longest history on the planet earth, the highest success rate on the planet earth of people healing cancer,” he said in a Hamilton, Ont., talk, recorded and uploaded to YouTube in 2010. “We have dealt with mostly stage-three, stage-four catastrophic cancers — a big percentage of them, probably 25%, have been told they’re going to die. We have seen thousands and thousands of those people recover.”
Of course, Clement never manages to present anything resembling credible evidence to back up this claim.
There’s another segment as well with Steven Pugh, former Director of Nursing, HHI, who relates stories of Clement ordering blood work without a doctor and telling Pugh that he would review the results himself. This is what led Pugh to quit and sue. Because he is a registered nurse, Pugh can’t take orders for lab tests or other medical interventions from non-physicians. If Pugh’s allegations are true (and I personally have little doubt myself that they likely are), that is most definitely practicing medicine without a license:
“Almost every single patient there, the majority of patients, got an appointment with Anna Maria and/or Brian to go over their medical history, their labs, blood work, their disease process or just their wellness process and they would recommend treatment,” alleges Steven Pugh, Hippocrates’ former director of nursing and one of the ex-employees suing the facility.
Johnson offered a written response on Thursday to Pugh’s statement: “All blood tests are administered by a medical professional and reviewed by the medical director. As nutritionists, the Clements review the guests’ entire health history, which includes the blood tests, with a view toward nutritional recommendations. . . . The medical director is responsible for all medical decisions of any kind.”
Hippocrates, which houses as many as 100 people at a time, has one licensed medical doctor working for the facility — Dr. Paul Kotturan.
I had never heard of Dr. Paul Kotturan before; not surprisingly, I wondered what kind of physician would associate himself with an institute like the HHI. So I did some Googling. Dr. Kotturan appears to run an urgent care center, Hillsboro Urgent Care in Deerfield Beach, Florida. His role at HHI is described on its website thusly:
Under the supervision of Dr. Paul Kotturan, Hippocrates’ specialized therapies include hyperbaric oxygen therapy, cranial electrotherapy stimulation, IV nutrition and antioxidants, Aqua Chi detoxification therapy, advanced diagnostics, bio-frequency research, targeted supplementation, thermography and more.
What does that “more” include? According to Alamenciak’s report, it includes quackery such as:
One of the treatments often mentioned by Clement in videos is Cyber Scan — a machine that claims to read your “bio-frequency” and tells which diseases you have or are at risk for. The machine then spits out a magnetized card — similar to a debit card — that contains the “morphogenetic footprint” of whoever put their hand on the device.
For Pugh, the most surreal treatment moment came when he saw a man blowing a long alpenhorn on the feet of a guest at the centre. The man claimed to be removing “toxins,” Pugh said.
And, of course, supplements:
The institute also sells its own line of supplements, called LifeGive, as well as a store stocked with everything from $400 amulets that claim to block electromagnetic waves to a stool designed to angle one’s feet while on the toilet that is said to promote “more complete bowel evacuation.”
And, of course, there are stem cell treatments. Given that on the surface, the South Florida Bone Marrow/Stem Cell Transplant Institute looks relatively straightforward, treating hematologic malignancies with what sound like fairly standard-of-care treatments, “why Dr. Dipnarine Maharaj would affiliate himself with an entity like the HHI?” is the first question I asked. Surely it does not speak well of him to be featured on the HHI website.
But back to Dr. Kotturan. I was actually rather amazed that it was difficult to find out much about him. He seems to have kept a relatively low profile compared to other doctors administering dubious therapies, at least with respect to the ability of Google searches to reveal much other than his clinic. (And, make no mistake, the medical therapies administered at HHI are highly dubious, ranging from wheatgrass enemas, to the “Cyber Scan” test, to the most unbelievably quacky treatments like Aqua Chi “detox footbaths.”) One thing I was able to find out is that he was a site principle investigator of TACT.
For those who don’t remember, TACT stands for “Trial to Assess Chelation Therapy“; it was a $30 million unethical boondoggle of a multiinstitutional study designed to assess whether chelation therapy has any value for treating cardiovascular disease. It was basically a negative study, but its principal investigator, Gervasio Lamas, has been spinning it furiously as showing that chelation very well might work for cardiovascular disease and that, of course, “more study is needed” (preferably in the form of another large NIH grant to do a follow-up multiinstitutional study. In this Annals of Internal Medicine publication, Kotturan is listed as one of the investigators, which means he must have been administering chelation therapy during the timeframe of the study, which was several years. Certainly, Kotturan’s name comes up as offering chelation therapy and IV vitamin therapy for at least one “holistic retreat.” His name also pops up in this TACT Talk newsletter as one of the site investigators who won a Persistence Award in the 2005 TACT Derby for enrolling five patients over three months. He’s also a member of the American College for Advancement in Medicine (ACAM), a leading proponent of chelation therapy and what Dr. Kimball Atwood likes to refer to as a pseudomedical pseudoprofessional organization. His ACAM entry lists him as providing “Allergy, Chelation Therapy, Cosmetic Laser Surgery, Family Practice, Gynecology, Holistic Medicine, IV Therapies.” One wonders what else is covered in the “holistic medicine” part. Does he offer the same sorts of quackery at his own practice as he does at HHI? Inquiring minds want to know! Actually, I suspect that I do know. I rather suspect that Dr. Kotturan probably keeps it legitimate at his own practice and uses HHI as the outlet for his more “holistic” approaches, but that’s just an educated guess.
Alamenciak’s article adds more detail to a story carried by the local NBC affiliate WPTV affiliate a couple of weeks ago :
Overall, it’s not a bad start to uncovering HHI’s cancer quackery. Note how posh the HHI campus is, as well. I’ve described the “treatments” offered by Brian Clement as part of HHI’s “Life Transformation Program” before. They include almost every imaginable form of cancer quackery, including “detoxification,” colonics, wheatgrass, ozone pools, “bio-energy treatments,” the aforementioned “Cyber Scan,” and, of course, the Aqua Chi “detox footbaths.” One particularly silly treatment offered by HHI is called a “wheatgrass implant”, which, it turns out, are actually wheatgrass juice enemas. Indeed, if you believe the hype on the HHI website, there’s nothing that wheatgrass can’t do. If the HHI is to be believed, wheatgrass can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many other fantastically beneficial alleged effects. Basically, combine a raw vegan diet with a veritable cornucopia of other kinds of quackery, and you have the HHI.
Elsewhere, a little Googling reveals this woman’s account of what HHI offers:
The list of therapy options was impressive: hyperbaric therapy, cranial stimulation, hydrocolon therapy, IV Vitamin C and other IV therapies, complete blood analysis upon arrival, hormone therapy, and thermography.
There were several other therapies that I was not familiar with that are also included in your stay with HHI such as Ceregam-RH, H-Wave Therapy, Lymphatic Drainage Bed, Migun, MRS 2000, Ondamed Biofeedback Treatment, Q1000 Laser, Soft Laser, Theragem, Turbosonic Therapy, and Viofor.
Amazingly, I haven’t heard of some of these things, which led me to add them to my “to-do” list for SBM posts. I can’t help but note that it was touted that Coretta Scott King had visited HHI. She died of her cancer in a Tijuana clinic.
Lately, it seems, Clement is getting into “vibration” and “quantum.” For instance, get a load of this video on Quantum Biology:
I admit that I didn’t watch the whole thing. Not even close. It was just too darned painful, given how much pseudoscience is packed into nearly two hours. Nor do I expect you to watch the whole thing; that is, unless you’re a total glutton for punishment. (Seriously, physicists and chemists viewing this video will feel a near-irresistible urge to claw their eyes out.) One brief example occurs at 1:11:30 or so, when he shows a highly simplified version of the cell followed by pure vitalism, where he talks about the “life force” gathered through nutrients. The cell is surrounded by words representing vitamins, protein, water, minerals, essential fatty acids, and oxygen (to which he verbally adds “electromagnetic frequencies”). After this, there is this text:
These elements with their varied frequencies are attracted to the magnetic energy of the cell. This allows building and life maintaining processes. It also expels exhausted and used matter from the cell.
Clement “translates” this to mean that if you have the life force in the cell and the life force in the nutrients, they’re attracted to each other.
Elsewhere, he describes quantum biology thusly:
Painting a picture to describe this fruitful exploration begins with yourself. Beyond the protein that holds your body together, the vitamin and mineral sheathing that covers it, the essential fats that fuel it and the water and oxygen that shape it, the underlying purpose for your body’s existence is the electricity that it takes in and creates. There is a continual and perfect communication from cell to cell and from gathering of cells (organs and / or skeletal) to gathering of cells. This communication also reaches beyond your body to all other life outside.
This rhythmic and energetic process is strong, yet fragile. It can be thrown off by a weakening of the anatomical integrity of the cells or their central electrical frequencies. This weakening can occur via poor nutrition, dehydration and / or polluted hydration, lack of oxygen, intake of heavy metals or chemicals or renegade electromagnetic fields such as cell phones, Wi-Fi, etc.
All abnormalities that have been labeled as diseases stem from the negative energies that are endured from the poor lifestyle choices and unsustainable environment that we have created on planet earth today.
Our core vulnerability stems from the reduction of bio-frequency that occurs in the cell, which heightens its fragility to make it ineffective in communication and contribution. When these disturbances are critical, they can even cause a cell to mutate.
When you ingest ionized, rich, raw plant-based foods, it provides foundational energy. You then have to consider avoiding negative energy fields or at least protecting yourself from them with electromagnetic field interrupting devices or tools.
What is more difficult to avoid and personally restrain from is the negative energy that we absorb or spew from discontented emotional states. Most of you have seen this and experienced it. Certain people, places or environments can make you feel uncomfortable, on edge and literally drained.
I couldn’t take any more! Not only is Clement spewing total and utter BS about quantum theory and science à la Deepak Chopra, but he explicitly embraces a “Secret”-like concept that “negative energy” from people’s “discontented emotional states” causes disease. Oh, and let’s not forget “toxins” needing “detoxification.” You get the idea. Clement understands neither physics, chemistry, nor biology. He thinks wheatgrass, either eaten or administered as enemas, is a cure-all. He treats cancer with a raw vegan diet plus a wide variety of quackery, even detox foot baths. He blathers spiritual nonsense about god, “energy” and consciousness.
Particularly galling was his response to a breast cancer surgeon at around the 1:20 mark who, even though she appeared to buy into some of what Clement was selling, did challenge him about surgery for cancer. One thing I learned in his response is that Clement clearly does not understand cancer stem cell theory, stating categorically that no cancer comes from anything other than stem cells. That is not true; some cancers have been strongly linked to cancer stem cells. Others have not. It’s not as though cancer stem cell theory is settled science. It’s an area of active investigation and, yes, controversy. Based on his misunderstanding and his claim that he might not be able to “activate” the immune system fast enough with the raw vegan diet and wheatgrass, he then launches into a spiel about how he brings in “advanced therapies” such as cold laser, electromagnetic therapies, that, he claims, fire up the stem cells with a “higher frequency.”
He then denigrates the claim that cancer surgeons can produce 90% survival with stage I breast cancer. I must admit that I chuckled when Clement states, “The only disease in history that they put a five year survival criteria on is cancer.” No, it’s not. We do it for heart disease. We do it for stroke. We do it for renal failure. What’s the difference? In many cancers, if you survive five years, for all intents and purposes you can be considered “cured,” because the disease is very unlikely to recur after five years. (Breast cancer, unfortunately, is an exception to that rule.) Be that as it may, contrary to what Clement claims, we didn’t choose five year survival as a surrogate for cancer cure arbitrarily. Indeed, the difference between diseases like diabetes compared to cancer is that if you survive five years after cancer, depending on the cancer, you probably are “cured.” If you survive five years after being diagnosed with diabetes or heart failure, you still have diabetes or heart failure.
Marketing HHI: Testimonials a-go-go
If there’s one thing all three stories show, it’s that Clement makes a lot of money running HHI. Blackwell’s story, for instance, reports that filings to the IRS indicate that Brian Clement and his wife Anna Maria Gahns-Clement, the latter of whom serves as HHI vice-president, earned almost $1 million between them in 2013, even though the HHI is classified as a non-profit institute and therefore tax-exempt. Almenciak reports that Clement and his wife were paid $529,363 and $432,291 in income and benefits that same year and that the HHI reported receiving $15.1 million in fees for its “services.” Given that HHI has been operating in West Palm Beach since 1987, one can imagine how much wealth the Clements have amassed from its operations and their evangelizing speeches all over the world. It’s also not hard to see where he might “earn” such money, given that he charged JJ and Makayla $18,000 each for their “treatment.” All three stories feature photos and video showing just how large and fancy the grounds and facilities of HHI are.
Like Stanislaw Burzynski, a key element of the Clements’ marketing campaign includes patient testimonials. They can be found on the HHI website and YouTube channel. I very well might analyze several of these testimonials, either here or at my not-so-super-secret other blog, but for now, given the length of this post, I’ll just look at two.
First, there is this testimonial from Dr. Jackie Campisi:
Jacki Campisi’s story is horrifying. Basically, she started out by denying herself her one best shot at survival after her diagnosis. My observations on the brief video include:
    • It is not clear in the video whether Dr. Campisi ever had surgery for her primary tumor or not. She says that she was told that she would require “chemo, radiation, and drugs.” Besides the chemo, which drugs? Tamoxifen? Arimidex? Herceptin? It turns out that she did have a mastectomy, but I had to do some Googling to discover this (and also to discover that she’s an optometrist, not a physician). In any case, that same link revealed that she embraced quite a bit of cancer quackery six and a half years ago, before she ever encountered Brian Clement.
    • Dr. Campisi recurred six years later with spine metastases. Doesn’t that tell you that what she did wasn’t really working? Unfortunately, her spine metastases resulted in fractures, as spine metastases all too frequently do.
    • It’s quite possible that Campisi had a fair amount of healing from her fractures while at HHI, but it’s obvious that she still couldn’t walk until after she had surgery. Also, her weight loss probably made a big difference.
    • It’s good that her spine surgery helped her quite a bit. Surgery for malignant fractures usually does help. It’s unclear to me what operation she had, though.
    • A four day hospitalization sounds about right for the surgery Dr. Campisi had, neither too long, but certainly not significantly shorter than the usual range.
    • It’s very telling that Dr. Campisi doesn’t explicitly say whether she still has spine metastases or if her tumor is gone. She does, however, go on and on about the oxygen in her blood, her blood glucose levels, etc. I presume the cancer is still there.
    • Overall (and fortunately for her) Dr. Campisi seems to have a variety of breast cancer that is slow-growing and indolent. That it took six years to recur suggests it’s probably estrogen receptor-positive, and that it doesn’t seem to have progressed much since also argues that it’s probably fairly indolent. If this is true, she could still live quite a long time with such a tumor, as it appears to have favorable biology. However, it would be interesting to know some things: Stage at diagnosis; status of estrogen and progesterone receptors; HER2 status; the specific operation she had.
Basically, here we have a woman who underwent surgery alone for a stage III cancer, apparently refused radiation and chemotherapy in favor of a raw vegan diet and other “alternative” treatments, had a recurrence in the spine, found Brian Clement, and is continuing to make the same mistakes. I’m glad she seems to be doing better, but, sadly, Clement is not going to save her. Nothing can. Fortunately, she might still live several more years because of the seemingly-favorable biology of her tumor. Unfortunately, she might have done even better if she had accepted standard-of-care palliative therapy. Also, she will likely credit Clement for how well she does.
Another testimonial, mentioned in Blackwell’s article, is Samantha Young:
One Canadian woman, Samantha Young, says she was given just months to live after being diagnosed with pancreatic cancer, and maintains she was rid of the frightening disease after visits to Hippocrates.
Young’s testimonial can be found on the HHI website as well, oddly enough, filed under “Depression,” rather than cancer:
Back in the late nineties I found myself suffering unimaginable fatigue, nausea and constant interrupted sleep brought on by the excruciating pain in my stomach. My physician conducted some investigative blood work which appeared completely normal. Finally, upon my insistence, she suggested an ultrasound. That revealed a ten centimeter mass in the tail of my pancreas.
The doctor explained that if I were older, she would believe that the tumor was benign. However, because I was young she suspected it might be cancer. Just that word instilled so much fear in my heart. My mind started to race, ruminating on all the medical statistics about the increase of cancer and how treatments most often are more harmful than helpful. Of course the doctor advised that my options were surgery, chemotherapy, and radiation.
What could that benign diagnosis have been? If there are any general surgeons or gastroenterologists reading, I bet they know. I’ll get to it momentarily. In the meantime:
Finally, my physician suggested that I see a specialist, Dr. Taylor, who supported the pancreatic cancer diagnosis with finality. Thank God my five daughters came and nurtured me. They adjusted their schedules and stayed with me at the onset of this sad period of my life. They described my color as gray green. Every day seemed insurmountable. On top of all of this the doctors finally admitted that although chemotherapy and radiation treatment were suggested, they ultimately would not make any difference in my case, nor would they prolong my life. They told me, “I am sorry, Samantha, get your house in order.”
We’ve heard this story before. Of course, a 10 cm mass in the tail of the pancreas would make me consider something other than pancreatic cancer in the diagnosis. Run-of-the-mill pancreatic cancer, the kind that kills most patients within a couple of years of diagnosis even if operable and successfully resected (expected five year survival after a Whipple operation, for instance, for pancreatic cancer is only on the order of 25%), generally doesn’t grow to 10 cm without metastasizing. That this one did implies that it’s either a less aggressive form of pancreatic cancer or not pancreatic cancer at all. Notice, in any case, that nowhere is there a report of a biopsy confirming the diagnosis. (Actually, rereading the testimonial, I don’t see any evidence that Young ever had even a CT scan, which is considered mandatory for determining whether a pancreatic cancer might be resectable.) Of course, if pancreatic cancer has already metastasized, then expected survival is measured in months. So what happened? Young found Dr. Clement, of course, and this happened:
I slowly adopted the program and was so impressed when I microscopically viewed cancer cells thriving on cooked food. This wrenched me into the full adoption of the living food diet. Slowly but surely, my color returned to a more acceptable yellow pallor, and as time passed my normal complexion prevailed.
In addition to the diet I also used far infrared therapy to gently heat my body up to 40 degrees Celsius. I also made sure to include lots of massage and reflexology, as well as continuing my medication and creative visualization, along with copious amounts of wheatgrass.
After two years the tumors had shrunk from 10 centimeters to 4.5 centimeters.
Before I knew it, I was in remission. Now I understood fully that cancer can be beaten.
In other words, she did nothing to treat her presumed cancer. Of course, I doubt that she ever had cancer in the first place. Given her clinical history, what I rather suspect (and, I bet, any general surgeons out there suspected) is that she really had was a pancreatic pseudocyst. Pseudocysts often arise after a bout of pancreatitis. Early in her testimonial, Young describes herself “suffering unimaginable fatigue, nausea and constant interrupted sleep brought on by the excruciating pain in my stomach,” all of which can be symptoms of pancreatitis. Not knowing more of her clinical course, I find it not hard to envision that Young suffered pancreatitis and developed a large pancreatic pseudocyst, which slowly resolved spontaneously, as many pancreatic pseudocysts, even ones larger than 5 cm, do. Moreover, pancreatic pseudocysts are sometimes misdiagnosed as cancer and vice-versa, but less commonly these days given that virtually any large pancreatic mass can be biopsied pre-operatively, something that wasn’t necessarily true 20 years ago when I trained. Again, we have no evidence of a tissue diagnosis anywhere to help guide us, and, given that, I rather suspect that this was indeed a pancreatic pseudocyst that resolved.
In Blackwell’s story, we learn:
Mr. Pugh said it is quite possible that some of the cancer patients at Hippocrates are cured, but in the little over a year that he worked there, he was not personally aware of any such successes.
“I would get emails occasionally from a family member saying a patient had succumbed to cancer,” he said.
I’d be willing to bet that no one at HHI survives cancer due to anything done for them at HHI. Indeed, as Alamenciak reports, there are testimonials on the HHI website whose stories have not been updated to report that the patient died, patients like Annalisa Cummings, who died in 2009.
Cancer quackery unfettered
The more I learn about Brian Clement, the more I wonder: How on earth has this guy been operating for three decades in Florida? Clearly, the State of Florida has utterly failed to protect its citizens from quackery. In fact, given how many people, such as Makayla Sault, come from all over the world, Florida has failed to protect everyone. Clement and his wife are both registered as nutrition counselors. Clement’s PhD in nutrition comes from the University of Sciences, Arts and Technology, a school licensed by the government of Montserrat, an island in the Caribbean with a population of about 5,000. It’s widely viewed as a diploma mill. Yet, thanks to a loophole in Florida law (see below), the Clements continue to get away with making promises they can’t fulfill, all the while with a “wink-wink, nudge-nudge” disclaimer that they “don’t promise cures,” even though everything they say in their promotional literature and talks would lead one to think that they can cure stage III and IV cancers where scientific medicine can’t.
What’s going on is so obvious, too. The Hippocrates Health Clinic has a Massage Establishment license, issued by the Florida Board of Massage Therapy. Also, the Florida Agency for Health Care Administration (AHCA) licenses health care facilities, such as health care clinics and hospitals, and processes complaints about the quality of care in these facilities. Further, it is known that a complaint was filed with ACHA against the HHI for operating a health clinic without the proper state license. However, as our resident Florida lawyer and SBM regular contributor Jann Bellamy informed me when I asked her about it, under state law, only clinics receiving reimbursement from third-parties, such as public or private insurers, are required to have an AHCA-issued license. Because Hippocrates is a cash-only business, AHCA was apparently without jurisdiction to take action. The result of this gap in state law is that clinics offering only unproven treatments, which aren’t reimbursed by insurance, are the very ones who are outside the reach of state supervision. Meanwhile the FTC won’t say whether it’s investigating or not.
In both the WPTV report and Tim Alamenciak’s report, Clement is asked about accusations that he gives cancer patients false hope. He immediately replies, “There is no such thing as false hope.”
Wrong, wrong, wrong, wrong. Hope is important, but cancer patients need that hope to be tempered with a realistic assessment of their prognosis. Clement takes that away from them, and he’s damned callous about it too, as his answer to Alamenciak’s same question reveals:
When confronted with the testimonials people wrote — testimonials full of hope, that have not been updated to indicate those who later died — Clement says:
“That’s not false hope. I’m going to die. Do you realize that? You’re going to die,” he says. “I have hope that I’ll become a multi-billionaire some day and be able to change the world. Is it going to happen?
“I would never tell somebody don’t do chemotherapy. I’m not a medical doctor, nor do I believe I should tell them to do that … I’m going to die; they’re going to die. Does it mean that I did something wrong because they came here? Maybe they were very, very sick at some point and they went home and eventually died? What do I have to do with that? Explain, what does Hippocrates have to do with that?” said Clement.
In response to questions about Stephanie O’Halloran, Clement is quoted thusly:
” … From a one-hour lecture in Dublin, this woman decided that I could heal her? That’s not even realistic when you think about that,” said Clement said in an interview in his Florida office.
These are, of course, the sorts of questions that a con man asks when confronted to deflect responsibility from himself to his marks. It’s not his fault they believed him! Unfortunately, Florida law lets the Clements continue to offer false hope at a high price with impunity. Until the HHI is shut down, there will be more patients like Makayla Sault, Stephanie O’Halloran, and Annalisa Cummings spending tens of thousands of dollars to chase the false hope that Brian Clement offers.

Florida tells Brian Clement to stop practicing medicine
Jann Bellamy on March 5, 2015
Link


Note: Also posted today is a brief profile of a new blog, Naturopathic Diaries: Confessions of a Former Naturopath, by Britt Marie Deegan Hermes, a trained naturopath who became disillusioned with her profession. I encourage you to have a look!
The State of Florida has finally taken action against Brian Clement.
David Gorski, Orac, and the Canadian media, especially the Canadian Broadcasting Corporation (CBC), have done an excellent job of chronicling the activities of “Dr.” Clement. All have reported on Florida’s taking action against Clement. I’ll give a brief background here, most of which comes from Dr. Gorski’s most recent post, as well as add some information and observations to theirs.
Hippocrates Health Institute, located in West Palm Beach, Florida, is licensed as a massage establishment by the state and run by Brian Clement and his wife, Anna Maria Gahns-Clement. Clement and Hippocrates came to the attention of the Canadian media when, last year, the families of two Canadian aboriginal girls withdrew their children from conventional cancer treatment, including chemotherapy. Prior to that, Clement had basked in the glory of fawning reports from local media, one of which described him as having an “inimitable, engaging style.” Another described him as coming “fresh from a detoxifying sauna” to the interview.
Had they completed conventional treatment, both girls had a very good chance of survival. The families opted instead for traditional medicine as well as “alternative medicine” at Hippocrates. Each paid a reported $18,000 for participation in a “Life Transformation Program” there. This included, for at least one of the girls, cold laser therapy, vitamin C injections and a strict raw vegetable diet.
Sadly, one of the girls, Makayla Sault, died in January. The other girl cannot be identified due to a court-ordered publication ban, but is referred to as “JJ” in news reports. As of last November, Hippocrates was still providing care for JJ by analyzing blood test results sent by mail. According to her mother, JJ must maintain a raw diet for two years with absolutely no sugar, presumably at Clement’s direction.
In previous statements, Makayla’s and JJ’s mothers identified Clement’s assurances of successful treatment at Hippocrates as the reason they decided to stop conventional cancer treatment. After all, why would any parent pay that kind of money and take her child out of the country had she not been convinced by someone that this considerable effort offered a real possibility of saving her daughter’s life? However, they are now walking back from those statements. The families are claiming that the girls’ trips to Hippocrates were a “family vacation.”
Clement has been fudging on his credentials, referring to himself variously as a naturopathic doctor, an NMD [naturopathic medical doctor] and a Ph.D. He has used the honorific “Dr.” (as recently as last November, on the HHI website) and called himself a “scientist.” But his degrees are from diploma mills. He is correct in claiming he is licensed by the state a nutritionist, a matter we’ll return to in a moment. His bio on the Hippocrates website is more circumspect since his troubles started. He still claims he is a Ph.D and is LN (licensed nutritionist).
Clement has made some wildly exaggerated claims about the effectiveness of treatments offered at Hippocrates. He’s asserts that “thousands and thousands” of people have “reversed” their cancer via Hippocrates treatments. He was recorded on video as saying:
We have the longest history on the planet Earth, the highest success rate on the planet Earth, of people healing cancer.
In response to the question “What ailments have you cured by putting your patients on a vegan diet?” posed on another video, he said:
Every known disease. Of course, we’re most notable for all of the people that have healed cancer.
And, in another video:
We’ve seen thousands and thousands of people reverse stage-four catastrophic cancer.
Medical experts have been widely quoted in news accounts debunking various nostrums offered there. David’s post last week thoroughly deconstructs these treatments:
They include almost every imaginable form of cancer quackery, including “detoxification,” colonics, wheatgrass, ozone pools, “bio-energy treatments,” the aforementioned “Cyber Scan,” and, of course, the Aqua Chi “detox footbaths.” One particularly silly treatment offered by HHI is called a “wheatgrass implant”, which, it turns out, are actually wheatgrass juice enemas. Indeed, if you believe the hype on the HHI website, there’s nothing that wheatgrass can’t do. If the HHI is to be believed, wheatgrass can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many other fantastically beneficial alleged effects. Basically, combine a raw vegan diet with a veritable cornucopia of other kinds of quackery, and you have the HHI.
Unlicensed practice
Practicing any licensed health care profession without the appropriate license is a third-degree felony in Florida, with a penalty of up to 5 years in jail and a $5,000 fine. It is subject to administrative sanctions as well, such an order to cease and desist and a fine. According to the Florida Department of Health (DOH):
The Unlicensed Activity (ULA) program protects Florida residents and visitors from the potentially serious and dangerous consequences of receiving medical and health care services from an unlicensed person. The ULA unit investigates and refers for prosecution all unlicensed health care activity complaints and allegations.
The ULA unit works in conjunction with law enforcement and the state attorney’s offices to prosecute individuals practicing without a license. In many instances, unlicensed activity is a felony level criminal offense. More importantly, receiving health care from unlicensed people is dangerous and could result in further injury, disease or even death.
And:
investigations involving the unlicensed practice of a healthcare profession are criminal investigations that require the development of sufficient evidence (probable cause) to present to law enforcement or file charges with the State Attorney’s Office in the county of occurrence.
Florida law defines the practice of medicine as:
the diagnosis, treatment, operation, or prescription for any human disease, pain, injury, deformity, or other physical or mental condition.
Last November, I filed a complaint against Brian Clement for the unlicensed practice of medicine with the DOH. I also filed a complaint against Hippocrates Health Institute with the Florida Agency for Health Care Administration (AHCA) for operating a health care facility without the proper state license. AHCA licenses health care facilities, such as health clinics and hospitals. As I stated in the complaints, these allegations were not based on personal knowledge, but rather upon Canadian media reports. However, in light of what I had read, I felt an obligation to report Clement and Hippocrates to the state. It appeared to me that the health of these girls and others was at stake and it was appropriate for the state investigate what was going on.
The AHCA complaint was resolved first, with a surprising result. According to a January 28th email from AHCA:
After some additional Agency research, unfortunately this “Health Center” does not meet the definition of a Health Care Clinic, see [Florida Statutes] Section 400.9905(4),
“Clinic” means an entity where health care services are provided to individuals and which tenders charges for reimbursement for such services, including a mobile clinic and a portable equipment provider.
Since this institute is a cash-only business, it does not fall under AHCA’s regulation. The only recommendation I have, is to file complaints with the Department of Health (Board of Medicine) against the individual doctors, thanks.
In other words, since Hippocrates doesn’t get reimbursed by third party payers, such as health insurance companies, it does not need a license and AHCA had no jurisdiction to do anything about the clinic.
Interestingly, by not accepting insurance, Hippocrates avoids the usual limitations on insurance reimbursement for unproven treatments, typically deemed “experimental” in insurance policies and therefore not covered. It is thus able to escape any scrutiny a health insurer would normally apply to the treatments offered there, scrutiny that might otherwise raise suspicions among its clients when their insurance claims were denied.
The other complaint against Clement met with more success. On February 10th, I learned that DOH had taken action. First, DOH issued a Notice to Cease and Desist, saying
The Department has probable cause to believe that Brian Clement of Hippocrates Health Institute . . . is not licensed by the Department or the Board of Medicine and is practicing medicine in violation of [state law]. The practice of medicine without an active, valid license or permit is strictly prohibited [by law] and constitutes a crime.
Wherefore, in accordance with [state law], Brian Clement . . . is hereby notified to cease and desist from practicing medicine . . . unless and until Brian Clement is appropriately licensed by the Department.
An event that, we can safely assume, won’t take place.
It goes on to state that, if he violates the Notice, DOH can seek a court order to stop the violation and recover attorneys’ fees and costs.
DOH also issued a citation in the amount of $3,738 ($2,500 fine plus costs) for practicing or attempting to practice medicine without a license.
There is no right of appeal from the cease and desist notice but he can challenge the citation. Clement can request an administrative hearing within 30 days. This means he would have an opportunity to introduce testimony and evidence on his behalf before an Administrative Law Judge. The state, of course, would introduce testimony and evidence supporting the citation. If he loses, he can file an appeal to a state appellate court. If he does not challenge the citation, he would not get a hearing and the citation becomes a final order of the agency. However, he can still get another crack at it by filing an appeal, although his ability to argue against his being cited would be greatly limited.
According to Clement’s PR person, to whom we’ll return in a moment,
We deny these allegations from the Department of Health in their entirely and are vigorously contesting these allegations through the administrative process.
So it looks like Clement will be requesting a full administrative hearing.
DOH also notified Clement that
THE CITATION DOES NOT PREVENT OTHER ADMINISTRATIVE, CIVIL OR CRIMINAL PROSECUTION INVOLVING THE SAME FACTS AS USED IN THIS AGENCY ACTION.
And indeed, the investigative report states that DOH notified the Palm Beach County Sheriff’s Office about the matter on February 13th. Prosecution would be handled by the State Attorney.
In the investigative report accompanying the citation and notice, we learn that the DOH investigator reviewed the Hippocrates website and confirmed that Clement was using the title NMD. The report notes that Clement had been issued an informal Notice to Cease and Desist in the past for advertising and using the title NMD on the website.
The report says that the investigator did not attempt to obtain a release of patient information authorization from the Canadian girls because “their names were not provided or noted in the Canadian News Release.” This omission is curious because Makayla’s name and location were in several news reports and I mentioned her as well in my communication with DOH.
We also learn that a DOH investigator, who also reviewed the website and media reports, went undercover to Hippocrates on February 10th for an appointment with Clement, using an assumed name. He discussed his (unidentified) medical condition with Clement who gave him a “menu.” Based on the exhibit referred to in the report, this menu is a handwritten list, as follows:
Lifegive [a brand sold by Hippocrates] internal cleanser
2 AM, 2 PM
Mon, Wen, Fri, Sun
Lifegive B12
1 every morning
Pollen, teaspoon AM, PM
Quinoa Burger
Rice Pasta
Non Soy Burgers
Amy [brand?] Dinners
All Grains
Clement asked the investigator to provide a copy of his blood screen results; presumably, the blood screen was done prior to the appointment. Clement also gave the investigator a “specimen collection box” and told him to forward a sample to the company listed on the box. An attached exhibit shows a “fecal collection specimen box.” According to the report, Clement didn’t diagnose the investigator but said that the Hippocrates “medical team would review” his file.
Later, when the investigator revealed his true identity, Clement denied using the title “Naturopathic Medical Doctor” on the Hippocrates website despite his earlier run in with DOH for that exact thing.
A letter from DOH dated February 23rd notified me that “Dietetics & Nutrition Practice Council v. Brian R. Clement” was under review and, after an investigation, the DOH’s attorneys would look at the case and make a recommendation to the probable cause panel of the Council. (The Council operates under the auspices of the state medical board.) Although it is not clear, it appears as if DOH views me as the complainant in that case as well although my complaint did not include any allegations specifically regarding his nutritional counselor license.
Clement does hold a “clear/active” license to practice as a nutrition counselor. Florida no longer licenses nutrition counselors but they were grandfathered in under a newer law licensing dietetics/nutritionists, who have a broader scope of practice. Because they are no longer licensed, the statute does not tell us what the original educational and training requirements were.
By law, nutrition counselors can evaluate a person’s nutrition needs:
using appropriate data to determine nutrient needs or status and make appropriate nutrition recommendations.
One would assume that “Lifegive internal cleanser” and pollen are not an “appropriate” nutrition recommendation but I do not know if that is the basis of the complaint. It could be that his credentials were not in order when he applied.
Other legal problems and a PR offensive
According to media reports, Clement’s troubles with DOH are not his only legal problems. A complaint filed against Hippocrates with the Federal Trade Commission remains open. Several former employees, including the former director of nursing and an MD, are suing him over allegations that they were fired when they expressed concerns about Clement and other employees practicing medicine without a license. One RN alleges he was fired for refusing to follow Clement’s orders, which could be legally given only by an MD.
It is interesting that the Board of Directors of Hippocrates has not, to my knowledge, asked Clement to step aside pending resolution of these legal troubles, if not outright fire him. They would certainly be within their rights to do so absent some contractual arrangement with Clements that nixes his being ordered to stop practicing medicine as a firing offense, which is unlikely. It makes one wonder how closely the Board is overseeing the operations at Hippocrates.
Clement and/or Hippocrates have hired a top Florida PR firm to help handle the media heat. One can hardly blame them, considering the fact that Clement’s media interviews were just making him look like, well, like himself. Vicki Johnson, the PR firm’s VP, accused the Toronto Star of taking Clement’s “thousands and thousands” statements “out of context.”
As (Clement) has repeatedly emphasized, what Hippocrates does is educate people about the benefits of raw foods and exercise, and how a healthy lifestyle arms the body to fend off disease and in many cases heal itself.
Johnson might want to consider relying on medical information from someplace other than Hippocrates before she speaks to the media.
Johnson claims that all blood tests are administered by a medical professional and reviewed by the medical director. All Clements and his wife do is review the “guest’s” health history, including blood tests, to make nutritional recommendations. She says the medical director is responsible for all medical decisions. As the article points out, Hippocrates houses as many as 100 people at a time but has only one licensed medical director, Dr. Paul Kotteran. Sounds like a busy guy.
Johnson also challenged criticisms from a former Hippocrates employee who accused Clement of getting “as much money as possible” from deathly ill people:
He has dedicated his life to the health and well-being of his guests . . . Hippocrates grants thousands of dollars’ worth of scholarships to guests on an annual basis.
Lucky them.
Clement himself has also denied as “erroneous” a 2013 tax return filed with the IRS reporting his income as $529,000 and his wife’s at $432,000. We’ll see if an amended tax return is filed, as is required by federal law.
Clement and Hippocrates are clearly in the sights of the media and the blogosphere. The lawsuits by employees, the FTC action, the Florida Department of Health’s continuing investigation and the possibility of criminal charges will all be followed. Too bad Clement and Hippocrates have been able to successfully rake in millions of dollars by scamming so many people, some of whom died after they withdrew from conventional treatment, before the state decided to act.
What will be the actual effect of the Notice to Cease and Desist and Citation on Clement? That remains to be seen. Neither requires that the quack treatments or sales pitches to gravely ill people and their families be stopped. Hippocrates can continue to operate as a “massage establishment.” Clement will not suffer any penalty (other than the citation) for what he has done unless the FTC or state attorney take action. Any recovery in the suits brought by employees would go to them, not to the families of those who stopped treatment and died. Hopefully, the FTC and the state attorney will act to ensure more people don’t die because they abandoned conventional treatment for quackery.

Naturopathic Cancer Quackery
Naturopaths treat cancer with an array of implausible concoctions that are not based on clinical science, and then defend themselves with cease and desist letters.
Steven Novella on September 6, 2017
Link

Britt Marie Hermes is a former naturopath who had the requisite intellectual and moral integrity to realize and admit to herself that her chosen profession was a pseudoscientific fraud. Further, rather than just sulk away and go on with her life, she decided to share what she learned with the world, in the hopes of mitigating the damage caused by her former profession.
Of course, no good deed goes unpunished. For her trouble she has been harassed and legally threatened. She was recently sent another cease and desist letter from Colleen Huber, for a post in which she explains why she thinks Huber is cybersquatting on domains with Hermes’ name:
The Wix account of BrittMarieHermes.com is registered with an email address at the domain natonco.org, the official website for the Naturopathic Cancer Society and a non-profit organization in Tempe, Arizona run by naturopathic cancer “doctor” Colleen Huber, NMD and her surrogate Hazel Chandler. The organization raises money for cancer patients who desire to use, but cannot afford, expensive alternative cancer therapies such as intravenous vitamins, mistletoe injections, and special diets, which is then funneled to Huber’s clinic Nature Works Best and others.
Huber is a naturopath who treats cancer with “natural” therapies. She makes some extraordinary claims, without the evidence to back them up. Huber and her clinic treat cancer with IV therapy and diet. Their website states:
The intravenous nutrients are tailored specifically to each patient’s condition and chosen for their targeted, time tested, and research-documented anti-cancer, or tumor fighting effect. The nutrients we use are different for each patient, but some of nutrients used may include a combination of Vitamin-C, Sodium Bicarbonate, DMSO, in addition to many others. Before we have done a full workup we cannot know which of these nutrients may be used for your treatment, if they are used at all. These treatments are made specifically for each patient, their type and stage of malignancy and may be used exclusively or as a supplement to chemo and radiation.
They specifically state that they do not treat their patients with chemotherapy or radiation. Further, they appear to discourage standard treatment as evidenced by this statement on their website:
Your best opportunity is to begin the natural treatments before the conventional treatments (chemo, radiation, etc.) sicken and weaken you and ultimately strengthen the disease. Many of the patients who opted for only natural treatments never even got sick and saw no side effects.
So in their view chemotherapy strengthens the cancer. Meanwhile they recommend implausible treatments that are not evidence-based. David Gorski has already done an excellent job reviewing the literature on vitamin C and cancer – bottom line, it doesn’t work.
Baking soda (sodium bicarbonate) treatment for cancer is based on the fact that solid cancers often exist in an acidic environment. Mouse studies suggest that treatment with an alkalinizing agent may reduce the ability of solid tumors to metastasize. There are, however, no clinical trials showing that it actually works in humans. A 2017 paper discusses the problem:
However, a concern in translating these results to clinic has been the presence of counter ions and their potential undesirable side effects (e.g., hypernatremia).
I found one preliminary clinical trial registered at clinicaltrials.gov, which was completed in 2015, but there are no published results. I wonder if they are still crunching the numbers after two years, or if this is an example of the file drawer effect.
This is an excellent example of pseudoscience in medicine. Start with a semi-plausible idea, such as countering the acidic environment of solid tumors. This is a bit simplistic, and I would guess that simply giving an alkalizing agent like baking soda would not work, but it is enough of a justification to do some serious research. Perhaps it will lead to a more nuanced treatment. The basic and animal research has had mixed results, with positive effects in some tumors but not others. Concerns about serious side effects are also raised. At best these results are preliminary and point the way to a modified approach and perhaps justify preliminary human trials.
However, we are still a decade of research away from definitive clinical evidence that can be used as the basis of evidence-based treatment. Most possible treatments at this state will ultimately fail. But this preliminary data can give the impression that one is being scientific and evidence-based – just a misleading impression.
What about the notion that sugar feeds cancer? This is also not based on any clinical science, just a handwaving notion that cancer cells are hungry. As a Cancer Research UK review states:
There’s no evidence that following a “sugar-free” diet lowers the risk of getting cancer, or boosts the chances of surviving if you are diagnosed. And following severely restricted diets with very low amounts of carbohydrate could damage health in the long term by eliminating foods that are good sources of fibre and vitamins.
The Mayo Clinic also states:
Sugar doesn’t make cancer grow faster. All cells, including cancer cells, depend on blood sugar (glucose) for energy. But giving more sugar to cancer cells doesn’t speed their growth. Likewise, depriving cancer cells of sugar doesn’t slow their growth.
I could not find any published study supporting the claim that reducing sugar in the diet improves cancer outcome. But I did find this study that looked at glucose levels in diabetics with cancer, and found:
Higher glucose and HbA1C levels in diabetes patients with incident cancer are not associated with worse overall survival following cancer diagnosis. Among insulin-treated patients, higher glucose levels may be associated with improved survival.
Again, the notion of starving cancer cells by depriving them of sugar is overly simplistic. The problem is that all healthy cells need energy too. The goal of cancer treatment is to find a way to harm cancer cells only, or at least significantly more than healthy cells. Depriving all cells of carbohydrates doesn’t cut it.
So, in keeping with what I find to be the general approach of naturopathy, Huber’s cancer treatment is a hodgepodge of barely plausible treatments not based on convincing clinical research, but that can be marketed to the public as “natural.” She simultaneously scaremongers about established effective treatment. In my opinion, the term “quack” fully applies here.
But the real howler comes from Huber’s published “study” in which she claims:
However, our success rate of 93% in steadfast patients following all protocols as recommended, from Stage I through early Stage IV (Table 5) is unprecedented and unequalled in both conventional and natural medicine in all clinics that report their results in detail as we do in this paper.
Sounds impressive – better results than any other clinic treating cancer, including those using conventional therapy (with the caveat that this includes those clinics who report their full results). But let’s take a look at Huber’s data more closely.
Many patients voluntarily left our practice, against our advice, primarily for financial reasons, while still having cancer. Of the remaining patients, 175 either went into confirmed, complete remission, which we define by no evidence of cancer remaining in the body on imaging, or have remained in good to excellent wellbeing, as determined retrospectively by prolonged stable health of at least 6 months after leaving our care and needing no other physician supervised cancer care, and as confirmed by annual telephone conversation with either the patient or a family member. Those patients in remission stayed in our care an average of 3.7 months; those who left, 2.7 months, (this data last measured in 2010). Eight additional patients went into remission after leaving our clinic, and while being treated at a different clinic, and it is unlikely that our treatments were the decisive factor in that remission. We were still treating 22 patients at July 1, 2014 plus giving ongoing maintenance treatments to some of those who are still in remission. 44 died while still our patients. Of those 44, 12 died after a significant dietary dispute with us. That is 32 patients died although they received our treatments and complied with our requested diet. 22 more were killed by hospital procedures and/or chemotherapy and/or radiation side effects while still our patients. 45 total patients chose to have chemotherapy while having our treatments. Yet, of the 175 who went into remission, only 12 had chosen to have chemotherapy while having our treatments. Stages 1, 2, 3 and early Stage 4 patients at start of treatment had much better outcomes than late Stage 4 patients in general.
Those familiar with cancer research may immediately notice when reading through this paper the distinct lack of survival curves, which is a standard way of tracking how patients do with cancer treatment. There is also a clear lack of any proper controls. There is no comparison of patient with similar cancers and stages with conventional or any other treatment.
But the biggest problem, which even a non-expert might notice, is the clear bias in the way the patient outcomes are tracked. Patients who left the practice for whatever reason were not counted. There is a known bias in which patients who do well with a treatment stick with it, and those who do not do well stop the treatment or seek other alternatives. It is highly likely that those patients whose cancer progressed while getting treatment tended to not follow up, and so are not counted. Patients who did well would be more likely to stick around and be counted.
This factor alone makes Huber’s numbers worthless. Any clinic can look good if you track outcomes this way. Since she is mixing patients and treatments in a clinical setting, the best method for tracking outcome would likely be an intention-to-treat analysis, in which all patients who begin treatment are counted. These patients should be compared to matched controls who present to a standard cancer clinic.
Huber’s numbers are simply not scientific. They are useful only for self-promotion and convincing customers that her treatments are effective, when the best science available does not support that claim.
This sloppy and worthless paper is apparently what passes for science in the naturopathic world. What this suggests (along with a great deal of other evidence) is that if you go to a naturopath you are likely to be treated with implausible treatments that are not based on reliable scientific evidence, but marketed as “natural” and presented as superior to science-based treatments.
Hermes criticism, in light of this, seems completely justified. Huber has apparently chosen to fight back not with facts or logic, but with legal thuggery.

Be careful what you wish for…
A “naturopathic oncologist” on Twitter challenged me to examine the work of his two “naturopathic oncology” mentors. It did not go well…for him.
David Gorski on November 19, 2018
Link

I must admit that these days I probably spend too much time on Twitter. On the other hand, Twitter is a lovely place to find blog fodder for days when the inspirational juices aren’t flowing quite as well as I would like and there doesn’t seem to be a study or news item so urgent that the burning desire to write about it jars me into action. So it was yesterday when somehow I got involved in a Twitter “discussion” with a couple of naturopaths. One of them was named Paul Theriault, and the other is someone familiar whom I’ve written about on this blog and elsewhere before, Dugald Seely, the “naturopathic oncologist” who helped develop the Society for Integrative Oncology’s guidelines for breast cancer care and has two grants worth a total of $7 million dollars from an anonymous donor to try to “prove” that naturopathy improves survival in various cancers. Not surprisingly, Twitter being Twitter, Theriault and Seely were defending naturopathic oncology, while I (and a few other hardy skeptics) were pointing out that any specialty of which homeopathy is an integral component is not science-based. This led to Theriault challenging me:
On this topic David, you inherent bias has prevented you from an objective assesment of the facts.
How can your research on websites and things failed to have evaluated Drs. Paul Anderson, or Neil Mckinney? How could it have such vast blind spots?
— Dr. Paul Theriault BSc, ND, VNMI (@DrPaulND) November 17, 2018
To which I sarcastically responded:
Be very careful what you wish for, Not a Doctor Paul. I might just decide to do that.😏
— David Gorski, MD, PhD (@gorskon) November 17, 2018
At the time I was just joking, yanking Not-a-Doctor Theriault’s chain, so to speak. Really I was. I swear! But then I saw this response:
OMFG. Anderson the superquak from Seattle? Who throws around with big words (epigenetics, genomics, crispr) but has no clue to what they mean? Who uses SNPs and mutations as synonyms? Who thinks mitochondrial dysfunction is the primordial cause for cancer, and detox can “cure”?
— Sartorius Medicus (@SartoriusMD) November 17, 2018
That made me curious, and my curiosity led me to start to do some digging.
I then realized that Anderson’s name sounded very familiar and kicked myself (metaphorically speaking) for not having immediately recognized it. I’ve mentioned him before. He is a proponent of intravenous curcumin, the treatment that resulted in the sudden death of a young woman in California, and issued a rather clueless defense of the practice in the wake of that tragedy. As Jann Bellamy characterized him, he’s also a tireless campaigner against FDA attempts to rein in compounding pharmacies of the sort that produced the curcumin that resulted in the woman’s death. In any event, he runs a practice in Seattle, Advanced Medical Therapies.
I didn’t recall having heard about McKinney before; so I Googled him too. He runs a practice called Vital Victoria Naturopathic Clinic, Ltd. Both Anderson and McKinney bill themselves as “naturopathic oncologists”, and apparently Theriault “trained” (if you can call it that) under both of them.
At this point, let me remind everyone that the discussion on Twitter involved Theriault jumping into a discussion about homeopathy to defend it, with Seely chiming in to call me (and others) dogmatic defenders of the medical “orthodoxy” while claiming that the arrogance of doctors, areas where medicine is not as evidence-based as it should be, and all the other problems in medicine make naturopathic medicine’s record appealing, thus giving me not one, but two opportunities to cite Ben Goldacre’s famous retort to these sorts of arguments:
Quacks citing problems in pharma make me laugh. FLAWS IN AIRCRAFT DESIGN DO NOT PROVE THE EXISTENCE OF MAGIC CARPETS.
— ben goldacre (@bengoldacre) January 31, 2013
So I decided to look into these “naturopathic oncologists”, who, if you believe Not-a-Doctor Theriault, are paragons of evidence-based practice. It’s a good exercise, and time was tight this weekend because my wife and I are fostering a rescue dog and her litter of puppies and their pen in our basement needs a good cleaning. Indeed, before I dig into the records of the two naturopaths, I think I would be remiss not to let you know where to see them if you so desire. Videos from the last week on my YouTube channel have the story, and the story of the other puppies we fostered this time last year can be seen there too, as well as a video that’s very appropriate for my discussion below:
Yes, we do discuss homeopathy in this post, because we have to. The post is about naturopathic oncologists and naturopathy.
Not-a-Doctor Paul Anderson: Chelation, micronutrients, and other nonsense
Visiting Not-a-Doctor Anderson’s website, it didn’t take me long to find this introductory video:
In the video, he touts “advanced processes” and “advanced protocols” in which he orders naturopathic interventions by protocols that he’s developed over his career. Now here’s an interesting thing:
AMT was founded by Dr. Paul Anderson with a specific focus on advanced therapies that he has developed over the past three decades to improve health via therapeutic synergy. With staff trained by Dr. Anderson, Advanced Medical Therapies (AMT) offers infusion therapy (IV), hyperbaric oxygen therapy (HBOT), and infrared sauna – mild hyperthermia (IRMHT).
AMT physicians are guided by Dr. Anderson’s protocols. Patients receive the most up to date treatments and protocols created in a team setting with Dr. Anderson and AMT physicians.
Dr. Anderson does not see patients one on one.
So, basically, this sounds like a franchise or a way for Anderson to make money and have a lot of patients seen without having to do a lot of work himself. The video itself also features Anderson explaining how some of his patients come with a plan of care to which he adds naturopathy and for some there is “nothing left” that conventional medicine can offer and how his processes are different for each kind of patient. No doubt (I’m guessing) he has to keep some of the rankest pseudoscience toned down for patients who are still seeing real doctors.
So what “services” does Anderson offer? It states that his clinic’s practice areas include IV therapy, hyperbaric oxygen therapy, and infrared medical therapies. None of these can be said to have high quality evidence supporting their use in the conditions for which Not-a-Doctor Anderson is using them. For example, check out the infusions they offer in his section on IV therapy:
Here at advanced medical therapies we offer a wide variety of infusions, ranging from nutritional IVs with vitamins, minerals, and amino acids to chelation and detox services, to ozone and pharmaceutical therapies, including treatments such as antibiotics. With regard to nutritional IVs, these are infusions that have been designed and formulated from the collective experience of over three decades from the minds of Dr. Anderson and the other physicians at AMT, guaranteeing that you are given a customized and tailored approach for whatever symptoms or condition you may be experiencing.
So what about these “therapies”? I’ve written about “micronutrient therapy” in detail before. Suffice to say that it is pretty much useless and has resulted in FDA action against at least one company selling it. Chelation therapy is not only useless for anything other than actual medically documented acute heavy metal toxicity (as opposed to the bogus “heavy metal toxicity” diagnosed by tests sold by dubious companies to naturopaths to do “provoked urine testing”), it is potentially dangerous and can kill. It does not treat autism; it does not treat cardiovascular disease; it doesn’t treat much of anything except for the relatively rare case of acute metal poisoning; and it certainly doesn’t treat the plethora of chronic diseases and other conditions for which naturopaths prescribe it.
The same is true of “detox”. The whole concept of “detox” is based on the idea that our body is bombarded with unnamed “toxins” that are causing all manner of chronic diseases and that the only way to eliminate them is to “detoxify” by whatever scientifically-nonsensical means naturopaths (and other alternative or integrative medicine practitioners) come up with. A variant of the idea is that our bodies are “poisoning themselves” with our waste products (and have 20 lbs. of poop backed up in our intestines to boot!), meaning that we must “cleanse.” It’s an idea that actually dates back to ancient Egypt but was particularly popular during the Victorian era, when surgeons would actually do colectomies to eliminate the “autointoxication” and treat diseases having nothing to do with the colon, including psychiatric illness. (Because of the lack of antibiotics, this was a high mortality procedure back then.) As I like to point out, our livers and kidneys (and lungs) are quite good at eliminating “toxins” and only need help when they are failing. Such failure is not generally a subtle diagnosis. Renal and liver failure produce distinct clinical syndromes, for instance. Basically, “detoxification” is more akin to religious ritual purification than anything else. It’s a scam in our opinion.
I could go on and on about my conclusion that Not-a-Dr. Anderson’s protocols are pseudoscientific nonsense, just like most naturopathic treatments, but you already know that. After all, he offers intravenous ozone, high dose vitamin C, and a very cornucopia of infusions, all while claiming to be able to treat these disorders:
Additionally, when evaluating really any disorder or symptom, oftentimes at its root is an elegant solution based upon your complex biochemistry and physiology. Providing nutrients or cofactors for certain biological processes or tailoring nutrients for your genetics may be the missing piece in your treatment.
There is always a place for infusion services in your treatment; however, at AMT we specialize in complex, chronic degenerative diseases and conditions which generally do not respond to conventional medicine. IVs are used alongside the other treatments to assist with a variety of conditions such as for those suffering with chronic infections, neuropsychiatric conditions, pediatric disorders, and supporting persons with cancer.
Chronic infections? I wonder if he means chronic Lyme disease, a favorite fake diagnosis of naturopaths. He also claims his infusions can offer “immune support”—whatever that means; it’s basically a fancy way of saying a favorite meaningless quack phrase, “boost the immune system“.
And I haven’t even discussed the hyperbaric oxygen treatment (which is only evidence-based for a very few conditions not including many of the conditions for which Anderson uses it, like autism) and infrared sauna mild hyperthermia, which Anderson claims can be used for “anti-infective, cancer, toxicity and many others”.
Of course, Anderson has also written a book, Outside the Box Cancer Therapies: Alternative Therapies That Treat and Prevent Cancer. Not surprisingly, the excerpt featured on the website touts an alternative cancer cure testimonial in which the patient survived five years with metastatic cancer but there was no mention of whether the cancer size actually decreased or increased, just that it was still there. He also offers review courses for the naturopathic licensing examination and sells webinars.
He’s also heavily into epigenetics and has even posted what is entitled a “master class” in epigenetics, nutrigenomics, and cancer. I tried listening to it, but soon abandoned it to protect my battered neurons. Let’s just say that @SartoriusMD (whose Tweet was quoted above) was correct in his characterization of Anderson’s beliefs about metabolism, cancer, and epigenetics. You can watch if you like, but don’t say I didn’t warn you:
Let’s just put it this way. If Theriault wanted to provide an example of a naturopathic oncologist who is practicing every bit as much evidence-based and science-based medicine as any conventional oncologist, Paul Anderson was a poor choice. I can see why Theriault trained under him.
Not-a-Doctor Neil McKinney: Homeopathy!
So let’s move on to Theriault’s other hero, Neil McKinney. He was even easier to peg as a typical naturopath than Anderson. For instance, he unabashedly and unashamedly uses “classical constitutional and complex homeopathy for acute and chronic illnesses.” He also embraces “energy medicine,” in particular reiki, or, as I like to refer to it, faith healing substituting Asian religious beliefs for Christian religious beliefs, complete with a reiki master in his practice:
Reiki (“Ray-Key”) is the laying on of hands in a traditional manner to direct healing energy to a specific part of the body, or the entire body. Reiki is not a religion, cult, dogma, or specific doctrine.
Reiki will…
    • Alleviate Pain, accelerate physical healing
    • Promote deep emotional release, relaxation, and bring peace to agitated minds
    • Support allopathic and holistic healing
    • Allow space for spiritual connections
    • Balance the energy system in our bodies.
Reiki is compatible with all other modalities of healing, whether traditional or alternative. It is non-invasive, safe and gentle for all ages. During your treatment, all your clothes are left on (except shoes). Usually your whole body is treated, while you lay on your back on a treatment table.
Not surprisingly, McKinney also offers acupuncture, traditional Chinese medicine, as well as these:
Dr. McKinney has innovated new and affordable therapies for cancer as well as powerful support for conventional care such as chemo radiation and surgery as well as palliative care. He has also formulated reinforcing therapies for maintenance, cancer prevention and remission.
Dr. McKinney provides alternative therapies for the treatment of cancer which may include high dose vitamins, tinctures and vupplements [sic] including Reishi mushroom, Indole 3 Carbinol, Curcumin etc. He also uses powerful therapeutics such as artemesinin, mistletoe therapy and low dose naltroxone.
Because he also uses low dose naltrexone too.
Particularly amusing is McKinney’s list of references supposedly supporting naturopathic oncology. It’s basically everything but the kitchen sink. If any supplement any time ever was shown to kill cancer cells in a dish, its reference is probably there. If there’s an alternative cancer cure testimonial turned into a publication in a quack journal, it’s probably there too. If there’s an article touting a supplement or alternative treatment to alleviate the side effects of chemotherapy, it’s likely there too. Overall it’s 86 pages, too long to examine in detail today, although perhaps I should peruse some of the articles in a future post.
Again, if Not-a-Dr. Theriault thought he would impress me by naming Not-a-Dr. McKinney as a practitioner of evidence-based “naturopathic oncology” treatment (yes, I know that’s a contradiction in terms), he was sadly mistaken.
Be careful what you ask for, Mr. Theriault…
This entire post started almost as a lark. I wasn’t sure if there was anything useful to be gleaned from taking Theriault up on his seeming challenge to look at the work and careers of two of his naturopathic mentors. Let’s just say that his mentors were less…impressive…than Theriault believes them to be. I suppose it’s no wonder that when I looked at his blog on his practice website I found that the vast majority of his posts were defenses of homeopathy in which he claims that homeopathy has good in vitro evidence, calls the claim that homeopathy lacks clinical trial evidence a “lie” (all while making excuses for why homeopathy can’t be easily subjected to double blind randomized placebo-controlled trials), and even suggests potential homeopathic “provings” for crocodiles. (I kid you not.)
Maybe this post is still a bit more “lark-like” than my usual post, but I still think it was a useful exercise. It served to demonstrate to me (and, I hope, to you) that what a naturopath considers to be “evidence-based” or “science-based” is a far cry from what is really evidence- or science-based. Even “naturopathic oncologists”, who seem to think of themselves as the most scientific and evidence-based of naturopaths, embrace rank quackery. Same as it ever was.

Herbal Products and Cancer Treatment
Oncologists increasingly are warning their patients away from alternative herbal treatments, and with good reason.
Steven Novella on November 20, 2019
Link
In 2017 David Gorski discussed a study that showed that cancer patients who rely on alternative treatments had a worse survival. He wrote:
…alternative medicine use was associated with a 2.5-fold increased risk of death for combined breast, prostate, lung, or colorectal cancer patients, and a whopping 5.7-fold increased risk of death for breast cancer patients.
Essentially this study suggests that alternative treatments do not work, or at least they do not work as well as conventional treatment. But what about patients who use both conventional and alternative treatments? This David covered in 2018, reporting on another study that showed that cancer patients who use alternative medicine in addition to standard medicine also have worse survival.
When the authors looked at specific cancer types, they noted that the use of CM was associated with poorer five-year survival for breast cancer (84.8% vs 90.4%) and colorectal cancer (81.8% vs 84.4%). However, they did not note any statistically significant differences seen in 5-year survival for patients with prostate or lung cancer.
More data on different kinds of cancer and patient uses would be helpful, but the evidence we have shows that relying on alternative treatments is extremely dangerous, and complementing with alternative treatments does not help, may hurt, and is associated with a higher risk of refusing standard treatment. One aspect of this net negative effect from alternative cancer treatments is the potential drug-drug interactions between over-the-counter (OTC) herbal products and cancer treatments. Oncologists are starting to push back against this trend, warning their patients about possible interactions. Speaking at the Advanced Breast Cancer Fifth International Consensus Conference, Surgeon Prof Maria Joao Cardoso warned about some possible interactions and emphasized the importance of doctors being proactive in asking their patients about herbal product use.
Notice that I referred to these interactions as “drug-drug” interactions. That is because herbal supplements are drugs – they are taken for the pharmacological activity of their constituents. And just like any drug, they can have effects on other drugs and how the body handles other drugs.
Cardoso gives as an example of one type of interaction, herbal products that can potentially cause blood thinning. She lists: green chiretta, feverfew, garlic, ginkgo, ginseng, hawthorn, horse chestnut, and turmeric. Often cancer patients are given blood thinners in careful doses based on the best evidence available. A blood thinner is a great example of the core concept in medicine of risk vs benefit – thinning the blood reduces the risk of blood clots, but also increases the risk of bleeding. Cancer patients often have increased blood clotting and can get complications like deep vein thrombosis (DVT). Blood thinners are used to compensate – but they have to be carefully dosed. Too much blood thinner can increase the healing time of skin lesions and increase scarring. They also increase the risk of hematoma.
Other cancer researchers have also warned about other possible interactions. Antioxidants, for example, are especially problematic. They represent another balancing act critical to cancer therapy – balancing toxicity with efficacy. Chemotherapy is essentially the strategy of giving powerful poisons to patients that kill cells, but they kill cancer cells more than healthy cells. The idea is to shoot for a sweet spot in which the probability of killing all the cancer cells is maximal with the least amount of toxicity to healthy cells. This balancing act is carefully researched and calibrated.
Some chemotherapy drugs work by causing oxidative stress that kills the rapidly dividing cancer cells. This, by the way, is also one mechanism by which your immune cells kill invaders. If a patient takes a high dose of an anti-oxidant in order to reduce the side effects of chemotherapy, they may also be reducing the effects of the chemotherapy. They are adjusting the toxicity-efficacy balance, likely moving away from the carefully researched sweet spot. Add to this the fact that the doses of herbal products are highly variable and poorly regulated, and it becomes impossible to predict what effect such products will have.
Some herbal products may affect the absorption of oral chemotherapy drugs, or affect their metabolism. All of the standard drug-drug interactions are in play.
Another interaction that may be specific to some cancers are hormonal effects:
Botanicals such as red clover and soy products are known to have mild estrogenic effects and may stimulate the growth of hormone-sensitive cancers.
Such products could literally stimulate the cancer to grow, and interfere with standard treatment which is designed to block that very stimulation.
One fairly complicated area of biological activity from herbal drugs is immune function. Many herbal products claim to be either anti-inflammatory (which by definition is immunosuppressive) or to “boost the immune system“. These claims are often vague or even untrue, but the extent to which they are true is likely to be problematic. Immune activity, again, can be a delicate balancing act, even in a healthy individual. The immune system is our body’s army that goes out and kills invaders, but the killing activity often has serious side effects, and healthy cells can get caught in the cross-fire.
There are two contexts here. The first is healthy immune function, in which the immune activity is properly targeted against either infection, foreign bodies, or unhealthy or cancerous host cells. This immune activity is beneficial and we don’t want to interfere with it. However, it can cause unpleasant side effects, such as fever, redness, or pain. How much we can reduce the side effects of inflammation before we reduce the effectiveness of the immune system is a complicated calculation and the focus of much research. For example, the best evidence currently suggests that we should not treat mild fevers, but rather tolerate them as our immune systems do their job. Of course, there are limits – a high fever can be dangerous – and special populations, for example children with fever-induced epilepsy. So complex individual decisions are often required.
On the flip side are “immune boosters”. This does not really exist as a scientific medical concept, because it implies that the treatment is improving the function of the immune system. It is more accurate, rather, to view such effects as shifting the balance toward greater immune activity. In healthy individuals, the balance has been carefully tweaked over millions of years of evolution, so I probably wouldn’t mess with it without good reason and good evidence. In disease states, doing anything to affect the immune system is complicated and even experts guess the net effects of interventions incorrectly. Clinical research has made experts humble about such predictions.
All this does not mesh well with a system in which untrained individuals can treat themselves with OTC drugs making broad and vague claims and that actually affect their immune function. With cancer, we don’t want to impair the body’s ability to fight off cancer cells. With auto-immune diseases, we don’t want to stimulate the immune system further, as it is already overactive. In fact standard treatment is immunosuppressive, again with careful monitoring and balancing beneficial effects from side effects (like increased susceptibility to infections).
One thing to keep in mind is that when manipulating a complex dynamic homeostatic system, such as the body, in either a healthy or disease state, figuring out the net effects of any intervention is extremely difficult. It takes decades of research by experts thinking very carefully to calibrate the proper balance, and then individualizing that information to each specific patient. While doing this, it is generally not helpful for the patient to be interfering with the whole process by taking poorly regulated products often with unknown ingredients, of highly dubious quality control, and in doses that are essentially anyone’s guess.
Further, in medicine there is rarely any free lunch, meaning that any significant medical intervention is a compromise between desired effects and unwanted side effects. We always have to take a careful risk vs benefit approach to any intervention. But herbal products, especially for things like cancer, are often sold with the myth that they are magically free of the compromises that real medicine faces. They are often claimed to magically target cancer cells while leaving healthy cells alone, or “improving” some function when actually they are just pushing a homeostatic system out of balance.
They are also often marketed as “natural” as if that means they operate in some way other than their drug-like effects.
Don’t be conned. Don’t fall for DIY cancer treatment with dubious poorly-studied drugs.

Escharotic Treatment for Cervical Dysplasia: A New Incarnation of Black Salve?
Bloodroot (Sanguinaria canadensis) and black salve (which contains bloodroot) are promoted and sold as a cure for many things, including cervical dysplasia. While it does kill cancer cells, it does so just like a flamethrower – indiscriminately, killing lots of normal cells along the way.
Harriet Hall on May 26, 2015
Link


Cervical dysplasia is a precancerous condition picked up by Pap smears. It is most often caused by human papillomavirus (HPV) infection. Mild cases may resolve spontaneously and can be followed by observation with frequent Pap smears, but cervical dysplasia can progress to cancer. The standard treatment is to remove the abnormal cells with a cone biopsy (using a knife) or a Loop Electrosurgical Excision Procedure (LEEP) using a wire loop heated by electricity. Those procedures not only treat the disease, but they provide a pathology specimen that can be examined to rule out more serious or invasive disease. Both LEEP and cone biopsy are 85-90% effective in removing all the abnormal cells. If cancer is suspected, a cone biopsy is preferable because LEEP may damage the edges of the specimen and make it more difficult to interpret. Otherwise, LEEP is often preferred because it is less expensive and doesn’t require anesthesia or an operating room. I have discussed misguided attempts by alternative medicine practitioners to treat cervical dysplasia before.
Surgery is often perceived as scary and not “natural,” so it’s not surprising that a “natural” treatment has been devised to replace surgery. Escharotics are corrosive salves that get their name from the thick dry scab that they can produce called an eschar. The “natural” escharotic treatment alternative for cervical dysplasia involves applying a solution of bloodroot (Sanguinaria canadensis) and zinc chloride. They claim that the solution selectively kills abnormal cells of the cervix while leaving healthy cells unaffected. That claim is almost certainly false, and the efficacy and safety of escharotic treatment has not been properly tested or compared to conventional treatment.
Who is using escharotic treatments?
Not mainstream doctors. Neither the American Congress of Obstetricians and Gynecologists (ACOG) nor the American Cancer Society (ACS) even mention escharotic treatments on their websites. The only proponents I could find were naturopaths and chiropractors.
Dr. Nicholas LeRoy bills himself as a “holistic medicine physician” but he is actually a chiropractor who is also trained in acupuncture and oriental medicine. His website says he “designs unique therapies” for the treatment of cervical dysplasia and other conditions, and he integrates chiropractic, diet, nutrition, acupuncture, and herbal supplementation. He also offers breast thermography and makes misleading claims for it, and he spreads misinformation about “90 deaths and thousands of injuries” from HPV vaccines. He has a book coming out on HPV and cervical dysplasia. It is ironic that someone who is putting himself forward as an expert on cervical dysplasia is discouraging the HPV vaccine, the one thing that offers an effective way to prevent the disease.
Naturopathic treatment of cervical dysplasia
A naturopathic review of cervical dysplasia recommends this approach to treatment:
    • A comprehensive nutritional intake and dietary counseling
    • Education on safe sex
    • Smoking cessation
    • Dietary supplements: folic acid, indole-3-carbinol, antioxidants like CoQ10 and vitamins C and E, green tea extract, and Coriolus versicolor (a mushroom)
    • Escharotic treatment with bromelain or zinc/sanguinaria
    • Vaginal suppositories with magnesium sulfate, glycerin complex, Hydrastis tincture, thuja oil, tea tree oil, bitter orange oil, vitamin A, ferric sulfate, and ferrous sulfate.
    • Vaginal green tea suppositories
They admit that critics of natural medicine say there is no published evidence that these options work or are backed by science, but they say several recently published articles explain the science and patient outcomes. They don’t list those “several” articles; they only cite a single published case report of one patient who was treated with 10 escharotic treatments along with an oral vitamin and botanical protocol.
Another naturopathic website makes similar recommendations and adds detoxification, exercise, stress management, homeopathy, and flower essences. It never ceases to amaze me how naturopaths will throw everything but the kitchen sink at a disease hoping something will stick. If the treatment works, they have no way of knowing what part of the treatment worked; so they convince themselves that the whole schmear was necessary and that they have some kind of holistic wisdom that guided them to know what particular mix of treatments would work.
Their reasons to prefer escharotic treatment
They claim escharotic treatment is superior to LEEP because it is natural, doesn’t damage normal cells or leave a scar, doesn’t cause complications like infection or reduced fertility, stimulates regrowth of normal tissue, is preferred by most women, and is less expensive. Every one of those claims is questionable. They only admit one drawback: escharotic treatment requires more visits (ten versus one). They don’t mention that the tissue removed in LEEP can be examined for invasive cancer, which is not possible with escharotic treatment. They also don’t mention that LEEP is covered by medical insurance, while escharotic treatment is not.
What is the evidence?
A PubMed search produced only the same single case report mentioned above. The only other evidence I could find anywhere online consisted of references to two studies reportedly published in an obscure, unobtainable naturopathy journal. A 2003 review article on cervical dysplasia in the Alternative Medicine Review describes those two studies. The references for those studies list the same author, Hudson TS, and a journal called J Naturopathic Med. That journal is not listed in PubMed and I have been unable to even find any reference to such a journal on the Internet except in a very few citations on naturopathic websites. I even tried to locate it by asking one of the proponents of the therapy for help, but my query went unanswered. Note: I did find an International Journal of Naturopathic Medicine, but it was founded in 2004, long after the 1991 and 1993 dates of the studies in question.
So I can’t evaluate the studies for myself; I can only copy the description of the two studies provided in the review article:
First study:
A small study using local escharotic treatment was conducted on seven women with carcinoma in situ of the cervix. Three levels of treatment were employed: local treatment to the cervix, systemic treatment, and constitutional treatment. Local escharotic treatment utilized preparations of ZnCl, bloodroot, bromelain, and Calendula succus. Local treatment was repeated twice weekly for five weeks with treatments 2-3 days apart. Topical vitamin A was applied following each local treatment. Systemic treatment was comprised of ascorbic acid 6-10 g per day, beta carotene 120,000-180,000 IU per day, and selenium 400 mcg per day. Patients were also prescribed a vegan diet to eliminate animal fats and two botanical compounds to enhance immune function – Taraxacum officinalis and Arctium lappa. Systemic treatment was continued for not less than three months. Constitutional treatment consisted of a homeopathic remedy prescribed on an individual basis.
All seven patients received one year of follow-up. Four of the women remained disease free after the one-year period. One woman improved to atypia and then reverted to mild dysplasia. One woman had resolution of the cells of the endocervix and not the ectocervix, and one woman had resolution of the cells of the ectocervix and not the endocervix. The latter patients appeared to be non-compliant with regard to diet and lifestyle changes, suggesting the influence of synergistic effects of this multi-modality approach.
Comment: That dose of beta carotene is 60 times the RDA, and The Medical Letter says no one should take high-dose beta carotene. The addition of homeopathic remedies to the protocol speaks volumes about the author; it does not inspire confidence. This was a very small uncontrolled preliminary study with only 7 subjects, and the results were not promising. The success rate of 4 out of 7 is far inferior to the 85-90% success rate with conventional treatment. And then they have the gall to blame the treatment failures on the patients for non-compliance with peripheral recommendations that were highly unlikely to have affected the study results. They say it suggests the influence of synergistic effects of their multi-modality approach. No, it doesn’t. It suggests that the escharotic treatment is less effective than LEEP or cone biopsy.
Second study:
A follow-up study was performed by the same group on 43 cases, including cervical atypia (n=7), cervical dysplasia (n=26), and carcinoma in situ (n=10) during the following two years. A similar protocol was used, with the addition of 10 mg folic acid daily. The results of the study were encouraging as 38 of the women had complete regression to normal, while three of the women had partial regression and two had persistent lesions. The two women with persistent lesions had lowgrade dysplasia. These studies yield promising results, suggesting the need for a multi-faceted approach to preventing cervical cancer. Table 3 summarizes the escharotic treatment.
You can read the details of Table 3 here. It describes the protocol for applying bromelain and washing it off with a solution of Calendula succus, then applying a zinc/bloodroot mixture, and washing that off. Finally, two vaginal suppositories of vitamin A are left in the vagina for 24 hours.
Comment: This study mixed in cases of atypia, dysplasia, and carcinoma in situ, and without access to the study, we can’t determine the success rate for the various diagnoses. What if the seven cases of atypia were all in the group that had complete regression to normal? What if they were all mild cases of atypia that would have resolved spontaneously without any treatment? While larger than the first study, it is still small and preliminary, and there is no control group, so we have no way of knowing if it is less, more, or as effective as conventional treatments like LEEP. I am left wondering why they chose to add folic acid, and why they used such a large dose, a whopping 25,000 times the RDA, a level that has been shown to increase the risk of cancer and heart problems. One of the instructions, “avoid contact of the zinc/sanguinaria mixture with the vaginal wall,” is a tacit acknowledgement that it does damage normal cells, contradicting their claim that it only affects the abnormal cells.
I found the same description of these two studies almost exactly word-for-word on a naturopath’s website, making me wonder whether the naturopath had read the studies herself or merely copied the description from the review article.
Bloodroot and black salve
Bloodroot is one of the main ingredients in black salve, a dangerous topical quack treatment for cancer. In the form of Cansema, black salve containing zinc chloride, bloodroot and other ingredients has been banned by the FDA for use as a cancer cure. But it is still readily available online.
Steven Barrett says “The idea that bloodroot kills only cancer cells and spares normal ones is preposterous.” There is good evidence that bloodroot does damage normal cells. A woman who used it for skin blemishes developed a large eschar on her neck and was left with a scar. Black salve products containing bloodroot are known to cause necrosis of normal tissue along with scarring, granulomatous inflammation, implanted foreign material, reactive stromal atypia, suppuration, and residual cancer. A 2012 review of bloodroot pointed out that it can cause significant tissue destruction, scars, and keloid formation.
Quackwatch warns against using escharotics, and shows a picture of a woman whose naturopath treated her with a black herbal salve for a bump on her nose. It ate away a large part of her face and her nose sloughed off. It took 3 years and 17 plastic surgeries to reconstruct her face. The picture is not pretty; click on the link only if you don’t mind being grossed out.
Andrew Weil used a bloodroot paste to treat skin lesions on his dog and on a friend (neither had biopsies to establish a diagnosis) and thought the results were satisfactory, so he started recommending it. According to Quackwatch, his advice persuaded a woman to use it and it destroyed her nose.
In 2014, a letter in The Medical Journal of Australia reported the case of a 55-year-old man who used a bloodroot-containing black salve on a lesion he suspected might be cancerous. It left an inch-wide hole in his head. There is a picture of the resulting hole here. Viewer discretion advised.
What about bromelain?
The only reference to bromelain and cervical dysplasia in PubMed is that same single case report. Bromelain is a mixture of proteolytic enzymes derived from pineapple; it is used as a meat tenderizer in cooking. It is approved in Europe for the removal of dead and damaged tissue in severe burn wounds. It is not harmless to normal cells: the healthy surrounding skin has to be protected with a sterile paraffin ointment.
Conclusion: Bloodroot is neither safe nor effective
The escharotic treatment of cervical dysplasia is not evidence-based, is not approved by any professional organization, and is used only by a few chiropractors and naturopaths. The claim that it doesn’t harm normal tissue is false: there is clear evidence that both bromelain and bloodroot damage normal cells. Sure, they can kill cancer cells, but as Rose Shapiro pointed out in her book Suckers: How Alternative Medicine Makes Fools of Us All, you can destroy cancer cells in a petri dish with a flamethrower or bleach. I suppose that anything that destroys tissue ought to be effective for cervical dysplasia (sulfuric acid? a cigarette lighter?). I suspect that they have used escharotics very cautiously and have been lucky to avoid adverse effects so far. The effectiveness and safety of escharotic treatment has not been established, and until it has, I think it is irresponsible to offer it as an alternative to evidence-based conventional treatments. There is reason to think it may be less effective than conventional treatments and there is reason to think it may be dangerous.

Cowabunga! Can Cow Therapy Cure Cancer?
A hospital in India offers to cure cancer in 11 days with Ayurveda and cow therapy, giving patients a drink of desi cow milk, yogurt, ghee, urine, and dung. It’s very unlikely that cow therapy can cure cancer; but in another sense, the author of the book Holy Cancer says it “healed” him.
Harriet Hall on July 31, 2018
Link


You have probably heard of urine therapy and pet therapy. You may even have heard of train track therapy. But have you ever heard of cow therapy for cancer? You can read about it in this book: Holy Cancer: How a Cow Saved My Life, by Amit Vaidya.
Vaidya was living in the US when he developed cancer, gastric adenocarcinoma. Chemotherapy put him into remission, but it recurred. Despite more chemotherapy, radiation, and a clinical trial, he had metastases to the lungs, liver, and spine and was given 6 months to live. He returned to India to visit his relatives and to “perhaps have other treatment options”.
Although he got the best conventional cancer treatments, he was open to natural and alternative treatments to help with side effects. He had already tried acupuncture and supplements (neem, tulsi) with some success. Once back in India, he adopted the practice of kunjal kriya, drinking a quart and a half of warm water in the morning on an empty stomach and vomiting it all out. He says, “The science behind the act was to remove all the old mucus and waste from the bottom of the stomach to cleanse the stomach, esophagus, and lungs.” He thought it was helping.
A relative showed him an article about a cancer hospital that claimed to cure cancer in 11 days with Ayurveda and “cowpathy” for one rupee (equivalent to less than 2 cents). It was the Laxmiprasad Cancer Hospital, a Jain institution. Patients were required to bring their own caregiver, but Vaidya managed to get around that requirement.
The hospital kept desi cows, an Indian variety, on its grounds. The main component of cow therapy was Panchgavya, a drink composed of five ingredients:
     1.  Desi cow milk
     2.  Desi cow yogurt
     3.  Desi cow ghee
     4.  Desi cow urine
     5.  Desi cow dung
After drinking this in the morning and struggling to keep it down, he was given 12 Ayurvedic pills and two syrup solutions. The Panchgavya drink was repeated in the afternoon. At mid-morning he was given a drink with neem, holy basil, turmeric, ginger, and cinnamon, along with other undisclosed ingredients.
The hospital provided a strict Jain diet, vegetarian with no root vegetables such as potatoes, garlic, and onions. The food was organic, macrobiotic and gluten-free; only seasonal fruits were permitted. He thought he detected the smell of medicine mixed into the food.
Twice daily, he coated all his tumor areas with fresh cow dung and stood in the sun until it dried. There was meditation, spiritual instruction, yoga, breathing exercises, assemblies with singing, and medicated massage. A staff member offered additional office hours for energy healing, one-on-one meditation, crystal therapy, and conversational spiritual counselling. The final treatment of the day was a glass of desi cow milk with ghee. The day’s activities and treatments were regulated with military precision.
Patients were encouraged to purchase coupons for food to feed the cows. The personal interaction with cows was said to provide blessings. When a cow licked his palm, the previously numb palm “felt alive again.” He really liked the cows and felt a connection to them.
He developed relationships with other patients and felt a sense of comfort and love. There were no side effects except that some patients developed diarrhea. After the 11-day course, he felt some improvement in his neuropathy and he had more energy. He went back for a second 11-day course.
After the hospital stay, patients were encouraged to stay in the area and continue the treatment on their own for two years. He ended up moving into a rudimentary shack in a tiny village where he had access to desi cows and where the community embraced him and became his family. They gave him far more love and support than his own relatives had. He had been very overweight, but on the restricted diet he lost all the excess weight. His level of physical activity increased to where he was jogging regularly. He visited the desi cows daily; he massaged them and talked to them, one in particular. He kept in touch with patients he had met in the hospital; most of them died. He continued to get scans to monitor his metastases: some of them vanished and other shrank.
Eventually he left the village and returned to a big city, where he found “an organic path of sharing knowledge and becoming a fulltime wellness empowerer“. He founded the Healing Vaidya Foundation. He doesn’t recommend any specific treatment to others, but encourages them to find their own path. He says, “I’m alive because of faith, routine, discipline, humanity money, chemotherapy, cow therapy, radiation, friends, family, strangers, villages, cows…the list is endless”.
What really happened?
He doesn’t provide enough medical details to understand the course of his cancer. He doesn’t claim that the cows cured him, and there are other possible explanations. Early in the book he mentions taking cancer medications every three weeks and continuing to take a trial drug that he was committed to for life. It’s not clear when he stopped those drugs. It would be fascinating to read a detailed case history from his American oncologists and to hear what they thought. Was the regression of his metastases spontaneous? Was it due to the earlier chemotherapy and the clinical trial? Was his sense of wellbeing largely due to his diet, exercise, and weight loss? There is no way to know. It seems very unlikely that the cows had any direct therapeutic effect. The hospital’s promise to cure cancer is clearly false, since most of its patients died.
We can laugh and/or learn
Some of the things he tried were laugh-out-loud funny. Imagine a hospital that makes patients drink cow dung and coat themselves with it in the belief that it will cure cancer! What will alternative medicine come up with next? We can laugh at the treatments, but we mustn’t laugh at the patients. They were grasping at the last straw of hope. They were desperate and vulnerable and believed that the “experts” at the hospital knew what they were doing.
The subject cries out for cow jokes and puns. Calf you heifer herd such udder bull? What do you call a cow who has recently lost a lot of weight? De-calf-inated.
We can laugh at the silliness, but we can also learn much from Vaidya’s experience. His story is not about cows curing cancer. It is:
…a memoir about a journey of letting go, finding peace, facing realities and developing the grace to accept love, whoever it comes from. The book is about my discovery of an organic way of life in which treatment becomes secondary to a continuous process of healing in a physical as well as emotional sense.
He says,
As much as desi cows were integral to saving my life, so too was the land, the trees, the plants, the soil, the air, the water and the entire eco-system that relies on this preservation. There were people too who I met along this journey. And it was my own discovery of who I am and who I can be in engaging with these varieties in nature and not limited to a hospital or a doctor.
Conclusion: Wisdom, not cows
Conventional oncology has three main goals:
     1.  Eliminate cancer
     2.  Prevent recurrence
     3.  Manage symptoms
Sometimes we lose sight of another important goal: to maximize quality of life. It makes sense to think in terms of health, rather than just to fixate on disease. Vaidya doesn’t claim cows cured his cancer; he says they saved his life in quite another sense. They helped him re-orient his thinking, adopt a healthier life style, and appreciate life. There is a kind of healing that doesn’t involve curing the disease.
Vaidya’s mother taught him:
…no matter what adversity we face in life, end the day living it to the fullest, going to sleep at night thankful for that day and literally being at peace if that were to be the last day of my life.
There is wisdom in those words.

Cantron: A tale of false hope for cancer
David Gorski on June 18, 2012
Link
A couple of months ago, a reader sent me an article that really disturbed me. In fact, I had originally been planning to write about it not long after I received it. It is, as you might imagine given my specialty and what disturbs me the most wehen I encounter quackery, a story of a cancer patient. Worse, it’s the story of a cancer patient in my neck of the woods. True, it’s not in the same country, but my cancer center is only around two or three miles from the Detroit River and the Canadian border; so it’s plenty close enough. Too close, in fact. Reading the story, in fact, I realized that it features a form of cancer quackery that, as far as my searches have been able to tell me, we haven’t covered before here at SBM, which alone makes it worth taking on, even though the story is two months old. The “cure” is called Cantron, and it is deeply rooted right here in my metropolitan area. Not only that, its siren song and false promises are attracting patients from across the boarder in Canada. Bernie Mulligan is one such patient:
To Bernie Mulligan, chemotherapy is just a temporary setback.
The 45-year-old carpenter at the University of Windsor refused all traditional treatments for his terminal stomach cancer for about two months, until complications from an expanding liver landed him in the hospital.
On Monday, he reluctantly started chemotherapy for the first time.
Doctors say Mulligan will be lucky if he lives another two months, but he said he’s not worried. He just needs the chemotherapy to shrink his liver to the point where he can get back to the real cure, he said — a supplement in a rainbow-coloured bottle called Cantron.
“That’s the stuff that’s going to cure me. This stuff is not a cure, chemo’s not a cure,” he said. “When I got rushed into the hospital two weeks ago, yes, I thought I was done. But now I’m confident.”
Mulligan is one of many Windsor cancer patients who have crossed the border over the years to attend meetings of an organization based out of Warren, Mich., that promotes Cantron as a miracle cure.
Stomach cancer is, generally speaking, a bad actor. It’s the sort of tumor that’s hard enough to treat even when it’s localized to the stomach, but when it’s metastasized to the liver, as it has in Mr. Mulligan’s case, it’s incurable.
According to a video on the Windsor Star website, back in February Mulligan had been experiencing pains in his upper abdomen. He thought it was a “stomach bug” and was going to see his family doctor that very day when he started vomiting blood and ended up in the emergency room. At the time, it was found that he had numerous metastases in his liver. Ultimately the primary cancer was located and turned out to be what sounds to me like an upper stomach cancer or a cancer at the gastroesophageal junction, which, if true, is more esophageal cancer than gastric cancer. Be that as it may, esophageal cancer is a bad actor, too.
It’s a horrible thing when a man this young is faced with a terminal cancer diagnosis, and that’s exactly what Mulligan was facing. However, if there’s one thing I always try to emphasize, it’s that “incurable” does not mean “not treatable.” If there’s one area of cancer care that’s advanced enormously over the last 20 or 30 years, it’s palliative care. Even though palliative care is not designed to prolong life but rather to relieve symptoms, there is evidence that good palliative care results in prolongation of life. Of course, I realize that telling a 45-year-old man, who probably expected to live another 35 or 40 years, that we have good palliative care is not a message that is likely to be satisfying. We all want to live!
Enter the cancer quacks
Although it is the ethical and science-based thing to do to provide an honest assessment of prognosis based on the patient’s presentation and what we know from science, unfortunately, there are plenty of “alternative” medicine practitioners out there who are more than happy to give a message of hope when there is little or no hope. Such a message causes a lot of harm, such as leading the patient to waste huge amounts of money to the point where he might bankrupt his family and leave nothing left for them after he’s gone, causing unnecessary pain and complications, and, to put it bluntly, deceiving the patient with false hope. Of course, some patients are more susceptible to false hope than others, and Mulligan appears to be one of those patients. In his video, he talks about eschewing conventional therapy and going for homeopathic remedies before discovering Cantron.
But what is Cantron? The same basic formula has appeared under a wide variety of names, such as Sheridan’s Formula, Jim’s Juice, JS–114, JS–101, 126–F, Crocinic Acid, and, of course, Entelev, Protocel, and Cantron. The version of the magic cancer cure being used by Bernie Mulligan is sold by a company called Medical Research Products. It comes in bottles festooned with happy, cheerful colors, and its sales pitch runs like this:
Cantron® is an amazing bio-electrical wellness formulation. It provides astonishing health benefits like no other substance on Earth. It is the world’s most potent antioxidant and scavenger of abnormal proteins which accumulate in the blood, tissues, organs and joints. Cantron is known to dramatically aid the body’s own natural defenses. Since 1984, it has received rave reviews from those who have taken it. One customer summed it up perfectly on an Internet chat site when she emphatically stated: “How blessed we are to know about Cantron.”
I’ll be the judge of that. Notice the pure snake oil-style appeal mixed with what I like to call science word salad. “Bio-electric wellness formulation”? It’s a meaningless term. “Scavenger of abnormal proteins”? Highly unlikely. “Dramatically aid the body’s own natural defenses”? That’s just another way of phrasing the quack’s favorite meaninglessly vague claim that his nostrum “boosts the immune system.” Then, of course, there is the appeal to testimonial, wherein no science is presented but instead we’re told how much people like the product and how much good it’s allegedly done for people.
But what is Cantron? It turns out that there are several products that are very similar to Cantron. The original was Entelev, later rebranded as CanCell, which, as described in the article and on various web pages and articles as having first been conceived and compounded in the 1936 by a chemist working for the Dow Chemical Company named James V. Sheridan, who first called his concoction Entelev. Why did he choose that name? In an interview, Sheridan once said that the idea came to him in a dream that he believed to be inspired by God, explaining many years later that the name Entelev came from “entelechy” (that part of the living process known only to God) and “ev” (which came from the word “electrovalent”), the latter being added so that the name would have something for everyone. Another version of the tale, told by a believer, can be found here.
According to the company website, Sheridan apparently did some animal studies in the late 1940s (one wonders why it took him 10 or 12 years to go from making up his concoction to doing animal studies), but there is precious little objective evidence from parties not selling the compound that he ever did anything of the sort. It’s also claimed that he attempted to do clinical trials while working at the Michigan Cancer Institute back in the 1950s. That claim actually raised an eyebrow, because, being in Michigan, I had never heard of the Michigan Cancer Institute. However, it sounded suspiciously like the Michigan Cancer Foundation, which was the precursor institution to the cancer institute where I work! There is currently a Michigan Cancer Institute. However, it doesn’t appear to be a research-based institution but rather part of a private hospital. As is so often the case in stories like this, the history just doesn’t add up. It sounds very fishy. Although I can’t be sure that such an institute never existed, there now appears to be no such thing as the Michigan Cancer Institute, at least not in a form where one could investigate an agent like CanCell; so the story slides, sounding credible to most people. It’s noted in this article that Sheridan was fired from his job at the Detroit Institute for Cancer Research, which was actually one of the institutions that merged to form the Michigan Cancer Foundation in 1966, but there’s still no Michigan Cancer Institute. My guess is that somehow, in the retelling of the story over the years the Detroit Institute for Cancer Research somehow morphed into the “Michigan Cancer Institute.” On the other hand, in this story, told by someone who became Dr. Sheridan’s partner in the 1980s, Dr. Sheridan did work at the Michigan Cancer Foundation before it merged with the Detroit Institute for Cancer Research. In any case, if it is true that the Detroit Institute for Cancer Research or the Michigan Cancer Foundation fired Sheridan, back in the 1950s, it sure makes me feel better about one of the precursor institutions to the precursor institution to my cancer institute.
Be that as it may, according to the company website the next phase of the story occurred in the late 1950s through the 1960s, when, it is claimed, Sheridan was working for Battelle Laboratories, he did more work on his treatment. I don’t have direct knowledge that can help me evaluate this claim (although I do find it curious that so little is revealed about what Sheridan was doing , but I did do a PubMed search for James V. Sheridan and failed to find any publications by him at all. Given that he continued to work on Entelev at least into the 1980s, if he had published anything in the peer-reviewed literature it should be locatable on PubMed. It’s not. Then, from 1974 to 1983, Sheridan reportedly gave the formula away free of charge to over 1,000 people. In any case, the only evidence out there that I could find that Sheridan ever tried to do clinical trials is the existence of an application for investigational new drug (IND) status for CanCell (IND #20258) from 1982, which was not granted because the FDA asked for more information but didn’t get it. Specifically, the FDA asked for the chemical formulation (which is proprietary and has not been revealed by Sheridan or any others making the compound) and animal studies demonstrating activity against cancer, which are pretty basic bits of information required for all INDs.
Then, in 1984, a man named Edward J. Sopcak acquired the formula for Entelev. How this came about is somewhat unclear, but we do know that in 1984 the FDA issued an order to cease and desist distributing Entelev to patients. Whether that happened before or after Sopcak acquired the formula is unclear. The company claims it was before, because Sheridan realized the jig was up and that the FDA was going to shut him down; so he wanted to get the formula out to others. (Obviously, that’s not how they put it.) Particularly revealing, albeit no doubt unintentionally so, is this tidbid on the Medical Research Products website describing Sheridan, in which he is described thusly, “Jim also had no tolerance for complying with rigid manufacturing procedures that the FDA demanded.” No doubt, given that at that time he was manufacturing his product in his house, as documented in a famous Detroit Monthly article in 1984, Hope on a Hot Plate (the title was based on the way Sheridan cooked up Entelev on a hot plate in his pantry), and in another incident was observed to be carrying out pH testing in his kitchen while his wife was cooking chicken for dinner.
In any case, Sheridan apparently teamed up with a history teacher from Plymouth, MI named Don Wilson who became a “missionary” for Sheridan; Orville “Orz” Feather, a chemical engineer; and, of course, Ed Sopcak. Thus was CanCell born; it was basically Entelev renamed. By 1989, the FDA asked for and received a permanent injunction against Sheridan and Sopcak prohibiting them from introducing their compound into interstate commerce on the basis that they were adulterated, misbranded, and unapproved new drugs. For several years, this seems not to have stopped Sopcak, who superseded Sheridan as the primary promoter of CanCell, from distributing it under the names Protocel and Entelev. Ultimately, in the 1990s, Sopcak and Sheridan complied, but that didn’t stop other companies from making the same or similar products.
Cantron: False hope
So what are Cantron, Entelev, Protocel, and the plethora of products based on Jim Sheridan’s original “juice”? Finding that out isn’t exactly easy because the formula has been proprietary. Moreover, the purported explanations of how it supposedly works are, to put it kindly, a moving target. However, there are several explanations in common that resemble to some extent the paragraph I cited above. For instance, the Alternative Cancer Treatments Comparison and Testing website, which has a wonderfully catty criticism of Protocel relative to Cantron, which is, according to the website, so much better than Protocel, even though the unwashed masses buy more Protocel because they “mistakenly believe that the Protocel formula is controlled by the developer or his surviving family”:
Both Cantron and Protocel work by reducing the ATP energy (adenosine triphosphate) in each cell of your body. (This is also one of the cancer fighting effects of Paw Paw and Graviola.) Our cells have an electrical potential that effects how the cell processes energy producing substances mostly blood sugar and oxygen from our blood supply…
By reducing this voltage level from 70 to 110 mv to something in the 50 mv region, normal cells can still function. However, cancer and viral cells cannot process energy at this low voltage level and start to starve. The process of starving is a slower process than being poisoned which is why Cancell works slower than chemo and why there was a dramatic reduction in the weight of tumor cells in the two day NCI test of Cancell, but only a small number of dead cells. Had that test run longer, all the tumor cells that showed such dramatic weight reduction would have starved to death. For more on the NCI test, go to the Comments on the NCI Test Summary for Cancell page.
It is always amusing to see such gross ignorance of basic biology. Viruses are not cells. You can’t starve them. They also apparently don’t know that the membrane potential of cells is generally expressed as a negative voltage. I do, however, like the special pleading that the NCI test didn’t measure the right thing, as if the NCI doesn’t know what to measure when testing putative new cancer therapies in vitro and in vivo. Similarly, the part about reducing the resting electrochemical gradient across the cell membrane to the -50 mV range is pure nonsense. The main reason the voltage potential across a cell membrane decreases is either because the cell lacks ATP (which is the source of chemical energy for most cellular reactions, such as the ion pumps that maintain the gradient); something else (a poison, for instance) is inhibiting the ion pumps; or the membrane is leaky, dispersing the ion gradient. In any case, cells have a wide variety of resting potentials, and, in fact, promoters of Cantron get it exactly wrong. In actuality, resting potential corresponds with proliferative potential. Cells with a low proliferative potential tend to have high resting membrane potentials (say, -90 mV), while cells more able to proliferate have a lower resting potential. That includes cancer cells. Of course, it’s more complicated than that in that tumor cells tend to undergo a hyperpolarized phase (higher voltage) while replicating, but the makers of Cantron get the biology all wrong. More differentiated cells tend to have higher resting membrane potential, and lower resting membrane potential tends to be associated with dediffrentiation.
Another claim by Cantron promoters for how it works is Sheridan’s original rationale. In his IND application, he stated that cancer is a protein disease and that there are three kinds of cells: normal, primitive, and cancerous. In a “cancer relationship,” Sheridan argues, cellular proteins become less differentiated than usual and can only replicate cancer proteins. Of course, one notes that in general proteins do not replicate; they are made by transcription and translation of the cell’s DNA, but that didn’t stop Sheridan from claiming that Entelev allowed cancer cells to attain the “primitive state,” which would lead them to self-destruct. This is such utter nonsense from a biological standpoint that it defies reason that a biochemist could believe it, but apparently Sheridan did.
Sopcak’s explanation, on the other hand, was slightly different in that he claimed that cancer cells are mutated anaerobic cells caused by lack of proper diet that causes chemical and electrical damage. His idea of cancer causation is that Progenitor cryptocides becomes active and helps healthy cells respire anaerobically. According to Sopcak, when the cell’s energy needs outstrip the ability of anaerobic metabolism to supply them, the cell mutates and becomes a cancer cell in an irreversible process. One must admit that this sounds a heck of a lot more plausible than Sheridan’s explanation, with its clever co-optation of the Warburg effect and hypotheses that have been around a while about how metabolism can contribute to cancer development. So how does Entelev reverse this process? Here’s where Sopcak goes off the deep end. He claimed that Entelev changed the “vibrational energy and frequency” of cancer cells until they reach the “primitive state” postulated by Sheridan. The cells then autodigest, to be eliminated through the urine, feces, being coughed up, through perspiration, or even through a vaginal discharge. After this happens, cancer cells are replaced by normal cells.
Amusingly, Sopcak has also been quoted as saying that he believes all medicine in the future will ultimately be practiced by adjusting vibrational frequencies. Perhaps that’s why it didn’t take him too long to get into homeopathy. He even made a homeopathic version of CanCell and called it—I kid you not—CanCell, thus causing no end of confusion, particularly because the clear homeopathic version looked very different from the dark-colored original version. In any case, Enteleve/CanCell/Cantron has been promoted as a cure for AIDS, herpes, chronic fatigue syndrome, lupus, endometriosis, Crohn’s disease, fibromyalgia, diabetes, emphysema, scleroderma, Lou Gehrig disease, multiple sclerosis, cystic fibrosis, muscular dystrophy, Parkinson disease, Alzheimer disease, hemophilia, high and low blood pressure, mental illness, and some forms of epilepsy.
And ya might not believe this, little fella, but it’ll cure your asthma, too. (OK, I’ll stop. I know I’ve used that joke two weeks in a row. I just couldn’t help myself, though.) I do note, however, that Cantron, or whatever one wants to call it, has been administered orally, rectally, and topically. If you want the nitty gritty of his pseudoscience, he expounds upon his beliefs and claims for Cantron in detail in this interview from 1996. In this interview, he admits that CanCell is nothing but “very pure water” and claims that it’s a “programmed crystal.” Even more amusingly, from a standpoint of homeopathy, he claims that he removes the memory from these water crystals and imprints the memory he wants. Elsewhere, he describes CanCell as a “vibrational catalyst.” Either way, if Cantron is the same as CanCell, it’s basically water. From the photos on the Medical Research Products website, though, Cantron looks like the dark liquid that Jim Sheridan used to sell as Entelev.
So what’s in Entelev/CanCell/Cantron? Not a lot, actually. In 1989, an FDA review found that it is made up of fairly unremarkable chemicals, including nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, inositol, and catechol. The Cantron website says that it contains copper, sodium, sulfur, postassium, as well as traces of iron, zinc, and bromine. None of what’s in Cantron appears to have any anticancer activity at the levels one might expect in the human body, per the NCI:
In 1990 and 1991, samples of Cancell/Cantron/Protocel were evaluated in NCI’s in vitro 60 Human Tumor Cell Line Screen. The test results are available online. The graphs and the numerical designations for each of the three cancer cell growth criteria (GI50, concentration required for 50% inhibition of cell growth; TGI, concentration required for total inhibition of cell growth; and LC50, concentration required for 50% cell lethality or death) are somewhat complicated, but a technical explanation is provided in the Appendix 3. There is little evidence that any of the constituents of Cancell/Cantron/Protocel would be available in the bloodstream of a patient in significant concentrations after its ingestion. Activity was seen in two-thirds of the cell lines, though at levels that would be roughly 275 times higher than the theoretical maximum concentration achievable in serum. Therefore, the in vitro effects are likely due to nonspecific effects of changes in salt concentration. Furthermore, cells in the NCI Tumor Cell Line Screen are grown in artificial media under conditions that do not truly mimic the in vivo situation in animals or humans, and that results obtained with the screen may not accurately reflect possible effects in humans. To place the findings for Cancell/Cantron/Protocel in perspective any conventional drug exhibiting this low level of in vitro activity in the NCI human cancer cell line screen would normally not be investigated further by NCI.
A dietary supplement?
So how do the manufacturers of Cantron and its many imitators get away with it? How is it that they keep selling it? The answer is easy: Blame the DSHEA of 1994. Cantron, according to Medical Research Products, is a dietary supplement, as explained in these bullet points:
    • Cantron is offered only as a dietary supplement.
    • Medical Research Products makes no claims nor prescribes this product (or any other product) for the cure, prevention or mitigation of any chronic disease.
    • Cantron is not approved by the FDA or endorsed by the AMA for the treatment of any medical condition.
    • The FDA has not evaluated any statements of “health claims” made by MRP.
    • DO NOT IGNORE THE ADVICE OF YOUR PHYSICIAN. Do not use Cantron in lieu of any life saving treatments which have been prescribed by your physician.
    • Cantron is one very important part of a Total Wellness Program where one treats the whole nature of the individual through nutritional supplementation, diet, exercise, meditation, prayer, etc..
    • Cantron may be taken by itself, however, it is the primary product in our ‘Total Wellness Program’, which is a portfolio of synergistic products designed to stimulate the body’s own natural healing processes.
This brings us back to Bernie Mulligan. How on earth is it that Bernie Mulligan can be deceived to believe that Cantron will cure his stage IV esophageal cancer, with his liver packed with metastatic tumor? Certainly Medical Research Products isn’t telling him that. To the company, it’s all just a “supplement” that “promotes wellness naturally.” Jerome Godin even emphasizes that in the article, stating in no uncertain terms that he is very careful to obey the law. He does, however, disingenuously add, “I just make my product and those who believe in it usually promote it on their own.”
People like Andy Johnson:
On April 18, Johnson did what he does on the third Wednesday of every month at noon — went to a hall in Warren, unloaded cardboard boxes full of photocopied pamphlets, books and bottles of Cantron, approached the podium and preached the good news.
And preached. And preached. Johnson, an 82-year-old man with wire-rimmed glasses, a neatly trimmed moustache and a tucked-in yellow golf shirt, spoke for an hour. He paused for half an hour to allow people who believe Cantron cured their cancer to tell their stories before launching back into his speech for another 40 minutes.
And:
Johnson made all the claims the company that produces Cantron can’t, and then some. Cantron cures cancer, he said — along with AIDS, knee problems and the common cold. He jumped up and down to illustrate the part about the knee problems.
So what we have in Andy Johnson is a true believer, and, unfortunately, he has a group, the H.O.P.E. Group, to which he can preach his belief every third Wednesday of the month, promoting misinformation such as this, where he recommends that cancer patients use Cantron with a variety of other supplements, including shark liver oil, Enzyme Formula Tablets, Willard’s Water, and Pancreatin. Even worse, Johnson apparently encourages his group members to avoid science-based treatments. Interestingly, though, Johnson’s online footprint is actually quite small, as though he’s flying under the radar. His group doesn’t appear to have its own website, and it’s hard to find out much about him online.
Be that as it may, what we have here is, in my professional opinion, a cancer quack. That he believes in his quackery makes it even worse, because it probably makes him a more effective salesman. Meanwhile, we have a company doing the old “wink, wink, nudge, nudge,” while Johnson says the things that the law prohibits the company from saying about its product. A nice arrangement, isn’t it? The treatment isn’t cheap, either, its manufacturer’s claims of wanting to make it available to everyone notwithstanding. According to the article, it costs about $500 every 20 days.
Unfortunately, the article, after having revealed this quackery, dilutes its message by in essence adding some apologia for “complementary and alternative” medicine. For instance, the author Claire Brownell writes that it’s difficult for patients to separate science from fiction and hearsay (true) but that the also “won’t necessarily get much help from their doctors, who are usually poorly trained about alternative treatments and often dismissive of the entire concept.” She also notes that the case of Cantron “doesn’t mean all alternative treatments are a scam or useless” and then cites a completely inappropriate example to illustrate her point. That example is an application for clinical trials of a dandelion root extract that apparently showed some activity against leukemia in preclinical models. Again, people, that is not in any way “alternative” or “complementary.” It’s pharmacognosy (i.e., natural products pharmacology), which is an old and productive branch of pharmacology. To equate pharmacognosy to pure quackery like Cantron is an insult to cancer pharmacologists everywhere.
I don’t know whether Mulligan is still alive. The last report I could find about him is dated May 27 and is about his attending the Telus Motorcycle Ride for Dad. The saddest part, however, is that, even after Cantron has clearly failed him to the point where even with his aversion to conventional medicine in general and chemotherapy in particular he agreed to take chemotherapy, Bernie Mulligan still believes. It’s a truly horrible thing for a man in his 40s to see the specter of his end approaching 30 or 40 years too early, to contemplate not living to see his daughters grow up, or to have the joy of seeing grandchildren. It’s entirely understandable that, lacking the scientific background to realize that there is no scientifically plausible reason to think that Cantron will work and no scientific evidence supporting its efficacy against any cancer, a man like Mulligan might grasp at anything that he thinks can save him and participate in fundraisers to raise money for an “experimental” cancer treatment. It’s companies like Medical Research Products, whose owners give no indication of being the least bit troubled by the claims being made for its products by people like Andy Johnson, that are to blame.

“Eliminating cancer” with Traditional Chinese Medicine and other state-sanctioned quackery
State-approved continuing education courses pump a steady stream of fresh pseudoscience into acupuncture and Traditional Chinese Medicine practice. Courses include claims of “eliminating cancer” and “reversing pediatric asthma” as well as anti-vaccination tropes.
Jann Bellamy on October 24, 2019
Link

Via the magic of Legislative Alchemy, state legislatures incorporate pseudoscience into health care practitioner licensing laws, giving chiropractors, naturopathic “doctors”, and acupuncturists free rein to impose their particular paradigms of nonsense on patients. For acupuncturists, that paradigm is control of the body’s putative “energy” (or, “qi”), which allegedly flows via “meridians”, to treat disease by sticking patients with needles at specified (but elusive) “acupuncture points”. Having legalized this magical system of human functioning, the legislatures include a cornucopia of quackery in the practitioner’s toolkit via the authority, for example, to prescribe dietary supplements, Chinese herbs, and homeopathic remedies and to perform gua sha, moxibustion, and cupping.
Acupuncturists are licensed or registered in 47 states and D.C. In some jurisdictions they can also practice what is variously called Traditional Chinese Medicine (TCM), Oriental Medicine, and East Asian Medicine. Their scope of practice can approach that of a medical doctor. While the methods allowed are different (e.g., surgery vs. cupping), the scope – treating any patient of any age with any disease or condition – is similar.
New Mexico, for example, defines acupuncture as
the surgical use of needles inserted into and removed from the body and the use of other devices, modalities and procedures at specific locations on the body for the prevention, cure or correction of any disease, illness, injury, pain or other condition by controlling and regulating the flow and balance of energy and function to restore and maintain health.
[Emphasis added.]
“Oriental medicine” is the use of
all allied techniques of oriental medicine, both traditional and modern, to diagnose, treat and prescribe for the prevention, cure or correction of disease, illness, injury, pain or other physical or mental condition by controlling and regulating the flow and balance of energy, form and function to restore and maintain health.
[Emphasis added.]
“Doctors of Oriental Medicine” in New Mexico are allowed to call themselves physicians and practice primary care.
Acupuncture regulatory boards add even more pseudoscience (and additional income streams) to the mix via their rules and regulations. The Florida Board of Acupuncture allows acupuncturists to use Kirlian photography as a diagnostic method. The Arkansas Board of Acupuncture permits the use of bleeding.
But wait, there’s more! Perhaps underappreciated in its perniciousness, these regulatory boards (operating under the fiction that they are protecting the public’s health by requiring practitioners to remain up-to-date in their field) approve continuing education courses that pump a steady stream of fresh pseudoscience into the system. Freed from the strictures of actual science, courses can offer their own permutations of pseudoscience for practitioners to foist on their patients. (Unfortunately, “integrative medicine” practitioners do the same thing.) Today, we’ll take a look at some of these courses and see how, once again, the states are serving as handmaidens to the quackery industry.
The National Certification Commission on Acupuncture and Oriental Medicine (NCCAOM), a private agency organized and run by acupuncturists and TCM practitioners, creates and administers exams required in 46 jurisdictions to become licensed. It also approves courses accepted for continuing education credit by many states. Some merely fleece the gullible; others are downright dangerous. (Actual course names [with link] are followed by a brief description of the course.)
Stroke, cancer, and other serious conditions
10,000 needles: The Future of Stroke Rehab Using Nanopuncture: Teaches post-stroke rehab for paralysis, a “highly effective system” that can “produce drastic improvements” in post-stroke patients. Claims acupuncture is “highly effective” for treating post-stroke sequelae.
The TCM Treatment of Post Stroke, Apoplexia & Paraplegia: “Covers the classifications, diagnosis, and treatment plans via TCM; with the most commonly used acupuncture points and herbal formulas.”
Advanced Chinese Medical Oncology: Treating cancer patients with Traditional Chinese Medicine, including learning to make early diagnosis and using “Shen Xiang Wen Tong Therapy to recall the lost immunity and restore the homeostasis, eventually eliminating cancer.”
A Case Study Analysis: Lung Cancer Symptoms to Brain Tumor: A “renowned pulse diagnostician . . . shares how to treat symptoms of lung cancer and a brain tumor . . . what the pulse can reveal and what are the most appropriate herbal formulas to treat the symptoms.” [Link added.]
Acupuncture Technique for Cancer Care: Teaches how to treat nose and throat cancer with acupuncture point prescriptions for each of three types of diagnosis: “A. Heat pathogen invades Lung, B. Liver depression with phlegm congestion, and C. Blood stagnation interrupts the channels.”
Acupuncture for Parkinson’s Disease and Dementia: “Skillful acupuncture approaches to the treatment of Alzheimer’s Disease and Parkinson’s Disease.”
Clinical Orthopedic Strategies: Arthritis and Bi Syndrome: “Designed to give the practicing acupuncturist a working knowledge of various forms of arthritis, including how to make a differential diagnosis using physical exam, laboratory and x-ray.” [For an “explanation” of Bi Syndrome see here.]
A Complete Course of Treating Diabetes Mellitus by Acupuncturists – Part I: “An effective TCM way to treat diabetes mellitus – the ear magnet therapy is introduced. . . Related health conditions such as ear magnet treat food craving, weight lose [sic], insomnia, nausea, etc. are presented.”
Heart Disease Prevention and Treatment: Using Traditional Chinese medicine to recognize, diagnose, and treat the conditions of chest pain, arrhythmias, hyperlipidemia, hypertension, coronary artery disease, and heart failure.
Treating lupus and infections using Tung points and nutrition: Acupuncture point prescriptions and TCM herbal remedies for treating lupus.
Dr. Tan’s Balance Method for Traumas and Sports Injuries: Learn “the five systems of the Balance Method to uncover the magic healing power of acupuncture for all types of traumas and sports injuries.”
Modern and Classical Chinese Medicine Approach to Multiple Sclerosis: “Important treatment protocols effective for MS using some body and scalp acupuncture, moxibustion and herbal medicine.”
Cholesterol, Asthma, Depression, and More! Drugs and Their Herbal Alternatives: Discussed “Western medications for cholesterol, asthma, and depression, their actions, side effects and herbal alternatives.”
Allergies, IBS, and Chronic Infection: Acupuncture, Hara, and Herbs – Part I: Based on “extensive clinical research and time-tested protocols” learn “to easily find effective distal points for internal conditions relating to the Lung and Heart such as the common cold, allergies, nasal issues, palpitations, anxiety, and insomnia.”
Treating HIV and AIDS with Western and Oriental Medicine: Learn to “identify the western and TCM diagnosis for HIV and AIDS and its chief clinical manifestations. Both western and TCM treatments for HIV and AIDS, common side-effects associated with prescription drug treatments, and an herbal alternative treatment.”
Cardiovascular & Respiratory Disorders: Pulse Dx & Herbal Tx: “Using Master Chang’s unique system of pulse diagnosis techniques, derived from years of clinical experience, you can learn to correctly identify and effectively apply his strategic herbal treatments towards the treatment of cardiovascular and respiratory disorders.”
Pregnancy, women’s health, and pediatrics
Complex diseases of pregnancy: Covers “difficult to treat conditions that many experienced practitioners seem to treat effortlessly” including TCM diagnosis and treatment of “abdominal pain, hypermobility, acute and chronic digestive and urinary complaints, and conditions such as pre-eclampsia.”
Pregnancy Complications: Differential Pulse Diagnosis & Herbal Treatment: Using “unique diagnostic methods” of pulse diagnosis, skin temperature, vital signs and the ears in treatment of pregnancy complications, including “appropriate herbal formulas.”
Pregnancy: Maternity Acupuncture Care: Problem Solving Through Clinical Scenarios: Acupuncture treatment for birth preparation, medical induction, miscarriage, stillbirth, and breech presentation.
Why Treat Children: “Major childhood ailments such as asthma. [sic] allergies and chronic infections can be easily and effectively treated with acupuncture, herbal medicine and diet therapy.”
Effective Immune Support from Pediatrics to Geriatrics and Understanding the Vaccine Myths: “Immunizations are widely touted by conventional medicine and mainstream media as being responsible for eradicating and preventing many infectious diseases. This course will cover the following: Discussions and research reviewing the history and current risks and use of vaccinations; debating mass vaccination and the history of vaccine implementation; vaccine adverse reactions and mortality. The seminar presents objective data on the history, questionable efficacy and inconsistent safety of vaccine programs. It goes on to train clinicians in using safe, effective and practical tools for improving the immune health of their patients.” The course was given by Standard Process of North Carolina, a dietary supplement company that sells through licensed healthcare professionals in N.C. This is not the only course teaching anti-vaccination tropes sponsored by a company affiliated with Standard Process.
The Treatment Of Children Using Classic Formulas: Teaches how to integrate “the type of child with the type of illness.” For example, “which type of child with allergic purpura will respond well to Xiao Chai Hu Tang, Ban Xiao Hou Po Tang, Ma Xing Shi Gan Tang or Xiao Jian Zhong Tang”, all of which can be used to treat this illness based on “differentiating the type of child.”
Acupuncture Manipulation and Scalp Needling for Pediatric Autism: “The most important and most difficult technique in all manipulations is Heat-producing Needling and Coldness due to Heaven-penetrating. . . . This unique acupuncture method is widely used in medicinal diseases. Although the operation is difficult, as long as you master the key points and practice more, you can still master it.”
Advanced Pediatrics: Childhood Eczema & Dermatology: Teaches the etiology and pathogenesis of eczema from the Oriental perspective and the “importance of the Spleen, Lungs and Kidney in the progression of eczema.” Looks at “the conventional methods of treatment and the harm they do in the long term”. Covers TCM patterns of differentiation, acupuncture point prescriptions, sho-ni-shin protocol and herbal formulas with modifications for acute and chronic eczema.” [Sho-ni-shin is apparently a panacea for pediatric illnesses.]
Advanced Pediatric & Sho-ni-shin: Behavioral Disorders: Covers “a wide range of children’s behavioral disorders, from hyperactivity, Attention Deficit Disorder and autism as well as anxiety, insomnia and night terrors.” In-depth treatment protocols with acupuncture, Sho-ni-shin techniques and herbal medicine. “On Sunday afternoon I will demonstrate on live children.”
Chinese Medicine Pediatrics and Ear Infections: Covers diagnostics, treatment principles, acupuncture point prescriptions, herbal formulas, moxa techniques, shoni-shin techniques and dietetics recommendations for pediatric ear infections-otitis media. “Learn how to diagnose and treat pediatric ear infections by downloading the course material, taking an online quiz and receiving a certificate of completion.”
Reversing Pediatric Asthma with Chinese Medicine: “Helps practitioners who aren’t sure how to treat pediatric asthma, learn the step-by-step process for using Chinese medicine to address acute asthma symptoms for immediate relief” and “to create and implement long term treatment plans to reverse asthma symptoms altogether.”
Chinese Medicine Pediatrics and Gynecology: “Chinese Medicine pediatric and gynecologic case histories. Learn treatments for life-threatening illnesses to newborn babies, complications after labor and delivery, irregular menstruation, infectious diseases and chronic gynecological and pediatric conditions.”
Advanced Gynecology: Treatment of many common gynecological conditions “as per the Chengdu University of TCM and the extensive clinical experiences of” the instructor. Includes “irregular cycles, dysmenorrhea, amenorrhea, menorrhagia, metrorrhagia, PCOS (polycystic ovaries and syndrome), Leiomyomas (fibroids), Bartholins cysts, dermoid cysts / teratoma’s, endometriosis and adenomyosis, P.I.D. (Pelvic Inflammatory Disease), vulvovaginitis, HPV and granuloma, HSV (genital Herpes), vaginismus, vaginal dryness, vaginal discharges and infections (parasitic, bacterial, viral and fungal), and UTI’s.”
Integrative quackery
(Like integrative medicine, but without the real medicine part.)
First Aid Homeopathy: ‘First Aid Homeopathic Remedies for acute and or emergency situations. . . Includes a chart with easy to understand diagram and useful remedies.”
Introduction to Drainage Homeopathy: “Both Chinese Medicine and Homeopathy rely on the bodies [sic] natural healing ability. . . .The Unda drops are unique homeopathic formulations which are based on strongly stimulating the bodies [sic] ability to free itself from the heaviness of both mental and physical toxins allowing the body to follow the natural course of healing itself.”
Acu-point Injection Part IV: Herbs & Homeopathy: For certification in “acu-point injection”. Class covers “herbal injectable preparations” for “specific maladies” and homeopathy. Includes “hands on practice.”
CranioSacral Therapy for Pediatrics: “How to work with the special issues that surround the application of CranioSacral Therapy and SomatoEmotional Release as they relate to infants and children.” [Link added.]
Mending the Mind: Using Nutrition, Herbs and Lifestyle to Reawaken the Brain from Dementia: “Learn how to recognize and address the root causes of dementia from a nutritional, herbal and functional medicine approach.” [Link added.]
Functional Medicine: GI, Thyroid & Adrenal Assessment: “Utilizing Functional Medicine to optimize health using patient symptoms as a guide to the underlying cause of specific conditions. Healthcare professionals will learn more about autoimmunity, leaky gut and how to address symptoms and conditions with diet and nutrients, as well as specific testing that should be done.” Course was presented by a dietary supplement company.
Essential Oils for Colds, Flu, Viral & Bacterial Infection: “Discover how essential oils have been used safely and with proven efficacy for herpes virus, shingles, MRSA and other viral and bacterial infections. The antimicrobial action (antibacterial, antifungal, and antiviral) of essential oils is one of their most effective properties.” Course given by Bastyr University.
Adrenal Fatigue: “In terms of TCM, exhaustion of mingmen fire will affect production and distribution of qi and blood, and negatively impact stomach fire and heart yang.” Diagnosis with lab saliva testing, various Oriental medicine approaches to diagnosis and differentiation, therapeutic use of Chinese herbal products and formulas, and Chinese and Japanese acupuncture approaches. [“Adrenal fatigue” is explained here.]
Endocrine Mastery: Optimizing Thyroid, Adrenal and Blood Sugar: “The combined, cumulative and negative effects of chemical toxicity, over medication, radiation exposure, vaccinations, and genetically-modified foods are devastating. Endocrine-related conditions are spreading at an alarming rate, and include diabetes and pre-diabetes (#1), hypothyroid (#2), adrenal fatigue, obesity, cardiovascular disease, infertility, insulin resistance and metabolic syndrome.”
Reversing Thyroid Conditions and Brain Inflammation with Acupuncture and Stem Cells: “Confidently assess clinical and sub- clinical inflammation in patients who present with thyroid and brain conditions [and] . . . learn treatment protocols to address the cause of the inflammation using acupuncture techniques and stem cells.”
Aesthetics and more nonsense
4 Hour Advanced Cosmetic Acupuncture Video: Learn to “treat and significantly improve aging facial conditions” (e.g., wrinkles, skin sagging), general health, and overall well-being using cosmetic acupuncture.
Celestial AcuLift – Cosmetic Acupuncture: For a “deeper insight into how and why cosmetic Acupuncture works.” The “first time old and new, traditional Chinese medicine and 5 element are combined in such a way.”
Bodyintuitive: “The language and philosophical understandings of Chinese medicine are woven together with a Western medical view of the mind and body . . . You’ll become fluent in both languages, moving back and forth between what are known as the rarified energies of the body – Qi, Blood, Yin, Yang and Essence – and the latest 21st century scientific understanding of hormonal, structural and biochemical imbalances . . .”
Acupuncture is a theatrical placebo, effective for nothing. Yet acupuncturists and TCM practitioners, with the states’ blessing, are claiming they can treat serious illnesses. Many of their continuing education courses seem to be little more than marketing opportunities for the dietary supplement companies who sponsor them. As well, practitioners are fabricating even more fantasy therapies, slapping the term “acupuncture” or “TCM” on them, and selling them to the public, again with the states’ blessing. They appear to have little sense of professional responsibility or ethics. Without intervention from the state legislatures, this situation will only worsen.
And the states’ response? Expanding their scope of practice.

Presidential candidate Ben Carson: Shilling for Mannatech with his very own alternative cancer cure testimonial?
David Gorski on October 11, 2015
Link


Over the years, mainly at my not-so-super-secret other blog, I’ve frequently made the points that the vast majority of physicians are not scientists and, in fact, that many of them suffer from a severe case of Dunning-Kruger when it comes to science outside of biomedical sciences—or even biomedical sciences outside of their medical field of expertise. The most common science I’ve seen physicians embarrass themselves attacking has generally been evolution, with a disturbingly high number of physicians denying evolution and embracing creationism. Of these, the doctor I wrote about most frequently back in the day was the creationist neurosurgeon Michael Egnor, but with the onset of the 2016 Presidential race there’s been a new creationist neurosurgeon in town with arguably even more ignorant attacks on evolution. I’m referring, of course, to noted neurosurgeon Ben Carson, whose creationist stylings have been so bad that I had to use him as a poster child to demonstrate how the vast majority of physicians are not scientists and all too many of us have an inordinate and unjustified confidence in medicine as a “check on BS.”
Over the last couple of weeks since my post on the second Republican debate, in which Donald Trump spewed antivaccine nonsense and Ben Carson pandered to antivaccine views, even though past statements by him demonstrate that he knows better, unfortunately Carson has continued to spew statements that are nothing but downright embarrassing, be they his statement in the wake of the Oregon mass shooting that it would be better to attack an armed gunman during a mass shooting “because he can’t get us all” (complete with a seeming attitude that those who died were cowardly), his doubling down on that by claiming that if the Jews had been armed maybe things would have turned out differently in the Holocaust (neglecting the fact that Jews did resist), or his many other statements that make me wonder how someone with so little critical thinking skills could get through medical school and a neurosurgery residency to become such a respected surgeon.
While I knew Dr. Carson shows an uncanny lack of critical thinking when it comes to most issues outside of medicine, I had never in general doubted his medical judgment. Oh, sure, I was disturbed and disappointed when during the second Republican debate, instead of repeating his previous full-throated defense of vaccines and school vaccine mandates, he waffled and pandered to the G.O.P. base regarding Trump’s antivaccine views, but I didn’t think that was because he truly thought vaccines cause autism but rather because he was too cowardly to speak out as clearly as he had in the past. I expected behavior like this from Rand Paul, the other physician running for office, but not from Ben Carson, at least not based on his history.
Ben Carson – company shill
Then, last weekend, while I was away at the American College of Surgeons meeting, there was an article in the Wall Street Journal entitled “Ben Carson Has Had Ties to Dietary Supplement Firm That Faced Legal Challenge.” Unfortunately I’m not a WSJ subscriber, so I can’t read the whole article. Fortunately, there’s enough of it excerpted out there in various blogs and other news outlets that I can get the gist of the story and what he said. Actually, you and I can experience everything he said by watching this 2004 YouTube clip of Ben Carson shilling for Mannatech:
The video is 1:19 hr. long, so I admit that I haven’t had time to watch the entire thing; however, most of the relevant statements are in the early part of the video. What I have seen in it is quite disturbing. A bit of background was in order. Over ten years ago, Ben Carson faced prostate cancer at a relatively young age, his early 50s, and he went to an unexpected source for help:
Faced with a prostate-cancer diagnosis more than a decade ago, Ben Carson, the Republican presidential hopeful and retired surgeon, consulted an unusual source: the medical director of a Texas company that sells nutritional supplements made of substances such as larch-tree bark and aloe vera extract.
The company doctor “prescribed a regimen” of supplements, Mr. Carson told its sales associates in a 2004 speech.
The video above is basically an infomercial for Mannatech. The video was taken down from the company’s website, apparently after the WSJ made inquiries about it, but the Internet never forgets, and so the video is still around, allowing me to embed it above.
The prostate cancer cure that wasn’t
According to Carson, a couple of years before his talk, he was diagnosed with prostate cancer. He described himself as an individual who underwent routine medical screenings and annual physicals and had his PSA checked. However, he noticed that when he was in the operating room for long periods of time he became very interested in the clock because, unlike in the past, he couldn’t go many hours without having to go to the bathroom. So he went to see the chief of urology at Johns Hopkins, who thought at first that he had some prostatitis and gave him antibiotics. The symptoms, however, didn’t go away. So the urologist suggested that maybe he had some prostatic hypertrophy and gave him some Flomax, but the symptoms still didn’t resolve. His PSA was checked again, and it was somewhat elevated so a biopsy was recommended. Now, I have to admit, Carson is a very folksy and engaging speaker, particularly the part where he described undergoing his prostate biopsy. I can see why Mannatech would want him to shill for it: A famous neurosurgeon who is a very likable speaker (or at least was, as I don’t find much of Carson’s schtick that likable any more) makes for great PR.
In any case, he related getting the news in the operating room that he had high grade cancer. Now, personally, if I were in the operating room and received news like that, I’m not entirely sure that I could “put it out of my mind” the way Dr. Carson relates, and continue with the operation. On the other hand, that’s what surgeons do; patients must not be abandoned just because of our own personal traumas. Be that as it may, next Carson described getting an MRI and having a copy given to him without a radiologist’s reading. Looking at it, he saw “lesions up and down my spine.”
So how did his association with Mannatech begin? Basically, somehow the news got out that Carson had some sort of cancer, and as a result people started sending him products from all over the world. (Even at that time, Carson was pretty famous.) The father of one of Carson’s patients also apparently heard the news and asked him if he had ever heard of glyconutrients. This recommendation from his patient’s father led Carson to contact Mannatech and a “Dr. Reg,” who I can only assume must have been Dr. “Reg” McDaniel, who was at that time medical director of Mannatech and is now Director of Research at Wellness Quest, LLC, who doesn’t appear to be particularly science-based. Let’s just say that “Dr. Reg” is proud of having been awarded the “Discovery of the Year Award” by the American Naturopathic Medical Association in 1996 for his glyconutrient work and claims and that he’s still selling dubious dietary supplements. In any case, Carson described how Dr. Reg sent him some products and prescribed a regimen. He began to take it, and “within about three weeks my symptoms went away, and I was really quite amazed.” Carson even stated that “I actually toyed with the idea of not having surgery done, because it was recommended that I undergo surgery.”
Let’s stop right there for a second. According to his story, Dr. Carson was diagnosed with high grade prostate cancer. He apparently thought it had metastasized to his spine based on reading his own MRI scan. That’s a terminal diagnosis, although prostate cancer can be fairly indolent and even at stage IV take a long time to kill. Yet, surgery was still being recommended to remove the prostate? Something about this story didn’t quite add up to me, because usually the treatment for metastatic prostate cancer is not surgery, but castration, as most prostate cancers are androgen-dependent. In the old days (back when I was a resident), that would have been surgical castration, but these days chemical castration is the treatment, usually with a drug like Lupron. Castration can often give a long period of palliation before the prostate cancer inevitably becomes androgen-independent and starts growing again. As I listened to Carson’s speech, all I could think was that Carson’s surgeon must have thought that the cancer was still localized and therefore potentially curable. Otherwise, it’s doubtful he would have offered radical prostatectomy, which, even if done laparoscopically, is an operation not without risk and the potential for significant morbidity.
In any case, Carson continued on about how he read up on the “theory behind” Mannatech, the “bolstering of the immune system,” saying “this makes an awful lot of sense,” and thought about whether the cancer could just be controlled. The very fact that Carson thought Mannatech’s “theories” were ones that “made and awful lot of sense” was depressing because, whatever Carson’s shortcomings in critical thinking in non-medical areas, this was the first time I had seen evidence of a similar lack in an actual medicine topic. Indeed, his whole story by this point had turned into an alternative medicine cancer cure testimonial, starring Mannatech, complete with his discovery of the cure and his having actually been cured by surgery rather than the alternative cancer treatment. That’s right. Carson did, fortunately for him, ultimately undergo surgery, making his story in essence no different than that of, for example, Suzanne Somers beating cancer or Chris Wark curing his own cancer, except that he doesn’t credit the alternative medicine supplements for his good fortune as pointedly as they do.
Excuses, excuses, backpedaling, and more excuses
Here’s why he decided not to rely solely on Mannatech:
Then I began to realize that, having a high profile, if I did that, a lot of other people might follow that example too, but they might not be quite as diligent as I was about taking the product, and there might be a lot of needless deaths, and I didn’t feel as though I could have that on my conscience. So I went ahead and had the surgery done.
So let me get this straight. He thought that Mannatech’s product would work but that others would die if they followed his example because they wouldn’t be as awesomely diligent as Dr. Carson at following the regimen? Yes, Dr. Carson’s rationale for undergoing the surgery was, apparently, that he might be able to cure himself with Mannatech’s supplements but others would die because they wouldn’t follow the protocol closely enough. How many times have I discussed this victim-blaming explanation for the failure of alternative cancer cures? More times than I can remember. It’s a common thread in alternative cancer cure advocacy, that if you don’t follow the protocol to the letter it will fail and it will be your fault. So, awesomely selfless guy that Carson was, he underwent major surgery in order to save people from that fate. Or perhaps he didn’t believe quite as strongly as he made it sound in his speech. Probably the latter. No, strike that. Almost certainly the latter. Darth Vader Mannatech would find his lack of faith…disturbing.
Whatever the case, Carson underwent a nerve-sparing prostatectomy, which is designed to spare the nerves responsible for sexual and bladder function whose damage was a common complication of radical prostatectomy, later to discover that the MRI findings in his spine were a congenital abnormality of the bone marrow and not metastatic cancer at all. The cancer was within 1 mm of the capsule of the prostate, but still confined to the prostate, meaning that the surgery was potentially curative. (A urologist pointed out to me that this close margin could well be due more to the aggressiveness of the surgeon in sparing the nerves than the true margin of the tumor.) Given that it’s something like 12 years later and Carson is still alive and kicking, the surgery was just curative. In his talk, Carson attributed his good fortune to prayers more than Mannatech, but he was still basically shilling for Mannatech. In fairness, Carson also pointed out that, although people have told him that it was the glyconutrients that cured him—an odd thing to say, given that he still had cancer in his prostate that was almost to the capsule—he does advocate what might be called “integrative” medicine, at least with respect to Mannatech:
Now some people have concluded that I was cured without surgery and that I was just cured by the glyconutrients. Maybe it would have happened, maybe it would not have. I do not advocate abandoning traditional medical cures that have been shown to work. What I would, however, advocate is using natural products to supplement what’s done by traditional medicine. The two things do not have to be adversarial. In fact, they can be extremely complementary.
Oddly enough, he then said that he was not a Mannatech associate, because he didn’t think that would be appropriate, nor was he a Mannatech spokesman, because he didn’t think that would be appropriate either. Really? He just gave what amounts to a Mannatech cancer cure testimonial to an auditorium full of Mannatech associates! He might not have been an associate, but he was definitely at least an unpaid spokesman. He has also denied knowing anything about Mannatech’s business practices while boasting how “I’ve been taking them [Mannatech supplements] for more than a decade” and how “since I’ve been taking them, I almost never get sick anymore. I used to get sick a lot.” There is, however, this non-denial denial by his own business manager:
“I don’t know that he’s ever had a compensated relationship with Mannatech,” says Armstrong Williams, Carson’s business manager, when asked about those appearances. “All we know is that the Washington Speaker’s Bureau, which booked hundreds of speaking engagements for him through the year, booked these engagements. He had no idea who these people are. They’re booked through the speakers’ bureau. The question should be asked to the Washington Speakers Bureau, when did they have a relationship with Mannatech, because Dr. Carson never had one.” (At Washington Speakers Bureau, Carson is listed as a level-6 speaker, meaning his fee is more than $40,000 per speech.)
Carson even pointed out how he set up a system in his office to direct people asking him about Mannatech to the “right people” and described how he and his wife were still taking Mannatech glyconutrient supplements every day and later said in a promotional video:
The wonderful thing about a company like Mannatech is that they recognize that when God made us, He gave us the right fuel. And that fuel was the right kind of healthy food. You know we live in a society that is very sophisticated, and sometimes we’re not able to achieve the original diet. And we have to alter our diet to fit our lifestyle. Many of the natural things are not included in our diet. Basically what the company is doing is trying to find a way to restore natural diet as a medicine or as a mechanism for maintaining health.
Fast forwarding in time, it turns out that this wasn’t the only time Carson promoted Mannatech. He spoke at Mannatech conferences in 2011 and 2013 and spoke about glyconutrients for a PBS special just last year. His relationship with Mannatech thus went on for at least a decade, apparently only to be severed when he decided he wanted to run for President.
Mannatech is a really dubious company
Before I conclude, it must be emphasized just how dubious Mannatech is. As this National Review article points out:
Mannatech has a long, checkered past, stretching back to its founding more than a decade before Carson began touting the company’s supplements. It was started by businessman Samuel L. Caster in late 1993, mere “months,” the Wall Street Journal later noted, before Congress passed the Dietary Supplement Health and Education Act of 1994, which greatly loosened restrictions on how supplement makers could market their products. Within a few years of its inception, the company was marketing a wide variety of “glyconutrient” products using many of the same tactics previously described in lawsuits against Eagle Shield, Caster’s first company.
In November 2004, the mother of a child with Tay-Sachs disease who died after being treated with Mannatech products filed suit against the company in Los Angeles Superior Court, seeking damages for intentional infliction of emotional distress, negligent misrepresentation, and conspiracy to commit fraud. The suit alleged that the Mannatech sales associate who “treated” the three-year-old had shared naked photos of the boy — provided by his mother as evidence of weight gain, with an understanding that they’d be kept confidential — with hundreds of people at a Mannatech demonstration seminar. The sales associate was further accused of authoring an article, in the Journal of the American Nutraceutical Association in August 1997, explicitly claiming that Mannatech’s supplements had improved the boy’s condition, even though the boy had, by that time, died. The suit also presented evidence that Mannatech was still using photographs of the boy in promotional materials on its website in March 2004, “with the clear inference that [the boy] was alive and doing well some seven years after his actual death.”
I also note that Mannatech’s associates hawk one of its products, Ambrotose, as a near cure-all for everything from cancer to multiple sclerosis to AIDS. It’s even been described as a sham in a journal article. I might have to do a separate post on Mannatech one day, but in the meantime if you doubt the dubious nature of the company and its products, Quackwatch has a resource.
As disturbing as Dr. Carson’s advocacy of pseudoscience like creationism is, I find this revelation about his longstanding relationship with Mannatech to be far more disturbing, striking as it does at the heart of his strength, his reputation as an excellent physician and neurosurgeon. It turns out that Carson’s lack of critical thinking skills goes beyond just evolution, the Big Bang Theory, geology, history, and physics. As great a neurosurgeon as he was, he was so easily persuaded by pseudoscience that he was willing to promote nonsense like Mannatech as a treatment for prostate cancer. This is not a trait I want in a physician or a political leader.

Supplement vendors make unfounded cancer treatment claims
A new analysis shows widespread marketing of natural health products for the prevention or treatment of cancer.
Scott Gavura on March 5, 2020
Link

Fear is a powerful motivator. And few events may be as frightening as a cancer diagnosis. It shouldn’t be surprising that the unscrupulous may try to take advantage of your fear in order to sell you something.
While the specifics vary by country, dietary supplements tend to be subject to weaker regulations than those for prescription and over-the-counter drugs. This includes the claims that can be made about a product. While drugs are subject to very specific marketing requirements, there may be more latitude given to manufacturers of dietary supplements. Even where regulations and requirements for these products exist, they may not be routinely enforced. In the United States, supplement vendors can make “structure/function” claims (e.g., “Helps maintain proper joint function”) but cannot make specific statements (e.g., “Relieves joint pain”). However, regular readers of this blog may recall many products promoted with claims that are not based on any credible evidence, or would be considered to meet regulatory requirements.
Canada has a similar, though not identical approach. Notably, prescription drugs cannot be advertised to the public in Canada, but “natural health products” can be advertised. Health Canada (Canada’s equivalent to the Food and Drug Administration) forbids treatment claims for natural health products for conditions like cancer, but does permit preventative claims, but only if those claims are approved by Health Canada. It’s a narrow window, that, if enforced to a science-based standard, could balance the desire to provide information on products while making sure statements are supported by evidence.
Recently the Canadian science advocacy group Bad Science Watch undertook a review of the online marketing of Canadian natural health products. Specifically, they looked at statements made regarding cancer, and whether or not those claims were appropriate and authorized by Health Canada. The results will not surprise you.
The approach
The overall intent of this survey was to develop and evaluate a methodology towards assessment of whether Canadian online retailers of natural health products were marketing their products in alignment with the authorization provided by Health Canada. The specific condition examined was cancer. Content from Canadian retailers was collected based on the keyword “cancer” (and related terms, like tumor or metastasis) and each statement was examined for accuracy. Both direct and indirect claims were identified:
Direct: e.g., “It is also important in the prevention and treatment of breast and colon cancer.”
Indirect: e.g., “”Bloodroot extracts have also been promoted by some supplement companies as a treatment or cure for cancer.”
The specific websites themselves were identified from a convenience sample from the Canadian Health Food Association Retailer Directory.
Twenty-three trained volunteers evaluated the claims for each page identified. Overall, 31,686 web pages were identified and ultimately 2,324 were screened. (Full methodology is here.) In the end, 558 unique web pages were identified, and this was what was found:
20% (113) of web pages made a direct claim of treatment or cure
30% (166) made an indirect claim of treatment or cure
Only 3 out of the 558 pages had claims that were Health-Canada-approved.
There’s an infographic of all of the results.
What this means
This isn’t the first post to remind you to be skeptical of what you read on the internet. Consumers facing frightening conditions like cancer may be tempted to try these products, despite the lack of evidence to substantiate these claims. As I have blogged before, dietary supplements appear to be, at best, neutral with respect to cancer survival, and there is no indication that they offer advantages or benefits to those that take them. We also know that cancer patients that opt for alternative medicine have higher rates of cancer death than those that use conventional therapies. It’s for these reasons that consumers deserve robust regulation, and enforcement of those regulations, to prevent these forms of opportunistic marketing.

Do dietary supplements affect the survival of cancer patients?
Do dietary supplements offer advantages or risks to breast cancer patients undergoing chemotherapy?
Scott Gavura on January 9, 2020
Link

If you’re a regular reader of this blog, you’ve probably observed that we as a group of contributors tend to be pretty critical of dietary supplements. These concerns include:
    • The manufacturing quality of supplements is inconsistent, meaning consumers can’t trust that what is on the label is actually in the bottle.
    • Marketing claims go well beyond proven science.
    • There is little convincing evidence that most dietary supplements do anything useful or beneficial. Sometimes supplements are adulterated with actual drugs to give them the appearance of efficacy.
For the past several years there has been increasing concern that dietary supplements may not simply be useless, but that taking supplements could actually be harmful. This question is especially pertinent for those undergoing treatment for cancer. Cancer treatment can be debilitating and maintaining good dietary health can be difficult. Vitamin supplements may be viewed as a prudent way of supporting dietary intake. More generally, supplements are routinely promoted as treatments for cancer, and cancer patients may be drawn to products promoted as offering “natural” effectives. But because the mechanism of some cancer chemotherapies is to generate reactive oxygen species, there is concern that supplements such as anti-oxidants may actually reduce the effectiveness of treatment. And given the quality control standards of dietary supplements is questionable, there could be unpredictable and unanticipated interactions with chemotherapies that could have negative effects. As I have written on this topic before, there is a lot we do not understand about the effects of supplements on cancer survival. Now a new paper examines the effect of dietary supplements on survival in breast cancer patients.
What did the researchers set out to answer?
This was called the Diet, Exercise, Lifestyle and Cancer Prognosis (DELCaP) study, and the findings were published in the Journal of Clinical Oncology on December 18, 2019. The lead author is Christine Ambrosone, and the study was funded through a number of grants from government and other organizations, with no industry funding (supplement, pharmaceutical, or otherwise). Because of ongoing concerns about the effects of supplements on the effectiveness of cancer chemotherapy, the investigators set out to prospectively evaluate the relationship between the two.
What approach did they take?
This study ran concurrently with a phase 3 clinical trial (S0221) that studied different breast cancer chemotherapy treatment schedules. 80% of participants in that trial agreed to participate in the DELCaP trial, completing a baseline set of questions which asked about regular (at least 1x/week) use of supplements before beginning chemotherapy. A second survey was sent to participants about 6 months later, as chemotherapy was concluding. Among patients alive and without disease recurrent at that six-month point, patients were followed from that point until death from any cause. The median follow-up was 8.1 years.
Patients were then stratified into four categories and analyzed.
    • YN – took supplements at baseline but not during chemotherapy
    • YY – took supplements at baseline and during chemotherapy
    • NY – no supplements at baseline but taken during chemotherapy
    • NN – no supplements consumed before or during chemotherapy
What types of patients were enrolled?
A total of 1,340 patients completed questionnaire one and 1,134 completed both questionnaires. Participants were female, in their fifties, and predominantly white. Overall there were 251 recurrences and 181 deaths. Patients who experienced recurrence were more likely to be older, postmenopausal, and to have a higher BMI.
The overall prevalence of supplement use, compared to other literature reports, was low:
    • Vitamin C was used by 20.5% of patients before treatment and just 12.2% during treatment.
    • Vitamins E and A were taken by <10% of participants.
    • Antioxidant (Vitamins C, A, E, carotenoids, coenzyme Q10) were taken by 17.5% of participants.
    • In contrast, 44% of patients took multivitamins.
What did the researchers find?
    • Patients who used any antioxidant both before and during treatment were at increased hazard of recurrence. The hazard ratio was 1.41, with a confidence interval of 0.98 to 2.04, meaning it wasn’t statistically significant (P=0.06). There was also a suggestion of a negative effect on the risk of death (HR=1.4, confidence intervals 0.9 to 2.18) which was also not significant. There was no relationship found between antioxidants and these outcomes if taken only before chemotherapy or only during chemotherapy.
    • There were no associations found for the single antioxidants, multivitamins, and vitamin D at any point.
    • Vitamin B12 both before and during treatment was associated with poorer disease free survival (HR 1.95, confidence intervals 1.15 to 2.92) and overall survival (HR 2.04, confidence intervals 1.22 to 3.40).
    • Similar findings were made for iron with respect to disease free survival during treatment (HR 1.79, confidence intervals 1.20 to 2.67) and, non significantly, DFS with use before and during treatment (HR 1.91, confidence intervals 0.98 to 3.70).
    • Use of omega-3 fatty acids before and during treatment were associated with poorer disease-free survival (HR 1.67, confidence intervals 1.12 to 2.49) but no effect on overall survival.
What conclusions can we draw from this study?
Dietary supplements appear to be, at best, neutral with respect to cancer survival, and there is no indication that they offer advantages or benefits to those that take them. While this was a small trial with low levels of supplement use, we have the benefit of a concurrent cancer treatment trial that ensured that all patients received standardized chemotherapy regimens. There is a strong suggestion that some dietary supplements may have a negative impact on disease-free survival and overall survival. Notably, the use of any antioxidant was associated with a 41% increase in the hazard of recurrence in this study (albeit, this was statistically non-significant.) However, there were significant negative findings with B12 and iron. The results of this study should provide additional information to cancer patients and their clinicians when discussing the potential risks and benefit of dietary supplements during the course of cancer chemotherapy.

Medical marijuana as the new herbalism, part 2: Cannabis does not cure cancer
Medical marijuana. It’s promoted as a seeming panacea that can cure whatever ails you. In particular, it’s touted, primarily in the form of cannabis oil extract, as a cure for cancer that “they” don’t want you to know about. While there are potentially useful medicinal compounds in marijuana, in general the medical marijuana movement vastly oversells the promise. While some cannabinoids do have modest antitumor activity in vitro, there is no compelling evidence that cannabis can cure cancer.
David Gorski on August 11, 2014
Link
About a month ago, I finally wrote the post I had been promising to write for months before about medical marijuana. At the time, I also promised that there would be follow-up posts. Like Dug the Dog seeing a squirrel, I kept running into other topics that kept me from revisiting the topic. However, over the past couple of weeks, the New York Times gave me just the little nudge I needed to come back and revisit the topic, first by openly advocating the legalization of marijuana, then by vastly overstating the potential medical benefits of pot (compare the NYT coverage with my post from a month ago), and finally this weekend by running a story lamenting the federal law that makes research into medical marijuana difficult in this country.
I stated my position on marijuana last time, which is that marijuana should be at least decriminalized or, preferably, legalized, taxed, and regulated, just like tobacco and alcohol. I also likened the cult of medical marijuana to the “new herbalism,” because it (1) vastly inflates the potential of medicinal uses of marijuana and (2) ascribes near-mystical powers to smoking or making extracts out of marijuana, rather than identifying and isolating constituents of the plant that might have medicinal value. All of this is very much like herbalism in alternative medicine. Indeed, promoting laws legalizing medicinal marijuana is such an obvious ploy to open the door to full legalization that some advocates don’t even bother to disingenuously deny it any more. Given that I tend to support legalization, as a physician this sort of deception irritates me. It also has consequences, particularly when overblown claims are made for what cannabis can do. Perhaps the best example of this is the claim that cannabis cures cancer, which pops up all over the Internet in memes such as the one in the image above.
Don’t believe me? Just Google “cannabis cures cancer” or “marijuana cures cancer.” To my relief, you’ll find the National Cancer Institute’s page on cannabis and cannabinoids, which, as I discussed last time, dwells more on whether cannabinoids are useful for pain relief, nausea, and cancer cachexia than on whether they can be used to treat cancer directly. However, you’ll also find pages like 20 Medical Studies That Prove Cannabis Can Cure Cancer, a Facebook page Cannabis Cures Cancers!, and articles like Rick Simpson’s Hemp Oil Medicine, which resembles a lot of articles for various alternative medicine and quackery in terms of providing lots of testimonials of cures for skin cancer, diabetic ulcers, and other skin diseases and conspiracy mongering but no hard evidence. Indeed, a commenter by the ‘nym of “Danman” showed up at another blog many of you are familiar with and proceeded to make hilariously bad arguments for the healing power of cannabis and how a post at that blog was a “prohibitionist hit piece,” even though it expressed the opinion that marijuana should be legalized over the course of over 150 comments. Meanwhile, others are recommending hash oil for gliomas with a near-religious fervor, touting the same sort of evidence that Stanislaw Burzynski uses to claim he can cure gliomas with antineoplastons.
So what is the story, really?
Cannabinoids versus cancer: Hype versus science
The first problem one encounters when examining the evidence concerning the effect of cannabinoids on cancer is that the vast majority of studies touted by advocates claiming that “cannabis cures cancer” are either in vitro or animal studies. In vitro and animal studies are what we in the biz call “preclinical data,” meaning data obtained before trying a treatment in the clinic. As the American Cancer Society put it:
More recently, scientists reported that THC and other cannabinoids such as CBD (cannabidiol) slow growth and/or cause death in certain types of cancer cells growing in laboratory dishes. Some animal studies also suggest certain cannabinoids may slow growth and reduce spread of some forms of cancer. However, these substances have not been tested in humans to find out if they can lower cancer risk. There is no available scientific evidence from controlled studies in humans that cannabinoids can cure or treat cancer.
This basically says it all, and it’s tempting to wind up this post right there, but, as Han Solo said after being urged to be quiet while taking out some storm troopers, “Hey, it’s me.” Besides, you, our SBM readers, expect science in addition to my self-absorbed blather, as amusing as it might sometimes be. So you shall have it. As good a place as any to start is, as you might imagine, 20 Medical Studies That Prove Cannabis Can Cure Cancer. After all, I assume that Arjun Walia, the person who put this list together, wanted to provide the very best evidence that could be found, particularly given the emphasis that “this is a short list.” I perused the papers in the list and was—shall we say?—underwhelmed. I’ll divide my discussion into tumor types, the way the list does. First, you have to understand that CBD, one of the cannabinoids found in marijuana, is viewed as particularly promising because it does not produce the same psychotropic effects as Δ9-tetrahydrocannabinol (THC), making it a particularly attractive for developing treatments whose side effects don’t involve being stoned all the time.
Glioma. The first thing that jumped out at me is that one of these papers has nothing to do with cancer, specifically this study that suggested that cannabinoids could protect the brain against neurodegeneration in neonatal rats caused by the toxin ouabain (an Na+/K+-ATPase inhibitor). The vast majority of the other studies were in human cell lines, such as this one studying the effect of cannabidiol, a nonpsychoactive cannabinoid, on glioma cell lines. As a cancer researcher, I noted that the IC50 (the concentration that produces 50% of maximal inhibition of the parameter being measured), was 25 μM, which is a bit higher than we like for an anticancer compound. I was thus not particularly impressed, although in fairness subcutaneous injection of CBD was able to inhibit the growth of glioma xenografts implanted subcutaneously in athymic nude mice, although no dose-response was demonstrated, and a dose of 0.5 mg per mouse is a pretty generous dose (25 mg/kg for a typical 20 g mouse). So while there does appear to be antitumor effect against the glioma cell lines tested, it was, at best, modest. Certainly it wasn’t the sort that would knock my socks off as a cancer researcher. A different study, which combined THC and temozolomide, produced more impressive results, not for the THC, which produced at best modest antitumor effect, but for the combination, which looked a bit more promising. Of course, one also must note that this is not hash oil or smoked pot, but the purified THC component. That THC might be useful against glioma does not tell us that hemp oil or smoking the weed will be useful against glioma any more than the fact that digoxin works in congestive heart failure tells us that it would be a good idea to ingest foxglove leaves.
Skeptical Raptor puts it in perspective:
In one study, the researchers determined that it would take a concentration of cannabinoids of approximately 10 µmol/L to cause the death breast cancer cells in cell culture. This converts to around 3.14mg/L of THC. So, you’d have to assume that to kill any breast cancer cells, you’d need at least a blood level of 3.14 mg/L to achieve breast cancer cell death. So how close to that 3.14 mg/L can we get by just smoking a joint or two? According to research, smoking one joint will give you a blood level of THC of around 1.3-6.4 ng/mL serum, or about .00013-.00064 mg/L. In other words, to get an anti-cancer effect, you need to light up around 1000 joints per day.
The IC50 values in these studies were higher than 10 μM.
Finally, there was one human study in the list of glioma papers. Basically, this was a phase I trial testing a method of administering THC. This was also some strange science in that nine patients with recurrent glioma had their tumors resected, but a catheter was left in the cavity left behind after surgery, and then:
Each day an aliquot of the THC solution (100 mg ml−1 in ethanol) was dissolved in 30 ml of physiological saline solution supplemented with 0.5% (w v−1) human serum albumin, and the resulting solution was filtered and transferred to an opaque syringe. This process was performed at the Department of Pharmacy of the Hospital Universitario de Canarias. Owing to the high hydrophobicity of THC, we controlled by gas chromatography/mass spectrometry (see below) the actual concentration of THC in the final solution. The THC solution was administered to the patients for different times starting at days 3–6 after surgery at a rate of 0.3 ml min−1 with a syringe pump connected to the subcutaneous reservoir. In the case of Patients 1 and 2, who received THC for 30 and 26 days, respectively, biopsies were also taken after the THC-treatment period and various tumour-cell parameters were evaluated.
As you can see, this is very different from smoking marijuana or ingesting hash oil. It involves directly infusing THC solution at a high concentration directly into the brain cavity where the tumor had been, in the hope of killing off any remaining tumor cells surrounding the cavity. Let’s just put it this way. There’s a reason why direct intratumoral injection of any drug is generally frowned upon, and that’s because it’s invasive and rarely works. Moreover, no one generally bothers with intratumoral infusion of a drug unless it requires a very high concentration to work. Mean survival was 24 weeks, and two patients survived approximately a year. The authors try (rather like Stanislaw Burzynski, actually) to argue that this is better than would be expected based on other studies and controls, and to claim that some patients responded. I find no convincing evidence of this in the paper, and in a cohort of nine patients though, it’s pretty darned hard to conclude this. I agree with Harriet. There is nothing “earth shattering” about these results. They could be consistent with an antitumor effect, but they could just as easily be consistent with no effect. Worse, this was not simply ingesting, smoking, or being injected with cannabinoids. The study involved having catheters sticking out of the subjects’s heads and having THC infused directly into the brain.
Breast cancer. I’m a breast cancer surgeon; so I’m going to go out of order here. There are four breast cancer studies listed. The first study examines CBD activity against a mouse breast cancer cell line 4T1 (another cell line I’m quite familiar with, having used it in my lab and because it was a cell line developed by a now retired investigator whom I know), and the breast cancer cell line MDA-MB-231 (which I’m more familiar with than I’d like to be). Basically, the study showed a modest effect against these two cell lines in vitro and in mouse models using 1 mg/kg and 5 mg/kg CBD. The second study looked at five different cannabinoids and found that CBD was the most potent inhibitor of breast cancer cell growth in vitro (IC50 between 6.0 and 10.5 μM) and that CBD and “CBD-rich oil” could inhibit the growth of MDA-MB-231 tumor xenografts. In this study, the effects of THC on cancer cell growth were weak (IC50 between 14.2 and over 25 μM, depending on the cell line). The third study showed similar results for HER2/neu(+) tumor cell lines using THC and specific synthetic agonists (activators) of cannabinoid receptors CB1 and CB2 (Win55,212-2 and JWH-015, which activate CB1 and CB, respectively) except that THC was not as weak. The fourth study didn’t look at marijuana cannabinoids at all, but rather the endogenous cannabinoid anandamine, with similar results.
Lung cancer. The next set of three studies look at lung cancer. The first study used a cell line with which I’m quite familiar, A549 lung cancer cells, using both cell culture and mouse xenograft models. I must say that I was singularly unimpressed with the effect sizes, at least in the in vitro studies, which also required fairly high concentrations (15 μM) of THC. In a mouse tail vein injection model of lung metastases, 5 mg/kg of THC decreased metastases by 50%, which is not bad, and in a straightforward xenograft model resulted in a 50% growth delay of the tumors, which is also not bad. The next study found similar results testing CBD against lung cancer cell lines and tumor cells from a patient in cell culture and mouse models. The third study showed that stimulation of cannabinoid receptors (CB1 and CB2) with synthetic agonists, Win55,212-2 and JWH-015, which activate CB1 and CB2, respectively, inhibited the growth and invasion of A549 lung cancer cells in vitro and their growth and metastases in mouse models.
And so it goes. Nearly all of these studies look at purified cannabinoids, usually either THC or CBD, but sometimes the endogenous cannabinoid anandamine (which isn’t even in marijuana), as with the breast cancer study above and this prostate cancer study. Some use synthetic agonists, such as the breast cancer and lung cancer studies above, or this study of mantle cell lymphoma that tested R(+)-methanandamide in addition to Win55,212-2, or this study of non-Hodgkin’s lymphoma, which also used R(+)-methanandamide. With the exception of the glioma study, all were preclinical studies looking at cell culture models and mouse models. One was a review article. One, as I pointed out above, had nothing to do with cancer, and I suspect the author included it to round up his list of studies to 20.
Unfortunately, it’s a highly intellectually dishonest list of studies if your goal is to provide evidence that “cannabis” (as in the plant or extracts from the plant) can cure cancer. Unfortunately, this is not the first time Arjun Walia has constructed such a list. Last year, Liz Ditz nailed him for constructing a similarly intellectually dishonest list of studies that “show vaccines cause autism.” Let’s just put it this way. In 2013, Walia was still citing some highly discredited studies, such as studies by Mark and David Geier.
The intellectual dishonest of representing this list of studies as evidence that cannabis cures cancer aside, it is a group of moderately interesting papers that suggest that purified cannabinoid receptor agonists can produce reasonable, albeit by no means spectacular, antitumor effects in preclinical models. As a whole, they suggest that some of these purified cannabinoid agonists, whether naturally occurring, such as THC, CBD, or synthetic, such as R(+)-methanandamide, or specific to CB1 or CB2, such as Win55,212-2 and JWH-015, might be worth investigating further. Again, we’re talking about pharmacology, isolating active substances and purifying or chemically modifying them to improve their activity and safety profile, not smoking weed or using hash oil. Cancer Research UK concludes:
But claims that this body of preclinical research is solid “proof” that cannabis or cannabinoids can cure cancer is highly misleading to patients and their families, and builds a false picture of the state of progress in this area.
It’s also noted that the best results in the lab have come from using a combination of highly purified THC and CBD, but that there have also been positive results with synthetic cannabinoids, such as a molecule called JWH-133, just as I’ve described, through mechanisms that include:
Triggering cell death, through a mechanism called apoptosis
Stopping cells from dividing
Preventing new blood vessels from growing into tumors
Reducing the chances of cancer cells spreading through the body, by stopping cells from moving or invading neighbouring tissue
Speeding up the cell’s internal ‘waste disposal machine’ – a process known as autophagy – which can lead to cell death
Unfortunately, as good as that sounds, it’s not all good. There is also evidence that cannabinoids, under some circumstances, can stimulate cancer cell growth and possibly contribute to tumor progression. They can also have different effects depending on dose and the level of cannabinoid receptors on the tumor cells being treated. For instance, this study suggests that cannabinoids only induce apoptosis in cells that express low levels of receptors that couple to a signaling pathway called ERK1/2 but don’t induce apoptosis in cells that have high levels of receptors because they then couple through a survival pathway known as AKT. Interestingly, cannabinoids also seem able to induce cell death through pathways that don’t involve cannabinoid receptors. In other words, it’s complicated, because cancer is complicated, and cancer drugs tend to work only against certain cancers. If cannabinoids do have anticancer effects in humans, it will likely only be against certain cancers, most likely combined with existing chemotherapy and targeted drugs. We also know from the preclinical work that has been done that it will take purified THC and/or CBD and/or synthetic cannabinoid receptor agonists to produce even the modest effects observed thus far, effects that are too modest to expect cannabinoids to be any sort of cure for cancer on their own. Smoking weed or using hash oil just isn’t going to cut it.
But what about the anecdotes?
On that other blog that you all hopefully know and love, one of the commenters, Justin Kander, cited a case report that’s been going around social media as “proof” that cannabis cures cancer. This case report describes a 14-year-old girl, PK, who presented with symptoms of “weakness, shortness of breath and bruising when she was taken to the Hospital for Sick Children, Toronto, Canada, on the 10th March 2006.” She was diagnosed with acute lymphoblastic leukemia (ALL) and underwent standard chemotherapy for ALL for six months. Upon analysis, she was found to be positive for a mutation in the Philadelphia chromosome, which is found in 2-10% of pediatric ALL cases. Philadelphia chromosome-positive ALL tends to have a poorer prognosis than other ALL. PK underwent a bone marrow transplant but was noted to have blast cells six months after treatment and therefore underwent aggressive chemotherapy along with a tyrosine kinase inhibitor. After more recurrences and more treatment (such as radiation therapy to the brain for a presumed, but never completely documented, infiltration of the brain by leukemia, it was stated in the case report:
On the 4th February 2009, blood was noted in the patient’s stools and a blood cell count revealed the presence of blast cells. As a result, all treatment including the disatinib was suspended and the patient’s medical staff acknowledged failure in treating her cancer. It was charted by the patient’s hematologist/oncologist that the patient ‘suffers from terminal malignant disease. She has been treated to the limits of available therapy… no further active intervention will be undertaken’. She was placed in palliative home care and told to prepare for her disease to overwhelm her body and from which she would suffer a stroke within the next 2 months.
The family found articles on how cannabis supposedly cures cancer, and found their way to Rick Simpson, who has been featured in utterly credulous articles in High Times and SF Weekly (the latter of whose editors really should have known better) as the man who can cure cancer with hemp oil, who provided her with hemp oil mixed with honey (because of the bitter taste and viscous nature of hemp oil). This was administered in daily doses. It is claimed in this case report that there was a strong correlation between increasing dose of the hemp oil and decreases in PK’s blast count (a measure of leukemia cells in the blood), but looking at Figures 1, 2, 3, and 4, I have a hard time seeing it. Figure 1 shows increasing doses of hemp oil from what was called the “chronic” strain. That’s the closest we see to decreasing blast counts correlating with hemp oil dose. By day 15, the chronic strain was gone, and PK started taking Hemp Oil #2 from an outside source. In actuality in Figure 2, we see the blast count increasing with increasing dose until day 27, when it starts falling. Figure #3 shows Hemp Oil #3 (Afghan/Thai strain) from days 44 to 49. Given that the blast count stayed the same one can’t say much about this. Then Hemp Oil #4 was tried from day 50 to day 67, and her blast counts started rising. Finally, Hemp Oil #5 was tried and PK’s blast count fell between days 69 and 78. During that time, PK suffered the psychotropic effects of the hemp oil, including euphoria, disoriented memory, and the like.
Unfortunately, PK developed gastrointestinal bleeding and bowel perforation with peritonitis on day 78 and passed away. So, basically, she lived two and a half months after being placed on hospice. The authors assert that a dose-response curve was achieved, but to my eye I really don’t see it, except perhaps at the beginning, nor do I really buy the claim that the bumps in blast counts correlate with using “lower potency” strains. They also assert because PK was treated for tumor lysis syndrome (a syndrome in which the waste products of tumor breakdown, often seen after intense chemotherapy in hematopoietic malignancies, injure organs such as the kidneys), it must mean that the hemp oil was effective.
Unfortunately, even if a mild dose-response effect was observed that would not rule out spontaneous remission. Spontaneous remission is known to occur in ALL, although it is usually temporary, and spontaneous tumor lysis syndrome has been reported, although it is rare. In any case, one has to wonder whether the patient’s bone marrow was petering out near the end, something that is hard to determine because almost no laboratory values other than blast counts are presented, except at the end, when she had a very low platelet count (8K; normal 150K to 450K), a low white blood cell count (1.4, normal 4.5-13.0), and severe anemia (hemoglobin 8.2; normal: 13 to 16). It wasn’t established how the diagnosis of tumor lysis syndrome was made other than that the patient had elevated urate levels. Indeed, the entire case report seemed to have been written with the belief that it was the hemp oil that accounted for the decrease in blasts. A lot of information has been left out about the patient’s clinical course. All we know is that, after being placed in hospice, she was fortunate to have her blast count fall, developed a central line infection, and was treated for tumor lysis syndrome. We can also infer that she was still having considerable issues with her gut because she was on total parenteral nutrition (being fed by vein) and had trouble when they started to try to feed her orally again.
It should also be remembered that, whether or not hemp oil was responsible for the decline in blasts (which is possible but not convincingly demonstrated by this case study) or whether it was “burnout” of the bone marrow in the terminal phase of the disease or even spontaneous remission, the patient still died. She still developed GI bleeding and a GI perforation with peritonitis and died of it only 78 days after going on hospice. There’s no way of knowing whether hemp oil prolonged her life. Probably it did not, as a two to three month survival after going into hospice after being declared terminal for leukemia is well within what is expected. In other words, this case report is mighty thin gruel indeed.
Of course, the sad story of PK and the treatment of her terminal relapsed ALL with hemp oil is probably the highest quality cancer cure testimonial out there, and unfortunately its quality is not that high at all. The rest of the anecdotes I ran into tended to be about as convincing to someone familiar with cancer as nearly all the other alternative cancer cure testimonials I’ve found; i.e., not very. If you don’t believe me, take a look at this article, in which Rick Simpson claims his success rate for patients with terminal cancer is around 70% and says:
“The ones that can’t be saved are usually the ones who’ve had the most chemotherapy and radiation, or wait too long to start the treatment,” he says. “They have to be able to stay alive long enough for the oil to start to work.” In fact, most patients who undergo chemotherapy die from the treatment, not the disease.
No, it is not a “fact” that most patients who undergo chemotherapy die from the treatment, not the disease. It’s a lie. In any case, Rick Simpson is just like cancer quacks the world over, who have no firm evidence to back up their miraculous-sounding cure rates and excuse their failures by claiming that the treatment patients had before prevented the quackery from working. Quacks like Rick Simpson do those who think that cannabinoids have promise in treating cancer no favors.
Conclusions
There’s a lot of interesting research about the role of cannabinoid receptors in cancer and whether targeting them with cannabinoid agonists from marijuana or other natural sources, synthetic agonists, or endocannibinoids will be a useful tool to add to the armamentarium of anticancer therapies. From what we know now, it is quite clear that cannabis does not cure cancer, at least not by itself and certainly not ingested or smoked as marijuana or ingested or applied topically as hemp oil. Even in purified form, naturally-derived or synthetic cannabinoid agonists show relatively modest antitumor activity in preclinical models, which means that they will have to be combined with existing chemotherapeutic regimens. If they do find their way into the routine clinical treatment of cancer, it will be through rigorous pharmacological studies and rigorous clinical trials, the latter of which, in particular, are painfully lacking. Indeed, if you search ClinicalTrials.gov, you’ll quickly find lots of trials of cannabinoids to treat cancer-related symptoms and side effects, but precious few to treat cancer itself. There’s this phase I trial of Dexanabinol in Patients With Advanced Solid Tumors, which has been open two years and is still accruing patients, as well as this one of Dexanabinol against brain cancers. It’s not a lot, and suggests that there is not much interest in even synthetic cannabinoids as a treatment for cancer. After all, there are so many other promising avenues that a class of drugs that show the modest effects that the cannabinoids I’ve discussed do just don’t excite researchers that much.
In any event, the claims of advocates that “cannabis cures cancer” are nothing more than herbalism infused with the magical thinking of the naturalistic fallacy. Just because it’s “natural” does not make it better. In the case of cannabis for cancer, the only potentially promising way forward is to isolate the active components and figure out which of the hundreds of different cancers in which these components have activity against.
Finally, I have no objection to lobbying for the legalization of marijuana for recreational use. I would support such measures myself. However, trying to use hugely exaggerated claims of medicinal benefit as a back door path to legalization gets my skeptical antennae all a’twitchin’ about all the other claims made by advocates and provides ammunition for critics whose real goal is prohibition.

Medical marijuana as the new herbalism, part 3: A “cannabis cures cancer” testimonial
Medical marijuana is often touted, primarily in the form of cannabis oil extract, as a cure for cancer that “they” don’t want you to know about. While some cannabinoids do have modest antitumor activity in vitro, there is no compelling evidence that cannabis can cure cancer. Yet that doesn’t stop a proliferation of testimonials claiming that cannabis cured cancer. They are no more valid evidence than alternative medicine cancer cure testimonials.
David Gorski on March 16, 2015
Link

It’s been a while since I discussed medical marijuana, even though it’s a topic I’ve been meaning to come back to since I first dubbed medical marijuana to be the equivalent of herbalism and discussed how the potential of cannabinoids to treat cancer has been, thus far, unimpressive, with relatively modest antitumor effects. The reason I refer to medical marijuana as the “new herbalism” is because the arguments made in favor of medical marijuana are very much like arguments for herbalism, including arguments that using the natural plant is superior to using specific purified cannabinoids, appeals to how “natural” marijuana is, and claims of incredible effectiveness against all manner of diseases, including deadly diseases like cancer, based on anecdotes and testimonials. Now, as I pointed out before, not only am I not opposed to the legalization and regulation of marijuana for recreational use, even though I’ve never tried it myself, but I support it. What I do not support are claims for medical effects that are not backed up with good scientific evidence, and for medical marijuana most claims fall into that category. That’s why I tend to view medical marijuana as a backdoor way to get marijuana legalized. Personally I’d rather advocates of marijuana legalization drop the charade, argue for legalization, and stop with the medical nonsense.
The last time around, I discussed the evidence supporting claims that “cannabis cures cancer” and found them to be wanting based on science. I didn’t however, discuss the “cannabis cures cancer” testimonial machine that drives the claim that marijuana is useful for treating cancer; at least, I only touched on it by discussing briefly Rick Simpson, who claims that his hash oil cures approximately 70% of patients with terminal cancer and a published anecdote in which it was claimed that hemp oil was effective in treating acute lymphoblastic leukemia. (It wasn’t. At least, the evidence presented was not convincing.) Since then, I’ve wanted to revisit the topic of “cannabis cures cancer” testimonials, and, for whatever reason, now seems like a good time to do it.
Stephanie LaRue
Last week, I discovered the “cannabis cures cancer” testimonial of a young woman named Stephanie LaRue. Hers is a sad story in that she was diagnosed at a young age (30 years old) after her boyfriend found a lump in her breast and misdiagnoses by three different doctors. In many ways, her story is an inspiring one based on her will to fight and her activism, which have led her to have served on the Board of Directors for the Los Angeles Susan G. Komen for the Cure, Southern California’s Breast Cancer Network of Strength, and the USC Norris Cancer Center’s Cancer Survivorship Advisory Council. Near and dear to my heart, she also is very much into rescuing and fostering many wounded, mistreated and special needs dogs. Indeed, I approach this particular testimonial with more than a little trepidation because there’s an incredible amount to admire about LaRue and, more importantly, her involvement with Komen and other breast cancer charities means that people I respect and admire (who might read this) very well might know her—or even be friends with her. Still, given the direction her story has taken, I feel obligated to discuss it.
Here’s a video of her from 2007 when she was still undergoing chemotherapy:
Notice the themes we see so often in cancer patients, particularly young cancer patients: Why me? There must be a reason. It can’t have “just happened”. Breast cancer is a disease of older women. (Indeed, the mean age at diagnosis is around 61.) There must have been something in the environment. Possibly. As I’ve pointed out before, for breast cancer, environment- and lifestyle-attributable causes account for a much smaller fraction of cancer diagnoses than most people believe, and 1.8% of cases of breast cancer occur in women 34 and under. Given that there are approximately 233,000 new cases of breast cancer diagnosed every year in the U.S., that means that close to 4,200 women under 34 are diagnosed each year with breast cancer. Still, being diagnosed with breast cancer at age 30 is unusual; so it’s understandable that LaRue would wonder why it happened to her.
Worse, LaRue was diagnosed with Stage IV disease, as described in an article by Sonja Renea published on the Medical Jane website entitled “Meet Stefanie LaRue: Cancer Survivor and Medical Marijuana Advocate“:
Stefanie was sent home several times with several rounds of antibiotics, which is quite telling of younger folks being misdiagnosed. By the time she could be tested thoroughly, the cancer had spread to her bones. Doctors diagnosed her with Stage 4 Metastatic Breast Cancer, which is cancer that has spread beyond the breast to other organs in the body. The prognosis was grim: she was given a year to live, at most.
Three weeks later, Stefanie began her first round of chemotherapy. To make matters worse, she had to to [sic] cope with her employer, who showed little sympathy for her situation. Despite her job in commercial real estate being very stressful, she was expected to work through her cancer treatment.
This is a big problem with health care in the U.S. besides the difficulty many people have affording health insurance, a problem only partially alleviated by the Affordable Care Act (a.k.a. Obamacare), which didn’t exist in 2005. You can be diagnosed with metastatic breast cancer and still be screwed as far as work goes. It happens far too often in this country.
So LaRue ended up quitting her job and filing for disability. She underwent six rounds of chemotherapy and then a mastectomy. At this point reading her story I had a question. If LaRue had bone metastases, it’s not clear to me why her surgeon and oncologist would recommend that she undergo a mastectomy. Three possible reasons suggest themselves to me as a breast surgeon. One is that it was done to prevent the primary tumor from growing through the skin and turning into en cuirasse disease, although usually such surgery is not done right after chemotherapy but when the tumor has started to grow again. Another is that she had a complete radiologic response to the chemotherapy, meaning that all her breast and bone disease disappeared. When that happens and the patient has been rendered “no evaluable disease” (NED), we will often treat her as though she were not stage IV and undertake surgery with curative intent. The final possibility is that surgery was done with the intent of prolonging survival even though metastases were still present. It’s been an ongoing controversy in breast cancer over whether removing the primary tumor prolongs survival in stage IV disease or whether the apparent improvement in survival due to surgery is due to selection bias; that is, bias towards healthier patients with less aggressive disease who are chosen to undergo surgery preferentially. More recent evidence suggests that removing the primary probably doesn’t improve survival, but that was not at all clear back in 2005. (To be honest, it still isn’t quite clear.)
On her website, LaRue reports that her tumor was 8 cm in diameter (which is big). Apparently her tumor didn’t shrink enough to be removed in a lumpectomy; so she needed a mastectomy:
After chemo she had surgery to remove the cancer. But her margins were not clear, so another surgery followed. She was left with only skin and a nipple on the right side of her chest. Her breast surgeon had scraped all the way down to the chest wall removing all the breast tissue possible but sparing the skin. Despite the advanced stage of her cancer, she got to keep the outside of her breast because she had a skin-sparing mastectomy. A plastic surgeon was later able to reconstruct her breast, restoring her shape, her femininity and her sexuality.
At this point in my reading, I was unclear as to why a surgeon would do a skin-sparing mastectomy in a patient with stage IV disease. Most plastic surgeons are reluctant to do reconstruction in such a patient because reconstruction can be a big operation, and if the patient isn’t expected to live more than a year it just doesn’t make a lot of sense to have the patient spend a significant chunk of her remaining time recovering from surgery, having additional surgeries to “touch up” the reconstruction. The willingness of her surgeon and plastic surgeon to undertake a skin sparing mastectomy and reconstruction suggests to me that she had a very good response to the chemotherapy and/or that her prognosis as a stage IV patient was viewed as being considerably more favorable than usual.
Whatever the case, during the chemotherapy that she underwent before her surgery, LaRue looked to alternative medicine to ease her symptoms:
She found help with an integrative oncologist at UCLA, where she learned how to make changes to her diet, use natural supplements, get acupuncture, and work on personal fitness; all of which are integrative, complementary, and alternative treatments to go along with chemotherapy.
Now here’s the thing. As a patient with stage IV disease, LaRue did really well for eight years. It’s hard to find a good detailed description of what happened between November 2005 (when she was diagnosed with breast cancer) and 2013, but she didn’t start using cannabis oil until 2013, which means that conventional oncology is what got her through nearly eight out of the nine and a half years she’s survived with her stage IV cancer. It’s important to remember that when looking at a lot of the articles about LaRue, because before 2013, although she had gone all in for “integrative oncology,” she hadn’t yet discovered cannabis and was still being treated with mostly conventional medicine. So, between 2006, when she finished her initial treatment, and at least September 2013, when she posted a series of images to Instagram of her hospitalization for thoracoscopic surgery, conventional medicine is what kept LaRue alive. So when Sonja Renea of the Medical Jane website writes that “Stefanie LaRue was 30 years old when she was diagnosed with Stage 4 Metastatic Breast Cancer and given the dismal prognosis of less than a year to live” and follows it up with, “That was nine years ago,” she is being deceptive.
This is how it’s described in the Medical Jane:
In 2013 Stefanie had a Video-Assisted Thoracoscopic Surgery (VATS) and the results were not good. This was now her third reoccurrence of cancer. The chemo sensitivity testing concluded there were five lines of chemo treatments that would work on the tumors.
Stefanie declined the treatment. “I did my homework. I researched as much as I could. I watched. I listened. I read. I contacted. I prayed. Most of all, I believed. I weighed my options, which were essentially chemotherapy or cannabis oil, and I decided to take the natural route this time…” she says.
Stefanie followed the Rick Simpson Oil (RSO) protocol until she was cancer-free. “Cannabis oil killed all of the tumors in my body. My monthly lab and quarterly scan results are proof that the cannabis oil treatment worked,” she says. Her doctor, who had previously been skeptical, now credits these “alternative” treatments as the reason for her speedy recovery.
On Instagram, LaRue described it thusly in a posting dated October 2, 2013:
Dear cancer, as we both know, yesterday was a big day of news. And sadly for you, you lost. You lost your “upper hand” you tried to claim in that you were potentially showing up again (unwelcomed in my body) not as a metastatic reoccurrence, but as a possible new primary cancer. Which would have been a much more challenging ass kickin match between you and I. None the less, I would have enjoyed. But since you are now known as the same initial metastatic breast cancer reoccurring, I hope you are preparing for what is coming to you. Because now I have the upper hand. When the chemo sensitivity tests are complete on my biopsy tissue at Caris Labs we will know exactly what to come after you and all your little friends with! Poor you. I know your still cowardly hiding in my body but you have pissed off some pretty important people that care a lot about me and guess what… Now they too are coming in to whip your ass!!!
We’ve encountered Caris Labs before in the context of discussing Stanislaw Burzynski’s incompetent “personalized gene-targeted cancer therapy.” Basically, Caris is a company that will do various genomic tests and immunohistochemistry on a tumor sample to try to identify which targeted agents it might be sensitive to. I’ve basically discussed how the routine use of such a test is premature, given that there isn’t any good evidence that using a test like the one from Caris or other competing tests results in better response rates or prolonged survival, but such tests have still proliferated and their use is not uncommon, even in academic medical centers.
In any case, at this point in the fall of 2013, LaRue was facing her third recurrence of cancer. Unfortunately, this is a story very much like the many alternative cancer cure testimonials I’ve deconstructed over the years in that we lack a lot of key information, which means that I can only speculate. First, we don’t know how extensive a cancer recurrence LaRue had. Given that she underwent thoracoscopic lung surgery (a thoracoscope is like a laparoscope, except that instead of letting a surgeon operate in the abdomen it allows the thoracic surgeon to operate in the chest with minimal incisions), presumably she had a lung nodule. In a patient with stage IV disease, most such lesions would be biopsied using a core needle under CT scan guidance, rather than excised surgically through a laparoscope. Why did the surgeon choose this course?
A couple of possible reasons suggest themselves from the story. First, perhaps she did undergo a CT-guided core needle biopsy and the diagnosis was uncertain. Certainly LaRue’s Instagram posting, in which she gloats over her tumor for not being a new primary tumor but just the same as the other recurrences of her original tumor, suggests that this could be the case. After all, a new suspicious lung nodule in a breast cancer patient is usually considered a new metastasis until proven otherwise. In any case, in patients with metastatic disease, a tissue diagnosis is always imperative before beginning treatment if at all feasible. Another possibility is that this tumor, whatever doctors thought it was before surgery, was the only site of disease detectable. In such a case, particularly in a young patient who had been doing well for nearly eight years even if she did have stage IV disease, strong consideration would be given for excising the cancer and eliminating the only known site of disease even though the evidence that metastasectomy (removing the metastasis) will prolong survival in breast cancer is mostly without controls and thus prone to selection bias. (Metastasectomy of liver and lung metastases can definitely prolong survival in colorectal cancer.) Still, there is evidence that in select patients removing pulmonary metastases can result in significant survival benefit. Whether LaRue is one of those select patients is unclear.
So here’s what I think probably happened. After surgery LaRue (understandably) did not want to undergo further chemotherapy. For whatever reason, she latched on to Rick Simpson’s hemp oil as the treatment that would control her cancer. How she found out about it and why she became convinced it would cure her, it’s hard to say from publicly available information. In the Medical Jane story, LaRue proclaims that “cannabis oil killed all the tumors in my body” and that her “monthly lab and quarterly scan results are proof that the cannabis oil treatment worked.” It is, of course, impossible to confirm or dispute this assessment without knowing what all her scans showed.
There is, however, a photo on Instagram of LaRue receiving a shot, which she identifies as Xgeva, which LaRue described as “bone mets maintenance.” And so it is. It’s a monoclonal antibody against the RANK ligand, a protein that acts as the primary signal for bone removal, and it prevents fractures in patients with bone metastases. So this implies that LaRue still has bone metastases. It also makes one wonder what other non-chemotherapy conventional therapy she might be taking. There’s also a post by her on Twitter asking about Afinitor (everolimus):
New treatment protocol side effects (third reoccurrence) should I take or seek other alt options? #cancersucks pic.twitter.com/hlAbCaa462
— Stefanie LaRue (@stefanielarue) October 28, 2013
Afinitor is a drug that inhibits an enzyme called mTOR and is used in cancer that is positive for the estrogen receptor after it develops resistance to anti-estrogen therapy. Apparently she did not take Afinitor, because on March 14, 2014 LaRue posted a photo on Twitter:
This is about the time when getting #treatment really sucks! #zoladex #injections #stomach #fuckcancerpic.twitter.com/MwNIqvwm0k
— Stefanie LaRue (@stefanielarue) March 8, 2014
In the photo, LaRue is receiving an injection of Zoladex (goserelin), a drug used to suppress production of sex hormones. In other words, six months after her thoracoscopy, LaRue was receiving conventional medical therapy, specifically a treatment to shut down her ovaries’ production of estrogen. Thus, LaRue appears to be the case of a cancer patient who chose unproven alternative medicine but at the same time continued to receive conventional medical therapy for her cancer and did very well. As is the case with most such patients, she attributes her excellent outcome, at least after her most recent relapse, far more to the alternative treatments (in this case, Rick Simpson’s hemp oil) than she does to the conventional therapy she is also taking, even after her discovery of hemp oil. I also can’t help but point out that the very fact that LaRue survived nearly eight years with stage IV cancer before discovering hemp oil is a pretty strong argument that from a biological standpoint her tumor is pretty indolent, as some tumors positive for the estrogen receptor are; so it’s not surprising that she would still be alive a year and a half after her thoracoscopy on Zoladex and Xgeva alone (plus whatever other conventional medical therapy she is receiving). Only LaRue and her oncologist know for sure, though, and her oncologist can’t tell anyone without her permission.
Cannabis versus breast cancer
As much as I admire the grace and determination with which Stefanie LaRue has endured over 9 years after her cancer diagnosis, as a cancer doctor it bothers me profoundly that she has allowed herself to fall under the spell of the “cannabis cures cancer” alternative medicine crowd, in particular Rick Simpson. I discussed Simpson the last time I wrote about cannabis and cancer. As I said at the time, Rick Simpson is just like cancer quacks the world over, who have no firm evidence to back up their miraculous-sounding cure rates and excuse their failures by blaming the treatment patients had before they started the quackery. Quacks like Rick Simpson do those who think that cannabinoids have promise in treating cancer no favors.
I also discussed how the vast majority of studies touted by the “cannabis cures cancer” advocates tend to be preclinical studies in cell culture or animal models that show relatively modest antitumor effects due to various cannabinoids. Indeed, this article on Medical Jane, “Studies Show Cannabinoids May Help Fight Triple-Negative Breast Cancer“, fails to provide particularly convincing evidence that they do. Before I look at the studies, I can’t help but note that triple negative breast cancer is breast cancer that makes neither the estrogen receptor (ER), the progesterone receptor (PR), nor overexpressed HER2. Yet the article invokes Stefanie LaRue, who clearly has ER(+) breast cancer.
Another thing that needs to be pointed out. Every single one of the studies invoked by Medical Jane has nothing to do with hemp oil, be it Rick Simpson’s hemp oil or some other type. Each of the studies examines either purified cannabinoids or, in the case of this study, a chemically modified cannabinoid. This study cited in Molecular Cancer, for instance, looks Δ9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist. Both inhibit the growth of HER2(+) breast cancer cells in cell culture and in mice, but the concentrations needed are pretty high, with an IC50 (concentration that is 50% of maximum inhibition) in the range of 5 to 10 μM, concentrations achievable with injection of purified compound but certainly not by smoking pot
You are also unlikely to achieve these levels by drinking hemp oil, which, by the way, usually contains so little THC that it is below the limit of detection for common assays and manufacturers brag that it’s impossible to fail a drug test if you’re consuming hemp seed oil because “THC levels in our products are barely measurable.” Of course, I do realize that Rick Simpson calls his oil hemp oil even though it’s really cannabis oil derived from the buds rather than the seeds, but even he brags that “following the dosage previously described, many people can take the full treatment and never get high,” which implies that his oil achieves nowhere near the concentration of THC in the blood necessary to be active against cancer. Moreover, oral bioavailability of THC from such oils is notoriously low, between 4-20%, making it unlikely that concentrations well above the 10 μM necessary to inhibit or kill more than 50% of the cancer cells are achievable with oral dosing.
Thus, the various studies cited, such as this one, which shows inhibition of the epidermal growth factor pathway by purified cannabidiol (CBD), a non-psychotropic cannabinoid; this one, the aforementioned study that examines purified Δ9-THC and JWH-133 against HER2(+) breast cancer; and this one, which also examines CBD in breast cancer, are interesting and very preliminary. Moreover, they all examine cannabinoids purified from cannabis, and one even examines a chemically modified cannabinoid. In other words, even if cannabinoids make the jump from preclinical models to humans, these studies do not support the use of medical marijuana, either smoked as the plant or ingested as an oil, to treat breast cancer. They also do not suggest sufficient activity to produce miracle cures of stage IV cancer as described by Rick Simpson. Indeed, a recent review concludes that “current preclinical data does not yet provide robust evidence that systemically administered Δ9-THC will be useful for the curative treatment of cancer,” although CBD might have a role based on preclinical data.
Neither cannabinoid, however, is likely to be curative for advanced cancer. It’s possible that specific cannabinoids might have a role to play in the multimodality treatment of cancer, but, given what we know about them from preclinical studies, it’s highly unlikely that cannabinoids, medical marijuana, or Rick Simpson’s hemp oil can cure stage IV cancer of any kind.
Hope versus hype
I have no doubt that Stefanie LaRue honestly believes that Rick Simpson’s hemp oil is the reason why she’s still alive today and doing so well. I can’t help but point out that Stanislaw Burzynski’s patients, for example, also honestly believe that his antineoplastons are what saved their lives, even though even Burzynski can’t produce good evidence that they have antitumor activity. Depressingly, it just goes to show how even such an accomplished woman can fall prey to the same human cognitive shortcomings that we all share and confuse correlation with causation. If it were just her, I wouldn’t have felt obligated to write this post, but LaRue makes it very clear that not only does she believe that Rick Simpson’s hemp oil allowed her to heal herself of her longstanding metastatic cancer:
Did you know that the Rick Simpson hemp oil is being used to treat cancer patients? I’m one of them. And it’s working pic.twitter.com/XGX9tzJHTo
— Stefanie LaRue (@stefanielarue) July 4, 2014
But she plans on becoming an evangelist for Rick Simpson’s hemp oil and medical marijuana:
In this video she notes that she’s had multiple recurrences and they’re all gone, after which she challenges the viewer to “explain that.” Believe it or not, personally, I’d be overjoyed if something as simple as hemp oil could treat stage IV cancer so effectively. I really would, as it would mean that I’d rarely have to see a breast cancer patient die. However, although I can’t be sure without a lot more information (which is highly unlikely to be forthcoming) and I do have to concede the possibility, albeit remote, that Rick Simpson’s hemp oil is the reason why LaRue has survived a year and a half since her last new metastasis, I nonetheless suspect that it is far more likely than not that it is the Zoladex and the Xgeva (not to mention whatever other conventional treatments that LaRue may be taking that she hasn’t mentioned on social media) that are keeping her going now, combined with her disease’s already-demonstrated indolent biology.
And long may they continue to do so!
For nearly eight years, Stefanie LaRue fought a battle with courage, inspiring intelligence, and grace. Her story was (and still is) a story of hope for women with stage IV cancer that they can live a long time with the disease with good quality of life. Unfortunately, a year and a half ago her story took a turn into pseudoscience, becoming a cautionary tale of how even the most intelligent, ambitious, and determined person can be subject to magical thinking. This would not be an issue with me were it not that, inadvertently, and with the best of intentions, LaRue has declared her determination to promote Rick Simpson’s hemp oil as a cancer cure, using her own story as an example of what it can do. Given her proven history of advocacy and her numerous accomplishments with organizations like the Komen Los Angeles County Affiliate from 2008 to 2010 (before she discovered hemp oil), I can’t help but be worried that she will in her quest to save women from stage IV breast cancer end up doing exactly the opposite for some women.
I still hold out hope that, given her history, LaRue will eventually realize that her true story is a cause for hope for women with stage IV disease. Thanks to advances in breast cancer care, more and more women with stage IV disease are living a lot longer than expected, even ten years, all with no need to resort to unproven treatments promoted with testimonials, like Rick Simpson’s hemp oil.
That’s the real reason for hope.

   Hash Oil for Gliomas? What Would You Do?
Published by Harriet Hall
Link
A friend asked me to look at the evidence for hash oil as a treatment for glioma. His teenage daughter was recently diagnosed with brain cancer: a grade 3 anaplastic ependymoma. It recurred very rapidly after surgery and radiotherapy and the latest tissue diagnosis shows an aggressive grade IV glioma. Her prognosis is not good. No further attempts at curative therapy are indicated; the oncologist prescribed only palliative therapy with temozolomide. Her father, who had recently lost his wife to cancer (breast cancer metastatic to lungs and brain), was understandably devastated. As he puts it, he remains “focused on the belief that just maybe a cure can be found.” He stumbled on what he calls “earth-shattering news” regarding hash oil. He and his friends established a private wiki website which they are constantly updating with information about THC (tetrahydrocannabinol, the active ingredient in marijuana and hash) and other possible cancer cures: everything from curcumin to diet. He asked me to look at the information he has accumulated. He said
I hope to convince you in the same way I have done with my daughter’s GPs and her neuro-oncologist at BC Children’s Hospital.
The oncologist was not exactly convinced. He didn’t say he thought hash oil was likely to work; he only said it would be reasonable to try it as a complementary therapy. He said
the data published so far appears very preliminary, most of its potential effectiveness in vivo so far appears in colonic disease, having said that there doesn’t appear to be any obvious down side as a complementary therapy and may have synergistic effect, so may be reasonable as add on to temodal if she tolerates it
I wasn’t convinced either.
I will discuss two issues here:
     1.  What does the evidence say about gliomas and hash oil?
     2.  When is it reasonable to try an unproven treatment as a last resort?
What Does the Evidence Show?
Several plausible mechanisms have been demonstrated, suggesting that it might work; but the evidence consists almost entirely of in vitro (test tube) and animal studies, with only a couple of small pilot studies in humans and a lot of speculation.
The Guzman study was a pilot study of 9 patients who got THC injected directly into their tumors.
The Salazar study concluded
we identify what we believe is a new route that links the ER stress response to the activation of autophagy and promotes the apoptotic death of tumor cells. The identification of this pathway will help to understand the molecular events that lead to activation of autophagy-mediated cell death by anticancer drugs and may contribute to the design of new therapeutic strategies for inhibiting tumor growth.
The Kogan study elucidates cellular anti-cancer mechanisms of THC but warns “sometimes they can act also as pro-cancer agents, especially in low concentrations, acting mostly through growth factors and their receptors activation/induction.” It concludes
In summary, cannabinoids possess some anticancer activity. Possibly they may represent a new class of anticancer drugs that retard cancer growth, inhibit angiogenesis and the metastatic spreading of cancer cells.
None of these studies concluded that we should be treating glioma patients with any form of THC.
A study by Foroughi reports spontaneous regression in 2 glioma patients. One happened to have smoked pot almost every day, the other used it twice a week. They speculate that the THC might have had something to do with the regression. But it might just as well have been coincidental. Spontaneous regression is known to occur in gliomas. A 2004 German study showed spontaneous regression in a mouse model. A study in the Archives of Ophthalmology documented 13 cases of spontaneous regression in humans with large optic gliomas.
The literature is confusing because it addresses different doses, different compounds, and different routes of administration: THC, smoking pot, hash oil, injecting it directly into tumors, applying it topically to skin tumors, inhaling, taking it by mouth, etc. Positive pilot studies are an encouragement to further studies; they are not proof that the treatment works.
The information on the Internet includes glowing testimonials but is contaminated with obvious bias. Advocates come mostly from the ranks of notorious “legalize marijuana” activists. Emotions run high. Many arguments in favor are full of the kind of fallacies we often discuss here, including “they didn’t listen to Semmelweis.” Protestations that THC research is being unfairly suppressed are not credible. Cancer researchers want to find cures, and even Big Pharma stands to reap huge benefits if active molecules can be separated out, modified, and turned into prescription drugs.
I didn’t find anything I would call “earth-shattering” or even anything that could be considered credible evidence that hash oil can cure advanced gliomas. The most I can conclude from my research is that hash oil has promise and is worth studying.
Last Resort?
When a patient is out of options, it is natural to grasp at any straw. Even though the evidence for hash oil is inadequate, there are some preliminary indications that it might help, and some plausible mechanisms have been elucidated. Isn’t it better to try something that possibly might work than to just give up?
How do you know what to try? The private website addresses all kinds of other possible cancer treatments, including curcumin, garlic, diet, etc. Incidentally, it cites a lot of very untrustworthy sources, such as a book by a doctor who repeats the old myth about cancer and sugar and a company that is selling curcumin pills. Should you try all of these treatments at once? If you try hash oil, how do you decide how much and how often?
We read articles in the popular press, for instance in Reader’s Digest, about the child with the rare disease whose heroic parents refused to give up and kept searching until they found the one doctor in the world who was able to cure their child with a new treatment. We hear about these success stories because they are unusual.
We don’t hear about the vast majority of cases where parents wasted time and money in a futile search.
It disturbed me to read through the private wiki, because it was “déjà vu all over again.” I’ve seen this so many times. Someone desperately wants to find a cure, latches onto something that he thinks might work, locates a mass of evidence to confirm his bias, but fails to appreciate the limitations of that evidence and fails to seek out information that argues against his bias (like the possibility that cannabinoids might have pro-cancer effects, mentioned above). In the course of my long career I’ve seen so many promising treatments bite the dust that I have become not only skeptical but probably cynical about it.
Yes, hash oil might be an effective treatment for gliomas and for other cancers. But we can’t possibly know until we test it properly. A patient with glioma today can’t wait for the results of future tests. Forgoing the treatment might mean dying sooner than necessary, but it is far more likely that using the treatment will be useless. It’s a gamble. Where is that crystal ball when we need it?
When you try a treatment on your own, you are essentially acting as a guinea pig in an uncontrolled experiment. Ideally, you could enroll in a randomized controlled trial that would result in some useful knowledge for future patients. But such trials are not always available, and you might not get the treatment; you run the risk of being assigned to the placebo group.
Is aggressively pursuing a cure really the best goal? Success is possible but very unlikely; and the search can become obsessive; dominate the searcher’s life; and consume time, funds, and energy that might be best employed otherwise. How about pursuing other goals that have a much higher chance of success: spending quality time with the loved one, trying to make the most of whatever time she has left, helping her cope, trying to make her remaining life as worthwhile as possible, saying goodbye, creating good memories for the survivors?
I’m going to be mean and ask some difficult questions. Is this father really doing this for his child or for himself? He wants to be able to say he did everything possible and left no stone unturned, so he will have no guilt feelings afterwards. Is the daughter really on board with all this, or is she cooperating mainly to please her father, knowing that it gives him comfort? Is she giving up the foods she loves to follow a restricted diet that has no proven benefit? Would it be better for all concerned to accept the terrible prognosis and confront its reality in more constructive ways? Do false hopes do more harm than good? There are always real hopes: that palliative therapy might extend life, that a spontaneous regression might occur, that life might still be rich with meaningful experiences?
Conclusion
Hash oil has enough promise to warrant further research but not enough evidence to warrant prescribing it as a cancer cure. Is it worth trying anyway? I don’t know. I am asking questions, not condemning. I can’t imagine what it is like to learn that your beloved child has a fatal illness. I don’t know how I would react, or whether I would want to try something like hash oil. It’s possible that I might feel desperate enough that all my judgment, skepticism, and common sense would fly out the window and I might be persuaded to try even the most wildly irrational things. I do know that refusing to accept reality often has unfortunate consequences. It distresses me when families aggressively pursue a will-o’-the-wisp that ends in failure and uses up precious time they might have spent otherwise to make the patient’s last days more meaningful and to create lasting memories.
What would you do? I welcome readers’ input in the comments.

CBD Oil Fails to Improve Symptom Control in Advanced Cancer
Has the hype outpaced the evidence when it comes to cannabis? A new clinical trial fails to show any benefit of CBD oil in patients with advanced cancer.
Scott Gavura on January 19, 2023
Link
With so many articles in the archives and over a decade of writing to refer to, it’s fascinating to look back at how the contributors to this blog have examined emerging medical issues. Over the same period of this blog’s life, the availability of marijuana for medical use has expanded dramatically, paving the way for eventual legalization. Even very early on, this blog was cautious about the hype about its medical potential. The earliest post I can find was from 2009, when Peter Lipson wrote about its emerging use. He noted:
As marijuana becomes increasingly available for medical use, practitioners of science-based medicine need to evaluate the evidence for the use of this drug. In evaluating a new drug, we must ask a number of questions, including those of safety, efficacy, and perhaps redundancy. Claims for the efficacy of marijuana tend to be hyperbolic, with no condition being exempt from its benefits.
In 2014, David Gorski wrote a series of posts on medical marijuana, likening it to “the new herbalism” and noting:
It’s not enough just to say cannabis (or whatever cannabinoid drug or derivative you might wish to use) is “efficacious” against this disease or this condition. We need to know how efficacious it is compared to the existing standard of care.
The public enthusiasm for the recreational and medical use of marijuana is clear. Use has grown dramatically despite limited evidence. Now we have a study that helps to further clarify its potential role as a medicine. In a new paper published in the Journal of Clinical Oncology, researchers studied if cannabidiol (CBD) improved symptom control in patients with advanced cancer.
Cannabidiol (CBD) oil is one of the many chemical compounds called cannabinoids that are isolated from cannabis. Cannabis contains over 400 chemicals including at least 120 cannabinoids, which stimulate cannabinoid receptors in the body. (Yes, we have cannabinoid receptors and we even produce our own cannabinoids.) The most well-studied cannabinoids in the research setting are delta-9-tetrahydrocannabinol (THC) and CBD. CBD does not have the psychoactive profile of THC, and while it has been the source of considerable medical interest, its primary established role as a medical product is for the treatment of forms of childhood epilepsy.
Cannabidiol is a plausible and even promising treatment for the symptoms of advanced cancer. Patients with advanced stages of cancer can experience fatigue, anorexia and other distressing symptoms. Cannabis has been promoted as a more “natural” treatment option, so this study was designed to evaluate if CBD oil, in combination with standard pallative care, reduced patient symptom burden.
The trial
The study, titled “Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)”, was a randomized, placebo-controlled study of CBD that took place in five medical centres in Queensland, Australia. Participants had advanced (palliative) cancer, and were over the age of 18 with symptoms causing distress (as measured by a standardized scoring tool), had no THC in their urine, and had adequate mobility (performance status) and cognitive function.
All patients in the study were to receive standard palliative care treatment. Patients were randomized to receive CBD oil (100mg/mL) or a matched placebo. Doses were increased gradually every third day, as they could tolerate, over 14 days, starting at 50mg once daily up to a maximum of 200mg three times daily. Patients were given the option of staying on the desired dose for two additional weeks.
Patients were assessed by telephone using a standardized instrument (assessing pain, fatigue, nausea, sleepiness, shortness of breath, appetite, anxiety, depression and overall well-being) every 3-4 days, with face-to-face assessments at days 14 and 28. This score, at day 14 compared to day zero, was the primary outcome measure. Secondary measures included individual symptom scores, pain control (as measured by oral morphine equivalents), and adverse events.
Results
Of 215 patients invited to participate, ultimately 144 participants were randomly assigned over a 33-month period. Two patients were eventually removed leading to 58 participants on CBD and 63 on the comparable placebo. The groups were comparable in terms of how many patients remained in the study at day 14 and day 28. Patient characteristics were comparable with the exception of the placebo group having a worse baseline symptom score at randomization.
Total symptom burden: Symptoms improved in both groups with no significant differences between the two group. (Symptoms actually improved more in the placebo group, but not significantly). Adjusted for the difference in the baseline score, there was basically zero difference between the two groups at day 14. There was also no difference in the proportion of “responders”, defined as a decrease in the symptom scale of six or more:

Change in individual symptoms: All measures in the symptom scale improved (fell) over time in both groups. There was no difference between groups in terms of physical, emotional, or well-being, or in any individual component (e.g., pain, nausea, appetite):
Participant-selected dose: The median final dose selected by participants was 6mL/day in the placebo group and 4mL/day in the CBD group (equivalent to a dose of 400mg/day).
Pain control: There was no difference detected between arms in terms of oral morphine equivalents used, or the changes in use over the duration of the study.
Other medications: There was no correlation between the participant-selected dose of CBD/placebo and opioid dose, or the use of drugs like benziodiazepines and antipsychotics.
Global impressions of change: Most participants reported feeling better or much better at day 14 and 28, often despite no change in the symptom score. There were no differences between the groups.
Adverse effects: There were no differences in events of special interest between the groups at days 14 and 28 in terms of adverse events, with a nonsignificant increase in somnolence and abdominal pain and a trend of more vomiting in the placebo group. In terms of other adverse events, there was a significant increase in shortness of breath reported in the CBD group. There were no differences in hospitalizations (none related to the study drug) or in overall survival.
Conclusion
While there has been significant enthusiasm in the use of cannabis as a medical treatment, this randomized controlled trial of CBD oil in patients found no benefit over standard care. Despite a plausible mechanism of action, CBD did not improve anxiety, depression, or any individual symptom substantially. CBD oil was well tolerated and there were few side effects with the possible higher rate of somnolence related to CBD use.This trial differs from other research in that it was well-designed to minimize bias, used a standardized, verified CBD product, and was powered to detect if CBD offered any meaningful benefits. It measured effects using a validated scale that captures meaningful patient symptoms. The authors conclude:
This study has significant implications for policymakers regarding both approved indications for MC and its safe use. Medical cannabis has been approved in several countries for palliative care in the belief that it might improve the [quality of life] of patients with advanced disease. CBD is a popular cannabis product in the community as it has no psychoactive effects and does not impair driving ability. With current evidence, it is difficult to justify government subsidization of the cost of CBD nor recommend that patients pay for CBD products.
While no single study is definitive, this trial suggests that CBD, despite its popularity, may not offer any benefit to patients managing the symptoms of advanced cancer in a palliative setting.

   CAM Use by Brain Tumor Patients
Steven Novella
Link
A recent article in the journal Neurology reports the results of an observational study regarding the use of so-called complementary and alternative medicine (CAM) by patients with an incurable brain glioma. They found that 40% of patients sought some type of CAM treatment. These results are in line with prior surveys, but require closer inspection.
The study defined CAM as:
Complementary therapy was defined as methods or compounds not used in routine clinical practice and not scientifically evaluated.
This is a problematic definition, but reflects the fact that there is no universally accepted and clean definition of CAM. CAM is a hodge-podge of therapies and modalities that have only one thing in common – they have not met the science-based standard of care. It is not accurate to say that they are “not scientifically evaluated.” Some CAM therapies have not been evaluated, but many have, and have already been adequately found to lack efficacy. In the current study homeopathic remedies were the most commonly reported. Homeopathy has certainly been studied – and found to be indistinguishable from placebo.
Even my quick definition above does not constitute an operational definition of CAM. There are some modalities that have not yet been demonstrated to be safe and effective, but are used in conventional medicine because they are highly plausible and effective alternatives are lacking – so plausibility needs to be taken into account as well. I think the best definition of CAM is that it constitutes a double standard, by which therapies are promoted with a philosophical justification (because they are “natural” or empowering, for example) and deviate from the accepted ethical and science-based standard of an appropriate risk vs benefit analysis in the context of informed consent. In other words, they are therapies that should be rejected based upon the usually accepted calculus of clinical decision making, but sneak through the back door through the bait-and-switch of feel-good philosophy or deceptive marketing.
The definition of CAM used in the study is not a small detail, but a central feature of studies of CAM use that has a profound effect of the results. Many previous surveys of CAM use have used an overly broad definition of CAM and therefore have grossly elevated the apparent size of the CAM phenomenon. For example, some studies have included prayer as CAM – so any time a loved-one prays for their sick family-member, they are using CAM. Vitamin supplements are an example of something that is in the gray zone. Taking megadoses of vitamins as a therapeutic intervention should be considered CAM. But not everyone who takes vitamin supplements as nutritional insurance during a serious illness should be considered as using CAM. In fact, nutritional supplementation during chemotherapy or around surgery is standard of care. Exercise, simply getting a relaxing massage, or psychologically based therapies are too lumped in with CAM.
In the current study, which was conducted in Germany:
Of those who used alternative treatments, 39 percent used homeopathy, 31 percent used vitamin supplements and 29 percent used various psychological methods.
Therefore, 60% of those who were counted as using CAM in this study either took vitamins or used some sort of psychological therapy. These are both categories that can contain legitimate or dubious interventions, so it is impossible to know how to interpret those numbers. Homeopathy, which made up 39% (leaving only 1% for everything else) is 100% nonsense and unequivocally qualifies as CAM. It should be noted that homeopathy is fairly popular in German (and Europe generally) and so this result is not surprising.
Further, this study utilized a questionnaire, which means there was self-selection in those patients who chose to complete and return the questionnaire. It is likely that this method would artificially elevate the numbers, as those patients who are interested in CAM may be more likely to fill out a questionnaire about CAM.
The study also found that CAM use is greater in those who are younger, in women, and those with greater education. This also fits with prior surveys. The increased use in those with higher education likely relates to the availability of disposable income. However, studies have also shown that increased education correlates with increased openness to the paranormal and other pseudosciences (until you get to the level of postgraduate science eduction). This phenomenon is likely affected by other variables and at least one other study showed a slight negative correlation between education and paranormal belief.
The survey also found that people chose to use CAM primarily because they wanted to add an additional modality to their standard treatment – again, in line with prior studies. Essentially, people want to hedge their bets and make sure they are availing themselves of anything that might help. This is like playing the health-care lottery – they may know there is a small chance of benefit, but they don’t want to lose that small chance. The good news is that most people who did use CAM used it in addition to conventional therapy.
Such decisions are often based upon the false belief that CAM therapies are harmless, which is further often based upon the justification that they are “natural.” In the case of homeopathy, most homeopathic remedies are directly harmless in that they contain nothing (although some may be only slightly diluted and contain measurable amounts of substance that can be toxic – as was seen in the recent Zicam case). However, not all CAM therapies are non-toxic. Megadoses of vitamins can have side effects – even serious side effects. Herbs are drugs that have all the toxicity and drug-drug interactions of prescription medication. Even psychological therapies can cause direct harm, as is evidenced by false-memory syndrome.
However, much of the harm that comes from CAM use derives from indirect harm – mostly from a delay or absence of evidence-based therapy. In a recent article the Australian Pediatric Surveillance Unit reports that between 2001-2003 there were 39 separate reported incidences of serious harm resulting form CAM use in children. Most of the harm was caused by a delay in proper treatment.
The survey also found that patients chose to use CAM because they wanted control over their own treatment. This supports the observation that CAM is often promoted based upon that appeal – self-empowerment.
Respondents to the survey generally did not report that they chose to use CAM because they were dissatisfied with their physicians or their care. This is often the claim made by CAM proponents, that the alleged popularity of CAM is driven by deficiencies in conventional medicine. But there is not evidence to support that claim, and this and other surveys show it is not the case.
Conclusion
This study, which has significant weaknesses, none-the-less supports prior studies about CAM use. It demonstrates that the popularity of CAM is generally exaggerated, primarily by expanding the loose definition of CAM to include common activities. Most patients who use CAM do so in addition to conventional therapy, and primarily for philosophical reasons ad not out of dissatisfaction with conventional care.

   Steve Jobs’ cancer and pushing the limits of science-based medicine
David Gorski 
Link
An Apple fanboy contemplates computers and mortality
I’m a bit of an Apple fanboy and admit it freely. My history with Apple products goes way back to the early 1980s, when one of my housemates at college had an Apple IIe, which I would sometimes use for writing, gaming, and various other applications. Indeed, I remember one of the first “bloody” battle games for the IIe. It was called The Bilestoad and involved either taking on the computer or another opponent with battle axes in combat that basically involved hacking each other’s limbs off, complete with chunky, low-resolution blood and gore. (You youngsters out there will be highly amused at the gameplay here.) Of course, it’s amazing that nothing’s changed when it comes to computer games except the quality of graphics. Be that as it may, this same roommate was one of the first students to get a hold of the new Macintosh when it was released in early 1984. I really liked it right from the start but only got to play with it occasionally for a few months. After using a Macintosh SE to do a research project during my last year of medical school, I have used the Macintosh platform more or less exclusively, and the first computer I purchased with my own money was a Mac LC back in 1990 or 1991. Today, I have multiple Apple products, including my MacBook Air, my iPhone, and my old school iPod Classic, among others. Oddly enough, I do not have an iPad, but that’s probably only a matter of time, awaiting software that lets me do actual work on it.
All of this is my typical long-winded way of explaining why I was immensely saddened when I learned of Steve Jobs’ death last week. Ever since speculation started to swirl about his health back 2004 and then again in 2008, capped off by the revelation that he had undergone a liver transplant for a rare form of pancreatic cancer in 2009, I feared the worst. Last week, the end finally came. However, there is much to learn relevant to the themes of this blog in examining the strange and unusual case of Steve Jobs. Now, after his death five days ago, which coincidentally came a mere day after the launch of iCloud and the iPhone 4S, it occurs to me that it would be worthwhile to try to synthesize what we know about Jobs’ battle with cancer and then to discuss the use (and misuse) of his story. Of course, this is a difficult thing to do because Jobs was notoriously secretive and I can only rely on what has been published in the media, some of which is conflicting and all of which lacks sufficient detail to come to any definite conclusions, but I will try, hoping that the upcoming release of his biography by Walter Isaacson in couple of weeks might answer some of the questions I still have remaining, given that Isaacson followed Jobs through his battle with cancer and was given unprecedented access to Jobs and those close to him.
In the meantime, I speculate. I hope my speculations are sufficiently educated as not to be shown to be completely wrong, but they are speculations nonetheless.
Jobs and pancreatic cancer
Back in 2003, Jobs was flying high. Ousted from Apple in 1985 and then brought back in 1997, over the last six years he had brought the company back from the brink of bankruptcy, first with the launch of the iMac and then a few years later with the wildly successful iPod. It was at this time that he received news that no one wants to hear. Having recently undergone an abdominal CT scan, a mass had been found in his pancreas, apparently at the head of the pancreas.
Now, for all the reports I’ve read of this initial diagnosis, it’s utterly unclear to me exactly what the indication for the scan was, and at the time Jobs’ diagnosis was shrouded in secrecy. It wasn’t until 2008 that an article was published in Fortune entitled The Trouble With Steve Jobs and described his diagnosis thusly:
During a routine abdominal scan, doctors had discovered a tumor growing in his pancreas. While a diagnosis of pancreatic cancer is often tantamount to a swiftly executed death sentence, a biopsy revealed that Jobs had a rare — and treatable — form of the disease. If the tumor were surgically removed, Jobs’ prognosis would be promising: The vast majority of those who underwent the operation survived at least ten years.
So, right from the beginning, SBM bumped up against how Jobs was treated, as even now, the indications for “routine” abdominal CT scanning in an otherwise healthy man in his late 40s are virtually nonexistent, as Sharon Begley points out in an article published last week:
He reportedly had the scan — which is seldom done, much less advised, as a routine part of a physical — because he had a history of gastrointestinal problems, but he also may have been experiencing symptoms, most likely gastrointestinal ones.
Whatever the reason Jobs underwent a CT scan, either “routine” (which is almost never indicated) or for vague symptoms (for which the indication might have been weak but not nonexistent). At the time, Jobs would appear to have been incredibly lucky in two ways. First, he was lucky in that his tumor was discovered by what would in the absence of clear cut symptoms normally be a very low-yield test that exposes patients to both the risk of intravenous contrast and radiation exposure. These risks are quite low, but difficult to justify without clearer indications. However, CT scans are frequently overused in this country, and it is not surprising that Jobs underwent one for “soft” indications; it’s just that this time he was the exception, with disease detected early, rather than the rule, where the scan usually finds nothing helpful. Secondly, a biopsy of the lesion demonstrated that it was not the much more common (and deadly) form of pancreatic cancer, adenocarcinoma, which arises from the ducts of the pancreas, is rarely cured, and generally produces a median survival of less than a year. Rather, he had the much less aggressive form of pancreatic cancer, a neuroendocrine tumor. These tumors are often indolent and slow-growing. Unfortunately, they also tend to secrete hormones, which also tend to be responsible for most of the symptoms they cause. In Jobs’ case, it was insulin and his tumor was an insulinoma. Although, again thanks to Jobs’ secrecy, we have no idea what symptoms he was experiencing at the time, insulinomas typically result in a profound drop in blood sugar, and this hyperinsulinemia can lead to symptoms of insulin shock, such as tremors, cold sweats, nausea and vomiting, blackouts, and neurological symptoms such as confusion, apathy, and irritability.
Whatever Jobs’ talents, it became obvious that one of them was not good judgment about medicine. Whatever his business and design savvy, when it came to medicine, he demonstrated critical thinking skills that, if applied to his business dealings, would bring Apple down from its heights to utter ruin. Neuroendocrine tumors of the pancreas make up less than 2% of all pancreatic tumors, and he was lucky enough to have gotten that form rather than the more common deadly version. Surgery would have a high probability of curing him.
Here’s more of the story:
But Jobs sought instead to treat his tumor with a special diet while launching a lengthy exploration of alternative approaches. “It’s safe to say he was hoping to find a solution that would avoid surgery,” says one person familiar with the situation. “I don’t know if he truly believed that was possible. The odd thing is, for us what seemed like an alternative type of thing, for him is normal. It’s not out of the ordinary for Steve.”
Apple director Levinson, who has a Ph.D. in biochemistry, monitored the situation for the board. He and another director, Bill Campbell, tried to persuade Jobs to have the surgery. “There was genuine concern on the part of several board members that he may not have been doing the best thing for his health,” says one insider. “But Steve is Steve. He can be pretty stubborn.”
If it was fear that motivated Jobs, I can understand it. Although he was fortunate enough to have an islet cell cancer instead of the more common and deadly adenocarcinoma of the pancreas, it was in the head of the pancreas, the part that is closest to the duodenum. Lesions in the tail of the pancreas can often be removed with an operation called a distal pancreatectomy, which involves removing only part of the pancreas. Because of the anatomy of the head of the pancreas, its attachment to the duodenum, and the blood vessels in the area, the only way to remove lesions in the head of the pancreas is to do a much larger operation known as a pancreaticoduodenectomy, or, as it is more commonly known, the Whipple operation. There are a lot of potential complications to a Whipple operation. Sometimes, we weigh those complications and how long they would keep a patient in the hospital, against how long a patient has left. If a pancreatic cancer patient has only a few months left, doing an operation that will have him spending a significant chunk of his brief remaining time left in the hospital is a real consideration. However, that wasn’t a consideration for Steve Jobs. He would very likely be cured by the surgery. Moreover, in competent hands, the complication rate from a Whipple is acceptable, particularly if the patient is otherwise healthy. Even though the article quotes a 5% mortality rate, that is usually in the case of patients with pancreatic adenocarcinoma, most of whom tend to be somewhat debilitated to start with due to the tumor. It would probably have been less in Jobs’ case. True, because the duodenum is removed, another expected sequela of the operation is, depending on whether the pylorus is spared, having to eat a diet like that of patients who have their stomachs (or large portions thereof) removed (more on that later)
This is not a controversial issue in medicine; there is no other effective treatment for these neuroendocrine tumors:
By the standards of medical science, it was an open-and-shut case: There was no serious alternative to surgery. “Surgery is the only treatment modality that can result in cure,” Dr. Jeffrey Norton, chief of surgical oncology at Stanford, wrote in a 2006 medical journal article about this kind of pancreatic cancer. It was Norton, one of the foremost experts in the field, who eventually operated on the Apple CEO, Fortune is told. (He declined to comment.)
Dr. Roderich Schwarz, chairman of surgical oncology at the University of Texas Southwestern Medical Center in Dallas, who has performed the procedure more than 150 times (but who was not involved in Jobs’ case), says that waiting more than a few weeks with this diagnosis “makes no sense because you don’t know what the potential for growth or spread is.” Schwarz says he knows of no evidence that diet can be helpful. “But the patient decides. If they believe an herbal diet can do miracles, they have to make the decision. Every once in a while you have somebody who decides something you wish they wouldn’t.”
I couldn’t resist including this quote because Rod used to be one of my partners back in the day when I worked at The Cancer Institute of New Jersey. In any case, even though insulinomas tend to be indolent, waiting nine months to undergo surgery was probably not the best idea. It might not have hurt him (or it might have), but it certainly didn’t help (more on that later). Nowhere have I been able to find a detailed description of how large the tumor was upon its discovery or by how much it grew during those nine months. Whatever the case was, the surgery was apparently a success, with complete removal of the tumor.
For four years, Jobs appeared to do quite well after that.
Complications of the Whipple operation or something more dire?
In June 2008, Apple introduced the iPhone 3G, its second-generation iPhone. When Jobs took the stage to dazzle the crowd with his usual aplomb, many in the audience were shocked at his gaunt appearance. Soon after, it was revealed that he had undergone a second surgical procedure to reverse some nutritional issues related to his first surgery.
At the time, I thought I knew what might be going on. Jobs underwent a Whipple operation, more correctly referred to these days as a pancreaticoduodenectomy. This is a huge operation, one of the biggest and most radical rearrangements of a patient’s anatomy that is done routinely. What’s done is that the head of the pancreas and duodenum are removed en bloc (mainly because their close proximity to each other and their shared blood supply make it virtually impossible to remove the pancreatic head alone). This tour de force operation then necessitates putting things back together thusly: 
Link
There are many potential complications of the Whipple procedure, because it’s a big operation and it’s an operation on the pancreas. There’s a famous saying in surgery that goes, “Eat when you can, sleep when you can, but don’t mess with the pancreas.” (Usually another, far less savory word than “mess” is used.) In any case, there are almost always long term nutritional consequences that derive from rearranging a patient’s anatomy in so radical a fashion. First off, patients almost always lose 5-15% of their body weight right off the bat, although that usually levels off fairly quickly. Jobs, however, was never exactly what you would call robust-looking. He was always on the thin side; so losing that much weight for him could be more problematic. Although it has been speculated that Steve Jobs was a vegan or vegetarian, apparently such was not the case (he was pescetarian, which is basically a vegetarian diet plus seafood). So post-surgical difficulties maintaining nutrition because of a special diet that might not have meshed well with Jobs’ new anatomy could have been the problem. Some other potential serious problems over the long term include glucose intolerance or even diabetes requiring insulin; malabsorption because of diminished production of pancreatic enzymes; delayed gastric emptying; the afferent loop syndrome; or the “dumping syndrome,” which is common after stomach resections and results from undigested food being “dumped” too fast into the proximal small intestine, which draws in fluid.
At the time, I speculated that perhaps it was afferent loop syndrome (ALS) that necessitated another operation. You’ve probably never heard of it unless you’ve been unfortunate enough to have it (or are a surgeon or gastroenterologist), but ALS is a potential complication after a certain type of gastrojejunostomy, which is when the stomach is connected to a loop of small bowel in an anastomosis. This leaves two “loops.” The efferent loop is the small bowel leading away from the anastomosis. The afferent loop is the loop proximal to the anastomosis, whose peristalsis runs towards the anastomosis. Bile and pancreatic juice dump into the afferent loop, as can be seen in the illustration above. If there is a mechanical problem with the afferent loop, it can result in symptoms soon after surgery or as long as many years later. That Jobs seems to be rather quickly looking worse nearly four years after his operation also suggests ALS.
There are two forms of the problem, acute and chronic. Acute ALS involves a high grade obstruction of the afferent limb, in which pancreatic juices and bile back up behind the obstruction under pressure, and is potentially life-threatening. The more common and chronic form is what can produce nutritional deficiencies over time. Usually, approximately 10-20 minutes to an hour after a meal, the patient will experience abdominal fullness and pain as the liver and pancreas pump bile and pancreatic juice into the partially obstructed afferent limb. These symptoms usually last from several minutes to an hour, although they occasionally last as long as several days. Pressure will build up and the obstruction will resolve by then, sometimes with vomiting. Prolonged ALS with stasis of digestive juices in the afferent limb can result in bacterial overgrowth of the digestive juices sitting there, fatty stools, diarrhea, and vitamin B-12 deficiency. The treatment is surgical, and if Jobs had ALS then his undergoing additional surgery made perfect sense.
Unfortunately, my speculation was wrong, as I found out a year later.
Pushing the limits of science-based medicine
The real bombshell regarding Steve Jobs’ health came in 2009. It’s a useful story to discuss because it demonstrates the limits of SBM and how sometimes they can be pushed in the cases of rare diseases for which there is little data. In early January, Jobs reported that he had been experiencing a “hormone imbalance” that needed treatment. In retrospect, even with all the secrecy, it should have been blazingly obvious that his insulinoma had recurred. All the signs were there, even through the veil of Apple secrecy, but somehow it was kept mostly out of the news until June, when the Wall Street Journal reported that Jobs had undergone a liver transplant:
In early January, Mr. Jobs said he had a hormone imbalance that was “relatively simple and straightforward” to treat. But about a week later, he announced that the issue was more complex than he had thought, and in a letter to employees he said he would be taking a leave and Mr. Cook would take over temporarily.
William Hawkins, a doctor specializing in pancreatic and gastrointestinal surgery at Washington University in St. Louis, Mo., said that the type of slow-growing pancreatic tumor Mr. Jobs had will commonly metastasize in another organ during a patient’s lifetime, and that the organ is usually the liver. “All total, 75% of patients are going to have the disease spread over the course of their life,” said Dr. Hawkins, who has not treated Mr. Jobs.
Getting a liver transplant to treat a metastasized neuroendocrine tumor is controversial because livers are scarce and the surgery’s efficacy as a cure hasn’t been proved, Dr. Hawkins added. He said that patients whose tumors have metastasized can live for as many as 10 years without any treatment so it is hard to determine how successful a transplant has been in curing the disease.
At the time, I looked into the issue, given that it had been a long time since I had finished my surgical oncology fellowship and I no longer took care of patients with neuroendocrine tumors, having specialized in breast cancer. In general, for neuroendocrine tumors metastastic to the liver, the first options to be considered are ablative options. These can include surgery, if the tumors are resectable, or ablation by various methods, such as radiofrequency ablation (RFA, or, as we like to say, “cooking the tumors”) or cryoablation (cryo, a.k.a. freezing the tumors). Surgery can be curative if the lesions are confined to a volume of liver that can be completely resected, and RFA is generally reserved when there are lesions in multiple lobes not amenable to surgical resection. For the consideration of a liver transplant, a patient must have multiple lesions in multiple lobes of the liver that are too numerous even to be cooked by RFA or frozen by cryo. Moreover, there can be no evidence of tumor anywhere other than in the liver. In addition, another indication is that symptoms must be such that they can’t be controlled by medical therapy. For an insulinoma, controlling the symptoms due to hypoglycemia can actually be quite difficult; so the type of tumor Jobs produced symptoms that are more difficult to palliate than the average neuroendocrine tumor.
So what are the results of liver transplant for neuroendocrine tumors? Because these tumors are so uncommon, there’s never going to be a randomized clinical trial. All that can be found in the literature consists of small case series or retrospective analyses.The kindest and most generous characterization that can be made is that that the evidence for treating neuroendocrine tumors metastatic to the liver with liver transplantation is mixed at best. A recent retrospective analysis of the UNOS database produced this survival curve (click to embiggen):
Link
A picture’s worth a thousand words, and based on this curve alone Jobs had a little better a 50-50 chance of living as long as he did (almost two and a half years). Unfortunately, he fell out on the wrong side of those odds. Jobs’ case aside, the authors conclude:
Although surgical resection still should be considered the treatment of choice in patients with liver metastases from NETs, transplantation for unresectable disease is indicated in patients with stable disease without disseminated metastases. A national database should be developed to better understand predictors of outcomes in this patient population and to help produce and standardize selection criteria to obtain better outcomes. We believe it is time to carefully revise this indication.
Who could argue with more research? Jobs’ case is, however, an excellent example of the difficulties in deciding on a course of action when the evidence available is sparse. For instance, if he had progressive disease (and in retrospect it sounds as though he probably did), he probably should not have undergone transplantation, given that immunosuppression would probably facilitate the growth of microscopic tumor deposits and also given that it is possible to provide prolonged palliation by other means. Yet, to Jobs and his doctors at the time, the picture was probably anything but clear, other than that things were getting worse.
The war to claim Steve Jobs’ narrative
Since the death of Steve Jobs, there has been a struggle to claim his narrative as “evidence” to support a world view. On the one side, there are quacks using and abusing Jobs’ memory, as they’ve used and abused those of so many other dead celebrities to “prove” that “conventional medicine killed them.” Predictably, first out of the box is the despicable crank known as Mike Adams. Adams has made a not-so-savory name for himself for ghoulishly (and gleefully) taking advantage of the death of celebrities in order to blame “conventional” medicine for having killed them. It’s a depressing and predictable pattern that continued with Steve Jobs. Indeed, Adams produced an article on Steve Jobs’ death so quickly (within hours of the announcement of Jobs’ passing) that I have to wonder if he had already had it written and teed up, just waiting for Jobs to die. Whatever the case, Adams entitled his article, again predictably enough given his past history, Steve Jobs dead at 56, his life ended prematurely by chemotherapy and radiotherapy for cancer, which begins with a typical charge (from Adams) that Jobs’ gaunt appearance was due to chemotherapy, not the progression of his cancer, blaming his death on the “cancer industry” and claiming that it was “toxins” that caused his cancer and that “natural” treatments could have cured him.
Just yesterday, Joe Mercola chimed in, apparently managing to interview Nicholas Gonzalez right after Jobs’ death to produce this video:
Link
Gonzalez, you may recall, is the originator of the “Gonzalez therapy” for pancreatic cancer, a therapy involving various juices, dietary manipulations, coffee enemas, and many, many supplements, as many as 150 pills per day. Also recall that his therapy, besides having no biological plausibility, has been convincingly demonstrated not to work.
The truly ironic thing, of course, is that Jobs lived a lifestyle very similar to the one that Adams touts as an all-purpose cancer preventative. As I mentioned before, Jobs was widely reported to be a vegan but was a was in fact a pescatarian. Jobs did not eat meat and the animal rights group PETA has paid homage to him after his death for being a vegetarian and sympathetic to animal rights causes. The point, of course, is that Steve Jobs ate a diet and lived a lifestyle far more similar to the kind that Adams touts as a cure-all or prevent-all for cancer than the “typical” fat- and meat-laden American diet that Adams lambastes. Upon his initial diagnosis, as we have seen, he eschewed surgery for nine months, trying to treat his cancer with a “special diet.” It’s not clear just what, exactly, this “special diet” was. Oddly enough, Gonzalez hints that he knows something:
He wanted to see an alternative. In fact when he was first diagnosed, he got some dietary program — again, he was very secretive of that — So I don’t exactly know what he did at that point. But through his acupuncturist, there was communication. He was getting acupuncture, and he was doing some alternative things as far as I know. This acupuncturist actually talked to me, discussing the situation. She was really anxious for him to come and see me. But he chose not to do that.
You know, I always respect the patients’ right to choose the therapy they want to choose, so I would never dispute that. The patients have to make the decisions based on what they want to do. But she was very adamant; in fact, she knew about all my works in the alternative world. He had seen alternative-type practitioners. She really wanted for him to come and see me. He chose not to do that. From my perspective, it was unfortunate, because he was such a gift to the world in terms of his inventions and genius in the past 30 years.
Yes, that’s Gonzalez claiming that he could have saved Jobs if only Jobs had listened to an acupuncturist.
For as much as the quacks are trying to claim that they could have cured Jobs if only they had given them the chance, there is, however, the chance of taking the opposite argument, namely that Jobs might have died because of his embrace of non-science-based treatments, too far in the other direction. Unfortunately, there is a skeptic who should really know better who did just that, using Steve Jobs’ death as evidence of the harm that alternative medicine can do. Now, given my reputation as someone who relentlessly applies the cudgel of reason, science, and critical thinking squarely to the back of the head of woo on a regular basis, you just might think that I would heartily approve of this line of argument. You’d be wrong, and not because I have any qualms whatsoever about appropriately blaming alternative medicine when someone pursues alternative medicine and ultimately dies. (I have, after all, done it myself on several occasions.) The key word is “appropriately,” and the reason that I’m not so hot on using Jobs’ death as a “negative anecdote” against “alternative” medicine is because I’m not so sure how appropriate doing so is in Jobs’ case. While Jobs certainly didn’t do himself any favors by waiting nine months to undergo definitive surgical therapy of his tumor, it’s very easy to overstate the potential harm that he did to himself by not immediately letting surgeons resect his tumor shortly after it was diagnosed eight years ago. Unfortunately, Brian Dunning does exactly that in his post A Lesson in Treating Illness (also posted over at Skepticblog):
I’m sad that today I’m adding a slide to one of my live presentations, adding Steve Jobs to the list of famous people who died treating terminal diseases with woo rather than with medicine.
Except that Jobs didn’t; at least, he didn’t for the most part. Aside from the initial nine months, Jobs, as far as we know, relied on exclusively on conventional therapy to treat his disease. In fact, he underwent the most invasive, cancer aggressive operation (the Whipple pancreaticoduodenectomy), which is one of the biggest, if not the biggest operation, that surgical oncologists do. Then, after his tumor recurred in his liver, he underwent the biggest, mot technically complex type transplant operation there is, a liver transplant. When his cancer recurred a second time earlier this year, Jobs was seen going to the Stanford Cancer Center in Palo Alto, California, looking frail and thin.
Moreover, the other “alternative” therapy reportedly pursued by Jobs in Switzerland was a therapy based on radiation therapy, you know, the kind of therapy known to the likes of Adams as “burning” the cancer. In any case, Jobs apparently traveled to the University Hospital of Basel in Switzerland to receive a form of “hormone-delivered radiotherapy.” For some reason this is being portrayed in the press as somehow “alternative.” In reality, from what I can tell, it’s science-based, but experimental. Basically, in this therapy, radioisotopes are linked to a peptide hormone, receptors for which are found on the tumor being treated. The hormone then binds to the receptors, bringing the radioisotope close enough to the tumor cells to deliver a high dose of radiation. This therapy is not “alternative”; although it’s not standard of care, it’s definitely science-based.
All of this leaves the sole remaining question regarding the issue of “alternative” medicine and cancer in the case of Steve Jobs as: Did Jobs significantly decrease his chance of surviving his cancer by waiting nine months to undergo surgery? It seems like a no-brainer, but it turns out that that’s actually a very tough question to answer. Certainly, it’s nowhere near as certain as Dunning tries to make it seem when he writes things like:
Eventually it became clear to all involved that his alternative therapy wasn’t working, and from then on, by all accounts, Steve aggressively threw money at the best that medical science could offer. But it was too late. He had a Whipple procedure. He had a liver transplant. And then he died, all too young.
One has to be very, very careful about making this sort of argument. For one thing, it could not have been apparent that it was “too late” back in 2004, when it became clear that Jobs’ dietary manipulations weren’t working. For another thing, we don’t know how large the tumor was, whether it progressed or simply failed to shrink over those nine months, and by how much it increased in size, if increase in size it did. Again, I hope that information will be revealed in the Jobs’ biography; such data would go a long way in clarifying just how much, if at all, Jobs might have compromised his chance for cure by delaying. Right now, we just don’t know enough to make even a good guesstimate. Based on what we do know now, the thing that has to be remembered is that neuroendocrine tumors of the pancreas tend for the most part to be fairly indolent, slow-growing tumors It’s very much overstating the case to write, as Dunning does:
As he dieted for nine months, the tumor progressed, and took him from the high end to the low end of the survival rate.
We don’t know that this was the case, and we certainly can’t say that for sure — or even with a great deal of certainty. Dunning is massively overstating the case in his eagerness to attack alternative medicine. This is a mistake. Again, I would certainly agree that Jobs did himself no favors by waiting. If I were his physician or the surgeon to whom he was referred, I would have done my best to talk him out of such a course of action, but I would do so more out of the uncertainty of not knowing how fast his tumor would progress. So, is it possible, even likely, that Jobs compromised his chances of survival? Yes. Is it definite that he did? No, it’s not, at least it’s not anywhere as definite as Dunning makes it sound. In fact, based on statistics alone, it’s unlikely that a mere nine months took Jobs “from the high end to the low end of the survival rate,” as Dunning puts it. That’s just not how insulinomas usually behave from a biological standpoint. They’re too indolent, and that’s not even taking into account issues of lead time bias and other confounding factors that would make comparisons of operating early versus operating later not as straightforward as one might think. Remember, Jobs’ tumor was probably what we call an “incidentaloma”; i.e., a finding picked up incidentally on a diagnostic test done for another reason. Consequently, it might not have caused symptoms for a long time. Or it might have already been causing symptoms, just symptoms that normally don’t warrant a CT scan. We don’t know; there isn’t enough information. Be that at it may, I have no doubt that Jobs might well have compromised his chances of survival by delaying, but it’s just not scientifically supportable to leap to the conclusion, as Dunning does, that he compromised his chances so much that “alternative medicine killed him.” What is known about Jobs’s case and insulinomas do not support such a conclusion; at worst they support a conclusion that Jobs might have decreased his chances somewhat.
If there’s one thing we’re learning increasingly about cancer, it’s that biology is king and queen, and that our ability to fight biology is depressingly limited. In retrospect, we can now tell that Jobs clearly had a tumor that was unusually aggressive for an insulinoma. Such tumors are usually pretty indolent and progress only slowly. Indeed, I’ve seen patients and known a friend of a friend who survived many years with metastatic neuroendocrine tumors with reasonable quality of life. Jobs was unfortunate in that he appears to have had an unusually aggressive form of the disease that might well have ultimately killed him no matter what. That’s not to say that we shouldn’t take into account his delay in treatment and wonder if it contributed to his ultimate demise. It very well might have, the key word being “might.” We don’t know that it did, which is one reason why we have to be very, very careful not to overstate the case and attribute his death as being definitely due to the delay in therapy due to his wanting to “go alternative.” Finally, Jobs’ case illustrates the difficulties with applying SBM to rare diseases. When a disease is as uncommon as insulinomas are, it’s very difficult for practitioners to know what the best course of action is, and that uncertainty can make for decisions that are seemingly bizarre or inexplicable but that, if you have all the information, are supportable based on what we currently know.

   Steve Jobs’ medical reality distortion field
David Gorski 
Link
As I pointed out in my previous post about Steve Jobs, I’m a bit of an Apple fan boy. A housemate of mine got the very first Mac way back in 1984, and ever since I bought my first computer that was mine and mine alone back in 1991 (a Mac LC), I’ve used nothing but Macintosh computers, except when compelled to use Windows machines by work—and even then under protest. Indeed, as I searched for jobs at various times in my life, I asked myself whether I could accept a job at an institution that didn’t permit me to have a Mac in my office, such as the V.A. Fortunately, I never had to make that choice. All of this explains why I paid a lot of attention to Steve Jobs and also why his death saddened me and, relevant to this blog, the clinical history of the cancer that killed him fascinates me.
It’s often been said that there was a sort of “reality distortion field” around Steve Jobs. It was a part joking, part derogatory, part admiring term applied to Jobs’ talent for persuasion in which, through a combination of personal charisma, bravado, hyperbole, marketing, and persistence, Jobs was able to persuade almost anyone, even developers and engineers, of almost anything. In particular, it referred to his ability to convince so many people that each new Apple product was the greatest thing ever, even when that product had obvious flaws. Unfortunately, as more news comes out about how Steve Jobs initially dealt with his diagnosis of a neuroendocrine tumor of the pancreas (specifically, an insulinoma) back in 2003 and 2004, it’s become apparent that Jobs had his own medical reality distortion field, at least in the beginning right after his diagnosis of a rare form of pancreatic cancer, that allowed him to come to think that he might be able to reverse his cancer with diet plus various “alternative” modalities.
In the immediate aftermath of Steve Jobs’ death, I summarized the facts about Jobs’ case that were known at the time. In particular, I took issue with the claims of a skeptic that “alternative medicine killed Steve Jobs.” At the time, I pointed out that, although it was very clear that Steve Jobs did himself no favors by delaying his initial surgery for nine months after his initial diagnosis, we do not have sufficient information to know what his clinical situation was and therefore how much, if at all, he decreased his odds of survival by not undergoing surgery expeditiously. To recap: Did Steve Jobs harm himself by trying diet and alternative medicine first? Quite possibly. Did alternative medicine kill him? As I’ve argued before, that’s impossible to say, and any skeptic who dogmatically makes such an argument has taken what we known beyond what can be supported. Regular readers know that when I see a story that looks as though “alternative medicine” directly contributed to the death of someone, I usually pull no punches, but in this case I had a hard time being so definitive because the unknowns are too many, with all due respect to Ramzi Amri, a Research Associate at Harvard Medical School who in my opinion also went too far. I did, however, point out that I’m always open to changing my opinion if new evidence comes in. Jobs was always incredibly secretive about his medical condition, so much so that it didn’t even come out in the press until after it had happened that he had undergone a liver transplant in 2008 for metastatic insulinoma in his liver, just as his cancer diagnosis in 2003 remained secret for 9 months, not being revealed until he sent an e-mail to Apple employees announcing that he had undergone surgery.
It turns out that, with the imminent release of a major biography of Steve Jobs, more information is finally trickling out about his medical history. For instance, Jobs’ biographer Walter Isaacson is going to appear on 60 Minutes this Sunday, and apparently he is going to say this:
Everyone else wanted Steve Jobs to move quickly against his tumor. His friends wanted him to get an operation. His wife wanted him to get an operation. But the Apple CEO, so used to swimming against the tide of popular opinion, insisted on trying alternative therapies for nine crucial months. Before he died, Jobs resolved to let the world know he deeply regretted the critical decision, biographer Walter Isaacson has told 60 Minutes.
“We talked about this a lot,” Isaacson told 60 Minutes of Jobs’s decision to treat a neuroendocrine tumor in his pancreas with an alternative diet rather than medically recommended surgery. “He wanted to talk about it, how he regretted it….I think he felt he should have been operated on sooner… He said, ‘I didn’t want my body to be opened…I didn’t want to be violated in that way.’”
Isaacson is also quoted as saying about Jobs:
He’s regretful about it… Soon everybody is telling him, ‘Don’t try and treat it with these roots and vegetables and these kinds of things…’ By the time they operate on him they notice it has spread to the tissues around the pancreas.
You know, I think I’ll have to buy this book when it comes out next week, if only to read the chapters on Jobs’ illness. Assuming that the account above is true, what does it tell us? First, it doesn’t significantly change my original assessment that, at the time of surgery in 2004, Jobs probably didn’t have metastatic disease. The reason I say that is because if Jobs had any evidence of metastatic disease, it is highly doubtful that a surgical oncologist would have undertaken as huge an operation as the Whipple procedure, an operation that is usually only performed with curative intent. It’s very rare that this operation is done for solely palliative purposes, because the potential for complications is fairly high, and even when there are no complications it permanently alters the GI physiology of the person undergoing it. With that in mind, the report above implies to me is that Jobs’ tumor had grown larger and started to invade through the capsule of the pancreas into the surrounding fatty connective tissue. Further, it’s also not clear whether this tumor was seen on imaging before his operation or whether it was the finding of microscopic tumor deposits outside of the pancreas in the surgical specimen removed. Given how indolent insulinomas usually are, especially if they’re functional, as Jobs’ tumor appears to have been from all news reports (when it recurred Jobs attributed his medical leave to a “hormone imbalance”), it’s not clear that his surgeon wouldn’t have found tumor spread found outside of the pancreas if he had undergone surgery right away. As Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society has pointed out, people “live with these tumors far longer than nine months before they’re even diagnosed.” I suggest going back and read my post on the early detection of cancer, particularly the part about lead time bias, for an explanation of why the nine month delay might not have mattered much. As I have said before, biology is king and queen, and for certain tumors in certain patients biology trumps whatever we can throw at them.
Another interesting tidbit of information coming out just now is just what Jobs did during those nine months during which he delayed having surgery. This ABC News report hints at it:
Jobs, fascinated by Eastern mysticism in his youth, believed in alternative herbal treatments, and sources have told ABC News in the past that they thought he minimized the seriousness of his condition. One source close to Jobs said he kept his medical problems private, even from members of Apple’s board of directors — who finally had to persuade him his health was of critical importance to Apple’s success and the value of its stock to shareholders.
And this AP report states:
Instead, he tried a vegan diet, acupuncture, herbal remedies and other treatments he found online, and even consulted a psychic. He also was influenced by a doctor who ran a clinic that advised juice fasts, bowel cleansings and other unproven approaches, the book says, before finally having surgery in July 2004.
This is fairly vague, although one wonders if this acupuncturist is identified in the book, you know, the one who allegedly told Dr. Nicholas Gonzalez that she was trying to get Jobs to see him. Maybe Gonzalez wasn’t lying after all, because the description in the passage above does sound a lot like the Gonzalez protocol, which involves juice fasts, a whole lot of supplements, various other radical diet manipulations, plus daily (or more) coffee enemas. Could it be that Gonzalez did for a while influence Jobs?
Perhaps the book will tell.
Then there’s this video from the ABC News report: Link
There he is, at right about the 2:00 mark: Dr. Dean Ornish. In fact, from the news report, it appears that Dr. Ornish was not only Jobs’ friend but his doctor as well. Dr. Ornish is a problematic woo-prone physician in that, while hanging out with the likes of Andrew Weil, Rustum Roy, and Deepak Chopra, he tries to do actual science but unfortunately just doesn’t do a particularly good job of it. That in and of itself wouldn’t be so horrible, except that he draws very strong inferences from what his data show that go far beyond what is supportable by the science. Despite all these problems, there is still hope that Ornish is reachable by science-based medicine; he just has to give up his tendency to keep linking his diet with “complementary and alternative medicine” (CAM) and “integrative medicine” and embrace more rigorous, hypothesis-grounded science.
So, until I can get my hands on the book (and actually have time to read it, or at least the chapters on Jobs’ illness), what can I reasonably conclude based on what is known now? First, my original assessment has changed only slightly. Based on this new information, it appears likely to me that Jobs probably did decrease his chances of survival through his nine month sojourn into woo. On the other hand, it still remains very unclear by just how much he decreased his chances of survival. My best guesstimate is that, thanks to the indolent nature of functional insulinomas and lead time bias, it was probably only by a relatively small percentage. I also feel compelled to point out that accepting that Jobs’ choice to try “alternative medicine” first probably decreased somewhat his chances of surviving his cancer is a very different thing than concluding that “alternative medicine killed Steve Jobs,” which is in essence what Ramzi Amri and Brian Dunning both did. The first statement is a nuanced assessment of probabilities based on science and taking into account uncertainty; the latter statement is black-and-white thinking, in essence the mirror image of Nicholas Gonzalez’s claim that if only Jobs had come to see him he could have been saved.
Finally, what does this incident say about alternative medicine for cancer? Certainly, it shows that even someone as brilliant as Steve Jobs can be prone to denial, and, yes, even magical thinking, as this ABC News report points out:
How could Jobs have made such a decision?
“I think that he kind of felt that if you ignore something, if you don’t want something to exist, you can have magical thinking…we talked about this a lot,” Isaacson told CBS News.
No doubt that’s another key component of the appeal of alternative medicine: Magical thinking. Just eat this root, do these colon cleanses, let this healer manipulate your energy fields, and everything will be fine. No nasty invasive surgery that will permanently alter your body and how it functions. No poisonous chemotherapy. Unfortunately, reality doesn’t work this way, no matter how powerful the reality distortion field. Ultimately, reality intrudes, as it did for Jobs. When it did, when a followup scan apparently revealed that his insulinoma had grown, Jobs realized he had made a horrible mistake and tried to correct his course by undergoing surgery right away. It’s not clear whether his time in his self-created medical reality distortion field ultimately led to his demise or whether his fate was sealed when he was first diagnosed. Again, there’s just too much uncertainty ever to know for sure, and even if Jobs did decrease his odds of survival significantly it’s impossible to say whether the delay meant the difference between life and death in his specific case. What is clear is that no reality distortion field can long hold cancer at bay. Reality always eventually wins over magical thinking, no matter how much it might appear that magical thinking is winning at any given time.

   “And one more thing” about Steve Jobs’ battle with cancer
David Gorski
Link
I’ve written quite a bit about Steve Jobs in the wake of his death nearly four weeks ago. The reason, of course, is that the course of his cancer was of intense interest after it became public knowledge that he had cancer. In particular, what I most considered to be worth discussing was whether the nine month delay between Jobs’ diagnosis and his undergoing surgery for his pancreatic insulinoma might have been what did him in. I’ve made my position very clear on the issue, namely that, although Jobs certainly did himself no favors in delaying his surgery, it’s impossible to know whether and by how much he might have decreased his chances of surviving his cancer through his flirtation with woo. However much his medical reality distortion field might have mirrored his tech reality distortion field, my best guess was that Jobs probably only modestly decreased his chances of survival, if that. I also pointed out that, if more information came in that necessitated it I’d certainly reconsider my conclusions.
The other issue that’s irritated me is that the quackery apologists and quacks have been coming out of the woodwork, each claiming that if only Steve Jobs had subjected himself to this woo or taken this supplement, he’d still be alive today. Nicholas Gonzalez was first out of the gate with that particularly nasty, unfalsifiable form of fake sadness, but he wasn’t the only one. Recently Bill Sardi claimed that there are all sorts of “natural therapies” that could have helped Jobs, while Dr. Robert Wascher, MD, a surgical oncologist from California (who really should know better but apparently does not) claims that tumeric spice could have prevented or cured Steve Jobs’ cancer, although in all fairness he also pointed out that radical surgery is currently the only cure. Unfortunately, he also used the failure of chemotherapy to cure this kind of cancer as an excuse to call for being more “open-minded” to alternative therapies. Even Andrew Weil, apparently stung by the speculation that Jobs’ delay in surgery to pursue quackery might have contributed to his death, to tout how great he thinks integrative cancer care is.
Last week, Amazon.com finally delivered my copy of Walter Isaacson’s biography of Steve Jobs. I haven’t had a chance to read the whole thing yet, but, because of the intense interest in Jobs’ medical history, not to mention a desire on my part to see (1) if there were any new information there that would allow me to assess how accurate my previous commentary was and (2) information that would allow me to fill in the gaps in the story from the intense media coverage. So I couldn’t help myself. I skipped ahead to the chapters on his illness, of which there are three, entitled Round One, Round Two, and Round Three. Round One covers the initial diagnosis. Round Two deals with the recurrence of Jobs’ cancer and his liver transplant. Finally, Round Three deals with the final recurrence of Jobs’ cancer, his decline, and death.
Before I start, a warning: I’m going to discuss these issues in a fair amount of detail. If you want “medical spoilers,” don’t read any further. On the other hand, one spoiler I will mention is that there was surprisingly little here that wasn’t reported before; the only difference is that there is more detail. However, the details are informative.
Round One
If there’s one thing I wanted the most information about from this biography, it was more details about Jobs’ initial presentation. After all, I had put my name on the line by arguing that his delay in surgical therapy probably didn’t make that much of a difference, and I was very curious to find out whether there was more information that would allow me to assess whether I should change my initial assessment. I was also interested in whether there was more information about what specific kinds of pseudoscience Jobs had pursued.
I was disappointed on both counts, but that’s not to say that this chapter didn’t provide me with some useful information.
The first thing I learned was the reason Jobs was getting CT scans. Remember, the diagnosis of his cancer was actually serendipitous. It was, as we like to call it, an incidentaloma in that it was an incidental finding on a scan done for a different purpose. In this case, the purpose of the CT scan was to examine his kidneys and ureter, as he had developed recurrent kidney stones beginning in the late 1990s. Jobs attributed them to his working too hard running both Apple and Pixar. In any case, in October 2003, Jobs just happened to run into his urologist, who pointed out that he hadn’t had a CT scan of his urinary system in five years and suggested that he get one. He did, and there was a suspicious lesion on his pancreas. His doctors urged Jobs to get a special CT scan known as a pancreatic scan, which basically provides a lot more detail in the region of the pancreas. He didn’t; it took a lot of urging before he did it, and when he did at first his doctors thought he had standard pancreatic adenocarcinoma, the deadly kind that few survive. As has been reported before, though, Jobs underwent a transduodenal biopsy, and the diagnosis of neuroendocrine tumor was made.
Unfortunately, no further information is provided that we didn’t already know about regarding what Jobs did during the nine months he tried “alternative” therapies. He kept to a strict vegan diet that included large quantities of fresh carrot and fruit juices. (Shades of the Orange Man!) In addition:
To that regimen, he added acupuncture, a variety of herbal remedies, and occasionally a few other treatments he found on the internet or by consulting people around the country, including a psychic. For a while, he was under the sway of a doctor who operated a natural healing clinic in southern California that stressed the use of organic herbs, juice fasts, frequent bowel cleanings, hydrotherapy, and the expression of all negative feelings.
Unfortunately, the natural healing clinic wasn’t identified. I did a bit of searching, but I couldn’t narrow down the possibilities. There’s a lot of woo in southern California. Even so, as much as many of us here would like to condemn Dean Ornish, who was Jobs’ friend, apparently Ornish did try to do right by him:
Even the diet doctor Dean Ornish, a pioneer in alternative and nutritional methods of treating diseases, took a long walk with Jobs and insisted that sometimes traditional methods were the right option. “You really need surgery,” Ornish told him.
Ornish appears for once to have been right.
There’s still more in this chapter. For example, the book states that on a followup CT scan showed that the tumor “had grown and possibly spread.” In addition, the operation that Jobs underwent was described as not being a “full Whipple procedure” but rather a “less radical approach, a modified Whipple that removed only part of the pancreas.” I can only speculate what Isaacson meant by that. A Whipple, standard or not, by definition removes part of the pancreas, specifically the head. Because of the anatomic constraints of the pancreas, the head of the pancreas usually can’t really be removed without removing a significant portion of the duodenum and the common bile duct, and often some small intestine. That’s why, by definition, a Whipple operation includes removing the duodenum and part of the intestine; if those are not removed, then it’s not a Whipple procedure. I suspect that what Isaacson probably meant was a pylorus-sparing Whipple, as I discussed before. In this operation, part of the duodenum is still removed, but not part of the stomach, as in a standard Whipple. The advantage is that a pylorus-sparing Whipple can often alleviate many of the digestive complications of a Whipple operation, such as the “dumping syndrome,” because the pylorus is preserved.
Finally, it is revealed:
During the operation the doctors found three liver metastases. Had they operated nine months earlier, they might have caught it before it spread, although they would never know for sure.
Or, on the other hand, chances are very good that those liver metastases were there nine months before. Insulinomas tend not to grow so fast that they can progress from micrometastases to metastases visible to the surgeons in that short a period of time. So, while on the surface this revelation would seem to the average lay person to indicate that Jobs’ delay very well might have killed him, in reality, thanks to lead time bias, it probably means that his fate was sealed by the time he was diagnosed. Certainly, it means that claims such as the one made by Dr. Robert Wascher are not based in science and in fact are irresponsible:
In a recent interview with Newsmax Health Wascher explained how the simple act of consuming turmeric, a natural spice popular in Asian and Indian food, may be enough to prevent and cure the type of pancreatic cancer that afflicted former Apple CEO Steve Jobs, as well as other forms.
The same goes for Nicholas Gonzalez’s claims that he could have saved Jobs.
Round Two
What’s primarily interesting in the new information in this chapter are the details about Jobs’ being listed for liver transplant and how he ended up getting a liver in Tennessee. There has been a lot of speculation that somehow Jobs used his great wealth to “jump the queue” and get a liver more rapidly than he was entitled. As I’ve argued before, he did not, as you will soon see.
One thing I learned that I was right about is that a significant reason for Job’s emaciation in the wake of his surgery was what I had speculated: Complications from his Whipple procedure combined with his obsessive vegan diet. That is, that was the cause before his cancer recurrence. Isaacson described how, even after he had married and had children, he continued to have dubious eating habits. For example, he would spend weeks eating the same thing and then suddenly change his mind and stop eating it. He’d go on fasts. His wife tried to get him to diversify his protein sources and eat more fish, but largely failed. His wife hired a cook who tried to cater to Jobs’ strange eating habits. Indeed, Jobs lost 40 lbs. just during the spring of 2008. Another thing I learned was just how sick Jobs was at this point. His liver metastases had led to excessive secretion of glucagon; he was in a lot of pain and taking narcotics, his liver apparently full of metastases.
It turns out that Jobs was listed for liver transplant in both California and Tennessee, as approximately 3% of transplant recipients manage to list themselves in two different states. Isaacson describes:
There is no legal way for a patient, even one as wealthy as Jobs, to jump the queue, and he didn’t. Recipients are chosen based on their MELD score (Model for End-stage Liver Disease), which uses lab tests of hormone levels to determine how urgently a transplant is needed and on the length of time they have been waiting. Every donation is closely audited, data are available on public websites (optn.transplant.hrsa.gov), and you can monitor your status on the wait list at any time.
Regarding the multiple listing in California and Tennessee:
Such multiple listing is not discouraged by policy, even though critics say it favors the rich, but it is difficult. There were two major requirements: The potential recipient had to be able to get to the chosen hospital within eight hours, which Jobs could do thanks to his plane, and the doctors from that hospital had to evaluate the patient in person before adding him to the list.
Isaacson also reveals that it was a fairly close call. Jobs’ condition was deteriorating rapidly. If he hadn’t been listed in Tennessee, he very likely would have died before a liver became available to him in California. As it was, it wasn’t clear that he wouldn’t die before a liver became available to him in Tennessee. It might seem a bit ghoulish, but it’s the sort of thinking that everyone who’s ever undergone a liver transplant has a hard time avoiding. Isaacson reports that by March 2009 Jobs’ condition was poor and getting worse, but that there was hope among his friends that, because St. Patrick’s Day was coming up and because Memphis was a regional site for March Madness, there was a high likelihood of a spike in automobile crashes due to all the revelry and drinking associated with those events. We even learn that the donor was a young man in his mid-twenties who was killed in a car crash on March 21. It also turns out that Jobs had complications after his surgery. From what I can gather from Isaacson’s account (it wasn’t entirely clear to me) Jobs refused a nasogastric tube when he needed it and as a result aspirated gastric contents when he was sedated, developing a severe postoperative aspiration pneumonia from which at that point “they thought he might die.” Worse, although the transplant was a success, his old liver was riddled with metastases throughout, and surgeons noted “spots on his peritoneum.” Whether these “spots” were metastatic tumor deposits, Isaacson does not say, but it’s a good bet that they probably were.
Assuming Isaacson’s report is accurate and if those “spots” on the peritoneum were indeed metastatic insulinoma, this new information leads me to question more strongly than I did in the past (actually, I didn’t question the decision much at all) whether a liver transplant was a reasonable course of action in Jobs’ case, given that Jobs’ tumor burden in his liver seems to have been much higher than previously reported. If the spots were not cancer, then the transplant, although not contraindicated, was still high risk. In retrospect, it is not surprising that Jobs’ tumor recurred fairly quickly, less than two years after his transplant. Even Isaacson notes that by characterizing Jobs’ transplant as “a success, but not reassuring.” That’s because extrahepatic disease (disease outside of the liver, which peritoneal implants qualify as) is usually an absolute or near-absolute contraindication for liver transplant for cancer, at least in the case of hepatocellular cancer, because the chance of recurrence is so high. I make the analogy to adenocarcinoma of the pancreas, the much more lethal pancreatic cancer that is far more common than the insulinoma that Steve Jobs had. Often, surgeons will perform laparoscopy before attempting a curative resection (the aforementioned Whipple operation). If nodules are noted on the peritoneum, they are biopsied, and if the frozen section comes back as adenocarcinoma, the attempt at curative resection is aborted. The same is true when undertaking a curative resection for liver metastases from colorectal cancer, which can result in long term survival 30-40% of the time, but not if there’s even a hint of a whiff of extrahepatic disease. Although evidence is sketchy for insulinomas, because they’re such rare tumors, it’s hard not to conclude that the same is likely true for them and that extrahepatic disease is a contraindication to liver transplant.
Round Three
This chapter was, as you might imagine, a depressing read. In actuality, there wasn’t much new there or even much in the way of medical details that add much to what we know about Jobs’ course, aside from one revelation that I’ll discuss. First, to begin, in late 2010 Jobs started to feel sick again. Isaacson describes it thusly:
The cancer always sent signals as it reappeared. Jobs had learned that. He would lose his appetite and begin to feel pains throughout his body. His doctors would do tests, detect nothing, and reassure him that he still seemed clear. But he knew better. The cancer had its signaling pathways, and a few months after he felt the signs the doctors would discover that it was indeed no longer in remission.
Another such downturn began in early November 2010. He was in pain, stopped eating, and had to be fed intravenously by a nurse who came to the house. The doctors found no sign of more tumors, and they assumed that this was just another of his perioic cycles of fighting infections and digestive maladies.
In early 2011, doctors detected the recurrence that was causing these symptoms. Ultimately, he developed liver, bone, and other metastases and was in a lot of pain before the end.
The other issue discussed in this final chapter that is of interest to SBM readers is that Jobs was one of the first twenty people in the world to have all the genes of his cancer and his normal DNA sequenced. At the time, it cost $100,000 to do. This sequencing was done by a collaboration consisting of teams at Stanford, Johns Hopkins, and the Broad Institute at MIT. Scientists and oncologists looked at this information and used it to choose various targeted therapies for Jobs throughout the remainder of his life. Whether these targeted therapies actually prolonged Jobs’ life longer than standard chemotherapy would have is unknown, particularly given that Jobs underwent standard chemotherapy as well. It is rather interesting to read the account, however, of how Jobs met with all his doctors and researchers from the three institutions working on the DNA from his cancer at the Four Seasons Hotel in Palo Alto to discuss the genetic signatures found in Jobs’ cancer and how best to target them. Isaacson reports:
By the end of the meeting, Jobs and his team had gone through all of the molecular data, assessed the rationales for each of the potential therapies, and come up with a list of tests to help them better prioritize these.
The results of this meeting were sequential regimens of targeted drug therapies designed to “stay one step ahead of the cancer.” Unfortunately, as is all too often the case, the cancer ultimately caught up and passed anything that even the most cutting edge oncologic medicine could do. It’s always been the problem with targeted therapy; cancers evolve resistance, as Jobs’ cancer ultimately did.
What can we learn?
Even now, nearly four weeks later, there remains considerable discussion of Jobs’ cancer and, in particular, his choices regarding delaying surgery. Just yesterday, a pediatrician named Michele Berman speculating How alternative medicine may have killed Jobs. The article basically consists of many of the same oncologically unsophisticated arguments that I complained about right after Jobs’ death, some of which are included in another blog post on Celebrity Diagnosis. Clearly, an education in lead time bias is required. Does any of this mean that it was a good idea (or even just not a bad idea) for Jobs to have delayed having surgery for nine months? Of course not. Again, surgery was his only hope for long term survival. However, as I’ve pointed out before, chances are that surgery right after his diagnosis probably wouldn’t have saved Jobs, but there was no way to be able to come to that conclusion except in retrospect, and even then the conclusion is uncertain.
Although it’s no doubt counterintuitive to most readers (and obviously to Dr. Berman as well), finding liver metastases at the time of Jobs’ first operation strongly suggests this conclusion because it indicates that those metastases were almost certainly present nine months before. Had he been operated on then, would most likely would have happened is that Jobs’ apparent survival would have been nine months longer but the end result would probably have been the same. None of this absolves the alternative medicine that Jobs tried or suggests that waiting to undergo surgery wasn’t harmful, only that in hindsight we can conclude that it probably didn’t make a difference. At the time of his diagnosis and during the nine months afterward during which he tried woo instead of medicine, it was entirely reasonable to be concerned that the delay was endangering his life, because it might have been. It was impossible to know until later—and, quite frankly, not even then—whether Jobs’ delaying surgery contributed to his death. Even though what I have learned suggests that this delay probably didn’t contribute to Jobs’ death, it might have. Even though I’m more sure than I was before, I can never be 100% sure. Trust me when I say yet again that I really, really wish I could join with the skeptics and doctors proclaiming that “alternative medicine killed Steve Jobs,” but I can’t, at least not based on the facts as I have been able to learn them.
More interesting to me is part of the book where Isaacson reports on what was, in essence, Jobs’ indictment of a flaw in the medical system that he perceived after his second recurrence:
He [Jobs] realized that he was facing the type of problem that he never permitted at Apple. His treatment was fragmented rather than integrated. Each of his myraid maladies was being treated by different specialists—oncologists, pain specialists, nutritionists, hepatologists, and hematologists—but they were not being coordinated in a cohesive approach, the way James Eason had done in Memphis. “One of the big issues in the health care industry is the lack of caseworkers or advocates that are the quarterback of each team,” Powell said.
Isaacson contrasts the fragmented approach to Jobs’ care at Stanford to what is described as a far more integrated approach at Methodist Hospital in Memphis, where Jobs underwent his transplant and where Dr. James Eason was portrayed as having “managed Steve and forced him to do things…that were good for him.” Although it is certainly possible that the difference could be accounted for more by the lack of a person at Stanford with a strong enough personality to tell Jobs what he needed to do and get him to do it, compared to Dr. Eason, who clearly had a personality as strong as Jobs’, the description of fragmented care rings true to me, as I’ve seen this problem myself at various times during my career. One wonders if there is a way to infuse healthcare with some Apple-like integration of care, to build it into the DNA of the system itself as it is built into Apple’s DNA, without having to rely on personalities as strong as Dr. Eason’s apparently was.
Steve Jobs’ eight year battle with his illness is remarkable not so much because he had a rare tumor or because he flirted with alternative medicine for several months before undergoing surgery. Rather, I see Jobs’ case as providing multiple lessons in the complexity of cancer, the difficulty of the decisions that go into cancer care, and how being wealthy or famous can distort those choices. I’ve said it before, but now is as good a time as any to say it again: In cancer, biology is still king. Perhaps one day, when we know how to decode and interpret genomic information of the sort provided when Jobs’ had his tumors sequenced and use that information to target cancers more accurately, we will be able to dethrone that king more than just part of the time and only in certain tumors.

Is shameless self-promotion of your science a good idea?
David Gorski on September 10, 2012
Link
As part of my ongoing effort to make sure that I never run out of blogging material, I subscribe to a number of quack e-mail newsletters. In fact, sometimes I think I’ve probably overdone it. Every day, I get several notices and pleas from various wretched hives of scum and quackery, such as NaturalNews.com, Mercola.com, and various antivaccine websites. I think of it as my way of keeping my finger on the pulse of the antiscience and pseudoscience wing of medicine, but I must admit that I don’t really read them all, but they do allow me to know what the quacks are selling and what new arguments they’re coming up with without actually going to each of their websites. I can then judge by the headlines and the blurbs included in the e-mails whether I think it’s worth it to go to the website itself and, of course, whether the topic might represent fodder for a good blog post. I will admit that not all the sites I monitor are as loony as the Health Ranger’s. In fact, I monitor the blogs and websites of the National Center for Complementary and Alternative Medicine (NCCAM), various naturopath organizations, and the like in order to learn of the “respectable” arguments being used to tout various nostrums.Sometimes—albeit rarely—I even learn about some interesting new science.
One of the most common themes (besides antivaccine hysteria, claims that diet can prevent 95% of all cancers, etc.) tends to be one of a variety of pitches for various “cures” of serious diseases like cancer and heart disease that “they” don’t want you to know about; i.e., the Kevin Trudeau gambit. Who this “they” is can range from doctors to pharmaceutical companies to universities to the government, but the central message is that someone out there doesn’t want you to know The Truth. A variation of this sort of appeal is the claim that there is a promising new therapy, a cure even, usually natural, that is languishing somewhere because it can’t be patented, because pharmaceutical companies would lose money if it were ever validated and brought into clinical use, or because it goes against current medical dogma. It doesn’t even have to be natural. After all, dichloroacetate (DCA) is not exactly “natural.” After it was shown to have promise in animal models, a pesticide salesman named Jim Tassano sold DCA bought from chemical companies to desperate cancer patients from a website that claimed to be selling it only for pets with cancer, a ruse that fooled no one. Yet the “natural treatment” crowd embraced it whole-heartedly because it looked as though sellers of DCA were sticking it to The Man.
Unfortunately, it’s not just the quacks who use this method of selling their wares. I wish it were, but it’s not. Over the years, I’ve come across scientists who have used pitches that sound disturbingly like the pitches that I’ve just described. Sometimes, as I recently discussed, these pitches are no more than overselling results in university and medical journal press releases. Sometimes, they involve direct pitches to the public to fund their research. In many of these cases, I wonder whether the scientist involved is at the heart of it or whether he’s along for the ride, having been seduced by the blandishments of fundraisers, PR people, or others whose agenda might involve promoting his science but doesn’t necessarily involve safeguarding the scientist’s reputation. In fact, even Evangelos Michelakis, the University of Alberta researcher who discovered the antitumor effects of DCA, did some of that, albeit not in a manner that bothered me. It can be very tempting, I would imagine, if one has a therapy that’s been in the news and is frustrated by the inability to obtain funding to pursue what appears to be a promising line of research. This is particularly true these days, given the exceedingly tight paylines at the NIH and private foundations. Nevertheless, it makes me uncomfortable, and I was reminded of this discomfort when recently I came across a series of articles, in which a journalist was using a variant of the sales pitches above. While I’ll grant that what he’s trying to raise money for appears to be worthwhile research (more later), I also left feeling very uncomfortable at the sales pitch he had chosen, which resulted in his article “going viral” into other articles like this:
    • A cheap and effective cancer treatment … so why is it sitting in a Swedish laboratory refrigerator?
    • A virus that eats away cancer but is languishing in freezer
    • A virus that kills cancer: the cure that’s waiting in the cold
    • A Possible Cure for Neuroendocrine Cancer — It Can Be Named for You or a Loved One
    • A Virus That Kills Cancer~ Would Big Pharma Ever Allow It To See The Light Of Day? Never!!
Interestingly, I haven’t seen anything yet in the skeptical blogosphere about this story (although it’s quite possible I might have missed it given that I’ve only gone down a few pages of Google searches); so I thought I’d dig in, even at the risk of bringing more attention to the issue. Also, to be fair, I must point out that this hype seems to be eminating mainly from a British writer, Alexander Masters, whose friend Dido Davies suffers from pancreatic neuroendocrine cancer, essentially the same cancer that claimed the life of Steve Jobs nearly a year ago, and not the scientist working on the project, Prof. Magnus Essand of the Uppsala University in Sweden. In fact, at several points he tries to throw out a note of caution. That doesn’t stop him from taking advantage of Masters’—shall we say?—enthusiasm, nor does it stop the usual suspects from using Prof. Essand’s work to attack big pharma, promote conspiracy theories about “natural” cancer cures “they” don’t want you to know about, and in general attack science. And no wonder. Let’s take a look at Master’s article:
On the snow-clotted plains of central Sweden where Wotan and Thor, the clamorous gods of magic and death, once held sway, a young, self-deprecating gene therapist has invented a virus that eliminates the type of cancer that killed Steve Jobs.
‘Not “eliminates”! Not “invented”, no!’ interrupts Professor Magnus Essand, panicked, when I Skype him to ask about this explosive achievement.
‘Our results are only in the lab so far, not in humans, and many treatments that work in the lab can turn out to be not so effective in humans. However, adenovirus serotype 5 is a common virus in which we have achieved transcriptional targeting by replacing an endogenous viral promoter sequence by…’
It sounds too kindly of the gods to be true: a virus that eats cancer.
‘I sometimes use the phrase “an assassin who kills all the bad guys”,’ Prof Essand agrees contentedly.
Yet, Masters tells us, this miraculous cancer cure virus (in actuality, a virus that might or might not represent a promising new treatment) is sitting in a little freezer near Prof. Essand’s office “gathering frost,” even though it is “exquisitely precise,” “only causes mild, flu-like side effects in humans,” and results in tumors in mice “melting away.” Those bastards! Why won’t they fund this science? Can’t they see that it’s so groundbreaking that it must be funded? Can’t they see that every month that this virus sits in Prof. Essand’s freezer is a month when millions of patients (OK, thousands of patients—well, maybe hundreds of patients) are dying unnecessarily?
I exaggerate a bit, of course, but that is basically the tone of Masters’ article, leavened occasionally with only the gentlest words of caution that this is all preliminary, that it might not work out. Indeed, Masters lays down an incredible piece of utter nonsense in describing how he finds potential new therapies in science that might have promise:
It was on one of those evenings that I came across a blog about a quack in Mexico who had an idea about using sub-molecular particles – nanotechnology. Quacks provide a very useful service to medical tyros such as myself, because they read all the best journals the day they appear and by the end of the week have turned the results into potions and tinctures. It’s like Tommy Lee Jones in Men in Black reading the National Enquirer to find out what aliens are up to, because that’s the only paper trashy enough to print the truth. Keep an eye on what the quacks are saying, and you have an idea of what might be promising at the Wild West frontier of medicine. This particular quack was in prison awaiting trial for the manslaughter (by quackery) of one of his patients, but his nanotechnology website led, via a chain of links, to a YouTube lecture about an astounding new therapy for neuroendocrine cancer based on pig microbes, which is currently being put through a variety of clinical trials in America.
I don’t know about you, but if I were Prof. Essand, I wouldn’t exactly be flattered that this is how Masters came across my work. In fact, I’ve actually had a couple of quacks cite my work before, and if I’m ever in the mood maybe I’ll blog about it sometime. In the meantime, all I can say about what Masters writes here is that it meets the criteria of being so wrong it’s not even wrong. What you’re more likely to find on quack cites are treatments based on prescientific understandings of cancer (in essence, humors and “imbalances”); wishful thinking like The Secret (the German New Medicine, for example); a complete misunderstanding of human physiology and science (such as Robert O. Young’s quackery claiming that all cancer is due to excess acid or, of course, homeopathy); or, if you’re lucky, maybe the sort of understanding of cancer we had 100 years ago, such as the trophoblastic hypothesis that underlies the quackery that is known as the Gerson therapy. Where you do see cutting edge science on quack websites, you will see its abuse, not its being put to use to develop promising therapies outside the mainstream. Deepak Chopra’s abuse of quantum theory comes to mind. What you are incredibly unlikely to find is any sort of cutting edge science applied to the problem of cancer or other diseases in a way that’s likely to do anything except to fleece the marks. How Masters could be so extravagantly clueless about how science works is truly astonishing.
Still, Masters’ article intrigued me enough that I did some PubMed searches for Essand’s work and any other work related to this particular viral construct, Ad5[CgA-E1A-miR122]PTD. You probably all know me well enough by now to realize that, whenever I see a story about science or medicine that piques my interest, I try to “go to the tape,” so to speak; i.e., find the original research articles in the peer-reviewed literature describing the work. The reason, of course, is obvious; what is reported in the news about science and the actual science itself are sometimes related solely by coincidence.
In any case, this article from 2011 in Gene Therapy, this article from 2010 in PLoS ONE, and this article from 2007 in Clinical Cancer Research appear to be the main articles describing this particular virus. In brief Prof. Essand appears to have done a fairly clever thing. He’s taken an adenovirus and altered it to target it to neuroendocrine tumors while at the same time decreasing its ability to replicate in other cell types. He’s done this using two strategies. First, he took a promoter that is highly active in cells of neuroendocrine origin, the chromogranin-A (CgA) promoter. A promoter is a stretch of DNA that controls the expression of a gene. Depending upon what transcription factors (proteins that control gene expression) bind to its sequences, it can turn genes off or on based on intracellular signals, cell type, and any number of factors. CgA is a protein in secretory granules of neuroendoocrine cells that serves as a precursor of several biologically active peptides made by the cells. For purposes of targeting the adenovirus, the CgA gene is highly expressed in neuroendocrine tumors and CgA is known to be a sensitive and specific tumor maker for neuroendocrine tumors. So the basic idea is to use the CgA promoter to drive the adenovirus (dubbed Ad[CgA-E1A]) infecting the neuroendocrine cancer cells to make the E1A protein, which results in replication of the virus only in cells that normally make CgA; i.e., neuroendocrine cells. The final act of the adenovirus life cycle is to lyse the cells and release all the replicated viral particles, hence the term “oncolytic” virus. These new viral particles then disperse and infect nearby cells, repeating the cycle.
This isn’t the clever part of what Prof. Essand has done. Thus far, all he’s done is to make a pretty straightforward choice of a promoter that is as tissue- or cell-specific as he can think of, stick it into an adenoviral vector, and use it to drive the adenovirus to make the genes that promote its replication. It’s a nice trick but nothing we haven’t been doing at least since the 1990s to make an oncolytic adenovirus more cell-specific. What was clever was what he did to address a major problem that adenoviral gene therapy can have, namely liver toxicity. The CgA promoter isn’t perfectly specific (no promoter is). It has some activity in liver cells (hepatocytes), which means that, especially for liver metastases (which is where neuroendocrine cancers tend to metastasize first, there is the potential for even this specific virus to replicate in hepatocytes and lyse them just as it’s lysing tumor cells, just at a lower level. The result would be liver injury, hepatitis in essence. Enough hepatocyte death, and it could mean patient death.
To lessen the chance of that, Prof. Essand took advantage of microRNAs. MicroRNAs are small RNA sequences (usually around 20-22 nucleotides long) that are complementary to (and therefore bind to) specific sequences in the messenger RNAs (mRNA) for various genes, preventing the mRNA from being turned into protein by either preventing translation or by inducing the degradation of the mRNA. In other words, microRNAs (miRs) block protein synthesis at the mRNA level. Indeed, microRNAs have become increasingly appreciated as a major mechanism regulating gene expression. (I’ve even published a couple of papers on microRNAs.) What Prof. Essand did was to take target sequences for a microRNA, miR-122, and tack six copies of this target sequence on to the 3′-untranslated region of the E1A gene. It turns out that hepatocytes make a lot of miR-122, so much miR-122 that this single microRNA makes up around 70% of the total microRNAs that hepatocytes make. What that means is that in hepatocytes miR-122 will silence (shut down) E1A before it can even be made into protein. That’s the even neater trick.
Finally, apparently Prof. Essand has made one other modification, namely adding the protein transduction domain (PTD) of the HIV-1 Tat protein (Tat-PTD) inserted into the viral fiber, hence the name Ad5[CgA-E1A-miR122]PTD. The reason to do this is to increase the ability of the virus to bind to cell types not making the coxsackievirus-adenovirus receptor (CAR), which adenovirus requires for entry into the cell. Although his methods for adding the Tat-PTD to adenoviral vectors re described in this paper, in which Prof. Essand reports the construction of Ad5-PTD vectors, I haven’t been able to find a paper reporting the construction of Ad5[CgA-E1A-miR122]PTD or a paper showing its efficacy against xenograft models of neuroendocrine cancers, although I have found a paper in which Prof. Essand fiddled with his vector some more by adding somatostatin motifs that bind to somatostatin receptors expressed by neuroendocrine cancers, comparing his previous vector Ad5[CgA-E1A-miR122] to his new, improved, more somatostatin-y virus Ad5fkFWKT[CgA-E1A-miR122] in tissue culture for their ability to infect neuroendocrine cancer cells.
Perusing Prof. Essand’s papers, I note that Ad[CgA-E1A] does a pretty good job of suppressing neuroendocrine tumor growth in mice and prolonging their survival in xenograft models. I also note that Ad5[CgA-E1A-miR122] does appear to demonstrate better targeting in that it causes less liver toxicity in mice associated with more specific silencing of E1A expression in hepatocytes in mice. What I did not see was an experiment demonstrating that either Ad[CgA-E1A], Ad5[CgA-E1A-miR122], or Ad5[CgA-E1A-miR122]PTD “melting tumors away.” What I do see are some interesting results in preclinical models. Do these results warrant following up, perhaps even in clinical trials? Sure. I’d like to see them followed up. Are they so amazing that it is a crime that the clinical trial hasn’t been funded yet? No. Funding is very, very tight right now, and there are a lot of great projects out there (mine among them, I would say at the risk of being too boastful) going unfunded because, in the US at least, the NIH is only funding at about the 7% level through the NCI. Yet that is exactly the impression that Masters gives in his article. It’s full of colorful language, such as describing the virus as surging “through the bloodstreams of test animals, rupturing cancerous cells with Viking rapacity”; a “virus that eats cancer”; and similar overblown language. Even Prof. Essand gets in on the act, calling his virus “an assassin who kills all the bad guys.” This virus, even if it works exactly as advertised in Masters’ article does not “eat cancer.” It kills cancer cells with a high degree of specificity. That’s a good thing, but far from a cure. Even though Masters does occasionally tamp down the rhetoric below 11, it doesn’t sound convincing:
The closer you get to manipulating the cellular forces of human existence, the more you sound like a schoolboy babbling about his model aeroplane. Everything in the modern genetics lab is done with kits. There are no fizzing computer lights or fractionating columns dribbling out coagulations of genetic soup in Magnus’s lab; not a single Bunsen burner. Each narrow laboratory room has pale, uncluttered melamine worktops running down both sides, wall units above and small blue cardboard cartons dotted everywhere. Even in their genetics labs, Swedes enjoy an air of flatpack-ness. The most advanced medical lab in the world, and it looks like a half-fitted kitchen.
Nothing at all against Prof. Essand. He seems like a nice enough guy and a good scientist, but I highly doubt that he has the most advanced medical lab in the world, particularly in light of his funding difficulties moving his virus to the next stage.
Besides the tone of Masters’ article, which is at its core not that far removed from a lot of articles I saw on DCA and some e-mails I get about various cancer “cures,” particularly the part where he cites that infamous Amgen study at face value claiming to find that most basic science research can’t be reproduced (hopefully you will remember my deconstruction of this article), there’s another thing that bothers me:
What costs the £1 million (less than two per cent of the price of Francis Bacon’s Triptych 1976) that Magnus needs to bring this medicine to patients is not the production, but the health-and-safety paperwork to get the trials started. Trials come in three phases. What Magnus was suggesting for his trifling £1 million (two Mont Blanc diamond-encrusted pens) was not just a phase I trial, but also a phase II, which, all being well, would bring the virus right to the point where a big pharmaceuticals company would pay 10 or 100 times as much to take it over and organise the phase III trial required by law to presage full-scale drug development.
‘So, if Calvin Klein or Elton John or… Paris Hilton stumped up a million, could they have the virus named after them?’
‘Why not?’ Magnus nodded, showing me the bacteria incubator, which looks like an industrial clothes washer, only less complicated. ‘We can make an even better one for two million.’
I don’t know about you, but I’m not sure I like the idea of wealthy donors getting to name potential cures after themselves if they fork over enough money. It’s one thing to put their name on a building (and even that can cause problems, as the Robert Wood Johnson University Hospital found out when it sold the naming rights to its new children’s hospital to Bristol Myers-Squibb. Of course, if a pharmaceutical company were to buy the rights to Prof. Essand’s adenovirus, it would be able to call it anything it wants if it turned it into a product. Be that as it may, imagine the Calvin Klein adenovirus or the Elton John cure for cancer or maybe the Lady Gaga cancer tenderizer. The possibilities are endless.
Regular readers know that I’m not someone who is somehow anti-capitalist or against pharmaceutical companies making profits on general principle. Nor am I opposed to universities doing some fundraising to try to start clinical trials on promising therapies that they don’t have funding for. In fact, I’ll even direct you to Prof. Essand’s oncolytic virus fundraising page. If you’re so inclined, donate. It looks like worthwhile research, and as a fellow biomedical researcher I’d like to see it advanced.
But remember this. Despite what Masters implies in his article and what others citing his article are saying explicitly about Prof. Essand’s virus, it is not because “they” don’t want you to know about Essand’s research that it is not being funded. It’s probably not even because pharmaceutical companies can’t profit from it. They certainly could. They could take Essand’s viruses and modify them more to make them even more specific and more oncolytic, patent the new viruses, and potentially make boatloads of money.
I’ll tell you the most likely real reason for Prof. Essand’s difficulties securing funding for his trial as someone who used to do gene therapy research himself back in the late 1990s and early 2000s: Gene therapy for cancer (which, let’s face it, is what oncolytic viral therapy in essence is) has fallen out of favor in the cancer research world. The primary reason is the highly publicized death of Jesse Gelsinger in a clinical trial of adenoviral-delivered gene therapy, a death that also reminds us that adenoviral gene therapy is not necessarily as safe as it is being advertised. True, much progress has been made in the last 13 years, and it’s virtually certain that adenoviral therapies are likely safer than they were when an idealistic 18-year-old paid the ultimate price for his altruism. But we don’t know, and scientists have become considerably more gun shy when it comes to adenovirus-mediated gene therapy. There’s just not much interest in it anymore, and I’ve noticed a marked fall-off in the number of abstracts describing gene therapy being presented at the big cancer conferences over the last decade or so.
Look at it this way. There are hundreds, if not thousands, of promising therapies out there. Gene therapy is hard. Heck, Prof. Essand shows us that. Look at all the manipulations of his adenovirus backbone he had to do to try to get it to infect the cells he wants it to infect, replicate in the cells he wants it to, and, just as importantly, keep it from replicating in the cells in which he doesn’t want it to replicate. Then remember that, to eliminate cancer, this virus has to destroy virtually every cancer cell. That is the magnitude of the challenge. Add to that the various other difficulties that any sort of virus-based therapy faces in terms of manufacturing clinical grade material and assuring its safety, and it’s not too surprising that pharmaceutical companies are taking a “wait and see” attitude. This is especially true given that life-threatening neuroendocrine cancers are not that common, limiting the number of patients who would benefit from this form of gene therapy that would require a high cost to develop. Worse, there’s no a priori way to know that Prof. Essand’s treatment would be any more likely to succeed than any of the other promising experimental treatments currently in the pipeline for various cancers. From the published information, which doesn’t appear to include Ad5[CgA-E1A-miR122]PTD, I can’t even hazard a guess.
Yet the assumption is that it is. It’s human nature, after all. People who develop a new treatment always assume that it is more worthy than other people’s new treatments, and people who know someone with the disease will tend to agree because they want their loved one to live. Unfortunately, those of us in the biz have seen these “miracle cures” before that eliminate tumors in mice but don’t to nearly as much in humans. It was immunotherapy in the 1980s. Then in the 1990s it was antiangiogenic therapy and, yes, gene therapy, including therapy with oncolytic viruses. In fact, my primary research interest for a long time was antiangiogenic therapy, and I had high hopes for it. Now, having come down to earth based on clinical studies done over the last 15 years, I’m a lot more skeptical of the sorts of treatments touted by someone like Masters. I only wish that Prof. Essand hadn’t let himself be sucked into being part of the hype.

NIH funds training in behavioral intervention to slow progression of cancer by improving the immune system
James Coyne on October 29, 2012
Link
Editor’s note: Because of Dr. Gorski’s appearance at CSICon over the weekend, he will be taking this Monday off. Fortunately, Dr. Coyne will more than ably substitute. Enjoy!
NIH is funding free training in the delivery of the Cancer to Health (C2H) intervention package, billed as “the first evidence-based behavioral intervention designed to patients newly diagnosed with cancer that is available for specialty training.” The announcement for the training claims that C2H “yielded robust and enduring gains, including reductions in patients’ emotional distress, improvements in social support, treatment adherence (chemotherapy), health behaviors (diet, smoking), and symptoms and functional status, and reduced risk for cancer recurrence.” Is this really an “empirically supported treatment” and does it reduce risk of cancer recurrence?
Apparently the NIH peer review committee thought there was sufficient evidence fund this R25 training grant. Let’s look at the level of evidence for this intervention, an exercise that will highlight some of the pseudoscience and heavy-handed professional politics in promoting psychoneuroimmunological (PNI) interventions.
The report of the single study (full article available here) evaluating the efficacy of this intervention for physical health outcomes appeared in the American Cancer Society journal Cancer in in 2008. An earlier report (full article available here) claimed to demonstrate the effects of the intervention on the “secondary outcomes” of mood, immune function, health behaviors, and adherence to cancer treatment and care.
The abstract of the 2008 Cancer article described the group intervention as a set of strategies to “reduce stress, improve mood, alter health behaviors, and maintain adherence to cancer treatment and care.” The abstract reported not only a reduced risk of cancer recurrence but proclaimed “psychological interventions as delivered and studied here can improve survival.” If this intervention indeed improved survival, it is curious that the claim was not echoed in the advertisements for this training program.
When the article first came out, I did a simple chi-square calculation on the raw recurrence and death events in a pair of 2×2 cross tabulations of outcomes for intervention versus control group. No matter how I played with the data in figure 2, group differences nowhere near approached significance. Here is the online calculator and below are the data in Table 2 so that you can experiment for yourself (click to enlarge):
My colleagues and I decided to take a close look at the reports on this trial and write a commentary to be submitted to Cancer. We took the position that claims about reducing risk of recurrence and extending the survival of breast cancer patients are medical claims that should be held to the same standards as claims about medications and medical devices improving health outcomes. These standards include consistency between the abstract and findings reported in the results section of an article, pre-specification of one or two primary outcomes and follow up period, pre-specification of analytic plan, presentation of results in a way that allowed readers to evaluate the appropriateness of choice and interpretation of statistical tests. The latter would include transparent presentation of unadjusted primary outcomes in analyses for time by treatment interactions and avoidance of substitution of secondary and subgroup analyses.
To help ensure the standards are met, most biomedical journals have embraced CONSORT as the standard for reporting results of both clinical trials and, more recently, for abstracts. Many journals also require publicly accessible preregistration of trials for the publishing of later results, i.e., that investigators declare ahead of time their intentions for sample sizes, outcomes, and analyses, before they run the first patient. These standards are enforced less consistency with psychosocial trials, and reregistration was not in place at the time this clinical trial was implemented in the mid-90s. However, by the time these papers were published in 2004 and 2008, it had already been established that not meeting the CONSORT reporting standards involved a high risk of bias and unreliability of results. And investigators do not need the coaxing of CONSORT standards for abstracts to presume that abstracts should accurately reflect the results reported in the rest of the article.
When we submitted the commentary to Cancer, it was initially rejected, with the editor citing a standing policy of not accepting critical commentaries if authors refused to respond. We asked the editor to re-evaluate the policy and reconsider the rejection of our commentary. We argued that the policy was inconsistent with the growing acceptance of the necessity of post publication peer review. Essentially the policy allowed authors to suppress criticism of their work, regardless of the validity of criticism. Furthermore, our commentary presented not only a critique of the article, it called attention to a failure in editorial review that was worthy of note in itself. We therefore requested that we be allowed to expand our commentary substantially beyond the strict word limitations of correspondence about a particular study. After a meeting of the editorial board, the editor graciously accepted our requests.
In the commentary, we pointed out that the trial did not report significant tests for unadjusted outcomes and gave no rationale for the particular follow up period of 11 years (7 to 13) in which progression or deaths were recorded. Investigators committing themselves to a particular observation period ahead of time prevents post hoc shrinking or extension of the observation period to get more favorable results based on a peeking at the data. Nonetheless, we could find no significant differences in the proportion of women experiencing recurrence or dying, despite claims of the investigators to the contrary. Furthermore, the difference in median time to recurrence, six months, or to death, was small, given the length of observation period.
How were the investigators able to claim significant effects? By relying on dubious multivariate analyses with too high a ratio of covariates to events (recurrence or death). I’ll leave much of the technical statistical arguments to the commentary, but basically, the investigators’ approach had a high risk generating spurious effects. It’s always reassuring when results for simple unadjusted primary outcomes in a randomized trial hold up after adjustments for possible confounds, although the rationale for undertaking control of any initial differences between groups is unclear because randomization is itself supposed to take care of any. When results are not obtained in simple unadjusted analyses, but then show up in multivariate analyses, the suspicion is that they are spurious, because results of multivariate analyses are often dependent on arbitrary decisions about which covariates to include and how to score them, decisions that can be made and revised based on peeking at the data. We should be particularly suspicious when, as is the case in this trial, too many covariates are entered as controls.
We went on to critically examine the earlier study of psychosocial measures, adherence, and immune function.
Andersen BL, Farrar WB, Golden-Kreutz DM, et al: Psychological, behavioral, and immune changes after a psychological intervention: A clinical trial. Journal of Clinical Oncology 22:3570-3580, 2004
The abstract of this article reported testing the hypothesis “psychological intervention can reduce emotional distress, improve health behaviors and dose-intensity, and enhance immune responses.” The results presented in the abstract were uniformly positive in terms of effects on anxiety and improved dietary habits, smoking, and adherence, with no negative results mentioned.
When we examined the actual methods section, we found at least nine measures of mood, eight measures of health behavior, four measures of adherence, and at least 15 measures of immune function were assessed. There was no independent way of determining which of these measures represented the primary outcome for each domain. With so many outcomes examined, there was high risk of obtaining apparent effects by chance.
Turning to the actual results, only one of the 9 measures of mood was significant in time by treatment interactions. The intervention seemed to have a significant effect on dietary behavior (although it is unclear why the seemingly very different dietary behaviors were not analyzed) and smoking, but no effect on exercise. As is often the case with early breast cancer patients, rates of adherence to chemotherapy were too high to allow any differences between intervention and control group to emerge. In terms of immune function, results were not significant for CD3, CD4, CD8 counts cell counts, or six assays of natural killer cell lysis. If we compare this overall pattern of results to what was stated in the abstract, we see a gross confirmatory bias in the suppression of negative results and highlighting of positive ones.
Subsequent papers from this project amplified the confirmatory bias of these two papers by declaring a reduced risk of recurrence and death from breast cancer for intervention participants and gains for all secondary outcomes. These papers also cast doubt on whether the 2004 paper disclosed all of the outcome measures that were assessed. One article stated that for the subgroup of patients with elevated Center for Epidemiologic Studies-Depression (CES-D) scores, the intervention reduced depressive symptoms. This outcome is not even mentioned in earlier reports, but these subgroup analyses seem to imply that a reduction in depressive symptoms did not occur for the full sample. It is a reasonable inference that this null finding was suppressed in earlier reports. CES-D scores would seem to be the preferred primary measure of mood outcome for such studies. The CES-D has validated clinical cut points, and it is commonly believed that depression is the mood variable most strongly related to immune function. Another article referred to the Beck Depression Inventory (BDI), also an excellent candidate for a primary outcome in a study attempting to affect recurrence and survival via links between psychological variables and the immune system.
Our close reading of the results reported in these two articles suggests that the intervention is inert with respect to mood and immune function, and has no effect on progression and survival. The intervention is hardly ready for dissemination into the community. The designation of this intervention in advertisements for the free training as “the first evidence-based behavioral intervention designed to patients newly diagnosed with cancer” is premature and exaggerated. What could be meant by “evidence based”? Claims of “robust and enduring gains” in all categories of outcomes are simply wrong.
My colleagues and I gave our now familiar argument that there was lack of evidence that any psychosocial intervention could reduce risk of recurrence and improve survival. There was also a lack of evidence for possible mechanisms by which such effects could conceivably be achieved.
Cancer published our commentary without a response from the authors because they continued to refuse to provide one. Our commentary was instead accompanied by a response from Peter Kaufmann, MD. We wondered why the choice came down to Dr. Kaufmann and why he would accept the offer to reply to us. He had not written much about cancer, but he is Deputy Chief of the Clinical Applications and Prevention Branch of National Heart Lung and Blood Institute (NHLBI) and at the time his commentary was written, he was President of the Society of Behavioral Medicine.
The Cancer to Health (C2H) intervention package is based on the assumption that psychological variables have clinically significant effects on physical health via the immune system. Despite the lack of support for this idea with respect to cancer, the idea remains highly attractive and resistant to rejection because it lends prestige to psychosomatic and behavioral medicine. At the annual meeting of SBM at which Dr. Kaufmann became president, the keynote address was delivered by David Spiegel and basically involved debating in absentia skeptics and critics of the notion that psychosocial intervention could extend survival of cancer patients, including me. I complained to Dr. Kaufmann that if Spiegel wanted to debate me, I should have been invited to respond. Kaufmann indicated that I would get an invitation for keynote in the future to remedy this imbalance, but the occasion never materialized.
Subtitling his commentary “To Light a Candle,” Kaufmann conceded that my colleagues and I had raised valid criticisms about the design and interpretation of the C2H intervention trial. However, he took issue with our recommendation that clinical trials of this kind be suspended until putative mechanisms could be established by which psychological variables could influence survival. Quoting our statement that an adequately powered trial would require “huge investments of time, money, and professional and patient resources,” he nonetheless called for dropping a “preoccupation with mechanisms and secondary aims,” and instead putting the resources to increasing the sample size and quality of an intervention trial.
I remain puzzled by Kaufmann’s argument. In the absence of specification of a mechanism by which psychological variables could have such an effect, was Kaufmann nonetheless suggesting that we needed a large trial to overcome the lack of power of the moderate sized C2H trial? I cannot imagine a NIH administrator making a similar argument for a large scale study of an herbal product or coffee enemas or other intervention with a similar undocumented mechanism of influence.
Barbara Andersen, the principal investigator on both the C2H trial and the grant for trained professionals in delivering the intervention, has never responded in print to our criticisms and charges that the trial does not affect progression or survival. However, she has complained to administrators of the institutions of a number of her critics and asked that they put a stop to behavior having negative ramifications for the field of behavioral research in cancer. She also campaigned unsuccessfully to get another critique of a work that we published retracted.
It is unlikely that NIH showed favoritism in funding the training grant, relying instead on scores obtained in peer review. Reviewers must have been swayed by the consistent confirmatory bias in presentation of the results of C2H. However, there is a bias in NIH supported forums given to claims about psychosocial interventions affecting physical health outcomes. Andersen and those making similar claims regularly get invited to annual NIH sponsored symposia at professional meetings and reiterate the claims again and again. Apparently, there’s no room for critics on such panels.
The two papers presenting the outcomes of C2H have inaccurate abstracts and data analytic strategies that hide that they are basically null trials. In this respect they are not alone. Elsewhere I have documented that other psychosocial trials [1,2,] conducted by PNI investigators would be revealed to be null trials if time x treatment interactions were transparently reported for primary outcomes. Here is what to look for:
    • Ignoring of negative results in main analyses of primary endpoints.
    • Favor secondary analyses, subgroup analyses, and endpoints developed post hoc over negative findings for primary analyses.
    • Positive spin to abstract, highlighting best of results obtained using these strategies.
    • Negative findings presented as if positive in subsequent publications.
PNI cancer researchers take a Texas sharpshooter approach to identifying positive effects for immunological variables. The apocryphal Texas sharpshooter drove drunk around Texas with his rifle and a can of red paint and shot up the sides of buildings. Afterwards, he would draw a bull’s-eye with some of his hits in the center, creating the impression of an expert marksman who always hit his mark. PNI researchers similarly collect numerous PNI measures, not on the basis of their known association with cancer, but based on their ease of assessment. Measures derived from saliva samples are particularly popular. Investigators then declare whatever measures prove significant as evidence that they have tapped into the PNI of cancer. Further, they claim to replicate existing studies, when existing studies obtained significant effects with different measures. Any positive result obtained with a battery of measures is declared a replication, even when it is not a precise replication.
Compared to cancer, behavioral interventions in HIV+/AIDS have the advantage of well validated mechanisms by which behavioral interventions might conceivably influence the immune system, and in turn, readily measurable assessments of any clinically significant impact. This area has attracted considerable interest from PNI researchers, who, similar to cancer PNI researchers, praise their own and each other’s success in modifying clinically relevant immunological parameters. But a meta-analysis of 35 randomized controlled trials examining the efficacy of 46 separate stress management interventions for HIV+ adults (N = 3,077) tells a different story”
To our surprise, we did not find evidence that stress reduction interventions improve immune functioning or hormonal mechanisms that could influence immunity. These findings contrast with the PNI perspective that guided our work and most of the interventions included in our review (Antoni, 2003; Robinson et al, 2000). Thus, even though chronic stressors are known to suppress both cellular and humoral markers (see Segerstrom & Miller, 2004) the short-term use of stress-management strategies does not seem to reverse these processes in patients with HIV.
PNI cancer researchers remain a self-congratulatory group with a strong confirmatory bias in their mutual citations of the field’s claimed successes. Judging by citation patterns in the incestuous journal Brain, Behavior, and Immunity, one can readily get the impression that there are never any negative studies in the PNI cancer literature.
The articles reporting results for the C2H trial continue to be highly cited, with little apparent effect of our criticism. With a lack of other positive trials that can be cited, particular importance in the PNI literature has been attached to the claims that C2H extend survival of cancer patients. There is apparently little concern about conveying unrealistic expectations to patients concerning effects of psychosocial intervention on their immune system, and these claims fit with patents’ impressions and motivations for going to peer support groups and group therapy.
Cancer patients sometimes faced difficult choices about medical interventions to manage their disease. It is unfortunate if they are provided with misinformation that all they need to do is get stress management interventions to slow progression and extend their survival. Belief that these interventions are effective can discourage them from committing themselves to more effective, but painful, fatiguing, and disfiguring medical interventions.

The Mind in Cancer: Low Quality Evidence from a High-Impact Journal
James Coyne on August 3, 2012
Link
My science writing covers diverse topics but increasingly concerns two intertwined themes in cancer and psychology. First, I bring evidence to bear against an exaggerated role for psychological factors in cancer, as well as against claims that the cancer experience is a mental health issue for which many patients require specialty mental health interventions. Second, I explore unnoticed social and organizational influences and publishing practices, which limit evaluation of the best evidence for theories and practices claiming to be evidence based, especially those recommended (and even mandated) by professional organizations and accrediting bodies.
I benefit from a great set of international collaborators, and my colleagues and I have repeatedly debunked claims that psychological interventions increase the survival time of cancer patients by improving their immune systems. Wally Sampson and Bernie Fox provided important inspiration for these efforts. A key source of such claims is the classic Lancet study by David Spiegel, which I will dissect in a later post for ScienceBasedMedicine.org (for now, see our published critique of Spiegel).When specifically asked, I recommend support groups for cancer patients who want to participate. Emotional support and validation are reasonable goals, but patients should not be misled into believing that they are extending their lives. Sadly though, many breast cancer patients do go to support groups based on the belief that they are bolstering their immune systems and thereby improving their chances of survival. Unfortunately, they can find lots of encouragement for this belief in media coverage of the claims of prominent psychiatrists and psychologists.
My colleagues and I have also questioned exaggerated estimates of the psychiatric disorder associated with cancer — comorbidity with mental health problems is no higher than for other chronic and acute physical illness — and the wisdom of professional guidelines recommending (and mandating) that all cancer patients receive routine screening for psychological distress and depression, if improvement in patient well-being and quality life is the goal. Oncologists who have been ignoring such guidelines — and even the most resourced cancer centers have not consistently implemented them — will soon be unable to close the electronic record for a particular patient until they have screened the patient for psychological distress and reported what interventions they provided if the patient is distressed. Pfizer gave a psychologist $10 million to develop a set of quality indicators that can be used to monitor electronic records and the American College of Surgeons and other groups are mandating documentation of screening as a condition for accreditation.
The evidence for screening and other aspects of psycho-oncology remains weak. Guidelines and mandates that are being promulgated are consensus-based, not evidence-based. My colleagues and I continue to point to the lack of evidence that mandated routine screening will improve patient well-being, and we continued to warn that implementing screening may even disrupt existing efforts to provide cancer patients with the support and clinical and practical information that they need to cope. At some cancer centers, after being identified as “distressed” by a screen, a patient may have to pay up to $200 for an interview with a mental health professional, and yet no psychiatric disorder is found in most cases. Most patients decline services. Why not let interested patients directly access the support and services they want without this expensive intervening step?
Our efforts to introduce evidence into discussions about practices that are branded as “evidence-based” have met with considerable resistance from individuals and professional organizations with a vested interest in promoting these practices. A number of professionals have refused to debate me in print or in symposia, and instead have written letters of complaint to my university’s administration or attacked me on the internet. At the same time, I’ve noticed that “evidence” consistent with the favored views — that psychotherapy improves survival, that psychiatric disorders are rampant among cancer patients, and that screening improves patient outcomes — is all met with uncritical acceptance, privileged access to publication in high impact journals without peer review, and protection from criticism, all no matter how weak the evidence may be. Sometimes the “evidence” has even been demonstrated to be fraudulent, as with the Eysenck/Grossarth-Maticek data denying a link between smoking and lung cancer because personality explains both smoking and lung cancer. In Eysenck and Grossarth-Maticek’s view, any apparent relationship between smoking and developing lung cancer is spurious. These data keep getting cited, demonstrating a persistent reluctance to exclude the fake data from consideration when they are impressively supportive of the view that mind matters in cancer. As my grandmother used to say in Italian, “Se non è vero, è bene trovato”, which she claimed to be translated as “If it is not true, it ought to be.”
Difficulty publishing embarrassing evidence or getting commentaries published about flawed reasoning and bad data has sensitized me to my second theme: the need to explore social and political influences on the availability, suppression or distortion, and interpretation of “evidence.” What is available in the literature and cited in practice guidelines and other official statements as “evidence” is continually artificially edited, constrained, and manipulated. We need to recognize that the claim of being “evidence-based” is an important marketing tool, and strong vested interests mobilize to protect that labeling of their practices from encounters with embarrassing evidence.
I cover these topics in my peer-reviewed papers, but also in my Skeptical Sleuth blog, which is designed to disseminate critical skills for interpreting both the scientific journals and media reports and to encourage a general skepticism towards these sources. If people believe everything they read in the journals, they shouldn’t be reading.
For my inaugural post here, I will touch on both of my major themes in discussing how the Journal of Clinical Oncology is not a reliable source for evidence about the relationship between cancer and the mind. JCO has a high journal impact factor of 18.97 for 2010 and a high rate of rejection, but this does not guarantee that what is published there is best evidence, particularly in the case of articles espousing a role for psychological factors in the incidence, progression and outcome of cancer. From time to time, I have challenged especially outrageous JCO articles, which are often accompanied by laudatory editorials. It is rather quixotic to do so and I’ve recently run afoul of unwritten editorial policies of JCO, whereby post-publication peer commentary can be squelched by authors whose articles are criticized. No matter how fundamental the flaw being identified, the author of an article is the final judge of whether the critique will be published.
Let’s start with the article for which JCO would not publish my commentary because the authors refused to reply. I co-authored the commentary with an eminent expert on posttraumatic stress disorder, Naomi Breslau and I have drawn on it with her permission and enthusiasm for my writing this blog.
Rampant Post Traumatic Stress Among Cancer Survivors? Not really
Smith SK, Zimmerman S, Williams, CS, et al: Post-Traumatic Stress Symptoms in Long-Term Non-Hodgkin’s Lymphoma Survivors: Does Time Heal? JCO, Dec 1;29(34):4526-33
This article claimed that more than a third of long-term survivors of non-Hodgkin’s lymphoma experience persistent symptoms of posttraumatic stress disorder. Clinicians need to be aware of this risk and screen survivors with standardized measures and provide treatments to alter survivors’ perceptions of the cancer experience in order to improve their long-term outcomes. The authors drew parallels between NHL survivors and victims of disaster and violence. They claimed their results provide “strong messages” and called for psychosocial treatments, including cognitive behavior therapy, as well as recognition that NHL patients from deprived backgrounds are at highest risk. They can concede, however, that “there were no known psychosocial interventions developed specifically for NHL survivors,” but suggest that other evidence-based treatments can be tailored to meet the unique needs of NHL survivors.
Critique. This article displayed some typical flaws found in psycho-oncology studies providing inflated estimates of psychiatric diagnoses from checklists administered to patients without involving a trained interviewer to explain to them what is being asked of them or probe their responses. Also typical is that diagnosis was made on the basis of complaints that are nonspecific and common across health conditions which give patients good reason to worry about their future. The PTSD checklist used in this study was validated with combat veterans who had been exposed to a war zone, but who had left. The stressor was securely in the past for these vets, unlike for cancer patients facing a high likelihood of recurrence or actual recurrences. A third of this sample of cancer patients had a recurrence before completing the questionnaire. Yet, the only complaints that were endorsed by at least a 1/6 of them as being moderately to extremely bothersome were: trouble falling or staying asleep, having difficulty concentrating, loss of interest in activities previously enjoyed, feelings of your future will somehow be cut short, being more watchful or on guard. These are not specific to PTSD, but are reasonable and expectable responses to actual or anticipated recurrence of cancer. More generally, these complaints become symptoms of PTSD only when they co-occur as part of a syndrome, not just in isolation, and when they can be linked to exposure to a past psychological threat. The authors did not establish a syndrome or a link.
If these cancer patients were actually suffering posttraumatic stress, the most empirically supported cognitive behavioral treatment would be exposure therapy, in which a patient is exposed to the traumatic situation with evidence that danger is no longer present, a luxury that current and former NHL patients do not have. I am skeptical that this treatment would benefit many NHL patients and that they would take up the offer of therapy until the threat of the disease was assuredly in the past.
It’s a reasonable recommendation that clinicians making a special effort to ensure that low-income patients have access to supportive services and that clinicians more generally make an effort to reduce the negative impact of the treatment and diagnosis of NHL on appearance, body image, and everyday functioning. But this recommendation is not derived from the data presented in this article and making a psychiatric issue of the patients’ predicament would not seem to help.
I am disappointed that JCO let these authors decide that our critique could not be published and I remain quite interested in how they would have responded.
Not Demonstrating That Talk Therapy Improves 10 Year Survival of Cancer Patients
Kuchler, T., B. Bestmann, et al. (2007). “Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial. JCO,25(19): 2702-8.
This article claimed that an average of just 222 minutes of psychotherapy produced a 10-year survival benefit among a mixed group of patients with gastrointestinal cancer. “Lots of bang for a few bucks” proclaimed an accompanying editorial. The editorial went on to concede the methodological problems of studies claiming effects of therapy on survival and that this study was no exception, but when “all is said and done and the appropriate methodologic mea culpas have been muttered, 10-year survival in the treatment arm was more than twice that of the control arm (21% v 9%).” The editorial ended with a call for more such studies, particularly given the low cost of a potentially life extending intervention.
Critique. Nonsense. Steve Palmer and I pointed out that preliminary reports of this clinical trial had designated quality of life as the primary outcome, but that no effect on quality of life was ever reported. The authors conceded that no effect on survival had been hypothesized. There was no manual guiding this therapy, but patients received an eclectic mix of supportive talk therapy, crisis intervention, and a small amount of relaxation training, with considerable time taken up with strategizing and rehearsing interactions with oncology physicians and nurses. The oncology treatment team was aware of which patients were in the intervention group and the therapists spent as much time meeting with the surgical and nursing teams as with the patients. As a result, the patients assigned to psychotherapy got considerably more medical treatment: almost twice as many days of intensive care, and they were twice as likely to receive postoperative chemotherapy, five times as likely to receive radiotherapy, three times more likely to receive alternative treatments, and four times more likely to receive a combination of three treatments in the post-treatment period. This co-treatment confound can’t be dismissed in claiming the intervention’s effect are due to some occult psychological process. Furthermore, our inspection of the survival curves for the two groups indicated that an advantage for the group getting psychotherapy was observed immediately and lasted for a few months with no additional advantage accumulating in years 2 through 6.
Better medical surveillance and treatment for patients getting talk therapy in this study are the most likely source of differences between groups, particularly since the investigators could not identify a possible mechanism by which talk therapy should influence survival. As for a larger literature demonstrating that psychotherapy improves survival, the studies claiming an effect do not withstand scrutiny.
JCO is a prestigious journal that frequently provides results of clinical trials of biomedical interventions. I seriously doubt that the biomedical trials enjoy such relaxed standards for reporting or interpreting results or that a biomedical trial with such co-treatment confounds or increased surveillance given to the intervention group would go unchallenged.
Talk Therapy as Pro-Biotic Yogurt: Linking “Depression,” the Immunity System and Survival
Steel, J. L., D. A. Geller, et al. (2007). Depression, immunity, and survival in patients with hepatobiliary carcinoma. JCO, 25(17): 2397-2405.
This study found that over a third (37%) of hepatobiliary carcinoma patients reported elevated depressive symptoms on a standardized questionnaire. The subsample that had elevated symptoms (23 patients) had lower NK cell numbers and a “robust” statistical trend linked NK cell number to survival and a mediational model “preliminarily” supported a link between depressive symptoms and survival via NK cell count number. The authors conclude “If the tenets of this research are correct, then reduction of depressive symptoms through psychotherapy and/or pharmacologic intervention in patients diagnosed with HBC may enhance immune system functioning and possibly survival.”
An accompanying editorial conceded that the link between depressive symptoms and cancer progression remains “elusive,” but cited purported evidence that psychosocial intervention with patients with malignant melanoma decrease their depressive symptoms while increasing NK cell activity. The editorial called for research evaluating of interventions to reduce depressive symptoms that incorporated designs by which the effects on cancer progression and survival could be examined.
Critique. This editorial refers to post hoc claims by Fawzy that his stress reduction intervention increased NK cell activity and improved survival in malignant melanoma patients to which. My colleagues and I previously dispensed with this claim in a detailed critical analysis.
While 37% sounds like a high prevalence of depressive symptoms in these cancer patients, it is the same as what is found among patients recruited from a primary care waiting room and the mean depression score for these cancer patients was only 2.1 points higher than the general population. And it is not clear what is represented by these “depressive symptoms.” About a third of elevated scores represent treatable clinical depression, but, as with checklist PTSD, symptoms are quite nonspecific and variously represent general malaise, sickness burden, demoralization, and social economic deprivation. Psychologist Paul Meehl has coined the term crud factor to indicate that negative affect variables like depression have so many antecedent, concurrent, and subsequent correlates that prospects for identifying tight causal models are bleak. Notoriously, “causal associations” between depressive symptoms and physical health outcomes including mortality come and go with introduction of statistical controls.
If anything, what is surprising that is that cancer patients do not have higher rates of depressive symptoms.
The efforts of these authors to show causality are thwarted by many factors, but most basically the small number of patients with depressive symptoms. The simple unadjusted statistically significant relationship between depressive symptoms and survival would be undone by reclassification of one patient. And the use of multivariate statistics is simply inappropriate and prone to uncovering spurious findings. The authors’ “mediational model” is not merely preliminary, it is voodoo statistics. First, a mediational model would require demonstration of a simple statistical association between the mediator, NK cell activity, and survival, and there is none there. Second, with only 23 participants, the authors included at least 11 variables in their regression equation attempting to link depression to survival via NK cell activity. It is difficult to believe that a statistician was involved in the peer review of this article.
Overall, this article is typical of psychoneuroimmunological studies of links between “depression,” the immune system, and progression and survival of cancer. There has yet to be a demonstration that reducing clinical depression or depressive symptoms will affect the course of cancer. With inconsistent evidence that “depression” predicts progression and survival, and inconsistent evidence as to what an elevated score on a depression questionnaire represents, tooth fairy science is required to explain how an association happens when the association has not been established in the first place.
Studies claiming to demonstrate that association typically include a large battery of measures of immune function and a cherry picking of any findings that are significant and post hoc explanation why this particular measure proved significant. What is missing is any demonstration of clinical significance of findings and the complex pathways between available measures of immune function and cancer progression and outcome are yet to be established.
An early criticism of psychoneuroimmunological studies remains valid:
Each of the measures used in this literature represents only a small facet of a complex, highly redundant system. It would therefore be inappropriate to conclude that intervention-related changes in any specific immune parameter signal a state of “immune enhancement” or altered susceptibility to immune-mediated disease. The normal functioning range for most immune measures is very broad, and psychological interventions typically do not induce changes of sufficient magnitude to move people outside of these boundaries (p. 48).
Unfortunately, cancer patients desperate to take control of their condition are vulnerable to advice that by improving their immune system, they can “fight” cancer. The claims of psychoneuroimmunology are no more grounded in science than the claims for probiotic yogurt.
Fitting the Evidence to Preconceived Notions
This has not been not a systematic review, but can be seen as a black swan review that calls attention to the fact that not all psycho oncology studies in JCO are white swan exemplars of good science and evidence-based recommendations. Psycho-oncology studies do not appear in every issue of JCO, but when they do appear, they are usually of poor quality and yet accompanied by laudatory editorials. There is a strong confirmatory bias, often manufactured by putting a positive spin on findings that actually show psychotherapy does not improve survival, psychiatric disorders are no more common among cancer patients than other medically ill populations, or that screening improves patient outcomes over simply giving them the opportunity to discuss their problems. It is best to first read the results section of JCO psycho-oncology articles before the introduction and discussion sections, and to skip the laudatory editorials.
Psycho-oncology once had more modest aspirations to which it should return. Wikipedia defines it in reasonable and attainable terms:
a field of interdisciplinary study and practice at the intersection of lifestyle, psychology and oncology. It is concerned with aspects of cancer that go beyond medical treatment and include lifestyle, psychological and social aspects of cancer.
Being able to extend the life of cancer patients is a much stronger claim than merely being able to improve the quality of their lives. The prestige that would go with demonstrating that the mind influences cancer is difficult to resist and a recent commentary in the International Society of Psycho-Oncology journal Psycho-Oncology offered a redefinition — “The very name ‘psycho-oncology’ implies interaction between brain and body” — and went on to make discredited claims of psychotherapy improving survival without any citation of the numerous critiques of this literature that have appeared.
The majority [of intervention studies] show a survival advantage for patients randomized to psychologically effective interventions for individuals with a variety of cancers, including breast, melanoma, gastrointestinal, lymphoma, and lung cancers. Importantly, for breast and other cancers, when aggressive anti-tumor treatments are less effective, supportive approaches appear to become more useful.
My colleagues and I carefully reviewed the same studies as this commentary, and concluded
No randomized clinical trial designed with survival as a primary endpoint and in which psychotherapy was not confounded with medical care has yielded a positive effect.
    • With its unsubstantiated claims about psychological factors influencing cancer incidence, progression, and outcome by way of the immune system, psycho oncology is approaching the woo of complementary and alternative medicine. Recently, David Gorski, Christoffer Johansen, and I published a critical commentary on an article in the American Cancer Society journal Cancer that claimed psychoneuroimmunological mechanisms for energy field therapy. David also elaborated upon it here on SBM. At about the same time, the prestigious journal Brain, Behavior, and Immunity published an article about a very similar therapeutic touch therapy for cancer patients and also explained its effects in psychoneuroimmunological terms. It is getting increasingly difficult to differentiate psycho-oncology from woo science. Articles in JCO covering psycho-oncology warrant careful scrutiny and readers should be forewarned to approach them with a healthy skepticism.

Fenbendazole is fast becoming the laetrile of the 2020s
Antivaxxers who “repurposed” deworming drugs like ivermectin and fenbendazole are peddling cancer “miracle cure” testimonials that remind me of laetrile and Stanislaw Burzynski. Truly, everything old is new again.
David Gorski on March 4, 2024
Link

Nearly 17 years ago, Dr. Mark Hoofnagle coined a term, crank magnetism, to describe how believers in one form of pseudoscience, quackery, and conspiracy theory almost inevitably start believing in multiple forms of pseudoscience, quackery, and conspiracy theories. At the time, he was discussing how creationists were attracted to the arguments of HIV/AIDS denier Peter Duesberg because they thought that these arguments somehow also undermined evolution as well. Back around the same time, inspired by Dr. Hoofnagle’s term, I noticed so many more examples. I’ll cite a few, not so much because readers might be familiar with them (although some longtime readers might), but just to show that crank magnetism, as new as it might seems to so many of my colleagues who had never noticed it before, is, in fact nothing new:
For example, Phillip Johnson, one of the “luminaries” of the “intelligent design” creationism movement is also a full-blown HIV denialist who doesn’t accept the science that demonstrates that HIV causes AIDS. Another example is Dr. Lorraine Day, who is heavily into dubious alternative cancer therapies and is also a conspiracy theorist and Holocaust denier. More recently a creationist, Johannes Lerle, was jailed as a Holocaust denier in Germany, and crank supreme Larry Fafarman proudly claims himself to be a “Darwin doubter” and a “Holocaust revisionist.”In a similar vein, antivaccinationist Pat Sullivan, Jr. is also a “Darwin doubter,” while regular contributor at Bill Dembski’s home for ID sycophants Dave Springer (a.k.a. DaveScot) not only rejects the science of evolution in favor of the pseudoscience of ID, but is also a global warming denialist crank and encourages unsupervised experimentation with an unproven anticancer agent by desperate cancer patients.
Sound familiar? (As an aside, I also note that, until I started checking out all those links to make sure they were still live or to substitute Archive.org or more up-to-date links, I hadn’t known that Dr. Day had passed away last November.)
A specific subset of crank magnetism applies to quacks and the antivaccine movement, examples of which I’ve discussed fairly recently in relation to the COVID-19 pandemic antivaccine movement, which has embraced “repurposed” drugs like hydroxychloroquine, ivermectin, and fenbendazole as supposedly highly effective treatments for COVID-19. (They are not.) Specifically, I’m referring to the manner in which increasingly believers in these drugs have “discovered” that they can use them to treat all manner of diseases, including cancer. For example, a year ago I noticed Dr. Tess Lawrie, a founder of the British Ivermectin Recommendation Development (BIRD) Group, a group that had teamed up with the US group the COVID Frontline COVID-19 Critical Care Alliance (FLCCC) to vigorously promote ivermectin as a highly effective treatment for COVID-19 despite all evidence to the contrary (including basic pharmacokinetics), starting to make the false claim that ivermectin could cure advanced cancer; that is, before she went on to embrace homeopathy for COVID-19 and long COVID. It didn’t take me long to quip that ivermectin was becoming the new Miracle Mineral Solution, a.k.a. MMS, given that quacks soon started treating autistic children with it, using it as yet another bit of quackery in their “autism biomed” toolkit.
The point, besides my oft-repeated mantra that “everything old is new again,” is that inevitably the embrace of one quackery will lead to the embrace of others, but the corollary to this that I want to talk about now is how there is always an “indication creep” for quackery. Once quacks “discover,” for instance, that ivermectin “treats COVID-19,” it is never long before they start “discovering” that it can treat all manner of diseases until it becomes a cure-all. This is a phenomenon that has accelerated with a vengeance for fenbendazole, which I first saw popping up not that long ago in ivermectin-like stories of “cures” for COVID-19 but is now a full-blown quack “cancer cure” being promoted everywhere. In particular the odious blogger 2nd Smartest Guy in the World (2SGitW) has been using his Substack to convince his readers that fenbendazole is a miracle cure for advanced cancer, complete with “miracle cure” testimonials. Unfortunately, though, he is not alone.
Let’s start with the article that caught my attention over the weekend, Triple-Negative Breast Cancer Eradicated by Fenbendazole, in which 2SGitW brags, “Fenbendazole kills the cancer cells responsible for killing cancer patients.” As I learned, it’s a followup to a cancer cure testimonial published a week earlier on the Substack in which 2SGitW massively exaggerated the the significance of some promising preclinical and lab studies suggesting that fenbendazole might have anticancer activity against triple-negative breast cancer written by someone going under the ‘nym of BenFen, who claims to be a “retired University scientist who happened across fenbendazole when a loved one developed terminal cancer” and runs a Substack that publishes cancer cure testimonials due to fenbendazole.
More interestingly, it turns out that fenbendazole repurposing has been a favorite “alternative cancer cure” since at least 2017, if not earlier, but the rise of ivermectin and other dewormers as “cures” for COVID-19 resurrected fenbendazole as one of the most favored unproven drugs being sold as cures for cancer in the age of the pandemic.
Fenbendazole versus triple negative breast cancer?
This particular article caught my attention because I have long been writing about how alternative cancer cure testimonials mislead, but even more so because it involves my area of surgical specialty and research interest, breast cancer. Before I discuss the testimonial, let me just review what “triple negative” breast cancer is and how it is normally treated, so that you can see the contrast and perhaps spot the common misleading part of this particular testimonial.
When we characterize breast cancer clinically, pathologists look at three different markers that guide systemic drug therapy used in combination with surgery and radiation therapy to treat it. The following is somewhat simplified (but hopefully not too much so). The first two are the hormone receptor proteins for estrogen and progesterone, which roughly two-thirds of breast cancers make, rendering them responsive to these hormones for growth. More importantly, the presence of these receptors means that the tumor can be treated with targeted endocrine therapy that blocks estrogen using drugs such as selective estrogen receptor modulators (SERMs) like tamoxifen or drugs that block the production of estrogen, such as aromatase inhibitors. The third marker is HER2, an oncogene that is amplified in a subset of cancers. When a cancer is HER2-positive, it can be effectively treated with drugs that target HER2, such as trastuzumab (Herceptin®), usually also with chemotherapy.
What makes triple negative cancer so problematic is that it lacks any of these three markers, which means that targeted therapy is not possible. Moreover, triple negative breast cancer (TNBC) tends to be more aggressive, metastasize to bone, brain, lung, and liver, and recur earlier after treatment than hormone receptor-positive varieties. In general, before about four years ago, the only systemic treatment that was effective against TNBC was standard cytotoxic chemotherapy with a regimen called ACT (Adriamycin-Cytoxan-Taxol). However, after the KEYNOTE-522 trial was published in 2020, the standard of care for TNBC rapidly changed to include not just chemotherapy but immunotherapy with pembrolizumab (Keytruda®). In brief, the standard of care for most “curable” TNBCs (e.g., TNBC that has not spread to distant organs) is the KEYNOTE-522 regimen; i.e. neoadjuvant chemoimmunotherapy, usually with Taxol or another taxane with carboplatin, plus pembrolizumab, with the pembrolizumab being continued after surgery for a total of a year. It is a regimen that has pushed pathologic complete response (pCR) rates to well over 60%, and pCR correlates with improved survival. (A pCR occurs when there are no detectable viable tumor cells in the resected specimen.) In brief, the KEYNOTE-522 regimen is the most significant improvement to the treatment of women with TNBC that I can recall since I started my career as a breast cancer surgeon in the 1990s.
With that background on how TNBC is normally treated in 2024, let’s look at the anecdote, which was also published earlier on BenFen’s Substack, Fenbendazole can cure cancer. First, though, I’m going to point out that the blurb after the title is a hint:
No Chemotherapy or Radiation; Fenbendazole Only = Full Remission
See where this is going? Once again, this is an example of how these testimonials often leave out critical information. Let’s take a look, where BenFen starts out with mostly accurate information before the misleading narrative takes off:
This Case Report is from a 45 year old woman with metastatic Stage III triple-negative breast cancer that had spread to nearby lymph nodes. According to the Cleveland Clinic, triple-negative breast cancer (TNBC) is an especially dangerous form of invasive breast cancer, accounting for 15% of all invasive breast cancer cases. Unlike most breast cancers, triple-negative breast cancer cells don’t have receptors for estrogen and progesterone. Because this type of breast cancer doesn’t have the hormone receptors used by the current drugs to attack most breast cancers, the prognosis is very poor using traditional treatments like chemotherapy. Recall that receptors are molecules on cells’ surfaces that determine what substances can attach to cells and affect what the cells do. Triple-negative breast cancer cells don’t have these receptors, so the traditional chemotherapies used to target breast cancer cells by their hormone receptors don’t work. So there is a dire need to find treatments that actually work.
Notice how the word “metastatic” is used. Here, BenFen is clearly trying to imply that this is an incurable cancer. However, by definition stage III is not incurable; rather, it is considered locally advanced and therefore potentially still curable. Moreover, while it is true that “traditional chemotherapies used to target breast cancer cells by their hormone receptors” don’t work against TNBC, the way this statement is phrased is misleading. We generally don’t call such treatments “chemotherapy.” Rather, we call them “endocrine” or “hormonal” therapy, as what is being discussed in this sentence are drugs like tamoxifen or aromatase inhibitors. I realize that pedants might try to counter that, yes, endocrine therapy is indeed a subset of chemotherapy if you mean the more general definition of “chemotherapy” in which it refers to any chemical/pharmaceutical therapy, but the use of the phrase in this manner was clearly intentional and meant to imply that chemotherapy doesn’t work. While the KEYNOTE-522 regimen is a major improvement in the treatment of TNBC, the chemotherapy regimen used before this study did work. It’s just that TNBC, by its nature, tended to develop resistance and recur; however, we still managed to “cure” large numbers of women with TNBC using the “old” regimen dating back decades.
Now, let’s look at the actual testimonial:
I was diagnosed with Stage III*, Triple Negative Breast Cancer in October of 2022 after noticing some changes on the skin of my breast and some pain in the area. Mammogram, CT scan and biopsy confirmed that it was breast cancer….triple-negative breast cancer. I had stage 3 triple negative breast cancer involving my lymph nodes, the worst one to get, and it (fenbendazole) worked for me.
The cancer had spread to the nearby lymph nodes and was causing the skin on my breast to discolor. I took Safe-Guard (fenbendazole [2SG: PetDazole is 3rd party tested pharmaceutical grade fenbendazole that is offered at a less expensive price-point]) for 14 weeks, started the 3 days on, 4 days off protocol that I read about for about the first 7 weeks. Then increased from 1 box a week (each box has 3 packets), to a box and a half (about 5 packets of 222 mg each) per week.
The first thing I noticed was my skin clearing up, the small spots on my breast disappeared at about 11 weeks after starting fenbendazole. This was the 222mg dose. No side effects at all.
My advice, take fenben, and don’t stop. At least not until it’s gone. I’ve been cancer-free for almost 16 months. Best of wishes to all of you!
L. K. T., Tucson AZ, December 5, 2023
I note that the “*” did lead to an admission that this was not stage IV cancer tacked onto the very end of the post:
*Stage III: At this stage, the cancer has spread beyond the point of origin. It may have invaded nearby tissue and lymph nodes, but it hasn’t spread to distant organs. Healthcare providers may use the term “locally advanced breast cancer” to describe Stage III cancer.
Now, let’s look at this in a bit more detail. Notice how LKT doesn’t mention at all whether she had surgery or not, but BenFen pointedly states “no chemotherapy or radiation” (emphasis mine). Surely, if the woman had not had surgery, BenFen would have included it in the blurb, given how advocates of unproven cancer therapies always like to emphasize the conventional treatments not used. I also noticed rather quickly that surgery was left out of the entire anecdote as well, which led me to wonder: What form did this “biopsy” take? Was it a core needle biopsy, which is the most commonly used form of biopsy for breast cancer now? A core needle biopsy, often guided by ultrasound or mammography, uses a large needle to take tissue cores from the tumor, leaving the tumor intact. In contrast, an excision biopsy removes the whole mass and can in some cases be curative by itself because the mass is removed. (Seriously, I’m getting acid flashbacks to my very early days discussing “cancer cure” testimonials nearly two decades ago.) In any case, most likely this women underwent surgery of some sort, refused chemotherapy and radiation therapy, and then attributed her good fortune to the fenbendazole rather than the conventional treatment. We can’t know, though, because the anecdote leaves out key information that would allow a reasonable assessment.
I wanted to find out more; so I started doing some Googling. I failed to find more on this women’s story, although there is a closed Facebook group that I encountered (Triple Negative Breast Cancer Fenbendazole) that might be hers, although probably not given that it appears to have been inspired by a 2016 story that showed me that the “repurposing” of fenbendazole for cancer goes back at least to 2017. So I perused some of the other testimonials on FenBen’s Substack. One recent testimonial reminded me very much of Chris Wark of Chris Beast Cancer fame, in which a stage III colorectal cancer was cured with surgery alone but the person making the testimonial attributed his good fortune to the quackery chosen, in this case fenbendazole. Another testimonial came from a woman with colon cancer metastatic to the liver. Of course, any surgical oncologist can tell you that it is possible to resect some liver metastases for colorectal cancer and produce long-term survival, and that’s what this woman appears to have undergone. She also underwent additional chemotherapy and surgery, with the tumors reportedly “returning,” although it is not said how they were diagnosed or whether they were ever biopsy-confirmed.
Yet another anecdote involved a patient adding fenbendazole to chemotherapy and radiation for esophageal cancer and then attributing the disappearance of the tumor to—you guessed it!—the fenbendazole, even going so far as to refuse the recommended surgery (esophagectomy) and then explicitly saying so:
Q: Do you think the chemo/radiation did the trick or was it the combination of chemo/radiation + fenbendazole?A: I assume a combination but lean heavily toward the fenbendazole. Here’s why. The doctors were quite surprised (after the cancer was gone from their treatments). They wanted to do surgery after their chemo/radiation treatments to remove the esophagus and part of his stomach because they didn’t believe the chemo/radiation would get all the cancer. We refused the surgery. Esophageal cancer is very aggressive, I believe it didn’t spread beyond the one lymph node because we caught it early with fenbendazole.
Let’s put it this way. A pathologic complete response (pCR) due to neoadjuvant chemoradiation for squamous cell esphogeal cancer is far from unheard of, particularly for a tumor of the type described in the anecdote, specifically, with spread to a single regional lymph node. For example, this series quotes a pCR rate of over 40% for multimodality neoadjuvant therapy of squamous cell carcinomas of the esophagus. Basically, it was the chemoradiation that cured this patient, not the fenbendazole added to the regimen, but, as is typical, the patient attributed her good fortune not to the conventional therapy but to the unproven treatment chosen, conceding that, at most, it might have been the “combination” of the fenbendazole plus the conventional neoadjuvant therapy. I also note that for most cancers, achieving a pCR is associated with a much better prognosis. I further note that oncologists and surgeons are actively investigating whether patients who achieve what looks like a pCR after neoadjuvant therapy can safely forego surgery, and, if so, which patients.
Why are testimonials so convincing?
Basically, there are many reasons why alternative cancer cure testimonials are convincing. Indeed, let’s review a few common features of alternative cancer cure testimonials—hat tip to a longtime reader—that make them unreliable as evidence that the treatments tried had any effect:
    • Misunderstanding of the natural history of cancer and survivorship bias. Some cancers, including colon cancer, can have a highly variable natural history. Remember that median survival means nothing more than that half of patients die before the median and half after. One example that I like to point out is a 1962 study of survival in women with untreated breast cancer at Middlesex Hospital in England from 1805-1933 that reported a median survival of 2.7 years, but a long “tail,” with a handful of survivors out as far as 15 years. Many times in these testimonials, the prognosis given (or heard) is far too pessimistic (e.g., “I was sent home to die”) and didn’t take into account the natural variability of cancer. In the cases of colon and breast cancer, for instance, our cancer institute has patients who have survived several years and are doing well. There’s a serious survivorship bias in these testimonials because, as I like to say, dead patients don’t give testimonials. Also, when they say the “doctor was amazed,” sometimes that is more of an indication of a doctor that is inexperienced with cancer than with an outcome far outside of the realm of the expected.
    • Confusing adjuvant therapy for definitive therapy and misattributing their survival to quackery. There’s a whole subgenre of alternative cancer cure testimonials in which the patient giving the testimonial have undergone surgery for a solid tumor—again, commonly breast or colorectal—underwent curative surgery for the cancer but then refused adjuvant therapy, be it chemotherapy, endocrine therapy, immunotherapy, or radiation therapy in favor of whatever quackery they chose. (Examples include Chris Wark, Suzanne Somers, and many others.) Inevitably, if they survive they attribute their good fortune to the quackery, not to the definitive surgery that cured them, forgetting that the adjuvant therapy only decreases the chance of relapse after surgery and that surgery was what cured them. Sometimes, as Chris Wark did, they acknowledge this argument but then find a reason to claim that “surgery never cures patients like me.”
    • Misdiagnosis by quacks. A number of alternative cancer testimonials feature failure to actually diagnose cancer by accepted methodology, substituting instead diagnoses by quacks using unscientific methodology that doesn’t include an actual tissue diagnosis from a pathologist.
    • General vagueness. One thing. that I’ve learned dealing with alternative cancer cure testimonials like these is that I’ve been deconstructing fort two decades is that the testimonials are nearly always frustratingly vague from an oncological standpoint in a way that makes it very difficult to tell exactly what the patient had, how the tumor was treated, what the true stage actually was, and more. I’ve used my training as a surgical oncologist and cancer surgeon to infer from these testimonials what the true situation probably was, but one can never be sure.
    • Old testimonials. Although fortunately this isn’t the case (yet) for any of these patients, often the ultimate outcome of these patients is death. However, testimonials often have an afterlife and live on, promoted by quacks long after the patient has died without a mention that the patient did ultimately die of cancer.
There are more features in addition to these, but when examining any alternative cancer cure testimonial, here are a few useful questions:
    • Was the cancer still present when the alternative therapy was started? (Again, often surgery eliminated the cancer, and the patient is confusing cure with adjuvant therapy designed to decrease the risk of relapse.)
    • Were all treatments disclosed? I forgot to mention above that often not all conventional treatments are described in these testimonials. Sometimes, I only find out that a patient had surgery by doing a deep Google dive to find all the appearances and interviews that I can, and even then I only find it mentioned in passing on social media posts by the patient.
    • Was there ever a biopsy proving the existence of cancer? Were there reliable scans proving metastasis? You’d be surprised at how often the answer to one or both of these questions is no.
You will find many of these elements and questions in pretty much every fenbendazole testimonial presented, including one that hasn’t shown up on FenBen’s Substack (at least not as far as I’ve been able to tell) but did go viral earlier this year because it was featured on the podcast of comedian Jim Breuer.
But what about the science?
As is often the case with unproven treatments for cancer, advocates love to try to convince you that there’s lots of scientific evidence to support them and make the “miracle cure” testimonials more plausible. BenFen is no exception and apparently has used his background to try to summarize the evidence for fenbendazole as an anticancer agent. This is my territory too, as I have spent a number of years investigating whether the repurposing of an FDA-approved drug for another indication can result in effective treatments for breast cancer, and here’s what I can fairly say. There’s preclinical evidence in the form of cell culture studies and animal tumor studies that suggest that fenbendazole could have anticancer activity in humans. What I can also fairly say is that there is nothing in the preclinical evidence presented to suggest that, even if fenbendazole does have significant anticancer activity, it could ever be reasonably expected to produce the sorts of “miracle cures” described on his Substack.
FenBen starts out by summarizing a bit about what is known about cancer stem cells and then goes on to wildly over interpret the preclinical evidence for fenbendazole against breast cancer:
A recent 2022 study in the scientific journal Breast Cancer Research found that mebendazole (fenbendazole)1, a safe, readily available, inexpensive, side-effect free medicine that has had decades of favorable safety and efficacy data, prevents and eradicates triple-negative breast cancer and also prevents the development of metastases by reducing the likelihood of Cancer Stem Cells developing in distant regions.
Did you know that all cancer cells are not created equal? There is a process whereby cancer cells change, either due to treatments intended to help, genetics, and/or the passage of time (most likely an interaction of one or more above-named factors, and other factors yet to be identified), whereby cancer cells become more lethal (Brash, 2019 for example). According to Greaves & Maley (2012) cancer chemotherapy kills some tumor cells, but often creates chemotherapy resistant clones. Cancer Stem Cellsare of particular concern because these cells perform cancer initiating and propagating functions that are characteristics of metastatic spread from one location to another (Greaves & Maley, 2019). Most cancer deaths are caused by these spawned cells, therapeutically resistant to conventional treatments, that then colonize and disrupt the functioning of distant organs.
The part about cancer stem cells is accurate enough, as far as it goes, although I would point out that not everyone is completely down with the idea of “cancer stem cells,” preferring to view them more as a renaming of the long known heterogeneity of cancer cells, specifically the subpopulations that produce metastasis and resistance. Don’t get me wrong. The debate about cancer stem cells and their role in cancer progression and resistance is highly technical and complex, and I don’t want to oversimplify. I just mention it to point out that BenFen is overselling his point, which he continues to do with this paragraph:
An elegant series of experiments from the Riggin’s lab at Johns Hopkins University has demonstrated that physiological doses of mebendazole (fenbendazole) eradicated various forms of breast cancer, including triple-negative breast cancer, and, most important to this particular Substack article, mebendazole also was effective in reducing or eliminating distant organ metastases (Joe et al., 2022).
Let’s just say that the word “eradicated” is doing a lot of heavy lifting here, but let’s look at the specific reference, Joe et al, because it’s the one that BenFen cites most extensively. Let’s put it this way. Yes, the paper does show that mebendazole appears to have antitumor effects against TNBC in preclinical models, but it far from demonstrates that the drug “eradicates” TNBC, characterized by BenFen in the conclusion thusly:
There is a lot to unpack here but let’s not get off the main path: it certainly appears that there is overwhelming evidence that mebendazole (fenbendazole) eradicates cancer.
Notice something? BenFen keeps conflating mebendazole and fenbendazole as though they were the same drug. Although related, they are not the same drug; so BenFen’s citing a study about mebendazole as though its results would also apply to fenbenedazole is profoundly deceptive. Even alternative cancer cure advocates point this out:
For many years, scientists have been researching the anti-cancer benefits of benzimidazole anthelminthics, like mebendazole. The activity against gliomas was initially discovered accidentally when scientists noticed that mice, that were being treated with fenbendazole for pinworm infections, showed a resistance to the glioma grafts they were given. In other words, when the mice were taking fenbendazole, their bodies rejected the tumors that were injected into them! As astounding as this is, subsequent research showed much better performance with mebendazole and albendazole. Shortly after, two different studies showed extended survival in GBM animal models, up to a 63% increase in the average survival time.
In comparison, survival was not significantly increased in the animals treated with fenbendazole. This is probably due to low bioavailability and the fact that it does not cross the blood brain barrier well and therefore, cytotoxic doses do not accumulate near the cancer cells.
Previous cell studies show mebendazole inhibits glioma cells through disrupting microtubule formation. The drug binds to tubulin and prevents mitosis in the cancer cells. Subsequent animal and human studies have corroborated this. We do NOT have the same supporting data with fenbendazole!!
At the end of his post, after having cited all sorts of studies of mebendazole and simply equating it with fenbendazole, BenFen even admits:
Fenbendazole vs. Mebendazole vs. Albendazole vs. Flubendazole: The benzimidazoles are very similar chemically and they have very similar mechanisms of action with respect to disrupting microtubule function, specifically defined as binding to the colchicine-sensitive site of the beta subunit of helminithic (parasite) tubulin thereby disrupting binding of that beta unit with the alpha unit of tubulin which blocks intracellular transport and glucose absorption (Guerini et al., 2019). If someone asks you how fenbendazole kills the cancer cells, the answer is in italics in the previous sentence.
The class of drugs known as benzimidazoles includes fenbendazole, mebendazole, albendazole and flubendazole. Mebendazole is the form that is approved for human use while fenbendazole is approved for veterinary use. The main difference is the cost. Mebendazole is expensive ~$555 per 100 mg pill, while fenbendazole is inexpensive ~48 cents per 222 mg free powder dose (Williams, 2019). As you may recall, albendazole is the form used to treat intestinal parasites in India and these cost 2 cents per pill. FYI, to illustrate how Americans are screwed by Big Pharma, two pills of mebendazole cost just $4 in the UK, 27 cents per 100 mg pill in India and $555 per 100 mg pill in the US.
While most of the pre-clinical research uses mebendazole, probably because it is the FDA-approved-for-humans form of fenbendazole, virtually all of the self-treating clinical reports involve the use of fenbendazole. Because the preclinical cancer studies use mebendazole (ironically the human form of fenbendazole) and humans self-treat their cancers with fenbendazole (the animal form of mebendazole) it is very reasonable to assume that mebendazole and fenbendazole are functional equivalents with respect to cancer. It would be helpful if future investigations simply used fenbendazole as a practical matter. For the purposes of this Substack, fenbendazole, mebendazole and albendazole are used interchangably.
No, you can’t just assume that a related drug will be as effective as the drug you’re talking about. You just can’t. Sure, it’s not unreasonable to assume that fenbendazole probably has similar effects as mebendazole, but so many things could impact that based on the pharmacology of the individual drugs, including absorption, serum half-life, maximal achievable concentrations in the serum, toxicity profile, and so many other things. Heck, the investigators who published the study cited by BenFen used a delivery system that mixed the mebendazole with a special sesame oil carrier mixed with a high fat diet. They even speculated that increased bioavailability and absorption of the drug, thanks to this carrier, was why their results had been better than previously published results by another group.
None of this stops BenFen from proclaiming at the end of his post:
We have a cure for cancer. What is lacking is the courage and political will to apply that knowledge in an altruistic manner to help those who desperately can not wait.
In any event, nothing cited by BenFen about mebendazole actually demonstrates this. Antitumor activity against the cell lines examined? Yes. “Eradicating” TNBC? Not so much. A “cure for cancer”? Definitely not.
Take a look at what I mean in Figure 1. It’s OK; you don’t need to understand it all, just some of it:
I’m familiar with all of these cell lines and have extensively used the MDA-MB-231 cell line, a frequently used model for TNBC. The favorable finding in the figure above (panel A) is that mebendazole has an IC50 (the concentration that inhibits the growth of the cells by 50%) that is less than 1.0 micromolar (μM). That’s pretty good and within an acceptable range for further investigation. Panel B shows that only a percentage of the cells recover after a 48 hr treatment with mebendazole at various concentrations. One curious thing about Panel D that I noticed is this: Why did they leave out the 0.1 μM dose and go straight from 0.05 to 1 μM? That struck me as a bit odd, but whatever. Additional results shown in Figures 2 and 3 are that the drug decreases cell migration, inhibits cell cycle progression, and induces programmed cell death, all desirable traits for any anticancer drug.
Now let’s look at Figure 4:
Panels A-C show how much varying doses of mebendazole mixed with the mouse feed inhibited the growth of MDA-MB-231 xenografts in NOD-SCID Gamma (NSG) immunodeficient mice. Figures G-J show how much the regimen decreased metastases to liver and lung, particularly liver, where it was very effective in preventing metastasis. (Figure 5 did basically the same experiments with 4T1, a mouse mammary tumor cell line that can be grown in immunocompetent mice.) Additional experiments show that the drug decreases the expression of genes associated with the cancer stem cell phenotype as well as indicators of the phenotype itself. All of these results suggest that repurposing the drug could be effective in humans, but not in the way the FenBen claims.
There’s just one problem. The drug tested is not febendazole. Indeed, a more recent study examining the effect of febendazole on breast cancer cell lines found that the IC50 for the drug for the MDA-MB-231 cell line is 10.5 μM, or over 100-fold—yes, 100-fold!—greater than the IC50 for mebendazole against this cell line in the study cited by BenFen. That is a concentration that would be very difficult, if not impossible, to safely achieve in humans.
The authors of the study put it this way (BC=breast cancer; MBZ=mebendazole):
TNBC is the most challenging BC subtype to treat and results in higher mortality due to the high incidence of metastatic cases and paucity of treatment options. Most patients with BC would survive their disease if metastasis could be prevented. Our preclinical results showed that MBZ reduced metastasis with no side effects in mice, and it is well tolerated in humans even at higher doses and for longer durations than used in mice [27]. Given this safety profile, MBZ is a candidate for long-term use and may have promise as adjuvant therapy following surgical resection to prevent BC metastasis. Future studies considering the addition of MBZ to the standard of care treatment are warranted in order to advance MBZ in clinical trials for patients with breast cancer.
This is the way most such drugs are tested and their usage advanced. Indeed, this podcast by BreastCancer.org featuring Brian Wojciechowski, MD discussing fenbendazole tells the tale in an easily understandable fashion. Particularly interesting to me was how scientists noted the “signal” that the drug might have antitumor activity:
What was happening a couple years ago, they did a study at Johns Hopkins. They had these mice that were completely immunosuppressed. They had no immune system, so these mice would be inoculated with tumors. Because there was no immune system, the tumors would grow easily in the mice, and then the cancer researchers could test various cancer drugs against these tumors. So were they testing fenbendazole against the tumors? No. Actually, the fenbendazole, because it was an anti-parasitic, was actually being given to the mice in their food…
…and they noticed that the ones that got the fenbendazole, the tumors wouldn’t grow. So then they started testing, you know, giving some mice fenbendazole, and some mice didn’t get fenbenzadole, and they found that there was a real signal there. The fenbendazole seemed to be helping to kill these tumors in these mice.
We also learn that fenbendazole is an inhibitor of microtubules, which is similar to a mechanism by which Taxol, for instance, exhibits anticancer activity. Does that mean fenbendazole works? No. Nor does it mean that it doesn’t work either. There is fairly promising preclinical evidence for fenbendazole and related drugs, but no good human evidence, and anecdotes of the sort promoted by BenFen don’t count.
What I like is how Dr. Wojciechowski tackles the granddaddy of all anecdotes for these drugs, which are often mixed together in protocol popularized by a man named Joe Tippens and is often referred to as the Tippens protocol, which in addition to fenbendazole included curcumin and cannabidiol oil. Mr. Tippens had a bad cancer and survived, attributing his good fortune to his protocol. Here’s what Dr. Wojciechowski says about it:
Yeah, so small-cell lung cancer metastatic is a devastating disease, and on average people live only about 9 to 12 months with that particular cancer. But every oncologist has seen a small percentage of people, say maybe 5%, who live up to 5 years with this disease. And there could be a lot of different reasons for that. Even within small-cell lung cancer, everyone is different, and everyone will respond to different treatments in different ways. So one possibility, of course, is that fenbendazole works. Okay? We can’t discount that possibility. The other possibility is that the other chemo drugs that he was on, which also have antimicrotubular activities — for example, Taxol, which has antimicrotubular activities just like fenbendazole, so if he was on that drug you have to ask, maybe it was the Taxol that did it, which has similar properties. It’s hard to know for sure. I’m not his doctor, and I don’t know the details of his case, but my patients ask me about these sort of things all the time. And I’m not going to stand in anyone’s way. I’m not going to say you can’t take X, Y, or Z medication. But on the other hand, people ask me for my advice based on my experience and expertise. And when patients ask me about these things, it usually goes something like this: Well, it hasn’t been studied in human beings, so we don’t know if it helps. But it’s almost as important that we don’t know if it’s harmful either. I would never want to recommend to my patients anything that I was uncertain about, especially when there are other medicines and treatments which do have good studies and we do have a lot of good data and information as to whether or not it helps and what the side effects are.
This is an excellent summation of the problems involved in interpretation of anecdotes like this. In addition, I found out something about Joe Tippens that I hadn’t heard before:
The fenbendazole scandal was an incident wherein false information that fenbendazole, an anthelmintic used to treat various parasites in dogs, cured terminal lung cancer spread among patients. It started with the claim of American cancer patient, Joe Tippens, but rather became sensational in South Korea. It caused national confusion and led to fenbendazole being sold out at pharmacies across the country in South Korea. Contrary to what the people know, however, Joe Tippens was a participant in the Kitruda clinical trial at the MD Anderson Cancer Center, and his improvement was likely to be the effect of immuno-cancer drugs.
Sound familiar? (Also, this is the same drug that was used in the KEYNOTE-522 protocol for TNBC.) Elsewhere:
There is still no comprehensive approach. And J keeps on going. It is important to note several things. J is on Keytruda as well. His oncologist at MD Anderson is unwilling to commit that it is the fenbendazole is making the difference.
Of course not. No responsible oncologist, much less one employed at one of the premiere cancer centers in the world, would conclude that fenbendazole is what “cured” Joe Tippens. Moreover, I note that it’s not straightforward to discover this information about Joe Tippens at all; I’ve only found a couple of sources thus far, and it took considerable Googling. (Same as it ever was.) Just go back to my section on the sorts of questions you need to ask whenever you see an alternative medicine cancer cure testimonial.
Fenbendazole: The new laetrile?
As I wrote this, I thought that maybe I had been too harsh on fenbendazole. By that I don’t mean that I think it could possibly produce the miracle remissions described in the anecdotes I’ve discussed. What I do mean is that the drug does have some preclinical evidence (e.g., this study published in November that showed activity against one kind of lymphoma in mice but not another and this study that showed activity against MDA-MB-231 cells) that suggests that it might be repurposed effectively to treat some cancers; it’s just that there is no human clinical trial evidence yet that I have been able to find. Laetrile, on the other hand, had a much sketchier level of preclinical evidence, as I recall. Indeed, preclinical studies failed to find any evidence of anticancer activity attributable to laetrile in mice. Of course, our friend BenFen has a built-in excuse for why even the mebendazole study that he cited wasn’t even more impressive:
(It is important to note that several of the experimental protocols used here were not optimized to kill all the TNBC cells, only to impair their growth or spread for the purposes of the specific experiment).
See? Scientists weren’t really trying, now, were they? I mean, if they were, they’d buy into BenFen’s speculation that the reason cancer rates in developing countries are lower than in developed countries is because so many of them have to take anthelminthic medications due to how common worm infestations are there. It couldn’t possibly be because the populations are younger and die more commonly of diseases not related to aging, like cancer, could it?
Still, I don’t think that the comparison is entirely unwarranted. Even if fenbendazole is found to have clinically useful anticancer activity in humans, it won’t be as a single agent. As Dr. Wojciechowski related, the next step in testing the drug would be to add it to known existing regimens to determine if its addition can improve outcomes; that is, after careful phase I testing in which the maximum tolerated dose in cancer patients is assessed. Further studies would be based on existing preclinical studies and a careful consideration of which make the most scientific sense to add the drug to.
Finally, I can safely make a couple of predictions. First, no single drug is a miracle cure for any cancer, which means that even if fenbendazole is validated in clinical trials against cancer it will not be prescribed as a single agent. Second, if fenbendazole is validated as an effective anticancer agent in clinical trials, its contribution to cancer survival will be incremental, not miraculous. I like to remember how in the 1990s, when I was but a wee graduate student and postdoc, angiogenesis inhibitors were touted as a near “cure” for cancer that would turn cancer into a chronic and manageable disease. (Truly, this was a heady time in the world of cancer research.) What happened instead is that Avastin (for example) produced an incremental improvement in results for some cancers when added to existing treatment regimens and didn’t work at all for others. That is the best that a science-based perspective would predict for fenbendazole; either that, or it doesn’t work in humans. Time will tell, but in the meantime these cancer cure testimonials are doing what such testimonials always do: Produce false hope in cancer patients..

No turbo cancer at ASCO: William Makis vs. Scott Adams and A Midwestern Doctor instead?
I was in Chicago this weekend attending the ASCO meeting, the largest oncology meeting in the world. Nary a talk or poster about “turbo cancer” was seen, but that doesn’t mean there wasn’t cancer quack fight online to distract me from the meeting.
David Gorski on June 2, 2025
Link
This weekend, I’ve been attending the annual American Society of Clinical Oncology (ASCO) meeting. I’m still here, but leaving for home this afternoon. (I’m leaving a little early and, unfortunately, will miss tomorrow’s sessions, but I have surgery tomorrow.) On Friday afternoon, as I was flitting from one session to another, a thought crossed my mind: Funny, but there were no sessions on “turbo cancer” on the program. In fact, not only were there no sessions, but there are no individual talks, abstracts, or even posters about “turbo cancer” on the program. This led me to post sarcastically:
I mean, it’s the biggest cancer meeting in the world, but no turbo cancer in the program?😂
— David Gorski, MD, PhD (@gorskon) May 30, 2025
One of my followers asked:
Not in the plenary session?

😂🤣🤣🤣🤣
— David Young M.D. (@davideyoungmd) May 30, 2025
Nope. Not on the plenary session.
“Turbo cancer” is, of course, a nonexistent phenomenon. While it is true that antivaxxers had been claiming that COVID-19 vaccines could cause cancer as early as mid-2021, “turbo cancer” is, as far as I’ve been able to ascertain, a term made up by antivaxxers sometime in 2022 to put a catchy, pithy name to the nonexistent phenomenon of a wave of cancers so aggressive, so nasty, so untreatable, and so fatal that they weren’t just your run-of-the-mill cancers to which everyone is prone. Never mind that, at the time, the vaccines had only been rolled out less than two years before, and we know enough basic science about cancer to know that the time from carcinogenic insult to a clinically diagnosed cancer is years—decades even. Indeed, as I’ve cited many times, studies of survivors of the Hiroshima and Nagasaki atomic bombings have shown:
What do these data show? First, the risk of developing a radiation-induced cancer is dose-related—the higher the dose, the greater the probability a cancer in an A-bomb survivor was caused by radiation exposure. Second, the A-bomb data allow us to determine the briefest interval from radiation exposure to cancer diagnosis. For leukemias, this is about 2 years, and for solid cancers, about 10 years. These increased risks, especially those for solid cancers, were most easily detected after 30 years and remain over a person’s lifetime.
In other words, it’s biologically incredibly implausible that COVID-19 vaccines could have caused a wave of cancers that started showing up a year after they were rolled out, even if they were as carcinogenic as large doses of ionizing radiation like what is released by an atomic bomb exploding. (It’s also rather ironic that the passage above comes from an article on radiation exposure at Chernobyl published in The ASCO Post. Not that anything like extreme biological implausibility bothered the antivaxxers and cancer quacks who glommed onto the “turbo cancer” narrative. Indeed, one eminent oncologist—the director of a cancer center even, someone who is at this meeting—has shown a disturbing receptiveness to this concept, even though there is no evidence to support the idea that there has been a wave of highly aggressive cancers since COVID-19 vaccines were introduced, and even the observation that there has been an increased incidence of cancer in younger people is often mis-cited by antivaxxers, who cite a study that looked at the decades before 2019. In other words, it’s true that cancer incidence among younger people has been rising, but the increase predates COVID-19 by decades, and there is no evidence an acceleration of the increase since December 2020, when the vaccines were introduced.
Arguably the most prominent and activist promoter of the “turbo cancer” myth has been delicensed nuclear medicine radiologist rebranding himself as an oncologist, Dr. William Makis. Makis, as you recall, lost his medical license in Alberta, Canada in 2017. While I can’t tell whether he or someone else made up the term “turbo cancer,” I do know that by late 2023 Makis was all-in on the claim that COVID-19 vaccines were causing “turbo cancers” and turning into a cancer quack under the guise of being a “health coach.” In Makis’ telling, COVID-19 vaccines are so full of mutating evil humors that they cause cancers that are not just run-of-the-mill cancers that anyone can get as they get older, but rather cancers so fast-growing and malignant that the are called “turbo cancers,” cancers. Never mind that he can’t define what the heck a “turbo cancer” is compared to regular cancers or provide any good evidence that cancer, much less “turbo cancers,” are associated with COVID-19 vaccination. Unsurprisingly, he was also all-in with using the anti-helminthic agent ivermectin to treat not just COVID-19 but cancer, including the fantasmagorical “turbo cancers.” As often happens, his protocol appears to have evolved to include other drugs that treat diseases caused by roundworms, like fenbendazole and mebendazole, which, in fairness, had been promoted as cancer cures before the pandemic. Going back through SBM archives, I noticed that I hadn’t written nearly as many posts about Makis as I thought, given how vociferously he’s pushed cancer misinformation and quackery.
Then I learned about a quack fight. However, I learned about the quack fight because I followed Makis’ reaction to being criticized by a high profile patient of his who realized that his quackery doesn’t work. Most surprising of all, this patient was Scott Adams. This led a quack who goes by the pseudonym of A Midwestern Doctor (AMD), whom I now prefer to refer to as A Midwestern Quack (AMQ).
First, let’s look at Scott Adams, who’s famous for being the cartoonist who created Dilbert, but who later turned to a lot of COVID minimization and denial during the pandemic, as well as antivaccine views towards the COVID-19 vaccine.
Scott Adams makes an announcement
I haven’t written much about Scott Adams before, other than to note that over time he has increasingly embraced COVID-19 minimization, antivax narratives (even saying that “antivaxxers were right“), and conspiracy theories, although there were signs as long ago as 2007 that he was slowly heading down the rabbit hole of unreason. (These days, he’s become fairly Trumpy, and President Trump apparently even called him after his announcement to check on how he was doing.) Adam’s history aside, a little more than a week ago he announced that he had been diagnosed with metastatic stage 4 prostate cancer; within a day or two of that came the post/Tweet cited above.
It’s unclear when Adams was initially diagnosed with prostate cancer, but he was fairly calculating about when he chose to announce his diagnosis. In fact, he quite frankly says that he decided to do so after former President Joe Biden had announced that he had been diagnosed with stage 4 prostate cancer:
It was not clear when Mr. Adams was diagnosed, but he said that he decided to share the news after learning that Mr. Biden had the same disease, in part because he hoped that Mr. Biden’s announcement would draw attention away from his own. He had kept quiet about it to prolong a sense of normalcy, he said: “Once you go public, you’re just the dying cancer guy.”
Mr. Adams said he was also wary of sharing his diagnosis because he wanted to avoid the kind of negative online attention that Mr. Biden has received since his office announced the news on Sunday.
“One of the things I’ve been watching is how terrible the public is,” he said, adding that people had been “cruel.”
“There’s no sympathy for Joe Biden for a lot of people,” Mr. Adams said. “It’s hard to watch.”
It’s true, too. Biden’s announcement immediately unleashed a storm of conspiracy theories, ranging from claims that his prostate cancer was a “turbo cancer” caused by COVID-19 vaccines to claims that he had been diagnosed last year and had kept it covered up so as not to affect his reelection chances. (That latter conspiracy theory doesn’t explain why he waited until a couple of weeks ago to announce his diagnosis.) Of course, even as he expressed concern about how news of his diagnosis would be received, Adams couldn’t resist adding to his statement that he had had his cancer longer than Biden has had it, “well, longer than he’s admitted having it“—and that after after having spent several minutes of the first part of his podcast wondering if Biden had known about his cancer in 2024.
I most definitely do get the idea. Makis has been burned by a famous, high profile cancer patient—not just a cancer patient, but a patient with stage IV incurable cancer!—announcing on his podcast that he has prostate cancer. Worse, he had tried ivermectin, mebendazole, and fenbendazole and had concluded that Makis’ concoction doesn’t work, saying:
Do you remember last year I was making a big deal online about the claims that ivermectin and fenbendazole are a cure for this exact condition? Well, in case you’re wondering, I did try that and I did try it with the assistance of the doctor who was the the famous doctor Dr. Makis, and it wasn’t that I believed it would work. It was just that there wasn’t much downside risk; so with my doctor’s you know blessing—he didn’t think it would work, of course—and it didn’t work at all. So I did it for a few months. My PSA probably went up by a factor of ten during that time. So what I was hoping was that it would work and then I could be, you know, part of the solution. Wouldn’t that have been cool? And so I was teasing you that I was working on something that that could be, like, life-changing but it didn’t work. So I can’t say that it never worked for anybody with some different cancer or some different situation, but I can tell you it didn’t work at all for me. So that’s all I know about that.
First of all, I do feel bad for Scott Adams. He repeatedly describes how he’s in pain all the time, how painful his eventual demise is likely to be, and how he was proud of having been part of activism to push for the State of California to allow terminally ill patients the right to assisted suicide. I also have to give him credit for quickly realizing that Makis’ quackery wasn’t working and that his cancer was continuing to progress. Given all that, I can overlook his digs at Joe Biden, his insinuations that he had known about his cancer for a long time before announcing it, and the like.
Adams even posted this to X on the same day as his podcast:
UPDATE 1:

Please don’t recommend I take Ivermectin and Fenben. 

I tried that last year, via Dr. Makis, to no effect. There are claims of it working, but I am aware of no patient who benefitted from it. Neither are you. 

Please don't recommend fasting or any diet-related…
— Scott Adams (@ScottAdamsSays) May 22, 2025
This post enraged Makis. Within hours of Adams’ announcement Makis posted on his Substack to respond to Adams’ having announced that Makis’ protocol didn’t work for him, calling the article Scott Adams reveals his Prostate Cancer and our attempts to beat it – my response to Scott’s Podcast:
I want Scott to beat prostate cancer, and respecting patient confidentiality, I will say this:
Ivermectin and Fenbendazole combination has about a 75% response rate across all cancers.
While that’s better than any cutting edge cancer treatment out there, I wish it was 100%. It isn’t.
There is no way to predict who will respond and who won’t. It’s not an issue of prostate cancer. I have dozens of Prostate Cancer success stories.
It comes down to the individual’s unique cancer cell type.
For every patient who doesn’t respond, we adjust the dosing and the Ivermectin Treatment Protocol and we fight on to try and beat the cancer.
I have had several situations where 1000mg Fenbendazole didn’t work, but 2000mg Fenbendazole did.
I have had situations where 1000mg Fenbendazole didn’t work but 1000mg Mebendazole did.
I have had situations where 1000mg Mebendazole didn’t work but 2000mg Mebendazole did.
You get the idea.
I most definitely do get the idea. Makis has been burned by a famous, high profile cancer patient announcing on his podcast that he has prostate cancer. Worse, he had tried ivermectin, mebendazole, and fenbendazole and had concluded that Makis’ concoction doesn’t work. Despicable character that he is, rather than just shutting up and waiting for it to blow over, Makis has to attack, in the process using all the old tropes that cancer quacks use when it is shown to them that their quackery doesn’t work, including classics like:
    • It worked for other people.
    • Hey, Adams is an outlier, because my concoction works 75% of the time!
    • The dose was wrong.
    • Maybe he should have tried my other unproven drug, in this case mebendazole.
    • It was Adams’ fault for giving up too soon. (That last part is implied, an insinuation.)
What really riles Makis up is a subsequent video by Adams, in which he reveals that he’ll be taking an experimental drug—no, not an “experimental drug” as quacks like Makis mean it, but a real drug that’s undergone real testing—even though it only has a 0%-30% response rate. At least, that’s what it sounds like. Certainly it’s what Makis thinks it is, given his reaction, as ranted in his Substack entitled SCOTT ADAMS and the Betrayal of Modern Medicine (love the selective all caps), although in the clip from Scott Adams’ podcast included with the post Adams remains kind of coy about it, saying for instance:
However, I have decided on a path of treatment that I’m not gonna tell you about. Now, it has to do with real doctors. It’s not going to be me grazing in my backyard and rubbing mud on myself like most of you are recommending. I’m not going to be taking ivermectin. I’m not going to be spending more time in the sun. I’m sure all those are good things. but I don’t believe any of them would make me better. I think somebody would have noticed if you could cure incurable cancers with just sort of minor diet changes and things like that. So the reason I’m not gonna tell you what I’m gonna do is because I know what the reaction would be
Adams then notes that the reaction “had started to turn” with the antivaxxers coming out and asking him if he got his cancer after getting a COVID-19 vaccine. Yes, Adams is right to say that these are “just terrible people,” because they are. In any case, Adams continues a little later:
So if you’re saying to yourself, I wonder if it’s X, no, because you’ve heard of it. If you say, I wonder if it’s Y, no. It isn’t because you’ve heard of that. So only a very few of you would have ever been heard of the path I’m taking. But it’s with top doctors. It’s not something I’m making up. It’s not some little thing I’m doing on my own. It’s with top doctors in the field who know a lot about this. And it looks like my odds of survival may have jumped from zero to something closer to 30%, which means don’t do my funeral yet. I’ve got a solid 30% chance of getting on the other side of this. And by the way, this is brand new. Like, this is information that I was not aware of until just recently. So I will give you updates at some point, but not until I know if it’s working, which actually won’t take long. So in a matter of, I don’t know, a month or so, I should have a pretty good idea if it’s working. But I’ll let you know.
To me, it sounds as though Adams is probably enrolling in a phase I or II trial of a new anticancer drug. I am, however, skeptical that anything could produce a 30% durable remission rate against metastatic prostate cancer, and I also suspect that Adams is probably conflating response rate (percentage of patients with measurable tumor shrinkage) with a “cure” rate. Be that as it may, I wish him well, as it sounds as though Makis is probably correct to conclude that Adams has enrolled in an experimental protocol of some kind.
Unsurprisingly, Makis can’t handle a high profile cancer patient like Adams repudiating his quackery as not having worked and choosing instead an experimental therapeutic with a low, but measurable, chance of prolonging his life; so he amps up his “blame the victim” narrative, even as he tries to pretend to be sympathetic to Adams as a having been “betrayed” by “Modern Medicine.” The giveaway is Makis’ complaints before he talks about Adams:
I was pleasantly surprised when Scott approached me in October 2024 for help with a serious health condition. Of course, I agreed to help.
Fast forward to May 19, 2025. Scott let the world know that he has terminal Stage 4 Prostate Cancer metastatic to bones, that he tried Ivermectin and Fenbendazole with my assistance and that it didn’t work.
He followed that up with a May 22, 2025 Tweet that again mentions my name and he has it pinned. It now has 2.3 million views.
Since Scott’s May 19, 2025 video, my Twitter account has been flooded with hundreds of negative messages, attacks, threats, smears and I have had to block hundreds of Twitter accounts to protect myself from the tsunami of abuse.
As they say: “No good deed goes unpunished”.
Poor baby. If you’re a cancer quack promoting misinformation and treating patients with unproven and disproven treatments, it’s to be expected that when a famous person tries your quackery and it doesn’t work you will be called out—and rightfully so! Some of your patients with treatable cancer likely paid with their lives, and you’re complaining of a little social media piling on? Seriously, dude, you’re pathetic.
So, what, according to Makis, happened? I bet you can guess. That’s right; there’s a whole lot of blaming the victim going on, but not before he blames Adams’ oncologists for having failed “to stop Scott’s cancer from progressing rapidly to a “terminal stage” in a short period of time,” because, if you believe Makis, “Prostate Cancer patients can live many years, even decades without progression, with the proper Cancer Treatment.” (Capitalizations his, not mine.) Of course, as any oncologist or urologist who treats prostate cancer knows, this characterizations is often, but far from always, accurate. Yes, mostprostate cancer patients who have the most common indolent varieties of prostate cancer die with prostate cancer rather than of it. Yes, we often speak of how in autopsy series 75% of men who live into their 80s have detectable tiny foci of prostate cancer in their prostates. These men with indolent disease, however, are usually older than Adams, who is only 67 years old, usually in their 70s and 80s (and beyond). Moreover, around 5-10% of prostate cancers are metastatic at the time of diagnosis, and there are aggressive subtypes that can grow and metastasize rapidly. Stepping back, we don’t know what stage Adams’ cancer was at diagnosis (mainly because he hasn’t really told us). Nor do we know which conventional treatments he’s undergone other than that apparently he’s never had surgery to remove his prostate and his primary tumor, which implies to me that the cancer was probably advanced and at least unresectable at the time of diagnosis.
The next section of Makis’ lament is a master class in quack deflection and victim-blaming. Seriously, Stanislaw Burzynski couldn’t have whined more plaintively. First, he says that Adams was “betrayed” by Modern Medicine (again, Makis’ capitalization), because he took the COVID-19 vaccines, characterizing it as a “life-changing betrayal.” Actually, Adams had it right the first time getting vaccinated; where he went wrong was when he fell under the sway of antivaxxers and came to doubt vaccines.
Here’s the part that made me laugh out loud as Makis complains about Adams’ oncologist, whoever that oncologist might be:
In addition to failing to treat his cancer properly, Scott’s Oncologist lied to him, repeatedly.
First, he told Scott that Ivermectin wouldn’t work, even though he had no way to know whether it would or wouldn’t.
Second, he told Scott that he had 0% chance of survival and would die shortly.
I wish Scott had told us the name of his Oncologist, and the name of the Cancer Center he was treated at, so that other Cancer patients could avoid them and save themselves from harm. Unfortunately, he hasn’t given us these names.
Instead, he has given the world my name, for reasons I don’t understand.
Later on, he repeats his lament:
And yet, amidst all of this betrayal of Modern Medicine, Scott doesn’t give us his doctors’ names, or the name of the Cancer Center that failed to treat him properly.
Instead, he has my name pinned with 2.3 million views.
Again, poor baby! Actually, I rather suspect that Makis loves being the center of attention and is hoping to gain a few new marks from it, his expressed unhappiness notwithstanding. In any case, I approve. I always try to name and shame quacks like Makis whenever I can. Second, Adams was probably actually pretty smart here, given the social media reaction from antivaxxers to his post in which he announced that he had stopped Makis’ ivermectin and febendazole protocol.
I laughed even harder as I watched Makis try to avoid admitting that he’s almost certainly practicing medicine without a license:
I have never been Scott’s doctor. I was his Health Coach, very briefly.
How does a delicensed and disgraced quack avoid being prosecuted for practicing medicine without a license? He calls himself a “Health Coach” and then practices medicine anyway! Also, one wonders how much Makis charges for his “Health Coaching” services, one does! Actually, one doesn’t have to. You can Google him and find stories of his charging patients $650 just for email consultations in which he sends people a “personalized protocol.” Nice grift if you can get it. One wonders how much he charges for an in-person consultation (if he does them) or for a “telehealth” visit.
His grifting aside, it doesn’t take long before Makis goes on to claim that he barely knew Scott Adams:
Our Health Coaching relationship lasted 1.5 months, at which point Scott left.
Scott supposedly tried Ivermectin and Fenbendazole, for a total of 1 month.
Scott never completed my Ivermectin Protocol, which is a minimum of 3 months with follow-up blood work and imaging.
So we will never know if Ivermectin and Fenbendazole would have worked for him or not. Trying it for one month and then stopping, is not sufficient to make any sort of conclusion.
It is the equivalent of doing one chemo cycle, stopping and declaring chemo doesn’t work.
I might say “Fair enough” in response to Makis’ excuse-making, but there’s a difference. Chemotherapy has copious evidence developed over decades to show that it works, how it works, how it should be used, how long a course of therapy should be for the best balance between efficacy and safety, as well as hard data about its success and failure rates. Makis just makes it up as he goes along, clainming that it takes at least three months for his concoction to work and that it is not unusual for a prostate cancer patient’s PSA to rise during treatment because, according to him, that’s just evidence the magic of the treatment killing cancer cells. Where have I heard variants of “it’s just killing the cancer” in response to clinical evidence that a cancer is progressing? Hint: Lots of places and times!
Yet, like quacks the world over who make excuses when their patients don’t get better or their patients’ cancers progress, Makis claims:
Scott didn’t try Ivermectin and Fenbendazole in any proper shape or form and we will never know if it would have worked for him or not.
Actually, we can know. It didn’t work. It wouldn’t have worked if Adams had stuck with it. There’s no good evidence, clinical or medical, to suspect otherwise.
Scott Adams is a bit of a crank, but that doesn’t matter now. I don’t like to see anyone suffer and die from cancer, not Scott Adams. If this is a crank fight, I know which crank I’m rooting for, even if Adams couldn’t resist conspiracy mongering about Joe Biden’s recent diagnosis of metastatic prostate cancer. Everything I’ve observed about William Makis leads me to the opinion that he is not just an antivaxxer, but he’s a cancer quack—and a grifting cancer quack at that!—as well as a truly unpleasant person, to boot. Whatever my opinion of a cancer patietn as a person, I’m always going to be on the side of the patient against a quack like Makis. Always.
I especially will always be against cancer quacks like Makis when they brag about being asked for an interview by a New York Times reporter:
BREAKING NEWS: The New York Times has asked me for an interview about my Ivermectin Cancer Clinic!
New York Times reporter Stuart Thompson has reached out to me regarding a story he is working on “about cancer treatment groups that organize online”
“I’ve seen your name come up a lot in these groups and I was hoping to connect with you to hear more about the experiences you’ve seen and the cases you have shared in support of the recommended treatment protocols.”
Should I do it?
I run the world’s largest Ivermectin Cancer Clinic. We have the most Stage 4 Cancer success stories and we post them daily.
Looks like we’ve caught the attention of the mainstream establishment!
But then the quack realizes that Stuart Thompson covers the misinformation beat, specializing on how misinformation spreads online, and decides to “politely decline,” although he has to announce his refusal to be interviewed online loudly for his followers to admire that he had been approached by a NYT reporter, as well as his “brave” stand for having declined. Seriously, man, I’ve been interviewed by NYT reporters a number of times. I don’t announce it when they email me to ask for an interview, and I don’t announce the results until and unless they are published in the NYT. (It’s not uncommon for me to be interviewed and be disappointed to find that the reporter used little or none of my quotes. That’s the biz. I don’t take it personally, and I don’t rant about it.)
Also, note to Mr. Thompson: If you happen to see my post, I’d be more than happy to talk to you about cancer quacks like Makis. I’ve been writing about them for over two decades, and Makis is very much a typical cancer quack, only on steroids in terms of his conspiracy mongering and sensitivity to being called out.
Then I noticed that another crank (who’s a big fan of DMSO, rather than ivermectin, as a cancer treatment) has entered the fray, and Makis is really, really unhappy about it. Makis vs. AMQ? Now there’s a quack fight I can enjoy, particularly given that I’m now saddened to have learned about Adams metastatic prostate cancer.
A Midwestern Quack enters the fray, and Makis loses it
One of the entertaining things about quack fights is that, under other circumstances, often the quacks engaging in the quack fight agree on almost everything else, and that is the case with A Midwestern Quack and Makis, the main difference being that AMQ really, really likes the solvent DMSO as a cure-all for cancer. Even more amusing, AMQ has been touting some truly bizarre “mechanisms” for how COVID-19 vaccines supposedly “shed” from the vaccinated to infect the unvaccinated with their evil humors.
So let’s see what Makis says in response to a Substack post by AMQ criticizing the sorts of quackery that Makis likes, in favor of AMQ’s favored DMSO quackery, which to him—and unlike that really, really, really works. Of course, Makis thinks that even mild criticism is part of a “coordinated attack.” As you will see, AMQ’s criticism is fairly mild, but that doesn’t stop Makis from labeling him as a sell-out.
After listing a long quote from a post by AMQ entitled Turbo Cancers and Alternative Cancer Treatments (seriously, AMQ is even more logorrheic than I am, and this post is basically one long screed disguised as science about the nonexistent phenomenon of “turbo cancers” caused by COVID-19 vaccines), Makis rants:
Midwestern Doctor’s smearing of Ivermectin, Fenbendazole, Mebendazole is more subtle than the very public approach taken by Scott Adams.
Midwestern Doctor admits he has ZERO experience but paints Ivermectin, Fenbendazole, Mebendazole as having only “small chance” of success. He states he only knew one case of success and it was “exaggerated”. He conveniently ignores the hundreds of success stories I have already posted on my substack.
Makis neglects to mention that the vast majority of his “success stories” on his Substack are behind a paywall. You have to subscribe to his paid Substack to read them. Moreover, the ones I’ve looked at have been no more convincing than any other alternative medicine cancer cure testimonials of the sort that I’ve been writing about now for over 20 years.
Makis also, unsurprisingly, thinks that AMQ has been co-opted because he praised Casey Means for Surgeon General. No, seriously:
They all show their true colors sooner or later, don’t they?
I was shocked when Midwestern Doctor came out in full support of Casey Means for the position of Surgeon General and the reasons for supporting her.
“Charisma”
“extremely effective communicator”
“advance MAHA message in to enter elite circles” (Elite circles??? Really???)
What I found far more distressing here was the apparent revelation that AMQ was approached about a position in the new administration:
Both I and colleagues who've spoken out against COVID were offered political appointments. While the prestige was tempting, we all declined because we knew we weren't the right fit and thus wouldn't help MAHA. Casey has the charisma to be SG and a voice that will reach America.
— A Midwestern Doctor (@MidwesternDoc) May 8, 2025
I almost wish AMQ had taken the position. Then he/she/it wouldn’t be able to hide behind a pseudonym anymore. In any event, let’s see what AMQ actually said about Makis:
In my case, I learned about fenben (and then mebendazole) roughly a decade ago, and from consulting colleagues, found it sometimes worked, but in many cases recurrences followed. For these reasons, over the years, my network rarely used it, and I hence refrained from discussing the topic as I had no direct experience with it. Recently ivermectin got added into the mix in the and people began extensively discussing the miraculous cancer cures some combination of those drugs created. Because of that, I began to hear much more about it and:
    • Periodically came across people in my community who’d used them without success.
    • In the success stories I heard, enough other things were in the mix, I could not say if it was what worked.
    • Both me and the Vigilant Fox received messages from people who’d taken it, it hadn’t worked and they were now desperate for our help because their cancer had metastasized and they didn’t know what to do.
    • I came across one case where a widely seen success story attributed to this protocol was exaggerated and did not accurately reflect the patient’s medical records.
    • A few doctors have shared with me that generally speaking, a positive response to ivermectin will be seen within the first 30 days, but it normally takes about 4 months to know if it will work (as the initial positive response can be followed by a treatment failure or a miraculous recovery). As such, many testimonials online that are based off only the first month of results are highly misleading.
Because of this, I feel that this protocol is something worth trying as it relatively safe, very affordable and accessible, and has a small chance of making a dramatic improvement that spares you from the nightmare of going through chemo and radiation therapy (hence making it dramatically better than most of the conventional options). However, I also believe the rampant use of miraculous testimonials to promote it (rather than consecutive cases or trials that also show the treatment failures) has created a massive inflation of its efficacy and individuals choosing to eschew other treatments who then either die or lose much of their faith in unconventional treatments.
Note: the only dataset I’ve come across where some aspect of this protocol has a high rate of success has been from people using topical ivermectin in conjunction with DMSO (discussed further here). In addition to a few success stories from readers, one doctor has tried this in his practice and reported topical DMSO-ivermectin treated a metastatic colon cancer, appeared to have a good response in 5 prostate, 1 breast and 1 ovarian cancer that had not metastasized (e.g., 4 PSA’s normalized), and may have helped a brain cancer (but for those 8 cases, conclusive data through imaging is still being awaited). Additionally, 30 or so other patients were recommended the protocol, but no followup was possible with them (due to his practice being both in person and a Telehealth, and those 30 being Telehealth rather than in person patients), so it is not known if they did the protocol or it worked for them.
I included this rather extensive quote because this is what apparently had set Makis off. Does it sound all that critical to you? Basically, AMQ thinks that Makis’ fenbendazole/mebendazole protocol is “wroth trying” because it’s “safe, very affordable and accessible, and has a small chance of making a dramatic improvement.” The only criticism seems to be that testimonials have been used to promote Makis’ protocol (which is based on a protocol commonly called the Tippens protocol), rather than consecutive case series. This made me laugh out loud, as testimonials and cherry picked stories are basically the evidence base that AMQ uses to promote his DMSO quackery.
Even more hilariously, later on in the same lengthy post, AMQ goes on and on about how complicated cancers are, but with the same sort of quack twist that cancer quacks about whom I’ve written have used going back to long before I started writing about this stuff 20 years ago:
One of the immensely challenging things about treating cancer is that to some extent what each cancer responds to differs and typically, there are a variety of precipitating factors in the background that cause cancers (e.g., certain nutritional deficiencies, traumatic emotions, excessive unopposed estrogen, systemic disturbances of the body’s microbiome, chronic infections such as those within root canals, poor sleep overwork and chronic stress, or impaired detoxification pathways).
Because of this, while certain treatments have a rather broad spectrum of applicability to cancers (e.g., IV vitamin C), the specific treatments people need greatly vary and the specific protocols we give people often greatly differ. Conversely, the only thing I know that works consistently is using complementary therapies to mitigate the effects of a conventional treatment (e.g., ultraviolet blood irradiation for chemotherapy or DMSO for radiation therapy) or potentiate them so lower doses are more likely to elicit a cure.
Yes, treating cancer is immensely difficult and complex. That’s why I come to meetings like the annual meetings of ASCO, various surgical societies, and the American Association for Cancer Research (AACR), to learn about the latest science regarding cancer and, sometimes, to present my research results. In contrast, what AMQ does is just to throw woo upon woo, quackery upon quackery, made up mechanism upon made up mechanism. That might look like complexity. It might even be complexity. However, it’s not a complexity rooted in reality, but rather in fantasy.
As for this quack fight, I hope to see what subsequent rounds reveal, not just for my entertainment, but to use as fodder to contrast what real science-based cancer care looks like compared to what quacks like Makis and AMQ deliver. In the meantime, I wish Scott Adams well and hope that he has a good response to whatever experimental drug he’s getting. If that doesn’t work, I hope that he seeks out and receives the best palliative care that science-based medicine has to offer. If there’s one difference between science-based medicine and medicine practiced by AMQ and William Makis, it’s that, whatever its shortcomings, SBM knows its limitations and doesn’t promote fantasy cures.
Finally, there’s a reason why there are no abstracts, talks, or sessions about “turbo cancer” here at ASCO. It’s the same reason why—although before he was appointed to run Center for Biologics Evaluation and Research CBER) at the FDA I had wondered if I might run into Dr. Vinay Prasad this weekend—I’m in zero danger of running into “Dr.” Makis or AMQ anywhere at the cavernous McCormick Place here in Chicago.


Tess Lawrie: Ivermectin isn’t just for COVID-19 but cures cancer too!
In a turn that should surprise exactly no one, the BIRD Group’s Tess Lawrie effortlessly pivots from promoting ivermectin as a cure for COVID-19 to promoting it as a cure for cancer. It’s another example of how single-issue quacks almost inevitably embrace more diverse quackery.
David Gorski on January 23, 2023
Links

Way, way back in 2007 or so, a friend of mine, Dr. Mark Hoofnagle, coined the term “crank magnetism” as a pithy phrase to describe a very simple concept, specifically that those who tend to believe one piece of pseudoscience, quackery, and/or conspiracy theory (e.g., antivax pseudoscience and conspiracy theories) will often also be attracted to—and come to believe in—other forms of pseudoscience (various forms of quackery, such as “autism biomed,” alternative medicine, evolution denial, HIV/AIDS denial, and more). These beliefs are often—but do not have to be and often are not—related to each other; they can even be mutually contradictory. The term also describes the tendency of even “one-issue” cranks and conspiracy theorists to accumulate more conspiratorial beliefs over time. It’s almost as though, once one’s brain is “opened” enough so that one’s brains fall out, it’s a two-way street, with that opening allowing all manner of nonsense to enter as well. We’ve definitely seen the same phenomenon play out in a huge way since COVID-19 hit and the disease minimizing, anti-public health, “miracle cure” (e.g., hydroxychloroquine, ivermectin) pushing conspiracy theorists joined forces with antivaxxers before there even was a vaccine against COVID-19, which brings me to Tess Lawrie, who reminded me of this last week with a post on her Substack titled “Can cancer really be cured with ivermectin and other safe, old treatments?” This post reminded me instantly of Mark’s old phrase, while providing an “in” to discuss not only how general conspiracism has spread throughout the COVID-19 minimization/antivax movement while at the same time looking at the claim made in this post.
And if that weren’t enough, the tagline to Lawrie’s post got me:
Big pharma will say no – but this cancer survivor and TOP scientist knows otherwise
Yep, it’s the cures “They” don’t want you to know about—shades of Kevin Trudeau! Also, the all caps on the word “TOP” just made me chuckle. Moreover, as you will soon see, linking Jane McLelland’s story to ivermectin turns out to be a bit of a “bait-and-switch.” I’ll explain later in the post and as indicated in this “teaser“:
Jane’s own diagnosis and treatment began back in the 1990s and she describes the amazing support she received from her doctors at the time. It seems that when she would suggest a particular drug or protocol, they would be open to the idea, and agreed to let her just try.
So McLelland’s cancer was diagnosed nearly three decades ago, long before the pandemic hit and ivermectin as a miracle cure for COVID-19 became a thing. So where does ivermectin even come in? Patience. Before I get to that, though, I think it’s important to recap Dr. Lawrie’s past activities with respect to ivermectin.
Before cancer, Tess Lawrie hawked ivermectin as a cure for COVID-19
Regular readers might remember that we at SBM have written about Tess Lawrie before, mostly in 2021, as she became a leading voice in promoting ivermectin against all evidence as a miracle treatment for COVID-19, leading me to quip that ivermectin is the new hydroxychloroquine in multiple posts, based on how, as high quality randomized controlled trial (RCT) evidence failed to find a significant treatment effect for hydroxychloroquine, COVID-19 “miracle cure” advocates switched to ivermectin and spun all manner of conspiracy theories about why “They” kept denying that it was a cheap, safe, and highly effective treatment for COVID-19. What was predictable about Lawrie is how she denied being an antivaxxer but by last June was appearing at the antivax Better Way Conference with Dr. Robert “inventor of mRNA vaccines” Malone, Bret Weinstein, Geert Vanden Bossche, Jessica Rose, and even Robert F. Kennedy Jr. supposedly in attendance, leading Tim Hume to describe the meeting as the “Davos of conspiracy theorists.”
I don’t want to rehash a lot of what I’ve written about in detail before, but I do think it important to point out that early in the pandemic hydroxychloroquine, a repurposed malaria drug that also has mild immunosuppressive activity that makes it useful to treat rheumatoid arthritis, was recommended, based on no high quality (or, truth be told, even moderate quality evidence) as a first line drug to treat COVID-19. As I’ve described a number of times, this was based on a report out of Wuhan in early 2020 from Chinese physicians that none of a group of 80 patients with rheumatoid arthritis taking hydroxychloroquine caught COVID-19. As a result of that and old in vitro evidence of antiviral activity, they became interested in using these antimalarial drugs to treat COVID-19. Based on anecdotal reports and small preliminary clinical trials, in March 2020 the Chinese government published an expert consensus recommending chloroquine or hydroxychloroquine for patients with COVID-19. Soon after, a number of nations followed suit. From there, a French “brave maverick scientist” named Didier Raoult—remember him?—latched onto the drug as the “answer” to the COVID-19 pandemic, publishing risibly bad studies claiming to show its efficacy. Tech bros such as Elon Musk discovered the claims about hydroxychloroquine and Raoult’s bad science, leading to Donald Trump Tweeting favorably about his study and, ultimately, to the FDA issuing an emergency use authorization for the drug to treat COVID-19 that it was forced to revoke by the end of April 2020, and by summer 2020 it was very clear that hydroxychloroquine was not only not a “miracle treatment” but almost certainly ineffective, all the familiar-sounding—to SBM readers, anyway—“miracle cure” anecdotes touted by Fox News personalities notwithstanding.
An old pal in Los Angeles (no Trump fan) just texted me that seven friends of hers (here and in Sweden) ALL took hydroxychloroquine, all recovered quickly, zero side effects. Called it a “godsend.”
— Laura Ingraham (@IngrahamAngle) April 10, 2020
Enter ivermectin, a drug that is highly effective in treating parasitic diseases of human and animals due to roundworms (helminths). Based on in vitro studies showing activity against SARS-CoV-2, the coronavirus that causes COVID-19, advocates like Tess Lawrie latched onto ivermectin as the new hydroxychloroquine; i.e., a cheap, safe, and effective treatment for the disease. The problem with this claim was obvious right from the beginning to anyone who applies science-based approaches to medical problems. As I discussed, the concentration needed to inhibit SARS-CoV-2 in cell culture is at least 50 times higher than what can be safely reached in the bloodstream. Just from a pharmacokinetics and pharmacodynamics standpoint, it was always a highly implausible hypothesis that ivermectin would be an effective drug for prevention, postexposure prophylaxis, or treatment of COVID-19, and eventually RCTs showed that it isn’t any of these things. It doesn’t work, leading me to call it the acupuncture of COVID-19 treatments and use it as an example of why science-based medicine isn’t just for “integrative medicine,” but for all medicine.
In any event, Lawrie is one of the founders of a UK group known as the BIRD Group, which exists mainly to promote ivermectin as a miracle cure for COVID-19. Just take a look at the landing page of its website in June 2021:

And here is what it looked like yesterday as I was writing this:

When it comes to the BIRD Group and ivermectin, apparently 2023 is the new 2021.
Now, on to the crank magnetism.
Ivermectin: A miracle cure for cancer?
With that background out of the way, let’s take a look at Lawrie’s post from Thursday and the claims made there. First, Lawrie leads with the antivax myth that COVID-19 vaccines cause cancer (or “turbo cancer,” as they sometimes call it) to set up her narrative:
As we covered back in December, researchers and oncologists like Professor Angus Dalgleish are seeing a disturbing proliferation of cancers, in particular following Covid injection. Even before the pandemic, the incidence of cancers was increasing and a recent study has found that the occurrence of brain cancer is related to both GDP and mobile phone usage.
Actually, no. There is no good evidence that cell phone radiation causes cancer, particularly given how there is no good physical or molecular mechanism that would explain how it might do so. I might have to look into that study more, but I can tell from the abstract alone that there are a lot of caveats there. In the meantime, it’s not surprising that Lawrie is moving into more crankery:
Today, I want to focus on what on earth we can do about it. To help me, I’m consulting not an oncologist, or a pathologist, but an exceptional woman who became an expert by necessity. She’s called Jane McLelland and her knowledge in this area is worthy of a PhD.
Jane is one of several people I have met in the last three years who are top scientists, just without the long line of initials after their names. Her own Stage IV cancer diagnosis forced her down a path of inquiry and investigation – and this research quite literally saved her life. That was about two decades ago, and she’s been helping others ever since.
As I say whenever I discuss alternative medicine cancer cure testimonials—and, make no mistake, that’s exactly what Ms. McClelland’s story is, an alternative medicine cancer cure testimonial—I always preface them by saying that I’m happy the person is doing well and so far surviving her cancer. Always. As a cancer surgeon myself, I don’t wish cancer on anyone, and I particularly don’t want anyone to die from cancer. Unfortunately, however, Ms. McClelland, Dr. Lawrie’s claim that she is a “TOP scientist” notwithstanding, is a fake expert, who claims that her self-discovered knowledge trumps that of experts who have formal training and have devoted their lives to studying cancer and/or treating cancer patients. For one thing, she has no training in oncology or scientific research, being a Chartered Physiotherapist who worked in the UK’s NHS and private practice for twelve years, specialising in Neurology and then Orthopaedic.
Does this sound familiar at all? Similarly, does this part about how “They” don’t want patients to have access to ivermectin, which in the video clip included McLelland claims to be also highly effective against triple negative breast cancer (TNBC)—and that’s my area of expertise!—to cure their COVID-19?
Of course it does:
When the pandemic was at its height, we were inundated with pleas from people who were desperate to get ivermectin to their loved ones in hospital, but who were blocked at every turn. Doctors and hospitals would not even entertain the idea of trying this safe medicine, even when a patient’s prognosis was poor and there was little to lose. In our conversation, I mention one instance where we quite literally helped smuggle ivermectin in a chocolate bar to a woman in intensive care:
It makes me wonder: if this pandemic had arrived in the mid-nineties, it might well have been over within a few weeks. I imagine word would have spread that ivermectin, together with other nutraceuticals such as vitamins D, C, quercetin and zinc, were doing the trick and that would have been that. How things have changed!
Of course, it couldn’t possibly have been all the supportive care in the hospital that saved her—I wonder if she got monoclonal antibodies—but of course it had to be that single dose of ivermectin smuggled to her in a chocolate bar. Let’s just say that when someone’s lungs start getting better it can sometimes happen faster than expected. This reminds me very much of testimonials attributing “miracle cures” to hydroxychloroquine that were circulating early in the pandemic, such as one from April 2020 from a local Michigan State Representative named Karen Whitsett, a New Jersy man named Billy Saracino, and an Alabama man named Carl Shuck (who was still on a ventilator for two weeks), all of whom I discussed at the time and explained why they weren’t good evidence that the drug worked. As I said at the time, were we to believe the media accounts, if you receive hydroxychloroquine (±azithromycin) and recovered, no matter how much time it took, obviously it was the drugs that had cured you. Such was the narrative the media was feeding the public, and such is this narrative. Indeed, I explicitly likened these narratives to the “miracle” cure narratives for Stanislaw Burzynski’s antineoplastons and other alternative medicine “miracle cure” cancer testimonials.
Nor could it have been all the other treatments that Jane McLelland used in addition to ivermectin, which, as you will see, struck me as a small part of the numerous dubious and quack treatments that she used. The similarities between ivermectin miracle cure testimonials and cancer miracle cure testimonials couldn’t be more clear, though. If a patient used a bunch of other treatments plus the miracle cure, it must have been the miracle cure that made the difference. Again, we’ve seen this phenomenon before—and I’ve discussed it more times than I can remember since 2008—with miracle “cures” for cancer, autism, and, yes, COVID-19.
Jane McLelland’s story
So let’s look at Jane McClelland’s “miracle cure” testimonial for ivermectin, as described both in her post from Thursday and from Sunday, the latter of which is titled “How to starve cancer” (a title that, unsurprisingly, caused my cancer quackery detection antennae to start twitching even more furiously than they had been twitching after the first article) and includes a video interview. I sighed when I realized that the interview is over 40 minutes long because I realized that I was going to have to watch the whole thing in order to discuss her testimonial in detail. However, going in I couldn’t help but note this part:
Here are just a few highlights:
    • A ketogenic diet can help starve cancers – but diet alone rarely works. It’s also important to be careful about the type of fat you consume.
    • The skin of sweet potatoes has anti-cancer properties – so no more binning the peel!
    • Cancer tries to find different routes to feed itself – so it’s essential to block all pathways, not just one.
    • Different cancers will use different, dominant pathways, so the treatment strategy must be tailored accordingly
    • Safe, effective, repurposed drugs such as ivermectin are an essential element of blocking the right pathways – but they’re usually overlooked (surprise, surprise)
    • Cancer stem cells are unaffected by chemo and radiotherapy, so they’re left behind to seed new tumours. It’s essential, then, to target these – Jane explains how
    • Ferroptosis is a strategy that effectively weaponises cancer’s need for iron, stopping it in its tracks
This is a rich conversation with so much valuable information and I learnt so much speaking with Jane. Please feel free to share with anyone you think may benefit.
Once again, which is it? I’ve discussed how claims for ketogenic diets—which have even been claimed to “beat chemo for almost all cancers” are overblown at best and completely wrong at worst and have even noted how ketogenic diets have been associated with decreased quality of life in cancer patients; so I won’t dwell on that much. I will give her credit; like so many non-experts, she has learned the language. I will admit that, prior to this, I had been unaware that cancer quacks had latched onto ferroptosis, as well, and her mention of it actually piqued my interest because in an effort to restart my lab, which did not do well during the pandemic, I recently started collaborating with an expert on ferroptosis. Of course, like so many cancer quacks, Ms. McLelland knows the lingo but doesn’t really understand it. In this way, she reminds me of Dr. Stanislaw Burzynski, who in addition to his antineoplastons developed something he called “personalized gene-targeted” therapy, which when I examined it turned out to be basically a “throw everything but the kitchen sink at it” approach to cancer, in which he used a bunch of very expensive targeted therapies without much thought about how they might interact, all while claiming he was better at personalized cancer therapy as M.D. Anderson Cancer Center—and had even invented it.
I’m also going to point out that in the clip included in Dr. Lawrie’s very first post, McLelland made a statement that is, to put it kindly, completely wrong. Remember where I mentioned that she claimed that ivermectin is a “fantastic drug” for cancer, specifically TNBC? Right after that, she claims:
I suggest that people look at that [ivermectin] particularly for things like triple negative breast cancer, where the breast cancer is known to be a “cold” tumor; so it doesn’t respond to immunotherapies. But if you take ivermectin it becomes a “hot” cancer that does respond to immunotherapies, and this is a big thing. You know, if we could get more people to take more immunotherapies that could work, that is a big potential step forward. So ivermectin for triple-negative breast cancer works very well and is in fact synergistic with our ferroptosis protocol as well. Ivermectin I love for various factors; it really targets the EGFR mutations and HER2, which is very commonly associated with breast cancer and other cancers that use the HER2 as well.
TNBC doesn’t respond to immunotherapy? TNBC are “cold” tumors that the immune system doesn’t recognize? Quite the opposite, at least for a large subset of TNBCs! I’d like to refer Ms. McLellan to the KEYNOTE-522 clinical trial published in 2020 and NCCN guidelines, which showed that adding pembrolizumab (KEYTRUDA) to standard-of-care neoadjuvant chemotherapy (chemotherapy before surgery) resulted in a significant increase in the pathological complete response rate (the percentage of patients whose surgical specimens contain no residual tumor detectable by pathologists looking at them through the microscope) and benefited even patients with metastatic disease if their tumors expressed the protein PDL-1 Of note, pembrolizumab is an immune checkpoint inhibitor, and immune checkpoint inhibitors are considered immunotherapy. In fact, the use of this immune checkpoint inhibitor is now standard-of-care for operable TNBC. (For those of you not familiar with TNBC, this subtype of cancer lacks the receptors estrogen and progesterone hormones, as well as the HER2 oncoprotein, and tends to be more aggressive than hormone receptor-positive cancers.) Let me say that again. Chemoimmunotherapy is the new standard of care for TNBC since 2020.
Conveniently enough, I encountered this illustration on Twitter of KEYNOTE-522:
Here's the EFS endpoint from KEYNOTE-522. 7.4% absolute improvement for patients who received pembro over placebo = 37% reduction in event free survival. #tnbc #bcsm #BestofBreast23 pic.twitter.com/rXfqxE6Vix
— Total Health | Oncology 📖🔬 (@TotalHealthConf) January 22, 2023
And don’t even get me started on how often TNBC has higher levels of tumor-infiltrating lymphocytes, another indicator of an immune response from the patient. Again, on this one issue, Ms. McLelland doesn’t know what she’s talking about. She also goes on to claim that ivermectin also—conveniently enough—targets HER2, which led me to think: You do know that if a breast cancer overexpresses (makes too much) HER2, by definition it’s not TNBC, right?
As for any published data on the use of ivermectin to treat TNBC, a search of PubMed produced just one article from 2015, which showed that ivermectin could potentially restore sensitivity to the anti-estrogen drug tamoxifen in the TNBC cell line MDA-MB-231 (a cell line that I’ve worked with extensively over the years) and MMTV-Myc mouse TNBC cells in vitro. In other words, it’s a single study in cell culture that does not say anything about ivermectin resulting in TNBC responsiveness to immunotherapy. Let’s just put it this way. Ms. McLelland is flat-out wrong about this, and when I see two statements that obviously wrong about something I know a lot about (e.g., TNBC is not immunogenic and sensitive to immune therapy and that ivermectin makes these “cold” tumors “hot”), I immediately wonder what other wrong statements she’s making. In fairness, there are studies examining cell culture and animal models of various cancers that show that ivermectin can apparently inhibit the motility in vitro and metastasis in a mouse model of some cancer cell lines and inhibit EGFR signaling (which stimulates cancer growth), but that’s a long way from any good clinical evidence and just shows how cancer quacks like to cherry pick in vitro data and represent it as meaning a treatment works. (For instance, one of these studies used estrogen receptor-positive cells, not TNBC.) I also noticed immediately that these studies used very high concentrations of ivermectin, just like the in vitro studies testing ivermectin against SARS-CoV-2.
So what about Ms. McLelland’s story? She was diagnosed with cervical cancer in 1994 at age 30 and “did all the normal stuff, chemoradiotherapy” and what sounds like a radical hysterectomy. Sadly, this was before she had married and rendered her unable to have children. In 1999 the cancer recurred in her lungs, but in the meantime her mom was diagnosed with stage IV breast cancer, which had led her to look for treatments. This search had led her to one of the favorite areas of cancer abused by cancer quacks, the Warburg effect, or aerobic glycolysis. (Remember dichloroacetate, anyone?) She also developed leukemia, that was apparently attributed to her cancer treatment.
Here I must note a couple of things. First, it is true that stage IV cervical cancer is usually incurable. However, around 15% of patients with stage IV disease can survive more than five years, although it could well be a much lower percentage after a recurrence. Look at it this way. Even if it’s only 1% of patients with recurrent cervical cancer who survive more than five years, the far more likely explanation for Ms. McLellan’s good fortune and continued survival is that she was fortunate enough to be one of these lucky few who survived, not that she somehow through trial and error stumbled onto a regimen of old repurposed drugs—including dipyridamole (Persantine, a drug that I haven’t dealt with in decades), statins, naltrexone, metformin, and others—that cured her. (Actually, clearly even she doesn’t think she’s cured, as she’s still taking them and appears to be adding to the regimen fairly regularly.) Whatever the case, she relates about how a cocktail of “kitchen sink” drugs led to remission and that she is still taking these drugs. This is how her story as touted on Dr. Lawrie’s Substack is a “bait-and-switch.” Ms. McLelland never actually appears to have treated her cancer with ivermectin as far as I can tell from the interview, although she did use it to treat her COVID-19, and even if she did she used it decades after she had a cancer recurrence.
Whenever I hear a “miracle cure” testimonial like this, particularly from someone who has been promoting her “miracle cure” since the late 1990s, I wonder: Why is there no evidence other than the anecdote? Why hasn’t this regimen been studied? Why aren’t there publications showing how effective it is? (Ms. McLelland’s book describing how she “did her own research” doesn’t help.) I also found it odd how little she mentioned her leukemia afterward, given that when she mentioned it she seemed to be saying that it was the more “incurable” of her two cancers. Unsurprisingly, a lot of cancer quackery tropes are in this interview, including the hoary, ever-popular claim that sugar “feeds” cancer, even to the point where near the middle of the interview Ms. McLelland and Dr. Lawrie complain about how hospitals often raise money using bake sales selling “sweet things” and how discordant that supposedly is. (How many times have I heard this before?)
Ms. McLelland also complains that cancer cell metabolism is not taught in our training, which might have been true 30 years ago but most definitely is not true now—nor has it been for a long time. Indeed, back around 2010 I marveled at how targeting the Warburg effect seemed to be the dominant theme at cancer meetings like the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), the two biggest cancer professional organizations in the country, the former dedicated more to basic and translational science and the latter to clinical research. Then, as I went to these meetings year after year, the Warburg effect faded in prominence as other targets rose, such as—you guessed it—immunotherapy with immune checkpoint inhibitors like pembrolizumab. Nor was this because “They” were trying to keep you from knowing about ketogenic diets, targeting tumor metabolism, and the like as treatment modalities. Rather, it’s because the results didn’t quite live up to the hype. It reminded me of how a decade before that even, targeting tumor angiogenesis (the growth of new blood vessels to feed the tumor) dominated these meetings but, as drugs that blocked that process increasingly showed themselves, while effective, not to produce the near-miraculous results observed in mice in the 1990s, oncologists and oncology researchers integrated them—e.g., Avastin—into standard cancer care and started looking for new molecular targets.
None of this stops these two from repeating the same old cancer quack complaints (which are the same complaints of COVID-19 quacks about ivermectin) that “They” (pharmaceutical companies) don’t want you to know about these cheap, safe, and supposedly highly effective treatments for cancer and that Ms. McLelland had succeeded where oncology had failed:
Diagnosed with terminal cancer in the prime of her life, and with no viable treatment options, she used herself as a human guinea pig, putting together a cocktail of low toxicity drugs, not normally used for cancer, alongside a low glycaemic diet and powerful supplements. These ‘starved’ her cancer of glucose, glutamine and fat, which she demonstrates with her ingenious, easy-to-follow ‘McLelland Metro Map’.
Which brings me to ferroptosis.
Ferroptosis
Ms. McLelland’s hyping of ferroptosis as target for cancer therapy caught my interest because it was a rehash of the same quack narrative about sugar “feeding” cancer, namely that you don’t want to consume a lot of iron because it “feeds” cancer cells. Unsurprisingly, it turns out that ferroptosis is more complicated than what Ms. McLelland describes, in which you somehow get cancer cells to release ferritin (a protein-iron complex) and then oxidize it in order to attack the cells by using high dose vitamin C or use old rheumatoid arthritis drugs to induce ferroptosis.
Basically, ferroptosis is a form of programmed cell death that depends on iron. It is, of course, true that targeting ferroptosis in cancer is a hot research topic right now. Indeed, I did a PubMed search for just the year 2022 and came up with close to 500 references, and a Nature Reviews Cancer article from last year notes:
Ferroptosis, as a unique cell death mechanism, has sparked great interest in the cancer research community as targeting ferroptosis might provide new therapeutic opportunities in treating cancers that are refractory to conventional therapies. In recent years, substantial progress has been achieved in understanding the role of ferroptosis in tumour biology and cancer therapy. On the one hand, multiple cancer-associated signalling pathways have been shown to govern ferroptosis in cancer cells14. The engagement of ferroptosis in the activities of several tumour suppressors, such as p53 and BRCA1-associated protein 1 (BAP1), establishes ferroptosis as a natural barrier to cancer development15,16, whereas oncogene-mediated or oncogenic signalling-mediated ferroptosis evasion contributes to tumour initiation, progression, metastasis and therapeutic resistance17,18,19. On the other hand, the distinctive metabolism of cancer cells, their high load of reactive oxygen species (ROS) and their specific mutations render some of them intrinsically susceptible to ferroptosis, thereby exposing vulnerabilities that could be therapeutically targetable in certain cancer types20,21,22,23,24. Furthermore, some cancer cells appear to be particularly dependent on ferroptosis defence systems to survive under metabolic and oxidative stress conditions; consequently, disruption of those defences would be fatal to such cancer cells while sparing normal cells9. These recent data suggest that ferroptosis represents a targetable vulnerability of cancer in certain contexts. Ferroptosis has also been recognized as a critical cell death response triggered by a variety of cancer therapies, including radiotherapy (RT), immunotherapy, chemotherapy and targeted therapies25,26,27,28. Thus, ferroptosis inducers (FINs) hold great potential in cancer therapy (Box 1), especially in combination with conventional therapies25,29,30.
I recommend that those of you with the background to understand this review take a look. For lay people, suffice to say that what Ms. McLelland says about ferroptosis is sort of correct in some parts—e.g., it is true the catalysis by iron of the oxidation of lipids in the cell membrane is a trigger for ferroptosis—but vastly exaggerated. There is so much more complexity to the process, as the review quoted above discusses. Just take a look at this illustration from the article to get an idea:

Any similarity between Ms. McLelland’s simplistic take and the complexity above is mainly by coincidence only. Indeed, I want to call her version of ferroptosis “ferrobabble,” a nod to the term “technobabble” in Star Trek, the same way I refer to quacks invoking the immune system as spouting “immunobabble.” As an aside, I’ve written a couple of—as yet unfunded, alas—grants looking at targeting the cystine transporter SLC7A11 in order to induce ferroptosis using a repurposed drug. That’s one reason why I laughed listening to these two women say that no one is interested in repurposed drugs. Lots of investigators are interested in repurposed drugs and derivatives of repurposed drugs to treat cancer. This has been true ever since I first met up with a surgeon and a basic scientist who were researching the repurposed drug that I’ve published on.
Unsurprisingly, near the end of the interview, Ms. McLelland relates how she had been “pressured” to take the COVID-19 vaccines, first a non-mRNA vaccine and then two doses of an mRNA vaccine, after which she resisted getting a second booster. Then she got COVID-19 and—surprise! surprise!—got better almost immediately after a single dose of ivermectin. Also, her regimen has supposedly cured her “late onset cystic fibrosis,” because of course it has.
Again, I’m happy that Ms. McLelland is continuing to do well and remains, as far as we know, cancer-free. However, as much as I don’t want anyone to die of cancer, that doesn’t mean that I won’t, when I see a believer who thinks she’s cured herself of a deadly disease with quackery turn around to start promoting and selling that quackery, hold back on calling it quackery and explaining why. Think, for example, Chris Wark of “Chris Beat Cancer” fame. (He did beat cancer, but it was the surgery, not the quackery, that saved him.)
Crank magnetism or crank expansion?
Long before the pandemic, we were discussing cases of how “single issue” cranks and quacks seemed almost inevitably to embrace more and more forms of pseudoscience, conspiracy theories, and quackery. In a way, I think this might well be a related, but distinct form of crank magnetism that I like to refer to as, “Come for one conspiracy theory, stay for conspiracism.” We’ve seen so many examples of this phenomenon, too, beginning with how COVID-19 minimizers and the conspiracy theorists who thought it was a “plandemic” or “bioweapon” soon embraced all manner of other conspiracy theories and pseudoscience, including conspiracy theories involving antivaccine activism, QAnon, antisemitic conspiracy theories, big pharma supposedly suppressing “miracle cures” that “They” don’t want you to know about. Just look at how, for example, Drs. Robert Malone, Pierre Kory, Peter McCullough, and the whole crew of “America’s Frontline Doctors,” among many, many others, have expanded from their single issue “alternative treatments” for COVID-19 to embrace pretty much every conspiracy theory about COVID-19 that there is, including those of “depopulation” and “died suddenly” (of the vaccine) and political conspiracy theories involving how Russia is not the aggressor in Ukraine. Similarly, “old school” antivaxxers like Joe Mercola and Robert F. Kennedy, Jr. have eagerly glommed onto the new COVID-19 conspiracy theories and “miracle cures.” There seems no end to their “magnetism” for crankery.
Dr. Lawrie started out, as far as I can tell, mainly as a believer in ivermectin as a cheap, safe, and highly effective treatment for COVID-19, but then gradually (or not so gradually) embraced more and more pseudoscience until now she’s promoting cancer quackery of the sort that Ms. McLelland has been peddling since the 1990s. Ms. McLelland, in the meantime, has naturally glommed onto ivermectin as the new “in” drug among the COVID-19 conspiracy crowd.
Crank magnetism marches on..

COVID-19 antivax quacks are now “repurposing” ivermectin for cancer
A year ago, I noticed that COVID-19 quacks were touting the “repurposing” of ivermectin to treat cancer. Now, familiar COVID-19 antivaxxers—cough, cough, FLCCC—have turbocharged this quackery.
David Gorski on February 5, 2024
Link

About a year ago, I started to notice Dr. Tess Lawrie was promoting ivermectin as a miracle cure for cancer. Dr. Lawrie, as you might remember, is a British physician who first made a name for herself in the COVID-19 contrarian and antivax movement as one of the founders of the Bird Group in the UK, a group that was (and still is) dedicated to the “approval” by regulators of ivermectin as a treatment for COVID-19. Basically, my take at the time was that the Bird Group is basically the UK version of the Frontline COVID-19 Critical Care Alliance (FLCCC), an American antivax group born during the pandemic that promotes all manner of COVID-19 minimization, antivaccine views, and, of course, “cures” for COVID-19, in particular ivermectin, which they have claimed to be “repurposing” to be a prominent part of its “protocols” to treat the disease. Unsurprisingly, Dr. Lawrie has been closely aligned with American COVID-19 quacks like Dr. Pierre Kory at least since 2021, and even less surprisingly the “indications” for ivermectin started expanding beyond COVID-19 and cancer, leading me to quip last March that ivermectin now reminds me of Miracle Mineral Solution/Supplement (MMS), a.k.a. a form of bleach. It was then brought to my attention last week that the FLCCC is apparently all-in now when it comes to “repurposing” ivermectin to treat not just COVID-19, but cancer:
During today's panel discussion on 'Cancer: Practical Solutions', @drpaulmarik1 announced that FLCCC and Dr. Kathleen Ruddy @DocRuddy have partnered to begin a groundbreaking 5-year study to determine the efficacy of repurposed drugs in treating cancer. https://t.co/XVveOic3tM pic.twitter.com/73cpqBJ02S
— FLCCC Alliance (@Covid19Critical) February 2, 2024
Ivermectin. They’re mainly talking about ivermectin.
I had never heard of Dr. Kathleen Ruddy before, but apparently she is a breast cancer surgeon in New Jersey, which embarrasses the hell out of me as a breast surgeon devoted to science who once practiced and did research in New Jersey for over eight years. All I have to do is to link to her blog to show why, given how the blog provides ample evidence that she is at least hardcore COVID-19 antivax. In addition, her X/Twitter profile looks like this:
She’s going to run a study on repurposing drugs to treat cancer?
I note that Radius Health Exchange is a standard “health freedom” doctors’ website, basically a directory for COVID-19 quacks but also maintains an “unvaccinated blood” registry for those antivaxxers who need a transfusion and think that blood products from people who have received COVID-19 vaccines are hopelessly “contaminated.” I was half-tempted to create an account, you know, for yucks and to see what sorts of emails I would get, but ultimately thought better of it.
Moving on (and more relevant to her medical beliefs), I note that Dr. Ruddy is also the founder of the Breast Health & Healing Foundation, the goal of which is to “answer the question, Does a virus cause breast cancer in women? within five years” and has published a book entitled The End of Breast Cancer: A Virus and the Hope for a Vaccine, whose primary thesis is that a virus “plays a significant role in 40-94% of human breast cancer.” (So apparently she’s not antivaccine when it comes to cancer vaccines. Interesting.) In brief, she believes that a mouse virus known to cause mammary tumors in mice called, appropriately enough, mouse mammary tumor virus (MMTV), causes 75% of human breast cancers., which she has also called the “pink virus.”
I also note that Dr. Ruddy states that she has a continuous desire to find a “pure cure” for cancer. That’s a red flag. So is the claim that there is one primary cause of any cancer.
I was puzzled by this whole hypothesis, not so much because I don’t believe that viruses can’t cause breast cancer, but rather because Dr. Ruddy had chosen a mouse virus as The One True Cause of (most) breast cancer. Moreover, it is true that regulatory elements from the virus have been studied in human breast cancers and that the virus produces a mouse model that resembles human breast cancer more than most mouse models. However, MMTV is a mouse retrovirus. It is true that there is evidence of a virus similar to MMTV in some human breast cancers (BC), but, as a recent review characterized the question, “controversy about whether this virus was linked to BC has raged for over 40 years in the literature,” and the review actually lays out that controversy quite well, stating that there is “compelling evidence that HMTV may be involved in its tumorigenesis,” that therefore the “effort to investigate HMTV-positive neoplasms and the virally related immunological alterations in further depth should go forward in order to develop more effective prevention, control, and therapeutic strategies,” concluding that further “investigations are needed to solidify these observations.” (HMTV=human mammary tumor virus.)
Also from the review:
In 2005, Indik et al. showed, first, that MMTV could infect human cells [24], and then that human cells could support replication of MMTV [106], thus suggesting that human cells are permissive for MMTV. These were two essential prerequisites to hypothesize that an infectious agent similar to MMTV might play some role in human BC. A study in 2010 reported that, in humans, MMTV-like virus could be detected in between 14% and 74% of breast cancers [107]. However, over time, the results of these studies were questioned. Indeed, other groups worldwide could find no evidence of this virus in BC tissue nor any association between HMTV and human BC. Others regarded positive detection of HMTV in samples as environmental contamination, or as non-specific [6,10]. As a matter of fact, the search for an MMTV-like virus has been complicated by the potential presence of HERVs integrated in the human genome, as well as Mtv in the murine one, that required differentiating from possible MMTVels.
In other words, let’s just say that Dr. Ruddy is presenting a scientific controversy about the role of an MMTV-like virus in breast cancer as though it were settled science being “suppressed” by The Man, another red flag for a crank. That, and her willingness to collaborate with the quacks at FLCCC do not reflect well on how science-based a physician and surgeon Dr. Ruddy likely is, given what a grifting quack Dr. Marik has consistently demonstrated himself to be.
On to the FLCCC conference, at least what I can find out about it.
The FLCCC is “repurposing” drugs for cancer by teaming with quack clinics
The FLCCC hasn’t released video of its conference, at least not as of my writing this yesterday, but they have issued a press release, FLCCC Alliance Announces Its First Groundbreaking Study to Determine Efficacy of Repurposed Drugs in Treating Cancer. The first red flag that strongly suggests that this “study” won’t be science-based is in the first sentence:
A team of U.S. clinicians will participate in an observational study to determine improvements in the five-year survival rate for several types of cancer.
That’s right. The FLCCC is touting an observational study that will look at the five year survival rates for various types of cancer. I couldn’t help but get a bit sarcastic on X, the platform formerly known as Twitter, when I saw the FLCCC post:
Seriously, I’m supposed to be impressed by this? I’ve been studying repurposing an Alzheimer’s disease drug for triple negative breast cancer for a long time now. Repurposing drugs is not nearly as easy as you make it sound and most attempts fail. https://t.co/5EBElthvDw
— David Gorski, MD, PhD (@gorskon) February 3, 2024
Oops. I meant an FDA-approved drug for amyotrophic lateral sclerosis (ALS), NOT Alzheimer’s disease (although riluzole is under study for Alzheimer’s). Brain fart. Oh, well.
In any event, come back to me when you have some compelling preclinical data and/or early phase clinical trial data. This observational bullshit you plan to do won’t tell us anything.
— David Gorski, MD, PhD (@gorskon) February 3, 2024
Was I too harsh?
That’s right. I’ve been studying the repurposing of a legitimate FDA-approved drug for amyotrophic lateral sclerosis (ALS), riluzole, to treat triple-negative breast cancer for a number of years. Ironically, problems that I’ve encountered, such as difficulty achieving in vivo the blood levels required to kill cancer cells previously measured in vitro, are very similar to the problems with ivermectin and COVID-19, although not nearly as marked. As I’ve discussed, the concentration in vitro required to inhibit the replication of SARS-CoV-2, the virus that causes COVID-19 is 50- to 100-fold higher than what can be safely achieved in the human bloodstream. At least for riluzole (in mice at least) the difference is nowhere near that dramatic, but it’s still a challenge for repurposing the drug.
So let’s look at what the FLCCC actually plans to do:
Today, at their sold-out education conference, the FLCCC Alliance announced that it has partnered with renowned breast cancer physician and researcher Kathleen Ruddy, MD, to conduct an observational study in five U.S. clinics to track patient responses to various adjunct cancer therapies using repurposed drugs and determine improvements in the five-year survival rate to several types of cancer including breast, prostate, lung, and colorectal.
Notice how the FLCCC assumes that there will be improvements in five-year survival rates in these cancers due to their repurposing drugs to treat them. A more objective way to have phrased this would have been “determine changes,” not “determine improvements,” but the FLCCC already believes that their repurposed drugs will treat cancers:
“We hope that our research will bring attention to often overlooked methods for treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, M.D., FCCM, FCCP, lead author of the study, chief scientific officer of the FLCCC and former Chief, Pulmonary and Critical Care Medicine at Eastern Virginia Medical School. “Our research is intended to advance a better understanding of how cancer can be treated more efficiently, with fewer side effects, through using well-studied approaches that include readily available medications that are well-studied and known to have minimal side effects.”
The final study results will focus on improvements in the five-year survival rate of certain cancers and include patients from five clinics nationwide that will collaborate and share anonymous patient information in a centralized collection tool where the data will be tracked and analyzed.
“Cancer continues to increase at an alarming rate, especially among younger populations, creating an imminent public health crisis,” said Kathleen Ruddy, MD, founder of the New Jersey-based practice Breast Health and Healing. “For over a year, I have been observing and advising 50 patients using a variety of repurposed treatments in the regimen, with some having remarkable results. More is to be learned, so I am excited to partner with the FLCCC on this new research.”
This statement suggests that Dr. Ruddy has already been treating patients with “repurposing” of various drugs. She even claims that she’s had “remarkable” results, but what does that even mean? I also have to wonder: Where is the ethical approval for this study? Where is the institutional review board (IRB) approval? Sadly, quacks have long done “studies” like this without IRB approval because there’s really no way to enforce IRB approval outside of the need for FDA approval for a drug or device, or the investigator having obtained government funding through the NIH, NSF, or other agency to support the study and/or working for an academic or research institution that accepts federal funds. Long is the sordid history of quacks doing “studies” without IRB approval (or, as in the case of Mark and David Geier, for instance, creating their own dubious IRB to approve their studies, as did cancer quack Stanislaw Burzynski). And, no, “anonymous sharing” doesn’t relieve that burden. These “institutions” are purporting to do human subject research, and, while the data might be anonymized, there must still be a database that links the clinical data to protected health information (PHI) of the subjects.
Now let’s look at the sites where this “study” is being carried out:
The five clinics participating in the study are:
    • Breast Health and Healing, led by Kathleen Ruddy, MD.
    • Leading Edge Clinic, led by Pierre Kory, MD, MPA and Scott Marsland, FNP-C
    • Brio Medical, a holistic, integrative cancer healing center, led by Nathan Goodyear, MD
    • Meakin Metabolic Care, led by Charles Meakin, MD
    • James Clinic, led by Mollie James, MD
It’s interesting to me that Dr. Ruddy’s Breast Health and Healing clinic seems to have a very low Google profile. I couldn’t find an actual practice website, only a website for Dr. Ruddy that declares her to be a “surgeon, author, inventor, healthcare leader.” Sadly, as has been the case with many doctors who’ve “gone rogue,” Dr. Ruddy appears to have wasted excellent credentials, having done a breast surgery fellowship at Memorial Sloan-Kettering Cancer Center in the 1990s. She also has some not-so-great credentials that are big red flags to me, such as touting here appearances at COVID Madness events, where she appeared with antivax cranks and quacks like Stephanie Seneff, Peter McCullough, Christiane Northrup, Geert Vanden Bossche, Lee Merritt, David Martin, Aseem Malhotra, Sherri Tenpenny, Pierre Kory, Bret Weinstein, Mark Skidmore, and others, a veritable who’s who of the COVID-19 era antivax movement.
As for the Leading Edge Clinic, run by Pierre Kory, there’s not much to say other than to refer you to all the times we at SBM have written about this COVID-19 quack who’s been branching out into more general quackery. If you want to know just how quacky Dr. Kory has become, let’s just say that he has been promoting stories of COVID-19 vaccine “shedding” in which men would pick up the “shedding” from contact with the general public in their everyday life, bring it home, and then transmit it to their wives through oral sex. (Seriously, I kid you not.) Before I discuss the actual “study” proposed by FLCCC, let’s take a look at the rest of the “experts” who will supposedly be carrying it out.
What about the other doctors “repurposing” COVID-19 quackery to cancer?
I had never heard of most of these doctors; so let’s dig in and see what sort of quacks we’re dealing with, and, make no mistake, they are very quacky quacks:
Nathan Goodyear and Brio-Medical. Unlike the case for Breast Health & Healing, it didn’t take me long to find the Brio-Medical website and learn that it’s an alternative cancer clinic in Scottsdale, Arizona, run by “integrative cancer expert Dr. Nathan Goodyear, a renowned authority in integrative medicine.” (Hint: There are so many red flags in just that brief phrase.) Brio-Medical offers a veritable cornucopia of cancer quackery, such as insulin potentiation therapy (IPT), a dangerous and ineffective therapy based on the idea that sugar feeds cancer cells and that one should lower a patient’s glucose as much as feasible with insulin to “potentiate” the activity of “low dose chemotherapy.” Basically, any clinic offering IPT is a quack clinic, but there are so many more quack cancer treatments listed on the Brio-Medical website, including hyperbaric oxygen, vibrational therapy, EBOO ozone therapy, high dose intravenous vitamin C, and many, many more quack treatments. I could go on, but regular readers who peruse the website of Brio-Medical will immediately recognize the quackery. If that’s still not enough, though, just note that Dr. Nathan Goodyear is not just an OB/GYN, but an MDH (homeopath) as well. Yes, one of the investigators of this “study” is a practitioner of what I like to call The One Quackery To Rule Them All. How much confidence does that give me in his ability to carry out his part of a study like this? Let’s just say a homeopathically diluted amount, except that in this case more dilution doesn’t make my confidence stronger.
Meakin Metabolic Care. Dr. Charles Meakin is no better. The name of his clinic, Meakin Metabolic Care, should tell you all you need to know about him, but also know that he’s an oncologist who claims that all cancer is in fact a metabolic disease. (I could go on and on about the controversy over how much cancer is in fact a metabolic disease compared to the contribution of gene mutations, as it’s a controversy that flares up at the scientific meetings from time to time, but whenever someone says that cancer is all metabolic (often invoking the Warburg effect), it’s usually a pretty good indication of quackery, especially when it comes from a doctor who offers a panel that he calls his Metabolic Optimization Protocol, which is described thusly:
Our current healthcare system does an abysmal job at preventive medicine. The annual blood work prescribed in a traditional primary care setting aims to detect disease after it occurs, not prevent it from occurring in the first place. Traditional laboratory values were developed to detect a disease state when values exceed a predetermined range yet fail to ask the critical questions that drive to the heart of preventive care: What are the value ranges for optimal health? What laboratory values signal the ideal cellular and organ function that elevates our health and prevents the chronic disease so common in old age? The cornerstone of the MOP program is more frequent and relevant bloodwork that provides deep insights into cellular and organ function. Our quarterly bloodwork panel looks at the laboratory markers most pertinent to health optimization and has actionable interventions that can bring them into the optimal range.
This sounds a lot like the quackery that is functional medicine, or, as I like to call it, reams of useless tests in one hand, a huge invoice in the other. (No, seriously, the fee for this program is $850 per quarter, or $3,400 per year.) He also sells modified citrus pectin supplements for cancer, but my favorite bit of quackery has to be Dr. Meakin’s Cancer Metabolic Optimization Protocol, which very much resembles the Metabolic Optimization Protocol, just for cancer, and costs $950 a quarter, or $3,800 a year. Tellingly, neither “optimization program” includes the cost of all the supplements and “repurposed medications” recommended, which range from $50-$150 per month); so the overall expense will be considerably more. (No wonder Dr. Meakin is so hot to repurpose ivermectin and other COVID-19 quackery for cancer!) As for the actual labs:
The full list of labs included in the C-MOP Program includes: Complete Blood Count, Complete Metabolic Panel, Lipid Panel, Hemoglobin A1C, C-Reactive Protein, Thyroid Stimulating Hormone, Magnesium Level, Lactate Dehydrogenase, Homocysteine Level, Vit D3 level, Uric Acid, Ferritin Level, Fasting AM Total Cortisol, and Fasting Insulin Level.
These are some pretty basic labs that any primary care doctor could order, most of which are fairly routine and easy to justify ordering and having them paid by insurance. To all this, Dr. Meakin adds Scan Shield, a bunch of antioxidant supplements that, he claims, will protect you from the effects of ionizing radiation that you might receive as a cancer patient undergoing scans. Through it all, Dr. Meakin requires patients to pay to get supplements and repurposed drugs from his partner’s compounding pharmacy rather than obtaining the repurposed drugs from a real pharmacy using their own health insurance, justifying it by saying that repurposed mebendazole is too expensive and:
They incorporate the traditional repurposed drugs in the same mailing package for convenience and organization for the patient to determine the proper way to take the medications. Using individual insurance plans and pharmacies directed by health insurance frequently leads to a detailed pre-approval analysis of repurposed drugs and off-label use. MMC strives to provide the lowest cost service, and we do not have staff to attempt to process through standard pharmacies and insurance plans, which are highly time-consuming.
Sure you do, Dr. Meakin. Sure you do. Functional medicine just loves “repurposing” drugs and supplements to treat whatever fantastical diagnoses it can come up with, based on ordering a crapton of unnecessary labs. There’s a reason why I refer to functional medicine as the “worst of both worlds,” combining the excessive ordering of tests that conventional medicine sometimes indulges in with a belief in pure woo.
James Clinic. Finally, there’s the James Clinic, founded by Dr. Mollie James. Unsurprisingly, she, too, is a functional medicine quack:
Dr James is board certified in general surgery and critical care medicine. She trained at Mercy Medical Center-Des Moines and the University of Minnesota. After practicing for five years, she realized she needed additional tools to help her patients. Functional medicine was the answer. She combined functional medicine into her surgery practice for patients with GI issues presenting for endoscopy and it had immediate benefit to patients. By using interventions such as elimination diets and gut-healing protocols, patients would often say they felt the best they ever had.
Not to mention:
Dr. James has now become an activist for medical freedom, patients right to choose, and physicians right to practice medicine unencumbered.
Because of course she has.
The James Clinic offers the usual assortment of quackery, including ozone therapy in the form of EBOO (extracorporeal blood oxygenation and ozonation), which “involves placing an IV in each arm and running blood out from one IV, through a dialysis filter, and exposing it to oxygen and ozone gas.” Then, of course, there are the usual IV vitamin infusions, unnecessary “bioidentical hormones,” and bogus treatments for “vaccine injuries,” among others. The clinic also features an online supplement store, because of course it does. (And, wow, are those supplements pricy!)
These are the doctors and clinics running this observational study. Even if the protocol were reasonably defensible from a scientific standpoint, I’d have serious doubts about the ability of these doctors to rigorously and, most importantly, ethically carry out even an observational study.
But what about the evidence and study?
I realize that I’ve spent a long time discussing the “who’s” of this study, but what about the study itself? I can just see antivax-sympathetic readers who happen to come across this post accusing me of ad hominem; i.e., attacking the idea of repurposing drugs for cancer and rejecting the study based on who is doing it rather than the study itself. Here’s the thing. In the absence of an actual protocol to study, all that’s left is the who, as in who’s doing the study, and the track record of these people. Moreover, far be it from me to be opposed to repurposing drugs for cancer, having spent the last decade-plus studying whether repurposing an ALS drug to treat breast cancer is feasible. (Just search PubMed for my name plus “riluzole.”) I wouldn’t have spent all that time and effort and applied to so many funding entities if I didn’t believe that repurposing certain drugs to treat cancer could work.
In fact, my background is a huge reason why this study sent up big red flags. Again, it’s strictly observational, and, given the nature of alternative medicine clinics for cancer, subject to extreme selection bias in that the patients are self-selected and very likely to be able to afford the high expense of such clinics and to have disease that is less severe. Indeed, the only clinical evidence that I could find reminded me very much of the cancer cure testimonials that I’ve been deconstructing since 2005, for example the case of John Ross, whose treatment for colon cancer at the James clinic was recounted in a Substack post Ivermectin Squares Off in a New War on Cancer:
John Ross was fifty-one years old when he was diagnosed, after more than a year of discomfort and growing unwellness, with Stage 3B colon cancer. A three- to four-inch tumor had almost completely blocked and broken through the organ wall; his surrounding lymph nodes were enlarged and presumed cancerous.
In May 2023, Ross started the traditional treatments offered by mainstream medicine—simultaneous radiation and an oral chemotherapy. He did not tell his mainstream cancer doctors that he was also taking, among other things, the repurposed generic drug ivermectin. The drug was famously—and wrongly—vilified as a horse medication during Covid, though it was in reality a Nobel Prize-winning “wonder drug” with huge untapped potential.
Ross and Dr. Mollie James, a functional-medicine physician who oversaw his nontraditional treatment, are modern-day medical trailblazers who might change the way cancer is treated. If they and others in a growing effort are successful, cancer care will be less painful, more affordable, and—the greatest hope—more effective. Practicing in a suburb of St. Louis, Dr. James had used ivermectin and other therapies to successfully fight Covid-19. (I wrote about her treatment of her brother in January of 2022.) She is now taking what she learned in the pandemic and turning it to cancer.
I suspect that you know what the problem with this cancer cure anecdote will be. If you don’t yet, let’s make it clear:
“I don’t know how you are standing here today—I’ve never seen blood this bad,” Dr. James told Ross after his thyroid result came in. First, she said, “I want to get you as healthy as possible before treatment.” Starting three weeks before radiation and chemotherapy, Ross began, along with ivermectin, infusions of high-dose Vitamin C and glutathione; major auto-hemotherapy, also called ozone therapy; and hyperbaric oxygen therapy, along with supplements like high-dose melatonin.
In the ensuing nearly six weeks of radiation and chemotherapy, oncologists, and others caring for Ross remarked repeatedly on how well he was doing. “Even the (radiation) technician, at the last week of treatment, made comments how this is so abnormal to have somebody that wasn’t dealing with any of the burns or anything like that,” including hair loss, Ross recalled.
The clincher, however, came in Ross’s MRI and CT scans in July of 2023. After twenty-eight radiation and chemotherapy treatments and nearly three months of the ivermectin protocol, “Ninety percent of his tumor had turned fibrous, meaning into scar tissue,” Ross’s wife, Roxanne, told me. “And the lymph nodes were half the size,” John added. An oncologist’s report called that an “excellent response.”
Now do you see it? As is so often the case with alternative medicine cancer cure “testimonials,” Mr. Ross underwent standard-of-care chemotherapy and radiation plus all the quackery. Basically, for stage 3B colon cancer that cannot first be removed surgically, the treatment is neoadjuvant chemotherapy and radiation before surgery to shrink the tumor and make it operable. (Neoadjuvant therapy is given before surgery.) There is therefore no way of telling from this anecdote whether the quackery added anything to the treatment response. The most parsimonious explanation, of course, is that the chemotherapy and radiation produced such a dramatic response in Mr. Ross’ colon cancer, given that neoadjuvant chemoradiation produces a significant response in the majority of patients, with a median reduction in size of nearly 70%. Contrary to the implication in the anecdote, the treatment response observed in Mr. Ross’ tumor was nothing out of the ordinary. It was completely within the range of what an oncologist would likely expect just from conventional therapy, given that such therapy can produce a complete pathologic response (no viable tumor cells detectable in the surgically resected specimen) in 5-10% of patients. I also couldn’t help but note with alarm that Mr. Ross appears never to have told his oncologists that he was taking other drugs. If there had been an interaction between the repurposed drugs and the chemotherapy, he could have suffered severe adverse reactions. Basically, Dr. James, by not insisting on letting Mr. Ross’ physicians know about the other drugs she was repurposing and administering to him while he was also undergoing chemotherapy and radiation, practiced highly unethical medicine, in my not-so-humble opinion. Moreover, Dr. James called this a “complete clinical response without surgery.” It’s not, and, even if it was, you can’t say that it was without surgically resecting the affected area of the colon and proving that there are no viable tumor cells left.
Let me show you what I mean:
Told that 10 percent of his tumor remained viable, John Ross started a second round of chemotherapy in late August of 2023, receiving one infusion followed by two weeks of oral drugs—in six two-week cycles with a recovery week between. Within twenty minutes of the first infusion, he experienced intense sensitivity to heat and cold in his mouth, hands, and feet; later, he had cramping and muscle spasms so severe he thought he was having a heart attack.
“John was absolutely miserable,” Roxanne said. Ross quit the infusion after the third dose when an oncologist told him the infusions were only contributing 10 to 15 percent to the effectiveness of the regimen. Five months later, Ross still feels numbness, cold sensitivity and burning in his feet, side effects he said doctors mentioned but “made it seem insignificant.”
So basically, Mr. Ross appears to have been unable to tolerate the infusion anymore but continued the oral chemotherapy and did this:
After that experience, Ross pulled back. He reduced the oral medication, taking six pills daily instead of the prescribed ten.
He also did something else. Early that fall, he switched from ivermectin to fenbendazole, a medication used to treat parasites in animals, which, Dr. James said, he opted to take and obtained himself. Fenbendazole has shown effectiveness in three human cancer cases and in laboratory experiments on ovarian and colon cancer cells.
When the second set of scans were done in November, no cancer was found. Some “high-grade dysplasia,” a cancer precursor, was detected in biopsied cells—a possible outcome, a gastroenterologist told Ross, of the radiation treatments. Doctors want to surgically remove part of the colon, and the Rosses are weighing their options. They are thankful for the chance encounter that led them to Dr. Mollie, as they call her.
It sounds to me as though Mr. Ross was taking oral capecitabine (trade name Xeloda), which is metabolized into 5-fluorouracil, a potent chemotherapeutic agent against colorectal cancer. The number of pills sounds about right, as does the reduction in dose, which is not uncommon. Let’s translate the woo-speak above to more science-based language. Basically, Mr. Ross had an excellent response to two rounds of chemotherapy, with no obvious signs of cancer detectable on colonoscopy after treatment, but he attributes his good fortune to the ivermectin and fenbendazole, along with all the other quackery that Dr. James was “repurposing” to treat him with. Again, as is the case with nearly all alternative cancer cure testimonials, particularly those from patients of cancer quack Dr. Stanislaw Burzynski, the patients and quacks attribute the patient’s good fortune to the quackery and not all the conventional therapy undertaken. In this particular case, the response observed by Mr. Ross is well within the expected range of responses of locally advanced colon cancer to neoadjuvant chemotherapy, no appeal to ivermectin, fenbendazole, or anything else needed.
I only hope that Mr. Ross takes his oncologist’s recommendation and finally does undergo resection of the segment of his colon containing his tumor. If he does, his chances of survival will be quite good; if he does not, his odds of recurrence will be high. Although it irks me a bit, I’ll just accept that, should Mr. Ross undergo surgery and do well, every COVID-19 and cancer quack out there will attribute the outcome to the ivermectin, fembendazole, and all the other quackery to which he was subjected, and not to good, old-fashioned boring “conventional” multimodality treatment of cancer. If the price for Mr. Ross’ survival is that he becomes another Chris Wark, who attributed his survival of locally advanced colon cancer not to the surgery that he underwent but to all the quackery he embraced after surgery, I’m OK with that. I’d rather see a living victim of a quack than one killed by quackery.
But what about the preclinical evidence for ivermectin against cancer?
The post discussed above did mention another patient supposedly “cured” by ivermectin, but there were no details, making it impossible to tell whether there was any plausible treatment effect. However, the post also referred to a recent webinar done for FLCCC by Dr. Ruddy, as well as a number of preclinical studies in cell culture and mice, that suggest that ivermectin has antitumor properties:
Two years before Covid, researchers analyzed published data that strongly suggested ivermectin could be repurposed, namely put to another off-label use, for cancer. In about twenty laboratory studies, ivermectin was found to inhibit cell proliferation and induce “apoptosis”—cell death—in cancer cell lines of the breast, prostate, ovary, head and neck, colon, and pancreas. In six studies in mice, the drug was effective against glioblastoma, leukemia, and breast and colon cancer. Based on these studies, predictions were made that ivermectin could be employed safely and soon.
“The in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies,” stated the 2018 article in the American Journal of Cancer Research. “Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients.”
Yes, it’s true. Table 1 shows the possibility. However, I note that the dose needed to achieve these blood concentrations (Table 3 in the paper) is many times higher than the standard dose of ivermectin for roundworm infestations and even then only barely achievable. According to Table 1, for instance, it took 1.4-2.0 mg/kg ivermectin to achieve micromolar levels in vivo, although the highest concentration (Cmax) never surpassed 0.25 μM. We’re talking micromolar (μM) concentrations for most antitumor effects, and a good rule of thumb is that any anticancer pharmaceutical that requires micromolar concentrations and above is going to be a tough sell as an effective cancer agent from a pharmacokinetic standpoint, although in fairness there are a handful of effects observable at 0.1 μM. (The question, of course, is whether these effects would be enough in vivo.). Moreover, large doses are needed in mouse models to achieve an antitumor effect (Table 4).
As for toxicity, the review article notes:
There are several toxicological reports of ivermectin in different species. The lethal dose 50 (LD50) reported in mice [19] is 25 mg/kg administered orally, whose human equivalent dose (HED) is 2.02 mg/kg. The LD50 increases up to 30 mg/kg when this compound is administered intraperitoneally in mice (HED 2.43 mg/kg). For rats the average lethal dose is 50 mg/kg orally (HED 8.01 mg/kg) and 55 mg/kg intraperitoneally (HED 8.91 mg/kg). In rabbits it is 406 mg/kg in topical application, while in dogs it is 80 mg/kg administered orally (HED 43.24 mg/kg) [20]. Clearly, it seems that the higher the phylogenetic scale the lower toxicity by ivermectin. These data are in accord with the findings in a review paper on avermectins poisoning (14 on suicidal attempt). In this retrospective review, among 18 patients exposed to abamectin and one to ivermectin, 15 were poisoned by oral ingestion. Four were asymptomatic and 8 had minor symptoms with a mean ingestion of 23 mg/kg (range in 4.2-67 mg/kg). Seven patients manifested severe symptoms, such as coma (seven), aspiration with respiratory failure (four), and hypotension (three), after a mean ingestion of 100.7 mg/kg avermectin (15.4 mg/kg for ivermectin and 114.9 mg/kg for abamectin). All 7 seven patients received intensive supportive care; 1 patient died 18 days later as a result of multiple organ failure [21].
Let’s, for the moment, accept that a concentration that is potentially effective against cancer is barely achievable in humans at safe doses. Let us even accept that the activity of ivermectin against various cancer cell lines in preclinical models through mechanisms involving promoting apoptosis (programmed cell death), blocking cell cycle, targeting cancer stem cells, and even potentially reversing drug resistance (reviewed in 2021 by Tang et al) is very interesting and suggests that it might be useful as another weapon in our armamentarium against cancer. Far be it from me to discourage repurposing such a drug! In fact, I encourage it, as long as it is done the right way, in a scientifically rigorous manner, which is exactly what FLCCC, Dr. Ruddy, and the various quacks at the five clinics where the study is open are not doing.
In addition, even if all the preclinical data presented is translatable to humans and the drug can be administered safely at a concentration that achieves the biological effects against cancer cells observed in cell culture, it is incredibly unlikely to be effective as monotherapy. This is, of course, a general principle for all putative anticancer drugs, whether new or repurposed. In general, treatment of cancer is multimodality therapy, and even if ivermectin demonstrates clinically useful anticancer effects, it will almost certainly be used in combination with other therapies, be they chemotherapy, targeted therapies, or immunotherapy. If there’s one thing I’ve learned when it comes to repurposing a drug, even one as free of serious side effects as riluzole, it’s that you can never assume that it will remain free of side effects when you combine it with other drugs. Synergistic toxicity can occur. Moreover, the toxicity reported in the review I discussed only looks at single doses of ivermectin. Any cancer drug is going to have to be administered in multiple doses, likely daily, for weeks or even months in order to have a clinical relevant effect. Do Drs. Marik and Ruddy even consider these issues? Of course they don’t, at least not in any of the articles I read.
So I checked out their hour long webinar on the topic, Cancer and Repurposed Drugs, from a couple of weeks ago, featuring an interview with Drs. Marik and Ruddy:
Interestingly, right in the beginning the host mentions the FLCCC Alliance Cancer Care guide. I perused it, and ivermectin was only listed in the “tier two repurposed drugs” with a “weak recommendation,” along with wheatgrass, low dose naltrexone, and captopril. I was amused. I was less amused by her invoking overdiagnosis from mammographic screening as a reason why the death rate from cancer is decreasing; that is, until she showed that she showed that she doesn’t understand what overdiagnosis is by saying that “the pathologists know what they’re doing” and that if they say it’s breast cancer it’s breast cancer. That misunderstands the entire concept of overdiagnosed cancers, which are cancers that, if untreated, are sufficiently indolent that they would never endanger the life of the patient. Then, confused as she appears to be, she seems to understand that overdiagnosed breast cancers “act as though they are benign,” which is nothing more than what Dr. Welch was saying.
Clearly, Dr. Ruddy was tripped up by the term “overdiagnosis.” Basically, she invoked screening as a reason why we might not really be impacting cancer survival. Let’s just say again that I was not impressed, given that the death rate from breast cancer has declined by nearly 40% since 1990. As I’ve explained before, declines in mortality, not increases in 5-year survival, are the true way to tell whether or not we are doing better treating breast cancer, and mortality from breast cancer has declined markedly in the last three decades. Either Dr. Ruddy doesn’t understand this basic principle, or she is misrepresenting it. Of course, it doesn’t help that Dr. Marik leapt in right after her to claim that “the jab” is causing “turbo cancer.” It’s not.
At around the 23 minute mark, they finally get to a discussion of what I was interested in, namely the FLCCC “study.” Hilariously, she likens her effort to the Framingham Heart Study, which was indeed a longitudinal observational study in which participants were regularly interviewed every two years that linked a number of risk factors to heart disease. While she correctly notes that the Framingham Heart Study did find an increased risk of heart disease associated with hormone replacement therapy, she doesn’t mention that this result was different from the results of a number of other studies and that today the preponderance of evidence suggests that hormone replacement therapy’s actions are more complex than just “bad for heart,” with conflicting evidence about timing and effect of hormone replacement therapy that is still debated to this day. In brief and at the risk of oversimplifying, timing of initiation of therapy appears to have major effects on whether it is beneficial or not to cardiovascular health.
Dr. Ruddy also seems to conflate Women’s Health Initiative studies with Framingham, when by bringing in the question of hormone replacement therapy and the risk of breast cancer, she implies that Framingham also found an increased risk of breast cancer associated with estrogen replacement therapy. I suspect that this was more sloppy thinking and talking than lack of knowledge, but maybe I’m giving Dr. Ruddy too much benefit of the doubt. Whatever the case, the question of hormone replacement therapy and the risk of breast cancer is actually more complex than usually discussed. Estrogen replacement alone doesn’t increase the risk of breast cancer—quite the opposite, in fact!—but can’t be given in women who have not undergone hysterectomy because it does increase the risk of endometrial cancer. In contrast, combined estrogen/progesterone replacement does appear to be associated with an increased risk of breast cancer. Unfortunately, Dr. Ruddy oversimplifies to the point of misrepresentation and says that that estrogen causes breast cancer because over two-thirds of breast cancers are estrogen-responsive. And she’s a breast cancer surgeon?
Her stated excuse for not doing a real study is blatantly self-serving as well. Basically, she claims that, because there were consequences for doctors who promoted ivermectin for COVID-19, she didn’t think it would be a good idea to do an actual protocol-driven clinical study of ivermectin for cancer and that an observational study would be better. Of course, I note that there does not appear to be a single person among the persons listed doing the study who might be able to design and run a proper observational study that might answer some of the questions that Dr. Ruddy says that she has: No epidemiologists or biostatisticians, for instance, to determine sample sizes for each endpoint to be examined, just her and her quack buddies. Worse, the study is patient-funded, which is at best ethically dubious and at worst completely unethical. Even in the cases of properly designed clinical trials, it is an ethically fraught question how to have patients fund such trials in a manner that is ethical and does not exploit them. Not for Drs. Ruddy and Marik and their quack buddies are such trivial questions of ethics! They’re brave maverick doctors! Also, the patients want ivermectin, and giving it to them is “empowerment of the patient”! Dr. Marik even says so later in the interview!
I also laughed when Dr. Ruddy said that they were going to look at signals in survival in their “study.” Didn’t she just say that screening and other factors make survival measurements not the best way to determine if we were “winning the war on cancer”? (She did.) Again, survival could very well be affected by selection bias, and there will be a huge self-selection bias for observational study of this sort. This made me cringe mightily later in the interview, when both Drs. Ruddy and Marik went on and on in a a typical conspiratorial fashion (for quacks) about how the profit motive is what maintains the status quo of surgery, chemotherapy, endocrine therapy, and radiation, for cancer treatment. In this, they both sounded just like any other cancer quacks, which, come to think of it, they are.
The bottom line
The FLCCC Alliance is a group of quacks that arose in the era of the pandemic mainly for ideological reasons, specifically opposition to the public health measures instituted to try to mitigate the damage done by COVID-19 before there was a vaccine. Once there was a vaccine, they pivoted effortlessly to being antivaccine. Through it all, they’ve promoted ivermectin and the “repurposing” of their other drugs as part of their “COVID protocols,” because if there are inexpensive and safe treatments for COVID-19, then public health interventions would be unnecessary, as would vaccines. Unfortunately, I’ve observed that it seems to be a general principle that embracing one form of quackery almost always leads doctors down the path to embracing other forms of quackery and becoming just general quacks. This “study” examining the “repurposing” of ivermectin to treat cancer is just the latest example of how the FLCCC Alliance has gone down that path.
Basically, the alternative cancer cure testimonials and shoddy evidence are exactly the same. Only the drugs and “cures” have changed. In the 1970s it was laetrile. Today, thanks to COVID-19 conspiracy theorists, it’s ivermectin and fembendazole.

Mark Sircus and “natural allopathic medicine”? Now I’ve heard everything from quacks
The term “allopathic medicine” was invented by homeopaths in the 19th century as a disparaging term for medicine. So to see a quack like Mark Sircus try to coopt it as “natural allopathic medicine” is quite something.
David Gorski on March 25, 2024
Link

“Allopathy” or “allopathic medicine” is commonly defined as “system in which medical doctors and other health care professionals (such as nurses, pharmacists, and therapists) treat symptoms and diseases using drugs, radiation, or surgery,” with synonyms including—but not limited to—terms like biomedicine, conventional medicine, mainstream medicine, orthodox medicine, and Western medicine. Regular readers, of course, will immediately see the problem with this definition, as well as the synonyms, most of which are favored by quacks, but what many people don’t realize is where the term “allopathic medicine” came from in the first place. The term “allopathy,” and hence “allopathic medicine,” was originally coined by the inventor of The One Quackery To Rule Them All, homeopathy, in order to distinguish homeopathy from conventional medicine. According to Hahneman the word “allopathy” derives from the Greek word allos, meaning other or opposite. Hahnemann meant it to describe what he viewed as a medical system that treats a symptom with something that causes its opposite, as in using a laxative to treat constipation. In comparison, his quackery homeopathy was based on the Law of Similars, which is often phrased as “like cures like” and states that to treat a disease you should use massively something that normally causes the symptom being treated (diluted to nonexistence according to the Law of Infinitesimals, of course). Basically, because Hahnemann viewed homeopathy as superior, his use of the term “allopathy” was coined with an implied denigration of any medicine that wasn’t homeopathy.
Unfortunately, over the following two centuries, all too often practitioners of science-based medicine have been wiling to ignore the origin of the word “allopathy” and accept the false dichotomy originally posited by Hahnemann, calling conventional, science-based medicine “allopathic medicine.” You can even find its unironic use that accepts the false dichotomy used to coin the term in many papers published in PubMed. Stamping out the term “allopathic medicine” for its implication that such medicine is inferior to the quackery that is homeopathy is, sadly, a battle that was lost long ago. If you want to see just how lost the battle was, I refer you to a doozy of an article by Mark Sircus, Ac., OMD, DM (P) (acupuncturist, doctor of oriental and pastoral medicine, whatever “pastoral medicine” is) entitled Natural Allopathic Medicine is Brilliant.
Before I get to the article itself, which, while an obvious rebranding of “natural medicine,” is also a rather clever rebranding, I note that I haven’t really written about Mark Sircus much here on SBM, although I have written about him on my not-so-secret other blog.
Who is Mark Sircus?
As I wrote above, Mark Sircus bills himself as an “acupuncturist, doctor of oriental and pastoral medicine.” Regular readers will realize that, contrary to the claims of acupuncturists, acupuncture is quackery based on a prescientific understanding of how the human body works whose popularity in the “West” is based largely on a clever retconning of the history of traditional Chinese medicine by China’s Chairman Mao Zedong in the 1950s through the 1970s, while TCM is mostly quackery. As for “pastoral medicine,” I decided to look it up. It turns out that “pastoral medicine” is a form of quackery that claims to be medicine based on the Bible, although now its definition has broadened to be basically any religion-based “medicine.” A pseudomedical group known as the Neuroscience Institute of Pastoral Medicine describes “pastoral medicine” thusly:
Pastoral Science and Medicine (PSM) is the term devised by the Pastoral Medical Association (PMA) to describe the system of natural approaches founded upon spiritual principles used by PSM practitioners for promoting and improving physical, mental and spiritual health. Health improvement results from making positive lifestyle changes and following other natural procedures that are biblically sound, science-based and professionally administered pursuant to acceptable standards of care.
Personally, my favorite post on the Pastoral Wellness Alliance is entitled Are Your Holistic Services Legally Protected? and describes how to avoid getting in trouble with state medical boards and the law and how to have a ready legal defense if you ever do. In any event, notice how “pastoral medicine” is careful to use the weaselly language about “natural procedures that are biblically sound, science-based and professionally administered pursuant to acceptable standards of care.” Of course, if that’s all pastoral medicine practitioners did, there would likely be little trouble, but one look at Sircus’ website shows that he, at least, does not follow anything resembling science-based standards of care.
For one thing, Sircus is a big fan of treating disease with bleach. For those not familiar with what I’m talking about, he very much advocates treating various diseases with Miracle Mineral Solution, which is a form of industrial bleach used for water purification and cleaning. For example, he advocates treating COVID-19 with MMS—as an alternative to vaccines!—as well as treating COVID-19 “vaccine-induced” cancers with MMS, as well as using “voltage healing” to treat cancer and a number of other diseases, while a brief perusal of his website uncovers a whole lot of quackery, particularly with MMS being advocated to treat a host of other diseases. Moreover, the very first time I ever encountered Sircus was in 2011 in the context of his advocating the killing of CDC scientists in a post charmingly titled String the Bastards Up. This was a precursor of the violent rhetoric of the antivaccine movement that science advocates have become all too familiar with since the pandemic arrived four years ago.
Basically, Sircus is a quack who’s been around a long time. But what about “natural allopathic medicine”?
Mark Sircus and “natural allopathic medicine”
In retrospect, I can’t believe that I haven’t written about this topic before, given that the first time I ever encountered Mark Sircus and his “natural allopathic medicine” was nearly a decade ago, when he was advocating it to treat Ebola. (You might remember the Ebola outbreaks of 2014 in Africa and the fear mongering that accompanied it.) Back then, Sircus described “natural allopathic medicine” as a “new therapeutic principle that revolutionizes both allopathic and naturopathic medicine offering a radical shift in medical thought and practice” focusing on “pH management, cell voltage, magnesium and iodine medicine, cannabinoid medicine, carbon dioxide medicine, re-mineralization of the body, increasing oxygen transport and oxygenation of the tissues, opening up of blood vessels, saturation and healing of cells with concentrated nutrition via superfoods, breathing retraining, emotional transformation processing, detoxification and removal of heavy metals and radioactive particles.”
This is, as I like to call it, “biobabble.” Remember “technobabble” from Star Trek: The Next Generation? Basically, technobabble is usually a word salad of real scientific terms thrown together almost randomly, often mixed with made-up “science-sounding” terms or acronyms, the result being impressive-sounding nonsense—impressive-sounding, at least to those without the scientific background to recognize it as nonsense. “Biobabble” is the same concept, just about biology. Unsurprisingly, quacks and antivaxxers are masters of biobabble and use it to provide impressive-sounding nonsensical “mechanisms” for whatever it is they are advocating, be it highly implausible treatments or how vaccines supposedly cause autism, cancer, or whatever, and Sircus appears to be no exception.
So what is he saying about “natural allopathic medicine” now? He begins:
Natural Allopathic Medicine is a form of medicine brilliant in its simplicity. It is as simple as surgeons washing their hands before surgery. It is as apparent as giving water to a person coming out of a desert who is severely dehydrated. It is brilliant because it prescribes magnesium as the first medicine for patients who are magnesium deficient, which is just about everyone. Meaning magnesium is applicable in all medical situations. However, because mainstream doctors do not know how to reason about medicine and health, they never prescribe it.
The value of surgeons washing their hands before surgery came to be appreciated through science, basically a combination of the work of Ignaz Semmelweis plus Louis Pasteur’s germ theory, which provided the mechanism by which handwashing could decrease the incidence of postoperative infection. I have to wonder whether Sircus also considers wearing sterile rubber gloves to operate is “natural allopathic medicine.” I once described how in the late 1800s surgeons demonstrated that wearing such gloves greatly diminished the chance of infection after surgery and how they came to be the standard for surgery. As for giving water to someone who is severely dehydrated, it’s clear that Sircus is definitely not-a-doctor. For someone who is severely dehydrated, it’s not enough to give just water. Solutions containing salt, such as saline, are much more efficient and effective in reversing dehydration and expanding intravascular volume.
As for Sircus’ fixation on magnesium, I wondered what the heck he was talking about. Sure, magnesium is an important mineral. It’s essential to cardiac function, for instance. But how does Sircus claim that “everyone” is “magnesium deficient”? Because that’s just plain not true.
Sircus’ very premise is also, of course, a false dichotomy. Is it actually “natural” to wash one’s hands before doing surgery? I could make a plausible claim that doing so might remove beneficial bacteria whose presence can actually help the patient. How can we know which is the more accurate claim? Obviously, the only reason that we know which is true, whether handwashing by surgeons is good or bad for the patient, is science, at which point the distinction between “natural” and “not natural” is nothing more than branding.
I admit, though, that I was amused by this passage:
If one’s motive is to treat and heal people of their disorders, the first thing to think of and do is to give the body what it needs. It is fundamental medical reasoning. Even the best doctors who are brave enough to confront the mainstream narrative on COVID-19 vaccines cannot bring themselves to address the real needs of their patients. They always have their favorite drugs, even if they are repurposed pharmaceuticals deemed safe. Doctors’ biggest mistake is prescribing medications before meeting patients’ basic physiological needs.
That’s a dig at physicians falsely claiming that repurposed drugs like ivermectin and hydroxychloroquine can cure COVID-19, which amused me. That being said, much of medicine actually does involve giving the body what it needs. Indeed, anyone who’s taken care of patients in an ICU setting knows just how much time and effort are expended making sure that deficient electrolytes and nutrients are repleted, for example, and that the lungs are receiving sufficient oxygen and that the blood is transporting that oxygen to the tissues that need it. There’s a whole specialty devoted to “giving the body what it needs” in such a way as to improve health. It’s called nutrition, and its practitioners are called dietitians.
Next up is a passage that provoked much facepalming:
Add iodine, selenium, glutathione, and sulfur to the list of essential medicines for the chronically ill. Zinc. Vitamin C and D and copper, too. One can also legally obtain and use chlorine dioxide if you pretend not to treat disease with it. Dentists, campers, and public water experts use it, so why shouldn’t you? There is nothing like cleaning the blood and treating red blood cells with it.
Notice the clever trick here. Yes, iodine, selenium, glutathione, and sulfur are essential compounds. (Note that glutathione contains sulfur.) However, most people get enough from their diets. However, MMS (chlorine dioxide) is not a nutrient or an essential mineral. You don’t need it. Sircus, however, throws it in there as though it is an essential nutrient, mineral, or vitamin. There is no evidence that it “cleans the blood” (whatever that means) or that the blood even generally needs “cleaning”; that is unless you’re talking about “cleaning” it with hemodialysis in the presence of kidney failure, which Sircus most assuredly is not.
Sircus is just getting started, though:
Natural Allopathic Medicine treats cold conditions with infrared heat. Why can doctors not see and do this? It is smart enough to give oxygen in intense ways to hypoxic patients. It is innovative in administering hydrogen inhalation therapy to people suffering from inflammation and oxidative stress, which describes 100 percent of the chronically ill.
Natural Allopathic Medicine offers a path to medical simplicity and the brilliance of medicine sometimes found in ambulances, emergency rooms, and ICU wards, where some of the best medical practices are found. Did you know sodium bicarbonate (baking soda) is commonly used as an emergency medicine? Or that injected magnesium is the best medicine for cardiac arrest when people are at death’s door.
In the emergency room, medicines must be safe while delivering instant life-saving healing power. Most of the above-listed medicines are already used in the best hospitals. If they are safe and robust enough for emergencies, they will also help us with chronic and acute diseases. Thus, what is presented is astounding regarding safety, low cost, and proven effectiveness.
It’s been a while since I’ve done ACLS (advanced cardiac life support), but even so I looked askance at this claim about magnesium. So I looked it up. It turns out that in the latest ACLS guidelines it’s recommended for the treatment of treat polymorphic ventricular tachycardia with a pulse, acute coronary syndrome with hypomagnesemia (low magnesium), life-threatening ventricular arrhythmias due to digitalis toxicity, and atrial fibrillation with rapid ventricular response. It’s not generally recommended for cardiac arrest unless hypomagnesemia is suspected or the arrest occurred after a specific arrhythmia, Torsades de pointes, which can be caused by low magnesium.
As for sodium bicarbonate, well, yes, it has a number of uses. It has also been overused. I still remember the debates in the ICU when I was a resident over when it was appropriate to administer bicarb in the setting of severe acidosis. In cardiac arrest, earlier ACLS guidelines recommended routine bicarbonate administration as part of the ACLS algorithm, but more recent guidelines no longer do. While it is true that the debate in the literature continues, right now SB administration is only recommended for cardiac arrest related to hypokalemia (low potassium) or overdose of tricyclic antidepressants. Indeed, there has been a trend over the last decade against routinely using sodium bicarbonate to treat cardiac arrest, a trend supported by guidelines published by professional societies and organizations, with one recent article about bicarbonate in cardiac arrest arguing it’s “time to put it away.”
Funny how complex medicine is, isn’t it? It goes beyond just what’s “natural” and what is not, and it’s certainly more complex than just “giving the body what it needs.” None of this stops him, however, from opining:
Modern medicine poisons people with drugs when patients already have high levels of toxicity. To top off their madness, they give medicines that make patients’ nutritional deficiencies worse.
The best natural medicines are the ones you must have—no matter what—to continue your life. Nutritional law is vital to resolving disease—not pharmaceuticals damaging cellular environments. Our cells need the right conditions for health and recovery from disease. There is no substitute for a nutrient that is lacking in the body. No pharmaceutical can make up for a nutritional deficiency.
Today, we need more nutrients, not less, because toxicities of too many types are a plague affecting the entire biosphere. We consume extra nutrients in the process of detoxification. However, over the last fifty years, the nutritional values of foods have been dropping, so we get less, we get sick, and we die. Superfoods help us make up the slack by addressing profound dietary deficiencies.
That’s truly some amazing biobabble, isn’t it? I mean, “nutritional law”? What th heck is that? Unlike physics, there are few “laws” in biology; rather, there is science and scientific theories. Quacks like Hahnemann do love to label their quackery as some sort of immutable “laws” of nature, though. Also, the biobabble has all the buzzwords, including “superfoods,” a meaningless term, nothing more than marketing nonsense. So is “detoxification,” a concept that vague, poorly described, or even unnamed “toxins” cause disease and need to be “detoxified,” which has become fashionable nonsense and ritual purification.
My favorite rebranding, though, has to be “natural chemotherapy.”
“Natural chemotherapy” vs. “regular chemotherapy”?
Sircus starts this discussion the same way that so many cancer quacks discuss cancer and chemotherapy, by demonizing chemotherapy:
Chemotherapy is like a battering ram; it feels like a battering ram with apparent harmful effects that patients have to suffer through. No one should have to endure harsh treatment’s avoidable impact, but that is not how oncologists see it. Most oncologists push the dose of chemo agents as high as they can. Dr. Patricia LoRusso, who leads drug discovery at Yale Cancer Center, said, “You get side effects, and then you have to stop the drug to recover from the side effects, and the tumor can grow.”
Adding:
I do not know what doctors are doing, but they are not practicing rational medicine. When it comes to cancer or any other disease, if the first thing recommended is not magnesium, then they are guilty of medical malpractice. On that same list of essentials would be bicarbonates.
Oncologists who use chemo and radiation but ignore magnesium are committing their patients to much higher incidents of death. Surgeons not using magnesium before, during, and after operations also make surgery more dangerous. Cardiologists who prescribe Statin drugs and ignore magnesium, which most still do, are dooming their patients and societies to extremely high death rates via cardiac arrest.
What is it with this obsession with magnesium as a cure-all, even for cancer? None of this is evidence-based. Indeed, elsewhere Sircus lists his reasons and the evidence for claiming that magnesium (and bicarbonate) should be used to treat cancer, calling it “nontoxic natural chemotherapy“:
Magnesium deficiency seems to be carcinogenic, and in case of solid tumors, a high level of supplemented magnesium inhibits carcinogenesis.[v] Culture of lymphocytes from humans in Mg-deficient media, resulted in morphologically and functionally abnormal cells. Mg is strongly related to the immune system in both nonspecific and specific immune responses, also known as innate and acquired immune responses.
Some medical scientists believe that mitochondrial problems may be at the heart of all chronic diseases, including cancer. People’s health and energy largely depend on how much oxygen they have and how well their mitochondria utilize it.
I can’t help but note that the articles that he cites date back to 1986 and even, later in his article, to 1930. Naturally, I looked up the articles. The 1986 article abstract states:
It is known that carcinogenesis induces Mg distribution disturbances which cause Mg mobilization through blood cells and Mg depletion in non-neoplastic tissues. Mg deficiency seems to be carcinogenic in cases of some particular haemolymphoreticular diseases only, more often, in cases of solid tumors, it inhibits carcinogenesis.
Oops! So, according to Sirucs’ own reference, low magnesium isn’t usually carcinogenic—just in a small subset of cancers—and actually inhibits the development of the more common solid epithelial malignancies. Seriously, do these quacks read even just the abstracts of the articles they cite? As for treating cancer with sodium bicarbonate, that is a longtime favorite bit of cancer quackery, often paired with some truly outrageously stupid claims, such as the claim that all cancer is a fungus.
I might have to do a post just on that article, and all the “natural chemotherapy” touted by Sircus, but for now, I’ll leave with an observation before moving on. The broadest definition of “chemotherapy” for cancer is any chemical administered to treat the disease, or “the treatment of disease by the use of chemical substances, especially the treatment of cancer by cytotoxic and other drugs.” Colloquially, the term is rarely used outside of the cytotoxic chemotherapy of cancer, the sort of drugs that do indeed range from toxic to very toxic and that tend to target the replication of tumor cells. The amusing thing, though, is that we already use a number of “natural chemotherapy” agents according to this very definition. Taxol, for instance, is derived from the bark of the Pacific yew tree. In addition, many other plant-based antitumor drugs remain in clinical use, such as vinblastine, vincristine, and podophyllotoxin analogs, and screening natural products for anticancer activity is a very active area of research. In other words, it’s not as though science- and evidence-based oncology ignore “natural chemotherapy.” Scientists and oncologists just require that a drug work, while not caring so much where it came from.
“Natural allopathic medicine”: A meaningless buzzword
Near the end of his article on “natural allopathic medicine” and how “brilliant” it supposedly is, Mark Sircus claims:
It took me twenty years to develop Natural Allopathic Medicine, yet professionals and patients alike can learn how to practice and think about its basic tenets in a few hours. Until this year, one had to navigate through drsircus.com’s 1800 pages or do private consultations with me. I have now developed a multi-media course that aims to quickly get patients up and running the protocol.
Perish forbid that knowing how to treat disease takes years and years of education. You can be up and running treating yourself with “natural allopathic medicine” in a few hours, or so Sircus seems to be claiming; that is, if you pay for his multimedia course. But don’t worry, the price is a low, low…well, this:
The first course is tailored to cancer patients with no time to lose in starting their treatments. The course can be purchased as a standalone or with consultations, as well as my 99-lesson cancer course. It will be offered free to anyone signing up for an hour consultation, but when it is officially published, the standalone course will cost 275 dollars.
Only $275? What a bargain! Only $25 more than a one-hour consultation, too! Truly, the grift is strong in this one.
Circling back to what I originally said about “allopathic” medicine versus homeopathy, though, I can’t help but be amused how a quack like Sircus, who obviously desperately wants to be taken seriously, thinks that branding his quackery as “natural allopathic medicine” will do it. While it’s funny how thirsty he is for the apparent scientific cred that comes from associating himself deceptively with conventional medicine, it’s kind of depressing that Hahnemann’s 200 year old disparaging term for conventional medicine has become so ubiquitous that almost no one knows its origin or realizes that it was not meant as a complement when it was coined, so much so that even quacks seeking to rebrand their quackery as scientific try to coopt it.
Quacks like Mark Sircus.

Clínica 0-19: False hope in Monterrey for DIPG patients (part 1)
Drs. Alberto Siller and Alberto Garcia run Clínica 0-19 in Monterrey, Mexico, which has become a magnet for patients with diffuse intrinsic pontine glioma (DIPG), a deadly brain cancer. Unfortunately, their treatment is an unproven combination of 11 chemotherapy drugs injected into an artery feeding the brainstem, plus an unknown and unproven “immunotherapy.” Of course it all costs $300,000 or more for a complete course of treatment, and the good doctors are “too busy to do clinical trials” or even publish their survival and recurrence statistics, despite having used this protocol for 20 years. I say: If it quacks like a duck…
David Gorski on June 25, 2018
Link

I’m going to begin the story of Addy Joy Sooter and Clínica 0-19 at its end, because the end is so tragic. It came to public attention two weeks ago, when an image posted by her father to her Facebook page Hope for Addy Joy – Fighting DIPG went viral. It’s a heart-rending photo of Addy Joy’s 6-year-old brother Jackson saying goodbye and trying to comfort her as she lay on her deathbed in hospice.
There were a number of stories about this image and the story of Addy Joy and her family, from news outlets as varied as Arkansas Patch, Today, various FOX affiliates, CBS News, etc.
Addy herself died of DIPG a few hours after the photo was taken. Those of you who have read my many deconstructions of Stanislaw Burzynski‘s anecdotes and testimonials designed to show that he could cure deadly brain tumors might remember that DIPG stands for diffuse intrinsic pontine glioma and that DIPG is a particularly deadly brainstem cancer. Addy Joy’s story, unfortunately, began similarly to the way all too many Burzynski patient stories began and played out the same way as that of a typical Burzynski patient.
Addy Joy, however, was not a Burzynski patient.
What caught my attention in stories about this viral image were passages that mentioned an “experimental treatment” in Monterrey, Mexico that Addy had undergone. These mentions made me very, very curious, particularly given that the name of the clinic and hospital were almost never revealed in these stories, and the treatment was included in the narrative a very matter-of-fact manner, as though it were an actual legitimate experimental therapy. However, having had so much experience discussing “experimental treatments” in Mexico that were in reality cancer quackery, learning that Addy Joy Sooter had undergone treatment in Monterrey, combined with seeing no mention of what that treatment was, and topped off with reports that the parents had spent over $200,000 on the treatment all conspired to set my skeptical antennae a’twitchin’ mightily. So I did some digging. What I found was horrifying, and Addy Joy’s family was not by any means the only family victimized by doctors selling what, it turns out, is an unproven and potentially dangerous treatment.
Before I explain what I’m talking about, however, it will be necessary to go back to the beginning of this story.
Addy Joy Sooter versus DIPG
In October 2016, Addy Joy Scooter was a healthy, happy two-year-old living with her parents in Arkansas. That’s when, during a trip to the Silver Dollar theme park in Missouri, the parents noticed something very wrong:
The family’s ordeal began in October 2016, when the Sooters spent a day at the Silver Dollar City theme park in Missouri. There, Matt’s mother noticed that Adalynn — who the family calls “Addy” — was walking “funny.” Matt, who first shared his story with Love What Matters, says he noticed a “hitch” in Addy’s step as well.
“We were confused, but we thought it could be because of the growth spurt she had just gone through,” he tells PEOPLE. “As it got worse, we became more and more concerned.”
Throughout the weeks that followed, Matt and Chandra noticed that Addy was having even more trouble walking, often stumbling and falling. He says the little girl even had difficulty holding her eating utensils.
Worried, they took the then-2-year-old to the hospital where doctors found a tumor growing on the girl’s brain stem. She was diagnosed with diffuse intrinsic pontine glioma (DPIG). Doctors said the little girl would likely live for only a few more months.
Thus began an all-too-familiar (to me) story: A toddler facing almost certain death at far too young an age due to a deadly disease. Her family is devastated and desperate to save her life by any means necessary. Like most such parents in these stories, initially they utilized science-based medicine to treat their girl. Unfortunately, as is usually the case with DIPG, the treatments were only effective for a relatively short period of time after her therapy began at Arkansas Children’s Hospital in November 2016:
Over the next few weeks, Addy endured dozens of radiation treatments and, much to the family’s delight, the tumor shrank to nearly half its size.
“We were relieved and we hoped and prayed she would be one of the rare ones whose tumor would stabilize,” Matt says. “But we knew the odds were that it would come back.”
And it did. By July 2017, doctors noticed the tumor had begun to grow again. They told the devastated parents that there was nothing more they could do for the little girl.
If this were an article about Burzynski, regular readers would know what was coming next. It’s not, though. That doesn’t mean that what was coming next isn’t all too familiar:
For nearly a year, they’ve taken the little girl to Monterrey for treatment and Matt says a single trip can last up to 12 days. Travel and medical expenses have cost the family more than $200,000 — but Matt says he and Chandra would do anything for their now 4-year-old daughter.
The story thus far comes primarily from a PEOPLE Magazine story from a little over a month ago. The story is also laid out in considerably more detail on both the Sooters’ Facebook page and copious updates to her GoFundMe page. At that point, the “experimental therapy” in Monterrey had clearly failed, but the Sooters nonetheless thought it had done her daughter some good before it “ceased to work”:
Now — more than 18 months later — the Rogers, Arkansas, girl has shocked medical officials with her survival. But the girl’s parents, Matt and Chandra Sooter, say they know her days are numbered.
“The fact that she’s survived over 18 months now is purely incredible. Her doctors have grown to love her and have been amazed by how well she has done,” Matt tells PEOPLE. “While we’re doing everything we can to change the outcome we don’t expect to win this fight. We haven’t given up, but it seems we are losing the war.”
Here we see a common theme in alternative cancer cure testimonials, that of a patient far exceeding the life expectancy that doctors initially gave them and that patient’s good fortune being used as evidence that the treatment works. It’s impossible to know if it was because the doctors were too pessimistic (although any oncologist worth his salt always leavens a dire prognosis by pointing out that such estimates are medians and that half of patients will live longer, a few a lot longer) or whether the parents, as distraught parents are wont to do, latched on to the most pessimistic part of the prognosis. It doesn’t matter, really. The girl was suffering, and her parents still are. For purposes of this discussion, what does matter is that such estimates feed into the narrative used to sell unproven treatments that “treatment X kept this patient alive far longer than the doctors thought she would live.” Never mind that in this case (as in many cases) Addy Joy had received the full course of conventional therapy, with a very good response lasting seven months.
In a more detailed account of Addy Joy’s story published in Love What Matters, there’s not much more detail about this experimental treatment in Mexico:
In July of 2017 an MRI confirmed that her tumor was once again growing. During those months we searched the globe for a treatment. We spoke with doctors in New York, London, Mexico, and nearly everywhere in-between. The week before Addy’s MRI we received word that she had been accepted into an experimental program in Monterrey, Mexico. After the MRI I sent my wife, Addy, and our son to spend the weekend with family while I made preparations to travel to Mexico. The next week we were all on a plane toward a lot of unknowns. We prepared for a long trip because we didn’t know how long we would be there. Our first meeting with the doctors in Mexico and Addy’s first treatment all went well and we were able to return home after only a few days. Since then we’ve been traveling back and forth every three to six weeks to have treatment. These treatments have been expensive, totaling over $250,000 for treatments and airfare since July 2017. God has provided through many generous people who have continually partnered with us to care for our little girl.
Unfortunately, the outcome was inevitable:
On Monday, May 7th, Addy and my wife were once again in Monterrey for treatment. We were anxious about this trip because Addy had been presenting some symptoms and we were unsure of what was causing them. After her MRI, the doctors came out and informed us that she had developed hydrocephalus, a fluid build up in her brain, and that she would need a shunt placed immediately to drain the fluid. Treatment was postponed and my wife booked a flight straight to Little Rock. Addy’s shunt was placed and an MRI performed on her spine based on some things the doctors saw on another MRI of her brain. On Wednesday the 9th, we found out that Addy’s cancer had spread to the lower part of her brain and on down her spine as well. Her Mexico treatment that has kept her cancer stabilized is no longer working either because the protocol has changed, or because the tumor has mutated.
And so Addy’s story ended tragically, leaving a devastated family having spent a quarter of a million dollars for a treatment whose components we don’t even know. As is usually the case with unproven treatments like this, it’s not the doctors’ fault the treatment didn’t work. The tumor must have mutated.
Addy Joy’s not alone, either. There is a veritable pipeline from Australia to Monterrey for patients with DIPG to be treated in the same clinic where Addy Joy Sooter was treated, as you will see.
Clínica 0-19
I observed at the beginning of this post how the lack of mention of the name of the clinic in Mexico where Addy Joy Sooter was treated in so many news stories was one of the things that first got my skeptical antennae twitching (well, that and the $200,000—and counting—bill for the treatments). It was difficult to learn, but, as it turns out, not impossible. Some persistent Googling and perusing of the Sooters’ Facebook page revealed the name of the clinic in a story in—where else—The Daily Mail:
A week before the bad news, Addy was accepted to receive experimental treatment at the 0-19 Clinic in Monterrey, Mexico, which is where they headed on Tuesday morning.
There, she will receive intra-arterial delivery method of chemotherapy, which will hopefully be able to get as close to the tumor as possible in order to kill it.
Her family found out about the clinic through DIPG groups they are a part of on Facebook, according to her father, Matt.
‘Some others in the group were already there receiving treatment, others were asking about it,’ Matt told Daily Mail Online. ‘I was given a couple of names to contact. Through them we started talking about getting her down here and sending MRI results and her medical info.’
When I read this, I shuddered. Intra-arterial chemotherapy? Into the brainstem? Well, it is an experimental therapy. I found some references to a trial at Johns Hopkins, for instance. It is, however, a phase I trial. It involves the use of intra-arterial Melphalan, two doses. Because it is a phase I trial, it is definitely not an efficacy trial; indeed, the ClinicalTrials.gov entry specifically states that it is a feasibility study to “perform a qualitative evaluation of whether or not we can safely deliver IA chemotherapy to patients with progressive DIPG.” Also, the status of the trial is listed on ClinicalTrials.gov as “Suspended (Study has been placed on hold for an interim review.)” In this context, “suspended” means that the trial was halted early but might start up again. Interestingly, the Johns Hopkins website says the trial is “currently closed for analysis.” To me, a suspension makes me wonder if there were toxicity problems, but there is no way of knowing why the trial was suspended without contacting the PI or when (if ever) the trial will be restarted. It’s also hard not to note that the study start date was in 2013. Five years is a long time to take to accrue to a phase I study, given how small phase I studies usually are, even if the investigators are allowing two years for assessment of progression-free survival. A search of PubMed reveals that the results of the trial haven’t been published yet; hopefully the study will be completed and published soon.
Let’s just put it this way. Whatever the status of the Johns Hopkins phase I trial, the thought of intra-arterial chemotherapy being done outside of an academic medical center, much less by dubious doctors in Mexico, makes my skin crawl. Remember, this is a technique that’s being done at Hopkins, but that the group there hasn’t published on yet. That makes it not only experimental, but nowhere near proven or even shown to be promising yet. That’s assuming that the doctors at the Mexican clinic are even doing the same or a similar protocol. Then they’re adding some sort of immunotherapy. It’s all unspecified, though. Nowhere is there published a protocol, results, or anything other than testimonials and anecdotes, as you will see.
So what do we know about this clinic? When I did a Google search for “DIPG Monterrey,” the first website that came up was Making DIPG History in Monterrey, along with the site’s Facebook and Instagram pages. These sites are all run by a naturopath named Kim Beauchamp, who has a relative with DIPG:
The cost of one year of treatment in Monterrey amounts to over $300,000—without accounting for unexpected complications and extended hospital stays. But when parents find something that can help save their child’s life, they’ll stop at nothing to provide it for them.
Kim Beauchamp is a naturopathic doctor and writer. In the fall of 2016, her cousin Jeni’s daughter Kira was diagnosed with DIPG. Since then, Kim’s become intimately involved in the DIPG community—researching, advocating for families, and spreading awareness of DIPG with the hope of stopping this devastating disease.
After spending a week with Jeni and Kira in Mexico and witnessing first hand the effects of DIPG on children, the incredible demands on their caretakers, and the profound changes that the treatment in Monterrey is making for the children receiving it, Kim reached out to photographer and pediatric cancer awareness Project 3.8 founder Robyn Ivy about going to Monterrey to chronicle these children’s journeys with DIPG together.
Here, I note that in my original version of this post I mistakenly characterized Ms. Beauchamp’s site as affiliated with Clínica 0-19. It is not, although there’s no doubt that, even if not affiliated with the clinic, her website provides excellent PR for Clínica 0-19 given that it is very likely the first site most parents with DIPG encounter when searching for alternatives to conventional treatment in Mexico and how positively it presents stories of children treated by Drs. Siller and Garcia. Amusingly, Ms. Beauchamp also includes what skeptics like to call a “quack Miranda warning” on every page of her website:
The information contained in this site is for educational and/or informational purposes only, and is not intended to diagnose, treat, or prevent any condition. If you have any concerns about your own health or that of a family member, you should always consult with a healthcare professional.
I definitely consider a quack Miranda warning fitting for a site run by a naturopath. As an aside, since the original post was published, Ms. Beauchamp sent me an email objecting to my implication that her website is affiliated with Clínica 0-19 as incorrect. I regret the error and was happy to correct it above. However, after publication of the corrected version on June 27, Beauchamp then sent an email objecting to my added opinion that her site is fan site, characterizing my opinion, risibly, as “libelous,” and failing to notice that I had also quoted her description of the origin of her website almost in full, thus providing a full hearing to her intentions for the site. In any event, let’s just say that, if Ms. Beauchamp’s site isn’t a fan site for Clínica 0-19, it sure did fool me. However I am grateful to her for the additional opportunity to improve the accuracy of this section and hope that Ms. Beauchamp will agree that my post is much improved for it.
Annoying naturopath libel insinuations aside, it turns out that Clínica 0-19 does have a website. My Spanish isn’t so great, but, bolstered with Google Translate, it’s good enough to figure out what’s being offered. For instance, the website declares that “we are experts in the integrative and alternative management of cancer” and boasts about using the “most advanced techniques of traditional and alternative medicine.” I also must say that I wasn’t too impressed by this passage:
Requesting a Second Medical Opinion is a fundamental right that every patient and their family have in order to know more about their condition or type of cancer.
In the United States, medical errors are already the eighth cause of death and the great majority occurs due to the lack of a Second Medical Opinion. In other countries, it has been shown that in 15% of the cases a change or precision in the diagnosis is necessary and in up to 70% of the patients a modification in their treatment is required.
I suppose I should be relieved Clínica 0-19 didn’t repeat the trope that medical errors are the third most common cause of death in the US. Looking at the clinic’s list of doctors didn’t exactly give me confidence, either, given that there is an “orthomolecular therapist.” Orthomolecular medicine, as you might recall, is a quackery that basically uses megadoses of vitamins and nutrients to treat all manner of diseases. Linus Pauling’s high dose vitamin C treatments for cancer.
Basically, there wasn’t much in the way of information on either the marketing website or the Clínica 0-19 website. So my Googling went on. Searching for the name of the medical director, Dr. Alberto J. Siller, however, did lead me somewhere, but not anywhere good.
Drs. Alberto Siller and Alberto García and the Instituto de Oncología Intervencionista
So what is this “experimental treatment” at Clínica 0-19 that attracted Addy Joy Sooter’s family as the last resort to try to save their daughter? It all boils down to Drs. Alberto Siller and Alberto Garcia of Instituto de Oncología Intervencionista (IDOI), which also has a slick website declaring it to be ” leader of the intra-arterial brain tumors procedure and recognized for its Diffuse Intrinsic Pontine Glioma (DIPG) treatment.” There’s also an application to be treated asking for basic information (name, age, etc.), clinical history, plus videos of the child eating, walking, and speaking, along with MRI files. Demonstrating that crowdfunding is basically a part of this “institute’s” business model, there is also a question, “If the patient has a funding campaign, please share it with us so we can promote it with local nonprofit organizations who focus on raising funds for these causes.” Basically, what I gathered from various websites is that IDOI sees its patients in consult and followup at Clínica 0-19 but does the actual invasive radiology procedures at local hospitals in and around Monterrey, primarily at Hospital Angeles, admitting them there for treatment.
That’s all well and nice, but what is the treatment? Here, I was frustrated again to find just this:
The intra-arterial treatment exists since long and is performed continuously in diverse countries. What IDOI does differently is the preparation, mixing, dosage and sequential administration of the different medications that integrates the treatment’s model. It also uses the intrathecal route to administer certain medication.
The interventional oncology that IDOI performs consists in a puncture made in the femoral artery through which a micro catheter is inserted and directed by fluoroscopy to the blood supply site of the tumor.
The risks related with the procedure are minimal and imply the formation of a hematoma in the puncture site (less than 5%) and a possible vascular event such as a stroke (less than 0.7%). The other part of the procedure consists in making a lumbar puncture after the intra-arterial treatment with the application of medications.
The inherent risks of this procedure are pain in the puncture site, the formation of a hematoma and some irritation of the cauda equine(radiculitis) that occurs in less than 1% of the cases.
All medication used by IDOI are approved by Cofepris and FDA.
Imagine my relief that all the drugs are FDA-approved.
A particularly glaring omission here is…oh…you know…the risk of injecting chemotherapy right into the major arteries leading to the brainstem! The institute does, however, include a video from the University of Rochester about using intraarterial treatment for stroke, which is totally the same thing. The FAQ isn’t any more illuminating:
How successful are you in your treatments?The treatment program of the Institute of Interventional Oncology for patients with DIPG began many years ago. We have treated adult and child patients with different types of brain tumors in addition to DIPG. The response rate to our management scheme is very high and treatment-related toxicity is very low. Many of these patients are free of disease years after their treatment has been discontinued and some have died from accidents or situations unrelated to the tumor and / or treatment.
Are there any publications in the peer-reviewed medical literature or statistics provided? Of course not! (More on that later.) Even worse, they will not even give examples of which drugs are used:
What agents are being administered?Since the beginning of our program the treatment scheme has maintained a basic structure of medicines used to treat cancer. We are constantly evaluating new drugs and replacing each one with the purpose of improving our results. All the medications we use are FDA approved. What makes this program different is not only the route of administration but the dosage and sequence of administration of the products. With the arrival of a new category of products called molecular targeted therapy, our results have significantly improved.
This is utter nonsense. Dr. Siller could provide examples of the drugs (or a subset of the drugs) used if he wished to. He does not, and that is utterly irresponsible. Indeed, Dr. Siller is providing even less information about his treatment than cancer quack Frank Arguello provides about his “atavistic chemotherapy,” and he provided very little. At least Stanislaw Burzynski tells his patients what he is giving them. He might not inform them adequately how toxic it is, but he does tell them what they’re getting. In terms of transparency, these guys are worse than Burzynski!
But what about the “immunotherapy”? This is about all the clinic website says:
Can you explain the immunotherapy done in your program?Our Immunotherapy program consists in the application of patient’s own immunological cells extracted previously and “activated” to recognize and destroy the tumor cells of the patient.
Who knows what this means? This could mean anything from just removing the patient’s white blood cells and treating them with various cytokines to “activate” them to doing a poor man’s CAR-T therapy. I rather suspect the latter, because clearly Drs. Siller and Garcia are all about combining treatments in a “make it up as you go along” manner. On the other hand, CAR-T cells are very hard to make and require quite a sophisticated laboratory setup, plus special expertise. Color me cynical, but somehow I doubt that level of expertise and equipment are available at a clinic like this or even the hospitals they work with, particularly since the FAQ also includes questions about high dose vitamin C treatment, hyperbaric oxygen chamber therapy, and hydrogen peroxide therapy, all quackery. The bottom line, I have to conclude, is that I have no idea what these guys are doing and calling “immunotherapy.” I also have little idea what they are doing except injecting chemotherapy into arteries leading to the brainstem given that they don’t state which drugs they are using or on what basis a chemotherapy regimen is chosen for each patient. Their treatment is a black box.
Meanwhile, Drs. Siller makes excuses:
While Dr Siller admitted they are to an extent making things up as they go along, he said this was driving their success. He said the main problem with established medical protocol was that “you cannot move a millimetre outside what is written because you are out of the protocol. We are not using that. We are tailoring our treatment to every patient based on the circumstances.
“That’s a big, big issue. And nobody seems to understand that we are not in the protocol world. We understand that, but we rather prefer to take every single child according to their…circumstance.”
In other words, we make it up as we go along and can’t tell you how we do it in a sufficiently clear manner to make it possible to write a protocol to do it in a clinical trial. This, of course, also means that they can’t teach their technique for picking chemotherapy drugs to anyone else. How convenient. It’s the same damned excuse that homeopaths use to dismiss clinical trials of homeopathy that don’t include “personalization” of the treatment. I also can’t help but retort that there are now ways to test “personalized” treatments. Doctors are doing it all over the place.
The Australian connection
It didn’t take me long to discover that there is a direct pipeline between Clínica 0-19 and Australia, because multiple stories came up of children from Australia being treated at this clinic. Australian newspapers have published several Daily Mail-like credulous articles about Australian children with DIPG being taken to Monterrey by their parents for “last resort” experimental therapy. For example, in February, there was a headline in the Daily Telegraph “Little Annabelle Potts and her family have found hope with brain tumour treatment in Mexico.” Annabelle Potts is a now six year old Australian girl with, sadly, DIPG. Like so many other families of children with DIPG, Annabelle’s family is desperate to do anything to save her. It’s $30,000 a treatment, and the objections of Australian doctors are waved away:
But Annabelle’s battle is far from over. Her family know she isn’t cured, and even though Australian doctors don’t support the findings from Dr Siller and Dr Garcia in Monterrey, Annabelle’s parents believe they are their best shot at buying time until there is a cure.
So that means every six weeks, they cough up $30,000 from anywhere they can find it, sometimes through Facebook fundraising, and Adam takes time off work as a carpenter to fly Annabelle from their Canberra home to visit Clinica 0-19.
There’s another girl with DIPG being treated named Annabelle, Annabelle Nguyen. I learned some useful things from her GoFundMe page. First, it tells me one thing I needed to know about Annabelle Ngyen’s cancer, namely that it is less aggressive than the usual DIPG. After all, she survived well over a year and a half after her diagnosis without progression having received only conventional treatment. I also learned this:
They combined around 11 cocktail of drugs go in through the groin and then through the back with catheters, and inject a certain sequence of drugs to the brain stem and then they combine with Immunotherapy. We are looking at lifelong treatment till we get NED.
NED means “no evidence of disease.” It’s what we look for in tumor response, basically the equivalent of, “We can’t find any cancer anywhere with our imaging studies.” Eleven drugs, though? Eleven? That is an incredible, shocking number. What are these drugs? How is the sequence in which they are given determined? Again, we don’t know. Dr. Siller doesn’t say. Lifetime treatment? How do you know? You don’t. But lifetime treatment at $30,000 a pop is an excellent revenue stream.
We’ll return to Annabelle Potts and Annabelle Nguyen later. In the meantime, I point to similar stories about other children from Australia, such as Doris Sun, Riaa Kulkarni, and several others.
“We’re too busy saving patients to publish our results!!!”
Drs. Siller and Garcia have not gone without criticism, of course, although it’s hard to find much specific criticism among the glowing testimonials because so little is known about just what these doctors are doing. There was, however, a story in the Daily Telegraph in January describing some of the issues the international oncology community has with Clínica 0-19. The article starts with a discussion of Doris Sun and her cancer treatment, noting:
There is only one small but relevant condition keeping Doris from receiving the treatment back home: there are no peer-reviewed studies proving it works, only anecdotes of its effectiveness.
The controversial intra-arterial chemotherapy and immunotherapy treatment is the brainchild of Monterrey-based doctors Alberto Siller and Alberto García, who developed their technique two decades ago and offer it through their clinic, Instituto de Oncología Intervencionista. They have refused to cooperate with the international medical community and have never published their results.
Refuse to cooperate with the international medical community? That strongly suggests to me that these guys are quacks right there. In any case, next comes a quote from an Australian oncologist:
But leading Sydney paediatric oncologist Professor David Ziegler is highly critical of the Mexican doctors.
“They have been doing this for 20 years, so if it works, why don’t they publish their findings? I don’t know why they don’t, but you’d be concerned that it is not working and that’s why they don’t want to release the information,” Prof Ziegler said.
Neurologist Dr Brian Owler, from Cure Brain Cancer, said the regulatory system in Australia required “proof of principle” that a trial may work based on peer-reviewed studies, which the Mexican doctors have not published. Until that exists, no Australian trial can take place.
Exactly. Siller and Garcia have been at this two decades. They should be able to publish at least a case series, but they don’t. They should be able to publish their statistics for overall survival and recurrence-free survival, so that they can be at least compared with historical controls. It’s not ideal, but significantly higher survival statistics might indicate that they are on to something, although I can’t help but note that even in that case the figures would still have to be interpreted with caution. This is, after all, a highly selected population of children with families able to raise $300,000 in a short period of time and who are also able to endure multiple long trips to Mexico to receive therapy. They’re likely in better physical shape than the average DIPG patient. It doesn’t matter though. Siller and Garcia haven’t published their survival and recurrence statistics. Why?
Here’s why:
The doctors have received criticism from Australian experts because they have not published any data on their techniques or their success rate, but the doctors say they are too busy treating 70 plus patients from around the world.
It was at this point that I wanted to throw something at my computer screen. Fortunately, I restrained myself. “I’m too busy saving lives to publish my results or do clinical trials to test my treatment” is the oldest and lamest quack excuse there is. It’s also hard not to wonder whether the reason they don’t cooperate with Australian oncologists is that, if their treatment actually did work and were available outside of Mexico, their lucrative revenue stream would dry up in short order.
The only thing Drs. Siller and Garcia seem to cooperate for is publicity, which unfortunately they got, thanks to a highly credulous Daily Telegraph article with a nauseating teaser, “Miracle Cancer Clinic Saving Aussie Kids.” I don’t have access to it because it’s behind a paywall. Fortunately, I got a hold of it through PressReader. The title, “Where Hope Lives,” is entirely credulous. There was also another story for the Sunday Times entitled “Inside the Miracle Factory in Suburban Mexico Keeping Our Kids Alive.” Both are largely the same article with some minor differences.
Inadvertently, though, the article reveals a very Burzynski-like practice:
Professor David Ziegler, paediatric oncologist at the Kids Cancer Centre, Sydney Children’s Hospital, Randwick, has been highly critical of the doctors because they have never released their research and findings to be peer reviewed. “I have not seen any results that show this treatment is effective,” Prof. Ziegler said.
“On occasion the team in Mexico has released limited scans which do not accurately depict the tumour” and are not able to be used to tell if the treatment is doing anything at all.
This is exactly the sort of thing Burzynski does. Dr. Siller also appears to share another trait in common with Burzynski, arrogance:
“I told an Italian doctor… ‘if you have something to give to your patient better than what we are using, feel free’,” Dr. Siller said.
Elsewhere in the story, Dr. Siller is quoted as saying that he and Dr. Garcia aren’t making much money from their treatment. Never mind that the story also reports that their DIPG treatment makes up the bulk of their business now, that they now employ ten physicians, and have struck deals with local hospitals, such as Hospital Angeles, to treat their patients there. They also claim that they’d love to publish their results, but, sorry, they’re too darned busy working 18 hour days to save lives.
They do, however, add:
“We are starting to do some basic numbers,” Dr. Siller said. “Our thoughts are to start publishing the results in the coming months.”
Wait a minute. You’ve been doing this for twenty years, and you’re only now “starting to do some basic numbers”? That’s the excuse of quacks.
As a result of the Telegraph story, though, in early March the Cure Brain Cancer Foundation responded to the call for Australian authorities to investigate Dr. Siller and Garcia’s claims of anecdotal success treating DIPG:
“We’re willing to sponsor a DIPG expert to visit the lab and verify Clinica 0-19’s claim,” Michelle Stewart, CEO of CBCF said.
“Last week’s report (in The Sunday Telegraph) said the doctors were too busy to report their findings, and if we can provide assistance for them to get this information out, we are more than happy to.
“We want to send a DIPG expert who can report back on the drugs used so if any learning can be found, we can use that to treat patients locally. “
The CBCF has sent a letter requesting permission for the expert to attend and research the procedure and drugs used.
“We want to make the information available so that if researchers wanted to do a trial here, we could provide funding,” Ms Stewart said.
And what was Clínica 0-19’s the answer? Let’s just say that it was…not unexpected:
Violeta Montes de Oca, a public relations consulted hired by the clinic, said they needed time to “be able to develop a program that allows receiving invited doctors”.
“Today, the clinic’s only priority is to devote all its attention and energy to trying to restore health and improve the quality of life of patients under treatment,” she said.
“As you will understand, it is very difficult at this time to offer a date to receive them.”
That sure sounds as though the clinic was continuing to make excuses and trying its best to delay. It’s been nearly four months, and, to the best of my ability to search, I have found no evidence that Clínica 0-19 has not allowed an outside expert to visit and help Drs. Siller and Garcia to do the required analyses for publication. In the meantime, there have been developments.
NED? Not so fast…
Drs. Siller and Garcia also claim they have four patients with NED, including Annabelle Potts and Annabelle Nguyen, who were discussed above. Let’s look at updates for Annabelle Potts first. On her GoFundMe page we find an update from last month:
Last week, Annabelle just had her 10th IA treatment. The results from the MRI is not the news is not what we have hoped for. The original tumour is still essentially ‘dead’, but it looks as if there is some small new growth into the cerebellum. While this is absolutely not what we hoped for, we are so grateful that the doctors in Mexico picked this up before treatment and treated the area immediately!
Sadly, this is not NED. It’s also not unexpected. I also can’t help but wonder if some of the progression observed in some of these patients was the same phenomenon that so often fooled Burzynski: Pseudoprogression. Pseudoprogression is a common phenomenon in brain tumors where, after conventional treatment with radiation and/or chemotherapy, the tumor will appear to be progressing because inflammation around the dying tumor appears indistinguishable from tumor on MRI. Any treatment, even ineffective treatment, will appear to “work” if administered while the cancer is in pseudoprogression because eventually the inflammation settles down and the area that lights up as a mass on MRI shrinks. The problem, of course, is that one can’t say whether apparent progression is pseudoprogression or real progression except in retrospect. Also, these are real pediatric oncologists treating many of these children who should be (and almost certainly are) aware of the phenomenon. Of course, confounding factors like this are yet another reason why anecdotes don’t cut it for showing efficacy. Clinical trials are needed, with rigorous monitoring of tumor sizes by neuroradiologists who know what they’re doing, careful survival and recurrence measurements, and monitoring for adverse reactions.
Speaking of adverse reactions, I feel compelled and at the same time deeply sad to finish on a horrific cautionary note, and unfortunately that note is an update on Annabelle Nguyen in the form of a story over the weekend in The West Australian. Basically, Annabelle Nguyen has fallen into a coma, and her family is stuck in Monterrey:
But after initial success, when the tumour disappeared and the family packed up to move home, it returned and Annabelle fell into a coma, which she remains in to this day.
“She said she had a monster in her head and she wants to fight it, I believe she is fighting it,” Sandy said.
But while Annabelle silently fights, her prognosis is not improving. Her family is spending $2500 a day to keep her in a hospital in Monterrey and desperately wants to bring her back to Australia.
That flight, however, cannot be taken commercially and will cost the best part of $250,000.
“A lot of people tell me that we’re holding her back, that we should let her go but they are not in our shoes,” Sandy told 7 News.
As I said before, it is not surprising that the tumor returned. It’s not even clear to me from anything that I can find out online that Siller and Garcia’s treatments actually did Annabelle any good, although it’s very clear that they cost her parents a whole lot of money. Now Annabelle is trapped in an ICU in a foreign country thousands of miles from home, her parents racking up $2,500 a day in medical bills, unable to leave because a medical flight back to Australia would cost a quarter of a million dollars, this after having already spent $300,000. And the greatest tragedy of all? Their daughter will die soon regardless, and from an ethical standpoint, as painful and horrible as it is to contemplate, taking her off life support and instituting comfort measures only almost certainly represent the best course of action for Annabelle. Unfortunately, the Nguyen family are victims of arrogant and unscrupulous doctors, aided and abetted by social media that lead new victims to their clinic.
        ◦ If Drs. Siller and Garcia truly have made a major advancement in the treatment of DIPG, they have a moral obligation to publish their existing results and to accept help from the international medical oncology community to test their treatment in proper clinical trials. Continuing to charge $30,000 a pop for an unproven treatment for 10+ treatments is immoral given that there is no evidence that their treatment is superior to existing therapies. The longer they fail to do that, the more I suspect that the reason they don’t do it is because they don’t want to endanger their revenue stream.

Clínica 0-19: False hope in Monterrey for brain cancer patients (part 2)
Last week, I discussed Clínica 0-19, a clinic in Monterrey, Mexico whose doctors claim to be able to treat the deadly brainstem cancer DIPG using intra-arterial chemotherapy and immunotherapy. This week, I discuss what I’ve learned since last week, specifically a lot more about just what it is that these doctors do, why it is scientifically dubious and unproven, and why I am becoming even more harsh in my assessment of this clinic, which shows every indication of being a predatory clinic selling an unproven treatment for a very high price.
David Gorski on July 2, 2018
Link

Last week’s post about Clínica 0-19, a clinic in Monterrey, Mexico that offers what is often incorrectly characterized as a “revolutionary” and “experimental” new therapy for diffuse intrinsic pontine glioma (DIPG), a deadly cancer of the brainstem that disproportionately affects children, certainly provoked a reaction. Indeed, I don’t recall a reaction like this since the early days of my posting about Stanislaw Burzynski. At Clínica 0-19, the founders of Instituto de Oncología Intervencionista (IDOI, or the Institute of Interventional Oncology), pediatric oncologist Dr. Alberto Siller and interventional neuroradiologist Dr. Alberto Garcia, offer poorly-described and ill-defined intra-arterial chemotherapy to the brainstem combined with an even less defined and described “immunotherapy” to the desperate parents of children suffering from DIPG, charging patients $30,000 a treatment and requiring ten or more treatments, performed mostly at nearby Hospital Angeles.
Reading the stories of desperate families, mainly from the US, UK, and Australia, selling possessions, cars, and houses and going to social media and crowdfunding to try to come up with the huge sums of cash required to pay for the treatment provoked a sickening feeling of déjà vu, given my long experience writing about the Burzynski Clinic and antineoplastons. So, too, did the form many of the news stories about families of children with DIPG taking them to Monterrey remind me of news stories about families of Burzynski’s DIPG patients going to Houston in that, with but a precious few exceptions, they uncritically described the treatment offered by IDOI as “experimental” therapy or an “experimental” protocol, with only a passing mention, if any mention at all, of the criticism directed at these doctors. Let’s just put it this way. To be an experimental therapy, the treatment has to be in active testing in the lab and in clinical trials, and the doctors running IDOI are not doing any research. They’re just treating and charging patients, excusing themselves from even the most basic requirement of publishing their own survival and recurrence statistics by saying they’re “too busy saving lives.” But it’s worse than that. In March, in response to credulous stories in the Australian press about “miraculous results,” the Cure Brain Cancer Foundation (CBCF) in Australia offered to sponsor a DIPG expert to travel to Monterrey to examine what Drs. Siller and Garcia are doing at Clínica 0-19 and Hospital Angeles and see if they might be on to something, further offering to fund a clinical trial of the IDOI protocol if its expert determined Clínica 0-19’s results were promising. The answer consisted of more excuses and stonewalling. It’s now four months later, and, as far as I’ve been able to ascertain, Dr. Siller still hasn’t taken CBCF up on its offer.
I didn’t expect to be writing about Clínica 0-19 again so soon, but, as I mentioned above, the response to last week’s post rather mandates that I do. I received emails from several people. Amusingly, naturopath Kim Beauchamp was very unhappy with my characterization of her Making DIPG History website first, mistakenly, as part of Clínica 0-19. That was an error I was happy to correct. However, when she then objected to my characterization of her site as a “fan site,” calling it “libelous,” I changed the text to point out her use of the quack Miranda warning and mention how I thought naturopathy was quackery. (As I wanted to tell Not-a-Doctor Beauchamp, be careful what you ask for.)
More importantly, I received some emails from parents who took their children to Monterrey to treat their DIPG. Uniformly, they were unhappy with me. I also received an email from a person who had a relative whose parents had taken her to Monterrey and were much less impressed with Drs. Siller and Garcia. Finally, I learned a lot more about the chemotherapy and immunotherapy being used. Let’s just say that I was less than impressed.
It was all too much for one post, even accounting for Gorski levels of logorrhea. So I decided to divide my discussion in two. First, for this post, I’ll primarily focus on what I’ve learned about what Drs. Siller and Garcia actually do and why it is unsupportable scientifically or ethically. Next week or sometime later in July, I’ll finish by making a trilogy out of this (the way I did for Rigvir), the last post focusing on individual patient testimonials. Let’s just put it this way. Clínica 0-19 is now on my radar screen, the way Stanislaw Burzynski showed up on my radar screen seven years ago. I will be paying attention, and these three posts, of which this is the second installment, are likely to be just the beginning.
The mystical magical intra-arterial chemotherapy offered by Clínica 0-19
If you read my last post, you’ll know that I spent a fair amount of verbiage trying to figure out just what it was that Drs. Siller and Garcia were offering. They don’t publicize, publish, or even mention online exactly what chemotherapeutic agents they inject into the arteries leading to the brainstem. Indeed, on the IDOI website under “medications,” this is all they say:
As part of our protocol we use an array of different drugs. Some of the drugs are helpful for cytotoxic chemotherapy, molecular targeted therapy, and immunotherapy. All these drugs are used in a particular sequence and dosage. All drugs are perceived as an important parameter in a pre-established time of infusion. All these conditions are extremely important to get the results we have. We worked for decades in order to improve these techniques and this is how we differentiate ourselves from others.
Notice how they don’t mention even a single example. One might speculate, for example, that temozolomide might be one of the chemotherapeutic agents used. Although it doesn’t improve overall survival over radiotherapy alone, there is evidence that it improves survival in a subset of DIPG patients. In existing clinical trials of intra-arterial chemotherapy, such as the one at Johns Hopkins Hospital, they use melphalan. In contrast, from various reports from parents I’ve discovered that Drs. Siller and Garcia use up to 11 different chemotherapy agents, with no rationale or algorithm for how they are selected.
An oncologist also contacted me after my post and let me know that there had been reason in the past for her to contact Drs. Siller and Garcia and ask them what they use. The response revealed that they used cisplatin 1 mg, cetuximab 15 mg, doxorubicin 0.25 mg, and Avastin 12.5 mg. Cisplatin is a platinum-containing chemotherapeutic agent that interferes with DNA replication in fast-dividing cells, while doxorubicin is an anthracycline antibiotic that inserts itself into DNA and interferes with replication as well. Cetuximab interferes with the activity of the epidermal growth factor receptor, and is most commonly used for cancers like colorectal cancer and head-and-neck cancer. It has not been shown to prolong survival in DIPG, at least when combined with irinotecan. Avastin, of course, is an antiangiogenic agent (a drug that inhibits the ingrowth of new blood vessels by the tumor to feed itself). Results of a phase II trial testing it plus irinotecan against recurrent DIPG (which, let’s face it, is what most patients going to Clínica 0-19 have) were disappointing as well, with no responses.
I also can’t help but note that these doses are very low. For instance, a typical dose of Avastin is between 5-15 mg/kg every three weeks. For a typical child weighing 10-20 kg, we’re looking at a dose that could be as much as 20 times lower than recommended. (That’s leaving aside the fact that Avastin has not been FDA-approved for use in children, as far as I can tell, thus showing that Drs. Siller and Garcia are not being entirely accurate when they say they only use FDA-approved medication.) Similarly, it’s been pointed out to me that the doses of doxorubicin and cisplatin are even lower. For instance, a dose of cisplatin in children for brain tumors off-label is around 60 mg/m2. (This is body surface area, or BSA, based dosing.) A typical three year old girl at the 50th percentile would be 95 cm tall and weigh around 14 kg, requiring a dose of 26 mg. Similarly, doxorubicin is normally dosed in children between 35-75 mg/m2. You get the idea. These are very low doses. Now, an argument can be made that if you’re injecting it intra-arterially into the tumor you can achieve drug levels in the tumor high enough to do the job; that’s kind of the idea. However, does anyone think that Drs. Siller and Garcia actually did the difficult pharmacokinetic and pharmacodynamic studies in animals and humans necessary to determine these lower doses? I certainly don’t. Personally, I think they just made it up. If they did do the work and didn’t publish the results, then that’s arguably just as bad because they’re keeping important information secret. But, again, I’d be shocked if Drs. Siller and Garcia did anything resembling the rigorous preclinical work to determine their dosages.
Basically, when you sum it up, the results of clinical trials of chemotherapy for DIPG have been very disappointing. So, basically, what we have here are several chemotherapeutic agents with no documented significant demonstrable activity against DIPG. I also note that this oncologist strongly suspected that Dr. Siller was not revealing the entire regimen, noting that either that was the case or they have incredibly expensive suppliers for their medication. (Personally, I agree but also wouldn’t be surprised if this were the current regimen, with a generous markup charged to patients.) She also noted that even what was revealed was considerably more toxic than palliative radiation therapy, which is undeniably true. (Review articles that I read noted a fairly high incidence of bleeding into the tumor as a complication of some of these chemotherapy agents.) Add to that the utter lack of transparency in which chemotherapy agents are used and especially how Dr. Siller determines which chemotherapy agents to use for which patient and in which order, and my skeptical antennae are twitching faster than ever. Dr. Siller claims there’s an algorithm by which he makes these decisions, but won’t reveal it. To me, that suggests, more than anything else, that he’s just making it up as he goes along and that his use of the “personalized” nature of his regimen as an excuse as to why it can’t be easily studied in a clinical trial is akin to the same excuse that homeopaths make for their woo.
And then, another person who’s had interaction with Dr. Siller wrote me and gave me a more comprehensive list dating to last year. The list includes trade name, generic name, and the process that the drug inhibits:
    • Zaltrap (ziv-Aflibercept) (VEGF, angiogenesis)
    • Laedemab (Nimotuzumab) (EGFR)
    • Camptoop (Topotecan) (Topoisomerase)
    • Opdivo (Nivolumab) (PD-1)
    • Avastin (VEGF, angiogenesis)
    • Trixilem (Methotrexate) (dihydrofolate reductase)
    • Jevtana (Cabazitaxel) (Microtubule inhibitor)
    • Yervoy (Ipilimumab) (CTLA-4)
    • Adriamycin (Doxorubicin) (topoisomerase, histone eviction)
    • Blastolem (Cisplatin) (DNA replication)
Wow! Now that’s throwing everything but the kitchen sink at the tumor with no rhyme or reason. Some of those drugs are old and not very expensive (e.g., methotrexate, doxorubicin), but some of them are new and damned expensive (e.g. Opdivo). Some of them are also redundant. Why, for instance, are two drugs needed to target VEGF? Why Opdivo, which is a PD-1 inhibitor that targets T-cells? Also, the more drugs you add, the more chances there are for adverse reactions, unexpected interactions, and synergistic toxicity. My jaw dropped when I read this full list. Also remember that this list is a year old. Who knows what Dr. Siller has added to his witches’ brew?
Yes, it is possible that these chemotherapy agents, particularly injected right into the arteries leading to the brainstem, could produce responses in terms of tumor shrinkage, but only at the cost of significant toxicity. Let’s also not forget that these are children, some of whom are toddlers. Every time they undergo intra-arterial chemotherapy, they have to undergo general anesthesia, meaning that they undergo repeated anesthesias. Let’s also not forget that each time they undergo intra-arterial chemotherapy, a large catheter has to be introduced into the femoral artery and guided to the proper arteries under fluoroscopy. The children also undergo repeated lumbar punctures to introduce the drugs intrathecally (into the cerebrospinal fluid that bathes the brain and central nervous system).
So what’s different about this protocol? The answer I find on the IDOI FAQ isn’t exactly persuasive and likely wouldn’t be persuasive to anyone treating cancer patients from a science-based perspective:
IA treatment has been tried before what is the difference this time round?Certainly the treatment by this route (intra-arterial) has been tried in the past and still they do it in certain places. What makes it different is the preparation, mixing, dosing and sequential administration of the different drugs that make up our treatment model. We also use the intrathecal route to administer certain drugs.
Translation: It’s our magical protocol that we won’t tell you about. Trust us.
Here’s the thing. It’s entirely possible that infusing toxic chemotherapy and targeted therapy directly into the arteries feeding the tumor and into the cerebrospinal fluid could cause a DIPG to shrink. The problem, however, is the counterintuitive experience over many decades that tell oncologists that initial tumor response/shrinkage does not necessarily mean improved overall survival. Certainly shrinkage is better than no shrinkage or growth through treatment, but many have been the trials where tumor shrinkage initially did not result in prolonged survival. That’s why clinical trials in which overall survival is determined in the treatment group are essential. Add to that the fact that there are outliers who survive longer—sometimes much longer—than the original prognosis given and that clinics like Clínica 0-19 are subject to survivor bias, in which we hear about the patients who do better than expected but not so much (more like nothing, really) about patients who do average or worse than expected, and the need for Dr. Siller to publish his survival data becomes a moral and scientific imperative. If his survival statistics are significantly better than historical controls, he might be onto something, or he might not. Remember, the patients he treats, particularly those from Australia and the UK, can all withstand repeated long trips to Mexico, which suggests that they are in better shape physiologically than the average DIPG patient, and they come from families who either can afford the $300,000 in charges or can raise that much money rapidly. One would expect that these patients as a group would be likely to do better than average anyway.
But what about the immunotherapy?
One of the patients’ parents who wrote took umbrage at my speculation that the “immunotherapy” that Dr. Siller was using might be some sort of poor man’s CAR-T therapy. CAR-T is the latest flavor of immunotherapy in which the patient’s T cells are harvested, genetically modified to attack the patient’s tumor, and then reinfused. The only reason I speculated that is because I couldn’t find anywhere else what on earth Dr. Siller might be doing. Fortunately, this parent, as angry as she might have been at me and as much as she thought she had a “gotcha” moment, filled me in:
Furthermore, their immunotherapy is also not done at the clinic. The blood is sent to a lab at the University of Monterrey, the white and red blood cells are separated and dendritic T Cells are added, which are closely monitored by published Doctor Cristina Rodriguez and her chemists. Once matured, which takes 7 days, they are transported to Hospitale Angeles where they are infused back into the child’s body during their treatment.
The name Cristina Rodríguez had come up before in some of my reading, but I hadn’t been clear if there were a connection to Clínica 0-19. Knowing her name, I was able to do some searches. First, I found out that there is no faculty with that name at the University of Monterrey. However, there is a María Cristina Rodríguez Padilla, PhD at the University of Nuevo Leon who looks as though she fits the description based on her CV and university webpage, which show her to be Professor and Chairman of Department of Microbiology and Immunology, and Head of the Laboratory of Virology and Immunology, School of Biological Sciences Universidad Autonoma de Nuevo Leon. Her lines of research include:
    • Trinomial: Immune-Cancer-Virus
    • Biotechnological Development of biological response modifiers for diagnosis and therapy
    • Formulation and implementation of biologicals
Yes, this sounds like the right Prof. Cristina Rodríguez, although I can’t be 100% sure. Certainly she appears to have the right qualifications.
But dendritic cells? Seriously? This is 1990s technology. I remember reading about dendritic cells as a new means of delivering immunotherapy when I was a graduate student in the 1990s. It was the hot new thing nearly a quarter century ago. Basically, dendritic cells are antigen-presenting cells. Their main function is to process antigen and then present it on their cell surfaces to T cells. This makes them a crucial component of the mechanism by which vaccines generate specific immune responses. Methods for exploiting dendritic cells to treat cancer generally include either stimulating them to accentuate their anticancer activity or to remove them, stimulate them in a test tube outside of the body, and then reinfuse them. There are a variety of strategies for achieving this stimulation. Without knowing exactly what it is that Rodríguez is doing, it’s hard to figure out how likely she is to be successful.
Dendritic cells as a strategy for cancer immunotherapy are still under study, but results have been disappointing, with classic objective tumour response rates rarely exceeding 15%. More importantly, there are very few data on dendritic cells as a potential treatment for DIPG. The most recent study I could find was this one from Spain, which concluded nothing more than that it was possible to use dendritic cells to generate a DIPG-specific immune response. That’s not to say that combining some form of dendritic cell vaccination with other therapies might not end up being effective, but in DIPG at least this strategy is in its infancy, with what can at best be described as potential proof-of-principle studies published. Using dendritic cells along with intra-arterial chemotherapy without a lot more clinical and preclinical data is not justified scientifically. In fact, it’s downright unethical.
As for Prof. Rodríguez-Padilla, I was hard-pressed to find anything on PubMed that resembles what she is supposed to be doing with dendritic cells and DIPG. There are no publications by her on DIPG, and there is only one publication by her involving dendritic cells and AIDS. She isn’t even the first author, either. She does have papers on immunotherapy and cancer, though. (Oddly enough, she’s also co-author on an article about the psychological effects of group hypnotherapy on breast cancer patients during chemotherapy.) Still, I’m hard-pressed to figure out why she would be doing this sort of work for a dubious clinic like Clínica 0-19, although I can speculate. I also find it very telling that there is no mention of this work that I can find anywhere on her university webpages or other webpages about her. It’s almost as though she wants to keep her collaboration with Drs. Siller and Garcia on the down low. (Either that, or I picked the wrong Cristina Rodríguez, but I highly doubt that I did.) That’s why I’m thankful that that patient’s mother told me about her. I might never have found out who was doing the “immunotherapy” for Clínica 0-19 and IDOI and what that “immunotherapy” is.
The cost of everything
All of this unproven therapy with 10 or more chemotherapeutic and targeted agents plus an unproven do-it-yourself homemade immunotherapy cost a lot of money—a hell of a lot of money. This became apparent from a post in a Facebook group, DIPG Support and Awareness:
Here we learn:
In order to get a list of medications used you will need to set up a call because the treatment is tailored to the child’s tumor and needs, and your child’s medical history. He uses multiple drugs and it’s the delivery method that is important as well, not just the medications used. The medication is based around the tumor. Again, if you are wanting to know more about treatment protocol you will need to call the clinic and set up a conference call.
Well, I already know that I’m not at all impressed by Dr. Siller and Garcia’s protocol. It’s very much like Burzynski’s use of targeted therapy and chemotherapy: He throws everything but the kitchen sink, without expertise or thought, at the tumor, and it sure does look as though that’s what Dr. Siller does too.
Now here’s the pricing. It’s a veritable racket, as you will see:
Below you will find a post with the most recent info on the treatment and pricing by by [sic] a DIPG mom who inquired with the clinic and kindly shared the info in a post for other parents. Generally parents have said to expect each treatment and trip to be around $20,000. Please read:
“Dr Siller and Dr Garcia have been doing IA treatment for 18-20 years on various brain tumors. Different drugs are used for different tumor types and makeup. It is not a one size fits all situation. The newest drugs are producing more advanced results. Over the years he has had children with different brain tumors reach NED. The longest one is at 5 years and they are in observation still. They do regular visits with their local Onc and Dr Siller and Garcia, They [sic] are in school full time and not on steroids. With the current program of drugs for DIPG, and immunotherapy, there is a lot of promise to be able to reach NED. They are currently working with their local hospital to have it accept out of country insurance. As in they will work with your insurance company for payments.This has not gone through yet but they are hoping it will soon.
Pricing: 15-17K USD. Breakdown – $7500 for professional fees for Dr Siller and his entire team in total. $3500 negotiated for the drugs with the pharmacy. Total of $11000 USD to be paid up front prior to appointment confirmation. After that $5000-6000 for ICU/Procedure/MRI before procedure to be paid to hospital. Immunotherapy: typically would begin after multiple cycles and off steroids for a few months. This is an IA and cervical lymph node infusion. They require 200 ml of blood to get dendritic and other cells. This varies from IOZK immunotherapy. This is $10,000 USD and is through the local immunotherapy clinic. You initially will plan for 4-6 weeks of stay. If you are deemed well you can leave as soon as possible however you must be fully functional. After the initial visit you will return every 3 weeks, for the $15-17K every time until NED is reached. For IA and Immunotherapy together you can expect to spend about $33,000+ (that’s just for treatments) each time (£25,000).
NED, as I discussed last week, means “no evidence of disease.” Look at the charge list, though. Look at how much it resembles the Burzynski model: Cash up front on the barrelhead, or, as this post puts it:
Medication is administered to the brain stem Basilar & Femoral arteries. The procedure is performed minimum every 17 days. An MRI will be taken before each IA procedure to allow them to see how the tumor has reacted and tailor the following treatment. 2 insertions are made, one in the groin and one in the back. Children are taken straight to ICU after then moved into a private room. The amount of nights/days in the hospital will depend on how your child recovers. Children also have a pediatric doctor assigned to them while in the hospital. You will need to have access to “I-translate” as most of the nurses and hospital staff don’t speak English. You pay for every little thing you need, everything. You are required to pay a deposit when you arrive at the hospital and then pay the remainder before they discharge you. They accept Credit/debit cards and cash.
Because of course they do. Reading this makes me understand why the administration of Hospital Angeles is willing to let Drs. Siller and Garcia do their thing there. It’s a profit center. The hospital makes money if everything goes smoothly, and it makes even more money if patients don’t do so well and required prolonged hospitalizations. For instance, as I mentioned last week, Annabelle Nguyen is in a coma, her DIPG having recurred. It’s costing the family $2,500 a day, and her parents can’t get her home to Australia because a medical flight would cost $250,000. As of this weekend, she was still there; today represents 60 days in a coma. I can’t imagine a more horrible dilemma for a family to be in, trapped thousands of miles from home and racking up huge medical bills because it costs too much to bring your child home.
No conventional therapy preferred
I’ve often said that one characteristic of a quack is that the quack will blame conventional therapy, such as chemotherapy and radiation, that the patient might have undergone before coming to him for any failure of his nostrums to cure the patient. In that very same Facebook post listing the costs and providing information for families, we learn this:
The treatment is Intra-arterial Chemotherapy Infusion Treatments and immunotherapy. They do immunotherapy but the child has to be totally off any steroids for several months.
As I’ve discussed many times before when discussing Stanislaw Burzynski, the reason steroids are administered to brain cancer patients is to cut down on inflammation and swelling provoked by the tumor. Because the skull is a non-expandable space, any swelling will result in increased pressure, which will damage brain tissue. I listed another reason above why these children with DIPG treated through Clínica 0-19 are likely to be in better shape physiologically than the average DIPG patient. Here’s another. They have to be off steroids, not just briefly but for several months. Any child with DIPG who can be off steroids for several months had a tumor that responded very well to radiation therapy and remained dormant for quite some time and/or is a more indolent, slow-growing variety of DIPG.
Speaking of conventional therapy, here’s another disturbing aspect of IDOI’s protocol that I didn’t mention last week:
It is preferred that the child has NOT had radiation before IA treatment, but is not required. They will treat children who have had radiation and have even treated children who have had it twice. After treatment – The child may experience headaches, sickness, fever, backache, groin pain, and loss of appetite immediately after treatment.
On the IDOI FAQ:
What are your thoughts on radiation?Usually we do not indicate radiotherapy in our patients, when we come to need it (very occasionally), we indicate it in a particular way in an attempt of being the least aggressive with healthy brain tissues around the tumor.
Can we get treatment without doing radiation?Yes, that would be ideal. For us, radiation is the last choice.
Most patients who end up at Clínica 0-19 appear to have already had radiation therapy and then shown evidence of recurrence, the recurrence being what drives parents to seek out alternatives. However, telling parents that they should forego radiation therapy in favor of an unproven treatment, saving it for absolutely the last resort while Drs. Siller and Garcia subject their child to their unproven, invasive, and potentially toxic therapy, is the height of irresponsibility.
The more I find out, the more horrified I am
When I first discovered Clínica 0-19 and IDOI, I was willing to give Drs. Siller and Garcia a little bit of the benefit of the doubt. Sure, I was very suspicious based on first impressions that what they were doing was, in essence, quackery, their boasting of using only FDA-approved medications notwithstanding. The more I find out, the more convinced I become that my initial impression was probably correct. All the red flags are there: a highly secretive clinic whose doctors won’t publish their protocol or even survival statistics; charging families enormous sums of money, cash on the barrelhead; no science to support their claims; and a network of patients and supporters who both sell the clinic’s treatment through their testimonials and attack critics. That is Burzynski’s model. It is also the Hallwang Clinic’s model. It is Clínica 0-19’s model.
As a result, patients and families suffer, as we will see in the next installment, which I promise to write before the end of July.
The complete series
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 1
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 2
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 3
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 4
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 5

Clínica 0-19: False hope in Monterrey for brain cancer patients (part 3)
This is the conclusion of my series on Clínica 0-19, the cancer clinic where Drs. Alberto Siller and Alberto Garcia see patients with DIPG, a deadly brain tumor, whom they treat at Hospital Angeles in Monterrey Mexico with an unproven combination of intra-arterial chemotherapy with up to 11 drugs and a poorly defined dendritic cell immunotherapy. Some people have asked me: What’s the harm? In this concluding post, I attempt to answer that question.
David Gorski on July 9, 2018
Link

Over the past couple of weeks, I have been writing about a clinic and doctors whose activities selling an unproven cancer therapy to desperate families of children with diffuse intrinsic pontine glioma (DIPG) for huge sums of money astounded even me, and, remember, I’m the blogger who’s written at least a couple of dozen posts about cancer quack Dr. Stanislaw Burzynski and his antineoplastons. Indeed, it was the resemblance of so many of the stories that I came across of children with DIPG whose families took them to Monterrey in Nuevo Leon, Mexico to Clínica 0-19 to the stories of Burzynski patients that first led me to take notice. The desperation, the false hope, the parents crowdfunding to raise the $300,000 or more plus travel expenses that it cost to undergo the combination of intra-arterial chemotherapy and “immunotherapy” all combined to give me a serious sense of déjà vu.
The only difference was that, in this case, what Drs. Alberto Siller and Alberto Garcia are doing through their Instituto de Oncología Intervencionista (IDOI, or the Institute of Interventional Oncology) at Hospital Angeles involves more invasive treatments than Burzynski’s, including multiple cerebral angiographies (with the attendant sedations and anesthesias necessary) and the injection of up to 11 toxic chemotherapy drugs directly into the brain. Last week, I explained why, based on what I learned of the protocol, this treatment is highly improbable, with doses of chemotherapy too low to do anything even accounting for being injected directly into the arteries leading to the brainstem and a dendritic cell-based immunotherapy that can’t possibly result in a sufficient number of dendritic cells to do anything. Unsurprisingly, this combination therapy is completely unproven, and Drs. Siller and Garcia have never even bothered to publish their protocol or survival statistics, blithely dismissing criticisms based on their failure by saying they’re “too busy saving lives” to publish. The details are here, for anyone who is interested. This week’s installment will, instead of detailing more about why I consider what Drs. Siller and Garcia are doing unethical and almost certainly quackery, focus more on patient stories. If you remember the stories of Burzynski patients, you’ll get the same sense of déjà vu that I have. Then I’ll conclude with some feedback that actual parents sent me and why it is that parents are willing to spend so much money and effort pursuing a treatment that almost certainly does their child no good and has demonstrably harmed some children.
I also want to point out that I do not blame these parents in this, nor do I intend to criticize them. A fuller explanation is in the concluding segment of this post.
Annabelle Nguyen
In my first post in this series, I discussed the case of Addy Joy Sooter, a four year old girl from Arkansas who recently died of DIPG after an 18 month course, mainly because an image that her father took of Addy Joy’s older brother comforting on her deathbed went viral a month ago. That image led me to the Sooters’ story, which led me to news stories that mentioned an “experimental treatment” for DIPG in Monterrey without much description, which led me to figure out the name of the clinic and the doctors, which led me to investigate their claims. In my second post in the series, I briefly discussed Annabelle Nguyen, a four year old Vietnamese girl living in Australia, who a few months ago had been touted by Dr. Siller and his supporters as an example of a complete response, a girl with no evidence of disease (NED), and how the family is now stranded in Mexico because Anabelle’s tumor had recurred and she has lapsed into a coma. Her story is sad and deserves to be considered in more detail.
Perhaps the most succinct description of Annabelle’s initial course comes from a combination of her GoFundMe page and the website that comes up number one for any Google search of “DIPG Monterrey,” Making DIPG History in Monterrey. As I described in both posts, it’s a highly biased website run by a naturopath named Kim Beauchamp, who insinuated that my description of her site as a “fan site” was libelous, a characterization that made me laugh. In any event, here is what happened beginning in August 2015:
Annabelle was diagnosed with DIPG less than a month before her 3rd birthday. Her parents noticed that she was walking differently, wobbling from side-to-side and leaning forward. She also initiated a new bedtime routine of screaming and rubbing her eyes uncontrollably.
They were living in Vietnam at the time, and Annabelle’s first MRI was inconclusive, so they flew to Australia for an emergency follow up scan, which showed a tumor in her brainstem. The medical care in Australia was par for the course for DIPG treatment: radiation, and wait for the inevitable. Annabelle completed 30 rounds of radiation, and then the family returned to Vietnam, where Annabelle’s father Trung took a job with the family business.
The family returned to Vietnam in January 2016, but by May of that year:
While living in Vietnam, Annabelle was treated using acupuncture, Chinese medicine, and qigong. She’d been faring quite well, until a routine scan in May showed that Annabelle was in progression. At this point, Sandy and Trung sought out other options.
They learned about Mexico the way a lot of other families have—through social media. After selling most of their belongings to afford the first treatments, Sandy brought Annabelle to Monterrey, leaving Trung and Annabelle’s 2-year-old sister Alyssa behind. They arrived in Mexico on May 22nd, and Annabelle had had two IA treatments and one immunotherapy at the time we visited with them.
Here we see the extreme similarity to the stories of Burzynski patients with DIPG and other brain tumors. There’s the diagnosis and the shock at how grim the prognosis is. Then there’s the initial conventional treatment. Then there’s the recurrence, after which the family finds the clinic, in this case Clínica 0-19, through the Internet and social media. These days, I suspect that most patients are finding this clinic through Beauchamp’s website, given that it is usually the first hit for Google searches of “DIPG Monterrey” and always high on the list of related searches. Then comes the financial sacrifice, which often involves selling the family home, as the family of an Orlando boy named Alan Vasquez did.
Then there’s the fundraising. So. Much. Fundraising. The fundraising happens on Facebook. It happens on GoFundMe. It happens in the media, particularly in tabloids like the Daily Mail, which frequently post glowing stories about children like Nguyen that help their families to raise still more money. Just like the Burzynski model, Clínica 0-19’s business model relies on the existence of these crowdfunding sites. Without them, few families could manage to fundraise so prodigiously. Crowdfunding sites like GoFundMe and YouCaring are a testament to the inherent generosity and goodness of many people, of their desire to help their fellow human beings, but there’s a dark side. That dark side is that the existence of such fundraising platforms makes the proliferation of clinics like Clínica 0-19 possible and far more profitable given that before only the rich could afford such clinics. It also makes the existence of quack stem cell clinics so much more lucrative, given the prodigious amounts of money that can be raised, as shown in a recent study.
The story continues:
Though Annabelle’s tumor has only shrunk by a small percentage since starting treatment, it shows less contrast, meaning that the cancer cells aren’t as active. This might not seem like a big deal, but this tumor grows aggressively, sometimes killing children in a matter of days to months after diagnosis. So anything that helps slow it down, makes it less active, and shrinks it even minimally is cause for celebration.
Here again, we see another aspect of the story reminiscent of Burzynski patients. Remember Amelia Saunders? Burzynski told her parents that cysts forming in the tumor were a hopeful sign that her DIPG was responding to therapy. I had to explain that they weren’t. Solid tumors, as they grow, not infrequently outgrow their blood supply, so that the central part of the tumor dies and liquefies, which can look more cystic than the rest of the tumor. At this point in the story, I’m getting the same vibe, a lot of handwaving and representing findings as more hopeful than they are, and the same thing could have been happening here. Also, tumors remodel as they grow, and unless the shrinkage is very clear, small differences in size could be misinterpreted as tumor shrinkage when in fact the tumor has not changed.
Then, early this year, stories started appearing about Annabelle, stories like “Australian girl, 5, is miraculously HEALED of cancer thanks to revolutionary treatment in Mexico after doctors gave her just weeks to live when she was diagnosed with an ‘incurable’ brain tumour.” (Yes, it’s the Daily Mail.) The article was horrible, complete with captions like “Annabelle Nguyen (pictured) has been cured of a fatal brain tumour Diffuse Intrinsic Pontine Glioma (DIPG) according to her parents.” It appears to have been largely based on this post by the parents on January 24:
The family shared images from the scans with the newspaper, and you can see them above and in the article. I’m not a neuroradiologist, but first of all there are nowhere near enough images to tell whether the tumor has responded to treatment. (Again, this is a classic Burzynski move being emulated here by Drs. Siller and Garcia.) Second, there’s no way of knowing that what happened with Amelia’s tumor isn’t what’s happening here. Yes, it’s better to have low (or no) PET activity on a PET-CT scan than to have high activity. However, there are a lot of caveats. MRI is the preferred diagnostic imaging test, because, as is explained here, the findings on CT scan can be rather subtle. (Indeed, look at the CT shown here and tell me that it isn’t very similar to Annabelle’s CT.)
Also note this:
Contrast enhancement is seen in the minority of DIPG, and when present is typically mild. There may be some indication of necrosis, and the basilar artery is commonly engulfed by tumor. Hemorrhage and calcification are uncommon.
In other words, these tumors typically don’t light up a lot on MRI. If you look at the PET scans on the same page, you’ll also see that the tumors there are dark (the center part of the images). So, basically, these images don’t tell us anything one way or the other about whether the treatment worked. Yet Dr. Siller told the family:
Here it is: The tumor that was in Annabelle’s pons is no longer visible on any scan, and there is ZERO tumor activity anywhere in her brain. Because of some residual inflammation, they are not able to say for certain that there is no evidence of disease (NED), but they did say that this is the “most perfect report they have seen.”
Without going over the complete set of images of every scan with a qualified neuroradiologist and properly comparing the last few scans with proper measurements according to RECIST criteria (for anyone interested, this is what I mean), I can conclude nothing of the sort. However, that didn’t stop Dr. Siller from telling the parent that, despite her worsening symptoms, Annabelle really was cured:
So what about the scary symptoms? The PET scans also helped determine the cause of those. Annabelle has some hypoxia (low oxygen) and inflammation in the region surrounding the previous location of the tumor, which are likely causing her balance problems and headaches. She also has an infection in her nasal passages that could be contributing to her symptoms. Both of these issues are treatable, and we are already planning how to address them with her doctors.
Now the reality sets in. We know for certain that this treatment is saving Annabelle’s life. But it is expensive, and we are out of funds. Please, please find it in your heart to help her in any way you can. We would never beg for ourselves, but we are begging for our daughter. We chased this treatment to the other side of the world, and Annabelle has to continue it, especially now that we know it’s saving her. Stopping now would mean certain death, and we cannot let our child die.
Can you imagine the horrible burden that was laid on Annabelle’s parents in late January? Because of Dr. Siller, they truly believed that their daughter was cured of an incurable brain tumor but that if they stopped the treatment the cancer would come back and she would die. Thus, they had to keep going with their prodigious fundraising…indefinitely. Again, at this point, I ask: Even if the CT-PET scan were as Dr. Siller claimed, how do they know how long to continue the treatments? They don’t, because they haven’t done anything even resembling a clinical trial. As for the “hypoxia” and “inflammation,” again, without seeing the full set of images I have a hard time commenting, but I can say that my Burzynski quack sense was tingling something fierce as I read that passage. It’s very possible that Drs. Siller and Garcia were mistaking tumor for inflammation. In any event, this story got plastered all over the UK and Australian tabloid media, with claims that Annabelle had been cured, or at least that her tumor had shrunk away to nothing, all based on this Facebook post.
Three months later, Annabelle’s symptoms started worsening again and she started becoming hypoxic, leading her to be placed in a hyperbaric chamber and to be scheduled for another scan on April 28:
Unfortunately, the news was not good:
Basically, Annabelle’s tumor had recurred—again, I doubt that she was ever rendered NED—and begun to progress, with an additional tumor in her pons, and both tumors extending into her cerebellum. What did Dr. Siller and Garcia want to do?
This:
In our discussion with the doctors about our next steps, they said that they want to move her treatments up to every three weeks. They feel confident that they can get the tumors under control by doing this.
Based on what evidence did they want to do this? Again, none. Any competent oncologist would at this point recommend switching to palliative care, to spare the child as much suffering as possible, but not Dr. Siller. Worse, this new plan heightened the burden and horror placed on poor Annabelle’s parents:
Of course, this brings up many concerns for us. We are worried about the possibility of side effects from treatment. While the drugs target and kill tumor cells, they can also cause unwanted effects, including inflammation. But this is a risk that we have to take.
Which leads us to our second concern: finances. We have been struggling to fund each treatment, and pushing them even closer together means we have to raise more money, faster.
I wish I could express the absolute terror that this brings us. Without this treatment, Annabelle WILL die.
I know it’s so much to ask. I know that we ask again and again. But I have to keep asking.
I am on my knees begging you to please keep supporting our precious daughter. She was on her way to beating this beast before, and I know in my heart that she can do it again. But we simply cannot do it alone.
Here, my sadness and empathy for Annabelle and her parents was mixed with pure rage at Dr. Siller for wanting to double down on a treatment that has no reliable scientific evidence of efficacy, thus cranking up the pressure on this poor couple to come up with ever-increasing sums of money because they believed that doing so would mean the difference between life and death for their daughter. Dr. Siller wasted no time, either. The next treatment for her was on May 1. Three days later:
Yes, poor Annabelle became unresponsive and needed the surgical insertion of a shunt to drain the fluid accumulating in her brain’s ventricles. After the procedure, she was basically unresponsive, in a coma. She underwent an EEG, which showed very low activity. A few days later, Annabelle suffered a collapsed lung, most likely a ventilator-related complication:
A week and a half after her treatment, Annabelle underwent another CT scan:
According to her mom, this showed widespread inflammation. It’s at this point that I can’t help but begin to suspect that the treatment was the cause of Annabelle’s acute deterioration that was overlaid on her previous slow deterioration. Meanwhile, the bills kept coming in, $18,000 for the shunt surgery and her time in the ICU up to that point, with, as I mentioned last week, $2,500 per day in hospital charges.
Annabelle’s Facebook feed becomes increasingly hard to read after this point, full of updates with no change in her condition interspersed with news stories and desperate pleas for funds and posts like this, where her mother resists pleas to “let her go”:
It’s here that we learn from a new GoFundMe page that the cost to bring Annabelle home to Australia would be $220,000 USD and that is the goal of the fundraising page. As of Friday, Annabelle’s condition hadn’t changed:
I’ll update this post when new information becomes available about Annabelle
Parker Monhollon
Parker Monhollon was a girl from Silver Lake, Kansas, who was diagnosed with DIPG at age 8 in January 2016 and, sadly, passed away almost exactly a year ago in Monterrey. I’m presenting her case because she suffered quite a few complications during the course of her treatments, thus illustrating that Dr. Siller’s treatments are not only unproven and very likely ineffective, but also not benign. Her story is documented on Making DIPG History in Monterrey, her Facebook page, and her parents’ Parker Loves Life website. It also turns out that, like Amelia Saunders did in the UK, Parker became somewhat famous because of her plight. She got to meet Eminem in Detroit through the Make-A-Wish Foundation, for instance, and a campaign was started to get her onThe Ellen DeGeneres Show.
Parker hit social media like a true child of the Internet age, announcing her diagnosis in a YouTube video on January 16, 2016:
Who wouldn’t be saddened by such a video and want to help this girl? The video got some press attention, leading to the Twitter hashtag #ParkerLovesLife to trend and a number of local celebrities, such as Kansas City Royals pitcher Chris Young making an answering video. Meanwhile, Parker posted near daily updates to her Facebook page Parker Loves Life, some from Memphis, where she and her parents had gone to seek treatment at St. Jude’s Children’s Research Hospital.
Here’s her story:
About a week before Christmas, 2015 Amanda and Danny started to notice that Parker’s eyes were looking different, the left one would stray toward the nose when it should’t [sic] be. She asked her sister to check them out on Christmas day and it was decided to get her an eye exam. Amanda had the eye appointment made for January 19, 2016. Meanwhile Parker’s school nurse had contacted Amanda about concerns with Parkers vision. Amanda told her that an appointment has been made for two weeks from then. The next week the school nurse called again and her and Amanda both agreed that Parker’s eyes looked worse and Parker had complained of headache and some double vision by now. Amanda was able to get her in to see Dr. Hefner on Tuesday January 12,2016 and he told Amanda his recommendation is an MRI, to just rule out anything and then hopefully start vision therapy and possibly an eye surgery if needed.
The MRI was finally done on January 15, 2016. A very long 3 days when your [sic] told your child needs an MRI. Parker was able to do the MRI without sedation which we all thought would get us out of there in plenty of time to take her for her IHOP blueberry pancakes, since she had to go with out food until the MRI at 10:30a.m. They originally planned to sedate her for it so this was great news when she didn’t need sedation because she was so brave and laid still so well for it.
Mom and Aunt Missy were waiting for them to discharge us so we could get Parker those pancakes. This is when our world changed forever. The Pediatric Oncologist and Pediatric Intensive Care physicians came to Amanda and said they needed to speak in private. A Brain Tumor was the diagnosis. A phone call to Dad who arrived and was also given the news. We left there thinking an upcoming surgey, [sic] but needed to wait and hear back from a neurosurgeon for their plan.The next day, Saturday January 16, 2016 we received the news of the type of brain tumor, a DIPG. Now the battle has begun to fight this monster and your support, thoughts, and prayers are very appreciated. #parkerloveslife
Then:
Parker underwent radiation at St. Jude’s Hospital, immunotherapy in Germany, a biopsy of her tumor at UCSF—which ended up disturbing the cells and spreading the cancer to her spine, and re-radiation beginning in October of 2016. In November, Parker asked her mom to look into other treatments, as her right side was becoming weaker. That’s when Amanda discovered Monterrey.
Then began the complications, but even so Parker kept making videos with her parents, for instance here before another round of treatment:
Notice how puffy she’s become, almost certainly from a lot of steroids. Of course, this makes me wonder if at this time Dr. Siller still required patients to have been off steroids for months before he would treat them. It turns out that she was on a steroid taper when this happened:
There was leakage from around the stitches of her Ommaya reservoir. An Ommaya reservoir is a catheter system for infusing drugs into the cerebrospinal fluid. It involves a semi-permanent catheter and a reservoir placed beneath the scalp that can be accessed much like a Mediport. Ultimately, as all too often happens when the incision fails to heal, the reservoir became infected:
Of course, Parker didn’t need an Ommya for the simple reason that there’s no good evidence that the Clínica 0-19 protocol is effective and no good clinical trial evidence that using such a system to infuse chemotherapy prolongs the lives of DIPG patients. Consequently, this was an unnecessary complication, much as Mediport and other catheter infections were unnecessary infections suffered by Burzynski patients.
Parker was basically in the hospital for three weeks without having had any treatment for her cancer because of the complications from the Ommaya reservoir that required placement of an external shunt, and she was having problems with her Mediport, which had been placed a year before, to the point where it had to be replaced. Then, she developed pneumonia and had to be placed on a ventilator, and her left eye couldn’t be closed all the way:
Because of the multiple complications and prolonged hospital stay, this next post started to sound a lot like Sandy Nguyen’s posts:
The family’s financial situation was grim:
Our daughter continues to fight and we love her beyond words. However, the fact remains that with all the love in the world we can not continue to stay in Monterrey, Mexico. We are simply out of money due to the 2+ month stay in the hospital. One month in a regular room and another in ICU. Plus, multiple minor surgeries, antibiotic, pneumonia treatments and now a bladder infection.
We plan to get her well enough to travel home. Then we will continue care in KS which will cost us more money. However, the hope will remain that we will keep her well enough to continue another treatment. We are not giving up, we just don’t have the funds to have another treatment after we pay the doctors and hospital bills. She is such an inspiration that we have seen and continue to see…
Unfortunately, it wasn’t long before Parker developed a recurrent pneumonia:
By then, the hospital bill had climbed to six figures. While this is much less than the bill would have been for such a stay in a US hospital, health insurance wouldn’t cover this, leaving the family on the hook for the whole bill. Interestingly, the doctors there decided to do a tracheotomy, G-tube, and Nissen fundoplication to address her recurrent pneumonias. The doctors must have thought they were due to gastroesophageal reflux and subsequent aspiration of stomach contents. The operation basically involves wrapping the upper part of the stomach around the esophagus to make it harder for gastric fluid to reflux up into the esophagus.
The last two posts are beyond sad. The family was still in Mexico. Their daughter had deteriorated, suffering many complications that had cascaded from the initial insult from the infection of the Ommaya reservoir. On July 5, 2017, Parker’s mother Amanda posted that she basically knew her daughter was going to die. Then, she posted this video. I warn you. It’s hard to watch a mother in such distress describing what has to be one of the worst situations imaginable:
In this video, Ms. Monholland revealed that Parker no longer had any brain activity (i.e., she was apparently brain dead) but that the hospital wouldn’t disconnect the life support because, according to her, Mexico doesn’t allow advanced directives or Do Not Resuscitate orders. That meant, according to here, that they were just going to wait until Parker’s heart stopped.
Doing a little searching, I discovered that it’s not true that Mexico doesn’t have a law permitting advanced directives (it passed one in 2008) but that it is true that the law is not well known. It is also true that palliative care is a big problem in Mexico, with few public healthcare institutions offering it, particularly for children. A review of palliative care in Mexico suggests that the doctors there did not give Amanda Monhollon and the rest of the family accurate information when they informed them that Parker’s life support could not be removed after the child’s neurologic function had ceased or even after she had lapsed into a coma with a terminal cancer. That appears to be a hospital policy, not a law in Mexico. I try not to be cynical, but, try as I might not to, I can’t help but wonder if it isn’t a policy that allows the hospital to recover a few days more of hospital charges.
Parker died the next day.
Ever since I first started learning a lot about DIPG seven years ago as I explored Stanislaw Burzynski’s quackery, I’ve come to hate the disease. What I hate even more, though, are doctors like Burzynski and, of course, Drs. Siller and Garcia, who in my view take advantage of the powerful love that someone like Sandy and Trung Nguyen or Danny and Amanda Monhollon have for their daughters, a love that leads them to do everything in their power to save their daughter’s life, even at the expense of essentially bankrupting themselves, raising their other daughter largely in a foreign country, and ceaselessly begging for money because they believe it’s the only thing that will keep their daughter from dying. Add to that the likelihood that the complications from the Ommaya reservoir infection started a cascade of complications that resulted in Parker’s deterioration and distinct possibility that the last treatment that Annabelle underwent on May 1 might very well have been, given her slow deterioration at that time, what tipped her over the edge into a coma, trapping her and her parents in Mexico until she dies, and my disgust knows no bounds.
This is particularly true given Dr. Siller’s arrogance. I will remind you of something he was quoted as saying in an actual positive news articles on him:
“I told an Italian doctor… ‘if you have something to give to your patient better than what we are using, feel free’,” Dr. Siller said.
I also learned from someone who wrote me that Dr. Siller does not like patients’ parents who are a bit too…inquisitive. Basically the story that was related was that a relative had a child with DIPG and went to Clïnica 0-19 for a consultation. Here’s the story as related to me in an email with permission to post it as long as I anonymized everything:
Prior to my relative travelling to Mexico I assisted him in preparing a list of approx 20 questions for Drs Siller and Garcia including requesting details of all the drugs that would be administered, specific outcome data on all patients they had treated, why their results weren’t published etc etc. The final question was on the ethics of withholding their treatment protocol from international colleagues and thereby precluding children being treated in their own countries without the costs and social disruption frequent trips to Monterrey entail. The answers to the questions were grossly inadequate and the final question made Dr Siller annoyed. My nephew, a lawyer, decided this treatment was not appropriate for his daughter and they returned to Australia. His daughter died in January this year.
All of these questions were entirely appropriate. If Dr. Siller can’t or won’t answer them for potential patients, he cannot be said to be giving them true informed consent, which is also incredibly arrogant, paternalistic, and unethical, so much so that I strongly suspect that Drs. Siller and Garcia know that what they’re doing is ethically unacceptable and quite possibly know that their treatment does no better for DIPG than conventional therapy and possibly even worse.
I emphasize again here that I do not blame the parents. I never have when discussing Burzynski’s patients, and I never will. I can only imagine what it is like to face the impending death of a child and to be told that the only way to save that child is to come up with hundreds of thousands of dollars for what you come to believe to be the only doctors who can possibly save your child’s life, as I’ve never experienced it. I do, however, blame Drs. Siller and Garcia, as well as the leadership of Hospital Angeles, which profits off of the complications suffered by these patients. I realize that that parents of these children might see this post and that if they do it is likely to cause them pain. However, my goal is to provide a counterweight to the overwhelmingly positive coverage that is out there of this clinic, with narratives of heroic parents selling everything and raising incredible amounts of money to save their brave children fighting a deadly disease. The families and parents are brave and admirable in many ways, particularly for their doggedness, but there is no evidence that the treatments they are pursuing are doing their children any good, and, as you see above, there are complications that can happen, serious complications. This is true of any invasive procedure, which is why doctors should insist on the highest standard of science-based medicine in determining when such procedures are appropriate.
Why do parents do it?
After the publication of my first post two weeks ago, in which I discussed the case of Addy Joy Sooter, Addy Joy’s father Matthew emailed me and posted the email in the comments. Basically, he demanded that I remove the viral photo of his son and daughter from my post, claiming copyright. I wasn’t going to argue with a grief-stricken father over whether my use was fair use (it almost certainly was); so I removed it. His other demand was that I remove his daughter’s story from my post. That was a response that I had to decline as kindly and gently as I could. There was nothing about the story that I hadn’t found on public websites, and, as much sympathy and empathy as I felt for Mr. Sooter, he cannot be allowed to control the narrative.
Mr. Sooter did, however, give me an insight into the thinking of many parents. I received emails from a couple of other parents of DIPG patients treated through Clínica 0-19, and they echoed what he said:
In this article you attempt to do nothing but bash and defame other doctors and the clinic that worked so hard to give my little girl more time on this earth. I understand that this is just what you do and have done with others such as Burzynski and his clinic, but have you ever put forward a better treatment option for these families fighting DIPG, or do you only make them feel like they’re crazy for even trying? The doctors in Monterrey gave my little girl 10 months that the rest of the medical community could not and for that I am thankful. Were those months worth the money spent? Yes. Without a doubt and I’d do it all over again.
And what parent wouldn’t have this attitude if he really believed that the doctors had prolonged his daughter’s life? What parent, if he truly believed that a clinic like Clínica 0-19 could either save the life of his child or at least substantially prolong her life, wouldn’t be willing to go to the lengths to which Mr. Sooter went? Clearly, quite a few of the parents of Clínica 0-19’s parents do believe this, and, given human nature, I realize that there’s no way I’m ever going to persuade them differently. All I could do is to restate my position with respect to Clínica 0-19 and all the other dubious clinics that I write about.
If Drs. Siller and Garcia have really made a significant advance in DIPG treatment, it is a moral imperative that they publish their survival and recurrence data and perform definitive clinical trials to show whether or not their treatment has efficacy. If they are unable to conduct such trials, they should ask for the help of the international pediatric oncology community. In the absence of such data, I consider it immoral of them to charge parents like the Sooters, the Nguyens, and the Monhollons hundreds of thousands of dollars for an unproven treatment that might actually be harmful. That they do not speaks very poorly of them. That they make excuses, claiming that they are too busy treating patients to publish their results, that they have been stonewalling Australian cancer experts who want to visit their clinic and examine their patient records in order to determine their survival is unacceptable. They have been doing this for several years, after all. I don’t expect to convince parents like the Sooters, Nguyens, and Monhollons that I’m not their enemy and that I wasn’t trying to criticize or hurt them. I remain, however, the enemy of quacks and those who would take advantage of cancer patients and their families. I make no apologies for it.
The complete series
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 1
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 2
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 3
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 4
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 5

Clínica 0-19: False hope in Monterrey for brain cancer patients (part 4)
Last week, Annabelle Potts, a girl with the deadly brain cancer DIPG, passed away. She had made the news in Australia and worldwide because she had been treated at Clínica 0-19 in Monterrey, Mexico, where Drs. Alberto Garcia and Alberto Siller treat DIPG patients with a secret unproven mix of intra-arterial chemotherapy injected directly into the arteries feeding the brainstem, all while charging tens of thousands of dollars a pop. Also, I was sent an email by a mother who had taken her child with DIPG to Monterrey and gave me permission to publish her story. These two events told me it was time to revisit these cancer quacks.
David Gorski on January 21, 2019
Tweet

Last summer, I learned about a particularly awful pair of cancer quacks whose patients had been making the news in Australia and elsewhere. I’m referring, of course, to Dr. Alberto Garcia and Dr. Alberto Sillar at Clïnica 0-19 in Monterrey, Mexico, who claim to have much better results than conventional treatment for a particularly nasty form of brain cancer known as diffuse intrinsic pontine glioma (DIPG). Indeed, one might say that it’s their specialty, and dozens of families of children with this horrific cancer have made the trek to Monterrey to the tune of tens of thousands of dollars per visit and hundreds of thousands of dollars total per patient to have their child undergo Drs. Garcia and Siller’s invasive interventional radiology procedures to inject chemotherapy straight into the brainstem plus an unproven dendritic cell immunotherapy. I’ve described why these two are quacks in my usual detail in a three part series (part 1, 2, 3); so I won’t go into detail. Rather, I plan on discussing two incidents that led me to revisit these two particularly pernicious quacks.
Many of the patients in the stories about alternative cancer cure testimonials that I’ve deconstructed about over the years had brain cancer, the majority of which were diffuse intrinsic pontine glioma (DIPG), a tumor of the brainstem that is nearly always fatal and, although rare overall, more common in children. It’s true that there are a handful of long term survivors of DIPG reported in the medical literature, and there are occasional patients who show dramatic responses to conventional therapy (and even spontaneous regression), but, by and large, the prognosis for DIPG is very, very dismal. The mainstay of therapy, radiation, is strictly palliative. It will sometimes shrink the tumor, but not eliminate it, and the tumor starts growing again not long after. The added survival time is rarely more than a few months.
This brings me to what led me to revisit Clínica 0-19; a famous patient with DIPG from Australia, a girl named Annabelle Potts, has died:
Longtime readers of SBM and my not-so-secret other blog might remember how I frequently used to blog about cancer quack Stanislaw Burzynski. One of the recurring types of posts that I used to do was to note the deaths of various patients whose families had been the most outspoken advocates for Burzynski. You might remember these names, such as Amelia Saunders, Billie Bainbridge, Rachel Mackey, McKenzie Lowe, and many others. These were the patients who rose to fame (or at least social media fame, which back then was just becoming a thing) through either their crowdfunding campaigns to raise the money to travel to Houston to be treated with Burzynski’s antineoplastons or his thrown-together “personalized gene-targeted therapy” for whatever deadly cancer they had happened to be unfortunate enough to be diagnosed with or for having appeared in one of the two propaganda movies made to lionize Burzynski as a pioneering researcher rather than the quack that he is.
The reason I did this was not to be morbid, nor was it to “dance on their graves”. I had (and have) nothing but empathy and sympathy for the families of these patients and their struggles to deal with a terminally ill family member. Rather, it was to make sure that their deaths did not go unnoted, because one of the problems with alternative cancer cure testimonials, such as the ones provided by many of Stanislaw Burzynski’s patients, is that they can take on lives of their own and outlive the patients who provide them, leading new patients astray and thus endangering their lives. I also wanted to provide closure to my blogging about their stories, given that they were usually patients whose glowing testimonials about Stanislaw Burzynski were used to help him sell his cancer quackery and/or to be weaponized against regulators trying to shut the Burzynski Clinic down.
That’s one reason why I’m took note of the death of Annabelle Potts. Another reason is to point out how the media are complicit in enabling cancer quacks. I will then contrast how these two cancer quacks are portrayed by the media with a story sent to me by the parent of an actual patient who traveled to Monterrey. Some of this I’ve discussed over on my not-so-secret other blog. Some I have not.
Annabelle Potts and the media
Like Stanislaw Burzynski, Drs. Garcia and Siller use patients to promote their quackery. As happened with a number of Burzynski patients throughout the years, credulous and glowing news accounts of patients whose family see Clínica 0-19 as their “last hope” show up in British and Australia tabloids (and sometimes even in US newspapers). Crowdfunding efforts flood the Internet, because Drs. Garcia and Siller charge a lot of money, with bills for patients’ families reaching the six-figure range fairly rapidly, with at least one patient’s bills reaching the high six-figure range. Like the case for Burzynski, families sell their possessions, drain their bank accounts, max out their credit cards, and devote nearly all their time to fundraising because most of them are not rich enough to come up with $300,000 cash in a matter of a few months or less. Annabelle Potts was just such a patient whose family took her to Monterrey. For instance, here’s a story about her from February last year. Note the headline, “Little Annabelle Potts and her family have found hope with brain tumour treatment in Mexico“:
But Annabelle’s battle is far from over. Her family know she isn’t cured, and even though Australian doctors don’t support the findings from Dr Siller and Dr Garcia in Monterrey, Annabelle’s parents believe they are their best shot at buying time until there is a cure.
So that means every six weeks, they cough up $30,000 from anywhere they can find it, sometimes through Facebook fundraising, and Adam takes time off work as a carpenter to fly Annabelle from their Canberra home to visit Clinica 0-19.
Often the struggle is described in heroic terms:
Although last Tuesday was gruelling and at times painful for Annabelle, she barely complained. For the four hours News Corp Australia spent with her preparing for and undergoing two scans, her dad was a calm, solid and gentle presence for the little girl with whom every day is a bonus.
When asked how he was handling it all so well, he said it was far from their worst day in Monterrey.
Such a spin is understandable. No one, other than the parents actually suffering through the ordeal of seeing their child diagnosed with a terminal illness, knows what they are going through. We can only imagine, and the parents are often brave and determined. They go to incredible lengths to raise the vast sums of money required to get their children treated in Monterrey and are there with their children every step of the way, like Annabelle Potts’ father. It’s that inspiring parental love and devotion that Drs. Garcia and Siller take advantage of. It’s that same parental love that lead reporters astray covering these quacks, resulting in stories portraying their quackery as “experimental” treatment rather than a proprietary thrown-together concoction of expensive targeted treatments injected directly into the arteries leading to the brainstem combined with unproven dendritic cell immunotherapy. Never mind that Dr. Garcia drops the old quack excuse of “we’re too busy taking care of patients to do clinical trials” and has refused to let international experts travel to Monterrey to evaluate his methods and help him set up a proper clinical trial. To reporters, the human interest angle, particularly the hope, is the only angle they care about. They don’t really care if the treatment is a legitimate experimental therapy or not.
Even in death, the Australian press is still spinning her story the same way. For instance, here’s 9News:
Canberra girl Annabelle Potts, who has been travelling to Mexico for experimental cancer treatment, has died, her family has announced.
The brave five-year-old travelled to Mexico several times to treat a rare cancer called Diffuse Intrinsic Pontine Glioma (DIPG).
Next up, the “she was told to go home and die” part of the testimonial:
She was diagnosed with the cancer two years ago.
Her battle with the illness and her family’s fight to find a cure had captured the nation’s hearts.
Doctors in Australia had refused to operate on the cancer, citing the size and location of the tumour.
Instead her parents were told to “go home and make some memories with Annabelle”.
This is always followed by the family’s refusal to give up, which is portrayed as brave and the family’s efforts to raise money to pay for the quackery laudable:
But her family did not give up, instead going to Mexico for experimental treatment.
Her fight also came with the added difficulty to paying the bills for her treatment.
Flying to Mexico, where her treatment was unsubsidised, cost her family about $33,000 each time.
But the generosity of strangers helped ease the financial burden of the trips.
The families’ efforts are brave and laudable, but the fact that they are also misdirected and placed in the service of quackery cannot be denied. As for the fundraising for quackery, I’ve referred to this as quacks taking advantage of the generosity of strangers. Crowdfunding has become part of the business model of many cancer quacks. Certainly, encouraging families to take advantage of the sympathy people naturally feel for a child and family in this situation leading to their generosity is part of Dr. Garcia’s and Dr. Siller’s business model. Also, as I recently ranted (a little bit) about, I very much object to the false dichotomy. If there is no curative therapy, we’re told, then the choice is between quackery (albeit not properly described as such) and nothing (i.e., “going home to die”). There is, of course a third and entirely appropriate option, palliative care and, when the time comes, hospice. Palliative care and hospice are not “doing nothing”, and, although they are basically “going home to die”, they are a means of actively making sure that a patient with an incurable terminal condition can live out the last weeks and months of her life with as little suffering as possible.
Another newspaper, The Daily Telegraph, used one of the challenges that Annabelle Potts’ family used to raise awareness of brain cancer:
Just 10 weeks ago Annabelle Potts challenged everyone to suck on a lemon and pull a face in an attempt to raise awareness for “the little kids with bumps in their head”.
The five-year-old had the most devastating of all childhood cancer, diffuse intrinsic pontine glioma, or DIPG.
Yesterday morning she died in the arms of her loving parents Kathie and Adam two years after she had been diagnosed with the brain stem tumour which is always fatal and mostly affects children.
Then, the same narrative:
When Annabelle was diagnosed in December 2016, her parents were told she had just nine months to live and, Kathie and Adam Potts were told to go home and make memories.
In the face of no treatment on offer in Australia, the Canberra family flew to Mexico to trial experimental chemotherapy at a secretive clinic in Monterrey. After 10 rounds at $30,000 a pop, Annabelle’s tumour had shrunk to the point it could no longer be detected. That was March 2018 but the joy was short-lived.
The tumour came back.
For over two years, the Potts have tirelessly campaigned for more money for research, challenging doctors, writing to politicians and facilitating Annabelle’s Lemon Face Challenge.
As I pointed out at the time, the tumor hadn’t really shrunk to the point where it couldn’t be detected. It appears that Drs. Garcia and Siller share another trait with Stanislaw Burzynski, overly optimistic readings of brain MRIs.
Then, here’s the kicker:
On the morning of her death, the Potts finally received what they had been pushing for.
The news report is referencing this:
While it’s a good thing that the efforts of Annabelle Potts’ family have led to money being appropriated for DIPG research, it irks me to see real experimental therapies, like CAR-T immunotherapy and polo kinase-1 targeting, being mentioned alongside Clínica 0-19 quackery, as though they were equivalent.
A child’s story: The reality behind the quackery
In response to my three-part series in June, I received several emails from actual relatives of patients whose parents had taken their children to Clínica 0-19. Their stories, as you might imagine, were heart-wrenching, every bit as much as that of Annabelle Potts or another patient whose plight made the news, Annabelle Ngyuen, an Australian girl of Vietnamese descent whose parents took her to Clínica 0-19 and who was treated in Hospital Angeles in Monterrey, the main hospital out of which Drs. Garcia and Siller operate. As you might recall, this Annabelle suffered a number of complications while in Monterrey that landed her in the ICU at Hospital Angeles. There, she stayed, racking up $2,500 a day in hospital charges and her parents unable to fly her home to Australia because a medical airlift would cost $220,000.
Unfortunately, none of these parents were willing to have their story told publicly, and, as soon as I mentioned that I knew a reporter who was interested in doing a story on Clínica 0-19 and asked if they would be willing to speak with her, they ghosted me. It didn’t matter that, by the time this had happened a few times, I prefaced my request with ironclad guarantees that if they said no I would honor their wishes and never reveal their identities; they ghosted me just the same, to the point where I stopped asking. There was one exception, one parent who was willing to write up an account of her story and give me permission to post it, as long as I preserved her anonymity. I never asked her about speaking to a reporter, because it’s been months since I’ve been in contact with any reporter interested in this story, but she did give me permission to post her story, and here it is, unedited other than to correct minor typos (English appears not to be her first language):
My husband and I had one of the worst experiences in our lives with these doctors. They were totally arrogant, and what they are doing seem to be clearly unethical and unacceptable.
It’s hard for us to write about this because we don’t want to take hope away from all the parents that are here from different countries, I think they are doing the best they can to save their children…and as you said we can’t blame them. I’ve been there, and of course as a parent we do EVERYTHING for our kids. But the doctors seem to be taking advantage of the families’ situation just to make money.
We don’t understand why they don’t officially publish anything on their works, investigations and findings if they are certain that it works. They have been doing it for twenty years!!!
In our case didn’t work at all, our daughter had a brain tumor, not DIPG, but anyway it didn’t work.
She passed away. The doctors lied to us about many things and besides the intra-arterial drugs, they carried out other procedures neither discussed nor authorized by us.
They physically reviewed my daughter just once before the treatment because I asked them to…and never visited her after the treatment! I told them that she was doing really badly after the treatment and they didn’t seem to care at all! They just sent another doctor…and never went to see my daughter again. They didn’t answer my calls, they just didn’t care! We requested the list of the drugs that were used during the treatment to be able to review them with the doctors originally in charge of my daughter’s case, but they strongly refused to share their “magic formula”.
We are worried about all these kids and families that are coming from other countries because there is a lot of publicity about this. I have been doing some research and noticed that the treatments seem to just buy some time to the patients.
I repeat, it’s really hard for me to write about my experience, I don’t want to disappoint all these families that have done a tremendous effort in providing the best to the their children with the hope to save them.
But I think the families should know more about these doctors and the so-called treatment…
Very important too, we felt truly mislead about the MRI results which were apparently manipulated with contrasts and angles to show us supposedly that the brain tumor was reduced after the treatment.
They told me the tumor was a lot smaller, (actually that was the only visit from Dr. Siller at the hospital without looking at my daughter) but we ordered another MRI a week later just to realize that the tumor was even bigger and our original doctors confirmed the unfortunate interpretation of the images.
Our daughter was in a really bad shape after that treatment and she remained hospitalized for many many days to make her stable.. Of course with different doctors that really helped her a lot.
I don’t want to get anyone upset, but I had to let you know.
Maybe I’m wrong because I don’t have the information of all the international patients.
But I felt that I had to tell you my personal experience.
I don’t know how to help those families, they have to know about this…
As I said, this account is difficult to read. It tears me up to note how concerned this mother is with not taking away hope from other parents of children with DIPG or other brain tumors traveling to Monterrey to be treated by Drs. Garcia and Siller, of not upsetting them. After living through a tragic experience that most of us can only imagine with horror, she doesn’t want to cause distress in others living the same experience now. I must admit that I have a hard time understanding this perspective, but then I recognize that I’ve never faced what she has faced, nor have any of my relatives or friends. Unlike her, I don’t face these situations through personal experience. I approach them from the perspective of a skeptic and consumer advocate trying to warn other parents of what I consider to be fraud. As I’ve said many times before, I don’t blame the parents who take their children to Monterrey. Faced with the impending death of a child whom they love, they’re desperate and will grasp at any straw of a chance that might save their child’s life. I place the blame squarely where it belongs, on Dr. Garcia and Dr. Siller.
Also note other aspects of this mother’s story. First, there’s the unwillingness on the part of the quacks to interact with the patient’s family once their child’s condition starts deteriorating. How often have I heard that before, particularly about Stanislaw Burzynski? As long as the patient seems to be doing well, particularly if he’s doing better than the average patient with the cancer he has, quacks will be all jovial and happily interact with the patient. Once the disease begins its inevitable progression and the patient’s clinical situation deteriorates, they disappear. They don’t return phone calls. They farm out the patient’s care to one of their lackeys, as Drs. Garcia and Siller did here, or they basically ghost the parents.
I’ve also heard the part about misreading MRI scans before, too. You might recall that about Stanislaw Burzynski. In stories about patients treated at the Burzynski Clinic, I frequently heard of how Burzynski had told parents and patients that MRI scans showed much better results than they did. One example was the case of Amelia Saunders. Burzynski told Amelia’s parents that the formation of cysts in her tumor meant that his treatment was working when, as I discussed long ago, it didn’t necessarily mean anything of the sort; it could have meant that the tumor had simply outgrown its blood supplies and its center was dying. There are other examples of Burzynski telling parents and patients one thing about their CT or MRI scans and physicians at home telling the them something quite different; in all cases, Burzynski’s interpretation was unjustifiably optimistic.
This mother’s account is also consistent with the accounts of other patients of Drs. Garcia and Siller that I’ve read, such as Annabelle Ngyuen, where they gave the parents unrealistically optimistic interpretations of her brain scans and only provided a few images, nowhere near enough to determine whether Annabelle’s tumor had actually shrunk. They also used the wrong kind of scan to evaluate DIPG properly. Even worse, Dr. Garcia told Annabelle’s mother that she had been cured, but that if they stopped the treatments the tumor would grow back and she would die. (Hint: That’s not what “cured” means.) Still worse yet, when the tumor started progressing again, Dr. Siller recommended increasing the frequency of treatments in order to “get it under control,” thus extracting more money out of the parents.
This mother’s observation of the arrogance of Drs. Garcia and Siller rings true, as well. You might remember Dr. Garcia’s excuse for why he hasn’t done clinical trials. It’s the same excuse that quacks have used from time immemorial (or at least since the era of randomized clinical trials began), namely that he was “too busy treating patients” to do proper clinical trials. Meanwhile, Dr. Siller was quoted in a laudatory article that featured both Annabelle Potts and Annabelle Ngyuen thusly:
The pair is scorned by the international medical community, some of whom label them as cowboys preying on vulnerable parents of dying children. They question their science, the drugs they use, and the scans they use to judge tumour size.
“I told an Italian doctor…’if you have something to give your patient getter than what we are using, feel free’,” Dr. Siller said.
Now that’s some arrogance and callousness. I’ll also quote again an email from a relative of a father of a child with DIPG who had traveled to Mexico for a consultation but ultimately decided not to have Drs. Garcia and Siller treat their children that I received after my original posts on the topic:
Prior to my relative travelling to Mexico I assisted him in preparing a list of approx 20 questions for Drs Siller and Garcia including requesting details of all the drugs that would be administered, specific outcome data on all patients they had treated, why their results weren’t published etc etc. The final question was on the ethics of withholding their treatment protocol from international colleagues and thereby precluding children being treated in their own countries without the costs and social disruption frequent trips to Monterrey entail. The answers to the questions were grossly inadequate and the final question made Dr Siller annoyed. My nephew, a lawyer, decided this treatment was not appropriate for his daughter and they returned to Australia. His daughter died in January this year.
As I said at the time, given that Drs. Siller and Garcia won’t answer these questions, I suspect that they know their treatment is unethical and probably doesn’t work. Also, quacks tend not to like to be questioned too closely (just look at how Stanislaw Burzynski reacts to criticism). Certainly, the abstract they published (which was hard to find) isn’t good evidence, as I will now discuss. Perhaps this is the answer to this mother’s question about why they haven’t published their results; their results are…underwhelming.
The best evidence they can muster?
It turns out that Dr. Siller and Garcia had presented their results in an abstract at a Mexican conference not long before I wrote my original three posts about them, their clinic (Clínica 0-19), and their practice Instituto de Oncología Intervencionista (IDOI). However, I couldn’t find the actual abstract, search as I might. A few months ago, a reader let me know that the abstract could be found, having been published in Immuno Mexico 2018, XII Congress of the Latin American Association of Immunology and XXIII Congress of the Mexican Society of Immunology, and I’ve been meaning to discuss it ever since. The abstract is on page 369 and entitled “Super-selective intraarterial chemotherapy in the primary management of diffuse intrinsic pontine glioma: 2-year experience from an institution in México” by Alberto García, Alberto Siller, Paola García, and Sixto Trejo.
I’m going to reproduce the entire abstract because that will make it easier to discuss:
Introduction: Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive tumor in the pons with a median overall survival of 9 months, ≥90% of patients won’t survive 2 years after diagnosis.
Super-Selective Intraarterial Chemotherapy (SSIAC) is a delivery method that allows higher drug concentrations at the tumor site while exhibiting only mild systemic toxicity due to relatively low levels of the agent in circulating blood.
Aims: The presented study focuses on our experience treating patients diagnosed with DIPG using SSIAC with a non-protocolized, individualized set of Chemotherapeutic drugs.
Experimental strategies: Eligible subjects are under 18 years of age, with a radiological diagnosis or proven DIPG biopsy, excluding those whose tumor extends beyond the pons or with the presence of metastasis.
Initial evaluation and follow-up consist of MRI, PET/CT and Lansky play-performance score.
Results: From March 2016 to April 2018, 62 patient’s clinical and radiological conditions were evaluated and treated by our team with intraarterial chemotherapy. A median of 7 intraarterial procedures per patient were performed. With age ranges between 2 and 17 years, 8 years on average, 22 male and 40 female, with a median of survival after the diagnosis of 489 days and counting.
The follow-up range for these results has a median of 6 months. A median of Lansky score 60% before treatments and a median of 80% after treatments.
45 are with stable disease, none with progression of the disease and 2 of them in remission, all presenting response to treatment. 17 deaths related to treatments prior to our intervention.
Immunological parameters were taken into account to perform the treatments.
Conclusions: Given the inconsistent efficacy of radiotherapy and the limitations of systemic chemotherapy, innovation in adaptable therapeutic methods is a necessity
Patients with DIPG can benefit from being treated with SSIAC, resulting in radiological improvement and better quality of life.
My reaction? Simple: That’s it? These are the fantastic, miraculous results that justify charging families five figures a pop for treatment? Let’s explain why these results are not that impressive, at least as published in the abstract. (Maybe their poster or talk had more information, but somehow I doubt it.) First, though, let’s look at the description of the treatment itself, which is basically bare bones. It’s not unexpected that Drs. Siller and Garcia don’t list the chemotherapy agents used; they never do. Indeed, getting that information out of them has proven to be…challenging. I only obtained such information because a medical oncologist from the UK asked for some information and one patient’s family provided me with a list of drugs used, and my information was not necessarily generalizable because Dr. Siller touts his “individualization” of treatments, which basically means making it up as he goes along. Oh, wait. He objects to that characterization? Until he can describe how he picks one set of chemotherapy drugs for one patient and another for a different patient using a scientific rationale, I will continue to characterize this concoction this way. More odd, no mention of “immunotherapy” is made. The abstract says “immunological parameters were taken into account,” but there’s no way of knowing what the heck that actually means. In any event, this entire conference is an immunology conference. Without the immunotherapy there wouldn’t have been much reason for this abstract even to be submitted to this particular meeting.
One part I found depressing to contemplate was where the number of treatments patients undergo was listed: A median of seven intra-arterial treatments per patient. That’s a median of seven general anesthesias, at least for children too young to cooperate under local anesthesia with sedation; seven angiography procedures, each with its attendant risks of bleeding, unnecessary radiation dosing, kidney failure due to the intravenous contrast dye, and the actual chemotherapy injected. What is not mentioned in this abstract is whether these seven intra-arterial treatments include seven intrathecal treatments as well, given that many of the descriptions I read from parents involved intrathecal chemotherapy as well. (Remember, Parker Monhollon’s cascade of complications began after the insertion of an Ommaya reservoir, a catheter system for infusing drugs into the cerebrospinal fluid.)
But what about the reported results? I find it interesting that the authors didn’t say how they analyzed survival (Kaplan-Meier?) Did they use an intent-to-treat analysis to estimate responses and survival? The authors estimate a median survival of 489 days for their treated patients. That’s basically 1.34 years, or roughly 16 months. The most frequently quoted median survival for DIPG treated conventionally is less than a year, but with a fairly wide range among studies, as summarized by the DIPG Registry. Considered this way, an estimate of 16 months for median survival is at the high end of existing reported studies. It’s superficially impressive but nothing that much out of the ordinary, and that’s if you actually believe that Drs. Siller and Garcia calculated median survival correctly, a contention that, given their history, I am understandably quite skeptical of.
What raised my eyebrows even more was the part where Drs. Siller and Garcia stated that there were 17 deaths “related to treatments prior to our intervention”. Oh, really? How was it adjudicated for each patient who died that the cause of death wasn’t tumor progression or complications from IDOI’s treatment? Now that, if anything, is a determination that would need to be made by an outside doctor, because doctors actually using an unproven “experimental” treatment like that of IDOI can be automatically assumed to be biased, too invested in the therapy to be neutral. That doesn’t go just for this treatment, but any experimental cancer treatment. Let’s just put it this way. Any of those 17 patients who received even one round of the IDOI treatment should be counted for purposes of determining median survival. My guess is that, were that to be done, the survival of this group of patients would not be so impressive. Worse, as has been the case before when Dr. Siller has said that he prefers that patients who come to Clínica 0-19 have not had radiation and requires that the patient be off steroids prior to his treatment.
Then there’s the issue of “stable disease”. Stable disease means disease that isn’t progressing. Let’s just say that I don’t have a lot of faith in IDOI to use appropriate imaging interpretation to decide whether a given DIPG is progressing or not, given what I just discussed earlier in this post. Also, nowhere have I seen evidence that a competent neuroradiologist is interpreting these scans, and I’ve noted in the past that IDOI often orders PET-CT scans instead of the preferred imaging modality for DIPG, MRI. Dr. Paola Garcia, for instance, is on the IMED Hospitals Oncology Service and appears to be a palliative care doctor.
It was also pointed out to me that the IDOI changed its website, adding this about its treatments for DIPG:
A European Society of Pediatric Oncology (SIOPE) and the International Society of Pediatric Oncology (SIOP) collaborative report, which gathers records of Diffuse Intrinsic Pontine Glioma (DIPG) and was published in July 2018, reveals that the average survival rate in more than 700 cases is 11 months.
As of mid-2018, IDOI has treated 67 patients with an average age of 9 years diagnosed with DIPG. After treatment, the median survival was 18 months. Just over 70 percent of the patients had over 1 year of survival and almost 20 percent more than 2 years of survival. The Institute continues to advance and improve.
IDOI stands out as an institution by virtue of its statistics, since it has almost 10 percent of the SIOPE and SIOP patient registry, and for obtaining more favorable patient outcomes on average.
So this sounds as though they added five more patients to the mix, to bring the total up to 67.
In any event, although these numbers sound at least better than average compared to the usual results obtained treating DIPG, there is a lot of reason to doubt that IDOI and Clínica 0-19 have made any sort of breakthrough. One thing, again, is the general shadiness of Dr. Siller’s excuses about why he hasn’t published his results or protocol in the peer-reviewed literature or allowed international DIPG experts from Australia to visit Monterrey, audit his results, and help him set up a clinical trial to test whether his protocol actually improves outcomes for DIPG patients compared to the standard of care.
Another major potential confounder is that there could be considerable selection bias in the patients treated by Drs. Siller and Garcia; i.e., patients whose families can bring them to Mexico are not like typical DIPG patients. First, they are wealthy enough or sufficiently involved and ambitious enough to raise a lot of money very fast to pay for expensive treatments and trips to Monterrey. Such children are likely to be healthier and in better shape from a general health standpoint. Next, the treatment involves long international flights to Mexico every few weeks for treatment. All other things being equal, a child who can tolerate such frequent travel to a distant city is likely to have less advanced disease than a child who cannot. Finally, there’s the requirement that a child receiving this therapy be off steroids for several months. A general use for steroids in neuro-oncology is to control the brain swelling around a tumor. The skull is a closed space, and the swelling caused by brain tumors can cause a dangerous increase in intracranial pressure that can, if allowed to progress too far, kill quickly. Thus, any patient who can tolerate being off steroids for prolonged periods of time, even a period as short as a few weeks, almost certainly has a smaller and/or less aggressive tumor. Ditto any child who can go without radiation therapy long enough to get to Mexico and receive this intra-arterial chemotherapy. The bottom line is that there’s nothing in Dr. Garcia and Dr. Siller’s results that can’t be explained by selection bias and failure to do an adequate intent-to-treat analysis.
The price of pediatric cancer quackery
I end this post, as I end all such posts, by emphasizing that I am not criticizing the parents. The parents of Annabelle Potts, Annabelle Ngyuen, Parker Monhollon, Lucy Moroney, Edie Molyneux, the unnamed child whose mother gave me permission to publish her account, and all the dozens of other children treated by Drs. Garcia and Siller in Monterrey clearly love their children with an intensity that led them to go to incredible lengths to try to save their lives. No family deserves this fate, and I have nothing but sympathy for them. I am, however, calling out the quacks, Drs. Garcia and Siller, for taking advantage of that love by selling false hope to the tune of $20,000-$30,000 per treatment, not just to the Potts family but to dozens of families thus far and counting. I’m also calling out the crowdfunding platforms that make stories like that of Annabelle Potts so depressingly common these days.
Finally, I’m calling out the media for shoehorning all these stories into the same narrative of loving families who had been told to “take their child home and make memories” but refused to give up and instead found an “experimental” therapy, while either not mentioning or very much underplaying the utter lack of evidence for the therapy. Indeed, I just saw another example the other day using that very narrative for Lucy Moroney and Edie Molyneux, both of whom were treated in Monterrey for DIPG and died recently. (They reporter even described Dr. Garcia and Siller’s treatment as “revolutionary” and “pioneering”!) I’m calling out media outlets who then spin the story of the child’s inevitable demise when it happens into a tale of triumph, rather than what it is, the story of a family victimized by unethical and arrogant doctors who to me are more accurately described as quacks.

Clínica 0-19: False hope in Monterrey for DIPG patients (Part 5, A dubious poster is presented)
Clínica 0-19 is a clinic run by Instituto de Oncología Intervencionista (IDOI) Drs. Alberto Swiller and Alberto Garcia in Monterrey Mexico that claims to have a much higher rate of survival for patients with DIPG, a deadly brain cancer, than conventional treatments. Patients come there from all over the world for an unproven concoction of chemotherapy drugs administered directly into arteries feeding the brain, plus dubious immunotherapy. Recently, they published their results in a poster. Let’s just say that their results are underwhelming and do not justify the high cost of the treatment.
David Gorski on November 18, 2019
Link

One of the most painful things to encounter as a doctor is the limit of science-based medicine. Unfortunately, in oncology we encounter SBM’s limits all the time, as most cancers that have spread to sites distant from their organ of origin are still incurable. There are exceptions (e.g., testicular cancer), but for the vast majority of patients with metastatic cancer the only options are palliative, to slow or temporarily reverse tumor progression and to relieve pain and suffering due to the cancer before the cancer inevitably claims the patients. Most brain cancers also fall into this category, and doctors treating these patients bump up against the limits of SBM all the time, most agonizingly when the brain cancer victim is a child suffering from, for example, diffuse intrapontine glioma (DIPG). Of course, as heart wrenching as it is for doctors, nurses, and other caregivers to be unable to save these children, it is nothing compared to the pain that the parents of a child stricken with DIPG experience as their beloved child suffers and her condition deteriorates. It is this pain that understandably leads parents to look for anything, anywhere, that can save their child when SBM can’t. It is this desperation that leads them straight into the arms of cancer quacks. So it is that when one of these cancer quacks that I’ve written about publishes its data, I take note.
A brief recap: Clínica 0-19 and DIPG quackery
Let’s briefly recount some background about the most prominent cancer quacks preying on patients with DIPG. There are two quack clinics that I’ve written about extensively over the years. The first, of course, is the Burzynski Clinic, founded in Houston over 40 years ago by Polish expat physician and non-oncologist Dr. Stanislaw Burzynski. Back in the mid-1970s, Burzynski reported the isolation of peptides in the blood and urine that he dubbed “antineoplastons” whose purpose, he postulated, was a natural cancer suppression system that could be used to treat patients with cancer. He opened his own clinic in the late 1970s and has been administering antineoplastons to cancer patients since then, with only the occasional interruption by an FDA shutdown. Even investigations by the Texas Medical Board failed to stop him. Since then, he’s also branched out to “personalized gene-targeted therapy” (his incompetent take on precision medicine) and selling an orphan drug as a cancer cure. Of note, Burzynski was the first to weaponize his patients against the FDA and state medical board to rally public opinion to his side. Also of note, he’s never published any sort of convincing evidence that his antineoplastons detectably slow the progression of DIPG or other cancers.
The second clinic was founded much more recently in Mexico, and it shares a lot of hallmarks of Burzynski’s “pioneering” cancer quackery. Founded by Drs. Alberto Siller and Alberto Garcia of Instituto de Oncología Intervencionista (IDOI), Clínica 0-19 in Monterrey, Mexico has become a magnet for patients with DIPG. There, Dr. Siller, a pediatric oncologist, and Dr. Garcia, an interventional neuroradiologist, administer combinations of chemotherapy agents injected straight into the arteries feeding the brainstem and the tumor, charging patients up to $30,000 a treatment and requiring ten or more treatments, which are performed mostly at nearby Hospital Angeles. These combinations of agents are proprietary, although occasionally when a patient’s oncologist asks what her patient was given she’s gotten an answer, and that answer doesn’t inspire hope, as Drs. Siller and Garcia apparently use several chemotherapeutic agents with no documented significant demonstrable activity against DIPG at doses much lower than usual. Over the three or four years that Drs. Siller and Garcia have been in operation, they’ve treated dozens of patients from all over the world, resulting in sympathetic stories that ultimately caught my attention. Basically, when you see some variation of the term “experimental treatment for DIPG” in Monterrey, Mexico, in a news story about a patient with DIPG, it’s almost certainly referring to Drs. Siller and Garcia, Clínica 0-19, IDOI, and Hospital Angeles.
In fairness, the idea that intra-arterial chemotherapy for DIPG might produce better results is not in and of itself quackery. After all, there was a pilot phase 1 clinical trial at Johns Hopkins, which was very careful to note that its intra-arterial chemotherapy is not the same as others patients might have heard about. The red flags for quackery in Monterrey are the same as they were with Stanislaw Burzynski and then some:
    • They charge large amounts of money for the treatment.
    • They rely on social media and word-of-mouth to recruit patients from all over the world.
    • They do not publish their results in peer-reviewed scientific journals
In fact, these guys are arguably worse than Burzynski in that they are even more secretive, not even revealing the exact drug combination that they use, except occasionally in private to other oncologists who contact them, and they don’t even try to do clinical trials, making the excuse that they are “too busy treating patients” to do clinical trials while stonewalling Australian cancer experts who wanted to visit their clinic and examine their patient records in order to determine their survival and to help them set up and conduct proper clinical trials.
Drs. Siller and Garcia publish a new case series of DIPG patients
With background taken care of, let’s look at the latest results reported by Drs. Siller and Garcia. They come in the form of an abstract presented a week and a half ago as a DOI México poster for SMeO’s (Sociedad Mexicana de Oncología, A.C.) 6th International & 37th National Oncology Congress. The poster is in Spanish, but an English translation has been provided. The title is “Superselective intraarterial and intrathecal combination chemotherapy in the compassionate management of diffuse intrinsic pontine glioma”.
My first thought reading the title was: Why the use of the word “compassionate”? Are they admitting that their treatment is just palliative? Of courses, as I’ve noted many times before, given that these patients are children, every time they undergo an invasive procedure requiring the puncturing of a major artery with a large catheter, general anesthesia is required because most of the children are too young to cooperate with a procedure like this under local anesthesia with sedation.
The last time IDOI published its results was last year, although I couldn’t get a copy of the abstract until early 2019. Let’s just say that I was less than impressed. Are the results reported with this abstract and poster any better? Not really. For one thing, the Siller and Garcia only added seven more patients to the case series and now have 69 patients (and, when you come down to it, that’s all it really is, an observational, single-arm study, a decent-sized but uncontrolled case series).
Let’s summarize what Drs. Siller and Garcia report this year and compare it to their last report. First, they note:
Superselective Intraarterial chemotherapy is a delivery method that allows higher drug concentrations at the tumor site.
The heterogeneity of the blood brain barrier (BBB) caused by the abnormal tumor vasculature, the invasion of glioma cells and radiotherapy, together with the local administration of hyperosmotic solutions, allow the improved transitory passage of chemotherapeutic agents administered through the BBB.
The administration of chemotherapy by the intrathecal route seeks to prevent tumor implants in the ependyma by neoplastic cells traveling in the subarachnoid space of the central nervous system.
The “compassionate use” of a drug or therapy exists to offer an alternative to patients whose life is immediately threatened with a serious illness or condition, for which there is no satisfactory therapy.
No, at least not in the US. In the US, “compassionate use” is a different term for expanded access, an FDA program that allows patients to receive experimental drugs not yet approved off of clinical trial. Maybe the term means something different in Mexico.
Be that as it may, here is Dr. Siller and Garcia’s description of the treatment used:
The SSIAITCC was performed in a hemodynamics unit, under general anesthesia.
A lumbar puncture was performed for intrathecal administration of cytarabine, methotrexate, topotecan and dexamethasone.
A femoral catheterization was performed for intraarterial administration of mannitol, bevacizumab, cabazitaxel, cisplatin, liposomal doxorubicin, irinotecan, gemcitabine, nimotuzumab, temsirolimus.
The treatments were carried out every 3 to 5 weeks until the therapeutic failure or abandonment of the treatment.
As I’ve noted before, that’s throwing everything but the kitchen sink at the tumor with no rhyme or reason. Some of the drugs are old and not very expensive (e.g., methotrexate, doxorubicin), but some of them are new and damned expensive, with no good evidence to suggest that they are effective against DIPG. Even the most complicated regimens against hematologic malignancies generally don’t contain nearly as much drug. I also find it interesting to note a bit of new information, namely that Drs. Siller and Garcia included steroids in their intrathecal concoction. Recall how they demonized steroids, discouraging their use and requiring that patients be off steroids for months before undergoing their treatment. (In brain cancer, steroids are used to decrease swelling and thereby decrease intracranial pressure.) It’s also interesting that they include mannitol in the intra-arterial concoction. (Mannitol decreases intracranial pressure by osmotically drawing water into the vasculature from the tissues, allowing it to be excreted by the kidneys.)
So let’s look at their results. First, here are the clinical presentations:
69 patients were included in this study, which included 42 female (60.9%) and 27 male (39.1%), with a median age at diagnosis of 6.3 years (range 1.3-17.5 years).
63 of the 69 patients (91.3%) were accepted while the disease was already in progression.
63 of the 69 patients (91.3%) received various treatments, including steroids, radiotherapy and systemic chemotherapy before our intervention.
The IDOI-1 chemotherapy scheme started between day 7 and day 1537 after the initial diagnosis with a median of 215 days.
A median of 9 treatments were performed on each patient.
The results were reported thusly:
100% of the patients evaluated presented a positive clinical and radiological response to the treatment, maintaining Stable Disease, with no evidence of tumor progression or the appearance of new clinical symptoms until therapeutic failure or abandonment of treatment.
The cohort presented a median overall survival after the diagnosis of 590 days (19.4 months) and counting to date.
61 of the 69 patients (89.1%) were still alive 1 year after diagnosis.
23 of the 69 patients (33.4%) were still alive 2 years after diagnosis.
The cohort presented a median increase in KPS from 60% in the initial evaluation to a maximum of 90% during our intervention.
As of July 31, 2019, 56 of the 69 patients have died.
The follow-up interval for these results has a median of 337 days from the start of our intervention, with 804 days being the longest follow-up (and counting).
The figure represents the survival function according to the survival time of the patients, by the method of Kaplan Meier.
I note that stable disease isn’t necessarily a response to treatment. All “stable disease” means is that the tumor didn’t grow appreciably. I note in particular the phrase “until therapeutic failure.” Presumably that means the tumors started growing again, which almost inevitably eventually happens in cases of treating a tumor like this with chemotherapy. Similarly, an important question is why the patients in the latter category (“abandonment of treatment”) abandoned treatment? Was it toxicity? Was it tumor progression? Was it financial toxicity, as some families paid over $300,000+ for all these treatments?
In any event, here’s the Kaplan-Meier survival curve from the poster:
So, yes, Drs. Siller and Garcia present a survival curve that is somewhat better than historical controls. Does that mean anything? As I’ve said before, I doubt it. Why? A major potential confounder is that there was likely considerable selection bias in the patients treated by Drs. Siller and Garcia; i.e., patients whose families can bring them to Mexico are not like typical DIPG patients. First, these families are wealthy enough or sufficiently involved and ambitious enough to raise a lot of money very fast to pay for multiple trips to Monterrey from as far away as Europe and Australia, along with prolonged stays in hotels while their children are treated, plus IDOI’s very expensive treatments. Such children were likely to be healthier and in better shape from a general health standpoint before diagnosed with their disease. Next, aside from the issue of socioeconomic status, the treatment involves long international flights to Mexico every few weeks for treatment. All other things being equal, a child who can tolerate such frequent travel to a distant city is likely to have less advanced disease and a better performance status than a child who cannot. Finally, there’s the aforementioned requirement that a child receiving this therapy be off steroids for several months prior to treatment. A general use for steroids in neuro-oncology is to control the brain swelling around a tumor. The skull is a closed space, and the swelling caused by brain tumors can cause a dangerous increase in intracranial pressure that can, if allowed to progress too far, kill quickly. Thus, any patient who can tolerate being off steroids for prolonged periods of time, even a period as short as a few weeks, almost certainly has a smaller and/or less aggressive tumor. Ditto any child who can go without radiation therapy long enough to get to Mexico and receive this intra-arterial chemotherapy. The bottom line is that there’s still nothing in Dr. Garcia and Dr. Siller’s results that can’t be explained by selection bias.
Here’s another issue. Did you notice something? I’ll repeat it:
The IDOI-1 chemotherapy scheme started between day 7 and day 1537 after the initial diagnosis with a median of 215 days.
And:
The cohort presented a median overall survival after the diagnosis of 590 days (19.4 months) and counting to date.
This goes along with Dr. Siller and Garcia’s results being more about selection bias than anything else. Note that half of these children had already survived more than seven months before treatment ever commenced (median time between diagnosis and treatment by IDOI of over seven months). One had even survived 1,537 days, which is four years, two and a half months! Given that the median survival reported in the huge series to which Dr. Siller and Garcia compared their results was 11 months overall, it makes one wonder. Of course, there’s a nifty little analysis showing that longer symptom latency, lack of CN palsy, and systemic therapy at diagnosis were predictors of long-term survival. A lot of the patients had survived their disease a long time before ever having been brought to Monterrey by their parents. Another question I had is whether Drs. Siller and Garcia used an intent-to-treat analysis. That’s an analysis that includes every patient enrolled in the study, regardless of whether the patient received the entire treatment or even received any treatment at all. There’s no mention of that in the methods. A good statistician would have told them how to do the Kaplan-Meier analysis correctly, but I don’t see the name of a statistician credited on the poster, just Drs. Siller and Garcia. My guess is that they just entered their numbers into a commercially available application without knowing how to set up the analysis first.
The abstract concludes with a case report:
13.8 year old male patient is diagnosed with DIPG on December 15, 2017.
Comes to us with neurological impairment qualified with 50% KPS. The pons, comprising the tumor, covers an area of 13.38 cm2, measured on February 20, 2018. It begins IDOI-1 67 days after its diagnosis, receiving a total of 18 sessions conducted every 3 to 5 weeks. Presents overall clinical improvement qualified with KPS 90%. The pons recovers normal anatomy, measuring 8.25 cm2 on April 1, 2019.
Due to clinical improvement and no radiological evidence of tumoral activity, it is decided to suspend treatment, with periodic evaluations.
As of July 31, 2019, 593 days after diagnosis and 2 months after completing our IDOI-1 treatment, the patient continues to improve clinically, has returned to his daily life and does not present evidence of tumor activity.
Now, I’m not a radiologist, but I’m a bit…skeptical…of the claims made here. For one thing, yes, the tumor no longer lights up on MRI after the treatment, but its outline is still present. Does that mean the treatment worked in this patient? Maybe, but a lot more information would be required to make an inference. You can also be sure that this is the single best example that Drs. Siller and Garcia could come up with out of their case series, because that’s how it’s done. No one chooses anything less than his best example from a case series to present along with a report on the whole series.
Differences in reporting that make one wonder
The issues with the new poster that stand out most to me is that, comparing it with Dr. Siller and Garcia’s previous abstract, I noticed a fair number of differences that make me think something…odd…is going on. These inconsistencies are not subtle, either, and I highly doubt they can be explained by adding a few more patients to the series and following the patients for another year or so. There are also some lapses in description of the treatment, as well as inconsistencies between what was reported before and what I had found out about the IDOI protocol and what is reported in this most recent poster.
Some key differences between what was reported last year and this year:
    • A total of 69 patients in the cohort compared to 62 last year.
    • A median of nine intra-arterial treatments compared to seven in the previous series. Did they do a lot more treatments on the seven new patients included?
    • A median survival of 590 days after diagnosis compared to 489 days reported in last year’s abstract. Could seven additional patients really make that much difference?
    • The new poster explicitly says that intrathecal chemotherapy was also used in addition to the intra-arterial chemotherapy. The prior year’s abstract did not.
    • The previous study noted 17 deaths “related to treatments prior to our intervention” whereas the current abstract says nothing about these deaths. (This would become very important in an intent-to-treat analysis.)
    • The new poster identifies the drugs used, although not the doses.
These differences made me immediately suspicious. The addition of only seven patients should not have made such a huge difference in the survival statistics, unless the seven patients were really outliers. Another question came to mind: Did all these patients receive the same treatments, the same chemotherapy agents? Drs. Siller and Garcia tout their “individualization” of his treatments, and the list of chemotherapeutic agents in this poster doesn’t jibe with the list I got before. Both lists include bevacizumab (Avastin), carbazitaxel (Jevtana), nimotuzumab (Laedemab), cisplatin, and doxorubicin (Adriamycin) for the intra-arterially administered chemotherapy agents. Methotrexate and topotecan were mentioned before, and I had assumed that they, too, were given intra-arterially, but maybe they were administered intrathecally. However, no mention is made in the poster of Zaltrap (ziv-Aflibercept), Opdivo (Nivolumab), or Yervoy (Ipilimumab). Another oncologist who had been in contact with IDOI over its treatment of her patient reported that she was told that the regimen consisted of cisplatin 1 mg, cetuximab 15 mg, doxorubicin 0.25 mg, and Avastin 12.5 mg. There are a lot of inconsistencies here.
Nor was any mention made of the “immunotherapy” that has been touted as part of the IDOI protocol. (Remember the immunotherapy? It appeared to be some sort of unremarkable dendritic cell therapy.)
I also can’t help but note that the protocol in the poster is referred to as IDOI-1, implying that it was the first protocol developed by IDOI and Clínica 0-19 and that there might be more protocols. Given how Drs. Siller and Garcia tout the “individualization” of their treatments and until now have never listed the chemotherapeutic agents in their protocol. I note that they still haven’t reported the doses used, and even on a poster presentation of a clinical trial or case series the doses (or at least dose ranges) are usually reported. Given the number of anecdotal patient reports out there and the claims by Dr. Siller and Garcia that they are “too busy” to do a clinical trial, I highly doubt that IDOI and Clínica 0-19 have treated just 69 patients over the last three years. Indeed, I strongly suspect they’ve cherry picked cases for this series, and, again, what happened to the deaths reported in last year’s abstract that they blamed on previous treatments?
This highly dubious poster presentation is yet another reason why it is imperative that outside experts in neurooncology and clinical trial design, as well as qualified statisticians, be allowed to examine the medical records of patients treated by Drs. Siller and Garcia and carry out an independent analysis of their results. Whether the inconsistencies in their reporting of their results are due to incompetence in reporting clinical evidence from case reports or fraud (and it could easily be either), it is imperative that someone who knows what they’re doing analyze the survival statistics, complication rates, and other data, after having found out which treatment modalities and drugs (along with dosages) were actually used for each patient. It’s also critical that we learn how many patients Drs. Siller and Garcia have really treated and at what cost. In the meantime, they should be forbidden from providing any more treatments with their protocol until the analysis and inspection of their facilities are complete. In a country with a functioning regulatory body for medicine, this would happen. Sadly, Mexico is not such a country, which is why I’m not optimistic that this will happen any time soon. I fear that Drs. Siller and Garcia will continue to sell what is almost certainly false hope to desperate parents of children with DIPG at a high price for some time to come.

The complete series
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 1
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 2
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 3
    • Clínica 0-19: False hope in Monterrey for brain cancer patients, part 4
    • Clínica 0-19: False hope in Monterrey for DIPG patients, part 5

German alternative cancer clinics: Combining experimental therapeutics with rank quackery and charging big bucks for it
You think that Mexico has the most quack cancer clinics? Don’t be so sure of that. When it comes to clinics peddling a mix of snake oil and a dash of real medicine, Mexico’s got nothing on Germany.
David Gorski on October 24, 2016
Link

A couple of months ago, I discussed patient deaths at an alternative medicine clinic in Europe, where a naturopath named Klaus Ross had been administering an experimental cancer drug (3-bromopyruvate, or 3-BP) to patients outside the auspices of a clinical trial. 3-BP is a drug that targets the Warburg effect, a characteristic of cancer cells first reported in the 1920s by Otto Warburg in which the cancer cell changes its metabolism to shut off oxidative phosphorylation (the part of glucose metabolism requiring oxygen that produces the most energy) to rely almost exclusively on glycolysis and anaerobic metabolism. From a cancer cell evolution standpoint, one can understand why cancer cells would behave this way, as this change allows them to survive in environments with much less oxygen than normal cells, but the side effect of the Warburg effect is that cancer cells consume a lot of glucose for their energy needs. Indeed, positron emission tomography (PET scanning) takes advantage of this characteristic of cancer cells to use glucose labeled with a positron-emitting isotope that accumulates in cells. The result is that cancer cells, which in general use a lot more glucose than normal cells, light up compared to the surrounding tissue, allowing the identification of areas suspicious for cancer. Targeting the Warburg effect is therefore a strategy to attack cancer cells preferentially.
Since I wrote about the tragic deaths of those cancer patients, I’ve been seeing stories about German alternative medicine cancer clinics popping up in my newsfeed over and over again. Intuitively, you’d think that a scientifically advanced economic powerhouse like Germany would have stricter regulations over the practice of medicine, but, the more I looked into these clinics, the more I realized that there are a lot of quack clinics in Germany every bit as quacky as any clinic in Tijuana, but with a twist. Like Mexican alternative medicine clinics, German clinics often charge enormous sums of money for treatments that range from the unproven to the dubious to pure quackery. However, in addition to the rank quackery, German cancer clinics include legitimate experimental drugs that are as yet unproven and might even only have cell culture or animal evidence supporting its potential efficacy. Indeed, 3-BP is just such an example. It is a legitimate candidate cancer drug that’s in the pipeline, having shown promise in cell culture and animal experiments, but that has no human data from systematic clinical trials yet, just a handful of anecdotes when it was tried in humans under desperate circumstances. Not surprisingly, Klaus Ross’ main clinic is in Germany, and, like so many other clinics there, he was administering an as-yet-unapproved drug to humans.
So, prodded by a couple of recent stories from the UK, I decided to take another look at these German cancer clinics.
“Written off” by doctors and now doing well
In the world of alternative medicine cancer cures, testimonials for a treatment almost always include the patient bitterly recounting that conventional oncologists “wrote her off” before she discovered whatever miracle cure that she believes to have saved her. There are many variants. There’s the “I was given six months to live” (or one year or two months or whatever) trope, followed by the exulting that it’s now several years later and “I’m still alive.” There’s the “doctors told me to put my affairs in order” trope. It turns out, though, that the vast majority of the time, the patient’s good fortune to remain alive can be explained by the biological variability of the disease, a mistake on the doctors’ part in estimating prognosis (always a tricky and inexact art), or a better response than expected to previous treatment with conventional medicine. Sometimes, these anecdotes rely on exaggeration on the part of the alternative medicine practitioner about the odds of surviving. I’ve deconstructed more of these testimonials over the years than I can remember.
Stanislaw Burzynski, the Polish expat physician (but not oncologist) who treats patients with what he calls “antineoplastons,” is a master of this technique and several others to make it look as though he is saving lives when in fact he is not. For example, he routinely brags that there has never been anyone who has survived, for example, diffuse intrinsic pontine glioma (DIPG), and thus if there is any patient of his who survived it must be because of his antineoplastons. While it is true that the vast majority of patients with DIPG do very poorly, it is not true that none survive. There is even a registry of survivors maintained. Burzynski is also a master of exploiting diagnostic uncertainty. Because DIPGs, by definition, are located in the brainstem, often they are not biopsied because of the hazard and instead are diagnosed based on how they appear on MRI. It turns out that there are MRI abnormalities that can mimic the appearance of DIPG but are something else. Then there is biological variability. For example, deadly gliomas are indeed almost uniformly fatal within 12-18 months, but there is a “tail” to the survival curve, and patients surviving five years and beyond, while definitely not common, are not as uncommon as Burzynski would have you believe.
I mention biological variability because another aspect of these stories that can mislead the public is that patients frequently don’t understand that not enough time has passed to say with any confidence that they are survivors. This brings us to the story of Pauline Gahan, a rather extreme and sad version of this aspect of alternative cancer cure testimonials.
Because I have Google Alerts set up for various terms related to alternative medicine and cancer, I frequently become aware of stories about alternative medicine cancer cures. Such was the case last week, when a Google Alert led me to this snippet from an interview that aired Thursday a BBC Radio 5 show, under the title ‘Why I spent 300k on “unproven” cancer treatment’ abroad‘.
This is a shorter snippet from a longer interview by Emma Barnett on 5 live Daily from October 20 with Pauline Gahan, a woman who spent £300,000 at a German alternative medicine clinic to treat her metastatic stomach cancer. To raise the money, she sold her house and her car, renting her house back so that she could continue to live there. The full segment begins around the 10:25 in the three hour radio show. Unfortunately, the story is framed around the question, “What do you do when the NHS says no? What extent will you go to?” Barnett does then note that an oncologist, Professor Karol Sikora, has expressed concern about patients from the UK are spending “vast amounts of money” on experimental treatments abroad with no proof of benefit.
A celebrity testimonial
We’ll get back to the full interview in a moment, but first I have to mention another pernicious phenomenon exhibited by this interview, and that’s the celebrity testimonial for alternative cancer cures. The first one I remember covering, at least with respect to German cancer clinics, is that of Farrah Fawcett, who in 2007 sought out a German cancer clinic for “experimental” treatment of her recurrent anal cancer. Although her publicist denied vehemently that she was being treated with alternative medicine, I couldn’t help but note that she was treated at Klinik Winnerhof in Bad Wiessee, which at the time was best known for galvanotherapy, also sometimes called bio-electric therapy. Not surprisingly, it is unproven and implausible. We don’t know whether Fawcett used galvanotherapy, but we do know that she did go to a clinic best known for offering it and that ultimately she died of her disease in 2009 at the age of 62.
Before interviewing Pauline Gahan, Barnett referenced the story of British actress Leah Bracknell, best known for having played Zoe Tate in the British soap opera Emmerdale from 1989 to 2005, who was diagnosed with stage IV lung cancer recently. What brought Bracknell into the news, aside from her being a celebrity with a terminal cancer diagnosis at a relatively young age (52), is that she has been raising money to go to a German cancer clinic. The last report I saw showed her having raised £30,000 of the £50,000 needed. Indeed, Prof. Edzard Ernst wrote about her story a couple of weeks ago noting:
Why Germany? You may well ask.
Germany has long been praised by fans of alternative medicine for its liberal stance on all sorts of unproven or disproven treatments. In Britain, there are just a few physicians who are devoted to alternative medicine; in Germany, there are thousands of them. In addition, Germany has a healthcare profession called the ‘Heilpraktiker’, a poorly regulated leftover from the Third Reich. Recently, a German Heilpraktiker was implicated in the deaths of several cancer patients who had travelled from abroad to receive his treatments, because German law is more liberal in these matters than other European countries. A Heilpraktiker has not studied medicine, yet is legally permitted to make all sorts of unsubstantiated claims and treat many serious diseases with unproven therapies.
Ernst notes that the German clinic to which Bracknell wants to go is the Hallwang Private Oncology Clinic. It turns out that this is very same clinic at which Pauline Gahan is being treated. So it’s worth taking a look at this clinic, what it offers – and what it claims.
Hallwang Private Oncology Clinic: Quackery, quackery, quackery
Upon learning the identity of the clinic where Bracknell wants to go and Gahan has gone, it befell me to fire up Safari and check out its website. Not surprisingly, the Hallwang Clinic website contains a number of very obvious red flags. For instance:
Healing-oriented and individualised medicine considers all aspects of lifestyle and not only relies on conventional treatments and recent cutting-edge developments in medicine, but also takes into account our experience in natural remedies and is open for alternative treatment options in order to work in synergy with conventional treatment strategies. We always try to be as natural as possible and as conventional as needed to achieve the best results. Integrative Health Concepts are successfully used in many diseases including malignant diseases, neurological disorders as well as in prevention and rehabilitation.
That’s nothing more than the usual blather you see on most integrative medicine websites, but take a look at what Hallwang offers: homeopathy, dichloroacetate (DCA), micronutrients and orthomolecular medicine, high dose vitamin C and other nutrients, whole body hyperthermia, ozone therapy and hyperbaric oxygen, and “many more according to your needs.”
It should hardly need to be mentioned to SBM readers that homeopathy is pure quackery, but, given that its inventor Samuel Hahnemann was German, German quacks still seem to love it. I discussed DCA in the context of my discussion of 3-BP, because both drugs have a similar mechanism of action in that they both target the Warburg effect. DCA became popular among cancer quacks back in 2007 after a promising rodent study was published and made the news. Eventually, a pesticide salesman named Jim Tassano started importing DCA, which is easily synthesized, from China and other places, and selling it online. Thus was born DCA as an alternative cancer treatment. Like 3-BP, it is a legitimate experimental drug. It even has more evidence in humans that 3-BP. Unfortunately, like 3-BP, it is still thus far unproven, and its having been co-opted by quacks makes it doubtful that it will ever be validated as an effective cancer treatment. Then, of course, orthomolecular medicine and high dose vitamin C (and other vitamins) are pure quackery, as are ozone therapy and hyperbaric oxygen therapy (HBOT). HBOT has legitimate uses in burns and wound healing, but for cancer, not so much.
So what we have here is a clinic offering a variety of quackery, but there was another red flag, one that I can’t recall ever having seen on any alternative medicine clinic website before. Actually, more appropriately, it’s something I don’t recall ever having failed to see: who’s running the clinic and who the doctors are there. For instance, under Your Physicians, the website says:
We take pride in the commitment of our physicians to provide excellent care to our patients and their families.
Our team of head physicians and experienced clinical residents is specifically trained in internal and oncological medicine and lead an intensive research and academic program on cancer medicine.
That’s nice, but who are these physicians? I looked throughout the website and couldn’t find them. I did Google searches and couldn’t find out who runs Hallwang. Even the quackiest of quack clinics and naturopaths identify who runs the clinic and post short bios. The same sort of information-free blurbs can be found under Nursing Team. No, wait. There was one exception. The section on Psycho-Oncological Care shows a photo of someone named Benjamin Morlok, but not much else. Morlok has a Facebook page and a website, which identifies him as a financial coach, dream therapist, and cancer counselor. To say that I found this very odd and troubling is an understatement. Notably, Barnett also notes on her radio show that she tried to get someone from Hallwang to provide comments but that the clinic representative said that Hallwang’s policy is not to do interviews. Nor would the clinic provide evidence of how successful its treatments are. Not having any names, I was unable to find anything on PubMed published for Hallwang Private Oncology Clinic, and searching for the clinic name turned up nothing.
I was able to find a name, Dr. Jens Nolting, mentioned by patients on discussion boards here, here, and here, but I was able to find little or nothing else out about him.
Color me unsurprised.
The false cancer narrative: Hope versus the NHS
With that background, let’s circle back to the story of Pauline Gahan. First, however, let’s take a look at the sort of news coverage she’s engendered in the UK media. Here’s a sampling of typical headlines:
    • “Woman who was ‘written off’ by doctors in the UK is now responding well to cancer treatment in Germany“
    • “NHS told me I was going to die of cancer… but now I’ve almost beaten the disease, thanks to treatment in Germany“
    • ‘Family of terminal cancer mum “written off” by UK docs say life-saving treatment in GERMANY having “profound effect”‘
    • “Terminally ill mum close to beating cancer“
    • “Wunderbar! German Docs Give Cancer Gran New Hope ; TERMINALLY-ILL WOMAN RESPONDS TO SPECIAL TREATMENT AFTER BEING ‘WRITTEN OFF’ IN UK“
    • “I sold my house to fund cancer treatment in Germany“
There’s another pernicious narrative buried in these alternative cancer cure testimonials that is particularly prominent in stories out of the UK, and that’s to blame the NHS for not covering unproven treatments. Basically, many of the stories are spun in such a way as to portray the NHS as cold and heartless for not paying for unproven cancer treatments, which are portrayed as the patient’s only chance to live, whether they actually are or not:
Another example is here.
Notice how at the end of each story, it’s pointed out that the Gahans will have to raise a lot more money to continue the treatments.
It’s a narrative that popped up time and time again five years ago, when there seemed to be a steady procession of British patients with incurable brain tumors raising money in a very similar way to how Gahan and Bracknell are raising money to go to the Burzynski Clinic in Houston. Story after story portrayed these patients as victims of the NHS and the NHS as being too interested in saving money to pay for Burzynski’s “experimental” treatment. Being a government entity, the NHS was also an easy target for those with a political ax to grind. Never mind that the NHS trusts are quite reasonable in not wanting to waste government funds to pay for ineffective or unproven treatments in foreign countries. In fact, it would be quite irresponsible for the NHS to do otherwise. After all, should the NHS pay £300,000 for an unproven treatment? It just doesn’t make sense.
So what treatments did Pauline Gahan undergo, anyway?
So back to the story of Pauline Gahan, as told to Emma Barnett. Basically, she was admitted to the hospital in May with leg pain after a flight home from Australia, which turned out to be due to deep venous thromboses. She suffered internal bleeding from anticoagulation, which led to an endoscopy, which found stomach cancer. She had two “operations” for her clots. It’s not clear to me what those might have been, unless she underwent thrombectomy. She even admits that the reason she had trouble walking was because of her DVTs, which meant that she couldn’t fly to Germany and instead went there in a camper van. After three weeks there, she states that she felt much better. That could partially explain the pictures of her looking so ill back in May compared to how she looks now, which is much better. She was probably fresh from her diagnosis and the procedures done on her. Be that as it may, once again, a familiar story is told. A patient receives a devastating diagnosis. She hears testimonials from a dubious clinic. She decides to go there, but it’s expensive. So she and her family sell the house and car, undertake prodigious fundraising (e.g., through GoFundMe), and go to the clinic
Having been able to find so little in various news stories and on the Hallwang website, I was actually most interested in how Gahan described her initial treatment. According to her, every day she had five or six infusions, including vitamin B, and “liver detox.” That didn’t interest me much, as it was fairly run-of-the-mill quackery that you can find at any naturopathic clinic. My main concern with the quackery is that none of it is effective for anything other than draining a patient’s wallet and that we have little idea how these treatments might interfere with the use of real medicines. Gahan also mentioned something that sounded like “renavap,” but I couldn’t quite catch it. There is something called RenaVast, which is an unapproved veterinary drug claimed to be able to treat renal disease. Somehow I doubt that’s what the clinic gave her, as she said they told her it would transiently raise her body temperature. I note that German alternative cancer clinics are very big on whole body hyperthermia, but this sounds like a half-assed attempt at it, because usually when it’s done it requires the use of whole body thermal chambers or hot water blankets. There’s also not a lot of evidence that whole body hyperthermia is an effective adjunct to treat metastatic cancer, although there are clinical trials ongoing. It is at best experimental.
Again, one of the key characteristics of German alternative medicine clinics, particularly when compared to Mexican alternative medicine clinics, is that they often combine unapproved and experimental drugs with all the quackery. (True, Mexican clinics often administer stem cell treatments.) That’s why the next part of the interview is where my ears pricked up. Gahan mentioned that her immunotherapy consisted of a drug called Keytruda (generic name: pembrolizumab). This is a member of a class of new biologics and drugs known as immune checkpoint inhibitors. It’s a drug that is FDA-approved for metastatic melanoma and metastatic non-small cell lung cancer, with clinical trials having accrued for metastatic head and neck cancer and urothelial cancer.
I recently discussed immune checkpoint inhibitors, such as drugs and antibodies targeting PD1, a key protein, in the context of Vice President Joe Biden’s Cancer Moonshot initiative. Basically, drugs like Keytruda target Programmed T cell death 1 (PD-1), a membrane protein found on the surface of a class of immune cells (T cells), which, when bound to a protein known as programmed T cell death ligand 1 (PD-L1) on tumor cells, results in suppression of T cell activity and reduction of T cell-mediated immune responses. That’s why PD-1 and PD-L1 are referred to as immune down-regulators or immune checkpoint “off switches.” Targeting this off-switch, shutting it down, can reactivate the body’s immune response against the tumor. There’s no doubt that immune checkpoint inhibitors are a big deal, and this class of drugs is one of the hottest areas of research in academia and pharma today. In some cases, dramatic responses have been observed using these drugs.
On the other hand, immune checkpoint inhibitors are no panacea. Even the Cancer Moonshot report acknowledges this:
The success rates of first-generation cancer immunotherapies, such as checkpoint inhibitors, genetically engineered T cells, and new immune activators have improved remarkably over the last 10 years, resulting in durable, long-term survival—and, in some cases cures—for a subset of patients with advanced cancers such as melanoma, blood, and lung cancers. However, only 10-20% of patients with these cancers have long-term responses to current immunotherapies. We must learn why some patients who have melanoma (such as President Carter) or lung cancer respond to checkpoint blockade immunotherapy, whereas patients with many other types of adult cancers, including ovarian, breast, pancreatic, brain, and prostate cancer—as well as most pediatric cancers—have brief responses or do not respond at all.
Gahan has stomach cancer, and there is actually evidence that Keytruda is active against stomach cancer—if the cancer makes PD-L1. The Lancet recently published a phase I trial of Keytruda in gastric cancer that studied 39 patients, 36 of whom were evaluable for tumor response. Eight patients (22%) were deemed to have had an overall response, but all responses were partial. Given that gastric cancer generally doesn’t respond well to chemotherapy, these results were actually pretty good, good enough to be considered sufficiently promising to warrant phase II clinical trials. It is, however, no miracle cure, contrary to the way it’s being represented to the press, which is how Hallwang appears to have represented it to Gahan. Actually, it’s not being represented at all, because most of the news stories don’t bother to identify the immunotherapy being used at Hallwang. They just call it “immunotherapy.” It wasn’t until I actually listened to this interview that I could figure out which specific experimental treatment that Hallwang was actually using.
Hallwang also used some sort of vaccine therapy, which Gahan describes as having been made from her own DNA. It’s hard to tell what, exactly, Hallwang was doing, but it sounds like a neo-antigen vaccine. The basic idea behind such a vaccine is simple, although the production is very difficult. Tumor is collected by biopsy. Its DNA is sequenced and compared to the DNA sequence of normal cells. Mutations in the cancer cells are identified, of which there can be as few as ten or as many as thousands. Bioinformatics algorithms are then used to identify which mutated genes make cell surface proteins that could potentially serve as antigens, and peptides are synthesized in the laboratory based on the identity of those proteins to make a vaccine. The problem, of course, is that this technique is highly experimental as well, as this review article and article in the lay press show. It’s also, at least for now, very expensive because of all the sequencing, analysis, and synthesis of custom peptides that are required. Basically, it’s not clear whether these vaccines will pan out.
Did Hallwang cure Pauline Gahan?
Reading this story, you might well ask the question: Did Hallwang cure Pauline Gahan? It’s a reasonable question given her glowing testimonial and apparent good health now. The answer, sadly, is: Almost certainly not. I can hope that she is cured, and I can be happy that she is doing well, but my scientific knowledge of the natural history of metastatic gastric cancer tells me that she is incredibly unlikely to have been cured.
Unfortunately, the way this story has been presented is that Gahan is “almost cured.” However, remember that she was only diagnosed less than six months ago. That’s nowhere near enough time to tell if she’s even survived longer than expected. For one thing, the five year survival rate for stage IV gastric cancer is 4%. So people treated normally with conventional therapy can and do survive five years. It’s very uncommon, but it happens. In fact, Gahan has just passed her expected median survival for a woman age 55-64, roughly five months. While I can understand the Gahans’ joy that their mother is still alive, from an oncology standpoint it’s hard to be too optimistic about how she’s doing less than six months after diagnosis. Not nearly enough time has passed.
Since none of us have seen the scans, we can only rely on her report that the tumors in her stomach, esophagus, and lymph nodes have disappeared and that she only has tumors left in her liver. What that means is that, after £300,000 of experimental drugs mixed with pure quackery, Gahan has had a respectable partial clinical response. In other words, she’s one of the lucky 20% or so whom we would expect to have had a partial response to Keytruda based on the study I cited above. Unfortunately, partial responses are not cures, and there’s little reason to expect that further treatment will eliminate the remaining tumors. It might, but even if that happens the most likely outcome will still be recurrence and death. We know this because we know gastric cancer is a nasty actor and that, once it’s metastasized, long term survival is very rare. Also, while there is no doubt that tumor shrinkage in response to therapy is certainly better than no shrinkage or tumor growth, tumor shrinkage often does not correlate with prolonged survival.
Perhaps the worst part of writing about these stories is having to be the voice of reality. That’s often misinterpreted as being the voice of doom, and I’m acutely aware that, should the Gahans read this, they will think I’m trying to crush their hope. In actuality, I really do hope their mother is cured and can live a long time, but that hope does not change my assessment of the Hallwang Private Oncology Clinic, which is selling false hope to desperate cancer patients like Gahan at a very high price. It doesn’t change my opinion that the Hallwang Private Oncology Clinic is engaging in very unethical behavior.
Hallwang: Combining quackery with misuse of cutting edge treatments
In thinking about the Hallwang Private Oncology Clinic and the many German cancer clinics that operate in a similar manner, I have to conclude that they are as bad as Stanislaw Burzynski, if not worse. Hallwang, for instance, doesn’t publish its results and won’t even report its results. Its Facebook page might be full of testimonials of happy patients whose lives Hallwang claims to have saved and glowing scientific reports about immunotherapy of cancer, but none of these scientific reports actually come from Hallwang.
Basically, like any good con, Hallwang asks patients to trust its doctors, to take it on faith that its protocols do what is claimed for them. It does this in order to extract large quantities of money from their wallets, even if it forces them to do things like Gahan, such as selling their houses and other valuables, taking to the Internet to raise money, and going into deep debt to pay for a combination of seemingly state-of-the-art experimental therapies that haven’t been approved or validated for what they’re being used for plus outrageous quackery. After all, believing that Hallwang is the only place that can save your life is powerful motivation to go out and raise that money. As Prof. Sikora put it later in the interview, Hallwang uses very experimental treatments in a “blunderbuss” fashion, basically throwing everything but the kitchen sink together with no sophistication. We can’t even know if these doctors know what the hell they are doing. Patients are treated, and, as far as we can tell, no systematic record of how well these patients do and how long they survive is kept, or, if such records are kept, they are kept secret.
That’s the worst thing of all. Think of it this way. What if the doctors at Hallwang and other German cancer clinics really do have protocols using experimental drugs that cure cancers that can’t now be cured and save lives that can’t now be saved by conventional medicine? Failure to publish these protocols and their results is not just unethical, it’s downright criminal because, without publication, no other patients can benefit from their protocols unless they come to Hallwang. The doctors at Hallwang basically treat their protocols as trade secrets, so that their clinic is the only place such good results can be obtained.
That’s the best case scenario. Now let’s look at the worst case scenario.
Consider another possibility about clinics like Hallwang. Their protocols don’t work any better than conventional medicine. They almost certainly don’t even work as well as conventional medicine. However, combining a “make it up as you go along” approach to the use of experimental drugs with the addition of “holistic quackery” appeals to desperate patients who want hope, are prone to believe the “best of both worlds” sales pitches, and like the idea of “individualized” treatment regardless of whether it really is or not. Publishing their true results would be a threat to their ability to charge outrageous sums of money to patients like Pauline Gahan.
Of the two possibilities, the first is criminal, and the second is even more criminal. I also know which possibility that I consider more likely.

Cancer quackery from Germany to Australia
Sadly, cancer quackery is a worldwide phenomenon. Here, we examine its reach from Germany to Australia.
David Gorski on November 4, 2016
Link

Last week, I wrote about alternative medicine clinics in Germany that offer a combination of alternative cancer cures plus experimental therapeutics administered improperly outside the auspices of a clinical trial. In particular, I discussed two cases. The first was British actress Leah Bracknell, who is raising money to go to one of these alternative cancer clinics to treat her stage IV lung cancer. the second was a British woman named Pauline Gahan, who was diagnosed with metastatic stomach cancer and has thus far spent £300,000 for a combination of vitamin infusions, “detox,” and Keytruda (generic name: pembrolizumab). This is a drug belonging to a new class of promising anticancer therapies known as immune checkpoint inhibitors. It’s FDA-approved for some cancers, but hasn’t yet been shown to be effective against stomach cancer, although there is one phase I trial that is promising and thought to be sufficient evidence to justify phase II and III trials. None of this stopped the clinic to which both Bracknell and Gahan traveled, the Hallwang Private Oncology Clinic.
One thing I noticed about the Hallwang Private Oncology Clinic when I wrote about it is that nowhere did it list the doctors who own and operate it or who consult there. I did find one name, Dr. Jens Nolting, mentioned on patient discussion boards as working at Hallwang. The lack of mention of who runs the clinic and who practices there was an enormous red flag to me, I think for obvious reasons. Fortunately, a commenter with more knowledge than I and thus a better idea of what to Google for, jumped in to comment and helped out. So I thought I’d do a follow-up post and then segue to a report that aired on Australian TV on alternative medicine for cancer there to show the consequences of clinics like this, which are, unfortunately, a problem in many advanced countries. Thus, this post might be a bit “odds and ends”-ish, but it’s a topic that’s been of intense interest to me ever since I discovered the depths of alternative medicine applied to cancer, and I didn’t want to leave last week’s post, in essence, unfinished. Also, there is at least one interesting connection that I hadn’t realized as I wrote my post last week.
Ursula Jacobs and Farrah Fawcett
The key bit of information that I didn’t know when searching for who owns Hallwang Private Oncology Clinic was that it used to be known as the Private Clinic of Dr Ursula Jacob, a name change that occurred in 2014. She also apparently has a clinic known as the Day Clinic for Prevention and Regeneration. Her CV shows an early career that appeared rather conventional. She studied medicine at the Semmelweis University in Budapest from 1985-1991, trained in general medicine and family practice from 1991-1995. Then things went wrong, as she took a job at Leonardis Klinik in Kornwestheim in internal medicine and hematology from 1995-2000, becoming senior physician there in 1997. You might recall that Leonardis Klinik was—apparently it’s closed now—one of the premiere German alternative cancer clinics.
In fact, the Leonardis Klinik sounded very familiar to me, as did the name Ursula Jacob. I thought and thought, trying to remember, and then I decided to see if I’ve ever written about either before, either here or at my not-so-super-secret other blog. Guess what? Back in 2009, Dr. Ursula Jacob, who by then had started working at another German alternative cancer clinic, Klinik-Alpenpark, treated Farrah Fawcett with “vitamin preparations that she says boost the immune system.” She was also treated at Leonardis Klinik. She also underwent treatment that is not alternative but was probably not appropriate for her, chemoembolization.
Towards the end of her life, Fawcett became disillusioned with the German alternative medicine clinics that she had trusted, as shown in a documentary that she made about her cancer diagnosis and treatment, Farrah’s Story. As I’ve described before, Fawcett was diagnosed with anal cancer. She underwent what sounds like the standard chemoradiation protocol known as the Nigro Protocol. Unfortunately, she recurred locally at the anus, and the only treatment for a local recurrence of anal cancer after the Nigro Protocol is an operation known as an abdominoperineal resection (APR), in which the rectum and anus are removed, the hole sewn shut, and the patient left with a permanent colostomy. Not surprisingly, Fawcett didn’t want that. (No one does.) Unfortunately, she heard the siren call of the German alternative cancer clinics, which were doing the same thing then as they are now, combining experimental treatments with pure quackery:
Instead, she opted to put herself under the care of two German specialists, Professor Thomas Vogl and Dr Ursula Jacob.
Mrs Stewart said: ‘She believed it would be less drastic.’
Professor Vogl, 50, who practises in Frankfurt, offers cancer patients a treatment called chemoembolisation, during which chemicals are injected directly into organs at a cost of £3,500 a session.
During filming, Miss Fawcett was shown groaning and writhing in pain as a long needle was thrust into her liver by Professor Vogl.
She also underwent a surgical procedure called laser ablation, which heats up the tumour to around 38C (100F) to destroy cancer cells.
Professor Vogl later assured Miss Fawcett that all the ‘active tumours’ had been removed, while Dr Jacob, who uses vitamins to boost the immune system at her Alpenpark Clinic in the Bavarian Alps, claimed it was a ‘miracle’.
However, just a few weeks later, Miss Fawcett underwent a scan that showed the original tumour was larger than ever and that the cancer had spread to her liver.
Chemoembolization is a legitimate treatment for liver tumors, as is laser ablation. Basically, chemoembolization involves injecting chemotherapy and small synthetic particles directly into the hepatic artery. The chemotherapy attacks the cancer, and the particles embolize (travel along the artery) until they lodge and block the blood flow to the tumor. Similarly, this laser ablation sounds like nothing more than a fancy version of thermal ablation of tumors that uses laser instead of radiofrequency waves to generate the heat. Although these treatments can be palliative, it is very uncommon for them to be curative; so it is not at all surprising that Fawcett’s tumors came roaring back. As for the “immune boosting vitamins” administered by Dr. Jacob, there’s no good evidence that such treatments do anything at all other than to produce expensive urine.
Not surprisingly, both Dr. Jacob and her apologists are quick to blame anything other than her treatments for Farrah Fawcett’s death. First, here’s what Dr. Jacob said:
I asked Dr. Jacob where Farrah went wrong in her cancer treatment. She replied that when Farrah returned to the United States, she went back to receiving high-dose chemotherapy.
Dr. Jacob doesn’t like chemo because it’s so toxic. If she uses chemo at all, she only uses it in low doses — about one tenth of the amount that conventional cancer doctors give. And she sometimes recommends chemo-embolization, as she did in Farrah’s case.
Dr. Jacob considers chemo a bad idea unless a chemo sensitivity test is used to match a patient’s cancer cells to the chemotherapy drug that’s most likely to kill them. The test indicates that a specific kind of chemo will work, and thereby avoids the hit-or-miss approach of conventional cancer doctors, who will administer one chemotherapy drug after another (in high doses, of course), hoping to find one that works.
If a chemo sensitivity test shows that no chemo is likely to work against a particular cancer, Dr. Jacob says NO chemo should be used.
Chemosensitivity tests of the sort that Dr. Jacob advocates are not generally used because their predictive value has not been validated and when tested, in general has not been very good. These sorts of tests are very old, dating back almost to the dawn of chemotherapy for cancer. That’s why the American Society of Clinical Oncology (ASCO) concluded in 2011 that in vitro chemosensitivity testing has promise but should only be used as part of clinical trials, the same conclusion it came to in 2004. Moreover, given the advances in genomic testing, chemosensitivity testing is downright quaint and difficult to do.
Dr. Jacob also blamed stress for Fawcett’s death:
Dr. Jacob also reminded me about another factor that contributed to Farrah’s death: the stress of a family crisis. During her struggle against cancer, Farrah’s 25-year-old son, Redmond, got in trouble with the law. He was put behind bars on April 5, 2009, two months before she died, for a drug offense.
And Andrew Scholberg blames—of course!—sugar:
Unfortunately, Farrah had a weakness for Coca-Cola, which is jam-packed with sugar. Coke was Farrah’s favorite beverage, as her best friend Alana Stewart noted in her diary entry for June 1, 2007. Even in the midst of her cancer treatments, Farrah couldn’t stop drinking Coca-Cola. Believe it or not, each 12-ounce Coke contains an astounding 10 cubes of sugar! That’s right. Drinking one Coke is like eating 10 sugar cubes.
Farrah’s German medical team is not to blame for her death. In fact, they helped Farrah extend her life and gave her a better quality of life. My reporting points to at least three factors beyond the control of Farrah’s German doctors that contributed to Farrah’s death:
     1.  Her addiction to sugar
     2.  Stress from her son’s drug conviction and incarceration
     3.  Her decision to revert to high-dose chemo, a toxic treatment
Sugar does not “feed” cancer. That is a myth.
Of course, Farrah Fawcett’s death was not the fault of alternative medicine or the doctors who administer it. Deaths like hers never are. The bottom line is that, unfortunately, Farrah Fawcett’s best chance of surviving her cancer was to undergo APR. It’s a horrible choice. No one wants a permanent colostomy, but I’ve taken care of a number of patients over the years who’ve had one. It is quite possible to live a fulfilling life with one. Once Fawcett declined that option, her odds of surviving her cancer plummeted dramatically. It was possible that local ablation of the tumor might have resulted in long term survival, but highly unlikely. The die was cast when Fawcett refused surgery.
Dr. Ursula Jacob today
So what is Dr. Jacob up to today? At her (apparently other) clinic’s website, she advertises a fairly standard variety of alternative medicine quackery (but I repeat myself), including detoxification and intestinal cleaning:
We offer individually designed examinations of the stool from which we can build an individual programme of detoxification, working on the colon and lymphatic system in order to repair the damaged systems and restore balance to the flora in the gut.
We’re talking enemas, of course. I’ve yet to see an “intestinal cleaning” and “detoxification” protocol that doesn’t involve enemas, coffee or saline.
Then there’s intermittent hypoxia:
Intermittent Hypoxia (sometimes known as ”Altitude Training”) is used to improve oxygen supply to the cells which can regenerate the brain and the body, used together with specific amino acids, the overall cell energy can be improved. This leads to better performance and a natural ”anti-aging”.
This is utter woo babble (like techno-babble in Star Trek, just with woo).
Then there’s boosting the immune system, the all-purpose (and vague) claim, beloved of quacks everywhere:
We carry out blood tests that can show how severely the individual systems are damaged from which we devise therapeutic treatment plans. We work with natural anti-inflammatory and immune complex-depleting substances, photopheresis and regenerative therapies.
Then there’s reflexology:
Reflexology, is a therapy involving the physical act of applying pressure to the feet with specific thumb, finger, and hand techniques without the use of oil or lotion. It is based on stimulating reflex areas that relate to the internal organs of the body which can improve the circulation, relieve stress and stimulate self-healing processes.
Or, as I like to call it, a foot massage with delusions of grandeur.
I think you get the idea. These German alternative medicine cancer clinics thrive based on the desperation of cancer patients with the means to travel to Germany or at least the means to raise the large sums of money required to travel to Germany and be treated at these clinics. Hallwang, run by Dr. Ursula Jacob, is just one of them.
The other quacks of Hallwang
Thanks to my reader, I also learned who else works at Hallwang. These doctors include:
    • Dr. Fatiha-Nora Mühe
    • Dr. Asir Kopic
    • Dr. Emina Kopic
    • Dr. Greg Schwarz
Oddly enough, there’s not much to be found online about these four doctors. Dr. Fatiha-Nora Mühe appears to be an internist.
Dr. Asir Kopic appears to be an oncologist, and has a website. That website lists him as the chief physician of Hallwang from 2012-2014, but not beyond. So it’s not clear whether he still practices at Hallwang. It is, of course, quite possible that he still consults at Hallwang, but now maintains his own Stuttgart private practice with what appears to be his wife, Dr. Emina Kopic, who is listed at the same website as an “orthomolecular therapist.” Remember that “orthomolecular medicine” is a form of quackery popularized by Nobel Prize winner Linus Pauling. The high dose vitamin C treatments that he advocated to treat everything from cancer to the common cold are basically part of orthomolecular medicine, which advocates superdoses of various nutrients to treat diseases. As I like to put it, in orthomolecular medicine, if some is good, more is always better.
I’ll get to Dr. Greg Schwarz in a minute. First, however, I can’t resist mentioning that my commenter pointed out that the website for the Hallwang Private Oncology Clinic is registered under the name of Dr Albert Schmierer, who is CEO of “Dr Zinsser Pharmaceuticals.” He’s described thusly:
Dr. Albert Schmierer is one of the leading German researchers in the field of cell mitochondrial as well as homeopathic treatments with a keen interest in anti-ageing medicine, including cell therapy with the emphasis in cell mitochondrial treatment for rejuvenation, regeneration and fighting premature ageing. He is also the chief pharmacist for mitochondrial and homeopathic therapy at the Private Hospital Dr Ursula Jacob GmbH as well as the owner and CEO of Dr Zinsser Pharmaceuticals.
More woo babble. Not surprisingly, Dr. Jacob is also featured prominently on the company website. But what does this company actually make and sell? It appears to be mostly anti-aging products:
ZÉLL-V started its operations in 2007 with the mission to enable every individual to enjoy a healthy, vibrant, beautiful and quality life. As the process of ageing remains untreatable with conventional medicine, ZÉLL-V aims to defy ageing by harnessing the body’s own healing and revitalising power through cellular therapy.
With this, ZÉLL-V has partnered with international medical experts to develop an exclusive formulation – the most advanced cellular therapy to activate cellular repair and regeneration through the use of cutting-edge biotechnology.
Obviously, this is more woo babble, but what does it mean, if anything? It means “live cell therapy,” which, translated, basically means grinding up animal glands and injecting them:
Cellular therapy is a complete biological treatment using fresh cells or cell factors to stimulate intra-cellular repair mechanisms and cell rejuvenation and regeneration, thereby slowing down the natural process of ageing and counteracting chronic degenerative diseases.
Cellular therapy was discovered by Professor Dr Niehans by chance in 1931 when he saved a woman writhing with convulsions after an operation on her thyroid gland by injecting her with a suspension of animal parathyroid glands – an unknown treatment at that time.
The woman went on to live another 30 years, well into her 90s. Later, at his clinic in Montreaux, Switzerland, Professor Dr Niehans went on to administer live cell injections to thousands and thousands of patients, including many of the crowned heads, presidents, Pope Pius XII and numerous Hollywood stars.
Today, ZÉLL-V cellular therapy is widely used across the globe. Possessing limitless potential to restore people’s health, youth and quality of life, cellular therapy is touted as the future of medicine and health maintenance.
The example of Paul Niehans injecting parathyroid glands is a highly dubious story. It’s not that it’s all that implausible on one level. After all, the hormone made by parathyroid glands (parathormone or parathyroid hormone, abbreviated PTH) is critical for regulating calcium levels in the blood. Indeed, severe hypocalcemia (low calcium) is a known complication of total thyroidectomy because the parathyroid glands are intimately associated with the thyroid gland. If all four of them are injured or accidentally removed with the thyroid, potentially fatal hypoparathyroidism can result. That’s why a common practice is to remove one or more of the parathyroids, mince them, and implant them into a skeletal muscle, a practice known as parathyroid autotransplantation. The cells survive, thanks to the blood supply of the muscle, and keep producing parathormone. The story above is, of course, nonsense, as a quick look at even Wikipedia will tell you, as the function of the parathyroid glands was known as 1908.
In any case, live cell therapy is basically a quack treatment based on the concept that there is some sort of “essence” in various animal cells that can rejuvenate and repair human tissue, as described here:
In order for this to happen, ZÉLL-V Cellular Therapy supplies the human body with young and active cellular material obtained from sheep embryonic or early foetal cells and placenta. These active cellular materials are young and full of vitality, as such, once taken into the body, they are able to imprint their vigour upon the body’s weak and old cells, thereby ‘teaching’ them to regenerate themselves, resulting in an overall improvement and restoration of our bodily systems.
Even more ridiculously, these animal organs and glands are often produced in pill form, to be consumed rather than injected, so that, even if there were something in the cells that could affect human physiology, chances are that it would be destroyed by the digestive tract. Quackwatch, of course, has an excellent discussion of live cell therapy and why it is quackery. It’s also not safe. There have been reports of fatal immunological reactions, gangrene at the site of injection of sheep cells, and other problems.
None of that stops Zéll-V from selling sheep placenta pills for up to $1,920 a package and claiming all manner of health benefits. I was, however, amused to learn that there are organizations called the German Society for Thymus Therapy and the International Association for Organ Therapy Specialists Switzerland and Germany.
So, regardless if all of the doctors I’ve discussed up to now still practice at Hallwang, there is no doubt that, between Dr. Jacob and Dr. Schmierer, Hallwang Private Oncology Clinic still delivers the quackery.
The Australian connection
But wait. I’ve overlooked someone. Actually, no, I haven’t. What I did notice in my searches is that Dr. Greg Schwarz is no longer at Hallwang Private Oncology Clinic. In fact, he’s moved to Australia to join Gore Street Medical in South Hobart, where he is described as having “returned from working at a specialised cancer centre in Germany,” bringing “his expertise in nutritional medicine and environmental medicine to Gore St Medical” as well as this:
Dr Schwarz is a medical practitioner focussing on integrative health care, targeted, individualised, holistic therapies for complex, chronic medical problems including cancer, autoimmune conditions, inflammatory conditions, fatigue including ME/CFS/fibromyalgia, neurological conditions including autism and dementia support, gastro-intestinal conditions, allergies and food intolerances, recurrent and chronic infections, and general preventative health.
And what sort of therapies does Gore Street Medical offer? The usual. Here are just a few:
    • Naturopathy
    • Herbal medicine
    • Hobart hyperthermia
    • Bowen therapy
    • Traditional Chinese medicine with acupuncture
    • Bioresonance
And, of course, there are iron and vitamin infusions and heavy metals chelation.
I was particularly amused by the woo babble in this video describing bioresonance:
Yep, it’s all about the “vibrations,” man. Basically, a machine determines the “bioenergetic” resonance of a compound suspected of causing problems and then determines if that’s what’s causing a patient’s symptoms. Yes, it’s basically a machine that goes ping, as in an expensive machine that doesn’t really do anything useful but sure looks impressive to the rubes.
In the end, the cancer quackery of the German alternative cancer clinics has produced a small metastasis to Australia in the form of Dr. Schwarz. How Gore Street Medical contributes to the problem is described in an excellent short report that aired a week ago on Australia’s Science Channel:
Be it Germany, Mexico, Australia, or even the US, unfortunately cancer quackery is a problem everywhere. The German cancer clinics epitomize much of this problem, and there’s no sign that they’re going away any time soon. Patients not only end up undergoing ineffective treatment, they spend lots and lots of money doing it. I searched GoFundMe for Hallwang Private Oncology Clinic, and came up with five pages of patients trying to raise money to go to Hallwang. The GoFundMe pages had names like Saving Dad, Help Michelle’s Fight, Claires Medical Fund to Germany, Please Help My Mum Get Treatment!, and Hayley’s Cancer Treatment Fund.
As the Australian report above points out, conventional medical treatments must be supported with science and evidence from randomized clinical trials. As I pointed out last week, clinics like Hallwang rarely, if ever, publish their results, but that doesn’t stop them from taking advantage of the desperation of cancer patients by offering them false hope at a very high price.

Cancer Centers and Advertising Practices
Harriet Hall on April 14, 2015
Tweet


You have probably seen the TV commercials or other ads for Cancer Treatment Centers of America. They make it sound like “the place to go” if you have cancer. They claim to be “different,” to combine the best cancer technologies with natural therapies in a humane, patient-centered approach that helps you fight the disease and maintain your quality of life. They offer a kinder, gentler, more effective oncology. Those ads are misleading.
Dr. Gorski has written about the practices of Cancer Treatment Centers of America here and here. He has shown how they “integrate” real medicine with nonsense like homeopathy and how they misrepresent components of science-based medicine like exercise and diet, re-branding them as “alternative.”
A recent study by Vater et al. published in the Annals of Internal Medicine asked “What are cancer centers advertising to the public?” They found that the ads appealed to emotion, failed to provide important information, falsely portrayed testimonials as typical, and should be viewed as critically as any other advertising.
History and ethics
There is an excellent article by N.D. Tomycz in the Journal of Medical Ethics titled “A profession selling out: lamenting the paradigm shift in physician advertising.” It covers the history of the relationship between doctors and advertising and the ethical issues involved.
From the first American Medical Association (AMA) Code of Ethics in 1847 to 1975 any advertising by doctors was strictly forbidden. Advertising was a commercial business practice; medicine was a profession, not a business. Only quacks and snake oil salesmen advertised. Advertising was considered incompatible with ethical patient care, and publishing testimonials or promises of cures was grounds for ostracism. Other professions followed suit; the American Bar Association prohibited advertising in the early 20th century. A U.S. Supreme Court decision in Goldfarb v. Virginia State Bar determined that lawyers were “engaged in trade or commerce” and therefore were not exempt from antitrust laws. In 1975 the Federal Trade Commission (FTC) accused the AMA of exercising “restraint of trade” in violation of antitrust laws and persuaded the medical profession to allow advertising. This led to what we have today: prescription drugs widely advertised in the media, doctors advertising their practices, and advertisements for cancer treatment centers. This commercialization may well have diminished public trust in the medical profession. In other countries, the ban on advertising persists.
Tomycz offers these ethical arguments:
Patients are not consumers in search of a commodity. There is a unique vulnerability that comes for want of relief from disability and disease, and patients are unlikely therefore to be capable of defending themselves with the incredulousness they may normally bring to other forms of advertising.
Physician advertising manipulates choice by presenting limited and biased information that aims to entice rather than inform. Advertisements often fail to cite complications and rarely present treatment alternatives not offered by the physician. The fleeting medium of advertisement—billboards, short radio segments, fliers, rapid television infomercials—is not appropriate for initiating the informed and often complex decision making process that should underlie all health interventions.
Now that medical quackery has returned with unprecedented sophistication, annually draining billions from the population with unproven treatments and supplements, physicians may be more tempted than ever to advertise and secure some piece of the healthcare pie. Yet no matter what the law permits, advertisement in medicine should remain a taboo that unifies doctors in the defence of professionalism and the unique covenant they share with patients.
Cancer center advertising study
Vater et al. did a systematic content analysis of cancer center ads in top consumer magazines and on television networks in the US in 2012. After excluding duplicates, employment opportunities, fundraising ads, etc. they found 409 unique advertisements promoting clinical services at 102 cancer centers. They most commonly promoted cancer treatments (88%) rather than cancer screening (18%) or supportive services (13%). They frequently made vague claims like “Our team has saved lives through groundbreaking technology, personalized treatments, and research.” The type of cancer treatment was not specified, and very few mentioned palliative care or symptom management services. Less than 2% mentioned the possibility of risks from treatment. Only 5% mentioned costs or insurance coverage.
85% included emotional appeals relating to survival or potential cure. 61% used language that evoked hope (“your last hope,” etc.). 31% mentioned that treatments would be tailored to the individual. Nearly half of the ads included endorsements from patients, testimonials that emphasized survival or cure. Only 15% included a disclaimer that these results were not typical, and no ads described the outcome that a typical patient could expect. The FTC has recently mandated that testimonials include disclaimers and a description of results that a typical patient may expect to see. Most of these advertisers were not in compliance.
The ads failed to provide crucial information that patients need to make an informed decision about where to seek cancer treatment. They seldom mentioned risks and failed to quantify benefits.
The authors mentioned the limitations of their study. They did not include other media such as the Internet, newspapers or radio. Their sample may have been incomplete. Most importantly, they did not examine the effect of advertising content on patients.
An accompanying editorial praised the rigor of the study but expressed some caveats about its potential implications. It said it would be unreasonable for such ads to present quantified survival data because that data is easily manipulated and difficult for consumers to evaluate. It pointed out that advertising has potential benefits such as destigmatizing cancer. It mentioned a survey that asked whether these ads should be banned; only 11% of respondents supported a complete ban, 33% favored limited restrictions, and 56% believed no changes should be made. It concluded:
If marketing increases or decreases that burden for patients with cancer, it behooves us to know how. Vater and colleagues should be commended for taking an essential first step toward that goal.
Conclusion
The advertising by cancer centers is frequently misleading, but we don’t yet have any data on how those ads actually impact patients. It would be a mistake for consumers to base their decisions about where to go for treatment only on the incomplete information in the ads.

Rigvir: Another unproven and dubious cancer therapy to be avoided
Recently, the Hope4Cancer Institute, a quack clinic in Mexico, has added a treatment known as Rigvir to its coffee enemas and other offerings. But what is Rigvir? It turns out that it’s an import from Latvia with a mysterious history. Proponents claim that it is an oncolytic virus that targets cancer specifically and leaves normal cells alone. Unfortunately, there is a profound paucity of evidence for its efficacy against cancer. The story of Rigvir is the story of an unproven treatment that, because of its origin in a small country, has flown mostly under the radar. Until now, that is.
David Gorski on September 18, 2017
Link
This blog is based in the United States, but, more than that, all of our regular bloggers are American and the vast majority of our guest bloggers are American. This produces a difficult-to-avoid baked-in bias towards medicine as it is practiced in the US and, to a lesser extent, as it is practiced in the UK, Canada, and Australia. The same bias exists with respect to pseudo-medicine, with our concentration having been primarily on either quackery that is practiced in the US, UK, Canada, or Australia (and sometimes New Zealand). It’s not because we are not interested in medicine and pseudo-medicine as practiced in non-English-speaking countries. It’s just that we lack the tools in terms of language and bloggers with local knowledge to assist us. That’s why, whenever I or others have tried to cover alternative medicine or “integrative medicine” in non-English-speaking countries, such as when I discussed alternative cancer clinics in Germany or the situation with stem cell clinics in Italy (as bad as or worse than in the US), I always feel that I’m missing something. After all, Google Translate often doesn’t really provide more than the gist of what a foreign-language article is trying to say.
A dubious Latvian cancer treatment shows up on my radar
Perhaps the language barrier, coupled with its being primarily a treatment from a very small country, is part of the reason why I haven’t discussed a new form of dubious cancer treatment known as Rigvir before. It’s a form of treatment that has been popularized mainly in Latvia. This situation has made finding sufficient information about Rigvir, the claims made for it, what it is, and what it supposedly does, rather challenging. After all, I don’t speak Latvian, and I don’t know anyone who does. (And, no, having a Lithuanian background on my mother’s side doesn’t help.) I was prodded from my complacency by an article published earlier this month from LSM.lv, “Health ministry defends claimed cancer treatment.” Basically, a Latvian news magazine, De Facto, reported earlier this year that multiple Latvian medical associations had written to the Latvian Health Ministry about Rigvir:
Crucially, it [Rigvir] is included on the health ministry’s list of reimbursable medicines, meaning public as well as private money is spent on it.
Yet as De Facto revealed, in January three professional medical organizations, including the Latvian Oncology Association, wrote to the Health Ministry expressing concern that research and publications used to establish the credentials of Rigvir treatment were of poor quality and scientifically questionable: for example in one study supposedly comparing the outcomes for two groups of patients, one group used Rigvir and the other did not, with the Rigvir patients doing considerably better than the control group. However, the Rigvir patients also used chemotherapy, while the control group did not, which should have rendered the findings highly dubious.
Oncologists asked that Rigvir be removed from the list of reimbursable medicines and the National Drug Register pending proper clinical data, and also asked for a review of the official guidelines for the treatment of melanoma involving Rigvir.
In February, the health ministry publicly pledged to review the registration of Rigvir and its inclusion in the list of reimbursable medicines. However, De Facto uncovered that a decision to ignore the oncologists’ concerns had already been made in the spring.
What most grabbed my attention about this article was the response of Health Minister Anda Čakša to inquiries about why the Health Ministry decided the way it did. It’s a response that’ll make a skeptic’s jaw drop:
“One of the key issues to change anything in drug registration or compensation conditions is clear evidence that the medicine is or is not effective and safe; that there are or are not side effects,” Minister of Health Anda Čaksa told De Facto.
“A letter by some social group saying they don’t like something – it’s just not helpful. Show us data that this medicine does not work for your patients. We don’t have anything to react to at the moment,” said Health Minister Anda Čakša.
My reaction was predictable: This is exactly backward! It is up to the company selling a product to provide evidence that it does work for the conditions for which it is marketed, not to critics to show that it doesn’t work! The article also notes that Rigvir is the fifth top selling prescription medicine in Latvia, with growing sales, which is another reason to be concerned. So is the marketing of Rigvir outside of Latvia. For instance, quack cancer clinic in Mexico that I’ve discussed before, Hope4Cancer, offers Rigvir, which it describes in glowing terms:
Rigvir®, the world’s first and only non-genetically modified cancer virotherapy agent, is a non-replicative live virus; it is non-pathogenic, and does not reproduce inside the human body or transmit to others. Once introduced in the body, Rigvir® selectively seeks out cancer cells to replicate within, effectively killing the cell in the process.
While virotherapy is only now emerging as a new wave of oncological therapies, Rigvir® has been intensely studied by researchers for over 50 years, passing all phases of clinical trials, and is registered by the International Virotherapy Center in Latvia as a prescription anti-cancer drug. Though registered as a drug, Rigvir offers a completely safe clinical profile, high therapeutic index, absence of side effects, and ability to selectively target cancer cells – making it unlike most available therapeutic agents.
Not surprisingly, according to Hope4Cancer, Rigvir is fantastic for basically all the common cancers: breast cancer, melanoma, lung cancer, colorectal cancer, pancreatic cancer, prostate cancer, liver cancer, and more. The clinic even goes so far as to claim:
However, given its universal mode of action, it is likely that Rigvir® is effective against a much larger range of cancers that have not been fully studied yet. In fact, at Hope4Cancer, we have used Rigvir® effectively against many cancers not listed here.
It is important to note that since Rigvir® is a defined pharmaceutical entity that has been established through a process of validated studies to qualify as a drug, it does not completely fall into the category of conventional, alternative, or integrative medicine. Instead, Rigvir® represents a completely new paradigm in cancer treatment, and we at Hope4Cancer are proud to offer it to our patients.
No, if Rigvir works, it would be conventional medicine. Viruses that target specific cancers are very much the hot topic now, although results have generally been mixed. The only thing “alternative” about Rigvir is that it is unproven and sold by a quack cancer clinic in Mexico.
Meanwhile, over at the International Virotherapy Center in Latvia, where Rigvir is primarily marketed, there are the sorts of glowing testimonials (complete with a link to the Virotherapy Foundation, which provides even more glowing testimonials) that automatically set my skeptical antennae a’twitching. For instance, here is a woman named Zane who was diagnosed with stage I (yes, stage I) melanoma that was completely surgically excised. Yet Latvian doctors prescribed her “virotherapy” (a.k.a. Rigvir) afterward:
The treatment for stage I melanoma is basically complete surgical excision with an adequate margin of normal tissue around the melanoma, plus examination of the regional lymph nodes through a procedure called a sentinel lymph node biopsy, if the melanoma is stage IB. (Presumably the woman’s lymph nodes were negative, or else she would no longer have stage I melanoma. Rather, she’d have at least stage III melanoma.) There is usually no need for any further treatment. Basically, Zane was exposed to “virotherapy” unnecessarily and massively overtreated for her melanoma. Yet she’s promoted as a success story, who gushes about how she had feared losing her hair and feeling sick but didn’t and how she was able to have a normal baby.
This testimonial is a bit more disturbing:
Basically, it’s a British woman named Nadine who had melanoma in 1999 that recurred in 2009. It sounds as though it’s been metastatic, but there are no details that would allow a cancer surgeon like me to know where it metastasized to, how rapidly it grew, and other critical information. We learn that Nadine has apparently undergone radiotherapy, chemotherapy, and surgery, along with being a “guinea pig” for experimental vaccine therapies, suggesting that she must have been a subject in at least one clinical trial. She’s convinced that Rigvir is helping her, but there’s no way to know for sure. Metastatic melanoma is a strange beast among cancers. It can have an incredibly variable course, rapidly growing and killing some patients, and in others exhibiting a much more indolent behavior. Also, excising melanoma metastases can be curative, if they are single or only a few and can be completely excised surgically. Surgical excision of recurrences and metastases could well have prolonged Nadine’s life greatly, but insufficient information is given for me even to speculate whether this is the case with her.
Basically, there is no way of knowing whether Rigvir helped Nadine or not, but she’s convinced that it did. What’s disturbing is the segment near the end, where Nadine urges patients to “seek alternative therapies.” Near the end, she also states that the melanoma has metastasized “all over my body,” but it’s not clear where that means. Organ metastases are much more serious than skin metastases, for instance. Whatever the case, this one woman is not evidence that “virotherapy” works for melanoma.
There’s a lot more where that came from.
What is Rigvir?
The Rigvir website describes the treatment thusly:
RIGVIR® – the worlds [sic] first oncolytic virotherapy medicine, which is approved for cancer treatment and introduced in medical practice. RIGVIR® contains a live nonpathogenic ECHO-7 virus that has not been genetically modified.
RIGVIR® is oncotropic and oncolytic virus. It finds and selectively infects tumour cells. Then replicates in tumour cells and destroys them. Both of these processes, oncotropism and oncolysis, are selective for tumour cells and normal healthy cells are minimally if at all affected.
Oncolytic virotherapy with RIGVIR® is safe and effective cancer treatment, which improves time to progression, survival and quality of life of cancer patients.
I perused what passes for a product information sheet. Rigvir is provided as a 2 ml frozen solution of an adapted and selected ECHO-7 virus strain, Picornaviridae family, Enterovirus genus, Enteric Cytopathic Human Orphan (ECHO) type 7, group IV, positive-sense single-stranded RNA virus produced under GMP. The titer is not less than 106 – 108 TCID50/ml. (TCID50 is a measure of active viral particles.) A brief word is in order here. “Orphan” indicates a virus not known to be associated with any disease. (Since the discovery of ECHO viruses, they have been linked with diseases to the point where most ECHO viruses are no longer considered orphan viruses. Even so, the name stuck.) Echoviruses were first isolated from the feces of asymptomatic children in the context of epidemiological studies of polioviruses and are now known to be one of the leading causes of acute febrile illnesses in children. 90% of ECHO virus infections are asymptomatic, but in the 10% that produce symptoms those symptoms can range from mild to severe, depending on the age, gender, and immune status of the host and the subgroup, serotype, and enteroviral strain. We’re talking anything from a nonspecific febrile illness to aseptic meningitis to respiratory symptoms to myocarditis.
What I find most implausible about Rigvir is the claim that it attacks only cancer cells and leaves normal cells alone. It takes a look into the history of Rigvir to get an idea where this claim came from.
Aina Muceniece: Discoverer of Rigvir
The story of Rigvir began several decades ago with a Latvian immunologist Professor Aina Muceniece. Discovering unbiased information on Prof. Muceniece and her discovery of Rigvir is damned near impossible these days, because searches on her name will produce a host of links related to laudatory descriptions of Rigvir and/or associated with the International Virotherapy Center. However, one article does describe the origin of Rigvir thusly:
In the 1960s a young scientist named Aina Muceniece discovered a way to use a virus to assist in identifying and marking melanoma cells. Using this discovery, she was able to create a medicinal substance which could possibly increase the life expectancy of melanoma patients when used alongside other therapeutic methods. The substance underwent preliminary studies and was proven to be harmless. These results made it possible for the scientist to use it in the treatment of melanoma, while recording her observations.
Unfortunately, even the unfailing enthusiasm of Aina Muceniece was unable to successfully turn Rigvir (its name honours Riga, the capital of Latvia), into an approved and widely applied treatment. Efficacy studies would have required much larger resources than were available.
A PubMed search on Prof. Muceniece’s name doesn’t turn up very much, just two Russian language articles and a frequently touted clinical study from 2015, to which her name must have been added posthumously given that she died in 2010 at the age of 85. Of course, given the time period of the discovery of what is now called Rigvir (the height of the Cold War), it is perhaps not too surprising that there are few publications indexed in PubMed about it. Be that as it may, the peer-reviewed English literature is not a good place to find out very much about the origin of Rigvir, although there is a 2012 review article on oncolytic (cancer destroying) viruses that gives some hints. I find this passage rather telling:
Oncolytic activity of ECHO viruses was also studied from the beginning of the 1960s by the group of Dr. Muceniece in the Kirchenstein Institute of Microbiology [59]. The oncolytic activity of natural enterovirus strains was increased by multiple passaging in human tumor cell cultures. Clinical trials of five attenuated oncolytic ECHO enterovirus strains began in 1968. The trials were performed in stage IV cancer patient volunteers, when the conventional therapy had proved inefficient. Viral preparations were administered by intramuscular injections. In some patients, a portion of tumor cells were destroyed that show characteristic cytopathic signs, but the overall therapeutic efficiency was low, supposedly because of the large bulk of the tumor and the rapid development of antiviral immunity. Accordingly, the suggested treatment strategy included radical surgery with subsequent virotherapy for the eradication of residual tumor cells and metastases and the stimulation of antitumor immunity [75].
Based on the results of the trial, ECHO virus strain ECHO-7, which showed the most pronounced oncolytic properties, was selected for further research and named Rigvir [76, 77]. In 1988, phase III clinical trials began, which compared the efficiency of Rigvir with that of surgery and radio- and chemotherapy. In 2004, a patent was issued for Rigvir, and it was officially registered in Latvia, becoming the first enterovirus medication worldwide to complete the full cycle of clinical trials and to be applied in cancer therapy. Since 2008, Rigvir has been available in Latvia as a prescription medication. The information on its properties and usage is available at the site of the Latvian Virotherapy Center (www.viroterapija.lv).
From what I can tell synthesizing the evidence that I’ve been able to find, Dr. Muceniece made an interesting discovery in the early 1960s in which she observed that some ECHO viruses appeared to have cytolytic effects on tumor cells (i.e., caused them to lyse, or break apart), but the effect was weak, observed in only a few patients, and attenuated by the rapid development of immunity to the virus. In other words, lost in the mists of scientific history, this is an interesting dead end that appeared to go nowhere. Moreover, assuming this account is reasonably accurate, it certainly casts into doubt the stories of “miracle cures” of patients with stage IV cancer, given that those early trials apparently only looked at patients with stage IV cancer and Rigvir didn’t work in them. There are anecdotes from surviving contemporaries of Dr. Muceniece that in melanoma Rigvir produced “such excellent results that all medical staff involved were astonished,” but no published data, and, pointedly, many of her contemporaries are happy to express their admiration for her but decline to evaluate the medication that she is credited with developing.
Unfortunately, the only primary literature referenced are publications by Dr. Muceniece in Latvian. I searched and could not find any published results of these alleged phase III trials begun in 1988 showing that Rigvir prolongs survival in cancer. Neither could Eduards Ritums, who wrote an extensive article in Latvian translated into English about Rigvir. Ritums notes:
The chain of events should have stopped there. But just a few decades later Rigvir was suddenly included in the list of state-reimbursed medicines and reappeared under new circumstances and in a completely new light, despite the lack of any further trials and contemporaneous developments in similar fields of medical research.
Although Aina Muceniece has passed away, a group of enterprises was formed using her name as a cover. The profits of these enterprises come from the sales of Rigvir and illegitimate advertising, consequently attracting desperate patients from abroad. This medicine is used as treatment not only for melanoma patients, but for other cancer patients as well, and advertised in a way that discredits other currently approved cancer treatment methods. It is unlikely Aina Muceniece would have supported or wanted something like this to happen.
So what evidence is there for Rigvir’s anticancer activity? As you will see, it’s pretty weak and unconvincing. Even so, somehow Rigvir was approved by the Latvian version of the FDA in 2004 and even more mysteriously found its way onto the list of Latvian state-reimbursed medicines in 2011.
Evidence for Rigvir’s anticancer activity: Thin gruel indeed
I did PubMed searches and Google Scholar searches, and, as anyone who tries the same will discover, rapidly found that the published data on Rigvir in the peer-reviewed scientific biomedical literature is incredibly sparse. Ritums notes this in his article:
However, Peteris Alberts, a spokesperson of the Virotherapy Center, referenced many articles in the medical literature (impressing patients who are looking for possible treatment) in an article written by Gunita Nagle titled “Sellers of Hope”, appearing in the Latvian magazine “Ir” [1]: “Are these not studies? We believe they are convincing.” We should mention that doctors obtain information from internationally recognized databases which are compiled by specific search engines, e. g., Medline. These searches return just a few old articles regarding Rigvir. The most recent information the Virotherapy Center can offer are three retrospective case studies. After reading one of the articles, Janis Eglitis asks a rhetorical question: “Did the long-term remission of three patients occur due to Rigvir? No, this story only tells us that three patients used this drug. Unexplained remission in oncology is possible. That can happen either with the use of Rigvir, or anything else – even vitamin C. That does not reflect or prove a trend.” A similar approach is used by authors of self-help books, namely: “I was doing all sorts of things, using anything available, but I believe only this particular something was helpful, so let us all use only this one particular approach!”
Inara Rubene, a pharmaceutical consultant in private practice who has international experience in conducting clinical trials, compares Rigvir’s inclusion in the register of medicinal products with the activities of Ostap Bender (translator’s note: a character from Russian literature, a liar and a boaster, often referred to as ‘the great manipulator’): “The list of clinical trials is absolutely insufficient. Generally recognized phase III trials involving “gold standard” endpoints and overall survival (time to disease progression) are completely absent. Only the great manipulator in his hometown Vasuki would be able to register a medication using such trials.”
Indeed, if you look at the Virotherapy Center’s page of clinical studies, you won’t be surprised to see how thin it is. The early studies are described thusly glowingly, but without enough detail or evidence to judge how convincing the data are. No mention is made of whether the studies were randomized (I get the impression that they were not), how the cases were matched, and survival rates are reported as ranges, which makes me wonder how on earth the investigators were determining their survival rates. For instance, it is claimed that in melanoma patients the three year survival rate for patients treated with surgery alone was between 46% and 58%, while it was 57% to 84% for those treated with surgery plus Rigvir. I assume that the Virotherapy Center is pooling multiple trials, but this sure isn’t any meta-analysis. Without a lot more detail, it’s impossible to tell what the investigators did several decades ago.
What about more recent evidence? As Ritums notes, there is nothing more to be found besides three retrospective studies carried out post-registration, as a perusal of the Virotherapy Center’s page on its post-registration studies shows. For instance, there is this 2015 study published in Melanoma Research by Donina et al, Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. Basically, it is as the title says, a retrospective, unrandomized study that looked at 79 patients who had undergone excision of their primary melanoma and classified as stage IA, IB, IIA, IIB, or IIC according to surgical findings. The rationale was as follows:
Current guidelines for melanoma advise no treatment postsurgery for patients who are classified into substages IB and IIA. Patients in substages IIB and IIC are provided three options: participation in a clinical trial, observation and interferon 7,8. In the absence of strict guidelines, treatment with Rigvir was offered. Thus, 52 study participants received Rigvir and 27 were observed according to the guidelines. The patients who had been treated with interferon were excluded from the present analysis as, in the registry, they were too few to allow for any comparison.
So let me get this straight. This is the rationale? No post-surgical therapy is generally recommended for melanomas Stage IIA and below; so let’s just give them Rigvir, instead. This is not a randomized trial. Patients were all offered Rigvir, were treated, and then a retrospective analysis was done after treatment. There was no blinding. There was no evidence of rigorous inclusion criteria. We have no way of knowing whether the Virotherapy Center included all the patients it treated for melanoma of the selected stages during the given time period or if it excluded cases in a way that could bias the results. Also, quite tellingly, no treatment/observation group is, on average, ten years older than the Rigvir group, and has proportionally over twice as many in the stage IIB group, which would have a worse prognosis than earlier stage melanoma. Basically, this study is worthless. I’m disappointed that Melanoma Research, normally a very good journal, published this dreck.
The rest isn’t any better. For instance, there is a 2016 paper with three case reports of patients with stage IV melanoma, stage IIIA small cell lung cancer, and a stage IV histiocytic sarcoma, all of whom were treated with Rigvir and all of whom have survived longer than expected. Of course, case reports can be useful for hypothesis generation, but do not generally show efficacy. Another study is listed (but not linked to). It’s a retrospective study published in Latvijas Ārsts (Latvian Doctor) that looked at the progression-free period for stage II melanoma patients and observed that patients treated with surgery and observed were 6.7 times more likely to recur than those treated with oncolytic virotherapy after surgery. This study suffers from the same problems as the 2015 study. It’s not randomized. It’s retrospective. We have no way of knowing how the cases were selected.
All of this leads to the question: Does Rigvir have anticancer activity, particularly against melanoma? My answer is simple: Damned if I know given the lack of valid, rigorous clinical trial evidence, but I tend to doubt it strongly. Rigvir might have weak activity in melanoma (although I doubt even that), but there’s no way Rigvir is curing patients with stage IV cancers and it’s incredibly unlikely that it is active against the range of cancers for which it is used.
Rigvir is most likely cancer quackery
There are many aspects to the Rigvir story that strongly suggest that Rigvir is probably cancer quackery. First, there is its mysterious origin story. As I read more about Rigvir, I couldn’t help but hear echoes of the story of Stanislaw Burzynski, with the exception that there is no evidence of which I’m aware that Dr. Muceniece ever supported the uses to which Rigvir has been put since its registration in Latvia in 2004. The echoes I heard, however, were distinct and came from the lack of information about the origin of this therapy, which goes back even further than the 1970s origin of Stanislaw Burzynski’s antineoplastons. True, the parallel is not anywhere near airtight, but it’s troubling.
Next, there is the way Rigvir is marketed, which is straight out of the cancer quack playbook. There are slickly produced videos on the International Virotherapy Center website full of appealing patients singing the praises of how Rigvir saved their lives in personal anecdotes and even a foundation that promotes Rigvir, again with glowing testimonials. This is definitely a red flag.
Then there’s how the International Virotherapy Center has represented the registration of Rigvir. In brief, it tries very hard to make it sound as though the drug was registered in accordance with European Union standards when it wasn’t. Again, Ritums tells the tale:
Rubene is embarrassed that “manipulative patient testimonials are disseminated, and that magazines and newspapers are flooded with promotional articles where Virotherapy Center representatives without any medical education declare Rigvir to be the the [sic] first drug in its group and state there are no similar agents available in the world [2-4]. Rigvir advertising materials also emphasize that this agent was registered in an EU country, thus misleading patients and making them believe that Rigvir was registered according to EU standards, although it is well-known this medication was registered before Latvia joined the European Union. Academic, chemist and Rigvir shareholder Ivars Kalvins (translator’s note: known also as the inventor of meldonium (Mildronate)) [5] keeps asserting without the smallest feeling of guilt that Rigvir is the first-choice agent for the treatment of a “sensitive” tumor [6], even after multiple objections.”
Then, like many dubious clinics, the Virotherapy Center disparages conventional medicine and portrays Rigvir as “natural”:
Communications expert (translator’s note: online writer on science and evidence-based medicine) Ksenija Andrijanova emphasizes that the way the Virotherapy Center advertises itself is not typical for a medical facility, even though they are trying very hard to look like one. After exploring fraudulent treatment methods (there are many in oncology), Andrijanova has noticed two common features: “First, conventional treatment approaches are blatantly discredited, especially radiation and chemotherapy since they have side effects (which is true). However, the claim that these therapies do not help and recovery chances are very low is much more dangerous, and it is a false statement. Secondly, there are statements that oncology patients can be treated in a ‘natural way,’ and the real cancer treatment agent is safe, natural and harmless. Both features were present in the Virotherapy Center’s materials.”
Others have noted that Rigvir, when first sold, was inexpensive, but with its growing popularity the price has gone up. A telling quote comes from the Medical Director of the center, Dace Baltina, who was quoted in the magazine Ir as saying, “We do not promise to heal”, but “a patient is ready to pay believing the recovery will happen.” Sound familiar? And that doesn’t even take into account the association the Virotherapy Center now has with what is without a doubt a quack clinic in Mexico, Hope4Cancer. As I documented before, in addition to Rigvir, H4C offers high dose intravenous vitamin C, alkalinization, coffee enemas, juice fasting, near infrared saunas, detox routines, and more quackery. None of this has stopped the EU from providing support under Horizon 2020 for a “feasibility” study as a prelude to a phase 2 trial to support registration with the European Medicine Agency. Somehow I doubt Rigvir will make it that far. At least, I sincerely hope that it doesn’t, unless of course rigorous clinical trials show that it actually works, which is, based on my reading of the existing data, highly doubtful, albeit not impossible.
What we have in Rigvir is yet another example of alternative medicine co-opting an interesting treatment from history that had been largely abandoned, resurrecting it, and riding it to profits. Immunotherapy, including the use of oncolytic viruses to target cancer, is all the rage these days in oncology; so a treatment like Rigvir is easy to sell based on its supposed immunological mechanism. Never mind that there is such a paucity of evidence that it actually works. Cancer patients, beware.

Ty Bollinger’s “The Truth About Cancer” and the unethical marketing of the unproven cancer virotherapy Rigvir
Last week, I wrote about Rigvir, a “virotherapy” promoted by the International Virotherapy Center (IVC) in Latvia, which did not like what I had to say. When a representative called me to task for referring to the marketing of Rigvir using patient testimonials as irresponsbile, it prompted me to look at how Ty Bollinger’s The Truth About Cancer series promoted Rigvir through patient testimonials and how the IVC itself uses such testimonials. The word “irresponsible” doesn’t even begin to cover it.
David Gorski on September 25, 2017
Link

Last week, I wrote about Rigvir, a highly dubious cancer therapy developed in Latvia. Rigvir is an oncolytic virus, and its proponents claim that it targets only cancer cells for destruction, leaving normal tissue alone. Its history and how it came to be approved in Latvia in 2004 and added to the Latvian Health Ministry’s list of reimbursable medications in 2011 remain rather mysterious, but how it is being marketed does not. For example, Rigvir has become a new favorite treatment at a number of quack clinics, such as the Hope4Cancer Institute in Mexico, where Rigvir is offered along with coffee enemas and a wide variety of quackery. Moreover, as I described last week, there is a striking paucity of evidence supporting the efficacy of Rigvir against any cancer, even melanoma, the cancer for which Rigvir is approved in Latvia and for which there appears to be almost no published evidence at all. Certainly there is nothing resembling well-designed randomized clinical trials supporting the efficacy of Rigvir. Basically, few outside of Latvia and Eastern Europe had heard of Rigvir, as it had flown under the radar, most likely because Latvia is a small country. Then Ty Bollinger featured Rigvir in Episode 3 of his alternative medicine propaganda video series The Truth About Cancer (TTAC), complete with “miracle cure” testimonials, and suddenly Rigvir wasn’t so obscure any more.
The Truth About Cancer promotes Rigvir
As I’ve discovered since last week, the people who run the International Virotherapy Center, where Rigvir is manufactured and sold, are not particularly happy about the increased level of attention directed at them. Indeed, within 15 hours of last week’s post going live, I had received an e-mail from someone named Lelde Lapa, whose title was listed as Assistant of Business Development Department at the International Virotherapy Center (IVC). She was quite…unhappy with my post. Personally, I was amazed at how fast I received such a long e-mail after publishing my post. Clearly the IVC has many Google Alerts set for Rigvir and its name and is fast to act.
As of this writing, the exchange is up to four e-mails, two from Ms. Lapa and two responses from me. One thing stood out, and that was how my charge that IVC irresponsibly markets Rigvir using patient testimonials seemed to produce the most defensive response. Based on that, I thought I would look a bit more at how Rigvir is actually marketed, starting with how Ty Bollinger featured it in Episode 3 of TTAC. (After all, Ty Bollinger’s video series is where most cancer patients interested in alternative medicine learn about Rigvir.) Although I couldn’t force myself to watch more than about the first half hour of the first episode of TTAC when it was first released, fortunately Harriet could and I did download all the episodes off of YouTube when they were briefly available for free. This allowed me to watch the segment on Rigvir, which starts at around the one hour mark and takes up most of the last half hour of the episode.
The segment begins with an interview with Kaspars Losans, MD, IVC’s medical director. Dr. Losans claims that Rigvir is a “very good” virus that specifically targets cancer cells and leaves normal cells alone. Next up, we meet Ivars Kalvins, PhD, who is the Director of the Latvian Institute of Organic Synthesis, which is a “state research institute specializing in pharmaceutical research, organic chemistry, molecular biology and bioorganic chemistry.” (The appearance of a scientist from a Latvian state research institute made me wonder a bit about collusion between the government and the IVC, for obvious reasons.) In his narration, Bolinger notes that Dr. Kalvins is a member of the European Academy of Sciences and one of three finalists for the European Medicine Award in 2015 and has many publications and patents. In contrast, he does not mention that Dr. Kalvins owns a 3% stake in Rigvir. Googling him, I found that he is best known for developing a heart medication, Mildronate (generic name: meldonium). Interestingly, although Bollinger claims Kalvins has over 650 publications, I could only find ten in PubMed.
In any case, my first thought was: If such a seemingly good “conventional” scientist is behind Rigvir, then why is it that the IVC has not published anything resembling good science supporting its claims for Rigvir? This is not a person who doesn’t know how to publish. Oddly enough, he is not co-author of any of the few publications I could find in PubMed about Rigvir. Less oddly, given his support of Rigvir, he is not well-regarded outside of Latvia, basically because he makes claims for meldonium that are equally unsupported. Indeed, meldonium was the alleged performance-enhancing drug that Russian tennis player Maria Sharapova was caught using last year, leading to her suspension. Although it is approved in Latvia and several former Soviet Republics, it is not approved in the U.S. or European Union. Maybe Dr. Losans isn’t quite the good conventional science that the first impression gave me.
Be that as it may, Dr. Kalvins goes through the standard “history” of Rigvir, specifically about how Prof. Aina Muceniece discovered it. Interesting to me is Dr. Kalvins’s claim that Rigvir is used “very, very successfully” to treat melanoma and “not only melanoma.” I also wondered about his claim that Rigvir is a native, non-modified virus. That, of course, is likely true, as Rigvir is an Echovirus, specifically ECHO-7. As I mentioned last time, Echoviruses are RNA viruses that were thought to be orphan viruses (viruses with no known disease associated with them) but in fact do cause mostly (but not always) mild febrile diseases. In any case, Dr. Kalvins claims that Rigvir is a “non-mutating” virus, which, of course, also set my skeptical antennae a’twitching given that there is no such thing as a totally non-mutating virus. I suppose it’s possible that he means the ECHO-7 strain used in Rigvir doesn’t cause mutations in human cells, but who can tell for sure?
We also meet another physician, Peteris Alberts, MD, PhD, who is IVC’s Head of Research & Development. After Bollinger says that Rigvir’s activity was first demonstrated in mice, Dr. Alberts says:
Dr. Peteris Alberts: They found that if you take a tumor from a patient, put it into a hamster, then it will start growing, or something like that. If you put [it] on the virus, it will just fade away. Do you know who did that observation first? Ms. Garklava, the lady you saw this morning.
Ty: Really?
Dr. Peteris Alberts: Yeah. She did that.
There is a very brief shot of Bollinger interviewing an old woman, but none of the interview is heard, which I found odd.
Indeed, there are a lot of claims made for Rigvir, none of which seem to be supported by any publications that I’ve been able to find indexed in PubMed. For example, Dr. Kalvins is shown saying:
There are at least ten different cancers, locations of cancer like renal cancer, like breast cancer, like stomach, lung, many others, also prostate cancer, which is very, very common for men. But, approved officially, it is only for melanoma now, but this is a very, very big success because we see that the people who use this virus for other indications of other types of cancers also can be healed.
If this is true, then the IVC should publish these results. One of the excuses that IVC makes for not having published clinical trials to support Rigvir’s efficacy and safety against cancer is lack of finances. However, if the IVC has already done preclinical work that shows all this, there is absolutely nothing preventing it from publishing those results. It hasn’t. Why is that? (I think I know the answer.)
Another claim is made by Elita Shapovalova, MD, an oncologist at Riga East Clinical University Hospital:
In melanoma cases, in earlier stages when patients receive Rigvir, the percentage survived is 92 percent. And later stages, for example, if they receive Rigvir it’s 60 percent. If they don’t receive it, it’s only 9 percent. There’s no chemotherapy medicine that can treat melanoma, at least not found. In the beginning, we were using radiotherapy. But then, it got rejected. So we could not use it because it kills the immune system and it’s very hard to fight. We come back to chemotherapy — the medicine in the chemotherapy field is not found to cure melanoma. And the second negative is that it has side effects, which simply destroys the immune system, which lowers the quality of life of the patient, and simply changes the whole life of the patient by these side effects.
Again, if this is true, then the IVC should publish these results. As I discussed last week, the existing publications indexed in PubMed supporting the efficacy of Rigvir against melanoma are very unconvincing, and there are no randomized clinical trials to speak of, at least none to which I have access. (In actuality, in our e-mail exchanges, Ms. Lapa basically admitted that the IVC has no clinical trial results that meet modern standards.) For other cancers, the paucity of evidence is even more obvious.
None of that stops Dr. Kaspars Losans from claiming:
Then comes the second mechanism of RIGVIR. Whenever those RIGVIRs are attracted to cancer cells, those cancer cells become visible for the human immune system. Until that time, they are invisible, they have the natural ability to be hiding from the immune system. And due to the RIGVIR guidance, because RIGVIR is attached, and attach to cancer, and RIGVIR is inside the cancer cell. So the immune system, due to RIGVIR, recognizes cancer and starts to react against this cancer.
One more time, if this is true, than IVC should publish these results. This is the sort of immunological mechanism that would take a lot of cell culture, animal, and clinical work to demonstrate properly. That’s a detailed mechanism that Dr. Losans is claiming. If IVC has the experimental and clinical results to demonstrate such a mechanism, it should publish them. If it doesn’t, it has no business making claims like this on a documentary by a well-known proponent of cancer quackery, or anywhere else, for that matter.
Also, Dr. Alberts should stop making the ridiculous claim that prefaced Dr. Losan’s description of Rigvir’s mechanism of action that Rigvir is “the first real cancer therapy where you have an oncolytic virus which also has immunomodulating activity.” There are lots of oncolytic viruses under study with immunomodulatory activity. That’s the point! That’s the whole idea behind oncolytic viruses, that they “promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity.” Seriously, even if everything the IVC and its minions say about Rigvir is true regarding its mechanism of action, Rigvir is not the only oncolytic virus with a dual mechanism of action!
Finally, having Antonio Jimenez, the director of the Hope4Cancer Institute opining about how Rigvir boosts the immune system doesn’t help the credibility of Rigvir:
Often times, in clinical practice, we focus on optimizing the immune system – getting the best immune system possible. And that’s great. But still, cancer cells have now developed a way to bypass immune recognition. And the International Virotherapy Center here in Latvia, with the studies on RIGVIR, they have concluded that the RIGVIR is binding to the receptor site on the cancer cell surface, called the CD55. When it binds to this receptor, now the T-cells, the B-cells, the natural killer cells, will recognize the cancer cells and mount a specific immune response.
Again, that’s a very specific mechanism that Jimenez is proposing. Where’s the evidence to support it?
Again, seriously, any truly scientific institute that had developed a drug would not want a quack like Ty Bollinger or Dr. Jimenez endorsing its discovery. That’s the kiss of death as far as scientific credibility goes. Yet IVC embraces these quacks, sells to the Hope4Cancer Institute, and gladly lets its product be featured on a video documentary series designed to attack conventional oncology and promote alternative cancer quackery.
I also can’t help but scoff at the claims, made by several IVC boosters, that Rigvir has “no side effects.” For one thing, there is no such thing as an effective medicine that has absolutely no side effects. It’s clearly just not true. After all, even in the Melanoma Research paper from 2015 that I trashed last week as being so badly done, the authors noted that in previous clinical studies Rigvir had caused subfebrile temperature (37.5°C for a couple of days), pain in the tumour area, sleepiness, and diarrhea. Again, whenever anyone claims that an anti-cancer medication (or any medication, for that matter) is completely without side effects, I start becoming very suspicious.
But what about the testimonials?
A key part of TTAC‘s segment on Rigvir consists of three testimonials. The first was from a woman named Khrystyna Yakovenko, who in 2012 was diagnosed with melanoma that had metastasized to the liver:
It all started in the end of 2012. When I contacted my doctor, he diagnosed melanoma of the fourth stage, with a metastasize of the liver. They prescribed the plan of chemotherapy and at that time, I even didn’t understand what is what. I completely trusted our Ukrainian doctors and I trusted the methods they are using. I trusted this plan of chemotherapy. So I simply didn’t realize — I didn’t realize the effect of this diagnosis completely, entirely at that moment.
I can’t help but note that here Bollinger invokes a typical trope used by quacks, that you have to “believe” in the therapy, saying, “one of the very important parts about a successful cancer treatment is that you believe in it and you’re ready to fight to save your life.” After that, Yakovenko relates:
I was not feeling afraid. I was not falling into panic. Simply, I understood that I had no right to leave it. I had to fight. When I first came to my therapy center, doctors didn’t say, “Yes, we will do it.” They said, “We will try.” Because the stage was late. I think that sometimes on the earlier stages — on the initial stages people who have this very scary diagnosis, they sometimes are by themselves. They lose hope. They stop the fight. And they simply leave it. But, sometimes there are people who, even at late stages, they continue to fight, and continue to find the out of the situation. In this case, as the disease simply just is overwhelming.
So, basically, Ms. Yakovenko is a woman who was given a “maximum” of a couple of years to live, but was alive in late 2015 or early 2016, when this film was being made. That’s about three years, which is very good but not evidence that Rigvir prolonged Ms. Yakovenko’s life. Melanoma can have a highly variable course, and there are patients who survive with stage 4 melanoma for years. They are the outliers, of course, but there are too many of them to take someone who survived less than twice as long as predicted as slam dunk evidence that whatever cancer treatment she chose worked. I also can’t help but notice that no scans are shown, and no mention is made of whether her cancer shrank, was stable, or progressed. Yes, this is yet another unconvincing cancer cure testimonial.
A more recent interview, dated December 2016, is published on the blog of the Virotherapy Foundation (mentioned last week). Thus, Ms. Yakovenko’s story is continuing to be used to promote Rigvir, with her saying, “I have already been alive for 2 years and 7 months thanks to Rigvir,” which suggests that this interview occurred in the latter half of 2015, given that she started Rigvir in February 2013.
The next testimonial is a man named Ruslan Isayev, who reports that he was only given seven months to live. In the interview, we are not even informed what kind of cancer Mr. Isayev had, other than that he had surgery for it. I presumed that he had melanoma, which turned out to be correct, as you will see, but it’s very sloppy not to have specified the cancer. In any event, Mr. Isayev states that he tried chemotherapy after his surgery but couldn’t take it and stopped, living “for one year more without chemotherapy,” after which he decided to start Rigvir. Naturally, he credits the Rigvir with saving his life and even holds up a picture of his son, noting that he had been told that it would be very difficult for him to have any more children and that when he learned that his wife had become pregnant he vowed that “if were to be a girl, a daughter, I would name her after Aina Muceniece — after Professor Aina Muceniece, who was the discoverer, the great person, so Aina. And if it were to be a boy, then I would name him after the chairman of virotherapy, Jurgis, who is the grandson of Professor Aina Muceniece.” It was a boy, and he named him Jurgis.
A little Googling revealed, though:
In an interview on May 28, 2014, Ruslan Isayev gave a personal account of his experience with stage III skin melanoma. When he was diagnosed in 2010, the Chechen Republic doctors refused to operate on Ruslan. He went to Dagestan for surgery and after two weeks of lying in bed, the doctors gave Ruslan just seven months to live. He went to Grozny for chemotherapy, but after four doses he began to feel worse and worse. A local doctor then prescribed Interferon Alfa, a pharmaceutical drug meant to slow down tumor growth. Ruslan took this drug for one and a half years until a friend mentioned RigVir, an oncolytic virus created by the Latvian Academy of Sciences. After his third injection of RigVir, the doctors said his lymphonodus had shrunk and metastases disappeared. After a year of taking RigVir, Ruslan is alive and healthy.
Stage III melanoma is curable, I note. True, its survival rate is not great, but if the surgery is adequate long term survival is possible. I also note that Isayev received what sounds like considerable conventional therapy, including chemotherapy and a year and a half of interferon-alpha. As is the case with most such testimonials, it’s very difficult to ascertain whether the treatment had anywhere near the effect claimed because too little information is given. An account in Spanish reveals a rather convoluted story in which Mr. Isayev had surgery, had a number of complications, briefly underwent chemotherapy, and then underwent treatment with interferon-alpha, during which time he claims that his disease did not progress but that it “didn’t help me, either.” (Stable disease is actually a desirable outcome.) He then claims that after he switched to Rigvir his lymph nodes shrank, his metastases disappearing. Overall, it’s a convoluted story that does not really show that Rigvir is the reason why he’s still alive. Again, most likely, it’s the variable course of melanoma progression, the surgery, and interferon-alpha that have resulted in his continued survival.
Finally, there is a Russian woman named Zoya Sokolova, who states that she was diagnosed with “third stage cancer.” Again, the cancer isn’t identified, and I assumed that it was melanoma as well. This time, I was incorrect. It was sarcoma, as you will see. (Google is my friend.) In any case, in TTAC, Ms. Sokolova reports:
It was— the diagnosis was very sudden for me. It was after a very strong stress, and then after a month and a half, I was diagnosed with a third stage cancer. Already after the surgery I had my chemotherapy, then they assigned another six chemotherapy and a full course of radiotherapy. My condition allowed only for chemotherapy to be handles, and after the fourth, I wasn’t able to stand up from the bed. I became a bed patient. Before these courses of chemotherapy I was told about a center, about a treatment, but I believed in our doctors and their treatment methods. So I decided to follow that path.
Then:
It seemed that they wanted it to be so for me, but they couldn’t give a warranty, they couldn’t say for sure that I would [beat] this disease. That moment when I couldn’t stand up from the bed on my own. I was so weak, and my relatives decided to take a van, to make a bed for me, and simply drive me to Riga, to the center. Before coming to Riga I made a blood test and a complete observation for the doctors here to have the full picture of my condition. When the doctor saw my blood test she was really astonished because all the blood tests was lower than for a live person. She was astonished how I managed to get here, staying alive.
Here’s what it sounds like to me as a surgeon, based on the account above and the TTAC book that told me she was being treated for sarcoma. Stage III sarcoma means that either the cancer is larger than 5 cm in diameter and grade 3 histology or that it has spread to nearby lymph nodes. I note that stage III sarcomas are still potentially curable. Actually, even some cases of stage IV sarcoma are potentially curable if the distant metastases can be completely resected by surgery. Indeed, surgeons frequently resect lung and liver metastases from sarcoma, when they are few enough and small enough to be completely resected.
My reconstruction of the testimonial is that Ms. Sokolova underwent radical surgery for her cancer, followed by chemotherapy and radiation, both of which are frequently used to treat sarcoma. She obviously had a very bad time of it, suffering multiple complications to the point where she was bedridden. After she began the Rigvir, she slowly recovered from the complications that she had suffered and, of course, attributed her recovery to Rigvir. At no point in this testimonial is any evidence provided that the Rigvir had any effect on her tumor. As far as I could tell from every description of her case, she was tumor-free at the time she chose to use Rigvir, just very ill from complications of surgery, radiation, and chemotherapy. Rigvir almost certainly did not save her, as much as Ms. Sokolava believes that it did, tells the Virotherapy Foundation that it did, and now uses virotherapy to “strengthen her well-being” and prevent recurrence. Again, there is no evidence that Rigvir prevents the recurrence of sarcoma.
Not surprisingly, Bollinger laps up this story as evidence of how great Rigvir is as a cancer treatment.
A previously discussed testimonial revisited
In my post last week, I briefly mentioned a testimonial that is featured on the International Virotherapy Center website:
In brief, Nadine is a British woman who had melanoma in 1999 that recurred in 2009. We know that she’s undergone surgery, radiation therapy, and chemotherapy, but that she still has cancer. She is portrayed in the video as doing well after having started Rigvir, even though she is not cancer-free. What I didn’t know (but perhaps should have discovered through Googling) last week is that Nadine has a GoFundMe page that paints a much more dire picture of her situation. It was last updated six months ago, which makes me worry about whether she is still alive:
Recently, she has seen huge success from a treatment she had at the Global Virotherapy Cancer Clinic in Latvia. The centre there offers holistic care and a course of virotherapy. Incredibly, just one week after returning from Latvia, Nadine’s scan showed that the 2cm tumour on her lung had completely disappeared and all-but-two of her other tumours had shrunk significantly. This is a huge breakthrough and so now Nadine needs to obliterate all the other ones too and go back to Latvia every three months for further treatment at a cost of around £7,000 a time.
Although this treatment isn’t available in the UK, it is something that is now being trialled in the USA in combination with immunotherapy, which Nadine is receiving through our amazing NHS.
This treatment is working amazingly well at keeping surface lumps and bumps at bay – a few injections at sites near them sees them shrinking and vanishing – so this must be kept going.
Unfortunately though, the cancer has managed to take up residence in her lower intestine, making it impossible to eat or drink. Nadine, as resilient and incredible as ever, hasn’t taken this lying down and has insisted the surgeons try to clear enough of her stomach to allow fluids to pass. As soon as this happens, she will be heading to Hungary for Gerson Therapy. This holistic therapy has been responsible for some fantastic results in other melanoma patients, and Nadine is determined to get out there and get this thing back under control. This therapy will cost around £7,000 too. So, Nadine really needs YOUR help!
Malignant small bowel obstruction due to melanoma is definitely not good. Fortunately, update #2 shows that she did undergo surgery for her bowel obstruction:
Just a little note to say Thank you to everyone who’s checked in with me after my operation on Tuesday.
I’ve been using the cannabis oil instead of morphine and codeine for pain relief, with the added bonus that I can’t be bothered to speak or move…. My kids and sister are delighted!!!! Lol
I am soooooo happy too, that with your help I’m almost at my target to help towards my next batch of treatment…I can’t thank you enough.xxxI promise to send each of you a thank you message , bear with me… Xxxxx
So next week once the shoulder starts to heal I have a full on week of getting back on track.
Monday I’m meeting a lady to discuss Biomagnetism therapy, Tuesday follow up at the nutritionists, weds back to hospital for checks, Thursday we get back on the virotherapy injections…..and Saturday I start the spring mindfulness course, this is key in keeping my mind focused and living in the moment.xxxxxxxx
Some times people ask me what I’m doing for work, as you can see, my full time job is trying to stay as well as possible and keep plugging away at trying to find why I’ve got this disease in the first place.
That was six months ago. It is unclear when the video featured on the IVC website was shot, but it’s dated August 11, 2017. However, in it Nadine doesn’t mention any surgery for a bowel obstruction; so either that was intentionally not mentioned, with the bowel surgery falling under the rubric of “many operations,” or this video was recorded before her bowel obstruction, which, I note, happened while she was undergoing virotherapy, as was made clear to me reading her GoFundMe page. Obviously, the Rigvir didn’t stop her tumor from progressing. Yet, the IVC is still using Nadine’s testimonial in a deceptive—dare I say irresponsible—manner to sell Rigvir. Yes, I stand by my original assessment, and unfortunately that irresponsible and unethical use of patient testimonials to promote Rigvir is having an effect, particularly now that more and more alternative cancer clinics appear to be offering it.
Meanwhile, Rigvir marketers appear to be using using legal thuggery to try to silence Latvian critics. For example, Riga Stradiņš University recently received a letter from Sorainen, a law firm representing Rigvir Holding, regarding Dr. Santa Purvina, who is faculty there. The letter asked whether Dr. Purviņa’s statement that the studies upon which the approval of Rigvir were based were inadequate represented the view of the University. If that isn’t an attempt at intimidation, I don’t know what is.
The more I learn about Rigvir and the International Virotherapy Center, the more I think the whole operation stinks to high heaven. It should be interesting to see what lands in my e-mail in box this week. Be assured that I do plan on publishing the entire e-mail exchange eventually. I merely held off because I was particularly interested in how the IVC will respond to the e-mail that I sent on Friday. In the meantime, the whole Rigvir operation is starting to remind me of the Burzynski Clinic, only worse given the marketing to alternative cancer clinics and the even more transparent than usual excuses for not doing clinical trials. What I do see is the marketing of Rigvir using the same methods that Stanislaw Burzynski uses to market antineoplastons, patient testimonials and through alternative medicine-promoting hucksters like Ty Bollinger.
That’s not a good strategy for a company marketing a science-based treatment. It is, however, a good strategy if you’re marketing quackery. Which is it, Rigvir?

Rigvir strikes back, or: A conversation with a Rigvir flack
My skeptical analysis of Rigvir, a “Virotherapy” from Latvia being promoted by alternative medicine clinics as a cancer cure, caught the attention of the International Virotherapy Center (IVC). The result was a long and very telling e-mail exchange between its Assistant of Business Development and myself. I post it because the arguments used in the discussion are very telling about where the IVC is coming from when it comes to science. Hint: It’s not a good place.
David Gorski on October 2, 2017
Link

Over the last two Mondays, I’ve been writing about an unproven cancer therapy that I hadn’t really heard much about before. The cancer treatment is called Rigvir; it is manufactured in Latvia and marketed primarily through a Latvian entity called the International Virotherapy Center (IVC). To recap, Rigvir is an unmodified Echovirus, specifically ECHO-7, that, according to the IVC, seeks out cancer cells, replicates in them, and thus lyses the cancer cells (causes their membranes to break, spilling out the cancer cells contents, thus killing the cell), hence the term “oncolytic virus.” Somehow, mysteriously Rigvir was approved by the Latvian equivalent of the FDA in 2004 for the treatment of malignant melanoma despite what appears to have been grossly inadequate supporting evidence and then even more mysteriously placed on the Latvian Health Ministry’s list of reimbursable medications in 2011. I suspect that the reason that I didn’t look into Rigvir earlier was probably because its use had been primarily restricted to Latvia, Georgia, and Armenia. Also, there was the language barrier. Nearly everything available on the web about Rigvir is in Latvian, a situation that has only recently begun to change.
It was Antonio Jimenez and Ty Bollinger who plucked Rigvir from obscurity. Dr. Jimenez runs the Hope4Cancer Institute clinics in Baja and Cancun, Mexico, and, for whatever reason (probably profit), these clinics started offering Rigvir relatively recently. Then, Jimenez, who’s clearly worked with Bollinger in the past, must have turned Bollinger on to Rigvir, and Bollinger included it in a long segment of Episode 3 of his The Truth About Cancer (TTAC) propaganda series of videos. It was this connection and the deceptive use of patient testimonials by both Bollinger and the International Virotherapy Center to sell Rigvir that formed the basis of my second post on Rigvir last week.
As you might imagine, apparently the management of the IVC was not happy about my posts. In fact, so unhappy was the management of the IVC that within 15 hours of my first post about Rigvir going live I got an e-mail from someone named Lelde Lapa, whose title was listed as Assistant of Business Development Department at the IVC, protesting and attempting to refute my post. As I noted before, I was amazed at how fast I received such a long e-mail after publishing my post. Clearly the IVC has many Google Alerts set for Rigvir and its name and was fast to act. What followed was an exchange that currently stands at five e-mails, three from Ms. Lapa, with two responses from me, with Ms. Lapa’s tone (if it indeed was only one person writing these) becoming more strident as the exchange went on. Because these e-mails are a great insight into the thinking (such as it is) at the IVC, I decided that a most excellent way to conclude my series on Rigvir as a trilogy would be to annotate and publish these e-mails, and then to compose a final response to Ms. Lapa’s third email, at the end of which Ms. Lapa told me that I didn’t need to respond.
Clearly she don’t know me vewy well, do she?
So let’s begin. Remember that English is not Ms. Lapa’s native language; so be kind. I wasn’t kind, but not because of any difficulties Ms. Lapa might have had with English.
Rigvir strikes back, round 1
So on the afternoon after my first post about Rigvir went live, I was greeted by this in my e-mail in box:
From: Lelde Lapa To: [email protected]Subject: Blog about RIGVIRDate: Tue, 19 Sep 2017 00:54:53 +0300Organization: RIGVIR Development department
Dr. Gorski
Yesterday we encountered one of your blogs (https://sciencebasedmedicine.org/rigvir-another-unproven-and-highly-dubious-cancer-therapy-to-be-avoided/?utm_source=dlvr.it&utm_medium=twitter)
Due to the fact that this blog is now widely spread by non-professionals with the title – independent conclusion from international expert, we believe we have the rights to inform you that you are used now as a tool in competition wars. Which we believe was never your intention.
The medicine RIGVIR has a clinical experience for more than 50 years and it is registered for melanoma for more than 13 years and before the era of modern trials and most of the evidences is not published. Doctors and clinics in Latvia use this medicine for majority of melanoma patients in Latvia for many years. In Latvia medicine is prescribed only in national clinics and by certified doctors and they have also other alternatives, so probably they know what they do.
2 years ago we started EMA (centralised EU) commercialisation process and even obtained EU commission support from Horizon2020 grant, we also obtained EMA regulatory advice. There is no doubts about the efficacy and safety of the medicine, however we acknowledge that we miss modern trials for centralised registration and we are working on them. This was never a secret to discover.
But year ago a group of very active, mostly anonymous people appeared that started to attack us, our cooperation partners, even EU commission, spreading bias data or even lies. They are very aggressive. Part of the sources they use does not exists, part of materials are generated by them self and republished in different sources mostly social networks, then in blogs and then cross-referenced. Part of material is made as compilation of different phrases and translated in English with certain pseudo professionals on them (By the way two such persons appears also in your blog, these persons however has no proper educations, has never been involved in medicine or science). Moreover at the spring anonymous letter (your blog also indicated it ) appeared. It was signed by few professional organisations of which only 2 are related to oncology and in fact were represented by the same people, this letter contains ~80 lies and tendentious distortion of information. Unfortunately there is no author on the horizon to be responsible for aspersion, but there have been cases when TV and portals have withdrawn similar articles and information about us already.
Mostly your blog analyses openly available data, but partially it contains false information. It contains also comments of pseudo professionals or anti-PR specialists but the producer of RIGVIR was never approached for clarification or comments. Which is sad especially, referring to the statement from the blog: “Somehow I doubt Rigvir will make it that far. At least, I sincerely hope that it doesn’t….”
We believe that also blogs should be objective and respectable professors should use only proven data and also verified sources. So please consider to here also our position and obtain more information about virotherapy with RIGVIR, like clinical trial data and post-registration experience.We do provide special trainings for doctors and medical scientists.
I hope you are interested,
Looking forward for your replay.
Best Regards,Lelde LapaAssistant of Business Development Departmentwww.virotherapy.eu
Of course, I had no idea who this Lelde Lapa was. I couldn’t really find anything about her. A Google search of the IVC website for her name didn’t reveal anything. For my purposes, it doesn’t really matter, but I did find it odd.
I can’t help but note here that, although I do not claim to be completely objective, my bias is rather well known: I favor science as the basis of determining which medical treatments do and do not work. I make no bones about that. Moreover, I couldn’t help but immediately note that it’s pretty hard to use “only proven data” when there is so little in the way of proven data upon which to evaluate Rigvir. That was, in fact, my key problem with the drug, that it is unproven and being marketed without sufficient scientific and clinical evidence that it does what is claimed for it.
Here was my response, sent later that evening:
Dear Ms. Lapa:
The Virotherapy Institute must be very on top of its social media to have noticed my post and composed such a lengthy e-mail to me within 15 hours or so after my post went live. If you have any specific examples of errors in my post, feel free to point them out. What I see in your letter is not that; rather, it is spin, as nothing you wrote actually casts into doubt any facts included in my post or in any of my interpretations of those facts.
Yes, I used publicly available information because that’s what many bloggers do when they compose posts. Besides, I was interested in what I view as the irresponsible marketing of Rigvir for more than just melanoma, and there is plenty of that to be found on the Internet and social media. The two videos on your website that I discussed fall into that category, without a doubt. In your e-mail, you state that there are “no doubts about the efficacy and safety of the medicine,” but there are doubts—a lot of doubts—so much so that my jaw dropped when I read that. The reason is simple. You yourself said it: “…we miss modern trials for centralised registration.” Basically, you don’t have anything resembling the level of scientific evidence required before we accept any drug as effective and safe. You have no randomized double-blind clinical trials. All you have are a handful of case reports, a couple of very poorly done retrospective studies, and ancient evidence from decades ago that cannot be inspected and assessed for scientific rigor. In my country, our Food and Drug Administration would laugh at such data.
If you’re making health claims for your product, particularly the glowing claims made about Rigvir’s anticancer activity, then all that matters to me is whether there is solid evidence to back up those claims published in the peer-reviewed medical literature as indexed on PubMed. Of course, this evidence must be in the form of papers reporting improved recurrence-free and overall survival in well-designed, randomized double blind clinical trials of your product for every cancer for which a claim of efficacy has been made. I do not care about unpublished data that I cannot examine myself. I do not care about claims. I do not care about “registration,” as clearly the registration process in Latvia at the time Rigvir was registered left a lot to be desired. I do not care about pilot grants to start to work on approval by the EU. None of that matters when evaluating a therapy if there is no good clinical trial evidence supporting its efficacy and safety. Unless you can provide me with those data, I have no choice but to find your complaints about my article to be without merit.
If Rigvir has been proven safe and effective and isn’t quackery, then why are you selling it to quack clinics in Mexico and Germany? I’m serious. Hope4Cancer, for instance, is a notorious quack cancer clinic that attracts Americans with cancer. This is not in dispute and can be verified by simply reading the Hope4Cancer website and examining the treatments it offers cancer patients. Also, if Rigvir has been proven safe and effective and isn’t quackery, then why was it featured on Ty Bollinger’s “The Truth About Cancer” video series and, more importantly, why is the administration of the International Virology Center proud of being featured in his videos? Bollinger is a notorious promoter of cancer quackery. (I can provide many examples of him promoting dubious, unproven, and quack treatments for cancer.) No reputable company selling a cancer treatment scientifically proven to be effective and safe would ever want to be associated in any way with the likes of Hope4Cancer or Ty Bollinger, because it would tarnish its brand and bring it into disrepute.
In actuality, your response makes me more confident than I was originally that I was correct in my assessment. Your paranoia, for instance, is makes me very suspicious. You rail against “anonymous people” attacking Rigvir and the Virotherapy Center, but isn’t it true that the complaints to the Latvian Health Ministry came from the two main oncology professional associations in Latvia? That’s hardly “anonymous.” They are respected professional medical societies! I also have seen quite a few criticisms of Rigvir on blogs and have been able to identify everyone making the criticisms so far. Perhaps you meant The Mad Virologist, but he isn’t really anonymous either. His name is in his Facebook profile, which I found in two minutes. Complaints about “anonymous” people out to disparage a product always make me think a company has something to hide.
Finally, I understand that you and Latvia are proud of Prof. Muceniece’s accomplishments, but ask yourself this: If she were alive today, would she want her name associated with selling her discovery before it’s actually scientifically demonstrated to prolong the lives of cancer patients or cure specific cancers?
David
In actuality, I had no idea whether Prof. Muceniece would care what the IVC is doing. I just wanted to see if there was any sense of shame over what the IVC was doing with her invention.
Rigvir strikes back, round 2
A couple of days later, I received this. For reference, the blog by Eduards Ritums was discussed in my first post and used in part as a basis for some of my criticisms. In any case, note the somewhat paranoid tone. I also showed my e-mails to a skeptic from Latvia who has been active investigating Rigvir, who thought that the style changed enough that it might have been written by someone else. I don’t know for sure if that is the case (you can judge for yourself), but I do know that the fallacies and dubious arguments flow freely and with paranoia:
From: Lelde Lapa To: ‘David Gorski’ References: <[email protected]><[email protected]>In-reply-to: <[email protected]>Subject: RE: Blog about RIGVIRDate: Thu, 21 Sep 2017 10:03:42 +0300Organization: RIGVIR Development department
Dear Dr. Groski
As we indicated in our last email your blog now is spread widely in Latvia as a proof that our medicine is not effective. Was it a goal of your blog?
We got impression that the blog is a part of wider campaign that is currently in place in Latvia and therefore we just wanted to warn you ASAP and protect your reputation by providing more information if you are ready to hear it.
Part of your blog is based on the article that is published by author E.Ritums initially in very specific marketing magazine for Pharmacies. This magazine is published by Medicine Information Centre (http://mic.lv/materia-medica/ ) that is not registered in the register of mass media and even provide marketing services (http://mic.lv/materia-medica/). In addition the content of this magazine (according to law in Latvia) is considered to be specialised publication and may not have public access. The author however (based on google search) is young graduate from faculty of Chemistry that in addition to this particular article has published few (~3) more small articles and hardly is respectable journalist. Particular publication consists of number of fact errors and doubtful allegations and there is no respectable or proven sources, books or reviewed publications indicated as reference. Moreover former manager (for 12 years) of the same publisher and magazine Inara Rubene ( https://www.linkedin.com/in/inara-rubene/) is presented as independent expert here. The biggest issue is, however, the fact that this article later, bypassing limited access info (according to law) to specialists, was translated (with inconsistencies) and spread widely with help of very small, non registered NGO – Skeptiskā Biedrība (https://www.lursoft.lv/lapsaext?act=URCP&ref=LurTop&regcode=&task=search&company_name=&tipas=&CompanySearchForm%5BcompanyName%5D=Skeptisk%C4%81+Biedr%C4%ABba&CompanySearchForm%5Bcountry%5D=&utf=0&general=Skeptisk%C4%81+Biedr%C4%ABba&cid=LVA_NG_PROD), that operates web site – www.skepticisms.lv. Do you consider this as trustworthy source to build part of your story on?
Please note that official page of the product RIGVIR is rigvir.com and there is no marketing at all. Page virotherapy.eu is mostly dedicated to therapy not medicine – there are news, testimonials and trainings. It is not a clinic or pharmacy to speak about marketing. Should we hide testimonials, if there are such?In Latvia there are very strict regulations for marketing of pharmaceuticals and there is no official judgment from Latvian Health Inspection about as you say “irresponsible marketing”. Moreover the only one claim from Latvian Health Inspection, that initially was stated so, is already changed clearly stating that we cannot be responsible for third party activities.
As you know the clinical studies are done mostly for official approval of medicine and according to Bloomberg at least one third of studies are never published. So if you are clearly stating that you don’t care about unpublished data, then please adjust title of your blog to something like “Analysis of published data of RIGVIR”. Because ignoring unpublished clinical trials for more than 30 years, you simply don’t have all the facts to loudly state that our medicine is not effective or it should be avoided.
Let us clarify that medicine RIGVIR is registered in Latvia in 2004 for Melanoma, before the era of modern requirements for trials, but based on clinical trials during 30 years period in which ~700 patients was treated with the medicine RIGVIR (there is also registration in Georgia and Armenia). The medicine is used as conventional therapy in Latvian, Georgian and Armenian clinics. In addition to that, patients from all over the world are coming to Latvia or sometimes are sending relatives or trust-persons to Latvia to buy this medicine in case traditional therapies have not succeeded or are not well tolerated. Yes we do train medical doctors from all over the world and probably their patients also have acquired medicine from Latvia. We know that the medicine is effective, we have seen it working on many thousand cases and we clearly know that it has no side effects. So knowing that, should we refuse to help patients of any Doctor?
We are not company that is developing innovative solution and according to the heritage of the founder prof. A.Muceniece the medicine should be available to as many patients as possible. We are not refusing the knowledge and information to any official doctor, official clinic or patient groups. So we don’t see any problem also from appearing in The Truth About Cancer series.
Most of our critics and also yours complains are catch-22 logic – “give us evidences before you use it -> new evidences requires investments -> to provide investments we need to use medicine –> to use medicine we need to be commercialised -> but with the existing evidences you doubt us to be commercialised …” As if only rich pharmaceutical or biotechnological companies may work in the field…
You are stating that you don’t care about existing registration, but unfortunately your analysis is used to doubt the registration. Which is off course strange, because nowhere in the world rules and regulations (in our case standards for clinical trials) are used with backward date.Yes for new registrations – we know the rules – we will provide proper RCT data, but as for now, please respect that the medicine is prescription medicine that is prescribed only in national clinics and by certified doctors for last 13 years. They have alternatives and even reimbursed ones. So obviously these doctors have deeper knowledge about the therapy with RIGVIR, than just analysis of published data, since it is used for more than 70% of Melanoma patients in Latvia.
We suggest you to learn about this therapy and try it yourself for your patients (that follows entrance criteria) as well. In such case and with your commitment to make case report and publish it, we would provide all the necessary assistance and medicine free of charge.
Best Regards,Lelde
Gee, Ms. Lapa makes the observation that my blog post has been circulated far and wide in Latvia as evidence that Rigvir doesn’t work as though that were a bad thing! In actuality I can’t help but feel a bit of a warm and fuzzy feeling in the pit of my cold, black heart that my post has actually been circulated far and wide in Latvia. Those behind IVC will probably take this as evidence that I’m out to get them, but I’m not. I’m out to protect cancer patients. If the IVC had the goods, as far as evidence, the easiest thing for its management to do would have been to publish it or somehow show it to me and other skeptics who are concerned that Rigvir is cancer quackery. We can be persuaded, but it takes evidence.
Finally, notice that last part, in which “Ms. Lapa” tries to co-opt me, thinking that if I were to try Rigvir I would conclude that it works. I’ve noticed this pattern before, and where I’ve noticed before it isn’t flattering to Rigvir or the IVC. You see, I’ve discovered that when it comes to cancer quackery or unproven cancer treatments I seem to have special cachet because I am a cancer surgeon and researcher. Thus, from time to time, cancer quacks try to convince me to try the treatment they are selling on my own patients. In my response, I decided to stomp down hard on this offer after giving a bit of a lecture. See what you think:
Ms, Lapa,
Although I appreciate your concern about my reputation, I think I’m probably the best judge of what will or will not damage it. In other words, I’ll take my chances.
Regarding Eduards Ritums’ article, which I did cite extensively, I tend to judge an article and its main arguments far more by quality in terms of evidence, science, and reason than by who wrote it. Even though the article I read was an English language translation, Mr. Ritums’ central thesis and arguments nonetheless came across as very sound. It doesn’t matter if he’s young and early in his career and thus hasn’t published very many articles yet. In other words, who cares if Mr. Ritums published his article in a pharmacy magazine and is a new journalist? I certainly don’t. As for whether the magazine is “registered” or not, as far as I’m concerned that is a matter of your country’s specific laws and ways of doing things. It means very little to me as an American reading a translation of the article. In fact, it wouldn’t matter to me if Mr. Ritums wrote for an unregistered blog under a pseudonym if his arguments, science, and evidence were sound. Certainly, you have not demonstrated that they are not sound; you state that there are a “number of fact errors and doubtful allegations,” but, oddly enough, you have not actually specified the errors of fact or “doubtful allegations,” much less used evidence and science to show that they are factual errors or doubtful allegations. You have instead engaged in nothing but ad hominem, which is a logical fallacy. To convince me, you’re going to have to get a lot more specific and provide the evidence to back up your criticisms, something you have not yet done after two long e-mails. I find this very telling.
As for your claim that official Rigvir website is not about marketing, I beg to differ. The whole website is clearly all about marketing, as all pharmaceutical company websites are. Indeed, it looks just like any other pharmaceutical company webpage promoting its products, complete with slick videos, like the one on this page. Basically, your website looks like any of a number of websites pharmaceutical companies maintain for individual products, like Herceptin, OncoTypeDX, or various new drugs. It’s not quite as slick, but it is very similar in appearance and content. True, it doesn’t contain patient testimonials, but that doesn’t make it any less a marketing website. Regarding the testimonials on the Virotherapy Center website, as a surgical oncologist, I find them quite misleading. Insufficient information is provided to allow me to judge whether Rigvir might have had an effect, and one in particular is definitely not evidence that Rigvir had a positive effect. Again, when I accused you of irresponsible marketing, I did it from my perspective as a cancer surgeon and researcher. Again, I really don’t care what Latvian law says with respect to marketing pharmaceuticals. Clearly, from my perspective, Latvian law is far too lax if it allows you to market Rigvir.
You say that Rigvir was registered in 2004, “before the era of modern requirements for trials.” I hate to tell you this, but the basic standards for modern clinical trials were codified decades before that. In the US, it was 55 years ago in 1962 when the Kefauver-Harris Amendment to the law creating the FDA mandated that the FDA to require rigorous clinical trial evidence of efficacy and safety before it approves a drug for marketing. Are you honestly telling me that 42 years after that Latvia still didn’t require such evidence before approving a drug? If true, I find that shocking. Be that as it may, Latvia’s lax drug regulation 13 years ago is not an argument in support of the efficacy and safety of Rigvir even for melanoma, much less other cancers. Certainly, it doesn’t excuse you from selling the drug to a quack clinic in Mexico. And, make no mistake, Hope4Cancer is a quack cancer clinic, as I have documented elsewhere. (It even offers coffee enemas.) I’d suggest that, if you really want Rigvir to be accepted outside of Latvia, Georgia, and Armenia, selling it to a quack clinic to market to patients it is not a winning strategy. It will taint Rigvir with the stench of quackery. I’d highly suggest that you sever all ties with these clinics immediately, but I suspect that suggestion will fall on deaf ears.
You say over and over that you “know” that Rigvir is effective. The fact is that you do not, at least not based on science and clinical trials, which is how doctors are supposed to know which drugs work and which do not. You claim that I ignored 30 years worth of clinical trials. Whose fault is that? You haven’t published them in a form that can be critically examined. If you had, I would have critically examined them. You wouldn’t even have to translate them into English. I’m sure I could find someone to translate the data for me if you were to publish all this data. Why don’t you?
No, I will not change the title of my post. It is accurate, as far as I am concerned. I stand by my opinions and conclusions, and, yes, I still strongly believe that you should stop marketing Rigvir until such a time as clinical trials show it to be safe and effective. Certainly it should not be used for any cancer other than melanoma, and even for melanoma I don’t think you’ve shown sufficient evidence that it works to justify marketing it. Again, I say this because you can’t show me any decent scientific or clinical trial evidence to change my mind. Again, why is that? Does this evidence actually exist, or does it actually show Rigvir has such miraculous effects against melanoma? I suspect that it either does not exist or is not nearly as impressive as you claim. Indeed, there is a contradiction here. You say that 70% of melanoma patients in Latvia since 2004 have been treated with Rigvir. Why is it, then, that you could only find 52 melanoma patients treated with Rigvir for your 2015 Melanoma Research paper?
Finally, although I am intrigued by your offer to provide Rigvir for free for me to try on my patients, unfortunately I don’t see how I can do it. Let me explain to you how we do things in the US. Doctors here can’t just go around administering unapproved drugs willy-nilly to patients if we feel like it. Were I to administer Rigvir to patients without proper approvals, I would quickly find myself in deep legal trouble—and rightly so! Were I to want to administer Rigvir to patients, it would have to be in the form of a clinical trial. I would first have to submit an Investigational New Drug (IND) application to the FDA, because Rigvir is not approved in the US. The FDA would then have to approve it. Next, I would have to write a protocol for a clinical trial. Let’s say I chose to do a phase I clinical trial, which would not require randomization. That application would have to be approved by the FDA and approved by my institution, specifically my cancer center’s Protocol Review and Monitoring Committee and my university’s Institutional Review Board (IRB). Both would almost certainly say no, based on lack of evidence to justify the trial. They would want preclinical evidence in cell culture and animal models, at the very least, or more compelling human evidence. You can provide me with neither.
Of course, certainly I would be happy to review the educational materials you provide doctors who wish to administer Rigvir to patients. Maybe they would start to change my mind, although I’ll be honest with you and inform you that I doubt it. However, contrary to what you think, my mind is not closed. What it takes to open it more is high quality scientific and clinical evidence. Provide it, and perhaps it will convince me. If you continue to fail to provide it, and you’ll never change my mind. The ball is in your court.
Sincerely
David
P.S. My last name is GORSKI, not GROSKI!
OK, I admit that that last bit might have been a bit petty, but I’ll let you in on a secret. When I was in grade school and junior high, other kids used to call me “Grosski.” So it irritates me to see it again. Mea culpa. I’m human.
Rigvir strikes back, round 3
The IVC didn’t respond right away. It took a few days. Indeed, I was beginning to wonder if Ms. Lapa was going to respond again at all, particularly after nothing arrived immediately after my second post about Rigvir. Then, just as I was about to send a quick e-mail to tweak Ms. Lapa and see if I could get a response, this hit my e-mail in box:
From: Lelde Lapa To: ‘David Gorski’ References: <[email protected]><[email protected]> <[email protected]>In-reply-to: <[email protected]>Subject: RE: Blog about RIGVIRDate: Tue, 26 Sep 2017 18:55:40 +0300Organization: RIGVIR Development department
Dear, Dr. Gorski
I am sorry that misspelled your last name in our previous mail.
We are very grateful for every objectively critical remark that is addressed to RIGVIR and we always are trying to provide additional information to the source in order to improve objectivity. This time we however are relay surprised that someone who calls for scepticism and ask for proves, can easily believe to articles without any proven references or sources, that contains statement from people openly in conflict of interest and that is published in non-official portals in order to avoid responsibility for aspersion. And particularly we are sad that you was never interested in our position or in our facts that we openly offered and that are not published.
During last month we have seen lots of false news and lies that was spread in Latvia in order to neglect RIGVIR, part of these news is spread under the name of respectable organisations. But unfortunately most of the stories does not have real authors. Most of this campaign is done via social networks so we need time to respond to attacks and we will inform you about the results. In the meantime we are open to organise professional seminars and conventions to share our information. For example, last Friday during the 8th Latvian Doctors Congress, satellite symposium about virotherapy and RIGVIR took place. Reports on clinical trials and post-marketing experience in clinical practice were presented to doctors. Around 5000 doctors were invited and everybody had chance to ask any question to our leading managers. We however received no question from the audience.
Regarding rigorous clinical trials, most probably the definition has changed over time. For example the 1.st RCT ever was run just after the WWII. What we today call rigorous was defined only in the late 1990ies. While for example the FDA started requiring 5 year survival data for oncologic drugs, in the early 2000 those kind of data were still available only for a portion of NDAs. However A very direct outcome of WWII was that Latvia lost its independence. As a consequence, Latvia was literally thrown decades back, as well as held back, in all aspects of an advanced society. You may find that shocking to learn in 2017, but we can assure you that was a shocking “experience” already at that time on site. And it lasted for 50+ years. A slight and minor side effect, was that regulatory requirements did not adhere to the US framework. They were the so called Soviet style, which include lack of publication as well. Today, however, Latvia is part of EMA territory with the most up-to-date regulatory requirements. Therefore, the mode of showing efficacy has changed both over time and in space. Nevertheless, the requirements regarding efficacy were and are fulfilled. And this again is approved by the Ministry of Health of the Republic of Latvia that on 4th of September 2017 issued official statement supporting that RIGVIR is registered and included in the list of reimbursed medicines appropriately (see English translation enclosed) and here is in latvian source: http://www.vm.gov.lv/lv/aktualitates/preses_relizes/5507_par_zalu_registracijas_kartibu_/
Regarding the use of Rigvir in Latvia. It may also come as a surprise to you that the medical records system in Latvia has not really changed since WWII. This, of course is not the companies responsibility. It may perhaps assist you in appreciating inclusion criteria used and the effort in managing the analysis published in Melanoma Research.
When you discuss about our clinical trials or reproach us about lack of publications we are kindly ask you take into consideration also the economic differences between USA and Latvia fully into account, for example GDP per Capita in Latvia is around 15 thousand Dollars, while in USA it is 52 thousand Dollars or for example the whole budget for melanoma treatment of Latvia is around 0.7 MUSD. In other words you know how much those things costs and you should not judge from the stand point of the most advanced economy with the highest healthcare and science budgets.
We are founders (Prof. A.Muceniece) family owned company that’s heritage is to provide this innovative treatment to any patient in the world who needs it and we will not discriminate any patient regardless from which clinic the patient comes.
In your latest blog you have analysed part of testimonials about virotherapy with RIGVIR (Please note however that Ty Bolinger’s activates are not related to us). We have seen complains that stories of our patients was just coincidence or that there were other factors behind the survival. But what if we would provide you with many dozens of such testimonials and cases? Is there something at all to convince you? This brings us back to the offer to you – to try the medicine for your patient. For early stage patient they should use medical tourism to Latvia, but with late stages or in cases where there are no other treatment solutions, you might consider in application of extended use of non-registered medicine on-name basis to use the medicine in USA. Off course all the time with your supervision to monitor closely the efficacy. This means that it would be case analysis not a clinical trial. Due to work with EMA we would not initiate any activity with FDA yet, although we have preclinical and clinical evidences to start.
We find this discussion, your blog and your activity in twitter really wired. If you suggest that there are better medicine for cancer patients, please use it. We have never limited anyone doing that. RIGVIR is a prescription medicine, patients cannot get the medicine by them self without doctor involvement.
So to wrap up – if you would like to explore virotherapy and use it as a treatment, we are ready to cooperate with you and teach you about our evidences.But further correspondence and the exchange of opinions is not necessary any more.
Sincerely,Lelde
Ms. Lapa (or whoever I’ve been corresponding with) might not think that an exchange of opinons “is not necessary any more” and that she can flounce off, digitally speaking, but I beg to differ. So, instead of responding right away, I decided that a public response would be more appropriate, to be unveiled this morning. So here’s my response to Ms. Lapa. I’ll be sure to send her a link to this after this post goes live. After all, why bother if the person to whom I respond doesn’t see my response?
So here we go. Here’s my response written over the weekend:
Dear Ms. Lapa:
You clearly don’t know me very well if you thought I would not respond to this. Indeed, given what Rigvir Holding and the IVC are doing, I think it’s a public service to show what you have been telling me to my readers. It’s also not true that I am not interested in your position. If that were the case, I would never have bothered to engage in this lengthy e-mail exchange. That’s the point. I’ve been trying to find out what evidence you have to support all the claims being made for Rigvir’s efficacy in melanoma and other cancers. All that’s indexed in PubMed is very thin gruel indeed when it comes to clinical evidence. It’s not at all convincing. Yet you keep claiming you have this highly convincing evidence while making excuses for not publishing it and whining about people criticizing Rigvir on social media. Well, I have news for you: That’s the world. Social media matters. You keep claiming that what’s being said about Rigvir is false, but somehow you never actually bother to prove it to be false. And do you know how you could prove that it’s false? Show us the data, just like drug companies in the US and EU have to do!
So you had a satellite symposium on virotherapy at the 8th Latvian Doctors Congress. That’s great, but not enough. A Google search shows that you had this conference but nothing about its results. Most satellite conferences publish abstracts of the work presented at the meeting, at least. Such abstracts are not viewed as being as convincing as a publication in a peer-reviewed journal indexed on PubMed, but they are at least something. After your conference, I am currently still left with nothing. It wouldn’t even matter to me if the abstracts or conference proceedings were in Latvian. Show me the data! You claim to have clinical trial results and postmarketing results presented at this conference? Publish them! After my previous two posts on Rigvir, I’m sure that I can find someone to translate them if necessary. In the end, I can’t help but wonder if your symposium was more of a marketing presentation than an actual scientific conference.
Next, I do not need a discourse on the history of clinical trials and FDA requirements for approval of drugs, as I am well aware of that history and when the first randomized clinical trials (RCTs) similar to what we do now were carried out. I mentioned the 1962 Kefauver-Harris Amendment to the law creating the FDA mandated that the FDA to require rigorous clinical trial evidence of efficacy and safety simply to point out that evidence from high quality RCTs has long been a requirement for drug approval in the US and Europe. In oncology at first that meant measuring an endpoint known as overall (or objective) response rates (ORR), which measures what percentage of the patients treated demonstrate tumor shrinkage. Unfortunately, ORR is not a great surrogate for overall survival. So by the early 1980s, the FDA started to require evidence of improvement in OS. While it is true that these days, in order to speed up the process of drug approval, the FDA has been accepting surrogates for OS, such as pathologic complete response (pCR) and granting provisional approval for drugs that produce such surrogate endpoints, I note that Rigvir has no convincing published data supporting the conclusion that it can even meet those lower standards for provisional approval.
I also do not buy your excuse that Latvia’s medical record system hasn’t changed since World War II. Believe it or not, until very recently, many US hospitals still used paper charts and relatively primitive record keeping. Many private practices still do. It took laws and incentives from the US government to prod our medical system into adopting electronic health records, and, even then, I note that we will probably never have the excellent centralized medical record systems that some countries in Europe do. As for your excuse that Latvia is a poor country. I counter that the very fact that Latvia is a poor country relative to the US and much of Europe is a very good reason that its government shouldn’t be wasting money on cancer treatments whose manufacturer cannot produce strong evidence of efficacy! Yet, since I took an interest in Rigvir recently, I’ve seen claims that up to 70% of melanoma patients in Latvia are treated with Rigvir. In a country like Latvia, that is insanity if true! Think of what could be done with all that money if it were redirected to treatments that work!
I also see Rigvir being advertised as effective against a wide variety of cancers when not even you have claimed to me that it is effective against any cancer other than melanoma. You claim that Ty Bollinger’s activities are not related, but I don’t see it that way. In making the long segment on Rigvir in Episode 3 of The Truth About Cancer (TTAC), Bollinger obviously had the full cooperation of the IVC’s leadership. He brought Dr. Antonio Jimenez with him, who runs the quack cancer clinic Hope4Cancer and is now selling Rigvir in Mexico. He had access to your clinic and interviewed luminaries such as Dr. Ivars Kalvins, your medical director Dr. Kaspars Losans, and your director of research and development Dr. Peteris Alberts, as well as three of your patients. The resulting segment was highly laudatory and presented Rigvir as a miracle cure based on dubious testimonials. Like many cancer patients who found out about Rigvir from TTAC, I had heard very little about your virotherapy before TTAC was released and view the video series as the best marketing for Rigvir I’ve seen anywhere. Somehow, I doubt that you would have cooperated so much with Mr. Bollinger if you thought his segment would do anything other than praise Rigvir and the IVC the way it did.
I conclude by again addressing your offer. I will be blunt. My opinion is that it is unethical, and I will not accept it. Basically, you appear to be paying for case reports that you can publish. My impression of this is backed up by this article on your website about grants for publications, in which the IVC announces that it is offering €5,000 “grants” for “publications on clinical studies of oncolytic virotherapy, observations or clinical cases in a publication that can be quoted in PubMed” and that the study “is intended on using oncolytic virotherapy rather than using oncolytic virotherapy in combination with other cancer therapies, medication etc.” In other words, you want case reports or studies looking only at virotherapy, which, given the doubt about Rigvir’s efficacy, would be highly unethical. I note that you also request that grant applicants “inform IVC on the publication topic and present to IVC the document draft before commencing the project and submitting it to the chosen journal.” To me this sounds as though you expect the paper to be written, regardless of whether the study has already been done or not, but in fairness I will allow that the ambiguity could be due to a poor grasp of English on the part of whoever wrote this web page.
Finally, before you express such disappointment with my blog posts and my activity on Twitter, I note that the Business Development Manager of Rigvir Holding, Kārlis Urbāns, has been attacking me on Twitter using fake news sources. He’s been quite nasty. Here are examples:
Jā ļoti neatkarīgs Onkologs no ASV, kas nez kāpēc perfekti citē Latviešu valodu un jau iepriekš barojies no farmas – https://t.co/ENKPlndHFi
— Karlis Urbans (@kurbans) September 29, 2017
I note that he cites a post made by a notorious antivaccine blog, Age of Autism. I note that the bloggers at Age of Autism don’t like me because I routinely skewer antivaccine pseudoscience.
Here’s another example:
Un cik nav fake itkā-onkologu vēstule? Ir jau vēl daudz, piemēram, https://t.co/bBX9uS8IPg
— Karlis Urbans (@kurbans) September 29, 2017
TruthWiki is a fake wiki maintained by Mike Adams, who runs the quack and alt right (yes, both) website NaturalNews.com and got his start selling Y2K scams. The conversation after that is quite amusing, even though I can only read it through the stilted English from computer translation from Latvian on Twitter. I note that Mike Adams has been defaming me on his website for a year and a half now and is up to around 40 lie-filled posts about me. You’ll excuse me if I don’t take your lamentations about how mean and nasty I’ve been to the IVC seriously when the BDM and CFO of Rigvir Holding is quoting fake news sources that routinely lie about me and trying to portray me as a tool of big pharma out to destroy Rigvir.
So to wrap up – if you would like to provide acceptable scientific and clinical evidence for the efficacy of Rigvir against any cancer, I am ready to cooperate with you and learn about it. Otherwise, further correspondence and the exchange of opinions are not necessary any more.
Sincerely,
David H. Gorski, MD, PhD, FACS


“Chemotherapy is for losers”: A tragic tale of cancer, naturopathic quackery, and murder
When a patient and her family trust a naturopath rather than oncologists and oncologic surgeons, the result is often tragic. In this case, Fikreta Ibrisevic trusted naturopath Juan Sanchez Gonzalez instead of real doctors to treat her rhabdomyosarcoma in 2015. The results were as tragic as expected, and she died. What happened next was not expected and amplified the horror of the outcome, as, in his grief over his wife’s death Ibrisevic’s husband Omer Ahmetovic, went beyond just suing.
David Gorski on March 13, 2017
Link


We at Science-based Medicine (SBM) have written rather copiously about naturopathy over the years, because naturopaths are pseudo-physicians with delusions of grandeur whose quackery endangers patients. Basically, naturopathy is a cornucopia of unscientific, pseudoscientific, and mystical “medicine” (e.g., homeopathy, traditional Chinese medicine, various bogus diagnostic tests and treatments) and some borderline medical practices (e.g., herbal medicine, whose benefits naturopaths massively oversell), all “integrated” with modalities appropriated from conventional medicine and rebranded as being “alternative” and part of naturopathy, such as nutrition, diet, exercise, and other lifestyle interventions (and in some cases, even prescription medications). Unfortunately, the core belief that “natural” is better and the tendency of naturopaths to embrace any quackery, as long as it seems “natural” (e.g., “functional medicine,” which combines lifestyle interventions with the very worst excesses of conventional medicine), leads naturopaths to lobby for licensure. (That and the fact that licensure makes reimbursement by third party payers more likely and gives naturopathy respectability through the imprimatur of state endorsement and regulation.) Never mind that naturopathic training is, contrary to how naturopaths portray it, far inferior in both time and content to that of MDs and DOs, and completely inadequate to the task of being a primary care physician who deals with common diseases such as diabetes, while the oversight of “naturopathy boards” is grossly lax, as is their research ethics. Also, naturopaths, by and large, tend to be antivaccine, with very few exceptions, and those exceptions tend to have at least some dubious views about vaccines themselves. Basically, naturopathy is a “specialty” (if you can call it that) whose precepts are rooted in prescientific concepts, which is why there is no real standard of care in naturopathy, as can readily be deduced from what naturopaths say to each other when they think no one is listening.
I’ve written about the sorts of horrible outcomes that occur when patients trust a naturopath, rather than a real oncologist or surgeon, and this is one such tale. However, it comes with a twist that makes it even worse. I’ll just start with this story from the Bowling Green Daily News:
A Bowling Green man accused of killing naturopathic doctor Juan Sanchez Gonzalez had, at the time of Gonzalez’s death, an active lawsuit filed against Gonzalez in Warren Circuit Court alleging that Gonzalez guaranteed he could cure the man’s wife of cancer.
Omer Ahmetovic, 35, 501 Eric Ave., G51, was charged Wednesday with murder in Gonzalez’s death, according to his arrest citation. The citation doesn’t list a possible motive in the death.
Ahmetovic’s wife, Fikreta Ibrisevic, died Feb. 27, according to the Warren County Coroner’s Office.
Ahmetovic is being held in the Warren County Regional Jail in lieu of a $1 million bond. A hearing is set in the case for Wednesday in Warren District Court.
Clearly, the motive being attributed to Gonzalez’s alleged killer has to do with his having deceived Ahmetovic and Ibrisevic into thinking that he could cure Ibrisevic’s cancer. When he failed, Ahmetovic sued, but even that was allegedly not enough for him; so now he stands accused of murder. What started out as one potentially preventable death turned into two deaths, with a grieving husband facing murder charges. How did this happen?
“Chemo is for losers,” or: Naturopathy fought cancer, and cancer won

As I learned more details by doing relevant searches and finding more news stories, it turned out that the story was even worse than that first take sounds. Ahmetovic’s wife, Fikreta Ibrisevic, was diagnosed with rhabdomyosarcoma in late 2015. Sarcomas are a form of soft tissue cancer and usually form in muscle, bone, or connective tissue. When localized, treatment usually consists of a wide excision with a healthy margin of normal tissue ± radiation (usually plus) ± chemotherapy, depending on the type and stage of sarcoma. Rhabdomyosarcoma is a form of sarcoma that develops in skeletal muscle and is usually a childhood cancer, although it can occur in adults, in whom it is rare. Although the five year survival in children treated for rhabdomyosarcoma is around 70% or even higher, survival in adults is poorer. Indeed, recent review of 25 adult cases reported a 45% five year survival with a combination of surgery, radiation therapy, and chemotherapy. I couldn’t find a report of where Ibrisevic’s primary cancer was located, extremity versus trunk versus head and neck, nor could I get a copy of the actual lawsuit in time because they don’t appear to be available online; you have to request them. The lawsuit was filed on January 25, and Ibrisevic died on February 27. For purposes of this narrative getting into the serious details doesn’t really matter.
This does:
Ibrisevic was diagnosed with rhabdomyosarcoma, a soft-tissue cancer, in late 2015 to early 2016, according to the lawsuit. The couple were interested in natural therapies while Ibrisevic waited to be scheduled for the beginning of traditional cancer treatments.
On or near Jan. 11, 2016, Gonzalez told the couple that traditional cancer treatments such as radiation and chemotherapy were for “uneducated” people and he could “guarantee” Ibrisevic would be cancer free with his treatments within three months, according to the lawsuit. He is further accused of telling Ibrisevic that “chemotherapy is for losers.”
So basically, Ibrisevic and her husband were a bit woo-prone and wanted to investigate “natural” therapies for her newly diagnosed cancer. If the claims in Ahmetovic’s lawsuit are accurate, his wife was planning on undergoing conventional therapy for her cancer but changed her mind and decided to pursue naturopathic treatments in response to Gonzalez’s statement that “chemotherapy is for losers” and his other claims, particularly his claim that he could render her cancer-free within three months without the toxicity of surgery, radiation, and chemotherapy. It’s easy to see how someone, when faced with a life-threatening disease that can only be treated by a combination of potentially disfiguring surgery, toxic chemotherapy, and radiation therapy, which has its own potentially unpleasant side effects, would be tempted by a confident statement by a charlatan like Gonzalez that he could cure her within three months without her having to endure all that. One can imagine the temptation if the patient already had leanings toward wanting “natural therapy,” as Ibrisevic clearly did.
This is what happened next:
Ibrisevic began treatments which included buying herbs from Gonzalez, massages, foot soaks, dietary instructions and other treatments. From January through May 2016, Ibrisevic and Ahmetovic paid Gonzalez and Natural Health Center for Integrative Medicine more than $7,000 for the treatments and herbs, according to the lawsuit.
When Ibrisevic began treatment, she had one tumor. When she discontinued treatment with Gonzalez she had seven tumors, according to the lawsuit.
“The original tumor became so large to the extent that it was visible outside of her body,” according to the lawsuit. “Her eyes began to turn yellow and her legs began to swell. After she discontinued treatment with the defendants, after one round of traditional chemotherapy, the only tumor that remained was the original tumor.”
Now, I will admit that I was surprised at how little Gonzalez charged the couple for his services. Although $7,000 is by no means a small amount of money for most people, usually when I read these stories I see totals in at least the tens of thousands of dollars, and, when it’s someone like Stanislaw Burzynski, hundreds of thousands of dollars. Be that as it may, rhabdomyosarcoma is usually a pretty aggressive form of sarcoma; so it’s not surprising that, left untreated (and, make no mistake, that’s what it was, untreated with anything that could potentially stop it), the tumor grew and metastasized. The fact that Ibrisevic’s eyes turned yellow tells me that her liver was likely affected, leading to jaundice either from masses obstructing the bile duct or from sheer burden of metastatic disease in the liver. Alternatively, the jaundice could have been due to toxicity from some of the herbal medicine. Similarly, the observation that her legs swelled leads me to think that she probably had developed metastatic disease in her abdomen that was compressing the inferior vena cava or her external iliac veins (the veins in the pelvis to which the veins from the lower extremities drain). Either of these would be a bad sign. Both were even worse, particularly coupled with a tumor that, from what it sounds like, was starting to erode through the skin.
Basically, Ibrisevic died because she trusted a quack instead of conventional medicine. Yes, she had probably a 50% chance of dying anyway if she had accepted conventional treatment before it was too late, but that’s a 50% chance she didn’t have once she believed Gonzalez’s claims and acted upon them.
The lawsuit
By January, I can make an educated speculation that it was obvious that Ibrisevic was not going to survive. So Ibrisevic and her husband filed a lawsuit accusing Gonzalez and his Natural Health Center for Integrative Medicine of negligence, fraud, violation of the Kentucky Consumer Protection Act, loss of consortium of spouse and children, lack of informed consent, battery, practicing medicine without a license, and intentional infliction of emotional distress.
In summary:
In alleging negligence, the couple asserted Gonzalez provided services and herbs “without adequate scientific or medical foundation when compared to substantial risk involved,” which Ahmetovic and Ibrisevic were not told and by his criticism of traditional cancer treatments as being ineffective. Ahmetovic and Ibrisevic also accused Gonzalez of failing to use reasonable care in the herbs provided, causing toxic levels that prevented her body from being able to heal.
The fraud allegation accuses Gonzalez of misleading Ahmetovic and Ibrisevic regarding his qualifications and his ability to treat cancer patients.
Ahmetovic and Ibrisevic are Bosnian refugees and English is not their native language, making them “more vulnerable to being misled,” according to the suit. As a result of that and other statements included in the lawsuit, they claim a lack of informed consent in that they were not informed of the risks of treatment provided by Gonzalez and in foregoing traditional cancer treatment.
The lawsuit also said Gonzalez violated state law in practicing medicine without a license. The lawsuit seeks unspecified compensatory and punitive damages.
A review of the timeline can’t help but sadden; so, to the best of my knowledge based on my reading on the case, I reconstructed one. It began in late 2015, when Ibrisevic was diagnosed with this cancer. In January 2016, they sought out Gonzalez, who treated them for a period of time that isn’t clear from the news reports. By late 2016 or so, it was clear that Gonzalez’s quackery wasn’t working and that Ibrisevic’s tumor was progressing. During that time, she still consulted with other naturopaths, who reported that Gonzalez had administered so many herbs that Ibrisevic had a toxic reaction. At this point, she apparently returned to conventional care and underwent chemotherapy, but it was too late. Although some of her tumors responded to chemotherapy, she clearly by this time had metastatic disease and was doomed. So on January 27, 2017, she and her husband filed suit, which was answered on February 6. However, sadly, she died a month later, on February 27.
Then, on Friday, March 3, a mere four days after his wife’s death, Ahmetovic allegedly walked into Gonzalez’s office after hours and shot him dead. One can imagine him waiting until after his wife’s funeral, and then doing the deed.
The victim
Juan Sanchez Gonzalez founded and ran the Natural Health Center for Integrative Medicine in Bowling Green, Kentucky. The website for his clinic looks a lot like a lot of other websites I’ve examined for naturopaths. Its front page advertises a lot of obvious quackery, and his self-description reads thusly:
I am a Naturopathic Doctor, Iridologist, Master Herbalist and currently working towards my phD in integrative medicine. I offer an iridology evaluation prior to recommending a non-invasive method of treatment to establish a health protocol which may include medicinal herbs. The evaluation is a critical component whose aim is to remove the source of the disease and facilitate healing in a non-invasive, non-toxic manner. Evaluating a person’s condition requires in-depth knowledge of biochemistry, chemistry, biology, physiology, anatomy, psychology, and all other systems which comprise the totality of who we are.
Iridology, of course, is the rankest of quackery, akin to phrenology 150 years ago. Basically, like chiropractic, it’s a pseudomedical specialty invented out of whole cloth by a “brave maverick doctor.” It’s a lot like reflexology in that, as reflexology claims that various organs and body parts “map” to specific parts of the soles of the feet and hands, iridology “maps” body parts to parts of the iris. Basically, it’s the homunculus model. Like many alternative medicine practitioners, he claims to have “converted” after “Western medicine” failed him. In this case, Gonzalez was diagnosed with diabetes and “discovered that western medicine as a whole could not heal this condition.” He enlisted in the Army, went to college, received a degree in Business Management, after which he got his MBA. Then he attended the Trinity School of Natural Health.
This is a school we’ve met before, and it’s not even an “accredited” school of naturopathy. Basically, its graduates can’t be licensed in states that license naturopaths, which gives you an idea of how bad this school is. It’s ultimately more of a Bible school than anything else, being highly religious. As Harriet recounted a few years back, the only admission requirement for Trinity’s ND program is a high school diploma or GED, and the curriculum consists of 15 installments of a correspondence course, with a list of classes full of quackery: Bach flower remedies, reflexology, iridology, homeopathy, applied kinesiology, acupressure techniques, aromatherapy, dry blood analysis, assessing health by acid/alkaline balancing, and so on. So Gonzalez is not even what naturopaths would call a “real” naturopath in that he got his degrees through a correspondence course that’s not even recognized by naturopathic quacks as valid.
Not surprisingly, Gonzalez’s list of services reads like Quackwatch, only credulous: iridology, far infrared sauna, BrainTap™ brain wave balance, heart variability rate monitor, medicinal herbs, body detox and the dreaded “detox footbath” (which is about as quacky as you can get), cellular antiaging therapy, and more. Indeed, the site even advertises a hyperbaric oxygen chamber, listed as “coming soon.” Surprisingly, he appears not to have offered acupuncture.
Clearly, Gonzalez was not a doctor, not even an ND, which, although I like to say ND stands for “not a doctor,” still tends to get newspapers and other media outlets to call naturopaths “doctor.” He clearly had no qualifications whatsoever to be treating a patient with a rare cancer, like Fikreta Ibrisevic. None of this has stopped Erin Elizabeth at HealthNut News from lionizing him. In case you don’t remember, Elizabeth is Joe Mercola’s girlfriend and deep into promoting quackery through her website. Indeed, after the death of antivaccine activist Jeff Bradstreet by suicide before the FDA had him arrested for selling a bogus “cure” for autism, she was the one who concocted a conspiracy theory in which Bradstreet was taken out by…it’s never exactly clear who. Starting with the death of Nicolas Gonzalez, who died of a heart attack about a month after Bradstreet, Elizabeth then proceeded to latch on to every alternative medical practitioner who died under mysterious circumstances and posit a “conspiracy” in which all those killings were related. She’s still at it, and her list of “mysterious” deaths of alternative medicine practitioners now numbers over 60 and has even influenced television.
So naturally, she was quick to jump at the Gonzalez case:
Patients have emailed (and even posted in the comments below) that Dr Gonzalez was treating cancer patients- successfully. In fact, he had (allegedly) asked a few to testify as he had some upcoming court dates, apparently for treating said cancer patients. As we all know, the government doesn’t like holistic doctors treating cancer patients.
If you click here you can access the full list of 60+ doctors and their stories, who have been found dead in the last year and a half. Just this last week 48 hours and Criminal Minds (both on CBS national television) showed my collages and or quoted my site and this uninteded series. Sadly, neither named my site (I’m not surprised), as that would give the people too much info. My mission is not to let their stories die.
You can see her laying the groundwork to add Gonzalez’s name to her list. Oddly enough, she appears not to have followed up since March 4. I wonder why. It couldn’t be that learning that the chief suspect in the murder is the grieving husband of a patient who died because Gonzalez convinced her to let him treat her instead of a real doctor didn’t fit in with her conspiracy theory, could it?
Why don’t more people sue quacks like Juan Gonzalez?
If Omer Ahmetovic really did kill Juan Gonzalez, I can understand and even empathize with his motivation, even though I can’t approve of his crime. I’ve always believed that the law is far too lax on health fraud, allowing quacks like Gonzalez to defraud patients like Fikreta Ibrisevic, who, frightened at the prospect of rough treatments like surgery, chemotherapy, and radiation therapy, might not be sophisticated enough to see through his claims. I don’t just say that about alternative medicine quacks either. When I learned that Christopher Duntsch, a neurosurgeon who had left a trail of paralyzed and dead patients in his wake in Texas, so much so that he had been nicknamed “Dr. Death,” was actually going to be tried for assault, I was shocked and overjoyed. When I learned that he had been convicted and sentenced to life imprisonment, I felt that justice had finally been done. I also knew that this sort of result is rare, but I sure wish that it could have happened with Juan Gonzalez’s case.
The more interesting question that Ahmetovic’s murder of Gonzalez brought up for me was: Why don’t victims of quacks sue more often? Remember, Ahmetovic and his wife sued Gonzalez a month before her death. The case hadn’t proceeded very far, as Gonzalez’s attorneys had entered their response. As far as I know, discovery hadn’t begun yet, but, again, I don’t have access to the court documents. The point, though, is that this lawsuit was unusual. Quacks are seldom sued by patients or the patients’ families when bad things happen.
In Quackwatch, Stephen Barrett points to a book by historian James Harvey Young, Ph.D., The Health Robbers: A Close Look at Quackery in America, where Young pointed out:
Along with fright go tenderness and self-confidence. Most quacks manage a superb “bedside manner.” Since they can’t really provide a cure if major disease is present, they specialize in promises, sympathy, consideration, concern, and reassurance. The patient responds to such attention. This helps explain one of the odd paradoxes relating to quackery—that failure seldom diminishes patient loyalty. When regulatory agencies seek to prosecute quacks, the agencies have a difficult task getting hapless patients to testify in court. Partly this results from the desire to avoid public exposure as a dupe; but often this objection to testifying rests on an inability to realize that deception has taken place. Many quacks do such a good job of exuding sincerity that their explanations seem all too plausible. Even patients faced with death believe in the “kindly” person who says the special remedy would have worked if treatment had only begun a little sooner.
Regular readers here will note the ring of truth of these words. To prosecute or sue a quack, the patient (or the patient’s family) must first admit to themselves that they were taken in by the quack, that they were fooled to make the worst possible life-or-death decision. They frequently blame themselves. Worse than that, by publicly bringing charges against or suing a quack, they are publicly admitting that they were dupes. Never mind that human nature makes us all easy to fool, particularly in areas where we don’t have a lot of expertise, as most people don’t know much about medicine, but human nature also means that pride and shame conspire, often coupled with exhaustion from having fought (and often lost) a serious disease, to sap the motivation to seek justice.
Then there’s this. Young notes something that those of you who have been following the Stanislaw Burzynski tale will find very familiar:
Many times the regulator must compromise, allowing a wrongdoer to escape severe penalty because full prosecution would overtax the limited resources of the regulator. At other times, the regulator must suffer the leniency of the courts. While the average judge may become duly outraged when a victim of quackery is seriously harmed, in the majority of cases, no such victim is in sight. The con artist who peddles phony “reducing belts” for $9.95 is unlikely to be sent to prison even if his total take amounts to millions of dollars. For small sums of money, the courts seem to feel, fools must be allowed to suffer the consequences of their folly.
The regulator’s task would be eased greatly if victims of quackery would rally to his support. But an opposite trend is evident: many victims are so thoroughly deceived that they engage in political activities that oppose regulation. During the 1970s, when the FDA tried to limit false claims and dangerously high doses of vitamins, a coalition of vitamin sellers and their brainwashed customers persuaded both Congress and the courts to limit FDA jurisdiction over this matter (see Chapter 28). When the FTC considered banning commercial use of the words “natural” and “organic,” another avalanche of protest persuaded the agency to back down. The health-food industry continues to lobby fiercely to prevent the FDA from strengthening labeling regulations to curb the industry’s deceptions.
In some instances the regulator has been so cleverly labeled a villain in the quack’s promotion that the very existence of regulation has been made to enhance quackery’s appeal. Events like Vietnam and Watergate created widespread disillusionment with government. Inflation, the filling-out of tedious forms, and other irritating circumstances evoked widespread assertions of overregulation. Quacks profit from such distrust. It makes them sound credible when they charge that health regulators are not interested in the welfare of the individual but are conspiring selfishly with the medical profession, the drug industry, or the food industry.
Sound familiar? It’s the Stanislaw Burzynski case writ large, who has benefited many times from the limited resources of the Texas Medical Board and FDA (who have tried to prosecute him but in general failed to shut him down completely), as well as compromises by regulators (as when the FDA allowed him to reopen his clinical trials), and the leniency of the courts (as when the court opened the way to Burzynski setting up his infamous 72 clinical trials that he used to keep administering his quackery over more than 20 years). Given rising tide of anti-government and anti-regulatory sentiment, this problem is likely to get worse before it gets better, if get better it ever does.
It’s hard not to wonder, as Mark Crislip did yesterday, whether this will result in the premature deaths of more people due to naturopathic “doctors.” I hope not. I’d much prefer that the legal system deal with these quacks.

Did cannabis oil save Deryn Blackwell, the “boy in seven billion,” when his bone marrow transplant for two cancers was failing?
In a forthcoming book The Boy in 7 Billion, Callie Blackwell claims that cannabis oil, which she had started giving her son Deryn to relieve his symptoms during a bone marrow transplant for two cancers, actually saved his life when the bone marrow transplant appeared to be failing. Unfortunately, her story appears to be another testimonial that confuses correlation with causation.
David Gorski on March 27, 2017
Link

[Note: Callie Blackwell has commented after the post. Although I can’t agree with her conclusion that Deryn’s story is strong evidence that cannabis played a vital role in his recovery from bone marrow failure, she did make one good point, specifically that she never claimed that cannabis cured Deryn’s two cancers and that I shouldn’t have represented the excerpt to her book that way. She has a point. Although she clearly portrays cannabis as having been vital to her son’s seemingly miraculous recovery, to her it was because it somehow helped rescue the failing bone marrow transplant, not because it cured his cancer. Because I strive for accuracy in what I write and don’t even want to give the wrong impression stating facts, I have edited this post to remove any passage that said (or sounded as though it were saying) that Ms. Blackwell ever claimed that cannabis cured her son’s cancers. Mea culpa. Unfortunately, I doubt that the UK media will be so quick to stop representing Deryn’s story as proof that cannabis can cure cancer.]

It’s been a while since I’ve written about the burgeoning business of selling marijuana as a cure for whatever ails you. As I’ve written before, there exists a mystical faith that is very much like herbalism that marijuana is a magical plant that can cure, well, almost anything, including cancer, glaucoma, autism, ADHD, and many other conditions, when in fact the evidence is rather shaky for most, if not all, of these claims. Regarding cancer, the usual claim is not that smoking marijuana cures the disease, but rather that cannabis oil isolated from marijuana cures cancer, a claim that Rick Simpson has profited from after claiming to have cured his skin cancer with cannabis oil in 2003.
Over the years, I’ve examined a number of “cannabis cures cancer” (or, truth be told, “cannabis cures” this or that condition) testimonials (e.g., Stephanie LaRue’s story). Like most alternative cancer cure testimonials, when you take a closer look, inevitably the case being made that it was the cannabis oil (or whatever derivative from marijuana was used) cured the cancer (or saved the patient’s life after complications of therapy) is nowhere near as convincing as the advocates making the testimonial claim. Usually, there is another explanation for how well the patient is doing and/or the link between starting cannabis oil and clinical improvement is not nearly as convincing as it seems on the surface. As with the case of the belief that vaccines cause autism, human beings mistakenly attribute correlation to causation. Add to that a dash of confirmation bias, something we human beings all suffer from, and it’s very easy to come to develop an unshakable belief in a post hoc ergo propter hoc fallacy in which something they observed or did before something else happened must have caused that something else to happen, be it vaccines “causing” autism or cannabis “curing” cancer.
I bring this up because there is a new “cannabis cures” testimonial going around the UK that was brought to my attention yesterday. It was about a boy named Deryn Blackwell, who beat leukemia and the very rare Langerhans sarcoma through multiple bone marrow transplants (BMT). The cannabis comes in during his last BMT, when his mother gave him cannabis oil to relieve his symptoms as his transplant appeared to be failing and was overjoyed when her son recovered after having been in hospice for over a month. Her story portrays cannabis oil as being responsible for bringing Deryn back from the brink of death. Predictably, the British tabloid media is portraying his story as a “cannabis cures cancer” story, even though, even taken at face value, it is not. I had already started a post on another topic when I saw this, and it grabbed my attention to the point where I abandoned what I was writing before to take a look at this testimonial. On the surface, it is a very convincing testimonial, which is why I decided, as Seth Myers would put it, to take a closer look.
The story of Deryn Blackwell, as told in the media
Deryn Blackwell is a 17-year-old boy whose story appeared in The Daily Mail over the weekend in an article entitled “I gave my little boy CANNABIS to help cure his cancer: Mother reveals how her teenage son who was given days to live made a miracle recovery when she gave him the drug behind his doctors’ backs.” (As an aside, besides its being a tabloid rag, it’s always irritated me how The Daily Mail loves ridiculously long headlines.) Other papers featured basically the same story with long similarly long headlines like “‘I GAVE MY BOY CANNABIS’ Mum reveals she gave her cancer-stricken son CANNABIS in bid to ease his pain… and now he’s made a miracle recovery.” Basically, Deryn’s story was all over the UK press over the weekend. The Daily Mail story is an excerpt from a forthcoming book (of course) chronicling Deryn’s battle with cancer entitled The Boy In 7 Billion, by Callie Blackwell with Karen Hockney, to be released on April 6. The description of the book reads:
The powerful and moving true story of a remarkable relationship and a tenacious fight for survival. Callie reveals her son’s struggle through the physical and mental torment of battling cancer against impossible odds, and the truth behind her son’s ‘miraculous recovery’ that she has held secret for years.
And it’s true. Deryn’s story is indeed remarkable, as you will see. The “secret” that Callie Blackwell has never revealed—until now!—is that it was cannabis that saved her boy when he was on the brink of death due to a failing bone marrow transplant. But was it? Let’s take a look at that excerpt. It starts out with this heart-rending description of Deryn as he got sicker:
The pain was getting worse. The tips of my son Deryn’s fingers were hard and black from a superbug infection. His nails were peeling away and any remaining live flesh was covered in weeping sores.
Every day, he begged me: ‘Please tell them to cut my hand off, Mum. I can’t take this any more.’
Deryn was nauseous and, worse, had become addicted to his anti-sickness drugs. He was allowed a dose every seven to eight hours but within an hour of being given some, he would press the buzzer to call the nurses back in.
What mother wouldn’t be utterly distraught watching her son suffer like this? What mother wouldn’t start to consider things that she normally wouldn’t, if only she could ease her son’s suffering. So Callie Blackwell did this:
Deryn had suffered enough. In 2010, when he was just ten years old, he had been diagnosed with leukaemia.
Eighteen months later, he was told he had a secondary cancer, the extremely rare Langerhans cell sarcoma. Only 50 cases have ever been recorded and only five people in the world currently have it. But no one had ever been found to have the two cancers combined, making Deryn unique. One boy in seven billion people.
By 2013, after nearly four years of hospital treatment, it seemed that the only thing left for him were opiate drugs to ease the pain as he reached the end of his life.
Like any mother would be, I was desperate to find something to alleviate his suffering.
I spent hour after hour researching on the internet, and that’s where I came across reports of a substance called Bedrocan, a cannabis-based painkiller that wasn’t available in the UK. Surely Bedrocan had to be a better option than mind-numbing morphine?
But the doctor told me that while it was effective, it had not been tested on children and she couldn’t prescribe it.
So Simon and Callie Blackwell, in an effort to ease their son’s suffering, sought out cannabis. Simon nobly took responsibility for obtaining some marijuana, using the rationale that if anyone were to go to jail for this he wanted it to be him and didn’t want Callie to be away from their son. The two of them did what most people who’ve decided to use alternative treatments do and read extensively on the Internet, where they learned to make cannabis extract suitable for a vaporizer pen using a rice cooker and vegetable glycerin, noting that in 2013, when they first decided to use cannabis:
Back at the hospital, meanwhile, our son’s latest bone marrow transplant had failed. Staff were giving up on him. It seemed Deryn’s death was a done deal and now all we could do was wait until he drew his final breath. If there was no improvement in two weeks, he would be placed in palliative care.
So what happened? Callie Blackwell went through with her plan. She brought her son the vapor pen:
Deryn sucked on the pen, breathed in and blew out a massive cloud of vapour – and we frantically waved our hands around trying to disperse it, although there wasn’t the smell of cannabis. It smelt more like popcorn. After ten minutes, Deryn said that the pain had decreased a little and he felt more relaxed – the words we had been longing to hear.
Alas, his condition continued to worsen. By December 2013, Deryn had moved out of hospital and into a hospice, where he planned his own funeral. His bravery attracted national attention and some of his favourite celebrities, including Paul Hollywood, Pauline Quirk and Linda Robson came to meet him.
I note that, here, despite Ms. Blackwell having started to sneak a cannabis vapor pen to her son for an unclear number of times, her son continued to deteriorate, and the vapor pen was only providing him with modest relief from the pain. He went to hospice, as far as I can reconstruct, two weeks after his mother started to sneak him puffs of cannabis. This is hardly the sort of “cannabis saved my child” story that sounds promising, at least not to this point.
Further deterioration…and then a “miracle”
What happened next is that, as Deryn’s condition continued to deteriorate during the two weeks after Callie Blackwell started to give him cannabis oil. Because he complained that he didn’t want any more morphine because it made him “feel like I’m not here,” she wanted to provide better relief and started wondering whether she could achieve a higher dose of cannabis by giving it to him orally. In actuality, she was almost certainly providing him a higher dose through the vapor pen, but she nonetheless decided to try. So on New Year’s Eve in 2013, roughly five weeks by my reckoning after she started sneaking her son cannabis oil by vapor, she tried it:
I was sitting next to him, a nightly vigil, and held his hand. Once again, the situation seemed quite desperate. What would happen, I wondered, if I gave Deryn a small amount of golden cannabis tincture directly in his mouth? The vaporiser had brought him some relief but could a higher dose have better results?
I took a small, empty syringe from the medicine cupboard in the hospice and quickly checked that there was no one outside. It was New Year’s Eve so staff levels were minimal. I drew up 5ml of the honey-like substance, which had a sweet, floral flavour.
Still sobbing uncontrollably, Deryn opened his mouth and I popped the syringe underneath his tongue. Deryn held it for a minute before swallowing. Half an hour passed. He was no longer having a panic attack. He looked peaceful. I asked him how he was feeling.
‘I feel relaxed,’ he told me. ‘I’m aware of everything. I just feel at peace, Mum. It’s beautiful.’
It’s a powerful story. No wonder it’s so compelling. Indeed, it’s an archetypical story, that of the parents who will go to any length to save their child from a deadly disease and succeed in doing so. Ms. Blackwell further relates that, after he swallowed the 5 ml of cannabis oil, he refused a dose of cyclizine, the antinausea drug upon which he had become dependent and that he virtually never refused. If there’s one part of this anecdote that puzzled me, it was the part about the cyclizine. Basically, cyclizine is painted as this powerful, addictive antinausea medicine when in reality it’s a histamine blocker and anticholinergic that is pretty well tolerated, with the usual adverse events of anticholinergic drugs, like dry mouth, and, less commonly, constipation, urinary retention, and double vision. Yet in this excerpt, the drug is painted as if it were a powerful, addictive opioid.
Be that as it may, the story certainly makes it sound as though 5 ml of cannabis oil beat cyclizine for nausea, although certainly there could be significant placebo effect here given his mother’s care and her giving him something new. Convinced it was working, Ms. Blackwell continued to give her son cannabis oil whenever he “felt a twinge somewhere.” Then, one evening:
One evening, I heard Deryn yell: ‘Mum – look!’ The bandage on his middle finger had worked its way loose and completely come off, showing his third finger – which had been blackened and dead – had now healed. How on earth had a child with no immune system and no way of fighting infection managed to heal himself after being off medication for more than three weeks?
I called Deryn’s team to tell them what had happened. Not one of them could give me any answers.
We knew his bone marrow wasn’t functioning and it was not scientifically possible for his wounds to heal. Deryn had spent months in isolation because a common cold could be fatal – yet, somehow, he had overcome three catastrophic infections.
Hundreds of people had been praying for Deryn, blessing him in their own ways. Was this a miracle?
Later that evening, the hospice doctor arrived. ‘We’re no longer sure Deryn is dying,’ she admitted.
The doctors were not sure whether or not the hospice was now the best place for us.
The story sure makes it seem like a miracle. One can only imagine the delight and relief, mingled with confusion and fear, that the Blackwells experienced, as their son, to whom they were preparing to say goodbye forever, made a sudden and unexpected recovery. Human nature being what it is, not surprisingly, Ms. Blackwell started looking for a cause for her son’s good fortune, and, human nature being what it is (and confirmation bias being what it is in all of us), she soon found one:
When we’d arrived four weeks earlier, he’d been given three days to live. Now here he was a month later, in far better health than when he’d left his hospital room. They had no idea how this was possible.
Then it dawned on me. Only one thing had changed since Deryn started to recover: the cannabis tincture. I couldn’t tell the doctors what we’d done.
Now, three years later, she’s revealing to the world what she did, and presenting it as a case of cannabis saving her son’s life. But did it? There is considerable reason to doubt. Those of you who are regular readers can probably identify the issues in this testimonial that make it less than convincing as evidence that cannabis salvaged Deryn’s failing bone marrow transplant. See if you can identify them before reading the next section.
The forthcoming book based on Deryn’s story aside, I’m very happy to report, Deryn returned to school and appears to be doing quite well now. Until now, his story popped up every so often as a human interest story in the UK press of a boy who beat what seemed like insurmountable odds to beat two different forms of cancer after “four failed bone marrow transplants,” while religious groups present him as a miracle. He even wants to study biochemistry, although he still suffers from sequelae of his disease:
“Deryn still struggles with mobility a bit and he gets very tired.
“But the main reason for going back was so he can develop emotionally and socially in that way teenagers, particularly boys, need to at that age.
“He has spent two years in a room by himself with just a nurse or me around, so it is good for him to just be normal for a while.”
Even after defeating cancer Deryn has had to confront other serious threats such as aplastic anaemia.
The family has also set up a charity, Do Everything, although currently the website is listed as Under Construction.
Did cannabis save Deryn’s life? It’s doubtful.
Remember how Ms. Blackwell discussed visits by celebrities to see Deryn around December 2013, as things looked very grim and doctors thought that Deryn’s final days were upon him? The beauty of his brief celebrity back then was that there are contemporaneous accounts of what was happening then that we can compare to Ms. Blackwell’s account today. It also turns out that Deryn and his family had a fairly robust social media presence (for 2013 back then, with a Twitter feed, Facebook page (which appears to be no longer there), and website. Although the website turns up as “Under Construction,” fortunately the almighty Wayback Machine lets us see what was on it as recently as 2015, which will be helpful in my discussion. Deryn’s Twitter feed has no Tweets since this one:
Please everybody go and follow my mums page about me 🙂 @_DoEveRYthiNg
— Deryn Blackwell (@DerynChemoKid) March 25, 2014
Perusing this Twitter feed and Ms. Blackwell’s recently set up author Twitter feed, I didn’t see any mention of cannabis until this flurry of weekend stories. For instance, the announcement of the book didn’t mention cannabis:
Some incredibly exciting news for @DerynsMum – You can now pre-order Callie’s book ‘The Boy in 7 Billion’ https://t.co/5mlL9e24fV Exciting! pic.twitter.com/hDz62pm2D8
— 1in7billion! (@_DoEveRYthiNg) February 20, 2017
I found all this very curious, how Ms. Blackwell said absolutely nothing about cannabis until this weekend, even when her book release was announced and as she provided updates on her progress on her personal Twitter feed. Maybe the publisher made her keep it a secret. [Note: This is confirmed in the comments below.] Be that as it may, I found it instructive to fire up the almighty Wayback Machine and look at what the Do Everything Foundation website said. Helpfully, it provided a timeline, which was not nearly as clear in the book excerpt published by The Daily Mail. I think it’s worth posting the entire timeline from his last bone marrow transplant, which encompasses the time when Deryn went into hospice:
On 17th October 2013, his own cells failed because of extremely rare complications.
Thankfully Deryn had one more chance left, he had one more bag of his own cells.
The Dr’s gave Deryn more chemotherapy and on the 29th of October 2013, Deryn has his own and final bag of cells transplanted into his body.
Three days after the transplant, Deryn trapped his fingers and suffered TWO catastrophic infections in his hand.
He had Cellulitis and Herpes whitlow in his hand and he also had Klebsiella in his mouth, another catastrophic infection.
40 days after a bone marrow transplant, the Dr’s told us that it is highly unlikely that someone will graft if they haven’t already – after 50 days there is no way someone can graft.
In their experience, no one has ever grafted after 50 days.
On December 11th 2013, at day 46, we were moved to a hospice where it was expected that Deryn would die within a few days.
We were told that Deryn’s fourth and final transplant had in fact failed and there was nothing more they could do, it was believed that once they took away the life supporting drugs that Deryn would leave us very quickly.
Deryn had NO immune system and NO way to fight off even a simple cold.
After two Christmases, one New Year’s Eve and quite a few worrying moments, on day 78 Deryn’s bandages accidentally came off his fingers and he was – infection free!
Deryn continued to improve and he started to produce his own blood products.
On day 104 – Deryn officially engrafted!
Not one Dr can explain how Deryn fought off THREE catastrophic infections with NO immune system and then went on to engraft with what recent tests said was empty bone marrow!
On February 25th 2014, Deryn had his line removed from his chest and was officially ‘Off treatment.”
After coming to terms and accepting that he was going to die, Deryn was finding it harder to accept that maybe he wasn’t.
It all happened so quickly.
His future is still very uncertain and he is still poorly.
BUT
We are for the first time, starting to plan for a future with Deryn.
Thank you so much for visiting Deryn’s page and for reading his wonderful story.
** Miracles do happen and dreams can come true **
It’s not entirely clear exactly when Ms. Blackwell started giving Deryn cannabis oil, but it was clearly some time before he went into hospice on December 11, 2013. In the excerpt above, in the context of giving Deryn his first dose of cannabis, that the doctors would give him two weeks to improve and then, if he didn’t, move him to hospice, which suggests that she started dosing him in late November 2013. Then, by her own account, she didn’t start giving Deryn oral cannabis until New Year’s Eve 2013. Day 78 after his transplant would have made it January 15, 2014 when the bandages came off his fingers and revealed that he had healed much of his ulcers, and Day 104 would have been February 10, 2014.
One can see how this timeline might have led Ms. Blackwell to think that what had saved her son was the cannabis oil. She started giving him oral cannabis oil about two weeks before the ulcers on his hands unexpectedly healed. However, there are a number of reasons to doubt that it was the cannabis. For one thing, from this account we have no idea what strain of cannabis was used, making it difficult to estimate the cannabinoid content of the oil and therefore how much and what types of cannabinoids were in the actual oil Ms. Blackwell used. We don’t know the cannabis to oil ratio. We don’t even know the regularity of the dosing except that she gave it to her son “whenever he had a twinge.” Given the experimental data I’ve discussed before that shows that the various cannabinoids only have a modest anti-cancer effect, it’s hard to conclude that the doses Ms. Blackwell was giving her son were high enough to have had such a dramatic effect. For another thing, what Ms. Blackwell is claiming is not so much that “cannabis cured her son’s cancer,” but rather that cannabis somehow fired up his immune system so that it could fight off the infection and his cells could actually engraft after three times the length of time it normally takes. In reality, the evidence regarding cannabinoids and the immune system is mixed, with at least one study showing that they can suppress immune function. Indeed, cannabinoids are being studied more as a potential treatment for autoimmune diseases rather than as any sort of means of increasing immune cell engraftment. Basically, it’s not very plausible at all based on what we know about cannabis that Ms. Blackwell’s secret treatment of her son resulted in such a dramatic turnaround.
So what happened? Did cannabis really rescue Deryn Blackwell’s bone marrow transplant?
What probably happened is that Deryn Blackwell was a highly unusual case in which his last stem cell infusion took a far longer amount of time to engraft than the doctors at the hospital treating him had observed before. It just so happened that, as Deryn was deteriorating, his mother, anguished at watching him suffer and desperate to do anything possible to alleviate his suffering, decided to give vaporized cannabis oil a try to help his symptoms. Unfortunately, her son continued to deteriorate and entered hospice. She decided to give him the cannabis oil by mouth three weeks after he entered hospice, and it seemed to relieve his symptoms somewhat more effectively. Two weeks later, the “miracle” occurred, and the bandages fell off. Deryn’s rare and unexpected recovery, happily, manifested itself. The rest, as they say, is history.
Deryn’s recovery was unexpected, but unexpected and rare recoveries do occur in medicine. Given what we know about cannabis oil, its rather modest effect on cancer, and the tendencies of cannabinoids to be, if anything, immunosuppressive, it strains credulity on a strictly scientific basis to attribute Deryn’s turnaround on homemade cannabis oil. That’s not to say it’s impossible that cannabis oil was responsible for Deryn’s recovery, only that it’s incredibly improbable. Remember, we know a fair amount about cannabinoid activity against cancer and its activity in the immune system, and what we know doesn’t support the plausibility of Ms. Blackwell’s testimonial. However, as is the case with a lot of other alternative cancer cure testimonials, the all-too-human tendency to want to attribute cause, combined with the form of selective memory known as confirmation bias, which leads all of us to tend to remember what confirms our beliefs and to forget what does not, has led to a conclusion that is almost certainly not correct. Remember again, Ms. Blackwell seems not to remember the several weeks she was giving her son cannabis oil via vapor stick and he was continuing to deteriorate to the point of entering hospice. I repeat that again because it is important. This testimonial is almost certainly a case of confusing correlation with causation.
But what about this claim:
Yet there was a direct correlation between Deryn having the cannabis tincture and his improved blood counts. Whenever he didn’t have it, they dropped. It was enough hard evidence to suggest that cannabis tincture was playing a vital role in his recovery. I hadn’t imagined in my wildest dreams that it could have saved Deryn’s life.
Without very detailed record keeping in which Deryn’s counts were listed by date and then correlated contemporaneously with whether or not he was taking cannabis oil and at what dose, it’s impossible to support or refute this claim. It’s probably more confirmation bias.
Be happy for Deryn Blackwell, but be skeptical
Although I highly doubt that cannabis oil had anything to do with Deryn Blackwell’s “miraculous” recovery, I am very happy that he did recover. Nothing pains me more than seeing children die of diseases like cancer. I can also understand why Callie Blackwell and her husband Simon have come to believe that cannabis cured their son. They are human. They have all the cognitive quirks that lead humans to incorrect conclusions that we all have, and those tendencies are only magnified when it is someone they love deeply that is the object of their hopes and prayers. Confirmation bias is a very powerful thing indeed under these circumstances. Unfortunately, the timeline that I have been able to reconstruct is thin gruel indeed to support Ms. Blackwell’s belief that cannabis oil saved her son by somehow helping his immune cells engraft in his bone marrow.
Unfortunately, what I fear is that a combination of love for Deryn, confusing correlation with causation, and confirmation bias have led the Blackwells to become true believers on the order of Rick Simpson, but with an even more dramatic story in which cannabis is portrayed as having literally pulled their son back from the brink of death. Consider this. Deryn’s story is quite inspirational without the cannabis angle. Yet what excerpt did the publisher decide to release first as part of the book’s publicity campaign? Yes, it released the part describing how Callie Blackwell surreptitiously dosed her son with cannabis oil, and the Daily Mail and the rest of the UK tabloid media responded predictably with stories portraying Deryn Blackwell as proof that cannabis can cure cancer, even when his story shows nothing of the sort. Unfortunately, the narrative that is being spun has the potential to influence patients with cancer and parents to try unproven and quack treatments, like cannabis for cancer and who knows what else. In seeking to do good, I fear that the Blackwells could actually make it less likely that future Deryns actually survive their cancers. It saddens me to say it, but it has to be said.

The return of marketing hype for “whole body scans”…now with AI!
Two decades ago, I cut my skeptical teeth countering advertising for whole body scans by companies making extravagant promises for their products. This particular medical fad faded for a while, but now it’s back with a vengeance…with AI! Looking at these products, what I see is basically the quackery that is functional medicine on steroids and powered by AI.
David Gorski on July 10, 2023
Link

It just struck me the other day that, in less than a year and a half, I will have been at this blogging thing for two whole decades. I’ve been writing for SBM for over fifteen and a half years, having started my first blog more than three years before that and having been active on Usenet countering quackery and antivaccine pseudoscience for five or six years before that. (Yes, I’ve been at this in one form or another since the late 1990s.) I was reminded by a recent spate of laudatory (or at least very unskeptical) stories about Neko Health last week touting their “lofty promise of preventative healthcare via full-body scans backed by AI software” of the very first time that I actually put my then relatively recent turn to combatting dubious medicine into action with respect to a medical fad that had been going on for quite some time, that of whole body scans for preventative healthcare.
Reading some of these stories, I immediately felt a profound sense of what Yogi Berra would have called “déjà vu all over again”:
Neko Health, a healthcare technology company co-founded by Hjalmar Nilsonne and Spotify founder Daniel Ek, announced the successful completion of a €60 million ($65 million) series A funding round. The company aims to revolutionize the health industry through artificial intelligence (AI)-driven full-body scans, specifically focusing on preventative healthcare.
Do tell. What, exactly, does this “whole body scan” involve? Let’s find out:
Neko Health has introduced an innovative medical scanning technology that enables extensive and non-invasive health data collection, prioritizing speed, accuracy and convenience.
The company operates private clinics with proprietary and off-the-shelf diagnostic products, including its own 360-degree full-body 3D scanner integrated with over 70 sensors. The scanner can collect 50 million data points within minutes.
This data undergoes analysis by a “self-learning AI-powered system,” providing doctors and patients with insights.
So Neko Health is a bit more than what I dealt with, lo, those many years ago. Clearly, the industry hawking “whole body scans” as a health panacea has evolved since I last seriously dealt with these products. Two decades ago, when I first started complaining to a local NJ radio station about ads by a company called AmeriScan making unrealistic and extravagant claims for “whole body scans” and “screening MRIs” that’s all it was, CT scans and MRIs. Now it appears that “whole body scans” involve so much more, both a proprietary “its own 360-degree full-body 3D scanner integrated with over 70 sensors” and a raft of other test, to the point that it reminds me very much of how I once described “functional medicine”: reams of useless tests in one hand, a huge invoice in the other. the only difference being that companies like Neko Health add artificial intelligence to the mix, because it’s the latest tech fad.
In fairness, the invoice for Neko Health’s “whole body scan” isn’t that huge (€250), but it’s still at least not insubstantial. None of this changes my perception that Neko Health simply represents the latest iteration that, consistent with the latest tech fad of the times, just adds AI to a very old idea, that some variant of “whole body scans,” whatever the form they take, is a magical tool for finding disease super early and managing health.
You think I’m being unfair by using the word “magical”? Take a look at this LinkedIn post by one of the company’s founders, Hjalmar Nilsonne:
Again, the sales pitch is very much like the sales pitch favored by practitioners of “integrative medicine,” including naturopaths and “functional medicine” practitioners, representing their methods as The One True Preventative Medicine. I note that, among the many commenters praising Neko Health, there was one commenter who exhibited the appropriate level of skepticism, a question that I will expand on as I look at Neko Health’s product and products like it:
Instead of alleviating pressure on our health systems this will probably just add to it. All scans find ‘something’, will Neko help ‘solve’ them or just refer the patient to the already struggling general practitioners and public hospitals?
Excellent question, Mr. Bateman! Did Nilsonne answer it? Nope. Only one person did, and he appears not to be affiliated with the company:
Why rely on human eyeballs when computer vision can easily detect and track hundreds of 2mm skin lesions over time?
We say the same thing to physios and personal trainers about recording movement in pixels and milliseconds, and some insist they can see/measure and report dysfunction with their eyes, and adequately report it with text.
If Mona Lisa were to be described in words alone, she would have many faces!
The cost of bias, malpractice and delayed intervention will easily outweigh the cost of early diagnosed and early intervention.
In any case, this seems like out of pocket for now. They should be paid a % of saved future costs for early detection, based on historical data IMHO.
Mr. Bilby’s faith in computer algorithms is….touching, as is his faith that screening everyone willy-nilly like this will do anything more than cost more money in downstream confirmatory tests and procedures. It’s not as though we haven’t gone down this road before many times. It is up to the promoters of a new technology like this to show that it does what it says, not to critics to show that it doesn’t, but for some reason it never seems to work out that way. I do like the Mona Lisa analogy, though. It sounds so profound without actually saying anything substantive about the technology. I also note that, if all this does is to take images of skin lesions and track whether they grow over time or not, it’s just a more sophisticated way of doing skin screening exams in a way that more systematically records every lesion on the skin, of which most people have dozens, if not hundreds.
Moreover, there is also already a rather extensive scientific literature on the use of AI to classify skin lesions and carry out skin screenings, particularly for people with darker skin, (Does Neko use recommended best practices for its image acquisition, for example?) for which AI could be particularly useful given the difficulty in identifying and classifying moles as benign versus potentially malignant in darker skin types. However, as this recent review put it, for non-melanoma skin types, AI has “sensitivity and specificity that are not inferior to those of trained dermatologists,” which is hardly a ringing endorsement. Neko Health will have to show that its system is superior to the many existing systems under development and testing. Can it? I sure can’t tell from what I can find out.
Also concerning is this:
What’s perhaps most notable about Neko at this juncture is its aversion to interviews, particularly against the backdrop of high-profile health techs such as Theranos’ spectacular fall from grace after making bold claims with little foundation. Indeed, Neko Health declined to give interviews to international media when it formally launched earlier this year, and little opportunity was given to ask questions ahead of today’s funding announcement.
It is, of course, difficult not to get a Theranos vibe from Neko Health, although the difference here is that, unlike the case with Theranos, where the technology was clearly half-baked and arguably even impossible, the technology clearly exists to produce the devices and tests that Neko Health markets. Indeed, as you will see, other than the “whole body scan,” Neko appears to be doing nothing particularly novel, not even coupling AI with existing technology The main problem is the assumptions behind this raft of tests and the seeming lack of concern about the well-known negatives of screening people for so many measurements at once. The company claims it is doing clinical trials, but searching PubMed failed to find any published results, as did scanning the Neko Health website. I found the latter observation particularly telling, because, if there’s one thing companies marketing a new medical test love, it’s to tout their scientific publications on their websites.
What is Neko Health selling, though?
Neko Health’s “whole body scan”
I noted when I first visited the Neko Health website to see what it says about its whole body scans that the website is incredibly slick but rather lacking in much detail, coupled with language that sounded very much like that used by AmeriScan, the company whose “whole body CT” and screening MRIs had caught my attention back in 2003. Touting its products as “Your health checkup got upgraded, Neko Health brags:
Try the Neko Body Scan, get instant results, and let us monitor your health—so you don’t have to.
Sounds nice, but doesn’t the paternalism of this message conflict with the “take control of your own health” pitch going on elsewhere? And:
Detect. Prevent. Relax. Your body is constantly changing. By measuring, analyzing, and following millions of data points, we create an individually tailored overview of your health.
This is just another form of a favorite advertising buzzword among both conventional physicians and quacks designed to make patients feel special—”individual”—if they use the product being touted. Which use of the “individually tailored” or “personalized” view is being touted here? Let’s take a look.
First, however, let’s see what Neko Health promises with “its own 360-degree full-body 3D scanner integrated with over 70 sensors” (plus, as you will see, a lot of other tests). Neko Health’s Twitter feed touts three main aspects of its products.
First, skin:
How long do you think it will take you to capture every mole on your body? pic.twitter.com/jXskiMjn57
— Neko Health (@NekoHealth) June 20, 2023
I see many punch biopsies in this woman’s future.
Then the cardiovascular system:
How is your heart feeling today? Better health is only a heartbeat away. pic.twitter.com/xw3tGz1p7R
— Neko Health (@NekoHealth) June 28, 2023
And, finally, the scan:
Ahead of your health. The more you understand, the more you can improve how you feel. pic.twitter.com/JmuCrBqmX4
— Neko Health (@NekoHealth) July 3, 2023
The scanner reminds a bit like an over-wide version of the cryogenic tubes featured in Lost in Space in the 1960s:
Read more about our latest financing round here: https://t.co/SXA7ytQy7I
— Neko Health (@NekoHealth) July 5, 2023
And, because I couldn’t resist, here’s what I mean, dedicated to those of you too young to remember the original Lost in Space:

But what, exactly, does Neko Health do at its clinics, in particular its Stockholm clinic that is currently the only location where it has its super-duper-AI-powered whole body scanner? It’s clearly popular. The website brags that all the available appointments are booked and that, if you want one of these whole body scans, you need to get on a waitlist.
First, let’s look at how Neko Health characterizes its whole body scans:
Start with a 360-degree skin scan
Everyone knows it’s important to take care of your skin and regularly check for birthmarks, but seeing a specialist can take months. Neko Body Scan images every centimeter of your skin in less than 20 seconds and tracks every birthmark—so you don’t have to worry.
Full body scan in underwear
Detects birthmarks, rashes and age spots
Follows changes as small as 0.2mm
This is basically a dermatologic skin screening on steroids and AI. While it is true that skin screening is an important modality to detect early cancers, particularly melanoma, one has to wonder how this AI system will do better than the experienced eyes of a dermatologist or melanoma surgeon in detecting suspicious lesions. One way that I could envision such a system having utility would be if it can decrease the number of false negative skin biopsies done on suspicious lesions, but there seems to be nothing on the website even addressing the question. Also, why exclude parts of the body covered by underwear? You can get skin cancer on your buttocks, perineum, and anywhere else covered by underwear.
As I read through Neko Health’s website, I was surprised at how mundane most of it was. For instance, part of the screening involves taking a fasting blood sample for routine labs like a lipid panel and a “full-body blood pressure with 8 non-invasive sensors.” A more detailed description of the tests can be found here, where Neko touts its three clinical trials, which it calls Cardio Alpha, DermaFlow Alpha, and Spectrum 1.
Cardio Alpha is described as a clinical trial “about evaluating the suitability of a novel Laser-Radar-based technology, to assess arterial stiffness and its correlation to cardiovascular risk and diseases” and consists of collecting heart sounds, pulse wave analysis, pulse wave velocity, blood pressure, ECG, and cardiac ultrasound images, none of which is particularly novel or even all that interesting.
Next up, there’s DermaFlow Alpha:
This clinical trial is about evaluating the suitability of multi-modal imaging technology that virtually covers the entire body, to assess the potential of screening and early detection of disease.
The multi-modal technology is based on camera systems, which can capture high-resolution color images (visible spectrum), 3D, and thermal images (infrared spectrum).
By studying the correlation and sensitivity between disease states, gradients, and asymmetries in collected image data, the potential can be evaluated.
Did they say “thermal images”? Holy thermography, Batman! Neko Health is using a fancy, tarted up version of thermography coupled with high resolution images. It’s hard for me not to recall that thermography is an imaging modality that’s long been a favorite of naturopaths, “holistic practitioners,” and other quacks (but I repeat myself), who make extravagant unsupported claims about its ability to detect many diseases, but in particular breast cancer. (Christine Northrup is a big fan, as I first noted in 2010.) To me, this sounds suspiciously like nothing more than an observational study designed to collect a dataset to train Neko’s AI. Recruiting patients to evaluate and test a new technology and train its AI is nothing nefarious in and of itself, but such a mundane goal rather conflicts with all the company’s hype for its products. Do patients who pay for these tests know what they’re signing up for? They expect to be given reassurance (no disease) or to find disease early, the assumption being that finding disease early will result in a better outcome. Do they know that in many cases such tests will trigger further tests and even invasive procedures?
These first two studies are just the buildup to what Neko Health obviously considers its main accomplishment, its “whole body scan.” (I’m surprised that the company didn’t come up with a pithier name for it.) So let’s look at how it describes its Spectrum 1 trial:
Most skin conditions affect and/or are caused by the skin’s microcirculation (blood flow in the smallest vessels). Microcirculation in the skin is also affected by many systemic diseases, such as for example, diabetes and autoimmune diseases.
The disease of large vessels (macro-circulation) can also be caused by basic problems with microcirculation.
Today, there is little opportunity to detect microcirculatory problems early, and it is often discovered when the course of the systemic disease has gone quite far.
This clinical trial will evaluate a trial device that uses a projector to depict patterns on the skin, which the skin absorbs, reflects, and spreads depending on skin composition and structure.
There’s a lot to unpack here. First of all, it is true that many diseases have dermatological manifestations, but certainly by no means do all diseases manifest themselves on the skin in a manner that can be picked up by a system like this. Yet the company makes grandiose claims for this system, which, besides the visual images it records, also measures concentrations of oxyhemoglobin (oxidized hemoglobin) and deoxyhemoglobin (non-oxidized hemoglobin), as well as the “oxygenation within the measured skin area,” to which the wag in me can’t help but say: Congratulations! You’ve reinvented the pulse oximeter as a whole body pulse oximeter! In fairness, the device also measures the concentration of water and melanin in the skin area examined, but in reality it is sounding more and more like a glorified pulse oximeter that measures a few other things.
Again, like the others, this clinical study looks to me like nothing more than a method to gather a training dataset for the company’s AI, which, again, is nothing nefarious in and of itself. What is dubious to me is having your patients fund the research and development of your technology by paying for an unproven test to be part of its AID training dataset. This is the sort of activity that should be funded by the company developing the experimental technology, not patients, but that’s not what appears to be happening. Moreover, the company appears to be enticing patients by making promises, albeit vague ones, about their test being the ultimate in preventive medicine. If that’s not what the company is doing, I have been unable to find any evidence telling me what the specific questions they are asking are.
I was particularly taken by this quote:
Nilsonne said that the company has already proven the resonance of its unique approach to preventative healthcare. Strong demand signals a genuine need and desire for change, which has propelled the company to broaden its horizons and accelerate its growth by forming partnerships with external investors for the first time.
This is nothing more than an appeal to popularity. All it says is that Neko Health’s marketing of its as yet unproven device has been effective.
“Whole body scans” as functional medicine?
Having perused the company website and as much as I could find with Google and PubMed, I was left…dissatisfied. I understand a company wanting to protect its proprietary intellectual property, but the vagueness of the claims was frustrating, especially coupled with the lack of detail about what, exactly, Neko Health’s scans will actually be used for other than a generic “health screening” that will somehow revolutionize preventative medicine. I was interested in learning the identities of the physicians running the clinical development of this technology, because screening asymptomatic populations for occult disease in the hopes that early intervention will result in better outcomes is an area of medicine that is highly complex and fraught with pitfalls, such what to do with “incidentalomas” (lesions or abnormalities found incidentally on a test that a patient is undergoing to look for something else, but more importantly the problem of overdiagnosis, lead time bias, and length bias. Yet, under the “leadership” and “transparency” section of Neko Heath’s website, all I could find were the identities of the founders of the company and its systems for safety, documentation, and quality improvement, which apparently are in accordance with Swedish law. Its press kit was no more informative, consisting mainly of photos of its device.
As the late Dr. Harriet Hall, who was a family physician who served as a flight surgeon in the Air Force, pointed out well over a decade ago, even the yearly physical examination with routine bloodwork is a medical screening tool that has come into question given its low yield in most healthy, asymptomatic patients who have no symptoms or signs of disease and are not a high risk of certain specific diseases.
She also noted:
We are increasingly questioning screening tests that were formerly recommended. The annual chest x-ray, tine test, and urinalysis are long gone. The recommended age limits for mammography have changed. Routine PSA testing is being discouraged. A recent study suggested that a woman whose DEXA scan shows normal bone density or mild osteopenia need not be rescreened for 15 years.
We don’t need to examine all the published literature on screening tests, because the U.S. Preventive Services Task Force (USPSTF) has done all the work for us. They continually update recommended screening tests for different age and risk groups based on the latest studies. There are other organizations in the US and elsewhere that make similar recommendations but that may differ to some degree in different countries. In general, a specialty organization is likely to recommend more screening in its particular area of interest, based on a different focus in interpreting the same published evidence. The American Academy of Family Physicians, with a broader perspective, generally follows USPSTF recommendations.
Any new screening test needs to be viewed very skeptically in the light of these observations. For some reasons why, feel free to review some of my articles that discuss the issues involved with any screening test. I discussed mainly screening tests for cancer, like mammography for breast cancer, PSA for prostate cancer, and thyroid ultrasound for thyroid cancer, all of which can artificially inflate survival statistics for cancer, but all involved problems of overdiagnosis, lead time bias, and length bias. (It’s not just these cancers, either.) In fact, let me cite a couple of graphs that I always like to cite whenever the topic of screening comes up. First, here’s an illustration of lead time bias:

Here’s another illustration of the concept that I like to cite. Note that lead-time bias is a factor in screening for any disease that can result in death, not just cancer:
As a result of lead time bias, it’s very easy for screening to make it look as though patients are doing better after early detection of their disease, whether they are, in fact, doing better or not. One of the best explanations of the concept of lead time bias that I’ve ever encountered can be found here.
The other factor most relevant to cancer screening is overdiagnosis and length bias illustrated here with the concept of overdiagnosis:
The above graph demonstrates how screening favors the diagnosis of relatively slowly growing cancers, known as length bias. Fast growing cancers, like Tumor D, grow so fast that they become symptomatic or detectable on physical examination between screenings. As a breast surgeon, I see this occasionally, the woman who laments that she gets her mammograms regularly but felt a lump 6 months after her last mammography that turned out to be cancer. This graph also illustrates the problem of overdiagnosis that also results from length bias, as Tumor B is what happens when a slow growing cancer reaches the stage of being detectable by a screening test but is so slow growing that the patient will die of other causes before it causes any problems. Also, remember that this whole discussion only applies to patients who have no symptoms or physical findings. If the patient has symptoms or physical findings, then the test is no longer a screening test but a diagnostic test. If you have symptoms or physical findings that are worrisome for serious disease, you should always see your doctor to have them checked out.
None of this is to say that screening tests are useless, don’t save lives, or at the very least allow less invasive and radical treatments to succeed. Several are not. However, what these entrepreneurs selling new unfocused screening tests for even healthy people always seem not to understand (or even be much concerned about) is that screening for any disease involves a difficult balancing act between disease biology and natural history versus any benefits of intervening in the disease process in its asymptomatic phase. Remember, overdiagnosis is not a false positive, although that is a frequent misunderstanding of the concept. For example, breast cancers and prostate cancers overdiagnosed by mammography and PSA, respectively, are real cancers. Upon biopsy, they look like any other cancer under the microscope to the pathologist. Overdiagnosis represents the diagnosis of a real medical disease or condition that progresses so slowly that, if left alone, it would never put the patient’s life at risk or significantly impact the patient’s health but ends up being overtreated because we currently have no reliable tests to differentiate overdiagnosed disease from disease that needs intervention. These issues are why some screening tests (e.g., mammography) make the cut for clinical utility while others (PSA for prostate cancer) are increasingly questioned. It’s also why the indications for screening tests like mammography (e.g., age to begin screening, interval between tests, etc.) undergo continuous reevaluation based on new science.
One Twitter doc noticed the issue right away, this issue is a problem that we have seen in the past many, many times with these sorts of technologies. The only difference nowadays is that tech people think that adding AI will fix the problem; that is, if they ever even bothered to consider this problem at all, which Neko Health appears not to have:
Do investors think no one in medicine ever had the idea of doing imaging to detect cancer? Or more cynically do they think the worried well will just shell out $317 for a low res scan read by a buggy algorithm? Have they considered the enormous liability of missed diagnoses?
— Nick Mark MD (@nickmmark) July 6, 2023
If there’s one area that AI might have utility, it’s in identifying factors that allow us to differentiate between overdiagnosed disease detected by screening and disease that requires treatment. Frustratingly, from what I’ve observed during the last two decades that I’ve been paying attention to these issues, companies like Neko Health never seem particularly interested in attacking this more difficult problem, again, because they lack the necessary domain evidence and. Again, it “just makes sense” to people without the requisite background expertise who might tell them that their misconception that finding things early will always be good is often not true, or, as one Twitter user put it:
They don’t know what they don’t know likely describes Hjalmar Nilsonne and Daniel Ek quite well. It’s a common occurrence whenever tech entrepreneurs venture into healthcare.
Unfortunately, we know from long experience that in some cases screening for disease does more good than harm (e.g., breast cancer, hypertension, hyperlipidemia, and others), but more often all these sorts of screening tests do is to trigger additional tests, some invasive, that can result in harm. You need physicians and scientists with the necessary expertise and a proven track record demonstrated by peer-reviewed publications evaluating the sensitivity, specificity, and positive predictive value of screening tests in addition to your AI experts. In fact, you probably need an even rarer breed, the physician or scientist with experience assessing screening tests who also understands AI and AI algorithms.
One commenter nailed it:
I don’t understand how anyone thinks this is going to save money, either. As soon as you shell out $317 for the scan, that’s gonna lead to thousands of dollars of potentially unnecessary appointments, labs, more imaging that doctors will actually trust, and biopsies.
— chelsea 🙂 (@chelseadjones) July 6, 2023
Before I move on, though I have to contradict one thing that Dr. Mark said. If there’s one thing the history of such tests demonstrates, it’s that the worried well will shell out far more than a mere $317 to undergo various iterations of the “whole body scan.” In fact, there is a whole area of pseudomedicine that tells us that: functional medicine, and Neko Health’s whole body scan and other companies adding AI to a very old idea of doing whole body scans reminded me of this
The comparison between functional medicine and its “everything but the kitchen sink” approach to lab tests was driven home when I found this chart on the Neko Health website:
Here’s where Neko Health reminds me of functional medicine. Remember how I characterized functional medicine as “reams of useless tests in one hand, a huge invoice in the other“? That’s because functional medicine takes a very similar approach of doing lots and lots of tests (both standard and nonstandard) and then correcting every abnormality, whether it’s truly an abnormality or not given that all tests have false positives and if you do enough of them you will by random chance alone get a few abnormal test results, and whether it needs to be “corrected” or not. I’m very much getting a functional medicine sort of vibe from Neko Health.
The whole body scan—with AI!—gold rush
I don’t want to pick on just Neko Health though. It’s far from alone in its rush to raise venture capital to fund the development of this sort of product and suite of tests. It appears to be quite the gold rush out there to add AI to the very old (and discredited) practice of offering whole body scans to the healthy worried well as “preventative medicine.” For example, there’s one startup, Ezra, that’s marketing whole body screening MRI scans. The company claims that “its full-body MRI service monitors for possible cancer and more than 500 other conditions in up to 13 organs,” offering “three-year memberships for $5,300 or five-year plans for $7,000. They include annual exams along with a 45-minute follow-up consultation.” Another company, Prenuvo, is backed by Cindy Crawford and offering another AI-fueled whole body MRI scan direct to consumers for a mere $2,499, showing that, yes, the worried well will pay a lot more than $317 for tests more likely to cause them harm than good, although price competition is coming to this industry, with companies like SimonMed Imaging trying to undercut companies like Prenuvo, although its product doesn’t appear to use AI.
Most of these startups are covered pretty credulously by the press, but I have to give credit to Radiology Business for including some serious skepticism about at least one of them, Prenuvo:
However, some are expressing concern that the service could cause more harm than good. Catherine Livingston, MD, a family medicine specialist who served as lead author of a 2016 report recommending against this practice, is one such skeptic.
“There is certainly not enough known about the use of [artificial intelligence] in direct-to-consumer imaging services,” Livingston, an associate professor of family medicine at Oregon Health Sciences University School of Medicine, told the newspaper. “We don’t even know that the benefits outweigh harms for whole body scans in asymptomatic people. Adding in … AI is a Pandora’s box.”
And, from a December story about Prenuvo:
Dr. Matthew Davenport, the vice chair of the American College of Radiology’s Quality and Safety Commission, said that using MRIs to screen the general population is not likely to improve patient health.
“It is a terrible idea,” he said.
Davenport said there’s a big risk with using a scan as sensitive as an MRI of finding abnormalities that are later found to be benign. Screening may make sense for people with a higher risk for disease.
But Davenport said that for the general public, imaging every organ with such a sensitive test “will harm the patients.” Even if the scan itself doesn’t pose much of a risk, he said, more procedures down the line might pose a bigger risk.
“You find all sorts of stuff that would never occur to the patient,” he said. “And you end up triggering workups, biopsies for imaging studies, operations, for findings in the body that would never have any importance for the patient.”
Precisely. This is the aspect of screening healthy people for everything under the sun that the general public doesn’t understand. Unfortunately, neither do the tech bros who think that AI will make everything better. As always, the devil is in the details, and from my perspective it’s profoundly unethical to charge patients large sums of money merely to provide you with another data point in your training dataset for your AI.
None of this phases the tech people running these startups, unfortunately. For example, listen to Andrew Lacy, founder and CEO of Prenuvo:
“The current healthcare system is reactive. For many, health information comes too late, once a disease or condition has progressed, has symptoms, and is more difficult and expensive to treat,” Lacy said in a statement last fall announcing the $70 million fundraising round. “Our series A financing is validation of Prenuvo’s mission to catch conditions before they become crises and transform the healthcare approach as we know it to one that is rooted in proactive health.”
I love how Lacy equates success in raising venture capital with the medical and scientific value of its technology, which it claims to be unique, because all these companies claim that their AI is unique and better than the others. For example, last year Lacy said:
Lacy said Prenuvo uses proprietary software and artificial-intelligence tools invented by Attariwala to make its whole-body scans different from other scans offered in hospitals.
“Most MRI scans rely on anatomical imaging, which simply shows organ structures,” Lacy said. “Core to Prenuvo’s imaging protocols is a heavy reliance on the combination of anatomical imaging together with newer functional imaging techniques, which increases the ability of MRI to accurately discriminate many conditions.”
Prenuvo’s website indicates it charges $1,000 for a torso scan, $1,800 for a head-and-torso scan, and $2,500 for a whole-body scan, and it doesn’t take insurance. The website says the scans are performed by MRI technologists and analyzed by radiologists trained to read Prenuvo scans.
Lacy said that if a scan finds something abnormal, it shows up in a patient’s dashboard — that patient can take the result to their primary-care physician.
My experience is that primary care physicians are not fond of this sort of thing, because they often don’t know what to do with the results of such scans—or at least are unsure—because these tests are prone to discover all sorts of things that might or might not be harmful but then require a workup. Unsurprisingly, like all companies imaging such imaging systems, Prenuvo claims that its technology avoids pitfalls described by because of its special proprietary technology. How does Prenuvo know this?
Unsurprisingly:
Prenuvo has not published any studies finding that these scans catch diseases early and improve people’s health. Lacy said Prenuvo is recruiting for a clinical trial.
I’m shocked—shocked!—to find that Prenuvo started selling its test for big bucks first and only now is trying to prove that it works. I’m also shocked—shocked!—that a search of PubMed for the name of the company showed no clinical trials open, although a search for “MRI” and “artificial intelligence” resulted in dozens of hits for clinical trials looking at AI in imaging. Add the term “screening,” and you’ll find a bunch of clinical trials utilizing AI-fueled MRI to screen for specific diseases, such as breast or pancreatic cancer. Add the term “whole body,” and the number drops to basically zero.
Perhaps this is why I found no clinical trials from Prenuvo:
Andrew Lacy, Prenuvo’s founder and chief executive, said his company plans to partner with researchers to further study its model. It has not yet published data but plans to soon in concert with the American Academy of Neurology conference, among other events.
So, not only has Prenuvo not published any clinical trial results, but it seems to have no clinical trials registered with ClinicalTrials.gov. Does anyone want to bet that what Prenuvo plans is just a large case series of all of its customers who have purchased its scans, a study that without controls is highly unlikely to be informative.
While it’s nice that Prenuvo plans to “partner with researchers to further study its model,” my retort is always; The time to partner with researchers to study your model is before you market it to the public, not after. Also note the utter lack of understanding of the potential complications of using such screening tools. At the very least, event thought the gadolinium used as contrast for MRI scans is safe, gadolinium is not without risk. That’s why yearly doses of gadolinium should at least trigger a risk-benefit analysis, something that none of the companies marketing whole body MRI screening using AI appear to have done, just as AmeriScan never bothered to consider the risk-benefit ratio of yearly doses of gadolinium, plus all the other potential unnecessary workup and biopsies, compared to the potential benefits of its yearly screening.
AmeriScan and a number of “whole body CT scans” and “whole body MRI scans” proliferated two decades ago, only to disappear (for the most part) for several years. Unfortunately AI has provided a seemingly reasonable rationale to resurrect these discredited screening modalities in the likely vain hope that AI will somehow eliminate or at least mitigate the problems associated with old-fashioned whole body scans, be they CT, MRI, or Neko Health’s fusion of photography and thermography coupled with cardiovascular scans. Unfortunately, whether AI can succeed in this is very much an open question, but that doesn’t stop these companies from using AI as a marketing buzzword to sell their product before it’s been proven superior (or at least not inferior) to existing diagnostics.
Truly, these companies are the AmeriScan of the 2020s.

FitScript™: Functional health quackery and a misleading alternative cancer cure testimonial
Perusing the hellscape that is what Twitter has degenerated into as X, I found an alternative cancer cure testimonial, which led me into “functional health” nonsense that I hadn’t encountered before. Introducing FitScript.
David Gorski on May 20, 2024
Link

It’s been a long time since I’ve had a real alternative cancer cure testimonial to dissect that didn’t involve, for instance, ivermectin or fenbendazole, the new laetriles of the post-COVID era. So it was with interest that I was tagged on X, the hellsite formerly known as Twitter, and discovered FitScript™:
We cured her cancer.Paula was diagnosed with breast cancer.She did 0 chemotherapy. Just followed our exact protocol.Now?Doctors say based on her blood work, it’s hard to believe she ever had cancer.Here’s exactly what we did: pic.twitter.com/YEfxvBpW4t
— Michael Morelli (@morellifit) May 17, 2024
I had never heard of Michael Morelli before, nor had I heard of his service, Fitscript. After a flurry of questions and pushback, Mr. Morelli posted this:
Re: CANCER CURE Post ❤️Many people have been asking for specifics regarding the post yesterday. What protocols we used, how we did the detox, what was the diet. If there is ONE thing you MUST understand it is this:Healing of any kind only works when done on an individual… https://t.co/PIVvkZCE4x
— Michael Morelli (@morellifit) May 18, 2024
To finish off the long post, so that you don’t actually have to visit X unless you want to, I’ll add the completion:
Healing of any kind only works when done on an individual basis specifically for the person.
Social media is full of generic advice that people think they should follow as it’s worked for someone else.
Our treatment for people is based on them as an individual and is unique to them. It’s what separates us from the others – so what we did for Paula is just an example of how effective we are.
It ALL starts with your OWN FiTScript.
Oh, goody. The treatment is “unique” to each individual, and, oh boy, the rest of the thread is full of red flags. I realize that some of you don’t like reading long X/Twitter/Xitter threads, but I think it’s worth it to see the depths of quackery being plumbed here; that is, before I explain why Paula’s testimonial does not demonstrate that anything Morelli did contributed to her being cancer-free:
We needed to get to the root of the issue first.So we did our extensive blood work & lab testing.One of those being a toxicity test.Using that test on Paula’s body, we found: pic.twitter.com/pxwnOiVUlq
— Michael Morelli (@morellifit) May 17, 2024
We’ll get back to this list later in the post.
To do this, we did heavy detoxing.& after we focused on getting the negative things OUT of her body…The next step was to starve the cancer from the inside.We did this by focusing extensively on diet.The main things we focused on removing from Paula’s diet:
— Michael Morelli (@morellifit) May 17, 2024
On top of this, we had Paula on low calories & periods of intermittent fasting.2 things that would help starve the cancer/remove its fuel.This would do a lot of the “heavy lifting”But we wanted to make the environment completely inhabitable for the cancer.So…
— Michael Morelli (@morellifit) May 17, 2024
David Grimes posted a good thread about why this is all nonsense. You can’t cure cancer with diet, and restrictive diets in particular are potentially harmful to cancer patients.
I’ll create an unpleasant environment for Paula’s tumor to live.So we implemented this protocol for her.Another molecule we implemented for Paula was something that the cancer would initially like…
— Michael Morelli (@morellifit) May 17, 2024
Although it’s been touted as a cancer cure since Linus Pauling in the 1970s, there remains no good evidence that high dose intravenous vitamin C has anything more than a marginal effect on any cancer. Certainly, there is no evidence that it can cure cancer.
Only 6 months later…The cancer was completely eliminated.Paula sent us this message after visiting her doctor.Amazing stuff.Not only am I happy to be a part of something so phenomenal…But I’m incredibly happy for Paula in general.I’m so glad she’s healthy again. pic.twitter.com/t8wLWgLasU
— Michael Morelli (@morellifit) May 17, 2024
Those of you who have read some of the previous discussions I’ve done of alternative cancer cure testimonials will probably realize that immediately had…questions. Of course, before I get to those questions, I do note that a fair number of people pointed out that you can’t tell if a breast cancer is gone using blood work. True, tumor markers are sometimes used to assess response to treatment in patients with metastatic disease, but for the most part they aren’t a thing in breast cancer. As for what the markers were, I will get back to the post where he bragged about the hundreds of markers that had been checked. In the meantime, let’s look at the questions that I had:
    • How was the cancer diagnosed?
    • How large was it? Were there involved lymph nodes? What stage was it at diagnosis?
    • What subtype was it (e.g., infiltrating ductal vs. infiltrating lobular carcinoma)?
    • What was its marker status with respect to hormone receptors—estrogen receptor (ER) and progesterone receptor (PR)—and HER2?
    • Did Paula ever undergo surgery to resect the primary tumor?
Such are the questions that I have asked ever since I became interested in this topic and first wrote a general post on how to approach alternative medicine cancer cure testimonials back in 2009. Indeed, even before I examine whether the quackery used might even have “worked,” I like to look at the patient’s story and show why the anecdote doesn’t even provide evidence that the cancer “cure” or intervention had any effect on the progress of the cancer. So let’s start with that, and then I’ll discuss FitScript itself.
Paula’s story
Getting back to the story of this woman named Paula. As nearly always is the case with testimonials like hers, let’s just say that Morelli left out some…very important…information. Can you guess what it was? I must admit that, while I wasn’t surprised to learn this, I was somewhat surprised about one aspect of it. Here are two Instagram post found by others of the woman, Paula Macedo Hood, that tell the tale:




View this post on Instagram










A post shared by Paula Macedo Hood (@lilpaula40)
I’m not sure what she means by a “double lumpectomy,” unless she had two primary tumors, which is possible. I do, however, have to wonder whether she meant “double mastectomy.” Unfortunately, the followup post does not clarify, although it does tell me what I needed to know:




View this post on Instagram










A post shared by Paula Macedo Hood (@lilpaula40)
We still don’t know the answers to all the other questions that I had, but in reality, for purposes of this one woman, it doesn’t matter. We know she had her breast cancer resected. We know that the resection had negative margins, which means that the tumor had a rim of normal breast tissue surrounding it and that the tumor didn’t go up to any of the cut edges of the specimen, and we know that she had negative axillary lymph nodes. Resection with negative margins is the goal of every curative breast cancer surgery, and finding negative nodes is a good prognostic sign, as tumor in the axillary lymph nodes means that the primary tumor has not spread past the breast. Whatever operation she had, though, later photos on her Insta suggest that it was probably not bilateral mastectomies, as she doesn’t look as though she did and, even if she underwent bilateral mastectomy with immediate reconstruction, I doubt she’d be back to weight lifting so soon afterwards, as shown in her more recent photos:




View this post on Instagram










A post shared by Paula Macedo Hood (@lilpaula40)
It turns out that she had a bilateral lumpectomy, which implies that she had two tumors, one in each breast:




View this post on Instagram










A post shared by Paula Macedo Hood (@lilpaula40)
We might not know enough about the clinical features of her cancer (or cancers) to make a definitive recommendation with respect to treatment, but we do know that she had surgery to remove her primary tumor(s). I am also glad that Ms. Hood is doing well enough to be back into weight training and physical fitness. I will, however, admit that I had expected that she would have had her surgery at the beginning of her story, soon after her diagnosis. That is the usual form of these alternative cancer cure testimonials that I’ve seen over the years. Usually, the patient has surgery and then decides to forego adjuvant therapies, such as chemotherapy, endocrine therapy (e.g., tamoxifen), or radiation. Then, as I like to say, they attribute their survival to the woo that they chose after their surgery, not to the surgery itself. This is a general principle of many alternative cancer cure testimonials for cancers normally treated with surgery; Chris Wark’s testimonial about how his quackery cured his colon cancer comes to mind, which became the basis of his entire business.
Since I haven’t reviewed this in a while, I thought that now would be a good time to review in more details why in general these sorts of breast cancer testimonials tell us nothing about whether the quackery being touted works. The treatment of breast cancer is divided into two phases, locoregional control (treatment of the disease in the breast and and axillary lymph nodes) and systemic control (prevention of distant metastases). Surgery and radiation therapy are modalities used for local control; chemotherapy and hormonal therapy, for systemic control. Adjuvant therapy is one of these modalities administered after surgery. Adjuvant radiation therapy will improve local control and lower the rate of recurrence in the breast. Adjuvant chemotherapy and hormonal therapy will improve systemic control and decrease the rate of development of metastases, which are usually what kill patients. Such adjuvant therapies are what I like to call “icing on the cake” of surgery.
The reason breast cancer testimonials sound so convincing is that most lay people don’t know a lot about the disease, particularly that surgery alone “cures” many breast cancers. Early stage cancers are cured by surgery alone more often than not, and a significant minority of patients with even large tumors and multiple positive lymph nodes still have fairly decent chance of long term survival with surgery alone. I’ll start with a very common example. In the case of a lumpectomy, the local recurrence rate in the breast can be as high 30-40%. Radiation can reduce it to less than 5-8%. That means that women who forgo radiation are still more likely than not to avoid local recurrence in their breast, particularly if their tumor is small. In terms of distant metastases, which is what kills in the case of breast cancer and virtually all solid malignancies, chemotherapy and hormonal therapy decrease the risk of systemic recurrence and improve overall survival. The improvement can be small on an absolute basis in patients with early stage cancers but becomes more impressive with more advanced operable tumors. Because many breast cancer patients will do well with surgery alone, clinical trials with large numbers of patients are needed to find true treatment effects due to adjuvant systemic therapies in early stage breast cancers. Indeed, one of the hottest areas of cancer research is to determine molecular characteristics of tumors that will allow oncologists to differentiate women with low risk disease, who could forego chemotherapy safely, from those with high risk disease, who would be far more likely to benefit. As it is now, we give chemotherapy to the many in order to benefit the few simply because we do not know which specific women will benefit.
These facts help to explain breast cancer survivors who have undergone surgery but decided to forego chemotherapy and/or radiation therapy in favor of “alternative” medicine (Suzanne Somers, for instance). When such patients have a tumor with a good prognosis, where recurrence is uncommon or have a more advanced tumor but are lucky enough not to recur, they attribute their survival not to the primary surgery, but rather to whatever alternative therapy they have decided to take, even though it almost certainly had nothing to do with their survival. To them, it was the alternative medicine that “saved” them, not good old-fashioned surgery. In contrast, women who opt for alternative therapy and then recur obviously don’t provide good testimonials to sell alternative medicine, which is why you almost never hear about them. They’re bad for business.
Revisiting the topic today after so many years, there is a further wrinkle in understanding alternative cancer cure testimonials for breast cancer. The wrinkle doesn’t change the essence of the problem with these testimonials, namely that it’s the surgery and not the woo that cured the cancer, but things have changed—and fairly recently, as in during last few years—when it comes to the treatment of certain subtypes of breast cancer. For the most common type of cancers, the hormone receptor (ER/PR)-positive cancers with negative HER2, the old standard and order of treatments still generally apply: surgery, followed by radiation for breast-conserving surgery and then endocrine therapy to block estrogen with tamoxifen or a type of drug called an aromatase inhibitor . One reason that I asked for markers is that other subtypes of breast cancer at certain stages are now treated with neoadjuvant therapy (chemotherapy first), followed by surgery and then radiation, often with targeted therapy added in. For instance, if the tumor is positive for amplification of the HER2 oncogene regardless of hormone receptor status, then the treatment order is neoadjuvant chemotherapy plus HER2-targeted drugs, usually trastuzumab (Herceptin) and pertuzumab (Perjeta), followed by surgery and radiation. Based on the KEYNOTE-522 trial published in 2020, triple-negative cancers (negative for all three markers) that are greater than 2 cm in diameter are now treated with neoadjuvant chemoimmunotherapy consisting a combination of chemotherapy drugs plus an immunotherapy with pembrolizumab (Keytruda), followed by surgery. There are also studies of neoadjuvant endocrine therapy for hormone receptor-positive/HER2(-) tumors, but this is not standard of care for most such tumors; so that’s all I’ll say about it for now.
Both regimens, KEYNOTE-522 for triple-negative breast cancer and neoadjuvant chemotherapy plus HER2-targeting for HER2(+) cancers are so successful that they can produce pathologic complete response rate (pCR, no living tumor detectable in the surgical specimen after surgery) up to over 60%, to the point where there are now trials to determine whether surgery is even needed after a clinical complete response (the tumor is no longer detectable on physical exam or imaging), along with how to determine whether a clinical complete response is indeed a pCR. (When there isn’t a pCR, what is often found are microscopic nests of residual tumor cells.) None of these new advances in breast cancer treatment changes the overall problem with Paula’s alternative cancer cure testimonial, though, nspecifically that she had surgery.
In fact, thinking about this, it occurred to me that a smart quack (which Mr. Morelli does not appear to be) would tout his woo in a patient like Paula as “neoadjuvant” treatment before surgery, but he didn’t do that. Basically, he claimed that FitScript and the “treatments” guided by it did it all and didn’t even mention Paula’s surgery until after he was called out. Of course, one can’t help but note that, if his quackery actually did cure the cancer, then why did Paula decide three years after her diagnosis that she would undergo surgery? To me that suggests that, best case, the cancer wasn’t going away, or, worst case, that it had been getting bigger, leading Paula to decide to let a surgeon remove it and check her lymph nodes. Let me also say that it’s great that she had her tumor successfully removed and that her lymph nodes were negative. That’s what we try to achieve in the breast and want to see in the lymph nodes. That means that her prognosis is most likely good, although it would be better if she were to agree to the recommended adjuvant therapies, which would be guided by her cancer stage and tumor markers. I hope that she changes her mind.
I would also point out another thing. Let’s, for the sake of argument, accept that whatever “tumor markers” being followed by her functional medicine quack are actually science-based and reliable. (They’re almost certainly not—see next section—but let’s just assume for the moment that they are.) It seems not to occur to anyone that maybe—just maybe—the reason they are now zero is because she had her primary tumor surgically removed in January.
Hilariously, when called out by someone who had found Paula’s Instagram, Mr. Morelli basically blamed the functional medicine quack who had treated her and his social media team, while scoffing that he “doesn’t care what you think”:
The tweet was written / published yesterday by our team and the functional medicine practitioner responsible for her results. I don’t have exact dates / timelines. I also don’t care what you think. This is just one of many we’ve been apart of. pic.twitter.com/iPJslqLclH
— Michael Morelli (@morellifit) May 19, 2024
Pathetic.
You see? It’s faith-based. Mr. Morelli just knows that woo based on his test cured Paula. He just knows. Moreover:
One of the funniest things I've ever seen. https://t.co/pB6yYsyQMe pic.twitter.com/YfAuPcdj80
— John Holowach (@johnholowach) May 18, 2024
Indeed, if you look at the FitScript website, you’ll find Mr. Morelli’s bio:
Years ago, I was far from the picture of success. Bankrupt, divorced, and struggling with addiction, my life was a far cry from where I stand today.
But I’m hardly an overnight success story. At the age of 31, I was a bankrupt and newly divorced drug addict living on my mother’s couch.
In and out of rehab for a decade, I’d built a $5 million business and lost it all. But hitting rock bottom was the start of something new.
Facing fatherhood, I took a hard look at my life. I knew it was time to make radical changes. In just 113 days, I went from 25% body fat to 8%, but it was more than just a physical transformation.
Hint: 8% body fat is the sort of level that competitive bodybuilders strive for. It’s very low and not necessarily healthy. Indeed, one thing that I’ve learned since I started resistance training is that even bodybuilders usually don’t try to stay at 8% all the time because it’s too difficult and not necessarily healthy. (In women, such a percentage body fat of 10-12% or lower will often shut down menstruation, for instance.) They get there when preparing to compete and then tend to go for 10-15% body fat the rest of the time. Let me just say that there’s nothing wrong with bouncing back after hitting bottom. Normally that would be quite admirable. What’s not so admirable is bouncing back by selling quackery like functional testing and functional medicine.
In response, Mr. Morelli basically bragged about his lack of qualifications:I
Their brains are melting. They can’t figure out how a guy without a white lab coat or a phd can possibly get these kind of results. Remember, your doctor was only taught to treat the symptom(s), not to cure or heal you. Just wait, there’s so many more to share. https://t.co/0whevgKlwD
— Michael Morelli (@morellifit) May 18, 2024
Not really. We’re just calling out grift and quackery from an unqualified entrepreneur when we perceive it. Again, there are no “results.” Paula’s anecdote doesn’t demonstrate that Mr. Morelli’s woo cured Paula. What it demonstrates is that she was fortunate enough to have a tumor that was growing slowly enough that she could wait three years to have it surgically resected and it (probably) didn’t spread to distant organs and become incurable.
But what about FitScript and the woo?
Functional medicine and FitsScript: Reams of useless tests revisited
I once described functional medicine as “reams of useless tests in one hand, a huge invoice in the other,” and FitScript appears to fit the bill perfectly. Let’s revisit the tests in the video posted to X on Saturday:
We needed to get to the root of the issue first.So we did our extensive blood work & lab testing.One of those being a toxicity test.Using that test on Paula’s body, we found: pic.twitter.com/pxwnOiVUlq
— Michael Morelli (@morellifit) May 17, 2024
The narrator brags about 124 markers, 87 from blood, the rest from urine. The first thing that I noticed is that a lot of these are pretty standard labs with blood work, such as a complete blood count (CBC), which is broken down into its four individual components, which, I guess, count as four. Practically everyone gets a CBC whenever bloodwork is drawn, in order to detect anemia or abnormalities in white blood cell (WBC) or platelet counts. Of course, as functional medicine quacks often do, there are also a lot of thyroid function tests, whether indicated or not, plus a bunch of nonstandard tests. From this, apparently FitScript comes up with an estimated likelihood of dysfunction in various body systems ranging from blood sugar regulation to kidney function to thyroid function, which is questionable but not too far outside what regular doctors do. Of course, they can’t resist adding measures for “toxicity” or “toxic load,” because nearly all quacks blame nearly all health conditions on “toxins,” which seem so mystical, magical, unidentifiable, and amorphous that I sometimes like to refer to them as evil humors, which is what they resemble. The key here is that, based on massive overtesting, functional medicine doctors then try to “correct” every nutritional deficiency that they find by selling you supplements, whether the “deficiency” is real or clinically significant or not.
Indeed, there’s a reason why I describe functional medicine as the “worst of both worlds.” In a nutshell, functional medicine combines the massive overtesting to which conventional medicine can become prone with the quackery of alternative medicine in order to “correct” these tests. Moreover, if you order enough tests, by random chance alone some of them will be outside of the normal range. In an ideal world, where the “normal” range of a test is the 95% confidence interval around the mean found in a “normal” population, that would mean that roughly 5% of the lab values would likely be “abnormal” and need “correcting. Now look at this screenshot from the FitScript website:
600 biomarkers! Yowza!
Elsewhere on the website:
We analyze 124 biomarkers for health, the most comprehensive in the industry, covering everything from functional body systems to nutrient deficiencies.
Compare this to a standard blood test with just 12 to 20 biomarkers, and you’ll see why our approach is leaps and bounds ahead.
Because, apparently, more is always better. Not for quacks like Mr. Morelli and his team of functional medicine are standard panels of blood tests with a mere 12-20 biomarkers. He does 124 and apparently organizes them into 600 different biomarker combinations, thus increasing the chance for false positives. But customers love it:
This is basically a statement of one of the core principles of “functional medicine,” that of “biochemical individuality.”
Remember, one of the core “principles” of functional medicine is “biochemical individuality.” While it is true on a trivial level that no two people are exactly the same, that doesn’t mean that there is so much “individuality” that everyone will require a perfectly individualized plan or treatment for them. I’m also particularly amused by the claim that they can somehow tailor-make an exercise training program “as unique as your DNA.” If there’s one thing I’ve learned since I started going to the gym and engaging in resistance training, it’s that anyone who makes a claim that inflated is nearly always full of…well you know what. Training programs are, of course, personalized to the person, but not to the level of being “as unique as your DNA.” Another “tell” here is the “tailored supplement recommendations.” Basically, FitScript exists to sell you supplements to “correct” lab abnormalities and “nutritional deficiencies” that might or might not (probably not) need correcting, all according to plans cooked up by the company’s functional medicine quacks.
In any post about functional medicine, I feel compelled to remind our readers that the principle of each person’s “biochemical individuality” is, in essence, a “get out of jail free” card for basically anything its practitioners want to do. They can always find ways to justify any form of treatment, be it science-based or quackery, simply by invoking the “biochemical individuality” of the human being whom they are treating. I also like to remind my readers of my retort to this: Yes, human beings are individuals, and each human being is unique. However, we’re not so unique that our bodies don’t all work pretty much the same way. In other words, in terms of biology, physiology, and yes, systems biology, human beings are far more alike than they are different. If that weren’t the case, modern medicine, developed before we had the tools to probe our genetic individuality, wouldn’t work as well as it does. Functional medicine fetishizes “biochemical individuality”, not so much because humans are so incredibly different that each one absolutely has to have a markedly different treatment. We’re not. Functional medicine fetishizes “individuality” because it distinguishes functional medicine as a brand distinct from science-based medicine and, I suspect, because it makes functional medicine practitioners feel good, like “total” doctors never at a loss for an explanation for a patient’s symptoms or clinical condition, and makes patients feel like special snowflakes whose every bit of “individuality” is being catered to. In brief, functional uses science the same way a drunk uses a lamp post – not for illumination, but for support.
Speaking of quacks, the functional medicine practitioner in FitScript is Paul Burgess, who is described as “a trailblazing entrepreneur renowned as the visionary founder of two highly esteemed entities: Paul Burgess Functional Medicine Ltd, a global telehealth practice, and Paul Burgess Wellness, a transformative healthcare clinic.” I checked out his practice website and was amused to find how he described some of his treatments. For instance:
DNA testing for a truly bespoke exercise and nutrition plan, only you have your DNA so why follow a diet that everyone else does?
We are now able to unlock your genetic code and develop a diet and program specific to you and your goals.
All the guesswork is taken out so you can be sure that your time and effort is not wasted, either in the kitchen or in the gym.
Again, this is utter nonsense, and his use of the word “bespoke” to describe the exercise and nutrition plans that he comes up with are a huge tell. That’s not a word that we generally use in medicine, but rather in tailoring or other services in which a product is made for an individual customer.
The whole industry of DNA testing to come up with “individualized” nutrition and exercise plans is a topic too big to discuss here. Suffice to say, it’s the Wild West out there, with little that is truly evidence-based.
I did find something interesting on the website. Paula Hood is featured there as a success story:
This looks like some standard functional medicine quackery, particularly the mold and heavy metals.
First, I called it. Her tumor had grown, and no doubt that is why she decided to undergo surgery. In other words, the quackery wasn’t working, and so a surgeon saved her. Also, this suggests that I was correct that her tumor was likely fairly slow growing and indolent, given that it had only grown 0.4 cm in the absence of treatment and she in essence waited three years to have any science-based treatment for it at all. Moreover, any tumor that’s been present for three years but hasn’t yet gone to the lymph nodes is not a particularly aggressive tumor. Basically, Ms. Hood is a great example of survivorship bias in that she gambled and, fortunately for her, won. I expect that she will likely do well no matter what she does, although absent at least radiation therapy she does have a pretty high risk of a recurrence in the breast. She’s fairly likely to get away with it, though, and I hope for her sake that she does.
Another thing is that I couldn’t find anywhere whether Paul Burgess is an actual doctor or not…of anything. He appears to be a health coach, which is all that his website seems to claim. I did find this elsewhere:
Paul Burgess has been a healthcare provider for over 20 years. Having had a keen interest in health from a very young age, Paul gained qualifications and began exploring different modalities. About 15-20 years ago, Paul decided to make revolutionising healthcare his main pursuit, finding it more fulfilling than anything else. Rather than having healthcare on the side as a “hobby”, where many practitioners struggle commercially and don’t get paid enough, Paul committed to developing his practice into a proper commercial business. He currently has a global online practice.
“Gained qualifications and began exploring different modalities”? What does that even mean? To me, it means that he’s not a physician and probably not even a naturopath. Otherwise, he’d trumpet that on his website.
So what we have with FitScript are two quack/entrepreneurs named Michael Morelli and Paul Burgess who epitomize my characterization of “functional medicine” as “reams of useless test results in one hand, a huge invoice in the other.” This would be bad enough if all they were doing was “treating” the worried well, but they’re not. They’re victimizing cancer patients like Paula Hood. I only hope that Ms. Hood ultimately realizes her mistake, as she realized her mistake—apparently without admitting that it was a mistake, when her tumor grew while she was being treated with Morelli and Burgess’ quackery—and decides to undergo appropriate adjuvant treatment with radiation and whatever systemic therapy is recommended to minimize her chances of recurrence.
ADDENDUM 5/20/2024: A reader sent me a link to a Facebook post by Ms. Hood dated March 21, 2022. In the comments, she tells what her tumor markers were:
OK, it was a favorable set of markers.
ER(+)/PR(+)/HER2(-) is the most common subtype of breast cancer; two-thirds of breast cancers have this marker combination. This type of tumor doesn’t need adjuvant chemotherapy, although if you want to get technical we do recommend chemotherapy if the tumor (1) has positive axillary lymph nodes and/or (2) has a high recurrence score on various gene-based tests like OncoType or Mammaprint, but that’s just getting into the weeds. The most important thing is that we do generally recommend endocrine (estrogen-blocking) therapy with tamoxifen (premenopausal women) or an aromatase inhibitor (postmenopausal women) for these tumors, and Ms. Hood apparently isn’t getting that. If she truly wants to maximize her chances of never having a recurrence and never dying of her breast cancer, I hope that Ms. Hood will accept radiation therapy followed by appropriate endocrine therapy, most likely tamoxifen given her age.

So-Called Alternative Medicine for Cancer
Edzard Ernst’s new book on alternative medicine for cancer addresses cancer prevention, treatment, and palliative care. It is an invaluable, accessible guide to the evidence for each modality.
Harriet Hall on September 28, 2021
Link

Edzard Ernst definitely knows what he’s talking about. The world’s first professor of complementary medicine, he headed a research team that conducted dozens of clinical trials, did over 300 systematic reviews, and published over a thousand articles in medical journals. He probably knows more about alternative medicine than anyone else in the world. In his latest book, So-Called Alternative Medicine for Cancer, he evaluates alternative medicine’s claims relating to cancer.
Many have argued that alternative medicine is benign and harmless, that it meets psychological needs, that it’s worth trying because it couldn’t hurt and might possibly help. I don’t doubt that alternative medicine may do some subjective good as a placebo. It can provide comfort and can empower patients, letting them feel they are taking action to help themselves and letting them imagine they have some control over an uncertain fate.
But alternative medicine can be deadly for vulnerable patients, especially those with cancer. They are frightened, desperate, and ready to believe any charlatan who offers certainty and hope. They don’t ask whether it might be false certainty and false hope; if it’s false, they don’t want to know. Some of them reject conventional treatments that might have cured them, and they die unnecessarily.
Edzard Ernst is particularly concerned about these potential dangers after what happened during his wife Danielle’s treatment for endometrial cancer. Her nurse tried to convince her that chemotherapy was poison and would cause horrendous side effects. The nurse told her she should refuse conventional treatment and instead follow the anti-cancer diet of Dr. Schwartz, which “would surely cure her”. Ernst promptly fired the nurse and is convinced his wife would be dead today if she had listened to her. Instead, Danielle followed the advice of her oncologist, had conventional surgery, radiation, and chemotherapy, and today is cancer-free.
I have reviewed several of Ernst’s previous books:
    • Trick or Treatment: The Undeniable Facts about Alternative Medicine with co-author Simon Singh
    • Alternative Medicine: A Critical Assessment of 150 Modalities
    • Homeopathy: The Undiluted Facts
    • SCAM: So-Called Alternative Medicine
    • More Harm Than Good: The Moral Maze of Alternative Medicine co-authored with a medical ethicist
    • Don’t Believe What You Think: Arguments for and Against SCAM which he called “a crash course in critical thinking”
In the new book, he starts by explaining why he refers to alternative medicine as SCAM:
It is clearly not an alternative. If a therapy does not work, it cannot possibly be a reasonable alternative to an effective treatment. And if it does work, it simply is part of medicine.
The introductory section explains what evidence is, why it is important, common misconceptions about SCAM, why people are attracted to it, ethical concerns and truly informed consent, science vs. pseudoscience, and why clinical trials can reach false conclusions. Then he proceeds to briefly describe the various SCAM modalities that have been offered to cancer patients in separate sections covering cancer prevention, cancer treatment, and palliative/supportive care. He grades each modality on five factors: plausibility, effectiveness, safety, cost, and risk/benefit balance. He uses the same simple system of colored thumbs that he used in his earlier book Alternative Medicine: A Critical Assessment of 150 Modalities: a green thumbs-up symbol for positive, a horizontal yellow thumb for debatable, and a red thumbs-down for negative.
In two final chapters, he covers the risks of SCAM, interactions between SCAMs and conventional cancer drugs, and published evidence showing that cancer patients who use SCAMs don’t have improved quality of life, are less compliant with prescribed pharmaceuticals, and don’t live as long as patients who don’t use them.
Palliative care
He is scrupulously honest in following the published evidence. He doesn’t disparage anything just for being alternative. He willingly gives good grades to a number of interventions that studies have shown to be helpful in palliative and supportive cancer care. Propolis (for oral mucositis), ginger (for chemotherapy-induced nausea and vomiting), guided imagery, probiotics, and melatonin are rated mostly thumbs up.
Cancer prevention
After reviewing many proposed candidates, he concludes:
Overall, the belief that SCAM plays a major role in the prevention of cancer is built more on wishful thinking than on strong evidence…some supplements could even have a negative influence.
Cancer treatment
Homeopathy gets a thumbs up for safety and cost, but thumbs down for plausibility, effectiveness, and risk/benefit balance. So do prayer, therapeutic touch, and spiritual healing.
In addition to the usual suspects, he covers some modalities that were new to me, such as Lakhovsky’s Oscillator, Powerlight (based on the physics of antimatter!), Factor AF2 (a mixture of liver and spleen cells from sheep embryos), Breuss Cancer Cure, and Danshen.
Conclusion: A very useful manual
        ◦ This book presents a world of useful science-based information in a very accessible format. The reader can easily look up a SCAM modality and see at a glance from the color-coded thumbs whether it’s worth trying. The people who most need to read this book probably won’t. I wish oncologists would take pre-emptive action against cancer SCAMs by giving each patient a free copy of this book at the time of diagnosis. A few of them might even read it and learn from it.

The Cancer Cure Anecdote
Steven Novella on January 4, 2012
Link
Dr. Ian Gawler, a veterinarian, suffered from osteogenic sarcoma (a form of bone cancer) of the right leg when he was 24 in 1975. Treatment of the cancer required amputation of the right leg. After completing treatment he was found to have lumps in his groin. His oncologist at the time was confident this was local spread from the original cancer, which is highly aggressive. Gawler later developed lung and other lesions as well, and was given 6 months to live due to his metastatic disease.
Gawler decided to embark on an alternative treatment regimen, involving coffee enemas, a vegetarian diet, and meditation. Eventually he was completely cured of his terminal metastatic cancer. He has since become Australia’s most famous cancer survivor, promoting his alternative approach to cancer treatment, has published five books, and now runs the Gawler Foundation.
At least, that is the story he believes. There is one major problem with this medical tale, however – while the original cancer was confirmed by biopsy, the subsequent lesions were not. His oncologist at the time, Dr. John Doyle, assumed the new lesions were metastatic disease and never performed a biopsy. It was highly probable – the timing and the location of the new lumps following a highly aggressive cancer. But even a diagnosis that is 95% likely will be wrong in 1 patient out of 20 – which means a working physician will have patients with the 5% diagnosis about once a week. The standard of practice today would be to do a biopsy to get tissue confirmation of the diagnosis, and rule out the less likely alternatives.
Recently oncologists Ian E Haines and Ray M Lowenthal published a paper in which they advance a plausible alternative theory to the story Gawler has been telling for 30 years. Another part of Gawler’s history is that, at the same time he was pursuing alternative treatment for his presumed metastatic cancer, he was diagnosed and treated for tuberculosis. He was having night sweats, losing weight, and coughing up blood – all symptoms that can be explained by disseminated TB. Gawler acknowledges that he had TB and was successfully treated for it, but contends that he had cancer and TB. Haines and Lowenthal propose their alternate hypothesis, and point out that all of Gawler’s symptoms (following successful treatment of his sarcoma) could be explained by TB.
Haines and Lowenthal conclude in their paper:
This hypothesis is advanced for two reasons. The first is to underline the modern recognition of the need to consider diagnostic investigations, including biopsy, before assigning the diagnosis of advanced cancer to any patient. This principle is especially vital in cases where two diseases can present in the same way.  The second is that there a risk that if diseases are incorrectly labelled, incorrect treatments may be given. This can lead to misleading interpretations being made about non-traditional treatments providing “cures,” which can influence the decision-making of patients seeking answers and even lead them away from potentially curative traditional treatments.
As oncologists they want to emphasize the point that biopsy is necessary in such cases – that is a fairly accepted position. They go further to point out that incorrect diagnosis is one source of misleading stories that could convince many cancer patients that an ineffective “alternative” treatment is effective, and therefore interfere with their informed decision making. This is an excellent point.
No one is doubting the sincerity of Ian Gawler himself, although even if sincere he can still be profoundly mistaken. It is easy to understand how someone who was given a terminal diagnosis and then survived would credit whatever they did to treat themselves. This is a profound personal experience, and certainly affected the course of the Gawler’s subsequent life. It is a powerful story that will resonate with anyone facing a cancer diagnosis.
All the more reason to set the story straight, or at least point out that Gawler’s interpretation of his own story is not the only possible interpretation. This points to the fallacy of relying on anecdotes in medicine – 37 years after the fact we have no way of determining whether or not Gawler had metastatic cancer or TB. This means that his case cannot be used as evidence for the efficacy of diet and meditation in curing cancer. But that is exactly how Gawler is using it.
In his latest book, The Mind that Changes Everything, Gawler writes:
It is our mind that regulates our present and our future. Do you imagine a happier world with better health? More vitality? More success with the ability to fulfil your potential when it comes to sport, business, relationships, healing and peace of mind?
This is a typical New Age, Chopra, The Secret type of claim – if meditation can cure cancer, then the mind can do anything. It is pure wish-fulfillment fantasy, but can sound compelling when backed up by an apparent dramatic story.
In a news report on their new article, Haines is quoted as saying:
”I’ve seen beautiful young girls with their whole lives ahead of them and they go into these holistic therapies and spend hundreds of thousands of dollars and then in the end we have to look after them. They all eventually get to us.”
I need to point out that while Haines’ experience is important, it is also anecdotal. He is only seeing those patients who come to him after CAM treatment failure. It is possible that there are those who are cured that he is unaware of because they don’t “get to” him. All we can say is that there are cases of patients who pursue alternative cancer cures, they do not work, and then they present to an oncologist in an advanced stage of their disease. What we need are controlled studies of any proposed treatment to see if they are safe and effective. Of course, there are no such studies supporting the use of alternative cancer cures – that’s why they are alternative.
Gawler has believed for the last three decades that diet and meditation can cure cancer. He has spent that time writing books and promoting his personal story, convincing many others of his beliefs. While he may mean well, the far better course of action would have been to study the hypotheses that stemmed from his dramatic experience, not to conclude that he must be correct and proceed with premature conviction. That is the difference between a crank and a scientist.
In medicine well-meaning (and not-so-well-meaning, for that matter) cranks can do a lot of harm. It’s good to see mainstream doctors recognizing the risk and doing something about it.

Paul Marik: Disparaging chemotherapy in order to sell cancer quackery
Everything old is new once again, as COVID-19 quacks rehash old cancer quack claims that chemotherapy doesn’t work in order to sell their preferred cancer quackery.
David Gorski on July 1, 2024
Link

I realize that I say it perhaps far too often, but, truly, since COVID-19 hit four years ago everything old is new again. It started out with everything old being new again in the world of antivaccine misinformation, complete with false claims of infertility, death, cancer, and the same old, same old “vaccine injuries” due to COVID-19 vaccines. Then, as predictably as night follows day follows night, “new school” antivaxxers started to embrace “old school” antivax tropes and became just antivax. Then, given the affinity between quackery and antivax, “new school” antivaxxers started embracing more general quackery, including cancer quackery, as they quickly “repurposed” drugs that they claimed as effective against COVID-19 (e.g., ivermectin) to treat cancer and then embraced other more general quackery, including even homeopathy. So it should come as no surprise that co-founder of that group of COVID-19 cranks known as the Frontline COVID-19 Critical Care Alliance (FLCCC Alliance), Dr. Paul Marik, is now promoting a very old narrative long promoted by cancer quacks that chemotherapy doesn’t work.
It’s so obviously the old narrative in that the claim goes further than that, to say that chemotherapy “only cures” 5% of all cancers. Sound familiar? It should. I’ve written about it before, although back in the day it was claimed that “only 2%” of cancers were curable with chemotherapy. That’s why, seeing this old trope again all these years later, I felt that I should see what new form it’s taken and what new, if any, evidence Marik cherry picks to try to promote this misleading impression, while being surprised that quacks have now admitted more than double the efficacy of chemotherapy compared to what they used to admit.
I had seen mentions of Marik’s earlier in the week, but what really tweaked me to write about this yesterday, as I was perusing my usual sources, was seeing former Trump administration HHS science advisor Dr. Paul “We Want Them Infected” Alexander promoting this claim in a Substack post with one of his characteristically annoying and lengthy headlines that read BOOM! 2nd Smartest Guy in the World (support this stack) again delivers a seminal piece with a hero of mine, Dr. Paul Marik on the fraud of cancer chemotherapy; never worked!
As an aside, what is it with the “BOOM!” in so many right wing articles and social media posts? Whenever I see that “BOOM!” I can’t help but be reminded of Marvin the Martian, because there usually is no “BOOM!” in these “exposés,” except in the deluded head of someone like Alexander:
“BOOM!” right back at ya, Dr. Alexander!
But I digress.
It was the blurb for Alexander’s Substack entry that got my attention:
Just like the Malone Bourla Bancel COVID mRNA vaccine, it never worked, it worked in your head! Marik: “only “about 5% of all cancers are actually curable with chemotherapy.” not for 95%
And there you go. Sure, it’s not 2%, but it is only 5%. I was also amused, mainly because it very quickly became clear to me that Marik is not up-to-date with respect to cancer chemotherapy, given the claims that he spews. I am more than happy to slap him in the face with some actual data. Alexander, Marik, and the self-proclaimed “2nd Smartest Guy in the World” (2ndSGitW) also willfully misunderstand that most cancers these days are treated with multimodality therapy that can include a combination of any or all of modalities including surgery, chemotherapy, radiation therapy, immunotherapy, endocrine therapy, and targeted therapies, the exact combination and identities of which depend on the tumor type, stage, and overall health of the cancer patient. Few cancers, mainly hematologic malignancies, are treated with just chemotherapy anymore.
The article being referred to by Alexander and 2SGitW was published early last week by the disinformation spreader The Vigilant Fox under the title, Dr. Paul Marik Exposes the Truth About Chemotherapy, with the tagline, “You won‘t hear this from your typical oncologist.” Of course, there’s a reason you “won’t hear this from your typical oncologist,” mainly because it’s, to put it mildly, bullshit. Also, one can’t help but note that Marik isn’t even an oncologist or any specialist related to oncology. I mean, holy hell, as much as I can’t stand Dr. William “turbo cancer” Makis, at least as a nuclear medicine radiologist he did image cancer patients and use some targeted radiotherapies to treat some cancer patients back in the day before he lost his medical license. Marik doesn’t even have that tenuous link to oncology. I also note that there is what I would call a paucity of actual citations to the literature—or any sources other than Marik—in this article. There is, however, a link to the FLCCC page on The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer, where I hoped to find the “rationale” (such as it is) for Marik’s claims.
Paul Marik echoes cancer quacks going back at least 50 years
Let’s start the discussion of the “meat” of Marik’s claim (if you can call it that) by seeing what Marik says, at least in his interview with The Vigilant Fox:
Dr. Paul Marik, a renowned critical care physician, has shed light on the harsh realities of chemotherapy’s ineffectiveness in treating cancer. He revealed that only “about 5% of all cancers are actually curable with chemotherapy.”
This small fraction of cancers that are chemo-responsive includes testicular cancer, Hodgkin’s lymphoma, acute lymphatic leukemia, and a short list of others. (See image below)
The image is this:
Note that this screenshot comes from the video podcast of Robert F. Kennedy Jr.’s antivax group Children’s Health Defense, which I quickly found and saw that—everything old is new again!—the person interviewing Marik was Andrew Wakefield’s old buddy and coconspirator Polly Tommey. I also note that this is all in the context of selling “repurposed” drugs like ivermectin and dubious “metabolic interventions” to treat cancer, because of course it is. That’s always been the purpose of cancer quacks’ attacking chemotherapy.
I tried to find a source to back up Marik’s claim, both in his e-book and slideset, and was unable to locate one. Quelle surprise. Marik also says:
But for the remaining 95% of cancer cases, the prognosis is far less optimistic. Dr. Marik stated, “Chemotherapy is palliative at best,” highlighting that while chemotherapy might prolong survival by one or two months, it comes with a significant cost to the patient’s quality of life.
And:
The truly sobering detail that Dr. Marik mentioned was that despite advancements in chemotherapy, immunotherapy, and surgical treatments over the past 30 years, the overall life expectancy of a cancer patient has been extended by a measly 3.9 months.
Again, this is highly deceptive, and Marik provides no citations. He also conflates the minority of cancers that are diagnosed when metastatic, for most of which chemotherapy is palliative and likely only to provide a survival improvement on the order of months, with the earlier stage, operable, treatable cancers that make up what most cancer patients are diagnosed with. Marik’s conflation of the two is highly deceptive.
As I’m sure that any actual oncologist reading this post will immediately recognize, this is an example of the misrepresentation and outright omission. First of all, it’s deceptive to include a column of metastatic disease in a slide about chemotherapy “curable” cancer, because, with rare exceptions (e.g., testicular cancer, for which even stage IV disease is still potentially curable with chemotherapy, surgery, and radiation—just ask Lance Armstrong), chemotherapy for stage IV disease is almost always palliative. Moreover, Marik’s antivax “thinking” is at play here, in that, just as antivaxxers seem to think that any endpoint other than death (e.g., severe illness) is not important with respect to COVID-19 interventions, he seems to think that palliation of advanced cancer is worthless. While palliative chemotherapy might not prolong survival by long for many of these cancers, contrary to this stereotype, it can prevent cancer-related complications and improve quality of remaining life.
There are also curious—and glaring—omissions and inclusions in the “prolongs survival” part of this chart. For example, chemotherapy most definitely does prolong survival when used as adjuvant therapy after surgery for colorectal cancer, which makes its omission from the “improves survival” group basically a lie by omission. For colon cancer that is stage III (or high risk stage II), chemotherapy is recommended and does decrease the risk of recurrence and prolong survival, even as scientists are further personalizing treatment. Also, multiple myeloma should be in the “potentially curable” column, as chemotherapy can result in long term survival. It is true, of course, that these days monoclonal antibodies (e.g., against CD38 or SLAMF7) play an important role in multiple myeloma treatment, but high dose chemotherapy and stem cell rescue (bone marrow transplant, BMT) can be curative for more advanced disease. (I have a childhood friend who underwent BMT for multiple myeloma and has been disease-free for years. I even recently bumped into her at my cancer center as she came in for a followup visit with her oncologist.) I was also puzzled by the inclusion of thyroid cancer in the “improves survival” column. Most thyroid cancer is treated with surgery alone, sometimes with radioactive iodine to ablate remaining microscopic disease. Chemotherapy is rarely used for thyroid cancer and, when it is, is usually palliative for a particularly nasty—and, fortunately, rare—subtype, anaplastic thyroid cancer.
Finally, let’s look at the cancer that I treat routinely, breast cancer, the second most common cause of cancer death in the US in women. Approximately one-third of all breast cancers are either triple-negative (they do not make estrogen or progesterone receptor proteins) or HER2(+) (they have amplified HER2 oncogene). For these cancers, as I like to say, the oncologists might be putting us surgeons out of business. Here’s what I mean. Using the KEYNOTE-522 regimen (neoadjuvant chemotherapy plus immunotherapy) before surgery for triple-negative breast cancer, we see a greater than 60% pathologic complete response rate; i.e., there is no viable cancer seen by pathologists in the resection specimens. Results are so good that there are now clinical trials being carried out to determine whether surgery is even necessary after a clinical complete response (tumor no longer detectable on imaging studies) and how to determine whether a clinical complete response equates to a pathologic complete response. Similar results are being achieved for HER2-positive cancers after treatment with chemotherapy plus the HER2-targeting drugs trastuzumab and pertuzumab, which produce pathologic complete response rates almost as high as KEYNOTE-522 does for triple-negative breast cancer. As I said, five or ten years from now surgery might not even be necessary for up to one-third of breast cancers. (Good thing I plan on retiring within a decade.)
I could go on, but will for now leave finding additional errors, omissions, and dubious choices for this chart as an exercise for the reader, particularly my oncologist colleagues. Think of it this way. There are already so many errors, dubious placements, and questionable categorizations in the chart that it should make you doubt everything else that Marik says, given that he can’t even get this chart right. As for the chart itself, it didn’t take me long to see that it came from a Webinar slideset on the FLCCC website that so flagrantly mixes nonsense with facts that I could (and maybe should) do a series picking it apart, or perhaps picking apart, chapter by chapter, Marik’s cancer quackery e-book on the website, shown below with its cover and Table of Contents:
Screenshot
Screenshot
Screenshot
Does Marik’s claim have any validity? I suspect you know the answer: It’s a grain of truth distorted.
Paul Marik vs cancer science
Looking at all of this, I wondered where Marik got his figure of “only 5%” of cancers being cured with chemotherapy; so I subjected myself to the CHD podcast in which Polley interviewed him. It was less than three minutes in that Marik was repeating the straw man about cancer beloved of quacks, one that I’ve discussed so many times that Marik’s repetition of it probably caused injury to my extraocular muscles, so hard did I roll my eyes. In brief, Marik claimed that oncologists would say that cancer is caused by mutations and chromosomal abnormalities, when in reality it’s a “metabolic disease.” (And, yes, he did invoke Otto Warburg, who first proposed this idea in 1928.) Only a person who hasn’t been to a cancer conference or read the scientific literature on cancer seriously over the last 10-20 years could say something so out of touch with the reality of what oncologists and cancer scientists actually say about the causes of cancer. Seriously, just do a PubMed search for “cancer” and “metabolism.” It’s so well-accepted that metabolism contributes to cancer formation and progression that there are numerous review articles about it going back a decade. (If Marik really wants to have his mind blown, he should do a PubMed search for “cancer” and “metabolic reprogramming.”) Oh, sure, he concedes that we know that some people have genetic susceptibilities to cancer—who can deny that?—but blithely goes on to say that those genetic susceptibilities probably all cause metabolic changes that cause cancer.
To provide some perspective, I can’t help but interject here that Douglas Hanahan and Robert Weinberg even updated their classic “hallmarks of cancer” article from 2000 to include cancer metabolism (“deregulating cellular energetics”)… in 2011. As time has gone on, I’ve come to suspect that the reason quacks love to invoke “metabolism über alles” as the cause of cancer (and most other disease) is because that makes it much easier for them to argue for dietary interventions as the cure for all disease. Indeed, Marik even cites BRCA1 and BRCA2. Many of you might be aware that certain mutations in these genes can result in a lifetime risk of breast or ovarian cancer approaching 80% (for breast cancer). Moreover, BRCA1 and BRCA2 are tumor suppressor genes that code for proteins whose function is DNA damage repair. When they don’t work due to a mutation, cancer becomes much more likely because DNA mutations accumulate without being repaired, something that would seem to belie Marik’s claims that cancer is metabolic derangement über alles.
In a mind-bogglingly stupid statement, Marik does not state the function of the proteins produced by BRCA1 and BRCA2 (likely because doing so would undermine his entire claim that cancer is mainly a metabolic disease), treats the two as though they were a single gene “the BRCA1/BRCA2 gene” (which they most definitely are not), and then cites a claim that the risk of cancer in mutation carriers used to be “only” 50% 20-30 years ago, but now is 70%, which left me scratching my head. He also neglects to note that the risk is different depending on which gene has a mutation, with oncogenic BRCA1 mutations portending a much higher lifetime risk of breast cancer than oncogenic BRCA2 mutations. Seriously, Marik has no idea what he’s talking about here, but that doesn’t stop him from claiming that “something” else must be going on. OK, so what? Let’s say Marik is correct here. Even in that case, then a gene mutation can cause cancer 50% of the time, and “other factors” at most increase that risk by an additional 20%. He undermines his own argument that cancer is always a “metabolic disease” through his own misunderstanding. Moreover, I couldn’t find any citation or reference in Marik’s cancer e-book to support his misleading factoid. Also, it never seems to occur to him that newer and more intensive testing for BRCA mutations and better epidemiological studies might play a role in changes in estimates of lifetime risk of breast and ovarian cancer in mutation carriers. (These days, a lot more women undergo genetic testing than in the 1990s.)
Unsurprisingly, to support his claim that cancer is a “metabolic disease,” Marik cites Thomas Seyfried, one of the main proponents of the overblown claim that cancer is primarily a metabolic disease. It’s been almost exactly a decade since I last wrote about Seyfried, specifically his risibly overblown claim that ketogenic diets “beat” chemotherapy for the treatment of cancer. As I said at the time, a few years prior to my writing that post, the hypothesis that cancer is primarily a metabolic disease was all the rage in oncology, and I remembered attending several sessions and lectures on the Warburg effect and cancer at the AACR meetings. I also noted that, by 2014, interest in the hypothesis had been waning somewhat, most likely because it had thus far failed to deliver much in the way of therapeutic targets and strategies. I also noted that Seyfried had expressed pride at having been interviewed by Joe Mercola. Here’s a hint: If you’re science-based, you avoid Mercola like the plague. It was true ten years ago, and it’s even more true now, given that Mercola has recently fallen under the spell of a psychic medium grifter claiming to channel an ancient powerful entity even to the point of taking his advice on how to run his business and firing longtime associates, including even his sister, and ghosting friends. So far, not a great source.
Of course, the question of whether the metabolic changes cause the mutations and chromosomal changes seen in cancer or vice-versa is a longstanding debate that Marik glides by as though it were totally settled. As is the case with cancer quacks, he vastly oversimplifies cancer science in favor of one hypothesis and ignores the likelihood that multiple changes contribute to the development, growth, and progression of cancer cells, likely in different combinations at different times, depending upon the step in carcinogenesis that the cancer has reached. I like to cite my previous primary area of research, tumor angiogenesis, the ability of cancer cells to stimulate the ingrowth of new blood vessels to support their growth. You might recall that without that ability cancer cells can only form tumors the size of a small lump of cells, because diffusion of oxygen and nutrients limits their growth to that. Until a new cancer somehow flips the “angiogenic switch,” that’s all it can be, a lump of cells. However, once it starts stimulating the ingrowth of new blood vessels, it can grow almost unchecked. I also recall that back in the 1990s targeting tumor angiogenesis was viewed as a potential cure for cancer, or at least as a strategy that could turn cancer into a chronic, manageable disease like hypertension or diabetes through prolonged use of angiogenesis inhibitors. Unfortunately, it didn’t turn out that way, although angiogenesis inhibitors have taken their place in the multimodality pharmacological treatment of cancer as an incremental advancement—just like most new cancer therapies.
In fact, let’s take a look at a couple of classic figures from Hanahan and Weinberg’s 2011 “hallmarks of cancer” review, compared to the original “hallmarks of cancer” figure from their 2000 review:
Hannahan and Weinberg, 2000
Hannahan and Weinberg, 2011
Hannahan and Weinberg, 2000
As I like to say, liberally paraphrasing what Douglas Adams said about space, cancer is complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think rocket science is complicated, but that’s just peanuts to cancer. That’s why it should be a huge red flag any time you see someone like Marik proclaiming just One True Cause of Cancer.
But what about the “5%” figure? I rather suspect that Marik pulled it out of his nether regions, or—shall we say?—”repurposed” the old “2% gambit” by making it less pessimistic. Given that I can’t find any new sources that I haven’t addressed before I will therefore refer you to my previous posts refuting the old and deceptive claim that chemotherapy “cures only 2%” of cancers and explaining how chemotherapy does work after all.
Chemotherapy vs. “repurposed drugs”?
One claim by cancer quacks like Marik that’s always irked me is that they are somehow the only people who have ever thought of “repurposing” drugs approved for other purposes to treat cancer. Seriously, I published a number of papers investigating the possibility of repurposing a drug for Alzheimer’s disease to treat cancer. My annoyance became very acute when I saw Marik flash this slide in his interview:
This is yet another of Marik’s deceptive tables. For example, the claim that repurposed drugs can affect “all malignant cells” is just nonsense. Different repurposed drugs can target different tumor cells, as such drugs work against certain cancers mainly because they target certain signaling or metabolic pathways that the disease for which they were approved has in common with those specific cancers. Similarly, there’s no good evidence that repurposed drugs in general—cough, cough, ivermectin—enhance adaptive immunity. And WTF does “improves/enhances” tumor microenvironment even mean? While it is true that tumor microenvironment (the cellular milieu, including immune cells, surrounding the tumor) can have a huge effect on tumor growth and progression, no evidence is presented that any of the “repurposed drugs”—cough, cough, ivermectin—has any effect on the tumor microenvironment.
Seriously, I laughed out loud at the claim that tumor cell resistance doesn’t develop against “repurposed drugs.” Here’s a hint for Marik: Tumor cell resistance can develop against pretty much any drug, chemotherapy, targeted therapy, immune therapy, or whatever. I remember in the 1990s how it was widely speculated that cancers would not develop resistance to antiangiogenic therapy because the therapy targeted normal vascular cells. Guess what? Just like in Jurassic Park, life (in this case, cancer, which is a particularly tenacious form of life) was not contained and did find a way. There are now known to exist multiple mechanisms by which tumors achieve resistance to angiogenesis inhibitors. The same will almost certainly be true for any repurposed drugs that, unlike most of what Marik lists, are shown to actually be efficacious as cancer treatments. Cancer finds a way, and resistance eventually develops. It’s a huge red flag for quackery when anyone claims otherwise, Marik’s claimed “deep dive into the literature” in which he supposedly personally reviewed “over 900 peer-reviewed” papers in one of his videos notwithstanding.
“New school” COVID-19 antivaxxers and quacks have now become just run-of-the-mill grifting antivaxxers and quacks, complete with the same claims of having “done their own research” in which they cherry pick the studies that they like, ignore the longstanding history of cancer research, and portray themselves as someone who has discovered something about cancer that “they” don’t want you to know about. The claim that chemotherapy “only cures 5%” ignores the difference between adjuvant chemotherapy and primary chemotherapy as treatment and that most cancers are now seldom treated with just one modality anymore. It is, in essence, a marketing tool in which the cancer quack disparages the competition in order to sell you something. In the case of Paul Marik, he’s selling ivermectin and other “repurposed” drugs for cancer, while in the case of The Vigilant Fox and 2ndSGitW, it’s the Joe Tippens protocol, which both include at the end of their articles featuring Marik.
The more things change, the more they stay the same in quackery world, and, of course, everything old is new again. Marik is just peddling the same old snake oil that cancer quacks have been peddling ever since chemotherapy started to enter the treatment regimens for various cancers, even as he portrays himself as promoting “integrative oncology.”

DA blacklists cesium chloride, ineffective and dangerous naturopathic cancer treatment
The FDA recently issued an alert warning of significant safety risks associated with cesium chloride. It is a mineral salt promoted by naturopathic “doctors” and “integrative” medicine practitioners as an alternative treatment for cancer, despite the lack of evidence of safety and efficacy in treating cancer or any other disease.
Jann Bellamy on August 2, 2018
Link


The FDA recently issued an alert warning of significant safety risks associated with cesium chloride (CsCl). CsCl is a mineral salt promoted by naturopathic “doctors” and “integrative” medicine practitioners as an alternative treatment for cancer, despite the lack of evidence of safety and efficacy in treating cancer or any other disease. In another chilling example of the harm so-called “complementary medicine” causes cancer patients, dangers cited by the FDA include death, QT prolongation (“a dangerous abnormality that can impair the heart’s ability to maintain a normal rhythm”), arrhythmias, cardiac arrest, low potassium, seizures, and fainting.
The FDA also announced that it would take regulatory action, such as issuing a warning letter, seizure of product, seeking a court injunction, or criminal prosecution, against any pharmacy or health care practitioner compounding a drug containing cesium chloride. Until the announcement, CsCl was on a list of substances, called “Category 1”, that could be used in compounding without fear of regulatory action, pending further review of the substance by the FDA. The FDA has now moved CsCl to what is known as the “Category 2” list, substances that are effectively banned from use in compounding because of significant safety risks.
The FDA took this action in response to a Citizen Petition filed by Public Citizen in December of 2017, and only then on the heels of a lawsuit filed by Public Citizen last month. The suit chastised the agency for sitting on its hands for two years after the FDA’s own reviewers determined that cesium chloride had not been shown to be effective for “the prevention or treatment of any form of cancer,” presented “serious safety concerns”, and is “not safe for human use”.
Given these grave concerns, how did cesium chloride ever get on the Category 1 list in the first place, enabling healthcare practitioners to use it as a bogus cancer treatment by either compounding it themselves, or having a pharmacy compound it, and injecting it into patients? Because the American Association of Naturopathic Physicians, the Alliance for Natural Health, the Integrative Medicine Consortium, and McGuff Compounding Pharmacy Services, citing a quack cancer treatment “theory” and cherry-picked evidence of safety, nominated it for Category 1. The FDA decided that this was “sufficient supporting information” for the FDA to refrain from taking any action against its use pending further review.
Before we return to this little rogues’ gallery and their successful efforts to fend off the FDA from banning their bogus cancer treatment, it’s helpful to understand a bit about compounding and how it is regulated.
Compounding 101
A licensed pharmacist or physician can legally combine ingredients to create a medication tailored to the needs of an individual patient. This is called “compounding.” Compounded drug products, when prescribed and produced appropriately, can, according to the FDA, serve an important role for patients whose clinical needs cannot be met by an FDA-approved drug product. However, precisely because they are not FDA-approved, compounded drugs have not undergone premarket review for safety, effectiveness, and quality, nor are pharmacists and healthcare practitioners who engage in traditional compounding required to comply with current good manufacturing practices.
In 2012, an outbreak of fungal meningitis due to contaminated injectable drug products shipped by a compounding pharmacy to patients and health care practitioners across the country resulted in 60 deaths and 750 cases of infection. In response, both Congress and the FDA took steps to clean up the compounding industry’s act.
As part of this effort, the FDA announced it would develop a list of approved substances (called the “503A list,” or “503A bulks list,” named after the section in the FD&C Act authorizing it) that could be legally used in compounding and that the agency would take nominations for inclusion on that list. (Substances that are already the subject of an USP or National Formulary monograph or are a component of an FDA-approved drug can be used in compounding without further review.) However, pending a more extensive review for inclusion on the FDA’s final approved 503A list, the agency divided nominated substances into three categories:
Category 1: substances nominated with sufficient supporting information to permit FDA to evaluate them.
Category 2: substances nominated with sufficient information for evaluation, but which pose “significant safety risks related to [their] use in compounding.”
Category 3: substances nominated without sufficient supporting information.
The FDA said it would forego any regulatory action against Category 1 substances, essentially allowing their use unless and until they fail to make the FDA’s final cut. Category 2 and 3 substances cannot currently be used in compounding, although they are still technically eligible for the 503A list.
Naturally, if you will, the FDA’s action was met with some consternation among naturopaths, who like to whip up concoctions of unproven remedies and inject their patients with them, sometimes with disastrous results. The turmeric injection that killed Jade Erick was a compounded remedy for eczema injected by her California-licensed naturopathic doctor.
In 2014, in response to the FDA’s new compounding regulatory scheme, the American Association of Naturopathic Physicians nominated favorites like Artemesia, Boswellia, calcium EDTA, Echinacea, DHEA, DMPS, DMSA, co-enzyme Q10, and germanium, along with cesium chloride, for FDA-approved use in compounding. It also wanted to dump the entire Homeopathic Pharmacopoeia of the United States and the USP Dietary Supplements Compendium on the approved list, even though the law specifically limits compendia to the USP or National Formulary.
The AANP complained bitterly that the FDA was requiring evidence – imagine that! – which busy naturopathic clinicians could not be bothered to supply, a tacit admission that naturopaths were using these substances without sufficient proof of safety and efficacy. The AANP also pontificated as to how the conventional medical system had failed the typical naturopathic patient (whose “immune systems are often depleted”), but, because naturopaths
are trained to find the underlying cause of a patient’s condition rather than focusing solely on symptomatic treatment, [they expertly prescribe and administer] safely compounded medications – including nutritional, herbal, and homeopathic remedies [which] prove efficacious to meet their needs every day in doctors’ offices across the country.
So, these substances are efficacious, according to the AANP, they just couldn’t tell the FDA how they came to that conclusion.
Germanium ended up on the FDA’s Category 2 list. Other naturopathic favorites are on the list of substances nominated without adequate support (Category 3) and therefore cannot legally be used in compounding. These include Coenzyme Q10, ginger root powder, ginkgo biloba standardized extract, nux vomica extract, and colloidal silver.
Cesium chloride
With that background, let’s turn to cesium chloride and its appearance on the FDA’s Category 1 list. As noted, CsCl was nominated by the AANP, joined in its efforts by representatives from the fringes of medicine: A group calling itself the “Integrative Medicine Consortium,” which includes a couple of Pseudomedical Pseudoprofessional Organizations that have appeared on SBM’s radar before – the American Academy of Environmental Medicine and the American College for the Advancement in Medicine – as well as the AANP and the International College of Integrative Medicine. The Integrative Medicine Consortium was also speaking on behalf of the Academy of Integrative Health and Medicine, whose mostly online “fellowship” program allows one to sit for the American Board of Integrative Medicine exam and become board-certified in the dubious specialty known as “integrative medicine“. The Alliance for Natural Health, a faux “grassroots” organization that advocates for the protection of quackery and against vaccination and fluoridation, and McGuff Compounding Pharmacy, whose self-interest in the subject should be obvious, rounded out the list of organizations nominating CsCl.
Supporters wanted to be able to compound up to 500 mg/mL in a multiple dose vial for injection for use in the treatment of cancer. (To access documents in support of their nomination, see Tab A, at p. 38, of this FDA Briefing Document.) In support of their nomination of CsCl as an effective treatment for cancer, they claimed:
Cesium chloride 500 mg/ml has been helpful and useful in combination with other natural substances in treating individuals with numerous types of cancers, by a presumed alkalinizing effect. Cancer has been found to thrive in a low-pH environment, and to be hindered in a high pH environment. It has been known for decades that a thriving cancer cell produces an acidic micro-environment, and a weak cancer cell does not. (Jahde and Rajewsky, “Tumorselective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues.” Cancer Research. 1982 Apr 42(4): 1505-12). This is known to be due to cancer’s product, lactic acid. However, it is also known that acidic fluid holds less oxygen than alkaline fluid. Thus the acidic, deoxygenated water in the cancer microenvironment is conducive to anaerobic metabolism, which is the default metabolism of cancer cells. Thus an alkaline agent that can be delivered to that intracellular and extracellular microenvironment indirectly has a selectively suppressive effect on cancer cells.
Wow! It’s pH woo déjà vu: “Dr.” Robert Young’s pH Miracle Living and the alkaline diet, all rolled into one and delivered via injection. Or, as the Memorial Sloan Kettering Cancer Center put it, more politely,
Supporters claim that cesium neutralizes the toxic material produced by tumor cells and prevents them from dividing. There is no scientific evidence to support these claims.
And this, from the nominators of CsCl:
Cesium chloride has a history of use among various professions in integrative medicine in the U.S., and many hundreds of patients have been helped by cesium chloride in their fight against cancer.
Of course, “a history of use among various professions in integrative medicine” is meaningless as far as evidence of safety and effectiveness is concerned. Homeopathy, which is demonstrably worthless as a treatment for anything, also has “a history of use among various professions in integrative medicine.” There is absolutely no reliable evidence that “many hundreds of patients have been helped” and none is cited.
Finally, these outrageous statements,
No existing drug matches the advantages of cesium chloride against cancer: the evident ability to enter the cancer cell together with the pH rise, as well as the high remission rate and lack of observed side effects at therapeutic dose. Generally safe and non-toxic substances such as cesium chloride are a viable alternative . . . No approved drug product exists that addresses the condition of cancer adequately. Conventional cytotoxic chemotherapy drugs are generally very poorly tolerated, having life threatening side effects, and a high mortality rate. With a realistic assessment of their odds, there are patients who choose to avoid chemotherapy, and have opted instead for alternatives, including cesium chloride.
As for safety, they ignored published animal studies and human safety data and minimized the few adverse events (e.g., “anecdotes on the internet”) they did recognize in their nomination.
For undisclosed reasons, the FDA found that CsCl was nominated “with sufficient information for evaluation” and placed in Category 1, pending further review.
Subsequently, in May, 2016, FDA’s expert reviewers recommended against adding cesium chloride to the 503A list substances approved for use in compounding, in part because of “serious safety concerns related to [its] use.” The reviewers cited animal studies showing CsCl caused ventricular tachycardia and other heart risks, decreased motor activity, autonomic disturbance, diarrhea, and developmental issues in offspring. Thus, “the toxicity profile of cesium chloride in animal studies weighs against its inclusion on the 503A list.” (Their report starts at p. 60 of the FDA Briefing Document.)
As for human risks, the reviewers concluded:
The limited information available about the safety of cesium chloride gives rise to significant concern about its use in compounding. The evidence of cesium chloride causing hypokalemia [low potassium levels], seizures, QT prolongation, and cardiac arrhythmias is particularly concerning.
Possibly as a rejoinder to the AANP’s swipe at chemotherapy drugs, the reviewers noted:
There are numerous FDA-approved agents that have demonstrated safety and efficacy for the treatment of patients with various cancers.
Speaking of efficacy,
Cesium chloride has not been shown to be efficacious for the prevention or treatment of any form of cancer. . . evidence of clinical benefit from cesium in human cancer is limited to one case series published in 1984 by Sartori [cited by the AANP et al.]. That case series has major flaws including its uncontrolled nature, retrospective design and probable case selection bias. Therefore, the results cannot be considered reliable.
The reviewers also noted:
In addition, use of cesium chloride may cause a patient to delay the use of treatments that have been found to be safe and effective for treating cancer.
Thus, the reviewers concluded that cesium chloride is not a suitable substance for the 503A list.
In June, 2016, the FDA’s Pharmacy Compounding Advisory Committee considered the nomination of CsCl to the 503A list and recommended, based on the reviewers’ concerns as well as their own, by a unanimous vote of 11-0, that the FDA should not place CsCL on the list. (Transcript here, see p. 75.) As one committee member, a pharmacology professor, said:
So even if you state the point that the efficacy is not demonstrated, it has a major safety issue, and safe doses have not been established, forget the fact that we know nothing about effective doses.
The Committee’s recommendation awaits final FDA action.
The only problem was, even in light of the FDA’s own damning review, CsCl remained on the Category 1 list, meaning nothing was stopping naturopathic doctors and integrative physicians from plugging their patients with CsCl. This prompted Public Citizen to file its Citizen Petition in December of last year, asking the FDA (1) to immediately add cesium chloride to the Category 2 list of substances that raise significant safety risks, thereby effectively prohibiting it use for the time being, and (2) to promulgate a rule excluding CsCl from the 503A list, thereby permanently prohibiting its use.
The FDA did nothing until suit was filed against it in federal district court by Public Citizen in July, seeking to compel the agency to act on its Petition. Within hours, the FDA granted the Petition in part, issued its alert warning “of significant safety risks associated with cesium chloride” and moved CsCl to Category 2. In addition to the data discussed in the Pharmacy Compounding Advisory Committee’s 2016 recommendation, the FDA conducted a comprehensive review and found three more published cases of adverse events related to cesium chloride describing “life-threatening neurologic and cardiac toxicity”. The agency declined, however, to promulgate a rule excluding CsCl from the 503A list, although it said it will make a final determination at some point.
On the same day suit was filed, Public Citizen filed another Citizen Petition asking the FDA to immediately remove dietary supplements containing CsCl from the market. The Petition is based on the same safety risks and lack of efficacy recognized by the FDA and the promotion of CsCl-containing dietary supplements in the treatment of cancer. The FDA has yet to respond.
It’s hard to imagine that cesium chloride will make it onto the final 503A list of substances approved for compounding in the treatment of cancer given the Pharmacy Compounding Advisory Committee’s recommendation. For now, its use in compounding risks regulatory action, including a criminal complaint, by the FDA. Of course, unless the FDA acts to ban it as a dietary supplement ingredient as well, it will remain available and its promotion as a quack cancer treatment will continue.
FDA inaction aside, what this whole episode should demonstrate to everyone (including state legislators and medical boards) is the absolute disregard for evidence of safety and effectiveness on the part of naturopathic “doctors” and integrative physicians and their “professional” organizations. Not only did they cherry-pick the published literature on safety, which alone should disqualify cesium chloride’s use, they credulously promoted a highly dubious mechanism of action and questionable case reports as evidence of efficacy, all the while complaining that they had to provide the FDA with evidence in the first place. I realize that the naturopaths may not have known better, given their substandard education and training. As for the integrative physicians, I’ll chalk it up to their “specialty’s” penchant for mendacity and colluding (if I may use that word) with naturopathic “oncologists“.

Yes, Chris beat cancer, but it wasn’t quackery that cured him
Chris Wark is a young man who was diagnosed with stage 3 colon cancer in 2003 at age 26. He underwent appropriate surgery for his cancer but declined adjuvant chemotherapy in favor of quackery. Now promotes his testimonial, in which he tries to convince people that it was the quackery, rather than the surgery, that cured him. He even claims that surgery alone can’t cure stage 3 colon cancer, which is just plain wrong. Yes, Chris beat cancer, but it was the surgery, not the quackery, that did it.
David Gorski on October 15, 2013
Link
I like to think that one of the more important public services I provide here at Science-Based Medicine is my deconstructions of alternative cancer cure testimonials. After all, one of the most powerful marketing tools purveyors of cancer quackery have in their arsenal is a collection of stories of “real patients” with cancer who used their nostrums and are still alive and well. These sorts of analyses of alternative cancer cure testimonials began right near the very beginning of my not-so-super-secret other blog way back in 2004, metastasized—if you’ll excuse my use of the term—to SBM in 2008, and have continued intermittently to this very day, most recently with a bevy of posts showing why the testimonials of Stanislaw Burzynski’s patients do not constitute good evidence that he can cure cancers considered incurable by “standard” medicine. In other words, Burzynski’s “success stories” aren’t the slam-dunk evidence he and Eric Merola want you to believe them to be regarding the use of antineoplastons to cure brain cancers.
Sometimes, these patients who believe that alternative medicine somehow cured their cancers are so transformed, so energized, that they basically devote their lives to selling, in essence, their story, along with all the stuff they did to “cure” their cancer. I just came across one such person, a man by the name of Chris Wark, whose website and blog Chris Beat Cancer sells the idea that he beat his cancer with nutrition and “natural therapies” that he used to “heal himself.” All of this wouldn’t be quite so horrible—after all, there are lots of people who believe in woo and say so publicly—except that Wark is now also selling all sorts of misinformation about cancer, at $175 for a two hour phone consultation. Regular readers will recognize right away where Mr. Wark goes wrong in his story. Even so, I think it’s worthwhile to take a look because since discovering Mr. Wark’s site I’ve seen his name popping up all over the place promoting “natural” cures, and his site has become a repository of all sorts of “alternative cancer cure” testimonials, as well as credulously promotional material for quackery like Gerson therapy, the Beck protocol, and the Gonzalez protocol.
First, let’s take a look at Mr. Wark’s story. Since his story is so simple to deconstruct, I’ll then look at more of the material on his website. Right on the front page of Mr. Wark’s website, there is a brief blurb about him that reads:
My name is Chris Wark. I was diagnosed with stage 3 colon cancer in 2003, at 26 years old. I had surgery, but refused chemo. Instead I used nutrition and natural therapies to heal myself. By the grace of God, I’m alive and kicking, and cancer-free!
Elsewhere, Mr. Wark states:
In December 2003 I was diagnosed with Stage 3 Colon Cancer. There was a golf ball sized tumor in my large intestine and the cancer had spread to my lymph nodes. It was two weeks before Christmas and I was 26 years old.
The oncologist told me I was “insane” but I decided against chemotherapy after surgery. After prayerful consideration I radically changed my diet and did every natural non-toxic therapy I could find.
I started this blog in 2010 to share my story and everything I’ve learned about nutrition and natural therapies for cancer. I didn’t expect it to blow up, but it has.
Regular readers will recognize right away that Mr. Wark is making a common mistake, namely confusing adjuvant chemotherapy with chemotherapy administered for curative intent.
And here is a video:
Again, regular readers will recognize immediately that this is the most common variety of alternative cancer cure testimonial. It’s so common that I really should think of a pithy name for it. Maybe the “adjuvant gambit”? Basically, such testimonials completely confuse the role of two different modalities (surgery and chemotherapy) in treating their malignancies. Mr. Wark’s testimonial contains the same sort of error about cancer therapy that, for example, Suzanne Somers routinely makes when she relates her breast cancer “cure” testimonial. That error is to confuse the use of chemotherapy for primary curative intent with the adjuvant use of chemotherapy. Many cancers, such as hematological malignancies, are treated primarily with chemotherapy, but solid tumors (i.e., tumors arising from organs) are treated primarily with surgery to extirpate the primary lesion. Most hematological malignancies, if they are going to be “cured,” are cured with chemotherapy and sometimes radiation therapy. Most solid tumors, on the other hand, require complete surgical extirpation to cure them.
The problem, of course, is that many solid tumors have already had cells detach from them and either invade further into the organ or circulate in the bloodstream. Only a very small fraction of these cells can lodge somewhere and form a metastasis, but when you’re dealing with billions of cells or more the risk starts to become significant. In the case of Suzanne Somers’ breast cancer, she underwent excision of her primary tumor, biopsy of her axillary lymph nodes, and adjuvant radiation therapy (although she now says that if she had to do it all over again she would refuse radiation as well). What she did refuse were adjuvant chemotherapy and adjuvant Tamoxifen, the estrogen-blocking drug that was (and still is) commonly used as adjuvant therapy for breast cancers that make the estrogen receptor. No doubt, given her well-known promotion of “bioidentical” hormones as a fountain of youth, Somers did not wish to do anything that would block the action of these hormones. I’m also sure that her doctors almost certainly told her that she needed to knock it off with the bioidentical hormones while being treated for her cancer, a recommendation that was unlikely to have been well-received.
In any case, adjuvant therapy is intended not as a primary cure, but rather to decrease the chances of a cancer recurrence. Radiation therapy is used to decrease the chance of a local recurrence (i.e., a recurrence in the organ or area where the tumor was resected), while chemotherapy or hormonal therapy is used to decrease the risk of a systemic recurrence (i.e., a recurrence elsewhere in the body). Somers did her radiation and thus maximized her chances of not having a local recurrence, but she refused the drugs that would decrease her chance of a systemic relapse. But how big of a risk did she take in doing this? Well, I ran her clinical information through Adjuvant! Online, an online tool that allows doctors to estimate risks and benefits of therapies based on known clinical trial data. This estimate found that, with surgery alone, Suzanne Somers had a 77% chance of living 10 years. Adding hormonal therapy would increase that chance by 5.7% and adding chemotherapy would increase it by 5.9%. Taking both would increase her chances of living 10 years by 9.9%. So, basically, by eschewing chemotherapy and radiation, Suzanne Somers reduced her chances of surviving 10 years from roughly 87% to 77%. That’s the “miracle.”
I’m sure you can see where I’m going with this. Wark states that he had stage III colon cancer. What this means is that the cancer has spread to the regional lymph nodes. Sure, it’s a bit more complicated than that. There are stage IIIA, IIIB, and IIIC colon cancer, the A, B, or C part depending upon the number of involved lymph nodes and whether the tumor has invaded through various layers of the colon or not, but the basic idea is simple: Node-positive colon cancer that has not spread to distant organs equals stage III. For purposes of discussion, that’s all you need to know. Of course, oncologists would not divide stage III into A, B, and C if the differences didn’t matter, but overall all these “flavors” of stage III share one thing in common, and that’s that the tumor has spread to regional lymph nodes, usually in the mesentery (the double layer of peritoneal membrane that suspends the colon and in which the vasculature supplying and the lymphatics draining the colon are located). That’s why an oncologically sound resection of colon cancer mandates resecting the mesentery all the way down to the root of the mesenteric vessels supplying the segment of colon being resected, and a measure of quality of colon resection is a minimum number of mesenteric lymph nodes included in the specimen.
Now here’s the thing. The primary treatment for stage III colorectal cancer is still complete surgical resection. Everything else is icing on the cake. To illustrate this point, I ran an Adjuvant! Online estimate for the benefit of chemotherapy for a patient like Wark, who was 26 at the time of his diagnosis. This is a bit hard to do because I don’t have complete staging information. However, Wark was nice enough to inform his readers that he had four positive lymph nodes and a “golf ball sized tumor.” The latter bit of information doesn’t help, because for purposes of staging size doesn’t matter so much as how far the tumor has invaded through the layers of the wall of the colon, but the first bit of information about how many positive lymph nodes were discovered is quite useful because it tells me, when combined with the size of the cancer, that the original tumor was probably not stage IIIA. Most likely, it was stage IIIB, although it is certainly possible that he had stage IIIC disease. For purposes of discussion, I am going to assume he had stage IIIB disease. It’s close enough to make the point, and if he had stage IIIC disease, it would only make the case for chemotherapy stronger.
There are also two main chemotherapy regimens for colorectal cancer. One is basically 5-fluorouracil (5-FU) plus leucovorin and has been the mainstay of treatment of colon cancer for decades. However, over the last 10 or 15 years, a newer, more effective regimen known as FOLFOX has been developed that include 5-FU, leucovorin, and oxaliplatin. There’s also an even newer regiment called FOLFIRI that is 5-FU, leucovorin, and irinotecan, but that one is not yet in Adjuvant! Online. So I’ll stick to 5-FU and FOLFOX. What I did was to enter information provided by Mr. Wark on his website into Adjuvant! Online and make educated guesses about the rest in order to provide you with a graph that shows a ballpark range for the survival benefit that adjuvant chemotherapy would provide him. First, here is stage IIIB disease plus 5-FU-based regimens:
Next, here is stage IIIB disease and FOLFOX:
In both cases, with surgery alone, Mr. Wark’s odds of surviving five years are around 64%. That’s pretty good for such advanced disease, but we can do better. 5-FU-based chemotherapy regimens increase those odds by around 12% to a 76% chance of surviving five years. FOLFOX, as you can see, does even better, increasing the odds of surviving five years by around 16%, all the way to 80%. Since colon cancer, unlike, for example, breast cancer, rarely recurs after five years, five year survival rates in colon cancer are pretty close to equivalent to the chances of being “cured” of colon cancer. So basically, by eschewing chemotherapy, Mr. Wark decreased his chances of surviving his disease by approximately 12-16%. Since his odds of surviving his disease with surgery alone were greater than 60% to begin with, although he was lucky that his refusing chemotherapy didn’t put him into that 12-16% of similar patients for whom chemotherapy prevents a recurrence, the odds of his surviving were still in his favor if my educated guess about his stage at diagnosis is reasonably accurate. If, however, I underestimated his stage and he had stage IIIC disease, the argument for chemotherapy would be even stronger:
Note that in this graph, Mr. Wark’s odds of surviving 5 years with surgery alone would only be 30%, with FOLFOX chemotherapy increasing the odds to around 55%, nearly double. Of course, even in this extreme case, 30% is around a one in three chance; so survival without chemotherapy would not be that unusual. Although he would, in this case, have to be quite a bit luckier than in the case of stage IIIC disease, his survival would not be so unusual that it could be attributed to whatever woo he decided to partake of. Sadly, as is evident in an e-mail from Mr. Wark reprinted in a credulous article about his story, Mr. Wark does not understand the basics of adjuvant chemotherapy, or, if he does, he is not relating it correctly:
Surgery does not cure cancer, especially not stage 3. If it did, that’s all they would do. There would be no need for chemo and radiation. The medical industry has known that surgery does not cure cancer for at least 100 years. Cancer is a systemic metabolic disease, the result of a body that is nutrient deficient, overloaded with toxins, and has an overloaded or suppressed immune system. If the body is not given the essential nutrients it needs to repair, regenerate and detoxify, cancer will most assuredely [sic] come back after surgery. A diet rich in fruits and vegetables, juices and smoothies is the most powerful way to promote the body’s ability to heal itself. All processed food must be eliminated. Animal products should be severely restricted or eliminated for a season until the cancer is gone. And it’s ok if some people don’t believe me. I know lots of survivors that have healed cancer without surgery, but skeptics won’t believe them either.
He is, quite simply, wrong that surgery does not cure cancer. For solid tumors like colon cancer, surgery is almost always the only way it can be cured. Indeed, even in the case of some stage IV disease (specifically, metastases to the liver), surgery can still “cure” colorectal cancer. Be that as it may, Mr. Wark had an estimated 30-64% chance of being “cured” of his cancer by surgery alone. However, those odds aren’t good enough. Why should they be, when we can make them significantly better with chemotherapy? It is sad that Mr. Wark decided to decrease his odds of surviving his disease, particularly given how young he was at the time of diagnosis. It is even sadder still that he has decided to dedicate his life to persuading other cancer patients to make the same foolish choice that he did. As for “survivors that have healed cancer without surgery,” as I have shown time and time again in other contexts, these stories rarely stand up to scrutiny either. In any case, looking at his testimonial, I see that his oncologist estimated that he had a 60% chance of survival. It’s not clear whether that is with or without chemotherapy, but most of the time oncologists assume that the patient will accept standard-of-care therapy. That’s why this piece of information makes me think that Mr. Wark was closer to a stage IIIC than IIIB and therefore leads me to believe that Mr. Wark took an even bigger chance with his life than I had originally thought.
It’s also instructive to take a look at the naturopath who treated Mr. Wark, a guy named John Smothers. Perusing his website you will find the usual naturopathic nonsense about “detoxification,” chronic Lyme disease, “anti-aging” diets, and the like. On Mr. Smothers’ page on cancer, you will find metabolic blood tests, anticancer diets, intravenous vitamin therapy, detoxification, infrared sauna treatments, enzyme therapy, lymphatic massage, and something called Theotherapy, which purports to “release destructive emotional patterns that cause weakness in the body through prayer and grief processing. The body is a slave to the soul. What is in the soul will manifest itself into the physical body. Patterns of unforgiveness will lead to breakdown. Forgiveness must come from the heart. Most of the time this is in many layers.” In other words, Mr. Smothers offers the usual cornucopia of pseudoscience and mysticism that naturopaths love so much, and Mr. Wark has completely bought into it. Indeed, take a look at his reasoning (such as it is) for refusing chemotherapy:
Right from the start, it’s easy to tell that Wark’s reasoning will not be sound. He talks about how nurses have to wear gloves and try to protect their skin from chemotherapy while expressing horror that this is the same stuff that is put into patients’ veins. Of course, patients go through their chemotherapy for six or nine or twelve months—or whatever regimen—and get dosed once every one to three weeks or so. Nurses deal with the substances day in and day out on a chronic basis, possibly over many years. The two are not comparable situations. Next, Wark refers to chemotherapy as “poisoning your way back to health.” Well, yes and no. Sometimes, as Nick Lowe would say, you have to be cruel to be kind (in the right measure). Yes, chemotherapy is toxic, but it works and, unfortunately, we haven’t found anything that works as well yet. Perhaps the silliest thing Wark says in this video is that he has to “believe” in the therapy he chooses and that “if I really believed in chemotherapy maybe it would’ve worked.” Here’s a hint: Truly effective anti-cancer therapy doesn’t require you to “believe” in it. As has been said before, you can be in a coma, and antibiotics will still cure your pneumonia. In the same way, you can “disbelieve” that chemotherapy can treat a cancer, and it will still work. Wark also doesn’t help his case by citing the “2% gambit” about chemotherapy, which is misleading trope beloved of cancer quacks the world over. Wark is no exception.
His last trope is that chemotherapy destroys the immune system. He discusses how, if you have cancer, it is the immune system that is keeping it in check and the reason that it’s “not all over your body.” Well, not exactly. He seems to forget that if his immune system had been as awesome as he thought it was he probably would never have grown a golf ball-sized tumor in his colon that spread to his mesenteric lymph nodes in the first place. Of course, his explanation is that it’s the “toxins” that overloaded the immune system and let the tumor develop. He then brings up an example of the patient who undergoes surgery and chemotherapy, thinks he’s tumor-free, and then a few months later develops widespread metastatic disease. To Wark, this is because chemotherapy “destroyed the immune system.” Yes, chemotherapy, depending on which drugs are being used, can temporarily suppress the immune system, but it doesn’t destroy it. The immune system is quite good at rebounding after chemotherapy is done, and the destruction of the immune system is not the main reason why cancer can recur after a seemingly successful treatment. It’s because our treatments aren’t yet good enough to eliminate every last cancer cell. Some can go dormant, only to emerge later.
Of course, Mr. Wark’s testimonial is not enough. He’s begun to collect testimonials of his own. The vast majority of them don’t provide enough information to tell me one way or the other whether there’s anything to them or not. I might have to take a look at a couple of them in more detail in the future, but for now I’ll “cherry pick” a couple. Most of them are maddeningly vague, although some have fairly obvious explanations. For example, Ann Cameron claims to have cured herself of stage IV colon cancer with carrot juice. She had stage III colon cancer, underwent surgery, and refused chemotherapy. Later, she was noted to have lesions in her lungs suspicious for metastases. These supposedly disappeared with carrot juice. However, there is no record of any of these lesions having been biopsied. A PET scan showed “spots” that looked like lymph nodes, but again there is no mention of these lesions ever having been biopsied. My conclusion? These almost certainly were not metastatic cancer.
Next up is a man named Jeffery Williams, who was diagnosed with stage III testicular cancer. He underwent surgery to remove the testicle but was found to have a mass in his abdomen. What follows is a prolonged story of his refusing chemotherapy, using megadoses of carrot juice, and following the Hallelujah Acres Diet, with Angstrom ionic liquid cesium and potassium, Solaray Tumeric and Essiac Tea, along with insinuations that his doctors lied to him about the tumor in his abdomen. At one point, he says he couldn’t find a doctor willing to biopsy the mass, which sounds very odd given that an abdominal mass that’s suspicious for tumor in a patient with a history of testicular cancer almost mandates a biopsy. Finally, a biopsy supposedly showed “100% dead cancer cells.” Of course, a biopsy showing “100% dead cancer cells” does not mean that therapy was working; it could simply mean that the tumor outgrew its blood supply, its center died, and the biopsy (presumably a needle biopsy) only got the center of the tumor. Be that as it may, this is what Williams describes after that:
I also found a surgeon who was willing to remove my tumor. On April 20th 2010 I had a 9.5 hr. surgery to remove the tumor at Cleveland Clinic. I received 4 inches of incision from my first surgery in 2009 and 26 inches of incisions on my second surgery on April 20th 2010. I have had a cat scan once a year since April 20th and I have had no problems.
One notes that he doesn’t say what the pathology showed that the tumor was, which is by itself quite odd. The whole thing sounds very fishy, but even if the story is as Williams represented it, it sounds as though two operations cured him. Even odder still, if Williams was so convinced that his “natural” treatments had cured him of his tumor, why on earth did he go to such lengths to find a surgeon willing to resect the mass? As I said, the pieces of this testimonial don’t all fit together.
Of course, there are breast cancer testimonials, including those of Monique Norton, Susan Macco, and Ashlie Sanders (who appears to have had her entire tumor removed by the biopsy). They’re all of the same variety as Suzanne Somers’ testimonial. They all underwent surgery and eschewed other therapies, meaning that the surgery cured them. They all attribute their survival to whatever quackery they chose to pursue rather than the surgery. I’m tellin’ ya, as a breast cancer surgeon I sometimes get depressed at how little credit we are given.
As glad as I am to see a cancer patient overcome the odds and beat his disease, it’s truly depressing to see that same patient spread misinformation about the science-based medicine that saved him and then to promote all sorts of quackery. Look at his Resources page, for instance. It’s a veritable cornucopia of quackery, up to and including Hulda Clark and Bob Beck, Gerson therapy, Ty Bollinger, Russell Blaylock, and more. Worse, he hides behind a variant of the quack Miranda warning in which he prefaces his advice with “I’m not a doctor and can’t give medical advice,” after which he basically gives medical advice. A great example is in response to a question from a 32 year old woman with breast cancer who has undergone surgery and is understandably frightened at the prospect of beginning her chemotherapy. Here’s Wark’s response:
I’m not a doctor and can’t give medical advice, but obviously I chose not to do chemo because yes, it does destroy your immune system, and it is also a carcinogenic substance. I decided to do every natural therapy I could find FIRST. If none of it worked, then chemo would be my last resort. That was my plan.
Doctors do not control your life, you control your life.
Two of my favorite quotes:
“Courage is not the absence of fear, but the realization that there is something more important than fear.”
and “If you’re scared, Do it scared.”
My opinion is that mainstream cancer treatment does more harm than good. That is my opinion.
Your cancer could be all gone, but your body may still be a place where new cancer cells could thrive. This is why it’s critical to get hardcore about your health, which it sounds like you’re doing already.
If you decide to postpone chemo, there is a support system for you that I can help you connect with.
All of which sounds very much as though Wark is trying to dissuade this woman from undergoing chemotherapy. He does this even though he tries to cover his behind with a disclaimer like this:
I am not a doctor.
I don’t prevent, diagnose, treat, or cure disease.
I do not practice medicine.
I have no certifications of any kind and I don’t plan on getting any.
What I do have is nearly 10 years of experiential expertise. As you can tell by the vast amount of info on this site, I am an avid researcher on nutrition and natural therapies. I am deeply immersed in the alternative health community and I know many people who have healed themselves.
We can learn from the experiences of others. That is how I healed my body of cancer. Whatever your health challenge (cancer, heart disease, diabetes, obesity, high blood pressure, etc.) I am confident that YOU can heal it.
Chris Wark charges $100 an hour or $175 for two hours to impart his “healing wisdom” to you. One wonders how many people with cancer this not-a-doctor has led astray, potentially to their demise, and how what he is doing isn’t practicing medicine without a license.

Chris Beat Cancer: A Comprehensive Guide to Making a Killing
Chris Wark has a new book out, with the unsurprising title of Chris Beat Cancer. It purports to be a guide to beating cancer. It’s not.
Braden MacBeth on cBethSeptember 5, 2019
Link

Chris Wark is one of the most prominent figures in the alternative medicine cybersphere. He has a huge social media following, and he’s appeared on just about every quack or crank website and documentary you can think of. A few notable examples include: Flipping the Script: Parents Fight Back, The Truth About Cancer, and The C Word. Wark recently published his book Chris Beat Cancer: A Comprehensive Guide to Healing Naturally, which is what I want to talk about today. Wark was diagnosed with stage 3 colon cancer in 2003 and underwent surgery. Wark chose to refuse adjuvant chemotherapy, which significantly reduced his survival risk, and instead pursued alternative therapies, to which he attributes his survival rather than the surgery. While his survival after surgery was statistically probable, he insists that he wasn’t lucky or special and that the odds were stacked against him. As Dr. Gorski explains in his article “Chris Beat Cancer, but it wasn’t Quackery that Cured Him“, that simply isn’t true:
In both cases, with surgery alone, Mr. Wark’s odds of surviving five years are around 64%. That’s pretty good for such advanced disease, but we can do better. 5-FU-based chemotherapy regimens increase those odds by around 12% to a 76% chance of surviving five years. FOLFOX, as you can see, does even better, increasing the odds of surviving five years by around 16%, all the way to 80%. Since colon cancer, unlike, for example, breast cancer, rarely recurs after five years, five-year survival rates in colon cancer are pretty close to equivalent to the chances of being “cured” of colon cancer. So basically, by eschewing chemotherapy, Mr. Wark decreased his chances of surviving his disease by approximately 12-16%
Wark isn’t a doctor or have any scientific education, he has a bachelor’s degree in marketing. While such a background probably wouldn’t prepare you to understand basic physics, I imagine it would be very helpful if you were looking to make millions of dollars through a large affiliate marketing network. Wark’s comprehensive guide is little more basic common sense dietary and lifestyle advice coupled with copious amounts of pseudoscience, fear mongering, and a dash of victim blaming.
Cancer isn’t a man-made illness
After telling his story in the opening chapter of the book, Wark attempts to set up his key premise in the second chapter titled “Survival of the Sickest”. Wark aims to convince readers that cancer is a made-made illness: the result of sedentary lifestyles, poor dieting decisions, and GMOs. The chapter begins with him citing a perspectives piece published in Nature back in 2010 titled “Cancer: an old disease, a new disease or something in between?“. The authors summarize numerous historical accounts of cancer using both historical texts, histological studies of rehydrated mummy tissues, and examination of skeletal remains. The authors explain that very few malignancies were identified using rehydrated mummy tissues; only a few benign neoplasms, and a rectal cancer in an Egyptian mummy. It was the first cancer to be identified in a mummy using this technique. Does that mean cancer is a man-made disease that’s purely the result of our way of life in 2019? Of course not, as an article from the UK Cancer Research Society’s site explains in-depth. Age is the biggest risk factor for cancer, and according to the Facts and Figures report by the American Cancer Society over 87% of all cancers diagnosed in the United States are in people over the age of 50. The very article that Wark references states: “…together with the paleopathological evidence, confirms that the average lifespan of the wealthier classes was between 40 and 50 years, and a lower age-at-death between 25 and 30 years is shown in paleopathological studies of non-elite groups.”. Bottom line: cancer isn’t a new thing (dinosaurs got cancer), it’s not always the result of lifestyle, but a combination of risk factors, genetics, and time.
Wark spends the rest of the chapter discussing the many causes of cancer, some of which are real, some not so much. But you don’t need to learn that obesity, smoking, and HPV increase your cancer risk from a guy that will also tell you that coffee enemas fight cancer (wrong!). Wark claims that glyphosate causes cancer, when numerous studies have shown there is no association between glyphosate exposure and cancer. It sounds plausible because of a recent lawsuit against Monsanto where the plaintiff claimed glyphosate caused his cancer and won, but juries don’t decide science. He also claims that genetically modified foods “have been shown to be hazardous to the people and animals that eat them”, but doesn’t actually bother to cite any peer-reviewed research to back his claim (wrong!). The chapter is rife with examples like this, and I simply don’t have time to go through every single one.
One of the more ridiculous examples is cheese, which Wark implies should be avoided because it contains sodium aluminum phosphate. He claims that sodium aluminum phosphate has been linked to Alzheimer’s disease. According to the CDC, there is conflicting evidence that high levels of aluminum exposure can cause Alzheimer’s. There’s also no link between aluminum exposure and cancer, and Wark doesn’t even try to draw a connection between the two. Aluminum sodium phosphate is used in many baked goods as a leavening agent, and the National Library of Medicine states that it is not classifiable as a carcinogen. There are many other ridiculous examples and I have to assume he put some of these things in the book to inflate the page length like a college senior on a final paper. Wark provides a ridiculously long list of things that he believes are carcinogens, to the degree that it would be impossible to avoid all of them. This would probably leave the reader with the question: “Other than the obvious things, what do I need to prioritize avoiding?” A question for which the book provides no answers. But that’s the whole point.
The beat cancer victim blaming mentality
After spending almost half of the book trying to convince you cancer is entirely your fault, and that you should listen to him, the “comprehensive guide” begins with the “Beat Cancer Mindset”. The chapter begins with Wark retelling the time when he met with a structural integration practitioner three months after he was diagnosed with cancer. The practitioner asked him a question that surprised and scared him: “Before we get started, I need to know if you really want to live”. He pondered this, wondering if his cancer was “a manifestation of years of painful insecurity and mental and emotional self-sabotage”. The idea that cancer is affected by your emotional state somehow has come up on SBM before. In short: cancer doesn’t care about your feelings. While I would normally invoke Hitchen’s razor, that which can be asserted without evidence can be dismissed without evidence, I actually have evidence that cancer isn’t caused by crippling insecurity. Harley Davidson’s entire marketing strategy is centered around building long-term relationships with customers, and I’m unable to find any evidence that Harley owners get cancer at rates higher than the general population (also, wrong!).
Despite no evidence that one’s emotions don’t cause or help treat cancer, Wark believes it is the most important part of beating cancer. Chris tells a classy story that reflects well on him to demonstrate why the “Beat Cancer Mindset” is so important. His cousin Jeff was diagnosed with stage IV colon cancer with a prognosis of only six months to live. Jeff accepted his fate, and also refused to try the natural and alternative treatments Wark and his mother suggested. He rightly believed there was no evidence that they would work, and would likely be a waste of time and money. He died a few months later, and Wark came to this conclusion as to why he survived but his cousin didn’t:
As I thought about my cousin’s cancer experience and reflected on the path he chose, I’ve come to realize that he was right. He and I are different. Introspection does not come naturally to me (clearly), but as I began to teach others about health, nutrition, healing and survival, I was often asked why I made the decisions I made and I was forced to self-analyze. It was the difference I adopted, which was born out of my determination to get well and to live.
This is the definition of survivorship bias; Chris is attributing his success and his cousins failure to something that really had no impact. But as you’ll recall from Dr. Gorski’s post:
Mr. Wark had an estimated 30-64% chance of being “cured” of his cancer by surgery alone. However, those odds aren’t good enough. Why should they be, when we can make them significantly better with chemotherapy?
You might be wondering, what’s the harm in the feel-good self-help advice? When the chapter’s 12 page-length isn’t covering the same ideas as Shia LeBeouf did in a little over a minute, it amounts to victim blaming. There are five components to the “Beat Cancer Mindset”:
     1.  Accept total responsibility to your health
     2.  Be willing to do whatever it takes
     3.  Take massive action
     4.  Make plans for the future
     5.  Enjoy life and the process
These all are nice platitudes, but they’re all oblivious the realities of cancer and cancer treatment. While there are many factors that we can control that change one’s risk of getting cancer, you can still get cancer as a result of genetics or just plain bad luck. However, Wark claims that it’s important to accept the blame of bad health decisions they may or may not have made over the course of their life in order to take control of their lives for the better. Who can help them with this undertaking? Chris Wark and his $200 cancer coaching series!
Take out the trash? I’ll pass
One of the later chapters is titled, “Take Out the Trash” where Wark recommends limiting your exposure to things that pose absolutely no cancer risk or so minimal they’re not even worth considering. For instance, Wark claims that electromagnetic fields (EMFs) can increase cancer risk:
Two pooled studies and a meta-analysis found a 1.4 to 2-fold increase in risk of leukemia in children exposed to electromagnetic fields.
The NIH states that “for the two pooled studies and the meta-analysis, the number of highly exposed children was too small to provide stable estimates of the dose-response relationship. This means that the findings could not be interpreted to reflect linear increases in risk”, and Wark admits this later in the section. No mechanism has been discovered by which non-ionizing EMFs could damage DNA and cause cancer. Despite no evidence that EMFs have any negative health effects, Wark still recommends limiting exposure by not charging your phone near your nightstand, replacing fluorescent bulbs with LED bulbs, and using a gauss meter to check your house for EMF “hot spots” to limit your exposure. If you’re a bit confused about the technical details, fear not. He has a lengthy blog post explaining both the supposed “dangers” of EMF exposure, in addition to special links to helpful products such as gauss meters and fear-mongering books about the dangers of EMFs. Those links also make him money when you buy the products. Does he disclose this fact? Of course not.
Wark also implies that cell phones cause brain cancer, despite no good evidence that’s the case. We’ve discussed the non-link between cell-phones and cancer multiple times on SBM: there’s just no link. Wark states that according to data from the National Cancer Institute there has been no increase in brain or central nervous system cancers between 1992 and 2015, and if cell phones caused those types of cancers we would see an increase in proportion to the increase in cell phone usage. So case closed right? Of course not, that would be just too sensible. Wark still advises caution because the World Health Organization has classified cell phone use as potentially carcinogenic for no reason. He recommends not putting the phone up to your face and instead using speakerphone or earbuds. My main issue is that he could convince people to use speaker phone for cell phone calls in public places, because we really need more of that, and it won’t prevent cancer.
In the section titled “Clean Our Your Cleaning Supplies”, Wark recommends avoiding laundry detergents, dryer sheets, and household cleaning products. Wark cites a 2018 study published in American Respiratory and Critical Care Medicine that looked at spirometry data for 6,231 people over 20 years, and found that women who responsible for cleaning at home or occupational cleaners had declining respiratory function. There was no such association between increased respiratory decline and cleaning in men. While the evidence is far from conclusive by itself, Wark presents the study’s findings as “women who reported using cleaning products at least once per week in their home or cleaned professionally for 20 years had substantial lung damage, equivalent to smoking 20 cigarettes a day”. While the study found that the respiratory decline was similar to that of women who smoked, it’s still not the same as damage that would be caused from smoking 20 cigarettes a day. The study also found that cleaning activities were not statistically associated with COPD, but smoking is the leading cause of COPD.
Wark claims that laundry detergents and dryer sheets can also be “polluting” and that an analysis of gases produced by laundry machines found more than 25 volatile organic compounds including known carcinogens such as benzene and acetylaldehyde. The problem with Wark’s reasoning here is that any exposure to said exhaust is very low amount, so low it’s not even worth considering. While I’m sure he almost certainly has someone else do his laundry for him (I would too if I had that kind of money), I’m sure he realizes that dryer vents exist. Furthermore, most people don’t have their laundry machines located anywhere near where they would be around to inhale high concentrations of those chemicals. He still recommends that you replace them with organic cleaning products. Products for which there doesn’t seem to be any evidence they wouldn’t release the same type of carcinogenic chemicals when put in the drying machine anyway.
Dubious dieting advice
Wark’s nutrition advice is all over the place in this book. In addition to advising readers to avoid just about anything that isn’t GMO-free organic kale, he recommends regular fasting. According to him, this causes the body to enter a state of ketosis and cancer cells will keep trying to grow without food, grow weak, and die. This theory doesn’t hold much weight when you consider that your body is just going to get its fuel from fat, which would also feed said cancer cells. It’s also quite silly considering Wark despises the ketogenic diet, the entire goal of which is to put the body into a state of ketosis. There’s not enough evidence to support the claim that fasting prevents or treats cancer, and the same is true of the ketogenic diet. There have been numerous studies looking at fasting as a potential strategy to aide in the treatment of certain cancers. While there have been some positive results, the media has hyped up fasting far, far more than it deserves. As one correspondence published in 2016 in Nature Reviews Cancer explains:
Over the past year, only one pilot crossover trial in 34 patients with gynaecological cancer receiving chemotherapy showed that quality of life impairment was lower during STF [short-term fasting] than in non-fasted periods. Larger studies to prove the effect of STF as an adjunct to chemotherapy have been lacking, and the need for larger studies has been stressed by several reviews published in the past 8 years
The authors continue, stating that the media has blown the results of such preliminary studies to such a degree that fast-mimicking diet kits are already being commercialized and sold. They also point out that trials looking at fasting or fast-mimicking diets exclude patients with lower body weights or patients who have experienced unintentional weight loss. This is a pretty big issue because there is a very high prevalence of sarcopenic obesity and malnutrition in cancer patients. The prevalence of sarcopenic obesity and malnutrition can be as high as 80% in patient groups depending on tumor stage and site. Furthermore, fasting can have health risks, and these risks pose much more of a threat to someone with cancer in treatment. If someone is suffering from sarcopenia or malnutrition while being treated for cancer and they attempt a fasting diet, they would continue to lose muscle mass at an increased rate which would not only lower their quality of life but put them at a higher risk of dying.
Outside of fasting, Wark recommends a plant-based based diet going so far as to say that the “anti-cancer diet” is a plant-plant based or vegan diet. While there is good evidence that reducing the amount of red meat in your diet could have protective effects against some types of cancer, it will only reduce your cancer risk, not eliminate it. Wark really stretches the truth when he claims: “One significant anti-cancer effect of a whole-foods, plant-based diet appears to be its ability to insulin-like growth factor-1 (IGF-1) in the body…a growth hormone directly linked to uncontrolled cancer growth”. Wark cites a study that he reports found that breast cancer patients who ate a “whole foods”, plant-based diet for two weeks had lower-levels of IGF-1 in their blood. Wark seriously misrepresents the study as the subjects were not breast cancer patients, they were all overweight, post-menopausal women and they also participated in an exercise program. The link between elevated IGF-1 and breast cancer exists but it’s just one of many risk factors, and the drop in IGF-1 could’ve been attributable to either the diet change, the exercise program, or both.
Another “benefit” of a plant-based diet for cancer that he touts is the restriction of the amino acid methionine, on which many cancer cells are dependent. The problem here is that normal cells also need methionine, and you have to get it through your diet. As you can probably guess, meat has a high amount of methionine, and fruits and vegetables have relatively low amounts. Just because certain foods are high in methionine doesn’t mean they’re bad for you. One pseudoscientific diet focused around methionine restriction is the NORI protocol which Dr. Gorski covered in May. While there is some preclinical evidence (cell culture and rodent studies) that methionine restriction could have some role in treating cancer, there haven’t been any studies in humans showing that it works. Wark twists the findings of studies and preclinical evidence to overstate the benefits of a vegan diet. While it might be a good idea to reduce your red meat intake, it is not the magic cancer shield he claims it to be.
Making a killing
If you read Science-Based-Medicine a lot, you’re probably a bit confused right now. Why would I cover this book, of all things? This book is, if you’ll excuse my choice of words: benign. It’s just a conglomeration of myths about cancer that have been debunked on this blog and other reputable sites dozens of times. That’s just the problem; it’s not about what Wark recommends in this book. It’s about what he doesn’t recommend, but has in the past and presumably still does recommend. Wark has promoted basically every debunked diet and therapy you can think of such as the Gerson Therapy, the Alkaline diet, IV vitamin C, black salve, laetrile, the list goes on and on.
The book fails as both a comprehensive guide to beating cancer, and as a guide. This book isn’t a guide, it’s a propaganda piece designed to set up false premises in the minds of unaware or uninformed viewers to lead them through to a singular conclusion: that doctors cannot be trusted because they only want to make money and that chemotherapy hasn’t improved – neither of which are true. That cancer is purely the result of lifestyle, diet and that preventing cancer is entirely within one’s own control; it’s not. That if readers can just change their lifestyle, diet and just have the correct mindset – they too can beat any cancer. Wark wants to convince readers that diet, exercise, and pure will alone are a sword that can cut through any cancer or disease. That he, and he alone can be their Syrio Forel. But in reality: he’s Petyr Baelish.
The advice in the “guide” portion of the book is noticeably lacking in details, it’s confusing and even contradicts itself at points. Wark detests the ketogenic diet, but also promotes fasting because it causes the body to enter a state of ketosis. He admits that there is no evidence to support the idea that Wi-Fi causes cancer but still advises that you should turn your Wi-Fi off at night for some reason. But that’s all by design, it’s meant to confuse readers. He wants readers to read his website, purchase stuff from the referral links, and buy his $200 web series.
One of the book’s chapters is titled “It’s not like I need your business”; but he really, really does. There’s a small skeptic YouTuber I’ve been following for a few months now, AddictedToIgnorance, who has made numerous hard-hitting videos about Chris Wark and the things he’s uncovered are truly shocking. Wark hired a company called East 5th Avenue to increase his sales of his Square One cancer coaching program and he brought in 2.5 million from the launch of Square One alone. That was before the book release. That doesn’t even include the revenue he gets from affiliate links on his site, but with his large social media we can safely assume that is a healthy revenue stream. Not only does Wark have stuff to sell you, he’s getting rich from it.
That’s not all AddictedToIgnorance has uncovered however, he also reviewed every single testimonial on Chris Wark’s Youtube channel and determined whether each person was alive, sold supplements or other alternative medicine services, actually had a confirmed diagnosis of cancer, and more. One example is the testimonial of Carla Camarillo, who was diagnosed with Stage 4 breast cancer in 2015, and believed she was completely cured without using chemotherapy, surgery or radiation. Carla appeared in a testimonial on not only Chris Wark’s website, but in the quackumentary Cancer Can Be Killed as well. But if you search Wark’s website or Youtube channel, you will find her video noticeably absent. The reason is because according to a Youtube comment from one of her friends, she passed away in 2017 a month after having surgery because “the tumor in her left breast was so large it was ready to protrude through the skin”. Upon learning this, Wark promptly removed all traces of her testimonial from his sites. Carla still had the video on her YouTube channel, which Wark took down with a copyright claim.
Wark spends nearly three chapters attempting to poison the well against modern medical science and medical professionals but while also claiming to be not be anti-medicine, or anti-chemotherapy. Chris Wark wants you to see him as just an innocent guy who survived cancer “naturally” and is trying to preach the good word of alternative cancer treatments. But when you look behind the curtain, the goal of the book is becomes pretty clear. Chris Beat Cancer: A Comprehensive Guide to Healing Naturally is a propaganda piece designed to suck people into an affiliate network of quacks and cranks that will bleed desperate cancer patients dry with pricey, ineffective, and potentially dangerous cancer treatments. It has no place on anyone’s bookshelf.

3-Bromopyruvate: The latest cancer cure “they” don’t want you to know about
Why is it that whenever naturopaths and other quacks embrace a new “cancer cure,” somehow “they” (whoever “they” are) don’t want you to know about it? In this case, it’s 3-BP, an actual experimental drug that shows some promise but is by no means ready for prime time (or FDA approval) yet.
David Gorski on August 15, 2016
Link


I’ve not infrequently written about various dubious and outright quack clinics in different parts of the word with—shall we say?—somewhat less rigorous laws and regulations than the US. Most commonly, given the proximity to the US, the clinics that have drawn my attention are located in Mexico, most commonly right across the border from San Diego in Tijuana for easy access by American patients. Sometimes, in the case of dubious stem cell clinics, they are located in countries like China, Argentina, or Kazakhstan. That’s not to say that there aren’t a lot of quack clinics right here in the US (particularly for stem cell treatments), but, by and large, the clinics doing the truly dangerous stuff tend to be less common in the US.
There is, however, another country where alternative medicine clinics, particularly for cancer, are common and thriving, specifically Germany. I first learned of these clinics when the story of Farrah Fawcett’s battle with anal cancer hit the news nine years ago. Ultimately, she died of her disease at age 62, but before she did she sought treatment at a clinic in Germany, which administered alternative treatments as well as radioactive seed implants, the latter of which, despite sounding nice and “conventional,” were not standard-of-care for recurrent anal cancer. What this led me to learn is that German alternative cancer clinics tend to use both alternative medicine and experimental “conventional” medicine that has not yet been shown to be safe and effective in clinical trials.
I thought of Farrah Fawcett when news about a German cancer clinic hit the news again beginning more than a week ago, when two patients from the Netherlands and one from Belgium died shortly after having undergone treatment at the Biological Cancer Centre, run by alternative practitioner Klaus Ross in the town of Brüggen, Germany. Two others were hospitalized with life-threatening conditions. I didn’t blog about them at the time because the only reports I could find were those sent to me by readers, and they were in German or Dutch. They also didn’t have a lot of detail. Both reported that on July 25, a 43-year-old Dutch woman went to the Biological Cancer Center in Brüggen-Bracht for treatment of breast cancer and that she unexpectedly died on July 30 of unknown causes. The Dutch report stated that the death occurred under mysterious circumstances and that there were two other deaths, that of a Belgian woman the week before, and a Dutch man.
Elsewhere, Irish newspaper TheJournal.ie reports:
Dutch police, who are supporting the inquiry, appealed for information from other patients, as newspapers reported the clinic had been using an experimental transfusion.
Concern was first raised when a 43-year-old Dutch woman with breast cancer complained of headaches and became confused after being treated at the clinic on 25 July.
She later lost the ability to speak, and died on July 30 although the “cause of her death remains unclear,” the German prosecutors said in a statement earlier this week.
Later, it was learned that the identities of the suspected victims were Joke Van der Kolk, age 43; Leentje Callens, age 55; and Peter van Ouwendorp, age 55.
Unfortunately, the early reports were fairly basic, without much detail, and only a couple with any names. Fortunately, now there is an article in Science that reports more. It turns out that the suspected cause of death is an experimental cancer drug known as 3-bromopyruvate (3-BP) that has not yet been approved for use in humans. So what happened?
What we know thus far
The Science article, published on Friday, reports more than I have been able to discover thus far. First, of all, we learn the treatment that is suspected of having caused the deaths of these three patients and the poisoning of at least two more, 3-BP. Second, we learn that this is a cancer drug that was developed at Johns Hopkins University but has not yet been tested in clinical trials. Then we learn:
The drug in question, 3-Bromopyruvate (3BP), has been hailed by some researchers as a potential breakthrough, but so far the only human data about its efficacy and safety are anecdotal. Many scientists say the drug should not be administered to patients except in carefully controlled experimental settings. If the link to the three deaths is confirmed, that could cloud 3BP’s commercial prospects.
German police took action on 4 August after two patients from the Netherlands and one from Belgium died shortly after undergoing treatment at the Biological Cancer Centre, run by alternative practitioner Klaus Ross in the town of Brüggen, Germany, 50 kilometers west of Düsseldorf. Two other patients had to be treated for life-threatening conditions, the prosecutor’s office said in a press release today. Police in Germany, the Netherlands, and Belgium have urged other patients treated at the center to contact local health authorities; at least 26 have done so. Media reports suggest that cancer patients often sought Ross’s help after they ran out of conventional therapy options, or to avoid aggressive chemotherapy. He offered a 10-week “basic therapy” against cancer for €9900 ($11,057).
On his website, Ross touted 3BP as “currently the best compound to treat tumors.” In its press release, the prosecutor said the investigation has “reinforced” suspicions that the three deceased patients actually received the compound, as media interviews with relatives and other sources had previously suggested.
So what is 3-BP?
3-BP, DCA, and the Warburg effect
Basically, 3-BP is a member of a class of drugs that target a unique feature of cancer cell metabolism, its reliance on glycolysis; i.e., anaerobic metabolism or metabolism not requiring oxygen. Glycolysis is the first enzymatic chemical process through which cells convert glucose to chemical energy in the form of a molecule known as ATP, and does not require oxygen. Indeed, evolutionarily speaking, it’s one of the most ancient metabolic pathways, present in anaerobic and aerobic organisms. It also does not generate very many ATP molecules per molecule of glucose, unlike the next steps, the Krebs’ citric acid cycle and oxidative phosphorylation, the latter of which occurs in the mitochondria, which generate lots of ATP but require oxygen. Basically, anaerobic metabolism is a lot less efficient a source of ATP than is aerobic metabolism.
The details of these processes are taught in basic biochemistry and biology courses the world over, but for the purposes of cancer what’s important is that cancer cells frequently utilize almost exclusively anaerobic metabolism through glycolysis and then utilization of lactic acid. This is known as the Warburg effect after Otto Warburg, who first observed it in 1928. Indeed, rapidly growing malignant cells can have rates of glycolysis up to 200 times that of normal cells. This characteristic of many (but not all) cancer cells is the basis for PET scanning, in which glucose labeled with a positron emitting atom (usually fluorine-18, to produce fluorodeoxyglucose, or FDG) is injected into the bloodstream. Where the FDG tracer accumulates indicates a high level of glycolysis, which makes it useful for detecting metabolically active cancer anywhere in the body. These days, PET scans are often combined with CT scans (PET-CT) in order to show more precisely where the areas of increased FDG uptake are located.
I’ve discussed the Warburg effect before here on SBM in the context of another drug designed to target glycolysis, dichloroacetate (DCA). What drew my attention to this drug initially was a widely-publicized experiment in rats carried out at the University of Alberta by Evangelos Michelakis that was touted by far too many in the press as a major breakthrough in cancer. (Hint: It’s never appropriate to do that based solely on a single animal experiment, however impressive.) Because DCA was a simple small molecule and had been used as a drug before to treat a metabolic disorder, it spawned a unique self-treatment phenomenon. Basically, a pesticide salesman named Jim Tassano bought up DCA from chemical companies in China and sold it as “Pet DCA” and later claimed to be synthesizing pharmaceutical-grade DCA. Of course, with a wink-wink, nudge-nudge, cancer patients found out about DCA, all to treat their pets, of course. Obviously, that wasn’t the intent, and it soon became obvious that cancer patients were buying DCA to treat themselves, despite the fact that at the time the drug had not been tested in humans against any cancer. Ultimately a small phase I trial was carried out adding DCA to standard of care treatment for radiation and showed, as is so frequently the case in phase I trials after promising animal studies, frustratingly equivocal results. Later, at least one Canadian family practice was selling DCA to desperate cancer patients.
DCA also spawned a whole series of conspiracy theories of the type that should be familiar to any regular reader of this blog. The most common one was along the lines of the cure for cancer “they” don’t want you to know about. Because DCA was out of patent and not a lot of pharmaceutical companies were interested in it, it’s not surprising that that would be the dominant conspiracy theory. Today, a quick search of PubMed shows a lot of in vitro work, a couple more small phase I studies, and a single case report of a complete remission in a patient treated with DCA for non-Hodgkin’s lymphoma. It’s also still being sold as a cancer cure.
What does Klaus Ross claim about 3-BP?
Not surprisingly, Ross’ Facebook page and website have been taken down in the wake of these deaths. There are no Archive.org pages, but fortunately the Google Cache still exists. Also, the website for his Biological Centre in the Netherlands is still up. It’s also, unfortunately, all in Dutch, and clicking on the little British flag icon under “Language” doesn’t pull up an English language version. Fortunately, thanks to Google Translate, I got the gist of Ross’ claims for 3-BP, which Ross characterizes as the “current best preparation for tumor treatment” and “more effective than the current chemotherapeutics.” How he knows this, given that there have not been any human clinical trials yet, he does not say, not that that’s stopped quacks before from wildly extrapolating from preclinical studies.
In any case, Ross lays down the usual blather about the Warburg effect, stating that “classical” chemotherapy can harm normal cells, which is of course true, and that it quickly becomes less effective because tumor cells evolve resistance, which is often true depending on the tumor. In contrast, it is implied, 3-BP does not produce resistance. Of course, real cancer researchers know that this is not true. Tumor cells are quick to evolve and adapt, and treatment even with selective metabolic poisons can result in the evolution of resistance. Be that as it may, these are the key claims made by Ross for 3-BP:
     1.  It acts on the energy metabolism of the tumor cell, thus leading to cell death
     2.  It is not toxic to healthy cells and thus does not poison the body
     3.  The immune system is not damaged or weakened
     4.  It has a high selectivity to cancer cells with increased glucose needs
     5.  It does not cause drastic side effects the way chemotherapy or radiotherapy do
Notice how clever Ross is. As you will see, some of these claims are true. For example, 3-BP does act on tumor cell metabolism, does not appear to damage the immune system, and is selective for tumor cells with increased glucose utilization. We don’t know, however, how toxic 3-BP is in humans because the clinical trials haven’t been done yet to show one way or the other the full range of toxicity of the drug. In any event, even if all five of these claims were indisputably true, it would not necessarily mean that 3-BP is an effective anticancer agent. The properties listed are definitely desirable properties in any anticancer drug, but they are not sufficient.
I used to like to point out that several years ago, targeting the Warburg effect was the hot new craze in cancer research. Indeed, attending one of the largest basic science cancer meetings in the world years back, that of the American Association for Cancer Research (AACR), I noticed that everything seemed to be about the Warburg effect and that cancer metabolism was the hot area of research, much as angiogenesis research had been several years before that. And certainly some promising results were reported. Now, several years later, cancer metabolism, while still popular, has taken a back seat to immune checkpoint inhibitor drugs and precision medicine. That’s how cancer research goes. A new discovery is made (or, in the case of the Warburg effect, old knowledge rediscovered in light of new findings), and there is huge enthusiasm that this will be THE breakthrough. After a few years, there’s a reality check, and the limitations of the new discovery become apparent, after which that new discovery is assigned a place in the existing armamentarium of cancer treatments based on data demonstrating its usefulness and limitations.
Of course, one reason why quacks love the Warburg effect so much is that it’s knowledge discovered nearly 80 years ago that was, although not ignored, definitely not given its proper due for decades, only to be “rediscovered” about a decade ago. It also lets alternative medicine practitioners invoke all sorts of woo about “metabolism” and claim that diet somehow targets the Warburg effect, a good example being the so-called “ketogenic diet” touted as “beating chemo for almost all cancers.” (Hint: It doesn’t.) So it doesn’t surprise me at all that a naturopath like Ross would be enamored of 3-BP, particularly since elsewhere he touts cancer treatments involving detoxification, deacidification, correcting the “water balance,” offsetting “mineral deficiency,” supplemental oxygen therapy, craniosacral therapy, high dose vitamin C, MMS, and, of course, “boosting the immune system.”
3-BP: The evidence
As Science points out, 3-BP is a member of a class of small molecule drugs and was first studied as an anticancer agent at Johns Hopkins more than a decade ago by biochemists Young Hee Ko and Peter Pedersen, together with a radiologist named Jeff Geschwind. A couple of early papers showed some promising preclinical results. For instance, this 2001 paper showed that 3-BP induced apoptosis in liver cancer cells. This 2002 paper reported that injection of 3-BP into the appropriate arteries in rabbits could suppress the growth of liver tumors and lung metastases. More impressive, in this 2004 paper, Ko et al treated rats with large hepatocellular carcinoma tumors using 3-BP and reported that in all 19 animals “advanced cancers were eradicated without apparent toxicity or recurrence.” This led one quack cancer clinic to equate this result with that of a human with a “watermelon-sized” tumor on his arm having complete shrinkage and disappearance due to 3-BP. While this comparison is accurate, it is also highly misleading, as it implies that 3-BP can eliminate a watermelon-sized tumor in a human with no toxicity based only on an analogy to a rat study. Don’t believe me? Here’s the graphic:

Other papers in human cell lines demonstrated that 3-BP showed variable levels of antitumor effect and that the drug could potentiate the efficacy of standard of care chemotherapy, but also, contrary to the claims of Ross, also showed toxicity. In any case, the only human study is a single patient study, described in Science thusly:
In 2009, Pederson and Ko teamed up with radiologist Thomas Vogl at the University Hospital Frankfurt in Germany for what appears to be a first experiment in a single patient. With the approval of the local ethics committee, a 16-year-old boy with a rare type of liver cancer called fibrolamellar hepatocellular carcinoma was given infusions of 3BP into the blood vessels supplying the tumor, formulated in a proprietary and patented fashion. Although he died at age 18, the researchers described the experiment as a success in a 2012 paper. “The rate of tumor necrosis due to 3BP treatment seems to exceed all known cytostatic drugs,” they wrote. No major toxic effects were observed, and the patient “was able to survive a much longer period than expected with an improved quality of life, which is clearly attributable to the treatment with 3BP,” the scientists concluded. In retrospect, Vogl says it would have been better to write “probably” instead of “clearly” because a single case report isn’t strong evidence. Still, “we were surprised how long the patient survived and that we saw no toxic side effects,” he says.
Naturally, I looked up Pederson and Ko’s 2012 paper. It describes the aforementioned 16-year-old boy with a rare type of liver cancer called fibrolamellar hepatocellular carcinoma. The authors noted that there is no known treatment for fibrolamellar hepatocellular other than liver transplant and that this patient did not meet the criteria for transplant due to the presence of tumor in the choleductus and spinal lymph nodes. Next, this happened:
Right after the diagnosis, Sorafenib had been approved for primary HCC patients as an orphan drug. Treatment with Sorafenib was started, varying the doses from 200, 400, to 800 mg/day. However, due to lack of experience with such young patients, the treatment outcome was carefully monitored and stopped according to the manufacturer’s instruction when ALT and /or AST values exceeded the tolerable values. Initial results with Sorafenib were encouraging. Thus, tumor growth appeared to have halted during the first 2 months of Sorafenib application, even with some regression of tumor volume. However, after 6 months, CT scans indicated a renewed expansion of the tumor’s mass, and Sorafenib treatment was halted. By now, the health condition of the patient had deteriorated, in fact, so far that he could not consume sufficient amounts of food to sustain life. On the basis of this condition, a duodenal feeding tube was installed and continuous (24 h) enteral feeding was started. The caloric intake was adjusted to 2000–3000 kCalories per day.
So basically the only plausible treatment, Sorafenib, seemed to work for a while but then resistance developed. The next set of treatments was more complicated than described by alternative cancer treatments. It didn’t consist of just intravenous 3-BP but rather other drugs administered by Transcatheter Arterial ChemoEmbolization (TACE), which involves the direct injection into the hepatic artery of various drugs, including cytotoxic chemotherapeutic agents as well as tumor embolization with EmboCept®, which blocks off small arteries feeding the tumor, thus depriving it of blood flow:
Then, the first TACE was performed with Gemcitabine and Cisplatin on January 26, 2009. After delivery of these cytostatics, the blood vessels were blocked temporarily by EmboCept®. Then, the tumor locations were viewed immediately by infusion of Lipiodol® followed by a CT scan. Due to cyto-toxicity, this was the first and last use of these two chemo-drugs. Likewise, the use of Lipiodol® was not continued during 3BP treatment due to a possible interaction between Lipiodol® and 3BP. One month later, permission from the Ethics committee was obtained. The patient was treated immediately via TACE with specially formulated 3BP (patented and proprietary) twice on the first day of treatment (February 26, 2009), a total dose 250 mg. More clearly, the delivery was bolus, meaning a rapid push of the entire dose into the artery over just a few minutes. Therefore, the 3BP delivery can be called a ‘Transcatheter Intra-Arterial Bolus Injection’ followed by a brief emboliza- tion with EmboCept®. The patient did not experience any discomfort during the first treatment with 3BP.
Reading the case report, I would agree with Vogl. Vogl and crew definitely screwed up writing such a definitive conclusion that the patient’s prolonged survival and improved quality of life were “clearly attributable” to 3-BP, and a failure of peer review to let that phrasing stand. That single phrase was the tentpole on which a thousand quacks have been constructing their quack therapies. This should be a lesson to cancer researchers with promising new treatments to be more circumspect in what they write because, not surprisingly, a more recent paper in 2014 described the treatment of a 28 year old man with metastatic melanoma in which the antitumor effect observed was minimal. The drug did, however, have an acceptable toxicity profile.
In brief, what we have here is a drug that shows some promising results in preclinical studies involving cell culture and animal tumors based on a method that targets tumors with high glucose utilization. In science-based medicine (and evidence-based medicine), the next step, given that this treatment has a fairly high degree of biologic plausibility based on mechanism and preclinical studies, would be to do a phase I clinical trial. That hasn’t been done yet, but is planned, according to Science:
But 3BP has yet to undergo formal clinical trials. PreScience Labs, a U.S. company founded by Geschwind, received approval for a phase I study from the U.S. Food and Drug Administration in 2013. Geschwind says the trial has yet to start because the company needs partners to finance it.
So, basically, outside of a clinical trial or a single-patient trial such as the two described above performed with the approval of an ethics committee, 3-BP should not be used in patients with cancer, particularly given that we don’t know its effects in humans when infused intravenously.
None of that has stopped the quacks, though.
Conspiracy theories and a new DCA
3-BP appears to be fast becoming DCA all over again. The “alternative” cancer cure press has been publishing articles with titles like “Cancer Cured, Again“, “Cancer Cure Found by Dr. Ko at JHU“, and, of course, the ever popular “Is a Cancer Cure Being Suppressed?” In each case, as happened for DCA, it’s insinuated (or outright claimed) that 3-BP is a drug that cures cancer but the pharmaceutical companies are “suppressing” it to protect their profits. It’s all a predictable game plan. For example:
A decade has passed since that first animal lab experiment and humanity is still waiting for a human trial to commence in what may be THE CURE for cancer.
The delays seem to be more commercial than scientific. Researchers have scrambled to make patentable analogs (synthetic look-alike molecules) that work better or at least do the same thing. It appears millions of cancer patients may be needlessly dying while researchers battle it out on the commercial front to gain patents.
Virtually the same thing was written on hundreds of quack websites a decade ago, when DCA was the latest darling “suppressed cancer cure.” It doesn’t help that apparently there is some sort of patent issue going on between Ko and JHU. Of course, when a university investigator discovers something while working for a university, the university owns the patent, usually giving the investigator a share of the credit on the patent and a share of the revenue generated if that patent is purchased and leads to a product. I also note that at the time of the discovery of 3-BP, Ko was first author, which strongly suggests to me that she was a graduate student or postdoc and not an independent investigator. Unfortunately, not all principal investigators cut their underlings in when they discover something working in their lab. My PI was nice enough to cut me in on a discovery I made while working as a graduate student in his lab back in the early 1990s, but he was under no obligation to do so. I can’t help but speculate that this might be what’s going on when the above article claims that JHU is trying to develop 3-BP without Ko.
Unfortunately, drugs like DCA and 3-BP, which are easily synthesized and can be obtained from a number of chemical suppliers, are like catnip to quack clinics, which can buy the chemicals cheaply and administer them, particularly German cancer clinics. Such cancer clinics are loosely regulated in Germany, and they specialize in all manner of cancer quackery in comfortable, spa-like facilities. However, they also seem to like to latch on to experimental cancer treatments like 3-BP that have not been validated yet. Whether it’s to appear “cutting edge” or simply because they sense an excellent profit center is unclear. Unfortunately, the damage done by this practice is not just to the patients. As I pointed out with DCA, the widespread use of 3-BP leading to complications such as these deaths of patients under Ross’ care could endanger its clinical trials and approval. After all, what companies or venture capital firms would want to partner to fund studies of 3-BP after this news? If 3-BP is really an effective anticancer treatment in humans, this recklessness on the part of alternative cancer clinics could deny cancer patients a truly effective drug by tainting it with their association.
Klaus Ross might now be banned from practicing in the district where his cancer clinic is located, but there are plenty of other quack clinics offering 3-BP to continue the potential harm, even in the good old USA.

Beetroots Don’t Cure Cancer
Steven Novella on April 13, 2016
Link
Alternative medicine, like all good marketing, is largely about creating a narrative. Once you have sold people on the narrative, products essentially market themselves. That narrative has been evolving for literally centuries, although it seems to have accelerated with the advent of mass media and now the internet. It is optimized to push emotional buttons in order to sell products.
There are countless examples available on the internet, with many peaking above the crowd for their 15 minutes of fame. In my feed this morning came this typical example: “Cancer Cells Die In 42 Days: This Famous Austrian’s Juice Cured Over 45,000 People From Cancer And Other Incurable Diseases!”
The story has many of the typical alternative medicine narrative talking points: natural is good, a healthful diet can cure anything, anti-inflammatory, anti-oxidants, and detoxification are all good.
The narrative is so well established, especially within the target audience, that many components don’t have to be stated outright, they are just implied. The story is of a lone individual working for years to find a natural cure for cancer, and then finding it. The idea is simple – just starve tumors of the protein they need to live. His special organic raw vegetable juice (of mostly beetroot) will keep you healthy while you starve the cancer, while providing detoxing antioxidants to boot.
What’s wrong with this story?
The scientific narrative is very different from this alternative. Scientists want to know what is actually real, and in order to do so they have to painstakingly construct a picture from rigorous evidence filtered through critical analysis and logic. This is tedious, and often does not give us the answers we want, but they have the virtue of being more likely to be true.
First, there are problems with the big picture of this and similar claims. The most glaring is that cancer is not one disease, but a category containing many diseases. For this reason there will likely never be one cure for all cancer (at least not with any extrapolation of current technology). Right there any “cure for cancer” claims are highly suspect.
Further, cancer is complicated. Scientists around the world have been investing a great deal of resources trying to understand and treat cancer for decades. They have made a lot of progress, but also have discovered how complex and tricky cancer is as a phenomenon.
For this reason any significant new treatment for cancer would have a paper trail of supporting research behind it. By the time we are doing clinical trials there is a mountain of pre-clinical and preliminary clinical studies supporting a potential treatment.
The article claims, for example, that solid tumors require protein to survive, and therefore starving them of protein is the key to killing the tumor cells. OK, where is the evidence for that? That claim contradicts actual studies which show, if anything, cancer cells rely on sugar to maintain their rapid metabolism (though unsurprisingly, it’s a little more complicated than that).
Even still, starving tumors of sugar in the diet does not kill them off. Cancer cells are cancerous partly because they are versatile – if they are starved of sugar they switch to a different energy source. Mutations in cancer cells turn off the usual restraints that limit healthy cells from growing without limit.
In short, the 42-day juice diet is unlikely to starve cancer cells.
Another major problem with this kind of narrative is that, if there were such a treatment and it were as successful as claimed (they claim 100% success – itself suspect), then there would be no way to keep that treatment contained. If it were possible to cure any cancer in 42 days, everyone would be using by now. The effects would be undeniable. Such a homerun would be easy to demonstrate in even a simple clinical trial.
A dramatic cure for cancer would be like aliens landing on the White House lawn – everyone would know about it. Knowledge of the cure or aliens would not be hiding in the dark recesses of the internet.
When confronted with this argument, the narrative (like many cancer cells) adapts. It just invokes the grand conspiracy – the evil medical establishment is clearly hiding the cure. This, of course, is impossible. No institution has that reach or power.
Even when unstated, an establishment conspiracy is implicit in the narrative. That’s why doctors aren’t prescribing beetroot juice diets for all cancers.
Detox and anti-oxidants
There are also some specific problems with this particular narrative, invoking anti-inflammatory, anti-oxidant, boosting the immune system, and detoxification as further mechanisms for the alleged benefits of beetroot juice. These are the alternative narrative buzzwords of the day. Marketing has created a health halo around these terms, and all you have to do is sprinkle them on top of any product claim.
Detoxification is not even a legitimate concept. There are no products that generally detoxify the body. There are, of course, specific treatments for some specific toxins, but that is very different than general detoxification. This is just a vague term that sounds good but does not really mean anything.
“Boosting the immune system” is similar – it’s not really a thing. It has no coherent scientific meaning.
Interestingly, anti-inflammatory and antioxidant effects are the opposite of “boosting” the immune system. The immune system uses inflammation and oxidative stress as part of its defense against things like cancer cells.
Metabolism creates reactive oxygen species, which require antioxidants to keep them in check. Cancer cells require increased antioxidants to handle their increased metabolism. So, putting more antioxidants into the system would help cancer cells survive, if anything.
Beetroot extract does, in fact, contain betanin, which is an antioxidant. It also has some anti-tumor effect in vitro, but only 8.6% as effective as similar compounds already in use. This also does not say much about its activity when consumed because then bioavailability needs to be considered. Bioavailability is one of those things that scientists worry about, but is not part of the alternative narrative at all.
Conclusion: The narrative collapses
If you dig even slightly below the surface of the narrative, it starts to fall completely apart. There is no cure for all cancer. No treatment is 100% effective. Cancer is too complex for a lone researcher to find a cure, without a mountain of research leading the way – research that would require collaboration, resources, and create a paper trail.
There is no such thing as detox or boosting the immune system. Inflammatory and antioxidant effects are part of a complex homeostatic system within the body, and when you alter them the effects will be complex and just as likely to be harmful as beneficial. In this case, anti-inflammatory and antioxidant effects would very likely be counterproductive by helping tumor cells survive and suppressing the immune system’s ability to fight them.
The scientific narrative, in my opinion, is also very compelling, much more so than the simplistic marketing narrative purveyors of dubious treatments would have you believe. The scientific narrative, however, takes more activation energy.

Can Ivermectin and Mebendazole Treat Cancer?
A Closer Look at a Viral Claim
David Weinberg on May 5, 2026
Link

A report posted on the website of The Wellness Company has been generating considerable social media attention for a new cancer treatment with announcements such as these: 84% of patients experienced “clinical benefit” and nearly a third showed “no current evidence of disease.” Before you share this with desperate friends and relatives, it is important to look at how these numbers were derived, what they mean, and what they do not.
What is the Wellness Company
The Wellness Company (TWC) sells supplements and prescription medications via a network of tele-health providers. Peter McCullough, MD, MPH, is the chief scientific officer of TWC. You may recall Dr. McCullough as a hydroxychloroquine evangelist, turned ivermectin evangelist, turned general COVID contrarian. Among TWC’s prescription medications is a combination ivermectin 25 mg/mebendazole 250 mg capsule. Both drugs are FDA-approved as anti-parasitics.
All of the authors of the paper are affiliated with and/or salaried by the Wellness Company. This is disclosed openly. It is not unusual for authors to have such conflicts of interest, especially in privately funded studies. It is useful context in interpreting results.
The Study
Subjects in this report were patients with a diagnosis of cancer who were prescribed TWC’s combination of ivermectin and mebendazole. The manuscript states that these were confirmed cancer cases, but because this report is based on self-reported data, it is not clear what is meant by “confirmed.” These medications were prescribed for off-label use by licensed providers affiliated with TWC. Off-label prescription of medications is considered within the scope of medical practice and not prohibited by the Food and Drug Administration (FDA). However, research involving the off-label use of medications is often regulated.
Patients were invited to participate, and participation was optional. Volunteers were sent electronic surveys at the time the prescription was filled and again 6 months later.
No TWC doctors examined these patients for the study. No scans were ordered or reviewed. No blood tests were ordered or reviewed. The oncologists caring for these patients were not contacted to confirm the cancer diagnosis or verify the status of the cancer. The cancer diagnosis, the disease status, the reported outcomes all came from patients answering questionnaires on electronic devices.
Results
197 patients completed the baseline survey, and 122 at 6 months. The most common cancers were prostate (27.9%), breast (18.3%), and lung (8.6%), with a wide variety of other malignancies. Most patients had already undergone conventional therapy (such as surgery, chemotherapy, radiation). There were only 2 choices for the status of their cancer at baseline: Actively progressing (37.1%) or not currently spreading (62.9%).
At 6 months, there were 122 responses (61.9% of the original patients). Data included medication dose and adherence, concomitant treatments, and various measures of cancer control. 1/3 of the patients who responded at 6 months were no longer taking the medication. A large number of patients were using other forms of therapy for their cancer, some conventional (chemotherapy, radiation), and others such as supplements, diets, etc. Compared to the baseline survey, a different scheme for classifying disease was used at 6 months: No current evidence of disease (NED) (32.8%), regressed (15.6%), stable disease (36.1%), spread or progressed (15.6%). Some of these results were combined into outcomes such as: NED+Regression (48.4%), as well as Clinical Benefit Ratio (CBR) (the sum of NED+Regression+Stable) (84.4%)
Problems with the data and analysis
     1.  No control group. This was a highly diverse group of cancer patients, most of whom had undergone, or were undergoing, cancer treatment at the time of enrollment. Many continued to receive treatment during the 6 months of the study. Over 60% reported their cancer “not currently spreading” at baseline. How would this group, or a similar group, behave without the ivermectin/mebendazole? Without a control group, it is impossible to know if treatment with ivermectin/mebendazole influenced the status of the cancers in any meaningful way.
     2.  Self-reported outcomes. Oncology studies typically assess cancer status using strictly defined, pre-specified criteria based on physician assessment, imaging studies, and other cancer biomarkers. TWC authors assessed cancer status based solely on patient-reported data. We have no idea if or when each patient had a systematic search for cancer or when they last saw a qualified oncologist. The TWC study uses the same terminology as high-quality clinical trials, such as: NED, regression, and Clinical Benefit Ratio, but without the standardization and rigor. The “Clinical Benefit Ratio” deserves special attention because it is a headline statistic in TWC’s dissemination of the study results. In legitimate cancer research, CBR is used in studies of aggressive metastatic cancers where most patients would be expected to deteriorate rapidly without treatment. It requires repeated imaging studies at specified intervals to confirm. For the TWC study, 62.9% of patients reported “not currently spreading” at baseline—a very different patient population than is usual for a CBR endpoint.
     3.  The missing 38%. The fact that over 1/3 of the patients did not participate in the 6-month survey is a serious red flag. Patients who leave a study tend to differ from those who remain, a phenomenon known as attrition bias. Patients who are doing poorly are more likely to leave a study, and those doing well are more likely to remain. Among the TWC patients who did not respond at 6 months: How many died? Dead patients do not reply to questionnaires. How many were infirm due to progression of their cancer? How many dropped out due to real or perceived progression of their cancer? How many had intolerable side effects?
Each of these three flaws individually is an enormous weakness. Collectively, they render this study incapable of supporting any conclusions about the efficacy of ivermectin/mebendazole in cancer treatment. The treatment could be helpful, harmful, or indifferent.
What is human research?
Beyond the sloppiness of this study, there are other serious concerns.
Despite the fact that this looks like human research and smells like human research, and is reported like human research, TWC authors want you to know that their project is certainly not human research. Here is the statement from their article:
Institutional Review Board (IRB) Statement: This project was conducted as a retrospective analysis of a prospective clinical program evaluation. Consistent with established frameworks for quality improvement and internal assessment of clinical services, the project utilized voluntary, patient-reported data. As such, it did not meet the definition of human subjects research and did not require Institutional Review Board (IRB) review.
Why would they make such a declaration? There are certain rules and expectations about how human research is conducted. If this is indeed “not human research”, those rules would not apply.
Definitions and Regulation of Human Research
There are a few entities within the Department of Health and Human Services (HHS) that are responsible for the oversight of research. The Office for Human Research Protections (OHRP) regulates HHS-funded human subjects research, including strict rules for IRBs and rules for investigators performing human research. The policy for protection of human subjects is codified in 45 CFR 46, also known as the Common Rule.
Here are the relevant definitions:
Human subject means a living individual about whom an investigator (whether professional or student) conducting research:
(i) Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information [emphasis added] or biospecimens; or
(ii) Obtains, uses, studies, analyzes, or generates identifiable private information [emphasis added] or identifiable biospecimens.
Research means a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.
What is an Institutional Review Board?
TWC investigators asserted that their work did not require Institutional Review Board (IRB) review because it was not human research.
An Institutional Review Board (IRB) is a committee that reviews research involving human participants. Its job is to protect the people in the study. Before a research study begins, the IRB reviews the plan in detail, how participants will be recruited, what risks they face, what they will be told, and how their privacy will be protected. Most importantly, the IRB oversees the informed consent process, ensuring that participants genuinely understand they are in a research study and agree to participate with full informed consent.
    • They would need to be informed of risks, including possible loss of confidentiality.
    • They would need to be informed that their participation is voluntary, that there is no penalty for declining participation, and that they can withdraw consent at any time.
    • They would need to be informed whether or not their data will still be used if they decide to withdraw from the study.
    • The investigators would need to declare whether any personal health information would be stored and whether the study records could be linked back to individual patients.
Because TWC determined that their study did not qualify, we do not know to what extent the patients were afforded these protections.
What is quality improvement?
TWC authors classify their project as quality improvement instead of human research. Quality improvement (QI) is a legitimate and important category of investigation. QI activities are usually distinct from research and typically do not require IRB oversight.
Quality improvement is not defined as rigorously as research. Here is what CMS has to say:
Quality improvement is the framework used to systematically improve care. Quality improvement seeks to standardize processes and structure to reduce variation, achieve predictable results, and improve outcomes for patients, healthcare systems, and organizations. Structure includes things like technology, culture, leadership, and physical capital; process includes knowledge capital (e.g., standard operating procedures) or human capital (e.g., education and training).
In other words, quality improvement is an exercise within an institution to improve the delivery of healthcare. Quality improvement is meant to identify and solve problems within an organization or healthcare system. In contrast, research is meant to contribute to generalizable knowledge.
Examples of things that would be quality improvement projects:
    • Studying how the location of hand-sanitizer dispensers influences compliance with institutional hygiene policy.
    • Tracking visits to figure out how to decrease patient wait times.
    • Studying missed or cancelled appointments to develop strategies to improve patient follow-up.
For a telemedicine company like TWC, quality improvement projects might be:
    • Tracking how quickly providers respond to patient messages.
    • Comparing strategies to ensure prescriptions are filled accurately and promptly.
    • Questionnaires to determine how well patients understand how to take their medications?
What is the nature of this study?
A project does not become “not research” because the authors declare it to be so. Rules and definitions determine whether or not a project is human research, and sometimes the parameters are ambiguous or borderline. If the nature of the study is ambiguous, investigators can go to an IRB in advance and get an expert opinion. IRBs issues these types of advisory opinions regularly.
In my opinion, the identification of this as a quality improvement project is incorrect and disingenuous. The questionnaire did not ask questions relevant to a quality improvement project. The questions were relevant to the efficacy and safety of their ivermectin/ mebendazole combination treatment.
In practice, the authors don’t seem to believe their own opinion. Let’s dissect this paragraph from the paper’s Introduction.
Despite compelling preclinical data and documented safe use in cancer patients [4], robust clinical evidence evaluating the ivermectin–mebendazole combination in oncology remains limited. The present prospective clinical program evaluation was therefore conducted to assess real-world self-reported cancer outcomes, medication adherence, tolerability, and patient experience among individuals prescribed a compounded ivermectin–mebendazole formulation through a telemedicine platform.
They make the case for ivermectin and mebendazole as a cancer treatment based on preclinical and early clinical data. They frame a gap in the current knowledge about the two drugs. The next sentence is an explicit explanation that the “prospective clinical program” was to assess cancer outcomes, etc.
In the “conclusions” section of the abstract, they say:
These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit … these findings should be interpreted as hypothesis-generating.
Later in the paper, they use these results to advocate the need for urgent randomized clinical trials.
“Clinical signals” that are “hypothesis generating” and augment an appeal for further research are pretty definitive claims of generalizable knowledge, a key component of the definition of research.
Recall the carefully crafted wording on the preprint manuscript declaring that their study: “…did not meet the definition of human subjects research and did not require Institutional Review Board (IRB) review.”
And suddenly… it is research!
In an Instagram video, Nicolas Hulscher, MPH, hypes the “absolutely shocking” results of the study. At the end of the video are these words: “…this is all very, very promising research.” Nicolas Hulscher is not a random Instagram influencer. He is the first author of the study. An author who had preemptively asserted that this project was not research is now declaring it as “very, very promising research.”
Screenshot from: https://www.instagram.com/reels/DW4QVMgkT7B/
Is this study under the jurisdiction of the FDA?
The FDA operates in a different regulatory lane from the Common Rule. Many of the practices are harmonized, but regulatory requirements differ in many ways.
Because this research is privately funded, TWC has a potential loophole from IRB oversight. The Common Rule explicitly applies to government-funded research. Unlike the Common Rule, FDA regulations apply regardless of the funding source.
Whether or not this project is under their jurisdiction would ultimately be determined by the FDA. Things are especially complicated for this investigation because it involves a compounded medication, which involves its own set of regulations.
The FDA often requires the sponsor to file an Investigative New Drug application (IND) for certain investigations. An IND is required for studies of unapproved new drugs seeking FDA approval, and often for approved drugs that are being used outside the constraints of the current FDA approval (such as dose, route, or indication). Filing an IND application is a major effort.
There is a list of exceptions for an IND, and if ALL the exceptions are met, the research is exempt. Among the exemptions are these.
The clinical investigation does not involve a route of administration, dose, patient population, or other factor that significantly increases the risk (or decreases the acceptability of the risk) associated with the use of the drug.
Both ivermectin and mebendazole are FDA-approved for the treatment of certain parasitic infections.
In the FDA-approved form, Ivermectin comes in 3 mg tablets, and dosing is 200 µg/kg for 1 day.  A 75 kg (165 lb) individual would receive a single 15 mg dose.  
Mebendazole comes in 100 mg tablets, and the dose ranges from 1 pill for one day to one pill twice a day for 3 days.
The TWC formulation was 25 mg ivermectin and 250 mg mebendazole. Cancer patients were prescribed 1 or 2 pills per day for up to six months. This checks many of the boxes usually necessitating an IND: off-label indication (cancer vs parasitic infection); doses up to several multiples of the labelled doses; durations that exceeded the label 20-fold or more.
Since this is a compounded medication, however, different rules apply. Compounded medications are not evaluated or approved by the FDA for any indication.
Center Watch is a company focused on the clinical trials industry. They provide a variety of services to clinical investigators, including guidance in fulfilling regulatory requirements for research. They have a page specifically about IND regulation of compounded drugs. Here are some relevant quotes. “Modifications to the lawfully marketed drug” refers to compounded drugs.
Research involving modifications to the lawfully marketed drug may also be IND-exempt, provided they do not introduce risks exceeding those associated with the product’s standard, labeled use. This exemption would typically apply to low-risk modifications to the lawfully marketed dosage form, such as minor variations to solid oral dosage forms. For example, changes to the color, scoring, or capsule size of the marketed dosage form for blinding purposes would generally be considered low risk, if they do not involve significant manufacturing or formulation changes.
While sponsors are primarily responsible for determining the need for an IND (21 CFR 312.2(a)), Institutional Review Boards (IRBs) play a critical role in ensuring study compliance with regulations, protecting the rights and welfare of participants, and assessing that the research does not introduce new risks (21 CFR 56.101). IRBs rely on sponsors and investigators to provide the documentation to support IND exemption claims.
Ultimately, the FDA has the final authority to determine the requirements for investigating the compounded drug in the research. Sponsors and investigators should proactively consult the FDA when studying compounded versions of lawfully marketed drugs to determine IND requirements.
Summary and opinion
In addition to being an investigator on numerous human research projects, I have many years of service on IRBs at two research institutions. I cannot make a definitive ruling on how an IRB or the FDA would regulate this study, but I can come to an informed opinion.
Declaring this work as a quality improvement project, in my opinion, was not credible. It insulated them from the motivation to seek review from an IRB. Had they sought such an opinion, it is likely that an IRB would have declared this a human research project. It is also likely that the IRB would have requested that the investigators present an IND, or an IND exemption from the FDA.
This is a shoddy research study presented as a quality improvement project. This dubious classification functioned as an excuse for lack of interface with relevant regulatory bodies.
There is validity to the assertion that ivermectin and mebendazole show anticancer activity in preclinical studies. This study provides no meaningful evidence for or against the efficacy of such treatments in humans with cancer.

A shoddy, ethically-challenged cancer study gets published… for now.
Update on ivermectin/mebendazole cancer study
David Weinberg on July 9, 2026
Link

In May 2026, I wrote my impressions of an unpublished study released by The Wellness Company (TWC). TWC sells supplements as well as various on-label and off-label prescription medications through their telehealth providers. The Chief Scientific Officer is Peter McCullough, MD, MPH. You may recall Dr. McCullough as a highly published cardiologist turned hydroxychloroquine evangelist, turned ivermectin evangelist, turned COVID contrarian.
The authors touted the study as supportive of the utility of ivermectin and mebendazole in the treatment of cancer. Ivermectin and mebendazole are anti-parasitic medications sold as a compounded combination by TWC. These drugs have demonstrated some anticancer activity in preclinical studies, but there are no good studies supporting their use for the treatment of cancer in humans.
The paper has 12 authors, all of whom are affiliated with and/or salaried by TWC. Conflicts of interest are appropriately disclosed in the paper.
The TWC study had fatal methodological weaknesses, rendering the data impotent to support assertions the authors (and others) were making on social media. There were also some problematic ethical issues regarding the oversight of the study and adequate protection of the study subjects. At the time, the study had not been published in a peer-reviewed journal, but was displayed prominently on the TWC website and circulated widely on social media.
Methodological Madness
Briefly, subjects in this study were Wellness Company telehealth patients. Patients reported a diagnosis of cancer, and were prescribed a combination of ivermectin and mebendazole by a Wellness Company telehealth provider. Patients were invited to fill out online surveys including demographic information and the type and status of their cancer, at baseline and again at 6 months. I pointed out multiple methodological weaknesses in the study rendering the results worthless in assessing the effects of these 2 repurposed drugs on cancer, including:
    • Completely patient-reported data. Generally, clinical trials in cancer depend on structured, pre-specified, meticulously verified data. None of the investigators in this study examined the patients, ordered or reviewed scans or lab tests. It is not even noted that investigators independently reviewed medical records. All of the information about the type of cancer, prior treatment, ongoing treatments, health status, and status of cancer were provided by the patient. The article says these were “confirmed cancer diagnoses.” It is unclear what is meant by “confirmed” given these are exclusively patient-reported data.
    • No control group. Patients in this study had over a dozen types of cancer. Most of the patients had received or were currently receiving conventional therapy such as surgery, chemotherapy, radiation therapy, etc. The majority of patients reported that their cancer was “not spreading” at baseline. To determine whether or not ivermectin and mebendazole had any influence on the cancer 6 months later, we would need to compare to a similar control group that was not receiving ivermectin and mebendazole.
    • Dropouts. 38% of the baseline subjects did not fill out a survey at 6 months. We have no idea how many of these patients had worsening of their cancer, how many had intolerable side effects, and how many died. Attrition of over 1/3 of patients in 6 months is a serious limitation and an enormous red flag.
Based on these weaknesses, it is impossible to determine if ivermectin and mebendazole individually or collectively are helpful, harmful, or indifferent in treatment of cancer.
Ethical ambiguity
There are standards for the ethical conduct of research involving human subjects. The Declaration of Helsinki is a foundational document in enumerating these ethical principles. The Declaration was first adopted in 1964, but it is a living document, with the latest revision in 2024. Although the specific regulatory frameworks vary from country to country, they are largely harmonized under principles expressed in the Declaration of Helsinki.
The role of the Institutional Review Board
In the US, Institutional Review Boards (IRBs) are the bodies that assess and regulate human research on a study-by-study basis. IRBs operate under the “Common Rule” or 45 CFR 46. The Common Rule explicitly applies to research funded by the US government, but other factors can trigger the application of the Common Rule. Research done under the jurisdiction of the FDA is regulated under the Common Rule, as well as other regulatory standards. Private funders usually want to ensure that their grants are used to fund ethical research. Scientific journals usually have standards for the ethical conduct of research they publish, including IRB review.
Even research that involves only surveys or questionnaires may be under the jurisdiction of an IRB. For projects of this type, questions addressed by IRBs include:
    • Was subject participation truly voluntary?
    • Were subjects informed that the data they provide was going to be used for research?
    • Were subjects informed of risks of participation, including loss of privacy?
    • Was informed consent obtained and properly documented?
    • Were subjects able to withdraw from the study, and were they informed of such?
    • Was personal health information protected?
In the report posted on their website, TWC authors made the case that the nature of this study was not human research. TWC authors were explicit in characterizing their study as “quality improvement,” therefore not human research, and not subject to oversight by an IRB. Quality improvement is, indeed, a category of study that is usually (but not always) exempt from IRB review. For reasons I articulated in detail in my previous report, the assertion by TWC authors that their study was quality improvement was, in my opinion, specious and self-serving.
If I had a car but wanted to drive it without a license and without regard for the rules of the road, I could simply declare my vehicle a go-kart. Go-karts are vehicles that actually exist, but they are not subject to the same laws as cars. Calling my car a go-kart does not make it so. Despite my go-kart assertion, the sheriff will still require me to have a license to drive my automobile.
If I were truly uncertain whether my vehicle was a car or a go-kart, I could consult with the DMV and get a definitive answer. In ambiguous cases, study investigators can consult with an IRB to determine whether or not their study is classified as human research. TWC authors have provided no evidence that they sought an opinion from an IRB about the nature of their study.
Study gets published!
The TWC ivermectin/mebendazole “study” — Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort — was published in the journal Anticancer Research on May 27, 2026. Anticancer Research is not a top-tier journal, but it is an indexed, peer-reviewed journal.
According to metrics provided by the journal, the article was received April 8; revision received April 20; and received final acceptance April 24, 2026. This is remarkably fast in the publication business. The time from submission to review, to first decision, to revision, to re-review, and to acceptance was a mere 16 days.
The published version of the paper differs little from the version available for download on TWC’s website, with a notable exception. The TWC version contains this disclaimer [emphasis mine]:
Institutional Review Board (IRB) Statement: This project was conducted as a retrospective analysis of a prospective clinical program evaluation. Consistent with established frameworks for quality improvement and internal assessment of clinical services, the project utilized voluntary, patient-reported data. As such, it did not meet the definition of human subjects research and did not require Institutional Review Board (IRB) review.
This is the “I have a go-kart” declaration, in which the authors opine that this study did not require IRB approval.
No such declaration appears in the Anticancer Research version. In fact, no statement about IRB approval or informed consent or ethical conduct of the study is mentioned in the published study at all.
In Anticancer Research’s Editorial Policies are the following statements [emphasis mine]:
Ethical Policies and Standards
Authors must adhere to ethical principles in the conduct of their research, including obtaining informed consent from human subjects, minimizing harm to subjects, and protecting their privacy and confidentiality. Research involving human subjects must be approved by an institutional review board or ethics committee and must comply with international ethical guidelines, such as the Declaration of Helsinki, and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001……. Before starting the study, all used protocols must have an ethical approval from the local Institutional Review Board (IRB) or any other appropriate ethics board to ensure that the study meets national and international guidelines for human experimentation. A written statement that acknowledges this, including the name of the Institutional Review Board and the reference/approval number (if any), must be included in the submitted manuscript. If a non-interventional study does not require ethical approval, or if a study is exempt from an ethics committee, then this should be fully detailed in the submitted manuscript. For an approved study, the name of the Institutional Review Board that approved it must also be given. Ethics approval is required for all studies before the research is conducted. Authors should be prepared to provide additional information to the journal editors upon request.
Notably, the journal requires compliance with externally established ethical principles and standards such as the Declaration of Helsinki and the Common Rule (45 CFR 46). These standards specifically require IRB pre-approval or a detailed accounting of how a study is deemed exempt from such oversight.
An expeditious “Expression of Concern”
At the top of the TWC article on the Anticancer Research website is a box with the statement: “This article has a correction. Please see:” with a link to “Expression of Concern – June 01, 2026.”
What is an “Expression of Concern?
An Expression of Concern is an alert to notify the public that an investigation for an article is underway.
The Committee on Publication Ethics (COPE) is an organization committed to promoting integrity in research publication. The Anticancer Research editorial policy states that they adhere to COPE’s Principles of Transparency and Best Practices in Scholarly Publishing. According to COPE’s guidelines regarding expressions of concern:
Expressions of concern should be issued if an editor of a journal determines that concerns raised about an article are substantial and credible enough to warrant alerting readers, but insufficient information is available to decide whether a correction or retraction is required.
Editors should consider issuing an expression of concern if:
    • significant and credible concerns have been raised but the evidence is unclear as to whether the work, or parts of the work, are potentially unreliable. The unreliability may be due to error, incorrect analysis, or concerns about research integrity and publication ethics that affect the main findings.
    • an institutional, funding, or other formal oversight investigation is ongoing that may result in corrections to the literature based on the reliability of the work.
    • the authors have been asked to provide additional information to address the concerns that have been raised, and this information is not immediately available.
    • there is a breach in the journal or publisher policy that cannot be resolved (eg, article data were available when the article was published but were later withheld by the authors).
    • a resolution is not expected to be reached at all or for some time (eg, several months).
The Expression could be removed if the issue is resolved and the article exonerated. It could be removed after a correction. If the concerns are confirmed, the article could be retracted. If the issue cannot be resolved one way or another, the Expression of Concern may be permanently affixed to the article.
What was the expression of concern for TWC’s article?
It is worth quoting the Expression of Concern in full [emphasis mine];
Regarding: Hulscher et al., “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” Anticancer Research Vol. 46, No. 6, pp. 3243-3255, 2026.
The Editorial Board of Anticancer Research is issuing an official Expression of Concern regarding the article cited above. The study was published purely as “hypothesis-generating”, opening the discussion for repurposing of these substances, establishing the ground for future approved, randomized clinical trials. Following publication, serious scientific concerns were raised by the international medical community regarding the verifiability and statistical reliability, and ethical oversight of the underlying dataset.
In formal correspondence to the journal dated June 4, 2026, the authors clarified that the study cohort was not drawn from an unverified consumer survey, but instead comprised “provider-screened cancer patients enrolled in a structured prospective cohort” managed via an internal clinical workflow and licensed provider consultations.
While the Editorial Board acknowledges the authors’ transparency regarding the text-level limitations of self-reported data, a study published in a peer-reviewed oncology journal that reports a “Clinical Benefit Ratio of 84.4%” and specific percentages of “tumor regression” must rest on a verifiably real clinical foundation and adhere to established ethical frameworks for human subject research to maintain its validity in the permanent scholarly record. Anticancer Research does not endorse or condone the unvalidated off-label use of medications for unapproved oncological indications. Disclosing limitations does not exempt a clinical dataset from the foundational scientific requirements of empirical verifiability and independent ethical oversight.
Accordingly, based on the authors’ confirmation of an established clinical provider-patient workflow, the journal is initiating a formal Post-Publication Data Integrity and Ethical Oversight Audit. This investigation will evaluate the mandatory Institutional Review Board (IRB) approval or exemption documentation, the de-identified, source-verified clinical records confirming the baseline cancer diagnoses of the 197 initial participants and the objective medical documentation supporting the reported anatomical regressions.
This Expression of Concern will remain prominently appended to the publication record online and in all indexing databases while this formal data and ethical verification audit is underway.
Considering that the article was published on May 27, and the Expression of Concern is dated only 4 days later, the influx of scientific concerns from the international medical community was swift and persuasive.
What does this mean?
The editors have attached the Expression of Concern to notify readers that there have been concerns raised regarding the ethical oversight of the study and the integrity of the data used in the study. They are also informing readers of actions being taken to resolve these questions. The editors have initiated a “Data Integrity and Ethics Oversight Audit.”
Data Integrity Audit
The editors will be auditing: “…de-identified, source-verified clinical records confirming the baseline cancer diagnoses of the 197 initial participants and the objective medical documentation supporting the reported anatomical regressions.” In other words, the editors are requesting source documents to validate the data used in the analyses. “De-identified” likely means that they will be requesting that the authors redact certain identifying information to protect the identities of the study subjects.
The authors explicitly explain that their analyses were based on patient-reported data from voluntary surveys. The authors did not claim independent review of any clinical records to verify diagnoses or tumor responses. It is unclear how the TWC authors will be able to provide the requested information to the editors.
Ethical Oversight Audit
Here, the editors intend to review the documents necessary to ensure the article adheres to their own Ethical Policies and Standards. They are requesting “mandatory” IRB approval or exemption documents. The ability to produce these documents would have required the authors to have submitted their study protocol to an IRB before starting the project.
If submitted to an IRB, there would be two possible outcomes. The IRB could have determined the project was exempt from IRB oversight. This would have freed them from any ambiguity about the nature and regulation of this project. Alternatively (and more likely) the IRB would have determined that this study is human research, obligating the authors to proceed under the jurisdiction of an IRB. In either instance, these IRB determinations would be in writing, and auditable.
Nothing I have seen in the statements of the authors suggests that they navigated these details. To the contrary, they have argued that these steps were unnecessary.
The fact that such methodological and ethical concerns escaped the editors and peer reviewers does not speak highly of their standards and/or process. Peer review is an imperfect process, and sometimes things slip through the cracks. Kudos to the editors for responding quickly to the outcry from the international medical community.
We will patiently wait to see how this Expression of Concern is resolved.
Stay tuned for further updates.

Is An Israeli Company About to Cure Cancer?
Hyped claims for a cure for all cancers are inherently unbelievable. So don’t believe them.
Steven Novella on January 30, 2019
Link

There is a good rule of thumb – whenever a headline asks a question, especially a provocative question, the answer is usually no. This article is no exception. This is a particular type of scam, or at least very misleading claim, that I encounter often. Usually I am sent an e-mail asking hopefully, even if skeptically, if the claims being made are true. This falls under the category of “overhyped corporate promotion”.
Sure, all companies do this to some degree. It’s called advertising. But at some fuzzy point, overhyped advertising claims become fraudulent. Sometimes the goal is to sell product, and sometimes it is to attract investors (or both). In extreme cases, like the now infamous Theranos, the claims are not only overhyped, they are implausible and ultimately illusory. In still other, more extreme cases, like the Steorn company and their Orbo free energy device claim, it seems the scam was to endlessly attract investors, without ever producing a viable product.
Where are we on this spectrum with the current claims? Let’s start with the claim:
“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi)
Impressed? But wait, there’s more:
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”
There is another rule of thumb that sounds like a cliché, but holds some wisdom – if something sounds too good to be true, it probably is. In the realm of corporate promotion, beware claims of the implausibly perfect product. In this case Aridor (son of Arithor – OK, I may have just made that up) is claiming to have a cure for all cancers that is low cost, rapid, and with minimal side effects. It also whitens your teeth and perfumes your flatulence.
We have discussed here many times before that the “cure for all cancers” is an inherently implausible claim. Cancer is not one disease, but a category including many related diseases. Different cancers involve different tissues, different mutations, and different behaviors and features. While some treatments are effective against a variety of cancers, there is no one treatment effective against all cancers (let alone a cure for all cancers).
Further, as a general rule, the greater the advance itself the more implausible, even if the claim itself is not impossible. This is due to a few reasons, primarily that complex advances take time. With mature, robust areas of research, the low-hanging fruit has already been picked. Advance is made in a continuous series of baby-steps. They add up over time (as I discussed recently) but the probability of a giant leap is inherently implausible – and the greater the leap the greater the implausibility.
It simply takes a lot of time and a lot of research to put all the pieces together. Also, it is very unlikely that one lab will make all of the necessary advances all by themselves. The basic science would likely be a collaboration of many labs, publishing over years, leaving a paper trail that any expert could follow. There would be presentations at meetings, and the basic science would be discussed in the community.
The world is investing billions of dollars a year in cancer research (the NIH alone invests about $5 billion per year). Any clinical advance that was ripe because the basic science was there would likely be researched by many labs.
So any claim that would require not just one step, but multiple steps, happening largely in secret in one lab over a relatively short period of time stretches credulity.
We can also ask – how does Aridor know that his alleged treatment will have the features he boasts? In other words – where’s the beef? So far all they have are mouse studies, nothing yet in humans. That is very thin gruel given the boastful claims he is making. That is considered pre-clinical evidence, not even preliminary clinical evidence. In other words – he is just largely making up all those claims. He may suspect that his treatment will be as effective as he says, but he really has no idea.
It will take years, perhaps decades, to really know what the potential of this new approach is. It will have to be studied for years in each type and stage of cancer. Making claims about effectiveness and side effects now is pure speculation. Saying you have a potential “cure for all cancer” is downright irresponsible.
With all this in mind, let’s take a look at the actual science. The treatment is based on the technology of phage display, which was the recent recipient of a Nobel Prize. Phages are viruses that attack bacteria, and can be made to display antibodies on their outside. AEBi claims that they can use this technology to instead display small peptides. With this they create what they call MuTaTo – multi-targeted toxins. They have three peptide toxins on one phage, each of which targets an aspect of a cancer cell without targeting healthy cells, and further they can target the cancer stem cells to prevent recurrence.
This all sounds fine, a reasonable basis for cancer research. The problem is extrapolating from the basic idea to implausible clinical claims. Such hot ideas in cancer research come up all the time, and if you recklessly extrapolate from basic mechanisms and assume maximal effectiveness, you could make a convincing-sounding argument that any of them are a “cure for cancer”. But so far, that never turns out to be the case. Cancer has always proven to be more difficult than such optimistic predictions assumed. Many of them turn into viable cancer treatments, adding another incremental baby step to cancer survival, but none of them are ultimate cures.
Aridor keep saying that his treatments “should” do this or that, but he is just making unrealistically optimistic assumptions. He also appears to be assuming that because he can imagine something, it will work out. We will just find targets that are unique to the cancer cells, leaving healthy cells unharmed. Really? That is the basis of pretty much all cancer treatments, and yet they all have side effects, sometimes severe.
Another example is the multi-targeting to increase effectiveness and reduce the emergence of resistance. He states this as if it is a new idea, when it is already the basis of most cancer treatment. That is why multiple chemotherapeutic agents are often used at the same time. That does increase effectiveness and reduce resistance, but it does not eliminate resistance. The only new idea I see here is the use of modified phage display to deliver toxins. Otherwise, he is just stating basic principles of cancer treatment that are already standard as if they are new and as if they are silver bullets that will magically produce the perfect cancer treatment.
It is not even clear at this point if this technology will work, let alone be the Holy Grail of cancer treatments. Hopefully it will work wonderfully, and add to our armamentarium of anti-cancer treatments, adding another incremental advance.
Oh but wait – here is a study from 2002 titled: “Tumor cell-targeting by phage-displayed peptides“. Putting “cancer” and “phage-displayed peptides” into PubMed resulted in 253 results, and looking through them they mostly look relevant, and going back to 2001. So this idea is at least 18 years old, and is being researched in labs all over the world.
So really they are just taking already off-the-shelf technology, rebranding it as their own, perhaps making some incremental changes, and then making ridiculously overhyped claims about their “breakthrough.”
To be clear, phage display is a great technology, and using it to target cancer cells is a great idea and an active area of research. But as you can see, it has already been researched for the last 18+ years. That is how long it takes to develop a new technology into a viable treatment.
Not specifically referencing Aridor or AEBi, but you can see how easy it is for a company do a little research to find some cutting-edge technology that the public is not generally familiar with, and then wrap some extreme claims around that technology, promising some new product or treatment. You can even cite the published research to apparently support your claims. It all sounds like cutting edge technology, but it is a Potemkin village. It is a clever type of pseudoscience that can be very effective. It takes a high degree of specific scientific knowledge, and perhaps even the ability to search and understand the technical literature, to see through the deception.
That is how Theranos was able to build an illusory company valued at $10 billion before the house of cards collapsed. But again – that is only the most famous and extreme example, there are many smaller examples all along the spectrum from overhyped but legitimate to pure scam.
The lesson is to be skeptical of any claims for a breakthrough, and the greater the claims the greater should be your skepticism. Amazing advances do not come out of nowhere, and usually if the basic science is there, multiple companies will be exploiting it. Beware Holy Grail perfect products that just seem too good to be true. You will never go wrong being skeptical of hyped claims.


CAM Promotion in Adolescent and Young Adult Cancer Programs
Cancer in the 18-39 age range is uncommon, but still occurs. When they should be dealing with school, friends, new jobs, and starting families, instead they must worry about medical bills, appointments, and infertility. Added to this are the costs of “integrative” treatments often foisted upon cancer patients, or built-in to the few adolescent and young adult-focussed centers that currently exist.
Jesse Luke on September 29, 2017
Link

Adolescents and young adults (AYA, ages 15-39) with cancer are an often-underserved group in the field of oncology. Though most people are aware that cancer can strike at any age, older patients and children are often the first thought of. The patient population is significant; each year approximately 70,000 AYA cancers are diagnosed in the US, and an estimated one million worldwide. Young adults are roughly six times more likely to be diagnosed than children under 15. The types of cancer diagnosed can be more prevalent in either the pediatric or alder adult populations. In addition, due to the age of the patient population there are additional concerns such as fertility, graduating university, and starting a family. As a result, in the past few years there has been an effort to create care centers in hospitals geared towards this age group of patients. Being diagnosed with cancer at any age is a terrible thing, and the challenges of life in AYA certainly do not help – but this is made worse by the infiltration of integrative medicine practitioners into AYA cancer care centers that have little to no evidence of their claims and serve only to provide false hope, alternative facts, and various placebos…for a price.
Young adults and CAM
The most likely user of CAM according to the NCCIH is a white, educated, older (around 50) and relatively wealthy female. This should not give the impression that they are the only users, or that use in other demographics is rare. In this regard, it is not surprising that young adults use CAM, or that in those under 18 it may be pushed on patients by parents. Though dedicated studies on the AYA group concerning CAM use are lacking, we do have approximate percentages available for the age groups. The values range from a low at 16.4% among 12 to 17 year olds, to 39.6% in 30 to 39 years olds. It should be noted that these numbers are from 2007 and that the number of integrative programs in hospitals have increased dramatically since.
Patients and parents may not have sought CAM therapies of their own accord, various “interventions” may have been directly marketed to these patients and families as an extra component or more popular today, an essential part of care to promote “wellness”. Therefore, patients that may never have thought of using any form of CAM therapies are pressured into usage through careful marketing, rebranding, and clever (to the average person) lies concerning the scientific legitimacy of proposed therapies.
Concerning the treatments used in dedicated integrative settings, they vary by center but none are unique to these programs and they have all been thoroughly analyzed on SBM and elsewhere. The treatments are either nonsense or a legitimate part of medicine that proponents try to pass off as integrative with the marketing term “holistic”. Integrated (but not integrative) care settings for AYAs hold the possibility of tremendous benefit for patients if done correctly and pseudo-medicine is excluded. There are centers that for the most part aim to do this but unfortunately there are many that utilize every bit of quackery they can get their hands on.
The good ideas
A good example of what a dedicated program for AYAs could look like is Roswell Park Cancer Institute in Buffalo, New York. The center includes a dedicated onco-fertility program which is essential when dealing with younger patients as many treatments can alter or completely destroy fertility. This can include stopping sperm production for men, and early menopause for women. Through consultations, patients can be adequately informed of these risks and can be recommended options such as sperm freezing and egg/embryo banking to facilitate future reproduction if desired. The program also employs a psychologist to help patients deal with anxiety, duress, and concerns that come with cancer at a young age. The center is also set-up to deal with long term medical issues that may arise such as relapse, secondary cancers due to initial treatment, and social factors such as returning to work or school. They also run support groups and organize events where young adults can get together outside of the clinical environment. The only place where this program seems to come up short is that they don’t seem as committed to clinical research for the age group, which is an important issue as AYA cancers are by far the most underrepresented in the field of research.
Another center that has taken similar steps is Sloan-Kettering. Fertility consultations are recommended for all new AYA patients along with a consulting center that is comprised of psychiatrists and psychologists. As a result of MSK’s status, many of them have extensive experience with AYA patients. Aside from the clinical offerings the hospital has made further efforts to make patients more comfortable by introducing several features for those in their teens and 20s. This includes a lounge that is set up specifically for the age group that includes:
    • kitchen stocked with snacks
    • TV with cable and movies
    • art supplies and classes
    • video games and tournaments
    • dry-erase graffiti wall
    • movie nights
    • computer stations
    • board games
    • books and resources
    • weekly programming and special events
The goal is to make younger patients feel more comfortable, and help address the social isolation from their peers that all too often can arise at that age.
This is not to say that either MSK or Roswell Park are perfect when it comes to the World of Pseudo-medicine. Roswell Park announced a trial acupuncture program in June of this year, starting in pediatrics. MSK has an integrative medicine program that includes reiki and acupuncture along with rather nebulous advice on herbalism all over their website, and they even have an app. Out of the many academic medical centers I have reviewed they sit comfortably on the lower end of the insanity scale.
The nonsense
This is the category that most of the centers I have reviewed fit into. They have the capability to create useful programs and in the sense of actual medicine are quite good, but have opted to promote treatments of either unknown efficacy or that are ineffective.
A prime example is the young adult program at UCLA. Rather than creating a dedicated program as part of general oncology, they opted to place the program under the Simms/Mann-UCLA Center for Integrative Oncology. The center does seem to have a psychologist and psychiatrist on staff but neither appear to be solely dedicated to the young adult program. I also wasn’t able to discern whether or not they promote integrative psychiatry or psychology practices. In fact, there seems to be nothing focused solely on young adults beyond a support group. Patients are instead steered towards meditation classes, qi gong groups, guided imagery groups, and integrative medicine consults that focus largely on dietary supplements. Not surprisingly they also sell supplements directly to patients.
Another center that focuses on the younger end of the AYA spectrum is at Columbia University (embarrassingly, my old school) through the Center for Comprehensive Wellness. Multiple treatments are offered including acupuncture, acupressure, reflexology, reiki, aromatherapy, herbalism, supplementats, and massage. Most of these are complete bunk but massage therapy may stick out. It is true that in general there is nothing really wrong with a standard massage but I would hardly call it alternative. The real problem is with some of the forms offered:
    • Shiatsu – A massage system based upon the metaphysical idea of meridians and ki (Japanese version of qi essentially)
    • Tui Na – A component of TCM that shiatsu is derived from, claims to balance qi (chi) flow through the manipulation of meridians that is essentially the same as shiatsu with perhaps slightly different actions
Though most of the above treatments are provided free of charge at Columbia and carry the potential for little harm (and “little” isn’t none) there are several points that are important to realize. First and most importantly, these are all meant to be provided to children and adolescents. Because of this if parents choose not to allow these charlatans to treat their children they may feel that they are not doing everything to help their child (this personally nauseates me). Second, these treatments provide nothing but false hope to parents or older children when the placebo effect kicks in. Finally, even though such services may be offered for free to patients there is still a cost, and every dollar spent on the program is a dollar that could have gone towards research or services that could truly help or possibly even cure these patients.
AYA oncology doesn’t need CAM
Though there is an enormous opportunity and necessity for programs that address the needs of AYAs in the field of oncology, this has become diluted by the influx of integrative medicine into the field. The focus of care has shifted from what could truly help such patients get through what in all likelihood will be the worst experience of their lives, to being greeted in world renowned medical centers by pseudo-scientific delusions. If you provide care for adolescents or young adults with cancer, or know anyone who is currently being treated, I urge you to think of the evidence and do what is best for them based on real evidence. As well-intentioned as some integrative medicine proponents may be, it is important that when it comes to the patient’s well-being they are nothing but “mad, bad, and dangerous to know”.

Cold Caps Combat Hair Loss from Chemotherapy
Hair loss from chemotherapy can be prevented with cold caps, but scalp hypothermia has some downsides and may not be acceptable to all patients.
Harriet Hall on March 24, 2020
Link


To gain FDA approval for marketing, chemotherapy drugs must have been tested and shown to be effective and reasonably safe. But of course, we all know they are not entirely benign. There are a lot of adverse effects, one of which is hair loss. Around 65% of people who get chemo will lose their hair. Some take it in stride, shaving the sparse remaining hair, wearing wigs, turbans, and colorful scarves, joking about it, and waiting patiently for the hair to re-grow, which it will do gradually over a period of months. Susan Gerbic, founder of Guerilla Skepticism on Wikipedia, demonstrated a great attitude and a great sense of humor: she took advantage of her temporary baldness to have friends draw a phrenology map on her scalp in preparation for a skeptical costume party. For others, because of vanity or self-image concerns, teasing, and the reactions of others, it can be terribly distressing, Fortunately, there is an effective remedy: cold caps.
The why and the how of scalp hypothermia
It makes sense to cool the scalp. Decreased blood flow can be expected to reduce the amount of chemo drugs absorbed by hair follicles, and colder hair follicles will be less active and less able to take up the drugs. Also known as scalp hypothermia, cooling can be provided by ice packs or by devices known as cold caps, cooling caps, or hypothermia caps. These caps have other medical uses including treatment of newborns with encephalopathy.
Ice packs are cumbersome, difficult to apply to the entire scalp, and must be changed frequently as the ice melts.
Cooling caps are something like a helmet filled with frozen material. Caps must be replaced as they warm up.
Scalp cooling systems use a helmet attached by a hose to a cooling machine, allowing for complete scalp coverage and temperature regulation. A second insulating cap is worn over the cooling cap
Clinical trials
Clinical trials have established the effectiveness of scalp hypothermia for preventing hair loss. Effectiveness was confirmed by a recent systematic review. But counterintuitively, another systematic review showed no improvement in quality of life.
A 2017 study of stage 1 and 2 breast cancer patients was multicenter, randomized, and controlled, with 142 participants and with blinded evaluators. It used a scalp cooling system for 30 minutes prior to and during and 90 minutes after each chemotherapy infusion.
It found that half of the treatment group and none of the untreated control group had hair preservation, defined as no hair loss or less than 50% hair loss and no need to wear a wig. Degree of effectiveness varied by chemotherapy drug and by study site (perhaps due to differences in experience fitting the caps or to demographic differences?). Treatment did not improve psychological or social functioning. Six subjects withdrew because of discomfort, anxiety, or claustrophobia. Most subjects found the device reasonably comfortable. Side effects were generally mild; they included chills, dizziness, headache, nausea, paresthesia, pruritus, sinus pain, skin and subcutaneous tissue disorders, skin ulceration, scalp pain, and dry skin.
Caveats
Not everyone is eligible. Cold caps are not appropriate for patients with lymphoma or leukemia. There is a long list of contraindications. Thick hair may impede success. There are numerous scalp cooling systems on the market such as Dignicap and Paxman; there are no comparison studies. Some cold caps are FDA approved; others aren’t (Penguin, Arctic, and others). The cost may be as high as $3,000. Putting the device on involves a cumbersome wrapping and fitting procedure. Most insurance doesn’t cover these treatments. Paxman warns that the first 15-20 minutes can be very uncomfortable until the patient acclimates to the cold; they suggest that pain medication might help. The system must be used for 30 minutes before the chemotherapy infusion, throughout the infusion (however long that takes, sometimes a matter of hours) and for 90 minutes after the infusion. When treatment decreases hair loss, the reduced hair loss does not appear to improve the patient’s psychological or social functioning or quality of life, so patients may wonder why they should go to all that bother for no real benefit. Is having more hair worth it if it doesn’t make you feel any better?
Conclusion: Effective, but not for everyone
There is good scientific evidence that scalp cooling systems for appropriately selected chemotherapy patients will reduce their hair loss. Some patients will embrace these treatments as worthwhile, but others may balk at the expense, the long time the cap must be worn, the discomfort, and the cumbersomeness of the systems. Patients should be fully educated about the pros and cons so they can make an informed decision.

IBM’s Watson versus cancer: Hype meets reality
Five years ago, IBM announced that its supercomputer Watson would revolutionize cancer treatment by using its artificial intelligence to digest and distill the thousands of oncology studies published every year plus patient-level data and expert recommendations into treatment recommendation. Last week, a report published by STAT News shows that, years later, IBM’s hubris and hype have crashed into reality.
David Gorski on September 11, 2017
Link


For nearly as long as I can remember, I’ve been a fan of Jeopardy! Indeed, if I’m at home at 7:30 PM on a weeknight, Jeopardy! will usually be on the television. Given that, I remember what was basically a bit of stunt programming in 2011, when Jeopardy! producers had IBM’s artificial intelligence supercomputer Watson face off against two of the most winning champions in the history of the show, Ken Jennings and Brad Rutter. Watson won, leading Jenning’s to add to his Final Jeopardy answer, “I, for one, welcome our new computer overlords.”
Watson’s next challenge was similarly highly hyped: cancer. Since 2012, IBM has been collaborating with several cancer institutes to apply Watson’s talents to cancer treatment. For instance, Memorial Sloan-Kettering Cancer Center describes its Watson Oncology initiative thusly:
Watson Oncology is a cognitive computing system designed to support the broader oncology community of physicians as they consider treatment options with their patients. Memorial Sloan Kettering clinicians and analysts are partnering with IBM to train Watson Oncology to interpret cancer patients’ clinical information and identify individualized, evidence-based treatment options that leverage our specialists’ decades of experience and research.
As Watson Oncology’s teacher, we are advancing our mission by creating a powerful resource that will help inform treatment decisions for those who may not have access to a specialty center like MSK. With Watson Oncology, we believe we can decrease the amount of time it takes for the latest research and evidence to influence clinical practice across the broader oncology community, help physicians synthesize available information, and improve patient care.
Not surprisingly, Watson’s entry into cancer care and interpretation of cancer genomics was, just like its appearance on Jeopardy!, highly hyped, with overwhelmingly positive press coverage and little in the way of skeptical examination of what, exactly, Watson could potentially do and whether it could actually improve patient outcomes. Overall, as Watson moved into the clinical realm, you’d be hard-pressed not to think that this was a momentous development that would change cancer care forever for the better. There were plenty of headlines like “IBM to team up with UNC, Duke hospitals to fight cancer with big data” and “The future of health care could be elementary with Watson.” The future looked bright.
An article in STAT News last week by Casey Ross and Ike Swetlitz suggests otherwise, at least so far: “IBM pitched its Watson supercomputer as a revolution in cancer care. It’s nowhere close.”
Watson: Hype versus reality
In the story, STAT looked at Watson for Oncology’s use, marketing, and actual performance in hospitals around the world, interviewing dozens of doctors, IBM executives, and artificial intelligence experts and concluded that IBM released a product without having fully assessed or understood the challenges in deploying it and without having published any papers demonstrating that the technology works as advertised, noting that, as a result, “its flaws are getting exposed on the front lines of care by doctors and researchers who say that the system, while promising in some respects, remains undeveloped.” From my perspective, that’s an understatement. Indeed, STAT observes:
Perhaps the most stunning overreach is in the company’s claim that Watson for Oncology, through artificial intelligence, can sift through reams of data to generate new insights and identify, as an IBM sales rep put it, “even new approaches” to cancer care. STAT found that the system doesn’t create new knowledge and is artificially intelligent only in the most rudimentary sense of the term.
While Watson became a household name by winning the TV game show “Jeopardy!”, its programming is akin to a different game-playing machine: the Mechanical Turk, a chess-playing robot of the 1700s, which dazzled audiences but hid a secret — a human operator shielded inside.
In the case of Watson for Oncology, those human operators are a couple dozen physicians at a single, though highly respected, U.S. hospital: Memorial Sloan Kettering Cancer Center in New York. Doctors there are empowered to input their own recommendations into Watson, even when the evidence supporting those recommendations is thin.
Another way of saying this is that Watson isn’t really an artificial intelligence when it comes to cancer, but rather a very powerful computer that is very good at coming up with treatment plans based on human-inputted algorithms that it’s taught. An example from a hospital in Florida is presented as an example:
On a recent morning, the results for a 73-year-old lung cancer patient were underwhelming: Watson recommended a chemotherapy regimen the oncologists had already flagged.
“It’s fine,” Dr. Sujal Shah, a medical oncologist, said of Watson’s treatment suggestion while discussing the case with colleagues.
He said later that the background information Watson provided, including medical journal articles, was helpful, giving him more confidence that using a specific chemotherapy was a sound idea. But the system did not directly help him make that decision, nor did it tell him anything he didn’t already know.
But it’s more than that. You might have noted in the MSKCC blurb I quoted above that MSKCC is described as “Watson’s teacher.” That is very literally true. Indeed, the STAT story refers to Watson as “essentially Memorial Sloan Kettering in a portable box,” noting that its treatment recommendations are “based entirely on the training provided by doctors, who determine what information Watson needs to devise its guidance as well as what those recommendations should be.” This reliance on a single institution introduces an incredible bias. MSKCC is, of course, one of the premiere cancer centers in the world, but it’s a tertiary care center. The patients seen there are not like the patients seen at most places—or, to some extent, even at my cancer center. They’re different, both in the mix of race and socioeconomic status. (MSKCC tends to attract more affluent patients.) Also, the usual differences between the patient mix in a tertiary care center and a typical hospital are more pronounced, because not only is MSKCC a tertiary care center, but it’s one of the premier cancer tertiary care centers in the world. There are more advanced and unusual cases, patients who have failed multiple lines of treatment and are looking for one last chance. The mix of patients, cancers, and other factors that doctors at MSKCC see might not be relevant to hospitals elsewhere in the world—or even in different parts of the US. As Pilar Ossorio, a professor of law and bioethics at University of Wisconsin Law School, points out in the article, from the cases used to train Watson, what Watson will learn is “race, gender, and class bias,” basically “baking those social stratifications in” and “making the biases even less apparent and even less easy for people to recognize.”
Bias is inevitable, particularly when it is only one institution’s physicians who are doing the teaching.
It’s also widely known in the oncology community that there is a “MSKCC way” of doing things that might not always agree with other centers. Yet IBM denies that reliance on a single institution to “teach” Watson injects bias, to the point where I literally laughed out loud (and was half tempted to insert an emoji indicating that) when I read a quote by Watson Health general manager Deborah DiSanzo, saying, “The bias is taken out by the sheer amount of data we have.” (She is referring to patient cases and millions of articles and studies fed into Watson.) I can’t help but also note that it isn’t just treatment guidelines that MSKCC is providing. It’s basically choosing all the medical literature whose results are inputted into Watson to help craft its recommendations. As I read the STAT article, as a clinician and scientist myself, I couldn’t help but marvel that IBM is either blissfully unaware that this is a self-reinforcing system, in which one institution’s doctors would tend to recommend the very literature that would support the treatment recommendations that they prefer.
And, MSKCC being MSKCC (i.e., a bit arrogant), the doctors “training” Watson don’t see the bias as a problem:
Doctors at Memorial Sloan Kettering acknowledged their influence on Watson. “We are not at all hesitant about inserting our bias, because I think our bias is based on the next best thing to prospective randomized trials, which is having a vast amount of experience,” said Dr. Andrew Seidman, one of the hospital’s lead trainers of Watson. “So it’s a very unapologetic bias.”
I laughed out loud at that quote, too. Having a “vast amount of experience” without having clinical trials upon which to base treatments can just as easily lead to continuing treatments that don’t work or hanging on to beliefs that are never challenged by evidence. I’m not saying that having experience is a bad thing. Far from it! However, if that experience is not tempered by humility, bad things can happen. It’s the lack of humility that I perceive here that troubles me. There are awesome cancer doctors elsewhere in the world, too, you know:
In Denmark, oncologists at one hospital said they have dropped the project altogether after finding that local doctors agreed with Watson in only about 33 percent of cases.
“We had a discussion with [IBM] that they had a very limited view on the international literature, basically, putting too much stress on American studies, and too little stress on big, international, European, and other-part-of-the-world studies,” said Dr. Leif Jensen, who directs the center at Rigshospitalet in Copenhagen that contains the oncology department.
And:
Sometimes, the recommendations Watson gives diverge sharply from what doctors would say for reasons that have nothing to do with science, such as medical insurance. In a poster presented at the Global Breast Cancer Conference 2017 in South Korea, researchers reported that the treatment Watson most often recommended for breast cancer patients simply wasn’t covered by the national insurance system.
None of this is surprising, given that Watson is trained by American doctors at one very prestigious American cancer center.
Then there’s a rather basic but fundamental problem with Watson, and that’s getting patient data entered into it. Hospitals wishing to use Watson must find a way either to interface their electronic health records with Watson or hire people to manually enter patient data into the system. Indeed, IBM representatives admitted that teaching a machine to read medical records is “a lot harder than anyone thought.” (Actually, this rather reminds me of Donald Trump saying, “Who knew health care could be so complicated?” in response to the difficulty Republicans had coming up with a replacement for the Affordable Care Act.) The answer: Basically anyone who knows anything about it. Anyone who’s ever tried to wrestle health care information out of a medical record, electronic or paper, into a form in a database that can be used to do retrospective or prospective studies knows how hard it is. Heck, just from my five year experience working on a statewide collaborative quality initiative in breast cancer, I know how hard it is, and what we were doing in our CQI was nowhere near as complex as what IBM is trying to do with Watson. For instance, we were looking at only one cancer (breast) and a subset of one state (25 institutions in Michigan), and we were not trying to derive new knowledge, but rather to look at aspects of care where the science and recommendations are clear and we could compare what our member institutions were doing to the best existing evidence-based guidelines.
What can Watson actually do?
IBM represents Watson as being able to look for patterns and derive treatment recommendations that human doctors might otherwise not be able to come up with because of our human shortcomings in reading and assessing the voluminous medical literature, but what Watson can actually do is really rather modest. That’s not to say it’s not valuable and won’t get better with time, but the problem is that it doesn’t come anywhere near the hype. I mentioned that there haven’t been any peer-reviewed studies on Watson in the medical literature yet, but that doesn’t mean there are no data yet. At the American Society of Clinical Oncology (ASCO) meeting this year, there were three abstracts presented reporting the results of studies using Watson in cancer care:
The first study carried out at the Manipal Comprehensive Cancer Centre in Bangalore, India, looked at Watson’s concordance with a multi-disciplinary tumour board used for lung, colon and rectal cancer cases. The AI achieved a concordance rate of 96% for lung, 81% for colon and 93% for rectal cancer.
The second study compared Watson’s recommendations to those made by oncologists at Bumrungrad International Hospital in Bangkok, Thailand – this time across multiple cancer types. Its concordance rate was 83%.
The third concordance study compared Watson’s decisions for high-risk colon cancer to a tumour board from Gachon University Gil Medical Centre in Incheon, South Korea. Its concordance rate in terms of colon cancer decisions was 73%, however, it was only 43% in gastric cancer.
The company explained this was due to differences in treatment guidelines for the disease in South Korea, compared to where it was trained at Memorial Sloan Kettering.
This is mighty thin gruel after such grandiose claims for the technology. Sure, it’s a very good thing that Watson agrees with evidence-based guidelines a high percentage of the time. It’s not so great that its concordance with recommendations was so low for gastric cancer, but it is that lack of concordance that shows the weakness of a system so dominated by American oncologists and cancer surgeons. The reason that treatment recommendations in Asia differ so markedly from those in the US is because of differences in prevalence (which is much higher in Asia) and even biology.
Of course, it’s important that Watson be able to replicate evidence-based treatment recommendations for common cancers, but you don’t need a computer to do that, much less an AI. Where Watson was hyped by IBM was for its supposed ability to “think outside the box” (if you’ll excuse the term) and come up with recommendations that humans would not have thought of that would result in better outcomes for cancer patients. Even these modest results are being hyped in the form of embarrassing headlines. For instance, ASCO, touting the results of the three studies presented at its annual meeting and other results, wrote “How Watson for Oncology Is Advancing Personalized Patient Care.” It read like a press release from IBM. Another article proclaimed that “IBM’s Watson is really good at creating cancer treatment plans.” That’s nice. So are nearly all oncologists, and it’s even arguable that Watson is as good as a typical oncologist.
The M.D. Anderson experience
The M.D. Anderson Cancer Center was, along with MSKCC, one of the early adopters of Watson. Its experience with the project is another cautionary note that shows what can happen when not enough skepticism is applied to a project and how a project like Watson can turn into a massive boondoggle. This was revealed when the partnership between M.D. Anderson and IBM basically fell apart earlier this year:
According to a blistering audit by the University of Texas System, the cancer center grossly mismanaged its splashy program with IBM, which started back in 2012. The program aimed to teach Watson how to treat cancer patients and match them to clinical trials. Watson initially met goals and impressed center doctors, but the project hit the rocks as MD Anderson officials snubbed their own IT experts, mishandled about $62 million in funding, and failed to follow basic procedures for overseeing contracts and invoices, the audit concludes.
IBM pulled support for the project back in September of last year. Watson is currently prohibited from being used on patients there, and the fate of MD Anderson’s partnership with IBM is in question. MD Anderson is now seeking bids from other contractors who might take IBM’s place.
As Matt Herper noted over at Forbes:
Usually, companies pay research centers to do research on their products; in this case, MD Anderson paid for the privilege, although it would have apparently also owned the product. This was a “very unusual business arrangement,” says Vinay Prasad, an oncologist at Oregon Health & Science University.
According to the audit report, Chin went around normal procedures to pay for the expensive undertaking. The report notes “a consistent pattern of PwC fees set just below MD Anderson’s Board approval threshold,” and its appendix seems to indicate this may have occurred with payments to IBM, too.* She also didn’t get approval from the information technology department.
Yes, it was that bad.
Hype and hubris in AI: Beyond IBM
It’s very clear that AI will play an increasingly large role in medicine. The massive amount of genomic data being applied to “personalized medicine,” or, as it’s now more commonly called, “precision medicine,” basically demands it because no human can sift through the terabytes and petabytes of genomic data without assistance to find patterns that can be exploited in treatment. What I do have a problem with is hype, and IBM is clearly incredibly guilty of massively hyping its Watson product before it was ready for prime time, apparently not recognizing just how difficult it would be to train Watson to align company hype with scientific reality.
One way to think about it is to consider how machine learning works, how AI is trained to recognize patterns, come to conclusions, and make recommendations. In other words, how can a machine go beyond human-curated data and recommendations? It’s incredibly difficult:
To understand what’s slowing the progress, you have to understand how machine-learning systems like Watson are trained. Watson “learns” by continually rejiggering its internal processing routines in order to produce the highest possible percentage of correct answers on some set of problems, such as which radiological images reveal cancer. The correct answers have to be already known, so that the system can be told when it gets something right and when it gets something wrong. The more training problems the system can chew through, the better its hit rate gets.
That’s relatively simple when it comes to training the system to identify malignancies in x-rays. But for potentially groundbreaking puzzles that go well beyond what humans already do, like detecting the relationships between gene variations and disease, Watson has a chicken-and-egg problem: how does it train on data that no experts have already sifted through and properly organized? “If you’re teaching a self-driving car, anyone can label a tree or a sign so the system can learn to recognize it,” says Thomas Fuchs, a computational pathologist at Memorial Sloan-Kettering, a cancer center in New York. “But in a specialized domain in medicine, you might need experts trained for decades to properly label the information you feed to the computer.”
That’s the bias introduced by relying on MSKCC physicians. It’s a bias that’s much worse than it needs to be because of how IBM relies on one institution and one relatively small group of physicians to train Watson, but, in fairness, it is an unavoidable bias at this stage in the development of an AI. The problem, as it all too often is, is arrogance. IBM appears to have vastly underestimated the challenge in moving beyond the training dataset (as it’s often called in studies like this), for which the answers are known in advance to the computer’s analysis, to the validation dataset (for which the answer is not known in advance).
None of this is to say that AI won’t eventually make a major contribution to the treatment of cancer and other diseases. Rather, it’s just to say that we’re nowhere near there yet. Moreover, IBM is no longer the only player in this game, as has been noted:
Since Watson’s “Jeopardy!” demonstration in 2011, hundreds of companies have begun developing health care products using artificial intelligence. These include countless startups, but IBM also faces stiff competition from industry titans such as Amazon, Microsoft, Google, and the Optum division of UnitedHealth Group.
Google’s DeepMind, for example, recently displayed its own game-playing prowess, using its AlphaGo program to defeat a world champion in Go, a 3,000-year-old Chinese board game.
DeepMind is working with hospitals in London, where it is learning to detect eye disease and speed up the process of targeting treatments for head and neck cancers, although it has run into privacy concerns.
Meanwhile, Amazon has launched a health care lab, where it is exploring opportunities to mine data from electronic health records and potentially build a virtual doctor’s assistant.
A recent report by the financial firm Jefferies said IBM is quickly losing ground to competitors. “IBM appears outgunned in the war for AI talent and will likely see increasing competition,” the firm concluded.
And:
But the “cognitive computing” technologies under the Watson umbrella aren’t as unique as they once were. “In the data-science community the sense is that whatever Watson can do, you can probably get as freeware somewhere, or possibly build yourself with your own knowledge,” Claudia Perlich told Gizmodo, a professor and data scientist who worked at IBM Watson Research Center from 2004 to 2010 (at the same time Watson was being built), before becoming the chief scientist at Dstillery, a data-driven marketing firm (a field that IBM is also involved with). She believes a good data-science expert can create Watson-like platforms “with notably less financial commitment.”
None of this is also to say that IBM is alone in its hubris. It’s not. This hubris is shared by many tech companies, particularly those working on computing and AI. For instance, last year Microsoft was roundly (and properly) mocked for its claim that it was going to “solve cancer” in a decade based on this idea:
The company is working at treating the disease like a computer virus, that invades and corrupts the body’s cells. Once it is able to do so, it will be able to monitor for them and even potentially reprogramme them to be healthy again, experts working for Microsoft have said.
The company has built a “biological computation” unit that says its ultimate aim is to make cells into living computers. As such, they could be programmed and reprogrammed to treat any diseases, such as cancer.
And:
“The field of biology and the field of computation might seem like chalk and cheese,” Chris Bishop, head of Microsoft Research’s Cambridge-based lab, told Fast Company. “But the complex processes that happen in cells have some similarity to those that happen in a standard desktop computer.”
As such, those complex processes can potentially be understood by a desktop computer, too. And those same computers could be used to understand how cells behave and to treat them.
Yes, there is a resemblance between cancer and computing in much the same way that counting on your fingers resembles a supercomputer. The hubris on display was unbelievable. My reaction was virtually identical to Derek Lowe’s, only more so. Indeed, he perfectly characterized the attitude of many in tech companies working on cancer as a “Gosh darn it fellows, do I have to do everything myself?” attitude. Yes, those of us in cancer research and who take care of cancer patients do tend to get a bit…testy…when someone waltzes onto the scene and proclaims to breathless headlines that he’s going to solve cancer in a decade because he has an insight that you stupid cancer biologists never thought of before: The cell is just a computer, and cancer is like a computer virus.
But I digress. I only mention Microsoft to demonstrate that IBM is not alone when it comes to tech companies and hubris about cancer. In any event, I made an analogy to Donald Trump earlier in this post. I was not surprised to find this article making a similar analogy:
“IBM Watson is the Donald Trump of the AI industry—outlandish claims that aren’t backed by credible data,” said Oren Etzioni, CEO of the Allen Institute for AI and former computer science professor. “Everyone—journalists included—know[s] that the emperor has no clothes, but most are reluctant to say so.”
Etzioni, who helps research and develop new AI that is similar to some Watson APIs, said he respects the technology and people who work at Watson, “But their marketing and PR has run amok—to everyone’s detriment.”
Former employees who worked on Watson Health agree and think the way that IBM overhypes Watson for Oncology is especially detrimental. One former IBM Watson Health researcher and UX designer told Gizmodo of a time they shadowed an oncologist at a cancer center that has partnered with IBM to train Watson for Oncology. The designer claims they spoke with patients who had heard of Watson and asked when it could be used to help them with their disease. “That was actually pretty heartbreaking for me as a designer because I had seen what Watson for Oncology really is and I was very painfully aware of its limitations,” the designer said. “It felt very bad and it felt like there was real hope that had been served by IBM marketing that could not be supported by the product I know.”
That’s part of the problem. Patients see the hype and believe it. They then want what IBM is offering, even if it is not ready for prime time. Watson Health general manager Deborah DiSanzo even said, “We’re seeing stories come in where patients are saying, ‘It gave me peace of mind,'” and concluded, “That makes us feel extraordinarily good that what we’re doing is going to make a difference for patients and their physicians.” Patient peace of mind is important, but not as important as actually producing a product that demonstrably improves patient outcomes.
Again, don’t get me wrong. AI is very likely to be quite important in years (more likely decades) to come in health care. Maybe one day it will lead to a real Tricorder, just like in the original Star Trek series. It’s just not there yet. I suspect that Watson will not be the last medical AI effort to fail to live up to its early grandiose claims.

   Cell Phones and Cancer

   New Data on Cell Phones and Cancer
Steven Novella 
Link
This is a science and medicine story we have been following for a while – out of personal and scientific interest, and the need to correct confused or misleading new reporting on the topic. Are cell phones linked to an increased risk of brain cancer or other tumors? New data is reassuring.
David Gorski and I have both written on this topic. To give a quick summary, there is no convincing data to link cell phone use and brain cancer. Epidemiological studies have not found an increase in the incidence of brain cancer following the widespread adoption of cell phones in the mid 1990s – as one would expect if there were a causal relationship. Further, large scale studies have not found any consistent correlation between cell phone use and brain cancer.
It is clear from the literature that there is no measurable increased risk from short term cell phone use – less than 10 years. There is no evidence to conclude that there is a risk from long term use (> 10 years) but we do not yet have sufficient long-term data to rule out a small risk. Further, the data is somewhat ambiguous when it comes to children – still no convincing evidence of a link, but we cannot confidently rule out a link.
Further, the plausibility of a connection is quite low. While electromagnetic radiation from cell phones is a physical mechanism that can potentially have an effect, it is generally too weak to have any plausible biological effect. This by itself is very reassuring, but still cannot rule out a possible effect from cell phones through some as yet undiscovered biological effect of cell phone radiation.
So the claim for a link between cell phones and brain cancer has low plausibility, good epidemiological evidence for a lack of association for less than 10 years of exposure in adults, and equivocal but generally negative evidence for children and greater than 10 years of exposure in adults. Longer term studies will hopefully address these latter issues more definitively.
With that as background, we have the newly published results of the Interphone study. This is an epidemiological study involving 13 different countries looking for any correlation between cell phone use and two common types of brain tumors – glioma and meningioma. Parts of this data have been previously published, but this is now the first time data from all 13 participants has been published – including “2,708 people with glioma, 2,409 with meningioma and 7,658 matched controls.”
The overall findings of the study were negative – no clear association between cell phone use and gliomas or meningiomas. However, there were two interesting subgroup findings. For those with regular use of cell phones there was a 20% decrease in risk of tumors compared to those without any use of cell phones.
As implausible as it is that cell phones cause brain cancer, it is even more implausible that they protect against cancer. So, it’s possible this is just noise in the data. However, epidemiologist Anthony Swerdlow, who was involved in the UK arm of the study, gives another explanation:
“We have evidence that the people who refused to be controls are people who didn’t use phones. This meant that the control group, consisting of people without cancer, was rather skewed, appearing to have more mobile-phone use than would be found in a representative sample from the general population. “The controls were over-represented with phone users.”
These results, therefore, were very likely due to a systematic bias in the data – such are the perils of epidemiology.
The other correlation found was a 40% increase in risk of brain tumor among the top 10% of mobile phone users. This is an interesting result, because it suggests a dose response effect. However, this result is also questionable and may be due to methodology. It turns out that many of the people answering the survey used in the study reported improbable amounts of cell phone use – such as 12 hours per day. It was therefore considered to be an unreliable method of determining cell phone use. Number of calls made per day gave more realistic results, and therefore may be easier for people to understand or remember. When the data is viewed with number of calls made instead of time per day, the correlation with brain tumors disappears.
So at the end of all this, we are pretty much where we started. There is still no evidence to link cell phone use and cancer. This data has a few quirks in it, but in the final analysis is probably negative. So we can be a bit more confident in the lack of correlation – or we can think of it as shrinking a bit further the upper limit of any possible effect from cell phone use.
The study does extend the duration of our data somewhat as well – to about 15 years. But we still lack long term data for exposure greater than 15 years.
Unfortunately, the wrinkles in this study lead to some confusion among the media. While reporting this study it is possible to emphasize the increased risk among the highest cell phone users, while either missing or glossing over the fact that further analysis shows this correlation is probably not real. For example, Science News reports: “Interphone study finds hints of brain cancer risk in heavy cell-phone users.” Many other outlets repeated the headline that the study was “inconclusive.”
Conclusion:
Cell phones are an increasingly common tool of modern society. It is certainly necessary and valid to carefully study their safety and monitor for possible adverse health outcomes from their regular use. I am reassured by the current evidence, however, that there is no large risk from cell phones. There is either no risk or a very small long term risk.
Consider, however, that you are probably at greater risk of premature death from using your cell phone while driving, or from driving at all. So as individuals we always need to balance a small risk against the convenience of new technology. The better data we have and the better we understand that data – the better we will be able to make informed decisions for ourselves.

   Critique of “Risk of Brain Tumors from Wireless Phone Use”
Lorne Trottier
Link
Following my recent critique here of the book Disconnect by Devra Davis, about the purported dangers of cell phones to health, David Gorski asked me to comment on a recently published “review article” on the same subject. The article is entitled “Risk of Brain Tumors from Wireless Phone Use” by Dubey et al [1] published in the J. Comput Assist Tomography. At the outset, the same question occurred to both of us: what is a “review article” about cell phones and brain tumors doing in a highly technical journal dedicated to CT scans and CT imaging? While we are both still guessing about the answer to this question, we agreed that the article itself is a hodge-podge of irrational analysis.
As you might surmise, Dubey and his Indian co-authors come to the conclusion that “that the current standard of exposure to microwave during mobile phone use is not safe for long-term exposure and needs to be revised.” But within the conclusion there is also the following: “There is no credible evidence from the Environmental Health and Safety Office (I presume in India) about the cause of cancer or brain tumors with the use of cell phones. It is illogical to believe that evidence of unusual brain tumors is only because of hundred’s of millions of people using cell phones worldwide.” What?! These are opposite and contradictory statements. The main body of the article includes a lot more instances of such inconsistency.
Dubious Sources, References, & Studies
Another highly dubious feature of this review article is the nature of its sources. Many of its references are merely news reports, not scientific articles and some even come from pseudo-scientific web sites. For example, figure 1 purports to illustrate cell phone radiation penetrating a 5 year old, 10 year old, and adult head. It purports to show that cell phone radiation penetrates a child’s head much more deeply than an adult’s. The source given for this image is www.environmentalhealthtrust.org — the web site of none other than Devra Davis! The main feature on this web site is the promotion of her book Disconnect!
This particular image is one that is frequently used by alarmists. The original source is a 1996 paper by Gandhi et al [2]. This paper has long been discredited and the image is simply wrong. Gandhi himself published an update in another paper in 2002 [3] with quite different results. Numerous papers have been published examining the issue of cell phone penetration of the head. The consensus is that RF absorption in children’s heads is not greater than adults and is well within exposure limits [4].
One particularly dubious reference is to a book by the notorious industry gadfly George Carlo that even Devra Davis treats with caution. A number of the scientific papers that are listed are of dubious quality and/or have failed to be reproduced in follow up studies. For example one of the sections is entitled “Male fertility damaged by radiation.” Orac has written a critique on this hypothesis in which he takes apart one of the studies cited by Dubey et al. Male fertility is also one of the principle subjects in the book Disconnect, which I rebutted in my review on SBM. To summarize the three papers cited by Dubey et al. are of poor quality and/or have failed attempts at replication. The authors do not list or comment on the negative studies that contradict the one’s they listed.
Other statements and references that have been contradicted by follow up studies include claims that:
“The RF emissions from cell phones have been shown to damage genetic material in blood cells”
“Long-term cell phone use can increase the likelihood of being hospitalized for migraines and vertigo by 10% to 20%”
“Cell phone radiation damages DNA, an undisputed cause of cancer”
“Cell phone radiation has been shown to cause the blood-brain barrier to leak”
The fact that each one of these “findings” has failed replication attempts in rigorous follow up studies is not even mentioned.
In the conclusion, Dubey et al. makes the bold claim that: “Moreover it was repeatedly confirmed that the radiation from base stations is harmful to health. The existing ICNIRP and FCC exposure limits are based on a false premise that only thermal effects cause harm.” Here they are referring to cellular telephone base stations. But no references are provided to support either of these assertions.
Industry Funding
Figure 2 in the article is a chart that purports to show industry bias in brain tumor research. This establishes the principle theme of this article: the claim that most of the studies on brain cancer and cell phones with negative results have been funded by industry. This is not a scientific argument, it is a conspiracy theory. Other posts on SBM have observed that conspiracy theories are a favorite tactic of purveyors of pseudo-science. This “industry funding” theory is also the main thesis of the book Disconnect and alarmist cell phone web sites. The source given for this “industry funding bias” chart is the web site www.psrast.org/mobileng/mobilstarteng.htm. The organization behind this web site is a group called: “Physicians and Scientists for Responsible Application of Science and Technology (PSRAST).” This web page is full of references to the usual unscientific alarmist material found throughout the Internet.
Dubey et al. do not mention the generally accepted alternative explanation for the dichotomy in positive vs. negative studies. First there is the issue of publication bias [5]. If a researcher makes an initial positive finding, he is more likely to rush his results to publication. An initial negative finding is less likely to ever be published. Rigorous studies with all necessary controls and a large number of trials are more expensive to conduct. It is important to note that virtually all such follow-up replication studies have been negative.
An extremely important fact that is not discussed by Dubey et al. is that expert reviews by virtually all of the industrialized world’s public health organizations have come to the same conclusion as the World Health Organization “that current evidence does not confirm the existence of any health consequences from exposure to low level electromagnetic fields.” One presumes that they have also been either co-opted or duped by this industry funded conspiracy.
Hardell vs. Interphone
By far the largest and most important case control study on the possible link between cell phones and brain cancer was the Interphone study [6]. The Interphone study was an international collaboration involving 13 countries which was coordinated by the International Agency for Research on Cancer (IRAC) which is part of the WHO. The conclusion of Interphone was “Overall, no increase in risk of glioma or meningioma was observed with use of mobile phones. There were suggestions of an increased risk of glioma at the highest exposure levels, but biases and error prevent a causal interpretation. The possible effects of long-term heavy use of mobile phones require further investigation.”
Dubey et al. characterize the important Interphone study as follows: “This nonblinded, interview-based, substantially wireless industry-funded case-control study….” They are clearly discounting Interphone with the “industry funding” conspiracy theory. They compare the Interphone studies with another set of case control studies conducted by the Swedish researcher Lennart Hardell. “The 2 sets are the industry-funded Interphone studies and the independently funded Swedish studies reported by Hardell team.” Dubey et al. make a number of additional dubious criticisms of Interphone. To support these criticisms they list a number of letters to a journal including a couple by Hardell. Much of this criticism boils down to splitting hairs over who did a better job of controlling for “recall bias.”
Those of you who are regular readers of SBM may have seen a post by David Gorski commenting on another cell phone cancer review article in which the work of Hardell was given prominence. Gorski had this to say about Hardell: “Whenever one group of researchers keeps finding a result that no other group seems able to replicate or that otherwise disagrees with what everyone else is finding, that’s a huge red flag for me. Remove those studies, and even the wisp of a hint of a shadow of the association between cell phone use and cancer found in this study disappears. I’d have a lot more confidence in this seeming association in “high quality” studies if the association didn’t depend upon a single researcher and if this researcher was not also known for being an expert witness in lawsuits against mobile phone companies.” It would appear the Hardell himself has a conflict of interest.
A pair of review articles on cell phone brain cancer studies in the journal Epidemiology [7, 8] had this to say about Hardell: “One notable feature of the literature to date is that authorship by Lennart Hardell is associated with finding an adverse effect of mobile telephone use for several different endpoints. The discrepancy between the findings of Hardell and those of other scientists was striking enough that Ahlbom et al presented some of their summary findings in 2 forms, including and excluding the studies by Hardell and colleagues.”
Case control studies such as those conducted by Hardell and Interphone involve recruiting subjects who have been diagnosed with brain cancer. The subjects respond to a questionnaire in which they are asked to recall – purely from memory – how much they had used their cell phones over the years. The cancer patients are matched with a healthy control group who respond to the same questionnaire. If the study shows that people who have brain cancer used cell phones more that the controls, the conclusion is that cell phone use increases the risk of brain cancer.
But case control studies such as this suffer from a number of limitations, the most serious being “recall bias.” Brain cancer patients are certainly aware of the theory that cell phone use may lead to brain cancer. This theory has been in the news for years. Such patients are likely to over report past cell phone use when completing a questionnaire. Memory is notoriously unreliable, and it becomes more so over time. I don’t know about you, but I could only make a wild guess about how much I used my cell phone 10 years ago. This simple fact alone makes it hard to interpret conflicting studies.
Dubey et al. seem to acknowledge the issue of recall bias, but their treatment of the issue is inconsistent and contradictory. The authors even discount one of Hardell’s studies with the following: “this finding is probably explained by recall bias, with patients with glioma systematically overreporting use on the same side as their tumor and consequently underreporting use on the opposite side.” Yet despite this admission, Dubey et al. accept all of the Hardell studies and include them in their meta-analysis. They give greater credence to Hardell than Interphone and conclude: “The meta-analysis shows that long-term cell phone use can approximately double the risk of developing a glioma or an AN (acoustic neuroma) in the more exposed brain hemisphere.” This opposite to the conclusion of mainstream scientists as reflected in papers such as Ahlbom et al. [8].
What about incidence rates?
Perhaps the simplest and most compelling argument against any possible cell phone brain cancer association is the fact that brain cancer incidence rates have remained unchanged since the introduction of cell phones. Dubey et al. dismiss this evidence with a one sentence section entitled: “Outdated Central Brain Tumor Registry of the United States Tumor Data” and the statement that “the most recent data are already at least 4 years outdated.” The authors reference only a couple of older studies, and ignore the most recent ones from Europe, the US, and the UK that show no increase in brain cancer incidence up to 2003, 2006, and 2007 respectively [9, 10 11]. Furthermore, the data in the US & UK studies are more recent than any of Hardell’s studies!
Conclusion
The Dubey et al. review article is sprinkled with statements such as:
“Most studies have not found any association between cell phone use and the development of head tumors”
“There is generally a lack of convincing and consistent evidence of any effect of exposure to RF field on risk of cancer”
“Although some positive findings have been reported, so far the totality of epidemiological evidence (meningioma) does not demonstrate an increase in risk of meningiomas related to mobile phone use”
“There was no association between the use of cellular or cordless phones and salivary gland tumors found, although few studies reported for long-term heavy use”
As I wrote at the beginning of this review: these statements are opposite and contradictory to the overall conclusion of Dubrey et al. One supposes that the authors are trying to give the appearance of “balance.” However they reconcile these contradictory findings not with a scientific weight of evidence approach, but with their “industry funding” conspiracy theory. This brings me to add an additional question on top of our original query about what an article about cell phones is doing in a specialized journal on CT imaging. How did an article that promotes Internet conspiracy theories with a hodge-podge of irrational analysis even get published at all?
About the Author
Lorne Trottier is a co-founder of Matrox Ltd. and holds B. Eng., M. Eng., and Doctorate (honoris causa) degrees from McGill University. He has had a lifelong passion for science and technology and believes in the importance of combating pseudoscience. He is President of the Board of the Montreal Science Center Foundation, and is also a board member of a number of science outreach organizations including the NCSE, CFI Canada, and The Planetary Society. Trottier sponsors the annual Trottier Symposium at McGill University that deals with a variety of science topics of interest to the public, such as Confronting Pseudoscience. Trottier also maintains a web site on the subject of EMF and Health.
References
     1.  Risk of Brain Tumors from Wireless Phone Use J Comput Assist Tomogr Vol 4 No 6,Nov/Dec 10. doi: 10.1097/RCT.0b013e3181ed9b54
     2.  Gandhi O P, Lazzi G and Furse CM. Electromagnetic absorption in the human head and neck for mobile telephones at 835 and 1900 MHz IEEE Trans. Microw. Theory Tech. 44:1884–97, 1996. doi: 10.1109/22.539947
     3.  Gandhi O and Kang G. Some present problems and a proposed experimental phantom for SAR compliance testing for cellular telephones at 835 and 1900 MHz Phys. Med. Biol. 47:1501–18, 2002. doi: 10.1088/0031-9155/47/9/306
     4.  Beard et al. Comparisons of Computed Mobile Phone Induced SAR in the SAM Phantom to That in Anatomically Correct Models of the Human Head, IEEE Trans. Electro Comp, Vol. 48, No. 2, May 2006. doi: 10.1109/TEMC.2006.873870
     5.  Vijayalaxmi et al. Genetic Damage in Mammalian Somatic Cells Exposed to Radiofrequency Radiation: A Meta-analysis of Data from 63 Publications Radiation Research 169, 561–574, 2008 doi: 10.1667/RR0987.1
     6.  Cardis et al. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study Int’l Journal of Epidemiology 2010; 1–20. doi: 10.1093/ije/dyq079
     7.  Rothman. Health Effects of Mobile Phones Epidemiology Vol 20 No 5, Sept 2009. doi: 10.1097/EDE.0b013e3181aff1f7
     8.  Ahlbom et al. Epidemiologic Evidence on Mobile Phones and Tumor Risk Epidemiology Vol 20 No 5, Sept 2009. doi: 10.1097/EDE.0b013e3181b0927d
     9.  Inskip et al. Brain cancer incidence trends in relation to cellular telephone use in the United States, Neuro Oncol 12(11): 1147-1151 , 2010. doi: 10.1093/neuonc/noq077
     10.  Deltour et al. Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974–2003, J Natl Cancer Inst,101(24):1721–4, . 2009 Dec 16. doi: 10.1093/jnci/djp415
     11.  Vocht et al. Time Trends (1998–2007) in Brain Cancer Incidence Rates in Relation to Mobile Phone Use in England Article first published in Bioelectromagnetics online 28 Jan 2011. doi: 10.1002/bem.20648

Are Cell Phones a Possible Carcinogen? An Update on the IARC Report
Lorne TrottieronApril 2, 2012
Link
EDITOR’S NOTE: Because I am at the annual meeting of the American Association for Cancer Research in Chicago, between the meetings, working on a policy statement, working on a manuscript, and various other miscellaneous tasks, I alas was unable to produce a post worthy of the quality normally expected by SBM readers. Fortunately, Lorne Trottier, who’s done a great job for us twice before, was able to step in again with this great post about “safe” cell phone cases. Speaking of the manufactroversy over whether cell phone radiation causes brain cancer, there’s a session at the AACR that I’ll have to try to attend entitled Do Cell Phones Cause Brain Cancer? Who knows? It might be blogging material. I also might post something later that those of you who know of my not-so-super-secret other blog might have seen before. However, I often find it useful to see how a different audience reacts. Now, take it away, Lorne…

In May of last year, the International Agency for Research on Cancer (IARC) issued a press release (1) in which it classified cell phones as Category 2B, which is “possibly carcinogenic to humans“. This ruling generated headlines world wide. Alarmist groups seized on it and now regularly cite this report to justify their concerns for everything ranging from cell phones to WiFi and smart meters.
IARC maintains a list of 269 substances in the 2B category, most of which are chemical compounds. A number of familiar items are also included in this list: coffee, pickled vegetables, carbon black (carbon paper), gasoline exhaust, talcum powder, and nickel (coins). The IARC provides the following definition of the 2B category (2  P 23): “This category is used for agents for which there is limited evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals. It may also be used when there is inadequate evidence of carcinogenicity in humans but there is sufficient evidence of carcinogenicity in experimental animals“.
The Category 2B “possible carcinogen” classification does not mean that an agent is carcinogenic. As Ken Foster of the University of Pennsylvania pointed out to me. “Their conclusion is easy to misinterpret.” “Saying that something is a “possible carcinogen” is a bit like saying that someone is a “possible shoplifter” because he was in the store when the watch was stolen. The real question is what is the evidence that cell phones actually cause cancer, and the answer is — none that would persuade a health agency.”
None the less this ruling was highly controversial. Expert groups of most of the world’s major public health organizations have taken the same position as the European Commission’s Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) which had stated that (3  P 8): “It is concluded from three independent lines of evidence (epidemiological, animal and in vitro studies) that exposure to RF fields is unlikely to lead to an increase in cancer in humans“. The representative of the US National Cancer Institute walked out of the IARC meeting before the voting. The NCI issued a statement (4) quoting other studies stating that: “overall, cell phone users have no increased risk of the most common forms of brain tumors — glioma and meningioma“.
Immediately following the IARC decision the WHO issued a reassuring new Fact Sheet (5) on mobile phones and public health: “A large number of studies have been performed over the last two decades to assess whether mobile phones pose a potential health risk. To date, no adverse health effects have been established as being caused by mobile phone use”. Since this controversial IARC classification, several new papers have been published that substantially undermine the weak evidence on which the IARC based its assessment.
The evidence that IARC cited to support its assessment was poor to begin with. Their initial press release (1) was followed by a more complete report that was published in the July 1, 2011 issue of the Lancet Oncology as well as online (6). In this article, I will review the evidence cited by IARC in support of its conclusion. I will also review updates from new papers published over the past year that cast further doubt on IARC’s conclusion.
Brain cancer incidence rates
Brain cancer is one of the rarer forms of cancer. In Canada, it ranks as #15, well below the leading cancers such as lung, breast, and prostate. There are more than 5 billion cell phones in the world. The fact that brain cancer incidences rates have remained flat  in the US and elsewhere is one of the simplest and strongest indicators that cell phones do not cause cancer. Yet in the Lancet article, IARC dismisses the value of studies of brain cancer incidence rates with the statement that they “have substantial limitations because most of the analyses examined trends until the early 2000s only“. This is surprising, since at the time of IARC’s assessment there were already a couple of studies that found flat cancer incidence rates up to the end of 2006 in the US (7) and 2007 in the UK (8). These important papers are certainly past the “early 2000s”.
In the same month as the IARC assessment, a new study was published online in Environmental Health Perspectives that examined brain cancer incidence in Sweden up to the end of 2009 (9). Fig 1 of the Supplemental Material (see below) shows that brain cancer incidence rates in Sweden were essentially flat up to 2009. Furthermore, in the past year two more studies have been released which looked at cancer incidence rates up to 2008 in the Nordic countries (10) and the US (11) respectively. All of these papers show no increase in brain cancer. Thus the IARC statement dismissing the flat brain cancer incidence rate statistics because they: “examined trends until the early 2000s only” is simply not accurate. The fact that brain cancer rates are unchanged to date continues to be the simplest and strongest indicator that cell phones do not cause cancer.
Fig 1: Incidence Rates of Glioma in Sweden 1970 – 2009 (from 9)
Epidemiologic studies
In making its assessment, IARC relied primarily on two epidemiological studies including Interphone (12), and the Swedish group of Hardell et al (13). It is important to examine these studies in greater detail in order to assess the strengths and weaknesses of the evidence on which IARC based its assessment. Some new studies also shed important new light on this evidence.
There are two basic kinds of such studies: case control and cohort studies. In the case control studies on cell phones, subjects diagnosed with brain cancer respond to a questionnaire about their past history of cell phone use. Their responses are compared with those of controls who do not have brain cancer. The results are tabulated to produce an OR or “odds ratio” of developing brain cancer as a function of past use. An OR of 1 means no risk. An OR of 2 means a 2X risk. Case control studies suffer from a number of limitations, of which the most serious is “recall bias”. The results are entirely dependent on the accuracy of memory of brain cancer patients and control subjects regarding their past cell phone use.
The occurrence of recall bias, in which brain cancer patients overestimate past cell phone use in comparison to controls, has been documented in a recent study (14). “In conclusion, there was little evidence for differential recall errors overall or in recent time periods. However, apparent overestimation by cases in more distant time periods could cause positive bias in estimates of disease risk associated with mobile phone use.”
Cohort studies are another type of epidemiologic study. Cohort studies follow a population of cell phone users over a period of time and monitor how many develop brain cancer. Cohort studies are generally more robust than case control studies because exposure is more reliably assessed, using records rather than individual memory. A series of “retrospective” cohort studies were done in Denmark (15, 16). The Danish studies are “retrospective” because they used existing cell phone records to establish the number of years subjects had been using their phones. Accessing government medical records, they determined which cell phone users developed brain cancer. From this they were able to assess if the risk of developing brain cancer increased with the number of years of cell phone use. These studies have the advantage of not depending on memory. They are limited however by the uncertainty of whether the subscriber was the actual user, and the necessary elimination of business phones (the names of individual business users were not available). The initial studies (15) involved 420,095 subjects, some of whom had used cell phones for up to 21 years. No cancer risk was found.
The Danish group released another study (16) in Oct 2011 after the IARC assessment (1 ,6). In this follow up study the number of person years of long term users was much higher than any previous study. “We followed up the mobile phone subscriber study to 2007, with a focus on tumours of the central nervous system. Longer follow-up increased the numbers of person years for subscribers, particularly in long term subscribers (≥10 years), in whom the total of person years under risk increased from 170,000 to 1.2 million”. Their conclusion for long term users was: “When restricted to individuals with the longest mobile phone use—that is, ≥13 years of subscription—the incidence rate ratio was 1.03 (95% confidence interval 0.83 to 1.27) in men and 0.91 (0.41 to 2.04) in women”
Because this series of studies was based on hard data, it is generally considered quite solid. Surprisingly, IARC dismissed these studies with the statement that: “In this study, reliance on subscription to a mobile phone provider, as a surrogate for mobile phone use, could have resulted in considerable misclassification in exposure assessment”. The NCI (4) took the opposite view of IARC by saying this about these studies: “Furthermore, a large population-based cohort study in Denmark has found no evidence of increased risk of brain tumors”.
The Hardell et al. studies
In making its assessment, IARC (1 & 6) relied primarily on case control studies including Interphone (12), and the Swedish group of Hardell et al (13). “A Swedish research group did a pooled analysis of two very similar studies of associations between mobile and cordless phone use and glioma, acoustic neuroma, and meningioma”. Most epidemiologists consider that Hardell is an outlier in the scientific literature (20).The Hardell study (13) which IARC used in its risk assessment appears to be a rehash of a pair of similar papers published in 2006 (17 & 18). It is curious the Hardell timed the release of this “new” study just before the IARC meeting. In other words, Hardell repackaged a couple of old papers based on data collected in 2003, originally published in 2006, and then republished in 2011. At the time of the original publication, Hardell’s “pooled analysis” studies generated something of a media sensation. A number of expert groups felt compelled to comment on and critique these studies.The FDA issued the following statement: “The FDA received numerous media inquires about a recently published paper (Pooled analysis of two case–control studies on use of cellular and cordless telephones and the risk for malignant brain tumors diagnosed in 1997–2003by Hardell et al.)…. The results reported by Hardell et al. are not in agreement with results obtained in other long term studies. Also, the use of mailed questionnaire for exposure assessment and lack of adjustments for possible confounding factors makes the Hardell et al. study design significantly different from other studies. These facts along with the lack of an established mechanism of action and absence of supporting animal data make it difficult to interpret Hardell et al. findings.The same studies were also criticized by the EMF-NET which was established by the Institute for Health and Consumer Protect of the European Commission (19). Their report states that: “The results of the pooled study by Hardell et al. differ from most previously published studies, including the recently published studies with large numbers of long-term users”. The SCENIHR also criticized these studies (3, P 17): “However, both studies are non-informative because of inappropriate exclusion criteria and combination of studies”.
A 2009 paper by the Ahlbom et al on behalf of ICNIRP (International Commission for Non-Ionizing Radiation Protection) Standing Committee on Epidemiology (20) did a systematic review of the epidemiologic studies of cell phones and cancer. This paper had this to say about Hardell’s studies: “The studies by Hardell et al. are particularly problematic because of variation across their publications in the exact constitution of case groups, criteria for exclusion, exposure definitions, and the selection of results for presentation in the multiple overlapping publications….all studies found risk estimates close to or below unity, except the 2  most recent studies by Hardell et al., where up to 4-fold risk increases were reported. It is interesting to note that at the meeting where the IARC made its assessment, Alhbom was removed because he served as a board member of his brother’s telecommunications company. But Hardell remained and was permitted to vote despite the fact that he has testified as an “expert witness” in litigation by brain cancer patients against cell phone companies and has probably earned fees doing so. In any case, he got to vote on the merits of his own paper.
Despite all these criticisms, IARC used Hardell’s rehashed paper as primary evidence in its assessment. “Although both the INTERPHONE study and the Swedish pooled analysis are susceptible to bias—due to recall error and selection for participation—the Working Group concluded that the findings could not be dismissed as reflecting bias alone, and that a causal interpretation between mobile phone RF-EMF exposure and glioma is possible”. IARC could not dismiss Hardell’s results on the basis of recall bias even though studies such as (14) have shown that this is a likely source of error.
Over the years Hardell et al. have published more epidemiologic studies on cell phones than any other researcher. Virtually all his studies have used the same methodology of mailed questionnaires to establish the level of cell phone use. He has presented his findings in many different ways including by type of telephone (analog and digital cell phones as well as cordless phones), brain cancer type, cumulative hours of use, and number of years of use. Virtually every one of his studies has concluded that cell phones (and wireless and cordless phones) increase the risk for brain cancer.
Testing Hardell
If Hardell is correct in his finding that cell phone use causes brain cancer, this should cause an increase in brain cancer incidence rates. The fact that these rates have remained flat over the 25 years since cell phones were introduced and the roughly 15 years since use became widespread and common in the population can now be used to test some of his findings. In the paper cited by IARC (13), the Hardell finding that cancer risk increases with the number of years is easy to test. Table II (reproduced below) of Hardell’s paper (13) shows cancer risk increasing over the three latency periods listed. The highest risk is for >10-year latency with an OR of 2.1, 2.5 and 1.6 for wireless phones, mobile phones and cordless phones respectively.
Table II  From (13): Pooled analysis of case-control studies on malignant brain tumours and the use of mobile phone; Hardell et al.;  Intl Journal Oncology 2011 38: 1465-1474
Fig 1 of Swerdlow’s (9) Supplementary Data that I referred to earlier shows that brain cancer incidence rates in Sweden were essentially flat up to 2009. Fig 2 below shows the history of cell phone subscriptions in Sweden from 1987 — 2010. This chart shows that in 1999 (10 years before 2009), approximately 50% of the population of Sweden had a cell phone. Using Hardell’s finding that >10 year mobile cell phone users have a 2.5 OR, simple arithmetic predicts that brain cancer incidence should increase by 75%:(50% pop nonuser x OR 1) + (50% pop cell phone users x OR 2.5) = Average OR 1.75.But there is no change. It is interesting to note that Hardell also conducted his studies in Sweden – the same country as Swerdlow’s data. Hardell’s finding on users >10 years is flatly contradicted.
Hardell’s case control studies as INTERPHONE were entirely dependent on the memory of people suffering from brain cancer. The IARC report states that Hardell used “Self-administered mailed questionnaires were followed by telephone interviews to obtain information on the exposures and covariates of interest.” As we have noted “recall bias” (14) is a major potential source of error in this these studies. The hard data from the Swedish cancer incidence rates and cell phone subscriptions is reliable and it flatly contradicts Hardell.
Fig 2: Cell phone subscriptions in Sweden 1987 – 2010 (from 9)
Since the publication of the paper by Swerdlow et al. (9) other major studies have been published that used brain cancer incidence data to explicitly test the findings of Hardell’s case control studies. A study (10) by Deltour et al. did an extensive analysis of brain cancer incidence rates against cell phone subscription history using data from the Nordic countries. It tested various values of OR and latency, including those Hardell claims to have found. The conclusion states: “Several of the risk increases seen in case-control studies appear to be incompatible with the observed lack of incidence rate increase in middle-aged men. This suggests longer induction periods than currently investigated, lower risks than reported from some case-control studies, or the absence of any association”.
Another rigorous study which tested Hardell’s results was authored by scientists from the National Cancer Institute Little et al. (11). “In this study, we compared the observed patterns for glioma incidence trends in the US in 1992-2008 with projected incidence rates for the same period based on relative risks reported by the two epidemiological studies forming the basis of the IARC Working Group classification”. Their conclusion states: “Raised risks of glioma with mobile phone use, as reported by one (Swedish) study forming the basis of the IARC’s re-evaluation of mobile phone exposure, are not consistent with observed incidence trends in US population data, although the US data could be consistent with the modest excess risks in the Interphone study”. Their results are best illustrated with one of the graphs from the study (Fig 3). From this it is clear that Hardell’s findings (dashed red line) diverge sharply from the actual cancer incidence trend. It is also clear why they could draw no conclusion concerning the Interphone results, since modest risks implied by some of the Interphone results produced a flat cancer incidence curve.
Fig 3: NCI Brain cancer incidence rate projections vs. observed (From 11)
The Interphone study
It is important to remember that even though the Interphone study (12) found a modest increase in cancer risk in a subset of the study, the overall conclusion was: “Overall, no increase in risk of glioma or meningioma was observed with use of mobile phones. There were suggestions of an increased risk of glioma at the highest exposure levels, but biases and error prevent a causal interpretation. The possible effects of long-term heavy use of mobile phones require further investigation”. It is interesting to note that while the authors of Interphone understood that “biases and error prevent a causal interpretation”, IARC none the less cited Interphone to support its “possibly carcinogenic” ruling.
The only part of Interphone with a significant “positive” result was an OR of 1.4 for glioma in the 10th decile of call time (> 1640 cumulative hours of use). However this result was contradicted by the results for cumulative number of calls where the OR was less than 1 even for the highest decile. A close look at the “positive” call time data shows another glaring inconsistency. Among users with the highest call time the OR is 3.77 for people with 1 – 4 years of use, OR of 1.28 for 5 – 9 years, and OR of 1.34 for > 10 years of use. There is no logical progression with time — no dose response relationship. These inconsistent results are most likely due to recall bias and other errors. As a result, the authors of Interphone refrained from drawing any conclusion. For a more complete analysis of the Interphone study see (* 21).
Other items in IARC’s report
The IARC report in the Lancet (6) included a reference to a study (22) by Cardis et al. which attempts to correlate the physical location of gliomas in the brain with the area of maximum radiation from the cell phone. IARC makes the following statement in connection with this study: “Associations between glioma and cumulative specific energy absorbed at the tumour location were examined in a subset of 553 cases that had estimated RF doses. The OR for glioma increased with increasing RF dose for exposures 7 years or more before diagnosis, whereas there was no association with estimated dose for exposures less than 7 years before diagnosis”. In other words, this study claims to have found a higher risk of glioma in parts of the brain receiving the highest energy.
It is interesting to note that the original IARC press release (1), contained a reference to another paper by Larjavaara et al (23) that examined the same issue. The Larjavaara paper (23) is listed in note 4d of the press release. However, this study reached the opposite conclusion of the Cardis paper (22). The Larjavaara abstract included the following conclusion: “These results do not suggest that gliomas in mobile phone users are preferentially located in the parts of the brain with the highest radio-frequency fields from mobile phones“. At the time, I found it curious that the IARC would reference a study that seems to contradict their precautionary 2B categorization of cell phone EMF. But what is most surprising is that in its report one month later in the Lancet (6), IARC had dropped any reference to this paper!! Again it is worth noting that Elizabeth Cardis also served on the IARC committee and voted to have her own paper count as evidence for the “possible carcinogen” ruling.
Conclusion: Cell phones probably aren’t category 2B carcinogens
From all this it would appear that the decision making process in which IARC classed cell phones under Category 2B as “possibly carcinogenic” was flawed. IARC was ill informed on the true state of studies of brain cancer incidence rates, claiming that (6) “most of the analyses examined trends until the early 2000s only“. It ignored numerous warnings by expert groups who had determined that the case control studies by Hardell et al. were outliers in the literature. It accepted a reincarnation of an old study (13, 17, 18) that had been roundly criticized. It undervalued studies which established the existence of recall bias (14) with the statement that: “the Working Group concluded that the findings could not be dismissed as reflecting bias alone, and that a causal interpretation between mobile phone RF-EMF exposure and glioma is possible”. IARC undervalued the solid cohort studies (15, 16) by Schutz et al. of Denmark. “In this study, reliance on subscription to a mobile phone provider, as a surrogate for mobile phone use, could have resulted in considerable misclassification in exposure assessment”
Since the IARC published its report the evidence against its conclusion has grown stronger. Three new studies (9, 10, 11) of cancer incidence rates have shown that rates have remained flat up to at least 2009. The findings of Hardell et al. have been put to the test in these same three studies. A large portion of Hardell’s results (13) have been shown to be wrong. This undermines one of the main pillars for IARC’s finding. The authors of Interphone (12), the other main pillar have stated that biases and error prevent a causal interpretation of their results. Finally, IARC appears to have been disingenuous in removing reference to a study (23) that contradicted one of the papers cited in their final report in the Lancet.
As the WHO stated in their updated Fact Sheet of June 2011 (5): “A large number of studies have been performed over the last two decades to assess whether mobile phones pose a potential health risk. To date, no adverse health effects have been established as being caused by mobile phone use”. While it is still cannot be ruled out that brain cancer incidence rates might increase in the future — say if latency is 20 years or more – this appears to be increasingly improbable. It is unfortunate that the IARC decision making process was flawed. But it is unlikely that IARC will ever change its Category 2B classification. Like coffee and pickled vegetables, cell phones may well remain in this category forever. IARC lists a grand total of one substance under category 4 which is “The agent is probably not carcinogenic to humans”. Alarmist groups will continue to exploit and misrepresent this flawed ruling.See our website for more science based information on the issue of EMF and health (www.emfandhealth.com).
References
     1.  Open article: IARC Press Release May 31, 2011:  http://www.iarc.fr/en/media-centre/pr/2011/pdfs/pr208_E.pdf Return to text
     2.  Open Article: IARC Document on Carcinogens:  http://monographs.iarc.fr/ENG/Preamble/CurrentPreamble.pdf Return to text
     3.  Open document: European Commission Scientific Committee on Emerging and Newly Identified Health Risks (SCEHINR): Report Health Effects of Exposure to EMF Jan 2009:  http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_022.pdf Return to text
     4.  Open article: NCI Statement: International Agency for Research on Cancer Classification of Cell Phones as “Possible Carcinogen” May 31, 2011:  http://www.cancer.gov/newscenter/pressreleases/2011/IARCcellphoneMay2011 Return to text
     5.  Open article: WHO Fact Sheet: Electromagnetic fields and public health: mobile phones June 2011:  http://www.who.int/mediacentre/factsheets/fs193/en/index.html# Return to text
     6.  Open article: IARC follow up report July 1, 2011 Lancet Oncology and online:  http://press.thelancet.com/tloiarcsum.pdf Return to text
     7.  Open Access:  Brain cancer incidence trends in relation to cellular telephone use in the United States; Inskip et al.; Neur-Oncology July 2010:  http://neuro-oncology.oxfordjournals.org/content/early/2010/07/16/neuonc.noq077.full.pdf+html Return to text
     8.  Time Trends (1998-2007) in Brain Cancer Incidence Rates in Relation to Mobile Phone Use in England; Vocht et al.; Bioelectromagnetics July 2011, first published online Jan 28, 2011:  http://onlinelibrary.wiley.com/doi/10.1002/bem.20648/abstract Return to text
     9.  Open access: Mobile Phones, Brain Tumors and the Interphone Study: Where Are We Now?; Swerdlow et al.; Environ Health Perspect; published online July 2011:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226506/?tool=pubmed Return to text
     10.  Mobile Phone Use and Incidence of Glioma in the Nordic Countries 1979–2008; Deltour et al.; Epidemiology Vol 23 No 2 Mar 2012:  http://www.ncbi.nlm.nih.gov/pubmed/22249239 Return to text
     11.  Open Access: Mobile phone use and glioma risk: comparison of epidemiological study results with incidence trends in the United States; Little et al.; BMJ 2012; 344:  http://www.bmj.com/content/344/bmj.e1147 Return to text
     12.  Interphone study; Cardis et al.; International Journal of Epidemiology May 2010; 39; 675–694   http://ije.oxfordjournals.org/content/39/3/675.full.pdf Return to text
     13.  Pooled analysis of case-control studies on malignant brain tumours and the use of mobile phone; Hardell et al.; Intl Journal Oncology 2011 38: 1465-1474 Return to text
     14.  Recall bias in the assessment of exposure to mobile phones; Vrijheid M J et al.; Expo Sci Environ Epidemiol 2009; 19: 369-81:   http://www.ncbi.nlm.nih.gov/pubmed/18493271 Return to text
     15.  Open access: Danish cohort studies: Cellular Telephone Use and Cancer Risk: Update of a Nationwide Danish Cohort; Schuz et al.; JCNI J Natl Cancer Inst 2006 Vol 98 Issue 23:  http://jnci.oxfordjournals.org/content/98/23/1707.full Return to text
     16.  Open access: Use of mobile phones and risk of brain tumours: update of Danish cohort study; Schuz et al.; BMJ Oct 2011; 343:   http://www.bmj.com/content/343/bmj.d6387 Return to text
     17.  Pooled analysis of two case–control studies on use of cellular and cordless telephones and the risk for malignant brain tumours diagnosed in 1997–2003; Hardell et al.; Int Arch Occup Environ Health 2006 79: 630–639 Return to text
     18.  Pooled analysis of two case-control studies on the use of cellular and cordless telephones and the risk of benign brain tumours diagnosed during 1997-2003; Hardell et al.; Intl Journal Oncology 2006 28: 509-518 Return to text
     19.  EMF-NET: Comments on the study by Hardell et al.: Pooled analysis of two case-control studies:   http://web.jrc.ec.europa.eu/emf-net/doc/efrtdocuments/EMF-NET%20EFRT%20Hardell%20Paper%2024APR2006.pdf Return to text
     20.  Epidemiologic Evidence on Mobile Phones and Tumor Risk: A Review Ahlbom et al. (Epidemiology 2009; 20: 639–652;   http://www.ncbi.nlm.nih.gov/pubmed/19593153 Return to text
     21.  Commentary on the Interphone Study:  http://www.emfandhealth.com/InterphoneStudy.html 
     22.  Risk of brain tumours in relation to estimated RF dose from mobile phones – results from five Interphone countries;  Cardis et al.; Occup Environ Med 2011; 68: 631-640;  http://oem.bmj.com/content/early/2011/06/09/oemed-2011-100155.abstract Return to text
     23.  Location of gliomas in relation to mobile telephone use: a case-case and case-specular analysis; Larjavaara et al.; Am J Epidemiol 2011 Jul 1; 174(1): 2-11;  http://www.ncbi.nlm.nih.gov/pubmed/21610117 Return to text
    • 

   Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer!
David Gorski
Link
Before I start into the meat of this post, I feel the need to emphasize, as strongly as I can, four things:
     1.  I do not receive any funding from the telecommunications industry in general, or wireless phone companies in particular. None at all. In other words, I’m not in the pocket of “big mobile” any more than I am in the pocket of big pharma.
     2.  I don’t own any stock in telecommunications companies, other than as parts of mutual funds in which my retirement funds are invested that purchase shares in many, many different companies, some of which may or may not be telecommunications companies. (I should probably go and look at the list.)
     3.  None of my friends or family work for cell phone companies.
     4.  I don’t have a dog in this hunt. I really don’t.
I say this because these are the most common accusations I hear whenever I venture into this particular topic area, and I thought I’d just clear that up right away in order (hopefully) to preempt any similar comments after this post. Indeed, one of the favorite retorts to anyone who criticizes fearmongering about cell phones is to try to insinuate that that person is only doing so because he or she is in the pocket of industry, and I’ve been at the receiving end of such claims. Unfortunately, I’m sure someone will probably show his or her lack of reading comprehension and post one of those very criticisms of me. It’s almost inevitable. Even though posting such disclaimers never works against the “pharma shill” gambit when I write about vaccines or dubious cancer cures, nonetheless hope springs eternal.
Now that that obligatory unpleasantness is out of the way, let me move on to say that I’m very puzzled about something that happened last week.
I know that being puzzled isn’t particularly unusual for me. Indeed, I’m frequently puzzled about a great many things. I can’t figure out how, for example, anyone with the slightest bit of reason or critical thinking ability can believe that homeopathy is anything other than water treated with, in essence, magical spells accompanied by shaking or do anything other than laugh when informed what homeopathy really is and how it supposedly “works.” I can’t figure out how anyone can look at the mass of interlocking evidence from multiple different scientific specialties supporting evolution and reject still reject one of the most powerful scientific theories ever to spring from the human mind, deciding instead that creationism or its bastard offspring, “intelligent design” creationism is anything more than pure religion or rank religion-inspired pseudoscience. I can’t figure out why American Idol or Survivor is so amazingly popular.
And I can’t figure out why on earth the University of Pittsburgh Cancer Center released this warning about cell phones last week:
PITTSBURGH July 24, 2008, 07:13 am ET · The head of a prominent cancer research institute issued an unprecedented warning to his faculty and staff Wednesday: Limit cell phone use because of the possible risk of cancer.
The warning from Dr. Ronald B. Herberman, director of the University of Pittsburgh Cancer Institute, is contrary to numerous studies that don’t find a link between cancer and cell phone use, and a public lack of worry by the U.S. Food and Drug Administration.
Herberman is basing his alarm on early unpublished data. He says it takes too long to get answers from science and he believes people should take action now — especially when it comes to children.
“Really at the heart of my concern is that we shouldn’t wait for a definitive study to come out, but err on the side of being safe rather than sorry later,” Herberman said.
Dr. Herberman is a highly respected cancer center director whom I’ve in general thought well of, and the University of Pittsburgh Cancer Institute is a highly respected cancer center. I know a few people there, and in the past I’ve worked closely with two surgeons who trained there. One in particular remains my collaborator, even though I’ve moved on from the institution where we were once partners.
That’s why I can’t help but wonder just what on earth Dr. Herberman was smoking when he decided to issue this warning, given my general respect for the University of Pittsburgh to the point where I once even tried to land a faculty position there. His announcement strikes me as being rash in the extreme, especially given that its text even admits outright that the published data at present do not appear to support a link between cell phone use and brain tumors. Consequently, I conclude that this is alarmism that, I suspect, even a prominent blogger known to be somewhat receptive to the claim that cell phones cause brain tumors (Revere) would have a hard time supporting, because it goes far beyond the published evidence and is based on “early unpublished data.” Scaring the nation based on “early unpublished data” that can’t be examined by the entire medical and scientific community is generally not a good idea. That’s why I’ve been asking over the last few days: Why on earth did Dr. Herberman do it?
The question of whether cell phones cause or contribute to the development of brain tumors is not as easy a question to answer as one might think. Indeed, I suspect that the very difficulty of answering the question is what contributes to the amount of woo that has come to surround the whole issue of cell phones, complete with useless “cell phone shields” and various other devices that will supposedly obviate any risks, whether real or not. First, there is the issue of biological plausibility. Radiowave energy at the power level used by most cell phones, is not ionizing. It’s not even close, being several orders of magnitude too weak to break chemical bonds. Our understanding of cancer is that, in general, ionizing radiation is what is required for radiation to cause or contribute to cancer. That does not mean that there might not be a potential, as yet undiscovered, mechanism by which non-ionizing radiation might cause cancer, but simple physics and chemistry make the hypothesis that cell phone radiation causes or contributes to brain tumors not particularly plausible on the basis of currently understood biology. Too, we can actually test radiofrequency radiation in the same power range used in cell phones on cells in cell culture in order to determine whether exposure to such radiation can cause changes associated with malignant transformation. There is one confounding effect that has to be controlled for in such experiments (but is not always), namely that radiofrequency radiation interacts with water in order to heat it. Still, there are no compelling studies showing any specific effect of radiofrequency radiation on cells to induce changes associated with malignant transformation, at least none that I’m aware of. Animal studies are prone to the same sorts of problems as cell culture studies, but even so there is no good quality animal data that I’m aware of implicating cell phone radiation in the formation of cancer. On a basic science basis, at present there doesn’t appear to be strong evidence (or much of any evidence at all) supporting plausible mechanism by which cell phone radiofrequency radiation might cause cancer or an actual effect in which they do.
Another form of evidence that might be suggestive that cell phones are causing cancer would be in the form of pure incidence data. Cell phones were first introduced into the U.S. in the 1980s, but their use didn’t become widespread until the late 1990s, mainly because before that they were too expensive, bulky, and generally unreliable. I got my first cell phone in 1997, and the thing was a brick, with high per-minute charges and really high charges for roaming or long distance. In fact, it wasn’t long before I wondered why I bought the damned thing and signed up for a three year–yes, three year–contract, given how little I ended up using it. In any case, we might expect that, if cell phones were causing brain tumors, there might be a generalized spike in the number of cases of brain tumors recently. There hasn’t been any such dramatic increase over the thirty year period from 1975-2005.
Of course, we may not have been using cell phones widely for long enough to see the increase, given that the lag time from an exposure to the development of cancer is often two decades. That brings us to epidemiological studies. For us to consider any epidemiological to be support for the hypothesis that cell phones cause brain cancer, there must be a few key results. First, there must be an increased incidence of brain cancer in cell phone users. It’s even more convincing if there is some sort of dose-response phenomenon. In other words, there should be an increasing risk of cancer that is strongly correlated with increasing cell phone use. Other results that also support the hypothesis would be tumors correlated with proximity. In other words, do people who primarily use their left hand to hold their phones to their ears tend to get tumors primarily on the left and people who primarily hold their phones with their right hand tend to get tumors primarily on the right? Finally, there should be a plausible lag time between exposure and tumor development consistent with known lag times for cancer, say 10-20 years, and some specificity. In other words, does exposure to cell phone radiation correlate with certain types of tumors and not others? There are other aspects of the results of a study that can more strongly support the hypothesis that cell phones cause brain cancer, but these are the main ones.
In general, however, getting “clean” data from an epidemiologic study of cell phone use that can support a strong enough correlation to suggest causation is very difficult indeed. In order to correlate cell phone use with an increased incidence of brain tumors, it’s necessary somehow to be able to reliably quantify cell phone usage. This presents a big problem. It’s generally not possible to continuously observe people with their cell phones for years on end and obtain objective measurements, and certainly it’s not impossible to do so for people who have brain cancer now and whose exposure ten or twenty years ago is the possible contributory factor that we are interested in studying. Another way to try to come by this information is to ask people how much they use their cell phones. However, memories are unreliable, and such methods are very prone to recall bias in the form of people with brain tumors being more likely to remember their cell phone use as having been “heavy.” That’s not even counting trying to control of the number of potentially confounding factors, such as heavy cell phone use being associated with certain jobs or professions or, especially for 10-20 years ago when cell phones were far less common, with higher socioeconomic status, or even region of the country, given the uneven penetration of cell phone technology out from the urban areas that were covered first–especially 10-20 years ago. Then there’s the shift in technology from analog to digital cell phone technology that occurred in the early 2000s, which changed the power and frequencies used.
There are ways to overcome the limitations of retrospective studies. For example, an investigator can try to look at cell phone bills and see the number of minutes used per month, but who keeps their bills from 10 or 20 years ago, which is the time of exposure most relevant to the development of cancer? Alternatively, one can abandon the retrospective study altogether and follow people prospectively and have them report their cell phone usage from their bills every month. However, because brain tumors represent an uncommon form of cancer, thousands upon thousands of subjects would have to be followed this way, and it would take at least a decade or two to start to see any results. Also, it would be very hard to find and enforce a viable control group, given the ubiquity of cell phones.
Despite the difficulties, several epidemiological studies have been done, with largely negative results. Surprisingly, the NPR report actually summarizes them pretty well; so I don’t see a compelling reason to do anything other than quote the article:
The issue that concerns some scientists — though nowhere near a consensus — is electromagnetic radiation, especially its possible effects on children. It is not a major topic in conferences of brain specialists.
A 2008 University of Utah analysis looked at nine studies — including some Herberman cites — with thousands of brain tumor patients and concludes “we found no overall increased risk of brain tumors among cellular phone users. The potential elevated risk of brain tumors after long-term cellular phone use awaits confirmation by future studies.”
Studies last year in France and Norway concluded the same thing.
“If there is a risk from these products — and at this point we do not know that there is — it is probably very small,” the Food and Drug Administration says on an agency Web site.
And:
A French study based on Interphone research and published in 2007 concluded that regular cell phone users had “no significant increased risk” for three major types of nervous system tumors. It did note, however, that there was “the possibility of an increased risk among the heaviest users” for one type of brain tumor, but that needs to be verified in future research.
Earlier research also has found no connection.
Our fearless leader Steve Novella also summarized the state of the evidence regarding cell phone use and the risk of cancer and concluded that we can probably rule out a strong correlation between cell phone radiation and cancer, but we do not yet have enough data to rule out a small increased risk of brain tumors due to cell phones, particularly in children. I mostly agree with this characterization of the state of the evidence at present, which is why I find statements like this to be overblown fear-mongering:
A driving force behind the memo was Devra Lee Davis, the director of the university’s center for environmental oncology.
“The question is do you want to play Russian roulette with your brain,” she said in an interview from her cell phone while using the hands-free speaker phone as recommended. “I don’t know that cell phones are dangerous. But I don’t know that they are safe.”
I think that a friend of mine, PalMD, got it right when he sarcastically retorted:
Hey, I don’t know for an absolute certainty that my popcorn won’t spontaneously combust, but I’m not yelling fire either.
To which I’d add: Hey, I don’t know with absolute certainty that vaccines don’t cause autism, but I’m not joining the anti-vaccinationists or planning to head off to the second annual “Green Our Vaccines” rally next year as a speaker. (Don’t worry; it’ll never happen unless anti-vaccine activists can provide evidence at least as compelling as the evidence that vaccines are safe.)
The actual warning is even worse, delving into some truly dubious comparisons:
In the early 1980′s, the owners of asbestos mines were reduced to bankruptcy as a result of lawsuits brought by the families of deceased exposed workers. A few years later, a key executive of Johns Manville, the most prominent company, drew lessons from the years of struggle of his industry against medical data and the scientists who were drawing attention to the risks of asbestos. He concluded with regret that greater warnings for the public, the establishment of more effective precautions, and more extensive medical research “could have saved lives, and probably also shareholders, the industry, and the benefits of its product.” [13, 14]
We call on the cell phone companies to provide independent access to records of use so that appropriate studies can be carried out.
I don’t know about you, but personally I wouldn’t want investigators combing through my cell phone records without my permission. Of course, it’s hard to see what investigators would do with such data; after all, it wouldn’t be hard to get study participants to agree to give permission to examine their cell phone records, and in that case there would be no need for cell phone companies to provide “independent” access to anything. If investigators are planning on using aggregate ecological data instead of subject-level data, for instance, to try to correlate regions of where cell phone use is heavy with regions where the incidence of brain tumors is higher, then there would be a very high danger of falling prey to the ecological fallacy of epidemiology which is a principle that states that ecological (or group level) analyses are particularly prone to false positive correlations, as happened with this study and this study.
Worse, earlier in the report there was even a comparison with tobacco! Here’s the difference that makes these comparisons specious. Tobacco smoke is a known carcinogen. We have many in vitro and animal studies that allow us to elucidate the mechanisms by which its components can induce lung cancer and other forms of cancer. Similarly, although the mechanism of how asbestos induces cancer is not as clear, we similarly have animal studies that show that asbestos can indeed induce characteristic cancers. In marked contrast, we have no such studies showing biological plausibility for cell phone radiation. That’s why even bringing up the comparison strikes me more as poisoning the well more than anything else. As Steve Novella points out, how do we know that a better comparison isn’t silicone breast implants, which were initially thought to be associated with autoimmune diseases but were later exonerated by the science–but not before Dow Chemicals was bankrupted by lawsuits in the 1990s? We don’t. We need more science. Premature warnings can be almost as bad as warnings that come too late.
Particularly strange is Davis’s statement:
She said 20 different groups have endorsed the advice the Pittsburgh cancer institute gave, and authorities in England, France and India have cautioned children’s use of cell phones.
As PalMD astutely pointed out, these 20 groups did not actually endorse UPCC’s report; rather they endorsed recommendations similar to the recommendations in the report. The recommendations are not too far out there, although they are probably more cautious than current evidence warrants.
I later discovered that Dr. Herberman gave an interview with The Cancer Letter that was published shortly after he issued his warning:
The [Interphone] study was completed and analyzed over two years ago, but “the frustration is, it has not been published yet,” Herberman said. “I’ve talked with several people who are experts, and everyone I’ve talked to who has seen the data say there is clearly at least a two-fold increase in tumors on the side of the head where the cell phone tends to be used.
Even if this characterization of the Interphone study is completely accurate, I still can’t figure out what on earth possessed Dr. Herberman to allow it to be issued now. Even if the unpublished data are as alarming as implied (unlikely, given the number of previous studies that found either no risk or a questionable very slight risk and the low number of brain tumors seen in the U.S. each year to begin with) and the National Research Council in the U.S. is mistaken about its being highly skewed due to selection bias, as a responsible leader in public health and cancer, you don’t pull something like this. It’s irresponsible. A few months to get the data published in a peer-reviewed journal or, if that’s taking too long, presented at a major meeting (where the peer review process is usually less rigorous for abstracts) are not going to make a difference, given the long lag time of cancer. After all, cancer is a disease that develops over years, and even under the worst-case scenario, hypotheses for cell phone use causing cancer postulate years of heavy use as being necessary to result in cancer. Waiting until the data can be published would at least allow scientists and physicians to vet the data and decide if, on balance taking into account its limitations, it warrants such a strong warning. Alternatively, if you really believe you can’t wait a few months because the risk is so compelling, then release the data with the warning, so that scientists can judge whether the warning is warranted.
Of course, that the study authors are having trouble getting their results published makes me wonder whether their findings are as strong as advertised in this warning. No doubt the conspiracy crowd will claim that cell phone companies are somehow “suppressing” the evidence, but nothing’s stopping the authors from publishing their data and conclusions on an open access journal like Public Library of Science Medicine. Doing so would make the data public much faster, and I urge the study authors to consider this option; that is, if getting the data out where it can be evaluated by the cancer community is more important than publishing it in the New England Journal of Medicine.
Fortunately, many Americans seem to have more common sense than our cancer leaders:
“I think if they gave me specific numbers and specific information and it was scary enough, I would be concerned,” Loughran said, planning to call her mother again in a matter of minutes. “Without specific numbers, it’s too vague to get me worked up.”
I couldn’t have said it better myself.
In the meantime while we’re waiting for the data to be published, I hope my boss isn’t one of Dr. Herberman’s golfing buddies.

   Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer! (revisited)
David Gorski
Link
It’s been about a year and a half since I’ve written about this topic; so I thought I’d better update the disclaimer that I wrote at the beginning:
Before I start into the meat of this post, I feel the need to emphasize, as strongly as I can, four things:
     1.  I do not receive any funding from the telecommunications industry in general, or wireless phone companies in particular. None at all. In other words, I’m not in the pocket of “big mobile” any more than I am in the pocket of big pharma.
     2.  I don’t own any stock in telecommunications companies, other than as parts of mutual funds in which my retirement funds are invested that purchase shares in many, many different companies, some of which may or may not be telecommunications companies.
     3.  None of my friends or family work for cell phone companies.
     4.  I don’t have a dog in this hunt. I really don’t.
There. That’s better. Hopefully that will, as it did last time, serve as a shield against the “shill” argument, which is among the frequent accusations I hear whenever I venture into this particular topic area. So, as I did back in 2008, I just thought I’d clear that up right away in order (hopefully) to preempt any similar comments after this post. Unfortunately, as I have known for a long time, I’m sure someone will probably show his or her lack of reading comprehension and post one of those very criticisms of me. It’s almost inevitable, either here or elsewhere. Posting such disclaimers never seems to work against the “pharma shill” gambit when I write about vaccines or dubious cancer cures. Even so, even after nearly ten years involved in skepticism and promoting science-based medicine, hope still springs eternal.
There are two reasons that I think the issue of mobile phones and cancer needs an update on our blog: First, it has been a year and a half since I last wrote about it. At that time I castigated Dr. Ronald B. Herberman, who at that time was director of the University of Pittsburgh Cancer Institute for what I viewed as fear mongering over cell phones and cancer based on at best flimsy evidence. Second, there have been two fairly high profile studies looking at whether there is a link between mobile phone use and cancer. One of these our fearless leader Steve Novella has already discussed, but there was another one that he didn’t see because it didn’t get quite as much publicity, possibly because the corresponding author is based in Korea. I will take this opportunity to discuss them both.
Over the last several years, as cell phones have become not only ubiquitous but have morphed into in essence pocket computers with Internet connections, there has developed a cottage industry of cell phone “shields” that allegedly protect people from horrible microwaves emitted by cell phones that supposedly cause cancer. These shields, of course, do nothing of the sort; objective tests of many of them show that they don’t even do a good job of blocking electromagnetic radiation emitted by cell phones. However, the data looking at the question of whether cell phones can cause some form of cancer has been mixed at best and consistent with no detectable association or possibly a very tiny association that just rises above the background noise, but even that is arguable.
One reason we have a lot of doubts over whether cell phone radiation can actually cause cancer goes back to a longtime focus of this blog and one reason why we emphasize science-based medicine rather than evidence-based medicine, namely scientific plausibility. From a biological standpoint, a strong link between cell phone use and brain cancer (or any other cancer) is not very plausible at all; in fact, it’s highly implausible. Cell phones do not emit ionizing radiation; they emit electromagnetic radiation in the microwave spectrum whose energy is far too low to cause the DNA damage that leads to mutations that lead to cancer. True, it is possible that perhaps heating effects might contribute somehow to cancer, but most cell phones, at least ones manufactured in the last decade or so, are low power radio transmitters. It is also possible that there is an as yet undiscovered biological mechanism by which low power radio waves can cause cancer, perhaps epigenetic or other, but the evidence there is very weak to nonexistent as well. Worse, as has been pointed out many times, epidemiological evidence for people who have used cell phones heavily for more than 10 years is sparse.
Moreover, it’s not possible to study the issue by randomized studies, because it is impractical to the point of being virtually impossible to randomize people into groups that do and do not use cell phones given how essential cell phones have become to most people in industrialized nations and then to follow them for the 20 years or so that it would take to identify a link. That leaves retrospective data, with all the perils and pitfalls inherent in retrospective studies. One potential approach to such a study is to formulate a simple hypothesis. If mobile phone use causes cancer, then after the widespread introduction of cell phones into a population there should be a detectable significant increase in the incidence of tumors that could potentially be due to cell phone use, particularly 10 to 20 years later. That is the hypothesis that the investigators who published recent Danish study (Deltour et al, Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974–2003) decided to examine. It is a good population to examine this question in because the populations of these countries is homogeneous, cell phone use became widespread earlier than it did in the U.S., and these countries have nationalized health systems that allow centralized collection of cancer data in national cancer registries.
The basic design of the study was as follows. Investigators examined the cancer registries of these nations for the first incidence of brain tumors in patients aged 20-79, noting this background:
Previous investigations in Denmark, Finland, Norway, and Sweden found that the incidence of glioma was relatively stable from 1983 to 1998 ( 7 ) and that the incidence of meningioma increased from 1968 to 1997, more so for women than for men (8). Time trends in brain tumor incidence after 1998 are likely to be relevant for evaluating possible associations with respect to radio frequency exposure from mobile phones after 5 – 10 years of exposure. We investigated time trends in brain tumor incidence rates in these four Nordic countries to evaluate whether trends in the incidence of brain tumor changed in Denmark, Finland, Norway, and Sweden from 1998 to 2003.
This information is important to know, because if brain tumor incidence were rising before the widespread use of cell phones, then to find a correlation that might indicate causation, there would have to be a more rapid increase in brain cancer, starting with an appropriate lag time after the use of cell phones became so prevalent, likely at least five to ten years. This is very much like the evidence for an epidemiological link between smoking tobacco and lung cancer, except that for the tobacco-lung cancer link there was a 20-30 year lag between the introduction of inexpensive, mass-marketed cigarettes and the increase in lung cancer incidence. In any case, the resultant population examined in this study was, in essence, the entire populations of these four countries, where 59,984 brain tumor cases that were diagnosed from 1974 to 2003 among 16 million adults aged 20 –79 years. They say that a picture is worth a thousand words; so here is Figure 1 from the paper:
Panels A and B present incidence rates for gliomas and meningiomas, respectively, in men; panels C and D present incidence rates for gliomas and meningiomas, respectively, in women. Circles indicate rates for those aged 20 – 39 years, squares indicate rates for those aged 40–59 years, triangles indicate rates for those aged 60–79 years, and a solid line indicates the regression curve. As described in the paper:
During this time, the incidence rate of cancers known as gliomas increased gradually by 0.5% per year among men and by 0.2% per year among women.
For cancers known as meningioma, the incidence rate increased by 0.8% among men and, after the early 1990’s, by 3.8% among women.
This more rapid change for women was driven, the researchers say, by the 60-79 year age group.
In other words, there was a slow rate of increase in these tumors that did not change in the 1998-2003 cohort. The reasons for this slow rate of increase are unclear, but because it began before the widespread insinuation of mobile phones into the population it is almost certainly not due to mobile phone radiation. One possibility that could have contributed to this is the increasing use and sophistication of imaging technology like CT and MRI, which, as the authors pointed out in the introduction, can lead to an increased apparent incidence without any changes in etiological factors through the detection of asymptomatic meningioma, for example. (Sound familiar?) In any case, there was no detectable evidence of an uptick in the incidence of these brain tumors after 1998. The lack of evidence for a change in the rate of increase of these tumors is consistent with three conclusions. Either there is no link between cell phone use and these brain tumors; the “lag time” for such an effect is greater than 5-10 years; or the effect is too small to be detected in an overall population level. One area where I will disagree with our fearless leader (somewhat) is that I don’t consider this study to be weak evidence. It is, in fact, strong evidence that, if a link between cell phone use and brain cancer exists, it is almost certainly weak and small. Add to that the biological implausibility of a link, given our current knowledge about cancer, and I remain less than impressed with the claims that cell phones cause brain cancer. I would be happy to change my mind if new evidence, either in the form of a biological mechanism being discovered that could explain how long term exposure to low energy radio signals could cause cancer or epidemiological evidence showing a clear association between cell phone use and cancer (preferably both), came to light.
Unfortunately, the second study does not qualify as either form of evidence. (How’s that for a segue?) In fact, from my perspective, it is one of the best examples of how meta-analyses can be tortured to find tenuous correlations where none probably exist. The study, which appeared in the November 20 issue of the Journal of Clinical Oncology, apparently slipped by my notice when it first appeared as an online publication on October 13. In any case, the study (Myung et al, Mobile Phone Use and Risk of Tumors: A Meta-Analysis) is, as the title says, a meta-analysis, meaning it’s a formal way of combining multiple studies that may or may not have statistically significant results on their own, that may or may not have found a correlation, and trying to see if the weight of the evidence suggests a correlation between mobile phone use and cancer. In this case, 465 articles were winnowed down to 22 articles using specific selection criteria, which were:
We included epidemiologic studies that met all of the following criteria: case-control study (to date, no randomized controlled trials and only one retrospective cohort study published in four different articles have been reported; therefore, we included only case-control studies in this study); investigated the associations between the use of mobile phones, cellular phones, or cordless phones and malignant or benign tumors; reported outcome measures with adjusted odds ratios and 95% CIs, crude odds ratios and 95% CIs, or values in cells of a 2(1)2 table (from which odds ratios could be calculated). If data were duplicated or shared in more than one study, the first published or more comprehensive study was included in the analysis.
I’ll cut to the chase right now. This meta-analysis does not–I repeat, does not–show any correlation between cell phone use and cancer, at least not in the overall results. The authors even say so:
As shown in Figure 2, the overall use of mobile phones (use v never or rarely use) was not significantly associated with the risk of tumors in a random-effects model meta-analysis of all 23 case-control studies (odds ratio 0.98; 95% CI, 0.89 to 1.07).
Let me repeat that again. The overall meta-analysis did not find any significant association between mobile phone use and tumors.
Of course, whenever an investigator does a meta-analysis and finds a result like this, he can never rest there. He has to slice and dice the data to try to find a group for which there is a correlation. There’s nothing wrong with that in and of itself. In prospective studies, post hoc subgroup analyses that were not planned in the original protocol right from the beginning are generally frowned upon because they have a high tendency to find associations that are usually spurious. I tend to look at it as being a lot like making multiple comparisons but not controlling for them. By doing a study to look at one population and a set of outcome measures but then, upon finding a negative result, going back and doing subgroup analyses, one is basically doing multiple comparisons without correcting for multiple comparisons. Anyone who’s been a regular reader of this blog should know that if one doesn’t correct for multiple comparisons, the more comparisons the higher the likelihood of finding one or more false positives.
Even so, it’s not necessarily scientifically dubious to do subgroup analyses if one looks at it as a hypothesis-generating exercise, rather than any actual conclusions. Correlations that are found may or may not be “real,” but strong correlations may be worth further investigation. What bothers me about this study is not so much that it did subgroup analysis on the populations studied, but rather how it did a sort of dubious “subgroup analysis” on the actual studies themselves:
However, a significant positive association (ie, harmful effect) was observed in eight studies 7,12,14-16,18,23 and one study by another group10) using blinding (odds ratio1.17; 95% CI, 1.02 to 1.36), whereas a significant negative association (ie, protective effect) was observed in 15 studies (nine INTERPHONE-related studies17,20-22,24-28 and six studies by other groups8,9,11,13,19) not using blinding (odds ratio 0.85; 95% CI, 0.80 to 0.91). No publication bias was observed in the selected studies (Begg’s funnel plot was symmetric; Egger’s test, P for bias .21; Fig 3)
[...]
Subgroup meta-analyses by methodologic quality of study revealed a significant positive association in the high-quality studies (odds ratio 1.09; 95% CI, 1.01 to 1.18), whereas a negative association was observed in the low-quality studies. In subgroup meta-analyses by malignancy of tumor, no significant association was observed for malignant tumors. However, a significant negative association was observed for benign tumors. Neither the use of analog phones nor the use of digital phones was associated with the risk of tumors.
First, note that these odds ratios are barely statistically significant, ranging from 1.02 to 1.36 and 1.01 to 1.18; in other words, the 95% confidence interval barely misses overlapping with 1.0. More importantly, I was very puzzled by the way that they chose to differentiate “high” quality studies from “low” quality studies. Basically, although it is only one of the eight criteria used in the Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Case-Control Studies to evaluate study quality, for some reason the Myung et al decided to focus primarily on whether the studies were blinded or not, specifically whether the status of patient cases and controls was blinded at interview (blinded or not blinded/no description). This struck me as most curious. So studies that were blinded showed a positive association between cell phone use and brain tumors upon meta-analysis of just their results. The authors also report that their subgroup analysis demonstrated that studies of higher methodological quality (greater than or equal 7 points) also showed a positive association between cell phone use and cancer for just these studies.
So does it mean anything that lumping the studies together that are of “high quality” produces a positive result where the low quality studies don’t? Normally, I’d think that it might. After all, the studies showing the positive result are considered to be methodologically rigorous, although it should be noted that several of them individually didn’t find a significant association. In this case, I doubt it means much of anything, and here’s why. Seven of the eight “high quality” studies were all by a single group of researchers, Dr. Lennart Hardell’s group in Sweden. Whenever one group of researchers keeps finding a result that no other group seems able to replicate or that otherwise disagrees with what everyone else is finding, that’s a huge red flag for me. Remove those studies, and even the wisp of a hint of a shadow of the association between cell phone use and cancer found in this study disappears. I’d have a lot more confidence in this seeming association in “high quality” studies if the association didn’t depend upon a single researcher and if this researcher was not also known for being an expert witness in lawsuits against mobile phone companies. Don’t get me wrong; these studies could be correct, but replication is one of the checks on research in science-based medicine. If other groups can’t replicate Dr. Hardell’s work, I wonder why. Is it something about the methodology? Is it something specific about Swedes? Is it something about the population? Are there confounders unique to his work that aren’t operative elsewhere? Until I see other researchers independent of Dr. Hardell and using a variety of different analyses find the same results, I don’t have a lot of confidence in them. Even the authors acknowledge that a weakness of their study is that “we did not explore potential confounding factors in the studies by Hardell et al that reported positive results not found by other study groups.”
There was another passage in this paper that I also found most curious:
We feel the need to mention the funding sources for each research group because it is possible that these may have influenced the respective study designs and results. According to the acknowledgments that appeared in the publications, the Hardell et al group was supported by grants from the Swedish Work Environment Fund, Orebro Cancer Fund, Orebro University Hospital Cancer Fund, and so on. Most of the INTERPHONE-related studies were mainly supported by the Quality of Life and Management of Living Resources program of the European Union and the International Union Against Cancer; the International Union Against Cancer received funds for those studies from the Mobile Manufacturers Forum and the Global System for Mobile Communication Association.
I don’t know about you, but I’ve never seen a passage like this in a research paper or meta-analysis before. It stands out like the proverbial sore thumb, and I can only think that it was placed there to try to cast aspersions, representing Dr. Hardell as the exemplar of Truth, Justice, and Science while painting the studies that failed to find an association between cell phone use and cancer as hopelessly biased, the product of Big Cellular. At least that’s how it came across to me. It struck me as gratuitous.
So where do we stand now? My interpretation of the evidence thus far is that we can say with some confidence that there is no short term risk of brain cancer from cell phone use. However, after more than ten years the evidence is less clear but trends towards either no detectable risk or a very small risk that barely rises above the noise. It’s possible that there may well be a risk; it’s possible that there is hitherto undiscovered biology that provides a mechanism by which non-ionizing radiation like the radio waves from cell phones could over time induce cancer beyond ten years. Because more and more people are using cell phones over longer and longer periods of time, it’s worth studying this issue. If there is an increased risk, it may be possible to mitigate that risk by using headsets or through the design of phones that use less energy. Mobile phone technology is a relatively new technology, though, and has only been widely available since the mid-1990s. In the U.S., it didn’t become truly ubiquitous until the early part of this decade. Consequently, there hasn’t been enough lag time for us to be truly confident of studies showing little or no risk. On the other hand, it is reassuring that early studies are pretty resoundingly negative and that there really is no good biological mechanism that we have been able to find by which cell phone radiation could cause cancer. In the next 5-10 years, more studies will be done, and, over that time, I expect evidence will answer the question one way or the other.
In the meantime, it’s useful to keep things in perspective. Each and every year, there are approximately 40,000 to 45,000 fatalities due to auto collisions. Getting in a car and driving to work every day is among the most dangerous things the average person does. Yet we accept this risk because automobiles are such an incredibly useful tool in modern life; indeed, they are indispensable to most people. Cell phones are clearly in that category as well; so even if cell phones are ultimately found to increase the risk of brain cancer by, for example, 10-20% after 10-20 years, it would most likely be a risk that most people would end up living with in order to be able to use these incredibly useful devices. My personal reading of the data is that there probably isn’t a significant risk of brain tumors due to the use of cell phones, but I am not sufficiently certain to make any blanket statements. I, like everyone else, will have to wait for the evidence to settle things one way or the other.
REFERENCES:
Myung, S., Ju, W., McDonnell, D., Lee, Y., Kazinets, G., Cheng, C., & Moskowitz, J. (2009). Mobile Phone Use and Risk of Tumors: A Meta-Analysis Journal of Clinical Oncology, 27 (33), 5565-5572 DOI: 10.1200/JCO.2008.21.6366
Deltour, I., Johansen, C., Auvinen, A., Feychting, M., Klaeboe, L., & Schuz, J. (2009). Time Trends in Brain Tumor Incidence Rates in Denmark, Finland, Norway, and Sweden, 1974-2003 JNCI Journal of the National Cancer Institute DOI: 10.1093/jnci/djp415

No, a rat study with marginal results does not prove that cell phones cause cancer, no matter what Mother Jones and Consumer Reports say
David Gorski on May 30, 2016
Link


There are certain myths that are frustratingly resistant to evidence, science, and reason. Some of these are basically medical conspiracy theories, where someone (industry and/or big pharma and/or physicians and/or the government) has slam-dunk evidence for harm but conspires to keep it from you, the people. For example, despite decades worth of negative studies, the belief that vaccines are harmful, causing conditions ranging from autism to sudden infant death syndrome, to all varieties of allergies and autoimmune diseases, refuses to die. Fortunately, this myth is one that, after more than a decade of hammering by scientists, skeptics, and public health advocates, has finally taken on enough of the patina of a fringe belief that most mainstream news sources no longer feel obligated to include the antivaccine side in stories about vaccines for “balance.” It is a zombie myth, one that, no matter how often it is “killed,” always seems to rise again. Unfortunately, the same cannot be said for the myth that cell phones cause cancer, as some very credulous reporting late last week demonstrated in the form of headlines like this:
    • “Game-Changing” Study Links Cellphone Radiation to Cancer (Mother Jones)
    • Cellphone-Cancer Link Found in Government Study (WSJ)
    • Questions abound after study links tumors to cellphone radiation (Science)
    • Major US study links cellphone exposure to cancer — at least in rats (STAT)
    • “It actually has me concerned, and I’m an expert”: Major cell phone radiation study reignites cancer debate (Salon.com and Scientific American, the latter under a less inflammatory, but still overblown headline.)
    • Government study finds link between cell phones and cancer in rats (Yahoo! Finance and Consumer Reports
    • Massive government study concludes cell phone radiation causes brain cancer (NaturalNews)
Yes, I know that NaturalNews.com is not a mainstream news site. Rather it’s a quack site run by Mike Adams. Just search this blog or my not-so-super-secret other blog for numerous posts about the contortions and abuse of science and medicine by Mr. Adams. I included his article, quite simply, to illustrate that some headlines from mainstream news articles on the study don’t sound all that different from Mike Adams. Also notice how many of these headlines leave out an important fact, namely that this study was not done with humans, but with rats.
Let me show you what I mean. Here’s a quote from the Consumer Reports article:
The results of this large, long-term study could dramatically shift the national debate over cell phone safety. The NTP’s website says that the results may be used by the Food and Drug Administration and the FTC in determining how best to protect consumers from the potential harms of radiation that comes from cell phones.
The CDC might also consider reinstating the cautions it pulled from its web site. (We’ve reached out to the agency for comment, and will update our story once we hear back from them).
Likewise, the cell phone industry may have to alter its stance. The wireless association trade group CTIA has maintained that cell phones are completely safe, and has fought to block San Francisco from passing laws that would require electronics retailers to notify consumers about the proper handling of cell phones.
From Mother Jones:
It’s the moment we’ve all been dreading. Initial findings from a massive federal study, released on Thursday, suggest that radio-frequency (RF) radiation, the type emitted by cellphones, can cause cancer.
The findings from a $25 million study, conducted over two-and-a-half years by the National Toxicology Program (NTP), showed that male rats exposed to two types of RF radiation were significantly more likely than unexposed rats to develop a type of brain cancer called a glioma, and also had a higher chance of developing the rare, malignant form of tumor known as a schwannoma of the heart.
Now, NaturalNews:
After decades of denials and attacks by the media which called people concerned about cell phone radiation “tin foil hat-wearing conspiracy theorists,” a massive, multi-year study funded by the federal government now concludes that yes, cell phone radiation causes brain cancer.
The study is published here and it’s entitled, “Report of Partial Findings from the National Toxicology Program Carcinogenesis Studies of Cell Phone Radiofrequency Radiation in Hsd: Sprague Dawley SD rats (Whole Body Exposures).”
“The findings, which chronicle an unprecedented number of rodents subjected to a lifetime of electromagnetic radiation, present some of the strongest evidence to date that such exposure is associated with the formation of rare cancers in at least two cell types in the brains and hearts of rats,” reports Scientific American.
To be fair, NaturalNews includes Adams’ usual conspiracy-mongering about vaccines, GMOs, and the like, linking them all to “government coverups,” but when you are a mainstream publication like Consumer Reports or Mother Jones and your headlines and much of your text are not that far removed from something published on NaturalNews, you are doing it wrong. As Matthew Herper put it writing for Forbes about the reporting on this study, “Yesterday’s cell phone cancer scare scares me a little about the future of journalism.” In fact, if you look at some of the stories linked to above, you’ll note that many of them include notes at the end mentioning something like, “This article was updated to reflect criticism of the study’s conclusions by outside researchers.” That’s the press jumping first and being forced to backtrack under reasonable criticism. Unfortunately, none of them seem actually to make it very clear specifically how the stories were altered in response to criticism, which is bad.
Let’s take a look at some background, and then on to the study.
A little background: The science of the cell phones-cancer link
I can predict right now that someone will object to my starting this post by comparing the belief that cell phones cause cancer to the quack belief that vaccines cause autism, but I’m going to go one further. The idea that vaccines cause autism is actually more plausible than the idea that cell phones cause cancer—a lot more plausible. (Look for that sentence to be quote mined someday.) Moreover, I say this as someone who has criticized a physicist and famous skeptic for using a what I view as a simplistic “Cancer Biology 101” understanding of carcinogenesis to state that radio waves of the frequency used in cell phones cannot possibly cause cancer because of their low energy, which is very much insufficient to break chemical bonds in DNA, which is how many carcinogens cause cancer. I’ve even been criticized for perhaps being a little too open to the idea that radio waves can have significant biological effects that might even include causing cancer, and in one case I probably was.
Still, from the standpoint of basic science, specifically basic physics and biology, the likelihood that radio waves can cause cancer is incredibly unlikely, or, as I like to put it, not quite homeopathy-level implausible but damned implausible nonetheless. Indeed, from a biological standpoint, a strong link between cell phone use and brain cancer (or any other cancer) is not very plausible at all; in fact, it’s highly implausible. Cell phones do not emit ionizing radiation; they emit electromagnetic radiation in the microwave spectrum whose energy is far too low to cause the DNA damage that leads to mutations that lead to cancer. While it is possible that perhaps heating effects might contribute somehow to cancer, most cell phones, at least ones manufactured in the last decade or so, are low power radio transmitters. It is also necessary to acknowledge the possibility that there might be an as-yet-undiscovered biological mechanism by which low power radio waves can cause cancer, perhaps epigenetic or other, but the evidence there is very weak to nonexistent as well. Basically, based on what we know about carcinogenesis, a postulated link between cell phones and cancer is highly implausible.
In the absence of better basic science that nails down a heretofore-undiscovered potential biological mechanism by which exposure to radio waves could cause cancer, I have a hard time managing to muster any enthusiasm about recommending more studies than the ones that are already going on, particularly in light of various recent studies that we’ve examined that purport to find a link between cell phones and cancer but really do not, as described in these posts dating back to 2008, listed for your convenience if you want more in-depth information and discussion:
     1.  Cell Phones and Brain Tumors (Steve Novella)
     2.  Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer! (David Gorski)
     3.  Cell phones and cancer again, or: Oh, no! My cell phone’s going to give me cancer! (revisited) (David Gorski)
     4.  New Data on Cell Phones and Cancer (Steve Novella)
     5.  A Disconnect between cell phone fears and science (Lorne Trottier)
     6.  Critique of “Risk of Brain Tumors from Wireless Phone Use” (Lorne Trottier)
     7.  Are Cell Phones a Possible Carcinogen? An Update on the IARC Report (Lorne Trottier)
     8.  No, carrying your cell phone in your bra will not cause breast cancer, no matter what Dr. Oz says (David Gorski)
     9.  About that Cell Phone and Cancer Study (Steve Novella)
In other words, as a skeptic who’s probably the most open-minded (perhaps almost to the point of my brains falling out) to the claim that cell phones cause cancer, I still consider the claim, on basic science considerations alone, so incredibly implausible as to be an incredible, albeit not quite physically impossible, claim. I base this opinion on a preponderance of evidence that shows that brain cancer incidence is not increasing, inconsistent cell culture and animal studies that suffer from publication bias and when considered in the context of Bayesian prior plausibility are in fact negative, several epidemiological studies that failed to find a cell-phone cancer link, and the fact that the only epidemiological studies that claim to find a cell phone-cancer link have come from one group in Sweden whose principal investigator is known for being an expert witness in lawsuits against mobile phone companies.
Against that background, the background that journalists should have taken into account in writing about this study, let’s take a look at its results.
The National Toxicology Program study: Design
You will notice two points in nearly every story about this study, which was published at biorxiv.org. First is that the study was an expensive one. It cost $25 million. Second, it is frequently described with language like “one of the biggest and most comprehensive experiments into health effects from cellphones” and as “reigniting the debate” over cell phones and cancer. Personally, what I noticed about this study boiled down to two questions: How on earth can you spend $25 million on rat and mouse experiments? No, seriously. I do mouse and rat experiments myself in my lab, and, yes, they are expensive, but even with 90 rats per group, breeding rats, and repetitions I have a hard time figuring out how a study like this could cost $25 million. Hell, I could do a respectably large multicenter clinical trial for that much money. Indeed, I have a grant application in that proposes a reasonably sized pilot clinical trial for less than $2 million. I’m not saying that science isn’t expensive, but what’s going on here? My second question is this: Why was this release to the public instead of going through peer review first and being published in a decent journal? Basically, this is a report of a partial finding of a study not published in the peer-reviewed medical literature, with the report noting, “The findings in this report were reviewed by expert peer reviewers selected by the NTP and National Institutes of Health.” Something odd is going on here. As Matt Herper noted:
This paper was different. It was published on something called bioRxiv, a server for scientific papers run by Cold Spring Harbor Laboratory. It’s modeled on similar servers used by economists and physicists to share papers quickly, without the cumbersome process of going through peer review at medical journals. This is already par for the course for economists and physicists, but news in those fields tends to dribble out to the public. For medical studies, news can come in a giant, crushing wave.
After Microwave News released a story about the preliminary results of this study, according to Science the NTP investigators “decided to release the rat data before completing their analysis and writeup of the entire study, which isn’t scheduled to be finished until 2017, because of high public interest and the intriguing results.” See where that got them. This is one good reason why great care should be taken releasing preliminary results. What the NTP did borders on science by press release.
Now let’s look at the design of this study. One thing I found odd about it was that exposure to cell phone radiofrequency radiation (RFR) began in utero. Pregnant rats were exposed to 900 MHz GSM– or CDMA-modulated RFR beginning at on Gestation Day (GD) 5 and continuing through gestation. After birth, pups were exposed to the same RFR until weaning on postnatal day (PND) 21, at which point the mothers were removed and the exposure of 90 pups per sex per group was continued for up to 106 weeks. Pups remained group-housed from PND 21 until 24 they were individually housed on PND 35. All RFR exposures were “conducted over a period of approximately 18 hours using a continuous cycle of 10 minutes on (exposed) and 10 minutes off (not exposed), for a total daily exposure time of approximately 9 hours a day, 7 days/week.” Control rats were treated identically, except that they were not exposed to RFR.
Before doing this study with 90 rats per group, the NTP investigators did some pilot studies in order to establish that the RFR field strengths used didn’t raise the body temperatures of the rats, which could affect the results. They also did 28 day toxicology pilot studies before doing the massive experiment, which ended up with seven experimental groups:
     1.  Control (no RFR)
     2.  GSM 1.5 W/kg
     3.  GSM 3.0 W/kg
     4.  GSM 6.0 W/kg
     5.  CDMA 1.5 W/kg
     6.  CDMA 3.0 W/kg
     7.  CDMA 6.0 W/kg
At 90 rats per group, that’s 630 rats, but the rats were actually divided by sex, and 90 rats were used for each sex, which means that there were actually 1,260 rats. That’s a lot of rats.
The NTP study: Brain tumor results
The first thing that jumps out at me as I read the NTP report is this result:
At the end of the 2-year study, survival was lower in the control group of males than in all groups of male rats exposed to GSM-modulated RFR. Survival was also slightly lower in control females than in females exposed to 1.5 or 6 W/kg GSM-modulated RFR. In rats exposed to CDMA-modulated RFR, survival was higher in all groups of exposed males and in the 6 W/kg females compared to controls.
What I found particularly irritating about how this was reported was how difficult it was to find convenient, easy comparisons of the survival results for each group. Some Kaplan-Meier survival curves would have been really nice here, as we do in pretty much every medical paper in which survival is noted, including preclinical studies using rodents. If this paper were to have been submitted to a journal and I was asked to review it, I would insist on this because it takes way more effort to figure out what the authors found than it should. That being said, I can’t resist noting that some skeptics have been joking that in reality this study should have been reported with headlines like, “Cell phone radiation makes rats live longer.” True, saying that is just as misleading as many of the headlines about the study, but, then, that’s rather the point.
But what about cancer? What’s problematic about this study is that, even though there were 90 rats in each group, that’s actually a small number to detect meaningful differences in low frequency events. Here’s what I mean. The study reports increased incidences of tumors in the brains and hearts of the male rats. Specifically, there were noted to be increased incidences of malignant glioma and cardiac schwannomas in some of the groups exposed to GSM or CDMA RFR. Now here’s where the problem of small numbers comes in. The highest number of any single lesion in any single experimental group reported was 6, or 6.6% of the group. All numbers were in the single digits, and most were less than 3. Comparing such low frequency events between groups can be very problematic, particularly in the case low plausibility associations with multiple comparisons.
Let’s dive in a bit. In the male rats the number of gliomas detected for GSM RFR among 90 rats in each group was 3 (3.3%), 3 (3.3%), and 2 (2.2%) for 1.5 W/kg, 3 W/kg, and 6 W/kg, respectively, while for CDMA RFR the same numbers were 0 (0%), 0 (0%), and 3 (3.3%) for the same doses. Compare this to zero gliomas in the control group, and on the surface this looks alarming. There are a couple of problems. First, for GSM RFR, there doesn’t appear to be a dose-response, unless there is a threshold level that is, for example, below 1.5 W/kg. In fact, it’s a problem that the number of gliomas observed in the control group is zero, because according to historical controls in previous studies, that number should be around 2% (11/550 (2.0%), with a range from 0-8%), as is noted under Table 1. Examining the study that way, I have to be very concerned that there was something off about the control group, particularly given the lack of a clear dose-response effect and comparing to historical controls. Given that, color me very skeptical that this is a “real” result, particularly given that there was no statistically significant difference among the female rats, that there is no clear biological mechanism that would explain why GSM radiation would be more “carcinogenic” at the same exposure levels, and adding the very low prior plausibility that RFR causes cancer.
Bottom line: I believe that this result is almost certainly spurious and not indicative that cell phone RFR causes malignant gliomas in rats.
NTP Results: Schwannomas
In humans schwannomas are benign nerve sheath tumors (only 1% ever become malignant) composed of Schwann cells, the cell type that normally produces the insulating myelin sheath covering peripheral nerves. As noted in the introduction of the NTP study, there have been studies (that I consider unconvincing) linking cell phone RFR to acoustic neuromas, which are also known as vestibular schwannomas, thanks, presumably, to the proximity to the ear of the RFR source (the cell phone) when being used for a conversation. Why schwannomas would occur in nerves in the hearts of rats whose whole bodies were exposed to whole body cell phone RFR is puzzling and would be unexpected; that is, if these results are to be believed.
What the NTP investigators found in terms of the incidence of schwannomas was similar to what was found with respect to gliomas. There was no difference in incidence in females. In males, there was a statistically significant difference in schwannomas of the heart, but when the investigator looked for schwannomas elsewhere, they found:
In contrast to the significant increase in the incidence of schwannomas in the heart of exposed males, the incidence of schwannomas observed in other tissue sites of exposed males (GSM and CDMA modulations) was not significantly different than in controls (Table 5). Additionally, Schwann cell hyperplasia was not observed in any tissues other than the heart. The combined incidence of schwannomas from all sites was generally higher in GSM- and CDMA-modulated RFR exposed males, but not significantly different than in controls. The Schwann cell response to RFR appears to be specific to the heart of male rats.
In other words, the only significant result was an increase in schwannoma incidence in the hearts of male Sprague-Dawley rats exposed to cell phone RFR, while there was no difference between the control group and the exposed groups for total incidence of schwannoma at all sites. Another way of looking at this (at least from my point of view) is that, because the incidence of schwannoma at all sites did not differ between controls and the RFR-exposed groups of male rats, in the RFR-exposed group there was a redistribution of schwannoma to the heart. Considering that there is no known plausible biological mechanism to explain how RFR might somehow sensitize the heart to schwannoma formation only in males and given that high level of biological implausibility that RFR even causes schwannoma in the first place, again the most likely explanation is that this, too, is a spurious result.
The problems with this study
To its credit, the NTP included the peer reviews that it did ask for. One reviewer, a veterinarian named Diana Haines, commented mainly on the pathology and, although she agreed that the results should be considered “likely the result of exposures to GSM—and CDMA—modulated RFR,” she did have some caveats, particularly how well the scheme of exposing the rats beginning in utero represented actual human exposure (my assessment: not very well). Another reviewer, Maxwell Lee of the National Cancer Institute Laboratory of Cancer Biology and Genetics, analyzed the data and concluded that the association with glioma was significant for schwannomas but probably not for glioma. Of course, my retort is whether it’s biologically significant, something I sincerely doubt.
A third reviewer, Aleksandra M. Michalowski, also of the NCI Laboratory of Cancer Biology and Genetics echoed my complaint about the presentation of the overall survival of each group and actually did what the authors should have done and constructed a table of the median survival of each group, which showed that the median survival in the males receiving 6 W/kg CDMA RFR was 8% longer, which makes me want to change my sarcastic headline to “Cell phone radiation makes male rats live 8% longer on average.” In any case, she was concerned about the potential for bias and agreed that the glioma data were marginal, although she thought the schwannoma data were likely indicative of carcinogenesis. Multiple reviewers also noted that the survival of the control group of male rats was poorer than most historical controls (only 28% were still alive at two years, compared to a mean of 47%, range 24% to 72%), which might have skewed the results.
Perhaps the most comprehensive critique came from Michael S. Lauer of the Office of Extramural Research at the NIH, who noted potential problems with blinding, use of the intent-to-treat principle, and the like. He even did some simulations and power analyses and concluded that:
Based on these inputs, the recommendations in Table 13 of the FDA guidance document, and a sample size of 90 rats in each group, I find very low power (<5%, see Appendix 2). Even allowing for a risk ratio of 5.0 (a level that is clinically unlikely), the power for 2-sided alpha=0.005, k=3 and low lethality is only ~14% (see Appendix 2).
And:
The low power implies that there is a high risk of false positive findings2, especially since the epidemiological literature questions the purported association between cell phone exposure and cancer.
He was lead to conclude that he was “unable to accept the authors’ conclusions,” adding:
I suspect that this experiment is substantially underpowered and that the few positive results found reflect false positive findings. The higher survival with RFR, along with the prior epidemiological literature, leaves me even more skeptical of the authors’ claims.
So do I. So does Aaron Carroll, a.k.a. The Incidental Economist, who notes:
Where to begin? I didn’t see any sample size calculation, nor any discussion of what they expected to see. One of the reviewers did a power calculation for them (page 37) and found that based on 90 rats per group, the power was about 14%. This means that false positives are very likely. The cancer difference was only seen in females, not males. The incidence of brain cancer in the exposed groups was well within the historical range. There’s no clear dose response. Why schwannomas? Schwannomas in other locations than the heart were not significantly different. These are rats. I don’t know how this compares to real world exposure. And one more thing – the survival of male rats in the control group was relatively low, and if these tumors developed later in life, this could be the whole reason for the difference.
Yep.
I become even more skeptical by taking a Bayesian approach to the analysis and considering the very low prior probability of a positive result based on what we know about biology coupled with the multiple outcomes examined. Taking these issues into account, I agree with Lauer that the results reported are almost certainly due to chance and are not indicative of a real biological effect. There are just so many red flags in the study that should have told journalists that there’s a lot less there than meets the eye. I could tell this, and I’m not even a statistician.
Lessons to be learned
I had considered not blogging this, given how much digital ink had been spilled on the study within 24 hours after its being announced, but sometimes there is an advantage to having to wait three days before writing about a science story. It provides time to see how the reporting develops. To their credit, at least Scientific American, STAT, and Mother Jones altered their articles after criticism and noted that they had done so, with the results being much less alarmist stories. The same can’t be said about Consumer Reports or The WSJ.
I realize that news of the preliminary results of this NTP study had been reported by Microwave News (and in a very alarmist manner, I might add), and that that was likely the impetus for the NTP to rush to publish a preliminary report in a non-peer-reviewed source. I can even understand why the NTP might have done it. After all, imagine the conspiracy mongering that would have gone on after this report if the NTP had said that it wasn’t going to publish the results until it had been accepted to a peer-reviewed journal. I can picture the headlines: “Government hides evidence of cell-phone cancer link.” Still, I wish the investigators had waited, rather than to publish an incomplete study that was not peer-reviewed. Given that this is only a partial result, I anticipate a lot more seemingly-positive results that will likely be no more convincing than this publication was.
Matthew Herper, in criticizing how the press handled this story, noted that it scared him, correctly noting this about how all the caveats and red flags about this study were lost in the shuffle:
Those caveats should have come with the study when it came out. Instead, readers were told why they should be scared before they found out the reasons they should calm down.
I fear that this is not the last set of results from the NTP study that will be released to the public in this manner.

About that Cell Phone and Cancer Study
Steven Novella on August 5, 2015
Link


Recently there was another round of scaremongering headlines and articles claiming that cell phones can cause brain cancer. The Daily News wrote: “The scientists were right — your cell phone can give you cancer.” Many online news sites declared: “SHOCK STUDY: CELLPHONES CAN CAUSE CANCER,” in all caps to make sure you understand that you should be alarmed. None of the mainstream reporting I saw looked past the press release.
The study
Let’s take a look at the actual study: “Oxidative mechanisms of biological activity of low-intensity radiofrequency radiation” published in Electromagnetic Biology and Medicine.
The first thing to note as that this is a review article. It does not present any new data. It is not an experiment or observational study. It’s not even a meta-analysis. It is just a group of researchers looking at the literature and proclaiming that it confirms what they already believed.
Review articles serve a legitimate purpose in science. They are a primary way that researchers communicate with each other and express their opinion. But they should not be presented as if they are new data, or as if they confirm one side in a debate. They can be abused, however, in a process called citation bias – packing the review with citations that support your side to make it seem like it is more robust than it actually is (a process which can even start inadvertently just by relying reference lists rather than databases).
The lead author of the current review (to avoid confusion it really shouldn’t be called a “study”), Igor Yakymenko, has published several articles arguing that low intensity radio-frequency radiation (RFR) can increase oxidative stress in tissues and this is a possible mechanism of increased disease risk. In his current review he argues that the published evidence supports this position.
While the evidence may support the notion that RFR can increase markers of oxidative activity in tissue, it does not establish that this increase is biologically important and can actually lead to specific diseases. It also does not establish that cell phone use causes any harm by this mechanism.
At this point Yakymenko’s hypothesis is still speculative, and there is no evidence to make claims for actual health effects. There is no problem with him publishing a review of the data and arguing for his hypothesis, but it is dubious behavior to send out a sensational press release declaring victory in a scientific debate because of your own review, and then linking your claims to scary health concerns.
As we have argued here many times on SBM, basic science studies looking at complex biological markers in vitro or in animal studies are very difficult to extrapolate to net health effects in humans. It is tempting, however, for researchers to speculate wildly from biochemical changes measured in cells to downstream health effects. This applies equally to claims for health benefits as to claims for health risks.
Cell phones and cancer
I have written several times over the years about the scientific literature examining a possible link between cell phone use and cancer risk. At present there is no convincing evidence for a link, but the possibility of a link is not without controversy.
A 2012 systematic review of the literature looking at a possible connection concluded:
Meta-analyses of the epidemiology studies showed no statistically significant increase in risk (defined as P < 0.05) for adult brain cancer or other head tumors from wireless phone use. Analyses of the in vivo oncogenicity, tumor promotion, and genotoxicity studies also showed no statistically significant relationship between exposure to RF fields and genotoxic damage to brain cells, or the incidence of brain cancers or other tumors of the head.
However, a 2013 study looking at the CERENAT case-control data, found an increased risk of gliomas and meningiomas in the heaviest users. They found no association between cell phones and cancer as a whole, only in these subgroups.
Further there is some suggestion that the side of cell phone use correlates with the side of the tumor, but in this data this association was generally not statistically significant.
A 2014 study looking at cell phones, cordless phones, and acoustic neuroma concluded:
The findings do not support the hypothesis that long-term mobile phone use increases the risk of acoustic neuroma. The study suggests that phone use might increase the likelihood that an acoustic neuroma case is detected and that there could be bias in the laterality analyses performed in previous studies.
It also needs to be noted that there is a pretty solid consensus at this point among scientists that there is no convincing evidence for a link between cell phone use and cancers. There is a notable outlier, however, Swedish researcher Lennart Hardell. David Gorski wrote the definitive assessment of Hardell:
Whenever one group of researchers keeps finding a result that no other group seems able to replicate or that otherwise disagrees with what everyone else is finding, that’s a huge red flag for me. Remove those studies, and even the wisp of a hint of a shadow of the association between cell phone use and cancer found in this study disappears. I’d have a lot more confidence in this seeming association in “high quality” studies if the association didn’t depend upon a single researcher and if this researcher was not also known for being an expert witness in lawsuits against mobile phone companies.
Perhaps the most reassuring data is that brain tumors overall have not been increasing overall in the last 30 years. The data shows a slight increase in the 1970s and early 1980s, which was almost certainly due to the introduction of CT scans and then MRI scans allowing for more accurate diagnosis.
Trends in brain cancer
Since 1990, when cell phones started to be used, brain tumor incidence has been flat, possibly even declining slightly. This trend continues to the present day. We therefore have about 25 years of data showing that a dramatic increase in cell phone use over that time has not resulted in an increase in brain tumors overall. This is a powerful argument against any causal connection between cell phone use and brain tumors.
Of course, there are those, like the author of the current review, who argue that we need still more time. Perhaps it takes 30 years for the effect to manifest.
This is always the issue we run into with scientific data regarding possible risks – the data is always limited. We can never prove zero risk. Absence of data showing a connection can also be dismissed with arguments that the dose was not high enough, exposure was not long enough, or we did not look at the correct sub-groups. You can make these arguments about any absence of risk in the scientific data.
While we can’t prove zero risk, at some point the probable remaining risk becomes too small to worry about. At some point you are more likely to die because you did not have access to a cell phone, than from the radiation from cell phone use.
Conclusion – The failure of the media
This latest review was gleefully met by the mainstream media with utter credulity, which allowed them to post sensational click-bait headlines scaring the public yet again about cell phones and cancer. Few bothered to put this review into a proper context.
Interestingly, a recent survey finds that most people focus on the wrong risks for cancer. While awareness of tobacco and sun exposure is very high, many people focus on dubious risks, such as GMOs and pesticides, while failing to note proven risks, such as lack of exercise and eating too few fruits and vegetables.
Even more interesting, cell phone use did not even make the list. Other surveys find that even when consumers hear about a possible link between cell phones and cancer, they state they will not change their behavior.
It seems that in this one case, our addiction to the convenience of cell phones trumps dubious fear.

Cell phones and cancer: random chance in clinical trials
The full results of the National Toxicology Program’s study of cell phones and cancer are finally in. They are somewhat complicated, but ultimately do not support the idea that cell phones can cause cancer.
Christopher Labos on April 1, 2018
Link

[Editor’s note: Here is a guest post from a new contributor, Dr. Christopher Labos! Dr. Labos is a cardiologist at the University of McGill in the Great White North, and is a peer of Dr. Joe Schwarcz in McGill’s Office for Science and Society. We’re publishing it today as an extra bonus post the day before to complement Dr. Gorski’s usual Monday post because, unfortunately, the claim that cell phones cause cancer is back in the news again, thanks to the study Chris deconstructs in this post. Dr. Gorski’s post tomorrow will discuss a particularly egregious bit of reporting on cell phones and cancer. Enjoy!]
If anyone has ever tried to convince you that cell phones cause cancer, then they have probably cited the results of the National Toxicology Program (NTP) study. There have, of course, been other studies over the years, most of which aren’t nearly as conclusive as some would have you believe. Despite what IARC says, the evidence for a cell phone cancer link is very flimsy. For example, the Interphone study is often quoted as supporting a link between cell phones and cancer even though it was an overall negative study.
The NTP study though was an attractive argument for proponents of the cell phone – cancer link because it has the veneer of government respectability, was billed as a massive multimillion-dollar trial, and generated a lot of press attention. When they released the partial findings of their study in 2016 and showed an association between cell phones and cancer (specifically gliomas and cardiac schwannomas), a huge wave of frightening news headlines followed. The researchers told Science that they decided to release the data before completing their analysis and write-up because of “high public interest” in the results.
That these were partial or preliminary findings seems not to have bothered or deterred many people from claiming that cell phones cause cancer. Fortunately, the full data is now available, although it will still go through an external peer review and we may yet see further modifications.
The NTP study design
Before looking at the new full results, it is worth looking at the study itself. David Gorski and others have pointed out some of the issues with the study. To briefly summarize, the NTP study was an animal study and it had no human subjects. The rats and mice being studied had their entire bodies exposed to the radio frequency radiation (RFR) from cell phones for nine hours a day, every day, for two years, starting not at birth but in utero. In the press release accompanying the release of the full study results, one of the senior scientists of the NTP, John Bucher, acknowledged:
The levels and duration of exposure to RFR were much greater than what people experience with even the highest level of cell phone use, and exposed the rodents’ whole bodies. So, these findings should not be directly extrapolated to human cell phone usage.
Now to be fair, the NTP’s goal was to test toxicity and not to establish if human use was dangerous, which is essentially the difference between hazard and risk. But even if you accept the NTP study as true (and bear in mind we aren’t done with its limitations yet), its results do not have a direct bearing on how you as a human being use your cell phone. To their credit, the NTP researchers seem to be acknowledging this in the relatively nuanced way they have discussed their findings in the media.
But there were other problems, notwithstanding the lack of applicability to humans. The rate of cancer was very low in the control group and inconsistent with historical controls. There was no consistent dose-response meaning that higher levels of RFR did not clearly increase the risk of tumor formation. Finally, the rats exposed to cell phones lived longer than the rats in the control group.
This final point got very little press in the popular media. Most likely “cell phones cause cancer” was felt to be a more eye-catching headline than “cell phones make you live longer.” Nevertheless, many people were more than willing to ignore any findings that didn’t fit with their pre-determined narrative. While this may be understandable in terms of human nature and marketing, it is certainly not good science.
Malignant gliomas
Regardless of these limitations, the NTP study has spent the past 2 years being used as an argument in support of the claim that cell phones cause cancer. The full results released earlier this year were surprising, to me at least, because they were different from the initial preliminary results in a few notable ways. Most notably, the full results did not show a clear association between brain tumors and cell phone use. The discrepancy between these results and the 2016 preliminary findings had to do with a difference in their statistical analysis.
The authors explained that their preliminary analysis did not adjust for litter effects. Litter effects occur because pups born in the same litter are more similar to each other than they are to other rats. In effect, two pups in the same litter getting a disease is the not the same as two random unrelated pups getting the disease. While this may seem like a very minor and subtle statistical point, it was enough to change the authors’ interpretation of their data.
There was only one very small sliver of statistical significance (with a very notable absence of clinical significance). There was no positive association between cell phones and brain neoplasms for female rats, male mice, or female mice. The link occurred only in male rats and only for one type of signal modulation. The NTP study actually tested two different types of modulation schemes used in cell phone technology: GSM and CDMA. For GSM there was no statistically significant result for malignant gliomas or any other type of brain neoplasm. For CDMA, the rats exposed to 6W/kg had three (3) malignant gliomas, compared to none (0) for those exposed to 3W/kg, 1.5W/kg, or no exposure.
If you said that this finding could have been solely due to chance then you are to be congratulated in your astute observation. In reality when you compared the 6W/kg to the control group, there was no statistical difference. The statistically significant finding only occurred when you compared all four groups in a linear trend test.
Now, the super observant of you will have noticed that the 3W/kg and 1.5W/kg group had no brain tumors in them and you might be somewhat puzzled as to why adding zero brain tumor cases to a statistical analysis would make a result go from non-significant to significant. The answer is somewhat mathematically convoluted but, to put it simply, different statistical tests ask and answer slightly different questions, some of which are more meaningful than others. If your question is “Does the highest cell phone exposure group (6W/kg) have more brain tumors than the control group?” then the answer to your question is no.
You would be hard pressed to call the brain cancer results definitive. The authors called the results “equivocal,” which in my mind is somewhat generous. In any case, they did not suggest there was an association between cell phones and brain in the press release accompanying the release of their data, essentially walking back the claim from the 2016 preliminary findings.
Cardiac schwannomas
In the end, the only finding highlighted in the summary statement was the association with cardiac schwannomas. Schwannomas are tumors arising from Schwann cells that produce the myelin sheath around peripheral nerves. There has been concern that cell phones, because we hold them up to our ears when speaking into them, could increase the risk of a similar type of tumor called an acoustic neuroma. Some studies have suggested a link between acoustic neuromas and cell phones. Then again other studies do not suggest such a link and it is worth noting the positive studies seem to come mostly from one research group.
Thus, when the NTP found an association between cell phone exposure and cardiac schwannomas, it could be seen as supportive of the cell phone -acoustic neuroma link, since both types of tumors are histologically similar. Drilling down into the data though poses some problems for this association because, like the glioma analysis, the association only occurred in male rats. It did not occur in female rats, male mice, or in female mice.
The other odd point about the cardiac schwannoma analysis is that the rats had their entire bodies irradiated. Since there is no immediately obvious reason why these tumors should be localized to the heart, the schwanommas could have and did occur in any nerve through the rats’ bodies. The researchers found schwannomas in other organs including the pituitary gland, trigeminal nerve, salivary gland, and eye. However, when you look at all schwannomas, not just the ones in the heart, there was no significant difference between the exposed and control rats. Therefore, for this analysis to be positive (and therefore concerning to anyone) you have to ignore the rest of the body and focus only on the tumors occurring in the heart.
The play of chance and miracle dice
There is, however, another more mathematical reason to be skeptical of the NTP results. The NTP study is a vast undertaking and the current reports are over 650 pages long for both rats and mice. But that vastness is its Achilles heel. They present dozens upon dozens of analyses, and if you do enough analyses you will eventually get a positive result simply due to the play of chance.
To understand how pernicious the play of chance can be in medical research, it is worth reviewing the study of Carl Counsel and his miracle dice. Counsel gave his statistics students red, white and green dice as part of a class exercise. He had them roll the dice repeatedly to simulate the results of clinical trials (rolling a 6 meant the patient died from a stroke while rolling a 1 through 5 meant the patient survived). He told his students some dice were loaded and would produce more or less sixes. After generating and analyzing their data, his students found that red dice increased the odds of “death” and that white and green dice were protective. Therefore, in their minds, they had discovered which dice were loaded.
They were sadly quite mistaken since Counsel had purposely deceived them and given them perfectly normal, evenly-balanced dice. The positive association occurred because Counsel’s students went looking for a result (any result) and subsequently found one. They were so convinced by their data that when Counsel explained to them that the dice were fair, some of them didn’t believe him:
Some of the participants were convinced that their own dice was really loaded. Trialist A described his reaction to his first trial… he rolled one six, followed by another and then a third. He said that his room felt eerily quiet as he rolled a fourth six: he had never rolled four sixes in a row in his life. By the time he had rolled the fifth, he was certain that the dice was loaded, and the sixth six only confirmed his belief that DICE therapy clearly had an effect.
Counsel explained in his paper that he “undertook this slightly tongue in cheek study to illustrate just how extraordinary the effects of chance can be” and that even high methodological standards are no defense against it. He explains:
Chance does not get the credit it deserves. Most doctors admit that chance influences whether they win the Christmas raffle but underestimate the effect of chance on the results of any clinical trials they read about.
So could the results of the NTP study have been purely due to chance? Given the multiplicity of analyses, I think we need to concede that this is possible and in fact is pretty likely. The entirety of the NTP study essentially had four different groups (male rats, female rats, male mice, female mice) that were analyzed for many different types of cancer (heart, brain, pituitary, adrenal, liver, prostate, kidney, pancreas, mammary gland, and thymus cancer among others). In reality they looked at many different subtypes of cancers and of course some cancers would only occur in one sex (like prostate cancer or ovarian cancer). But for the sake of mathematical simplicity let’s assume they analyzed seven types of cancer, which could have occurred in all four groups of rodents. Seven types of cancer across four groups of subjects yields 28 different analyses, and it is highly likely that you would get at least one false positive result due purely to chance.
If you assume that the chance of a false positive result is 5% (which is a standard assumption) then if you do one analysis, the chance of a false positive is:
1- 0.95 = 0.05 or 5%
Do two analyses and the chance of at least one false positive is:
1- 0.952 = 0.0975 or 9.75%
Do 5 analyses and the chance of at least one false positive is:
1- 0.955 = 0.23 or 23%
Do 28 analyses and the chance of at least one false positive is:
1- 0.9528 = 0.76 or 76%
If a researcher does enough statistical tests, then some false positive results are inevitable simply due to the play of chance. The ISIS-2 study demonstrated this fact perfectly. The ISIS-2 is historically important in the field of cardiology because it demonstrated that giving aspirin to patients after a heart attack improved outcomes. However, even though the study was overall positive one subgroup of patients showed no benefit. That subgroup was patients born under the zodiac signs of Gemini and Libra. Fortunately, 1988 was apparently more reasonable time and no one suggested that astrology become a complementary or integrated field of cardiology. In fact, the authors of the ISIS-2 study purposely highlighted this rather ludicrous and totally spurious statistical finding to demonstrate that “all these subgroup analyses should be taken less as evidence about who benefits than as evidence that such analyses are potentially misleading.”
Adjusting for random chance
We are not helpless when it comes to the problem of randomness though, and there many things we can do to avoid falling into the trap. The first option is to avoid multiple testing in the first place and simply test one hypothesis in a well-powered study that will address the question you want to answer. If you must test everything under the sun, then replicating your findings is crucial, though repeating a multi-year study obviously takes considerable time, money and effort.
Since waiting for someone to replicate your findings is not useful in the short-term, one potential solution to the multiple-hypothesis testing problem is to use the Bonferroni correction. The Bonferroni correction is a rather simple statistical adjustment and requires very little extra math. If you do one analysis, you can stick with the standard p<0.05 threshold for statistical significance (I personally do not agree with using p-values as a statistical threshold for multiple reasons but I will bite my tongue for now).
If you choose to do multiple tests, then you simply divided 0.05 by the number of tests you intend to perform to establish your new threshold.
    • So if you perform two tests then your new threshold is 0.05/2 = 0.025.
    • Perform 10 tests and the new threshold should be 0.05/10 = 0.005
    • Perform 20 tests and the new threshold should be 0.05/20 = 0.0025
In the field of genetics, where researchers can test over a million genes at a time, the Bonferroni correction is regularly used to avoid false positives and statistical associations may have to reach p-values of p<5×10-8 in order to be deemed significant. We do not need to go that far, but the point is that there is nothing magical or even intuitive about the p=0.05 threshold, and in a study that plans to perform dozens of different analyses, a lower threshold is certainly justified. Not everyone agrees with the Bonferroni corrections and some say that it is too conservative, meaning that the p-value threshold is too low. More permissive alternatives to the Bonferroni correction do exist, although it has remained popular due to its mathematical simplicity and its intuitive straightforwardness. Whatever strategy you subscribe to, the point is that when testing multiple hypotheses within the same dataset, it is important to down the p<0.05 threshold, that researchers seem to be obsessed with, downwards. If the NTP had implemented a Bonferroni correction none of the “statistically significant” results would have met the cut, since most barely squeaked by the p<0.05 threshold.
The NTP study in context
So is it logical to assume that cell phones induce cancer in male rats, but not female rats, or in mice? Is it logical to assume that cell phones increase the risk of cardiac schwannomas but not of schwannomas in the rest of the body? Is it logical to assume that cell phones increase the risk of cancer while also extending survival? I would say no.
Given the sheer number of statistical tests performed one must be prepared to find some false positives and this is very likely what happened here. Paradoxically, though many had trouble calling the brain cancer and cardiac schwannoma finding spurious, they were more than willing to attribute the increased survival to the play of chance. Remember that rats exposed to cell phones lived longer then controls, probably because the control group rats developed more kidney disease for some unknown reason. No one truly believes that cell phones will extend survival, but people’s preconceived notions allowed them to dismiss some “statistically significant” results and not others.
It is also worth remembering that the amount of cell phone exposure given to these rodents (whole body irradiation 9 hours a day for 2 years) is unlike anything you will experience as a human being. I do not think that this study should affect your life in any way. Although, perhaps John Bucher, the NTP researcher I quoted earlier, put it most succinctly in an interview with Reuters.
Asked what the public should take from the study, Bucher said, “I wouldn’t change my behavior based on these studies, and I haven’t.”
If Bucher isn’t going to change his behavior, then you probably shouldn’t either. The only suggestion I would make about cell phone is to stop using them while you drive since thousands of people die every year due to distracted driving. Like Counsel’s student who rolled all those sixes, we are remarkably unwilling to admit that sometimes our results are the product of random chance. The link between cell phones and cancer in the NTP study is very likely due to random chance. The link between cell phones and traffic accidents is very real.

The Nation indulges in fear mongering about cell phones and cancer
An article published last week in the Nation likens wireless telephone companies to tobacco and fossil fuel episodes in their tactics of spreading fear, misinformation, and doubt regarding the science of cell phone radiation and health. To produce this narrative, the investigation’s authors rely on unreliable sources and cherry pick scientific studies, ignoring the scientific consensus that cell phone radiation almost certainly doesn’t cause cancer, all the while disingenuously claiming that they aren’t taking a position on the health effects of radio waves.
David Gorski on April 2, 2018
Link

Far more frequently than I’d like it to be necessary, we here at Science-Based Medicine (SBM) find ourselves writing about various health fear mongering about cell phones and wifi. The idea that the radiofrequency electromagnetic radiation used by cell phones and wireless networks is somehow causing horrendous health effects in humans, be it cancer (brain, breast, or other), behavioral problems, mental illness, or whatever is, like antivaccine pseudoscience, a claim not supported by evidence that just will not go away. Indeed, some take it a step further, inventing a syndrome called “electromagnetic hypersensitivity,” in which certain people are especially sensitive to the claimed adverse health effects due to radio waves. It doesn’t help, either, that organizations like the World Health Organization’s International Agency for Research on Cancer (IARC) erroneously categorized cell phone radiation as a “possible carcinogen” or that the U.S. National Toxicology Program (NTP) wasted $25 million on a study of cell phone radiation in rats that, at the time of a partial report of its results for gliomas and cardiac schwannomas, had produced singularly unconvincing results for a link between cell phones and cancer, but it produced sensationalistic headlines claiming a link. As of last month, the full study has shown no more convincing evidence. As Dr. Christopher Labos, our latest guest contributor explained in his post earlier today, the results are most consistent with random noise.
The latest magazine to publish a sensationalistic story about cell phones is The Nation. Amusingly, someone in The Nation‘s PR department thought it would be a good idea to send me a link, as though we would blog about it. Of course, I’m happy to oblige, because this story is an example of much of what is wrong with reporting on the issue of cell phones and health effects due to cell phone radiation. Written by Mark Hertsgaard and Mark Dowie and entitled “How Big Wireless Made Us Think That Cell Phones Are Safe: A Special Investigation.” Its tagline? The disinformation campaign—and massive radiation increase—behind the 5G rollout. The basic thesis of the article is that “big wireless” is a lot like “big tobacco” in hiding the science or preventing definitive science from being done because, presumably, it has something to hide. It’s the very same sort of argument that antivaxers like to make about big pharma and vaccines, likening vaccine manufacturers to big tobacco and claiming the same sort of disinformation campaign that big tobacco waged for decades to hide, minimize, and obfuscate the emerging scientific evidence of the harm cigarette smoking was causing through causing lung cancer, heart disease, and a variety of other diseases.
No one, least of all I, is claiming that big telecom and big pharma are pristine, as clean as the driven snow. We do know from science, however, that vaccines do not cause autism and that cell phone radiation not only does not cause the health effects attributed to it but almost certainly cannot cause those health effects because the energy carried by radio waves is too low to do what is claimed. It’s basic physics. For instance, I like to say that, although a link between cell phone radiation and cancer is not homeopathy-level implausible, it is incredibly implausible, simply because most of mechanisms of carcinogenesis we know involve as an inciting event the breaking of chemical bonds in DNA to cause mutations, and even the mechanisms we’re coming to understand that might require chemical bond breakage as an inciting event are incredibly unlikely to be impacted by such low energy waves.
Enter The Nation.
A disingenuous disclaimer
In discussing The Nation‘s fear mongering story, I can’t help but start part way through the article, with its disclaimer:
This article does not argue that cell phones and other wireless technologies are necessarily dangerous; that is a matter for scientists to decide. Rather, the focus here is on the global industry behind cell phones—and the industry’s long campaign to make people believe that cell phones are safe.
That campaign has plainly been a success: 95 out of every 100 adult Americans now own a cell phone; globally, three out of four adults have cell-phone access, with sales increasing every year. The wireless industry is now one of the fastest-growing on Earth and one of the biggest, boasting annual sales of $440 billion in 2016.
This disclaimer is disingenuous in the extreme, given that the central theme of the article is that, as big tobacco and big oil worked to hinder research examining the deleterious health effects of smoking or the effects of the burning of fossil fuels and climate change, respectively, and spread fear, uncertainty, and doubt about scientific results that cast their products in a bad light, big telecom has engaged in a multidecade campaign to do the same with results that allegedly show adverse health effects from cell phone radiation. The reason? As the passage above claims, it was all about profits, just as it was for the tobacco and fossil fuels industries. The way the authors cherry pick studies to cite and how they portray the telecom industry leads one to picture its executives twirling their moustaches as people die of brain cancer from their products, I call BS on the disclaimer above. This article has a point of view, and that point of view boils down to: (1) cell phones are harmful and (2) the telecom industry has been covering up science supposedly showing those harms.
Indeed, the article starts off with a description of how George Carlo was led off the premises of the Cellular Telecommunications and Internet Association (CTIA) grounds:
Things didn’t end well between George Carlo and Tom Wheeler; the last time the two met face-to-face, Wheeler had security guards escort Carlo off the premises. As president of the Cellular Telecommunications and Internet Association (CTIA), Wheeler was the wireless industry’s point man in Washington. Carlo was the scientist handpicked by Wheeler to defuse a public-relations crisis that threatened to strangle his infant industry in its crib. This was back in 1993, when there were only six cell-phone subscriptions for every 100 adults in the United States. But industry executives were looking forward to a booming future.
Remarkably, cell phones had been allowed onto the US consumer market a decade earlier without any government safety testing. Now, some customers and industry workers were being diagnosed with cancer. In January 1993, David Reynard sued the NEC America Company, claiming that his wife’s NEC phone caused her lethal brain tumor. After Reynard appeared on national TV, the story went viral. A congressional subcommittee announced an investigation; investors began dumping their cell-phone stocks; and Wheeler and the CTIA swung into action.
Lorne Trottier has called Carlo an “industry gadfly,” and he’s correct. My reading of his activities and publications since the 1990s suggest to me that he’s also become a bit of a crank. Let’s just put it this way. If you’re featured on Whale.to with a glowing profile, the chances that you’re championing good science are slim and none. Indeed, Carlo’s work is widely cited by the usual assortment of cranks and quacks promoting “electromagnetic hypersensitivity” diagnoses and selling “shielding” and blankets that are claimed to protect you from the dreaded electrosmog. Also, one can’t help but note that Carlo’s publication record dropped off precipitously to near zero after around 2000, with only three publications between 2013 and 2015 since then. I also can’t help but note that I could find around the time of the events described in this article (the 1990s) only one paper co-authored by Carlo and published in the New England Journal of Medicine that looked at the effect of cell phone radiation on implantable pacemakers. His relative dearth of publications even before he took over the WTR project makes me wonder whether he was actually competent to oversee the studies tasked to him.
Indeed, Carlo published a paper claiming to have found a link between cell phone radiation and autism. It was unimpressive, so much so that Steve Novella blogged about it. Let’s just say that he didn’t think it was an example of good science. (Actually, he described it as “a mishmash of pseudoscientific nonsense.”) I note, however, that, while Dr. Novella was unimpressed, Whale.to was quite impressed, so much so that it’s hosting a copy of the study.
Things left unsaid
In fairness, The Nation‘s reporting does make a reasonable case that the wireless industry prevented the publication of the full findings of the WTR project, although a summary of its results was published in Medscape General Medicine in 2000, and the industry’s treatment of Carlo, complete with guards escorting him from campus and the like, was rather suspicious:
Whatever Carlo’s motives might have been, the documented fact is that he and Wheeler would eventually clash bitterly over the WTR’s findings, which Carlo presented to wireless-industry leaders on February 9, 1999. By that date, the WTR had commissioned more than 50 original studies and reviewed many more. Those studies raised “serious questions” about cell-phone safety, Carlo told a closed-door meeting of the CTIA’s board of directors, whose members included the CEOs or top officials of the industry’s 32 leading companies, including Apple, AT&T, and Motorola.
Carlo sent letters to each of the industry’s chieftains on October 7, 1999, reiterating that the WTR’s research had found the following: “The risk of rare neuro-epithelial tumors on the outside of the brain was more than doubled…in cell phone users”; there was an apparent “correlation between brain tumors occurring on the right side of the head and the use of the phone on the right side of the head”; and “the ability of radiation from a phone’s antenna to cause functional genetic damage [was] definitely positive….”
I also suspect that we’re reading only one side of the story, Carlo’s, spoon fed to Hertsgaard and Dowie. Indeed, the choice that the authors made to mention the lawsuit by David Reynard very early in their article tells you all you need to know about the level bias in the story. That was one of the more ludicrous lawsuits ever brought over cell phones and cancer. The reason? Reynard’s major claim was that his wife’s brain tumor looked like a cell phone antenna and that’s what convinced him that the cell phone must have caused her brain tumor. Don’t believe me? Read the transcript of an interview with Reynard on Larry King Live in 2000 and an article in the New York Times from 2011. Funny how that was left out.
The story left out a lot, actually. Again in fairness, it is true, as the Nation article points out, that Carlo got his start as an industry flack, although it was even worse than described, as he actually worked for the “Association for the Advancement of Sound Science”, which was funded by Philip Morris to undermine any research showing any adverse effects of secondhand tobacco smoke. Perhaps that explains his sparse publication record, even before he was hired by the wireless industry. I also wonder if mentioning that Carlo was formerly a tobacco company shill before being hired by the CTIA would have made him look so bad that his “conversion” to a gadfly tormenting the wireless industry would have been less convincing. Whatever the case, in fairness, one has to concede that the wireless industry’s original hire of Carlo does indeed have the stench of the tobacco industry about it. However, it’s not just that. It’s that there’s a lot more to the story of Carlo’s breakup with the wireless industry than Hertsgaard and Dowie report, and a lot of what is left out is information that would cast doubt on Carlo’s motives and competence.
For instance, Sourcewatch (no friend of industry, much less the wireless industry) has a very interesting entry on George L. Carlo, which does not paint him in a very good light at all. It cites an article from the May/June 2003 issue of Microwave News, reviewed the progress of the WTR project:
George Carlo’s Wireless Technology Research (WTR) had run a confidence game on behalf of the mobile phone companies… Carlo and the industry he represented never wanted to do any actual research… WTR’s $25-million research budget was by far the largest pot of money ever earmarked for RF research. It was squandered. The public is a loser because Carlo brought us no closer to understanding the health risks from cell phone radiation… For close to a decade, its members were denied the chance to do the promised research. Carlo’s strategy was clever and effective. By dangling a huge amount of money in front of the cash-starved RF community, Carlo guaranteed silent obedience. Anyone who dared complain risked being cut off from his millions. There was the added benefit that scientists were discouraged from helping lawyers who were thinking about suing cell phone companies. WTR’s bank account is now empty.
SourceWatch also notes:
Carlo broke with the Cellular Telephone Industry Association after the money finally ran out (they eventually funded him to the tune of $27.5 million). His demand for further funding fell on deaf ears, and the dispute also led to an acrimonious exchange as a consequence of Carlo’s disputed divorce settlement when the CTIA refused to make WTR accounts available to his lawyers. They became implacable enemies.
At this late stage Carlo had a Damascian conversion, and overnight he became an enemy of the cellphone industry, charging that the CTIA was responsible for covering up some of the scientific findings uncovered by WTR funding, which he says had showed cellphones were dangerous. He never specified exactly what research funded by WTR and shown these dangers, but he was effective with the media and got his message across.
Further oddities included the following:
    • Carlo teamed up with a product liability lawyer who wanted to sue the mobile phone companies on behalf of clients who had brain cancer. However, that project collapsed because the scientific links could never be convincingly demonstrated. It is tempting to liken Carlo to Andrew Wakefield here, who got his start studying vaccines and autism doing research for a trial lawyer.
    • Carlo also wrote a book with Martin Schram that was noticeable more for what it avoided discussing than what it revealed. (Cellphones: invisible Hazard in the Wireless Age).
    • Carlo joined forces with a “bio-shield” company {BioPro]] to promote a stick-on device to protect against “harmful cellphone radiation.” (These devices are worthless and do not work. They’re basically scams.) This arrangement also collapsed in acrimony. (This seems to be a recurring theme with Carlo, acrimonious breakups with former employers or partners.)
I found this all out with just a little bit of Googling, plus an article that’s still available on Archive.org about Carlo. One wonders if Hertsgaard and Dowie bothered to Google a bit about George Carlo and, if they did, why they only told one side of his story, the side that paints him as a brave whistleblowing warrior for scientific truth. I mean, seriously. The SourceWatch entry was incredibly easy to find.
Conspiracies everywhere!
I started with the disingenuous disclaimer above because it strains credibility beyond breaking to believe that the authors are not arguing that cell phone radiation is harmful and that it should be “left up to the scientists,” given that the scientific consensus is currently strongly in favor of the conclusion that there is no detectable increased risk of brain cancer or other adverse health outcomes associated with cell phone radiation, particularly given that the article states bluntly, “Billions of cell-phone users have been subjected to a public-health experiment without informed consent.” Let’s just put it this way. You don’t use language like that if you think that the product you’re discussing is benign. Indeed, it’s exactly the same sort of language antivaxers use when they describe vaccines. You could substitute the words “vaccinated children” for “cell phone users” and the sentence would not be out of place on any antivaccine website or blog.
More interesting, however, is how the authors consistently want it both ways. For example:
This Nation investigation reveals that the wireless industry not only made the same moral choices that the tobacco and fossil-fuel industries did; it also borrowed from the same public-relations playbook those industries pioneered. The playbook’s key insight is that an industry doesn’t have to win the scientific argument about safety; it only has to keep the argument going. That amounts to a win for the industry, because the apparent lack of certainty helps to reassure customers, even as it fends off government regulations and lawsuits that might pinch profits.
Central to keeping the scientific argument going is making it appear that not all scientists agree. Again like the tobacco and fossil-fuel industries, the wireless industry has “war gamed” science, as a Motorola internal memo in 1994 phrased it. War-gaming science involves playing offense as well as defense: funding studies friendly to the industry while attacking studies that raise questions; placing industry-friendly experts on advisory bodies like the World Health Organization; and seeking to discredit scientists whose views depart from the industry’s.
Funding friendly research has perhaps been the most important component of this strategy, because it conveys the impression that the scientific community truly is divided. Thus, when studies have linked wireless radiation to cancer or genetic damage—as Carlo’s WTR did in 1999; as the WHO’s Interphone study did in 2010; and as the US National Toxicology Program did in 2016—industry spokespeople can point out, accurately, that other studies disagree. “[T]he overall balance of the evidence” gives no cause for alarm, asserted Jack Rowley, research and sustainability director for the Groupe Special Mobile Association (GSMA), Europe’s wireless trade association, speaking to reporters about the WHO’s findings.
Notice the sleight of hand here. The implication behind the entire argument and claim made above is that the scientific community agrees that cell phone radiation causes adverse health effects and that only industry-sponsored studies find otherwise. This is a gross misrepresentation of the state of the science, when in reality the scientific consensus is on the side of the lack of a correlation between radio wave exposure due to cell phone use and cancer, making the scientists who believe that cell phone radiation is dangerous the ones who are in a clear minority. Don’t believe me? Take a look at this list of consensus statements from governments and expert panels regarding the heath effects and safe exposure levels of radiofrequency energy. There are a whole lot of statements like:
The balance of evidence to date suggests that exposures to RF radiation below NRPB and ICNIRP guidelines do not cause adverse health effects to the general population…[and]The balance of current research evidence suggests that exposures to the radiofrequency energy produced by cellphones do not cause health problems provided they comply with international guidelines. Reviews of all the research have not found clear, consistent evidence of any adverse effects.
There are many more such consensus statements.
The National Cancer Institute, the American Cancer Society, the CDC, and the FDA all conclude that there does not appear to be a risk of adverse health outcomes, including cancer, attributable to cell phone use.
It’s also rather telling which studies Hertsgaard and Dowie use as proof of the all-powerful telecom industry’s power. For instance, there was the Interphone study:
To be sure, the industry could not have been pleased with some of the Interphone study’s conclusions. The study found that the heaviest cell-phone users were 80 percent more likely to develop glioma. (The initial finding of 40 percent was increased to 80 to correct for selection bias.) The Interphone study also concluded that individuals who had owned a cell phone for 10 years or longer saw their risk of glioma increase by nearly 120 percent. However, the study did not find any increased risk for individuals who used their cell phones less frequently; nor was there evidence of any connection with meningioma.
When the Interphone conclusions were released in 2010, industry spokespeople blunted their impact by deploying what experts on lying call “creative truth-telling.” “Interphone’s conclusion of no overall increased risk of brain cancer is consistent with conclusions reached in an already large body of scientific research on this subject,” John Walls, the vice president for public affairs at the CTIA, told reporters. The wiggle word here is “overall”: Since some of the Interphone studies did not find increased brain-cancer rates, stipulating “overall” allowed Walls to ignore those that did.
We’ve discussed the Interphone study before. It was actually a negative study and provided nothing even resembling compelling evidence that cell phones might be linked to cancer, the efforts of people like George Carlo and journalists like Hertsgaard and Dowie to paint it as a positive study notwithstanding. In this article, the Interphone study is portrayed as being a disappointment to the study scientists’ telecom paymasters for supposedly having a positive result, while real scientists explaining the nuance of the study and why it is not a positive study are evidence of the telecom industry “spinning” an “inconvenient result.” Elsewhere, supposedly a $4.7 million contribution to the World Health Organization led to the inclusion of industry representatives on the IARC, which only classified cell phone radiation as a “possible carcinogen.” Of course, as we’ve pointed out before, based on the existing evidence, even that’s a stretch, but Hertsgaard and Dowie represent it as the outcome of nefarious activity by the telecom industry, rather than science.
When Lorne Trottier last discussed the IARC classification of cell phone radiation as a possible carcinogen on SBM, he quoted Ken Foster, who pointed out, “Their conclusion is easy to misinterpret…Saying that something is a ‘possible carcinogen’ is a bit like saying that someone is a ‘possible shoplifter’ because he was in the store when the watch was stolen. The real question is what is the evidence that cell phones actually cause cancer, and the answer is — none that would persuade a health agency.”
He also noted that the IARC relied too heavily on some seemingly positive studies by Lennart Hardell’s group in Sweden. His group is viewed by most epidemiologists studying links between cell phone radiation and cancer as an outlier, and Trottier pointed out that his studies appear to rehash the same data set using highly flawed methodology. Guess which scientist Hertsgaard and Dowie like besides George Carlo? You guessed it. Lennart Hardell. Of course, they paint all the scientific criticism of Hardell’s studies as nothing more than the telecom industry striking back. Even more than that, they provide a link to a petition by Hardell that very much resembles (to me at least) the “dissent from Darwin” petition pointed to by creationists. Here’s a taste of the rhetoric:
The Nuremberg code (1949) applies to all experiments on humans, thus including the roll-out of 5G with new, higher RF-EMF exposure. All such experiments: “should be based on previous knowledge (e.g., an expectation derived from animal experiments) that justifies the experiment. No experiment should be conducted, where there is an a priori reason to believe that death or disabling injury will occur; except, perhaps, in those experiments where the experimental physicians also serve as subjects.” (Nuremberg code pts 3-5). Already published scientific studies show that there is “a priori reason to believe” in real health hazards.
Again, this sounds very much like the sort of argument made by antivaxers, who regularly like to invoke the Nuremberg code in claiming that the current vaccination program is actually medical experimentation causing harm. Hint to Professor Hardell (and to Hertsgaard and Dowie): If you want to convince someone that you’re arguing good science, don’t sound like an antivaxer.
What, you might ask, is the goal of the nefarious machinations of the telecom industry as reported by Hartsgaard and Dowie? To prevent any resistance to the development of the “Internet of things” and products using 5G wireless, which, Hertsgaard and Dowie direly warn us, will “will require augmenting today’s 4G technology with 5G, thus massively increasing the general population’s exposure to radiation.” Of course.
The narrative
The most striking thing about this Nation article was, as far as I’m concerned, the disingenuousness of it all. The authors argue with a straight face that they are not taking a position one way or the other regarding whether cell phone radiation causes cancer or other health problems and that they believe that “scientists should decide” if cell phone radiation is dangerous. Yet, tellingly, they don’t quote a single scientist of any standing on the issue and appear to have constructed their story largely around the narrative promoted over nearly two decades by George Carlo, hardly a reliable source and someone who appears to me to be a science denialist who switched sides after a falling out with his last industry paymasters that occurred when the money ran out. Carlo’s narrative is presented as fact, with no mention of the various other troublesome aspects of his history, such as his history of having hawked bogus products to “protect” against cell phone radiation. Such facts would, of course, have painted Carlo in a less flattering picture and diluted the intended message of the story. It’s also ancient history at this point. There’s been a lot of science done since then, and it doesn’t support the fear mongering.
Of course, any attempt by corporate interests to cover up inconvenient science would be rather pointless if there weren’t actual evidence of harm. After all, if tobacco weren’t highly carcinogenic, there would have been no point in tobacco companies going to such lengths to cover up the emerging science supporting links between tobacco and cancer and various diseases. Similarly, framing an article in a way that compares the tactics of telecom companies with respect to the biology of cell phone radiation is kind of pointless if that radiation doesn’t cause harm. So, their claims that they take no position on whether cell phone radiation causes health problems notwithstanding, Hertsgaard and Dowie do their damnedest, if not to prove such a link, to cite all sorts of studies that they consider suggestive of such a link, ignoring biological plausibility, and ignoring the studies making up the scientific consensus that cell phone radiation hasn’t been linked with cancer or health problems. Basically, they cherry pick. For instance, they cite a study in plants (Vicia faba seedlings) purporting to show that radiofrequency energy can interfere with DNA replication as though it has any relevance to humans. They misrepresent the Interphone study as an actual positive study. The list goes on. They also represent the view of someone like George Carlo as the scientific consensus, with those arguing that existing scientific evidence shows no detectable health effects from cell phone radiation as industry shills. It’s really that blatant.
Of course, the story had to be this way once the authors decided that the narrative was going to be that telecom companies are like tobacco companies. Even if the telecom industry did indeed try to prevent studies examining the health effects of cell phone radiation or to co-opt science through the WTR project, there wouldn’t be nearly as much reason for outrage if the actual science doesn’t show any harm, and this story is clearly meant to outrage readers. In the end, all I can say is this: For people who claim to be agnostic about whether cell phone radiation causes cancer and other bad things, Hertsgaard and Dowie sure have a strange way of showing it. This was irresponsible journalism at its most irresponsible.

No, carrying your cell phone in your bra will not cause breast cancer, no matter what Dr. Oz says
Dr. Oz continues promoting quackery, this time fearmongering that cell phone radiation causes breast cancer if a woman keeps her phone in her bra.
David Gorski on December 16, 2013
Link
I don’t think very highly of Dr. Oz.
Yes, yes, I realize that saying that is akin to saying that water is wet, the sun rises in the east, and that it gets damned cold here in the upper Midwest in December, but there you go. This year, I’ve been mostly avoiding the now un-esteemed Dr. Mehmet Oz, a.k.a. “America’s doctor,” even though his show could, if I paid much attention to it anymore, provide me with copious blogging material, because I’ve come to the conclusion that he is beyond redemption. He’s gone over to the Dark Side and is profiting handsomely from it. There’s little I can do about it except for, from time to time, writing about some of Dr. Oz’s more egregious offenses against medical science and reason, putting our tens of thousands of readers per day against his millions of viewers per day. It’s an asymmetric battle that we don’t have much of a shot at winning. However, at least from time to time I can correct misinformation that Oz promotes, particularly when it impacts my speciality. Consider it doing something pre-emptively to help myself. When one of my patients ask about something that’s been on Oz’s show, I can simply point her to specific blog posts, as I did the last time around when Oz arguably flouted the human subjects protection regulations of his own university and of the Department of Health and Human Services by running in essence a poorly-designed clinical trial to show that green coffee bean extract can promote weight loss. Of course, it showed nothing of the sort.
This time around, Dr. Oz caught my attention about a week and a half ago. I had planned on blogging about it last week, but the case of the Amish girl with cancer whose parents stopped her chemotherapy after less than two full courses, thus endangering her life, intervened. (It also didn’t help that I hadn’t recorded the show and the segment hadn’t shown up on Dr. Oz’s website by Sunday night last week.) I figured that I probably wouldn’t get back to Oz, but—wouldn’t you know it?—a week later I’m still annoyed at this story. So better late than never.
The story aired on December 6 and was entitled Why You Should Keep Your Cell Phone Out of Your Bra. The entire segment, lasting ten minutes or so, is one blatant piece of fear mongering. Even by the usual low standards of a typical Dr. Oz segment, this one was bad. How bad? I’ll give you a taste. Let me start just by asking what you might expect in a segment claiming a link between an environmental exposure of some sort and a specific cancer? You’d expect some actual scientific evidence, wouldn’t you? Some epidemiology, perhaps, showing that women who hold their cell phones in their bras have a higher risk of breast cancer, perhaps with some relative risks that were at least statistically significant. You might expect some scientific evidence suggesting why the proposed mechanism is plausible. You might even expect that there would be convincing (or at least suggestive) evidence that women who put their cell phones in their bras, when they develop breast cancer, develop it more frequently on the side where they stick their cell phone. These would be reasonable things to expect that, even though they wouldn’t be convincing proof, would at least raise concerns.
There was none of that at all. Zero. Nada. Zip. In fact, I was shocked at how evidence-free this whole segment was. Usually Oz at least tries to slather a patina of scientific evidence on his pseudoscience. OK, maybe not usually, but he does at least sometimes try when he’s not doing a story on alternative medicine, “complementary and alternative medicine,” or “integrative medicine,” anyway. Not here. It’s as if Dr. Oz’s producers weren’t even trying for this one.
So what evidence do we get? It starts out with Dr. Oz saying how he understands how easy and convenient it is for women to stick their cell phones into their bras because it leaves their hands free. A prerecorded segment shows several women listing all the things they keep in their bras these days and why, things that include money, keys, and credit cards, among other things—and, of course, cell phones. One woman even keeps her son’s pacifier in her bra, which sounds kind of disgusting to me. I suppose if she’s still breast feeding, what’s a little more spit? In any case, we get the message. Bras hold more than breasts these days.
Dr. Oz then points to an image on a screen in the studio, repeating how he understands how convenient bras are to carry things, but then goes on to warn that he never wants you to do this again. A breast surgeon like myself can recognize the image immediately as a breast ultrasound, with a mass in it. The mass is darker than the surrounding tissue (hypoechoic, as we call it) and irregular. It looks suspicious, and it is suspicious, because Oz tells us that it’s breast cancer, which is never convenient. (No kidding, doc. No one knows that better than a breast surgeon like myself, except for breast cancer patients, of course!)
Here’s where Dr. Oz introduces a young woman named Tiffany Frantz, who believes that carrying her cell phone in her bra caused her cancer because it was on the same side and in the same area where her phone came into contact with her skin. Tiffany tells the audience that she kept her cell phone there for four years and that her cancer was right where the phone used to sit, helpfully demonstrating at Dr. Oz’s request how she would carry it in her bra. I noted immediately that she happened to carry it in such a way that it covered (mostly) her upper outer quadrant, which is the most common location for breast cancers to appear because anatomically there is more breast tissue there. Right away, I was sure that this was almost certainly a coincidence.
It’s also an idea planted in her head by her mother, Traci Frantz, who apparently didn’t like the way that her daughter used to carry her cell phone in her bra, particularly the way it stuck out. Once her daughter got breast cancer at age 21, her mother latched on to the cell phone as the cause, after, of course, doing her “research” on the Internet. She emphasized that Tiffany was young and healthy, that there was no family history of breast cancer, and that she didn’t have any genetic mutations known to predispose women to cancer, sometimes at a very young age. She also mentioned that she had been contacted by a “half a dozen” women who were convinced that their cell phones caused their breast cancer. It all sounds very convincing if you don’t know much about breast cancer.
Naturally, those nasty doctors didn’t believe her and produced, as Dr. Oz put it, “pushback,” as though their skepticism was unreasonable. When Dr. Oz asked Mrs. Frantz about this, her response was very telling. She didn’t say that she was trying to figure out whether cell phones cause breast cancer. Instead, she said:
My objective now is to collect the data necessary in order to validate a possible link between cell phones and breast cancer.
In other words, she’s looking for evidence to confirm what she already believes to be true. I know this from other news stories about Tiffany in which her mother has weighed in, such as this one, in which Mrs. Frantz is quoted as saying, “I absolutely believe that storing her cell phone in her bra gave her cancer. No doubt.” If you absolutely “believe” something, there’s no room to change your mind, at least not easily. Don’t get me wrong. I can completely understand the shock Mrs. Frantz felt when her daughter felt a lump in her breast and it turned out to be cancer. Breast cancer is rare in women under 30. But how rare? Stay tuned.
In the meantime, I can’t help but note that Tiffany Frantz and her mother have been appearing all over the media over the last couple of years, for example, here:
And here:
Note how the doctor interviewed in this segment says that breast cancer at this young age is “unheard of.” Let me tell you that it is not. Uncommon, even rare? Yes. “Unheard of”? No. Not really. Let’s just put it this way: I’ve seen a case in a woman even younger than 21. So let’s look at the medical expert brought in for the second half of the segment. It’s a breast surgeon named Dr. John West, who is based in Los Angeles. A quick bit of Googling on his name revealed rather quickly that Dr. West also strongly believes that carrying cell phones in the bra can cause breast cancer. His explanation as to why, both on Dr. Oz’s show and elsewhere, is less than convincing. He starts out with the story of a 39-year-old patient of his who developed breast cancer. Now, I’ve seen plenty of 39 year olds (and younger) with breast cancer; so this patient’s age doesn’t raise any suspicions of an environmental cause. To his credit Dr. West acknowledged this. However, unfortunately he also related how this woman was totally convinced that her cancer had been caused by carrying her cell phone in her bra. Dr. West also said that she had multiple tumors that corresponded “basically” to where the cell phone used to rest. He even presented the case to a conference of breast surgeons (hmmm, I wonder if it was an American Society of Breast Surgeons Meeting that I attended—probably not, as I would have remembered) and that he “got laughed off the stage.”
An appropriate reaction, I would say. I’m relieved that my fellow breast surgeons understand at least that much.
The rest of Dr. West’s evidence consists of three more patients with breast cancer, one of whom was Tiffany. Interestingly, he mentions one of these patients as having come to his attention six months ago, although from articles from 2012 it’s clear that he’s believed in this link for a while. This was another 21-year-old with breast cancer. Dr. Oz intones gravely how he “wasn’t convinced” (of course not!) until he saw these images. A breast MRI is shown with a typical ductal pattern of enhancement, where the “bright spot” follows a ductal distribution. Dr. Oz acts as though this were some sort of major surprise, but it’s not. Breast cancer most commonly arises from the milk ducts, so it’s not surprising to see this sort of pattern. In this particular case, however, because the pattern involved ducts on the lateral side of the breast, which is where this woman held her cell phone, obviously it must have been the cell phone. The funny thing is that the “phone” drawing that is superimposed on the MRI image only matches up with one-half to two-thirds of the distribution of abnormal enhancement. In other words, even the “correlation” is not that convincing. This is even more true when you consider that only a small part of the phone, the antenna and radio, is actually responsible for generating the radio waves, not the whole phone. So it’s almost completely irrelevant whether the phone matches where the tumors were. What matters is whether the antenna and radio match where the tumors were. The same goes for all these cases.
Be that as it may, how common is breast cancer in young women? It turns out that the median age at diagnosis for breast cancer in this country is 61. Dr. West brags that he’s been practicing for 40 years and has personally treated 10,000 women. That’s about 250 women a year, which is not an unbelievable number for a busy breast surgeon. What I find rather hard to believe is Dr. West’s claim that he’s only seen three women with breast cancer who were under 30. Let’s just put it this way. I’ve only been practicing less than 15 years, and, because I run a lab, I haven’t even been practicing full time. I’ve treated far fewer women with breast cancer than Dr. West says that he has, but I’ve already seen at least five patients under 30 with breast cancer. My youngest patient ever was 19 years old when she was diagnosed. I know of a patient treated at my institution before I arrived who was 14 at the time of diagnosis. I do realize that I’ve spent all my career at two different NCI-designated comprehensive cancer centers. These are the best of the best, and there are only 41 such centers in the country, which means that we probably see more young patients than the average private practice breast surgeon. Even so, it strains credulity that Dr. West has seen so few young patients in his 40 years of practice.
I’ll try to show you what I mean. Dr. West goes on to state that only 3 out of the 10,000 patients he’s treated over the course of his career were under 30 at the time of diagnosis. If you go to the SEER Registry, which tracks cancer cases in the US, you’ll see that 1.8% of new cases of breast cancer occur in women under 34. That means, by random chance alone, if his patient population were a representative sample of the breast cancer population at large, Dr. West would expect to see somewhat less than 180 patients under 30. Because of the difference between age 30 and 34, let’s take a conservative estimate, which would be that he should probably have seen at least 100 patients under the age of 30. (In fact, I operated on a 33-year-old with breast cancer in the last month.) That’s a little more than two per year. Yes, that’s rare, but not that rare. Either Dr. West’s memory is faulty, or his patient population does not correspond to the normal age distribution of breast cancer cases. I’m assuming the latter, in which case no wonder he’s so amazed at having seen 21 year old with breast cancer and is so susceptible to leaping to the conclusion that it must be due to an environmental exposure! Moreover, if a large percentage of young women keep their cell phones in their bras at least part of the time, you can assume that by random chance alone most women under the age of 34 who develop breast cancer will have carried their phone in their bra. Half of those women by random chance alone will have a breast cancer on the same side as they usually carry their cell phone, and a significant number of those women, again by random chance alone, will have a tumor near where they carry their phone.
That’s why careful epidemiological studies are so important. Word to Dr. Oz and Dr. West: The plural of “anecdote” is not “data.” In fact, your anecdotes aren’t even all that suggestive; that is, if you look at them without the lens of a pre-existing belief that there is a cause-and-effect relationship.
I would also be remiss if I didn’t cover the issue that was mentioned multiple times, namely that Tiffany didn’t have a “gene” predisposing to breast cancer. I hate to be blunt (well, actually, no I don’t), but that means very little. The vast majority of breast cancer cases, including breast cancer in young women, are not linked to genetic predisposition. Indeed, only 5-10% of cases are inherited, and less than 20% are associated with a genetic predisposition. That means that over 80% of cases are sporadic, which basically means “we don’t know what caused them.” They are not linked to a strong family history or mutations in a gene known to predispose to breast cancer. It means almost nothing that these women didn’t have a family history or other evidence of a genetic predisposition. As for women under 40, it is hardly impressive to have found four women under 40 with breast cancer who might have been keeping their cell phones in their bras. To put it into more perspective, there are approximately 232,000 new cases of breast cancer a year. If 1.8% of those cases are in women aged 34 and under, that means that there are approximately 4,200 new cases of breast cancer in women under 35 every year.
Finally, besides pointing out the utter lack of evidence linking cell phone radio waves and breast cancer, we at SBM have written many times about both the scientific implausibility of the concept that radio waves cause cancer and the lack of any sort of compelling clinical evidence supporting a link. There just isn’t any biological plausibility. Radio wave energy at the power level used by most cell phones is not ionizing. It’s not even close, being several orders of magnitude too weak to break chemical bonds. Our understanding of cancer is that, in general, ionizing radiation is what is required to cause or contribute to cancer. That does not mean that there might not be a potential mechanism, as yet undiscovered, by which non-ionizing radiation might cause cancer, but simple physics and chemistry make the hypothesis that cell phone radiation causes or contributes to cancer not particularly plausible on the basis of currently-understood biology. On a basic science basis, at present there doesn’t appear to be strong evidence (or much of any evidence at all) supporting plausible mechanism by which cell phone radiofrequency radiation might cause cancer or an actual effect in which they do.
Add to this that the stories presented as evidence that cell phones cause cancer (i.e., the anecdotes) aren’t even that convincing, including Tiffany Frantz’s story, based on the lack of a plausible biological mechanism and a time frame between four and six years during which Tiffany Frantz said she was carrying her cell phone in her bra. (I note that she said four years in the Dr. Oz segment but her mother said six years in another segment.) I can understand why her being diagnosed with breast cancer was such a shock, given her young age, but it’s not unheard of. Certainly if I’ve taken care of a 19 year old with breast cancer, it’s not so unbelievable that a couple of 21 year olds could have breast cancer. I feel bad for the Frantzs, as no one should have to face a diagnosis like breast cancer at such a young age. It’s even worse, given that apparently Tiffany Frantz has bone metastases now, a horrible thing at such a young age. However, just because I feel bad for these patients does not mean I must accept their belief that cell phone radiation caused the breast cancer.
On the other hand, I can blame Dr. Oz for fear mongering not supported by science, and I do. I can also blame Dr. John West, and another surgeon, Dr. Lisa Bailey, for a depressing lack of critical thinking skills that led them to promote this concept. Truly, they embody the human trait of craving settling on a causative explanation. It’s very understandable why a patient like Tiffany and her mother might leap to confuse correlation with causation (except that it’s not even clear that there’s a correlation here). It’s the same need for causality that leads parents to become antivaccinationists. However, physicians and surgeons should know better. Unfortunately, they often do not. Indeed, Dr. Bailey and Dr. West have even been featured on that font of all things quackery, NaturalNews.com:
A new study raises concerns of a possible association between cell phone radiation exposure and breast cancer in young women.
The research team, led by Dr. Lisa Bailey, a former president of the American Cancer Society’s California Division and one of California’s top breast surgeons, studied four young women – aged from 21 to 39 years old – with multifocal invasive breast cancer.
The researchers observed that all the patients developed tumors in areas of their breasts next to where they carried their cell phones, often for up to 10 hours per day, for several years. None of the patients had a family history of breast cancer. They all tested negative for BRCA1 and BRCA2 – breast cancer genes linked to about one-half of breast cancer cases – and they had no other known breast cancer risks.
Imaging of the young girls’ breasts revealed a clustering of multiple tumor foci in the part of the breast directly under where their cell phones touched their body.
Here’s the study, and a less convincing collection of four anecdotes is hard to imagine. Case 1, for instance, is particularly unconvincing, given that the cancer takes up the whole side of the breast, with an area of pleomorphic calcifications measuring 12 cm, the description being too vague to make any correlations. (Maybe this woman’s cell phone was a Samsung S4 or something even bigger.) Particularly hilarious is the claim that having invasive cancer intermixed with extensive ductal carcinoma in situ (malignant-appearing cells that haven’t invaded through the basement membrane) is unusual. It’s not. All in all, it’s a pretty sad attempt to link a biologically-implausible carcinogen to breast cancer. There’s nothing unusual about the locations or the histology of the cancers; yet Drs. West and Bailey try to claim that these cases are incredibly worrisome based on nothing but confusing correlation with causation. Is it possible that cell phone radiation can increase the risk of breast cancer? Sure, but it’s incredibly unlikely. There’s no currently known biological mechanism by which it could happen, although I won’t bore you with more than a brief one of usual swipes at people with a simplistic, “Cancer Biology 101”-level understanding of cancer declaring piously that it is absolutely physically impossible because radio waves can’t break chemical bonds and thus can’t cause mutations. Carcinogenesis is more complex than that. Even so, at least the people claiming cell phones cause brain cancer try to present epidemiological evidence to support their case. It’s almost uniformly negative and unconvincing evidence, but at least it rises above the level of anecdotes. Drs. West and Bailey (and, of course, Dr. Oz) have nothing.
As I said, I’ve given up on Dr. Oz’s ever seeing the light again. Money and fame have corrupted a man who was once a promising academic cardiovascular surgeon, combined, of course, with a propensity for woo. All I can do anymore is to try to counter his misinformation when I can, which is not that often. After all, I could easily devote a whole blog to trying to refute the medical misinformation that Dr. Oz dishes up every day on his show. Instead, I choose to comment only when his misinformation impacts my area of expertise or for whatever reason catches my interest. It’s all I can do anymore.

One more time: No, wearing a bra does not cause breast cancer
David Gorski on September 8, 2014
Link
EDITOR NOTE: THERE IS AN ADDENDUM, ADDED SEPTEMBER 10.
Besides being a researcher and prolific blogger, I still maintain a practice in breast cancer surgery. It’s one of the more satisfying specialties in oncology because, in the vast majority of cases I treat, I can actually remove the cancer and “cure” the patient. (I use the quotes because we generally don’t like to use that term, given that some forms of breast cancer can recur ten or more years later, but in many cases the term still fits, albeit not as well as we would like.) Granted, I get a little (actually a lot of) help from my friends, so to speak, the multimodality treatment of breast cancer involving surgical oncology, radiation oncology, and medical oncology, but breast cancer that can be cured will be primarily cured with surgery, with chemotherapy, hormonal therapy, and radiation therapy working mostly to decrease the risk of recurrence, either local in the breast or distant elsewhere in the body. Through this multimodality approach, breast cancer mortality has actually been decreasing over the last couple of decades.
However, as a breast cancer surgeon, I not infrequently have to deal with many of the common myths that have sprung up around breast cancer. Some are promoted by quacks; others are just myths that sound plausible but aren’t true. (That’s why they persist as myths.) One such myth has been in the news lately, in particular last week; so I thought now was a good time to take a look as any. Besides, I spent most of the weekend out of town visiting my wife’s family, and I didn’t have a lot of time for this post. So this week sticking to something I know well makes sense and inspired me to make like Harriet Hall and Steve Novella and keep my post to a reasonable length for a change. There’s also so much less mucking about on PubMed and Google that way to make sure I’m not missing something, too.
Those who pay attention to breast cancer news (and, of course, I do have a Google Alert set up for just such news) can’t help but notice that late last week there was a flurry of stories (no, not that kind of flurry) about a study looking at the risk of breast cancer due wearing a bra. I’ll cut to the chase. According to this study, there was no increased risk of breast cancer due to wearing a bra, a result that, to breast cancer specialists, was about as surprising as the observation that the sun rises in the east and sets in the west, water is wet, and gasoline flammable. However, the myth that wearing bras increases the risk of breast cancer is one of those unsinkable rubber ducks (as James Randi would put it) of a myth that just won’t die. (Most recently it showed up in a Facebook- and Twitter-spread article entitled “Your Bra May Be Killing You – Scientists Call For Boycott Of Komen“, as well as on—of course!—NaturalNews.com.) I keep hoping that a study will do to this myth what a wooden stake in the heart does to the vampires in True Blood, but unfortunately this is one of those unsinkable rubber ducks of a myth (as James Randi would put it) that refuses to die. So I consider it worthwhile to briefly (for me) discuss how it came about.
It’s unclear where and how long ago this myth first appeared, but there’s little doubt on when it was first popularized: 1995. That was the year that a book by Sydney Ross Singer and Soma Grismaijer entitled Dressed to Kill: The Link Between Breast Cancer and Bras was published. The central thesis of the book was that bra-wearing is a major cause of breast cancer because of its claimed effect on lymphatic circulation. Basically, the idea was (and still is) that bras interfered with lymphatic drainage and thereby, though unclear mechanisms, caused cancer. The claim was that there are all sorts of “toxins” (of course) that cause cancer and that the lymph vessels drain those “toxins” away from the breast. Thus, if you believe Singer and Grismaijer, these “toxins” are concentrated in the breast by the constriction that bras produce and result in breast cancer.
This concept, that “toxins” somehow accumulate if lymphatic drainage is somehow blocked is one of the key concepts behind the quackery that is “detoxification,” used by quacks of many stripes. Such “detoxification” often consists of diets that result in purging, coffee enemas, chelation therapy to “remove heavy metals,” and many other treatments without a solid basis in science. However, “manual lymphatic drainage” is yet another form of quackery, at least when it’s claimed to “detoxify.” Sometimes, the quackery becomes rather amusing, such as when people come up with ideas like the “Brassage.”
Perhaps the best example of these beliefs can be found in an article entitled “Can a Bra Cause Breast Cancer? The Answer May Surprise You“, in which we find claims like:
Now, if enough pressure is put on your lymphatic system to produce pain and swelling, as in the example of your feet, you’d notice and fix it. Meaning, you’d take off your shoes, put your feet up, and bring the swelling down.
But, what if the pressure were too slight for you to notice? Or, what if it had gone on for so long, you no longer realized your discomfort? This is the case when it comes to bras. Many women simply “get used to” the discomfort of a bra and pay no attention to the indentations bras leave on their skin. Some researchers believe it’s precisely this indentation that, over a period of time, causes long-term mild impairment of the lymphatic function.
One of the largest clusters of lymph nodes is located in the armpit and upper chest area. That lymph cluster filters drainage from the breast, arm, and upper chest. But, if your bra is too tight, it constricts drainage from the lymph nodes in your armpit area.
Drainage to the breastbone lymph nodes also gets constricted, especially by bras with underwire. On top of that, shoulder straps from bras potentially cut off drainage of the lymphatics along the top of the breast to the armpit. Also, pressure from the cups of the bra may hinder drainage down to the liver.
If the researchers are right and this is what’s happening, what does it mean? Simply this: Toxins are not being drained from the breast area, so breast tissues are more susceptible to degeneration and eventual cancer.
Another variant of this concept includes:
Women evolved under conditions where there was BREAST MOVEMENT with every step that they took when they walked or ran. My reading of the scientific literature about lymphatic flow shows me that this may be as important as the constriction factor. Every subtle bounce of the breast while moving, walking, running, etc. gently massages the breast and increases lymphatic flow and thus cleans the breast of toxins and wastes that arise from cellular metabolism.
There are a lot of jokes I could make here, but, through enormous self-restraint, I will refrain, other than to point out that Ralph Reed, PhD has a rather intense interest in the bouncing of breasts.
In their book, Singer and Grismaijer claimed to have found the following (and you will see this list with minor variations in phrasing scattered throughout alternative medicine sites):
    • Women who wore their bras 24 hours per day had a 3 out of 4 chance of developing breast cancer (in their study, n=2056 for the cancer group and n=2674 for the standard group).
    • Women who wore bras more than 12 hour per day but not to bed had a 1 out of 7 risk.
    • Women who wore their bras less than 12 hours per day had a 1 out of 152 risk.
    • Women who wore bras rarely or never had a 1 out of 168 chance of getting breast cancer. The overall difference between 24 hour wearing and not at all was a 125-fold difference.
Other claims included that breast cancer is only a problem in cultures where women wear bras. In contrast, in cultures where women don’t wear bras, breast cancer is a rare event. I’m guessing you can tell the major flaw in reasoning there, but let’s go on. Specifically, Singer and Grismaijer claimed to have observed that the Māori of New Zealand, who are integrated into white culture and therefore wear bras, have the same rate of breast cancer, while the aboriginals of Australia, who are bra-free, have practically no breast cancer. They made the same claim for “Westernized” Japanese, Fijians and other bra-converted cultures. They even claimed that women who don’t wear bras have the same risk of breast cancer as males. (Males have an incidence of breast cancer about 100-fold less than that of women.)
Of course, this “study” was not published in a scientific journal. It was published for the first time in Singer and Grismaijer’s book, which was updated in 2005. Naturally, cancer scientists immediately pointed out the massive flaws in the “study,” such as:
    • Lack of controlled epidemiological data correlating bra-wearing with the risk for breast cancer
    • Lack of proof that the pressure exerted by a bra reduces the flow of lymph
    • Lack of proof that lymph contains carcinogens
    • Lack of proof that there are carcinogens in the human body that can induce breast cancer
    • Existence of published data correlating obesity with post-menopausal breast cancer
This doesn’t even consider the utter lack of even a perfunctory attempt to control for well-established epidemiological risk factors for breast cancer, such as age at menarche, age at menopause, age of first live birth, obesity, Western pattern diet, and others. There was no proper statistical treatment of the data, and the study participants knew the study hypothesis before they took the survey. By any reasonable scientific standard, Singer and Grismaijer’s “study” was a complete mess, but it had a huge impact on popular views of breast cancer and popularized a myth that’s persisted for nearly two decades. Naturally, Singer and Grismaijer reacted to criticism of their study and book in predictable ways, pulling the “garment industry shill gambit,” saying, “The bra industry is a multi-billion dollar enterprise. And billions of dollars are spent each year researching and treating this disease. Ironically, ending breast cancer can cause financial hardship for many people.”
And, most ridiculously:
We have become a breast cancer culture. As a result, our information was seen as a threat to that culture. Sometimes a disease is less threatening than change.
Unfortunately, in that time, very little actual research existed to refute or confirm this myth. A search of PubMed for “bras” and “breast cancer” results in mainly articles on breast edema after breast cancer treatment, designing bras after breast cancer surgery, and cosmetic implications of breast cancer surgery. There is one study from 1991 cited by Singer and Grismaijer as evidence in support of their hypothesis. There’s just one problem: The article said nothing of the sort. Rather, it concluded that “bra cup size (and conceivably mammary gland size) may be a risk factor for breast cancer.” The reason for this association is almost certainly not because women with larger breasts are more likely to wear a bra regularly and for longer periods of time but rather because they have more breast tissue and are more likely to have larger breasts because they are obese. (Obesity is a known risk factor for breast cancer.)
The utility of this latest study, by Chen et al. at the Fred Hutchinson Cancer Center, is that it’s about as rigorous a study as there’s ever been about this issue. Basically, it’s a case-control study that examined women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), comparing them to women without breast cancer matched for relevant risk factors as follows:
Briefly, cases were women between 55 and 74 years of age first diagnosed with invasive breast cancer between January 1, 2000, and March 31, 2004, while residing in the Seattle-Puget Sound area. The Cancer Surveillance System, the region’s population-based cancer registry also participating in the Surveillance, Epidemiology, and End Results program of the National Cancer Institute, was used to identify cases. All ILC cases (identified using ICD-O histology codes of 8520, 8522, and 8524) and a random sample of 25% of the IDC cases (identified using ICD-O histology code of 8500) were targeted for recruitment to enroll equal numbers of ILC and IDC cases. A total of 1,044 out of 1,251 eligible cases were interviewed (83%), consisting of 454 IDC and 590 ILC cases. A common control group, frequency matched 1:1 to the ILC cases within 5-year age groups, was selected from the general population of women living in the three-county area by random-digit dialing.
There were a total of 454 cases with IDC, 590 with ILC, and 469 controls. The authors then looked for differences between cases and controls in various aspects of bra wearing, including bra cup size, recency, average number of hours/day worn, wearing a bra with an underwire, or age first began regularly wearing a bra. They found no correlations. As far as epidemiological studies go, this one is quite good. The only significant weakness, acknowledged by the authors, is that bra wearing was so ubiquitous that it was not possible to examine any differences between women who never wore bras and those who did. So instead the authors concentrated on, in essence, the “dose” of bra wearing; i.e., the number of hours a day on average, cases and controls wore a bra. In this, it is not unlike a previous study of vaccines, in which there was not a true unvaccinated group but there was no correlation between thimerosal dose in vaccines and autism. In epidemiology, it’s not always possible to have a true unexposed group.
In any case, I’m happy to see this study. Before, when confronted with a patient who had heard this myth, I would have to argue on lack of evidence and the extreme implausibility of it all, given that there was no evidence that axillary lymphadenectomy (a.k.a. lymph node dissection) increases the risk of breast cancer. Quite the contrary, in fact. A notable study that looked at breast cancer risk after axillary lymphadenectomy for melanoma found no increased risk of breast cancer.
Sadly, as busted as this myth has been and is now, I fully expect that even this study will not bury it for good.
It occurs to me that I should do more posts about these breast cancer myths. My only concern is that there are so many. I could easily spend the rest of the year, doing a post on a different breast cancer myth each week, and still have more left over. Maybe I’ll do it during Breast Cancer Awareness Month. It’s only three weeks away, after all.
ADDENDUM:
Sadly, as busted as this myth has been and is now, when I first read this study, I fully expected it would not bury it for good. In fact, it hasn’t, as the rotting hand of this myth has pushed its way through the dirt to try to grab the rational and frighten women. Of course. Just the other day, one of the authors of Dressed to Kill, Sydney Ross Singer, published an article on one of the many wretched hives of scum and quackery that I monitor regularly, The Cover-Up Continues: New Study Claims Bra-Cancer Link a “Myth” This response is particularly lame, even for Singer. Get a load of this utter piffle:
A new study was just announced in mainstream media declaring the bra-cancer link does not exist. The study looked into the bra wearing habits of women ages 55 and older who had all worn bras since puberty. They concluded that women should be “reassured” that bras are not causing breast cancer.
Actually, this study supports the bra-cancer link, since all the women in the cancer group were bra wearers.
Notice that I just addressed this specious criticism above. Clearly, Singer does not understand the concept of dose-response. The only way this is a legitimate criticism, at least in the way Singer meant it, would be if the cancer-causing power of bras was so incredible that even a brief exposure to bra wearing causes cancer. He then goes on to cite the very same 1991 paper that I described above as “evidence” that bras cause breast cancer. As I described, that paper shows nothing of the sort. Then there’s this:
Why this study focused only on POST-menopausal women, instead of researching the positive association of pre-menopausal women, suggests a bias and agenda.
Again, the reason for this is simple. Breast cancer is primarily a disease of aging, with the average age of diagnosis being 62. The bra-breast cancer hypothesis is an environmental exposure; so presumably the number of years of “exposure” matters. So it makes perfect sense to look at postmenopausal women, for whom the prevalence of breast cancer is much higher than in pre-menopausal women and for whom the “exposure” to bra wearing would be the longest. There’s no bias or agenda; this was clearly a scientific decision that makes perfect sense. Studying premenopausal women in an exposure/risk factor study like this would have resulted in much reduced sensitivity to detect a true difference in breast cancer prevalence, given how much lower breast cancer prevalence is in them, and would have meant smaller differences in cumulative bra wearing. Clearly, Singer doesn’t understand the basics of case control studies, where one wants to maximize the chances of finding significant differences in the exposure of interest between cases and controls.
None of this stops Singer from ascribing dire motives. Instead of the “pharma shill gambit,” think the clothing industry shill gambit:
It seems there is, indeed, a hidden agenda. The main author, who is a PhD student, did not mention that The Fred Hutchinson Cancer Research Center, where this study was done, receives money annually from a “Bra Dash” fundraiser, where bras are worn on the outside of clothing during a 5K race to raise funds.
It would be very ironic to criticize bras for causing cancer when they are used to raise funds for cancer research.
Uh, no. Seriously. No.
Singer doesn’t stop there, though:
The fact that this poorly designed study without proper controls is used to conclude that there is no bra-cancer link also reveals a bias. The authors should have called for more research.
All this study really shows is that some women who have worn bras for 40 years or longer will get breast cancer and some will not. We already knew that. You can say the same thing about smokers and lung cancer.
Of course, as the bra-cancer link gains increasing public awareness, there are bound to be studies trying to refute it. Billions of dollars annually are at stake. There are also studies that try to refute the cigarette-cancer link. So I take all this as a good sign of progress, since it brings the topic into mainstream consciousness, and these attempts at denial are expected.
Ugh. The “tobacco industry” gambit, the very same gambit beloved of antivaccine advocates. It’s hard to take the criticisms of someone who’s already demonstrated himself to be utterly incompetent at epidemiological research seriously. His smoking analogy is also silly. If there’s one thing research on smoking shows, it’s that dose matters; if you compare a group that has less than a 10 pack-year smoking history, for instance, with a group with more than a 30 pack-year history, for example, you will find a big difference in lung cancer prevalence.
Again, is this study on bra wearing ideal? No. However, it does look at whether there were any differences in the “dose” of bra wearing or the characteristics of bra wearing between cases (women who had had a diagnosis of breast cancer) and controls (those who had not). Ideally, it would be nice to find a group of women who never wore bras who don’t have so many other confounding factors (such as being aboriginals) that comparisons between them and bra-wearing women are highly problematic, but that’s impractical. In the US and other industrialized countries, the vast majority of women wear bras from puberty on for at least their waking hours, and very few women never wear bras. Given that fact, looking for dose-related effects is the best epidemiologists can do. Given the utter implausibility of the hypothesis, it’s even arguable whether the money and resources should have been spent to do this study, but it was done and it was negative—exactly as one would expect.
No, as much as Singer thinks that someday he’ll “show them all,” it’s nothing more than the fallacy of future vindication.

   Breast Cancer

   The mammography wars heat up again
David Gorski
Link
PRELUDE: THE PROBLEM WITH SCREENING
If there’s one aspect of science-based medicine (SBM) that makes it hard, particularly for practitioners, it’s SBM’s continual requirement that we adjust what we do based on new information from science and clinical trials. It’s not easy for patients, either. To lay people, SBM’s greatest strength, its continual improvement and evolution as new evidence becomes available, can appear to be inconsistency, and that seeming inconsistency is all too often an opening for quackery. Even when there isn’t an opening for quackery, it can cause a lot of confusion; some physicians are often resistant to changing their practice. It’s not for nothing that there’s an old joke in medical circles that no outdated medical practice completely dies until a new generation of physicians comes up through the ranks and the older physicians who believe in the practice either retire or die. There’s some truth in that. As I’ve said before, SBM is messy. In particular, the process of applying new science as the data become available to a problem that’s already as complicated as screening asymptomatic people for a disease in order to intervene earlier and, hopefully, save lives can be fraught with confusion and difficulties.
Certainly one of the most contentious issues in medicine over the last few years has been the issue of screening for various cancers. The main cancers that we most commonly subject populations to routine mass screening for include prostate, colon, cervical, and breast cancer. Because I’m a breast cancer surgeon, I most frequently have to deal with breast cancer screening, which means, in essence, screening with mammography. The reason is that mammography is inexpensive, well-tested, and, in general, very effective.
Or so we thought. Last week, yet another piece of evidence to muddle the picture was published in the New England Journal of Medicine (NEJM) and hit the news media in outlets such as the New York Times (Mammograms’ Value in Cancer Fight at Issue).
Before I discuss the study, let’s look at the background. As I’ve written about over the last couple of years, evidence has been accumulating that is muddying the picture regarding the benefits of screening mammography, So let’s be clear on what we are discussing here: screening mammography is different from diagnostic mammography in that it is performed at regular intervals in asymptomatic women in order to detect cancer at an earlier stage and thereby allow earlier intervention, resulting in the saving of more lives than if we waited until breast cancer produces symptoms (such as a lump) that lead to diagnosis. If a woman feels a lump or some change in her breast and undergoes mammography, that is not screening. In that case, mammography is being done for diagnostic purposes. We are not discussing diagnostic mammography. We are discussing screening mammography. I can’t emphasize that distinction enough.
What we’re discovering is not that screening mammography is ineffective, but rather that it is probably not as effective as advertised in preventing death from breast cancer, which, let’s face it, is the primary reason we subject women over age 40 to mammographic screening. The reason is that phenomena such as overdiagnosis and overtreatment, coupled with lead time and length time bias, conspire to confound what conceptually is very simple but in practice is very complex indeed, catching breast cancer at an earlier stage and thereby saving lives. Overdiagnosis, for instance, is the diagnosis of cancer that, for whatever biological reason, would never threaten the life of the patient because it either progresses so slowly that the patient dies of natural causes before it ever reaches the point of endangering the patient’s life, never progresses at all, or possibly even spontaneously regresses. Because we do not yet have reliable methods to distinguish indolent tumors from those that will grow and metastasize, we as cancer doctors have the moral obligation to treat all tumors discovered by screening as though they could potentially kill the patient. These treatments are often not benign, and can include surgery, radiation, and even chemotherapy. Overdiagnosis leads to overtreatment, and overtreatment is not a benign thing either. Unfortunately, until recently we haven’t always taken into account the potential harm from overtreatment into account or the biology of the various cancers and the very nature of screening itself, which preferentially detects more indolent disease.
As a result of the accumulation of evidence suggesting less benefit from mass screening programs than we had hoped and more potential harm than we had feared, the oncology world has been rethinking screening for cancer, in particular for prostate and breast cancer. Clearly, the most problematic cancer to screen for has been prostate cancer, because the common blood test used to detect it, prostate-specific antigen (PSA) is fraught with false positives, leading to morbid surgery (prostatectomy) or somewhat less morbid radiation therapy to treat early lesions that probably would never develop into life-threatening cancer. After all, autopsy series have shown that approximately 75% of men over the age of 80 have small foci of cancer in their prostate glands, but nowhere near 75% of men die of prostate cancer. In other words, more men die with prostate cancer than from it, and most are asymptomatic. That is why the American Cancer Society no longer recommends routine PSA screening.
Screening for breast cancer is less problematic, because mammography has a lower incidence of false positives, but, as we have been discovering, it’s still problematic. As many as one in three breast cancers may be overdiagnosed by mammography; as many as one in five mammographically-detected breast cancers in asymptomatic women might spontaneously regress. As a result of accumulating evidence, last fall the United States Preventative Services Task Force (UPSTF) revised its recommendations for screening mammography to recommend that it begin at age 50 rather than age 40. The resulting kerfuffle led to emergency meetings at various cancer centers regarding how to reassure women. From my perspective, it was depressing how much we seemed to concentrate on “damage” control and protecting the current recommendations, rather than explaining the new recommendations.
Enter this new Norwegian study, hot off the presses.
DECREASED BREAST CANCER MORTALITY: DUE TO SCREENING OR BETTER TREATMENT?
I first became aware of the new study from a Google News Alert that led me to a NYT story by Gina Kolata entitled Mammograms’ Value in Cancer Fight at Issue:
A new study suggests that increased awareness and improved treatments rather than mammograms are the main force in reducing the breast cancer death rate.
Starting in their 40s or 50s, most women in this country faithfully get a mammogram every year, as recommended by health officials. But the study suggests that the decision about whether to have the screening test may now be a close call.
The study, medical experts say, is the first to assess the benefit of mammography in the context of the modern era of breast cancer treatment. While it is unlikely to settle the debate over mammograms — and experts continue to disagree about the value of the test — it indicates that improved treatments with hormonal therapy and other targeted drugs may have, in a way, washed out most of mammography’s benefits by making it less important to find cancers when they are too small to feel.
Previous studies of mammograms, done decades ago, found they reduced the breast cancer death rate by 15 to 25 percent, a meaningful amount. But that was when treatment was much less effective.
It should come as no surprise to regular readers that the commonly accepted estimate of how much mammographic screening of a population reduces the death rate from breast cancer is around 20-25%. These numbers are based on randomized clinical trials, most of which were carried out more than 20 years ago. Based on these trials, many countries instituted mass screening programs using mammography. Because it would violate clinical equipoise, given that it is generally accepted that screening mammography decreases deaths from breast cancer, there will likely never be another randomized, controlled clinical trial of mammography, even though technology has progressed and we have better treatments that may affect the outcome. That leaves observational studies, a less rigorous form of evidence, to investigate the issue. However, it is still quite possible to obtain useful data from such studies, and that is what this Norwegian group did when they examined the effect on breast cancer mortality of introducing mammographic screening programs. The results, published in the September 23 issue of the NEJM, provide an unexpected, even startling, answer.
This study, Kalager et al, was performed in a very clever manner. To understand how it was carried out, it’s necessary to know a bit about Norway first. Norway is a nation of 4.8 million people that, because it has a centralized public health care system, has records far more complete and centralized than anything we have in the United States. In brief, this is a study that could never have been done in the US:
Norway, with a total population of 4.8 million, has a public health care system. Patients generally receive treatment in their county of residence, and there is no private primary care for breast cancer.8 The nationwide Cancer Registry of Norway is close to 100% complete.9,10 Patients are identified in the registry by their individually unique national registration number, which includes the date of birth. The registry runs the Breast Cancer Screening Program, which began as a pilot project in 4 of the 19 Norwegian counties in 1996. Two years later, the government decided to expand the program, and over a period of 9 years, the remaining 15 counties were enrolled in a staggered fashion11 The rollout of the program followed no specific geographic pattern. Since 2005, all women in the country between the ages of 50 and 69 years have been invited to participate in screening mammography every 2 years.
Before enrollment in the program, each county was required to establish multidisciplinary breast-cancer management teams and breast units.12 As a result, breast-cancer management became centralized for all residents within each county, and dedicated teams of radiologists, radiologic technologists, pathologists, surgeons, oncologists, and nurses managed the care of all patients, regardless of age.
The study followed, in essence, a staggered cohort design. The authors compared rates of breast cancer deaths based on incidence in four groups: one group of women who during the years of the rollout of the mammography screening program (1996 to 2005) were living in counties with screening (the screening group); one group of women who were living in counties without screening during that time (the nonscreening group); and two groups of historical controls who from 1986 to 1995 mirrored the screening and nonscreening group. They then analyzed data from 40,057 women with breast cancer during that period of time. In order to try to isolate the effect of the breast cancer screening program, they calculated mortality in the screening group including only deaths from breast cancer in women who had received the diagnosis after the screening program was implemented. This avoids inclusion of breast cancer deaths that occurred after the implementation of the screening program that were actually diagnoses that were made before the screening program.
In addition, the authors divided up Norway’s 19 counties into six regions, chosen for having entered the screening program at approximately the same time. Death rates were then compared separately for each region, allowing similar followup times for each region. In addition, this strategy allowed for the comparison of trends in mortality from breast cancer over time. They then performed these analyses:
First, we compared women in the nonscreening group with their historical counterparts to determine the temporal change in mortality that was not attributable to the introduction of the screening program and that was likely to reflect improved treatment and earlier clinical diagnosis. Then, we compared women in the screening group with their historical counterparts to determine the change in mortality after implementation of the screening program. In this second comparison, the difference in the rate of death between the two groups can be attributed both to the screening program and to temporal trends in mortality that were unrelated to the screening program. Thus, the reduction in mortality that was related to the screening program was the difference between the rate ratio for death among women in the screening group as compared with their historical counterparts and the rate ratio for death among women in the nonscreening group as compared with their historical counterparts.
To boil it down, using this method, the authors could come up with two numbers for improvement in breast cancer mortality over time, an improvement not attributable to screening, which is therefore attributable to better treatments, and a number that is attributable both to screening and better treatments. The result is a graph (click to enlarge):
Fig1
As can be seen, the estimate for how much of the improvement in mortality due to breast cancer between the two time periods in Norway is due to mammography is attributable to screening mammography is approximately one third of the overall improvement (10% out of an overall improvement of 28%). Moreover, statistically, there is enough uncertainty in this estimate that it could be as little as 2% of the decrease in breast cancer mortality that is due to mammographic screening. Most of this improvement in survival was observed in women with stage II tumors:
Among women between the ages of 50 and 69 years in the screening group, those with stage I tumors had a relative reduction in mortality of 16%, as compared with their historical counterparts (rate ratio, 0.84; 95% CI, 0.63 to 1.11); among women in the nonscreening group, the corresponding reduction was 13% (rate ratio, 0.87; 95% CI, 0.62 to 1.23). Among women with stage II tumors, those in the screening group had a marked 29% reduction in mortality, as compared with their historical counterparts (rate ratio, 0.71; 95% CI, 0.58 to 0.86); among women in the nonscreening group, the reduction was 7% (rate ratio, 0.93; 95% CI, 0.76 to 1.12).
Among women with more advanced tumors (stage III and stage IV), there was no effect attributable to screening. Although there was still a 30% reduction in mortality in this group, none of it could be attributed to screening. Intuitively, this makes sense; stage III and stage IV tumors are generally detected clinically because of symptoms, not in a screening program. It also intuitively makes sense that the death rate from stage I tumors would be less affected than that from stage II tumors because (1) stage I tumors would be much more likely to be overdiagnosed by screening and (2) the followup time in this study is relatively short (8.9 years for the group with the longest followup), which may not be sufficient time for the full benefit of screening to show for earlier stage tumors; and (3) stage II tumors can still be detected mammographically in asymptomatic women but, because they are more advanced, have already shown themselves to be potentially deadly. It should also be conceded that, because of improvements in imaging and in detection of lymph node metastases (such as sentinel lymph node biopsy), this result might also be partially due to selective stage migration among those who undergo screening. If that were the case, part of the improvement in survival among those with stage II disease could be apparent rather than real.
Being retrospective, this study is, of course, not bullet-proof. As the authors themselves concede, the maximum followup time of only 8.9 years may be too short for a full benefit to have been seen. In addition, because the screening program was rolled out gradually in the counties, diagnoses were made more recently in the screening group, which may actually overestimate the benefit associated with the screening program. Finally, it’s possible that, because the multidisciplinary breast cancer teams were established before the screening program was rolled out, it’s possible that some of the women in the nonscreening group might have undergone mammography associated with this, thus “contaminating” the nonscreened group and lowering the apparent benefit of screening. The authors offer several reasons why they think this latter problem is unlikely to have been significant, including how limited access to mammography was before screening programs were implemented, the fact that there was no financial incentive to providers to order mammography, and because, as expected, the implementation of the screening program in the various counties resulted in a substantial increase in the number of diagnoses of breast cancer, with no similar trend in counties that had not yet joined the screening program.
Overall, because most of the more recent observational studies of mammographic screening use historical controls without an attempt to control for the confounding variable of temporal downward trends in breast cancer mortality, the authors conclude that the benefit of screening in terms of decreasing a woman’s odds of dying from breast cancer is smaller than previously estimated. In aggregate, they estimate that, in Norway at least, approximately one-third of the decrease in breast cancer mortality is due to screening, and two thirds to other factors, which (we hope) includes better treatment.
MAMMOGRAPHY: A LONG RUN FOR A SHORT SLIDE?
Not surprisingly, there was an accompanying editorial. I was, however, rather surprised at who was chosen to write the editorial, namely Dr. Gilbert Welch, a long-time critic of screening mammography, who entitled his article Screening Mammography — A Long Run for a Short Slide? Personally, I was expecting that any accompanying editorial would be written by an advocate of mammographic screening. The crux of his argument is in this paragraph:
The juxtaposition of such a charged medical debate in the face of such an exhaustive scientific investigation is in itself instructive. For context, one trial involving fewer than 150 men who were followed for less than 2 years was sufficient to convince physicians of the value of treating severe hypertension.1 That physicians are still debating the relative merits of screening mammography despite the wealth of data suggests that the test is surely a close call, a delicate balance between modest benefit and modest harm.
Dr. Welch is referring to this study from 1967, which found a marked difference in morbidity and mortality over a relatively short followup period in men with diastolic blood pressures ranging from 115 through 129 mm Hg. The results were so clear-cut that after that study no one could argue against treating someone with a diastolic blood pressure that high. Personally, I viewed this comparison as a bit of a cheap shot by Dr. Welch in that the study he chose looked at men with a severe health condition known to predispose to stroke, myocardial infarction, and other complications. He compared this clinical situation to the screening of an asymptomatic population, where it’s known going in that it will be harder to show benefits, requiring a lot of patients and a lot of followup. That aside, though, Dr. Welch is correct that more recent evidence suggests that the benefits of mammography are more modest than we have traditionally been taught.
That brings us to the question of why this study found results different than the results cited by the USPSTF when making their recommendations. Dr. Welch offers two possibilities. First, this study could be wrong. That is, of course, always possible given that it is not a prospective randomized trial. However, situations change with time, and it is no longer possible to do a randomized trial to determine whether mammography saves lives. Clinical equipoise again. So all we are left with are studies like this Norwegian study, where investigators do the best they can to reduce confounders. Looking at the design of the study, I tend to agree with Dr. Welch that it is unlikely that these confounders would be enough to account for the difference between the much higher reductions in breast cancer mortality observed in early randomized studies (the ones cited by the USPSTF) and Kalager et al found. Most likely, Kalager et al is correct, or at least not too far off. That leaves several questions.
First and foremost, is a 10% reduction in mortality from breast cancer adequate to justify mass screening programs? Whenever I am asked a question like this (for example, about Avastin), my tendency is to respond that this is not a scientific question. It is a moral question that asks us to make a value judgment as a society. Think of it this way. It is estimated that approximately 40,000 women will die of breast cancer in 2010. If Kalager et al is correct and its results are applicable to the U.S., that means that, without screening, approximately 44,000 women would die of breast cancer. What are 4,000 lives worth? I can’t answer that question. Dr. Welch frames it a bit differently, to make the benefit seem even more modest:
If we assume that mammography screening is associated with a 10% reduction in the rate of death from breast cancer (making the optimistic assumption that all the benefit comes from screening mammograms), the 10-year risk of breast-cancer death for a 50-year-old woman in the United States is now about 4 per 1000 women.6 If we assume that this risk already incorporates the benefit of screening mammography, the risk estimate without mammography would be about 4.4 per 1000 women.
Benefits that look very modest when looked at as a risk per 1000, however, can produce fairly large absolute numbers when applied to millions of women. I tend to view Kalager et al’s results as the lower bound of estimates for the benefits of screening mammography. It wouldn’t surprise me if the true benefits are higher. Remember those 4,000 women, who are all someone’s mothers, wives, and/or daughters. However, so are the women potentially harmed:
Because we are all subject to framing effects, it is important to consider the reverse frame. The number of women who will not die from breast cancer rises from 995.6 to 996 per 1000 women with the addition of screening mammography. Although readers may each respond differently to these frames, both reflect the same absolute benefit: 0.4 per 1000 women. In other words, 2500 women would need to be screened over a 10-year period for 1 to avoid death from breast cancer.
What happens to the other 2499 women who had to undergo screening to achieve this benefit is also relevant. Estimates of harm vary considerably. In the United States, more than 1000 women would be expected to have at least one false positive result,7 a number that would be considerably lower in Europe.8 Less frequent but more worrisome is the problem of overdiagnosis. Somewhere between 5 and 15 women would be expected to be needlessly treated for a condition that was never going to bother them, with all the accompanying harms.9,10
Another estimate that I discussed came from an article last year by Laura Esserman, who estimated that to avert one death from breast cancer with mammographic screening for women between the ages of 50-70, 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of DCIS. That’s roughly three times the benefit estimated by Kalager et al.
Whatever the true benefit of mammographic screening, how we balance the potential benefits of mammographic screening with the potential harms is more of a philosophical and moral question. Science-based medicine can inform us regarding the values of mammographic screening, but it can’t tell us what we value.
A MIDDLE GROUND?
Figuring out the benefits of screening for cancer, be it with mammography or by other means for other cancers, is by its very nature a difficult issue, full of scientific and ethical confounders. Unfortunately, this scientifically muddy issue, to be applied successfully to a mass population, is often sold uncritically and with far more confidence than the data support. Mammography is represented uncritically as pure good, and women are told that every woman should start having mammography religiously at age 40. That’s why, when the USPSTF recommendations were released last fall, which stated that screening should begin at age 50 and be offered every two years instead of every year (which, by the way, is what Norway does), the reaction against them was so vociferous, particularly given that the recommendations were released right in the midst of the debate about President Obama’s health insurance reform bill and its opponents were raising the specter of arbitrary government rationing of health care. It was science-based medicine reexamining an existing accepted belief about breast cancer and running right into the perfect storm of resistance from advocacy groups, politics, and physician practice patterns. It turns out that all too often both patients and physicians want certainty, not the ever-evolving recommendations based on new science.
Moreover, there are a lot of issues at play here, as Dr. J. Leonard Lichtenfeld of the American Cancer Society points out:
We have moved to a different age, but I have to admit that I have a bias that we run the risk of going back in part to that future. Today, with screening mammograms we find more cancers that are smaller than can be detected by physical examination and no amount of self-awareness or physician awareness is going to change that. Patients and physicians have not suddenly become more astute in their diagnostic skills. If anything, they have become less effective in that arena.
There is also downsides of our success:
    • We do find breast cancers today through mammography that years ago would never have been discovered and may never have caused a woman any difficulty.
    • We do treat more women than benefit from that treatment, but we don’t have tests that can tell us which breast cancers don’t require any treatment as compared to those which are lethal.
    • We have studies that show us formal, structured breast self examinations don’t appear to save lives.
    • We have ethnic groups in this country that have had significant reductions in breast cancer mortality and others that have not, in part because too many don’t have access to quality medical care.
In short, this is a complicated issue. I am not certain that all of the relevant facts and considerations applicable to the circumstances in the United States are necessarily reflected in this particular study. Yet I suspect the headlines will be that mammograms don’t work or that they make little difference.
We must find our way out of these dilemmas. Messaging to the public has become garbled and confusing. The sad fact is that if we make the wrong decisions about the value of screening mammography, it will be years before we find out if we were mistaken.
“Dr. Len” has a point. However, he, too, is a bit guilty of black and white thinking here. He seems to think that we either preach the benefits of mammography or not. There is, however, a third way, and this was described by Drs. Kerianne H. Quanstrum and Rodney A. Hayward, M.D. at the University of Michigan in an NEJM editorial published two weeks before Kalager et al entitled Lessons from the Mammography Wars.
After describing the violent reaction to the USPSTF guidelines, Quanstrum and Hayward pointed out two very simple things. First:
In reality, this independent panel, the Preventive Services Task Force, simply recommended that routine screening mammography begin at the age of 50 years, whereas women between the ages of 40 and 49 years should make individual decisions with their doctors as to whether their preferences and risk factors indicate screening at an earlier age. The panel also recommended that screening mammograms be performed every other year, which they suggested would reduce the harms of mammography by nearly half while maintaining most of the benefits provided by annual imaging.5 In short, the panel concluded that we had previously overestimated the value of mammography: that mammography is good, but not that good; that it is necessary for many women, but not all; and that it should be performed at some frequency, but perhaps not every year, for every woman.
And second:
Behind the panel’s conclusions regarding mammography lurks an unwelcome reality that our profession has often failed to acknowledge. Every medical intervention — no matter how beneficial for some patients — will provide continuously diminishing returns as the threshold for intervention is lowered. Mammography is just one case in point. For women between the ages of 40 and 49 years, the false positive rate is quite high, and the expected benefits are quite low: more than 1900 women would need to be invited for screening mammography in order to prevent just one death from breast cancer during 11 years of follow-up, at the direct cost of more than 20,000 visits for breast imaging and approximately 2000 false positive mammograms. Conversely, for women between the ages of 60 and 69 years, fewer than 400 women would need to be invited for screening in order to prevent one breast-cancer death during 13 years of follow-up, while accruing approximately 5000 visits and 400 false positive mammograms.6 In short, as the risk of breast cancer increases, the benefits of mammography increase, whereas the relative harms become progressively less significant.
Which strikes me as exactly correct. If there’s one rule of screening for any disease, it’s that the more you screen the more disease you will find, but much of it will be subclinical and much of it would likely never have killed the patient. Another rule is the law of diminishing returns. This leads to an observation, namely that for any screening test, there will be a population for whom the benefits clearly outweigh the risks, one for whom the risks clearly outweigh the benefits, and one for whom the answer is not so clear. What we have now is a model in which a threshold is set and there is in essence a binary system: Screen or don’t screen. What Quanstrum and Hayward argue is that there should be three options, which they represent thusly (click to enlarge):
model
And, it seems to me, that’s all that the USPSTF was suggesting: That for women without other risk factors for breast cancer between the ages of 50 and 70 the benefits of mammography clearly outweigh the risks. For women without other risk factors for breast cancer under age 40, the risks outweigh the benefits. For women between 40 and 50, the answer is unclear, and these women should discuss the issue with their doctors and come to a decision based on a frank discussion of the benefits and risks, acknowledging that screening may not be right for some women under 50, while for others it is. The problem is, binary decision-making is easier than more complicated models.
In the end, that’s probably what drives me the most batty about debates over screening for breast cancer. It’s not a black-and-white question, but advocates and physicians who become invested in the status quo sell it as such. Evidence and the science change, but policy recommendations become fossilized because certainty is perceived as being better than nuance. I will admit that three or four years ago I probably would have been one of the docs circling the wagons in the face of these new studies. No longer. I also detest the “other side,” who represent mammographic screening as useless because the benefits appear to be more modest than we originally believed. I believe that patients are far more capable than we give them credit for of understanding and acknowledging that there are gray areas in medicine. We should not be selling certainty when there is none.

The mammography wars heat up again (2012 edition)
David Gorski on August 6, 2012
Link
One issue that keeps coming up time and time again for me is the issue of screening for cancer. Because I’m primarily a breast cancer surgeon in my clinical life, that means mammography, although many of the same issues come up time and time again in discussions of using prostate-specific antigen (PSA) screening for prostate cancer. Over time, my position regarding how to screen and when to screen has vacillated—er, um, evolved, yeah, that’s it—in response to new evidence, although the core, including my conclusion that women should definitely be screened beginning at age 50 and that it’s probably also a good idea to begin at age 40 but less frequently during that decade, has never changed. What does change is how strongly I feel about screening before 50.
My changes in emphasis and conclusions regarding screening mammography derive from my reading of the latest scientific and clinical evidence, but it’s more than just evidence that is in play here. Mammography, perhaps more than screening for any disease, is affected by more than just science. Policies regarding mammographic screening are also based on value judgments, politics, and awareness and advocacy campaigns going back decades. To some extent, this is true of many common diseases (i.e., that whether and how to screen for them are about more than just science), but in breast cancer arguably these issues are more intense. Add to that the seemingly eternal conflict between science and medicine communication, in which a simple message, repeated over and over, is required to get through, versus the messy science that tells us that the benefits of mammography are confounded by issues such as lead time and length bias that make it difficult indeed to tell if mammography—or any screening test for cancer, for that matter—saves lives and, if it does, how many. Part of the problem is that mammography tends to detect preferentially the very tumors that are less likely to be deadly, and it’s not surprising that periodically what I like to call the “mammography wars” heat up. This is not a new issue, but rather a controversy that flares up periodically. Usually this is a good thing.
And these wars just just heated up a little bit again late last week.
Applying the heat were two Dartmouth Medical School faculty, whose criticisms of the “overselling” of mammography led to headlines like this on Thursday and Friday:
    • Breast Cancer: Komen Oversells Mammograms, Doctors Say
    • Breast cancer charity overstated screening benefits, researchers say
    • Breast Cancer Screening: How Komen Oversold the Benefits of Mammography
    • Susan G. Komen’s emphasis on mammograms during breast cancer awareness month called into question
All of these news reports are based on an editorial published Friday in the BMJ by Steven Woloshin and Lisa Schwartz entitled Not So Stories: How a charity oversells mammography (PDF available). It tells the story of an advertisement used by the Komen for the Cure Foundation during last year’s Breast Cancer Awareness Month. It is an ad that is still present on the Komen website.
Before I take this on, I need to clearly state my conflict of interest here. Specifically, I have a professional relationship with our local Komen affiliate. Sometimes I have disagreed with Komen, in particular three years ago when, it seemed, I was the only person I knew who was receptive to the recommendations of the USPSTF regarding mammographic screening. Far more of the time, I have admired the work done by our local affiliate “on the ground,” so to speak and remained honored to know and work with so many dedicated people, who work year in and year out to raise money for breast cancer research, screening, and treatment. It is also why it pains me to take this issue on. However, I feel it is my obligation as the resident breast cancer expert here on Science-based Medicine to do so, particularly given the confusion this development is likely to cause.
Also, before I go on, however, as I always do, I want to make sure that we are very clear on what is being discussed here. We are discussing screening mammography; i.e., using mammography on asymptomatic women at regular intervals in order to detect breast cancer before it becomes symptomatic. We are not discussing diagnostic mammography, which is undertaken either in the case of a woman who feels a lump, in order to evaluate that lump or mass, or in women whose screening mammography reveals an abnormality. We are not discussing diagnostic mammography. We are discussing screening mammography. Once again, I can’t emphasize that distinction enough. Women with symptoms should have mammography and other imaging modalities, such as ultrasound and MRI, as medically indicated. I also have to emphasize yet again, that what we are talking about is screening in women at average risk for breast cancer, not women who are at elevated risk due to family history, genetic predisposition, or other factors. In these women, screening is more effective because their chances of developing breast cancer are elevated.
With those two important issues and clarifications out of the way, let’s dive in.
Using the wrong statistics? Unfortunately yes, but so do a lot of doctors.
The first thing I wondered about is why the authors picked on Komen when Komen is not the only breast cancer advocacy organization making claims for the benefits of mammography that might be a bit overblown. For instance, the American College of Radiology has a website Mammography Saves Lives, which uses arguments even worse than the argument in the specific Komen ad that Woloshin and Schwartz criticize do, as I will show later. Of course, ACR is not a breast cancer advocacy organization; rather it is, like the AMA, a trade organization that protects the interests of its constituents, namely radiologists, and it is in the ACR’s interest to keep mammographic screening programs going. Also, Komen is obviously the biggest kid on the block as far as breast cancer advocacy groups go and thus the biggest target as well. The National Breast Cancer Coalition, which Woloshin and Schwartz mention (see below), is actually not nearly as well known as Komen, and it also advocates the completely unrealistic goal of “eliminating” breast cancer by 2020. Its opinion is a minority opinion, at least with respect to screening.
In the meantime, let’s see what Woloshin and Schwartz’s criticism boils down to. They begin with a description of how Breast Cancer Awareness Month has become such a big deal over the last 20 years as a lead-in to this provocative observation:
Unfortunately, there is a big mismatch between the strength of evidence in support of screening and the strength of Komen’s advocacy for it. A growing and increasingly accepted body of evidence shows that although screening may reduce a woman’s chance of dying from breast cancer by a small amount, it also causes major harms.5 6 In fact, the benefits and harms are so evenly balanced that the National Breast Cancer Coalition, a major US network of patient and professional organisations, “believes there is insufficient evidence to recommend for or against universal mammography in any age group of women.”7 Even the chief medical officer of the American Cancer Society, which has long promoted screening, calls for balanced information to ensure that women understand the benefits and harms of mammography.8 Recently in the United Kingdom an independent panel began reviewing the evidence for mammography to help the NHS decide whether the balance of benefits and harms justifies its national screening programme.9
Over the last three or four years that I’ve been assessing newer studies of mammography, I sometimes wonder if this sort of “coming down to earth” by mammography is an example of the “decline effect,” namely the tendency in medicine for early results for any intervention to show much more efficacy and for that apparent efficacy to “decline” with time. For instance, early randomized clinical trials examining mammographic screening demonstrated significant reductions in breast cancer-specific mortality in the screened group, and it was on this basis that large population-based screening programs were implemented beginning around 30 to 35 years ago in the U.S. Now that we have some 20 to 30 years’ worth of followup data, we are now finding that perhaps in the real world mammography screening isn’t as effective as it once seemed in clinical trials. Even so, it probably still presents a 15% decrease in breast cancer mortality in screened populations, if one accepts this Cochrane Review estimate. That’s not too shabby. In fact, it’s much better than “not too shabby.” Think of it this way. If mammography really does achieve a 15% reduction in breast cancer mortality, that would potentially be roughly 6,000 lives saved per year given that there are around 40,000 deaths from breast cancer each year in the U.S. Having lost my mother-in-law to breast cancer three years ago, I can only imagine the amount of pain, both emotional and physical, such a number represents. So, while there is no doubt that mammography can save lives, the debate remains over how many and at what cost. Balancing these risks and benefits then becomes a question that relies on our values and how much we as a society are willing to pay to save one life. These are not questions that can be answered by science alone, but science must inform the answers.
Arguments over the efficacy of mammographic screening for reducing breast cancer-associated mortality in the real world, aside, here is the meat of the criticism of the ad Komen ad (pictured above):
The advertisement states that the key to surviving breast cancer is for women to get screened because “early detection saves lives. The 5-year survival rate for breast cancer when caught early is 98%. When it’s not? 23%.”
This benefit of mammography looks so big that it is hard to imagine why any woman would forgo screening. She’d have to be crazy.
But it’s the advertisement that is crazy. Why? Because screening changes the point during the course of cancer when a diagnosis is made. Without mammography screening, a diagnosis is made when the tumour can be felt. With screening, diagnosis is made years earlier when tumours are too small to feel. Five year survival is all about what happens from the time of diagnosis: it is the proportion of women who are alive five years after diagnosis. Because screening finds cancers earlier, comparing survival between screened and unscreened women is hopelessly biased.
I must also give props to Barnette Kramer for the best analogy ever to explain lead time bias to the lay public, an analogy cited by Woloshin and Schwartz:
Barnett Kramer, director of the National Cancer Institutes’ Division of Cancer Prevention, explained lead time bias by using an analogy to The Rocky and Bullwinkle Show, an old television cartoon popular in the US in the 1960s. In a recurring segment, Snidely Whiplash, a spoof on villains of the silent movie era, ties Nell Fenwick to the railroad tracks to extort money from her family. She will die when the train arrives. Kramer says, “Lead time bias is like giving Nell binoculars. She will see the train—be ‘diagnosed’—when it is much further away. She’ll live longer from diagnosis, but the train still hits her at exactly the same moment.”
In other words, for any screening test, it is very difficult to tell how much of the measured effect on five- or ten-year survival rates is due to binoculars or an actual effect on slowing down or stopping the train. I once again refer readers to previous posts that I’ve written on the issue. Add to this the tendency of mammography or other routine screening tests to detect preferentially slower-moving trains (or even trains that have stopped). That’s why mortality statistics, at least from a population standpoint, are more reliable. In terms of determining if a test is efficacious, randomized controlled trials are an excellent starting point, but it is mortality statistics that measure the “real world” effectiveness of the test.
Whether Komen realizes it or not, this is exactly the same fallacy that I described a while back in deconstructing a poorly done study that purported to demonstrate that the United States does a lot better than Europe in terms of diagnosing and treating cancer, all with the subtext that single-payer and government-funded universal health care programs don’t do as well as our supposed “free market” approach. The authors compared the survival data for cancer in several countries and found that survival in the U.S. was better. Not surprisingly, this difference in apparent survival was driven mostly by breast cancer and prostate cancer, the two cancers for which we in the U.S. screen more aggressively than is done in Europe. Also not surprisingly, when one looks at mortality data, one finds that there is very little difference between the U.S. and Europe and that some countries appear to be doing better than we are for certain cancers. In other words, when you look at five- and ten-year survival statistics, it looks as though the U.S. is doing much better, but when you look at mortality data, it’s a mixed bag, with the U.S. doing better for some cancers and not as well for others.
It is also a fallacy to which, unfortunately, many doctors (who really should know better) fall prey, as a recent survey of primary care physicians demonstrates. Basically, when polled about hypothetical scenarios about a new screening test, physicians were much more impressed by a reported increase in five year survival or increased detection than they were by a reported decrease in mortality. This survey indicates that many physicians do not understand the concepts of lead time and length bias. Indeed, many physicians who, even more than a family physician, should know better, don’t, for example, Dr. Deborah Rhodes. That is why I think that it is unlikely that Komen was intentionally trying to deceive or oversell mammography with this advertisement. Rather, I strongly suspect that this add came about from the same basic misunderstanding of the proper methodology to determine the utility of a screening test for cancer that large swaths of the medical field, including, unfortunately, oncologists and radiologists, also suffer from.
I also couldn’t find the source of the assertion that breast cancers discovered early is 98% while it is 23% when not discovered early. Presumably, the ad is comparing stage I disease versus stage IV disease and implying that mammographic screening is the difference between being diagnosed at stage I and being diagnosed at stage IV. As Woloshin and Schwartz correctly point out, the five year survival for early and late stage cancers tells nothing about the benefits of screening. In fact, it is known that tumors detected by mammography tend to have a better prognosis than those detected by other means (i.e., symptomes), but figuring out how much of that difference is “real” and how much is due to lead time bias is anything but simple. In actuality, the majority is probably lead time bias, although it is clear that there is some benefit due to screening.
Absolute versus relative benefit versus population benefit versus overdiagnosis
Another issue that demands clarity but often does not receive it that is illuminated by this latest blowup is the issue of absolute risk versus relative risk. When I refer to a 15-25% reduction in risk of breast cancer in populations screened using mammography, what, exactly does that mean? I’ve pointed out before in discussing screening by mammography that to avert one death from breast cancer with mammographic screening for women between the ages of 50-70 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of ductal carcinoma in situ (DCIS). In other words, mammographic screening is very labor- and resource-intensive, and a lot of women have to be screened to save one life.
Woloshin and Schwartz also point out that for women between the ages of 40 and 49, mammographic screening is associated with a reduction in risk of dying of breast cancer over 10 years from 0.35% to 0.30% (a relative risk reduction of 14%); between the ages of 50 and 59, from 0.53% to 0.46% (a relative risk reduction of 13%); and between the ages of 60 and 69, from 0.83% to 0.56% (a relative risk reduction of 33%). When examined on a relative basis, a risk reduction of 13 to 33% looks impressive. However, when examined on an absolute basis, these risk reductions sound a lot less impressive. It is generally a truism in medicine that, if you want to make the apparent benefit sound as good as possible, you use relative risk reductions but that if you want to make relative risk reductions sound as unimpressive as possible you use absolute risk reductions. That’s because absolute risk reduction incorporates the risk a person has of developing the condition being intervened against. This is the same issue that comes up when discussing improvements in five year survival brought about by chemotherapy in cancer. For instance, I can tell you that, if you have a stage I cancer, chemotherapy will improve your five year survival by 30%. That’s a relative number. However, if I cite it in terms of absolute risk reduction (rounding to make the numbers easy), it is a 3% absolute improvement in survival (from 90% to 93%). Personally, I believe in quoting both figures.
There’s another way to look at it, too. Let’s take a look at the 50-59 year old age group. In the most recent census, there were approximately 21,506,000 such women in the U.S. A decrease in the chance of dying of breast cancer of 0.07% translates into approximately 15,000 deaths over ten years, or approximately 1,500 deaths per year. The comparable figure for the 40-49 year age range is roughly 11,000 deaths averted over ten years; for the 60-69 year age range, 30,000 deaths over 10 years, using these figures. Note that these numbers add up to roughly 5,600 breast cancer deaths a year averted, which is pretty close to the original estimate I made above of 6,000, reassuring me that at least I’m in the ballpark. Obviously, these are are not inconsequential numbers. Each one is a woman’ life saved from dying of breast cancer. They are, however, aggregate estimates for the entire population, which makes them useful as a guide to policy estimating how many women can be saved but not particularly useful for a single woman trying to decide whether to undergo screening.
Finally, there is the issue of overdiagnosis. It is inherent in any screening test that it will pick up “subclinical disease.” The question in cancer is whether this subclinical disease will ever progress to endanger the life of the patient. In the case of breast cancer, as I’ve discussed on many occasions before, lead time bias and, in particular, length bias mean that mammography tends to detect lesions that are slower growing, some of which might be so slow growing that they would never become clinically apparent, much less endanger the life of the patient, within her lifespan. Part and parcel of this tendency is the vastly increased incidence of DCIS. Back in the early 1900s, DCIS was rare because by the time it grew large enough to be a palpable mass, it almost always had become invasive cancer. Now, thirty years or so after mass mammographic screening programs began, DCIS is common. Indeed, approximately 30-40% of breast cancer diagnoses are in fact DCIS. Indeed, a recent study found that DCIS incidence rose from 1.87 per 100,000 in the mid-1970s to 32.5 in 2004. That’s a more than 16-fold increase over 30 years, and it’s pretty much all due to the introduction of mammographic screening. Now, when it comes to DCIS, we don’t have a good handle on what percentage of DCIS will progress to invasive cancer, but we do know that a significant percentage will not. The problem, of course, is that there is no way to predict right now for any individual patient whether her DCIS will progress; so we treat them all the same. Similarly, a significant percentage of invasive cancer detected by mammography alone will not progress appreciably; yet they are all treated because we cannot tell which ones will and will not progress. In other words, over diagnosis leads to overtreatment. Unfortunately, consideration of all these issues is not easily compatible with the need for simple messages that motivate people to act.
I also can’t help but note that the ad above is jarringly out of sync with the science-based recommendations elsewhere on the Komen website. For instance, its screening recommendations for women at average risk are in line with the scientific consensus, recognizing the areas of controversy regarding screening women between ages 40 to 49, along with a handy-dandy table summarizing the mammography recommendations of the various cancer organizations about when and how often to screen. There’s also a statement from Dr. Eric Winer, Komen’s scientific advisor, that is about as reasonable and middle-of-the-road as you could ask for:
Any health-related decision is a personal one that involves balancing risks and benefits. At Susan G. Komen for the Cure®, we encourage all women to follow the recommended breast cancer screening guidelines based upon age, personal risk and physician recommendation. These include getting a mammogram every year starting at age 40 for women at average risk and getting specific screening recommendations from physicians for women at higher risk. We also encourage women to discuss these guidelines with their health care providers, and if they are concerned about overdiagnosis or the value of a screening test, to raise these concerns. Ultimately, each woman needs to make medical decisions that are in keeping with her values and, ideally, maximize her chance of having a long and healthy life.
Dr. Winer even mentions a study that I blogged about a few years back that found that as many as one in three mammography-detected breast cancers might be overdiagnosed. To be objective and fair, Woloshin and Schwartz really should have at least made a brief mention of the other material on Komen’s website to put their criticism of the Komen ad pictured above in proper context. That they did not suggests to me that they might have an agenda with respect to Komen that goes beyond this one ad, because in totality the information Komen distributes about mammographic screening is not out of line with what most relevant organizations recommend, and Komen does recognize and deal with the controversy. Woloshin and Schwartz might not agree with Komen’s conclusions, but they seem to attack this one advertisement as a straw man representing their perception of what Komen actually says about mammography.
Be that as it may, my guess—and, again, this is just a guess—is that Komen fell into the trap of looking for simple messages combined with the lack of understanding of why survival statistics are not a valid measure of the efficacy of a screening test in preventing death from cancer. In that, Komen is not alone. Indeed, as I mentioned above, if you really want to see arguments even worse than the one in the advertisement above, look no further than the American College of Radiology:
The USPSTF agrees that mammography screening saves lives beginning at age 40. They used the smallest possible decrease in deaths (15%) that can be derived from the most rigorous scientific studies called randomized, controlled trials (RCT). As a result of not having experts on the Panel, they did not realize that the RCT are designed in such a way that they underestimate the benefit of screening so that 15% was the very lowest benefit. They ignored the other scientific evidence that shows that the benefit is at least twice that. In the United States the death rate from breast cancer was unchanged for 50 years prior to the onset of mammography screening in the mid 1980’s. Soon after, the death rate began to decrease, and since 1990 it has declined by 30%. This is not a victory over breast cancer, but a remarkable achievement. The USPSTF not only agreed that the benefit applied to women in their forties, but that the decrease in deaths has been even higher among these women. Relying on computer models (sophisticated financial computer models failed to predict the economic crash), they ignored direct studies from the Netherlands and Sweden that showed that most of the decrease in deaths was due to mammography screening and not new therapy. In Sweden, where women take fuller advantage of screening, the death rate had decreased by over 40% in several studies. Using these figures, instead of the 15%, women in their forties would have been well within the threshold that the Task Force had, arbitrarily, set for supporting screening.
Note the poisoning of the well (the reference to financial computer models, which is irrelevant to whether the models used by the USPSTF are valid). Note the blatant confusing of correlation with causation. Just because a decline in breast cancer mortality began around the same time mammographic screening programs became widespread does not mean that it was the mammographic screening that caused it. Without knowing that the specific studies to which the statement refers, I can’t analyze them, but I do know that the latst studies from that part of the world, if anything, actually suggest that the vast majority of the decline in breast cancer mortality is due to better treatment. Also, it was during that same time that results of the NSABP trials confirmed that adjuvant chemotherapy results in a significant reduction in breast cancer mortality and as a result its use became widespread. The result has been a major decline in breast cancer mortality due to the use of adjuvant chemotherapy. Finally, note the complete misunderstanding, whether willful or not, of what RCTs actually do. It’s ridiculous to point out that RCTs are designed to underestimate benefits; that statement is so wrong that it’s not even wrong. The correct way to state the concept is that RCTs are designed to eliminate biases that tend to lead to overestimates of effect sizes. There’s a huge difference. The ACR seems to be arguing that we should rely on less rigorous studies because they show larger effect sizes. Regular readers know who often makes arguments of this sort.
In fact, the wag in me can’t help but wonder if Woloshin and Schwartz will take on the ACR next. I’d love to see that.
My usual sarcasm aside, the “overselling” of screening tests is widespread, and it’s not just Komen that can be accused of having at times done it. Moreover, contrary to the claims of quacks like Mike Adams that Komen is lying and perpetrating a fraud and that mammograms kill women, it’s almost certainly not due to malice or intentional distortion, but rather from a genuine belief that the tests save lives coupled with a lack of understanding of the issues involved in determining whether a given screening test actually achieves what its proponents claim it can do. Science is messy, and the science of screening tests is among the messiest. I can only hope that Komen learns from this and doesn’t use the same ad this October.

A holiday round in the mammography debate
David Gorski on November 26, 2012
Link
There are times when the best-laid blogging plans of mice and men often go awry, and this isn’t always a bad thing. As the day on which so many Americans indulge in mass consumption of tryptophan-laden meat in order to give thanks approached, I had tentatively planned on doing an update on Stanislaw Burzynski, given that he appears to have slithered away from justice yet again. Then what to my wondering eyes should appear in my e-mail in box but news of a study that practically grabbed me by my collars, shook me, and demanded that I blog about it. As if to emphasize the point, suddenly e-mails started appearing by people who had seen stories about the study and, for reasons that I still can’t figure out after all these years, were interested on my take on the study. Yes, I realize that I’m a breast cancer surgeon and therefore considered an expert on the topic of the study, mammography. I also realize that I’ve written about it a few times before. Even so, it never ceases to amaze me, even after all these years, that anyone gives a rodential posterior about what I think. Then I started getting a couple of e-mails from people at work, and I knew that Burzynski had to wait or that he would be relegated to my not-so-secret other blog (I haven’t decided yet).
As is my usual habit, I’ll set the study up by citing how it’s being spun in the press. My local home town paper seems as good a place to begin as any, even though the story was reprinted from USA Today. The title of its coverage was Many women receiving unnecessary breast cancer treatment, study shows, with the article released the day before the study came out in the New England Journal of Medicine:
Up to 70,000 American women a year are treated unnecessarily for breast cancer because they were screened with mammograms, according to an analysis in today’s “New England Journal of Medicine” that’s likely to reignite a running debate over the value of cancer screening.
The study, whose results are already being challenged by other cancer experts, finds that nearly one in three breast cancer patients – or 1.3 million women over the past three decades – have been treated for tumors that, although detectable with mammograms, would never have actually threatened their lives.
The study lays bare perhaps the greatest risk of cancer screening, called “overdiagnosis,” long acknowledged by doctors and even advocates of mammograms, but unknown to most women who undergo the procedures.
That’s actually a fairly sober assessment, as was this one by the LA Times:
About a third of all tumors discovered in routine mammography screenings are unlikely to result in illness, according to a new study that says 30 years of the breast cancer exams have resulted in the overdiagnosis of 1.3 million American women.
The report, published Thursday in the New England Journal of Medicine, argues that the increase in breast cancer survival rates over the last few decades is due mostly to improved therapies and not screenings, which are intended to flag tumors when they are small and most susceptible to treatment. Instead, the widespread use of mammograms now results in the overdiagnosis of breast cancer in roughly 70,000 patients each year, needlessly exposing those women to the cost and trauma of treatment, the authors wrote.
My first thought was: Here we go again. My second thought was: Wow. The result that one in three mammographically detected breast cancers might be overdiagnosed is eerily consistent with a study published three years ago that looked at mammography screening programs from locations as varied as the United Kingdom, Canada, Australia, Sweden, and Norway, which I discussed at the time it was released. The consistency could mean either convergence on a “true” estimate of overdiagnosis, or it might mean that both studies shared a bias, incorrect assumption, or methodological flaw. If they do, I couldn’t find it, but it’s still an intriguing similarity. In any case, let’s dig in. The article is by Archie Bleyer and H. Gilbert Welch (the latter of whom has featured prominently in this blog several times before) and is entitled Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence.
Overdiagnosis and overtreatment in diseases we screen for
Before I go on I feel obligated to point out, as I always do when this subject comes up, that what I am referring to here are breast cancers detected by screening mammography in asymptomatic women. I cannot emphasize this enough. This study (and most of the studies I blogged about above) do not apply to women who have detected a lump, suspicious skin change, or any other symptoms of breast cancer. For such women, as far as we’ve been able to ascertain, the likelihood of overdiagnosis is vanishingly small. These cancers will almost certainly progress. Therefore, this study and my post do not apply to these cancers. If you feel a lump in your breast, get it checked out. If it is cancer, it will not fail to progress, nor will it go away. Again, I cannot emphasize this enough.
Regular readers are, I hope, familiar with the concept of overdiagnosis. After all, both Harriet Hall and I have written a fair amount about it before; so I’ll hope those who’ve read our discussions will bear with me a moment as I review the concept for those who might not be familiar with the concept. In doing so, I’ll steal shamelessly from my previous writings, after pointing out that it four and a half years ago when I first pointed out that the relationship between early detection of cancer—any cancer—and improved survival is more complicated than most people, even most doctors (including oncologists), think.
Screening for a disease involves subjecting an asymptomatic population, the vast majority of whom don’t have the disease, to a diagnostic test in order to find the disease before it causes symptoms. This is very different from most diagnostic tests used in medicine, the vast majority of which are ordered for specific indications. Any test to be contemplated for screening thus has to meet a very stringent set of requirements. First, it must be safe. Remember, we’re subjecting asymptomatic patients to a test, and invasive tests are rarely going to be worthwhile, except under uncommon circumstances (colonoscopy screening for colon cancer comes to mind). Second, the disease being screened for must be a disease that is curable or manageable. It makes little sense to screen for a disease like amyotropic lateral sclerosis (Lou Gehrig’s disease) because there is very little that will slow its progression. The one drug that we do have, Riluzole, only slows the progression of ALS slightly. Thus, diagnosing ALS a few months or a few years before symptoms appear won’t change the ultimate outcome. A very important corollary to this principle is that acting to treat or manage a disease early, before symptoms appear, should result in a better outcome, and the authors of this study point this out. I’ve discussed the phenomenon of lead time bias in depth before; it’s a phenomenon in which earlier diagnosis only makes it seem that survival is longer because a disease was caught earlier when in reality treatment had no effect on it. The condition progresses at the same rate as it would without treatment. Lead time bias is such an important concept that I’m going to republish the diagram I last used to explain it, because in this case a picture is worth a thousand words:
Then there’s this graph, from this paper, that demonstrates how screening preferentially detects less aggressive cancers (more details in my post here):
Another requirement for a screening test is that the disease being screened for must be relatively common. Screening for rare diseases is simply not practical from an economic standpoint. Economics aside, it’s bad medicine, too, because vast majority of “positive” test results will be false positives. Another way of saying this is that the specificity of the test must be such that, whatever the prevalence of the disease in the population, it does not produce too many false positives. In other words, for less common diseases the specificity and positive predictive value must be very high (i.e., a “positive” test result must have a very high probability of representing a true positive in which the patient actually does have the disease being tested for and the false negative rate can’t be too high; either that, or screeners must be prepared to do a lot of confirmatory testing for a large number of false positives). For more common diseases, a lower positive predictive value is tolerable. The test must also be sufficiently sensitive that it doesn’t produce too many false negatives. Remember, one potential drawback of a screening program is a false sense of security in patients who have been screened, a drawback that will be increased if a test misses too many patients with disease. Finally, a screening test must also be relatively inexpensive.
So what is overdiagnosis? Stated simply, overdiagnosis is a term used to describe disease detected in asymptomatic individuals that would never go on to threaten the life or health of those individuals. Many people subscribe to a simplistic view of cancer in which after the initial transforming event occurs to create a cancer cell the cancer will inevitably progress over time until, if left untreated, it will kill the individual. In such a view, detecting cancer earlier is an unalloyed good because it is assumed that, if left untreated, such tiny cancers will inevitably progress. However, as I first started to point out a few years ago, this is not necessarily true. people have a lot of cancer in them that never causes a problem. For instance, it’s well known that autopsy series reported on who died at age 80 or older have consistently shown that the majority of men over 80 (60-80%) have detectable foci of prostate cancer. Yet, obviously prostate cancer didn’t kill the men in these autopsy series, and they lived long enough to die either of old age or a cause other than prostate cancer. In other words, they died with early stage cancer but not of that cancer. Similarly, thyroid cancer is pretty uncommon (although not rare) among cancers, with a prevalence of around 0.1% for clinically apparent cancer in adults between ages 50 and 70. Finnish investigators performed an autopsy study in which they sliced the thyroids at 2.5 mm intervals and found at least one papillary thyroid cancer in 36% of Finnish adults. Doing some calculations, they estimated that, if they were to decrease the width of the “slices,” at a certain point they could “find” papillary cancer in nearly 100% of people between 50-70.
The list of conditions and diseases for which screening has increased apparent incidence goes on and on far beyond cancer.
One might ask what the problem is with overdiagnosis; i.e., what’s the harm? The harm arises from the consequence of overdiagnosis, which is overtreatment. If the screen-detected condition, be it tumor or other medical condition, would never progress to harm the patient even if untreated, then “treating” that condition can only cause harm, not benefit. That’s not even counting the risks from additional followup studies that are frequently required when a screening test finds an abnormality. In the case of breast cancer, the subject of the current study, those additional tests might mean more images (and the extra radiation they involve), invasive needle biopsies, and even surgical biopsies. In the case of screening for lung cancer, biopsies are more risky than for breast cancer, given the large blood vessels in the lung and the ease with which the a pneumothorax can occur. All mass screening programs involve a tradeoff, a balancing of risks and potential benefits, and it’s not even always clear how great the benefits might be. For instance, lead time bias can lead to an overestimation of benefits of treatment and a huge apparent increase in survival even if treatments don’t have an effect on the disease. That’s why mortality rates are the appropriate metric, not five-year survival rates, when evaluating a disease for which lead time bias is a consideration. It’s also why, when we do use survival rates in cancer, in order for them to be comparable they have to be stage-adjusted.
On to the study
In order to understand Welch’s study, it is important to realize that there is a huge assumption underlying its methods. That assumption, although reasonable, is not unassailable (more on that later). Specifically, as Welch states in the very first paragraph:
There are two prerequisites for screening to reduce the rate of death from cancer.1,2 First, screening must advance the time of diagnosis of cancers that are destined to cause death. Second, early treatment of these cancers must confer some advantage over treatment at clinical presentation. Screening programs that meet the first prerequisite will have a predictable effect on the stage-specific incidence of cancer. As the time of diagnosis is advanced, more cancers will be detected at an early stage and the incidence of early-stage cancer will increase. If the time of diagnosis of cancers that will progress to a late stage is advanced, then fewer cancers will be present at a late stage and the incidence of late-stage cancer will decrease.3
In other words, a screening test that does not overdiagnose will find cancers earlier. These cancers will be successfully (or at least more successfully) treated, and thus pulled out of the pool of early stage cancers that are progressing to late stage cancers. This removal of early stage cancers from the total pool of cancer diagnoses should thus shift the stage distribution of breast cancer to earlier stages and result in an absolute decrease in the number of late stage cancers being diagnosed. In other words, as the number of cancers being detected early goes up, the number of cancers being detected at advanced stages, particularly at stage IV (which can be treated but not cured), should go down. Thus, the overall hypothesis is that, if mammography is effective, there should be an increase in the incidence of early stage cancer diagnosed and a corresponding decrease in the incidence of late stage cancer. If the diagnosis of early stage cancer increased faster than the diagnosis of late stage cancer decreased that likely represents overdiagnosis.
To test this hypothesis and try to estimate the amount of overdiagnosis going on, Welch used the Surveillance, Epidemiology, and End Results (SEER) database to examine stage–specific incidence of breast cancer over time. This database covers approximately 10% of the U.S. population. Using such a database was complicated by two issues. First, the authors had to choose a baseline, more specifically, a time period that they set as their baseline breast cancer incidence for cancers detected without mammography. For various reasons, including an underestimate in the earliest years of the SEER database in the early 1970s and because of a brief spike in breast cancer diagnoses in the wake of Betty Ford’s diagnosis, the authors chose 1976 to 1978 as this baseline. Second, there was a period from the late 1980s to early 2000s when hormone replacement therapy with mixed estrogen-progesterone combinations was popular and is widely believed to have increased the incidence of breast cancer. This time period, according to the authors, ended in 2006. To correct for this in current estimates of breast cancer incidence from 2006 to 2008, they truncated the observed incidence from 1990 to 2005 to remove “excess” cases from previous years. This part of the approach actually puzzled me a bit, because although it would result in a lower apparent incidence of breast cancer it’s not clear how it would do what the authors stated and “provide estimates that were clearly biased in favor of screening mammography — ones that would minimize the surplus diagnoses of early-stage cancer and maximize the deficit of diagnoses of late-stage cancer”; i.e., provide a “best case scenario” for screening mammography.
Another area where I quibble a bit with Welch is his assumption that the change in the incidence rate of breast cancer among women under 40 (who do not undergo screening in this country) is a valid estimate of the true incidence of breast cancer. Breast cancer in women under the age of 40 is arguably biologically different than the more “typical” breast cancer. At the very least, it tends to be more aggressive. I realize that in the SEER database there is no better surrogate for the incidence of breast cancer in an unscreened population, but the question of the biological relevance of this “control” group was pretty much glossed over in this paper.
The first “money” figure is Figure 1, which shows the incidence of early and late stage cancer over time:
There are two things to note here. First, as I’ve discussed before on multiple occasions, the apparent incidence of early stage breast cancer skyrocketed after the introduction of mass mammography screening programs in the late 1970s and early 1980s and has only leveled off in the last six or seven years. Second, the incidence of cancers diagnosed at late stage did decrease, but not by a lot. The authors state:
The large increase in cases of early-stage cancer (from 112 to 234 cancers per 100,000 women — an absolute increase of 122 cancers per 100,000) reflects both detection of more cases of localized disease and the advent of the detection of DCIS (which was virtually not detected before mammography was available). The smaller decrease in cases of late-stage cancer (from 102 to 94 cases per 100,000 women — an absolute decrease of 8 cases per 100,000 women) largely reflects detection of fewer cases of regional disease. If a constant underlying disease burden is assumed, only 8 of the 122 additional early diagnoses were destined to progress to advanced disease, implying a detection of 114 excess cases per 100,000 women. Table 1 also shows the estimated number of women affected by these changes (after removal of the transient excess cases associated with hormone-replacement therapy). These estimates are shown in terms of both the surplus in diagnoses of early-stage breast cancers and the reduction in diagnoses of late-stage breast cancers — again, under the assumption of a constant underlying disease burden.
I’ve discussed how mammography has increased the apparent incidence of DCIS before. Ironically enough, I did it in the context of refuting a common antivaccine trope that “increased detection” and increased awareness couldn’t possibly result in an increase in the number of autism diagnoses. The observation that increased screening for virtually any condition can and does reliable result in the detection of preclinical disease and an increase in incidence is perhaps nowhere better shown that for the case of mammography and DCIS.
The second “money figure” (in this case, “money table”) from the paper is Table 2, which looks at the excess estimation of breast cancers by screening mammography based on four assumptions a base case (constant “underlying” incidence of breast cancer); best guess (breast cancer incidence rising at 0.25% per year, as estimated from the rate of increase of breast cancer incidence in women under 40); an extreme assumption (breast cancer incidence increasing 0.5% per year, twice that of the “best guess”) and a “very extreme assumption” (0.5% per year increase in breast cancer incidence plus using the highest estimate of baseline incidence of late stage disease). Here’s the table:
The authors point out that, regardless of the method they used to calculate it, their estimate of the number of women overdiagnosed with breast cancer over the the last 30 years was at least 1 million, and the proportion of cancers that were overdiagnosed were 31%, 26%, and 22% in the best guess, extreme, and very extreme estimates, respectively.
Although Welch’s estimate is consistent with a growing literature that is consistent with a rate of overdiagnosis for screen-detected breast cancers of over 20%, there are still problems with it. Most of these problems derive from using SEER data. For one thing, SEER is often slow to incorporate new clinical and scientific findings. For example, a few years ago I wanted estimates of the number of patients in our SEER catchment area who are HER2-positive. I couldn’t get it, because at the time SEER hadn’t yet incorporated HER2 status into its database, even though it had been used as a prognostic marker for several years before. SEER does now incorporate HER2, but the point is simply that it’s often behind the times because it’s a big database and decisions regarding how to change in response to evidence and new clinical findings often come slowly.
Another issue is how stage definitions change over the years. However, perhaps one thing that I might have expected someone like Welch to consider but that he apparently did not (at least not if his discussion is any indication) is the issue of stage migration. Welch defines his stages thusly:
The four stages in this system are the following: in situ disease; localized disease, defined as invasive cancer that is confined to the organ of disease origin; regional disease, defined as disease that extends outside of and adjacent to or contiguous with the organ of disease origin (in breast cancer, most regional disease indicates nodal involvement, not direct extension9); and distant disease, defined as metastasis to organs that are not adjacent to the organ of disease origin. We restricted in situ cancers to ductal carcinoma in situ (DCIS), specifically excluding lobular carcinoma in situ, as done in other studies.10 We defined early-stage cancer as DCIS or localized disease, and late-stage cancer as regional or distant disease.
Fair enough, as far as it goes. However, when one looks at breast cancer over 30 years, one can’t help but note that how we detect node-positive disease (i.e., regional disease) has changed. In fact, the new standard of care, known as sentinel lymph node biopsy, can detect lymph nodes with much smaller tumor burdens, particularly when immunohistochemical stains are used, which could mean that over the last decade or so we could be seeing stage migration, largely as a result of detecting smaller metastases. Stage migration is a phenomenon that occurs when more sophisticated imaging studies or more aggressive surgery leads to the detection of tumor spread that wouldn’t have been noted in an identical patient using previously used tests. What in essence happens is that technology results in a migration of patients from one stage to another. This is not an insignificant consideration. One study suggested that the stage migration rate was as high as one in four; i.e., 40% of patients having “positive” axillary lymph nodes with SLN biopsy compared to 30% having positive nodes using axillary dissection. Another study reported similar results. How this would affect Welch’s analysis is hard to tell, and correcting for it is probably not possible using the SEER database, particularly given that the extent of “up-staging” is not fully known yet. Be that as it may, an increase in the apparent incidence of patients with positive lymph nodes would increase the apparent incidence of advanced disease and decrease any decline in the incidence of advanced disease. How large this effect is, I don’t know, but it would suggest that the rate of overdiagnosis is lower than what Welch estimates. How much lower, or whether stage migration is even a significant factor, I don’t know, but I wish that Welch had at least mentioned it.
The bottom line
This latest study by Bleyer and Welch is not, as I’m sure some proponents of “alternative” therapies and “alternative” means of diagnosing breast cancer, such as thermography, will try to argue, evidence that mammography doesn’t work or that it doesn’t save lives. It does. Randomized controlled trials have demonstrated that. However, those trials are old, and it’s not infrequent that “real world” applications of medical tests and treatments will be less effective than demonstrated in RCTs. There is also the “decline effect” to contend with, and I sometimes wonder whether the re-evaluation of mammography that is going on right now is simply one more example of a test not being as good as RCTs originally suggested. On the other hand, there are studies (for instance, this one) that strongly suggest mammography’s value in saving lives, even in younger women (aged 40-49), for whom there is the most controversy regarding mammographic screening.
Be that as it may, the Bleyer and Welch study is simply more evidence that the balance of risks and harms from mammography is far more complex than perhaps we have appreciated before. It’s very hard for people, even physicians, to accept that not all cancers need to be treated, and the simplicity of messaging needed to promote a public health initiative like mammography can sometimes lead advocacy groups astray from a strictly scientific standpoint. One has only to look at the reactions of some doctors to see this. For instance:
The study was roundly criticized by radiologists who specialize in breast imaging, who questioned its methodology and the suggestion that some cancer-like growths should be ignored.
“It’s kind of unbelievable that they’re telling us we’re finding too many early-stage cancers,” said Dr. Stamatia Destounis, a breast imager in Rochester, N.Y. “Isn’t that the point?”
And:
“This is simply malicious nonsense,” said Dr. Daniel Kopans, a senior breast imager at Massachusetts General Hospital in Boston. “It is time to stop blaming mammography screening for over-diagnosis and over-treatment in an effort to deny women access to screening.”
Dr. Kopan, I’m afraid, is completely wrong. This study is not “malicious nonsense.” It has weaknesses and might well overestimate the rate of overdiagnosis, but overdiagnosis is a real phenomenon. Only someone utterly ignorant of basic cancer biology or (as I suspect) protecting his turf would say something so nonsensical (word choice intentional). We’ve seen him say these sorts of things before, most prominently in response to the USPSTF guidelines proposed three years ago when he made dire warnings that large number of women will die because of them and said of the members of the task force, “I hate to say it, it’s an ego thing. These people are willing to let women die based on the fact that they don’t think there’s a benefit.”
As I said, it’s hard for many physicians to accept that not all cancer necessarily needs treatment. Certainly this is likely to be true for ductal carcinoma in situ (DCIS), which consists of cancerous cells that have not yet invaded through the basement membrane of the ducts. Unfortunately, this is the predominant form of breast cancer that is detected by mammography. Indeed, the authors even point out that their method didn’t allow them to disentangle the incidence of DCIS from that of invasive breast cancer, thanks to the way that the SEER database is set up. The problem, of course, is that we don’t know how to predict which cancers will progress and which cancers will not.
Finally, for all the confusion this study causes, there is one spot of good news, and that’s the observation that much of the decline in breast cancer mortality over the last 20 years—yes, contrary to what you might have heard, breast cancer mortality has actually been steadily decreasing—is likely due to improvements in treatment. The authors point this out:
Whereas the decrease in the rate of death from breast cancer was 28% among women 40 years of age or older, the concurrent rate decrease was 42% among women younger than 40 years of age.6 In other words, there was a larger relative reduction in mortality among women who were not exposed to screening mammography than among those who were exposed. We are left to conclude, as others have,17,18 that the good news in breast cancer — decreasing mortality — must largely be the result of improved treatment, not screening. Ironically, improvements in treatment tend to deteriorate the benefit of screening. As treatment of clinically detected disease (detected by means other than screening) improves, the benefit of screening diminishes. For example, since pneumonia can be treated successfully, no one would suggest that we screen for pneumonia.
Ironically, it might be that one of the reasons that the mammography wars are heating up again, with concerns of overdiagnosis and overtreatment beginning to call the benefits of mammography into question might be that mammography is a victim of the success of breast cancer treatment. The multidisciplinary combination of surgery, chemotherapy and targeted therapies, and radiation oncology has made breast cancer treatment, even for relatively advanced cases, far more effective than it was 30 years ago. It might be that treatments for breast cancer have improved so much over the last couple of decades that the role of mammography will inevitably decline. Maybe.
There is, however, a lot more that needs to be done before we can conclude that; right now reports of the death of mammography are very premature. To me, what is most important in breast cancer screening right now is to develop reliable predictive tests that tell us which mammographically detected breast cancers an be safely observed and which ones are likely to threaten women’s lives. We are currently at a point where imaging technology has outpaced our understanding of breast cancer biology, or, as Dr. Welch put it, “Our ability to detect things is far ahead of our wisdom of knowing what they really mean.” Until our understanding of biology catches up, the dilemma of overdiagnosis will continue to complicate decisions based on breast cancer screening.

The Canadian National Breast Screening Study ignites a new round in the mammography wars
David Gorski on February 17, 2014
Link
The last couple of weeks, I’ve made allusions to the “Bat Signal” (or, as I called it, the “Cancer Signal,” although that’s a horrible name and I need to think of a better one). Basically, when the Bat Cancer Signal goes up (hey, I like that one better, but do bats get cancer?), it means that a study or story has hit the press that demands my attention. It happened again just last week, when stories started hitting the press hot and heavy about a new study of mammography, stories with titles like Vast Study Casts Doubts on Value of Mammograms and Do Mammograms Save Lives? ‘Hardly,’ a New Study Finds, but I had a dilemma. The reason is that the stories about this new study hit the press largely last Tuesday and Wednesday, the study having apparently been released “in the wild” Monday night. People were e-mailing me and Tweeting at me the study and asking if I was going to blog it. Even Harriet Hall wanted to know if I was going to cover it. (And you know we all have a damned hard time denying such a request when Harriet makes it.) Even worse, the PR person at my cancer center was sending out frantic e-mails to breast cancer clinicians because the press had been calling her and wanted expert comment. Yikes!
What to do? What to do? My turn to blog here wasn’t for five more days, and, although I have in the past occasionally jumped my turn and posted on a day not my own, I hate to draw attention from one of our other fine bloggers unless it’s something really critical. Yet, in the blogosphere, stories like this have a short half-life. I could have written something up and posted it on my not-so-secret other blog (NSSOB, for you newbies), but I like to save studies like this to appear either first here or, at worst, concurrently with a crosspost at my NSSOB. (Guess what’s happening today?) So that’s what I ended up doing, and in a way I’m glad I did. The reason is that it gave me time to cogitate and wait for reactions. True, it’s at the risk of the study fading from the public consciousness, as it had already begun to do by Friday, but such is life.
Mammograms don’t save lives, quoth the BMJ (and everyone covering the study)!
After my obligatory navel-gazing explanatory introduction that infuriates some and entertains others, let’s jump into the study itself. It was published in the BMJ and is, as the title tells us, the Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. Before we delve into the findings, I should take a moment to explain what the Canadian National Breast Screening Study (CNBSS) actually is. The first thing you need to know is that this study has been contentious since its very beginning. In particular, radiologists have been very critical of the study. One radiologist in particular, whom we’ve encountered before, pops up time and time again in articles critical of the CNBSS. This doesn’t mean that his criticisms of the study are invalid, but this particular radiologist sends up a red flag given his track record of some truly badly thought-out criticisms he’s leveled at other mammography studies, most notably about a year ago.
The CNBSS, conceived in the late 1970s and begun in 1980, was a randomized clinical trial that was designed to answer two questions, depending upon the age group: (1) to compare regular breast examination to breast examination plus screening mammography (age 50-59) and (2) compare screening mammography plus “usual care” (age 40-49). These were questions that had arisen from the only existing large study published at the time, the New York Health Insurance Plan (HIP) Study, which in 1963 had randomized (without informed consent) women between the ages of 40 and 64 such that around 30,000 received annual two-view mammography and clinical breast examination for three screens, with another 30,000 serving as controls who received “usual care” (i.e., clinical breast examination). The results, first published in 1977, indicated a statistically significant reduction in breast cancer mortality of 23%. However, no benefit was seen in the 40-49 year old age group. Also, over an eight-year period after diagnosis, breast cancer cases that were positive only on mammography when screened had a case fatality rate of 14%, compared to 32% for cases positive only in the clinical examination and 41% for cases positive on both modalities. The thought at the time was that the reason no difference was seen in younger women was because the incidence of breast cancer is so much lower in women aged 40-49 than it is in women aged 50-64. As I’ve discussed many times before, the less common a disease is in a population being screened, the more false positives there will be and the harder it will be to detect a decline in mortality from that disease due screening because the smaller (on an absolute basis) any observed decline will be. That’s almost certainly why the early mammography studies that led to the implementation of widespread mammographic screening programs for the most part were unable to demonstrate a benefit in terms of preventing death from breast cancer in women under 50.
In any case, the HIP Study had raised the question of what the incremental benefit of screening mammography was over “usual care,” which included, in most cases, regular visits to one’s primary care doctor and breast self-examination. This was described in the introduction to the study reported last week, thusly:
In 1980 a randomised controlled trial of screening mammography and physical examination of breasts in 89,835 women, aged 40 to 59, was initiated in Canada, the Canadian National Breast Screening Study.4 5 6 7 It was designed to tackle research questions that arose from a review of mammography screening in Canada8 and the report by the working group to review the US Breast Cancer Detection and Demonstration projects.9 At that time the only breast screening trial that had reported results was that conducted within the Health Insurance Plan of Greater New York.10 11 Benefit from combined mammography and breast physical examination screening was found in women aged 50-64, but not in women aged 40-49. Therefore the Canadian National Breast Screening Study was designed to evaluate the benefit of screening women aged 40-49 compared with usual care and the risk benefit of adding mammography to breast physical examination in women aged 50-59. It was not deemed ethical to include a no screening arm for women aged 50-59.
So basically, there were two parts to this study: Mammographic screening plus regular clinical breast examination versus usual care in women aged 40-49 and mammographic screening plus regular clinical breast examination plus regular clinical breast examination alone in women aged 50-59. Here’s the study schema:
Women with any abnormal findings, be it on physical examination or mammography, were referred to a special review clinic directed by the surgeon affiliated with the study center, where, if indicated, diagnostic mammography was performed. (This study was carried out at 15 screening centres in six Canadian provinces, located in teaching hospitals or in cancer centers). I deem it important right here to emphasize yet again that all of these mammography studies were carried out in asymptomatic women (i.e., women who didn’t have any symptoms or lumps in their breasts). The reason I consider it important is that screening and diagnostic mammography are frequently confused in the minds of the lay public, and there is no controversy about what a woman who detects a lump in her breast or whose doctor detects one should do: Get it checked out with diagnostic mammography and (often) ultrasound, sometimes complemented with MRI. That’s the difference between diagnostic and screening mammography. Diagnostic mammography is done with the intention of working up an abnormality found on physical examination or screening mammography to determine if it needs to be biopsied. Pontification thus ended, I now point out that women who needed biopsies got them done by a surgeon to whom their primary care doctor referred them, and women who were thus diagnosed with cancer underwent treatment by surgeons and oncologists chosen by their primary care doctor.
Study subjects who enrolled had a physical examination (clinical breast exam) and were taught breast self-examination by trained nurses. Then they were randomized according to the schema above as described in the protocol:
Irrespective of the findings on physical examination, women aged 40-49 were independently and blindly assigned randomly to receive mammography or no mammography. Those allocated to mammography were offered another four rounds of annual mammography and physical examination, those allocated to no mammography were told to remain under the care of their family doctor, thus receiving usual care in the community, although they were asked to complete four annual follow-up questionnaires. Women aged 50-59 were randomised to receive mammography or no mammography, and subsequently to receive four rounds of annual mammography and physical examination or annual physical breast examinations without mammography at their screening centre.
In reporting the results, the investigators refer to the mammography plus breast physical examination arm in both age groups as the mammography arm, and the no mammography arms (usual care for women aged 40-49 and annual breast physical examinations for women aged 50-59) as the control arm. Also, the study is often referred to in two ways. The arm for women aged 40-49 is often referred to as CNBSS-1, and the arm for women aged 50-59 is often referred to as CNBSS-2. Just to make that clear.
So let’s get to the results. But before I do, let’s look at the last times the results were reported for this study, the 13 year follow-up in 2000 for CNBSS-2 and the 11-16 year follow-up in 2002 for CNBSS-1. The first report on CNBSS-2 showed no difference in breast cancer-specific mortality between the two groups in women aged 50-59; actually, the numbers showed slightly more deaths in the screening group, but that difference was nowhere near statistically significantly different. Although there was an unwritten assumption that there was likely to be a benefit to the addition of mammographic screening that just hadn’t shown up yet because the follow-up time was too short, the authors were forced to conclude that “our estimates of effect exclude a 30% reduction in breast cancer mortality from mammography screening” and that “chance is an unlikely explanation for our findings.” In the second study reporting the results for CNBSS-2, the investigators concluded:
After 11 to 16 years of follow-up, four or five annual screenings with mammography, breast physical examination, and breast self-examination had not reduced breast cancer mortality compared with usual community care after a single breast physical examination and instruction on breast self-examination. The study data show that true effects of 20% or greater are unlikely.
In other words, as of 2002, no benefit to adding mammography to routine care in women under 50 or to regular clinical breast examination in women 50-59 had yet been observed. The current study, unfortunately, completes the trend. Here’s the graph of all-cause mortality (all deaths of study participants):
And here’s the graph for breast cancer-specific mortality (women who died of breast cancer)
As you can see, the curves line up almost exactly. There is no statistically significant difference. There’s not even a whiff of a hint of a statistically significant difference.
Now that the data are more mature, the investigators could do what they couldn’t do before, namely to make an estimate of how much overdiagnosis was occurring in the study. (Overdiagnosis is the detection of disease that doesn’t need to be treated, disease that would never progress within the lifetime of the patient to endanger her life.) The authors noted that at the end of the screening period, there was an excess of 142 breast cancer cases in the mammography arm compared to the control arm (666 versus 524). By fifteen years after enrollment, the excess became constant at 106 cancers, which was 22% of all screen-detected breast cancers. Because the mortality rates were the same between the mammography versus control groups, these cancers represent overdiagnosis.
One notes that this number is remarkably similar to the estimates of overdiagnosis found in other clinical trials and epidemiological studies of mammography that I’ve discussed over the years. For example, way back in 2008, I discussed a study that suggested that 22% of breast cancers detected by screening mammography spontaneously regress.
Whoa. Maybe I shouldn’t have been so skeptical of that result when I wrote it up. And I’m not alone in noting how strikingly similar this number is to the rate of overdiagnosis in other studies. In an accompanying editorial, Kalager et al note the same thing, pointing out that “the amount of overdiagnosis observed in the previous randomised controlled trials is strikingly similar (22-24%).” Of course, there are others, many other studies, and in fact the 22% estimate is rather at the low end of some of the more recent studies. For example, the most recent “blockbuster” mammography study estimated the rate of overdiagnosis to be between 22% and 36%, depending upon the parameters used in the investigators’ model. One study that I discussed even suggested that one in three mammography-detected cancers were in fact overdiagnosed and overtreated, and I said:
Don’t get me wrong. There is no doubt that mammographic screening programs produce a rate of overdiagnosis. The question is: What is the rate? Unfortunately, the most accurate way to measure the true rate of overdiagnosis would be a prospective randomized trial, in which one group of women is screened and another is not, that follows both groups for many years, preferably their entire life. Such a study is highly unlikely ever to be done for obvious reasons, namely cost and the fact that there is sufficient evidence to show that mammographic screening reduces breast cancer-specific mortality for women between the ages of 50 and 70 at least, the latter of which would make such a study unethical. Consequently, we’re stuck with retrospective observational studies, such as the ones analyzed in this systematic review.
Well, the CNBSS is a randomized trial that follows women for their entire lives. Whatever its flaws (which will be discussed in the next section as I try to put it into context), it’s about as close to what I wanted four and a half years ago as we’re ever likely to get, which means that an overdiagnosis rate of somewhere around 20% or so is probably about as good an estimate of overdiagnosis of breast cancer by screening mammography as we’re ever likely to get. The problem, of course, boils down to two issues. First, we can’t tell which cancers diagnosed by screening mammography are overdiagnosed; i.e., which ones will never progress within the lifetimes of the women for whom they’re detected to endanger their lives. That leaves us a mandate to treat them all. Second, there is the question of whether this level of overdiagnosis is “worth it” for the level of benefit in reducing breast cancer mortality provided by screening mammography. The first problem, of course, can be solved by better predictive tests to separate the nasty players from the overdiagnosed players, but the second question is not so easy to answer.
Another important point is that this is the only large randomized study reported in the era of effective multimodality therapy with surgery, adjuvant chemotherapy regimens (chemotherapy administered after initial treatment to reduce the risk of recurrence), adjuvant Tamoxifen (Tamoxifen blocks the action of estrogen and can be used to decrease the risk of recurrence of tumors that respond to estrogen), and radiation therapy. This brings up the question of whether the reduction in mortality from breast cancer that we have observed since 1990—contrary to what you frequently hear, mortality from breast cancer is indeed falling and has been falling since around 1990—is primarily due to better treatment rather than earlier detection. There have been studies published over the last five years that suggest that this might be the case. But is it?
The knives come out, allowing me to (try to) put it all into context
Predictably, as always happens after a study like this, the knives came out, mostly wielded by radiologists. As is often commonly the case, the criticisms were a mixture of the reasonable, the ridiculous, and the obviously turf-protecting. What’s depressing about many of the criticisms of the study is that too many of the people making them seem unaware (or seem to deny) some very basic concepts about screening, namely overdiagnosis, overtreatment, lead time bias, and length bias. I’ve discussed them all before on multiple occasions, pointing out that the early detection of cancer does not always result in improved survival, and more sensitive tests can often lead to upstaging and more aggressive therapy without benefit. I’ve discussed overdiagnosis already. Lead time bias is a situation where early detection of the cancer doesn’t result in improved survival but only appears to do so because the disease is detected earlier and the patient lives longer with it. The best explanation of overdiagnosis (besides mine, of course) I’ve ever found can be read here. Length bias simply describes the tendency of screening to detect more slowly growing, indolent tumors. These problems have led to a major rethinking of prostate cancer screening and is beginning to do the same for breast cancer screening.
Indeed, the 15-25% reduction in breast cancer mortality cited by mammography proponents translates to an absolute risk picture in which averting one death from breast cancer with mammographic screening for women between the ages of 50-70 requires screening 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of ductal carcinoma in situ (DCIS). As reported in the New York Times treatment of this study, approximately 1 in 424 women in the CNBSS received unnecessary cancer treatment. In other words, mammographic screening is very labor- and resource-intensive, and a lot of women have to be screened to save one life. As I’ve also said many times in the past, whether this is “worth it” is more a value judgment than a scientific judgment, although that value judgment has to be informed by accurate science.
Of course, the CNBSS is not without shortcomings. Indeed, it’s been attacked nearly from its earliest reports, mostly by radiologists. Indeed, it’s instructive to peruse the criticisms posted after the article (one advantage of BMJ journal articles). They range from the reasonable to real howlers. An example of the latter comes, not surprisingly, from Daniel B. Kopans, a professor of radiology at the Harvard Medical School and someone who’s well known for attacking any study that questions mammography, particularly after the USPSTF guidelines were published in 2009, and who almost a year-and-a-half ago gave us this howler:
This is simply malicious nonsense,” said Dr. Daniel Kopans, a senior breast imager at Massachusetts General Hospital in Boston. “It is time to stop blaming mammography screening for over-diagnosis and over-treatment in an effort to deny women access to screening.”
He was referring to H. Gilbert Welch’s study published in late 2012 in the New England Journal of Medicine that found a high degree of overdiagnosis due to mammography. As I pointed out at the time, Dr. Kopans was completely wrong, and overdiagnosis is a pitfall of screening programs. He’s also known for saying things like this about the members of the USPSTF task force that published a set of recommendations in 2009:
I hate to say it, it’s an ego thing. These people are willing to let women die based on the fact that they don’t think there’s a benefit.
It’s therefore not surprising that after the BMJ article, Dr. Kopans makes the same sorts of statements, statements echoed in a statement on the American College of Radiology’s website and in an article entitled We do not want to go back to the Dark Ages of breast screening, by Dr. László Tabár and Tony Hsiu-Hsi Chen, DDS, PhD published on AuntieMinnie.com, described as providing “the first comprehensive community Internet site for radiologists and related professionals in the medical imaging industry”. Many of the criticisms are shared, although Dr. Tabár does appear to me a bit disingenuous when he says that “Canadian trials could not evaluate the independent impact of mammography because of the confounding effect of physical examination.” I suppose that’s why they compared physical examination to physical examination plus mammography in the 50-59 year old group.
Dr. Kopans’ first criticism was that the quality of the mammograms was below state-of-the-art, even for the 1980s. Indeed, Dr. Kopans has made these arguments before for the last 24 years. However, as has been pointed out, the purpose of the CNBSS was to examine whether the addition of mammography added anything to breast cancer screening and resulted in decreased mortality from breast cancer using community-based settings, in other words, using mammography as it was practiced in the community. Moreover, as others have pointed out, the quality of mammography increased over time. In any case, this and many of the criticisms leveled by Dr. Kopans and others have been fairly convincingly refuted CNBSS investigator Cornelia J. Baines, who published an article entitled Rational and Irrational Issues in Breast Cancer Screening, and by an article in which Kopans himself was a coauthor, which showed that, although only 50% of mammograms had satisfactory image quality in 1980, by 1987 85% were judged to have satisfactory quality.
Perhaps the most serious charge made by Dr. Kopans is that there was misallocation of nastier cancers to the control arm. In other words, he charges:
In order to be valid, randomized, controlled trials (RCT) require that assignment of the women to the screening group or the unscreened control group is totally random. A fundamental rule for an RCT is that nothing can be known about the participants until they have been randomly assigned so that there is no risk of compromising the random allocation. Furthermore, a system needs to be employed so that the assignment is truly random and cannot be compromised. The CNBSS violated these fundamental rules (6). Every woman first had a clinical breast examination by a trained nurse (or doctor) so that they knew the women who had breast lumps, many of which were cancers, and they knew the women who had large lymph nodes in their axillae indicating advanced cancer. Before assigning the women to be in the group offered screening or the control women they knew who had large incurable cancers. This was a major violation, but it went beyond that. Instead of a random system of assigning the women they used open lists. The study coordinators who were supposed to randomly assign the volunteers, probably with good, but misguided, intentions, could simply skip a line to be certain that the women with lumps and even advanced cancers got assigned to the screening arm to be sure they would get a mammogram. It is indisputable that this happened since there was a statistically significant excess of women with advanced breast cancers who were assigned to the screening arm compared to those assigned to the control arm (7). This guaranteed that there would be more early deaths among the screened women than the control women and this is what occurred in the NBSS. Shifting women from the control arm to the screening arm would increase the cancers in the screening arm and reduce the cancers in the control arm which would also account for what they claim is “overdiagnosis”.
Make no mistake, Dr. Kopans is accusing the investigators running the CNBSS of scientific fraud here. I’m surprised he’s so bold about it. You’d think he’d have strong evidence to back up this charge. You’d be wrong. If what Dr. Kopans said were true, then the Canadian government should be going after the investigators. The authors themselves are aware of this charge and even answered it in their article:
We believe that the lack of an impact of mammography screening on mortality from breast cancer in this study cannot be explained by design issues, lack of statistical power, or poor quality mammography. It has been suggested that women with a positive physical examination before randomisation were preferentially assigned to the mammography arm.12 13 If this were so, the bias would only impact on the results from breast cancers diagnosed during the first round of screening (women retained their group assignment throughout the study). However, after excluding the prevalent breast cancers from the mortality analysis, the data do not support a benefit for mammography screening (hazard ratio 0.90, 95% confidence interval 0.69 to 1.16).
I actually agree with Dr. Kopans on this one point: Only women with no physical findings should have been randomized to screening mammography. That is perhaps the biggest flaw in the design of the CNBSS. However, excluding women diagnosed with a cancer on the first round of mammography, as the authors argue, and finding no difference in breast cancer mortality do rather argue that it probably didn’t make a difference. The authors also address another criticism, apparently leveled by Siddhartha Mukherjee in The Emperor of All Maladies, that the women in the mammography group were somehow at a higher risk for cancer. The authors point out that breast cancer was diagnosed in 5.8% of women in the mammography arm and in 5.9% of women in the control arm (P=0.80), showing that the risk of breast cancer was the same in both groups. Finally, there were reasons for why the allocation was done the way it was, and the explanation was not unreasonable:
Randomization was performed by the center coordinators after nurse examiners had clinically examined the participants. Center coordinators were blind to the results of the breast examination.
What in fact was the situation vis-a-vis randomization?
Most tellingly there was no incentive for screening personnel to subvert randomization. The CNBSS protocol required that anyone with an abnormal finding on [clinical breast examination] had to be referred to the study surgeon who would order a diagnostic mammogram when clinically indicated. Symptomatic women require diagnostic mammography, not screening mammography. It was not necessary to “place” as claimed [24] clinically positive participants in the mammography arm of the study in order for them to get a mammogram.
In the CNBSS there were more than 50 variables (demographic and risk factors) which were virtually identically distributed across control and study groups, clear evidence of successful randomization [25,26].
That certainly decreases—although it does not completely eliminate—my concern about the original design. There have also been other studies before that looked for evidence of subversion of randomization in the CNBSS and have failed to find evidence of nonrandom allocation of patients sufficient to affect the results of the trial. As was pointed out by a commenter after the BMJ article named Rolf Hefti, Dr. Kopans never mentions these studies that disagree with his conclusion, fails to note counterarguments that have been made to his accusations, and disingenuously complains about the low rate of detection by mammograms alone (32%), even though that number is consistent with rates reported in the 1990s, years after the screening period in the CBNSS ended.
And so the battle rages on, same as it ever was. What simultaneously amuses and depresses me most about this is the seeming underlying assumption that the CNBSS investigators wanted to find no benefit due to screening mammography. My guess is that they were probably horribly disappointed when they reported the first analysis and found no benefit to screening mammography and even more disappointed when the second analysis in the early 2000s found the same thing. No one does the enormous amount of work and spends the money to do a large multicenter trial involving tens of thousands of women because he wants to end up with a negative study, to the point that he would be willing to mess with the randomization to make it happen. The assumption underlying Dr. Kopans’ accusation is ludicrous.
The bottom line
I’m going to give you my bottom line, although it’s going to sound wishy-washy. Does the CNBSS “prove” that screening mammography is useless? Of course not, not any more than any single study ever could, given such a complex issue as screening for breast cancer. The CNBSS is a flawed study that could possibly be a false negative, such that any true benefit in terms of prevention of breast cancer mortality by mammography is buried in statistical noise. However, it is not nearly as flawed a study as its critics, such as Dr. Kopans and Dr. Tabár, would have you believe, nor is it a fraudulent study, as Dr. Kopans would apparently have you believe. It is the result of a group of investigators doing the best they could with the materials they had based on the knowledge they had in the late 1970s and must be weighed against all the other studies examining mammography finding benefit or no benefit. Moreover, it is not new information. It’s just a longer term follow-up of results first reported in the early 1990s and last reported more than ten years ago.
That being said, I still think it’s entirely appropriate for the study authors to conclude that “the data suggest that the value of mammography screening should be reassessed.” This isn’t a new conclusion either. It’s part of an evolution that’s been going on since before the USPSTF released its guidelines back in 2009. You’ll remember that back then I characterized those recommendations, which included not beginning routine mammographic screening until age 50, as “not the final word.” Clearly the CNBSS won’t be the last word, either, but it should be included as part of the evidence base for the reevaluation of mammography screening guidelines.
What doesn’t help is denial that overdiagnosis is a real phenomenon and rejection of the now-irrefutable contention that detecting a cancer earlier does not necessarily result in improved survival. There are some who are arguing that because patients with tumors detected by mammography-only in this study had better five year survivals than patients with tumors detected clinically, it means the mammography is worthwhile. That’s a horrible argument, because in reality the increased survival as observed in this study is, if anything, evidence in favor of overdiagnosis, an observation that was made, shockingly, in an article published in The Atlantic, given how much nonsense about medicine has been published in that magazine before. As I pointed out before, decreases in mortality, not necessarily improvements in survival, are the gold standard that shows a screening test (as opposed to a treatment) really does work.
Radiologists also argue that imaging technology is so much better today than it was in the 1980s. Even mammography itself is much better. This is undoubtedly true, but better, more sensitive imaging, while it could potentially make modern mammography screening programs more effective in preventing breast cancer, could also greatly exacerbate the problem of overdiagnosis. Overdiagnosis is real, and there are diminishing returns in the detection of cancer. If treatment of screen-detected cancers, adjusted for lead time bias, doesn’t clearly result in improved survival, then there’s a problem.
The point, obviously, is to find the “sweet spot,” which maximizes the benefit of screening and minimizes the harms due to overdiagnosis and overtreatment. Based on current evidence, of which the CNBSS is just one more part, I’m more and more of the opinion that our mammography screening guidelines need to be tweaked and personalized because the current “one size fits all” regimen is probably too aggressive for most women at average risk for breast cancer. It’s an evolution in my thought that’s been going on for years. In any case, in any statement I’d put something in there about determining what the “sweet spot” is for mammography. It’s also reasonable, for now at least, to stick with existing guidelines, with perhaps more of a personalized approach to screening of women between ages 40 and 49. That’s what I intend to do until new evidence-based guidelines emerge. And emerge they will, likely within a year.
ADDENDUM: Dr. Miller’s response to the criticisms leveled at the CNBSS have been published, and he very convincingly put Dr. Kopans and others in their place.

In which Dr. Gorski is taken to task by an eminent radiologist for his posts on mammography
David Gorski on May 26, 2014
Link

Introduction: An unexpected e-mail arrives
One of the consequences of the growing traffic and prominence of this blog over the last few years is that people who would otherwise have probably ignored what I or my partners in blogging write now sometimes actually take notice. Nearly a decade ago, long before I joined this blog as a founding blogger, if I wrote a post criticizing something that a prominent academic said, it was highly unlikely that that person would even become aware of it, much less bother to respond to whatever my criticism was. I was, quite simply, beneath their notice, sometimes happily, sometimes unhappily.
It appears that those days might be over. Last week Dr. Daniel Kopans, a prominent Harvard radiologist and well-known long-time defender of screening mammography, sent me a rather unhappy e-mail complaining about my “attack” on him on this blog, a charge that he repeated in a subsequent e-mail. Before I publish his initial e-mail verbatim (with his permission), I would like to point out that, while it’s true that I did criticize some of Dr. Kopans’ statements rather harshly in my post about the Canadian National Breast Screening Study (CNBSS), even characterizing one statement as a “howler,” I would hardly characterize what I wrote as an “attack.” That to me tends to imply a personal attack. Using Dr. Kopans’ apparent definition, what he has said and written about investigators like those running the CNBSS, as documented in my post, about H. Gilbert Welch, who published a large study in 2012 estimating the extent of overdiagnosis due to mammography, and the U.S. Preventive Services Task Force (USPSTF), the group that in 2009 suggested changing guidelines for routine screening mammography in asymptomatic women to begin at age 50 instead of age 40, would appear to also qualify as “attacks.”
Be that as it may, I also wondered why Dr. Kopans hadn’t noticed my CNBSS post until more than three months after it had originally appeared. Then, the day after I received Dr. Kopans’ e-mail, my Google Alert on mammography popped up an article in the Wall Street Journal by Dr. Kopans entitled “Mammograms Save Lives: Criticism of breast-cancer screenings is more about rationing than rationality.” That’s when I guessed that someone probably had either posted or e-mailed Dr. Kopans a link to my previous post in response to that article. Given the confluence of events, I think it’s a perfect time to discuss both Dr. Kopans’ e-mail and his article, because they cover many of the same issues.
Before I go on, I feel obligated to repeat my mandatory disclaimer for posts about the controversy over screening mammography: What I am talking about is screening of asymptomatic women with mammography to detect breast cancer. If you have a lump or other breast symptoms, none of this discussion applies, and you should have your lump or other symptoms investigated by your doctor and undergo whatever imaging is deemed medically appropriate.
Dr. Kopans is displeased with Dr. Gorski
Here is the text of the e-mail from Dr. Kopans that arrived on Thursday:
Dear Dr. Gorski:
I was astonished and disappointed when I came across your “Posts” concerning breast cancer screening and your attacks on me. In particular the inflammatory statement that I was accusing the Canadian investigators in the Canadian National Breast Screening Study of “fraud”. I have never stated this and it was inappropriate for you to suggest it. There is no evidence of fraud in the CNBSS trial, but there is clear evidence that the fundamental requirements of a randomized, controlled trial were violated. I do not make up the rules for these trials. You are well aware that blind allocation is critical. When there is a statistically significant excess of advanced cancers allocated to the screening arm and the coordinators had knowledge of the clinical examination findings and they allocated the women on open lists, and there was an excess of cancer deaths among the screened women you have to completely suspend scientific thought to not be concerned that there was a problem.
On top of that when there is not a single expert who does not agree that the mammography was poor to unacceptable and the size of the cancers was the same for the mammography group and the non-mammography group why would you even consider this a test of mammography screening? If you were involved in a trial and you felt that you had done a good job, you would defend your work against all criticism. I am unaware of any radiologist or technologist in the CNBSS who has defended the trial. I assume you do breast surgery. Dr. Miller has insisted that the nurses doing the clinical breast examination detected most of the cancers in the mammography arm. How often can you feel the cancers detected by mammography even when you know where to feel? How often do radiologists have to guide you to the lesion?
How can you defend a trial that has major implications and fundamental compromises by saying that we will simply get rid of the prevalence cases? Since it was not blinded, we have no idea how the allocation was compromised. Furthermore, Dr. Miller has acknowledged that as many as 25% of the control women had “diagnostic’ mammograms so they were not really contaminating the control arm. As I am sure you know, diagnostic mammography starts off with a bilateral screening mammogram so this is simply not true. The trial started with insufficient power (I am certain as an expert who is publically critical of a critic, that you have read all of the papers on the CNBSS ??)
Dr. Miller went public in the 1990’s claiming that mammography was squeezing cells into the blood leading to earlier deaths in the mammography arm. After causing major concerns, he withdrew the claim invoking ataxia telangiectasia, but now says it was because removing the primary allowed the metastatic lesions to grow faster. Even in mice where this happens it is a short lived phenomenon and the mice do not die any sooner – a point that Prof. Miller neglects to make.
If all of the problems with the CNBSS had occurred in a surgery or chemotherapy RCT you would be outraged that the results made it through peer review. You seem to have no problem defending a corrupted (in scientific jargon) trial when it comes to mammography screening. I have little doubt that your ego will not allow you to recognize your hypocrisy.
By the way – I am attaching my critique of the Bleyer and Welch paper. Dr. Bleyer has admitted in his rebuttal that they used “best guesses”. He also admitted that since they had no data on mammography, they could not fault mammography – yet they did. He is critical of my use of the data from the Connecticut tumor registry, yet the papers that I can find that looked at breast cancer incidence prior to SEER all used the Connecticut tumor registry. If you use the Connecticut data there is no overdiagnosis of invasive cancers (there were actually fewer than expected)
DCIS is a major unresolved issue, but this is well known. The Bleyer and Welch paper would have never been published had they only raised concerns about DCIS so they combined it with small invasive cancers just the way all experts combine the two – not actually.
I assume that since you defend the Bleyer and Welch paper you have seen a number of invasive cancers disappear on their own. Certainly with 70,000 each year you must have seen many such disappearing cancers.
If you are so concerned about overtreatment (over [sic] course overdiagnosis is the pathologists’ failing) why are you (oncologists) poisoning so many women who do not need it? Among women diagnosed with breast cancer (all palpable) in the 1940’s treated only by mastectomy 30% were alive 30 years later, yet all would be treated with systemic therapy today. Why are you overtreating all these women?
There are numerous legitimate concerns about breast cancer and breast cancer screening, but it is not reasonable to withdraw support for a test that has been shown with greater certainty than any other screening test to save lives, by supporting flawed “science” and misleading physicians and the public.
Daniel B. Kopans, M.D.Professor of Radiology, Harvard Medical SchoolSenior Radiologist, Breast Imaging DivisionDepartment of Radiology, Massachusetts General HospitalAvon Comprehensive Breast Evaluation Center
I must admit that I was disappointed in this response.
Dr. Gorski responds to Dr. Kopans, with trepidation
It’s always a bit of a wake-up call to be so castigated by such a prominent radiologist. Did I err? What makes me think I have what it takes to get into a serious discussion with the likes of Dr. Kopans? After all, what’s a relatively unknown surgeon and translational researcher compared to such an eminent radiologist as Dr. Kopans? Still, one of the greatest things about the Internet (and simultaneously the one of the worst things, as I have acknowledged), is that it lets anyone with an Internet connection voice his opinion. So here goes.
First, however, let me point out that there is actually some common ground between Dr. Kopans and me, in the hopes that he will understand that I am not his enemy, merely a critic of certain statements of his. There is a difference. Also, contrary to how I am sometimes portrayed (and what Dr. Kopans seems to be implying), I am most definitely not in the camp that believes that mammography screening programs should be abandoned, as has been proposed by various researchers and pundits, and I do believe that mammography saves lives. I’m even the team captain for our cancer center’s team in the local Komen Race for the Cure! Where I differ with Dr. Kopans is that I also accept the emerging evidence that overdiagnosis due to mammographic screening is a significant problem that leads to overtreatment. In other words, in some women mammography can cause harm, and more harm than Dr. Kopans would apparently acknowledge, and I believe that our current guidelines should be changed to reflect that emerging science and find the “sweet spot,” where benefits are maximized and harms minimized. Having looked into this for nearly five years now, I understand the acute discomfort of change that comes from questioning a medical intervention that I once accepted and finding that I agree that the guidelines do need to be changed.
Next, let me deal with what I view to be the most heartening revelation, namely that Dr. Kopans denies accusing the CNBSS investigators of research misconduct. This is a good thing, because such charges should never be made lightly. It is odd to me, however, how clearly puzzled Dr. Kopans appears to be that a reasonable person might have honestly interpreted his rather over-the-top characterization of the CNBSS randomization process that way, which makes me feel reluctantly obligated to explain again how that could have happened and requires that I quote some of Dr. Kopans’ own words again:
In order to be valid, randomized, controlled trials (RCT) require that assignment of the women to the screening group or the unscreened control group is totally random. A fundamental rule for an RCT is that nothing can be known about the participants until they have been randomly assigned so that there is no risk of compromising the random allocation. Furthermore, a system needs to be employed so that the assignment is truly random and cannot be compromised. The CNBSS violated these fundamental rules (6). Every woman first had a clinical breast examination by a trained nurse (or doctor) so that they knew the women who had breast lumps, many of which were cancers, and they knew the women who had large lymph nodes in their axillae indicating advanced cancer. Before assigning the women to be in the group offered screening or the control women they knew who had large incurable cancers. This was a major violation, but it went beyond that. Instead of a random system of assigning the women they used open lists. The study coordinators who were supposed to randomly assign the volunteers, probably with good, but misguided, intentions, could simply skip a line to be certain that the women with lumps and even advanced cancers got assigned to the screening arm to be sure they would get a mammogram. It is indisputable that this happened since there was a statistically significant excess of women with advanced breast cancers who were assigned to the screening arm compared to those assigned to the control arm (7). This guaranteed that there would be more early deaths among the screened women than the control women and this is what occurred in the NBSS. Shifting women from the control arm to the screening arm would increase the cancers in the screening arm and reduce the cancers in the control arm which would also account for what they claim is “overdiagnosis”.
He also went on to accuse the investigators of the CNBSS of intentionally ignoring an issue that would allegedly allow those doing the randomization to subvert the randomization. One notes that the American College of Radiology (ACR) response to the publication of the CNBSS uses very similar language, leading me to believe that Dr. Kopans had a major hand in writing it. If you don’t believe me, compare Dr. Kopans’ criticism of the study in the BMJ that I quoted in my original post and the ACR press release criticizing the study. The wording of the relevant sections about subversion of randomization is almost identical.
Given its virtually-identical charges against the investigators of the CNBSS, I find Dr. Jen Gunter’s discussion of the charges quite informative. She read the ACR press release and found its arguments…wanting. She even entitled her post Did the American College of Radiology accuse the BMJ mammography authors of misconduct? In her post, she looked at it a different way than I did when I wrote about the CNBSS, a way that to me is simultaneously simpler but probably more revealing than how I did it, by pointing out that the CNBSS authors stated in their paper that their randomization was blinded (true, as I pointed out). She then put it in context:
So the authors are saying their randomization was blinded and the ACR’s counter-claim is that is couldn’t have been. Both can’t be right. The ACR is either accusing the author of lying or saying he had rogue study nurses who didn’t follow protocol. The ACR does not provide any references to support this claim.
This last part of the ACR claim sounds a lot like school yard taunt, “You lied. How do I know? Because I said so.” It is the kind of claim one makes when one A) hasn’t thought it all through and is letting emotions rule, B) has an otherwise weak argument that needs to be bolstered, or C) you want to be over the top to get page clicks. This accusation actually leads me to evaluate the ACR’s other two claims with greater scrutiny.
One notes that an accusation that is in essence an accusation that the investigators lied in their scientific papers about the randomization process of their study or accusation that (1) they had rogue nurses who ignored study protocol in order to subvert randomization and (2) that they ignored evidence that their nurses were subverting randomization in that way is an accusation of fraud in my book. I further note that Dr. Gunter wrote both the Canadian and American Colleges of Radiology for evidence to support this accusation and got none. True, the ACR did respond, but provided no evidence. As I pointed out in my original article, I believe the authors did this adequately in both their paper reporting the results of the CNBSS and another article in which they answered charges like those leveled by Dr. Kopans and the ACR, and other reviews of the CNBSS failed to find convincing evidence for subversion. In any case, the vitriol in the debate over mammographic screening, particularly of women in their 40s, is nothing new.
While I do believe that Dr. Kopans does not think he was accusing the CNBSS investigators of research misconduct/fraud when he made those criticisms of the CNBSS randomization process, I can’t help but also note that back in the 1990s he did explicitly accuse other investigators of “manipulat[ing] data in a fashion that borders on scientific fraud” in their article in JAMA. He even sent letters with this accusation to George Lundberg, then editor of JAMA, and Haile Debas, then dean of the UCSF medical school. Around the same time he characterized a recommendation by an NCI panel not to recommend screening for women in their 40s as “fraudulent” and “meant to mislead.” Even Laszlo Tabar, for instance, a radiologist who directs the Swedish Two County Trial of mammography, and a strong defender of mammographic screening programs whom I quoted in my post about the CNBSS, admitted in 1997 in the same article in Science that Dr. Kopans can be overly belligerent.
In any case, I suspect that Dr. Kopans is so convinced that mammography is such an unalloyed good that he does not react well to criticism of it and that Dr. Kopans and the ACR, honestly believing the CNBSS to be flawed beyond any redemption, wanted to show just that, to the point that they let their rhetoric get away from them. The bottom line is that at least two reasonable people (Dr. Gunter and myself), both of whom work in medical fields in which we have every reason to support mammography, were left with the impression that Dr. Kopans’ and the ACR’s criticisms of the CNBSS report in the BMJ were accusations of research misconduct. If there are two of us who interpreted it that way and were willing to blog about it, I’d be willing to bet that there were a lot more of us out there who interpreted his words that way. One hopes that Dr. Kopans will rein in his overheated rhetoric in future discussions and not be surprised how, given his history, his words are interpreted.
But what about the rest?
A lot of it is what has become fairly standard anti-CNBSS boilerplate that’s been repeated before over and over again, such as the claim that the mammography was substandard. This issue has been addressed before, as I discussed. As for the issue of Dr. Miller (the principal investigator of the CNBSS), even if true it’s irrelevant to whether the CNBSS results were valid or not; so I call non sequitur on that one. As for Dr. Kopans’ accusation that I am a hypocrite and such an egotist that I will never admit that I’m wrong, now—as Crocodile Dundee once said about a knife—that’s a personal attack. (True, it’s in an e-mail, but Dr. Kopans gave me permission to post it; so it’s not as though he’d be likely to shy away from saying it in public.) It’s unlike any criticism I wrote in my original post and anything that I’ve written in this post. He’s also wrong. If I saw a surgical study with flaws correctly judged as massive as the flaws portrayed in the CNBSS by Dr. Kopans, I quite likely would comment. It’s just that I don’t agree with Dr. Kopans’s characterization of the magnitude of the flaws of the CNBSS. In any case, I leave the reader to make his or her own judgment reading my original post, Dr. Kopans’ response, and this post, particularly in light of his denigration of my qualifications with respect to his, as I move on to other substantive points.
The Bleyer and Welch paper, as regular readers might remember, was published in the New England Journal of Medicine about a year and a half ago. I discussed it in detail when it first came out. One notes that my assessment was not quite as effusive as Dr. Kopans portrays it. I thought its findings were in line with the emerging body of evidence suggesting that overdiagnosis of breast cancer is more common than previously suspected. A key prediction of the hypothesis that detecting breast cancer earlier will lead to fewer deaths from breast cancer is that a screening test that leads to the detection of more early-stage cancers—and, yes, it is, contrary to Dr. Kopan’s assertion, reasonable to include ductal carcinoma in situ (DCIS) among early-stage breast cancers if one believes that a significant number of DCIS lesions will progress to invasive cancer—should lead to a decrease in the number of late-stage cancers. Bleyer and Welch didn’t find that. They found a large increase in the incidence of early-stage cancers but a much smaller decrease in the incidence of late-stage cancers. That’s it.
It’s not as simple as Dr. Kopans makes it out to be
What I’ve found since I first took a more intense interest in this topic is that many of the criticisms of such studies boil down to not believing that overdiagnosis is a real phenomenon in breast cancer. Yet, as I’ve explained before, translating earlier detection of breast cancer—or any cancer, for that matter—into better survival is far more complicated than most people, even physicians, think. Besides overdiagnosis, there are the complicating factors of lead-time bias (explained by yours truly here, here, and here) and length bias, in which the tumors detected by screening tests tend to be the more indolent and less deadly (explained by yours truly here and here). In the past, I have pointed out that the prevalence will increase for virtually any disease that is intensely screened for, using autism as my main example, as well as hypercholesterolemia and hypertension, and comparing it to the prevalence of DCIS, the latter of which has increased by 32-fold since the 1970s. Given that autopsy series routinely show that large percentages of people who die of other causes have foci of cancers such as prostate, breast, and thyroid cancer that never become clinically evident, why is it a surprise that mammography might lead to at least some degree of overdiagnosis?
Finally, I can’t help but note that a couple of observations Dr. Kopans makes are just silly, disappointingly so. (No, that’s not a personal “attack,” simply a characterization of my opinion of what he wrote. If Dr. Kopans can call me a hypocritical egotist, then the least concession he can give me is to let me refer to something he writes as “silly.”) First, there’s the part about how I must have seen so many tumors disappear on their own. I’m sorry, but there’s no polite way to say it: That statement is based on a complete misunderstanding of the concept of overdiagnosis. Those studies only include screen-detected tumors, but more importantly the current standard of care would be to treat all such tumors detected, meaning that every woman I see who has a screen-detected breast cancer will receive some combination of surgery, radiation therapy, chemotherapy, and/or hormonal therapy. I do not simply watch women with invasive breast cancer to see how many of them might regress. Because it would be completely unethical to propose doing so in a randomized clinical trial because of the lack of clinical equipoise in such a design, overdiagnosis must be inferred from population-level data, and it has been. Moreover, it’s important to note that it is currently not possible to identify which woman has been overdiagnosed at the time of diagnosis. I wish it were, because then we could obviate the major harm in mammography screening, and virtually eliminate overdiagnosis. Figuring out strategies to do so for DCIS has been a recent interest of mine as well.
Let’s go back to something that Dr. Kopans also wrote:
If you are so concerned about overtreatment (over course overdiagnosis is the pathologists’ failing) why are you (oncologists) poisoning so many women who do not need it? Among women diagnosed with breast cancer (all palpable) in the 1940’s treated only by mastectomy 30% were alive 30 years later, yet all would be treated with systemic therapy today. Why are you overtreating all these women?
In fact, I have discussed many times how it is important to provide women with the absolute benefits due to chemotherapy as well as the relative benefits. I like to use the example of a woman with a stage I cancer. I tend to round the numbers a bit for simplicity’s sake, but they’re close enough to make the point to a lay audience (and medical students, for that matter, when I’m teaching). So I tend to give an example of a woman with a stage I cancer who has a 90% ten-year survival with local therapy alone. If chemotherapy produces a 30% relative survival benefit (roughly correct, perhaps slightly too high), that would translate only to a 3% absolute survival benefit. In other words, 90 out of 100 women would have survived anyway but got treated, in retrospect “unnecessarily,” while seven women out of 100 would have died regardless but got treated, in retrospect “unnecessarily.” Only three out of a hundred who would have died were saved by chemotherapy. In other words, the number needed to treat (NNT) to save one life is 33. This is the main reason why a hot area of research is predictive testing, to identify who will and won’t benefit from adjuvant chemotherapy, and why we in the field view the OncoType DX test, as imperfect as its predictive power is, as a major advance that has saved thousands of women with early stage estrogen-responsive cancers from chemotherapy who wouldn’t benefit from it.
Of course, it should be noted that the higher the stage, the higher the risk of relapse and death, and thus the larger the absolute benefit of adjuvant chemotherapy. That’s why I’ve done a number of posts in which I take hypothetical cases and run them through Adjuvant!Online to illustrate my points. But I sure don’t sugarcoat problems with adjuvant chemotherapy, contrary to Dr. Kopans’ question. In any case, I’ve pointed out that chemotherapy has contributed to a major improvement in survival of breast cancer patients, even while lamenting how frustratingly…incremental…improvements in chemotherapy drugs have been. I obviously don’t expect Dr. Kopans to have read all my old stuff (that would be ridiculous), but he does seem rather eager to leap to conclusions about me.
It might be instructive to compare the NNT for chemotherapy, which at its worst in stage I breast cancer, is around 33 to 50, to the number needed to screen (NNS) to save one life for mammography. For instance, Esserman et al. estimate that to avert one death from breast cancer with mammographic screening for women between the ages of 50-70, an age range intentionally chosen because it is the age range for which mammographic screening is the least controversial, 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of DCIS. The additional price of this was estimated to be 90 biopsies and 535 recalls for additional imaging, as well as “many cancers treated as if they were life threatening when they are not.”
It’s also been noted that the younger the patient group, the higher the NNI (number needed to invite to screening) is, ranging from 377 for women aged 60-69, resulting in an absolute risk reduction of dying from breast cancer in the next ten years of approximately 0.3%, to 1,904 for women aged 40-49, translating to an absolute risk reduction of 0.05%. Of course, mammography is not chemotherapy, but I could still turn Dr. Kopans’ argument around and ask him, why we are screening all these women who do not need it, all to produce an absolute reduction in the risk of dying from breast cancer that is so small? (I realize that chemotherapy is “poison” and mammograms are not, but it is still not an unreasonable point.) I would point out that it’s a value judgment to say how small a survival benefit is too small, but there must be a cut-off. If there were not, there’s no reason not to start screening women as soon as they hit age 21, but not even Dr. Kopans proposes doing that, as, below a certain age, the benefit becomes either too small or nonexistent. The risk of breast cancer with age is a smoothly increasing curve; there is no sharp cutoff. Where we choose the cutoff to begin screening, age 40 or age 50, is a value judgment based on an assessment of the risk-benefit ratio and, yes, to some extent cost. That’s reality. I happen to believe that it’s likely worth it for women over age 50; I’m no longer so sure it is for women under age 50, hence my endorsement of a recommendation for personalized screening below age 50, a concept that is anathema to Dr. Kopans. Either way, his choice of age 40 as the time to start screening is no less arbitrary a cut-off than is age 50, and the observation that cancer mortality in Europe is not higher than it is in the US reassures me that I’m at least not entirely mistaken in my conclusions.
In his e-mails and his WSJ article, Dr. Kopans portrays any questioning of the value of mammography as “a disconcerting effort afoot to reduce a woman’s access to mammography screening for breast cancer by making it seem useless or even harmful,” or similar language in which he ascribes dire motives to those with whom he disagrees. To Dr. Kopans, it seems, there can’t be an honest scientific and medical disagreement that leads some researchers and clinicians to question the “one size fits all” design of the current mammographic screening guidelines. Oh, no. It has to be rationing, and that’s how he portrays it in his WSJ article. When Bleyer and Welch estimate a large amount of overdiagnosis from screening mammography, it can’t be because they go where the science leads them or have a legitimate academic disagreement with Dr. Kopans. Oh, no. It has to be yet another effort to “reduce access to lifesaving screening tests.” Dr. Kopans dismisses as a “new effort to limit access to screening” the reasonable suggestion, based on analysis that screening produces more overdiagnosis the less prevalent a disease is in a population screened (which is the reason why even Dr. Kopans doesn’t propose screening women below the age of 40—breast cancer incidence is too low) that developing risk-based screening could improve the efficacy of mammographic screening programs, reducing overdiagnosis and therefore overtreatment. He even concludes his op-ed, “It would be unfortunate to deny women access to screening based on flawed analyses or rationing in the guise of altruism.”
Disappointingly, that is a profoundly insulting characterization of researchers on the other side of a scientific disagreement, one that is beneath a professor of radiology as eminent as Dr. Kopans.
Those of us who take care of women with breast cancer all want what’s best for them. I accept that Dr. Kopans, pit bull that he is defending mammography against all attacks, does so out of a desire to help women to avoid dying from breast cancer. I just wish he’d grant his critics the same consideration. It’s understandable that he’s upset that I would have the temerity to criticize his statements. He should think of it as a dose of his own medicine—and a comparatively mild dose at that.

Screening for disease in people without symptoms: The reality
David Gorski on February 2, 2015
Link
One of the most contentious questions that come up in science-based medicine that we discuss on this blog is the issue of screening asymptomatic individuals for disease. The most common conditions screened for that we, at least, have discussed on this blog are cancers (e.g., mammography for breast cancer, prostate-specific antigen screening for prostate cancer, ultrasound screening for thyroid cancer), but screening goes beyond just cancer. In cancer, screening is a particularly-contentious issue. For example, by simply questioning whether mammography saves as many lives lost to breast cancer as advocates claim, one can find oneself coming under fire from some very powerful advocates of screening who view any questioning of mammography as an attempt to deny “life-saving” screening to women. That’s why I was very interested when I saw a blog post on The Gupta Guide that pointed me to a new systematic review by John Ioannidis and colleagues examining the value of screening as a general phenomenon, entitled “Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials.”
Before I get into the study, let’s first review some of the key concepts behind screening asymptomatic individuals for disease. (If you’re familiar with these concepts, you can skip to the next section.) The act of screening for disease is based on a concept that makes intuitive sense to most people, including physicians, but might not be correct for many diseases. That concept is that early intervention is more likely to successfully prevent complications and death than later intervention. This concept is particularly strong in cancer, for obvious reasons. Compare, for example, a stage I breast cancer (less than 2 cm in diameter, no involvement of the lymph nodes under the arm, known as axillary lymph nodes) with a stage III cancer (e.g., a tumor measuring greater than 5 cm and/or having lots of axillary lymph nodes involved). Five year survival is much higher for treated stage I than for treated stage III, and, depending on the molecular characteristics, the stage I cancer might not even require chemotherapy and can be treated with breast conserving surgery (“lumpectomy” or partial mastectomy) far more frequently than the stage III cancer. So it seems intuitively true that it would be better to catch a breast cancer when it’s stage I rather than when it’s stage III.
Unfortunately, that’s not necessarily the case. The reasons are phenomena known as lead time bias, length bias, and overdiagnosis. Lead time bias has been explained multiple times (e.g., here and here), but perhaps the best explanation for a lay public I’ve ever found of lead time bias (although he doesn’t call it that) involves a hypothetical example of cancer of the thumb by Aaron Carroll. Given that cancer survival is measured from the time of diagnosis, if a tumor is diagnosed at an earlier time in its course through the use of a new advanced-screening detection test, the patient’s survival will appear to be longer, even if earlier detection has no real effect on the overall length of survival, as illustrated below:
Lead time bias, in other words, can give the appearance of longer survival even when treatment has no effect whatsoever on the progress of the disease. Patients are simply diagnosed earlier in the disease time course and only appear to live longer when in reality they simply carry the diagnosis screened for longer.
The second concept is length bias. In general, we can’t continually screen for disease so an interval has to be chosen. This introduces a bias. Length bias refers to comparisons that are not adjusted for rate of progression of the disease. The probability of detecting a cancer before it becomes clinically detectable is directly proportional to the length of its preclinical phase, which is inversely proportional to its rate of progression. In other words, slower-progressing tumors have a longer preclinical phase and a better chance of being detected by a screening test before reaching clinical detectability, leading to the disproportionate identification of slowly-progressing tumors by screening with newer, more sensitive tests, with the faster-growing tumors becoming symptomatic “between screenings.” Thus, survival due to the early detection of cancer is a complicated issue.
Finally, there is overdiagnosis. This is a term that refers to disease detected that would likely never progress within the timeframe of the patient’s remaining lifetime to cause a problem. For cancer (for example) it seems completely counterintuitive that there could be overdiagnosis, but there is. As we have learned over the last several years, cancer overdiagnosis is definitely an issue, particularly for the prostate and breast, with perhaps as high as one in three mammography-detected breast cancers in asymptomatic women being overdiagnosed. Basically, this chart illustrates the concept well:
In this chart, which shows growth rates of four hypothetical tumors (A, B, C, and D), tumor D would not be detected because it was growing too fast, while tumor A is growing so slowly that it would likely be overdiagnosed when it reaches the threshold of detectability. Only tumors B and C could potentially benefit from being detected while still confined to the organ. This sort of graph explains why ever-more-sensitive tests that detect disease earlier and earlier have the potential to result in more overdiagnosis.
Finally, overdiagnosis almost inevitably results in overtreatment. Once physicians have detected a disease, be it a cancer, an asymptomatic abdominal aortic aneurysm, or whatever, the onus is on them to treat it.
Now, on to Ioannidis’ review.
Screening, huh! What is it good for? (Probably not absolutely nothing.)
In Ioannidis’ systematic review of meta-analyses and randomized clinical trials, he and coauthors Nazmu and Julianne Saquib take a different approach than I’ve usually seen. Most such systematic reviews and meta-analyses examine screening for only one disease, while this one examines screening for a number of diseases. Also, the key questions to be asked included:
     1.  Does the screening test result in a decrease in mortality due to the disease being screened for (known as disease-specific mortality)?
     2.  Does the screening test result in a decrease in mortality due to all causes?
The background is explained right in the introduction:
Screening for disease is a key component of modern health care. The rationale is simple and attractive—to detect diseases early in asymptomatic individuals and to treat them in order to reduce morbidity, mortality and the associated costs. However, the role of screening often comes into question. Some high-profile controversies have appeared lately in this regard. For example, for breast cancer, the United States Preventive Services Task Force (USPSTF) currently recommends against routine mammographic screening for women aged 40–49 years after retracting its previous recommendation in favour of mammography, as the data failed to show that benefit outweighed harm. The decision against screening drew sharp criticism from various interest groups including patients who overestimate the benefit of screening. Similarly, USPSTF now recommends against screening for prostate cancer in healthy men because harms from prostate specific antigen (PSA) screening exceed the benefit, trials do not show improvement in long-term survival and screening carries a high risk of over-diagnosis with adverse consequences. Again, heated debates have been generated around this change of recommendation, both in the scientific and the popular press.
Some screening tests were entrenched in clinical and public health practice before randomized controlled trials (RCTs) became widely used. As the screening agenda encompasses a large number of tests, and new ones are continuously proposed, it is useful to reassess the evidence supporting their use. Our research question is whether recommended screening tests, among asymptomatic adults, have evidence from RCTs on mortality for diseases where death is a common outcome. In particular, is there evidence of mortality reduction, either disease-specific or all-cause, from screening? To this end, we have compiled and examined systematically the evidence from individual RCTs and meta-analyses thereof for screening tests that have been proposed for detecting major diseases in adults who have no symptoms.
None of this should come as a surprise to regular readers of this blog. But how to answer such a large question regarding the potential benefits and harms of routine screening? Basically, what Saquib et al. did was search the United States Preventive Services Task Force (USPSTF), Cochrane Database of Systematic Reviews, and PubMed, looking for recommendation status, category of evidence, and availability of randomized clinical trials (RCTs) on mortality for screening tests for diseases in asymptomatic adults (excluding pregnant women and children) from the USPSTF. They then identified the relevant RCTs. The chart below summarizes the existing state of evidence identified in the systematic review:
You can examine the data in Tables 1 and 2 yourselves, in which Saquib et al. examined meta-analyses and individual trials for 39 screening tests for 19 diseases in asymptomatic adults. What is very clear is that there is little strong RCT evidence of benefit for disease-specific mortality for many of these modalities. Indeed, The Gupta Guide notes that, for the six diseases/conditions for which the USPSTF recommends screening, only five of them have strong RCT evidence for a reduction in disease-specific mortality: breast, cervical, and colorectal cancer; abdominal aortic aneurysm (AAA); and type 2 diabetes. There were no randomized trials for screening for hypertension.
Basically, in the individual RCTs examined, the risk of disease-specific mortality was reduced in 16 out of 54 tests (30%), while all-cause mortality was reportedly reduced in 4 of 36 RCTs (11%). Examples of tests for which disease-specific mortality was reduced included ultrasound for AAA (42%-73% risk reduction), mammography for breast cancer (0% to 27% risk reduction), and screening for cervical cancer (11% to 48% risk reduction). For the meta-analyses examined, the risk of disease-specific mortality was reduced in analyses of four of eleven tests, but none for all-cause mortality. Examples of screening tests for which disease-specific mortality was reduced included ultrasound for AAA (again, risk reduction of 45%) and mammography (10% to 25% risk reduction). However, none of the meta-analyses showed an all-cause mortality benefit, while all-cause mortality was reduced only by 3%-13% in the RCTs examined. Basically, the findings were disappointing.
The authors note several possible reasons for their findings:
There are many potential underlying reasons for the overall poor performance of screening in reducing mortality: the screening test may lack sufficient sensitivity and specificity to capture the disease early in its process; there are no markedly effective treatment options for the disease; treatments are available but the risk-benefit ratio of the whole screening and treatment process is unfavourable; or competing causes of death do not allow us to see a net benefit. Often, these reasons may coexist. Whether screening saves lives can only be reliably proven with RCTs. However, even for newly proposed tests, we suspect that their adoption in practice may evade RCT testing. A very large number of tests continuously become available due to technological advancement. One may be tempted to claim a survival benefit of screening based on observational cohorts showing improved survival rates, but these are prone to lead-time and other types of bias. Even RCTs can be biased sometimes, as has been discussed and hotly debated in the controversy over mammography.
The authors also note that they did not examine evidence from other trial designs, such as cohort and case-control studies, which could be a potential weakness. Of course, they also make the obvious defense that these studies are generally less robust than RCTs and more prone to biases. The other concession they make is that it can be incredibly difficult to detect reductions in all-cause mortality for the simple reason that the disease being screened for almost always represents only a fraction of causes of death. This means that even a large drop in mortality due to screening for one disease would, even under ideal conditions, result in only a much smaller drop in all-cause mortality. Such a drop is very difficult to detect in an RCT because of the enormous numbers involved.
What is the proper metric to evaluate a screening test?
This point leads us naturally into the discussions of this study. Presented with the study were commentaries by Peter C. Gøtzsche of the Nordic Cochrane Center and Paul Taylor of the Institute of Health Informatics, University College London, entitled “Screening: a seductive paradigm that has generally failed us” and “Tempering expectations of screening: what is the most authoritative advice we can give, given the data that we have?“, respectively. Basically, Gøtzsche, as one might expect based on his previous criticisms of mammography, argues that total mortality should be the primary outcome in screening trials of mortality and that the main focus of screening trials should be to “quantify the harm.” Taylor, on the other hand, argues that in reality the results of Saquib et al. are not so bad, given that 30% of trials showed a disease-specific benefit and even proponents of screening would expect more trials to fail than not. He also points out the difficulties of using all-cause mortality as the primary outcome.
First, let’s see what Gøtzsche argues:
Screening proponents often say that disease-specific mortality is the right outcome, arguing that in order to show an effect on total mortality, trials would become unrealistically large. I believe this argument is invalid, for both scientific and ethical reasons. We do randomized trials in order to avoid bias, and our primary outcome should therefore not be a biased one. Drug interventions are usually more common in a screened group, and they tend to increase mortality for a variety of non-disease related reasons.
While it is true that overtreatment could potentially increase mortality for reasons other than disease, I believe that Gøtzsche is holding screening to an unrealistically high standard. Using his standard, it would be pointless to screen for virtually anything. Why? I like to use breast cancer as an example to illustrate the difficulties of using all-cause mortality as the be-all and end-all for screening. I know the numbers are rough and the analysis simplistic, but the magnitude is illustrative and close enough to give you an idea of the issues involved. This argument takes the form of a simple thought experiment. Consider first that approximately 40,000 women a year die of breast cancer in the US. However, there are approximately 2.5 million total deaths per year, which means that approximately 1.25 million women die every year (estimated to be 1.26 million in 2011). Thus, breast cancer is the cause of approximately 3.2% of female deaths every year. Consequently, if we could prevent 100% of breast cancer deaths (an unrealistic goal), at most we would expect to see a reduction in all-cause mortality of 3.2%.
Aha! I hear some of you saying. You’re counting all female deaths, even those of children, where breast cancer is so incredibly unlikely to be a cause that these deaths should be discounted. Fair enough. Let’s look at women under the age of 40 (the age at which screening begins, making this the group of women for whom screening is instituted with the goal of preventing death from breast cancer). If we subtract the 63,125 deaths that occur per year in women before the age of 40, we’re left with 1,196,875 deaths, which leads us to estimate the number of breast cancer deaths as 3.3% of total deaths of women aged 40 and above—not much different. Of course, some women do die before age 40 of breast cancer. In the US, approximately 1,160 women under 40 die every year of the disease. That brings the proportion of deaths in women over the age of 40 due to breast cancer back down to 3.2%
So let’s say mammography, as an upper estimate, results in a 27% decrease in breast cancer-specific mortality in women over 40. Under ideal circumstances, that would translate into a less than 0.9% decrease in all-cause mortality. The numbers of subjects and years of follow-up in an RCT needed to detect such a small number would be prohibitively expensive. Obviously, for diseases that cause a higher percentage of overall deaths, it will be easier to detect a reduction in all-cause mortality, but for most diseases it’s very difficult indeed to tease out an all-cause mortality except using clinical trials so huge as to be impractical. Of course, this cuts both ways. If you see a decrease in overall mortality due to screening reported that’s bigger than the proportion of deaths expected to be caused by the disease in the age group studied, then something odd is going on, possibly bias.
In any case, I realize my “back of the envelope” calculations are simplistic. They don’t, for example, rigorously consider the trial period and how many deaths would be expected during, for example, one, two, three, or four decades or adjust for age other than in the crudest manner. My point in having done them isn’t to give exact numbers, but rather to illustrate that the question of whether to use disease-specific mortality or all-cause mortality as a primary endpoint in trials screening for diseases that can result in death is not as straightforward a question as Prof. Gøtzsche argues, although he is correct to note that screening is not without harm and that the harms of screening for some diseases can outweigh the benefits. In an ideal world, he’d be correct about all-cause mortality as an endpoint, too, but our world is not ideal, and detecting such small differences in all-cause mortality is often beyond what is feasible and our resources can support.
Taylor, in his response, also notes another confounder:
But there’s the rub. If breast cancer deaths are reduced, but all-cause mortality is unaffected, is this because detecting the latter requires that more statistical power be deployed? Or is it, as Gøtzsche has suggested, because the harms of screening increase deaths from other causes? The most serious cause of harm is overdiagnosis. The independent UK panel took the view that the best estimate of overdiagnosis could be provided by comparing the rates of cancer detection in the screened and the unscreened groups of randomized controlled trials. The problem is that when most trials ended, screening was offered to the women in the control groups, creating overdiagnosis in the follow-up period. The panel therefore restricted their attention to three trials in which no screening was offered to the control group during follow-up. This is a very limited set of data. Saquib, Saquib and Ioannidis ignore the question of harms presumably because there simply are not enough RCT data to review.
In other words, even in these studies, it’s hard to tease out the sorts of data we are interested in so many decades later. Gøtzsche concludes, without presenting concrete evidence to that effect, that the harms of screening negate the benefits, thus resulting in no detectable decline in all-cause mortality. Advocates assume, without proving, that it is a matter of lack of statistical power, as I discussed above, and that bigger trials with more power would detect all-cause mortality decreases. Chances are, it’s both, the relative proportion of each contribution varying according to the specific disease and screening test under study. One thing is certain, though. All screening results in some degree of overdiagnosis. As I’ve said time and time again, whenever you screen for a condition, you will always find a lot more of it. Always. Just consider the 16-fold increase in the incidence of ductal carcinoma in situ since the mammography era began.
There is no doubt in my mind that screening has, in general, been oversold, represented in some cases as a magic bullet that will save far more lives than it actually can. It’s been a relatively recent realization on the part of physicians that overdiagnosis is a real problem because it leads to overtreatment, which can cause harm. Also, in the case of cancer, improvements in treatment could well be blunting any benefits observed due to screening, as Taylor noted in his commentary. On the other hand, that screening has not lived up to its promise does not mean it is useless, as some critics have charged. It is not unreasonable, as Taylor described, to value other outcomes besides mortality. Unfortunately, we’re in the messy and contentious process of trying to determine which screening tests do save lives. As Saquib et al put it:
We argue that for diseases where short- and medium-term mortality are a relatively common outcomes, RCT should be the default evaluation tool and disease-specific and all-cause mortality should be routinely considered as main outcomes. Our overview suggests that even then, all-cause mortality may hardly ever be improved. One may argue that a reduction in disease-specific mortality may sometimes be beneficial even in the absence of a reduction in all-cause mortality. Such an inference would have to consider the relative perception of different types of death by patients (e.g. death by cancer vs death by other cause), and it may entail also some subjectivity. For diseases where mortality outcomes are potentially important but only in the very long term, one has to consider whether the use of other, intermediate outcomes and/or other quasi-experimental designs that may be performed relatively quickly with very large sample sizes (e.g. before and after the introduction of a test) are meaningful alternatives to very long-term RCTs or may add more bias and confusion in a field that has already seen many hot debates. Screening may still be highly effective (and thus justifiable) for a variety of other clinical outcomes, besides mortality. However, our overview suggests that expectations of major benefits in mortality from screening need to be cautiously tempered.
In other words, the science of screening is messy, and we need to be careful not to be too optimistic. Personally, I tend to agree with Taylor, that better risk stratification will be necessary. Screening tends to benefit most populations at high risk for the disease being screened for. Such stratification could allow for—dare I say it?—personalized screening based on individual risk factors.
One wonders how much of that sort of research will be funded in President Obama’s Precision Medicine Initiative, should it be funded. I might have to look into that for a future topic.

   The USPSTF recommendations for breast cancer screening: Not the final word
David Gorski
Link
Preface: On issues such as this, I think it’s always good for me to emphasize my disclaimer, in particular:
Dr. Gorski must emphasize that the opinions expressed in his posts on Science-Based Medicine are his and his alone and that all writing for this blog is done on his own time and not in any capacity representing his place of employment. His views do not represent the opinions of his department, university, hospital, or cancer institute and should never be construed as such. Finally, his writings are meant as commentary only and are therefore not meant to be used as specific health care recommendations for individuals. Readers should consult their physicians for advice regarding specific health problems or issues that they might have.
Now, on to the post…
“Early detection saves lives.”
Remember how I started a post a year and a half ago starting out with just this statement? I did it because that is the default assumption and has been so for quite a while. It’s an eminently reasonable-sounding concept that just makes sense. As I pointed out a year and a half ago, though, the question of the benefits of the early detection of cancer is more complicated than you think. Indeed, I’ve written several posts since then on the topic of mammography and breast cancer, the most recent of which I posted a mere two weeks ago. As studies have been released and my thinking on screening for breast cancer has evolved, regular readers have had a front row seat. Through it all, I hope I’ve managed to convey some of the issues involved in screening for cancer and just how difficult they are. How to screen for breast cancer, at what age to begin screening, and how to balance the benefits, risks, and costs are controversial issues, and that controversy has bubbled up to the surface into the mainstream media and public consciousness over the last year or so.
This week, all I can say is, “Here we go again”; that is, between downing slugs of ibuprofen for the headaches some controversial new guidelines for breast cancer screening are causing many of us in the cancer field.
On Monday evening, the United States Preventative Services Task Force (USPSTF) released new recommendations for screening mammography, which it published in the Annals of Internal Medicine, that have, let me tell you, shaken my specialty to the core. I must admit I was surprised at the recommendations. No, I wasn’t surprised that recommendations to change the ages and intervals recommended for mammographic screening were released. I saw something like this coming based on a series of studies, some of which I’ve discussed right here on this very blog, such as a study suggesting that one in three mammographically detected breast cancers are overdiagnosed and that as many as one in five breast cancers may spontaneously regress, coupled with evaluations suggesting that the number of lives saved by mammography is not as great as previously thought, such as this Cochrane Review updated last year. What surprised me is how much of a departure from current mammography guidelines the USPSTF recommendations were and, even more so, that they were released this year. I hadn’t expected recommendations like this this soon. But I have to deal with them, and in doing so I might as well try to help SBM readers understand them too.
The first thing that women need to understand is that these recommendations are for asymptomatic women at average risk for breast cancer undergoing routine screening for breast cancer. They are most assuredly not for women judged to be at high risk due to genetic mutations, strong family history, or other factors resulting in an elevated risk for breast cancer. Neither are these guidelines for women who are not completely asymptomatic. If you’re a woman, particularly if you’re over 40 but not limited to women over 40, and have felt a lump, that lump needs to be evaluated by a physician. Period. Screening by definition is administering a test to an asymptomatic population. These recommendations should not be used as a reason to delay or forego the evaluation of masses or other breast abnormalities. I mention this point ad nauseam because I sometimes see confusion between screening and diagnostic mammography in discussions of this issue. Again, screening mammography is for asymptomatic women. Diagnostic mammography is for women with a lump or who have been found to have abnormalities on a screening examination.
The second thing that needs to be understood is that these recommendations do not usurp the current standard of care, although it may seem that way from how they have been portrayed in the press. The American Cancer Society and other cancer organizations have not adopted them. That being said, I do rather suspect that the USPSTF guidelines are the first shot in a battle that is likely to change how we screen for mammography. How much our guidelines will change, I doubt that we will know for quite some time. That always leaves the question of what to do in the meantime. For me, that is to adhere with the current standard of care, albeit with perhaps a bit more flexibility for younger women.
First, the discussion to follow will make a lot more sense if I mention right now that the USPSTF grades its levels of evidence using this grading scale:
And ranks its level of certainty using this scale:
And here are its recommendations summarized:
    • The USPSTF recommends against routine screening mammography in women aged 40 to 49 years. The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient’s values regarding specific benefits and harms. (Grade: C recommendation.)
    • The USPSTF recommends biennial screening mammography for women aged 50 to 74 years. (Grade: B recommendation.)
    • The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years or older. (Grade: I Statement.)
    • The USPSTF recommends against teaching breast self-examination (BSE). (Grade: D recommendation.)
    • The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. (Grade: I Statement.)
    • The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of either digital mammography or magnetic resonance imaging (MRI) instead of film mammography as screening modalities for breast cancer. (Grade: I Statement.)
And the summary for patients states:
The USPSTF found fair evidence that women who have screening mammography die of breast cancer less frequently than women who do not have it, but the benefits minus harms are small for women aged 40 to 49 years. Benefits increase as women age and their risk for breast cancer increases. However, there are relatively few studies of mammography for women aged 75 years or older. The potential harms of mammography include anxiety, procedures, and costs due to false-positive results and receiving a diagnosis and treatment of cancer that never would have surfaced on its own within a woman’s natural life time. They found that the benefit of mammography every 2 years is nearly the same as that of doing it every year, but the harms are likely to be half as common. They found no evidence that self- or clinical examination reduces breast cancer death rates.
There are two bombshells here. The first is the recommendation against routine screening mammography in women between 40 and 49. That’s the change that’s caused all sorts of controversy. Almost as big a bombshell is the recommendation for screening every other year, rather than every year. Add these two together, and it’s a recipe for confusion and controversy among women. After all, we’ve been recommending for a long time that women undergo mammography beginning at age 40 and then every year thereafter, no ifs, ands, or buts. It was a simple message, easy to transmit to women, easy to understand, simple to promote, although I would point out that it was anything but easy to convince women to undergo regular screening. Fear that it will be harder to persuade women to undergo screening may well be part of the nearly universally negative reaction to the recommendation that I’ve seen thus far from advocacy groups such as the Susan J. Komen Foundation and the American Cancer Society. I can understand how these new recommendations could be profoundly confusing to women.
That’s why it’s important to understand on what evidence these recommendations are based. It might help if you go back and read a post I wrote a couple of weeks ago that discusses a review of the literature that urged a rethinking of screening mammography. In that article, it was estimated that, for women between the ages of 50 and 70, 838 women have to be screened for over 5,866 screening visits to sayve one life. It often shocks people to hear these sorts of numbers, but they are not beyond the pale for screening programs. More importantly, the USPSTF based its update of its 2002 recommendations on newer studies, including a study included in the same issue of the Annals of Internal Medicine that used several models to estimate breast cancer risk reduction using various screening paradigms, as well as newer randomized clinical trials, such as the Age Study and updated Gothenberg trial data. These models and results are consistent with randomized clinical trial results that indicate that there is a reduction in breast cancer mortality that results from beginning screening at 40 years but the reduction is “modest and less certain than mortality reductions observed from screening women aged 50 to 69 years.” By using data from randomized clinical trials, the USPSTF estimates that averting 1 death from breast cancer requires screening 1,904 women aged 40 to 49 years; 1,339 women aged 50 to 59 years; or 377 women aged 60 to 69 years. As described above, there was little difference in the benefits between screening every year versus screening every other year, but there were considerably more harms.
The USPSTF’s recommendation not to teach breast self-examination (BSE) is another point of controversy. Despite a lot of enthusiasm for the practice, Cochrane Reviews and other evidence have failed to find convincing evidence that routine regular BSE saves lives. I wish it were otherwise, but it appears not to be, even though there are compelling anecdotes out there of women who did find a lump on BSE and it turned out to be cancer. Unfortunately, overall, the evidence to support BSE is weak. On the other hand, even the Cochrane Collaboration, which I have in the past sometimes accused of methodolatry and “nihilism” with respect to screening concluded:
Some women will continue with breast self-examination or will wish to be taught the technique. We suggest that the lack of supporting evidence from the two major studies should be discussed with these women to enable them to make an informed decision. Women should, however, be aware of any breast changes. It is possible that increased breast awareness may have contributed to the decrease in mortality from breast cancer that has been noted in some countries. Women should, therefore, be encouraged to seek medical advice if they detect any change in their breasts that may be breast cancer.
Indeed, on a purely practical level, I see nothing wrong with women being taught to be aware of how their breasts normally feel and to bring to a physician’s attention any changes that concern them and still encourage that.
So what are the harms of screening? First, there are “unnecessary” biopsies. I used quotation marks because we don’t know that the biopsies were unnecessary except in retrospect because our imaging technology is not good enough to differentiate benign from malignant as well as we would like, with as many as 80% of biopsies being negative. Second, as I’ve discussed before, there is a significant rate of overdiagnosis. Overdiagnosis is the detection of tumors that would never lead to life-threatening disease over the lifetime of the woman. Overdiagnosis leads to overtreatment because, again, we can’t identify which of these diagnosed tumors will and won’t progress; so we have to treat them all. The question then becomes: What is the risk-benefit ratio of screening. For ages 40-49, the analysis of the results by the USPSTF showed a 15% reduction in breast cancer mortality, which was similar to the risk reduction for women aged 50-59 while the risk reduction was 32% for women aged 60-69 However, given the lower incidence of breast cancer in the younger age range and the higher chance of false positives and overdiagnosis, the absolute number of lives saved is much smaller and comes at a higher cost.
But enough of all these numbers. For one thing, the supporting articles in the Annals of Internal Medicine are rather poorly written (no doubt written by a committee) and make it hard to tease out the clear comparisons of the numbers of women potentially harmed. Rather, what I want to emphasize here is that these new recommendations are a classic example of what happens when the shades of gray that characterize the messy, difficult world of clinical research meet public health policy, where simple messages are needed in order to motivate public acceptance of a screening test. It’s also an example where reasonable researchers and physicians can look at exactly the same evidence for and against screening at different ages and come to different conclusions based on a balancing of the potential benefit versus the cost and potential harms. The USPSTF simply came down on a side more like how many European nations screen for breast cancer. How this all will play out is an open question, because how breast cancer screening ultimately evolves will depend upon how women undergoing screening and we as a society end up deciding how to balance the risks and benefits of screening. It will also be affected by advances in technology and our understanding of the biology of breast cancer. The only prediction I can make is that the standard of care for breast cancer screening will almost certainly change. I doubt it will change all the way to the USPSTF’s new guidelines, but likely it will move in that direction, although I cannot predict how far. In any case, it’s always messy when that happens and leads to blowback. For instance, a professional society to which I belong issued a highly embarrassing press release, a case study in the wrong way to respond to a new set of recommendations like those of the USPSTF. The worst part of this press release was this:
We believe these recommendations effectively turn back the clock to pre-mammography days by making the diagnosis of breast cancer occur only when the tumor is large enough to be felt on a physical exam. The Society will continue to advocate for routine annual mammography screening for all women beginning at age 40. Mammography screening reduces breast cancer mortality and saves lives.
By this standard, I suppose much of Europe is “pre-mammography,” given that many countries in Europe use guidelines for screening mammography very much like what the USPSTF recommended. Nothing in the guidelines even suggests going back to those days. Reasonable physicians and scientists can disagree over whether the new guidelines represent a defensible attempt to apply current evidence about screening mammography to public health policy, but demonizing the USPSTF’s recommendations with such inflammatory language is neither productive nor reasonable. If you’re going to argue against the new guidelines, at least try to argue the evidence and counter what the guidelines actually say, as the American Cancer Society did:
    • The USPSTF says that screening 1,339 women in their 50s to save one life makes screening worthwhile in that age group. Yet USPSTF also says screening 1,904 women ages 40 to 49 in order to save one life is not worthwhile. The American Cancer Society feels that in both cases, the lifesaving benefits of screening outweigh any potential harms. Surveys of women show that they are aware of these limitations, and also place high value on detecting breast cancer early.
    • With its new recommendations, the USPSTF is essentially telling women that mammography at age 40 to 49 saves lives; just not enough of them. The task force says screening women in their 40s would reduce their risk of death from breast cancer by 15 percent, just as it does for women in their 50s. But because women in their 40s are at lower risk of the disease than women 50 and above, the USPSTF says the actual number of lives saved is not enough to recommend widespread screening. The most recent data show us that approximately 17 percent of breast cancer deaths occurred in women who were diagnosed in their 40s, and 22 percent occurred in women diagnosed in their 50s. Breast cancer is a serious health problem facing adult women, and mammography is part of our solution beginning at age 40 for average risk women.
This is a far more reasonable and nuanced critique that encapsulates starkly what the issues are. In essence, the ACS agrees with the conclusions of the data used by the USPSTF to support its recommendations but disagrees with the value judgments behind its recommendations to back off on screening in women under 50 and to decrease screening frequency to every other year. However, even the ACS couldn’t resist a little holding back in that it didn’t mention the raw numbers of lives potentially saved in each age group. In any case, I think the response from the American Society of Clinical Oncology (ASCO, a society to which I also belong) was much better. It did what I support, namely defending the availability of mammography to women over 40, while suggesting a more personalized approach to screening that represents a reasonable compromise between current screening recommendations that encompasses what the USPSTF has recommended:
Today’s recommendations from the USPSTF recognize the value of mammography in reducing breast cancer deaths, affirm the importance of mammography among women aged 50 and older, and emphasize that mammography should be seriously considered in women 40 to 49 after assessment of the risks and benefits. It is therefore of concern that at present more than a third of women who are now recommended for screening are not getting regular mammograms. While the optimal scheduling of regular mammograms is being discussed by experts in the field, ASCO would not want to see any impediments to mammography screening for any woman age 40 and above.
From ASCO’s perspective, the critical message is that all women – beginning at age 40 — should speak with their doctors about mammography to understand the benefits and potential risks, and determine what is best for them.
And that’s what it’s really about. The patient and her physician collaboratively determining what is best for her. Indeed, the current recommendations of the USPSTF are no less arbitrarythan previous recommendations for screening. What they reflect are newer studies and a different analysis of the the risk-benefit ratio, in which the more modest benefits of routine mammography in women between ages 40-49 at average risk for breast cancer are judged not to be worth the potential harm caused. Others may look at the same data and decide that the benefits of screening mammography in this age range are worth the potential harms. Individual women may hear the same benefits and risks and decide differently for themselves. Neither view is clearly inherently “right” or “wrong,” and what I hope we should all be able to agree upon is that women should be aware of and understand as much as possible those tradeoffs regardless before deciding upon screening.
In the meantime, I’m not quite buying that these new recommendations are so clearly more “science-based” than the older recommendations when, as the ACS points out, the USPSTF arbitrarily decided that screening 1,300 women to save one life is an acceptable cost but screening 1,900 to save a life is not. I do, however, think that we health care professionals have probably not sufficiently described the potential harms that come from screening in the past, and the controversy surrounding these guidelines is that failure coming home to roost. As I’ve written before, I sincerely hope that better technology and the discovery of new biomarkers can decrease these high numbers by increasing the specificity of mammographic screening and, possibly, even allowing us to identify which mammographically detected tumors don’t need treatment. Indeed, to me, the one advance that could most reduce the potential for overtreatment of image-detected breast cancer would be molecular tests that would accurately allow us to identify accurately the subset of breast cancers that are unlikely ever to progress and threaten the life of the woman. Another advance would be better imaging technology that could more accurately distinguish cancer from non-cancer or achieve the same thing as mammography without compression or radiation, which could lead to greater acceptance of screening. Finally, better biomarkers and tests that allow us to assess more accurately a woman’s true risk of developing breast cancer would permit targeted recommendations tailored to a woman’s individual risk. All of these are being actively researched, some at my own institution, but until such technologies and tests are developed we are left with mammography. As imperfect as it is, it is the best screening tool we currently have.
In the meantime, the application of science-based medicine to screening asymptomatic people for disease cannot avoid becoming interwined with a parallel discussion of how to balance risks and benefits, as well as a discussion of values. In the case of breast cancer, starting at 40 appears only to modestly decrease the absolute number of lives lost from breast cancer but at a fairly high cost of overdiagnosis and overtreatment, while screening yearly only increases the detection of breast cancer marginally compared to screening every year, also at a high cost in terms of more biopsies and more overdiagnosis. Whether the cost is judged to be worth it or not has to be evaluated on two levels. First and foremost, what matters is the woman being screened, what she values, and what her tolerance is for paying the price of screening at an earlier age, such as a high risk for overdiagnosis, excessive biopsies, and overtreatment in order to detect cancer earlier versus a relatively low probability of avoiding death from breast cancer as a result of undergoing regular screening. The next level is the public health policy level, where we as a society have to decide what tradeoffs we’re willing to make to save a life that otherwise would have been lost to breast cancer. Although screening programs and recommendations should be based on the best science we currently have, deciding upon the actual cutoffs regarding who is and is not going to be recommended to undergo screening and how often women should be screened unavoidably involves value judgments by those being screened, physicians recommending screening, and society at large.
It is just those value judgments that are driving the debate spawned by the USPSTF recommendations, a debate that is too frequently acrimonious when it doesn’t have to be.

   Another wrinkle to the USPSTF mammogram guidelines kerfuffle: What about African-American women?
David Gorski
Link
A while back I wrote about rethinking how we screen for breast cancer using mammography. Basically, the USPSTF, an independent panel of physicians and health experts that makes nonbinding recommendations for the government on various health issues, reevaluated the evidence for routine screening mammography and concluded that for women at normal risk for breast cancer, mammography before age 50 should not be recommended routinely and should be ordered on an individualized basis, and that routine formalized breast self-examination (BSE) should also not be routinely recommended. In addition, for women over 50, it was recommended that they undergo mammography every other year, rather than every year. These recommendations were based on a review of the literature, including newer studies.
To say that these new recommendations caused a firestorm in the breast cancer world is an understatement. The USPSTF was accused of misogyny; opponents of health care reform leapt on them as evidence that President Obama really is preparing “death panels”; and HHS secretary Kathleen Sebelius couldn’t run away from the guidelines fast enough. Meanwhile, a society I belong to (the American Society of Breast Surgeons) issued a press release accusing the USPSTF of sending us back to the “pre-mammography” days when, presumably women only found breast cancer after it had grown to huge size (just like Europe and Canada, I guess, given that the recommendations for screening there closely mirrors those recommended by the USPSTF). Meanwhile, in the most blatant example of protecting its turf I’ve seen in a very long time, the American College of Radiology went full mental jacket with a press release that was as biased as it was insulting. Meanwhile some physicians even likened the recommendations to going back to being like Africa, Southeast Asia and China as far as breast screening goes in that he actually speculated that he’d now become very busy treating advanced, neglected breast cancers. Unfortunately, as Val pointed out, the communication of the USPSTF guidelines to the public was almost a perfect case study in how not to do it. Even though the science was in general sound and the USPSTF recommendations were in essence close to identical to what other industrialized nations do, they were communicated in just such a way as to produce maximum misunderstanding and misuse for political purposes.
Despite all the hysterical and in some cases disingenuous attacks on the new guidelines, there is one criticism that actually resonates with me because I work at a cancer center in a very urban environment with a large population of African-American women. Last week I heard on NPR this story:
Many African-American women don’t fit the profile of the average American woman who gets breast cancer. For them, putting off the first mammogram until 50 — as recommended by a government task force — could put their life in danger.
“One size doesn’t fit all,” says Lovell Jones, director of the Center for Research on Minority health at Houston’s M.D. Anderson Cancer Center. Jones says the guidelines recently put out by the U.S. Preventive Services Task Force covered a broad segment of American women based on the data available. “Unfortunately,” he says, “the data on African-Americans, Hispanics and to some extent Asian-Americans is limited.”
So while the recommendations may be appropriate for the general population, he says, it could have a deleterious affect on African-American women who appear to have a higher risk of developing very deadly breast cancers at early in life.
And this is actually true. Some of the studies used to develop the latest mammographic guidelines were performed in Scandanavian countries, and in the others arguably African-American women were underrepresented. As the article points out:
When you look at the death statistics for breast cancer in African-American women and compare them to white women, it’s stunning. Beginning in their 20s, into their 50s, black women are twice as likely to die of breast cancer as white women who have breast cancer. In older black women, cases of breast cancer decline, but the high death rates persist.
Overall, breast cancer deaths have been declining for nearly a decade (by 2 percent annually), yet deaths of African-American women have been dropping at a much slower pace. In 2009, an estimated 40,170 women will die from breast cancer. Nearly 6,000 will be African-American women.
Why this disparity exists is unclear. One potential reason is that, for whatever reason, African-American women tend to develop a more aggressive form of breast cancer known as “triple negative” cancer. What triple negative means is that the tumor is estrogen receptor negative [ER(-)], progesterone receptor negative [PR(-)], and HER2/neu negative [HER2/neu(-)]. The lack of estrogen receptor means that these tumors don’t respond to antiestrogen drugs, while the lack of HER2/neu means that they don’t respond to Herceptin. In other words, there are no targeted therapies for these tumors, only cytotoxic chemotherapy or nothing.
More importantly, there is something about the biology of these tumors that makes them more aggressive. They may respond well initially to chemotherapy but they tend to relapse rapidly and kill quickly. This subtype of tumor generally makes up around 15% of cancers among women who are not black, but among African Americans it makes up nearly 40% of tumors. This is a striking difference, and five year survival for women with triple negative cancer is considerably lower than for other types of breast cancer, particularly for young, premenopausal African-American women.
With that background, it’s not unreasonable to ask what “normal” risk for breast cancer is for purposes of recommending a program of screening mammography. On the one hand, if young African-American women are at a higher risk for breast cancer, then beginning their screening at an earlier age makes sense because it is the lower risk of breast cancer in women in their 40s that led the USPSTF to conclude that the risk-benefit ratio of mammography was less favorable in this age range. On the other hand, the more aggressive nature of breast cancer in young, premenopausal African-American women means that length bias becomes a consideration. Basically, length bias means that mammographic screening tends preferentially to pick up slower-growing, more indolent tumors. Faster-growing, more aggressive tumors tend to “pop up” between screening intervals. So, even if screening were started earlier for African-American women, it’s not clear that the benefits would be as dramatic as we might hope. Indeed, the NPR story alludes to this:
Sheppard even wonders if the old guideline of routine screening every year beginning at age 40 is good enough. “The tumors are growing fast and the intervals that we prescribe may not work,” she says. “How can we have better diagnostic tools, better screening tools that can capture the women that aren’t the average woman?”
A blogger going by the pseudonym of Isis the Scientist brought up this very issue the other day has a point when she wonders:
The other thing I wonder about is the effect these recommendations will have on the perception of health care equity. A black woman is more likely to develop aggressive cancer than a white woman before age 50, yet the USPSTF has recommended not to actively screen women less than. I wonder how this will be interpreted by that community? Black women experience a distrust of scientists performing clinical trials (second reference here), operate within a healthcare that is not always sensitive to their needs, and use mammography as a resource less frequently than white women. Will these new recommendations foster feelings of distrust and reinforce the notion that the current health care system does not adequately meet their needs?
There is a legitimate concern that the USPSTF guidelines may not be a good fit to African-American women because not only do they tend to have more aggressive disease at a younger age but they have been underrepresented in many of the large screening trials that have been used to formulate the recommended mammography guidelines. For that reason, upon further reflection I don’t think that the USPSTF guidelines should be used to determine how and when African-American women should undergo screening, as I consider them to be at a high enough risk that screening beginning at 40 makes sense.
However, as much as she did raise a valid point when she questioned whether the current mammography guidelines should apply to African-American women, still I must remonstrate with Isis and point out that the article by Nicholas Kristof that she cited in support of her speculations is dubious at best and a load of grade-A woo at worst. For example, Kristof states:
Dr. Philip Landrigan, the chairman of the department of preventive medicine at Mount Sinai, said that the risk that a 50-year-old white woman will develop breast cancer has soared to 12 percent today, from 1 percent in 1975. (Some of that is probably a result of better detection.)
What’s very important to realize is that 12% of women do not get invasive breast cancer as compared to 1% in the past. Moreover, “some of that” is not “probably” a result of better detection. Most of it is almost certainly a result of better detection of earlier breast cancer, including pre-invasive lesions like ductal carcinoma in situ (DCIS), through widespread mammography screening programs. Indeed, as this report by the American Cancer Society shows, the incidence of invasive breast cancer per 100,000 women is not increasing nearly that fast. In fact, it’s not increasing at all. On the contrary, since 2002 breast cancer incidence has actually declined, very likely due to the massive decrease in hormone replacement therapy use in the wake of the 2002 report from the Women’s Health Initiative showing that HRT doesn’t decrease cardiovascular risk but does increase the risk of breast cancer. Figure 1 in particular shows this trend, while Figure 2 shows what’s really driving the apparent increase in breast cancer diagnoses, a massive increase in the incidence of preinvasive DCIS.
We’ve known for quite some time that what’s driving this increase is nearly all mammographic screening; indeed, the article speculates that we may have finally reached the plateau in the increase of DCIS cases with the widespread use of mammographic screening over the last 20 years. That 12% figure is not just invasive cancer; it includes DCIS. While invasive cancer diagnoses are more or less stable, diagnoses of DCIS skyrocketed due to mammography. Indeed, this dovetails nicely with my earlier discussions of overdiagnosis due to mammography, because this is exactly what I’m talking about. Mammography picks up early cancers that may or may not ever threaten the life of the woman; that’s what overdiagnosis is. Moreover, overdiagnosis leads to overtreatment, as we don’t have a good handle on what percentage of DCIS lesions progress to life-threatening breast cancers if left alone. So we treat them all with surgery, nearly all of them with radiation, and most of them with Tamoxifen after surgery and radiation.
Unfortunately, in the article Kristof takes a somewhat reasonable suspicion and runs right off the dock with it into woo land, and Isis appears not to have been skeptical enough about his claims, given that she then used Kristof’s article as the basis for speculation that maybe African-American women, tending to be of lower socioeconomic status than Caucasian women, are exposed to more toxic chemicals and endocrine disruptors. Unfortunately, as Peter Lipson characterized his article, Kristof has clearly fallen for the “one true cause” fallacy so beloved of practitioners of woo, labeling endocrine disruptors such as BPA as a major environmental cause of the apparent increase in breast cancer diagnoses. Don’t get me wrong, there may well be something there in that BPA and endocrine disruptors may contribute to breast cancer, but almost certainly not to the extent that Kristof claims, even given the evidence he cites.
In addition, if there’s one thing about breast cancer, it’s that no single environmental exposure has been found to be strongly correlated with it; most of the correlations other than family history and exposure to hormone replacement therapy, including both positive and negative correlations, have been in general pretty weak. Indeed, I was recently peripherally involved in an effort to design a project to study environmental influences in breast cancer, and there are amazingly few validated environmental factors that increase the risk of breast cancer. Also, timing is very important; it may well be that it is exposure to these factors in adolescence or childhood in a “window” of susceptibility, not in adulthood, which is when they are normally studied. Right now, that’s where the current research efforts seem to be focused. In addition, breast density, which is primarily genetically determined, is a known risk factor for breast cancer as well, and investigators are actually planning to study that at our institution. All in all, it’s a hideously complicated business combining genetic and environmental factors that I am only beginning to wrap my brain around, while Kristof’s article was simplistic and alarmist in the extreme. For better information, I recommend a report from the Endocrine Society for the more sober, balanced perspective, and a report from the Breast Cancer Fund for arguments more explicitly in favor of a link. More information, including the chemical industry’s viewpoint (if you’re interested), can be found here.
I firmly believe that the recommendations for how we screen for breast cancer were overdue for an overhaul. Badly. However, the USPSTF guidelines may have gone too far too fast, at least for public consumption in light of the years of urging by the government and private advocacy organizations for all women over 40 to be screened, recommendations that say that mammography before age 50 may not be particularly beneficial were a hard pill to swallow. As I think about it more, though, one big flaw in the guidelines is that there was little consideration of how changing screening recommendations would impact special populations that may be at higher risk, such young African-American women. Worst of all, the USPSTF recommendations are an example of some of the astoundingly worst science communication I’ve seen in a long time. No groundwork was laid to prepare the public; the guidelines were just announced; and the spokespeople for the USPSTF looked like deer in the headlights when they showed up in the media to defend the guidelines. Specialty groups protecting their interests such as the American Radiologial Society and its President Dr. Kopans ate them for lunch and then laughed at their discomfiture. Meanwhile high ranking government officials couldn’t distance themselves fast enough, and lawmakers and ideologues had a field day playing politics with the guidelines.
In the end, while I still think that the new guidelines are reasonable for most non-black women, after thinking about it I doubt that they should be applied to African Americans. Finally, I’m now convinced more than ever that screening will only have limited effects in decreasing mortality from breast cancer, regardless of the test used, as long as we have so poor an understanding of the aspects of breast cancer biology that govern which early cancerous lesions will progress, which will not, and which will regress. Until we do, if there were developed a test to replace mammography, the same problems of overdiagnosis and overtreatment would remain. More than ever, we need to develop an understanding of the biology of breast cancer sufficiently advanced that it permits us to develop imaging tools and biological markers that can differentiate breast cancers that will progress and those that are not going to threaten the life of the woman. At the very least we need better indicators of risk. Until we have these things, screening will remain a highly imperfect tool that doesn’t save as many lives as it has the potential to.

   The early detection of cancer and improved survival: More complicated than most people think
David Gorski
Link
“Early detection of cancer saves lives.
How many times have you heard this statement or something resembling it? It’s a common assumption (indeed, a seemingly common sense assumption) that detecting cancer early is always a good thing. Why wouldn’t it always be a good thing, after all? For many cancers, such as breast cancer and colon cancer, there’s little doubt tha early detection at the very least makes the job of treating the cancer easier. Also, the cancer is detected at an earlier stage almost by definition. But does earlier detection save lives? This question, as you might expect, depends upon the tumor, its biology, and the quality and cost of the screening modality used to detect the cancer. Indeed, it turns out that the question of whether early detection saves lives is a much more complicated question to answer than you probably think, a question that even many doctors have trouble with. It’s also a question that can be argued too far in the other direction. In other words, in the same way that boosters of early detection of various cancers may sometimes oversell the benefits of early detection, there is a contingent that takes a somewhat nihilistic view of the value of screening and argues that it doesn’t save lives.
A corrollary of the latter point is that some boosters of so-called “alternative” medicine take the complexity of evaluating the effect of early screening on cancer mortality and the known trend towards diagnosing earlier and earlier stage tumors as saying that our treatments for cancer are mostly worthless and that the only reason we are apparently doing better against cancer is because of early diagnosis of lesions that would never progress. Here is a typical such comment from a frequent commenter whose hyperbolic style will likely be immediately recognizable to regular readers here:
Most cancer goes away, or never progresses, even with NO medical treatment. Most people who get cancer never know it. At least in the past, before early diagnosis they never knew it.
Now many people are diagnosed and treated, and they never get sick or die from cancer. But this would have also been the case if they were never diagnosed or treated.
Maybe early diagnosis and treatment do save the lives of a small percentage of all who are treated. Maybe not. We don’t know.
As is so often the case with such simplistic black and white statements, there is a grain of truth buried under the absolutist statement but it’s buried so deep that it’s well-nigh unrecognizable. Because we see this sort of statement frequently, I thought it would be worthwhile to discuss some of the issues that make the reduction of mortality from cancer so difficult to achieve through screening. I will do this in two parts, although the next part may not necessarily appear next week
Shortly after I learned that Elizabeth Edwards’ breast cancer had recurred in her bones last spring, meaning that her cancer is now stage IV and incurable, I read for our journal club a rather old article. However, this old article still has a lot of resonance today; indeed it was eerily prescient given the technological leaps that have driven the development of ever more sensitive imaging instruments and other diagnostic tests that have occurred over the last 15 years. The article, written by William C. Black and H. Gilbert Welch and entitled Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy, appeared in the New England Journal of Medicine in 1993, but could easily have been written today. All you’d have to do is to substitute some of the imaging modalities mentioned in the article, and it would be just as valid now, if not more so. Until someone writes a better one, this article should be required reading for all physicians and medical students.
The article begins by setting the stage with the essential conflict, which is that increasing sensitivity leads to our detecting abnormalities that may never progress to disease:
Over the past two decades a vast new armamentarium of diagnostic techniques has revolutionized the practice of medicine. The entire human body can now be imaged in exquisite anatomical detail. Computed tomography (CT), magnetic resonance imaging (MRI), and ultrasonography routinely “section” patients into slices less than a centimeter thick. Abnormalities can be detected well before they produce any clinical signs or symptoms. Undoubtedly, these technological advances have enhanced the physician’s potential for understanding disease and treating patients.
Unfortunately, these technological advances also create confusion that may ultimately be harmful to patients. Consider the case of prostate cancer. Although the prevalence of clinically apparent prostate cancer in men 60 to 70 years of age is only about 1 percent, over 40 percent of men in their 60s with normal rectal examinations have been found to have histologic evidence of the disease. Consequently, because the prostate is studied increasingly by transrectal ultrasonography and MRI, which can detect tumors too small to palpate, the reported prevalence of prostate cancer increases. In addition, the increased detection afforded by imaging can confuse the evaluation of therapeutic effectiveness. As the spectrum of detected prostate cancer becomes broader with the addition of tumors too small to palpate, the reported survival from the time of diagnosis improves regardless of the actual effect of the new tests and treatments.
In this article, we explain how advances in diagnostic imaging create confusion in two crucial areas of medical decision making: establishing how much disease there is and defining how well treatment works. Although others have described these effects in the narrow context of mass screening6,7 and in a few clinical situations, such as the staging of lung cancer, these consequences of modern imaging increasingly pervade everyday medicine. Besides describing the misperceptions of disease prevalence and therapeutic effectiveness, we explain how the increasing use of sophisticated diagnostic imaging promotes a cycle of increasing intervention that often confers little or no benefit. Finally, we offer suggestions that may minimize these problems.
Since 1993, CT and MRI scans have now become so powerful that they now routinely “section” people into “slices” much thinner than 1 cm, making currently achievable imaging sensitivity considerably higher than it was 14 years ago. What the essential conflict is, at least in the case of cancer, is that far more people have malignant changes in various organs as they get older than the number of people who actually ever develop clinically apparent cancer. The example of prostate cancer is perhaps the best example of this phenomenon. If you look at autopsy series of men who died at an age greater than 80, the vast majority (60-80%) of them will have detectable microscopic areas of prostate cancer if their prostates are examined closely enough. Yet, obviously prostate cancer didn’t kill them. After all, they all lived to a ripe old age and died either of old age or a cause other than prostate cancer. In other words, they died with early stage cancer but not of cancer.
Now, imagine if you will, that a test was invented that was 100% sensitive and specific for detecting prostate cancer cells and that, moreover, it could detect microscopic foci of prostate cancer less than 1 mm in diameter. Now imagine applying this test to every 60 year old man. Somewhere around 40% of them will register a positive result, even though only around only 1/40 of those apparent positives would actually have disease that needs any treatment. Yet, they would all get biopsies. Many of them would get radiation and/or surgery simply because we can’t take the chance, or because, in our medical legal climate, watchful waiting and observation to see if it is going to grow at a rate that would make it clinically apparent in the case of potential cancer are a very hard sell, even when they’re the correct approach. After all, we don’t know which of them has disease that actually will threaten their lives. It may well be that eventually using expression profiling (a.k.a. gene chip) testing, something that did not exist in 1993, will eventually allow us to sort this question out, but in the meantime we have no way of doing so. Even so, I note that there is nonetheless an increasing trend towards “watchful waiting” rather than aggressive surgery or radiation therapy in many cases of prostate cancer with less aggressive histology.
Of the most common diseases, the various forms of cancer are probably the diseases that are most likely to be overdiagnosed as our detection abilities, either through increasingly detailed imaging test or through blood tests, both of which are becoming ever more sensitive. Breast cancer is the other big example other than prostate, but I plan on holding off on that one until Part 2 of this series. So instead I’ll look at another example from the article, namely thyroid cancer. Thyroid cancer is fairly uncommon (although certainly not rare) among cancers, with a prevalence of around 0.1% for clinically apparent cancer in adults between ages 50 and 70. Finnish investigators performed an autopsy study in which they sliced the thyroids at 2.5 mm intervals and found at least one papillary thyroid cancer in 36% of Finnish adults. Doing some calculations, they estimated that, if they were to decrease the width of the “slices,” at a certain point they could “find” papillary cancer in nearly 100% of people between 50-70. This is not such an issue in thyroid cancer, which is uncommon enough that mass screening other than routine physical examination to detect masses is impractical, but for more common tumors it becomes a big consideration, which is why I will turn to breast cancer in the next post.
The bottom line is that the ever-earlier detection of many diseases, particularly cancer, is not necessarily an unalloyed good. As the detection threshold moves ever earlier in the course of a disease or abnormality (in the case of cancer, to ever smaller tumors all the way down to the level of clusters of cells), the apparent prevalence of the disease being screened for increases, and abnormalities that may never turn into the disease start to be detected at an increasing frequency.In other words, the signal-to-noise ratio falls precipitously. This has consequences. It leads, at the very minimum, to more testing and may lead us to treating abnormalities that may never result in disease that affects the patient, which at the very minimum leads to patient anxiety and at the very worst leads to treatments that put the patient at risk of complications and do the patient no good.
This earlier detection can also lead to an overestimation of the efficacy of treatment. That’s the grain of truth in the comment above. The reasons for this are two types of bias in treatment studies known as lead time bias and length bias. In the case of cancer, survival is measured from the time of diagnosis. Consequently, if the tumor is diagnosed at an earlier time in its course through the use of a new advanced screening detection test, the patient’s survival will appear to be longer, even if earlier detection has no real effect on the overall length of survival, as illustrated below:
Unless the rate of progression from the point of a screen-detected abnormality to a clinically detected abnormality is known, it is very difficult to figure out whether a treatment of the screen-detected tumor is actually improving survival when compared to tumors detected later. To do so, the lead time needs to be known and subtracted from the group with the test-based diagnoses. The problem is that the use of the more sensitive detection tests usually precede such knowledge of the true lead time by several years. The adjustment for lead time assumes that the screening test-detected tumors will progress at the same rate as those detected later clinically. However, the lead time is usually stochastic. It will be different for different patients, with some progressing rapidly and some progressing slowly. This variability is responsible for a second type of bias, known as length bias.
Length bias refers to comparisons that are not adjusted for rate of progression of the disease. The probability of detecting a cancer before it becomes clinically detectable is directly proportional to the length of its preclinical phase, which is inversely proportional to its rate of progression. In other words, slower-progressing tumors have a longer preclinical phase and a better chance of being detected by a screening test before reaching clinical detectability, leading to the disproportionate identification of slowly progressing tumors by screening with newer, more sensitive tests. This concept is illustrated below:
The length of the arrows above represents the length of the detectable preclinical phase, from the time of detectability by the test to clinical detectability. Of six cases of rapidly progressive disease, testing at any single point in time in this hypothetical example would only detect 2/6 tumors, whereas in the case of the slowly progressive tumors 4/6 would be detected. Worse, the effect of length bias increases as the detection threshold of the test is lowered and disease spectrum is broadened to include the cases that are progressing the most slowly, as shown below:
The top image represents an idealized example of disease developing in a cohort of patients by two different hypothetical tests, the first one being the less sensitive standard test and the next one being the “advanced” test, which has a lower threshold of detection. The cases detected by the more sensitive advanced test are represented in the stippled area. The standard test detects only the cases that are rapidly progressive. However, the new test detects all cases, including the ones that are slowly progressive and, if left alone, would not have killed the patient, who would have died from other causes before the tumor became clinically detectable by the “standard” test. These latter two patients would be at risk for medical or surgical interventions that would not prolong their lives and carry the risk of morbidity or even mortality if subjected to the more sensitive test. This is one reason why “screening CT scans” are usually not a good idea.
As the authors state:
Unless one can follow a cohort over time, there is no way of accurately estimating the probability that a subclinically detected abnormality will naturally progress to an adverse outcome. The probability of such an outcome is mathematically constrained, however, by the prevalence of the detected abnormality. The upper limit of this probability can be derived from reasoning that dates to the 17th century, when vital statistics were first collected. If the number of persons dying from a specific disease is fixed, then the probability that a person with the disease will eventually die from it is inversely related to the prevalence of the disease. Therefore, given fixed mortality rates, an increase in the detection of a potentially fatal disease decreases the likelihood that the disease detected in any one person will be fatal.
In other words, early detection makes it appear that fewer people die of the disease, even if treatment has no effect on the progression of the disease. It will also make new treatments introduced after the lower detection threshold takes hold appear more effective:
Lead-time and length biases pertain not only to changes that lower the threshold for detecting disease, but also to new treatments that are applied at the same time. Whether or not new therapy is more effective than old therapy, patients given diagnoses with the use of lower detection thresholds will appear to have better outcomes than their historical controls because of these biases. Consequently, new therapies often appear promising and could even replace older therapies that are more effective or have fewer side effects. Because the decision to treat or to investigate the need for treatment further is increasingly influenced by the results of diagnostic imaging, lead-time and length biases increasingly pervade medical practice.
This month there was a study out of Norway that shows just how variable the growth rate of a tumor can be, a variability that suggests just how difficult it is to optimize a screening strategy that applies to a wide population. Indeed, this study shows that not only are cancers of different organs different diseases, but arguably different cancers in the same organ behave almost like different diseases. In brief, imaging and cancer incidence data were modeled from 395 women and the rates of breast cancer growth thereby estimated. What was found was an enormous variability in tumor doubling times. The mean time for a tumor to double from 1 cm to 2 cm in diameter was 1.7 years. However, 5% of the subjects with breast cancer had tumors whose doubling time was less than 1.2 months. Of course, the doubling of the diameter of a tumor is in actuality an eight-fold increase in tumor volume, which makes this result even more impressive. Not surprisingly, women with such rapidly growing tumors tended to be younger. On the other end of the spectrum, 5% of the women had tumors whose doubling time was greater than 6.3 years. the study also suggested that most breast cancers become detectable on imaging when they reach a diameter of between 0.5 and 1.0 cm. It’s not hard to see how, taken together, this data suggests that no screening regimen is likely to detect a cancer before it reaches 2 cm in diameter except maybe 10% of the time. The converse of this is that women with slow-growing tumors could do just as well with screening every three years. Of course, the problem is that we have no way of knowing who will fall into which category. Such are the complications that have made it difficult to demonstrate a decrease in cancer-specific mortality from mammographic screening. The evidence that it does so in women over 50 is fairly strong; less srong–equivocal, even–is the evidence supporting a decrease in mortality attributable to mammographic screening in women between 40-50.
There is another complication that these more powerful imaging modalities can lead to that wasn’t discussed in the paper, stage migration. This is a phenomenon that occurs when more sophisticated imaging studies or more aggressive surgery leads to the detection of tumor spread that wouldn’t have been noted in an identical patient using previously used tests. This phenomenon is colloquially known in the cancer biz as the Will Rogers effect. The name is based on Will Rogers’ famous joke: “When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states.” This little joke describes very well what can happen in cancer. What in essence happens is that technology results in a migration of patients from one stage to another that does the same thing for cancer prognosis that Will Rogers’ famous quip did for intelligence. Consider this example. Patients who would formerly have been classified as, for example, stage II cancer (any cancer), thanks to better imaging or more aggressive surgery, have additional disease or metastases detected that wouldn’t have been detected in the past. They are now, under the new conditions and using the new test, classified as stage III, even though in the past they would have been classified as stage II. This leads to the paradoxical statistical effect of making the survival of both groups (stage II and III) appear better, without any actual change in the overall survival of the group as a whole. This paradox comes about because the patients who “migrate” to stage III tend to have a lower volume of disease or less aggressive disease compared to the average stage III patient and thus a better prognosis. Adding them to the stage III patients from before thus improves the apparent survival of stage III patients as a group. The converse is that patients with more disease that was previously undetected, tended to be the stage II patients who would have recurred and done more poorly compared to the average patient with stage II disease; i.e., the worst prognosis stage II patients. But now, they have “migrated” to stage III, leaving behind stage II patients who truly do not have as advanced disease and thus in general have a better prognosis. Thus, the prognosis of the stage II group also ends up appearing to be better with no real change in the overall survival from this cancer.
Does all of this mean that we’re fooling ourselves that we’re doing better in treating cancer? That, after all, is the charge being made. Not at all. It simply means that the question of sorting out “real” effects on cancer survival attributable to new treatments being tested from spurious effects due to these biases is more complicated than it at first seems. For one thing, it points to the importance of carefully matching any experimental groups in clinical trials according to stage as closely as possible using similar tests and imaging modalities to diagnose and measure the disease. These factors are yet another reason why well-controlled clinical trials, with carefully matched groups and clear-cut diagnostic criteria are critical to practicing science-based medicine. It also means that sorting out lead time bias, length bias, and the Will Rogers effect from whether there is actually a better effect from new treatments can be a complex and messy business. If we as clinicians aren’t careful, it can lead to a cycle of increasing intervention for decreasing disease. At some point, if common sense doesn’t prevail (and in the present medical-legal situation, it’s pretty hard to argue against treating any detectable cancerous change), it can reach a point of ever diminishing returns, or even a point where the interventions cause more harm than good to patients. The authors have similarly good advice for dealing with this:
Meanwhile, clinicians can heed the following advice. First, expect the incidence and prevalence of diseases detectable by imaging to increase in the future. Some increases may be predictable on the basis of autopsy studies or other intensive cross-sectional prevalence studies in sample populations. Others may not be so predictable. All types of increases should be expected. The temptation to act aggressively must be tempered by the knowledge that the natural history of a newly detectable disease is unknown. For many diseases, the overall mortality rate has not changed, and the increased prevalence means that the prognosis for any given patient with the diagnosis has actually improved.
Second, expect that advances in imaging will be accompanied by apparent improvements in therapeutic outcomes. The effect of lead-time and length biases may be potent, and clinicians should be skeptical of reported improvements that are based on historical and other comparisons not controlled for the anatomical extent of disease and the rate of progression. Clinicians may even consider that the opposite may be true — i.e., real outcomes may have worsened because of more aggressive interventions.
Finally, consider maintaining conventional clinical thresholds for treating disease until well-controlled trials prove the benefit of doing otherwise. This will require patience. A well-designed randomized clinical trial takes time. So does accumulating enough experience on outcomes from nonexperimental methods that can be used to control for the extent of disease and the rate of progression. From the point of view of both patients and policy, it is time well spent.
These words are just as relevant to day as they were 15 years ago. On the surface, they would appear to support the words of our cranky commenter from the beginning of this post, but they do not. The reason, of course, is that it is quite possible to control for lead time and length bias, the Will Rogers effect, and stage migration, and it’s what clinical investigators do. It’s just difficult, and careful trial design is necessary. Indeed, in carefully controlled studies for a number of cancers the efficacy of our various inteventions against cancer have been demonstrated. In addition, in science-based medicine, unlike the blandishments of “alternative” medicine, we know that there is a cost for every new intervention. The detection of ever-smaller cancers the percentage of which that will endanger the patient’s life we do not know and can only roughtly estimate, leads to increasing numbers of biopsies and treatments that subject the patient to the risk of complications and overtreatment while doing some patients no good even as they may lead to the saving the lives of others. Finding the “sweet spot,” where increased detection reaches a point that maximizes the diagnosis of treatable tumors at an early stage but minimizes the number of “unnecessary” biopsies and therapeutic interventions is a complex business that doesn’t always give the clear-cut answers that our commenter clearly wants.
Compounding the difficulty is that it is very difficult to convince patients and even most physicians that, if we can detect disease at ever lower thresholds that we shouldn’t and that if we can treat cancer at ever earlier time points or ever smaller sizes that we shouldn’t. Moreover, the answer will also not be the same for all tumors. Remember, cancer is not a single disease, but rather a collection dozens, if not hundreds, of diseases. For some tumors (pancreatic cancer, for instance), clearly we need to do better at early detection, but for others (perhaps prostate cancer and breast cancer) spending ever more money and effort to find disease at an earlier time point will yield ever decreasing returns and may even lead to patient harm. It is likely that each individual tumor will have a different “sweet spot,” where the benefits of detection most outweigh the risks of excessive intervention. Similarly, different tumors require different clinical trial designs to rule out the effects of the various biases discussed in this post. Contrary to what our commenter says, it is not only possible to find each sweet spot in terms of early detection versus overtreatment and sorting out the effects of confounding biases, it is imperative that we do so. It’s just that doing so is far more difficult than the frequently simplistic slogans urging more early detection or attacks on “conventional” oncology as not curing anyone because “most cancers don’t progress” would suggest.

The uncertainty surrounding mammography continues
David Gorski on July 13, 2015
Link

Mammography is a topic that, as a breast surgeon, I can’t get away from. It’s a tool that those of us who treat breast cancer patients have used for over 30 years to detect breast cancer earlier in asymptomatic women and thus decrease their risk of dying of breast cancer through early intervention. We have always known, however, that mammography is an imperfect tool. Oddly enough, its imperfections come from two different directions. On the one hand, in women with dense breasts its sensitivity can be maddeningly low, leading it to miss breast cancers camouflaged by the surrounding dense breast tissue. On the other hand, it can be “too good” in that it can diagnose cancers at a very early stage.
Early detection isn’t always better
While intuitively such early detection would seem to be an unalloyed Good Thing, it isn’t always. Although screening for early cancers appears to improve survival, the phenomenon of lead time bias can mean that detecting a disease early only appears to improve survival even if earlier treatment has no impact whatsoever on the progression of the disease. Teasing out a true improvement in treatment outcomes from lead time bias is not trivial. Part of the reason why early detection might not always lead to improvements in outcome is because of a phenomenon called overdiagnosis. Basically, overdiagnosis is the diagnosis of disease (in this case breast cancer but it is also an issue for other cancers) that would, if left untreated, never endanger the health or life of a patient, either because it never progresses or because it progresses so slowly that the patient will die of something else (old age, even) before the disease ever becomes symptomatic. Estimates of overdiagnosis due to mammography have been reported to be as high as one in five or even one in three. (Remember, the patients in these studies are not patients with a lump or other symptoms, but women whose cancer was detected only through mammography!) Part of the evidence for overdiagnosis includes a 16-fold increase in incidence since 1975 of a breast cancer precursor known as ductal carcinoma in situ, which is almost certainly not due to biology but to the introduction of mass screening programs in the 1980s.
As a result of studies published over the last few years, the efficacy of screening mammography in decreasing breast cancer mortality has been called into question. For instance, in 2012 a study in the New England Journal of Medicine (NEJM) by Archie Bleyer and H. Gilbert Welch found that, while there had been a doubling in the number of cases of early stage breast cancer in the 30 years since mass mammographic screening programs had been instituted, this increase wasn’t associated with a comparable decrease in diagnoses of late stage cancers, as one would expect if early detection was taking early stage cancers out of the “cancer pool” by preventing their progression. That’s not to say that Bleyer and Welch didn’t find that late stage cancer diagnoses decreased, only that they didn’t decrease nearly as much as the diagnosis of early stage cancers increased, and they estimated the rate of overdiagnosis to be 31%. These results are in marked contrast to the promotion of mammography sometimes used by advocacy groups. Last year, the 25 year followup for the Canadian National Breast Screening Study (CNBSS) was published. The CNBSS is a large, randomized clinical trial started in the 1980s to examine the effect of mammographic screening on mortality. The conclusion thus far? That screening with mammography is not associated with a decrease in mortality from breast cancer. Naturally, there was pushback by radiology groups, but their arguments were, in general, not convincing. In any case, mammographic screening resulted in decreases in breast cancer mortality in randomized studies, but those studies were done decades ago, and treatments have improved markedly since, leaving open the question of whether it was the mammographic screening or better adjuvant treatments that caused the decrease in mortality from breast cancer that we have observed over the last 20 years.
Given that it’s been a while since I’ve looked at the topic (other than a dissection of well-meaning but misguided mandatory breast density reporting laws a month ago), I thought now would be a good time to look at some newer evidence in light of the publication of a new study that’s producing familiar headlines, such as “Mammograms may not reduce breast cancer deaths“.
Here we go again.
An ecological study of mammography and breast cancer
The study that produced a brief flurry of the usual headlines last week was published in JAMA Internal Medicine a week ago by Harding et al, “Breast Cancer Screening, Incidence, and Mortality Across US Counties“. It was a collaborative effort from doctors Seattle, Harvard University, and Dartmouth. One disclosure that I have to make here is that one of the authors is H. Gilbert Welch, whose studies I (and others) have discussed here before on multiple occasions. Back then, however, I had had little contact with him. Now, however, I must disclose that I am working on a brief commentary on cancer screening with him and another coauthor. However, I had nothing to do with the study under discussion. Thus endeth the disclosure.
So what did the study do? In concept, the study is very simple in design, although carrying out such a study is devilishly difficult. To boil down the concept of the study to a single question, the investigators asked whether differences in rates of screening mammography correlate with differences in breast cancer mortality. In other words, does a high frequency of screening correlate with lower breast cancer mortality and vice-versa? To accomplish this, the authors used the Surveillance, Epidemiology, and End Results (SEER) database to perform an ecological study of 16 million women aged 40 or older who resided in 547 counties reporting to the database. The study covered a period from January 1, 2000 to December 31, 2010 and included 16 million women, of which 53,207 were diagnosed with breast cancer and followed for the next ten years, a population that is drawn from approximately one quarter of the US population. The extent of screening in each county was assessed as the percentage of included women who underwent screening mammography within the last two years. The main outcomes were breast cancer incidence in 2000 and incidence-based breast cancer mortality during the ten year followup. These were calculated for each county and age-adjusted to the US population. Incidence-based mortality was chosen as the endpoint because it excludes cancers diagnosed before the study period and is insensitive to overdiagnosis.
Here is the schema for how subjects were chosen:
The not-unexpected, and unexpected results
So what were the results? Not unexpectedly, there was a positive correlation between the extent of screening and breast cancer incidence. This is not in the least bit surprising, and, in fact, I would have been surprised if this result was not found. Basically, an absolute increase of 10 percentage points in the extent of screening was associated with 16% more breast cancer diagnoses. This increase in detection of breast cancer, unfortunately, was not associated with a decline in breast cancer incidence-based mortality. A picture is, as they say, worth 1,000 words, and here’s the “money” figure, so to speak:
Notice how there is a correlation between incidence and increasing percentage of women 40 and older who received mammography during the previous two years, but there is no correlation between the percent screened and 10-year incidence-based mortality from breast cancer. I realize that this looks like what we sometimes call a “star chart,” but for population-level data like this the correlation between percent screened is striking; equally striking is the lack of correlation between percent screened and mortality.
Next, the authors stratified the data based on tumor size, to determine whether screening had more of an effect on small versus large tumors, the cutoff being 2 cm in diameter. The reason that cutoff was likely chosen is because tumors less than 2 cm in diameter are considered stage I (assuming negative axillary lymph nodes), while tumors greater than 2 cm are at least stage II. Consistent with the results reported in the 2012 NEJM study, the effect of mammography was more marked on smaller tumors, with a 10% increase in mammography screening associated with a 25% increase in the incidence of small tumors and only a 7% increase in the incidence of larger tumors. Of note, no decrease in the incidence of larger tumors was observed associated with screening mammography, again contrary to what one would predict based on the hypothesis that early detection prevents the presentation of disease at later stages because, or so it is presumed, early detection results in treatment of early stage tumors that decreases the number of tumors that make it to later stages before being detected.
Finally, the authors looked at disease stage and extent of surgery. The reason they did this is because one rationale for mammography is that, even if early detection doesn’t have much of an effect on incidence-based mortality, at least treating such cancers earlier allows women to undergo less invasive, less aggressive therapy. Here the results are somewhat mixed. The authors reported that a 10 percentage point increase in screening is associated with an increased incidence of early disease (stages 0-II) but no change in the incidence of locally advanced and metastatic disease (stages III and IV). That’s consistent with what they found in their first analysis and what Welch found in 2012. The authors also found that a 10 percentage point increase in screening is indeed associated with more breast-conserving surgical procedures (lumpectomy) but that there is no concomitant reduction in mastectomies. In other words, putting it all together, I’d describe this result as finding that all the additional breast-conserving surgery went towards the excess early stage cancer found by screening.
The authors conclude:
For the individual, screening mammography should ideally detect harmful breast cancers early, without prompting overdiagnosis. Therefore, screening mammography ideally results in increased diagnosis of small cancers, decreased diagnosis of larger cancers (such that the overall risk of diagnosis is unchanged), and reduced mortality from breast cancer. Across US counties, the data show that the extent of screening mammography is indeed associated with an increased incidence of small cancers but not with decreased incidence of larger cancers or significant differences in mortality. In addition, although it has been hoped that screening would allow breast-conserving surgical procedures to replace more extensive mastectomies, we saw no evidence supporting this change.
And ask:
What explains the observed data? The simplest explanation is widespread overdiagnosis, which increases the incidence of small cancers without changing mortality, and therefore matches every feature of the observed data. Indeed, our cross-sectional findings are supported by the prior longitudinal analyses of Esserman et al29 and others,30,31 in which excess incidences of early-stage breast cancer were attributed to overdiagnosis. However, four alternatives are also logically possible: lead time, reverse causality, confounding, and ecological bias.
The authors do a convincing job of arguing that three out of four of these are not a major factor. For instance, lead time bias can become an issue in counties where screening had recently increased as cancer diagnoses are advanced in time, as they describe in the supplement:
Tumors in screened women are diagnosed earlier than tumors in unscreened women. It is not known exactly how much advanced notice (lead time) is provided by mammography screening. If mammography screening results in long lead times, then breast cancer incidence should increase when more women are screened. For example, suppose a woman receives her first screening today, and the screening detects a breast tumor that otherwise would not have been detected for another two years. Accordingly, the incidence of breast cancer would be increased today, and would also be decreased two years from now.
By examining correlations between screening frequency in counties at different time points in counties that had recently increased their rates of screening, they failed to find an effect that could be attributed to lead time bias. Using additional analyses, they were able to counter criticisms that the results they observed were due to confounders, such as differing incidences of breast cancer in various counties that might lead to increased emphasis on screening (reverse causality) or because risk factors for breast cancer happen to be associated with screening.
Epidemiology and the “ecological fallacy”
But what about the ecological fallacy? In epidemiology, the word “ecological” has quite a different meaning than it does in biology or every day colloquial usage. Most medical studies are done at the level of the individual. In other words, data are gathered for each individual, such as risk factors, diagnosis, age and other demographic factors, treatment, and outcome; the individual is the unit of analysis. In contrast, in an ecological study, data are collected at the group level, and the group is the unit of analysis. In the current study, data were collected at the county level and the unit of analysis was the population of each county assessed. This can be a problem.
The term “ecological fallacy” was first coined by the sociologist H.C. Selvin in 1958, but the perils of imputing correlations found in groups to the individuals composing them have been known at least since 1938, when psychologist Edward Thorndike published a paper entitled, “On the fallacy of imputing the correlations found for groups to the individuals or smaller groups composing them”. Basically, relative risks detected by ecological analyses can be magnified upwards by many-fold, the cause being a greater sensitivity to problems such as model misspecification; confounding; non-additivity of exposure and covariate effects (effect modification); exposure misclassification; and non-comparable standardization.
As the authors point out in their supplement, ecological biases arise because values that are identified for individuals are aggregated before analysis, resulting in a loss of information, particularly when the aggregation takes place at a larger scale. They also concede that ecological biases can’t be completely ruled out without access to individual-level data, but they did their best, taking note that one warning sign of ecological bias is seen when the results of an analysis vary based on the population of each county analyzed. Counties with larger populations would be expected to show more ecological bias than counties with smaller populations, but this was not seen. As the authors point out, similar relationships between screening and incidence were found regardless of whether the counties included 5,000, 50,000, or 500,000 women, and there was no significant relationship between screening and 10-year mortality from breast cancer in any of them. While this analysis doesn’t rule out ecological biases (again, only access to individual-level data can do that), it does reassure that there were no obvious warning signs that such a bias was creeping in. The authors also note that, in essence, you can’t get away from ecological analyses when trying to estimate rates of overdiagnosis, because “overdiagnosis is currently not observable in individuals, only in populations,” which is quite true, citing a recent comparison of methods for estimating overdiagnosis that concluded that “well conducted ecological and cohort studies in multiple settings are the most appropriate approach for quantifying and monitoring overdiagnosis in cancer screening programs.”
A usual suspect chimes in
Not unexpectedly, a radiologist whom we’ve met before chimed in almost immediately in his usual inimitable fashion. I’m referring, of course, to Dr. Daniel Kopans, Director of Breast Imaging at Massachusetts General Hospital and outspoken—to say the least!—mammography advocate. Predictably, he didn’t take long at all to come up with one of his bombast-filled criticisms that he is so well-known for in which he imputes dishonest motives to those with whom he has a scientific disagreement, a character trait that both amuses and annoys because he himself is so sensitive to criticism. In this case, his attack is even more off-base than usual. Indeed, I’m going to go straight to the paragraph in his response to Harding et al that shows that Dr. Kopans almost completely missed the point of Harding et al:
One also has to wonder what the authors have done with the data. Between 2000 and 2010 (10 years of follow-up), the SEER breast cancer death rate fell from 26.6 deaths per 100,000 women to 21.9 deaths per 100,000 women — a decline of 18% (almost 2% per year), yet the authors claim there was no decline in deaths over the same period using SEER data. Something is wrong. This should have been recognized by the peer review and the fundamental discrepancy addressed.
Puzzled by this particular criticism, I actually looked through the paper again to find where the authors made the claim that breast cancer mortality had not decreased from 2000 to 2010. I failed to find it. In any event, what Dr. Kopans is criticizing is not the analysis the authors did. They did not look at whether the death rate from breast cancer fell over the ten years of the study. What they did was to look at one year! That year was 2000. They then analyzed the rates of mammography uptake in each county for that year and compared them with the ten year mortality. I mean, bloody hell! It’s right there in the abstract:
Breast cancer incidence in 2000 and incidence-based breast cancer mortality during the 10-year follow-up. Incidence and mortality were calculated for each county and age adjusted to the US population.
The primary measure was not breast cancer mortality over time, so there was no reason to point out that breast cancer mortality declined between 2000 to 2010. But they did anyway. In the supplemental data, the authors did note that breast cancer mortality has been declining, observing, “As breast cancer mortality has been decreasing since 1990,4 there is no reason to suspect that breast cancer mortality in future years will exceed breast cancer mortality in 2000.” In any case, in this study the primary measure was ten year mortality of a cohort from a single year, the year 2000, who were diagnosed with breast cancer in that year. That’s why the SEER database had to be examined to 2010. Thus, this particular criticism by Dr. Kopans is irrelevant to the study and is so egregiously wrong that it is tempting to use it to invalidate everything else he wrote.
Hints, allegations, and things that should have been left unsaid
Also note how, here and throughout the article, Dr. Kopans insinuates that the authors did something dishonest. He’s perhaps a little less blatant about insinuating scientific fraud than he used to be (perhaps he learned his lesson from his previous similar insinuations about the CBNSS), but to Dr. Kopans, the authors aren’t just wrong, but dishonest or at least so ideologically motivated that they don’t care. Don’t believe me? Look at his very first paragraph:
The ploy used by Harding et al in their new study is classic. Explain why using your approach is scientifically unsupportable, and then go ahead and use it claiming there is no alternative.
Also note the part where he claims that studies like this are “being used to reduce access to screening,” even going so far as to put the word “studies” in scare quotes. This is a common theme in Dr. Kopans’ oeuvre with respect to mammography, as well as that of various radiology groups: That there is a coordinated attack by anti-mammography ideologues out there who want to take away women’s access to mammography and don’t care that (if you believe Kopans’ claims) thousands will die unnecessarily as a result. Indeed, I frequently quote Dr. Kopan’s famous statement about the 2012 Bleyer and Welch NEJM study:
This is simply malicious nonsense,” said Dr. Daniel Kopans, a senior breast imager at Massachusetts General Hospital in Boston. “It is time to stop blaming mammography screening for over-diagnosis and over-treatment in an effort to deny women access to screening.”
Here’s what he said after the USPSTF task force recommended against routine mammographic screening of 40-49 year old women in 2009:
Asked for a possible reason why the task force would ignore expert opinion, Dr. Kopans told Medscape Radiology that there is a nucleus of people who have long been opposed to mammography.
“I just got some updated information that they were involved with the task force. I hate to say it, it’s an ego thing. These people are willing to let women die based on the fact that they don’t think there’s a benefit.”
One notes that if “they” don’t think there’s a benefit, then “they” don’t think they’re consigning thousands of women per year to die, as Dr. Kopans does. Consistent with these positions, Dr. Kopans goes on the attack again in his response to this most recent study:
The claim of massive overdiagnosis of invasive cancers has been manufactured. No one has ever seen an invasive breast cancer disappear on its own, yet it has been claimed there are tens of thousands each year. When we looked directly at patient data, we found that more than 70% of the women who died of breast cancer in major Harvard Medical School teaching hospitals were among the 20% of women who were not participating in screening.3
Note the word choice: “Manufactured.” Once again, he is imputing dishonest—or at least ideologically biased—motives to those with whom he disagrees.
What Dr. Kopans won’t admit is that the result of the study he cites has numerous weaknesses, in particular a bias towards younger women with more aggressive cancers (not unexpected in a tertiary care hospital) who, not surprisingly, would be less likely to have been screened, as well as the simple observation that, by definition, overdiagnosis can’t occur in women who die of breast cancer. Be that as it may, Dr. Kopans concludes:
Enough is enough. The effort to reduce access to screening has been relentless by a small group that has continued to use specious arguments and scientifically flawed analyses to support their agenda. At some point, peer reviewers need to read more carefully and stop the publication of scientifically unsupportable and misleading material.
My retort is that, at some point, scientists need to call out Dr. Kopans for so frequently assuming that those who disagree with him do so out of less than honorable motives. I don’t even make that assumption for most leaders of the antivaccine movement, who, though profoundly wrong, are motivated by what they mistakenly believe to be an evil that must be opposed. I realize that Dr. Kopans really does appear to believe that those who do studies that conclude that mammography might not be as effective at preventing deaths from breast cancer as he believes it to be are monsters willing to lie and twist science to deny women mammography, but such is not the case. For example, does Dr. Kopans really think that the authors of the CNBSS wanted their study to find that screening did not save lives? Of course they didn’t! Scientists don’t start large, expensive, multi-institutional studies hoping for a negative result! They just don’t! They’re too much work and require too many resources. Worse, any time Dr. Kopans is called out for assuming the worst about physicians and scientists with whom he disagrees, he disingenuously assumes an attitude of, “Who me? I never accused anyone of that.”
One also can’t help but notice that in their paper Harding et al bend over backwards to be clear and up front about the limitations of their study, particularly the ecological fallacy. That’s just good science. It’s also what Dr. Kopans turns into a weapon to try to discredit the entire study. Finally, the usual error that results from the ecological fallacy is the tendency to find associations that don’t exist or to overestimate associations that do exist. Consequently, the most probable error in Harding et al is to have overestimated the association between screening and breast cancer diagnoses, which makes the negative finding with respect to mortality stand out all the more.
The bottom line: Breast cancer screening is not simple
It must be re-emphasized that Harding et al is just one study among many. Although it reinforces the growing consensus that mammographic screening leads to significant overdiagnosis, it is nowhere near the final word. Indeed, there is a much more measured commentary on the study published alongside it by Joann G. Elmore, MD, MPH and Ruth Etzioni, PhD at the Fred Hutchinson Cancer Research Center. Elmore and Etzioni express proper caution at interpreting the results of ecological studies, noting:
Most scientists now acknowledge that there is some level of overdiagnosis in breast cancer screening, but the frequency of overdiagnosis has not been conclusively established. Estimates in the literature cover a frustratingly broad range, from less than 10% to 50% or more of breast cancer diagnoses. Published studies of overdiagnosis vary widely not only in their results but also in their populations, methods, and measures.4 In practice, the frequency of overdiagnosis is likely quite different for DCIS and invasive tumors.
Sadly, we are left in a conundrum. Women will increasingly approach their physicians with questions and concerns about overdiagnosis, and we have no clear answers to provide. We do not know the actual percentage of overdiagnosed cases among women screened, and we are not able to identify which women with newly diagnosed DCIS or invasive cancer are overdiagnosed. Many screening guidelines now mandate shared and informed decision making in the patient-physician relationship, but this is not an easy task.
Indeed, it is not, particularly when data conflict. For example, just last month, the World Health Organization through its International Agency for Research on Cancer (IARC) published new recommendations on screening mammography. After considering older randomized clinical trials and voicing some skepticism over whether they are still relevant, the IARC examined evidence from 20 cohort and 20 case-control studies, all conducted in the developed world (Australia, Canada, Europe, or the United States) that they considered informative for evaluating the effectiveness of mammographic screening programs. Based on its analysis, the IARC notes that screening mammography could be associated with as much as a 40% reduction in the risk of dying from breast cancer and concluded:
After a careful evaluation of the balance between the benefits and adverse effects of mammographic screening, the working group concluded that there is a net benefit from inviting women 50 to 69 years of age to receive screening. A number of other imaging techniques have been developed for diagnosis, some of which are under investigation for screening. Tomosynthesis, magnetic resonance imaging (MRI) (with or without the administration of contrast material), ultrasonography (handheld or automated), positron-emission tomography, and positron-emission mammography have been or are being investigated for their value as supplementary methods for screening the general population or high-risk women in particular.
However, the IARC also cautioned about the risks of mammography, including overdiagnosis. Interestingly, its estimate of overdiagnosis, ranging from 4-11%, was lower than most I have seen.
Unfortunately, there remains a large contingent of radiologists who, like Dr. Kopans, believes that overdiagnosis either does not exist or is such a small problem as not to be worth the consideration it is currently receiving. Fortunately, that appears to be changing. For instance Academic Radiology‘s 2015 issue will center around the theme of overdiagnosis, and several of the articles have already been published electronically ahead of release of the issue, such as this one by Archie Bleyer updating Bleyer and Welch’s 2012 NEJM article, a commentary by H. Gilbert Welch,” Responding to the Challenge of Overdiagnosis“, and an article by Saurabh Jha, an academic radiologist, “Barriers to Reducing Overdiagnosis“, the last of whom notes that the first steps in reducing overdiagnosis are to admit that overdiagnosis occurs. I couldn’t have said it better myself and I might very well be blogging about these in the future.
Implications for primary care and beyond
It’s not just radiologists, either, who seem to have a problem with the concept of overdiagnosis. I’m frequently surprised at how few primary care physicians and even oncologists, both medical and surgical, “grok” the concepts of overdiagnosis, lead time bias, and length bias in screening for asymptomatic diseases, especially cancer. Examples of this misunderstanding sometimes even appear in the lay press; for example, this a doctor accusing the New York Times of “killing” his patient because it published news stories about studies questioning the value of PSA screening. It’s also true that the lay public assumes that early diagnosis is always better, damn the consequences. How are they to be educated if we physicians do not adequately understand the complexities and tradeoffs involved in screening ourselves?
Although Dr. Kopans has implied that I belong to the evil cabal of anti-mammography ideologues against whom he regularly does battle, I actually still recommend screening mammography for my patients 50 and over. The reason is simple. I still believe it offers benefits in terms of reducing the risk of dying from cancer, albeit benefits more modest than I used to believe. However, I also point out the potential harms now. For women aged 40-49, I’m much less dogmatic than I used to be. If there’s high risk due to family history or other factors, I will more strongly recommend screening, but if there isn’t I will tell them about screening, explaining the potential benefits and risks, and then more or less leave it up to the patient. Of course, you need to realize that most of my patients already have breast cancer or have had breast cancer, which makes them high risk for developing another breast cancer, even if they are under 50; I don’t see too many 40-something year old women just asking about screening.
We can overcome the problems of overdiagnosis and overtreatment due to cancer screening. Developing better screening tests will not be sufficient to achieve this end, however. What will be required is the development of predictive tests that tell us which lesions found on mammography or future screening tests are likely to progress within the patient’s lifetime to cause death or serious harm and which are unlikely to do so. Such information would allow us to stratify cancers into those that need to be treated promptly and those that can safely undergo “watchful waiting.” This will not be an easy task. In the meantime, we do the best we can with the data that we have—and its uncertainty.

The American Cancer Society’s new mammography guidelines: Déjà vu all over again
David Gorski on October 21, 2015
Link

One of the things that feels the weirdest about having done the same job, having been in the same specialty, for a longer and longer time is that you frequently feel, as the late, great Yogi Berra would have put it, déjà vu all over again. This is particularly true in science and medicine, where the same issues come up again and again and again, often with the same arguments on either side. Sometimes the same players are even involved. So it is with mammography recommendations. Indeed, I’m feeling déjà vu all over again right now, as I read headlines like “Women advised to get mammograms later, less often“, “American Cancer Society, in a Shift, Recommends Fewer Mammograms“, and “ACS: Breast cancer screening should begin at age 45“. What provoked these headlines was a major revision in the American Cancer Society’s recommendation for mammographic screening for breast cancer in women at average risk of the disease. In a seeming replay from 2009, when the United States Preventative Services Taskforce (USPSTF) sent shockwaves through the breast cancer world by recommending that most women not start mammography until age 50 and then only to have it done every two years instead of every year, the American Cancer Society (ACS) has now just similarly ratcheted back its recommendations for screening mammography, just not as much as the USPSTF did. The new recommendations were communicated in a special communication published by JAMA on Tuesday.
What changed regarding mammography recommendations
Before we get to the issues, how, specifically, did the ACS change its mammography recommendations? Before this change, the ACS basically recommended the same thing that most other American professional societies dealing with breast cancer did: yearly mammography starting at age 40 for the rest of a woman’s life. The new guidelines now recommend that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years and continuing annually until age 54. From age 55 and older, the ACS recommends that women transition to every two years. (More details below.) As I Tweeted when I saw these recommendations, basically it appears that the ACS has more or less split the difference between the old recommendations and the USPSTF recommendations.
So why is the ACS changing its recommendations? And what does this say about the science and our values regarding cancer screening? If you’ve been reading this blog, you know that over the last several years there has been a steady drip, drip, drip of studies that range from highlighting the downside of widespread mammographic screening to downright questioning the value of mammography. That’s why I’ve been discussing rethinking screening for breast cancer since at least 2008. Basically, you can go back and read my old posts and, if you have a lot of time and are enough of a glutton for punishment to read them all, watch the evolution of my thinking about breast cancer screening over the last seven years.
Back in the day, I used to fully support breast cancer screening beginning at age 40 and proceeding yearly throughout. As I examined more and more of the evidence, I became less enthusiastic about screening so intensely and started to believe that starting at 40 was too young for most women. Indeed, I was probably the only breast cancer doctor at my cancer center in 2009 who supported the USPSTF recommendations when they were announced, which led to some—shall we say?—interesting discussions about what should be said to the press and what a press release our cancer center wanted to release ASAP should actually say. I also got myself into a little…trouble…for criticizing colleagues in radiology—not from my institution, I hasten to add!—for some rather blatant turf protection. Let’s just say that a prominent radiologist, one who’s achieved far more renown in his field than I ever have in mine, was most displeased with some of my commentary and let me know about it. I found this displeasure odd, given that I am most definitely not a nihilist with respect to mammography screening (and, make no mistake, there are quite a few of those out there these days). I’m just a lot more balanced and aware of its limitations than I used to be. On the other hand, I did call him out for some of his more obnoxious comments that implied that those who question mammography are cackling gleefully at the thought of more women dying of breast cancer. Interestingly, I don’t seem to get asked to contribute to such press releases that much anymore, but in fairness neither do most of the other breast cancer clinicians I work with; so I probably can’t blame it on my previous outspokenness.
What brought me to this point is an increasing understanding of the concepts of overdiagnosis and lead time bias, coupled with a string of studies that show more modest benefits (and, in one case, no benefit) from screening mammography. To be honest, the attack dog reaction by some mammography supporters to some of these negative studies also set my skeptical antennae a’twitchin’ as well.
Overdiagnosis: Driving change in screening guidelines
So what is overdiagnosis? I’ve discussed it many times before, but it’s a concept relevant to any program in which masses of asymptomatic people are screened for a disease with a test. I like to boil the concept down to the idea that the harder you look for something (in this case, a disease), the more of it you will find. The problem is that some of what you find will be disease that either won’t progress or is so slow-progressing that it would never threaten the life of the patient or cause her major problems. In essence, such discovered disease does not need treatment, but it’s treated anyway if discovered by screening. It has to be, because, unless doctors have a way of determining whether a disease will progress, they’re morally obligated to treat it as though it will progress. This is true for breast cancer. Indeed, there is evidence that as many as one in three mammography-detected breast cancers are overdiagnosed and that as many as one in five can spontaneously regress. Granted, other estimates are lower which adds a large degree of uncertainty to these discussions, but it is clear that overdiagnosis is a major problem, radiology societies’ tendency to deny it notwithstanding.
Nowhere is the problem of overdiagnosis of breast cancer as acute as it is for the entity known as ductal carcinoma in situ (DCIS). DCIS is basically defined as cancerous cells in the breast ducts that have not yet broken out of the ducts to invade the surrounding breast tissue. As I’ve discussed before, it’s not clear whether we should consider DCIS cancer, precancerous, or something else. It’s clear that a significant percentage of DCIS will ultimately progress to breast cancer, but we don’t yet have reliable tests to determine which DCIS will and which will not progress to cancer. Here’s where the overdiagnosis comes in. Back before the 1970s, DCIS used to be a very uncommon diagnosis because by the time DCIS forms a mass there is usually invasive cancer in it as well. However, between the 1970s and 2000s, the incidence of DCIS increased by more than 16-fold. Does anyone think that the incidence of DCIS really increased that much in such a short period of time, a mere three decades? Of course not. We’re just finding a lot more of it. Unfortunately, a significant fraction of it is overdiagnosed and, inevitably, overtreated, even though a recent study has called into question our aggressive treatment of DCIS.
Another issue that confounds the correlation between finding cancer early and decreased mortality is lead time bias. Basically, lead time bias is a phenomenon in which the early detection of cancer leads to an apparent increase in cancer survival even if early detection has no effect whatsoever in the progression of the disease. Because disease is detected earlier, the time from detection to when the disease would have become symptomatic is added to the time from symptoms to death to produce this inflated survival rate. It takes careful study design to tease out whether an improvement in survival is due to lead time bias or a real treatment effect. For more information, read this classic brief explanation of this phenomenon. Another problem is length bias, which is the tendency of screening tests to detect slowly progressing (and therefore likely less aggressive) disease while still asymptomatic. Sharon Begley summarizes the difficulties thusly:
It turns out that some cancers detected by mammograms would never have posed a threat to a woman’s health or life. Others are so slow-growing that even if they’re not detected until they cause symptoms, they’re treatable. Still others are so aggressive that even catching them “early” is too late. In these situations, mammograms therefore have little effect on whether a woman will die of breast cancer.
The ACS recommendations
With these confounders in mind, let’s take a look at the ACS analysis, which is was published in JAMA in the form of a communication laying out the guidelines and their rationale, a systematic review of the benefits and harms of mammography, and an accompanying editorial. The systematic review found that screening was associated with a reduction in breast cancer mortality of around 20%, which is consistent with a lot of previous data. Basically, the ACS incorporated standards recommended by the Institute of Medicine into its guidelines development protocol “to ensure a more trustworthy, transparent, and consistent process for developing and communicating guidelines.” It selected the Duke University Evidence Synthesis Group to conduct an independent systematic evidence review of the breast cancer screening literature in response to a request for proposals, a process it referred to as the evidence review. In addition, the ACS commissioned the Breast Cancer Surveillance Consortium (BCSC) to update previously published analyses of screening intervals and outcomes. The methods were described thusly:
In accordance with the new guideline development process, the ACS organized an interdisciplinary guideline development group (GDG) consisting of clinicians (n = 4), biostatisticians (n = 2), epidemiologists (n = 2), an economist (n = 1), and patient representatives (n = 2). The GDG developed 5 key questions using the general approach of specifying populations, interventions, comparisons, outcomes, timing of outcomes, and settings (PICOTS) for each question. After evaluating available methods to grade the evidence and the strength of recommendations, the GDG selected the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system. GRADE is an accepted approach with a defined analytic framework, an explicit consideration of values and preferences in addressing patient-centered outcomes, the capacity for flexibility in evaluating results from observational studies, and separation between quality of evidence and strength of recommendation.
Prior to the ACS submitting its final guidelines for publication, it had them externally reviewed by 26 relevant outside organizations and 22 expert advisors.
For purposes of the review, the ACS considered “average risk” to mean (1) women without a personal history of breast cancer; (2) without a confirmed or suspected mutation that increases the risk of breast cancer (e.g. BRCA1); or (3) a history of previous radiation therapy to the chest at a young age. Studies examined included:
    • Controlled studies, including RCTs, pooled patient-level meta-analyses, systematic reviews, and study-level meta-analyses.
    • Observational studies (prospective and retrospective cohort studies, incidence-based mortality studies, case-control studies, or cross-sectional studies) published since 2000 that included 1000 or more average-risk women.
    • Modeling/simulation studies, because these studies may be the only way to generate estimates of long-term outcomes associated with screening that are not adequately addressed by the RCTs or using modern technology and protocols.
The key innovation in the approach used by the ACS is that, for purposes of estimating risk-benefit ratios, it broke down breast cancer risk not into ten year age intervals, but five year intervals instead. I’ve explained time and time again that the benefits of screening depend upon the prevalence of a disease being screened for in the population being screened. The lower the prevalence, the more likely screening will result in false positives and overdiagnosis. Also, the lower the prevalence of the disease, the fewer women screened who will potentially benefit. For young women, this is particularly true. Here is the relevant age distribution for breast cancer (click to embiggen):

And this is the breast cancer incidence by five-year age groups (click to embiggen):

As you can see, for women below the age of 35 breast cancer risk is very low but rapidly climbs with age. It’s also a continuous curve, but recommendations usually have to be concrete and pick a cutoff age (or ages). As I like to explain whenever the topic of mammography comes up, why not screen beginning at age 20? Why not make that, or 30, the cutoff age to begin screening in average risk women? This table shows why. The risk of breast cancer is so low at age 20 that in essence virtually all findings will be false positives or overdiagnosis. That’s why not even the most outspoken advocates of mammography recommend screening 20 years olds—or even 30 year olds. Obviously, when we get to the 40-50 year age range is when we enter the gray area.
In any case, the ACS ranked its recommendations thusly, with “strong” meaning the group reached consensus that the benefit of the intervention outweighs the harm and “qualified” meaning that there is clear evidence of benefit but less certainty about the balance of risks and benefits. These are the results:
     1.  Women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years. (Strong Recommendation); 1a. Women aged 45 to 54 years should be screened annually. (Qualified Recommendation); 1b. Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually. (Qualified Recommendation); 1c. Women should have the opportunity to begin annual screening between the ages of 40 and 44 years. (Qualified Recommendation)
     2.  Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. (Qualified Recommendation)
     3.  The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age. (Qualified Recommendation)
These recommendations are qualified by a further recommendation that women “should have the opportunity to begin annual screening between the ages of 40 and 44 years,” presumably if that’s what they and/or their doctors want and that women 55 and older who want to keep screening annually should be able to, again, if that’s what they and their doctors want. Overall, as I mentioned above, to me these recommendations come across as “splitting the difference” between the USPSTF recommendations and older recommendations.
One surprising recommendation is the ACS statement that clinical breast examinations (CBE) are not recommended for average-risk women as a qualified recommendation. Here’s the rationale:
Previous guideline recommendations for routine CBE have acknowledged the limitations in evidence. For Key Question 3, the evidence review found a lack of evidence showing any benefit of a CBE alone or in conjunction with screening mammography. There is moderate-quality evidence that adding CBE to mammography screening increased the false-positive rate. No studies were identified assessing other critical outcomes. A supplemental search identified studies on CBE performance characteristics, most of which show that the addition of CBE will detect a small number of additional breast cancers (ie, 2%-6%) compared with mammography alone.93- 95 There are no data on whether patient outcomes are improved with CBE. Given the lack of benefit concurrent with the increase in false-positive rates, CBE is not recommended for breast cancer screening among average-risk, asymptomatic women at any age. Recognizing the time constraints in a typical clinic visit, clinicians should use this time instead for ascertaining family history and counseling women regarding the importance of being alert to breast changes and the potential benefits, limitations, and harms of screening mammography.
This recommendation would not affect my practice, because by definition any woman referred to me is suspected of having breast disease, either benign or malignant; so a clinical examination is warranted. It is clearly directed more at primary care physicians, who, after all, do the vast majority of breast cancer screening and refer patients with positive findings to the relevant specialists. Nor would this apply to women who have had breast cancer and are undergoing follow-up after treatment.
Putting things in perspective
Whenever looking at screening guidelines, I always find that it helps to put things in perspective by looking at absolute numbers rather than percentages. Sure, it’s great to say that mammography results in a 15-20% reduction in breast cancer mortality, but what does that really mean? In the accompanying editorial, Nancy L. Keating and Lydia E. Pace point out:
As clinicians embark on shared decision making about breast cancer screening with their patients, several key messages are worth highlighting. First, the vast majority of women who are diagnosed with breast cancer will do well regardless of whether their cancer was found by mammography. For women in their 40s and 50s, randomized trial evidence suggests that screening mammography modestly decreases breast cancer mortality by approximately 15%. Although more recent observational studies may suggest a larger benefit, given the methodologic limitations of such studies, it seems that the randomized trial estimates, while imperfect, are likely to be most accurate. Thus, about 85% of women in their 40s and 50s who die of breast cancer would have died regardless of mammography screening. More sophisticated screening tests that confer a greater reduction in breast cancer mortality would likely decrease breast cancer mortality much more than expanding screening mammography for women in their 40s and 50s.
Moreover, because the risk of breast cancer is low for women in their 40s and to some extent women in their 50s, the modest relative benefit of 15% translates to a very small absolute benefit (approximately 5 of 10 000 women in their 40s and 10 of 10 000 women in their 50s are likely to have a breast cancer death prevented by regular mammography).24 The absolute benefit will be higher for women with a higher absolute risk of breast cancer, underscoring the importance of identifying higher-risk women. Especially for average-risk women, decisions to undergo regular mammography screening must also consider the harms of mammography—most notably the possibility of overdiagnosis and resultant overtreatment (age-specific estimates of which are lacking) and also the risks of false positives and unnecessary biopsies (known to be greater in younger women and women screened more frequently).
As the JAMA article noted, overdiagnosis is the most severe harm caused by screening, because it results in overtreatment; i.e., women undergoing surgery, radiation, and sometimes even chemotherapy for a condition that would not endanger their lives. Unfortunately, estimates of overdiagnosis vary wildly, from 5% to as high as 50% of screen-detected cancers being overdiagnosed. Personally, my interpretation of the existing literature leads me to see the percentage of screen-diagnosed breast cancers that are overdiagnosed converging around 15-20%, but even that number has a lot of uncertainty. Indeed, even nearly 40 years since the advent of mass screening programs for breast cancer utilizing mammography, it is frustrating to note how much uncertainty remains over the benefits of mammography. One thing is for sure. Before the USPSTF recommendations were first announced, the risks of mammography were rarely discussed in the lay press. Now a more balanced discussion is taking place, and I consider this a good thing. It’s paternalistic to tell patients to undergo yearly screening beginning at 40 without giving them as clear an idea as we can of the risks and benefits of doing so compared to other options, such as starting at age 50 and/or screening less frequently.
The backlash
If there’s one thing I’ve noticed since 2009, it’s that the criticism of studies that find less benefit and/or more harm due to mammography than previously believed seems to be less intense than what greeted the USPSTF recommendations, which exploded like the proverbial bombshell in the national consciousness when they were announced and provoked harsh resistance from radiologists. At least this time around with the ACS recommendations, I have yet to see a radiologist claiming that we’ll be killing women, the way several prominent ones did in 2009. That’s not to say that they haven’t been critical:
Radiologists, who administer mammograms, blasted the new guidelines. “If a woman wants to reduce, as much as possible, her risk of dying of breast cancer, she will choose yearly mammography starting at age 40,” Dr. Debra Monticciolo of the American College of Radiology said in a statement.
As before, the American College of Radiology regurgitated its same old talking points, such as this:
While ACS states that transitioning to biennial screening is an option for older women, they note that either one or two year intervals would be appropriate as a woman ages. The ACR and SBI strongly encourage women to obtain the maximum lifesaving benefits from mammography by continuing to get annual screening.
If the ACS is correct (and I think it is) and screening every one or two years doesn’t matter after menopause, then what, I ask, are the “maximum lifesaving benefits” of mammography done every year in this age range?
Then there’s this:
“The ACS has strongly reaffirmed that mammography screening saves lives. The new ACS guidelines show that if a woman wants to reduce, as much as possible, her risk of dying of breast cancer, she will choose yearly mammography starting at age 40. A recent study in the British Medical Journal confirms this, showing that early detection of breast cancer is critical for improving breast cancer survival, regardless of therapy advances. Moving away from annual screening of women ages 40 and older puts women’s lives at risk,” said Debra Monticciolo, MD, FACR, chair of the American College of Radiology Breast Imaging Commission.
That particular BMJ study was an observational study that examined the Netherlands Cancer Registry for 173,797 breast cancer patients diagnosed between 1999 and 2012, subdivided into two time cohorts on the basis of breast cancer diagnosis: 1999-2005 and 2006-12. Not surprisingly, the study found that stage at diagnosis is still, even in this age of more effective chemotherapy, strongly correlated with survival: the higher the stage, the worse survival. Of course, as large a study as this was, its result was still about as “Well, duh!” a result as I can imagine, and the study mentions virtually nothing about mammographic screening or the potential effect of lead time bias that could contribute to apparent longer survival. In other words, it does not show that mammography decreases breast cancer mortality.
Finally, as usual, the ACR claims that estimates of overdiagnosis are “vastly overinflated due to key methodological flaws in studies,” while laying down howlers like this:
    • The overdiagnosis range is likely 1-10 percent and is principally due to ductal carcinoma in situ (DCIS)
    • Very few invasive cancers are over-diagnosed
    • NO evidence shows that an invasive cancer has ever gone away or shrank without treatment.
One notes that no studies are provided to support the claim that overdiagnosis is between 1%-10%. I also note that 10% would still be high, and the ACR seemingly allows for the possibility that overdiagnosis is that high. While it is probably true that most overdiagnosis is due to the detection of DCIS, I also note that there is considerable morbidity due to the overtreatment of women with DCIS. Doesn’t the ACR think that’s important, even if DCIS is unlikely to result in death? Women not-uncommonly undergo mastectomies for DCIS, and a recent study suggests that this intensive treatment does not decrease mortality from breast cancer. Finally, while it is true that there is no direct evidence showing that an invasive cancer has ever gone away, there is plenty of circumstantial evidence to show that some invasive cancers either do not progress or even regress.
Not content to use bad scientific arguments, the ACR even resorts to an anecdote of a woman who got her first mammogram at age 38. Of course, this wasn’t exactly a screening mammogram, as the woman was not really asymptomatic. She was concerned about pain and a bruise after being bumped by her child at a water park. The bruise concerned her enough that she made an appointment with her doctor, who was concerned enough to order a mammogram, in part because the woman was nearing 40. The mammogram found a cancer. Of course, we can all find outliers like this. I could point to women from my own practice over the last decade and a half who religiously got their mammograms every year and still were diagnosed with aggressive, nasty breast cancers. Anecdotes appeal to emotions; to make population-level decisions, we require as much objective data as possible.
Data alone, however, are not enough.
Mammographic screening: A value judgment
I criticize the ACR a lot for it history of bad arguments against any study that questions mammography or any new guidelines that suggest that we can do as well detecting cancer with less harm by starting screening later and/or doing it less frequently, and, yes, I do sometimes think there is an element of turf protection going on there. I also believe that these radiologists genuinely believe that they are doing great good. In other words, leaving aside turf, they value detection of breast cancer so much that the potential harms of mass mammographic screening are either downplayed or are considered to be a price worth paying for decreasing breast cancer mortality. I and others who have changed our minds about the intensity of mammographic screening, value reducing harm more, given the minuscule additional benefit that comes from more intensive screening compared to less intensive screening, and the price paid for that tiny additional benefit.
I’ve often said that the question of screening women for breast cancer is not just a scientific question. Science can provide estimates of sensitivity, specificity, the odds of decreasing death from breast cancer, the chances of harm through overdiagnosis and overtreatment, the risk of false positives, and other numbers needed to evaluate the usefulness of screening. What we in the medical profession and society do with these numbers is much more a matter of values than it is of science. Some advocate doing everything possible to decrease death from breast cancer; others are more sanguine about the potential harm in that approach. It all comes down to what we value and, yes, what we are willing to pay for as a society. It’s a debate that’s now been going on for decades. If you want to understand why I say I’m feeling déjà vu all over again, just read this NYT article from 1992 on whether screening should start at age 40 or 50.
Feeling it yet?
In terms of specific medical recommendations, how, exactly, do we balance the potential harms of a screening program like mammography with its known benefits? The ACS guidelines are just the latest attempt to answer that question. Indeed, both the ACS and USPSTF guidelines interpret a vast pool of messy evidence, emphasizing some pieces more than others and coming to slightly different conclusions. Their conclusions are actually remarkably similar to one another but still subject to considerable uncertainty. What individual patients do with these recommendations is a subject of shared decision-making between a woman and her doctor.

Mammography and overdiagnosis, revisited
Another new study supports the hypothesis that overdiagnosis is a major problem in mammography screening programs. Predictably, it is attacked based on a misunderstanding of what overdiagnosis is.
David Gorski on October 17, 2016
Link

I knew it. I just knew it. I knew I couldn’t get through October, a.k.a. Breast Cancer Awareness Month, without a controversial mammography study to sink my teeth into. And I didn’t. I suppose I should just be used to this now. I’m referring to the latest opus from H. Gilbert Welch and colleagues that appeared in the New England Journal of Medicine last week, “Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness.” Yes, it’s about overdiagnosis, something I’ve blogged about more times than I can remember now, but it’s actually a rather interesting take on the issue.
Before 2008 or so, I never gave that much thought to the utility of mammographic screening as a means of early detection of breast cancer and—more or less—accepted the paradigm that early detection was always a good thing. Don’t get me wrong. I knew that the story was more complicated than that, but not so much more complicated that I had any significant doubts about the overall paradigm. Then, in 2009, the United States Preventative Services Task Force (USPSTF) dropped a bombshell with its recommendation that mammographic screening beginning at age 50 rather than age 40 for women at average risk of breast cancer. Ever since then, there have been a number of studies that have led to a major rethinking of screening, in particular screening mammography and PSA testing for prostate cancer. It’s a rethinking that affects discussions even up to today, with advocates of screening arguing that critics of screening are killing patients and skeptics of screening terming it useless. Depending on the disease being screened for, the answer usually lies somewhere in between. Basically, screening is not the panacea that we had once hoped for, and the main reason is the phenomenon of overdiagnosis. Before I go on, though, remember that we are talking about screening asymptomatic populations. If a woman has symptoms or a palpable lump, none of this discussion applies. That woman should undergo mammography.
Overdiagnosis, a(nother) primer
Basically, overdiagnosis is a phenomenon that can confound any screening program in which large populations of asymptomatic patients are subjected to a diagnostic test to screen for a disease. The basic concept is that there can be preclinical disease that either does not progress or progresses so slowly that it would never threaten the life of the patient within that patient’s lifetime, yet the test picks it up. Because we don’t have tests that can predict which lesions picked up by such a screening test will or will not progress to endanger the patient, physicians are left with little choice but to treat each screen-detected lesion as though it will progress, resulting in overtreatment and the resulting iatrogenic harms. This situation is very much the case for mammography and breast cancer, for example, for which there is evidence that as many as one in five to one in three screen-detected (as opposed to cancers detected by symptoms or a mass) breast cancers are overdiagnosed. As a result, physicians are much less confident in traditional recommendations for screening mammography than we once were. And you can add to that the phenomenon of lead time bias, in which earlier detection doesn’t actually impact survival but only gives the appearance of prolonged survival.
The rate of overdiagnosis due to mammography is probably higher than previously thought
With that background in mind, let’s take a look at Welch’s latest. The basic idea behind the study is rooted in the key assumption behind mammography, which is that the detection of small tumors that have not yet become palpable, will prevent progression and, over time, lead to fewer large or more advanced tumors being diagnosed. Welch et al also note the difference between efficacy (how well a treatment or screening test works in randomized clinical trials) and effectiveness (how well an intervention works when “unleashed” in the community):
Although it may be possible to show the efficacy of screening mammography in reducing cancer-specific mortality in the relatively controlled setting of randomized trials, those trials may not accurately reflect the actual effectiveness of screening when it is used in clinical practice. Differences between efficacy and effectiveness with respect to the benefit of screening may be particularly stark when the treatments administered in practice have markedly changed from those administered in the trials that led to the implementation of widespread screening. Furthermore, although trial data may provide an assessment of some negative consequences of screening, such as false positive results and associated diagnostic procedures, such assessments may understate what actually occurs when screening is implemented in the general community. The collection of data regarding other harms, such as overdiagnosis (i.e., tumors detected on screening that never would have led to clinical symptoms), requires additional long-term follow-up of trial participants, and those data are often either not available or they reflect patient follow-up and testing practices from decades earlier.
This actually reflects a key controversy in breast cancer treatment. We know that breast cancer mortality has been steadily declining since 1990 or so, roughly 30% since then. The controversy is not over whether breast cancer mortality is declining. It is. The controversy is over what’s the cause: screening, better treatment, or some combination of the two. Indeed, Welch et al even note that in models used by the Cancer Intervention and Surveillance Modeling Network the estimates of the contribution of screening to the observed reduction in breast-cancer mortality range from as little as 28% to as much as 65%. To approach this question, Welch et al decided to take a very simple approach. At least, the question is simple. They decided to look at a metric that’s been measured for many years: The size of breast cancer tumors at the time of diagnosis. The hypothesis, of course, is that mammography should produce a shift towards smaller tumors. So Welch looked at breast cancer diagnoses in the SEER Database from 1975 to 2012, which encompasses the time period before the advent of mass mammographic screening in the US, the period during which screening programs were implemented, and the period after. Size at diagnosis was recorded and divided into the following groups:
    • Less than 1 cm
    • 1 – 1.9 cm
    • 2 – 2.9 cm
    • 3 – 3.9 cm
    • 5+ cm
There were a fair number of complexities, the main one having to correct for missing tumor sizes in the database, which were common decades ago but became less common as time went on. Without going into the details, I can point out that the results were as follows:
At first glance, this looks as though mammography is doing exactly what it’s supposed to be doing. Notice how, beginning in the early 1980s, there was a shift in the distribution of tumor size at diagnosis from larger tumors to smaller tumors. For example, the combination of in situ and tumors less than 1 cm increased from 11% to 40%, while the percentage over 3 cm in size decreased from 38% to 18%. So far, so good, right?
Not exactly:
The observation here is that the increase in the number of small tumors was considerably greater than the decrease in the number of large tumors. Indeed, the results look very much like the results of Welch’s last study, which compared the incidence of advanced versus early cancers and found basically the same thing: The introduction of mammographic screening was associated with a greater increase in the incidence of early cancers than there was a decrease in the incidence of more advanced cancers. Thus, we have fairly consistent results showing in two different studies that, while the introduction of mammographic screening appears to have resulted in a decrease in the incidence of larger/more advanced tumors, it resulted in a far larger increase in the diagnosis of smaller/less advanced tumors. In the last study, Welch estimated the rate of overdiagnosis to be around 30%. What about in this study?
This was the magnitude of the shift:
However, this shift in size distribution was less the result of a substantial decrease in the incidence of large tumors and more the result of substantial increases in the detection of small tumors(Figure 2B). Nevertheless, modest decreases were seen in the incidence of large tumors. The changes in size-specific incidence of breast cancer after the introduction of screening mammography are shown in Table 1. The incidence of large tumors decreased by 30 cases of cancer per 100,000 women (from 145 to 115 cases of cancer per 100,000 women), and the incidence of small tumors increased by 162 cases of cancer per 100,000 women (from 82 to 244 cases of cancer per 100,000 women). Assuming that the underlying burden of clinically meaningful breast cancer was unchanged, these data suggest that 30 cases of cancer per 100,000 women were destined to become large but were detected earlier, and the remaining 132 cases of cancer per 100,000 women were overdiagnosed (i.e., 30 subtracted from 162).
This is an estimate of overdiagnosis even greater what previous studies have found, roughly 80% or 132/162 additionally detected tumors were overdiagnosed, and the estimated decrease in mortality attributable to mammography was 12 per 100,000 women in the earlier time period after mammographic screening was introduced. In more recent years, with better treatment, the estimated reduction in mortality was smaller, around 8 per 100,000. In comparison, the estimated reduction in mortality due to better treatment was 17 per 100,000. Thus, overall, better treatment has reduced mortality from breast cancer more than screening has. However, that’s not to say that mammography doesn’t save lives. It does. It’s just that the effect is more modest than previously believed.
Here’s a video in which Welch explains his results:
The case against the case against mammography
Not surprisingly, not everyone accepted Welch’s results. For instance, Elaine Schattner, a physician and journalist who was diagnosed with breast cancer by her first mammography at age 42, was not impressed, taking to her Forbes blog to provide what she calls “The Case Against the Case Against Mammography.” Unfortunately, her objections to the study do not stand up to scrutiny. For instance, she begins:
The world’s leading medical journal has published yet another skewed analysis of mammography, overdiagnosis and breast cancer trends. I’m disappointed that the New England Journal of Medicine would promote such an assumption-riddled, estimate-loaded piece to dissuade readers of screening’s value.
Note the loaded language. Dr. Schattner characterizes Welch’s analysis as “skewed” and refers to it as “assumption-riddled” and “estimate-loaded,” but nowhere in her op-ed does she actually identify which specific assumptions behind the study or estimates used she questions and why or why those assumptions or estimates invalidate Dr. Welch’s findings. Don’t get me wrong. Welch’s study is not perfect, but if you’re going to portray it as a hit piece against mammography (which it is not, by the way), you really do need to do a lot better than that.
Next, Dr. Schattner simply “restates” her “three go-to points on why this mammography ‘news’ should not influence any woman’s decision”:
1. The overdiagnosis campaign reflects a lack of respect for women’s capacity to make rational choices about their health. If a woman learns she has a breast tumor, she can weigh the information and consult with her doctor about the best plan forward.
I couldn’t disagree with this assertion more. First, I resent the dismissive characterization of studies like this as the “overdiagnosis campaign.” It’s a term that intentionally portrays scientists like Dr. Welch as being hopelessly biased and perhaps even having less-than-reputable motivation, a recurring theme among defenders of mammography. I’ve published (once) with Dr. Welch; I know this not to be true. Also, personally, I always thought that the negative reaction against any study that raised questions about how effective mammography is in preventing death from breast cancer tended to betray a lack of respect for women’s capacity to make rational choices about their health. After all, why wait until a woman is diagnosed with a mammography-detected cancer before allowing her to “weigh the information and consult with her doctor about the best plan forward”? Why wait until a screen-detected cancer that could well have been overdiagnosed is found? Doesn’t respecting a woman’s ability to weigh the evidence and choose for herself involve also respecting her ability to weigh studies like this? A woman and her doctor, using the information that studies like Welch’s provide can do that before the woman decides if she wants to begin a screening campaign. Moreover, Welch himself is not opposed to screening mammography or seeking to tell women not to undergo the test. He’s trying to provide them the very information they need to decide whether the test is right for them.
Next up:
2. The report rates old technology. The most recent mammograms in this “ecological” study would be from 2002. Mammography equipment has since shifted to digital, among other leaps forward.
While this is true, its relevance is questionable. After all, better, more sensitive mammography equipment of the type we have now, if anything, could just as easily exacerbate, not alleviate, the problem of overdiagnosis. In fact, more sensitive detection usually exacerbates overdiagnosis.
Then:
3. The paper ignores differences among radiologists, and the potential to improve screening outcomes in the U.S. population by assuring that all breast imaging is done by doctors who do only that.
Again, this is an observation of little relevance to Dr. Welch’s analysis. Remember, overdiagnosis is a cancer. In overdiagnosis, a mammogram detects a lesion, that lesion is biopsied, and it comes back histologically as ductal carcinoma in situ or invasive cancer. A breast cancer can’t be overdiagnosed if there isn’t a lesion on mammography that is biopsied. Dr. Schattner seems to assume that better, more specialized radiologists doing only mammography will not flag lesions that will turn out to be overdiagnosed, but that’s an incorrect assumption for one very simple reason. There is no difference, mammographically, between breast cancers that are overdiagnosed and those that will progress to endanger the life of the woman. No matter how well trained the radiologist is, he or she can’t tell the difference. All the radiologist can tell is that there’s a suspicious mass, bit of architectural distortion, or cluster of microcalcifications requiring biopsy. All the pathologist can tell is whether, on histology, there is DCIS or cancer there, or not.
The same is true of her other criticisms. For instance, Dr. Schattner also criticizes Welch for not considering “alternative and new screening methods: breast ultrasound to evaluate dense breasts, 3D mammography, MRI or molecular breast imaging.” That’s like criticizing a golf course for not being a baseball diamond. That is not what the study was about. It was about mammography. But to address her objection, none of these tests has yet been validated as tools for the mass screening of asymptomatic populations, and they all have their own problems. MRI is very expensive relative to mammography and too sensitive, not to mention that it also requires intravenous contrast. Widespread adoption of MRI would cost a lot more money than anyone’s willing to spend, and it would likely exacerbate, not alleviate, the problem of overdiagnosis. Molecular breast imaging (MBI) uses a radiolabeled tracer and operates much like PET or bone scanning. Given that, it doesn’t show anatomy very well and it too could be too sensitive. It’s been oversold. 3D mammography is also more expensive. It might be useful, but, again, it hasn’t been validated as a screening tool and it is unclear whether it would alleviate the problem of overdiagnosis given that the 3D images are constructed from mammographic images and thus suffer from the same problems as mammography and that 3D mammography is touted as “finding more tumors,” which, again, could exacerbate, not alleviate, overdiagnosis.
Dr. Schattner also mentions Welch’s study “skips over advances in pathology” and that doctors “have tools, now in everyday use, to evaluate biopsies, to distinguish aggressive tumors from slow-growing ones to avoid overtreatment.” I’d sure love to know what those advances and tools are, because I am a breast cancer surgeon and I don’t know of any test in everyday use that is reliable enough to tell me which mammography-detected breast cancer or DCIS lesion is safe to watch and which needs immediate treatment. All the pathologist looking at the biopsy of that mammographic abnormality can tell histologically is that it is breast cancer. What neither of them can tell is if it is overdiagnosed breast cancer (i.e., cancer that will never progress or will progress so slowly that it never becomes a problem in the patient’s lifetime) or breast cancer requiring treatment. As a breast cancer surgeon, when confronted with a biopsy-proven histological diagnosis of cancer in a patient, I have no choice but to treat that cancer as though it threatens the life of the patient because I have no reliable test to tell me which ones are safe or not. I am aware that some cutting-edge surgeons (if you’ll excuse the term), like Dr. Laura Esserman do sometimes use watchful waiting for low grade DCIS, but most surgeons don’t (yet) have the intestinal fortitude for that, and I doubt that even Dr. Esserman’s intestinal fortitude is up to the level where she would use “watchful waiting” as the initial management of an invasive cancer.
An eminent radiologist counterattacks
As much as I might have been disappointed in Dr. Schattner’s reaction, I understand it, at least as much as someone who has never had (and is incredibly unlikely ever to have) breast cancer can. I take care of women like her, and I am active with our local Komen group. So I think I get where Dr. Schattner’s coming from.
Unsurprisingly, though, it didn’t take long for a man who is known as a pit bull defending mammography against all studies that cast even an infinitesimal amount of doubt on it as a pure, unalloyed good for all women (over 40, at least) all the time, Dr. Daniel Kopans, to jump into the fray in his usual inimitable and entirely predictable fashion. We’ve met Dr. Kopans before. He is an eminent radiologist. Dr. Kopans is also prone to apocalyptic rhetoric about the consequences of any study that might decrease the rate of uptake of mammograms, basically portraying anyone who questions whether mammography is as effective as he thinks it is as wanting to kill women. His overall message is that overdiagnosis doesn’t exist and, even if it does, it isn’t a problem—except that it doesn’t exist. (I exaggerate, but not by much.) Unfortunately, his attitude towards anyone who suggests otherwise, especially if they publish a study, is a problem is to attack, attack, attack. I know. I’ve had e-mail exchanges with some on the receiving end of Kopan’s “bull in a china shop” tactics and have even myself encountered them. It wouldn’t surprise me if I encounter them again if he ever becomes aware of this post.
So it’s not surprising that Dr. Kopans was—shall we say?—less than thrilled with the latest NEJM paper by Welch et al. Personally, I would have been surprised if he hadn’t weighed in rapidly, and the title of his “rebuttal” is actually pretty mild for him: New NEJM paper offers rehash on “overdiagnosis.” As usual, Dr. Kopans ridicules the study and portrays Welch and his co-authors as not just incompetent, but biased.
Here’s an example of what I mean:
It is surprising that the New England Journal of Medicine allowed an author to publish an almost identical analysis to a paper previously published in 2012. The new article by Welch et al is little more than a rehash of the 2012 paper by Bleyer and Welch that falsely claimed massive overdiagnosis of breast cancer.
The current study uses a similarly faulty methodology to that earlier work in the analysis of the incidence of breast cancer and its relationship to mammography screening. In the 2012 paper, Welch “guessed” that the incidence of breast cancer, had screening not begun in the mid-1980s, would have increased by 0.25% per year.
Notice the use of scare quotes and the dismissive language. Note its focus on the 2012 study, rather than the present study. The problem is that Archie Bleyer has already written a detailed defense of his and Welch’s methodology. Contrary to Dr. Kopans’ seeming view that Bleyer and Welch were biased against mammography, in fact, Welch and Bleyer did analyses to give mammography every benefit of the doubt. I don’t want to get in the weeds too much, but basically, Welch and Bleyer did analyses that took into account the sorts of complaints Dr. Kopans would later make. Also, the analysis, while similar to that of the 2012 paper, is not “identical.” For one thing, it doesn’t consider lymph node status.
What irritates me about Kopans is how he seems to willfully misunderstand the arguments and data supporting the concern that overdiagnosis is a problem:
By extrapolating this “underlying” rate to 2008, the authors estimated what the incidence would have been in 2008 had there not been any screening. Since the actual incidence was much higher, they claimed that the difference between the actual and their “guesstimate” represented cancers that would have never been clinically apparent had there not been mammography screening.
They called these cases “overdiagnosed,” suggesting that the cancers would have regressed or disappeared had they not been found by breast screening. They went on to claim that there were 70,000 of these “fake” cancers in 2008 alone, despite the fact that no one has ever seen a mammographically detected invasive breast cancer “disappear” on its own.
This is an obvious straw man argument, as any fair reading of the work of Welch et al from 2012 or now would show. Dr. Kopans is fond of claiming that those who are concerned about overdiagnosis, such as Dr. Welch, are saying that overdiagnosed breast cancers would “melt away” if left alone, obvious inflammatory straw man language designed to make Welch look ridiculous. Overdiagnosis means nothing of the sort. Again, overdiagnosed cancers might fail to progress, or they might progress so slowly that they don’t endanger the health of a woman in her remaining lifetime (however long that might be), or they might regress. We don’t know what proportion fall into which category of behavior—or even which cancers are overdiagnosed.
No one other than Dr. Kopans and those who don’t believe that overdiagnosis is real calls overdiagnosed cancers “fake” cancers. The very fact that Dr. Kopans would use such a flagrantly incorrect term shows that he either does not understand the concept of overdiagnosis or that he denies it and the cancer biology behind it. Again, as I emphasized above, overdiagnosed cancers are real cancers, not “fake.” They simply have a biological behavior that we are not used to thinking about. Because we do not yet have the tools to tell which screen-diagnosed cancers will or won’t progress, we end up overtreating a significant number of cancers. I’m also not entirely sure that no one has ever seen a mammographically detected invasive cancer disappear on its own, but even if that is true it shouldn’t be surprising. These days, we treat them all! From an ethics standpoint, we have to. Until we have the tools to predict biological behavior, we have to assume every cancer detected by mammography could endanger the life of the woman, and it would be unethical to do otherwise.
Dr. Kopans doesn’t stop there, though:
The NEJM published this denigration of mammography screening despite the fact that the authors had no data on which women had mammograms and which cancers were found by mammography. I have never seen a scientifically based paper in which an intervention (mammography) is blamed for an outcome when there are no data on the intervention relative to the outcome, yet the prestigious NEJM published the nonscience faulting mammography based on a “guess.”
I’m sorry. I realize that Dr. Kopans is an incredibly eminent radiologist who works at Harvard, and so much more famous, awesome, and influential than a mere peon like me, but writing that paragraph with a straight face must have been difficult. At least, it should have been. The study is epidemiology. We know when widespread mammographic screening was introduced. We also know that, between 1980 and 1990, the percentage of women having had a mammogram in the last two years went from a very low level to 50% of the population. Dr. Welch even cites those data in the supplemental material! Add to that all the disparaging language (“denigration” of mammography) and characterizing Welch’s estimates as “guesses” when Welch explains in great detail why he made the choices he did for his estimates in the supplemental materials, complete with sensitivity analyses for the assumptions. It’s far easier and lazier for Dr. Kopans just to dismiss them as “guesses,” though. Welch also notes that observed incidence always reflects “observational intensity.” In other words, the harder you look for a disease, the more of it you will find. This is a principle not unique to breast cancer. It applies to most diseases:
There is another piece of evidence suggesting that the increase in invasive cancer incidence observed during the 1980s does not reflect a true underlying increase in clinically meaningful breast cancer. Breast cancer mortality among women age 40+ was stable from 1975-1993 at 70-74 per 100,000, before beginning its steady decline to 48 per 100,000 in 2012 (a decline we argue is primarily treatment mediated). Stable mortality spanning the period of a 30% increase in invasive breast cancer incidence further argues that the increased incidence instead reflects the increased observational intensity associated with screening.
Dr. Kopans seems to spend most of his time attacking Welch’s 2012 paper rehashing the same tired arguments refuted by Bleyer, frequently not being entirely clear whether he’s criticizing the 2012 paper or the 2016 paper. Be that as it may, what bothers me the most about Dr. Kopans is his refusal to treat the question of overdiagnosis as a scientific disagreement over the exact amounts and types of harms to balance with the benefits of mammography and to portray those with whom he disagrees as villains. I don’t say this lightly. He has a long history of doing just that dating back over many years, for example, he has characterized Dr. Welch in the past as “trying to get thousands of women killed with his scientifically unsupportable ideas” and accused the investigators of a study that found no mortality benefit due to mammographic screening (the Canadian National Breast Screening Study) of scientific misconduct and then denying that he did that. He even called me a hypocrite and such an egotist that I would never admit I am wrong.
While it’s true that I might now have a bit of an ego, it’s not true that I won’t admit when I’m wrong. Dr. Kopans has just thus far failed to convince me. Certainly painting your opponents in a scientific debate as deceptive monsters intent on killing women doesn’t help him make his case, but it’s something Dr. Kopans has been doing at least since the 1990s.
Overdiagnosis is real
Given the randomized controlled clinical trials that show a much larger reduction in breast cancer mortality due to screening mammography, why is it that more recent studies like this one show a much more modest effect of screening on breast cancer mortality and a troubling degree of overdiagnosis? Well, it’s frequently the case that “real world” effectiveness is less than what is found in clinical trials; so this observation should not come as a surprise, particularly given that screening programs for cancer can take decades to provide sufficient data to evaluate their “real world” effectiveness. It should also not be a surprise that breast cancer treatment has been getting better and that that might make mammography less useful than it was 30 years ago. It’s also very complicated, as Welch points out:
There is no perfectly precise method to assess the population effects of cancer screening. Screening mammography performed in an asymptomatic population that has an average risk of cancer can, at best, have only a small absolute effect on cancer-specific mortality because the vast majority of women are not destined to die from the target cancer. Because the mortality effect is necessarily delayed in time, the availability of improving cancer treatment over time further complicates the assessment of the contribution of screening. Inferences regarding overdiagnosis are equally imprecise since overdiagnosis cannot be measured directly.
I also note that I’m not claiming that there are not legitimate criticisms to be made about Dr. Welch’s paper. Oddly enough, Dr. Kopans almost ignored them. For instance, one can question the assumptions Welch et al made to fill in missing tumor size values for the early years of the SEER Database, when it wasn’t as complete to estimate size-specific incidence. The paper isn’t perfect. Because it’s based on data in the SEER Database, it is, like most epidemiological papers based on that database, rather messy. However much we can argue about the magnitude of the problem, I was unable to find sufficient problems with Welch’s methodology to seriously question his conclusion that overdiagnosis is real and a major problem with mammography. Neither was Joann G. Elmore, MD, MPH, after noting in an accompanying editorial that Welch et al “rely on data with extensive missing values, forcing them to make assumptions about underlying disease burden that cannot be verified, which is why they acknowledge that their estimates are imprecise.” I don’t think they’re imprecise enough to invalidate this paper, however.
More importantly, Dr. Elmore also provides an excellent money quote to think about whenever we discuss screening for breast cancer:
We are using archaic disease-classification systems with inadequate vetting and defective nosologic boundaries. Diagnostic thresholds for “abnormality” need to be revised because the middle and lower boundaries of these classification systems have expanded without a clear benefit to patients. Disease-classification systems are often developed by experts on the basis of a small number of ideal cases and are then adopted broadly into clinical practice — a system that is antithetical to the scientific process. The National Academies of Sciences, Engineering, and Medicine recently deemed improvement of the diagnostic process “a moral, professional, and public health imperative.” Rigorous analytic methods are required for the development of disease nosologies, and physicians need more sophisticated tools to improve diagnostic precision and accuracy. At the patient level, we need better methods of distinguishing biologically self-limited tumors from harmful tumors that progress.
Exactly. In cancer, I consider that last need to be the most critical of all. Mammography is a test that detects anatomic abnormalities to diagnose disease, but if there’s anything we’ve learned over the past couple of decades it’s that, when it comes to cancer, anatomy is not king. Biology is. We require biological markers that tell us which of these tumors detected by mammography are safe to keep an eye on through “watchful waiting” and which are dangerous. Until we have these tools (and, contrary to Dr. Schattner’s assertion, we do not as yet have these tools), overdiagnosis will remain a problem.
Here’s the thing. People will see what they want to see in this study. Those who believe screening saves lives will argue that the small benefit observed is worth the cost of overdiagnosis or will try to argue that Welch greatly overestimates how much overdiagnosis there is. Even so, contrary to Dr. Kopan’s disparaging dismissal of overdiagnosis as, in essence, a campaign against women to reduce access to lifesaving screening tests, there is a growing evidence supporting a broad consensus that overdiagnosis due to mammography is a significant problem to be overcome. Indeed, new suggested mammography guidelines that have been recommended in the last few years have come about because of a desire to decrease overdiagnosis and overtreatment while maintaining early detection of potentially dangerous tumors. In contrast, the mammography “nihilists,” as I like to call them, will point to this study as saying that screening mammography is useless.
Overdiagnosis is a real problem. We might argue about the magnitude of the problem, whether its frequency is nonexistent (as Dr. Kopan seems to argue), a few percent (as radiologists will frequently argue) or whether it is as high as 80%, as this study implies, but, contrary to the claims of prominent radiologists, it is a real phenomenon and a real problem. It confounds more than just mammographic screening programs; it confounds any screening program, because, as we’re discovering, preclinical disease in asymptomatic patients that either never progresses or progresses very slowly is far more common than we have previously suspected.
In the end, science can never really fully answer whether a woman should undergo mammography or whether mass screening programs are worthwhile, be they for breast cancer, prostate cancer, or other diseases. The reason is that no matter how much science is brought to bear, there will be no escaping the facts that the final decision will boil down to a value judgment informed by the science and that, because, contrary to what Dr. Kopans has suggested in the past, we can’t do a randomized clinical trial of mammography any more because there would not be clinical equipoise. In the US, we are very pro-screening, but that doesn’t necessarily mean that our care is better. In any case, when it comes to mammography, the value judgment to be made is simple to state but very hard to answer: Is the small decrease in a woman’s chance of dying of breast cancer worth the not-inconsiderable risk of overdiagnosis and subsequent harm from overtreatment? Many women will answer yes. Some will answer no. Different women will make different choices, and different people will have different opinions, depending on what they consider more important.

   Early detection of cancer, part 2. Breast cancer and MRI
David Gorski
Link
When last I left this topic three weeks ago, I had discussed why detecting cancer at ever-earlier stages and ever-smaller sizes is not necessarily an unalloyed good. At that time, I discussed in detail a landmark commentary in the New England Journal of Medicine entitled, Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy. The article, although nearly 15 years old, rings just as true today in its cautioning doctors about whether ever-increasing diagnostic sensitivity that imaging technology and new blood tests were (and are) providing was actually helping patients as much as we thought it was. Before we dive into this problem as applied to breast cancer, let’s review what Drs. Black and Welch had to say about screening tests for breast cancer 15 years ago, as way of background and linking my last post and this one:
Before the widespread use of mammography, most breast cancers were discovered on physical examination, as palpable lumps. In one of the few studies to assess directly the accuracy of physical examination in screening for breast cancer, only 27 percent of tumors more than 1.0 cm in diameter and 10 percent of those less than 1.0 cm in diameter were detected by physical examination. However, the mean size of breast cancers detected by state-of-the-art screening mammography is about 1.0 cm, and many of the cancers detected as microcalcifications are only a few millimeters in size.
Again, prevalence depends on the degree of scrutiny. According to the Connecticut Tumor Registry, clinically apparent breast cancer afflicts about 1 percent of all women between the ages of 40 and 50 years. In a recent medicolegal autopsy study, however, small foci of breast cancer were found in 39 percent of women in this age group. Most cancers were in the form of ductal carcinoma in situ. Furthermore, over 45 percent of the women with cancer had two or more lesions, and over 40 percent had bilateral lesions. Although it has been argued that such small in situ lesions are not detected by and are therefore irrelevant to screening mammography, about half the lesions in that study were detected, usually as microcalcifications, on postmortem plain-film radiography of the resected breasts. Because of continual technical improvements and increasingly broad criteria for the interpretation of mammograms, the detection threshold for breast cancer has fallen considerably since the time of the Breast Cancer Screening Project of the Health Insurance Plan of Greater New York (1963 to 1975). This can explain the increased prevalence of cancer on mammographic screening, from 2.717 to 7.614 per 1000 examinations (with the incidence increasing from 1.517 to 3.214 per 1000 examinations). The lower detection threshold can also explain the increase in the percentage of carcinomas in situ (stage 0) among all mammographically detected cancers — from 12.7 percent to over 30 percent. The principal indication for biopsy has changed from suspicious mass to suspicious microcalcifications. This can explain why the reported incidence of breast cancer has increased and why most of the increase is in smaller lesions, particularly ductal carcinoma in situ.
About a year ago, three major articles hit the medical press that made me start thinking about this more than I had in the past. It’s my job, after all, because breast cancer surgery is a large part of my practice, and I do breast cancer lab-based research. What also tweaked me not to put off doing part 2 of this series is that, just two days ago, there was an abstract presented at the American Society of Clinical Oncology Meeting (where I still am today) that also serves to highlight just how difficult this question of integrating a test as sensitive as MRI into a screening regimen for and preoperative evaluation of breast cancer is and how MRI should fit into in this regimen can be.
Let’s begin with the older data. A little more than a year ago, a major set of metanalyses looking at the value of screening mammography in younger women (ages 40-49) was published in the Annals of Internal Medicine as a a pair of companion articles, one as a metanalysis and another as clinical guidelines. Remember, as mentioned for prostate cancer and thyroid cancer in my previous post, a large percentage of apparently healthy women, if you look at their breast tissue closely enough, will have evidence of ductal carcinoma in situ (DCIS), the latter of which is, depending on how you look at things, either a premalignant lesion or cancer that has not invaded outside of the breast ducts yet. Either way, very few women die of DCIS if they are treated. We do not know how many would die if untreated, but we do know that the vast majority of women from 40-49 with microscopic evidence of breast cancer or DCIS will never die of cancer, because either the cancer does not progress or progresses so slowly that, even in the 30-40 years remaining for women in this age range, it does not manifest itself as clinical cancer and the women die of something else. This situation is a classic example of how lead time bias and length bias lead to an increase in the number of diagnoses of cancer and a shift towards less rapidly progressive disease being diagnosed, as I described in part 1. The problem, of course, is that we have no way of identifying which of these lesions will turn into clinically apparent cancer, leaving little choice but to treat all detected cancer, even tiny microscopic lesions, as though they are potentially life-threatening.
The issues complicating the question of mammographic screening of women under 50 are now, as they were then, that breast cancer is not nearly as common in this age group as it is in women over 50, for whom the preponderance of evidence from clinical trials and epidemological studies support the value of mammographic screening in decreasing mortality from breast cancer. In contrast, the value of yearly screening mammography in women aged 40-49 has historically been somewhat more controversial controversial, and a recent set of guidelines published in the Annals of Internal Medicine, includes a metanalysis of studies on screening mammography in this age range, accompanied by a set of consensus clinical guidelines from the American College of Physicians. The introduction sums up the data fairly well:
In the United States, breast cancer is one of the most common causes of death for women in their 40s. In 2002, almost 5000 women between 40 and 49 years of age died of breast cancer, compared with the 6800 women who died of heart disease or 1500 women who died of HIV (5). However, despite the relative importance of breast cancer in this age group, the burden of breast cancer among women in their 40s is low for a population-based screening program. More than 98% of women will not develop breast cancer between 40 and 50 years of age, but they will be subject to the risks of population-based screening. Of the 44,000 women who die of breast cancer each year, fewer than one fifth received their diagnoses between the ages of 40 and 49 years.
That is indeed the problem with all mass screening programs. For a mass screening program to be effective, the disease being screened for must be common and treatable, and there must be a screening test that has an acceptable sensitivity and does not turn up too many false positives. In other words, it must be common enough so that the “noise” from false positives from the test is small in comparison to the true incidence of the disease being screend for. In addition, if it is being applied to mass populations, a test must also be inexpensive and safe. For women over 50, these conditions certainly apply with respect to breast cancer and mammography, and, indeed, studies of the issue, taken together, support the conclusion that there is a 20-25% reduction in breast cancer mortality in this age range in populations that are screened with mammography compared to populations that are not. In contrast, for women from 40-49 years of age, the benefit is clearly more modest, and some argue that there is really no benefit at all. What is cited is approximately a 15% decrease in mortality after 14 years; however the error bars are fairly wide. Indeed, the low end of the range is a mere 1% benefit in decreased mortality. This is one of the reasons why some European countries do not recommend routine screening mammography for breast cancer until age 50, unless there are risk factors, such as a strong family history or mutations in breast cancer susceptibility genes, such as BRCA1 and BRCA2.
Among the other findings of the metanalysis was that the risk from the radiation is quite small. However, the most problematic finding was that the risk of false positive results is high. After 10 mammograms, there is a 20-56% risk of a false positive. All of these will require, at the minimum, further imaging and workup; some will require a referral to a breast surgeon for evaluation and some of those will end up getting biopsies, the majority of which (75-80%) will be benign. This does not even count the mental and emotional distress that abnormal mammograms cause between the time the woman is informed of the result and the time that either additional imaging or a biopsy. Given this information, unfortunately, the guidelines suggested by the ACP last year were so vague as to be almost useless, at least to me:
     1.  In women 40 to 49 years of age, clinicians should periodically perform individualized assessment of risk for breast cancer to help guide decisions about screening mammography.
     2.  Clinicians should inform women 40 to 49 years of age about the potential benefits and harms of screening mammography.
     3.  For women 40 to 49 years of age, clinicians should base screening mammography decisions on benefits and harms of screening, as well as on a woman’s preferences and breast cancer risk profile.
     4.  We recommend further research on the net benefits and harms of breast cancer screening modalities for women 40 to 49 years of age.
Those of you who are gynecologists, internists, or family practice docs (you know, the docs who generally take care of routine screening tests), tell me: Do those guidelines help you at all to decide whether you should screen women between 40-49? The problem is, the above guidelines do not tell me as a clinician how I should balance risk and benefit and how I should counsel patients to balance risks and benefits, and, quite frankly, the discussion after each guideline in the original paper do not help much. In addition, the elephant in the room that no one wants to acknowledge is the medical-legal climate. In the United States, one of the most common causes of lawsuits, if not the most common, is failure to diagnose breast cancer. What primary care doctor has the intestinal fortitude not to screen women from 40-49, when the majority of radiology and medical organizations still recommend mammography every 1-2 years between ages 40 and 50, even if the evidence upon which they base these recommendations is not as compelling as that for women over 50? Not too many. Indeed, in the U.S. it is not uncommon for me to see women in the 35 to 40 year old age range being referred to me after their first mammograph turns up an abnormality that is almost certainly not cancer but has to be evaluated.
There is, of course, now a newer imaging modality that really brings home the points in the Black and Welch commentary from 14 years ago. I am referring, of course, to MRI. MRI stands for magnetic resonance imaging, and, over the last decade, MRI of the breast has been developed and fine-tuned. MRI can produce stunning images and is highly sensitive. There’s little doubt that it can pick up lesions that mammography can miss, although it is not as good for picking up DCIS as it is for breast cancer. Given that we have probably come close to the limits of resolution and sensitivity in mammography with the newer digital mammography machines, not surprisingly, the question of what role MRI should play in the screening of women for the early detection of breast cancer is now coming to the forefront. There is good evidence that MRI adds benefit in the screening young women at a high risk of breast cancer, such as women carrying BRCA1 or BRCA2 mutations. But what about the general population, whose age-adjusted risk of breast cancer is average and thus much lower than these very high risk women?
Enter the second article last year, namely a review by the American Cancer Society, which tried to come up with some recommendations for when using MRI as an adjunct to screening mammography is appropriate. The last time it had updated its guidelines in 2003, at which time the ACS stated that there was insufficient evidence to recommend MRI as a screening test, except perhaps for women at high risk of breast cancer. I’ll boil down the most recent recommendations, which come in a large paper published in CA: A Cancer Journal for Clinicians by listing them as the appear in Table 1:
Recommend Annual MRI Screening (Based on Evidence*)
BRCA mutation
First-degree relative of BRCA carrier, but untested
Lifetime risk 20-25% or greater, as defined by BRCAPRO or other models that
are largely dependent on family history
Recommend Annual MRI Screening (Based on Expert Consensus Opinion)
Radiation to chest between age 10 and 30 years
Li-Fraumeni syndrome and first-degree relatives
Cowden and Bannayan-Riley-Ruvalcaba syndromes and first-degree relatives
Insufficient Evidence to Recommend for or Against MRI Screening
Lifetime risk 15-20%, as defined by BRCAPRO or other models that are largely
dependent on family history
Lobular carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH)
Atypical ductal hyperplasia (ADH)
Heterogeneously or extremely dense breast on mammography
Women with a personal history of breast cancer, including DCIS
Recommend Against MRI Screening (Based on Expert Consensus Opinion)
Women at <15% lifetime risk
Of course, it’s hard not to point out that recommending MRI screening for women with BRCA mutations is nothing new; such women are at extraordinarily high risk for developing breast and ovarian cancer, with some variants producing a lifetime risk of cancer as high as 80%. Indeed, these are the women who often undergo prophylactic bilateral mastectomies or take estrogen-blocking drugs in order to try to decrease their risk. What I am unclear about is how the ACS came up with the recommendation that women who have a lifetime risk of developing breast cancer of 20% or greater should undergo MRI screening. The rationale for choosing that number as the cutoff was not at all clear to me from reading the paper; certainly no clear risk-benefit analysis was presented that suggests that, above a 20% risk MRI is worthwhile and below a 15% risk it is not.
Once again, consistent with the Black and Welch paper, I will point out that the increased sensitivity of MRI comes at a price. If a woman gets an MRI, she is twice as likely to get a biopsy as compared to getting just a mammogram and, if needed, an ultrasound. Remember, MRI is more sensitive than but not as specific as mammography. It picks up all sorts of lesions that mammography misses, but most of them are not cancer. Remember, also, the possible confounding effects of lead time bias and length bias. It is not at all clear if detecting breast cancer by MRI at an even earlier point in its development than it would be detected by mammography and/or physical examination will truly improve breast cancer survival independent of lead time bias, nor is it clear what percentage of these smaller cancers would ever grow to cause any problems at all. Remember the autopsy study cited earlier. Among even 40-50 year old women, 40% will have microscopic evidence of breast cancer if you look hard enough. Also, if you look at the Gail Model, it’s pretty easy to come up with a common scenario that pushes a patient’s lifetime risk of breast cancer to 20% or more. For instance, I modeled a 40 year old woman with a single breast biopsy (which was benign), age at first menstruation of 11, and her age at first childbirth over 30, and the lifetime risk is already approaching 18%. True, the Gail model has its problems, but it is still widely used. It doesn’t take much to reach this level of risk.
MRI has also been increasingly used for preoperative evaluation of women with breast cancer. It’s not hard to see why it’s attractive; the images it can produce are stunning, and it can give an idea of extent of disease that MRI and ultrasound may not always be able to. However, as with using MRI for screening, this increased sensitivity when MRI is used for preoperative evaluation may come with a price: More mastectomies. Around the same time last year, there was another study that, perhaps more than any single study, drove surgeons to order more preoperative MRIs in their breast cancer patients. Indeed, it had a huge impact when it landed on the pages of the New England Journal of Medicine and simultaneously all over the news media. Before I discuss it, remember two terms from last time: stage migration and the Will Rogers effect. (If you don’t know what they are, go back and read part 1.) As a background, I will mention that careful evalution of the opposite breast in newly diagnosed breast cancer patients will reveal occult tumors up to 10% of the time, a statistic known for quite some time. Here’s a summary of the findings:
MRI detected clinically and mammographically occult breast cancer in the contralateral breast in 30 of 969 women who were enrolled in the study (3.1%). The sensitivity of MRI in the contralateral breast was 91%, and the specificity was 88%. The negative predictive value of MRI was 99%. A biopsy was performed on the basis of a positive MRI finding in 121 of the 969 women (12.5%), 30 of whom had specimens that were positive for cancer (24.8%); 18 of the 30 specimens were positive for invasive cancer. The mean diameter of the invasive tumors detected was 10.9 mm. The additional number of cancers detected was not influenced by breast density, menopausal status, or the histologic features of the primary tumor.
This study, as the others did, got wide play in the media at the time. Indeed, my partner at the time, whose practice is nearly 100% breast surgery, quipped during one tumor board while presenting a patient that his patient had come in the day after the results of this study had been announced and wanted bilateral MRI; so she was getting a bilateral breast MRI. Period. Such is the power of media hype of a study.
Unfortunately, this particular study told us little to help us decide whether detecting these tumors at the time of diagnosis of the main breast cancer, as opposed to later, when clinically relevant tumors would certainly show up on mammography or ultrasound, improves patient survival at all. All it says is that they can be detected. Not surprisingly, some of the media accounts featured women in which MRI found small cancers in the opposite breast telling how MRI “saved my life.” It’s possible that that might be true in some women, but we do not know what proportion or even if earlier detection in this scenario saves any women. Remember again the concepts of lead time and length biases. Indeed, for really small tumors in the other breast (particularly DCIS) that will now be detected by MRI, it is quite possible that the adjuvant chemotherapy given after surgery could well eradicate a significant percentage of them such that they never become a problem or that small foci of DCIS might never grow to cause the patient problems. We just don’t know. Finally, also remember that only 3% of breast cancer patients in this study had a tumor found in the other breast that was not apparent on mammography. That’s a pretty small number. In addition, only 18 of these (approximately 1.8%) were invasive cancer; the rest were DCIS, a precancerous lesion whose course we cannot predict and some percentage of which may never turn into cancer. So, if you boil it all down, you have to do MRI on close to 10,000 breast cancer patients to identify 18 cancers in the opposite breast in order that they can be treated simultaneously instead of sequentially.
Adding to the concern that MRIs are leading to more radical surgery, two days ago a study out of the Mayo Clinic in Rochester entitled Trends in mastectomy rates at the Mayo Clinic Rochester: Effect of surgical year and preoperative MRI was presented at the ASCO Meeting, and this study was suggestive that just such a negative effect on mastectomy rates may well be occurring due to preoperative MRI. I attended the session and took some notes. This was a retrospective study looking at the rates of mastectomy in women who had undergone a preoperative MRI of the breasts. By way of background to introduce the study, ever since the NIH consensus conference in 1990 that stated that long term survival rates for women undergoing mastectomy or breast-conserving surgery (lumpectomy and radiation) are equal, there has been a trend towards doing fewer mastectomies. At least there was. Over the last five years or so, however, there has been a reversal of that trend, with more women opting for mastectomy. One hypothesis is that a major contribution to this reversal is the emergence of MRI, which has been demonstrated to find up to 16% more lesions in the ipsilateral and 3% in the contralateral breast, as a preoperative imaging modality. This study was designed to look at just that question.
Basically, the investigators examined mastectomy rates for women being treated for breast cancer at the Mayo Clinic in Rochester from 1997-2006 and correlated them with pre-operative MRI. The first data shown was that there was a very nice correlation of an increasing mastectomy rate since 2003 with an increase in the use of MRI, with 2003 being the year in which the mastectomy rate was the lowest. Of course, readers of this know that correlation does not necessarily equal causation; so multivariate analyses were performed in a model adjusted for age, stage, contralateral breast cancer, and density. both MRI and surgical year were independent predictors of mastectomy, with the odds ratio of MRI being 1.7, meaning a woman who underwent an MRI was 70% more likely to undergo mastectomy. This being a retrospective study, however, there was difficulty controlling for confounders. Perhaps the most glaring one was that the mastectomy rate also increased from 2003 to 2006 in women who did not undergo preoperative MRI studies; it just didn’t increase as much. Something else is going on there. One of the questions asked was whether a surgeon with a bias toward mastectomy joined the Mayo faculty in 2003, which could partially explain the results. None had. Although it’s likely that MRI did contribute to an increased mastectomy rate in this study, there do appear to be other factors driving the trend towards mastectomy for smaller tumors as well. Speculation included better reconstructive options, patient preference for whatever reason, and increased emphasis on family history and genetic testing. Still, it is curious that, after decades worth of high quality, long term data showing that, using mammography and ultrasound alone to evaluate extent of disease within the breasts showing equivalent survival between breast-conserving therapy and mastectomy, more surgeons and women are opting for mastectomy.
MRI has other problems as well. For one thing, it’s expensive, easily costing up to $1,000 for the test. In addition, it requires the intravenous injection of a contrast agent, gadolinium. It’s a safe contrast agent, but if we start doing millions of screening MRIs every year we’re going to start seeing a lot more adverse and allergic reactions to it. Finally, there is a big access problem. Although the large urban areas are almost covered, MRI is still not available everywhere, particularly in rural areas (in some rural areas, there aren’t enough mammography machines to go around). There are also not enough radiologists trained in reading breast MRI to permit any sort of mass screening of even high risk women, nor are there enough genetic counselors to identify all the women who might be at high enough risk to qualify for MRI screening. Moreover, there are not enough facilities with the capability of doing MRI-guided biopsies of lesions that aren’t visible on any other imaging study. Finally, these recommendations were made on the basis of zero data regarding whether such screening results in a decrease in mortality due to breast cancer in the population undergoing MRI. Once again, remember lead time and length bias.
I’m beginning to fear that the increase in mastectomy rates could well be an unintended consequence that is happening now as MRIs are done for most patients with breast cancer, at least in urban centers. For this discussion, remember the terms “stage migration” and overtreatment. There is little doubt that MRI will be more likely to find additional suspicious lesions in the breast with the known cancer an/or to indicate that the cancer goes further than it appears on mammography. As I asked three weeks ago (rhetorically, of course), how can this not be good thing? Four years ago, Dr. Monica Morrow, then Chairman of the Department of Surgical Oncology at the Fox Chase Cancer Center was frighteningly prescient in an editorial in an editorial in JAMA:
Is it possible to reconcile the fact that MRI detects additional carcinoma [in the same breast] in as many as a third of patients, yet clinical outcomes for patients undergoing breast-conserving therapy on the basis of clinical and mammographic selection are excellent? At this point, some clinicians may be experiencing a sense of déjà vu. In the 1970s when the prospective randomized trials of breast conserving therapy were being initiated, pathological studies demonstrating multicentric foci of carcinoma separate from the primary tumor site in 38% to 54% of patients were used to argue that even early stage breast carcinoma was a disease of the entire breast, and treatment with less than complete mastectomy was inappropriate. Extensive clinical experience has shown that the majority of these tumor foci are controlled with breast irradiation and these deposits of microscopic cancer have largely been forgotten for the past 20 years. Now, MRI technology is capable of identifying some of these occult tumor foci. Is this an appropriate reason to start doing more mastectomies? The answer is no. Prior to adopting MRI as a routine part of the evaluation of the patient with breast cancer, there should be evidence of benefit to the patient in the form of a reduced rate of ipsilateral breast tumor recurrence. This reduction in breast recurrences will need to be weighed against the number of extra biopsies resulting from the routine use of MRI, the cost, and the delay in surgical treatment.
[...]
In the absence of trials with a clinical end point, breast cancer patients undergoing MRI should be advised that this step forward in technology may take them right back to the 1970s and result in a mastectomy for disease that can be controlled with radiation.
Exactly, or, as Dr. Seema Khan of Northwestern University said recently in reference to the ASCO study:
In some cases, the additional tumors that MRI reveals might be effectively treated with more limited therapies, such as removing the initial lump followed by radiation and hormone treatment, said Dr. Seema Khan, director of the program for early detection and prevention of breast cancer at Northwestern Memorial Hospital. But once a scan uncovers additional tumors, many patients instinctively opt for a full mastectomy.
“There’s a huge question of whether we’re being led down a path of overtreatment by routinely using MRI,” said Khan, who was not part of the Mayo research team.
Everything old is new again. Alas, the older I get, the more I realize how often this is the case in medicine, with the very same issues popping up decade after decade in new guises. Black and Welch nailed it 14 years ago when they wrote:
Misperceptions of disease prevalence and therapeutic effectiveness can promote a cycle of increasing medical intervention, despite the best intentions of all parties. The cycle usually begins with some form of increased testing that lowers the threshold for detecting disease, such as technical improvement in imaging tests, more frequent testing, or closer scrutiny of the images. This immediately leads to a higher diagnostic yield of the disease and a spectrum of milder cases. These effects are almost always interpreted as indicating progress and provide immediate reinforcement for the increased testing, despite the caveat that earlier detection is a double-edged sword…Tests that are more sensitive…are accepted as better, even though they detect a broader spectrum of disease that includes a subgroup whose natural history and response to intervention are unknown. Consequently, the assessment legitimizes the use of the more sensitive imaging test and becomes a distraction from the fundamental question: How should patients with this newly detectable subclinical disease be treated?
Don’t get me wrong. I’m no Luddite; I love new gadgets and tests as much as the next doctor. Nor am I saying that MRI doesn’t have a role in breast screening or the workup of breast cancer. There is little doubt that a major cause of the decline in breast cancer mortality since the 1980′s has been the detection of breast cancer at earlier stages with mammography. It is quite possible that detecting tumors at still smaller and earlier stages with MRI could result in a modest further decrease in mortality from breast cancer, even taking into account the confounding factor of lead time bias. Moreover, there is an argument that taking care of the cancer in the opposite breast at the same time saves the patient with a synchronous contralateral cancer a second set of operations and treatments when her second tumor manifests itself clinically. It is nonetheless premature to conclude that MRI should be used in screening for any but the highest risk women or that MRI should be part of the routine battery of tests that women newly diagnosed with breast cancer undergo. It’s an expensive test (radiologists like it because they get paid a lot more for it than mammography); it’s operator-dependent and has a steep learning curve; there is no evidence that using it decreases mortality in women screened by it; and there is no evidence that its wanton use improves survival or decreases recurrence in patients with breast cancer thought to be treatable with breast conserving therapy, such as lumpectomy. Moreover, it has the real potential to result in more aggressive and disfiguring surgery for an unclear and possibly even nonexistent benefit to patients. More studies are clearly needed to determine whether MRI screening decreases mortality.
Unfortunately, in the wake of these new recommendations and studies, doing the high quality followup studies that answer the question of whether the use of MRI truly improves breast cancer care will be very difficult, and it will be very difficult for a clinician to justify not doing bilateral breast MRIs in, for example, patients with newly diagnosed cancer. Because of the medical-legal climate with respect to malpractice in this country coupled with media coverage that stokes patient demand, I reluctantly predict that it will not be long before all women (at least those with insurance, anyway) will undergo MRI screening (and a lot more biopsies as a result) and every breast cancer patient will have bilateral breast MRI upon diagnosis (and a lot more mastectomies as a result). It will take several years, if not a decade, to sort out whether this change in the standard of care for screening and for breast cancer patients actually results in improved survival and/or decreased rates of recurrence, or whether even the best technology and intentions will be thwarted again by lead time bias, length bias, and stage migration.
Back to the future we go!
REFERENCES:
1. Armstrong, K., et al. (2007). Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians. Annals of Internal Medicine, 146(7), 516-526.
2. Qaseem, A., et al. (2007). Screening Mammography for Women 40 to 49 Years of Age: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine, 146(7), 511-515.
3. Saslow, D., et al. (2007). American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography. CA: A Cancer Journal for Clinicians, 57, 75-89.
4. Lehman, C.D., et al. (2007). MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast Cancer. New England Journal of Medicine, 356, 1295-1303.

   The cancer screening kerfuffle erupts again: “Rethinking” screening for breast and prostate cancer
David Gorski 
Link
I see that the kerfuffle over screening for cancer has erupted again to the point where it’s found its way out of the rarified air of specialty journals to general medical journals and hence into the mainstream press.
Over the last couple of weeks, articles have appeared in newspapers such as the New York Times and Chicago Tribune, radio networks like NPR, and magazines such as TIME Magazine pointing out that a “rethinking” of routine screening for breast and prostate cancer is under way. The articles bear titles such as A Rethink On Prostate and Breast Cancer Screening, Cancer Society, in Shift, Has Concerns on Screenings, Cancers Can Vanish Without Treatment, but How?, Seniors face conflicting advice on cancer tests: Benefit-risk questions lead some to call for age cutoffs, and Rethinking the benefits of breast and prostate cancer screening. These articles were inspired by an editorial published in JAMA last month by Laura Esserman, Yiwey Shieh, and Ian Thompson entitled, appropriately enough, Rethinking Screening for Breast Cancer and Prostate Cancer. The article was a review and analysis of recent studies about the benefits of screening for breast and prostate cancer in asymptomatic populations and concluded that the benefits of large scale screening programs for breast cancer and prostate cancer tend to be oversold and that they come at a higher price than is usually acknowledged.
For regular readers of SBM, none of this should come as a major surprise, as I have been writing about just such issues for quite some time. Indeed, nearly a year and a half ago, I first wrote The early detection of cancer and improved survival: More complicated than most people think. and then followed it up with Early detection of cancer, part 2: Breast cancer and MRI. In these posts, I pointed out concepts such as lead time bias, length bias, and stage migration (a.k.a. the Will Rogers effect) that confound estimates of benefit due to screening. (Indeed, before you continue reading, I strongly suggest that you go back and read at least the first of the aforementioned two posts to review the concepts of lead time bias and length bias.) Several months later, I wrote an analysis of a fascinating study, entitling my post Do over one in five breast cancers detected by mammography alone really spontaneously regress? At the time, I was somewhat skeptical that the number of breast cancers detected by mammography that spontaneously regress was as high as 20%, but of late I’m becoming less skeptical that the number may be somewhere in that range. Even so, at the time I did not doubt that there likely is a proportion of breast cancers that do spontaneously regress and that that number is likely larger than I would have guessed before the study. Of course, the problem is that we do not currently have any way of figuring out which tumors detected by mammography will fall into the minority that do ultimately regress; so we are morally obligated to treat them all. My most recent foray into this topic was in July, when I analyzed another study that concluded that one in three breast cancers detected by screening are overdiagnosed and overtreated. That last post caused me the most angst, because women commented and wrote me asking me what to do, and I had to answer what I always answer: Follow the standard of care, which is yearly mammography over age 40. This data and these concerns have not yet altered that standard of care, and I am not going to change my practice or my general recommendations to women until a new consensus develops.
Before I discuss the JAMA analysis, let me just sample a bit of how this issue is being portrayed in the popular press:
        ◦ This week the conversation garnered national attention when physicians at the University of California, San Francisco, and University of Texas, San Antonio, published an analysis in the Journal of the American Medical Association expounding on their concerns about the ongoing harm inflicted on patients who undergo prostate and breast cancer screening. One problem is that screening often picks up harmless or non-life-threatening tumors that could have gone unnoticed for a lifetime, leading to unnecessary and aggressive treatment for patients. In the days before widespread mammography, for instance, physicians rarely encountered ductal carcinoma in situ (or DCIS), a type of low- to intermediate-grade breast cancer that grows slowly and may even regress, meaning that the body may rid itself of the tumor. But today DCIS accounts for nearly 30 % of all breast cancer diagnoses (more than 60,000 cases a year), leading to an untold amount of treatment and patient distress. (TIME Magazine)
        ◦ The purpose of screenings is to detect cancer early, when treatments are most likely to be effective, and to save lives. That the tests do so for colon, breast and cervical cancer has been well-established for middle-age adults but is not indisputable for those who are older, as most studies have been done in people younger than 65. Research on routine PSA screening has yet to prove a definitive benefit at any age. On the other side are the potential costs, which can include unnecessary treatments for cancers that never would have become life-threatening, the anxiety and distress associated with cancer diagnosis, the complications associated with screening procedures or therapies, and medical expenses. (Chicago Tribune)
        ◦ Call it the arrow of cancer. Like the arrow of time, it was supposed to point in one direction. Cancers grew and worsened. But as a paper in The Journal of the American Medical Association noted last week, data from more than two decades of screening for breast and prostate cancer call that view into question. Besides finding tumors that would be lethal if left untreated, screening appears to be finding many small tumors that would not be a problem if they were left alone, undiscovered by screening. They were destined to stop growing on their own or shrink, or even, at least in the case of some breast cancers, disappear. (New York Times)
        ◦ The American Cancer Society, which has long been a staunch defender of most cancer screening, is now saying that the benefits of detecting many cancers, especially breast and prostate, have been overstated. It is quietly working on a message, to put on its Web site early next year, to emphasize that screening for breast and prostate cancer and certain other cancers can come with a real risk of overtreating many small cancers while missing cancers that are deadly. (New York Times)
The latest kerfuffle is simply the latest bubbling up of a controversy that has been going on for years. It’s also a classic example of the difficulty of applying messy science to public health issues. Science is messy, but public health initiatives, to be successful, arguably need a simple message that resonates with the public, a message like
    • Screening for cancer catches cancers at an earlier stage when they are more easily treated.
    • Screening for cancer saves lives.
    • You should get screened if you’re older than N years old.
Thus, when evidence that calls into question any of these messages appears, it causes consternation among the lay public. Worse, cranks leap to take advantage of such controversies and make claims, such as “mammography is useless” and publish cartoons like this. Even people who should know better say similar things. As I’ve said before, science-based medicine is hard and not always clear-cut. Moreover, I would argue that debates such as this demonstrate that the claims of cranks that physicians all march in lockstep or that there is a “conspiracy” to keep shortcomings of SBM from patients are nothing but the rankest nonsense. Finally, cranks often conflate, either through ignorance, willful ignorance, or often outright hostility to “Western medicine,” screening mammography with diagnostic mammography. Screening mammography is designed to detect disease in asymptomatic women. If a woman feels a suspicious lump, nothing–I repeat, nothing–in any of this data says that she should not have a physical exam and appropriate imaging, including mammography and ultrasound at the minimum, posthaste. That’s diagnostic mammography, and that is not what this kerfuffle is over. Suspicious lumps, especially in women over 40, need to be worked up, period. I can’t emphasize that strongly enough.
So what did Esserman et al say? They lay out the problem thusly:
A large fraction of the US population participates in screening for prostate cancer and for breast cancer. About 50% of at-risk men have a routine prostatespecific antigen (PSA) test and 75% have previously had a PSA test.3,4 About 70% of women older than 40 years reported having a recent mammogram.5 Two decades of screening have resulted in a significant increase in detection of early cancers. Prostate-specific antigen testing has nearly doubled the chance that amanwill be diagnosed with prostate cancer in his lifetime: In 1980, a white man’s lifetime risk of prostate cancer was 1 in 116; today it is 1 in 6.1 A woman’s lifetime risk of breast cancer was 1 in 12 in 1980; today it is 1 in 8.1 If ductal carcinoma in situ (DCIS) is included, the risk of being diagnosed with breast cancer, like prostate cancer, has almost doubled as well.
The increase in early cancers as a fraction of total cancers detected is not necessarily beneficial. The introduction of an optimal screening test should be followed by an increase in the rate of early disease followed by a decrease in regional disease while the overall detection rate remains constant.7 FIGURE 1 illustrates hypothetical optimal, worst case, and intermediate-case scenarios, using 1980 breast cancer incidence rates as a starting point. In the worst case, screening leads to an increase in local disease detection without a corresponding decrease in regional disease, thereby increasing costs and morbidity due to overdetection and overtreatment of non–life-threatening cancers.
They conclude that current screening protocols for breast and prostate cancer result in a case that is intermediate between the worst case and optimal case scenarios. Because their graph illustrates this problem better than words can, I present it here:
(Click for larger image.)
Esserman et al then point out that the incidence of early stage breast and prostate cancers has increased dramatically as a fraction of total cancers detected, while regional and metastatic cancers have decreased dramatically as a fraction of those cancers detected. One example is the form of breast cancer known as ductal carcinoma in situ, abbreviated DCIS. DCIS is considered to be breast cancer, but “pre-invasive” cancer, given that the sine qua non for its diagnosis is seeing cancerous-appearing breast epithelial cells confined within the ducts with no evidence of their having invaded through the basement membrane that separates the ducts from the surrounding tissue. Thus, DCIS has been labeled “stage zero” cancer, and its 5 year survival is close to 100%, although a small proportion of patients does recur and ultimately die of breast cancer. There is even a debate over whether DCIS truly represents a precursor to cancer, as it is unclear what percentage of DCIS lesions progress to frank cancer, making the treatment of DCIS very confusing to patients. Before the mammographic screening era, which began in earnest after 1980, diagnoses of DCIS were uncommon. Now DCIS makes up nearly a third of new breast cancer diagnoses. Again, because we don’t know which of these lesions will progress and which won’t (or even which ones might regress), we treat them all, and this treatment involves nearly all the treatments used for breast cancer, with the only treatment not used on DCIS being chemotherapy.
As for more advanced regional tumors (tumors with lymph node metastases or involvement of local structures) and metastatic tumors, the absolute numbers have also decreased, but not very much. If screening were having a huge effect on breast cancer, the expectation would be that removing tumors at a smaller stage would, nearly three decades later, ultimately result in fewer advanced cancers being detected, their having been preempted by screening and appropriate treatment by surgical excision and adjuvant therapy. (This is one reason why screening for colorectal cancer has been more effective; removal of polyps is effective at preventing the subsequent development of colorectal cancer.) The conclusion, which again should be nothing surprising for anyone who saw my post from last year, is that screening by nature preferentially detects slower growing, more indolent cancers, which by their very nature tend to be less lethal and some of which may not even ever progress enough to endanger the life of the patient. The fastest-growing, most lethal cancers grow so fast that they seem to “pop up” between screenings. As a breast cancer surgeon, I see such tumors occasionally. A woman will come in with a palpable mass and an very ugly mammogram after having had a mammogram less than a year before that shows no trace of abnormality or, sometimes, an abnormality that is only appreciated in retrospect because it was so subtle. Naturally, such women are distraught because they have “done everything right” and obtained their yearly mammography just as their primary care doctors told them too. However, no practical screening program could catch tumors such as these because it would require too frequent screenings, which would also, unfortunately, increase the chances of finding abnormalities that lead to overdiagnosis. The dilemma, again, was discussed in my post, and, indeed, Figure 3 in the JAMA article is in essence the same figure that I reproduced to help me discuss length bias, only with much better design sensibilities and a dash of color:
The most distressing conclusion of Esserman’s analysis is just how many patients need to be screened to save one life. It is well-accepted that screening women over age 50 for breast cancer does decrease mortality due to breast cancer by approximately 30%, but what does this reduction really mean? This:
Essentially, mammography reduces the odds of a 60-year-old woman dying of breast cancer in the next decade by 30%. Sounds impressive, until you look at her absolute risk: by getting her annual mammogram, her chances of dying from breast cancer are whittled from 0.9% to 0.6%. Overall, for every 1,000 women in their 60s screened for breast cancer in the next 10 years, mammograms will save the lives of 3 people but 6 others will still die. (The numbers edge up or down in lockstep with a woman’s age.)
Esserman et al conclude that, to avert one death from breast cancer with mammographic screening for women between the ages of 50-70, an age range intentionally chosen because it is the age range for which mammographic screening is the least controversial, 838 women need to be screened over 6 years for a total of 5,866 screening visits, to detect 18 invasive cancers and 6 instances of DCIS. The additional price of this was estimated to be 90 biopsies and 535 recalls for additional imaging, as well as “many cancers treated as if they were life threatening when they are not.” For prostate, to prevent one death from cancer, 1,410 men need to be screened over 9 years, for a total of 2,397 screening visits and 48 cancers detected. In other words, screening takes a lot of effort for, on an absolute basis, not as many lives saved as we had hoped. The authors also point out that technology exacerbates this problem. We push for ever greater sensitivity at the cost of lower specificity, which means that we detect more and more lesions that turn out not to be cancer or to be indolent, non-lifethreatening cancer. Yet all of these cancers end up being treated the same, again because we cannot distinguish between them. The addition of hypersensitive modalities such as MRI only exacerbate this problem even further. As Esserman et al state:
After 2-1/2 decades of screening for breast and prostate cancer,conclusions are troubling: Overall cancer rates are higher, many more patients are being treated, and the absolute incidence of aggressive or later-stage disease has not been significantly decreased. Screening has had some effect, but it comes at significant cost, including overdiagnosis, overtreatment, and complications of therapy, problems likely to be exacerbated as the US population ages. Additional gains are unlikely with the current approach and may inadvertently add to the burden of treatment and diagnosis for relatively indolent disease.
So what’s the solution? Should we give up on screening?
I’ll answer the second question with an emphatic absolutely not. There is no doubt that screening can save lives; the problem is that we’re doing it “bigger” not and not necessarily better or smarter, using more or less a one-size-fits-all approach when a more tailored approach is necessary. In essence, we’re using 20th century technology, when 21st century technology can find a way out of these conundrums. Here’s where I (mostly) agree with Esserman et al. We need to change how we screen for common cancers using the latest advances in biochemistry, molecular biology, and technology to differentiate which lesions are most likely to be cancer and which are not, which cancers are likely to progress to the point of threatening a patient’s life in their remaining lifespan and which ones are not. To this end we need the following tools:
    • Develop biological and genetic markers of risk for various cancers. It’s long been known that screening is more effective in populations where a disease is common. The more common the disease (to a point) the more likely screening is to save lives. Thus, if we could develop better tools to identify women most at risk for breast cancer, for example, we could start screening such women at a younger age and perhaps screen them more frequently. We already do this to some extent, but our current tools (family history to identify higher risk populations, a handful of genetic markers, and ethnicity) are crude measures at best. Equally important would be to find similar markers to identify women at lower risk, who might start screening at an older age and undergo screening less frequently. Most important of all, identifying high risk patients more effectively would open up the possibility of prevention to a far greater extent than is possible now.
    • Identify biological markers to differentiate minimal risk cancers from cancers with significant risk. Again, we have begun to do this to some extent. For example, tests such as the Oncotype DX multigene test are now clinically used to determine which women with early stage, estrogen receptor-positive breast cancers would and would not benefit from chemotherapy. It’s relatively crude as a tool goes, but we will do better. Indeed, we are beginning to develop the tools that would allow us to go much further. It would not surprise me if, in a decade or so, we routinely do a battery of such tests on newly diagnosed tumors and then use the results to decide which ones can undergo “watchful waiting,” which ones need aggressive therapy, and which ones can undergo less aggressive therapy. Eventually, we will be using therapy targeted to the individual genetic alterations in an individuals tumor. Yes, I know I’ve expressed skepticism over such “targeted” therapy before, but that’s not because I don’t believe the concept will work; it’s because the boosters of targeted therapy often seem not to realize just how difficult and complex it is and will be to identify targets and how hard it will be to turn the targeting of proteins and genetic alterations into therapies that result in decreased mortality from cancer. In other words, I believe that genetic and biomarker analysis will ultimately allow us to tailor therapy to an individual’s tumor; I just think that getting there will take a lot longer and be a lot messier than the current generation of biotech cheerleaders either understand or will let themselves admit.
    • Develop better markers of response to therapy. Right now our primary assessment of whether a therapy is working or not boils down to one of two things: survival rates (the ultimate endpoint) or whether a tumor shrinks or not in response to therapy. Both are very crude. The former is the ultimate measure, but it is not helpful in the case of an individual patient, who wants to know if her treatment worked or not before she dies. The latter is notoriously inaccurate, with tumor shrinkage only showing a weak correlation to overall survival. This is one area where tests similar to the ones being developed to determine the aggressiveness of a tumor could potentially help.
    • Develop better imaging tools to assess risk. This is the one area that Esserman et al neglected almost completely in their review. This is an area that I have only recently become very interested in for our research program. Technology is progressing to the point where it soon may well be possible to identify a lesion as cancerous or not with greater than 90% using a “virtual biopsy” and then further to determine its risk of causing the death of the patient, when combined with biochemical and genetic analyses. Such tools would allow us to choose patients who might be appropriate for “watchful waiting” with far less anxiety over whether we’re doing the right thing than there is now and, even better, potentially to identify tumors that are likely to regress spontaneously.
None of this will be easy, and the process of getting from where we are now to this futuristic vision will be be full of fits and starts. At times it will be controversial. Advances in science-based medicine always are. Moreover, there will be significant barriers to its implementation, not the least of which is the relatively simplistic thinking that has come to predominate how we view cancer screening, not in the rarified air of the research institutions that actually study the pros and cons of screening, but “in the field” at the level of individual practitioners trying to put these screening recommendations into practice. It is not the fault of these practitioners that these fine points are not more widely known. Rather, the reason derives from the conflict between the need for simple messages to tell patients and the difficulty of applying epidemiological science to individual patients.
So what do we do in the meantime? One thing I am not going to say is to stop undergoing screening. Women should continue to undergo mammographic screening as recommended according to the standard of care. Whether men should continue to undergo routine prostate screening as previously recommended is now controversial, with less evidence to support it than mammography except in high risk populations. Until a consensus develops for changing the current regimen, it is the best we have, and, for all its shortcomings, mammography remains the best and most cost-effective tool we have to detect cancer. (The case for routine mass PSA screening, in contrast, now strikes me as considerably weaker.) Even in the worst case scenario that breast cancer screening results in the appearance of a benefit all due to lead time bias (which it isn’t; I present this as a worst case scenario), treatment of cancers caught at an earlier stage is still less invasive and less morbid. True, this has to be weighed against overtreatment of lesions that would never progress, but even so the benefit of using less invasive therapy is one that is routinely discounted by the new generation of what I am sometimes tempted to call “screening nihilists,” a group that seems to think that nearly all screening is worthless.
The problem is not that screening is worthless. For example, even mammography under the most pessimistic estimates routinely touted as evidence that it’s pointless to screen clearly does save lives. A relative reduction in risk is not meaningless or of insignificant worth, either, as some nihilists will suggest. Also, don’t forget that even small absolute percentages when applied to millions upon millions of people, can result in large numbers of lives saved. That being said, I also think that these recent trials suggest that we are not doing an adequate job of informing patients of the down side of screening, such as excessive biopsies, a down side many might well be willing to accept if they were informed of it and understood it. After all, as I’ve mentioned before with regards to breast cancer, I’ve seen polls where most women say they would agree to undergo cytotoxic chemotherapy to improve their odds of surviving breast cancer by 1%. To save more lives relative to the number of women overtreated and overdiagnosed, we need to learn how to screen smarter. Our current screening regimens are not good enough. Improving them will require science-based medicine, and, unfortunately, will be controversial. Watching the jolting, jarring journey to a new scientific consensus about something as important as screening for breast and prostate cancer is much watching the proverbial sausage being made. I also can’t help but point out the contrast to “alternative” medicine, which rarely questions and almost never changes practice in the face of new data. It may well be that our hopes for screening for breast cancer and prostate cancer were too high, but in science-based medicine evidence eventually wins out. Screening practices will likely change in the face of new evidence, and that is a good thing. Certainly it’s better than the alternative, namely not changing and not improving.

   Do over one in five breast cancers detected by mammography alone really spontaneously regress?
David Gorski
Link
It figures.
Last Wednesday, right before the four-day Thanksgiving holiday weekend, as I was far more interested in preparing to have family over the next day than in what was going on in the medical news or the blogs, the results of a most fascinating study hit the news. In Medscape, the title of the news report was Mammography Study Suggests Some Breast Cancer May Spontaneously Regress; on WebMD, the story ran under the title Can Breast Cancer Disappear?; on Medical News Today, Mammograms May Identify Cancers That Would Otherwise Just Regress by Drs. Per-Henrik Zahl, Jan Maehlen, and H. Gilbert Welch. Not surprisingly, the study found its way out of the medical news and into mainstream media outlets as well, given how provocative the findings seemingly are. From the Medscape report on this study:
A mammography study from Norway has come up with the controversial proposal that one fifth of breast cancer detected on screening may spontaneously regress. But there is no easy way to verify whether this is the case, say experts.
The study was published in the November 24 issue of the Archives of Internal Medicine. It found that the cumulative incidence of invasive breast cancer in a cohort of women, aged 50 to 64 years, who received 3 mammograms over 6 years was 22% higher than in a control group of age-matched women who received only 1 mammogram at the end of a 6-year period.
In their review of possible explanations for the difference in the breast cancer rates between the 2 groups — which had similar risk factors for breast cancer — the researchers write that the “natural course for some screen-detected breast cancers may be to spontaneously regress.”
“I anticipate that many clinicians will react negatively to the possibility of spontaneous regression, said coauthor Jan Maehlen, MD, PhD, professor of pathology at the Ulleval University Hospital, in Oslo, Norway, in an interview with Medscape Oncology.
Before I discuss the study itself, let me briefly discuss why clinicians may have a bit of a problem with the implications of this study, if they accurately reflect the biology of breast cancer.
The essential problem with this study is not the results per se. Rather, it is that, even if it is true that as many as 22% of breast cancers regress spontaneously, we currently have absolutely no way of distinguishing this minority of tumors from the vast majority that will progress without treatment. Consequently, although this study’s findings are provocative and might even be true (although I do think that Dr. Maehlen oversells and exaggerates his results a bit–more on that later), to the average primary care physician or to the average breast surgeon (like me), this study provides no guidance on what to do. If we see an abnormality on mammography and ultrasound that looks suspicious, we are still obligated to work it up and, if necessary, biopsy it. We are still obligated to excise it if it turns out to be a breast cancer. In other words, because we have no way of distinguishing the “good” cancers from the “bad,” so to speak, we are morally obligated to treat both the same because this study provides zero guidance about which tumors might safely be observed to see if they regress. Worse, it induces doubt in patients over whether or not they truly need a biopsy, which, until we find some way of identifying the tumors that won’t progress, they do. Add to that the fact that failure to diagnose breast cancer consistently ranks either number one or in the top three among causes for malpractice lawsuits, and you can see why primary care physicians might not appreciate this study.
Of course, here’s one area where Dr. Maehlen overstates the negative reaction a bit. I suspect that most surgeons, medical oncologists, and radiation oncologists who actually specialize in breast cancer will be skeptical of the magnitude of the rate of spontaneous regression reported by Dr. Maehlen but unlikely to reject out of hand that such regression may occur more often than has been documented. The reasons for this skepticism are buried within the methodology of the study itself, particularly its underlying assumptions. To some extent, I fear that Dr. Maehlen is confusing overdiagnosis by mammography with spontaneous regression in that he seems to be assuming that all the “overdiagnosed” tumors must have spontaneously regressed, an assumption that is not tenable.
To understand why I’m not particularly surprised that mammography might pick up breast cancers that ultimately spontaneously regress, I refer SBM readers to a series of posts that I wrote a few months back entitled The early detection of cancer and improved survival: More complicated than most people think and Early detection of cancer, part 2: Breast cancer and MRI. In particular, concentrate on the concepts of lead time bias, length bias, and overdiagnosis. Also note that in autopsy series, among women from 40-50 years old, 39% had detectable foci of breast cancer or ductal carcinoma in situ, a rate far higher than the overall percentage of women who will ever be diagnosed with breast cancer somtime during their lifetime. These data alone suggest that there are quite a number of cancers that either regress or never progress beyond a small tumor.
Now, on to the study.
A study of this sort could only have been accomplished in a nation with a government-run health care system with extensive databases linking information from every hospital in the nation, and that’s true of this study, which was carried out in Norway. Indeed, the numbers of women in each study are staggering: 109,784 in the control group and 119,472 in the “screened” group. So here’s what Drs. Zahl, Maehlen, and his colleagues did.
In essence, they took advantage of a change in the routine screening protocol in Norway. In 1995, the Ministry of Health and Care Services instituted the Norwegian Breast Cancer Screening Program, in which women between the ages of 50 and 64 were invited to undergo a two-view biennial screening program. The women in this study who make up the “screened” group thus underwent a first round of screening mammography in 1996-1997, a second round in 1998-1999, and a third round in 2000-2001. The control group consisted of women (age range 50-69 years) who would have been invited to participate in the screening program between 1992 to 1997, had the Norwegian Breast Cancer Screening Program existed then. (If you’re interested in the details, the study is available free online.) These women only underwent one screening mammogram at the end of their six year period, compared to the three mammograms the women in the screened group underwent. One thing that’s impossible for me not to mention here is that this is thus a retrospective study and therefore prone to all the problems to which retrospective studies are prone. However, in the case of this study, the screened and control groups are about as well matched as can be done, but never forget that there could be biases inherent in the retrospective study design that can be very hard to ferret out.
Having settled on the two groups, Dr. Zahl then looked at how many diagnoses of breast cancer were made in each group, and they excluded non-invasive (or preinvasive) breast cancer, more commonly referred to as ductal carcinoma in situ (DCIS). Instead, they concentrated only on invasive carcinoma. The screened group had 22% more diagnoses of invasive carcinoma than the group that only received one screening test at the end of a six year period. The authors make a fairly strong argument that the additional invasive cancers in the screened group are unlikely to be explained by better cancer ascertainment with time (ascertainment was excellent for the entire time period covered by the study); increasing sensitivity of mammography (estimated sensitivity and specificity were not significantly different at the beginning of the study time period compared to the end); an increase in the actual incidence of breast cancer (highly unlikely over a six year period, and an increase in the underlying incidence of breast cancer could only explain at most 4% of the observed difference); or hormone replacement therapy, which does confer an increased risk of breast cancer.
Instead, the authors’ favored explanation is regression of some tumors. This is where, I believe, their argument is least convincing, at least to me: They disregard the possibility of stable tumors that do not progress. True, they do posit what they call an “extreme” case, where 50% of breast tumors are stable and are picked up with 50% sensitivity on each round of screening and show that such a case can at most account for the 22% excess number of breast cancers in the screened group, the implication being that their case is so “extreme” that it makes an explanation of stable cancers that do not progress seem very unlikely. However, what they neglect is the case where far more than 50% of breast tumors are stable, which may be the case, at least if the autopsy series I reference above is correct. In that case, it would be quite easy to postulate an explanation where stable cancers, coupled with increasing quality of mammography, could result in an apparent 22% excess number of cancers diagnosed in the screened population. However, I’m not so convinced that that “extreme” case is all that extreme. Even so, I am also not dismissing Dr. Zahl’s contention that 22% of mammographically-detected breast cancers spontaneously regress, either. What I am arguing is that it is doubtful that all 22% of tumors detected in the screened group must have regressed.
There are also methodological problems with Dr. Zahl’s trial to contend with, as an accompanying editorial by Drs. Robert Kaplan and Franz Porzsolt points out:
Because the study by Zahl et al2 was not a randomized clinical trial, methodological concerns may lead to other explanations for these findings. One possibility is that the larger number of mammograms in the multiple screen group could account for the differences. We know, for example, that between 20% and 30% of visible lesions are overlooked. Studies suggest that detection rates are higher if films are reviewed by multiple radiologists. One study showed that among 108 radiologists, there was a range of 40% in the sensitively for detecting breast lesions.12 Women who have had 3 consecutive mammograms may be up to 20% more likely to have a positive result on 1 of the 3 tests. However, the study by Zahl et al2 included 1 additional screen in each group. If the multiple vs single screen explanation is correct, we should have seen a narrowing of the difference between the 2 groups following the additional screen. That did not occur. Furthermore, if we assume that tumors missed in early screens continue to progress, they should have showed up in the tumor registry. They did not. The design of the study has many imperfections, but we should not overlook its strengths. It was population based, it had very high participation, and the outcomes were well documented in an independent tumor registry. Considering the strengths and weaknesses of the methodology, the findings should not be dismissed.
Another reason not to disregard the findings of Zahl et al is that they are consistent with several observations that have troubled investigators for years. For example, randomized clinical trials rarely show the benefits of screening, particularly for women younger than 50 years. The Canadian National Breast Screening Trial hinted of spontaneous regression, and the Wisconsin Breast Cancer Epidemiology Simulation Model required a concept like spontaneous regression to account for observational data. Although the findings of Zahl et al seem counterintuitive, the spontaneous regression hypothesis is difficult to rule out.
Indeed it is, although Drs. Kaplan and Porzsolt overstate the difficulty in finding a survival advantage due to mammographic screening, which in women over 50 is pretty clear, less so in women 40-50 years of age. In any case, the only sure-fire way to rule the hypothesis in or out would be a randomized clinical trial because any such trial designed to answer the question of whether some breast cancers undergo spontaneous regression would require that a significant number of women with diagnosed breast cancer go without treatment. Any such trial would clearly be unethical, because even if this study is correct and roughly one in five breast cancers detected on mammography will regress, that still means that four out of five cancers will progress, meaning that withholding treatment from women with breast cancers detected on mammography would have an 80% chance of resulting in harm in terms of delaying therapy. This means that the real question is not whether some percentage of breast cancer patients didn’t actually require therapy. It’s very likely that some small percentage don’t, although I tend to think that Zahn et al overestimate the level of overdiagnosis, given multiple previous studies suggesting it to be considerably lower. The question is what the risk-benefit ratio is. It also has to do with patient choice and what her tolerance for risk is. After all, if we were to come up with a test that could predict which tumors were likely to regress (or at least not to progress), there would still be a chance of the test being wrong and the tumor’s progressing. Watchful waiting as a management strategy for such tumors may not sit well with patients, many of whom are so terrified of breast cancer that they would rather undergo invasive procedures to biopsy mammographic abnormalities, even when the likelihood of cancer is low. Some will even request bilateral mastectomies for small tumors that could easily be treated with lumpectomy. Indeed, on occasion, I’ve had to try to talk patients out of such overkill. Such situations are where science-based medicine sometimes conflicts with patient desires.
If Dr. Zahn’s results hold up, though, there is one rather interesting implication, and that is with regards to “alternative” medicine modalities that, it is claimed, treat breast cancer. Very early on in the history of this blog, I wrote a post that described how it can appear that “alternative medicine” that is completely ineffective can nonetheless lead to the appearance of efficacy and thus to “testimonials” by some women about how they were “cured” by “alternative” medicine. In essence, many breast cancers are cured by surgery alone, which can consist of the excisional biopsy that diagnosed the cancer in the first place, if the biopsy completely removed the cancer. The addition of radiation therapy and chemotherapy are “icing on the cake,” so to speak, in that they decrease the risk of recurrence but are not the primary cure. In cases where patients undergo surgical excision of their breast cancers but eschew chemotherapy and/or radiation in favor of “alternative” medicine, they almost always attribute their survival to the alternative medicine rather than the surgery alone. After all, surgery is a nasty and brutally “primitive” and “disfiguring” business, and in the world of alt-med it can’t possibly be of value, can it?
Now add to this a facet of breast cancer biology in which 20% or more of mammographically detected breast cancers spontaneously regress. If true, this observation could explain an additional set of breast cancer “testimonials,” in which the woman giving the testimonial had a needle biopsy but never underwent curative surgery. Indeed, if Dr. Maehlen is correct and 20% of mammographically detected breast cancers spontaneously regress, that would be a major addition to the pool of women who gambled with “alternative” medicine to treat their breast cancer and ended up being one of the lucky one in five. Indeed, if Dr. Mahlen’s results hold up, he may well have done skeptical physicians an unwitting service by providing another potential explanation for the ever-ubiquitous breast cancer “alt-med” testimonial, his exceedingly unfortunate use of the very bad choice of the term “pseudocancers” to describe the additional cancers picked up by mammography notwithstanding.
Finally, if there’s one thing that this study highlights more than anything else, it’s just how little we know about the natural history of small mammographically detected breast cancers, as pointed out in the accompanying editorial:
Perhaps the most important concern raised by the study by Zahl et al is that it highlights how surprisingly little we know about what happens to untreated patients with breast cancer. In addition to not knowing the natural history of breast cancer for younger women, we also know very little about the natural history for older women. We know from autopsy studies that a significant number of women die without knowing that they had breast cancer (including ductal carcinoma in situ). The observation of a historical trend toward improved survival does not necessarily support the benefit of treatment. Improved survival is equally well explained by lead-time bias. Widely cited studies describing the dire consequences of refusing treatment may not be entirely credible. In the best known of these, Verkooijen and colleagues compared women who refused surgery with those who had accepted surgery. In their analysis of 5339 women in the Geneva cancer registry, Verkooijen et al found 1.3% who refused surgery. Among these, approximately half received no treatment at all. Survival among the women who refused treatment was lower than it was for women who accepted treatment. However, the groups were in no way comparable. Those who refused were 10 years older, more likely to be of lower income, single, and at more advanced stages of disease. Larsen and Rose reviewed the literature going back to the first part of the last century and concluded that spontaneous remission of breast cancer occurs but only rarely.
I think that Drs. Kaplan and Porzsolt overstate their case a bit, namely because we do have evidence from earlier this century about the natural history of untreated breast cancer. Granted, these tumors were not mammographically detected, but it’s just not correct to say that we do not have a reasonable idea of what the natural history of untreated breast cancer is likely to be. Drs. Kaplan and Porzsolt would have made a better point if they had said that our knowledge of untreated breast cancer that is not palpable and is detected by mammography alone is less than what we would like it to be. Also, one must keep in mind that this study is definitely an outlier. It’s not as though this issue hasn’t been studied before. Indeed, I discussed the extreme variability of breast cancer growth based on another study out of Norway. Come to think of it, this study uses much of the very same data that Dr. Mahlen used, namely women screened in Norway during the period of 1995 to 2001, and it used a far more sophisticated model and design compared to those of Dr. Mahlen’s study, not to mention much larger numbers. I wonder why no one mentioned this study to Dr. Mahler in the context of his trial or why he didn’t cite the study in his manuscript. It’s highly relevant, especially since it looks at a dataset that certainly has significant overlap with the dataset studied by Zahn et al. Surprisingly, the reaction of the American Cancer Society was even more overblown:
The American Cancer Society took issue with the thinking that cancer may regress on its own. “The conclusion that more than 1 in 5 invasive breast cancers is destined to regress without incident if not detected by mammography [the 22% figure cited in the study] is nothing more than an overreaching leap in logic,” Robert A. Smith, PhD, director of cancer screening for the American Cancer Society, says in a prepared statement.
Other studies have found that “overdiagnosis” — not the same as regression — probably occurs in less than 5% of all screen-detected cancer cases if it exists at all, Smith says.
He says the benefits of regular mammograms far outweigh any limitations, such as false-positive results and “possibly a small rate of overdiagnosis.”
I would respectfully disagree that the conclusion of this study is an “overreaching leap in logic.” Although this is only one study and, I suspect, it probably overestimates the rate of overdiagnosis due to mammography, it does make an at least plausible case that spontaneous regression of breast cancer may be more common than than previously thought. Reactions like Dr. Smith’s play right into the hands of certain people who are–shall we say?–less than friendly to science-based medicine who claim that the medical profession views this study as a profound threat.
In any case, the bottom line is that the matter of screening mammography is far more complex an issue than it is often portrayed to be. It’s a matter of balancing the benefits of detecting cancer at an earlier stage versus the risk of overdiagnosis. Moreover, it is quite possible that a significant proportion of breast cancers detected by mammography (although, I hasten to add, not cancers detected as palpable masses) may indeed regress. The problem is that we do not yet know enough to identify which tumors will progress and which may not. Even under the most optimistic scenario, in which Dr. Mahlen’s study is confirmed, four out of five breast cancers will progress and become life threatening. Those are not odds that I would want to mess with, unless someone can develop a predictive test that allows me to identify cancers that it’s safe to subject to watchful waiting to see if they regress. Unfortunately, there ain’t no such beast, but I’m optimistic that there may well be before my career comes to an end.
Finally, it should be remembered that mammographic screening in the U.S. is different than it is in much of Europe. We begin screening at age 40, whereas few European countries start mammographic screening before age 50 except in women with factors that put them at high risk. We tend to screen every year, whereas in Europe, most countries screen every other year, which is the sort of screening regimen institute in Norway in 1995 around which this study was built. Such a screening regimen would be more likely to be able to detect regression were it not for the fact that any suspicious abnormality is in general biopsied and, if malignant, excised. in addition, as mentioned before, doing a randomized study would be unethical, because it would necessitate some women with biopsy-proven breast cancer being left untreated. The complexities involved in determining the efficacy of any mass screening program thus provide an excellent example of just how difficult getting answers in science-based medicine can be. Between the ethical problems that make a gold standard trial impossible, the variable biology of breast cancer, and the imperfections in screening tests, science-based medicine is hard. It’s always risk/benefit analyses and shades of gray. Perhaps that’s why quackery is so attractive. There isn’t all that messy dealing with difficult-to-interpret evidence.
REFERENCE:
Per-Henrik Zahl, MD, PhD, Jan Mæhlen, MD, PhD, H. Gilbert Welch, MD, MPH (2008). The Natural History of Invasive Breast Cancers Detected by Screening Mammography Archives of Internal Medicine, 168 (21), 2311-2316

Mammography and the acute discomfort of change
David Gorski on April 7, 2014
Link
As I write this, I am attending the 2014 meeting of the American Association for Cancer Research (AACR, Twitter hashtag #AACR14) in San Diego. Basically, it’s one of the largest meetings of basic and translational cancer researchers in the world. I try to go every year, and pretty much have succeeded since around 1998 or 1999. As an “old-timer” who’s attended at least a dozen AACR meetings and presented many abstracts, I can see various trends and observe the attitudes of researchers involved in basic research, contrasting them to that of clinicians. One difference is, as you might expect, that basic and translational researchers tend to embrace new findings and ideas much more rapidly than clinicians do. This is not unexpected because the reason scientists and clinical researchers actually do research is because they want to discover something new. Physicians who are not also researchers become physicians because they want to take care of patients. Because they represent the direct interface between (hopefully) science-based medicine and actual patients, they have a tendency to be more conservative about embracing new findings or rejecting current treatments found not to be effective.
While basic scientists are as human anyone else and therefore just as prone to be suspicious and dismissive of findings that do not jibe with their scientific world view, they can (usually) eventually be convinced by experimental observations and evidence. As I’ve said many times before, the process is messy and frequently combative, but eventually science wins out, although sometimes it takes far longer than in retrospect we think it should have, an observations frequently exploited by advocates of pseudoscience and quackery to claim that their pseudoscience or quackery must be taken seriously because “science was wrong before.” To this, I like to paraphrase Dara O’Briain’s famous adage that just because science doesn’t know everything doesn’t mean you can fill in the gaps with whatever fairy tale that you want. But I digress (although only a little). In accepting the validity of science that indicates either that a medical intervention that was commonly used either doesn’t help, doesn’t help as much as we thought it did, or can even be harmful, they have to contend with the normal human reluctance to admit to oneself that what one was doing before might not have been of value (or might have been of less value than previously believed) or that, worst of all, might have caused harm. Or, to put it differently, physicians understandably become acutely uncomfortable when faced with evidence that the benefit-risk profile of common treatment or test might not be as favorable as previously believed. Add to that the investment that various specialties have in such treatments, which lead to financial conflicts of interest (COI) and desires to protect turf (and therefore income), and negative evidence can have a hard go among clinicians.
Examples abound in the history of medicine. In my own specialty, some surgeons resisted the transition over to doing needle biopsies of breast cancers because that meant more radiologists and fewer surgeons would be doing breast biopsies. There was also resistance to the concept that doing only partial mastectomies (“lumpectomy”) was safe and effective. Urologists weren’t too thrilled with the development of drugs that could shrink benign prostatic hypertrophy (BPH), the proliferation of which resulted in a dramatic decline in the number of transurethral resections of the prostate (TURPs) performed. The proliferation of angiographic stenting of coronary blockages led to turf battles over which lesions needed surgical bypass and which ones could be safely stented by cardiologists. Tonsillectomy is another good example of a procedure that was widely done (I had one when I was around 6) but now seldom done because in the vast majority of cases before it was unnecessary.
All of which brings us to screening mammography, in my usual meandering way, because there were two new studies from JAMA last week that add to the drip, drip, drip of mammography studies that all seem to be converging on similar conclusions. Once again, I must emphasize that I am not talking about diagnostic mammography; i.e., mammography ordered to evaluate a lump or other symptoms in the breast. Nothing—I repeat—nothing has changed with respect to that. If a woman has a lump in her breast or concerning symptoms, mammography is indicated. What I am referring to is screening mammography performed on women without symptoms in order to detect breast cancer before it becomes symptomatic. I cannot emphasize that enough.
Yet another mammography study…times two
Last week, as has been happening more frequently, there was a study published that cast more doubt on current mammography guidelines. It is not like the Canadian National Breast Screening Study whose results were published a couple of months ago in that it does not find that screening mammography does not result in a benefit. However, it does find that the benefit-risk ratio of routine screening mammography is not as favorable as believed in the past. Rather, it is more like studies by Gilbert Welch, a Norwegian study, and studies highlighting the problem of overdiagnosis, in which significant percentages of screening-detected cancers are overtreated and some even spontaneously regress. Before I get to the study itself, I often like to give you a flavor of how the press reported the study. An example of pretty good reporting is the news story from NPR covering the study.
Here’s the study by Lydia E. Pace and Nancy L. Keating, entitled A Systematic Assessment of Benefits and Risks to Guide Breast Cancer Screening Decisions. It’s not behind a paywall, indicating that JAMA must have thought it important enough that it should be widely available. It’s also pretty well written and (mostly) understandable, even if you don’t necessarily have a high level of expertise in mammography and epidemiology. What the authors did was to search MEDLINE for relevant randomized clinical trials (RCTs), meta-analyses, systematic reviews, and observational studies from 1960 to January 19, 2014, as well as the references of key articles, reviews, meta-analyses, and practice recommendations, which were searched manually. They also included meta-analyses of randomized clinical trials (RCTs) of mammography screening examining breast cancer mortality. From 525 articles identified, 20 meta-analyses met these criteria, and the authors, quite appropriately, focused most of their attention on the 5 meta-analyses published after 2006, which include the last RCT of mammography.
Another thing that the authors did was to emphasize their estimates of number needed to invite (NNI) to screening, as well as absolute risk ratios. Frequently, results of clinical trials (not just RCTs of mammography) are presented as relative risk reductions (e.g., “mammography decreases the risk of dying of breast cancer by 19%), which can be misleading if the absolute risks and risk reduction are low. I’ve described this phenomenon before in the context of RCTs of adjuvant chemotherapy for breast cancer, where a 30% relative risk reduction might actually mean only a 2-3% absolute decrease in the risk of dying of early stage breast cancer. In adjuvant chemotherapy for breast cancer, the absolute magnitude of the survival benefit increases along with the absolute risk of dying. In other words, a given adjuvant chemotherapy regimen might produce a similar, say, 30% decrease in the risk of dying for all breast cancers of a certain subtype, but that 30% means more on an absolute basis for nastier tumors. Put it this way. If you have a 50% chance of dying of your disease, a 30% relative risk reduction of that risk translates to a 15% lower chance of dying on an absolute basis. If, on the other hand, you only have a 10% chance of dying of your disease, that same 30% relative risk reduction translates to only a 3% absolute risk reduction.
A similar principle exists for screening tests, and this review explains that quite well, boiling it down into a couple of concise tables. Since the article is free, I don’t feel obligated to reproduce Table I and Table II so I’ll just discuss them. Table I shows pooled mortality reductions due to mammography for different age ranges. I could discuss how the authors derived their estimates ad nauseam. Certainly, if anyone wants to get into that level of detail, he’d have to have a detailed understanding of the studies that went into coming up with these numbers. Given that the numbers are roughly consistent with estimates that Laura Esserman derived in her review and a fair number of other estimates, I’ll spare you. Basically, Table I was derived from Nelson et al., the meta-analysis conducted for the USPSTF. The key parts of the estimates is this: The younger the patient group, the higher the NNI is, ranging from 377 for women aged 60-69, resulting in an absolute risk reduction of dying from breast cancer in the next ten years of approximately 0.3%, to 1,904 for women aged 40-49, translating to an absolute risk reduction of 0.05%.
Table II shows the estimated benefits and harms of screening mammography for women in the various age ranges studied for 10,000 women undergoing screening using Surveillance, Epidemiology, and End Results (SEER) estimates from a recent review by Welch and Passow. Not unsurprisingly, the error bars are large. The lower number reflects a minimal breast cancer mortality of 5% based on RCTs reporting no benefit, while the upper number reflects a reduction of 36% based on the clinical trial reporting the highest benefit, the always-cited Swedish trial by Tabár et al.
Also included are estimates of overdiagnosis, false positives screening studies requiring more imaging and/or biopsy, and the number of patients who underwent one or more unnecessary biopsies during the ten year period. Again, the numbers for overdiagnosis are similar, actually slightly lower, than the numbers I’ve discussed before, which have generally converged around an estimate of 20% or slightly more of screen-diagnosed breast cancers turning out to be overdiagnosed. I note that in all age ranges the upper estimates of overdiagnosis approach 40% but that in women aged 40-49 the upper estimate is over half. For women starting screening at age 40 or 50, the chance of at least one false-positive result is 61%, while it’s 49.7% for women undergoing screening between the ages of 66 and 74.
These results lead the authors to conclude:
Although some of the challenges of mammography can be resolved with further research to guide individualized decisions and thoughtful development and dissemination of decision aids, better breast cancer screening tests are needed. More sophisticated tools, for example, could distinguish aggressive vs indolent tumors, reducing the burden of overtreatment.86 Mammography screening appears to be associated with reduced breast cancer mortality, but for some patients, the harms may outweigh the benefits. Until better screening methods are available, improved understanding of these harms, enhanced strategies to identify the highest-risk patients, and tools to help patients and clinicians incorporate these in their decisions should be research priorities.
Or, as one article reporting on the study characterized it, Stop One-Size-Fits-All Mammography. This is a reasonable take-home message from the study. The problem, of course, is that our risk assessment tools and models are still, even a decade into the genomic revolution, grossly inadequate to the task.
Adding to the confusion is a review article that appeared in the same issue of JAMA by Louise C. Walter and Mara A. Schonberg, entitled Screening Mammography in Older Women: A Review. It begins with a patient story:
Mrs M is 91 years old and has had annual screening mammograms since age 50. She lives alone in her apartment and independently performs all activities of daily living. Her chronic medical conditions include hypertension and osteopenia, and she was diagnosed with intermittent claudication in 2010. Her medications include valsartan, furosemide, and isosorbide dinitrate. Mrs M had her only child at age 16, experienced menopause at age 50, and never used postmenopausal estrogen or progesterone. She had a negative breast biopsy in 1984. Her daughter died of breast cancer at age 37.
In 2008 at age 87, Mrs M had an abnormal screening mammogram with microcalcifications in the left medial inferior breast, interpreted as category 3 (Breast Imaging-Reporting Data System [BI-RADS]; probably benign). She subsequently underwent scheduled 6-month follow-up diagnostic mammograms over the next 18 months. The third mammogram, performed in 2010, showed interval increase in the number of heterogeneous microcalcifications and was classified as a BI-RADS category 5 (highly suggestive of malignancy). The lesion was not amenable to biopsy under stereotactic guidance. Therefore, she underwent excisional biopsy of the left breast lesion using needle localization. The biopsy identified ductal carcinoma in situ (DCIS), intermediate grade without comedo-type necrosis, on 2 of 9 slides. Estrogen receptor staining was strongly positive. One area of DCIS was less than 1 mm from the anterior margin so she underwent reexcision and no residual DCIS was identified. Mrs M met with a radiation oncologist who did not recommend radiation therapy, and she declined tamoxifen due to concerns about adverse effects. She continues to undergo annual mammograms, which have been negative, and she is seen by a breast oncologist every 6 months.
PerspectivesMrs M: I get mammograms every year. I know you don’t get them all your life.
Dr P: I think people might say: “What are you doing getting mammograms in a 91-year-old?” but you have to meet this lady. She is a lot more likely to live to be 100 than I am.
It might be surprising to you, but there are no RCTs examining screening mammography that included women over 74. All the major studies that showed a decrease in death due to breast cancer in women screened by mammography excluded older women. Most guideline panels and organizations have therefore recommended that screening mammography in women 75 and older be decided based on an individualized approach that weighs potential benefits and harms of screening in the context of a woman’s overall health, life expectancy, and preferences. It’s a shocking hole in our evidence base with regards to screening mammography, but there it is. Clinicians, as is so often the case, have to apply an incomplete data set lacking rigorous studies to individual patients.
To examine the issue of mammography in women 75 and older, the investigators attempted to look at the balance of risk and benefit in such women. It’s not just a woman’s risk of breast cancer, as in the first study, that drives the risk-benefit consideration. It’s also how long a woman is likely to live, which drives the risk that a women will (1) develop breast cancer in her lifetime and (2) that that breast cancer will kill her before something else does, such as old age. The authors therefore searched PubMed for English-language studies in peer-reviewed journals published from January 1, 1990, to February 1, 2014, to identify risk factors for late-life breast cancer in women aged 65 years and older and to quantify the benefits and harms of screening mammography for women aged 75 years and older. Their first search identified 864 articles, of which 24 provided data on risk factors for breast cancer in women aged 65 years and older. The second search resulted in 2,121 articles of which 13 provided data on survival benefits and/or false-positive results and biopsies following screening mammography specifically for women aged 75 years and older.
Their conclusions/recommendations from their review of the literature included:
    • Advancing age is the greatest risk factor for developing breast cancer. Risk factors that reflect hormonal exposures in the distant past (eg, age at first birth, age at menarche) may be less predictive of late-life breast cancer than factors indicating recent hormonal exposures (eg, high bone mass or obesity).
    • Randomized trials of screening mammography did not include women aged 75 years and older. Observational studies suggest benefit of continued screening mammography in older women who have a life expectancy of more than 10 years.
    • Potential harms of screening mammography include overdiagnosis (ie, finding a breast cancer that would not have clinically surfaced in the absence of screening) as well as pain and anxiety associated with false-positive results and biopsies.
    • Breast cancer treatments are effective among older women in good health; however, the harms of breast cancer treatment increase as women age, particularly among older women with limited life expectancy.
    • Providing information about life expectancy along with potential benefits and harms of screening mammography may help older women’s decision making about screening mammography.
Regarding #4 above, the authors also note that screening women over 74 will only be effective if effective treatments exist for early stage aysmptomatic breast cancer in such women. Unfortunately, few breast cancer treatment clinical trials included women aged 75 years and older or women with multiple comorbidities or frailty. In other words, not only are women older than 74 not represented in RCTs of mammography, but they are underrepresented in RCTs testing breast cancer treatments. Indeed, women 65 and older are grossly underrepresented in breast cancer clinical trials. Confusing things even more is that breast cancers diagnosed in older women tend to more indolent tumors, exactly the kind that are more frequently overdiagnosed, thanks to length bias. Thus, overdiagnosis tends to increase with age, both because older women tend to develop more indolent tumors and, to put it bluntly but very simply, there’s less time for diagnosed cancers to kill them. This led to an estimate by the authors that roughly 32% of breast cancers diagnosed by screening mammography in older women will be overdiagnosed.
Overall, the authors’ recommendations are reasonable, but, as is the case in the first article, maddeningly vague, leaving the primary doctor to do pretty much what he or she thinks is best, with little hard guidance as to what is best. Overall, however, adding these two studies to the pile of studies that have been published over the last six years or so, I am definitely coming to agree with Pace and Keating that the era of one-size-fits-all mammography is almost certainly coming to an end. Indeed, even the Komen Foundation seems to recognize this in its statement about the first study. If you read it, you’ll notice a subtle backing-away from a concrete recommendation that screening begin at 40, with a shift in emphasis towards the need for better tools to evaluate a woman’s risk of breast cancer to guide screening decisions. To that I’d add that we desperately need better tests for diagnosed cancers and DCIS, in order to determine who does and doesn’t require aggressive treatment.
In the meantime, however, clinicians are left with uncertainty, and clinicians, understandably, don’t like uncertainty.
Putting it into context
Being a translational researcher in addition to a surgeon, I’m a bit “schizophrenic” in that I live in both worlds, the world of the clinician and the world of the basic/translational scientist. Because until relatively recently I didn’t do much clinical research, I tended to think much more like a basic scientist in some areas but, when it came to routine practice, I thought much more like a clinician. So it was that I didn’t think much about the guidelines for mammography until around six years ago or so. The guidelines were the guidelines, and I followed them, not really showing much interest in the science behind them. Then in 2008, I rediscovered the concept of overdiagnosis, something that doctors tend not to be taught about as much as they should be and therefore something that they either know little about or tend to dismiss. The result was my first post about how difficult it is to show that early detection of cancer results in improved outcomes, thanks to the issues of lead time bias and length bias. Then in 2009, I noted a review/commentary article by Laura Esserman regarding the need to rethink how we screen for breast and prostate cancer, highlighting the high numbers of people who need to be screened to prevent one death from the cancer screened for and the not inconsequential harm of overtreatment that can occur.
It seemed like karmic justice that two weeks later the United States Preventive Services Task Force (USPSTF) published its suggested guidelines with regard to screening mammography, in which it recommended that screening begin at age 50, not 40, and that it be conducted every other year rather than every year. I commented on the guidelines, of course, noting that they were not the final word, a prediction about as safe as predicting that the sun will rise in the east or that this year’s election will be contentious. It was also my first acutely-uncomfortable experience with new findings regarding mammographic screening, as I found myself in the distinct minority among my colleagues in not being alarmed by the results or feeling the need to explain them away. Worse, this was the first time that I had ever been in any sort of position where I was asked to help craft the official public response by my cancer center, a task that had to be completed within a day or so because of the number of inquiries we were getting. It was my first real experience trying to communicate science in a way that had real consequences. Blogging is just blogging, and I can spout off more or less what I’m thinking without worrying overmuch about it. In contrast, this time, I was trying to help craft a statement as part of my real world job, a statement that could have real effects on patients.
The reason it was so hard is because over the years the guidelines that stated that screening mammography should start at age 40 and be done yearly had become very entrenched, and persuading women that this was a good thing to do required a simple, concrete message. The USPSTF guidelines laid bare in a highly publicized story how messy the scientific process and, in particular, the process of translating basic and clinical science into guidelines is. Predictably, cancer quacks seized on these guidelines that “mammography doesn’t work,” while advocate groups were dismayed and had to defend their guidelines, while some radiologists used what can only be described as despicable claims to protect their turf (and still do).
It’s instructive to look at what the American Cancer Society has recommended over the years, which is conveniently found in a table form on the ACS website. It wasn’t until 1997 that the ACS started recommending yearly mammography for women between 40 and 49. Before that, the recommendation was for a baseline mammogram at or around age 40 and then mammography every 1 to 2 years. Before that, the recommendation was for a woman to consult her physician, and before that the recommendation was: “May have mammogram if they or their mother or sisters had breast cancer.” This occurred not long after two other occurrences. First, there was an NIH consensus conference on mammography in women aged 40-49 held earlier that year.
The press release about that conference and the controversies discussed sounds eerily familiar to much of what I just discussed above. Second, the National Cancer Advisory Board recommended “that the National Cancer Institute (NCI) advise women 40 to 49 to get screening mammograms every one to two years if they are at average risk for breast cancer.” Interestingly, no mention was made of overdiagnosis and overtreatment; the only harms listed were false positives, which, it was noted, are more common in younger women. The NCAB also notes that its decision reversed a previous decision in 1993 to withdraw its recommendation for routine screening mammography between ages 40 and 49. Not coincidentally, the NCI reversed itself less than a week after the ACS and American College of Radiology (ACR). Although the NCI denied that its decision was influenced by it, there was intense political pressure brought to bear, with the Senate previously having unanimously passed a resolution urging mammograms for women in their 40s. In addition, Sen. Arlen Specter, R-Pa., had threatened the NCI director’s job over the controversy, as his Senate subcommittee that oversees federal health spending practically ordered the NCI to do the same, and several legislators wrote or called the NCAB with the same request.
In other words, everything old is new again. Most people aren’t aware of the long strange trip mammography took to become what it is now. Politics has been and continues to be a factor in determining mammography guidelines.
Of course, the American College of Radiology, as has been the case every time a study has been published that found that either the risks of mammography were higher than thought before or the benefits not as great as previously believed, is at it again, this time with the Society of Breast Imaging. The two professional societies issued a joint press release last week, and it’s full of the usual spin:
The American College of Radiology (ACR) and Society of Breast Imaging (SBI) agree with statements made by Pace and Keating, in their recent article published in the Journal of the American Medical Association (JAMA), that women should discuss mammography with their doctor and breast cancer diagnosis and treatment may one day be more individualized. However, at present, breast cancer screening based primarily on risk — as discussed in the JAMA article — would miss the overwhelming majority of breast cancers present in women and result in thousands of unnecessary deaths each year.
Utter piffle, so much so that another post might well be required to explain why. Suffice to say that the press release trots out the same tired (and discredited) arguments that somehow the CNBSS has been “discredited” (it hasn’t) and a paper purporting to show that overdiagnosis is not nearly as big a problem as recent studies have indicated, which might require an entire new post of its own. In the meantime, suffice also to say that there’s less to the attacks on, for example, Bleyer and Welch’s study from 2012 than certain radiologists would like you to believe.
What to do?
Contrary to the hysterical denunciations of the recent studies that have led me to this conclusion, women won’t be dying in droves if screening recommendations are made less intense. Most developed countries don’t start screening until age 50 for most women, and most only recommend biennial screening. Yet, these countries have breast cancer mortality rates comparable to what is observed in the US. That means one of two things: Either Europeans have better treatments for breast cancer than we do, sufficient to compensate for later diagnosis due to less intensive mammographic screening, or starting screening at age 50 doesn’t detectably affect mortality from breast cancer compared to starting at age 40. I doubt that Europeans have treatments for breast cancer that are that much better than those in the US; the second explanation is more likely the correct one.
As a surgeon and a scientist, I’ve found the resurrection of the debate over the efficacy of screening mammography to prevent breast cancer deaths to be simultaneously frustrating, educational, and confusing. I also realize that, although I specialize in the surgical treatment of breast cancer, in a way I’m not “on the front lines” in that I don’t see a lot of healthy women and advise them about whether to get their yearly mammogram beginning at age 40 or not. By the time they see me, they either have breast cancer, a suspicious lump (which means they will get more imaging if they haven’t already had it) or a mammographic abnormality that can’t be needle-biopsied and needs a surgical biopsy. That being said, as hard as it is for me sometimes to believe, I have served as leader of our breast cancer program and still work closely with existing leaders. I cannot avoid “taking a stand.”
Until recently, my stand was that we should stick with the existing guidelines until our professional organizations can examine the science and come up with new guidelines that reflect more recent studies. However, more and more I am of the opinion that we do over-screen. I still believe that mammography is of benefit in women of average risk beginning at age 50, but I’m becoming much less convinced of its utility in women under 50, at least those without identifiable risk factors for breast cancer. Such women should indeed have an individualized approach to screening. I say that, even though I recognize that our currently existing tools are grossly inadequate to give any more than a rough estimate. However, I also recognize that part of the equation has to be an accurate understanding of the absolute numbers and what the individual woman being screened values.
What that will mean remains to be worked out. Again. And the process will be messy. Again.

Is watchful waiting for ductal carcinoma in situ (DCIS) safe? Preliminary results of the COMET trial
Ductal carcinoma in situ is a precursor of breast cancer that is usually treated with surgery, radiation therapy, and estrogen blockade. A new study suggests that watchful waiting might be safe for some women with DCIS.
David Gorski on January 13, 2025
Link

It’s been a long time since I’ve written much about the one area where even quacks, cranks, and antivaxxers can’t argue that I don’t have expertise: Breast cancer. Oddly enough, it’s been a while since I’ve written about it, other than early after the introduction of COVID-19 vaccines, when radiologists were noting reactive enlarged lymph nodes under the arm after vaccination that were sometimes leading to unnecessary biopsies Oddly enough, even though I was aware of this study last month and had been meaning to write about it, what tweaked me to actually do so was an article that I encountered from an antivaxxer whom I’ve written about periodically, Maryanne Demasi, DCIS: should we stop calling it “breast cancer”?, with a blurb of, Renewed calls to minimise the overdiagnosis and unnecessary treatment of breast abnormalities.
Well, yes and no.
Demasi’s post is a paid Substack post; so I can’t read the whole thing. However, I distinctly remember it showing up at first as the full post. What I can say is that she is exaggerating when she extrapolates from the results of this study an implication that mammographic screening is useless. I also find it telling that, in her post on X, the hellsite formerly known as Twitter, she tags certain contrarians, specifically Drs. Vinay Prasad and Peter Gøtzsche, the latter of whom was her co-author on a study that used deceptive methodology to exaggerate the risk of COVID-19 vaccination. Also, keep in mind that Ms. Demasi is not exactly the greatest source for a take on this study. That being said, the introduction sounds deceptively reasonable:
The debate over how to manage ductal carcinoma in situ (DCIS) has gained momentum following a recent study suggesting that surgery might not be necessary for women diagnosed with the condition.
Often described as “stage zero breast cancer” or “a very early form of breast cancer,” DCIS is not actually cancer but rather a cluster of abnormal cells contained within the milk ducts.
Despite its non-cancerous status, the use of terms like “carcinoma” or “cancer” can cause considerable anxiety, prompting many women to choose aggressive treatments such as surgery and radiation—interventions that may not offer any clear benefit to their outcomes.
Last month, a new randomised trial, published in JAMA once again, challenged the necessity of surgery for DCIS.
She’s referring to the COMET trial, which stands for Comparing an Operation to Monitoring, with or without Endocrine Therapy. I’ll admit that it’s a rather tortured acronym, but the name basically describes the study: It’s a multicenter randomized controlled clinical trial that compares standard-of-care therapy, which includes surgery, radiation, and endocrine therapy (estrogen-blocking drugs like tamoxifen or aromatase inhibitors) with close monitoring and intervention only if there are signs of progression. I also note something that Ms. Demasi neglects to mention, namely that the trial is only enrolling women with low-risk DCIS. What that means specifically, I’ll get to in a minute, but we’re not talking extensive DCIS or DCIS with features that suggest it has a high propensity to progress to invasive cancer (or that it is likely to have already progressed, with the core needle biopsies having missed the invasive component. I also can’t help but mention that “de-escalation,” sometimes referred to colloquially as “less is more,” is not a new or radical concept when it comes to breast cancer, and particularly its precursor DCIS. Debates over the best treatment for DCIS (or whether it even needs to be treated at all) go way back. I’ve even written about some of them, such as in my 2013 post How Should We Treat DCIS? It’s therefore not entirely surprising that the study by Hwang et al, which I’ll discuss in more detail shortly, found no statistically significant difference in the primary outcome examined, the 2-year cumulative risk of ipsilateral (same side) invasive cancer diagnosis, according to planned intention-to-treat and per-protocol analyses. The authors concluded:
Women with low-risk DCIS randomized to active monitoring did not have a higher rate of invasive cancer in the same breast at 2 years compared with those randomized to guideline-concordant care.
First, though, a refresher course on what DCIS is.
DCIS: Cancer, premalignant lesion, or something else?
DCIS is, as Ms. Demasi states, commonly referred to as “stage 0” breast cancer. Personally, I’ve always had a bit of a problem with that designation and often say so to patients, preferring to categorize it as a premalignant lesion that, if left alone, can go on to turn into invasive breast cancer. The lesion is characterized by milk duct cells that appear malignant but remain confined to inside of the milk ducts. In other words, they haven’t invaded the tissue surrounding the ducts yet. It is also true that, even now in 2025, general, DCIS is treated similarly to breast cancer, with surgical excision, either by mastectomy or breast-conserving surgery, followed by radiation therapy if breast conserving surgery is used. Then, depending on its hormone receptor status, adjuvant treatment consists of blocking estrogen for five years. The only definite difference in treatment that I tell patients is that we never use chemotherapy to treat DCIS. (It is a common misconception that DCIS can require chemotherapy.)

The rationale for this treatment strategy is the view of DCIS as being a precursor to fully invasive breast cancer and that treating the DCIS will prevent the development of breast cancer. Indeed, in the accompanying editorial (which I’ll get to later), Drs. Monica Morrow and Andrea Barrio use a term for DCIS that I very much like, nonobligate precursor of invasive breast cancer. In other words, DCIS has a propensity to progress to invasive breast cancer, but it doesn’t always, and we’ve been arguing about what percentage of DCIS lesions progress and how fast for the last 100 years. Personally, I like to refer to DCIS to patients as the last stop on the train to breast cancer, which communicates the idea that DCIS is late in the process of cancer development but also that it’s not guaranteed to progress to become cancer.

Over the last three of decades, however, it has become clear that not all DCIS is created equal. Much of it will never progress to breast cancer in the lifetime of the woman (particularly if the woman is older, which means less time for fully malignant transformation to occur). Evidence suggesting this includes studies showing an increase in DCIS incidence by 16-fold since the 1970s, when mammography started to be introduced on a large scale, with little change in the incidence of invasive cancer. Today, 20-25% of mammography-detected breast cancer diagnoses are DCIS; fifty years ago, DCIS was an uncommon diagnosis, except associated with an invasive cancer. Now it is common, all thanks to mammographic screening. One model of breast cancer progression is illustrated below:
Breast cancer progression. (ADH=atypical ductal hyperplasia; DCIS=ductal carcinoma in situ.)
Screening for breast cancer tends to be based on the concept that progression from normal duct cells to invasive cancer follows more or less a linear progression, and then invasive cancer grows in the primary organ and eventually spreads, either through lymph vessels or the blood, to distant sites. By this paradigm, effective screening should result in finding disease earlier and thus preventing patients destined to develop metastatic disease from progressing to that point because the disease is removed before it can metastasize. This should result in what is referred to as a “stage shift,” in which the incidence of metastatic disease at diagnosis and of locally advanced disease declines, “shifting” the stage lower, to smaller, more localized disease. Unfortunately, although there is evidence of a small stage shift for breast cancer, the decline in incidence of advanced disease is far lower than the amount of DCIS diagnosed, meaning that most DCIS is almost certainly overdiagnosed, with large numbers of DCIS that never would have progressed to invasive cancer being treated as though they would.
There is also additional complexity in that the above linear model might be only one of multiple pathways by which breast cancer develops, and DCIS exhibits considerable heterogeneity, hence the designations of low, intermediate, and high risk DCIS. A lot of work has been done trying to identify the molecular mechanisms through which DCIS progresses (or doesn’t progress) to invasive ductal carcinoma (IDC)—I even co-authored a review article on this topic over a decade ago—but, suffice to say, there remains controversy. A recent review article provided this excellent timeline of concepts and research regarding DCIS:
For those who are interested, there are a number of models being tested other than just the linear model above:
Proposed models of DCIS progression. a Independent lineage model, which presumes that DCIS and IDC derive from two distinct normal epithelial cells which share no overlapping CNAs or mutations. b Evolutionary bottleneck model, which presumes that a specific clone within DCIS is selected and it evolves into IDC. c Multiclonal invasion model, which presumes that multiple clones escape and co-migrate to invasive regions to generate IDC. d Convergent phenotype model, which presumes that subclones of different genotypes within DCIS can all give rise to an invasive phenotype to establish IDC
Another way of looking at some of these models is here:
We don’t need to go into all of these models. Again, suffice to say that a significant percentage of DCIS lesions never progress (and a significant percentage do). We just don’t know for sure the percentages and how rapidly. Moreover, questions have been raised regarding the value of surgery in decreasing the risk of dying of breast cancer for a woman diagnosed with DCIS. Indeed, the post that I referenced from 2013 discussed a study concluding that aggressive treatment of nearly all DCIS does not appear to lead to a reduction in breast cancer mortality, which was consistent with an analysis of the NSABP B-17 and B-24 trials published four years prior. Basically, adding radiation therapy after lumpectomy also appears to have no effect on the risk of breast cancer mortality and might even be slightly higher. What this result suggests is that radiation therapy might not be necessary for the majority of DCIS cases. These are the sorts of studies and data that inspired the COMET trial.
COMET trial
The COMET trial is a pragmatic randomized controlled clinical trial of active monitoring of DCIS versus surgery and standard of care. The COMET schema was published in 2019:
COMET trial schema. Patient flow for accrual and registration. Eligibility criteria for low-risk DCIS include 40 years of age or older, grade I/II DCIS without invasive breast cancer diagnosed on core, vacuum-assisted or surgical biopsy; ER(+) and/or PR(+); HER2(−); and no mass on physical examination or imaging with exception of fibroadenoma at a distinct/separate site from the site of DCIS. The primary study endpoint on which the sample size is based is rate of 2-year invasive breast cancer diagnosis among patients randomised to GCC compared with AS. ITT analyses adjusted for drop-out, non-compliance and contamination will be performed on all randomised patients including those who do and do not accept the arm to which they are randomised. Patient-reported outcome surveys will be collected from all patients who are registered for the study, including those who crossover. Mammograms will be performed q6 months for the index breast and q12 months for the contralateral breast in the AS arm and q12 months in both the index and contralateral breast in the GCC arm. No chest wall imaging will be performed if mastectomy has been performed. AS, active surveillance; COMET, Comparison of Operative versus Monitoring and Endocrine Therapy; DCIS, ductal carcinoma in situ; ER(+), oestrogen receptor positive; GCC, guideline concordant care; HER2 (−), human epidermal growth factor 2 negative; ITT, intention to treat; PR(+), progesterone receptor positive; q, every.
As reported by Hwang et al, the flow was:
Patient acceptance of randomized intervention was defined at 6 months, but the primary outcome was cumulative during the 2-year follow-up period. COMET indicates Comparing an Operation to Monitoring, With or Without Endocrine Therapy for Low-Risk DCIS.
So what did Hwang et al report in the first report on the results of the COMET trial? In brief:
Trial participants were:
The study population included women with newly diagnosed DCIS who were aged 40 years or older and had screen-detected, nuclear grade 1 or 2 estrogen and/or progesterone receptor–positive (≥10% staining for Allred Score ≥40), ERBB2-receptor negative (immunohistochemistry scores of 0, 1+, or 2+ if tested) disease, without evidence of invasive cancer. Concurrence of 2 pathologists’ reviews of diagnostic specimens was required to confirm eligibility. Patients with breast symptoms or mass on baseline breast imaging were excluded.
While guideline-concordant care consisted of:
Patients randomized to guideline-concordant care had usual-care treatment for their diagnosis, including surgery. The choice of mastectomy or breast-conserving surgery was made by patients together with their surgeons. Patients undergoing breast-conserving surgery were offered adjuvant radiation treatment in accordance with standard practice. Diagnostic mammograms were required every 12 months for both the affected (if not treated with mastectomy) and unaffected breast.
And active monitoring consisted of:
Patients in the active monitoring group were regularly monitored with imaging and physical examination. Diagnostic mammograms were required every 6 months for the affected breast as part of active monitoring and every 12 months for the unaffected breast. Patients with a new breast mass, nipple/skin changes on physical examination, or imaging findings concerning for disease progression (eg, a new mass, new architectural distortion, and/or increase in extent of calcifications ≥5 mm in ≥1 dimension) were recommended to undergo core needle biopsy. Surgical intervention was required if the needle biopsy identified invasive cancer. For benign breast changes, atypia, or DCIS, continued active monitoring was recommended. Patients who wished to have surgery at any time, for any reason, proceeded to surgery in consultation with their treating surgeon, with the reason for surgery and pathology diagnosis at surgical excision recorded.
That last part is important. Without the ability of the patient to choose to switch to standard-of-care at any time she wished, the trial could not be ethical. Come to think of it, I would marvel that the investigators got this study through an institutional review board (IRB), but the safeguards to avoid harm to study subjects appear more than adequate.
Here is a chart illustrating the active monitoring protocol:
Surveillance protocol for COMET trial. Mammogram (MMG) not required if mastectomy performed. **Criteria for progression: (A) New mass/architectural distortion/density on surveillance MMG in either breast according to American College of Radiology Breast Imaging Reporting and Data System; (B) Increase in extent of calcifications ≥5 mm in at least one dimension compared with the most recent prior MMG of the index breast; (C) New suspicious findings on other radiological studies (ultrasound, MRI) in either breast. AS, active surveillance; COMET, Comparison of Operative versus Monitoring and Endocrine Therapy; DCIS, ductal carcinoma in situ; GCC, guideline concordant care; SoC, standard of care.
As for the results, as of two years, they are quite striking in their lack of difference between groups:
The median age of the 957 participants analyzed was 63.6 (95% CI, 55.5-70.5) years in the guideline-concordant care group and 63.7 (95% CI, 60.0-71.6) years in the active monitoring group. Overall, 15.7% of participants were Black and 75.0% were White. In this prespecified primary analysis, median follow-up was 36.9 months; 346 patients had surgery for DCIS, 264 in the guideline-concordant care group and 82 in the active monitoring group. Forty-six women were diagnosed with invasive cancer, 19 in the active monitoring group and 27 in the guideline-concordant care group. The 2-year Kaplan-Meier cumulative rate of ipsilateral invasive cancer was 4.2% in the active monitoring group vs 5.9% in the guideline-concordant care group, a difference of −1.7% (upper limit of the 95% CI, 0.95%), indicating that active monitoring is not inferior to guideline-concordant care. Invasive tumor characteristics did not differ significantly between groups.
Here are the recurrence curves for IDC:
Shaded areas indicate 95% CIs. A, In the intention-to-treat analysis, the 2-year cumulative rates of invasive cancer were 5.9% (95% CI, 3.71%-8.04%) in the guideline-concordant care group and 4.2% (95% CI, 2.31%-6.00%) in the active monitoring group, for a difference of −1.7%. B, In the per-protocol analysis, the 2-year cumulative rates of invasive cancer were 8.7% (95% CI, 5.06%-12.21%) in the guideline-concordant care group and 3.1% (95% CI, 2.31%-6.00%) in the active monitoring group, for a difference of −5.6%.
Also, at the time of analysis, six patients had died, two in the guideline-concordant care group and four in the active monitoring group, but none of them died of breast cancer.
The authors also noted the possibility of selection bias. You might have noticed how many patients in each group switched groups: 57/484 in the active monitoring group switched over to guideline-concurrent care, and 227/473 in the guideline-concurrent group crossed over to the active monitoring group. The design of the study was such that a 30% nonacceptance of allocation was anticipated and accommodated, but the nonacceptance rate in the guideline-concordant care group was 44%, about which the authors commented that “we did not anticipate the strong preference for monitoring over surgery among study participants.” The authors go on to note:
Recognizing the unexpectedly high rate of nonadherence to allocated intervention with potential for bias due to self-selection of treatment, we evaluated patient characteristics in 4 subgroups: those who were randomized to guideline-concordant care and received guideline-concordant care; those who were randomized to guideline-concordant care but received active monitoring; those who were randomized to active monitoring and received active monitoring; and those who were randomized to active monitoring but received guideline-concordant care. We found no obvious imbalance between groups (eTable 1C in Supplement 1).
This is somewhat reassuring, although the authors also note that they “cannot exclude the introduction of important unmeasured differences between groups, leading to selection and participation biases despite the prospective randomized design.”
A couple of things need to be emphasized here. First, even though the rate of ipsilateral invasive cancer was lower than I would have guessed, two years is not a very long time in the natural history of breast cancer. In other words, all this study shows is that, for short term outcomes, active monitoring is safe. The survival curves could, however, diverge with more time. Breast cancer, particularly estrogen receptor-positive breast cancer, can be an indolent disease, with ten or more years required to detect differences in outcomes. The authors recognize that and note:
Longer follow-up will help determine whether active monitoring offers durable safety and acceptability for patients in the management of this low-risk disease.
In other words, these results are preliminary, but encouraging.
What does this all mean?
Overall, from my perspective, the findings of the COMET trial thus far are modest. The results thus far suggest that “low risk” DCIS can be safely treated in the short term with active monitoring but have not yet demonstrated long term safety and efficacy. You wouldn’t know that looking at Demasi’s posts:
Mayo Clinic refers to DCIS as "stage 0 breast cancer" and "very early breast cancer". 

But DCIS is not "cancer" and the treatments for DCIS – such as surgery – may not actually improve outcomes for women. pic.twitter.com/So47nTDcnA
— Maryanne Demasi, PhD (@MaryanneDemasi) January 9, 2025
Sometimes in medicine, LESS is MORE. 

For the FULL story, click the link https://t.co/rUyAZEVyLO pic.twitter.com/6Vi4QeODx6
— Maryanne Demasi, PhD (@MaryanneDemasi) January 9, 2025
Let’s just say that nothing in the JAMA Open Network article reporting initial results of the COMET study questions whether we should be calling DCIS cancer or not. That’s really rather a separate debate that should be based on biology and clinical behavior rather than just one trial.
The accompanying editorial by Drs. Monica Morrow and Andrea Barrio, Is It Time to Abandon Surgery for Low-Risk DCIS?, is worth reading to put the results of this study in a much more reasonable and proper perspective. (Spoiler alert: Betteridge’s law of headlines applies, and the answer to the question is no, at least not yet.) First, Morrow and Barrio note that existing evidence from trials of surgical excision versus observation suggest that, as I mentioned above, for women diagnosed with DCIS the curve plotting incidence of invasive cancer versus time never plateaus. We also already have evidence from prior trials that IDCs detected on active monitoring of DCIS tend to be larger than those detected as recurrences after surgery for DCIS. Moreover, “low grade” DCIS does not necessarily mean that cancers that develop from the DCIS will be low grade. This leads them to come to a much less concrete conclusion that Demasi:
The COMET trial provides reassurance that in patients with DCIS and a limited life expectancy, surgical therapy, and possibly even endocrine therapy, can be omitted, although the more clinically relevant question is why such patients would be having mammographic screening to begin with. For the remainder, who constitute the large majority of women with DCIS, the safety of active monitoring remains in question. The long-term risk of invasive cancer development with active monitoring is unknown at this time but, based on ECOG-ACRIN E5194 and RTOG 9804, will be at least 0.6% per year, and possibly higher given the absence of surgical excision. Women enrolling in COMET demonstrated a strong preference for active monitoring; almost half of those randomized to guideline-concordant care did not have the prescribed surgery. However, COMET participants may not be representative of the population of women with DCIS at large. Population-based studies of women with DCIS have shown that concern about recurrence, invasive or DCIS, is the most important factor in patient selection of type of surgical therapy,10 so the proportion of women for whom any potentially avoidable risk of recurrence is unacceptable is unclear. Longer follow-up will also clarify the benefit of endocrine therapy in a successful active monitoring strategy. Acceptance of endocrine therapy following surgical excision of DCIS has historically been low, and adherence to 5 years of endocrine therapy is poor even in women with invasive cancer.11 Whether 5 years or longer of endocrine therapy is preferable to a brief outpatient surgical procedure remains to be seen. Meanwhile, adoption of active monitoring as a standard management strategy for low-risk DCIS requires longer follow-up for the majority of patients. The initial report of COMET does not provide the safety data necessary to omit surgery as part of DCIS management.
Precisely.
COMET suggests that there is a group of women with DCIS for whom surgery is unnecessary, although at the cost of every six month monitoring and likely repeat biopsies for the rest of their lives. That’s all we can say so far. It will take several more years before the data from COMET mature enough to let us say anything more definitive.


How should we treat DCIS?
David Gorski on August 23, 2015
Link

I’ve written more times than I can remember about the phenomenon of overdiagnosis and the phenomenon that is linked at the hip with it, overtreatment. Overdiagnosis is a problem that arises when large populations of asymptomatic, apparently healthy people are screened for a disease or a condition, the idea being that catching the disease at an earlier stage in its progression will allow for more successful treatment. Two prominent examples include—of course—screening for breast cancer with mammography and screening for prostate cancer with prostate-specific antigen (PSA) testing, and I’ve written about the problem of overdiagnosis with each of them on many occasions. Basically, overdiagnosis occurs when the screening test picks up what we call “preclinical” disease (i.e., disease that hasn’t become symptomatic) that, if left untreated, would never become symptomatic or endanger the health or life of the patient). Although intuitively, it seems to the lay public (and, truth be told, most doctors) that detecting cancer earlier must be inherently better, it turns out that it’s way more complicated than you think. There is a price to be paid for early diagnosis in the form of overtreatment of disease that doesn’t need treatment and for disease that is destined to threaten the life of the patient earlier treatment doesn’t always result in better outcomes. Also, whenever you screen for a condition in asymptomatic people, you will always—always—find much more of it, and the significance of those added diagnoses is not always clear, as a new study in JAMA Oncology shows.
DCIS and mammography: Some background
Before I get to the meat of the study, from my perspective, nowhere is the problem of overdiagnosis and overtreatment in cancer screening as pronounced than in the condition known as ductal carcinoma in situ (DCIS). DCIS is commonly referred to as “stage 0” breast cancer and is characterized by milk duct cells that appear malignant but remain confined to the milk ducts. In other words, they haven’t invaded the tissue surrounding the ducts. In general, DCIS is treated similarly to breast cancer, with surgical excision, either by mastectomy or breast-conserving surgery, followed by radiation therapy if breast conserving surgery is used. Then, depending on its hormone receptor status, adjuvant treatment consists of blocking estrogen for five years. The rationale for this treatment is the view of DCIS as being a precursor to fully invasive breast cancer and that treating the DCIS will prevent the development of breast cancer. Over the last couple of decades, however, it has become clear that not all DCIS is created equal. Much of it will never progress to breast cancer in the lifetime of the woman (particularly if the woman is older, which means less time for fully malignant transformation to occur). Evidence suggesting this includes studies showing an increase in DCIS incidence by 16-fold since the 1970s, when mammography started to be introduced on a large scale, with little change in the incidence of invasive cancer. Today, 20-25% of mammography-detected breast cancer diagnoses are DCIS; forty years ago, DCIS was an uncommon diagnosis, except associated with an invasive cancer.
Screening for breast cancer tends to be based on the concept that progression from normal duct cells to invasive cancer follows more or less a linear progression, and then invasive cancer grows in the primary organ and eventually spreads, either through lymph vessels or the blood, to distant sites. By this paradigm, effective screening should result in finding disease earlier and thus preventing patients destined to develop metastatic disease from progressing to that point because the disease is removed before it can metastasize. This should result in what is referred to as a “stage shift,” in which the incidence of metastatic disease at diagnosis and of locally advanced disease declines, “shifting” the stage lower, to smaller, more localized disease. Unfortunately, although there is evidence of a small stage shift for breast cancer, the decline in incidence of advanced disease is far lower than the amount of DCIS diagnosed, meaning that most DCIS is almost certainly overdiagnosed. Indeed, in the accompanying editorial to this study, Laura Esserman and Christina Yau note that long-term epidemiology studies have demonstrated that the removal of 50,000 to 60,000 DCIS lesions annually has not been accompanied by a reduction in the incidence of invasive breast cancers. The problem, of course, is that we don’t know which cases of DCIS are destined to progress and which are not; so we have to treat them all the same.
A new wrinkle in the science
This new study introduces a new wrinkle into the situation. You’ve probably seen the stories about it, such as one in The New York Times entitled “Doubt Is Raised Over Value of Surgery for Breast Lesion at Earliest Stage.” The reason is that the study questions whether treatment of DCIS actually decreases a woman’s risk of dying of breast cancer, based on an analysis of the Surveillance, Epidemiology, and End Results (SEER) database, a massive database maintained by the National Cancer Institute of cancer cases and outcomes. Specifically, the investigators (Narod et al.) from the Women’s College Research Institute, Women’s College Hospital, and the Dalla Lana School of Public Health at the University of Toronto looked at the SEER18 database, which covers approximately 28% of the U.S. population. (The SEER database is maintained by a number of local registries so it is basically a database of multiple local cancer registries.) From the SEER database, Narod et al. identified 108,196 patients with DCIS diagnosed from 1988 to 2011 who formed the cohort studied. Patients with microinvasion (a tiny area of invasive cells) were excluded because that is generally considered invasive cancer. They then calculated a standardized mortality ratio (SMR), which is the ratio of the risk of dying in the study cohort compared to the risk of death in all women in the US population.
The first finding of the study is that the breast cancer-specific mortality over 20 years was 3.3% (95% CI, 3.0%-3.6%), which is similar to the lifetime risk of all women of dying of breast cancer, according to the American Cancer Society (2.7%). Next, the risk of death from breast cancer among all women with DCIS was 1.8 times greater than that of the US population (SMR, 1.8 [95% CI, 1.7-1.9]). Not surprisingly, the SMR decreased with increasing age at diagnosis, from 17.0 for women with DCIS before age 35 years to 1.4 for women older than 65 years. This is to be expected, given that younger women have a much longer time to live during which breast cancer can develop than older women. It makes intuitive sense. Indeed, as Esserman and Yau observe, DCIS in women under 40 is likely biologically different, because it would not in most cases be detected by mammographic screening and would thus be first noticed as a lump or other symptom. For these women, continuing current treatment protocols is probably appropriate.
There were other risk factors besides age at diagnosis of DCIS that predicted breast cancer mortality. For example, black women had a higher risk of death from DCIS than white, non-Hispanic women (HR 2.42 [95% CI, 2.05-2.87]; p < 0.001). Other factors were related to the tumor itself and included tumor size, grade, and the presence of a characteristic of DCIS called comedo necrosis, which has long been known to be a marker of more aggressive DCIS. The results of this analysis were robust and did not change substantially when patients with microinvasion or patients with a breast cancer death or recurrence within 6 months of the DCIS diagnosis were included.
Another result of the study is that aggressive treatment of nearly all DCIS does not appear to lead to a reduction in breast cancer mortality, which is consistent with an analysis of the NSABP B-17 and B-24 trials published four years ago. Basically, adding radiation therapy after lumpectomy also appears to have no effect on the risk of breast cancer mortality and might even be slightly higher. What this result suggests is that radiation therapy might not be necessary for the majority of DCIS cases.
The last finding is one that will be harder for doctors and patients to wrap their brains around, which is that DCIS might be more of a risk factor for ultimately developing breast cancer than a precursor to breast cancer. The reason is how similar ipsilateral (same side) and contralateral (opposite side) recurrence rates were, 5.9% and 6.2%, respectively, at 20 years. Recurrence of DCIS was not associated with increased risk of death for breast cancer, but an invasive recurrence was, hazard ratio 18.1 for ipsilateral recurrences, 13.8 for contralateral recurrences. As the authors put it:
The finding of greatest clinical importance was that prevention of ipsilateral invasive recurrence did not prevent death from breast cancer. Women with DCIS who developed an ipsilateral invasive in-breast recurrence were 18.1 times more likely to die of breast cancer than women who did not. For patients who had a lumpectomy, the use of radiotherapy reduced the risk of developing an ipsilateral invasive recurrence from 4.9% to 2.5% but did not reduce breast cancer–specific mortality at 10 years (0.9% vs 0.8%). Similarly, patients who underwent unilateral mastectomy had a lower risk of ipsilateral invasive recurrence at 10 years than patients who underwent lumpectomy (1.3% vs 3.3%) but had a higher breast cancer–specific mortality (1.3% vs 0.8%). Patients who had a mastectomy had cancers with a larger mean size and higher grade than patients who had a lumpectomy (eTable 5 in the Supplement). After adjustment for tumor size, grade, and other factors, the difference in survival for mastectomy vs lumpectomy was not significant (HR, 1.20 [95% CI, 0.96-1.50]; P = .11).
In other words, the type of treatment for DCIS didn’t matter. The risk of death from breast cancer was the same regardless, and very low. Moreover, these data challenge the existing paradigm of DCIS as a precursor of breast cancer:
Only a fraction of treated DCIS lesions progress to invasive breast cancer,13 but in the absence of treatment, the risk of invasive cancer is much higher.14 Also, mortality from breast cancer in women with DCIS increases substantially following the development of an invasive local recurrence.4,5 However, if DCIS were truly a (noninvasive) precursor of breast cancer, then a woman with DCIS should not die of breast cancer without first experiencing an invasive breast cancer (ipsilateral or contralateral), and the prevention of an invasive recurrence should prevent her death from breast cancer. Surprisingly, the majority of women with DCIS in the cohort who died of breast cancer did not experience an invasive in-breast recurrence (ipsilateral or contralateral) prior to death (54.1%). Furthermore, preventing the invasive in-breast recurrence (with mastectomy or radiotherapy) does not reduce mortality from breast cancer. This is in keeping with the findings of other studies.
Some weaknesses (but not many)
This study is, of course, not without weaknesses. Any study that relies on the SEER database will have the weaknesses inherent in how the SEER database is put together. The database has been in existence many years and undergone multiple revisions. It’s also a bit slow to add data elements considered important to breast cancer treatment, such as HER2 status, as I discovered in 2009 when I wanted to do a project involving the SEER database. For instance, it’s possible that some cases of DCIS actually had microinvasion. Also, the authors didn’t have data on which DCIS cases were detected by mammography and which were symptomatic, although it’s likely that a small minority were symptomatic given that the vast majority of DCIS is detected by mammography. There were also no data on margin status. A positive margin (a margin in which tumor cells actually reach the surgical margin) is associated with a higher risk of recurrence. There are also vagaries of how multiple recurrences are coded.
Where do we go from here?
So where to go from here? In a very rare occurrence, I cannot agree with Monica Morrow about this:
Dr. Monica Morrow, chief breast cancer surgeon at Memorial Sloan Kettering Cancer Center, said it made more sense to view D.C.I.S. as a cancer precursor that should be treated the way it is now, with a lumpectomy or mastectomy. She questioned whether those women who were treated and ended up dying of breast cancer anyway had been misdiagnosed.
In some cases, pathologists look at only a small amount of tumor, Dr. Morrow said, and could have missed areas of invasive cancer. Even the best mastectomy leaves cells behind, she added, which could explain why a small number of women with D.C.I.S. who had mastectomies, even double mastectomies, died of breast cancer.
Given the large numbers, I find it to be bordering on wishful thinking to speculate that so many of these women had been misdiagnosed that it significantly affected the results of this study. Yes, pathologists only look at a relatively small sampling of tumor, because to look at the whole thing for every patient would be so labor-intensive and expensive as to be impractical. The same could be said of any operations we do, and we’ve accepted this limitation since pathologists started looking at tissues under the microscope. It’s highly unlikely that rates of misdiagnosis are so high as to have made a difference.
What I think this study really means is that there is an urgent need for better molecular markers to determine which cases of DCIS are dangerous and which are not, something I’ve joined with others in arguing before in the medical literature. Until we have such prognostic markers, we will have this dilemma. Esserman and Yau suggest:
Narod and colleagues4 have assembled an impressive analysis on the basis of SEER data. There are limitations of SEER, but the large numbers and long-term follow-up provide a compelling case that it is time for change. The community of radiologists and surgeons needs to be part of the call for change. Given the low breast cancer mortality risk, we should stop telling women that DCIS is an emergency and that they should schedule definitive surgery within 2 weeks of diagnosis. The sum total of the data on DCIS to date now suggest that:
     1.  Much of DCIS should be considered a “risk factor” for invasive breast cancer and an opportunity for targeted prevention.
     2.  Radiation therapy should not be routinely offered after lumpectomy for DCIS lesions that are not high risk because it does not affect mortality.
     3.  Low- and intermediate-grade DCIS does not need to be a target for screening or early detection.
     4.  We should continue to better understand the biological characteristics of the highest-risk DCIS (large, high grade, hormone receptor negative, HER2 positive, especially in very young and African American women) and test targeted approaches to reduce death from breast cancer.
Of these, I think #4 is the most important, but unfortunately this approach will take years to bear fruit. In the meantime physicians and patients are left to struggle through as best we can with incomplete data. Nothing should yet change in the near term in our approach to DCIS in young women and with unfavorable characteristics, but it’s becoming increasingly clear that something needs to change is in our approach to lower risk forms of DCIS, such as low and intermediate grade DCIS.

Mandatory breast density reporting legislation: The law outpaces science, and not in a good way
David Gorski on June 8, 2015
Link

Over the years, our bloggers here at Science-Based Medicine have written time and time again about the intersection of law and science in medicine. Sometimes, we support a particular bill or law, such as laws to protect children against religion-inspired medical neglect; laws making it harder for manufacturers of homeopathic “medicines” to deceive the public; or California Bill AB 2109, a bill whose intent was to make it more difficult for parents to obtain nonmedical exemptions to vaccine mandates but whose implementation after being passed into law was profoundly sabotaged by Governor Jerry Brown. or, more recently, California SB 277, a bill currently wending its way through the California legislature that would eliminate nonmedical exemptions to school vaccine mandates and has, not surprisingly, engendered extreme resistance from the antivaccine crowd, including by Robert F. Kennedy, Jr. In the vast majority of cases we explain how the law lets us down when it comes to science in medicine, and, unfortunately, examples are many: Naturopathic licensing laws; supplement regulation (or, more appropriately, lack of regulation); misguided, deceptive, and patient-hostile “right-to-try” laws; state laws regulating medical practice that allow quackery to flourish unchecked; laws regulating pharmaceutical cost transparency that ask the wrong question.
The case I will discuss here is unusual in that it is a case of the law getting ahead of what the science says in a manner that will likely do little, if any, good for patients, cause a lot of confusion until the science is worked out better, and end up costing patients money for little or no benefit. I am referring to laws mandating the reporting of high-breast-density to women with dense breasts undergoing mammography. These laws are sweeping the country (albeit not as rapidly as “right-to-try” laws), with a total of 22 states having passed them as of today since Connecticut became the first to do so in 2009. The most recent of these laws went into effect in my own state of Michigan exactly one week ago:
Women with dense breast tissue — the sort that can hide potentially deadly tumors from routine mammograms — must be notified in writing and encouraged to consider additional tests under a new state law that is effective Monday.
While mammograms remain the gold standard for detecting breast tumors, they’re less reliable in almost half of women with dense breast tissue. Dense or fibrous tissue shows up as splotches of white on a mammogram — so do tumors.
That will likely surprise many of the millions of women who rely on mammography for catching the earliest signs of cancer, said Nancy Cappello. The Connecticut woman was shocked in 2004, when her gynecologist found a lump — advanced cancer that had already spread to her lymph nodes — just months after a mammogram deemed her cancer-free.
Yes, mammography is imperfect, and we here at SBM have not shied away from describing its imperfections (or the difficulties in general with screening asymptomatic patients for any disease) including one large study that found no reduction in breast cancer-related mortality that was relentlessly (and falsely) attacked as fraudulent by a prominent radiologist. Regular readers know that the sensitivity of mammography is not optimal, and that it likely results in significant overdiagnosis and overtreatment, particularly of the pre-cancerous entity known as ductal carcinoma in situ (DCIS). All these issues aside, a review by the World Health Organization (WHO) International Agency for Research on Cancer (IARC) of mammographic screening hot off the presses last week in the New England Journal of Medicine nonetheless concluded that, for women between the ages of 50 and 74 at least, there is sufficient evidence to conclude that mammographic screening results in a significant reduction in the risk of dying of breast cancer, although the same report affirmed doubts about the adequacy of evidence for women between the ages of 40 and 49 that the USPSTF originally used in 2009 to base its recommendation that mammographic screening not begin until age 50 for most women. In other words, mammography, as imperfect as it is, does reduce the risk of death from breast cancer in women over 50.
Breast density, mammography, and cancer risk
It has long been known that mammography tends to be less effective in women with dense breasts. What is causes “density” on mammographic imaging is the high level of fibrous and glandular tissue relative to fatty tissue compared to breasts that are not considered dense. The reasons why mammographic screening of dense breasts might be less effective are fairly simple to understand. Mammography is basically an X-ray of the breast taken in a specified, highly standardized manner. As such, the image rendered shows up as areas of white and dark, with the white representing denser tissue and the dark less dense tissue, usually fat, which lets X-rays pass through easily. Lesions suspicious for breast cancer manifest themselves as a density that stands out among the darker, less dense tissue, of which there are two kinds: a tissue density or calcifications. I could ramble on and on and on about what characteristics make a tissue density or an area of calcifications suspicious and another area of tissue density or calcifications benign-appearing (or at least much less suspicious). The details aren’t important for purposes of this post. What is important for purposes of understanding the effect of mammographic density on the ability to detect cancer is that it depends on the contrast between the denser lesions that are suspicious for cancer and the surrounding breast and fatty tissue. The less contrast there is, the harder it is for the radiologist, even with computer-aided detection, to differentiate between suspicious lesions and normal breast tissue. That’s why mammography works really well in breasts that are largely replaced by fatty tissue, as is the case in many postmenopausal women, in whom dense breast tissue is less common than in premenopausal women. Basically, as estrogen and progesterone levels plummet, over time the glandular tissue in postmenopausal breasts becomes replaced with fatty tissue.
Just to give you an idea, here are images of breasts of low, intermediate, and high density on mammography:

And here is an example of what microcalcifications look like:

And of how breast cancers appear on mammography:
You can see how it would be more difficult to see these lesions in dense breasts, especially when they are more subtle and not as obvious. Indeed, the National Cancer Institute (NCI) points out on its website that the “main cause of false-negative results is high breast density.” In any case, the reason why mammography is more problematic in women aged 40 to 49 boils down to the fact that most premenopausal women have denser breasts due to higher levels of hormones and the incidence of breast cancer is lower, such that a positive finding is much more likely to be a false positive than a true positive than it is in older women. As I’ve explained before, for a screening program to be effective, the disease being screened for has to be sufficiently common for this not to happen. There’s a reason why even the most zealous supporters of mammography don’t recommend that routine screening begin before age 40; breast cancer incidence is just too low in this age group.
So far, so clear (I hope). However, recent science has thrown a new wrinkle into the equation. That science is the consensus that has emerged over the last couple of decades, based on numerous studies, that breast density is an independent risk factor for the development of breast cancer. In other words, women who have dense breasts, all other clinical characteristics being equal, have a higher risk of developing breast cancer. According to a recent review article, women with the highest breast density have a risk that is 2 to 6 times higher than women with the lowest breast density, and that as many as 30% of postmenopausal women still have dense breasts. Breast density correlates with a number of factors, including age (negative correlation), serum and tissue hormone levels (positive correlation), genetics, and body mass index (negative). Paradoxically, although high BMI is correlated with decreased breast density, obesity is correlated with an increased risk of breast cancer in postmenopausal women.
Because breast density is an independent predictor of breast cancer risk, naturally, the question has been asked what the biology is behind this and whether it is a modifiable risk factor. (Indeed, in the interests of full disclosure, I have been involved in a study that asks that very question and uses a new ultrasound technology to quantify breast density.) It is known, for instance, that Tamoxifen can decrease breast density, and it is also known that Tamoxifen can decrease the risk of breast cancer significantly in women at high risk. Are the two related? Does Tamoxifen’s ability to decrease breast cancer risk have to do with its ability to decrease breast density? We don’t yet know. Does the decrease in breast density due to Tamoxifen cause the decrease in risk or is the decreased breast density an epiphenomenon associated with the decreased risk? We don’t yet know. Does reduction in breast density over time correlate with decreased breast cancer risk? Yes, to some extent. A recent case control study, for instance, found that women who did not develop breast cancer showed a decrease in mammographic density between first and second prediagnostic mammogram compared to women who did develop breast cancer, who did not.
In other words, it’s complicated, and the science is far from settled. We know that breast density is associated with an increased risk of breast cancer, but the biology is not well understood, we don’t yet know if it’s a modifiable risk factor, and we don’t know the molecular basis. All we know are factors that are associated with increased breast density and that increased breast density is an independent risk factor for breast cancer. Research is ongoing and likely will be ongoing for quite some time before answers start to become clear.
Mandatory breast density reporting
It’s impossible to discuss mandatory breast density reporting laws without discussing the woman who started the movement, Nancy Cappello, PhD, and her organization Are You Dense? Advocacy, whose mission is described as:
To ensure that women with dense breast tissue have access to an early breast cancer diagnosis. To that end, women need to be informed of their breast density, the limitations of mammography to find cancer in dense breast tissue and the increased risk factor of dense breast tissue.
As described in the story I first cited above, Cappello’s gynecologist found a lump months after she had had a “negative” mammogram in 2004, and she was diagnosed with stage IIIC breast cancer. As she herself relates in a recent article, “Decade of ‘Normal’ Mammography Reports–The Happygram“:
I ate healthy, exercised daily, examined my breasts regularly, and underwent yearly mammography. I had no family history of breast cancer. In 2003, my annual screening mammogram was reported as normal, just as the decade of reports before 2003. I was faithful to my health care regimen; my routine annual gynecologic examination was 6 weeks later. As my physician was examining my breasts, she felt a ridge in my right breast and ordered diagnostic mammography and ultrasound. The diagnostic mammogram revealed nothing, but the ultrasound examination revealed a 2.5-cm mass. A breast biopsy confirmed invasive cancer, which was later verified as stage IIIC breast cancer. At the time of diagnosis, my tumor was more than 1 inch in size, and it had metastasized to 13 lymph nodes. The American Cancer Society reports the 5-year survival rate for stage IIIC breast cancer as 49%, compared with stage I at 88% [1]. I expected, in the event of a cancer diagnosis, an early stage because of my faithful program of annual screening mammography. I questioned my doctors as to what had happened. This was the first time that I was told that I had extremely dense tissue and that, as breast density increases, the sensitivity of mammography decreases.
I was stunned that my doctors knew about dense breast tissue and its impact on the effectiveness of mammography but had never informed me. I also discovered that my physician received reports generated by radiologists that included more details about my mammographic results and, as in most reports, my breast tissue composition. This information is usually not reported in the patient’s “happygram” report. My decade of radiologists’ reports, unknown to me, read, “Patient has extremely dense breasts…no change from prior exam.” My radiologist knew that I had dense breasts. My doctor knew that I had dense breasts. The only person who did not know was me: the woman with the dense breasts.
Regular readers who have been paying attention to my posts on mammography and screening know that there is a huge misconception in this story, namely the belief that catching a cancer earlier results in a better chance of survival. It’s a common misunderstanding, even among physicians. Clearly, Cappello doesn’t understand the concept of lead time bias, but she’s in good company. Neither do a lot of physicians. Basically, earlier detection can make survival after diagnosis seem longer even if the treatments used have no effect at all. It seems an opportune time to explain why this is by resurrecting one of my favorite explanations for lead time bias, by Aaron Carroll:
Let’s say there’s a new cancer of the thumb killing people. From the time the first cancer cell appears, you have nine years to live, with chemo. From the time you can feel a lump, you have four years to live, with chemo. Let’s say we have no way to detect the disease until you feel a lump. The five year survival rate for this cancer is about 0, because within five years of detection, everyone dies, even on therapy.
Now I invent a new scanner that can detect thumb cancer when only one cell is there. Because it’s the United States, we invest heavily in those scanners. Early detection is everything, right? We have protests and lawsuits and now everyone is getting scanned like crazy. Not only that, but people are getting chemo earlier and earlier for the cancer. Sure, the side effects are terrible, but we want to live.
We made no improvements to the treatment. Everyone is still dying four years after they feel the lump. But since we are making the diagnosis five years earlier, our five year survival rate is now approaching 100%! Everyone is living nine years with the disease. Meanwhile, in England, they say that the scanner doesn’t extend life and won’t pay for it. Rationing! That’s why their five year survival rate is still 0%.
As I’ve said before, I don’t think screening for breast cancer is useless. Neither does the WHO. It’s just that the relationship between screening, finding cancer earlier, and increasing cancer survival is not simple. Would finding Cappello’s cancer earlier have increased her chance of survival? There’s no way of knowing because she was one of the lucky ones who survived stage IIIC cancer. In fairness, her treatment probably would have been less brutal, but it’s impossible to know in any single case whether early detection would have made a difference.
So Cappello became an advocate, and a successful one. Over the last several years, she and her collaborators have successfully gotten notification bills passed in 22 states. The new law in Michigan is typical. In the case of a finding of increased breast density, it mandates that the patient receive a letter that states:
Your mammogram shows that your breast tissue is dense. Dense breast tissue is very common and is not abnormal. However, dense breast tissue can make it harder to find cancer through a mammogram. Also, dense breast tissue may increase your risk for breast cancer. This information about the result of your mammogram is given to you to raise your awareness. Use this information to discuss with your health care provider whether other supplemental tests in addition to your mammogram may be appropriate for you, based on your individual risk. A report of your results was sent to your ordering physician. If you are self-referred, a report of your results was sent to you in addition to this summary.
So what’s wrong with this? More information is always a better thing, right? Even if it’s vague and just tells the patient to discuss the matter with her health care provider? There’s more wrong than you might think.
The problem with mandatory breast density reporting laws
There are a number of problems that these laws produce. The most difficult to navigate problems include what to recommend for these patients and how to reassure them. The reasons are simple. First, there is as yet no standardization for determining breast density, and, indeed, measuring density is still a fairly subjective process that radiologists do, with rather high interobserver variability. It is true that there are now automated systems designed to estimate breast density using image analysis, such as Volpara (there are other competing software systems), but most breast centers don’t yet have them and still use the American College of Radiology BI-RADS lexicon. My breast center does (it’s an NCI-designated Comprehensive Cancer Center, after all), but most mammography centers do not. Over time, no doubt the whole process will become much more standardized, but until then there will remain a lot of subjectivity in breast density assessments.
More importantly, indeed, most importantly of all, there is no consensus as to what to do next. As described in an editorial by Marcia Javitt, Section Editor for Women’s Imaging Director of Medical Imaging, Rambam Healthcare Campus in Israel, no large randomized clinical trials have shown that breast cancer mortality is reduced by alternative screening and “although the use of alternative imaging techniques, such as breast ultrasound, breast MRI, digital breast tomosynthesis, and molecular breast imaging (MBI) may enable the detection of mammographically occult cancers in patients with increased breast density, refinement and validation are required for successful large-scale supplemental screening.” The American Cancer Society guidelines call for MRI screening in addition to mammography for women at high lifetime risk (20-25%) to develop breast cancer, but states there is “insufficient evidence to recommend for or against MRI screening” in women whose mammographs indicate extremely dense or heterogeneous breast tissue. Javitt also notes that the potential number of women who would need to be considered for additional imaging after being informed of having heterogeneously or extremely dense breast tissue could be huge, adding that “if all of these women opt for adjunct screening procedures, a staggeringly high number of alternative screening studies in the United States could overwhelm the available resources.”
One of the most commonly suggested alternative additional modalities to use, whole breast ultrasound, is highly operator-dependent and has never been shown to decrease breast cancer mortality, although it can increase the detection rate in dense breasts, but at a cost. For example, the American College of Radiology Imaging Network (ACRIN) 6666 trial showed that using breast ultrasound to supplement mammography in women with dense breast tissue and increased risk for breast cancer resulted in improved cancer detection (an additional 4.3 cancers per thousand women screened) at the cost of an increased recall rate, a large increase in the false positive rate, and reduced positive biopsy rate. Also, there was no control group, and the study only evaluated women at increased risk of breast cancer, not women of average risk. (Once again, in the interests of full disclosure, my cancer center has developed a 3D ultrasound imaging technology that we have high hopes for.)
And I forgot to mention: The vast majority of these laws do not mandate that insurance companies pay for additional screening, which is a big problem, since most insurers don’t cover additional imaging for women with “clean” mammograms. The Affordable Care Act doesn’t require it, and, with the exception of Connecticut, Illinois, New Jersey, and Indiana, states with these mandatory reporting laws don’t require it. So, in most states that have passed these laws, women who get these notices are faced with the choice of just living with it or paying out of pocket for additional testing that has not been validated as being able to decrease their risk of dying of breast cancer. For some tests, MRI for instance, that expense could be quite high.
Finally, not all dense breasts are created equal, if you’ll excuse the cliché. Some are truly high risk, and some are not. At a website set up by radiologists to try to navigate the vagaries of these laws, BreastDensity.info, there is a flow sheet that informs us that:
     1.  If the report states her density is heterogeneously dense, this is associated with minimal risk above average (RR=1.2 compared to average breast density).
     2.  If her density is extremely dense (also sometimes called simply dense), this factor doubles her risk of breast cancer compared to average density, similar to the risk associated with a family history of breast cancer in a mother, sister, or daughter. For example, having extremely dense tissue on its own raises the 10-year risk of breast cancer in the average 50 year old woman from 1 in 42 to 1 in 21.
It also goes on to point out that, in the absence of other risk factors associated with breast cancer, elevated breast density alone does not put a woman at high risk for breast cancer. For instance, a recent prospective cohort study with over 365,000 women found that, in the absence of other risk factors for breast cancer, high breast density alone has a rather modest effect on breast cancer risk, leading the authors to warn:
Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patient–provider discussions about alternative screening strategies.
The study also found that about half of all women with heterogeneously or extremely dense breasts did not meet the threshold for high rates of interval breast cancer and that the threshold of screening all women with heterogeneously dense breasts required 1,124 supplemental tests per additional cancer case detected. In other words, an emphasis on breast density alone is probably ill-advised based on what we know now.
I can understand why women like Nancy Cappello become activists. I really can. They think they’ve been wronged by the medical system and that they’ve discovered something that doctors either aren’t aware of or didn’t think important enough to tell them. Unfortunately, in the case of breast density that something is information that is both unreliable and does not as yet have a consensus about it over what to do. As a result, what they’ve done is advocate for laws that are ahead of where the science is, but not in a good way.

Thermography is Not Approved for Breast Cancer Screening in Canada
Breast cancer thermography is being promoted across Canada as a reliable and effective way of identifying breast tumors. There is no evidence thermography is actually capable of doing so.
Blythe Nilson on October 12, 2018
Link

Canadian women are responsible for deciding on their own breast health management. In consultation with primary care physicians, most choose mammography – the gold standard for breast cancer screening in Canada. Despite this, a growing number of private clinics across Canada offer an unregulated service called “thermography” (also called thermal imaging, infrared imaging, or digital infrared thermal imaging) for breast cancer screening. Thermography has been discussed several times on SBM but as a refresher, it is a digital technique that measures skin temperature using an infrared camera. An image of the heat distribution across the chest, called a thermogram, is interpreted by a thermogram reader and reported to the client in exchange for a fee of up to several hundred dollars.
Does thermography work?
Thermography providers claim that malignancies can be detected by measuring breast skin temperature. They claim that the increased metabolic and vascular activity in tumors will cause an increase in the temperature of the overlying skin. These claims are not supported by science and primary care physicians do not recommend thermography as an alternative to mammography. Sadly, many Canadian women are choosing thermography apparently because the private clinics are very good at advertising.
The premise underlying thermography for breast screening is plausible at first glance. Tumours are indeed metabolically active and, as they grow in size, they recruit blood vessels to deliver the oxygen they need to keep expanding. This extra blood flow brings additional heat and this is what thermography claims to be able to detect. However, regulation of skin temperature is complex and surface (skin) temperature is not a reliable proxy for what is going on in deeper tissues. Thermography was initially investigated as a method for identifying breast malignancies and abnormalities in the 1970s, but scientists found that it showed poor detectability and high false positive rates, and that mammography and clinical examinations were demonstrated to be superior methods of detection for breast cancer.
Recent systematic reviews conclude there is no evidence to support the use thermography as a screening test, a diagnostic tool, an assessment tool, or even as an adjunct to mammography. There are no randomized controlled studies on thermography and, without proper clinical trials, the claims made by practitioners of thermography do not stand up to scrutiny. Yet, many Canadian women choose this procedure and some forego mammograms. These clinics are not part of the Canadian health care system and are in a grey zone of regulation. Unfortunately, there are no statistics to track the harm they may be doing.
Regulatory action in the United States
In the United States, the Food and Drug Administration (FDA) approved Class I telethermographic systems for the use of “adjunctive diagnostic screening for detection of breast cancer” in 1982. This means that thermography may be used only in conjunction with, not in place of, mammography for the screening and diagnosis of breast cancer. In recent years, though, the FDA has issued warning letters to companies that were inappropriately marketing and selling thermography devices and systems.
Regulatory action in Canada
Health Canada has not approved thermography for breast cancer screening either alone or as an adjunct to approved screening methods, and it issued a safety alert about thermography screening in 2012. At around that time, a thermography clinic in St. John’s, Newfoundland and Labrador was instructed by the province’s Health Minister to cease and desist for the reason that thermal imaging for breast cancer screening is unregulated in the province. Also, a thermography clinic in Winnipeg, Manitoba was directed by the provincial Health Minister to halt operations while health officials carry out an investigation.
A more recent Health Canada safety alert, issued in 2017, informs us that “[w]hile thermography devices are available in Canada, these devices have not been licensed in Canada to screen for breast cancer.” Thermography devices are licensed only for a very limited use as specialized thermometers. The safety alert also tells consumers that “…thermograms…are not a substitute for mammograms used for routine monitoring and screening for breast cancer” and that mammography “…is the most reliable technique in screening for early-stage breast cancer”. Health Canada asserts that it “…is not aware of any clinical evidence that thermography devices can be used effectively for the early detection of breast cancer” and cautions that “[i]f women are relying solely on thermography results, there is a potential risk that cancer could go undetected.” As a result, Health Canada restricted the sale of thermography equipment: “Health Canada is following up with several manufacturers to inform them that it is prohibited to advertise or sell thermography devices (such as cameras and imaging systems) to screen for breast cancer in Canada.”
The Canadian Cancer Society shares information and concerns similar to those of Health Canada. The Society concurs “…current evidence doesn’t show that thermography is an effective tool to detect breast cancer and therefore, we do not recommend thermography as a screening tool for breast cancer.” The Society adds that when private clinics advertise thermography as a reliable method of detecting breast cancer, it “…creates a confusing message for women” and that women who have been tested with thermography may have “…a false sense of security about their breast health”.
Use of breast thermography in Canada
Despite the lack of scientific evidence for the efficacy of thermography as a method of breast cancer detection, the lack of approval to use thermography for the purpose of breast cancer screening, and the prohibition on sales of thermography equipment, there are many businesses and private clinics in Canada that offer thermography service and devices for breast cancer screening. One such business is Thermography Clinic Inc., a Toronto-based company with thermography clinics established around the world. In Canada, Thermography Clinic Inc. has 22 clinics (including the head office) located across Alberta, British Columbia, Ontario, and Quebec. The company’s mission is “[t]o bring non-invasive imaging technology to the forefront of health care and to impact breast cancer statistics globally.” Thermography Clinic Inc.’s website characterizes the procedure as safe, pain-free, radiation-free, and non-invasive, all selling-points for potential customers considering this procedure.Thermography Clinic Inc. sells “turn-key” thermography systems to existing clinics or new start-up businesses and supports them with system installation, personnel training, and results reporting. Practitioners who undergo just three days of training are provisionally certified by the College of Medical Thermography to write and interpret breast thermography reports for consumers.
A close inspection of Thermography Clinic Inc.’s website reveals some concerning points. The website appears to feature misleading information and unproven claims about thermography, such as:
To deny the efficacy and [sic] of thermal imaging of the breast as an adjunctive assessment in the overall management of the patient is a grave error.
And:
We cannot ignore the tremendous role of breast thermography as an early risk indicator or as a monitor of treatment.
Furthermore, the technology appears to be advertised for unlicensed uses and unapproved purposes. The following statements are some examples from their brochure [PDF]:
Early Detection is important, but prevention is the key! [brochure title]…Breast Thermography is a breakthrough imaging procedure where infrared images of the breasts are analyzed and rated to determine the risk of developing breast cancer.…Breast Thermography is one of the best early-detection systems available today.
Conclusion: The exploitation of fear
Thermography clinics capitalize on the unjustified fears some women have that radiation doses from mammograms are dangerous and can be avoided by using thermography. The truth is that thermography is unproven and can burden women with false negative or false positives that can cause psychological stress, delayed treatment, unnecessary treatment, or worse, and charge a lot of money for the experience. In Canada, mammograms are free and they are the gold standard for breast cancer detection, so stay away from thermography.
The Canadian Cancer Society offers women guidelines for appropriate breast cancer screening.

Center for Inquiry CanadaThe Centre for Inquiry Canada supports science-based medicine in Canada and advocates for empirically-supported medical interventions.

   Are one in three breast cancers really overdiagnosed and overtreated?
David Gorski
Link
Screening for disease is a real pain. I was reminded of this by the publication of a study in BMJ the very day of the Science-Based Medicine Conference a week and a half ago. Unfortunately, between The Amaz!ng Meeting and other activities, I was too busy to give this study the attention it deserved last Monday. Given the media coverage of the study, which in essence tried to paint mammography screening for breast cancer as being either useless or doing more harm than good, I thought it was imperative for me still to write about it. Better late than never, and I was further prodded by an article that was published late last week in the New York Times about screening for cancer.
If there’s one aspect of medicine that causes more confusion among the public and even among physicians, I’d be hard-pressed to come up with one more contentious than screening for disease, be it cancer, heart disease, or whatever. The reason is that any screening test is by definition looking for disease in an asymptomatic population, which is very different from looking for a cause of a patient’s symptoms. In the latter case, the patient is already being troubled by something that is bothering him. There may or may not be a cause in the form of a disease or syndrome that is responsible for the symptoms, but the very existence of the symptoms clues the physician in that there may be something going on that requires treatment. The doctor can then narrow down range of possibilities for what may be the cause of the patient’s symptoms by taking a careful history and physical examination (which will by themselves most often lead to the diagnosis). Diagnostic tests, be they blood tests, X-rays, or other tests, then tend to be more confirmatory of the suspected diagnosis than the main evidence supporting a diagnosis.
In contrast, screening for a disease involves subjecting a population, the vast majority of whom don’t have the disease and nearly all of whom are asymptomatic, to a diagnostic test in order to find disease before it has begun to cause symptoms. This is very different from the vast majority of diagnostic tests used in medicine, the vast majority of which are done for specific indications. Any test to be contemplated for doing this thus has to meet a very stringent set of requirements. First, it must be safe. Remember, we’re subjecting asymptomatic patients to a test, and a risky, invasive tests are rarely going to be worthwhile, except under uncommon circumstances. Second, the disease being screened for must be a disease that is curable or manageable. For instance, it makes little sense to screen for a disease like amyotropic lateral sclerosis (Lou Gehrig’s disease) because there is very little that can be done for it; diagnosing it a few months or a few years before symptoms appear won’t change the ultimate outcome. A corollary to this principle is that acting to treat or manage a disease early, before symptoms appear, should result in a better outcome. I’ve discussed the phenomenon of lead time bias in depth before; it’s a phenomenon in which earlier diagnosis only makes it seem that survival is longer because it was caught earlier when in reality it progressed at the same rate as it would without treatment. Lead time bias is such an important concept that I’m going to republish the diagram I last used to explain it, because in this case a picture is worth a thousand words (and who more than I, other than perhaps Kim Atwood, can lay down a thousand words so easily?):
Another requirement for a screening test is that the disease being screened for must be relatively common. Screening for rare diseases is simply not practical from an economic standpoint, as the vast majority of “positive” test results will be false positives. Another way of saying this is that the specificity of the test must be such that, whatever the prevalence of the disease in the population, it does not produce too many false positives. In other words, for less common diseases the specificity and positive predictive value must be very high (i.e., a “positive” test result must have a very high probability of representing a true positive in which the patient actually does have the disease being tested for and the false negative rate can’t be too high; either that, or screeners must be prepared to do a lot of confirmatory testing for a large number of false positives). For more common diseases, a lower positive predictive value is tolerable. The test must also be sufficiently sensitive that it doesn’t produce too many false negatives. Remember, one potential drawback of a screening program is a false sense of security in patients who have been screened, a drawback that will be increased if a test misses too many patients with disease. Finally, a screening test must also be relatively inexpensive. One of the reasons there is so much controversy over using MRI as a screening test for breast cancer, for example, is because an MRI easily costs over $1,000 per test. In contrast, good, old-fashioned mammography is between 10- and 20-fold less expensive. Consequently, MRI is currently not recommended for breast cancer screening in the general population and is instead reserved for younger women at high risk due to a strong family history or a known mutation in a cancer susceptibility gene, as I discussed last year.
Recently, there has been a bit of a kerfuffle in the literature and in the lay press reporting on the literature regarding the risks and the benefits of various screening tests, including mammography. For example, three weeks ago Harriet wrote about a study that measured the cumulative rates of false positives from screening tests for prostate, lung, colorectal, and ovarian cancer and, earlier, about ultrasound screening for prostate cancer. Prostate cancer, for example, is a particularly difficult disease to screen for because there is such a high incidence of disease that never causes a problem. In autopsy series of men over 80, at least 75% of men have evidence of at least one focus of prostate cancer somewhere in their prostate glands, but obviously it never caused them any problem and they died of something else, including old age. On the other hand, prostate cancer is consistently one of the top cancers in men, resulting in 30,000 deaths a year. Sometimes, it can be quite aggressive. Because we don’t have reliable tests to differentiate prostate cancer that will progress from prostate cancer that will never cause a problem, whenever we find prostate cancer by screening there is always the question of what to do with it, to treat or not to treat.
Since my specialty is breast cancer, in the wake of the aforementioned New York Times article In Push for Cancer Screening, Limited Benefits and multiple news stories about a study that purports to show that 1 in 3 breast cancers detected by mammographic screening are overdiagnosed and overtreated, entitled, appropriately enough, Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. This study was done by Karsten Juhl Jørgensen and Peter C. Gøtzsche at The Nordic Cochrane Centre. Here’s how an AP story described the study:
LONDON – One in three breast cancer patients identified in public screening programs may be treated unnecessarily, a new study says. Karsten Jorgensen and Peter Gotzsche of the Nordic Cochrane Centre in Copenhagen analyzed breast cancer trends at least seven years before and after government-run screening programs for breast cancer started in parts of Australia, Britain, Canada, Norway and Sweden.
The research was published Friday in the BMJ, formerly known as the British Medical Journal. Jorgensen and Gotzsche did not cite any funding for their study.
Once screening programs began, more cases of breast cancer were inevitably picked up, the study showed. If a screening program is working, there should also be a drop in the number of advanced cancer cases detected in older women, since their cancers should theoretically have been caught earlier when they were screened.
However, Jorgensen and Gotzsche found the national breast cancer screening systems, which usually test women aged between 50 and 69, simply reported thousands more cases than previously identified.
Overall, Jorgensen and Gotzsche found that one third of the women identified as having breast cancer didn’t actually need to be treated.
This is more or less a half way decent CliffsNotes version of the study, but let’s look at the study in a bit more detail, because I have–shall we say?–issues about it. First off, it’s important to remember that this is a systematic review. Actually, it is part systematic review, part meta-analysis, which is one reason why I have issues with it. Whether you call it a systematic review or meta-analysis, as a consequence it is highly dependent upon the selection of studies and how the studies are interpreted. I wasn’t encouraged by this statement in the introduction:
It is well known that many cases of carcinoma in situ in the breast do not develop into potentially lethal invasive disease. In contrast, many find it difficult to accept that screening for breast cancer also leads to overdiagnosis of invasive cancer.
While this may be true of certain advocacy groups, the implication seems to be that many physicians also find it “difficult to accept” that screening can lead to overdiagnosis. No evidence is presented to support this little dig, and overall it sets the tone of settling scores. This is not terribly surprising, because these two authors are well known for publishing articles about mammography that absolutely, positively always downplay the benefits of screening mammography and play up the risks, as a couple of quick PubMed searches show (1, 2). They’re also known for writing letters to scientific journals that dispute points of papers that find a benefit from screening mammography. This doesn’t mean that Jørgensen and Gøtzsche are wrong, of course, only that they do appear to have a definite point of view, which should be kept in mind as much as anyone else’s point of view when examining a scientific paper. While I like their work to some extent as a counterweight to too much boosterism for ever earlier screening, I do find that they tend to go a bit too far at times in downplaying the usefulness of mammography, and at times they seem to be on a mission to cast doubt on mammography, as when they led a campaign to change a British leaflet used to encourage women to undergo mammography and making statements like:
But “it has not been proven that screening saves lives,” they insist, and new evidence shows less benefit and substantially more harm from screening than previously thought.
In fact, this balance between risk and benefit has changed so much in recent years that nationwide programs of breast screening would be unacceptable, they say. “We believe that if policy makers had had the knowledge we now have when they decided to introduce screening about 20 years ago . . . we probably would not have had mammography screening.”
Personally, I think that’s a huge overstatement. However, in fairness, I must mention that Michael Baum ChM, FRCS, MD, FRCR hon., a breast surgeon in England and someone I respect, also signed on to this campaign. I don’t entirely agree with everything he said, but I do take him, as well as Jørgensen and Gøtzsche, seriously. In any case, what bothers me about Jørgensen and Gøtzsche’s systematic review the most is the assumption behind it. Let’s look at how Jørgensen and Gøtzsche estimated overdiagnosis. Basically, the assumption is that in a population that begins screening, intitial cancer diagnoses should increase and there should be a compensatory decrease in cancer diagnoses in the population as women get older. The reason, if this model is valid, is that cancers that wouldn’t have been diagnosed until later ages are now being diagnosed when women are younger. So what Jørgensen and Gøtzsche did was to look for compensatory drops in breast cancer diagnoses in older women. One thing that also has to be emphasized is that this study looked only at mammographically detected breast cancers found by screening, not breast cancers detected by the palpation of a lump in the breast or other symptoms. If a woman has a lump in the breast, ruling out cancer is imperative, especially if the woman is over 40.
One thing that needs to be understood is that the countries examined in this study (United Kingdom; Manitoba, Canada; New South Wales, Australia; Sweden; and parts of Norway) have very different screening protocols than we do in the United States. In most of these countries, for women at an average risk for breast cancer, screening with mammography doesn’t begin until age 50, and in some countries mammography is performed only once every two years, rather than every year. In addition, in many of these countries, screening ends after age 70 or so, which is one reason why Jørgensen and Gøtzsche break down the groups they look at into “too young for screening,” “screening age” (50-64 or 50-69, depending on the nation), or too old for screening. In the U.S., screening generally begins at age 40 and continues on a yearly basis in essence forever, a system that is, quite frankly, not well grounded in evidence and designed to maximize overdiagnosis, given that the evidence that screening between ages 40-50 reduces breast cancer mortality is rather weak, that the prospective randomized controlled trials evaluating mammography to date have excluded patients older than 74, and that few studies have rigorously looked at screening in women over 80. It’s also rather fascinating to those of us in the U.S. that mass screening programs in some of these countries didn’t start until the 1990s.
Basically, what Jørgensen and Gøtzsche found was that in these countries there was, as expected, an increase in the rate of diagnosis of both invasive breast cancer and ductal carcinoma in situ (DCIS), a lesion that is considered cancer but has not yet invaded out of the breast ducts. This is one problem that I have with this article, namely that it lumps together invasive cancers and DCIS. The reason is that DCIS is a condition of uncertain significance in that it is known that a significant percentage of DCIS never progresses to full cancer. Consequently, the inclusion of DCIS is guaranteed to inflate the estimate of overdiagnosis; from my perspective, DCIS should be analyzed separately. For one thing, it would give us a better idea of just how much overdiagnosis there might be in invasive breast cancer; more importantly it might provide evidence that “watchful waiting” might be safe in some cases of DCIS. Dumping the two together, however, confuses things. For example, what if 80% of the overdiagnosis is due to DCIS? Then overdiagnosis of invasive cancer would be much less, telling us that we should treat invasive cancers discovered by mammographic screening.
Another problem with the study was pointed out in the rapid responses on BMJ by Dr. Daniel B. Kopans, Professor of Radiology at the Harvard Medical School and the Massachusetts General Hospital. I noticed this problem, too, but couldn’t formulate it as clearly at first. The problem is that this study is not looking at a fixed cohort of women before and after screening began. Consequently, every year, new women turn 50 and begin screening, and screened women “age out” of the screening system. Finally, another huge confounder that I don’t think that Jørgensen and Gøtzsche adequately account for is the use of hormone replacement therapy and the decrease in inherent breast cancer incidence that has begun since the report from the Women’s Health Initiative study that found increased risk of breast cancer, heart disease, stroke and blood clots in women taking hormone replacement therapy (HRT) led to a dramatic decrease in the number of women using HRT.
Don’t get me wrong. There is no doubt that mammographic screening programs produce a rate of overdiagnosis. The question is: What is the rate? Unfortunately, the most accurate way to measure the true rate of overdiagnosis would be a prospective randomized trial, in which one group of women is screened and another is not, that follows both groups for many years, preferably their entire life. Such a study is highly unlikely ever to be done for obvious reasons, namely cost and the fact that there is sufficient evidence to show that mammographic screening reduces breast cancer-specific mortality for women between the ages of 50 and 70 at least, the latter of which would make such a study unethical. Consequently, we’re stuck with retrospective observational studies, such as the ones analyzed in this systematic review. One trial that has a stronger design, as far as I’m concerned, was reported in 2006 by Zackrisson et al entitled Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study, which found a rate of overdiagnosis of between 10% and 18%, depending upon how the data were analyzed. For one thing, the Malmö study has the advantage of looking at individual women over time randomized to screening or no screening, rather than population-level numbers, as well as having a 15 year followup. Its disadvantage is that the Malmö mammographic screening trial was one of the classic ongoing studies, for which the screening occurred between the years 1976 to 1986. In the interim, mammography has become more sensitive, with improved imaging and digital mammography. Consequently, it is quite possible that the rate of overdiagnosis is higher than what was reported in the followup to the Malmö study.
There’s another wrinkle. As I discussed last December, there was recently a study that purported to show that roughly 22% of mammographically detected cancers might actually spontaniously regress. You may recall that I disputed whether the number was that high, but accepted that it’s probable that some percentage of mammographically-detected cancers might regress. (Remember, though, I’m referring to mammographically-detected cancers in asymptomatic women. There is no good evidence that cancers detected by palpation of a mass or other symptoms regress at an appreciable rate; they might do so rarely, but certainly not at anything approaching 20%.)
On an issue like this, I like to try to look for confluences of studies, and I think I’m starting to see one here. Overall, if you look at the literature, there appears to be a convergence of estimates of the rate of overdiagnosis for mammographically detected breast cancers of somewhere around 20-25%. Jørgensen and Gøtzsche’s work tends to represent the high end (and, indeed, seem custom-designed to me to make the estimate of overdiagnosis as high as possible), while the Malmö study representing the low end. Throw in the Norwegian study that estimates that one in five mammographically detected breast cancers spontaneously regress, and science seems to be honing in on a “true” rate of overdiagnosis that is probably in the range of one in five to one in four. The problem then becomes: What do we do with that information.
The aforementioned Michael Baum actually commented on the study under the title Attitudes to screening locked in time warp, where he advocates a complete rethink of the British breast cancer screening program. He’s right to some extent, but he goes too far in implying that the improvements in our understanding of the biology and natural history of breast cancer are such that we know enough to be highly confident in what to do about the program:
Next, as described in Jørgensen and Gøtzsche’s paper, estimates of harm through over-diagnosis have increased. At the same time our understanding of the biology of breast cancer has improved so that the idea of latent or self limiting pathology that is so counter-intuitive to the screening community, is no longer surprising to those who have bothered to keep up to date.
Finally, whilst the screening programme remains an inviolate bovine deity, treatment regimens have improved by leaps and bounds further narrowing the window of opportunity for screening to demonstrate an impact.
Actually, its a huge overstatement to say that treatment regimens have improved by “leaps and bounds” over the last 20 years. They have definitely improved, but not so dramatically that we can, as Baum appears to do, so blithely discount the potential benefits of detecting breast cancer earlier. Even if earlier detection, because of lead time bias, doesn’t change the overall prognosis, at the very least detecting cancer earlier makes it possible to use less disfiguring surgery in more women and to use less aggressive chemotherapy. This is not a benefit to be sneezed at, but it is one that is frequently completely ignored in discussions of this sort.
Where Baum is more on target is his suggestion for risk-adjusting our recommmendations for mammographic screening. I might quibble with his exact approach (and I do, actually), but it is becoming clear that mass screening programs of the “one-size-fits-all” variety for breast cancer are probably not doing as much good as advertised or are arguably doing more harm than previously expected. The time is coming for a less dogmatic approach than has been the norm. One approach might be an evidence- and science-based discussion of the known risks and benefits of mammographic screening. In an accompanying editorial, H. Gilbert Welch tried to provide a “balance sheet” of the risks and benefits for 1000 women undergoing annual mammography for 10 years starting at the age of 50 years. These include:
Benefits
    • 1 woman will avoid dying from breast cancer
Debits
    • 2–10 women will be overdiagnosed and treated needlessly
    • 10–15 women will be told they have breast cancer earlier than they would otherwise have been told, but this will not affect their prognosis
    • 100–500 women will have at least 1 “false alarm” (about half these women will undergo biopsy)
Unfortunately, the error bars around these estimates are very high. Where Welch is correct is here:
Mammography is one of medicine’s “close calls”—a delicate balance between benefits and harms—where different people in the same situation might reasonably make different choices. Mammography undoubtedly helps some women but hurts others. No right answer exists, instead it is a personal choice.
To inform that choice, women need a simple tabular display of benefit and harms—a balance sheet of credits and debits
And:
Equally important are the estimates themselves. Zackrisson and colleagues reported 62 fewer deaths from breast cancer and 115 women overdiagnosed—a ratio of one death avoided to two women overdiagnosed. Recently, Gøtzsche and colleagues argued in the BMJ that the ratio is one to 10. For many women, the tipping point may be within this range. Careful analyses that explicitly lay out their assumptions and methods, which will improve the precision of these estimates, are sorely needed.
The problem in changing the way that screening programs for breast cancer are done is likely to be convincing women that a more selective approach to mammographic screening is desirable. To people not educated in cancer, it makes intuitive sense that detecting cancer earlier will result in better outcomes, and it is hard to explain the down side, namely over diagnosis, unnecessary biopsies and treatment, and the emotional distress that such false positive diagnoses make. Also, the maintenance of public and therefore political support often depends upon keeping the message as simple as possible. Including a discussion of the risks of mammography will likely be seen by many public health officials as “muddying the waters” and harming their efforts to promote screening. Moreover, great care has to be taken to make sure that the public understands that this discussion is only about the screening of asymptomatic women. Women with breast masses or other symptoms worrisome for cancer should not be led to refuse mammograms because of this discussion.
Unfortunately, well-meaning legislators who don’t have a grasp of the potential for harm that screening has are uncritically promoting ever more mammographic screening, even for conditions for which it hasn’t been shown to result in a decrease in mortality. For example, in the U.S., we screen beginning at an earlier age than nearly every other industrialized nation, and we recommend mammography every year instead of every other year. For women over 50, screening has been shown to result in a 15-25% reduction in mortality due to breast cancer, but in women from 40 to 50 years of age demonstrating a major reduction in mortality due to screening is much more difficult and in women under 40 no such reduction has been noted, mainly because of two reasons. First, as the NYT article describes, younger women tend to have denser breast tissue, which makes mammography less sensitive. Second, although there is the perception that there is a lot of breast cancer in women under 40, in reality it is relatively uncommon:
Dr. Love and other critics have also argued that a public health campaign could cause younger women to overestimate their chances of dying from breast cancer. Of the estimated 41,000 deaths a year in the United States from breast cancer, about 1 in 14 involve women younger than 45, according to the C.D.C. Only 1 in 33 breast cancer deaths — about 1,200 a year — occurs in women younger than 40.
Remember what I said about screening for uncommon diseases? The less common the disease, the harder it is to screen for, and the more specific the test has to be to do have a chance of doing more harm than good. Targeting younger women for breast cancer screening not only shifts to a population that has a lower incidence of breast cancer but mammography is less sensitive in that population, two characteristics that combine to increase the potential for harm and decrease any potential for benefit. However, that’s exactly what Representative Wasserman Schultz (D-FL) is trying to do with her sponsorship of the Breast Cancer Education and Awareness Requires Learning Young Act of 2009, also known as the EARLY Act. It’s a well-intentioned, but would almost certainly lead to these complications:
But critics say the House bill promotes techniques like breast self-exams that have not proved to find cancer at an earlier stage or to save lives. The concern is that the technique could cause younger women — a group for whom breast cancer is a rare disease — to find too many medically insignificant nodules that would lead doctors to perform unneeded biopsies, in which tissue is removed for testing.
Scarring from biopsies could make breast cancer harder to detect when the women are older and have a much higher risk of getting the disease, critics say. And such false alarms can also cause women to distrust the medical system and skip mammograms later in life when the tests have been proved to reduce the death toll, said Dr. Otis W. Brawley, an oncologist who is the chief medical officer of the American Cancer Society.
The problem is that what seems intuitively obvious, namely that if some screening is good more screening must be better, is neither obvious nor science-based, and it’s really, really hard to explain that in a way that neither oversells the benefits or mammography nor leads women to think that mammography is useless.
What I hope for one day, and what may well come out of the emerging sciences of oncogenomics and proteonomics, is a manner of determining with more accuracy exactly which cancers will and will not progress. In that case, one potential harm of overtreatment of breast cancer, for example, would be obviated, namely treating women who don’t need them with aggressive surgery, radiation, and chemotherapy. Indeed, we already have some progress in this area with the Oncotype DX gene assay and related products, which have already changed the way oncologists practice by giving them information about which estrogen receptor-positive breast cancer patients can safely forego adjuvant chemotherapy. The problem with such assays, of course, is that they still require tissue, which means that women with overdiagnosed breast cancers would still have to undergo a biopsy. Much better would be an imaging study that could provide the same risk information. Ten years ago, I would have thought such a system to be science fiction. Now I’m optimistic that by the end of my career we will be doing things that way, although what could scuttle any new technology is likely to be cost, which means that mammography is unlikely to be going anywhere any time soon.
In the meantime, we’ll have to muddle through with our imperfect screening systems, and try to tow a middle line between screening advocates who view screening as the be-all and end-all of breast cancer diagnosis and skeptics like Jørgensen and Gøtzsche, who seem to be arguing that screening programs for breast cancer are useless.
REFERENCE:
Jorgensen, K., & Gotzsche, P. (2009). Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends BMJ, 339 (jul09 1) DOI: 10.1136/bmj.b2587

You’ve been diagnosed with breast cancer. How soon do you need treatment?
Timely surgery for breast cancer is obviously better than delaying surgery, but how long can a patient safely wait for surgery once diagnosed. Because a randomized controlled clinical trial to answer this question would be unethical, this has been a difficult question to answer. Fortunately, a new study provides an estimate of how much of a delay it takes before outcomes start to suffer.
David Gorski on January 4, 2016
Link
A new year is upon us yet again, and Science-Based Medicine has been in existence for eight years now. It seems only yesterday that Steve Novella approached me to ask me to be a contributor. Our part-serious, part-facetious predictions for 2016 notwithstanding, one thing about 2016 is certain: I will almost certainly encounter some form of cancer quackery or other and deconstruct it, probably multiple forms. In any case, a topic I’ve been meaning to write about is based on a couple of studies that came out three weeks ago that illustrate why, even if a patient ultimately comes around to science-based treatment of his cancer, the delay due to seeking out unscientific treatments can have real consequences.
When a patient with breast cancer comes in to see me, not infrequently I have to reassure her that she doesn’t need to be wheeled off to the operating room tomorrow, that it’s safe to wait a while. One reason, of course, is that it takes years for a cancer to grow from a single cell to a detectable mass. The big question, of course, is: What is “a while”? Two studies published online last month attempt to answer that question. One study (Bleicher et al) comes from Fox Chase Cancer Center and examines the effect of time to surgery on breast cancer outcomes; the other (Chavez-MacGregor et al) is from the M.D. Anderson Cancer Center and examines the effect of time to chemotherapy on outcome. Both find a detrimental effect due to delays in treatment.
Prompt surgery is better
Because I’m a surgeon I’ll take a look at Bleicher et al first. This study looks at two large cancer databases, the Surveillance, Epidemiology, and End Results (SEER)-Medicare–linked database and the National Cancer Database (NCDB). The SEER-Medicare cohort included Medicare patients older than 65 years, and the NCDB cohort included patients cared for at Commission on Cancer–accredited facilities throughout the United States. Analyses performed assessed overall survival (OS) as a function of time between diagnosis and surgery and evaluated five intervals (≤30, 31-60, 61-90, 91-120, and 121-180 days). It also looked at disease-specific survival at 60 day intervals. The patient cohort included women diagnosed with invasive breast cancer that had not metastasized beyond axillary lymph nodes who were treated with surgery first. Patients with inflammatory breast cancer were excluded, which makes sense because inflammatory cancer is generally treated first with chemotherapy. The SEER-Medicare cohort included 94,544 patients 66 years or older diagnosed between 1992 and 2009, while the NCDB cohort included 115,970 patients 18 years or older diagnosed between 2003 and 2005.
The tale is told by this graph, from the SEER-Medicare cohort and the NCDB cohort (click to embiggen):
As you can see, there is a decrease in survival with each increase in time from diagnosis to surgery, so that by the time you get to the 90 day interval it is quite striking, with a difference in long term survival larger than the improvement produced by most chemotherapy regimens. In the SEER-Medicare cohort, for each increasing interval, the hazard ratio (HR) was 1.09. Results from the NCDB cohort were similar. The added risk of death from all causes for each interval increase in time to surgery was 10% (HR, 1.10; 95% CI, 1.07-1.13; P < .001).
Now here’s the kicker. This adverse effect from delays in surgery was most marked in the very patients most likely to delay their surgery for alternative therapy, namely patients with early stage disease. In the SEER-Medicare database, for instance, the effect of delays in treatment on breast cancer-specific mortality in stage I disease resulted in a HR of 1.84 (95% CI 1.10-3.07, P = .02), while the HR for stage II and III disease was not statistically different from 1.0. In other words, a delay of greater than 120 days was associated with a nearly two-fold increased risk of dying of breast cancer. In terms of overall survival, time to surgery was correlated with a decrease in overall survival in stage I (HR, 1.13; 95% CI, 1.08-1.18; P < .001) and stage II disease (HR, 1.06; 95% CI, 1.01-1.11; P = .01), but not in stage III (HR, 1.06; 95% CI, 0.97-1.16; P = .17). In the NCDB cohort, delay in surgery was associated with decreased overall survival for stage I (HR, 1.16; 95% CI, 1.12-1.21; P < .001) and stage II disease (HR, 1.09; 95% CI, 1.05-1.13; P < .001) but not stage III (HR, 1.01; 95% CI, 0.96-1.07; P = .64). Again, patients with stage I or II disease, which can often be associated with little or no symptoms (particularly stage I, which often does not even present with a palpable mass), are exactly the ones most likely to eschew chemotherapy.
You might wonder why there is less of an effect of treatment delay in stage III disease. So did the authors:
We have found that OS declines when the TTS [time to surgery] increases, with OS affected in stage I and II but not stage III disease. The data for DSS [disease specific survival] are similar, with cancer-specific mortality data only available in the SEER-Medicare dataset, where patients with stage I cancer exhibited lower survival as TTS increased. This observation that preoperative delays affected only stage I DSS and stage I and stage II OS could be due to lower numbers of patients with higher-stage disease, but we believe that breast cancer survivability in its earliest stage is more influenced by the TTS than it is in later stages because baseline mortality is smaller relative to the effect imposed by a delay in treatment. In both cohorts, OS and DSS for stage III disease were not influenced by TTS, suggesting either partial biologic predestination of outcome or a mortality risk that overshadows any small effect of reducing delay by a matter of months. This effect may also be attenuated by patient age owing to competing mortality risks. Because of this and because final stage is only available postoperatively, we believe that efforts to minimize preoperative delay for all patients is advisable.
My thought is that the effect of a delay in time to surgery is relatively small on an absolute scale and therefore hard to detect in retrospective databases like SEER-Medicare and NCDB. Of course, it would be unethical to do a randomized, controlled clinical trial testing time to surgery; so these sorts of analyses are the best we’re going to get when it comes to answering this question. It’s also important to point out that, although the absolute value of the decrease in OS is small, it’s definitely not insignificant:
The effect of TTS on survival is a ubiquitous concern of patients with cancer and a question frequently posed in consultations with surgeons. Elimination of undue delay is desirable to both reduce anxiety and lower risk, and we believe that this study provides clinicians needed data to answer patients’ questions about TTS and its effect on outcome. While the absolute magnitude of the 5-year survival difference was small (4.6% and 3.1% for ≤30 days vs 91-120 days in SEER-Medicare and NCDB patients, respectively), this benefit is comparable to the addition of some standard therapies, such as the recent extension of tamoxifen therapy from 5 to 10 years, while not having the adverse effects or costs found with most interventions.
Exactly. As the authors point out, achieving surgery in less than 30 days is difficult and therefore 30 days might be an unrealistic goal, particularly when immediate reconstruction after mastectomy is being considered and when imaging techniques and more extensive workups can cause delays that easily stretch beyond 30 days, particularly for patients seeking multiple opinions. However, 60 days should be achievable in most cases. Either way, waiting months to undergo surgery, particularly for early stage disease, can decrease chances of survival by as much as foregoing adjuvant therapy. Speaking of adjuvant therapy, delays in chemotherapy are not good, either, as we shall see.
Timing of chemotherapy matters
The next study, Chavez-MacGregor et al, asked basically the same question, except that the authors looked at time to adjuvant chemotherapy after definitive surgery. Adjuvant chemotherapy is chemotherapy given after surgery with the intent of decreasing the chance of tumor recurrence. It is standard of care for many kinds of breast cancer. For instance, in two of the kinds of breast cancer with poorer prognosis, triple negative breast cancer [PDF] and HER2(+) breast cancer, except in the case of very small node-negative tumors, nearly every patient who is healthy enough to handle it will be recommended adjuvant chemotherapy.
Their rationale:
Most patients with breast cancer start adjuvant chemotherapy within 30 to 40 days of surgery. It is thought that chemotherapy administration delayed beyond this time can decrease the benefit provided by cytotoxic systemic therapies. Possible explanations for these effects include accelerated growth of micrometastases after resection of the primary tumor, increased tumor angiogenesis, or development of primary resistance. The optimal time of chemotherapy administration for patients with breast cancer is not precisely defined. Furthermore, it is possible that the time to chemotherapy (TTC) has a different effect according to tumor subtype, tumor stage, and tumor grade. Administration of combination systemic chemotherapy within 120 days of diagnosis in women younger than 70 years with T1cN0M0 or stage II or III hormone receptor–negative breast cancer is considered a quality metric by the Centers for Medicare & Medicaid Services. This metric will now be reported by 11 cancer hospitals as part of the Prospective Payments System-Exempt Cancer Hospital Reporting Program.
The effect of delayed TTC administration has been evaluated retrospectively with contradictory results. In a recent study, we reported that a delay of 61 or more days of adjuvant chemotherapy administration was associated with adverse outcomes among patients with stage II and III breast cancer and also among patients with triple-negative and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)-positive tumors. Our findings suggest that among these specific patient subgroups, every effort should be made to avoid delayed adjuvant chemotherapy initiation.
This study didn’t use the SEER database or NCDB. Instead it examined a total of 24,843 patients from the California Cancer Registry diagnosed with stage I to III breast cancer between January 1, 2005 and December 31, 2010 treated with adjuvant chemotherapy. Time to chemotherapy was defined as the number of days between the last surgery for breast cancer and the first dose of chemotherapy, and delayed time to chemotherapy was defined as 91 or more days. Overall, the authors found no evidence of adverse effects when patients started chemotherapy between 31-60 or 61-90 days after their surgery as compared to patients who started their chemotherapy in 30 days. However, for patients who started their chemotherapy 91+ days after their surgery the results weren’t so good. These patients experienced worse overall survival (hazard ratio [HR], 1.34; 95% CI, 1.15-1.57) and worse breast cancer–specific survival (HR, 1.27; 95% CI, 1.05-1.53). The authors then did a subgroup analysis examining different subtypes of cancer to subtype, longer time-to-chemotherapy was associated with worse OS in the subgroups one would predict. Specifically patients with triple-negative breast cancer had worse overall survival (HR, 1.53; 95%CI, 1.17-2.00) and worse breast cancer–specific survival (HR, 1.53; 95%CI 1.17-2.07). This finding intuitively makes sense because it is patients whose tumors are estrogen receptor-negative for whom there is the greatest benefit due to adjuvant chemotherapy.
Not surprisingly, the authors found a correlation between prolonged time to chemotherapy and Hispanic ethnicity, non-Hispanic black race, lower socioeconomic status, and nonprivate insurance. This is similar to what Bleicher et al found with respect to time-to-surgery, namely that the proportion of patients with black race or Hispanic ethnicity increased with each interval delay. This is by no means a new finding; disparities in health care of this sort have been documented in many previous studies. Indeed, these sorts of disparities are likely one reason (of many) why minorities and people of lower socioeconomic status experience worse outcomes in many cancers. Indeed, there are a lot of potential confounders, many of which couldn’t be accounted for in either study, as Chavez-MacGregor et al note:
Our study is limited by its retrospective nature. However, that we are aware of, this study is the largest published cohort of patients with breast cancer of known breast cancer subtype treated with contemporary regimens. We acknowledge that in clinical practice a number of factors determine the optimal TTC, and that in many cases, this time frame is determined by comorbidities or complications associated with surgery. Unfortunately, data concerning comorbidities and complications with surgery are not available in the CCR data database, and we cannot exclude that the factors associated with delays in chemotherapy administration are not also related to worse outcomes. However, the fact that we observed consistent results in our OS and BCSS [breast cancer specific survival] risk estimates makes this scenario unlikely. In addition, we acknowledge that the potential determinants of chemotherapy initiation include the recommendation of the medical oncologist and the entire multidisciplinary team. Additionally, from the patient-centered care perspective, a patient’s preferences are likely to play a role, which we were unable to take into account.
Similar comments apply to the time-to-surgery study, based on the strengths and weaknesses of each database used. But, again, it’s unethical to do a randomized trial studying a question like this.
The bottom line: Timely treatment is better than delay
I realize that these two studies are about as close to “Well, duh!” studies as there are. Of course, delaying surgery for breast cancer is not a good thing. Of course, delaying chemotherapy when it’s indicated is also not a good thing. These are results that are not unexpected. However, these studies are still very important because they give us estimates of how much of a delay is safe and at what point delaying care starts to have a measurable impact on patient outcomes. Putting the results of these studies together suggests that it’s best to do surgery within about 60 days in patients not needing chemotherapy first, and that for patients with disease lacking the estrogen and progesterone receptor it’s best to start chemotherapy within 90 days of surgery.
We can thus reassure anxious patients who want their surgery tomorrow while at the same time tell patients balking at surgery or chemotherapy how long they can safely wait before the delay starts adversely affecting their chances of survival. Unfortunately, in my practice, due to the socioeconomic status of a lot of patients, by the time some of my patient see me it’s already been more than 30 days since their biopsy and diagnosis.
This sort of analysis is also yet another bit of data demonstrating that conventional treatments work. After all, if a conventional treatment didn’t work, it wouldn’t matter how long you waited to administer it. For instance, if you treated a woman with breast cancer with homeopathy right away, the results would be the same if you waited 120 days. I’ve discussed examples of patients who paid a steep price for their delaying effective treatments for their cancers, beginning with breast cancer patients over eleven years ago and a man I encountered as a resident with rectal cancer who had turned himself orange with megadoses of carrots trying to treat his disease. We also know that the use of alternative medicine as a primary treatment in breast cancer is associated with recurrence and death. Using alternative therapy for breast cancer is a good way to die when you don’t have to or to die sooner than you would otherwise. Refusing surgery also results in death.
Fortunately, however, relatively few patients rely only on alternative medicine. I mention them mainly because the delays in treatment leading to unnecessary death from such treatments has been a major theme of my blogging over the years. However, where this study is most helpful is in providing patients with evidence-based recommendations regarding how urgently they need to proceed with treatment, calming those who think they’re going to die if they don’t get their surgery or chemotherapy tomorrow, and trying to persuade those who are indecisive or too slow to act. They will also help those of us in quality improvement determine whether time to treatment should be a metric we measure and, if so, what standards we should set. Prompt treatment is better, but it’s tricky to define what exactly constitutes “prompt.” These studies help.

   Oprah’s buddy Dr. Christiane Northrup and breast thermography: The opportunistic promotion of quackery
David Gorski
Link
As many readers know, October is Breast Cancer Awareness Month. What that generally means at our cancer center and in the rest of the “real world” is that, during the month of October, extra effort is made to try to raise awareness of breast cancer, to raise money for research, and promote screening for cancer. Unfortunately, what Breast Cancer Awareness Month means around the Science-Based Medicine blog is that a lot of breast cancer-related pseudoscience and outright quackery will be coming at us fast and furious. There’s no way, of course, that I can deal with it all, but there’s one area of medical pseudoscience related to breast cancer that I just realized that none of us has written about on SBM yet. Actually, it’s not really pseudoscience. At least, the specific technology isn’t. What is pseudoscience is the way it’s applied to breast cancer and in particular the way so many “alternative” medicine and “complementary and alternative medicine” (CAM) practitioners market this technology to women. The technology is breast thermography, and the claim is that it’s far better than mammography for the early detection of breast cancer, that it detects cancer far earlier.
I’ve actually been meaning to write about thermography, the dubious claims made for it with regard to breast cancer, and the even more dubious ways that it’s marketed to women. In retrospect, I can’t believe that I haven’t done so yet. The impetus that finally prodded me to get off my posterior and take this on came from what at the time was an unexpected place but in retrospect shouldn’t have been. You’ve met her before quite recently when SBM partner in crime Peter Lipson took her apart for parroting anti-vaccine views and even citing as one of her sources anti-vaccine activist Sherri Tenpenny. I’m referring, unfortunately, to one of Oprah Winfrey’s stable of dubious doctors, Dr. Christiane Northrup. Sadly, Peter’s example of her promotion of vaccine pseudoscience is not the first time we at SBM have caught Dr. Northrup espousing anti-vaccine views. We’ve also harshly criticized her for her promotion of “bioidentical hormones” and various dubious thyroid treatments. However, Dr. Northrup is perhaps most (in)famous for her advocating on Oprah’s show the use of Qi Gong to direct qi to the vagina, there apparently to cure all manner of female ills and promote fantastic orgasms in the process. This little incident ought to tell you nearly all that you need to know about her. Even Oprah looked rather embarrassed in the video in which Dr. Northrup led her audience in directing all that qi goodness “down below.”
What brought Dr. Northrup to my attention again was my having joined her e-mail list. As you might imagine, I’m on a lot of e-mail lists, ranging from that of Mike Adams, to Generation Rescue, to Joe Mercola and beyond. I do it all for you, in order to have the blogging material come to me rather than my having to seek it out. True, the price is that my e-mail in box is frequently clogged with quackery, but it’s a small price to pay. This time around, Dr. Northrup’s e-mail brought my attention to a post of hers, Best Breast Test: The Promise of Thermography. It was truly painful to read, and I consider it inexcusable that someone who claims to be an advocate of “women’s health” could write something that reveals such ignorance. But, then, I suppose I shouldn’t be surprised after her recent flirtation with anti-vaccine views. If it isn’t already complete, Dr. Northrup’s journey to the Dark Side is damned close to complete. You’ll see what I mean right from her very introduction:
Every year when Breast Cancer Awareness Month (October) comes around I am saddened and surprised that thermography hasn’t become more popular. Part of this is my mindset. I’d rather focus on breast health and ways to prevent breast cancer at the cellular level than put the emphasis on testing and retesting until you finally do find something to poke, prod, cut out, or radiate.
Let me take a moment to note the framing that Northrup uses. She’s all about “prevention,” or, at least, that’s what she wants you to think she’s all about. This is no doubt meant to be a stark contrast to us reductionistic, “Western,” “allopathic” physicians who, according to typical “alt-med” tropes, don’t give a rodent’s posterior about prevention but only care about, as Northrup so quaintly put it, “poking,” “prodding,” “cutting out,” and “irradiating.” The only alt-med trope Northrup left out of her attempt to don the mantle of prevention is “poisoning.” (I suppose I should be thankful that she managed to restrain herself that much.) But what does it mean to “prevent breast cancer at the cellular level”? That’s just a scientifically empty and meaningless buzz phrase, especially coming from her.
How would thermography achieve “prevention at the cellular level”, anyway? Thermography is just another test. In intent the use of thermography is no different than mammography in that its advocates claim that thermography can find breast cancers at an early stage. Its advocates also use thermography in damned close to exactly the same way that we use mammography. They use the test on asymptomatic women periodically to try to detect cancer early. There’s zero “prevention” involved. Even if thermography worked as well as its proponents (like Dr. Northrup) claim, there would still be zero prevention involved. Northrup’s use of the term “prevent breast cancer at the cellular level” is as empty as her head is apparently of knowledge about breast cancer and as empty as her handwaving about thermography.
Yes, it’s utter nonsense, but Dr. Northrup’s blather does echo many of the claims made for thermography. For instance, if you go to BreastThermography.com, a site that is clearly pro-thermography, you’ll find a whole bunch of similar claims, such as that thermography detects cancer earlier, that it can provide an “individualized breast cancer risk assessment,” that it’s better for younger women, and that it can detect “thermal signs of hormone effects” that can be used for breast cancer prevention. It ends up including the groundless recommendation that “every woman should include breast thermography as part of her regular breast heath care.” Pointing out that the “incidence of breast cancer is on the rise” (it isn’t, by the way, and hasn’t been for years; in fact, it’s decreasing), the website then makes the completely baseless recommendations that every woman should have a baseline scan at age 20 and then be scanned every three years between ages 20-30 and every year after age 30.
BreastThermography.com also has a quack Miranda warning on its front page:
Disclaimer: Breast thermography offers women information that no other procedure can provide. However, breast thermography is not a replacement for or alternative to mammography or any other form of breast imaging. Breast thermography is meant to be used in addition to mammography and other tests or procedures. Breast thermography and mammography are complementary procedures, one test does not replace the other. All thermography reports are meant to identify thermal emissions that suggest potential risk markers only and do not in any way suggest diagnosis and/or treatment. Studies show that the earliest detection is realized when multiple tests are used together. This multimodal approach includes breast self-examinations, physical breast exams by a doctor, mammography, ultrasound, MRI, thermography, and other tests that may be ordered by your doctor.
All of which would be fine as far as it goes, except that thermography shouldn’t be considered anything more than an experimental technique and the above paragraph does not describe how Northrup is promoting thermography.
thermography
Thermography: The Data
What is thermography and how is it used to detect breast cancer? As its name implies, thermography measures differences in temperature. Most systems use infrared imaging to achieve these measurements. There’s nothing magical about it; the technology has been in use for various applications for decades. The rationale for applying thermography to the detection of breast cancer is that breast cancers tend to induce angiogenesis, which is nothing more than the ingrowth of new blood vessels into the tumor to supply its nutrient and oxygen needs. A tumor that can’t induce angiogenesis can’t grow beyond the diffusion limit in aqueous solution, which is less than 1 mm in diameter. These blood vessels result in additional blood flow, which results in additional heat. In addition, the metabolism of breast cancer cells tends to be faster than the surrounding tissue, and cancer is often associated with inflammation, two more reasons why the temperature of breast cancers might be higher than the surrounding normal breast tissue and therefore potentially imageable using infrared thermography.
Although thermography is scientifically plausible, unfortunately its reality has not lived up to its promise, Dr. Northrup’s claims notwithstanding. Let’s take a look at those claims:
I understand that mammography has been the gold standard for years. Doctors are the most familiar with this test, and many believe that a mammogram is the best test for detecting breast cancer early. But it’s not. Studies show that a thermogram identifies precancerous or cancerous cells earlier, produces unambiguous results (which cuts down on additional testing), and doesn’t hurt the body.
No, studies do not show anything of the sort, other than that thermography probably doesn’t hurt the body. In particular thermography does not produce unambiguous results—far from it! That’s the problem, and that’s the reason why thermography has not caught on. It’s unreliable, and it doesn’t provide much in the way of anatomic information that allows a better localization of the breast cancers it does find. You’ll note if you look at Dr. Northrup’s article that the most recent article she cites that directly addresses the use of thermography to detect breast cancer is from 1982. There are more recent reviews and studies, as you might expect, but, oddly enough, Dr. Northrup doesn’t cite them.
One aspect of thermography for breast cancer detection that its advocates almost always mention is that it is FDA-approved for the detection of breast cancer. That is true, but not in the way it is often implied. Yes, thermography is FDA-approved for the detection of breast cancer, but what they don’t tell you is that thermography is not approved alone for screening women for the detection of breast cancer. It’s approved to be used in conjunction with mammography. What thermography boosters also fail to tell you is that the reason why thermography fell out of favor 30 years ago was as a result of a study by Feig et al in 1977 that found thermograpy to come in dead last among existing screening modalities of the time in finding breast cancers. Mammography detected 78% of breast cancers. In contrast, thermography only detected 39%, and in all 16,000 women in the study thermography was interpreted as positive in 17.9%. This is not a stellar record. In a separate trial in the early 1970s, the Breast Cancer Detection Demonstration Project (BCDDP) planned to compare thermography, mammography and clinical examination. However, BCDDP investigators decided to drop thermography early in the project due to a high false positive rate and low sensitivity.
Of course, technology was a lot more primitive back then, both in its ability to detect differences in temperature and its ability to produce images; it’s not at all surprising that thermography would not perform as well. Add to that the problems of bulky equipment, some of which required liquid nitrogen to work, and the lack of computational power to analyze images, and it’s not surprising that, compared to mammography, thermography never really caught on. Indeed, in a 1985 review, Moskowitz analyzed the data from the BCDDP trial. Of the 1,260 patients with more than one positive thermogram from 1973 to 1976, 1.9% subsequently developed breast cancer from 1977 to 1983. That finding was not statistically significantly different from the 1.3% of patients who developed cancer and never had a positive thermogram. His review of the literature supported the dismal record of thermography for detecting breast cancer.
That was 30 years ago, though. What about now? Computing power has increased almost ridiculously since then, and newer thermal sensors can detect temperature differences of 0.08° C. Has technology evolved to the point where the shortcomings of the original studies that buried thermography as a viable competitor to mammography for breast cancer screening no longer apply?
Maybe. Maybe not. That’s exactly the problem. As pointed out by Gregory Plotnikoff, M.D., M.T.S., and Carolyn Torkelson, M.D., M.S. in a 2009 commentary in Minnesota Medicine entitled Emerging Controversies in Breast Imaging: Is There a Place for Thermography?:
The biggest question concerns the efficacy of thermography to detect breast cancer. Despite various studies that suggest positive results for thermography, there has never been a major randomized controlled trial to determine baseline measurements of sensitivity and specificity. It is hard to imagine thermography being accepted by the conventional medical establishment without such data or evidence of cost-effectiveness.17 In addition to questions about the effectiveness of thermography, research needs to be conducted to determine the cost of using it for widespread cancer screening.18
Even two naturopaths reviewing the thermography literature in 2009 in one of the most woo-friendly journals imaginable, Integrative Cancer Therapies, conclude:
In light of developments in computer technology, and the maturation of the thermographic industry, additional research is required to confirm and/or continue to develop the potential of this technology to provide effective noninvasive early detection of breast cancer.
Even though the naturopaths tried very hard to spin the data into as favorable a view as possible, they just couldn’t bring themselves to recommend routine thermography. Meanwhile, virtually every reputable professional organization whose purview includes breast imaging and breast cancer does not recommend it. Here is a typical position statement, this time from cancer organizations in New Zealand.
That’s not to say that there aren’t “positive” trials of thermography. The problem is that they don’t rise to the level necessary to justify recommending thermography to all women, as many of these chiropractors and naturopaths are doing. There was a recent study of 92 women in 2008 that, using a technology called Digital infrared thermal imaging (DITI), found a sensitivity of 96% and a specificity ranging between 12-44%, depending upon the setting of the machine. While this is promising, it’s not possible to justify the widespread use of this technology on the basis of such a small clinical trial. One also has to remember that thermography also has downsides relative to mammography. For example, women have to let their skin temperature equilibrate to the room temperature of the thermography suite by sitting naked from the waist up in the dressing room for 15 minutes before the examination can be done:
For the scan, the patient is asked to stand about 10 feet in front of the camera with her arms raised over her head while three views of the breast (anterior and two lateral views) are taken. The next step in the process is a “cold challenge” where the patient is asked to place both hands in cold water at 10°C for one minute; then these same three images are retaken.43,44 The breasts exhibit thermal patterns that are captured by the infrared camera. It is these thermal captured image patterns that are interpreted by a trained thermographer.
Other protocols I’ve read about include blowing cool air on the breasts to speed the equilibration.
There is also considerable opportunity for subjectivity in the interpretation of thermograms. This is because, in marked contrast to mammography, there aren’t any widely agreed-upon standards for the performance and interpretation of breast thermography. Plotnikoff and Torkelson described the state of the industry quite well, with one huge blind spot:
In its current state in the United States, thermography is a balkanized industry. Although thermography never took root in mainstream medicine, it has begun to flourish in alternative settings as a breast cancer detection service offered by some physicians, chiropractors, and naturopaths. In lieu of any industry or professional standards for thermography, a variety of practices and protocols have emerged among practitioners and equipment manufacturers. As one practitioner described it, the industry is in its “Wild West” days.19 This fragmented state weakens the credibility of the entire field because consumers have no way to distinguish credible from inferior thermographic techniques. As thermography emerges as an alternative screening tool, consumers are led to believe that it has been validated for efficacy and compared with mammography. This misconception could raise public-safety concerns.
“Misconception”? Have Plotnikoff and Torkelson been reading the ads for breast thermography on the web? These go far beyond simply claiming that thermography has been validated for efficacy and compared with mammography.
Thermography--The-Science-of-Breast-Screening1-kitchener-tvfc1
The marketing of thermography by CAM practitioners
Thermography has become very popular among chiropractors, homeopaths, naturopaths, and a wide variety of “alternative practitioners.” Indeed, many are the ads that claim that thermography is safer than mammography and that it can replace mammography for breast cancer screening, particularly for younger women. Typical of such marketing and propaganda is this article by Joe Mercola entitled Revolutionary and Safe Diagnostic Tool Detects Hidden Inflammation: Thermography as a means of marketing the test at Dr. Mercola’s Natural Health Center in the Chicago area:
In this ad, Mercola claims that mammograms cause breast cancer, that the compression used during mammography can lead to “a lethal spread of any existing malignant cells,” and that thermograpy can identify inflammation that leads to cancer that can be treated—all using diet and Mercola’s supplements, of course—to prevent breast cancer. He also claims that thermography is good for more than just breast cancer detection. If you believe Mercola, it can also detect a whole panoply of conditions, including arthritis, immune dysfunction, fibromyalgia, carpal tunnel syndrome, irritable bowel syndrome, diverticulitis, and Crohn’s disease.
Geez, is there anything thermography can’t do?
Well, if we’re to believe Dr. Northrup, this is another thing breast thermography can do:
The most promising aspect of thermography is its ability to spot anomalies years before mammography. Using the same ten-year study data,2 researcher Dr. Getson adds, “Since thermal imaging detects changes at the cellular level, studies suggest that this test can detect activity eight to ten years before any other test. This makes it unique in that it affords us the opportunity to view changes before the actual formation of the tumor. Studies have shown that by the time a tumor has grown to sufficient size to be detectable by physical examination or mammography, it has in fact been growing for about seven years achieving more than twenty-five doublings of the malignant cell colony. At 90 days there are two cells, at one year there are16 cells, and at five years there are 1,048,576 cells—an amount that is still undetectable by a mammogram. (At 8 years, there are almost 4 billion cells.)”
Of course, even if this were true (and no evidence is presented to show that it is), as I’ve pointed out time and time again, ever earlier detection of cancer is not always a good thing because not all early lesions progress to become cancer. In other words, detecting breast cancer earlier is in general a good thing most of the time, but there clearly exists a point of diminishing returns and a point beyond which detection that is too early has the potential to cause harm. The very issue in the recent rethinking of recommendations for mammography (most recently discussed just two weeks ago) hasn’t been that mammography is not sensitive enough, but rather its potential to detect too many breast cancers that would never progress to endanger the life of the woman.
Let’s put it this way. Even if everything Northrup says or cites is absolutely accurate and thermography can detect inflammatory states that lead to cancer several years before mammography, that would not necessarily save even a single life but would have the potential to cause even more harm through overdiagnosis and overtreatment, particularly given that as many as one in five mammographically detected breast cancers might never progress—and some might even regress. Detecting such lesions five to ten years earlier could only exacerbate the problem of overdiagnosis and overtreatment. It might also lead to the perfect situation for CAM practitioners. They could find breast “lesions” with thermography; prescribe “treatments” in the form of dietary manipulations, supplements, or whatever; watch the lesions either disappear spontaneously or not progress; and then claim credit for having “cured” or “stopped the progression of” the cancer. Even if the cancer progresses to where it requires surgical removal and other treatment, the quack can claim credit for having detected it “before mammography.”
If you want evidence that Dr. Northrup has truly gone completely woo, look no further than this next passage:
As with anything, I suggest you let your inner guidance help you in all decisions about your health. If you feel it’s best to get an annual mammogram, then by all means continue with them. Just be aware of the drawbacks and risks associated with the test. One helpful way to assess your risk for breast cancer—which in turn can help you decide how often you want to have mammograms—is to use the National Cancer Institute’s Breast Cancer Risk Assessment Tool, available online at www.cancer.gov/bcrisktool. After you answer seven simple questions, it calculates both your risk of getting invasive breast cancer in the next ﬁve years as well as your lifetime risk, and it compares each to the risk for the average U.S. woman of the same age and race or ethnicity.
You would be surprised by how many women tell me their doctors make them feel guilty for not having a mammogram. Women who just know they have healthy breasts. Don’t be intimidated if you prefer to forgo annual mammography.
If Dr. Northrup truly tells her patients that it’s medically acceptable for them to forego mammograms and use thermography instead for their routine screening for breast cancer, she is guilty of gross malpractice, in my opinion. If she doesn’t tell her patients that but writes articles like the one I’m citing, she’s guilty of hypocrisy. Her statements are scientifically unjustified, profoundly unethical, and potentially dangerous to patients. Many are the women whom I’ve met who “just knew” they were fine until their family persuaded them to undergo mammography, which then found real, invasive cancers. I don’t have much faith in anyone’s “inner guidance” with regard to asymptomatic disease. In essence, Northrup is urging women to base their health care decisions on intuition rather than science.
The bottom line
Thermography is a technology that has some degree of scientific plausibility but has not been validated as a diagnostic modality to detect breast cancer. The studies from 30 years ago showed it to be markedly inferior to mammography for this purpose, the claims of naturopaths, chiropractors, and various other quacks notwithstanding. While it’s true that advances in technology and computing power might have brought thermography to a point where it might be a useful adjunct to current imaging techniques, large randomized clinical trials have not been done to define its sensitivity and specificity and determine its utility when added to routine mammographic screening. In addition, thermography doesn’t provide any information that breast MRI can’t provide—and provide better. MRI measures in essence the same thing that thermography does (blood flow, which is what the heat maps that thermography produces are surrogates for) and adds to it detailed anatomic information that can guide biopsy and excision. That’s something thermography can’t do.
Currently, my take is that thermography might be useful as an adjunct to mammography. Indeed, I’ll make a confession. Back when I worked at The Cancer Institute of New Jersey, I became involved with a project that was testing a thermography-like machine. (I can’t say more than that about it.) A startup company was testing its new device to determine if the combination of mammography plus this technique could improve the sensitivity and specificity of breast cancer detection. I don’t know what ever became of the company or the device, but I still view thermography basically the same way now as I did then. It’s a test that might be useful as an adjunct to mammographic screening. In order to determine whether thermography is useful as an adjunct to other imaging techniques, however, its proponents need to do the proper scientific validation and clinical testing first, which haven’t been done yet and will require large clinical trials. Until that testing is done, thermography should not be offered to women outside of a clinical trial, and it should never be offered to women in lieu of mammography to detect breast cancer. Science does not support the former indication, although I have to concede that it might one day. More importantly, science most definitely does not support the use of thermography instead of mammography, a use that I doubt any clinical trial is likely ever to support because clinical equipoise demands that thermography be added to mammography in any clinical trial, not tested instead of mammography.
The ironic and sad thing about thermography is that it is not per se quackery itself. The concept of breast thermography is based on a reasonable and scientifically plausible idea, namely that tumors produce more angiogenesis, which leads to more blood flow, which leads to more heat that can be detected and imaged. However, the way it is marketed and promoted as a replacement for mammography is quackery, and Dr. Northrup is buying into such highly dubious promotion, coupled with a condescending appeal to “women’s intuition.” Unfortunately, the tight embrace of quacks to thermography contributes to the unsavory reputation the technique currently has in the medical community and continues to hinder its development in mainstream scientific medicine. On the other hand, maybe the quacks like it that way. If mainstream medicine were ever to validate thermography scientifically, then it would become science-based medicine, and the quacks can’t have that. It’s too profitable to market the test through fear and misinformation.

   Avastin and metastatic breast cancer: When science-based medicine collides with FDA regulation
David Gorski
Link
One of the most frustrating aspects of taking care of cancer patients is that in general, with only a few specific exceptions, we do not have good curative therapies for patients with stage IV cancer, particularly solid tumors. Consequently, patients with stage IV disease are viewed as “incurable” because, the vast majority of the time, they are incurable. Over the years, we have thrown everything but the kitchen sink at patients with stage IV disease, largely with dissapointing results. That’s not to say that the few specific exceptions to which I alluded are not a reason for hope. After all, patients with colorectal cancer and liver metastases used to have a median survival of around 6 months, but these days, with newer chemotherapeutic regimens like FOLFOX plus Avastin, median survival has more than tripled. While expecting to live less than two years is cold comfort to cancer patients with this particular clinical situation, the prognosis is far better than it was.
Of course, I specifically mentioned Avastin because it’s been in the news a lot recently with respect to my area of clinical specialty, breast cancer. Specifically, beginning in July there started appearing a spate of stories about the FDA considering revoking the approval of Avastin for advanced breast cancer based on recent studies that demonstrate that it does not prolong survival in these patients. Many lay people and patients find this reconsideration of Avastin to be quite puzzling, given that the drug was granted accelerated approval in 2008 and has since gone on to be used fairly widely. Given that the case of Avastin in breast cancer is rapidly becoming a classic case study of how messy science-based medicine can be when practiced in the public eye and debated among pharmaceutical companies, the government, and patient advocacy groups.
The promise of angiogenesis inhibitors
Avastin (generic name: bevacizumab) is a class of drug that attacks cancer by attacking its blood supply. Basically, Avastin targets a protein called vascular endothelial growth factor (VEGF), which is growth factor that stimulates the cells lining the blood vessels to undergo a process of angiogenesis, sprouting out new blood vessels in the direction of the cells secreting VEGF. Angiogenesis is a normal physiological function used during embryogenesis and pregnancy, wound healing, during the proliferative phase of the female menstrual cycle, and a variety of other processes. Diffusion of oxygen and nutrients through an aqueous medium is limited to around 1 mm, and malignant tumors get around this limitation by hijacking the normal process of angiogenesis by secreting large amounts of pro-angiogenic factors like VEGF in order to provide themselves with the oxygen and nutrients that they need to grow. During the 1990s, largely inspired by the work of one of my scientific heroes, Judah Folkman, scientists discovered strategies to target the process of angiogenesis to treat cancer. After spectacular results in mouse models of various cancers, however, as is all too often the case the use of angiogenesis inhibitors in humans produced far less dramatic results and, in some cases, didn’t work at all. However, for some cancers, such as colorectal cancer, combining Avastin with conventional chemotherapy has been effective. To those of us “in the biz” since the mid-1990s, this is not a revelation or surprise. In fact, I was involved with some of the first research demonstrating that combining anti-angiogenic therapy with radiation resulted in synergistic anti-tumor effects.
Over the last decade, Avastin has tended to be a magnet for controversy. The major reason that Avastin has attracted a lot of attention is that it’s so expensive (up to $100,000 a year per patient), and part of the reason it’s so expensive is that it is a protein rather than a small molecule. Basically, Avastin is an antibody directed against human VEGF. More specifically, it’s a humanized monoclonal antibody against VEGF. What that means is that the antibody has been modified to get rid of most of the mouse sequences that can provoke an immune reaction against the protein in humans. In any case, developing and producing such a molecule, which is a large protein, are not cheap. Even so, there has been considerable criticism of Genentech, the manufacturer of Avastin, for allegedly overpricing it. In addition, Genentech has pulled some very questionable stunts to protect its profits with regard to some off-label uses of Avastin, for example, for macular degeneration.
Be that as it may, the number of uses of Avastin have expanded to a number of cancers, now including colorectal, lung, breast, and renal cell cancers. Perhaps the most controversial expansion occurred in 2008, when the FDA approved Avastin on what is known as the “fast track” for use in metastatic breast cancer. This allows certain promising drugs for life-threatening conditions to be granted in essence provisional approval quickly, so that patients can have access to them before the usual large phase III randomized, double-blind trials are completed. To understand why this decision was controversial and why it is now being reconsidered, a brief review of terminology is required.
How to evaluate an anticancer therapy
Cancer therapies are generally evaluated using a number of endpoints. The most commonly used include overall survival (OS) and progression-free survival (PFS). There are, of course, other endpoints related to survival that are measured, but these two are the most relevant for this discussion. Overall survival is what it sounds like: How long do patients survive their cancer after diagnosis? Period. It’s hard for an endpoint to be more objective than that: Either the patient is alive or he is dead. This number is usually expressed in terms of median survival, which is the period of time after which half of the patients under study are still alive and half have died. This includes all causes, not just cancer. If a patient with cancer under study dies of a heart attack that is not related to his cancer or his cancer treatment, that counts. Traditionally, OS has been the “gold standard” endpoint in measuring the efficacy of a cancer therapy, because the primary goal has been to prolong survival, the ideal case being prolonging survival to the point where it is indistinguishable from life expectancy if the patient never had cancer in the first place. PFS is survival without progression; i.e., how long the patient with cancer survives before his or her tumor starts measurably growing again or metastasizes. While PFS is often measured as well as OS, it’s generally considered less useful because it is entirely possible for a treatment to prolong PFS without prolonging OS. This sort of result can happen when the treatment is effective at shrinking a tumor or slowing its growth but its toxicities can result in death. Thus, PFS improves with no improvement in OS.
Which brings us to Avastin.
In 2008, that’s exactly the sort of data upon which the FDA’s fast track approval of Avastin was based. Back in 2005, the National Cancer Institute (NCI) announced that in a randomized trial Avastin combined with paclitaxel had increased PFS approximately 4 months over the use of paclitaxel alone. Eventually, by the time an FDA panel voted to approve Avastin in 2007, the E2100 study published in the New England Journal of Medicine had reported encouraging results that Avastin improved PFS in women with metastastic breast cancer. Unfortunately, E2100 also failed to find any benefit in terms of OS. Specifically, Paclitaxel plus Avastin significantly prolonged progression-free survival compared to paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001). Adding Avastin to paclitaxel also increased the objective response rate (36.9% vs. 21.2%, P<0.001). Unfortunately, however, the overall survival rate (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P=0.16). Complications were also more frequent in the group receiving Avastin. Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P=0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P=0.02), all complications common from antiangiogenic therapies, were more frequent in patients receiving paclitaxel plus Avastin. Infection was more common in patients receiving paclitaxel plus Avastin (9.3% vs. 2.9%, P<0.001).
These data were thin gruel indeed to approve Avastin for the indication of metastatic breast cancer, which the FDA did in February 2008. Although the increase in PFS was impressive, the lack of effect on OS was very disturbing, strongly suggesting that drug toxicity was "taking back" all the benefit the addition of the drug was providing against the cancer. However, based on a program to "fast track" promising drugs that was developed in 1990s, the FDA gave provisional approval to Genentech to market Avastin for metastatic breast cancer with the condition that Genentech had to perform additional studies to verify the results upon which the original approval had been based. At the time, there was a great deal of argument over whether this was a wise decision, particularly given how expensive Avastin is and the lack of evidence that it improved quality of life or overall survival. Indeed, I recall attending a talk at ASCO in June 2008 in which the approval of Avastin was strongly defended and the speaker (who it was now escapes me) attacked the use of OS as the basis upon which to approve drugs and argued that PFS should be enough, given the potential improvements in quality of life that can result from a longer period of time without tumor progression.
In the press at the time, Dr. Kathy Albain at Loyola University defended the approval of Avastin thusly:
Dr. Kathy Albain, a breast cancer specialist at Loyola University Medical Center in Maywood, Ill., polled colleagues and patients and found overwhelming support for approving drugs based on delaying tumor progression. It would be ideal to show that a drug also prolongs life, but that may not be realistic, she said. The reason is that when a woman’s cancer progresses, doctors change the drugs they use, hoping to slow the cancer. That dilutes any impact of the first drug — in this case Avastin.
Personally, although I can see where Dr. Albain is coming from, I’ve always been uneasy with this view. Yes, I can see the utility of a drug that slows tumor progression but does not prolong survival. However, I can see its usefulness in only one situation: There must also be good evidence that that drug also improves quality of life, evidence that was lacking for Avastin. In fact, the evidence that existed was suggestive of increased complications due to Avastin. Now, it may be a bit of a judgment call whether it is worth it to slow down tumor progression if there is no improvement in survival and there are drug-related complications, but I remained unenthusiastic about a drug that didn’t prolong OS but did appear to produce markedly more complications. How is that improving the quality of life of a cancer patient? I can also understand the argument, which was made in 2008, that perhaps Avastin benefits certain subsets of patients; we just don’t know who they are yet. My response to that would be that we should be doing the studies to identify those patients rather than exposing large numbers of women to the risk of the drug outside the auspices of clinical trials that could identify them.
The promise is not confirmed
In any case, the followup studies, known as the AVADO and RIBBON-1 trials were indeed performed, and the results published. The AVADO trial was a phase III randomized double-blind clinical trial (N=736 subjects) comparing docetaxel with docetaxel plus Avastin in women with stage IV HER2-negative breast cancer. Its results were less than impressive. While it did demonstrate a decrease in PFS due to the addition of Avastin, PFS did not improve anywhere near the five months it did in the E2100 trial; rather it improved from 8.2 months to 9.0 months, a mere 0.8 month or 24 days. As in E2100, there was no detectable effect on OS. There was, however, a troubling trend towards a shorter OS in women who received Avastin. Even though the difference was not statistically significant, women who did not receive Avastin survived a median of 31.9 months; those who received the lower dose survived a median of 30.8 months; and those who received the higher dose level of Avastin survived a median of 30.2 months. In contrast to E2100, in the AVADO study Avastin did not increase the toxicity of treatment measurably. In the discussion, the authors of the AVADO study concluded:
Taken together with the results of the E2100 study, these data suggest that the combination of bevacizumab with taxane chemotherapy should be considered as an option for the first-line treatment of HER2-negative MBC.
The initial results of the RIBBON-1 trial were reported at the American Society of Clinical Oncology (ASCO) meeting last year and were similarly disappointing. In the trial, Avastin was tested in a randomized, double-blind study enrolling 1,237 patients. Oncologists could choose from capecitabine, taxane, or anthracycline-based chemotherapy, and patients would be randomized to that plus or minus Avastin. The results were that Avastin improved PFS by 2.9 months when added to capecitabine, and 1.2 months when added to anthracycline-based chemotherapy. Again, there was no improvement in OS in women receiving Avastin. In fact, it was these studies that led the FDA advisory panel to vote 12-1 to revoke FDA approval for Avastin for use in breast cancer:
An FDA advisory committee voted 12 to 1 on July 20 to withdraw Avastin’s authorization for advanced breast cancer based on two new studies that the advisers concluded had not shown that the drug extends life. Not only that, the committee concluded that the studies indicated the drug slowed tumor growth for even less time — perhaps as little as about a month. “The vast majority opinion of the committee was that the drug was not doing very much, and what it was doing was more than offset by the negative,” said Wyndham Wilson of the National Cancer Institute, who chaired the committee. Avastin can cause a variety of potentially serious side effects, including blood clots, bleeding and heart failure. “In our best judgment, we did not feel this drug was safe to give relative to its benefits,” Wilson said.
The recommendation has been praised by many cancer experts and by advocates for breast cancer patients.
“The FDA should never have approved Avastin for breast cancer to begin with,” said Fran Visco of the National Breast Cancer Coalition. “We don’t see evidence of benefit, but we do see evidence of harm.”
I tend to agree, although I must admit that back in 2008 I was ambivalent about the FDA approval of Avastin rather than necessarily opposed to it. Now, I’m more of the opinion that the FDA would be justified, based on science alone, in revoking Avastin’s approval, although I can also understand, if not agree, with a lot of the multitude of opinions in the breast cancer oncology world regarding the FDA’s decision. However, there is more than science at work, which is why where the rubber hits the road practicing science-based medicine in intersection with public policy can be so messy and contentious. Just practicing SBM alone is contentious enough, but add a biotech company trying to protect its profits and expand its market, regulatory agencies trying to fulfil their mandate in the case of ambiguous data, and advocacy organizations trying, well, to advocate for their members, and the whole debate can turn into a huge kerfuffle in a hurry. In this case, the FDA is scheduled to make a final determination in September. In the meantime, patients receiving Avastin are afraid, because if the FDA revokes its approval using Avastin for breast cancer will become and off-label use, and insurance companies will no longer pay for it.
Politics intrudes
The whole controversy, where science, economics, politics, and dying cancer patients intersect in what are sometimes very ugly ways, is taking an even uglier turn, thanks to the entire healt insurance reform debate and the intrusion of partisan politics and the unrelenting opposition of Republicans to what they often derisively term “Obamacare.” The reason is that right wing bloggers have jumped on the bandwagon of criticizing the FDA’s decision on Avastin as “evidence” of the impending arrival of socialized medicine-style rationing, thanks, of course, to “Obamacare.” For example, Senator Dave Vitter (R-LA) characterized the decision thusly:
Reviving allegations of government death panels, Sen. David Vitter of Louisiana said Wednesday that an FDA advisory panel’s negative recommendation on a contested breast cancer drug amounts to rationing health care. “I shudder at the thought of a government panel assigning a value to a day of a person’s life,” Vitter said in a press release about the drug Avastin. “It is sickening to think that care would be withheld from a patient simply because their life is not deemed valuable enough.”
Several right wing and rightward-leaning blogs, such as Red State, Hot Air, and Big Government characterized the decision as the FDA being made complicit in “rationing” health care. Perhaps the most despicable post I’ve seen about the matter is this one by Moe Lane at Red State, entitled Obamacare worth 17.5K dead women a year? This is, of course, utter demagoguery of the most vile and despicable sort, as my previous discussion of the evidence demonstrates and the simple observation that Avastin, even under the most optimistic scenario imaginable, only prolongs disease-free survival; it does not save lives of breast cancer patients, at least not as far as we can tell. Also at Red State, Ed Morrissey resorted to exaggerating the benefits and downplaying the results of clinical trials that failed to find much, if any, benefit and did find potential evidence of harm, even going so far as to accuse the FDA thusly:
With the new ObamaCare regime in place, the issue of cost has now become openly part of the FDA process. This is a perversion of their mission, which is supposed to only involve product safety and effectiveness, not bean-counting. If Medicare doesn’t want to cover Avastin, that should be a separate issue handled by CMS and HHS. This strongly suggests that the FDA has become politicized to a degree where their recommendations lose credibility — a dangerous situation for consumers and providers alike.
The Wall Street Journal chimed in with a fallacy- and demagoguery-filled editorial whose deconstruction would be worthy of a separate post of its own (perhaps an exercise for my more “insolent” friend elsewhere?), entitled The Avastin Mugging, in which the anonymous editorialist harped on the earlier E2100 trial and cherry picked the very best numbers out of the AVADO and RIBBON-1 trial, completely ignoring the fact that OS was no different with Avastin and that it might even be worse. He or she made liberal use of straw men arguments and even misquoted findings, at one point even claiming, “At any rate, even the 31% reduction in the risk of disease progression or death is better than the status quo.” The problem is that none of the studies showed a 31% decrease in the risk of death–or any decrease in the risk of death for that matter. The editorialist also referred to to chemotherapy as “savagery” and asserted:
The Avastin mugging is really an attempt to undermine regulatory modernization like accelerated approval that offends the FDA’s institutional culture of control and delay. It is also meant to discourage innovations like Avastin that the political and medical left has decided are too costly, with damaging implications for the next generation of cancer drugs.
No, the reconsideration of decisions like the decision to approve Avastin is an absolutely necessary part of the fast track approval of drugs. If we are going to approve drugs on the basis of relatively scarce preliminary evidence with the quite reasonable requirement that more studies be done and the issue of FDA approval be revisited after those studies are completed, we have to expect that we will find in at least some cases where follow up studies will suggest that FDA approval wasn’t justified, that the drug isn’t particularly useful, and that FDA approval should be revoked. If that doesn’t happen from time to time, then why bother requiring additional studies? Just use fast track approval and forget it, which is, of course, what the pharmaceutical companies would very much like to see.
Although it may not be unreasonable to be concerned that the law may evolve to consider cost more strongly, as the law exists now and as has been reported in the Wall Street Journal and the AP, FDA advisory panels do not consider the costs of the drugs they are evaluating, only the evidence. Whether they should or not is certainly something we as a nation will have to decide. I don’t consider it at all unreasonable to ask whether it’s worth over $8,000 a month to produce a 1.2 month increase in DFS, no increase in OS, and an increased risk of complications such as bleeding, stroke, hypertension, and bowel perforation.
FDA approval, science-based medicine, and politics
So how will this all play out on September 17, which is when the FDA is expected to make its final determination. The FDA could decide to side with the panel recommendation to revoke approval for Avastin, ignore the recommendation, or chart a middle course, continuing approval and asking for still more studies. It wouldn’t surprise me if the FDA chose that last option. It is also important to remember that Avastin may well have uses in breast cancer other than in stage IV disease. One area where it shows some promise is in the neoadjuvant therapy (therapy before surgery) of inflammatory breast cancer. However, the way to find out whether this promise will be realized is to wait for the clinical trials.
Whatever the FDA decides in this particular case, determining which drugs to approve for metastatic breast cancer (or nearly all metastatic solid malignancies) is a particular challenge to SBM because SBM cannot cure the disease. Consequently, the goals in treatment must be palliative; i.e., to relieve symptoms and prolong survival as much as possible. Sometimes these goals are in conflict. In the case of Avastin, this may well be the case. The drug improves PFS very modestly, but there must be a cost in terms of complications that decrease quality of life. The Avastin saga is a saga the likes of which we are probably going to see with increasing regularity.
Another lesson of the ongoing Avastin saga is about the very nature of science-based medicine itself. We have stated that we believe that medical care should be science-based. However, although medicine should be based on science, medicine itself can never be a pure science because so many non-science-based considerations impact on it. On the patient level, there is patient choice and how the doctor and patient weigh the patient’s personal situation and personal considerations in choosing from among science-based therapies. At the national level, considerations of cost, politics, and values cannot be separated from medical policy considerations. Science can tell us that Avastin does not prolong overall survival in breast cancer patients and that it only very modestly prolongs progression-free survival. It can tell us that even that modest increase in PFS comes at a cost of complications that prevent improved PFS from translating to improved OS. What science can’t tell us is whether that modest benefit is worth the cost. That’s a value judgment that must be made both at the level of society as a whole and at the level of each patient and physician.
With more research, I can only hope that science will soon be able to tell us which women with breast cancer are most likely to benefit the most from Avastin.

   Molecular breast imaging (MBI): A promising technology oversold in a TED Talk?
David Gorski
Link
Occasionally, there are topics that our readers want — nay, demand — that I cover. This next topic, it turns out, is one of them. It’s a link to a TED Talk. I’m guessing that most of our readers have either viewed (or at least heard of) TED talks. Typically, they are 20-minute talks, with few or no slides, by various experts and thought leaders. Many of them are quite good, although as the TED phenomenon has grown I’ve noticed that, not unexpectedly, the quality of TED Talks has become much more uneven than it once was. Be that as it may, beginning shortly after it was posted, readers of both this blog and my other super-not-so-secret other blog started peppering me with links to a recent TED Talk by Dr. Deborah Rhodes at the Mayo Clinic entitled A tool that finds 3x more breast tumors, and why it’s not available to you.
At first, I resisted.
After all, I’ve written about the issues of screening mammography, the USPSTF guideline changes (here, too), the early detection of cancer (including lead time and length time bias, as well as the Will Rogers effect), and a variety of other topics related to the early detection of breast cancer, such as overdiagnosis and overtreatment. Moreover, to put it bluntly, there really isn’t anything radically new in Dr. Rhodes’ talk, at least not to anyone who’s been in the field of breast cancer for a while. Certainly, there’s no new conceptual breakthrough in breast imaging and screening described. As I will discuss in more depth later in this post, there’s an interesting application of newer, smaller, and more sensitive detectors with a much better spatial resolution. It’s cool technology applied to an old problem in breast cancer, but something radical, new, or ground-breaking? Not so much. What Dr. Rhodes describes in her talk is the sort of device that, when I read about it in a medical journal, produces a reaction along the lines of, “Nice technology. Not ready for prime time. I hope it works out for them, though. Could be good.” So it was with molecular breast imaging (MBI), which is the topic of Dr. Rhodes’ talk. So I continued to resist for about two or three weeks.
Then our very own Harriet Hall sent me the link. I cannot resist Harriet. When she suggests that perhaps I should blog about a topic, it’s rare that my response would be anything other than, “Yes, ma’am. How soon would you like that post and how many words?” I keed, of course, but only just. The best I could come up with was a wishy-washy “But this isn’t really anything all that new,” which is true enough, but the way Dr. Rhodes tried to sell the audience on the idea of her technology brings up a lot of issues important to our audience. I also thought it was important to put this technology in perspective. So here I go. First, I’ll start by describing what really set my teeth on edge about Dr. Rhodes’ talk. Then I’ll go to the primary literature (namely her brand, spankin’ new article in Radiology describing the technology) and discuss the technique itself.
The truth? You can’t handle the truth!
What irritates me about Dr. Rhodes’ TED Talk starts right at the beginning:
There are two groups of women when it comes to screening mammography — women in whom mammography works very well and has saved thousands of lives and women in whom it doesn’t work well at all. Do you know which group you’re in? If you don’t, you’re not alone. Because the breast has become a very political organ. The truth has become lost in all the rhetoric coming from the press, politicians, radiologists and medical imaging companies. I will do my best this morning to tell you what I think is the truth. But first, my disclosures. I am not a breast cancer survivor. I’m not a radiologist. I don’t have any patents, and I’ve never received any money from a medical imaging company. And I am not seeking your vote.
Later in the talk, Dr. Rhodes says:
If this technology is widely adopted, I will not benefit financially in any way. And that is very important to me, because it allows me to continue to tell you the truth.
I bet you can guess what irritates me about these statements. Actually, it’s two things. First, it’s Dr. Rhodes’ invocation of “The Truth.” Strictly speaking, there is no “truth” in science or medicine. There are hypotheses that are supported by evidence, experimentation, and, in medicine, clinical trials, and there are hypotheses that are not. Most scientific hypotheses are not black and white “true” or “false,” either. Rather, individual hypotheses fall somewhere closer to being true or false, based on the evidence, and they can move closer to or father away from being “true” as new evidence comes in. Indeed, the object of scientific investigation is to falsify hypotheses. Hypotheses that are easily falsified fall by the wayside quickly. Those that are not advance to more intense testing. Those that have withstood the most attempts to falsify them and provide highly useful explanatory and predictive value might eventually graduate to being full-fledged theories.
The next thing that irritates me is Dr. Rhodes’ implication that everyone else has an ax to grind (and is therefore probably lying to you), where as she does not because she doesn’t receive money from medical imaging companies, isn’t a breast cancer survivor, and is not a radiologist. Don’t get me wrong; financial conflicts of interest (COIs), particularly undisclosed ones, are very, very important to know about, because they can (and all too often do) warp the perspective of even the most diligent, honest, rigorous scientist. However, financial COIs are not the only COIs. Just because someone proclaims that she has no financial COIs (or professional COIs) does not mean that she does not have biases or COIs that can be just as strong as the financial COIs of scientists who stand to make a lot of money if their research results in a marketable drug, treatment, or medical device.
Before I examine Dr. Rhodes’ invention (and her claims for it) in a bit more detail, in the interests of full disclosure, I’ll point out that I actually have a non-financial interest in a competing imaging technology for the breast. Researchers at our cancer institute have developed what I consider to be a truly innovative and promising breast imaging device. It’s based on ultrasound and can produce images of the breast almost as striking as those produced by breast MRI. This device has even resulted in a startup company that was featured in our governor’s state of the state address last week. As you can see, it’s a big deal to our cancer center. Since, through some fluke of flukes, I’ve somehow managed to find myself in leadership positions within the clinical and research breast cancer programs at my cancer center (obviously, the cancer center director hasn’t realized his mistake yet), I have a stake in the success of this device. More importantly, not only do we see the chance to have a major positive impact on women’s health if this device is validated but it would bring all sorts of prominence to our institution in general and my programs in particular, just as the success of Dr. Rhodes’ MBI device would improve women’s breast screening and bring all sorts of glory to the Mayo Clinic and her programs. None of this means that either Dr. Rhodes or I are likely to be lying or stretching the truth, but we both have COIs based on our belief in our respective devices. Arguably, my COI is less intense, because this device had been developed before I accepted my current job, and I am not directly involved in its commercialization. A COI does, however, exist nonetheless, and I acknowledge it.
Another thing that bugs me about Dr. Rhodes’ talk is her implication that the radiology world is somehow closing ranks to keep her from bringing this technology to the masses. While she does have a point that some radiologists were utterly shameless in protecting their turf and launching what can only be called histrionic attacks on the new guidelines (the quote by Dr. Daniel Kopans, a very prominent breast imaging radiologist at Harvard, about the USPSTF guidelines that Dr. Rhodes cites at 2:49 in the video being an excellent example), it’s a bit of a stretch to claim that somehow radiologists are so biased against her technology that they won’t give her a fair shake. Before I explain, I mention a couple of points that Dr. Rhodes makes that are correct. First, Dr. Rhodes is correct that breast density appears to be an independent risk factor for breast cancer that has only relatively recently been appreciated as such. Unfortunately, it is in dense breasts where mammography has the biggest problem in detecting cancer. Indeed, that’s part of the reason why it’s not as good in women under 50; their breasts tend to be denser. Second, she is most likely correct that digital mammography is probably not more sensitive or specific for detecting breast cancer, particularly in women with dense breasts, although I will point out that the evidence is not as cut and dried for this assertion as Dr. Rhodes makes it out to be.
Dr. Rhodes also fails to mention that digital mammography does have some major advantages over conventional film mammography and that they are not inconsequential advantages, either. These include permanent storage and duplication of as many copies of a study as needed. In other words, if a woman goes for a second opinion, instead of taking a jacket full of films (what I was used to until relatively recently), she can take a CD and provide an exact copy of her suspicious mammogram to the consulting surgeon. In the old days, she would have to sign out her jacket or bring an inferior film copy. Lost films are a thing of the past, and instead of huge rooms full of large manila envelopes stuffed with X-ray films, the studies can now be stored on hard drives and backed up off site. Digital mammography also allows for the digital manipulation of the image, not to mention the development of image analysis algorithms that can assist the radiologist in detecting suspicious lesions. Finally, digital mammography probably requires less radiation, particularly in women with dense breasts, the very group in whom Dr. Rhodes is trying to increase sensitivity and specificity of breast cancer detection, although this benefit hasn’t been fully verified yet.
Now, I wouldn’t be all that surprised if there was some skepticism over her idea. I’ll explain why in a bit more detail in the next section. However, I really do think Dr. Rhodes goes overboard in implying in at least two parts of her talk that the radiology world and the mammography world are somehow conspiring (or at least so resistant to new ideas that the practical effect is the same as conspiring) to prevent new breast imaging technologies (like hers) from gaining a foothold. Perhaps the most egregious example is this passage, where she talks about having submitted her article to four different journals and having it rejected by each one:
After achieving what we felt were remarkable results, our manuscript was rejected by four journals. After the fourth rejection, we requested reconsideration of the manuscript, because we strongly suspected one of the reviewers who had rejected it had a financial conflict of interest in a competing technology. Our manuscript was then accepted and will be published later this month in the journal Radiology.
At least she didn’t mention Galileo or Ignaz Semmelweis. I’m grateful for small favors.
In any case, this is a highly explosive charge to make so casually, without describing the evidence that led the authors to suspect that one of the reviewers had a financial COI in a competing technology. In fact, if three journals rejected her manuscript before Radiology apparently rejected it and then reconsidered it, did it ever occur to her that perhaps her manuscript just wasn’t very novel? Actually, the manuscript that ultimately was published in Radiology was pretty decent, but there are other reasons that papers, sometimes even good papers, have trouble being published. For instance, she didn’t say which journals she tried first before settling on Radiology. For instance, if she had tried the New England Journal of Medicine, The Lancet, and the Journal of the American Medical Association (JAMA), the reason her manuscript was rejected would be fairly obvious. It’s an interesting new technology with promising preliminary results, but not interesting enough to a broad enough audience to be likely to be published in such high impact journals. None of this implies that Dr. Rhodes’ work isn’t solid work, but the reluctance of journals to publish her results doesn’t suggest that MBI is a technology “they” don’t want you to know about, either.
Everything old is new again
There is no doubt that Dr. Rhodes is charming and a very effective advocate for her preferred breast imaging technology. Nowhere is that more clear than the middle portion of her talk, where she describes the genesis of the MBI. Who wouldn’t be moved at her description of a friend who found a lump in her breast while she was pregnant (and Dr. Rhodes was pregnant as well), the fear it engendered, and how that event inspired Dr. Rhodes to wonder if there was a better way to detect breast cancer? Who didn’t find her account of serendipitously bumping into physicists, who told her about a new kind of gamma detector that was much smaller than previous generations of such devices, compelling? Who wasn’t appreciative of her description of the first device the medical physicists and Dr. Rhodes cobbled together with duct tape and those early primitive tests of its ability to detect radiotracer concentration in the breast? Certainly not me. The image of a bunch of brand new tiny gamma detectors cobbled together with duct tape was priceless. Nor do I in any way want to detract from the hard work and development that went into her MBI device. I do, however, have a small problem with how Dr. Rhodes discussed it in her TED Talk.
That problem is that scanning the breast with radiotracers as a means of looking for breast cancer is not a new technology at all. It’s been around for at least three or four decades. Go back to the 1960s, in fact, and it’s not difficult to find references to the detection of breast cancer using various injected radioisotopes. Since then, at various times such techniques been called scintimammography or sestamibi breast imaging, and they’re all based on the same concept as many nuclear medicine imaging modalities: Inject a small amount of radiotracer that is differentially taken up (or not taken up) by the cell of interest or by cells exhibiting the disease process of interest (i.e., cancerous cells), and then take pictures. Positron emission tomography (PET) scans work this way. So do MUGA scans and bone scans. About 20 years ago, 99mTechnetium sestamibi became the most commonly used radioisotope for breast cancer detection in the breast (as opposed to looking for metastatic disease).
Indeed, if you read Dr. Rhodes’ recently published study in Radiology, you’ll quickly see that what Dr. Rhodes and her team are doing is nothing more than sestamibi breast scanning. Specifically, she is using technetium (99mTc) sestamibi scanning combined with mammography. Currently, only one 99mTc sestamibi compound, Miraluma, which is manufactured by DuPont Pharmaceuticals, is FDA-approved for breast imaging in the United States, which is why such scans are sometimes referred to as Miraluma scans. The same isotope is sold for cardiac imaging under a different name (Cardiolite). The problem with the various nuclear medicine breast scans for screening purposes has always boiled down to an unacceptable lack of specificity and sensitivity. That’s why I have to wonder if the reason for the skepticism that greeted Dr. Rhodes’ results isn’t at least in part due to a collective shrug of the shoulders, as reviewers thought, “Been there, done that.” Certainly, fair or unfair, that probably would have been my initial reaction if this paper had come across my desk.
Not that it’s a bad study or a technology without promise. Neither is true. In fact, as a proof-of-principle study it’s perfectly acceptable, and that’s all it’s billed as in the paper. The findings of the paper are summarized quite well in this figure (click to enlarge):
As you can see, the study started out with 1,007 women with heterogeneously dense breasts enrolled and ended up with 936 women who completed all imaging whose data were available for analysis and whose cancer status was verified. Positive cancer status was defined as a positive biopsy showing cancer, while negative cancer status was defined as women who had a subsequent negative mammogram in the following year, a negative biopsy, or a negative prophylactic mastectomy. Reported sensitivities were 27% for mammography alone, 82% for gamma imaging (MBI) alone, and 91% for a combination of mammography and gamma imaging. The corresponding specificities were 91%, 93%, and 85%. All in all, these are good numbers, particularly when compared to mammography alone in women with dense breasts. Diagnostic yield was 3.2 per 1,000 for mammography alone, 9.6 per 1,000 for gamma imaging alone, and 10.7 per 1,000 for both. Finally, the positive predictive value (the chance of having cancer if the test is abnormal) was 3% for mammography, 12% for gamma imaging, and 8% for both. Basically, the study suggests that the addition of MBI with 99mTc sestamibi can increase the sensitivity and specificity of breast cancer detection in women with dense breasts.
Still, it has to be pointed out that there were only 11 women with breast cancer in the entire population. This is lower than one would normally expect for a typical study of mammography, likely because of the large number of younger women (as young as 25) in the population studied. The reason for this was in order to include a lot of women with dense breasts. Unfortunately, this means that it doesn’t take very much to skew the numbers one way or another. What this implies is that a much larger study is very much indicated in order to get a more precise estimate of what the sensitivity and specificity of this test is and how much it really adds to mammography. My guess is that it will add something to the mammographic screening of dense breasts, but probably not as much as this initial study suggests. Sadly, the decline effect will likely rear its ugly head.
There is another consideration here, namely the question of radiation. Dr. Rhodes touches on this issue in her talk:
So now that we knew that this technology could find three times more tumors in a dense breast, we had to solve one very important problem. We had to figure out how to lower the radiation dose. And we have spent the last three years making modifications to every aspect of the imaging system to allow this. And I’m very happy to report that we’re now using a dose of radiation that is equivalent to the effective dose from one digital mammogram. And at this low dose, we’re continuing this screening study, and this image from three weeks ago in a 67 year-old woman shows a normal digital mammogram, but an MBI image showing an uptake that proved to be a large cancer. So this is not just young women that it’s benefiting. It’s also older women with dense tissue. And we’re now routinely using one-fifth the radiation dose that’s used in any other type of gamma technology.
When I heard this, I wondered something. What is the effective total body dose? Injecting a radioisotope is a different thing than aiming an X-ray beam at the breast. 99mTc has a half-life of around six hours, which means that it takes 24 hours for the radiation levels to fall to 1/16 of the original. In this study, Dr. Rhodes administered 99mTc equivalent to 20 mCi. According to the chart included in this drug information, the estimated radiation dosimetry for a dose of 30 mCi of this tracer is 0.2 rads (approximately 0.2 cGy) to the breast, meaning that the dose used in this study was approximately 0.13 rads. Dr. Rhodes is correct that this is approximately the same amount of radiation as a single mammogram administers. However, she leaves out consideration of the dose of radiation to which other organs are exposed. For instance, 20 mCi of Miraluma results in a dose of approximately 2 rads to the small intestinal wall, 2.6 to 3.6 rads to the wall of the large intestine, 1.0 rads to the ovaries, and 0.3 rads to the bone marrow. In a single dose, these doses are not very high, but remember that we are talking about a screening test that is meant to be administered repeatedly, possibly even yearly, to women with dense breasts. Over the course of 30 years (or even more) of screening, the radiation dose to tissues other than the breast could rapidly add up, in addition to also adding to the dose of radiation to the breasts. These are not trivial concerns, particularly the potential for a significant cumulative whole body dose of ionizing radiation over decades of screening.
The return of the revenge of the Will Rogers effect
Finally, I hate to be a spoilsport, but some of the images that Dr. Rhodes displayed to me did not impress me that much. For example, she showed an image where a mass was not seen on mammography but showed up on MBI. Here’s what bugged me: It was a 5 cm tumor, and, quite frankly, the signal from MBI was not that impressive at all. I also wonder if anyone actually — oh, you know — examined the patient. Most 5 cm tumors are palpable as masses. True, I’ve seen the occasional patient where such a large tumor is difficult to detect, but these patients are relatively uncommon. In another part of the talk, Dr. Rhodes showed one slide in which the mammogram showed one lesion, but the MBI showed three, one of which was only 3 mm in diameter. Unfortunately, she did not say whether pathology of the resected tissue verified that these were indeed separate foci of cancer.
What this leads me to believe is that Dr. Rhodes either doesn’t acknowledge or doesn’t seem to understand the concept of the Will Rogers effect, more formally known as stage migration. This is the phenomenon where a new imaging modality detects tumor that couldn’t be detected before. The name is based on Will Rogers’ famous joke: “When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states.” This little joke describes very well what can happen after a new imaging modality is introduced into cancer diagnosis. Basically, the increased sensitivity of a new technique (like MBI) can result in a migration of patients from one stage to another that does the same thing for cancer prognosis that Will Rogers’ famous quip did for intelligence. For example, patients who would formerly have been classified as stage II cancer (any cancer) have additional disease or metastases detected that wouldn’t have been detected in the past, thanks to the new imaging modality. They are now, under the new conditions and using the new test, classified as stage III, even though in the past they would have been classified as stage II. This leads to a paradoxical effect in which the survival of both groups (stage II and III) appears better, even though there has not been any actual change in the overall survival of the group as a whole. This paradox comes about because the patients who “migrate” to stage III tend to have a lower volume of disease or less aggressive disease compared to the average stage III patient and thus a better prognosis. Adding them to the stage III patients from before thus improves the apparent survival of stage III patients as a group. Meanwhile, the patients who have extra disease detected by the new technology tend to be the stage II patients who would have recurred and done more poorly compared to the average patient with stage II disease; i.e., the worst prognosis stage II patients. But now, they have “migrated” to stage III, leaving behind stage II patients who truly do not have as advanced disease and thus in general have a better prognosis. Thus, the prognosis of the stage II group also ends up appearing to be better with no real change in the overall survival from this cancer.
There’s another effect, as well, an effect that was first noticed when breast MRI began to be widely used for the preoperative workup of breast cancer. Because of the greater sensitivity of MRI, frequently more disease was discovered than expected, leading to more extensive surgery. The mastectomy rate, which had been falling for decades as a result of the greater understanding among surgeons that breast conserving surgery resulted in the same survival rate as mastectomy, began to rise again. Over the last few years, evidence has been accumulating that the routine use of preoperative MRI does not improve survival rates or increase the rate of lumpectomies with negative surgical margins but does increase the rate of mastectomies (blogged here). In other words, when it comes to screening, as I have described many times before, more sensitivity is not always better. It might be better in the case of MBI because the sensitivity of mammography in women with dense breasts is pretty low, but we won’t know until we do the studies.
Which brings me to another part of this talk that irritated me:
Mammography isn’t perfect, but it’s the only test that’s been proven to reduce mortality from breast cancer. But this mortality banner is the very sword which mammography’s most ardent advocates use to deter innovation. Some women who develop breast cancer die from it many years later. And most women, thankfully, survive. So it takes 10 or more years for any screening method to demonstrate a reduction in mortality from breast cancer. Mammography’s the only one that’s been around long enough to have a chance of making that claim.
Elsewhere, on the TED Blog, Dr. Rhodes says that she thinks we should stop debating mammography:
So the problem is whenever a new technology comes around, the mammography mafia, as we call them, says, “Your test is no good, because you can’t demonstrate a mortality benefit.” Well, of course we can’t demonstrate a mortality benefit. Mammography’s been around since the 1960s; they’re the only ones who have a prayer of demonstrating a mortality benefit, because it takes that long to demonstrate.
First, we need to stop debating mammography and put our resources into developing and evaluating alternative screening techniques for women with dense breasts. MBI is certainly a very promising technique, and there are other promising techniques. Second, we need to accept an endpoint for success that is not strictly mortality-based. Although mortality is the most important outcome, there are intermediate outcomes that can serve as acceptable proxies for mortality. For example, instead of insisting that each technique must demonstrate a reduction in mortality from breast cancer, I believe it is acceptable instead to evaluate whether one technique can find tumors at an earlier stage – in other words, small tumors that have not spread to the lymph nodes.
The “mammography mafia”? Nice. I also wonder if Dr. Rhodes has considered the possibility of lead time bias and length bias in her screening test. Whatever the case, in essence, Dr. Rhodes’ argument boils down to a case of special pleading, wherein she insists that a different, more lenient, standard be applied to her favorite technology than was applied to mammography and than is applied to any other screening test. I can’t agree. MBI should be subject to the same standards as any other screening test for breast cancer. If there’s one thing we’ve learned over the last 30 years or so of mammographic screening is that it’s harder than it seems it should be to save lives with a screening test and that screening tests have unintended costs and produce unintended harms. These have to be balanced against the benefits. We will never know for sure what these risks and benefits are for MBI if we don’t do the studies, and if it takes a decade or more to find out what they are, then so be it, particularly given that there is potential for harm as well as benefit. That’s how long it will take. Also remember this: MBI subjects the entire body to radiation in order to try to save lives from breast cancer. How do we know that repeated doses of 99mTc sestamibi won’t result in the increased incidence of, for example, colorectal or ovarian cancer that cancel out any decrease in mortality observed that is attributable to better screening for breast cancer?
We don’t. And we won’t unless we do the studies.
Dr. Rhode’s MBI methodology is an example of a test that is evolutionary, not revolutionary. There is nothing whatsoever wrong with that, either. That’s how science advances, building incrementally on what has gone before. In fact, Dr. Rhodes and her coworkers are to be commended for taking a test that never caught on widely because of its low sensitivity and specificity and recognizing that the technology had developed to the point where it might be possible to overcome these limitations. I just wish she wouldn’t sell it to the general public as though it were some radical new test that the “mammography mafia” don’t want you to know about.

   Breast implants and anaplastic large cell lymphoma (ALCL): Is there a link?
David Gorski 
Link
I must admit that I have a bit of a love-hate relationship with breast implants. On the one hand, as a breast cancer surgeon, I see them as a major benefit to my patients who are unfortunate enough to require mastectomy in order to control their disease. The armamentarium of techniques for reconstructing breasts after mastectomy generally falls into one of two categories, either various form of muscle flaps or breast implants. However, some women are, for various reasons, not eligible for various muscle flap reconstructions. That leaves either breast implants–or nothing. Certainly, some women are perfectly fine with no reconstruction after mastectomy, but many, if not most, women are not. For these women, it would be difficult to overstate how much of a boon to body image and self-esteem reconstruction can be, particularly given how much better at it plastic surgeons have become over the last couple of decades.
On the other hand, breast implants make my life as a breast cancer surgeon more difficult for a variety of reasons. First, they tend to make mammography more difficult by obscuring part of the breast, thus decreasing the sensitivity of mammography. Good mammography facilities can get around this to some extent by using various displacement techniques, but it takes some effort, and it doesn’t completely correct the problems that implants cause for mammographic screening. Moreover, when a woman who has had implants placed for cosmetic reasons comes to see me for a breast mass or an abnormal mammogram, the presence of the implants can complicate treatment decisions. If the abnormality or mass is close to the implant, we worry about rupturing it in the process, particularly if the implant is not below the pectoralis major muscle. Even when the implant is subpectoral, the muscle overlying it frequently ends up being so stretched out that the muscle in essence forms part of the capsule around the implant and ends up being a lot thinner than you might expect. Let me tell you, my anal sphincter tone is always much tighter when operating near an implant, particularly a silicone implant. True, I’m perfectly capable of removing an implant if it’s accidentally ruptured, but such an outcome is not desirable, particularly with silicone implants, where cleaning up the leaking silicone can be difficult.
It doesn’t help that silicone breast implants have been the subject of controversy since the late 1980s and early 1990s, when thousands of women with silicone implants reported a variety of ailments, including autoimmune disease and a variety of other systemic illnesses. These reports led to a rash of lawsuits and, ultimately, the banning of silicone breast implants for general use in 1992. After that, silicone breast implants were only permitted in women requiring breast reconstruction or women enrolled in clinical trials studying breast implants. This ban was partially lifted in 2006, as evidence accumulated that the claims of autoimmune diseases and increased cancer risk due to silicone breast implants were not supported by clinical and scientific evidence and two products made by Allergan Corp. (formerly Inamed Corp.) and Mentor Corp. Not surprisingly, given that the furor over silicone breast implants as a cause of autoimmune and other systemic diseases is based on about as much solid scientific evidence as the antivaccine furor over vaccines as a cause of the “autism epidemic,” there was widespread criticism of this decision. Even now, it is not difficult to find articles about breast implants with titles like Breast Implants: America’s Silent Epidemic and websites like the Humantics Foundation and Toxic Breast Implants . I do note, however, that the number of such sites and articles does appear to be declining and, at least to my impression, seems to have decreased markedly over the last 10 years or so.
Having reviewed the literature and found evidence for a link between silicone breast implants and the systemic diseases attributed to them to be incredibly weak at best, I had little problem with the FDA’s decision. Actually, the only thing I had a problem with at the time, my opinions of how breast implants interfere with breast cancer detection and treatment notwithstanding, is that the FDA was probably being more cautious than the evidence warranted after 14 years.
Was I wrong?
Breast Cancer and anaplastic large cell lymphoma (ALCL): The FDA steps in
I ask this question because last week there was a widely reported story about a warning that the FDA issued regarding breast implants. Indeed, on Wednesday, our press people were circulating copies of the advisory and asking if any of us were available to comment to the press before the evening news deadlines. Unfortunately (or fortunately, depending on your point of view), I was holed up for our NCI site visit rehearsal and thus in essence unavailable. So it was that the national media missed its opportunity to hear me opine my wisdom on the matter to a breathlessly waiting nation. Talk about dodging a proverbial bullet (our nation, that is). Be that as it may, this FDA advisory led to stories in the media like this one by ABC News, FDA Reports Link Between Breast Implants and a Rare Cancer:
The FDA advisory states:
After an intensive review of known cases of a rare form of cancer in breast implant recipients, the Food and Drug Administration says women with implants may have a very small, but increased risk of developing anaplastic large cell lymphoma, or ALCL.
FDA scientists reached that conclusion after examining scientific literature that focused on cases of ALCL in 34 women with breast implants, as well as information from agency reports, international regulatory agencies, scientific experts, and breast implant manufacturers.
But with an estimated five to 10 million breast implant recipients worldwide, agency experts say the known ALCL cases are too few to say conclusively that breast implants cause the disease. FDA believes there are about 60 of these ALCL cases worldwide, though that number is difficult to verify because not all of them were chronicled in scientific publications and some reports may have been duplicated.
This is the sort of epidemiological question that drives physicians and scientists crazy. The reason is quite simple. ALCL is a rare type of non-Hodgkin’s lymphoma (NHL). Indeed, it is classified as a “rare disease,” which for purposes of U.S. policy is defined as affecting less than 200,000 Americans. In actuality, ALCL affects far fewer Americans than that. According to the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI), approximately 1 in 500,000 women is diagnosed with ALCL in the the U.S. every year. ALCL of the breast is even more rare, with 3 in 100 million women per year being diagnosed with the disease. Not surprisingly, that means it’s incredibly hard to get enough patient numbers to make firm conclusions regarding whether the risk of ALCL is truly higher in women with breast implants, and the FDA report, Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses, reflects this uncertainty.
Reading the FDA’s report, I was struck by how little there evidence is one way or the other because of the relative rarity of the disease. Basically, the evidence portion of the FDA report concentrates on case studies and the three existing studies that tried to determine whether there is an association between breast implants and ALCL. Given that the report strikes me as being pretty accessible to the lay person, I recommend reading it, because it reveals a careful sifting of the thin gruel of evidence and how the FDA came to its decision to issue this warning. I’ll try to summarize its 21 pages for you and give you my take on the studies used to justify the warning, but go to the full report for details.
Breast implants and ALCL: The evidence
The FDA performed a review of the scientific literature. This included a search of PubMed, Embase, Web of Science, Cambridge Scientific Abstracts (CSA), EBSCO, and BIOSIS for published papers and abstracts about ALCL and breast implants. After duplicates were accounted for, the FDA found that the entire world scientific literature has reports of 34 women with breast implants who were diagnosed with ALCL of the breast. As pointed out above, the number might be as high as 60, as is described in the report:
In a thorough review of scientific literature published from January 1997 through May 2010, the FDA identified 34 unique cases of ALCL in women with breast implants throughout the world. The FDA’s adverse event reporting systems also contain 17 reports of ALCL in women with breast implants. Additional cases have been identified through the FDA’s contact with other regulatory authorities, scientific experts, and breast implant manufacturers. In total, the FDA is aware of approximately 60 case reports of ALCL in women with breast implants worldwide. The exact number is difficult to verify because reports from regulatory agencies and scientific experts often duplicate those found in the scientific literature.
It’s estimated that there are between 5 and 10 million women in the world with breast implants. Given these numbers, the number of women with breast implants who have developed ALCL of the breast is higher than would be expected from SEER data alone. Moreover, another thread of association that is concerning derives from the spatial pattern noticed in these case reports:
Of the 34 cases, the median time from breast implant placement to ALCL diagnosis was 8 years, with a range from 1 year to 23 years. Most patients were diagnosed when they sought medical treatment for implant-related symptoms such as persistent seromas, capsular contractures, or peri-implant masses warranting breast implant revision operations. In each case, lymphoma cells were found in the effusion fluid (seroma) surrounding the implant, in the fibrous capsule, or within a peri-implant mass. Typically, there was no invasion beyond the fibrous capsule into the breast parenchyma.
It should also be noted that it couldn’t be determined whether there was a higher risk of ALCL that could be attributed to silicone versus saline implants, as twenty-four had silicone implants, seven had saline, and the type of implants was unknown. Similarly, there didn’t appear to be a correlation between the indication for implant placement and the risk of ALCL. Of the 34 cases, eleven patients had their implants placed for breast reconstruction, nineteen patients received implants for breast augmentation, and in four cases no reason for placement of the implants was reported.
Unfortunately, these case reports are not particularly illuminating.
Given that, perhaps the epidemiology will be more revealing. Except that it isn’t. There are only three studies cited looking at whether there is an association between the presence of breast implants and ALCL of the breast. There were no prospective cohort studies. Indeed, all three studies were in essence retrospective studies. Of these, only one of them was designed to look specifically at a correlation between breast implants and ALCL of the breast, rather than observations of non-Hodgkin’s lymphoma and other cancers in women with breast implants. This study (de Jong et al, 2008) is an individually matched case-control study that mined a nationwide population cancer database from the Netherlands. Since 1971, all reports on cytological and pathological diagnoses generated by every pathology department in the Netherlands have been stored in a central database (PALGA, Pathologisch Anatomisch Landelijk Geautomatiseerd Archief).
Going to show that lymphoma of the breast is a rare entity, between 1990 and 2006, only 429 cases of histologically proven lymphoma of the breast were found, and, of the 389 women eleven had a diagnosis of ALCL. Using these cases as the basis, de Jong et al performed an individually matched case-control study thusly:
Subsequently, we performed an individually matched case-control study, nested in the same cohort of 389 female patients. For each case patient with ALCL in the breast, we attempted to select 3 to 7 controls with other lymphomas in the breast, matched on age at diagnosis (±5 years) and year of diagnosis (±2 years). For all 47 potential controls, we obtained pathology reports. Furthermore, for all cases and controls, we sent a standardized questionnaire to the treating physician to obtain information on medical history, including previous malignancies, staging results, and presence of a breast prosthesis, including mammography results.
Conditional logistic regression analysis was performed to estimate the odds ratio (OR) of ALCL associated with breast prosthesis, using EGRET for Windows, 1999 (CYTEL Inc, Cambridge, Massachusetts).21​ The OR was used as a valid risk estimate of relative risk and is therefore referred to as such. An estimate for absolute risk was made based on breast prosthesis sales figures for 1999 to extrapolate the number of women with breast prostheses.
Based on this analysis, de Jong et al estimated the odds ratio of ALCL associated with breast implants to be 18.2 (95% CI 2.1-156.8). What this means is that the odds of having a breast implant were 18.2 times higher in ALCL patients than in the control lymphoma patients. Personally, I have a few problems with this analysis. First, the matching was done on only two criteria, age and year of diagnosis. Although there was no statistically significant difference in age between the groups, there’s no way of knowing if there were any confounding factors that were associated with ALCL of the breast. The numbers are just too small. Consequently, it’s hard to say much about this series except that it is suggestive that there is an elevated risk of ALCL due to breast implants. As the authors themselves say:
Although an 18-fold increased odds for the development of a specific lymphoma in the breast may cause significant concern among women with breast prostheses, it should be realized that the absolute risk remains very low due to the exceedingly rare occurrence of ALCL in the population (estimated incidence at all sites 0.1/100,000 per year).
Which is about one in a million. Even if the estimate made by de Jong et al is accurate, that would put the risk at around 18 in a million.
As for the other two studies, they’re not exactly studies. One (Brinton et al) is a systematic review of the literature looking for evidence of an association between breast implants and cancers at other sites. Brinton et al concluded that breast lymphomas in women with breast implants tend to be associated with the periprosthetic capsule, or in proximity to the implant. Moreover, in the general population, breast lymphomas tend to be a rare entity and most are of B-cell origin. In contrast, breast lymphomas in women with implants tend to be of T-cell origin. The second, Lipworth et al, examined five long term studies of women with breast implants including 43,000 women to assess the risk of lymphoma in these women. This review actually found that there was a slightly decreased risk of lymphoma in women with breast implants, but, as the FDA report noted, it had a at least two weaknesses. First, all the studies began following women more than 35 years before the study, and the entity of ALCL was not defined pathologically until 1985. Second, the number of women studied was inadequate to rule out a rare relationship between breast implants and ALCL.
As you can see, the evidence for a link between ALCL and breast implants is fairly sparse. Of the evidence, de Jong et al is probably the most suggestive, but even it is relatively weak, at least based on numbers alone. However, another piece of evidence comes from the characteristics of implant-associated lymphomas. The FDA report includes a good illustration to show where the lymphoma cells were typically found. In all cases, they were either found in fluid surrounding the implant (it’s not uncommon for implants to have a fluid collection surrounding them) or in the connective tissue capsule that develops around many breast implants:
Add this to the seeming statistical association between breast implants and ALCL, and there might just be something there. It’s not possible to conclude with any degree of certainty that there is such a risk right now; there are simply too few cases and ALCL is too rare, both in the general population and in women with breast implants.
What should be done?
Despite the controversy over the years over breast implants, particularly silicone breast implants, there has been no convincing evidence of a link between systemic diseases, such as autoimmune diseases or cancer. Indeed, since the 1990s, there have been at least a dozen comprehensive systematic reviews looking at a potential link between silicone breast implants and systemic diseases (conveniently listed at Wikipedia), none of which have found convincing evidence for a link. In 2006, Brinton et al found an increased risk of death from lung cancer and suicide in women with implants, but these risks were attributed to increased smoking and psychiatric disorders in women who have implants placed.
This report from the FDA suggests that there might be an increased risk of a rare cancer in women with breast implants, but the numbers are so low that it’s difficult to conclude anything with much certainty, which is why the FDA concludes:
There is a possible association between breast implants and ALCL.
At this time, it is not possible to identify a specific type of implant associated with a lower or higher risk of ALCL.
There is uncertainty about the true cause of ALCL in women with breast implants.
Adding:
Based on available information, it is not possible to confirm with statistical certainty that breast implants cause ALCL. Because ALCL is so rare, even in breast implant patients, a definitive study would need to collect data on hundreds of thousands of women for more than 10 years. Even then, causality may not be conclusively established.
These are reasonable conclusions based on the current state of the evidence, which is inconclusive at best, weak at worst. Given the high degree of uncertainty, what the FDA has done is not entirely unreasonable, although one could argue that it’s a tad alarmist. Basically, the FDA wants clinicians to consider ALCL in women with implants who have persistent seromas (fluid collections) around their implants, recommending that seroma fluid be sent for cytological analysis to rule out lymphoma. In addition, the FDA recommends that any confirmed cases of ALCL associated with implants be reported and is establishing a registry in collaboration with the American Society of Plastic Surgeons to track cases of implant-associated lymphoma. Even this might not be able to detect or confirm a link between implants and ALCL, given the rarity of the disease, but it is a start.
Even accepting the most pessimistic assumption, namely that there really is a significantly elevated risk of ALCL in women with breast implants due to the implants, which has been suggested but not by any means established, this risk, if it exists, should be put into perspective. For example, it should also be noted that, based on what we know, in women who choose implants for reconstruction after breast cancer surgery, the risk of recurrence of their breast cancer is orders of magnitude greater than any theoretical risk of ALCL due to implants. Indeed, in women who have never had cancer and choose implants for breast augmentation, the risk of developing breast cancer is also orders of magnitude higher than of developing ALCL. There is no evidence that implants increase the risk of breast cancer or breast cancer recurrence after breast cancer surgery.
In fact, the most significant risk due to breast implants is not the risk of systemic diseases, such as autoimmune diseases or cancer. Far more significant is the rate of local complications, such as capsular contracture or implant rupture. Due to such complications, many women with implants require reoperation. Indeed, reoperation rates have been estimated to be as low as 3% after seven years to as high as 20% over three years. These are by far the most significant risks due to breast implants.
While I am not a big fan of elective breast augmentation or cosmetic surgery in general (that’s just me, I guess, in that my assessment of the risk-benefit ratio of having a surgeon cut into me to make me better looking probably won’t come down on the side of surgery unless I eer suffer some sort of traumatic injury that leaves me disfigured enough to require reconstructive surgery), if there is informed consent in which the risks of breast augmentation are clearly explained based on science and clinical evidence and not inflated by the addition of claimed risks that are not supported by science, women should be free to choose implants if they so desire. From my perspective as a clinician, more importantly I strongly believe that, for women with breast cancer, implants are an important option to be made available for reconstruction after mastectomy. In particular, given how small the risk would be even if it is confirmed, this new information from the FDA regarding breast implants and ALCL does not change that.

   Abortion and breast cancer: The manufactroversy that won’t die
David Gorski
Link
Editor’s note: Given the controversial nature of the topic, I think it’s a good time to point out my disclaimer before this post. Not that it’ll prevent any heated arguments or anything…
The Science-Based Medicine blog was started slightly over two years ago, and this is a post I’ve wanted to do since the very beginning. However, since January 2008, each and every time I approached this topic I chickened out. After all, the topic of abortion is such a hot button issue that I seriously questioned whether the grief it would be likely to cause is worth it. (Take the heat generated any time circumcision is discussed here and ramp it up by a factor of 10.) On the other hand, there is so much misinformation out there claiming a link between abortion and the subsequent development of breast cancer when the data simply don’t support such a link, and the name of this blog is Science-Based Medicine. Why should I continue to shy away from a topic just because it’s so religiously charged? More importantly, in my discussion how can I focus attention on the science rather than letting the discussion degenerate into the typical flamefest that any discussion of abortion on the Internet (or anywhere else, for that matter) will almost inevitably degenerate into. Indeed, such discussions have a depressing near-inevitability of validating Godwin’s law not once but many times — usually within mere hours, if not minutes.
My strategy to try to keep the discussion focused on the science will be to stay silent about my own personal opinions regarding abortion and, other than using it to introduce my trepidation about discussing the topic, the religious and moral arguments that fuel the controversy. That’s because the question of whether abortion is the murder of a human being, merely the removal of a lump of tissue, or somewhere in between is a moral issue that, at least as far as I’m concerned, can’t ever be definitively answered by science. That is why it is not my purpose to sway readers towards any specific opinion regarding the morality of abortion. Indeed, I highly doubt that any of our readers care much about my opinions on the matter. On the other hand, I would hope that I’ve built up enough trust over the last two years that our readers will be interested in my analysis of the existing data regarding something another related issue. It is my purpose to try to dispel a myth that is not supported by science, specifically the claim that elective abortion is causes breast cancer or is a very strong risk factor for its subsequent development. That is a claim that can be answered by science and, for the most part, has been answered by science with a fairly high degree of certainty. Despite the science against it, the medical myth that abortion causes breast cancer or vastly increases the risk of it is, like the myth that vaccines cause autism, a manufactroversy that won’t die, mainly because it is largely fueled by religious beliefs that are every bit as immune to science as the ideological beliefs that drive the antivaccine movement.
A bit of background
Let me step back a bit. Several years ago, I didn’t pay much, if any, attention to the ABC (“abortion-breast cancer”) claim. Then two years ago events conspired to force me to start paying attention. The first item was nothing more than a skeptic encountering bad science. The second thing that happened struck a lot closer to home. The first thing that happened was that in the fall of 2007 I saw this article in the Chicago Tribune entitled Snubbing cancer study will only hurt women: Research showing link to abortion ignored by media (also mirrored on John Byrne’s blog):
During National Breast Cancer Awareness Month, it is fitting and proper that women be informed about any newly discovered dangers, even as the public groans under the weight of all the warnings surrounding the mere act of living.
For example, a well-researched Chicago Tribune story last week disclosed that women who have just a couple of alcoholic drinks daily increase their breast cancer risk by 13 percent. Coincidentally, a new study reported that abortion is an important breast cancer risk factor, yet I couldn’t find a word describing the research in mainstream media.
How to explain this disparity? I’ll be vigorously advised that “most” studies disprove an abortion-breast cancer link. Or that the study in question appeared in a “conservative” scientific journal. Or that the study is bogus or unimportant. Or, more rudely, that the whole breast cancer argument has been concocted by anti-abortion rights advocates to make women afraid to have abortions. The issue is dead, I’ll be notified. Kaput. Here I would remind critics that in science it’s not who says it or how many say it that counts. What does count are the data and the rigor with which they are collected, analyzed and held up to a scientifically credible hypothesis.
Curious to find out what this study was, what it found, and whether or not it was evidence that I should change my mind, I decided to go straight to the source. That tends to be my reaction whenever I see such a veritable panoply of crank language, not unlike what we hear from “intelligent design” creationists when whining about why they are not taken seriously. The science that has failed to validate ABC may not be as well settled as the science supporting the theory of evolution, but the arguments against established science used by ABC advocates are disturbingly similar. As for the “disparity,” perhaps it could be because even the mainstream media has learned that the medical “journal” in which this dubious “study” appeared (and I use the terms “journal” and “study” very loosely) is a right wing propaganda rag masquerading as a medical journal. It’s also a “journal” with which regular readers of this blog should be very familiar. Yes, my friends, we’re talking about the Journal of American Physicians and Surgeons (JPANDS for short), and the study was entitled The Breast Cancer Epidemic: Modeling and Forecasts Based on Abortion and Other Risk Factors, by Patrick Carroll.
It’s hard not to note that one significant indication that the study is likely to be really, really, really bad is the very fact that it appeared in JPANDS. As you may recall, I’ve discussed JPANDS before, as has Kathleen Seidel. Of course, the fact that the study appeared in JPANDS does not necessarily mean it’s a bad study, although it does make it highly likely that it is, particularly given that a good study can get into a real scientific journal. In this case, it was a very bad study indeed. In fact, it was one of the most hilariously inept examples of confusing correlation with causation and abusing statistics that I had ever seen anywhere, any time. Truly, the Flying Spaghetti Monster’s example of correlating global warming with the decrease in the number of pirates seemed reasonable by comparison. Unfortunately, the Carroll “study” (if it can be called that) achieved its purpose. It got credulous pundits like Byrne presenting it as if it were actual evidence of an ABC link.
What surprised me, however, was not the incredibly inept attempt at “science” in this article. What actually surprised me was the second thing that made me stand up and take notice of the ABC activists, something that I came across while investigating whether or not there is a link between abortion and breast cancer. What I found was that someone I actually knew, someone who was actually connected to The Cancer Institute of New Jersey (where I was on the faculty from 1999 to 2008) due to her affiliation with one of the private hospitals affiliated with CINJ. I’m referring to Dr. Angela Lanfranchi, who is an anti-abortion activist, cofounder of the Breast Cancer Prevention Institute, which promotes the ABC link, and one of the foremost promoters of the link between abortion and breast cancer. Indeed, as far as I can tell, Dr. Lanfranchi is probably the foremost promoter of the link who actually takes care of breast cancer patients for a living. Worse, she has published arguments in favor of ABC in JPANDS, which, as regular readers of this blog know, is always a bad sign as far as pseudoscience or ideologically motivated anti-science goes. Sadly, after discovering her “other side,” in marked contrast to her generally strong competence as a surgeon, I soon found articles by Dr. Lanfranchi using classic crank language to make incompetent, ridiculously exaggerated, and scientifically unsupported statements:
It amounts to child abuse to take a teenager in a crisis pregnancy for an abortion. At best, it will give her a 30% risk of breast cancer in her lifetime. At worst, if she also has a family history of breast cancer, it will nearly guarantee this. As a mother, I need to be informed of this to protect my daughter. Medical professionals have an unfortunate history of continuing to harm women if it means admitting that they have injured or killed them with their treatments.
This is best illustrated through the well-known story of Ignaz Semmelweis, MD. He was an obstetrician-gynecologist in the 1840s who proved that hand washing would reduce mortality rates from childbed fever from 30% to 2% on maternity wards. His reward for this was ridicule from his professors and loss of his hospital appointments. Women continued to die needlessly for another 30 years until the germ theory proved Semmelweiss was correct. It must have been very embarrassing for a lowly resident to have told the greatest medical professors of his time they were responsible for many women’s deaths.
I’ve occasionally had the extreme chutzpah to propose “laws” and then to name them after myself, such as when I proposed Gorski’s Law of Testimonials at the SBM Conference during my talk at TAM7 or facetiously coined Gorski’s Law of the Pharma Shill Gambit right here on SBM. I’m seriously tempted to do so again here regarding the invocation of Semmelweis’s name. Whenever someone invokes the name of Ignaz Semmelweis in the context of overblown, hyperbolic language, that person is almost certain not to be basing her criticism of medicine on science. It applies to the anti-vaccine movement. It applies to Mike Adams of NaturalNews.com, and it applies here. In any case, the above is an incredible exaggeration that even the research of one of the foremost scientists making the ABC claim doesn’t support. (More on that later.)
Although I still miss CINJ from time to time, it was a really good thing, at least for my comfort level dealing with the local practitioners, that it was within a month after that I decided leave my old job to accept my current position. Less than four months later I was gone from CINJ. I can’t imagine the tension that would have occurred when I ran into Dr. Lanfranchi at her hospital’s tumor board, which I was occasionally assigned to attend because CINJ sent its faculty out as guests to the various tumor boards of its affiliates. In retrospect, I don’t know how I could have been right there in central New Jersey for so long and yet so oblivious to what was going on, but I was.
Back to the future
So what tweaked me to write about the question of whether abortion predisposes women to breast cancer after all this time? Last week, several readers forwarded me this article from WorldNet Daily by Janet Stanek, a prominent activist promoting claims of a link between abortion and breast cancer, in which she claims that a “Top scientist finally admits abortion-breast cancer link,” a sentiment echoed on her blog. Included in this article is an amazing claim about the NCI workshop in 2003 that concluded that there is no link between abortion and breast cancer:
At the time, 29 out of 38 studies conducted worldwide over 40 years showed an increased ABC risk, but the NCI workshop nevertheless concluded it was “well established” that “induced abortion is not associated with an increase in breast cancer risk.”
Brind went on to write a minority report NCI alludes to on its website without publishing or listing its author and did not even mention in its workshop summary report.
Life went on, except for post-abortive women inflicted with breast cancer anyway.
But six years later something happened. Dr. Brinton either flipped her lid, flipped ideologies, restudied the evidence and decided to recant, or couldn’t sleep at night – and she began righting her wrong.
In April 2009, Brinton co-authored a research paper published in the prestigious journal Cancer Epidemiology, Biomarkers and Prevention, which concluded that the risk of a particularly deadly form of breast cancer that attacks women under 40 raises 40 percent if a woman has had an abortion.
Stanek then gloats:
For nine months, that little bombshell of a disaster for pro-abortion ideology was published without the NCI acknowledging it or changing its stance.
Then this month, Brind spotted and wrote about Brinton’s concession and NCI’s hypocrisy.
In case you don’t know who he is, Joel Brind is a born-again Christian and professor of biology and endocrinology at Baruch College who has become one of the most prominent voices in the ABC movement. Arguably the most famous supporter of the idea that abortion causes breast cancer, he has campaigned tirelessly to promote his view that abortion predisposes to breast cancer. I also love how Stanek just counts studies without any consideration of quality or scientific rigor, as if all studies are equivalent. Truly, she’d fit right in with creationists or the alt-med movement. Be that as it may, one has to wonder about her claim that Dr. Brinton “flipped her lid.” To do that, I had to look up the actual study that Stanek is holding up as vindication, although I find it odd that it took the ABC supporters 9 months to discover this study, entitled Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Do they not keep up with the medical literature? It’s pretty easy to set up an automatic PubMed search for “abortion AND breast cancer risk”) that will send automatic updates every day.
In any case, I decided to see whether this study is such slam dunk evidence of a nefarious plot to hide the ABC link.
Back to the future, take two
Before I continue, it’s worth it to go over a bit of background. First of all, you need to know what “triple-negative” breast cancer is. Clinically, breast cancer is divided by whether or not it makes three different proteins: estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. ER(+) tumors tend to be better differentiated and less aggressive, but, more importantly, they respond to therapies designed to block estrogen action. HER2/neu is an oncogene that a subset of breast cancers express and that tends to portend a worse prognosis. However, when it is present, the tumor can be treated with a targeted therapy designed to counteract its activity, specifically Herceptin. Triple-negative cancers, by contrast, make no ER, PR, or HER2/neu (hence the “triple-negative” moniker). More importantly, they tend to be more aggressive and more poorly differentiated. Paradoxically, they tend to respond well to chemotherapy but have a proclivity to relapse afterward. They’re nasty, nasty tumors and make up around 15% of all breast cancer. (Indeed, one of them killed my mother-in-law nearly one year ago.) More recently, breast cancers have been characterized on the basis of global gene expression into subgroups known as luminal A and B and basal-like breast cancer. Consistent with previous work, we know that the vast majority of triple-negative tumors fall into the basal-like classification, and basal tumors tend to be aggressive histologically, unresponsiveness to typical endocrine therapies, and poor prognosis.
Another critical piece of background that’s important is the known risk factors for breast cancer. Currently agreed-upon risk factors based on history for the development of breast cancer are:
     1.  Age (breast cancer becomes more common as women age)
     2.  Sex (men can get breast cancer, but it is very uncommon)
     3.  Personal history of breast cancer (a history of breast cancer in one breast is probably the strongest risk factor of all for the subsequent development of cancer in the contralateral breast)
     4.  Family history of breast cancer and genetic risk factors (BRCA mutations, for example)
     5.  Age at first menstrual period (earlier is worse)
     6.  Race (breast cancer is slightly more common in Caucasians but African Americans are more likely to die of the disease)
     7.  Age at menopause (older is worse)
     8.  Age at first live birth (older is worse)
     9.  Number of children (more is better, with nulliparity conferring the highest risk)
     10.  Previous chest irradiation (for childhood lymphoma in the chest, for example)
     11.  Oral contraceptive use (this is a very weak and somewhat controversial risk factor; women who have not taken OCPs for 10 years are at no higher risk than those who have not taken them)
     12.  Hormone replacement therapy
     13.  Certain pathological findings on breast biopsy (such as atypical ductal hyperplasia, lobular carcinoma in situ, etc.)
     14.  Breastfeeding (a weak protective effect)
     15.  Alcohol
     16.  Obesity
Also, before I get to the study, for purposes of my discussion of the alleged link between abortion and breast cancer, one theme that runs through the risk factors due to reproductive history is that the more time a woman spends having menstrual cycles uninterrupted by pregnancies, the higher the risk of breast cancer. That’s why more pregnancies are protective and why an earlier age at menarche and a later age of menopause are thought to be risk factors. Leaving aside family history, a personal history of breast cancer, or a biopsy with a high risk lesion (the three strongest risk factors of all), the woman at highest risk of developing breast cancer is one who has never been pregnant, had an early menarche, and has a late menopause. This relationship between reproductive history and breast cancer is thought to be due to a higher lifetime exposure to estrogen unopposed by progesterone and other pregnancy hormones. One consequence of these observations observed thus far is that the tumors that develop in women with these risk factors are more commonly ER(+), which makes sense from a biological standpoint. Indeed, strategies designed to decrease breast cancer risk in women at high risk by blocking estrogen action do decrease the risk of ER(+) breast cancer but have no effect on the risk of ER(-) breast cancer, which makes sense from a biological standpoint.
Triple-negative breast cancer, being ER(-), has become a hot research topic lately because it tends to strike younger women, especially African-Americans, and it tends to be deadlier than other forms. Worse, because it does not make ER or HER2/neu, there are no targeted treatments for it. Tamoxifen and aromatase inhibitors (which block the action of estrogen) don’t work; neither does Herceptin (which blocks the action of HER2/neu). All that leaves is chemotherapy. Paradoxically, triple-negative tumors tend to respond well initially to chemotherapy, but they have a high propensity to recur after an apparently good initial response. No doubt much of the impetus for this study were these well-known facts, coupled with how little is known about the risk factors for triple-negative breast cancer as opposed to other more common subtypes
Another thing that you need to know about the ABC claim is that the evidence is quite conclusive that spontaneous early miscarriages neither protect against nor decrease the risk of breast cancer. Other than possibly for women who have suffered more than three spontaneous miscarriages (the data are equivocal), pregnancy loss appears to be more or less neutral with respect to influencing breast cancer risk, neither increasing nor decreasing it. These observations are fairly strong suggestive evidence that an elective abortion would probably not behave any differently than a spontaneous miscarriage at the same point in pregnancy from a biological standpoint. These data are not enough to dismiss the ABC link in and of themselves, but they do lessen the biological plausibility of such a link. Not enough to reject further study, but enough to cast a skeptical eye on the retrospective studies that exist.
The final thing you need to know is about this study itself, specifically that it is not really a new study at all. Rather, it is a reanalysis of existing data from two studies of women from the 1980s and 1990s, as the methods section shows:
The cases included in this study were originally ascertained for two previous studies through the population-based Seattle–Puget Sound Surveillance, Epidemiology, and End Results cancer registry. Eligible cases from the first study population included all primary invasive breast cancers within the three-county Seattle metropolitan area, diagnosed between January 1, 1983, and April 30, 1990 (ages, 21-45 y). The methods for this study have been described elsewhere (17, 18). The study was confined to Caucasians because of the small representation of minorities in the region.
And:
The second population included the Seattle site participants of the multicenter Women’s Interview Study of Health, the methods for which have been described (19). Eligible cases included women in the Seattle area diagnosed with invasive breast cancer between May 1, 1990, and December 31, 1992 (ages 21-44 y).
References 17 and 18 are:
White E, Malone KE, Weiss NS, Daling JR. Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst. 1994 Apr 6;86(7):505-14.
Daling JR, Malone KE, Voigt LF, White E, Weiss NS. Risk of breast cancer among young women: relationship to induced abortion.J Natl Cancer Inst. 1994 Nov 2;86(21):1584-92.
And reference 19 is:
Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995 Jun 7;87(11):827-35.
For two out of the three studies, the purpose was to ascertain whether oral contraceptives pose a risk for breast cancer. In the current study, pooling the two studies ended up with subjects that included 897 women who had developed breast cancer before age 45 and 1,569 controls. These studies were all retrospective, with all the potentials for confounding factors to which retrospective studies are prone. Moreover, it was a study based on interviews, in which women were interviewed about their health history and known and suspected causes of breast cancer. Recall bias is a well-known confounding factor that plagues studies of abortion. One reason is that, because of the social stigma associated with abortion, women tend not to tell everything about their history when it comes to abortions, either not admitting to the procedure or, if they’ve had more than one, not admitting to all of them. This may have been particularly true for older studies, when abortion had even more of a stigma attached to it. The other reason is that women with breast cancer who have had an abortion in the past tend to be more likely to admit to having had an abortion they think it might be a cause of their predicament. It’s very hard to evaluate the significance of recall or response bias and how much they might have affected the results of individual studies. In any case, such problems are why prospective studies are less likely to produce spurious associations. Also, many of the cases of breast cancer in these studies occurred before one of the commonly used markers that we test all new breast cancers for, HER2/neu, was routinely tested for, meaning that the investigators had to locate the pathology specimens and have them tested for HER2/neu, because separating triple-negative tumors from the rest depends upon it.
Now, on to the study. Here’s what Malek and Brind are crowing about. It’s part of the “money table” that summarizes the results:
Note the yellow at the bottom pointing out the line referring to abortion, thanks to Colby Cosh. According to the table, the odds ratio (OR) for breast cancer in women who have had one or more abortions is 1.4 (95% confidence interval 1.1 to 1.8), a barely statistically significant result. One thing that leapt right out at me and bothered me was not so much this result. For one thing, the original study (18) of the group that looked at this question found an OR = 1.5 (95% CI = 1.2 to 1.9). I would have been shocked if the odds ratio was significantly different in this study. In any case, it’s barely statistically significant and comes from a pooled retrospective study where the most recent cases date back to the early 1990s, both factors that make it very prone to bias or spurious results. More recent research done prospectively should have (and does have) greater weight.
Stranger still is an odd consistency in the data on abortion and breast cancer in this study when they broke down the numbers into triple-negative versus non-triple-negative breast cancers. For all potential breakdowns (all cancers, triple-negative cancers, non-triple-negative cancers), the OR is the same, 1.4. That struck me as quite odd. Under either of the common biological justifications posited by advocates of the ABC concept, there should be a difference. If it’s estrogen overexposure unopposed by progesterone, then we would predict that abortions would result in more ER(+) tumors than ER(-) (including triple-negative) tumors if abortion is truly a risk factor for breast cancer. If it’s the newer straws that the ABC movement is grasping at, namely stem cells, one might hypothesize that abortion would increase the risk of ER(-) or triple-negative tumors, since stem cells don’t make ER. True, there weren’t that many triple-negative tumors in this study (187); so who knows? But it’s still rather odd that the numbers are basically identical. It tends to suggest more of a statistical fluke than a specific biological mechanism.
What also makes this OR of 1.4 less convincing is that, if you look at the 1,569 controls, they broke down pretty similarly between having had one or more abortions and never having had one; i.e., 27.1% of controls had an abortion and between 32% and 35.5% of women with breast cancer had one or more. Nowhere is it analyzed whether that difference is statistically significant, but even if it is it’s not a huge difference. Moreover, this study only addressed breast cancer risk in women under 45. This is a relatively small fraction of the total cases of breast cancer; so even if this study did show a “40%” increased rate of breast cancer, it would only apply to a relatively small portion of the population. Given the problems with the study and in light of data gathered over the 15 years since the last of the three studies whose subjects make up this reanalysis was completed, I am completely underwhelmed with this study as any sort of strong evidence for an ABC link.
Finally, an OR = 1.4 is not a large odds ratio, particularly in a retrospective study. Colby Cash is not correct when he dismisses any OR under 2.0 as being insignificant, but small odds ratios do require multiple replications from different groups in different populations all converging around similar numbers before epidemiologists take them seriously. That’s what it took before secondhand smoke exposure, which routinely results in odds ratios around 1.3 for heart disease and lung cancer, was accepted as significant risk for health problems. Other aspects that might make ABC more credible would be if there were a “dose-response” effect, in which more abortions would increase the risk even more, or some apparently biological specificity for certain subtypes of cancer. Neither of these exist, and this study sure doesn’t provide such evidence. In light of that, more than likely this is simply a spurious result that has been refuted by later studies. Certainly it doesn’t even approach slam-dunk evidence that an ABC link exists, much less is being “covered up.”
The evidence
Here’s what the American Cancer Society says about the ABC link:
The Collaborative Group on Hormonal Factors in Breast Cancer, based out of Oxford University in England, recently put together the results from 53 separate studies conducted in 16 different countries. These studies included about 83,000 women with breast cancer. After combining and reviewing the results from these studies, the researchers concluded that “the totality of worldwide epidemiological evidence indicates that pregnancies ending as either spontaneous or induced abortions do not have adverse effects on women’s subsequent risk of developing breast cancer.”
And here’s what the National Cancer Institute says about it:
The relationship between induced and spontaneous abortion and breast cancer risk has been the subject of extensive research beginning in the late 1950s. Until the mid-1990s, the evidence was inconsistent. Findings from some studies suggested there was no increase in risk of breast cancer among women who had an abortion, while findings from other studies suggested there was an increased risk. Most of these studies, however, were flawed in a number of ways that can lead to unreliable results. Only a small number of women were included in many of these studies, and for most, the data were collected only after breast cancer had been diagnosed, and women’s histories of miscarriage and abortion were based on their “self-report” rather than on their medical records. Since then, better-designed studies have been conducted. These newer studies examined large numbers of women, collected data before breast cancer was found, and gathered medical history information from medical records rather than simply from self-reports, thereby generating more reliable findings. The newer studies consistently showed no association between induced and spontaneous abortions and breast cancer risk.
And here’s what the American College of Obstetrics and Gynecology said about it in 2009:
The relationship between induced abortion and the subsequent development of breast cancer has been the subject of a substantial amount of epidemiologic study. Early case-control studies that reported an association between induced abortion and subsequent development of breast cancer had significant methodological problems, most notably reliance on retrospective reporting of abortion history. A key methodological consideration in interpreting the evidence for any relationship between abortion and breast cancer risk is the sensitive nature of abortion, which could affect the accuracy in retrospective studies that rely on participant reports of having had an abortion.
[...]
Early studies of the relationship between prior induced abortion and breast cancer risk were methodologically flawed. More rigorous recent studies demonstrate no causal relationship between induced abortion and a subsequent increase in breast cancer risk.
A few of the most recent studies that have failed to find an ABC link include the California Teacher’s study, a large, prospective cohort study with detailed pregnancy history data; the Nurse’s Health Study II, which included over 100,000 women; and the EPIC Study, which included over 250,000 women. Numerous studies (including some of the above) that failed to support an ABC link are linked to here1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17.
Given the preponderance of evidence, although it is still possible that there may be a link between abortion and breast cancer, it is unlikely that there is, and, if there is, it’s likely to be very, very small, given that numerous epidemiological studies have failed to uncover it. In this, the evidence for the ABC link is not unlike the state of evidence regarding vaccines and autism. Early studies, not as large, well-designed, or rigorous, suggested that there might be an association, but the larger and better-designed the study, the smaller the OR became until it converged on 1.0. Current evidence does not support the ABC link, and there are enough studies to allow us to conclude either that there probably is none or that it’s very small. That’s as good as it gets in epidemiological studies, which, unfortunately, can never entirely eliminate the possibility of a correlation. They can only conclude that the chance of a significant correlation is very, very low. Moreover, contrary to the inflated claims of some activists, even Joel Brind’s own infamous meta-analysis from 2003 does not show a 30% risk of breast cancer if a young woman has an abortion before the age of 18, much less a virtual certainty that she’ll develop breast cancer if she has a strong family history as well. In fact, Brind’s own work, which is held up as “proof” of an ABC link, only suggests at the most an OR = 1.3 to 1.5, which is nowhere near high enough to produce the 30% lifetime risk of breast cancers claimed by overwrought activists like Dr. Lanfranchi.
Despite the evidence, however, if you do a Google search for “abortion and breast cancer” what you will find is a preponderance of websites pushing a link that is not scientifically supported. The purpose of trying to push a link between breast cancer and abortion, as far as ideologues go, is clearly to frighten women about abortion. However, ABC is also being pushed to make physicians who perform abortion fearful of malpractice lawsuits by women who have abortions and later develop breast cancer, which, given how common breast cancer and abortion are, there are many by chance alone. The grounds for suing being advocated by ABC promoters is an alleged failure to inform women of the increased risk of breast cancer due to an abortion. In other words, if scaring women won’t work, then maybe threatening doctors with malpractice suits will.
Whatever you think of abortion, whether it’s murder, a necessary evil that’s not murder, a morally neutral surgical procedure, or a moral good (the last of which to me is going too far), I would hope that we could all manage to agree that attributing risks to the procedure that are not supported by strong science and epidemiology does not contribute anything to the debate other than confusion and fear. Of course, that’s exactly what such claims are meant to place in the minds of women of reproductive age: confusion and fear. They serve primarily as a means of frightening women with the specter of breast cancer if they consider the option of terminating a pregnancy. Indeed, dubious studies such as the Carroll study and putting dubious spins on studies that are not themselves dubious (like the study Stanek made such hay over) are a transparent attempt to abuse epidemiology to find a link between abortion and breast cancer that probably does not exist. They only serve to obfuscate the issue.
It’s one thing for anti-abortion activists to consider abortion to be evil and to lobby and demonstrate to have it outlawed. That is their religious belief, and the First Amendment guarantees that they can believe what they want and say nearly anything they want. However, it’s quite another to spread misinformation about an ABC link based on either horrifically bad science or on putting a deceptive spin on existing studies. If anti-abortion activists think that abortion is morally wrong because of their religion, then they should argue that. If they have any actual evidence that the procedure causes serious harm, they have every right to present that evidence. However, when they spin and distort science, behaving just like every other denialist, be it a creationist, a 9/11 Truther, an alt-med believer, or whatever, they should expect to be called on it.

   Alternative medicine use and breast cancer
David Gorski
Link
Of all the posts I and my cobloggers have written for SBM over the last 15 months, most provoke relatively few comments. However, a few stand out for having provoked hundreds of comments. The very first post that provoked hundreds of comments was Harriet’s excellent discussion of the International Network of Cholesterol Skeptics. In fact, Harriet seems to be quite good at writing posts that provoke a lot of comment, as another of her posts, specifically the one in which she discussed circumcision, also garnered hundreds of comments. However, to my great surprise, the one post that stands out as having received the most comments thus far in the history of SBM is one that I wrote. Specifically, it was a post I called Death by “alternative” medicine: Who’s to blame?, which has collected an astonishing 611 comments thus far. The topic of the post was a case report that I had heard while visiting the tumor board of an affiliate of my former cancer center describing a young woman who had rejected conventional therapy for an eminently treatable breast cancer and then returned two or three years later with a large, nasty tumor that was much more difficult to treat and possibly metastatic to the bone, which would make it no longer even potentially curable. My discussion centered on what the obligation of a physician is to such patients who utterly refuse the science- and evidence-based medicine that we know to be able to cure them of a potentially fatal disease, and I was not only surprised but somewhat taken aback by the vehemence of the discussion.
Since that post, I’ve always been meaning to take a look at what, exactly, the effect of choosing “alternative” medicine over “conventional” medicine is on the odds of survival for breast cancer patients. Even though intuitively one would hypothesize that refusing scientific medicine and relying on placebo medicine instead would have a detrimental effect on survival, it turns out that this question is not as easy to answer as you might think. For example, if you do a search on PubMed using terms like “alternative medicine,” “breast cancer,” and “survival,” the vast majority of the hits will be studies of complementary and alternative medicine (CAM) and breast cancer with little reference to what possible effect these therapies might have on survival. I can envision several reasons for this, the first being that–thankfully–relatively few women actually use alternative medicine exclusively to treat their breast cancer. Also, those that do probably drop off the radar screen of their science-based practitioners, and it is difficult, if not impossible, to capture data regarding their outcomes, given that they all too often stick with their alternative healers until the end. True, they may pop up again in their surgeon’s or primary care doctor’s office with huge, fungating tumors, only to be told that they have to undergo chemotherapy to shrink the tumor before any surgery is possible, after which they will often disappear again. Another important reason is that the natural history of breast cancer is extremely variable, from nasty, aggressive tumors that kill within months to indolent, slow-growing tumors that, even when metastatic, women can survive with for several years. (It is, of course, these women who usually show up in “alternative medicine” testimonials, because they can survive a long time with little or no treatment before their tumors progress.)
Because it’s important to understand the natural history of breast cancer, I’ll reference a classic study examining the natural history of untreated breast cancer. It was published in 1962 by H. J. G. Bloom, W. W. Richardson, and E. J. Harries, and examined data from Middlesex Hospital from 1805 to 1933 where 250 cases of untreated breast cancer were identified and studied. They calculated survival as the period of time from onset of symptoms to death. What they found was that 18% of the 250 patients survived five years; 3.6% survived 10 years; and 0.8% survived 15 years. Of note, it was 19 years before all patients were dead. Overall, the median survival was 2.7 years. A survival graph from this classic paper is below:
It should be noted that all of these tumors were detected as (at the very minimum) lumps in the breast, given that there was no other way of detecting them at the time. However, the reason we go back to this study time and time again is because, at least in developed countries, it is the rare woman with breast cancer who does not undergo treatment of some kind for it. These days, most tumors are detected at far less advanced stages; indeed, most are detected by mammography. What that means is that, if such a study could be done today, it is very likely that lead time bias would significantly increase the apparent median survival, because increasingly tiny tumors are being found. It is also possible that a significant number of such small tumors may spontaneously regress, which further complicates the issue today, not to mention making it easier to find women who have rejected some or all of “conventional” medicine to treat their cancers and survived significant lengths of time to produce alternative medicine testimonials.
With this background, I have found a couple of studies that can help answer the question. The first one was published in 2005 in the Annals of Surgery by a group in from Geneva University Hospitals. This study involved a search of Switzerland’s database between 1975 and 2000 and included 5,339 patients diagnosed with nonmetastatic breast cancer. The strength of this study is that the Geneva Cancer Registry includes data from all patients from the Geneva canton who underwent treatment and allowed the investigators to compare the outcomes of the women who refused to undergo surgery with curative intent with those who underwent surgery. In the Registry, there were identified 70 patients (1.3%) who refused surgery and concluded:
These women [those who refused surgery] were older, more frequently single, and had larger tumors. Overall, 37 (53%) women had no treatment, 25 (36%) hormone-therapy alone, and 8 (11%) other adjuvant treatments alone or in combination. Five-year specific breast cancer survival of women who refused surgery was lower than that of those who accepted (72%, 95% confidence interval, 60%–84% versus 87%, 95% confidence interval, 86%–88%, respectively). After accounting for other prognostic factors including tumor characteristics and stage, women who refused surgery had a 2.1-fold (95% confidence interval, 1.5–3.1) increased risk to die of breast cancer compared with operated women.
It is true that this is not a randomized study; rather, it is a retrospective study. Consequently, it’s impossible to rule out selection bias, but, as the authors point out, this is one case where doing a randomized study is completely unethical. Moreover, half the women accepted some form of other standard, effective treatm,ent, such as hormonal therapy alone. In any case, what this study shows is that women with no surgery can still live a long time, but are far more likely to die of their cancer than women who do undergo surgical extirpation.
As far as I can find, there is one study that specifically looked at the question of what happens to women who opt for alternative medicine instead of scientific medicine. This study, like the one I just cited, was published in the surgical literature, namely American Journal of Surgery. Given the nature of the question it was seeking to answer, its design is single-armed and retrospective, using prognosis estimated by Adjuvant! Online, an online tool into which clinicians can enter prognostic factors of a breast cancer at the time of presentation and come up with an estimate of chances of survival and recurrence with and without treatment. This, of course, is a weakness, but, again, randomizing patients to scientific medicine or alternative medicine would be completely unethical. In the case of such questions, we scientists have to make do with whatever methodology we can; i.e., do the best we can with what we have. Unfortunately, the study was also small, only 33 patients. Even so, given the huge difficulties involved in undertaking such a study, the investigators, who, as private practitioners operating a community practice in Eugene, OR, went above and beyond the call by trying to look at their data and answer this question. That their study has a number of shortcomings is not their fault; they appear to haved done the best they could with what they had, which includes patients who underwent a panoply of alternative therapies, including coral calcium, herbal therapy, mushrooms, high dose vitamins, whey, chelation therapy, hemlock, and coenzyme Q10.
So what were their findings?
They’re summed up in the following table:
The authors comment:
We found that the overwhelming majority of the patients who initially refused surgical treatment for breast cancer developed disease progression. Five of these patients ultimately underwent surgical resection. Of the other 6 patients, 5 had developed metastatic disease that precluded benefit from surgery. Furthermore, the disease progression caused by the delay in surgery was associated with an increase in the estimated 10-year mortality rate.
Patients who declined chemotherapy or hormone therapy faired slightly better. Optimism for this strategy should be severely tempered by the fact that the length of follow-up evaluation in these patients was relatively short, and these patients had early stage (I or II) disease. By software estimates, the 10-year mortality rate for these patients is still expected to be more than 50% higher than it would have been if the patients had taken their recommended therapy.
A number of patients who expressed their intention to pursue alternative therapies did not return for follow-up evaluation. Attempts were made to contact these patients. Those for whom follow-up evaluation was unavailable were excluded from this study. Although their omission may introduce a selection bias in the results, the effect of this bias is expected to be small because relatively few patients (14 of 47) were in this category.
I find two points important about this study. First, it confirms once again the importance of surgery as a therapeutic modality for breast cancer, especially early stage. Second, and more importantly, it strongly suggests that foregoing or delaying surgery or chemotherapy is at the very least associated with a significantly decreased chance of recurrence-free survival. The authors do note that it is impossible to tell whether this increase in mortality was solely due to delay or refusal of effective therapy or whether the modalities chosen were deleterious. My guess is that it was almost certainly due to the ineffectiveness of the alternative therapies chosen.
More evidence of the uselessness of “alternative” medicine in breast cancer was published two years ago by Edzard Ernst, author of Healing, Hype or Harm? A Critical Analysis of Complementary or Alternative Medicine, which Harriet reviewed about a month ago. In 2006, he wrote a review for the Breast Journal along with Katja Schmidt, MSc, C Psychol, and Michael Baum, MD, ChM, a review entitled Complementary/Alternative Therapies for the Treatment of Breast Cancer. A Systematic Review of Randomized Clinical Trials and a Critique of Current Terminology. The objective of the study was to examine all studies randomized clinical trials (RCTs) for “alternative cancer cures” (ACCs). Treatments examined included various methods of psychosocial support such as group support therapy, cognitive behavioral therapy cognitive existential group therapy, a combination of muscle relaxation training and guided imagery, the Chinese herbal remedy Shi Quan Da Bu Tang, thymus extract, transfer factor, melatonin, and factor AF2.
The first finding was that the methodological quality of the studies was, by and large, pretty low. The most common deficiencies included: lack of power sample calculation; small sample size; lack of adequate randomization and/or (patient and assessor or only assessor) blinding; and insufficient follow-up periods. It was noted that only one trial applied an intention to treat analysis. From the 15 studies Ernst examined, this is what was concluded:
The totality of the data fails to show a single intervention that would be demonstrably effective as an ACC. The paucity and the often-low methodological quality of the RCTs are as unexpected to us as they are disappointing. Most trails had small sample sizes; thus a type II error is conceivable. But even if this were true, one would be correct in stating that to date, no effective ACC has been identified.
A lot of this is, of course, true based on discussions of prior plausibility alone. One could argue that, given the poor quality of the studies examined by Ernst, there might be an effect that was missed. However, if an effect were missed, it would have to be small or, at most, moderate. That is not what is claimed for many of these ACCs. What is often claimed is a near-miraculous “cure” for cancer, which, if it were true, would be relatively easy to detect. As I’ve often argued about, for example, the Gonzalez regimen for pancreatic cancer, if such ACCs really were cures, it would actually be fairly easy to show. In the case of pancreatic cancer, for instance, just producing well documented case reports of a few five year survivors among patients with documented metastatic adenocarcinoma of the pancreas would, I daresay, make even Wally Sampson and Kimball Atwood sit up and take notice. Somehow, we never see this. Of course, what makes the question in breast cancer more difficult to answer is its highly variable natural history. In contrast, the vast majority of patients with pancreatic cancer die within the first year (more than half die within six months); fewer still live beyond two years; and very close to none live beyond three years. In contrast, lots of women with metastatic breast cancer live longer than two or three years; a few.
Finally, about five years ago, there was a study out of Norway that looked at the effect of alternative medicine on cancer survival. This study did not limit itself to breast cancer, but it is interesting and useful nonetheless. The hypothesis of the study was that the use of alternative medicine does not have any effect on the survival of cancer patients, and to test the hypothesis investigators studied data from surveys done by the Norwegian Board of Health, which asked patients standard demographic information, but then asked them about their use of alternative medicine as follows:
In the questionnaire presented to the patients, AM was defined as any treatment outside of mainstream therapy that had been used to treat their cancer. A multiple-choice list consisting of the best known and frequently used non-proven methods in Norway was presented. Patients also had the opportunity to add other types of alternative therapy in response to an open question.
The following alternative methods were described in the multiple choice questionnaire: Use of biological treatments, herbs, faith healing or healing by hand, homeopathy, reflexology (zone therapy), megadoses of vitamins, diet treatments, injection therapies such as iscador (a mistletoe preparation) and a Norwegian injection therapy called “Nitter therapy”. Nitter therapy consists of vitamin B12, gammaglobulins, tranexamic acid, multivitamins and nutritional supplements.
Modalities such as relaxation, psychotherapy, participation in a self-help group or changes in lifestyle activities that were used to reduce distress and to improve the patient’s subjective well being were not coded as AM.
I actually very much approve of the fact that the investigators did not define relaxation, psychotherapy, lifestyle changes, etc., as “alternative.”
A total of 515 patients were analyzed, and results were as follows:
In January 2001, survival data were obtained with a follow-up of 8 years for 515 cancer patients. A total of 112 (22%) assessable patients used AM. During the follow-up period, 350 patients died. Death rates were higher in AM users (79%) than in those who did not use AM (65%). In a Cox regression model adjusted for demographic, disease and treatment factors, the hazard ratio of death for any use of AM compared with no use was 1.30, (95% Confidence Interval (CI) 0.99, 1.70; P=0.056), suggesting that AM use may predict a shorter survival. Sensitivity analyses strengthened the negative association between AM use and survival. AM use had the most detrimental effect in patients with an ECOG (Eastern Cooperative Oncology Group) performance status (PS) of 0 (hazard ratio for USE=2.32, 95% CI, 1.44, 3.74, P=0.001), when compared with an ECOG PS of 1 or higher. The use of AM seems to predict a shorter survival from cancer. The effect appears predominantly in patients with a good PS.
In other words, not surprisingly, use of alternative medicine is correlated with poorer surival in the patients with a good performance status and thus who are likely to have a more favorable prognosis. Patients with a poor performance status are more likely to undergo less aggressive therapy because they are less able to tolerate, for example, radical surgery or heavy-duty chemotherapy regimens.
The authors speculated about a number of reasons why use of alternative medicine might be associated with poorer survival. Obviously, it may not be causative. (Remember again that correlation does not necessarily equal causation. One possible explanation is that users of alternative medicine are less likely to undergo optimal medical therapy. One interesting possibility is that users of alternative medicine were more likely to be having severe symptoms, which led them to turn to “alternative medicine” to try to relieve their symptoms. In any case, this study had a number of problems, including a high attrition rate that could have resulted in significant selection bias.
Putting it all together, I conclude that there is no compelling evidence for a significant survival benefit due to any “alternative” therapy, nor is there good evidence for significant treatment effects. The studies that do purport to show an effect are virtually all plagued with methodological difficulties and tend to show effects that are barely above background noise. Even the much touted psychosocial support of late has failed to demonstrate any improvement in the survival of cancer patients. Moreover, although there is a relative paucity of studies, and they, too, are generally retrospective and difficult to interpret, what evidence is out there is that alternative medicine use among cancer patients is associated with an increased risk of dying from cancer, particularly when conventional therapy is eschewed. Taken together, these data make it very hard not to conclude that at best the vast majority of alternative therapies are either useless, no more than placebos, or might even be harmful. That is why they have no role in science-based medicine at present.
As Edzard Ernst put it:
The idea of an “alternative cancer cure” assumes that conventional oncology would not adopt a cancer treatment simply because it originates from an area outside of mainstream medicine. We feel that, should such a cure one day emerge, it would be investigated without delay by oncologists and adopted into routine care as soon as the data supporting it are convincing. Plant-based cancer medications such as Vincristin and Vinblastin (both extracted from the plant Vinca rosea) or Taxol (Taxus baccata) could be employed to back up this theory. It follows that the term ACC is and most likely will always be a contradiction in terms.
Or, as I frequently put it: There is no such thing as “alternative” medicine. There is medicine that is effective, medicine that is not, and medicine that has not been tested yet. Nearly all of so-called “alternative” medicine falls into one of the latter two categories, and those that have not been tested yet nearly all fall into the category of being so wildly improbable that testing them without more positive evidence makes no sense. In any case, as a cancer surgeon, I don’t care where a therapy came from. I really don’t. If someone could show me that reiki or homeopathy cures cancer, I’d use either. In the meantime, I will continue to argue that the very concept of “alternative” medicine is a potentially deadly false dichotomy for cancer patients.
REFERENCES:
H. J. G. Bloom,, W. W. Richardson, & E. J. Harries (1962). Natural History of Untreated Breast Cancer (1805-1933) British Medical Journal, 2, 213-221 DOI: PMC1925646
Chang, E., Glissmeyer, M., Tonnes, S., Hudson, T., & Johnson, N. (2006). Outcomes of breast cancer in patients who use alternative therapies as primary treatment The American Journal of Surgery, 192 (4), 471-473 DOI: 10.1016/j.amjsurg.2006.05.013
T Risberg, A Vickers, R.M Bremnes, E.A Wist, S Kaasa, & B.R Cassileth (2003). Does use of alternative medicine predict survival from cancer? European Journal of Cancer, 39 (3), 372-377
Verkooijen, H., Fioretta, G., Rapiti, E., Bonnefoi, H., Vlastos, G., Kurtz, J., Schaefer, P., Sappino, A., Schubert, H., & Bouchardy, C. (2005). Patients’ Refusal of Surgery Strongly Impairs Breast Cancer Survival Annals of Surgery, 242 (2), 276-280 DOI: 10.1097/01.sla.0000171305.31703.84

Alternative medicine use and breast cancer (2012 update)
David Gorski on September 3, 2012
Link
[Editor’s note: It’s a holiday here in the U.S.; consequently, here is a “rerun” from my other super not-so-secret other blog. It’s not a complete rerun. I’ve tweaked it a bit. If you don’t read my other blog, it’s new to you. If you do, it’s partially new to you. See you all next week with brand spankin’ new material. It also (I hope) complement’s Scott’s excellent post from Thursday discussing the same issue and the same paper, but from a different perspective.]
As a cancer surgeon specializing in breast cancer, I have a particularly intense dislike reserved for cancer quacks, which I have a hard time containing at times when I see instances of such quackery applied to women with breast cancer. I make no apologies. These women are, after all, the type of patients I spend all my clinical time taking care of and to whose disease my research has been directed for the last 13 years or so. That’s why I keep revisiting the topic time and time again. Unfortunately, over the years, when it comes to this topic there’s been a depressing amount of blogging material. Indeed, Scott Gavura took a bite out of this particularly rotten apple just a few days ago. Even though he handled the discussion quite well, I thought it would be worthwhile for a breast cancer clinician to take a look. Our perspectives are, after all, different, and this is an issue that, from my perpective, almost can’t be discussed too often.
One question that comes up again and again is, “What’s the harm?” Basically, this question boils down to asking what, specifically, is the downside of choosing quackery over science-based medicine. In the case of breast cancer, the answer is: plenty. The price of foregoing effective therapy can be death; that almost goes without saying. In fact, it can be a horrific and painful death. It is, after all, cancer that we’re talking about. Aside from that, however, the question frequently comes up just how much a woman decreases her odds of survival by avoiding conventional therapy and choosing quackery. It’s actually a pretty hard question to answer. The reason is simple. It’s a very difficult topic to study because we as physicians have ethics. We can’t do a randomized trial assigning women to treatment or no treatment, treatment or quacke treatment, and then see which group lives longer and by how much. If a person can’t see how unethical that would be without my having to explain it, that person is probably beyond explanations. (As an aside, I can’t help but point out that a randomized trial of not vaccinating versus vaccinating is unethical for exactly the same reason; physicians can’t knowingly assign subjects to a group where he knows they will suffer harm. There has to be clinical equipoise.) There’s no doubt that foregoing effective treatment causes great harm.
So when it comes to figuring out just how much harm a woman risks by choosing quackery, all we’re left with, and rightfully so from an ethical standpoint, are lower quality studies, usually retrospective, and, fortunately, not very many of them. The reason is that they’re very hard to do, again because they’re retrospective and generally it’s hard to locate a sufficient number of women who turn down all surgery. The last time I discussed such a study was three years ago. It was a small study of only thirty three patients, but it found significantly decreased survival among the patients examined who eschewed conventional therapy in favor of “alternative” medicine. For example, five out of six patients who refused surgery progressed to stage IV metastatic disease, with a median time to being diagnosed with metastases of 14 months. Another study examining 5,339 women who refused surgery alone, but not necessarily other treatments, found that patients who refused surgery had a significantly decreased survival and a two-fold higher chance of dying of their disease.
Just this month, another such study was published in the World Journal of Surgical Oncology. It’s a study out of Alberta, specifically the University of Alberta and the Cross Cancer Institute and is entitled simply Outcome analysis of breast cancer patients who declined evidence-based treatment. Its design was relatively simple; it was a retrospective chart review of breast cancer patients who refused recommended treatments from 1980 to 2006. Patients who had “refused standard therapy” were defined thusly:
Any patient who has completely refused the recommended standard primary treatment plan following biopsy confirmation of breast cancer is considered as refusal of standard treatment. Primary treatment could be surgery, neoadjuvant radiotherapy or chemotherapy. Patients who refused adjuvant treatments following surgery were not included in this analysis.
That makes this study one of the uncommon studies that really tries to look at what happens when women refuse all standard therapy for breast cancer. Regular readers will remember that I’ve written about the “breast cancer alternative cure testimonial” for a long time; indeed, one of my very first posts for this blog was on just that topic. What’s important to remember about these testimonials is that, in almost all cases, the woman will have undergone some sort of potentially curative surgery, usually a lumpectomy or an excisional biopsy large enough to qualify as a lumpectomy, and then have refused further therapy; i.e., adjuvant chemotherapy, antiestrogen therapy (such as Tamoxifen), and/or radiation therapy. Adjuvant therapy is just that; it’s an adjuvant to the main treatment, which is surgery. As I’ve pointed out so many times, surgery is the main curative therapy for breast cancer for stage I and II breast cancer; the adjuvant chemotherapy and radiation therapy are just “icing on the cake,” so to speak. Radiation therapy decreases the chance that the cancer will recur in the local area in the breast where it was cut out, while chemotherapy and hormonal therapy decrease the chance that it will recur elsewhere in the body and kill the patient. (That’s a simplistic description, because there is good evidence that radiation therapy also contributes to a survival benefit, but it is, roughly speaking, a good way to articulate the benefits of adjuvant chemotherapy and radiation therapy.) In stage III breast cancer, surgery, radiation, and chemotherapy are usually all required to effect a cure, but surgery can in some cases still cure such a woman; the odds are considerably lower. It’s also important to remember that, before there was chemotherapy and radiation, surgery was the only modality that could cure breast cancer. William Halsted himself (the surgeon who developed the radical mastectomy) cured some women 120 years ago with nothing more than radical surgery.
What you will find in most breast cancer testimonials for alt-med “cures” is a woman refusing chemotherapy, hormonal therapy, and/or radiation therapy and then crediting her survival to whatever quackery she decided to try instead, when in reality it was the surgery that cured her. (Peter Moran also noted this and explained it well.) All she accomplishes by refusing additional therapy is to increase the odds that her tumor will return, but, given that in early stage cancer surgery alone has a pretty high cure rate, the woman’s odds were pretty good before receiving any chemotherapy. So right away, that makes this study important. At 185 patients, it’s one of the larger series looking at the outcomes of patients who refuse all conventional therapy. The authors used a matched analysis to pick a control group by picking matched patients who underwent conventional therapy who matched the following characteristics of the patients refusing therapy: age (± 3 years), calendar year and clinical stage at diagnosis. This control group consisted of five controls for every patient refusing therapy.
The authors then excluded patients over 75 because that has been the cutoff for clinical studies and active treatment protocols with chemotherapy in the past. This is actually one of the weaknesses of the study. Although it wasn’t all that long ago that we didn’t consider chemotherapy for women over 70, such is no longer the case. These days 75 years old no longer represents a cutoff above which chemotherapy won’t be administered. Even 80 years old is not a hard cutoff. I’ve seen our tumor board recommend chemotherapy on occasion for patients on occasion who were well into their 80s. If a patient is reasonably healthy and has a good performance status, oncologists are now increasingly willing to administer chemotherapy to much older people. However, this is a relatively recent development, and surgery has never traditionally been withheld from these elderly patients unless they are in really poor health with a life expectancy that is less than a couple of years. It’s also had not to note that the pendulum appears to be swinging back the other way, just not for older women but for all women. In other words, with the development of tests like the OncoType DX, we are getting better at figuring out who will and won’t benefit from chemotherapy at all ages. Still, given that the time period encompassed by this study is large, it was probably reasonable to make this exclusion, because in the earlier parts of the study it was probably rare for a woman over 75 to receive chemotherapy.
Be that as it may, that exclusion criteria left 87 patients under 75 who initially refused all therapy. The majority of patients who refused therapy were married (51%), older than 50 (61%), and urban residents (66%). As far as diagnostic criteria went, 57 patients had biopsy confirmation of their tumor only, while 30 ultimately underwent delayed surgery. 50 patients decided to undergo alternative medicine treatment, while the reasons the other 37 refused therapy were unclear or not described. The characteristics of the patients arelisted below:
It should be noted that the average delay of surgery in the patients who ultimately underwent surgery was between 20 and 30 weeks, while the delay among women who presented with stage I disease (or stage 0 disease, otherwise known as ductal carcinoma in situ) ranged from 41 to 101 weeks, with a median delay of 62 weeks. All the stage II and III patients returned to the cancer center with Stage IV disease, while the stage I patients returned with stage II, III, or IV disease. To put it more bluntly, nearly every patient who initially refused treatment progressed to a higher stage. In only four patients did the cancer fail to progress, and in none of them did the tumor shrink and downstage. It’s even uglier when we look at survival. The following graph compares disease-specific survival between patients who refused therapy and those who did not:
The difference in survival between those who underwent standard therapy shortly after thye were diagnosed with breast cancer and those who refused. The results are summarized thusly:
The 5-year overall survival was 43.2% (95% CI: 32.0 to 54.4%) for those who refused standard treatments and 81.9% (95% CI: 76.9 to 86.9%) for those who received them. The corresponding values for the disease-specific survival were 46.2% (95% CI: 34.9 to 57.6%) vs. 84.7% (95% CI: 80.0 to 89.4%).
Differences this huge are seldom seen in survival curves. Going back a ways to an older discussion of mine, in which as part of the discussion I discussed a classic paper by Bloom and Richardson that looked at the natural history of untreated breast cancer from the late 1800s to the early 1900s. The graph looks like this:
A proponent of so-called “complementary and alternative medicine” (CAM) might look at this curve and ask why the five-year survival for untreated breast cancer was around 18% while in the current study it was 43%? Aha! they might say, CAM does something! Well, not really. First, remember that 30 of the patients in the current series did ultimately undergo surgical therapy, just delayed by many weeks to several months. More importantly, remember that 100 years ago there was no mammography or ultrasound. Each and every cancer diagnosed was diagnosed when the woman had symptoms, the vast majority of a time a lump in the breast. Nearly all women were stage II or III when diagnosed. In fact, we have no idea of how many of those women already had metastatic disease at the time they were diagnosed. After all, there were no CT scanners, bone scans, or, in the early part of the time period covered by the Bloom and Richardson study, even chest X-rays. In marked contrast, far more patients from 1980 to 2006 were diagnosed by mammography, which led to a larger number of stage I cancers and especially noninvasive cancers (i.e., DCIS), which take longer to kill because they are earlier in their progression.
In brief, we’re comparing two different time periods, and we have no idea what the distribution of tumor characteristics were in the Bloom & Richardson paper compared to the characteristics of the patients in the current series. In other words, it’s just not possible to compare the two series, and, even in the absence of treatment (which includes the use of CAM, in my book), you can’t compare the series. Either way, by today’s standards, a five year median survival of 43% for all comers in breast cancer is pathetic. It probably is close to the expected five year survival in essentially untreated cases of early stage breast cancer over the last 20 years. Fortunately, we have no way of knowing for sure, as doing so would involve observing untreated women and measuring their median survival.
But wait! Let’s look at one more graph. This is a comparison of five year, disease-specific survival between women who chose to undergo CAM therapies instead of effective therapy and women whose reason for refusing therapy is unknown:
The authors write:
Since 58% of patients received different kinds of CAM, a comparison of the outcome was performed between groups who received CAM and those whose treatment details were not known. Figure 2 compares the survival patterns of women who refused treatment who either received CAM or for whom the reason for refusal was unknown. The 5-year overall survival was 57.4% (95% CI: 42.7 to 72.1%) for women who received CAM and 26.3% (95% CI: 11.3 to 41.3%) for those whose treatment details were unknown. The global survival for the CAM group was better than for women whose reason for refusal was unknown (p ≤ 0.05), and disease-specific survival for the CAM was better for women whose reason for refusal was unknown, but this was not statistically significant (31.5%; 95% CI: 15.1 to 48.0%).
I could see CAM supporters grasping at this graph to argue that CAM has an effect on survival. That would be grasping indeed. First, the difference in breast cancer-specific survival is not statistically significant, although the difference in overall survival is. Second, we have no idea what the distribution of stages and other relevant tumor characteristics is. Are they well matched? Probably not, but we have no idea. We also need to remember that the “unknown” group is just that, unknown. We don’t know why these patients refused therapy, and we don’t know whether or not some of them underwent some form or other of CAM treatment. In other words, more than likely the two groups were not matched for some characteristic or other. Did some of the patients who refused all therapy do so because they were at a more advanced stage and, instead of trying alternative therapy, had decided to give up? We don’t know. Were the patients who refused all therapy older? Were they sicker and therefore more afraid of undergoing therapy? We don’t know.
No matter how anyone tries to spin it, this study adds to the slowly growing body of evidence that, taken as a whole, conclusively demonstrates that (1) “conventional” science-based care works for breast cancer and (2) eschewing “conventional” science-based care has the potential to have disastrous consequences. I always tell patients after they’re first diagnosed that if there’s one “good” thing about breast cancer it’s that it’s not an emergency. There is time to think about therapeutic options and decide upon a treatment plan. The tumor has, after all, been there many months to many years, and, from a strictly biological standpoint, a delay of a month or two in treatment almost never makes much of a difference in outcomes. However, longer delays are dangerous, with the danger increasing along with the length of the delay. Choosing CAM or, let’s call it what most of it is, quackery, serves no purpose but to delay effective treatment, increase the likelihood that the cancer will progress to become incurable, and decrease the likelihood of cure. That progression can be horrible, too. Just go back and look at the case of Michaela Jakubczyk-Eckert. Do not click on the link, however, if you have a weak stomach.
At best, choosing CAM over effective therapy can preclude less invasive therapy and necessitate more radical treatments after the tumor has progressed, forcing a mastectomy when lumpectomy would have done if the tumor had been treated in a reasonable amount of time. At the worst, it can allow sufficient time for the tumor to metastasize and progress to stage IV. Choosing CAM over effective medicine not only increases the chance of dying from breast cancer, but it increases the chance of dying horribly from cancer. Suffering from carcinoma en cuirasse is a horrible, horrible way to die, and certainly refusing surgery increases the risk of carcinoma en cuirasse just as much as refusing chemotherapy increases the risk of dying of metastatic disease. This study is just another piece of evidence that reminds us of this.

Aromatase inhibitors and acupuncture in breast cancer: Spinning a negative study, four years later
Four years ago, I wrote about an essentially negative study looking at whether acupuncture could alleviate joint pain caused by aromatase inhibitors, a common treatment for estrogen-sensitive breast cancer. The study’s back, and it doesn’t look any more positive.
David Gorski on November 14, 2022
Link

Before the pandemic, acupuncture was a frequent topic on this blog because it was a perfect example of what we at SBM mean when we distinguish between evidence-based medicine (EBM) and science-based medicine (SBM). In evidence-based medicine, randomized controlled clinical trials (RCTs) and meta-analyses of RCTs are at the very top of the pyramid of evidence. In general, this is a reasonable pyramid of evidence with a caveat: The treatments being tested need to have biological plausibility as well as preclinical (cell culture and animal studies) and early clinical evidence, such as small preliminary clinical trials, to justify RCTs. Where this concept breaks down is for what is now known as “integrative medicine“, having been rebranded from its previous name, “complementary and alternative medicine” (CAM). The reason is that the treatments being “integrated” into “integrative medicine” by and large tend to be treatments that have very low biological plausibility and/or are based on prescientific mysticism and belief, such as homeopathy, reiki and other forms of “energy medicine“, and, yes, acupuncture, particularly for conditions for which the primary endpoints are subjective and therefore very prone to placebo effects, such as, of course, pain. For such conditions, the clinical trial results are nearly always equivocal, even when positive, and tend to reflect more the noise and bias inherent in even well-designed RCTs than any actual positive results. As I like to ask about, for example, homeopathy, what is more likely, that a remedy diluted to nonexistence—in other words, water—has clinically relevant therapeutic effects or that a noise- and bias-laden clinical trial came up with a false positive result? You can ask the same thing about reiki and “energy healing”.
This is why, before the pandemic, we at SBM used to argue routinely for a more Bayesian approach that takes into account prior plausibility and probability in analyzing clinical trial results. Basically, prior plausibility informs how likely a “positive” result of a clinical trial is likely to be truly positive, the lower the prior plausibility the lower the required p-value. That is, of course a simplistic discussion, but it is in essence what we argue—and have argued since the very beginning of this blog.
Implausible treatments…like acupuncture
Unsurprisingly, acupuncture advocates like to try to argue that acupuncture is different, that it’s not like the faith healing of reiki or the sympathetic magic of homeopathy because it’s a physical intervention. The acupuncturist is sticking needles into the patient, after all! Unfortunately, though, all the concepts behind acupuncture are based on prescientific Asian mysticism, particularly the meridians through which qi (or life energy) flows and that the acupuncture needles supposedly impact. Moreover, modern acupuncture is nothing like ancient acupuncture, having been reinvented with the development of thin, filiform needles in the 1930s and then its entire history was retconned by Chairman Mao in the 1950s, along with the rest of traditional Chinese medicine. In brief, the narrative became that this “ancient treatment” demonstrates a near-miraculous efficacy for, well, just about everything. Never mind that the filiform needles associated with modern acupuncture didn’t exist until around 1930, when a Chinese pediatrician named Cheng Dan’an proposed that needling therapy be resurrected because its actions could be explained through neurology and replaced the previously-used coarse lancet-like needles with the fine needles in use today. Of late, during the pandemic, I have pointed out how the lessons of acupuncture trials should have been applied to hydroxychloroquine and ivermectin, repurposed drugs touted as highly effective treatments for COVID-19 based on in vitro activity against SARS-CoV-2, the virus that causes COVID-19, in cell culture. The problem was that the concentrations required were many times higher than what could be safely achieved in human blood, which presented a serious plausibility problem on the basis of pharmacodynamics and pharmacokinetics alone. That’s why I was not surprised when RCTs ultimately demonstrated that neither drug works against COVID-19, leading me to call ivermectin the “acupuncture of COVID-19 treatments“, because it was always a highly implausible treatment that nonetheless was subjected to way more RCTs than its preclinical evidence justified.
All of this brings us to an acupuncture study published in JAMA that I discussed four years ago that tested whether acupuncture could alleviate joint pain caused by a class of estrogen-blocking drugs known as aromatase inhibitors. I called it “spinning another essentially negative study“, particularly based on interviews with one of the main authors in which it was spun that way. Over the weekend, a reader sent me a link to another acupuncture study, published on Friday, this time in JAMA Open Network and titled “Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor–Related Joint Pain“. I immediately thought: This looks very, very familiar. So I did a search for acupuncture and aromatase inhibitors on SBM, and I found my post from 2018. Looking at the author list, I saw the same names. Looking at the ClinicalTrials.gov number, I saw that it was the same, NCT01535066. It was the same study! So what was the difference? Basically, this was a long-term follow-up that claimed that acupuncture could result in long-term relief of the joint pain symptoms commonly associated with aromatase inhibitors like anastrozole.
Aromatase inhibitors and arthralgias
Before I move on to discuss the study design, first let me discuss the problem for which acupuncture was being studied. Given that over two-thirds of breast cancers have the estrogen receptor, that means that they are estrogen-responsive and blocking estrogen can inhibit breast cancer growth. Consequently, there are a lot of patients undergoing treatment with estrogen-blocking drugs. Unfortunately, these drugs can often have a serious deleterious effect on a woman’s quality of life, causing menopausal symptoms in premenopausal women and worsening menopausal symptoms in post-menopausal women. These symptoms, particularly hot flashes, are very hard to treat with anything other than estrogen. Indeed, I still remember the first patient I ever operated on as a new attending and how she simply could not tolerate her Tamoxifen, no matter how much her oncologist tried to work with her to make it possible for her to take it. The seriousness of the effects of these drugs on patient quality of life should not be underestimated.
One significant potential complication associated with aromatase inhibitors (almost always the first choice of antiestrogen drug for postmenopausal women) is osteoporosis. However, the most vexing side effect for most women on these drugs is severe musculoskeletal pain, specifically arthralgia (joint pain). The mechanism causing this joint pain is poorly understood, but the side effect can be debilitating enough that the only choice is to stop the medication and try another class of drugs. As a result, it would be highly useful to be able to alleviate the joint pain that aromatase inhibitors can cause, given that aromatase inhibitors are associated with a large decrease in the risk of recurrence after successful initial treatment of breast cancer. So one can understand why acupuncture advocates would want to test acupuncture on women undergoing aromatase inhibitor therapy.
As I like to put it, we have a medical problem whose solution we haven’t been able to identify yet; so let’s try magic. Why not?
The study
As I perused the list of authors, now as in 2018, one name jumped out right away: Heather Greenlee. You might recall that she is a naturopath at the Fred Hutchinson Cancer Center at the University of Washington in Seattle. We’ve met her before, for example, when the guidelines for the “integrative oncology” care of breast cancer patients published by the Society for Integrative Oncology (SIO) were endorsed by the American Society of Clinical Oncology (ASCO). Also, now as in 2018, I was also disappointed to see that the University of Michigan, my medical alma mater, was one of the sites at which this study was carried out. Of course, U. of M. has gone all-in with “integrative medicine”, even to the point of embracing anthroposophic medicine, acupuncture, homeopathy, and naturopathy, with its family medicine department including a naturopath. So I guess that I shouldn’t have been surprised.
The study involved eleven academic medical centers and clinical sites, which recruited: Women with early stage ER(+) breast cancer who scored at least 3 on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain) and who were either (1) postmenopausal and taking an aromatase inhibitor or (2) pre- or perimenopausal whose ovarian function had been suppressed with a gonadotropin-releasing hormone agonist and were taking an aromatase inhibitor. Exclusion criteria included prior acupuncture treatment for joint symptoms at any time; history of bone fracture or surgery of the affected joints within 6 months prior to enrollment; severe bleeding disorder; or a latex allergy. Also, study participants must not have received opioid analgesics, topical analgesics, oral corticosteroids, intramuscular corticosteroids, or intra-articular steroids, or any other medical therapy, alternative therapy, or physical therapy for the treatment of joint pain or joint stiffness within 28 days prior to registration. The trial ran from March 2012 to February 2017 (final date of follow-up, September 5, 2017).
Patients were randomized in a 2:1:1 ratio to receive either true acupuncture, sham acupuncture, or to be on a wait list. As for the acupuncture used:
Study participants were randomized 2:1:1 to TA vs SA vs WC, with randomization dynamically balanced by study site. Both TA and SA consisted of twelve 30- to 45-minute sessions administered during 6 weeks (2 sessions per week) followed by 1 session per week for 6 more weeks. For TA, stainless steel, single-use, sterile, and disposable needles were used and inserted at traditional depths and angles. The SA protocol consisted of a core standardized prescription of minimally invasive, shallow needle insertion using thin and short needles at nonacupuncture points. The SA protocol also included joint-specific treatments and an auricular sham based on the application of adhesives to nonacupuncture points on the ear. The WC group received no acupuncture during the initial 24 weeks of study participation. At 24 weeks, all patients received vouchers for 10 TA sessions to be used before the 52-week visit.
The outcomes were:
The original protocol-specified primary end point was the BPI-WP score at 6 weeks. The short-form version of the BPI was administered at 6, 12, 16, 20, 24, and 52 weeks. For this long-term analysis, the primary end point was the 52-week assessment of BPI-WP (which was not previously reported), examined using multivariable linear regression. Secondary end points for this long-term evaluation included the BPI average pain, pain interference, pain severity, and worst stiffness scores at 52 weeks. All BPI scores range from no symptoms to worst on a 0- to 10-point scale (with higher scores indicating worse symptoms). In addition, we evaluated pain using the PROMIS Pain Interference–Short Form (PROMIS PI-SF), which has scores ranging from 6 to 30. This instrument was also administered at 6, 12, 24, and 52 weeks and has 5 response levels (low scores [not at all] to high scores [very much]), with higher scores reflecting worse symptoms.
We examined 2 functional measures: grip strength and Timed Get Up and Go test. Grip strength was measured with a digital hand grip strength dynamometer (DHS 88, Detecto) in kilograms. Patients were asked to make 3 maximal voluntary contractions with 1 minute between each. The maximum contraction was used. The Timed Get Up and Go test is a physical function assessment tool of speed that is an estimate of impairments in balance and gait.
It’s useful now to discuss the specific acupuncture interventions and controls. First, there’s nothing wrong with including a waitlist control; it’s a perfectly valid way to assess for placebo effects, but what about the sham intervention chosen? The first thing I noticed the first time around was that there was no blinding of the acupuncturists to intervention. Of course, not blinding the waitlist control is fine. That’s why there is a waitlist control in the first place, to estimate the magnitude of placebo effects. The important control is the sham acupuncture. At the time of the publication of the first study, the authors tried to justify not blinding the acupuncturists to the experimental group:
Still, Hershman knows critics will take issue with the sham treatments, which weren’t double-blinded. Practitioners knew they were giving fake treatments and may have sent subconscious signals to their patients.
Using retractable needles designed to blind practitioners to the sham wouldn’t have helped, Hershman said, because studies suggest that both patients and acupuncturists can tell the difference.
“We looked at a whole slew of studies…of different sham modalities,” Hershman said. “They all had advantages and disadvantages. We felt in looking at the collective literature out there that this was probably the best approach.”
As I said at the time, I did take issue with the sham treatments. It was simply not true that sham needles don’t work. I’ve lost track of the number of studies I’ve read where sham retractable needles were used and double-blinding was fine. My guess at the time was that the acupuncturists recruited to participate in the study didn’t want to use them, and I see nothing to reassess that guess. So right away, we knew all the crowing about the “rigorous design” of this trial is still a load of fetid dingos’ kidneys, especially given that, according to the 2018 study, subjects in the true acupuncture group were more likely to believe that they were receiving true acupuncture (68%) than those in the sham group (36%). I’ll still grant that the rest of the study was pretty well-designed, particularly given that a waitlist control was included, but the inadequate blinding, along with other factors, was enough then to explain the results of the study, and remains so.
To help explain why, I will reproduce the graph comparing adjusted mean group difference in Brief Pain Inventory Worst Pain Scores in true acupuncture (TA) versus sham acupuncture (SA) and TA vs waiting list control (WC) at 6, 12, 16, 20, 24, and 52 weeks:

So what do you think? Can you see what this result shows? Notice how, short term, there is a highly statistically significant difference in the pain score between the TA group and both the SA and WC control groups. There are two explanations for such a result. Either the study was unblinded, or there was an actual difference between TA and SA. As I argued above, I think the lack of blinding explains the result quite well. I also note that the authors had stated that they had hoped to see a difference of 2.0 or greater in the pain score, which further reinforced my conclusion that this result was due to the lack of blinding. Now look at the graph. None of the differences reported are greater than 2.0, and the only one that approaches 2.0 is the difference in pain scores at 12 weeks between TA and WC.
Notice also, how for the timepoints at 16, 20, and 24 weeks the differences between TA and SA were not statistically significant and were at most a half a point. As a commenter said after the last post:
After the fact, Dr. Hershman asserts (without citations) that differences in pain scores as low as 0.7 points are clinically significant. You must be f***ing kidding me. Okay, maybe on a scale of 0-2. The references I’ve seen say 1.5 – 2 points on a 0-10 scale, and this makes sense. Keep in mind, this is the MINIMUM clinically significant difference. That is, patients are willing to say that their pain was lessened a little bit. That’s different from “this treatment provided me with adequate pain relief.”
Exactly. The same applies now in the new study.
Admittedly, the final data point at 52 weeks shows both TA versus SA and TA versus WC having roughly 1.0 point difference that is statistically significant. Given the timeframe after the intervention (twelve 30- to 45-minute sessions of TA or SA administered during 6 weeks (2 sessions per week) followed by 1 session per week for 6 more weeks) and the fact that the WC group, although it received no TA or SA treatment during the first 24 weeks, did receive vouchers for acupuncture treatments afterward, which can muddy the analysis. Also, again, a mere one-point difference in pain scores has at best questionable clinical significance.
Now here’s the most important issue that I have with the study, having thought about it some more. What is the reason that we want to alleviate the symptoms that can be caused by aromatase inhibitors? True, we don’t want women to suffer unnecessarily, but we also want them to stick with the treatment for at least five years, something they are less likely to do if they are having severe joint pain. That brought up a question that I should have hammered home in my first post about this study: Why wasn’t one of the primary endpoints the discontinuation rate of aromatase inhibitor (AI)? Usually, patients who can’t tolerate AI therapy for their breast cancer will be forced to discontinue the drug within the first several months. In this study, what did the authors report? They reported that the “overall AI discontinuation rate within the 52 weeks of follow-up was 12.1% and did not differ by intervention group.” In other words, TA made zero difference in the only outcome that really matters for purposes of treating the patients’ breast cancer, their continuation of their AI therapy.
The authors then looked at pain medication use among patients who reported taking no pain medication at the start of the study:
To examine incident use of pain medications during the study, we also evaluated patterns among patients who did not report pain medication use at baseline (n = 91 [40.3%]). Among these patients, new use of pain medications during the study occurred in 20 of 44 patients (45.5%) in the TA group, 16 of 23 (69.6%) in the SA group (P = .06), and 16 of 24 (66.7%) in the WC group (P = .09). Taken together, pain medication use was less likely for patients in the TA compared with the SA or WC groups combined (20 of 44 [45.5%] vs 32 of 47 [68.1%], P = .03).
In other words, there was no statistically significant difference in the rate of initiation of pain medications between TA and SA; so the authors combined the SA and WC group to compare to the TA group and found a significant difference. That’s a bit dodgy to me right there.
Finally:
No differences were observed between groups in assessments of grip strength (eTables 3 and 4 in Supplement 2) or Timed Get Up and Go (eTables 5 and 6 in Supplement 2) for any assessment time compared with baseline.
These are functional measures that are objective, and acupuncture did not affect them at all. My conclusion: Four years later, with follow-up out to 52 weeks, this is still a negative acupuncture study. The authors, however, did not see it that way:
In this randomized clinical trial, we found that among postmenopausal women with early breast cancer who experienced AI-related arthralgias, a 12-week intervention of TA compared with SA or WC resulted in statistically significant sustained reduction in joint pain at 52 weeks. This study highlights the durability of the acupuncture response through 1 year, as well as the importance of having both SA and WC groups to fully evaluate the effect of the acupuncture intervention.
No. Just no. This study, although barely “positive” for some measurements, was, due to lack of blinding and the low effect size observed, functionally, clinically, and practically a negative study. TA didn’t result in any functional improvement. It didn’t decrease the percentage of patients who had to stop their AI therapy. It only barely showed any improvement in a subjective pain score, and even then that effect varied wildly at different time points and was at most time points not statistically significant. (I didn’t even get into the uneven subject allocation to groups, something I discussed in my 2018 post.) Because of the lack of blinding and the very low prior scientific plausibility of acupuncture as a treatment for AI-induced joint pain, the SBM conclusion is that acupuncture didn’t work in this study for the outcomes studied. In contrast, EBM ignores these considerations, so that the analysis of this study left room to conclude that acupuncture does work against AI-induced joint pain or is at least promising.
Science-based medicine vs. evidence-based medicine
Before the pandemic, a not-infrequent criticism of our discussions of acupuncture studies like these tended to be based on methodolatry. This is a term that I learned in 2009 from an eminent epidemiologist defined as the profane worship of the RCT as the only valid method of clinical investigation. Let’s just say that there is a lot of methodolatry in EBM, which is how a treatment represented as ancient that is really a reinvention less than a century ago of a significantly different ancient treatment whose history has been heavily retconned can even reach the stage of being subjected to an RCT despite its extreme biological implausibility and its basis in ancient vitalist beliefs. It would be one thing if any well-designed RCT of acupuncture were ever to show a large, undeniable effect size against a clinical endpoint of interest that can’t be explained by placebo effects. Then one might start to ask whether we were wrong and there actually is a biological basis for acupuncture to work for that condition. Such is not the case, however, and so we continue to do study after useless study testing whether the magic of acupuncture works against condition after condition, finding equivocal results along the way because clinical trials are messy, and it’s not uncommon to find marginally statistically significant results if you do enough of them. Given the extreme biological implausibility of a modality like acupuncture for arthralgias due to AI treatment, in light of findings like this the SBM conclusion is that acupuncture doesn’t work.
In the age of the pandemic, the difference between EBM and SBM is even more salient. The perfect example is ivermectin for COVID-19. As I wrote many moons ago, SBM mavens all immediately realized that, even if you accepted the rationale proposed at face value, ivermectin was incredibly implausible as an effective therapy for COVID-19 just based on the in vitro data alone. It was basic pharmacology. A drug (like ivermectin) that only inhibits the target protein at a concentration that is at least nearly 70-fold higher than the highest blood concentration of drug that can be safely achieved using standard dosing is incredibly unlikely to be an effective treatment. It’s also a general principle that most highly effective drugs inhibit their target at nanomolar or ng/ml concentrations, not micromolar or μg/ml concentrations. Candidate drugs that only inhibit their target at such high concentrations, in general, tend to be incredibly unlikely to be useful drugs. Surprise! When higher quality RCTs were completed (compared to a number of low quality RCTs that showed an effect of ivermectin on COVID-19), it turned out that ivermectin is ineffective against the disease.
My hope now, as it was the last time I wrote about ivermectin, is that SBM thinking will be more likely to sway EBM adherents who don’t really take into account prior plausibility in evaluating RCT evidence and therefore take much longer to reach a conclusion that is obvious to SBM about a treatment, in the case of ivermectin that it doesn’t work against COVID-19. Unfortunately, the example of acupuncture tells me that it’s unlikely that this will ever happen, given that decades after it was apparent that acupuncture is nothing more than a theatrical placebo, studies like this one are still being carried out and reported as positive when, for all practical purposes, they are not.

   An all-too-common breast cancer testimonial for “alternative medicine”
David Gorski
Link
One of the consistent themes of SBM since its very inception has been that, when it comes to determining the efficacy (or lack thereof) of any particular medicince, therapy, or interventions, anecdotes are inherently unreliable. Steve Novella explained why quite well early in the history of this blog, and I myself described why otherwise intelligent people can be so prone to being misled by personal experience and anecdotal evidence. Unfortunately, as I have also demonstrated, it’s not just patients who can allow themselves to be misled by anecdotes, but certain physicians who do not understand the scientific method but in their hubris think that their “personal clinical experience” trumps science, clinical trials, and epidemiology.
None of this is to say that there aren’t frequent instances when applying data from population-based studies to individual patients is problematic. It can indeed be. However, it often goes beyond that, and, indeed, if there is one defining characteristic of a quack that I’ve never failed to find when looking at individual cases, it’s a belief that he is able to identify when a treatment works based on his own personal experience and anecdotes. Unfortunately, it’s not just quacks who sometimes fall prey to this, because humans are cognitively wired to infer causation from correlation. This tendency, which was no doubt adaptive early in our evolution, simply doesn’t work well when it is applied to medicine and science. Without a doubt, it is the key driver, for example, behind the widely believed myth that vaccines somehow cause autism and that chelation therapy and other biomedical quackery can “cure” autism, a view popularized most recently by the very popular but very ignorant Jenny McCarthy in the U.S. and before that by the outright dishonest Andrew Wakefield in the U.K.
One of the other reasons why testimonials for quackery seem convincing is because most people simply do not know enough about disease, be it my specialty (cancer) or any other disease, how it is treated, and what its natural course can be expected to be. That is why, when I came across an example of just such a testimonial, specifically a breast cancer testimonial, I saw what is known as a “teachable moment. This teachable moment occurred on the very popular science blog Pharyngula, written by the ever sarcastic biology professor from Minnesota, P.Z. Myers. It actually surprised me in that the usual topics on Pharyngula include evolution, biology, the pseudoscience known as “intelligent design” creationism, politics, and atheism. P.Z. doesn’t usually dabble much in the realm of medical quackery, but my guess is that he was attracted to this particular piece of pseudoscience because of the religious angle.
Specifically, the quackery under consideration is known as God’s Answer to Cancer (GAC). Basically, it looks a lot like any number of quack electronic devices that promise to cure cancer; examples include Bill Nelson’s Electro Physiological Feedback Xrroid (EPFX) machine (1, 2, 3), Hulda Clark’s parasite zapper, or Alan Back’s Advanced Bio-photon Analyzer. All of these devices promise, in essence, to use low level electrical energy to “boost the immune system” and “replenish your life energy” plus or minus an additional promise to “zap parasites” (Hulda Clark’s unique spin on these devices, in which she claims that all cancer, AIDS, and most other diseases are due to a liver fluke, which her device supposedly “zaps.” Like these devices, the maker of GAC promises vague “immune system boosts,” but with the added twist that he claims that all disease is due to original sin (along, apparently, with the conventional alt-med “toxins,” diminished qi, and uncharacterized immune dysfunction). Amusingly, the Monsignor who created this device also disses Hulda Clark and advocates the use of laetrile and Linus Pauling’s orthomolecular medicine. The main difference is that he claims to have received the design for the device from God through a dream.
A discussion of these various forms of quackery is beyond the scope of this post, and some of them have already been discussed before on this blog. such as Linus Pauling’s advocacy of vitamin C. Suffice it to say that it is quackery, with no basis in science. What caught my interest was a testimonial by a commenter on P.Z.’s blog. He was most unhappy at some of the snarky comments and decided to provide a very typical cancer testimonial for alt-med that I thought to be worth deconstructing as a learning exercise. It began with a discussion of the Royal Rife device, which, suffice it to say is also quackery, albeit a form of quackery that hasn’t much been discussed on SBM. (Hmmm. Perhaps some blog fodder for next week?) The commenter, going by the ‘nym “gp,” began:
The research of Royal Rife is largely obscured in mystery, and very few folks have been able to replicate his results based upon that secrecy. The work of Dr. Bob Beck on the other hand is well documented and with measurable results.
Actually, the reason that no one has been able to replicate the work of Royal Rife is because it’s pseudoscientific nonsense. Bob Beck’s protocol isn’t any better. In essence, it consists of what Beck calls “microcurrent” therapy, and a brief description of it should convince most readers of just what nonsense it is (although I do reserve the right to use it as more blog fodder in the future, as a detailed discussion may be worthwhile; perhaps a general post about a number of these devices):
The Bob Beck Protocol started out as an electromedicine treatment for AIDS / HIV, however, it has turned out to be a superb cancer treatment.
There is certainly no other electromedicine treatment for cancer that is anywhere near as effective as the Bob Beck Protocol. It is far better than any Rife Machine, far better than any Multi-Wave Oscillator (MWO), far better than anything Hulda Clark has out, and so on.
The reason the Bob Beck Protocol is so absolutely superior to other electromedicine treatments is that it is the direct result of an incredible discovery in medicine.
Two medical doctors, Dr. Kaali and Dr. Lyman, discovered, in 1990, that a small electric current could disable microbes from being able to multiply, thus rendering them harmless. It was, in fact, the greatest medical discovery in the history of medicine because virtually all diseases are caused by, or enhanced by, a microbe. Their discovery was a cure for almost every disease known to mankind.
A video can be found here, which postulates something called “blood electrification.”
A good rule of thumb, one that I have yet to find to have been wrong, is that, whenever someone says their device or treatment is a “cure for almost every disease known to mankind,” it’s quackery. Run, don’t walk, away from anyone telling you that. Moreover, when someone like Beck tells you that his therapy won’t work if you take any other therapy, be it conventional chemotherapy, surgery, and radiation, or even any other “alternative” therapy, that’s just icing on the cake for identifying quackery. In any case, that gp believes in Beck’s protocol so strongly should tell you what’s coming next, namely an anecdote:
With that said, my wife was diagnosed with invasive ductal carcinoma (3.5 cm tumor) last year with metastatic lymph node activity, the lay translation of which is terminal breast cancer that had spread to her lymph nodes.
Although I’m sorry that gp’s wife developed breast cancer, having just watched my mother-in-law die of the disease a mere three and a half weeks ago, my personal feelings won’t stop me from pointing out the misunderstanding of breast cancer here. Unless his wife had metastatic disease in distant sites other than the lymph nodes under her arms, she did not have “terminal” breast cancer. In fact, even if a lot of lymph nodes under her arm were positive for metastatic breast cancer, she would still be potentially curable. Granted, depending on the number of positive lymph nodes, gp’s wife could be as high as a stage IIIA or, if the primary tumor was considered inoperable due to extension to the chest wall, stage IIIB, but stage III breast cancer is still potentially curable. As I guide you through the rest of the testimonial, I’ll try to fill in what probably really happened based on educated guesses. You will see that what probably happened does not support the efficacy of the quackery pursued. But, before I do, let’s look at three questions in reading alt-med cancer testimonials that can, if answered properly, can be indicative that an “alternative” therapy might actually have value. These questions were provided by our ever-intrepid commenter and occasional gadfly here around SBM, the retired Australian cancer surgeon Peter Moran:
Was cancer definitely present , as shown by reliable tests, when treatment was commenced?
Did it go away? (or clearly respond otherwise, as judged by the same tests)
Was the advocated treatment the only one used ? (within 2-3 months of the apparent cancer response)
Thus far, the answer to question number one appears to be “yes.” However, I would say that Dr. Moran’s list is incomplete in that I would add to it: Was sufficient reliable information presented in the testimonial to allow me to do a reasonably accurate staging of the tumor? In other words, if a person giving a testimonial says that the cancer was “incurable” with conventional therapy, was it, in fact, incurable? In this case, as I pointed out before, we can answer fairly confidently that gp’s wife’s cancer was not incurable. It is possible, even likely, that it was a fairly nasty tumor (more on that later), but it does not appear to have been stage IV disease, because it’s a pretty safe bet that if it were gp would have pointed out that his wife had metastases to lung, liver, bone, or wherever, in order to emphasize the hopelessness of the situation.
Let’s continue with gp’s testimonial:
I interviewed and met with three separate cancer specialists including the head of oncology for a cancer research center in the top 10 worldwide; the answer to her cancer was an extensive regiment of cytotoxins followed by radiation, despite her heart tests which came back with less than 50% efficiency for her left ventricle.
Whether gp’s wife’s axillary lymph nodes were positive or not, a 3.5 cm primary tumor would mandate at least some chemotherapy; positive lymph nodes would indicate the need for a longer and more intensive course of chemotherapy. In addition, radiation therapy is standard of care for any form of breast-conserving therapy. As I tell patients, if your breast stays in place, you need radiation. There are only a few exceptions. Without it, the risk of local recurrence can be as high as 30% or slightly more. Of course, as I’ve pointed out before, this very fact (namely that about 2/3 or more of women who undergo lumpectomy will do fine without radiation) often leads to other testimonials by women who have had a lumpectomy, eschewed radiation in favor of some alternative woo or other, and and then attributed their doing well not to the surgery, but rather to the woo. The same goes for chemotherapy. Remember, surgery is the main curative modality in breast cancer that is curable. Radiation is the icing on the cake that sharply decreases the risk of local recurrence, and chemotherapy reduces the risk of distant recurrence; i.e., recurrence outside of the breast or axillary lymph nodes, such as in the bone, liver, lung, or other organs. Finally, gp’s comment about his wife having “less than 50% efficiency” refers to a MUGA scan, which is indicated before the use of Adriamycin-based chemotherapy regimens, which can indeed injure the heart. Radiation to the left breast or chest wall can also “leak” and injure the heart, but the risk is very small with modern techniques of planning and advanced equipment aiming the beam, which now allow for very accurate radiation dosage, with little or no collateral damage.Clearly, Mrs. gp’s oncologists thought that her cardiac reserve was adequate to handle it.
gp continues:
I personally challenged each of her oncologists to a simple question and answer session about the mortality rates associated with chemotherapy used in conjunction with radiation; they were only able to cite the statistics published by the American Cancer Society which are now deceptively reported within a 5 year window (if there is no reoccurance of cancer within 5 calendar years, the patient is cured of cancer; if there is a reocurrance after the 5 year window, they are reclassified as a new patient). Her oncologists had not one suggestion for a change in her diet, a change in aerobic activity, or any solution other than the administration of very expensive cytotoxins followed by a 30 day bout of nuclear medicine, to further suppress and completely annihilate her immune system to get the cancer out of her. Napalm for humans.
The reason doctors have no suggestions other than generic suggestions is because there is no evidence that specific dietary interventions can treat an established cancer. There is, of course, that diet can influence our risk for cancer, and there is even weak and controversial evidence that an extremely low fat diet might be able to slow the progression of very early stage prostate cancer with favorable histology, but that is a far cry from treating an established cancer. Moreover, one can’t help but note that gp is parroting the usual alt-med tropes about cancer therapy, including the classic “poisoning” and “burning” (although I’ve never seen anyone refer to it as “napalm for humans” before), in addition to the exaggerated fears of “annihilating” the immune system. In fact, the immune system recovers quite well from breast cancer chemotherapy.
As for gp’s claim that the American Cancer Society has somehow jiggered its statistics on survival, there’s no other way to put it, I’m afraid, other than that it’s nonsense. It is true that about five years ago the ACS changed its statistical models for estimating the number of cancer cases and cancer deaths; this was done to reflect more accurately the incidence and number of deaths using the SEER database. It should also be remembered that the ACS state-by-state reporting of cancer incidence and deaths is not intended to estimate how successful treatments are, because it doesn’t break the data down stage by stage, treatment by treatment, but rather only by tumor type. Results of randomized clinical trials and other studies looking at stage-by-stage survival rates are required for this purpose, and such studies, I assure gp, do not count recurrences after 5 years of breast cancer as new cancers. Breast cancer is well known as a cancer that has a propensity to recur later than five years, which is why survival rates for breast cancer are often reported as ten year survivals. Indeed, from the landmark clinical trials in the 1970s and 1980s by the NSABP that now have 25 and 30 year survival rates reported. The literature on this subject is long and deep, and, even if the ACS were “jiggering” its figures in the way described by gp, it would not affect that literature.
The story continues:
The cancer research center (Moffitt Research here in Tampa) has a McDonald’s in the lobby. I had a Big and Tasty with a large Coke each day while she was in the hospital recovering from the bi-lateral mastectomy.
From this we learn that gp’s wife had a bilateral mastectomy. It is not mentioned whether she also underwent an axillary dissection on the side of the tumor, but presumably she did if she had a positive lymph node there. No competent breast surgeon would be willing to do just a mastectomy under those circumstances without a fight. Indeed, if Mrs. gp had stage IV disease, it is also very highly unlikely that any surgeon would want to perform a bilateral mastectomy on her right off the bat. It is true that there is retrospective evidence suggesting that removing the primary tumor in patients with metastatic disease might be helpful in terms of prolonging survival, but that’s only in patients who have stable disease after chemotherapy. Be that as it may, assuming Mrs. pg had a modified radical mastectomy on the side of the tumor (includes the lymph nodes) the answer to Peter’s second question is: Yes, the tumor did go away. You can’t make a non-stage IV cancer go away any more effectively than to remove both breasts. However, the tumor went away before any alternative therapy was tried, thanks to a trusty neighborhood surgical oncologist at Moffit.
It would be interesting to know whether his wife chose a bilateral mastectomy. Personally, as a breast surgeon, I am very reluctant to perform a mastectomy on the other side unless (1) there is another cancer there (which gp didn’t mention; so I presume that there wasn’t) or (2) a documented mutation in a gene like BRCA1 that predisposes to hereditary cancer. I admit that these days I’m a bit of a dinosaur that way, because increasingly women are demanding bilateral mastectomies, even though there is no evidence that their routine use improves survival.
In any case, that Mrs. gp required a mastectomy implies that her surgeon judged her tumor too large to perform a lumpectomy or partial mastectomy with a decent cosmetic result. Another interesting wrinkle is that these days giving chemotherapy before surgery can often shrink such tumors to the size where lumpectomy is possible, allowing preservation of the breast. However, for this approach to work, the woman has to be willing to undergo both chemotherapy and radiation, and Mrs. gp was unwilling to accept either:
We then opted to decline chemotherapy (you will be dead within a year) as well as decline radiation (seriously, you are really dead within a year now, take the chemo and radiation you crazy person with cancer) and instead began the Beck Protocol based on Dr. Robert Beck’s open source schematics (the “quackery” referenced in the previous two posts) which he published in 2002, originally as a way of bulking up the immune system of individuals diagnosed with HIV.
I don’t know where gp and his wife got the idea that chemotherapy and radiation would lead his wife to be dead within a year. Most breast cancers, even metastatic ones, don’t necessarily lead to death within a year. Median survival is in general over a year; so a significant number of women with metasatic breast cancer live longer than a year. Some can even live several years. As for the Beck protocol, gp describes it thusly:
For the ozone generation component we opted for a clinical grade ozone generator and oxygen concentrator purchased from Longevity Resources; cancer itself is an anaerobic function so increasing blood/oxygen saturation is a key component to fighting cancer of any type. Ozone is used primarily in Europe as a disinfectant and has only recently been adopted by U.S. hospitals to disinfect operating rooms, burn units etc.
For the blood electrification equipment we went with a vendor that replicated the work of Dr. Bob Beck’s open source schematics and in accordance with the research of Dr. Kaali and Dr. Lyman’s report from 1990, which is now the core focus of electroporation equipment (that curiously also uses the same square wave advocated by Rife’s research) now approved by the FDA and in clinical trials with cancer research centers here in the U.S. The unit I bought for the blood electrification is non-FDA approved, built to spec as described by Kaali/Lyman/Beck.
For the magnetic coil pulser I ordered a unit from Australia with measurable output according to the Beck Protocol, non FDA approved.
For the silver component we went with 2 gallons of medical grade collodial silver from a supplier here in the U.S. with a lab certified 20 ppm content (Utopia Silver, http://www.utopiasilver.com).
We also used a daily dosage of 60 bitter apricot pits initially (now a 20 pit per day maintenance routine) due to high concentrations of Laetrille/B17 (illegal for resale in the U.S. per the good folks at the FDA).
My goodness, the Beck protocol is a panoply of cancer quackery! It’s all there, even laetrile! Of course, there is one bit of possible non-woo in with all the woo, and that’s the electroporation equipment. Electroporation is sometimes used to potentiate DNA vaccines, to increase the uptake into the skeletal muscle cells of the plasmid DNA being used to immunize the patient. It does not surprise me that the device gp picked up is not FDA-approved. As for colloidal silver, apparently gp is unconcerned with what I like to call the “Blue Man syndrome” but what is more commonly called agyria that can occur as a result of its use.
Finally, let me just address the ozone issue. Apparently the idea is to increase the blood saturation of oxygen somehow by increasing the amount of oxygen dissolved in the blood. The problem is that the vast majority of oxygen in the blood is bound to the hemoglobin in the red blood cells. Only a small minority of the oxygen in the blood is dissolved. Moreover, the oxygen binding curve for hemoglobin is saturable; if the hemoglobin is greater than 90% saturated (as it is in most people at sea level or near sea level), it’s impossible to increase the oxygen content of the blood by more than a couple of percent by adding more oxygen. Worse, ozone is a very strong oxidant. Did it ever occur to gp that there’s a reason it’s used as a disinfectant? It kills bacteria, but its oxydizing properties do exactly the same thing to normal cells.
So how did Mrs. gp do? Let’s see:
Her initial tumor markers were off the charts in all areas; after three months of treatment and her surgery, she scores 1 out of 40 for her tumor markers – and she refused chemotherapy or radiation.
We use http://www.caprofile.net/ for bi-monthly blood tests that show her progress in terms of her cancer markers and the other empirical indicators of cancer (PHI enzyme levels, hCG levels, etc). We have to pay the $300 for this test out of pocket as insurance will not cover it; the blood tests from her oncologist (covered by insurance and 10X the costs) don’t even show the basic levels associated with cancer such as PHI and hCG.
Note what he says: After the surgery. Of course her tumor markers fell. Remove the tumor, and the tumor markers will usually fall.
Now’s as good a time as any to answer Peter’s third question, and the answer is a resounding “yes.” She did receive other therapy. She received the primary therapy for her tumor. In fact she received highly aggressive surgical therapy for her tumor. Once again, I reiterate: Chemotherapy and radiation in this setting are adjuvant therapies. Surgery is the primary therapy, and they are useful for decreasing the risk of cancer recurrence. Back in the “old days” before there were effective adjuvant chemotherapy or radiation therapy regimens, surgery was the only treatment for breast cancer, even relatively advanced tumors. The survival rate wasn’t fantastic, but a significant minority of women were cured of their cancers by surgery alone and still are. It is highly probable that gp’s wife falls into that category, although, at the risk of being pessimistic, I have to point out that we don’t know how far out she is from her surgery. She’s still not out of the woods yet by any means. I wish her only the best, but really wish she had increased her odds of overcoming breast cancer by accepting conventional treatment.
Finally, there is the issue of all those “tumor markers.” The following of tumor markers for breast cancer is a complicated and controversial minefield. In fact, there are a number of tumor markers for breast cancer of wildly varying validity and reliability, the vast majority of which aren’t much good. Indeed, breast cancer tumor markers are in general not closely followed after primary surgery for breast cancer; rather they are sometimes followed in the case of advanced disease. Some oncologists I’ve known don’t follow them at all, thinking them to be a waste of time. Unfortunately, those of us who take care of breast cancer don’t have a marker as reliable as CEA is for colon cancer and would very much love to have one whose high degree of utility is science- and evidence-based. There’s a reason why insurance companies don’t pay for that many of them, and I can only guess at what other dubious markers gp was paying quacks to measure.
No testimonial, of course, would be complete without an appeal to emotion and conspiracy:
Simple, rational logic dictates that cellular toxins of any sort destroy the body’s ability to fight cancer, as does radiation.
Simple, rational logic also dictates that nuclear medicine is proven to cause additional forms of cancer and debilitating diseases, all of which are considered by modern day oncology as “effective” means of combating metastatic cancer which is now at epidemic levels worldwide.
Simple, rational logic says that the body’s immune system is the first line of defense against any form of life threatening illness, and bolstering – not destroying – the body’s immune system is the most effective way of combating cancer of any sort.
Further, Big Pharma and their minions at the FDA would rather allow corporate profit motives to drive cancer research, while only treating the symptoms of cancer and never the root causes of what causes cancer in the first place.
“Simple, rational logic” is, alas, all too often only the former of the two based on a profound misunderstanding of biology. It is true that chemotherapy is toxic, but the point is that it’s more toxic to cancer cells that are rapidly dividing than it is to normal cells. The same thing is true of radiation when administered correctly. Indeed, the concept of “fractionating” radiation (i.e., giving it in small daily doses over 30 or so fractions, which is what is done with breast cancer) is predicated on the fact that normal cells can repair their DNA after such low doses but cancer cells can’t. The cancer cells thus accumulate damage, while normal cells repair themselves during the “rest” periods. Moreover, although it is true that secondary malignancies are a risk with radiation therapy and chemotherapy, numerous studies have been done on this issue, and it turns out that the risk of these secondary malignancies is far outweighed by the therapeutic benefit of the chemotherapy. The problem with so many mavens of alt-med is that they are like antivaccinationists in that they seem to think that there must be medical interventions with absolutely zero risk. All medical treatment is composed of a risk-benefit analysis. For a disease like cancer, which has the potential to kill, more risks are considered acceptable to wipe it out.
gp’s testimonial illustrates very well the inherently deceptive nature of the vast majority of alt-med cancer testimonials. This deception is rarely intentional; rather, far more commonly it is the result of a poor understanding of cancer, how it’s treated, its prognosis, and the extreme variability of its course. Indeed, breast cancer is a disease with a particularly variable course, which, when coupled with its high degree of prevalence (it’s the most common cancer diagnosed in women), virtually guarantees large numbers of women who are “outliers,” doing much better than expected. Some of these women will take alternative medicine and attribute their good fortune to alternative medicine rather than their tumor biology. The reason that these testimonials often sound convincing is that the people listening to them are not physicians and do not know enough about the expected natural course of a specific cancer, how that cancer is normally treated. Another common misunderstanding is what the role of chemotherapy and radiation is for treating solid tumors, for which the primary treatment is almost always surgical and for which surgery can often be curative.
Finally, not how gp claims that “conventional medicine” treats “only the symptoms” of cancer rather than the “root cause.” This is a frequently claim made by alt-med advocates not just about cancer but about virtually all human disease. It is also one I consider most ironic, given that scientific medicine actually does try to discover the actual cause of cancer and treat it. It looks at genes, the functions of the proteins they express, and how the environment interacts with them. They study tumor biology and how seemingly “normal” stroma can influence the growth of tumors for good or ill. Science modifies its views in response to new data, observation, and experiments. The contrast with “alternative” medicine could not be more stark, where we false causes of cancer are identified and targeted: Liver flukes causing “all cancer”; vague disorders in unmeasurable “life energy”; unnamed “toxins”; uncharacterized immune system “weakness”; or, my favorite when it comes to inanity, the claim that cancer is not a disease at all, but rather a manifestation of internal conflict.
Unfortunately, if gp or his wife sees this, no doubt they will see it as yet another example of a close-minded physician. However, I am a physician who sincerely hopes that Mrs. gp does not become like some women described by Peter Moran:
The studies <1,2> that predict a favourable outcome for many with lumpectomy alone predict misery for others. The women on the wrong side of the gamble, those trying to cope with persistent cancer either eventually have to accept further medical care, usually mastectomy, or can be observed making fleeting visits to their old Internet stamping grounds, asking for advice on what to do about the pain or smelly discharge, or regarding what last-ditch methods they should try, having by now used most of the treatments on offer…
Amazingly, some of these unfortunate women still fly the “alternative” flag, remaining proud that they have have “treated” their breast cancer “without using any conventional methods”. This is a tribute to the occasional success of malicious propaganda that claims, despite mountains of evidence to the contrary, that medical treatment of cancer doesn’t work or makes things worse. The truth is that the prognosis for cure of breast cancer is very good, especially if found early via screening. In fact, even when all stages of the disease are included [4] 80% of women with breast cancer survive for ten years, with most of these being cured permanently.
I’m also reminded that I’ve just returned home from a meeting in Phoenix, where I met a former fellow from my old program who now practices in nearby Scottsdale. She happens to have read this blog, and our discussion turned to the fact that Arizona is ground zero for a whole lot of woo, which led her to describe a couple of patients whom she’s seen in just a year and a half of practice with advanced, fungating tumors that had been treated by, as she put it, “naturopaths putting various salves on them.” I concluded that I would have a hard time practicing in Arizona, as in eight and a half years in New Jersey I had never seen such a case. I had seen neglected tumors due to denial, but I had never personally seen one treated by a naturopath. I was also reminded yet again that this sort of quackery kills. 

Why do some women refuse treatments for their breast cancer?
Adjuvant therapy after surgery, such as chemotherapy, hormonal therapy, and radiation therapy, has contributed to a 39% decrease in breast cancer mortality since 1989. Unfortunately, a significant number of women decline evidence-based adjuvant therapy. A recent study suggests that distrust of the medical system plays a significant role in such refusal.
David Gorski on November 13, 2017
Link
I write about alternative cancer treatments a lot, in particular the lack of evidence for such practices, many of which are at best pseudoscientific and at worst pure mystical nonsense. The reason, of course, is simple. I’m a breast cancer surgeon, and I hate seeing people who might be saved from death due to cancer falling prey to treatments that demonstrably lessen their chances of survival, either by leading patients to reject effective treatment in favor of ineffective or even harmful treatments or, at the very least, to delay effective treatment until the patient realizes that the quackery chosen isn’t preventing the growth and spread of his or her tumor. This can sometimes take a long time. I’ve seen women with breast cancer whose breasts were basically eaten away until there was nothing left but an ulcerated mass on their chest—more than that, a bleeding, rotting, malodorous ulcerated mass. Yes, it’s an ugly picture, but I’ve seen it all too many times.
These sorts of cases are less common, though. Fortunately, relatively few are the women who reject conventional medicine altogether. Indeed, most women will accept surgery of some sort or another, either a lumpectomy or a mastectomy. Sometimes, they undergo an excisional biopsy, not realizing that that for smaller tumors an excisional biopsy can remove the whole tumor and in some cases be curative. No, far more common is the case where a woman accepts surgery but then refuses chemotherapy, hormonal therapy, and/or radiation, either altogether or in favor of some form of quackery. In doing so, such women, whether they simply refuse adjuvant therapy altogether for whatever reason or go beyond that and fall prey to quackery, fail to maximize their chances of surviving their breast cancer, sometimes by quite a bit, and that is something to be concerned about.
Indeed, these sorts of cases were one of the very first topics I ever wrote about on this blog and have remained a staple of the blog ever since, whether I was discussing Suzanne Somers, who had surgery and radiation but apparently refused Tamoxifen for her breast cancer and then later had what she thought to be a recurrence that almost certainly wasn’t, other alternative breast cancer cure testimonials (like this one or this one), or even testimonials for other cancers where chemotherapy and/or radiation are used in addition to surgery.
The reason such alternative cancer cure testimonials are compelling is that most people don’t understand the difference between the primary treatment for breast cancer and an adjuvant treatment. In the case of breast cancer, for instance (and colorectal cancer as well, among other solid tumors), surgery is the primary treatment and can be curative by itself. What chemotherapy, radiation therapy, and hormonal therapy can add to the treatment of, for example, breast cancer is to decrease the chance of its recurring after successful surgical excision, whether by mastectomy or lumpectomy. All a breast cancer patient does in refusing radiation therapy after successful breast conserving surgery is to accept a risk of recurrence in the breast of 30-40% instead of 5-8%. All a woman does by refusing recommended chemotherapy after surgery is to refuse a relative decrease in their risk of dying of a recurrence of breast cancer by 25-30%, a benefit that is, in absolute terms, much greater for more advanced but still curable breast cancers. However, many of these women who turn down adjuvant therapy in favor of quackery will still survive, thanks to the surgery, and the ones whose cancers recur rapidly disappear from the alternative cancer cure industry PR machine, never to be seen again.
Because adjuvant chemotherapy, targeted therapies, and hormonal therapies have contributed to a decline in mortality from breast cancer of 39% since 1989, it is important to determine why women refuse these treatments and fail to optimize their chances of long term survival. To a lesser, but still important extent, it’s important to try to understand what motivates women to turn down effective adjuvant therapy, as that is the first step in developing strategies to persuade them. Recently, there was a relatively large study that addressed just this question.
Patient refusal of adjuvant therapy: A question of trust?
Earlier this month a number of news stories and press releases appeared about a study published in late September by investigators at Johns Hopkins Bloomberg School of Public Health, Columbia University, and Massachusetts General Hospital looking at trust—or, more specifically, a lack of trust—as a key motivator in women refusing adjuvant therapy recommendations and opting for discordant care; i.e., care that doesn’t conform to evidence-based care recommended by the patient’s physicians. It’s an issue that hasn’t been studied as well as it should be, as the authors, Lorraine T. Dean, Shadiya L. Moss, Anne Marie McCarthy, and Katrina Armstrong point out in the introduction:
Relatively little is currently known about the relationship between healthcare system distrust and cancer treatment. A previous study of distrust and adjuvant cancer treatment (3) found that distrust in medical institutions was associated with increased risk of not initiating adjuvant treatment in a sample of 258 early stage (Stage I and II) breast cancer patients from one urban area. However, that study did not include the following in their analysis: which treatments were recommended by the physician, the extent to which physician distrust mediated the relationship between healthcare system distrust and cancer treatment, and an assessment of those who may have initiated treatment but did not fully adhere to the treatment plan. Other studies of distrust among women with a history of breast cancer have focused on healthcare system distrust and: mental health or psychosocial outcomes (13), quality of care (14,15), greater emotional, physical, financial, and sexual problems after treatment (16), less comfort with the use of de-identified information from medical records for research (17), less endorsement of the necessity of adjuvant chemotherapy (18); and provider distrust and quality of care (19).
The current study was designed to answer two related questions: Is healthcare system distrust associated with whether or not patients follow their physician’s recommendations for adjuvant treatment after breast cancer; and does physician trust mediate the relationship between healthcare system distrust and receipt of adjuvant treatment? It expands on prior work by including a large population based sample in two different US states, Pennsylvania and Florida, based on physician recommendations for several adjuvant treatments with explicit testing of the potential mediating role of physician distrust, and assesses patients who did not complete the full treatment plan. To our knowledge, it is the largest study of healthcare system distrust among women with a history of breast cancer and adds innovation of recruiting through a cancer registry to survey participants about healthcare system distrust.
To this end, the authors used Pennsylvania and Florida cancer registries, using data from a population from a study originally intended to assess the differences in breast cancer women associated with race. The inclusion criteria for the study included localized invasive breast cancer, age under 65 at the time of diagnosis, residency in either Pennsylvania or Florida at the time of diagnosis, and diagnosis between January 1, 2005 and December 31, 2007. Exclusion criteria included patients over 65, cognitive impairment, inability to speak English or Spanish, and metastatic disease at presentation. The overall response rate was very good for surveys of this type, 61%.
For purposes of the survey, cancer treatment discordance was defined as any difference in treatment that a patient reported receiving compared to the treatment the patient reported as having been recommended to her by the treating surgeon and/or oncologist. Now, I know what you’re probably thinking: Is this accurate enough? It turns out that simple self-reporting like this is 90% accurate, particularly for yes/no questions about different kinds of therapy. Since the adjuvant therapies used after surgery for breast cancer include radiation therapy, chemotherapy, and hormonal therapy, the authors constructed a combined measure of treatment discordance based on how many of the three therapies patients accepted or declined. Of course, if a particular adjuvant therapy was not recommended for a patient, then not undergoing it couldn’t be considered discordant. (For example, depending on the specific characteristics of the tumor, not all breast cancer patients are offered chemotherapy or hormonal therapy; and most patients—but by no means anywhere near all patients—undergoing mastectomy don’t require radiation therapy.)
Patients were also assessed for their level of trust in the health care system and their physicians. Trust in the health care system was assessed using the 9-item Health Care System Distrust scale which measures of domains of values and competence distrust on a 5-point agreement scale (1 = strongly disagree, 5 = strongly agree), producing a score ranging from 9 to 45. The authors report that this measure has “acceptable construct validity and high internal consistency (ɑ=0.84 in the current sample).” To measure trust in patients’ physicians, researchers used the 7-item Trust in Physician Scale, which uses a 7- point agreement scale (1=strongly disagree, 7=strongly agree), to produce a score ranging from 7 to 49. Information was also requested on socio-demographic factors, such as age, race, ethnicity, income, education, marital status, employment status, health insurance status, and state of residence at the time of diagnosis. They also went to the cancer registry databases to verify clinical treatment factors, such as stage, surgical removal of cancer, and recurrence.
So what did the authors find? There were 2,754 women included in the final analytic sample, of which 69.8% (n=1,922) reported always receiving the cancer treatments their surgeon or oncologist recommended, and 30.2% (n=832) reported not pursing at least one recommended treatment. I must admit that I was rather surprised that the percentage of discordant cases was so high, but maybe I shouldn’t have been. In any case, in the total sample, 10% declined radiation treatment; 11% declined chemotherapy; and 18% declined hormone therapy. (Note that some women turned down more than one modality.) Looking at the numbers, though, some of this does appear to jibe with my clinical experience, in that I’ve encountered more women who have turned down hormonal therapy than who have turned down others. The reason is probably that hormonal therapy, although only a pill as opposed to chemotherapy, is administered for five or, in more recent recommendations, as many as ten years, and women who can tolerate the much more severe side effects of chemotherapy only have to endure them for a few months, whereas they have a harder time dealing with the side effects of Tamoxifen or aromatase inhibitors for five or ten years.
The authors found:
The mean healthcare system distrust score was 28 (SD=3; range 9-40), while the mean physician trust score was 29 (SD=4; range 9-35). Bivariate models suggested that greater healthcare system distrust was significantly associated with older age, being Black, having attended some college, and being employed, while less healthcare system distrust was associated with greater physician trust, being married, having health insurance, and living in Pennsylvania. Only marital status, being employed, physician trust, and living in Pennsylvania were still associated with distrust in a fully adjusted model (Table 2). Participants reporting treatment discordance were significantly in the top tertile of healthcare system distrust (p=0.003) as well as being more likely to be older (p=0.04), be diagnosed at Stage 1 (p<0.001), and live in Florida (p=0.003). In contrast, physician trust was not a significant predictor of discordance (p=0.49). Although healthcare system distrust was significantly associated with discordance (p=0.03) and physician trust (p<0.001) (Figure 1), a mediation analysis (Table 3: Models A & B) suggested that physician trust was not a mediator of the relationship between healthcare system distrust and treatment discordance (total indirect OR=1.00 [1.00,1.01]). Thus, rather than treat physician trust as a mediator, it was included in the final model as a covariate.
Basically, those in the group with the highest distrust of the healthcare system were 22% more likely to have refused or fail to complete one or more adjuvant treatments. In other words, patients who had the most distrust of the healthcare system were more likely to be discordant in their adjuvant therapy; i.e., to refuse or fail to complete a recommended course of therapy. Interestingly, in this study, neither race nor socioeconomic status were significant drivers of discordance in this study, which is a good thing because these are not modifiable factors.
Physician trust versus a more generalized distrust
How could these results be? The authors note that attempts to increase physician trust as a strategy to reduce mistrust in the healthcare system have had results ranging from zero to very modest, which makes sense if patients view the two issues as separate. I like to make an analogy to Congress. Voters routinely express extreme distrust of Congress, but most voters actually like their own representative. Similarly, it’s not hard to envision how most patients might actually like and trust their own doctors, while simultaneously having a great deal of mistrust for the health care system as a whole.
As the authors note:
The limited research to date about reducing distrust in healthcare has focused on increasing trust in physicians with null to modest (30-32) results. However, given that the relationship between distrust and treatment discordance was not mediated by physician trust, these results suggest that addressing healthcare system distrust may be an important and distinct effort from strategies focused on lack of physician trust. Rather than playing a mediating role, patients may view physician trust as independent of their trust in the healthcare system as an institution; that is, even if patients distrust the healthcare system, they may still have trust in their personal physicians. Patients may be able to exercise greater choice in physicians, but may not have the same breadth of choices in using the healthcare system. Addressing healthcare system distrust might be informed by strategies that have addressed distrust in other types of institutions, such as corporations (29), according to the values and competence domains. For example, addressing the subdomain of values might be achieved through expanded access to adjuvant care, while addressing the subdomain of competence might be achieved through expanded access to health professionals while deciding to start or continue adjuvant treatment. Of course, any intervention to reduce healthcare system distrust would first need to be tested before implementing wide-scale changes.
The authors also note a rather interesting potential wrinkle to the problem of patients refusing adjuvant therapy, namely that greater cancer treatment discordance will always lead to worse healthcare outcomes, noting that it is “possible that distrust could perform a function in course-correcting treatment that is overprescribed or too aggressive” and that such distrust “might lead to treatment discordance that was ultimately beneficial rather than detrimental.” When I read that part, I had to concede that it is possible that this could be true, but unlikely. My own experience in quality improvement initiatives means that I’ve become fairly familiar with the literature on the relationship between concordance with evidence-based treatment guidelines and patient outcomes. That literature generally supports that better concordance results in better outcomes. So I couldn’t help but smile as I continued to read and noted that, consistent with that, the authors examined a separate model of treatment discordance, looking at its association with cancer recurrence, and found that the model suggested a 40% increased risk of cancer recurrence for patients who reported treatment discordance, after adjusting for adjusting for healthcare system and physician distrust and relevant racial and socioeconomic factors. This result suggests that that discordance due to distrust may lead to poorer health outcomes.
So what to do?
The authors note that improving trust in the healthcare system will require more than just trying to build trust in patients’ physicians, noting:
“If ordinary businesses can learn to increase trust in their brands, why not the same with health care institutions?” Dean says.
This is, of course, much easier said than done, and this study doesn’t address how increasing trust in the healthcare system might be accomplished. That will be the task for the future. It is an important task, though, because, although I might be extrapolating more than the evidence supports (yet), I’d bet that such strategies could also help address the antivaccine movement as well. In any case, if we want to save as many savable lives of people with cancer as possible, this is where the healthcare system needs to pay more attention, and a salutary side effect would also be to make alternative cancer cure testimonials less common.

Just in Case
What oncology’s hardest decisions can teach the rest of medicine.
Dr. Jonathan Storey on July 19, 2026
Link

Her recent breast surgery went perfectly. The tumor is out, margins are clear, and none of her scans show any cancer. So, she is understandably distraught when I begin to discuss the option of chemotherapy. “But I thought they got it all,” she says.
As a medical oncologist, I have had some version of this conversation hundreds of times, but it never gets easier. We call it adjuvant therapy — the medical practice of giving a person four to six months of chemotherapy after their cancer surgery, just in case. The underlying logic of adjuvant therapy rests on a single uncomfortable fact. Even when seemingly found early, a solid tumor may have already started to spread. The surgeons remove everything they can see in the operating room, but rogue cancer cells may already be growing in the liver, the lungs, bone, or brain. If those microscopic deposits survive and are allowed to multiply unchecked, they will eventually grow into incurable disease.
Adjuvant chemotherapy
The idea of giving someone chemotherapy after surgery to kill off remaining cancer cells seems obvious now, but it took a generation of trials to prove that it actually worked. Gianni Bonadonna’s group in Milan initiated a landmark clinical study in 1973 showing that chemotherapy given after breast surgery improves survival. Additional trials run by large cooperative groups in the United States validated and further refined this approach in breast cancer. Today, the benefit of adjuvant therapy has been proven across many of the most common types of cancer.
When meeting with a patient who just completed a “successful” surgery, simply asserting that there is a benefit to chemotherapy is insufficient. Patients demand more information when confronted with chemotherapy and its associated toxicities, both real and perceived. As such, oncologists must be prepared to quantify the benefit and risk whenever possible. For breast cancer, this need has led to the creation of online nomograms (or calculators) such as PREDICT. After inputting information about the specific patient and their cancer, the odds of benefiting from chemotherapy are returned. The estimated benefit is reported in absolute terms and takes into account competing (non-cancer-related) causes of death. The most informative graphic displays the predicted outcomes of 100 patients who choose adjuvant therapy.
Who will benefit?
The truth that follows from these types of calculations is humbling. Even in high-risk patients, the majority of treated patients will not benefit from adjuvant chemotherapy. Instead, it is more likely that a patient falls into one of the two groups that were never going to benefit from the therapy. The first group was already cured by surgery, so the chemotherapy adds only toxicity. The second group will relapse even after receiving months of chemotherapy. A minority of treated patients sit in the narrow therapeutic band that oncologists are aiming for; those are the patients that are cured by the addition of chemotherapy.
Oncologists regularly recommend months of adjuvant chemotherapy when it benefits 5% of our patients. In that scenario, we must treat 20 patients with chemotherapy to save one life. For some patients, that number is too small to consider chemotherapy. Perhaps they recognize that they are much more likely to be among the 19 patients who endured toxic therapy with little to show for it. Meanwhile, others are eager for any chance to improve their odds no matter how small. I often try to put myself in their shoes, but it is difficult… these are high-stakes decisions made under duress.
Transforming the adjuvant landscape
The most encouraging development in adjuvant therapy is that we keep getting better at assigning the odds. Compared to ten years ago, I often feel like I have the luxury of seeing an extra poker card before placing our bet. Tests such as Oncotype DX use genomic information from the surgically removed tumor and identify more women who can confidently forego chemotherapy. Newer genomic blood tests can now detect early evidence of residual cancer cells before they are visible on scans and may one day transform the adjuvant decision. This newer generation of tools is one of the great success stories in oncology — using better information to limit our therapies to those predicted to truly benefit.
Once you recognize the general shape of the “adjuvant” decision, you find it nearly everywhere. Consider the statin prescribed to a person who has never had a stroke or a heart attack. Most of the patients on these medications are never going to have one of those events. Furthermore, even in patients whose cholesterol numbers improve, some will still go on to have a stroke or heart attack. Only a minority are “saved” by the intervention, and we do not know who in advance. Consider the antihypertensive, the bisphosphonate, the screening colonoscopy. Each is an imposition — a pill, a needle, a procedure, a cost — accepted in exchange for a chance at extending life. Structurally, each of these decisions is identical to deciding whether to order additional therapy after surgery.
What would medicine look like if we consistently treated each “ordinary” prescription and intervention with the same rigor reserved for adjuvant chemotherapy?
Making the right choice
Oncologists, arguably more than any other specialty, practice a radical form of shared decision-making. This is accomplished by focusing on a few habits, none of them unique, but most uncommon once you leave the cancer clinic. We demand absolute numbers over relative ones. Chemotherapy that cuts relative disease risk by 18% sounds more impressive than the reality that it only helps 3 out of 100 patients. We acknowledge that in most instances, people taking a preventative medication will ultimately not benefit from it. We never confuse the recommendation, even when pulled from the guidelines, with the decision. We review the cost of every intervention, not just its promise. A good oncologist is also constantly looking for chances to do less rather than more when the numbers support it.
So, I think back to the woman whose surgery went well as we sit down to discuss the pros and cons of adjuvant chemotherapy. We spend most of our time focusing on her values and her priorities. I offer a recommendation, but in truth, the most important thing I bring is an honest assessment of the numerical odds. The precision of those numbers stands in stark contrast to the uncertainty that awaits her. Next comes the most important part of my job… I trust her to make the “right” choice.
Most choices in life, even the mundane ones, are a variation of the “adjuvant therapy” decision — staking certain costs today against an uncertain tomorrow. Choose wisely… just in case.


   Psychological support and breast cancer – again
Wallace Sampson
Link
Does the degree of efficacy is depend on the time at which it is measured? Apparently so. The case of psychological support and breast cancer longevity again.
After an original 1989 report of positive effects on metastatic breast cancer, by 2006- 7 the majority of RCTs on such effects had settled the issue in the negative. This was only after 20 years of repeated research grants and RCTs based on hunches and feelings that somehow emotional support really affected the course of cancer. Investigations continued despite analyses showing the few original positive studies had been so flawed in design or defective in reported details, that they should have been dismissed and perhaps excluded from systematic reviews. (Spiegel D, Bloom JR, Kraemer H, Gottheil E. Psychological support for cancer patients, Lancet ,1989 Dec 16;2(8677):1447., Fawzy FI, Fawzy NW, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence an survival 6 years later. Arch Gen Psychiatry. 1993 Sep;50(9):681-9.)
But to advocates, conflicting results served as motive to prove the claims by repeating the studies for 20 years, “doing them right this time.” As of mid-2008, consensus was the issue was still “negative.” Now another study, claimed to be positive, makes the news.
Here is the part of the abstract of the latest study, published in the December 15 issue of the journal Cancer:
METHODS. A total of 227 patients who were surgically treated for regional [stage 11-111] breast cancer participated… Patients were randomized to Psychologic
Intervention plus assessment or Assessment only study arms. The intervention was psychologist led; conducted in small groups; and included strategies to reduce stress, improve mood, alter health behaviors, and maintain adherence to cancer treatment and care….
RESULTS After a median of 11 years of follow-up, disease recurrence was reported to occur in 62 of 212 (29%) women and death was reported for 54 of 227 (24%) women. Using Cox proportional hazards analysis, multivariate comparison of survival was conducted. As predicted, [emphasis added] patients in the Intervention arm were found to have a reduced risk of breast cancer recurrence (hazards ratio [HR] of 0.55; P 5.034) and death from breast cancer (HR of 0.44; P 5.016) compared with patients in the Assessment only arm. Follow-up analyses also demonstrated that Intervention patients had a reduced risk of death from all causes (HR of 0.51; P 5.028).
CONCLUSIONS. Psychologic interventions as delivered and studied here can improve survival. 
Andersen et al, Cancer 2008;113:3450–8.
What does the statement mean that as predicted, the support group had a reduced risk of recurrence and death? There was too little evidence on which to predict a positive outcome at the time of the trial’s conception. (In a later interview, the senior author made this contradicting statement: “Nobody was more surprised with the results than we were,” said study lead author … in an interview with Medscape Oncology.” (http://www.medscape.com/viewarticle/583889) How is one to interpret the authors’ conclusions? Despite the fact that realistically, most investigators have an outcome in mind, such a prediction (as expected) is a bit odd.
Nevertheless, let us assume that bias did not affect patient assignment or affect objective outcomes such as recurrence and death. One nevertheless – in order to gain perspective on the results – can examine the raw data.
Each arm of the study contained slightly over 100 subjects. At the median of 11 years recurrences were 33 in the control group, 29 in the support group, a difference of 4; deaths from breast cancer were 19 in the support group, 25 in the controls, a difference of 6. I submit that the difference on both counts (and they are not independent outcomes) was not practically significant. A difference of initial assignment of 1 or 2 cases from the support to the control group would have altered the outcome significantly.
The authors presented the results in a manner that tends to magnify differences. They compared the differences in number of recurrent disease patients rather than relaying the differences between the overall percentage of patients. They concluded that psychosocial support reduced the risk of recurrence by 56 percent, and reduced the risk of death by 45 percent. That is quite a difference, but is similar to a result stated as a risk of death being reduced 50 percent by reducing the number of deaths from 2 to 1.
The graphed results showed 75 treatment subjects free of disease and 65 control patients disease free – a difference of four and six patients in a pool of slightly less than 200 who completed the study – hardly impressive – at least not as impressive as reported.
Furthermore, in the treatment group 10 patients were lost to follow-up, while in the controls 5 were lost. Given the small numbers being dealt with here, the difference leaves yet another potential for an unbalanced result – due to dropouts. Unbalanced dropouts leave unanswered the questions as to why a patient would leave a treatment arm of a study – knowing one had already had “the maximum”? Would one want to seek treatment elsewhere when suspecting a recurrence? The significance of the results seem to diminish with each question.
A side issue is that the authors state in their rationale for doing the trial that stress is associated with increased death rates, so that perhaps reducing stress would modify that trend. But both arms of this study had 5 deaths from other cancers (3) and other causes (2) – evidence against that rationale. But the authors did not comment on it.
The illustrations of the results added to magnification. The two graphs showing recurrence rates and death rates showed only the scale from 65 percent to 100 percent, thus magnifying the visual impression of the differences (e.g., 75 v 65.) The two lines of each graph would have been portrayed much closer together if shown on a scale from 0 to 100 percent. And again, a randomization assignment difference of just one or two subjects in either scale would have made the curves close to identical (a difference of from 4 to 3 or 2.)
The small difference between the two groups should point one toward examining any differences in initial risk factors for recurrence such as receptor status, stage, type, grade, and size, any of which could affect outcome. My first run through showed such minor differences that did not draw attention. However a second look for minor differences showed several that favored the treatment group; more benign cell type and more benign grade. They differed by several percent (2-3.) Receptor status, size were close to equal, and node status ( 2 v 3) favored the controls. None varied more than for about 2-4 subjects, but the differences in grade and cell type characteristics could well have explained part of the difference in outcomes.
The authors presented the current status of the question (effect of psychosocial support on cancer progression) as conflicted in the literature. In fact, once the various reports were evaluated for quality one could not conclude efficacy. The first two studies purporting to show positive effects of psychological support on breast cancer (Spiegel et al, Lancet 1989, Fawzy et al, Ann Psychiat 1995) were analyzed and found to have shared problems of abnormal control groups, retrospective analysis, and small numbers (Fox BH, A hypothesis about Spiegel et al.’s 1989 paper on Psychosocial intervention and breast cancer survival. Psychooncology. 1998 Sep-Oct;7(5):361-70. Sampson W, Errors in Alternative Medicine Literature. (Abst) Proc. AAAS 1997; Sampson W, Cancer and the Mind… Seminars in Oncology (Suppl), Dec 2002.)
In their discussion, the authors speculated on mechanisms for their positive findings, but did not explore the above artifacts, nor other explanations of chance findings. They speculated about peripheral possibilities for which little to no significant evidence exists – immune function, cytokine secretions, and other speculative intermediate mechanisms. That is as much as I could glean from the actual report. Others may see more in it, or may disagree. But the story goes on.
A Reuters dispatch on the report played up the quoted survival difference, as follows:- Psychological group therapy for women with breast cancer may help them not only to cope better with their disease but also live longer… The idea that such therapy can extend survival in cancer patients has been controversial for two decades. Past studies have yielded conflicting results.
… After 11 years, the women who participated in the group therapy were 56 percent less likely to die of breast cancer and 45 percent less likely to have their cancer return, the researchers wrote in the journal Cancer. “– and that’s a huge health outcome,” [the author] who helped lead the therapy groups, said in a telephone interview. By repeating the magnified 5 and 56 percent presentation, Thus the reporter leads a casual reader to believe there is a highly significant effect of psychology support on cancer recurrence and survival.
Medscape offered a summary for continuing medical education with highlights, author quotes, and the following conclusions:
For cancer patients, studies have shown that stress-related psychosocial factors have led to higher cancer incidence in initially healthy people, poorer survival in patients diagnosed with cancer, and higher cancer mortality rates. Psychologic interventions demonstrated a reduction in the risk for breast cancer recurrence, death, and risk for death from all causes.
Offered for continuing medical education (CME,) the article had no reference to the analyses of the subject of stress and cancer by James Coyne PhD of Columbia University, who analyzed the claims and found them nearly baseless, nor was there reference to the fact that the literature on psych support on cancer survival is not just conflicted; the positive evidence is flawed, and the major initial positive studies were repeated several times with negative results (Coyne JC, Palmer SC. Does Psychotherapy extend survival? Some methodological problems overlooked. J Clin Oncol. 2007 Oct 20;25(30):4852-3; )
Failure of replication is evidence of disproof. Unless rules of science have been changed…
Neither the Reuters nor the Medscape report included the statement by Michael Stefanek, PhD, spokesman for the American Cancer Society, which co-funded the study: “We should not conclude that psychological interventions increase survival among women with early stage breast cancer. The results were quite modest, […] and may well have been due to small differences in medical attention received between the groups […].
Our reasons may differ, but the conclusion is the same.

   More Breast Cancer Awareness Month pseudoscience from (who else?) Joe Mercola
David Gorski 
Link
I have mixed emotions regarding Breast Cancer Awareness Month. On the one hand, I look forward to it because it provides us with a pretext to get out science-based messages about breast cancer and to highlight a lot of the cool science that we do at our cancer center. On the other hand, the quacks see an opportunity in Breast Cancer Awareness Month to spread their message too. That message, not surprisingly, generally involves attacking science-based modalities for the detection and treatment of breast cancer and promoting their “alternative” methods. For example, last year, Christiane Northrup promoted thermography as somehow being better than mammography for the early detection of breast cancer. It’s not. Yet there she is this year again, still promoting the same nonsense. In years past, I’ve seen people like Dennis Byrne promoting a link between abortion and breast cancer, a link that is not supported by science. I’ve seen the likes of Mike Adams claiming that Breast Cancer Awareness Month is nothing more than a conspiracy by the male-dominated “cancer industry” to keep women down and misinformation about “myths” of breast cancer while likening the “cancer industry” to Nazi extermination camp commanders and chemotherapy to Zyklon-B. I kid you not about that last part. Indeed, during October, I frequently get to look forward to images like this one (click for a larger image):
Link
Or this one:
Link
You get the idea.
This year, things have struck me as being unusually quiet on the Breast Cancer Awareness Month-related quackery front. That’s not to say that there hasn’t been anything. It’s just that it seems to have started later in the month (usually the Adamses of the world are chomping at the bit and start their barrage right around October 1) and been somewhat lacking in the sheer—shall we say?—looniness of past years. Sure, it’s possible that I haven’t been looking in the “right” (if you can call them that) places. There is still a week left in the month; I’ll try harder. In the meantime, leave it to Dr. Joe Mercola to provide me with a couple of examples.
For example, just yesterday Mercola dropped this blob of misinformation entitled The Cancer Time Bomb Sitting in Your Refrigerator – Will You Stop Consuming It? Its message can be boiled down to: “Recombinant bovine growth factor in milk causes breast cancer.” The article begins:
There is one food you may be surprised to learn, that is directly linked to breast cancer—and that is pasteurized dairy in the form of milk or milk products.
The risk lies in consuming milk from cows treated with a synthetic, genetically engineered growth hormone called rBGH, and unfortunately, this applies to about one third of the dairy cows in America.
When you consume dairy products from these cows, every product made from their milk is contaminated with this dangerous hormone—be it cheese, ice cream, yogurt, butter—or just plain milk.
Cows are injected with rBGH to boost their milk production.
To back up this contention, he included an interview with Dr. Shiv Chopra, a man who trained as a veterinarian in Punjab and then later emigrated to Canada, where he received a PhD in Microbiology from McGill University. Outside the quack world, he is known for a whistleblowing incident and claimed that he had been pressured to approve animal drugs of questionable safety. Since then, he appears to have drifted further and further into dubious medicine, including anti-vaccine views (Chopra has even said that “no flu vaccine has ever worked”) and crankery about genetically modified foods (GMOs). His bête noire appears to be—you guessed it—bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST). Here is the interview:
Link
BGH is a peptide hormone that is produced using recombinant DNA techniques. It is used by farmers to increase milk yield by cows, which it can do by as much as 10%, and it has been fairly controversial. According to Wikipedia, the U.S. is the only developed country that allows human consumption of milk from cows injected with rBGH. I’m not going to comment whether in general it is a good or a bad idea to be using rBGH to increase milk production or what other health effects on those who consume the milk might be. It’s generally agreed that rBGH is associated with a number of health problems in cows, including infertility, lameness, hoof disorders, and shortened lifespan, according to a review and meta-analysis in the Canadian Journal of Veterinary Research, although most of the relative risks are relatively small. It’s also known that rBGH is associated with an increase in clinical mastitis, but it is not clear whether this is a direct effect of the hormone or an indirect effect of increased milk production due to the hormone.
So what about breast cancer? Hold on for just a little bit longer. I’m getting to it. According to Mercola and Chopra:
IGF-1 is a potent hormone that acts on your pituitary gland to induce powerful metabolic and endocrine effects, including cell growth and replication. Elevated IGF-1 levels are associated with breast and other cancers. When cows are injected with rBGH, their levels of IGF-1 increase up to 20-fold, and this IGF-1 is excreted in the milk.
According to some confidential, unpublished industry studies, IGF-1 levels consistently elevate by 25 to 70 percent in rBGH milk. In reality, it is probably worse than that, since standard calculation techniques used by the dairy industry underestimate IGF-1 levels by a factor of four.
In one study, a six-fold increase in IGF-1 levels in milk were found as early as seven days following rBGH treatment.
IGF-1 stands for “insulin-like growth factor-1,” which is a peptide hormone that’s been much studied in relation to cancer. Indeed, if you search PubMed for “IGF-1 and breast cancer,” the search returns 1,375 references, in part because IGF-1 plays an important role in mammary development but, more importantly, because IGF-1 and the IGF system are promising targets for therapy in breast cancer; i.e., blocking IGF-1 signaling could well be an effective treatment. So how does this translate to the basic message of this article, which is a claim that milk from rBGH-treated cows causes breast cancer? This is how Mercola and Chopra make the link:
Only one of every 10 breast cancer cases is attributed to genetics—the other nine are triggered by environmental factors, some of which are dietary. The fact that increased IGF-1 levels in hormone-treated milk increase your risk for breast, colon, and prostate cancers as has been documented in about 50 scientific publications over the past three decades. Among them is the 1998 Harvard Nurses Health study, which showed that premenopausal women with elevated IGF-1 levels had up to a seven-fold increase in breast cancer. And women younger than age 35 who have elevated IGF-1 have more aggressive breast cancer.
The very first sentence of the paragraph above is full of so much wrong that it’s hard not to chuckle. The wrong is the assumption that because only one in ten breast cancer cases can be attributed to clearly defined genetic causes then that must mean that all of the rest must be triggered by environment. In a word: No. The genetics of breast cancer are complex and multifactorial, and many breast cancers are due to spontaneous mutations in key genes. With the exception of certain well-known genetic mutations, such as in BRCA1 or BRCA2, the division between “genetic” causes of breast cancer and other causes is not so clear cut. As for associations between elevated IGF-1 levels and cancer, they are just that: Associations. Correlations. The observation that elevated levels of IGF-1 appear to be correlated with some cancers does not mean that consuming IGF-1 causes cancer. After all, many cancer cells themselves make IGF-1. Indeed, a review from several years back concluded that “circulating concentrations of IGF-I and IGFBP-3 are associated with an increased risk of common cancers, but associations are modest and vary between sites.”
Here’s another hole in Chopra and Mercola’s “theory,” milk consumption from cows not treated with rBGH has been shown to increase IGF-1 levels, as a meta-analysis from two years ago found. Most of the studies evaluated in the meta-analysis were not from the U.S.; in fact one of them included children from Mongolia and the U.S. The authors point out that milk naturally contains IGF-1. Also remember that IGF-1 is a protein. In general, proteins are not well-absorbed; in general they are broken down to their constituent amino acids or to di- or tri-peptides, which is how they are absorbed by the intestinal tract. The authors also point out:
In addition to a direct effect of milk-borne IGF-I, the observed association may reflect increasing protein or total energy intake. Studies showed that protein-energy malnutrition decreased IGF-I levels. The IGF-I level was increased in response to improvements of both protein and energy intake during re-feeding (Crace et al. 1991; Zamboni et al. 1996). Indeed, of these cross-sectional studies we identified, eight studies reported that protein, especially animal protein intake, was positively correlated with circulating IGF-I levels (Giovannucci et al. 2003; Holmes et al. 2002; Hoppe et al. 2004a; Colangelo et al. 2005; Larsson et al. 2005; Rogers et al. 2006; McGreevy et al. 2007; Norat et al. 2007). Of note, one study indicated that milk consumption was no longer a significant predictor when protein was adjusted (Giovannucci et al. 2003). Thus, the possibility of protein intake as an intermediate of milk consumption and IGF-I level cannot be excluded. It is likely that milk, as an important resource of protein for humans, provides some specific essential amino acids that are the most important nutrient determinants of IGF-I (Takenaka et al. 2000). In addition to protein, calcium— another important nutrient in milk—was considered a component stimulating the IGF-I level (Rosen 2003). In five cross-sectional studies reporting that milk consumption was positively associated with IGF-I, calcium also showed a positive correlation with the IGF-I level (Ma et al. 2001; Holmes et al. 2002; Colangelo et al. 2005; Budek et al. 2007; Norat et al. 2007). Therefore, milk-borne IGF-I, protein and calcium in milk may be responsible for the increase of circulating IGF-I level in milk consumers.
In other words, whatever health problems might or might not be attributable to the consumption of milk from cows treated with rBGH, breast cancer is not one of them. There’s no evidence that the IGF-1 in milk is a major source of elevated IGF-1 in humans; indeed, it’s probably not even absorbed in sufficient amounts to make a difference. Any elevation of IGF-1 due to milk that has been reported appears to be due to the milk itself, or milk consumption is a marker for more protein consumption, which is the real cause of elevated IGF-1 levels in the serum. Finally, it’s not even clear whether IGF-1 is a biomarker that correlates with other risk factors associated with breast cancer or whether it is in any way causative. to put it bluntly, the quacks, as usual, have extrapolated far beyond what available data show. Indeed, in animal models, elevated rBGH doesn’t even correlate with mammary carcinogenesis.
Oh, no! Aluminum is deadly!
So, let’s see. If we are to believe Mercola, milk, particularly milk from cows who received the dreaded rBGH, is deadly and will give you breast cancer; that is, of course, unless it’s raw milk, which if you believe Mercola and his ilk is a nutritional panacea. But it turns out that milk isn’t the only deadly threat that will cause breast cancer on Planet Quack. Mercola asks: Are Aluminum-Containing Antiperspirants Contributing To Breast Cancer In Women? The answer: Almost certainly not, although Mercola tries his damnedest to dance around the evidence to demonstrate that it is a horrific risk factor for breast cancer. Specifically, it’s supposed to be the aluminum:
Research, including one study published this year in the Journal of Applied Toxicology, has shown that the aluminum is not only absorbed by your body, but is deposited in your breast tissue and even can be found in nipple aspirate fluid a fluid present in the breast duct tree that mirrors the microenvironment in your breast. Researchers determined that the mean level of aluminum in nipple aspirate fluid was significantly higher in breast cancer-affected women compared to healthy women, which may suggest a role for raised levels of aluminum as a biomarker for identification of women at higher risk of developing breast cancer.
The report discussed is a small pilot study of 35 patients, 16 with breast cancer and 19 with no cancer. While the results are somewhat provocative, it is important to remember that (1) the study is small and (2) the significance of the results are unknown. More importantly, there were a lot of confounding factors not controlled for. For example, presumably both women with breast cancer and those without in the study there was no serious attempt to control for confounding factors or to quantify the use of aluminum antiperspirants. Indeed, there are significant differences between the two groups. For example, the median age of the cancer group was 56, while it was 40 for the no cancer group. Perhaps something as simple as age could account for the difference. Does something happen after menopause leading to increased accumulation of aluminum from the natural exposure that we all have? Who knows? No analysis was done. Another possibility is that breast cancer might somehow accumulate aluminum more than normal tissue.
In other words, the study tells us absolutely nothing about whether or not aluminum-containing antiperspirants contribute to breast cancer risk.
Mercola’s next red herring is this:
In a 2007 study published in the Journal of Inorganic Biochemistry, researchers tested breast samples from 17 breast-cancer patients who had undergone mastectomies. The women who used antiperspirants had deposits of aluminum in their outer breast tissue. Concentrations of aluminum were higher in the tissue closest to the underarm than in the central breast.
Why is this a glaring red flag?
Aluminum is not normally found in the human body, so this study was a pretty clear sign that the metal was being absorbed from antiperspirant sprays and roll-ons. Please note that aluminum is typically only found in antiperspirants. If you are using a deodorant-only product it is unlikely to contain aluminum but might contain other chemicals that could be a concern.
Aluminum is not normally found in the human body? Did Mercola even read the previous article he cited? That article in and of itself demonstrated that aluminum is found in measurable quantities in normal human breast tissue nipple aspirates. Its finding was simply that it was found at higher levels in breasts with cancer. Come to think of it, did he even bother to read the study he just cited? It showed detectable levels of aluminum in normal breast tissue, too!
In any case, the claim that aluminum antiperspirants cause breast cancer is a classic case of confusing correlation with causation. The argument you will frequently see made is that most breast cancers occur in the upper outer quadrant of the breast. Because that quadrant of the breast is closest to the underarm, which is where antiperspirants are used, it must be the antiperspirants! And global warming is most definitely due to the decreasing number of pirates over the last three centuries. In fact, about half of all breast cancers develop in the upper outer quadrant of the breast, but it’s not because of antiperspirant use; it’s just because of a very simple thing. There is more breast tissue there than in other quadrants of the breast, and the number of breast cancers diagnosed there is proportional to the amount of breast tissue. Moreover, there is good evidence that there is no correlation between the use of antiperspirants and breast cancer. At the most, we can say that there might be such a link, but a fair assessment of the evidence suggests that such a link is unlikely.
And all the rest
Now that I’ve dealt with the two relatively serious claims regarding breast cancer and various environmental factors, let’s conclude by moving on to the fun stuff. also in the second article are some real howlers. For example:
In his 1975 article, Chinese Lessons For Modern Chiropractors, Dr. George Goodheart – known as “the father of Applied Kinesiology” — explained what he calls the “Antenna Effect.” Essentially, he discovered that by taping a small metal ball over an acupuncture point, you could achieve longer-term stimulation to that point in question. This discovery led to what are now known as AcuAids — small magnetic patches that are used by thousands of doctors across the world.
However, just like a small metal ball, any metal constantly applied to any given energy channel or point on your body can have the same stimulating effect. Over time, the continued stimulation can cause a subsequent decrease in function of important neuro-lymphatic reflex points located below your breasts.
In addition, the metal wire may act as an antenna attracting electromagnetic fields, which may also increase your risk of breast cancer. Fortunately, you can easily remove the piece of metal wire and replace it with a plastic rod of comparable size, which will provide the support but not simulate the antenna effect.
Yes, that’s right. Don’t wear those underwire bras, ladies. They concentrate electromagnetic radiation around the breasts. This is, of course, utterly ridiculous; the magnitude of such fields is minimal and the likelihood that they have any effect whatsoever on the risk of breast cancer even less. I would point out that advice from someone whose claim to fame is to be the “father of applied kinesiology,” a particularly silly form of quackery is likely to be as based in science as applied kinesiology is; i.e., not at all.
Much of the rest of the article includes typical misinformation about mammography, including exaggerated fears about the radiation. I’ve discussed such issues before many, many times before; so I refer you to various links. Suffice it to say: Mercola, as usual, doesn’t know what he’s talking about.
Breast Cancer Awareness Month is the proverbial two-edged sword. On the one hand, those of us in the field can take advantage of the event to highlight issues of breast cancer and breast health and try to call attention to new science and new discoveries about breast cancer. On the other hand, we have promoters of pseudoscience like Mike Adams and Joe Mercola to contend with. Given that there’s still a week left in the month, I have to wonder what, if anything, they’ll come up with next. Whatever it is, you can be sure it won’t be based on science.

Angelina Jolie, radical strategies for cancer prevention, and genetics denialism
David Gorski on May 20, 2013
Link
I had been debating whether to blog about Angelina Jolie’s announcement last week in a New York Times editorial entitled My Medical Choice that she had undergone bilateral prophylactic mastectomy because she had been discovered to have a mutation in the BRCA1 gene that is associated with a very high risk of breast cancer. On the one hand, it is my area of expertise and was a big news story. On the other hand, it’s been nearly a week since she announced her decision, and the news story is no longer as topical as it was. Also, I’ve already written about it a couple of times on my not-so-super-secret other blog, making the division of blogging…problematic. So, if some of this is a bit repetitive to those who are also fans of my more—shall we say?—insolent persona, I apologize, but try to be patient. I will be doing more than just rehashing a couple of posts from last week (although there will unavoidably be at least a little of that), because there have been even more examples of reactions to Jolie’s announcement that provide what I like to consider “teachable moments.” I will start by asserting quite bluntly that in my medical opinion, from the information I have available, Angelina Jolie made a rational, science-based decision. How she went about the actual mechanics might have had some less than scientific glitches along the way (more about that later), but the basic decision to remove both of her breasts to prevent breast cancer associated with a BRCA1 mutation that she carried was quite reasonable and very defensible from a scientific standpoint.
One advantage of waiting nearly a week to write about this story is that it provided me with the opportunity to sit back and observe the reactions that Jolie’s decision provoked. One thing that I really didn’t expect (although in retrospect maybe I should have) is the pure denialism on display that genes have any effect whatsoever on cancer. I say “in retrospect I should have” because I’ve written at least a couple of times before about how quacks use and abuse the term “epigenetics” in the same way that they abuse the word “quantum” and how they seem to believe that wishing makes it so (through epigenetics, of course!) to the point where they believe that genetics is irrelevant to cancer. Indeed, they go far beyond that, asserting that, in essence, environment is all. From what I’ve been reading thus far, the second strongest strain of reaction to Jolie’s announcement (after revulsion at the “mutilation” of women that it represented to certain quacks) is pure denial that mutations in BRCA1 and BRCA2 genes portend such a high risk of ultimately developing breast cancer. This denial is often accompanied by conspiracy mongering about BRCA1 and BRCA2 mutations being a “conspiracy” on the part of the “cancer industry” and Myriad Genetics & Laboratories, the company that holds the patents on BRCA1 and BRCA2, to increase genetic testing and preventative mastectomies. Myriad happens to have a complete monopoly on BRCA1 and BRCA2 testing because of this patent and has been criticized for its high prices and stifling of competition. There is currently a case before the U.S. Supreme Court regarding whether human genes are patentable under the law. I’m not a big fan of Myriad, and I’ll tell you why later. (Not that it matters; I’m stuck with them for now.) My personal distaste for Myriad Genetics aside, this sort of conspiracy mongering is part and parcel of the quack approach to denying the significance of BRCA1 mutations.
This denial is usually coupled with confident blather that Angelina Jolie didn’t need to undergo “disfiguring” surgery to prevent BRCA1-associated breast cancer but instead could have achieved the same—or even better!—risk reduction if only she had used this magic herb or that miracle supplement and making certain “lifestyle” changes. It’s utter nonsense, of course, but it’s everywhere.
Before I get to the reactions to Jolie’s announcement, let’s first take a look at what she did, why, and the science behind it.
BRCA mutations, Angelina Jolie’s cancer risk, and preventative surgery
On May 14, in the NYT editorial page, after recounting how her mother had battled breast cancer for nearly a decade only to succumb to it at age 56, Angelina Jolie described trying to reassure her children that she wouldn’t die the same way, announcing:
We often speak of “Mommy’s mommy,” and I find myself trying to explain the illness that took her away from us. They have asked if the same could happen to me. I have always told them not to worry, but the truth is I carry a “faulty” gene, BRCA1, which sharply increases my risk of developing breast cancer and ovarian cancer.
My doctors estimated that I had an 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer, although the risk is different in the case of each woman.
Only a fraction of breast cancers result from an inherited gene mutation. Those with a defect in BRCA1 have a 65 percent risk of getting it, on average.
Once I knew that this was my reality, I decided to be proactive and to minimize the risk as much I could. I made a decision to have a preventive double mastectomy. I started with the breasts, as my risk of breast cancer is higher than my risk of ovarian cancer, and the surgery is more complex.
BRCA1 and BRCA2 are genes in which certain mutations are most commonly associated with either breast or ovarian cancer, although they are also associated less strongly with several other cancers as well, such as cervical cancer, uterine cancer, pancreatic cancer, early onset prostate cancer (men) and colon cancer (BRCA1) or pancreatic cancer, stomach cancer, gallbladder and bile duct cancer, and melanoma (BRCA2). BRCA1 codes for a protein known as breast cancer type 1 susceptibility protein, a protein belonging to the RING-type zinc finger (RNF) family whose function involves repairing damaged DNA. Specifically, it repairs double-stranded breaks. In the nucleus of a variety of normal cells, the BRCA1 protein interacts with other proteins, such as RAD51 and BARD1, to repair double stranded breaks resulting from radiation and other environmental exposures, as well as breaks that occur during natural processes, such as homologous recombination. The BRCA1 protein is important in multiple functions, including transcription (conversion of the DNA sequence to RNA message), repair of double-stranded DNA breaks, ubiquitination, and other functions. If BRCA1 can’t repair the break, it then promotes cell cycle arrest and apoptosis (programmed cell death). The result of defects in BRCA1 function is increased sensitivity to anything that causes DNA damage and an increased risk of the development of cancer. BRCA2 encodes a protein that, while very different in structure from BRCA1, serves a similar function, namely the repair of double-stranded DNA breaks.
Mutations in BRCA1 and BRCA2 are associated with familial cancer syndromes, most commonly involving breast and ovarian cancer, but not limited to these cancers. Moreover, it needs to be understood that BRCA mutations are not binary. You do not either “have the mutation” or not. There are many mutations, some of which confer high risk of cancer, others of which confer increased risk but not nearly as high, and some of which whose significance is unknown. In other words, BRCA mutations produce a spectrum of increased risk, ranging from the 87% lifetime risk of breast cancer cited by Angelina Jolie based on the mutation she has to unknown significance (and possibly not even any increased risk of breast cancer). The same is true of BRCA2 mutations, although the maximal risk for breast cancer even the worst mutations in BRCA2 produce are not as high as the maximal risk from BRCA1 mutations. In any case, a good genetic counselor will go through these risks and explain the significance of the dozens of mutations that are known. Either that, or quacks will seize upon various BRCA mutations of either unknown significance or that produce only mildly elevated risk, as though these were the mutations for which doctors recommend preventative surgery. This complexity is why I’m a firm believer that genetic testing for BRCA mutations should usually not be done outside of a center with either skilled genetic counselors or a physician trained in genetic counseling who can explain the risk and help the patient weigh the pros and cons of genetic testing and, if that testing is positive, the various surveillance and preventative strategies available for women carrying BRCA mutations. Also very important is to weigh the ethical and practical issues of genetic testing, such as whether a mutation carrier should inform her family, what effects that it might have on her ability to obtain health insurance, and the many other issues that are inextricably bound with genetic testing, not the least of which is affordability.
In other words, recommendations should be personalized by practitioners using science-based practice. (I know. I couldn’t resist.) It should also be remembered that in the US, BRCA mutations account for only a small minority of cases of early onset breast cancer (2-3%) and ovarian cancer (8%), a proportion that can vary widely based on geography and ethnicity. To put it another way, approximately 25% of women with a breast cancer diagnosis are younger than 50 years, and almost 10% of these women will have a BRCA mutation So, while there is a point to be made that most breast cancers are not associated with BRCA mutations, for carriers of mutations with a high risk of breast or ovarian cancer the mutation is already there, and the risk is already there. The point no longer applies.
All of this leads to recommendations regarding who should be screened. At my cancer center and many others, we use the recommendations of the National Comprehensive Cancer Network (NCCN) guidelines (summarized here). These include:
    • A personal history of breast cancer at age 50 or younger
    • A personal history of triple negative breast cancer (breast cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2/neu receptor-negative)
    • A personal or family history of male breast cancer
    • A personal or family history of bilateral breast cancer (cancer in both breasts)
    • A personal history of ovarian cancer
    • A parent, sibling, child, grandparent, grandchild, uncle, aunt, nephew, niece or first cousin diagnosed with breast cancer at age 45 or younger
    • A mother, sister, daughter, grandmother, granddaughter, aunt, niece or first cousin diagnosed with ovarian cancer
    • A family history of both breast and ovarian cancers on the same side of the family (either mother’s or father’s side of the family)
    • Ashkenazi Jewish heritage and a family history of breast or ovarian cancer
Indeed, there is even a little BRCA mutation carrier risk calculator that can be used to estimate a patient’s risk of being a mutation carrier based on family and personal history.
In the end, although Angelina Jolie tells us that she is a BRCA1 mutation carrier, she does not tell us which specific mutation she carriers. She does tell us that her doctors told her that the specific mutation conferred upon her an 87% lifetime risk of developing breast cancer and a 50% lifetime risk of ovarian cancer. As a result, she decided to undergo a prophylactic bilateral mastectomy with immediate reconstruction and apparently will undergo bilateral oophorectomy (removal of her ovaries) later, her rationale being that her risk of breast cancer is higher and her breast surgery was “more complex.” It’s not an unreasonable rationale for prioritizing preventative surgery that way.
What Angelina Jolie did
Conceptually, what Angelina Jolie decided to do was simple, but the actual mechanics of carrying it out was complex. Basically, to put it bluntly, she decided to have both of her breasts removed. That’s the big picture, the basic decision. However, there is often a lot more to bilateral mastectomy than just removing the breasts, particularly when one factors in the options for reconstruction. A woman like Angelina Jolie is exceedingly unlikely to have a bilateral mastectomy without some form of immediate reconstruction, given her career. Some women choose the option of no reconstruction, however, and their choice must be respected.
Jolie decided to have her breast surgery done through a clinic that I’ve heard of before, the Pink Lotus Breast Center, which advertises itself thusly:
The Pink Lotus Breast Center is a comprehensive and integrative breast center exclusively dedicated to the prevention, screening, diagnosis and treatment of breast cancer.
Expedited scheduling; quick answers; less stress; top doctors; female-run; not hospital-owned; no facility fees; and a single location for all of your needs. Just a few of the many reasons why PLBC’s integrative approach to breast care is unsurpassed and puts each patient first, every single time!
If you think this doesn’t sound promising, you’re correct to a point. Pink Lotus first came to my knowledge when Sheryl Crow had her breast cancer treated there by partial mastectomy (colloquially called “lumpectomy”). She now has an imaging center at Pink Lotus named after her, and Pink Lotus advertises “screening ultrasound” for women with dense breasts, even though there is no good evidence to support such a practice. Apparently, Shannon Tweed was also treated there. Unfortunately, Pink Lotus is not above using these celebrities rather shamelessly to promote itself, as a quick perusal of its website will show, including Sheryl Crow’s Ultimate Breast Cancer Prevention Guide, which is chock full of questionable recommendations and overblown assertions, including recommendations to drink lots of green tea for breast cancer prevention.
The Pink Lotus Breast Center also features a detailed description of the treatment Angelina Jolie underwent written by her surgeon Dr. Kristi Funk, whose credentials appear quite impressive (although I must admit that I couldn’t find any publications on breast cancer by her on PubMed, although it is certainly possible that they were published under her maiden name, which I do not know). Unfortunately, she is also enamored of “integrative medicine.” Angelina Jolie appears to have undergone a mixture of the science-based (bilateral prophylactic mastectomy for risk reduction due to BRCA1 mutations) tinged with pure pseudoscience, like recommending homeopathic remedies such as Arnica Forte (which consists of Arnica Montana 30x, Bromelain, Antioxidants, Bioflavonoids) as a means of decreasing bruising during surgery, plus Exchem and Lymphomyosot (“to help eliminate anesthesia from the system”). Yes, I’m referring to “detox,” which is the purpose for which Lymphomysot is advertised.
From a strictly surgical point of view, three aspects of Jolie’s care caught my eye. First, she chose implants for reconstruction rather than tissue flaps. Next, of course, was the “nipple delay,” in which the tissue underlying the nipple is cut in order to “improve the blood flow.” At the time this tissue is cut, a biopsy is taken of the ductal tissue underlying the nipple in order to rule out cancer. The idea is that the nipple delay procedure cuts the normal blood supply to the nipple three weeks ahead of time and thus “forces” the nipple to rely on the surrounding skin for its blood supply, thus making the chance of nipple necrosis (in which the nipple turns black and falls off due to low blood flow) much less likely. It’s a procedure usually reserved only for patients who have had previous breast surgery around the nipple. Not having looked into the scientific literature on the procedure for a long time, I decided to do a bit of searching in PubMed to see if I could find more science-based information about it. In reality, there is little or no evidence that nipple delay is useful as a routine procedure in women of average risk of nipple loss after nipple-sparing mastectomy; its use is generally indicated only in women thought to be at a high risk for nipple loss due to previous surgery in the area, as summarized in this study by noted breast surgeon Armando Giuliano, which concluded that “surgical delay of the nipple areolar complex 7–21 days before nipple-sparing mastectomy allows safe preservation of the nipple–areolar complex in patients who generally would not be considered candidates for nipple-sparing mastectomy.” Now maybe Angelina Jolie had previous surgery in the area of the nipple-areolar complex. We know she didn’t have ptotic breasts. On the other hand, Angelina Jolie was a smoker, and there are lots of reports that she still is a smoker. That is definitely a risk factor for wound complications after breast surgery, thanks to decreased blood flow. So maybe that’s the reason why she was offered a nipple delay, although that alone doesn’t seem like enough.
Finally, more questionable is the use of a procedure known as prophylactic dye injection. During breast cancer surgery, we do a procedure known as sentinel lymph node (SLN) biopsy, which involves injecting (usually) two kinds of dye before surgery: A short-lived radiotracer and a blue dye, both of which are taken up by the lymphatics and head to the first draining lymph node (or lymph nodes) under the arm, known as the axillary lymph nodes. These nodes are removed and checked for cancer. In the old days (about 12 to 15 years ago), we used to remove all the lymph nodes under the arm in a procedure known as axillary dissection. These days, we get the same information (whether the axillary lymph nodes are involved or not) with much less morbidity using the sentinel lymph node procedure. When we do prophylactic mastectomies, however, we don’t know if there’s cancer there. There probably isn’t, although there might be. Consequently, we usually do sentinel lymph node biopsies, in case there is cancer in one of the breasts, because once the breast is gone we can no longer do that procedure, and SLN biopsy is pretty low risk. However, that is not acceptable at Pink Lotus, or so it would appear:
Whenever a breast contains cancer and the armpit lymph nodes cannot be felt on exam, we routinely perform a sentinel node biopsy, which is the removal of the first nodes that receive breast lymphatic drainage. By injecting blue dye into the breast, which then travels to the lymph node(s), we find out if cancer spread beyond the breast. Until now, the trend has been not to perform sentinel node biopsies in conjunction with prophylactic (preventive) mastectomies since the discovery of cancer in breasts removed prophylactically only ranges from 2-8%. Therefore, most women do not want to take the additional risks associated with a sentinel node biopsy, especially since they can have complications, such as pain, numbness, arm swelling (lymphedema), fluid buildup (seroma), limited arm movement, and infection. This dilemma has been resolved with a new technique that was pioneered at the Pink Lotus Breast Center, called Prophylactic Breast Dye Injection, or PBDI. PBDI allows the sentinel node to be identified, but not surgically removed, giving more control and peace of mind to women. I developed this technique while treating Angelina, and I hope other women will now benefit from it. It was at her friendly insistence that I wrote the rationale for it in our blog post, Prophylactic Breast Dye Injection.
If you peruse the rationale published by Dr. Funk, you’ll find that she invented this procedure in February 2013. I’ll actually give Dr. Funk credit. PBDI is actually not a bad idea. In fact, in concept, it’s a pretty good idea. However, by Dr. Funk’s own admission, it’s also a new idea thought up by her while treating Jolie that is completely unproven. (One wonders whether Jolie balked at bilateral SLN biopsy.) Hence, from my perspective it is irresponsible to promote PBDI in the context of Angelina Jolie’s surgery given that, also by Dr. Funk’s own admission, there is no evidence for the superiority (or even non-inferiority) of the procedure compared to standard sentinel lymph node biopsy. She even includes a disclaimer:
Disclaimer: We at the Pink Lotus Breast Center have started using the PBDI technique very recently. It is currently unknown which factors influence the precise length of time that the dye remains in the sentinel nodes. Further studies in that regard are needed.
In that case, Dr. Funk and colleagues should be doing preclinical trials in animals and clinical trials in humans to answer the question of what factors determine how long the dye persists in the sentinel nodes and why, not offering this procedure to, in essence, any woman undergoing prophylactic mastectomy.
Still, Angelina Jolie did undergo an appropriate procedure (overall) after finding out that she carried a dangerous BRCA1 mutation, and I can’t criticize her for that. Having done so, according to a recently published model, she has significantly decreased her risk of dying before age 70. For example, a typical 25 year old woman has an 84% chance of living to be 70. Of those not surviving, 11% die of breast or ovarian cancer, the rest of other causes. However, a 25 year old woman with a BRCA1 mutation who undergoes no screening or preventative treatment has only a 53% chance of living to be 70. 77% of the women with BRCA1 mutations who die before 70 die from breast or ovarian cancer. The effectiveness of interventions to reduce risk are summarized below (PO = prophylactic oophorectomy; PM = prophylactic mastectomy):
With no intervention, survival probability by age 70 years is 53% for BRCA1 mutation carriers versus 84% for the general US population (Table 2). The most effective single intervention is PO at age 40, yielding a survival probability of 68% by age 70, which represents a 15% absolute gain compared with no intervention (68% v 53%). Delaying PO to age 50 yields half the survival gain provided by PO at age 40 (8%: 61% v 53% with no intervention). In comparison, PM at age 25 yields a 13% gain relative to no intervention, whereas delaying PM to age 40 yields a small (2%) decrement in gain compared with PM at age 25. Breast screening alone from ages 25 to 69 yields the lowest gain (6%).
The most effective combination strategy is PM at age 25 plus PO at age 40, providing a 26% survival gain by age 70 compared with no intervention (79% v 53%). Postponing PM until age 40, in the presence of screening from ages 25 to 39 and PO at age 40, reduces survival gain by 2%. Eliminating PM and substituting breast screening from ages 25 to 69 while performing PO at age 40 reduces survival gain by an incremental 3%. When added to PO at age 40, breast screening offers 5% lower survival probability than does PM at age 25 (74% v 79%) and 3% lower survival probability than does PM at age 40 (74% v 77%). If PO is delayed until age 50, breast screening offers 5% lower survival probability than PM at age 40 (69% v 74%). Results by age 80 are similar (Table 2). Figure 1A presents survival probability, and Figure 2A presents distribution of health status by age 70 years in BRCA1 mutation carriers under various intervention scenarios.
There is copious other literature that prophylactic surgery can greatly decrease the risk of death due to breast or ovarian cancer in BRCA1 and BRCA2 mutation carriers. Indeed, prophylactic surgery tends to be the single most efficacious intervention for this purpose, although intensive screening with MRI and mammography can also be effective for breast cancer mortality reduction. (Unfortunately, there is no good screening test for ovarian cancer, which tends to be deadlier, making this option much less attractive.) It should be noted, however, that surgery is not foolproof and does not reduce the risk of cancer to zero. Mastectomies do not remove every last cell of breast epithelial tissue at risk for cancer, for instance. We as practitioners of science-based medicine must be careful not to oversell the benefits of preventative surgery for cancer.
Unfortunately, cranks have no such qualms about exaggerating the harms and minimizing the benefits of such surgery.
Angelina Jolie and science-based medicine versus genetics denialism
It took less than a day for various quacks to attack Angelina Jolie’s decision, as reasonable and science-based as it was, to undergo prophylactic bilateral mastectomies to prevent breast cancer. First out of the box, as is all too frequently the case when it comes to despicably using and abusing celebrity health stories, was the “Health Ranger” Mike Adams, founder of the NaturalNews.com website. He’s done it before many times, for example about Patrick Swayze’s pancreatic cancer. Then, of course, he worked himself into a fine lather of righteous indignation over Christina Applegate’s “maiming” when she announced that she had undergone bilateral mastectomies for her breast cancer and a BRCA1 mutation. You can tell a lot by Adam’s chosen title, Angelina Jolie inspires women to maim themselves by celebrating medically perverted double mastectomies.
First, you need to take note. The purpose of this article is blatant, and it’s to sell stuff. After Adams has seemingly gotten his readers all fired up over the horror of Jolie’s decision to “maim” herself, the very last section of the article advertises this:
Inform yourself and you can protect your body from the insane, knife-wielding cancer surgeons. Get the New Cancer Solutions CD set and empower yourself with real answers rather than cancer industry disinformation and deadly propaganda.
It comes complete with a video (included in Adams’ despicable article) that has to be seen to be believed, entitled The female anatomy of Modern Medicine. In any case, the CD includes a talk by Adams himself entitled The Consciousness of Cancer, which is billed as a “new way” of looking at cancer. No doubt it is, but also no doubt it is a way that has nothing to do with science. From the title, my guess is that Adams subscribes to something similar to the German New Medicine or Andreas Moritz‘s “wisdom of cancer cells” quackery, in which cancer is represented as a survival mechanism.
Now that that point is out of the way (and it’s arguably the most important point, which is why I skipped to the end of Adams’ screed first), Let’s get a real taste of what Adams thinks, if you can stand it and if you can call it “thinking”:
Angelina Jolie announced yesterday that she had both of her breasts surgically removed even though she had no breast cancer. She carries the BRCA1 gene, and she has been tricked into believing that genetic code is some sort of absolute blueprint to disease expression — which it most certainly is not. Countless millions of women carry the BRCA1 gene and never express breast cancer because they lead healthy, anti-cancer lifestyles based on smart nutrition, exercise, sensible sunlight exposure and avoidance of cancer-causing chemicals.
Jolie, like many other women who have been deluded by cancer quackery, decided the best way to prevent the risk of breast cancer was not to lead a healthy, anti-cancer lifestyle, but rather to surgically remove her breasts in what she describes as “three months of medical procedures.”
…just in case, you know. Because you can never be too careful these days, with the cancer industry scaring women half to death at every opportunity. “My breasts might murder me!” seems to be the slogan of many women these days, all of whom are victims of outrageous cancer industry propaganda and fear mongering.
And later Adams adds:
Oh, what a mess Jolie has made of herself. She has maimed her own body with no medical justification whatsoever, then celebrated this horrible disfiguration through some sort of twisted perception of what womanhood really is. Being an empowered woman doesn’t mean cutting off your breasts and aborting live babies — even though both of these things are often celebrated by delusional women’s groups. Being an empowered woman means protecting your health, your body and your womanhood by honoring and respecting your body, not maiming it.
And, Adams “coup de grace”:
Wonderful? To cut off parts of your body that have NO disease? With this logic, abortions are cancer prevention, too, because those babies might one day grow up and develop tumors. Better to kill them early and “prevent cancer,” right?
One can’t help but note that Adams is indulging in a favorite pastime of quacks every where: Denialism of genetics and wishful thinking that genetics doesn’t rule. Yes, it’s true that in some cases genetics doesn’t rule. If a gene doesn’t have a high penetrance, interacts with other genes, or has an activity that is highly influenced by environment, genetics isn’t always destiny, but in the case of the particular BRCA1 mutation that Jolie reports having, there is an 87% lifetime risk of developing breast cancer. Given that breast cancer is a type of cancer that is not highly lifestyle- and diet-dependent (note, that is not to say that lifestyle and diet have no effect, just that the effect tends to be relatively small), no amount of “anticancer lifestyle, “smart nutrition,” and “avoidance of cancer-causing chemicals” is going to lower that 85% chance of breast cancer by very much, no matter how much Adams’ wishful thinking might try to mislead other women that such interventions can.
Adams then followed up with a post entitledHow Angelina Jolie was duped by cancer doctors into self mutilation for breast cancer she never had:
With her breasts removed, she says her risk of breast cancer is now reduced to a mere 5 percent. The same bizarre logic can also be applied to men who cut off their testicles to “prevent testicular cancer” or people who cut out their colons to “prevent colorectal cancer.” But that would be insane, so nobody does that, because one of the most basic principles of medicine is that you don’t subject patients to the considerable risks and costs of surgery and anesthesia to remove organs that have no disease!
If there existed a gene mutation that conferred a similar risk of testicular cancer as Angelina Jolie’s BRCA1 mutation does for breast cancer, you can be assured that there would be consideration of prophylactic surgery or medication. Also, people do remove their colons to prevent colorectal cancer. Adams is even more ignorant than I thought, apparently never having heard of, for example, familial adenomatous polyposis (FAP). It’s a condition in the colon in which there are numerous polyps that predispose patients with condition to colon cancer such that by age 40 or 50 the risk approaches 100%. The treatment? Prophylactic colectomy. Yes, that’s right, removal of the colon to prevent colorectal cancer. There’s also hereditary non polyposis colorectal cancer (HNPCC), which involves a mutation in a gene with a similar function to that of BRCA1, the gene in which Angelina Jolie had a mutation that predisposed to breast cancer, specifically a gene involved in the repair of DNA damage. The risk from HNPCC isn’t as high as it is for FAP, but it’s plenty high, more than high enough to justify prophylactic surgery to avoid colon cancer.
Sadly, Adams is not alone in his ignorance of oncology. There’s also Sayer Ji, who claimed that vaccines are “transhumanism” that subverts evolution and made one of the most spectacularly clueless arguments against evidence-based medicine I’ve ever seen, dismissing it as a “coin flip.” This time around, Ji’s denying that genes cause cancer, the same way that Adams did, but he tries to put a “science-y” sounding gloss on the statement:
Despite the commonplace refusal of so-called ‘evidence-based medicine’ to acknowledge the actual evidence of genetics, we moved into a Post-Genomic era over a decade ago following the completion of first draft of the entire human genome in 2000. At that moment, the central dogma of molecular biology – that our DNA controls protein expression, and therefore disease risk – was disproved. Our genome was found to contain roughly 20,000 genetic instructions – not even enough to account for the 100,000 proteins in the human body!
As a result, we must now accept that factors beyond the control of the gene, known as epigenetic factors, and largely determined by a combination of nutrition, psychospiritual states that feed back into our physiology, lifestyle factors, and environmental exposures, constitute as high as 95% of what determines any disease risk. In fact, even the psychological trauma associated with being diagnosed with cancer can drive malignancy via adrenaline-mediated multi-drug resistance,[i] and according to a recent NEJM study, lead up to a 26-fold increased risk of heart-related deaths in the seven days following diagnosis.[ii]
Epigenetics. You keep using that word. I do not think that it means what you think it means. Ji also doesn’t seem to understand that through alternative splicing and various other mechanisms, one gene can easily produce multiple different proteins. Not only is Ji ignorant of oncology, but he’s ignorant of biology.
Ji also beats on the straw man that I mentioned at the very beginning of this post, namely the belief that you either “have the gene” or don’t when it comes to BRCA1 and BRCA2. Indeed, he even goes so far as to twist himself in knots when he perseverates over an observation that there is actually a known BRCA2 mutation that has been associated with a lower risk of cancer. So what? The existence of such a mutation is irrelevant to the question of whether Angelina Jolie made the right choice in undergoing bilateral mastectomy.
If you don’t believe me when I say that cranks and quacks completely deny the reality that certain gene mutations are so highly associated with cancer, I can’t resist finishing with some truly ignorant commentary by a man named Richard Schulze, a.k.a., the Herb Doc. First, Schulze denies that BRCA1 is even a problem:
But specifically, with breast cancer, scientists think that they have discovered a gene, they refer to as BRCA1, that is a genetic marker for the potential development of breast cancer. The reason I say “think” is simply because almost all this testing science is proven false or at least faulty a decade or so later, like the AIDS test, or the PSA test for prostate cancer (that has now been proven defective), or giving millions of mammograms to young women whose breast tissue was too dense to see anything, which caused breast cancer and so this practice is now condemned. Regardless of the history of medical testing blunders, many women who test positive for this particular BRCA1 gene are now opting to have their healthy breasts removed, as did Angelina Jolie in February.
And I am telling you right now, that in a decade or two, surgically cutting off healthy breasts because someone tests positive for the BRCA1 gene will be seen as a huge horrific medical mistake.
Maybe so, but only if sometime between now and two decades from now we discover a drug that reduces the risk of breast cancer in BRCA mutation carriers as much as prophylactic surgery does. Even in that case, depending on the safety and efficacy of the drug, it wouldn’t be an unreasonable decision to opt for a one-time surgery over potentially decades of taking a pill every day. Besides, we have to work within the context of the science that we have now. For example, the Halsted radical mastectomy, as “barbaric” as it is perceived now, was not an unscientific or inappropriate treatment 100 years ago. Given that adjuvant chemotherapy and radiation therapy did not exist back then, if a cancer was going to be cured, surgery was the only modality that could cure it. Given that there was no mammographic screening back then, most breast cancers were pretty large by the time they were noticed; so if surgery was the only way to cure breast cancer, then it had to be radical surgery to get all of it. And the radical mastectomy was more efficacious than any other procedure at the time. Surgery’s mistake was to continue to do more radical surgery once evidence beginning in the middle part of the last century started to make it clear that such radical surgery was not necessary. But that’s a minor issue compared to Schulze’s mix of misinformation (HIV denialism, misunderstanding of mammography, and the like) with issues that medical science, not quacks, is already working on correcting. None of this stops Schulze from opining:
All that genetic markers say is that you have the potential to develop a disease, like breast cancer. It simply means that you have genes in your body, that when stimulated, irritated or woken up, can mutate and develop into cancer. Well, what wakes these genes up is no mystery, and ALL medical and cancer researchers know exactly what turns these genes on, but they don’t want to touch this subject, simply because it’s unpopular. What turns these genes on and makes them mutate, is junk food, toxic chemicals, French fries, pharmaceutical drugs… the list is long; it’s the aftermath of the American Dream.
Except that, in the presence of genetic markers as strongly associated with cancer as BRCA1 and BRCA2, there is very little that diet, lifestyle, and the like can do to lower the risk significantly. There is one thing, though, at least in the case of BRCA2-related breast cancers, that is quite effective in lowering risk, but Schulze won’t like it. I’m talking about Tamoxifen, which significantly reduces the risk by as much as 62%. Unfortunately, it’s not as clear whether Tamoxifen is as effective in preventing BRCA1-associated tumors because they tend to be estrogen receptor-negative. Either way, contrary to what Schulze is saying, it’s not diet and lifestyle that can reduce risk in the case of BRCA mutations. It’s either surgery or—gasp!—pharmaceutical drugs.
The bottom line
Celebrity health stories like that of Angelina Jolie are a two-edged sword. On the one hand, Jolie made a perfectly rational, evidence-based choice to undergo prophylactic bilateral mastectomy. I don’t like the center she chose or how that center uses “integrative medicine” and seems a bit too eager to jump the gun on using surgical procedures that haven’t yet been validated in clinical trials, but her overall decision, if you can ignore the mechanics of how she carried out that decision, was sound. As such, her story can raise awareness and potentially help increase the rate of genetic testing in women who are candidates for it, as genetic counseling and testing are woefully underutilized.
Her case also publicizes various socioeconomic and political issues. There’s no doubt about it, Jolie is filthy rich, thanks to the success of her and her fiance Brad Pitt in Hollywood. She has access to the best of everything, and she doesn’t have to worry about paying for BRCA testing, prophylactic mastectomy, or the very finest breast reconstructive surgery available. Most women can’t say that, and, unfortunately, as has been pointed out, the issue of genetic testing can result in dilemmas for some women. Although the Patient Protection and Affordable Care Act will, when fully implemented, require that appropriate, evidence-based genetic testing and preventative surgery be covered, until now many women could not afford genetic testing and did not have insurance companies that covered preventative surgery, much less breast reconstruction. Moreover, there is the potential problem that publicity will result in a push for more screening in women for whom there is not an indication, with the potential to cause harm.
Finally, there is the issue of the gene test itself, on which Myriad Genetics has a monopoly. If there’s one thing the quacks have written that has a bit of traction, it’s the criticism of Myriad, whose patent has crushed any competing BRCA mutation tests. I said before I’m not a fan of Myriad. I view its stranglehold on BRCA testing as stifling innovation, which is why I’m glad that the U.S. Supreme Court is hearing a case against Myriad about the legal validity of its patents. Even though Myriad’s patents are only good for two more years, one can only hope that a precedent is established. I also can’t help but wonder whether all these newer next generation sequencing tests coming out will mean the end of Myriad’s monopoly anyway, given that they will give information on all potential cancer-associated gene mutations, including BRCA mutations. To the extent that the Angelina Jolie case sheds light on this issue, it’s all to the good.
In the end, leaving aside all these political and class issues, however, the decision regarding preventative surgery is an intensely personal one. Angelina Jolie made her decision based on evidence, and I can’t argue with her decision. Were she my patient, I would have counseled her to do what she did, minus the homeopathic remedies “integrated” into her care. What I find particularly ironic is how a common theme running through so much of the criticism quacks are sending Jolie’s way is that she made the wrong decision, that she was “duped” by the “cancer industry.” The contempt, although denied with a disclaimer of how they “understand” how difficult the decision was, is palpable. I thought “alternative” health was all about empowering the patient to make her own decisions. Apparently such “empowerment” is only admirable to people like Mike Adams, Sayer Ji, and Robert Schulze, if the empowered patient makes a decision they agree with.

Angelina Jolie, surgical strategies for cancer prevention, and genetics denialism (revisited)
David Gorski on March 30, 2015
Link

Sometimes, weird things happen when I’m at meetings. For example, I just got home from the Society of Surgical Oncology (SSO) meeting in Houston over the weekend. Now, one thing I like about this meeting is that, unlike so many other meetings these days—cough, cough, ASCO, I’m looking at you—at the SSO there wasn’t a single talk I could find about “complementary and alternative medicine” (CAM) or, as its proponents like to call it now, “integrative medicine.” It’s also a great chance to get caught up on new science and clinical guidelines in cancer surgery, as well as to see people I tend only to see at these meetings.
However, I must admit that by the last day I tend to be “meeting-ed” out and sometimes my attention wanders. Unfortunately, there are ample ways to indulge that attention deficit. Actually, it’s my iPhone. And it’s Twitter. So it was an odd coincidence that right after a talk by Dr. Deanna Attai about whether surgical oncologists can or should offer genetic counseling services to their patients, when I somehow let myself get into an exchange with Sayer Ji, the “natural health expert” responsible for GreenMedInfo, over BRCA1 mutations and the risk of breast and ovarian cancer, in other words, exactly the sort of thing that Dr. Attai had just discussed. For example:
@ackdoc @sayerjigmi Where are your ncbi citations, or Gorski’s? Its remarkable how unicorn and not evidence-based supposed skeptics are.
— GreenMedInfo (@GreenMedInfo) March 28, 2015
After a bit of back-and-forth, I got fed up:
.@ackdoc @GreenMedInfo The sad thing is, @sayerjigmi‘s misunderstanding of genetic and biology is dangerous to patients.
— David Gorski (@gorskon) March 28, 2015
This minor Twitter exchange came about because of Angelina Jolie’s announcement in a New York Times op-ed last week entitled “Diary of a Surgery” that she had had her ovaries removed to prevent ovarian cancer due to her being a carrier of a high-risk mutation in BRCA1. As you might recall, I wrote about Jolie’s case two years ago, when she first announced in a NYT op-ed entitled “My Medical Choice” that she had undergone a bilateral mastectomy with reconstruction to decrease her BRCA1-related risk of breast cancer. Although I had discussed the story before, I thought it worth doing again here in a bit more detail.
Now, let’s just say that Ji is not known for his science-based proclamations, and he’s hostile to evidence-based medicine. Although he wields the peer-reviewed scientific literature like a sword and shield to protect his pseudoscientific blather, to anyone who actually understands the science, it’s painfully obvious that he doesn’t know what he’s talking about but is good at misunderstanding and cherry-picking studies that make it appear to lay people that he does. In particular, he’s very hostile to the concept that there is a genetic cause of cancer, as he demonstrated when Jolie first announced her mastectomy. That’s why hereditary cancers and how they are prevented really set him off. This time around, he doubles down on his genetics denialism. Ji’s cherry picking and misinterpretation of studies can be either amusing or infuriating, depending on my mood. More on that later. First let’s look at the story.
Angelina Jolie and BRCA1 mutations
Back in 2013, Angelina Jolie startled the world by announcing in a NYT op-ed that she had had both of her breasts removed to prevent cancer because she had been found to have a specific BRCA1 mutation that results in a high risk of cancer. At the time, knowing what had been disclosed by Jolie, I considered the decision to be a reasonable one, although I was not pleased with the publicity her surgery gave to the Pink Lotus Breast Center, a Los Angeles-area breast center that puts the “integrate” into “integrative medicine,” using a homeopathic concoction to prevent wound breakdown and various “detox” regimens to eliminate anesthesia from the system. Still, Jolie’s decision to decrease her risk of breast cancer this way was quite reasonable, given this:
We often speak of “Mommy’s mommy,” and I find myself trying to explain the illness that took her away from us. They have asked if the same could happen to me. I have always told them not to worry, but the truth is I carry a “faulty” gene, BRCA1, which sharply increases my risk of developing breast cancer and ovarian cancer.
My doctors estimated that I had an 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer, although the risk is different in the case of each woman.
As I’ve discussed on more than one occasion, BRCA1 and BRCA2 are genes in which certain mutations are most commonly associated with either breast or ovarian cancer, although they are also associated less strongly with several other cancers as well, such as cervical cancer, uterine cancer, early onset prostate cancer (men) and colon cancer (BRCA1) or pancreatic cancer. BRCA1 codes for a protein known as breast cancer type 1 susceptibility protein, a protein belonging to the RING-type zinc finger (RNF) family whose function involves repairing damaged DNA. Specifically, it repairs double-stranded breaks. In the nucleus of a variety of normal cells, the BRCA1 protein interacts with other proteins, such as RAD51 and BARD1, to repair double stranded breaks resulting from radiation and other environmental exposures, as well as breaks that occur during natural processes, such as homologous recombination, or just from living. The BRCA1 protein is important in multiple functions, including transcription (conversion of the DNA sequence to RNA message), repair of double-stranded DNA breaks, ubiquitination, and other functions. If BRCA1 can’t repair the break, it then promotes cell cycle arrest and apoptosis (programmed cell death). The result of defects in BRCA1 function is increased sensitivity to anything that causes DNA damage and an increased risk of the development of cancer. BRCA2 encodes a protein that, while very different in structure from BRCA1, serves a similar function, namely the repair of double-stranded DNA breaks.
Mutations in BRCA1 and BRCA2 are associated with familial cancer syndromes, most commonly involving breast and ovarian cancer, but not limited to these cancers. Moreover, I must emphasize again that BRCA mutations are not binary. You do not either “have the mutation” or not “have it.” There are many mutations, some of which confer a very high risk of cancer, as high as an 87%. Indeed, family-based studies by the international Breast Cancer Linkage Consortium looking at 237 BRCA1 carrier families that have four or more members with breast cancer estimated a 72-95% (overall 87%) lifetime risk of breast cancer due to BRCA1 mutations and a 63% lifetime risk of ovarian cancer. These are high numbers. Overall, looking at a survey of recent studies that include family-based and population-based studies, BRCA1 mutations can produce a lifetime risk of breast cancer ranging from 45% to 87% and of ovarian cancer ranging from 31% to 63%. By any stretch of the imagination, these are high risks of potentially-deadly cancers.
When Jolie wrote about her decision to have both breasts removed, she did point out that she was told by her physician that she had a lifetime risk of ovarian cancer of 50%. Think of it this way. The average woman has a lifetime risk of ovarian cancer on the order of 1.8%, which makes Jolie’s estimated risk more than 25-fold elevated. In comparison, given that the average woman has a lifetime risk of breast cancer on the order of 10-12%, an 87% lifetime risk conferred to Jolie by her BRCA1 mutation is well over seven-fold higher. Again, these are high risks, and it is in the context of such high risks that considering risk-reducing prophylactic surgery becomes reasonable.
Now for the irony. As I said, this exchange with Ji occurred in the Q&A session after a talk about whether surgeons can effectively provide genetic counseling to breast cancer patients. It’s easy for surgeons like myself, who practice in large cities, particularly surgeons like myself who practice in NCI-designated comprehensive cancer centers with excellent genetic counseling programs, simply to refer patients to genetic counseling. A good genetic counselor will go through these risks and explain the significance of the dozens of mutations that are known. This complexity is why I generally have been a firm believer that genetic testing for BRCA mutations should usually not be done outside of a center with either skilled genetic counselors or a physician trained in genetic counseling who can explain the risk and help the patient weigh the pros and cons of genetic testing and, if that testing is positive, the various surveillance and preventative strategies available for women carrying such mutations. Unfortunately, there is a huge shortage of qualified genetic counselors in many states (I seem to recall Dr. Attai saying that, for example, Wyoming has none). So sometimes surgeons do need to do genetic counseling. At the very least, we breast surgeons need to know the indications for genetic counseling and how to take a proper family history. Also important is to weigh the ethical and practical issues of genetic testing, such as whether a mutation carrier should inform her family, what effects that it might have on her ability to obtain health insurance, and the many other issues that are inextricably bound with genetic testing.
In other words, as I like to say, recommendations should be personalized by practitioners using science-based practice. It should also be remembered that in the US, BRCA mutations account for only a small minority of cases of early onset breast cancer (2-3%) and ovarian cancer (8%), a proportion that can vary widely based on geography and ethnicity. To put it another way, approximately 25% of women with a breast cancer diagnosis are younger than 50 years, and almost 10% of these women will have a BRCA mutation.
There’s also the issue of just how nasty ovarian cancer is compared to breast cancer. The main reason ovarian cancer is so nasty is that it’s rarely caught when it’s confined to just the ovary or Fallopian tube. Rather, the symptoms of early ovarian cancer tend to be vague and nonspecific abdominal or pelvic complaints. Usually, it has started to spread throughout the abdomen before it is discovered, and by then the surgery needed to control it becomes much more extensive, and the chemotherapy needed to mop up the leftover tumor deposits after surgery becomes more grueling. Corresponding with this, the chances of curing ovarian cancer go down considerably. Also, unlike the case for breast cancer, there is no good screening test that has been shown to decrease mortality from ovarian cancer when applied to the general population.
Surgery is effective, too. Bilateral prophylactic mastectomy reduces the risk of breast cancer in women with high risk BRCA1 mutations by at least 90%. (See, for example, Hartman et al, 1999; Domchek et al, 2010; Rebbeck et al, 2004; Meijers-Heijboer et al 2001.) Removal of the ovaries is also highly effective in reducing mortality from ovarian cancer in such patients, lowering the risk by 70-90%. (See, for example, Kauff et al, 2002; Kauff et al, 2008; Finch et al 2014.) That prophylactic oophorectomy to prevent ovarian cancer and prophylactic bilateral mastectomy to prevent breast cancer in carriers of high-risk BRCA1 mutations are highly effective is not even controversial. Such recommendations are “baked” into major evidence-based guidelines, like those of the NCCN, as a significant option for women found to have such mutations to consider. Other options exist, such as enhanced screening (which has not been shown to be effective in ovarian cancer) or chemoprevention. Tamoxifen may decrease the risk of breast cancer in BRCA1 mutation carriers, and oral contraceptives can decrease the risk of ovarian cancer. None of these options are as effective as prophylactic surgery, unfortunately, meaning that, for carriers of dangerous BRCA1 mutations, there just aren’t any really good options.
Jolie, in her NYT article, explained why she decided to have her ovaries and Fallopian tubes removed:
TWO years ago I wrote about my choice to have a preventive double mastectomy. A simple blood test had revealed that I carried a mutation in the BRCA1 gene. It gave me an estimated 87 percent risk of breast cancer and a 50 percent risk of ovarian cancer. I lost my mother, grandmother and aunt to cancer.
I wanted other women at risk to know about the options. I promised to follow up with any information that could be useful, including about my next preventive surgery, the removal of my ovaries and fallopian tubes.
Unfortunately, as was the case last time, she also couldn’t resist layering in a bit of woo:
I did not do this solely because I carry the BRCA1 gene mutation, and I want other women to hear this. A positive BRCA test does not mean a leap to surgery. I have spoken to many doctors, surgeons and naturopaths. There are other options. Some women take birth control pills or rely on alternative medicines combined with frequent checks. There is more than one way to deal with any health issue. The most important thing is to learn about the options and choose what is right for you personally.
In my case, the Eastern and Western doctors I met agreed that surgery to remove my tubes and ovaries was the best option, because on top of the BRCA gene, three women in my family have died from cancer. My doctors indicated I should have preventive surgery about a decade before the earliest onset of cancer in my female relatives. My mother’s ovarian cancer was diagnosed when she was 49. I’m 39.
See what I mean? I’m glad that Jolie ultimately decided upon a reasonable, science-based course of action, but I really wish she could have restrained herself from including this passage and in essence representing quacks on the same level as surgeons and oncologists. Naturopaths? Need I repeat how much quackery is embedded in naturopathy? Rely on alternative medicines and frequent checks? There is no known “alternative medicine” that can reduce ovarian or breast cancer breast in BRCA1 mutation carriers; so this strategy is akin to just close surveillance, which is ineffective in ovarian cancer. And don’t even get me started on the fallacy of “Eastern” versus “Western” medicine again! How many times do I have to point out that that is a rather racist construct, in which the “East” is implied to be more “holistic” and woo-ey, while the “West” is cold, reductionist and scientific? Medicine is medicine. The only thing that matters is the evidence supporting it. Still, at least Jolie in the end made a medically-reasonable and justifiable choice to have her ovaries removed in order to prevent ovarian cancer down the road. It was probably the least bad of bad options for her, and her bringing attention to this issue is to be commended.
That is, unless you’re a quack.
Sayer Ji steps in it
Regular readers might remember that when actress Angelina Jolie first announced in a New York Times opinion piece that she had undergone bilateral prophylactic mastectomies because of her BRCA1 mutation, quacks were not pleased, not at all. For example, Mike Adams, ever the restrained one, declared “Angelina Jolie inspires women to maim themselves by celebrating medically perverted double mastectomies.” Interestingly enough, given Adams’ attempt to reinvent himself as a legitimate food safety researcher, that article might have had too much crazy in it even for him. There is now a message there about how “this article has been removed because it is no longer aligned with the science-based investigative mission of Natural News” now that Adams has “transitioned from outspoken activist to environmental scientist.” You can still find generous samples of Mike’s original rant in my original discussion of it. The text of Adams’ followup article, “How Angelina Jolie was duped by cancer doctors into self mutilation for breast cancer she never had“, has also disappeared, to be replaced by the same bizarre message. Again, you can see just how bad it was for yourself in the same discussion of this despicable article, in which Adams claimed Jolie could have reduced her risk of cancer to very low levels with “natural” methods, an utterly ridiculous claim for a woman with a BRCA1 mutation.
The reason alternative medicine mavens were not pleased with Jolie’s decision to remove first her breasts and then her ovaries to try to prevent the cancer that her BRCA1 mutation had a high probability of causing is because of what I like to term “genetics denialism.” Because alternative medicine is all about “control” (or, as I like to call it, a “Secret”-like form of wishful thinking in which we have near-absolute control of our bodies simply by willing what we want and willing ourselves to do the “right” things, eat the “right diet,” take the “right” supplements, and think the “right” thoughts,”) alternative medicine practitioners deny that genes have anything to do with disease. It’s what I refer to as the “central dogma” of complementary and alternative medicine, namely that wishing makes it so.
Often genetic denialists invoke the science of epigenetics, often with hilariously (or infuriatingly) wrong conclusions. It always comes off in much the same way that creationist tropes about “junk DNA” do: With a superficial understanding of science that, because it is so superficial, is twisted into supporting unscientific arguments. Sayer Ji is a master of this technique. No, that’s not a compliment.
What Ji lacks in Adams’ penchant for histrionics, he makes up for in verbal prestidigitation that ignores medical knowledge. He also was fast out of the gate, throwing together this article the same day Jolie’s article appeared, entitling it ‘Beware of Organ Removal for “Cancer Prevention”: Jolie’s Precautionary Tale.’ It’s basically a rehash of an older article of his, “Ovarian Cancer: What We Think We Know May Harm Us“, and both articles include the same sort of misinformation about overdiagnosis that is irrelevant to BRCA1 carriers because Ji cites studies of screening in the general population. The misinformation begins early and comes fast and furious:
With Angelina Jolie’s recent announcement that she had her ovaries and fallopian tubes removed because of both a BRCA ‘gene defect’ and a history of breast and ovarian cancer in her family, the idea that genes play a dominant role in determining biological destiny and cancer risk is proliferating in the mainstream media and popular consciousness uncontrollably like a cancer.
See the genetics denialism? Again, the idea is that you can control your health, so much so that genes don’t matter, at least not that much. Examples abound, with Deepak Chopra attacking genetic “determinism” and Mike Adams claiming that human DNA is incapable of storing the complete blueprint of the human form and referring to genetics as a “big lie.” If you listen to Ji, you’ll see he’s basically saying, “Never mind that pesky BRCA1 mutation.” He further tells women they have nothing to worry about:
The reality is that the average woman’s lifetime risk of ovarian cancer is exceedingly small, with the overall risk of developing ovarian cancer by 65 years of age being 0.8 percent and the lifetime risk 1.8 percent.[2] For those with a first-degree relative developing ovarian cancer, as is the case for Jolie, the risk estimates show increases to 4.4 and 9.4 percent, respectively.[3]
It is also important to realize that lifetime ovarian cancer risk does not exist in a vacuum. Considering that it is not cancer (at any site) but heart disease that is the #1 killer of women, focusing on ovarian cancer risk as the primary threat to health is myopic at best, faulty reasoning with deadly consequences at worse. If Jolie had chose [sic] to go without radical surgical intervention, it is statistically more likely she would have died from heart-related death than cancer of any kind. The reality is that the lifetime risk of heart disease related death in women is in top position at 23.5%, according to CDC statistics, versus cancer which takes #2 position at 22.1%. And within cancer related deaths in women, breast, lung, colorectal cancer, uterine, thyroid, non-Hodgkin’s lymphoma and melanomas are top on the list, with ovarian cancer in the 8th in position.
Can anyone spot the fallacies here? These are numbers for women who don’t have a documented BRCA1 mutation!!! They are irrelevant to Jolie’s situation, where she has a mutation that, according to her doctors, confers an estmiated 50% lifetime risk of developing ovarian cancer. The study cited by Ji was, in actuality, a case control study that only examined the three known major risk factors by history: a history of ovarian cancer in the mother or sister, years of oral contraceptive (OC) use, and number of term pregnancies. That’s it. It didn’t even look at the known BRCA1 mutation that Jolie had.
Next up, Ji goes on to discuss overdiagnosis of ovarian cancer resulting from ultrasound screening. Yes, as I’ve pointed out more times than I can remember, any time you screen for a disease, you will diagnose more cases and some of those cases will be overdiagnosed; i.e., disease that would never progress within the lifetime of the patient to cause serious health problems. He even invokes the case of ductal carcinoma in situ (DCIS), a premalignant condition of the breast whose prevalence has skyrocketed with the advent of mammographic screening. Here’s the thing. The frequency of overdiagnosis is related to the chance of disease in the population being screened. The lower the chance of disease, the greater the chance that a positive screening test results in overdiagnosis. That’s why we don’t screen women under 40 for breast cancer; the expected prevalence of disease is too low. Indeed, as I’ve discussed many times, even age 40 might be too young, hence all the controversy over the USPSTF recommendations five years ago.
Can you see where I’m leading? With Jolie’s expected lifetime risk of ovarian cancer being 50%, Ji’s discussion of overdiagnosis is also irrelevant to her case. Yes, there is a problem with screening for ovarian cancer. It doesn’t work very well, if it works at all, and there’s a lot of overdiagnosis. That doesn’t mean that it’s not appropriate to screen a woman at a risk far higher than the general population for the disease.
Ji concludes by cherry-picking evidence suggesting that BRCA1-associated ovarian cancers might be less aggressive. Indeed, it’s a point he brought up again on Twitter:
@gorskon How do you resolve the fact that there are over 500 BRCA SNPs identified, with variations like BRCA1 K1 183R reducing cancer risk?
— GreenMedInfo (@GreenMedInfo) March 28, 2015
Note that @GreenMedInfo and Sayer Ji are one in the same. Ji switched from the Twitter account under his name to his blog account during the exchange.
In his article, one study Ji cites found that it’s likely a better response to platinum-based chemotherapy in BRCA1-associated cancers that results in better outcomes. Indeed, a recent meta-analysis suggests that BRCA1 carriers who develop ovarian cancer do indeed have higher overall survival, but that such women who develop breast cancer have a worse survival (which has been known). My answer? So what? They still develop a cancer that has an unfortunately high probability of killing them! Yes, the ovarian cancers they develop might be less deadly than ovarian cancer that just “pops up,” but they’re still plenty deadly! Holy hell, Ji angers me with this line of “reasoning,” if you can call it that, that because the average woman has a relatively low chance of developing ovarian cancer, and heart disease kills far more women than ovarian cancer, it is inappropriate to try to reduce the risk of ovarian cancer in a woman with an ovarian cancer-predisposing mutation.
After that, I needed a chuckle, and Ji gave me one, namely that he thinks he understands promoter hypermethylation, an epigenetic process. Basically, he cherry picks a study that shows a lot of methylation (attachment of methyl groups chemically) to the promoter (the DNA region near a gene that controls how much protein the gene makes) silencing (shutting off) BRCA1 in ovarian cancer and concludes that BRCA1 mutations are irrelevant to ovarian cancer because epigenetics is more important:
Up until now, most of the focus on breast and ovarian cancer risk has been on the inherited BRCA1 mutations and how they interfere with proper BRCA function. The new study reveals that epigenetic processes, working from the outside in, as it were, can produce the same functional outcome as an inherited mutation. BRCA gene deactivation through hypermethylation can be stimulated through chemical exposures, such as to dioxins, for instance. There is also research indicating this can be prevented through natural compounds such as resveratrol and soy, putting diet – and so-called nutrigenomic interventions – at the forefront of cancer prevention and treatment.
Any geneticists or cell biologists out there? I know you’re there. I hope I didn’t cause you too much pain by quoting that passage. As you know, what the study cited by Ji really shows is the importance of BRCA1 in ovarian cancer and how loss-of-function can lead to cancer development in sporadic ovarian cancers; i.e., ovarian cancers not associated with a specific gene mutation. Somehow, during the process of carcinogenesis epigenetic mechanisms silence BRCA1 in a lot of ovarian cancers, which just goes to show how important BRCA1 is for the development of ovarian cancer. Now here’s the thing. High-risk mutations impair or destroy the function of the BRCA1 protein permanently, epigenetics be damned. Ji must not understand that you’re not going to restore the function of BRCA1 through epigenetics if the gene itself has a mutation in it that leads to its protein product not functioning. I don’t care how much resveratrol and soy a woman consumes.
None of this stops Ji from plumbing the depths of his ignorance of genetics near the end of his article:
The concept – the meme – that hereditary determines one’s biological destiny is archaic. After the first draft of the human genome project was completed in 2005, they only found 23,000 genes! That’s not enough protein-coding genes to explain the existence of our body, which contains at least 100,000 different proteins. What this epic failure revealed is that it is not the genes themselves that determine health or disease, rather, what factors in our environment, lifestyle and nutrition that activate the expression of certain genes, and silence the expression of others. In the case of BRCA1 and BRCA2, we now know that silencing these genes from the ‘outside in’ results in the same result as being born with a defective gene from the ‘inside out,’ with the important difference that epigenetic – ‘outside in’ – gene silencing can actually be reversed or mitigated. Our genome results from millions of years of evolution, whereas our epigenome is influenced by day to day decisions, many of which depend on what we decide to eat or avoid eating, right now. Choice, therefore, becomes central to determining disease risk. And given that Jolie’s decision to remove her breasts, and subsequently her ovaries, was predicated on a belief that she is helpless in the face of predetermined risk – her decision does not reflect the evidence and biological science itself.
How do we end up living in a world where people believe that their genes – which they do not have access to without biomedical surveillance — determine their destiny? How we end up thinking that ‘gene defects’ are so powerful that removing healthy organs from our body is the only reasonable way to prevent experiencing cancer within them?
If we take this logic to its fullest expression, why wouldn’t someone determined to have a greatly increased risk of brain cancer remove their head prophylactically?
One can only wish that Ji would take his own advice. That part about the 23,000 genes but 100,000 proteins was truly ignorant. Has Ji never heard of alternative splicing? (Speaking of which, check out this cool animation of RNA splicing.)
Yes, depending on the disease, it is not uncommonly a mixture of environment and genes that determine what happens. However, that ratio is not the same for every disease, and for many diseases it’s many genes that influence development of the disease. Single-gene diseases, like cancer due to BRCA1 mutations, are a lot less common than sporadic cancer. There’s also the concept called penetrance, which describes how likely a person harboring a certain allele or mutation is to demonstrate the phenotype (i.e. physical characteristic like height, eye color or disease) associated with that allele. 100% means everyone with that mutation gets the phenotype. 50% means half do, like Angelina Jolie’s BRCA1 mutation and ovarian cancer. It’s generally not 100% or none; penetrance is a spectrum. Ji seems to think the variable penetrance of different BRCA1 mutations means that these mutations can’t cause cancer. Some of them can and do, some of them at a very high frequency, and no amount of changing one’s diet, lifestyle, or thinking is going to reverse biology. That’s not to say that women with deleterious BRCA1 mutations shouldn’t avoid things that can increase the risk of breast cancer, such as obesity or excess alcohol consumption, but the magnitude of the expected benefit will be tiny in comparison to the magnitude of risk due to the mutations. Unfortunately, the strongest risk reduction in the case of certain cancer-predisposing mutations comes from surgically removing the organ at risk.
Sadly, in the case of BRCA1 mutations, genetics does rule, by and large. We’ve already seen that for breast cancer, depending on the specific BRCA1 mutation, the lifetime risk of cancer can be as high as 90%. The same is true for a number of mutations that vastly increase the risk of colorectal cancer to the point where the vast majority of carriers develop colorectal cancer before middle age. Examples include the familial adenomatous polyposis (FAP), which is caused by mutations in a gene called APC that results in numerous polyps in the colon at a very young age, leading to colon cancer in nearly 100% of people carrying deleterious APC mutations, and hereditary nonpolyposis colorectal cancer (a.k.a. HNPCC or Lynch syndrome), which is due to mutations in the DNA mismatch repair pathway that lead to an 80% lifetime risk of colorectal cancer. Both of these syndromes, like BRCA1, also predispose a patient to other forms of cancer at a lower penetrance. In both of these syndromes as well, strong consideration of prophylactic surgery to remove the colon and rectum at a relatively young age is recommended.
Ji’s apparent belief that genetics doesn’t matter and “choice” is all, is nothing more than The Secret of epigenetics, in which wishing makes it so and we can completely control our health, genetics be damned. If only that were true. It’s not. In fact, in the case of ovarian cancer due to deleterious BRCA1 mutations, a very important recent study (Finch et al, 2014) showed that earlier prophylactic surgery likely results in better outcomes, which suggests that Jolie might have waited a bit longer than is currently considered advisable to have her ovaries removed. That same study showed a 77% overall decrease in a BRCA1 mutation carrier’s risk of death by age 70.
By promoting such flagrant misinformation about hereditary cancer, Sayer Ji endangers the lives of women with BRCA mutations everywhere. His arguments are nothing more than pure genetics denialism.

Angelina Jolie’s surgeon peddles misinformation about…breast cancer!
Dr. Kristi Funk is a surgeon to the stars in Beverly Hills who operated on Sheryl Crow and Angelina Jolie for breast cancer. This year, she published a book about breast health and breast cancer. Unfortunately, it’s full of misinformation and radical advice with little or no basis in science.
David Gorski on July 30, 2018
Link

I’m a breast cancer surgeon and researcher. As such, I’ve dedicated my professional career to the multidisciplinary care of women (and men) with breast cancer, using my clinical judgment and surgical skills to the best of my ability to surgically extirpate breast cancer from my patients, either before or after chemotherapy, in collaboration with medical and radiation oncologists, as well as plastic surgeons in the cases of women who require total mastectomy to eliminate their cancer. I’ve also managed to keep a lab funded for 19 years studying various aspects of breast cancer, including tumor angiogenesis and glutamate signaling. Here at Science-Based Medicine, I’ve dedicated my efforts to combatting medical myths and pseudoscientific medicine, but I do take a special interest in such misinformation about breast cancer because, well, it’s my specialty. So it was with great annoyance that I read an article I saw on Twitter late last week about Dr. Kristi Funk, who, it just so turns out, is Angelina Jolie’s breast surgeon:
Angelina Jolie’s breast surgeon explains what to eat and how to live to help avoid cancerhttps://t.co/kW3xPQNzS9
— i newspaper (@theipaper) July 29, 2018
The article to which they refer is this excerpt from her book entitled “Angelina Jolie’s breast surgeon explains what to eat and how to live to help avoid cancer.” The article reminded me that, two weeks ago, Dr. Funk had promoted a very similar message in an interview in the The Sunday Times in the UK entitled “Meet Kristi Funk, Angelina Jolie’s cancer doctor.” That’s pretty generic, but the subtitle gives away the game: “Kristi Funk is the go-to breast surgeon in Beverly Hills. She thought she knew everything about cancer risk, then she looked into diet.” I was at NECSS at the time, and therefore didn’t have a chance to write about it. By the time I remembered it again, I thought I had blown my chance and just moved on. Thankfully (well, not really) Dr. Funk has a book to promote:
I'll be chatting about my book, "Breasts: The Owner's Manual" on @TheDoctors and live on KCal 9 News with @CBSLAsandra today. Be sure to tune in! #BreastManual https://t.co/KQkIE49J6b
— Dr. Kristi Funk (@drkristifunk) April 4, 2018
And:
It's Book #ReleaseDay. So thankful to everyone who is making this such a smashing success (you all know who you are and I love you)! Keep spreading the good word, there is a woman out there whose life will be saved as a result! #BreastManual https://t.co/Twyy0wRPsa pic.twitter.com/O3X3WagVDe
— Dr. Kristi Funk (@drkristifunk) May 2, 2018
And:
I’m so thrilled for my friend and doc @DrKristiFunk on the release of her new book, BREASTS: The Owner’s Manual! You will LOVE this book, and it will become the Breast Bible for women all over the globe. https://t.co/VqPy9MMv0V #BreastManual pic.twitter.com/leGYIVu0DB
— Sheryl Crow (@SherylCrow) April 30, 2018
And:
To keep the girls pain-free, @drkristifunk says you should first think about what you put on your plate! https://t.co/JvYeTDzPSt
— Rachael Ray Show (@RachaelRayShow) July 26, 2018
Most importantly, though, for purposes of this slew of interviews and op-eds in the UK, apparently her book was just published in the UK this month:
Today we're proud to publish this straight-talking, myth busting guide to breast health from @drkristifunk. https://t.co/g6uVTMHhdO #OutNow #NonFiction pic.twitter.com/UKbGfhGXiT
— HQ Stories (@HQstories) July 12, 2018
So obviously, Dr. Funk’s appearances in UK newspapers are part of her book promotion. Nothing wrong with that. What I do have a problem with is that Dr. Funk is promoting a message that is not well-rooted in science. Actually, that’s putting it mildly, particularly her claims about how much a woman can reduce her risk of breast cancer with lifestyle and diet interventions alone. But, first, who is Dr. Funk?
Dr. Kristi Funk: Breast cancer surgeon to the stars
I’ve mentioned Dr. Funk before in the context of discussing Angelina Jolie’s breast cancer surgery five years ago, specifically Jolie’s decision to undergo a bilateral mastectomy because she has a BRCA1 mutation. At the time, I noted that Dr. Funk founded the Pink Lotus Breast Center in Beverly Hills, where Dr. Funk has become the breast surgeon to the stars, including Sheryl Crow and Angelina Jolie. Basically, she appears to be a former academic breast surgeon who’s found a far more—shall we say?—lucrative niche taking care of wealthy and famous women in southern California. Her previous bio (no longer on the Pink Lotus website, but available through the Wayback Machine) lists an impressive set of credentials: Medical school at Stanford; residency at UC Davis, fellowship at Cedar-Sinai in Los Angeles; Director of Patient Education at the Cedars-Sinai Breast Center until 2009, when she opened her Beverly Hills office. She claims several accomplishments:
Dr. Funk graduated with distinction from Stanford University in 1991, and received her medical degree from the University of California, Davis, School of Medicine. She is also a former Oxford University scholar, and worked as a research assistant at the University of California, Los Angeles (UCLA) and Baxter Diagnostics. An outstanding investigator, Dr. Funk patented a surgical device used to increase operating room efficiency, assisted in the development of a method for the rapid detection of cytomegalovirus, and helped design an in vitro antimicrobial susceptibility test.
After surgical residency at Virginia Mason Medical Center in Seattle, WA, she completed a surgical breast fellowship at Cedars-Sinai Medical Center in 2002, where she then excelled as a surgeon and Director at the Cedars-Sinai Breast Center until 2009.
Dr. Funk’s published works have appeared in Advanced Therapy of Breast Disease, Surgical Clerkship Manual, Archives of Surgery, the Journal of Gastrointestinal Surgery and the Journal of Clinical Microbiology. As a frequent presenter, she has addressed crowds at national and international Breast Cancer conferences, multiple Los Angeles-area hospitals, the Society of Nuclear Medicine, Southwestern Surgical Congress, Pacific Northwest Vascular Society, British Esophageal Group, Seattle Surgical Society, Virginia Mason Medical Center and the American Society for Microbiology, as well as numerous community audiences.
I did a bit of PubMed perusing. I must say that her publication record in the peer-reviewed literature is quite a bit less impressive than I was led to believe by her now-defunct bio. Under her maiden name (Kristi Pado), I only found two articles. I did find an article in the Archives of Surgery and in the Journal of Clinical Microbiology. She was not first or last author on either. (First author indicates the most intellectual involvement and doing most of the work, while last author usually indicates the senior author in whose lab or under whose supervision the work was carried out.) Neither had anything to do with breast cancer. Both occurred in the 1990s, when Dr. Funk was still a trainee, either as a resident or a fellow. Looking under Dr. Funk’s current name, I found one paper reporting a multicenter evaluation of a new surgical guidance technology for localizing non-palpable breast lesions. Clearly the Pink Lotus Breast Center was just one of fourteen sites where the new technology was tested. This is no big deal. Lots of clinicians agree to be site principal investigators for tests of new surgical technologies. Let’s just put it this way. Three publications in the peer-reviewed literature indexed in PubMed over 24 years, none of them first author, do not impress me that much. Other than her participation in a multicenter evaluation of a new product, she’s published nothing in the peer-reviewed literature since 1997.
As for her patents, searching for “Pado” in the inventor name column brought up 14 patents, none of them with her name. Searching with “Funk” as the name brought up 1,226 patents. Narrowing it down to Kristi Funk brought up no hits. So either she’s…mistaken…or I don’t know how to search the patent database very well. Either way, color me unimpressed—either with me or with Dr. Funk. Take your pick. If I manage to discover what her patent was, I’ll update this paragraph and give myself 100 lashes with a wet noodle for not having found it.
One thing that I did mention when I discussed Angelina Jolie’s surgery is that Dr. Funk is also enamored of “integrative medicine”. Indeed, it’s something promoted and offered by Pink Lotus, whose website proclaims that “integrative medicine is not just a marketing slogan but rather the essence of what we practice” and that “holistic medicine” is one of its services. Angelina Jolie appears to have undergone a mixture of the science-based (bilateral prophylactic mastectomy for risk reduction due to BRCA1 mutations) tinged with pure pseudoscience, like the use of homeopathic remedies such as Arnica Forte (which consists of Arnica Montana 30x, Bromelain, Antioxidants, and Bioflavonoids) as a means of decreasing bruising during surgery. Steve Novella recently wrote about how the use of homeopathic Arnica is pure quackery, with no evidence to support it, although he apparently didn’t know at the time that Dr. Funk used it on Jolie. Dr. Funk also used Exchem and Lymphomyosot (“to help eliminate anesthesia from the system”) when operating on Jolie. So, yes, Dr. Funk recommends “detox,” which is the purpose for which Lymphomysot is advertised, to get rid of anesthesia agents after surgery.
To sum up thus far, Dr. Funk was at one time on the academic surgery track but hasn’t done any significant research in decades and her publication record is not impressive. She was involved in education for a long time at Cedars-Sinai, but she left that behind ten years ago when she went private and founded Pink Lotus Breast Center. Since then, she’s been heavily into “holistic” treatments mixed with standard breast cancer surgery, mixing the sensible and science-based with exaggerated claims for the effects of diet on breast cancer risk and pure woo like homeopathy during surgery. Thanks to her success in attracting Hollywood glitterati as her patients, she’s become rather famous and is frequently seen on TV and in the media. Now she’s written a book, whose UK launch was accompanied by a lot of her misinformation. So what are we talking about?
The Clones of Dr. Funkenstein: Dr. Kristi Funk versus breast cancer genetic risk factors
Dr. Funk’s tweets were met with a strongly critical response by Dr. Liz O’Riordan, a British breast surgeon who has herself been diagnosed with recurrent breast cancer. In this section, I basically explain why Dr. O’Riordan’s criticisms are correct. (I know, I know, she’s a surgeon in the UK; I don’t care, given that I’m in the US right now.) Here’s what she says:
WTF? This woman claims that if you are tall or eat cheese or any meat you will get breast cancer. SCARY and WRONG! https://t.co/RMMzLf9OkS
— Dr Miss Dr Mrs Liz O'Riordan (@Liz_ORiordan) July 12, 2018
And:
WTF? “80% of all breast cancer could be eliminated from planet Earth if women understood that daily choices eg food, drink, and mindset create the environment inside the cells of our breasts, which turn malignant” @Independent this is DANGEROUS and WRONG! https://t.co/FpTF2lo0uM
— Dr Miss Dr Mrs Liz O'Riordan (@Liz_ORiordan) July 28, 2018
If the interviews she’s done and the articles she’s published are any indication, the key message that Dr. Funk appears to be promoting in her book, Breasts: The Owner’s Manual: Every Woman’s Guide To Reducing Cancer Risk, Making Treatment Choices, And Optimizing Outcomes, is one of control. For example, take a look at this most recent article in the UK’s inews:
One big problem with breast cancer awareness is erroneous public perception.
Most women believe that family history and genetics determine who gets breast cancer – but 87 per cent of women diagnosed do not have a close relative with the disease.
On the other hand, research really does tell us that if women embrace a lifestyle, before reaching menopause, that prioritises exercise, not smoking, not drinking alcohol, and a diet shifted away from meat and dairy toward whole-food, plant-based eating, their odds of getting breast cancer are slashed in half. And for older women, risk drops by 80 per cent.
One of the most dangerous falsehoods is that your diet doesn’t impact breast health, which is completely wrong. What you put into your body influences oestrogen levels – which fuel 80 per cent of all breast cancers – as well as inflammation, blood vessel formation, cellular function, and destructive free radicals, to name a few cancer-related factors.
One can see why Dr. Funk’s message is so appealing. She’s basically telling women that they can reduce their risk of breast cancer by 80%! In her interview in The Sunday Times, she was even more blunt:
When polled, most say that breast cancer is down to genetics, when in fact 87 per cent of women diagnosed do not have an immediate relative with the disease. Funk says that up to 90 per cent of the risk factors for the disease lie in our control, “not your doctor’s, genes or fate”. Funk assumed that they were the usual commandments to exercise and avoid chub and alcohol, but she was surprised to see study after study proving how much diet plays a role.
What is the biggest lifestyle risk factor for breast cancer? “Definitely nutrition. Then obesity, alcohol, exercise, hormone replacement therapy, stress.”
Unfortunately, Dr. Funk’s “logic” is based on a faulty understanding of genetics and risk. Nowhere could I find a better example of that than in an excerpt from her book that was published in Kevin, M.D., entitled, “Debunking breast cancer myths: the truth about genes, gender, and destiny.” (By the way, WTF are you doing publishing this rot, Dr. Pho? Seriously, your blog has gone way, way downhill!) Get a load of the first passage:
Genetics play a less important role than you probably think. Consider this fact: the identical twin sister of a woman with breast cancer has only a 20 percent chance of getting breast cancer one day—which, by the way, is the same risk as anyone with an affected sister. Since these twins share the exact same DNA, if genetics called all the cancer shots, risk should approach 100 percent—but it doesn’t, because genes aren’t the be-all end-all many people think they are.
Patient after patient tells me that there isn’t any breast cancer in her family, so she’s not really at risk. Yet 87 percent of women diagnosed with breast cancer do not have a single first-degree relative with breast cancer. In fact, only 5 to 10 percent of breast cancers currently prove to be hereditary, meaning that they occur because abnormal gene mutations pass from parent to child.
I sense a thousand geneticists out there grinding their teeth in unison at these statements. I know that she’s trying to counter a myth that breast cancer is entirely genetic in nature, but in doing so she goes way, way too far in the other direction. She assumes that just because only around 5-10% of breast cancers have a mutation in a known cancer-causing gene (like Angelina Jolie did in BRCA1) and only 13% of patients have a first-degree relative with breast cancer that genetics is much less important than sold and that 87% of breast cancer cases are potentially preventable. This is rubbish of the highest order. For one thing, increased risk due to relatives with breast cancer is more complex than that. More importantly, though, it’s “dose-dependent”. For instance, one first degree relative with breast cancer roughly doubles a woman’s risk, but if she has more than one first degree relative her risk is three- to four-fold higher. Age at diagnosis matters, too. The younger a first-degree relative is diagnosed with breast cancer, the more it matters, particularly before age 40. These are all indications of a genetic predisposition. I will give Dr. Funk credit for mentioning that the male side of the family matters, but her assumption that 80% or more of breast cancer can be prevented is not well-supported by evidence. And, make no mistake, she does make exactly this claim in her book (about 50 pages of which are available as an excerpt on Google Books), claiming that if you do what she says and exercise, don’t drink alcohol, don’t smoke, and shift your diet away from meat and dairy towards “whole food” plant-based eating before menopause you will slash your postmenopausal risk of breast cancer by 80% (p. 14).
I can’t help but note that the most potent known breast cancer-causing mutations in the BRCA1 gene only result in a roughly 80% lifetime risk of breast cancer, which is around seven times higher than that of the average woman.
The Clones of Dr. Funkenstein: Dr. Kristi Funk vs. lifestyle-based risk factors for breast cancer
It’s kind of depressing to read several of the articles by Dr. Funk and interviews with her, because you quite regularly see her saying that you must give up meat and dairy because they “fuel” breast cancer. She does it in hyperbolic terms, as well, citing the aforementioned claim that you can decrease your risk of breast cancer by up to 80%. Indeed, in the Sunday Times article, she even laid the fear on the journalist doing the article, Helen Rumbelow, by scaring her about her daughter’s love of dairy:
After this, my mind wanders to my adolescent daughter, who likes to drink a glass of full-fat milk a day because the evidence shows that this boosts height. A preliminary study by Michigan State University showed that a high-saturated fat diet in puberty sped up breast cancer in adult women.
“If she drinks milk she will grow because her body’s response to that is to spike her insulin-like growth factor, but she will also be setting the stage for illness. So I’d rather her be a little shorter,” says Funk.
Given that I’m in Michigan, I was really curious what this study was. I couldn’t find it in her book excerpts, and I couldn’t find it in any of her articles or interviews. So, I Googled, with not a lot of hope of finding the study. Find it, I did, though, through a press release by MSU. I call foul. Notice how Dr. Funk refers to this as a preliminary study. That is true, but in actuality it is a preclinical study in that it was a study done in mice! Worse, this was a mouse study where prepubertal mice were fed a low fat or high fat diet and then subjected to a chemical mutagen to induce mammary carcinogenesis. In other words, it’s a highly artificial model. While it’s an interesting result, whether or not it has anything to do with human puberty is less than a coin toss in likelihood. While mouse mammary development has been a useful model, there are many differences between human and mouse mammary glands. I’m guessing that SBM readers can see why such a study might not tell us much about the situation in humans.
What is the evidence regarding dairy as a breast cancer risk in humans? Let’s just say that it’s quite a bit less…impressive…than Dr. Funk seems to think. In fact, it’s largely negative or at the very least controversial and highly questionable. For instance, a study published just this year found “no overall association between dairy consumption during adolescence or early adulthood and breast cancer risk” and that dairy consumption during adolescence “may not be a significant predictor of breast cancer incidence.” (My reading of the study is that it was negative.) Indeed, a meta-analysis of prospective cohort studies published in 2011 suggests that “increased consumption of total dairy food, but not milk, may be associated with a reduced risk of breast cancer.” (That’s cheese and other dairy products they’re talking about.) That’s not the only one. A study from 2002 found decreased risk associated with dairy intake. Meanwhile another study found results “not supportive of a positive independent association between consumption of animal fat and breast cancer, although findings may be sensitive to the type of dietary instrument used in cohort studies.” A study from Roswell Park found no significant association between total dairy consumption and breast cancer risk but noted a positive association between milk consumption and certain subtypes of breast cancers. Finally, a 2004 meta-analysis concluded that “available epidemiologic evidence does not support a strong association between the consumption of milk or other dairy products and breast cancer risk.” In other words, it’s complicated. Several major studies consistently found lower risk associated with total dairy intake, but some found higher risk of certain subtypes of breast cancer associated with certain types of dairy. Basically, if dairy consumption does increase breast cancer risk (and my reading of the current literature is that it probably does not), the effect size is almost certainly quite small, at the limits of detection in epidemiological studies.
But what about meat? Dr. Funk makes it sound as though meat, especially processed meat, is a deadly breast cancer-inducing food that women should avoid like the plague. There might be something there, but, again, Dr. Funk appears to be vastly exaggerating the increased risk attributable to meat consumption. For example, a study from this year found an odds ratio for breast cancer of 1.16 among women with the highest consumption of processed meat. A recent British cohort study and meta-analysis found a relative risk of 1.21 among the highest tertile of processed meat consumption. However, when combined with ten previous cohort studies, the relative risk fell to 1.06 overall. That broke down to no association between processed meat consumption and breast cancer in premenopausal women and a relative risk of 1.09 in postmenopausal women. We’re talking single digit increases in risk here. As for red meat, there was no correlation. An earlier review and meta-analysis concluded that “red meat and processed meat intake does not appear to be independently associated with increasing the risk of breast cancer.” I could go on, but you get the idea.
Basically, Dr. Funk appears to have cherry picked studies finding the largest associations, while ignoring the mass of epidemiological evidence that came to conclusions she doesn’t like, such as:
     1.  Although there might be a small increased risk due to high consumption of processed meat (but not red meat), it’s only among those consuming the most. There is no good rationale, based on these studies, to give up meat as a means of dramatically reducing breast cancer risk.
     2.  The epidemiological data regarding dairy consumption and breast cancer risk is noisy, but is fairly clear that there probably isn’t an increased risk attributable to overall dairy consumption—and might even be a decreased risk. There might be a modest increase attributable to specific kinds of dairy products for specific subtypes of breast cancer, but my reading of this data is that the data are dicey and not very strong evidence for an association. That means that there is no good scientific basis for recommending eliminating dairy as a strategy to dramatically reduce one’s risk of breast cancer.
That’s about it. Basically, Dr. Funk makes a lot of claims that aren’t supported by science.
Dr. Funk oversells vegan diets
But what about vegan diet as a means of decreasing breast cancer risk? One message that Angelina Jolie appears to have imbibed from Dr. Funk is that going vegan will radically reduce her risk of recurrence and, among women who have never had breast cancer, greatly reduce the risk of it in the first place. Here’s what Dr. Funk claims:
The studies on vegans and breast cancer risk are, she concedes, somewhat muddy. The numbers of vegans have just been too low in the West, although it is worth noting that populations with low breast cancer rates typically eat little meat or dairy. The largest study on vegans and breast cancer is the Adventist Health Study, in which vegans (as opposed to vegetarians) showed a 44 per cent drop in breast cancer rates compared with meat eaters, or, as the researchers wrote in the journal Cancer Epidemiology, “vegan diet seems to confer lower risk for . . . female-specific cancer than other dietary patterns”.
Funk is confident that future studies will prove more conclusive because of other research done on the effects of animal fat and protein. Essentially, this is where the hormones and “growth factors” that make westerners so big, tall and possibly cancerous are stored. So, in the case of dairy, studies show no breast cancer risk of consuming low fat.
Actually, the studies don’t show much (if any at all) risk due to high fat dairy either. Be that as it may, Dr. Funk is really reaching here. She’s correct that there isn’t a lot of strong evidence. For instance, this study suggest that a vegan diets can modestly decrease total cancer risk, but the relative risk was only 0.92 (an 8% risk reduction). As for the Adventist Health Study (AHS), I can’t help but note a couple of things. First, it doesn’t seem to matter much what kind of vegetarian one is in terms of all-cause mortality, which is what really matters: The adjusted hazard ratio (HR) for all-cause mortality in all vegetarians combined vs non-vegetarians was 0.88 (95% CI, 0.80–0.97). The adjusted HR for all-cause mortality in vegans was 0.85 (95% CI, 0.73–1.01); in lacto-ovo–vegetarians, 0.91 (95% CI, 0.82–1.00); in pesco-vegetarians, 0.81 (95% CI, 0.69–0.94); and in semi-vegetarians, 0.92 (95% CI, 0.75–1.13) compared with nonvegetarians. Those numbers are all pretty similar; so I want to keep eating my fish, dairy, and eggs. Second, as for the risk of breast cancer, I’m confused. The latest publication from the AHS I could find was from 2016, and its findings were not nearly as striking as what Dr. Funk reports:
As compared with non-vegetarians, all vegetarians combined did not have a significantly lower risk (hazard ratio (HR) 0·97; CI 0·84, 1·11; P=0·64). However, vegans showed consistently lower (but non-significant) point estimates when compared with non-vegetarians (all cases: HR 0·78; CI 0·58, 1·05; P=0·09). In summary, participants in this cohort who follow a vegetarian dietary pattern did not experience a lower risk of BC as compared with non-vegetarians, although lower risk in vegans is possible. These findings add to the very limited literature associating vegetarian diets with BC risk and can assist nutritionists when evaluating the impact of these diets. The findings will also motivate further evaluation of vegan diets and their special characteristics.
Going back through the publications based on the AHS (and there are many), I think I found what happened. The most generous conclusion is that Dr. Funk confused studies. The publication that she cited to Rumblelow reported a decreased risk of female-associated cancers (breast, ovarian, endometrial), with a relative risk of 0.66, and included the exact same phrase (taking the ellipse into account) that Dr. Funk had provided in her article (“vegan diet seems to confer lower risk for overall and female-specific cancer compared to other dietary patterns”). Of course, she cited a 44% decreased risk, and this study found a 34% decreased risk, but I suspect she just had a brain fart and made a mistake in mental subtraction. (Again, that’s the most generous interpretation.) What can’t be reconciled is the claim that a vegan diet decreased the risk of breast cancer by 44% in the AHS and the actual evidence. The study cited does not show that, because breast cancer wasn’t broken out from “female-associated cancers”. A more recent publication (but still not so recent that she shouldn’t have been aware of it before the publication of her book), the very study that Dr. Funk cited, failed to find that a vegan diet confers a lower risk of breast cancer compared to a non-vegan diet. It found that a vegan diet might confer lower risk. Might. That’s a heck of a lot less definitive than the message that Dr. Funk is promoting, which is that meat and dairy are killing women by giving them breast cancer.
Finally, there is the issue of obesity. Obesity is definitely a risk factor for breast cancer. This has been known for a while. The relative risk varies among studies, but in general the risk is highest in postmenopausal women and for estrogen receptor-positive tumors, and can be as high as a relative risk of 1.7. So maintaining a healthy weight is indeed one way to decrease one’s risk of breast cancer. However, Dr. Funk comes across as borderline victim-shaming in discussing this. I’m not the only one who thinks so. Here’s the thing, though. Being obese, no matter how a woman got there, is probably the single most potent non-genetic lifestyle-based risk for breast cancer. Given that vegans tend to be slimmer, I find it interesting that the available evidence shows that a vegan diet probably doesn’t decrease a woman’s risk of breast cancer.
Alcohol: The cause of and solution to all the world’s problems
Dr. Funk is correct when she points out that alcohol increases the risk of breast cancer. However, the effect size is relatively modest, although it is dose-dependent. Cancer Research UK has a handy-dandy infographic that tells the story. For under three units a day, the additional risk is less than 5%, but it rapidly rises between 3-6 units/day and for >6 units/day. In other words, unless you’re a heavy drinker, the added risk from alcohol consumption is small.
Here’s where Dr. Funk goes from crystal clarity (“it is crystal clear that the body’s cellular response to animal protein and fat is nothing but dangerous“) to downright fuzzy, in inverse relation to the fuzziness of the evidence. The data with respect to meat and dairy as risk factors for breast cancer range from negative to only suggestive. Yet Dr. Funk is near-absolutist telling women not to eat dairy or meat, portraying them as full of inflammation-causing, cancer-inducing poisons whose elimination will dramatically decrease a woman’s risk of breast cancer. In direct contrast, there is no doubt in the literature (and hasn’t been for at least two decades) that alcohol significantly increases the risk of breast cancer in a dose-dependent fashion. Yet with alcohol she waffles. Here’s her take:
She is not unrealistic. Yes, any alcohol consumption increases breast cancer risk, but because of alcohol’s heart-healthy benefits she compromises on about one glass a day — and studies suggest that red wine may be the least damaging to breasts. Also, you know that thing people do when they eat a big salad to “trade off” their drink? It’s not ridiculous, it actually works. In the Nurses’ Health Study, among those drinking at least one glass of wine a day, those who also ate a few servings of green vegetables (adding up to 600 micrograms of folate) had 89 per cent less breast cancer than drinkers who did not.
This is rationalization at its finest. Dr. Funk likes wine; so she finds a reason why she can have a glass of wine every day. She’s not unreasonable, either. Everything is balancing risks and benefits in medicine, including diet. Yet she doesn’t apply the same reasonableness to meat, dairy, and all the other evil (to her) things that she views as breast cancer-causing killers. She also overestimates the evidence again, to allow her to rationalize her glass of wine a day. It’s not nearly as clear as she makes it that a daily glass of wine is heart-healthy. The issue is still fairly controversial.
Putting it all in perspective
Unfortunately, along with the sensible advice for decreasing breast cancer risk (lose weight; don’t smoke; exercise), Dr. Funk is selling a lot of dubious advice too (vegan diets, no meat, no dairy). It goes even beyond what I’ve discussed thus far. Apparently, earlier this year in an interview with Good Morning America, she suggested interventions like eating more cruciferous vegetables, antioxidant-rich berries, turmeric, Indian Gooseberry, mushrooms, and soy. Let’s just say that the evidence that any of these foods decrease the risk of breast cancer is slim to nonexistent. Perhaps the most bizarre advice she gave was to use bar soap instead of antibacterial soap to lower the risk of exposure to “toxins”. Again, this is basically nonsense, as was her advice to fill your home with houseplants to “absorb toxins”. Indeed, her message is so muddled and without support that a group of surgeons in the UK wrote a letter to The Sunday Times:
The Times published a shocking article from Dr Kristi Funk saying women were responsible for getting breast cancer – they shouldn't be tall or eat cheese or meat… This is the response from a group of senior Drs with cancer – they cut the letter but you get the point… pic.twitter.com/F4E045Xj0a
— Dr Miss Dr Mrs Liz O'Riordan (@Liz_ORiordan) July 17, 2018
Finally, above all Dr. Funk’s message is one of control. While it’s good to give patients a sense of control over their destiny, it does them no service to give them such an exaggerated sense of control wherein she tells them that they can reduce their risk of breast cancer by 80% when the evidence does not support that. Therein lies the path to blaming the victim. Contrary to what she claims, many of the risk factors for breast cancer are outside of a woman’s control. That doesn’t mean that there aren’t things a woman can do to significantly decrease her risk, such as losing weight, exercising, and not drinking to excess. (Believe it or not, smoking is not a strong risk factor for breast cancer, although it’s still a good idea not to smoke because obviously smoking is a strong risk factor for lung and several other cancers, as well as cardiovascular and lung disease.) However, there will always remain factors beyond her control. For example, the two strongest risk factors are female sex and age. Most cases of breast cancer are diagnosed over age 55 (median age 62). Other factor are family history, age at menarche and menopause, and the like. Others are, strictly speaking, controllable, but not really that practical to control. After all, who’s going to have a child at a young age to decrease her risk of breast cancer? Who’s going to have a lot of children just to reduce her risk of breast cancer? These are, of course, risk factors that have been known for a long time.
The bottom line is that evidence-based recommendations for how to reduce breast cancer risk are not sexy. Lose weight. Exercise. Don’t drink too much. Boring! That sort of advice doesn’t sell books, and it sure as heck doesn’t make one feel special or superior for having the will to radically change her life by giving up meat, dairy, and becoming a vegan who eats only “whole, plant-based foods,” which basically means no oils, no extracts, no vegan baking, no nothing. That’s what Dr. Funk is really selling.

A formal request for retraction of a Cancer article
James Coyne on May 12, 2014
Link

I am formally requesting that Cancer retract an article claiming that psychotherapy delays recurrence and extends survival time for breast cancer patients. Regardless of whether I succeed in getting a retraction, I hope I will prompt other efforts to retract such articles. My letter appears later in this post.
In seeking retraction, I cite the standards of the Committee on Publication Ethics (COPE) for retraction. Claims in the article are not borne out in simple analyses that were not provided in the article, but should have been. The authors instead took refuge in inappropriate multivariate analyses that have a high likelihood of being spurious and of capitalizing on chance.
The article exemplifies a much larger problem. Claims about innovative cancer treatments are often unsubstantiated, hyped, lacking in a plausible mechanism, or are simply voodoo science. We don’t have to go to dubious websites to find evidence of this. All we have to do is search the peer-reviewed literature with Google Scholar or PubMed. Try looking up therapeutic touch (TT).
I uncovered unsubstantiated claims and implausible mechanisms that persisted after peer review in another blog post about the respected, high journal-impact-factor (JIF = 18.03) Journal of Clinical Oncology. We obviously cannot depend on the peer review processes to filter out this misinformation. The Science-Based Medicine blog provides tools and cultivates skepticism not only in laypersons, but in professionals, including, hopefully, reviewers who seem to have deficiencies in both. However, we need to be alert to opportunities not just to educate, but to directly challenge and remove bad science from the literature.
A brief history
You may recall my previously blogging about the article that I am now requesting be retracted. I described how the authors unsuccessfully attempted to block publication of a criticism of their study. They then refused to respond when the criticism was published. The article spun faulty analyses and avoided simple analyses that showed that giving cancer patients breathing exercises and encouragement of healthy behaviors does not forestall recurrence or extend their lives.
But earlier papers from the same project did some spinning as well. For instance, one paper tested the more reasonable hypothesis that psychological interventions can reduce emotional distress, improve health behaviors and dose-intensity, and enhance immune responses.
There is no evidence that any changes in the immune parameters that were studied would be clinically significant or that there exists any plausible mechanisms by which recurrence and survival might be affected. But why wouldn’t we expect a support group intervention to affect mood and health behavior in the way that was hypothesized?
The abstract claimed uniformly positive results in terms of effects on anxiety and improved dietary habits, smoking, and adherence, with no negative results mentioned. However — and here I draw on my past blog post — the authors cast a wide net, with the methods section revealing assessment of at least:
    • 9 measures of mood (there is evidence from other articles that there are even more measures of mood assessed that were not reported in this article);
    • 8 measures of health behavior;
    • 4 measures of adherence;
    • 15 measures of immune function.
Turning to the actual results, only 1 of the 9 measures of mood was significant in time-by-treatment interactions. The intervention seemed to have had a significant effect on “dietary behavior” (although it is unclear why the results for very different individual dietary behaviors were not individually provided) and smoking, but no effect on exercise. As is often the case with early breast cancer patients, rates of adherence to chemotherapy were too high to allow any differences between the intervention and control groups to emerge.
In terms of immune function, results were not significant for counts of CD3, CD4, or CD8 cells, or six assays of natural killer cell lysis.
These overall results suggest that what we were told in the abstract represents a gross confirmatory bias — the suppression of negative results and the highlighting of positive ones likely to be due to chance.
Claims about biomedical outcomes such as recurrence and death need to be evaluated as such. It is unlikely that claims about a new form of chemotherapy or radiotherapy would be accepted if they were based on faulty post-hoc analyses of a study with such a small sample size, and with results contradicted by more straightforward, appropriate analyses. But for a variety of reasons, claims about psychological interventions improving survival are often given special consideration not only in the media, but in scientific journals.
Let us get real. Given the effectiveness of current treatments for early breast cancer, an effort to demonstrate an improvement over results obtained in guideline-consistent routine care would have to involve thousands of patients, not the 227 recruited for this study. In the U.S. the 5-year survival rate for women with localized breast cancer is now 98.5%. And then of course there is the lack of plausible biological mechanism by which group therapy could slow recurrence and extend survival.
Mind over cancer
The idea that the power of mind can triumph over physical illness is deeply rooted in Western folk culture and has its roots in classical Greek and Roman thinking. Yet, we showed in a systematic review of the literature, that “No randomized trial designed with survival as a primary endpoint and in which psychotherapy was not confounded with medical care has yielded a positive effect.”Investigators who had undertaken ambitious, well-designed trials to test the efficacy of psychosocial interventions but obtained null results echoed our assessment with reviews declaring “Letting Go of Hope” and “Time to Move on.”
I provided an extensive review of the literature concerning whether psychotherapy and support groups increased survival time in an earlier blog post. Hasn’t the issue of mind-over-cancer been laid to rest? I was recently contacted by a science journalist interested in writing an article about this controversy. After a long discussion, he concluded that the issue was settled — no effect had been found — and he would not succeed in pitching his idea for an article to a quality magazine.
But hold on.
Considering the question open is vital to continued federal funding of the field of psychoneuroimmunology (PNI). Without having established that psychological interventions actually improve survival of cancer, PNI seeks to explain how these interventions succeed. It is classic tooth fairy science.
The NCI in particular provides financial support to efforts to promote psychoneuroimmunology in articles in special issues of journals and symposia that exclude any anyone who might express skepticism. As an example, see an extraordinary 2013 article, “Psychoneuroimmunology and cancer: a decade of discovery, paradigm shifts, and methodological innovations published by McDonald, O’Connell & Lutgendorf in Brain, Behavior, and Immunity (30, S1-S9).The article celebrated a decade of NCI support for psychoneuroimmunology, starting with a 2002 conference and resulting 2003 monograph. The three authors were a NCI program officer, a science writer paid by NCI, and a proponent of Therapeutic Touch. The 2013 article introduced a collection of carefully selected invited reviews:
This [2003] seminal volume captured state-of-the-science reviews and commentaries by leading experts in psychoneuroimmunology (PNI) and served as a catalyst for biobehavioral1 research conducted in a cancer context. In the decade prior to the NCI commissioned supplement, Brain, Behavior, and Immunity published only 12 cancer-relevant articles. Since the 2003 supplement, the journal has featured 128 cancer-relevant papers that have generated 3361 citations (data from SCOPUS, retrieved November 1, 2012), relative to 55 papers on PNI and cancer, published in other peer review journals during the same time period. These bibliometric data highlight Brain, Behavior, and Immunity as a leading scholarly outlet for research on the biology of psychological and social experiences and the integrated mechanisms associated with cancer as a complex disease process. The current volume celebrates the 10-year anniversary of the 2003 supplement. This collection of invited reviews and research articles captures important discoveries, paradigm shifts, and methodological innovations that have emerged in the past decade to advance mechanistic and translational understanding of biobehavioral influences on tumor biology, cancer treatment-related sequelae, and cancer outcomes.
This paragraph can be interpreted in different ways. B, B, & I’s editorial board is a tight club of PNI researchers , many of those with NIH funding. The journal rarely has an article without positive findings and seldom is seen a skeptical word about PNI. The journal could represent the success of NIH funding for PNI research, particularly NCI, or the poor reception of PNI research in the larger scientific literature. Outside the incubator, PNI mostly does not survive peer review.
In 2014, a NCI program officer placed solicitations on a listserv for free training in Cancer to Health (C2H), supported by a NCI R-25 grant. The evidence mustered for the R-25 application is the project from which the Cancer article came.
At a 2014 meeting of the Society Behavioral Medicine, the NCI supported a symposium with a NCI program officer as a discussant. The author of the article for which I have requested a retraction renewed her claims of the powers of her intervention and solicited applications from professionals interested in free training with support from the NCI R-25 training grant.
In August 2014, the author of the Cancer article will fly to Groningen, the Netherlands, with another NCI program officer and again present her claims at the International Congress of Behavioral Medicine.
For political reasons, not science, the NIH is interested in keeping this line of research alive, even if it is on life support. The idea is that behavioral interventions can extend life, not just improve its quality. And to study exactly how requires not only investigator-initiated R01s but larger program grants. When the author of the Cancer article refused to respond to our critique, the task was accepted by Peter Kaufmann. He is the Deputy Chief of the Clinical Applications and Prevention Branch of National Heart Lung and Blood Institute (NHLBI) and at the time his commentary was written, President of the Society of Behavioral Medicine.
As I note in my earlier post:
Subtitling his commentary “To Light a Candle,” Kaufmann conceded that my colleagues and I had raised valid criticisms about the design and interpretation of the C2H intervention trial. However, he took issue with our recommendation that clinical trials of this kind be suspended until putative mechanisms could be established by which psychological variables could influence survival. Quoting our statement that an adequately powered trial would require “huge investments of time, money, and professional and patient resources,” he nonetheless called for dropping a “preoccupation with mechanisms and secondary aims,” and instead putting the resources to increasing the sample size and quality of an intervention trial.
Wow, so we should ignore the lack of evidence for biologically-plausible mechanisms. Kaufmann suggests we should pour what would have to be millions of dollars into a trial to test whether psychotherapy and support groups extend the lives of cancer patients.
The call for retraction
May 7, 2014
Fadlo R. Khuri, MD, FACPEditor-in-Chief, Cancer
Dear Dr. Khuri:
This open letter formally requests retraction of a 2008 Cancer article
Andersen, B. L., Yang, H. C., Farrar, W. B., Golden-Kreutz, D. M., Emery, C. F., Thornton, L. M., … & Carson, W. E. (2008). Psychologic intervention improves survival for breast cancer patients. Cancer, 113(12), 3450–3458.
According to the Committee on Publication Ethics (COPE; http://tinyurl.com/kd5q28o), journal editors should consider retracting an article if
they have clear evidence that the findings are unreliable, either as a result of misconduct (e.g. data fabri­cation) or honest error (e.g. miscalculation or experimental error)
I call your attention to the basic data reported in the flow chart in Figure 2 of the cited article. Analyses that can be readily performed but that are not provided in the article directly contradict the claims that are stated in the title, get amplified in the abstract, and are repeated throughout the text. When simple 2×2 chi-square calculations are performed on raw recurrence and death events from the figure for intervention versus control group, differences do not approach significance for the proportion of women experiencing a cancer recurrence in the intervention (25.4%) versus control conditions (29.2%; Odds Ratio = 0.83, CI = 0.46 – 1.48, p = .525). There is no difference between the proportion of women who died in the intervention group (21.1%) versus the control condition (26.5%; Odds Ratio = 0.74, CI = 0.40 – 1.36, p = .332). Similar results are obtained if one examines only those deaths due to breast cancer.
My colleagues and I previously published a commentary in Cancer arguing that the authors’ data failed to support their conclusions.
Stefanek, M. E., Palmer, S. C., Thombs, B. D., & Coyne, J. C. (2009). Finding what is not there. Cancer, 115 (24), 5612-5616.
Our commentary was originally submitted as a briefer letter. It was first rejected, with a previous editor citing a standing policy of not accepting critical commentaries if authors refused to respond. This policy essentially allowed authors to suppress criticism of their work, regardless of the validity of criticism. We asked the editor to re-evaluate the policy and reconsider the rejection of our commentary. The editorial board reconsidered and invited the extended commentary that was published. However, the authors still refused to respond, a choice which many would consider extraordinary.
Our criticisms would have been directly addressed if the authors had simply provided a report of positive findings for standard, unadjusted outcomes, such as a Kaplan-Meier estimate of the survival function. We indicated strong reasons why such analyses would not be significant. Regardless of their choice not to respond to our letter, the authors had a responsibility to provide these data.
Instead of results for unadjusted outcomes, the authors had provided in the article dubious multivariate analyses with a high risk of spurious findings. Both unadjusted and adjusted analyses should have been provided. When positive results are obtained with unadjusted outcomes, readers’ confidence in them are increased when findings persist after adjustment for possible confounds. However, when positive results are obtained with unadjusted outcomes, contradictory findings after adjusting for confounds warrant special scrutiny. Interpretation of adjusted outcomes assumes complete specification of possible confounds and measurement without error, assumptions that are not typically tested or met. Analyses with adjusted outcomes are not necessarily more generalizable than those with unadjusted outcomes. On the contrary: Positive findings with adjusted outcomes may variously reflect overfitting, residual confounding, incomplete specification and imperfect measurement of covariates, and covariate selection procedures that capitalize on chance.
The multivariate analyses presented in Anderson et al.’s article control for initial group differences in a number of potential confounds. This is remarkable because the authors also reported ‘‘no significant differences between study arms in sociodemographics, disease, prognostic factors, type of surgery received, or adjuvant treatments.”
The authors relied on a backward elimination procedure to select control variables from a larger pool of at least 15 candidate variables. Eight to ten of these factors were retained as covariates in analyses predicting time to recurrence, death from breast cancer, or death from any cause. Aside from capitalizing on chance, the number of covariates was simply too high relative to the number of events being explained (i.e., recurrences, breast cancer deaths, other deaths). Anderson et al. consistently violated the general rule that predictors should not be added to the equation if the ratio of outcome events to predictor variables is not at least 10:1. For instance, the final model for recurrence-free survival included 11 predictors for 62 events: a ratio of 5.6:1.
You may ask why a claim for retraction is occurring at this time. First, the authors have continued to cite this claim in other publications without acknowledging objections to the analyses. Second, this paper continues to be widely cited and specifically as evidence that psychosocial intervention prolonged survival, a claim that does not otherwise have support. Third, this particular paper served as the basis for federal funding to disseminate training in this intervention. The paper is specifically cited in solicitations (http://tinyurl.com/n2den7g) for training at Professor Barbara Andersen’s Training Institute For Empirically Supported Biobehavioral Interventions for Cancer Patients.
Claims about time to recurrence and cancer-specific and all-cause mortality are claims about biomedical outcomes. I seriously doubt that had such claims concerning chemotherapy or radiotherapy based on flawed analyses in a small sample in a study in which survival was not a predesignated outcome been made, they would go unchallenged. I believe that these authors’ claims should be held to the same standards as other biomedical interventions.
The American Cancer Society website (http://tinyurl.com/l2f63c7) has posted a statement
The research is clear that support groups can affect quality of life, but the available scientific evidence does not support the idea that support groups or other forms of mental health therapy can by themselves help people with cancer live longer.
This is in response to widespread beliefs among patients and their families that persons with cancer can somehow boost their immune system and thus extend their chances of survival if they attend such groups.
The Andersen et al. Cancer article that lends credibility to these groups stands in direct contradiction to that statement by the ACS. Either the statement should be revised or the finding should be retracted.
Thank you for your consideration. I await your response with interest.
Sincerely,James C Coyne PhDProfessor Emeritus of Psychology in PsychiatryPerelman School of Medicine of the University of PennsylvaniaProfessor of Health PsychologyUniversity Medical Center, Groningen

Frightening Breast Cancer Patients with Bad Science
James Coyne on September 28, 2012
Link
No Time to Waste: Avoidant Coping Style Scrambles Circadian Rhythms in Breast Cancer Patients, warned the headline of an article in Clinical Psychiatry News. The article went on to claim
Even in the earliest days following a diagnosis of breast cancer, maladaptive coping styles are associated with a disruption in circadian rhythms –which are proven in metastatic disease to be a prognostic indicator of mortality. The surprising finding… holds potentially profound implications for the timing and tailoring of psychosocial interventions in newly diagnosed patients.
And it invoked psychoneuroimmunology for an authoritative sounding warning to breast cancer patients:
The fact that circadian disruption was significant in a subset of patients a mean 19 [sic] days after diagnosis suggests that there may be no time to waste in identifying and treating potentially maladaptive coping responses that could impact not only their adjustment, but also their prognosis.
Women who are diagnosed with breast cancer, enroll yourself immediately in a stress reduction program or support group, if you want to stem the progression of your disease and prolong your life! If you have metastatic disease, maybe you can blame your “maladaptive coping,” your inept handling of the days and weeks immediately after your diagnosis. Such frightening messages to women who are vulnerable because they have just received their diagnosis should require high standards before being released. This article reeks of hype and distortion, starting with its emotional title, No Time to Waste and “Scrambles Circadian Rhythms,” continuing with claims of “profound implications for the timing of psychosocial interventions,” and ending with an exhortation to breast cancer patients that “early breast cancer patients certainly warrant paying closer attention to coping from Day 1.”
The issue is not just skewered science, because the article contains information that is easily misunderstood without a proper context. Breast cancer patients are urged to take get psychosocial intervention under the threat that if they do not, they are missing an opportunity to control the progression of their disease. This is an example of the irresponsible nonsense that I have been complaining in the past two blogs. There is simply no evidence that psychological interventions can slow progression of cancer or extend life. Claims to the contrary serve to burden cancer patients with an unrealistic responsibility for the outcome of their medical condition. Patients who experience progression to a terminal condition are provided with an irrational sense that they are to blame because they did not take the right steps, namely avail themselves of effective psychological interventions. This article implies that breast cancer patients with an unfavorable course have brought it on themselves by getting too stressed out.
It’s not clear whether journalist Betsy Bates Freed, PsyD. actually interviewed the authors of the study on which the story is based. Media coverage often offers direct quotes that appear to have been obtained directly from authors when they actually come from the scientific article. In this particular case, Freed provides a highly speculative direct quote that “circadian cycles regulate tumor growth” as if it came directly from the mouth of the lead author of the study. For the record, there is some evidence of an association between circadian rhythms and progression of metastatic breast cancer, but it is not clear that it is causal or affects”regulation” or in what direction any causal arrows run. Importantly, such findings have not been replicated with early breast cancer patients.
Clinical Psychiatry News is not some dubious CAM website, but an Elsevier published monthly newspaper with an advisory editorial board with recognizable scientist and clinician psychiatrists. It has largely free web access because of pharmaceutical company support. One has to question what editorial control over content is exerted before releasing articles like No Time to Waste.A recent cohort studyof hyped and distorted news coverage of clinical trials concluded that distorted press coverage often begins with distortion in the abstracts of the articles reporting the clinical trials, specifically the conclusion sections. Is that what occurred with this coverage of the study?
The conclusion of the abstract that prompted the wild claims reads:
Maladaptive psychological responses to breast cancer diagnosis are associated with disruption of circadian rest/activity rhythms. Given that circadian rhythms regulate tumor growth, we need greater understanding of possible psychosocial effects in cancer related circadian disruption.
This seems to have prompted the journalist’s hype and distortion, although the journalist goes much further. The declaration of “maladaptive psychological responses to breast cancer diagnosis” is suspect. The sample included only 57 presurgical breast cancer patients, and although there is understandably some distress immediately after a diagnosis, there is also a naturally occurring trajectory of substantial reduction in distress over the next few months. Even if it comes as a surprise to them, most breast cancer patients bounce back quite well from a diagnosis, at least in conventional psychological terms. I am skeptical about just how much “maladaptive psychological responses” would be found in such a small sample and how the immediate response of these women could even be considered maladaptive. What might be considered maladaptive if it is chronic and unrelenting can be quite normal as an acute response. But we need to refer to the article to further examine the claims in the abstract. Given such a short period of observation, it is questionable whether these authors obtained enough variation in “maladaptive response” in such a short time of observation to establish any association with circadian rhythms.
The article that prompted this press release had just come out in Annals of Behavioral Medicine and can be accessed through a pay wall here. If you cannot access it through your university library website, you can try e-mailing the senior author at [email protected] and requesting a copy.
Let’s give a close look to the article.
The 57 breast cancer patients studied an average of 19 days after diagnosis were mostly Stage 0 to Stage IIa and only 3 had Stage 4 metastatic breast cancer.
The authors hypothesized they would find
Interrelationships between stress (intrusions) and coping (avoidant coping), circadian disruption (rest/activity and salivary cortisol rhythm), and endocrine activation (cortisol awakening response [CAR], mean saliva cortisol levels). Rest/activity and salivary cortisol rhythms were chosen as circadian disruption measures because of their demonstrated prognostic significance in cancer…
Whoa! It is only in metastatic breast cancer that circadian disruption measures have demonstrated prognostic significance. There is a considerable inferential leap here.
The study involved the women providing four days of data from home: brief self-report psychological data collected each morning, and 12 saliva samples on three consecutive days: at waking, a half-hour after waking, at 4 PM, and immediately before bedtime.
In addition to the saliva samples, circadian rhythm was measured with an actigraph worn on the wrist, a movement recording device that registers body motion. The women wore the device for three days and four nights except for when showering or bathing. To assist in interpretation of the movement data from the actigraph, they recorded each morning in a diary times they got into bed, time they fell asleep, when they woke and the time they got out of bed.
It may seem impressive that the method section reports assessments of maladaptive coping and disrupted rest/activity circadian rhythm as measured by 24-hour autocorrelation coefficients obtained with actigraphy. But let’s take a closer look at these measures. I happen to have done some of the earliest work with coping checklists designed to measure what goes on everyday life. I at first had great enthusiasm for their potential, but grew disillusioned, and much to the dismay of those who were adopting the Ways of Coping Checklist that my group had produced, I wrote an article suggesting it be labeled
WARNING!!
Hundreds of studies have established that use of this instrument is unlikely to yield findings of substantive importance and that the risk of confounded and otherwise spurious results is high.
I was really reluctant to disrupt all of the attention that our work was getting, but I decided that coping measures performed that badly and that their brief items really did not give much indication of what was going on people’s lives. The same holds true of the coping measures that came after ours.
I also did some work with actigraphy assessments of prostate cancer patients undergoing androgen deprivation in which I tried to determine if their hot flashes caused sleep disturbance. Actigraphy assessments are basically just a matter of the registering of arm movement or leg movement, if that’s where the device is placed. Making sense of short periods of measurement can be quite difficult, particularly without considerable additional information and if assessments made during waking hours reflect subjects simply sitting or doing sedentary tasks.
Readers who don’t usually wander further into methods and results sections of journal articles might want to skip the next eight paragraphs and get to my conclusion that there is not a lot exciting going on in this article and there is certainly no basis for the outrageous claims in the news article based upon it. However, my whole point is to teach skepticism about psychoneuroimmunology, and it would defeat my purpose if readers uncritically accepted my interpretations. Please, be skeptical of me too.
The particular coping measure used in this study was only six items long and the items are highly ambiguous. The two items for self distraction were “turning to work or other activities to take my mind off things” and “doing something to think about it less, such as going to movies, watching TV, reading, daydreaming, sleeping or shopping. These sound like reasonable strategies. The two items for denial were “saying to myself ‘this isn’t real’” and “refusing to believe it happened,” which certainly could be expected to occur less than three weeks after diagnosis of breast cancer. The two items for behavioral disengagement were “giving up trying to deal with it” and “giving up the attempt to cope.” I am sure that a mentally healthy woman who’s been told she has breast cancer would have times when she endorsed these items. Looking past the authors’ dubious labeling of the scale, none of these items do not seem particularly maladaptive when occurring in the days after diagnosis of breast cancer. There are no norms or established cutpoints for adaptive or maladaptive, and I suspect that the normal range of adjustment after something unsettling like a diagnosis of breast cancer would be quite wide. Bottom line: the authors don’t have a good basis for assuming what they’re measuring is maladaptive and there is no precision to the designation.
The measure of intrusive thoughts was originally developed to assess reactions to stressful events that were already securely in the past. It makes sense to consider high scores maladaptive for a Vietnam War veteran years after he has left the combat zone, but the meaning is much less clear in the immediate aftermath of a diagnosis of breast cancer. But do we make of for instance, of the items “any reminder brought back feelings about it.” Or “I thought about it when I didn’t mean to”? What would be maladaptive for a Vietnam War veteran years later might reflect adaptive deliberation and active problem solving for a woman just diagnosed with breast cancer. Bottom line: I would make too much of the measure of intrusive thoughts. In this study, the scores were actually low for breast cancer patients, but the authors cannot judge the scores representing maladaptive responses with any confidence. What is their proposed cutoff for “maladaptive” and where is the evidence validating it. The measure is sensitive to the normal upset in response to a diagnosis of breast cancer that will mostly resolve over time.
Actigraphy assessment during time in bed basically captures restlessness versus restful sleep and getting up versus remaining in bed. To be confidently interpreted, such assessments need to be accompanied by reports verifying what subjects were doing, including when they went to bed and how long before they fell sleep and whether they got up in the tonight.
Women with newly diagnosed early breast cancer are generally not physically impaired, and so actigraphy assessments of their daytime activity can be highly ambiguous. If they’re not registering much activity, they could be riding in a car, watching movies, relaxing reading a book, or sitting with a couple of coffee, contemplating the news they just received and the implications for their future. Such daytime actigraphy data is more readily interpretable if experimenters have some diary information, just as in actigraphy assessments of time in bed. And keep in mind the impressive designation “24-hour autocorrelation coefficient”is simply a matter of comparing the consistency of rest/activity patterns on the first day to what is obtained at the same time on the second and third days. We have no information as to whether assessment days were weekdays or weekends , and for which women, which can make a big deal of difference.
In contrast, actigraphy assessments of metastatic breast cancer patients register that they are ill. That is one of the problems associated with trying to make sense of the prognostic value of disrupted circadian rhythms It is even more difficult to make comparisons to a sample of women with early breast cancer, most of whom are asleep the majority of the night and out of bed most of their waking hours.
When I go to the Results section of an article, I expect to find simple basic statistics so I can decide for myself what is going on before plunging into complex multivariate statistics for which I depend a lot on the authors’ interpretation. I look for basic correlations. After all the authors are proposing that coping is related to salivary cortisol and actigraphy measures, and they end up taking the position that one can only look at these associations after controlling for income. Why only income? When I couldn’t find basic correlations among key variables, I emailed the senior author and asked her if she could send them to me. She stated that she was on sabbatical, and would send them when she got back. I sent her a message asking if that was a refusal, and she did not reply. I should point out that even if she were on sabbatical, she could certainly have passed on the request to one of her six co-authors who presumably were not so out of touch.
Rather than reporting simple correlations, the authors reported multivariate analyses first controlling for age, cancer stage, and income, before variables like intrusive thoughts or avoidant coping were considered. No associations were found between intrusive thoughts and avoidance on the one hand and salivary cortisol on the other. Given that salivary cortisol was considered a measure of circadian rhythm, this would seem important disconfirmatory result, but little more is said about it. Neither intrusive thoughts nor avoidant coping were related to nighttime restfulness, which also seems surprising. If these women were coping so badly presumably it would disturb the restfulness of their sleep. Avoidant coping and intrusive thoughts were related to how sedentary the women were during the day, and that seems to have influenced the autocorrelation coefficient. But what can we make of this? Some of the avoidant coping items reflect reading, and going to the movies, and I would hesitate to construe has circadian rhythm disruption.
Easily overlooked in these multivariate analyses is that income is as strongly related to circadian rhythm as the coping variables are. I have no idea what to make of this, but it is important not to cherry pick the associations that are consistent with investigators’ hypotheses and avoid those that are troublesome to interpret.
Overall, this article is not transparent in a way that allows independent evaluation of its claims, but is transparent enough to generate some skepticism about any interpretation that women with early breast cancer are hurting themselves by stressing out and not sleeping. Like a lot of psychoneuroimmunology studies, it generates excitement not by its findings, but its claims of relevance to unmeasured things like progression and survival. And it gives a strong sense of confirmatory bias by overlooking predicted associations that were found in highlighting those that were. We are not told enough about the nature or circumstances of measurements, nor are we provided basis statistics, and in the end, we are given no more basis for claiming that disrupted circadian rhythms promote tumor growth in early breast cancer than we started with. There is currently no evidence that disturbed circadian rhythms affect or even predict progression of early breast cancer, and this study only assumed rather than tested this relationship.
I do not blame the authors for the hype and distortions in the Clinical Psychiatry News article. But they could have done a much better job in setting the context of their study, acknowledging the limits of existing research, describing the methods, and reporting their results in ways that did not generate premature claims about clinical relevance or encourage alarm among breast cancer patients. And if they were overcome with enthusiasm about their study, the editor and reviewers at Annals of Behavioral Medicine should have reeled them in.

Breast cancer myths: No, antiperspirants do not cause breast cancer

David Gorski on October 6, 2014

Antivaccine activists frequently claim that aluminum salts used as adjuvants in vaccines cause autism. However, if you listen to the quacks and cranks, that’s not all aluminum does. Oh, no, that nefarious metal is also being blamed for breast cancer. But don’t throw away your antiperspirant just yet. The evidence cited to support this connection is utterly unconvincing. Much of it even borders on pseudoscience.
David Gorski on October 6, 2014
Link

Four weeks ago, I wrote a post in which I explained why wearing a bra does not cause breast cancer. After I had finished the post, it occurred to me that I should have saved that post for now, given that October is Breast Cancer Awareness Month. The reason is that, like clockwork, pretty much every year around this time articles touting various myths about breast cancer will go viral, circulating on social media like Facebook, Twitter, Pinterest, and Tumblr like so many giant spider-microbes on the moon on Saturday. Sometimes, they’re new articles. Sometimes they’re old articles that, like the killer at the end of a slasher film, seem to have died but always come back for another attack, if not immediately, then when the next movie comes out.
So I thought that this October I should take at least a couple of them on, although I can’t guarantee that I’ll stick to the topic of breast cancer myths for the whole month. After all, our “atavistic oncology” crank (you remember him, don’t you?) is agitating in the comments and e-mailing his latest “challenge” to my dean, other universities, and me. It was almost enough for me to put this post on hold for a week and respond to our insistent little friend’s latest “evidence,” but for now I’ll just tell Dr. Frank Arguello, “Be very careful what you ask for. You might just get it.” Maybe next week. Or maybe on my not-so-super-secret other blog. Or maybe never. Because Dr. Arguello has officially begun to bore me.
In the meantime, I’m going to stick with the original plan, at least for now.
So, first up this week is a myth that I can’t believe that I haven’t covered in depth sometime during the nearly seven years of this blog’s existence, other than in passing a couple of times, even though it’s a topic that deserves its own post. I’m referring to the claim that antiperspirants cause breast cancer. I bet you’ve seen articles like this oldie but not so goodie from über-quack Joe Mercola entitled “Are Aluminum-Containing Antiperspirants Contributing To Breast Cancer In Women?” or this older and even moldier article from seven years ago entitled “Why women should avoid using anti-perspirants that could cause breast cancer” or this one from last year entitled “Attention Deodorant Users: New Studies Link Aluminum To Breast Cancer“. Surprisingly, I haven’t found that many from this year yet. (Maybe the Ebola scare is distracting the usual suspects and diverting their efforts.) The same ones, however, keep reappearing every year, and they’re all based on the same sorts of claims and the same studies. So let’s dig in, shall we?
Spaced…1999
It all began, at least as far as it is possible to figure out the precise origin of any recurring myth about health, with an e-mail dating back to 1999, as described on Snopes.com:
BREAST CANCER PREVENTION
Not just for women — men don’t forget to tell mom, cousins, etc. Deodorants (non-antiperspirants) are very hard to find but there are a few out there.
I just got information from a health seminar that I would like to share.
The leading cause of breast cancer is the use of anti-perspirant.
What? Yes ANTI-PERSPIRANT. Most of the products out there are an anti-perspirant/deodorant combination so go home and check your labels.
Deodorant is fine, anti-perspirant is not. Here’s why:
The human body has a few areas that it uses to purge toxins; behind the knees, behind the ears, groin area, and armpits. The toxins are purged in the form of perspiration.
Anti-perspirant, as the name clearly indicates, prevents you from perspiring, thereby inhibiting the body from purging toxins from below the armpits. These toxins do not just magically disappear. Instead, the body deposits them in the lymph nodes below the arms since it cannot sweat them out. This causes a high concentration of toxins and leads to cell mutations: a.k.a. CANCER. Nearly all breast cancer tumors occur in the upper outside quadrant of the breast area. This is precisely where the lymph nodes are located.
Additionally, men are less likely (but not completely exempt) to develop breast cancer prompted by anti-perspirant usage because most of the anti-perspirant product is caught in their hair and is not directly applied to the skin. Women who apply anti-perspirant right after shaving increase the risk further because shaving causes almost imperceptible nicks in the skin which give the chemicals entrance into the body from the armpit area.
PLEASE pass this along to anyone you care about. Breast Cancer is becoming frighteningly common. This awareness may save lives. If you are skeptical about these findings, I urge you to do some research for yourself. You will arrive at the same conclusions, I assure you.
The origin of this myth is rooted in a typical misunderstanding of biology that regular readers probably recognized immediately, namely the issue of “toxins.” It is simply not true that apocrine sweat glands (the variety of sweat gland that are found predominately under the arm and in the groin area that can produce substances that the bacteria on the skin feast upon to make the characteristic stinky aroma) are a major source of “detoxification,” nor is there any compelling evidence that blocking these sweat glands, which is how aluminum-containing antiperspirants tend to work, results in the accumulation of “toxins” under the arm. There’s also another misunderstanding here. If, as is described, nicks from shaving the armpit allow the evil chemicals from the antiperspirant to get in, what would be far more likely to happen than what this e-mail assumes is either that (1) the chemicals would get into the bloodstream and disperse throughout the body, highly diluted, or (2) the chemicals would remain in the dermis (the layer of the skin immediately below the epidermis, which is usually all that is nicked by shaving). In the case of #2, let’s just put it this way: If the skin was cut all the way through the dermis that would be one hell of a cut. Also, with the use of modern safety razors, a cut that goes more than just a little bit into the dermis is highly unlikely. So, if #2 were true, we’d expect an elevated risk of skin cancer in the area, not breast cancer, because there is no plausible mechanism by which the evil chemicals from the antiperspirant to get much beyond the dermis, much less to accumulate in the breast tissue. Given that the apocrine sweat glands are located in the subcutis or at most the superficial subcutaneous fat, the same would be true even if antiperspirants caused toxins that would otherwise escape through sweat to be bottled up in the sweat gland.
So, right off the bat, we see a plausibility problem to this hypothesis. Of course, we’re not talking homeopathy-level implausibility here, but it’s hard to imagine a logical, science-based mechanism whereby antiperspirants could lead to a highly elevated risk of breast cancer in just one quadrant, the upper outer quadrant, of the breast.
But what about the claim that “nearly all” cancers occur in the upper outer quadrant of the breast and the observation that that is “precisely where the lymph nodes are located.” Well, yes and no. First off, this observation seems to be confusing sweat glands and lymph nodes, as though blocking off sweat glands would cause backups of those mysterious, never identified “toxins” in the lymph nodes. They’re two different things, and lymph nodes are not connected to the sweat glands, as this e-mail (and many articles claiming that antiperspirants cause breast cancer) seems to assume.
Also, it is not true that “nearly all” breast cancers are in the upper outer quadrant (the quadrant closest to the armpit), although it is true that there is a propensity for breast cancer to appear there first. Why is this? The reason you will frequently see cited is that most breast cancers occur in the upper outer quadrant of the breast. Because that quadrant of the breast is closest to the underarm, which is where antiperspirants are used, it must be the antiperspirants! And global warming is most definitely due to the decreasing number of pirates over the last three centuries. In fact, it is true that a little more than half of all breast cancers develop first in the upper outer quadrant of the breast, but it’s not because of antiperspirant use. It’s just because of a very simple fact of anatomy. Contrary to what people intuitively think when they hear the word “quadrant,” the distribution of breast tissue is not equal among the quadrants. In other words, each quadrant does not contain one-quarter of the breast tissue making up that breast. Rather, there is much more breast tissue in the upper outer quadrant than there is in other quadrants of the breast, because of a part of the breast known as the “axillary tail” or the “tail of Spence,” which consists of breast tissue extending toward the underarm. It turns out that the number of breast cancers diagnosed in the upper outer quadrant is proportional to the amount of breast tissue located there. There is no preponderance for upper outer quadrant cancers when the distribution of breast tissue in the different quadrants is taken into account.
The best evidence for a link is not so good
To me, the poor quality of evidence cited to support such a link between antiperspirants tends to be epitomized by an article that was being touted a few years back by Sharyl Attkisson. (You remember Sharyl Attkisson, don’t you?) At the time, she was touting an article by Dr. Kris McGrath in Medical Hypotheses, whose speculative nature and lack of peer review has been discussed elsewhere. I’ll start with this evidence and then work my way up to the best evidence cited by proponents of an antiperspirant-breast cancer link.
The evidence first cited is a study by McGrath in which he investigated a group of women with breast cancer and reported that the sooner they began using antiperspirants in their youth, the more frequently they used them, and the more frequently they shaved under their arms, the earlier they were diagnosed with breast cancer. Unfortunately this study was not very convincing. Besides being a retrospective study prone to recall bias, it had an enormous flaw in it, a flaw so obvious that I’m surprised this article got published. There was no control group. It’s a single-arm study that only looked at women who got breast cancer, and it didn’t control for a variety of confounders. For instance, women who started using antiperspirants or shaving earlier probably went through puberty earlier and, as a consequence, had their first menstrual period earlier. Starting menses early is a risk factor for breast cancer that has been known for a very long time. Ditto women who started shaving their underarms earlier. Worse, another, much better-designed study that did look at women both with and without cancer (and twice as many of each) had been published the year before and found no correlation between the use of antiperspirants and the risk of breast cancer.
According to McGrath, underarm antiperspirants clog the pores of apocrine sweat glands and cause the absorption of sex steroids into the blood. It’s a hypothesis that sounds very much like the one in the e-mail in which clogging the pores results in unnamed “toxins” backing up, just substituting sex steroids for “toxins.” It’s a pretty implausible hypothesis at best. The reason is that the amount of sex hormones made by the skin is dwarfed by what is made by the ovaries. Indeed, one of the main enzymes responsible for the production of estrogen in the peripheral tissues is aromatase. In the treatment of breast cancer, aromatase inhibitors don’t work in premenopausal women. The reason is that the ovaries of premonopausal women are still cranking out estrogens, which far outweigh the amount of estrogen produced in peripheral tissues. That’s why aromatase inhibitors are only used in postmenopausal women, where the ovaries have in essence shut down, leaving the aromatase in peripheral tissues as the only source of estrogen, which aromatase inhibitors shut down quite nicely. From a biological standpoint, it’s highly implausible that blocking the apocrine sweat glands can lead to a backup of sex hormones and their absorption into the breast tissue at concentrations sufficiently high compared to the normal levels made by the ovaries in women and the testicles in men.
Of course, “implausible” doesn’t mean “impossible,” and McGrath’s concept, although quite implausible biologically, is not as implausible as, say, homeopathy or reiki. However, because of its implausibility, it would take some pretty compelling evidence to make us as scientists reconsider our understanding of the biology. So does McGrath have compelling evidence or even highly suggestive evidence? Let this graph from his Medical Hypotheses paper speak for itself:
It’s very similar to this figure from the previous paper:
These are plots of antiperspirant sales in the U.S. versus the incidence of selected cancers, including prostate, breast, and a couple of others. Does this remind you of anything? Oh, this, maybe? It’s a beautiful example of the fallacy of confusing correlation with causation. It’s also amazingly sloppy in that the incidences of breast and prostate cancer were clearly increasing for at least two decades before the sales of antiperspirant started to take off, and antiperspirant sales have been increasing far faster than the cancer incidence rates shown. I also wonder if there was any attempt to control for common confounders, like age of menarche and number of live births per woman. Early age at menarche, increasing age of first childbirth, and decreasing numbers of children and up to nulliparity, all correlate with a higher risk of breast cancer. Regarding these factors, what have three major trends been over the last century? Earlier age of menarche, fewer children per woman, and an older age at first childbirth. Add to that the use of hormone replacement therapy during the 1980s and 1990s, and there are multiple huge confounders far more likely to explain the increasing incidence of breast cancer not even addressed in McGrath’s hypothesis.
OK, what else do we have?
Well, Joe Mercola referenced a couple of studies in his little bit of viral breast cancer fear mongering. Specifically, if you believe Mercola, it’s supposed to be the aluminum:
Research, including one study published this year in the Journal of Applied Toxicology, has shown that the aluminum is not only absorbed by your body, but is deposited in your breast tissue and even can be found in nipple aspirate fluid a fluid present in the breast duct tree that mirrors the microenvironment in your breast. Researchers determined that the mean level of aluminum in nipple aspirate fluid was significantly higher in breast cancer-affected women compared to healthy women, which may suggest a role for raised levels of aluminum as a biomarker for identification of women at higher risk of developing breast cancer.
The report discussed was a small pilot study of 35 patients, 16 with breast cancer and 19 with no cancer. While the results are somewhat provocative, it is important to remember that (1) the study was small and (2) the significance of the results remains unknown. More importantly, there were a lot of confounding factors not controlled for. For example, presumably for both women with breast cancer and those without in the study there was no serious attempt to control for confounding factors or to quantify the use of aluminum antiperspirants. Indeed, there are significant differences between the two groups. For example, the median age of the cancer group was 56, while it was 40 for the no cancer group. Perhaps something as simple as age could account for the difference. Does something happen after menopause leading to increased accumulation of aluminum from the natural exposure that we all have? Who knows? No analysis was done. Another possibility is that breast cancer might somehow accumulate aluminum more than normal tissue.
In other words, the study tells us absolutely nothing about whether or not aluminum-containing antiperspirants contribute to breast cancer risk.
Mercola’s next red herring is this:
In a 2007 study published in the Journal of Inorganic Biochemistry, researchers tested breast samples from 17 breast-cancer patients who had undergone mastectomies. The women who used antiperspirants had deposits of aluminum in their outer breast tissue. Concentrations of aluminum were higher in the tissue closest to the underarm than in the central breast.
Why is this a glaring red flag?
Aluminum is not normally found in the human body, so this study was a pretty clear sign that the metal was being absorbed from antiperspirant sprays and roll-ons. Please note that aluminum is typically only found in antiperspirants. If you are using a deodorant-only product it is unlikely to contain aluminum but might contain other chemicals that could be a concern.
Aluminum is not normally found in the human body? Did Mercola even read any of the articles he cited? The first article in and of itself demonstrated that aluminum is found in measurable quantities in normal human breast tissue nipple aspirates. Its finding was simply that it was found at higher levels in breasts with cancer. Then, the second article that there were detectable levels of aluminum in normal breast tissue, too! Again, what it purported to find was that there was more aluminum in areas of the breast closer to the underarm.
Here’s the study. Basically, in the study Exley et al. measured aluminum content in mastectomy specimens taken from 17 women with breast cancer. Four biopsies were taken, one from each quadrant, and measured the aluminum content. Suffice to say, there were huge variations between the concentration of aluminum in the fat and the breast tissue between individuals, so much so that, looking at the evidence, I can’t see a clear difference. The authors claim they found a “statistically higher concentration of aluminium in the outer as compared with the inner region of the breast” even though their statistics showed that there was not. Meanwhile, a followup study by the same group from 2013 found “no statistically significant regionally specific differences in the content of aluminium” and found that the concentrations of aluminum in patients with breast cancer were “comparable with those reported in non-diseased human tissues from other areas of the body.”
In a recent review article, Exley, try as he might, just can’t seem to develop a compelling case for the involvement of aluminum from antiperspirants (or anywhere else, for that matter) in increasing breast cancer risk. In another recent review article, Pineau et al. emphasize in vitro results but downplay the negative epidemiological and pathological evidence. Yes, aluminum might increase proliferation in MCF10A cells, which, contrary to what is claimed are not exactly “normal” (I’m well familiar with this cell line) and MCF-7 breast cancer cells, but there’s no compelling evidence that this has any relevance to the real world, given that there is no compelling evidence from epidemiology, pathology, and toxicology studies linking aluminum-containing antiperspirants with breast cancer. Moreover, there is good evidence that there is no correlation between the use of antiperspirants and breast cancer, and a comprehensive literature review failed to find convincing evidence of a link, concluding, “After analysis of the available literature on the subject, no scientific evidence to support the hypothesis was identified and no validated hypothesis appears likely to open the way to interesting avenues of research.”
In other words, although it’s possible that there is a link between antiperspirants and cancer, current existing evidence doesn’t support one and doesn’t even suggest potentially-fruitful avenues of research.
But what about parabens?
Of course, unlike the case among antivaccinationists, where aluminum fears supplanted mercury fears, in terms of breast cancer aluminum fear mongering is old school. New school is parabens. Parabens are hip. They’re now. They’re happening. In fairness, on the surface, there appears to be more of a reason to suspect them as potentially contributing to breast cancer than there is to suspect aluminum-containing antiperspirants. That’s not saying that there’s a compelling reason to suspect them, only that there is a modicum of plausibility. Parabens is a term used to describe a series of parahydroxybenzoates or esters of parahydroxybenzoic acid (also known as 4-hydroxybenzoic acid), chemicals most commonly used as preservatives by the cosmetic and pharmaceutical industries because of their bactericidal and fungicidal properties. They’re found in a variety of products including shampoos, commercial moisturizers, shaving gels, personal lubricants, topical/parenteral pharmaceuticals, spray tanning solution, makeup, and toothpaste. Most major brands of antiperspirant are paraben-free these days, but that doesn’t stop them from being examined as a cause of breast cancer. Typical of such articles is one by—you guessed it!—Joe Mercola entitled “Parabens: 99% of Breast Cancer Tissue Contained This Everyday Chemical (NOT Aluminum)“:
The featured study by Barr et.al. discovered one or more paraben esters in 99 percent of the 160 tissue samples collected from 40 mastectomiesiii. In 60 percent of the samples, all five paraben esters were present. There were no correlations between paraben concentrations and age, length of breast feeding, tumor location, or tumor estrogen receptor content. The median values in nanograms per tissue for the five chemicals were:
     1.  n-propylparaben 16.8
     2.  methylparaben 16.6
     3.  n-butylparaben 5.8
     4.  ethylparaben 3.4
     5.  isobutylparaben 2.1
While antiperspirants are a common source of parabens, the authors note that the source of the parabens cannot be established, and that 7 of the 40 patients reportedly never used deodorants or antiperspirants in their lifetime. What this tells us is that parabens, regardless of the source, can bioaccumulate in breast tissue.
The study to which Mercola refers is this one by Philippa Darbre at the University of Reading. It’s one of multiple follow-up studies to a study by Darbre from 2004 that is thought to have started the concern about parabens. Basically, it measured the concentration of parabens in samples of 20 human breast tumors using high-pressure liquid chromatography followed by tandem mass spectrometry and found measurable parabens concentrations in all of them, with a mean of approximately 20 ng/g tissue. As noted by Joe Schwarcz, at the time the study received extensive press coverage, with few stories mentioning that there was no control group, making the significance of this observation unclear. That didn’t stop Darbre from promoting the idea that parabens cause breast cancer by pointing out that these chemicals have estrogen-like activity and that such activity has been linked to breast cancer. Since 2004, Darbre has built her career on doing studies trying to demonstrate that parabens and endocrine disrupters cause breast cancer, as a perusal of her PubMed publication list will easily demonstrate. She’s also co-authored articles examining aluminum-containing antiperspirants and breast cancer.
So, it would seem, we have a chemical that is widely used as well as a seemingly plausible mechanism (estrogenic activity) to cause breast cancer. There’s a problem, though. As Schwarcz, who is a chemist, also pointed out:
What she failed to mention was that the estrogenic activity of the various parabens is thousands of times less than that of estrogenic substances found in foods such as soybeans, flax, alfalfa and chickpeas, or indeed of the estrogen produced naturally in the body.
The study cited by Mercola was just the latest of her studies at the time. It suffers from the same sorts of problems as her 2004 study, although these problems are better hidden because more breast specimens were used and there was an attempt to correlate the parabens levels with location in the breast. One notes that, consistent with the 2004 study, Darbre found that every single breast specimen had detectable levels of parabens, even patients who didn’t use antiperspirants. I also note that “no direct, formal adjustment to the significance levels of the multiple Friedman ANOVA analyses has been made,” which makes me wonder about the actual statistical significance of the differences reported, particularly since the differences were so small and Darbre reports ANOVAs for each paraben, resulting in five different comparisons of four breast regions, one for each of the five parabens examined. For example:
Notice how small the differences are in general and how only one of the five parabens shows a statistically significant difference. The whole paper is like that, with multiple comparisons galore for the five parabens. Even though Darbre used an ANOVA, which is designed for multiple comparisons, for each paraben, she didn’t correct for the multiple ANOVA comparisons she did for each experiment. My guess is that, if she did, her statistically significant findings would disappear. Then there’s her observation that parabens levels did not correlate with tumor location, which rather argues against a correlation between parabens and breast cancer development. Most recently, Darbre has published an in vitro study of the effect of long term exposure (20 weeks) to parabens on the migration of breast cancer. It’s not clear to me how relevant these findings are to much of anything, given the lack of clinical evidence to demonstrate the relevance. None of this stops her from handwaving away all the problems with her studies and doing what, for example, antivaccinationists do when confronted with negative results: Invoke “individual susceptibility” without evidence for it.
Conclusion
Given how difficult it is in science ever to prove a negative beyond a doubt, it’s not impossible that something in antiperspirants, be it aluminum or parabens, might contribute to breast cancer development. However, given the existing state of the scientific evidence, it seems incredibly unlikely that there is a causal relationship here, given that no one has yet been able to convincingly demonstrate even a correlation. It’s certainly not for lack of trying. Indeed, scientists convinced of this hypothesis sometimes go to ridiculous extremes to show a “correlation,” as McGrath did in the graphs above.
Unfortunately, by far the most powerful predictors of breast cancer risk are not environmental. They are related to genetics (family history) and biology (age at menarche, age at menopause, number of live births, age at first live birth, breastfeeding, etc.). Lifestyle and environmental factors play a much less significant role, with protective effects due to exercise (for instance) or increased risk due to alcohol consumption (also for instance) producing much smaller effects than the previously mentioned risk factors and protective factors. None of this means that we shouldn’t study environmental risk factors for breast cancer, but it does mean that we should be cautious about spending too much time studying factors lacking strong biological plausibility when the studies aren’t yielding strong evidence of a correlation with breast cancer despite considerable effort to show a link.
It’s a matter of prioritization. Existing evidence is sufficient to conclude that there is no strong link between antiperspirant use and breast cancer and that there is very likely not even a weak link. Given such findings, it is appropriate to move on to other, more promising, avenues of research regarding environmental and lifestyle risk factors for breast cancer. This one’s been investigated and not found to be important.

Blaming breast cancer on autism
David Gorski on November 9, 2014
Link


Gayle DeLong has been diagnosed with what she refers to as “autism-induced breast cancer”. She’s even given it an abbreviation, AIBC. Unfortunately, as you might be able to tell by the name she’s given her breast cancer, she is also showing signs of falling into the same errors in thinking with respect to her breast cancer as she clearly has with respect to autism. As a breast cancer surgeon, regardless of my personal opinion of DeLong’s anti-vaccine beliefs, I can only hope that she comes to her senses and undergoes science-based treatment, but I fear she will not, as you will see. Her brief post announcing her diagnosis and blaming it on autism, however, does provide what I like to call a “teachable moment” about cancer.
We’ve met DeLong before on this blog. For instance, she published an execrably bad study that—of course!—tried to link vaccine to autism and failed miserably, despite doing some amazing contortions of analysis, combining diagnoses willy-nilly, all in the service of the discredited vaccine-autism hypothesis. As I said at the time, it just goes to show that someone who is an associate professor of economics and finance shouldn’t be doing epidemiological research. As I also described at the time, if the sorts of analytical techniques she used in her study are acceptable in the world of economics and finance, no wonder our economy has been so screwed up for so long. Another time, DeLong wrote a broadside against the regulatory machinery that oversees vaccine development and safety that was full of the usual antivaccine misinformation, tropes, and pseudoscience and hugely exaggerated perceived “conflicts of interest” among the various parties.
So it’s not surprising that DeLong latches on to dealing with her autistic children as the cause of her cancer:
I have autism-induced breast cancer (AIBC). While I am not absolutely certain that the 1.9 centimeter lump that grew in my left breast is the result of the stress of raising two autistic children, all indications point in that direction. There is virtually no cancer in my family, I eat organically, I exercise, I’m a good weight. OK, so I live in the toxic dump known as New Jersey, but that is the only other major risk factor. No, the drop in cortisol levels whenever one kid’s school calls or the other kid has a public “flare up” is enough for the cancer to take root.
First of all, it’s very telling to me that she blames her breast cancer diagnosis on having to take care of her autistic children as the root cause of her breast cancer. The implication, of course, is that her decision to vaccinate her children is what led to their autism and her breast cancer. Be that as it may, notice how DeLong is very emphatic in proclaiming her healthy lifestyle bona fides and that there’s “no cancer in my family.” It’s a very common misconception about breast cancer (indeed, nearly all cancer) that it must be familial. In the case of breast cancer, while it’s true that there is a familial component and that there are genes, such as BRCA1 or BRCA2, that, when mutated, result in an enormously elevated lifetime risk of breast cancer compared to women without them, the simple fact is that only around 10-15% of breast cancer cases have a familial or genetic component. That means around 85% of breast cancer cases are what we in the biz call “sporadic.” That basically means “we can’t identify a specific cause.” True, there are well-characterized risk factors for breast cancer, such as age, early menarche, late menopause, nulliparity, and others, but the magnitude of the risk increase due to these factors is way less than, say, a strong family history (i.e., a first degree relative with breast cancer) or an identified cancer-predisposing mutation in BRCA1.
Of course, people don’t like the concept of “sporadic” cancer, mainly because humans crave explanation. The default assumption is that everything must happen for a reason and there must be a cause for every disease or cancer. Perhaps the most emphatic statement of this that I’ve encountered thus far comes from (who else?) über-quack Mike Adams when he heaped contempt on the idea of sporadic disease as “spontaneous disease.” He did this in the context of a story four years ago when America’s quack, Dr. Mehmet Oz, followed recommended care and underwent screening colonoscopy to look for polyps and was shocked that he actually had some:
Dr Oz even seems to think he has a perfect health record, saying, “I have done everything right. I don’t have any family history, and yet I’m high risk now.” His personal physician, meanwhile, is implying that even though Dr Oz’s “healthy” diet was perfect, it wasn’t enough to prevent colon polyps, and therefore you might get them too. (And therefore everybody should get screened…)
This led Adams to bloviate:
Colon polyps, in other words, appear without any cause! Mainstream medicine, you see, believes in the theory of “spontaneous disease” that “strikes” people at random.
Sort of like disease voodoo.
No matter what you do, they say, you can’t be totally sure that you’re disease free. Therefore, you need all their disease screening protocols, mammograms, and CT scans (which irradiate your body and can actually cause cancer, by the way).
What a bunch of nonsense. As any real scientist knows, everything that happens in our universe has a cause. It’s a cause-effect universe, and unless you’re God or can magically change the laws of the universe, you can’t alter the laws of cause and effect.
So if you develop colon polyps, there is a cause for it, and that cause is without question related to the foods you’re consuming, because that’s what is in contact with your small intestine, large intestine and colon. (It’s not the only factor, but it’s the primary factor.)
This is exactly the sort of thinking DeLong is exhibiting. It’s understandable, particularly when you’ve been diagnosed with a potentially life-threatening disease. Indeed, it’s quintessentially human. We all want to know why, and our default is to assume that there must be a cause. It’s also wrong. At least, it’s wrong in the sense that while, yes, there are causes of breast cancer (or colon polyps or whatever), they are often highly multifactorial and can’t be placed into a simple “box” of diet, lifestyle, or failing to do the “right” thing. This whole idea feeds into magical thinking (which I’ve seen voiced before many times) that every disease can be prevented, if only you would do the right thing. The dark side of such thinking, of course, is the opposite assumption, which goes something like this: If every disease has a definite non-inherent (i.e., non-genetic) cause, such as crappy diet, then it’s the victim’s fault, in part or in whole, for getting sick. We’ve seen this same thinking from Bill Maher before as well when a few years ago he attacked the flu vaccine and proclaimed that the “soil” matters much more than the seed; i.e., if you live a healthy lifestyle and eat a healthy diet, your “soil” won’t be conducive to the flu virus and you won’t get the flu. This reached a ridiculous extreme when Maher proclaimed that he was so healthy that he wouldn’t get flu even if exposed in a closed-in space like an airplane, leading Bob Costas to snort, “Oh, come on, Superman!” Sometimes this thinking goes beyond even Maher’s, in that cancer or other diseases are blamed on “psychic trauma” or some other psychological factor. This idea is at the very heart of the quackery known as German New Medicine or its variant Biologie Totale. The attraction of such ideas is obvious: They give the illusion of control, that you as a cancer patient can cure yourself if only you will it enough and act on that will. The dark side of this idea is an even worse version of what I just described. Now, it’s not only your fault for being sick because you didn’t live a “good” lifestyle, but you’re sick because you either lack the will not to be sick or you secretly want to be sick.
As for the idea that stress can cause cancer, even the National Cancer Institute proclaims the evidence that stress can cause cancer to be “weak,” further pointing out that there is “no strong evidence that stress directly affects cancer outcomes.” Indeed, the evidence with respect to stress and cancer is at worst conflicting, at best quite negative, with the occasional study hyped in dubious outlets like the <cite.Daily Mail being proclaimed as evidence that stress causes cancer, but a recent meta-analysis of 116,000 people, found no significant correlation between stress and bowel, lung, breast or prostate cancers. So, despite it being a very common and intuitively seemingly-reasonable idea that stress and cancer are linked, they almost certainly are not, at least not as far as causation. That’s not to say that chronic, unrelenting life stress is a good thing for your health, but evidence strongly suggests that it doesn’t increase the risk of cancer. So, while it’s understandable that DeLong might think the stress of her raising two autistic children is the cause of her breast cancer diagnosis, she’s wrong about that. What’s more disturbing to me is how she views her children’s autism as the cause of her cancer to the point of even calling it “autism-induced breast cancer” and giving it an abbreviation AIBC.
Even worse is how she views autism itself as being as bad as cancer. Actually, I get the distinct feeling she views it as worse than cancer, given the title of her post “The Lesser of Two Evils: Breast Cancer and Autism“. Look at her comparison between how cancer is viewed and her perception of how autism is viewed:
So, I speak from experience when I say Stage 1 breast cancer has nothing on autism. The differences are vast and significant. Unlike autism, no one is telling me to “celebrate” my cancer. No one is telling me that cancer is “just a different way for cells to grow.” People have told me that we’ve always had cancer, but no one is using that is an excuse for not doing anything about it. No one is blaming me (or my mother) for my cancer. Unlike a person with autism, society does not say my cancer is my fault. Another difference is that in three years, I’ll either be dead or cured. Autism is not tangible, so it neither exists concretely nor definitely leaves the body. Although cancer could do to me what autism did to Avonte Oquendo, the chances of dying from a tumor that I treat properly are small and growing smaller.
First off, unless DeLong’s cancer is a certain subtype called triple negative (and even then not entirely), it’s not true that in three years she’ll be cured or dead. Such a binary outlook! Estrogen receptor-positive [ER(+)] tumors can recur 5, 10, 15, and even 20+ years later, and the treatment for ER(+) tumors involves Tamoxifen or an aromatase inhibitor for at least five years. Indeed, trends based on clinical research showing better results are moving towards the recommendation of ten years of anti-estrogen therapy to reduce recurrence risk. Triple negative tumors, while more aggressive at the outset, tend not to recur after five years, usually recurring within three years, but they certainly can recur later. More offensive is her explicit likening of autism to cancer, in which she proclaims that “no one is telling me that cancer is ‘just a different way for cells to grow.’” This suggests to me that she views her autistic children as cancers or at least their autism as bad as any cancer, hence her resentment at the neurodiversity movement that seeks to destigmatize autism.
Avonte Oquendo, by the way, was a teenage boy with autism who walked out of his school to go missing and whose remains were found months later. In other words, DeLong makes the connection between her view of cancer and her view of autism even more explicit: Both to her are killer diseases, but there is a difference. Her cancer is potentially curable.
Finally, if there’s one similarity we see between antivaccine thinking and other quackery, it’s made explicit by DeLong:
However, one major similarity exists between breast cancer and autism: the “wisdom” of the experts. The standard of care for cancer includes popping this sucker out of my breast, and I’m fine with that. However, I’m more than a bit uneasy about the radiation treatment that the surgeon has recommended post-op. Taking a sledge hammer to my breast may indeed kill the cancer, but what about the organ that lies directly under my breast, my heart? If 10 or 20 years from now I develop a heart condition – which is also unheard of in my family – would it be the result of the radiation or just bad stuff happening to good people? The cancer experts don’t care; after all, the cancer didn’t return! Except that sometimes (often?) cancer does return, perhaps because radiation can cause cancer? And don’t get me started about chemo! I didn’t question the established wisdom concerning vaccines, and my kids have autism. I won’t repeat that mistake. I’ll look for alternatives, weigh the options, and determine the best path for me. Amazing how a little pain in the breast can turn one into a huge pain in the derrière.
So her magical thinking with respect to vaccines is leading to magical thinking with respect to her cancer. I find it rather odd many times how patients often have no problem with surgery for their cancer but have so much trouble with other options. Of course, “cutting out” the tumor makes intuitive sense, so much so that I’ve not infrequently had patients show up in my clinic expecting that I would be doing just that that very day. In the old days, surgery alone was it, too; it’s the oldest and most reliable treatment for early stage breast cancer.
I’m assuming that the surgeon recommended a lumpectomy/partial mastectomy because DeLong has a stage I cancer (clinically, at least) and he’s recommending radiation. What DeLong doesn’t understand is that there’s a reason for the radiation. If she undergoes lumpectomy and doesn’t follow it up with radiation, the local recurrence rate (the chance of her tumor recurring in her breast near the surgery site) is 30-40%. With radiation, it’s in the range of 5-8%. That’s a huge difference. Of course, as I’ve described in many of my analyses of breast cancer testimonials going right back to the very beginning of this blog and beyond, in which women undergo surgery but refuse chemotherapy and radiation, it’s still more likely than not that the tumor won’t recur, but a roughly one in three chance of recurrence are not odds that I would be willing to take, particularly when the risk of serious heart impairment due to “collateral damage” from the radiation is so low when modern techniques are used. She’s also quite incorrect that radiation oncologists “don’t care” if she gets radiation-induced cardiac disease because “the cancer is gone.” They care very, very much. An enormous amount of research over the last three decades has gone into developing techniques that minimize the risk of heart damage.
The other question is chemotherapy. If DeLong has a stage I tumor, then it’s quite possible she might not even need chemotherapy! If her tumor is not HER2(+) but is ER(+), and she doesn’t have any positive lymph nodes, what will be recommended is Tamoxifen if she’s premenopausal or an aromatase inhibitor if she is postmenopausal. If she’s triple negative (negative for ER, progesterone receptor, and HER2), chemotherapy will be recommended, as it will if she’s node positive regardless of markers. If she’s HER2(+), chemotherapy with Herceptin or one of the newer anti-HER2 agents will be recommended. In any case, the benefit of chemotherapy in early stage breast cancer tends to be relatively low as an absolute percentage; so it’s quite possible to refuse chemotherapy and do fine. The veritable plethora of “I refused chemotherapy and I’m fine” breast cancer testimonials that I’ve analyzed over the years attests to that. It’s just that DeLong should understand that if she refuses recommended chemotherapy she is increasing her risk of recurrence and death due to cancer. In early stage breast cancer, that increased risk might only be a few percent, but she needs to understand now that if she refuses chemotherapy and does well, it will be because of the surgery that removed her tumor and (if she accepts it) the radiation that reduced the risk of local recurrence, not due to any “alternative” treatments she ends up choosing to use after surgery.
What I fear we’re seeing right here is the beginning of yet another alternative breast cancer cure testimonial. DeLong will likely have surgery and then refuse radiation and chemotherapy. Assuming she doesn’t have any positive lymph nodes (which might or might not turn out to be true), the odds are more likely than not that she’ll probably be OK, but her survival and failure to recur, assuming that’s what happens, will be due to surgery and a lot of luck to have dodged the 30-40% chance of local recurrence. Her odds could be so much better if she just accepted everything modern oncology has to offer for treating breast cancer, and her survival and lack of recurrence. Our locations on opposite sides of the divide over vaccines notwithstanding, I sincerely hope she does just that, because I hope that she does not become this kind of breast cancer testimonial.

ASCO endorses the integration of quackery into breast cancer care
In 2014, the Society for Integrative Oncology first published clinical guidelines for the care of breast cancer patients. Not surprisingly, SIO advocated “integrating” dubious therapies with oncology. Last week, the most influential oncology society, the American Society of Clinical Oncology (ASCO), endorsed a 2017 update to the SIO guidelines, thus endorsing the “integration” of quackery with oncology and paving the way for insurance coverage. The advance of quackademic medicine in oncology continues apace.
David Gorski on June 18, 2018
Tweet

Last week, I was perusing Twitter, which has become a primary source these days for blog fodder, when I came across this:
Proud to announce @ASCO has endorsed SIO’s Clinical Practice Guidelines for Integrative Therapies During and After Breast Cancer Treatment. A significant milestone for #integrativemedicine and oncology! https://t.co/UhABRnkDFV … … @integrativeonc #breastcancer
— SIO President (@SIOPresident) June 13, 2018
Yes, it was the President of the Society for Integrative Oncology, Linda Balneaves, crowing about how ASCO has endorsed its guidelines for therapies for the “integrative” medical care of patients with breast cancer, something she did on her own Twitter feed as well:
Proud as President of SIO to announce that @ASCO has formally endorsed SIO’s Clinical Practice Guidelines for Integrative Therapies During and After Breast Cancer Treatment. A significant milestone for the field of integrative oncology! https://t.co/BLzI7CyKJO @integrativeonc
— Lynda Balneaves (@LyndaBalneaves) June 12, 2018
ASCO itself had announced this endorsement, too:
We’ve endorsed @Integrativeonc‘s breast cancer treatment practice guideline https://t.co/dnapbGzck2 pic.twitter.com/3H4WpjcYyq
— ASCO (@ASCO) June 11, 2018
Elsewhere, even some National Cancer Institute-designated comprehensive cancer centers were touting the news. For instance, here’s the University of Washington with perhaps the worst Tweet of all from a “respectable” cancer center:
Is your oncologist dismissive of Qs about meditation, acupuncture, massage, yoga, etc? You can now tell them @ASCO has endorsed these as evidence-based ways to manage symptoms & side effects of conventional #breastcancer treatment. #IntegrativeOncology https://t.co/x7aquiG3FW
— Fred Hutch (@fredhutch) June 12, 2018
Unfortunately, the Hutch isn’t entirely wrong. ASCO (the American Society of Clinical Oncology) is one of the largest medical professional societies devoted to cancer in the world, if not the largest. Its meeting every year, usually beginning the weekend after Memorial Day, inevitably generates lots of press coverage and news stories about the latest clinical trial results for new cancer therapies. You might recall the flurry of news stories two weeks ago about the TAILORx trial, which clarified the use of the OncoType DX test to determine which patients with the most common subtype of breast cancer can safely forego chemotherapy. ASCO also publishes a number of guidelines for cancer care. Basically, when ASCO endorses a treatment or another organization’s guidelines, it’s a big deal. It’s hugely influential. Now ASCO has endorsed the “integration” of quackery into the treatment of breast cancer patients. To paraphrase David Byrne, “And you may ask yourself, well, how did we get here?”
The SIO clinical guidelines for breast cancer care, round one: Rebranding SBM and integrating quackery
When the first version of the SIO’s Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer was published in December 2014, I commented in detail about it in my usual inimitable fashion. First, I noted that the guidelines were published as a part of a monograph in the Journal of the National Cancer Institute (JNCI). Along with the guidelines, there were multiple other articles designed, among other things, to exaggerate the evidence base for the use of “integrative” therapies in cancer, to promote the “brand” of integrative oncology, and to tout the NCI’s portfolio of “complementary and alternative medicine” (CAM) research through its office with the most inappropriate acronym ever, the Office of Cancer Complementary and Alternative Medicine (OCCAM), whose budget has traditionally been roughly the same size as that of the National Center for Complementary and Alternative Medicine (NCCIH). OCCAM serves the same purpose in cancer research and treatment as NCCIH does for medicine in general: To fund mostly dubious studies on “integrative medicine” and to promote “education” and use of “integrative medicine.” The monograph also taught me that the NCI Community Oncology Research Program (NCORP) has been co-opted such that nearly one-third of NCI-sponsored clinical trials through the NCORP are for “integrative oncology.” Comparing the evidence base for integrative oncology to conventional oncology, it boggles the mind that such a huge chunk of an important resource for testing is diverted in this way.
As a prelude to discussing the updated guidelines, I have to ask: What about the original guidelines themselves?
I found them notable for the modalities that the SIO panel charged with developing the guidelines had excluded because they had become “mainstream,” such as cognitive-behavioral therapy, psychoeducation, counseling, and support groups. Of course, these modalities were never considered outside the mainstream, although admittedly some overblown claims have been made for support groups and cognitive-behavioral therapy as being able to improve cancer survival, claims that have not held up to scrutiny. Similarly, prayer and spirituality were also excluded for unclear reasons.
The treatment modalities that remained were subjected to a literature analysis in order to determine whether they can be recommended or not based on existing clinical evidence. The SIO used a scale adapted from the U.S. Preventative Services Task Force to grade the evidence that ranged from A (“Recommends the modality. There is high certainty that the benefit is substantial.”) to H (“Recommends against the service. There is moderate or high certainty that the harms outweigh the benefits.”). Of course there are also I (insufficient evidence) and various gradations between A and H, such that it’s probably worth reposting the table to guide the rest of this discussion:
Tellingly, the only grade A recommendations were for meditation, yoga, and relaxation with imagery for routine use for common conditions, including anxiety and mood disorders (Grade A). There were no grade A recommendations for anything having to do with pain, but only for symptoms with an even heavier subjective component, namely anxiety and mood. Of course, yoga is a form of exercise and therefore nothing out of the realm of conventional medicine, given the number of studies that have shown the benefits of exercise in cancer patients. Similarly, the only grade B recommendations included stress management, yoga, massage, music therapy, energy conservation, and meditation for stress reduction, anxiety, depression, fatigue, and quality of life. Interestingly, again, none of these, with the possible exception of meditation, can be considered in any way “alternative,” thus once again demonstrating how integrative oncology specifically and integrative medicine in general have co-opted treatments that should be considered conventional as somehow “alternative”. As for music therapy, massage, and the like, these represent modalities that I like to point to as examples of what we used to call supportive care that have been “medicalized” by CAM and turned into therapies when in reality they’re just activities and modalities that help patients feel a bit better or help pass the time, no specific effects intended. Oddly, SIO lumped massage together with “healing touch.” Healing touch, of course, is a form of “energy medicine” very much like reiki and thus total quackery. It was also telling that there was no acupuncture use that was rated grade B or above, except for “electroacupuncture” for chemotherapy-induced nausea and vomiting, and, as I’ve discussed before, that evidence is shaky at best.
At the time, I characterized the offerings as giving little or no support for real “alternative” treatments (e.g., homeopathy), although they did give mild support for a few potentially science-based modalities rebranded as CAM/”integrative oncology” and ,tellingly, insisted against evidence on including the quackery (or, if you prefer, the theatrical placebo) known as acupuncture in the guidelines. I wonder if it was because one of the authors of the guidelines, Misha Cohen, is an acupuncturist and practitioner of traditional Chinese medicine (TCM), and Gary Deng is also into TCM.
The SIO clinical guidelines for breast cancer care, round two: A pointless and unnecessary update
About a year ago, for reasons that eluded me then (and were partially why I didn’t do a follow-up post on this topic for SBM), the SIO decided to update its clinical guidelines for breast cancer care. Then, as before, the author list included MDs, some of them respected (e.g., Debu Tripathy). The current SIO President, Lynda Balneaves, was also an author. The author list also contained quacks (e.g., Misha Cohen, TCM practitioner and acupuncturist). It also contained three naturopaths, starting with the first author, Heather Greenlee. Dugald Seely is on the author list again, as well. We’ve met Seely before on multiple occasions. Indeed, he’s quite the flush little naturopathic quack, complete with millions of dollars donated by an anonymous donor to fund “integrative oncology” research at the Ottawa Integrative Cancer Center (OICC). Then there’s Suzanna Zick, who’s even worse than a naturopath. She’s a naturopath at my alma mater, the University of Michigan Medical School. It always depresses me to contemplate that U. of M. actually has a naturopath working for it, but, then, it also has an anthroposophic medicine program. So I guess it’s not a stretch any more for there to be naturopaths there.
Upon reading the introduction to the 2017 update to the SIO guidelines, I also couldn’t help but note that what the SIO apparently means by “recommendation” is not what most doctors producing evidence-based guidelines mean by the word:
Of note, it is important to define the use of the term recommendation in these clinical practice guidelines. In many settings, a clinical guideline recommendation suggests that it should be used as the standard of care and is favorable or equal compared with all other options based on best clinical evidence for benefit/risk ratio. Here, in the setting of integrative oncology, we use the term recommendation to conclude that the therapy should be considered as a viable but not singular option for the management of a specific symptom or side effect. Few studies have conducted a head-to-head comparison of a given integrative therapy against a conventional treatment, and most integrative therapies are used in conjunction with standard therapy and have been studied in this manner. Moreover, combination-based approaches and the interactions of the numerous permutations of integrative and conventional treatments have not been formally investigated, such that recommendations must account for this limitation of our knowledge. Despite these limitations to evaluating the use of integrative therapies in the oncology setting, there is a body of well conducted trials of specific therapies for specific conditions that provides sufficient evidence to warrant recommendations on the therapies as viable options for treating specific conditions.
Ah, “integrative medicine,” where even “recommendation” doesn’t mean what it does in real medicine. I couldn’t help but be reminded of the famous quote by Humpty Dumpty in Lewis Carroll’s Through the Looking Glass, “When I use a word, it means just what I choose it to mean—neither more nor less.” In clinical guidelines in real medicine, though, “recommendation” means just that: a recommendation to use the treatment in question, graded, of course, according to the strength of the evidence. Yet here in the world of integrative medicine, “recommendation” means something…squishier. One can’t help but make the analogy that integrative medicine’s evidence standard is squishier than that of real medicine. Of course, the answer to that question of whether the new studies included in the 2017 update to the SIO clinical guidelines added much of anything to the 2014 clinical guidelines was, as I suspected, no, at least as far as I could tell.
I can’t help but mention that, by embracing the newer SIO guidelines, ASCO has also put its imprimatur on language like this:
Acupuncture involves the stimulation of specific points, (ie, acupoints) by penetrating the skin with thin, solid, metallic needles.[154, 155] A variation of acupuncture includes electroacupuncture, in which a small electric current is passed along acupuncture needles to provide a stronger stimulus than acupuncture alone, with distinct effects suggested by functional magnetic resonance imaging.[156, 157] Acupuncture has been practiced in Asia for thousands of years as a component of traditional medicine systems (eg, traditional forms of Chinese, Japanese, and Korean medicine) and is thought to stimulate the flow of a form of energy called qi (chee) throughout the body. Traditional Chinese acupuncture, which is commonly used in North America, requires needle manipulation to produce a de qi sensation (a soreness, fullness, heaviness, or local area distension[157, 158]), along with a period of rest with the needles in place.[159] It is posited that this removes energetic blockages, thus reestablishing homeostasis. The mechanisms for acupuncture’s effects are not well understood but are thought to function in part through modulation of specific neuronal/cortical pathways.[160]
Neither SIO nor ASCO appear to be aware of how much revisionist history (or, as I like to call it, retconning) is contained in the passage above about acupuncture. The claim here was that acupuncture has been practiced “thousands of years,” most commonly for at least a couple of thousands of years. Yet two thousand years ago the technology to produce thin needles of the sort used by acupuncturists today didn’t exist. In fact, it’s unclear when acupuncture in something resembling its current form evolved, but it appeared to have evolved from bloodletting. Harriet Hall once related the story of Dugald Christie, a Scottish surgeon who served as a missionary doctor in northeastern China from 1883 to 1913, and his experiences observing traditional Chinese medicine (TCM), including acupuncture. Let’s just say that acupuncture practiced 100 years ago was rather brutal. In fact, acupuncture began as nothing more than a Chinese version of bloodletting, very much like “Western” bloodletting and has been called “astrology with needles.” In reality, acupuncture and TCM achieved their current form under Chairman Mao Zedong, who promoted their use when he couldn’t supply enough scientifically-trained doctors for his people and exported to the world, something China is still doing. It’s a history that’s been retconned, and the SIO panel just repeated that retconned revisionist history. No wonder there are so many forms of acupuncture.
Basically, there’s not much new in these guidelines. Relatively uncontroversial modalities like meditation, music therapy, stress management, and yoga are given the highest recommendations. However, acupuncture and its bastard offspring electroacupuncture (which really has no basis in TCM, given that there was no electricity hundreds or thousands of years ago to hook needles up to) consistently get B or C recommendations for several indications, despite acupuncture being nothing more than a theatrical placebo that hasn’t convincingly been shown to work for any clinical indication. That includes acupressure.
As is the case with most systematic reviews of integrative medicine, there are some head scratchers. For instance there’s this level C recommendation, meaning that they can be considered:
Acupuncture,[49-51, 91, 92] healing touch,[93, 94] and stress management[36-38, 95, 96] can be considered for improving mood disturbance and depressive symptoms.
And:
Acupuncture,[119-124] healing touch,[93] hypnosis,[125, 126] and music therapy[31, 34] can be considered for the management of pain.
Healing touch is the rankest quackery. It’s energy medicine that postulates that practitioners can manipulate human life energy fields. It’s such a silly form of quackery that even a 12-year-old girl could disprove it.
Basically, these guidelines, now endorsed by ASCO, were even more unnecessary and pointless than the first set of guidelines published in 2014. It’s not as though clinical studies have advanced knowledge enough to justify a new set of guidelines, and these guidelines suffer from the same issue that integrative medicine itself suffers from, mixing cow pie with apple pie as though they were equivalent.
The SIO clinical guidelines for breast cancer care, round two: Enter ASCO
So now we arrive at ASCO’s contribution to this sad saga. This time around, several of the authors are the same, but there are some additions. For instance, Dr. Lorenzo Cohen of the University of Texas-M.D. Anderson Cancer Center is senior author. I’ve discussed him before here on SBM a few times. Suffice to say that he is a heavy hitter in the world of “integrative oncology” and co-authored the introduction to the original JNCI monograph that contained the first iteration of the SIO breast cancer guidelines. He’s also edited a book on “integrative oncology” that was favorably reviewed in the New England Journal of Medicine by one of his friends. He’s also popped up as a strong advocate for integrative oncology in various news stories. He also co-authored an article using the Delphi method to try to define just what “integrative oncology” is. (He and his co-authors came up with a vague, pretty much useless definition.) Finally, relative to ASCO, Dr. Cohen was one of the main speakers for a session on integrative oncology at the ASCO meeting in 2014 where he argued that stress and mental state contribute to cancer development and progression and that reversing those “bad” mental states can contribute to the improved survival of cancer patients, citing a raft of dubious science to do it. (That was the first time I noticed that ASCO was starting to delve into woo.) Overall, I got the impression that Dr. Cohen believes in the central dogma of alternative medicine, namely that wishing makes it so.
As for the rest of the co-authors, naturopath Heather Greenlee is back. Another co-author, Judith Fouladbakhsh, is on the board of trustees of SIO and is an advanced practice nurse who developed the CAM Healthcare Model©. Overall, there are a lot fewer quacks on this author list (one naturopath versus three, for instance) than there were on the SIO guidelines author list, which in its own way is pretty depressing because it suggests that critical thinking skills are lacking in the very highest levels of academic oncology, so much so that these august authors concluded:
The ASCO Expert Panel determined that the recommendations in the SIO guideline—published in 2017—are clear, thorough, and based on the most relevant scientific evidence. ASCO endorsed the guideline with a few added discussion points.
Basically, ASCO updated the SIO literature review (yet again). You can read ASCO’s discussion and endorsement of recommendations for yourself. ASCO’s treatment suffers from the same problems as the original SIO recommendations did. As a result, I’m not going to go into incredible detail, but I am going to touch on some highlights (or lowlights if you prefer) of the ASCO discussion. One section in particular struck me, specifically the part on the results of the ASCO updated literature review, where it was noted that 26 publications considered potentially relevant to the updated analysis were reviewed by Heather Greenlee, and nine given to the panel for further discussion.
For example:
Quality of life: Caregiver-delivered reflexology during treatment of advanced breast cancer was compared with attention control in an RCT among 256 patient–caregiver dyads. Patients in the reflexology arm experienced reductions in average symptom severity and interference over 11 weeks. There were no significant differences between study arms in functioning, social support, quality of relationship, or satisfaction with life at weeks 5 and 11.17
One notes that this trial was not blinded and basically showed that a nice placebo foot massage made patients feel a bit better. Another study cited was a worthless single-blind study of two forms of acupressure versus waitlist control. In any case, the ASCO panel concluded that the studies they found “support, and in some cases may strengthen, current recommendations.” Given how poor most of the cited studies are, this is thin gruel indeed.
In the end, ASCO basically agreed with the SIO guidelines with three caveats. For chemotherapy-induced nausea and vomiting, ASCO basically walked back the SIO recommendation for acupuncture, at least a bit:
Induced Nausea and VomitingThese treatment modalities received a grade B recommendation in the SIO guideline, which supports the addition of either one to a standard antiemetic regimen to improve chemotherapy-induced nausea and vomiting. This varies from the 2017 ASCO antiemetic guideline, which concluded that the evidence for complementary therapies, including acupressure and acupuncture, remains insufficient for a recommendation.7 The ASCO Expert Panel noted that the two guidelines address different patient populations—the ASCO antiemetic guideline applies to all cancer types, whereas the SIO guideline focuses only on patients with breast cancer—and also discussed the low risk of adverse events from acupressure and electroacupuncture. Nevertheless, the ASCO Expert Panel favored a grade C recommendation for these therapies. As noted in the SIO guideline, several of the cited trials were conducted before current pharmacologic antiemetic regimens became available. Furthermore, trials to date have tended to be small; two of the three cited acupressure trials20-22 and one of the two cited electroacupuncture trials23,24 enrolled fewer than 40 patients.
Grade C is the weakest of the positive recommendations: “Recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences (there is at least moderate certainty that the net benefit is small—offer/provide this modality for selected patients, depending on individual circumstances).”
There were two other quibbles by ASCO. First, it wanted to highlight SIO’s grade C recommendation for ginseng for fatigue by pointing out that the efficacy and safety of ginseng extracts can vary by type of ginseng and extraction method. The panel was also concerned that some preparations of ginseng can have estrogenic properties and that it might not be the greatest idea to use them in estrogen receptor-positive breast cancer. The second is that subcutaneously injected mistletoe extract, for which the SIO gave a grade C recommendation for improving quality of life, is not FDA-approved. ASCO was also concerned that ingestion of high doses of mistletoe berry or leaf is “known to cause serious adverse reactions.”
In other words, ASCO fully endorsed the SIO guidelines with only minor quibbles.
The emerging narrative
I know what ASCO (and the SIO) would probably say in response to this. They’d think it unfair of me to characterize them as having endorsed quackery because most of what is “recommended” (to use the SIO term) in the guidelines is fairly unremarkable: exercise, lifestyle interventions, and the like, the sort of modalities that “integrative medicine” has been co-opting and rebranding as somehow “alternative or integrative” for at least a couple of decades now. While that is largely true, I argue that they don’t get a pass on recommending acupuncture, and they certainly don’t get a pass for recommending healing touch (which is “energy medicine” mystical quackery) just because they “only” gave it these modalities a grade C (or in one case, a grade B, later downgraded to grade C) recommendation. It’s as if the SIO couldn’t bear not recommending acupuncture or healing touch and bent over backwards to make sure the two modalities got at least their weakest level of recommendation.
Through it all, the utter lack of evidence found in the SIO review for so many modalities is glossed over. Here’s the table from ASCO itself:
Then there’s the narrative. Look at how the press release about the guidelines from the Fred Hutchinson Cancer Center at the University of Washington spins it:
The first time Elizabeth Johnson told her oncologist she wanted to start folding integrative therapies into her breast cancer treatment regimen as a way to alleviate side effects, he told her “Sure, you can try, but it’s not going to help.”
He also told her that the second, the third, and fourth time she asked.
“He’s no longer my oncologist,” said Johnson, a 28-year-old homemaker from Minnesota who’s a year out from diagnosis but still in treatment. “He was great in many ways but not a good fit for me. It’s really important for me to have an oncologist who has a reasonably open mind. All he knew about and apparently all he cared to learn about was chemotherapy.”
Breast cancer patients like Johnson can now tell their doctors that integrative therapies like acupuncture, meditation, massage and yoga have been endorsed by the world’s leading professional organization of cancer doctors, the American Society of Clinical Oncology, as evidence-based ways to manage symptoms and side effects of conventional breast cancer treatment.
The endorsement, published today in the Journal of Clinical Oncology, came from an expert panel that reviewed a set of clinical practice guidelines for integrative therapies put out by the 15-year-old professional organization, the Society for Integrative Oncology, or SIO.
Co-chaired by ASCO senior statesman Dr. Gary Lyman of Fred Hutchinson Cancer Research Center, the panel did not embrace each and every one of the practices recommended in the SIO’s guidelines.
But they did send a clear signal to breast cancer patients and their care teams: It’s OK to integrate.
It gets worse. The press release takes a contemptuous swipe at “skeptics,” with a section entitled “Serving patients, not skeptics.” Indeed, it’s downright insulting and built on a huge straw man. Before the straw men, however, come the “do it for the patients” line, with Lyman saying that oncologists “who scoff at these therapies should still respect their patients’ requests, record the use of any integrative therapy in their charts and encourage them to share results, particularly if they experience side effects.” No serious medical skeptic—and that includes every physician who writes for SBM—says otherwise, but Lyman makes it a point to portray us as being contemptuous of patients and their beliefs.
Then Heather Greenlee chimes in:
Naysayers tend to lump anything alternative into one big bucket, she said, while ASCO and SIO are trying to tease these therapies apart to determine which ones work and which ones don’t.
“We’re reporting on therapies that have clear biological mechanisms, where we have clinical trials showing whether they are effective or not, and whether they are safe,” she said. “We need to conduct more trials and we need to publish more guidelines. We need to get the information out there for patients and clinicians to use.”
I can’t help but burn that strawman with a bit of fire of irony. After all, it’s the promoters of “integrative medicine” who try to lump all the potentially science-based treatments, such as diet, exercise, and lifestyle interventions, with the quackery like acupuncture, energy medicine, and, yes, the vast majority naturopathy. (Again, Greenlee is a naturopath, and I’d love to know if she is willing to call homeopathy, which is an integral part of naturopathic training, quackery.) No, it is the skeptics who separate out the various parts of “integrative medicine” and examine the evidence for each of them individually. That’s why it’s not so much the SIO’s recommendations for music therapy, yoga, and exercise that bother me. It’s the conflation of these patient support measures and potentially science-based interventions with quackery based on mystical pseudoscience like acupuncture and healing touch. It’s the embrace of methods that are negatively correlated with the use of effective medicine for cancer, like chemotherapy. It’s the increasing number of NCI-CCCs embracing quackery. As for “biological mechanisms,” perhaps Greenlee can tell us how qi works or how healing touch can channel “life energy” to heal patients.
        ◦ In the end, you and I both know how this spin will play out. Promoters of quackery will trumpet ASCO’s endorsement of the SIO guidelines for breast cancer with a narrative like the Hutch’s other press release, “Mozart, meditation and a yoga mat: Oncologists welcome integrative therapies for breast cancer.” Those who advocate the integration of quackery into medicine will point to the ASCO endorsement as legitimizing many of their favorite dubious or quack treatments, and, unfortunately, that’s just what ASCO did. Even Greenlee and Lyman are touting this endorsement as a major “milestone” for integrative oncology, and, sadly, I can’t argue with that. I’m sure John Weeks will be adding it to his other “milestones” to his other milestones on the path to integrating quackery with medicine. In fact, I’m surprised I couldn’t find him already crowing about this. It’s only been less than a week since this new pebble in the quackademic avalanche has fallen.

Using alternative medicine to treat cancer, even alongside conventional therapies, is still a bad idea
With the MAHA movement poised to introduce a lot more “integrative” or “complementary and alternative” treatments into oncology (and medicine in general), a new study shows the likely result.
David Gorski on March 16, 2026
Link

I’ve been saying for a while that I needed to step back from all the madness being inflicted upon US public health, medicine, and biomedical research by Secretary of Health and Human Services Robert F. Kennedy, Jr. under the guise of his “make America healthy again” (MAHA) movement, and last week I intended to to just that with a new study published a couple of weeks ago in JAMA Network Open on outcomes in breast cancer patients who used “complementary and alternative medicine” (CAM); that is, until I got distracted by the appearance of a respected oncologist and cancer center director at the MAHA Institute‘s “Massive Epidemic of Vaccine Injury” (MEVI) Roundtable. I had thought about doing a followup post on the content of the conference itself, but, really, it was a week ago, which in these times seems like an eternity. Suffice to say before moving on to today’s topic that the MEVI Roundtable was basically as bad as I had predicted, so full of a mixture of old long-debunked antivax talking points and newer COVID-19 vaccine-era equally debunked talking points that it basically reminded me of Autism One conferences, c.2011, only without the MMS (bleach) treatments for autism—and I suspect that’s just because the new generation of antivaxxers hasn’t embraced bleach yet. One statement by antivax pediatrician Larry Palevsky should tell you all you need to know about the conference, when he described all vaccinated children as “injured” and stated adamantly that he never gives vaccines. Also, antivax activist Del Bigtree was a featured speaker. ‘Nuff said.
But back to the study, Use of Complementary and Alternative Medicine in the Management of Breast Cancer, whose corresponding author is Daniel J. Boffa, MD, MBA, Division of Thoracic Surgery, Yale School of Medicine; so a shoutout to Steve Novella’s former university before he retired last summer. Conveniently, since I myself am a breast cancer surgeon, researcher, and expert, it’s the perfect sort of topic for me. Also, I can’t help but note that just last week, HHS held its National Conference on Women’s Health, which, in addition to the usual sorts of topics relevant to women’s health (e.g., cervical and breast cancer, infertility, and menopause) included a fair amount of “CAM” material with a focus on Lyme disease (for no apparent reason), and talks by functional medicine doctors like Eboni Cornish (of Amen Clinics) and Tammy Born Huizenga, of the Born Clinic, which offers every “integrative” quackery under the sun, including chelation therapy, IV vitamins, heavy metal testing, and ozone therapy. Let’s just say that MAHA is almost as much about “integrating” quackery with oncology (and medicine in general) as many of the “integrative medicine” activists that I used to write about on a regular basis.
Let’s take a look at the study.
CAM (integrative medicine) vs oncology
I will say one thing right off the bat about the study is that the authors use outdated terminology to describe the “integration” of quackery with oncology, specifically the old term “complementary and alternative medicine” (CAM), rather than “integrative medicine. I could go on and on about the evolution of terminology in which “alternative medicine” became “complementary and alternative medicine,” which ultimately became “integrative medicine,” not because the new terms illuminated or clarified, but rather because they obfuscated what “integrative” doctors (and oncologists) have been trying to do since the 1990s, at least. Basically, “CAM” and “integrative medicine” are branding terms, not real specialties. On second thought, maybe it’s better that the authors used an older term that includes “alternative medicine” in it, given that “integrative” medicine specialists have desperately wanted to eliminate anything with a hint of “alternative” in it.
As for the study itself, it’s a fairly straightforward retrospective cohort study that examined over 2 million women with breast cancer whose cases were tracked in the National Cancer Database (NCDB). The NCDB is a database sourced from hospital registry data collected in more than 1,500 facilities accredited by the American College of Surgeons Commission on Cancer (CoC). It captures approximately 70% of newly diagnosed cancers in the US and has long served as a very important database for clinical cancer research and outcomes research, as well as to establish quality benchmarks for cancer care in the US that serve as the basis of quality improvement projects. As the study describes it:
The NCDB is a database of oncology patients developed through a collaboration between the Commission on Cancer of the American College of Surgeons and the American Cancer Society.19 The NCDB Participant User File for 2022, which contains deidentified patient information, was used for the purpose of this study. Female patients who were diagnosed with breast cancer from 2011 through 2021 were included. The 11 983 patients who were missing treatment information or who were missing values for traditional therapy and/or CAM were excluded. A sensitivity analysis did not identify any obviously important differences between this group and the study population. The study was approved by the Yale University Institutional Review Board, and patient consent was waived due to use of deidentified data. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline was followed.
One issue—whether it’s a problem or not is debatable—that I will note right away is exactly how “CAM” is defined in the NCDB:
Complementary or alternative treatment, defined in the NCDB as treatment administered by nonmedical personnel.
However, one has to do the study with the dataset that one has available, so to speak, and that’s what the investigators at Yale did.
Definition aside, with the rise of “integrative oncology” and, as I like to call CAM/integrative medicine in academic medical centers, “quackademic medicine,” sadly a lot of “integrative therapies” these days are administered by real, bona fide MDs and DOs, some even board-certified in oncology. (One might remember times that I’ve written about the Society for Integrative Oncology and how “integrative oncology” has been uncritically promoted at large oncology meetings like the American Society of Clinical Oncology, to the point where ASCO even endorsed SIO guidelines for breast cancer and partnered with SIO to develop more guidelines (e.g., for cancer pain), apparently regardless of how quacky they are, and Nature Reviews Cancer has published at least one uncritical review touting “integrative oncology.) Too bad this is yet another study that suggests not just that “integration” of CAM into oncology doesn’t help patients but that it probably actively harms them.
To look for differences in outcomes, the authors examined the cohort of women with breast cancer and then adjusted for relevant variables known to affect outcomes of breast cancer treatment, such as age, cancer stage at diagnosis, insurance status, region, race, Charlson comorbidity index (a standardized index of how “healthy” the patient was at the time of diagnosis), and facility where treated (private, academic, or unknown). They then compared four groups:
    • “Traditional” therapy (science-based oncology)
    • CAM plus “traditional”
    • CAM alone
    • No treatment
First, here’s the graph of unadjusted overall survival:
The trend is clear, but from this graph you might think there’s no real difference between using SBM and using SBM plus CAM. However, when the authors applied an adjusted Cox analysis, using patients receiving exclusively traditional therapy as the reference of 1.0, then the hazard ratios for mortality were:
In the adjusted data, both the addition of CAM to treatment and the use of only CAM were associated with an increased hazard ratio for mortality, as was, not unexpectedly, no treatment at all. Interestingly, CAM only was associated with the highest mortality, slightly higher than no treatment at all. Other factors associated with an increased hazard ratio were age, increasing comorbidities, and type of insurance.
The authors also explored why this relationship was observed, specifically the question of whether those who used CAM in addition to SBM skipped one or more modalities among the multimodality treatment of breast cancer, leading to this graph:
The authors note that surgery was more common among the traditional (SBM) therapy cohort than among the combination cohort, but not by a huge percentage. This tracks with my personal observations, albeit limited, that patients pursuing such “CAM” mostly tend to be accepting of surgery; it’s often the radiation, chemotherapy, and endocrine therapy that they are less accepting of. A more striking difference was observed for radiation therapy, in which those receiving combination therapy underwent radiation therapy less frequently than those receiving standard-of-care SBM treatment for disease that was stage I through III, which are the breast cancer stages for which treatment with curative intent is possible. (Stage IV disease is not curable, only manageable for palliation and delaying death.) Given that, for breast conserving surgery, radiation decreases the risk of recurrence in the breast by as much as five-fold and is also associated with a significant, albeit modest, survival benefit as well.
One thing that puzzled me about this study was that it states:
Receipt of chemotherapy and endocrine therapy was similar between the treatment groups across stages I to III. There were no statistically significant differences in receipt of any particular treatment modality for patients with stage IV breast cancer.
For endocrine therapy, at least, this text sure seems to conflict with what I see in the graph, which appears to show that usage of endocrine therapy was markedly lower among women with stage I through III tumors. (My guess is that the differences that seem to be shown on the graph for usage of chemotherapy are not be statistically significant, given that the sample size of patients who received CAM was only 841 patients.) Endocrine therapy generally consists of strategies that block the action of estrogen for women with estrogen receptor-positive (and therefore estrogen-responsive) tumors, such as tamoxifen, aromatase inhibitors, bilateral oophorectomy, or ovarian suppression. Given that approximately 75% of breast cancers are estrogen receptor-positive and that endocrine therapy can decrease the risk of recurrence by about 40-50% and of death by up to 40% in such patients, this is one possible reason explaining why CAM use could be associated with an increased risk of death. At the very least, there appears to be a large difference in the use of endocrine therapy for stage I patients. (Granted, these are the patients who can be predicted to do the best and have the highest overall survival.) Moreover, I know from experience that endocrine therapy is one of the types of therapies that patients seem to have the most trouble continuing, due to side effects (e.g., hot flashes) over at least five years. (Chemotherapy side effects are definitely worse than side effects from endocrine therapy, but most chemotherapy regimens are less than around four or five months.)
The authors did some sensitivity analyses to try to isolate the effects of omitting one of the recommended “traditional” SBM treatments, using patients with stage II disease:
To better understand the consequences of omitting 1 form of traditional treatment, a sensitivity analysis was conducted as an unadjusted survival analysis for patients with stage II breast cancer, stratified by the receipt of 4 of traditional therapies (chemotherapy, radiation, surgery, and endocrine therapy) (eFigure 3 in Supplement 1). Patients with stage II breast cancer treated with a combination of traditional therapy and CAM had lower survival if they omitted radiation, endocrine therapy, or surgery, but the implications of omitting chemotherapy for survival in this cohort were not statistically significant.
Again, I suspect it’s the small numbers of patients that lead to the impact of chemotherapy not statistically significant in this analysis.
CAM use is still associated with poorer outcomes
So what can we conclude from this study? There has been less research in this area than arguably there should be, but on the other hand doing studies like this is extremely difficult and nearly impossible to do except using databases like the NCDB and retrospective study design. In this case, the authors note:
In this cohort study, we found that the overall survival for patients with breast cancer who received CAM, either alone or in combination with traditional therapy, was shorter than that of patients who received traditional therapy. These findings are consistent with the results of a previous study that found that, when stratified by cancer types, receipt of CAM was associated with worse 5-year survival for breast, lung, and colorectal cancer.24 However, this earlier work had only 123 patients who received CAM for breast cancer and was conducted during an earlier time frame (2004 to 2013). Our study builds on previous findings, has a considerably larger sample size of patients who received CAM (841 patients), and further examines the survival of patients who received a combination of traditional therapies with CAM in subgroup analyses.
Naturally, I discussed that previous study when it was released in 2017. That study also used the NCDB and also used the category in the database of “other-unproven: cancer treatments administered by nonmedical personnel” to identify usage of CAM modalities. Unsurprisingly, it showed worse five year survivals for not just breast cancers but also lung and colon cancer associated with CAM usage. Even though this study examines a much larger sample of breast cancer patients who used CAM, that number is still a very small percentage of the total cohort, leading the authors to speculate:
The relatively low rate of CAM use documented in the NCDB raises a concern that patients may not be discussing their interest in alternative treatments with their oncology teams. Specifically, several studies have estimated considerably higher rates of CAM—closer to 30%—in the breast cancer population.9,44,52 Because the NCDB is limited to capturing CAM use that is documented in the health record, patients may not be including their intentions to use treatment administered by nonmedical personal with their treatment teams. To date, one study found almost half of patients with breast cancer used CAM; however, many of them were not comfortable discussing this with their conventional treatment team because they did not believe that team had enough expertise on CAM.52 Another study found that while many patients choose to use CAM in addition to conventional treatment in the process of their cancer care, clinicians often lack the expertise to counsel patients on the evidence or lack thereof regarding CAM treatments.44 Inviting patients to share their interest in CAM may present an opportunity to enhance shared decision-making, particularly as patients may be planning to forego traditional treatments.
To this I would add that the rise of the pseudospecialty of “integrative oncology,” complete with training programs, seemingly authoritative guidelines endorsed by ASCO, and the proliferation of quackademic medicine in National Cancer Institute-designated comprehensive cancer centers, also means that a lot of patients are getting what would be considered “CAM” treatments that the NCDB wouldn’t capture under a category of “other-unproven: cancer treatments administered by nonmedical personnel,” if only because they’re now being administered by medical personnel at actual cancer centers, under the auspices of ASCO-endorsed SIO guidelines. As is the case with most of these studies, under ascertainment of CAM usage is a problem, although the authors further speculate:
Beyond the traditional limitations that are associated with observational studies, this study has several limitations. The NCDB designation of alternative therapy likely misses many patients who choose CAM, some of which may have experienced meaningfully different outcomes. We suspect that many of these patients may fall within the group with no treatment, which has the worst survival.
May I quibble here a moment? By definition, CAM means “complementary and alternative medicine.” Remember how, back in the day, CAM advocates would argue themselves blue in the face that these modalities were intended to complement, not replace, science-based medicine. That’s a big part of the reason why the term “CAM” eventually gave way to “integrative medicine,” to imply more strongly that these unproven (and in some cases disproven) therapies would never, ever be given except alongside “traditional” science-based medical treatments. (Also, CAM advocates didn’t like including the word “alternative” to describe their favorite woo.) Also, one of the rationales among advocates for embracing “integrative oncology” has been that oncologists and surgical oncologists doing so would make it less likely that patients would forego science-based treatment with large bodies of evidence supporting their efficacy and safety.
I was also less than thrilled with the authors’ apparent No True Scotsman fallacy, namely implying that their study doesn’t show that “true CAM” (i.e., making sure that patients receive every science-based treatment modality that is standard-of-care) impacts survival:
At the same time, because skipping traditional therapies appeared to be common in the combination cohort, a scenario we could not isolate was one in which the patients who fully complied with traditional treatments and then added CAM to the traditional treatment protocol. While the merits of traditional cancer treatments are clear, there are also indicators that treatments that would fall under the category of alternative therapies in the NCDB could have benefits during the cancer journey. Multiple studies have reported on the benefits of CAM approaches for symptom management and quality of life improvement in patients with cancer, including acupuncture,44,45 massage therapy,46,47 and mindfulness-based practices.48,49 Indeed, such therapies are increasingly studied and becoming incorporated into practice guidelines.50,51 Therefore, while traditional therapy should not be replaced by CAM, this study does not present any evidence to support or refute the role of CAM strictly as an adjunct to traditional therapy.
I must point out that, protestations of its advocates otherwise, acupuncture has never been demonstrated to be more than a theatrical placebo, and references cited to support the contention that acupuncture is effective in symptom management consist of nonrandomized self-reported outcomes and the SIO monograph. As for massage, I’ve never really had a problem with massage for making patients feel better; I merely reject the overblown claims that many of its advocates make for it. You can see that what is cited tends to be the commonly cited “CAM” therapies that are probably, as The Hitchhiker’s Guide to the Galaxy famously described the planet earth, “mostly harmless” (which really is the best that can be said about acupuncture) and not a lot of the other “CAM” therapies, such as supplements, herbs, reiki, and a number of other bits of woo and quackery that often fall under the “integrative medicine” label.
All of this brings me back to MAHA. If one looks at how the MAHA movement formed through the coalescence of COVID-19 era antivaxxers, COVID-19 minimizers, and the preexisting alternative medicine movement, it was not surprising in retrospect how rapidly the movement embraced “alternative” treatments for cancer. That’s how a repurposed drug embraced by quacks to treat COVID-19, ivermectin, was soon repurposed again to treat cancer. It’s how so many MAHA-adjacent doctors are sounding more and more like run-of-the-mill cancer quacks from the beforetime. What I fear is that RFK Jr. will build on the pre-existing “integrative medicine” movement that had been growing in influence since at least the mid-1990s, in order to encourage more “integration” of quackery with science-based medicine, not just in oncology but in all medicine. What this study reminds us, once again, is that, just as MAHA vaccine policies will result in the deaths of children, MAHA will likely result in the deaths of cancer patients as well, not to mention just patients.
Crap, I came back around to the devastation that RFK Jr. and MAHA is doing to US public health, biomedical research, and medicine. I guess there’s just no escaping it.

   Media, Regulation, Law and Education

   The North Carolina Board of Medical Examiners, Dr. Rashid Buttar, and protecting the public from practitioners of non-science-based medicine
David Gorski
Link
One of the most contentious and difficult aspects of trying to improve medical care in this country is enforcing a minimal “standard of care.” Optimally, this standard of care should be based on science- and evidence-based medicine and act swiftly when a practitioner practices medicine that doesn’t meet even a minimal requirement for scientific studies and clinical trials to support it. At the same time, going too far in the other direction risks stifling innovation and the ability to individualize treatments to a patient’s unique situation–or even to use treatments that have only scientific plausibility going for them as a last-ditch effort to help a patient. Also, areas of medicine that are still unsettled and controversial could be especially difficult to adjudicate. Unfortunately, with medicine being regulated at the state level, there are 50 state medical boards, each with different laws governing licensure requirements and standards for disciplining wayward physicians, our current system doesn’t even do a very good job of protecting the public from physicians who practice obvious quackery. The reasons are myriad. Most medical boards are overburdened and underfunded. Consequently, until complaints are made and there is actual evidence of patient harm, they are often slow to act. Also, in my experience, they tend to prefer to go after physicians who misbehave in particularly egregious ways: alcoholic physicians or physicians suffering from other forms of substance abuse; physicians who sexually abuse patients; or physicians who are “prescription mills” for narcotics. These sorts of cases are often much more clear-cut, but most importantly they don’t force boards to make value judgments on the competence and practice of physicians to nearly the extent that prosecuting purveyors of unscientific medicine does.
Dr. Rashid Buttar: Autism and cancer
The reason I’ve been thinking about this issue again is because last Friday it was announced that one of the most dubious of dubious physicians of which I have ever become aware, Dr. Rashid Buttar of North Carolina, was, after many years of practice, finally disciplined by the North Carolina Board of Medical Examiners. Basically, the Board restricted his practice so that he could no longer treat children or cancer patients (more on why those two particular restrictions were imposed below). Once hailed as a hero by antivaccinationists and even once having testified to the Subcommittee on Wellness & Human Rights on autism issues, he is now disgraced.
Dr. Buttar runs a clinic called the Center for Advanced Medicine and Clinical Research, which features on its front page this quote:
“All truth passes through 3 phases: First, it is ridiculed. Second, it is violently opposed, and Third, it is accepted as self-evident.”- Arthur Schopenhauer, 1788-1860.
I can’t resist mentioning that any time I see this particular quote, I know that I’m almost certainly dealing with someone who is far on the fringe, because what one first has to realize about the quote is that non-”truth” never makes it past phase one or two–and rightly so. Right off the bat, we can see that Dr. Buttar has a greatly inflated view of his own importance.
I first became aware of Dr. Buttar around three years ago in the context of his “transdermal” chelation therapy for autism. Regular readers may be aware that the whole concept of “chelation” therapy for autism is based on the scientifically discredited notion that mercury in the thimerosal preservative that used to be used in childhood vaccines until the end of 2001 is a major cause of autism. Based on this highly dubious concept, all manner of methods to “detoxify” these children of the mercury (and other heavy metals) that, according to antivaccinationists, are the cause of autism, have been used on autistic children. Chelation therapy involves using chemicals that can bind to the metal ions and allow them to be excreted by the kidneys, and indeed this is standard therapy for certain types of acute heavy metal poisoning. However, when it is used for coronary artery disease or autism, on a strictly stoichiometric and pharmacological basis, it is extremely implausible. Moreover, it is not without potential complications, including renal damage and cardiac arrhythmias due to sudden drops in calcium levels. Such arrhythmias can and have led to deaths (more later). Despite this extreme implausibility, randomized controlled studies showing that chelation is no better than placebo for cardiovascular disease, and no evidence at all that it does anything at all for symptoms of autism, a veritable cottage industry of chelation therapy for cardiovascular disease and autism has sprung up. With most regimens costing $100 to $150 a treatment and “requiring” 30 to 40 doses, it’s a tidy little profit center for “alternative” physicians.
Dr. Buttar made his name in the autism community by coming up with a form of chelation therapy that did not involve intravenous medication, which led him to be lionized by boosters of the “mercury causes autism” such as Generation Rescue. He took an accepted chelator used for acute heavy metal poisoinging, including mercury, called DMPS, formulated it as a paste or cream, and dubbed it “transdermal” DMPS or TD-DMPS, or, as some wags have dubbed it, “Buttar’s butter.” His main claim is that it’s safer. Of that there is little doubt, but that’s because Dr. Buttar has either utterly refused or been unable to provide even the barest modicum of evidence to suggest that the DMPS is absorbed through the skin and into the bloodstream. That is the most basic question that any science-based physician would ask about any transdermal medicine, and Dr. Buttar’s reactions to such questions is very telling. For instance, Prometheus quotes him:
In answer to questions of whether he has tested to see if his transdermal DMPS (TD-DMPS) drops are, in fact, absorbed through the skin -
No, we haven’t done that. Why would I waste my time proving something that I already know is working innately?
And, in response to being challenged on this point, Dr. Buttar wrote in an e-mail exchange with a supporter of his named Pat Sullivan:
My purpose is not to prove that TD-DMPS is getting through the skin Patrick. I don’t care if it is a placebo, which obviously it isn’t….and our lancet paper
It is a “SAFETY” issue I’m talking about….I don’t care to prove a damn thing to those people that you have been dueling it out with.
In a later e-mail, Dr. Buttar wrote:
You see, first, you would have to actually have to have some type of test developed to actually detect the DMPS in it’s altered form as it is absorbed. That takes money, effort and time. As my friend says, why do it? Let someone who wants to establish biokenetics and half life do that. It is not necessary to do this from a clinical efficacy standpoint. It would be nice to know how it works, but it is irrelevant. It works based on empirical evidence.
So it’s absorption is not an issue for me or for anyone who is a true scientist because the empirical evidence is abundant. Only a pseduo scientist is going to get caught up with levels in serum, which it may not even show, since DMPS is highly neurophillic and may be possibly taken up by the nerves or distributed through the lymphatics…I don’t know and I frankly don’t care since it has no relevance to the clinical side of the house. But you see how absurd it is to simply assume it has to get into the serum? It most likely does, but it may not. The point is, it gets in and it works….and it works better than anything else out there.
Yes, Dr. Buttar “knows” his treatment works, based on his “clinical experience.” He don’t need no steekin’ science, like bothering to show that his drug actually gets absorbed through the skin into the bloodstream. (Never mind that Dr. Buttar has been promising a study since 2004.) This seems quite odd, given that it would in fact be pretty straightforward to document whether the DMPS is getting into the bloodstream and if it is actually chelating heavy metals. Why on earth would he not want to do it? Of course, as we know, the plural of “anecdotes” is not “data,” as Steve Novella has pointed out, and, as Prometheus has pointed out, autism is a syndrome of developmental delay, not developmental stasis, which is why randomized studies with a placebo-control group are so critical. Particularly telling is Dr. Buttar’s statement that he “doesn’t care if it’s a placebo.” Little more needs to be said about his attitude about science, but that hasn’t stopped him from promoting this unproven and dubious therapy for autism for several years now.
More recently, Dr. Buttar developed a new “protocol” for treating autism that involved more than just chelation therapy. It is described here by a parent who saw him for a consultation a couple of years ago:
Every 2 weeks our son will get IV EDTA and ozone (which will be infused in his blood and given via IV) and on the second day he will get minerals. The reason given for ozone is to reduce persistent organics in his system. There is no test being recommended to determine if the child will be a good candidate for ozone. Apparently, some children are seeing good results and Dr Buttar is trying this treatment on older children (greater than 7). Dr Buttar’s office has provided some research on ozone done by a MD researcher in NY whom we spoke with. The immediate reaction of this researcher was that there has not been any study with children while ozone therapy is safe and has been used on millions of people in Europe. The researcher was not aware of Dr Buttar or his protocol on children and said that one needs to establish first if ozone therapy is needed.
There is no biologic plausibility or evidence to support the use of such a regimen. But Dr. Buttar has reportedly gone even beyond this level of dubiousness. As reported by Kevin Leitch, parents on a Yahoo! discussion group about chelation therapy for autism were reporting in 2006 that Dr. Buttar was recommending, well, let Kevin describe it. First, a parent asks:
Have any of your tried, or even heard anything about, doing urine shots to help the immune system? I don’t know much about it yet, but I know you use your child’s own urine, and filter it with special filters, before injecting it into their hip. I’ve heard really good things about it from a friend who tried it.
Here are some answers:
    • “This was recommended by Dr. Buttar’s office for my NT son who has tons of allergies. I believe Dr. Imam in NY does it. It sounded too “out there” for us so we are currently sticking with justchelation for him.”
    • “My grandson went through this beginning in October. It was a once a week treatment for 10 weeks. Before he began, he had lots of allergy problems that would often advance into sinus infection and ear infections. It’s almost April and he has not had one problem since. The only thing that I see is an occasional stuffy nose that lasts only a very short time.”
    • “I only know this was described to me to be a procedure used by Dr. Buttar about a year ago when my son was his patient, but the nurse said it would require an extended stay near the clinic and we live in Texas. We never tried it and moved on to another doctor.”
As Kevin puts it:
Just in case you think you read it wrong, you didn’t. Rashid Buttar and others recommend taking some of the childs urine, filtering it and then injecting it back into them. This is apparently good for the immune system. Yummy.
Yummy, indeed.
Arguably even more egregious is Dr. Buttar’s treatments for cancer patients. Let’s see what Dr. Buttar says on his own website about how he treats cancer:
The standard method of treating cancer is comprised of a combination of chemotherapy, radiation and surgery. However, according to the conventional, traditional medical literature, 75 to 95 percent of all cancers are related to some type of toxicity which results in damage to the immune system. Also, 42 percent of all cancer patients die of malnutrition. Yet, how many doctors treating cancer address nutrition or help repair the immune system? Learn the 5 step treatment approach Dr. Buttar uses in repairing the immune system in conditions such as cancer and AIDS. Then reach your own conclusion.
None of Dr. Buttar’s treatments have been subjected to science or to randomized clinical trials. That doesn’t stop Dr. Buttar from being unbelievably cocky and making totally unrealistic claims to patients with incurable cancer:
Medical board documents don’t name the four patients whose cases are cited. But Stephanie Kenny, a Charlotte mother of three, told The Charlotte Observer she is one of those who complained, on behalf of her husband, Jeffrey Kenny.
After learning that his adrenal cell cancer had returned following surgery, Jeffrey Kenny sought help from Buttar in early 2004. “He said it didn’t matter what kind of cancer anybody had, he could cure it,” Stephanie Kenny said. “He kept reiterating he had a 100 percent success rate.”
And:
Jerry Messina, of Los Angeles, told The Charlotte Observer he also complained to the medical board on behalf of his aunt, Lori Kostin. He said she went to Buttar after three rounds of chemotherapy failed to cure ovarian cancer. The medical board said Kostin paid $10,000 of a $30,000 bill for two months of treatment with IV infusions.
Messina, who did not meet Buttar, said his aunt told him the doctor “treated every type of cancer the same” and bragged about his 100 percent success rate. Two weeks before she died, in November 2004 at age 52, “she just flat out told me `I wish I’d never gone to this Dr. Buttar,’” Messina said. “She felt that her cancer got a lot worse.”
It should be noted that Dr. Buttar claims that he has patients sign a form that “no claim to cure cancer with these therapies has been made.” Be that as it may, anyone, doctor or not, who claims that he or she has a 100% success rate in curing cancers like the ones described above is either deluded or a liar. Period. Not even cancers for which there is a good prognosis and for which we have very effective treatments are cured 100% of the time. Moreover, it is incredibly unethical to make such a claim and then accept tens of thousands of dollars for these treatments. Even worse, like the Gonzalez regimen, Dr. Buttar’s cancer regimen is very onerous for cancer patients to follow. Indeed, one of Dr. Buttar’s patients, a man with prostate cancer who has posted under the pseudonym Cajun Cowboy, summarized his regimen, and it’s incredible. It turns out that Cajun Cowboy was at first a big fan and happy patient of Dr. Buttar, but now he says:
All the information about Dr. Buttar is still on this site but I no longer am one of his patients and I do not recommend him to any one for any reason. If you go to him for treatment BEWARE, BEWARE and read Roger Mason’s books first and go to QuackWatch.org first!
His description of Dr. Buttar’s billing practices is heartbreaking, and Dr. Buttar has been known to go after patients’ estates for uncollected bills. Meanwhile, one of the Board recognized a cardinal sign of questionable medicine:
“Doesn’t it strike you as a little strange that every patient that comes through your door has heavy metal toxicity?” Dr. Art McCulloch, a Charlotte anesthesiologist, asked Buttar’s nurse practitioner, Jane Garcia.
I assume the question was rhetorical, as anyone who has taken the time to study such practitioners knows that giving the same diagnosis and treatment to every patient is practically pathognomonic of quackery.
The reason I’ve gone on so long about Dr. Buttar is first simply to show just how outside of the standard of care Dr. Buttar’s practice of medicine has been. Kathleen Seidel has documented all of the complaints leveled by the NC Board against him, and I encourage everyone to read it. My second purpose is to point out just how powerless the North Carolina Board of Medical Examiners seems to have been for so long. Yes, it is taking action now and has specifically restricted Dr. Buttar’s practice to exclude cancer patients and children (the latter of which should stop his treating autistic children), but Dr. Buttar practiced this way for several years and continued to do so in the many months during which the Board’s proceedings against him ground along. Moreover, it’s by no means clear that the Board’s recommendation against him will stand. Dr. Buttar has deep pockets and can indeed afford to fight this action all the way to the North Carolina Supreme Court. I have no doubt that he will try to do just that. Even worse, even if he loses, his license is not being taken away. He will still be able to practice, just not on cancer patients or children. There’s nothing in the Board’s recommendation that would prevent him from treating patients with cardiovascular disease with his TD-DMPS.
Other practitioners of dubious therapies
If Dr. Buttar were just one example of an “alternative” practitioner who manages to get away with practicing non-science-based medicine that does not help patients and arguably harms them, one might dismiss him as nothing more than an anomaly. However, just in the realm of autism alone, he is not alone. Dr. Roy Kerry, for instance, is an otolaryngologist near Pittsburgh who apparently has given up head and neck surgery and devoted himself to dubious allergy treatments and various “alternative” medical modalities, who killed an autistic child in 2005 with chelation therapy. Yet, despite this, the CDC got it wrong about why this happened, and it took nearly two and a half years before any substantive action was taken. I will give proper credit to the State of Pennsylvania, though, that Dr. Kerry will soon stand trial for negligent homicide, although I can’t resist pointing out that Dr. Kerry still has a license to practice medicine and has continued to see patients since 2005. I have no doubt that if the autistic boy Abubakar Tariq Nadama had not died, Dr. Kerry would still be happily chelating autistic children with no inteference from the government.
If Dr. Buttar and Dr. Kerry are two who actually are being brought to justice for their offenses against medicine, however, more are like the case of Dr. Mark Geier, who has served as an expert witness in numerous lawsuits against vaccine manufacturers. He has had, as far as I know, no actions taken against him by the Maryland Board of Physicians. Describing in detail the number of questionable and unscientific practices that Dr. Geier inflicts on autistic children would be the topic for another blog post entirely, but I can summarize them with a short list of links:
    • Advocating a combination of chelation therapy and androgen blockade with Lupron (the same drug used for chemical castration) for autistic children (also here)
    • Diagnosing most autistic children with “precocious puberty” without proper diagnostic tests (an example bordering on diagnosing all autistic children with the same condition)
    • Subjecting children to excessive blood draws for no good reason
    • Running a front “institute” that allows them to constitute an IRB packed with cronies and friends to supervise his “clinical trials” (more here). As a clinical researcher, it boggles my mind that anyone can get away with such an unethical arrangement.
Kathleen Seidel has done an in-depth series about Dr. Geier, as well.
Reform is needed
Advocates for science-based medicine cannot help but be appalled at how easily physicians practicing modalities that are clearly far outside the standard of care can continue to do so with little or no interference by state medical boards. In essence, it takes particularly egregious offenses to motivate a board to act, be it substance abuse, non-science-based treatments resulting in the death or severe injury of a patient, or blatantly illegal behavior. Part of the problem is that the attitude among doctors seems to be that a medical license is a right, not an incredible privilege bestowed upon us by society that takes an equally incredible commitment and skill to be allowed to keep. Physicians who are on these boards are also often unpaid and reluctant (as they see it) to strip a fellow doctor of the means of his or her livelihood. There’s also a cultural tendency among physicians to stick together. We understand the difficulty of making decisions that can have profound consequences in our patients’ lives, and we tend to want to bend over backwards to give fellow doctors the benefit of the doubt. Our patients deserve better. The vast majority of physicians are competent and try their best to deliver the best evidence-based care they can to their patients. However, doctors who consistently do not practice according to the standard of care, be it because they are incompetent, dishonest, impaired by substance abuse, or because they have come to believe in blatantly unscientific treatments that do not help and not infrequently harm patients, do not deserve to be physicians. Examples such as Drs. Buttar, Kerry, and Geier show that our system is broken. If we as a profession do not find a way to do better, I fear that legislators will do it for us.

Stanislaw Burzynski

Stanislaw Burzynski: The Early Years, part 1
David Gorski on July 22, 2013
Link
It’s been a week now since I got back from TAM, where Bob Blaskiewicz and I tag-teamed a talk about a man who has become a frequent topic of this blog, namely Stanislaw Burzynski. I’ve been meaning to come back to the topic of Burzynski, but from a different angle. There hasn’t been much in the way of news lately other than the release of Eric Merola‘s most recent propaganda “documentary,” Burzynski: Cancer Is A Serious Business, Part 2, but, believe it or not, there remain lots of loose ends that I haven’t covered. This time around, the angle is this: How did Burzynski get his start? His is a story that goes back over 46 years, and in the beginning he seemed to be a promising young academic physician and a perfectly respectable researcher. So what happened? How did he evolve from a seemingly idealistic young Polish physician to what he has been for many years now?
I started to think about this when I was writing my post about “alternative cancer cures” circa 1979, because one of the three articles written by Gary Null and various coauthors that appeared in Penthouse magazine in the fall that year, The Suppression of Cancer Cures, was dedicated primarily to Stanislaw Burzynski and his “antineoplastons,” which at the time were new news, so to speak. However, Null’s article, even though it was contemporaneous with Burzynski’s having recently struck out on his own and started his own clinic, didn’t reveal everything that I was interested in learning. Actually, the more I read, the more I realize that no source really reveals everything that I want to know about that time period in the 1970s and early 1980s that produced the Stanislaw Burzynski that we know and don’t love today. Available sources all tend to be either pro-Burzynski, Burzynski himself, or vague in the extreme about what happened. Fortunately, my research for my TAM talk will serve multiple purposes. Since the talk was so brief and required me to cover 40+ years of history in a mere 20 minutes, there was a lot left out. I hate to let all that research go to waste; so I’m going to use it for an intermittent series of blog posts.
While preparing for my TAM talk, I read two books from sources friendly to Burzynski. The first was Galileo’s Lawyer: Courtroom Battles in Alternative Health, Complementary Medicine and Experimental Treatments by Richard A. Jaffe. Jaffe was Burzynski’s lawyer for a long time, and in particular he helped Burzynski beat multiple raps in 1997, when it looked as though Burzynski might well be convicted of insurance fraud, violations of the Food, Drug, and Cosmetic Act, and other charges related to his antineoplaston therapy. Of the two, this book was the most revealing, because Burzynski wasn’t the focus of the book (although his story does take up roughly half of it). Rather, self-aggrandizement on the part of the author clearly is, which perhaps explains why Jaffe would say some things that he says that are particularly unflattering to Burzynski. True, Jaffe clearly thinks they are flattering (to him) and evidence of how clever he was in defending the misunderstood genius that he viewed Burzynski to be and beating the system in the mid- to late-1990s, but what they reveal to me about Burzynski’s current crop of phase 2 clinical trials is appalling. The second book is The Burzynski Breakthrough: The Most Promising Cancer Treatment and the Government’s Campaign to Squelch It by Thomas D. Elias. This book is more pure hagiography, a book designed to portray Burzynski as a Brave Maverick Doctor who can cure cancers that conventional medicine cannot. Amusingly, the latest edition boasts that there are now “clinical trial data” in it, which led me to wonder why Burzynski would provide such data to a columnist writing a hagiography about him rather than, oh, you know, publish it in the peer-reviewed scientific literature. However, Elias provides a bit more detail on certain aspects of Burzynski’s early years, and his account is interesting in that it doesn’t always agree with Jaffe’s account. Elias also provides testimonials from several of Burzynski’s patients who were treated before the Internet era whose stories are hard to find in detail online, for example, Tori Moreno. (For example, nothing in the chapter on Tori Moreno leads me to change my conclusions about how she survived.)
Obviously, given that both of these books are clearly pro-Burzynski, one has to take their claims and accounts with a grain of salt. (Actually, the salt mines under Detroit probably don’t contain enough salt for this purpose.) Even so and even noting that these are pro-Burzynski sources, I was shocked at the sorts of information in the books, there for all to see. To someone who knows cancer research, they contain some pretty damning information. Obviously, the authors didn’t see it that way when writing them, but I do.
The early years: Childhood
In many ways, Stanislaw Burzynski’s story is a prototypical immigrant rags-to-riches story. Stanislaw Burzynski was born in Nazi-occupied Poland in the city of Lublin on January 23, 1943, right as the Holocaust in Poland was gearing up in earnest. The previous year, mass killings had begun at Auschwitz-Birkenau, and mere months before Burzynski’s birth, the Sobibor and Treblinka camps had opened. So had the Belzen camp, to which the Jews of Lublin were deported soon after its opening. Other notable events in the year before Burzynski was born include the beginning of Operation Reinhard (the mass deportation of Polish Jews to concentration camps), the beginning of the liquidation of the Warsaw Ghetto, and many other atrocities. In 1943, the Jews of the Warsaw Ghetto mounted their uprising, and later Himmler ordered the liquidation of the remaining Jews in Poland.
Little is known about Burzynski’s early childhood and youth aside from what Burzynski himself has told sympathetic sources like Thomas Elias, from whose book I gleaned most of this account. Despite the devastation going on all over Poland, Stanislaw Burzynski was largely sheltered from the grim reality of Nazi-occupied Poland in his early years. His mother’s family was well-off and owned an ornate family house in the old part of Lublin built around three inner courtyards that had served as the local Roman Catholic bishop’s palace in the 1800s. It was designed in a Baroque Renaissance style, and its three-story facade bore elaborate sculptures around all the windows. Before the war, Elias reports, Burzynski’s grandmother used its large spaces to operate a private high school for girls. In the early 1940s, she gave her daughter and her husband an apartment in the building.
There was also a country house at the edge of the great Stary Las Forest outside of Lublin where the Burzynskis spent a lot of their time as well. Burzynski’s father, a teacher who was the son of a blacksmith, was apparently not well-regarded by his mother’s side of the family because he came from poverty and Poland was a very class-conscious society at that time. His father was also imprisoned by the Nazis because he kept teaching Jewish children, and the local Nazis did not like that. Interestingly, after the war, the Communists imprisoned Burzynski’s father for giving underground lessons that were apparently not politically acceptable. His father sounds as though he were quite the man. The son, on the other hand, was pugnacious and described himself as getting into fights almost every day, a situation that persisted until the fourth grade.
After the war, the Communist government confiscated the Burzynski house in Lublin and turned it into apartments, which were distributed to whoever needed them, although the Burzynskis got to keep their apartment. Elias also informs us that Burzynski’s brother Zygmunt was an anti-Communist fighter who was shot fighting the government in 1948 and died of meningitis as a result of his wound. In Elias’ book, Burzynski recounts these stories and uses his childhood pugnaciousness and belief that one should never duck a fight as a rationalization for not having moved his clinic to Tijuana years ago, saying:
So, the idea of fighting a government was nothing new to me when I began having troubles with the Food & Drug Administration.
And, based on the death of Zygmunt:
The idea of fighting people in authority became natural to me. I learned that you must never let them defeat you in your own core.
In some ways, these can be most admirable traits. Virtually all highly successful people who make a difference in the world possess some measure of this sort of determination and willingness to fight for what one believes. If only Burzynski had found a good cause to which he could yoke such them. Unfortunately, he found antineoplastons.
The early years: The dawn of antineoplastons
Despite his tendency to fight, Stanislaw Burzynski was, unlike his brother, academically inclined. He did very well in secondary school and entered medical school straight from there, which was how it was done in Poland at that time. Somehow, he became intensely interested in amino acids and peptides. Working for chemistry professor Irana Krzeczkowski and biochemist Janina Blaut, the young Burzynski studied peptides in wild mushrooms that grew in the Stary Las Forest because his mentor wanted to find uses for them in agriculture. By the time he graduated from medical school in 1967, he had published fourteen scientific papers, which, as we say, ain’t too shabby.
In 1967, Burzynski was ready to work on his doctoral thesis. He had become interested in differences in the amount and types of peptides found in the blood and urine of renal failure patients and cancer patients. He reported that some of these chemicals were found at high levels in the blood of renal failure patients. He also found that cancer patients had a low level of some of these substances, which were not, it turned out, peptides. Ultimately, his work in this area resulted in a thesis entitled “Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency.” Of note, according to Elias, Burzynski finished his thesis in 1968, which makes one wonder how he could have possibly gotten a PhD based on it in such a short period of time. However, my purpose here is not to worry about whether his PhD is legitimate, as Saul Green has done. I don’t really care if Burzynski’s PhD is legitimate or not. What I care about is what Burzynski has done with his medical education over the last 46 years.
Ultimately, in 1970, Burzynski decided that he couldn’t stay in Poland anymore. What hadn’t been clear to me from all the reports and retellings of his decision to come to the US is why he chose to leave Poland in 1970. Whatever happened between 1968 and 1970, Elias reports that in 1970 Burzynski was being recruited to join the Communist Party but refused to join. This was perhaps the first case, but definitely not the only case, where his stubbornness caused him serious problems. Burzynski learned he was going to be drafted into the Polish Army, where he would be sent to wherever the Soviet Union needed him, but, thanks to the intervention of a prominent scientist, managed to get a passport and get out of Poland before his draft notice was delivered in early September. He arrived, as he has said so many times, at JFK Airport with only $20 in his pocket. Later he learned that his position at the university had been terminated.
Burzynski stayed with an uncle in The Bronx but soon managed to get a job at the Baylor College of Medicine in the Department of Anesthesia, then headed by Georges Ungar, a Hungarian refugee with whom he hit it off. Ungar was famous for proposing that memory resided in peptides made by the brain, and he tried to “transfer” memory by transferring those peptides from one mouse brain to another. It’s a hypothesis that seemed to be supported by his experiments at the time but faded from favor as more research failed to support it. Burzynski split his time between working on Ungar’s project and working on his own peptides, which he had finally dubbed “antineoplastons. He even managed, with the help of an investigator at M.D. Anderson, to secure an NIH grant in 1974. These years were productive for Burzynski, and he and Ungar published a lot of papers. Burzynski apparently killed a lot of rats in his time at Baylor doing Ungar’s research, which is something I can totally relate to, having dispatched hundreds of mice myself while doing angiogenesis research in the 1990s. Basically, rats were trained at tasks by the hundreds, after which they were killed and the peptides from their brains isolated. These peptides were then injected into the brains of other rats in order to see if the “knowledge” could be transferred with the peptides. Fun times!
The long, slow ethical slide
It was in Stanislaw Burzynski’s later years at Baylor that, arguably, the seeds of what he has become today were planted. In 1973, after three years of study, Burzynski had managed to pass the medical board examinations and obtain his Texas medical license. However, as I’ve pointed out before multiple times, he had no U.S. specialty training in oncology. In fact, he doesn’t appear to have had any specialty training even in internal medicine, and an internal medicine residency is a prerequisite to doing an oncology fellowship and becoming a fully-trained oncologist. One thing I couldn’t figure out from either book or any of my other reading is how Burzynski got a license to practice medicine in Texas. Usually, getting such a license requires at least a year of postgraduate medical training (usually an internship) in addition to medical school and passing the national medical board examinations. I can only speculate that whatever postgraduate clinical training Burzynski might have done in Poland must have counted, because I can’t find any reference to him doing any clinical training after arriving at Baylor. That’s not really the most important issue here, but it is a curiosity to me as a physician.
It’s also indicative of the extreme arrogance that Burzynski exhibited at the time. Elias recounts how in 1976 Burzynski thought that because he had obtained his medical license in 1973 he was then qualified to be the principal investigator for the first clinical trial of antineoplastons. He didn’t want to let anyone else be in charge of such a trial, even though it is obvious to me that at the time Burzynski was completely unqualified to run even a small phase I oncology trial. It’s rather instructive to look at what happened here from three different perspectives, the narrative in Elias’ book, the narrative in Jaffe’s book, and the description in Gary Null’s Penthouse article. Oddly enough, for being nearly contemporaneous, Null’s article mentions very little about Burzynski’s time at Baylor and why he ultimately left, at least nothing more than I discussed when I originally considered this article.
So what did happen? From what I can gather from Elias and Jaffe, a confluence of events conspired to push Burzynski towards his fate. Yes, I’m exaggerating a little, but not much. As I discussed before, Burzynski successfully got an NIH grant in 1974, but was unable to renew it in 1976; it expired in 1977. In 1976, apparently internal politics led to Ungar’s ouster from the Department of Anesthesia. According to Elias, the new “boss of anesthesiology” (as Burzynski was quoted as putting it) was Lawrence Schumacher, who wasn’t interested in peptide research and didn’t think much of Burzynski. He also, arguably quite appropriately, didn’t think that Burzynski’s research was the sort of research that was appropriate to a department of anesthesia. So Ungar ended up taking a job at the University of Tennessee, and Burzynski had trouble renewing his grant. Apparently, if Burzynski is to be believed, the new cancer research center at Baylor wanted to hire him and even offered him a $30,000 start-up package (respectable at the time), but it also imposed two conditions that were unacceptable to him. First, it wanted the rights to his antineoplaston discovery. This has been common practice at universities for a long time. If an investigator discovers something patentable while working for a university, usually the university will patent it and share a significant cut with the inventor. Burzynski, however, didn’t want to share. Similarly, although Ungar offered Burzynski a position in Tennessee, Burzynski did not want to follow his friend there because he was afraid that the University of Tennessee would want his antineoplastons, too.
There was another condition, too, and it’s a problem that tells me that from a very early time in Burzynski’s career he didn’t “play by the rules.” However, it was more than that. Not only did he not “play by the rules,” but he didn’t much care for those pesky regulations and ethical codes designed to protect human subjects. Here’s where Elias and Jaffe diverge. According to Jaffe, shortly after he got his medical license Burzynski started a private practice on the side, and that practice became fairly lucrative. According to Jaffe, Burzynski joined someone else’s practice part time. Actually, Elias is inconsistent on this issue, at one point implying that it was Burzynski’s private practice and at another point saying that Burzynski worked for someone named Dr. Walker. Whatever the case was, both agree that before he even tried to undertake clinical trials of antineoplastons at Baylor, Burzynski had been giving ANPs to patients at his private practice. Just how long he had been doing that was not clear from either account, but it was clear that he did it before undertaking clinical trials. Indeed, that was why Baylor’s requirement as a precondition for his taking a position at the cancer research center that Burzynski give up his private practice that was such a sticking point to Burzynski, as Elias describes:
Despite the enhanced prestige, secure salary and tenure that could have been his had he gone along with the proposed changes, Burzynski hesitated. He didn’t like the idea of subjecting himself to the authority of an institution. As long as he had a private practice, he believed he could use whatever medications he thought most effective, subject only to the consent of his patients.
In any case, in late 1976, Burzynski applied to the Baylor Institutional Review Board to be able to begin a clinical trial of antineoplastons but was turned down. Both Elias and Jaffe claim (no doubt because Burzynski told them this) that the reason Baylor’s IRB turned Burzynski down is because he didn’t have an IND. An IND is an “investigational new drug” application, which the FDA requires before it will approve a clinical trial of an experimental drug. In both accounts, Burzynski laments that Baylor turned him down and that he couldn’t get an IND because, according to him, IRB approval was required to get an IND, leading to what he referred to as a circular process that dogged him for several years. Reading these accounts, I can’t help but think that there must have been more going on. For example, I’m not sure how much different it was in 1976, but in general the FDA requires the following information for an IND:
The IND application must contain information in three broad areas:
    • Animal Pharmacology and Toxicology Studies – Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).
    • Manufacturing Information – Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug.
    • Clinical Protocols and Investigator Information – Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators–professionals (generally physicians) who oversee the administration of the experimental compound–to assess whether they are qualified to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations.
In other words, an investigator doesn’t need to get IRB approval before applying for an IND. The investigator has to promise he will have the study that ultimately derives from an IND will be reviewed by an IRB, obtain informed consent from patients, and adhere to the FDA’s IND regulations. I can, however, see many reasons why an IRB might be reluctant to give its approval for a study using a treatment like ANPs. For one thing, in 1976 Burzynski had no animal data to speak of. In fact, the question of animal studies is an interesting one. Both Elias and Jaffe recount a story in which ANPs didn’t work in animal tumors, and Burzynski has been quoted in multiple places as claiming that ANPs are species-specific and that ANPs derived from human blood and urine don’t work in animal tumor models. This is in contrast to what Null reports in his near-contemporaneous account, in which he stated that in tissue culture and animal models Burzynski’s ANPs worked “specifically against certain types of cancer,” all with “no toxic side effects.” It makes one wonder whether the “species specificity” was an excuse developed later to explain the lack of animal data.
Whatever the case, it’s not surprising that an IRB would balk. From what I can tell from every account I’ve read, in 1977 there just wasn’t enough preclinical data to justify a clinical trial, nor was it even clear yet exactly what ANPs were, as Burzynski hadn’t yet identified all the constituent chemical compounds were that made them up. Worse, ANPs were derived from urine, which opened up the possibility of infectious agents being transmitted from ANP preparations made from human urine. Moreover, in 1977, as far as I can tell, Burzynski didn’t have the capability to isolate sufficient quantities of ANPs to treat patients, having told Elias that he required 30 L of urine per day per patient. It wasn’t until the early 1980s that Burzynski learned how to synthesize ANPs, and that was after he had left Baylor.
After Baylor’s IRB rejected his application, Burzynski tried the Park Plaza Hospital, which was affiliated with Baylor. Park Plaza turned him down. Ultimately, the IRB at Twelve Oaks Hospital, which is where he treated his first patients with ANPs, approved his application. At this stage, Jaffe’s account is more illuminating, because it demonstrates just how scheming Burzynski was at the time. He had lawyers investigate whether he could give ANPs to patients at his clinic and how he could avoid getting into trouble. Their advice to him was that, because Texas at the time didn’t have a “mini-FDA” act, in which only FDA-approved drugs could be given to patients, the only way he might get in trouble with the law administering ANPs was if he were to ship them across state lines and thereby fall under the federal Food, Drug, and Cosmetic Act and the FDA’s authority. Basically he was told that, as long as he was making ANPs in his own laboratory and giving them only to his own patients, it should be legal under Texas law.
Jaffe also recounts some amusing anecdotes of Burzynski’s early years after leaving Baylor. Back then, he really did isolate ANPs from blood and urine. Apparently before he left Baylor, he got ANPs mainly from blood:
For the previous few years, he had been obtaining antineoplastons from human blood in an unusual way. He got his raw material from the blood of his friends and acquaintances. He would go to parties and public gatherings with IV lines and bottles and beg and cajole his friends and colleagues to donate blood for his research.
After a while, he noticed he was getting fewer and fewer invitations to parties, and, when his friends would see him on campus or the street, they would turn and walk away quickly, pretending they didn’t see him.
This sounds a lot like Andrew Wakefield and his “experiments,” doesn’t it?
After he went into practice for himself, Burzynski’s need for raw materials skyrocketed, and the only feasible way to get them was from urine. To get it, Burzynski arranged to install urine collectors in public parks and the state penitentiary system. Most amusingly of all, apparently Burzynski collected urine from Gilley’s Bar, where Urban Cowboy was filmed. One wonders whether John Travolta contributed to some of those early antineoplaston batches.
Back to the future
In my next installment in this series (which probably won’t be next week), I’ll discuss some of Burzynski’s legal battles, up to and including his epic battle in the 1990s that led to his indictment in late 1995 on insurance fraud and violation of the Food, Drug, and Cosmetic Act and his ultimate acquittal based on a hung jury in early 1997, as well as how the Burzynski Patient Group was formed and used to bring pressure on the FDA and Texas Medical Board to rule in Burzynski’s favor, all with the help of some very powerful politicians, such as Representative Joe Barton of Texas. At some point, I’ll also look at the “clinical trial statistics” that Elias promised on the cover of his book. However, I will conclude by pointing out exactly what it is that Jaffe said that he really shouldn’t have. It’s of a piece with Burzynski’s history in that shows how, 20 years later, Burzynski wasn’t really interested in doing clinical trials. They are and always have been a means to an end: To let him give ANPs to patients unmolested by the authorities.
Jaffe in essence boasts about this in his book. Because Rep. Joe Barton had put such enormous pressure on the FDA through his Congressional hearings and bad publicity replete with crying cancer patients lamenting how they would die if Burzynski were shut down, in 1997-1998 the FDA was going to relent and let Burzynski apply to undertake clinical trials. In response, Burzynski put together a clinical trial known as CAN-1, which was basically a retrospective study of all the patients Burzynski had treated with ANPs up to that point in 1997. Listen to how Jaffe described it:
So we decided to hit the FDA with everything at the same time. All of his current patients would be covered in a single clinical trial which Burzynski called “CAN-1.” As far as clinical trials go, it was a joke. Clinical trials are supposed to be designed to test the safety or efficacy of a drug for a disease. It is almost always the case that clinical trials treat one disease.
The CAN-1 protocol had almost two hundred patients in it and there were at least a dozen different types of cancers being treated. And since all the patients were already on treatment, there could not be any possibility of meaningful data coming out of the so-called clinical trial. It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
This is Burzynski’s lawyer writing here. I thank him for his candor, particularly since he describes how the dozens of other clinical trials, 61 of which still show up on the ClinicalTrials.gov website, came into existence. According to Jaffe, it was not because Burzynski was so interested in knowledge and finding out whether ANPs work. It was because he already believed they worked and wanted to keep treating patients without interference:
CAN-1 allowed Burzynski to treat all his existing patients. That solved the patients’ problems, but not the clinic’s. A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future…Miracle of miracles, all of Burzynski’s patients were now on FDA-approved clinical trials, and he would be able to treat almost any patient he would want to treat!
And for patients who didn’t fit into one of these seventy-three clinical trial protocols (CAN-1 plus the other seventy-two), there were always single-patient INDs, otherwise known as compassionate use protocols. I also can’t help but wonder what the alt-med believers who support Burzynski would say if I were to say about my cancer center something like, “A cancer center cannot survive on existing patients. It needs a constant flow of new patients.”
Yes, from a very early time in the late 1970s to twenty years later in the 1990s to this very day, for Stanislaw Burzynski, clinical trials are but a means to an end, and that end is not scientific knowledge or to determine whether or not they work against cancer. The end is to allow Burzynski to treat cancer patients with ANPs. He is, after all, the Brave Maverick Doctor fighting the system, as he thought of himself as fighting the system in Communist Poland. From what I’ve been able to discern, to him government laws and regulations are not designed to protect patients but to keep him from curing them. So getting around them by any means necessary is not only justified but mandatory. The question becomes: Does Burzynski still believe himself to be the man who has cured several forms of cancer, or does he now know that ANPs almost certainly don’t work and are definitely not some sort of “miracle cure”?
To be continued…eventually

Stanislaw Burzynski: Bad medicine, a bad movie, and bad P.R.
David Gorski on November 28, 2011
Link
And the Lord spake, saying, “First shalt thou take out the Holy Pin. Then shalt thou count to three, no more, no less. Three shall be the number thou shalt count, and the number of the counting shall be three. Four shalt thou not count, neither count thou two, excepting that thou then proceed to three. Five is right out. Once the number three, being the third number, be reached, then lobbest thou thy Holy Hand Grenade of Antioch towards thy foe, who, being naughty in my sight, shall snuff it.
Cleric from Monty Python and the Holy Grail
I’ve always wondered about the power of the number three. When it comes to quackery propaganda movies, certainly three seems to be the magic number. For example, The Greater Good, an anti-vaccine propaganda film, features three anecdotes, three children allegedly suffering from vaccine injury, and it interspersed its interviews with experts, both real (such as Dr. Paul Offit) and phony (such as Barbara Loe Fisher) with vignettes from these children’s stories interspersed between them in a highly biased manner. I have to wonder whether these cliches are taught in film school, given that they seem to be so common. Such were the thoughts running through my brain as I watched the latest medical propaganda film by writer/producer Eric Merola that’s floating around the blogosphere and the film circuit, Burzynski The Movie: Cancer Is Serious Business. In this movie, there are three testimonials, and, if anything, they are far more manipulative than even the testimonials featured in The Greater Good, because each of them are of the type that portrays doctors as sending a patient home to die; that is, until a “brave maverick doctor,” one Stanislaw R. Burzynski, MD, PhD, comes to the rescue with his unconventional and unproven therapy. The only difference is that this film counts testimonials up to the number three in the beginning as “proof” that Burzynski can cure cancer before lobbing the Holy Hand Grenade of Burzynski towards its foes in the hopes that, being naughty in the filmmaker’s sight, the FDA and Texas Medical Board will snuff it. Or, as a caption says right at very the beginning of the movie:
This is the story of a medical doctor and PhD biochemist who has discovered the genetic mechanism that can cure most human cancers. The opening 30 minutes of this film is designed to thoroughly establish this fact — so the viewer can fully appreciate the events that follow it.
It turns out that the grenade is a dud.
The evidence presented to “thoroughly establish” that Burzynski “can cure most human cancers” consists not of clinical trials, not of animal studies, not of basic science. Rather, it consists of three testimonials that take up the first 30 minutes of the movie, along with testimony before a Congressional subcommittee by Sgt. Ric Schiff, who opines that because he is a policeman he can spot fraud and he doesn’t see any fraud in Dr. Burzynski. He tells the story of his daughter who, according to him, developed a highly malignant brain tumor that had “spread throughout her spine and brain” that Burzynski is said to have successfully treated.
The remaining tedious hour-plus of the movie consists of one big, JFK-style conspiracy theory. Because of Burzynski’s “miracle cure” for most cancer in the form of what he calls “antineoplastons,” the movie argues, the FDA, big pharma, and the rest of the “cancer establishment” want to put Burzynski out of business. The movie claims they want this not to protect the public but rather to protect industry profits and FDA power. The rest of the movie shows lots of archival footage with an ominous, biased voiceover, of the FDA, the NCI, the Texas Medical Board, and various other entities investigating, or, as the movie implies, persecuting this “brave maverick doctor” because he’s found a cure for most kinds of cancer.
But has he?
I’ve been meaning to do a post about Burzynski ever since the beginning of this blog but have tended to back away because summarizing the Burzynski situation would be more work than the average post. I’ve also been meaning to do a review of this movie for quite some time now, given that it was first released over the summer and was made available for free online for a period of time in June. Since then, it’s been percolating through the cancer quackery underground and showing up at various film festivals. In a way, I have Burzynski’s apparent shill himself, a man named Marc Stephens, to thank for reminding me to get to this topic, particularly given that I’ve been meaning to write about Burzynski since the very beginning of this blog. How Marc Stephens operates will inform you a bit about Burzynski; so I will briefly describe what happened last week.
One week ago, a skeptical blogger whose work I admire, Andy Lewis, wrote a post about two charity concerts that a British performer named Peter Kay was doing to raise money to pay for the medical care of a four-year-old girl named Billie Bainbridge, who, tragically, has an inoperable and very rare brain tumor known as Diffuse Intrinsic Pontine Glioma (DIPG). Now, given that the UK government funds the NHS, which guarantees health care for its citizens, you might wonder why such spectacular sums of money (in this case, £200,000) would be needed for this child. It turns out that the money raised is to be used to take Billie to the Burzynski Clinic in Texas. This reminded me very much of a campaign I remember seeing two years ago for a woman with medullary thyroid cancer named René Louis, who, although she had health insurance, wanted to pursue Burzynski’s methods, which her insurance quite correctly wouldn’t pay for. In fact, it turns out that this is not an uncommon scenario for Burzynski patients, with patients like Louis or families like the Bainbridge or the Hofsess family, having been convinced that Burzynski is their only hope, going to the media and managing to get human interest stories written about their campaigns to raise money. Some, like René Louis or the Hofsess family, go so far as to set up charitable organizations to continue to raise money for others seeking Burzynski’s treatment. Unfortunately, the “human interest” interest in these stories rarely mixes with a skeptical or science-based viewpoint, even though the more appropriate spin on such stories is to portray them as consumer issues. If only the spin on such stories was more like that of the story of Wayne Merritt!
Given that Burzynski is known for having promoted a scientifically unproven cancer treatment called “antineoplastons,” Andy was, quite understandably, alarmed and expressed his alarm in a blog post a few days ago entitled The False Hope of the Burzynski Clinic, in which he nicely summarized the history and evidence about antineoplastons. He pointed out that there is little or no convincing clinical evidence that antineoplastons have activity against cancer, much less that they offer hope to a desperate patient like Billie. As a result, legal thuggery commenced a couple of days later, courtesy of the aforementioned Burzynski fan Marc Stephens, whose name can’t be found on the Burzynski Clinic or Burzynski Research Institute‘s websites but can be found in Marketing and Sponsorship for the Burzynski Patient Group, a patient group that does not appear to be actually affiliated with the clinic. It turns out that this appears to be common practice for this Marc Stephens, as Peter Bowditch can attest. Indeed, recently, Mr. Stephens even decided to issue legal threats against a teenager named Rhys Morgan.
It was this confluence of events that led me to think that now is time to look at Burzynski’s claims from the perspective of a cancer surgeon and researcher; i.e., myself. Looking at the evidence presented in Burzynski The Movie seemed a perfect way to begin.
For those who have the time and inclination to do so before my discussion, the whole movie is still available on Mike Adams’ quack website and on YouTube:
NOTE: Apparently, The Documentary Channel has asserted some sort of copyright claim and forced YouTube to take down the video for this movie. The movie is, however, still available at that other wretched hive of scum and quackery (besides the Huffington Post), namely the video outlet for Mike Adams, NaturalNews.tv.
Burzynski and “antineoplastons”
Before I return to the content of the movie, it’s essential that I provide a bit of a background on Dr. Burzynski, his claims, and the evidence behind them. An excellent summary can be found in Quackwatch (of course), as well as at the NCI website, the American Cancer Society, and others. The short version of the story behind antineoplastons is that there is no good clinical evidence to suggest that they have any significant activity against cancer. A somewhat longer version follows, so that readers here have the background to understand my review of Burzynski The Movie.
Dr. Burzynski first gained fame for his cancer therapy back in 1988, when Sally Jesse Raphael featured four “miracle” patients of Burzynski’s, who, according to her, had had incurable cancer and failed conventional therapies but were rendered cancer-free, thanks to Dr. Burzynski. Unfortunately, four years later in 1992, Inside Edition followed up these four patients and found that two of the four had died and a third had recurred, while the fourth had had bladder cancer with a good prognosis. In that report, the widow of one of Raphael’s guests reported that her husband and five others had sought treatment from Burzynski and that all had died. In addition:
In 1995, a federal grand jury indicted Burzynski for mail fraud and marketing an unapproved drug. The indictment charged that he had billed insurance companies using procedure codes for chemotherapy, even though his treatment was not chemotherapy. He was tried in 1997 but not convicted.
Of course, antineoplaston therapy is chemotherapy, despite Burzynski’s attempts to portray it otherwise, but more on that near the end of this post. In the meantime, testimonials and no firm clinical trial data to support Burzynski’s methods have been par for the course ever since, for over three decades now. It all began in the late 1960s, when Burzynski proposed that a system separate from that of the immune system helped to keep developing cancer cells in check by “reprogramming misdirected cells.” He dubbed these compounds “antineoplastons” and believed them to be naturally occurring peptides and amino acid derivatives that inhibit the growth of malignant cells but do not harm normal cells. In early reports, he found that healthy people had more antineoplastons in their blood and urine than people with cancer (results portrayed in cartoon form in the movie). From this observation, Burzynski postulated that antineoplastons could be used to treat cancer. Not long after that, he left academia in the late 1979s, formed his own institute (the Burzynski Research Institute) and clinic (the Burzynski Clinic), and began doing research into antineoplastons. In 1980, Burzynski characterized the structures of antineoplastons and, instead of isolating them from urine, started synthesizing them chemically, whereas previously he had been isolating them from urine collected from underground tanks in public parks. These days, preparations now used in clinical studies to treat cancer are antineoplastons A10, AS2-5, AS2-1, A2, A3, and A5.
In reviewing Burzynski’s history, one thing that stands out to me as a cancer researcher who has been involved in drug development is data from the preclinical studies summarized by the NCI. To cut to the chase, the concentrations required in in vitro and in animal studies to show any effect at all are quite high:
Japanese scientists have tested antineoplastons A10 and AS2-1 in vitro for cell growth inhibition and progression in several human hepatocellular cell lines.[2,3] Tests were performed in a dose-dependent manner at concentrations varying from 0.5 to 8 µg/mL for A10 and AS2-1, and growth inhibition was generally observed at 6 to 8 µg/mL. This dose level is considered excessively high and generally reflects a lack of activity. Growth inhibition of one of the cell lines (KIM-1) was observed at low concentration for a mixture of cisplatin (CDDP) and A10, but this result was probably caused by the cisplatin, which was effective at concentrations of 0.5 to 2.0 μg/mL when tested alone.[4] AS2-1 was reported to induce apoptosis in three of the cell lines at concentrations of 2 and 4 μg/mL.
These are not results that would get me excited about these compounds, because levels that high would be very difficult to achieve in humans. This will become very relevant later. These observations are also why it it is not in the least bit surprising that the NCI ultimately came to this conclusion about antineoplastons:
Antineoplaston therapy has been studied as a complementary and alternative therapy for cancer. Case reports, phase I toxicity studies, and some phase II clinical studies examining the effectiveness of antineoplaston therapy have been published. For the most part, these publications have been authored by the developer of the therapy, Dr. Burzynski, in conjunction with his associates at the Burzynski Clinic. Although these studies often report remissions, other investigators have not been successful in duplicating these results. (Refer to the Human/Clinical Studies section of this summary for more information.) The evidence for use of antineoplaston therapy as a treatment for cancer is inconclusive. Controlled clinical trials are necessary to assess the value of this therapy.
“Inconclusive” is putting it mildly, but because Burzynski reports remissions, the ever-cautious NCI had little choice but to word its conclusion that way. In any case, the fact remains that Burzynski’s antineoplastons are not approved by the FDA for the treatment of cancer because there is no compelling evidence that they work. Not that that stopped Burzynski, who kept providing antineoplastons to desperate cancer patients. Ultimately, in 1998, the State of Texas secured a consent agreement with Burzynski stipulating that he:
     1.  cannot distribute unapproved drugs in Texas;
     2.  is allowed to distribute “antineoplastons” only to patients enrolled in FDA approved clinical trials, unless the FDA approves his drugs for sale;
     3.  cannot advertise “antineoplastons” for the treatment of cancer; and
     4.  on his website and in promotional material his ads must have a disclaimer that the safety and effectiveness of “antineoplastons” have not been demonstrated.
Obviously, big pharma got to Texas.
Dr. Burzynski is a rather difficult woo-meister to tackle for a variety of reasons. First, he apparently really is a legitimate MD/PhD (although Saul Green has questioned whether Burzynski’s PhD is legitimate), proving beyond a doubt that having an MD/PhD double-threat degree does not necessarily inoculate one from falling prey to pseudoscience. He’s also an example of a brave maverick doctor (specifically the “iconoclast” type) who has convinced himself that he’s discovered The One True Treatment for cancer. Like many brave maverick doctors, be they Mark and David Geier, Andrew Wakefield, or Robert O. Young, Burzynski appears to believe that he is a crusading researcher rather than a quack. He also has many of the trappings of a reputable scientist, including publications in good journals (although none recently). In all this, he resembles Andrew Wakefield before he was booted from Thoughtful House.
Burzynski also resembles Andy Wakefield in that other scientists have had a great deal of difficulty replicating his results. The substances that Burzynski claimed to have isolated from urine (his “antineoplastons”) have never been shown to do much against cancer by anyone other than Burzynski. As the article at Quackwatch points out, the NCI could not replicate Burzynski’s early results. Neither could drug company Sigma-Tau Pharmaceuticals. Neither could the Japanese National Cancer Institute. So what we have here is a therapy that, contrary to what some skeptics say, is not without a modicum of biological plausibility. After all, it’s not entirely implausible to think that the body might make substances that arrest the growth of cancer that can be isolated from the urine, and no less a figure than Dr. Judah Folkman himself demonstrated that the body produces endogenous anticancer substances. Indeed, I’ve studied some of these myself, including angiostatin and endostatin, both of which Judah Folkman first isolated from mouse urine.
However, the fact that the body does produce endogenous inhibitors of tumor growth and progression does not mean that antineoplastons function as endogenous inhibitors of cancer progression, and scientific evidence that they do function that way has been elusive at best, other than from Burzynski’s research institute and groups affiliated with him. If there’s one thing that should raise a red flag for pseudoscience, it’s when only one scientist can produce the reported results and no one else can. Replication is utterly key to the acceptance of science, and if other groups could replicate Burzynski’s work I might scratch my head and say, “You know, Dr. B may be on to something there.” But no one else has yet, and I’m left scratching my head and wondering how so many people can believe in Burzynski’s results given the paucity of science and evidence. And it’s not for lack of opportunity, either. Back in the 1990s, the NCI practically bent over backwards to give Burzynski every chance to prove that his antineoplastons have anticancer activity in humans.
Another red flag is that, like other brave maverick iconoclasts frustrated with the “arrogance,” “blindness,” and “inflexibility” of his academic colleagues, Dr. Burzynski founded his own clinic, which offers a “variety of alternative cancer treatments for patients diagnosed with over 50 different types of malignancies, including colon, pulmonary, breast, prostate, head and neck, ovarian, pancreatic, esophageal, hepatic, renal, bladder, brain, malignant melanoma, lymphoma, and many others,” and research institute, whose website describes it as “a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.” (Apparently it’s not just about the antineoplastons anymore.) Since then, it’s been a life on the fringes of science for Dr. Burzynski, and of late he appears not to be even trying anymore, as he hasn’t published in anything resembling a reputable journal for a long time. A PubMed search reveals no publications in the peer-reviewed literature since 2006, and the closest I find to a recent publication in a reputable journal is this report in 2004 of a single arm uncontrolled trial in children. Since 2004, Burzynski has only published three papers, two of which were published in Integrative Cancer Therapy (not a a good journal), one of which was a review article in Paedatric Drugs. His science, which was always weak to begin with, is getting even weaker still.
Instead, Burzynski relies on testimonials for evidence, all the while charging patients (like Billie Bainbridge) huge amounts of money to take part in his clinical trials, a practice that, while not illegal — although it should be — is highly unethical and quite properly viewed with suspicion by legitimate cancer clinical trialists like myself. It is in presenting these testimonials that Burzynski The Movie is its most manipulative.
Three testimonials
If you thought The Greater Good was bad in its emotionally manipulative use of testimonials, you ain’t seen nothing yet. Burzynski The Movie takes such manipulativeness to a new level, and, unlike The Greater Good, Burzynski The Movie doesn’t even try to present an alternative viewpoint, even if just to knock it down. The primary “expert” it relies upon is Julian Whitaker, who happens to have gained fame as Suzanne Somers’ doctor and claims he can cure diabetes. It shows, given that he is hugely impressed by unimpressive evidence; that is, as long as it supports Burzynski he likes it. Indeed, very early in the movie Whitaker is inordinately impressed with a case series from Burzynski, which he characterizes as the “most important discovery in cancer treatment—ever.” It’s not. It’s a series of “best cases” chosen by Burzynski himself. If you look at the cases, you’ll see that most of them are, at best, only suggestive of anticancer activity due to antineoplaston therapy. More importantly, we don’t know the denominator; i.e., how many patients with similar tumors were treated and didn’t respond. Remember, this is a best case series, and, although some of the cases look as though there might have been a antitumor response, I’d hardly call this the “most important discovery in cancer treatment—ever,” and that’s even if the data were exactly as reported.
Burzynski The Movie starts out with three testimonials. Actually, it’s four if you count the testimony of Sgt. Ric Schiff at the very beginning of the movie, but only three of them are listed on the website, complete with “interactive transcripts” and medical records. His story, while harrowing, doesn’t inform us if antineoplastons work, for the simple reason that it is a story where his daughter received conventional therapy in addition to the antineoplastons. That’s why this testimonial strikes me as being of the type of testimonial where the conventional therapy worked better than expected but the parents attribute their daughter’s cancer disappearance to antineoplastons. Ultimately, sadly his daughter died, and Sgt. Schiff goes on and on about how the radiation and chemotherapy had “destroyed her brain.” Given that, unlike the case of the three main testimonials, no medical records are presented, there’s no reason for this testimonial to be there other than for emotional manipulation, no matter how sorry I as a viewer feel for a loving father who lost his daughter as a child.
More useful are the three testimonials that follow. These include Jodi Fenton, Jessica Ressel, and Kelsey Hill. It turns out that jli has done an capable analysis of the three testimonials in this movie. As a cancer surgeon and researcher, however, I feel have something to add of my own, particularly in terms of clinical cancer treatment; so let’s dig in.
As a medical professional, the first thing I noticed about these medical reports is that they have the definite air of having been cherry-picked. For example, in none of them is there a good clinical history, a description of operative findings, or other essential information that helps with determining prognosis. They all consist of a series of radiology and pathology reports, and in one of them a key pathology report is missing. In the movie, little snippets of these reports, key parts of the text highlighted in yellow, are rapidly flashed onscreen, after which they disappear, all of which is designed to draw the viewer’s attention to what the filmmaker wants, as jli points out in the case of Jodi Fenton, who was diagnosed with an anaplastic astrocytoma (click to embiggen):
While jli is correct to concentrate on the sentence that was not highlighted, mainly that a mass like this could be lymphoma or an abscess, in the end as a clinician I can say that this uncertainty doesn’t really matter, because it’s trumped by the pathology report that shows this mass to be an “anaplastic astrocytoma which contains many gemistocytic forms.” So what the radiologist thought it was is less important after tissue for pathology was obtained. More important to me are two observations. First, it is reported that there is no mass effect, compression of the ventricles, or midline shift, all of which imply that this mass was probably fairly slow growing. Second, a growth curve based on serial MRI tests is presented that is most curious. Most of the pre-biopsy imaging suggests that the tumor is around 2 cm in diameter. However, the following table begins on 6/1/2000, which is two weeks after Fenton underwent a stereotactic biopsy of her lesion:
Notice something? The tumor’s maximum diameter is now 0.5 cm, which is less than one-quarter what was reported. Given that tumor volume is proportional to the cube of the radius, that means that the tumor volume two weeks after her biopsy was roughly 64-fold (or more) smaller than it was before the biopsy. What’s interesting is that then the residual tumor disappears within a month. It’s highly unusual for any chemotherapy (and, make no mistake, antineoplastons are chemotherapy) to shrink a tumor that fast.
This brings up an intriguing possibility, mainly that the bulk of the tumor was removed by the biopsy process. I’m not a neurosurgeon, but I’ve seen the same sort of thing happen occasionally in small breast cancers that undergo a core needle biopsy, especially using a large biopsy needle; so it’s not inconceivable to me that the same thing might happen in brain tumors. Whether such a thing is possible or not, it should also be noted that anaplastic astrocytomas can have a highly variable prognosis and growth rate, which means that Fenton’s prognosis might not have been as bad as portrayed in the movie.
So what happened here? It’s clear that this case was presented first because the film’s producers thought this was their strongest case, mainly because the patient hadn’t undergone any therapy before being treated with antineoplastons. So one of three things happened:
     1.  The biopsy removed the cancer, and what was left behind was an inflammatory reaction.
     2.  The biopsy removed much of the cancer, and antineoplastons worked on the rest
     3.  Fenton is an outlier whose tumor regressed on its own
Again, if Burzynski had real evidence that his therapy worked (i.e., clinical trial evidence), then he wouldn’t be resorting to anecdotes like this one, which doesn’t show conclusively that it was the antineoplastons that eliminated the tumor.
The second case was Jessica Ressel, who was diagnosed with a diffuse brainstem glioma in 1996. One thing that I noticed right away in perusing the records included with the film is that there is no pathology report. I found this rather curious, given that the pathology report was included in the other two cases presented. I also found the actual MRI view included in the report to be odd as well. See what I mean:
Do you see what bothers me? I’ll give you a hint: there shouldn’t be any yellow in this MRI scan. The authors obviously marked the area of abnormality with the same yellow marker that was used elsewhere. Trying to look under the yellow mark to see the most important parts of the scan, I don’t see anything “diffuse” about that glioma; it looks pretty well encapsulated. Unlike the definition of a diffuse brainstem glioma, it doesn’t take up anywhere near 50% of the brainstem diameter, although the yellow marking does conspire to make it look larger.
More importantly, looking at the tumor size tables, I see another problem, mainly that the size of the enhancing lesion is all over the place, jumping up and down for several months. In fact, it takes the tumor over a year to disappear, and it doesn’t even start to shrink consistently until nearly nine months after antineoplaston treatment started. This sort of behavior is strongly suggestive to me that the treatment probably had little to do with the disappearance of the mass, as drugs that are active against a tumor generally result in measurable shrinkage a lot faster than that and the tumor actually increased in size for a while during antineoplaston therapy. Moreover, the changes in tumor size don’t appear to correlate very well to the changes in dosage. After all, if the tumor shrank significantly on the MRI of September 21 and Burzynski attributes that to doubling the dose of antineoplastons, then how does he explain the tumor size increasing significantly again on the November 11 scan? In any case, the behavior of this tumor makes me wonder about the diagnosis, which makes me wonder why the pathology report isn’t included, as it was for the other two testimonials. Could it be that there was no biopsy of this tumor? If that’s the case, then there are many reasons to doubt that this was ever a brainstem glioma in the first place, first, because its behavior was not consistent with one and, second, because brainstem tumors are heterogeneous and even highly suspicious lesions on MRI can be benign 13% of the time.
No, testimonial number two is not very convincing either.
The last patient is Kelsy Hill. Basically, at age 6 months, Hill was diagnosed with a baseball-sized tumor in her abdomen, which, according to the parents was in her kidneys, as well as in her liver and lungs. She was operated on, and a mass was removed, as described on this pathology report. What was initially curious to me about this particular testimonial is the question of why a surgeon would have operated if the baby already had liver and lung metastases at the time of diagnosis. The only reason to operate in the presence of lung metastases that I could think of would be if the surgeon thought he was going after a neuroblastoma, which is not an unreasonable assumption, particularly if the adrenal cortical carcinoma was nonfunctioning. Neuroblastoma is a childhood tumor that presents as a rapidly growing abdominal mass, but even when there are metastases it is often still potentially curable. It’s also the most common cancer in infancy. Consequently, an infant presenting with a large abdominal mass and metastases is often considered to have neuroblastoma until proven otherwise, although the presence of lung metastases is more consistent with an adrenal cortical carcinoma. Finally, there is the issue of whether the child had an adrenal cortical carcinoma or adenoma. The former is malignant; the latter is benign, and it’s not always easy to differentiate the two. The parts of the pathology report with special stains that can help differentiate between the two are missing.
More puzzling is, again, the behavior of the multiple liver and lung masses noted in the supplemental data. First, the raw data presented don’t match the parents’ description in that there are no liver masses noted until 2/22/2006, which is nearly six months after the initial surgery. It’s also inconsistent with the narration of the movie:
Upon the removal of Kelsey’s left kidney and left adrenal gland, her diagnosis was confirmed at the University of Texas Medical Branch, and again at M.D. Anderson cancer center. Where, a month later, M.D. Anderson also confirmed that Kelsey’s cancer had spread to her lungs. After desperately researching Kelsey’s situation, her family decided to decline all chemotherapy treatments offered my M.D. Anderson, and instead, enroll Kelsey into one of Dr. Burzynski’s clinical trials. By this time, Kelsey’s cancer had also spread into her liver.
Again, Kelsy’s surgery was in September 2005; no evidence of liver metastases appears to have been noted until February 2006. When did she start the antineoplaston therapy? Was it shortly after surgery? If that’s the case, then her liver lesions developed and her lung lesions grew while she was on the antineoplaston therapy. Or did she not start antineoplastons until the appearance of liver lesions in February? If that’s the case, then why did her doctors leave her untreated for five months while her lung masses increased in size? No, what seems most likely is that antineoplaston treatment began soon after surgery, Kelsy’s tumors grew for several months after that, and new liver lesions appeared while she was on therapy. Of course, it’s not even clear if these lesions were metastases because there’s no evidence that Burzynski or Kelsy’s other doctors ever biopsied any of them. Again, there are no pathology reports of core needle biopsies of the suspected metastases.
In brief, Merola’s pledge that the the opening 30 minutes of the movie would “thoroughly establish” that Burzynski has discovered the genetic mechanism that can cure most cancers was not kept. These three testimonials do not constitute convincing evidence that antineoplastons can cure cancer. Given that they are almost certainly the absolute best cases that Burzynski could come up with, I’m once again forced to wonder what the denominator was. Meanwhile, interspersed throughout these testimonials are comparisons of Burzynski’s results to results of standard therapy that are deceptive in the extreme, given that small, unrandomized groups subject to selection bias are not comparable to larger clinical trials of standard-of-care treatments. Merola also can’t resist using all sorts of scary graphics when discussing the chemotherapy drugs used as standard of care, referring to doxorubicin as the “red death” and taking care to point out that mitotane was derived from an insecticide. One thing’s for sure, Eric Merola isn’t subtle. He hits you over the head with his pro-Burzynski anti-pharma message over and over and over again.
Help, help! I’m being persecuted!
The rest of the movie can be dispensed with rather quickly, as it’s basically one big conspiracy theory, in which the NCI, the Texas Medical Board, the FDA, and, of course, big pharma (as represented by PhRMA all persecute poor, poor Dr. Burzynski because, if you believe the Eric Merola, (1) Burzynski has cured cancer and is a threat to big pharma and its chemotherapy monopoly; (2) Burzynski is a threat to the fees big pharma pays to the FDA to oversee clinical trials; (3) the NCI can’t abide the competition. This whole section of the movie is introduced thusly by a narrator with an exceedingly creepy, robotic voice, complete with ominous-sounding background music:
The pharmaceutical industry is arguably the most profitable industry on our planet, with its profits being triple that of all of the Fortune 500 companies. Rising profits result in rising stock prices, the only way this industry can sustain this profitable momentum is by continuing to introduce new patented drugs. And since the pharmaceutical industry relies on the FDA as it’s gatekeeper to introduce these new drugs, it’s in their best interest to insure the FDA remains as compliant as possible. And since the FDA is also an office of the United States government, it’s in the government’s best interest to preserve one of it’s most powerful industries. The former editor-in-chief of the New England Journal of Medicine, Dr. Marcia Angell, has been very outspoken with the idea that it’s time to take the Food and Drug Administration back from the drug companies.
Repeat variations of this sort of passage over and over and over again interspersed with archival footage of various legal proceedings against Burzynski and excerpts of interviews with Drs. Whitaker and Burzynski, both of whom whine incessantly about how Burzynski is being persecuted, and you’ll get an idea of what the last hour of this poorly produced documentary is like. It was painful to sit through. Particularly disgusting was the liberal use of numerous testimonials of crying parents and patients telling various bodies of lawmakers or the Texas Medical Board that they or their children will die if Dr. Burzynski is convicted or has his license revoked. The paranoid conspiracy aura that surrounds Burzynski The Movie is palpable and becomes quite oppressive by the end of the movie. Pharma, the NCI, the FDA, the Texas Medical Board, and every medical authority are all against Burzynski, the lone heroic doctor battling against all odds to bring his cure for cancer to all. Yes, it’s just that nauseatingly blatant. At every point, antineoplastons are presented as nontoxic, effective, and downright miraculous when they are none of these.
How can Burzynski keep doing clinical trials?
Out of curiosity, I did a quick search of ClinicalTrials.gov for clinical trials by Burzynski or containing the word “antineoplaston.” I found 61 clinical trials, of which only ten are listed as still recruiting subjects, with one listed as not yet open. Over thirty are of unknown status, and only one is completed. This is an an apparently unrandomized, open-label phase II trial trial testing antineoplastons A10 and AS2-1 therapy in melanoma. In fact, none of the currently open antineoplaston trials are phase III trials, which are the type of trial that can potentially give a definitive answer about a therapy, because phase III trials are randomized, controlled trials. The only phase III trial listed is A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma After Carboplatin or Cisplatin Therapy. It’s a small trial (only 70 subjects) and appears at first glance to be underpowered to detect anything but very large differences in outcomes. I realize that many of Burzynski’s trials date back before the database used in ClinicalTrials.gov was active, but come on! Sixty-one clinical trials since the 1990s, with the end result being only one phase III trial, and that phase III trial hasn’t even started yet? And most of the phase II trials of “unknown” status and only one of them listed as “completed” (with that one apparently not having been published)? That’s a failure in my book. No drug company or researcher would keep doing trials of a drug (and, yes, antineoplastons are drugs when used this way) with such an abysmal track record. A drug company would give it up as unpromising, and a university researcher would soon find he could no longer secure funding for more trials.
All of this leads to the question of how Burzynski could have run so many clinical trials and have so little to show for it? There are at least 61 clinical trials registered at ClinicalTrials.gov; yet finding the results of any of them is very difficult. Among the open trials, most of them are several years old, some 16 years or more, but have not accrued their targets, even though they are all phase II trials with accrual targets of fewer than 50 subjects each. When a trial takes that long to accrue, the vast majority of the time its results will be meaningless.
Burzynski: A “brave maverick doctor” whose “antineoplaston” therapy remains unproven
Despite all the claims that they are somehow “natural,” antineoplastons are chemotherapy, as much as Drs. Whitaker and Burzynski try to portray them as “targeted.” In fact, they’re no longer even isolated from urine but synthesized and purified in Burzynski’s laboratory, something that would normally be anathema to the “natural remedies” crowd. Indeed, early in the movie, there’s a hilarious part where Burzynski, outraged at the criticism he received for using something extracted from urine, points out that hormone replacement therapy in the form of Premarin is isolated from horse urine. So obviously Burzynski’s antineoplastons are just like Premarin, and doctors don’t heap such contempt on that drug! The difference, of course, is that no one doubts that the estrogens and progesterone actually work; it’s just that the question of an elevated risk of breast cancer has led to Premarin’s having fallen out of favor.
One part of the movie that truly insults the intelligence of anyone with a modicum of knowledge about drug therapy occurs near the beginning of the movie. It’s a part that, as a cancer surgeon who is interested in targeted therapies for breast cancer, I found particularly idiotic. First, there is a screen with this caption:
Antineoplastons target the specific genes that allow cancer to grow and flourish.
No evidence is presented to demonstrate this, of course, but there are nifty (and very science-y) images of DNA double helices flying towards the viewer, along with the chemical structures of various targeted drugs. A little later we see:
There are currently over 25 FDA-approved gene-targeted cancer drugs on the market today.
Many of them can only target single genes.
All of which is true but irrelevant if Burzynski is trying to sell antineoplastons as targeted therapy. Now here’s the kicker:
You know what you call a drug that works on “close to 100 genes”? I don’t know either, but you don’t call it a “targeted” therapy unless all those genes are genes affected by the single target being inhibited. In other words, Burzynski is trying to have it both ways. He’s administering chemotherapy to patients on clinical trials and charging them for the privilege, but he’s trying to represent his treatment as being somehow “targeted.” Worse, despite Burzynski’s representation of his therapy as being “nontoxic,” in contrast to chemotherapy, some of his antineoplaston preparations are quite toxic. The reason is two-fold: (1) high doses of antineoplastons are required; and (2) some antineoplaston preparations are very sodium-rich. Dr. Burzynski’s therapy requires the adminstration of so much antineoplaston as sodium salts that several of his patients developed hypernatremia, in one case as high as 180 mEq/L. (A normal serum sodium level ranges between 135 and 145 mEq/L.) Personally, I’ve never seen a sodium level that high in a living patient. When sodium levels get into the 155 mEq/L and up range, clinicians start to get very worried and usually start aggressive treatment to bring the sodium levels down. Worse, these are patients with brain cancer. One danger is that, in correcting the hypernatremia, sometimes cerebral edema (brain swelling) will result. In a patient with a brain tumor, cerebral edema could be even more dangerous than in a patient without such a tumor. Despite reviewers being alarmed at the hypernatremia some of Burzynski’s patients developed, astoundingly he still claimed that he had no “significant toxicity.”
Repeat after me: Antineoplastons are chemotherapy. Worse, they’re chemotherapy that almost certainly doesn’t work against cancer. At best, looking at the evidence, I conclude that they might have very minimal anticancer activity, and even that’s doubtful.
Writer/producer Eric Merola uses Burzynski The Movie as a forum to pound on what he perceives as the shortcomings of the current regulatory system overseeing drugs. If anything, he’s right that our drug regulatory system has severe shortcomings, but not because it’s trying to shut Burzynski down. To me, the huge flaw in our drug regulatory system is that, after over 30 years, it has failed to determine once and for all whether or not antineoplastons have any anticancer activity, despite allowing Dr. Burzynski to treat thousands of patients with them. Although every indication thus far is that antineoplastons do not, in fact, have any appreciable antitumor activity (certainly Burzynski has utterly failed to show convincingly that any of them do), there is just enough uncertainty to allow Burzynski to portray himself to believers in alt-med as a poor, persecuted, brave maverick doctor. More disturbing from an ethics standpoint, somehow, Burzynski is still able to enroll patients on clinical trials, despite having failed to show compelling preclinical evidence of efficacy; worse, he charges them huge sums of money for the “privilege” of being on one of his clinical trials, something I and many others view as highly unethical, to the point of wondering how any Institutional Review Board could possibly approve such studies, particularly given that the FDA has warned Burzynski about how his IRB fails to protect human research subjects. Unfortunately, the Texas Medical Board failed to shut him down in the 1990s. One can only hope that it’s more successful in its next attempt, for which hearings are to commence early next year.
Dr. Burzynski is not a miracle worker. He is not a doctor who sees something that mainstream science has not and who therefore has a cure for many cancers that mainstream medicine scoffs at. He is not a bold visionary. Rather, he appears to be a man pursuing pseudoscience. The reason that mainstream scientific medicine has not accepted the existence of antineoplastons or their efficacy against cancer is not because it is “out to get” Dr. Burzynski or is trying to protect the hegemony of the FDA or the profits of big pharma. Rather, it’s because there is no credible scientific or clinical evidence to support this therapy. Perhaps that’s why Burzynski and his followers rely on testimonials and legal threats against critics far more than they rely on clinical trials and scientific studies.
The complete Burzynski series:
     1.  Stanislaw Burzynski: Bad medicine, a bad movie, and bad P.R.
     2.  Dr. Stanislaw Burzynski’s “personalized gene-targeted cancer therapy”: Can he do what he claims for cancer?
     3.  Dr. Stanislaw Burzynski, antineoplastons, and the selling of an orphan drug as a cancer cure

Dr. Stanislaw Burzynski’s “personalized gene-targeted cancer therapy”: Can he do what he claims for cancer?
David Gorski on December 5, 2011
Link
Last week, I wrote a magnum opus of a movie review of a movie about a physician and “researcher” named Stanislaw Burzynski, MD, PhD, founder of the Burzynski Clinic and Burzynski Research Institute in Houston. I refer you to my original post for details, but in brief Dr. Burzynski claimed in the 1970s to have made a major breakthrough in cancer therapy through his discovery of anticancer substances in the urine that he dubbed “antineoplastons,” which turned out to be mainly modified amino acids and peptides. Since the late 1970s, when he founded his clinic, Dr. Burzynski has been using antineoplastons to treat cancer. Over the last 25 years or so, he has opened a large number of phase I and phase II clinical trials with little or nothing to show for it in terms of convincing evidence of efficacy. Worse, as has been noted in a number of places, high doses of antineoplastons as sodium salts are required, doses so high that severe hypernatremia is a concern.
Although antineoplastons are the dubious cancer therapy upon which Dr. Burzynski built his fame, they aren’t the only thing he does. Despite the promotion of the Burzynski Clinic as using “nontoxic” therapies that “aren’t chemotherapy” by “natural medicine” cranks such as Joe Mercola and Mike Adams, Dr. Burzynski’s dirty little secrets, at least as far as the “alternative medicine” crowd goes, are that (1) despite all of the attempts of Dr. Burzynski and supporters to portray them otherwise antineoplastons are chemotherapy and (2) Dr. Burzynski uses a lot of conventional chemotherapy. In fact, from my perspective, it appears to me as though over the last few years Dr. Burzynski has pivoted. No longer are antineoplastons the center of attention at his clinic. Rather, these days, he appears to be selling something that he calls “personalized gene-targeted cancer therapy.” In fact, it’s right there in the first bullet point on his clinic’s webpage, underlined, even! Antineoplastons aren’t even listed until the third bullet point.
But what is “personalized gene-targeted cancer therapy,” according to Dr. Burzynski? Here is how it is described:
Our approach to cancer is a result of Dr. Burzynski’s extensive experience in cancer research in the field of genetics and genomics.
Personalized Treatments offered by the Burzynski Clinic are individual treatment plans, customized for each patient, based on:
    • Identification of oncogenes responsible for the growth of cancerous cells in individual patients
    • Selection of targeted pharmaceuticals that selectively kill cancer cells carrying the identified abnormal genes
The main goal of a Personalized Treatment is to match the right patient to the right treatment to achieve maximum effectiveness with minimum side effects.
Elsewhere, Dr. Burzynski claims:
In some cases conventional therapy is the most appropriate treatment for a patient. Our Clinic offers customized combination therapies consisting of conventional therapy and other approved targeted therapies to maximize effectiveness while minimizing the side effects that typically occur when using the traditional therapies alone.
And:
There are currently close to 30 targeted therapeutics approved by the FDA (as of January 2011). This number grows rapidly with the advancement of the research in genomics. All of the Food and Drug Administration (FDA)-approved gene-targeted medications are available for treatment at the Burzynski Clinic. The combination of targeted medications is customized for each patient and determined by the type of oncogenes involved in patient’s cancer (Personalized Treatment).
Dr. Burzynski is also not shy about being interviewed by promoters of alternative medicine, such as Mike Adams. For example, here are a typical radio interview (on Oprah Radio, of course!) and videos like this one:
And this one:
Note that the first few minutes of the second video are spent portraying Dr. Burzynski as a “brave maverick doctor” and pioneer being oppressed, suppressed, and persecuted by The Man, combined with Dr. Burzynski calling the FDA and NCI “criminal” and using every “health freedom” argument in the book. Antineoplastons are portrayed as a cancer cure that causes brain tumors to “vanish in many children.” Finally, around the 4:30 mark, we see Dr. Gregory Burzynski, Dr. Burzynski’s son, talking about genomic profiling of cancers and biomarkers in the blood and in circulating tumor cells. If this segment weren’t embedded in a bunch of paranoid conspiracy mongering about big pharma, the FDA, and the NCI, plus a claim that surgery will no longer be necessary for cancer, what’s left over doesn’t sound too different from what quite a few “conventional” cancer researchers say about “personalized medicine.” Well, that and what Dr. Burzynski says about tumor suppressors. He seems to think that all tumor suppressors prevent mutations, which is, of course, not true. Some of them do other things. Be that as it may, the claim made in the video is that, with a combination of antineoplastons and “personalized therapy,” Dr. Burzynski can cure many cancer patients with stage IV disease. But how credible is this claim? What, exactly, is he doing? It’s hard to figure out from his website, but looking elsewhere can provide hints. In the meantime, let’s start with a description of what “personalized medicine” means to cutting edge cancer researchers.
“Personalized cancer treatment” in science-based medicine
At the risk of annoying some colleagues I know, I’m going to point out that I never really liked the term “personalized cancer therapy” or its many variants, for the simple reason that it always struck me as more of a marketing term than a scientifically meaningful description of what targeting therapy to the genetic makeup of a patient’s tumor will eventually entail. In fact, I think I now prefer another term, which has been used by Cancer Research U.K., namely “stratified medicine.” The reason is that what we as clinicians are doing when we “personalize” or “individualize” therapies isn’t really “personalizing” the therapy so much as using various measurements and biomarkers to place patients into groups of patients who respond to specific therapies. What the modern version of “personalized” therapy is really doing is producing more and more groups of patients, each of which, is smaller than the last, to be matched to more and more therapies. Whether the groups will eventually reach an N of 1, I don’t know, but that is the goal. Only then will we truly have “personalized medicine.”
My personal irritation at the proliferation of certain terms notwithstanding, I actually do believe that the stratification and matching of patients with therapies based on genomics, proteomics, and biomarkers is the future of cancer treatment, and, to some extent, the future is now. However, “personalized” medicine is in its infancy, as I have pointed out in previous posts on the topic, Hope and hype in genomics and “personalized medicine” and Integrating patient experience into research and clinical medicine: Towards true “personalized medicine.” True, we do have several targeted therapies that inhibit or target a single important molecule. For instance, in breast cancer, Herceptin (trastuzumab) targets the HER2 oncogene, which is amplified in some breast cancers. Another example, Gleevec (imatinib mesylate), inhibits the tyrosine kinase activity of the bcr-abl oncogene product as well as receptor tyrosine kinases encoded by the c-kit and platelet-derived growth factor receptor oncogenes and is very effective against tumors that make too much of one these oncogenes, such as gastrointestinal stromal tumor and Philadelphia-positive (Ph+) hematological malignancies such as chronic myelogenous leukemia and acute lymphoblastic leukemia. Now, there are numerous other examples, so many that they are listed on the NCI website.
In fact, the idea of targeted therapy in cancer is not new. In fact, as I learned while writing my current grant, arguably the concept dates back over 100 years. Indeed, the very concept of targeted therapy was first applied to breast cancer when oophorectomy (removal of the ovaries) was first proposed as a therapy by Albert Schinzinger in 1889 and then George Thomas Beatson reported seven years later that oophorectomy could bring about complete remissions in young women with inoperable or locally recurrent breast cancer. Decades would pass before the development of the selective estrogen modulator, Tamoxifen, and it would be still more decades before aromatase inhibitors. Moreover, using biomarkers to follow cancer and to predict response to treatment is nothing new either. For example, it’s long been known that the presence of the estrogen receptor (ER) in breast cancer implies that treatment with antiestrogen drugs like Tamoxifen is likely to result in a a response and that lack of ER in a tumor means that Tamoxifen won’t work. Similarly, we’ve used prostate-specific antigen (PSA) as a biomarker for prostate cancer and carcinoembryonic antigen (CEA) as a biomarker for colon cancer for decades. The difference between the way drugs were targeted to cancers a couple of decades ago and now is the explosion of genomics knowledge that has occurred over the last decade. As I’ve pointed out, we are now producing terrabytes and petabytes of genomic data about cancers, a flood of information that we have only relatively recently started seriously developing the tools needed to analyze and disciplines (systems biology, bioinformatics, genomics, etc.) to organize and determine how best to translate it into therapies. We even use one such test in breast cancer, the Oncotype DX, assay, which has allowed oncologists to identify patients who can safely skip adjuvant chemotherapy, but it is a relatively simple test, consisting of only 21 genes, and its results are not always clear-cut.
What we are learning, as I have lightheartedly appropriated Douglas Adams’ masterwork to say before, is that cancer is complicated. You just won’t believe how vastly, hugely, mind-bogglingly complicated it is. I mean, you may think it’s complicated to understand basic cell biology, but that’s just peanuts to cancer. All you have to do is to look at the genetic derangements in typical prostate cancers to get a flavor for how daunting the task of developing personalized treatments of cancer will be, much less curing it. Think of it this way. The examples of genomic derangements in a few prostate cancers were incredible, and there are different sets of genomic derangements that vary by cancer type, of which there are hundreds. Add to that the fact that, as Dr. Burzynski himself emphasizes, cancers are heterogeneous, with different genetic derangements in different parts of the tumor, and you get a flavor of how difficult “personalizing” cancer therapy based on its genomic makeup and biomarkers will be. It will take an incredible amount of research, both basic and clinical, in order to learn the best ways to match the genomic makeup of patient tumors to the most effective targeted therapies. As a commentary by James H. Doroshow last year noted, even leaving aside the practical obstacles (FDA approval, access to fresh tissue, and the like) at least one huge obstacle remains:
Finally, if these obstacles are surmounted, widespread adoption of a predictive therapeutic biomarker assumes, as a matter of course, that the assay(s) for the biomarker in question is fit for its scientific purpose, and that our understanding of the molecular pathways to be investigated justifies the specific use of a particular portfolio of gene expression or mutational analyses, for example, and these are anything but trivial assumptions.
And there’s the problem. Burzynski’s approach to “personalized gene-targeted anticancer therapy” appears to fall prey to the assumption that the assays used are fit for the scientific purpose for which he is using them and, even worse, that he knows enough about the molecular pathways to be investigated to reliably use the results of such assays to guide anticancer treatment. In essence, it’s as though Dr. Burzynski read a book called Personalized Cancer Therapy for Dummies and decided he is an expert in genomics-based tailoring of targeted therapies to individual cancer patients. I’ll try to show you what I mean.
What Burzysnki claims he can do with “personalized gene-targeted therapy”
In order to determine what it is that the Burzynski Clinic is doing that it calls “personalized gene-targeted cancer therapy,” I started searching around the web. I also had a brief e-mail correspondence with Renée Trimble, Director of Public Relations for the Burzynski Institute. She’s the one who, in the wake of Marc Stephens’ harassment of bloggers, sent out a press release apologizing for his behavior while at the same time basically saying that the Burzynski Clinic would keep using the legal system to try to silence bloggers who criticize it. However, she was polite with me, probably because of the positions I hold at an NCI-designated comprehensive cancer center. Mostly, her information was only marginally more helpful than what I could find on the Burzynski Clinic website and around the Internet, but she did confirm at least one fact that needed confirming. Then, there is also this video, produced by the Burzynski clinic itself:
What interested me about this video, ironically enough, is how bland and unremarkable a lot of it was. Clearly, the producer went to great lengths to make Burzynski’s lab look like any other molecular and cell biology lab—even like my lab. The other thing that interested me was how the video emphasizes the use of FDA-approved medications. Finally, there was a clue (to me, at least) about what it is that Burzynski is doing. At around the three minute mark, the announcer states:
We combine gene-targeting drugs and low dose chemo, if needed.
Then a very sharply-dressed man named Azad Rastegar appears and says:
The way we look at cancer here at the Burzynski Clinic is that it’s more than just the tumor site. Obviously, that’s very important and significant for figuring out how to address the cancer in the patient, but what we want to do is to identify the genes that are involved in that particular patient’s cancer. With that, then we can start creating more customized and personalized treatment plans that involve gene-targeted medications targeting, obviously, the genes involved in that patient’s cancer. This way we’re able to reduce side effects. We’re able to reduce any time-wasting on ineffective drugs and cater it, obviously, much more to the patients and their individual cancer needs.
It all sounds so reasonable, and, indeed, this is exactly the sort of thing that lots of cancer centers are trying to do. But how this sort of approach is implemented makes all the difference in the world, and the question I had was whether Dr. Burzynski is taking anything resembling the right sort of approach to this problem. From the description above, it sounded very much to me as though Dr. Burzynski is combining various targeted agents with metronomic chemotherapy. I know a thing or two about metronomic chemotherapy, because I was involved in a project whose end result was to be the testing of metronomic chemotherapy against cancer and because the concept is a spinoff of the work of one of my scientific heros, the late Judah Folkman. Basically, metronomic chemotherapy is an approach to chemotherapy that uses repetitive, low doses of chemotherapy drugs (or even continuous infusions of low dose chemotherapy) designed to minimize toxicity and target the tumor blood vessels rather than targeting the tumor cells themselves. The concept behind this strategy is that blood vessels are lined by genetically stable endothelial cells, they do not evolve resistance, and chemotherapy can be antiangiogenic. The drawback to metronomic chemotherapy is that long periods of therapy may be required and the cumulative doses of chemotherapy may end up being actually higher than more standard therapies. On the other hand, this latter aspect may not be a drawback because metronomic chemotherapy may allow a greater cumulative dose, with a concurrent greater cumulative effect. As I wrote before the last time I discussed metronomic chemotherapy, it’s a promising concept, but thus far clinical trials in humans can only be characterized as fairly disappointing.
Whether this is what Dr. Burzynski is doing or not with the chemotherapy part of his approach, I don’t know for sure, but it sure sounds like it. For example, in Knockout: Interviews With Doctors Who Are Curing Cancer and How to Prevent Getting It in the First Place by Suzanne Somers, Dr. Burzynski is interviewed and, ironically, reveals a great deal (to me, at least) about what he is doing. For example:
For the majority of Dr. Burzynski’s patients he does not use any chemotherapy, but for some patients the chemotherapy is used in lower dosages, which are below the threshold of significant side effects. Dr. Burzynski takes advantage of the synergistic effect of such combinations…
Except that he doesn’t demonstrate that these combinations are synergistic in preclinical studies or clinical trials before prescribing them off-label.
Later in the interview, Somers (SS) asks Dr. Burzynski (SB) about breast cancer, and he replies:
SB: At the moment we use a different approach. We study which genes in individual patients are abnormal, trying to determine the genetic signature of cancer in these patients. With our methods, we can have answers for the patient in about three days based on blood tests. Once we identify the most important oncogenes involved in cancer for that individual, we select a group of four to six medications from those twenty-four which are now approved by the FDA and use them to hit those genes which are causing the cancer to progress. This is like “boutique treatment” because for every patient we design a treatment plan. When we do this we have a very good chance to have positive results in most patients.
SS: How many respond?
SB: About 85 per cent for whom we have the proper gene signature; about 15 percent do not respond. In our responders many of them have tumors which disappear completely and in others the tumors remain small. The problem is finding the genetic signature because for many of these different genetic signatures we don’t have blood tests…yet.
Note that at the time this book was published, Dr. Burzynski was claiming that he could identify who would benefit from specific targeted therapies simply from blood tests. If he could do this for real, Burzynski could easily publish in high impact journals like Clinical Cancer Research, the Journal of Clinical Oncology, or another high impact clinical cancer journal. Heck, a result like that could probably make it into general medical journals, such as the New England Journal of Medicine or The Lancet, which have an even higher impact factor. If he were able to demonstrate that his method of testing tumors and picking targeted therapy could result in a complete response rate anywhere near 85% for breast cancer, even more so. If, as he claims later in the chapter, Dr. Burzynski has patients with pancreatic cancer and advanced liver cancer whose tumors have disappeared within two months after he began treatment, the same would be true. If, as Burzynski claims, he achieves a 50% complete response rate in advanced brain tumors, again, the same would be true. He doesn’t submit his results to these journals. Why not? No doubt it’s The Man keeping him down.
So what tests does Dr. Burzynski use to determine the cocktail of targeted therapies to use in any given patient, anyway?
I learned from multiple patient blogs (and it was confirmed by Ms. Trimble) that Dr. Burzyski uses a test from a company called Caris Life Sciences. The test appears to be the Caris Target Now™ Molecular Profiling test, and this is how it’s described on the company website:
Caris Life Sciences’™ molecular profiling test, Caris Target Now™, examines the genetic and molecular changes unique to a patient’s tumor so that treatment options may be matched to the tumor’s molecular profile.
Caris Target Now helps patients and their treating physicians create a cancer treatment plan based on the tumor tested. By comparing the tumor’s information with data from published clinical studies by thousands of the world’s leading cancer researchers, Caris can help determine which treatments are likely to be most effective and, just as important, which treatments are likely to be ineffective.
The Caris Target Now test is performed after a cancer diagnosis has been established and the patient has exhausted standard of care therapies or if questions in therapeutic management exist. Using tumor samples obtained from a biopsy, the tumor is examined to identify biomarkers that may have an influence on therapy. Using this information, Caris Target Now provides valuable information on the drugs that will be more likely to produce a positive response. Caris Target Now can be used with any solid cancer such as lung cancer, breast cancer, and prostate cancer.
It’s also noted:
Caris Target Now™ was developed and its performance characteristics were determined by Caris Life Sciences, a medical laboratory CLIA-certified in compliance with the U.S. Clinical Laboratory Amendment Act of 1988 and all relevant U.S. state regulations. It has not been approved by the United States Food and Drug Administration.
From my perspective, this test looks perfectly fine as a test used for research and clinical trials, but clearly using it to treat patients with off-label cancer drugs outside of a clinical trial is something that I’d be very, very concerned about. But how does it work? It’s described thusly:
Caris Target Now begins with an immunohistochemistry (IHC) analysis. An IHC test measures the level of important proteins in cancer cells providing clues about which therapies are likely to have clinical benefit and then what additional tests should be run.
If there is access to a frozen sample of patient tissue available, Caris Life Sciences™ may also run a gene expression analysis by microarray. The microarray test looks for genes in the tumor that are associated with specific treatment options.
As deemed appropriate based on each patient, Caris will run additional tests. Fluorescent In-Situ Hybridization (FISH) is used to examine gene copy number variation in the tumor. Polymerase Chain Reaction (PCR) or DNA sequencing is used to determine gene mutations in the DNA tumor.
Immunohistochemistry is standard for many cancers. For example, in breast cancer, pretty much every pathology lab does immunohistochemistry (using antibodies to detect specific proteins) for at least two proteins, the estrogen receptor and the HER2 oncogene. Sometimes, depending upon the lab and the clinical situation, pathologists will stain for proliferation markers, like Ki-67, or other receptors such as epidermal growth factor receptor. Not uncommonly, pathologists stain for E-cadherin in order to differentiate between two common types of breast cancer, infiltrating ductal carcinoma versus lobular carcinoma. Similarly, breast cancers are often subjected to FISH in order to determine whether the HER2 oncogene is amplified. In other words, none of this is anything particularly remarkable from a clinical standpoint.
What Caris appears to do that’s different from normal clinical evaluation of a tumor sample is, if fresh frozen tissue is available, the performance of cDNA microarray analysis of the messenger RNA isolated from the tumor tissue. cDNA microarrays are a technology that allows scientists to analyze the level of messenger RNA from every known gene in the genome simultaneously. In actuality, technology has moved on from cDNA microarrays, which these days are so 2005, but they’re still good tools and still used to examine differences of thousands of genes simultaneously, either between tissues or in response to drugs or other interventions. Also, newer technology, such as next generation sequencing (NGS) and RNA-Seq. RNA-Seq, for instance, provides the same information that a cDNA microarray does, plus everything else in the transcriptome, such as microRNAs and long non-coding RNAs. microRNAs, in particular, are being appreciated as very important regulators of gene activity because a single microRNA can often regulate hundreds of genes. RNA-Seq is also unbiased in that cDNA microarrays can only measure genes we know, whereas RNA-Seq can be used for discovery of previously unknown RNAs.
However, these techniques are expensive and not yet as common and practical as cDNA microarrays. That Caris isn’t using the latest technology for the test doesn’t mean it might not be potentially worthwhile; after all, a cDNA microarray will detect the levels of all known oncogenes. Caris also apparently does some mutational analysis and fluorescence in situ hybridization (FISH), a test designed to measure gene copy number and thus detect amplified genes. The result is a report like this example report that Caris Life Sciences has posted on one of its websites. The problem, of course, is what a clinician should do with the results. That’s why I say that such a test should probably, except in rare circumstances, only be used for research purposes. Besides, much of what I see isn’t that helpful anyway. For example, if you look at the report, the first agents listed are anthracyclines, such as doxorubicin, because topoisomerase-2A is elevated and taxanes, such as paclitaxel, because TLE3 is elevated. These are basically “Well, duh!” suggestions, because doxorubicin and paclitaxel are normally standard-of-care chemotherapeutic agents for triple negative breast cancer anyway! Particularly useless is the mention that “Lack of HER2 amplification has been associated with lack of benefit from HER2-targeted antibody.” No kidding, given that trastuzumab was designed to treat HER2-positive breast cancer and that clinical samples are routinely checked for HER2 amplification as part of the standard-of-care!
As for the other recommendations, the gene associations listed, many of them are based on associations with response to specific therapies in other tumor types, such as irinotecan in ovarian cancer and cisplatin in gastric cancer, small cell lung cancer, for example. The relevance of many of these recommendations to breast cancer is questionable, to say the least. To apply them to individual patients outside the context of a clinical trial is hard to justify except in rare cases, but that’s exactly what Dr. Burzynski appears to be doing for large numbers of his patientss, picking off-label chemotherapeutic agents based on the results of this test and selling it as “personalized gene-targeted therapy” without letting patients know that (1) the evidence base behind these recommendations is often not relevant to the specific tumors being treated because it’s from different cancers; (2) the studies used to support these recommendations have a lot of uncertainty; and (3) most of these recommendations haven’t been validated in clinical trials.
Even worse, the very concept of “gene-targeted cancer therapy” hasn’t been convincingly shown to improve cancer outcomes, at least not yet. Believe it or not, I actually am in the camp who believes that eventually such a strategy will be proven useful and revolutionize cancer therapy, but that time is not yet. Gene-targeted cancer therapy is currently in its infancy and, except in rare situations outside of the existing currently validated biomarkers (such as HER2, ER, c-kit, and other genes for which targeted therapies exist) for the response of specific cancers, is not to be undertaken outside of the context of a clinical trial. In essence, Burzynski appears to be using such information on a “make it up as you go along” sort of fashion. Indeed, an e-mail from Renee Trimble confirmed this suspicion of mine when I pointed out to her that gene-targeted cancer therapy is in its infancy and that in the vast majority of cases we don’t know what to do with this information. I also wanted to know what the Burzynski Clinic was doing that is different from what the major cancer centers are doing. Her answer was, to put it mildly, unsatisfying, as I will discuss in the next section.
Compare and contrast
Before discussing how the Burzynski Clinic does personalized cancer therapy, I think it’s worth looking at how real scientists do it right now. In essence, real scientists use information of the sort provided by Caris Life Sciences or by their own genomic testing to stratify patients and identify them for clinical trials. An excellent example of this is a study hot off the presses in the November issue of Science Translational Medicine by a group from my very own alma mater, the University of Michigan entitled Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study. In essence, the investigators (Roychowdhury et al) began a pilot study to study the practical difficulties involved in using high-throughput sequencing in clinical oncology, which they identified in the introduction:
Translating high-throughput sequencing for biomarker-driven clinical trials for personalized oncology presents unique logistical challenges, including (i) the identification of patients who could benefit, (ii) the development of an informed consent process that includes a way to deal with incidental findings, (iii) the implementation of efficient and integrative computational pipelines for data analysis, (iv) the selection of the results that should be disclosed to patients, and (v) the completion of the sequencing analysis in a cost-effective and clinically relevant time frame (Table 1). We implemented an exploratory study that we call the Michigan Oncology Sequencing Project (MI-ONCOSEQ) to address these challenges.
The challenges, and the response of investigators, are well described in Table I:
Before undertaking this study in actual humans, in order to verify that their sequencing strategy would work, Roychowdry et al first grew in mice xenografts made from tissue taken from the tumors of two patients with metastatic prostate cancer. They performed their genomic analysis and found that one carried a common gene fusion found in prostate cancer and another previously undescribed gene fusion. They also found the androgen receptor gene was amplified and two tumor suppressors were inactivated. For purposes of the study, they set up a special tumor board to evaluate their findings and decide what clinical trials would be best for a patient. The authors then tried their strategy on two actual patients, one with colorectal cancer and one with melanoma. The tumor board suggested a combination of inhibitors that would be suitable for each patient on clinical trial. Unfortunately, at the time there were no appropriate clinical trials. This is the sort of preliminary work that needs to be done before genomic analysis of individual patient tumors, as will the implementation of clinical trials that patients can be assigned to based on their genomic information.
Other studies have tried to match genomic information gleaned from each patient’s tumor to individualized therapies with mixed results. One interesting approach was published about a year ago in the Journal of Clinical Oncology by a group from the Translational Genomics Institute (TGEN) led by Daniel D. Van Hoff entitled Pilot Study Using Molecular Profiling of Patients’ Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers, which uses an innovated, albeit controversial N of 1 trial design, with each patient serving as his own control. This summer, M.D. Anderson Cancer Center presented initial data at ASCO for over 1,000 patients in a phase I trial in which patients’ tumors were analyzed for genetic abnormalities and, when a drug existed to target that genetic abnormality, received that drug. Unfortunately, I didn’t go to ASCO this year; so I didn’t see the presentation, but the results are summarized on the M.D. Anderson Cancerwise blog:
For the 175 patients with one aberration, the medical response rate was 27% with matched targeted therapy. The response rate was 5% in 116 patients when treated with non-matched therapy.
Patients who received matched targeted therapy had median survival of 13.4 months, compared to nine months for unmatched targeted therapy. Median survival without cancer progression was 5.2 months for those receiving matched therapy, compared to 2.2 months for patients who received unmatched therapy.
True, this is not a home run by any means, but it suggests that “personalized” cancer therapy can improve outcomes.
Now let’s take a look at how the Burzynski Clinic does it, at least as far as I can figure out from my various sources and from Ms. Trimble. In response to my query about personalized gene-targeted therapy offered by the Burzynski Clinic, Ms. Trimble stated that a gene expression analysis is performed, as well as mutational analysis, FISH, immunohistochemistry for selected genes and that a blood test is also performed to measure the “concentration of proteins which are products of most important oncogenes.” How on earth they do this latter test, I really don’t know, because most oncogenes are not secreted proteins. Next, according to Ms. Trimble, the “medications which are shown to be best candidates for treatment, as well as those which are poor candidates, are identified from FDAs’ approved gene targeted medications and chemotherapy drugs list.” In addition, drugs are supposedly selected based on the patient’s clinical information, standard of care, FDA indication, data from phase II and III clinical trials. On the surface, up to this point it all sounded reasonable and not unlike what is being done at quite a few big cancer centers, hence my question (which was never answered to my satisfaction) of what Burzynski is doing that is different from (and presumably believed by Burzynski to be superior to) what everyone else is doing.
Then there was a hint. In addition, Burzynski then formulates a preliminary treatment plan that “will consist of medications which should cover approximately between 100 to 200 genes,” after sometimes doing a SNP analysis to “eliminate drugs which are not metabolized properly.” The result, or so it is claimed, is a set of drugs that have “synergistic activity which permits reduction of doses.” But why 100 to 200 genes? The very idea of targeted therapy is to hit the bare minimum of targets necessary to eradicate or control the tumor. Burzynski is going against the very concept of targeted therapy by making sure his therapy hits “100 genes,” a claim that resonates from what he said in the movie about him I reviewed last week. According to Ms. Trimble, “Antineoplastons and their prodrug, phenyl butyrate, are important ingredients of the combination because they cover the spectrum of approximately 100 genes.”
To support this claim, Ms. Trimble also sent me two papers from the Burzynski Clinic, both of which appeared in a journal I had never heard of before, the Journal of Cancer Therapy, which is clearly not indexed on PubMed because these papers never showed up when I searched PubMed for Burzynski. One described Burzynski’s approach for triple negative breast cancer (TNBC), the other for esthesioneuroblastoma and nonsmall cell lung cancer. What I found odd about both of these papers is that neither of them really examined whole genome expression profiling, although the paper about triple negative breast cancer did mention measuring the expression of “important” oncogenes. Meanwhile, the paper on esthesioneuroblastoma and nonsmall cell lung cancer primarily used sodium phenylbutyrate rather than any sort of gene targeting. The significance of this will become apparent in part III of this series, when I return to a discussion of antineoplastons. In the meantime, I note that, while the esthesioneuroblastoma is mildly interesting, it is a case report. I also note that the TNBC paper is a case report and small series in which a cocktail of targeted therapies plus chemotherapy appear to have produced somewhat durable responses. Unfortunately, in the absence of a control group or a clear prospective rationale for choosing these therapies, it’s hard for me to get too excited, particularly given that we don’t know the denominator; in other words, we don’t know how many patients with TNBC Burzynski has treated with this regimen who didn’t respond. We also don’t know the survival rates for these patients, only response rates.
It turns out that perhaps the best description of what “personalized” treatment means in Dr. Burzynski’s hands comes from the Texas Medical Board’s complaint against him, which can be found over at the Ministry of Truth or Casewatch. This complaint is based on the cases of two patients. First, here’s Patient A, who is described in the complaint thusly:
1. Patient A:
a. In approximately May of 2008, Patient A presented to Respondent with breast cancer that had metastasized to her brain, lung, and liver.
b. Respondent prescribed a combination of five immunotherapy agents – phenylbutyrate, erlotinib, dasatinib, vorinostat, and sorafenib-which are not approved by the Food and Drug Administration (“FDA”) for the treatment of breast cancer, and which do not meet the FDA’s regulations for the use of off-label drugs in breast cancer therapy.
c. In combination with the five immunotherapy agents, Patient A was prescribed capecitabine, a chemotherapy agent. The concurrent prescription of five immunotherapy agents in combination with a chemotherapy agent resulted in Patient A suffering unwarranted side effects.
d. Respondent owned the clinic pharmacy from which the multiple drugs were ordered. Respondent failed to affirmatively disclose to Patient A his ownership interest in the pharmacy.
This is what’s known as “throwing everything but the kitchen sink” at the tumor without any thought of interactions, as most of these agents have no proven role in the treatment of breast cancer. For example, erlotinib (brand name: Tarceva) is used to treat pancreatic cancer and non-small cell lung cancer. It works by inhibiting the tyrosine kinase of the epidermal growth factor receptor (EGFR) and is not FDA-approved for breast cancer. However, it’s not unreasonable to think that it could work in breast cancer, as EGFR is believed to be important in some breast cancers, which is why this is an area of active research. Dasatinib (trade name: Sprycel) is also a kinase inhibitor. It inhibits the Src family tyrosine kinase. Vorinostat is a histone deacetylase inhibitor approved for use against cutaneous T-cell lymphoma. Finally, Sorafenib is another tyrosine kinase inhibitor that inhibits the tyrosine kinases of different receptors, as well as raf kinases. The big problem with this sort of approach is that the more drugs you add, no matter how “targeted” they are, the more chance for interactions that increase toxicity, and throwing all these kinase inhibitors together in a cocktail with chemotherapy is a recipe for disaster, particularly because such cocktails haven’t been tested in proper phase I clinical trials to evaluate toxicity. They’re also all incredibly expensive as well, and Dr. Burzynski sells them through his own pharmacy.
Patient B appears to be the patient with esthesioneuroblastoma whose case report I described above. This is the relevant passage from the complaint:
Follow-up magnetic resonance imaging (“MRI”) scans were conducted in approximately August and December of 2003, and March of 2004, which showed progressive disease. Patient B was continued on phenylbutyrate during this 11 -month time period, and was not sufficiently informed about the drug’s lack of efficacy on her disease.
Which sounds rather unlike the glowing case report, now, doesn’t it?
Based on these cases, the Texas Medical Board accuses Dr. Burzynski of:
    • failure to meet the standard of care;
    • negligence in performing medical services;
    • lack of diligence
    • lack of informed consent;
    • nontherapeutic prescribing;
    • unprofessional conduct;
    • off-label prescribing that does not meet standards for off-label use unless an exemption is obtained.
These are aggravated by:
     1.  Harm to one or more patients;
     2.  Economic harm to any individual or entity and the severity of such harm;
     3.  Severity of patient harm;
     4.  One or more violations that involve more than one patient; increased potential harm to the public;
     5.  Intentional, premeditated, knowing, or grossly negligent act constituting a violation;
     6.  Prior similar violations
If the Texas Medical Board’s charges are upheld, then this is how Dr. Burzysnki does “personalized, gene-targeted therapy.”
Compare how Dr. Burzynski does it to how U. of M. does it, or to how M.D. Anderson does it, and there is a world of difference. More than anything, the way Burzynski does it resembles a pale imitation of how how Steve Jobs did it, as he has nothing even approaching expertise and intellectual firepower of the experts whom Jobs recruited to help him and without the extend and breadth of data upon which those experts based their recommendations. Unfortunately, we all know what the end result of “trying to stay one step ahead of the tumor” using targeted therapy was in Jobs’ case. That’s because cancer is hard, and even when we think we know the intracellular signaling pathways that have been disrupted there’s usually a level of complexity beyond that which we don’t understand.
The cost
It’s very telling to look at the literature that Dr. Burzynski sends to prospective patients, one example of which is reproduced by Xeno. For example, rather than summarizing sound papers describing well-designed clinical trials, Dr. Burzynski only lists “response rates.” Looking at the table included in the literature, I noticed immediately that Dr. Burzynski says nothing about survival rates, only what he calls “objective response rates,” which are not defined in a meaningful way. The pamphlet defines them as as anything from an “improvement” (defined as “decrease in size of the tumors, not confirmed yet by the second follow-up radiological measurement”) to “complete disappearance of all signs of cancer. This is not how it’s done. There are standardized ways of measuring tumor response agreed upon by radiologists and oncologists, such as the RECIST criteria. Burzynski lumps all responses together in an oncologically meaningless way. Also remember, Burzynski often uses standard-of-care chemotherapy along with his antineoplastons; so we would expect some responses. The chart above, however, is virtually meaningless, if only for the simple reason that initial tumor response often doesn’t correlate to overall survival, and overall survival is what we care about. As Xeno also notes, the out-of-pocket costs are staggering. Contrast this to the clinical trials I mentioned above, where patients do not pay for the genomic profiling or chemotherapy.
As bad, Dr. Burzynski massively oversells what he is doing. For example, one patient writes:
The gene targeted approach makes sense to me, in essence what these doctors are doing is testing your blood and tumor samples, what they look for is genetic markers that tell them what receptors and or channels your tumors are using to grow. When they’ve identified these receptors and or markers they begin to prescribe off label medications to suppress the channels that are allowinng the tumors thrive.
If only that were what Dr. Burzynski were really doing under the auspices of clinical trials like the University of Michigan trial! And if only he weren’t charging patients massive amounts of money to do it, while telling patients things like this, quoted from Suzanne Somers’ book:
SS: When you talk about gene-targeted therapy, is that chemotherapy?
SB: No, this is not chemotherapy. Most of my patients have already had chemotherapy and it has not been effective for them. The beauty of antineoplastons is that they are natural compounds. They exist in our blood and form a protective system against cancer. You don’t expect to have toxic side effects from chemicals which are normal in your blood. And they cover a broad spectrum of genes, which means from the very beginning we have a much better chance to help this patient.
Of course, chemotherapy affects more than hundreds of genes; so by Dr. Burzynski’s criteria cytotoxic chemotherapy should be the best therapy of all because it affects the most genes!
As we have seen, Dr. Burzynski does indeed give chemotherapy to his patients. He combines that chemotherapy with a gmish of “targeted therapies” based on a commercially available but not FDA-approved gene expression profile test and calls it “personalized gene-targeted therapy.” Unfortunately, in my not-so-humble opinion, he doesn’t have a scientifically supportable rationale for combining his targeted therapies. Instead, skirting the line between science and pseudoscience, Dr. Burzynski gives every appearance of recklessly throwing together untested combinations of targeted agents willy-nilly to see if any of them stick but without having a systematic plan to determine when or if he has successfully matched therapy to genetic abnormality. In this, Dr. Burzynski does indeed resemble alternative medicine practitioners when they claim to “individualize” treatments. The result is that his outcomes are basically uninterpretable, making them useless for determining whether his approach works. At the same time, the cost is personal in terms of giving patients false hope and of unnecessary side effects for little or no benefit and financial in terms of bills that run from tens to hundreds of thousands of dollars charged to patients who are so desperate that they will pay them for even a glimmer of hope.
There is still one more issue to be explored in the strange case of Dr. Stanislaw Burzynski. My next installment will return to antineoplastons and, hopefully, close the loop on this tale.
The complete Burzynski series:
     1.  Stanislaw Burzynski: Bad medicine, a bad movie, and bad P.R.
     2.  Dr. Stanislaw Burzynski’s “personalized gene-targeted cancer therapy”: Can he do what he claims for cancer?
     3.  Dr. Stanislaw Burzynski, antineoplastons, and the selling of an orphan drug as a cancer cure

The compassion gambit
David Gorski on December 19, 2011
Link
I’ve spent the last three weeks writing about a “brave maverick doctor” by the name of Stanislaw Burzynski who claims that he can cure cancers that regular oncologists cannot. He uses a combination of what he calls “antineoplastons” (which, it turns out, are more or less than the active metabolites of an orphan drug known as sodium phenylbutyrate) plus a very expensive cocktail of chemotherapy and targeted agents chosen in a haphazard fashion and thrown together with little rhyme or reason. This week, I had planned to move on. However, I felt that I had to mention the Burzynski saga because it provides me with the most appropriate segue to a topic I’ve been meaning to write about for a long time, possibly since this blog began. In fact, it’s about as perfect a framework as I can think of upon which to drape the points I want to make in this post.
What I will discuss is perhaps the most effective, devastating attack that proponents of quackery, woo, and nonsense aim at supporters of science-based medicine (SBM). As far as that is the case, it is not effective because it’s fact-based, evidence-based, or science-based. Far from it. Rather, it’s effective because it appeals to the emotions and very effectively demonizes SBM proponents to the point where they often have a hard time standing their ground when it is used. Sometimes, it preemptively prevents them from even speaking up in the first place. It’s a little tactic that I like to call the “compassion gambit,” which means trying to discredit critics of “alternative” medicine by painting them as cold, unfeeling, uncaring, arrogant monsters who want to hurt or kill children (and probably get a big smile on their faces when they torture puppies, to boot).
“Compassion” and the anti-vaccine movement
I first noticed this particular gambit as a distinct entity about three years ago, after I first wrote about the execrable “monkey business” study promoted by Laura Hewitson and Andrew Wakefield as “evidence” that thimerosal results in serious problems during development. The study, as I originally pointed out and then subsequently re-emphasized, was, scientifically speaking, a pair of fetid dingo’s kidneys, something I felt obligated to point out (not to mention obligated to explain why) because anti-vaccination activists were promoting the study as though it were smoking gun evidence that thimerosal-containing vaccines cause autism. They don’t, of course. In any case, around about that time I made the mistake of letting myself get into an e-mail exchange with a prominent anti-vaccine propagandist who shall remain nameless. Not surprisingly, the logical fallacies were flying at me fast and furious, as was, of course, a heapin’ helpin’ of the pharma shill gambit. This mass of logical fallacies was all topped off with this:
When it comes to autism, you seem to have lost something that I think every physician is well-served to have in abundance: compassion.
And there you have it, the distillation of the compassion gambit: the attempt to discredit an argument by arguing that the person making the argument is cold and heartless. In other words, it’s a form of the ad hominem fallacy, combined, of course, with a bit of non sequitur. After all, even if the person making an argument were actually cold and heartless, it doesn’t follow that his argument is incorrect.
In my experience, from nowhere else is the charge of meanness, cold-heartedness, and lack of compassion shouted at SBM proponents quite as vociferously and with as much venom as from antivaccinationists. Any criticism of their assertions that either mercury from vaccines or vaccines themselves caused their child’s autism is viewed not as a counterargument, but rather as a personal attack on them. The reason is obvious: many of them honestly and deeply believe that vaccines “poisoned” their children their interventions are in the process of “curing” their children, one particularly famous antivaccinationist mother even to the point where she believes that she could make her son autistic again if she were to let up, feed him the wrong foods, or—God forbid!—vaccinate him. Attacks on their beliefs are viewed as direct attacks on them, whether they are or not. The same applies to many in the thrall of so-called “alternative” medicine.
They misunderstand, of course.
I have nothing but the most enormous respect for parents who manage the incredible daily task of raising an autistic child—or any special needs child, for that matter—day in, day out, often with inadequate finances and difficulty obtaining insurance coverage, or even with no insurance coverage at all. It’s a huge challenge that I don’t necessarily know that I could meet were it to fall on me. No one knows if they can handle the job until they are thrust into that situation. Still, my compassion for the difficulties such parents face should not—must not—give them a free pass to spout antivaccinationist misinformation uncountered. The threat to public health—and individual children put at risk from diseases unnecessarily—is too great. Moreover, the use of the compassion gambit is often quite intentional. Many anti-vaccine activists count on the sympathy that their struggles to raise their autistic child evoke from reasonable and compassionate people blunt any criticism, all too often waving that plea for sympathy like a talisman in front of them to shame evil skeptics like me into silence. In this they are not alone.
The “alternative” medicine cancer cure industry: Using compassion as a fundraising tool
It’s not just those who speak out against the anti-science of the anti-vaccine movement who wield the “compassion gambit” against their foes. Not surprisingly, after my posts on Dr. Burzynski’s cancer cure claims, I got a couple of e-mails from his fans accusing me of the same thing, an utter lack of compassion for children dying of cancer. These sorts of complaints basically boil down to demanding of me, “How can you crush this desperate patient’s last hope, you uncaring, heartless monster?” It’s as if the people writing such screeds honestly believe that I revel in telling people with cancer (or the parents of a child with cancer) that there is nothing that can be done and that they are going to die. Or that I somehow get off on telling people with cancer going to the Burzynski Clinic that he can’t help them. One wonders whether people who write such things picture me twirling my mustache as I tie a young maiden up on the railroad tracks, as anti-vaccinationists apparently picture SBM proponents as preferring baby as the main course for their Thanksgiving feasts. Of course, they forget that, although fortunately I rarely have to do this anymore given my cancer specialty, I have indeed had to tell a depressing number of patients that they had a horrible cancer for which there was very little that medicine could do for them. I’ve watched patients and family members die of cancer, sometimes in horrible ways.
In any case, the compassion gambit is such a common attack on me and any other physician who would argue against woo that it is worth answering. The reason I decided to write about this phenomenon this week is because Dr. Burzynski appears, at least in part, to count on the compassion of strangers to fund his clinic. Indeed, through his minions, shills, and fans, Burzynski appears to quite intentionally portray his critics as standing between his patients and a cure for their cancer.
As you probably recall, what first drew my attention (and that of many other bloggers) to Dr. Burzynski’s dubious practices was the habit of his patients (apparently with his encouragement) to set up charitable funds to ask for donations to pay for their treatment at the Burzynski Clinic. For instance, the first case of this sort of fundraising appeal that I heard about was that of Rene Louis, who formed the I Promise campaign, first to try to fund her trip to the Burzynski Clinic to treat her thyroid cancer, then later to fund other cancer patients’ search for cures. This year, there was the case of Billie Bainbridge, a four-year-old British child with an inoperable brain tumor whose parents wanted to take her to the Burzynski Clinic. To fund this trip, Billie’s family took to fundraising on the Internet and elsewhere, ultimately managing to attract the attention of U.K. performer Peter Kay who did two sold-out charity concerts to raise £200,000. Billie’s story and the story of Kay’s concerts were told in an incredibly credulous article in which almost never was heard a discouraging word about Dr. Burzynski, whose claims were barely questioned—and then only as an afterthought. In response to criticism, the editors of the paper were completely clueless as to why their article was so heavily criticized. What also happened, besides a UK newspaper behaving irresponsibly, is that bloggers criticized the credulous coverage of the Billie Bainbridge story, the result was its PR flack named Marc Stephens issuing legal threats to critical bloggers, a move that spectacularly backfired.
You’d think that UK newspapers would have learned a thing or two about their coverage of this story, but you’d be wrong. Not long after the blogospheric kerfuffle that erupted over the Billie Bainbridge story and Marc Stephens’ ham-handed attempts to silence criticism of the Burzynski Clinic, I saw this story from the U.K. in which another family of a girl with an inoperable brain tumor was trying to follow in Billie Bainbridget’s footsteps:
The family of a five-year-old girl with a rare form of brain cancer are hoping to raise £130,000 to send her to a US clinic which could be the only chance of saving her life.
Chiane Cloete’s family in Enfield want her to be treated at the Burzynski Clinic in Texas after she was diagnosed with a highly aggressive form of cancer.
The clinic’s course of treatment, which aims to “switch on” the genes responsible for cancer suppression, is not available in Britain. Her father, Chris, a company director, stepped aside from his role this year to help her mother Andia look after their girl. The couple also have a two-year-old son Estian.
She is being treated at Great Ormond Street Hospital where an MRI scan next Thursday will see whether the cancer is spreading and if she is fit to fly.
Mr Cloete said the discovery of the cancer meant the family’s “whole world was turned upside down in a matter of seconds”, adding: “She is like any normal child. We are just a normal family, looking after her is so intense and takes up so much time. She is so brave for her age and a fighter. I have no doubt we will get the funds needed. The snowball effect is starting to take an effect.”
Chiane’s family is taking a similar approach to that of the Bainbridge family in that they’ve set up a website (Help Me Fight Cancer) that advertises fundraising events, Chiane’s Diary, and, of course, the appeal for funding for the Burzynski Clinic:
I need your Help to fight my Brain Cancer”
We desperately need to raise £130,000 for Chiane. We have to take Chiane to the Burzynski clinic in Texas (USA) for Innovative and pioneered cutting-edge Personalised Gene Targeted Cancer Therapy that is customised specifically for her.__The £130,000.00 covers her treatment costs ONLY. We did not include any costs or expenditure such as traveling, accommodation etc. to the States.__For more information please visit www.burzynskiclinic.com
Whenever I start getting too cynical about human nature, I think of all the people who are more than happy—eager, even—to send money children like Billie and Chiane, children whom they don’t know. I get a warm, fuzzy feeling inside; that is, until I think about the purpose for which the money is being raised, namely to pay for an overpriced, incompetently designed, unproven therapy that is incredibly unlikely to benefit the child. It’s horrible to contemplate the death of a child due to a disease as devastating as the brain cancers causing these children’s suffering, just as it’s profoundly saddening to consider the pain their families endure as these children become more and more ill, deteriorate, and ultimately die. Who wouldn’t want to do anything in his or her power to try to help these girls to live to a ripe old age? I understand. I understand why parents would go to such lengths and why they would be so susceptible to the promises of someone like Dr. Burzynski. Really, I do. I can’t even be sure that, if I had a child with a deadly tumor and were in the position of some of these parents, I wouldn’t be immune to the siren song of the claims made by someone like Burzynski, who takes on the trappings of science in the name of his “alternative therapy” but delivers bad science, bad medicine, and unproven therapies. Only my background in cancer surgery and oncology would have been likely to protect me, and most parents don’t have that.
Unfortunately, although what Dr. Burzynski is selling is hope, it’s a false hope that glimmers no more brightly than the hope offered by conventional therapies. Certainly he’s never been able to demonstrate that his results are any better than any other cancer center, and, as has been pointed out, patients he promotes as being success stories very frequently turn out, when someone follows up on them later, to be nothing of the sort. Often they turn out to be dead of their cancers.
Dr. Burzynski’s stock in trade, as far as evidence goes, is anecdotes and case series without control groups subject to major confounders and selection bias, all wrapped in a patina of science-y sounding gobbledygook designed to mimic what real oncologists and real science do. He keeps numerous clinical trials open to allow him to administer his unproven antineoplastons as part of a clinical trial but never seems to be able to progress to phase III trials or to publish his clinical trial in halfway respectable journals. Unfortunately, although Dr. Burzynski is a good mimic and very talented at portraying the “brave maverick doctor,” he’s not so good at actually doing oncology. As I have shown before, he uses the results of a commercial test that does nothing better that what a lot of other cancer centers do and produces recommendations that are facile and whose applicability to the tumor being tested ranges from the painfully obvious without the test to the highly questionable to come up with cocktails of chemotherapy and targeted therapies without regard to potential interactions. Then, of course, he throws antineoplastons—excuse me, phenylbutyrate—into the mix. The result is a gmish of up to six or seven drugs thrown together without consideration of potential drug interactions, the likelihood of which rises markedly with each new drug added to the cocktail. Worse, Dr. Burzynski tells the press and his patients that he is not giving chemotherapy when, in fact, he gives lots and lots of chemotherapy in a non-evidence-based manner.
It is not my intention or desire to crush the hope of such families. It is, however, my intention to put Dr. Burzynski’s claims in context for them, so that they understand what they are getting into and that Dr. Burzynski is not a savior. He isn’t even a good doctor, in my opinion, and he’s certainly not a good scientist. Parents need to realize that in reality their children are no more likely to survive due to Dr. Burzynski’s ministrations than they are if they just stick with their current oncologists. It might sound cruel to say so, but I would argue that it’s far more cruel to hold out false hope at a price of hundreds of thousands of dollars, which is what Dr. Burzynski does. It’s what Rashid Buttar used to do before the state of North Carolina limited his ability to treat cancer patients. It’s what innumerable “alternative medicine” clinics in Tijuana do. It’s the very epitome of “misinformed consent,” in which they are given a far more optimistic assessment than reality would warrant. Worse, if parents find a way to raise the money necessary and then spend it at the Burzynski Clinic, they’ll squander the short time they have left with their children subjecting them to Dr. Burzynski’s cocktails. In the end they’ll still have a dead child, but if they save the money and focus on good palliative care they can at least maximize their quality time remaining with their children. More importantly, the child will suffer less.
There’s another aspect about Dr. Burzynski that is disturbing. I had been thinking along these lines, although not as starkly, but wondered whether I should bring up the issue. I’m not entirely sure I agree with this viewpoint, but it’s something that is worth at least discussing. A few days ago, Ministry of Truth published a post, Burzynski – Conscience and Complicity. In it, he argues that, as bad as we feel for the parents of these children, it helps no one if we in essence “give them a pass” when, after falling for Dr. Burzynski’s patter, they promote his clinic and use their stories to raise money that goes to him. First, he notes something that’s painfully obvious to anyone who’s looked at Dr. Burzynski’s history over the last three decades:
For as much as I understand and accept the validity of the reasons given for taking a softly, softly approach with Burzynski’s patients and their families, the problem I have with it is it that it too readily fails to illuminate what is one of the most, if the most, despicable facets of the Burzynski Clinic’s business model.
By preying on people who are genuinely in a desperate situation and charging them huge sums of money to join one of the never-ending series of so-called clinical trials, the overwhelming majority of which fail to report any kind of results, Burzynski not only scalps these people for tens, and even hundreds of thousands of pounds/dollars but, in some (many?) case he also compels them to serve as his accomplices and even, when the critics begin to circle, as his own human shields.
This strikes me as the most despicable aspect of the Burzynski business model. Over the years, he has encouraged, if not outright built up, a cult of personality around himself, in which he is portrayed as the one doctor who can cure incurable cancers but, for all his efforts, is rejected and “persecuted” by the medical establishment when all he is trying to do is good. Any criticism directed against him inevitably results in patients and families coming out of the woodwork to extoll the virtues of this “brave maverick doctor” and proclaim him as the man who is saving their lives or the lives of their loved ones. It’s a strategy that, at times, has worked brilliantly, as demonstrated in the numerous scenes of patients in the incompetently produced propaganda piece Burzynski The Movie castigating lawmakers, the FDA, and the Texas Medical Board for going after Burzynski, telling heart-wrenching stories and proclaiming that they will die if Burzynski is shut down. It’s an incredibly potent P.R. weapon, and one that Burzynski is not in the least bit shy about using, as you can see in this video and Burzynski The Movie, which featured long, manipulative minutes of patients telling Burzynski critics, the Texas Medical Board and various regulators and legislators that if his clinic is shut down they will die. Burzynski counts on the media, full of sympathy for these families, not looking too closely at the stories they tell or being to skeptical.
Real compassion demands truth telling
Anti-vaccinationists and proponents of quackery often accuse skeptics and proponents of SBM of lacking compassion, while at the very same time using their very own tales of woe as both a defense against science-based criticism and a weapon with which to attack SBM proponents. In this, they are often encouraged by the very quacks who profit by selling various unscientific treatments. Compassion, whether real or not, is both a marketing ploy to lure new customers and a weapon against those who would warn the new marks that they are about to be taken. It’s a highly effective gambit, one that’s not easy to avoid or overcome. However, the compassion gambit is a double-edged sword.
So why am I so passionate against antivaccinationism and other forms of quackery, particularly cancer quackery?
It’s compassion for the victims that motivates me. In the case of cancer quackery, even patients who can’t be saved by conventional medicine become victims. Patients who, for example, are seduced by the blandishments of quacks to undergo the Gonzalez protocol, with its coffee enemas and hundreds of supplement pills a day, often do so at the expense of foregoing effective palliative care in order to undergo a harsh regimen that robs them of what little quality of life they might could achieve in the time they have left. Children and teens who choose quackery such as the Hoxsey therapy or high dose vitamin C instead of effective chemotherapy give up a reasonable chance of a cure and living to a ripe old age. Children whose parents believe that prayer is more effective than medicine in treating life-threatening diseases die when they could have been saved. Children of HIV mothers who don’t believe that HIV causes AIDS die of AIDS-related complications when combination antiretroviral therapy could have prevented their deaths. Autistic children whose parents believe that they were made autistic by vaccines are subjected to injections, restrictive diets, hyperbaric oxygen, blood draws, and even chemical castration. Children are subjected to unethical and scientifically worthless “clinical trials” in the service of pseudoscience. Some even die because of these nostrums. Many more will die if antivaccinationists get their way and vaccination rates fall to the point where herd immunity is no longer operative. Indeed, we see a disturbing glimpse of what might be in the resurgence of measles and mumps in the U.K. due to Andrew Wakefield’s litigation-driven pseudoscience.
Don’t all these people deserve compassion, every bit as much as Billie Bainbridge or Chiane Cloete?
I say yes! It is my compassion for them that drives me and my disgust at how they are taken advantage of by promises that no human can keep. As I have argued here and elsewhere many times, science- and evidence-based medicine are the best methods that we have to determine what causes disease and how to treat it. Whatever its faults (and there are many), science- and evidence-based medicine is at least constrained by law, ethics, and science itself to restrain the natural human impulse to promise more than can be delivered. When the shortcomings of EBM/SBM are revealed, I assure you, it’s almost never pseudoscientists and “brave maverick” doctors who think that they know better than scientific medicine that bring shortcomings and ethical lapses to light. It’s medical scientists and ethicists who bring the darkness to light.
Besides, if we’re going to play the compassion game, I’ll match my compassion with those of the practitioners who inflict this quackery on desperate patients and parents. How much do Mark and David Geier charge for administering Lupron to autistic children? You can be sure it’s not cheap. What about Dr. Roy Kerry, whose quackery and incompetence killed a five year old child? You can bet he didn’t do it for free, and let’s not forget the horror of the description of that child’s final hours, as he was held down as he was stuck multiple times to get an IV going, having been subjected to unnecessary IV infusions many times before. Then there’s Dr. Rashid Buttar, who charged dying cancer patients tens of thousands of dollars. He even tried to collect his blood money from the estates of his victims!
I could also ask: What about compassion towards the victim of Dr. Roy Kerry’s quackery, for example? Where’s that? Here’s an example in which a woman named Jan responded to the observation that chelation therapy killed Tariq Nadama:
We shall wait and see, and if it did, it happens, as with all procedures.
If I tried to defend an iatrogenic complication or death that occurred while a patient was undergoing “conventional therapy” with such a blasé riposte, you can bet that Jan, and others like her, would be outraged. Now compare Jan’s reaction to Tariq’s death with her reaction to the death of Jesse Gelsinger, the 18 year old who died while participating in a gene therapy trial in 1999:
Isn’t that most strange,,,,,,,,,,,,,,,,,,,,
This health fraud that KILLED a volunteering, caring, loving teenager, helping man kind, and the doctor who KILLED him who committed, FRUAD, COVER UPS, FALSE AND MISLEADING *REPEATED* AND *DELIBERATE* VIOLATIONS,,,,,,,,,,,,,,,,,,,, ,,,,remains on staff.
I detest either outcome: Death from quackery or death due to a clinical trial design that wasn’t as safe as its subjects were led to believe. That’s why efforts of pseudoscientists to get their trials approved by dubious IRBs packed with cronies and friends outrage me so. If they can get away with it, then big pharma can get away with it too.
The “lack of compassion” gambit is nothing more than a variant of the “mean skeptic” gambit. It’s a gambit that’s frequently used against scientists who argue against other forms of non-medical pseudoscience, such as “intelligent design” creationism, but it is a particularly potent gambit in medicine, because there is virtually always a suffering patient at the receiving end of the pseudoscience who thinks (or whose relatives or parents think) it will really, really help. Attacks on the pseudoscience can thus lead to the perception that the skeptic wants patients to suffer and does not want them to be “healed.” (Never mind that, as far as science can tell, no one is being “healed” for the most part.) In reality, what the “compassion gambit” is really designed to do is to neuter any criticism. Skeptics hesitate because they do not want to be perceived as ganging up or being unduly harsh on people who may be truly suffering or desperate or who may truly believe that the woo under criticism is the only chance for them or their children. Even though I try to reserve my harshest attacks and sarcasm for people who have demonstrated time and time again that they support pseudoscience and quackery and that they are virtually uneducable, I can’t always parry that attack. It’s a “heads I win, tails you lose” game. If as a skeptic I hold my fire or give undue respect to ideas that do not deserve it, pseudoscience is granted an undeserved patina of respectability, as though it really is a viable alternative to scientific medicine. If as a skeptic I am too harsh, I am accused of having “no compassion” for the suffering who turn to woo.
The way out I have chosen, which may or may not be the best way out, is not to play the game and to fire away. I may not always match the vociferousness of my attack perfectly to the level of the offense against science and reason, and hopefully I will usually recognize when or if I have “gone too far.” Either way, I will not allow the charge of not being sufficiently compassionate (in reality, not showing sufficient deference to pseudoscience) stop me. The victims of quackery deserve no less.

Dr. Stanislaw Burzynski’s antineoplastons versus patients
David Gorski on January 14, 2013
Link
Prelude: Doin’ the Antineoplaston Boogaloo with Eric Merola and Stanislaw Burzynski
In December I noted that Eric Merola, the “film maker” (and, given the quality of his work, I do use that term loosely) who was responsible for a movie that was such blatant propaganda that it would make Leni Riefenstahl blush were she still alive (Burzynski The Movie: Cancer Is Serious Business, in case anyone’s interested), was planning on releasing another propaganda “documentary” about Stanislaw Burzynski later this year. Merola decided to call it Burzynski: Cancer Is Serious Business, Chapter 2 | A Modern Story. Wondering what it is with Merola and the multiple subtitles, I had been hoping he would call the Burzynski sequel something like Burzynski The Movie II: This Time It’s Peer-Reviewed (except that it’s still not, not really, and I can’t take credit for that joke, as much as I wish I could) or Burzynski The Movie II: Even Burzynskier Than The First, or Burzynski The Movie II: Burzynski Harder. Mercifully, I doubt even Merola would call the film Burzynski II: Antineoplaston Boogaloo. (If you don’t get this last joke because you are either not from the US or are too young to remember, check out the Urban Dictionary.)
In any case, Merola named the sequel what he named it, and we can all look forward to yet another propaganda film chock full of conspiracy theories in which the FDA, Texas Medical Board, National Cancer Institute, and, for all I know, the CIA, FBI, and NSA are all out to get Merola’s heroic “brave maverick doctor,” along with a website full of a “sourced transcript” to be used by Burzynski minions and shills everywhere to attack any skeptic who dares to speak out. The only good thing about it, if you can call it that, is that I’m guaranteed material for at least one juicy blog post, at least as long as I can find a copy of Burzysnki II online, as I was able to do with Burzynski I, thanks to Mike Adams at NaturalNews.com and other “alternative sites” that were allowed to show the whole movie for a week or so before folks like Joe Mercola were allowed to feature the complete film on their websites indefinitely.
Maybe Eric Merola will send me a DVD review copy when the movie is released. Or maybe not.
What I didn’t tell you at the time (mainly because it hadn’t happened yet) is that Eric Merola himself contacted me to appear in Burzynski II. I kid you not. About a month ago, back in early December, out of the blue I got an e-mail from Merola. I responded, as you might imagine, skeptically, pointing out the blindingly obvious, namely that it would be very easy for Merola to edit me to look really bad. Indeed, I wouldn’t put it past him to try to light me from below, the way they did to William Shatner in that episode of Star Trek in which the transporter split James Kirk into two Kirks, a good Kirk and an evil Kirk. (Yes, it was the evil Kirk who got the under lighting.) Add a little heat on the location, and—voilà!—you have a sweaty, poorly lit Dr. Gorski looking even more disreputable than he normally does!
Merola returned with an offer in which he assured me that he would not be interviewing me, that I could say anything I want. Of course, the same problem applies. He could easily put my segment after images of children with brain tumors and parents railing at skeptics as cold, heartless bastards who want their children to die. Through the magic of creative editing, enter the cold, heartless bastard cast by the producer and director, to be torn apart elsewhere in the movie. No, it was obvious after consulting with trusted friends with more media experience than myself, as well as the media relations people where I work, all of whom agreed that I’d be crazy to do this, that I would in fact be very foolish to agree to Merola’s offer. Far be it from me to do something that my media relations people tell me would be a very bad idea to do; so I politely declined. If, however, there is a segment in Burzynski II attacking me, trying to make me look like some pharma shill loon, and then painting me as somehow cowardly (rather than rational) to have declined the opportunity to show up on Burzynski’s little infomercial, don’t be surprised and don’t forget: You heard it here first. It wouldn’t surprise me if there were, given that Merola actually contacted Bob Blaskiewicz’s place of employment to try to intimidate him into silence. No, I knew it wouldn’t be wise from the beginning, but my ego wouldn’t let me just say no right off the bat, which is what I should have done.
Mentioning Bob Blaskiewicz brings me to another development in the long-running Burzynski saga, and that’s a chance for some positive skeptical action to highlight what’s going on at the Burzynski Clinic. Indeed, because he’s spearheading this particular bit of skeptical activism is exactly why Merola targeted Bob Blaskiewicz for what I view as harassment at his place of employment. First, Bob set up a website that he called The Other Burzynski Patient Group, to counter the glowing testimonials and seemingly miracle cures found on The Burzynski Patient Group with examples of a more typical outcomes of Burzynski patients gathered from public sources and social media. In addition, he’s come up with a campaign to wish Dr. Burzynski a happy birthday this year, skeptic style:
In honor of Dr. Stanislaw Burzynski’s 70th birthday on January 23rd, 2013, the Skeptics for the Protection of Cancer Patients are fundraising for St. Jude Children’s Hospital. Our goal is to raise at least $30,000 by Burzynski’s birthday, the approximate cost of entering one of his clinical trials of antineoplaston therapy. On his birthday, we will deliver a present to the Clinic, a challenge to Dr. Burzynski to match the total sum donated by skeptics, science advocates, and others who value good research into devastating forms of childhood cancer. The more you give, the more we ask of Burzynski.
Please visit http://www.crowdrise.com/fightchildhoodcancer/ and donate to St. Jude, a fantastic organization that does not turn away patients who cannot pay.
As I’ve heard it said, if Burzynski actually agreed to do this and match whatever money is raised, it would be the only good thing he’s ever done for cancer patients in his entire miserable career. Of course, it’s impossible to shame a man who has no shame; so I doubt that Burzynski will match this generous gift. You can, however, help by donating or, if you are a blogger or podcaster, writing about the campaign and examining what Burzynski is doing for yourself. If you are a skeptic and support science-based medicine, it will be difficult to conclude anything differently than what I’ve concluded.
The time for comic relief in the form of my lame jokes is over. Let’s get serious and illustrate what I mean. Here is the latest sad tale I’ve learned about from the Burzynski Clinic. I started out light-hearted because Burzynski’s antics to promote himself can be quite funny at times, but the effect his clinic has on patients is anything but funny. It’s deadly serious.
The story of Seán Ó’Laighin
One thing that I regret about my “epic” trilogy of posts in late 2011 about the overblown claims, dubious science, and lack of any convincing clinical trial data to support the efficacy of Stanislaw Burzynski’s therapy is that I didn’t concentrate enough on the patients. The reason for that was because, at the time, I was very much interested in writing an updated scientific analysis of Burzynski’s claims. The QuackWatch entry on Burzynski and his “antineoplastons”, although containing useful material, was hopelessly out of date, so in reviewing Burzynski I I tried to update it. Most importantly, there was no information on Stanislaw Burzynski’s latest little project, namely hijacking the concept of personalized therapy based on gene expression profiles to do what he has referred to as “personalized gene-targeted cancer therapy.” So I wrote about that in order to point out that he was essentially doing “personalized cancer therapy for dummies” and that, contrary to his claims that his therapies are so much safer and less toxic, he was administering a lot of chemotherapy and expensive targeted agents. I plan to write more about that in the coming year, because I want to try to put it all together what it is that Burzynski is doing. Also, some Burzynski supporters have been sending me citations that (according to them) show that Burzynski has really and truly demonstrated that antineoplastons work! Finally, I noted that one of the antineoplastons that he had isolated was, in fact, an orphan drug known as sodium phenylbutyrate, which can be prescribed off-label.
A couple of weeks ago over the holidays, the Irish television station TG4 broadcast a report entitled Tar éis na Trialach (“After the Trial”) about a young man named Seán O’Laighin (also spelled Sean Lyne) who is celebrating his 21st birthday while battling an inoperable brainstem glioma. Part I of the 30 minute show can be found here and embedded below (note that part II will start playing automatically after a commercial at the end of part I):
It’s worth watching the whole thing. Even though most of it is in Irish, it does have subtitles. It’s a moving (and depressing) portrait of a young man who at age 19 was a talented hurler and nursing student with a promising career and his whole life ahead of him when he was diagnosed with an inoperable brainstem glioma. Shots of him as a boy (who really liked Eminem and Michael Jackson), as a vigorous and athletic young man, and as a student are interspersed with pictures of Seán in a wheelchair, having drugs infused, his family holding fundraisers to send him to the Burzynski Clinic, and, most poignantly, him sitting on the sidelines of a hurling pitch watching what I assume are his former teammates practice, himself no longer able to play because of the deterioration of his motor function to the point where he has difficulty walking. We learn that the first symptom that something was wrong was photophobia and difficulty learning to drive because he had trouble coordinating shifting and acceleration. He went to Beaumont Hospital, where a workup revealed that he had a mass in his brain accounting for his symptoms, and a biopsy of the mass revealed glioma. Seán was apparently given a prognosis of surviving approximately eight months to two years, and we see a shot of an oncologist named Dr. Aengus O’Marcaigh saying:
We can contain it with chemotherapy and/or radiation, but it’s incurable because it’s too dangerous to operate.
I’m sure that regular readers know what’s coming next, and it does. We see a shot of Seán’s mother, who tells viewers:
In the irish side, all really the talk was was of containment. And then we heard about Burzynski, and they offered the hope of a cure for us. Seán was only 19 so we decided to go for it.
Next is a very familiar story to those of us who have been following Burzynski. Treatment at the Burzynski Clinic easily runs into tens of thousands, if not hundreds of thousands, of dollars. Through a monumental effort, Seán’s family managed to raise €120,000 (which at today’s exchange rate is approximately $160,000) to go to Houston; so go to Houston they did. We see the video that appears to have been taken with an iPhone camera of the family, including Seán, his mother, his brother Tomás, and his sister Deirdre mugging for the camera in front of the Burzynski Clinic, overjoyed to be there because they think that this is Seán’s best hope for survival.
Although it grated me to hear the narrator describe antineoplaston therapy as “controversial” (it’s not controversial from a scientific standpoint; there’s no evidence that it works), I give the producers credit for making it very clear that antineoplastons have never been “granted a general license by the FDA,” and calling them in a relatively dismissive tone “just a trial drug.” Also to their credit, the producers point out that Burzynski has never submitted his drug for conventional randomized clinical trials, and indeed he hasn’t. Not really. As I’ve described before, after having claimed to have discovered these magical chemicals in the urine and to have discovered that they are endogenous natural inhibitors of cancer, Dr. Burzynski has set up a lot of preliminary phase I and II trials whose results he never seems to publish in the peer reviewed literature. Instead, he likes to publish case reports and minuscule patient series in journals that aren’t even indexed by PubMed. No wonder, as the narrator puts it, the “medical profession here in Ireland are completely against it [going to the Burzynski Clinic].” Unfortunately, that didn’t stop Seán’s family doctor from agreeing to oversee Seán’s care in Ireland, which the Burzynski Clinic requires before it will let someone return to his home country under his treatment.
It’s definitely an ethical dilemma for doctors like this, because monitoring someone like Seán as he undergoes antineoplaston therapy isn’t just a matter of making oneself available in case there are problems. It involves ordering MRIs and other tests, as well as ordering blood work three times a week. I can’t help but note that if as a physician you order blood tests on a patient you are obligated to follow up the results and act on them if they are abnormal. Given that, contrary to Burzynski’s claims, antineoplaston therapy is not “non-toxic,” there’s a not inconsequential chance that a patient like Seán will end up in the emergency room and need to be admitted at some point. Then it’s up to you to fix the hypernatremia that antineoplastons cause. (I couldn’t help but note that the concentration of the antineoplaston infusion listed on the bags was 300 g/L, or a 30 per cent solution. That’s mighty concentrated stuff! No wonder severe hypernatremia is a known adverse reaction to antineoplaston therapy.
Although I knew a lot about Burzynski and antineoplastons already, what Seán’s story taught me is just how difficult the treatment is that Burzynski puts his patients through. Fortunately for Seán, his mother is a registered nurse and was able to handle mixing up the solutions under sterile conditions, infusing them into his Hickman catheter, drawing the blood work, and in general being his around-the-clock private duty nurse. According to Seán’s sister, it takes his mother 45 minutes just to prepare the infusion by mixing up the antineoplaston solution. Meanwhile Seán’s father quit his job to help take care of him, as Seán quite understandably laments that he can’t take care of himself anymore and has a very hard time just doing routine activities of daily living. In fairness, Seán would still require much of this care even if he were not being cared for through the Burzynski Clinic, but certainly the intense labor that is required to mix up and administer the antineoplaston solution would not be necessary if he were not being treated by Burzynski, nor would the expenditure of €120,000 or the massive effort it took to raise that much money.
The last half of the show alternates between preparations by Seán and his family for his 21st birthday party, with his friend taking him shopping for clothes, his family bringing his sister back home to Ireland from San Francisco, where she lives now, to surprise him, and other preparations, and Seán undergoing an MRI to determine whether his tumor had responded to the several months of antineoplaston therapy he had been undergoing. Fortunately, for Seán, his results took a few days to come back, which meant that he could enjoy his birthday party without the devastating news that later came. Not only did his tumor fail to shrink, but it didn’t even stabilize. In fact, it grew by 35%. Since tumor growth is usually measured on a 2D image, that means in terms of volume, his tumor grew by as much as (1.35)3 = 2.46-fold. He was taken off the antineoplaston therapy and is next shown looking for other alternatives, with his doctors suggesting that he go on Aviston, which appears to be a different spelling of the word “Avastin” or an alternate trade name. Assuming that’s the case, this is not an unreasonable option, given that gliomas tend to undergo a lot of angiogenesis.
There are a number of things about this documentary that one can learn if one is involved in caner care and knowledgeable about Stanislaw Burzynski. First of all, I find it rather telling that no one from the Burzynski Clinic, not even Stanislaw Burzynski himself, apparently agreed to appear either on camera or via telephone interview. Burzynski loves media attention; you can tell when he’s on camera that he’s just eating up the attention. Indeed, from my perspective he’s an egomaniac, full of the arrogance of ignorance about things like personalized cancer therapy, prone to contemptuously dismissing and attacking anyone who has the temerity to question the Great and Powerful Burzynski. Indeed, he’s even taken credit for pioneering the concept of personalized cancer therapy based on genes and the concept that cancer is a genetic disease, claiming to have published a journal article about it 20 years ago, allegedly long before conventional scientists and oncologists even thought of it. The problem, of course, is that, as far as I can tell, he published no such paper and personalized therapy is a concept older than 20 years. Of course, Burzynski tends to clam up when questioned about patients who didn’t get better pursuing his treatment or from interviewers who are not likely to be sycophants, toadies, and lackeys (e.g., Eric Merola). Whenever he does agree to be interviewed by a real journalist, generally he can’t prevent himself from lashing out at critics and making grandiose nonsensical claims.
More importantly than no one from the Burzynski Clinic showing up, there’s the question of the clinical trial. Remember how, in the 1990s, the agreement between the Texas Medical Board and Stanislaw Burzynski that allowed him to keep his license stipulated that Burzynski:
    • Cannot distribute unapproved drugs [like antineoplastons] in Texas
    • Can distribute “antineoplastons” only to patients enrolled in FDA approved clinical trials, unless or until FDA approves his drugs for sale
    • Cannot advertise “antineoplastons” for the treatment of cancer
    • Must place a disclaimer to his website, promotional material and ads stating that the safety and effectiveness of “antineoplastons” have not been established
Interestingly, although in the Irish television show antineoplastons are described as “trial therapy,” we learn nothing of the actual clinical trial, nor do we hear any mention of informed consent, protocol documents, etc. I’d give my proverbial eye teeth to get a look at the informed consent, protocol documents, and the description of exactly which clinical trial into which Seán was enrolled. If you go to ClinicalTrials.gov and type in “antineoplaston” plus either “glioma” or “glioblastoma,” you’ll find 16 trials. Eliminating the trials for children or for which glioma is not the tumor type being studied, that leaves four trials:
    • Antineoplaston Therapy in Treating Patients With Brain Stem Glioma. The status of this trial is unknown. The study start date was listed as 1998, and the database entry was last updated in 2008. Given that it is very unusual for a phase II clinical trial to remain open for 14 years, it’s hard not to assume that this trial is dormant or closed. A search of the trial number (NCT00003459) on PubMed shows no publications.
    • Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas. Same as above, except that the last update was in 2009, and the study start date was in 1996. A search of PubMed for this clinical trial number (NCT00003473) was similarly negative.
    • Antineoplaston Therapy in Treating Patients With Brain Tumors. Same as above. A PubMed search for clinical trial number NCT00003457 yields nothing.
    • Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme. The same, except that it was last updated in 2008. A search for clinical trial number NCT00003456 yields no publications.
So what we have here are a bunch of phase II clinical trials, which are meant to be preliminary, all started in the 1990s, all with statuses on ClinicalTrials.gov listed as unknown, none having been updated in at least three or four years, and none, apparently, having been published in the peer-reviewed literature, at least not in a form linkable to their ClinicalTrials.gov number using PubMed. As the NCI states in its review of the evidence concerning antineoplastons and cancer:
Antineoplaston therapy has been studied as a complementary and alternative therapy for cancer. Case reports, phase I toxicity studies, and some phase II clinical studies examining the effectiveness of antineoplaston therapy have been published. For the most part, these publications have been authored by the developer of the therapy, Dr. Burzynski, in conjunction with his associates at the Burzynski Clinic. Although these studies often report remissions, other investigators have not been successful in duplicating these results.
Given that these are all case series, phase I studies, and non-randomized phase II studies, it’s hard to believe that the FDA would allow Burzynski to keep all his phase II studies open over 13 years, particularly in light of the inability of other investigators to replicate his reported complete remissions, but apparently it has. All of this brings up the question yet again: Which clinical trial was Seán enrolled in? Inquiring minds want to know! What “clinical trials” are all those other patients being enrolled on? Again, inquiring minds want to know! Finally, why doesn’t Burzynski offer Seán his “personalized gene-targeted cancer therapy.” It probably wouldn’t be that big a deal to get the blocks of tissue from Seán’s biopsy and have them analyzed. Yes, inquiring minds do want to know, because they have had a great deal of difficulty figuring out how Burzynski gets away with what he gets away with when it comes to his clinical trials.
The saddest part
Perhaps the saddest part of the show is the end, because it demonstrates how a person like Burzynski, by offering false hope, can tempt even highly intelligent people who would normally be skeptical of such claims. As I’ve said before, if I were facing a terminal disease like the Seán is facing, even I’m not entirely sure that someone like Burzynski couldn’t tempt me. I don’t want to die any more than Seán does. But that doesn’t change the insight into Burzynski’s hold on his patients, even when his antineoplastons don’t work. For instance, here’s Seán’s mother’s response to a question asking whether she thought going to Houston was a waste of time given that the antineoplastons didn’t work:
No, not at all because there was a girl that was there a month before us from England. She’s now tumor-free. If you didn’t try you wouldn’t know.
Of course, given Burzynski’s unreliability and his frequent misinterpretation of CT scans and MRIs, it’s impossible to know whether this girl truly is tumor-free or not. Burzynski has been known to give interpretations of MRI scans to families that are so wrong they’re not even wrong, as they say. For instance, in the case of Andy Cayon, Burzynski told him that his tumor had shrunk by 84% when it had not. It turns out that Burzynski had misinterpreted the MRI and measured the whole where part of the tumor had been removed, not the tumor itself. In essence, Burzynski misinterpreted the healing process from surgery as tumor shrinkage. Truly, Seán’s tumor must have grown so much that even Burzynski couldn’t spin it as somehow being a response to antineoplastons.
Similar to Cayon, in the case of another patient, Amelia Saunders, Burzynski told the parents that the cysts forming in her brainstem tumor meant that the antineoplaston therapy was working. Unfortunately, oncologists and surgeons like myself know that many solid tumors can outgrow their blood supply, such that the cells in the center of the tumor become ischemic due to low blood flow and die. This is something that is commonly seen in advanced solid malignancies. Tumors frequently, as they progress, evolve into a relatively thin rim of viable, growing cells surrounding a central area of necrotic tumor tissue. Sometimes, if you get into a tumor while trying to resect it, that necrotic cellular debris will squirt out like so much disgusting toothpaste out of a toothpaste tube. (We try to avoid this happening, as it means we didn’t get a good margin of normal tissue and can seed tumor cells.) In contrast, when tumors shrink due to chemotherapy or other treatment, they often shrink from the outside in (because that’s usually where the most rapidly proliferating cells are). True, they don’t always shrink that way and sometimes do have spread-out areas of necrosis, but that’s less characteristic. Of course, Amelia’s tumor wasn’t shrinking, which made it less likely that her cysts were due to treatment effect.
Fortunately, Amelia’s father, as much as he wanted to believe in Burzynski, was an intelligent man. He took the MRI to a real neuroradiologist at Great Ormond Street Hospital who told him the truth: Amelia’s tumor was progressing. Sadly, over the next few weeks, Amelia’s tumor progressed, and she died about a week ago. At least Amelia’s family had some time to try to come to terms with her impending death. How many of Burzynski’s patients and families are denied that?
Instead, Burzynski families and their patients often fall into the trap, like Seán’s sister:
I think with everything you do in life you will always have people who make negative remarks. One of my friends started telling me that she had heard bad things about Burzynski, and I just said, “Do you know what? I don’t want to hear it.” A positive mental attitude is so important. It’s so important to a person who is ill, to feel as if he has hope. To feel as if he has a reason to get out of bed in the morning.
The show concludes with an image of Seán sitting in his wheelchair, watching his ex-teammates practice hurling, and saying how after he is through with his cancer he wants so badly to get back to playing again. It’s a devastatingly poignant moment that increased my contempt for Stanislaw Burzynski and the false hope he gives cancer patients under the guise of research, often at the cost of hundreds of thousands of dollars borne by their families and friends.
How does he keep getting away with it? I don’t know. But I mean to find out if I can.
ADDENDUM: James Randi has recently posted an interview about his experience with science-based cancer treatment that’s worth checking out.

False balance about Stanislaw Burzynski and his disproven cancer therapy, courtesy of STAT News
David Gorski on June 5, 2016
Link


One common theme that has been revisited time and time again on this blog since its very founding is the problem of how science and medicine are reported. For example, back when I first started blogging, years before I joined Science-Based Medicine in 2008, one thing that used to drive me absolutely nuts was the tendency of the press to include in any story about vaccines an antivaccine activist to “tell the other side” or to “balance” the story. So in a story on vaccines, on one side you would have Paul Offit, a bona fide, legitimate vaccine expert, and on the other side you would have J.B. Handley, Jenny McCarthy, Andrew Wakefield, or a lesser light of the antivaccine movement. This same trope included stories about autistic children in which a reporter does a human interest story about a family struggling with raising an autistic child in which he lets the parents spout antivaccine misinformation, providing only a brief token quote by a scientist for “balance.” Thus, whether they intended it or not, the reporter would let the emotional impact of the story serve as persuasion to believe the parents’ antivaccine views. So, even though there was not (and hasn’t been at least since 2001 or probably much earlier) anything resembling legitimate scientific controversy over the question of whether vaccines cause or contribute to autism, the press aided the antivaccine movement in keeping alive the appearance of a controversy. It was, as I like to call these things, a manufactroversy, a controversy manufactured by the antivaccine movement to give the appearance of an actual scientific controversy. It’s a time-dishonored journalistic failing that is still a major problem with reporting on, for example, anthropogenic global climate change and genetically modified organisms (GMOs).
Sometimes, however, the press is teachable. A few years ago, after already having blogged about vaccines and autism for several years, I started noticing fewer stories with false “balance” and more stories that simply treated the antivaccine movement like the fringe movement it was, either not bothering to mention it or, if it had to mention it, basically letting scientists explain why it’s bad science and dangerous to public health. These days, false balance and stories that are antivaccine propaganda are relatively rare, aside from stories by fringe journalists like Sharyl Attkisson and Ben Swann. That’s a good thing. Unfortunately, I wish I could say that I really believe it was due to the efforts of skeptics and science advocates more than it was due to the discrediting of a major antivaccine figure, Andrew Wakefield, but even six years after Wakefield lost his medical license and saw his infamous 1998 Lancet paper linking the MMR vaccine to bowel disease in autistic children (the one that ignited the MMR scare in the UK) retracted, I’m not entirely sure. Be that as it may, there still remain blind spots in the press.
One of these blind spots, it would seem, is Stanislaw Burzynski. I can understand why his story might still be a blind spot. It’s nowhere near as big as the whole vaccine-autism or anti-climate-science manufactroversies. Being a niche story that not a lot of people know about, it’s a hard one for us to educate journalists on. Be that as it may, I saw just such an example of false balance in the form of a credulous human interest story featuring Burzynski’s cancer quackery in the same way that a lot of stories about autistic children were done ten years ago. It’s a story by Bob Tedeschi and Sheila Kaplan for STAT News (usually a fairly reliable source of medical news but one that’s slipped up recently) entitled “He’s 20. Has brain cancer. And is caught in the crossfire between the FDA and a renegade doctor.” It’s about a very appealing, brave, and unfortunate young man named Neil Fachon:
The dizziness didn’t much worry Neil Fachon. Neither did the double vision. He was recovering from concussions he had sustained while playing sports, and the symptoms weren’t enough to keep him from his engineering classes at Northeastern University in Boston.
Then came some inexplicable struggles with handwriting and swallowing.
Doctors scheduled an MRI. On March 4, his life came unhinged.
If you’re a regular reader of this blog and have read some of my posts about Burzynski, you can guess what’s coming next. Fachon was found to have a brainstem mass that turned out to be diffuse intrinsic pontine glioma (DIPG), a form of brain cancer that’s usually inoperable when discovered because of its connection to the brainstem. Unfortunately, a diagnosis of DIPG is more or less a death sentence, although there are rare long term survivors, contrary to Burzynski’s claim that there are no cases of anyone surviving DIPG in the medical literature—other than some of his patients, of course.
I can only imagine what Fachon and others with the same diagnosis go through, the desperation they feel. From the comfortable “old” age that I’ve achieved, I can’t imagine what it would have been like at that age to face such a fate. I wouldn’t have graduated from college, wouldn’t have become a physician, wouldn’t have gotten married, wouldn’t have become a scientist, wouldn’t have achieved my minor notoriety as a blogger. You get the idea. I can understand why a young man of 20 would want to try anything to have a shot at all those things.
Unfortunately, so does Stanislaw Burzynski.
Burzynski’s been a fairly frequent topic on this blog ever since I really became aware of him in 2011. For details, you can learn all you need about Stanislaw Burzynski from my article in Skeptical Inquirer, “Stanislaw Burzynski: Four Decades of an Unproven Cancer Cure,” and Bob Blaskiewicz’s article “Skeptic Activists Fighting for Burzynski’s Cancer Patients.” There has also been some excellent reporting on Burzynski, including the USA TODAY feature by Liz Szabo, a segment on the long-running BBC News program Panorama, and a recent NEWSWEEK article by Tamar Wilner. Then there’s The Other Burzynski Patient Group, which tells the tales of patients who died after having been taken advantage of by Burzynski. These resources, which show up in Google searches, are part of the reason that to me there’s no excuse for STAT News publishing an article like the one under discussion. There’s so much easily available on the web telling the ugly story of just how Burzynski has operated over the last 40 years and, in particular, since the late 1990s. A simple Google search is all it takes.
Be that as it may, the CliffsNote version of the infuriating saga of Stanislaw Burzynski is as follows. Burzynski is a Polish expat who, by the accounts we can find, was a promising medical student. In 1970, he fled his native country to the US in order to avoid being inducted into the Polish Army as a result of his refusal to join the Communist Party. Arriving with only $20 in his pocket, he stayed with an uncle and eventually got a job doing research at the Baylor College of Medicine, where he became interested in endogenous substances that prevented cancer. During that time, he discovered what he later dubbed “antineoplastons” (ANPs), substances isolated from the blood and urine that appeared to have antitumor activity in cell culture. So far, so good. There was nothing out of the ordinary, and by the mid-1970s Burzynski appeared to be a promising medical researcher. Then something went wrong.
It didn’t take him long to “go rogue” and start treating cancer patients in his private clinic with ANPs, beginning around 1976. Since then he’s been in near-constant battles with medical authorities as he built an empire based on treating the most hopeless cancer patients with ANPs, particularly patients with brain cancer. There were multiple attempts by the Texas Medical Board to remove his medical license. In the 1990s, Burzynski was facing prosecution for insurance fraud, but, as the result of a judge’s ruling, was allowed to continue to use ANPs as long as that use was part of an FDA-sanctioned clinical trial. So, as Burzynski’s then-lawyer Robert Jaffe put it, “If the judge wants clinical trials, we’ll give him clinical trials.” So that’s just what they did. As further described by Jaffe:
The CAN-1 protocol had almost two hundred patients in it and there were at least a dozen different types of cancers being treated. And since all the patients were already on treatment, there could not be any possibility of meaningful data coming out of the so-called clinical trial. It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
As a result:
CAN-1 allowed Burzynski to treat all his existing patients. That solved the patients’ problems, but not the clinic’s. A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future.
That’s basically been Burzynski’s modus operandi since 1997: Enroll desperate cancer patients in his bogus clinical trials and charge them huge “management fees” without charging for the actual drug itself. Thanks to word of mouth and rumor, not to mention two deeply deceptive propaganda films disguised as documentaries by Eric Merola, Burzynski built up quite a following, with dying cancer patients from all over the world wending their way to Houston, often after having raised huge sums of money to pay for the treatment by various means, including celebrity assistance, from kind-hearted individuals. Through it all, he didn’t manage to publish the results of any of his clinical trials until recently, and, not surprisingly, they showed deeply unimpressive results; basically there’s no good evidence, even 40 years after Burzynski started peddling ANPs, that they have significant anticancer activity. Meanwhile, patients who put their hope in Burzynski die just as surely as they would have if they hadn’t.
In the interim, Burzynski grossly abused the clinical trial process, in particular with his deeply unethical practices. Also part of his MO has been to use sympathetic cancer patients as shields whenever the Texas Medical Board, the FDA, or other governmental authorities try to shut him down, having them show up and proclaim either that Burzynski saved their lives or that they will die if Burzynski’s operation is shut down. Because, thanks to the hype and Burzynski’s blandishments, these patients really believe they will die without him, they are very, very convincing. They’re trying the same thing at Burzynski’s ongoing hearing in front of the Texas Medical Board.
It’s an effective technique, too. A few years back, when the death of a six year old child named Josiah Cotto due to severe hypernatremia (too much sodium in the blood, a common sequelae of ANP administration), led the FDA to put a partial clinical hold on Burzynski’s clinical trials, it was in part the lobbying of patients that apparently persuaded the FDA to back down and reinstate Burzynski’s trials.
It doesn’t help that over the years Burzynski patients have been featured in articles like the one by Tedeschi and Kaplan that use the lazy trope of the brave patient fighting the system and doing whatever it takes to gain access to the only therapy that might save his life. (Never mind that in this case it won’t.) We’ve been down this road before with Burzynski many times. The story usually takes a variation of the form used by Tedeschi and Kaplan: A young adult or a child is diagnosed with DIPG or some similarly-deadly cancer. The patient usually (but not always) undergoes conventional therapy that predictably fails, after which the family ultimately finds out about Burzynski. That patient then overcomes all obstacles, be they financial, government interference, or whatever, to reach the Great Man and undergo his magical ANP therapy. In general, the main obstacle is financial, hence the stories of Burzynski patients going to great extremes to raise hundreds of thousands of dollars to obtain ANPs. Examples include Chiane Cloete, whose family was “hoping to raise £130,000 to send her to a US clinic which could be the only chance of saving her life”; Billie Bainbridge, whose family raised hundreds of thousands of pounds and got celebrities involved to seek Burzynski’s care; and Rachel Mackey. All were young. All had families who managed to raise prodigious sums of money to go to the Burzynski Clinic. All died. But before they died, credulous journalists did stories very much like the STAT News story about Neil Fachon, spinning the story as a tragic but hopeful story of a brave young person battling all odds to obtain the one treatment that might save his or her life. It has become such a common trope, stretching back at least 20 years, in stories about Burzynski patients, that four years ago it was referred to as “kind-hearted strangers and the failure of medical journalism.”
Nor is Tedeschi and Kaplan’s story about Fachon by any means the first story about a young person battling for his life but not being allowed to access ANPs because of the FDA. When the FDA placed its first partial clinical hold on Burzynski’s trials in 2013, there was a spate of stories about children with brain cancer who couldn’t access ANPs because of the “cold-hearted” and excessively bureaucratic FDA; e.g., Mackenzie Lowe (complete with video) and Liza Cozad. In Fachon’s case, the obstacle to be overcome is not financial, but the framing of the story is very similar to that of those stories out of the British press. Thanks to the failure of the FDA and Tedeschi and Kaplan’s failure to dig deeper and provide actual context, Fachon’s story is framed as a battle against the FDA using the same sort of frame as advocates of “right to try” legislation do. Worse, they do exactly what reporters did with the vaccine-autism link, “balancing” the story of a very sympathetic, suffering person who believes in an unscientific treatment with the facts and science of the treatment shaded in a way to leave open the plausibility that it might work. Thus, we see statements from Fachon and his family plus claims of evidence of efficacy taken at face value interspersed with statements from scientists about ethics and the lack of evidence for ANPs plus a dispassionate description of Burzynski’s battles against the FDA and Texas Medical Board.
Science and evidence never had a chance.
Yes, the story is factually accurate, but the impression and message it leaves are profoundly misleading. For example:
Despite his record, the Food and Drug Administration authorized Burzynski to run a clinical trial of his treatment on a brain stem tumor. The clinical trial meant the family would not have to pay for the treatment, which can run in the tens of thousands of dollars and is not covered by insurance.
In mid-April, Neil became the one and only patient enrolled.
The Fachon family, who live in East Greenwich, R.I., had read critiques of Burzynski’s treatment on the websites of the National Cancer Institute (which says there’s no known benefit), and Memorial Sloan Kettering Cancer Center (which says it could be useful as a supplemental therapy for breast cancer). They’d read testimony, too, from Burzynki’s [sic] many impassioned, though less credentialed, fans. Neil and his sister, Evie, a senior at Northeastern, had even held a Skype conversation with a woman in Argentina who credited Burzynski with curing her fatal brain tumor.
And:
Everyone was shocked when the FDA abruptly ordered the trial shut down, without making public the reason. The agency reversed course just as abruptly, and just as mysteriously, last week, after the Fachon family filed their lawsuit. A federal court order dated May 27 indicated that the FDA would let Neil Fachon continue his therapy.
“I can’t put into words the stress and the mental trauma that the FDA put us through,” Wendy Fachon said. “How they treated us was absolutely abysmal.”
I understand completely why Ms. Fachon might feel that way. I really do. In reality, what the FDA was doing was to try to protect her son from exploitation by a quack, a con man, to protect him from subjecting himself to risk with no potential for benefit. That’s what the FDA is there to do.
I have actually been meaning to blog about this story for a while, as I did see news reports nearly two weeks ago in which US District Court Judge John J. McConnell, Jr. ruled that the “Defendants [FDA] are restrained and enjoined from interfering with this treatment for Mr. Fachon until a full hearing on a preliminary injunction takes place. The Court finds that there is a likelihood of success on the merits because Mr. Fachon has a liberty interest in continuing to receive a drug addressing his life-threatening disease that the FDA had previously allowed him to receive.” Of course, there is no good evidence that this drug actually addresses the life-threatening disease of Neil Fachon—or anyone else, for that matter. It also strikes me as a very dangerous precedent for a federal judge to overrule an FDA decision, as such rulings are seldom made based on science.
In fairness, though, I can see one point that the judge made, namely this: The reason the FDA shut down Burzynski’s clinical trial in April 2016 was on the basis of an inspection of ANP manufacturing facilities in March 2015, a delay that Judge McConnell characterized as “extraordinarily long and unexplained.” He not unreasonably wondered why the FDA took no action during the 13-month period between the inspection and the placing of a hold on the clinical trial in which Fachon was enrolled. Personally, I, too wonder about that.
As you know, in general I support the FDA. Indeed, I have on occasion written paeans to FDA heroes like Frances Kelsey, who prevented the approval of thalidomide in the early 1960s. I have explained how “right to try” laws are cruel shams of placebo legislation that promise cures to terminally ill patients but deliver, in essence, nothing and are in fact a long game to gut the authority of the FDA in the name of a libertarian ideology. Indeed, given that Texas recently passed its own “right to try” legislation, I’m rather surprised that Burzynski didn’t just administer ANPs to Fachon in Houston under Texas’ new law. There was nothing to stop him. On the other hand, perhaps Burzynski was concerned that his clinical trial being under a clinical hold might have invalidated right-to-try in this case, particularly if he were to do it while his trial in front of the Texas Medical Board was still in progress.
Unfortunately, as much as I’ve defended the FDA, I can’t defend its utter failure to protect the public from Stanislaw Burzynski. It has failed time and time and time again, and it failed yet again in this instance. It’s handling of the Stanislaw Burzynski case has been a travesty. I could (sort of) understand why the FDA backed down in the 1990s. Back then, Burzynski had powerful allies in Congress, such as Rep. Joe Barton (R-Texas), who used his powerful committee chair to torture then FDA Director David Kessler over the FDA’s treatment of Burzynski, complete with the aforementioned political theater of Burzynski patients pleading for their lives; more specifically, pleading for the FDA to let Burzynski continue.
Unfortunately, Neil Fachon’s family is cut from the same cloth. Wendy Fachon, for instance, works for a magazine called Natural Awakenings Rhode Island. I’m familiar with Natural Awakenings. We have our own version called Natural Awakenings Detroit. Basically, it’s a quack magazine. No wonder Neil Fachon was so open to the claims of Stanislaw Burzynski. His mother works for a magazine that basically exists to advertise quackery.
Overall, despite being factually accurate, the STAT News story gives a profoundly misleading impression, namely that there might be benefit due to ANPs and that Burzynski, despite his checkered past, should be allowed to continue. If you don’t believe me, look at the conclusion of Tedeschi and Kaplan’s article, which provides the impression that the authors clearly want to leave you with:
“Especially for kids going through this kind of thing — myself included — it’s something we need to be reminded of, because the whole situation can become so oppressive at times,” he said. “So to have that message of positivity and laughter and love for life … that’s the message I’m trying to bring to people.”
Meanwhile, Wendy Fachon said she is considering supporting legislative initiatives that might help patients in similar situations gain more control over their medical treatment. She has already heard of at least one other child who was blocked by the FDA from joining her son on Burzynski’s trial.
“My heart goes out to those families, because I know what it’s like,” she said.
As for Neil’s future, she said: “We are very optimistic for his recovery. His story can’t end now. I think his story is just beginning.”
Neil agreed.
“I’m feeling pretty good,” he said. “I don’t plan to stop feeling pretty good any time soon.”
Unfortunately, this is almost certainly not true. I realize that it’s not at all unlikely that the family might see this piece, and it gives me no pleasure that they might. No doubt Burzynski supporters will label me insensitive for being blunt, but it needs to be said, because pretending that Burzynski’s ANPs might be giving Fachon a fighting chance, as Tedeschi and Kaplan have done whether they realize it or not, does neither Fachon nor his family any favors. Worse, publishing an article like this potentially does other cancer patients damage by planting the idea that Burzynski might be on to something in their minds. Indeed, the spate of stories about UK patients with brain cancer raising money to come to Houston were the best advertising that Burzynski’s money couldn’t buy. This article is cut from the same cloth.
I stand for cancer patients, and part of that stand is to provide accurate information in as empathetic a manner as I can. Unfortunately, from my perspective, cancer patients are being deceived by Burzynski advocates who cloak Burzynski’s profoundly unethical activities in the mantle of “right to try.” Neil Fachon is a victim. He’s been dealt a horrible hand. Burzynski isn’t going to make it any better. Rather, he’s using Neil Fachon, and unfortunate patients like him, as advertising fodder, in essence victimizing him a second time, after the DIPG made him a victim the first time. Burzynski is also using such patients as weapons in his battle with the government, just as he did in the 1990s. Basically, in structure, this story is no different than the many stories I saw a decade ago that featured for antivaccine parents who blamed their child’s autism on vaccines and, based on that belief, subjected them to all manner of quack treatments. Sure, the denials of scientists were included, but the overall impression left was of brave parents bucking the system and doing anything the thought necessary to cure their children.
In the end, especially given the way that Tedeschi and Kaplan chose to conclude their article, the overall impression left by it is that the FDA was wrong to shut down Burzynski’s clinical trial, that Fachon should be allowed the “right to try” Burzynski’s disproven—that’s right, not unproven, disproven—treatment, and that his struggle could benefit other cancer patients by forcing the FDA to let patients have more access to experimental therapies. It will not, at least not if it prolongs the farce that is the Burzynski Clinic. In fact, it would be a great thing for patients with DIPG if the Burzynski Clinic were to shut down today. Stanislaw Burzynski has had 40 years to prove that his ANPs have anticancer activity. Even given opportunity after opportunity, he’s utterly failed. Tedeschi and Kaplan should realize that, but they didn’t. After all, that wouldn’t be a very uplifting message. It might, however, save new patients from making the same mistake that so many others have.

My Cancer Free Life: A reality series designed to promote Stanislaw Burzynski’s quackery
Stanislaw Burzynski has been selling a dubious treatment known as antineoplastons to desperate cancer patients since the late 1970s. Unfortunately, there are those who are all too willing to promote the myth of a Brave Maverick Doctor who can cure cancer. Several years ago, it was Eric Merola. Now it’s Uchenna Agu, a reality TV star turned producer. He plans on making a reality docuseries featuring patients “cured of cancer” by Burzynski. Worse, local Houston station KHOU-TV promoted his project on its morning show Great Day Houston.
David Gorski on October 15, 2018
Link

When I first encountered Stanislaw Burzynski and the Burzynski Clinic around a decade ago, I didn’t know what to make of him. Sure, he seemed quacky, with all the testimonials of miracle cures and the claims that he cured deadly brain cancers like diffuse intrinsic pontine glioma (DIPG) that conventional oncology could do no more than palliate. Sure, it was rather odd that he had never done a fellowship in oncology or an oncology-related specialty. However, he was a Polish expat who seemingly was an excellent student, and he did have a brief career as a real cancer researcher at Baylor in the early 1970s, during which he discovered the treatment for cancer (or so he thought) that led him to abandon Baylor around 1977 and set up a manufacturing facility to produce the treatment, which he had dubbed antineoplastons, and to administer them to patients, even though antineoplastons were not FDA-approved and for which, at best, Burzynski only had some relatively weak in vitro evidence of anticancer activity, a story I wrote about in detail for Skeptical Inquirer four years ago. Let’s just put it this way: more than forty years later, Burzynski has still failed to produce anything resembling convincing evidence that his antineoplastons are effective against cancer, but that hasn’t stopped him from continuing to charge massive “management fees” that can run into the hundreds of thousands of dollars to administer antineoplastons to desperate cancer patients. Neither have multiple investigations by the FDA and the Texas Medical Board (TMB) driven him out of business. Indeed, the most recent attempt by the Texas Medical Board to shut him down ended a year and a half ago in failure. Despite his having to pay a $360,000 fine and agree to submit to monitoring of his billing practices, to complete a medical ethics course (hilarious!), inform his patients that he owns the pharmacy he requires them to use, and submit his informed consent forms to the TMB for review, he’s still out there attracting desperate cancer patients to his clinic. He even has a local TV station, KHOU-TV, running on its morning show Great Day Houston what is basically an advertisement for a new “reality” series called My Cancer-Free Life, which is being produced by Uchenna Agu and features at least two Burzynski Clinic patients, Bo Edwards and Douglas Kruse, as testimonials for Burzynski’s “miracle cures.”
Here is the segment, which aired last week:
I had so many questions as I watch this eight-minute segment on Great Day Houston. Let’s dig in, but, before I discuss the segment above in depth, let’s first go through a little background regarding Burzynski and the media.
KHOU-TV has a history of promoting Burzynski
The first thing I wanted to know was why a local Houston TV station was promoting Stanislaw Burzynski. I had forgotten about it, but KHOU-TV has a long history of doing puff pieces on the Burzynski Clinic, so much so that Houston Press reporter Craig Malisow has even called them “B-jobs.” For instance, here’s a story from 2009 entitled “Controversial cancer doc: Proof on the way that urine treatment works.” Its tagline? “Every day, cancer patients from all over the U.S. come to Houston for treatment. But some drive right past MD Anderson and head for Dr. Stanislaw Burzynski’s clinic.” It’s a story full of false balance, with Burzynski touting how he’s going to show that his antineoplastons work interspersed with a doctor from the M.D. Anderson Cancer Center saying that there is no evidence that it works. It, too, raised the ire of Malisow, and rightly so. Remember, too, that this was more than thirty years after Burzynski broke away from Baylor and started selling his treatments himself. In 2014, KHOU ran a story about how grateful Stanislaw Burzynski was for having gotten to meet Pope John Paul II in the 1980s and in 1996. Here’s an excerpt:
Burzynski was recommended to the Vatican at a time when the Pope was rumored to be sick with colon cancer. The doctor was known for unconventional treatments, which did not involve surgery or chemotherapy.
“The government wasn’t too nice for my husband s discovery,” said Dr. Barbara Burzynski, Burzynski’s wife.
His treatments called Personalized Cancer Therapy are different from every other doctor. He said they target certain cancer cells to stop them from growing. Government officials and the medical community claimed his methods didn’t work or at least, there wasn’t any proof they did.
“I was being accused of a variety of things which I did not commit,” he said.
Thankfully the pope did not have cancer. But for his willingness to help, Burzynski was blessed with a medal from John Paul’s successor, Pope Benedict XVI, which he feels is a strong endorsement of his techniques.
Yes, this really did happen. Also, let’s just say that the Catholic Church or any other religion should not be trusted as a reliable guide to good medicine.
Also in 2014, KHOU-TV ran this nine-minute segment, “Overcoming cancer with the help of Dr. Burzynski“, which was actually sponsored by the Burzynski Clinic:
This is pure propaganda, basically a brief infomercial for the Burzynski clinic, complete with the host blathering about how other cancer centers are now adopting the methods of the Burzynski Clinic. (More on that later, but for now, I’ll simply call that claim what it is: Nonsense. For example, Burzynski has basically claimed to have invented precision medicine. He did not.) There wasn’t a single bit of misinformation or a single trope in this video segment that I hadn’t heard before. In particular, he claims that he has a 50% five-year survival for brainstem cancers, a claim for which Burzynski has never been able to produce anything resembling convincing evidence. The best evidence he can produce is not that good.
So we know right away that someone high up at KHOU-TV is a believer in Burzynski’s quackery. Since 2016, Great Day Houston‘s producer has been Ralph Garcia, and its executive producer Kathy Richey, which implies it’s someone higher up in the station who’s interested in seeing pro-Burzynski propaganda aired. One wonders if it’s Susan McEldoon, who’s been general manager there since 2007 and will be retiring soon. I couldn’t find any evidence, though. Whatever the situation, it’s clear that KHOU-TV has a thing for Burzynski. Who knows why or who it is who’s responsible?
Who is Uchenna Agu?
I’m guessing that some of my readers recognize the name Uchenna Agu, but I must admit that I had no clue who he was when I first encountered this story. Yes, I was reduced to doing what I always do when I don’t recognize a name: I Googled him. It turns out that Agu’s fame comes from his appearance with his wife Joyce as contestants for The Amazing Race 7 in 2005 (which they apparently won) and later in The Amazing Race All-Stars in 2007. Since I don’t think I’ve watched even a single episode of that show, I had no idea. In any event, he’s also appeared in Push (2014) and Sanitatum (2018). (I know. That didn’t help me either.) Apparently, he’s now a producer and a managing partner at the consulting agency UEA Group.
As for the production companies involved, I noted a couple of interesting things. The blurbs under the story and on the YouTube page suggests Big or Small Media Entertainment LLC (BOSMELLC.com) for more information. Clicking on that link goes to an unclaimed domain and a GoDaddy page. They also mention video from TKGmediaproductions.com, which, it turns out, is owned by someone named Tony Garcia. I can’t help but wonder if he’s related to producer Ralph Garcia in some way.
My Cancer Free Life? It begins.
So let’s get to My Cancer Free Life.
Given that there’s minimal, if any, video footage shown in this segment promoting My Cancer Free Life and I can’t find any with my prodigious Googling skills, I couldn’t help but wonder how early in production this “reality docuseries” is. Usually in cases of a producer, director, or actor doing promotional interviews about his project, he’ll be able to show at least a little footage. True, there is a brief clip at the beginning of the segment of Stanislaw Burzynski himself going on about how when he started it was the “dark ages of cancer treatment”. Whether that was provided by Agu or was stock footage from past KHOU-TV infomercials on Burzynski, I don’t know. It wasn’t revealed. Ditto some footage later in the segment of the Burzynski Clinic. I was impressed at how pedestrian it all looked. In any case, Great Day Houston host Deborah Duncan is next up to introduce the segment, which includes Uchenna Agu and the two Burzynski Clinic patients, Doug Kruse and Bo Edwards.
One thing that became apparent right away is that, unlike a lot of Burzynski Clinic patients, Kruse and Edwards maintain a low social media and Internet profile. Searches for their names plus “cancer” and/or “Stanislaw Burzynski” failed to turn up much other than this segment. Ironically, it turns out that Kruse once did comment on a blog that might be familiar to many of you on a post entitled How is it that in 2018 cancer Stanislaw Burzynski is still preying on desperate cancer patients? (Update). The date of the comment is August 6, 2018:
Dear Doctor. I say again….Hello! I came to Burzynski clinic March 2017 with stage 4 prostate cancer and kidney carcinoma. I responded well to treatment and returned to work at the office in December. This week my CT PET scan results are good and we are concluding treatment. I find several of the comments above blatantly false based on my experiences in being treated meeting with Dr. Burzynski about once a week for over a year. And, I have met in our IV room several who have recovered when standard of care was to go home and die, too. That includes one gentleman from Canada that go over pancreatic cancer as I observed week to week as a co-patient. I have spent the monthly cost for investment and am happy with the results noted. Request: Would you please increase the respectful part of your dialogue? Including complying with your own guidelines for comments and eliminating some of the abusive vocabulary, please. Respectfully, Douglas Kruse Jr. Houston, TX.
Clearly, there’s not much in this comment to help me understand his testimonial other than that Mr. Kruse has stage IV prostate cancer and kidney cancer. It’s not clear if he has both prostate and kidney cancer (which would be very unusual) or prostate cancer that’s metastasized to the kidney (less uncommon). I’ll discuss him more later on based on what he says on this KHOU-TV segment. As for Bo Edwards, I could find basically nothing about him other than links to the KHOU-TV segment. Searches on Facebook and Twitter didn’t yield anything either. It’s almost as though these patients were chosen for how little information about them is publicly available on Facebook, Twitter, YouTube, and various websites, even pro-Burzynski websites.
My Cancer Free Life? The propaganda is thick.
After we see Burzynski’s smiling face going on about how the sequencing of the human genome was the milestone that revolutionized cancer treatment, Great Day Houston host Deborah Duncan reads an introduction that will make anyone familiar with Stanislaw Burzynski’s four decade scam cringe, so much so that I wondered if Burzynski himself had written it. She basically recounts that Burzynski discovered a gene-targeted cancer therapy back in the 1970s. This is, of course, ridiculous. Contrary to the hagiography of Eric Merola’s two propaganda movies about Burzynski, Burzynski The Movie: Cancer Is A Serious Business and Burzynski: Cancer Is A Serious Business, Part 2, in which it is claimed that Burzynski is a pioneer of “gene-targeted cancer therapy,” Burzynski’s two go-to treatments include the unproven and likely ineffective (antineoplastons) and the “make it up as you go along” (his “gene-targeted therapy“).
Particularly risible have been Burzynski’s arrogant, ego-fueled claims (mindlessly repeated on this segment) that he first described “gene-targeted therapy” and that he invented precision oncology, with major cancer centers like M.D. Anderson only now catching up to his vision. (I first saw this claim in Suzanne Somer’s quackfest of a book, Knockout: Interviews With Doctors Who Are Curing Cancer And How To Prevent Getting It in the First Place.) It’s a message parroted both by Duncan and Agu in this segment, and it’s simply not true. Burzynski is not a “pioneer” in personalized gene-targeted cancer therapy and never has been. He is most definitely not a pioneer in immunotherapy either, contrary to Agu’s assertion. That the segment starts out with a message painting Burzynski as a scientist ahead of his time tells me that what I’m seeing is propaganda far more than journalism and that Agu’s docuseries will apparently preach this message tells me that Agu is more akin to Eric Merola than to a serious producer, at least when it comes to Burzynski. Let’s just put it this way. If Burzynski had never been born, major cancer centers would be embracing precision medicine and immunotherapy now in exactly the same way, mainly because Burzynski has had zero positive effect on oncology.
When the camera pans out to show all the guests for the first time, my first reaction upon seeing Bo Edwards was that he looks very, very sick. Inexplicably, his whole right arm is bandaged with and he has a catheter in place that is hooked up to a black bag that he’s carrying. It makes me wonder if he’s getting a continuous infusion of antineoplastons. In any event, he looks gaunt, and there’s something funny about how his loose shirt sits on his bandaged right arm. Certainly, he does not look the way that Agu describes him (and Kruse), “cured of cancer”.
In any event, we learn from Bo Edwards that the reason he went to the Burzynski Clinic after being diagnosed with stage IV cancer (type not yet specified) was because a friend of his wife with stage IV cancer (type not specified) had gone there 18 years ago and was cured. In any event, he was told that he could have chemotherapy (which probably wouldn’t work); he could have radiation (which would likely only prolong his life marginally); or he could have radical surgery that would involve removing his arm, shoulder, and part of his upper chest. When I heard this, all I could think of was forequarter amputation, the same operation recommended to Jessica Ainscough, whose promotion of “holistic health” and alternative medicine led her to be known in Australia as the Wellness Warrior. She ultimately died of her disease after a very prolonged course, but what had frightened her from conventional treatment was the prospect of a forequarter amputation, a brutal operation that is rarely performed these days. Seeing Edwards’ bandaged arm and hearing the recommendation that he have what sure sounded like a forequarter amputation, made me wonder if he has what Ainscough had, epithelioid sarcoma. In any event, the fact that he was offered such radical surgery suggested to me that he has some sort of sarcoma involving his upper arm and that he doesn’t have metastases to distant organs. If he did, there’s no way such radical surgery would even be considered.
So when was Bo Edwards diagnosed? It turns out that it wasn’t that long ago. He was given the three options, according to his story, in January 2018, only nine months ago. That’s an awfully short time to be declared cured of any cancer. We’re also shown zero evidence that Edwards is, in fact, cancer-free, as he claims. If he were cancer-free, I wonder, why is his arm bandaged and why is he still hooked up to an infusion device? As Edwards finished telling his story, I couldn’t help but feel a wave of sorrow and empathy for him. He really believes he’s been cured, and I hope he is, but everything about his story suggests otherwise and that he’s just been fortunate thus far. I also couldn’t help but notice that the Great Day Houston bug always seemed to be sitting over Edwards’ other arm, where the infusion catheter was inserted under a bandage.
Mr. Kruse recounted his story next, and it was much as what you read in his comment cited above. He was diagnosed in March 2017. According to him, his wife took him to the emergency room then because his “system shut down” and he had high blood pressure. From the sound of it, he had prostate cancer metastatic to kidney and bone. He added that he was told that he should just go home and grieve with his family. Now, I suppose that’s entirely possible, but it sounds a bit hard to believe. For one thing, prostate cancer, even metastatic prostate cancer, tends to be a slow-growing disease; it’s not that surprising that someone with stage IV prostate cancer could be alive a year and a half after diagnosis. For another thing, treatments for prostate cancer have improved markedly since I was in medical school and residency. At a decent cancer hospital (and, let’s not forget that M.D. Anderson is located in Houston), a patient with stage IV prostate cancer will be told that his disease is indeed incurable, but won’t just be punted home as Edwards described. He’ll be told that we have treatments that can slow down the progression of the disease and that he could have years left.
In fairness, I don’t know the full extent of Kruse’s disease. He didn’t say, either in the blog comment above or on this segment on KHOU-TV. However, whenever I hear a story like his I wonder whether there was a misunderstanding of his prognosis or whether he went to a crappy hospital that doesn’t do a lot of oncology. Again, I have no way of knowing from what I see here. In any event, Kruse’s wife and daughter persuaded him to go to the Burzynski Clinic.
What does Burzynski do differently?
The final part of the segment began with Duncan asking Agu, “What does Dr. Burzynski do differently?” The answer told me just how deep the propaganda will be in this docuseries. I also wasn’t too thrilled to see Agu invoke “right-to-try”. After all, right-to-try is a scam designed to weaken the FDA, and Burzynski has been using it to get around the FDA. Agu then says that there is a DNA test that each patient must take before getting into the Burzynski Clinic and “if you fall within that window, you’re golden.” At this point I was shaking my head and wondering just what the heck Agu was talking about. He seemed to be implying that there was a small “window of opportunity” during which a patient can benefit from Burzynski’s treatments. Given that Burzynski appears to specialize in extracting cash from patients who have advanced cancer, this statement makes little sense.
Duncan also pitched another slow, hanging ball right over the plate by asking, “Why isn’t every treatment facility doing it this way?” If I were on the show, I’d have answered that the reason is simple. Burzynski has never shown anything resembling compelling evidence that his approach works better than what we do now—or even that it works at all. Agu, of course, regurgitated an answer right out of the quackery defense league’s manual about how cancer doctors have developed a “standard way” of treating cancer over the years such that “everyone is ‘this is the way we do it’ and it doesn’t open the door to alternative treatment.” In other words, it’s the same ol’ same ol’. Doctors are too close-minded. Doctors can’t tolerate the competition. Doctors won’t try anything different. He then went on to say that doctors should be referring to Burzynski “on the front end” after a DNA test to see if the patient “fits” (whatever that means).
Apparently, the docuseries won’t just be about Burzynski, either, although clearly it looks as though Burzynski will be a major focus. Agu says he’ll also look at patients who have chosen conventional therapy and other alternative therapies. Anyone want to guess how well the ones who choose conventional therapy will do? I’m sure the selection will not be random. After all, Edwards and Kruse were given the opportunity to have almost the last word, which they took to go on about how Burzynski’s given them hope. Unfortunately, I know otherwise. I know Burzynski. I’ve examined more testimonials by patients of his than I can remember, many of them analyzed right here on this blog. My friend Bob Blaskiewicz, who runs The Other Burzynski Patient Group, has done likewise. Basically, Burzynski’s patients all pay tens or hundreds of thousands of dollars to be treated, often under sham clinical trials designed solely to let Burzynski avoid FDA actions. There is no good evidence that they do better than they would have done without Burzynski.
Conclusion: More Brave Maverick Doctor hagiography
I can’t help but note how vague Edwards’ and Kruse’s testimonials were. There’s so little information provided that I have a hard time figuring out what is going on with them (particularly Edwards with his right arm). I do know, however, that their stories fall into the classic format of alternative cancer cure testimonials, complete with their being told to “go home and die” (as many quacks like to characterize what doctors tell patients with incurable cancer) and then finding the Brave Maverick Doctor Burzynski. It sounds very much as though Agu’s project will end up being much more hagiography than even reality TV or video. Of course, anyone who pays much attention to reality TV should know by now that reality shows are anything but reality and that most are pretty heavily scripted. At the very least, the contestants or characters are very carefully chosen by the producers to fit the demands of the show, whatever they are, humor, conflict, entertainment, or a specific message.
I wish Edward Kruse and Bo Edwards nothing but the best and truly hope that they are the exceptions, rather than the rule, when it comes to Burzynski patients. I also hope that Burzynski doesn’t bankrupt them both before their cancers recur or advance. As for Uchenna Agu, I would urge him to read all the stories on The Other Burzynski Patient Group and to read up about Burzynski’s abuses of clinical trial ethics and selling of cancer quackery for forty years right here. Maybe he’s not beyond hope, even if KHOU-TV in Houston appears to be beyond hope when it comes to shilling for Burzynski. The producers of Great Day Houston and the management of the station should know better, given that they’re in the same city as he is. Unfortunately, in Texas, Burzynski has juice.

Dr. Stanislaw Burzynski’s cancer “success” stories
David Gorski on February 18, 2013
Link
The year 2012 was rung out and the year 2013 will be rung in by news that Eric Merola, propagandist for “brave maverick doctor” Stanislaw Burzynski who claims to have developed a cancer treatment far superior to current conventional science- and evidence-based cancer treatments, is releasing releasing a sequel to his wildly successful documentary (in the “alternative cancer” underground, that is) Burzynski The Movie: Cancer Is Serious Business. In fact, the sequel is coming out on DVD on March 5, and you can even preorder it now. I somehow doubt that Eric Merola will send me a screener DVD to review, but I did review the first movie because it easily falls into a genre that I like to refer to as medical propaganda movies, which are almost always made in support of dubious medical treatments. My mostly lame jokes about proposed titles aside (e.g., Burzynski II: Electric Boogaloo, Burzynski II: This Time It’s Peer-Reviewed, or even Burzynski II: Quack Harder), it’s very clear that in the wake of the Texas Medical Board’s decision to drop its case against Burzynski on a technicality, Burzynski and his very own Leni Riefenstahl named Eric Merola are planning on a huge publicity blitz, in which Burzynski will be portrayed as, yes, a “brave maverick doctor” whom “They” (as in the FDA, drug companies, and the Texas Medical Board, a.k.a “The Man”) tried to keep down but failed because he has The Natural Cure For Cancer “They” Don’t Want You Sheeple To Know About.
I come back to this again because Merola’s strategy for Burzynski II, as I pointed out, is going to involve “conversion stories” of oncologists who didn’t believe in Burzynski’s magic antineoplastons but do now, attacks on skeptics who have been critical of his work (like me), and, of course, testimonials for success stories. I don’t know how I missed this before, but what exactly that will mean in practice is actually spelled out pretty well in an installment of a video blog by a Burzynski patient named Hannah Bradley. Bradley became famous for her battle against a malignant brain tumor, her decision to go to the Burzynski Clinic, and the prodigious fundraising efforts of her partner Pete Cohen through their Team Hannah website and vlog. In this vlog, recorded on September 7, 2012, Pete and Hannah are happy because in their previous vlog of July 27, 2012, they reported that, after having received Dr. Burzynski’s antineoplaston treatment Hannah has had a “complete response,” and indeed the MRI scans shown in their movie, Hannah’s Anecdote, do appear to show just that (more on that later).

We then meet Eric Merola himself:
From the banter between Eric Merola, Pete Cohen, and Hannah Bradley, we learn that Hannah decided to go to the Burzynski Clinic after seeing the first Burzynski movie. We also learn that Hannah is going to feature very prominently in Merola’s sequel as a success story. Indeed, from this video, and the trailers on the Burzynski Movie website. It’s fairly clear how Burzynski II will be constructed, particularly if you look at the latest trailer, released just yesterday:
Taking the previous trailer and this one together, along with Merola’s appearance on Hannah and Pete’s vlog, I know that Burzynski II will likely consist of four elements:
    • Testimonials (or anecdotes), including Hannah’s, of “success stories” coupled with the aforementioned “conversion stories” of oncologists who have become Burzynski believers. These will be contrasted with a rehash of conspiracy theories from the first movie about the “cancer establishment” trying to suppress Burzynski because he is a threat to their profits. Never mind that, even if Burzynski’s antineoplastons were FDA-approved, they would be in the same class as the chemotherapies that are disdained in the trailer as being more for profit than anything else because they have to be given for a long time. One notes that Burzynski’s protocol requires at least 18 months of near-continuous infusion of high doses of his antineoplastons.
    • Attacks on skeptics and critics of Burzynski. If you don’t believe me, just read question #12 in Merola’s FAQ, in which he states, “You will notice the ‘anti-Burzynski’ bloggers refuse to do that or adhere to reputable sources. You might say, they are preying on desperate cancer patients and families of cancer patients by carelessly misleading their readers about Burzynski and his invention.” One marvels at Merola’s amazing level of projection. However, every movie needs a villain, and it doesn’t take psychic abilities to guess whom Merola will portray as villains. Certainly, villains will include the usual suspects, such as the FDA, the Texas Medical Board, and big pharma, but, particularly in light of the scene of Hannah crying at her treatment by “skeptics” who think Burzynski is a charlatan, I’m guessing that I’m going to be part of the group that, according to the trailer, was “formed to terrorize and misinform the patients,” along with Bob Blaskiewicz, Josephine Jones, Keir Liddle, and other bloggers critical of Burzynski. Merola also direly accuses and threatens, “In the worst case scenarios, some bloggers intentionally publish fabricated information to their readers in an attempt to curb new patients from going to the Burzynski Clinic. These individuals are also responsible for ‘gate keeping’ the Wikipedia Page on The Burzynski Clinic. This issue, as well as the identities of those involved, will be covered in great length in the new 2013 ‘Chapter 2’ documentary.” I can hardly wait. Neither can, I bet, a fair number of lawyers.
    • An attempt to reframe Burzynski’s enormous bills for his antineoplaston therapy and criticism that he’s making clinical trial subjects pay to be in his clinical trials. The new claim is that Burzynski isn’t making patients pay for his antineoplastons (see question #13 in Merola’s FAQ), just for “clinical management” (as if that weren’t incredibly transparent)
    • Vindication. A prominent mention of a supposed randomized clinical trial out of Japan plays prominently, but one wonders why these investigators appeared in Burzynski’s movie before they had published their results.
The last time I discussed Merola’s forthcoming movie, I mentioned that he had contacted me in December and asked me to appear as a Burzynski critic. After consultation with skeptics with more media savvy than I, not to mention the PR department at the Barbara Ann Karmanos Cancer Institute (whom I thought it wise to give fair warning that one of their faculty might be featured as evil incarnate in a new documentary and to give the background on what it’s all about, in case there were press inquiries), I politely declined. However, from the video above, it is very clear how I and other skeptics will be attacked. While going on and on about how he thinks most of us have “good motives” and how we want to be the white knight riding in to save patients from quackery (a desire he somehow manages to convey with clear dismissiveness and contempt), Merola turns immediately around to claim that we don’t know what we’re talking about and we don’t read the literature. This, of course, is complete nonsense, as I’ve read many of Burzynski’s papers (such as they are), delved into ClinicalTrials.gov to look at his clinical trials, examined the plausibility of his claims from a scientific standpoint, and examined the literature from others, both on antineoplastons and related topics. I’ve dissected Burzynski’s claims for antineoplastons based on science, assessed his “personalized, gene-targeted cancer therapy” claims and found them wanting, and pointed out how what he is peddling isn’t really anything new at all (more on that later), all based on my knowledge, skills, and understanding of cancer as a breast cancer surgeon and researcher. No doubt that’s why Merola needs to discredit me. Other bloggers who have been critical of Burzynski might or might not have my scientific background, but they’ve delved just as deeply into his claims and the evidence for them, and, as I have, they’ve found them highly overinflated and largely not based in science. They’ve also taken on aspects of the Burzynski phenomenon, such what I consider to be his questionable ethics and finding out what happened to a lot of patients who trusted Burzynski, far better than I have. Merola’s dismissal of Burzynski’s critics is, quite frankly, insulting to them and to me.
Merola also makes the unfounded claim that many of the bloggers critical of Burzynski are in the pay of big pharma or work for blogs that are in the pay of big pharma. I know exactly where he got that one from, at least with respect to me; so I’ll deal with it briefly right here and right now. I don’t know what sort of attacks on the UK bloggers who produce the bulk of the skeptical blog posts about Burzynski are coming in Burzynski II, but when it comes to me no doubt Merola is referring to this bit of yellow journalism in 2010 from an antivaccine propagandist named Jake Crosby, entitled David Gorski’s Financial Pharma Ties: What He Didn’t Tell You. The long version of why Crosby’s hit piece is without merit consists of two posts I wrote at the time, here and here. The short version follows. Crosby’s entire chain of logic can be summarized in a brief, blisteringly dumb thesis: My university (Wayne State University) has received grants from Sanofi-Aventis. I also work on the repurposing of a drug originally used to treat amyotropic lateral sclerosis that has anticancer properties that apparently Sanofi-Aventis markets. Even though I haven’t received a penny from Sanofi-Aventis to work on that drug, Crosby inferred that because my university apparently got a significant grant from Sanofi-Aventis my working on that particular drug must indicate a quid pro quo. (Never mind that I didn’t even know my university had gotten any funding from Sanofi-Aventis). Add a bit of conspiracy mongering and antivaccine pseudoscience blaming Sanofi-Aventis vaccines for the “autism epidemic” and how through my blogging I’m very much involved in countering such antivaccine misinformation, throw in a dash of Crosby’s paranoia, and the conspiracy theory writes itself. In any case, in the interests of complete transparency, let me just briefly state that I did once get a Bayer Healthcare Grants4Targets grant of €30,000 for one year, but that ended in 2012. That might sound like a lot, but it wasn’t even enough to pay the full salary and benefits of my postdoc for a year. Finally, I fully expect that my not-so-secret other blog will also come under fire for accepting pharmaceutical company advertisements and that that will also come into play in Merola’s movie. We won’t have long to wait to find out, unfortunately.
Predictable and tiresome attacks aside, Pete and Hannah’s video made me curious about the specific success stories that Merola will focus on as “proof” that Burzynski is on to something; so I decided I should look into their stories. Merola mentioned how he had been looking for patients before they even went to the Burzynski Clinic and even pointed out Amelia Saunders as one. Last year, Burzynski apologists frequently pointed to Amelia as a success story but, very sadly, her family saw her tumor begin to progress again in December, ultimately resulting in her death about a month and a half ago. In the process, Burzynski did what he all too often does and misinterpreted her MRI, in which cystic structures commonly seen in Amelia’s form of cancer as it progresses were seen, as evidence that her tumor was regressing. They were not. So let’s take a look at two cases frequently pointed out to me as Burzynski success stories: Laura Hymas (whose website is Hope for Laura) and the aforementioned Hannah Bradley (whose website is Team Hannah). On the surface to those not familiar with cancer they do look like success stories. If one digs deeper, the true story is a lot murkier. More importantly, as I will show, even if they really are success stories—which is not at all clear—they do not constitute convincing evidence of the general efficacy of Burzynski’s antineoplastons, nor do they justify what I consider to be Burzynski’s highly unethical behavior.
Go Team Hannah!
I will start with Hannah Bradley’s story because I’ve watched the entire 40 minute video Hannah’s Anecdote (whose title is even more appropriate than perhaps Pete Cohen imagined when he made it). The documentary ends triumphantly several months after the events portrayed during the bulk of the film with Hannah apparently having had a complete response to Burzynski’s antineoplaston therapy:
Let me just first say something before I begin my usual analysis. I love these two. I really do. They are the cutest couple, and their love for each other oozes from the video and envelopes the viewer, sucking him in like The Blob, but in a good way. The same is true of every video of them I’ve watched on their video blog. Yes, it’s true that Pete can be a bit annoying with his seeming desire to videotape everything, but I want Pete and Hannah to be able to live a long and full life together, growing old in each other’s company. I really do. In fact, I’d love to hang with these two and maybe buy them a pint or two at their local pub (except that it’s pointed out multiple times that Hannah can no longer drink alcohol). Sadly, this is unlikely ever to pass even if Hannah does completely beat her disease and is still around the next time I make it to London (which is likely to be at least a year or two), because I fear that if they see this (which is likely) they will misinterpret my analysis as trying to destroy their hope. Certainly the families of other cancer patients who have gone the “alternative” route, be it Burzynski’s treatment or other “alternative” cancer therapy, have attacked me in that way. Such is not my intent, but what are skeptics supposed to do? Shy away from undertaking a dispassionate analysis of patient anecdotes used to promote dubious cancer therapies for fear of what patients will say?
After talking about how he needed to raise £200,000 in order to take Hannah Bradley to the Burzynski Clinic for what he characterizes as “life-saving” treatment, a campaign that produced media coverage in the form of articles with titles like ‘I’ll try anything to beat brain cancer’, Pete Cohen describes Hannah’s diagnosis, and elsewhere we find out that Hannah underwent awake brain surgery as the surgeons tried to remove all the tumor:
I first met Hannah in April 2010 and we fell in love and since then our relationship has gone from strength to strength. Hannah is 28, has a great personality and has a fantastic sense of humour. Our world took a dramatic turn in February 2011 when, out of the blue, Hannah had a major seizure in the middle of the night. She lost consciousness and was rushed to hospital.
Hannah does not remember much about the two months that followed as she had constant headaches and a number of seizures. She was diagnosed with a very serious brain tumour called Anaplastic Astrocytoma. Hannah decided to have surgery and the 1st of April 2011 and underwent a six and a half hour operation. She was awake for nearly three hours of this operation.
The operation was a success and they managed to remove nearly all of the tumour. We had to wait for the results of the biopsy for a few weeks and we remained positive. However, the news was not good and our world was rocked once more as the results showed a Grade III tumour. Hannah’s bravery and resolve once again rose up as shortly after this she started a six week course of radiotherapy. This went well for the first few weeks but was followed by Hannah’s hair falling out and bouts of tiredness and lethargy.
On top of all of this, Hannah has been dealing with losing her driving licence as she has had a number of seizures and now has epilepsy.
Six weeks after the radiotherapy finished, Hannah had another MRI to see what was going on with the tumour, Once again more bad news, as there were still remnants of this aggressive tumour.
Hannah’s treatment options are very limited and her life expectancy is for this type of tumour is normally around 18 months and this is why I started a mission to find people who had the same condition and are still alive today. I managed to track down a number of these people to speak to them.
In his movie, Pete points out that these people all led back to Burzynski. Of course, as I’ve said before, dead patients don’t produce testimonials for alternative cancer cures. More importantly, Burzynski has a network of true believers, such as the Burzynski Patient Group and a filmmaker like Eric Merola, all of whom actively promote the Burzynski Clinic online. Add to that Suzanne Somers, who included Burzynski as one of her “doctors who are curing cancer” in her book Knockout: Interviews with Doctors Who Are Curing Cancer and How To Avoid Getting It in the First Place. Indeed, Chapter 7 is all about Burzynski, whom Somers describes as having invented “the most important and successful non-FDA-approved alternative cancer drug therapy ever in this country.”
In any case, that was the end of July 2011. By November 2011, Pete had raised £35,000, which was enough to go to Houston, and that’s where his documentary begins, as he and Hannah are preparing to fly to Houston in December 2011 to have a consultation at the Burzynski Clinic. These are interspersed with footage from earlier in which the couple document their quest, talk about how they were warned by their oncologists and other doctors not to waste their money and effort, and talk about their hopes. Not long after they appear at the Burzynski Clinic, they meet with doctors there who tell them that Hannah’s most recent MRI scan showed progression of her tumor (around 8:30 in the movie). Now, I’m not a radiologist, much less a neuroradiologist, but I wondered at all the enhancement on the superficial area of the brain, just under where her neurosurgeon must have raised the bone flap to remove what he could of the tumor. One wonders if much of the remaining enhancement could be still post-surgical and post-radiation change. Certainly, the tumor is cystic-appearing, and after surgery such cysts would likely shrink and be reabsorbed even if the tumor were to keep growing.
Be that as it may, there were a number of things I found very interesting in this video. First, one notes that patients don’t see the great Dr. Burzynski right away. Underlings see them first and commence treatment, assuring the patient that Dr. Burzynski is aware of what they are planning. Second, I’m not particularly impressed with the sterile technique used for putting her Hickman catheter in, nor am I particularly impressed with the sterile technique used to access it by the nurses, who appear to be rather inconsistent about wearing gloves and a mask when accessing the line.
As important as sterile technique is when inserting and accessing long-term indwelling catheters, these complaints are quibbles compared to what this video shows about antineoplaston therapy. First, I notice that nowhere was there anything mentioned about enrolling Hannah on a clinical trial. Remember, part of the consent agreement with the Texas Attorney General back in the late 1990s stated that Burzynski can distribute “antineoplastons” only to patients enrolled in FDA-approved clinical trials, unless or until the FDA approves his drugs for sale. Given what a thorough videographer Pete Cohen obviously is, I find this omission very curious. Certainly, given how much detail he’s used in this video and in his vlogs I’d expect that if the subject of clinical trials was mentioned he would have included it.
The other thing that struck me was just how much Burzynski is full of it when he advertises antineoplastons as not being chemotherapy and, more importantly, as being nontoxic. At least a third of the video consisted of the difficulties that Hannah had with her treatment, including high fevers, a trip to the emergency room, and multiple times when the antineoplaston treatment was stopped. She routinely developed fevers to 102° F, and in one scene her fever reached 103.9° F. She felt miserable, nauseated and weak. I’ve seen chemotherapy patients suffer less. I was also very puzzled at how the Burzynski Clinic could allow a cancer patient to linger with a fever of 102° F and sometimes higher, accompanied by shaking chills, in a temporary lodging without admitting her to the hospital. It’s not clear what sort of workup was done to evaluate Hannah either, what her white blood cell count was, or what her other labs were. Did they draw blood cultures? Did they get urinalyses and cultures? Did they do chest X-rays to rule out pneumonia? It’s all very unclear, other than that she apparently was given some antibiotics at some point. Did she have the flu, given her flu-like symptoms, or was this due to her antineoplaston therapy? The reaction of the clinic staff (i.e., rather blasé, even though at one point Hannah clearly demonstrates a change in mental status, appearing “drunk” and complaining of double-vision) made me wonder if this sort of problem was a common occurrence. At another point, Pete and Hannah come to believe that the fevers might have been due to the tumor breaking down, which strikes me as implausible. Later, she develops an extensive rash. It’s difficult to tell for sure what it is at the resolution of the video, but it looks like erythema multiforme, which is generally an allergic rash. What’s the most likely cause of such a rash? Guess. Erythema multiforme is usually a drug reaction.
Near the end of the video, we see a series of MRIs. Hannah and Pete are told that the first MRI, done about a month after the antineoplaston therapy started, shows that the tumor has decreased in enhancement and size, with a decrease of about 10%. I don’t know who this person is at the Houston Medical Imaging facility just up the road from the Burzynski Clinic is, but from what I could see it isn’t clear at all that the tumor decreased in size by 10%. In fact, it’s rather hard to tell if a tumor has decreased in size at all. With a tumor that size detecting a 10% decrease in size is almost within the margin of error of the test. Even Burzynski didn’t try to sell this as a true decrease; he called it stable disease, which is what it was:
However, later in the video, there are more convincing MRIs. Indeed, the MRI dated July 29, 2012 looks quite good, with little or no enhancement left. The question, of course, is: Does this mean that Burzynski’s antineoplaston treatment worked for Hannah? Sadly, the answer is: Not necessarily. It might have. It might not have. Why do I say this? First, she didn’t have much residual disease after surgery and radiotherapy, and in fact it’s hard to tell how much is tumor and how much is postop and radiation effect. Second, the median survival for anaplastic astrocytoma (which is a form of glioma) is around 2 to 3 years, and with different types of radiation therapy five year survival is around 15% or even higher. Thus, long term survival for patients with astrocytomas is not so rare that Hannah’s survival is so unlikely that the most reasonable assumption has to be that it was Burzynski’s treatment that saved her. More likely, Hannah is a fortunate outlier, although it’s hard for me to say even that because, at only two years out from her initial diagnosis, she’s only just reached the lower end of the range of reported median survival times for her disease.
I’m also very worried about Hannah. Her last couple of vlogs are the reason. For instance, in her vlog of December 2, 2012, in marked contrast to past vlogs, Pete is noticeably evasive when discussing her latest scan, and both Pete and Hannah appear uncomfortable:
Even more worrisome was a cryptic Facebook post from November 1, 2012:
It’s been a long time coming but here is our new Team Hannah Blog. I am sorry we don’t have the best of news but I am ok. http://www.teamhannah.com/2012/11/01/team-hannah-blog-011112/
The vlog entry referenced no longer exists. Then there was Hannah and Pete’s Christmas message:
In this vlog, Hannah and Pete are even more evasive than before, using vague terms about having had a “little blip” and saying that the latest scan showed that the treatment was working, almost as though they were trying to convince themselves that this was so. Particularly noticeable is the lack of new scans being shown on the Team Hannah Facebook page. The last scan shown was from August 27, 2012. Up until that point, Peter was religiously posting Hannah’s new scans and (quite understandably) exulting over the lack of visible tumor mass. All of this is why I really, really fear something bad has happened. I hope I’m wrong. Assuming that I am wrong, however, a single case tells us very little. Will the second case that I know that Merola will exploit tell us more? Let’s find out.
Is there Hope for Laura?
The other Burzynski success story that Burzynski supporters dare us to take on is that of Laura Hymas, whose website Hope for Laura. Her story is described on her website thusly:
Laura was diagnosed with an Oligodendroglioma, which is a rare brain cancer and in the UK there is no cure. The tumour goes deep into the brain and is in a location that is inoperable so our doctors applied a “watch and wait” approach which is standard for this type of cancer where you have a scan every three months to see if anything changes rather than applying treatment. However we recently had worse news in April 2011 Lauras MRI scan revealed growth and changes, she had a biopsy and we learnt that the tumour had progressed into a Glioblastoma Multiforme which is the most agressive type of brain cancer with a much poorer prognosis.
Many aspects of Laura’s story are similar to Hannah’s story, but one thing is different in that she started out with a less aggressive tumor, which was managed by “watchful waiting” for a time, until the tumor progressed. More details can be found at her page on the Burzynski Patient Group website. Laura started having more seizures; she was unable to care for her son; she felt as though her “life was slipping away,” and so it appeared to be. Then, like Hannah, she decided to go to Houston to the Burzynski Clinic, and like Hannah and Pete Laura and her fiance started raising money, succeeding in raising £100,000 in just a few weeks from donations. What happened next is described here:
I have now been on antineoplaston therapy since the 8th August 2011. The side effects I have suffered are tiredness, a skin rash which subsided after a few days when I began treatment and a severe thirst! The medicine is rich in sodium and I have to infuse 2 litres of it daily (a dose which lasts 90 minutes every 4 hours 24/7) so I drink approx 5 litres of water daily. This is a very full on treatment; it isn’t making me feel ill but while the pump is running it does affect my day to day decisions like for example going shopping or Ben is driving us to see family far away I need water to drink and a toilet close by! I am carrying around an infusion pump all day connected to my Hickman line in my chest. It’s like having another baby!
To be honest though, for me it’s really worth it. I won’t be connected to the medicine pump forever! I have an MRI scan at a private hospital every 6 weeks. When we came home in August it took me until the middle of October to slowly increase my antineoplaston dose up to “maintenance dose” – this is the dose that Dr Burzynski deems is most effective for my body weight.
Then six weeks later on the 29th November 2011 scan my tumour started shrinking, by 36%. On the 10th January 2012 I had another scan – 56% tumour decrease!
I just had a scan on the 21st February and it was even better news – 77% tumour decrease!
As of August 2012 there is now no trace of my Tumor at all. I always get a second opinion from a UK radiologist who confirms there is just a cavity left which should resolve over time.
So is Laura’s case proof that there’s something to Burzynski’s treatments? Is the fact that Burzynski has apparently discharged Laura as a patient slam-dunk evidence that Burzynski has cured her of her incurable tumor? Sadly, no.
For one thing, late complete responses to radiation are not as rare as Burzynski supporters imply, as described in this Medscape article on glioblastoma:
The responsiveness of glioblastoma multiformes to radiotherapy varies. In many instances, radiotherapy can induce a phase of remission, often marked with stability or regression of neurologic deficits as well as diminution in the size of the contrast-enhancing mass. Unfortunately, any period of response is short-lived because the tumor typically recurs within 1 year, resulting in further clinical deterioration and the appearance of an expansile region of contrast enhancement
Moreover, complete remissions in glioblastoma do occur. They’re very uncommon—rare, even—but they do occur. There are case reports in the literature, such as this one, and a recent series describes the outcomes of long-term glioblastoma survivors as rare, but increasingly common. The bottom line is that we don’t know why Laura is still alive. It’s possible that it was the antineoplastons; it’s possible that it was the radiation therapy alone.
Moreover, discharging a patient after her treatment for cancer is complete is something real oncologists almost never do right away. They usually follow their patients, often for five years, sometimes even longer. At this point, Laura is less than six months out from the first MRI scan showing no residual tumor, and she only just finished her antineoplaston therapy. Next, keeping an open mind I will admit that Laura’s case is more suggestive of an antitumor effect due to antineoplaston therapy than Hannah’s case is. What I find curious is the delayed effect. Laura started her therapy on August 8, 2011 but it was not until nearly four months later that the tumor showed evidence of shrinking. That’s a long time for an active therapy to start to work, particularly for a tumor that is as aggressive as a glioblastoma. It’s possible, but in general, even if antineoplastons really saved Laura, a treatment that takes three or four months to kick in is generally not that enthusiastically embraced by oncologists. Basically, Laura Hymas’ case seems a bit more consistent with an antitumor effect due to antineoplastons than Hannah Bradley’s case, but it is only a single case.
So what might be going on here?
Antineoplastons versus sodium phenylbutyrate
Back in late 2011, when I first took a serious interest in Stanislaw Burzynski and what he’s been doing, I wrote a three-part series in which I (1) analyzed Burzynski The Movie, its claims, and whether there was any evidence that antineoplastons do anything for cancer; (2) discussed why Burzynski’s claims that his “personalized gene-target cancer therapy” are overblown and nonsensical; and (3) how there might be a way to understand how antineoplastons might actually be real drugs, with the problem, of course, being that, when it comes to demonstrating efficacy, Burzynski is doing it wrong—very wrong indeed. They say that even a blind squirrel occasionally finds an acorn. Is it possible that antineoplastons are the acorn that Burzynski found?
I pointed out originally that antineoplastons A-2.1 and A-10 are nothing more than simple chemicals based on amino acids. Saul Green explained years ago:
By 1985, Burzynski said he was using eight antineoplastons to treat cancer patients. The first five, which were fractions from human urine, he called A-1 through A-5. From A-2 he made A-10, which was insoluble 3-N-phenylacetylamino piperidine 2,6-dione. He said A-10 was the anticancer peptide common to all his urine fractions. He then treated A-10 with alkali, which yielded a soluble product he named AS-2.5. Further treatment of AS-2.5 with alkali yielded a product he called AS-2.1. Burzynski is currently treating patients with what he calls “AS-2.1” and “A-10.”
In reality, AS-2.1 is phenylacetic acid (PA), a potentially toxic substance produced during normal metabolism. PA is detoxified in the liver to phenylacetyl glutamine (PAG), which is excreted in the urine. When urine is heated after adding acid, the PAG loses water and becomes 3-N-phenylacetylamino piperidine 2,6-dione (PAPD), which is insoluble. Normally there is no PAPD in human urine.
What Burzynski calls “A-10” is really PAPD treated with alkali to make it soluble. But doing this does not create a soluble form of A-10. It simply reinserts water into the molecule and regenerates the PAG (Burzynski’s AS-2.5). Further treatment of this with alkali breaks it down into a mixture of PA and PAG. Thus Burzynski’s “AS-2.1” is nothing but a mixture of the naturally occurring substances PA and PAG.
One notes that whenever a bag of antineoplastons is shown in any of these videos, it shows antineoplaston A-10 at a whopping 30% concentration (300 g/L). In any case, here’s a recent review article on a drug called sodium phenylbutyrate (PB):
Sodium phenylbutyrate (figure 1), a HDACI, is an aromatic fatty acid that is converted/oxidized in vivo into phenylacetate (PAA) by β-oxidation.[11] In humans the so formed PAA is eliminated by conjugation with glutamine to form phenacetylglutamine, which is excreted in the urine. This metabolic pathway is the mechanism by which phenylbutyrate acts as an ammonia scavenger in patients with urea cycle disorders (UCDs) and hyperammonemia.
If you peruse ClinicalTrials.gov for Burzynski’s current clinical trials, you’ll find that pretty much all of them use antineoplastons AS-2.1 and A-10; i.e., phenylacetic acid (PA) and phenyl acetyl glutamine (PAG). It turns out that PB is a prodrug for PA and PAG, which means that the drug is converted into an active metabolite to work. What Burzynski calls antineoplastons are nothing more than the byproducts of the body’s metabolism of the orphan drug sodium phenylbutyrate. In fact, according to this report, the “conversion of phenylbutyrate to phenylacetate was extensive (80 ± 12.6%), but serum concentrations of phenylacetate were low owing to rapid, subsequent conversion to phenylacetylglutamine.” In other words, phenylbutyrate is nearly completely converted to PA, which is then rapidly converted to PAG.
Remember my post about the use and abuse of the term “epigenetics” by various questionable practitioners, in which epigenetic effects and changes are invoked not unlike magic (or like another favorite buzzword “quantum”) to “explain” why various woo works? In that post, I explained a bit about epigenetics and why it’s a hot area in cancer research, as well as why histone deacetylase (HDAC) inhibitors are a promising new avenue for cancer therapy. I also puzzled about why HDAC inhibitors are considered “targeted,” given that they have the potential to affect huge swaths of chromatin and the expression of the genes in the DNA therein, but that’s just me. I guess I can’t fault Burzynski too much for “talking the talk,” even though it’s quite clear that when it comes to targeted therapy he doesn’t know what he is talking about, as has been amply documented. Indeed, Burzynski is so arrogant that he recently gave an interview in which he claimed to have been a pioneer — perhaps even the originator — of the concept of gene-targeted cancer therapy back in the 1990s. It’s utter rot, of course, but Burzynski really did make that claim.
Perusing the article, I find there is a fair amount of preclinical evidence that PB has antitumor effects in certain tumor types, specifically colon carcinoma, Burkitt lymphoma, primary acute myeloid leukemia, retinoblastoma, prostate cancer, U138 MG, T98G, U373 MG and A-172 glioma cells, medulloblastoma, and hepatocellular carcinoma. Ironically, however, its ability to pass the blood-brain barrier is a problem, which makes it odd that Burzynski keeps using it for brain tumors. In these preclinical models, PB shows evidence of being an HDAC inhibitor, chemical chaperone, and pro-differentiation agent. The clinical evidence is much less impressive, however. Indeed, I reviewed the clinical evidence for PB as an anticancer therapy the last time I discussed this, and all I found was a bunch of phase I studies showing safety but no real efficacy. Of course, phase I studies aren’t designed to show efficacy, but often investigators can get a hint of whether a drug is likely to have activity from phase I results. There was also a case report from 2002 showing a durable remission for four years in a malignant glioma treated with PB.
Given the impending release of Burzynski II, I decided to update my search, to see if there was anything more recent about PB and cancer. Of the references I found on PubMed, there were no new clinical trials published over the last 14 months since my last review. There were a few preclinical studies using cell culture and mouse models, but nothing new in human subjects. The state of our knowledge regarding PB and cancer can thus be correctly said to be more or less unchanged since late 2011. If Dr. Hideaki Tsuda, the Japanese anesthesiologist at Kurume University Hospital is correct when he states in the second trailer for the Burzynski sequel that he has done a randomized controlled clinical trial demonstrating the efficacy of antineoplastons in metastatic colorectal cancer, that would be the first convincing clinical evidence that antineoplastons (excuse me, PB) have significant efficacy in any cancer.
Of course, Tsuda hasn’t published the results of his clinical trial, which makes me wonder why he’s appearing in Burzynski II touting the results of his study when it hasn’t been published yet. The last study I see from his group is a study from 2005 examining breast cancer cell lines, although there is a case study from 2003 looking at colon cancer that shows mildly promising results. As Elton John would sing, I’ve seen that movie too. Burzynski’s been claiming he’ll publish the results of his clinical trials for decades now. Tsuda has been collaborating with Burzynski for over 25 years. Am I going to hold my breath waiting for him to publish the results of this randomized clinical trial he’s touting in the trailer? Not really. It’s time for Burzynski and Tsuda to put up or shut up.
The bottom line
So we come full circle, back to the question of whether the cases of Hannah Bradley and Laura Hymas are convincing evidence that Burzynski’s antineoplaston treatment works. Contrary to what Burzynski defenders claim, I started out agnostic regarding the question of whether antineoplastons have any value in cancer therapy. What I objected to was how Burzynski has continued to use them in patients and, in my opinion, abused the clinical trial process as a means of continuing to use them. Burzynski’s motivations and ethics aside, considering these cases and their (so far) good outcomes from from a purely scientific and medical standpoint, we have three possibilities:
     1.  Spontaneous remission
     2.  Treatment effect due to conventional therapy
     3.  Treatment effect due to antineoplastons
Note that the second and third possibilities are not mutually exclusive.
Given that spontaneous remission is rare in malignant brain tumors, possibility #1 is highly unlikely, albeit not completely impossible. In Hannah’s case, I tend to conclude that most likely possibility #2 is primarily at work here, although it’s not possible to exclude a contribution from possibility #3. The reason I conclude this is that the shrinkage of the enhancing part of her tumor is not outside the range of range of effects that can be observed due to her radiation therapy in mid-2011 in that the enhancing mass of her tumor continued to decrease in size. Given the biology of her tumor, a year and a half since her radiation therapy was completed is too short a time to conclude that Hannah is an antineoplaston success story, particularly in light of her more recent reports that make me suspect that her tumor might have recurred. How else can I explain their rather evasive comments in their last two vlogs, coupled with their cryptic Facebook comment, a vlog that is apparently no longer on her website, and the fact that they have not shown any of Hannah’s more recent scans, which is in marked contrast to what they did when her tumor was shrinking? I sincerely hope I’m mistaken. I don’t want either Hannah or Laura to recur and sincerely hope that they are, indeed, disease free and remain so for decades to come. But just because either of them might be disturbed by my frank discussion is no reason for me not to discuss their cases, particularly given that they have both apparently agreed to assist Eric Merola in producing his latest propaganda-fest.
Laura Hymas is different in that she provides somewhat more suggestive evidence for a possible antitumor effect from antineoplastons, given the longer period of time since she finished her radiation therapy and since her still being in complete remission five and a half months after her first scan showing no residual tumor. However, her case is by no means the slam-dunk evidence that Burzynski supporters claim it to be (or, for that matter, that Merola touts it as in his upcoming movie), given that it has been less than six months since confirmation of a complete response. Moreover, given that HDAC inhibitors do seem to have some efficacy against glioblastoma, it is not unreasonable to expect that antineoplastons might actually have had activity in Laura’s case. Making claims, as Burzynski does, however, that his antineoplaston therapy is more efficacious than conventional therapy is unwarranted based on a single patient. Conventional therapy can produce durable remissions and complete responses, too, and, although they are still rare, they are becoming more common. That’s why legitimate randomized clinical trials are needed to determine if PB/antineoplastons have antitumor effects in humans; which tumors are sensitive; if there are any biomarkers of sensitivity; and to separate the signal from the noise. Anecdotes like those of Hannah Bradley and Laura Hymas can be suggestive, but in and of themselves prove nothing.
It’s also why what Burzynski appears to be doing is an incredible disservice to cancer patients. If, in fact, he has a treatment that is so much more effective against “untreatable” cancers than anything we currently have, then he should have been able to demonstrate it by now. His excuses, in fact, are pathetic. He trots out the old alternative cancer treatment excuse that big pharma, the FDA, and the “cancer industry” are out to get him because they don’t want a cure for cancer. You can see in Merola’s second trailer that parroting this hoary old chestnut beloved of cancer quacks is going to play a central role in Burzynski II. Burzynski claims he has no pharma funding and no resources to do proper clinical trials, despite registering over 60 clinical trials since the 1990s and publishing none of them. This is in marked contrast to startup companies with fewer resources than Burzynski managing to take a drug concept through clinical trials within a few years. For example, contrast Burzynski’s story to a story like that of PLX4032, which was taken through phase I and II trials rapidly and is now in phase III trials.
No, I don’t buy Burzynski’s excuses at all.
Finally, what I have against Burzynski is not that I think he’s almost certainly wrong about antineoplastons being a huge advance in cancer. Scientists and physicians are wrong all the time; it’s the nature of science. I’ve been wrong on numerous occasions in my research. What I have against Burzynski is that, from my perspective, he’s “doing it wrong.” He’s abusing the clinical trial process. He’s having patients pay exorbitant sums of money to be on clinical trials and then not publishing the results. He’s hiring dubious PR flacks to deflect the criticism, getting well-known quack apologists (such as Suzanne Somers and Joe Mercola) to defend and promote him. His fans are attacking skeptics by characterizing them as “skeptics attacking recovering cancer patients on Twitter“. Worst of all, rather than publishing his results, he’s promoting his “results” in documentaries by a fawning sycophant whose primary business is to produce commercials and promotional videos for large corporations and demonstrating a large number of other worrisome warning signs of dubious medicine.
Burzynski is not doing what real scientists and clinical investigators do, and neither is Hideaki Tsuda. Publicizing their alleged research in a movie made by a Burzynski sycophant, toady, and lackey is just not the way science is supposed to be done, and his record, as demonstrated by the public record, appears dismal. Barring the publication of truly convincing clinical trial evidence by more sources than just Burzynski (given that Burzynski has already shown his methodology for conducting clinical trials to be questionable at best and that his preclinical data supporting his methods are at best weak and usually appear in publications that are not peer-reviewed), if we take in totality the evidence for the anti-cancer efficacy of PB along with all the evidence from the past 35 years for the anti-cancer efficacy (more properly, the lack of efficacy) of antineoplastons, the inescapable conclusion is that PB/antineoplastons might—I repeat, might—have very modest efficacy against some tumors through the HDAC inhibitor activity of PB. Whether that activity seen in some preclinical models truly exists and translates into human use and, more importantly, whether it is worth the not inconsiderable toxicity of antineoplastons as prescribed by Burzynski, are questions that Burzynski has, in my opinion, already shown that he will almost certainly never answer.
That’s why I hope that this time the FDA really does shut him down.

Dr. Stanislaw Burzynski’s cancer “success” stories update: Why is the release of the Burzynski sequel being delayed?
David Gorski on March 4, 2013
Link
It’s no secret that I happen to be on several mailing lists of groups or doctors whose dedication to science is—shall we say?—questionable. Of course, the reason I join such mailing lists is to keep my finger on the pulse of pseudoscience, so to speak. Between such lists and strategically selected Google Alerts (the latter of which appear to be failing me these days), I’m usually aware of potential blogging material fast on selected topics that have become my bailiwick on this blog. So it was that I became aware on Saturday of a development regarding the movie about Stanislaw Burzynski that was going to be released direct to DVD this week.
I wrote about this “documentary” a couple of weeks ago, because it had become pretty clear that a significant part of the movie will be dedicated to a PR counterattack (more like a smear job) on skeptics who have been critical of Burzynski, criticism that apparently goaded him to use a rather unhinged individual by the name of Marc Stephens to threaten skeptical bloggers who had written posts critical of Burzynski’s science (more appropriately, his lack of science), and his proclivity for charging patients huge amounts of money to be in clinical trials, a practice that is in general considered at best questionable. The brouhaha in the blogosphere led me to pay attention to Burzynski in a way that I hadn’t before. Sure, I had heard of him, but I hadn’t really delved deeply into his claims. That situation was rectified in late 2011, as I reviewed the first propaganda movie made about Burzynski by Eric Merola, Burzynski The Movie: Cancer Is Serious Business. As I delved deeper, I learned that Burzynski’s evidence for the anticancer efficacy of his “antineoplaston therapy” doesn’t hold up; that his “personalized gene-targeted cancer therapy” is anything but personalized or gene-targeted; and that he’s using an orphan drug now in what appears to me to be a strategy to bypass restrictions on his use of antineoplastons that he agreed to in a consent agreement with the Texas Attorney General back in 1998 that allow him only to use these drugs as part of a valid clinical trial.
So I awaited the approach of this week with a mixture of anticipation and trepidation; anticipation because I wanted to see what sort of bizarre new conspiracy theories (or new twists on old conspiracy theories) that Merola could weave, and trepidation because I don’t know how badly Merola will trash me (and people I know) in his movie and such attacks could cause me difficulties. Suffice to say, it looked very much as though Merola was going to resurrect Jake Crosby’s scurrilous attacks against me from three years ago. So it was with great surprise that I read this e-mail on Saturday morning, sent to the Burzynski Movie mailing list:
Dear Burzynski Movie Subscribers:
Major International Distribution Deal ForBurzynski: Cancer Is Serious Business, Part II:
We are pleased to announce that Burzynski: Cancer Is Serious Business, Part II has landed a major international distribution deal with one of America’s top distribution companies.
We can’t give out any specific details until everything is finalized, but promise to keep you informed. All we can say is, if you live in North America and own a television set, you will be likely able to see this new documentary by summer. However, the distribution deal stretches beyond just television.
Given this new development, we had to halt all pre-sales for the DVD to follow the protocols required of us by the distribution company. We are re-opening pre-sales now, with the new ship date being July 1, 2013 (instead of March 5, 2013).
The rest of the e-mail consisted of explanations of how those who had already preordered the movie for March 5 shipping would get a bonus if they kept their orders active and waited until July to receive their DVD.
On the surface, this would appear to be a horrible development, if Merola has indeed managed to secure some sort of international distribution deal. However, I’m not quite so sure that it is, as I’ll explain below. In fact, in retrospect an announcement of this sort should not have come as such a surprise to me for two reasons. The first reason is that, earlier this week, I had contemplated purchasing a copy of this movie so that I could know what it contained. However, not being thrilled with potentially revealing my name, credit card information, and home address to Eric Merola’s company, I thought that, if I were to order this movie, I’d do it through PayPal if that were an option and have it shipped to either my work address, which is public, or to a postal box. So I went to the Burzynski Movie website, only to find a message claiming that, due to high demand, orders were temporarily no longer being taken. That sounded odd to me, but oh, well…
Worst of all, there was also a notice that the first Burzynski movie will be shown twice on Thursday, March 7 on the Denver affiliate of Colorado PBS (discussed here). However, as I read this self-congratulatory bit of blather from Eric Merola, whose job it is to compose self-congratulatory blather for use in corporate infomercials, something seemed odd. I didn’t know what it was at the time, but it soon became apparent when someone sent me a link relevant to my post from two weeks ago about Burzynski’s cancer “success” stories that very likely aren’t. What I discovered is that Hannah Bradley, one of the “success stories” and a woman whose partner had made his own video about Burzynski and who will feature prominently in Eric Merola’s latest paean to the “brave maverick doctor” Burzynski, had finally posted a new vlog:
When last I discussed Hannah Bradley’s story, I pointed out how cute I thought Hannah and her partner Pete were. Their love for each other radiates from the screen. However, I also felt obligated to point out why I thought that she was not the “miracle cure” that she was being advertised as by Eric Merola. For a complete explanation, read my previous post. The CliffsNotes version for those who don’t want to read my previous lengthy post is that Hannah’s tumor, an astrocytoma (which is a form of glioma) did indeed appear to regress, but that regression can likely be explained by the surgery and radiation therapy that she had. The other part of the argument was that it is premature to represent Hannah as some sort of “miracle cure,” given that the median survival for someone with her tumor is in the range of two to three years, and she’s only just reaching the two year mark. In other words, contrary to the story being spun about her by Merola and Burzynski, it is not that surprising that her tumor has what appears to be a radiographically near-complete remission (by “radiographically” I mean what can be seen on imaging studies like MRIs) or that she is still alive. Her progress is still well within the expected behavior of the tumor that she has. If she were alive four or five years from now and tumor-free, that would be much more remarkable. Even then, however, it would not be evidence that the antineoplastons saved her because there are occasional complete remissions in this tumor type, and long term survivors, although uncommon, are not so uncommon that Hannah must be evidence that antineoplastons are so miraculously effective that they saved her when conventional medicine could not.
Finally, what most made me wonder about what was happening to Hannah was my simple observation that she and Pete have not posted images of any of her MRIs since late August. This is in marked contrast to each new MRI up to that point, which did show promising regression of the enhancing lesion and cystic area left over from her surgery. Also, she and Pete posted a vlog on November 1 that sounded as though it had bad news, but apparently took it down, as it’s not there anymore. As I said two weeks ago, I was worried. Real worried.
Now comes this latest vlog, and I’m more worried about Hannah than ever. Indeed, I almost fear to say what I feel obligated to say, because no matter how I do it, it’s likely to be spun, as Merola’s movie clearly has done to other skeptics with his ham-fisted shots of cancer patients crying about how skeptics are “attacking” them, as an “attack” on Hannah and Pete or as trying to rob them of hope. I also realize that there is a fine line between trying to use a case like Hannah Bradley’s as a means of educating the public about ineffective cancer “cures” and coming off as attacking someone with a serious cancer. I try very hard not to cross that line, and I think I’ve been successful, for instance, here. However, if there’s one thing I’ve learned during all these years, it’s that if the person I’m discussing finds out about my post, that person always perceives it as an attack and lashes out. Similarly, Burzynski’s groupies realize that it is very effective to appeal to emotions and cast Burzynski’s critics as heartless villains so in the thrall of big pharma, ideology, or whatever that they will viciously rip into a patient whose life is threatened with a deadly cancer. Personally, I’d be very happy for Hannah and Pete if she were to survive to outlive me, whether it were due to conventional therapy, Burzynski’s therapy, or a combination of the two. I hate seeing people die of cancer, which is one big reason I became a surgical oncologist in the first place. And if it were Burzynski’s antineoplastons that did the trick, I’d be both happy at the discovery and furious at Burzynski for jerking people around for so many decades instead of doing the work it takes to prove the value of his treatment.
So why am I even more worried than ever about Hannah? It started right from the first shot of her latest vlog. Look at her face. It’s subtle, but, I think real: an increased asymmetry in which her lower lip on the left part of her face is droopier than I had ever noticed before. I first noticed this in her Christmas vlog but it appears worse now, particularly in comparison to her in the 40 minute Hannah’s Anecdote, which included lots of shots of her from December 2011 and January 2012. In those shots, she appeared to have had a bit of this going on then, but it was quite subtle. It’s not so subtle anymore in her latest vlog and suggests that the tumor might be growing and impinging on nerves going to her face. She also struggles for words in a way that I don’t recall ever having seen her do before. At one point, she has a hard time thinking of the word “risk” and has to be prompted by Pete. All of this makes me wonder if she’s developed an anomic aphasia. I could be wrong about Hannah’s facial asymmetry; I’m not a neurologist. I’m also less sure about the aphasia; it could well be that she simply had a bit of difficulty finding a word, no worse than any other person. In fact, I’d like to be wrong about this (and any neurologists and/or neurosurgeons out there reading tell me if I’m wrong about this—I’ll tack on an addendum if you convince me). But I don’t think I am, at least not about the facial asymmetry.
Next, Hannah admits that she has a “really cystic area in my head” but insists that there’s no enhancing tumor and doesn’t really say if what is there is increasing in size or stable. Given her affect and the expression on her face when she discusses these issues, I truly fear that it must be growing. There’s also the issue of the marked change in how she and Pete discuss her scans. In Hannah’s Anecdote and their vlog of July 27, 2012, Hannah and Pete exult (and understandably so!) that Hannah has had a “complete response.” Now, “complete response” means just that: a complete response to therapy. No tumor detectable by MRI. That implies that anything seen on imaging now must have arisen between the scan of last August and now. Presumably, it arose between August and November, the time when she and Pete first noted that the news was “not the best of news.”
I hate to say it, but I’ve seen this story before. I’ve even encountered it before myself. Burzynski has a tendency to tell patients with brain tumors that the formation of “cystic areas” is a good thing that indicates his treatment is working. The most recent example I remember of this was Amelia Saunders, whose father reported on Facebook in November that Burzynski told them this:
Tonight is the update we’d always hoped we’d be able to write, but it has taken an enormous amount of faith and hard work to get this far – and there were many times we didn’t think this would happen.
Amelia’s tumour is dying, from the inside. We’ll be getting another opinion from here on this, but the scans do back this up. There are cysts forming inside the tumour where cancer cells would have been before.
For the moment, we seem to be winning our little battle.
We are trying our hardest not to get too excited yet. These cysts are forming inside the tumour but it isn’t shrinking – however this proves the treatment is working. Remember that Amelia has received no other treatment.
Amelia Saunders, as you recall, was the unfortunate little girl who developed an inoperable diffuse intrinsic pontine glioma and whose family managed to raise £200,000 in just 12 weeks to send her to the Burzynski Clinic for antineoplaston therapy. In September, several stories in the UK represented her as a “miracle cure” because she was able to attend her first day of school. Unfortunately, as I knew at the time, the “cysts” that Burzynski was holding out as evidence that the antineoplastons were working were nothing of the sort. I knew that they almost certainly represented areas of ischemia (low blood flow) leading to tissue death as the tumor outgrew its blood supply. This is a phenomenon commonly seen in advanced malignancy. I knew this because tumor angiogenesis has been one of my areas of research interest, and I’m a co-author on one of the first papers to show that combining antiangiogenic therapy with radiation showed promise in animal models. Basically, tumor cells are constrained in their growth to the diffusion of oxygen and nutrients in aqueous solution unless they can induce the ingrowth of blood vessels, a process called tumor angiogenesis. That’s why tumors can frequently outgrow their blood supply by growing faster than they can induce blood vessels to grow, and when that happens, areas in the center of the tumor will die and liquify. Surgeons are very familiar with this phenomenon, as are radiologists. Tumors frequently, as they progress, consist of a relatively thin rim of viable, growing cells surrounding a central area of necrotic tissue.
Not long after Burzynski’s whitewashing of Amelia’s November scan, Amelia started to deteriorate clinically. By late December, it was clear that she was dying. Sadly, Amelia finally passed away on January 6. Hers was a truly heartbreaking story, not the least of which because of the way that Stanislaw Burzynski appears to have strung the family along. I fear that he is doing the same with Pete and Hannah, who don’t deserve that any more than Amelia and her family did. One notes that in Pete and Hannah’s vlog of September 7, 2012, Eric Merola points out that Amelia Saunders was going to feature prominently in Burzynski II. This was shortly before stories about her going to school for the first time popped up all over the UK press, giving Burzynski some of the best press he’s ever had.
All of this brings us full circle to the sudden unexpected delay in release of Burzynski II: This Time It’s Peer-reviewed or Burzynski II: Electric Boogaloo (as I like to call the second Burzynski movie). Learning about Hannah’s latest scan right around the same time that I learned about the delay in release of Burzynski II made it difficult to avoid speculating that the two were somehow linked. Yes, it could well be a case of confusing correlation with causation and leaping to unwarranted conclusions. If that turns out to be the case, I will certainly admit I made a mistake. However, does it strike anyone else as odd that it is announced that the release of Merola’s movie is delayed three days before it was originally scheduled to be released and on the very same day we learn that one of its “stars” who was going to be presented as a “miracle cure,” as slam dunk evidence, along with Laura Hymas, that Burzynski cures incurable brain tumors, is no longer cancer-free? True, Hannah and Pete didn’t actually say that explicitly, but the inescapable implication is there. After all, when they thought that Hannah had had a complete response, they weren’t at all shy about saying so, while now they hem and haw. Again, this is one area where I’d be not just happy to be wrong, but downright ecstatic. Unfortunately, I fear I am not.
It might be that the reason for the delay in releasing Burzynski II is exactly as Merola has represented it. But one wonders why it would take four months and why the sudden last minute “distribution deal.” Maybe it’s not so odd if Merola needs time to re-edit the movie in light of recent developments, which include questions about Hannah’s condition, the audit of the Burzynski Clinic and Burzynski Research Institute by the FDA, which has shut its antineoplaston operation down at least temporarily, and one possible development that I know about but can’t really discuss publicly yet.It just wouldn’t do to release the movie now and have large parts of it be refuted by events occurring soon after its release, such as the FDA shutting down the Burzynski Research Institute for good or one of the movie’s two “success stories” turning out not to be as represented. After all, Merola acknowledged publicly that, unlike the case with the first Burzynski movie, this time around the subject is “fast moving” and events are moving rapidly. Maybe they’re moving more rapidly than even he thought.
Merola tries to paint Burzynski as the iconoclast, the “brave maverick doctor” who is curing cancer while big pharma, the “cancer industry,” and the government through the FDA try to shut him down to protect their hegemony. From my perspective, the real story needs to be emphasized again and again. There are many patients whose families have gone to huge lengths to raise sums as high as several hundred thousand dollars to pay for treatment at the Burzynski Clinic under the auspices of Dr. Burzynski’s “clinical trials” that never seem to produce much in the way of useful data despite his having opened and closed dozens of them since he was ordered in the 1990s by the Texas Medical Board and the FDA not to use antineoplaston therapy except in the context of a clinical trial. Despite that, Dr. Burzynski has set up quite the cottage industry in which patients pay hundreds of thousands of dollars for the “privilege” of being treated on a “clinical trial” with antineoplaston therapy, even though it is not FDA-approved, has never been convincingly shown to work, and has significant toxicities despite Burzynski’s claims that his treatment is so nontoxic. So we have many patients harnessing the generosity of kind-hearted strangers to pay for woo. It’s a depressing litany of people, mostly children, teenagers, and young adults like Billie Bainbridge, Kelli Richmond, Olivia Bianco, and Shana Pulkinen. And, most recently, there have been Rachael Mackey and Amelia Saunders. There are so many more.
And now there is Hannah Bradley, who, I hope, really is cured but unfortunately have ample reason to fear is not. All of these stories are used by Burzynski apologists and promoters to feed into the cult of personality that is Stanislaw Burzynski. Desperate, in many cases dying, people are used to sell what I consider to be the myth of Burzynski. Again, this is a delicate topic to take on, but I see little choice but to analyze these stories. As long as they are being used by people like Eric Merola to sell Dr. Burzynski’s “legend,” they have to be discussed. After all, film projects like Merola’s entice these patients to come from all over the world to spend precious weeks of their remaining time in a foreign country far away from home and pay hundreds of thousands of dollars that they don’t need to spend for a treatment that almost certainly cannot save them and for which there is no good published evidence. Remember, Hannah and Pete have even stated that Merola’s first movie about Burzynski was a huge reason they became convinced that the Burzynski Clinic was Hannah’s only hope. Stating publicly on this blog that it isn’t is not easy, because I take care of cancer patients. Even though I have thus far been fortunate enough not to have cancer myself, that doesn’t mean family members haven’t; indeed, my mother-in-law died nearly four years ago of a particularly nasty form of breast cancer. Even as a cancer doctor, I still wanted to believe that there was hope, even though all my knowledge told me that there wasn’t. At that point, even I might have been tempted by Burzynski. My only hope is that putting this sort of analysis of the patient cases used to sell Burzynski’s antineoplastons out there can give patients who are thinking of going to the Burzynski Clinic a science-based assessment of Burzynski’s work to allow them to make a much more informed choice, in marked contrast to the marketing that is all they will find in the work of Eric Merola and others who function in essence as unpaid advertisers to promote the glory that is Burzynski. These propagandists spin a story of one man who can cure cancers that no one else can, and that story is very compelling to desperate people with advanced cancer. Sadly, when it comes to Eric Merola, evidence doesn’t matter, and it is the patients who are potentially harmed.

Three myths about Stanislaw Burzynski and The Skeptics
David Gorski on March 11, 2013
Link
As I finished last week’s post, I promised myself that I wouldn’t write about Stanislaw Burzynski again this week. After all, counting this post I will have done 13 posts so far in 2013, and, counting this one, four of them will have been about Burzynski, and three out of the last five posts (three out of four, really, if we eliminate my blatant self-promotion for the talk I gave to the National Capital Area Skeptics over the weekend). It’s the same sort of thing that I sometimes comment about over at my not-so-super-secret other blog when seemingly all my posts are about the antivaccine movement for days at a time. Still, as Michael Corleone said in The Godfather, Part III (admittedly the weakest of the Godfather movies), “Just when I thought I was out…they pull me back in.” Except, I guess, that I never really was out and, as long as Burzynski’s propagandist is coming after skeptics, myself included, I’ve come to the reluctant conclusion that I can’t be out for a long time.
Besides, with the first screening of the Burzynski sequel, Burzynski: Cancer Is Serious Business, Part II (which I’ll simply call Burzynski II, given Eric Merola’s penchant for long titles with multiple subtitles) at the San Luis Obispo International Film Festival yesterday, it looks as though I will find myself on the receiving end of what, from what I can gather, will be a withering and deceptive campaign of personal attack directed against myself and other skeptics who are critical of Burzynski’s treatments and methods. Like Josephine Jones, I can’t help but admit to feeling a little trepidation over this. Meanwhile, given that the Burzynski movie is now finding its way out into the wild, I thought it would be worthwhile to compare the myth-making about Burzynski in the movie with reality. There are so many myths being perpetuated by Merola and Burzynski, so I thought I’d take on three of the most flagrant ones. At some point, once I know the nature of the attacks against me, I will have to respond to specific allegations. Unfortunately, that might not be possible until after the DVD release in July. However, for now, I hope to make this post a resource that takes on the most blatant examples of exaggeration, cherry picking, and spin likely to be in the movie. Hopefully after that I can leave this topic alone for a while and explore more of the big wide world of science-based medicine and offenses against it.
Myth #1: There is a cabal of “anti-Burzynski bloggers” who conspire to “terrorize” cancer patients and feed them misinformation
As you might imagine, this particular myth is the one that irritates me the most, because it is a direct personal attack on Bob Blaskiewicz, myself, and all the other skeptical bloggers promoting science-based medicine designed to paint us all as heartless bastards in the pay of big pharma, the National Cancer Institute, and the FDA, who delight in crushing the hopes of terminal cancer patients drawn to the Burzynski Clinic. It’s very clear from the Burzynski movie website, which I quote in its entirety, in case it disappears:
12. What is the story with all of the anti-Burzynski “bloggers”? As with anything new in the realm of science, you will always have detractors who will not take the time to review relevant scientific information, and instead project strategic cherry-picking of anecdotal data or taking data out of context. In the worst case scenarios, some bloggers intentionally publish fabricated information to their readers in an attempt to curb new patients from going to the Burzynski Clinic. These individuals are also responsible for “gate keeping” the Wikipedia Page on The Burzynski Clinic. This issue, as well as the identities of those involved, will be covered in great length in the new 2013 “Chapter 2” documentary.
Overall, you need to be able to think for yourself. Question everything, including me and this film. Feel free to verify all sources used for this film for yourself via the Sourced Transcript [link]. You will notice the “anti-Burzynski bloggers” refuse to do that or adhere to reputable sources. You might say, “they are preying on desperate cancer patients and families of cancer patients” by carelessly misleading their readers about Burzynski and his invention. This is a natural course of history when scientific innovation like this occurs, and is something that is to be expected. Never underestimate the irrationality of the human brain when it is confronted with something it doesn’t understand. These bloggers have an agenda, and are not open to rational discourse.
Our society is built on propaganda wars, and wars of information and disinformation. The fact that most people will basically believe anything they are told without bothering to find out if what they are told is true or not—makes them for easy prey, especially when they are dying of cancer. The writers of the “anti-Burzynski” bloggers know this—and take full advantage of this.
Then there is currently one review of Burzynski II published (scroll to the bottom; it’s the last entry in a list of several movies screened at the film festival):
Just as hard to understand is the Internet smear campaign that’s apparently emerged to confuse the public about the treatment, label Burzynski a quack, and harass patients for undergoing Antineoplaston therapy.
Merola wisely waits until the documentary is well underway, after the issues and the players involved have been introduced, before showing us this ugly angle. A group calling themselves “The Skeptics” even go so far as to claim that the doctor maintains a cult-like sway over his patients, whom they say he exploits for financial gain. “Skeptic” bloggers make it their mission to spread misinformation, the film asserts, while trying to pass themselves off as concerned citizens. Others create fake websites and Twitter accounts. It’s enough to make one extremely paranoid. When a documentary points to the existence of a conspiracy of such magnitude, it’s hard to know whom to believe. What if the whole Antineoplaston thing is a hoax? What if?
But the testimony of so many oncologists, surgeons, and neurosurgeons negates that possibility.
I must admit, I like the way the word “Skeptics” is capitalized, except they should call us The Skeptics, kind of like The Man. One wonders whether Merola mentions the single-purpose Twitter accounts that monitor the #burzynski hashtag, promote Burzynski, and swoop in to attack any Tweets critical of Burzynski, or the anonymous commenters who infest many blogs whose authors have the temerity to criticize Burzynski, his science, and practices. The promotional Tweets resemble an astroturf campaign, but the attack accounts appear to be more personal. For instance, there is the ever-morphing Didymus Judas Thomas, who first appeared at my not-so-super-secret other blog (or, as I think I’ll abbreviate it, NSSSOB), went on to infest other skeptical blogs, and metastasized to Twitter, abusing it to the point of getting one account suspended, always posting through proxies or cellular connections. Then there’s @BurzynskiSaves, who is known throughout the skeptical Twittersphere among critics of Burzynski as one of the most virulent Burzynski attack dogs, with a perseverating style that consists mainly of latching on to one minor point in a Burzynski critic’s Tweet and repetitively mocking it, usually with links to articles that do not support his point. His style is basically to try to flood Burzynski critics with “attack Tweets” directed at them and thus annoy them to the point where they just give up. It’s a sadly effective technique. It’s also suspected but as yet unproven, that @BurzynskiSaves works for the Burzynski Clinic, given that he discusses conversations with Burzynski patients on Twitter. Meanwhile, a reader has pointed out to me that anonymous users have created several single-serving Twitter accounts, possibly paid, seemingly created to hound actress Valerie Harper with suggestions to go to the Burzynski Clinic. Valerie Harper, it was recently announced, was diagnosed with an inoperable and incurable brain tumor and is not expected to live more than a few months.
No, it’s not Burzynski’s critics who are waging a major “information war.” After all, we don’t have a propagandist making documentaries to portray us as brave mavericks bucking the system and being persecuted by big pharma (although we do have C0nc0rdance), nor do we have PBS stations like Colorado PBS promoting the first Burzynski movie and giving Burzynski supporters a forum to promote Burzynski unopposed, blithely dismissing criticism. On the other hand, I can’t help but think that the very fact that Eric Merola and Stanislaw Burzynski are making such a concerted effort to attack critics is evidence that we are having an effect. They used to ignore us. Apparently no more.
Merola and Burzynski’s massive projection aside, let me address the issue of patients. Over the last year and half, which was when I first took a major interest in the Burzynski Clinic, its claims, and its patients, I have covered several patient stories, both on SBM and on my NSSSOB. It had actually begun a year earlier when I first noted the story of Rene Louis, who was the first patient I recall becoming aware of who resorted to fundraising to go to the Burzynski Clinic, but until November 2011, I didn’t revisit the topic of patients of Burzynski patients fundraising to go to his clinic. That’s when I reviewed the first Burzynski movie, discussing in great detail the various patient anecdotes included in it. If you combine my discussion with the discussion at the Anaximperator blog, you can see why we concluded that the testimonials included in Burzynski I were not nearly as convincing as Eric Merola thought they were. Meanwhile, other bloggers have spent a lot of time analyzing publicly available information on patients of Burzynski, mainly through their own blogs, Twitter feeds, and websites, and have concluded that they do not show what Burzynski wants you to think they show.
Contrary to what Merola wants you to believe, all the skeptics involved in analyzing these patient cases are acutely aware of the ethical issues involved and how easy it is to go too far, even with the best of intentions. None of us that I’m aware of “attack” or “terrorize” patients. What we do do is to discuss how the way these patients’ stories are portrayed is not compelling evidence for the efficacy of Burzynski’s treatments against advanced cancer. I can’t speak for the other bloggers, but I don’t take pleasure in doing this, as I’m well aware that some of these patients might actually see what I write. Indeed, I particularly worried about this when I discussed the case of Hannah Bradley, whose cancer, I fear, has probably recurred, because she’s such a great person and I really would like her to be a true Burzynski success story. Indeed, one time Amelia Saunders’ father commented on my NSSSOB, leading me to point out that it was never my intention to upset the Saunders family. I also pointed out that we have to be careful that our understandable anger and revulsion at what Burzynski does is never misdirected unintentionally at families who want nothing more than to see their family member with cancer live, even though some of them enthusiastically participate as cogs in the Burzynski propaganda machine. After all, no father knows how he will react to having a child like Amelia who develops a fatal malignancy until he actually has one, or how he will react to a diagnosis of an inoperable and terminal brain cancer. If you really believe that Burzynski is going to save you, then the desire to help promote him is understandable. It is Burzynski’s fault for misleading such patients, not the patients’ fault for falling for his line.
That being said, given the widespread harm that Burzynski has in my opinion been doing over the last 35 years and how these patients are being cynically used by Merola and Burzynski to promote the Burzynski Clinic, I also had to point out that we cannot allow the potential emotional reaction of families of Burzynski patients prevent us from discussing their cases. The stakes are too high for other cancer patients, and it is unreasonable to expect that information made public by patients themselves is off-limits to analysis. We can, however, try our best to be empathetic and respectful while keeping the focus on the target: Stanislaw Burzynski, his clinic, his research institute, and, of course, Eric Merola. Josephine Jones was absolutely correct when she says that Merola and Burzynski are cynically using cancer patients as human shields. Discussing patient anecdotes in detail from a science-based perspective leads to the inevitable scurrilous attack claiming that you’re “terrorizing” or “mocking” patients, nor is this a defensive technique unique to Burzynski. However, Burzynski II apparently puts that strategy on steroids in a way I haven’t seen before.
And the beat goes on.
Myth #2: Burzynski is pioneer of cutting edge personalized gene-targeted cancer therapy with overwhelming evidence such that “conventional” cancer centers are only now catching up
This one is a whopper. In fact, I would go so far as to say it is either massive self-delusion on Burzynski’s part or a flagrant lie. Burzynski is anything but a pioneer. I’ve discussed before how neither his antineoplaston therapy nor the way he does “personalized, gene-targeted cancer therapy” is novel. Indeed, I referred to what Burzynski does as “personalized gene-targeted therapy for dummies,” because he basically uses a commercial test to identify potential genetic drivers of a patient’s specific cancer and then throws everything but the kitchen sink at it, mixing and matching very expensive targeted therapies in combinations not previously validated to produce a witches’ brew of potential synergistic toxicity, all topped off with an orphan drug that he uses as a “prodrug” for antineoplastons.
Not too long ago, an alternative medicine “journal” published an interview with Burzynski, which Burzynski has posted on his very own website but has since taken down. The article to me serves as a distillation of the self-aggrandizement that is Burzynski when he speaks about his self-perceived scientific accomplishments. If the trailers for Burzynski II are any indication, this interview is a good preview of how his science will be spun by Merola. Sadly, the contrast between the picture of Burzynski as a misunderstood scientific and medical genius on par with Pasteur that his followers like to promote, and reality, is striking. And, of course, this genius is “persecuted” by the dogmatic medical establishment, who only want to “cut, poison, and burn.” Burzynski himself promotes both memes, but particularly the paranoia:
ATHM: Do you think that understanding in the medical community about your research is improving with time or evolving?
Dr Burzynski: Absolutely. Some of the brightest oncologists are working together with us. We have a group of about 100 top oncologists. We are treating patients together with oncologists from all over the world. We are talking about the brightest guys. The rest of the club does not understand what we do at all and hate us. They would like to get rid of us. They hate to see our good results. But this crowd also will change if the breakthrough comes. So at this moment, we have to convert oncologists one by one. Of course, I am giving lectures at the oncology congresses, but only a few of these doctors will pay attention to what I have to say because I am not from a big medical institution. They don’t believe something can come from a small clinic, a small research center. They all assume research must come from a big pharmaceutical company or big institutions. Unfortunately, not much good came from these institutions within the last decade. But a number of doctors are beginning to understand what we do, and the number of those who would like to be trained in our strategy is increasing all the time. We have oncologists coming to us from various countries almost all the time to learn how to use our approach.
This is about as unbelievable a paragraph as I’ve ever seen. In reality, oncologists shun Burzynski—and rightly so, given that he has yet to publish anything resembling a convincing result suggesting the efficacy of his antineoplastons against cancer. That’s not to say he doesn’t publish. He does, but he publishes in low-tier journals, often not indexed by PubMed, and he hasn’t published complete phase II trial results ever that I (or Keir Liddle) can find. It’s painfully obvious from this paragraph that Burzynski doesn’t know academic oncologists. None of them whom I’ve ever met assume that nothing useful can come out of a small clinic or research institute. That’s just rank stupidity if Burzynski really thinks that. The reason oncologists don’t respect Burzynski is because hasn’t show that his treatments work better than conventional treatments—or even that they work at all—and because of the way he abuses the clinical trial process by charging patients huge sums of money in “case management fees” to participate in his trials. Those are the reasons legitimate oncologists, at least those familiar with Burzynski, look askance at him. How could they do otherwise? The ones who don’t take him seriously are the ones who know him best.
Indeed, one could argue that that’s why the FDA and the NCI couldn’t work with him. They didn’t know him when they agreed to work with him in the 1990s, but as they worked with him over the course of a few years they learned his true nature, leading to an inevitable schism, which taught the NCI a lesson about the consequences of dealing with pseudoscientists. Now here’s where we see the sheer arrogance, the sheer ignorance of the man:
Dr Burzynski: I published the review article in a peer-reviewed journal almost 20 years ago on the principles of personalized gene-targeted therapy. But it was not understood yet at that time that cancer is a disease of the genes. The cancers have names like breast cancer or lung cancer but what is really causing cancer is abnormality in our genes. Now everybody knows about it, but 20 years ago, very few people realized it. The right way to treat cancer is to treat the genes that are causing the cancer. Do not treat just the name of cancer. Every case is somewhat different; that’s why we need to have a personalized approach. We need to identify changes in the genes and treat the genes which are “sick.” If we are successful, then we can have very good results. It’s not so difficult to understand.
When antibiotics were introduced for the first time, they were used for the treatment of infections such as pneumonia or kidney infections or whatever. But after a number of years, the doctors realized that what they need to do is treat microorganisms which are causing the infection rather than the name of infection. Do not treat just pneumonia by the same antibiotics, but identify the germs which cause pneumonia and treat the germs. And then we can have success.
Now the same principles are being applied to the treatment of cancer. We identify the genes which are causing the problem and treat the genes. It may happen that the same genes may cause breast cancer or stomach cancer, and then we would use the same medication for one patient’s breast cancer as well as another’s stomach cancer. Certainly, 20 years ago, this was heresy. And frankly speaking, very, very few medications could work on genes at that time.
I had to choke back a rising bile in the back of my throat as I read this. I mean, seriously, such a combination of arrogance (Burzynski apparently thinking that he really was the first person to think of the idea of personalized therapy and targeting genes for cancer) and ignorance of the entire field of cancer genetics and genomics is breathtaking! Let’s put it this way. I was in graduate school 20 years ago, and was taught back then that cancer was primarily a genetic disease.. There’s a term called “oncogene,” which describes genes that, when either mutated or too much is made, can result in cancer. When do you think this term was first coined? Robert Huebner and George Todaro first coined it in 1969, and the first oncogene, src, was described in 1970, twenty years before Burzynski claims to have understood that cancer is a genetic disease. Has Burzynski ever heard of the term “tumor suppressor gene”? Tumor suppressors are genes that normally put the brakes on cell growth or other phenotypic changes necessary for cancer. When tumor suppressor function is lacking, cells can become cancerous. The first tumor suppressor gene, the retinoblastoma gene, was characterized in 1986, at least six years before Burzynski’s apparent “revelation” that cancer is a “genetic disease.” As usual, science was way ahead of Burzynski. In fact, the genetic basis of cancer was suspected at least as far back as 1902, when German zoologist Theodor Boveri proposed the existence of cell cycle check points, tumor suppressor genes and oncogenes. Boveri even speculated that cancers might be caused or promoted by radiation, physical or chemical insults or by pathogenic microorganisms! That’s 90—count ’em—90 years before the time when Burzynski claims that it was “not understood yet at that time that cancer is a disease of the genes.”
Curious as to just what the heck Burzynski was talking about here, I searched PubMed for this alleged review article. I couldn’t find it on PubMed. His only publications from the 1990s had nothing to do with cancer as a “genetic disease” or “personalized gene-targeted cancer therapy” and everything to do with antineoplastons. Perhaps Burzynski proposed this “revolutionary” new idea in a peer-reviewed article that’s not indexed in PubMed, but if he did I couldn’t find it using Google and Google Scholar. (In fact when I entered “Burznski” and “personalized gene therapy” into Google Scholar, I got the article containing the transcript of Burzynski’s interview that I’m discussing at the top of the hit list!) The earliest publication by Burzynski that I could find that dealt with genetics at all was one from 2003 entitled, Aging: gene silencing or gene activation?, published in 2003 in—surprise! surprise!—that rag of a vanity journal, Medical Hypotheses.
I will give Burzynski credit for inadvertently making an analogy that has a grain of truth, but even in making that analogy he mangles history. Yes, antibiotics were used to treat specific infections, but that was because it was known which bugs antibiotics killed and which bugs most commonly were the cause of specific infections. So back in the early days of antibiotics, treatment tended to be more empiric because it wasn’t always possible to culture the causative microorganisms. Moreover, the first antibiotics discovered were often used to treat many infections, but that was because there were either no or very few alternatives. That doesn’t mean that antibiotics were being used to treat “pneumonia” or “kidney infections” without little respect to the causative organisms. After all antibiotics are defined as antibiotics on the basis of their ability to kill or inhibit the growth of microorganisms! One could draw an analogy in that we now target various genetic abnormalities in cancer much more precisely than ever, in sort of the same way that antibiotics today can be much more specifically targeted to specific organisms causing specific infections, than we used to do. It is also true that our considerations of subtypes of cancer are, thanks to the genomics revolution, becoming less organ-specific (i.e., based on what organ the cancer originates in) and more gene signature-specific, but it’s a slow process, and the empirical knowledge of how to treat different cancers from different organs is still very useful. We haven’t yet developed an organ-independent classification of cancers that is clinically useful, although it is possible that we might succeed in doing so in the next ten or twenty years. If we do, you can be certain that Stanislaw Burzynski will have had nothing to do with it and nothing to do to developing real “personalized gene-targeted cancer therapy.”
I could go on and on, picking apart virtually every paragraph of this interview. They’re all chock full of howlers like the passage above. Maybe I’ll come back to this article sometime when I’m bored. In the meantime, consider this statement by Burzynski:
The first medication which worked on genes was Herceptin for the treatment of breast cancer. Even today, oncologists will attack you if you try to use Herceptin for something else. But suddenly a year ago, Herceptin was approved for the treatment of stomach cancer. If the patient has abnormality of the gene on which Herceptin works, it can work very well. The crowd of oncologists learns the medicine by heart without understanding of what’s going on. However, they have started to realize that there is a need to identify what is causing cancer in every patient who is coming for treatment and to use the right combination of medications.
Unfortunately, we have a totalitarian approach toward treatment: Everybody should receive the same regimen for the same name of cancer. This is foolish. It contributes to billions of dollars in losses because typically the medications—single medications— work for less than 10% of patients. If you identify which patients will benefit from a particular medication, you can have good results and you can save a lot of money. But unfortunately, this approach still persists. I have been attacked by the Texas Medical Board for going overboard and using a logical, scientific approach toward treatment of the genes.
First off, Herceptin does not exactly “work on genes,” and no oncologist would characterize it as doing so. Herceptin is a humanized mouse monoclonal antibody that targets the HER2 protein, which is the product of the HER2 oncogene, which is overexpressed (i.e., too much of it is made) in some breast cancers. It’s been enormously successful in that HER2(+) breast cancer used to be considered a very bad actor. It still is a bad actor, but we have a targeted therapy that makes it less so. In any case, if Herceptin is a drug Burzynski defines as “targeting genes,” then he’s clearly wrong that it’s the first one. It was not. Arguably, Tamoxifen was. Tamoxifen, after all, specifically targeted a gene product (the estrogen receptor) in the same way that Herceptin targets HER2, and Tamoxifen has been around since the 1970s. Be that as it may, it is not “heresy” to use Herceptin to treat other forms of cancer besides breast. It is true that Herceptin was first used in breast cancer, but that is because HER2 is frequently overexpressed in breast cancer. As soon as it was discovered that HER2 was overexpressed in other cancers, oncologists and scientists proposed using it for those other cancers. We cancer researchers are very happy to apply new drugs to new cancers if we think they might be useful, but unlike Burzynski we insist on testing them in clinical trials first, to make sure they work.
Elsewhere, in response to criticisms of Burzynski’s concept of personalized therapy, Eric Merola Tweets a variant of this message:
The link in the Tweet is to M.D. Anderson’s Institute for Personalized Medicine. The funny thing about this is that there is a link on that very web page to a talk by John Mendelsohn, MD given at ASCO in 2011 that traces the history of targeted therapy back to 1908 and Paul Ehrlich. I would humbly suggest that Dr. Mendelsohn doesn’t go back far enough. The real birth of targeted therapy came in the late 1800s, when a German surgeon, Albert Schinzinger, first proposed oophorectomy as a treatment for breast cancer at a congress of German surgeons in 1889. A British surgeon named George Thomas Beatson performed the first oophorectomy for breast cancer in 1895, and reported a complete remission in a woman with advanced breast cancer, who went on to live four more years. Ultimately, this knowledge led to the development of Tamoxifen several decades ago, the real first targeted therapy for cancer. In any case, just watching Dr. Mendelsohn’s talk and then comparing what Burzynski does to what M.D. Anderson does should disabuse anyone other than Eric Merola of the idea that somehow Burzynski was a “pioneer” in gene-targeted therapy.
One issue that Burzynski never covers that I can find is the issue of driver mutations versus passenger mutations. Whenever he gets a report that lists a bunch of mutated or overexpressed genes, he simply throws targeted drugs at all of them. Here’s the problem. As I’ve described before, cancer genomes are messed up. Real messed up. There are always a lot of mutations, and evolution in the tumor cells produces more mutations as the tumor progresses. The big problem in personalized therapy is to identify which ones are “driver mutations” (i.e., the ones that drive tumor growth, invasion, and metastasis) and which ones are “just along for the ride” (i.e., “passenger mutations” that come about as a consequence of the driver mutations) and are usually neutral. This task is definitely far from trivial, and nothing I’ve seen from Burzynski indicates to me that he has even seriously considered this question when he picks his “personalized gene-targeted therapies.” I’ve seen patient reports on various websites of his throwing three, four, even five or more targeted therapies at a cancer, with unknown consequences in terms of toxicity, and his mixtures that I’ve seen almost always contain either antineoplastons or sodium phenylbutyrate. This “everything but the kitchen sink” approach to targeting therapy is not “personalized medicine.” It is a parody of “personalized medicine.” It is the equivalent of a first year biochemistry student telling the Professor that his understanding of genetics is completely wrong. He could be right, but the burden of evidence is on him to prove it. Burzynski doesn’t even come close to meeting that burden of evidence. That he has the unbridled hubris to make the claim that he led the way and cancer centers like M.D. Anderson are following his lead would be risible if it weren’t so pernicious.
Myth #3: Eric Merola is an objective “investigative reporter” with no agenda
Finally, in publicity interviews and appearances, Eric Merola portrays himself as an “independent filmmaker” and “investigative reporter” with no axe to grind and no connection to the Burzynski Clinic or Burzynski Research Institute prior to his becoming interested in them before he made his first Burzynski movie. For instance, on his website, he describes himself as having become “aware of Dr. Stanislaw Burzynski and realized his was a story that must be told. Having always been heavily influenced by the power of documentary films, he decided to stop accepting new clients, maxed out his credit cards, and took his chances at becoming an independent documentary film maker.” Josephine Jones noted that during the airing of the first Burzynski movie by Colorado PBS (CPT12) as part of its pledge drive last week, Eric Merola appeared with a representative of the Burzynski Clinic and portrayed himself as an independent film maker who had difficulty gaining Burzynski’s trust initially, a story consistent with what is in his press materials. Throughout every publicity interview I’ve seen or read, the story is always the same: Merola is an “objective” independent film maker who just became so interested in Burzynski that he had to make the first Burzynski movie.
While this account of how Merola became interested in telling Burzynski’s story might be true given that by his timeline he must have started working on Burzynski I in 2007 or 2008, it doesn’t quite tell the whole story. In his interviews Eric Merola conveniently neglects to mention that his cousin Domenica Prescott had been a patient at the Burzynski Clinic after having been diagnosed with glioblastoma multiforme in July 2010. He also doesn’t mention the outcome. She underwent two surgeries, six weeks of Temodar chemotherapy, and six weeks of standard radiation. Unfortunately her residual tumor did not respond, and she died on May 12, 2011. The details of her story can be found here.
Given that Ms. Prescott’s diagnosis occurred around the time of the initial release of Burzynski I, the fact that she developed brain cancer and died under Burzynski’s care doesn’t cast doubt on Merola’s account of how he became interested in the Burzynski Clinic. Indeed, Ms. Prescott herself credits her cousin for making her aware of Burzynski. On the other hand, it is rather curious that when asked why he is so passionate about his Burzynski movie projects Merola never mentions his cousin, and there is no mention of her in his press materials or, any longer, on his website. There was a mention of her in Merola’s April 27, 2011 newsletter, but it is no longer there, although it is still on still on Facebook. (Praise also be to Archive.org and now screenshots.) The newsletter ran with the title “Great News!” and described Ms. Prescott’s progress:
Some of you following this project through our newsletter remember Eric Merola’s cousin, Domenica Prescott, was diagnosed with a Glioblastoma Multiforme Grade IV brain tumor last year. Two surgeries, and 6 week of Temodar® chemotherapy and radiation failed to effect her deadly tumor.
After this “standard of care” failed her — about 4 to 5 weeks ago my cousin Domenica began Antineoplaston treatment. After only 4 to 5 weeks of treatment, her first MRI showed that the tumor is breaking down, and the enhancing portion of the tumor is diminishing! This means that she is responding to Antineoplaston treatment. If this continues, she should be on her way to a full recovery within a few short months.
This sounds eerily familiar to what Dr. Burzynski told Amelia Saunders’ parents when he tried to convince them that the cysts and decreased enhancement of their daughter’s brain tumor meant that the antineoplastons were working. Two weeks after being told her tumor was responding to antineoplaston therapy, tragically, Ms. Prescott died of her disease.
I do not bring up what undoubtedly must have been a horribly painful event in Eric Merola’s life in order to “attack” or “terrorize” him, although no doubt he will spin it that way if he sees this post and bothers to respond. Indeed, Merola will never believe me when I say this, but even in spite of all the vitriol he has unleashed in my direction he actually has my sympathy for the loss of his cousin at far too young an age. As someone who’s lost family members to cancer, I know as much as anyone that it definitely hurts. However, I do want to use this incident to show that Merola, contrary to the image of himself that he cultivates for the press and world of documentary films, is no neutral “investigative reporter.” Quite the contrary! He is without a doubt a true believer, having referred his cousin to Burzynski when conventional therapy failed her. After she died, he clearly still believed. After all, if he didn’t believe, he wouldn’t have started working on a second movie, in essence, doubling down on his commitment to Burzynski, and used it to lash out at Burzynski’s enemies, both real and imagined. If he were up front about his cousin’s tragic story and weren’t using other patients as human shields to ward off criticism, I would never have mentioned Ms. Prescott, but Merola does all of those things and seems to be trying to keep her story quiet, having scrubbed all trace of her from his website and not acknowledging her tragic outcome, which would no doubt bring about inconvenient questions during his publicity appearances if his cousin’s story were widely known.
The mythology of Burzynski and his defenders
Obviously, I “cherry picked” three examples of myths being propagated about Stanislaw Burzynski. There are more, oh so many more. Merola’s two movies about Burzynski are not reliable sources of information; rather, they are propaganda pieces made by a true believer who, while claiming his movies are “factual,” presents such a relentlessly one-sided story devoid of even the slightest bit of skepticism or balance that what he has done is at best a long-form advertisement for the Burzynski Clinic. Remember that if you have the opportunity to view either of Merola’s two Burzynski movies. They are about myth building, not science. The story is that of a brave maverick, despised by his dogmatic and unimaginative peers (who can’t understand his genius) and schemed against by an even more evil cabal of bloggers hiding in the shadows, who triumphs over all and cures cancer. It’s a nice fantasy, but unfortunately it’s just that, a fantasy. I can only hope that reality is finally intruding on the fantasy.

Now that Burzynski has gotten off in 2012, Burzynski The Movie will spawn a sequel in 2013
David Gorski on December 3, 2012
Link
About a year ago, I became interested in a physician named Stanislaw Burzynski who has been treating cancer with compounds that he calls “antineoplastons” for over three decades without, in my opinion, ever having ever produced any compelling evidence that antineoplastons have significant anticancer activity. Although I had been vaguely aware of Burzynski and his activities, it was the first time that I had looked into them in a big way.
Having found very few skeptical, science-based takes on Burzynski and having noted that the Quackwatch entries on Burzynski (1, 2, 3) were hopelessly out of date, I wrote a trilogy of posts about him, starting with a review of an execrably bad movie made by a simultaneously credulous yet cynical independent writer, producer, and director named Eric Merola whose primary business, appropriately enough, is mainly marketing. The movie was Burzynski The Movie: Cancer Is A Serious Business, a “documentary” (and I’m being polite here) that I characterized at the time as a bad movie and bad P.R. In brief, I saw this movie as a hagiography, a propaganda film so ham-fisted that, if she were still alive, it would easily simultaneously make Leni Riefenstahl blush at its blatantness and feel nauseated how truly awful it was from a strictly film making standpoint. It was also chock full of highly dubious science, in particular Burzynski’s latest venture, which is to sell “personalized gene-targeted cancer therapy” similarly lacking in oncological insight, so much so that I observed at the time that it was as though Dr. Burzynski read a book called Personalized Cancer Therapy for Dummies and decided he is an expert in genomics-based tailoring of targeted therapies to individual cancer patients. Finally, I completed the trilogy by pointing out that lately Burzynski has been rebranding an orphan drug that showed mild to moderate promise as an anticancer therapy.
Since then, I haven’t commented much about Stanislaw Burzynski on this blog (although fans of a certain Plexiglass box of blinking lights know that I’ve written about him elsewhere), except to use him as an example of a physician gone horribly wrong and an utter incompetent when it comes to personalized therapy. In essence, Burzynski represents the potential dark side of personalized medicine in that, even though he has no skills or expertise necessary to navigate the complex and cutting-edge field, he nonetheless orders cancer profiling tests from a company whose tests don’t look that useful to me, “interprets” the results, and then orders up a witch’s brew of expensive, targeted agents with potentially synergistic toxicities that have not been validated as combination therapy. Basically, the way Burzynski puts together “personalized therapy” reminds me of Severus Snape mixing potions together at Hogwarts—with one big difference. Snape knew what he was doing and his potions worked. The same cannot be said of Burzynski, who from my perspective understands neither molecular biology, genomics, nor, let’s face it, cancer.
However, a lot has happened in the year since I last wrote specifically about Burzynski on this blog, particularly in November. First, the long and sadly ineffectual effort by the Texas Medical Board to strip Burzynski of his license has come to an ignominious end—for the Texas Medical Board. Second, an announcement by Eric Merola on the Burzynski Movie YouTube channel that he is going to be releasing another movie about Burzynski in early 2013, which, according to Merola, will be “picking up where the first internationally award-winning documentary left off.”
I can hardly wait. No, really. I can hardly wait. Such targets only come around maybe once every few years.
First, let’s look at how Burzynski in my opinion got away with murder.
The Texas Medical Board flails once again
Right before Thanksgiving, I learned from Patrick “Tim” Bolen that apparently Burzynski might have slithered away from justice yet again. The last time, his hearing in front of the Texas Medical Board to strip him of his license was postponed by various legal maneuvers. Bolen gloated about the failure of “skeptics” and cited a letter from Burzynski’s attorney Rick Jaffe:
On November 19, 2012, judges of the Texas State Office of Administrative Hearings dismissed the Texas Medical Board’s pending case against Dr. Burzynski. The investigation started by the board in 2008 involved Burzynski’s novel off-label use of combination gene targeted therapy. Early on, two medical board informal settlement panels found that the use of these combination drugs on the advanced cancer patients involved was within the standard of care. However, the Texas Medical Board refused to drop the case and instead filed a formal complaint against Dr. Burzynski alleging the same standard of care violations previously rejected by the board settlement panels. After two years of intense litigation, the case was set for trial in April 2012. However, a week before trial, the administrative law judges dismissed most of the charges against Dr. Burzynski which forced the Board to seek to adjourn the case to do some reevaluation. After the judges denied the Board’s attempt to reverse the previous partial dismissal of the case, the Board did more reevaluation and moved to dismiss the entire case. We didn’t oppose the motion and on November 19, 2012, the case was dismissed.
The cutting-edge, multi-agent gene targeted therapy devised by Dr. Burzynski which was at the heart of this proceeding is still being given at the clinic and is helping countless patients. The Burzynski Clinic thanks all of its supporters and wishes all a Happy Thanksgiving and thanks – Rick.
Certainly, the gloating by the likes of Patrick “Tim” Bolen and Burzynski’s lawyer shed no light on the question, nor did this triumphant screed by someone who calls herself Sarah the Healthy Economist:
Why has Dr. Burzynski been so relentlessly persecuted first by the United States Government and then the Texas Medical Board for so many years?
Follow the money my friends!
The multi-agent gene targeted therapy called Antineoplastons is a nothing short of a huge medical breakthrough that promises to completely shatter the cut, poison, burn Standard Of Care – surgery, chemotherapy and radiation treatment. When clinical trials are completed and Antineoplastons approved, it will be the first time in history that a single individual and not a pharmaceutical company holds the exclusive patent to manufacture and distribute these gene targeted medicines on the open market.
Uh, no. Antineoplastons don’t represent “multi-agent gene targeted therapy.” The person who wrote this bit of gloating is clearly too ignorant of what Burzynski actually does and claims to know that the “gene-targeted” therapy he claims to provide is not antineoplastons (although Burzynski somehow manages always to include antineoplastons in his concoctions). Nor is what Burzynski does anything that will “completely shatter” the current cancer treatment paradigm.
None of this stops the hyperbole, though:
Parents have particular reason to rejoice that the case against Dr. Burzynski has been dismissed. One form of childhood cancer – diffuse, intrinsic, childhood brainstem glioma for which conventional medicine has no cure has been cured by Antineoplastons (with dozens of others). [ANP – PubMed 2003] [ANP – PubMed 2006] [ANP – Cancer Therapy 2007] [Rad & other – PubMed 2008] [Chemo/Rad – PubMed 2005]
Congratulations Dr. Burzynski on this huge win against the foes that are attempting to silence you and stop your amazing work. The road ahead is still long until treatment with Antineoplastons is widely available to all Americans, but this recent victory brings a big one home for the little guy!
The heart of the case brought against Burzynski brought by the TMB was his off-label use of targeted therapies in treating cancer patients, or, as I’ve referred to it a couple of times already, “personalized therapy for dummies.” It is actually astounding to see the number of targeted drugs in the drug cocktails used by Burzynski. Not only was Burzynski using chemotherapy and a lot of it, but he was using some very expensive products of big pharma in a medically unsupportable manner. So let’s head over to the actual legal rulings. I do this, of course, with a bit of trepidation because, of course, I’m not a lawyer. However, even not being a lawyer, I think the reasons for the dismissal become fairly obvious by reading some of the motions and rulings. Plus I had input from a real lawyer, our very own Jann Bellamy.
So why was Buryznski’s case dismissed? To find out, you too can get the relevant PDFs if you wish, just by going to the Texas State Office of Administrative Hearings (SOAH) and, using a guest account, and searching for docket 503-11-1669. The “money filings” are ORDER NO. 12 – RULING ON RESPONDENTS MOTION FOR DISPOSITION, STAFFS SPECIAL EXCEPTIONS, AND MEMORIALIZING PARTIES STIPULATION OF FACTS and ORDER N O. 16 » GRANTING AND DENYING IN PART STAFFS MOTION FOR RECONSIDERTION OF ORDER NO. 12. Basically, the TMB had gone after Burzynski based on the doctrine of vicarious liability, which means in essence that the TMB was arguing that Burzynski was responsible for the actions of the physicians working for him who had cared for the patients at the heart of the TMB case against Burzynski. In response, Burzynski moved to dismiss and/or strike TMB allegations against him to the extent that the allegations were based on the actions of other physicians working at his clinic. His attorney’s argument was that, under administrative law, there is no vicarious liability for the actions of others. This is apparently different from tort law (for example, medical malpractice), where the physician can be held liable for the actions of physicians working under his control or supervision in some circumstances. The bottom line is that the administrative judge ruled in Burzynski’s favor. From the RESPONDENT’S REPLY TO THE BOARD STAFF’S SUPPLEMENTAL RESPONSE ON THE CONSOLIDATE MOTION FOR DISMISSAL AND SUMMARY DISPOSITION:
Respondent’s ownership of the clinic and his self-designation as the clinic’s chief physician on some forms, his ability to hire and fire everyone, and even that the forms which state that he is in “charge of treatment” (as stated in the informed consent forms for patient A) is only evidence of responsibility under vicarious liability theory, given the fact that the medical records detail exactly what doctors provided services to these two patients and who was involved in the delivery of medical care to these patients.
The judge accepted this reasoning, which meant that the TMB apparently faced the bad option of trying to prosecute a case based only on what the complaint alleged that Burzynski himself did. It’s not clear why the TMB voluntarily dismissed the case after this ruling, but perhaps the TMB’s lawyers concluded that there wasn’t a strong enough case based only on the allegations against only Burzynski. Basically, by throwing his fellow physicians working for him under the bus, Burzynski walks. Why do I say “throwing them under the bus”? Simple. The TMB could, if it so desired, begin actions against the individual physicians who took care of these patients, and I sincerely hope that the TMB does just that.
As for the significance of the ruling, contrary to what Burzynski’s apologists would like you to believe, this ruling says absolutely nothing about whether what Burzynski is doing is good science or not. It says exactly nothing about whether what Burzynski is doing is good medicine or not. It says even less about whether Burzynski’s clinical trials are ethical or not. All the board found was that, as a matter of law, the TMB couldn’t bring action against Burzynski on the basis of actions performed by doctors under his supervision. So it’s a non sequitur when someone like Patrick “Tim” Bolen exults that Burzynski’s somehow been vindicated, Sarah the Healthy Economist says “alternative cancer treatment wins big,” or Burzynski’s lawyer Richard Jaffe says something like, “The cutting-edge, multi-agent gene targeted therapy devised by Dr. Burzynski which was at the heart of this proceeding is still being given at the clinic and is helping countless patients.” Just because the judge ruled on a narrow point of law regarding whether specific allegations were admissible in a case against Burzynski says nothing about the validity of Burzynski’s work, nor does it in any way vindicate him. He got off on a technicality, and that’s all. It’s even sillier when someone like Jeffrey Phelps tries to spin the outcome of this case as evidence that cancer quacks ranging from Max Gerson to Royal Rife (and quite a few in between) must be on to something and that their rejection by the scientific community was unfounded.
That still leaves the claim by Jaffe that “two medical board informal settlement panels found that the use of these combination drugs on the advanced cancer patients involved was within the standard of care.” Unfortunately, we have no way of finding out what the settlement panels did or didn’t find because the proceedings of such panels are confidential, being as the name implies an attempt to see if the parties can settle the case prior to litigation. One notes that the board appears to have disagreed with Burzynski’s characterization of the settlement proceedings.
I’m not going to lie or downplay it here, though. The dismissal of the TMB action against Burzynski is a major setback to efforts to stop what Burzynski is doing. He’s now basically free to continue to do what he’s been doing for the last thirty years. Once burned, it’s unlikely that the TMB will take another crack at him any time soon. The last time it did was back in the 1990s. Will it be in the 2020s before a future board decides to try again, or will Burzynski retire or die before then, leaving his son Greg to carry on the family business?
Unfortunately, it’s clear that this ruling sets the stage for Burzynski II — or is it III? Given that Burzynski managed to slither away from justice back in the 1980s, when the TMB and the FDA were both on his case, making the current incarnation of Burzynski the second installment, although he didn’t get a such a willing sycophant to make a movie about him back then.
And now, Burzynski The Sequel: Even Burzynskier than the first movie!
Just yesterday, my Google Alerts did what the name implies and alerted me to a new development in the Burzynski saga. Meanwhile, a couple of Burzynski fans dropped some links on my blog, for instance this one from the Burzynski The Movie website:
For most patients being treated by the Burzynski Clinic today—their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists—who simply do not understand Burzynski’s therapy—but also from their own friends and family who feel their loved ones are not making the correct treatment decisions—even though mainstream oncology has already left many of them for dead.
As this story unfolds, the audience will witness a real-time change of hearts and minds from many doctors and families.
Unlike the first documentary, we have interviewed board-certified oncologists, surgeons, and neurosurgeons for this film who witnessed their patients leave their care to return in great health, after opting for the Burzynski Clinic.
Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy that he calls, “Personalized Gene-Targeted Cancer Therapy”, where each patient’s Genomic Cancer Atlas is mapped, and a treatment regimen is personally tailored for each individual patient—vs. the conveyor belt, “one size fits all” approach that current oncology adheres to. This part of the film will likely be the first time most of the audience will become aware of this new direction.
Due to the slow-moving bureaucratic obstacles of Antineoplastons by the FDA, this new expanded “personalized gene-targeted” direction has allowed more patients who are denied access to Antineoplastons by the FDA to benefit from Burzynski’s practice in ways never before thought possible.
Note the framing. There are those nasty skeptics, oncologists, and promoters of science-based medicine who, out of concern for patients going to the Burzynski Clinic, try to warn patients that Burzynski doesn’t have the goods. Merola will show them! He’ll do it using what are, in essence, religious conversion stories, in which the metaphorical St. Paul is knocked off his horse by the sheer awesomeness that is Burzynski, recants his previous skepticism as the “miracle” of antineoplastons and Burzynski’s “personalized” therapy is revealed, and becomes a believer. Notice, however, no mention of—oh, you know—scientific evidence.
It also looks as though Merola is going to amp up the conspiracy theory angle again. I’m not sure how he will achieve this, given that the first installment in Burzynski The Movie was one-third anecdotes, two-thirds broadsides against the FDA and the Texas Medical Board chock full of conspiracy theories. In any case, I’d love to see what Burzynski and his propagandist have to say about his “personalized gene-targeted cancer therapy for dummies”-approach to personalized cancer therapy, because from what I can tell on his website and publicly available sources, not only does Burzynski completely misunderstand targeted therapy, thinking that working on more genes must be better (here’s a hint: chemotherapy works on a lot of genes), but he misapplies very basic knowledge of genomics by using a “one from column A, two from column B”-style mixing and matching of targeted agents devoid of any deep understanding of the consequences.
Let’s take a look at the trailer:
The clip starts off with what is very old news, a press conference by the director of the FDA through much of the 1990s David Kessler, being asked at a press conference whether the process of expedited review introduced then for anticancer therapies would speed up the approval of antineoplastons. Clearly, the two reporters asking questions are believers, as they keep badgering Kessler after he says that he doesn’t want to focus on any single anticancer agent. We’re then told ominously that less than one year after this press conference America’s federal and state agencies lost a “fourteen year campaign attempting to permanently revoke Burzynski’s medical license” and declares that “Burzynski’s victory” resulted in the government abandoning its attempt to “hijack” these medicines. Merola also accuses the government of colluding with one of Burzynski’s own scientists to file patents on Burzynski’s therapies, listed as patent numbers 6037376, 5635532, 5852056, 5654333, 5661179, 5635533, 5843994, 5710178 (which is the same as 5843994), 5877213 (listed as a continuation of 779744, which was abandoned), and 5881124. Several of these appear to be redundant, being continuations or combinations of other patents. Be that as it may, the researcher to which Merola refers is Dvorit Samid, who is currently Vice President of Medical Affairs at Synta Pharmaceutical and was Section Chief Differentiation Control, National Cancer Institute/National Institutes of Health Division of Cancer Treatment from 1990 to 1995. These patents have mainly to do with phenylacetic acid, which was one compound that Burzynski referred to as AS-2.1, and derivatives mostly as anticancer or differentiation compounds in in vitro systems. One of these patents (5881124) has nothing to do with antineoplastons and is in fact an imaging patent. Maybe it’s a typo that Merola will fix before he releases his movie.
Be that as it may, the claim that Dvorit Samid “stole” Burzynski’s antineoplaston patents strikes me as rather questionable (at best), given that, first, Samid was not “one of Burynski’s scientists” but a section chief at the NCI. Also, using Merola’s counting methods, Burzynski himself has four patents on antineoplastons, issued in the 1980s. These include 4,470,970, 4,558,057, 4,559,325, and 4,444,890 and since the 1990s has filed numerous patent applications for antineoplastons for everything from treating cancer using liposomal delivery systems, to treating hypercholesterolemia and Parkinson’s disease. What exactly happened between Burzynski and the NCI is difficult to discover, as it is documented objectively in few places but trumpeted around the web by Burzynski-friendly sources. Even a paper analyzing the incident from a sociological standpoint isn’t particularly revealing, given that it, too, slants towards Burzynski and was published in a highly dubious journal.
Next up is a mention of Burzynski’s infamous phase III clinical trial, A Randomized Study of Antineoplaston Therapy vs. Temozolomide in Subjects With Recurrent and / or Progressive Optic Pathway Glioma. What has always been puzzling to me, ever since I became interested in Burzynski and his antineoplastons, is why Food and Drug Administration (FDA) not only continues to let Burzynski set up phase II clinical trial after phase II clinical trial, nearly all of which never accrue enough patients to publish. Indeed, if you search ClinicalTrials.gov for “Burzynski” or “antineoplaston,” exclude all the trials with “unknown” status, you’ll find the aforementioned phase III trial, a whole lot of trials with “unknown” status, and a trial unrelated to antineoplastons for which a man named Joseph Burzynski appears to be an investigator at one of the sites.
One notes that Burzynski’s phase III trial, although approved in December 2010, is not yet open to accrual, even though it was scheduled to begin accruing patients in December 2011. In any case, the reason that this is an issue is that Burzynski apologists have been pointing to this study as “evidence” that there must be something to antineoplastons, the rationale being that otherwise the FDA would not have given the trial the go-ahead. Given that there is no good clinical data published by Burzynski that I’ve been able to find to support a phase II clinical trial, this has puzzled me and other skeptics, at least one of whom suspects that, however he persuaded the FDA to approve this trial, it suits Dr. Burzynski just fine that it has not opened yet. It is a suspicion that I share. Think about it. This phase III trial is the biggest and most effective club that Burzynski apologists have to beat skeptics over the head with. If Burzynski actually started accruing to the trial, its results would, by law, have to be posted to ClinicalTrials.gov. An approved but not yet accruing trial is an infinitely better weapon than a trial that accrues and produces no results. It’s also interesting to note that this clinical trial includes chemotherapy.
As for the phase II trials, there are lots of trials listed as having “unknown” status (meaning that their status has not been verified in over two years) but still listed as being “open” as well. There are also several studies listed as “withdrawn.” It’s a total of 62 trials over the last 20 years or so, and not a single one of them, as far as I and others who have looked at them have ever been able to tell, has produced any useful evidence for the efficacy of antineoplaston therapy. Is it any wonder that many of us suspect that these “clinical trials” are shams designed to get around the orders of the Texas Medical Board back in the 1990s that prohibited Burzynski from using antineoplastons except within the context of being tested in clinical trials?
The rest of the trailer consists of nothing more than the usual Burzynski blather, anecdotes, this time bolstered with two conversion stories involving credulous oncologists who are now Burzynski believers.
The human toll
If there’s one thing that disturbs me most of all about Burzynski, it’s my perception of how he abuses the clinical trials process, something he does as blatantly, if not more so, than antivaccine “researchers.” In this, Burzynski arguably exceeds the worst excesses of big pharma in that big pharma does not charge patients to participate in its clinical trials. Experimental drugs and all nonstandard care and tests related to the clinical trials are paid for by the drug company or, in the case of clinical trials funded by the government, but the grants funding the trials. In contrast, Burzynski typically charges tens to hundreds of thousands of dollars to participate in his “clinical trials.” When big pharma abuses the clinical trials process it is rightfully called out by Burzynski apologists. But when Burzynski does things as bad, such as using a biased and useless institutional review board to oversee his “trials,” and even worse from an ethical standpoint, such as charging patients huge sums of money to buy drugs at pharmacies he owns and using them as a “human ATM,” he is the brave maverick doctor being persecuted by The Man because he has the “natural” cancer cure that “they” don’t want you to know about and is given gushing coverage in a book by Suzanne Somers. Ben Goldacre recently released a book castigating big pharma for misleading patients and doctors. Burzynski supporters give us Eric Merola and his propagandistic “documentaries.”
Josephine Jones has been maintaining a master list of blog posts about Burzynski, and there you can find, along with several of my posts, links to a whole bunch of posts about patients and families who, lured by the false hope of the Burzynski clinic, spent hundreds of thousands of dollars for his antineoplaston therapy. Often, such families, who come from all over the world to the Burzynski Clinic in Houston, undertake truly prodigious fundraising efforts to come up with the requisite cash, a significant proportion of which is due up front. Most famously, there was Billie Bainbridge, a British girl diagnosed with intrinsic pontine glioma in 2010 who became famous in the U.K. because her family managed to persuade several British celebrities to hold two charity concerts to pay for her treatment at the Burzynski Clinic. Indeed, it was critical looks by U.K. bloggers, including a U.K. teen named Rhys Morgan, that led to a flack from the Burzynski Clinic making crude, thuggish, vacuous and bizarre legal threats to silence Morgan, behavior that that got even more bizarre after Burzynski, embarrassed and none too pleased by the attention, cut him loose while issuing a classic “notpology.”
Unfortunately but not unexpectedly, Billie Bainbridge died last spring.
Unfortunately, there are many other patients like Billie, the main difference being that most of them can’t muster the star power that Billie’s family could:
    • Brynlin Sanders, a four-year-old girl from Kansas who developed brainstem glioma. Her family held fundraisers, including one on New Year’s Eve that netted $50,000. Not surprisingly, Burzynski didn’t save her.
    • Jesse Bessant, a two-year-old boy from New Zealand with an inoperable brainstem tumor whose family raised over $300,000 to take him to the Burzynski Clinic.
    • Isabelle Tan, a young woman from Singapore with an inoperable brain tumor who went to the Burzynski Clinic.
    • Chiane Cloete, a six-year-old girl from the U.K. with a rare brain tumor whose parents are raising £130,000 to take her to the Burzynski Clinic.
    • Rachael Mackey, the most recent patient I am aware of, was a 28-year-old woman with an oligoastrocytoma. She underwent surgery to remove it, but it recurred, and the second time around the surgeons were not able to remove it all. She died on October 28. Bob Blaskiewicz over at Skeptical Humanities has started a Storify page that chronicles Rachael Mackey’s experiences with the Burzynski Clinic. It’s truly sad.
    • Amelia Saunders, a four-year-old girl from the U.K. who suffers from a large inoperable brainstem astrocytoma. As of October 4, they reportedly have raised £249,776 to pay for Burzynski’s treatments.
In fairness, the patients who have died after seeking care from Stanislaw Burzynski would almost certainly have died anyway. However, when they go to Burzynski they end up being charged tens or hundreds of thousands of dollars unnecessarily for his antineoplaston therapy, for which there is no compelling evidence of efficacy, although there are a lot of questionable anecdotes. They end up facing enormous financial pressures, and many of the families of these patients hold fundraisers and try to generate publicity, the better to attract donors to give them the money that they have been led to believe is the only hope their loved ones have to survive. Yes, these patients uniformly all eventually die, as is unfortunately virtually inevitable given the nature of their disease, but there’s no evidence that Burzynski prolongs their lives or contributes to their quality of life. Worse, Burzynski extracts huge sums of money from their families for the “privilege” of being on one of his many dubious clinical trials, funded by kind-hearted strangers and fueled by Burzynski’s cult of personality.
In the wake of his victory against the TMB (and, let’s not kid ourselves, even though a judge’s ruling on a fine point of law says nothing about the validity of Burzynski’s methods, this is a massive victory for Burzynski, at least in the arena of public opinion), it looks as though 2013 is going to be a year of a renewed push by Burzynski to convince the public that he isn’t a quack. Certainly the TMB isn’t likely to touch him again any time soon, although we can still hope it will go after the doctors working for him. One wonders if it’s possible to get a skilled, high-powered investigative journalist from a major news organization to look into this story. For a while, ABC News seemed to be interested (a producer actually contacted me in April to see if I would be willing to appear on camera). Unfortunately, apparently its news crew lost interest after Burzynski’s hearing scheduled for April was postponed, because I never heard from this producer again. I hope another organization will step up to the plate.

Burzynski: Cancer Is A Serious Business, Part 2: Like the first Burzynski movie, only more so?
David Gorski on March 14, 2013
Link

Film producer Eric Merola seems to think that there is a conspiracy of skeptics (whom he calls The Skeptics) who are fanatically hell-bent on harassing his hero, Brave Maverick Doctor Stanislaw Burzynski. According to his latest film Burzynski: Cancer Is A Serious Business, Part 2 (henceforth referred to as Burzynski II, to distinguish it from part 1, to which I will refer as Burzynski I), there is a shadowy cabal of Skeptics out there just waiting to swoop down on any Burzynski supporter who has the temerity to Tweet support for him, any cancer patient being treated by Burzynski who Tweets or blogs about it, and any cancer patient even thinking about going to the Burzynski Clinic. I know this because he’s made it very clear in the promotional materials of his movie that that’s what he thinks and that skeptics were going to be the main target of his “film making” in his latest hagiography devoted to Stanislaw Burzynski. Very clear indeed. And, given how ham-fisted he was in his conspiracy mongering in Burzynski I, I’d be lying if I didn’t admit that I was at least a little concerned, because Merola made an explicit promise to “name names.” So were some other skeptics. After all, Merola isn’t exactly known for intellectual honesty (or even talent) in film making. We expected a heavy duty sliming, and curiosity (not to mention concern over our reputations) made us very—shall we say?—curious about what Merola was going to say about us.
So it was with great interest that I learned that Burzynski II was going to be screened at a film festival in San Luis Obispo last weekend. Its DVD release having been delayed from March 5 to July 1, I had thought that my curiosity about the contents of the movie would probably have to wait, and it will, at least as far as seeing the movie. A review of the movie suggested dark insinuations about Burzynski critics abounded, but that was not enough. Fortunately, a small posse of skeptics, lead by the intrepid Brian Thompson, made posthaste for San Luis Obispo. When the reports and copious handwritten notes in perfect encoded reptilian script came back, however, I was faced with a problem. How does one review or discuss a movie second-hand? How does one report on a movie that one hasn’t seen, about which one has to trust the powers of observation (and not to mention the note taking capabilities) of someone else, no matter how well briefed beforehand about what to look for? I decided that there was only one thing to do, and that’s just to go ahead and do it. I realize that there are likely huge swaths of information missing, but I definitely got a flavor of the movie from Brian’s detailed account plus discussions, and a definite idea of how it is going to be promoted from what was reported to have been said during the Q&A. Then I’ll discuss each of these points, thus inflating the rather thin observations I have from our Skeptics into a real post. Unfortunately, more detail from me will have to wait until the official release of the movie, or until such a time as Merola tries to bring the movie to somewhere in my neck of the woods. (Wouldn’t that be amusing?)
So here are the five things I learned (secondhand) from the Burzynski II screening, thanks to The Skeptics.
1. Stanislaw Burzynski is a genius who invented “personalized gene targeted cancer therapy,” and is now being emulated by centers like M.D. Anderson, which are furiously trying to catch up.
One thing I noticed immediately from our Skeptics’ reports was that I was spot on when it comes to many of my predictions about the movie, so much so that I was tempted simply to do a link dump of my posts on various Burzynski claims in the form of “claim in Burzynski 2” juxtaposed with a link. But, as Han Solo said, “Hey, it’s me,” and I can’t do that. In any case, this should not be a surprise. Burzynski’s been telegraphing this particular message for the last few years, beginning at least as far back as 2009, when I first read his claims in Suzanne Somers quackfest of a book, Knockout: Interviews With Doctors Who Are Curing Cancer And How To Prevent Getting It in the First Place. According to our Skeptics, the very beginning of the movie was in essence more of Burzynski’s arrogance of ignorance about “personalized gene-targeted cancer therapy,” in which he demonstrates once again that he doesn’t know what he’s talking about with regards to genomics and targeted therapy and adds a healthy dose of special pleading that it is “impossible” to test Burzynski’s woo—I mean “personalized gene-targeted cancer therapy” (which I will henceforth refer to as PGTCT)—in randomized clinical trials (RCTs). This is not unlike the argument that homeopaths frequently make claiming that their woo can’t be tested scientifically. It’s also as nonsensical.
That’s why I can’t resist mentioning that it’s true that testing personalized cancer therapy scientifically poses certain challenges. It can’t be done in the same way that we’re used to doing RCTs. I discussed this very matter when I discussed Burzynski’s PGTCT the first time around, and even analyzed an example of how it can be done. My analysis is probably now out-of-date because the field is moving so rapidly, but the bottom line is that real scientists and real physicians at real cancer centers, contrary to what seems to have been insinuated, think about these issues all the time. The FDA is devoting considerable effort to figuring out how new genomic technologies will fit into its mission and how it can find a scientifically reasonable method to grant approval to such therapies. Once again, Stan’s arrogance of ignorance, hungrily lapped up by his lapdog Eric Merola, appears to be the order of the day. According to the reports, it’s made to sound as though Burzynski invented personalized gene-targeted therapy, which is, of course part of the mythology that I recently discussed. Burzynski didn’t invent PGTCT. He doesn’t even do it right. Indeed, at one point, Merola even has the cojones to assert that cancer centers like M.D. Anderson haven’t yet faced the problems Burzynski is facing because, I guess, Burzynski led the way. No doubt it’s true that M.D. Anderson doesn’t face the problems that Burzynski is facing. That’s because M.D. Anderson is trying to do it right; Burzynski is not.
2. Burzynski is a Brave Maverick Doctor who is curing patients that conventional science can’t cure, and it’s not his fault when he can’t
Early in the movie, as was the case in Burzynski I, there is a series of patient anecdotes, or, as I like to call them, testimonials. It turns out that nearly all of them are patient stories that I’ve discussed before in great detail. For instance, Hannah Bradley and Laura Hymas feature prominently, but since I’ve discussed both of them in depth recently, I refer you to that link if you want to know why Merola’s claims that Burzynski cured these patients is certainly contestable. One thing that was noted is that there was a long segment on Laura Hymas with a tape of her and her family trying to persuade her NHS oncologist to support her decision to go to Burzynski. I would very much like to hear that segment, because it could be instructive to see how an oncologist handled Hymas’ family’s pleas to be associated with something he definitely didn’t want to be associated with. I guess I’ll have to wait until July.
Now here’s the part that disturbed our intrepid viewers, and, when they told me about it, I was even more disturbed by it because I’ve seen less subtle variants of it before. I’m referring to the cases of two children from the U.K. with malignant brain tumors who became famous after their diagnoses because of their parents’ success at raising money and bringing their children’s plight before the British press and public. I’m referring to Billie Bainbridge, whose case led to widespread discussion in the British press in late 2011 because of very successful fundraisers featuring beloved celebrities, and Amelia Saunders. Both children, tragically, died of their disease, and I’ve discussed both cases, particularly Amelia Saunders, before. Now here’s what bothered us. After interviews with each set of parents and glowing reports about how each child did so well on Burzynski’s antineoplaston therapy, we learn of each child’s ultimate demise in voiceovers. In Billie’s case it’s apparently mentioned that Billie had had radiation therapy for her tumor, and the narrator noted that children who hadn’t had radiotherapy do better. Then, after an interview with Amelia’s parents, the narrator intones that two months after the interview Amelia’s brain tumor began to “swell and fill with fluid.” He further intones that there was “confusion and disagreement” between the Saunders’ radiologist in the U.K. and the radiologist in Houston over why this was happening, and that the Saunders decided to take Amelia off of antineoplaston treatment. It’s then noted that Amelia died on January 6, 2013 with her family around her.
Here we see only slightly less subtle versions of two ploys favored by Brave Maverick Cancer Doctors designed to absolve themselves of blame and excuse their failures. In the case of Billie Bainbridge, the ploy is to claim that if only the patient had come straight to us and not used “conventional” therapy first, she could have been saved. In fact, a lot more of this sort of claim is found later, during the Q&A when one questioner asks Greg Burzynski, Stanislaw Burzynski’s son, whether the clinic has statistics tracking how well patients who have never seen any conventional therapy before and instead came straight to the Burzynski Clinic for their only care did. It was actually a surprisingly good question. Burzynski junior couldn’t answer and instead made excuses, claiming that his father was trying to publish that data but had been rejected. Instead, he trotted out Mary Jo Siegel, another testimonial, and there was apparently considerable discussion; most of the panelists thought it was better not to receive conventional therapy before antineoplastons and that patients who went straight to antineoplaston therapy did better. It was all anecdotes and testimonials, no data. Maybe it’s just my status as an evil conventional cancer doctor, but I found that to be a profoundly irresponsible message that encourages patients to eschew conventional therapy in favor of the unproven; i.e., antineoplastons.
The second favorite tactic of Brave Maverick Doctors like Burzynski is to blame the patient (or, in this case, the patient’s family) when the patient doesn’t do well. The insinuation here about Amelia appears to be that the reason she didn’t do well is because her parents didn’t follow the Brave Maverick Doctor’s treatment plan to the letter. The implication in Amelia’s case appears to be that the reason Amelia’s condition deteriorated so rapidly and she died was because Mr. and Mrs. Saunders decided to take her off of the antineoplastons too soon. I’m sure I’ll be corrected if my report on the matter was inaccurate. (I’m always open to a screener copy of the movie or a transcript from Mr. Merola to allow me to get it all correct.) Assuming it’s accurate (and I have no reason not to), this sort of insinuation is despicable, particularly given the real story, which has been discussed before. It’s worth reminding my readers of what happened. On November 20, 2012, Richard Saunders posted this message on Amelia’s Facebook page:
Amelia’s tumour is dying, from the inside. We’ll be getting another opinion from here on this, but the scans do back this up. There are cysts forming inside the tumour where cancer cells would have been before.
For the moment, we seem to be winning our little battle.
We are trying our hardest not to get too excited yet. These cysts are forming inside the tumour but it isn’t shrinking – however this proves the treatment is working. Remember that Amelia has received no other treatment.
It was pointed out at the time that these “cysts” almost certainly represented areas of ischemia (low blood flow) leading to tissue death as the tumor outgrew its blood supply. Again, this is a phenomenon commonly seen in advanced malignancy. Tumor cells are constrained in their growth to the diffusion of oxygen and nutrients in aqueous solution unless they can induce the ingrowth of blood vessels, a process called tumor angiogenesis. Tumors frequently can outgrow their blood supply, and when that happens, areas in the center of the tumor will die and liquify. Tumors frequently, as they progress, consist of a relatively thin rim of viable, growing cells surrounding a central area of necrotic tissue. In contrast, when tumors shrink due to chemotherapy or other treatment, they often shrink from the outside-in because that’s usually where the most rapidly proliferating cells are. True, they don’t always shrink that way and sometimes do have spread-out areas of necrosis, but that’s less characteristic. Sadly, then, seeing “cysts” growing in Amelia’s tumor most likely said nothing one way or the other about whether or not Amelia’s tumor was responding to Burzynski’s antineoplastons. That was assuming that Burzynski’s interpretation of the scans is even correct, which I doubted. Unfortunately, this is part of Burzynski’s M.O. He has misinterpreted the formation of cystic areas in brain tumors before as indicating tumor response to therapy.
Unfortunately, I was correct. On December 11, 2012, Mr. Saunders posted this sad update on Facebook:
We had our meeting at Great Ormond Street yesterday and, sadly, they just don’t have anything for us. We kind of knew this before we went – but wondered if they might have a trial that we could take part in. Unfortunately they don’t.
They felt that Amelia is in the latter stages of the disease, and that what is called ‘progression’ has already started. This means her tumour is growing, the cancer is spreading and we don’t have a huge amount of time left. Again we had already guessed this was happening but it was good in a way to have another opinion of this.
The other thing to mention is that I know I posted on here a few weeks back that Amelia had cysts forming in her tumour. Sadly it just appears this theory was wrong, and thank God we didn’t get our hopes up too much about this. Chantal and I have been accustomed to trying to make sure we get lots of opinions about things, and ultimately Amelia’s decline clinically is the telling factor. Her right hand side is now pretty well locked in position and her speech is going. Other functions like swallowing are also beginning to fail.
It tore my heart out to see that message. This is one time when I was not happy that I had been correct. More importantly, my disgust for Burzynski was greater than ever. Getting a report of Merola implicitly excusing Burzynski and subtly suggesting that Mr. Saunders was somehow at fault for listening to a real radiologist only heightened my disgust. One question that comes up in the wake of this part of the film is just which radiologists it is that Burzynski uses. I’ve heard of so many examples of dubious readings of imaging studies that I have to wonder.
3. Burzynski is a real scientist with tons of data supporting antineoplaston therapy who is being unjustly hounded by the FDA, the NCI, and big pharma to prevent him from bringing his cancer cure to market
In the movie, apparently not only is Burzynski a genius and pioneer who invented PGTCT long befoe conventional cancer centers like M.D. Anderson thought of it, but he’s also been unjustly persecuted by the FDA, the Texas Medical Board, and the NCI. Merola goes to great lengths to point out that two chemotherapy drugs approved for glioma, Temodar and Avastin, never went through phase III clinical trials and were approved on the basis of phase II clinical trials. This is true. They were approved using the accelerated approval process, which was designed to bring promising drugs to market more rapidly and in Merola’s hands is apparently portrayed as being a tool of big pharma to increase its profits. Merola bemoans how unfair it is (to him) that the FDA is requiring a phase III clinical trials for Burzynski’s antineoplastons and refusing to grant accelerated approval for them, as it did for Temodar and Avastin.
It seems like a compelling point on the surface if you don’t know about the drug approval process or Burzynski; indeed, The Skeptics who viewed the movie wondered about this claim. Here’s what, as far as I can tell from my reports, Merola leaves out. Temodar and Avastin both had proper, completed, and published phase II trials before approval. Moreover, although Merola did apparently mention that the accelerated approval doesn’t exempt manufacturers from doing phase III clinical trials, he apparently neglected to mention that if those trials are done and are negative then the FDA can revoke the accelerated approval. If Burzynski had ever published a complete phase II trial for antineoplastons for brainstem glioma, he might be considered for fast track approval. On the other hand, given his history, it’s probably quite reasonable of the FDA not to grant him eligibility for fast track approval. Certainly another thing stated in the movie and mentioned in the Q&A, too, is that if antineoplastons were approved for the indication of brain cancers they could then be used off-label for any cancer. Assuming our Skeptics got it right, this means that getting antineoplastons approved for brain cancer and then encouraging their off-label use for pretty much every other cancer seems to be Burzynski’s long term business plan.
There’s also apparently a heapin’ helpin’ of conspiracy mongering in Burzynski II very much like the conspiracy mongering in the first Burzynski movie. Brian handles this issue quite well, but I can’t resist chiming in as well. For instance, Merola claims that the FDA serves pharma, which uses it to suppress antineoplastons. It’s basically a rehash of the same sorts of arguments from the first Burzynski movie, all conspiracy theories beloved of cranks, including that universities don’t want a cure for cancer because they would loose all that sweet, sweet, NCI and pharma money, plus the even sweeter indirect costs that the NIH provides with grants. Then there’s a claim that the FDA requires independent testing, but that no hospital will work with the Burzynski Research Institute to test antineoplastons because, apparently, they don’t want to jeopardize all that filthy NCI and pharma lucre. (Has Merola actually seen the paylines for NCI grants these days? Obviously not. When the pay line barely reaches the 7th percentile, a lot fewer people are enjoying anything resembling Merola’s fantasy of academic medicine.) This conspiracy mongering is taken to a ridiculous extreme in the Q&A, when Eric Merola reports in response to a question that David Axelrod saw a rough cut of Merola’s first movie in 2009. At the time, Axelrod was a senior advisor to President Obama. Merola told the audience that Axelrod said the film was very important but that the issue was too big to deal with then given that the economy was tanking. Incredibly, Merola claims that Axelrod also said that approving antineoplastons would devastate the pharmaceutical industry, sending the country back into recession, and that the stock market would plummet as a result as well. When I read that part, I couldn’t help but laugh out loud.
And, apparently, it’s not Burzynski’s fault that he hasn’t been able to publish, either. The movie claims that up until 2006 antineoplaston papers were routinely accepted. Well, maybe. Or maybe editors are finally on to ol’ Stan. Whatever the case, as I’ve pointed out Burzynski’s publications since 2000 are pretty thin gruel and quite unimpressive, all in lower tier journals, some in “integrative medicine” and CAM journals, and some review articles. Although he’s published preliminary results of one of his phase II trials, he’s never, despite having had over 60 phase II trials, published a complete phase II trial. An amazing example of the nefariousness of journals is given. In November Burzynski tried to submit the results of a phase II trial to The Lancet Oncology, but we’re told that the manuscript was rejected two hours after it was submitted with basically no explanation. Any scientist who’s tried to submit to a top tier journal is probably laughing now. We’ve all accumulated stories like this. True, I’ve never had a two-hour turnaround time for an editorial rejection, but I have had a rejection in less than 24 hours. It’s cutthroat out there, and the top tier journals get so many submissions that they frequently do a “first pass” of rejections of manuscripts that the editors deem to have virtually no chance of being published or that don’t fit within the scope of the journal tightly enough. In fact, The Lancet Oncology is unusual in promising a 72 hour turnaround time. That’s a startlingly fast turnaround time. Come to think of it, maybe I should try to submit something to The Lancet Oncology. There’s nothing to lose, as I would know if it was rejected within 72 hours, so that I could submit it to a different journal. Then I could have something in common with Stan.
4. The Japanese are on the verge of publishing definitive clinical trial evidence that antineoplastons work!
This one’s no surprise either. I’ve addressed the issue of research on antineoplaston by Japanese anesthesiologist Dr. Hideaki Tsuda, and Keir Liddle has pointed out why this research thus far is not so impressive. I agree. But I was intrigued; so I suggested that our Skeptics pay close attention to whether any specific results of the vaporware Japanese trial were described. What they learned was that it was a trial of 63 patients with colorectal cancer metastatic to the liver randomized to either chemotherapy or chemotherapy plus a course of antineoplastons. The movie tells us that the results were awesome, namely that the addition of antineoplastons pushed median survival from 36 months to 70 months. This would indeed be an impressive result if it were validated, although one can’t help but notice that, even in that case, antineoplastons would not be the cure that is often claimed. Even if the result held up, they would be a treatment added to chemotherapy. (Also never mind that antineoplastons are chemotherapy.) In any case, I can’t evaluate this claim until I see a publication in the peer-reviewed medical literature other than to say that most scientists frown on discussing one’s results in a propaganda movie before actually…oh, you know…publishing them in a decent peer-reviewed journal—and with good reason.
5. Skeptics are evil meanies who cackle evilly as they terrorize cancer patients online and delight in crushing their hope
This is the final thing my fellow Skeptics learned by going into the belly of the beast. Indeed, one of them even got to ask a question at the Q&A (more on that later). In this, I truly admire them, because they went into a theater where the film maker wanted to convince his movie’s audience that we are Evil Incarnate, so much so that we are no longer skeptics but The Skeptics and are, according to Merola, a well-organized international group. Well, Merola got one out of two correct. There are skeptics from different countries critical of Burzynski. But well organized? Not so much. Merola obviously doesn’t know any actual skeptics or skeptical organizations if he thinks that. Apparently we’re also so all-encompassing that Merola didn’t do what he had promised and actually name names. Features were apparently obscured, and names on Tweets and blog posts were treated similarly, while at one point the voice of a prominent Skeptic from a YouTube video was even electronically altered to make it sound really sinister, complete with an evil laugh at the end. I have no idea why Merola did that after all the hype about “naming names,” but he did. I’d be lying if I didn’t say I was a bit relieved that he did, too.
Be that as it may, no wonder our Skeptics were so interested in this part of the movie! They tell me that we Skeptics were accused of:
    • Attacking cancer patients online and telling them they should just die, accompanied by the image of Pete and Hannah crying, as previously seen in the latest Burzynski II trailer.
    • Keeping pro-Burzynski or even neutral Burzynski material out of Wikipedia. I will give Merola credit for one mildy funny line that our Skeptics remembered, namely that the only neutral information about Burzynski in Wikipedia is his date of birth and prior education. Apparently the audience thought it was funny too.
    • Publishing “death lists” of previous patients and republishing them on multiple blogs and websites to give the appearance of coming from more than one source.
    • Being paid by the government to attack Burzynski
    • Being paid by big pharma to attack Burzynski
    • Having been funded by the NCI, ASCO, and the Breast Cancer Research Foundation, (as though this were a bad thing)
I really wish I could have seen this part, because according to our Skeptics many Tweets and blog post excerpts were flashed on the screen, all designed to make The Skeptics look really, really bad. And I’m sure Merola could find some, too. I have seen the occasional Skeptic go too far in my opinion in what he or she says about Burzynski patients.
One “skeptic” charge that apparently rankles is that the Burzynski Clinic charges huge sums of money up front. Merola’s retort? He mentions a 2008 Wall Street Journal story about M.D. Anderson charging cancer patients $105,000 up front to begin therapy. Googling located the original article quickly, but I can’t get access to it. It is, however, extensively quoted here. As horrible as this story is, one can’t help but note that M.D. Anderson didn’t charge this patient for a clinical trial. This was for standard-of-care cancer treatment. That’s bad enough and doesn’t excuse such behavior, but it does reveal that Merola is comparing apples to oranges. The complaint is, after all, that Burzynski charges huge “case management fees” to his patients to be in his clinical trials. Whatever the case, saying in essence, as Merola does, “Hey, they do it too!” is not generally considered a particularly compelling defense, except perhaps among seven year olds.
The demonization appears not to have stopped with the movie, either. During the Q&A, I’m told, Merola used terms like this to describe us, helpfully transcribed by our Skeptics:
    • “No shame whatsoever.”
    • “Blind mules.”
    • “Really nasty people.”
    • “Slippery, slippery people.”
    • “Don’t care about the truth.”
The dislike Merola expresses for Skeptics in his movie is genuine, and I strongly suspect that he really believes that there is a massive conspiracy against Burzynski, and that we’re simply the latest party to it, joining the FDA, the NCI, the Texas Medical Board, and, of course, big pharma.
The underlying lessons
One problem with trying to write about a movie that you haven’t seen through second-hand accounts is that you just can’t get the whole experience the film maker intended because all you have to go on are discussions and other people’s accounts. For instance, I have no idea how effective the use of Hannah Bradley and Laura Hymas was, although if the first Burzynski movie was any indication I’m guessing that Merola pulled out all the stops to emotionally manipulate the audience. Similarly, although I do know from the trailer and our Skeptic mule’s report that the movie featured cancer patients crying at the “harassment” Merola alleges, I have no idea how effective his demonization of the Skeptics was because I only know what sorts of wrongdoing he accused us of, and a few of the adjectives he used to describe us in the film and in the Q&A. I have not experienced it all in context, with dialogue, music, sound, and images all combined to make Skeptics like me look like dogmatic, heartless bastards serving their pharma overlords’ interests. I can take satisfaction that when Brian got up to ask a question, identified himself as a Skeptic (a “skeptic mule,” to be precise), and, prefacing his question with the observation that Merola accused all of us of being funded by pharma, asked him about how he has funded his movies, Merola reportedly looked none too pleased. It was at this point that I think we get a full lesson in where Merola’s at.
In a way, Merola’s tenacity is admirable. He talked about how he so wanted to do his first movie that he took the easiest, highest paying jobs he could find, so that he could finance the Burzynski movie and work on it during nights and weekends. Ultimately he decided that he couldn’t finish the movie unless he went all in. So he quit his job, which shows to me both how much of a true believer he is but also bespeaks a certain boldness and willingness to take risks that’s admirable. It’s sad that he offered up this boldness and risk taking in the service of someone like Burzynski, who, if Merola is to be believed, didn’t trust him at first and had to be won over by a rough cut of footage about patients from the first movie. He also overcame other adversity, as during the first year after its release his movie didn’t do so well and he was seriously hurting for money. Then, he was interviewed by Dr. Oz, and über-quack Joe Mercola started promoting him, after which his first movie took off. This timeline makes sense in retrospect to me. Even though Burzynski I was released in 2010, I didn’t hear about it until well over a year later and didn’t find online access to review it until November 2011. Apparently this time around things are easier because Burzynski trusts Merola and he has a better distribution deal, but even now Merola claims he won’t start seeing any money until September. I can’t argue that, as he was reported to have said, Merola “put his financial ass on the line.” He also put a family member on the line in 2011, namely a cousin with a brain tumor whom he referred to Burzynski in 2011 and who tragically died despite antineoplaston therapy and whom he doesn’t mention in the Q&A.
Perhaps that’s why Merola is so vicious this time around in attacking his critics. He is clearly a True Believer, as evidenced by the work he did, the risks he took, and the price he paid, as only a True Believer would go to such lengths. Last time around, however, what he didn’t face were Skeptics criticizing his movie, mainly because we hadn’t heard of it, didn’t see it, and didn’t think much of it. That’s why it makes perfect sense that the rise of his movie paralleled the vast increase in criticism of Burzynski by skeptics. Also not mentioned by Merola is that it didn’t help that around the same time in 2011 Burzynski patients were getting into the news through their prodigious fundraising efforts, and Skeptics were taking note. Burzynski didn’t react well, siccing his attack poodle Marc Stephens on a teenaged skeptic in the U.K., and thus invoking the Streisand Effect in full force. The side spatter from that kerfuffle naturally started hitting Merola as skeptics looking into Burzynski’s activities started examining Merola’s movie, which was by then freely available to watch on various websites. The first time around, Merola flew in under the radar and was only noticed when people like Dr. Oz and Joe Mercola started promoting his movie. This time around, there is no free pass, no free year, and he can’t fly in under the radar. Merola has been noticed, thanks to the popularity of Burzynski I, and the scrutiny began as soon as he announced Burzynski II. This time he does not have over a year to say whatever he wants, do whatever he wants, and screen his movie only to adoring, credulous believers in “health freedom” and quackery before skeptics start to take notice.
This time, Merola’s not going to get the same year-long free ride with no skeptical evaluation that he got last time, and he doesn’t like it. However, this has nothing to do with a shadowy conspiracy of skeptics and everything to do with his having reached a high enough profile as someone who has become in essence the biggest advertiser for Stanislaw Burzynski in existence. Although I actually believe that Eric Merola believes he is doing the right thing (as he claims he believes The Skeptics think they’re doing the right thing), he is deluding himself when he claims to be an independent journalist. He was never such a thing and, in fact, has become such a True Believer in Burzynski that he is no longer capable of even a semblance of critical thinking about him. Instead of looking at the evidence objectively, he applies his skills as a former advertiser to cherry pick evidence and present only information that supports his True Belief. I’d almost admire him, if he weren’t so manipulative, deceptive, and unrelentingly and ham-handedly one-sided in his film making tactics.

Eric Merola’s conspiracy-mongering and more of Dr. Stanislaw Burzynski’s cancer “success” stories
David Gorski on April 15, 2013
Link
About a month ago, Eric Merola screened his second movie about “brave maverick doctor” Stanislaw Burzynski, Burzynski: Cancer Is A Serious Business, Part 2 (henceforth referred to as “Burzynski II”), a screening that Brian Thompson and an unnamed colleague from the James Randi Educational Foundation (JREF) attended, took notes, and even managed to ask a question. At the time, I took advantage of Brian’s awesome commentary about his experience on the JREF Swift Blog, his copious notes, and my read on Eric Merola’s trailers for the movie, what he said in the first movie, and his own promotional material to write about how Merola dishonestly demonizes what he refers to as “The Skeptics” (i.e., us) and five major misconceptions about Burzynski, cancer, and skeptics promoted in Burzynski II, all with a heapin’ helpin’ of conspiracy mongering. In this post, I will delve into a little more detail about the fundamental intellectual dishonesty behind Eric Merola’s conspiracy mongering and discuss two of the cases being used to “prove” that Burzynski can cure cancer, mainly because they are appearing along with Merola on the publicity trail. Merola himself, thankfully (I guess) has allowed me to do this by posting an edited version of that original Q&A to YouTube:
In particular, note how everything I said in my previous post about what went on at the Q&A is verified, and, in fact, you now have the details. I will try to mention the specific time points to refer to as I go along. Also note that there is a segment at about the 47:45 mark in which JREF’s Brian Thompson (blurred out but still recognizable) speaks with the husband of one of Burzynski’s patients that is worth watching and that I will briefly discuss further into this post.
Three things
Three things got me to thinking that I was probably due to write about Stanislaw Burzynski and his propagandist Eric Merola again. The first thing, of course, was the video posted above. The second thing, ironically enough, was Tori Moreno and Mary Jo Siegel, two Burzynski patients who are presented in the Q&A as “proof” that Burzynski can cure cancer. There are, of course, two more such patients, Hannah Bradley and Laura Hymas, both of whose cases I discussed a couple of months ago. My conclusions were that Hannah Bradley has very likely seen recurrence of her cancer while Laura Hymas thus far might or might not represent an actual long term remission due to Burzynski’s treatments. These other two, however, I didn’t discuss for the simple reason that their cases are difficult. I don’t mean that their cases are conceptually difficult; rather I mean that it’s hard to get much information about them. They were, after all, treated long before the rise of blogs, Twitter, Facebook, and the like, and consequently information is much more difficult to come by, consisting mainly of cherry picked records and tightly spun stories posted on sites such as the Burzynski movie website and the Burzynski Patient Group website (BPG). As a result for these two cases trying to separate Burzynski legend from Burzynski fact is far more difficult than it is for, say, Hannah Bradley, Amelia Saunders, Laura Hymas, and more recent Burzynski Clinic customers, many of whom have been very active on social media, posting scans, reports of treatments, descriptions of their experiences at the Burzynski Clinic, and much more.
The third thing was a rather odd online encounter that I had with Eric Merola a couple of weeks ago. It was so bizarre that it left me scratching my head and thinking that Merola really needs to look at how he appears online. Either that, or he’s losing it. Regular readers probably remember that a couple of weeks ago I posted a shameless self-plug featuring a link to a YouTube video of a talk I did for the National Capital Area Skeptics on March 9 (which I can’t resist embedding again, for those of you who might not have seen it—forgive me):
Amusingly, Jake Crosby finally got around this morning to sliming me over it (only six weeks later), but apparently Merola saw the video too. It didn’t take long at all for Merola to get himself hence to Twitter to start making fun of me and in general rubbishing me, as our friends in the U.K. like to say. He even went so far as to say this about me:
That’s right. Apparently to Eric Merola I’m a white supremacist. To his partial credit, Merola must have had second thoughts, as he rapidly deleted that Tweet, and I only know about it because a reader saved it and sent me the link, which made me want to be sure to immortalize it. I’m not sure if it was embarrassment or a stab of conscience, but that immortal Tweet is now gone from Eric’s Twitter feed. On the other hand, what’s worse than being a white supremacist?
Apparently I’m also a puppy eater:
Merola’s apparently deleted the Tweet above as well. Such is life. However, Merola’s ill-considered Twitter adventures got me interested in what he might be up to again, as did learning that he would be doing a Q&A after a screening of Burzynski II in Toronto. As with Merola’s screening at San Luis Obispo on March 10, this screening in Toronto, which occurred on April 5, was attended by at least one skeptic, who was kind enough to do the same thing our colleagues did in California and provide me with notes. I hope that my discussion of these Q&A’s and of the cases used as testimonials will serve, along with my previous discussions, as educational background for skeptics who attend further screenings of the Burzynski movie, for example the upcoming screening on April 27 at the Newport Beach Film Festival, which will feature the same two Burzynski patients (Mary Jo Siegel and Tori Moreno) that I am about to discuss and where, we are promised, there may be a “surprise special guest.” This latter promise makes me wonder if ol’ Stan himself is going to show, given that we already know that his son Dr. Greg Burzynski will be there. I certainly hope he does.
Eric Merola doubles down on the conspiracy mongering
The very first thing I noticed upon viewing the YouTube video of the Q&A from March was that the sheer conspiracy mongering that Merola engages in was not adequately captured by the notes. It is truly, truly over the top, fully into Gary Null, Mike Adams, Whale.to, and Alex Jones territory. For instance, take a look at the segment beginning at about the 13:56 mark, in which Merola discusses how former senior advisor to President Obama David Axelrod allegedly watched the film. I wrote about this in my first discussion of this movie a month ago, but the reports I got failed to convey the full scope of its true conspiracy theory awesomeness.
Here’s how Merola describes the alleged viewing and Mr. Axelrod’s alleged reaction to a rough cut of his first movie, which I will henceforth refer to “Burzynski I” to distinguish it from the sequel “Burzynski II”:
David Axelrod saw a rough cut of my first film in late 2009, privately through someone who was old college buddies with him. I wasn’t present during the private screenings.
David Axelrod was President Obama’s Chief of Staff at the time and after watching the film, he said that “it’s very important but it’s just too big.” He said “we can’t face this in this country not for at least ten years” and, he even alluded that the economy had just tanked. He even alluded that it could possibly send the country into a further recession because of what it would do to companies like Amgen which is 90% reliant on cancer therapies. It would, the stock market would, plummet if this thing was released. And this comes from the pharmaceutical world. It’s just the sad reality.
It’s almost as big as oil. I mean, countries have gone to war for a resource this valuable and it’s a really, really big deal in the market. They just can’t allow it and I can understand it from a market point of view. If I was a CEO or on the Board of pharma, from a purely preservation, self-preservation of the establishment point of view, I can understand where they’re coming from, but obviously from a morality point of view it’s much more difficult to wrap your heads around.
So what we have is a second hand story, in which an unnamed friend of Merola allegedly showed a rough cut of Burzynski I to Axelrod and then reported back that Axelrod thought the information was such a bombshell that if the Obama administration did anything about it it would risk tanking the economy again before it could recover from the 2008 financial meltdown by destroying major pharmaceutical companies like Amgen. This is not a mistake. Merola repeated this very same story near the very beginning of his Q&A in Toronto, although he apparently did preface it with a disclaimer to the effect of something like, “I have no proof of this. You can believe me or not.” Clearly, the David Axelrod story is going to be a regular feature of Merola’s movie publicity tour, and Merola plans on using it at every Q&A. I can only hope that my reporting on it last time led him to add that little disclaimer. More importantly, I would love to see whether David Axelrod will actually respond to this, particularly now that we have evidence that Merola is telling this story other than reports of promoters of science-based medicine who were brave enough to go into the veritable lions’ den a month ago.
The other thing that amazed me was how shameless Merola is about, in essence, publicizing Burzynski’s plan to break the spirit and possibly intent of the law. What I’m referring to is how Merola opengly brags that Burzynski wants to get antineoplastons approved for brainstem glioma through the accelerated approval mechanism (also known as “fast track”) and then to use that approval as the “foot in the door” to allow the use of antineoplastons off-label for other cancer types. While it is legal to use FDA-approved drugs off-label, openly planning to gain approval of a drug for one indication so that it can be used for a whole bunch of indications off-label is at least very shady to me. If it’s advertised in any way, it’s illegal; the FDA has come down on pharmaceutical companies for doing just that: Advertising off-label uses for their drugs. The double standard is also staggering, at least among Burzynski apologists. Can you imagine how some of them would react to a pharmaceutical company advertising off-label uses for its drugs? Oh, wait. We don’t have to imagine it. We already know. But somehow when Burzynski says he wants to get approval for one indication so that he can use antineoplastons for all cancer, suddenly instead of being a greedy sleaze, he’s some sort of hero of “health freedom.”
Next up, if you don’t believe me when I told you last time just how much Merola despises anyone whom he considers to be a member of “The Skeptics,” just mosey on over to the segments at the 21:25 and 35:45 marks. At the 21:25 mark, Merola is asked, “How did you discover the skeptics’ group and how did you gain access to the videoconference and do you know anything else about them?”
Merola’s answer:
Sure. Basically, these guys have no shame whatsoever. They have no problem letting everybody know their names and putting themselves out there. I really believe that the lower tier guys, like the guys that you saw, they put that on YouTube and were very proud of it. I went through a lawyer to get legal clearance to make sure I was safe. That’s why they’re blurred out and their names are hidden.
If you want to know the utter intellectual dishonesty of this answer, realize that the segment that Merola included in his movie of “skeptics plotting” was nothing more than a clip taken from the Virtual Skeptics podcast (episode 13, to be precise) in which Bob Blaskiewicz was talking about Burzynski and his plans to raise money for St. Jude’s for Burzynski’s 70th birthday in January. However, in the movie, Merola apparently implied that it was some sort of secret conclave of skeptics plotting, blurred out their faces, and gave Bob Blaskiewicz an electronically distorted voice while creepy music played over the parts where he talked about Burzynski and how skeptics have to answer him online. Indeed, Merola’s segment in Burzynski II was apparently so over-the-top that, after they heard about it from Brian Thompson’s report on the movie, Virtual Skeptics recorded a segment in which Bob put devil horns on himself and proposed some “video extras” for Burzynski II. Also note the disconnect between the movie, which, according to reports, implies that skeptics—excuse me, “The Skeptics,” to use Merola’s term in his movie—are some shadowy cabal, while in the Q&A he admits that this stuff is on YouTube.
But none of that matters anyway because, apparently:
But the guys at the top, like the one guy who’s on all the payrolls, you know, it makes sense that there would be a paid group to try to dismantle this by using the media, the social media, to try to confuse everybody. So, working on the film, I wasn’t really too aware of The Skeptics until the patients kept complaining, saying, “I go on Twitter, you know, to help my fundraising, and I got attacked by all these guys calling themselves The Skeptics. I put something on Facebook, and The Skeptics attack my Facebook page. You know, I put my own blog up showing my MRIs. The Skeptics are attacking me there. Skeptics are calling me an actress or an actor. Skeptics are saying I’m laundering money. Skeptics are saying I’m pretending to have cancer. What is going on?” And as you saw with Ben and Laura, they went through psychiatric therapy because they were so terrorized by them. And you saw Pete and Hannah crying because of them.
They are just shameless, spineless people. And it was really, quite frankly, the patients just kept mentioning them. Well, OK, this is clearly part of the story. And as time went on I noticed that they started going after me as well, for obvious reasons. But what’s interesting. About two years ago, they were nonexistent, not even two years ago. It’s been the last 18 months they’ve come out of nowhere, and I think it’s because of the success of the original film. They accuse me of making an infomercial. They come up with these conspiracy theories that I was paid by Burzynski. So, it’s fascinating. There was only one or two things up until 18 months ago, and now they’ve come out in full force, as you’ve seen.
I wonder if I’m one of the “guys at the top.” If I am, this is the first I’ve heard of it.
Gee, Merola says that last bit as though it were a bad thing. He goes on to complain about how skeptics have “completely hijacked” Burzynski’s Wikipedia page and how he really really wanted to “call them out,” but for “legal reasons” and “running time.” Of course, I explained why it is that “The Skeptics” are so much more active this time. The reason is quite simple. About 18 months ago, Burzynski made the huge mistake of siccing his attack Teacup Chihuaha Marc Stephens on a teen skeptic in the U.K. by the name of Rhys Morgan. In doing so, he invoked the Streisand Effect in full bloom. It was such a fiasco that the Burzynski Clinic was forced to disavow Stephens. Because Merola’s movie was such a major component of the propaganda machine supporting Burzynski at the time, it was only natural that “The Skeptics” started to take notice of him. Given his increasingly hysterical statements and the amazing degree of conspiracy mongering in Burzynski II, even compared to Burzynski I, coupled with Merola’s pre-release promises to “expose The Skeptics,” it’s only natural that the skeptical movement in general, and those of us who’ve been commenting regularly on Burzynski in particular, would continue to take notice. Why wouldn’t we? When someone like Merola promises to slime me in a movie that will see international distribution, I take notice. Wouldn’t you? Merola’s either foolish, deluded, or intellectually dishonest to think that it would be otherwise.
The conspiracy mongering about “The Skeptics” continues. Around the 35:45 mark, Merola is asked who is paying “The Skeptics” and whether it’s been investigated. Merola’s response:
Yeah, I’ve done a lot of that myself, but frankly as you can imagine for legal reasons I just didn’t want to call them out. I’m not going to call them out. Not yet. I know who most all of them are. I know what they’re doing. One of them did try to hack the Burzynski web page—successfully hacked it. It was down for three days. But for legal reasons, because these guys are vicious and do not care about the truth—they only care about winning—and I don’t want to give them any reason to damage me any further or at all, frankly. So, yes, it’s been done, but they’re slippery, slippery people, and I’m not going to go any farther than that. But that would be a great thing, to have someone do a separate investigative report on just these guys, because most people—the festival staff, most people that watched it—said, “I’ve never even heard of these guys. I didn’t even know they existed.” Then they go back online, and they realize, wow, so they’re the ones doing all the damage online. They’re the ones doing this and that. That’s the best I can answer that. I’ve been trying to be careful myself, because they’re really nasty people.
I was struck by how paranoid this sounded, even more so than I had expected based on reports I received. I was also further struck at how Merola describes Burzynski critics, who according to him are more than happy—proud, even—to “put their names out there” as “spineless,” when he himself has decided for legal reasons not to “name names.” One can’t help but wonder if maybe—just maybe—the reason Merola’s lawyers told him not to “name names” is because they realized that much of what he says is likely to be libelous. Certainly, I consider it so from what I’ve been able to gather. I’m also struck by how Merola refers to “The Skeptics” as “vicious, vicious people,” and then can go on Twitter and refer to me as a white supremacist and someone who’s too busy eating puppies to bother reading the scientific literature about Burzynski. In any case, what really bothers Merola is he knows damned well that I’ve actually read nearly every paper I can get my hands on about antineoplastons. I also have the skill set to analyze them, and I wasn’t impressed.
More cases
The saddest thing to me about Eric Merola and Stanislaw Burzynski is how willing they are to use proxies to fight their battles, recruiting Burzynski patients to provide “testimonials” about how great Burzynski is and how they would be dead right now were it not for the sheer awesomeness that is Burzynski, his antineoplastons, and his “personalized gene-targeted cancer therapy.” True, they are willing proxies, but their willingness becomes particularly problematic in the case of Tori Moreno.
Moreno is a Burzynski patient from the late 1990s who is now 14 years old. She appeared in the video above and is scheduled to appear again with Eric Merola at the Newport Beach Film Festival screening, along with her parents. She was clearly nervous on stage, and it was clearly her father who was driving the bus, so to speak. I must admit that I have a real problem with a young teen being used this way. It’s one thing for people such as Hannah Bradley, Mary Jo Siegel, and Laura Hymas to decide that they think that Burzynski cured them and they want to do something to repay him by offering their testimonials in support of the Burzynski Clinic and Eric Merola’s propaganda film. They are adults. I might disagree with them that it’s so clear that Burzynski saved them and that it’s right for them to try to persuade other patients to go to Burzynski too, but they have every right to decide to support Burzynski in any way that they see fit. More importantly, they are considered competent to make their own decisions with respect to speaking out however they wish. Such is not the case with an underage teen like Tori Moreno. From my point of view, poor Tori is being used as nothing more than a prop by Eric Merola and, sadly, her father to be presented as “living proof” that Burzynski’s therapy works. But is she? She was a baby at the time and clearly doesn’t remember anything about what happened. So we have to go to other sources to find out.
The first source one finds is, of course, Tori Moreno’s BPG entry. As it typical for BPG entries, there is not much information there. Basically, boiled down to its essence, the story is that Tori was diagnosed with a brainstem glioma in 1998 within weeks after birth. It was inoperable, and the family went to Burzynski, who got a compassionate use exemption for antineoplaston therapy, treated her, and ultimately cured her. That’s the story. Finding more detail is difficult. I went Googling, keeping in mind Peter Moran’s critical questions. Peter and I might have our disagreements, but when it comes to dubious cancer testimonials we are in agreement, and I frequently use his questions to illustrate why cancer testimonials are often not strong evidence of the efficacy of the treatments for which they are given:
     1.  Was cancer definitely present, as shown by reliable tests, when treatment was commenced?
     2.  Did it go away? (or clearly respond otherwise, as judged by the same tests)
     3.  Was the advocated treatment the only one used? (within 2-3 months of the apparent cancer response)
In fact, given how much so many Burzynski patients share about their stories, I was shocked at how little information there was and how difficult it was to find more detail. Usually when I Google Burzynski patients, I find detailed stories right away. When it comes to Tori Moreno, Googling “Tori Moreno” and “glioma” brings up the BPG page, other uninformative pages, and this interview with Dr. Burzynski. Doing a Google image search, which when done for most patients generally results in my finding MRI scans, revealed nothing. In this interview we find:
Let us talk a little about some of your most successful stories using Antineoplastons with children. Probably the most remarkable case is that of Tori Moreno . In August 1998 Tori was diagnosed with a stage 4 brainstem glioma that was inoperable. Her parents were told she would die in a few days or at the most, a few weeks. When did you start treating her?
Tori had Stage 4 brain stem glioma. The tumor was too risky for surgery. She was diagnosed shortly after her birth. The tumor was very large, about 3 inches in the largest diameter and located in the brain stem. Her parents consulted the best centers in the country and they were told there was nothing to be done. So finally she was brought to us, when she was about 3 ½ months old. This was in October 5 years ago. She was in such condition that we were afraid that she might die at any time. Fortunately she responded, and about 5 months later we determined that she obtained a complete response, which means complete disappearance of active tumor by MRI criteria. She is a perfectly healthy child and tumor free. She still takes small dosages of capsules of Antineoplastons, but we will discontinue this shortly.
Later on, there is an interview with Tori’s mother after the interview with Burzynski. It didn’t add anything except that Tori was on decadron at a dose sufficiently high to cause her to face to balloon up, a photo of which is included in the Burzynski interview. No scans are presented.
So let’s do Dr. Moran’s exercise, starting with the first question: Was the cancer definitely present? This is actually the crux of Tori’s story and the most difficult question to answer. From what I have been able to discover, it is not clear to me that whatever Tori had was actually a brainstem glioma. It might have been. More likely, in light of its behavior, it was not. From the parents’ story, it’s clear that at the time the doctors thought that it was a brainstem glioma based on MRI scans, but nowhere have I been able to find a biopsy report. It could be that I simply haven’t looked in the right places yet, but it’s also quite possible that no one did one because the brainstem lesion observed on MRI looked like a glioma. Here’s the problem. Gliomas, as I pointed out before during my review of Burzynski I (and as was also pointed out on the Anaximperator Blog), are a heterogeneous group of tumors, and there is a false positive rate for tumors observed on MRI alone. In other words, not all lesions that look like gliomas on MRI are, in fact, gliomas, when biopsied, which is why these days stereotactic biopsy is considered important when feasible and safe. For example, in this study investigators looked at 46 lesions detected on MRI and compared the MRI diagnosis of glioma with what was actually found on stereotactic biopsy. In 6/46 cases (13%), the lesions were not cancerous.
Admittedly, that study looked at adults, although there is considerable similarity between adult and childhood gliomas in terms of imaging characteristics. In any case, the differential diagnosis of brainstem lesions detected on MRI in infants, although limited, does include cancer, infection, vascular malformation and lesions associated with metabolic disease. It’s also not unreasonable not to get a biopsy in a case like Tori’s. The reason, of course, is that if the tumor does not appear operable on imaging studies, then a biopsy is all risk and little or no benefit. This was particularly true in 1998, which was before there were targeted therapies that could be attempted. However, not biopsying left open the small possibility that the lesion identified was actually not what it appeared to be, and its subsequent biological behavior certainly suggests that it was not a glioma. I have no doubt that Tori’s parents—and probably even Dr. Burzynski himself—believe that antineoplastons cured Tori of a brainstem glioma. To be intellectually honest, I have to concede that it is not impossible that they did. However, in the absence of a definitive tissue diagnosis, there will always necessarily be very significant doubt whether Tori ever actually had a brainstem glioma—far too much doubt to base treatment decisions on or to use the Moreno case as “proof” that antineoplastons can cure brainstem gliomas. Single cases can mislead, which is why well-designed clinical trials are so important. Answering Peter’s other questions, if the answer to question number one is, “I don’t know,” then the answer to question #3 is similarly, “I don’t know.” The only question that can be answered is number two, as we know that at least Tori received high dose steroids, which, if this were an inflammatory process and not a tumor, might well have settled it down.
No doubt if Merola or Tori’s father reads this, it will infuriate them and I’ll again be castigated as one of those evil, unfeeling skeptics (excuse me, “Skeptics”). Perhaps they’ll even accuse me of “attacking” Tori, even though I am doing absolutely nothing of the sort when I argue that Tori’s case is not definitive evidence that Burzynski cured her. There is considerable doubt, and it is not Tori who is making the claim that Burzynski cured her, anyway. She is simply repeating what her parents have been telling her since she was old enough to speak, her having been too young in 1998 to possibly have any recollection of what happened. It will probably infuriate them more when I point out that it is also not good for Tori herself to be trotted out in front of audiences as “proof” that Burzynski cured her, but it’s something that needs to be said publicly.
Mary Jo Siegel
Mary Jo Siegel and her husband Steve also appeared in the Q&A. Siegel’s case is simultaneously both more difficult and easier than that of Tori Moreno. It’s easier in that there are some actual records (no doubt carefully chosen given that they are hosted on the Burzynski Movie website along with video of her Congressional testimony, a transcript of which can be found here), but harder in that it’s really hard to tell how much of her story has in the last 20 years devolved into myth and how much is objectively told. It doesn’t help that her husband Steve is prone to inflammatory statements, in which he rants against conventional oncology as “quackery,” asking frequently some variation of the question, “Why is what Burzynski does called quackery and the bone marrow transplant recommended for my wife’s disease not?” He does it a couple of times just on the very video; so I’ll briefly discuss that before moving on to Siegel’s case.
The disease that Siegel was diagnosed with was non-Hodgkin’s lymphoma, stage IV, low grade small cleaved cell type. In other words, it was an indolent variety of lymphoma. The good thing about this sort of lymphoma—if there’s such a thing as a “good thing” about lymphoma—is that it’s indolent and a patient with it can live quite a few years. The bad thing about this sort of lymphoma is that it is almost never fully curable. So when Ms. Siegel says that the “outcome is always death” she is technically correct, but she’s leaving out that the median survival can be between 8 and 15 years, depending upon tumor characteristics, and that, according to the NCI, patients can have a 40-85% chance of living 10 years with the disease, depending on their risk factors. The only risk factor that Siegel clearly had was stage IV disease (likely due to her bone marrow involvement), which tells me that her chances of surviving ten years could well have been at the high end. Indeed, tumors with certain histological characteristics can have a median survival of over 13 years. According to the NCI, treatment options include:
Therapeutic options include watchful waiting; rituximab, an anti-CD20 monoclonal antibody, alone or with purine nucleoside analogs; oral alkylating agents; and combination chemotherapy.[16] Radiolabeled monoclonal antibodies, vaccines, and autologous or allogeneic bone marrow or peripheral stem cell transplantation are also under clinical evaluation.[16] Currently, no randomized trials guide clinicians about the initial choice of rituximab, nucleoside analogs, alkylating agents, combination chemotherapy, radiolabeled monoclonal antibodies, or combinations of these options. On a comparative basis, it is difficult to prove benefit when relapsing disease is followed with watchful waiting, or when the median survival is more than 10 years. Follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress and rarely require therapy.[17,18]
This is, of course, the problem with a disease like an indolent lymphoma. Survival is expected to be long compared to other cancers, and its course can be highly variable, which makes it exactly the wrong sort of tumor to draw any conclusion about treatment from looking at only one patient. Another problem with Siegel’s story is the time when she was diagnosed. Bone marrow transplant with stem cell rescue was all the rage back in the 1990s, and oncologists were trying it for almost everything. I’ve alluded to its use to treat advanced breast cancer and how, despite promising pilot studies, larger studies ultimately failed to find benefit for it in treating advanced breast cancer. So on the one hand Steve Siegel has a point that bone marrow transplant might not have been the best idea. On the other hand, in the context of the time, it was not an unreasonable suggestion, albeit radical and risky. After all, even though his wife’s short term prognosis was actually good, her long term prognosis was most definitely not, and for someone in her early 40s it’s easy to see that the likelihood of living only 10 or 15 more years (or possibly less) is devastating. After all, at that age most people expect to live another 30-40 years or even more! Unfortunately, over the years, it appears that Steve and Mary Jo Siegel’s distaste for the procedure appears to have become more and more violent. They now seem to revel in telling tales of doctors having said that his wife would be exposed to as much radiation as people only one mile from Hiroshima and how doctors would take her as close to death as they could. It’s a standard part of any appearance they make, and it’s not clear to me how much of it is from what their doctors told Mrs. Siegel and how much of it came from their reading on the subject.
So what happened? It’s impossible to say for sure in this “N of 1” trial. I looked over Dr. Burzynski’s notes and case summary, and I found the list of tumor measurements to be rather odd in the way that they were listed. Yes, some enlarged mesenteric and neck lymph nodes did shrink. However, on October 19, 1995, a single mesenteric lymph node measuring 1.0 x 0.8 cm was detected, and this apparently led to Burzynski starting antineoplaston treatment again, even though a 1 cm lymph node can be within normal range or due to inflammation or something other than cancer, and there was only one. This is the “recurrence” that the Siegels talk about that supposedly disappeared.
So what to make of all this?
The way I see it, there are two major possibilities, neither of which demonstrates the general efficacy of Burzynski’s antineoplastons or the legitimacy of his claims for them. First, there’s a possibility of a spontaneous remission or that Mrs. Siegel is fortunate enough to have a really indolent tumor that is so indolent that it is an outlier. In these cases, the antineoplastons had nothing to do with how well she is doing. This is actually probably the more likely scenario. The other option is that the antineoplastons actually did induce a remission. This is not impossible, given that the drug phenylbutyrate is metabolized into an antineoplaston, and there is preclinical evidence suggesting that phenylbutyrate might have activity against non-Hodgkin’s lymphoma. It has even been under investigation for treating non-Hodgkin’s lymphoma. Even if it is the case that antineoplastons induced a long-lasting remission of Mrs. Siegel’s lymphoma, it does not prove that Burzynski’s treatments work for other cancers, such as brainstem glioma, or that they even work for most non-Hodgkin’s lymphomas. To show that, you need clinical trials. Let’s just put it this way. Mrs. Siegel suffers from a disease with a very indolent, very highly variable course. It’s been over 20 years since she was diagnosed; so it seems unlikely that she will recur at this point, but it’s still not clear that Burzynski is responsible for her good fortune. I can understand why the Siegels think he is and even concede that it is possible that he might have been responsible, but I can’t agree with them that Mary Jo Siegel is somehow slam dunk evidence that Burzynski has discovered a cure for cancer.
Lessons for those who would oppose Burzynski
The Q&A session at San Luis Obispo and what I’ve learned about the Q&A session after the Toronto screening of Burzynski II provide many lessons for skeptics. First and foremost, to me, at least, is the lesson that Eric Merola can’t be trusted. He is a true believer, and he despises skeptics. For instance, he clearly plans on repeating an unbelievable story about David Axelrod. He demonstrates time and time again that he does not understand science, clinical trials, or why science-based oncologists do not take Burzynski seriously. He’s using every tool at his disposal to promote Burzynski and is willing to cherry pick and distort information, use what I consider to be dishonest filmmaking techniques more akin to the slimiest political attack ads than to even activist documentaries, and in general demonstrate no regard for the truth. He’s also willing to use whatever contacts he has gained over the last three years to try to publicize Burzynski. Indeed, at the Toronto Q&A, Merola bragged about how Burzynski had apparently signed a deal for a biopic, even going so far as to suggest Sean Penn or Christoph Walz as actors to play Burzynski. At least, so Merola claims, adding that the next step will be to try to convince a studio to “have the courage” to get behind it. Given that the vast majority of such deals never result in a movie, no doubt if this effort fails, Merola will view it as “evidence” that the pharma cabal succeeded. In other words, one thing that anyone who wants to criticize Burzynski should know is that Merola is not convincible, not trustworthy, and likely to use whatever media contacts he has to attack, and anyone who wants to confront Merola at a Q&A with a skeptical question needs to be prepared for the types of spin he will bring to bear. In particular, that includes not giving him what I like to call a “weasel” opening that allows him to attack based on one mistake and ignore everything else. He’s very good at that.
Perhaps the sharpest lesson in just this sort of error and about how deceptive Merola can be occurs at the end of the video, around the 47:20 mark. It is there that Brian Thompson is portrayed trying to engage Steve Siegel. I must say, I truly admire him for this effort, but I also must reluctantly say that, as well as he did on everything else, he fell into a really basic trap that anyone who has immersed himself in Burzynski lore could have seen coming a mile away. Go and watch and see if you can see what it was. On the plus side, Thompson stayed calm, respectful, and made some really great points about how Burzynski seems to think that the rules don’t apply to him and the balance between personal freedom and protecting desperate cancer patients from pseudoscience. That was awesome. Unfortunately, at one point, Thompson said that Burzynski doesn’t publish, and that there is this thing called Medline/PubMed where you can search for peer-reviewed publications.
I cringed. I knew what was coming next, and Burzynski’s defenders didn’t disappoint.
Predictably, Steve Siegel pounced, offering to take Thompson to lunch and show him reams of “peer-reviewed publications” about antineoplastons. Merola pounced, following Thompson with a shot of a PubMed search. Of course, I couldn’t help but laugh because the very first article on the PubMed search was one that I’ve blogged about before, as self-serving a bit of nonsense as I’ve ever heard from Burzynski. Certainly, it shows no new data, no clinical trials, no science other than Burzynski’s claims to be some sort of pioneer in “personalized gene-targeted cancer therapy” that M.D. Anderson and other renowned cancer centers are only now following. The whole thing closes out with a shot of Steve Siegel and Eric Merola gloating about how skeptics “don’t know what they’re talking about.” Ouch. It’s an incredibly easy trap to fall into if you aren’t intimately familiar with Burzynski, and unfortunately Thompson fell into it.
In fact, Burzynski does publish. His lack of publications is not the problem. The problem is the quality (more specifically, the lack thereof) and utterly unconvincing nature of Burzynski’s publications. He publishes in bottom-feeding journals and has not yet published a completed phase II clinical trial. That’s plenty bad enough. Burzynski has only published abstracts and partial reports on phase II trials, none of which are particularly convincing. His publications are all, as far as I’ve been able to tell, crap, and I’ve read nearly all of them.
Overall, I get the distinct feeling that all the criticism is starting to have an effect. According to the report on the Toronto Q&A, Burzynski is having difficulties. Apparently the clinic is struggling. Merola openly admits as much and blames it all on—you guessed it!—”The Skeptics.” Hilariously, he somehow seems to think that “The Skeptics” are responsible for the FDA’s “raid” on the Burzynski Clinic from January to March. Would that I had that sort of influence! Sadly, however, I do not. Merola now even openly talks about the clinic moving to other countries, which I presume he would not be able to do if Burzynski didn’t want him to. He even openly speculates that after Greg Burzynski eventually takes over for his father might be the time for the Burzynski Clinic to go full “cancer tourism.”
If there’s anyone who personifies the term “delusion of grandeur,” it’s Eric Merola. As skeptics, we need to remember that. We also need to stay utterly science-based in our criticism as possible. In other words, when it comes to reason, science, and medicine, we need to be the anti-Merola. At the very least, we have to be aware of his intellectual dishonesty and prepared for his gambits if we are to provide the science-based counterpoint to Stanislaw Burzynski and his propagandist Eric Merola.

Revealed by the FDA: The results of the most recent inspection of the Burzynski Clinic
The results of the latest FDA inspection of the Burzynski Clinic are in. They aren’t pretty. Why is this cancer quack still allowed to do his bogus clinical trials?
David Gorski on November 11, 2013
Link
After posting the talks that Bob Blaskiewicz and I gave at TAM this year, I realized that it’s been a while since I’ve written about the topic of those talks, namely Stanislaw Burzynski, the Houston cancer doctor who inexplicably has been permitted to continue to administer an unproven cancer treatment to children with deadly brain cancers for nearly 37 years now. Beginning in 1977, when he left Baylor College of Medicine and opened up the Burzynski Clinic, Burzynski has administered a cancer therapy that he calls antineoplastons to patients. After nearly four decades and several dozen phase II clinical trials started, he has never published a completed phase II trial. The only evidence he’s published consists mainly of cell culture studies, case reports, and couple of preliminary reports of his phase II clinical trials. Of course, Burzynski’s lawyer, Richard Jaffe, even dismissively admitted that these clinical trials are designed solely to allow Burzynski to keep giving antineoplastons.
So Burzynski operated from the late 1990s until summer 2012, charging exorbitant “case management” fees to enroll patients in his clinical trials, working with a credulous filmmaker who wanted to make a movie about him—twice—and flouting regulations designed to protect human subjects involved in clinical trials. Meanwhile, he branched out to “personalized gene-targeted cancer therapy,” which he promoted through Suzanne Somers; to AminoCare, which is basically antineoplastons sold as an antiaging nostrum (or, as Burzynski puts it, a “genetic solution to aging“); and to selling an orphan drug as a “prodrug” for antineoplastons.
So what happened in the summer of 2012? Apparently, there was a treatment-related death of a child, which led the FDA to issue a partial clinical hold on the Burzynski Clinic that prevented him from enrolling any new children on his clinical trials, although he could keep treating existing patients and enroll new adult patients. That partial clinical hold was extended to adults in January 2013, at which time the FDA arrived at the Burzynski Clinic to investigate. It was an event that was included at the tail end of Eric Merola’s second propaganda film about Stanislaw Burzynski and represented as, in essence, jackbooted fascists trying to keep the cure for cancer from The People. None of this stops credulous reporters from writing misleading articles with titles like Young mother with brain cancer given just a year to live BEATS the disease and gets married after having controversial treatment in the US, which is a story about Laura Hymas, a woman whose good fortune is most likely not due to Burzynski. Not long before that, there was another credulous article featuring another Burzynski patient, Hannah Bradley, as one of four patients treated for cancer with alternative therapies who are allegedly doing well. Again, Hannah Bradley’s good fortune is highly unlikely to be due to Burzynski’s nostrums.
All of this is why those of us who follow Burzynski have been waiting with the proverbial bated breath to find out what the FDA concluded. Just before the government shutdown the first shoe dropped, when the FDA released a warning letter to the Burzynski Research Institute (BRI). Then last week, the second shoe dropped, when the FDA released the original forms describing its findings regarding the inspection. The findings are, to put it mildly, damning in the extreme. In fact, now, more than ever, I wonder how on earth Burzynski has been allowed to continue to run clinical trials—or even practice—for so long. The findings include massive deficiencies in the Burzynski institutional review board (IRB), the committee responsible for making sure that regulations designed to protect human subjects in research are adhered to.
Stanislaw Burzynski versus human subjects protections: Human subjects protections lose
Before looking at the new FDA findings, let’s recap what is known about Burzynski’s IRB. First, we know that the IRB is headed by Carlton F. Hazlewood, PhD, who just so happens to be on the board of directors of the Burzynski Research Institute. As I noted before, given that the Burzynski Clinic has been trying for decades to commercialize antineoplastons, this is a profound conflict of interest. I also ask you to think of it this way again: What would Burzynski’s defenders say if they found out that a sitting member of the board of directors of Merck, for example, was serving on the IRB that oversees Merck’s clinical trials? Having Hazlewood serve on the BRI IRB is the same thing. True, it’s not quite as bad as having the principal investigator of a study chair the IRB overseeing his studies, as Mark Geier has done, but it’s pretty bad. Again, one wonders how Burzynski supporters would react if pharmaceutical companies or even research institutes trying to commercialize a discovery made by their investigators allowed high ranking leadership sit on their IRBs.
Last year, a certain “friend” of mine had discussed the problems with Burzynski’s IRB before, and these notes simply amplify and add detail to the problems that were already known. These notes suggest how Burzynski uses his IRB to get around some of the restrictions that were placed on him using antineoplastons. As you might recall, the Common Rule demands that all clinical trials by investigators whose institutions receive federal funding or that are being done in order to win FDA approval for a drug or device must be overseen by an IRB, whose purpose is to protect the human subjects who take place in the trials. This is an absolutely essential purpose of the IRB, its key reason for existence. It is not there to evaluate the science, except to the extent that badly designed clinical trials based on bad science endanger human subjects. Its purpose is to make sure that the risks and benefits of clinical trials are reasonably balanced, make sure that patients entering clinical trials receive adequate informed consent, and to keep an eye on the trial as it is being carried out, evaluating adverse event reports and, if necessary, shutting the trial down if there are too many or if one group starts doing too poorly relative to the other.
These are duties and functions that the Burzynski Clinic’s IRB utterly failed to carry out over the years. Before I take a look at the FDA warning letter and its accompanying notes, let’s go on a stroll down memory lane and recap some of the violations that the FDA has found in the past, gleaned from a a letter to the Burzynski Clinic Institutional Review Board from 2001; a report of a site visit to the Burzynski Clinic by the FDA Southwest Regional/District Office, Dallas District; and a warning letter from the FDA’s Human Subjects Protection Team, Division of Scientific Investigations, Office of Compliance, dated 2009:
    • Enrollment of subjects into antineoplaston study protocols prior to the protocol-specified interval following prior chemotherapy and/or radiation therapy.
    • Failure to report all serious adverse events (SAEs) and adverse events (AEs) to the agency and/or IRB.
    • Failure to follow proper informed consent procedures.
    • Failure to maintain adequate drug accountability records.
    • Discrepancies between case report forms and source documents.
    • Failure to keep a copy of the study protocol and informed consent form.
    • Failure to receive and/or require progress reports from the principal investigator for the study.
    • Failure to receive and/or require a final report from the principal investigator for the study prior to removal from the IRB’s active list of studies.
    • Failure to assure that FDA approval was obtained by the principal investigator for the study prior to the treatment of a patient under a special exception.
    • Approval of special exceptions via expedited review.
    • The IRB approved research without determining that the following criteria were met: That risks to subjects were minimized and that risks to subjects were reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result.
    • The IRB failed to prepare, maintain, and follow written procedures for conducting its initial and continuing review of research.
    • The IRB failed to ensure that informed consent would be sought from each prospective subject or the subject’s legally authorized representative.
    • The IRB failed to ensure that no member participated in the initial or continuing review of a project in which the member had a conflicting interest.
    • The IRB failed to conduct continuing reviews.
The latest round of findings from the FDA’s most recent investigation eight months ago reads like an acid flashback of investigations past. According to the FDA warning letter based on this FDA Form 483, covering the inspection dates from January 22 to February 7, 2013, here’s what the FDA dinged Burzynski for this time. The CliffsNotes version is this:
     1.  The IRB failed to follow FDA regulations regarding expedited review procedures [21 CFR 56.110(b)].
     2.  The IRB approved research without determining that the following criteria were met: risks to subjects were minimized [21 CFR 56.111(a)(1)]; risks to subjects were reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result [21 CFR 56.111(a)(2)].
     3.  The IRB failed to determine at the time of initial review that studies involving children are in compliance with 21 CFR part 50, subpart D, Additional Safeguards for Children in Clinical Investigations [21 CFR 56.109(h)]. This is a repeat violation from our 2010 inspection.
     4.  The IRB failed to prepare, maintain, and follow written procedures and maintain adequate documentation governing the functions and operations of the IRB [21 CFR 56.108(a), 21 CFR 56.108(b), and 21 CFR 56.115(a)(6)].
More detailed observations can be found in the Form 483. Basically, the Burzynski Clinic and BRI ran roughshod over human subjects protection. Most of the violations are fairly simple, even for lay people, to understand. For example, not making sure that patients enrolled on clinical trials meet the inclusion criteria, not reporting adverse events in a timely fashion, and not removing patients with adverse events from the study quickly are all fairly self-evident violations and not difficult to explain. It’s fairly easy to understand why failing to remove a patient who suffers an adverse event that the protocol says should be a reason to remove the patient from the protocol is a violation. One violation, however, is not as easy to understand for those not involved in clinical trials and therefore deserves a bit more discussion. I’m referring to Burzynski’s apparent abuse of the expedited approval process through his IRB. This seems to be the “theme” that ties together much of what is reported in this warning letter to the BRI; so I feel the need to explain a bit, in order to put it all into some context.
Quite reasonably, the Office for Human Research Protections (OHRP), the office in the Department of Health and Human Services that oversees IRBs, does not require the same sort of approval process for every sort of human subjects research. Not every study that involves human subjects research is a randomized clinical trial. For instance, in the case of human subjects research that involves pre-existing samples that have been de-identified can be exempted from full IRB review and oversight because, well, there are no human subjects to be endangered, even through linking of their identities to a specimen demonstrating a disease. Lots of research gets done this way, for example analyzing or staining pre-existing samples looking for a biomarker or a change in expression of a protein. I’ve done projects like this. This is commonly known as Exemption 4, and there are several other exempt categories.
However, Burzynski doesn’t abuse the exemption process, which, let’s face it, would be very hard to abuse for the most part. What he appears to have abused is the expedited approval process. The expedited review process generally involves approving things like minor revisions to research protocols and informed consent forms. “Expedited” generally means just that: Expedited. A full IRB review is not done, and a streamlined, faster process is used. Expedited approval can also be used for protocols that fall under categories that the Department of Health and Human Services (HHS) deems to be “minimal risk,” described thusly on the University of Kentucky website:
Expedited procedures can only be used to review a study if the only involvement of human subjects fits one or more of the categories specified in the federal regulations and if all of the procedures present no greater than “minimal risk.”
The IRB reviewer confirms that all of the research activities fit in one or more of the expedited categories. If the research includes activities that do not fit in the categories, the study is not eligible for expedited review even if the research involves “minimal risk.”
The Department of Health and Human Services defines minimal risk to mean “the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests” [45 CFR 46.102(2)(i)].
Investigators are asked to provide a risk assessment, but it is the IRB reviewer’s responsibility to determine whether the research meets the federal definition.
The IRB reviewer must consider two questions:
    • Is the probability of the harm or discomfort anticipated in the proposed research greater than that encountered ordinarily in daily life or during the performance of routine physical or psychological examinations or tests?
    • Is the magnitude of the harm or discomfort greater than that encountered ordinarily in the daily life or during the performance of routine physical or psychological examinations or tests?
If the answer is “yes” to either of these questions, then the research does not meet the definition of minimal risk.
A list of the types of research that can be approved through expedited review can be found on the OHRP website. These include things like blood draws, prospective collection of biological specimens by noninvasive means (one could collect urine specimens, for instance, under a protocol approved through the expedited review process), and research involving data that has already been collected. Here’s a hint: Approving “single patient protocols” for an investigational drug that is not FDA-approved does not fall into any of the categories for which expedited review is appropriate, particularly when so many of the patients involved are children and particularly when the drug being tested can cause severe hypernatremia. Basically, from my reading, Burzynski seems to be using the expedited review process to treat patients with antineoplastons who do not qualify for any of his numerous phase II trials, and until last year he was getting away with it. Again, one of the great mysteries is: How?
But that’s not all. The second Form 483 answers a question that many of us interested in Burzynski have wondered about for a very long time.
One mystery solved: What happened to all those complete responses?
There are two central mysteries about Stanislaw Burzynski that I would really, really like to see answered, and, hopefully, I will see them answered soon. The first is, of course: How has he gotten away with it for so many years? The second is: What are his real results? I’m not referring to the results Burzynski and his sycophants claim, but the real results? People like Paul Goldberg and others have been reporting for years that Burzynski’s results don’t seem to match his claims, with cancer experts who have seen some of his actual data reporting that Burzynski’s data “can never be useful to show true merit or lack of merit of his drug” because of an absence of rigorously reported results and independent verification” and “what we have here are bad trials that could never get past peer review of any clinical trials cooperative group.” Indeed, even back in the 1990s, serious adverse reactions were reported, mostly due to the hypernatremia. Now, thanks to these additional two FDA reports (here and here), we finally see a glimmering of light through the shroud of secrecy overlying the Burzynski Clinic.
Much of what is contained in these additional reports overlaps what I discussed before, but there is one kind of violation that does not. It’s a truly egregious violation that I find very difficult to comprehend, given how much it goes against every tenet of clinical research and clinical trials that I’ve been taught and learned over the years. It appears on this Form 483, where it’s discussed under “Observation 1,” and this other Form 483, where it’s discussed under “Observation 1” and “Observation 2.” The brief versions are stated either as “Failure to monitor the progress of an investigation under your IND”; “an investigation was not conducted in accordance with the signed statement of investigator and investigational plan”; or “failure to prepare or maintain adequate case histories with respect to observations and data pertinent to the investigation.” What does this mean? Basically, it means that the BRI misclassified tumor responses to therapy and adverse reactions. Worse, records that would allow the validation of responses to therapy are missing.
Before I get more specific, let me just briefly review what I mean by tumor response. Whenever a drug is given to treat a tumor, the response is the degree of tumor shrinkage that occurs in response to the treatment. In general, there are four categories of results defined and reported in clinical trials of new chemotherapeutic agent:
    • Complete response (CR): The tumors shrink away to the point that they are no longer detectable by physical examination, imaging studies (MRI, CT scan, etc.), or tumor markers. Obviously, this is the best possible result. This is further divided into a pathological complete response, which means that there are no detectable tumor cells in the resected tumor specimen. Obviously, when this happens, it is a very good thing and a very good prognostic sign. Sadly, it is not seen that often in clinical trials.
    • Partial response (PR): This is usually defined to mean that the tumors shrink by more than 50% (or, in the case where tumor volume cannot be measured easily, tumor markers fall by more than 50%) in response to therapy but remain detectable. More recent definitions have at times loosened this criterion to include tumors that shrink by 30% or more. Whatever the specific criteria used, a certain degree of tumor shrinkage, or evidence of tumor regression, defined before the clinical trial, must be observed.
    • Stable disease (SD): The tumors either shrink by less than the criteria for a PR or remain the same size. In some trials, this definition may be broadened to include tumors that increase in size slightly during therapy by less than, depending on the trial, 0-25%, although I’ve personally always been suspicious of calling any detectable growth above random variation in imaging measurements “stable.”
    • Progressive disease (PD): Tumors increase in size on therapy and/or new metastatic tumors appear. This is obviously strong evidence that in that patient the therapy did not work.
How tumor response is measured varies according to the tumor. Most commonly RECIST criteria are used. For brain tumors, there are criteria other than RECIST that are often used, such as the Macdonald criteria or its update, the RANO criteria. Other methods are being developed, as well. Obviously, there are pros and cons associated with each method. However, when you write a clinical trial, you have to pick one, stick with it, and use it appropriately to classify clinical trial subjects as either having CR, PR, SD, or PD. If these FDA reports are to be believed, Burzynski failed to do that. Worse, he either destroyed, or allowed to be destroyed, the original primary records used to make these determinations.
For example, the FDA notes that:
a. …For 18 of 27 (67%) of subjects, the investigator did not comply with the protocol requirements for assessing the efficacy endpoint of tumor response and recorded inaccurate assessments for tumor response in study records. For example:
    • Study [REDACTED]: Subjects 005297 and 007197 were inaccurately classified as Complete Response (CR). Subjects 004721 and 008765 were inaccurately classified as Partial Response (PR). Subjects 005974, 011373, 012184, 012206, and 12252 were inaccurately classified as Stable Disease (SD).
    • Study [REDACTED]: Subjects 06389, 11819, and 13660 were inaccurately classified as CR. Subjects 21428 and 23399 were inaccurately classified as PR.
    • Study [REDACTED]: Subject 009990 was inaccurately classified as CR. Subject 004881 was inaccurately classified as PR.
    • Study [REDACTED]: Subject 006239 was inaccurately classified as PR. Subject 004240 was inaccurately classified as SD.
b. You did not have a QA monitor properly monitor CRFs [case report forms] and subject records. The investigator destroyed critical subject case history records (target tumor measurement worksheets) or misplaced case history records (original subject CRFs) for all subjects.
Elsewhere, the FDA investigators note:
Your MRI tumor measurements initially recorded at baseline and on-treatment MRI studies for all study subjects were destroyed and are not available for FDA inspectional review.
The other Form 483 goes into a little more detail. Unfortunately, much of what I’d really, really like to know is redacted, specifically how each of these patients didn’t meet one or more of the criteria for the given response level to which Burzynski assigned them. Be that as it may, there’s plenty of damning information in these reports. For example, there are more examples of Burzynski’s failure to report adverse events (i.e., complications or bad things that happened to subjects being treated according to his protocols) in a timely fashion as required by the OHRP and the FDA. For example:
You failed to monitor as required by Section 16 of your Monitoring Plan. The investigator did not report adverse events (AEs) experienced by study subjects, including 18 cases of hypernatremia.
Now let’s look at what I mean when I said that Burzynski misclassified AEs. AEs are graded according to a system known as the Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE is nothing more than a list of AEs and SAEs (serious adverse events) commonly encountered in oncology. Each AE term is defined in the CTCAE and accompanied by a grading scale for severity. The AE terms are also organized by System Organ Classes defined by the Medical Dictionary for Regulatory Activities. The CTCAE is a long list, which can be downloaded as a Microsoft Excel spreadsheet, and it’s been updated several times. The most recent update is v.4.0, released in May 2009. Most of the AEs discussed by the FDA were from before that, so that CTCAE v.3.0 was being used to classify them. AE grades generally range from grade 1 (minor), grade 2 (moderate), grade 3 (severe), grade 4 (potentially life-threatening), to grade 5 (death).
Hypernatremia as I have discussed many times before, is a sodium concentration in the blood that is too high. If the hypernatremia is bad enough, it can be life-threatening. These reports document at least two subjects whose hypernatremia was graded a 2 when it should have been graded a 4. Of course, these two subjects pale in comparison to the number of patients whose hypernatremia either wasn’t reported or wasn’t reported for a long time. For example:
You failed to protect the rights, safety, and welfare of subjects under your care.
Forty-eight (48) subjects experienced 102 investigational overdoses between January 1, 2005 and February 22, 2013, according to the Weekly List of Hospitalizations/SAE [REDACTED] Overdose [redacted]/Catheter Infection report. Overdose incidents have been reported to you on a weekly basis during your Monday, Wednesday, and Friday staff meetings. There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects.
This last sentence bears repeating: “There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects.” So what we have here is a report finding that not only did Burzynski fail to report in a timely fashion a lot of SAEs, but that he tended to downplay the severity of the ones that he did report. Some AEs weren’t reported until as much as seven years later. Subjects also weren’t removed in a timely fashion for toxicity. For instance, one protocol stated that subjects would be removed after a third episode of Grade 3 or 4 toxicity or any single Grade 4 toxic effect that is “truly life-threatening or is not easily and rapidly reversible.” Of course, one wonders how the IRB could have approved such wording, as there is no distinction between “truly” life threatening and “life threatening” in the definition of Grade 4 toxicity. One patient had seven instances of Grade 3 or 4 toxicity but was not terminated from the trial until over a month after the seventh.
Other violations, although not as egregious, were nonetheless still quite bad. For instance, the informed consent didn’t include a statement of any additional costs to the subject that might result from the research. Several examples of patients who signed the informed consent days to weeks before they signed the billing agreement were presented. In addition, the Burzynski Clinic didn’t keep adequate records of its stocks of antineoplastons and could not account for how much was used by subjects. The number of bags of antineoplastons unaccounted for are truly staggering. One subject had 159 bags unaccounted for. Others ranged from one to 23 bags unaccounted for. Record keeping this sloppy would shut down nearly any clinical trial in and of itself.
The most serious violations of regulations designed to protect human subjects are clearly: (1) the BRI IRB’s misuse of the expedited approval process as an excuse to treat any patient Burzynski wanted to treat; (2) failure to keep original records to document baseline tumor measurements and tumor response; and (3) failure to report AEs and SAEs properly. However, there are a whole bunch of other lesser, but still serious, violations, so many that I find it hard to fathom.
The central mystery of the Stanislaw Burzynski saga
As a translational researcher who frequently works with clinical investigators, I just can’t figure out how Burzynski keeps getting away with it. Either the FDA is more impotent than I had thought, or Burzynski has some serious pull with some powerful people. If my university received even one report like one of the previous FDA reports about Burzynski, it would be quite possible that all federal research funding to the university for biomedical research would be suspended until the university fixed the problems to the satisfaction of the OHRP and FDA. Yet the FDA has found Burzynski to be deficient in numerous areas of human subjects protection multiple times over the last decade. These latest FDA Form 483 reports tell us nothing new, really, other than that Burzynski’s claims of complete responses are very likely nonsense.
If there’s one thing I’ve learned over the years about Brave Maverick Doctors, it’s that they often come to believe that the rules don’t apply to them. They crave the respectability of science, of course, but they are too impatient or too arrogant to play by the rules of science. Unfortunately, that often includes the rules designed to protect human subjects in clinical trials. We’ve seen it before with Mark and David Geier, who formed their own IRB stacked with their cronies. We’ve now seen it with Stanislaw Burzynski, who formed his own IRB. In the world of these Brave Maverick Doctors, the IRB apparently exists not to protect human subjects, but is instead viewed as a formality to funnel patients into whatever they want to do to treat them.
I’ve said it before, and I’ll say it again, though: The central mystery behind Burzynski is how he’s gotten away with what he’s gotten away with for nearly 37 years. It is the single question about Burzynski whose answer I want to know more than the answer to any other question about him before I shuffle off this mortal coil. Why does the FDA keep investigating him, finding serious violations, and giving him, in essence, a slap on the wrist? Since 2000, he’s been investigated multiple times, and he’s received FDA warnings for his violation of human subjects regulations. True, this is the first time since the 1990s that the FDA has taken substantive action against him, issuing a partial clinical hold that appears unlikely to be lifted any time soon, if ever. Still, I’m worried. If Burzynski comes up with a response that satisfies the FDA, he could conceivably have his same old bogus trials resurrected yet again. Why doesn’t the FDA shut down any clinical trials done by the BRI and Burzynski Clinic permanently? Why doesn’t it at least shut down the BRI IRB, which would have the effect of shutting down the Burzynski Clinic because no reputable IRB would ever approve the clinical trials that Burzynski proposes? To get its scientifically dubious clinical trials approved, Burzynski needs an IRB run by an old crony of his from Baylor (Carleton Hazelwood) who just so happens to be the chairman of the board of the BRI, a massive conflict of interest. Any other IRB with so many repeated violations and such a massively obvious conflict of interest would be shut down. Any other research institute with so many violations of FDA regulations would not be allowed to do clinical trials of any kind.
Yet the BRI persists. No matter how many times the FDA investigates it, no matter how many warning letters the FDA sends it, the BRI continues. In the 1990s, a powerful Congressman, Rep. Joe Barton, put serious pressure on the FDA through public hearings, the public dressing down of then-FDA director David Kessler, and who knows what behind-the-scenes pressure tactics to let Burzynski open clinical trials of antineoplastons. As Burzynski’s own lawyer put it, those trials were “all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment.” Since the FDA folded in response to Barton’s pressure in the 1990s, I haven’t heard news of Barton applying pressure to the FDA again over its investigations of Burzynski. True, the Republicans were in the minority during four years of the period since then, but even after they won the House back in 2010 I haven’t heard of any political pressure being brought to bear on the FDA. So I wonder: Is the FDA still so cowed from its previous experience that it can’t just pull the plug and shut Burzynski down completely?
It boggles the mind.

USA Today versus Stanislaw Burzynski
David Gorski on November 15, 2013
Link
This is an SBM public service announcement—with blogging! Think of it as a bonus post, and don’t forget to read Mark Crislip’s regular biweekly offering, as it’s about an article in Skeptical Inquirer that particularly irritated him—and me, as well. Because, as we all know, the world needs more Mark Crislip.
I’ve made no secret of how much I despise Stanislaw Burzynski, the self-proclaimed cancer doctor and medical researcher who has been treating patients with an unproven, unapproved chemotherapeutic agent since 1977, seemingly slithering around, under, over, and past all attempts to investigate him and shut him down. Indeed, just type his name in the search box of this blog, and you will see copious evidence of my disdain for the man. Over 37 years, Burzynski has become a hero to the cancer quackery industry, touted as the man who can cure incurable cancers that science-based medicine can’t, even though his treatment, antineoplastons, allegedly peptides isolated from blood and urine that normally keep cancer in check in healthy people, are by any reasonable definition chemotherapy. Indeed, they are toxic, with a number of side effects reported, the most common and dangerous of which being life-threatening hypernatremia (elevated sodium levels in the blood). All you have to do is to type Burzynski’s name into the search box of this blog, and you’ll find copious documentation of the abuses of patients, science, and clinical trials perpetrated by Stanislaw Burzynski and the cult of personality that has evolved around him. He’s even acquired his very own film propagandist, a credulous fellow named Eric Merola, who has made two astoundingly bad documentaries that are nothing more than unabashed hagiographies of the brave maverick doctor curing cancer where no one else can. They’re chock full of misinformation, pseudoscience, spin, and obvious emotional manipulation, and the first one at least, was very popular.
For the longest time, I’ve been hoping that major mainstream news organizations would take this story on. It’s happened from time to time, but until 2013 it hadn’t happened in a long time. Earlier this year, the BBC featured Burzynski in an episode of its long-running series Panorama. It was a mixed bag that took the fairly easy path of making it all about the patients and never really delved into what I believe to be the central mystery of the four-decade-long Stanislaw Burzynski story, and that’s how he’s managed to keep his medical license and register clinical trials right up until 2012. That was a disappointment, although much of the rest of the Panorama episode was very good. He still has his medical license, but as I’ve pointed out several times, the FDA placed a partial clinical hold on Burzynski’s antineoplaston phase II clinical trials back in the summer of 2012. A partial clinical hold means that no new patients could be enrolled, but patients already on them could continue to receive treatment. In 2012, apparently a child died on antineoplastons, and so a partial clinical hold was placed on the trials involving children. That clinical hold was extended to adults in January 2012, with much wailing and gnashing of teeth among Burzynski apologists, as the FDA investigated between January and March. We now know the results of that investigation, but we never knew much about how that partial clinical hold came about.
Now, thanks to Liz Szabo at USA Toda, we know from her article “Doctor accused of selling false hope to families“:
On the last day of his life, Josia Cotto’s parents gave him a choice.
The 6-year-old boy had been fighting an inoperable brain tumor for 10 months. When his mother, Niasia Cotto, found him in his bed, unresponsive and unable to open his eyes, “we knew there was nothing else that we could do,” she said.
An ambulance took Josia to a hospice room at a local hospital. His parents covered him in a soft, blue-and-white blanket, hugged him and held his small hand for the last time.
“We told him the choice was his, whether to keep fighting or be in peace with God,” said his mother. “He chose.”
Josia’s parents would have paid any price to save him.
A Texas doctor, two months, earlier, had given them one: $25,000 upfront, by cash or check.
It turns out that Josia Cotto was the child who died of complications from Burzynski’s treatment:
The FDA’s patience with Burzynski apparently wore out after Josia died.
In a report sent to the FDA after the boy’s death, Burzynski’s staff acknowledged that his last blood sample, taken the day he passed away, showed a blood sodium level of 205 millimoles per liter, a level that is typically fatal. Burzynski’s staff blamed that reading on a “false laboratory report based on a contaminated sample.”
Yet hypernatremia is one of antineoplastons’ most common side effects, known to doctors for two decades.
One of Burzynski’s own informed consent documents — the form that patients sign before they begin treatment — put the risk at 21%.
On July 30, 2012 — six weeks after Josia’s death — the FDA forbade Burzynski from giving antineoplastons to any new children.
I was astounded to see that number. I’ve never, ever seen a sodium level that high. Typically, normal is between 135 and 145 mEq/L, with slight variations of that range depending on the lab. Burzynski’s excuse, which I’ve heard at various times as being due to an “improper blood draw” or as described above, contamination, is purest nonsense. A bad blood draw typically produces falsely elevated potassium levels, not sodium levels. Unless the technician spiked Josia’s sample with 3% saline or something like that, there’s no way to get the level that high. Josia almost certainly died because of hypernatremia from antineoplaston therapy.
To me, this is the biggest revelation: The story and identity of the child who was killed by Burzynski’s treatments. We also learn that—surprise surprise!—Stanislaw Burzynski is an enormous tool. Look at him dismiss his critics, particularly former patients, many of whom, let’s recall, have terminal cancer, many of whom are dead:
Burzynski dismisses criticism of his work, referring to his detractors as “hooligans” and “hired assassins.”
As for criticism from former patients, Burzynski says, “We see patients from various walks of life. We see great people. We see crooks. We have prostitutes. We have thieves. We have mafia bosses. We have Secret Service agents. Many people are coming to us, OK? Not all of them are the greatest people in the world. And many of them would like to get money from us. They pretend they got sick and they would like to extort money from us.”
History will vindicate him, Burzynski says, just as it has vindicated other persecuted medical “pioneers,” such as Louis Pasteur. In the future, Burzynski says, everyone will use his therapies, and the cancer treatments used today — such as surgery, chemotherapy and radiation — will be regarded as barbaric. “There will be a time when people will see the light,” he says, “and our treatments will be used by everyone.”
You know, whenever I hear Burzynski fans like Eric Merola accuse skeptics of attacking cancer patients, accusing them of horrible things, I think I will throw this quote right back in their faces. Here’s Burzynski calling his patients prostitutes, thieves, and mafia bosses, and “not the greatest people in the world,” while accusing them of wanting to “extort money from us.” He also liberally uses the Galileo gambit, but that’s not surprising, as he’s repeatedly made the hilariously arrogant and scientifically ignorant claim that he is a pioneer in genomic and personalized cancer therapy and that M.D. Anderson Cancer Center and other world-class cancer centers are “following his lead.” Indeed, he claimed to have invented the field 20 years ago. Sadly, his publication record does not support such grandiose assertions.
There’s a lot more in this story, some of it contained in the sidebars “Experts dismiss doctor’s cancer claims” and “Families run out of hope, money after cancer treatments. Other than some of the revelations that I didn’t really know much about before, much of what is contained in the rest of this story will be familiar to regular readers here. For instance, experts are saying the same things I’ve been saying for a couple of years now about Burzynski’s anecdotes of “miracle cures,” such as Hannah Bradley and Laura Hymas. The reasons for these anecdotes include:
    • Burzynski often relies on anecdotes, which don’t tell the full story.
    • Burzynski’s therapies are unproven.
    • Burzynski’s patients may have been misdiagnosed.
    • Burzynski’s patients may have been cured by previous therapy.
There’s a reason why I’ve spent so much time deconstructing Burzynski anecdotes, and it’s for all of those reasons plus that anecdotes are often interpreted incorrectly by patients without medical training. Even doctors who are not oncologists sometimes interpret such anecdotes incorrectly to indicate that the cancer therapy chosen is the therapy that cured the patient. It’s not just Burzynski patient anecdotes, but it’s any cancer cure anecdote. That’s why clinical trials are necessary to differentiate all these confounding effects from actual effects due to the treatment. Indeed, the patients featured in Ms. Szabo’s article have nearly all been discussed by me before, including Mary Jo Siegel, who had a fairly indolent cancer for which the standard of care has changed from very aggressive treatment up to and including a bone marrow transplant to less aggressive therapy that acknowledges that these are slow-growing tumors. Worse, her story is lost in the mists of time, where what now exists are only highly selected medical records posted on various websites.
Indeed, Ms. Szabo even explains one aspect of the concept of pseudoprogression in a simpler way than a certain “friend” of mine did, lo, those many moons ago:
Many of Burzynski’s patients are terminally ill and have had one or more previous types of conventional cancer care — surgery, radiation or chemotherapy — before they see him.
But these therapies may have delayed benefits, taking weeks or months to shrink a tumor. So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer.
Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation. A patient who isn’t familiar with this phenomenon may assume her tumor is growing. When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says. In reality, the tumor was just returning to its previous size.
To avoid such confusions, researchers typically require patients to wait before starting a new treatment, Adamson says.
FDA inspections, obtained through the Freedom of Information Act, show that Burzynski has repeatedly failed to follow that basic practice.
Pseudoprogression can be a real confounder in assessing the response of brain tumors to therapy, being observed up to 28% of the time. It’s most common after surgery and radiation therapy, although it can happen after chemotherapy too. Not coincidentally, Hannah Bradley had surgery, chemotherapy, and radiation, and Laura Hymas had radiation and chemotherapy. These are the sorts of pitfalls that real cancer doctors doing real clinical trials already know about and work to minimize. Burzynski, in his arrogance, never thought he needed to bother with the sort of expertise that could validate his therapy. None of this stops Burzynski patients from being lured into spending hundreds of thousands of dollars on Burzynski’s treatments.
It’s very heartening to see a story like this in a major news outlet, and I must congratulate Ms. Szabo for her thorough deconstruction of the phenomenon that is Stanislaw Burzynski. True, a bit of false balance did sneak in here and there. For instance, the Siegels are featured, as are other Burzynski patients who believe he cured them when he almost certainly did not, in a video accompanying the story, and the title of the series is a rather clichéd “Science or Snake Oil.” However, the false balance that is so ingrained in the culture of journalism seems to be noticeably less apparent in this article than on many other stories about Burzynski that I’ve read. That’s good.
Before I close, I can’t help but mention that the most disappointing thing about this news story was that it still hasn’t revealed what I consider to be the two central mysteries of the Burzynski saga: First, how is it that Stanislaw Burzynski can still practice medicine? I know it’s Texas, but this has been going on for nearly 37 years. Second, why has he been allowed to continue to do clinical trials up until a little more than a year ago, and why is it that, even now, the FDA hasn’t shut him down permanently? Ms. Szabo sheds a little light on that, but nothing that regular readers of this blog don’t already know about the political machinations in the 1990s that led to Burzynski’s six dozen phase II clinical trials. Apparently, even Ms. Szabo and USA Today couldn’t crack that nut. Maybe public pressure can. The concluding section of the story tells us why we need to try:
No one told Josia’s parents about any of this.
Not Burzynski. Not the FDA.
Jose and Niasia Cotto had no idea that their son’s death prompted an investigation by the FDA, until they were contacted by USA TODAY.
The Cottos had long believed that Burzynski could have cured their son if only they had taken Josia to see him first, before giving him radiation and chemotherapy. They had even hoped to launch a non-profit, A Life for Josia Foundation, to help other children with cancer gain access to Burzynski’s treatment.
Now, they don’t know what to think.
Remember how I said that Bob Blaskiewicz will want your help? Now’s the time to contact him, if you haven’t already.

The Burzynski Empire strikes back
David Gorski on November 18, 2013
Link
You might have noticed that I was very pleased last Friday, very pleased indeed. Given the normal subject matter of this blog, in which we face a seemingly-unrelenting infiltration of pseudoscience and quackery into even the most hallowed halls of academic medicine, against which we seem to be fighting a mostly losing battle, having an opportunity to see such an excellent deconstruction of bad science and bad medicine in a large mainstream news outlet like USA TODAY is rare and gratifying. As you might recall, USA TODAY reporter Liz Szabo capped off a months-long investigation of Dr. Stanislaw Burzynski and his Burzynski Clinic with an excellent (and surprisingly long and detailed) report, complete with sidebars explaining why cancer experts don’t think that Burzysnki’s anecdotes are compelling evidence that his treatment, antineoplastons, has significant anticancer activity and a human interest story about patients whom Burzynski took to the cleaners. Most of this, of course, is no news to SBM readers, as I’ve been writing about Dr. Burzynski on a fairly regular basis for over two years now. It’s just amazing to see it all boiled down into three articles and ten short videos in the way that Szabo and USA TODAY did, to be read by millions, instead of the thousands who read this blog. Szabo also found out who the child was who died of hypernatremia due to antineoplastons in June 2012, a death that precipitated the partial clinical hold on Burzynski’s bogus clinical trials, about which both Liz Szabo and I have quoted Burzynski’s own lawyer, Richard Jaffe, from his memoir, first about Burzynski’s “wastebasket” trial, CAN-1:
As far as clinical trials go, it was a joke…it was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
And Jaffe’s characterization of the six dozen phase II clinical trials that Burzynski submitted in the late 1990s was this:
A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future…Miracle of miracles, all of Burzynski’s patients were now on FDA-approved clinical trials, and he would be able to treat almost any patient he would want to treat!
I’m just repeating those quotes again, because they can’t be emphasized enough. Quite frankly, if I were Burzynski, I’d fire Jaffe for having published such statements in his book. But that’s just me. In the meantime, let’s take a look at the counterattack and why Burzynski’s excuses regarding the deficiencies found in the FDA reports do not ring true.
The Burzynski shills strike back
My original plan for today had been to look into the story in a bit more detail than I had time for on Friday, in particular addressing the Burzynski Clinic’s response to the original FDA report in more depth and looking at some historical context. I figured that the Burzynski Clinic would strike back at some point, but it hasn’t yet, not really. Instead, it’s unleashed its resident propagandist and attack chihuahua Eric Merola, the man who wrote and directed two “documentaries” about Burzynski that were such propaganda about the “great man” that they’d make Leni Riefenstahl blush. Merola rapidly posted on his own website an open letter to Liz Szabo and then turned around and went full Godwin on her at his movie’s website. His responses are remarkable for their intensity; so I’ll briefly deal with them before I get into the “meat” of this post. His first response, which made the rounds within a few hours after Szabo’s story appeared, was his open letter/e-mail to Szabo. His second response appeared on the website for his movies and was entitled “Dear Burzynski Movie Subscribers“.
Both responses contain the same sorts of tropes, misinformation, and pseudoscience that we’ve come to expect from Merola: USA TODAY is biased and in the pocket of big pharma. It was a “hit piece.” Burzynski is far ahead of his time and will be vindicated (i.e., the Galileo gambit). It’s not just Burzynski, but the Japanese, who have “proven” that antineoplaston’s work. I’ve deconstructed these, and many more, of Merola’s nonsense over the last two years. What actually surprised me was the viciousness of the counterattack. For example, in his letter to Liz Szabo, he actually hopes that her child will get cancer, so that Burzynski supporters can gloat about it and Szabo will have to apologize to her children for her “perfidy” (in Merola’s eyes, at least):
Burzynski has found a life-saving cure for many cancers. You have just aided in helping to destroy that. I feel for you if your children get diagnosed with a pediatric brain tumor. You can look them in the eye and tell them “I’m sorry, I helped destroy the only thing that could have helped you.”
Such a nice guy. He denies that he hopes Szabo’s children will develop brain cancer, but then gloats gleefully over the possibility that she would have to face them after having—again in his mind—”helped to destroy the only thing that could have helped” them. In the dictionary, under the definition of “despicable,” there should be a picture of Eric Merola. Then, just when I thought Merola couldn’t go any lower, he does, this time in his longer response on his movie website:
Trying to “debunk” USA TODAY’s diatribe on Nov. 15, 2013 would be like someone living in Nazi Germany trying to debunk the writings of Joseph Goebbels, or an African American trying to explain to his slave master that he too is also a human being with rights and emotions, or the parents of an American soldier trying to explain to members of the Westboro Church how disrespectful it is to hold up signs that read “God Hates Fags” during their child’s funeral.
This type of unbridled hate and bigotry goes far too deep for any rational human discourse.
Obviously, to Merola asking Burzynski to follow normal rules regulating medical ethics and human subject protections in clinical trials is exactly like murdering millions of people, carrying out horrible medical experimentation, making untold numbers of Africans slaves, and harassing the grieving families of soldiers killed in battle. My first thought on reading this is that it’s rare to see an article in which someone “goes Godwin” so quickly and so despicably. It’s only the third sentence, fer cryin’ out loud! Didn’t anyone ever teach Merola that you need to build up to that sort of climax?
It’s also one reason that I don’t have any compunction about comparing Merola to Leni Riefenstahl. Of course, the big difference between Leni Riefenstahl, unfortunately, is that she had talent, and Eric Merola does not. Just watch his movies—if you can stand the robotic narration, the choppy editing, and the cheesy graphics—if you don’t believe me. However, the intensity of the images used by Merola do demonstrate the intensity of the hate he bears for critics of his hero Stanislaw Burzynski. To Merola, we are Nazis, slave owners, and bigoted religious fanatics. This explains quite well why he decided to attack us so viciously and clownishly in his most recent movie. At the time, I described it as almost Monty Pythonesque, except that Monty Python were brilliant and produced such effects on purpose. Merola is a hack and is only funny by accident because he has no filters that tell him when he’s going way over the top. To him, we are infidels. We do not share his belief, but, even worse, we have the temerity to criticize his god, or, to mix metaphors shamelessly, to point out that his emperor has no clothes.
Since I’ve dealt with so many of the tropes included in Merola’s not-so-little rant, I hardly see the need to repeat myself. However, as a cancer surgeon, I find one of Merola’s lies to be as despicable, or perhaps more so, than his Nazi/slavery/Westboro Baptist Church comparisons. In essence, he denies the toxicity of antineoplastons in terms I’ve never seen anyone try to downplay before:
ANP… is toxic?
This was perhaps the most stunningly malicious use of emotion to manipulate the reader in any of the propaganda pieces against ANP in history. Never mind that tens of thousands of people die from complications from approved and properly prescribed pharmaceutical drugs per year—being one of the leading causes of death in the USA. Never mind that the average Stage IV cancer patient dies from complications due to chemotherapy and radiation before the disease has a chance to kill the patient. USA TODAY will have you believe that “sleeping in excess” a little bit while under ANP is a dangerous and toxic side effect of the therapy.
Never mind that not one single cancer patient in the history of ANP’s existence has ever died from the therapy.
Ever.
Tell that to the parents of Josia Cotto. Josia, as readers of Liz Szabo’s report will know, was the six year old boy with an inoperable brain tumor who died of hypernatremia (elevated sodium levels in the blood) as a result of Burzynski’s therapy. As I pointed out last Friday and Szabo reported in her story, before his death Josia’s serum sodium was measured at 205 mEq/L, way above the normal range of 136-145 mEq/L and well into the lethal range. As I pointed out then, I’ve never seen a sodium level anywhere near that high. During my residency, the highest I recall ever seeing was maybe around 180 mEq/L. As for Merola’s swipe about “sleeping in excess” as a toxicity, it’s rare for someone (but not Merola) to reveal such ignorance in a single sentence. Lethargy and somnolence can be symptoms of hypernatremia, and are often followed soon after by seizures. They can also be symptoms of the tumor progressing. Absolutely they are adverse events. Truly, Merola’s ignorance of what is and isn’t considered and adverse event and why it’s important to report all adverse events in clinical trials approaches black hole-levels, from which no scientific knowledge can escape.
Of course, none of this is new information. A Cancer Letter article from 1998 pointed out that investigators had observed “severe toxicity” in 33% of patients that necessitated stopping treatment. One of those patients experienced—yes—somnolence before developing seizures. I also note that one of Burzynski’s most famous patients, Hannah Bradley, who with her partner Pete Cohen proclaims herself cured of her brain cancer, thanks to Burzynski, suffered some pretty serious toxicities from antineoplastons herself, including high fevers to 103.9° F, shaking chills, and severe rashes. Pete even documented how badly Hannah reacted to antineoplastons in his YouTube documentary “Hannah’s Anecdote”.
The rest of Merola’s rant reads like a greatest hits compilation from cancer quacks. The system is corrupt. Oncologists know chemotherapy doesn’t work and only administer it to make money. The FDA is fascist. You get the picture. That’s the wingnut counteroffensive against Liz Szabo’s article. Now let’s see how Burzynski, knowing that Szabo’s story would be published soon, tried to pre-empt the FDA findings that I described in detail last week.
Burzynski tries to defend himself
Before I discuss why Burzynski’s explanations don’t excuse his activities, I can’t help but point out that I find it rather curious that the FDA released the two Form 483’s describing what its investigators found at the Burzynski Clinic during their investigations from January to March 2013. To be honest, as I mentioned before, the biggest disappointment that I had over Szabo’s excellent reporting is that she apparently couldn’t get to the bottom of why the FDA has let Burzynski continue to run his dubious clinical trials for so long, despite multiple investigations over the preceding decade that had found deficiencies in his operation, particularly in how his institutional review board (IRB) works. (An IRB is a required committee that each institution doing human subjects research must have to approve and monitor human subjects research and ensure that it meets Office for Human Research Protections (OHRP) requirements.) Given that the USA TODAY story makes the FDA look very, very bad indeed—and more than justifiably so—it strikes me as more than a tad coincidental that the FDA finally released these preliminary reports a mere week before Szabo’s story was published, eight months after its investigation concluded. It’s almost as though the FDA were trying to cover its exposed posterior. One can only hope that Szabo’s story lights a fire under that same posterior to actually do something more about Burzynski, such as making the clinical hold permanent and banning him from ever doing any further clinical trials.
Be that as it may, let’s recap what the FDA found, summarized by yours truly. The findings came in two reports. The first set consisted of the first Form 483 and a warning letter issued by the FDA in late September:
     1.  The IRB failed to follow FDA regulations regarding expedited review procedures [21 CFR 56.110(b)].
     2.  The IRB approved research without determining that the following criteria were met: risks to subjects were minimized [21 CFR 56.111(a)(1)]; risks to subjects were reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may be expected to result [21 CFR 56.111(a)(2)].
     3.  The IRB failed to determine at the time of initial review that studies involving children are in compliance with 21 CFR part 50, subpart D, Additional Safeguards for Children in Clinical Investigations [21 CFR 56.109(h)]. This is a repeat violation from our 2010 inspection.
     4.  The IRB failed to prepare, maintain, and follow written procedures and maintain adequate documentation governing the functions and operations of the IRB [21 CFR 56.108(a), 21 CFR 56.108(b), and 21 CFR 56.115(a)(6)].
As I discussed before, this is a massive failure of the Burzynski Research Institute (BRI) IRB. It is, in essence, the abuse of a process designed to allow minor changes to clinical trial protocols to be approved by an IRB without a full meeting of the IRB for a purpose for which the expedited approval process was never intended: to approve single-patient protocols, which are, in essence compassionate-use exemptions that allow patients who normally wouldn’t meet the inclusion criteria of the trial to receive the experimental therapy. Such protocols require full meetings of the IRB to discuss. Of course, such abuses are not surprising, given that the BRI IRB is run by an old crony of Burzynski’s from his Baylor days, Charlton F. Hazlewood. There’s very little in the way of a response that Burzynski could make to these allegations and be convincing. OHRP rules on single-patient protocols are not unclear:
A “single patient use” allows a physician to obtain access to an investigational drug for the treatment of a single patient. Usually, the patient is in a desperate situation and unresponsive to other therapies, or in a situation where no approved or generally recognized treatment is available. Further, there is usually little evidence that the proposed therapy is useful, but may be plausible on theoretical grounds or anecdotes of success. Access to investigational drugs for use by a single, identified patient may be gained either through the sponsor under a treatment protocol, or through the FDA, by first obtaining the drug from the sponsor, and then submitting a treatment IND to the FDA requesting authorization to use the investigational drug for treatment use [21 CFR 312.35].
There are situations when it is allowed to do single-patient protocols without getting IRB approval first, but they are very uncommon:
First, the FDA human subjects regulations allow for a test article to be used in emergency situations without prior IRB approval provided that the emergency use is reported to the IRB within five working days; subsequent use of the test article must be reviewed by the IRB [21 CFR 56.104]. An emergency is defined as a life-threatening situation in which no standard acceptable treatment is available and in which there is not sufficient time to obtain IRB approval [21 CFR 56.102(d)]. [See Guidebook Chapter 2, Section B, “Food and Drug Administration Regulations and Policies.”]
In other words, IRB approval is required before single-patient use of investigational agents. This presentation confirms that. Indeed, it is listed as an impediment to single-patient protocols because of the time and expense of convening a full IRB meeting for a single patient. Expedited review, the very same process that the BRI IRB used to approve single patient protocols, is listed as a potential solution to the difficulties in getting single-patient protocols approved. Of course, that means that currently the expedited review process is not permitted as a method for an IRB to approve a single-patient protocol. Oddly enough, there’s not much in the Burzynski Clinic response about single-patient protocols.
The second set came from the second Form 483, which listed these deficiencies:
a. …For 18 of 27 (67%) of subjects, the investigator did not comply with the protocol requirements for assessing the efficacy endpoint of tumor response and recorded inaccurate assessments for tumor response in study records. For example:
    • Study [REDACTED]: Subjects 005297 and 007197 were inaccurately classified as Complete Response (CR). Subjects 004721 and 008765 were inaccurately classified as Partial Response (PR). Subjects 005974, 011373, 012184, 012206, and 12252 were inaccurately classified as Stable Disease (SD).
    • Study [REDACTED]: Subjects 06389, 11819, and 13660 were inaccurately classified as CR. Subjects 21428 and 23399 were inaccurately classified as PR.
    • Study [REDACTED]: Subject 009990 was inaccurately classified as CR. Subject 004881 was inaccurately classified as PR.
    • Study [REDACTED]: Subject 006239 was inaccurately classified as PR. Subject 004240 was inaccurately classified as SD.
b. You did not have a QA monitor properly monitor CRFs [case report forms] and subject records. The investigator destroyed critical subject case history records (target tumor measurement worksheets) or misplaced case history records (original subject CRFs) for all subjects.
There were several others, so many that I could do a series of posts about them, but these two stand out to me most of all:
    • Your MRI tumor measurements initially recorded at baseline and on-treatment MRI studies for all study subjects were destroyed and are not available for FDA inspectional review.
    • You failed to monitor as required by Section 16 of your Monitoring Plan. The investigator did not report adverse events (AEs) experienced by study subjects, including 18 cases of hypernatremia.
Let’s deal with what I view to be the worst of the worst, namely Burzynski’s apparent inability to accurately assess whether a patient is experiencing a complete response (CR) to therapy, a partial response (PR), stable disease (SD), or progressive disease (PD), terms that are fairly self-evident but that I defined in depth last time around. So how did Burzynski dance around the issue? He did it in a number of ways, because there were a number of reasons why individual patients were thought to have been misclassified. For example, the FDA notes:
Subject 23643 : The study protocol required the subject to be off chemotherapy for at least 4 weeks. The cbemotherapy on 7-17-12 and began treatment with the investigational product, one day later, on 7-18-12.
And indeed, the protocol did require:
At least eight weeks must have elapsed since the last dose of radiation therapy and at least four weeks must have elapsed since the last dose of chemotherapy (six weeks for nitrosoureas) or immunotherapy.
Since the full effectiveness of initial therapy (including radiation therapy) may not be seen until a few months after the initial therapy is completed, it is very difficult to analyze the effectiveness of initial therapy before the patient has completed treatment and follow-up. Because of this treatment decisions are usually not made on the base of radiological studies performed earlier than four weeks following completion of radiation therapy.
The only exception is:
However, patients with clear evidence of disease progression during the initial therapy may be enrolled less than (8) eight weeks following the last dose of radiation therapy, less than 4 weeks after surgery or the last dose of chemotherapy, if the investigator has determined that it is safe to administer antineoplastons to such patients.
I mentioned, but did not explain, the phenomenon of “pseudoprogression,” because I was impressed with how well Szabo had explained it in her story. Pseudoprogression can confound treatment decisions regarding second line therapy after initial treatment, being basically a phenomenon in which late effects of radiation therapy can produce enhancing lesions that look to all the world on MRI like tumor recurrence. There was a nice review of this topic a few years ago that describes the phenomenon thusly:
Now that concurrent TMZ and radiotherapy are used as standard therapy, the postradiotherapy radiological assessment is made earlier than before, when radiotherapy was given alone. However, it can be difficult to interpret the radiological image obtained, as any changes observed may be due to treatment-related pseudoprogression rather than true disease progression. In their recent study of 51 patients treated with radiotherapy and concomitant TMZ, Chamberlain et al.20 reported seven (14%) cases of early necrosis without signs of tumor recurrence; 26 patients had a radiological diagnosis of early disease progression and, of these, 15 underwent re-resection, with 7 (47%) of the 15 having a surgical diagnosis of radionecrosis. These data open a dual scenario: the possibility of a higher incidence of early radionecrosis and the risk of mistaking the latter for disease progression. In a series of 32 glioma patients, de Wit et al.21 observed that the first postradiotherapy MRI showed progressive enhancement in nine cases; in three of these nine cases, MR images showed improvement or stabilization for 6 months without additional treatment being given.
And:
In patients under treatment for brain tumors, worsening of the preexisting neurological focal deficits, suggesting tumor progression or recurrence, can be accompanied by a neuroradiological image of edema and contrast-enhancing lesion within the tumor bed. However, this radiological pattern is not necessarily associated with any clinical deterioration. These alterations, described in 1979 by Hoffman et al.3 in a group of patients treated with radiotherapy and carmustine (BCNU) at an interval of 8 weeks, were investigated with serial CT or MRI scans. Within 18 weeks following radiotherapy, 49% of patients had a deterioration that strongly suggested tumor progression. In 28% of the cases, however, spontaneous improvement occurred without a change in therapy. Following this pattern, which is indistinguishable from that of tumor recurrence, improvement usually occurs within a few weeks or months, with a thorough neuroradiological follow-up showing that these signs regress within 4–8 weeks. The timing of these clinical features, known as “early delayed reactions” following radiotherapy,4 seems to correspond to the turnover time of myelin.
As a reminder, I will also quote the USA TODAY article again, because it is the most succinct explanation of pseudoprogression I have ever seen:
Many of Burzynski’s patients are terminally ill and have had one or more previous types of conventional cancer care — surgery, radiation or chemotherapy — before they see him.
But these therapies may have delayed benefits, taking weeks or months to shrink a tumor. So patients treated by Burzynski may credit him for their progress, just because he was the last doctor to treat them, says Peter Adamson, chair of the Children’s Oncology Group, an NCI-supported research network that conducts clinical trials in pediatric cancer.
Conventional cancer treatment can also cause tumors to swell temporarily, due to inflammation. A patient who isn’t familiar with this phenomenon may assume her tumor is growing. When that swelling subsides, patients may assume it’s because of Burzynski, Adamson says. In reality, the tumor was just returning to its previous size.
To avoid such confusions, researchers typically require patients to wait before starting a new treatment, Adamson says.
In other words, in a small but not inconsequential number of cases (perhaps as much as 28%), apparent tumor progression really isn’t. That’s why it’s called pseudoprogression, and is defined as the delayed but still-early effects of therapy mimicking tumor recurrence on MRI scans. In other words, therapy of brain tumors can result in the enhancement seen on MRI associated with the tumor increasing in size due to increased blood flow due to inflammation. The same phenomenon is very likely true for many Burzynski patients who are presented as “success stories.” They show pseudoprogression, and, as pseudoprogression does, the “enlarging cancer” decreases in size after the patient is put on antineoplastons. However, the decrease has nothing to do with the therapy. That’s why in Burzynski’s case well-conducted clinical trials are absolutely essential, as well as why clinical trials require patients to be off therapy from 4-8 weeks to avoid the confounding effects of pesudoprogression. Of course, the number of patients exhibiting pseudoprogression who don’t ultimately develop a real recurrence that kills them is much, much smaller, but not so small that it can’t explain many of Burzynski’s testimonials. In fact, I bet pseudoprogression in patients who were lucky enough to be cured or have had their tumors shrunk enough that it takes a long time to recur probably explains the majority of Burzynski’s brain cancer testimonials.
Another big issue that the FDA noted was that some of the patients whose tumor responses to antineoplastons had been overestimated by Burzynski were still on steroids. Steroids are often administered to brain cancer patients to lessen the edema (swelling) that frequently occurs around tumors. Given that the skull is a fixed volume, any swelling can result in increased intracranial pressure, which can damage the remaining brain. The problem here is that if Burzynski’s patients were on steroids, it could make the tumors appear smaller than they really are. Burzynski started out his excuse with some obfuscation that the guidelines for determining CRs have changed twice over the last several years. Well, yes, that’s true. As referenced by Burzynski, the Macdonald criteria for response assessment were changed in 2010 to incorporate changes in steroid doses as part of the definition of responses. For a response to be assessed as a CR or PR, the patient now has to be on stable or decreasing steroid doses. Burzynski tries to justify some of the patients this way:
Our definition of a “patient off corticosteroids” is one who continues on the lowest dosage necessary for neurologic stability and is maintained at their level of comfort and function. This is ordinarily determined by decreasing the close until signs increase or become apparent and then increasing the dose until they subside. If deterioration is secondary to tumor growth or treatment–induced effects, the glucocorticoids dose may have to be increased to keep the patient comfortable. Hence, “off corticosteroids” in order to interpret response to treatment is defined as a patient that may either be off steroids or be receiving a stable steroid dose to maintain neurologic and physiologic stability.
Since the beginning of Phase ii study program under IND 43,742, the criteria used for assessing response to therapy in malignant brain tumors have changed twice. The most recent recommendations of the Response Assessment from the Neuro-Oncology Working Group became active in April, 2010. According to these recommendations, it has been accepted that complete and partial responses can be determined when the patient is on physiologic replacement doses of corticosteroids.
All of which is true, but irrelevant. Response criteria can’t be changed mid-stream in a clinical trial without actually altering the clinical trial. If the standard methodology of measuring tumor response changed, then if an investigator wants to use those changes he has to submit an amendment to his protocol to his IRB and the FDA and get it approved. Clearly, Burzynski didn’t do that, and according to his protocol the patient had to be off steroids. So the FDA called him on it.
Some of Burzysnki’s other excuses are ludicrous in the extreme, and I’ll deal with some of them briefly. For example, for one patient, Burzynski writes:
Patient 004240: An assessment of SD was determined based on the size of the enhancing lesion and does not reflect the overall increase of tumor size due to formation of a Cyst. The change in the overall size of the brainstem lesion on studies between 2/21’/96 and 5/22/96 is due to an increase (4/10/96) and collapse (5/22/96) of the cystic component of the lesion.
No, you don’t get to estimate tumor volumes that way, particularly back in 1996. It rather reminds me of the way Burzynski has played fast and loose calling responses when tumors get larger based on seeing increasing size of “cysts,” the way he did with Amelia Saunders.
For another patient, he seems to want to have it both ways:
Patient 005974: The enhancing portion of the tumor increased 30%, which met the criteria of SD using previously used criteria. Since we are amending the protocol, this patient will be reclassified as PD.
In other words, when I the old criteria don’t make me declare a patient as having PD, I use them. When they would force me not to call a CR or PR but the new criteria will, I use the new criteria. Again, you can’t flip back and forth between new and old criteria, picking whichever set of criteria gives you the better results. You have to pick one and stick with it for every subject on the trial. It’s acceptable to change to the updated criteria, but if as a principal investigator you choose to do that then you need to go back and reassess response for every single subject on your trial from day one using the new criteria.
I could go on and on, but even I get tired after a while. However, I can’t finish without looking at one claim that Burzynski made as an excuse that almost cost me a keyboard as I was drinking coffee as I read it. Perhaps the most damning finding of the FDA was the Burzynski Clinic’s failure to keep original scans and records on some patients. Here is the Burzynski Clinic’s excuse:
ICH E6, section 1.51, also defines source data as “All information in original records and ‘certified’ copies of original records or clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.”
The clinic notes contained copied source data of tumor measurements that had been verified, dated and signed, which from our interpretation would constitute being a “certified copy” of the data. We judged that the data of tumor measurements were accurate and could be audited back to the source document.
A5 for the issue of misplaced case history records original subject CRFS, we maintain that these original CRFs were populated with data that was derived from the patient case files and would not be considered original source data. The source data are the patient files. Back in the year 2000, BRI regulatory and clinical staff determined that the “original were considered inadequate and required redesigning in that they had a number of missing fields. As was done for the “original new CRFS were again generated from the source data in the case history records and not derived from the original CRFs. These “new are available for review. We retained a total of 132 of the “‘original which have been located in our archives. However, we do not plan to use these, based on the aforementioned reasons as well as not being source documents. The remaining ‘original which were not signed off on as true and accurate copies of source data were destroyed for the reason of being incomplete.
No, “certified” does not mean “copied onto new forms or into new computer database fields because we redesigned our forms.” Certified copies tend to be copies of medical records from other institutions used in the conduct of clinical trials; i.e., certified medical records such as any patient can request from a health care provider, as in photocopies of clinical records, copies of scans, or CDs or DVDs containing radiology tests. For a clinical trial, there is no excuse for destroying original documents from your own clinic used for a clinical trial. None. Ever. At least not without FDA and IRB approval before doing so. The reasons are obvious. It destroys the very paper trail that is critical to the trustworthy conduct of a clinical trial. Destroying such records indicates either gross incompetence or an investigator trying to hide something. This suspicion becomes particularly pertinent given that many of the original MRI scans of Burzynski patients appear to be missing, making it impossible for the FDA to do repeat measurements, in order to determine whether Burzynski’s response assessments were correct.
There are multiple other examples of dubious claims in Burzynski’s response, but I’ve mostly covered them in my original post on the FDA revelations. These include the hypernatremia cases that Eric Merola basically denied, which Burzynski tried to brush off due to changes in the Common Terminology Criteria for Adverse Events (CTCAE) over the years. In essence, he claimed that hypernatremia wasn’t listed on the earlier version of CTCAE; so he made up “clinical severity” criteria, which didn’t agree with the CTCAE. Now, the CTCAE has been around since 1983, although it was called the Common Toxicity Criteria until v.3 in 2003. Each version has added more criteria. Before 2003, Burzynski might have had a point; I can’t find whether CTC v.1 (1983 to 1996) or CTC v.2 (1996 to 2003) listed hypernatremia, but any time after 2003, he’s undoubtedly full of bovine feces, as CTCAE v.3.0 does list hypernatremia, as does CTCAE v.4.0.
Isn’t this enough?
I’ve written time and time again about what I call the central mysteries of the Burzynski saga. The first mystery is why the Texas Medical Board hasn’t been able to shut him down, despite over 30 years of trying. That’s the easier mystery to explain. The Texas Medical Board is a paper tiger, intentionally weak to protect doctors’ business interests. The second central mystery is why the FDA has let Burzynski get away with so many violations with respect to clinical trials. We know why he was allowed to register those clinical trials in the first place. Political pressure on the FDA from U.S. Representative Joe Barton and other woo-loving heavy hitters in the 1990s saw to him being able to register 72 phase 2 clinical trials, but what’s allowed those trials to remain registered, and why on earth did the FDA ever approve Burzynski’s one and only phase 3 clinical trial back in 2009, a trial that never accrued a single patient before closing?
The great thing about the USA TODAY story is that it is likely to be the most widely-read detailed story about Burzynski ever published, given how large the circulation of USA TODAY is, and it was a front-page story. As good as it was, it doesn’t have all the answers. The first step is shutting Burzynski down, but that’s not enough. We need to know what’s wrong with the FDA that allowed Burzynski (mostly) free rein for so many years, and we need to fix it.

The Skeptics for the Protection of Cancer Patients need your help
David Gorski on December 4, 2013
Link

We at SBM don’t normally ask our readers for much, if anything, other than to read and for the subset of you who like to be active in the comments to have at it. However, given the story of Stanislaw Burzysnki, which I’ve been covering with frequent blog posts for over two years now, how could I not listen to the appeal of my friend and co-conspirator (note to Burzysnki fans: that “co-conspirator” bit was sarcasm) to take action in the wake of the USA TODAY story that ran two and a half weeks ago. Despite the disingenuousness of Burzynski’s response, unfortunately he’s still managing to find his way into legitimate scientific meetings.
Friends,
As you know, the Skeptics for the Protection of Cancer Patients (SPCP) have launched a campaign to alert Congress to the horrendous research practices of the Burzynski Clinic that were uncovered by the FDA and to ask legislators to inquire into the circumstances that allowed Stanislaw Burzynski to peddle an unproven chemotherapy via his clinical trials. We are pleased to report that we are already hearing back from a number of congressional offices about this matter.
By sending them copies of the official observations from the FDA’s site inspections, we believe we are making the most powerful argument possible for an inquiry into how things were allowed to remain so bad for so long. At thehoustoncancerquack.com, we have letters for you to personalize that will introduce the Burzynski story to your representatives and will put the documents you send in context.
In order to run as efficient and evidence-based a campaign as possible, we have provided a feedback form so you can share your representatives’ responses. This is the most precious information that we can gather at this point in the campaign, because it will give us a sense of the audience we are crafting our message for.
The key committee regarding this matter in the House is the Committee on Oversight and Government Reform, and we certainly recommend that you look and see if your representative is on that committee. Anyone can approach the committee itself (or the Subcommittee on Energy, Health Care and Entitlements) for an investigation into the FDA’s continued approval of Burzynski’s catastrophically flawed trials. Send your documents here:
Committee on Oversight and Government Reform2157 Rayburn House Office BuildingWashington, DC 20515Phone: (202) 225-5074 Fax: (202) 225-3974
In the Senate, your best bet is the Committee on Health, Education, Labor and Pensions. If your senator is on one of these committees, please take special action and write to them directly.
This is not the type of campaign where we can be half-in. One patient, responding to the recent USA Today article, posted that the last time Burzynski was on trial, she sent over a thousand letters to members of Congress. This is what we are up against, people who believe that Burzynski is the only one keeping them alive. They will fight for him; a few dozen survivors are probably the reason this has gone on so long. They will counter-organize. The skeptics’ advantage is in our numbers and the facts of the matter, and we need to make the best use of those advantages in this critical time.
Thank you,
Bob
Skeptics for the Protection of Cancer Patients([email protected])
Lest you think this is not important, consider this. Even after the USA TODAY article, families of desperate cancer patients are still making appeals to raise money to take them to Houston to be treated by Stanislaw Burzynski. Right before the Thanksgiving holiday, there was an article on The Huffington Post entitled Child Cancer Patient Petitions For Brain Tumor Treatment Not Yet Approved By The FDA:
Last Thanksgiving, 12-year-old McKenzie Lowe was diagnosed with an inoperable brain tumor. Her family is petitioning New Hampshire’s governor to allow McKenzie to undergo Antineoplastons therapy, a treatment not approved by the FDA. The FDA has allowed 471 “compassionate use” exemptions to date, and McKenzie’s grandfather, Frank LaFountain, hopes she’ll be next in line.
“We’ve talked to survivors of this drug, who had the same condition McKenzie has,” he told HuffPost Live host Nancy Redd. “People say there aren’t any, but we know them. We’ve talked to them, and that’s what makes us so passionate about getting her this particular drug.”
And here’s the video:
Only a heartless bastard could fail to be moved by McKenzie’s story, which is, sadly, typical for pediatric patients with brain cancers. HuffPo pulled out all the stops to emphasize McKenzie’s cuteness and what a nice girl she is, while buying completely into the propaganda line that the Burzynski Clinic promotes.
It pained me to watch that video. It really did. But it also made me angry. Once again, Burzynski is offering false hope to families of cancer patients, and HuffPo deserves nothing but opprobrium for promoting this Change.org petition, which Eric Merola, producer of two propaganda “documentaries” for Burzynski is also promoting. As desperate as McKenzie’s situation is, Burzynski can’t help her. However, her family can help him, most likely unwittingly, by changing the narrative from a doctor without any training in internal medicine or oncology who is utterly unqualified to treat patients with advanced cancer who has cynically sidestepped the FDA and the Texas Medical Board for nearly 37 years while abusing the clinical trial process to keep giving a toxic, almost certainly ineffective chemotherapeutic agent to patients. And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise.
Do the Lowes know that Josia Cotto, a child with a similar tumor, died of massively elevated sodium levels from ANP therapy? Burzynski claims it was due to a blood sample contaminated by being drawn from an IV line with a solution with a lot of salt in it, but any physician would know that claim doesn’t pass the smell test, given that Cotto’s sodium level was 205 mEq/L (normal is between 135 and 145 mEq/L). Some IV lines do contain normal saline (NS), and if such IV lines contaminate a blood specimen they can indeed falsely elevate the measured sodium level. However, the concentration of sodium in NS is only 154 mEq/L of sodium (also expressed as 0.9%); so even a large-scale contamination can’t increase it much. Even if there were contamination from a line containing NS, it would be impossible to produce a sodium level of 205 mEq/L. The only way it would be feasible for contamination from an IV line to produce a sodium of 205 mEq/L would be if that line contained a much higher concentration of sodium. Physicians do sometimes infuse 3% sodium, the sodium concentration of which is 513 mEq/L, but its only real use is the rapid correction of acute hyponatremia (low sodium), and it is rarely used in children. (Usually hyponatremia is corrected by restricting free water intake.) In any case, as reported by the long-running British news magazine, BBC Panorama, the ICU over at nearby Texas Children’s Hospital all too frequently has to deal with desperately ill Burzynski patients that Burzynski can’t cope with. Meanwhile, families pay hundreds of thousands of dollars for Burzynski’s toxic, ineffective therapy.
In any case, the Change.org petition for McKenzie Lowe, as well-meaning as its sponsors are, is very misguided. The Friends of McKenzie Lowe are petitioning FDA Commissioner Margaret Hamburg to grant a compassionate use exemption for McKenzie so that Burzynski can treat her with ANPs. Recall that one of the very offenses that got Burzynski into hot water with the FDA was his investigational review board’s (IRB) history of playing fast and loose with single patient use protocols, in which patients were approved through the expedited approval process, which was never intended to be used for this purpose. Putting patients on compassionate single patient use requires full approval by the entire IRB. In essence, this petition is asking the FDA Commissioner to ignore those findings and let Burzynski do it again for McKenzie Lowe.
One also wonders whether the Lowes know other things about Burzynski. For instance, the FDA found that he had destroyed original patient records and, most importantly of all, misclassified partial and complete responses. Suffice to say, Burzynski’s explanations are underwhelming and unconvincing.
Finally, there is the oft-repeated claim that Burzynski is the only person who has ever cured the cancer that McKenzie has. These days, it is Burzynski’s favorite line, a line often parroted by his minions, particularly Eric Merola. Would that it were true! What Burzynski proponents can’t understand is that I would be very happy if there were a treatment that could actually cure children with diffuse intrinsic pontine glioma (DIPG). As I’ve discussed many times before, nearly all of Burzynski’s “cancer cure” testimonials, when examined more closely, are highly dubious with respect to whether it was actually ANPs that cured the tumor, with not a single one of them being particularly convincing when examined closely. Either there’s insufficient information (i.e., the timeline is vague), the possibility of misdiagnosis, or the mistaking of the natural reversal of pseudoprogression for an actual antitumor effect. Brainstem gliomas in children are a heterogeneous group of tumors. Moreover many of these tumors aren’t biopsied, because of their location, and are usually diagnosed by their appearance on MRI. However, MRIs, as discussed in the case of Tori Moreno, can sometimes find masses that look for all the world like tumors but aren’t. Finally, contrary to Burzynski’s claim, there are occasional long-term survivors, some of whom received little or no therapy, such as Connor Frankenberg, a child from Germany, and two patients who underwent spontaneous remission. (Yes, I know that one of the children listed is a Burzynski patient, Tori Moreno. One notes that the DIPG Registry does not mention Burzynski or ANPs at all.)
The DIPG Registry concludes that, although the vast majority of children with DIPGs do poorly:
The bottom line is: 1) we really don’t understand DIPGs, and 2) there are children who have been diagnosed with DIPGs-based on the incomplete knowledge that we currently have- who truly have had spontaneous regression of their tumors and 3) most of the children with reports of spontaneous regression have been very young.
The big problem is that, like many dubious cancer doctors, Burzynski appears not to keep good enough records to demonstrate that he can cure DIPG, and we already know he misclassified partial and complete responses. In brief, DIPG is a horrible disease, with only 10% surviving beyond two years, and there is no convincing evidence that Burzynski can do any better than conventional oncology, much less cure DIPG, as much as he repeats the claim that he can. Worse, he hasn’t published a single one of his completed phase II clinical trials, even though he’s had well over 15 years to complete them. With tumors this lethal, most such trials should be completed within five years.
All of this brings us back to Bob’s appeal.
The Lowes are petitioning various Senators and Representatives from New Hampshire and Massachusetts to lean on the FDA to grant the compassionate use exemption. This is what we are against, parents of children with cancer who truly believe that Burzynski is their family member’s only hope and will understandably do anything they can to put him back in business. That they are wrong is almost beside the point. What politician can say no to such an appeal? What human being doesn’t have difficulty saying no to such an appeal, even when he knows the family’s desperation has led them down a dark path to viewing Burzynski as the only man who can save their loved one? At the very least, they will look into it and put pressure on the FDA. That’s why, as much as we sympathize with the plight of these patients and their families, legislators should not overrule the FDA’s decision regarding antineoplastons. Indeed, the real investigation should be into why the FDA has allowed Burzynski to get away with what he’s gotten away with all these years.

Stanislaw Burzynski: Using 1990s techniques to battle the FDA today
In the 1990s, cancer quack Dr. Stanislaw Burzynski and his lawyer Richard Jaffe perfected a PR strategy in which patients who believed that Burzynski had saved their lives would protest and, often aided by friendly legislators, beg the FDA (or whatever regulatory body was trying to stop Burzynski’s abuses at the time) not to let them die. It was very effective political theater, which is why Burzynski is using the same strategy today against the FDA.
David Gorski on January 20, 2014
Link
It figures that I couldn’t go three weeks into 2014 without the topic of Stanislaw Burzynski rearing its ugly head. I had hoped to make it to February or even beyond before feeling the gravitational tug of the wretched hive of ignominious and unethical behavior, but here we are, only 20 days into the new year. So be it.
2013 finished with serious setbacks for Stanislaw Burzynski and his unproven cancer treatment that he dubbed “antineoplastons” (ANPs) way back in the early 1970s. As you might recall, in November, two things happened. First, the FDA released its initial reports on its inspection of the Burzynski Clinic and Burzynski Research Institute (BRI) carried out from January to March 2013. They were damning in the extreme, pointing out the shoddy operating methods of the institutional review board (IRB) used by the BRI to approve and oversee Burzynski’s “clinical trials” (and I use the term loosely) of ANPs. Violations included using expedited approvals to review single patient protocols, something so far outside the purview of what the expedited approval process was intended for, namely approving minor tweaks to human subjects research protocols without requiring a full meeting of the IRB, that the FDA called Burzynski out for it. Other violations included failure to report serious adverse events (SAEs) and adverse events (AEs) to the FDA and/or the IRB, failure to follow proper informed consent procedures, failure to determine that risks to subjects were minimized and that risks to subjects were reasonable in relation to anticipated benefits, if any, and a lot of other violations, which are listed in my previous post on the subject.
Later in November, Liz Szabo of USA TODAY published a fantastic expose of Burzynski entitled “Doctor accused of selling false hope to families,” in which, in addition to many of the violations revealed by the FDA, it was further reported that the child whose death in the summer of 2012 triggered the FDA investigation was Josia Cotto, and that the child died of hypernatremia (elevated sodium levels in the blood) caused by ANP therapy. In response to the reports of shoddy record keeping, lack of ethics, and contributing to the death of a child, Burzynski was his characteristically cuddly self, referring to his critics as “hooligans” and “hired assassins,” while claiming that they “pretend they got sick and would like to extort money from us.” When last I wrote about Burzynski in November, his empire was struggling to strike back. Eric Merola, the film maker responsible for two pro-Burzynski propaganda movies Burzynski: Cancer Is A Serious Business and Burzynski: Cancer Is A Serious Business, Part 2, likened USA TODAY to everything from Nazi propaganda under Joseph Goebbels, to slave masters, and to the Westboro Baptist Church protesting at the funerals of gay soldiers killed in the line of duty. Meanwhile Burzynski himself tried to answer the FDA findings and failed miserably, nor did his poster presentation of singularly unimpressive results at the Society of Neuro-Oncology Meeting right before Thanksgiving help. The year ended with the Texas Medical Board using the FDA’s findings as part of the basis of charging Burzynski with false advertising, meaning that Burzynski will be spending a lot of time defending himself against the TMB in 2014.
Unfortunately, beginning in December, Burzynski and his allies decided to go back to the future, so to speak (or maybe just back to the 1990s) and resurrect the campaign that worked so well for them the last time Burzynski’s back was against the wall. Unfortunately, this strategy, rooted as it is in using cancer patients to lobby Congress to force the FDA to allow Burzynski to use antineoplastons, could work. Pro-Burzynski forces, in a nod to the past, have even hired the same lobbyist who, or so it is claimed by the pro-Burzynski forces, succeeded so brilliantly in the mid-1990s in persuading Rep. Joe Barton (R-TX), then the chair of the House Subcommittee on Oversight and Investigations, to “investigate” the FDA’s “harassment” of Burzynski.
Using patients as human shields and missiles
If you want to understand Burzynski’s new strategy to keep using ANPs, you have but to go back and examine his previous strategy, which was to milk dying cancer patients for every bit of human sympathy they can evoke from lawmakers and the public. I realize that the way I chose to phrase that might be offensive to some readers, but how Burzynski has cynically exploited the sympathy we all feel for children dying of incurable brain tumors offends me, and he’s at it again. For example, there is the case of MacKenzie Lowe, a 12-year-old girl with an inoperable brain tumor whose story, entitled Child Cancer Patient Petitions For Brain Tumor Treatment Not Yet Approved By The FDA was published in The Huffington Post at the end of November:
Last Thanksgiving, 12-year-old McKenzie Lowe was diagnosed with an inoperable brain tumor. Her family is petitioning New Hampshire’s governor to allow McKenzie to undergo Antineoplastons therapy, a treatment not approved by the FDA. The FDA has allowed 471 “compassionate use” exemptions to date, and McKenzie’s grandfather, Frank LaFountain, hopes she’ll be next in line.
“We’ve talked to survivors of this drug, who had the same condition McKenzie has,” he told HuffPost Live host Nancy Redd. “People say there aren’t any, but we know them. We’ve talked to them, and that’s what makes us so passionate about getting her this particular drug.”
And here’s the video:
Only a heartless bastard could fail to be moved by McKenzie’s story, which is, sadly, typical for pediatric patients with brain cancers. HuffPo pulled out all the stops to emphasize McKenzie’s cuteness and what a nice girl she is, while buying completely into the propaganda line that the Burzynski Clinic promotes.
It pained me to watch that video. It really did. But it also made me angry. Once again, Burzynski is offering false hope to families of cancer patients, and HuffPo deserves nothing but opprobrium for promoting the Change.org petition, which Eric Merola, producer of two propaganda “documentaries” for Burzynski is also promoting. As desperate as McKenzie’s situation is, Burzynski can’t help her. However, her family can help him, most likely unwittingly, by changing the narrative from a doctor without any training in internal medicine or oncology who is utterly unqualified to treat patients with advanced cancer who has cynically sidestepped the FDA and the Texas Medical Board for nearly 37 years while abusing the clinical trial process to keep giving a toxic, almost certainly ineffective chemotherapeutic agent to patients. And, make no mistake about it, antineoplastons (ANPs) are chemotherapy, no matter how much Burzynski tries to claim otherwise.
The Change.org petition for McKenzie Lowe, as well-meaning as its sponsors seem to be, is exceedingly misguided. The Friends of McKenzie Lowe are petitioning FDA Commissioner Margaret Hamburg to grant a compassionate use exemption for McKenzie so that Burzynski can treat her with ANPs. Recall that one of the very offenses that got Burzynski into hot water with the FDA was his investigational review board’s (IRB) history of playing fast and loose with single patient use protocols, in which patients were approved through the expedited approval process, which was never intended to be used for this purpose. Putting patients on compassionate single patient use requires full approval by the entire IRB. In essence, this petition is asking the FDA Commissioner to ignore those findings and let Burzynski do it again for McKenzie Lowe. One also wonders whether the Lowes know other things about Burzynski. For instance, the FDA found that he had destroyed original patient records and, most importantly of all, misclassified partial and complete responses. Suffice to say, Burzynski’s explanations are underwhelming and unconvincing.
Finally, there is the oft-repeated claim that Burzynski is the only person who has ever cured the cancer that McKenzie has. These days it is Burzynski’s favorite line, a line often parroted by his minions, particularly Eric Merola. Would that it were true! What Burzynski proponents can’t understand is that I would be very happy if there were a treatment that could actually cure children with diffuse intrinsic pontine glioma (DIPG). As I’ve discussed many times before, nearly all of Burzynski’s “cancer cure” testimonials, when examined more closely, are highly dubious with respect to whether it was actually ANPs that cured the tumor, with not a single one of them being particularly convincing when examined closely. Either there’s insufficient information (i.e., the timeline is vague), or there exists the possibility of misdiagnosis, or the mistaking of the natural reversal of pseudoprogression for an actual antitumor effect. Moreover, brainstem gliomas in children are a heterogeneous group of tumors. Moreover, many of these tumors aren’t biopsied because of their location, and are usually diagnosed by their appearance on MRI. However, MRIs, as discussed in the case of Tori Moreno, can sometimes find masses that look for all the world like tumors but aren’t. Moreover, contrary to Burzynski’s claim, there are occasional long-term survivors, some of whom received little or no therapy, such Connor Frankenberg, a child from Germany, and two patients who underwent spontaneous remission. (Yes, I know that one of the children listed is a Burzynski patient, Tori Moreno. One notes that the DIPG Registry does not mention Burzynski or ANPs at all.)
The DIPG Registry concludes that, although the vast majority of children with DIPGs do poorly:
The bottom line is: 1) we really don’t understand DIPGs, and 2) there are children who have been diagnosed with DIPGs-based on the incomplete knowledge that we currently have- who truly have had spontaneous regression of their tumors and 3) most of the children with reports of spontaneous regression have been very young.
The big problem is that, like many dubious cancer doctors, Burzynski appears not to keep good enough records to demonstrate one way or the other whether he can cure DIPG, and we already know he misclassified partial and complete responses. In brief, DIPG is a horrible disease, with only 10% surviving beyond two years, and there is no convincing evidence that Burzynski can do any better than conventional oncology, much less cure DIPG, as much as he repeats the claim that he can. Worse, he hasn’t published a single one of his completed phase II clinical trials, even though he’s had well over 15 years to complete them. With tumors this lethal, most such trials should be completed within five years.
Unfortunately, Mackenzie Lowe isn’t the only such patient being used by Burzynski’s minions. Unfortunately, now there are now at least two more.
First up, there is a Jewish boy in Houston named Raphael Elisha Cohen:
Then, the unthinkable happened. A series of symptoms in the couple’s young son, Raphael Elisha, led to the diagnosis of medulloblastoma, an aggressive form of cancer of the brain and spine. Initially, the now-6-year-old underwent surgery to remove as much of the brain tumor as possible, followed by radiation and chemotherapy.
Unfortunately, Cohen’s tumor recurred in September 2012. After this, the story became sadly familiar. Well-meaning people set up a fund to send Raphael Elisha to Houston for treatment by Stanislaw Burzynski, as described in this article:
The Cohen family, of Houston, TX, is facing a battle none of us should have to go through – aggressive brain cancer in their 6-year old son Refael Elisha. Having recently received the devastating news from their doctors that “there is nothing more we can do for him,” the Cohens are turning to a last resort – Antineoplaston Therapy at the Burzyinski clinic. However, the FDA pulled their approval for this treatment in 2012 pending further clinical trials. We are told that the FDA is nearing approval to resume this treatment, but Refael Elisha does not have time to wait.
The FDA has the power to approve a “compassionate use exemption” so Refael Elisha can undergo this therapy to try and save his life.
We are asking the FDA to grant this exemption so we can continue to fight for his life.
Several other stories were written, including this story and a blog post by Ariela Davis for the Times of Israel that gave Cohen’s story international attention. Here’s the Whitehouse.gov petition, which uses language very similar to what is quoted above.
This sort of thing infuriates me, because it really does appear as though the Cohen family is being lied to. According to this editorial, the Cohens are aware of Burzynski’s reputation. However, obviously either Burzynski, Eric Merola, or someone from the Burzynski Patient Group has been feeding them “success stories.” As I’ve explained time and time again, these “success stories” appear compelling on the surface, but if you look at them with a knowledge of how cancer progresses and how cancer treatments work it rapidly becomes apparent that they are not evidence that Burzynski’s antineoplastons can do any better against deadly cancers than conventional therapy. Think Hannah Bradley and Laura Hymas. Think Mary Jo Siegel. Think Tori Moreno. It seems as though Burzynski cured these patients, but he almost certainly did not.
In addition, Burzynski has apparently been telling patients that the FDA is “nearing approval to resume” his clinical trials almost ever since the FDA imposed a partial clinical hold on Burzynski’s antineoplaston trials in the summer of 2012. That partial clinical hold meant that no further children could be enrolled on any of Burzynski’s clinical trials. Later, in early 2013, that partial clinical hold was extended to adults. Patients who were already receiving antineoplastons could continue to receive them, but no new patients could be enrolled in Burzynski’s clinical trials. Ever since then, Burzynski’s been dangling the hope that the FDA would lift the partial clinical hold. Now, apparently, he’s using those patients to try to get the attention of the White House, and in Cohen’s case he has been very successful.
Raphael Elisha is not alone, however. There’s an adult who is also going down the same road. This adult happens to be the wife of Sammy Hagar’s drummer. She is 46 and was diagnosed with an inoperable brainstem glioma. Her name is Liza Cozad, and to send her to the Burzynski Clinic there’s a Give Forward campaign. Her Change.org petition asks for the same thing as MacKenzie Lowe and Elisha Cohen’s families are asking:
Six months ago, Liza was diagnosed with a deadly brainstem tumor – called a DIPG – it rarely strikes in adults (only about 20 in the U.S. each year) but is unfortunately common among brain tumors in children – and just as deadly – a year to a year and a half to live. No doctor can perform surgery to remove due to its location, chemo has consistently shown to be ineffective on Liza’s type of tumor, and even the radiologist tells her her best case scenario with radiation is it would return in 1-2 years, more aggressively, and they could no longer radiate. There is one drug that could save Liza’s life. The drug – ANP – has been approved for Phase III clinical trials by the FDA. This means it has been deemed safe (Phase I trials) and effective (Phase II trials). The FDA has continually denied Liza’s request for the treatment under a Single Patient Protocol (the FDA format under which she could be approved), saying they have questions for the manufacturer about the drug based on one patient out of hundreds’ response to sodium levels. They have cotinued [sic] with this for a year – each time the manufacturer answers all their questions, the FDA keeps coming back with more – all the time denying any new patients – including Liza – from receiving this drug the FDA has itself acknowledged to be safe and effective. This precious and caring young woman has been fighting her fight since April, but her health is declining. This drug has a documented 27% success rate on her exact kind of tumor – which is 27% better than her odds with all standard therapies – and with some children still cancer-free over 20 years later.
Recently Cozad and her husband posted a video appeal to YouTube:
There is, of course, no evidence that Burzynski has a 27% success rate in treating DIPG, but the video is heartbreaking. Her story is depressingly familiar to those of us who know about the Burzynski saga. After being given the diagnosis and told that radiation would only delay progression of the tumor, she went on the Internet and, as all too many patients with inoperable brain tumors do, found Stanislaw Burzynski. In her desperation, as all too many cancer patients have, Cozad latched on to the false hope that Burzynski offers. As so many of Burzynski’s patients have done, they talked to Burzynski’s “success stories,” who, being convinced themselves that Burzynski saved their lives when he almost certainly didn’t, convinced Cozad and her husband that Burzynski was the only one who could save her life.
These are the patients are petitioning various Senators and Representatives to lean on the FDA to grant the compassionate use exemption. This is what those of us who want to protect cancer patients from this sort of predation are against, parents of children with cancer who have been convinced that Burzynski is their family member’s only hope. What human being doesn’t have difficulty saying no to such an appeal, even when he knows the family’s desperation has led them down a dark path to viewing Burzynski as the only man who can save their loved one? That they are wrong is almost beside the point. What politician can say no to such an appeal? At the very least, they will look into it and put pressure on the FDA. Meanwhile those of us who stand up and say no, who try to point out that Burzynski can’t save these patients, that they are being used by him so that he can re-open his ANP clinical trials, are pummeled with arguments like the one by Randy Barnes that we should “respect the parents’ choice.” After pointing out that he is “not a fan” of the Burzynski Clinic, and “agrees with many of the criticisms leveled at Stanislaw Burzynski and his treatments,” he asserts that “Raphael Elisha’s parents are the only ones with the right and responsibility to make the best decisions they can in a horrible situation that no one who has not faced the loss of a child can possibly understand.” He then concludes:
If you choose not to sign the petition that is fine, but please, allow the Cohens the dignity they deserve by respecting their right to make the choices they deem fit for their child. Publicly fighting the Burzynski Clinic in Raphael Elisha’s name will only bring more pain to an already suffering family.
This is the argument we’re up against as well, an argument that is every bit as invalid as when it is used to defend, for example, the family of Sarah Hershberger for relying on quackery instead of chemotherapy to treat a deadly lymphoma. We can respect the parents’ decision, to the extent that they are the parents. We can try to understand the desperation that led them to it, even though they are aware of all the criticisms of Burzynski. Most parents can only imagine how they would react under similar circumstances. Even I couldn’t guarantee that I wouldn’t be tempted by the blandishments of Burzynski and his followers if I were in the same position as the Cohens. However, sympathy and respect do not equal agreement, nor do they require us to acquiesce and just “shut up” when the Cohen’s grief and desperation lead them to do something profoundly harmful to public health, to use the power of their story to persuade lawmakers to call off the FDA.
The Alliance for Natural Health joins the fray
Right after the holidays, one of the most prominent pro-quackery advocacy groups in the country, scourge of any legislator trying to regulate supplements or “natural medicine,” the Alliance for Natural Health USA (ANH-USA) launched a series of articles urging its members and followers to write to their legislators to lean on the FDA to allow Burzynski to treat patients under compassionate use protocols:
Exclusive: Inside USA Today’s Smear Campaign Against Dr. Burzynski
Dying Patients Denied Access to Dr. Burzynski’s Potentially Lifesaving Treatment
If you want to understand how much contempt the ANH-USA has for its audience, I’ll show you briefly through one passage from one of these articles. The ANH-USA complains that Liz Szabo:
Cites the lack of published random-controlled trials (RCTs) as evidence of antineoplastons’ uselessness, while omitting the fact that the efficacy of the treatment has recently been confirmed by a randomized, clinical trial by Japanese researchers. And of course ANH-USA has repeatedly had to point out that RCT’s are enormously expensive. Nobody but drug companies can afford them, and they will usually only undertake them if the treatment is under patent and therefore a government enforced monopoly. In addition, there is growing evidence that RCTs, particularly in the context of individualized treatments, should no longer be considered the “gold standard” for drug efficacy.
Of course, this is the same nonsense Burzynski’s been peddling for the last couple of years about a vaporware randomized clinical trial carried out by Hidaeki Tsuda in Japan. This trial featured prominently in Eric Merola’s second movie. Unfortunately, although the trial sounds interesting as described in Merola’s movie, it has not yet been published. Now take a look at the article linked to in the ANH diatribe. It was published in Oncology Reports (not the greatest of cancer journals) entitled “Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells”. Do you notice something? I did, immediately. More accurately, I didn’t notice something, and that something was a clinical trial. This is nothing more than yet another in vitro study, and it’s not even that compelling of one, given that it uses enormous concentrations of AS-2, 2 mg/ml, way higher than is likely to be achievable in the bloodstream, even using the massive doses of ANPs that Burzynski advocates using. Yes, Burzynski really does have that much contempt for you that he tries to pass off an in vitro study as a clinical trial.
The rest of the ANH-USA’s attacks are largely nothing more than regurgitations of past Burzynski excuses and attacks. For example, in one article the ANH-USA twists the cases of Liza Cozad and McKenzie Lowe to its own ends, all but saying that the FDA is evilly laughing and twirling its metaphorical mustache as Cozad and Lowe die, as USA TODAY dutifully promotes the agenda of its pharma masters and the FDA. Hilariously, there was a third article claiming that the FDA violated patient privacy by providing Szabo with medical records of a patient without the parents’ permission. If you click on the link now, there’s nothing there. The article has apparently been taken down. There are, however, multiple links to it elsewhere, for example, here, here, here (our old friend Merola) and here. The article still shows up on the ANH sitemap, but there’s nothing there. Apparently, the ANH took it down, which is probably because it was full of misinformation and lies. I only wish I had saved a screenshot or web archive of the article. My mistake.
Bringing it all together: The ANP Coalition
It’s taken nine months since Burzynski supporters revealed in a video of the panel discussion after a screening of Eric Merola’s movie that various Burzynski patient groups were planning to form an organization to lobby Congress for fast track approval of ANPs. Indeed, Merola and his merry band of Burzynski sycophants were quite open about wanting fast track approval for ANPs so that Burzynski could then prescribe them off-label for virtually any cancer and presumably could also sell them to any doctor who wanted to use them for whatever purpose. Of course, advertising a drug for off-label uses is against the law, which is why the FDA takes such a dim view of it, but “word of mouth” and ANP-friendly groups like the ANH would make sure that word got around fast. Unfortunately for Stash, with the deficiencies of the procedures of the Burzynski Clinic and BRI with respect to running clinical trials having been laid bare in Liz Szabo’s article in USA TODAY, fast track approval for ANPs for glioblastoma is, at best, highly unlikely. So Burzynski’s allies have fallen back on lobbying Congress to lean on the FDA to allow single patient protocols, sometimes called “compassionate use” protocols, to allow Burzynski to treat patients with ANPs even though his clinical trials are shut down. To do this, they have formed a group called the ANP Coalition:
It is our fundamental belief that the discovery of Antineoplastons (ANP) can and will herald a new age of medical science and subsequent advancements in the treatment of previously incurable diseases. This benign yet effective drug contradicts the paradigm that cancer treatments have to be harmful to be effective, and redirects modern medicine back to its salient principal Primum non nocere, “first, do no harm”.
How does the ANP Coalition intend to accomplish our mission?
We will accomplish our mission by focusing on four main goals:
To educate the public as to the importance and benefits of ANP.
To advocate for patients who need access to ANP for medical conditions.
To expedite regulatory approval for ANP thereby making it available to all.
To further research and development of ANP.
Consistent with a lot of the rhetoric used by Eric Merola and the Burzynski Patient Group, the rhetoric on the ANP Coalition site is apocalyptic, painting the battle as nothing less than one of good versus evil:
This is not a time for all good men to act; it is a time when all good people must act. We live in an age of awareness, where technology has become the great equalizer. With technology comes communication, and through communication we can educate! Once armed with education, propaganda withers and dies!
This website is designed with the sole purpose of educating the public and exposing the truth. The battle starts here in cyber space, but the war is won in the real world, by real people who participate in real ways. It will be won by you!
We are no longer an organization of patients connected by a cure; we are the collective who will not allow evil to triumph.
I can provide a hint of why the rhetoric is so amped up. One has only to look at who owns the ANPcoalition.org. The domain is registered through Domains By Proxy, which makes one wonder why the ANP Coalition would want to hide who owns the domain. First of all, the pictures on the Contact page reveal several old friends, including Ric Schiff, whose wife Laura, not coincidentally, owns a related domain, theotheranpcoalition.org, and registered it under her real name and also appears on the Contact page. (A screenshot has been saved, of course.) Also there is Mary Jo Siegel and her husband Steve. These are the people behind ANP Coalition, just as they are heavily involved in the Burzynski Patient Group. In fact, in July 2013, Ric Schiff was elected to the board of directors of the BRI, which makes his involvement in this effort a massive conflict of interest.
Predictably, Elisha Cohen, Liza Cozad, and Mackenzie Lowe are featured as the stories used to drive petitions to lawmakers and the FDA to allow compassionate use of ANPs. In addition, there are two new patients, of whom I haven’t heard before, Laura Nowosad, a 7 year old girl from Canada with a DIPG whose story is sadly familiar to anyone who covers Burzynski:
Her parents, Janusz and Mira, are an amazing couple whose lives got shattered in an instant. Laura is their only child and their whole world. They couldn’t believe that this is happening to their little girl; they were hopeful that the doctors made a wrong diagnosis and went for a second opinion. Unfortunately, this diagnosis was confirmed. Words cannot explain the feelings of hopelessness, frustration, and terror they felt when they had to be faced with the truth.
Janusz and Mira are not giving up hope! They have taken Laura to The Burzynski Clinic in Houston, Texas. This clinic has seen significant improvement in patients facing similar diagnosis as Laura, using alternative therapies not available in Canada. However, the treatment is very expensive. The initial visit costs $25,000 and each month after is $30,000.
On the same page is yet another desperate family being used by Burzynski’s minions as well, that of Isaac DeHerrera, a five year old boy whose tale is presumably so new that there isn’t yet a fundraising website that I could find or a petition to let Burzynski treat Isaac with ANPs on a compassionate use protocol. I’m sure there will be more families added as soon as Burzynski and his minions can find them. Clearly Ric and Laura Schiff and Steve and Mary Jo Siegel believe that they can duplicate the success Burzynski patients had in the 1990s, which was the last time Burzynski was in a comparable amount of trouble, with demonstrations featuring patients chanting, “FDA go away! Let me live another day!” and the intense political pressure brought to bear by a compliant Senator or Representative, the way they persuaded Joe Barton to drag then-FDA director David Kessler in front of his committee four times over two years to explain why the FDA was “harassing” Burzynski. Only this time, they have the Internet, which was only in its infancy as an organizing tool back in 1995, which allows them to produce a “Meet the Miracles” section, which, presumably, will be full of glowing testimonials of Burzynski Patient Group patients. So far, there is only Jessica Ressel, who was featured in the first Burzynski movie and whose testimonial is not convincing, as I described in detail in my review. No doubt she believes Burzynski saved her, but it is almost certainly the case that he did not, which is the only reason I can forgive her regurgitating Burzynski Clinic talking points.
Perhaps the most concerning aspect of the ANP Coalition is that it’s hired a lobbyist named Antonio C. Martinez II:
His experience with ANP extends more than 18 years back when he represented the Burzynski Patient Group in 1995 and 1996, organizing numerous patient demonstrations and a Congressional Hearing on February 29, 1996 before the U.S. House of Representatives Energy & Commerce Subcommittee on Oversight & Investigations. These efforts helped Burzynski patients obtain access to ANP through Phase II clinical studies.
This isn’t cheap. Unless Martinez is serving pro bono, his hourly rates are $250 to $400. I have no reason to doubt the claim that he worked on organizing the Congressional Hearing in 1996 at which Burzynski patients vented at the FDA, but I wonder. I’ve read both Richard Jaffe‘s Galileo’s Lawyer: Courtroom Battles in Alternative Health, Complementary Medicine and Experimental Treatments and Thomas D. Elias’ The Burzynski Breakthrough: The Most Promising Cancer Treatment and the Government’s Campaign to Squelch It. Both books describe the Congressional hearings in which Burzynski patients testified from a very pro-Burzynski standpoint. I don’t recall seeing Mr. Martinez’s name being mentioned even once, and a quick flip through the indices and relevant sections of these books did not change that assessment for me. If Martinez were so important to the 1996 hearings, one would think that Jaffe and/or Elias would mention him and at least briefly describe his role in their books. They didn’t, as far as I can tell.
So what does the ANP Coalition want to accomplish? Its list of demands is long and some are completely unrealistic. For example, on its page where it tells people how they can help, it asks people to write to Wikipedia to:
…demand removal of the “Burzynski Clinic” webpage, since it has been high jacked by a paid group who identify themselves as “The Skeptics”, and is no longer open for public contribution. The Wikipedia page on “Burzynski Clinic” is filled with untrue statements, statements taken entirely out of context, cherry-picked information, sources that do not qualify as sources under Wikipedia rules, fake sources—you name it.
The Wikipedia team has already noticed the ANP Coalition’s attempts to astroturf its article on the Burzynski Clinic.
Others, however, are not unachievable. Certainly organizing petitions and getting people to write to their lawmakers are achievable aims, and that’s what concerns me: How do we respond? In the absence of sound scientific information showing that ANPs almost certainly don’t work and are very toxic, Burzynski’s claims notwithstanding, legislators and politicians are going to go with the sympathetic story; i.e., the stories told by Burzynski supporters of children with deadly brain tumors who will die soon if they aren’t allowed to have ANP therapy. That’s why it infuriates me to see how Burzynski so cynically uses patients with deadly cancers in his battle with the FDA. Make no mistake, that is exactly what he is doing here. He dangles false hope in front of patients like Eliza Cozad, Raphael Elisha Cohen, and McKenzie Lowe, and their families do the rest for him. Even in the case that a legislator understands the lack of evidence, he might well go with a “What’s the harm?” attitude, not appreciating that the harm can be appreciable given how toxic ANPs are, not to mention the financial harm done to the family raising tens or hundreds of thousands of dollars for an ineffective treatment. That’s why information to show why, as much as we sympathize with the plight of these patients and their families, legislators should not overrule the FDA’s decision regarding antineoplastons. Indeed, the real investigation should be into why the FDA has allowed Burzynski to get away with what he’s gotten away with all these years.
I also appeal to you, our readers, for help and ideas. Visit Bob Blaskiewicz’s appeal and take action. In the meantime, let’s hear ideas for how to counter this latest initiative.

Stanislaw Burzynski and Robert O. Young: How two quacks of a feather illustrate how poorly states regulate medical practice
David Gorski on November 23, 2015
Link


One of the weaknesses in our system of regulating the practice of medicine in the United States is that, unlike most countries, we don’t have one system. We have 50 systems. That’s because the functions of licensing physicians and regulating the practice of medicine are not federal functions, but state functions. Each state sets its own laws and regulations governing the practice of medicine, making for wide variability from state to state. Some states are lax in their regulation (cough, cough, I’m talking to you, Texas), others are not so lax.
Given how often state medical boards and the other enforcement bodies states use to protect the public from professional misconduct and quackery, I thought I’d take this opportunity to update our readers on two men who have been frequent topics of discussion on this blog, Stanislaw Burzynski and Robert O. Young. The reason is that, through some bizarre confluence of events, both of them faced justice last week, in the form of a hearing due to action against Burzynski by the Texas Medical Board, and in the form of the trial of Robert O. Young in southern California.
What these two quacks share in common is that they’ve gotten away with their cancer quackery for a very long time, two decades in the case of Robert O. Young and nearly four decades in the case of Stanislaw Burzynski, with attempts by the law to bring them to heel having been largely ineffective. They are different in that one is a physician (Dr. Burzynski) and one is not (Young) and therefore different legal considerations come into play. Young, for instance, is a self-proclaimed naturopath known for his “pH Miracle Living” cure, which, he claims, can be used to cure basically any disease by “alkalinizing” the body. After two decades of running, he is being tried for practicing medicine without a license, and, of course, fraud. Burzynski, although not an oncologist, is a licensed physician in Texas and has been administering an unproven and almost certainly ineffective “natural” treatment consisting of substances derived from blood and urine that he dubbed “antineoplastons” (ANPs) back in the 1970s. He is also different in that he’s gotten away with this largely through abuse of the clinical trial process, which is regulated at the federal level through the FDA and the HHS. It is not, however, the federal government that is pursuing action against Burzynski, but rather the Texas Medical Board (TMB). Thus, while Young is on trial and could go to jail if he loses, if Burzynski loses he will only lose his license to practice medicine in the state of Texas.
Despite their differences, both Stanislaw Burzynski and Robert O. Young illuminate major shortcomings in how the legal system deals with quacks.
The Texas Medical Board Versus Stanislaw Burzynski, Round 4 (at least)
Last week as I contemplated what to write about this week, realized that it’s been a long time since I’ve written about Stanislaw Burzynski, the expat doctor who fled Poland in 1970 and for six years actually did legitimate cancer research at the Baylor College of Medicine. Convinced that he had made a major breakthrough in cancer treatment with his discovery of antineoplastons and apparently frustrated with the difficulties involved in doing legitimate clinical trials, Burzynski left Baylor and started treating patients with his home brew concoction in a private clinic. Since then, despite the fact that he has no training in medical oncology, Burzynski has treated thousands of cancer patients with ANPs beginning around the time he left Baylor and established over the intervening decades a reputation as a “miracle” cancer doctor who can cure deadly brain tumors that current conventional medicine cannot. He has managed this feat despite the fact that he’s never even come close to showing that ANPs are effective and safe against the cancers for which he uses it. Even so, the FDA has, with a brief interruption two years ago, continued to let him do his clinical trials, and the Texas Medical Board, despite at least three attempts since the early 1980s, has failed to strip Burzynski of his medical license. The best it managed to do was to put him on probation between 1994 and 2004.
It’s not because there hasn’t been a lot happening, either. Over a year ago, the Texas Medical Board decided to have another go at Burzynski. Over the last 16 months, what a long, strange trip it’s been. This week, the beginning of the climax of this effort was upon us. Indeed, what reminded me that the climax of this struggle is approaching was an e-mail from one of the several quack email lists to which I subscribe (in this case, The Truth About Cancer), which urged its members to support Burzynski:
As we’ve shared many times before, actually curing cancer would be detrimental to the pharmaceutical industry. So much so that they’re willing to do whatever it takes to silence the doctors as to keep their poisons as the only solutions.
They’re trying to do that now with Dr. Burzynski by revoking his medical license and we need your help.
We’re asking for volunteers in the Austin area to go to the State Office of Administrative Hearings on the morning of Nov 19th and exercise their right to protest these absurd charges and hearings.
It’s 9:00am on Thursday, November 19, 2015, at 300 West 15th Street, Fourth Floor, Austin, Texas. Hearings will continue through November 25, 2015, before recessing until January 19, 2016, when it will reconvene at 9:00am and continue through January 29, 2016, if necessary.
There will be a lot of media attention and we need to show how powerful our voices are and that we will NOT be silenced.
Please arrive at 8:30am and bring signs that read “Dr. Burzynski saves lives” or “Stop persecuting Dr. Burzynski” or whatever else you’re inspired to write.
Unfortunately, I personally will not be able to travel and be in Austin but I’m doing my best to tell everyone I can and I’m hoping you will too. Even if you can’t make it in person, please tell everyone you can on Facebook and other social media sites.
Hopefully, if you’re in Austin (or inspired to travel there) you can go and represent our movement in a powerful way.
Thank you for your consideration.
Ty Bollinger
Meanwhile, other Burzynski supporters were also rallying. Eric Merola, the film maker who made two massively deceptive “documentaries” (which I like to call Burzynski I and Burzynski II: Electric Boogaloo, because those are far less awkward titles than the multiple-subtitled ones Merola actually gave the movies) that amounted to the equivalent of hagiographies portraying Burzynski as the “brave maverick doctor” persecuted by the medical profession because he doesn’t play by its rules and can cure cancer where conventional oncologists cannot. Truly, it is not for nothing that I like to refer to Eric Merola as Stanislaw Burzynski’s own personal Leni Reifenstahl, even at the risk of going Godwin and even though Reifenstahl herself, were she still alive today, would recognize Merola for what he is: A talentless hack. Not surprisingly, the Alliance for Natural Health USA has also been trying to drum up support.
The whole situation is like a replay of the 1990s. If there’s one way Burzynski is very predictable it’s in his response to investigation and criticism. Whenever Burzynski is in trouble or the law actually threatens his practice, he cynically uses desperate cancer patients as “human shields” against government investigation. He did it in the 1990s, when Burzynski was being prosecuted for 75 counts of insurance fraud and violations of the Food, Drug, and Cosmetics Act. It was cynical political theater featuring media appearances of the weeping parents of children with deadly brain tumors, national press stories about demonstrations by patients chanting, “FDA go away! Let me live another day!” It worked back then, although I note that at the time Rep. Joe Barton (R-Dallas) was also putting intense pressure on the FDA, dragging then-FDA Director David Kessler in front of his committee multiple times to harangue him about his “persecution” of Burzynski. The FDA told Burzynski that he could administer ANPs, but only under the auspices of an approved clinical trial. So, urged by his lawyer Richard Jaffe, Burzynski cynically submitted 72 clinical trial protocols to use ANPs to treat pretty much any cancer he wanted to treat, and the FDA approved them all. In the intervening 16 years from 1997 to 2013, Burzynski enrolled patients on his clinical trials and charged them enormous “case management” fees for the privilege, even though doing so is completely unethical.
Of course, two years ago, Burzynski’s clinical trials were placed on partial clinical hold after the death of Josia Cotto of hypernatremia (very high sodium levels in the blood, a known complication of ANP treatment). In the wake of that decision, Burzynski went back to the tactic that had served him so well, mobilizing his patient base to do the same thing it did in the 1990s. Not long after that, the FDA gave in and let him begin his clinical trials again, albeit with conditions. Specifically, Burzynski had to provide ANPs for free, and he couldn’t be the one administering the cocktail. Then, last year, the FDA lifted all restrictions on Burzynski’s clinical trials. Burzynski had won again, but not long after that, the Texas Medical Board acted to strip Burzynski of his license.
The TMB’s 200 page complaint documents the charges that Burzynski misled patients by:
Making patients pay a retainer before receiving any diagnosis or treatment.
Performing unnecessary tests and “non-therapeutic treatment” with no potential to help them.
Imposing “exorbitant charges” for drugs and lab tests, without telling patients that he also owned the pharmacy and lab being used.
Allowing unlicensed staff to treat patients, while describing the staff as doctors.
Burzynski was also charged with prescribing unapproved combinations of toxic chemotherapy, which is quite ironic. Burzynski has been treating patients with an unapproved cancer drug (antineoplastons) for nearly four decades, but that’s not the heart of the case. Rather, the heart of the case appears to be Burzynski’s off-label use of what I like to call Burzynski’s “make it up as you go along” cocktails of expensive targeted therapies that he touted as “personalized, gene-targeted therapy” and I more accurately described as “personalized, gene-targeted therapy for dummies.”
The Houston Cancer Quack has a nice (and, unlike one of my typical posts, brief) summary of what’s been happening to Burzynski’s case over the last several months. Basically, as is commonly the situation in cases like this, there have been a number of motions and countermotions. In March, the judge rejected a large number of Burzynski’s motions to suppress evidence brought by the TMB, including testimony by FDA inspectors, FDA inspection documents, and the testimony of a former employee, the last of which looked to be particularly damaging to his defense.
Perhaps the most interesting and unexpected aspect of this whole case occurred over the summer, and when I say “unexpected,” I really mean it. Remember Richard Jaffe, whom I mentioned earlier and who was the architect of Burzynski’s wildly successful strategy of submitting over 70 clinical trials to the FDA, a strategy that served as the basis for Burzynski’s reputation and increasing wealth over the better part of the last 20 years? It was a strategy that didn’t start to fall apart until the partial clinical hold was placed on his clinical trials and Burzynski was forced to substitute his far less popular “personalized gene-targeted therapy.” The reason it was far less popular is because ANPs, for whatever reason, were viewed among the alternative cancer cure crowd as being a “natural” treatment for cancer (presumably because they were originally isolated from urine and blood) while Burzynski’s “personalized gene-targeted therapy” consisted of cocktails of expensive targeted therapies made by pharmaceutical companies. It turns out that Jaffe is no longer Burzynski’s lawyer, even though he had been working for Burzynski for decades. As Skeptics for the Protection of Cancer Patients drolly noted, those of us trying to expose Burzynski’s quackery all thought that Jaffe would be buried in the Burzynski family crypt, so tight had Burzynski and Jaffe been for so many years.
Apparently not any more.
How this shocking situation came about is not entirely clear, but it appears to involve—gasp!—enormous unpaid legal bills. Basically, a new lawyer, Dan Cogdell, started filing motions for Burzynski. It turns out that Cogdell was part of Burzynski’s legal team before. In any case, the judge became concerned that it was late in the game to be switching lawyers; so another administrative law judge heard Jaffe’s explanation in private and ruled that Jaffe had to withdraw from the case. Per Judge Suzanne Marshall’s finding, Jaffe’s continued representation would violate the mandatory withdrawal provision of Rule 1.15. This provision reads:
A lawyer ordinarily must decline employment if the employment will cause the lawyer to engage in conduct that the lawyer knows is illegal or that violates the Texas Disciplinary Rules of Professional Conduct. Rule 1.15(a)(1); cf. Rules 1.02(c), 3.01, 3.02, 3.03, 3.04, 3.08, 4.01, and 8.04. Similarly, paragraph (a)(1) of this Rule requires a lawyer to withdraw from employment when the lawyer knows that the employment will result in a violation of a rule of professional conduct or other law. The lawyer is not obliged to decline or withdraw simply because the client suggests such a course of conduct; a client may have made such a suggestion in the ill-founded hope that a lawyer will not be constrained by a professional obligation. Cf. Rule 1.02(c) and (d).
So apparently Jaffe withdrew because he was concerned that his continued representation of Burzynski would somehow result in his violating a rule of professional conduct or other law. What could this mean? The explanation came when Jaffe withdrew from representing Stanislaw Burzynski’s son, Greg Burzynski and gave the following reason:
Respondent is a vice president and an employed physician at the Burzynski cancer clinic in Houston. The clinic is owned by Respondent’s father, Stanislaw R. Burzynski. Undersigned counsel had represented Stanislaw Burzynski in a related SOAH board case.
Undersigned counsel is taking legal action against Respondent’s employer which might have a material adverse effect on Respondent’s interests as an officer and employed physician at the clinic. As a result of such action, undersigned counsel will likely have a conflict of interest with Respondent, at least until the anticipated legal action is resolved.
In other words, Jaffe is suing Burzynski. But why? It turns out that Burzynski owes Jaffe nearly a quarter of a million dollars, and Burzynski hasn’t paid. In fact, Jaffe appears to be suing to force Burzynski into involuntary chapter 7 bankruptcy.
I tried not to go into too much detail in this post (which, as regular readers know, is hard for me) because a lot of the legal wrangling and back-and-forth comes across too much as “inside baseball.” It doesn’t help that I’m not a lawyer and don’t understand a lot of it. What I do understand is that, this week and in January, the TMB is doing its best to finally put an end to Stanislaw Burzynski’s cancer quackery, and I wish them the best in this endeavor.
To me, it’s a good sign that, for whatever reason, this time around the political theater that surrounded Burzynski’s 1997 trial is minimal to nonexistent, although there are some rather laughable letters being sent to the TMB. I have yet to see photos of terminally ill cancer patients with signs trying to shame the TMB, although there is a Change.org petition with over 13,000 signatures petitioning the TMB to “Save Doctor Burzynski’s Life-Saving Cancer Treatment,” complete with a video showing Hannah Bradley as one of Burzynski’s “success stories,” even though she was almost certainly saved by conventional treatment, not Burzynski. Thus far, news coverage of the disciplinary hearing has been minimal outside of local news media. I also hope that, with the rift between Burzynski and his former consigliere and architect of the strategy that has allowed Burzynski to abuse the clinical trial process for so many years to charge patients exorbitant sums to enroll in his clinical trials, Burzynski will finally fall.
Robert O. Young finally faces justice
Robert O. Young is a quack whom I’ve written about more on my not-so-super-secret other blog than here. Basically, Young is a naturopath (or claims to be one), two of whose seemingly-impressive degrees came from diploma mills and whose degree in naturopathy came from Clayton College of Natural Health, a nonaccredited correspondence school that taught a panoply of quackery. For twenty years he’s been plying his cancer quackery (and quackery for HIV and other serious diseases) at Rancho del Sol, an avocado and grapefruit ranch in Valley Center, California that he’s turned into a plush retreat called the pH Miracle Center, where he offers juicing, cleanses, and all manner of dubious and bogus treatments. He even has a coaching program in which he trains other quacks in his method and offers “group cleanses.” (Eewww!)
When I took note of Robert O. Young’s arrest in January 2014, I experienced not a small amount of schadenfreude, for which I felt no guilt in this case. Seeing quacks hauled before a judge makes me happy. Even so, as much as I enjoyed the sight of Young in a prison jumpsuit—if only it were orange instead of blue!—I nonetheless asked at the time: Will it stop him? During the nearly two years since his arrest, his arrest and impending trial for practicing medicine without a license and fraud seemed not to deter him in the least. He still did his “pH Miracle” cruises. (What is it with cranks and cruises these days? Is this a thing?) He still has his “pH Miracle” retreats planned in Como, Italy in December and January. (I wonder what will happen if he’s convicted.) He still runs his pH Miracle Center at the Rancho del Sol. He’s been promoting the “world’s first functionally structured alkaline water kiosk” and accepting awards from International Association of Colon Hydrotherapy. His blog, Twitter feed, and Facebook page have remained active this week promoting his activities, with nary a mention of his trial. Indeed, when I was first made aware that Young’s trial had begun last week, it caught me completely by surprise, given how little I had heard about what was going on since early 2014:
The author of a popular series of books espousing an alkaline diet as a way to improve health began standing trial this week in a Vista courtroom on charges that he practiced medicine without a license and took money under false pretenses.
In opening arguments Wednesday, prosecutor Gina Darvas described the defendant, Robert O. Young, as the proverbial “man behind the curtain,” making money peddling pseudoscience to desperate, dying people. Defense attorney Paul Pfingst said Young is under attack for espousing alternative views to traditional medicine.
Young, 53, faces nine charges linked to his work at his posh Valley Center compound, The pH Miracle Living Center, where people came for $2,000-a-day retreats. He is charged with seven counts of practicing medicine without a license — including inserting intravenous lines into people — and two counts of grand theft.
The trial is slated to last approximately four weeks, and thus far it hasn’t seemed to stop Young’s social media activity, although he makes no mention of his trial. No doubt he’d love to, in order to paint himself as the victim being persecuted by The Man (and Big Pharma) to keep his natural medicines from the people (which is always good for quack business), but I’m guessing his lawyer probably nixed that idea.
For those of you not familiar with Robert O. Young, a brief recap is in order. For this, a picture (or in this case, a PowerPoint slide that I’ve used before in various talks about cancer quackery) is worth a thousand words (not that that’ll stop me from using a thousand words to describe Young if I deem it necessary).
Basically, to Young, acid is the cause of all disease, to the point that he states that “overacidification” is the cause of all disease, an overarching theory of all disease that he has dubbed The New Biology, and about which he frequently states that “the pH Miracle Lifestyle and Diet is a program focuses on the foundational principal that the body is alkaline by design and yet acidic by function. This makes this program the ultimate program for preventing and reversing aging and the onset of sickness and dis-ease. I would say that the pH Miracle Lifestyle and Diet is the diet for immortality.” (Note that another of Gorski’s rules, besides the rule that health practitioner who invokes Béchamp over Pasteur is to be avoided like the plague, is that anyone who uses the term “dis-ease” instead of “disease” is to be similarly shunned.)
For example, after a beautiful aspiring young Brazilian model named Mariana Bridi da Costa died of sepsis after a urinary tract infection so severe that she had had to have her hands and feet amputated in a desperate bid to save her life, Young wrote a post entitled “Ignorance Caused Sepsis or Systemic Acidosis That Took The Life of a Young Brazilian Woman“, in which he blamed “acidic lifestyle choices, including acidic food, drink, and drugs” and proclaimed, “Most people believe that sepsis or acidosis is an infection. It is not!” He explicitly denies germ theory to the point where he has written posts like “The Illusion of Germ Theory“, in which he refers dismissively to “Pasteurian scientific dogma,” challenges “everything in the modern construct of immunology and what is said to be the immune system,” and characterizes viruses as “molecular acids.”
Oh, and so is cancer. Well, not exactly. Cancer is…well, let me just quote Young to give you an idea:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is [sic] localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
This is, as they say, so wrong it’s not even wrong. Worse, as I described before when Young was arrested, his quackery can be blamed for at least one preventable death, that of Kim Tinkham, the woman who became briefly famous when she went on television with Oprah Winfrey, shocking even Oprah with her assertion that she was so inspired by The Secret that she had decided to go her own way and treat her stage III breast cancer with Robert Young’s “alkaline diet.” She didn’t reveal that it was Young until later, when she did testimonials for Young and appeared in an interview that was on YouTube but has since vanished down the memory hole. (True fact: I happened to have saved that video from YouTube and was therefore more than happy to provide a copy to the San Diego County District Attorney’s office last year.) Ultimately, Tinkham died of what was almost certainly metastatic breast cancer.
Based on his “alkaline diet,” Young ran a very lucrative quack spa business, both at Rancho del Sol and “on the road,” so to speak, as far away as Italy. Add to that his numerous courses and speaking engagements, and Young did quite well. Ironically, what tripped him up was not his claim that he could treat patients with diet alone, but, as is the case with many quacks, overreach. Basically, he started offering other treatments. Investigators ran a sting operation on him using officers posing as cancer patients, and Young made bogus diagnoses and offered bogus treatments. Two years later, we will see if Young is convicted.
The problem with state medical regulation
Whenever I come across egregious cases of misconduct by physicians, be they quacks like Robert O. Young or incompetent surgeons like Christopher Dunstch, I note the problems with how state medical boards function. First and foremost most state medical boards are understaffed and have too few resources for the tasks that they are charged to carry out. They are also made up of physicians, which means that (1) they tend to be reluctant to question another physician’s judgment unless the case is so far beyond the pale that no physician would fail to consider it a gross violation of the standard of care and (2) physicians tend to sympathize with other physicians and not to want to deprive them of their means to earn a living by taking their licenses away. This problem is magnified in Texas, where the TMB, by design and statute, is weak and doctors’ rights are strongly protected in their interactions with the TMB. Consequently, they tend to stick to the most egregious, easily provable cases, such as physicians who are substance-impaired, commit fraud, or diddle patients. Outside of that, in Texas it is enormously difficult to take away a physician’s license to practice. In other states the situation is not as bad, but the same considerations apply. Add to that how expensive it is to prosecute a case like the one against Burzynski, who has up until now been able to afford the best lawyers and who has had significant political pull, and it’s a wonder that the TMB decided to act. The current TMB is to be commended for this. Even though the outcome is nowhere near certain and the disciplinary proceeding might well fail, the TMB is doing the right thing at significant cost.
The bigger failure in the Burzynski case is that of the FDA. Burzynski has been running his bogus clinical trials for more than 17 years now, and it took the death of a six-year-old before the FDA shut him down, even though the FDA had investigated him multiple times before that. Worse, the shutdown was temporary. All Burzynski had to do was to file a remediation plan sufficiently convincing to the FDA that he was cleaning up his act, and he was free to enroll patients again. Whenever I see quacks ranting about the “fascistic” FDA, I roll my eyes, given how the FDA suffers from many of the same problems as state medical boards. It’s chronically underfunded, and given the current antiregulatory bent of Congress that situation is unlikely to change any time soon, even as legislators try to weaken the FDA in the name of “innovation” with misguided bills like the 21st Century Cures Act. One day, the story of why the FDA failed so monumentally in the Burzynski case will come out. I just hope I’m alive to see it, because it’s the biggest question I have remaining about him.
The law has nearly as much difficulty stopping non-physician quacks like Robert O. Young from taking advantage of desperate patients. Notice how Young could have gotten away with practically anything as long as he only recommended dietary changes to treat cancer, and it took him hiring physicians to prescribe dubious treatments to trip him up. It also doesn’t help that so many states are licensing quack specialties like naturopathy, where there is no standard of care and, let’s face it, even treatments and ideas like those advocated by Young are not beyond the pale.
Then there are even more misguided “health freedom laws” and far too much deference shown to quackery. For example, in her opening statement, prosecutor Gina Darvas said that Young’s trial “is not an attack on alternative medicine.” When I read that, my first thought was: Why the hell not? Alternative medicine for cancer costs patients’ lives!
It won’t be, though. In California, for instance, there is SB 577. This bill was passed and signed into law back in 2002 and was designed to regulate alternative medicine practitioners. Basically, it allows the practice of medicine without a license, as long as the practitioner provides clients with a clear statement that he is not a licensed physician, a list of services provided, and a description of training. Because of this, I feel for Darvas. I don’t know what her evidence includes, but based on SB 577, my guess is that her best bet will be to get Young on the fraud charges because convicting him for practicing medicine without a license is going to be difficult. The California legislature intentionally made it that way 13 years ago.
California is by no means alone, either. Jann Bellamy has pointed to bills and laws that she refers to as the quack full employment act (Colorado) and “quack protection law” (Nevada). Such are the fruits of the “health freedom” movement and the increasing acceptance of pseudoscience that prosecutors, state medical boards, and the police have a hard time prosecuting and convicting even the most egregious and long-practiced quacks, like Robert O. Young. Add to that an insufficiently-rigorous and poorly-funded regulatory structure in most states, coupled with excessive deference to the prerogatives of physicians, and you have physician-quacks like Stanislaw Burzynski getting away with administering unproven cancer treatments since the 1970s. Worse, even if the TMB is successful in its action, the worst that Burzynski will suffer is the loss of his medical license.
Let the patient beware!

The Texas Medical Board vs. Stanislaw Burzynski, 2014 edition
Here we go again. I’ll give the Texas Medical Board credit for one thing. It’s persistent. It’s going after Stanislaw Burzynski’s medical license again. Will this finally be the time the TMB puts a stop to Burzynski’s abuse of the clinical trial process and patients? Or will this be a replay of the 1990s, with Burzynski slithering away yet again?
David Gorski on July 14, 2014
Link


As I begin this post, I’m on a miserably crowded, hot, stinky flight winging my way home from TAM. This puts me in the perfect mood to write about my bête noire to conquer all bêtes noires, namely Stanislaw Burzynski, the Polish expat doctor who claims to have much better results treating deadly brain cancers than conventional oncology, even though he is not an oncologist and has never even completed the prerequisite training for an oncology fellowship, namely an internal medicine residency. Actually, I don’t mean that in the way that you probably think I mean it. This time around, unlike the last time around, writing about Burzynski will put me in a better mood to endure being slapped into a sardine can in coach, barely able to move, barely able to type, but needing to get a blog post out on Monday.
If you remember, the last time I wrote about Burzynski, the Food and Drug Administration (FDA) had caved, and by “caved” I mean that it had lifted the partial clinical hold on Burzynski’s clinical trials. As is usual with the long and winding saga that is Burzynski, I feel compelled to give a brief review for any newbie who might encounter this post. Old hands at this story can skip ahead or just skim.
Two years ago, a child named Josia Cotto died of hypernatremia (elevated sodium level in the blood) due to receiving treatment for a brain tumor from the Burzynski Clinic using Burzynski’s “miracle drug” antineoplastons. Hypernatremia is a known complication of ANP treatment, and, as a result of this child’s death, the FDA put a partial clinical hold on Burzynski’s clinical trials for pediatric patients, which meant that he could continue to treat children already enrolled in his clinical trials but could not enroll any new patients. Six months later, this partial hold was extended to all of Burzynski’s clinical trials, and in early 2013 the FDA inspected the Burzynski Clinic and Burzynski Research Institute (BRI).
The reason why the FDA’s decision late last month to lift this clinical hold is so puzzling is because the results of the FDA’s inspection were so damning. In particular, the FDA found that Burzynski exaggerated responses to therapy using inappropriate criteria, didn’t have original scans of many patients, and played fast and loose with the rules regarding enrolling patients onto clinical trials under single patient INDs (otherwise known as compassionate use exemptions). Let’s just say that Burzynski’s institutional review board (IRB), the committee whose charge under the Common Rule (which clinical trials meant to be used as the basis for FDA approval of a drug must follow) wasn’t exactly rigorous about following federal regulations or protecting patient rights and safety, and let’s further say that Burzynski’s response was…less than convincing. More puzzling, this is not the first time that the FDA has investigated Burzynski and found the very same sorts of violations by the BRI IRB; it’s a pattern that goes back to at least 2001 and continued at least until the FDA inspection. Let’s just put it this way. IRBs are supposed to be as independent as possible, and Burzynski’s IRB has been (and still is) chaired by Carlton F. Hazlewood, PhD, who just so happens to be on the board of directors of the Burzynski Research Institute. The conflict of interest and lack of ethics are astounding. Yet the FDA still lifted the partial clinical hold, a breathtaking failure to protect cancer patients.
That was the bad news.
The Texas Medical Board tries to do the right thing
During this time, the Texas Medical Board, which has tried and failed to strip Burzynski of his medical license on multiple occasions over the last four decades, has decided to take another whack at the piñata. I’m glad it did, even though, as has been discussed before with respect to multiple cases, including Rolando Arafiles and Christopher Duntsch, the TMB is toothless by design, thanks to an anti-regulatory bias that has led to laws that have vastly weakened its already-weak regulatory authority. That’s why, although I’m not optimistic that this time the TMB will prevail where in the past it has not, I’m glad it’s giving it the old college try, which is what it has done with an amended complaint against Burzynski dated July 10, 2014. I warn you: It’s over 200 pages long, but the spacing and repetition are such that I was able to read most of it even though I was busy with TAM. It’s a devastating document that, if the allegations are proven in court, should finally end Burzynski’s career. I’ll apologize if I’m a bit pessimistic, though. Burzynski has slithered out of tighter spots before.
Still, it’s worth discussing the allegations. Because of the length of the document, I can only hit the high points, but the complaint is there for you all to read if you are so inclined. If you’ve been following the Burzynski saga it’s definitely worth taking the time to do so. The introduction sets the stage:
Board Staff alleges that Respondent created a medical practice model based on marketing his proprietary anti-cancer drugs to patients without adequate measures for patient safety and therapeutic value. Respondent misled patients knowingly by promoting these drugs as an attraction to bring patients to his medical practice when Respondent was aware that he could not legally include most of those patients in FDA-approved Phase 21 clinical trials of his proprietary anti-cancer drugs. Respondent further misled patients into paying funds as a retainer prior to receiving any evaluation, diagnosis or treatment. Respondent further misled patients into: (1) paying exorbitant charges for drugs and medical services; (2) accepting care from unlicensed persons while Respondent and Respondent’s employees misrepresented those unlicensed persons to be licensed medical doctors in Texas and the United States of America; and (3) accepting care from health care providers who had little advanced education or training related to cancer treatment while Respondent and Respondent’s employees misrepresented those health care providers to be doctors with significant advanced education or training related to cancer treatment.
Having followed the Burzynski saga for three years now, I’m always heartened to see when a regulatory or law enforcement body “gets it” the way this paragraph demonstrates that the TMB appears to “get it” now. This is in sharp contrast to the weaselly justifications by the FDA for unleashing Burzynski’s bogus clinical trials—which, recall, his own lawyer characterized as “an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment” so that Burzynski “would be able to treat almost any patient he would want to treat!”—on unsuspecting desperate cancer patients again. The new allegation that I hadn’t been aware of was the part about using health care providers with little or no education or skill and representing them to patients as being doctors. Now that’s really bad by any stretch of the imagination, and a profound betrayal of the cancer patients whose desperation led them to Burzynski.
Patient A
Several of those desperate cancer patients are described in the complaint. I’m not going to go through all the cases, because there’s a depressing similarity to them in terms of the allegations of Burzynski’s wrongdoing, but it’s worth discussing at least a couple of them. I’ll start with Patient A, not only because it’s the first patient listed but because it’s a different story than we normally see at the Burzynski clinic. This patient had suspected colon cancer. I say “suspected,” because at the time he first presented to Burzynski he had not had any biopsies.
Patient A presented to the Burzynski clinic with a diagnosis of “sigmoid colon carcinoma metastatic to the liver.” This diagnosis was made on the basis of imaging studies that showed lesions in the liver suspicious for metastases and a colonoscopy that showed a “polypoid mass consistent with high-grade dysplasia and suspicious for invasive adenocarcinoma.” This, unfortunately, is not an uncommon presentation of colon cancer, except for one thing. Usually, there’s a biopsy done. A cardinal rule for treating cancer patients is that you do not initiate treatment without a tissue diagnosis from a biopsy. This tissue both proves that the patient has cancer and identifies the kind of cancer it is. Indeed, these days, when molecularly-targeted therapy is being increasingly used, the tissue also allows analysis of gene expression patterns that can guide the choice of treatment. The situations in which it is considered acceptable to begin treatment of presumed cancer in the absence of a tissue diagnosis are very uncommon and boil down to rare cases where the imaging is pathognomonic of the kind of cancer suspected and the clinician judges that a biopsy would be too risky.
Basically, patient A should have had a biopsy of both his sigmoid colon lesion and one or more of his liver lesions. There was no reason not to do this, as colonoscopic biopsies and needle biopsies of the liver are in general low risk procedures and the treatment of colon cancer is, increasingly, being guided by newer gene tests. Now, in fairness, Patient A had refused to undergo a biopsy when his local physician had recommended it and also refused to consider chemotherapy with FOLFOX3 with Avastin after a biopsy, which is within the standard of care. However, if that’s the case then Burzynski should have refused to treat him. Not only is it considered a gross breach of the standard of care not to have a tissue diagnosis before treating a patient, but nearly all clinical trials for cancer treatments absolutely require a tissue diagnosis, which means that this patient was ineligible for any of Burzynski’s clinical trials. Instead, without even recommending a biopsy, Burzynski began to treat patient A with anticancer medications.
Now here’s the kicker:
9. At the time Patient A first met with Respondent and the other employees of the Burzynski Clinic, Respondent allowed Tolib Rakhmanov, a person who is not a licensed physician or health care provider in Texas or elsewhere in the United States of America, to represent to Patient A that Tolib Rakhmanov was a licensed medical doctor practicing medicine in Texas. Respondent and the other Burzynski Clinic employees under Respondent’s supervision and control continued to represent to Patient A and Patient A’s fiancee or to allow them to believe that Tolib Rakhmanov was a licensed medical doctor practicing medicine in Texas throughout Patient A’s treatment at the Burzynski Clinic.
10. Respondent and the other Burzynski Clinic employees under Respondent’s supervision and control referred to Tolib Rakhmanov as “Dr. Rakhmanov” in Patient A’s and Patient A’s fiancée’s presence. Respondent knew or reasonably knew that Tolib Rakhmanov signed documents, many of which were also signed by Patient A and Patient A’s fiancee, in manners that identified Tolib Rakhmanov as a medical doctor. Patient A and Patient A’s fiancée reasonably believed that Tolib Rakhmanov was a medical doctor licensed to practice medicine in the state of Texas. Respondent was responsible for the false, misleading and deceptive representation to Patient A and Patient A’s fiancée that Tolib Rakhmanov was a medical doctor licensed to practice medicine in the state of Texas.
Rakhmanov also performed tasks and services that obviously constitute the practice of medicine, including diagnosing and evaluating Patient A’s medical condition, making treatment recommendations, on numerous occasions (with all the dates listed). The TMB further alleges that Burzynski “directed and/or reasonably knew and allowed Tolib Rakhmanov, a person who is not a licensed physician or health care provider in Texas or elsewhere in the United States of America, to perform medical tasks that constituted the practice of medicine in the state of Texas in the evaluation, diagnosis and treatment of Patient A.”
Burzynski also promised the patient that he would receive ANPs and the FOLFOX/Vectibix treatment he desired, after which he demanded a large retainer for treatment. This is interesting, because Vectibix (generic name: panitumumab) is a targeted therapy that is only useful in cancers with a gene called KRAS that is not mutated. (KRAS is gene that is frequently mutated in colorectal cancer.) This is what I mean about how gene testing is becoming more important in colorectal cancer. Most colorectal cancers these days are tested for KRAS mutations to determine if Vectibix is an appropriate therapeutic regimen. According to the company’s website, Vectibix is “not indicated for the treatment of patients with KRAS-mutant mCRC [metastatic colorectal cancer] or for whom KRAS mutation status is unknown.” In other words, it was unequivocally not indicated for Patient A. That’s even leaving aside the issue of ANPs.
Actually, Patient A never received FOLFOX/Vectibix or ANPs. Instead, he received something else from Burzynski without his “adequately explaining to Patient A the difference in safety and efficacy between the therapy requested by Patient A and the therapy provided by Respondent and the employees of the Burzynski Clinic under his supervision and control.” Instead, Burzynski initiated treatment with phenylbutyrate. Remember phenylbutyrate? It’s the orphan drug that Burzynski touts as an ANP prodrug. Patient A also received a “partially FOLFOX equivalent regimen” consisting of oral Xeloda and intravenous Avastin, which I consider kind of a half-assed treatment that isn’t FOLFOX. Apparently Patient A improved for a while, which is quite possible given that he was receiving Xeloda (capecitabine), for which there is some evidence of efficacy, as well as Avastin, which is why it’s sometimes used as an alternative to FOLFOX. It’s unlikely that the phenylbutyrate did anything. I do have to note, however, that there is a passage in which “shrinkage” of a brain tumor is mentioned, which makes me think the TMB made a mistake and mixed up part of Patient B’s story with that of Patient A.
For some reason, Burzynski started changing drugs without adequate rationale. Eventually, the tumors started growing again, and the patient left Burzynski’s care, having paid an enormous amount of money, including a $4,500 monthly case management fee and a charge of $360 for 500 mg of sodium phenylbutyrate. During the course of Patient A’s treatment, Burzynski also used very expensive drugs that are not indicated for colorectal cancer, such as Afinitor (everolimus), which inhibits a protein called mTOR and is primarily used for kidney cancer and breast cancer, and Votrient (pazopanib), a tyrosine kinase inhibitor that blocks tumor growth, inhibits angiogenesis, and is used for renal cell carcinoma and soft tissue sarcoma.
The story is all very familiar if you’ve been following Burzynski and very depressing. There’s more, just in the case of Patient A, including failure to assess the patient’s mental status when recommending treatments, failing to provide anything resembling adequate informed consent, and having an ownership interest in the pharmacy dispensing the drugs Burzynski used, among other violations, but let’s move on to Patient B.
Patient B
Patient B is an interesting case, because part of it isn’t clear to me. In December 2010, Patient B had a diagnosis of brain cancer, which was successfully removed by craniotomy, which was followed by imaging studies that showed complete removal of the tumor. Post-operative chemotherapy and radiation therapy were recommended. Now here’s a part where it’s hard to understand what Burzynski did wrong if you don’t know a lot about him. The complaint alleges that Burzynski didn’t get a biopsy to confirm the existence of cancer before initiating anticancer treatment. Yet, conventional doctors had recommended postop chemotherapy and radiation, even though as far as they could tell the cancer had been completely removed. The difference is in intent. The chemotherapy and radiation therapy were being recommended as adjuvant treatments, in other words, treatments designed to decrease the risk that the tumor would recur, given that microscopic disease is almost always left behind. My guess (and it’s only a guess) is that Burzynski didn’t document that he was undertaking treatment for adjuvant purposes but rather made it sound in the medical record as though he were treating for therapeutic purposes for an existing cancer.
Later in the complaint it is alleged that “Respondent and/or employees under his direction and control failed to inform Patient B about the FDA-approved criteria for treatment with antineoplastons in one of Respondent’s sponsored clinical studies.” None of Burzynski’s trials that I can find are for the adjuvant treatment of brain cancer. They are, instead, for the treatment of existing brain tumors, most often recurrent or refractory brain tumors. Thus, Patient B almost certainly wasn’t eligible for any of Burzynski’s ANP clinical trials, because he had what we in the biz like to call “no evaluable disease,” often abbreviated NED, meaning that there wasn’t any currently detectable tumor whose response to therapy could be followed.
Next, we see the same depressing litany for Patient B as well, including lack of informed consent, failure to document treatment rationale, and, again, Burzynski Clinic staff who are not physicians being represented as such, including Tolib Rakhmanov and Larisa Tikhomirova. There again was the requirement for a large retainer to begin treatment. There was again the “bait and switch” in which Burzynski lured Patient B in with the promise of his ANP therapy and then used something different, including—of course!—phenylbutyrate, plus the usual witches’ brew of targeted drugs that we’ve seen before and that are not indicated in most brain cancers. It’s what I’ve referred to before as the “everything but the kitchen sink” approach.
In actuality, Patient B’s story in the complaint is poorly written and very confusing. I had trouble making heads or tails of part of it. It says that Patient B didn’t have any detectable tumor when he first consulted Burzynski in December 2010 and nails Burzynski for that, but then it describes Burzynski beginning treatment in February 2011 and an MRI scan:
On or about March 17, 2011, an MRI of Patient B’s brain revealed moderate decrease in the size of the brain lesion.
My guess, but I can’t be sure from the muddled and confusing description in the TMB complaint, is that this brain “lesion” was probably the inflammatory reaction to the patient’s surgery, which would have been expected to get smaller over the next three months anyway. A better way to say it would have been to be very clear from the start what the radiological findings were when the patient first approached Burzynski. If there was a lesion there, then it should have been pointed out whether it was suspicious for residual disease or whether the radiologists thought it was just normal postoperative changes. We can infer from the description that Patient B’s doctors must have thought that there was no residual disease, but then what is this “brain lesion” that was showing moderate decrease in size on March 17, 2011? I’m a cancer doctor who’s followed Burzynski, and even I’m not entirely sure what happened based on the description.
Be that as it may, many of the same complaints made against Burzynski for his treatment of Patient A apply to Patient B as well, and Patient B suffered considerable toxicity:
Respondent and other health care providers under Respondent’s direction and control treated Patient B without regard to the potential combined toxicities of drugs used pursuant to Respondent’s recommendations and directions. Respondent and other health care providers under Respondent’s direction and control referenced the case reports of other physicians not associated with the Burzynski Clinic as support for combined use of the drugs recommended and administered to Patient B. In those referenced case reports of physicians not associated with the Burzynski Clinic, however, those drugs were only used individually or in other combinations besides the combinations of drugs used for Patient B by Respondent and other health care providers under Respondent’s direction and control. In this regard, Respondent and other health care providers under Respondent’s direction and control violated the standard of care for reasons including:
a. Patient B suffered considerable toxicity affects.
b. Respondent violated the standard of care by failing to have an adequate medical rationale for this simultaneous use of these agents in anti-cancer therapy.
c. Respondent violated standards of adequate documentation by failing to document an adequate medical rationale for this simultaneous use of these agents in anti-cancer therapy.
d. Respondent also failed to adequately inform Patient B of this increased risk.
Same as it ever was. I note that Patient D’s case is a lot like Patient C’s case, one difference being that Sheryll Acelar was one of the non-physicians allegedly represented to the patient as a physician. Another name that came up as a Burzynski Clinic employees who was falsely represented to patients as being physicians was Lourdes DeLeon.
Patient G
Patient G is different in that Patient G was actually enrolled on one of Burzynski’s phase II clinical trials for a malignant astrocytoma of the optic nerve. For this patient, not only were there many of the same violations as listed for Patients A through F, but there were added allegations based on Burzynski’s treatment of the patient as part of this clinical trial:
14. Respondent failed to comply with federal regulations, the Burzynski Research Institute’s agreement with the FDA regarding the clinical study program for administration of antineoplastons and the approved protocols for the approved clinical study in which Patient G was enrolled. Such failures included Respondent’s direction and allowance for Patient G to be charged for the antineoplaston therapy and Respondent’s direction and allowance for these charges to be characterized as something else, “chemo prolong infuse” . This characterization was false, misleading and deceptive.
And:
40. The federal regulatory requirements for approval of single patient protocols for Phase 1 or Phase 2 clinical studies require that the investigator ensure that risks to patient/subjects are minimized and reasonable in relation to anticipated benefits.
41. Respondent, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, had a responsibility to ensure that risks to Patient G were minimized and reasonable in relation to anticipated benefits.
42. Ensuring that risks to patient/subjects are minimized and reasonable in relation to anticipated benefits requires (1) review of the subject’s medical records (history and physical examination) and (2) clarifying any outstanding issues with respect to the suitability of treating the patient/subject prior to granting institutional review board approval.
43. Respondent, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, failed to do the following to protect Patient G who was a patient/human subject in the clinical study of antineoplastons; (1) Respondent failed to take adequate measures to minimize risks to Patient G; and (2) Respondent failed to ensure that the risks to Patient G were reasonable in relation to anticipated benefits and the importance of the generalizable knowledge that may be expected to result.
44. Respondent’s failure, as principal investigator and as sponsor of the clinical study of antineoplaston therapy for Patient G, to ensure that risks to Patient G were minimized and reasonable in relation to anticipated benefits violated the standard of care, federal regulations, the Act and Board Rules.
This is the first time I’ve ever seen the TMB go after Burzynski for violating federal clinical trial regulations and human subjects research protections. I would like to see more of this. Another aspect of this case is unusual in that the TMB notes that the patient’s parent was allowed “to open an account whereby the public could read about Patient G’s medical and financial crisis and contribute money to that account.” The TMB alleges that Burzynski and his staff “reasonably were aware that the website that hosted this contribution account would provide any donations directly to the Burzynski Clinic to pay for the costs of Patient G’s treatment and that such costs had already been paid in advance by Patient G’s parent.” Patient G’s parent had a billing dispute with the Burzynski Clinic in which Burzynski refused to accept those donations as credit on Patient G’s account at the Burzynski Clinic and returned all the donations to the website that had acted as an intermediary for the donations. Burzynski also received significant reimbursement payments from an insurance company for Patient G’s care and refused to refund Patient G for benefits paid.
In other words, it’s all about making money from the dying and desperate.
And all the rest…
The TMB complaint also describes something that people who’ve been following the Burzynski case are well aware of, namely his advertising claims for ANPs, which are illegal under federal law because he made specific health claims for them and they are not yet FDA-approved for any indication. This is one thing that I haven’t been able to figure out. If a drug company did this, all the “natural health” advocates who defend Burzynski tooth and nail would howl bloody murder—and rightly so. But Burzynski does it, and he’s a hero being “persecuted” by the FDA and TMB. Ditto Burzynski’s failure to meet criteria for human subjects protection again and again, which are detailed very carefully in the last 30 pages or so of the complaint.
So what does it all mean? At the very least, it means that the TMB is serious this time. Does it mean that finally—finally—Burzynski is going down? I certainly hope so. Unfortunately, there’s no guarantee, and Burzynski has been found not guilty of similar charges before. Whatever happens with this case, thirty-seven years are too many, and no other cancer patient should pay hundreds of thousands of dollars for an ineffective treatment.

The Center for Inquiry weighs in on the FDA’s mishandling of Stanislaw Burzynski’s clinical trials
The Center for Inquiry points out how what Stanislaw Burzynski is doing corrupts the clinical trial process and harms patients.
David Gorski on July 3, 2014
Link
We interrupt our usually scheduled post for an important announcement. OK, we do nothing of the sort. Scott Gavura’s post will go live a little later this morning. In the meantime, here’s a public service announcement about a frequent topic of mine, Stanislaw Burzynski, that I’d like you to read.
As you recall, last week, the FDA inexplicably decided to lift the partial clinical hold on Stanislaw Burzynski’s bogus clinical trials of antineoplastons, which he’s used since the 1990s as a pretext to charge huge sums of money for “case management fees” to patients for a treatment whose efficacy he has never demonstrated. Yesterday, the Center for Inquiry laid in, and has sent a letter to legislators:
“We are frankly stunned to hear that the clinical hold against Dr. Burzynski has been lifted,” writes CFI in its letter. For decades, Dr. Burzynski and the Houston-based Burzynski Research Institute have been trafficking in unproven and scientifically baseless cancer treatments based on compounds known as antineoplastons, derived from human urine, which Burzynski claims — without evidence — can target and destroy cancer cells. He has taken advantage of desperate patients who are at their most vulnerable, and willing to pay any price.
After the death of a six-year-old patient in 2012, the FDA placed a hold on Burzynski’s trials with children, followed by a hold on trials with adults in 2013, prohibiting him from taking on new patients on whom he could experiment and from whom he could extract more money.
Over several decades, his clinic has proven it is unable to properly protect patient rights, adhere to basic ethical or scientific protocols, or even maintain correct patient records. It has also shown it is willing to exploit desperate cancer patients and their families, milking them out of enormous sums of money. But it has yet to show even a shred of evidence that its cancer treatments have any positive effect whatsoever.
“We struggle to see why the FDA continues to enable this deceptive, antiscientific, and unethical medical adventurism and profiteering, even for patients who are terminally ill,” writes CFI. “Given the behavior of Dr. Burzynski and the Burzynski Research Institute over the course of nearly three decades of failed research and trials, and in the face of a complete lack of scientific evidence demonstrating the efficacy of their expensive and dangerous antineoplaston treatment, we find the FDA’s decision perplexing and profoundly disturbing.”
The full text of the letter can be found here.
If only groups like the American Cancer Society would write similar letters. Cancer patients have been taken advantage of for nearly four decades, and Burzynski has made a mockery of the clinical trial process for nearly 20 years. It’s gone on way too long.

Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA caves
Sadly, it looks as though Stanislaw Burzynski is going to win his latest round with the FDA. Same as it ever was.
David Gorski on March 24, 2014
Link
Mark Crislip, founder of the Society for Science-Based Medicine, whose board of directors I’m proud to be serving on, an organization that you should join if you haven’t already, sometimes jokes that our logo should be an image of Sisyphus, the king of Ephyra whom Zeus punished by compelling him to roll an immense boulder up a hill. However, the boulder was enchanted and, as soon as Sisyphus reached the top, it would roll back down the hill. Sisyphus was thus forced to repeat this action throughout all eternity. The metaphor is obvious. Those of us who try to combat quackery and the infiltration of pseudoscience in medicine often feel a lot like Sisyphus. I always used to argue that, as amusing as it might be to have such a logo as an “in” joke, it’s far too much of a downer to inspire what SSBM wants to inspire: Action in the form of volunteers taking on projects, such as converting Quackwatch into a wiki and then continuously updating and adding to that wiki indefinitely. We have to believe that there is hope of someday succeeding. “Let’s push that boulder up a hill one more time!” does not exactly constitute an inspiring rally cry, although I can definitely understand the feeling at times the older I get and the longer I’ve been doing this. We can all appreciate gallows humor at times, and, besides, I’m not that pessimistic. I can’t afford to be.
Even so, I can understand the Sisyphus analogy right now with respect to an unfortunately frequent subject of this blog, the doctor in Houston who proclaims himself a cancer doctor, even though he has no formal training in medical oncology, isn’t even board-certified in internal medicine, the prerequisite for undertaking advanced training in medical oncology, and has no discernable training in clinical trials management. I’m referring, of course, to Stanislaw Burzynski, MD, PhD, the Polish doctor who since 1977 has been treating patients with substances that he has dubbed “antineoplastons” (ANPs). What are ANPs? Burzynski claimed to have discovered ANPs during his time at Baylor and described them as endogenous cancer-fighting chemicals in human blood and urine. Unfortunately, he soon became convinced that only he could develop them into an effective chemotherapy drug and left Baylor to administer ANPs to his own cancer patients. Patients flocked to him because he claimed to be able to cure cancers that conventional medicine can’t cure.
This led to a series of battles between Burzynski and various authorities, including the Texas Medical Board, the FDA, and various attorneys general, because of his use of ANPs, which are not and never have been FDA approved, as well as for various—shall we say?—issues with insurance companies. Ultimately, in the 1990s Burzynski beat the rap and effectively neutered the FDA’s case against him by submitting dozens of clinical trials to the FDA for approval, which, given how much pressure the FDA was under from Burzynski’s friends in high places (like Texas Representative Joe Barton), the FDA ended up approving. However, as Burzynski’s lawyer himself bragged, these clinical trials were shams designed to allow Burzynski to keep treating cancer patients, not clinical trials designed to produce any real evidence of efficacy. Not surprisingly, although Burzynski has published the odd case report or tiny case series, he has not yet published the full results of even a single one of his many phase II trials. There is, quite simply, no convincing evidence that ANPs have significant antitumor activity in vivo in humans, even after 37 years. Meanwhile, the FDA has found numerous examples of Burzynski’s abuse of clinical trials, failure to keep necessary data, and failure to protect human subjects, while exposés by BBC Panorama and Liz Szabo at USA TODAY have been most unflattering, revealing at least one dead child as a result of the toxicity of Burzynski’s drug and a pattern of minimizing and hiding reports of adverse reactions.
I had at least two other ideas for what I thought would be informative, entertaining, and timely posts, but then late last week I found out about a new development in Burzynski’s latest battle to try to use patients as weapons again to bring pressure to bear on the FDA (as he did in the 1990s) to allow patients with brain tumors to be treated with ANPs under single patient INDs, also known as compassionate use exemptions or expanded access programs. Such exemptions allow some patients who have no good conventional options access to unapproved investigational agents. Ironically, one of the most damning findings about the Burzynski Research Institute and Burzynski Clinic from the FDA investigation last year was how Burzynski would play fast and loose with the rules regarding approval by the institutional review board (IRB) of such exemptions. IRBs are committees mandated by the Office for Human Research Protections (OHRP) to protect human research subjects by approving and monitoring clinical trials to make sure that patients are not placed at undue risk, that proper informed consent is given, and that clinical trials conform to all ethical and legal requirements. Let’s just put it this way. The FDA caved. You’ll see what I mean shortly. Worse, it caved in a way that basically abdicated its responsibility.
Those of you who read my not-so-super-secret other blog will realize that I’ve already begun the discussion over there, making part of this post repetitive. However, there have been new developments over the weekend, and I very much want a record of this abdication of duty by the FDA on this blog as well—in more detail, of course.
“Just when I thought I was out, they pull me back in.”
Sadly, the brief little quote from Michael Corleone (as played by Al Pacino) in The Godfather, Part III, basically sums up my feelings with respect to Stanislaw Burzynski. Every time I think that I can give the topic a rest for a while (and, believe me, I do want to give it a rest), something invariably seems to happen to pull me back in. So it was Thursday evening, when I was made aware of a new development so disappointing that I’m still wiping the dirt off my chin from my jaw dropping to the floor. Even more amazing is that my disappointment stems from my perception of cynicism that actually was not Burzynski’s, but rather by the FDA in response to Burzynski’s cynical use of cancer patients as shields and weapons against the FDA that has led some of us who support science-based medicine to be subjected to criticism from the families of patients with cancer, who have been erroneously convinced that Stanislaw Burzynski is their loved ones’ last chance to survive. Actually, I can’t tell if it’s a cynical move or a breathtakingly naïve move, but it’s a huge mistake regardless, as you’ll see. I’m guessing that some will think of it as a very clever move, and so it is, but it’s a cleverness we could use less of.
About a year ago, Burzynski was once again investigated by the FDA. Because of the death of a patient due to hypernatremia (elevated sodium level) due to ANPs in 2012, the FDA put a partial clinical hold on his pediatric clinical trials and extended it to all of his clinical trials. What this means is that, although Burzynski can continue to treat patients who are already in his clinical trials, he can’t enroll any new patients in them. Of course, one of the big issues with Burzynski that contributed to his problems is that he abused the FDA process known as the single patient IND, which is more commonly known as the compassionate use exemption. These are special case exemptions in which a single patient is allowed access to an investigational agent outside the auspices of a clinical trial. Indeed, when the FDA slapped him down most recently, in December, one of its findings was just that: Burzynski abused the single patient IND process and his institutional review board (IRB), the committee that’s supposed to oversee clinical trials and safeguard the interests and safety of clinical trial subjects, played fast and loose with the rules.
Since the appearance of a USA TODAY story by Liz Szabo spelling out all of these issues, Burzynski has been frantically trying to save his empire. Whether “encouraged” by Burzynski or just by one of the patient groups that have become true believers, patients with deadly cancer have been starting petitions, pressuring legislators to intercede on their behalf to the FDA, and paint Burzynski’s ANPs as their only hope of survival. I have no doubt that these patients believe it, but they have the potential to inadvertently do great mischief to the law, either through their use of their tragic stories to promote misguided “right to try” laws or through their use of patient stories to pressure the FDA to loosen protections on human subjects in clinical trials. Perhaps the most tragic story is that of Rafael Elisha Cohen, a six-year-old child with medullablastoma who is not doing well and whose parents have been at the forefront of pressuring the FDA. As horrible as the Cohens’ situation is—and we all understand that it’s a horrible, horrible thing to have a child dying of brain cancer—unfortunately, the FDA appears to have decided to cave. The other day, on a Facebook page dedicated to raising money and pressuring the FDA, Devorah Teicher Cohen announced:
UPDATE-
Thanks to everyones hard work the FDA did end up approving the Antineoplastins for compassionate use – they do not let Dr B administer it.
The condition is, if an oncologist request this protocol FDA will issue compassionate use within 24 Hours.
FDA recognizes the data of those who survived aggressive brain tumors due to the ANP and is therefor after a long and cruel wasting TIME period allowing it. There are currently 8 pediatric patients that need this medicine NOW!!!!
Refael Elisha can not travel at this point…so we would need an oncologist in the NY area… we are in touch with other kids that are ready to get on a plain if they get the signal of a cooperating oncologist.
It is beyond words to express our sadness that FDA ended approving the drug but Elisha is in critical condition at the moment.
We are not holding our breath and are trying different alternatives , If HASHEM wills it we will get the medicine but if not, that is from Hashem for the good. in the meantime Please put your fillers out there and message me in privet if you have any leads , even if not in NY it might work out for the other desperate children.
im copying the announcement from ANP site
Wanted: One brave courageous oncologist or oncologists willing to examine and treat up to eight pediatric brain cancer patients who have run out of treatment options and now require a Compassionate Use IND Emergency Treatment protocol from the U.S. Food and Drug Administration. The ANP Coalition needs your help now. Please visit www.anpcoalition.org or call (925) 699-9116. Thank You
When I first saw this message on the Prayers for Elisha Facebook page, I was cautious. I could find confirmation of this news nowhere else, not even on the ANP Coalition webpage. Then, on Friday afternoon, Liz Szabo, the USA TODAY reporter who previously published her epic expose of the Burzynski cancer machine back in November, basically confirmed the report with a followup story in USA TODAY, FDA agrees to let patients get controversial drug:
The Food and Drug Administration has agreed to allow a handful of cancer patients to receive unapproved drugs from a controversial Texas doctor, but only if they can find another physician to administer them.
The drugs are made by Houston doctor Stanislaw Burzynski, who was the subject of a USA TODAY investigation last year. While his supporters consider him a medical maverick, mainstream doctors describe him as a snake-oil salesman. Burzynski has claimed for more than 36 years to be able to cure certain hard-to-treat brain tumors with drugs he calls antineoplastons. The National Cancer Institute notes that Burzynski has never published definitive evidence that his drugs cure cancer or even help people live longer.
Burzynski has been unable to give these drugs since 2013, when the FDA placed his experiments on hold after the death of a 6-year-old New Jersey boy taking antineoplastons. In December, the FDA sent Burzynski a warning letter, noting that he inflated his success rates and failed to report side effects and to prevent patients from repeatedly overdosing. The Texas Medical Board also charged Burzynski last year with false advertising.
None of this stopped the FDA from caving:
The FDA acknowledged Friday that it has agreed to allow them to use the experimental drug, but only if they can find a qualified, independent physician to administer the drug. Beyond infusing the drug and overseeing their care, the doctor would have to formally apply for expanded access to an “investigational new drug,” as well as get approval from an institutional review board, an independent panel that reviews safety and ethical issues involved in clinical trials.
Can anyone figure out why I can’t make up my mind whether this decision, if what the Cohens say is true, is stunningly cynical or stunningly naïve on the part of the FDA? Instead of standing firm for science and gently continuing to point out that it can’t allow any more single patient INDs for ANPs be approved based on science, Burzynski’s past violations of FDA regulations, and, above all, the need to follow the FDA’s mandate and mission to protect vulnerable cancer patients, instead the FDA has dangled more false hope of a single-patient IND in front of Elisha’s family (and the eight other children petitioning for such INDs). It’s hard to believe that the FDA is not aware that it is incredibly unlikely that any reputable pediatric oncologist would agree to administer ANPs under these conditions, given Burzynski’s reputation.
In a way, what the FDA is doing inadvertently compounds the families’ agony. Now they have hope again, except that this time it’s doubly false: False because, based on existing evidence and what we know now, ANPs almost certainly don’t work and false because of how incredibly unlikely it is that any pediatric oncologist will take on such a patient and administer ANPs, given Burzynski’s history, the utter lack of supporting science for the efficacy of ANPs, and the not-inconsiderable amount of work and expense that would be necessary in order to do so. The families will now be showing up in the offices of pediatric oncologists, begging them to agree to do a single patient IND and administer ANPs to these patients. Ditto some adult oncologists. Indeed, according to Szabo’s report, Liza Covad-Lauser, wife of rock star Sammy Hagar’s drummer David Lauser, claims that she has already found a doctor willing to administer the antineoplastons. One wonders if this doctor knows what he is getting himself into. As cynical as it might sound of me to say so, I can’t help but wonder whether being the wife of a member of a rock star’s band, who can garner signatures on petitions by other rock stars, has an effect.
Here’s why the FDA’s action is doubly cynical (or nave). As alluded to in Szabo’s article, according to FDA regulations, there are a number of requirements for a single patient IND and several things any physician seeking to administer an investigational agent as a single patient IND must do. Here’s the most important one that makes it even more unlikely that any single patient IND will be granted, except for perhaps briefly as an “emergency exemption” in which IRB approval can be briefly deferred:
5. Informed Consent Statement that states that informed consent and approval of the use by an appropriate Institutional Review Board (IRB) will be obtained prior to initiating treatment. In the case of an emergency, treatment may begin without prior IRB approval, provided the IRB is notified of the emergency treatment within 5 working days of treatment.
See what I mean? Even if a family were to find an oncologist willing to jump through all the hoops to get a patient on a single patient IND to be treated with ANPs, that single patient IND would still have to be approved by the IRB of the institution where that oncologist practices. Sure, the oncologist could declare the treatment an “emergency”—although in none of the cases that I’m aware of other than that of Elisha Cohen could be properly termed an emergency so urgent that the physician couldn’t wait a week or two to have the IRB formally discuss the IND, even if ANPs actually did have any efficacy—and start treatment pending IRB approval, but as soon as the IRB convened to discuss the IND, very likely the plug would be pulled. No more ANPs. Remember, these would be real IRBs, not Stanislaw Burzynski’s sham IRB chaired by an old crony of his.
There’s another question to consider. Stanislaw Burzynski routinely used to treat some of these patients for free, supplying ANPs for no cost and waiving case management fees. No doubt this offer was primarily for publicity, to blunt the accusation that, based on the exorbitant amounts of money charged to previous patients, Burzynski is in it for the money. So, not surprisingly, according to Szabo’s report, Burzynski is still offering to provide the drug for free. That’s all well and good, but it leaves all the other expenses of treatment, which will not be paid for by insurance because ANPs are not an FDA-approved drug. Who’s going to pay for all of that? While it is true that some of the families have raised quite a bit of money (Elisha’s family, for instance, has raised nearly $150,000), others aren’t so lucky.
A massive Burzynski propaganda victory?
Supporters of Stanislaw Burzynski wasted no time in using the FDA decision to defend Burzynski and, ironically, to attack the FDA. Many of you might remember McKenzie Lowe, the 12-year-old girl diagnosed with diffuse intrinsic pontine glioma (DIPG) in 2012. Her family has been trying to have her treated by Stanislaw Burzynski, making videos and lobbying Congress. Indeed, they succeeded in persuading their senator, Senator Kelly Ayotte (R-NH), to write to the FDA urging it to consider allowing McKenzie to be treated by Burzynski. On a Facebook page Friends of McKenzie Lowe, a message was posted on Sunday simultaneously rejoicing at the news as evidence that McKenzie has a chance to live and lambasting Liz Szabo:
As you all probably have read in the USA Today the FDA has agreed to let Mckenzie and the other people who want to use ANP CAN USE IT!!!! FANTASTIC!!!!! But as you can see the writer of the article is very bias on the negative side. As usual she one again took something good for these patients and in stead of focusing on the positive response from the FDA she took another swing at bashing Dr. Burzynski and his clinic. There was no mention of or comments from Anthony Stout, Rick Schiff, Jessica Ressel, Randy Hinton, Philip Norton and many many more..
Let’s go back in history to all the nay Sayers that said Christopher Columbus was crazy. The world is flat, you will fall off the end. Hmmm. Einstein was a quack… Hmmm. Isaac Newton and Galileo were also shunned by their peers… Thank god they had the fortitude to push aside the nay sayers and continue to prove them ALL wrong. Imagine where we would ALL be today if they had listened to their critics and not persevered with what they believed.
Unfortunately, this is known as the Galileo Gambit, a nice, concise term used to argue that if you are vilified for your ideas it must mean that you are right. Unfortunately, what supporters of pseudoscientists and quacks frequently forget is that there are two requirements necessary to be able to credibly claim the mantle of Galileo. Not only must you be vilified, but you must be correct. Only one of these applies to Stanislaw Burzynski, and it isn’t the second one.
As has been the case whenever I’ve discussed patients like McKenzie Lowe, Liza Covad-Hauser, Rafael Elisha Cohen, and others, I understand, at least as much as it is possible to understand without actually being in their shoes. As I’ve pointed out before, it was only five years ago that my mother-in-law died of widely-metastatic breast cancer. Burzynski couldn’t have saved her. ANPs couldn’t have saved her. And I know I’m going to take some flak for saying this, but ANPs cannot save McKenzie Lowe. At least, there is no convincing evidence that they can, and, quite frankly, the only blame for why this is true should be placed at the feet of Stanislaw Burzynski himself. He’s the one who, thinking himself the “brave maverick doctor” to whom the rules of science don’t apply, has failed to produce such evidence. While I understand the desperation these families are feeling, I keep hoping that they will realize that it is not doing McKenzie, Elisha, or any of the others any favors to subject them to toxic chemotherapy—and, make no mistake, ANPs are toxic chemotherapy, efforts of advocates to paint them as “natural” and “nontoxic” notwithstanding. As I’ve pointed out time and time again: If there’s anything worse than dying of a terminal illness, it’s dying of a terminal illness and suffering unnecessary complications or pain for no benefit in the process.
I can totally understand why families like the Lowes might become very excited about the possibility of being able to use ANPs. As misled as they have been and mistaken as their belief is, they do, after all, genuinely believe that ANPs represent the last chance their loved ones have to be able to survive their cancer. Unfortunately, our old “friend” and Burzynski’s very own propagandist, Eric Merola, who has produced two fawning “documentaries” about the Great Man chock full of misinformation and exaggerations, coupled with attacks on Burzynski critics and skeptics, has no such excuse and deserves none of the compassion that we should all have for patients dying of brain tumors and the families who love them. Not surprisingly, he, too, has leapt into the fray with a typically frothing-at-the-mouth conspiracy-laden pile of fetid dingos’ kidneys of a response to Liz Szabo’s story, in which he examines it line-by-line and basically responds with typical Burzynski propaganda, misinformation and lies.
There’s too much there for a full response in this post. Besides, most of the misinformation that’s there I’ve covered before, often multiple times. Perhaps I’ll respond a bit more on my not-so-super-secret other blog. Here, I simply want to point out a few of the most egregious examples. For example, here is probably the most egregious lie on Merola’s part:
A DIPG in a child has never been cured in medical history — why would the FDA make such a claim in this case? It’s quite simple, the science proved it works and cures in many cases, and therefore the science was allowed to progress. There are no “claims” other than what can be proven. Maybe it’s because the cancer industry doesn’t like anyone else “claiming” anything as they own the luxury of claiming what cancer medications work or not work — and we know how well that has worked out for us.
As I’ve pointed out before, this is, quite simply, untrue. It’s also been pointed out time and time again to Merola that this is untrue. Long-term survival for patients with DIPG is rare, definitely, but it’s always dangerous to make an absolute statement like the one that Merola has done. Contrary to Burzynski’s claim, there are occasional long-term survivors, some of whom received little or no therapy, such Connor Frankenberg, a child from Germany, and two patients who underwent spontaneous remission. There is even a site, the DIPG Registry, whose purpose is reporting on how patients with DIPG do and promoting Just One More Day, a registered non-profit 501(c)(3) organization dedicated to helping families affected by a diffuse intrinsic pontine glioma, established by the families of DIPG victims. The DIPG Registry concludes that, although the vast majority of children with DIPGs do poorly:
The bottom line is: 1) we really don’t understand DIPGs, and 2) there are children who have been diagnosed with DIPGs-based on the incomplete knowledge that we currently have- who truly have had spontaneous regression of their tumors and 3) most of the children with reports of spontaneous regression have been very young.
Young like Tori Moreno, I might add.
The big problem is that Burzynski appears not to keep good enough records to demonstrate one way or the other whether he can cure DIPG, and we already know from recent FDA findings and Liz Szabo’s USA TODAY report that he has misclassified partial and complete responses. Yes, DIPG is a horrible disease, with only 10% surviving beyond two years. Unfortunately, there is no convincing evidence that Burzynski can do any better than conventional oncology, much less cure DIPG, as much as his propagandist Eric Merola repeats the claim that he can. Worse, Burzynski hasn’t published a single one of his completed phase II clinical trials, even though he’s had well over 15 years to complete them. With tumors this lethal, most such trials should be completed within five years, which brings us to more of Merola’s misinformation:
The National Cancer Institute notes that Burzynski has never published definitive evidence that his drugs cure cancer or even help people live longer.
The above links are examples definitive published evidence. Notice how this writer links to a PDF highlighting her point, vs. the National Cancer Institute (NCI) website itself. Is it perhaps because on the NCI website it clearly says:
“A phase II study also conducted by the developer [Burzynski] and his associates at his clinic reported on 12 patients with recurrent and diffuse intrinsic brain stem glioma. Of the ten patients who were evaluable, two achieved complete tumor response, three had partial tumor response, three had stable disease, and two had progressive disease. Patients ranged in age from 4 to 29 years.”
The NCI felt its own source to be “definitive enough”, why not Liz?
*Source:http://www.cancer.gov/cancertopics/pdq/cam/antineoplastons/healthprofessional/page5#Reference5.12
Merola clearly does not understand the difference between “responses” and cures. Similarly, he does not understand what constitutes “definitive evidence.” (Hint: It isn’t case reports, tiny case series published in bottom-feeding journals, or incomplete phase II trials. Moreover, just because the NCI cited a crappy review article by Burzynski that reported partial results phase II trials, a ten year old partial report of a phase II trial, a dubious paper published in an integrative medicine journal, and another review article published by Burzynski in a journal that appears not to be even indexed by PubMed does not constitute “definitive evidence” that ANPs work. All it means is that the NCI was examining the existing published evidence on its way to writing this:
To date, no randomized controlled trials examining the use of antineoplastons in patients with cancer have been reported in the literature. Existing published data have taken the form of case reports or series, phase I clinical trials, and phase II clinical trials, conducted mainly by the developer of the therapy and his associates. While these publications have reported successful remissions with the use of antineoplastons, other investigators have been unable to duplicate these results [10] and suggest that interpreting effects of antineoplaston treatment in patients with recurrent gliomas may be confounded by pre-antineoplaston treatment and imaging artifacts.[11,14,16] Reports originating from Japan on the effect of antineoplaston treatment on brain and other types of tumors have been mixed, and in some Japanese studies the specific antineoplastons used are not named.[9] In many of the reported studies, several or all patients received concurrent or recent radiation therapy, chemotherapy, or both, confounding interpretability.
Mr. Merola, that’s hardly “definitive”! Nor is the “definitive” study by Hidaeki Tsuda featured in the second Burzynski movie, given that nothing has been published to allow us to evaluate the methods. Nor is the fact that The Lancet Oncology apparently editorially rejected a manuscript submitted by Burzynski evidence of any sort of “conspiracy” against him. Indeed, I now probably know why Burzynski’s manuscript was rejected. Look at the title: “Glioblastoma multiforme: A report of long-term progression-free and overall survival of 8 to over 16 years after antineoplaston therapy and a review of the literature”. Yes, the title seems to indicate that this is just another small case series. No wonder The Lancet Oncology didn’t even bother to send it out for review!
Of course, Merola can’t resist a swipe at yours truly, who was quoted in the article:
A guy who is paid to write blogs attacking this innovation and other innovations that compete with the status quo, a guy who has never once met a Burzynski patient, never once visited the Burzynski clinic, a guy who supposedly finished his residency and now writes “thought police” blogs for a living — yeah, let’s hear more about what this guy has to say, that’s productive. He does fit the angle for Liz’s one-sided propaganda, so I understand why she included his irrelevant opinion.
I don’t know whether to laugh or be annoyed at Merola’s continued lies about me. Once again, I do not need to visit the Burzynski Clinic to know that ANPs almost certainly don’t work. I did finish my residency and am board certified in surgery. If Mr. Merola doesn’t believe that, he can go to the American Board of Surgery website and search for my name in the section that lets the public verify the board certification of surgeons, realizing that you can’t become board certified without finishing an accredited residency. Finally, I don’t actually blog for a living. It’s my hobby. I’m not paid at all for my work at SBM, and at my not-so-super-secret other blog I make a small amount of money that I could completely do without if that gig ever went south or I decided to bolt. As for having something worthwhile to say, well, let’s just say that I’d put my record for science-based analysis against Mr. Merola’s record for pseudoscience-based propaganda any day, particularly in light of his latest paean to another brave maverick, this time promoting the long-discredited cancer quackery known as laetrile.
At least Merola included a link to my page on SBM. He seems to think it’s something nefarious, while I’m more than happy to include a link to it here. Please, read.
Why did the FDA cave?
What is puzzling to me is why the FDA caved. While it is true that the ANP Coalition managed to get a few misguided legislators, the most prominent of whom was Senator Kelly Ayotte (R-NH), to write letters to the FDA urging that it consider allowing ANPs to be made available through single patient IND/expanded access to their constituents, the letters were fairly wishy-washy. Moreover, the Change.gov petition to the White House response to a We The People online petition to have the FDA allow Elisha Cohen access to ANPs through compassionate use exemption resulted in a response that, boiled down to it essence, said that it’s the FDA’s job to make such decisions, and let the FDA do its job, along with links to various FDA web pages with information about investigational drugs and information about how the FDA could be contacted. It was a shockingly reasonable response.
One rationale reported in Szabo’s article seems to be that by allowing ANPs to be used but excluding Burzynski from having anything to do with administering them other than producing them, in essence, relegating him to the role of a drug manufacturer, useful data might be obtained and patients protected while obtaining that useful data. This is utter nonsense. As Howard Ozer is quoted in Szabo’s article:
“This is a cop-out,” says Ozer, director of the University of Illinois Cancer Center, who studied Burzynski’s research results in the 1990s.
“Because it can be toxic and cause life-threatening sodium problems, patients (who take antineoplastons) are at risk and could die,” Ozer says.
The scientific community will learn nothing by giving these patients antineoplastons, because there will be no comparison group, Ozer says. Any doctor who agrees to give antineoplastons could be biased in favor of them, which could skew the results.
Exactly. As Dr. Peter Adamson points out in the article, after 37 years, if antineoplastons were the wonder drugs that Burzynski claims them to be, scientists would know it by now. ANPs aren’t wonder drugs. There isn’t even any evidence that they’re better than standard-of-care, as dismal as that is for DIPG.
It is possible that one of the Senators or other legislators did indeed pressure the FDA, leading the relevant enforcement officials to come up with this decision in order to get them off their backs without actually doing anything. They could credibly say, “Hey, we offered compassionate use, but I’m sure you’ll agree that, given his history, we can’t let Burzynski be the one to administer the ANPs on compassionate use. Look at his history of playing fast and loose with IRBs and not obeying the rules with respect to INDs.” This might even sound convincing and seem clever, which is why I rather suspect that Dr. Henry Friedman is right when he says:
“It will deflect criticism from anybody who says the FDA is unilaterally denying dying patients something that could help them,” says Friedman, deputy director of the Preston Robert Tisch Brain Tumor Center at Duke University in North Carolina, who also reviewed Burzynski’s studies in the 1990s. “It will get FDA off the hook.”
That, I believe, is exactly why the FDA did it, not to help dying children. Unfortunately, the consequences of the FDA’s decision are likely to be disastrous. Long-suffering families will have false hope extended to them once again, only to find out that it’s a useless offer. In addition to continuing to scramble to raise money, they’ll scramble to find oncologists willing to do the not-inconsiderable work to get a single-patient IND approved and administer ANPs, something few, if any of them, are likely to succeed at. The families don’t know it yet, but what the FDA has done will only add to their misery. Indeed, I’ve already seen reports that patients have contacted “dozens” of pediatric oncologists looking for one who will administer ANPs, and, given that the number of pediatric oncologists in the US is small, a significant proportion of them are likely to be contacted.
Meanwhile, Burzynski gets a propaganda victory, thanks to the FDA’s failure to enforce its own standards, and alt-med proponents get another conspiracy theory to add to the list of conspiracy theories surrounding Burzynski already.

Stanislaw Burzynski’s propaganda victory on antineoplastons: The FDA really caves
Once more, the FDA fails to shut down Stanislaw Burzynski’s clinic and antineoplaston manufacturing operation. Cancer patients will suffer as a result of the FDA’s failure.
David Gorski on July 1, 2014
Link
It’s been a while since I wrote a substantive post for this blog about the Houston cancer doctor and Polish expat Stanislaw Burzynski who claims to have a fantastic treatment for cancer that blows away conventional treatment for cancers that are currently incurable. The time has come—and not for good reasons. The last time was primarily just a post announcing my article about Burzynski being published in Skeptical Inquirer. When last we saw Stanislaw Burzynski on this blog, it was a post that I hated to write, in which I noted that the Food and Drug Administration (FDA) had caved to patient and legislator pressure and allowed compassionate use exemptions (otherwise known as single patient INDs) to continue. The catch? Cynically, the FDA put a condition on its decision, specifically that no doctor associated with Burzynski nor Burzynski himself could administer the antineoplastons. This set off a mad scramble among Burzynski patients wanting ANPs to find a doctor willing to do all the paperwork and deal with Burzynski to administer ANPs. The family of one patient, McKenzie Lowe, managed to succeed.
It’s hard for me to believe that it’s been almost three years since I first started taking an interest in Burzynski. Three long years, but that’s less than one-twelfth the time that Burzynski has been actually been administering an unproven cancer treatment known as antineoplastons (ANPs), a drug that has not been FDA-approved, to patients, which he began doing in 1977. Yes, back when Burzynski got started administering ANPs to patients, I was just entering high school, the Internet as we know it did not exist yet (just a much smaller precursor), and disco ruled the music charts. It’s even harder for me to believe, given the way that Burzynski abuses clinical trial ethics and science, that I hadn’t paid much attention to him much earlier in my blogging career. After all, I’m a cancer surgeon, and here’s been this guy treating patients with advanced brain cancers using peptides that, according to Burzynski, do so much better against what are now incurable tumors than standard of care while charging huge sums of money to patients on “clinical trials.” It might be a cliché to quote the Dead this way, but what a long, strange trip it’s been. Because there has been a major development in this saga whose context you need to know to understand, I’m going to do a brief recap. Long-time regulars, feel free to skip the next couple of paragraphs, as they just try to bring people up to date and include a lot of links for background, or, if you haven’t already, read this summary of Burzynski’s history published earlier this year in Skeptical Inquirer. Newbies, listen up. Read the next two paragraphs. You need to know this to understand why I’m so unhappy. 
Incidents that I never blogged about here (but fortunately a certain “friend” of mine did on another blog) that have occurred since the FDA caved and (sort of) lifted the partial clinical hold on ANPs included:
    • For the first time in 37 years, Burzynski published what was purported to be the complete results of one of his phase I/II clinical trials. The results were—shall we say?—underwhelming.
    • Before that Burzynski had published 42.5% of one of his phase I/II trials, with even more unconvincing results.
Meanwhile, since he received that warning letter from the FDA late last year, in addition to making unconvincing claims excusing the issues described in the FDA warning letter, he’s been trying to enlist patients, both cute children and the semi-famous, to persuade legislators to pressure the FDA to let his clinical trials open again after they had been put on a partial clinical hold in the wake of the death of a child from hypernatremia (too much sodium in the blood), as reported by Liz Szabo in USA TODAY. All the while Burzynski has continued to charge patients large sums of money, while bragging that he didn’t charge for the actual ANPs. For those unfamiliar with the story, a partial clinical hold means that Stanislaw Burzynski can’t enroll any new patients on clinical trial but can continue to treat patients already enrolled.
Yes, three months ago—has it been that long already?—I noted with dismay that, under the onslaught of sympathetic cancer patients who understandably but incorrectly believe that Burzynski is their last chance to live, the FDA did indeed cave, although in the most weaselly way imaginable, stating that Stanislaw Burzynski could again enroll patients under compassionate use exemptions (also known as single patient INDs), even though the FDA warning letter had found gross deficiencies in the Burzynski Research Institute Institutional Review Board (BRI-IRB), which is run by an old crony of Burzynski’s who just so happens to be chair of the board of directors of the BRI and was found to be negligent in protecting patients by playing fast and loose with the regulations for enrolling patients on single patient INDs. The condition was that Burzynski himself or anyone working for him couldn’t be the physician treating the patients, leaving the patients to find a doctor willing to oversee the administration of ANPs.
And so it was for three months, with desperate patients with terminal brain tumors scrambling to find some doctor willing to do the paperwork to get the FDA to allow him to administer ANPs and also willing to work with such a disreputable character. McKenzie Lowe’s family, for instance, managed to find a retired family practitioner named Terry Bennett to agree to this. (More on this later.) Then, last week, this bombshell landed, courtesy of Liz Szabo again, in a story entitled “FDA gives controversial doc green light to restart work“:
The Food and Drug Administration has given a controversial Houston doctor the green light to resume administering experimental cancer treatments.
The FDA has lifted restrictions on a clinical trial run by Stanislaw Burzynski, who was the subject of a USA TODAY investigation last year. Burzynski, 70, has wrangled with state and federal medical authorities for nearly 40 years over his claims that he has discovered natural substances that can fight certain cancers.
You might think that my reaction upon reading this would be “WTF?” It wasn’t. However, that was only because I had had that reaction a week ago, when I read a press release from the BRI, “Burzynski Research Institute, Inc. Announces Lifting Of The FDA Partial Clinical Hold – Phase 3 Clinical Study Agreed Upon“:
The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.
The FDA’s decision to lift the clinical hold marks an important step in the development of Antineoplastons for the treatment of various forms of brain tumors in the US. At the same time, the Company is evaluating possible next steps for the Antineoplastons clinical program given the current progress and anticipated resource requirements of the ongoing program.
That was when I had my “WTF?” moment. However, noting the obviously intentionally vague language of the press release, I decided to wait until I could learn more and obtain confirmation rather than to blog the press release. For one thing, Burzynski could have just been spinning furiously, and there could have been a lot less to this press release than met the eye. It wouldn’t be the first time. Also, I just couldn’t believe that the FDA would so horrifically fail patients with brain cancer yet again the way it now has. I could sort of see why the FDA issued its previous ruling that allowed other doctors to enroll patients in single patient INDs of ANPs. At the time, the FDA was under a lot of pressure from legislators being contacted by constituents about families in their state or district with brain cancer who wanted to be treated by Burzynski. Its cynical solution must have seemed downright Solmonic at the time to the administrators who thought of it. But this? There’s nothing in the press release that says that the conditions that led to the partial clinical hold were resolved. Yesterday, however, there was this in Szabo’s story:
In a statement issued Wednesday), the FDA confirmed that it has lifted its restrictions on Burzynski because he answered all of their questions. In particular, Burzynski addressed “common and serious (and in some cases fatal) adverse drug reactions, as well as accurate information on how often tumors shrink after treatment with antineoplastons.”
Notice something missing? I did. The FDA said nothing about the BRI-IRB, which was soundly chastised for approving single patient INDs without full meetings of the committee. It also said nothing about the massive conflicts of interest that exist in the IRB and how it can’t possibly be independent. Sure, if Burzynski talked the talk adequately, I might see how the FDA might be either snowed or too tired to fight any more. I could see how it might be tempted to let him open his bogus clinical trials again—but only if Burzynski were forced to use a truly independent IRB, not his crony-packed IRB that basically rubber stamps whatever it is he wants to do with no questions and no evident effort to protect the welfare and rights of clinical trial subjects. Any IRB worth its salt will refuse to approve a clinical trial now and then and/or issue warnings to principal investigators for inadequate documentation, too many adverse events, etc. Has the BRI-IRB ever done this? Not as far as anyone I know can tell. Of course, it’s not really up to the FDA to oversee the function of IRBs. Rather, it’s more a function of the Office of Human Research Protections (OHRP). Long have I wondered: Where the heck has the OHRP been all these years?
It’s not as though Burzynski isn’t up to his old tricks again, either. Even with another physician overseeing the treatment of McKenzie Lowe, he’s managing to find ways to charge patients huge sums of money, even as he isn’t charging them for the ANPs. Indeed, the other day, Dr. Bennett, the physician who is overseeing the treatment of McKenzie Lowe whom I mentioned near the beginning of this article, was featured in an article in a local newspaper “Dr. feels misled in cancer treatment costs“. The money quotes are here:
But there was something Bennett didn’t know.
Bennett’s decision was based, in part, on a newspaper article that said Burzynski had agreed to donate the medicine required for McKenzie’s treatment. But what Bennett didn’t know is that Burzynki [sic] planned to charge the family for the clinical costs associated with the therapy.
LaFountain said the first month’s bill is expected to be $28,000. Every month after that is expected to cost $16,000. The treatment usually lasts eight to 12 months.
And health insurance won’t cover a dime of it.
And here:
Bennett says a representative of the Burzynski Clinic called him on that date seeking payment for the first month of McKenzie’s therapy. Prior to that, Bennett, who is donating his services, thought Burzynski was doing the same.
Instead, said Bennett, “I’m supposed to be the bag man for all of this. They want me to collect the 30 grand for the family and send it to Burzynski.”
Elsewhere, Bennett said, “It [the Burzynski Clinic] meets all the criteria for a bait and switch operation.” Yes, even Dr. Bennett found out the hard way how the Burzynski Clinic operates. None of this is anything new. Burzynski has been trying to dodge this tactic for years by saying that he doesn’t charge patients for his actual drug, the ANPs, giving the impression that he’s not charging them much of anything. However, the reality is that costs can rapidly add up to hundreds of thousands of dollars, which is why fundraisers by families of Burzynski patients have been a feature surrounding the Burzynski Clinic operation for decades, as has been documented time and time and time again.
This is a doctor who wants to help and is willing to take risks, even if inappropriately in this case, and he feels used by Burzynski. Indeed, his comparing himself to a “bag man” is a particularly apt metaphor, because that’s what he is in this: A bag man. It’s his job to collect the cash from the family of a dying child and ship it to Burzynski. Ironically, this news story appeared on the very same day as Burzynski’s press release, and, of course, Szabo’s story appeared yesterday. Did the FDA know Burzynski was doing this? It strains credulity to think that the FDA didn’t know about this abuse of a desperately ill child’s family, given that information regarding how it will be paid for is part of a single patient IND application, indeed part of all clinical trial applications. Indeed, that Burzynski gets away with this is yet more evidence that his IRB is nothing more than a rubber stamp, because any independent IRB would ask some very hard questions about such an arrangement. Very hard questions indeed. It’s painfully obvious that the BRI-IRB has never asked hard questions any IRB should be asking about any clinical trial Burzynski has proposed or about how his clinical trials are being carried out.
It’s even worse than that, though. Check out what I found on a website devoted to penny stocks, “Burzynski Research Institute (BZYR) Reignites On FDA Approaval” [sic]:
Focusing since 1967 on the isolation of various biochemicals produced by the human body as part of the body’s possible defense against cancer, the penny stock of Burzynski Research Institute, Inc. (BZYR) has exploded on the scene thanks to the efforts of CEO and President Stanislaw R. Burzynski, M.D., Ph.D. After notification that the U.S. Food and Drug Administration lifted its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections, shares of BZYR stock begun to trade and are putting on a good show thus far. Although only around 25 million shares issued and outstanding do not belong to the founder who is determined to treat of various forms of brain tumors, the large jump upwards has made this little biotech burz-worthy.
You know, with all the typos and English that sounds as though it were written by someone who isn’t a native English speaker, this made me suspicious that Burzynski or someone from Burzynski’s clinic wrote it. Either that, or the web page is written by non-English speakers, which seems likely given that I found the same sorts of weird-sounding sentence constructions in other articles and I know Burzynski’s people can produce serviceable English prose when they need to. Be that as it may, I have little doubt that the Burzynski clinic is trying to take advantage of the FDA decision to bolster its flagging finances, which have been reportedly hurting since the partial clinical hold was placed. Whether this article on a website hawking penny stocks has anything to do with it, I don’t know, but its appearance right around this time sure doesn’t seem coincidental to me.
So what happened? Why did the FDA cave so ignominiously? How could it ignore 37 years of Burzynski’s therapeutic misadventures and abuse of science and the clinical trial process? I have a few ideas, but none of them are satisfying, and all of them are speculation, ranging from educated to, well, just speculation. Back in the 1990s, it was powerful legislators like Joe Barton leaning on the FDA to let Burzynski be Burzynski. Today, there are no visible and obvious champions in Congress for Burzynski. Even so, that doesn’t necessarily mean that such congressional patrons don’t exist, given the campaign waged by patient families and the Burzynski clinic to get people to write their Congressmen and Senators. Another likely possibility is that the FDA is just tired. If it shuts Burzynski down, it will be portrayed for years as the bad guy denying patients a chance at life, and there will be an enormous court battle. If it decides to fight, the FDA could end up with years of litigation, and, given the FDA’s unfortunately limited budget, it has to pick its battles. Does it help the FDA’s mission overall if it drains so many resources fighting what it likely views as small fry like Burzynski that it finds late in the fiscal year that it can’t afford to go after a large drug company over lack of resources? I don’t know, but given how long Burzynski’s been at it, the FDA’s decision is still an extreme dereliction of its duty to the public.
Whatever the reason that the FDA caved, we’ll probably never know. We can make FOIA requests, but the FDA is notoriously tight with the information it permits to be releases because it’s forbidden from releasing information that might endanger trade secrets of the companies it regulates and it appears to take a fairly expansive view of what constitutes such information. At least, we’ll probably never know unless we can get a powerful Senator or Congressman (or two) interested and as outraged as we skeptics are. A Congressional investigation, as unlikely as that sounds, is probably the only thing that will get to the bottom of the FDA’s utter failure. It’s clear that in this case the FDA is no longer able or willing to protect the safety, finances, or rights of patients with advanced cancer.

Stanislaw Burzynski: A deceptive propaganda movie versus an upcoming news report
David GorskionJune 3, 2013
Link
Well, I’ve finally seen it, and it was even worse than I had feared.
After having heard of Eric Merola’s plan to make a sequel to his 2010 propaganda “documentary” about Stanislaw Burzynski, Burzynski The Movie: Cancer Is Serious Business, which I labeled a bad movie, bad medicine, and bad PR, I’ve finally actually seen the finished product, such as it is. Of course, during the months between when Eric Merola first offered me an “opportunity” to appear in the sequel based on my intense criticism of Burzynski’s science, abuse of the clinical trials process, and human subjects research ethics during the last 18 months or so, there has been intense speculation about what this movie would contain, particularly given how Merola’s publicity campaign involved demonizing skeptics, now rechristened by Merola as “The Skeptics,” a shadowy cabal of people apparently dedicated (according to Merola) to protecting big pharma and making sure that patients with deadly cancers don’t have access to Burzynski’s magic peptides, presumably cackling all the way to the bank to cash those big pharma checks.
The movie, Burzynski: Cancer Is A Serious Business, Part 2, was released to online sources on Saturday and will be released on DVD on July 1. As much as I detest Eric Merola and don’t want him to profit from his deceptions, I also wanted to see what the finished product actually looked like. So I swallowed hard, paid, and watched. It was probably the worst $15 I ever spent, but at least it’s tax-deductible for my not-so-secret other blog, from which I do earn a small amount of money for my writing. Of course, from my perspective, actually seeing the movie is almost anticlimactic given that we’ve had detailed reports from screenings of the movie by skeptics (excuse me, Skeptics) who attended, replete with conspiracy mongering, repeating claims to the movie to an echo chamber, and even Fabio Lanzoni. However, there are things one can’t adequately evaluate using second hand reports. Moreover, it just so happens that tonight the BBC will be airing an episode of its long-running news series Panorama about Burzynski. The episode is entitled Cancer: Hope for Sale? Although I fear the producers falling into the trap of false balance, I’ve heard enough from my connections to suspect that Burzynski won’t be happy at all about the story. After all, his minions have been pre-emptively attacking Panorama since Burzynski patients have let it be known that they had been interviewed for the report. Now, if we “Skeptics” were the all-powerful, overarching, nefarious force that Burzynski’s acolytes paint us as, one might think that we had planned it this way, to have the BBC Panorama episode come out the Monday after the release of Eric Merola’s movie. I’ll let Eric Merola puzzle over that one. No doubt he’ll build another one of his—shall we say?—imaginative conspiracy theories over this.
So what about the movie itself? First, let me point out that, after having seen the movie (which I will henceforth call “Burzynski II”, to distinguish it from the first Burzynski movie, which I will call “Burzynski I”), there’s nothing I would change in my original discussion of it. Burzynski II really is just like Burzynski I, only more so. I refer you to the link for my discussion of many of the problems with the movie. Here I will concentrate mainly on issues that I haven’t discussed before, because actually seeing Burzynski II was a revelation. (Heh, I put that sentence there on purpose Eric Merola; quote mine it if you dare!) First, as a movie, Burzynski II is at least as bad as Burzynski I. Eric Merola is a crappy, crappy filmmaker. The narration is done by the same creepy-sounding narrator such that it sounds like a low bit rate MP3 (say, 32 kbps); certain medical terms are mispronounced; there are lots of errors; and Merola demonstrates the same tendency to switch back and forth between camera angles in which the subjects of his interviews are looking at the camera to angles where they are not. The effect, I’m guessing, was intended to be edgy. What it ended up being (to me, at least) was irritating as hell. The music and cheesy graphics are also much the same as they were in Burzynski I.
The other thing that I wasn’t prepared for was just how unrelenting Burzynski II was in its propaganda. Burzynski I was one-sided to the point of ridiculousness, but Burzynski II takes that ridiculousness to the next level, much as each sequel to the original Transformers or The Fast and the Furious movies tends to be bigger, louder, and dumber than its predecessor. This is not a good thing. In Burzynski II, I mentioned that the messages are:
     1.  Stanislaw Burzynski is a genius who invented “personalized gene targeted cancer therapy,” and is now being emulated by centers like M.D. Anderson, which are furiously trying to catch up.
     2.  Burzynski is a Brave Maverick Doctor who is curing patients that conventional science can’t cure, and it’s not his fault when he can’t.
     3.  Burzynski is a real scientist with tons of data supporting antineoplaston therapy who is being unjustly hounded by the FDA, the NCI, and big pharma to prevent him from bringing his cancer cure to market.
     4.  The Japanese are on the verge of publishing definitive clinical trial evidence that antineoplastons work!
     5.  Skeptics are evil meanies who cackle evilly as they terrorize cancer patients online and delight in crushing their hope.
Unfortunately, in Burzynski II the messages are even less subtle (if that were possible) than in Burzynski I. Whereas Burzynski I hit you over the head with its messages repeatedly if they were a series of 2x4s, in Burzynski II the 2x4s have bricks attached to their ends.
Burzynski II does have a slightly different structure than Burzynski I, however, although overall it’s very similar in many ways. Burzynski I spent the first 30 minutes or so discussing patient anecdotes to “prove antineoplastons work,” and then spent most of its last hour or so lambasting the FDA, the Texas Medical Board, and big pharma. Burzynski II, on the other hand, although it begins similarly with some text declaring just how awesome Burzynski is and how evil the FDA, the Texas Medical Board, and big pharma are, followed by a montage of news and TV segments extolling Burzynski and/or attacking his critics, is a bit more free-form, interspersing patient anecdotes with attacks on big pharma, plus a truly bizarre segment attacking “The Skeptics” near the end. I’ve already dealt with at least four of these anecdotes before, those of Laura Hymas (whose anecdote is the main one), Hannah Bradley (who gets surprisingly little screen time), Tori Moreno, and Amelia Saunders (whose anecdote is perhaps the most heart-wrenching if you know what happened—more on that later); so I won’t dwell on these anecdotes again here except for aspects that I haven’t discussed before that seeing the actual finished movie bears light on.
An ethical conundrum dealt with correctly
One of the things I wondered about last time was a segment in the movie in which Laura and her fiancé Ben Hymas, having decided to go to the Burzynski Clinic, met with Ms. Hymas’ NHS oncologist to try to find out if the NHS would continue to cover her MRI scans, blood tests, and other medical “necessities” once she returned home to the U.K. Ms. Hymas, as you might recall, is a young woman who developed a brain tumor, underwent conventional therapy that only had limited success in slowing the tumor, and ultimately ended up deciding to go to the Burzynski Clinic. It is revealed in the movie that Ben Hymas had decided to record the conversation with the oncologist, and Eric Merola decided to include the recording in his movie. The results are not exactly what Merola intended. Merola clearly intended it to be damning of the NHS; in reality what I saw was a clinician desperately trying to do the right thing and dissuade Laura from a course of action that he considered to have almost no likelihood of helping. For instance, when Ms. Hymas says that the oncologist (who is not named) would not treat her if she went to Burzynski, here’s what he said:
Oh, no, no, no, no, no. Let’s make it very clear. Dr. Burzynski is a person who provides “private care,” in a non-conventional way—that we do not quite understand, or would condone.
Later, he says:
It’s not just his antineoplaston approach, which is controversial to say the least. I’ve had patients there who got cocktails of medications that could have a rationale to work in brain tumor patients but have never been tried and tested in this excessive combination.
The oncologist tries to point out that Burzynski’s clinical trials are not supported by the NHS or his hospital and explains that Ms. Hymas can’t expect the NHS to pick up the tab for tests required by Burzynski for a clinical trial not sanctioned by the NHS. He goes on to explain how the trial is not ethically approved at any NHS hospital and that because he’s not convinced that this is a useful therapy he can’t treat her according to Burzynski’s protocol and that he can’t provide care to her as long as she is under Burzynski’s care.
And here’s where the FDA’s failure has put doctors like this one in a bad position. Ms. Hymas’ mother keeps harping on how if the FDA approved these trials they must be legitimate and can’t be unethical. You know and I know that that’s not necessarily true (and, in fact, I’ve recently learned a lot about how and why these trials were originally approved by the FDA despite the lack of adequate preclinical evidence, but that’s a topic for another post). Another doctor at the NHS also apparently did agree to such an arrangement, which also put this poor oncologist on the spot in talking with the Hymas. Still, in the end, this oncologist said point blank that he does not feel it would be right of him to take instructions or even advice from Burzynski for what is and is not required, although he did appear to indicate a receptiveness to ordering Laura’s scans.
I keep thinking of what I would do if I were in that oncologist’s shoes. I don’t know. I do find it despicable that Merola would use an apparently secret recording of a private conversation and put it in a public movie. This should serve as a warning to all cancer doctors: If you have a Burzynski patient, expect to be taped and conduct yourself as though your words could show up in the next Merola infomercial.
The patients again and an ethical conundrum dealt with incorrectly
To the old familiar anecdotes are added new ones. I’m going to start with the one that is both new to me and most horrifying to me as a cancer surgeon, even more so than the cases I’ve discussed before such as Amelia Saunders or Hannah Bradley. I’m referring to Chris Onuekwusi, a man who was diagnosed with stage I colon cancer. Yes, you read that right. I’m referring to a patient with a stage I colon cancer. You should know that stage I colorectal cancer is very, very treatable. Resecting the involved segment of the colon or rectum containing the cancer has a high probability of curing it. Assuming it really is stage I, chemotherapy might not even be needed. (We don’t know for sure that Onuekwusi’s cancer really was stage I, because often surgeons don’t know the full stage of colorectal cancer until after surgery.) Instead of undergoing straightforward surgery that we know to have a high probability of success (which, I’ll also point out, can be done these days through minimally invasive laparoscopic techniques), Onuekwusi balked, as described in more detail than in the movie in this article on the Burzynski Patient Group website. He had even gone for a second opinion at one of the leading cancer centers in the world, the University of Texas M.D. Anderson Cancer Center, where the surgeon told him the same thing. He needed surgery first.
So what did Burzynski recommend instead of surgery? He recommended a cocktail of three drugs given off-label: Zolinza, Xeloda, and Avastin. Zolinza is vorinostat, a histone deacetylase inhibitor; Xeloda is capecitabine, which is a prodrug for 5-fluorouracil (5-FU), a pyrimidine analog that inhibits the enzyme thymidylate synthetase and thereby inhibits DNA synthesis to toxic effect in rapidly dividing cells; and Avastin is bevacizumab, a humanized monoclonal antibody directed against vascular endothelial growth factor-A (VEGF-A). As I described in a previous post about Burzynski’s “personalized, gene-targeted cancer therapy,” apparently Burzynski sent Onuekwusi’s tumor to Caris for testing. Caris generated a report, as it always does, and Burzynski came up with a witches’ brew of new expensive targeted agents, all said to be “off-label.” Well, not exactly. One of these drugs is just an old chemotherapy drug in a new form. Xeloda is, in essence, 5-FU, a chemotherapeutic drug that has been used to treat colorectal cancer, both as adjuvant chemotherapy and first-line therapy for metastatic disease, for over 40 years. There’s nothing really “targeted” about the drug except that it inhibits an enzyme, the way that many drugs do and have been known to do for decades. The advantage of Xeloda is that it can be administered orally, which is a good thing. Similarly, Avastin, although relatively new, is also commonly used for colorectal cancer, albeit usually for metastatic disease and not as adjuvant chemotherapy. That leaves Zolinza, which is an HDAC inhibitor used to treat cutaneous T cell lymphoma. One wonders if Burzynski included a second HDAC inhibitor, his second favorite drug after antineoplastons, sodium phenylbutyrate.
So why was I so horrified by this anecdote compared to others? The reason is simple. Onuekwusi appears to have had a relatively easily curable cancer with standard surgery, and that surgery is usually not particularly morbid, given that the scans shown in the movie indicated that it was a right colon lesion, as opposed to a sigmoid or rectal lesion. It is, in my opinion, medical malpractice to treat such a patient first with chemotherapy (and yes, what Onuekwusi received was chemotherapy, as Xeloda is basically an oral form of one of the workhorses of chemotherapeutic drugs, 5-FU). We know that chemotherapy usually doesn’t do a lot of good as primary therapy of solid tumors like colorectal cancers, although as adjuvant therapy it is quite effective at decreasing the risk of recurrence after surgery. In contrast, we know that surgery is highly effective for stage I colorectal cancer. We even know that if this really were stage I colorectal cancer, Onuekwusi wouldn’t even have even needed chemotherapy! Surgery alone is the treatment of choice. So, by Merola’s own description, what Burzynski did was to administer a toxic form of treatment that was probably not needed (chemotherapy) using drugs that were not approved for that indication, and apparently didn’t insist that the patient needed surgery. Now, it’s possible that the combination of drugs did eliminate the tumor. It’s also possible that the tumor was very small and completely removed with colonoscopic biopsy, leaving an inflammatory reaction behind to be imaged on the PET-CT images shown in the movie, a reaction that subsided over three months. Either way, Onuekwusi (and Burzynski) might have gotten lucky. But they both took an enormous gamble that could well have cost Onuekwusi his life. In my opinion, Burzynski deserves to have his medical license taken away on the basis of how he treated Chris Onuekwusi alone, not even considering all the other dubious things he’s done.
The rest of the “new” cases (i.e., cases I hadn’t been familiar with) followed a similar pattern to cases I’ve discussed before, wherein it’s impossible to tell whether the patient’s good fortune is due to Burzynski’s treatment or not. That includes the patients with brainstem gliomas. We are told repeatedly by the narrator that spontaneous remission of a brainstem glioma has never been documented in the medical literature, despite an exhaustive search. All I can say is that Merola and Burzynski must not have searched very hard, because I quickly found a few, for instance, of pontine glioma (and two more) and a brainstem cavernoma. Remember Tori Moreno? She is a teenager who was diagnosed with a brainstem glioma as a neonate who features prominently in this film as a Burzynski success story. Despite what Tori’s father and Eric Merola claim, it’s quite possible that she underwent a spontaneous remission. True, such remissions are rare, but it’s not correct to say that they never happen. Truly, Merola’s “exhaustive” research skills need some upgrading. It took me two minutes to find those articles. No, I’m not saying that that’s definitely what happened; I’m merely pointing out that it could have happened, which is why clinical trials are so important.
Among the “new” patients is also a woman named Patricia Clarkson with multiple myeloma, who is filmed with her husband in front of large windows with the sun shining in. Yes, they are mostly backlit; one would think that Merola could have found a better, less distracting room to interview them in. Be that as it may, the segment is introduced with in essence a rant about the FDA requiring that patient fail standard therapy before they can have antineoplastons. That is, of course, a standard requirement for new cancer drugs because on an ethical basis doctors can’t administer experimental therapy whose efficacy is unknown if there are treatments whose efficacy is known. Another common design for a clinical trial is to compare standard of care treatment against standard of care treatment plus the experimental therapy.
This segment is introduced by a black screen of white text that says:
Even if the FDA’s prerequisite if fulfilled, the FDA holds full dictatorial rights to refuse patients’ access to antineoplastons if they choose.
Merola says that as if it were a bad thing. It’s a rule designed to protect patients. Merola makes it sound as though this is an arbitrary rule designed solely to keep patients from getting antineoplastons. Mr. Clarkson, of course, rails against the FDA for making it so difficult for his wife to be treated with antineoplastons. What is not shown is that Burzynski did treat her with sodium phenylbutyrate, the orphan drug that is a prodrug for one antineoplaston. As is the case with nearly every Burzynski testimonial, it’s impossible to tell whether Burzynski’s treatment has done any good due to confounding factors. In Clarkson’s case, multiple myeloma tends to be a disease that has a highly variable clinical course and can take years before it can kill, sometimes several years. In other words, its survival curve tends to have a long tail. Mrs. Clarkson was only diagnosed in 2011 It’s also a drug that almost always seems to be included with Burzynski’s “personalized gene-targeted cancer therapy regimens,” almost no matter what.
Seeing is believing?
I can’t do a review of this movie without revisiting stories we’ve seen before. Even though I’ve extensively covered the cases of Laura Hymas and Amelia Saunders before, to me seeing is knowing just how intellectually dishonest Eric Merola is. For instance, seeing the Saunders family, rather than just hearing about them from second-hand reports, was truly heart wrenching. They are such a caring family who were so desperate to do anything for their daughter. Worse, however, is the way that Merola makes it sound as though the reason that Amelia Saunders ultimately did not survive her tumor is because her parents decided to take her off the antineoplaston therapy. I’ve discussed this issue before. Briefly, in November 2012 it was noted that Amelia’s tumor had started to develop cystic regions. Burzynski told the Saunders that this was evidence that the tumor was dying. As I pointed out at the time, this was almost certainly nothing more than the tumor outgrowing its blood supply and developing necrosis in the center, not evidence of an antitumor effect. Sadly, two weeks later, pediatric oncologists at the Great Ormond Street Hospital told the Saunders the same thing and that they thought Amelia was in the end stage of her disease. It was at that point that the Saunders made the completely reasonable decision to take Amelia off the antineoplastons.
This is how Merola describes it:
Two months after this interview, Amelia’s brain tumor began to swell and fill with fluid. There was confusion and disagreement between their local radiologists and the radiologists in Houston about why this was happening—so her parents decided to discontinue antineoplaston therapy. Amelia passed away with her parents at her side on January 6, 2013.
Merola then opines:
Brainstem glioma is as rare as it is deadly. Approximately 500 children a year in the United States and 40 a year in England are diagnosed with it. An exhaustive search spanning 27 years of all available medical literature worldwide reveals the absence of any patient ever being cured or living five years after diagnosis.
As I said before, Merola’s research skills leave much to be desired. True, five year survival is very uncommon, but not so uncommon that it can’t be studied. Similarly, as I pointed out before, it’s not true that spontaneous remission of brainstem tumors in children “never happens.” It’s rare, but it does happen.
Seeing The Skeptics
I’ve already extensively discussed Merola’s attacks on skeptics before, in particular his misinformation and paranoid conspiracy mongering. He goes out of his way to portray us as either incredibly misguided (“they mean good but do evil!”), hopelessly in the pay of big pharma, or so evil that we, as I put it before, cackle with glee as we condemn cancer patients to certain death by taking their antineoplastons away. It’s so heavy handed that even Leni Reifenstahl would turn away in embarrassment if she were alive today and subjected to a viewing. (Some of that would also be due to her recognition of Eric Merola as a talentless hack when it comes to being a filmmaker.)
Particularly seemingly damning are a series of Tweets flashed on the screen saying things like the Hope for Laura fund (the fund set up by Laura Hymas to pay for her treatment at the Burzynski Clinic) “appears to be just a money laundry for a lying quack fraud” and “when Laura dies #Burzynski will just move on to his next mark if she doesn’t run out of money first.” I think I know whose Tweets these were, and all I can say to that person is this: Zip it. In fact, if I’m correct about whose Tweets these are I think I have already done so on Twitter when I’ve seen this person getting too close to attacking cancer patients. Still, as utterly insensitive and “dickish” as those Tweets were, they do not represent the majority of skeptics, but rather a few jerks. However, we as skeptics need to remember that a few jerks perceived (or painted) as attacking cancer patients can do immeasurable damage to the cause of science-based medicine. So if you’re one of those skeptics making comments like that, knock it off. If I see you doing it, I will call you out publicly.
In contrast, I find it very hard to believe that any but the most deluded hard-core Burzynski believers will find the segment in which Bob Blaskiewicz, creator of The Other Burzynski Patient Group and the force behind the idea of promoting donations to a real cancer charity and challenging Burzynski to match it, anything but completely risible. His voice is electronically altered to make it sound ominous and evil; his face is blurred out, and the Virtual Skeptics podcast in which he discussed Burzynski is represented as a “Skeptics’ teleconference,” in which it is implied that Merola somehow obtained a secret discussion. It’s all very silly. I’d say it’s almost Monty Pythonesque, except that Monty Python were brilliant and produced such effects on purpose. Merola is a hack and is only funny by accident because he has no filters that tell him when he’s going way over the top.
So is Merola’s treatment of yours truly. There’s a hilarious picture of my SBM page with my picture partially blurred out, onto which Burzynski places marks for emphasis that I’ve been funded by the DoD (past tense, Eric, not the present tense that you used), the NIH, ASCO, and other organizations (as if getting peer-reviewed research funding were a bad thing). Then there’s the bit about my former funding, a small grant that’s been expired nearly a year now from Bayer Healthcare. Then, of course, there’s my not-so-super-secret other blog, which—gasp!—accepts advertisements from pharmaceutical companies. I knew about all of that before, but actually seeing it onscreen was rather bizarre. I can only wonder what it would have been like to be sitting at a screening of this movie and seeing it.
Then, there was the kicker.
Eric Merola and Laura Hymas’ fiancé Ben Hymas called me a liar. Regarding this particular blog post, they claim that I intentionally linked to an older blog post describing Ms. Hymas’ MRI results and ignored a more recent MRI. Their claim is patently untrue. Note the date of the post in question: November 30, 2011 at 1 AM. (Yes, the post was written on November 29 and set to go live at 1 AM the next day.) Now note when Ms. Hymas underwent that other MRI scan: November 29, 2011. Finally, note when Ms. Hymas posted the results of that scan? November 30, 2011, after the blog post in question went live. I suppose the accusation is that I am not psychic and able to have anticipated that there would be an MRI scan. Moreover, I agree with a commenter who showed up on January 8 and pointed out:
He never claimed they were the November results. He was analyzing the October vs. September results. In fact, the October vs. September results are more significant (in terms of size) than the November vs. October results. Laura is misrepresenting the report.
Here is a breakdown of the sizes of the tumor (in cm or cm2:
Sept = 2.0×2.5 = 5.00
Oct = 1.8×2.1 = 3.78
Nov = 1.7×1.9 = 3.23
Now, the percent reduction in size:
Sept->Oct = (5.00-3.78)/5.00 = 24.4%
Oct->Nov = (3.78-3.23)/3.78 = 14.6%
Sept->Nov = (5.00-3.23)/5.00 = 35.4%
In other words, the 36% reduction was over 12 weeks, not 6 as claimed, and about 2/3rds of that reduction occurred between the two scans ORAC analyzed. Interesting that Laura never posted the MRI from the November scan for comparison, nor any of the earlier scans from when she was undergoing conventional treatment. Also interesting that she claims she was told that her radiotherapy couldn’t have any effect because she only completed 7 of 44 doses of chemotherapy.
My post from November 30, 2011 was correct as written at the time it was written. Ben Hymas is quite mistaken in saying about me, “He’s lying to them.” Moreover, if I had screwed up, I would have admitted it. Indeed, part of the reason I looked into this so closely was because I wondered if somehow Merola had actually found a mistake I had made. You know the saying about the proverbial blind squirrel occasionally managing to find a nut? It’s possible, albeit unlikely, and in fact there was no mistake. Well, that’s not entirely true. I did misspell Ms. Hymas’ name; it’s a mistake I went back and corrected when I discovered it. (You’ll have to forgive me, as it was the first time I had read about the Hymas case.) In any case, the only reason I didn’t post an update was because the commenters had done such a good job addressing the criticisms that showed up a couple of days later. Whether you think that I should have posted an update or not, one can’t help but note that nowhere does Eric Merola mention that I wrote a much more recent analysis of Ms. Hymas’ clinical situation in February 2013 that incorporates all updates. It also pains me that Mr. Hymas would take Merola’s explanation at face value. I feel nothing but sympathy for relatives and friends of cancer patients, and I want Ms. Hymas to do well, but it hurts to hear Ben Hymas repeat Eric Merola’s demonstrably false accusation against me.
In case either Hymas sees this post, let me briefly repeat my most recent assessment of Ms. Hymas’ history as described online, my basic conclusion about Ms. Hymas’ case in February was this:
Laura Hymas is different in that she provides somewhat more suggestive evidence for a possible antitumor effect from antineoplastons, given the longer period of time since she finished her radiation therapy and since her still being in complete remission five and a half months after her first scan showing no residual tumor. However, her case is by no means the slam-dunk evidence that Burzynski supporters claim it to be (or, for that matter, that Merola touts it as in his upcoming movie), given that it has been less than six months since confirmation of a complete response. Moreover, given that HDAC inhibitors do seem to have some efficacy against glioblastoma, it is not unreasonable to expect that antineoplastons might actually have had activity in Laura’s case. Making claims, as Burzynski does, however, that his antineoplaston therapy is more efficacious than conventional therapy is unwarranted based on a single patient. Conventional therapy can produce durable remissions and complete responses, too, and, although they are still rare, they are becoming more common. That’s why legitimate randomized clinical trials are needed to determine if PB/antineoplastons have antitumor effects in humans; which tumors are sensitive; if there are any biomarkers of sensitivity; and to separate the signal from the noise. Anecdotes like those of Hannah Bradley and Laura Hymas can be suggestive, but in and of themselves prove nothing.
There is nothing in Merola’s deceptive movie to change my assessment of what happened in the case of Laura Hymas’ brain tumor or my opinion of Eric Merola. If anything, having seen Burzynski II, my opinion of Merola has plummeted even further, something I hadn’t thought possible.
Evidence, evidence, wherefore art thou, evidence?
Another section of the movie that I was highly interested in, having discussed it before twice, was Dr. Hideaki Tsuda’s antineoplaston research in Japan, which Keir Liddle characterized as underwhelming, and rightly so. This segment came near the end of the movie, right after the segment on The Skeptics and obviously meant as a retort to Burzynski critics.
What I learned about the trial was this. The trial was of a design like what I mentioned above, chemotherapy alone versus chemotherapy plus antineoplastons. Specifically, the trial tested 5-FU infused directly into the hepatic artery for liver metastases versus 5-FU plus antineoplaston A10 and AS2.1. A10 was administered intravenously for one week, and AS2.1 was given in the form of capsules for at least one year. Dr. Tsuda takes pains to insist that he got no advice or assistance from Burzynski, but that protocol is very specific. Why antineoplastons A10 and A2.1? Why A10 for only one week? Why A2.1 for a year? I also note that this is a rather old technique. Back in the 1990s, intra-arterial chemotherapy for liver metastases was all the rage, but these days, because of more aggressive resection of liver metastases and newer, more effective chemotherapy regimens for metastatic colorectal cancer, intra-arterial chemotherapy is seldom used anymore, much less intra-arterial 5-FU. That’s not even considering the technical complexity of placing the intra-arterial infusion pump and the potential complications from having a catheter in the hepatic artery. Dr. Tsuda is behind the times. Indeed, one notes that the CT scans shown from Dr. Tsuda’s group purporting to demonstrate responses to his combined regimen all date back to 1999, which makes me wonder just when this trial was done and, if it was done so long ago, why it hasn’t been published already.
As for the trial, were 65 patients, 33 in the control group and 32 in the antineoplaston group. Dr. Tsuda reported in the movie that the median survival for the control group was 36 months (which is actually rather long for liver metastases treated with intra-arterial 5-FU alone) and that the median survival for the 5-FU plus antineoplaston group was 70 months. Again, all I can do is to emphasize the usual things. This study is not published in peer-reviewed literature, and it was, in my estimation, highly irresponsible of Dr. Tsuda to promote it in a propaganda film before he actually published the results. We have no way of knowing whether the two groups were well-matched or if there were other methodological problems with the study. Let’s just put it this way. It’s way premature of Dr. Tsuda to proclaim that it’s “obviously not anecdotal any more.” Publish first, and let the scientific community be the judge of that.
There was also another part that makes me wonder whether this study will ever be published. Right after Dr. Tsuda proclaims antineoplastons not to be anecdotal any more, we’re treated to this quote from him:
We can’t go any further with these clinical trials allowing antineoplastons to gain market approval exclusively for the Japanese people—due to the Unites States FDA and the power they have over the world market.
The FDA would retaliate against any Japanese pharmaceutical company who would try to get antineoplastons approved in Japan by no longer approving their other drugs for the market in the USA.
It’s the perfect conspiracy theory. Dr. Tsuda claims to have data from a randomized clinical trial that’s good enough to use to gain approval for antineoplastons from Japan’s equivalent of the FDA, but he says he can’t because the FDA would retaliate against Japanese pharmaceutical companies. As I said, one wonders whether Dr. Tsuda will ever publish the results of his trial.
That leaves us with John James, who is listed as a research scientist with Targacept Pharmaceuticals, ranting about how cancer is profitable, how pharmaceutical companies have no incentive to find cures for cancers, instead preferring chronically administered drugs, and telling the sheeple (OK, he doesn’t actually use that word, but the meaning is clear) to “wake up.” What’s not pointed out is that Dr. James no longer works for Targacept and instead has started working for Healing Seekers, a group that does expeditions to remote areas of the world looking for “natural” cures. In fact, he appears to have left Targacept in October 2012, which makes me wonder whether if his participation in this movie had anything to do with it, as the timing fits. Or perhaps he was just a victim of the wave of layoffs that hit in October in the wake of the failure of Targacept’s two ADHD drugs in recent clinical trials. After a similar round of layoffs earlier in 2012, perhaps James saw the writing on the wall.
No, none of it is particularly convincing if you know anything about cancer research. I could change my mind if Dr. Tsuda actually published his results and it turns out that his trial was very well designed, but from seeing him describe them in a propaganda movie like this? Not so much.
In the end, if Burzynski had the evidence, he would have very likely published it by now. Through other skeptics who attended a screening of Burzynski II in the San Francisco area, I’ve learned that Ric Schiff, whom we’ve met before both here and elsewhere and who is now, according to reports I’ve been getting, really peeved that I questioned his claim that he is an “expert” in detecting medical fraud when as a cop he views himself as a “fraud expert,” is claiming that all the phase II studies recently wrapped up and are being prepared for publication. I have my doubts about that, but let’s assume it’s true for the moment. If that’s the case, then I submit that Merola should have waited until after some of those complete phase II have been published in the peer-reviewed literature to release his movie. Then his trumpeting of Burzynski’s “triumph” over the FDA, the Texas Medical Board, big pharma, and The Skeptics might have been somewhat more convincing. Data talks. BS walks. And there’s no doubt that Burzynski II is pure BS.
Now, all I have to do for now is to wait until I have access to the episode of Panorama airing tonight in the U.K.

BBC Panorama investigates Stanislaw Burzynski
David GorskionJune 10, 2013
Link
Last week, I reviewed a long-expected (and, to some extent, long-dreaded) documentary by Eric Merola, a filmmaker whose talent is inversely proportional to his yen for conspiracy, pseudoscience, and quackery. Through a quirk of fate that couldn’t have worked out better if I had planned it myself, a long-expected investigation of the Burzynski Clinic by the BBC aired on its venerable news program Panorama last Monday. It was entitled, appropriately enough, Cancer: Hope for Sale? Ever since learning that the BBC was working on this back in January or February, skeptics have been looking forward to it with a mixture of anticipation and dread, anticipation because we expected that the Panorama crew would “get it” (in the interests of full disclosure, I will mention that I was interviewed over the phone by a Panorama producer and exchanged e-mails to answer questions and suggestions), but a bit of dread because we feared the bane of all news reporting on issues of science and medicine: false balance.
So now that the report was finally aired, how was it? You can either watch it on iPlayer (if you’re in the UK) or on YouTube (if you’re not, assuming it’s still there):
Patients versus false balance, with regulatory issues missing
Although it’s better than the vast majority of reports on Burzynski that I’ve seen, I’m afraid it still ended up being a mixed bag. I’ll start with my general impression and then discuss some specifics that particularly stood out to me. Fortunately, there were parts of the report that hit home, and hit home hard. Unfortunately, every time I thought that Panorama was going in for the kill, the reporter (Richard Bilton) all too often seemed to back off. Perhaps it was the editing. From my interactions with a producer and reports I got from other skeptics who had similarly been contacted by the BBC, the team working on the report seemed to “get it,” which is why I can’t help but wonder if something got watered down in the final edit. Or perhaps it was the story structure imposed on this report, which was simultaneously a “he said, she said” portrait of a patient who believes in Burzynski and thinks he saved her, two Burzynski patients who died but whose families still express little or no regret over having decided to make the trip to Houston, and one patient who thinks Burzynski ripped him off. Interspersed with these stories was an overarching “where’s Waldo?” meta-story of Bilton trying to score an interview with the elusive subject of his report (whom he, predictably, gets to interview near the end of the report), all peppered with brief interviews with experts whose comments are generally critical but often softened with caveats that turn some of the criticisms into mush.
From my perspective, what is simultaneously the greatest strength and greatest weakness of this report is its relentless focus on patients. Specifically, the stories of four patients are covered: Hannah Bradley, Luna Petagine, Amelia Saunders, and Wayne Merritt. The first three patients were U.K. patients who travelled to Houston to be treated by Burzynski; Merritt lives in Georgia. This focus is a strength, because it provides an emotional hook upon which viewers can hang their attention, and, of course, the reason Stanislaw Burzynski’s activities are so harmful. However, this relentless focus is simultaneously a near-fatal weakness in that the obsessive focus on the patients seems to prevent the report from delving into a lot of issues that are also very important in any discussion of Stanislaw Burzynski. For instance, there was little or no mention of the recent FDA investigation of the Burzynski Clinic and the partial clinical hold placed on antineoplaston usage, zero mention of how Burzynski recently managed to beat an effort by the Texas Medical Board to strip him of his medical license by throwing his employed doctors under the bus, and only the most superficial treatment of how in general it is considered unethical to demand payment from patients to participate in clinical trials. Nor is there any mention of how the Burzynski Clinic waged a campaign of harassment against bloggers who criticized Burzynski back in 2011. Indeed, one of the victims of that harassment, Rhys Morgan, was interviewed by the Panorama crew, but he was informed that his interview was cut from the final version because it didn’t fit the narrative. There is even at least one howler in which Bilton intones that “nobody knows exactly what’s in his treatment,” when in fact it is fairly well known what antineoplastons are and has been for at least 25 years. All you have to do is to read Saul Green’s reports on Quackwatch and in The Cancer Letter from the 1990s.
Unfortunately, the story repeatedly falls prey to that weakness of first following this patient or patient’s family, then following that patient or patient’s family. Admittedly, the overall impression of Burzynski left behind is not favorable, but we don’t get a good overview of what he is doing and why it is so wrong, just what he did with respect to these four patients plus a little background. Of the patients, Luna Petagine’s and Amelia Saunders’ stories are the most heart-wrenching. Indeed, Luna’s story was featured last year on a BBC documentary about the Great Ormond Street Hospital, and some excerpts from this documentary are shown to introduce Luna and her story. One of them reminded me very much of the conversation with her NHS oncologist that Laura Hymas recorded and allowed Eric Merola to include in his propaganda piece, except that in video it is so much more intense. In this scene, the oncologist tries to point out to Ms. Petagine that he doesn’t know what Burzynski is doing or how to take care of her daughter when she returns. I really felt for this oncologist, too. However, this segment on Luna also highlights another irritating aspect of this report, which hit me over the head in the very next scene, when Ms. Petagine in essence lambastes the NHS oncologists because they couldn’t save her daughter’s life, saying, “The NHS told me Luna’s going to die. This man is telling me that he thinks he can cure her.”
The report includes interviews with experts like Professor Richard Grundy of Nottingham Children’s Hospital. Grundy points out that Burzynski has not published the complete results of any of his phase II clinical trials. Right after him is Professor Peter Johnson of Cancer Research U.K. discussing the importance of reproduction of results. Actually, this is one of the stronger segments in that it points out the importance of publishing scientific results in the medical literature and how that is the key to convincing other scientists of the validity of your work. That was very clear and concise. It’s also, unfortunately, simultaneously one of the weaker segments in that it ends up sounding as though there’s just no evidence and we don’t know about antineoplastons. In other words, it sounds as though they very well could work, if only the clinical trials were done. It’s a theme that is repeated throughout the report but that ignores the astounding level of sheer deception that goes on at the Burzynski Clinic, the allegations of overfilling, and how Burzynski has abused the clinical trial process to keep treating patients with antineoplastons without actually having to do the science that any other doctor would be required to do to validate a new treatment. True, not all the doctors who question Burzynski’s treatment are that wishy-washy. Dr. Elloise Garside, a research scientist, echoes a lot of the questions I have, such as why Burzynski never explains which genes are targeted by antineoplastons, what the preclinical evidence supporting their efficacy are, or what the scientific rationale is to expect that they might have antitumor activity. (Yes, we’re talking prior plausibility, baby!) This explanation was provided right after Bilton and she sat through a screening of the first Burzynski movie, which was a fairly nice touch.
None of this is to say that there weren’t aspects of the report that were very powerful and spot on. I just wish there were more of them or that more time had been allotted for them. For instance, there was the discussion of how Burzynski attracts new patients, which led to a trip to a screening of Eric Merola’s first foray into medical propaganda; i.e., his first movie in 2010 extolling the glory that to him is Stanislaw Burzynski. There’s even a sarcastic little rejoinder about how Burzynski takes his message to the movies rather than publishing in the peer-reviewed scientific literature. Particularly amusing is how Panorama includes a scene from the first Burzynski movie in which Burzynski lambastes the panel evaluating him, saying how he will get his antineoplastons approved all over the world and bring them to justice, while promising the hundreds of patients who died because of them will come back to haunt them until their deaths.
Yeah, Stan’s as warm and fuzzy as ever.
Panorama also confirms what skeptics have suspected for a long time now, namely that the Burzynski movie has been very, very effective in attracting patients to the Burzynski Clinic. During an interview with Hannah Bradley, whom we’ve met before. There’s no real evidence that Burzynski’s treatment is responsible for Bradley’s good fortune in having lived more than two years with her cancer thus far, but she attributes her survival to him. Unfortunately, she is also incorrect when she says that there’s no evidence that antineoplastons work or that they don’t work. The preponderance of evidence supports the contention that they don’t work, but there is uncertainty, which Burzynski exploits to the max. In any case, as lovely a young woman as I think Ms. Bradley is, the whole segment is painful to watch, as she asks ignorant questions like, “What says radiotherapy works?” When the reporter points out that the peer-reviewed literature says it works, Ms. Bradley says, “But not for everyone,” which is technically true but ignores that there isn’t any evidence comparable to that for radiotherapy that antineoplastons work for anyone. As much as I like Hannah Bradley and her boyfriend Pete Cohen and hope Hannah continues to do well, I can’t let such statements go unchallenged.
Ironically, I can’t help but note that Pete Cohen also showed up on the radio to be interviewed by Victoria Derbyshire on BBC Radio 5 Live (at around the 1:44 mark). I can’t help but mention it here, because Mr. Cohen gives away several interesting tidbits. For instance, it’s very obvious that the Burzynski Clinic is in communication with him, because Mr. Cohen claims that Burzynski is preparing manuscripts for publication and that he has even submitted several to “top journals.” He even claims that Burzynski has asked that they be independently reviewed. In doing so, Cohen echoes the claims in some of the Q&A’s after screenings of Eric Merola’s most recent movie that Burzynski’s papers have been rejected without being sent out for peer review. It’s also not exactly clear what Cohen means by that. Studies submitted to journals won’t be published without going out for peer-review. Maybe he’s referring to some of the papers we’ve heard about from Mr. Cohen and others that were editorially rejected and not even sent out for peer review because the editor either didn’t think them appropriate or didn’t want to waste the reviewers’ time. Mr. Cohen also repeatedly says how he has approached experts in brain cancer and begged them to come out to the Burzynski Clinic to “see for themselves.” Seemingly, he can’t understand that it is not necessary for a scientist or doctor to meet Dr. Burzynski or visit his clinic. It means nothing. Nada. Zero. Zip. In science, all that matters is what you publish, and Burzynski hasn’t published anything other than case reports, tiny case series, and unconvincing studies, mostly (at least over the last decade or so) in crappy journals not even indexed on PubMed.
Without a doubt, the most effective part of the story is the segment in which Dr. Jeanine Graf of the Texas Children’s Hospital is introduced. Dr. Graf is the director of the pediatric intensive care unit there and has taken care of lots of Burzynski patients, as her hospital is “just down the road” from the Burzynski Clinic and these unfortunate children are brought to her hospital when they decompensate. Indeed, coupled with this segment is an interlude where Luna Petagine’s mother complains that the staff there know and recognize Burzynski patients (and, she notes, hate the Burzynski Clinic). Particularly damning is how Ms. Petagine said that the Texas Children’s Hospital Staff “were always cleaning up Burzynski’s messes.” Luna was brought to the Texas Children’s Hospital during her time in Houston, and the staff there recognized right away that she was a Burzynski patient because they had seen so many similar patients suffering the same complications before. It was also clear how much contempt the staff there had for the Burzynski Clinic. If there’s one thing Panorama did right in this report, it’s showing how seeing so many already-dying children show up in their ICU because of hypernatremia due to antineoplaston therapy will do that. Perhaps the most devastating part of this segment was seeing Dr. Graf stating, point blank, that she’s never seen a Burzynski patient survive. True, she does point out that patients don’t come to her until they are in extremis, but the fact remains that she’s never seen any of them live.
It’s a sad and devastating segment.
Unfortunately, during the most critical part of the story of all, in which Bilton finally “finds Waldo” and is granted an audience with Stanislaw Burzynski, Bilton came across (to me, at least) as unprepared. Fortunately for Bilton, Burzynski was, as is so often the case, his own worst enemy, smirking and behaving in his usual arrogant, dismissive manner to any sort of challenge. (You can see a sample of it here, towards the end of the promo.) If Burzynski were a bit less full of himself and the greatness that he thinks he possesses, he could have wiped the floor with Bilton. As it is, the interview was pretty much a draw. Burzynski claims that antineoplastons can cure cancer, but not for everyone. Burzynski smirks when asked how many patients he’s treated and how many have survived, dodging the question by saying that the FDA won’t let him until he’s published his results. Bilton tells him that’s not true; the FDA has told him that Burzynski can tell him as long as he doesn’t promote antineoplastons. Burzynski asks Bilton why he doesn’t have a letter from the FDA. Burzynski dismisses Bilton with retorts like:
You look like a bright man but you’re asking me the same question again and again. Are you catching Alzheimer’s disease or what?
As I said, Burzynski’s arrogance, dismissiveness, and condescension make him his own worst enemy. Bilton was very, very lucky.
Burzynski also pulls out the old trope that, the FDA wouldn’t have let him use antineoplastons for 20 years in clinical trials if they weren’t safe and potentially effective, that the FDA wouldn’t let him “sell hope without evidence.” (Those of us following Burzynski for a while know, unfortunately, that that isn’t necessarily true.) Burzynski then promises that antineoplastons will be approved “soon” (they almost certainly won’t), after which he goes on to repeat the same refrain he’s been repeating for the last decade or so about how he’s on the verge of publishing all the results that will convince everyone. “Just you wait,” Burzynski is saying, in effect, “I’ll show them. I’ll show them all!”
One notes that we’re still waiting.
Ultimately, the Burzynski Clinic did release some results, stating that 776 patients with brain tumors were treated in trials and that 15.5% have survived five years. Of course, this is an utterly meaningless factoid (if factual it even is), because we don’t know what kinds of tumors, what grades, how they were treated beforehand, or any other confounding factors. Burzynski needs to publish, but I highly doubt that he will, at least not in a form that is informative to real oncologists.
Overall, the producers of Panorama did a decent, but flawed job of taking on Burzynski. Part of the problem might have been that a half hour is just too short. It’s really difficult to explain 36 years of history and the ins and outs of Burzynski’s battles with the law and patients in just a half hour; so apparently Panorama didn’t even try. That left it asking the question at the beginning of how Burzynski has gotten away with this for so long but not really even trying to give an answer at the end. It also might be that expectations were too high in the skeptic community, myself included. While I can understand the decision to concentrate on patients as the center of the story, the problem with that decision is that it’s a well-trod path that crowds out too many other important issues that ended up getting short (or, far more commonly, no) shrift in this Panorama episode. In the end, Panorama played it safe, and its report ended up being fairly unoriginal and guaranteed not to be the definitive look at Burzynski. It’s a very good thing that Panorama decided to shine a light into the recesses of the Burzynski Clinic, but at best it’s a first, flawed step. As good as much of this episode is, some of it is not, and I fear that an opportunity has been lost.
Stanislaw Burzynski against his own SEC filings
A lot of things happened last week with respect to Stanislaw Burzynski. In addition to Eric Merola releasing his documentary and Panorama finally airing its report, it was pointed out to me by a number of readers that there was new information to be had in Burzynski’s most recent SEC filings for the Burzynski Research Institute. The reason this is important is that it provides us with information against which we can compare Burzynski’s claims in both Merola’s movie and the Panorama report. Part of what inspired me to look into this was Josephine Jones openly asking whether Burzynski lied to the BBC. Regular followers of the Burzynski saga will remember that in January the FDA showed up at Burzynski’s operations to investigate. As Merola likes to harp on, FDA investigators stayed until March. Currently we are awaiting the FDA’s decision, which is usually posted to the FDA website in the form of a formal letter. In any case, the reason this is relevant is because the FDA put a clinical hold on antineoplastons and barred the enrollment of any new patients in any of Burzynski’s protocols. Moreover, in response to a warning letter from the FDA last fall about promoting an unapproved drug, in January the Burzynski Clinic removed all references to antineoplaston therapy on its website, which is rather like Major League Baseball removing all references to, well, baseball on its website.
To recap, we know that last year a child suffered a severe adverse reaction to antineoplaston therapy, which led to the FDA putting a clinical hold on antineoplastons for children. Then, in January apparently, the clinical hold was placed on antineoplastons for adults as well, although apparently patients already receiving them could continue to do so. Actually, I wondered about that when I saw a rather fascinating part of the Panorama report, namely a tour of Burzynski’s manufacturing facility, which, we are told, can crank out 300 L of antineoplaston solution per day.
Which brings us to the Burzynski Research Institute SEC report, something that Josephine Jones touches on as well. Throughout Eric Merola’s infomercial for Burzynski and the BBC Panorama report, we are told by Burzynski, his acolytes, and his shills that antineoplastons will be approved by the FDA “soon,” that he’s been doing the trials to gain FDA approval over the last 15 or 20 years, and, oh, by the way, not to worry. We have been promised repeatedly that all those phase II clinical trials that Burzynski registered will similarly be published “soon.” Even Pete Cohen, Hannah Bradley’s partner, showed up on BBC Radio 5 promising that Burzynski is furiously submitting manuscripts for publication. But what’s really happening?
Josephine Jones points us to this recent SEC report for the Burzynski Research Institute for the fiscal year ending February 28, suggesting that we read the section entitled Partial Clinical Hold on Phase II and Phase III Clinical Trials. So I did. Now I’m not a businessman, and I don’t understand anything but the very basics of business. A lot of these SEC reports might as well be Greek to me, but I do know cancer science. I also know what Burzynski and his acolytes have been saying, one of which is that the phase III trial will probably never be done because it’s “too expensive.” Yet in the report, we read:
On February 23, 2010, the Company entered into an agreement with Cycle Solutions, Inc., dba ResearchPoint (“Research Point”) to initiate and manage a pivotal Phase III clinical trial of combination Antineoplastons A10 and AS2-1 plus radiation therapy (RT) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma. Research Point has secured interest and commitments from a number of sites selected. Upon completion of this assessment, a randomized, international Phase III study will commence. The study’s objective is to compare overall survival of children with newly-diagnosed, diffuse, intrinsic brainstem glioma (DBSG) who receive combination Antineoplastons A10 and AS2-1 plus RT versus RT alone.
Three years should be plenty of time to line up clinical sites for a phase III trial. Of course, given that after three years the clinical trial hasn’t been opened, more than likely no reputable institution wants to partner with the Burzynski Research Institute, and ResearchPoint collected its checks. Then came the partial clinical hold, which affected this phase III trial as well as all the phase II trials, and, fortunately for patients, Burzynski’s antineoplaston operation is shut down. Revealed in the SEC report, of all places, is why.
It’s a long excerpt, but I think it’s important. There’s a lot of legalese and FDA bureau-speak, but the meaning should be fairly clear to a layperson:
In a letter dated June 25, 2012, the Company informed the FDA of a serious adverse event which may have been related to the administration of Antineoplastons. On July 30, 2012, the FDA placed a partial clinical hold for enrollment of new pediatric patients under single patient protocols or in any of the active Phase II or Phase III studies under IND 43,742. The FDA imposed this partial clinical hold because, according to the FDA, insufficient information had been submitted by the Company to allow the FDA to determine whether the potential patient benefit justifies the potential risks of treatment use, and that the potential risks are not unreasonable in the context of the disease or condition to be treated. The FDA cited 21 C.F.R. § 312.42(b)(2)(i), 21 C.F.R. § 312.42(b)(1(iv), and 21 C.F.R. § 312.42(b)(3)(i), as grounds for imposition of a clinical hold; and 21 C.F.R. § 312.305(a)(2), a criteria for expanded access use. The FDA advised the Company that until it resolved the matter to FDA’s satisfaction, the Company could not enroll new pediatric patients in any protocol under such IND. The Company later notified the FDA in a September 24, 2012 letter that it was closing pediatric protocol BT-10 (under IND 43,742) for enrollment effective September 25, 2012, and that it would also terminate the protocol once all active patients had completed the study.
In other words, no more antineoplastons for children, not now, and, hopefully, not ever. Burzynski can continue to treat children on his protocols who had already started treatment, but that’s it. This is very good news. After all, the Burzynski Research Institute is shutting down the pediatric protocol.
This ultimately led to the partial clinical hold being extended to adults:
In a teleconference on January 9, 2013 between the FDA and the Company, followed by a letter of the same date, the FDA notified the Company that the agency was placing IND [investigational new drug application] 43,742 on partial clinical hold, due to a lack of a complete response to the issues raised by the FDA and what the FDA deemed a misleading, erroneous, and incomplete investigator brochure. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R. § 312.42(b)(1)(iii), as grounds for imposition of a clinical hold. The FDA further advised the Company that until it resolved the matter to the FDA’s satisfaction, that the Company could not enroll new adult or pediatric patients in any protocol under such IND. The FDA also placed protocols B-52 and B-54 on clinical hold due to what the FDA deemed to be an unreasonable and significant risk of illness or injury to human subjects. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R.§ 312.42(B)(1)(i), as grounds for imposition of a clinical hold. The FDA advised the Company that until it resolved the matter to FDA’s satisfaction, the Company could not legally conduct the identified clinical studies under such IND.
In a letter dated April 9, 2013, the Company responded to the issues raised by the FDA in its January 9, 2013 letter to the Company. In a letter dated May 9, 2013 from the FDA, the FDA advised the Company that the Company’s April 9, 2013 letter was not a complete response to all the issues listed in the FDA’s letter dated January 9, 2013, and the FDA also identified the issues that were not fully addressed by the Company’s response. The FDA further advised the Company that until it satisfactorily addressed all the issues in the FDA’s letter dated January 9, 2013, that the FDA could not complete its review, and the clinical hold could not be removed.
So basically, the FDA extended its clinical hold; the Burzynski Research Institute answered the FDA’s charges; and the FDA was not satisfied. Until the Burzynski Research Institute can adequately address those concerns, there will be no new patients enrolled. If I were a betting man, I’d bet that no new patients ever will be enrolled because maybe, just maybe, the FDA is finally cracking down on Burzynski for real. At least, that’s what I hope. I’m all too aware that it looked just as bad for Burzynski in the 1990s, which was the last time the FDA made a serious run at the Burzynski Research Institute, and Burzynski managed to slither away to come back bigger and stronger than ever. Even so, Burzynski’s own SEC filings suggest that all the bold talk of imminent approval of antineoplastons by the FDA and publication of the papers that will prove to the world that antineoplastons work are pipe dreams, stories to keep the marks on board and hoping. Indeed, even the report seems to concede that antineoplastons will likely never be approved, even going so far as to point out that “the Company cannot predict if and/or when it will submit an NDA [New Drug Application] to the FDA, nor can the Company estimate the number or type of additional trials the FDA may require.” Burzynski also warns:
Notwithstanding the response results of the trials that have reached a Milestone, management believes it is likely that the FDA may require additional clinical trials based upon such protocols to be conducted by an institution not affiliated with the Company or Dr. Burzynski before advising that an NDA filing is warranted. In addition, the FDA has indicated it will not accept the efficacy data, but will accept toxicity data generated by the Phase II study according to Protocol CAN-1 because the trial was partially retrospective. At this time, the Company cannot predict if and/or when it will submit an NDA to the FDA, nor can the Company estimate the number or type of additional trials the FDA may require. Further, there can be no assurance that an NDA for antineoplastons, as a treatment for cancer, will ever be approved by the FDA.
No assurance can be given that any new IND for clinical tests on humans will be approved by the FDA for human clinical trials on cancer or other diseases, that the results of such human clinical trials will prove that antineoplastons are safe or effective in the treatment of cancer or other diseases, or that the FDA would approve the sale of antineoplastons in the United States.
That hardly sounds as though antineoplastons will be approved “soon.” After all, the Burzynski Research Institute’s own SEC filing states that an NDA hasn’t even been submitted and that it can’t be predicted when an NDA will be filed. Presumably if Burzynski were truly on the verge of getting antineoplastons approved by the FDA he would have said so in his SEC filing. That’s why his SEC filings are so revealing. Burzynski can distort and exaggerate when speaking to the public, but lying on an SEC filing could carry potentially serious consequences.
Another interesting tidbit in the SEC filing is Burzynski’s report of the results of several of his clinical trials. They aren’t really “results’ per se, in that the information presented really isn’t provided in a form that really allows other investigators to evaluate it and potentially replicate it. Basically it’s a big table listing Burzynski Research Institute clinical trials and response rates reported. One thing that I noticed right away is that in most trials, the number of evaluable patients is smaller, sometimes much smaller, than the number of patients accrued. This is a huge red flag. For instance, in trial BT-20, there were 40 patients accrued by only 22 were evaluable. This sort of dropout rate is a huge red flag. We don’t know the reasons for this dropout rate. It could certainly skew the results, but even that’s impossible to tell from just a table of response rates and no further information. Of course, I realize that this is an SEC filing, not a scientific paper in the peer-reviewed literature, but if Burzynski has all this data to produce this table it boggles the mind that, given at least a decade and a half since these trials began, he hasn’t been able to publish any meaningful data thus far. That he hasn’t been able to do so is also a big red flag.
One can’t help but wonder why BBC Panorama didn’t look at this information. It could easily have fit into the narrative. Imagine a more prepared reporter, faced with the confident and sarcastic bloviation from Burzynski that antineoplastons will be approved “soon,” pulling out Burzynski’s own SEC filings and telling him that that’s not what he said in those filings. I can only imagine two reasons Bilton didn’t do that: The report wasn’t out when the interview occurred (which is possible, given the mentions of a date in early May) or lack of preparation. If it were the former situation, a more prepared reporter could have hammered Burzynski on how he could possibly say so confidently that antineoplastons were going to be approved “soon” with partial clinical holds by the FDA on children since the fall of 2012 and on adults since January 2013. These are hardly the sorts of issues that suggest imminent approval, contrary to Burzynski’s statements, which now must be viewed, in my opinion, as outright lies. Indeed, even if the SEC filing wasn’t published yet at the time this interview took place, imagine a voiceover tacked on after Burzynski’s statement pointing out that his own SEC filings contradicted his assertions. Moreover, bringing up these issues would arguably have fit into the narrative perfectly to point out that Burzynski is still promoting antineoplastons through surrogates by saying that FDA approval is imminent when, according to his SEC filing, he apparently hasn’t even filed an NDA yet. As much as the BBC got right in its coverage of Burzynski, aspects of its Panorama episode on Burzynski were pure frustration to those of us who have been following Burzynski for a while.
I wonder if Brian Deer would be interested in looking into the Burzynski Clinic and the Burzynski Research Institute.

The Texas Medical Board lets Stanislaw Burzynski off lightly: A cautionary tale of the failure of regulating medicine
After three years and countless twists and turns, the final decision by the Texas Medical Board on the sanctions to be imposed on Houston cancer quack Dr. Stanislaw Burzynski were announced on Friday. Sadly, they were not enough. The Burzynski saga should serve as a cautionary tale that the regulation of physicians and medicine is too lax, not too strict.
David Gorski on March 6, 2017
Link


I’ve been blogging here fairly regularly about Houston cancer quack Dr. Stanislaw Burzynski since 2011, and now the story is over…sort of. Unfortunately, as you will see, the ending is not satisfactory. It is, however, somewhat better than I had feared it would be. What I’m referring to, of course, is the final ruling of the Texas Medical Board (TMB) regarding Dr. Burzynski, the Houston cancer doctor who has been a frequent topic of this blog because of his practices of charging desperate cancer patient tens (or even hundreds) of thousands of dollars for his “antineoplastons” (ANPs) and, later, what he refers to as “personalized, gene-targeted cancer therapy” (or, as I like to call it, making it up as you go along). Over the course of the last several years, a credulous filmmaker by the name of Eric Merola contributed to Burzynski’s reputation in the alternative medicine world as a “brave maverick doctor” with two blatantly deceptive “documentaries”, Burzynski The Movie: Cancer Is A Serious Business and Burzynski: Cancer Is A Serious Business, Part 2, or, as I like to call it, Burzynski 2: Electric Boogaloo.
Burzynski’s is a long and tangled story, one that I’ve blogged about many times. The details up to early 2014 are covered in an article I wrote for Skeptical Inquirer entitled “Stanislaw Burzynski: Four Decades of an Unproven Cancer Cure.” Burzynski has been selling cancer quackery since roughly 1977, which is around the time he left Baylor University to set up his own private practice and manufacturing facility to make and administer his ANPs for big bucks to desperate cancer patients, many of whom had terminal brain cancers like glioblastomas. The TMB and then, beginning in the 1990s, the FDA have been trying to shut him down ever since, all with only temporary success, as when the FDA managed to put a partial clinical hold on Burzynski’s clinical trials in 2013. It was initially issued for children but then extended to adults and was based on the death of a six-year-old boy named Josia Cotto the year before, of hypernatremia (too much sodium in the blood, a known complication of ANPs delivered at the doses Burzynski uses). The success was short-lived, as the partial clinical hold was lifted a year later, because, according to the FDA, the Burzynski Clinic answered all its questions and concerns.
Most recently, in 2014 the TMB, after a long investigation, decided once again to initiate legal action to strip Burzynski of his medical license. (It had tried and failed back in the 1980s and 1990s to do just that.) Unfortunately, the final ruling came in on Friday, and Burzynski was put on probation. He still has his medical license. Yes, there are conditions and TMB oversight that he’ll have to abide by, and yes, he was fined $60,000, but I view the sanctions as not a lot more than a slap on the wrist. Once again, the TMB has failed to shut Burzynski down. Before I discuss the latest ruling, let me step back a moment, for the benefit of those unfamiliar with Burzynski and those who might not remember enough to put this ruling into context, and provide a bit of background about why I consider him a cancer quack and how he’s shown the inadequacy of the TMB and the FDA in dealing with such brazenness.
Stanislaw Burzynski: The early years
On the surface, it’s easy to mistake Stanislaw Burzynski’s story for that of a classic riches-to-rags-to-riches story. Born in 1943 in Lublin, Poland, just as the Holocaust in Poland was entering its most deadly phase, Burzynski was fortunate enough to have been born to a mother whose family was wealthy and was therefore mostly sheltered from the horror of Nazi-occupied Poland. Of course, he wasn’t even two and a half yet by the time the Third Reich fell, but that occupation was soon replaced with another one almost as bad and much more enduring, that of the Soviet Union. After the war, when Burzynski was five, his older brother Zygmunt was killed fighting the newly installed Communist regime, which affected him his whole life. Basically, he idolized the idea of fighting authority.
Very little is known about the next couple of decades, other than that Burzynski was a good student, and that he got into medical school. By 1970, he was a promising researcher and was recruited by the Polish Communist Party. He refused to join, and in retaliation the Party saw to it that he was drafted into the Polish Army. So Burzynski fled to the US “with only $20” in his pocket in 1970 to stay with an uncle. He soon found a research position in the Department of Anesthesia at the Baylor College of Medicine in a laboratory headed by Georges Ungar, a Hungarian refugee with whom he immediately hit it off. Ungar was famous at the time for proposing that memory resided in peptides in the brain and for his experiments to “transfer” memory by transferring the putative “memory” peptides from one mouse brain to another. It was a hypothesis that seemed to be supported by his experiments but soon faded from favor. At Baylor, Burzynski split his time between working on Ungar’s projects and studying his antineoplastons. He appeared to be well on his way to becoming a successful cancer researcher, securing an NIH grant in 1974 and publishing several peer-reviewed papers.
Basing his concept on cybernetic systems and information theory, Burzynski hypothesized the existence of ANPs as the mediator or regulator of information exchange in autonomous systems that carried information about differentiation to the cells and began to look for peptides in the blood of cancer patients that might correct the abnormal differentiation of cancer. I don’t need to go into detail here about the whole story. However, if you’re so disposed, you can delve into the details in my SI article, a famous The Cancer Letter article, and the NIH website. In brief, based on his hypothesis, Burzynski used gel filtration of blood and urine fractions and tested them for activity against cancer cells. Although there were many fractions initially, these days “antineoplastons” generally refer to AS-2.1 (also known as Astugenal or Fengenal) and A-10 (also known as Atengenal or Cengenal). Basically, AS-2.1 is the sodium salt of phenylacetic acid (PA), a potentially toxic chemical produced by normal metabolism and detoxified in the liver to phenylacetylglutamine (PAG). To boil ANP chemistry down to its essence, AS-2.1 is primarily a mixture of PA and PAG, and AS-10 is primarily PA. Of note, PA had been studied as a potential anticancer agent years before Burzynski discovered it and, although it has been studied intermittently for fifty years, it has shown little promise against brain tumors. More recently, Burzynski has hijacked an orphan drug for urea cycle disorders, sodium phenylbutyrate, because it is a prodrug that is metabolized into PA.
In 1976, though, when he wanted to begin his clinical trials, his ANPs weren’t even fully chemically characterized, and only one of them had been tested in mice. It didn’t work, but Burzynski excused that failure by saying that ANPs were species-specific. Earlier, in 1973, Burzynski had gotten his Texas medical license. Even though he had not done a fellowship in oncology or even a residency in any medical specialty, by 1976 he thought himself uniquely qualified to do a clinical trial of ANPs. Again, all the details are discussed elsewhere, but Burzynski managed to do a case series, although it’s not clear if it ever had ethical approval, and, when the Baylor ethics board refused to approve a clinical trial, managed to get a nearby hospital to approve it. Ultimately, he left Baylor and formed his own practice, to administer ANPs to patients, setting up his own manufacturing facility, first to isolate the peptides from gallons of urine and then to synthesize them once their chemical identities had been worked out.
As I’ve recounted before, from the late 1970s to 1998, Burzynski was under nearly constant investigation by medical authorities, beginning with the Harris County Medical Society in 1979 and continuing with the TMB and the FDA. Indeed, before this most recent ruling, the TMB has tried to strip Burzynski of his license to practice twice, failing to do so in 1993 and 2012. The latter time, Burzynski got off on a technicality.
Why I view Burzynski as a cancer quack
It is my educated opinion that Burzynski is a cancer quack. I do not make that charge lightly and will back up my opinion. Beginning in the late 1970s, he began administering ANPs to cancer patients without their having been demonstrated to be safe and effective in well-designed clinical trials. The “brave maverick doctor” that he is, he just knew they worked, and, like many cancer quacks, over the years he accumulated what seemed like “success stories.” However, as I’ve discussed many times over the last 6 years, if you look at them more closely, these “success stories” can almost always be explained by the conventional treatment patients have undergone before they turned to Burzynski. Examples abound, patients such as Hannah Bradley, Laura Hymas, Tori Moreno, and Mary Jo Siegel, and Sheila Herron. I note that, of these, Laura Hymas featured prominently as a success story, only to die of recurrent cancer a year after the second Burzynski movie featured her so prominently. Particularly memorable was a scene in which audio was played of her and her family trying to persuade her NHS oncologist to do routine tests as part of Burzynski’s clinical trial and him trying to explain to her that he can’t do that because his was an unapproved treatment and his clinical trial was not approved by the NHS. As a fellow physician, I really felt for that oncologist, who was put in a very difficult position. These are but a few of the patients. Fellow skeptic Bob Blaskiewicz maintains a blog, The Other Burzynski Patient Group, patterned on a website set up by Burzynski patients to tout the “success stories,” that documents just how many of these patients have died.
More importantly, the website documents the suffering, both physical and financial, of patients who are lured to the Burzynski Clinic by promises of cures, most often promoted by Burzynski believers like Eric Merola. (Indeed, his Burzynski movies have probably generated more business for the Burzynski Clinic than anything else in Burzynski’s 40 year history.) Basically, Burzynski charges exorbitant fees for his services. He likes to claim that he charges nothing for his ANPs, and, after the FDA cracked down on him, that was true. However, he charges huge “case management” fees. For example, Pete Cohen, Hannah Bradley’s husband, documented why his fundraising target to get his then-fiancée treated in Houston was £200,000 (approximately $246,000 at yesterday’s exchange rate, a lot more back in 2012), estimating her monthly costs to be £8,600. Moreover, £200,000 wasn’t even that high for a Burzynski patient. The prodigious fundraising required to afford Burzynski’s treatments has been documented at TOBPG and all over the blogosphere and includes cases such as that of Seán Ó’Laighin (who did not survive), Rene Louis, Jesse Bessant, Rachel Mackey, Luna Petagine, Wayne Merritt. and Chiane Cloete. A lot of these people came from the UK, and perhaps the most famous two included Billie Bainbridge, whose family raised hundreds of thousands of pounds and got celebrities to help in order to travel to Houston, and Amelia Saunders, a lovely child who was unfortunate enough to be diagnosed with a brain tumor whose parents raised over £200,000 in 12 weeks in order to pay for Burzynski’s treatments and who was featured as a great “success story” by Merola and Burzynski. What really angered me (even more than a typical Burzynski story) is that Burzynski told the father that the formation of cysts in the tumor was the tumor dying because of treatment when in reality it is quite common for tumors to outgrow their blood supply, leading to the death of cancer cells in the middle. Sadly, Amelia also ultimately died.
Here’s where Burzynski is different—and worse—than typical cancer quacks, such as those in Tijuana. Basically, unlike the vast majority of other cancer quacks, Burzynski has had clinical trials open, lots and lots of them, and he has used them as a tool to continue to be able to administer ANPs. Worse, he charges patients enrolled in his clinical trials, a practice that is very much frowned upon and considered, with very few, defined exceptions, to be unethical.
Here’s how he pulled it off. It was the prosecution brought against Burzynski by the FDA during the 1990s that spawned the oft-touted “six dozen” clinical trials. In the fall of 1995, a grand jury indicted Burzynski for seventy-five counts of insurance fraud and violations of the Food, Drug, and Cosmetics Act. As part of this process, Judge Simeon Lake of the U.S. District Court for the Southern District of Texas, ruled that Burzynski’s “continued pretrial release” was contingent upon his administering his drugs exclusively through FDA-approved clinical trials. During the trial in the 1990s, Burzynski’s PR defense against prosecution established and has remained constant ever since. When threatened, he rallies his patients around him to accuse whatever regulatory agency is pursuing Burzynski this time of cruelty and wanting to let them (or their family members die). More recently, thanks to his newfound fame after Merola’s movies, he’s taken to dispatching celebrities like Suzanne Somers, Fabio Lanza (whose sister suffered from end stage ovarian cancer), and Sammy Hagar (whose drummer’s wife suffered from a terminal brain tumor) to defend him. He’s also cultivated powerful political allies, such as Representative Joe Barton (R-Texas), who held a series of hearings featuring cancer patients who were, quite understandably, terrified that Burzynski would be convicted. (Remember, these patients were completely convinced that Burzynski was the only person who could save them.) He also used to routinely drag the FDA Commissioner in front of his committee to castigate him for “persecuting” Burzynski.
As a result, the FDA entered negotiations to let Burzynski set up clinical trials, and Burzynski’s then-lawyer Richard A. Jaffe decided to take advantage of Judge Simeone’s ruling and the political pressure on the FDA, saying, in essence, “If the judge wants clinical trials, we’ll give him clinical trials.” So that’s just what they did. Prosecutors pleaded with the FDA not to give in because it would undermine their case, but the FDA overruled them. First, patients already being treated were enrolled in a wastebasket trial known as “CAN-1”, a retrospective trial looking at all patients then being treated at the Burzynski Clinic. Of this trial, Jaffe (2008) wrote:
. . . As far as clinical trials go, it [CAN-1] was a joke. Clinical trials are supposed to be designed to test the safety or efficacy of a drug for a disease. It is almost always the case that clinical trials treat one disease. The CAN-1 protocol had almost two hundred patients in it and there were at least a dozen different types of cancers being treated. And since all the patients were already on treatment, there could not be any possibility of meaningful data coming out of the so-called clinical trial. It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
I always repeat these quotes by Jaffe because they demonstrate the cynicism behind Burzynski’s actions. It gets worse, though. The FDA also permitted Burzynski to set up nearly identical phase 2 trials for every cancer that he wanted to treat. Burzynski claimed these were based on a protocol used in a trial done by the National Cancer Institute in the early 1990s when the NCI had tried to work with Burzynski. (This effort failed because of strife between the NCI and Burzynski, who viewed the NCI as trying to sabotage the trial. These trials had but one purpose, to allow Burzynski to continue treating patients with ANPs, as Jaffe himself boasted (2008):
CAN-1 allowed Burzynski to treat all his existing patients. That solved the patients’ problems, but not the clinic’s. A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future.
The prosecution was undermined, and the first trial ended in a hung jury in 1997. A second trial on a subset of the original charges resulted in Burzynski’s acquittal. Since then, Burzynski has practiced (mostly) untroubled by the FDA, other than intermittent inspections and warning letters. The TMB tried to take away his license in 2012 and failed on the slimmest of technicalities. Basically, the TMB went after Burzynski based on the doctrine of vicarious liability, which means in essence that the TMB was arguing that Burzynski was responsible for the actions of the physicians working for him who had actually cared for the patients at the heart of the TMB’s case against Burzynski. In response, Burzynski moved to dismiss and/or strike TMB allegations against him to the extent that the allegations were based on the actions of other physicians working at his clinic. His attorney’s argument was that, under administrative law, there is no vicarious liability for the actions of others. This is apparently different from tort law (for example, medical malpractice), where the physician can be held liable for the actions of physicians working under his control or supervision in some circumstances. The bottom line is that the administrative judge ruled in Burzynski’s favor. Basically, by throwing his fellow physicians working for him under the bus, Burzynski walked. Meanwhile, since 1998 he’s been enrolling patients on clinical trials, charging them, and not publishing his full results for a long time. Recently, he has published a few reports, but they’ve all been in bottom-feeding journals and/or don’t report the whole trial. The closest thing he had to a decent publication showed that ANPs didn’t work against colorectal cancer metastatic to the liver. He even just did it again last month.
Then, in 2014 the TMB decided to try again.
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The charges
In the summer of 2014, I learned through readers that the TMB was gearing up to take another go at Burzynski. I was surprised and cheered that the Board would be willing to try again so soon after its last defeat, but I remained pessimistic that anything would actually happen. The original complaint was over 200 pages long, but basically the TMB charges fell into three main categories:
     1.  Creating a “medical practice model based on marketing his proprietary anti-cancer drugs to patients without adequate measures for safety and therapeutic value.”
     2.  Misleading patients knowingly “by promoting these drugs as an attraction to bring patients to his medical practice when he was aware that he could not legally include most of those patients in FDA-approved Phase 2 clinical trials of his proprietary anti-cancer drugs” and “into paying funds as a retainer prior to receiving any evaluation, diagnosis or treatment.”
     3.  Misleading patients into: “(1) paying exorbitant charges for drugs and medical services; (2) accepting care from unlicensed persons while Respondent and Respondent’s employees misrepresented those unlicensed persons to be licensed medical doctors in Texas and the United States of America; and (3) accepting care from health care providers who had little advanced education or training related to cancer treatment while Respondent and Respondent’s employees misrepresented those health care providers to be doctors with significant advanced education or training related to cancer treatment.
Anyone who has paid attention to Burzynski should be able to tell that charges #1 and #3 are very provable. As for Charge #2, as I’ve discussed before, the Burzynski Clinic’s trials were on partial clinical hold, Burzynski did appear to be doing a “bait and switch,” where ANPs drew the patients in, and then he’d give them his jury-rigged “gene-targeted personalized” therapy consisting of cocktails of very expensive targeted therapies that were not known to be safe and effective when administered together. To prove these charges, the TMB described 12 patients (labeled Patients A through L) whose treatment did not live up to the standard of care in one or more of these three areas. For instance, the TMB charged that Burzynski treated Patient A with ANPs for colon cancer even though the patient had never had a biopsy and that non-physicians represented themselves as physicians to them. For Patient C it was a similar story; Burzynski treated the patient for mesothelioma without biopsy confirmation and without “adequately documenting Respondent’s medical rationale.” Patient G, for example, was charged for her treatment even though she was on a clinical trial, and there were multiple failures to follow FDA regulations about human subjects.
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The proceedings
The TMB proceedings have been going on against Burzynski for well over three years now, and during that time, Burzynski has been pulling out all the stops and using all the old propaganda tactics he’s used since his patients swarmed the courthouse during his trial in the 1990s. Sadly, he’s even had some success in that journalists who should know better fell for the “false balance” trope over a patient who was being denied ANPs because an FDA inspection of his manufacturing facility had turned up serious issues. That the proceedings have dragged on this long shouldn’t be a surprise; Burzynski is an old master at this, as was his lawyer Richard Jaffe. Of course, the amusing thing is that during the proceedings Jaffe actually withdrew as Burzynski’s attorney (and his son Greg Burzynski’s attorney) and apparently sued him for $250,000 in unpaid legal bills, further delaying the proceedings. Then, in December 2015, Burzynski informed the Board that he had had a heart attack and wouldn’t be able to proceed for a time, delaying the second phase of the proceedings for several months.
Then, in October 2016, there was a major setback when administrative law judges issued a proposed decision dismissing the bulk of the charges against Burzynski, largely because of gross incompetence on the part of the TMB. For example, instead of local cancer experts from, for example, M.D. Anderson and Texas Children’s Hospital, you know, the doctors who have to clean up the mess when one of Burzynski’s patients suffers the complications of his incompetence and the toxicity of his ANPs, the TMB relied on outside experts. In fairness, we can’t know for sure why the TMB didn’t use local experts because its spokesperson wouldn’t say. Given Burzynski’s famously litigious nature and his tendency to use his patients as shields and spears against his enemies, it could well be that local oncologists were cowed and didn’t want to speak out the way Dr. Jeanine Graf, director of the pediatric intensive care unit (PICU) at Texas Children’s Hospital did to the producers of the BBC news magazine Panorama when Panorama did a story about Burzynski, stating ,point blank, that she’s never seen a Burzynski patient survive.
Here’s what we got instead:
What we got, instead, was Dr. Cynthia Wetmore, who seems to have done a decent job in most aspects, but screwed up royally when it came to someone referred to as “Patient D.” The judges noted that Wetmore claimed that Patient D “did not receive the standard of care and was exposed to medications that are not documented to cross the blood brain barrier.”
The only problem with that, per the judges, was that “contrary to Dr. Wetmore’s testimony and report, Patient D received no treatment or therapy at the Clinic.” They wrote that “such inattentiveness to the accuracy of her report raises concerns about her credibility.”
This is one thing that utterly infuriated me. Burzynski is an old hand at this. He’s been slithering away from judgments by the TMB and FDA since the late 1970s. You cannot take him down with such inattention to detail. You have to have all your ducks lined up in the proverbial row. Your case has to be airtight and rock solid. On the other hand, the Chief Administrative Law Judge Lesli G. Ginn was not without fault, because she also accepted a lot of Burzynski propaganda as well. For instance, I’ve written many times how the Burzynski Institutional Review Board (IRB), the committee that is responsible for protecting human subjects and examining the ethics of any proposed clinical trial being carried out by an institution receiving funding from the federal government or any company or entity doing the clinical trial to gain FDA approval for a treatment or drug, is hopelessly compromised and packed with Burzynski cronies. Yet Ginn wrote, apparently with a straight face:
Dr. Burzynski testified that IRB was also created in 1983, but it is a separate entity from BRI. IRB was created to supervise the ethical conduct of clinical studies by approving or disapproving clinical trial protocols; to collect data on the toxicity and the response of the investigational agent; and to evaluate data on the efficacy of the investigational agent ANP.22 IRB is not in the business of practicing medicine.23 Neither Dr. Burzynski nor any of the Clinic’s employees is a member of IRB. The IRB consists of 14 members. Carlton Hazelwood, M.D., a retired professor of pediatrics and physiology at the Baylor College of Medicine, is IRB’s chairman.24 Dr. Burzynski testified that he had no role in the selecting the board members.25
Wrong. Carlton Hazlewood is on the board of directors of the Burzynski Research Institute, as has been pointed out many times.
So things looked bad in October, but fortunately this was only a proposed judgment. What did the final judgment say?
The Texas Medical Board vs. Stanislaw Burzynski, Round ∞: The Ruling
On February 15, the TMB issued a proposed decision in which Burzynski would be fined $360,000, required to pay $20,000 restitution to a patient. Unfortunately, although the proposed decision included the revocation of Burzynski’s medical license, the revocation was stayed, with Burzynski to be placed on probation with a public reprimand. In addition to the fine and his probation with reprimand, the TMB would require that Burzynski meet these conditions:
    • The billing practices of the Burzynski Clinic must be monitored and patient records reviewed.
    • Burzynski must complete a Physicians Ethics program and undergo continuing education to obtain credits of completion in several topics of medical research. (I laughed at this one. Burzynski knows medical research regulations; it’s how he’s so good at skirting them.)
    • Burzynski must submit his informed consent forms to the Board for review to show that they comply with relevant regulations and laws, and each patient must receive and sign these new forms before treatment.
    • Burzynski must inform his patients that he owns the pharmacy requires them to use. Ownership interest disclosure must be submitted to the Board for review.
    • Burzynski must pass a Medical Jurisprudence Exam.
Overall, this struck me as a fairly substantial penalty, but far less than he deserves. Worse, Burzynski would have the opportunity to submit a counterproposal, and that’s what resulted in the final decision issued on Friday, which is even less severe:
The board’s staff had originally recommended that Burzynski pay a $360,000 fine and $20,000 in restitution to a patient. They also wanted Burzynski put on probation, with the power to automatically revoke his medical license if he violated the terms.
Instead on Friday, the board opted for a lesser penalty that included a five-year probation with more lenient terms, a public reprimand, more training and oversight, along with $60,000 in fines and restitution.
Burzynski’s attorneys called the decision a win.
“It means that he gets to continue medicine. He gets to continue to save lives,” attorney Gregory Myers said.
That $60,000 includes $40,000 in fines and the aforementioned $20,000 in restitution to a patient. If Burzynski’s attorneys consider this decision a “win,” then for patients it is clearly a loss. Unfortunately, I haven’t been able to find the final final decision yet; so I don’t know exactly how the terms of his probation are more lenient.
Still, even though Burzynski can continue to practice, I have some hope. For one thing, Burzynski is no spring chicken any more. He’s 74, and he had a heart attack a little more than a year ago. The terms of his probation will likely take him through most of the rest of his 70s, and, at his age, can he really stand to practice with even more stringent monitoring? He’s always been stubborn and arrogant, and I can’t picture him tolerating the regular monitoring of his billing practices and patient charts that will occur with much equanimity at all. Will he actually complete courses on Physician Ethics and study for a medical jurisprudence exam”? I’m not sure I can see it happening. Maybe he’ll retire.
Or maybe not. That’s the problem. Burzynski is nothing if not expert at evading the spirit of constraints placed on him to continue to sell his unproven treatments to patients for exorbitant sums of money.
The failure of the FDA and state medical boards to protect the public from quacks
With the election of Donald Trump as President, I and my SBM co-conspirators have been warning about the consequences of the sort of massive deregulation that Trump wants. For instance, just this week, Jann Bellamy warned about efforts to remove impediments to “right-to-try” laws, shield wrongdoers, and hide adverse events, and Steve Novella has warned about Trump’s plan to deregulate pharmaceuticals. Before that I had been beating the drum about how every single candidate for FDA Commissioner under consideration by the Trump administration, such as Peter Thiel Crony Jim O’Neill, and honest-to-goodness pharma shill Scott Gottlieb, favor massively decreasing the amount of evidence for drug approval, when in fact the FDA functions pretty well given its underfunding and an argument can be made that the evidence bar for approval is actually too low.
Contemplating the case of Stanislaw Burzynski worries me. Consider that the FDA using its current guidelines has only been intermittently able to temporarily put a halt to Burzynski’s preying on patients in the name of clinical trials. Meanwhile, state right-to-try laws could be a boon to practitioners like Burzynski, who, indeed, has already taken advantage of the Texas right-to-try law. It’s not just Trump, though. The majority of the states are solidly held by Republicans, and, as I’ve pointed out many times before, state medical boards are generally underfunded and outgunned. That doesn’t even consider the “quack protection” and “quack full employment” laws regularly discussed by Jann Bellamy and others here that would license and protect naturopaths, chiropractors, and other quacks, all in the name of “health freedom,” a recurring theme among Trump’s candidates for FDA commissioner which is used as a justification for “right-to-try” laws.
The failure of the TMB strip Burzynski of his medical license reminds me that, if anything, the laws and regulations protecting the public from quacks are too weak, not too strong. I fear they will become a lot weaker soon.

Cancer quack Stanislaw Burzynski continues to prey on cancer patients in 2023
This year, cancer quack Dr. Stanislaw Burzynski turned 80. Unfortunately, he doesn’t seem to be slowing down charging patients with advanced cancer huge sums for false hope.
David Gorski on September 18, 2023
Link

Longtime readers of this blog will know that about a decade ago I used to write a lot about cancer quack Dr. Stanislaw Burzynski and his unproven (even disproven) treatment with antineoplastons. When I wrote about Burzynski, I often used to detail how, since the 1970s(!), he has been deceiving desperate patients suffering from deadly cancers, in particular brain cancers like diffuse intrinsic pontine glioma (DIPG). Even worse, the victims of his quackery have often frequently been children. Even worse still, the extreme expense of the Burzynski Clinic’s treatments, which not infrequently runs into the hundreds of thousands of dollars (or pounds, given that so many of his patients seem to come from the UK), families characteristically resort to mortgaging their houses and massive crowdfunding efforts to pay this exorbitant expense. Typically, these crowdfunding efforts—and, sadly, I’ve seen all too many of these over the last 15 years—feature a sympathetic cancer victim portraying Burzynski’s mix of antineoplastons plus his made-up “everything but the kitchen sink” variety of “personalized gene-targeted” therapy (which he claimed to have invented before M.D. Anderson Cancer Center, for instance) as their only hope to survive, all too often credulously bolstered by mainstream news publications. Then came the pandemic, and within a couple of months COVID-19 and the resulting tsunami of pseudoscience, quackery, antivaccine, and generally anti-public health misinformation and disinformation took over. Unfortunately, although I’m getting back to normal three and a half years later, COVID-19 still dominates. Indeed, although I’ve mentioned Burzynski since the pandemic in the context of how toothless state medical boards have been and how he had pioneered many of the techniques of misinformation used by COVID-19 cranks today, the last time I wrote a post that was primarily about Burzynski’s cancer quackery was almost five years ago, when he was developing an online series purportedly about patients whom he’s cured.
Perhaps I had thought that, after the Texas Medical Board’s most recent failure to shut the Burzynski Clinic down, Stanislaw Burzynski had faded into the quack sunset. He did, after all, turn 80 in January, and I had faint hope that he might finally decide to retire. Unfortunately, it turns out that I was wrong, as I was saddened to discover when a reader sent me a typical Burzynski cancer story that could easily have been a Burzynski cancer story in 2009 or 1999 or 1989 or even 1979. The story appeared on Fox News earlier this week and was framed with a very Fox News sort of headline (Pregnant woman with brain cancer refuses abortion: ‘Killing my baby wouldn’t have saved me’) and blurb (“Tasha Kann is defying her doctors’ predictions: ‘It’s a miracle from God that we are both here'”). It’s a story that appears to have come from a local northern Michigan news report, which was similarly credulous. Basically, what this story does is to graft an antiabortion message onto the very old, very familiar story that many victims of quackery come to believe, that their original science-based physicians were wrong, that they made the right choice to seek out “other” options,” and that the chosen quack is their only hope of living to see their children grow up. As I’ve discussed before with the cases of Hannah Bradley and some of Burzynski’s other “success stories,” quite frequently these stories come from people who are fortunate outliers and survive significantly longer than the (usually) median survival quoted to them. (As I like to say, medians have two sides, and patients who are unfortunate to be on the wrong side of that media survival estimate do not produce hopeful testimonials, mainly because they’re dead.) Also, as in the case of Ms. Bradley, often these patients have undergone significant courses of “conventional” treatment with chemotherapy, radiation, etc., that could impact how long they survive their cancers.
So what is Tasha Kann’s story?
Brain cancer vs. abortion: How Tasha Kann’s story has been framed
Let’s start with the Fox News story, because it is the most recent:
“We recommend that you get an abortion.”
That was the advice Tasha Kann received from doctors in Michigan shortly after she learned that she had brain cancer in 2022.
The young mother, who was 20 weeks pregnant with her second child, had just been diagnosed with anaplastic astrocytoma grade III, a rare and aggressive malignant tumor. Her doctors urged her to end her pregnancy so that she could receive chemotherapy and radiation.
“I told them absolutely not,” Kann shared with Fox News Digital in an interview.
As is the case for so many patients seduced by the promise of the Burzynski Clinic, Kann’s story is heartbreaking. She was young. She was pregnant. To treat her cancer, her doctors recommended that she terminate her pregnancy. I can only imagine what a harrowing situation that was to be in and how terrible the decision that had to be made was. Let’s see how Fox News portrayed her situation and decision:
Kann’s cancer battle began in 2021, with what she thought was a migraine.
As she was lying in bed waiting for the headache to pass, she started to feel tingling in her arms and legs, and was suddenly unable to move or stand.
Assuming she was having a stroke, Kann yelled for help and managed to call 911.
At the hospital, a CT scan revealed a large brain mass.
“I was a little scared, but I never lost hope,” Kann said of her diagnosis. “I knew I had to be strong for my baby.”
Kann said she still vividly recalls the moment that a group of three doctors entered her hospital room and stood at the foot of her bed.
“They all looked at me and told me my best chances of survival would be to get an abortion and start treatment immediately — which might give me five to eight years of survival,” she told Fox News Digital.
As a breast cancer surgeon, I wondered about this recommendation. Although it is not common, a diagnosis of breast cancer requiring chemotherapy made while a woman is pregnant is not that uncommon anymore. For such women, termination of pregnancy is presented as one option but generally not pushed. Why? We now have a long experience administering chemotherapy during pregnancy for breast cancer patients in their second and third trimesters. It can be done, and the outcomes after birth have been generally good. For example, here is what the National Cancer Institute has to say about breast cancer during pregnancy on its PDQ page for patients:
Chemotherapy
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).
Chemotherapy is usually not given during the first 3 months of pregnancy. Chemotherapy given after this time does not usually harm the fetus but may cause early labor or low birth weight.
Ending the pregnancy does not seem to improve the mother’s chance of survival.
Because ending the pregnancy is not likely to improve the mother’s chance of survival, it is not usually a treatment option.
Here’s what the American Cancer Society says about it:
For many years, it was thought that all chemo would harm an unborn baby no matter when it was given. But studies have shown that certain chemo drugs (such as doxorubicin, cyclophosphamide, fluorouracil, and the taxanes) used during the second and third trimesters (months 4 through 9 of pregnancy) don’t raise the risk of birth defects, stillbirths, or health problems shortly after birth, though they may increase the risk of early delivery. Researchers still don’t know if these children will have any long-term effects.
If you have early breast cancer and you need chemo after surgery (adjuvant chemo), it will usually be delayed until at least your second trimester. If you are already in the third trimester when the cancer is found, chemo may be delayed until after birth. The birth may be induced (brought on) a few weeks early in some women. These same treatment plans may also be used for women with more advanced cancer.
Chemo is generally not recommended after 35 weeks of pregnancy or within 3 weeks of delivery because it can lower the mother’s blood cell counts. This could cause bleeding and increase the chances of infection during birth. Holding off on chemo for the last few weeks before delivery allows the mother’s blood counts to return to normal before childbirth.
When I first saw this story, I wondered if the chemotherapy for this particular form of brain cancer was sufficiently different that these recommendations during pregnancy don’t apply. However, I then saw that the Fox News story features a physician relating more or less the same things, in particular that chemotherapy shouldn’t be given within three weeks of delivery for the very reasons mentioned above and who also noted, “”Pregnancy termination in a woman with a central nervous system malignancy may necessarily be a choice pending the clinical situation,” In general, though, although a number of chemotherapy regimens can be safely administered during the second and third trimesters of pregnancy, we avoid radiation therapy, endocrine therapy (treatments that block estrogen), and certain targeted therapies until after delivery.
I also wondered what hospital Kann went to. They live in Oscoda County, Michigan. Because I live in Michigan, I knew right away that the family lives in the northern lower Peninsula in a pretty rural part of the state. Even Bay City or Saginaw, neither of which are large cities, would be a pretty long drive (an hour to an hour and a half or more). There are a number of hospitals in Oscoda County, but they are generally small to medium-sized community hospitals unlikely to have the specialized capabilities necessary to optimize treatment outcomes in patients with brain cancers and even these hospitals could be a haul, depending upon where in the county the family lives. The only National Cancer Institute-designated comprehensive cancer centers in the state are in Ann Arbor (the University of Michigan) and Detroit (Karmanos Cancer Center), both in the southeast corner of the state.
But what about astrocytomas? What might have been Kann’s prognosis when she was identified? As is the case with most brain cancers, her prognosis wasn’t great, but it was actually better than a lot of patients with other kinds of brain cancer who went to the Burzynski Clinic. The Brain Tumour Charity notes for a grade III Astrocytomas that about “27% of people diagnosed with a high grade astrocytoma live for five years or more,” which, as we have seen, is actually significantly better than for most brain cancers that have been discussed on this blog in the context of cancer quackery. On the other hand, such prognoses generally assume beginning therapy expeditiously. In the case of a grade III anaplastic astrocytoma, generally the treatment recommendations include surgery (if the tumor is resectable), followed by radiation and chemotherapy.
As we know from the story, Kann did not undergo any of this upon diagnosis:
When making the decision about her care, Kann said her faith was the biggest factor.
“Aborting my baby was never an option to me because it goes against God’s will,” she said.
“I had many deep conversations with Jesus that week in the hospital, and knew that if I held onto the Lord and his promises, he would keep my baby safe.”
Kann said she was determined to keep her baby alive and deliver her safely — after that, she would worry about saving herself.
Even as her scans remained stable for the remainder of her pregnancy, Kann said she was “disgusted” that the doctors continued to recommend an abortion.
“If the cancer was already as bad as they said, killing my baby wouldn’t have saved me anyway,” she noted.
This is not an entirely unreasonable rationale for choosing not to treat the cancer until after the child was delivered, although clearly it was a risky choice for her and her fetus, although probably more so for the mother. Kann clearly knew this, as this local news story from June indicates:
She says she was told her best option for survival was to abort her baby and to start chemo and radiation right away. Tasha says giving up her child was never an option.
“I was going to keep her and fight and go home and fight it,” said Tasha.
Tasha says being a hospice nurse, she knows the odds are against her. She wants to beat them and watch her baby grow up. She gave birth to a healthy baby girl named Gracey back in October.
Now here’s where the story gets confusing. Kann delivered Gracey nearly a year ago. Now here’s where the story is unclear to me. You would think that, as soon as Kann had recovered from delivering her baby, she would have begun treatment for her brain cancer. It’s not at all clear to me that she actually did that. In fact, I did find a GoFundMe page dated June 2022 that told a somewhat different story; it also told me that Kann had gone to the Rogel Cancer Center at the University of Michigan, which (as you recall) is an NCI-designated comprehensive cancer center. This early GoFundMe only asked for funds because Tasha Kann was unable to work:
I’m Emma Tasha’s sister. With the encouragement of so many individuals looking to assist Tasha and her family we decided to start a gofundme.
Tasha was sent to the hospital on June 4, 2022 with stoke like symptoms. After multiple MRIs and CT scans she was diagnosed with an inoperable, incurable astrocytoma brain tumor.
As of now the only approach the doctors have is chemotherapy and radiation. Given Tasha is 20 weeks pregnant the doctors at U of M are hoping to wait until 28 weeks before starting treatment so they can deliver the baby but only time will tell.
Given the circumstances, Tasha will be unable to work. Please continue to lift up and pray for Tasha and her family.
Notice how different this is from the stories being told now. The doctors at U. of M. apparently did not tell her that she had to get an abortion to begin treatment. We do learn, however, that the tumor was apparently inoperable at the time of diagnosis last year. There’s also a discrepancy between the Fox News story, which says that her battle with cancer began in 2021, and all the other stories that say she wasn’t diagnosed until June 2022. Regardless of the discrepancy, reading between the lines I would speculate that the oncologists likely presented abortion as one option to consider, the other option being to delay treatments until at least 28 weeks gestation, when they could induce delivery and then begin treatment, a perfectly reasonable option. Given that she did not deliver until October, presumably Kann waited for her pregnancy to go to term and then delivered naturally.
Enter Stanislaw Burzynski
Again, nowhere could I find an account that indicated whether or not Tasha Kann underwent evidence-based treatment of her cancer between the delivery of her baby in October 2022 and around June 2023, when the appeals for funding to go to Houston (where the Burzynski Clinic is located) began, starting with this GoFundMe dated June 2, 2023. Unfortunately, it takes a form with which I’ve become all too familiar, and it tore my heart in half to read another one of these stories. Before I quote the GoFundMe, you need to know that apparently in May an MRI showed progression of her cancer. Again, it isn’t clear to me whether Kann had undergone any evidence-based cancer treatment from October 2022 to June 2023, but at this point it no longer matters, because at this point she fell into Burzynski’s clutches due to the false hope he offers, which led the family to withdraw a bunch of money from their retirement fund to begin treatment:
***UPDATE*** Tasha began treatment on 06/13/23 at the Burzynski Clinic in Texas. The initial payment of $22,000 was due on this date. These funds were from a 100% withdrawal from the family’s retirement and savings accounts. We are seeking donations to continue the treatment! Doctors are confident the treatment will be successful and we will be getting MRIs regularly to check the progress. Tasha Kann is 30 years old and from Northern Michigan. She is a wife and a mother to two beautiful children (Deklan,2 and Gracey, 8 months). Tasha is a registered nurse and has dedicated her life to helping others. During Tasha’s second pregnancy, she discovered the following: Almost a year ago Tasha was diagnosed with Anaplastic Astrosytoma Grade lll. Tasha was told the best chance of survival and to buy more time would be getting an abortion and starting radiation and chemo immediately. After much research and many prayers, Tasha decided her best outcome from this disease would be to continue her pregnancy and fight it as naturally as possible, refusing chemo and radiation. Tasha could get into details with statistics, but I will just say she made the right decision. Last week the Kann family received a call from the oncologist with some devastating news. The doctor informed the Kann family after reviewing her scans from the last year all together and looking at the entire picture, the cancer is growing from her central nervous system and is diffused deep, invading 3 lobes of her brain. Tasha no longer has a formal dx and they consider this Gliomatosis Cerebri. The prognosis is 12 months. With this, there are no treatment options. The doctors also told the family radiation to the CNS is never a treatment option and the new doctor was unsure why the doctors gave this as an option in the beginning. For the Kann family, this goes to show the Lord hears us! All of us. Tasha, refusing their treatment, inevitability saved her life. Jesus has carried her this far and I know he isn’t done yet. Most patients with this disease are bedridden and die within months. Tasha is here for the fight and she hopes she has made that clear to everyone. The Lord’s report over her health speaks volumes over the doctors’ reports and she is here to testify!! Tasha will continue to stand firm in her faith and in His promises! Over the last year, with the support of her family, friends and community, she has been able to continue with alternative treatments that have kept her strong, and healthy and have kept the cancer from growing/ spreading or forming additional tumors. Western medicine may have sent her home to die, but she is going to keep pushing on and living her life! Tasha and all of us refuse to give up, that’s something that doesn’t live in her. This is going to be a long journey ahead and we are so thankful for the gift of community and everyone’s support thus far. Tasha is in need of taking massive action which will involve seeking treatment from the Burzynski Clinic in Texas. Tasha was deemed a qualified candidate to be treated at the Burzynski Clinic in Houston Texas. The cost of the clinic is $17,000 a month for 12+ continuous months totaling well over $200,000. Insurance will not pay for this treatment. Thank you for your time and consideration!
From Fox News:
After visiting the clinic in person, Kann had a port installed in her chest so she can administer the immunotherapy treatments at home in Michigan.
Around the clock, she gets 12-minute infusions every four hours.
As of now, the Kanns said they cannot find an oncologist in Michigan who will work with them and the integrative clinic, so they will most likely have to go back to Texas every couple of weeks. Meanwhile, they are continuing scans in Michigan.
Longtime readers will recall how much this sounds like the case of Laura Hymas over a decade ago, in which the family couldn’t find an NHS oncologist in the UK willing to “work with them” administering Burzynski’s quackery. Their laments were captured in one of the two hagiographic propaganda films made about Burzynski by Eric Merola. At the time, I really felt for the oncologist and his ethical dilemma as he tried to explain to Hymas why he thought that Burzynski’s treatments didn’t work and therefore why he couldn’t administer them for her. Also, wow. I don’t recall Burzynski requiring infusions every four hours around the clock back in the day and wonder what the “rationale” for that is.
As is frequently the case, her husband’s coworkers are getting involved, as is the whole community:
Unfortunately, Burzynski’s still being Burzynski, still offering his bogus unproven (and disproven) treatments to desperate cancer patients like Tasha Kann, leading them to do the sorts of things that Kann and her family have done: Drain the family retirement account and start fundraising, which has thus far been very successful, so much so that the family has raised over $304K of the $350K goal from over 3,300 donors, likely as a result of all the news coverage her story has gotten, including this appearance on Wednesday morning on Fox And Friends.
It was also from video of the Fox and Friends appearance that I finally learned whether Kann accepted any treatment after the birth of her daughter Gracey. At about 1:58 in the video, the interviewer asks Tasha and her husband Taylor Kann what treatments she did after her baby was born. She doesn’t answer, exactly, but states that she’s now taking “alternative treatments” at the Burzynski Clinic after her doctors told her that they didn’t have anything that could help her anymore, an answer that makes me think that she probably didn’t undergo any chemotherapy or radiation after her baby was born. But, again, who knows?
From the Fox And Friends article accompanying the video:
Kann researched holistic approaches to help her fight the cancer while pregnant — including sticking to a Keto-like diet, exercising and taking supplements, she said.
Now, nearly a year later, doctors have changed her diagnosis as they discovered the cancer had spread — giving her less than a year to live.
This passage suggested to me that Kann stuck with the “holistic” treatments after she had given birth and that eight months later her tumor ha spread. In any event, gliomatosis cerebri is a subtype of astrocytoma and can result as an astrocytoma progresses. This progression led to a spate of stories in June about how “Western medicine” had “sent her home to die” but how the Burzynski Clinic was giving her hope.
At this point, I’m not going to relitigate the evidence showing that Burzynski’s antineoplastons, which he “discovered” in the mid-1970s, do not work against cancer, which I have discussed in great detail over the course of several years. You can click on some of the embedded links if you wish to learn more. Ditto Burzynski’s “personalized gene-targeted cancer therapy,” which is basically an “everything but the kitchen sink” parody of real precision oncology seeking to target driver mutations in an individual patient’s cancer. (I note once again that Burzynski is so arrogant that he claims to have invented precision oncology before renowned cancer centers like M.D. Anderson and Memorial Sloan-Kettering.) Instead, before I update the Burzynski story, I want to quote an update to Tasha Kann’s story, for instance August 3, 2023:
On Sunday afternoon, Tasha lost vision in her right eye which came back gradually shortly after. We have hope that this is the treatment making something happen or change in her brain.
And August 8, 2023:
Tasha has been having numbness in her face and feet and a fairly consistent headache. Tasha tries to stay strong during these times but it is challenging. Tasha continues to take the medication from the Burzynski Clinic in Texas.
These developments do not sound good. I feel for the Kanns. I really do. That will not stop me from continuing to discuss why Burzynski is a quack, however.
“Immunotherapy”?
Over the course of reading several of the news stories, blog posts, and propaganda pieces about Tasha Kann, I could not help but notice a recurring theme about how they describe Burzynski’s quackery. Specifically, here’s another passage from Fox News besides the one quoted above that describes Burzynski’s cocktail as “immunotherapy”:
She and her husband are seeking alternative immunotherapy at an integrative cancer treatment center in Houston, as Kann maintains her decision to not receive chemotherapy or radiation.
This reinforced to me just how much Burzynski labels what he is doing to be consistent with the latest trends in cancer treatment. For example, 10-15 years ago he rechristened his antineoplastons (plus other concoctions) as “gene-targeted therapy” in order to capitalize on the then-new wave of “precision oncology,” in which cancers were subjected to genetic and genomic analysis to try to identify what genes were driving their growth and spread and choose cocktails of targeted pharmaceuticals to treat them. Over the last 5 years or so, however, the latest wave in cancer treatment has been immunotherapy, including cancer vaccines but, more commonly, drugs that target regulators of the immune system, such as Keytruda (pembrolizumab). Indeed, the treatment of triple negative breast cancer (a particularly nasty subtype) has evolved so that the standard of care now includes for most patients Keytruda. So naturally, Burzynski has rechristened whatever it is that he’s doing these days at his clinic as “immunotherapy.”
Indeed, right there on the front page of the Burzynski Clinic website, I saw:
Our goal is to provide sophisticated cancer care utilizing a personalized and precision targeted immunotherapy approach.
Our personalized cancer therapy utilizes an understanding of each patient’s cancer genetic and immunotherapy make-up to unravel the biology of their cancer and to identify effective treatment strategies using targeted therapies and immunotherapies that are aimed at specific genes or proteins that are found only in cancer cells or their environment.
What, exactly, does this mean. Elsewhere on the website:
Personalized and precision cancer therapy utilizes an understanding of each patient’s genetic make-up to unravel the biology of their cancer. Using this information, our physicians attempt to identify treatment strategies that may be more effective and cause fewer side effects than would be expected with standard treatments. By performing genomic tests and analyses, our physicians customize treatment to each patient’s needs.
Personalized medicine may include the combination of targeted therapies and immunotherapies with conventional therapy. It may also involve the use of investigational agents (Antineoplastons), as approved by the law. Patients and/or their caretakers receive training for administering all therapies at home, as well as nutritional counseling.
So, as I rather expected when I started researching this post, Burzynski is still using his antineoplastons. He’s also still using his bogus brand of “personalized gene-targeted therapy.” To this he has added “targeted immunotherapies.” Because of course he has. Immunotherapy is one of the hottest areas of cancer research right now, and Burzynski has always been very talented at glomming onto the latest hot areas of cancer research. (In fairness, Stanislaw Burzynski far from the only cancer quack rebranding his quackery as “immunotherapy.”) The treatment options listed on the website are pretty vaguely described, as has traditionally been the case for Burzynski. As is also usually the case, the website is pretty short on actual scientific and clinical evidence, most being old publications (some of which I’ve discussed before) and case reports, but long on testimonials.
The saddest part
What I usually find to be the saddest part of stories like that of Tasha Kann is the realization that, while it’s true that the patient being lured by cancer quackery by someone like Burzynski or any other cancer quack generally has a high probability of dying of her cancer anyway even if she were to choose conventional therapy, quacks rob patients like her of two highly valuable things. The first is time spent pursuing ineffective treatment that could better have been spent on treatments to maintain quality of life so that the most can be made of whatever time is left with family and friends. The second is money. Although in this case, Kann’s family has successfully raised over $300K, that was only after a large withdrawal from the family retirement fund and in many other cases families end up draining their bank accounts and even selling their houses in order to pay the quack. Moreover, in this case, all the money raised by well-meaning family, friends, co-workers, and strangers on the Internet isn’t going to actually help Kann and her family. Instead, it will go to continue to enrich an already wealthy quack, so that he can continue to prey on patients just like Tasha Kann, as well as their families.
It’s worse in this particular case, too. Whenever a patient like Tasha Kann chooses quackery over medicine, the story is always portrayed as one of bravery, of free thinking, of daring to do the hard thing and go for a cure. However, Kann’s case has the additional overlay of her being portrayed as the most heroic of mothers, someone who chose to risk her life rather than kill her baby:
Gracey, Tasha and her husband Taylor’s second child, was born last October. She is now thriving, even as her mother continues to battle brain cancer.
“Every single day, I look at my beautiful baby and think about how easy it was for them to tell me to abort — like she was nothing,”
“If I had listened – like most patients do, because they trust their doctors and don’t do their own research – my baby wouldn’t be here,” she reflected. “It’s a miracle from God that we are both here.”
There is clearly an element of truth to the idea that it is brave for a mother to sacrifice for her children, even though this narrative seems somewhat at odds with the early narrative that Kann was apparently given the option of delivering her baby early versus, as far as I can tell, terminating the pregnancy and beginning chemotherapy eight weeks sooner. Here’s the problem. If you Google Tasha Kann’s name plus “cancer” you will find article after article on antiabortion websites proclaiming her as a hero and proclaiming how God convinced her to keep her baby. Unfortunately, if and when Tasha Kann succumbs to her brain tumor, the narrative will be seamlessly updated to portray her as a martyr, which is an even more compelling story to propagandists.
Whatever the ultimate outcome of the story ends up being, Stanislaw Burzynski will still have profited enormously from the suffering of Kann and her family and what is, in essence, free advertising provided by Fox News, which likely greatly increased the largess from the public that allows the Kann family to continue to pay him. It’s what he’s been doing for nearly five decades now. I fear that he will never retire and won’t stop until the inevitability of death finally takes him, as it eventually does all of us. Unfortunately, even though Burzynski is now 80 years old, he could potentially continue to prey on desperate cancer patients like Tasha Kann for another decade. Certainly, neither the Texas Medical Board nor the FDA has been able to stop him since he first got started in the 1970s, and, I fear, they won’t be able to stop him in the future either.

MAHA: Everything old is new again, except this time antiscience cranks (like Stanislaw Burzynski) are in charge
Returning from my hiatus, I couldn’t decide on a specific new topic, mainly because so much bad stuff happened in my absence. So, in this post I back up a bit to reflect on how RFK Jr.’s “make America healthy again” is nothing new. What is new is that the antiscience-cranks are in charge.
David Gorski on February 23, 2026
Link

I am returning from a two-week bereavement-related hiatus. Longtime readers deserve to know that two weeks ago my mother died after a long illness, and the funeral was held on Saturday. Since my father died a couple of weeks before Christmas 2024, I have been primarily in charge of my mother’s finances and house since then. Over the last year and a half my sister and I visited my mother several times a week and my sister from out of town would come in when she could; quite frankly, I’m feeling a strange emptiness from not knowing what to do with those many hours a week spent with Mom as her cognition and health declined. Coming back, I was seriously tempted to write a more personal post about how, during the three years since my mother’s stroke that resulted in her developing vascular demential and the 14 months since my father’s passing at the end of a long hospitalization, I as a physician have confronted the medical system from the other side, discovering in the process just how much the US healthcare system falls short and how much eldercare in this country stinks, but it’s just too soon. One day I will do such a post, but today is not that day. Feelings are still too raw. Maybe I’ll do it after the estate is taken care of.
Still, this blog beckons, and, although tempted, I really didn’t want to take a third week off because writing my weekly post will help me ease back into my regular routine.
As I contemplated what to write about this week, I must confess to having faced the tsunami of nonsense that has occurred during the three weeks since I last posted here and experienced an uncharacteristic feeling of being overwhelmed. There are so many things that I could have written about. For example, I was highly tempted to write about “Podcast Jay” Bhattacharya‘s having been appointed acting director of the Centers for Disease Control and Prevention, that in addition to his role as NIH Director. Let’s just say that his appointment as acting director of the CDC confirmed to me what I have been saying all along. Podcast Jay was never truly in charge of the NIH; he has been and continues to be a figurehead under whom Russell Vought and Matthew Memoli will transform the NIH into a research arm of MAHA and a grant awarding system based, as part of Lysenkoism 2.0, less on scientific merit than on patronage to reward friends of the administration and punish opponents. Similarly, Podcast Jay will not be in charge of the CDC either. He will be the temporary figurehead under which the longtime antivax activist who is currently our Secretary of Health and Human Services, Robert F. Kennedy, Jr., will degrade and ultimately destroy much of the CDC’s public health and vaccination programs. I just had to mention that in case I never get a chance to circle back around to this out in detail.
Instead, for some reason, I kept thinking about how there’s nothing new about RFK Jr.’s “make America healthy again” (MAHA) movement, except that the antiscience cranks, quacks and antivaxxers are firmly in charge. The led me to reflect on one the longest-standing bête noire of pseudoscience, Polish expat turned cancer quack Dr. Stanislaw Burzynski, and how his activities starting 50 years ago and continuing into the 2020s, helped lay a lot of the groundwork for the tactics and tropes of MAHA. There is nothing truly new under the sun in terms of quackery, other than that, even with my knowledge of medical history, I am not aware of a time when not only are the cranks fully in charge but when actual science-based medicine is in retreat.
The odd thing is, with MAHA ascendant and the ideological heirs of Burzynski, such as William Makis, Pierre Kory, and Tess Lawrie (among, sadly, many others) promoting outright cancer quackery in the form of repurposed drugs and at least one legitimate scientist (Dr. Wafik El-Deiry) falling down the MAHA rabbit hole and giving them aid and comfort with his hand-waving cherry-picked science and nonsense supporting the false view that COVID-19 vaccines cause cancer, we don’t hear much about Burzynski these days. But he’s still around, having recently celebrated his 83rd birthday still quacking loud and strong at his clinic in Houston.
I’ve been writing a lot about how, starting very early in the pandemic, COVID-19 minimizers, cranks, and quacks have touted “repurposed drugs,” such as hydroxychloroquine and ivermectin, for COVID-19. Then I noted how, as the pandemic was finally starting to wane, they pivoted effortlessly to touting the same repurposed drugs for cancer. William Makis and Pierre Kory have been particularly prodigious in this effort. William Makis, for instance, has been promoting a treatment protocol for cancer involving repurposing drugs like ivermectin and mebendazole, plus a variety of supplements, all while sharing “miracle cure” anecdotes on his Substack (most behind a paywall, of course). He even briefly sucked cartoonist turned MAGA populist Scott Adams, who, sadly, ultimately died of his metastatic prostate cancer last month, Even though he did ultimately abandon Makis’ quackery, he found out that there is no cure for stage IV prostate cancer. None of this stopped Makis from somehow securing a Florida medical license earlier this month, because of course Florida granted him a medical license. As for Kory, he’s been claiming miraculous results from a cancer treatment protocol involving ivermectin for two years now. Let me just remind you that, as good as a drug as it is for treating roundworm-related disease, ivermectin doesn’t work against cancer, the NCI’s decision to reinvent the wheel by restudying the drug in vitro notwithstanding. We’ve known this since 2021, at least, and I highly doubt that new studies will change that.
Again, all of these quacks are the 21st century heirs of Burzynski, who laid the groundwork for them 50 years ago.
Stanislaw Burzynski: From science-based physician to cancer quack
One of the sometimes startling characteristics of the current generation of cancer quacks and grifters who took their heel turn towards quackery during the COVID-19 pandemic is that some of them were pretty well-respected physicians. Makis, of course, was not one of those doctors, as his heel turn occurred years before the pandemic, but Pierre Kory and his cohorts were. So was Wafik El-Deiry. Longtime readers might recall that Stanislaw Burzynski was a highly promising physician who did his training during the 1960s in Poland, which at the time was under the control of a Soviet Communist puppet government. Born in Nazi-occupied Poland in the city of Lublin on January 23, 1943, as the Holocaust in Poland was entering its deadliest phase, Stanislaw Burzynski was mostly sheltered from the grim reality of Nazi-occupied Poland during his earliest years because of his mother’s wealth. After the war, when Burzynski was five, Stanislaw’s older brother Zygmunt was killed fighting the newly installed Communist regime. In his hagiography The Burzynski Breakthrough: The Most Promising Cancer Treatment and the Government’s Campaign to Squelch It, Thomas Elias quoted Burzynski invoking his brother thusly, “The idea of fighting people in authority became natural to me. I learned that you must never let them defeat you in your own core.” This sort of determination could have been an admirable trait—if only Burzynski had found a worthy cause to serve.
Sound familiar? This trait, of taking what can be a laudable thing (questioning authority) to extremes that lead away from science and into pseudoscience, seems to be a defining trait of many of the new cancer quacks whose rise occurred during the COVID-19 pandemic. Still, this alone is not enough of a similarity to draw a line from Burzynski to ivermectin pushers. It’s a characteristic that seems to have been found in abundance in quacks throughout history dating back decades, if not hundreds of years. What is interesting to me is that in the late 1960s and early 1970s the young Burzynski seemed to be the real deal, an academic physician who applied science to try to improve cancer treatment.
Indeed, by 1967 Burzynski was ready to work on his medical school doctoral research project. He had become interested in differences in the amount and types of peptides found in the blood and urine of renal failure patients and cancer patients. He reported that some of these chemicals were found at high levels in the blood of renal failure patients. He also found that cancer patients had a low level of some of these substances, which were not, it turned out, peptides. Ultimately, his work in this area resulted in a thesis entitled “Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency.” There is some question that will likely never be resolved about whether Burzynski’s doctoral degree is legitimate, but for purposes of this post I don’t really care. What I care about is what Burzynski has done since.
By 1970, Burzynski decided that he couldn’t stay in Poland anymore. Elias reports that in 1970 Burzynski was being recruited to join the Communist Party but refused to join. This was perhaps the first case, but definitely not the only case, where his stubbornness caused him serious problems. Burzynski learned he was going to be drafted into the Polish Army, where he would be sent to wherever the Soviet Union needed him, but, thanks to the intervention of a prominent scientist, managed to get a passport and get out of Poland before his draft notice was delivered. He arrived, as he has said so many times, at JFK Airport with only $20 in his pocket.
Burzynski stayed with an uncle in The Bronx but soon managed to get a job at the Baylor College of Medicine in the Department of Anesthesia, then headed by Georges Ungar, a Hungarian refugee with whom he hit it off. Ungar was famous for proposing that memory resided in peptides made by the brain, and he tried to “transfer” memory by transferring those peptides from one mouse brain to another. It’s a hypothesis that seemed to be supported by his experiments at the time but faded from favor as more research failed to support it. Burzynski split his time between working on Ungar’s project and working on his own peptides, which he had finally dubbed “antineoplastons. He even managed, with the help of an investigator at M.D. Anderson, to secure an NIH grant in 1974. These years were productive for Burzynski, and he and Ungar published a lot of papers. Burzynski apparently killed a lot of rats in his time at Baylor doing Ungar’s research, which is something I can totally relate to, having dispatched hundreds of mice myself (and hated doing it) while doing angiogenesis research in the 1990s. Basically, rats were trained at tasks by the hundreds, after which they were killed and the peptides from their brains isolated. These peptides were then injected into the brains of other rats in order to see if the “knowledge” could be transferred with the peptides. Fun times!
One thing that seems to have pushed Burzynski to “buck the system” (and become a quack) is similar to the sorts of things that seem to have pushed Kory, for instance, to do the same nearly 50 years later. In 1973, after three years of study, Burzynski had managed to pass the medical board examinations and obtain his Texas medical license. However, as I’ve pointed out before multiple times, he had no U.S. specialty training in oncology. In fact, he doesn’t appear to have had any specialty training even in internal medicine, and an internal medicine residency is a prerequisite to doing an oncology fellowship and becoming a fully-trained oncologist. One thing I couldn’t figure out from either book or any of my other reading is how Burzynski got a license to practice medicine in Texas. Usually, getting such a license requires at least a year of postgraduate medical training (usually an internship) in addition to medical school and passing the national medical board examinations. I can only speculate that whatever postgraduate clinical training Burzynski might have done in Poland must have counted, because I can’t find any reference to him doing any clinical training after arriving at Baylor. That’s not really the most important issue here, but it is a curiosity to me as a physician.
It’s also indicative of the extreme arrogance that Burzynski exhibited at the time. Elias recounts how in 1976 Burzynski thought that because he had obtained his medical license in 1973 he was then qualified to be the principal investigator for the first clinical trial of antineoplastons. He didn’t want to let anyone else be in charge of such a trial, even though it is obvious to me that at the time Burzynski was completely unqualified to run even a small phase I oncology trial. It’s rather instructive to look at what happened here from three different perspectives, the narrative in Elias’ book, as well as the the narrative in a chapter in the rather self-aggrandizing Galileo’s Lawyer: Courtroom Battles in Alternative Health, Complementary Medicine and Experimental Treatments by Richard Jaffe. (Note that Richard Jaffe is now serving as counsel for Children’s Health Defense, the antivax organization founded by RFK Jr. himself, and is lead attorney for at least one CHD lawsuit against vaccine mandates.
So what did happen? From what I can gather from Elias and Jaffe, a confluence of events conspired to push Burzynski towards his fate. Burzynski successfully competed for an NIH grant to study antineoplastons in 1974, but was unable to renew it in 1976; it expired in 1977. In 1976, apparently internal politics led to Ungar’s ouster from the Department of Anesthesia. According to Elias, the new “boss of anesthesiology” (as Burzynski was quoted as putting it) was Lawrence Schumacher, who wasn’t interested in peptide research and didn’t think much of Burzynski. He also, arguably quite appropriately, didn’t think that Burzynski’s research was the sort of research that was appropriate to a department of anesthesia. So Ungar ended up taking a job at the University of Tennessee, and Burzynski had trouble renewing his grant. Apparently, if Burzynski is to be believed, the new cancer research center at Baylor wanted to hire him and even offered him a $30,000 start-up package (respectable at the time), but it also imposed two conditions that were unacceptable to him. First, it wanted the rights to his antineoplaston discovery. This has been common practice at universities for a long time. If an investigator discovers something patentable while working for a university, usually the university will patent it and share a cut with the inventor. Burzynski, however, didn’t want to share. Similarly, although Ungar offered Burzynski a position in Tennessee, Burzynski did not want to follow his friend there because he was afraid that the University of Tennessee would want his antineoplastons, too.
There was another condition, too, and it’s a problem that tells me that from a very early time in Burzynski’s career he didn’t “play by the rules.” However, it was more than that. Not only did he not “play by the rules,” but he didn’t much care for those pesky regulations and ethical codes designed to protect human subjects. Here’s where Elias and Jaffe diverge. According to Jaffe, shortly after he got his medical license Burzynski started a private practice on the side, and that practice became fairly lucrative. According to Jaffe, Burzynski joined someone else’s practice part time. Actually, Elias is inconsistent on this issue, at one point implying that it was Burzynski’s private practice and at another point saying that Burzynski worked for someone named Dr. Walker. Whatever the case was, both agree that before he even tried to undertake clinical trials of antineoplastons at Baylor, Burzynski had been giving ANPs to patients at his private practice. Sound familiar? Many are the COVID quacks turned cancer quacks who did just this.
Still, these similarities are not enough. Quacks in general behave this way. If they are not grifters, they tend to believe so strongly in their quackery that they don’t think ethical considerations apply to them and twist medical ethics to convince themselves that subjecting their quackery to clinical trials to determine if they work and are safe and effective is actually the unethical thing to do. Somehow, though, that doesn’t seem to stop them from charging their patients huge sums of money for their unproven “cures.” As the 1970s careened towards their end, Burzynski was just a quack who, although he had a respectable academic background, had founded his own private clinic, where he charged desperate cancer patients thousands upon thousands of dollars for his “cure.”
There was one unique thing about Burzynski even at this stage. His “cure,” antineoplastons, were peptides isolated from the urine. In order to isolate and concentrate his antineoplastons, Burzynski needed 30 L of urine to isolate the antineoplastons needed to treat one patient, and it had to be human urine. He could also use human blood to isolate them. In his chapter on Burzynski, Jaffe recounts some amusing anecdotes of Burzynski’s early years after leaving Baylor. Back then, he really did isolate ANPs from blood and urine. Apparently before he left Baylor, he got ANPs mainly from blood:
For the previous few years, he had been obtaining antineoplastons from human blood in an unusual way. He got his raw material from the blood of his friends and acquaintances. He would go to parties and public gatherings with IV lines and bottles and beg and cajole his friends and colleagues to donate blood for his research.
After a while, he noticed he was getting fewer and fewer invitations to parties, and, when his friends would see him on campus or the street, they would turn and walk away quickly, pretending they didn’t see him.
This is, of course, a reasonable response.
After he went into practice for himself, Burzynski’s need for raw materials skyrocketed, and the only feasible way to get them was from urine. To get it, Burzynski arranged to install urine collectors in public parks and the state penitentiary system. Most amusingly of all, apparently Burzynski collected urine from Gilley’s Bar, where Urban Cowboy was filmed. One wonders whether John Travolta contributed to some of those early antineoplaston batches.
Burzynski the MAHA pioneer
While the little back story about how Burzynski isolated antineoplastons before he figured out how to synthesize them in the 1980s aside, how did Burzynski help pave the way for MAHA? Some early hints can be found, in of all places, in three issues of Penthouse published in the late 1970s. I first wrote about the three-part story Penthouse feature written by longtime quackery promoter Gary Null nearly 13 years ago, and these issues represent quite the time capsule into the cancer-focused proto-MAHA movement. How this series came about probably has to do with Penthouse publisher Bob Guccione’s belief in cancer quackery, which resulted in three articles published in successive issues of Penthouse: The Great Cancer Fraud by Gary Null and Robert Houston; The Suppression of Cancer Cures by Gary Null, which tells the story of Burzynski, c.1979; and Alternative Cancer Therapies by Gary Null and Anne Pitrone. You can either read the articles yourself or read my summary of them from 13 years ago, but together they portray Burzynski as a “brave maverick” whose cancer “cure” is being suppressed by the American Cancer Society and big pharma (The Great Cancer Fraud), and relating his antineoplastons to a longstanding bit of “folk medicine,” namely urine therapy (The Suppression of Cancer Cures), all while comparing Burzynski to Louis Pasteur, Ignaz Semmelweis, and Galileo.
Indeed, the myth-making and legend-building clearly had begun before Null wrote his article, the rest of which followed a script that was new back in 1979 but has become old and tiresome now. Any time anyone or any professional organization investigated Burzynski for unethical conduct, in this case administering his antineoplastons to patients even though (1) they were not approved drugs, (2) he hadn’t done any tests in animal tumor models yet, and (3) he wasn’t doing proper clinical trials, all of which were indications for an investigation, it couldn’t possibly have been because there were legitimate concerns about his activities. Oh, no. To Burzynski and his supporters like Null, it was (and still is) because the medical establishment was closing ranks to suppress a promising new cancer therapy.
The third article, Alternative Cancer Therapies, told a story of a number of clinics, several of which still existed 13 years ago (34 years after the Penthouse trilogy had been published) and several of which have found their way into MAHA, such as homeopathy and orthomolecular medicine (functional medicine hadn’t been invented in the late 1970s), using protocols that could include combinations of woo including laetrile, high dose vitamin C, and protocols involving combinations of therapies, such as chelation therapy, various nutritional interventions, “detoxification,” intravenous H2O2 (peroxide) and/or vitamin C.
While these are interesting as a historical interest, what caught my attention was the emphasis on “health freedom” and a lack of concern for clinical trials. This is where Burzynski made his first key “innovations,” although these advances in the proto-MAHA cause didn’t occur until the 1990s, with the help of Jaffe, who was Burzynski’s longtime lawyer until Burzynski stiffed him for legal bills. Before I discuss this, let me point out that antineoplastons do not work; there is abundant evidence of this that I reviewed in an article for Skeptical Inquirer in 2014. Indeed, From the late 1970s to the turn of the millennium , Burzynski was under nearly constant investigation by medical authorities, beginning with the Harris County Medical Society in 1979, and continuing with the Texas Medical Board and the FDA. Indeed, since the 1970s, the Texas Medical Board tried to strip Burzynski of his license to practice at least twice, failing to do so in 1993 and most recently in 2012.
To neutralize authorities, Burzynski “pioneered” three tactics in the 1990s. First, he mobilized his cancer patients into a sympathetic and persuasive force that could be weaponized against legislators, the Texas Medical Board, and federal regulatory agencies who were trying to hold him to account. Second, he cultivated powerful allies in the Texas and federal legislatures including in particular Representative Joe Barton (R-Texas), who held a series of hearings featuring cancer patients who were, quite understandably, terrified that Burzynski would be convicted. (Remember, these patients were completely convinced that Burzynski was the only person who could save them.) Between the cynical political theater, featuring weeping parents of children with brain tumors, national press stories of demonstrations featuring patients chanting “FDA go away! Let me live another day!” and the intense political pressure brought to bear by Barton, who dragged then-FDA Director David Kessler in front of his committee four times over two years to explain why the FDA was “harassing” Burzynski, the FDA ultimately relented and entered negotiations to let Burzynski set up clinical trials. Taking advantage of the ruling and the political pressure on the FDA, Burzynski and Jaffe decided, in essence, “If the judge wants clinical trials, we’ll give him clinical trials.” So that’s just what they did.
Guess what? Burzynski was among the first to pervert and weaponize the clinical trial process in order to let him continue to ply his quackery unmolested. How he did it in the 1990s was different than the weaponization of clinical trials today, but he and Jaffe twisted clinical trials to their quack ends nearly 30 years ago. His patient groups and contacts in Congress allowed him to do this in order to counter prosecution by the FDA for administering unapproved medications. First, patients already being treated were enrolled in a wastebasket trial known as “CAN-1,” a retrospective trial looking at all patients then being treated at the Burzynski Clinic. Of this trial, Jaffe wrote:
The CAN-1 protocol had almost two hundred patients in it and there were at least a dozen different types of cancers being treated. And since all the patients were already on treatment, there could not be any possibility of meaningful data coming out of the so-called clinical trial. It was all an artifice, a vehicle we and the FDA created to legally give the patients Burzynski’s treatment. The FDA wanted all of Burzynski’s patients to be on an IND, so that’s what we did.
The FDA also permitted Burzynski to set up nearly identical phase 2 trials for every cancer that he wanted to treat. Burzynski claimed these were based on a protocol used in a trial done by the National Cancer Institute in the early 1990s when the NCI had tried to work with Burzynski. (This effort failed because of strife between the NCI and Burzynski, who viewed the NCI as trying to sabotage the trial. These trials had but one purpose, to allow Burzynski to continue treating patients with ANPs, as Jaffe himself boasted in his book:
The FDA also permitted Burzynski to set up nearly identical phase 2 trials for every cancer that he wanted to treat. Burzynski claimed these were based on a protocol used in a trial done by the National Cancer Institute in the early 1990s when the NCI had tried to work with Burzynski. (This effort failed because of strife between the NCI and Burzynski, who viewed the NCI as trying to sabotage the trial. These trials had but one purpose, to allow Burzynski to continue treating patients with ANPs, as Jaffe himself boasted:
CAN-1 allowed Burzynski to treat all his existing patients. That solved the patients’ problems, but not the clinic’s. A cancer clinic cannot survive on existing patients. It needs a constant flow of new patients. So in addition to getting the CAN-1 trial approved, we had to make sure Burzynski could treat new patients. Mindful that he would likely only get one chance to get them approved, Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future.
The prosecution thus undermined, the first trial ended in a hung jury in 1997, and a second trial on a subset of the original charges resulted in Burzynski’s acquittal. Since then, Burzynski has practiced (mostly) untroubled by the law, other than intermittent FDA inspections and warning letters, none of which succeeded in shutting down his clinic. He also pioneered some MAHA cronyism. For example, chair of the IRB at the Burzynski Institute was for a long time an old Burzynski crony from Baylor and the current chair of the board of directors at the Institute, Carlton F. Hazlewood.
Of course, MAHA weaponizes clinical trials in the same and different ways. They do it the same way by using rather “fluid” requirements for clinical trial evidence necessary to support approving therapies that MAHA likes (e.g., stem cells, peptides, supplements, and the like), while invoking a fundamentalist version of evidence-based medicine (EBM) to require unethical and impractical clinical trials of new vaccines (and possibly even new versions of existing vaccines, such as influenza vaccines) before approval. Before Burzynski, the proto-MAHA movement just invoked the tired old quack trope about knowing that the quackery worked and that the quacks were too busy curing patients to bother with those pesky old clinical trials. Post-Burzynski, quacks do sometimes invoke that argument, but they often try to co-opt clinical trials to give the appearance of efficacy—or at least to be able argue that what they are doing is legitimate experimental medicine. All of this is now bedecked with the glittery label of “gold standard science” or “best practices,” both terms used to justify unscientific and pseudoscientific practices justified in large part by the perversion of the clinical trial process. For MAHA as for Burzynski, clinical trials are and always have been a means to an end: In Burzynski’s case, it was to let him give ANPs to patients unmolested by the authorities. In MAHA’s case in 2026, it is to serve as a scientific-seeming justification for FDA approval of quackery and to give the FDA a pretext not to approve new vaccines.
There’s are two other favored tactics that Burzynski “pioneered,” and that’s bullying. Robert Blaskiewicz documented many of the bullying tactics deployed against critics, as did I. For example, in 2011 his representative threatened a UK high school student,Rhys Morgan, who wrote a skeptical blog, with a lawsuit to silence him. Around the same time, other skeptical bloggers, including Andy Lewis, Peter Bowditch, Popehat, and others also received pseudolegal threats from the Clinic’s representative. The second tactic was the use of video and social media to promote stories of “miracle” cures of cancers, in particular two movies that portrayed him as a persecuted doctor who was curing cancer despite the best efforts of The Man to stop him, the first of which was responsible for attracting many desperate patients to the Burzynski Clinic in Houston, with the second movie buffing up Burzynski’s heroic image while also serving as an attack on “The Skeptics.” I assume that this all sounds familiar. Indeed, Burzynski took it even further, cultivating relationships with tabloid press, which touted “miracle cure” stories breathlessly and, in the UK, used them to attack the NHS for refusing to pay for antineoplastons for cancer patients, which had the further effect of publicizing crowdfunding efforts by Burzynski patients to afford the hundreds of thousands of dollars that his treatment could rapidly end up costing.
Seriously, there was no end to this man’s perfidy with respect to treating cancer patients, tactics emulated by legions of MAHA quacks, many of whom are now in charge of the federal public health, medical, and biomedical research establishment.
Unfortunately, MAHA owes a debt to Burzynski
Bringing it all together, it is clear that Burzynski was MAHA before there was MAHA. Indeed, he “pioneered” a lot of the tactics and rhetoric used by MAHA, including weaponizing patients, cozying up with legislators, perverting the clinical trial process, attacking critics on social media, and producing conspiracy-laden hagiographies that portrayed him as a persecuted brave maverick who’s curing cancer but being unfairly attacked by skeptics, the FDA, big pharma, and the law. To top it off, something I forgot to mention above is that he also was among the first quacks to use repurposed medical therapies. Indeed, around 13 years ago, he was promoting, in addition to his antineoplastons, “gene-targeted” therapy as if he had invented the concept of genomic medicine, an “innovation” that MAHA stans and quacks have taken as an example in their use of “repurposed drugs” and other dubious cocktails used to treat everything from COVID-19 to autism to cancer to the common cold. Basically, Burzynski learned to hop on the latest promising modality for cancer, adopt and pervert it, and then charge huge sums of money for it, in addition to his antineoplastons. Most recently, it’s immunotherapy.
Here’s the funny thing. At 83, even though he’s still quacking away, we hardly hear anything about Burzynski. At least, I don’t. The last time I wrote about him was in 2023, when I noted that his clinic was still operational and that he was still preying on desperate cancer patients. Looking at his clinic website now, what I see is a rebranding in which antineoplastons are deemphasized and various twisted versions of “personalized medicine” are front and center. Yes, he now offers a “bespoke, patient-centered” concierge approach, because that’s where the money is now. Just for yucks, I did multiple Google searches for information on Burzynski that is less than a couple of years old and found little. His clinic still exists, and, I must presume, continues to charge tens to hundreds of thousands of dollars for his “bespoke” treatments (nearly all of which include antineoplastons).
It’s rather funny. As I said before, you’d think that Burzynski, who has a five decade history of recognizing trends in medical pseudoscience that will benefit him and then jumping on the wave at the right time, seems not to have gone MAHA, something that I would have expected him to do. The further irony is that, even though he was MAHA before there was MAHA, Burzynski seems not to be recognized as the pioneer in MAHA-style quackery that he truly is. As he enters the twilight of his life, I have to wonder if that burns him, or if he’s just happy to keep quacking, keep representing himself as the brave maverick that The Man couldn’t shut down, and, above all, to keep profiting.
Maybe it doesn’t matter to him, as long as MAHA cranks are in charge and leave him alone to continue his half century of grift until he can’t grift any more.

Cancer quackery: Under MAHA, everything old is new again
A viral Instagram post claims that cancer is not a disease, but rather a defense mechanism against “toxins.” Everything old is new again under MAHA.
David Gorski on August 10, 2026
Link

As seems to be the case almost every week, as I sat down to do my weekly post for this blog, I had a hard time deciding what specific topic I should devote my attention to, thanks to the hellscape that is our current government when it comes to public health. News stories that Donald Trump is about to issue an executive order on autism and vaccines, ordering more research into the already massively studied question of whether vaccines increase the risk of autism? Let’s just say that if he had issued the order before this weekend, that would have been my topic, but I didn’t see the point of speculating right now just how bad it would be. News stories about how a notoriously bonkers “lab leak” conspiracy theorist is on the short list to succeed Dr. Anthony Fauci as head of the National Institute of Allergy and Infectious Diseases (NIAID)? I thought about both, but then an Instagram post making the rounds (which appears to have been deleted since going viral and spawning a bunch of reaction videos) caught my attention. Remember how during the pandemic I kept saying that everything old is new again and that there is nothing new under the sun when it comes to antivax narratives and lies? Unfortunately, under “make America healthy again” (MAHA), the slogan repurposed by our current Secretary of Health and Human Services, longtime antivax activist Robert F. Kennedy, Jr., the same is true of cancer, as I hinted at six months ago.
So, until we find out exactly how bad the predicted Presidential Executive Order on vaccines and autism really is, I thought I’d revisit a more “classic SBM” topic. Here are just a couple of the reaction videos to the original video that appears to be gone:





View this post on Instagram










A post shared by Dr Idrees Mughal (MBBS, MRes, DipIBLM) (@dr_idz)





View this post on Instagram










A post shared by James Cappola (@james_cappola)
Yes, it’s the revenge of the return of “cancer is not the disease but a body defense mechanism” against X, X being “toxins” or some other external problem caused by poor diet or external forces. And it’s all over social media again. But that’s not all, as you will see. In any case, I haven’t dealt with this particular claim in a long time, and so I thought it would be worth revisiting, given that it’s now seemingly everywhere. Truth be told, it never went away. No cancer quackery or misinformation ever does. Rather, it mutates, rather like the genome of a cancer cell, in response to the environment in which it finds itself.
Cancer is not the problem? (Robert O. Young)
It’s not difficult to find posts and content making this sort of claim, that cancer is not the problem, but rather a survival mechanism that is trying to protect the body, with the corollary claim that it is the medical treatments, not the cancer, that cause complications and death from cancer, which, if you believe the quacks, can be eliminated with “natural” interventions. Of course, that leaves the question of why you would want to eliminate the cancer if it is a protective mechanism. The answer, obviously, is that you’re treating the “root cause” or the “true cause” of the cancer, unlike that nasty surgery, chemotherapy, radiation, immunotherapy, and targeted treatments that modern oncology and surgery use now.
As I said before, the original Instagram post by Chelsea Chapman that inspired the two reaction videos above appears to be gone. (If one of my readers has come across it, let me know, as I’ve searched diligently and scrolled back through way too much of Chapman’s Instagram feed than is good for my mental well-being and been unable to find it.) However, here is a reel from a couple of years ago that says much the same thing:





View this post on Instagram










A post shared by Onuche Edebo James (@onucheedebo)
And:





View this post on Instagram










A post shared by Sinclair Fischer-Gray (@sinclairfischergray)
And:





View this post on Instagram










A post shared by Neil Ryan Dumra (@neilryandumra)
The man in the video above is Leonard Coldwell, an old-school cancer quack whom I’ve mentioned before. From the first video:
Cancer is not a disease, it’s a survival mechanism. So cancer is not trying to kill you, cancer is actually trying to save your life. Its creating a tumor, a place for all those toxins to be so that they don’t spread to other parts of the body. When you go to a doctor, the first thing they do is say okay, well let’s take a biopsy where they prick the tumor and they see if it was cancerous or not। well first of all whether the tumor is cancerous or not, your passive treatment is still the same so you don’t actually need; the biopsy. In fact, most people don’t actually die from cancer. They die from the treatment of cancer. Yes. And so so when they take that biopsy, remember that it we’re dealing with health care, so there’s no money to be made off healthy humans. And so when they prick the tumor, they’re opening it up and allowing the cancer cells and all the harmful toxins to now spread throughout the body. So now you go from having a tumor on biopsy, they come back, you know, a little bit later and they say, “Okay, well now the cancer spreading all throughout your body.” So we’re going to have to train uh you know, charge you more money and you’re going to have to do more radiation, chemotherapy and all that…
In the spirit of how everything old is new again, this particular claim, that a cancerous tumor is not the disease but rather the body’s defense mechanism against “toxins” is an old one. I first encountered it two decades ago, but it predates that by at least three decades. In what context did I encounter this claim? Does anyone remember Robert O. Young? I do, because it was in 2007 when I first encountered a post by him entitled What is the cause of cancer? Is there a cure? Let’s see how familiar this sounds:
Cancerous tissue, above all other consequences of choice, has countless secondary causes. But even for a cancerous condition there is only ONE PRIME ORIGIN and CAUSE. I have simply summarized this origin and cause of cancerous tissue in a few words. The prime origin and cause of cancerous tissue is the over-acidification of the tissues then the blood due to lifestyle and dietary choices. A cancerous tissue begins with our choices of what we eat, what we drink, what we think and how we live. Cancer is a liquid and this liquid is a toxic acidic waste product of metabolism or energy consumption.
According to Young, acid is the cause of cancer (of all disease, actually), and alkalinization is the cure in the form of what he referred to as “pH Miracle Living.” But where does the tumor come in? Let’s take a trip down memory lane. First, Young invokes the Warburg effect. I note that around 2007 was when studying the metabolic causes of and contributors to cancer were all the rage. After decades of being underappreciated, the Warburg effect became the focus of intense research because of observations demonstrating its importance. Indeed, here’s a graph from a very good 2016 review on the Warburg effect showing the explosion of scientific papers on the topic that started in the early 2000s:
For those who don’t remember, Otto Warburg won the Nobel Prize nearly 100 years ago for having discovered that many cancers switch from aerobic metabolism (metabolism based on respiration with oxygen) to anaerobic metabolism, in essence “choosing” (if you’ll excuse the anthropomorphizing of cancer) to use glucose as their fuel. You don’t need to understand the details of the Warburg effect to know that it posited that cancer was caused by metabolic derangements, which is why a lot of the advocates of “natural” cancer remedies immediately glommed onto it as justification for their claims that diet and lifestyle interventions were better than surgery, radiation, and chemotherapy for “curing” cancer.
Unsurprisingly, in the scientific literature, the debate is more along the lines of, “Which came first, the chicken or the egg?” What I mean is: Was the disordered metabolism observed in many cancer cells the result of the mutations which had caused the cancer, or were the mutations that caused the cancer a result of disordered metabolism? Of course, we know from copious experiments that there are single genes that can induce cancer, either by being overexpressed (induced to make too much of their gene product) or silenced, by themselves, but there is little doubt that there is a major metabolic contribution to cancer. That’s part of why the current consensus is that somatic mutations drive cancer and that the metabolic reprogramming is adaptive, allowing faster growth, rather than a cancer-inciting event. That disordered metabolism is the primary cause of cancer is very much a minority opinion in oncology, although that doesn’t mean that targeting the metabolism of cancer cells hasn’t proven to be useful for diagnosis, imaging, and some treatment.
But I digress. As I said, you don’t need to understand the Warburg effect to understand why the following blather from Young is nonsense:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
This is wrong on so many levels, particularly the part about cancer cells being healthy cells “spoiled by acid” but also including his claims that “alkalinizing the body” will cure cancer. I also note that he claimed that viruses are “molecular acids” (he claimed his “pH Miracle Living” could cure HIV/AIDS as well) and that he is basically a germ theory denialist as well, having used the tragic death of a Brazilian model due to sepsis to claim that sepsis is not caused by bacterial infection, but rather by “acidic lifestyle choices, including acidic food, drink, and drugs – especially dextrose and/or antibiotic IV’s given at hospitals around the world.”
However, the case that made Robert O. Young most infamous was that of Kim Tinkham. Tinkham, you might recall, was a woman diagnosed with breast cancer who appeared on The Oprah Winfrey Show over 11 years ago. During the interview, Tinkham told Oprah that she was not going to undergo surgery, chemotherapy, or radiation but that, thanks to The Secret, she believed that the universe would bring her healing, which was why she chose to use alternative medicine to treat her cancer. (Often forgotten these days is that Oprah was a big proponent of The Secret back then, which preaches that if you want something badly enough, visualize something clearly enough, the universe will manifest it for you.) Who was the quack that Tinkham chose? You guessed it: Robert O. Young. As a result, Tinkham became a passionate advocate for Young’s quackery, even recording YouTube videos with him to tout his “pH Miracle Living.” Ultimately, Tinkham died of her disease, although it did take over three years to happen. No one knows how many other cancer patients who didn’t talk to Oprah Winfrey chose to trust Young, with the same results.
Cancer is not the problem? (Andreas Moritz)
Robert O. Young might have been the first quack that I encountered claiming that cancer is a mechanism to protect the body against “spoiled” cells, but he is far from the first to claim that cancer is not the problem, but a reaction to the “real” problem. Around the same time, a cancer quack named Andreas Moritz published a book entitled Cancer Is Not a Disease! It’s a Survival Mechanism. (There’s even a chapter entitled “The Wisdom of Cancer.”) Here’s a taste of Moritz’s “wisdom”:
If the body is designed to live and not to destroy itself, why then would it suddenly allow the growth of extra cell tissue and kill itself? This does not make any sense at all. The main obstacle to finding real cures for cancer is that modern cancer treatment is rooted in the false assumption that the body sometimes tries to destroy itself. Medical students are trained to understand the mechanism of disease development, but they are left in the dark concerning the origins of disease. Viewed superficially, to the students, an illness appears to be something destructive and harmful to the body. Seen from a deeper perspective, however, the same illness is but an attempt by the body to cleanse and heal itself, or at least, to prolong its life. Since the medical textbooks offer few insights into the true causes of illness, it is understandable that the majority of doctors today believe that the body has self-destructive, and even suicidal abilities or tendencies. Claiming to be non-superstitious and objective, they inadvertently admit that certain cells suddenly decide to malfunction, become malicious, and randomly attack other cells and organs in the body. Based on this purely subjective and unsubstantiated belief, the doctor and his patient alike become almost obsessed with trying to protect the body from itself. Yet despite such undisputed notions of “truth,” none of this means that the body does, in fact, attempt or cause its own destruction. Would it actually astound you if I told you that cancer has never killed a person?
The only thing that would astound me about this claim is just how much of a lie that it is. I have, sadly, seen many die of cancer, including at least two family members thus far.
I love the whole argument from personal incredulity going on here. Just because Moritz can’t believe that the body would ever permit the growth of extra cells that will lead to its destruction and death, he assumes that, in fact, the body does not permit the growth of extra cells that will lead to its death and destruction. It is, of course, true that the body tries very hard not to allow the growth of cancer cells that threaten it. There are lots of very complex and elegant homeostatic mechanisms to keep cells from “going rogue,” as well as similarly complex and elegant immune surveillance mechanisms to destroy cells that “go rogue” before they can progress to full-blown life-threatening cancers. The error in thinking here is that these mechanisms are perfect, that they are foolproof, that they never, ever fail. Unfortunately, nothing in the world is perfect and works 100% of the time. Our body’s defense mechanisms against cancer are quite good, but they are unfortunately nowhere near perfect. They can and do fail, and they fail more often as we get older and damage to the genome accumulates.
Cancer is not the problem? (Ryke Geerd Hamer’s German New Medicine)
Still, Moritz didn’t think of the idea of cancer as a protective mechanism. Its origins go back at least a few decades earlier, to the late 1970s. Does anyone remember Ryke Geerd Hamer’s German New Medicine (Die Germanische Neue Medizin) and its bastard offspring, like the French version, Biologie Totale? Here’s the general idea:
THE GERMAN NEW MEDICINE provides us with illuminating explanations about the origin, development and healing of both physical and mental disorders. In 1981, Dr. Hamer discovered that every DISEASE is caused by a shock experience that catches us completely off guard. He found that this shock not only occurs in the psyche but simultaneously in the brain and on the organ level. At the moment the unexpected trauma takes place the shock impacts a specific area in the brain causing a lesion that is clearly visible on a brain scan as a set of sharp concentric rings. With the impact the affected brain cells communicate the disturbance to the corresponding organ. Whether the organ responds with a tumor growth (cancer), with tissue degeneration, or with functional loss, is determined by the exact type of conflict shock. Based on the analysis of over 40,000 case studies Dr. Hamer is the first to provide scientific proof that cancer is not caused by a malfunctioning organism producing deadly cancer cells but is rather the result of an innate meaningful survival program that has been successfully practiced for millions of years. Since HEALING can only occur after the conflict has been resolved, the GNM-therapy focuses on identifying and resolving the original conflict. By understanding healing symptoms such as painful swelling, infections, fever, or inflammation in their psychological, biological and evolutionary context, we are able to liberate ourselves from the fear and panic that often come with the onset of an illness. Dr. Hamer’s findings offer a completely new understanding of so-called diseases. His scientific discoveries revolutionize entirely our view of medical conditions and their causes.
The German New Medicine presents a comprehensive system that allows us to understand what type of conflict causes the onset of a particular disease, how the disease manifests itself in the conflict active phase, what can be expected in the healing phase, and how all the developments are connected to the brain, verifiable with a brain scan.
See what I mean? The general idea is the same, except that it’s not “cells spoiled by acid” or “toxins” or whatever that the cancerous tumor is protecting you from. It’s psychic trauma. In a way, Hamer’s conclusion is somewhat understandable if you know his history. It turns out that Dr. Hamer’s son was tragically shot in his sleep by Vittorio Emanuel, the last crown prince of Italy. After a prolonged course requiring multiple operations, his son unfortunately succumbed to his wounds, which undoubtedly caused Hamer immense emotional trauma, as the sudden loss of a child always does. Three years later, Hamer developed testicular cancer. After that, in a perfect case of post hoc ergo propter hoc reasoning, Hamer decided that it must have been the psychic shock of his son’s death that had caused his cancer. Forget about all that molecular biology. Forget about oncogenes and tumor suppressors. Forget about increased mutation rates. Hamer, like many cancer quacks before him, preached that everything that scientists thought they knew about the pathogenesis of cancer was wrong. To him, cancer was (and is) really due to a “psychic shock,” not genetic alterations in cells that lead to uncontrolled proliferation.
What about cancer patients who have lived happy lives devoid of “highly acute, dramatic, and isolating shocks”? There’s no such person, according to Hamer. If you search back far enough, you will find such a shock, and if that fails, you can always postulate some sort of birth trauma. As I always say when I discuss the German New Medicine, I don’t mean to minimize the tragedy that Dr. Hamer must have suffered because of the shooting of his son and the fact that the killer got off with a slap on the wrist because of his title and wealth, nor am I claiming that mental stress doesn’t contribute to disease. Unfortunately, Hamer took his tragic personal experience and generalized it to a ridiculous extreme, even to the point of basing rather arrogantly named “biological laws” on it. It’s as if the shock of losing his son unhinged his mind. I’m not going to reiterate all five of his “Iron Laws” of cancer and other diseases other than the First Law, a.k.a. the Iron Rule of Cancer, which is subdivided into three criteria:
    • The development of the conflict determines the exact development of the Hamer Focus in the brain as well as the exact development of the cancer or cancer-equivalent disease in the organ.
    • Every cancer or cancer-equivalent disease originates from a DHS (Dirk Hamer Syndrome), which is a serious, highly acute, dramatic and isolating shock that catches an individual completely off guard. The conflict shock occurs simultaneously in the psyche, the brain, and the corresponding organ.
    • At the moment of the DHS, the content(s) of the conflict determine the location of the Hamer Focus in the brain and the location of the cancer or cancer-equivalent disease in the organ.
According to Hamer, every cancer patient has suffered DHS, and the evidence is a lesion in the brain observable on CT scans called the Hamer Focus, visible “as a set of sharp concentric rings.” (HINT: No one has ever observed the Hamer Focus in cancer patients.) You can read in detail about the rest of the “Laws” that Hamer posited here, if you wish. Suffice to say that Hamer’s ideas were the “inspiration” behind so much quackery. Indeed, one variant of the “cancer isn’t the disease but the defense” is the risible claim by Tullio Simoncini that all cancer is a fungus.
One can argue that the basic germ of the idea that cancer isn’t really the disease but the defense against disease goes back even further, to an idea held by a minority of conventional pathologists around 1900. Sometimes referred to as the parasitic theory of cancer, the idea was that cancer was an attempt of the body to “encapsulate” pathogens. Of course, today we know that some cancers are indeed caused by infection, such as cervical cancer being caused by certain strains of human papillomavirus and stomach cancer being caused by H. pylori infection, but the mechanisms are nothing like what was proposed in the parasitic theory of cancer. A related concept is Antoine Béchamp’s terrain theory, which hypothesized that microorganisms were not the cause of disease, but a manifestation of diseased tissue or a “terrain” that was not in homeostasis.
Cancer is not the problem? Only if you don’t understand cancer!
These days, the idea that cancer is a protective mechanism nearly always posits unnamed “toxins” as the danger that cancer is supposedly trying to protect the body against. Worse, these influencers nearly always claim that cancer is completely—or almost completely—avoidable because it’s a consequence of lifestyle choices, as Robert O. Young put it in 2007:
Cancer is not something we get it is something we do as a consequence of daily choice of what we eat, what we drink, how we think and how we live. We either have an alkaline lifestyle and diet and enjoy a fit and healthy body or we have an acidic lifestyle and diet and experience the aches, pains and suffering from metabolic acids.
And:
A cancerous condition is the consequence of choice. For example, if you want to reduce your risk for cancereous tissue of the lung by 100%, then stop smoking and stop associating or working around people that do smoke.
Secondary smoke is just as acidic and damaging to the lung tissue.
If you don’t want a cancerous liver then stop drinking alcohol and carbonated drinks.
If you don’t want a cancerous pancreas then stop eating the acid, sugar.
If you don’t want a cancerous bowel then stop eating protein.
It is that simple.
The only things in the above passage that are correct are that stopping smoking will reduce your risk of lung cancer and stopping drinking will reduce your risk of liver cancer. Too bad Young comes to the right conclusions in these two cases for the wrong reasons. The idea, however, is very much of a piece with what MAHA has embraced, namely health as a consequence of virtuous health behavior, in which you are damned near entirely responsible for your own health. In this case, the health “reward” is freedom from cancer. Unfortunately, the flip side of this idea of personal responsibility for one’s health is that, if you aren’t healthy and are unfortunate enough to get cancer, then it must be your fault for not living a sufficiently “virtuous” lifestyle.
Unfortunately, this answer resonates among those skeptical or hostile to conventional medicine, leading to posts like this:
While I’m glad that this woman is apparently alive ten years after a diagnosis of a stage IV cancer, her survival doesn’t mean that cancer was beneficial to her and not trying to kill her.
Of course, we now know a lot about how cancer originates, progresses, evades the immune system, and ultimately kills its host if left untreated. Unfortunately, we do not know enough to come close to curing all cancers, and some cancers (e.g., pancreatic cancer) remain deadly and difficult to treat. We do, however, know enough that the death rate from cancer has been steadily declining for the last three and a half decades, having declined by approximately 34% since 1991. That’s what science can do, and deluding oneself into believing that cancer can’t and won’t kill you won’t change that, other than to provide a reason to blame cancer deaths on the treatment rather than the disease.
Sadly, there is nothing new about this. Everything old only seems new again because, before MAHA and the rise of so many quack influencers, most people hadn’t encountered quackery like the claim that cancer is not a disease, but a defense mechanism used by the body to protect itself from toxins.


pH Miracle Living “Dr.” Robert O. Young is finally arrested, but will it stop him?
David Gorski on January 27, 2014
Link
Being a cancer surgeon and researcher, naturally I tend to write about cancer a lot more than other areas of medicine and science. It’s what I know best. Also, cancer is a very common area for unscientific practices to insinuate themselves, something that’s been true for a very long time. The ideas don’t change very rapidly, either. Drop a cancer quack from 2014 into 1979, and he would probably be right at home. Of course, part of the reason is because the “elder statesmen” of cancer quackery today were getting their starts in 1979. Still, the same ideas keep recurring even as far back as a century ago and even older, and if you broaden your criteria, these ideas exist on a continuum, either having descended directly from various ancient ideas such as vitalism, miasmas, or humoral theory or branched off somewhere along the way. Others branch off from the progress of science, taking a germ of a seemingly reasonable idea and turning it into quackery. It is the latter with which I plan on concerning myself today, the reason being that over the weekend I heard some truly awesome news. One of the most egregiously practicing non-physicians who claim to be able to cure cancer that I’ve ever encountered was arrested—yes, arrested!—and arraigned on criminal charges. I’m referring to “Dr. Alkaline” himself, he of the pH Miracle Living program and his Articles of Health blog, “Dr.” Robert O. Young. Behold:
San Diego, California News Station – KFMB Channel 8 – cbs8.com
I so, so love seeing Robert O. Young in a prison jumpsuit. My only disappointment is that it wasn’t orange. Young deserves to be paraded around in prison orange. I also can’t help but note that I always wondered what the “O.” stood for. Now I know: Oldham.
I’ve mentioned Robert O. Young from time to time on this blog, but it’s been at least a couple of years since I’ve discussed him other than in passing. Consequently, now strikes me as an excellent time to revisit, review, and discuss what sorts of pseudoscience and quackery Young advocates to treat cancer and—as is the case with so many dubious practitioners—multiple other serious diseases, such as lupus, type I diabetes (you read that right, not type II diabetes), metastatic prostate cancer, and cancer in general. Not surprisingly, Young is also quite antivaccine, publishing anecdotes from parents who believe their child is “vaccine damaged” and appeals to support antivaccine groups like the National Vaccine Information Center (NVIC). Let’s take a look at what happened last week and why, given the law in California, I’m not sure that this case will be the slam dunk we’d all like it to be. The law in California could easily make it a difficult task for the prosecutor to secure a conviction, much less a 15 year sentence. First, however, for those who are not familiar with Dr. Young, it’s important to provide a little primer on who he is, what he does, and why I am so outraged that he’s been allowed to continue to practice for more than 20 years.
The disturbing saga of “Dr.” Robert O. Young
Robert O. Young is pretty famous as far as “alternative medicine” practitioners go, spawning acolytes like Errol Denton who’s been in a spot of similar legal trouble lately, who trained under Young and remains an admirer. Although I had heard of Young before and written about him more in an amusing than outraged manner, I really first became aware of Young through the case of a woman with breast cancer named Kim Tinkham. Not entirely coincidentally, Tinkham briefly became famous back in 2007 after having appeared on Oprah Winfrey’s daytime talk show in the context of her belief in The Secret, that mystical, magical, childish belief system that the universe will bring you what you want if you only want it badly enough. It’s a system of belief that goes far beyond the reasonable concept that people who want something badly enough will be more likely to try to obtain it and thus more likely to get it and into the realm of wish fulfillment, where “wishing makes it so,” a concept that, I’ve argued in the past, is the central dogma of alternative medicine. At the time, she had recently been diagnosed with breast cancer, described as stage III, and was being urged to undergo surgery. She refused. In 2007, Tinkham appeared on The Oprah Winfrey Show:
In this interview, Kim Tinkham attributes her decision to “heal herself” to The Secret. Oprah, to her credit, was horrified and even called Tinkham “irresponsible” for not taking advantage of modern medicine. It turns out that the “alternative” practitioner she somehow found was Robert O. Young. It also unfortunately turns out that she died of her disease three years ago, losing her battle with breast cancer. In the interim, however, she did testimonials for Young, even going so far as to agree to appear in an hour-long interview with him (now thrown down the memory hole, although I captured a copy of all six ten-minute segments of it for posterity and only wish I could put them back up on YouTube without a DMCA takedown notice and even potentially copyright charge). In any case, Tinkham is only one of Young’s victims, and she was fortunate enough to have survived longer than I would have guessed initially.
So who is “Dr.” Robert O. Young? Let’s take a look at his claimed credentials:
Before Dr. Young began his extensive nutritional research, his love for sports and science led him to the University of Utah—where he studied biology and business in the early 70’s. There he was granted a full athletic scholarship for tennis. His team was consistently one of the top 10 in the nation. He had the experience of competing with the likes of Stan Smith, Jimmy Connors, and Roscoe Tanner.
In the 80’s, following his schooling at the University of Utah, Dr. Young studied medical microbiology—training under Dr. Robert Bradford at the Bradford Research Institute in Chula Vista, California (www.bradfordresearchinst.org). Dr. Bradford is now a trustee and professor at Capital University in Washington, DC, where he teaches live and dry blood microscopy (www.ability.org.uk/holistic_courses_and_schools.html). Dr. Young also studied darkfield microscopy under Dr. Maria Bleker—who was the prodigy of the great late biologist, Dr. Gunther Enderlein—in Essen, Germany.
In 1993, Dr. Young received a MS in nutrition from the American College in Birmingham, Alabama. In 1995, he received his D.Sc. with emphasis in chemistry and biology. Dr. Young’s doctoral dissertation was on Disseminated Intravascular Blood Coagulation and Pathological Blood Coagulation. In 1997, Dr. Young received a Ph.D. from Clayton College of Natural Health. His Professor, James E. Harvey from San Diego State University, reviewed and accepted his dissertation as completing all the requirements for a doctorate of philosophy degree in nutrition. Continuing his studies and research, Dr. Young later received an additional doctorate degree in naturopathy (ND) from Clayton College (1999).
As Dr. Stephen Barrett notes, two of Young’s doctoral degrees were received from diploma mills and Robert Bradford, who was convicted of laetrile smuggling in the 1970s, didn’t even have a college degree. Also, Clayton College of Natural Health was a nonaccredited correspondence school that taught a panoply of quackery. Not long after the state of Alabama began requiring accreditation for license renewal, the Clayton College of Natural Health closed in 2010. As Dr. Barrett drolly notes, the Clayton College of Natural Health did (and does) serve one good purpose, “Its credentials are a reliable sign of someone not to consult for advice.” No kidding. And, even though he claims to have an ND degree, the school from which he obtained it was not accredited, which means that Young’s ND degree is even more worthless than an ND from an “accredited” college of naturopathic medicine, as hard as to believe that’s possible. As The Eleventh Doctor would say, “Basically… run.”
The pseudoscience of Young’s beliefs is hard to summarize in a reasonable amount of text, even taking into account my known tendency towards logorrhea, so massive are its breadth and depth. As has been noted before, Young is so full of pseudoscience that it would take a book to catalog it all, and it begins on the very same page that I cited above, in which Young creates out of whole cloth (well, not quite, but close) a whole “New Biology.” As I’ve said before, that’s always the sign of a crank from whom you should run, as is the claim on his site that over the last 25 years Young has “been widely recognized as one of the top research scientists in the world,” beginning:
In 1994, Dr. Young discovered the biological transformation of red blood cells into bacteria and bacteria to red blood cells. He has since documented several such transformations.
Seriously. If Young had really discovered such things and documented them, he’d deserve a Nobel Prize. Of course, he’s demonstrated nothing of the sort. Basically, part of what he’s selling is a form of regurgitated Antoine Béchamp, a contemporary of Louis Pasteur with a competing hypothesis. That debate was settled scientifically long ago–and not in Béchamp’s favor, for the most part, although 150 years later, germ theory denialists still invoke Béchamp and sometimes even claim that Pasteur underwent a deathbed recantation in which he admitted that Béchamp was right, a recantation that never happened. I frequently point out that, given what was known at the time, Béchamp was not unreasonable to hypothesize what he did, but the evidence clearly favored Pasteur, which is why Pasteur’s ideas won out and the germ theory of infectious disease became widely accepted.
Béchamp’s concept was known as the pleomorphic theory of disease. It stated that bacteria change form (i.e., demonstrate pleomorphism) in response to disease. In other words, they arise from tissues during disease states. We now know, of course, that bacteria do not arise from tissue, although they might have appeared that way because normal flora can sometimes cause disease. Béchamp further postulated that bacteria arose from structures that he called microzymas, which to him referred to a class of enzymes. Béchamp postulated that microzymas are normally present in tissues and that their effects depended upon the cellular terrain. Béchamp’s hypothesis was, however, superseded by Pasteur’s germ theory of disease and Koch’s later work that resulted in Koch’s postulates. Besides not fitting with the scientific evidence, Béchamp’s idea had nowhere near the explanatory and predictive power that Pasteur’s theory did. On the other hand, there is a grain of truth in Béchamp’s ideas. Specifically, it is true that the condition of the “terrain” (the body) does matter when it comes to infectious disease. Debilitated people do not resist the invasion of microorganisms as well as strong, healthy people. Unfortunately, Bechamp remains a frequently invoked scientist by germ theory denialists like Robert O. Young.
The most prominent idea that Young promotes is encompassed in this slide I once made for a talk on alt-med quackery (click to embiggen):
Basically, to Young, acid is the cause of all disease, to the point that he states that overacidification is the cause of all disease, an overarching theory of all disease that he has dubbed The New Biology, and about which he frequently states that “the pH Miracle Lifestyle and Diet is a program focuses on the foundational principal that the body is alkaline by design and yet acidic by function. This make this program the ultimate program for preventing and reversing aging and the onset of sickness and dis-ease. I would say that the pH Miracle Lifestyle and Diet is the diet for immortality.” (Note that another of Gorski’s rules, besides the rule that health practitioner who invokes Béchamp over Pasteur is to be avoided like the plague, is that anyone who uses the term “dis-ease” instead of “disease” is to be similarly shunned.)
For example, after a beautiful aspiring young Brazilian model named Mariana Bridi da Costa died of sepsis after a urinary tract infection so severe that she had had to have her hands and feet amputated in a desperate bid to save her life, Young wrote a post entitled Ignorance Caused Sepsis or Systemic Acidosis That Took The Life of a Young Brazilian Woman:
Sepsis is the number one cause of death in the world and happens every day at Intensive Care Units, Hospitals and Medical Clinics!
What is sepsis or septic shock and what is the cause?
Sepsis or septic shock is a systemic acidic condition caused by acidic lifestyle choices, including acidic food, drink, and drugs – especially dextrose and/or antibiotic IV’s given at hospitals around the world.
Yes, to Young it has to be those evil doctors who killed this beautiful young model with their reductionistic science, pumping her full of IV fluids containing 5% dextrose (which many IV fluids do) and antibiotics! Damn them and their inability to see the truth! Of course, the doctors must have been aided and abetted by Bridi da Costa’s apparently bad lifestyle in which she must have eaten what Young considers to be pure evil, namely “acid” foods:
When someone is over-acid and becomes tired, sick and/or injured and nothing is done to buffer or neutralize the excess environmental, dietary, metabolic, and/or cellular degenerative acids, then death from acidosis or sepsis becomes inevitable.
Most people believe that sepsis or acidosis is an infection. It is not!
It is an out-fection from personal acidic lifestyle and dietary choice. An out-fection, in the body, is the cell breaking down from the inside out from an emotional or physical stress or disturbance giving rise to increased acidity. Dietary and/or metabolic acids are generally the cause of all out-fections or cellular transformations – not the infection from some harmless bacterium and/or yeast. And, a bacterium and/or yeast present in the blood or tissues is the evidence of sepsis or an acidic state that gives rise to biological transformation or the birth of bacteria, yeast or mold.
Note how Young took a valid idea based on science (in this case, that lifestyle and diet can predispose to disease) and extrapolated it to the point where he ran right off into the deep end with it. Again, his arguments echo Béchamp, and he explicitly denies germ theory to the point where he writes posts like The Illusion of Germ Theory, in which he refers dismissively to “Pasteurian scientific dogma,” challenges “everything in the modern construct of immunology and what is said to be the immune system,” and characterizes viruses as “molecular acids”:
Here is a second example of Pasteurian scientific dogma. The word virus is originally Latin meaning poison, as in snake venom, (being too acidic). When a serious snake bite releases venom or acid into the skin and soft tissues, the small sweat vessels become so enlarged that red corpuscles can flow into the tiny seat glands, showing red skin patterns and allowing the venom or acids to escape through the skin. Acidity dissolves and enlarges blood vessels for the movement of acidic fluids or gases. Alkalinity constricts and normalizes the blood vessels.
The point being that viruses are molecular liquids or gases (venom) that can be created by chemical imbalances in humans, plants and animals (by malnutrition or toxic acidic food and/or drink consumption), also created in humans, plants and animal glands, sometimes used in defense (snake venom) or emergency (overactive adrenals), also can be crystallized in laboratories, rarely, if ever crystallized in vivo, and foolish to call viruses contagious when viruses are nothing more than acidic liquids or gases from biological transformation or rotting matter.
I love the way Young based his “rationale” for his arguments on the etymology of words and then ran right off the deep end with it. Unfortunately, he not only jumped off the deep end, but he went off the deep end of comprehensibility, too. He also demonstrated (and continues to demonstrate) just how ridiculous pseudoscientists can be when they rely on analogies instead of the scientific method for their “truth.” The passage above also demonstrates how Young has fixated on an idea and then attributed all disease to it. Consequently, to him the answer is always to alkalinize, even though his methods of measuring the acid-base balance are not based on any physiology or science. He even goes so far as to state explicitly an attitude I’ve found strongly implied in various alt-med ideas, namely the idea that if you get sick it is your own fault. He even uses exactly those very words, “If you get sick, it is your own fault and not the cause of some phantom virus that you can blame to cover your own lifestyle and dietary transgressions.” I couldn’t say it more explicitly than Young did, although, amusingly, while claiming that bacteria aren’t the cause of disease and sepsis, Young then claims that there is no such thing as “good” bacteria, denying any utility to probiotics. It might be said that a foolish consistency is the hobgoblin of small minds, but there does come a point where inconsistency can topple the mind of one who considers himself to be great enough to have created a whole “new biology.”
But what about cancer? This is what Young claims to be able to treat is most commonly associated with. I think it’s helpful to read this particular manifesto he wrote a few years ago that sums up his view of cancer, What Is The Cause of Cancer? Is There A Cure?, in which he describes the One True Cause of Cancer (to him) thusly:
Cancerous tissue, above all other consequences of choice, has countless secondary causes. But even for a cancerous condition there is only ONE PRIME ORIGIN and CAUSE. I have simply summarized this origin and cause of cancerous tissue in a few words. The prime origin and cause of cancerous tissue is the over-acidification of the tissues then the blood due to lifestyle and dietary choices. A cancerous tissue begins with our choices of what we eat, what we drink, what we think and how we live. Cancer is a liquid and this liquid is a toxic acidic waste product of metabolism or energy consumption.
He then summarizes his “ideas,” such as they are:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
This is so wrong on so many levels. Tumors are in reality a “protective mechanism” to encapsulate “spoiled” cells from “excess acid” that hasn’t yet been eliminated? That doesn’t even make sense on its own level. If the cells are “spoiled,” then why do they need to be protected from excess acid? Wouldn’t it be the rest of the body that would supposedly need to be so protected? Most outrageous of all is the claim that metastases are “localized acids spoiling other cells.” Utter nonsense. Although we may not understand all of its mechanisms, we do know quite a bit about the process of metastasis. We’ve detected tumor cells in the circulation or in the lymphatic vessels. Scientists have been able to find micrometastases that don’t start growing until they are able to induce the ingrowth of new blood vessels. That metastases represent “acid” spoiling other cells is about as ridiculous a description of the process as I have ever heard. Metastases derive from the primary tumor and can be shown to be derived from a clone or clones of cells from the primary. Claiming that it’s rogue acid going around “spoiling” other cells goes against pretty much all of our current understanding of cancer, just like everything else that Young preaches. None of this prevents him from making claims that, for example, he can reverse metastatic breast cancer.
The only germ of a semi-reasonable idea in the mish-mash of bizarre ideas at the heart of Young’s quackery in his many writings is that the body does produce excess acid from its metabolic processes. But guess what? The kidneys are very good at getting rid of those excess H+ ions by excreting them into the urine, where they are bound by various proton acceptors, such as ammonia and eliminated. Indeed, the tag team of the lungs and kidneys are very good at regulating bicarbonate ion concentration through a combination of respiration (which regulates it within minutes) and the ability to excrete or hold onto bicarbonate (which regulates over the long term). Thanks to these mechanisms, the body doesn’t need a constant intake of “alkaline” food or other source of alkaline. As for treating disease, routine alkalinization of the blood is not recommended except for a relatively few conditions where urine alkalinization is therapeutic, such as to prevent the formation of certain forms of kidney stones.
Young is a perfect example of one aspect of quacks that distinguishes them from practitioners of science-based medicine. Science-based medicine recognizes the complexity of disease; it delves into that complexity, trying to make sense out of it and use that knowledge to develop better treatments for disease. Quacks choose to make sense of disease another way, and that way would be insulting to disease, if disease had feelings, in that they often tend to boil all disease down to one cause or a handful of tightly related causes. I’ve often wondered why. It’s more than just the fact that they don’t understand the science behind disease. After all, Young appears to understand acid-base science, but he only understands it at a very superficial level, demonstrating once again that a little knowledge is a dangerous thing. What I end up wondering again and again is whether Young actually believes this nonsense. I suppose that on one level it doesn’t really matter. It continues to harm patients and it needs to be stopped. But will it?
Will Young be convicted? I’d ask a more disturbing question
The story about Young’s arrest, “Controversial alternative health provider charged”, besides telling us the facts, provides some disturbing information about the state of the law in California that makes me worry about whether this arrest will actually stop Young. First, I can’t resist mentioning how I detest how the news anchor says that his station has “both sides of the story.” On the other hand, I guess right now it’s a legal case more than anything else; so he has to say that. However, based on science alone, as is the case in so much of what we discuss here, there are not two sides of the story. That pet peeve expressed, let’s take a look now:
A man accused of going beyond advocating dietary changes and using intravenous treatments on “patients” he housed at his avocado ranch in Valley Center pleaded not guilty Friday to 18 felony charges, including practicing medicine without a license and grand theft.
Robert Oldham Young, 61, was ordered held on $100,000 bail, and Judge David Szumowski told the defendant to surrender his passport and not have any patients stay at his ranch.
Deputy District Attorney Gina Darvas unsuccessfully sought bail of $1 million, arguing that the defendant was a flight risk because he travels extensively and offers health retreats in other countries and has engaged in allegedly dangerous practices with patients.
“Alternative medicine, practiced properly in the state of California is legal,” Darvas said outside court. “But there are certain things that only physicians can do, and that includes practices that puncture the skin or harmfully invade the body, or treatment in conditions or circumstances that are … dangerous. The defendant is charged because he engaged in practices under those conditions. He did things that only a real doctor can do.”
Darvas alleged that Young sold treatment to people to people who were terminally ill, knowing that the treatment wouldn’t be effective.
Here are some key observations that came immediately to mind. First, Robert O. Young appears to be filthy rich from his business endeavors, so much so that he’s considered a flight risk because of his wealth and the numerous facilities around the world where he promotes his program. It’s mentioned elsewhere in the story that one patient paid $120,000 for treatments at his ranch. In the news report, it states that people seeking “treatment” at Young’s ranch pay up to $2,495 a night to stay there, with an image superimposed of a a price list ranging from $1,295 to $2,495 a night. There are top flight hotels in big cities that don’t charge that much for their luxury suites.
According to the Medical Board of California, here’s how the law ultimately caught up with “Dr.” Young:
The Medical Board worked in conjunction with the San Diego District Attorney’s Office after an undercover investigator infiltrated Young’s avocado ranch where he was illegally treating patients. Both the Medical Board’s investigator and an investigator from the San Diego District Attorney’s Office were diagnosed with diseases and offered very pricy treatments. Many of Young’s patients were actually chronically ill and spent sums of up to $50,000 for Young’s treatment.
Young is the author of the “pH Miracle,” a diet designed to “alkalinize the body. However, Young took it a step too far when he went beyond advocating dietary changes and began using intravenous treatments on patients housed at his avocado ranch in Valley Center.
So, basically, the law did an undercover sting operation and caught Young making bogus diagnoses and offering treatments for them. The sad thing to me, however, is the strong implication that if Young had advocated only dietary changes to treat cancer, he wouldn’t have gotten in trouble even though there is no evidence that dietary changes can cure any cancer. That is the state the law regulating medical practice, not just in California, but in many states.
More disturbing to me is the claim that alternative medicine, “practiced properly,” is legal, which ties into the description above. I’m not a lawyer (obviously), but one thing I note is that this appears either to be untrue or a gross exaggeration. For example, one of Young’s fellow alternative cancer cure advocates clearly thinks California law is the equivalent of the jack-booted fascist thugs endangering those poor benighted practitioners of naturopathy, homeopathy, Chinese and other forms of herbalism, ayurveda, reiki, and dozens of other beneficial healing modalities with the potential threat of prosecution. On the other hand, this person’s writings are a bit out of date, as California has permitted the licensure of naturopaths, with the regulation and licensure of naturopaths overseen by its Naturopathic Medicine Committee under the Naturopathic Doctors Act. Particularly depressing is what the Naturopathic Doctors Act permits naturopaths who have graduated from an “accredited” naturopathy school and become licensed in the state of California to do (paraphrased from the text of the law for brevity):
    • Order and perform physical and laboratory examinations for diagnostic purposes, including, but not limited to, phlebotomy, clinical laboratory tests, speculum examinations, orificial examinations, and physiological function tests.
    • Order diagnostic imaging studies, including X-ray, ultrasound, mammogram, bone densitometry, and others, consistent with naturopathic training as determined by the committee, but must refer the studies to an appropriately licensed health care professional to conduct the study and interpret the results.
    • Dispense, administer, order, prescribe, and furnish or perform food, extracts of food, nutraceuticals, vitamins, amino acids, minerals, enzymes, botanicals and their extracts, botanical medicines, homeopathic medicines, all dietary supplements and nonprescription drugs as defined by the federal Food, Drug, and Cosmetic Act; hot or cold hydrotherapy; naturopathic physical medicine inclusive of the manual use of massage, stretching, resistance, or joint play examination but exclusive of small amplitude movement at or beyond the end range of normal joint motion; electromagnetic energy; colon hydrotherapy; and therapeutic exercise; devices, including, but not limited to, therapeutic devices, barrier contraception, and durable medical equipment; health education and health counseling; repair and care incidental to superficial lacerations and abrasions, except suturing; removal of foreign bodies located in the superficial tissues.
    • Utilize routes of administration that include oral, nasal, auricular, ocular, rectal, vaginal, transdermal, intradermal, subcutaneous, intravenous, and intramuscular.
So the state of California has indeed basically legalized quackery, as long as it is performed by licensed quacks in the form of those with an “ND” (“naturopathic doctor” or, as I consider more appropriate, “not a doctor”) after their names. Particularly frightening is that NDs can order real medical tests, such as mammography, imaging studies, and the like. This puts MDs in a tricky moral situation. The radiologists who do and interpret these tests know that NDs are quacks, but the law tells them that these quacks can order medical tests and are thus entitled to receive the results and use them as part of their care. Indeed, I’ve spoken with a radiologist from California who occasionally gets orders from ND naturopaths for imaging studies like mammography and expressed to me confusion and consternation over having to provide reports to the naturopath.
A lot becomes clear, however, if you know about the Naturopathic Doctors Act, and that clarity is greatly disturbing. Perhaps the most disturbing thing that become clear (to me, at least) is this. As horrific as his “medical” practices are, as big an offense against medical science as they are, the only reason that the state of California can go after Young now is because it can plausibly charge him with practicing medicine without a license. (Indeed, if you search the California database for him it becomes clear that Robert O. Young is not a licensed health practitioner of any kind in the state of California.) I would argue, however, that if Young were, as the “ND” after his name implies, actually a licensed naturopathic physician in the state of California, there would be little or nothing that the state could have done even if Young continued to do exactly what he has been doing for the last 25 years.
Why do I say that? Simple. Nothing in Young’s ideas are any less pseudoscientific than what a lot of naturopaths believe and use as the basis of their treatments, particularly his advocacy of vegan “alkalinizing” diets to treat all manner of disease and his germ theory denialist ideas. As Kimball Atwood has documented extensively, naturopathy is rooted in prescientific vitalism and full of ideas no less pseudoscientific than anything that Young espouses, such as the actions of ubiquitous “toxins,” imbalances of qi, iridology, applied kinesiology, electrodiagnosis, live cell analysis (which Young himself not only practices, but teaches), hair analysis for those ubiquitous “toxins,” tongue diagnosis, and many others. His idea that cancer is due to “acidosis” due to “toxins” fits right in with what naturopaths believe, and what Young does would not be out of place in a typical naturopath’s practice. True, most naturopaths probably wouldn’t be bold enough to treat cancer with an “alkalinizing diet” without letting the patient undergo conventional therapy, but a lot of them do treat diabetes and other diseases (even type I diabetes) that way.
Like anyone who supports science-based medicine and abhors cancer quackery, I fervently hope that Robert O. Young will be convicted and that the state of California will throw the book at him, so that he’s a very, very old man when he’s finally released from prison. Even as I am happy at how Young has finally been prosecuted and am cautiously optimistic that he will be convicted, there remains a disturbing question that I can’t shake from my head: Had Robert O. Young actually obtained a real ND degree from an “accredited” school of naturopathic medicine, like Bastyr, would there have been anything that the state of California could do to stop him? The answer is even more disturbing: Probably not.

   “Integrative” oncology: Trojan horse, quackademic medicine, or both?
David Gorski
LInk
One of the main topics that we’ve covered here on this blog over the last couple of years is the relatively rapid, seemingly relentless infiltration of pseudoscience into what should be bastions of science-based medicine (SBM), namely medical schools and academic medical centers promoted by academics who should, but apparently don’t, know better. From the very beginning, we’ve written numerous posts about this infiltration and how it has been facilitated by a variety of factors, including changes in the culture of medical academia and our own culture in general, not to mention a dedicated cadre of ideologues such as the Bravewell Collaboration, whose purpose is to blur the lines between science and pseudoscience and promote the “integration” of quackery into science-based medicine. Certainly promoters of what Dr. Robert W. Donnell termed “quackademic medicine” wouldn’t put it that way, but I would. Indeed, promoters of quackademic medicine scored a major victory last month, when a credulous piece of tripe about acupuncture passing as a review article managed to find its way into the New England Journal Medicine, a misstep that was promptly skewered by Mark Crislip, Steve Novella, and myself. It’s rare for more than two of us to write about the same topic, but it was earned by a mistake as dire as the editors of the NEJM allowing rank pseudoscience to sully its normally science-based pages.
Today, I want to riff a bit on one aspect of this phenomenon. As a cancer surgeon, I’ve dedicated myself to treating patients with cancer and then subspecialized even further, dedicating myself to the surgical treatment of breast cancer. Consequently, the interface of so-called “complementary and alternative medicine” (CAM) in the treatment of cancer both interests and appalls me. The reason for my horror at the application of CAM to cancer patients, as you might expect, is that cancer is a disease that is highly feared and can be highly deadly, depending upon the specific kind of cancer. Cancer patients deserve nothing less than the best science-based evidence that we have to offer, free of pseudoscience. Yet in even the most highly respected cancer centers, such as M.D. Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, there are departments or divisions of what is increasingly called “integrative oncology.” The claim behind “integrative oncology” is that it is “integrating the best of science-based and ‘alternative’ medicine,” but in reality all too often it is “integrating” quackery with science-based medicine. I have yet to hear an explanation of how “integrating” pseudoscience or nonscience into science-based oncology benefits cancer patients, but, then, that’s probably just the nasty old reductionist in me. Let’s find out.
“Integrative oncology”
I was reminded by the level of “progress” in integrating woo into oncology last week when the July 25 issue of HemeOnc Today showed up. Right there on the front page I saw a story Integrative oncology combines conventional, CAM therapies, with a subtitle reading “This growing medical discipline incorporates methods such as yoga, acupuncture and stress management.” And so it does. But I worry that that’s just the beginning:
The National Center for Complementary and Alternative Medicine defines integrative medicine as treatment that combines conventional medicine with complementary and alternative therapies that have been reported to be safe and effective after being studied in patients.
Lorenzo Cohen, MD, PhD, of M.D. Anderson Cancer Center is conducting a phase 3 trial of the effects of yoga on women with breast cancer.
“Integrative medicine is a philosophy based on treating patients by focusing on the whole person and using both conventional and complementary therapies in a multidisciplinary care fashion,” Lorenzo Cohen, MD, PhD, director and professor of the Integrative Medicine Program at The University of Texas M.D. Anderson Cancer Center, told HemOnc Today.
“It is similar to complementary medicine, but one key difference is that there is an open communication between practitioners of the different traditions,” he said.
“Between the traditions”? Note the clever use of language that Kimball Atwood is so fond of pointing out. Note how Dr. Cohen equates “conventional” and “alternative” therapies (the latter of which he calls “complementary”) as though they had equal validity and equal efficacy. It’s just two different traditions! What’s the problem with bringing them together, and integrating one into the other? It’s the best of both worlds, right?
Also notice another thing. I’ve referred to certain aspects of CAM, sometimes called “integrative medicine” (IM) and, in this case called “integrative oncology” (IO), as a “Trojan horse” to bring woo into medical schools and academic medical centers. Most — but not all — academic medical centers do not use hard core quackery like homeopathy, although many appear to be using a modality just as bad, reiki, which happens to be Dr. Mehmet Oz’s favorite modality. In any case, whenever you see discussions of “integrative medicine” and in particular “integrative oncology,” chances are, the modalities discussed generally include yoga, various dietary modalities, exercise, and, quite frequently, acupuncture. Sometimes, they include various herbal remedies. In other words, “integrative oncology” rebrands modalities that have no reason not to be counted as part of science-based medicine as “alternative” or “integrative” and points to them as having some promise. They then lump together pseudoscience like reiki and acupuncture with the rebranded modalities, such as herbal therapies. This story demonstrates exactly what I mean in this passage:
According to Cohen, integrative medicine includes a plethora of therapies and methods but can be most easily classified into five categories: biologically based therapies, mind/body medicine, manipulative body-based practices, energy medicine and whole medical systems.
Biologically based therapies include ingestibles such as herbs and supplements, megadoses of vitamins or specialized diets. Mind/body medicine consists of techniques that typically help with stress management. These techniques include meditation, yoga, guided imagery and other forms of relaxation, according to Cohen. Manipulative body-based practices include therapies such as massage, medical acupuncture and chiropractic work.
The most controversial area of integrative medicine, according to Cohen, is energy medicine, which includes techniques such as healing touch, Reiki, a Japanese form of energy healing, or the use of magnets for healing. Healing touch techniques such as Reiki and Qigong, an ancient Chinese healing therapy, are based on the theory that human beings are energetic bodies and certain individuals with specific training can emit energy into another person for therapeutic purpose.
I realize that HemeOnc Today isn’t the NEJM, but on the other hand, given how the NEJM recently fell for the pseudoscience that is acupuncture, maybe they aren’t so different after all. In any case, this entire article is the sort of credulous treatment that drives me crazy, particularly the last paragraph quoted above. Energy medicine isn’t just “controversial”: it’s quackery, pure and simple, and Dr. Cohen should know that. The best that can be said about so-called “energy medicine” is that it is religion, not science, or that the various modalities that fall under the rubric of “energy medicine” are based on a prescientific understanding of how the human body works and how diseases attack it. Some of them are not even “ancient.” Reiki, for instance, only dates back to 1922. It was invented by a man named Mikao Usui, who wanted to find out how Jesus healed the sick. His answer, reiki, is no more than faith healing; the only difference between it and what Benny Hinn does is that reiki is based on Eastern mysticism instead of Christian faith. None of this discussion of “energetic bodies” and the claims that practitioners can either channel some form of “universal energy” or manipulate the flow of human “life energy” for therapeutic intent belongs in science-based medicine, at least until someone can characterize the claimed energy and actually show that these practitioners can actually do anything other than wave their hands over patients.
Cohen also speaks of “whole medical systems.” In other words he refers to ancient medical systems, such as traditional Chinese medicine and Ayurvedic medicine, characterizing them as having “their own methods and techniques for diagnosing patients, prescribing treatments and following patients over time.” That much is certainly true, but none of these techniques were based on science, either. They were based on much the same thoughts that early “Western” medicine was based on. After all, when you come right down to it, “balancing” or “adjusting” the flow of qi is not that different than the idea that the four humors must be balanced or that disease comes from “contamination” due to miasmas. As Ben Kavoussi has pointed out, there isn’t that much difference between the concepts used to justify blood letting as a treatment for disease. Yet, somehow “integrative medicine” and CAM love modalities based on Eastern mysticism. Where’s the love for black bile, yellow bile, phlegm, and blood, which make just as much sense, from a science-based standpoint as the concept of qi? In fact, they make more sense, because they, at least, exist and can be observed.
The Trojan horse
Time and time again, when I observe integrative oncology programs, I notice that many of them heavily emphasize modalities like diet and exercise. Indeed, in the HemeOnc Today article, the various advocates and “experts” in integrative oncology emphasized time and time modalities like yoga:
Karen Mustian, PhD, MPH, assistant professor of radiation oncology and preventive medicine at the University of Rochester Medical Center, discussed the findings of a yoga study at the 2010 ASCO Annual Meeting, held in Chicago in June.
Researchers enrolled 410 survivors of non-metastatic disease who participated in the Yoga for Cancer Survivors program. Survivors reported suffering from moderate or severe sleep disruption 2 months to 24 months after completing adjuvant therapy.
The participants were assigned to breathing exercises, 18 gentle Hatha and restorative yoga postures and meditation for 4 weeks with twice-weekly sessions.
Patients practicing yoga had greater improved sleep quality (22% vs. 12%), decreased incidence of clinically impaired sleep (31% vs. 16%) and less daytime sleepiness (29% vs. 5%) compared with those who did not practice yoga.
Adding to these findings, a study of the effects of yoga on women with breast cancer is also in the works. In April, Cohen received a $4.5 million grant to conduct a phase 3 trial in women with breast cancer to determine the improvement in physical function and quality of life during and after radiation treatment.
The results of the study presented at ASCO described above are, of course, utterly unsurprising. Would anyone expect that gentle exercise and meditation would harm quality of life and sleep quality? My guess is that substituting gentle exercise and prayer or non-yoga meditation would likely produce the same result. But yoga is “Eastern,” so it’s automatically way more cool than “Western” exercises. In any case, I bet I could save the NIH $4.5 million by predicting the results of Dr. Cohen’s study. Yes, yoga very likely will be found to improve physical functioning and quality of life, because, by and large, it is relatively gentle, low-impact flexibility exercise. In fact, in women who have undergone axillary dissection (removal of the lymph nodes under their arms), I would predict that yoga probably will decrease the incidence of impaired range of motion. The reason I make this latter prediction is because I already prescribe gentle stretching exercises to women who have undergone axillary surgery because it does decrease the incidence of impairments in range of motion. In fact, I would go so far as to predict that virtually any low impact exercise, be it yoga, Tai Chi, or simply low impact “Western” forms of exercise, such as walking and stretching, would produce the same results.
Oddly enough, I have been unaware of any investigators being awarded $4.5 million to study whether walking preceded by some gentle “limbering up” has all these effects in cancer patients. Why is that? This is the sort of stuff that is well-within the purview of science-based medicine, leading me to ask: Since when did exercise become “alternative” or “integrative”? Dr. Cohen’s study compares yoga versus “stretching/relaxation” (which is what I thought much of yoga was; so I’m not sure what the difference is) versus a wait list control group. So my being unaware of such a study is at an end, because apparently that’s just what Dr. Cohen will study. But does anyone think that the NIH would have funded such a study if it were about exercise and relaxation rather than yoga? My prediction for the outcome: the first two groups will both do better than the control group in terms of the outcome measures. I also wonder why on earth it will take $4.5 million and five years to answer this question. In any case, given the copious science already demonstrating that low impact exercise results in better quality of life outcomes for cancer patients, I would question the value, the “bang for the buck,” of spending $4.5 million in order to study an “alternative” or “complementary” therapy that is nothing more than a fancy form of stretching exercises and relaxation, the former of which is already known to be of benefit in cancer patients undergoing chemotherapy, surgery, and radiation. Surely such a study could be done for $1 million? Heck, for $4.5 million, I could start up a multi-investigator P01 with teams of investigators doing heavy duty basic science.
I know, I know. Sour apples. I really am in the wrong business.
The HemeOnc Today article, as credulous as it is, though, is merely an indication of just how far the concept of “integrative oncology” has gone. To appreciate just how far it has gone, I thought I’d peruse the websites of what are commonly accepted as two of the most respected institutions devoted to cancer in the United States, if not the world.
“Integrative oncology” invades and metastasizes
“Inspired” by the HemeOnc Today article, I decided to peruse the “integrative oncology” website of one of the two premier cancer centers in the country, that of the M.D. Anderson Cancer Center, as well as to take a peak at what the National Cancer Institute website says about various “alternative,” “complementary,” or “integrative” modalities. What many readers may not know is that the NCI has an Office of Cancer Complementary and Alternative Medicine (OCCAM, perhaps the most unfortunate acronym ever, given what it stands for). Moreover, OCCAM has a budget that is of approximately the same magnitude as that of the National Center for Complementary and Alternative Medicine (NCCAM), in the range of $121 million a year. Thus, OCCAM is potentially as large a force in studying and promoting CAM as NCCAM has ever been.
Let’s start with M.D. Anderson first. On its website, it has a webpage called Complementary/Integrative Medicine Education Resources (CIMER). On the CIMER webpage, perhaps the most telling and useful “resource” is a page on therapies. On this page are links to several review articles authored by CIMER staff and physicians in the Integrative Medicine Program of the M.D. Anderson Cancer Center.
Whenever I take a look at a cancer center’s website, I go straight for the most hard core quackery to see what it says about it. Usually, I go straight for homeopathy. If a website concludes anything other than that homeopathy is pure quackery and that there is not a single molecule of active substance in most true hemopathic remedies (the dilution and succussion process having diluted it to nothing), then I know I’m dealing with quackademic medicine. Here’s an excerpt from what the great M.D. Anderson says about homeopathy:
The practice of homeopathy is based on its “law of similars” which proposes that “like cures like”. That is, a substance that causes specific symptoms in a healthy person is believed to ultimately relieve those same symptoms in a sick person. A few homeopathic physicians treat cancer by prescribing minute doses of tumors and carcinogenic substances.
The intent of homeopathic medicine is to help the body begin the healing process. Rather than focusing on a specific diagnosis, prescriptions are tailored to an entire set of symptoms and may vary between individuals with the same disease.
Significant reduction of some side effects of cancer treatments has been reported in two randomized controlled trials justifying further research with larger trials.
Current research includes a National Cancer Institute (NCI) clinical trial of a homeopathic substance for chemotherapy induced mucositis in children.
So far, not so good. The passage above is completely credulous, without the least bit of skepticism about the very basis of homeopathy. It reports homeopathy as a homeopath would report it, which makes me wonder if it was written by a homeopath. Particularly disturbing is the “detailed scientific review” of homeopathy. I’ll give the author credit because he at least mentions Avogadro’s number, but then credulously parrots the typical homeopath claim that water has “memory.” The article also cites primarily articles from that journal of pure woo, whose editorial standards I’ve lambasted here and elsewhere time and time again, the Journal of Alternative and Complementary Medicine, as well as homeopathy journals, such as the British Homeopathic Journal. It is beyond the scope of this post to explain why such journals are generally not good sources (perhaps I’ll do a post on that someday), but they aren’t. The only “real” journal article I saw was the infamous TRAUMEEL S study from 2001 looking at whether homeopathic TRAUMEEL S can alleviate stomatitis in children undergoing treatment for lymphoma and leukemia. (I shudder at the unethical nature of testing magic water in a clinical trial with children as the subjects.) In any case, this study reported a positive effect; however, one might also note this from the study itself:
TRAUMEEL S® is a homeopathic-complex remedy that has been sold over the counter in pharmacies in Germany, Austria, and Switzerland for over 50 years. It contains extracts from the following plants and minerals, all of them highly diluted (10−1–10−9 of the stem solution): Arnica montana, Calendula officinalis, Achillea millefolium, Matricaria chamomilla, Symphytum officinale, Atropa belladonna, Aconitum napellus, Bellis perennis, Hypericum perforatum, chinacea angustifolia, Echinacea purpurea, Hamamelis virginica, Mercurius solubilis, and Hepar sulfuris. Information from the manufacturer indicates that TRAUMEEL S is used normally to treat trauma, inflammation, and degenerative processes.
In other words, this is an herbal remedy in which there is still ingredient, given that even a 10-9 dilution is not enough to dilute away what’s in there. Why it’s even called homeopathic, I have a hard time figuring out, given that there are many herbs and minerals in there, with no rationale of “like curing like” obvious for them all. If TRAUMEEL S “works,” it’s not any sort of validation of homeopathy; all it shows is that maybe some of the herbs or minerals in the concoction have a beneficial effect. One also notes that this is a small study (N=30, 15 per group) and that the distribution of disease in the two groups was very different and that this study has never been replicated. Both Edzard Ernst and the Cochrane Reviews note this study but conclude that there is no evidence that homepathy is any better than placebo for cancer side effects.
But apparently not M.D. Anderson. M.D. Anderson appears to believe in magic. If you don’t believe me, just take a look at its review on reiki, including the “scientific evidence” for its efficacy in cancer patients, or its review on healing touch, which is more or less reiki shorn of explicit Eastern mysticism. Particularly nauseating is this introduction to “energy therapy” methods, which divides the very concept of energy itself into “Western” and “Eastern” notions of energy. (Silly me, I thought that energy was energy, and it was defined scientifically.) The author then postulates the “blending” of “Eastern” and “Western” concepts of energy thusly:
Modern physics has shown that light can exist as two interchangeable forms: a particle (form and structure) and a wave (movement and vibration). The rest of nature can also be experienced in the form of a particle and a wave. For example, water in the ocean is both particles of water and movement of coastal currents, thermal layers and tides. As in the ocean, the human body contains and is affected by energy that can be blocked, flow freely or vary in frequency. Various forms have been postulated:
    • An all-pervasive background frequency without form that extends beyond the limits of the body structure
    • Vertical energy flows that serve as conduits to external energy
    • Additional currents of energy with identifiable paths and patterns
The extent to which a background field extends beyond a person reportedly varies with each individual. Some people have said that they are sensitive to these fields – seeing or hearing these projections. Heat emanating from a body is one form of energy and one expression of that person’s energy field8.
Notice that no evidence is presented showing that these claims are valid.
The introduction concludes:
Contemporary energy therapies are only recent manifestations of a larger and more ancient body of energetic and spiritual concepts that are beyond the scope of these reviews of a few contemporary energetic healing practices. MD Anderson recognizes that physical healing is only part of the cancer treatment process and also offers spiritual support through many different programs such as the Chaplaincy Services — representing a wide range of faiths and spiritual beliefs — and the Place … of wellness — where people touched by cancer can enhance their quality of life with activities that help to heal the mind, body and spirit.
Remember, this is the website of the M.D. Anderson Cancer Center, which is widely viewed to be one of the top two or three cancer centers in the United States, if not the world, and its Integrative Medicine Program appears to be based on magic more than anything else. Quackademic medicine, indeed.
Unfortunately, the NCI’s OCCAM website isn’t all that much better. Because I spent longer than anticipated going through the M.D. Anderson website, I’ll wrap it up fairly quickly. OCCAM has some fairly disturbing pages itself. For instance, its Categories of CAM Therapies is a simple list of CAM therapies with little discussion at all other than defining what they are in the way any woo-meister would be happy with. OCCAM is superior to M.D. Anderson’s CAM pages in that it does from time to time throw in passages like this:
Biofield therapies are intended to affect energy fields that purportedly surround and penetrate the human body. The existence of such fields has not yet been scientifically proven.
If there is no good science to show that these fields even exist, then why study trying to manipulate them? I never understood putting the cart before the horse like that. There’s a lot of that sort of stuff going on in the list of CAM therapies referenced by OCCAM, although a lot of the articles are in fact NCCAM articles. One article on a CAM therapy that is hosted by the NCI and apparently was written by NCI staff is entitled Questions and answers about acupuncture. Depressingly, it begins with a credulous discussion of qi and meridians that is credulous and full of magic. It also contains statements like:
Scientific studies on the use of acupuncture to treat cancer and side effects of cancer began only recently. Laboratory and animal studies suggest that acupuncture can reduce vomiting caused by chemotherapy and may help the immune system be stronger during chemotherapy. Animal studies support the use of electroacupuncture to relieve cancer pain.
And:
Human studies on the effect of acupuncture on the immune system of cancer patients showed that it improved immune system response.
One wonders just how critically the studies to which this article refers were evaluated. Certainly, the lists mix “electroacupuncture” (which is not acupuncture at all — as Mark says, where were those batteries in ancient China to hook up to the acupuncture needles?) with acupuncture studies. One wonders if this is another case of accepting the authors’ misinterpretation of their own results, as I discussed for one such study a couple of months ago. As for the effects of acupuncture on the immune system, the physician’s version of the review points out that all these studies were conducted in China, and, unfortunately, it’s well known that acupuncture studies from China tend to be overwhelmingly positive, in marked contrast to acupuncture studies from other countries, leading some writers of meta-analyses to question how to handle these studies. In any case, it would appear that the NCI, although its material on its website is not as credulous as that of M.D. Anderson, is not exactly a bastion of science when it comes to some “alternative” medical modalities.
Indeed, let me tell you a brief anecdote. Two years ago, at the AACR Meeting, I visited the NCI booth on the convention floor because I knew there was going to be a representative from OCCAM there. My confidence in the scientific rigor of the entire OCCAM enterprise was not boosted by the conversation I had there. In brief, after a brief (and neutral) conversation about what OCCAM does, I gently challenged the OCCAM representative regarding alternative medicine by pointing out that there really isn’t that much evidence for much of it and asking him if he could point me in the right direction. In particular, I asked him why one would think that a mixture of herbal medicines would do better than pharmaceuticals. He then began to pontificate about “royal herbs” and couldn’t provide a good rationale why anyone should conclude that impure mixtures of compounds would be more effective or reliable than pharmaceuticals. When he started going on about “emperor” herbs, “minister” herbs, and “assistant” herbs, I couldn’t take it anymore and looked for an opportunity to politely excuse myself.
“Integrative oncology”: The quackademic oncology that’s here to stay?
I first became aware of the phenomenon of quackademic medicine several years ago. Before then, I was blissfully ignorant. Over the last several years, in particular the last couple of years, I’ve become increasingly alarmed at just how much pseudoscience is finding its way into medical academia in general and into oncology in particular in the form of “integrative” oncology. When the websites of what have in the past been a bastion of science-based oncology, M.D. Anderson Cancer Center and the NCI, become infiltrated with this sort of pseudoscience, I become alarmed. But it’s far, far worse than that. I only picked two websites. There are many more out there, thanks to promoters of woo like the Bravewell Collaborative and others. I only picked on M.D. Anderson and the NCI because of their reputation for being much better than this, a reputation they are endangering by their embrace of woo. Cancer patients, as I say frequently, are among the most vulnerable of patients. Many of them are facing a very unpleasant death without treatment; seeing that they receive the most effective medicines and treatments we have, free of quackery, is a moral imperative, and I fear that we will soon be failing our patients. We now even have a Society of Integrative Oncology promoting the “integration” of pseudoscience into oncology.
The Trojan horse of herbals, diet, and exercise in the form of yoga may have breeched the walls of academia, bringing with it pseudoscience like acupuncture, reiki, and even homeopathy, but still I see reason for hope. Val Jones once coined the term “shruggie” for health care professionals who have seen the infiltration of pseudoscience into medicine and in essence shrug their shoulders, dismissing it as not being important or as not being their business if people choose quackery instead of science-based medicine. However, as the infiltration of pseudoscience reached a critical mass, it started to alarm even some of the shruggies. There has been pushback. We here at SBM like to think that we have been a significant part of that reaction, but we also know that there are many others, such as Edzard Ernst, Ben Goldacre, and Simon Singh. Even though a disturbing number of skeptics seem to have a blind spot when it comes to quackery, the broader skeptical movement appears to be taking more and more notice. I only hope that it’s not too late. When an admired and esteemed institution like M.D. Anderson goes woo, we have an uphill battle to reverse that.

   “Patient-Centered Care” and the Society for Integrative Oncology
Kimball Atwood
Link
Should Medical Journals Inform Readers if a Book Reviewer can’t be Objective?
At the end of last week’s post I suggested that book reviewer Donald Abrams and the New England Journal of Medicine had withheld information useful for evaluating Abrams’ review: that he is the Secretary/Treasurer of the Society for Integrative Oncology (SIO), the organization of which Lorenzo Cohen, the first editor of the book that Abrams reviewed,* is President. I also promised to look at material from the book and from the Society’s website in order to discover “data that will allow even the most conventional oncologists to appreciate [the value of 'integrative' methods].”
There is little question that Abrams and Cohen know each other, or at least that Abrams couldn’t have been expected to write an entirely objective review of Cohen’s book. Abrams is the Program Chair for the Society’s upcoming 5th International Conference, sponsored by the American Cancer Society. He and Cohen will be sharing the stage for the “Intro/Welcome.” Does it matter that most NEJM readers wouldn’t have learned of this association by reading the review? Probably not, in the case of readers who are well-versed in the misleading language of “CAM.”
I believe that most readers of medical journals are not so sophisticated. Otherwise, how could it have been so easy for “CAM” literature to seep through the usual evaluative filters, not only in medical schools and government but in the editorial boardrooms of prestigious journals? For anyone from the Journal who might be following this thread, Dr. Sampson’s satirical but deadly serious account of “how we did it” is obligatory reading.
Do “Integrative Oncology” Methods have Value?
Now let’s take a look at what Dr. Cohen’s book and the SIO are up to. The book’s introduction and table of contents are available on Amazon.com. The introduction contains the usual, misleading assertions and falsehoods that are ubiquitous in “CAM” promotions. I’ve added a few hyperlinks:
Many medical centers within the United States have formalized integrative medicine programs to help guide patients in the use of CAM and to provide CAM services…
Complementary and alternative medicine (CAM) has been defined by the National Center for Complementary and Alternative Medicine (NCCAM)…
The NCCAM is dedicated to exploring complementary and alternative healing practices in the context of rigorous science…
…using well-established tools of rigorous scientific design, conduct, and oversight.
[Integrative medicine] strives to integrate the best complementary and conventional modalities using a multidisciplinary approach through integrative services.
The Consortium of Academic Health Centers for Integrative Medicine has recently defined integrative medicine as the practice of medicine that reaffirms the importance of the relationship between practitioner and patient, focuses on the whole person, [etc.]
People who use complementary therapies are often seeking a more holistic and noninvasive approach to preventing and managing disease. They use CAM to maintain wellness, improve quality of life, assist in managing disease- and treatment-related side effects, boost the immune system, increase hope, and gain a sense of control.
Since 1991, the NCI [National Cancer Institute] has utilized [the Best Case Series Program] to evaluate data from CAM practitioners with the same rigorous scientific methods employed in evaluating treatment responses with conventional medicine.
What ”CAM” practices are we talking about here?
Complementary therapies typically used include mind-body approaches such as meditation, guided imagery, music, art, other expressive arts, and other behavioral techniques; energy-based therapies that seek to affect proposed bio-energy fields, whose existence is not yet experimentally proven, that surround and penetrate the human body. These can be individual therapies done through self-practice (e.g., Yoga, Tai Chi, or internal Qigong), manipulation of electromagnetic waves through the use of magnets, or through the use of the energy of individual practitioners (e.g., external Qigong, Reiki, Healing Touch); body-manipulative systems such as chiropractic and massage; alternative medical systems such as traditional Chinese medicine, homeopathy, and Ayurveda (Indian-based medicine); and biologically based approaches such as nutrition, herbal/plant, animal/mineral, or other products.
From the book’s table of contents we can identify the authors. I’ll mention one with whom I am familiar. Chapter 3 is titled “Using Legal and Ethical Principles to Guide Clinical Decision in Complementary/Integrative Cancer Medicine.” Its author is lawyer Michael H. Cohen, who a few years ago was “Director of Legal Programs, Division for Research and Education in Complementary & Integrative Medical Therapies, Harvard Medical School.” He is also a Board Member at Large for the SIO. His views on modern medicine and implausible medical claims are apparent in these excerpts from his writings:
[B]iomedicine by and large perpetuates a delusional sense that a human being is only material–a three-dimensional substance locked in the physical body, amenable to mechanical interventions that are tightly controlled by a series of carefully circumscribed rules. Biomedicine encourages over-identification with the body: it is fear-based; disease induces desperation in the “race for the cure” rather than focus on “care of the soul.”
Health and healing can involve the highest of which a human being is capable. Near-death experiences, encounters with angels, and events that touch the individual’s interior castle and border on mysticism-these experiences manifest ‘light,’ in the sense of coming closer to that which is Supreme at the edges of our consciousness.In the purest sense, therapies from hypnosis to meditation aim to free the dis-eased seeker, and the culture as a whole, from the matrix of mechanism, reductionism, and other ills, to a realm where the human spirit finds rest. As Vasistha says: “Subdue the mind with the mind. Purify the mind by the mind. Destroy the mind by the mind.” When the mind is purified, the real can be grasped. Complementary and alternative therapies offer this possibility.
What about legal principles and clinical decision making?
Would legal structures be able to handle the notion that healing involves mind, body, emotions, and spirit, but also such other dimensions of the human experience as inter-species communication and greater sense of earth-consciousness (Gaia)?
Until recently Mr. Cohen was a member of the Advisory Board of the American Association for Health Freedom (AAHF), an organization committed to protecting snake oil salesmen from legal repercussions. I wonder if some of the other authors of the “integrative oncology” book and some of the other officers of the SIO—who go to great lengths to distinguish between “alternative” (dangerous!) and “complementary” (good!)—would be surprised to find that at least 3 of Mr. Cohen’s fellow AAHF Advisory Board members pitch Laetrile: Schachter, Mindell, and Rowen.
It’s hard to tell from the brochure what much of the content of the SIO’s 5th International Conference will be, but it includes “biofield therapies for symptom management during acute radiation treatment,” “immune enhancement,” “Traditional Chinese Medicine,” and “mind/body medicine.” A few of the Conference Planning Committee members look familiar; at least one is a crackpot who’s become “establishment” in this era of Anything Goes Medicine: naturopath Leanna Standish, a psychokinesis enthusiast and a long-time recipient of public research funds.
The abstracts from the 2007 conference verify that psychokinesis (PK)—the notion that the mind can act on an object from a distance—is an important part of the SIO’s agenda. Consider that “biofield therapies,” Therapeutic Touch, Reiki, and “External Qigong” are all examples of PK. One of the recurrent themes in “CAM,” which would be worth a few posts of its own, is the famous quotation of philosopher George Santayana: “Those who cannot remember the past are condemned to repeat it.” In this case the relevant past consists of more than a century of failed attempts to demonstrate PK before the term “CAM” was even coined.
The “Integrative Oncology Practice Guidelines”
The real meat of the Society for Integrative Oncology is found in the Society’s Integrative Oncology Practice Guidelines. This is a more sober document than the conference brochure. It is presented in a formal EBM sort of way, complete with an explanation of the “levels of evidence.” One of its Primary Authors is Andrew Vickers, a member of the Cochrane “CAM” Field, previously discussed here. It does not discuss or even acknowledge prior probability.
Some of its recommendations are common sense and are either uncontroversial or embarrassingly obvious:
Recommendation 1: All patients with cancer should be asked specifically about their use of complementary and alternative therapies. Grade of recommendation: 1C
Recommendation 5: The application of deep or intense pressure is not recommended near cancer lesions or enlarged lymph nodes or anatomic distortions, such as postoperative changes, as well as in patients with a bleeding tendency. Grade of recommendation: 2B
Recommendation 14: It is recommended that dietary supplements, including both herbal product and megadoses of vitamins and minerals, be evaluated for side effects and potential interaction with other drugs. Those that are likely to interact with other drugs, including chemotherapeutic agents, should not be used concurrently with chemotherapy or radiation or prior to surgery. Grade of recommendation: 1B
Recommendation 17: It is recommended that patients be advised to avoid therapies promoted as ‘‘alternatives’’ to mainstream care. Grade of recommendation: 1A
Some are utterly “conventional”:
Recommendation 15: It is recommended that patients be referred to registered dietitians for guidelines on usual diets to promote basic health. Grade of recommendation: 1B
Some would likely detract from effective therapy, even if the authors think that they are advocating “integrative care,” and would likely be insulting to a sophisticated patient:
Recommendation 7: Acupuncture is recommended as a complementary therapy when pain is poorly controlled. Grade of recommendation: 1A
Some are ridiculous and and likely to be insulting to a sophisticated patient:
Recommendation 12: For patients suffering from symptoms such as dyspnea, fatigue, chemotherapy-induced neuropathy, or post-thoracotomy pain, a trial of acupuncture is recommended. Grade of recommendation: 2C
Some “strong recommendations” are wrong, even when considered from the formal EBM point of view:
Recommendation 9: Acupuncture is recommended as a complementary therapy when nausea and vomiting associated with chemotherapy or surgical anesthesia are poorly controlled or when side effects from other modalities, such as muscle spasm or dysfunction following head and neck surgery, are clinically significant. Grade of recommendation: 1B
Some are silly in the typical EBM-”CAM” sense of ignoring prior probability:
Recommendation 6: Therapies based on manipulation of putative bioenergy fields are safe but cannot be encouraged due to limited evidence on efficacy. Grade of recommendation: 1C
(And, er, who cares about “limited evidence of efficacy” if it makes some people feel better? Look at several of the other recommendations!)
Some are daft:
Recommendation 16: In cancer patients who either fail or decline antitumor therapies, it is recommended that use of botanical agents occur only in the context of clinical trials, recognized nutritional guidelines, or clinical evaluation of the risk/benefit ratio based upon available evidence. Referral to a qualified expert in CAM modality, such as an Doctor of Naturopathy (ND) who is board certified in naturopathic oncology, may be considered. Grade of recommendation: 1C
Do the Guidelines and the Book Reflect “Integrative Oncology Programs”?
Well, at least the Guidelines don’t mention homeopathy (although the “board certified” ND certainly will). But a big part of the book that Donald Abrams reviewed is a series of descriptions of the various “integrative oncology programs” at “leading cancer centers.” One of those is near me: the Dana Farber Cancer Institute.
It takes only a couple of clicks to find that “my” institute promotes homeopathy, psychokinesis, “mind healing,” “quantum healing,” and more, as explained by such luminaries as Dana Ullman, Andrew Weil, and Deepak Chopra.
“Patient-Centered” Care
I wonder why? Here’s a thought. One of the guidelines reflects a recurring theme in “CAM”:
Recommendation 2: All patients with cancer should receive guidance about the advantages and limitations of complementary therapies in an open, evidence-based, and patient-centered manner by a qualified professional. Grade of recommendation: 1C
It’s funny. I used to wonder what was meant by “patient-centered” (let’s see…as opposed to health care centered on the patient’s dog?). Now I know that when used in “CAM” contexts the term is a bait-and-switch deception. It was originally intended to imply a change in the doctor-patient relation, from its traditional paternalistic mode to a new physician-as-consultant mode, as explained by Steve Novella a couple of days ago. For some, however, it implies something else: that the physician ought to “respect” whatever the patient wants. Or more. After all, most patients don’t really know what to look for in a complementary therapy, so to speak, so we in the SIO are here to help!
* Integrative Oncology: Incorporating Complementary Medicine into Conventional Cancer Care. Edited by Lorenzo Cohen and Maurie Markman. 216 pp., illustrated. Totowa, NJ, Humana Press, 2008

   Tom Harkin, NCCAM, health care reform, and a cancer treatment that is worse than useless
David Gorski
Link
PRELUDE: SOME BAD NEWS FOR ADVOCATES OF SCIENCE-BASED MEDICINE
It was a bad week for science-based medicine. It was a good week (sort of) for science-based medcine.
First the bad.
There has been a development that anyone who supports science in medicine and opposes quackery will likely find disturbing. Do you remember Senator Tom Harkin (D-IA)? We’ve written about him extensively over the last several months on this blog. First of all, he is the man most responsible for the creation of that government-sanctioned, government-funded bastion of pseudoscience, the National Center for Complementary and Alternative Medicine. He’s also one of the men most responsible for the Dietary Supplement Health and Education Act (DSHEA) of 1994, which has done more to protect the supplement industry from making dubious health claims than any other piece of federal legislation. More recently, Harkin has made a name for himself in the health care reform debate currently ongoing by inviting advocates of “integrative” medicine (IM), which in essence integrates quackery and the pseudoscientific with scientific medicine, to Capitol Hill as a means of trying to persuade his fellow legislators to include a CAM/IM version of “wellness” care as part of any bill that might pass this fall. In essence, he is trying to hijack any health care reform bill to include government sanction of unscientific medicine. Meanwhile, he has been chastising NCCAM because it hasn’t “validated” enough “alternative medicine” for his taste. (Actually, it’s validated none, because virtually none of it is likely to be valid.)
This is the man who, according to reports, will almost certainly be taking over the chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP) after the death of its former chair, Senator Edward Kennedy. This committee is among the most important for government health policy and will be in the thick of the final negotiations and battles over any health care reform that may arise from Congress this fall.
The existence of powerful supporters of pseudoscience in the highest eschelons of government has real consequences. As I’ve described before, NCCAM, being based entirely on studying highly–even ridiculously implausible–notions about disease and how to treat it, has resulted in the infiltration of quackery into academia, where ideas once rightly dismissed as quackery are respectfully given deference and studied as though they were anything other than Tooth Fairy science, a process that Dr. R. W. Donnell has amusingly termed “quackademic medicine.” One result was the expenditure of $30 million on an unethical, poorly designed, and corrupt trial of chelation therapy for cardiovascular disease. Another result was an even more unethical trial of an even more scientifically implausible remedy for a deadly cancer. Although the fact that the trial was even done is a horror, at least last week we finally found out the results, which had been suppressed for nearly four years, namely that this protocol is not just useless, but worse than useless. It’s a Pyrrhic victory for science-based medicine and cold comfort to patients with pancreatic cancer who may have continued to use this protocol during those four years, but at least we finally know.
Let’s take a look at the study. But first, a little background.
PANCREATIC CANCER AND THE GONZALEZ PROTOCOL
Pancreatic cancer sucks.
There’s no other way to put it. It’s one of the most lethal, if not the most lethal, cancer there is. There are several reasons for this. Less than 5% of all patients diagnosed with pancreatic cancer are alive five years after diagnosis. To put it another way, pancreatic cancer is the tenth most commonly diagnosed cancer but number four in the list of cancer killers. That’s because most (at least 80%) are diagnosed with unresectable and/or metastatic disease, for whom surgery cannot be performed. Given that the only currently known possible chance of long term survival in pancreatic cancer comes from a complete surgical resection of the cancer with negative surgical margins (i.e., no tumor at the margins of the surgical specimens and a rim of normal tissue between the margin and the tumor), any pancreatic cancer patient who is not a candidate for surgery has incurable disease. Of the minority of patients who do have their cancer completely resected surgically, the five year survival rate is better, perhaps in the range of 15-20% or so, but still the vast majority will be dead within five years, usually much less. Moreover, known as a pancreaticoduodenectomy or Whipple procedure, the surgery necessary to remove a pancreatic cancer in the head of the pancreas (the most common location) is a huge operation that involves removing the head of the pancreas and the duodenum and then reconstructing the connections between the bile and pancreatic ducts and the GI tract and establishing continuity between the stomach and small intestine. It’s a tour de force operation that often takes 8 hours or more and is fraught with the potential for complications, both short term and long term. However, for someone with a potentially resectable pancreatic cancer in the head of the pancreas, it is the patient’s only hope. Even so, after surgery, median survival times still only range from 12 to 19 months.
Because the outlook for pancreatic cancer, particularly unresectable pancreatic cancer is so grim (the median survival has barely budged from less than six months for decades. Median survival for untreated metastatic pancreatic cancer is on the order of 3-4 months, although gemcitabine chemotherapy regimens combined with radiation) can result in median survivals of six months or more. For locally advanced pancreatic cancer that cannot be resected but has not metastasized, the median survival is on the order of 6-12 months depending on the study. Thus, we can rightly say that pancreatic cancer is one of those cancers for which science-based medicine has frustratingly little to offer that can cure it. That’s not to say that science-based medicine doesn’t have a lot to offer for palliation, but no one wants just palliation. We all want to live to a ripe old age, not just have our pain and nausea palliated for a few months before cancer claims us. Even scarier is that pancreatic cancer usually produces few or no symptoms until it is fairly advanced. Usual symptoms include vague upper abdominal discomfort, loss of appetite, and post-prandial nausea from intermittent gastric outlet obstruction, you know, the sorts of symptoms that nearly of us have from time to time and that primary care doctors see in their practice every day. By the time a pancreatic cancer causes severe pain or obstructs the bile duct leading to jaunice, it’s usually unresectable or metastatic. (Often the reason it causes such severe pain is because it invades a plexus of nerves just posterior to the pancreas.)
It is the very deadliness of pancreatic cancer and the lack of effective life-saving or life-prolonging treatments for it that make pancreatic cancer a ripe condition for quackery. Rising above most other quackeries to attract a lot of attention about a decade ago is a quackery known as the Gonzalez protocol. It is described on Dr. Nicholas Gonzalez’s website as involving dietary changes, supplements, the replenishment of pancreatic proteolytic enzymes, and “detoxification,” including coffee enemas. It is not an easy therapy to undergo. For example, Dr. Gonzalez states:
Overall, cancer patients will consume 130-175 capsules a day, including nutrients as well as enzymes. Non-cancer patients might consume in the range of 80-100 capsules a day, the exact number depending on their health status and medical problems.
I know of no science-based cancer protocol that requires a patient to consume 150 pills a day. There are also the dietary alterations that can be quite hard to follow, as well as the frequent coffee enemas. All in all, the Gonzalez protocol is an arduous regimen for a debilitated pancreatic cancer patient to follow. Still, for some reason, it gained some popularity in the “complementary and alternative medicine” (CAM) community, so much so that, based on poorly designed case series of eleven patients, Dr. Gonzalez managed to get a clinical trial funded by the NIH to study his method versus standard chemotherapy, a sordid story that Dr. Atwood has chronicled in detail in a long series of blog posts. That trial ended in 2005.
So why is it 2009 before we have the results of this trial, which show that the Gonzalez protocol is worse than useless? The trial, begun in 1999, is known formally as Prospective Cohort Study of Gemcitabine Versus Intensive Pancreatic Proteolytic Enzyme Therapy With Ancillary Nutritional Support (Gonzalez Regimen) in Patients With Stage II, III, or IV Adenocarcinoma of the Pancreas. The results were finally reported in an E-pub ahead of print manuscript for the flagship journal of the American Society of Clinical Oncology, the Journal of Clinical Oncology, and entitled Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer, written by John A. Chabot, Wei-Yann Tsai, Robert L. Fine, Chunxia Chen, Carolyn K. Kumah, Karen A. Antman, and Victor R. Grann.
A CLINICAL TRIAL STUDYING FAIRY DUST VERSUS CHEMOTHERAPY
One reason why we emphasize prior probability so much here at SBM is because it matters. Nowhere have I seen it matter quite as much as in the genesis of a trial of the Gonzalez protocol for pancreatic cancer. The reason is that the “scientific” rationale behind these megadoses of supplements and pancreatic enzymes plus “detoxification” by coffee enemas is what Harriet Hall terms “Tooth Fairy science.” The Gonzalez treatment is basically a modification of a protocol known as the Kelley Treatment, which in turn was very similar to the Gerson protocol. Chabot writes in the introduction to this study:
The Scottish embryologist John Beard first proposed pancreatic proteolytic enzyme treatment in 1906 and soon after published a monograph, entitled The Enzyme Therapy of Cancer. In 1981, Nicholas Gonzalez began to evaluate the use of proteolytic enzyme therapy. Twelve years later, in 1993, he was invited to present a series of cases at the National Cancer Institute (NCI), which led him to undertake a case series of alternative medical therapy that included proteolytic enzymes, diet, nutritional supplements, and detoxification procedures. Among 11 patients with inoperable, biopsy-proven, stages II to IV pancreatic adenocarcinoma, he reported 81% survival at 1 year and 45% at 2 years. Four of the 11 patients survived for 3 years.
This is the very example of an implausible hypothesis. True, it’s not as implausible as homeopathy (few hypotheses are), but it goes against everything we know about cancer in general and pancreatic cancer in particular. There is no evidence that pancreatic enzyme deficiency has anything to do with pancreatic cancer, for example. Nor is there any evidence that this discription of the rationale behind the Gonzalez protocol, cribbed straight from the NCI website, has any relationship to reality:
Two major concepts underlie use of the Gonzalez regimen in cancer treatment. The first concept is that the pancreas, like the liver, is an organ that performs a detoxification function and that pancreatic enzymes help the body eliminate toxins and help normal cells repair damaged cells.[2] The second concept is that cancer and most other human illness are related to physiological imbalances created by environmental toxins either consumed in food or contacted in the environment.[2,3]
Proponents of the Gonzalez regimen believe that toxins from sources such as processed foods and environmental pollution are responsible for human cancers. These toxins are thought to accumulate in tissues and over time create imbalances in the autonomic nervous system, diminish the normal immune response, and give rise to cellular damage that can lead to cancer.[2,3] If these toxins could be neutralized and eliminated from the body, proponents believe, both early and established cancers would be halted, and general health would be restored.[2,3]
Here’s the problem. These “toxins” are never identified, nor is there any evidence that the Gonzalez regimen actually removes them. It’s not that environmental exposures don’t have an effect on cancer susceptibility. Smoking can cause lung cancer and, ironically enough, increase the risk of pancreatic cancer as well. “Detoxification” quackery like the Gonzalez protocol takes science and turns it into Tooth Fairy science by giving near magical characteristics to these “toxins.” In any case, cancer is primarily a genetic disease. Even heavy smokers who smoke for 50 years “only” have about a 25% lifetime risk of developing lung cancer, which means more smokers don’t get lung cancer than do. In any case, think about it: Let’s say there is this host of unnamed, undefined “toxins” that give you pancreatic cancer. Remember, the toxins from tobacco smoke that predispose to lung cancer are largely known and quantifiable. Why would one think that coffee enemas would remove those “toxins”? Certainly there is no scientific basis to think that the special diet, the dozens of capsules of supplements and pancreatic enzymes, or the other aspects of the regimen would “detoxify” anything. Basically, the Gonzalez protocol appears to derive from a prescientific notion of disease that is almost religious in its nature blaming “contamination” as the cause of all disease and that one must “purge oneself” of this “contamination” to cure the disease.
But, say Gonzalez supporters, what about the case series of 11 patients with stage II to IV pancreatic cancer from the 1990s reporting 81% survival at 1 year and 45% at 2 years, with 4 of the 11 patients surviving for 3 years? As Dr. Atwood pointed out, this was a nonconsecutive case series, a so-called “best case” series. Basically, it’s a cherry-picked series, and I’ve criticized “best case” series before because they in essence intentionally look at outliers for whom the therapy may or may not have made a difference. Some patients with pancreatic cancer do survive longer than a year. Indeed, actor Patrick Swayze is one such patient, who has now been alive over a year and a half since being diagnosed with stage IV pancreatic cancer with liver metastases. Without knowing the denominator (i.e., how many patients Gonzalez treated to produce those 11 patients with significantly better than average survival for pancreatic cancer), his case series is meaningless. Indeed, back in my old Usenet days in the late 1990s and early 2000s, I would frequently comment that if I were to apply for a grant at the NIH to fund a clinical trial based on such a thin gruel of preliminary data, my application would have found its way to the cylindrical file. The trial for the Gonzalez protocol did not. Selection bias is a wonderful thing if you’re peddling unscientific cancer therapies, where patients who actually could undergo the rigorous Gonzalez protocol would be more likely to be doing better and thus more likely to continue to do better than average, therapy aside.
So what was this trial? These were the objectives:
     1.  Compare the survival of patients with stage II, III, or IV adenocarcinoma of the pancreas treated with gemcitabine versus intensive proteolytic enzyme therapy and adjunctive dietary and nutritional support.
     2.  Compare the quality of life in patients treated with these regimens.
The two arms of the study were described thusly:
This is an open-label study. Patients are stratified according to stage (II or III vs IV), performance status (0-1 vs 2) and nutritional status (well nourished or moderately malnourished vs severely malnourished). Patients are entered into 1 of 2 treatment arms at their choice:
Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy.
Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
Patients are followed at 1, 3, 7, and 12 months and then yearly thereafter.
Arm I is the very epitome of Tooth Fairy science.
A word needs to be said about the design of this study. It is not randomized, and it is not double-blinded. It was originally designed as a randomized but not blinded study, given the difficulty in blinding which group is getting coffee enemas, for example, and which were not. (I can see how placebo enemas would be a problem.) Even so, because placebo effects would not be evident in the objective outcome, namely survival, this would not be a major problem in a study of this sort, although the lack of blinding could conceivably affect the quality of life measurements. Unfortunately, investigators could only accrue three patients between 1999 and 2001; so in 2001, the trial protocol was converted from a randomized phase III design to an open label observational design. Basically, patients picked which therapy they wanted, and the investigators prospectively studied how they did. The figure below shows the ultimate flow of patients:
One serious problem with a nonrandomized design like this is the likelihood of selection bias. In this case, it would be “self-selection” bias in that investigators would have to worry whether patients who were either worse off or better off might opt preferentially for one arm of the trial over the other. I will address that point after we look at the results, which are quite striking:
In words:
At enrollment, the treatment groups had no statistically significant differences in patient characteristics, pathology, quality of life, or clinically meaningful laboratory values. Kaplan-Meier analysis found a 9.7-month difference in median survival between the chemotherapy group (median survival, 14 months) and enzyme treatment groups (median survival, 4.3 months) and found an adjusted-mortality hazard ratio of the enzyme group compared with the chemotherapy group of 6.96 (P<.001). At 1 year, 56% of chemotherapy-group patients were alive, and 16% of enzyme-therapy patients were alive. The quality of life ratings were better in the chemotherapy group than in the enzyme-treated group (P <.01).
Moreover, the quality of life, as measured by standardized surveys, was actually worse for the Gonzalez therapy group:
Patients in the two groups responded similarly to the questionnaires on quality of life before initiation of therapy, but the overall FACT-PA scores during 12 months decreased more in the enzyme group than in the gemcitabine group (Fig 3). Twenty-four percent of total measurements were missing. Quality of life scores of both groups were significantly different (P<.01). During the first 6 months of the study, pain scores increased in the enzyme group, but they decreased in the chemotherapy group (p <.05); however, few patients reported on use of analgesics. (Table 2).
In all my years in medicine, surgery, and surgical oncology, I have never seen a study with such a striking difference in outcome between the two groups. No wonder the Office for Human Research Protections (OHRP) issued a determination letter stating that it was appropriate to terminate the study before the full 72 patients were enrolled due to the study having reached its “predetermined stopping point.” These days, clinical trials are designed with periodic assessment of results and predetermined stopping points. These stopping points are invoked to shut down the trial in the event that one group is doing so significantly better than the other that enrolling the remaining patients could not possibly change the result. The purpose of such a stopping point is to protect clinical trial subjects from being enrolled in a study that no longer has clinical equipoise; i.e., the groups can no longer be predicted to have roughly equivalent outcomes based on what we know. Usually, it’s the experimental group that does better than the control group. At least that’s the intent. Sometimes, however, as in the case of the Gonzalez protocol, it’s the experimental group that did much worse, so much so that the study was halted before reaching its full accrual.
But it’s even worse than that. Not only was the median survival of patients in the Gonzalez therapy group worse than it was for the standard chemotherapy group, it was three times worse. At one year, 56% of the chemotherapy patients were alive; only 16% of the Gonzalez protocol patients were. But it’s still even worse than that for the Gonzalez therapy. Not only did Gonzalez therapy patients do worse than those receiving standard therapy, but they did worse than the “average” pancreatic cancer patient as determined by the survival curve derived from data from the SEER Database. The most likely reason to explain such a result is that the Gonzalez therapy is not just inferior to gemcitabine but is probably completely biologically inactive against pancreatic cancer. What we are looking when we examine the survival curve for the Gonzalez protocol group is, most likely, indistinguishable from a survival curve of untreated pancreatic cancer versus treated.
Is this study a slam dunk? Is the Gonzalez therapy, for all intents and purposes, dead? For the most part, yes, but there are a few problems. Of course, the nonrandomized nature of the trial makes it possible that biases crept in. As I mentioned before, that is always a potential problem with a nonrandomized study design. Fortunately, the patients in each group ended up being reasonably well matched in age, gender, and other demographics. There was, however, at least one relevant difference that no one discussed. Indeed, I’m surprised that the investigators didn’t mention it, as it could have at least partially suggested a reason why the Gonzalez group might have done so poorly early on. It’s unlikely to have made a difference big enough to have explained the huge difference between patient groups, but it would at least have been a straw to grasp at. Specifically, the serum albumin levels in the Gonzalez group were statistically significantly lower than they were in the control group. Albumin is a rough estimate of nutrition (although there are better parameters) and we surgeons know that lower albumin levels are associated with increased early mortality in pancreatic cancer. I doubt that this is anywhere near enough to explain such a huge difference in mortality between the two groups, especially since the difference between the albumin levels in the two groups was relatively small (4.3 g/dL versus 4.0 g/dL), with the Gonzalez group still having albumin levels within the normal range, but it is one difference that caught my eye. It is also likely (but not well explained) that there were differences in supportive care, such as the rate of inserting biliary stents to relieve bile duct obstruction or aggressively treating infections such as ascending cholangitis, which is one of the most common causes of death in pancreatic cancer patients. The obstructed bile duct causes bile to back up; the bile gets infected; and the patient develops a life-threatening infection. The primary treatment is biliary drainage, either through a tube inserted endoscopically into the bile duct or inserted through percutaneously into the bile ducts in the liver. Antibiotics are necessary, too, of course, but they don’t do much good without biliary drainage. Also, if there was a difference in palliative care between the two groups, that, too, would be yet another example of the unethical nature of this trial.
The one thing that surprised me about this study was not so much that the Gonzalez group had the same mortality and median survival as, in essence, untreated pancreatic cancer patients (which they are), but rather that the survival in the gemcitabine group was so long (14 months). This is better than most studies of gemcitabine-based regimens from the time period during which patients accrued to this study (although results of more recent trials have been better). This suggests a possibility of some unexpected selection bias. Alternatively, it could be that this is simply an outlier group. However, it’s highly unlikely that it invalidates the study. Given the striking difference between the two groups and the fact that the Gonzalez group did more poorly than historical controls, from this study we can confidently say that the Gonzalez protocol is almost certainly no better than no treatment.
In fact, it’s probably worse. Go back to Dr. Atwood’s post on this issue and consider the story of an unfortunate 40 year old man who enrolled in the trial and chose the Gonzalez protocol arm. This man was told to have his fillings removed and afterward tried as hard as he could to continue the regimen to the letter and suffered horribly as he did. At one point he was even told that increasing pain might be an indication that his tumors were “dissolving.” Although it may be that the Gonzalez protocol didn’t make his pain worse, it’s quite clear that the man’s pursuing the therapy kept him from persuing effective palliative care that might have made his last few months on this earth a lot less unpleasant. Indeed, this makes me wonder what the investigators did after the trial was closed. From an ethics standpoint, every patient in the Gonzalez arm should immediately have been informed of these results and been strongly encouraged to give up the Gonzalez protocol and undergo standard gemcitabine chemotherapy.
Finally, the most disturbing issue that this trial raises is the question of why it took nearly four years after the trial was stopped to publish the results. Dr. Atwood has speculated why this might be the case, namely to cover up the results that were unfavorable to Gonzalez. There is now no doubt that this trial was completely unethical right from the very beginning, but that lack of ethics was compounded by not having the results reported right away. In this, after having had a few days to think about it, I am going to have to strongly disagree with my co-blogger Dr. Atwood when he asserted, “A compelling argument can even be made that the JCO should not have published the report—as paradoxical as that sounds.” I can understand where he’s coming from. This study clearly violates the Helsinki Declaration, to which JCO requires the clinical trials that it publishes to adhere. However, I find an it equally, if not more, compelling to take the view that the patients who suffered in the Gonzalez group will have suffered in vain if the results of this trial were not published. I also tend to take the view that shining a light on such a trial, in the form of publication, is a good thing in this particular case because it eliminates the uncertainty over whether the results were as bad as we know them to be. Let’s put it this way: If the results were not published in a peer-reviewed journal but rather announced or mentioned in a report, they would seem less credible to shruggies. It is these people who need these bad results rubbed in their noses, the better to let the stench waft into their nasal passages and make them retch. When they ask, “What’s the harm,” we can tell them in no uncertain terms what the harm is. The same would apply if they were simply announced on ClinicalTrials.gov or mentioned in a report. It’s just not the same as a peer-reviewed publication in one of the highest impact oncology journals there is. This is truly a case where the greater good can be served by disseminating this data far and wide as soon as possible by the most scientifically credible means necessary.
One thing that is most remarkable is that this study was released without any fanfare whatsoever. You can bet that, had the results been positive, it would have been trumpeted with press releases. I bet that even if the results had shown that the Gonzalez protocol was no worse than “conventional” therapy, it would have been trumpeted as “Gonzalez therapy as good as conventional chemotherapy!” to the press. Yet, here we have exceedingly striking results, and what do we hear? Nothing.
TOM HARKIN, NCCAM, AND HEALTH CARE REFORM
I now return to the issue of Tom Harkin’s likely taking over Senator Kennedy’s old chair and why it matters. The reason it matters is because Tom Harkin is not a science-based man. He is the man most responsible for the creation of NCCAM and has in 2009 been doing his best to infiltrate coverage for CAM in any government health care reform legislation that may come. Yet that doesn’t stop organizations like The Foundation for the National Institutes of Health, Research!America, and the Albert and Mary Lasker Foundation from awarding Harkin a “Champions of Research” award. While it’s true that Harkin seems a strong supporter of the NIH on the surface, at the same time he is a corrosive influence, inserting his belief in CAM/IM into the NIH and pushing to promote it. Without NCCAM, Tom Harkin, and Dan Burton, the latter of whom in particular pushed the NIH to fund the Gonzalez protocol, this pseudoscientific and highly unethical study is highly unlikely ever to have been funded.
Now Tom Harkin, who has “distinguished” himself by trying to hijack health care reform to give undeserved legitimacy to therapies like the Gonzalez protocol and even to have the government pay for such quackery, is now in charge of one of the key committees involved with government health policy. I fear he’ll do for health care reform what he did for the NIH through NCCAM.
Be afraid. Be very afraid.
REFERENCE:
John A. Chabot, Wei-Yann Tsai, Robert L. Fine, Chunxia Chen, Carolyn K. Kumah, Karen A. Antman, & Victor R. Grann (2009). Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer Journal of Clinical Oncology : 10.1200/JCO.2009.22.8429 (E-pub ahead of print).

The FDA’s accelerated drug approval program is failing to protect cancer patients
Drug approval is a process that should be and, for the most part, is rooted in rigorous science. However, there is always a countervailing pressure to approve new drugs rapidly, particularly in cancer. That’s why the FDA created the accelerated approval program in the early 1990s. Unfortunately, increasingly this approval process appears to be failing us in oncology. Reform is needed.
David Gorski on June 3, 2019
Link
There is a tension inherent in the drug approval process between the desire to approve new drugs rapidly in order to treat suffering people and the need to be cautious, to make sure that new drugs are safe and effective before they are approved for sale. This weighing of the risks of too-rapid approval of drugs that doesn’t work (or doesn’t work well) and might cause harm versus the harm that can be caused by delaying approval of an effective drug that might help millions longer than necessary is complex, as is balancing the benefits of rapidly approving effective drugs versus the benefits of a more rigorous approval process that catches potentially dangerous drugs before they are approved.
Even under ideal circumstances, value judgments must be made, but add politics and profit to the mix, and it’s a very contentious process, with multiple players, most of whom don’t like delay. Drug companies want their drugs approved rapidly because of the potential profit. Patient advocates with serious diseases want promising new drugs sooner. Conservatives opposed to regulation like to push for faster drug approval as a means of making the Food and Drug Administration (FDA) less powerful, which was, of course, the origin of unethical “right-to-try” laws. Those harboring distrust of big pharma (which is often justified) want a more rigorous approval because they believe that the existing process is rigged in favor of the drug companies and don’t trust its results. It’s an uneasy tension that’s existed for many decades, ever since the formation of the FDA in 1906, through the 1962 Kefauver-Harris Drug Amendments to the Federal Food, Drug, and Cosmetic Act, which mandated evidence of efficacy in addition to evidence of safety before a drug could be approved. This was a law passed in the wake of the thalidomide disaster.
Since then, depending on who was in office and who the FDA Commissioner was, the pendulum has shifted back and forth over how rigorously safety and efficacy have to be show before a drug can be approved. In response to the HIV/AIDS crisis, for instance, the accelerated approval process was initiated to allow approval for drugs that fill an urgent unmet need for the treatment of serious conditions to be approved based on surrogate endpoints:
The FDA instituted its Accelerated Approval Program to allow for earlier approval of drugs that treat serious conditions, and that fill an unmet medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval.
Drug companies are still required to conduct studies to confirm the anticipated clinical benefit. These studies are known as phase 4 confirmatory trials. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from the market.
It was a reasonable response to a tough problem; or at least it seemed so at the time. Drugs in this pathway could, after 1992, be approved by the FDA if their makers could demonstrate an effect on a surrogate measure or intermediate clinical end point that is, according to the program, “reasonably likely” to predict a real clinical end point, such as changes in symptoms or mortality rates. Certainly, surrogate endpoints can be measured in a much shorter time frame than the several years it usually takes to identify improvements in overall survival. The accelerated approval program, however, rests on a big assumption, namely that the surrogate endpoint chosen is a good predictor of clinical outcome. So it’s reasonable to ask: How often do drugs approved through this process ultimately pan out and provide significant benefit to patients? A study asking this question was published in JAMA Internal Medicine last week, which made it into the news:
Many cancer patients and oncologists may turn to the US Food and Drug Administration’s accelerated approval program, which provides access to new cancer drugs faster — especially when a life-threatening cancer needs swift treatment or relief.
Yet a new study questions the clinical benefit of some drugs in the program and suggests ways in which the program could be improved.
It turns out that the study, carried out by researchers at Brigham and Women’s Hospital and Queen’s University in Canada, found that only one-fifth of oncology drugs that received accelerated approval were ultimately validated in confirmatory trials to have an effect on overall survival. Basically, the study calls into question the entire rationale of the FDA’s accelerated approval system, at least in oncology. Let’s dig in.
Surrogate endpoints in oncology versus real endpoints
Cancer therapies are generally evaluated using a number of endpoints. The most commonly used include overall survival (OS), progression-free survival (PFS), or recurrence-free survival (RFS). There are, of course, other endpoints related to survival that are measured, but these three are the most relevant for this discussion. Overall survival is what it sounds like: How long do patients survive their cancer after diagnosis? Period. It’s hard for an endpoint to be more objective than that: At a certain timepoint after diagnosis, either the patient is alive or she is dead. This number is usually expressed in terms of median survival, which is the period of time after which half of the patients under study are still alive and half have died. It should be noted that OS includes all causes of death, not just cancer. If a patient with cancer under study dies of a heart attack that is not related to his cancer or his cancer treatment, that counts.
Traditionally, OS has been the “gold standard” endpoint in measuring the efficacy of a cancer therapy, because the primary goal has been to prolong survival, the ideal case being prolonging survival to the point where it is indistinguishable from life expectancy if the patient never had cancer in the first place. PFS, on the other hand, is survival without progression; i.e., how long the patient with cancer survives without evidence that his or her tumor has measurably grown or metastasized, with dying of other causes with disease counting in the calculation. While PFS is often measured as well as OS, it’s generally considered less useful because it is entirely possible for a treatment to prolong PFS without prolonging OS. This sort of result can happen when the treatment is effective at shrinking a tumor and/or slowing its progression but its toxicities contribute to death from other causes. In such a case, PFS improves with no improvement in OS. Finally, RFS (also called disease-free survival, or DFS) is how long the patient survives without a recurrence of her cancer after successful initial treatment. PFS and RFS are often used as surrogate endpoints in cancer therapy clinical trials, although increasingly there is one other. In neoadjuvant chemotherapy (chemotherapy given before surgery), a pathologic complete response (pCR) has traditionally been considered a good surrogate endpoint. A pCR occurs when, at surgery, there are viable cancer cells detectable in the specimen removed at surgery. There is some controversy about this, in breast cancer at least, but in aggressive forms of breast cancer the correlation between pCR and improved overall survival is good, with a relatively recent meta-analysis having found that there is an 84% decreased chance of death in women with an aggressive subtype of cancer known as “triple negative” whose neoadjuvant treatment achieves a pCR.
Other surrogate endpoints include response rate (RR), defined as the percentage of patients whose tumor shrinks significantly in response to the therapy (usually 30% or more is the cutoff); and time to tumor progression (TTP, which is the same as PFS but doesn’t include deaths; it just measures time until the tumor detectably progresses). To these is being added a dizzying array of molecular surrogate endpoints that are less accepted, and it’s hard not to be tempted to pick your favorites if you’re an oncology researcher.
The debate about the use of surrogate endpoints in oncology has been going on as long as I can remember, dating back to before I entered the field of surgical oncology as a fellow back in the mid-1990s, and, as this study shows, is still going on. Unfortunately, the relationship between these surrogate endpoints and overall survival is not always clear or as tight as we would like to think. Nine years ago, I discussed in depth one such case, Avastin (bevacizumab), an angiogenesis inhibitor, and its use for advanced breast cancer. The drug had achieved accelerated approval for this indication in 2008 on the basis of trials showing improvements in PFS. However, by 2010, followup trials had failed to show an improvement in OS, and the FDA rescinded its provisional approval. When Avastin was approved, a prominent breast cancer oncologist justified Avastin’s approval based on PFS thusly:
Dr. Kathy Albain, a breast cancer specialist at Loyola University Medical Center in Maywood, Ill., polled colleagues and patients and found overwhelming support for approving drugs based on delaying tumor progression. It would be ideal to show that a drug also prolongs life, but that may not be realistic, she said. The reason is that when a woman’s cancer progresses, doctors change the drugs they use, hoping to slow the cancer. That dilutes any impact of the first drug — in this case Avastin.
At the time, I noted that, although I could see where Dr. Albain was coming from, I had always been uneasy with this view. I could see the utility of a drug that slows tumor progression but does not prolong survival, but I could only see its usefulness in one situation: There must also be good evidence that that drug also improves quality of life, evidence that was definitely lacking for Avastin, which, if anything, increased complication rates and was very expensive, to boot.
In any event, the FDA’s removal of its approval for Avastin for advanced breast cancer shows another problem with accelerated approval. When a drug is provisionally approved and then its approval rescinded based on later clinical trials, no one is happy. Certainly breast cancer advocates were very unhappy. I even experienced some of their wrath when I foolishly agreed to be on a radio show to discuss the issue. What I wasn’t told was that there would also be a breast cancer advocate on the show as well, an advocate who was receiving Avastin and believed that it was responsible for her continued survival. Politics also intruded. The Affordable Care Act had just been passed into law at the time, and conservative opponents of the ACA attacked the FDA’s decision on Avastin as “evidence” of the impending arrival of socialized medicine-style rationing, thanks, of course, to “Obamacare”, characterizing the decision as the FDA being made complicit in “rationing” health care.
It is a very thorny issue, which is why the study under discussion, by Bishal Gyawali at Brigham and Women’s Hospital, asks a very pertinent question: How often do oncology drugs approved by the accelerated approval mechanism show improvements in OS in the subsequent confirmatory clinical trials required by the FDA?
Disappointing results
To answer this question, Gyawali et al looked at drugs approved by the FDA based on surrogate endpoints. In the introduction, it is noted:
The FDA recently published an article on the 25-year experience with the accelerated approval pathway that examined the fate of 93 oncology indications granted accelerated approval from December 11, 1992, through May 31, 2017.9 The review found that 81 (87%) of the original 93 accelerated approvals were based on response rates—a surrogate marker in which the effect of an intervention is determined based on a change in tumor size. In addition, 8 (9%) of 93 accelerated approvals were based on PFS or time to tumor progression (TTP) and 4 (4%) were based on DFS or recurrence-free survival (RFS). Progression-free survival and TTP are surrogate markers that measure the time between the start of treatment and tumor growth beyond a certain size in the case of metastatic disease, whereas DFS and RFS measure the time from the start of treatment to disease recurrence when the drug is used as adjuvant therapy.
The FDA reported that in 51 (55%) of the 93 indications, confirmatory trials verified clinical benefit. In 5 cases (5%), approval for an indication was withdrawn in light of postapproval trial results, and postapproval evaluations were ongoing for the remaining 37 (40%) indications.9 The FDA concluded that the low failure rate in confirmatory trials was evidence that the accelerated approval pathway was operating effectively. We assessed the nature of the end points used for the verification of benefit in confirmatory trials and provide an update on the current status of the remaining indications for which confirmatory trials were ongoing at the time of the FDA’s analysis.
Gyawali et al wanted to update the outcomes reported by the FDA. So in May 2018, which was one year after closure of data collection for the FDA’s study, they searched PubMed, as well as the FDA database of postmarketing requirements and commitments, to determine the current status for postmarket trials for the indications that were labeled as “ongoing” in the FDA report. Confirmatory trials were categorized into three groups: (1) a trial that used OS or a quality-of-life end point, (2) a trial that used a surrogate measure different from the one used in the preapproval trial, and (3) a trial that used the same surrogate measure used in the preapproval trial. Here is the “money table,” which summarizes the study’s findings:
So, looking at the updated figures, I see that on the surface, it looks as though, for 62% of oncology drug approvals, clinical benefit was confirmed. But if you look more closely, you’ll see that only 20% of all 93 cancer drug accelerated approvals, or one-third of the ones claiming confirmation, had improvement in OS noted in confirmatory trials. What about the other 40%? 20% had improvement in the same surrogate in their confirmatory trial, which led me to a major facepalm when I read this result. What on earth is the purpose of just doing another study using the same surrogate endpoint? How does that “confirm” anything? The other 21% had improvement in a different surrogate in a confirmatory trial, which led me to a less vigorous, but still painful facepalm. Apparently it did the same to the authors, who wrote in the discussion:
Studying the same surrogate efficacy measure that had been used to earn accelerated approval was considered sufficient by the FDA to confirm approval in certain cases, although it is not clear that such follow-up studies should be used as verification of benefit. Rather, a postapproval trial that uses the same surrogate measure as its primary end point should be described as corroborating the effect on the surrogate measure, perhaps in a larger or different patient population, unless the surrogate measure has been well validated. In other cancer drug approvals that we reviewed, the confirmatory trials used a different surrogate end point than the one used in the preapproval trial. In this situation, patients and physicians continue to lack information about whether the cancer drug improves survival or quality of life, which is essential in the benefit-risk evaluation for clinical decision making, unless the new surrogate is a validated surrogate.
Indeed. What was the point of using surrogate endpoints in a second trial, meant to be confirmatory? That doesn’t “confirm” anything either. As for the rest, five drug accelerated approvals (5%) have been withdrawn and an additional three (3%) did not demonstrate improvement in the primary end point in confirmatory trials. Five (5%) trials were delayed, 9 (10%) remain ongoing, 10 (11%) remain pending, and one each were terminated and released. Thus, a significant percentage of confirmatory studies are delayed or pending, which means that considerable time can elapse between the approval of a drug and the completion of its confirmatory trials.
The authors also note:
In describing the accelerated approval pathway, current FDA rules state that confirmatory trials of a drug should “verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate end point to clinical benefit, or of the observed clinical benefit to ultimate outcome…such studies must also be adequate and well-controlled.” Although this language does not explicitly require that a confirmatory trial evaluate a clinical end point like OS, these rules do highlight that postapproval studies should be designed to resolve the uncertainty of the association between the surrogate measure and clinical benefit. This standard will be difficult to achieve via postapproval studies that use the same surrogate measures as those used in preapproval studies.
That last sentence is about as sarcastic a remark as you will ever find in a peer-reviewed medical study. Nice shade there, Dr. Gyawali!
In fairness, the authors do recognize the debate in oncology whether OS should remain the “gold standard” for oncology drug approval, or “whether achieving durable responses in single-arm trials should be sufficient to judge the clinical efficacy of a cancer drug”. The problem with this approach, from my perspective, is that many of these drugs are toxic, which means that a durable response could be at the cost of toxicity that negates (or worse, more than negates) any potential survival benefit attributable to the durable response.
There’s also a second study in the same issue of JAMA Internal Medicine by Chen et al, that looked at cancer drugs approved using only RR as the surrogate endpoint. (Shockingly, one-third of cancer drugs in the US are approved based only on RR.) Basically, they performed a comprehensive review of available package inserts for all oncology drugs that were FDA-approved on the basis of RR end points for any adult malignant disease from January 1, 2006, to September 30, 2018, including both accelerated and regular approvals. Of the 85 approvals that they examined, they reported that 14 (16%) had an RR less than 20%, 28 (33%) had an RR less than 30%, and 40 (47%) had an RR less than 40%, noting that “many cancer drugs are approved on the basis of low or modest RRs, typically in single-arm studies.” They noted in their conclusion:
Finally, many of these drugs have remained on the market for years without subsequent confirmatory data. When accelerated approvals based on RR were converted to full approval, 23 of 29 were made on the basis of surrogate end points (PFS or RR), 7 of 29 were made on the basis of RR, and only 6 of 29 were made on the basis of OS, an end point of clinical benefit. In summary, our analysis of drugs approved on the basis of RR end points suggests marked flexibility on behalf of the FDA to use this surrogate end point in the absence of randomized clinical trials.
These are shockingly low numbers.
What can be done?
An accompanying commentary by Richard Lehmann and Cary Gross notes that this is time of “unprecedented hope in the development of treatments for cancer.” noting that in comparison to many other regulatory agencies, the FDA “works to high standards of rigor and transparency” but that it “also works amid constant political clamor for faster access to innovative treatments.” They also note that these two studies “serve as a reminder that the accelerated approval pathway is a permissive process that tolerates nonrandomized trial methods and a variety of outcome measures that bear an uncertain relationship to patient benefit.” This is all true, unfortunately, and, as Chen et al show, there are a lot of drugs out there that undergo regular FDA approval based on surrogate endpoints and whose benefits in terms of OS are unproven. As Lehmann and Gross observe:
Such findings build on a growing body of work, which in aggregate, demonstrate a postmarketing evaluation process that is serving neither patients nor society well. First, the surrogates used for accelerated approval are poor predictors of clinically meaningful outcome. Second, study designs of postmarketing studies may not provide adequate information about comparative efficacy because some studies may not use appropriate control groups or rigorously account for treatment assignment bias. Third, there are concerns about whether postmarketing studies are being completed; it has been consistently reported that nearly half of postmarketing studies are delayed, and the proportion of completed studies remains low.1 Finally, nearly a quarter of these studies are not being publicly disseminated, even when completed.2
In other words, the postmarketing evaluation process is broken. As is noted in another accompanying editorial by Sarah DiMagno, Aaron Glickman, and Ezekiel Emanuel:
Second, using surrogate end points such as response rate to get drugs to patients quickly is only defensible if the studies’ findings are quickly evaluated in confirmatory postapproval trials that validly quantify overall risks and benefits, which inform physician and patient decision making. Manufacturers are required to conduct postapproval trials to ensure the signal from surrogate end points is real rather than noise.
Clearly, this is not being done nearly as fast or well as it should be. It’s a problem that needs to be fixed.
A complementary way to approach the problem is to find better surrogate endpoints and to work on assessing the correlation between the ones we use and clinical benefit in OS. As Gyawali et al note, their results, that only 20% of drugs approved based on surrogate endpoints improve OS, are consistent with other findings, and the use of these endpoints is not particularly rigorous. For example, a recent study by Kim and Prasad that found that in 56% of accelerated approvals and 37% of traditional approvals there was no formal analysis of the strength of the surrogate-survival correlation and that for accelerated approvals just four approvals (16%) were “made where a level 1 analysis (the most robust way to validate a surrogate) had been performed, with all 4 studies reporting low correlation (r≤0.7).” The conclusion? The use of surrogate end points for drug approval often lacks formal empirical verification of the strength of the surrogate-survival association. In another paper, Robert Kemp and Vinay Prasad noted:
We suggest this reliance on surrogates, and the imprecision surrounding their acceptable use, means that numerous drugs are now approved based on small yet statistically significant increases in surrogates of questionable reliability. In turn, this means the benefits of many approved drugs are uncertain. This is an unacceptable situation for patients and professionals, as prior experience has shown that such uncertainty can be associated with significant harm.
In other words, as I have argued before, if anything the FDA’s approval standards are arguably not rigorous enough, contrary to the arguments of anti-regulation ideologues who like to make ridiculous claims that the FDA is “killing” thousands of people by being too slow to approve life-saving new drugs or that you can replace the FDA approval process with, in essence, a “Yelp for drugs.”
I think DeMangno et al come closest to getting it right in their editorial when it comes to proposed solutions. Three problems are noted: that response rates are not meaningful clinical outcomes; that using surrogate endpoints to approve drugs is defensible only if the followup studies are done quickly and acted upon, which is not the case; and that the FDA still approves drugs even when the confirmatory data show no substantive benefit on clinically meaningful end points. They also note that there is no reason why the FDA has to rely on so many single trials using surrogate endpoints given that randomized trials in patients with metastatic disease could be done almost as quickly, given the shorter expected survival times. They then conclude:
Together, these 2 articles suggest that the ship of regulation has veered too far to one side, requiring at least 3 policy changes. First, the end point for confirmatory trials should never be the same surrogate end point used in the original study, and a new surrogate end point should be used only if there is a proven correlation between that end point and overall survival or improved quality of life. Most confirmatory trials should use overall survival and/or quality-of-life end points. Second, approval of drugs should be rapidly withdrawn when confirmatory trials report serious toxic effects or do not report meaningful clinical improvements. Finally, the confirmatory trials must be conducted promptly, with credible threats of reversed approval. Having more than a quarter of trials incomplete years after accelerated approval is unacceptable.
Lehmann and Gross note that postmarketing clinical trials are “expensive, requiring substantive infrastructure and oversight.” Of course, one argument for accelerated approval is that regular drug approval is too expensive and takes too long, implying that accelerated approval “gets cures to the patients” faster and for less money. Unfortunately, that observation can be countered by simply pointing out that many of these new drugs are nonetheless very expensive, and, as we have seen, too many of them are of marginal benefit at best, meaning that in far too many cases we pay a lot for not very much benefit. Clearly the FDA needs to do, at minimum, what DeMango et al suggest. Unfortunately, in the present political environment, all the political headwinds are pushing in a direction opposite of more rigorous standards for drug approval.

FDA issues warning letter to “holistic” practitioner offering thermography for breast cancer detection
Thermography for breast cancer detection is one of more than 65 products the FDA just announced it is going after for fraudulently claiming to prevent, diagnose, treat or cure cancer.
Jann Bellamy on April 27, 2017
Link


The FDA announced this week that it is taking action against 14 U.S.-based companies for illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. Products include pills, topical creams, ointments, oils, drops, syrups, teas and diagnostic devices, sold mostly on websites and social media platforms. In warning letters posted on the FDA’s website, the agency demanded responses within 15 days from the companies stating how the violations will be corrected. Failure to respond may result in legal action, including product seizure, injunction, and/or criminal prosecution. The FDA also posted “mug shots” of several of the products.
One of those letters went to Nature’s Treasures, Inc. In addition to selling quack cancer treatments for both humans and pets, Nature’s Treasures markets thermography for breast cancer detection. According to the FDA, the company’s claims for thermography “provides evidence that the device is intended for diagnostic screening for detection of breast cancer, including as a sole screening device,” which federal law prohibits.
The FDA’s warning letter says that “telethermographic systems,” as the agency calls them, are cleared as diagnostic medical devices only for adjunctive diagnostic screening for detection of breast cancer. The fact that Nature’s Treasure’s included the Quack Miranda Warning – that its “products are not intended to diagnose, treat, cure or prevent any disease” – was not the “get-out-of-jail-free” card the company apparently hoped for. As the FDA pointed out, that is exactly what the company claims for thermography: that it can diagnose disease.
We’ll get back to the company’s bogus claims in a minute, but first, some background on thermography.
Thermography’s deficiencies
SBM’s own breast cancer expert, Dr. David Gorski, covered thermography for breast cancer detection back in 2010:
What is thermography and how is it used to detect breast cancer? As its name implies, thermography measures differences in temperature. Most systems use infrared imaging to achieve these measurements. There’s nothing magical about it; the technology has been in use for various applications for decades. The rationale for applying thermography to the detection of breast cancer is that breast cancers tend to induce angiogenesis, which is nothing more than the ingrowth of new blood vessels into the tumor to supply its nutrient and oxygen needs. A tumor that can’t induce angiogenesis can’t grow beyond the diffusion limit in aqueous solution, which is less than 1 mm in diameter. These blood vessels result in additional blood flow, which results in additional heat. In addition, the metabolism of breast cancer cells tends to be faster than the surrounding tissue, and cancer is often associated with inflammation, two more reasons why the temperature of breast cancers might be higher than the surrounding normal breast tissue and therefore potentially imaginable using infrared thermography.
The problem is, as he pointed out, claims of “integrative” physicians, naturopaths, chiropractors and homeopaths notwithstanding,:
There aren’t any baseline measurements of sensitivity and specificity.
There are no widely agreed-upon standards for test performance and interpretation.
Even if there were accepted standards, we don’t know whether thermography is cost-effective.
There is the potential for over-diagnosis and over-treatment even if, as promoters claim, lesions are detected 5-10 years before mammography.
Even as an adjunct, thermography doesn’t provide any information that a breast MRI doesn’t provide, and provide better.
Just this month, UnitedHealthcare issued a new Medical Policy on Thermography, reviewing the evidence. It included a 2012 systematic review finding that
currently there is insufficient evidence to support the use of thermography in breast cancer screening. The authors stated that there is also insufficient evidence to show that thermography provides benefit to patients as an adjunctive tool to mammography or to suspicious clinical findings in diagnosing breast cancer.
The Medical Policy noted that the American Cancer Society (ACS), the American College of Radiology, and the American College of Obstetricians and Gynecologists (ACOG) do not recommend thermography for breast cancer detection. According to the ACS:
Thermography failed to detect 3 out of 4 cancers that were known to be present in the breast. Digital infrared thermal imaging (DITI) which some people believe is a newer and better type of thermography, has the same failure rate.
The American College of Clinical Thermography says that women with dense breasts can benefit from thermography, a claim rejected by the ACOG.
UnitedHealthcare notes that Medicare won’t cover thermography and neither will it, for anything:
There is insufficient evidence to conclude that thermography has a beneficial impact on health outcomes. The available evidence is limited and weak, and standards for image evaluation and cut-off values that would allow clinical recommendations based on this technology have not been established.
The FDA’s own consumer information recommends that
despite widely publicized claims to the contrary, thermography should not be used in place of mammography for breast cancer screening or diagnosis.
The FDA notes that it has previously issued warning letters to practitioners making misleading claims, including well-known anti-vaccinationist and quackery promoter Joe Mercola. (The link to the letter is no longer good, but you can find out more about the case on Quackwatch and in the Chicago Tribune.)
In sum, practitioners cannot legally advertise that thermography is a substitute for mammography or promote it as a stand-alone diagnostic tool for breast cancer. However, thermography devices have been cleared by the FDA for use as an adjunct, or additional, tool for detecting breast cancer, even though there is no reliable evidence it is useful for that either. With that in mind, let’s look at how the FDA saw through Nature’s Treasures claims.
Nature’s Treasures: Quackery galore, including thermography
Nature’s Treasures is run by Los Angeles-area “holistic health counselor and natural health educator,” who, oddly enough, doesn’t tell us her name in her bio. We can presume she is Raya Shanazarian, the person to whom the warning letter is addressed. She claims she “studied naturopathy” at “Trinity College,” (maybe Trinity School of Natural Health?) and received a diploma from Ashworth College in 2015, the same year this online school settled FTC charges it misled students about career prospects and transferability of credits. (An $11 million judgment was suspended based on the school’s inability to pay.)
Shanazarian is not a licensed California health care professional of any sort and seems to be skating mighty close to the unlicensed practice of medicine, although she may come under the aegis of California’s generous quack protection act, otherwise known as a “health freedom” law. That someone so grossly unqualified to offer medical advice and treatment practices openly is a testament to the sorry state of healthcare regulation in California. At least the FDA is taking action.
Shanazarian advertises all sorts of quackery on her Nature’s Treasures website. This, also from her bio, will give you the flavor of where she’s coming from:
I want people to know that the root cause of disease stems from the accumulation of toxins in the body, and daily exposure to a toxic living environment. These toxins come from air, water, genetically modified foods, pesticides, meat, dairy, soy, white flour, table salt, MSG (Monosodium Glutamate), microwaved foods, refined sugar, artificial sweeteners, caffeine, alcohol, electromagnetic radiation, heavy metals, parasites, industrial chemicals, prescription drugs and more.
In addition to her thermography claims, the FDA is warning her to take down statements regarding various nostrums she sells, such as:
“Oxicell is the best choice for Liver Disease or Cancer.”
“Dysbiocide . . . treat[s] patients suffering from stomach parasites.”
“Colostrum LD Capsules . . . eliminate[s] harmful pathogens and fight[s] infection.”
“NeurO2 . . . support[s] during neurodegenerative states, hypoxia states, stroke recovery, brain injury recovery.”
Clicking on “Thermography” takes you to the website of Thermography Today, also owned by Shanazarian, which offers both full body ($375) or breast ($275) thermography. With each, you get a report of the results, a consultation with Shanazarian, and “nutritional advice based on the report,” an obvious pretext for recommending dietary supplements and other dubious remedies of the sort Shanazarian sells on the Nature’s Treasures website.
The thermograms are presumably read by the two “doctors we work with,” “Dr. Ben Johnson, MD, NMD, DO,” who lives in Georgia and owns his own thermography firm in Chattanooga, Tennessee, and Gregory Melvin, a chiropractor.
So, what is Shanazarian saying about thermography that got caught the eye of the FDA? From the warning letter:
On the webpage titled “Breast-Cancer-Awareness”:
“[A]ll women 25 and older should get annual Thermography screenings…”
On the webpage titled “Mammography Vs Thermography”:
“[T]hermography looks for the body’s physiological response to cancer cells. These changes can often occur 8-10 years before the cells are large enough to be seen by a mammogram.”
“Thermography can detect the possibility of breast cancer much earlier…”
“Breast Thermography has: 99% Sensitivity, 90% Specificity, 90% Accuracy.”
“Thermography is far more sensitive than mammography.”
“Thermography benefits all women. They may be particularly useful for young women who want to monitor their breast health should start as early as possible.”
On the webpage titled “What is Breast Thermography”:
“As more and more women become knowledgeable in thermography they choose not to do mammography.”
“I myself have not done mammography since 2006, but have gone through the procedure of ultrasound twice.”
The FDA also found fault with Shanazarian’s description of the thermography process:
The webpage titled “What to Expect” discusses step-by-step how your firm uses the devices during an appointment. For example, Step 3 explains, “Your pictures will be sent out to our reading physician for analysis,” and Step 4 states, “We will set up an appointment to see you in ten days after your results have come back to us. You can share the report with your medical doctor and if he has further questions he can contact the doctor who read your report…” Step 5 concludes that “You will be recommended when to do your second thermography by the reading doctor.” This discussion promotes the use of the thermographic system with a report provided based solely on the thermographic image.
I had to chuckle when I read the part about sharing the report with your medical doctor. I’ve wondered what real physicians do when confronted with these worthless reports by patients who are understandably alarmed by the results. How do you tell a patient who has just shelled out $275 for breast thermography (and who may have shelled out even more for dietary supplements presumably indicated by the report) that she’s just wasted her money without alienating the patient?
It is interesting to note that while Shanazarian touts the putative advantages of thermography over mammography and says that she doesn’t use mammography, she never comes out and says that thermography is an actual substitute for a mammogram or that it is alone sufficient for diagnostic screening. Note also the FDA’s language about promoting the use of thermography “with a report based solely on the thermographic image.” This tells me that, if a practitioner is going to offer thermography for breast cancer screening, she’d better steer clear of the type of statements Shanazarian used, or make it absolutely clear that it is no substitute for mammography and is approved for adjunctive use only, although there’s no guarantee a qualifier would overcome statements like Shanazarian’s. I even question whether, based on the FDA’s warning, a practitioner could recommend thermography prior to mammography and without some rationale for why another diagnostic method is needed and a clear indication of what diagnostic uncertainty thermography is designed to clear up. Otherwise, she risks running afoul of the FDA.
Unfortunately, based on this testimonial on Thermography Today, discouraging mammography appears to be exactly what is happening:
I want to thank everyone who has been involved in the science of thermography. I am in my late 30s and I know I should not do mammogram.
Nor did the FDA approve of Shanazarian’s claims that “Digital Infrared Thermal Imaging is approved by the F.D.A.,” a statement the agency found “misleading . . . because such statements create an impression of official approval” when, in fact, the “FDA has never approved any telethermographic system for sole diagnostic screening . . .”
Shanazarian has 15 days to come up with a plan to comply with the law. If the violations are not corrected, they are punishable by up to one year in federal prison, five years’ probation and a fine of either $100,000 or twice the gain from the offense.
It is good to see the FDA going after cancer quackery, a “specialty” the agency has, unfortunately, aided and abetted in other cases. It is also good that the FDA included thermography among products it considers as making illegal cancer claims. Not that quacks care all that much about regulatory compliance, but at least the FDA’s action should make it clear to them that even implying thermography is in and of itself efficacious for breast cancer detection may cause the FDA to pull the plug on their claims.

Cancer quack Colleen Huber sues Britt Hermes over criticism
Naturopathic cancer quack Colleen Huber is attempting to silence criticism of her practices by suing Britt Hermes. Help Britt fight back with a donation to help defray legal expenses.
Jann Bellamy on January 18, 2018
Link

Today we interrupt our regularly scheduled post to bring you a special announcement. My usual post will appear tomorrow.
Britt Hermes is a familiar name to regular SBM readers. She’s the former naturopathic “doctor” who had the courage to leave naturopathic practice after she became disgusted with the abundant quackery and disregard for patient safety that permeates the field. Since then, she’s been busy exposing naturopathic pseudoscience via her own blog, Naturopathic Diaries: Confessions of a Naturopathic Doctor, as well as posts on our website, Kevin MD, and Forbes, and in media interviews and public appearances. Although left deeply in debt by her naturopathic “medical” education at Bastyr University, she successfully completed a Master’s of Science degree program at Kiel University. She still resides in Kiel, Germany, where she is pursuing a Ph.D. in evolutionary genomics in conjunction with the prestigious Max Planck Institute for Evolutionary Biology and the Institute for Experimental Dermatology at the University of Lübeck.
For these efforts she is regarded as a “terrorist” in some naturopathic quarters and legal threats have attempted to silence her criticism. Now she needs your help in fighting back.
In February, 2016, Hermes discovered that her name had been misappropriated in three registered domain names. One, brittmariehermes.com, was a snarky “tribute” website, while the other two redirected the reader to the homepage of the American Association of Naturopathic Physicians. Upon investigating further, Hermes found that one of the eponymous domain names was registered with an email address at the domain natonco.org, the website of an organization called the Naturopathic Cancer Society, a non-profit run by self-appointed cancer expert Colleen Huber, a “Naturopathic Medical Doctor” who practices in Arizona. The Society raises money for those who want to partake of unproven cancer treatments but who don’t have the money to pay for them. Huber also runs Nature Works Best, a naturopathic clinic which offers such treatments, claiming, among other things,
And:
It just so happens that around the time of Hermes’s discovery, the now infamous NatChat naturopathic discussion forum was engaged in a dustup over just who among their ranks was leaking information critical of naturopathy, with a big side of anti-vaccination pseudoscience thrown in for good measure. Among the accusations and counter-accusations, chat participant Colleen Huber let fly just what she thought of Hermes and her hanging out of copious amounts of naturopathic dirty laundry: Huber called Hermes a “terrorist” and claimed Hermes somehow controlled Wikipedia content presumably unfavorable to naturopaths.
Incidentally, chiming in on the NatChat vaccination debate, Huber also said she won’t administer vaccines, and neither should any other naturopath:
First Do No Harm requires that naturopathic physicians not administer vaccines, at least not in their present form. If a much safer, more effective vaccine is developed in the future, I will keep an open mind, but will not administer it until proven safe and effective in credible, uncorrupted double-blind studies. Those studies have not happened with current vaccines.
Those scruples apparently do not extend to her own cancer treatments. She claims that:
Nature Works Best is a natural cancer clinic located in Tempe, Arizona, that focuses on natural, holistic, and alternative cancer treatments. Our treatments have proved to be an effective alternative to traditional chemotherapy and radiation, which we do not use in our treatments. Rather, we have developed a natural method of treating cancers based on intravenous vitamin therapy which may include Vitamin-C, Baking Soda, and other tumor fighting agents as well as a simple food plan.
Our team of naturopathic medical doctors have administered an estimated 31,000 IV nutrient treatments, used for all stages and types of tumors. As of July 2014, 80% of patients who completed our treatments alone went into remission, 85% of patients who completed our treatments and followed our food plan went into remission.
None of the listed treatments has been “proven safe and effective in credible, uncorrupted double blind studies” nor are her statistics from “credible, uncorrupted double blind studies,” a point we’ll return to in a moment. In fact, one of the sources she touts as supportive of her baking soda treatments for cancer, Tullo Simoncini, was recently sentenced to 5 ½ years in prison for killing a patient with the treatment. (Article in Italian.)
“First Do No Harm” indeed.
Should you be able to stomach it, you can hear more of Huber’s naturopathic nonsense here.
In any event, based on her cyber-research, Hermes wrote a post on her blog: “Is dubious cancer ‘doctor’ Colleen Huber cybersquatting my name?” The post chronicled her discoveries about the misappropriation of her name and her efforts to fight back, including the fact that she had to go to the expense of hiring an attorney in the U.S. to assist in reclaiming her name. It also criticized Huber and her quack treatments, her use of a dubious Institutional Review Board (IRB) for her equally dubious research, and her questionable charitable organization. Hermes backed up her criticism of Huber’s research with a reanalysis of the data by Thomas Mohr, an oncology researcher at the Medical University of Vienna. Mohr’s comments:
Putting aside the ethical issues of the extremely bad study design, the lack of ethics committee approval or patients’ agreement, a quick n’ dirty analysis of the data reveals following odds ratio: 2.1 (95% CI 1.01 – 4.40, p<0.05) in favour of state of the art treatment. In other words, patients under natural care have more than a two-fold higher risk to die.
This is criminal.
And:
If one removes data of questionable quality and takes into account only those with complete data and in treatment resp. [respectively] died during treatment (i.e. in remission, not yet in remission, died), the odds ratio gets almost 10:1 in favour of state of the art therapy. This is really nasty.
Eventually, Hermes filed a complaint with ICANN and was able to take control of several domains using variations of her name which, she says, she assumes were registered by the same person. Then, she discovered that yet another variation of her name was being used as a domain name without her permission. According to Hermes, it linked to Huber’s Naturopathic Cancer Society and “has a similar look and feel to the former websites at the squatted domains.”
Rather than realizing the error of her ways, Huber doubled down. She hired a German attorney, who sent a cease and desist letter to Hermes, claiming the cybersquatting post defamed her. (This was actually the second cease and desist letter she received from the naturopathic community, the first coming from her alma mater, Bastyr University, also upset about her revelations about the school.) The letter demanded that she take down the post and pay Huber’s legal fees. Hermes refused and responded to these claims in a second post, “Is Colleen Huber a cancer quack? And more legal thuggery.”
Huber’s cease and desist letter boomeranged into a fresh round of criticism of her quackery. Our good friend Orac deconstructed Huber’s bogus cancer treatments and her questionable research over on Respectful Insolence. Steve Novella, MD weighed in as well here on SBM. Taken together, their comments left Huber and her research in shreds.
But Huber is nothing if not persistent. Perhaps due to good old forum shopping for a more plaintiff-friendly jurisdiction, Huber has now filed suit against Hermes for defamation in Germany, where there is no protection against SLAPP lawsuits.
Unfortunately for Huber, the boomerang struck again in response to her lawsuit. This time, it was Edzard Ernst, MD, raising anew questions about Huber’s extravagant claims. Orac also posted with an update on Huber’s latest attempt to silence Hermes.
The suit has also prompted an international effort against this attempted suppression of well-documented criticism of naturopathic practices. The Australian Skeptics are heading a fundraising drive to help Hermes pay legal expenses. Michael Marshall from the U.K’s Good Thinking Society, Steven and Jay Novella from The Skeptics Guide to the Universe, and Claire Klingenberg from the European Council of Skeptical Organisations (ECSO) are on the fundraising committee. The Australian Skeptics want donors to know that:
    • The funds donated are non-refundable.
    • We cannot guarantee that Britt will win her case.
    • Should more funds be collected than required to cover Britt’s costs, they will be held for a period of up to 12 months to ensure the legal risk to Britt has passed, after which they will be donated to Sense About Science or be put into a generalised Skeptics legal defence fund.
    • No entity linked to the campaign, including Britt, Australian Skeptics Inc. (ASI) or any of the collaborators, will receive any funds raised by the campaign.
    • ASI is not a registered charity in Australia and donors should not expect their donation to be tax deductible in Australia or anywhere else (depending on prevailing local regulation).
Eran Segev, President of the Australian Skeptics, commented in a a press release:
We are concerned by the case brought against Britt, not only over the merits or otherwise of the libel action, but particularly that the case may have the effect of silencing a major campaigner against unproven and disproven ‘medical’ practices through the imposition of considerable legal costs.
According to the press release:
The campaign, which hoped to raise at least £50k to help Britt with her legal defence, has garnered considerable attention – raising more than 60% of that initial milestone in just three days. Segev said of the early success: “While the response by the community has been incredible, legal cases can be protracted, unpredictable and expensive affairs, so we still require further donations to reach the £50k – or even more – that we need to ensure that Britt doesn’t risk financial ruin for writing about pseudoscience.
SBM fully supports Britt in her efforts to fight back against Huber’s attempt to silence her criticism. We hope you do too, and will give whatever you can via the Australian Skeptics website.

   Suzanne Somers’ Knockout: Dangerous misinformation about cancer (part 1)
David Gorski
Link
If there’s one thing I’ve become utterly disgusted with in the time since I first became interested in science-based medicine as a concept, its promotion, and the refutation of quackery and medical pseudoscience, it’s empty-brained celebrities with an agenda. Be it from imbibing the atmosphere within the bubble of woo-friendly southern California or taking a crash course at the University of Google and, through the arrogance of ignorance, concluding that they know more than scientists who have devoted their lives to studying a problem, celebrities believing in and credulously promoting pseudoscience present a special problem because of the oversized soapboxes they command. Examples abound. There’s Bill Maher promoting anti-vaccine pseudoscience, germ theory denialism, and cancer quackery on his show Real Time with Bill Maher and getting the Richard Dawkins Award from the Atheist Alliance International in spite of his antiscience stances on vaccines and what he sneeringly calls “Western medicine.” Then there are, of course, the current public faces of the anti-vaccine movement, Jenny McCarthy and her boyfriend Jim Carrey, the former of whom thinks it’s just hunky dory (or at least doesn’t appear to be the least bit troubled) that her efforts are contributing to the return of vaccine-preventable infectious diseases because she apparently thinks that’s what it will take to make the pharmaceutical companies change their “shit” product (her words), and the latter of whom spreads conspiracy theories about vaccines and contempt on people suffering from restless leg syndrome. Finally, there’s the grand macher of celebrity woo promotion, Oprah Winfrey, who routinely promotes all manner of medical pseudoscience, be it “bioidentical” hormones, the myth that vaccines cause autism (even hiring Jenny McCarthy to do a blog and develop a talk show for her company Harpo Productions), or other nonsense, such as Christiane Northrup urging Oprah viewers to focus their qi to their vaginas for better sex.
Unfortunately, last week the latest celebrity know-nothing to promote health misinformation released a brand new book and has been all over the airwaves, including The Today Show, Larry King Live, and elsewhere promoting it. Yes, I’m talking about Suzanne Somers, formerly known for her testimonial of having “rejected chemotherapy and tamoxifen” for her breast cancer, as well as her promotion of “bioidentical hormones,” various exercise devices such as the Thighmaster and all manner of supplements. Her book is entitled Knockout: Interviews with Doctors Who Are Curing Cancer–And How to Prevent Getting It in the First Place. It is described on the Random House website thusly:
In Knockout, Suzanne Somers interviews doctors who are successfully using the most innovative cancer treatments–treatments that build up the body rather than tear it down. Somers herself has stared cancer in the face, and a decade later she has conquered her fear and has emerged confident with the path she’s chosen.
Now she shares her personal choices and outlines an array of options from doctors across the country:
EFFECTIVE ALTERNATIVE TREATMENTS
without chemotherapy
without radiation
sometimes, even without surgery
INTEGRATIVE PROTOCOLS
combining standard treatments with therapies that build up the immune system
METHODS FOR MANAGING CANCER
outlining ways to truly live with the diease
Since prevention is the best course, Somers’ experts provide nutrition, lifestyle, and dietary supplementation options to help protect you from getting the disease in the first place. Whichever path you choose, Knockout is a must-have resource to navigate the life-and-death world of cancer and increase your odds of survival. After reading stunning testimonials from inspirational survivors using alternative treatments, you’ll be left with a feeling of empowerment and something every person who is touched by this disease needs…HOPE.
I first found out about Somers’ book about a month and a half ago and was fortunate enough (I think) that one of my readers who had a review copy of the book sent me a chapter list. The reason I wanted a chapter list was because I was really curious just who these doctors were whom Somers had interviewed. In particular, back then I predicted (and hoped) that one of the doctors would be one whom we’ve met before. It was. Can you guess which one? Think about it. What major study did I blog about in the middle of September? What form of cancer quackery has been covered so ably by Kimball Atwood since the very beginning of this blog? No, no, you don’t have to go back to the archives and search. I’ll tell you:
Dr. Nicholas Gonzalez. He’s the second featured doctor who is “curing cancer,” right there in Somers’ book in Chapter 6!
That’s right, one of these doctors who are “curing cancer” is a quack (in my opinion, of course) whose “protocol,” which includes 150 supplement pills a day topped off by a couple of coffee enemas per day, was recently shown to be worse than useless for pancreatic cancer and, indeed, based on a recent study, far worse than conventional treatment.
From my perspective, it was incredibly bad timing and bad luck on Somers’s part to have one of the subjects she lionized in your book to have his protocol shown to be not just worthless, but likely actively harmful, a mere two months before the release of her book. In case there are any journalists who might be interviewing Somers and are interested in more than a puff piece that lets her promote her book, I list all the posts on Science-Based Medicine that have discussed the rank pseudoscience that is the Gonzalez protocol because, as many of you have figured out, I’m never satisfied with a hammer to smack down a form of woo when going nuclear is so much more fun:
“Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part I: Results)
“Gonzalez Regimen” for Cancer of the Pancreas: Even Worse than We Thought (Part II: Loose Ends)
Tom Harkin, NCCAM, health care reform, and a cancer treatment that is worse than useless
Cancer Quackery is Dangerous – The Gonzalez Treatment
The Ethics of “CAM” Trials: Gonzo (Part I)
The Ethics of “CAM” Trials: Gonzo (Part II)
The Ethics of “CAM” Trials: Gonzo (Part III)
The Ethics of “CAM” Trials: Gonzo (Part IV)
The Ethics of “CAM” Trials: Gonzo (Part V)
The Ethics of “CAM” Trials: Gonzo (Part VI)
The “Gonzalez Trial” for Pancreatic Cancer: Outcome Revealed
Sadly, this bad timing appears to have had no effect whatsoever on the publicity blitz of an actress who every day tries to live down to the character she played on Three’s Company back in the 1970s or on the questions asked of her by interviewers. Somers has been all over the media this week, and I’ve seen nary a challenging question stronger than pointing out that some of the doctors featured in Somers’ book have gotten in trouble with their state medical boards, much less a much deserved question about Nicholas Gonzalez. Instead we’ve thus far been treated to cliched, credulous headlines like Suzanne Somers questions chemo in new book, Somers’ New Target: Conventional Cancer Treatment, or Suzanne Somers works to ‘Knockout’ cancer. The article circulating about her book on the AP wire begins:
Less than a year after the former sitcom actress frustrated mainstream doctors (and cheered some fans) by touting bioidentical hormones on “The Oprah Winfrey Show,” she’s back with a new book. This one’s on an even more emotional topic: Cancer treatment. Specifically, she argues against what she sees as the vast and often pointless use of chemotherapy.
Somers, who has rejected chemo herself, seems to relish the fight.
Let’s get one thing straight here. It is most definitely not, as implied by various articles about Somers, in any way amazing that Somers is still alive after having “rejected chemotherapy.” As I explained at the dawn of this blog, Somers had a stage I tumor with a favorable prognosis. If Somers is going to play the gambit of repeating, “I rejected chemotherapy and tamoxifen and I’m still alive” and attributing her survival to the alternative medicine woo she chose instead, perhaps now is the time to go into more detail than I’ve ever gone into before about her case. Well, not quite. I did go into quite a bit of detail in my talk at the Science-Based Medicine Conference at TAM7 in July. After all, I did the research; so I might as well get some more use out of it and spread it beyond the 150 or so people who heard my talk.
Prelude by flashback: Suzanne Somers’ breast cancer
In preparation for my talk at TAM7, I searched for all the information I could find that was publicly available about Suzanne Somers’ diagnosis of breast cancer back in 2000. For your edification, I’ve also uploaded the slides from my presentation relevant to Suzanne Somers’ breast cancer diagnosis as a PDF file. Suffice it to say, there is a great deal of misunderstanding of breast cancer in Somers’ testimonial. In this case, I don’t actually blame Somers all that much for her misunderstanding, because it is a very common misunderstanding that clearly derives from a misunderstanding of the difference between using chemotherapy for primary treatment of cancer versus adjuvant treatment of cancer. In early stage breast cancer, which can be surgically removed for cure, chemotherapy and radiation therapy are in general used as additional therapies that decrease the risk of recurrence of the cancer after surgery. That’s what adjuvant therapy is, extra therapy that improves a patient’s odds of surviving after a primary treatment. In the case of early stage breast cancer, the primary treatment is surgery.
From what I can find from publicly available information on the Internet (I’ve never read one of Suzanne Somers’ books), at age 54 Somers was diagnosed with a breast cancer that was treated by lumpectomy (excision of the “lump” or tumor) and a sentinel lymph node (SLN) biopsy, the latter of which was negative for tumor cells in the SLN, plus radiation therapy. For those not familiar with the SLN procedure, it is a procedure that developed in the 1990s to determine whether a woman’s breast cancer has spread to the axillary lymph nodes (the lymph nodes under the arm) without actually removing all of the axillary lymph nodes. Before the advent of SLN biopsy, the standard of care was to do an axillary dissection (removal of all the lymph nodes under the arm) on the side of the tumor in order to determine if and how many of the lymph nodes are positive for cancer. This is critical information, because the single most powerful prognostic indicator for potentially curable breast cancer (i.e., breast cancer that has not spread beyond the axillary lymph nodes to the rest of the body, such as bone, liver, or lung) is the presence of metastases in the axillary lymph nodes and, if they are present, how many. Unfortunately, as less invasive means of treating breast cancer were developed, such as lumpectomy, the part of the operation that carried the most morbidity was the axillary dissection. Consequently, as science-based physicians are wont to do, during the 1990s surgeons tried to find a way to get the same information (are the lymph nodes positive or negative) with a less morbid procedure and thus reserve axillary dissection only for patients who do have lymph nodes with breast cancer metastases in them.
Thus, the SLN biopsy was developed as a strategy to decrease the possibility of the most feared complication of axillary dissection, lymphedema, and still get the necessary information regarding lymph node positivity or negativity. Basically, an SLN biopsy is preformed by injecting both a radioactive dye and a blue dye (usually Lymphazurin Blue) into the breast. The dyes are then taken up in the lymphatics and head towards the axilla, where they lodge in one or more lymph nodes. This is (these are) the sentinel lymph node(s). The concept behind the procedure is that the sentinel node is the first lymph node a tumor cell that broke off from the tumor and got into the lymphatics will “see” and lodge in. In other words, the dye mimics the pathway that tumor cells take to metastasize to the axillary lymph nodes. If the sentinel node is negative, it’s an accurate indication that the rest of the lymph nodes are negative, and in general no further surgery is needed. Women are identified as node negative without removing all the axillary lymph nodes. Best of all, the risk of lymphedema from the procedure very, very small, far smaller than it is for axillary dissection (removing all the lymph nodes). Since the purpose of axillary dissection was far more diagnostic (to find out if the lymph nodes are contain tumor and, if so, how many), this is a good thing. On the other hand, if the SLN contains tumor, then axillary dissection is needed. In fact, far fewer women now undergo the procedure than in the past, and it is even coming under question whether a woman with a positive SLN truly needs a full axillary dissection.
Why do I mention this? Because I want readers to understand that Somers underwent, as far as I can tell, standard surgery for a favorable, estrogen receptor-positive stage I cancer. She also underwent radiation, although she has stated in the past and now states in Knockout that, if she had it all to do over again, she would not have opted for radiation. Be that as it may, she has been trumpeting proudly for a number of years that she rejected chemotherapy and tamoxifen and has done quite well. This claim, although true, says nothing about whether he decision to eschew those adjuvant therapies was a good one and even less about whether the woo she pursued after that had anything to do with her survival. As I described so long ago, however, surgical excision is curative for most small breast cancers. Radiation therapy reduces the risk of local recurrences (recurrences in the breast), and chemotherapy and antiestrogen therapy (like Tamoxifen) reduce the risk of systemic recurrences (recurrences elsewhere in the body). In other words, chemotherapy and radiation are “icing on the cake” after surgery. Indeed, there is a website known as AdjuvantOnline.com that allows physicians to calculate the estimated risk of recurrence and the estimated benefit of chemotherapy and, if appropriate, antiestrogen therapy. Given when Somers had her cancer diagnosed (2000) and because I know that she had a stage I tumor, i entered data for her assuming a tumor between 1-2 cm in size, mainly because most tumors under 1 cm would not warrant adjuvant chemotherapy. Here is a blowup of the key slide from my talk where I showed the results I got when I entered the known information about Suzanne Somers’ tumor into AdjuvantOnline:
(Click for a larger image.)
As you can see, based on what we know from publicly available sources, Somers had an 88.6% chance of living 10 years without any chemotherapy or Tamoxifen. Chemotherapy provides a survival advantage of 2.5%; tamoxifen, 2.5%; and combination therapy, 4.1%. In other words, eschewing chemotherapy and tamoxifen increased Suzanne Somers’ odds of dying of her cancer within 10 years by around 4%, not a huge number. As I’ve explained before, although the benefit of chemotherapy and tamoxifen for early stage breast cancer is around 30% on a relative basis, but it’s only around 4% or 5% on an absolute basis. You may think that’s not very much, but, I assure you, the vast majority of women are willing to undergo chemotherapy and hormonal therapy for that extra insurance. Indeed, I would point out that surveys I have seen have revealed that a majority of women would still opt for chemotherapy even if it provided only a 1% absolute survival benefit. Moreover, for more advanced tumors, that relative benefit generally stays around 30% or so, meaning that, as the risk of dying from cancer goes up, the absolute benefit of adjuvant chemotherapy goes up as well. Be that as it may, I’ve laid out this information to point out that testimonials like Somers’ are not particularly impressive if you know something about breast cancer. I also mention it to point out that, even though it’s a bad idea for Somers to be pumping herself full of “bioidentical hormones,” the favorable nature of her tumor means that she can get away with it. Even if it increased her risk of recurrence by 10 or 20%, the odds of survival would still be overwhelmingly in her favor, adjuvant chemotherapy and tamoxifen or not, thanks to her friendly neighborhood surgeon. So when you see a passage like this about Somers, remember what I’ve just told you:
Diagnosed with breast cancer a decade ago, she had a lumpectomy and radiation, but declined chemotherapy, as she did more recently when briefly misdiagnosed with pervasive cancer.
As I said before, Somers’ misunderstanding of the role of adjuvant therapy in breast cancer is somewhat understandable. It is a concept that can be difficult to communicate this to patients under the best of circumstances, and the absolute benefit of chemotherapy in treating a stage I ER(+) cancer is relatively small. Moreover, treatment paradigms change with new scientific evidence. Most women these days with a stage I ER(+) tumor would undergo Oncotype DX® testing, and the results of that testing would guide the decision of whether chemotherapy is recommended or not. Oncotype DX did not exist in 2000, and adjuvant chemotherapy was recommended for the vast majority of women with a stage I breast cancer with a tumor greater than 1 cm in diameter.
Somers’ second testimonial, however, is not as forgivable as the first, which is actually only somewhat forgivable, given how aggressively Somers has used her own testimonial to promote “alternative” medical treatments such as mistletoe extract (which may have some anti-tumor activity but the evidence is very weak–more on that perhaps in a future installment). It reveals such a profound ignorance of what she herself is recommending to women for their “health” that, as a breast cancer surgeon dedicated to providing only the best science-based surgical and medical care to my patients, I must call her out for it.
Knockout: Suzanne Somers’ “whole body cancer” scare
I do not yet have my promotional copy of Knockout, although, I’m assured, it’s on the way. I had debated whether to wait until I had read it to write about the book, but then last week I saw this interview with Ann Curry:
Visit msnbc.com for Breaking News, World News, and News about the Economy
It was also pointed out to me that Chapter 1 of Knockout is available online at the Random House website. It’s entitled A Cancer Story–Mine. I read it and was appalled at the degree of misinformation being discussed right there in the very first chapter of the book, so much so that I started to doubt whether it was such a good idea of me to get a copy of the whole book and do a review on it. Still, I’m made of fairly stern stuff, and Somers is out there promoting the hell out of this book; so I feel that it’s my duty to look critically at the story she begins her book with. Suffice it to say, after I read Chapter 1, I was left shaking my head that anyone would listen to Suzanne Somers about cancer or any other health issue, so deep is the ignorance and so strong the distrust of “Western medicine.” Somers starts out her book by describing a cancer scare. Specifically, she describes an incident in which she was brought to the hospital with what sounds like an anaphylactic reaction of some sort and was misdiagnosed with what she calls “full body cancer.”
Before I go on, let me say right here that I do not mean to denigrate or otherwise downplay the seriousness of what happened to Somers, nor do I mean to cast doubt on the veracity of her story. At the very least, Somers appears to believe what she is saying, and it is quite possible that she was misdiagnosed with widespread metastasis from her breast cancer. I also don’t want to under estimate how much it probably scared her. Imagine yourself having survived breast cancer and then, eight years later, being admitted to a hospital for something else and being told that you had widespread metastases. It’s a horrible thing, if it really happened the way Somers said it happened, and it’s the sort of experience that would terrify anyone.
Color me somewhat skeptical, however.
Certain elements of Somers’ story sound a bit fishy. First off, Somers declines to identify the hospital. Right at the outset, I wondered why that is and can guess at a couple of likely reasons. First, perhaps she’s worried about being sued. Of course, if you’re a celebrity and the truth is on your side you probably don’t have much worry about being sued. In such a case, it’s far more likely that the entity suing would get the worst of it, at least as far as negative publicity. More likely, Somers knows that, whatever hospital she had been admitted to and whatever doctors had cared for her, patient confidentiality and HIPAA law prevent the hospital and doctors from discussing her case–or even admitting that Somers was ever a patient. Indeed, neither the hospital nor any of the health care professionals involved with Somers care can discuss her case without her explicit permission. Their hands are completely tied, and Somers can write and say whatever she wants without fear that anyone will contradict her. That’s why it disturbs me that no one who has interviewed Somers yet has asked her a handful of very obvious–and inconvenient–questions based on the anecdote in Chapter 1, namely:
    • At what hospital were you hospitalized and when?
    • Who were your doctors?
    • Will you release some of your medical records and allow your doctors to speak about your hospitalization?
    • If not, why not?
These are questions that need be asked in addition to questions about Somers’ support for Nicholas Gonzalez, whose pancreatic cancer “protocol” was recently shown to be worse than useless, but I have yet to see anyone ask her these questions.
Now, on to Chapter 1:
I wake up. I can’t breathe. I am choking, being strangled to death; it feels like there are two hands around my neck squeezing tighter and tighter. My body is covered head to toe with welts and a horrible rash: the itching and burning is unbearable.
The rash is in my ears, in my nose, in my vagina, on the bottoms of my feet, everywhere — under my arms, my scalp, the back of my neck. Every single inch of my body is covered with welts except my face. I don’t know why. I struggle to the telephone and call one of the doctors I trust. I start to tell him what is happening, and he stops me: “You are in danger. Go to the hospital right now.” I knew it. I could feel that my breath was running out.
Right off the bat, to me Somers’ symptoms sound like an allergic reaction to something or an anaphylactic reaction. It could be something else (more later), but the first thing that comes to mind is an allergic reaction. Indeed, upon hearing this story, I couldn’t help but wonder if one of the many supplements that Somers takes on a routine basis was the cause. Did she start any new supplements recently? Certainly I’d wonder about that. (Again, more on that later; my speculation may well have been correct, just not in the way I thought at first.) Regardless of the initial cause, it certainly sounded as though the E.R. docs at whatever hospital Somers was brought to thought she was having some sort of allergic reaction. Based on that, they treated her appropriately with Benadryl, Albuterol, and steroids. Even someone as medically ignorant as Somers realized the most likely diagnosis:
I say to the doctor, “It seems to me that I’ve either been poisoned or am having some kind of serious allergic reaction to something. I mean, doesn’t that make sense? The rash, the strangling, the asphyxiation. Sounds classic, doesn’t it?”
“We don’t know. A CAT scan will tell us. I really recommend you do this,” the doctor says. “Next time you might not be so lucky — you might not get here in time. You were almost out.”
As I read this part of the story, I was puzzled, and certainly Somers didn’t initially give enough information for me to hazard a particularly educated guess about why her doctor ordered a CT scan. After all, a CT scan is not generally the test of choice for diagnosing the cause of anaphylaxis or respiratory distress, which is what it sure sounds as though Somers was being treated for. On the other hand, maybe doctors saw a mass on chest X-ray (quite likely, as we will soon see). They may also have suspected a pulmonary embolus (PE), for which chest CT has supplanted the older test previously to detect PE, namely the V-Q scan. There may have been other findings on physical examination that suggested that a CT scan might be indicated. (There almost certainly were.) Again, initially, at least, Somers doesn’t give us enough information to judge. She does, however, engage in typical pseudoscientific thinking. While acknowledging that those evil pharmaceuticals had saved her life, still she can’t help but attack them:
I am now dressed in a blue hospital gown, and so far I’ve been reinforced by three rounds of oxygen and albuterol. I’m starting to feel normal again. Drugs have been my lifesaver this time. This is what they are for. Knowing the toxicity of all chemical drugs, I’ve already started thinking about the supplement regime and detox treatments I’ll have when I get out of here, to get all the residue of pharmaceuticals out of me. I’m hopeful this will be the one and only time I have to resort to Western drugs.
Remember, whenever you hear an alt-med maven say “Western medicine” (shades of Bill Maher!), what that alt-med maven is really referring to is science-based medicine. As for supplements, if they have anything in them that does anything physiological, they contain “chemical drugs.” There is no difference between “chemical drugs” found in pharmaceuticals and “chemical drugs” found in supplements, other than that the drugs found in supplements are adulterated with all sorts of stuff. There is no magical difference between the two. They both contain chemicals, and the body responds to chemicals through its biochemistry. Nothing makes supplements magically immune to the laws of physics and chemistry. Moreover, “detox” treatments are completely unnecessary quackery. Somers apparently doesn’t realize it, but her body is more than capable of “detoxing” away those evil “Western” pharmaceuticals through its own amazing abilities. Somers appears to think that “Western” pharmaceuticals somehow leave their taint behind. Maybe she thinks the cells in her body have a “memory” in the same way that homeopaths claim that water has “memory” and that the taint has to be somehow purged, just as a Catholic believes that confession purges sins or certain Muslim sects think that self-flagellation will purge them of their sins. It really is religious thinking more than anything else for Somers to think that she was somehow “contaminated” by “Western” pharmaceuticals and needed to have that “contamination” purged.
But I digress. So what did the CT scan find? This, apparently:
We have very bad news,” he continued. My heart started pounding, like it was jumping out of my chest. “You have a mass in your lung; it looks like the cancer has metastasized to your liver. We don’t know what is wrong with your liver, but it is so enlarged that it is filling your entire abdomen. You have so many tumors in your chest we can’t count them, and they all have masses in them, and you have a blood clot, and you have pneumonia. So we are going to check you into the hospital and start treating the blood clot because that will kill you first.”
We already know that Somers did not, in fact, have cancer. (Otherwise, it would not have been a misdiagnosis.) So what she did have, I’ll get to shortly. In the meantime, let’s take a look at what Somers says about her oncologist:
The oncologist comes into my room. He has the bedside manner of a moose: no compassion, no tenderness, no cautious approach. He sits in the chair with his arms folded defensively.
“You’ve got cancer. I just looked at your CAT scan and it’s everywhere,” he says matter-of-factly.
“Everywhere?” I ask, stunned. “Everywhere?”
“Everywhere,” he states, like he’s telling me he got tickets to the Lakers game. “Your lungs, your liver, tumors around your heart … I’ve never seen so much cancer.”
So the oncologist who saw Somers first was a world-class jerk. It’s quite possible. Not every doctor has a good bedside manner, and some have a horrendous bedside manner. Sadly, some of them are oncologists, even though, if there’s a specialty that really demands a good bedside manner, it’s that of medical oncologist. On the other hand, as physicians we have to remind ourselves all the time that what we think we have said to the patient is not always how the patient has heard it and how we come across to the patient is not always how we have, in fact, come across to the patient. Maybe the oncologist was that uncaring, maybe not. We have no way of knowing because all we have is Suzanne Somers’ report. Maybe it’s also true that the other oncologist who saw her was somewhat less of a jerk but just as quick to jump to a conclusion prematurely:
Then the lung cancer doctor enters the room. Maybe he has better news. But no—he says, “I just looked at your CAT scan, and you have lung cancer that has metastasized.” He is nicer, more thoughtful. “I mean, I’m going to think about this,” he says. “Maybe it’s something else, but this sure doesn’t look good. I’ll be back tomorrow.” Leslie takes out pen and paper and is making notes. She will continue to do this the entire week, writing down everything everyone is saying. Thank God, because when you are stunned and on medication, things get foggy.
Day one is almost over. The most shocking, devastating day of my life, our life! I know the facts: when you have lung cancer and it has metastasized to your liver, heart, abdomen, and all over your body, you have at most two months—maybe only two weeks or less.
As a possible bit of perspective, I’ll point out that not too long ago I had to relearn the lesson of how my perception of what I say to a patient may not always jibe with the patient’s perception of what I said. A while back, I saw a patient with breast cancer in her hospital room, a woman I had operated on the day before. I thought I had calmly laid out the situation, reassured her that her tumor was treatable, and told her that she might not need chemotherapy. About an hour later I got a frantic page from the floor. The patient was in tears, and the family was in an uproar. I don’t know how I had done it, but I had somehow given this patient the impression that her situation was hopeless and that she was going to die. When her family arrived to take her home she was crying. Apparently she had interpreted my telling her that she might not need chemotherapy (mainly because of her age and tumor characteristics) as telling her that it was pointless to treat her more. I relearned a valuable lesson that day, one I (and, I daresay, most doctors, no matter how experienced) need to relearn periodically, namely that patients don’t always interpret what I tell them the way I think they will and that sometimes how I view a conversation with a patient may be very different than how the patient viewed the conversation. Fortunately, I was able to reassure everyone and correct the misconceptions that had been left, but I did not feel too good about my bedside manner that day. In fact, the rest of that day I felt like the most insensitive, idiotic doctor in the world.
Or maybe Suzanne Somers’ oncologist was indeed a flaming jerk. That would be the worst case for “Western medicine” in this story, and it is not nearly as uncommon as I’d like to admit for a physician to have the personality of a paper cup or the bedside manner of bully. Besides, it’s easier to assume that that is how the oncologist in question treated Somers. Even so, in that case, I’d say, “So what?” I’m sorry that Somers’ oncologist treated her badly. There’s no excuse for that. I’d also tell her simply to go and get another oncologist or go back to her regular oncologist, which she ultimately did. One nasty doctor does not invalidate “Western medicine,” nor does the occurrence of a misdiagnosis, even one apparently this spectacular. In any case, it’s quite possible that there was a bit of Somers hearing things one way when her doctors weren’t telling it the way she interpreted them as telling her. The reason I say that is because Somers goes on and on, mainly in interviews but also in the book, about how, over six days, doctors told her she needed chemotherapy. As someone who has dealt with medical oncologists every day for over 10 years, that part of her story just didn’t seem very likely to me. The reason is that, in general, oncologists are very reluctant to administer chemotherapy to a patient in the absence of a definite tissue diagnosis proving that they have cancer, be it metastatic cancer or any cancer.
This would be doubly true in a case like what Somers describes in her book, particularly given that she had one oncologist thinking that she had lung cancer, not a recurrence of her breast cancer. In any case, widespread cancer could be a recurrence of her breast cancer (especially given Somers’ proclivity to pump herself full of “bioidentical hormones” after having been treated for an estrogen receptor-positive cancer), but in a 63-year-old woman, there are lots of other possible malignancies. Chemotherapy would be used for breast cancer might not work very well against, say, colon cancer or ovarian cancer, both of which are other likely possibilities in a woman of Somers’ age. Another reason I seriously question whether doctors were pushing hard for chemotherapy in a mere six days is because, if they truly thought she had such a massively widespread recurrence of her breast cancer, particularly an estrogen receptor-positive breast cancer, all treatment would be palliative. We can’t cure most metastatic solid tumors, and the first rule in treating stage IV disease is usually the classic “First, do no harm.” Thus, oncologists usually tend to do the minimum possible that it takes to relieve symptoms and (hopefully) slow the progression of the tumor. Most likely, if this was indeed metastatic breast cancer, an oncologist would have chosen to treat Somers first with an anti-estrogen drug, probably an aromatase inhibitor (no tamoxifen if she had blood clots causing that much trouble!) and then seen how she did. In the case of a woman who has ER(+) cancer recur as stage IV disease, that is almost always the first option. In such cases, chemotherapy is usually reserved for the case when antiestrogen therapy fails. Indeed, if the cancer was truly as widespread as Somers reports, chemotherapy might not even be used at all if the likelihood of success is tiny; in such cases, hospice would be recommended.
Be that as it may, the very first thing that any competent oncologist would demand before initiating chemotherapy is a tissue diagnosis, either from a needle biopsy or other tissue, to prove that there was cancer and to identify the type of cancer, so that the correct chemotherapy could chosen. Cancer chemotherapy is not like antibiotic therapy. In the case of infectious diseases, it is not uncommon to begin an antibiotic empirically based on the most likely organisms to be causing the infection and then to tailor the therapy to whatever organism(s) can be identified by cultures. Oncologists, on the other hand, are incredibly reluctant to treat metastatic cancer empirically, particularly cancer that appears to have recurred eight years after the original diagnosis of a stage I tumor. Such cancer might very well be a different cancer from a different organ, and the chance of doing harm with chemotherapy for no benefit is too great.
That’s why I thought right away that there’s something very fishy about Somers’ story. It just doesn’t add up very well. What I suspect to have happened is that perhaps the oncologist did have a conversation about a probable need for chemotherapy, and, like my conversation with my postoperative patient, Somers saw the conversation differently from how her doctors did. She probably viewed various “what if” scenarios or “if this is recurrent breast cancer, then you will need this” conversations as “pressuring” her to take chemotherapy. If her oncologist wasn’t particularly warm and fuzzy or patient, she might have been even more likely to interpret his recommendations that way. Or perhaps her oncologists were incompetent enough to pressure her to take chemotherapy without a diagnosis of biopsy-proven cancer. Who knows? Even if the latter is true, it still doesn’t excuse Somers’ horrible ignorance that becomes manifest later in the chapter.
Ultimately, Somers did get a biopsy. She describes it in her interview above, “They cut into my neck and went in and took a piece of my lung, a piece of one of the so-called tumors around my heart turned out it was not cancer at all.”
So what was it?
I’ll admit that my first guess, sarcoidosis, was dead wrong. Given the symptoms of skin lesions, shortness of breath, and, apparently, “tumors around the heart” (which could indicate either pericardial involvement, or, more likely enlargement of the paratracheal nodes), I didn’t think it too unreasonable a first guess. (Besides, in the cases in House, MD, sarcoidosis almost always appears on the differential diagnosis list.) However, never having lived in the southwest, having forgotten my medical school learning about common fungal infections, and being what I self-deprecatingly like to call a dumb surgeon, I didn’t consider what turned out to be the real diagnosis right away, namely valley fever, or, as it’s known by its official name, coccidioidomycosis. Indeed, the description of the most severe disseminated form of coccidioidomycosis matches Somers’ presentation quite well:
The most serious form of the disease, disseminated coccidioidomycosis occurs when the infection spreads (disseminates) beyond the lungs to other parts of the body. Most often these parts include the skin, bones, liver, brain, heart, and the membranes that protect the brain and spinal cord (meninges).
The signs and symptoms of disseminated disease depend on which parts of your body are affected and may include:
Nodules, ulcers and skin lesions that are more serious than the rash that sometimes occurs with other forms of the disease
Painful lesions in the skull, spine or other bones
Painful, swollen joints, especially in the knees or ankles
Meningitis — an infection of the membranes and fluid surrounding the brain and spinal cord and the most deadly complication of valley fever
Now here’s the kicker. Take a look at these two (out of several) risk factors for the most severe form of coccidioidomycosis:
Weakened immune system. Anyone with a weakened immune system is at increased risk of serious complications, including disseminated disease. This includes people living with AIDS or those being treated with steroids, chemotherapy or anti-rejection drugs after transplant surgery. People with cancer and Hodgkin’s disease also have an increased risk.
Age. Older adults are more likely to develop valley fever than younger people are. This may be because their immune systems are less robust or because they have other medical conditions that affect their overall health.
These are risk factors for the serious disseminated coccidioidomycosis. Most people who contract coccidioidomycosis are either asymptomatic or exhibit relatively mild symptoms. Indeed, valley fever often presents as a flu-like illness from which people recover rapidly. Many people, in fact, are unaware that they’ve ever had coccidioidomycosis until there’s either an abnormality on chest X-ray done for another reason or they have a positive skin or blood test. It’s very much like histoplasmosis right here in the Midwest. So why did Somers get such a serious case? It’s a legitimate question, given how she represents her regimen of supplements, bioidentical hormones, and various other woo as a highly effective path to rejuvenation and health that she recommends to her readers. Let’s see. Somers is 63, but apparently in good health. She also takes all sorts of supplements which, or so she claims, “strengthen the immune system.” But her immune system was obviously not strong enough to prevent her from getting disseminated coccidioidomycosis. Why didn’t all those supplements ward off the fungus? For someone who takes handfuls of supplement pills every day and makes millions of dollars selling woo to “boost the immune system,” Somers sure doesn’t appear to have a particularly strong immune system, as it failed miserably to protect her from a severe infection due to an endemic fungus that usually causes only mild disease or any symptoms at all but almost killed her.
Another possibility presents itself. As we know from her previous books and appearances on The Oprah Winfrey Show, Somers takes boatloads of “bioidentical” hormones. She promotes them as a fountain of youth for women. One wonders if any of her various supplements or bioidentical hormones were somehow adulterated with corticosteroids, which suppressed her immune system, one does. Or at least I do.
One need wonder no more. Right there, in Chapter 1 of her book, is a highly plausible, highly likely explanation for why Somers became as ill as she did from coccidioidomycosis:
Day 5. Dr. Oncologist comes into my room. Now, you would think he’d say, “Well, sometimes it’s good to be wrong.” Or “Isn’t it great that you don’t have cancer?” But no. He walks in, doesn’t sit down, just looks at me and says angrily, “Well, you should have told me you were on steroids.”
I am flabbergasted. I don’t know what to say to him; I am so stunned by his lack of compassion that I just stare at him. I am not on steroids. I would never take steroids. But because he is stuck in old thinking and so out of touch with new medicine, he has no clue and doesn’t understand cortisol replacement as part of the menopausal experience.
I don’t know where to begin with him. He’s too arrogant to listen to a “stupid actress,” anyway. So much of his attitude with me has been the unsaid but definite “So you think all your ‘alternatives’ are going to help you now, missy?”
Why steroids would have anything to do with being misdiagnosed with full-body cancer, I can’t guess. But we still don’t know what has gone wrong in my body. We still have to find out what caused me to end up in the ER.
(Emphasis mine.)
It’s incredibly hard at this point not to go even beyond Mark Crislip-grade acid sarcasm at the arrogance of ignorance on display. Here we have a woman who is apparently taking cortisol as part of her “bioidentical hormone” cocktail, and this woman does not know that each and every one of those estrogens she is taking is a steroid hormone. More importantly, Somers apparently does not know that cortisol is a corticosteroid (“cortico,” get it?), the very same kind of steroid that is routinely used by us evil reductionist practitioners of “Western medicine” as an anti-inflammatory and immunsuppressant. When used that way by us evil pharma shills, cortisol is known as hydrocortisone, which is–gasp!–a pharmaceutical concoction! It’s also “bioidentical,” too, proving once more that “bioidentical” does not mean “risk-free.” Indeed, hydrocortisone is often included as one of the drugs in immunusuppressive protocols used to prevent the rejection of organ transplants. Given that Somers has said that she takes enough “bioidentical” estrogens to recreate the hormonal milieu of a woman in her 20s (in other words, far more estrogens than a 63 year old woman would ever have or need), it’s not beyond the pale to wonder whether she similarly takes a significant dose of hydrocortisone (sorry, cortisol) as part of her brew of “bioidenticals,” particularly in light of her having fallen seriously ill due to an organism that usually causes mild disease in immunocompetent hosts. Yes, valley fever can sometimes be a bad disease in immunocompetent hosts, but being immunocompromised for whatever reason is still a significant risk factor for disseminated disease or the reactivation of quiescent disease.
After reading Somers’ story in Chapter 1, I shook my head in disbelief that Random House apparently didn’t have better editors who could have told Somers that she had just written something incredibly contradictory and just plain dumb when she wrote that didn’t take steroids in the context of writing how she castigated her oncologist for “not understanding” the role of cortisol in her menopause treatments. Also, based on Somers’ (or her ghostwriters’) own words in Chapter 1 of her book, I think I have discovered the most likely explanation for Somers’ contracting disseminated coccidioidomycosis. True, it could be that she was just unlucky and getting old, given that age is indeed a risk factor for disseminated disease, but one can’t ignore all the supplements she was taking. One can’t ignore that Somers was apparently taking cortisol as part of the cocktail of “bioidentical hormones” to recapture her youth. It is thus very reasonable to wonder whether the reason that Somers became so ill last year was because she had been chronically dosing herself with cortisol and suppressing her very own immune system. Worse, Somers doesn’t even understand that cortisol is a steroid and an immunosuppressant and therefore can’t accept or admit that this is a possibility. Indeed, that misunderstanding is leading her to view her misdiagnosis as clear evidence supporting her worldview that “Western medicine” is hopelessly flawed, chemotherapy rarely works, and the “alternative” medicine doctors whom she interviews can actually cure cancers that “Western” medicine cannot. Even worse still, Somers is successful enough to be able to parlay her suspicion into a highly lucrative career, and her promotion of dubious, unproven, and even ineffective medical treatments for cancer may well result in cancer patients who might be saved eschewing science-based medicine and endangering their lives. At least, that is what I fear.
A panoply of unproven treatments and what’s to come
As I said before, I plan on looking at Knockout and writing a more formal review once I get my copy to read. That’s why this post is labeled “Part 1.” However, so incensed was I at the rank pseudoscience and dangerous misinformation being promoted relentlessly over the past week by a woman who is apparently utterly ignorant of what a steroid hormone is or that steroids are immunusuppressive that I decided to do this post now, while Somers’ media blitz is still at its height. I concluded that an antidote to Somers’ promotion of nonsense such as the Gonzalez protocol needed to be provided in clear, concrete, unequivocal terms was needed now, that someone needed to express his opinion now that pseudoscience such as the Gonzalez protocol is quackery, particularly given the limp, woo-friendly response of Dr. Otis Brawley, chief medical officer for the American Cancer Society. His article, Somers’ cancer advice is risky, appeared on CNN.com. In it Dr. Brawley practically bent over backwards to be conciliatory, calling Somers a “wonderful actress” (she’s not and never has been), writing that he is “not critical of the concept of alternative and complementary medicine” (I am) and that “open-mindedness to other ideas is how we advance conventional medicine” (apparently his mind is so open that his brains threaten to fall out), even going so far as to invoke the hoary old alt-med examples of aspirin being derived from tree bark or vincristine being derived from a plant as though pharmacognosy were the same thing as herbalism. It’s not. Moreover, I wanted to provide a handy-dandy resource for journalists who may be interviewing Somers or people who may be seeing her at book signings or promotional events, hoping against hope that skeptics will ask her why she doesn’t think a steroid like cortisol wouldn’t predisopose her to disseminated coccidioidomycosis or why she thinks that Dr. Gonzalez is “curing cancer” when a clinical trial was published a mere two months before her book was released that showing clearly that his protocol is worse than useless and that pancreatic cancer patients undergoing conventional therapy live three times longer than those undergoing the Gonzalez protocol.
A guy can hope, can’t he?
In the meantime, here’s a chapter list, which will give you an idea of what you have to look forward to when I get around to reading the book:
The Doctors Who Are Curing Cancer
Chapter 5: Stanislaw Burzynski, M.D.
Chapter 6: Nicholas Gonzalez, M.D.
Chapter 7: Burton Goldberg
Chapter 8: Julie Taguchi, M.D.
Chapter 9: James Forsythe, M.D.
Preventing Cancer Before it Starts
Chapter 10: Russell Blaylock, MD
Chapter 11: Steve Haltiwanger, MD
Chapter 12: David Schmidt
Chapter 13: Jonathan Wright, M.D.
Chapter 14: Steven Sinatra, M.D., F.A.C.C., F.A.C.N.
Chapter 15: Michael Galitzer
Chapter 16: Cristiana Paul, M.S.
Most names I actually don’t know, but some names stand out, such as Dr. Burzynski, whom we haven’t yet discussed much on this blog but should (reviewing this book will give me just that opportunity), and Dr. Blaylock, who is best known for videos like this about H1N1:
I’ll spare you parts 2 and 3 of Dr Blaylock’s video. You get the idea, and if you are masochistic enough top want to view them, you can easily find them on YouTube. Suffice it to say, showing up on Alex Jones’ Prison Planet TV is not exactly a way to burnish one’s scientific credentials. Jones’ websites, Infowars and Prison Planet, are repositories of conspiracy craziness on par with David Icke’s lizard people, including 9/11 Truthers, “New World Order” conspiracy theorists (including, of course, the Illuminati and the Rothschilds), and a heaping helping of anti-vaccine and alt-med conspiracy mongering. In fact, Dr. Blaylock isn’t too far from David Icke’s rant about how the swine flu vaccine is a plot by the Illuminati.
Such are Suzanne Somers’ “doctors who are curing cancer.”
The bottom line is that, whatever her intentions, whether they be to help people or make money or both, Somers is unwittingly promoting dangerous cancer “cures” that are anything but cures. They are treatments that are anything but science-based, as well. Just as Jenny McCarthy, Jim Carrey, and Bill Maher are promoting anti-vaccine pseudoscience to the nation and Oprah Winfrey is providing an unmatchable soapbox for all manner of promoters of woo, Somers is taking advantage of her position to bash conventional medicine and promote non-science-based medicine, most likely raking in the cash hand over fist.
People may well die as a result.

   Bill Maher endorses cancer quackery
David Gorski
Link
Over the last five years or so, I’ve often asked, “Is Bill Maher really that ignorant?” I’ve come to the conclusion that he is, and a couple of weeks ago laid out the evidence why right here on this very blog. (Lately Maher has been issuing Tweets that call people who get flu shots “idiots.”) Indeed, I even included in the post perhaps the most hilariously spot-on riposte to Maher’s crankery. This occurred when Maher proclaimed that he never gets the flu and wouldn’t get the flu on an airplane, which his guest Bob Costas to exclaim in exasperation, “Oh, come on, Superman!”
Bob Costas won my respect that day. My favorite part was when Maher looked at his guests, who were shifting in their seats, all embarrassed and unsure of what to say, and observed, “You all look at me as though I’m crazy.”
Why, yes, Bill, we do. Let’s put it this way. When Age of Autism likes you, you have a serious problem when it comes to being credible about medical science.
In that same post, I complained about Maher’s being awarded the Richard Dawkins Award by the Atheist Alliance International (AAI). I liken giving Bill Maher an award that lists “advocates increased scientific knowledge” anywhere in its criteria, not to mention being named after Richard Dawkins, to giving Jenny McCarthy an award for public health, given that, at least when it comes to medicine, Maher is anti-science to the core. Along the way, I’ve ruffled the feathers of some of both Dawkins’ and Maher’s fans.
I regret nothing.
Not only do I regret nothing, but on September 18, a mere two weeks before the AAI Convention, Maher provided me with more ammunition. In fact, this is probably the most blatant bit of crankery I’ve seen from Maher in a long time. Watch and learn. The “alternative medicine” nuttery begins at around the 0:50 mark:
Laetrile? Really? Laetrile?? How 1970s cancer quackery!
The segment above comes from something called Overtime With Bill Maher. Basically, it’s a segment in which the audience submits questions, a few of which Maher and crew pick to respond to on the web after Real Time with Bill Maher airs. This particular edition aired last Friday, and in it Maher makes several nonsensical and obviously erroneous claims.
It begins with a question from an audience member: “Will the implication of universal health care help or hinder alternative medicine?” You know that’s just like holding a piece of bloody, dripping meat in front of a pit bull that hasn’t eaten in two days, and Bill goes after it just like the pit bull would tear into a piece of meat–and with just as much grace. Well, Bill doesn’t do it immediately. Rather, he does it after his guest, Jeffrey Toobin, paraphrases one of my favorite sayings by pointing out that “medicine is medicine,” continuing, “If it works, it works. If it doesn’t, it doesn’t.”
To which Bill hops in ranting, “That’s not how this country works.”
Don’t we at SBM know it, Bill! Quackademic medicine is infiltrating medical academia at every level. How this country works these days is to accept pseudoscience and quackery as being on par with scientific medicine. How this country works is for woo-friendly legislators like Senator Tom Harkin to force pseudoscience upon the NIH and to try to slip provisions in one of the Senate versions of health care reform legislation declaring “alternative” medicine practitioners to be considered legitimate health care practitioners.
None of this keeps Maher from proclaiming that “alternative medicine often is illegal in this country.” As if that would be such a bad thing. Personally, I’d say right to Maher’s face that it’s a good thing to protect patients from charlatans who claim to be able to cure terminal cancer, like Hulda Clark or Nicholas Gonzalez, every bit as good as Bill thinks it would be to protect the public from large pharmaceutical companies. In fact, I’d tell Maher that, in my not-so-humble opinion, the problem with this country is not that “alternative medicine” often is illegal, but rather that the most egregious examples of quackery are not illegal often enough and that quacks all too frequently quite literally get away with murder.
Maher then goes on to say that you can go to jail for “so much as suggesting any alternative treatment for cancer.” Wrong, wrong, wrong, wrong, Bill. I bet Bill can’t name a single person who has ever been sent to jail for “suggesting any alternative treatment for cancer.” (Not even Kevin Trudeau, although he did go to jail for credit card fraud years before he discovered “alternative medicine.”) But Maher can go on to rant about how Toobin supposedly doesn’t “understand how much the pharmaceutical companies have their tentacles wrapped around the government in this country.”
Toobin then (weakly) challenges Maher by asking, “For selling people Laetrile?”
Maher responds that he “doesn’t know whether Laetrile works,” but that he knows that “the shit we’ve tried for the last 50 years doesn’t. I know they’ve made no progress as far as cancer in this country. So, yes, there are people who actually go out of this country when they get cancer. Some of them come back alive after a death sentence. But in this country you can’t talk about that. I might get arrested right now.”
Wrong, again, Bill. No one’s going to throw you in jail for spouting your ignorant nonsense. I would, however, love to know who these patients are who went out of the country for “alternative” medicine and survived? Coretta Scott King? Farrah Fawcett? Michael Landon? Steve McQueen (who, by the way, used Laetrile, among all sorts of other “alternative” or “unconventional treatments”)? Really, Bill, who are these survivors who were given death sentences and then remarkably cured at foreign clinics? Inquiring minds want to know!
Also, we do know that Laetrile doesn’t work. The studies were done well over 20 years ago and were resoundingly negative. The NCI states that Laetrile doesn’t work against cancer, and patients can suffer complications of cyanide toxicity from it. If you “don’t know” whether laetrile works or not, it’s because you’ve drunk the Kool Aid.
Bill’s other problem is a common one. Like all too many people, he appears to view cancer as one disease. It’s not. In some cancers, we’ve made enormous progress in the last 50 years. For instance, most leukemias and lymphomas were death sentences 50 years ago. Now many of them are highly treatable and even curable. Lest you think that I’m cherry picking the easy, another example is colorectal cancer. For patients with metastatic colorectal cancer, for example, the time of survival and quality of life can both be significantly improved by the new generation of chemotherapeutic, antiangiogenic, and targeted therapies, as The Cheerful Oncologist pointed out two years ago. In fact, I liked The Cheerful Oncologist’s posts so much that I’m going to steal the graph that he stole from this article to drive the point home:
As one can see, the survival for untreated metastatic colorectal cancer (mCRC) is in the range of 4-6 months. Older adjuvant chemotherapy regimens could result in median survivals of approximately 12 months. Over the last decade or so, recently developed chemotherapy regimens have pushed the median survival to nearly two years. In fact, my best friend’s father is evidence of that. He has metastatic colorectal cancer but has been doing well for quite a while now. He even still plays golf regularly. He knows that sooner or later his cancer will claim him, but in the meantime he’s enjoying his life for as long as possible, which is all that any of us can really do. As the authors conclude:
FU has been the cornerstone of treatment for mCRC for over 40 years. In the past few years, the introduction of more effective chemotherapeutic agents and targeted agents with their promising activities and mild toxicity profiles has pushed the overall median survival time from 12 months to 2 years. However, as discussed, there are still many challenges facing oncologists. Research is ongoing to understand these issues, and significant advances are expected through the implementation of well-designed clinical trials and continued preclinical investigation.
Moreover, if you look at the SEER Database, you will see a much different story. For all cancers, five year survival has improved from 50.2% in 1975 to 68.2% in 2001, and 10-year survival has increased from 44.5% in 1975 to 60% in 1996. Moreover, it’s not just quantity of life but quality of life. For instance, thirty or forty years ago, women underwent either radical or modified radical mastectomy for breast cancer. These days, maybe 25% still require mastectomy and virtually none of them require radical mastectomy. (Indeed, I’ve never even seen a radical mastectomy, and I began my surgical residency in the late 1980s.) That’s because surgeons, as part of multidisciplinary teams including medical oncologists and radiation oncologists, figured out that it’s usually not necessary to do a mastectomy to treat breast cancer. The same survival rates can be obtained with less invasive surgery. The same is true in other areas, such as the aforementioned colorectal surgery, where more and more colon operations are being done using minimally invasive methods.
It was science that accomplished this. Not the outrageous quackery that Bill Maher promotes. Science. Bill Maher doesn’t know what he’s talking about. As usual, at least when it comes to medical science. True, we have definitely not made as much progress as we would desire, and there are still a depressing number of cancers for which we still can’t do much, if any better, than a couple of decades ago, but overall there has been slow progress. It remains incredibly hard to have to tell so many cancer patients that we cannot cure them, but that there remain a number of patients with cancer that we can’t cure doesn’t mean we’ve made “no progress.”
That doesn’t stop Maher from parroting the usual alt-med nonsense about “wholistic” medicine as opposed to drugging people with the evil products of the even more evil big pharma, after which he finiishes with his usual rant about Western medicine, in which he claims that the reason “people are so sick” is because “Western medicine…only treats symptoms. That’s how they keep the scam going. If you only treat symptoms, of course people are always going to be sick. Yes, Nasonex will stop you from sniffling. It will shove the mucus right down your throat.”
I wish someone would shove the utter nonsense that Bill Maher spews on such a regular basis back down his throat.
I know some of my readers will think I’m beating a dead horse over this. I also know that I haven’t exactly endeared myself to AAI members by harping on just how idiotic it was to have chosen Maher for any award that has the word “science” anywhere in its criteria, given his support of anti-vaccine views, his apparent sympathy for HIV/AIDS denialism, and now his belief in cancer quackery shown in the video clip above. It wouldn’t have mattered on iota to me if the AAI had chosen to give Maher a “best atheist movie” award or some sort of activism award. But it didn’t. It chose to give Maher and award, one of the criteria of which involves advocating “increased scientific knowledge,” and that irritated me mightily. I even realize that my expressing just how disappointed I was in Richard Dawkins’ nonchalant, “he’s anti-religion; I don’t know about his views on alt-med and really don’t care” reaction to criticism of the selection doesn’t endear me to Dawkins’ fans.
I don’t care. His “shruggie” attitude towards someone who should have been featured in the second part of Dawkin’s documentary, The Enemies of Reason, as one of the quacks he skewered demands his being called out, preferably at the AAI conference, preferably along with Bill Maher.

   Mike Adams on Dr. Mehmet Oz’s colon polyps: “Spontaneous” disease?
David Gorski
Link
Given that it’s a holiday and I debated whether or not I even wanted to post anything today, I think I’ll keep things light and uncharacteristically brief today. After all, not every post can be like last week’s epic on Avastin or the week before’s epic on peer review. That’s a lot of work, and it is a holiday, after all. Besides, sometimes a perverse mood overtakes me, and I feel the need to go slumming.
Bring on Mike Adams.
Mike Adams, as regular readers may know, runs the website NaturalNews.com from deep in the jungles of Ecuador. His website is a one-stop shop, a repository if you will, of virtually every quackery known to humankind, all slathered with a heaping, helping of unrelenting hostility to science-based medicine and science in general. True, Mike Adams is not as big as, say, Joe Mercola, whose website, as far as I can tell, appears to draw more traffic than NaturalNews.com, but what Adams lacks in fame he makes up for in sheer crazy. If you don’t believe me, check out his latest hip-hop video Vaccine Zombie:
Personally, if I had anything to do with the Michael Jackson estate, I’d be suing for copyright infringement. Still, grudgingly, I have to admit that the animation is pretty good, although when Mike Adams raps, “‘Cause livin’ without a brain ain’t half bad,” I don’t think he realizes that he is apparently living proof of that. In fact, so full of crazy is Mike Adams, that there has even been disagreement among SBM bloggers over whether we should lower ourselves to deal with some of his loonier stuff. Guess which side I took?
The reason I argue that, even at the risk of wrestling the proverbial pig in mud, we should not shy away from taking on some of Mike Adams’ lunacy from time to time is because he illustrates certain aspects of the mindset that allows unscientific so-called “alternative” medicine to remain popular. Sometimes, articles on Adams’ website bring up the question of whether Adams really believes the utter nonsense he lays down or whether he is simply a scammer, much like Kevin Trudeau is a scammer, and doesn’t believe a word of it but has such contempt for his followers that he thinks nothing of lying to them to sell them whatever nostrums he’s hawking on his website. You’ll see what I mean in a minute. I hope.
On Friday, Adams decided to attack “America’s doctor” and a promoter of woo whom we have from time to time taken on here at SBM, Dr. Mehmet Oz because, of all things, Dr. Oz apparently underwent colonoscopy and was found to have a precancerous polyp. That this might have happened to him is not at all surprising given that Dr. Oz recently turned 50 and current guidelines recommend commencing screening by colonoscopy at age 50. Indeed, I’m only a couple of years from needing to submit to the same screening myself. In any case, Adams decided to write one of his patented screeds, entitled, Dr. Oz colon polyps raises question of “spontaneous disease” without cause. In it, he inadvertently reveals a lot about alt-med thinking, making it worth a brief discussion.
Adams starts out:
Dr Oz was recently found to have a precancerous colon polyp which was surgically removed. Following this experience, he appears to be surprised and confused about the origin of the condition, and he credits colonoscopy screening with saving his life.
Dr Oz even seems to think he has a perfect health record, saying, “I have done everything right. I don’t have any family history, and yet I’m high risk now.” His personal physician, meanwhile, is implying that even though Dr Oz’s “healthy” diet was perfect, it wasn’t enough to prevent colon polyps, and therefore you might get them too. (And therefore everybody should get screened…)
All of which is more or less correct. Everything in medicine is a matter of balancing risks versus benefits, and it is impossible to lower your risk of a disease as prevalent as colorectal cancer to zero. I don’t care how “correct” your diet is or how “healthy” your lifestyle is. Diet and lifestyle can lower the risk of colorectal cancer, but they can’t eliminate it. In this case, as in many cases (at least where he doesn’t indulge his love of mysticism and pseudoscience such as reiki), Dr. Oz is being quite reasonable. Disease risk falls on a continuum that depends on genetics, environment, diet, and lifestyle. Not to Mike Adams, though. Mike Adams, like so many who promote “alt-med” and non-science-based thinking, cannot deal with ambiguity:
Colon polyps, in other words, appear without any cause! Mainstream medicine, you see, believes in the theory of “spontaneous disease” that “strikes” people at random.
Sort of like disease voodoo.
No matter what you do, they say, you can’t be totally sure that you’re disease free. Therefore, you need all their disease screening protocols, mammograms, and CT scans (which irradiate your body and can actually cause cancer, by the way).
What a bunch of nonsense. As any real scientist knows, everything that happens in our universe has a cause. It’s a cause-effect universe, and unless you’re God or can magically change the laws of the universe, you can’t alter the laws of cause and effect.
Mike Adams is, of course, applying a flame thrower to a straw man of Burning Man proportions. Science-based medicine actually tells us a lot about how polyps form, what genes regulate the process, and how polyps can progress to outright colon cancer. There is the famous Vogelstein sequence of genetic alterations that lead to polyp formation and progression to dysplastic polyps and ultimately colorectal cancer. We know a fair amount about the contribution of genetics and diet. Do we know all the answers? Obviously not, but we do know quite a bit.
What I find most revealing about Adams’ rant is the inability to deal with probability and even the slightest degree of randomness. The idea that there is a stochastic component to disease is completely beyond him. Either that, or he full well understands that there is a random component to many diseases, including cancer, and intentionally creates a straw man that misrepresents the stochastic component of disease to mean that scientists are telling us that disease is completely random. The reason is that there is definitely a strain of magical thinking in alt-med, namely that of complete empowerment. That concept makes itself known in germ theory denialism, as I discussed previously, in which it is believed that, if you just eat the right foods, take the right supplements, and keep yourself “healthy” enough through exercise, infectious disease cannot strike you down.
Similarly, here Adams is peddling the idea that, if you only eat the right diet, you will never, ever develop colon polyps or colon cancer. He drives that point home by castigating Dr. Oz as not being sufficiently pure:
Now, Dr Oz says he eats a “healthy” diet, but he’s from the world of mainstream medicine. Even though Dr Oz has undoubtedly given a lot of really positive dietary advice to a lot of people, and even though his diet is no doubt far healthier than what most people eat, from the point of view of us who focus on superfoods nutrition, Dr. Oz is not really that deep into cutting-edge healthy eating.
He’s not an advocate of raw foods or veganism, for example, and while he smartly teaches people to avoid high-fructose corn syrup and sugar, he’s places very little emphasis on avoiding other harmful ingredients like MSG, aspartame and artificial colors.
He doesn’t strongly advocate organic foods, either, and eating pesticides from conventionally-grown produce is certainly one way to aggravate your colon. Nor does Dr Oz talk much about avoiding genetically modified foods (GMOs), which we now know may actually result in pesticides being manufactured and released directly in your gut. (He did, however, interview Jeffrey Smith on his Oprah radio show, to his credit.)
You see, Dr Oz is only considered really healthy by mainstream people who are ridiculously unhealthy by comparison. Sure, compared to what most people eat — or even what most doctors eat — Dr Oz has a fairly clean diet. But I don’t know anyone in the world of natural health who is really that impressed with Dr Oz’s dietary advice — most of which seems “watered down” to make it more acceptable to a mainstream television audience. People like Dr Mercola no doubt follow far healthier diets than Dr Oz, and raw food gurus like Dr Gabriel Cousens will probably never be diagnosed with colon polyps.
In other words, it’s all about orthodoxy. It’s about faith. It’s not about science; it’s about hewing to a dogma every bit as onerous as fundamentalist religion. In Adams’ world, the reason Dr. Oz developed a premalignant colon polyp is not because he may have a genetic predispostion or because he was simply unlucky. Oh, no. Like a three year old, Adams believes that everything must have a discrete cause. Probabilities and stochastic events are beyond his ken. He simply can’t imagine them because to him it’s not enough to be, as he disparagingly calls it, “mainstream healthy.” Oh, no. You have to go beyond that. You have to be “cutting edge healthy,” and the only way you can achieve “cutting edge healthy” is to start eating a radical raw food diet and taking supplements–supplements that Adams recommends, of course. To Adams’ way of thinking (if you can call it thinking), the reason Dr. Oz developed a premalignant colon polyp is because he was not sufficiently “virtuous” in his diet.
As I said before, according to Mike Adams and his ilk, you must hew to a fundamentalist religious dogma. Do so, he assures you, and you’ll be super-healthy, veritable super men and women immune to the ravages of disease, be it from germs (no vaccines necessary for Superman!), the common chronic and degenerative diseases to which we are all prone as we age (such as hypertension, heart disease, type II diabetes, arthritis), or other common diseases of aging that result in large part from accumulated “damage” to our cells and DNA (i.e., cancer). In other words, you have to listen to him as the prophet of health. Adams promises you perfect health, perfect “wellness,” but there is a price, and that price is to follow slavishly the advice that Mike Adams or other “alt-med” health gurus lay down. Worse, if you are unfortunate enough to become ill, it is because you didn’t follow Adams’ advice, and if you become ill while following Adams’ advice it means you didn’t follow it closely or radically enough. In other words, it’s all about accepting Adams and his fellow woos as your leader Don’t believe me? Adams makes it explicit here:
But don’t confuse Dr Oz with someone who has attained a state of perfect human health. Whatever polyps appear in Dr Oz’s colon are being predominantly caused by Dr Oz’s food choices. That’s because the body of Dr Oz follows the laws of physics, just like yours and mine. There is no law of the universe by which Dr Oz could follow a diet of perfect health and yet somehow a colon polyps would spontaneously appear in his body without cause.
If you believe that, you believe in magic. Or voodoo. Or luck. Heck, if you believe that disease is spontaneous and appears without cause, then you might as well just eat whatever you want and pray to the spontaneous disease gods that they don’t strike you down with some random affliction like diabetes.
Of course, science-based medicine does not deny that lifestyle, diet, and environment have effects on human health. Huge amounts of money and large groups of researchers are devoted to studying these very things, identifying risk factors for diseases, and determining strategies to overcome them using lifestyle and/or pharmacologial interventions. The difference between SBM and Adams, however, is the magical thinking that permeates everything Adams sells. SBM may tell you, for example, that certain diets may decrease your risk of, for instance, heart disease, but accept that it’s all probabilistic and that no diet will decrease your risk to zero, particularly if you are unfortunate enough to have a significant genetic predisposition. In Adams’ world, “the laws of physics” themselves–which Adams wouldn’t recognize or even be able to articulate were Newton himself to rise out of his grave and reconstitute enough of his corpse to bite Adams on his posterior while shouting “F = ma“–tell Adams that it’s easy to avoid these chronic diseases by following his diet, taking his supplements, in general doing whatever he advocates, and, above all, avoiding “chemical” or “conventional” medicine as though it were Satan itself (which, to Adams, it is). Particularly ironic is how in the video above and on his website, Adams represents following his dogma as “thinking for yourself” and “standing up to The Man” (as represented by the “zombie doctors” of the CDC), but in reality all he is doing is substituting himself for the usual set of medical authority figures, and he does not base anything he says on science.
In the end, I still don’t know whether Adams really and truly believes in the nonsense he promotes. I really don’t and still can’t tell. For example, did Adams’ relocate to Ecuador because he really believes in the “natural” lifestyle or did he do it to escape those pesky laws in the U.S. that frown on selling unproven remedies. I do know, however, that Adams appears to have an utter contempt for his own readers, as evidenced by his repeating outrageous straw men such as the claim that SBM says that susceptibility to disease is totally random and that there’s nothing anyone can do about it and bizarre falsehoods like his claim in the Vaccine Zombie video above that vaccines can make your testicles fall off. So, yes, taking on Mike Adams is, in a way, slumming a bit; he provides too easy a target. On the other hand, I look at him in the same way I look at parody. His version of “alt-med” thought is so exaggerated that it makes it easier for me to show you just what is wrong with it. I wouldn’t want to provide my readers with nothing but a steady deconstruction of various Adams bon mots. As amusing as that could be, it would rapidly grow tiresome. On the other hand, it is useful from time to time to take on certain particularly egregious or representative bits of nonsense that Adams lays down.
Which reminds me. None of us has gotten around to this bit of Adams’ misinformation. Maybe next week; that is, unless one of my partners in crime wants to take it on first.

ASCO endorses “integrative oncology” quackery for cancer pain
Last week, the American Society of Clinical Oncology and the Society for Integrative Oncology published guidelines for treating cancer pain. These guidelines endorsed quackery like reflexology and acupuncture. The infiltration of quackademic medicine continues apace in oncology.
David Gorski on November 21, 2022
Link

Before the pandemic, a frequent topic of this blog was the documentation of how rank quackery was being “integrated” into medicine to produce an unholy fusion dubbed “integrative medicine” or “integrative health” by its advocates. Rebranded from its previous name, “complementary and alternative medicine”—with the pithy acronym CAM, which was tossed aside because CAM adherents didn’t want the nostrums that they added to science-based medicine to be described as “alternative”—”integrative medicine” falsely promised patients the “best of both worlds,” the assumption being that there was a “best” of unscientific medicine based largely on religious prescientific understandings of how the body works and what causes disease to “integrate” into science-based medicine. Then the pandemic hit, and blogging about COVID-19 seemed to push nearly every other topic aside (for me, at least). However, just because we haven’t been paying as much attention as we used to do to the infiltration of what we used to like to call quackademic medicine into medical academia and then into community medical centers doesn’t mean that it didn’t continue during the pandemic, and not just in the form of claiming that various forms of alternative medicine could be used to treat or prevent COVID-19.
I was reminded of the continued creep of pseudoscience into medicine during the pandemic last week, which led me to write about a published four year follow-up of a negative study of acupuncture for debilitating joint pain caused by aromatase inhibitors (AIs), a class of drugs frequently used to treat breast cancer, that was spun as positive. Expecting that I’d come back to a COVID-19-related topic this week, I never expected that I’d be reminded yet again of how much quackery is infiltrating oncology and, worse, how much that quackery is being endorsed and promoted by the largest oncology professional society, but I was. That reminder came in the form of a news story from Healio, “Guideline provides recommendations for integrative approaches to manage cancer pain“, and the guidelines that it was referencing recommending some forms of “integrative medicine” to manage cancer pain. The guidelines were a joint project involving the American Society of Clinical Oncology (ASCO) and the Society for Integrative Oncology (SIO). Somehow I missed their original online publication back in September, which is why I’m grateful that the Healio publication popped up in my feed over the weekend.
The spin in the Healio story was clear:
The study — the first meta-analysis to examine natural, nonpharmacologic approaches to treat cancer pain — resulted in development of guidelines published in Journal of Clinical Oncology.
Healio spoke with researcher Jun Mao, MD, chief of the integrative medicine service at Memorial Sloan Kettering Cancer Center, about the importance of the study and the implications of the findings.
Dr. Mao summarizes the key findings of the study thusly:
    • Recommend acupuncture for joint pain due to AI therapy.
    • Recommend acupuncture for general pain management in cancer patients.
    • Recommend massage therapy for palliative care of patients with pain due to advanced cancer. (I’ll note right here that, of the recommendations, this one is the least objectionable because, even if massage is generally a placebo, it is relaxing and feels good, something that I would never object to promoting in patients with advanced cancer.)
There are actually several more recommendations in the guidelines, which is why I find it rather interesting that Dr. Mao chose to focus on these three (two, actually, if you count recommending acupuncture for pain due to cancer or cancer treatment to be one recommendation). In particular, you’d think that he would have been interested in highlighting more plausible “integrative” treatments, such as herbal medicines, which, depending on the specific herbs, might actually contain pharmacologically active components, in particular given that the paper itself states that the panel constructing the guidelines had sought to answer two questions:
     1.  What mind-body therapies are recommended for managing pain experienced by adult and pediatric patients diagnosed with cancer?
     2.  What natural products are recommended for managing pain experienced by adult and pediatric patients diagnosed with cancer?
It interested me how little verbiage was devoted to the second question compared to the first.
Also, there are two things you need to know before I dig in. First, Dr. Mao is a past president of SIO. Second, the Journal of Clinical Oncology (JCO) has been thought to be one of the best oncology journals out there. Certainly, it’s one of the most read and influential, with an impact factor of 50.717, placing it among the top 1% of academic journals. This is an astoundingly high IF for a specialty journal. By comparison, for example, the New England Journal of Medicine, a generalist medical journal, has an IF of 176.079; Nature, 69.504; and Science, 63.714. I do realize the problems with impact factors as measurements of a journal’s reach and influence, but by any standard, JCO is in at least the top 20 journals in the world, and it is widely read by pretty much every oncologist, as well as radiation oncologists and surgical oncologists (like me). So promoting “integrative oncology” in JCO is a big deal, with ASCO clearly putting its considerable weight behind these guidelines. It’s an indication that, depressingly, ASCO has gone all-in with integrative medicine quackery.
“Integrating” magical quackery with medicine
When it comes to “integrative medicine” or “integrative oncology,” framing is everything, as has been discussed more times than I can remember on this very blog. So it’s useful to see how Mao et al. frame the questions to be answered and the existing evidence base that led them to undertake this review. After correctly emphasizing that pain is a common problem in cancer patients and can be due to cancer, cancer treatments (surgery, radiation, and chemotherapy), or a combination of the two, Mao et al write:
As pain in patients and survivors of cancer is complex with different etiologies (eg, tumor burden, treatment-related, and non–cancer-related) and varying presentations (eg, neuropathic and musculoskeletal) and duration (eg, acute and chronic), pain management requires an interdisciplinary approach and should include both pharmacologic and nonpharmacologic treatments, where appropriate.
Of course, no one—and I do mean no one—would disagree with such a general and unobjectionable representation of pain management, even those of us here at SBM, who have long lamented the infiltration of quackery into medicine. The question, of course, is what is defined as “nonpharmacological treatments.” As I’ve discussed many times, evidence-based “nonpharmacological treatments” for pain are not the same thing as CAM or “integrative medicine,” no matter how much advocates try to conflate the two in order to persuade you that their nostrums are science- and evidence-based. Again, this is a common framing by integrative medicine advocates, which leads to the predictable follow-up:
An estimated 40% of patients with cancer use integrative medicine on an annual basis. The key guiding principle of integrative medicine is to use these interventions along with conventional pain management approaches (eg, medications, radiation, injections, and physical therapies) and it is not intended to replace conventional interventions.
Patients often seek integrative medicine because they perceive that conventional medical treatment is not completely meeting their needs, fear side effects from pharmacotherapies, prefer a holistic approach, or because it has been recommended by their family or health care providers. A growing number of well-conducted randomized controlled trials (RCTs) have found that interventions such as acupuncture or massage can alleviate pain in patients and survivors of cancer.
It’s a very common framing by “integrative medicine” advocates: First, present the unmet medical need in an unobjectionable manner that can’t really be argued against very strongly, if at all—in this case, better pain management in cancer patients. Next, frame “integrative medicine” as “nonpharmacological treatment” for that unmet need. Then appeal to the popularity of “integrative medicine”—40% use it!—while citing studies that define it as broadly as possible in order to come up with such large percentages. Finally, hype data that purportedly shows that theatrical placebos like acupuncture “work” in order to justify your study, which you know will be “positive” in at least some way.
So how were these guidelines arrived at? In brief, they were developed using a methodology that is often used to develop expert consensus guidelines, specifically an “Expert Panel was convened to develop clinical practice guideline recommendations on the basis of a systematic review of the health literature,” which was done thusly:
This SR-based guideline product was developed by an international multidisciplinary Expert Panel, which included a patient representative and a health research methodologist (Appendix Table A2, online only). The Expert Panel met via video conferences and corresponded through e-mail. Based upon the consideration of the evidence, the authors were asked to contribute to the development of the guideline, provide critical review, and finalize the guideline recommendations. The guideline recommendations were sent for an open comment period of two weeks allowing the public to review and comment on the recommendations after submitting a confidentiality agreement. These comments were taken into consideration while finalizing the recommendations. Members of the Expert Panel were responsible for reviewing and approving the penultimate version of the guideline, which was then submitted to the Journal of Clinical Oncology (JCO) for editorial review and consideration for publication. All SIO-ASCO guidelines are ultimately reviewed and approved by the Expert Panel, the SIO Clinical Practice Guidelines Committee, and the ASCO Evidence Based Medicine Committee before publication. All funding for the administration of the project was provided by SIO.
Of note, the members of this panel and the authors of these guidelines are all believers. Indeed, a number of names on the author list are familiar. Some are past presidents of SIO, such as Heather Greenlee, who is a—cringe—naturopath and an author on the study of acupuncture for AI-induced joint pain that I discussed. She’s also been associated with a number of efforts by SIO over the years to “integrate” quackery with oncology, in particular the care of breast cancer patients, although she has been instrumental in promoting “integrating” magic into oncology for all cancer patients as well. Claudia Witt also came to mind. She is Director of the Institute for Complementary and Integrative Medicine at the University of Zurich. Worse, she’s a believer in homeopathy, as Mark Crislip noted way back in 2010. Dr. Witt has argued that CAM is cost effective without actually showing that it’s effective and was lead author on a desperate attempt to define just what the heck “integrative oncology” is. Then there’s Ting Bao, immediate past president of SIO and believer in acupuncture.
Personally, whenever I look at guidelines, I like to look at the very strongest recommendation that the guideline panel comes up with, examine the evidence used for it, and then judge whether the recommendation is justified. For this set of guidelines, there’s clearly one recommendation that is first and strongest, that acupuncture should be offered to patients experiencing AI-associated joint pain:
Recommendation 1.1.Acupuncture should be offered to patients experiencing AI-related joint pain in breast cancer (Type: Evidence based, benefits outweigh harms; Evidence quality: Intermediate; Strength of recommendation: Moderate).
Literature review.Four SRs and five RCTs were conducted in the area of acupuncture and AI-related joint and muscle pain.19,27-30,44-47 The most definitive evidence is from a phase III sham-controlled RCT conducted among 226 patients with moderate to severe AI-related joint pain.19 After 6 weeks, true acupuncture reduced pain significantly more than sham acupuncture and standard of care (waitlist control; 2.05, 1.07, and 0.99 points, respectively, on a 0-10 point NRS). After 6 weeks, there were more responders who had a clinically meaningful change in pain (a two-point reduction on a 0-10 scale) 253 in the true acupuncture group compared with the sham and waitlist control groups (58%, 33%, and 31% respectively).
I wrote about the study in reference 19 in 2018, when it was first published. While it did include a waitlist, no intervention (at least initially) control group, which was good, it was not a double-blinded study. Despite the contortions that the authors went through to justify no blinding of the acupuncturists (specifically, the authors claimed that sham needles didn’t work and fooled no one, a claim not supported by other studies that did successfully use sham needles), the results of the study, given the very small effect size reported in the true acupuncture group, were actually most consistent with no clinically significant effect from acupuncture on AI-associated joint pain. Also, as I pointed out, the follow-up study published this month to examine long-term effects and treatment durability was no more positive, given how over time the differences between the true acupuncture and sham acupuncture groups fluctuated from nearly zero to still tiny and between statistically significant and mostly not statistically significant. In this, it was consistent with previous studies of acupuncture use to treat AI-associated arthralgias that we’ve written about going back to at least 2014 in that it was entirely consistent with placebo effects but spun as evidence that acupuncture is very effective against AI-associated joint pain.
I also find it rather interesting that for this, the very strongest recommendation made in this review, the best that even believers could say about the strength of the evidence was that the evidence quality was intermediate and the strength of recommendation was moderate. Let’s just say that it goes downhill rapidly from there. For example, the guidelines recommend yoga for AI-related joint pain, but the recommendation strength is weak, but based on evidence quality characterized as low. Yoga is also recommended for people experiencing pain after treatment for breast or head and neck cancers, again with low quality evidence and a weak recommendation.
In fact, rather than going through each recommendation in turn, I think I’ll just reproduce this chart from the paper, which is rather interesting in and of itself, for reasons that I’ll list after you have a chance to look at the chart without my commentary:

I’ll admit that I stole a bit of the thunder here by mentioning earlier that the very strongest recommendation is “intermediate” strength and the very strongest evidence cited is “moderate,” with the disclaimer that “benefits outweigh harms.” In any event, notice how little green there is (“intermediate quality of evidence, moderate strength of recommendation”) compared to black (“insufficient/inconclusive evidence”) plus blue (“low quality of evidence, moderate strength of recommendation”) plus red (“low quality of evidence, weak strength of recommendation”). Also note the modalities listed after first noting the literature search strategy used to search randomized controlled trials (RCTs), systemic reviews (SRs), and meta-analyses:
The recommendations were developed by using a SR of evidence identified through online searches of PubMed (1990-2021) and Cochrane Library (1990-2021) of RCTs, SRs, and meta-analyses. Articles were selected for inclusion in the SR on the basis of the following criteria:
    • Population: Adults and pediatric patients experiencing pain during any stage of their cancer care trajectory
    • Interventions: Integrative interventions for pain management, including acupuncture, acupressure, mind-body therapies, and natural products (note: see details in the Data Supplement, online only; therapies focused on pain prevention were not included)
    • Comparisons: No intervention, waitlist, usual care (UC) or standard care, guideline-based care, active control, attention control, placebo, or sham interventions
    • Outcomes: Pain intensity, reduction, or change in symptoms reported as the primary outcome in published manuscript
    • Sample size: Minimum total sample size of 20
Articles were excluded from the SR if they were (1) meeting abstracts not subsequently published in peer-reviewed journals; (2) editorials, commentaries, letters, news articles, case reports, and narrative reviews; or (3) published in a non-English language. The guideline recommendations were crafted, in part, using the Guidelines Into Decision Support methodology and the accompanying BRIDGE-Wiz software program.25 In addition, a guideline implementability review was conducted. On the basis of the implementability review, revisions were made to the draft to clarify recommended actions for clinical practice. Ratings for type and strength of the recommendation, and evidence quality are provided with each recommendation. The quality of the evidence for each outcome was assessed using the Cochrane Risk-of-Bias tool26 by the project methodologist in collaboration with the Expert Panel cochairs and reviewed by the full Expert Panel.
All of this is fairly standard in guideline construction. I’ll include the flow chart for the literature search and selection for a reason that you will see in a moment but hope that you’ll be able to glean a bit before I explain:

While it’s not unusual for the winnowing of articles from initial search to articles used in a systemic review or meta-analysis to be severe, given the broad search strategy I was actually rather surprised at how few articles were found initially involving relatively few modalities, which boiled down to acupuncture/acupressure, reflexology, yoga, massage, hypnosis, guided imagery, and music therapy, none of which produced evidence rising above an even generous characterization of intermediate quality or recommendations above moderate strength.
Interestingly (to me, anyway), herbal products were pretty much a bust, which is why none of them made it into even the 13 weak-to-moderate strength recommendations based on low-to-intermediate quality evidence. For natural products, the evidence taken as a whole was either inconclusive, for example:
There is insufficient evidence to recommend for or against the use of Xiao Zheng Zhitong paste, Jinlongshe granule, Shuangbai San paste, or Xiao-Ai-Tong decoction for general cancer pain. Four trials tested the effects of Chinese herbal preparations on treating general cancer pain, including Xiao Zheng Zhitong paste in patients with a range of different cancer types, Jinlongshe granules in patients with gastric cancer, Shuangbai San paste in patients with liver cancer, and Xiao-Ai-Ton decoction with and without morphine in patients with a range of different cancer types. Given that there was only one trial of each treatment intervention, variability in quality of the trials, there are insufficient data to make a clinical recommendation.
Or negative, for example:
Two RCTs tested the effects of glutamine on the incidence and severity of peripheral neuropathy. The first trial was a moderate-size (N = 86) trial comparing oral levo-glutamine compared with no intervention in patients with colorectal cancer receiving oxaliplatin. Patients who received levo-glutamine had lower incidence and severity of peripheral neuropathy symptoms; however, the trial did not control for placebo effects. The second smaller trial (N = 43) compared oral glutamate to placebo in women with ovarian cancer receiving paclitaxel. There were no differences between groups in incidence of peripheral neuropathy; patients who received glutamate reported lower pain severity. No clinical recommendations can be made on the basis of these results because of low study quality and/or small sample size.
If I were going to predict something about this systematic review the guidelines that result from it, I would have predicted that there would be at least one herbal treatment that showed promise, given that herbal treatments always have the possibility of containing one or more pharmacologically active compounds, compared to something like acupuncture, which is nothing more than an elaborate theatrical placebo.
Given how often we’ve discussed the biological implausibility of acupuncture, I’ll discuss reflexology instead. If acupuncture, with its “meridians” and claim that it works by altering the flow of qi (life energy) through those meridians is pure prescientific nonsense, then what can one say about reflexology, which proposes that every one of your organs “maps” to someplace on your feet? Here’s a representative chart that I pulled up just by Googling the term “reflexology”:

The idea behind reflexology is that by applying pressure to these various locations on the foot you can impact the function of the organ to which that location supposedly maps. That’s not how human anatomy works, and attempts to “modernize” reflexology have utterly failed to make it less utterly ridiculous from an anatomical and physiological standpoint. Unfortunately, like the case for acupuncture, its scientific implausibility and lack of evidence haven’t stopped some states from licensing its practitioners.
ASCO embraces nonsense
I’ve written on a number of occasions before how ASCO has increasingly embraced the nonsensical pseudoscience behind quackery like acupuncture, reflexology, and more. I was first gobsmacked by the blatantness of its embrace eight years ago, when I attended an ASCO meeting that featured a major session on “integrative oncology” full of credulous acceptance of alternative medicine modalities. Then, a few years ago, ASCO endorsed guidelines for the use of “integrative therapies” in the treatment of breast cancer patients, thus leading to a post by me explaining just how harmful this embrace of quackery was to cancer patients. I supposed that I shouldn’t have been too surprised, given that in 2010 JCO published a very disappointing editorial about a cancer treatment that was obviously rank quackery.
Unfortunately, ASCO and its journal JCO are not alone, as this sort of “integration” of quackery with medicine is finding its way into many journals, academic medical and cancer centers, and even NCI-designated comprehensive cancer centers. There are even, increasingly, training programs claiming to produce the next generation of “evidence-based” integrative practitioners, despite the inherent contradiction between “evidence based” and “integrative” practice.
It’s hard for me not to see a connection between the infiltration of the Trojan horse that is “integrative medicine” into academic medical centers and the tsunami of COVID-19 misinformation that we’ve been enduring. “Integrative medicine” trains physicians to ignore prior plausibility and embrace treatments that are wildly implausible from a basic biology perspective, and we’ve now seen a disturbingly large minority of doctors do the same thing with respect to COVID-19. You might think I’m overreaching, and it’s possible that I am, but when you embrace unreality in one area of medicine, how do you prevent that unreality from metastasizing to other areas of medicine? We normally expect professional societies like ASCO to be champions of science- and evidence-based medicine. Unfortunately, we are not living in normal times, and haven’t been since before the pandemic. The pandemic just accelerated the embrace of unreality.

Monsanto gets injunction against California’s mandated cancer warning for glyphosate
A federal district court permanently enjoined California from requiring a cancer warning for glyphosate on First Amendment grounds. The battle between the law and science continues.
Jann Bellamy on July 30, 2020
Link

In June, a federal district court ruled that California’s Proposition 65 cancer warning requirement for glyphosate violates the First Amendment rights of Monsanto and other plaintiffs and forbade the state from enforcing the warning mandate via a permanent injunction. (National Ass’n of Wheat Growers et al. v. Becerra [PDF])
The Safe Drinking Water and Toxic Enforcement Act of 1986, popularly known as “Proposition 65” or “Prop 65”, is a California law requiring publication of a list of substances (the “Prop 65 list”) known to the state to cause cancer or to be a reproductive toxicant. A substance’s being listed is determined by the scientific opinion of, among others, the EPA, the FDA, and the International Agency for Research on Cancer (IARC). The law prohibits businesses from knowingly exposing individuals to substances on the list without providing a “clear and reasonable warning”. Glyphosate was added to the Prop 65 list as a chemical known to cause cancer in July, 2017.
Noncompliance with Prop 65 can be expensive, resulting in penalties up to $2,500 per day for each failure to provide an adequate warning. Enforcement actions can be brought by the California Attorney General, as well as other state and local legal officials, like District Attorneys. The law also has what is known as a “bounty hunter” provision, allowing any person (whether they’ve suffered any harm or not) to bring a private enforcement action and recover 25% of the penalty, as well as attorneys’ fees and costs.
Before we return to the case, a brief SBM refresher on glyphosate. Glyphosate is an herbicide widely used to control weeds in various settings and is an active ingredient in Monsanto’s Roundup. In a 2014 SBM post, Steve Novella described glyphosate as “The New Bogeyman“, targeted by anti-GMO activists. As he explained, due to the introduction of Roundup-resistant GMO crops, its use has increased significantly in the last 20 years, hence its identification with GMOs. In this particular post, Dr. Novella deconstructs the claim that glyphosate causes autism and that “Half of All Children Will Be Autistic by 2025”, demonstrating how the “evidence” behind this claim confuses correlation with causation. In a more recent display of bogeyman hunting, anti-vaccine crank Robert F. Kennedy, Jr., claimed that vaccines and glyphosate are behind the current obesity epidemic, a ludicrous assertion David Gorski nicely eviscerated in a post earlier this year.
In 2018 and 2019, Dr. Novella again reviewed the scientific evidence, this time in the context of a lawsuit alleging that an agricultural worker’s lymphoma was caused by exposure to Roundup, resulting in a $289 million judgment against Monsanto, upheld on appeal.
At present from all existing evidence I think the best conclusion is that there may be a small correlation between the highest levels of agricultural exposure of glyphosate and some types of lymphoma, but the existing evidence is not of sufficient quality and consistency for a final determination. It does warrant further study, but also indicates that any potential risk is likely small. In the meantime it certainly makes sense for agricultural workers who deal with pesticides of any type to practice good safety – using protection suits and breathing masks, for example.
In adding glyphosate to the Prop 65 list, California itself did a bit of evidence cherry-picking. In 2015, the IARC classified glyphosate as “probably carcinogenic” to humans based on “sufficient evidence” that it caused cancer in experimental animals and “limited evidence” that it could cause cancer in humans. However, as the court pointed out in its decision, several other organizations, including the EPA, other agencies within the World Health Organization, and government regulators from multiple countries, have concluded that there is insufficient or no evidence that glyphosate causes cancer. The EPA reaffirmed its determination in April, 2019, and again in August 2019, stating that it would not approve herbicide labels with a Prop 65 warning, as such labels would be false and misleading and “misbranded” under the federal herbicide labeling law.
Nevertheless, as a result of the IARC’s classification of glyphosate as probably carcinogenic, it was added to the Prop 65 list, triggering the attendant warning requirement, to take effect in July, 2018.
In November, 2017, Monsanto and several farming associations, including the National Association of Wheat Growers and the National Association of Corn Growers, sued the State of California alleging that the listing of glyphosate under Prop 65 as a carcinogen, and the resulting warning requirements, violated their First Amendment rights by forcing them to make “false, misleading, and highly controversial statements”.
After earlier entering a preliminary injunction precluding California’s enforcement of the warning requirement, the court considered whether a permanent injunction was warranted.
California argued that the suit was not “ripe” for a decision because, due to certain “safe harbor” provisions in the Prop 65 law, enforcement action was unlikely. That argument was rejected by the court based, in part, on the “bounty hunter” feature of the law which, in the words of the California Court of Appeals, made institution of Prop 65 litigation “easy — and almost absurdly easy at the pleading stage and pretrial stages”.
The court then turned to the question of whether requiring Monsanto and the other plaintiffs to warn the public of glyphosate’s presumed carcinogenicity violated their First Amendment rights against “compelled speech”. As explained by one constitutional scholar, the government may no more compel one to speak (in this case, in the form of a public warning) than it can punish one for speaking.
Speech compulsions, the [U.S. Supreme] Court has often held, are as constitutionally suspect as are speech restrictions: “[T]he First Amendment guarantees ‘freedom of speech,’ a term necessarily comprising the decision of both what to say and what not to say.” [Citations omitted.]
However, the Supreme Court has held that the government can require disclosure of “purely factual and uncontroversial information” about commercial goods and services (e.g., requiring sellers to indicate where their products come from; requiring lawyers to disclose information about fees). That caselaw does not apply here, the court decided, in light of the inconsistency between the IRAC’s determination and that of others, such as the EPA, meaning that the Prop 65 warning about glyphosate was neither factual nor uncontroversial.
Thus, the Prop 65 warning would have to withstand a stricter test to pass muster under the First Amendment. As summarized by attorneys writing for the FDA Law Blog, under this standard, California
may restrict commercial speech when the restriction directly advances an important governmental interest and the restriction may not be more extensive than necessary to serve that governmental interest. The Court determined that the Prop 65 warning for glyphosate is misleading because it requires a warning that the chemical is known to the state of California to cause cancer when that statement is not true – only one organization concluded glyphosate was “probably carcinogenic” (IARC), and a multitude of other organizations that reviewed the safety of the product found the opposite. Requiring a misleading statement does not directly advance the interest of the state in informing consumers regarding potential cancer hazards. Thus, the warning could not be justified as a valid restriction on commercial speech and, therefore, is contrary to the First Amendment of the Constitution.
As of this writing, no Notice of Appeal appears on the U.S. District Court for the Eastern District of California’s online docket and the 30-day time for appeal has passed, indicating that California will not appeal the decision.
As the FDA Law Blog points out, the glyphosate decision may affect ongoing litigation involving the Prop 65 warning for acrylamide, “a popular target for bounty hunters”, which is under a similar First Amendment challenge.
Acrylamide is the result of a chemical reaction (known as the Maillard reaction) which takes place in certain types of starchy foods when they are cooked at high temperatures or otherwise processed using heat. The Maillard reaction contributes to taste, aroma and color. It occurs in a multitude of foods such as French fries, breakfast cereals, baked goods and roasted coffee.
The plaintiffs, including the California Chamber of Commerce, claim the Prop 65 warning, based on the IARC and the EPA’s determination of carcinogenicity, requires producers and sellers of foods containing acrylamide to make false, misleading, and controversial statements about their products and to mislead consumers, who will avoid their products based on incorrect information. This is because, they say, the IARC and EPA relied on studies of lab animals fed or injected with virtually pure acrylamide and, in fact, there is no evidence that acrylamide is a human carcinogen. The district court has yet to rule on that claim.
The glyphosate and acrylamide cases are two recent examples of litigation resolving clashes between government-compelled or, in some cases, prohibited speech and science. These cases have dealt with, among other subjects, a Florida ban on physicians discussing gun safety issues with parents, San Francisco’s sugar-sweetened beverage warning law, a prohibition against co-called “sexual orientation conversion therapy”, and physicians’ forced display of ultrasounds and recitation of government-scripted information to patients seeking abortions. No doubt they won’t be the last.

How Google listings are used by alternative cancer clinics to lure in desperate patients
I’ve long been writing about “alternative cancer clinics” (i.e., quack clinics) that sell false hope in the form of very expensive but ineffective treatments to desperate cancer patients. A recent study demonstrates how they use Google to do this.
David Gorski on August 12, 2024
Link

One longstanding topic of this blog (and my not-so-super-secret other blog) has been the discussion and evidence-based discussions of why so-called “alternative cancer cures” are not cancer cures and “alternative cancer clinics” peddle quackery. Of these, the Burzynski Clinic in Houston has featured on this blog a lot since 2011 or so, because discussing the “discovery” of its founder, Polish expat Dr. Stanislaw Burzynski, has provided excellent fodder to discuss why “alternative cancer cure” testimonials are almost never good evidence of efficacy, the manipulation of clinical trials by quacks, and how toothless state medical boards and the FDA have long been to stop these cancer quacks, such that after nearly five decades, Burzynski is still preying on cancer patients selling his antineoplastons and a “make it up as you go along” grab bag of expensive (and legitimate FDA-approved) targeted therapies, sold by a pharmacy in which he had a stake, as well as his “rebranded” orphan drug. Of course, the US is not the only country with these clinics. They can be found in Germany, Mexico, and many other countries as well and have existed for a very long time, with authorities in these countries seemingly unable or unwilling to shut them down.
One common characteristic of quack cancer clinics is that they often combine evidence-based cancer care like chemotherapy and immunotherapy with quackery, using the legitimacy of evidence-based treatments to make the quackery seem evidence-based as well. Sometimes, they also offer experimental therapeutics that have not as yet achieved regulatory approval by the FDA or other bodies in other countries responsible for approving drugs for use outside of the context of a clinical trial, although in some cases the quacks running the clinic set up legitimate-seeming clinical trials to use as an umbrella under which to sell their snake oil. Again, all of this is very expensive, and often patients at these clinics are driven to sell off possessions and utilizing crowdfunding to finance their treatments.
But how do these clinic attract their marks? It’s often word-of-mouth, but these clinics also actively recruit patients online with slick websites and large social media presences, which brings me to the topic of this post, a recent study published in BJC Reports by Marco Zenone et al entitled Alternative cancer clinics’ use of Google listings and reviews to mislead potential patients. This study illuminates how alternative cancer clinics manipulate Google reviews to provide a false sense that their treatments work by cultivating favorable online reviews.
Let’s take a look.
Google and alternative cancer clinics
The study examines on unexplored means by which alternative cancer clinics shape their appeal using Google search results and Google reviews. Basically, what the authors did was a content analysis of the Google listings of 47 alternative cancer cure clinics using Google entries and reviews collected on August 22, 2022. I note that that date was almost two years ago, which makes me wonder what took so long to get this study published. I speculate, based on my experience trying to get manuscripts like this published that they had difficulty and likely submitted to more than one journal after rejections. Basically, journals are leery of publishing studies like this, no matter how well done. In any event, the authors justify their approach after a discussion of the nature of alternative cancer clinics that offer “unproven, disproven, and questionable treatments with worse clinical outcomes than evidence-based cancer services [1, 2]”:
Alternative cancer clinics face several challenges in their attempts to attract potential patients. Regulators at different branches of government have attempted to regulate predatory alternative cancer treatment marketing [11,12,13]. Some such clinics have received negative news coverage that asserts they offer ‘false hope’ and ‘misleading’ treatments to persons in desperate situations [14, 15]. Dedicated blogs by qualified medical professionals warn against their treatments [16, 17]. Increasing research activities and attention to alternative cancer treatment outcomes put the spotlight on the questionable practices of many such clinics [1, 2]. Certain alternative cancer clinics are subject to lawsuits from prior patients [18, 19]. In some cases, the families of persons who tried alternative treatment, and died, warn others of the risks [20]. Conventional cancer information authorities warn against alternative cancer treatment services [10, 21].
Leading to this rationale:
An unexplored means where alternative cancer clinics can shape their brand is their portrayal across web search results. Google listings, which provide a summary of a business, location, or person, also provide descriptive information on the purpose of a business. This information is often the first point of contact by a Google search user Googling the name of a business. For example, if prospective cancer patients search ‘clinic xyz’, they will see a clinic description. Businesses control how they identify themselves and appear to users [24]. For an alternative cancer clinic, whose services are unsupported by authoritative medical bodies, this can lead to opportunities to self-declare as a qualified organization for primary cancer treatment. A prospective patient seeing such information may as a result have a distorted impression of the clinic.
Additionally, search results contain Google reviews, where previous clients of a business can post a 1-to-5-star rating of their services and a text explanation outlining their rating rationale. For alternative cancer clinics, reviews are an important indicator to prospective patients about the quality of services and experiences of former clients.
Noting that the “information environment provided by Google listings and Google reviews may contribute in part to misleading potential cancer patients about alternative cancer clinic qualifications, reputation, and treatment efficacy” and that “results can inform health policy to deter cancer patients from receiving unproven care and support advertising regulators to understand an unrecognized form of unproven medical advertising.” the authors note that they sought to answer the following questions:
     1.  How alternative cancer providers’ expertise and qualifications are portrayed in their Google listings.
     2.  How clinics are rated across their Google reviews.
     3.  For what reasons and outcomes Google reviews are rated positive (score 4 or 5) or negative (score 1 or 2).
     4.  If reviews contain an action statement recommendation to receive treatment from the provider
     5.  Who is making the reviews and in what situations.
     6.  If reviews contain evidence of reputational management.
The authors did not seek to cover all alternative cancer clinics, but rather the most prominent clinics that tried to recruit English-speaking patients, using clinics identified in an earlier study:
We sought to identify clinics which primarily offered as a key service, alternative cancer treatment. We retrieved a list of 47 alternative cancer providers identified in a previous study investigating how alternative cancer clinics market their services across paid Facebook and Instagram advertisements [8]. The study retrieved their list from a patient directory of alternative cancer clinic options (HealNavigator.com) and a study that investigated treatment destinations named where prospective cancer patients fundraised for alternative cancer treatment [3]. Taken together, our alternative cancer clinic identification strategy retrieves clinics actively courting patients online and with a vested interest in positive online portrayals.
So what did the authors find? First, they noted that most of these clinics didn’t declare themselves to be alternative cancer clinics. Indeed, of the 47 clinics, only 6 (12.8%) reported their clinic “alternative,” whereas 39 (83.0%) were labeled a cancer/medical clinic or hospital, while in two (4.3%) cases, clinics were not labeled or had another unrelated label. The clinics were also, by and large, given high ratings, with the average clinic having received 4.42 stars (median, 4.5; highest score, 5; lowest score, 3.2), represented graphically here:
As you can see, there are lots of four- and five-star ratings, not so many one- and two-star ratings.
Here are the most common reasons for positive reviews, most including improvement, the doctors, and the “holistic” nature of the treatments used:
You’ll note that the first example tells us nothing. The patient with stage 4 breast cancer was only six months out from her diagnosis. As I’ve said before, it’s common for patients with stage 4 breast cancer to live 6 months, even a few years. Indeed, whenever I discuss alternative cancer cures for breast cancer, I like to cite a 1962 study of the natural history of untreated breast cancer, which showed that even those with advanced disease occasionally can live more than ten years without treatment. Of the 1,444 Google reviews examined, only of the positive reviews 288 touted improvement in their cancers (e.g., remission) as a reason for the positive review, with some of the claims summarized below:
You’d think that, if (as they claim) these clinics were curing so many advanced stage 4 cancers, most of the reviews would be touting “miracle cures,” but they are not, which suggests to me that these clinics do no actually cure stage 4 disease, leaving most of the rest of the 1,444 positive reviews to focus on other things.
Specifically, reasons for positive reviews not related to improvement in cancer status included:
     1.  The treatment avoided the adverse impacts and limitations of conventional cancer care (for example, the harms of chemotherapy or radiation) (n = 146)
     2.  The treatment approach was holistic, whole-body, and integrative (n = 83)
     3.  The treatment was personalized to the patient (n = 69)
     4.  The treatment used the latest scientific or technological advancements (n = 43)
     5.  The treatment focused on natural approaches to healing vs. pharmaceutical strategies (n = 18)
This is all very well and good, but none of this tells us if the treatments offered by alternative cancer clinics actually work against any cancer, much less advanced cancers that these clinics claim to treat and cure.
What I was interested in, though, were the negative reviews. The positive reviews and alternative cancer cure testimonials are expected. They are part and parcel of clinics like this, whether the testimonials spread via Google reviews, elsewhere online, or word-of-mouth. There were a total of 188 negative reviews, which, interestingly, came from mostly from the families of patients (n = 60), with very few reviews coming from patients themselves (n = 17). One can speculate as to the reason for this, but based on my experience writing about these clinics I can speculate a bit. First, patients can’t provide testimonials in the form of Google reviews if they are dead. Second, I’ve seen how much patients come to believe that their choice of quackery helped them, even when objective evidence is clear that it did no good or even harmed them; likely, few patients are willing to admit publicly that they had made a horrific mistake.
Whatever the reasons, the entries on this table will be familiar to readers of this blog, as these are common features of quack cancer clinics:
Sound familiar?
The surgeon in me winced at the comment about placing ports under less than sanitary conditions. Ports are implantable intravenous devices with a port just under the skin that can be used to administer medications and to draw blood. They need to be placed under operating room-level sterile conditions. Port infections are no joke. There rest of the complaints are pretty typical practices of these clinics, in particular making false claims of efficacy for the treatments offered and, once they have the patient’s money, ghosting them and their families.
It also turns out that these clinics do online reputation management. (Quelle surprise.) The results:
Alternative cancer clinics responded to 35 negative reviews to dispute reviews detailing improper conduct. Clinics often sought to refute that their interventions did not work and that their providers were not qualified (n = 16). In response to patients’ condition worsening or dying, clinics stated that patients die due to aggressive or terminal cancers even when helpful treatment is offered (n = 8). In more aggressive rebuttals, clinics asserted that (1) negative reviews were fraudulent (n = 7); (2) that they do not make promises about treatment efficacy, promises of recovery, and that they only take patients they can help (n = 7); (3) it was the result of patients actions, not their own, that their situation not did not improve (n = 6); and (4) clinics do not lie about improvement or fake testimonials (n = 4). In softer rebuttals, clinics: (1) offered sympathy and prayers (n = 13) or (2) shared their institution’s history (n = 6). Sometimes, clinics apologized and made offers to correct the situation (n = 6). Rebuttals and responses are summarized in Supplemental Information File 3.
Among positive reviews, we found evidence certain Google reviews challenged negative reviews (n = 21). Here, reviews referenced the negative reviews and provided a rebuttal. For example, a review for [anonymized clinic name] hospital states: “I saw a post here talking about people being promised a cure. That is a lie. I have NEVER heard ANY of the doctors promise anybody a cure. That is completely asinine and really ticks me off that someone would lie like that in the comments!” It is not possible to state whether the reviewer had an affiliation with the clinic.
Again, does this sound familiar? In particular, blaming the victim is part and parcel of quacks. Basically, if the snake oil they conned you into purchasing doesn’t work, then it must have been because it was your own fault for not doing what the quack said, for not following the instructions closely enough. (One example in the study: “We know how to save lives of cancer patients, but only if they take our advice. Staff has confirmed several points of dispute between us and the patient.” How awful can these people be?) I also like the part about quacks denying that they made promises about efficacy of their treatments. In a pedantic way, that is usually true, but only because quacks always leave themselves some wiggle room, some plausible deniability regarding their claims of efficacy.
What can be done?
The authors conclude their discussion of their findings with several recommendations. First, they note that they don’t think that Google is intentionally allowing this situation to continue, noting that ” its systems are actively abused with limited, potentially negligent oversight.” Personally, though, I’d say that if Google doesn’t do anything to remedy this situation, it is complicit with the cancer quacks running these alternative cancer clinics. Still, it’s worth looking at the authors’ suggestions:
    • Alternative cancer clinics should not be allowed to label themselves as conventional cancer providers. While I agree with this, I do wonder how Google could manage something like this, given that deciding if a cancer clinic is “alternative” (i.e., quack) or not is a judgment that an algorithm or AI is not likely to be able to make, and we all know how much Google tries to keep human judgment to a minimum because humans are expensive to hire.
    • Warnings should be placed on questionable medical advertisers with linkages to qualified sources of information, such as the American Cancer Society or conventional health provider organizations, such as the American Medical Association. This is a good idea. The American Cancer Society used to keep a listing of unproven methods of cancer treatment that explained why treatments such as, for instance laetrile and antineoplastons, don’t work.
    • Google should not recognize alternative health professions, such as naturopaths or chiropractors, with the same status as conventional health provider groups, such as nurses, physicians, physiotherapists, and occupational therapists, when making content decisions. Yes! Unfortunately, it might be difficult to do this, given how many states now license chiropractors and naturopaths. These pseudomedical professions have been working for decades to appear more legitimate and, unfortunately, have been pretty successful at it.
    • Google should warn people reading medical clinic reviews that reviews are not substitutes for medical advice and that Google cannot confirm the veracity of claims. I would be in favor of this for all medical clinics, legitimate and quack.
    • Google should cease other business activities with alternative cancer clinics’ use of Google products, by, for example, demonetizing their YouTube accounts, prohibiting their use of Google ads, and reducing search result priority. Google has done this in the past with certain websites, such as when they delisted Mike Adams’ website, resulting in plummeting traffic from search and decreasing sales. They did the same thing with Joe Mercola’s website, with similar results.
I’ve long known that alternative cancer clinics are an indictment of our system of regulating medicine, given that they continue to exist and bilk patients despite the ineffectiveness and expense of their treatments. Google acted over the last several years to try to limit the reach of these sites and to keep them from easily monetizing their content as they attracted patients. After that, it seems that it has done little. Google can do better, but I fear that it might choose not to, because it would cost effort and money.

Facebook, Google, and social media vs. medical misinformation: An update
Over the last couple of weeks, there have been two major stories on the efforts of social media companies to combat health misinformation on their platforms. What are they doing, and are they succeeding? Dr. Gorski decided to look into these questions.
David Gorski on July 8, 2019
Link

There’s been a lot in the news lately about how online social media networks facilitate the spread of antivaccine misinformation and what, if anything, can be done about it, even though the last times I wrote about online health misinformation were in March, when I noted that streaming services like Amazon Prime and social media (e.g., YouTube and Facebook) were trying to remove or demonetize antivaccine content and about an attempt by physicians to organize online to defend pro-science advocates targeted by antivaccine swarms. However, a fair amount has occurred in the intervening three months or so, and, in fact, for some reason there have been reporters who have actually interviewed me about this for stories they were working on. The most recent of these was published in the Wall Street Journal right before the 4th of July by Daniela Hernandez and Robert McMillan and entitled “Facebook, YouTube overrun with bogus cancer-treatment claims“. Ironically, I don’t have a subscription to the WSJ but ultimately had someone email me the text. That’s why I’ll be a bit more liberal than usual in quoting the article. The story serves as a good jumping off point to update our readers on what has been going on.
The Wall Street Journal on cancer quackery on social media
In its story, the WSJ starts by noting:
Facebook Inc. and YouTube are being flooded with scientifically dubious and potentially harmful information about alternative cancer treatments, which sometimes gets viewed millions of times, a Wall Street Journal examination found.
Now, the companies say they are taking steps to curb such accounts. Facebook last month changed its News Feed algorithms to reduce promotion of posts promising miracle cures or flogging health services, a move that will reduce the number of times they pop up in user feeds, the company says. Some of the affected posts involve a supplement salesman who promotes baking-soda injections as part of cancer treatment.
“Misleading health content is particularly bad for our community,” Facebook said in a blog post set to publish Tuesday announcing the moves.
I’ll get to Facebook’s announcement, which was published just before the holiday last week, in a moment. First, let’s note in the article what social media companies have done thus far this year:
YouTube, which has guidelines that don’t allow videos that can result in immediate harm, considers medical misinformation especially concerning, a spokesman said. Videos conveying inaccurate medical information are among the 8.3 million videos the company says it has removed during the first three months of this year for violating its policies. The YouTube spokesman said that while the company’s systems aren’t perfect, YouTube’s results for searches for cancer information have improved.
Earlier this year, Facebook said it would crack down on false criticism of vaccines spread by skeptics, an effort that the company has acknowledged has a long way to go. YouTube also changed its algorithms to play down results for antivaccination content. And Pinterest has stopped surfacing vaccination-related search results because most cautioned against vaccines.
I had heard about Pinterest’s action, although I hadn’t known that the problem was so bad that vaccine-related searches turned up way more antivaccine content than science-based content. In any event, as I noted in March, YouTube is indeed a wretched hive of scum and quackery when it comes to health misinformation. Has it gotten any better? At the time Google, which owns YouTube, promised to deprioritize antivaccine and cancer quackery in its search results and to ban people and companies posting such content from monetizing it through its ad-serving system. Indeed, at the time, a number of prominent purveyors of medical misinformation started complaining loud and long about this, which is not surprising given that running YouTube ads on videos hosted on the platform can generate a considerable amount of income when the videos are viewed thousands—or even millions—of times. Add to that how YouTube allows content creators to host there for free on its servers, thus freeing them from the burden of hosting and bandwidth charges (which, if you’re streaming HD video, can become quite expensive rather quickly), and you can see how YouTube made the bar for publishing video online very low and the potential for profit for popular content creators very high. So if YouTube really has done what it said in March that it would do, you can easily see how that would impact the bottom line of those whose business model uses YouTube to promote its wares.
If the WSJ is correct, the results are, at best, mixed:
As of Monday, YouTube videos viewed millions of times were among the postings advocating the use of a cell-killing, or necrotizing, ointment called black salve to treat skin cancer. Use of the ointment can inadvertently burn or kill healthy skin, and doesn’t remove cancerous growths beneath the skin, as is claimed in some videos, said David Gorski, a professor of surgery at Wayne State University School of Medicine in Detroit who edits the blog Science-Based Medicine. The wounds could also lead to infection.
According to Dr. Gorski, misinformation about cancer on the internet is as much of a public-health issue as antivaccine misinformation. “It’s hard to argue which one is the worst,” he said.
It’s hard to get these concepts across when word count is so limited, but basically black salve burns. It’s an escharotic. So, yes, it can at times eliminate skin cancers, but the price is a far less precise extirpation and far more collateral damage to the surrounding tissue than a surgical excision would entail. (I guess ugly, disfiguring burns are better than a surgical scar as long as the burns were “natural”.) Also, claims that black salve can “draw out” cancerous tumors are utter nonsense, without scientific justification.
Just for yucks, I did some searches on YouTube yesterday. The results were not promising when I just searched for “cancer”. The first hit was the pseudoscientific Nutritional Chemotherapy: 4 Ways to Give Cancer a Biological Karate Chop by The People’s Chemist. It’s as pseudoscientific as the title suggests. The next two videos were fairly typical cancer videos, but the fourth video was by naturopath Paul Anderson, Epigenetics, Nutrigenomics & Cancer: MASTERCLASS: Dr. Paul Anderson. I’ve discussed how pseudoscientific this one is before. Basically, Not-a-Doctor Anderson is a “naturopathic oncology” quack. Next up (#5) was a video entitled Murdered for Curing Cancer: The Story of Dr. Max Gerson w/ Dr. Patrick Vickers, and slightly further down, that video in which Chris Wark interviewed Mark Simon about his NORI protocol. I discussed the NORI protocol in May, and let’s just say that it isn’t particularly science-based, claiming that a fruit-based diet can cure cancer. Then there was this video touting a new reality series looking at patients who treated their cancers “naturally” and survived, featuring our favorite cancer quack, Dr. Stanislaw Burzynski, who’s been peddling his unproven cancer “cure” for over 40 years now. I was not impressed.
I realize that Google personalizes its search results based on cookies and your previous searches, but let’s just say that YouTube still has some work to do in this sphere.
So does Facebook, it would appear:
Often the videos and social media postings are connected with online businesses seeking to generate sales of books, supplements and unproven products.
A Facebook page with more than 60,000 likes promotes baking-soda injections and juicing regimens to treat cancer sold by a supplement salesman named Robert O. Young. Mr. Young was convicted in a San Diego County court in 2016 for practicing medicine without a license.
Gina Darvas, the San Diego deputy district attorney who prosecuted him, said that Mr. Young used the internet—in particular YouTube and Facebook—to earn as much as $5 million a year before his conviction.
Mr. Young has multiple Facebook pages currently. He has a personal page and he and his affiliate run others dedicated to selling products and services, internationally and domestically. The pages contain posts with embedded videos and links to YouTube.
So Facebook and YouTube were somehow able to get rid of Mike Adams of Natural News, but still grants Robert O. Young accounts to promote his quacky business, even after he was convicted and had served prison time for practicing medicine without a license and one of his victims secured a $105 million judgment against him? Again, this is not promising.
Not promising at all:
Weeks after getting out of jail in November 2017, Mr. Young was back on Facebook. His main page gets frequent updates with posts selling his discredited cancer and dietary theories, plus services and products. Videos on an account featuring Mr. Young have earned more than 900,000 views, according to an analysis by socialmedia intelligence firm Storyful, which is owned by News Corp., The Wall Street Journal’s parent company.
In some cases, YouTube only demonetized a channel when reporters asked about it, For example, Chris Beat Cancer:
Purveyors of medical misinformation sometimes buy ads to promote their wares. The more popular ones on YouTube can serve ads with their videos and generate income. Ads for well-known brands, including pharmaceutical companies and auto makers, preceded videos for a channel named Chris Beat Cancer before the Journal asked about the channel and YouTube took away the advertising. The channel, which has 125,000 subscribers, plays down the benefits of preventive screenings like mammograms, and promotes non-validated tests, including so-called thermography.
Thermography is, of course, unproven. It’s never been validated as being “better than mammography”, as its sellers claim that it is. Unfortunately, it persists despite attempts by the US and Canada to tamp down on false and exaggerated advertising claims made for it. Unfortunately, the FDA still only reviews thermography claims on a case-by-case basis.
As for Chris of “Chris Beat Cancer” fame, he is a man who around 15 years ago was diagnosed at a very young age with a stage III colon cancer. He underwent appropriate surgery for his cancer. I’ve discussed his case in depth before. Suffice to say, the surgery cured him of his cancer, his attempts to claim that surgery can’t cure stage III colon cancer notwithstanding. Nonetheless, he attributes his survival to the quackery that he pursued after his surgery, rather than to his good fortune of being someone for whom surgery was sufficient to take care of his cancer. Since then, he’s built quite the lucrative “alternative health” online business and has been busily promoting dubious alternative cancer cure testimonials and cancer quackery like the NORI protocol.
In other words, social media companies are trying, but they’re still inadvertently facilitating the promotion of a lot of quackery.
The Washington Post weighs in
Apparently there’s enough interest in this topic that about a week before The Washington Post published a news report by Abby Ohlheiser, “They turn to Facebook and YouTube to find a cure for cancer — and get sucked into a world of bogus medicine“. It begins with an anecdote:
Mari pressed kale leaves through the juicer, preparing the smoothie that she believed had saved her life.
“I’m a cancer-killer, girl,” Mari told her niece, who stood next to her in the kitchen. The pair were filming themselves for a YouTube video.
Mari said she was in remission from a dangerous form of cancer, and the video was meant as a testimony to what she believed was the power of the “lemon ginger blast.” In went some cucumber, some apple, some bok choy, a whole habanero pepper.
While she pressed, she preached.
“I’m telling you, it’s anti-cancer,” Mari said. “It’ll kill your cancer cells.”
The video, first uploaded in 2016, remains on YouTube, but there’s an “important update” attached to the video’s description. It was written by Liz, the niece, a year later.
Mari’s cancer had returned, the note said, and she had died.
I embedded that very video in a post that I did about true believer and scammers in alternative medicine a year and a half ago, and, yes, the video is still there on YouTube. The patient was Mari Lopez, and the woman interviewing her was her niece Liz Johnson. Lopez represented a typical alternative cancer cure testimonial in that she had stage II breast cancer at age 37, underwent conventional surgery and adjuvant treatment. Later, thirteen years after her original treatment, Lopez’s cancer recurred in her lungs and liver and “everywhere”, as she put it in the video. The diet the two were promoting was Robert O. Young’s and treatments from a cancer quack named Alfredo Bowman, who went under the pseudonym Dr. Sebi to promote an intervention that he called Dr. Sebi’s Cell Food.
The reporter’s results a couple of months ago using incognito mode to prevent cookies and previous searches from skewing her results:
As recently as late April, searching “cure for cancer” in YouTube (turning on “incognito mode” so that my prior search history wouldn’t skew the results) surfaced several troubling results: The sixth video, with more than 1.4 million views, claimed that baking soda could cure cancer. The eighth was an interview with self-described cancer expert Leonard Coldwell, in which Coldwell explains that every cancer can be cured in weeks with a special diet that “alkalizes” the body, a claim that has been debunked by scientists. The video has more than 7 million views. (In an emailed statement to The Washington Post, a spokeswoman for Coldwell identifying herself as “Danielle” claimed that Coldwell, who no longer treats patients, had the “Highest Cancer Patient Cure Rate in the world,” and boasted that Coldwell remained popular despite being “the most blocked Cancer Patient Expert in the world.”)
Coldwell is among the quackiest and worst of cancer quacks. He claims that every cancer can be cured in 2-16 weeks, that alkaline is the way to “heal cancer,” and that medical doctors have among the shortest lifespan, all of which are simply not true.
Chris Wark also figured prominently in The Washington Post article, whose response to the observation that he had surgery and that’s what cured his cancer is to change the subject:
“Attempts to discredit me because I had surgery give far too much weight to my personal story, and miss the larger message. . . . People have healed all types and stages of cancer holistically (against the odds),” Wark said in a statement. “As a patient advocate, I am highly critical of the cancer industry and pharmaceutical industry,” he added, before saying that “I do not tell patients not to do the treatment.”
Surgery was the recommended primary treatment for Wark’s cancer, Gorski said. Chemotherapy is a secondary measure, meant to help prevent the cancer from coming back. Wark’s decision to forgo the post-surgery chemo was a risk, but by then the odds were in his favor.
Recall that, previously, his response was that surgery never cures stage III colon cancer. With that argument being untenable, Mr. Wark retreats into making it sound as though he never claimed that his survival was due to his embrace of alternative medicine and invokes the time-dishonored ploy of plausible deniability by cancer quacks: “I never told anyone not to undergo conventional treatment.”
What tech companies are doing: Google
A few weeks ago, I noticed a disturbance in the antivaccine and quack crankosphere. It began with Kelly Brogan, whom you might remember as the “holistic psychiatrist” who spoke at the In Goop Health Summit last year and who is also known for her rabidly antivaccine views and selling of a large variety of quackery. It came in the form of a Facebook post:
Brogan also noted that Joe Mercola was seeing similar results:
Mercola was complaining that search traffic to his website (which had been highly trafficked in 2012) had plummeted 99%:
Google traffic to Mercola.com has plummeted by about 99% over the past few weeks. The reason? Google’s June 2019 broad core update, which took effect June 3,1 removed most Mercola.com pages from its search results. As reported by Telaposts.com:2
“The June 2019 Google Broad Core Algorithm Update impacted the rankings of websites in Google’s Search Engine Results Pages. Several aspects of the algorithm were changed which caused some sites to gain visibility and others to lose visibility.
Generally speaking, sites negatively impacted will see a drop in rankings for many or all of important keywords or key phrases which they used to rank well for … The June 2019 Google Broad Core Algorithm Update impacted sites across the web, however, I am personally seeing the most impact on News and Health sites.”
Continuing his complaint:
Now, any time you enter a health-related search word into Google, such as “heart disease” or “Type 2 diabetes,” you will not find Mercola.com articles in the search results. The only way to locate any of my articles at this point is by searching for “Mercola.com heart disease,” or “Mercola.com Type 2 diabetes.” Even skipping the “.com” will minimize your search results, and oftentimes the only pages you’ll get are blogs, not my full peer-reviewed articles. Negative press by skeptics has also been upgraded, which means if you simply type in my name none of my articles will come but what you will find are a deluge of negative articles voicing critiques against me in your searches. Try entering my name in Yahoo or Bing and you will see completely different results.
So what had happened? I did a bit of digging at the time, not willing to trust Mercola’s biased presentation of information. Before I do, I note that one of the biggest problems with Google’s algorithm is that popular ≠ high quality. Having a lot of incoming links from popular sites (even reputable sites) is not necessarily an indication of high quality. That’s why now Google hires quality raters to evaluate the quality of websites. In May Google issued an update to its quality rating guidelines.
To understand search engine results, first, you need to know that Google uses two acronyms to describe what it’s looking for in terms of quality webpages: measurements, E-A-T and YMYL. E-A-T means “Expertise, Authoritativeness, Trustworthiness.” High-quality pages have a high level of E-A-T while low-quality pages don’t. Of course, how does Google measure E-A-T? There are a number of metrics, but one metric is important:
In order to be deemed high-quality, Google states that “websites need enough expertise to be authoritative and trustworthy on their topic.” It’s worth keeping in mind, however, that what comprises “Expert” content can vary depending upon a page’s type and purpose. For example, while high-level medical advice needs to be written by an accredited doctor in order to be considered “Expert” content, general information supplied on medical support forums can be considered “Expert” even if it’s been written by a layperson. Some topics inherently require less formal levels of expertise and, for these pages, Google is predominantly looking at how helpful, detailed, and useful the information provided is.
Of course, Mercola is a DO; so as a doctor he was considered an expert on medical topics by Google. The second aspect of Google rankings is known as YMYL, which stands for “Your Money or Your Life.” Basically, YMYL is a quality rating for websites that ask for your money or your life; i.e., usually financial transactions or medical advice:
YMYL stands for “Your Money or Your Life” pages and are comprised of pages that are important enough that, were they low-quality, they could have a potential negative impact on a person’s life, income, or happiness. As a general rule, the pages that Google requires to be written by experts are known as YMYL pages. Google thinks of the following categories as examples of YMYL pages:
Shopping or financial transaction pages
Pages that offer financial information, for example, investment or tax information
Pages that offer medical information about specific diseases or conditions or mental health
Pages that offer legal information about topics like child support, divorce, creating a will, becoming a citizen, etc.
Any page that has the potential to be dangerous or detrimental if it possessed low levels of E-A-T (car repair and maintenance, for example)
When it comes to these pages, Google has incredibly high page quality rating standards. This is Google’s effort to protect Google users from low-quality complex content that doesn’t possess the needed levels of E-A-T.
Basically, for pages that aren’t YMYL, Google doesn’t consider expertise as critical as it does for pages that are YMYL. Google’s own guidelines take this into account, although I truly cringed when I saw this section in the Google FAQ cited by Jennifer Slegg in an article on the May update regarding its page quality rating FAQs. You’ll see why in a minute. But first, I note that Mercola quotes this rather deceptively, mixing up commentary by Jennifer Slegg on TheSEMPost with actual excerpts from the Google FAQs. Here’s how Mercola does it:
There has been a lot of talk about author expertise when it comes to the quality rater guidelines … This section has been changed substantially … [I]f the purpose of the page is harmful, then expertise doesn’t matter. It should be rated Lowest!”
And here’s how it actually read, first the part by Jennifer Slegg:
There has been a lot of talk about author expertise when it comes to the quality rater guidelines, particularly with how site owners and authors can showcase their expertise. This section has been changed substantially to address this a bit more from Google’s perspective. Previously, it was implied that all content creators should have expertise. But they have lessened this slightly, for topics that don’t fall into YMYL pages.
And here’s the section from Google’s FAQ:
Pretty much any topic has some form of expert, but E­A­T is especially important for YMYL pages. For most page purposes and topics, you can find experts even when the field itself is niche or non­-mainstream. For example, there are expert alternative medicine websites with leading practitioners of acupuncture, herbal therapies, etc. There are also pages about alternative medicine written by people with no expertise or experience. E­A­T should distinguish between these two scenarios. One final note: if the purpose of the page is harmful, then expertise doesn’t matter. It should be rated Lowest!
Notice how Mercola used ellipses to stitch together Slegg’s commentary with the last sentence of the above answer to a question on Google’s FAQ. Of course, the example that Google uses in its FAQ is indeed cringeworthy, because experts in alternative medicine are quacks, and allowing quackery to rank on YMYL sites goes against Google’s own policy because by definition quackery has low E-A-T and is by definition harmful. Of course, what probably torpedoed Mercola’s and Brogan’s sites according to Google is that last section about how harmful content should always be ranked lowest. As Slegg notes, that part was not text that had been added or changed in the May update, but Mercola deceptively stitched together bits of text to make it seem as though it was part of that update. What might be different is that Google is now actually enforcing that guideline for antivaccine content, likely goaded by the light the current measles outbreak is shining on social media and search engines.
Joe Mercola, of course, views this as a huge conspiracy on Google’s part. He spends a fair amount of verbiage bragging about how his content used to show up near the top of Google search results, his expertise as a physician, how he even created a peer review panel of medical and scientific experts that review, edit and approve most of his articles before they’re published, and how his articles are “fully referenced, most containing dozens of references to studies published in the peer-reviewed scientific literature.” He then laments that “none of this now matters, as the very fact that the information I present typically contradicts industry propaganda places me in the lowest possible rating category.” No, Dr. Mercola, your information glorifies quackery, such as the time when you promoted cancer quack Tullio Simoncini, who thinks that all cancer is a fungus and that baking soda is the cure. I kid you not. Mercola’s been promoting quackery for 22 years now. His content has always been low quality, quackery disguised as real medical advice.
There’s also another reason why Mercola.com results were deprioritized. Here it is from Google itself:
This site diversity change means that you usually won't see more than two listings from the same site in our top results. However, we may still show more than two in cases where our systems determine it’s especially relevant to do so for a particular search….
— Google SearchLiaison (@searchliaison) June 6, 2019
Finally, the site diversity launch is separate from the June 2019 Core Update that began this week. These are two different, unconnected releases.
— Google SearchLiaison (@searchliaison) June 6, 2019
Basically, as is explained on Search Engine Roundtable, Google is also instituting a change that will restrict search results to only two listings from the same domain for most searches. The intent behind the change is to show more diverse results from different domain names and that Google will generally treat sub-domains as part of the main domain. This change, too, could easily have affected various quack websites. Indeed, Telapost listed Mercola.com as one of the biggest losers after the early June algorithm update, along with DrAxe.com, which no longer ranks highly for searches for “keto diet”. (Interestingly, the Daily Mail was also a big loser.)
Another thing that irritates Mercola is that Google now instructs its quality reviewers to use Wikipedia to evaluate the expertise and trustworthiness of its sources. Of course, I’ve had issues with Wikipedia, but Mercola’s anti-Wikipedia rant is just beyond the pale. I’ve also had my issues with Google, but in this case I’m glad Google is finally trying to deprioritize antivaccine and quack information.
Predictably, Mike Adams wasn’t pleased at this news (it hurt his website traffic too), and spun this as—you guessed it—a conspiracy theory, predicting that Google will block access to “natural health sites” at the browser level in Chrome in 2020. Of course, although Chrome is popular, there are a lot of other browsers; so I’m not sure to what end Google would do that. Be that as it may, Google still has a long way to go in cleaning up its act with respect to facilitating the spread of dangerous medical misinformation
What tech companies are doing: Facebook
In June, all purpose health scammer and conspiracy theory creator Mike Adams was banned from Facebook, with a predictably histrionic reaction on his part to the interruption of his grift due to social media blacklisting. Then, last week I was made aware of this press release from Facebook:
In our ongoing efforts to improve the quality of information in News Feed, we consider ranking changes based on how they affect people, publishers and our community as a whole. We know that people don’t like posts that are sensational or spammy, and misleading health content is particularly bad for our community. So, last month we made two ranking updates to reduce (1) posts with exaggerated or sensational health claims and (2) posts attempting to sell products or services based on health-related claims.
For the first update, we consider if a post about health exaggerates or misleads — for example, making a sensational claim about a miracle cure.
For the second update, we consider if a post promotes a product or service based on a health-related claim — for example, promoting a medication or pill claiming to help you lose weight.
We handled this in a similar way to how we’ve previously reduced low-quality content like clickbait: by identifying phrases that were commonly used in these posts to predict which posts might include sensational health claims or promotion of products with health-related claims, and then showing these lower in News Feed.
And:
Posts with sensational health claims or solicitation using health-related claims will have reduced distribution. Pages should avoid posts about health that exaggerate or mislead people and posts that try to sell products using health-related claims. If a Page stops posting this content, their posts will no longer be affected by this change.
One of the greatest changes in the online experience that I’ve experienced in my nearly 30 years online has been the rise of social media platforms. When I first started online, it was basically BBS, email, and Usenet. Later, by the mid-1990s there were websites (most of which had no commenting sections), and I didn’t get into blogs until the early 2000s. These days, various messaging apps and platforms appear to be supplanting email, and the vast majority of people too young to have been online 15 years or more ago have no clue what Usenet was. (Does anyone even still use it?) Basically, you can think of Usenet as Reddit-like social media before there was social media. It was (is) a massive worldwide mass of discussion forums. What was very different from what we have now is that Usenet was decentralized, without a dedicated central server and administrator, and pretty much uncontrolled by anyone, other than Internet service providers, who decided which subset of the 100,000+ newsgroups they’d allow their users to access and how much storage space they would devote to each newsgroup. Oh, sure, people could set up moderated newsgroups for whom members had to be approved, but most of Usenet was the Wild West. In contrast, today, social media is centralized and controlled by a few companies: Facebook, Twitter, Google (which owns YouTube and, of course, controls the vast majority of the search engine business all of us depend on to find information online), and a handful of other, lesser players plus the comment sections of various websites and blogs (which, increasingly, are being run by software from Facebook or other players like Disqus and whose main sites tend to be run by WordPress or a couple of other companies) and some specialized web-based discussion forums.
There have been several consequences of this centralization of social media. One consequence is that it’s become much easier for people to post content that can rack up thousands (or millions) of views. With Facebook and YouTube, for instance, you can post video, image, or sound files for free and don’t have to worry about hosting your own site or paying for your own bandwidth. Apple and other services let you post audio files for podcasts for free. Even better, YouTube and Facebook provide ways for you to monetize your content by running ads, with the company getting its cut of course. Another consequence is that clicks mean everything, because monetization depends on getting people to read, listen to, or watch your online content. In addition, because these platforms make it far easier to share media than ever before, it’s very easy for information (and misinformation) to “go viral” and spread exponentially, as more and more people share and reshare it. Old-timers might remember how complicated it was to share binary files to Usenet. (Anyone remember uuencode?) The binary file had to be encoded into ASCII, and then you had to have a program to decode the ASCII back to binary to retrieve the file. (Most of these files were pictures or sound files; video formats were not well standardized yet, and video files were just too massive.) It was worse than that, though. Because of character limits, the ASCII-encoded binary file often had to be split into many Usenet posts and then reassembled. Fun times, indeed.
Of course, the huge problem that’s arisen is that the ease with which media, be it written, images, sound, or video, can be shared and monetized has been a boon for quacks and antivaxers, who routinely use Facebook, Twitter, YouTube, and other social media to spread their health misinformation and hawk their quackery, while monetizing their content—not to mention to harass their opponents as well. (It’s not just health misinformation, as the rise of Alex Jones and his ilk demonstrated.) Add to that the way Google has worked is to rank websites by the number and reputation of incoming links. It was basically popularity and usefulness contest, with the most popular content that is useful according to the metrics that Google uses to determine usefulness showing up on the first page. As a result, a whole lot of quack and antivaccine websites showed up way too high on Google search results for a whole lot of health topics, including vaccines; that is, at least until Google tweaked its algorithm and started enforcing the quality guidelines that it had for its human reviewers a month ago.
Which brings me back to the Facebook announcement. All I could think about was: How is Facebook going to implement this? Its announcement says that its method will identify phrases that are commonly used in posts promoting health misinformation to predict which posts might include sensational health claims or promotion of products with health-related claims and use them to rank these stories lower in the newsfeed. It all sounds good, but how? For a system like this to work, you either have to know these phrases already, in which case I’d wonder who is telling Facebook engineers and coders what these phrases are, or you have to have a collection of quack and antivax websites that Facebook engineers can analyze to identify common phrases that are much more common in such websites. Either way, Facebook needs people to do this, and these people need to be experts in what is and isn’t reliable health information. Does it have these people? If so, who are they?
The thing is, the number of health care professionals who are experts in identifying dubious health claims is a pretty small percentage of the total population of health care professionals. The percentage of physicians, for instance, who are skeptics and able to identify quack websites is fairly low. Of course, it’s likely that Facebook is only going after the most egregious examples, the sort of content that pretty much any physician or nurse should be able to identify, which is helpful, but would still leave a lot of less obvious health misinformation on its platform. Maybe that’s enough. Maybe it’s the best that can be done.
Of course, being as algorithm-obsessed as it is, it wouldn’t surprise me if Facebook is trying to do this alone with AI and without much in the way of input from knowledgeable medical professionals. It could just be relying on users to flag pages, links, and websites, which would be unlikely to work very well, particularly given that there is no way that I’ve seen to flag a page or post for promoting dangerous medical misinformation. Facebook should really add that.
Predictably, another cancer quack, Ty Bollinger, was none too happy with The Washington Post article and what tech companies are doing, referring to it as the “War on Truth“:
The truth of the matter is that “Big Pharma” is behind the push to scrub the internet of all content that threatens their huge profits or reveals the very real risks of using their vaccines, drugs, and chemotherapy agents. And now, we have Facebook, Pinterest, Google, YouTube, and Twitter going “all-in” with the pharmaceutical giants and agreeing to become the “gatekeepers” and engage in coordinated censorship of natural health information.
Or maybe they’re just trying not to let their platforms be used to spread misinformation.
A major problem left unaddressed
Unfortunately, all the tweaks that Google, Facebook, and the other tech and social media companies are making to their algorithms ignore one huge problem, although this problem, is unique to Facebook. Ohlheiser nailed it in her Washington Post article:
On Facebook, I easily found groups devoted to sharing “natural” cures for cancer, where people who have cancer diagnoses, or care for someone who does, asked other group members for ideas for how to cure it. “Cancer Cures & Natural Healing Research Group” has just under 100,000 members. I joined the closed group in February, identifying myself as a Washington Post journalist to the administrators.
The administrator was willing to private message, but then blocked Ohlheiser and her access to the group. Then:
Facebook’s algorithms then began suggesting other groups I might like to join: “Alternative Cancer Treatments” (7,000 members), “Colloidal Silver Success Stories” (9,000 members) and “Natural healing + foods” (more than 100,000 members). I requested access to some of those groups, too, and several admitted me. People in the groups would ask one another for cancer-fighting advice. Some would be told to use baking soda or frankincense.
Rather than remove the groups, Facebook’s strategy to limit health misinformation centers on making it harder to join them unknowingly. Facebook said in an emailed statement that it “will alert group members by showing Related Articles” for any post already deemed false by Facebook’s third-party fact-checkers, for instance.
This is where Facebook falls short—and massively so. One of the most powerful ways that Facebook promotes the spread of medical misinformation is by giving quacks and activists the ability to create groups where like-minded individuals form a natural constituency (and great marks) for cancer quacks and antivaccine grifters. Even leaving aside the selling of products, they form self-reinforcing echo chambers and online spaces to encourage parents not to vaccinate and cancer patients to abandon conventional therapy. Parents who have concerns about vaccines find antivaccine groups, join them, and become vaccine-averse or even outright antivaccine. Cancer patients scared of chemotherapy find alternative cancer therapy groups, join them, and end up deciding that they will be able to cure their cancer naturally and learn to launch crowdfunding campaigns to pay for it. The same happens for many other forms of medical misinformation. In addition, these groups form excellent platforms to organize attacks on those trying to combat medical misinformation. Physicians are swarmed on Facebook and Twitter; their ratings are flooded with false negative reviews on various physician rating cites; their Facebook pages are swarmed. It’s a problem that those pushing back against misinformation have only recently begun to try to address.
As far as getting rid of these groups, critics will argue, going back to the example of BBS, Usenet, and web-based discussion groups, that such groups have always existed, and that’s true, but they’ve never existed in a centralized location on a platform that makes them so easy to join with a search engine that entices people by suggesting many similar groups once you join one. As long as these groups are available on Facebook, all the tweaks Google, YouTube, Facebook, and other social media platforms are making to their search algorithms and all their attempts to demonetize quack content are likely to be far less effective than they could be.
[Note: I will be speaking at NECSS next weekend, with a talk on Friday and panels over the weekend. As a result, I do not know whether I will have time to produce a post for next Monday or not. If I don’t, I’ll make sure there’s a guest post. If you’re attending NECSS, feel free to come up and say hi.]

Bad Documentary Review: Cancer Can Be Killed
Cancer Can Be Killed is a conspiracy thriller masquerading as a documentary. Don’t watch it.
Braden MacBeth on August 31, 2018
Link

[Editor’s note: This Friday we have a guest blog from Braden MacBeth. Welcome Braden!]
I found myself in the weird part of Amazon a few months ago. As it turns out Amazon is a big fan of sketchy health documentaries. You can view dozens of documentaries free of charge with Amazon Prime that support anti-vaccine views, peddle unproven cancer therapies, and all other sorts of nonsense. Which brings me to a documentary called Cancer Can Be Killed. Cancer Can Be Killed was produced by Jeff Witzeman and released in the summer of 2017. Witzeman claims that his wife’s bladder cancer was cured using these all-natural treatments provided by a clinic in Germany. In its opening scene Witzeman tries to pull the audience in with:
What if I told you that cancer can be killed naturally with no chemo, no radiation and no radical surgery in the form of organ removal? You’d probably say, yeah, that’s not real. So, I guess I’m gonna have to prove it you.
There’s no need for hypotheticals Mr. Witzeman, that’s not real. The “evidence” presented by Witzeman is always in the form of testimonials, testimonials make up at least 1/3rd of the film and are not a substitute for scientific evidence. The film goes exactly how you would expect; there is a laundry list of common alternative cancer treatment scams presented directly at the start. After presenting what in his mind is evidence, he then argues that the only reason the treatments presented aren’t standard is because the “medical system” prevents it somehow. Witzeman concludes the film by asking viewers to sign a petition to pass legislation that would force insurance companies to pay for these “natural” treatments.
The first thing you should know about the film is that none of the “treatments” showcased are new, and none of them have been proven effective. Many of the treatments showcased as effective not only have been proven be ineffective, they can be hazardous to your health. There are three “doctors” presented in the film, two of whom are not actually doctors, and all of whom have a history of slimy business practices, and their reasons for providing these alternative treatments are far from altruistic. But I guess I’ll have to prove it to you.
Bad science, bad treatments
Hyperthermia
There are a number of “treatments” on display in Cancer Can Be Killed with varying degrees of illegitimacy. The film tries to start out strong with a treatment that is used by real doctors, hyperthermia, but Witzeman’s doctors just choose to use it in a manner that the evidence suggests is ineffective. Hyperthermia is heating parts of the body to a high temperature, usually near the site of a tumor, which makes the tumor more susceptible to radiation and chemotherapy. However, Phillip Battiade (more on him later) states “to be honest it’s very rare on of my patients does chemotherapy or radiation, we seem to be able to manage things without that”. But there is no evidence to support the stand-alone use of regional or whole-body hyperthermia for the treatment of cancer, and we’ll learn later you shouldn’t trust a word Phillip Battiade says.
One of the main premises of Witzeman’s arguments in the film is that the “medical system” prevents all of these miracle cures for cancer. At the end of the film Witzeman asks the audience to sign a petition to propose legislation that would legalize standalone hyperthermia treatment. Witzeman states that Battiade “can’t do the “magic” that he does here in the States because “the FDA prevents it”. I am unable to find any legislation or binding recommendation by the FDA banning or limiting the use of hyperthermia. The device featured in the film, the Celsius TCS, is not FDA approved, however there are other hyperthermia devices that are approved such as the BSD-2000.
All-natural ineffective IV treatments
Witzeman tells us that “German Cancer Treatment” is focused heat (hyperthermia), ozone therapy, and IV vitamins, minerals, and amino acids. Which is total nonsense, science-based German cancer treatment is the same as what is the US, the laws of the universe do not change based on geography (of course, not all German cancer clinics use, or even include, science-based treatments). Let’s start with ozone therapy. The FDA states that “Ozone is a toxic gas with no known medical use in specific, adjunctive, or preventative therapy.” There is no evidence that ozone therapy is an effective treatment for any disease or disorder. But that won’t stop quacks from peddling ozone therapy for every disease in existence. Ozone therapy can be very dangerous, because apparently ozone is a toxic gas, and it can kill you like it killed Leslie Bramston.
There are a number of “all-natural” IV treatments showcased in the film such as vitamin-C, Myers cocktail, Laetrile, and chelation. Vitamin C has been studied quite extensively as a potential cancer treatment, but it’s been found to do nothing for cancer. Three randomized studies by the Mayo Clinic involving 367 patients found that high doses of vitamin C did not enhance survivability. High doses of vitamin C can also cause kidney failure in certain patients.
Myer’s cocktail is simply a mixture of various vitamins and electrolytes. Myer’s cocktail has not been proven to treat any disease or disorder. One placebo-controlled study looked at Myer’s cocktail as a treatment for fibromyalgia and it didn’t outperform placebo. But for some reason if you google “Myer’s cocktail” and the name of a health condition, you will find a naturopath trying to sell Myer’s cocktail as a treatment for that condition. It’s almost as if they don’t care if their treatments are effective or not.
Laetrile has also been studied as a potential cancer treatment and found to do nothing for cancer. In the phase two study conducted by the NIH in 1982, of the 175 patients treated with Laetrile only one met the criteria for a response with Laetrile and 45% of patients had measurable disease progression. Laetrile is also banned in the US because as it turns out, it’s quite dangerous. The side effects of Laetrile mirror the symptoms of cyanide poisoning because Laetrile breaks down in the presence of certain enzymes into glucose, benzaldehyde, and hydrogen cyanide. The NIH states that the symptoms of Laetrile and cyanide poisoning include nausea, vomiting, headache, liver damage, hypotension, ataxic neuropathies, fever, mental confusion, coma, and death. While the NIH states that these side effects are more severe in the oral form than injected Laetrile, they also state that the side effects can be amplified by raw almonds, beta-glucoside containing fruits and vegetables, or by taking high doses of vitamin C orally. Mixing IV vitamin C and Laetrile doesn’t sound like the greatest of ideas.
Chelation therapy is another nonsense treatment presented in the film that “helps that body detox”. Chelation therapy is used to treat heavy metal toxicity. Chelating agents bind to heavy metals in the blood and are then processed through the kidneys and removed from the body in the urine. There is no evidence, nor reason to believe, that chelation therapy treats any type of cancer. However chelating agents can cause kidney damage, liver damage, brain damage, and death.
The Suhk-Les theory of physiology and sugar feeds cancer nonsense
The ‘Suhk-Les’ theory of physiology is very popular in the alternative medicine sphere. Suhk-Les physiology suggests that by eating foods that create an alkaline soot when burnt, the pH of your blood will be made alkaline, and allegedly no disease can survive in an alkaline environment. None of this is true of course. The food you eat has no effect of the pH of your blood, as your body is equipped with an extensive buffering system to ensure your blood stays at the physiological pH of 7.4. Even small deviations of about .05 pH can cause life-threatening health problems. While it is technically true that no disease can live in an alkaline environment, the same is true for all other organisms if the pH is high enough. How biology premed students survive with higher blood pH levels while still falling ill is a mystery that requires further research.
The other prominent myth peddled in Cancer Can Be Killed is the idea that sugar feeds cancer. While cancer technically feeds on sugar (glucose), so do all of the other cells in your body. There’s no evidence that a diet with reasonable amounts of sugar causes or hastens the growth of cancer cells. However, consuming excessive amounts of sugar can cause obesity and diabetes, both of which are associated with an increased risk for certain cancers. Knowing simple biology makes a later portion of the documentary incredibly funny; there’s this segment in the middle part of the documentary with a real oncologist. Despite the selective editing, he comes across very well. They take a picture of the candy bowl in his waiting room like a he’s dentist giving out full size candy bars on Halloween, as if it’s some sort of conspiracy.The only problem I have with his candy bowl is that those appear to be peppermints, which are objectively the most disgusting kind of candy. Come on my dude, you run a civilized, sanitary establishment; nobody wants to be reminded of Pizza Hut. You can do better.
Dubious docs
Phillip Battiade and Infusio
Phillip Battiade is introduced as “a doctor in Beverly Hills”, however his title when he appears onscreen reads “HP”. Battiade is a ‘Heilpraktiker’ which is a licensed alternative health profession in Germany. You don’t need any formal education to get a heilpraktiker license, you only need to take a certification exam. However, Witzeman refers to him as “a doctor”, and one of the patients in the testimonials refers to him as “Dr. Phil”. It seems that Witzeman or Battiade himself is misrepresenting his credentials.
Phillip Battiade owns a business called Infusio or “Global Health Organization GmbH” which has clinics located in California and Germany. Battiade claims to be a “respected Medical Practitioner (Heilpraktiker) of alternative medicine in Germany, with over 20 years of medical experience, specializing in rehabilitative medicine, biological cancer therapies, and the treatment of chronic syndromes such as Lyme disease, Chronic Fatigue, and Fibromyalgia“. He is a respected medical practitioner who has trouble treating Lyme disease apparently. In his YouTube video The Message Every Lyme Disease Patient Needs to Hear he says Lyme disease is “an untreatable monster” and for which we need to take a new treatment approach by “changing the cellular terrain”. He gives this “cellular terrain” spiel in Cancer Can Be Killed, because that is how he “treats” every disease in existence.
It is a matter of no interest to Phillip Battiade if the diseases he treats are real, let alone if the treatments his patients pay for actually work. It doesn’t matter to him that doxycycline treats Lyme disease quite effectively, and you can pick it up at Rite Aid for twenty bucks after you get a prescription from a REAL doctor. There are two things that Phillip Battiade loves in this world, this first is himself, and the second is getting people to buy into his “5 Steps to Health”.
Phillip Battiade really loves himself; he quotes himself on a significant portion of the pages on Infusio’s website. He claims to have spent 15 years working as a medical consultant and practitioner on a non-profit basis developing a network of some of the world’s top physicians. I don’t know who any of these “top physicians” are, but anyone who graduated from a legitimate medical school is a top physician compared to him. The only published research I can find is in the African Journal of Neurological Sciences. Mr. Battiade publishes in only the most high-impact of journals. He also claims to be fluent in eight languages. He’s shameless, he exaggerates his own achievements, and pretends to be more important than he actually is.
The one thing Battiade loves possibly more than himself is his “5 Steps to Health”, or as I like to call them the “5 Steps to Wealth”. Here’s how it works. You have an illness, and according to Phillip Battiade, it’s because your body is out of balance. To figure out what the imbalance comes from we’re going to need to run some expensive tests after consulting with the “health expert”. He will then devise a treatment plan that he thinks you’ll pay for. This generally involves the same treatments as everyone else, but he calls what he’s doing “disease specific treatment” anyways. The film gives us visual evidence of this, in the form of an invoice from Infusio to Jeff Witzeman’s wife. In total they spent $30,000 on Infusio’s treatments, some of which include things like Dioxychlor. Dioxychlor is marketed as “a natural antibiotic that kills bacteria”. What are the ingredients in Dioxychlor? Each drop contains “25,000 ppm NaCl with Combined Oxygen.” Anyone that sells this to cancer patients and claims it is a “natural antimicrobial, which supplies oxygen to the cancer cells” and “in an infusion it may help eliminate toxins, parasites, viruses and yeast” is unethical and you should not take medical advice from them.
Colleen Huber
Colleen Huber has been the subject of articles from many skeptic sites, particularly from part-time biology PhD student and full-time legend, Britt Marie Hermes. Huber is now suing Hermes in Germany for defamation because Hermes accurately described her actions in a manner that she did not like and could not control. Huber is introduced in the middle of Cancer Can Be Killed, where Witzeman parrots her claim that her clinic has a “90%” success rate. If you’ve read Hermes’ article on Huber’s research, or even read the research yourself, you know that it’s total nonsense. Witzeman refers to Huber as doctor, however she just wasn’t smart enough for medical school and left the Arizona College of Osteopathic Medicine sometime around 2001. She did successfully graduated from the Southwest College of Naturopathic Medicine though, with an NMD degree. Witzeman claims that Huber published her research showing that her clinic had a “90%” cancer cure rate for all cancers, but the traditional medical community just wasn’t paying any attention. It is of course published in a predatory, open-access journal where anyone can publish anything for the low price of a thousand dollars or so.
One of Huber’s close friends, Hazel Chandler, appears in the film to praise natural cancer treatments. She’s presented as just another satisfied customer despite the fact that she is the executive director of the Naturopathic Cancer Society, of which Colleen Huber is the president. The Naturopathic Cancer Society is a non-profit that gives money to people who want to receive alternative cancer treatments but can’t afford them. It’s a society run by Huber to pay for treatments that pretty much only she offers. Why wasn’t Hazel Chandler’s affiliation with Huber or the Naturopathic Cancer Society noted in the film? I have no idea if this was intentionally excluded by Witzeman or if he legitimately didn’t know.
Carlos Garcia
Carlos Garcia and his clinic Utopia Wellness are introduced last in the film as a clinic that Witzeman “knows is so good, it was raided by the FBI”. Garcia is the only real doctor on the quack-side in this film, and he’s an anesthesiologist in addition to being a complete nutter.
You’re probably wondering about this ‘raided by the FBI’ thing. I’m unable to find any direct information about the investigation into Garcia even after hours of searching. However, I was able to find an appeal by Wilson Ellis in the case US vs. Wilson Ellis that mentions it. Wilson was indicted on one count of health care fraud and nine counts of false statements relating to health care matters, for intentionally using inappropriate billing codes to seek payment for chelation services provided at his clinic. Garcia was going assist Ellis by testifying as an expert witness, as a doctor who provided and successfully billed Medicaid for chelation therapy at his clinic in Florida. Around December 7th 2005, Garcia’s clinic was subjected to a search warrant as part of an open investigation by the OIG-HHS in Florida for his alleged “active and fraudulent billing of Medicaid in the State of Florida for chelation therapy”. Ellis tried to use this to dismiss the indictment under the 5th and 6th Amendments arguing that the OIG investigated Garcia the day after he was listed as a witness for the defense, in order to intimidate him. However, the court records show that he was already the subject of the open criminal investigation before he was ever listed as a witness in the case, and Ellis’s motion was denied.
Chelation is a term that keeps coming up, as it turns out Garcia is a proud member of the American College for Advancement in Medicine. It’s a very nice sounding organization, however ACAM pretty much exists to promote chelation therapy. ACAM and similar organizations work tirelessly trying to push legislation that will legally protect and promote their flavor of snake oil. It’s really no surprise Dr. Garcia is proud member of ACAM considering how many of its members have gotten in trouble for fraudulently billing Medicaid for chelation therapy.
Now I mentioned that Garcia is crazy, allow me to elaborate just how Coo-Coo-For-Cocoa-Puffs this guy really is. In his opinion the most common causes of cancer “are dental toxins in the form of root canals or teeth that have become cavitated or abscessed, or emotional issues”. There is no link between root canals and cancer despite woo-peddlers on the internet claiming that 97% of terminal cancer patients previously had a root canal procedure. There’s no evidence to support such an extreme claim. If you thought the dental issues thing was crazy, you know nothing Jon Snow.
Carlos Garcia also states that he thinks emotional issues are a major cause of cancer and these emotional issues are very non-specific. Here are the emotional issues he believes correlate with certain cancers as shown in the film:
Head, Neck and Lung Cancers	Opinion challenged, ignored or not accepted as fact.
Breast, Ovarian, Uterine, Cervical, Vaginal, Testicular, Penile, Some Prostate Cancers	Feel they have been betrayed by a loved one.
Reproductive Organ Cancers	The feeling that had the patient been able to do more, the loved one would not have had the negative outcome. A sort of self-imposed punishment.
Esophageal, Gastric, Colon, Intestinal, Kidney, Bladder, Prostate Cancers	Feel stuck in a situation where options are few. Feel helpless to change the outcome of what’s going on.
Musculoskeletal Cancers	Feel as though they have the weight of the world on their shoulders.
Liver Cancer	Patients are very angry and re-live angry episodes. //gg no re
Pancreatic Cancers	People who have been publicly humiliated. //We can be chemo buddies if you want.
Right Side Body Cancers	Correspond to issues with men
Left Side Body Cancers	Correspond to issues with women
What can I even say to this? This is impressively bad. It’s a collection of non-specific symptoms and doesn’t qualify as a scientific hypothesis because it’s not testable. But that hasn’t stopped Garcia from publishing an entire book about his insane cancer theories.
Conclusion: Sadly it’s not parody
If doctors were to make a parody documentary about the things alternative-medicine peddlers believe, Cancer Can Be Killed is the film that they would make. Jeff Witzeman even shows signs of self-awareness when he asks so many times “Is this too good to be true?” Witzeman concludes the film by proposing legislation to “legalize stand-alone hyperthermia” and “demand insurance pays for natural treatments”. As previously discussed, there is no legal limitation on the use of hyperthermia treatments that I can find. Requiring insurance companies to pay for these “natural” treatments, invalidates the key premise of Witzeman’s argument. Insurance companies’ financial interests are competing with the financial interests of hospitals and pharmaceutical companies. They want to pay for the least expensive treatment that is the most effective. Why would they participate in some grand conspiracy? The simple answer is that none of these treatments work, and no sane insurance company is going to pay for them.
Witzeman claims that he “followed the money” and that “cancer care in this country is $150 billion a year industry”. I too followed the money, but let’s evaluate why we spend so much money on cancer care not just in this country, but the entire world. As it turns out there are many different types of cancer with radically different pathologies that require radically different treatments. Many of these treatments require millions if not billions of dollars to develop and are only effective against types of cancer that only a few people have. This can make some treatments astronomically expensive. Treating cancer can involve a lot of inpatient care, and sadly a lot of end-of-life care – both of which involve tons of around the clock staff that need to eat too. Spending $150 billion as a whole is pretty easy when you combine all of these factors. Now while that might sound really sad, that’s real, that’s the best cancer care you can get. There’s no miracle cure in some cancer clinic in Germany that requires $30,000 up-front. All of the people that work in the real cancer care industry are motivated to give you the best evidence-based care possible. They’re using science to figure out the best care options, not making up reasons to give a vitamin IV.
Now let’s talk about a real conspiracy. Cancer is a very complicated illness even researchers and doctors don’t fully understand, and there’s a ton of misinformation online. Given that any type of cancer is a life-threatening illness, it creates the three feelings in patients that quacks love most: fear, uncertainty, and doubt. It’s easy for quacks to make up an explanation of what causes cancer, how to treat it, and put those feelings to rest. It’s easy for them to make patients feel safe so they’ll pay for whatever is being peddled. Let’s not pretend that the providers showcased in this video don’t have a financial motive to get patients to go with their cancer “treatments”. It’s already been proven that their “treatments” don’t work, whether the quacks know that or not doesn’t really matter. They have a lot of reasons to prey on desperate and sick people with fake cancer treatments; Phillip Battiade in particular has at least 1.4 million of them. Huber runs her own charity to pay for treatments that pretty much only she or her friends offer. Garcia has been investigated for fraudulently billing Medicare for chelation therapy. Let’s not pretend that these people have noble intentions, they don’t.
Cancer Can Be Killed peddles dangerous health advice from unethical and unqualified alternative medicine business entities. The treatments and theories showcased in the film aren’t new, and none of them have any evidence to support their efficacy. Witzeman accuses medical professionals of either being mindless drones that only do what they’re taught in medical school or actively working to suppress treatments that would save people’s lives, which is every bit wrong as it is insulting. Cancer Can Be Killed is an absolute dumpster fire, a Wal-Mart parking lot of films. If you’re going to watch Cancer Can Be Killed, not that I would recommend it, take the claims made in the film with a big grain of salt and an even bigger bottle of Smirnoff.

Crowdfunding: The fuel for cancer quackery
Ever since I first started taking notice about cancer quacks like Stanislaw Burzynski, I noticed how crowdfunding using social media and sites like GoFundMe appear to be an integral part of the business model of quack clinics. Thanks to an investigation by The Good Thinking Society published in BMJ last week, I now have a feel for the scope of the problem. The question, though, is: What can be done to turn off this lucrative revenue stream for quack clinics?
David Gorski on September 17, 2018
Link

Back in 2009, I discovered cancer quack Stanislaw Burzynski. I didn’t pay a lot of attention to him, however, until three years later, when he was attracting patients from the UK and all over the developed world, thanks to medical propaganda film disguised (poorly) as a documentary, Burzynski The Movie: Cancer Is Serious Business. After that, I started looking into his treatment, substances that he had discovered in the 1970s and dubbed “antineoplastons,” in great detail and determined that there was no evidence that they have significant anticancer activity. It’s not my intent to rehash my many, many discussions of Stanislaw Burzynski’s antineoplastons, how many times he’s slithered away from justice, and how he’s still taking advantage of the families of desperate cancer patients.
One thing that struck me right from the beginning is how much Burzynski’s treatments ended up costing patients and families hundreds of thousands of dollars; indeed, the mean seemed to be around a quarter of a million or so in the cases I examined. How did the families raise this much money? Besides selling possessions, the most common way that much money was raised was through crowdfunding, using Facebook and sites like JustGiving, GoFundMe, and YouCaring, the last of which has recently been acquired by GoFundMe. Parents of children with cancer or adults with cancer and/or their families would set up Facebook and GoFundMe pages, and, because of the generosity of strangers, were often able to raise tens, even hundreds of thousands, of dollars in a manner of weeks. As I became more interested in cancer quackery, I saw the same story repeat itself for other quack clinics, such as Hallwang Clinic and other German quack cancer clinics, quack stem cell clinics, and, most recently, Clínica 0-19 in Monterrey, Mexico, which treats children with diffuse intrinsic pontine glioma (DIPG) with an unproven (and secret) combination of chemotherapy agents administered every few weeks intra-arterially to the tumor plus a secret form of “immunotherapy,” leading parents from as far away as Australia to rack up hundreds of thousands of dollars in medical expenses.
For all of these cases and clinics, the story follows what to me is now an all-too-familiar trajectory. A patient is diagnosed with a deadly cancer, often (but not always) brain cancer. A grim prognosis is given by conventional oncologists. Understandably, the patient (or, in the case where the patient is a child, the family) searches for alternatives online. Because there are so many quacks online, they inevitably find one or more quack clinics. They contact the clinic and either get a phone consultation or travel to the clinic, where they are told that the quack can provide something better, that might even be able to save the patient’s life. The patient and/or family decide to go for it, but learn that it costs tens of thousands of dollars per treatment, plus travel and lodging expenses, and that insurance or, in the case of the UK or other countries with universal health insurance, the government won’t pay. So they drain their savings, often sell their house and/or car, and eventually run out of money, leaving crowdfunding as the only option to continue treatment. Given how many people I’ve chronicled doing this, I’ve often wondered how much is raised in aggregate, given that crowdfunding seems to be baked into the business models of these clinics.
Last week, BMJ published an investigation that starts to answer that question. The title of the article by Melanie Newman is apt, “Is cancer fundraising fuelling quackery?” Full disclosure: I was interviewed for the article.
Is cancer fundraising fuelling quackery? The answer is yes.
The investigation published in BMJ is an excellent example of skeptical activism doing some real good, as it’s the result of work by The Good Thinking Society, a UK charity founded by Simon Singh and for which Michael Marshall (whom I got to meet at NECSS in July and at QEDCon last October) serves as Project Director. Basically, The Good Thinking Society perused the UK GoFundMe and JustGiving sites in order to find cases of medical fundraising for alternative treatments and then estimated how much money had been raised.
Newman reports the results of their work:
Doctors face difficult conversations with patients with metastatic cancer for whom NHS treatment has failed. A growing problem is how to advise patients who opt to pursue expensive, experimental treatments in the private sector, including orthodox therapies given in unproved combinations and doses but also alternative therapies with no evidence behind their use. The BMJ today publishes figures that show how crowdfunding for alternative cancer therapies has soared in recent years (tables 1 and 2). The figures, collected by the Good Thinking Society, a charity that promotes scientific thinking, show that since 2012 appeals on UK crowdfunding sites for cancer treatment with an alternative health element have raised £8m (€9m; $10m). Most of this was for treatment abroad.
JustGiving’s own figures show more than 2300 UK cancer related appeals were set up on its site in 2016, a sevenfold rise on the number for 2015.
The phenomenon has allowed less well-off patients to access expensive, experimental treatments that are not funded by the NHS but have some evidence of benefit. But many fear it has also opened up a new and lucrative revenue stream for cranks, charlatans, and conmen who prey on the vulnerable.
Remember that these are figures from just two UK crowdfunding sites GoFundMe and JustGiving, although they are by far the largest sites. The figures are broken down in more detail by year of fundraiser, crowdfunding site, and country where the clinic of treatment was located. Table 1 breaks the money raised down by location, and you can tell right away at a glance that, far and away, most of the money raised was for clinics in Germany. Given that this is the UK and Germany is a quick flight or a less quick train ride away, it doesn’t surprise me that more money was raised to go to Germany than anywhere else, especially in light of all the German clinics that combine conventional medicine with alternative medicine (i.e., quackery like homeopathy and naturopathy) and unproven drugs that might or might not be legitimate experimental therapeutics. Even less surprisingly, the single biggest beneficiary of this largesse is the Hallwang Private Oncology Clinic. Newman explains:
The largest sums by far in Good Thinking’s dataset, accounting for £4.7m of the £8m identified, were ostensibly raised for trips to the Hallwang Private Oncology Clinic in the Black Forest of southern Germany. The clinic claims that some people have used Hallwang’s name to raise money but have not then proceeded to treatment and, in some instances, have done so without ever contacting the clinic.
The Hallwang carries out diagnostic tests on patients’ tumours and treats them with a combination of experimental immunotherapy, peptide vaccines said to train the immune system to attack cancerous cells, and unproved therapies such as vitamin infusions.8 Drugs offered include bevacizumab, which inhibits growth of tumours’ blood vessels, and pembrolizumab and ipilimumab, two members of a new class of biological therapy known as checkpoint inhibitors. All three drugs have proved benefits for certain types of tumour.
Costs are high: a patient was recently quoted more than €100 000 for an initial 10 day visit.9 However, the clinic states it offers intensive treatment monitoring, with a nurse to patient ratio of 1:2, in a highly private setting and in extremely challenging situations. It says many of its patients arrive with serious complications such as sepsis, tumour associated bleeding, or bowel obstruction, which it treats and manages. It also says that its innovative treatments are purchased at a high price, and because the costs are not met by any third parties such as insurers or charities, they have to be paid by patients. It insists patients only pay for and are given treatments after thorough discussion and with the patients’ explicit approval and consent.
Of course, an exposé of Hallwang Clinic published earlier this year by Lindsay Gellman argues otherwise. Gellman found that Hallwang’s business practices are arguably predatory and exploit the seriously ill. The clinic even often continues to use patient testimonials on its website after the patients have died!
Cancer quackery in Germany thrives because Germany has a long history of embracing “unconventional” therapies and outright quackery like homeopathy. Gellman notes in her exposé that German insurers typically reimburse patients for homeopathy and that German law extends robust protections to “certified” practitioners known as heilpraktikers, who are trained in homeopathy and other alternative medicine and are permitted to treat patients with non-infectious diseases, like cancer. Interestingly enough, these protections date back to the Nazi era, when the Nazi regime, in an attempt to regulate a growing group of “natural healers”, legitimized them but forbade the training of new heilpraktikers. The idea was to phase them out and push medical doctors to incorporate “natural healing” into their practices. Not surprisingly, after the war, the ban on heilpraktiker training was reversed. These days, unfortunately, in Germany alternative treatments are now gaining popularity with real medical doctors, many of whom have begun to seek out such training as an add-on to their medical training, and the heilpraktiker and homeopathy lobbies are very influential politically.
Even worse, big pharma is in on it. Hallwang, for instance, is owned by Hallwang Clinic GmbH, in which drugmakers have a significant ownership stake. For example, the company’s CEO Albert Schmierer, a pharmacist by training, personally holds a roughly one-quarter ownership stake in the Hallwang Clinic, and serves as the CEO and owner of Dr. Zinsser Pharmaceuticals, a medical-products company, and runs Rappen-Apotheke, a pharmacy that specializes in homeopathy and is located near the clinic, according to its website.
Of course, another country with a large share of UK crowdfunding for medicine is Mexico. This is not surprising, given the existence of so many quack cancer clinics in Mexico, including Clínica 0-19 in Monterrey and the numerous clinics in and around Tijuana, conveniently just over the US border. So, the basic answer is that, yes, crowdfunding is fueling quackery, but what to do about that? The answer is a bit more complicated than you might think.
Blurred lines
Before this investigation by The Good Thinking Society, I knew there was a problem with crowdfunding for quackery, as did pretty much any proponent of science-based medicine who paid attention to this issue. The question was: How big is the problem? In starting to answer that, The Good Thinking Society has done a great service. The question, now that we have an inkling of the scope of the problem (I’m guessing that it’s much larger than what this investigation shows, given the limitations of the investigation), is what to do about it. The issue is more complicated than it might sound on the surface. Remember, crowdfunding has, as Newman pointed out, allowed less well-off patients to access expensive experimental treatments with some evidence of benefit that are not currently funded by the NHS. Any solution that doesn’t take that into account could end up doing harm.
Here’s what The Good Thinking Society suggests:
Good Thinking wants the crowdfunding sites to vet cancer appeals and “reject outright proposals that refer to specific drugs that have been discredited, extreme dietary regimes, intravenous vitamin C, alkaline therapy and other alternative treatments.” Marshall says: “If a fundraiser is for treatment for a serious or life threatening condition such as cancer, it ought to be reviewed before it is sent live, especially if it contains terminology that raises red flags for quackery.”
Edzard Ernst, professor of complementary medicine at Exeter University, supports the move, pointing out that crowdfunding organisations already reject appeals involving violence or illegal activity. “Crowdfunding for a terror attack is out of the question,” he said. “Crowdfunding for cancer quackery is not any better and must be stopped.”
I, of course, agree that this sort of a system would be valuable to protect patients and cut off a lucrative revenue stream for quack cancer clinics. However, implementing such a system would not be easy. Indeed, here’s what I said in the article:
Working out how best to protect patients and donors—while supporting their informed choices—will be no simple task for the crowdfunding platforms, as David Gorski, a US surgical oncologist who campaigns for evidence based science, explains.
“I support the concept of not allowing crowdfunding for treatment at quack clinics but must admit that I struggle to see how it would work in practice for some of these centres,” he said. “How would they deal with clinics that offer conventional treatments alongside quackery?”
Alternative centres do not usually publish data on treatment efficacy but instead provide testimonials, in which patients often describe being given a short time to live before starting the treatment that “saved” them. “Patients often don’t understand that not enough time has passed to say with any confidence that they are survivors,” Gorski explains.
Let me elaborate a bit by referring to what Christian Ottensmeier, professor in experimental cancer treatment at the University of Southampton, was quoted as saying in the article. He notes that 20-25% of patients going to Hallwang might receive some benefit taking the immunotherapy drugs, which Hallwang often uses for diseases in which they have not yet been adequately tested and for which efficacy has not yet been determined (which is why the NHS and insurers won’t pay for them). The problem, of course, is what the practitioners at the clinic are telling patients about the chances that these drugs will work for them. As The Good Thinking Society’s investigation shows, many of the patients using the crowdfunding sites have an overly optimistic view of their prospects for long-term survival:
Anastasia Leslie’s Buy Another Day GoFundMe page said she was told by the Hallwang that “all of the ovarian cancer patients (approx 20 to 25 per year in the last 15 years) … are still alive, doing well and in remission.” Despite apparently spending £100 000 in just one week10 at the clinic, her death was announced on the funding page within months of her first trip to Germany. Her appeal raised £155 000.
Rekha Banerji’s appeal for her daughter Rebecca, who had stage 4 breast cancer, said: “Although in the UK, this is a hopeless case, the German doctors are extremely confident Rebecca will gain full remission.”11 The appeal raised £14 645, but her daughter also died within months of starting treatment, according to her GoFundMe page.
Ottensmeier also noted that for “For “a much smaller sum you can buy the same immunotherapy drugs and have them administered in the UK.” So there is profiteering to consider.
Banning fundraising for quackery is easy for clinics like the ones in Tijuana offering the Gerson protocol, which consists of 13 big glasses of fresh juice, dozens of supplements, and five coffee enemas a day. That’s obviously quackery, and crowdfunding sites should not fund it. Ditto Burzynski, who’s had 40 years to demonstrate anticancer activity due to his treatment and has thus far failed as he’s spent the last 20 years abusing the clinical trial process, using it as a recruiting tool more than anything else. On the other hand, for clinics that offer conventional therapy along with their quackery, it’s basically impossible to assure that any money raised goes for conventional or off-label treatments that might have benefit; so the most straightforward solution would be to ban fundraising for any clinic that offers quackery like homeopathy, regardless of what other treatments the clinic offers.
As of now, though:
GoFundMe, the platform that features most prominently in Good Thinking’s dataset, said it is already “taking proactive steps” in the US to make sure users of its site are better informed and will be doing the same globally over the coming months.
“Ultimately, we’ll be monitoring content of this kind more closely in order to provide tailored advice,” a spokesman said. But JustGiving told The BMJ, “We don’t believe we have the expertise to make a judgment on this.”
There are a lot of doctors practicing science-based medicine out there who would be happy to help, I bet. I’d also make another proposal that even JustGiving could implement immediately while trying to figure out a more rigorous solution: Crowdfunding sites should require that patients using them to raise money for treatment identify the clinic or hospital to which they plan to travel. That requires no expertise whatsoever in adjudicating whether a given clinic is a quack clinic but would at least allow skeptics like me to identify campaigns for quackery at a glance and write about them if we so choose.
The role of the media
Newman also mentions the role of the media in this problem, noting:
Newspaper and TV reports on people with cancer drive donors to the crowdfunding sites, sometimes attracting the attention of celebrities, who boost funds. They also encourage others to seek the same treatment. “These reports may look like uplifting human interest stories, but the reality can be much darker,” says the Good Thinking Society’s Michael Marshall. “They rarely highlight the dubious and pseudoscientific nature of some of the treatments involved or just how many of the success stories actually ended in tragedy.”
This was something I noticed right away when I first started paying attention to Stanislaw Burzynski in a big way. In particular, the British tabloid press loves—loves!—to publish these stories. The reasons are obvious, particularly in the case of children with cancer. Such cases lend themselves to a narrative in which a heroic patient with cancer (or a heroic mom or dad of a cute child with cancer), faced with doctors saying that there is no curative treatment (which is also often portrayed as no treatment), decides to risk everything and spend everything to go to an alternative clinic. There’s also a political element, as Newman notes:
Many stories follow a familiar narrative: a tragic patient, with everything to live for, is on the mend after “miracle” treatment denied them by the NHS. Gemma Nuttall is one example. The Daily Mail and ITV 1415 reported the young mother was now “cancer free” in February 2018, a few months after treatment at the Hallwang clinic, which was funded in part by film star Kate Winslet. Sadly, a recent update on Gemma’s GoFundMe page said the cancer had returned. This has not been reported.
Many of Britain’s tabloids are—surprise! surprise!—rightward leaning politically, but even if they weren’t the narrative of a parent denied the treatment that she believes will save her child’s life by a faceless insurance company or government agency, only to find it somewhere else and be willing to raise hundreds of thousands of dollars to save the life of her child, is an irresistible human interest story. Such stories can lead to huge donations, as was the case when Edie Molyneux, a girl with DIPG whose family had taken her to Monterrey for treatment, received an anonymous donation of £250,000. Other headlines blare “18-year-old new mother with terminal brain cancer flies to Mexico for experimental treatment in desperate bid to save her life“. Moreover, outlier survivors are publicized with headlines like “Girl, 7, whose family sacrificed everything and moved to Mexico for £350,000 brain tumour treatment, becomes one of longest-surviving UK patients EVER… but they’re still terrified of losing her“, and all the children and patients who died deriving no benefit from the quackery often never appear in the headlines again.
Celebrities not infrequently glom on to such cases, usually with the best of intentions, as Kate Winslet did. Sometimes they promote the clinic, as Fabio Lanzoni promoted the Burzynski Clinic or even do charity concerts, as UK star Peter Kay did for Billie Bainbridge to help pay for trips to the Burzynski Clinic, and an Ebay auction to raise money for her included a guitar donated by Radiohead.
It’s not just tabloid press, either. Last week, I saw a horrifying example of publicizing quackery as though it were “experimental therapy” in The Washington Post in a story by Petula Dvorak entitled, “How much would you pay for one more day, one more month with someone you love?” I immediately recognized it as a story about a girl with DIPG whose parents took her to Clínica 0-19 in Monterrey:
If someone you love is dying, how much are you willing to pay for just one more day with them?
Doing the math, Melany Knott figured it cost about $1,100 a day. That got them 21 months.
“No regrets,” Knott said. “I wouldn’t change a thing. And I won’t wonder about anything.”
The Knott family auctioned off chain saws, goats and guns to raise some of the $695,000 they spent. They raided their savings, college funds, maxed credit cards and doubled down on the double shifts. They did fundraisers at the county fair and ran online tote bag sales to pay for untested treatments offered at a medical clinic in Mexico.
This was not the battle for a cure to their 13-year-old daughter’s monstrous, fatal brain cancer.
Yes, the Knott family spent nearly $700,000 on Dr. Alberto Siller and Dr. Alberto Garcia’s unproven treatment. Unfortunately, this story frames the Knott family’s decision as a brave gamble to have just a little more time with their daughter rather than what it really is, the story of a family taken in by quacks. I was not happy when I read the story:
The clinic, of course, is almost certainly @019Clinica, where two quacks have been taking advantage of desperate families of children with DIPG with an unproven treatment. 2/ https://t.co/LpoVPAqbYw
— David Gorski, MD, PhD (@gorskon) September 14, 2018
The @019Clinica protocol, such as it is, is a secret “make it up as you go along” combination of intraarterial chemotherapy and an unspecified immunotherapy. 4/ https://t.co/x05pNS1yuY
— David Gorski, MD, PhD (@gorskon) September 14, 2018
Worse, there is harm. Children have been harmed, and parents have been stranded in Mexico, unable to leave because a medical flight is too expensive but racking up $2,000 a day. The tales are horrifying. 6/ https://t.co/LYCCofGG0I
— David Gorski, MD, PhD (@gorskon) September 14, 2018
So @washingtonpost and @petulad‘s portraying @019Clinica with the question, “How much would you pay for one more day, one more month with someone you love?” without acknowledging the lack of evidence for its treatments and financial toxicity to the families is irresponsible. 8/8
— David Gorski, MD, PhD (@gorskon) September 14, 2018
And something I thought of after wrapping up:
Oh, one last thing. Never, ever refer to what @019Clinica is doing as “experimental therapy.” It’s not. Drs. Siller and Garcia are not testing a therapy in clinical trials. They’re selling it without evidence to the desperate parents of dying children. 8a/8
— David Gorski, MD, PhD (@gorskon) September 14, 2018
Now here’s the problem. Dvorak clearly doesn’t “get” why I found the framing that she chose for the story so troubling:
Maybe it’s your tweet that is misleading, Dr. I mentioned your concerns a couple times, including this paragraph. Making bigger leaps without deep, scientific reporting is journalistic malpractice. My readers are smart enough to draw their own conclusions. pic.twitter.com/8Dp0xe1RSJ
— Petula Dvorak (@petulad) September 14, 2018
To which I responded:
The mention of concern about no science is minimal compared to the totality of the article and is immediately followed by, “But the Knotts were willing to gamble. One more day. One more month with their child. Maybe, one more year, even?” Overall narrative is as I described it.
— David Gorski, MD, PhD (@gorskon) September 14, 2018
You see the problem? Dvorak thought that her article was acceptable because she spent one sentence in an ~1,100 word article mentioning that there was no scientific rationale for the treatment, while peppering the article with passages like this:
Would Knott do anything differently?
All that flying, the fundraisers, nearly $700,000 gone. She has three other daughters, all in their teens, one in college.
Nope.
The U.S. doctors told her to “go home and make memories,” she said. But Kaisy — the little girl who always won big awards showing her giant livestock — is a fighter. And Knott was going to fight for every single day.
“You do anything for your kid,” she said.
And:
“We were looking for quality,” she said. “And the Mexican treatments were less invasive and gave her quality.”
She thinks that American doctors gave up too fast, giving her eight months to live after the first diagnosis. And she said they were timid about treating her after the Mexican infusions, refusing to buck decades of traditional radiation therapy.
There’s also a passage mentioning how well Kaisy did—for a while.
Here’s one thing I have trouble understanding. The Mexican therapies are anything but “less invasive”. They involve repeated puncturing one of the femoral arteries and the snaking of a catheter up to the arteries feeding her brainstem in order to inject chemotherapy every few weeks, which for most children requires general anesthesia (although at age 12 Kaisy might have been able to cooperate without general anesthesia). Also, the risk of repeated angiographies include kidney failure. The protocol in some cases involves placing an Ommaya catheter into the cerebrospinal fluid so that chemotherapy can be infused intrathecally. These can get infected and in at least one case I’m aware of in Monterrey contributed to the death of a girl with DIPG. This is about as invasive as you can get without doing brain surgery to try to remove the tumor, which is almost never done for DIPG because it’s impossible to remove most DIPG tumors completely without damaging the brainstem. Radiation therapy and steroids, the standard of care, are far less invasive than the protocol used by Drs. Siller and Garcia.
This brings us to the one issue I have with Good Thinking’s recommendations, and that’s what to do about the press:
“If the media want to report on medical fundraising stories, they should seek the advice of qualified medical experts,” Marshall said.
This is not the problem. The vast majority of stories I’ve seen about cases like Kaisy’s do quote at least one medical expert or at least acknowledge there is no evidence for the treatment being discussed. The problem is that the medical expert or the expression of doubt is usually used as the “token skeptic” and buried somewhere in the middle of the text. Sometimes, as Dvorak did after noting that the therapy has no evidence to support it, reporters even use consensus medical opinion as a foil, immediately pivoting to a “but…” and going on to portray what the family is doing as a brave gamble rather than what it is, an unfortunate desperate family being taken advantage of by quacks.
Until we can overcome this tendency in the reporting of these stories, crowdfunding, be it by existing companies or new companies that spring up in the future, will likely continue to be a major revenue source for quack clinics.

Crowdfunding: The fuel for cancer quackery (part 2)
In September, The Good Thinking Society released a study estimating the scope of crowdfunding for cancer quackery in the UK. Now, Jeremy Snyder and Tim Caulfield have done the same for the US, specifically for homeopathy for cancer. The results are alarming. Truly, crowdfunding is the fuel for cancer quackery. But will GoFundMe and other crowdfunding sites clean up their acts?
David Gorski on January 7, 2019
Link

I’ve been blogging more or less continuously for over 14 years now, an observation that hit me at 4 AM Saturday morning after I found myself stone cold awake and unable to go back to sleep. I don’t often suffer from insomnia, but when I do, it usually doesn’t take me long to realize that, for whatever reason, I’m not going to get back to sleep for a while and hence the futility of trying, particularly when the thoughts are swirling and dancing in my mind, flitting from one topic to the next. So, groaning, I decided to get up and do…something. Rather than just surf the Internet, peruse social media, watch TV, or read, I decided to get a head start on this post, because what else was I going to do at 4 AM on a Saturday morning, with sunrise still over four hours away? Because I didn’t want to make a pot of coffee until my wife got up, I popped a pod in the Keurig, fired up my MacBook Pro, and got to work. The topic is one that I’ve been writing about for a long time, both here and on my not-so-secret other blog, a topic that over the last year or so has finally, finally, finally been getting some play in mainstream medical journals and news outlets. I’m referring to crowdfunding for quackery and the article in the most recent Lancet Oncology by Jeremy Snyder and Tim Caulfield entitled “Patients’ crowdfunding campaigns for alternative cancer treatments.” (Note that, although Lancet Oncology is behind a paywall, this article is free if you register; so you can read it if you don’t mind registering.)
The last time I addressed this topic, it was in the context of a study by The Good Thinking Society published four months ago that examined crowdfunding platforms and how they are used for cancer quackery in the UK, with the primary beneficiary being the Hallwang Clinic, an alternative cancer clinic in Germany that I’ve written about before to discuss the deadly false hope that its doctors market to cancer patients. Before that, Jann Bellamy took note of a study earlier this year that tried to estimate how much dubious crowdfunding is going on for what can only be described as stem cell quackery, as did a certain friend of the blog. The bottom line is that crowdfunding platforms like GoFundMe (which is by far the dominant one) have facilitated the ability of desperate patients with serious diseases like cancer to raise huge sums of money for quackery. The Good Thinking Society made some recommendations on how to cut down on the abuse of these platforms that could represent a good start but, unfortunately, are likely to be very difficult to implement.
Crowdfunding for homeopathic cancer treatments
One problem with the literature thus far has been the paucity of studies how crowdfunding is used to promote pseudoscience. In this case, Snyder and Caulfield decided to look at crowdfunding campaigns for cancer treatments that were undeniably quackery, specifically, homeopathic cancer treatments, a subset of what I like to refer to as The One Quackery To Rule Them All. It’s a descriptive study, for sure, but it’s highly useful information. Except for one major issue I have with it, it’s a strong addition to the literature.
Crowdfunding for cancer has been studied before, first, as I mentioned above, by the Good Thinking Society in a study in The BMJ published in September, the one that I blogged about. The primary limitation of that study, of course, was that it was limited to the UK. In addition, although not the primary topic, the issue of crowdfunding for cancer quackery was also part of a broader analysis study published in JAMA in October that examined crowdfunding for five forms of quackery for different conditions: homeopathy or naturopathy for cancer, hyperbaric oxygen therapy (HBOT) for brain injury, stem cell therapy for brain injury and spinal cord injury, and long-term antibiotic therapy for “chronic Lyme disease.” Both analyses found disturbingly large numbers of people asking for large sums of money for unproven and disproven treatments.
So let’s dig in to what is an important, albeit flawed, study to find out what it adds to the subject. Here’s what Snyder and Caulfield did:
On June 8, 2018, we searched the crowdfunding platform GoFundMe for medical crowdfunding campaigns that included the words “cancer” and “homeopathic”, “homeopath”, or “homeopathy” using the platform’s search engine. We used variations of “homeopathy” to identify campaigns for clearly unproven cancer treatments. This process identified 220 unique campaigns.
For each campaign, we recorded information about the amount of money requested and pledged, number of donors, number of Facebook shares, location of the campaign host, date the campaign was initiated, recipient’s underlying medical condition, rationale for seeking CAM cancer treatment, alternative treatments (including those other than homeopathy) sought, activity claims made, and information about whether the recipient had died. For campaigns that had not recorded the recipient’s death, we searched obituary records and recorded when there was adequate personal information for the recipient.
It’s an interesting choice to examine only campaigns by patients looking to use treatments that include homeopathy. The reason for such a choice is obvious. Homeopathy is so utterly implausible in its tenets and methods so as to be reasonably considered, for all practical purposes, impossible. It is truly The One Quackery To Rule Them All. Consequently, there should be little argument over whether this is a worthless treatment, at least among the science-based community. Homeopaths will likely howl, but who cares if they do?
The number of campaigns Snyder and Caulfield found is surprising, even for me, given that they had limited the scope of their search to homeopathy for cancer. Of course, I know from long experience from looking at such campaigns that it’s rarely just homeopathic treatment being sought. Usually the alternative cancer clinics and practitioners to which these patients are lured offer a veritable cornucopia of quackery, with homeopathy being just one of many forms of quackery being used. Some, like Hallwang and many Mexican alternative cancer clinics, tout a “best of both worlds”—yeah, right—combination of conventional and alternative therapies. Some, like Hallwang and a lot of the German alternative cancer clinics, add legitimate experimental therapeutics that are as yet unproven for the indications for which they’re being used to the mix. One example is 3-bromopyruvate (3-BP), an experimental drug designed to target the Warburg effect that’s in development for cancer treatment but unproven in humans, not that that stopped a naturopath named Klaus Ross from using it to treat cancer. Unfortunately, 3-BP is fairly likely to have been responsible for the deaths of three cancer patients. Of course, Hallwang Clinic, being in Germany, also includes homeopathy with its other treatments, be they conventional, unproven experimental therapeutics, or alternative. Basically, utilizing experimental therapeutics off of a clinical trial in the manner that clinics like Hallwang do (giving them with no regard as to whether there is a legitimate reason to try an experimental drug off-protocol and charging big bucks for them) is highly unethical. Personally, I view it as health fraud.
One of the interesting (to me, anyway) findings of this descriptive study was the list of reasons why patients chose alternative medicine for their cancer. Snyder and Caulfield reported that they found three categories of rationales for seeking alternative cancer treatment: “individuals who want to try every available treatment and who are using it to complement traditional treatment; individuals who chose to forgo traditional treatment because of fear of its effects or skepticism about its activity; and individuals who cannot pursue traditional treatment for financial or medical reasons but do not wish to forgo treatment.” As I read that latter category, I couldn’t help but think first: Only in America! Then I thought a little more and realized that there was also a major problem with how the third category was defined. Indeed, it is the key flaw in this study. See if you can figure it out before I get to discussing it.
So let’s unpack the findings. First:
186 (85%) of 220 campaigners were located in the USA, 23 (10%) in Canada, eight (4%) in the UK, and one each in Germany, Ireland, and Spain. They requested US$5 795,602, and were pledged $1,413,482 (24% of the total requested) by 13,621 donors. These campaigns were shared on Facebook 112,353 times. Campaign recipients were a very ill group, as evidenced by the fact that at least 62 (28%) had died following the start of their campaigns.
I could be wrong, but my guess is that the percentage of patients who died following the start of their campaigns is likely higher than 28%. I base my speculation on my experience examining alternative cancer cure testimonials and how, these days, crowdfunding campaigns often serve a similar marketing purpose as testimonials did in the old days. As I noted when I discussed Rigvir, the testimonials often remain on websites (and GoFundMe pages) long after the cancer patient has either died or started to deteriorate. Regular commenter Peter Moran once noted that alternative cancer cure testimonials “have an afterlife,” adding that “I don’t think I have ever seen one retracted when the claims later proved false or the patient died, as is usually the case whenever someone tries to treat established cancer with alternative methods alone.” (I can recall only one or two, for instance, Cassandra Callender, but it wasn’t the quack—Ty Bollinger—who recanted. It was her by giving up the quackery and accepting science-based oncologic care.) Whenever I’ve investigated such testimonials, I’ve usually had to search to find whether the patient was alive or dead, and often I couldn’t determine the answer.
As for the amount of money, the total amount requested divided by the number of campaigners comes out to $26,344 per campaign, which is actually a lower mean than I would have predicted. It’s still a lot of money, and, as I’ve written about on multiple occasions, many patients are seeking hundreds of thousands of dollars. (I wonder what the median was.) After all, treatment at the Burzynski Clinic routinely approaches or even surpasses $300,000 after several treatments, with Stanislaw Burzynski’s monthly “medical management fee” running around $10,000 a month, while the patients at Clínica 0-19 routinely rack up similar levels of fees, with one family having spent $700,000 (!) for treatment.
Not surprisingly, homeopathy wasn’t the only treatment sought by patients in these crowdfunding campaigns. Snyder and Caulfield found that other treatments being used included dietary changes such as juicing and organic foods (n=85), supplements, vitamins, and herbal remedies (n=68), vitamin C infusions (n=30), oxygen, ozone, and hyperbaric treatments (n=24), acupuncture (n=20), cannabis-based treatments including cannabidiol (n=18), naturopathy (n=18), immunotherapy for unapproved settings (n=17), cleanses and detoxification (n=16), energy healing (n=13), hyperthermic treatments (n=10), traditional Chinese medicine (n=9), pH balancing and alkaline water treatments (n=9), mistletoe (n=8), Ayurveda, yoga, and meditation (n=8), light, ultraviolet, and infrared treatments (n=8), chiropractic treatments (n=6), lymphatic massage and drainage (n=6), massage (n=6), magnets (n=5), chelation therapy (n=5), essential oils (n=4), autohemotherapy (n=3), indigenous medicines (n=3), low-dose chemotherapy (n=3), osteopathy (n=3), and hypothermic treatments (n=2). I’m guessing that a large proportion of the “juicing” and dietary changes probably included the Gerson protocol, an alternative cancer treatment that involves 13 glasses a day of fresh, raw carrot/apple and green-leaf juices prepared hourly from fresh, organic fruits and vegetables; three full plant-based meals, freshly prepared from organically grown fruits, vegetables and whole grain; pancreatic enzymes and thyroid extracts; a boatload of supplements; and five coffee enemas per day. It is, unfortunately, one of the more popular forms of cancer quackery out there and frequently (mis)represented as “dietary treatment”.
Next up:
83 (38%) individuals used alternative treatments as complementary to traditional treatment. They wanted to try “every treatment method available”, often seeing homeopathic treatments as something that would “enhance” traditional treatments. 63 (29%) of 220 campaigns were for individuals who chose to forgo traditional treatment because of a fear of its effects or skepticism about activity. They often felt alternative treatments were a more natural alternative to “synthetic medicines”. Individuals who could not pursue traditional treatment for financial or medical reasons comprised 69 (31%) of the campaigns. A characteristic example of one of these campaigns included one recipient who saw alternative treatment as their “last and only hope”. Four (2%) of campaigns included two rationales and nine (4%) gave no rationale.
Obviously, the worst public health problem comes from the last two categories, patients who forego conventional therapy for quackery and those who choose quackery for financial reasons or medical reasons. These are the patients who are most at risk of dying unnecessarily or prematurely. Sure, it’s a waste of money, effort, and time to be adding quackery to conventional therapy, and it potentially harms patients, all of which constitute my objections to so-called “integrative oncology,” but in the end at least such patients are also getting effective science-based treatment for their cancers. Patients who forego science-based treatment for quackery are far more likely to die of their disease, either from untreated cancer or from delaying effective therapy until they realize that the quackery has failed, by which time their chances of survival are greatly diminished even with the best science-based treatment that exists.
Palliative care is conventional care
Now we come to the aspect of the study that truly frustrated me. To me it is the weakest aspect of the study. I’m referring to the last category of reasons for seeking alternative therapy, described by the author as either financial or medical reasons or not being able to “pursue traditional treatment for financial or medical reasons”. For the life of me, I cannot understand why Snyder and Caulfield chose to lump these two categories together, and it’s not really explained in the article. (I realize that the word count for this type of article is highly restrictive, but even so…)
Let me explain my problem with this category as defined for purposes of the analysis. There’s a huge difference between patients who chose alternative medicine because they couldn’t afford conventional therapy and those who chose it because they weren’t a candidate for conventional therapy (whatever that means). The former represent a failure of our health care system to provide needed medical care to everyone; the latter represents another issue altogether. Worse, lumping these two categories (financial and medical impediments to science-based treatment) leads to a serious issue with the estimates in the study.
Here’s what I mean. I would argue that a significant percentage of the patients in this category were misclassified in their reason for foregoing conventional therapy, specifically the patients who were described as not candidates for conventional therapy for medical reasons. I would further argue that these patients were in fact candidates for conventional therapy. All patients are candidates for conventional science-based therapy. Reading between the lines and calling on my experience analyzing alternative cancer cure testimonials, I gather that what’s really going on with these patients is that they were told that there was no curative therapy for which they were candidates; i.e., that their disease was terminal. I could be mistaken, but suspect that I am not based on how the authors describe a “characteristic example of one of these campaigns” as including “one recipient who saw alternative treatment as their ‘last and only hope.'” This is an absolutely classic reason given by patients with stage IV terminal disease for whom only palliative treatments are medically appropriate for choosing cancer quackery. I would thus argue that these campaigns should have been classified as the campaigns of patients who chose to forego conventional therapy in favor of alternative therapy, in other words as the second category rather than the third. The third category should just have been patients who crowdfunded for quackery because they couldn’t afford conventional treatment. Come to think of it, I would suspect that this reason is probably uncommon; patients who truly want to undergo conventional treatment would more likely try to use crowdfunding to pay for conventional treatment than to pay for quackery.
But let’s get back to the patients who are categorized as not being candidates for conventional therapy for medical reasons. No one—and I mean no one—is “not a candidate” for conventional therapies. It is, of course, true that many patients are not candidates for treatment with curative intent, whatever that treatment may be, but all patients are candidates for some form of conventional therapy. Consider it this way. If a patient is not a candidate for treatment with curative intent, then he’s a candidate for treatment with palliative intent, and palliative care is science-based conventional therapy. Indeed, I suspect that the patients who were not candidates for “medical reasons” consisted of either patients who were not candidates for treatment with curative intent from the beginning (e.g., were found to have widespread metastatic disease at the time of diagnosis, perhaps with other medical conditions that would make even palliative chemotherapy risky) or had disease that had progressed on therapy or relapsed, leading to their being treated with second- and third-line treatments and failing those too, to the point where it was no longer medically appropriate to continue to try to treat for cure. Again, medically, these patients are candidates for conventional therapy, just not curative. They are always candidates for palliative care. Always, always, always!
I know I’m repeating myself, but this is an important, and often overlooked, point about palliative care. Even doctors sometimes make this mistake of conflating palliative care with no care; i.e., “giving up”. Palliative care is anything but that. Indeed, treatment with palliative intent can be associated with in prolonged survival compared to patients going for last ditch heroic treatments that are far more prone to result in toxicity that shortens their lives (or at least diminishes the quality of their remaining life) than in meaningful prolongation of life. Most of the work suggesting that early palliative care can be associated with prolongation in survival has been in lung cancer patients but there is evidence for more than just that form of cancer. To be sure, not everyone is buying that palliative care prolongs survival compared to aggressive care, but at the very least it is reasonable to conclude that palliative care compares quite favorably in many ways to aggressive end-of-life treatment. Moreover, there is no doubt that quality of life is better with palliative care.
I know from experience that in alternative cancer cure testimonials, recommendations for palliative care only are often portrayed as nothing more than callously being told to “get one’s affairs in order” and/or to “go home and die“, while the alternative treatment being sought is portrayed as “my last chance.” Indeed, these are two of the main elements of alternative cancer treatment testimonials, one or both of which occur in pretty much every one. Of course, it’s understandable that a patient doesn’t want to be told that there is no curative treatment for his cancer and that he has only a couple of year—or even just months or week—to live. It’s entirely understandable that the patient might view a recommendation for palliative care as a recommendation for, in essence, “no treatment”. I will even concede that there are probably some facilities where the oncologists don’t fully appreciate the value of palliative services and might give such patients the impression of giving up. That doesn’t change the fact that palliative care is conventional care.
That’s just my pet peeve, though, albeit, I think, a very important and justified one. For the purposes of this study, the problem with the third category being defined as it was is that it almost certainly means that nearly all (or even all) of the patients who claimed not to be able to pursue treatment for “medical reasons” were misclassified. They should have been in the group who declined science-based care in favor of quackery. Thus, this misclassification has likely produced what is almost certainly a gross underestimation of the percentage of patients engaging in a crowdfunding campaign who were candidates for science-based conventional treatment but chose to forego it in favor of quackery. By how much? There’s no way to know without breaking down the patients in the last category, but, based on my experience analyzing alternative cancer cure testimonials, I strongly suspect that the number of patients crowdfunding for quackery because they can’t afford conventional care is probably the minority, particularly since the Affordable Care Act has greatly decreased the number of uninsured. Again, I could be mistaken about this, but I suspect I’m not. Moreover, as I mentioned before, patients who really want to undergo conventional therapy but can’t afford it would be far more likely to use crowdfunding to pay for conventional treatment than for quackery.
I would therefore argue that it is very likely more appropriate to combine into one group the 29% who chose to forego conventional treatment in favor of alternative therapy with the 31% who “could not pursue traditional treatment for financial or medical reasons.” In other words, it is very likely that around 60% of patients’ crowdfunding for cancer quackery are rejecting conventional therapy even though they are candidates for it.
Alternatively, the authors could have subdivided the third category, leaving four categories of treatments being funded through crowdfunding:
     1.  Alternative medicine to be added to conventional oncologic treatment (i.e., to fund the alternative medicine part of “integrative medicine”);
     2.  Alternative medicine instead of conventional oncologic treatment for cure;
     3.  Alternative medicine instead of conventional palliative care (patients with incurable cancer who are not candidates for aggressive treatment to prolong life, either due to having exhausted existing therapies, burden of disease, or medical comorbidities); and
     4.  Alternative medicine chosen primarily for financial reasons.
I’ll admit that I’m still skeptical that the fourth category even exists to a significant extent, but I’ll give Snyder and Caulfield the benefit of the doubt on that one because in general they’ve earned it. The result of this analysis would be very helpful, because it would stratify the patients who chose quackery instead of science-based medicine into those who are potentially curable and those who are not. There will probably be some cases that would be difficult even for an oncologist (or me) to assign to group 2 or 3 because the information provided on their crowdfunding page is insufficient, but that’s actually an argument in favor of my first proposed solution: just lumping together the potentially curable patients with the patients offered palliative care.
The problem of crowdfunding for quackery
Let me just say before I conclude that I don’t mean to be too critical of Snyder and Caulfield. Really, I don’t. Quite the contrary! Neither of them are clinicians, and they’ve done an excellent job quantifying and highlighting a problem that arose not long after websites and blogs did, and the one major flaw I found in their study is likely a consequence of their not being oncologists and perhaps their not having a 15+ year history deconstructing alternative cancer treatment testimonials. I only criticize their choice because I think it leads to a significant underestimation of the number of patients who choose to reject what conventional oncology has to say and act on that rejection.
Crowdfunding for quackery is a problem that started out small, given that setting up websites and blogs used to be difficult, but then was turbocharged by the rise of social media and crowdfunding platforms like GoFundMe. Indeed, the first time I remember taking note of the issue of crowdfunding quackery for cancer was in 2010. It was the case of Rene Louis, a patient with advanced thyroid cancer who started a website to raise money to go to Houston to be treated by Stanislaw Burzynski. She was also trying to set up a nonprofit foundation whose express purpose was to help others in her situation raise funds for treatment, both conventional and alternative. She was the first of many examples Stanislaw Burzynski’s patients who resorted to crowdfunding to pay his exorbitant fees. Indeed, it was through my interest in Stanislaw Burzynski’s cancer quackery that I came to be aware of the issue of crowdfunding. It was where I learned that crowdfunding has become, in essence, a major component of the business model of cancer quacks, stem cell quacks, and, increasingly, any quacks who charge exorbitant fees for their “services.” From there, I’ve seen this model in action in quack clinics as varied in location and type as Hallwang and Clínica 0-19.
In fact, the one major flaw in Snyder and Caulfield’s study reminds me that the rise of crowdfunding for quackery is a problem to which, like that of quackery in general, we in the medical profession have been far too oblivious for far too long. If a cancer clinician had been involved with this study, perhaps this would not have been an issue, although, to be honest, I’m not sure that even that would have prevented this misclassification, given how little attention most cancer clinicians pay to combatting cancer quackery and how even some doctors who aren’t advocates of palliative care might not argue with how the third group was defined—or even the existence of the group.
It also reminds me of the limits of blogging. Blogging about this problem is important; indeed, many have been the times that I’ve been approached by reporters about topics that I’ve blogged about. However, if you want to get the attention of physicians and be taken more seriously by mainstream media outlets, doing analyses like these is something we skeptics should be doing too. People like Tim Caulfield, Jeremy Snyder, Leigh Turner, Ford Vox, Arthur Caplan, Kelly McBride Folkers, Angela Turi, Michael Marshall of The Good Thinking Society, and a handful of others are leading the way. I also like to think that I’m doing my own small part as well.
So what do we do about this? In response to The Good Thinking Society’s report, GoFundMe claimed that it was already “taking proactive steps” in the US to make sure users of its site are better informed and will be doing the same globally over the coming months. However, I’ve seen no evidence thus far that GoFundMe has done a thing since September.
In the meantime, Snyder and Caulfield note:
In light of these findings, there should be concern that crowdfunding has the potential to exacerbate existing and create new problems within the market for alternative cancer treatments. Oncologists and other medical practitioners should be prepared to discuss these concerns with their patients. Cancer research agencies and patient support groups could raise the profile of these issues with public statements of concern around the role of crowdfunding in encouraging the use of unproven cancer treatments. Partnerships with crowdfunding platforms should also be sought to combat the worst forms of harm and misinformation transmitted via these campaigns.
These are good suggestions, but, although advocates are prodding GoFundMe to clean up its act with respect to quackery, I agree with Snyder and Caulfield. There is a profound financial conflict of interest that makes me doubt that GoFundMe will make anything more than cosmetic changes to its policy. That’s why I’ll repeat my suggested first step that could be implemented immediately and requires no judgment on the part of GoFundMe as to the scientific validity of a treatment or involvement of a skeptic or physician: Require that anyone crowdfunding for medical care reveal where he or she is being treated, who the doctors or practitioners will be, including whether they are medical doctors or not, and what specific treatments they wish to pursue. At the very least, that would allow skeptics like me to highlight crowdfunding for quackery and researchers like Snyder and Caulfield to categorize which quacks and quack clinics are profiting the most from crowdfunding. I would advocate banning crowdfunding campaigns for treatment by practitioners whose whole profession is quackery, like naturopaths, homeopaths, and the like. Unfortunately, though, I realize that even that seemingly reasonable suggestion might be difficult to implement, as state licensing of quackery could undermine such a policy. Patients and quacks could easily ask why, for instance, GoFundMe won’t allow crowdfunding for “licensed healthcare professionals”. That’s yet another reason why I oppose licensing naturopaths and other quacks.
Finally, Snyder and Caulfield left out one thing from these suggestions. Most physicians, even oncologists, are not familiar with the types and scope of unproven and disproven cancer treatments. That’s where skeptics, either as part of skeptical organizations or on their own, could be most helpful. Steve Novella has frequently pointed out that one role of the skeptic is consumer protection, to educate consumers to avoid the fraud of psychics, pseudoscience, and, yes, quackery. Here’s a perfect example where we could help.

More, please! A victim of cancer quack Robert O. Young wins a $105 million settlement
Robert O. Young is a cancer quack who claims to be a naturopath who promotes what he calls “pH Miracle Living.” He claims that cancer is caused by excess acid and that the way to prevent and cure cancer is to “alkalinize the blood.” Two and a half years ago, he was convicted of practicing medicine without a license. Last week, a woman whose breast cancer progressed to incurable while being treated by Young won a $105 million settlement in a lawsuit against him. Maybe civil suits can succeed where state medical boards have failed.
David Gorski on November 5, 2018
Link

A major focus of my blogging for Science-Based Medicine (SBM) has been to leverage my understanding of cancer as a cancer clinician and scientist to deconstruct alternative cancer cure testimonials. Whichever quack is behind such testimonials, over the years I’ve made it one of my main goals to demonstrate how seemingly convincing stories are damned near close to never good evidence of an anticancer effect due to the intervention used in the testimonial. Indeed, I refer to these stories as “testimonials” rather than anecdotes or case reports. In medicine, the word “case report” has a specific meaning as an organized, detailed description of a case, something that testimonials almost always lack. In reality, these testimonials are marketing, either to sell a product to make a profit, to sell a story because the patient telling the story has become a true believer in the quackery chosen, or both. Unfortunately, as we learned from a survey released by the American Society of Clinical Oncology (ASCO) last week, belief in alternative cancer cures is prevalent in the US, with 39% of the population agreeing with a statement that alternative medicine “natural treatments” can cure cancer by themselves, without conventional surgery, chemotherapy, or radiation therapy, a percentage that approaches 50% among young adults.
From my perspective, a large part of the reason for the prevalence of beliefs like this is that alternative cancer cure testimonials are effective. They’re the reason that cancer quacks like Robert O. Young attracted people with cancer to Rancho del Sol, his 40-acre ranch located in Valley Center, California, for so many years before the law finally caught up with him, promising to cure them with his “pH Miracle Living” program, which involves “alkaline water” and a number of other treatments claiming to “alkalinize the body.” I’ve written about Young’s quackery rather extensively, particularly in this post and on my not-so-super-secret other blog; so I won’t go into a lot of detail, other than to point out a couple of things. First, this was what Young claimed about cancer:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
This is wrong on so many levels, particularly the part about cancer cells being healthy cells “spoiled by acid” but also including his claims that “alkalinizing the body” will cure cancer. I also note that he claimed that viruses are “molecular acids” (he claimed his “pH Miracle Living” could cure HIV/AIDS as well) and that he is basically a germ theory denialist as well, having used the tragic death of a Brazilian model due to sepsis to claim that sepsis is not caused by bacterial infection, but rather by “acidic lifestyle choices, including acidic food, drink, and drugs – especially dextrose and/or antibiotic IV’s given at hospitals around the world.”
However, the case that made Robert O. Young most infamous was that of Kim Tinkham. Tinkham, you might recall, was a woman diagnosed with breast cancer who appeared on The Oprah Winfrey Show over 11 years ago. During the interview, Tinkham told Oprah that she was not going to undergo surgery, chemotherapy, or radiation but that, thanks to The Secret, she believed that the universe would bring her healing, which was why she chose to use alternative medicine to treat her cancer. (Often forgotten these days is that Oprah was a big proponent of The Secret back then, which preaches that if you want something badly enough, visualize something clearly enough, the universe will manifest it for you.) Who was the quack that Tinkham chose? You guessed it: Robert O. Young. As a result, Tinkham became a passionate advocate for Young’s quackery, even recording YouTube videos with him to tout his “pH Miracle Living.” Ultimately, Tinkham died of her disease, although it did take over three years to happen. No one knows how many other cancer patients who didn’t talk to Oprah Winfrey chose to trust Young, with the same results.
Oddly enough, none of them ever sued Young; that is, until now. Indeed, last week was a very bad week for Robert O. Young, because he was on the wrong end of a $105 million judgment of a lawsuit brought by one of his victims. First, however, let’s back up a couple of years to see what befell Young.
The further fall of Robert O. Young
As I alluded to above, the law finally did catch up with fake “doctor” Robert O. Young nearly three years ago, when he was arrested for practicing medicine without a license, as well as other charges, including fraud. He was convicted of multiple counts of practicing medicine without a license, but the jury deadlocked on other charges, including the fraud charges. The prosecutor planned to retry him for the charges over which the jury had deadlocked, but ultimately a plea deal was struck in which Young did spend time in prison, had to admit in open court that he was not a microbiologist, hematologist, a medical or naturopathic doctor, or a trained scientist, and could no longer offer any sort of medical treatments at his ranch. (Basically, Young claimed to be a naturopath, but he had actually gotten his degree from a diploma mill.)
Since he got out of prison, I haven’t heard much about Young, and that’s good. It means that he hasn’t been practicing his quackery. Oddly enough, though, I also never heard about the lawsuit brought against him in late 2015 by a former patient of his, Dawn Kali. (Oh, well, I guess I can’t catch everything.) The suit specifically charged Young with holding himself out as a licensed medical doctor, advising Kali (who had been diagnosed with breast cancer) not to have her tumor removed or to undergo chemotherapy, and treating her with his “pH injections” and other alternative medical therapies. Her further claim was that this was all done under the cover of a doctor named Ben Johnson who “did not have a physician-patient relationship with Plaintiff, but negligently allowed Defendants Young and pH Miracle Living to use his name and license as a cover for their negligent, unlicensed, conduct.”
Here’s a news story from a couple of weeks ago, when the case went to trial:
From the story:
He [Young] is now defending his controversial therapies in civil court, where former patient Dawn Kali is suing him for fraud and other wrongdoing.
Kali told the jury she was diagnosed with breast cancer 10 years ago. She explained in detail how she rejected chemotherapy, radiation and other conventional Western cancer treatments and instead followed Young’s advice and alternative treatments.
Kali said her cancer continued to spread, despite Young’s reassurances that his treatments, if followed strictly, would cure her disease.
One of Kali’s attorneys, Bibi Fell, said her client now has stage four invasive breast cancer and has a life expectancy of about four years.
Kali’s lawyers are asking the jury to award their client more than $10 million in general and punitive damages.
To be sure, a ten year course without treatment is considerably longer than average for breast cancer. As I’ve discussed many times before, we know from historical data from Middlesex Hospital in the UK that the median survival for untreated breast cancer in the pre-mammography era was 2.7 years. However, breast cancer is a very heterogeneous disease, and biologically it can behave very differently in many women, and we also know from the same study that there is a “long tail” to the survival curve, with 3.6% of women with untreated breast cancer being alive at ten years. These days, we would expect the number to be larger, given that so many breast cancers are diagnosed by mammography and are thus much earlier in their progression than cancers diagnosed during the period 85-203 years ago covered by the study to which I’m referring. None of this means that Young actually helped her or that any of his methods are effective against cancer. There’s no evidence that they could be or that they are. It just means that Kali likely has a more indolent form of breast cancer.
You might notice that the lawsuit only asked for $10 million (although another site implied that $50 million was being sought). The verdict, however, included an award to the plaintiff much, much larger than that:
I’m not a lawyer, but whenever a jury awards a plaintiff a lot more money in judgment than was being requested, it’s usually to send a message. This can be because the plaintiff was particularly sympathetic and/or the defendant was particularly unsympathetic or clearly lying and/or the offense was particularly egregious.
I only have part of the trial transcript, but it’s Young’s testimony (PDF1 and PDF2). Predictably, he testified that Kali knew he wasn’t a medical doctor and that she was free to seek conventional cancer care any time, but a lot of his other testimony was pretty damning. We learn from him that “retreats” at his ranch were a minimum of seven days and could run up to $2,000 a day. Of course, she likely heard disingenuous responses like this one, which came in response to a question about whether or not Young had ever done “blood analysis” on Kali’s blood:
Well, for the benefit of those who are listening to this testimony, the live blood test is a test where you take a finger prick and you take that one drop of blood and you put that on a slide. Then using a compound microscope you look at those cells. And there are specific ways that those particular cells should look. So it’s not a quantitative test. It doesn’t give you a number, it gives you a view.
And since red blood cells are being changed at 5 million per second, that picture could evolve different ways over a period of 120 days, which is the life of a red blood cell.
So I would take a drop of blood, not for diagnostic purposes, but I would take a drop of blood, I would put that on a slide and allow the client to see the quality of their blood.
And based on millions of samples of blood that I have taken over 40 years, it is obvious to someone who has been trained in live and dry blood cell microscopy by one of the greatest scientists in the world – – Professor Murray Reicher from Essen, Germany — that when you are studying looking at blood, it’s not to diagnose any disease, but to allow that person to see the quality of the blood and to note changes in that blood if someone is doing lifestyle changes or diet changes. It’s been the nature of my research for 40 years.
“Live blood analysis” (as well as “dried blood analysis”) is utter quackery. It’s basically looking at blood and making things up about it. It’s not for nothing that Mark Crislip once referred to it as “the modern auguries.”
Now here’s the disingenuousness:
I looked at Dawn’s blood and what I said, I can’t remember. But I would have commented not quantitatively, but qualitatively. I would show her a picture of what a healthy red blood cell looks like — which is round and symmetrical, even in color, even in shape, even in size — and I would show her a picture of what unhealthy blood looks like, which is uneven in shape, uneven in its color, and its form.
After this he denied telling Kali whether he saw cancer cells in her blood, going on about how you can’t see cancer cells in blood analysis. He also claimed that he was just trying to help, that he never charged Kali anything, and that the pH Miracle Ranch paid for thermography, cancer marker tests, ultrasounds, and more. Then he kept being disingenuous during his questioning by the plaintiff’s attorney:
Q. Did you advise Dawn Kali not to get a biopsy of the lumps in her breast and armpit?
A. That was her decision. I never told her not to get a biopsy. Never.
Q. Did you ever recommend to her not to get a biopsy?
A. Never.
Q. Did you ever recommend to her not to get surgery?
A. Never. That was her decision in 2007, 2009, 2012, even when she went to the doctor in 2013. This is all Dawn Kali.
Q. Did you ever recommend to her not to get radiation?
A. That subject never came up. I never heard that word, “radiation,” coming out of her mouth.
Q. Did you ever recommend to her not to get chemotherapy?
A. Absolutely not. We had clients that were receiving chemotherapy, and we supported any client and their medical doctors.
Q. Did you ever recommend to any of your clients not to get a biopsy?
A. That’s beyond my belief system. You know — yes, you know, Hippocrates says, you know, do no harm, but the bottom line is the patient is in control of their decisions. It’s their decision, not my decision. Absolutely would I — would I not tell somebody not to do something, especially if they are getting advice from their medical doctor. It’s just — I can’t — I can’t oversee that. And that just goes beyond — beyond my belief system.
I wouldn’t believe Young about any of this, given his long history of writing how the treatment for cancer is not chemotherapy, radiation, or surgery, but correcting the patient’s pH, and I’m guessing the jury didn’t believe him either, given that he was led through some of his past quack claims in one of his books by the plaintiff’s attorney and reconfirmed his belief in all of them. For example:
Q. (As read): “Cancer is not a cell but an acidic liquid that spoils ourselves, whatever acids are not properly eliminated through urination, perspiration, respiration or defecation.”
Do you agree with that statement?
A. Yes.
Q. (As read): “Hence, all cancers are the expulsion of acids from the blood and then tissues at different points and are essentially of the same character and evolving from the one cause, namely, systematic acidosis.”
Do you agree with that?
A. Absolutely.
Q. (As read): “Breast cancer is the leading cause of death in women, and these fatty tissues, parenthesis, breast areas, are being used by the body to bind or collect the acids in order to protect the organs that sustain life?” Do you agree with that statement?
A. Yes.
Q. (As read): “If you don’t want cancer, if you want to prevent it, you have to pee or eliminate your acid through urination or perspiration. And if you are a cancer sufferer, you have to pee your way to health because cancer is not a cell but a poisoning acidic liquid.”
Do you agree with that?
A. A poisoning acidic liquid of the cells, yes.
Q. Of the cells? You mean in the cells?
A. No. Can I explain?
Q. You’ll have a chance when your lawyer —
A. I’ll explain later. Okay.
Q. (As read): “So cancer is a systematic acidic condition that settles in the weakest parts of the body, not a local problem that metastasizes. You see, metastases is localized acid that spoil other cells much like a rotten apple spoiling the bushel of other healthy apples.” Do you agree with that statement?
A. I do.
Q. (As read): “The cure, the prevention, the reversal for cancer is not found in the treatment of tissue but rather in maintaining the alkaline design of the human organism. And the most important test that you can do to determine whether you are in a state of over acidity is testing the pH of the fluids.”
Do you agree?
A. I agree.
Q. (As read): “So are tumors bad or good? They are good because they are the expression of the body in preservation mode trying to prevent healthy tissue from spoiling.”
Agree or disagree?
A. I agree.
This goes on for several pages of the transcript, during which Young repeatedly confirms his belief in cancer as reaction to cells “spoiled by acid”, his belief that bacteria don’t cause infections, and a number of other pseudoscientific beliefs. Worst among these is victim blaming, in which he agreed with statements from his book stating that:
    • “All cancerous tissue is curable, not all patients are. I’ll say it one more time. All cancerous tissue is preventable, reversible, curable, but not all patients are because they are not willing to do what it takes to bring their body in balance.”
    • “Cancerous tissue by any name is nothing more than a consequence of choice.”
    • “Someone doesn’t get breast or brain cancer. You have to work on it every day.”
It kept getting worse and worse. Young claimed that over 300 patients had come to his ranch with cancer and left without it, that he had a high success rate with stage IV metastatic cancer.
He also compared himself to Jesus.
The verdict, and why more victims of quacks should sue
Assuming that the plaintiff’s attorney did her job well (and she appears to have), Young’s testimony had to be disastrous, as he blathered on about how cancer is the body’s reaction to cells “spoiled by acid,” how viruses are “molecular acids,” how cancer can be cured with diet and “alkalinization” alone, and tried to evade questions. We also learn that, since he got out of prison has been doing some lectures, although he denies that he’s done any retreats. On the other hand, he sounded as though he planned on doing a retreat in Italy in 2019. I got the impression from his testimony that Young was definitely planning on taking his quackery overseas as soon as he can. I can’t help but wonder if that’s another part of the reason that the jury ruled as it did, for a total of $105 million.
Young and his attorney Conrad Joyner also, predictably, blasted the verdict:
“It’s totally outrageous,” Young said of the verdict when reached by phone Friday afternoon. “It’s one-tenth of a billion.”
He also said it was “appalling” that the jury awarded so much more than the plaintiff had sought.
And Joyner’s reaction:
Joyner said he sees the case as “ripe for appeal”:
“I have never heard of a jury case with that much damages where the jury comes back in about three hours,” Joyner said. “I wonder how much thought they really put into it.”
Young said there was “a tremendous amount of evidence” he was not allowed to present to the jury. He said he would appeal.
Of course he will.
I’ve discussed before how ineffective state medical boards are in reining in even utter quacks. It’s problem that’s frustrated me ever since I started paying attention to cancer quackery and other alternative medicine. Not infrequently, I’ve wondered why victims of cancer quacks (or their families, given that the victims usually die of their cancers before a lawsuit can be concluded) don’t sue the quacks who victimized them more often. I suspect that part of the reason is embarrassment on the part of the patient and family that the patient has been taken advantage of and believed the quack. On the other hand, people who have been financially defrauded for other reasons don’t seem to have this same reluctance to sue.
Whatever the reason, if there’s one thing I can say about this case is that it couldn’t have happened to a more appropriate guy. Robert O. Young was one of the first cancer quacks I took notice of back when I was first discovering how deep the rabbit hole of alternative medicine is. He’s been one of the most egregious, preaching the most blatantly pseudoscientific nonsense and charging huge sums for it. So you’ll pardon me if I’m feeling more than a bit of schadenfreude to see him not only having had to serve time in prison, but to be facing a judgment and selling his ranch, for which he’s asking $3.2 million.
More please. I want to see more victims sue their quacks. Maybe if state medical boards can’t stop them, civil lawsuits can. A guy can dream, can’t he?

A whole issue of JACM devoted to “integrative oncology” propaganda? Oh, goody.
Last week, The Journal of Alternative and Complementary Medicine published a Special Focus Issue on “integrative oncology.” In reality, it’s propaganda that promotes pseudoscience and the “integration” of quackery into oncology.
David Gorski on October 1, 2018
Link

As I’ve discussed on this blog more times than I can remember over the last decade, I’m not a fan of so-called “integrative medicine” because it involves “integrating” pseudoscience and quackery such as homeopathy and acupuncture with real, science-based medicine (SBM) and co-opting basically all dietary, lifestyle, and non-pharmacologic interventions as somehow being “alternative” and therefore “integrative” when in fact they are and always have been a part of SBM. (Particularly annoying is how integrative medicine advocates are also co-opting the opioid crisis to promote the coverage of quackery like acupuncture by insurers as part of the solution to the problem.) Because I’m a surgeon specializing in treating breast cancer, I particularly detest the bastard offspring of “integrative medicine” known as “integrative oncology,” to the point that I even managed to publish a peer-reviewed commentary in Nature Reviews Cancer explaining why, contrary to how proponents like the Society for Integrative Oncology (SIO) portray it, integrative oncology is far from being the “best of both worlds,” even as they have a hard time defining just what their specialty actually is.
So when I saw a press release drop in my email in box last week about a “Special Focus Issue” of one of the flagship journals for “complementary and alternative medicine” (CAM), “integrative medicine,” or whatever you want to call it these days, I took notice. The journal is The Journal of Alternative and Complementary Medicine (JACM), which is edited by our old “friend” John Weeks, you know, the guy who once compared me to Donald Trump, thus guaranteeing that we will never be friends. The issue is a Special Focus Issue on Integrative Oncology:
A series of fascinating and thought-provoking articles from North America, Europe, the Middle East, and Asia – 6 invited reviews, 13 original research articles, 7 commentaries, and 2 editorials – have been selected to appear in this Special Focus Issue by Guest Editors Moshe Frenkel, MD, University of Texas Medical Branch, Director of the Complementary and Integrative Medicine Unit at Meir Medical Center, Israel and Lynda Balneaves, PhD RN, President of the Society for Integrative Oncology and Associate Professor, Rady Faculty of Health Sciences, University of Manitoba, Canada.
Yes, it’s a lot to go through, 28 articles. Fortunately, I don’t have to go through it all, and if I decide after writing this that I didn’t cover as much of the issue as I think I should have, I can always do a followup post in a week or two and tie up any loose ends that might be left (and, given how much there is to read here, there will be loose ends). The issue will be available free online until October 24; so you can read it if you wish. Naturally, I’ll tend to gravitate towards articles involving my own specialty, but certainly not exclusively. I’ll also probably (mostly) ignore the “original research articles,” because I’m more interested in what advocates want to do with integrative oncology than I am in the usual dubious research used to support integrating quackery with medicine or co-opting diet or exercise as somehow “integrative.”
The editors
Before I discuss the content, I think it’s worth briefly discussing the editors. Most of our regular readers probably know who John Weeks is. He’s been a relentless activist for incorporating pseudoscience and quackery into medicine, first in the form of CAM or integrative medicine. He’s been mentioned or the main subject in quite a few posts here and at my not-so-super-secret other blog, such as the aforementioned time when he compared advocates of SBM, including Tim Caulfield, Steve Novella, and myself, to Donald Trump, leading Steve to note drily, “I wonder if it’s time to extend Godwin’s law to include gratuitous references to Trump.” (Of course, this was two years ago, a month before Trump was elected President; so with the benefit of hindsight I respond, “Hell, yes!”)
I first noticed Mr. Weeks as editor of The Integrator Blog, one of the most vociferous boosters of CAM or “integrative medicine” on the Internet. Mr. Weeks is not a scientist or physician—or even a practitioner of one of the alternative medicine “disciplines” whose “integration” into real medicine he favors; yet somehow he was appointed editor of JACM in 2016, despite having no relevant experience as an editor and writer that would qualify him to be the editor of an academic medical journal. He is, however, very good at propaganda and promotion, and that the JACM valued those skills over the skills of an actual scientist or academic physician to the point of hiring someone like Mr. Weeks as editor should tell you all you need to know about the academic rigor of the journal.
But what about Moshe Frenkel, MD? I haven’t really written about him here, although I did mention him briefly in a post about how it’s a myth that integrative oncology never recommends alternative treatments without conventional medicine. Let’s just say that Dr. Frenkel, who used to be the chief of the integrative oncology service at U.T-M.D. Anderson Cancer Center but is now back in private practice while still holding a clinical faculty appointment at the University of Texas Medical Branch at Galveston, with an additional affiliation with the Institute of Oncology Meir Medical Center, is a believer in homeopathy. Indeed, he once wrote an article entitled “Is There a Role for Homeopathy in Cancer Care? Questions and Challenges“, which was lovingly deconstructed by a friend of the blog. I first encountered him when he published a rather terrible study in which he tested homeopathic remedies against breast cancer cell lines and got a positive result, almost certainly because his methodology was so shoddy, as explained by both Rachel Dunlop and the aforementioned friend of the blog.
Then there’s Lynda Balneaves, PhD RN, Associate Professor, Rady Faculty of Health Sciences, University of Manitoba, Canada. We’ve met her before, too, specifically in her role as the current president of the SIO, as well as for her contribution to “integrative oncology” guidelines for breast cancer, trying (and failing) to define just what the heck “integrative oncology” actually is, and getting the American Society of Clinical Oncology (ASCO) to endorse SIO’s guidelines for breast cancer. I was particularly annoyed by her dismissal of “skeptics”:
I believe that there are certain people who are professional skeptics. That is the focus of their career. They have a vested interest in promoting that perspective. A lot of their criticisms, when you unpack them, are grounded in philosophical differences. From my experience in oncology, when I get those comments, their concern stems from an experience in which a patient was given bad advice and their therapy was not evidence-based. I respect that perspective. I have seen it myself.
However, these critiques sometimes may reflect ignorance about the current state of evidence that exists in integrative medicine. Many of the individuals who provide these critiques have no experience in integrative medicine research or practice. They have very limited knowledge of the therapies that exist and the evidence that supports them. Many of them have never worked with patients, particularly those with a cancer diagnosis who are looking for therapies that are going to preserve their hope, give them a sense of control, and perhaps manage some of the toxic side effects that many of our conventional therapies have.
Yes, basically she’s dismissing critics who don’t actually practice or research “integrative medicine”. Let me just say that, although we don’t practice integrative medicine here (mainly because we view much of it as quackery), all of us have extensive knowledge of the therapies that exist and the evidence that supports them (or, to put it more accurately, the lack of evidence that supports them). I personally work with cancer patients. That’s why I was profoundly offended by Balneaves’ ignorant dismissal of skeptics.
So, yes, we have true believers editing this Special Focus Issue.
The propaganda begins
The first article in the issue is, as is usually the case for Special Focus Issues like this, an introduction by the editors. In this case, the introduction is entitled “Integrative Oncology: An Essential Feature of High-Quality Cancer Care“. I laughed out loud when I read that title and couldn’t help but think in my head my usual riff on The Princess Bride: “High-quality cancer care. You keep using that term. I do not think it means what you think it means.” Especially if you think that adding pseudoscience to cancer care means “high quality.” One thing I did learn from this article is that there’s a new buzzword in town that appears to be the preferred term for describe CAM or “integrative medicine”, and it’s “complementary and integrative medicine”. Unfortunately the abbreviation for this term (CIM) doesn’t slip as nicely off the tongue as the abbreviation for one of the old terms (CAM, for complementary and alternative medicine). The term is also rather self-contradictory as well. After all “complementary” is supposed to mean “in addition to” and is a term that integrative medicine has been trying to get away from over the last couple of decades because it implies that what its practitioners are doing is not necessary but merely “complementary” to real medicine. That’s the entire reason why the term “integrative medicine” evolved in the first place!
In any event, after using the usual appeal to popularity fallacy to justify integrative oncology, Frenkel and Balneaves note:
As a result, integrative oncology has emerged as a scientific field that aims to address this interest through collaborative practice and rigorous research. Integrative oncology, as defined in a recent article, “is a patient-centered evidence-informed field of cancer care that utilizes mind and body practices, natural products, and/or lifestyle modifications from different traditions alongside conventional cancer treatments.11 Integrative oncology aims to optimize health, QOL, and clinical outcomes across the cancer care continuum and to empower people to prevent cancer and become active participants in their healthcare before, during, and beyond cancer treatment.”11 This field has grown rapidly in the past decade, and integrative oncology practice has emerged in North America, Europe, the Middle East, and Asia.5,12
As integrative oncology has developed as a clinical specialty, so too has research on the efficacy and safety of CIM therapies in cancer care. In the past decade, researchers and clinicians at numerous academic centers worldwide have examined the potential supportive role of integrative oncology in symptom management and enhancing the QOL of cancer patients and their families.13–15 In addition, recent studies suggest that CIM integration might have direct effect on survival.16,17 Research in integrative oncology has now reached the point that clinical guidelines focusing on the role of integrative practices are being developed and endorsed by leading oncology organizations, including the American Society of Clinical Oncology and the Society for Integrative Oncology.18
That last part, unfortunately, is true. However, this is the first time I’ve heard it claimed by advocates of integrative oncology that “CIM” might have a direct effect on survival; so I looked up references #16 and #17. Then my memory returned. This is nothing more than the usual rebranding of exercise, nutrition, and other lifestyle changes as being “integrative”. The references list a bunch of studies regarding diet, exercise, and survival, some of which didn’t appear to control for obvious confounders. The authors of one paper were entirely too credulous towards the evidence regarding psychsocial and “mind-body” interventions in breast cancer, apparently not examining the evidence as skeptically as our occasional guest contributor Jim Coyne did. In any event, the finding that better nutrition and exercise can improve survival in some cancers is neither novel nor particularly surprising.
Teaching integrative oncology
Not surprisingly, there is a lot of emphasis on “teaching” integrative oncology, or, as I look at it, proselytizing. For instance, there’s an article by Claudia Witt, whom we’ve met before. As Mark Crislip pointed out, she’s a believer in homeopathy and has published multiple articles on it, including one on homeopathy for back pain. Amusingly, she was the lead author on an SIO-commissioned article developing a definition for integrative oncology. The article is, of course, about training oncology physicians to advise their patients on complementary and integrative medicine. Of course, I’m all for such training, but my idea of what would constitute good training in this skill is very different from what integrative oncology advocates would think of as good training.
Suzanna Zick, on the other hand, the naturopath who, much to my shame, runs the integrative medicine program for the Department of Family Medicine at my alma mater, the University of Michigan, where credulous grand rounds on homeopathy are now a feature, has just the thing: her Integrative Oncology Scholars Program, which she touts as a “model for integrative oncology education.” The goal of the program is:
It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Eligible participants, who are designated as IOS, include a multidisciplinary selection of physicians, physician assistants, nurses, psychologists, social workers, physical or occupational therapists, and pharmacists, who are actively engaged in clinical oncology practice. IOS instructors are experts in the field of IO and/or adult education and reflect the multidisciplinary nature of the program with professions as diverse as patient advocates to oncology clinicians. Details on course instructors, program eligibility, and how to apply are available on the IOS Program website.
All I can say is that if the curriculum of this program is anything like the eLearning program in acupuncture offered by Zick’s department, it’s going to be a load of credulous nonsense. I do agree, though, with Mark Crislip, who in his usual sarcastic fashion observed, in essence, that if you want someone to teach prescientific mysticism and medicine, you couldn’t do better than a naturopath, and this program just started in August with its first 25 trainees.
Attacking criticism
Next up, John Weeks can’t resist contributing an article, “Expanding the Circle for the Care of People with Cancer“. In it, he takes some verbiage to settle a score regarding a study published in July by Skyler Johnson and his colleagues showing that CAM, CIM, or “integrative medicine” use was associated with poorer survival in several cancers. Mr. Weeks is not at all happy about it, not at all:
In the closing days of making selections among the outpouring of nearly 70 article submissions, a research-inspired story hit the mainstream media with a force that underscored just why this continued bridge building and circle expansion are needed. Picture yourself as an individual in the throes of fear amid a new cancer diagnosis. You pick up the New York Times and read this headline: “People who used herbs, acupuncture and other complementary treatments tended to die earlier than those who didn’t.” The message, broadcast through many of the world’s most powerful media channels, was quickly challenged by leading integrative oncologists as a major misclassification error. The differences in lifespan found were all due to patients delaying or refusing recommended care—thus choosing “alternatives” to treatment rather than “complementary” care that would be part of an integrative oncology strategy.6 Yet, there it was for anyone considering their choices: research from a respected medical school, Yale, in a pre-eminent journal, JAMA Oncology, misleading patients who, quite likely, received little or no guidance on integrative practices from the narrow healthcare team at the institution where they are receiving their powerful and damaging cancer treatments.
This misclassification was symptom, not cause. Consider a group of male academics setting a curriculum in women’s studies, or of white people deciding how to involve people of color. The cause is the failure of the authors and the journal editors to have Thibault on their shoulder, urging them to expand their circle of collaboration. They did not need to look far to expand their circle and bring in an expert who knew something about the field on which they were passing a sort of life and death judgment. The American Society for Clinical Oncology has endorsed breast cancer guidelines from the SIO.7 The Journal of the National Cancer Institute partnered with SIO on an entire special issue.8 At the time of the Yale study, the late integrative oncologist Ather Ali, ND, MPH, was head of an integrative oncology program at a Yale teaching center for cancer treatment.
First off, Mr. Weeks points to Yale having a naturopath as the head of integrative oncology as though it were a good thing. It’s not, and I’m sure the fact that Yale had a naturopath running anything at Yale came close to giving our fearless leader Steve Novella a stroke. Naturopathy is quackery. We’ve written more articles and spilled more digital ink into the ether explaining why than there is room to recount here. It’s sad that Ali died at such a young age, but I wasn’t happy that he had a faculty appointment at Yale.
Ah, yes. Mr. Weeks does love his “no true Scotsman” fallacy. “No, no, no, it’s not us, the “respectable” ones advocating the integration of quackery into oncology”, Weeks seems to be saying. “We’d never do that.” Of course, the news stories I saw were careful to point out that this was an association, and Johnson and his coauthors themselves specifically chose patients who had used at least one conventional modality as part of their cancer treatment. They also did point out that the decreased survival observed appeared to be due to a higher tendency among those using CIM (I’ll give in and use the term Weeks likes to use, at least for this one post) to refuse at least one form of conventional therapy. I also pointed out that a common claim among “integrative oncology” advocates is that their addition of woo to the mix helps patients stay the course and make it through their treatments. As I said at the time, at the very least, the result of Johnson et al suggest that when the SIO or other CIM advocates claim that CIM is worthwhile because it keeps these patients undergoing conventional therapy, they’re either full of it or at the very least way, way, way overstating the case, and this bit of data further suggests that, even if integrative oncology does keep patients wanting “natural” therapies in the fold of SBM, it’s not doing a very good job of it. I was also amused by Weeks’ arrogance in claiming that, if only Johnson et al had consulted an integrative oncology expert, they could have avoided “embarrassing” themselves so.
But fear not. According to Mr. Weeks, integrative oncology shall overcome. He even invokes a name that quacks and pseudoscientists love to invoke when predicting that their beliefs will be vindicated, Thomas Kuhn and his book The Structure of Scientific Revolution, paraphrasing Kuhn and saying that “we see the most resistant behavior just before a paradigm shift occurs.” Maybe. Personally, I wish we saw more resistance to the creeping infiltration of quackery into oncology and medicine; from my perspective there hasn’t been nearly enough resistance, and resistance is declining, not increasing.
Exceptional responders and integrative oncology
If you want to get an idea, though, of the propaganda and how far it goes in this issue, you should check out Glenn Sabin’s contribution, “Exceptional Responders, Outliers, and Radical Remissions“. Oncologists use the term “exceptional responder” to describe a cancer patient whose response to therapy is, well, exceptional. That can range from complete remission where none is expected to a much better than expected response. The formal definition of an exceptional responder according to the National Cancer Institute is a patient with cancer who has:
    • a complete response to a drug(s) where complete response is seen in less than 10% of patients receiving similar treatment; or
    • a partial response lasting at least 6 months where such a response is seen in less than 10% of patients receiving similar treatment; or
    • a complete or partial response that lasts longer than 3 times the median response duration in the literature for the treatment
Exceptional responders are a hot research topic in precision medicine initiatives, because scientists now believe they have the tools to start to figure out why some people respond so much better to certain drugs and use that information to try to improve our treatments. Glenn Sabin, you might remember, is a man who believes he cured himself of chronic lymphocytic leukemia (CLL) using only alternative medicine and lifestyle interventions and now advocates “N-of-1” trials of alternative medicine. As I’ve explained in great detail elsewhere, the quackery almost certainly wasn’t what resulted in his good fortune. It’s far more likely that he underwent a spontaneous remission, which, albeit rare in CLL, is not so rare as to be less likely than all the quackery Sabin used having cured him, especially since Sabin suffered from his disease for 20 years before it resolved. In any event, he argues thusly:
Researcher Kelly A. Turner, PhD, based her doctoral thesis4 on so-called spontaneous remission. Turner conducted interviews with scores of cancer patients and healers from around the world for her book Radical Remission.5 Through the book’s website, Turner and her team have captured hundreds of outlier cancer cases. It is this author’s opinion that many of these remarkable patient narratives should be vetted and certified as exceptional responders. A subset of these cases should be developed into high-quality, peer-reviewed, published, and indexed case reports. The most remarkable of these cases should consider enrolling into the NEER trial and future trials that are sure to follow.
Integrative oncology delivered in academic settings has heretofore focused on supportive cancer care—utilizing lifestyle-based therapies, along with complementary interventions and agents—to mitigate the often-deleterious side effects of conventional care. There is a growing evidence base suggesting that these interventions and adherence to long-term positive behavior change may potentiate standard care, extend periods of disease-free survival, and possibly prolong overall survival.3 However, the academic integrative oncology field has heretofore not done enough to investigate and document exceptional responder cases. The author believes that this is a significant missed opportunity.
Only once investigators are curious enough to comprehensively investigate exceptional responders will they begin to understand how this may inform the evolution of precision medicine and the role of integrative oncology therein.
I’m all for studying exceptional responders, but Sabin seems to think that the various forms of quackery he espouses are part of the answer that explain why these patients were so fortunate and why their cancers regressed or didn’t progress, when it’s incredibly unlikely that the sorts of pseudoscientific treatments that Sabin believes to be effective had anything to do with it.
Show me the money
Finally, if there’s one thing that rankles “integrative medicine” practitioners, it’s that many of their services, such as they are, are not covered by government health plans like Medicare or Medicaid or by private insurance. (Insurance plan administrators are funny that way. They don’t like to pay for treatments that don’t work. Hell, they don’t like to pay for treatments that do work if they deem them too expensive.) Indeed, it’s long been a goal of various supporters of integrating quackery to get the quackery paid for, such as the manner in which advocates are on the verge of duping Oregon into paying for acupuncture treatments under the false pretense that it will decrease opioid use and, more importantly, abuse. This brings us to an article by Patricia Herman, “The Problematic Economics of Integrative Oncology“.
In this article, I found a frighteningly passage:
What can be done to improve the economics of integrative oncology?
There are several steps that can be taken to improve the economic impacts of integrative oncology, which will increase patient access and lower financial toxicity for patients. The first is a fairly simple step available to all integrative oncology practitioners: determine the cost of your care to patients. These data can be captured from clinical records even in the absence of a formal study, and these costs can be substantial. A recent article by Standish et al.24 reports on data collected from the medical records of (n = 324) breast cancer patients at six clinics directed by oncology board-certified naturopathic doctors in Washington State. Costs were estimated to be $1,594 per year for early stage breast cancer and $6,200 per year for stage 4 breast cancer patients. Across all patients in their study, 21% of these integrative oncology costs were out-of-pocket. Note that this percentage would be higher nationally because in Washington State coverage is available for every category of provider, including naturopathic physicians. Understanding these costs is important for improving costs to patients.
So in the state of Washington we have breast cancer patients paying up to $6,200 a year for snake oil, fairy dust, and quackery, all under the imprimatur of the state’s licensing board and its apparent law mandating insurance coverage for naturopaths. Of course, it would help a lot more if there were actual…oh, you know…evidence of efficacy. Herman recommends including a cost analysis in any randomized clinical trial of integrative medicine modalities undertaken, which is all well and good, but there’s no good scientific reason to do a lot of those studies in the first place given the extreme implausibility of many “CIM” modalities. In the end, she concludes:
The economics of integrative oncology are problematic because of the lack of good studies, the lack of historic incentives for efficiency, and the high cost of cancer care and its financial toxicity on patients. However, these problems can be overcome, with help from one good economic evaluation at a time.
Personally, my retort would be to forget about the economic analyses and just show your woo works first! In the meantime, stop integrating quackery into oncology.
There are so many more articles in this Special Focus Issue that I might have to revisit it before October 24, so that readers can check out the source material if they want to. In the meantime, know that this issue is advertising and propaganda, not science.

Dana-Farber Cancer Center’s Integrative Medicine Expansion
Clay Jones on August 12, 2016
Link


In June, an article in the Boston Globe covered yet another incursion of pseudoscience into a major academic medical center, this time at the Dana-Farber Cancer Institute. Dana-Farber, located just a couple of miles from the library where I’m writing this post, has provided world-class care for children and adults with cancer since 1947. It’s kind of a big deal.
Sidney Farber, already known as the “father” of pediatric pathology, was the first person to induce remission in pediatric acute lymphoblastic leukemia, which had a 100% mortality rate up to that point. He then went on to earn the title of “father” of modern chemotherapy by also curing Wilm’s tumor, a rare pediatric cancer of the kidneys. Farber, who was featured in the phenomenal book The Emperor of All Maladies: A Biography of Cancer by Siddhartha Mukherjee, would almost certainly be opposed the double standard being employed to justify quackery in the facility bearing his name (or anywhere else).
To Farber, a scientific approach to treating pediatric cancer patients was paramount, even to the point where he at first refused to initiate the combination therapy that would open the age of modern chemotherapy because he wanted to protect children from a potentially haphazard rush to cure them. He wanted strict scientific protocols in place and assurances that the evidence would be followed regardless of the outcome, so that the intense desire to find a cure for children that otherwise faced only suffering and death would not add to that suffering.
Unfortunately, combining science-based medical care with medical fantasy is hardly new at Dana-Farber. The Leonard P. Zakim Center for Integrative Therapies has been doing this since the fall of 2000. Using marketing clichés such as “providing cancer patients and their families with the opportunity to take a more active role in their care,” the Zakim Center has increased the number of patients seen yearly from 778 in its first year to 4,000 in 2008.
In 2015, 3,000 patients received acupuncture or massage alone, with many more taking advantage of other services, such as art, music, meditation, nutrition, and various forms of exercise. In addition to the list of interventions that have been co-opted by and relabeled as alternative, pure quackery like reiki, reflexology, and the aforementioned acupuncture are also available for patients. The Zakim Center was also a founding member of the Society of Integrative Oncology. If you aren’t convinced that Dana-Farber has sold its soul and placed marketing over ethical patient care, here is a recent post from their Insight blog entitled “How Can Reflexology Help Cancer Patients?”
Another meaningless anecdote
The recent Boston Globe article, entitled “Easing a patient’s pain – even without proof it works”, discusses Dana-Farber’s $2 million “integrative therapies” expansion that will allow twice as many outpatient appointments for Zakim Center services. But not before providing the typical opening anecdote to hook the reader and prep their brain to ignore the lack of actual evidence, because kids with cancer = emotions:
Massage therapist Maria Barbara “Bambi” Mathay roamed the pediatric clinic at Dana-Farber Cancer Institute, looking for takers. It wasn’t long before she spotted Carlie Gonzalez, 15, wrapped in a yellow blanket and weary from seven months of chemotherapy.
The image of a predator stalking its prey, or a carnival barker attempting to entice passersby, comes to mind while reading that. These patients are, in a very real sense, vulnerable to predation and misinformation. But maybe that isn’t fair. I believe that Mathay believes that what she is doing is helpful, that it helps to relieve some of the intense pain and nausea children with cancer sometimes experience. But does it matter what she believes? It would be one thing if she were simply giving relaxing massages, but…
As the liquid dripped into her arm, Carlie rolled up a pant leg for a session of foot reflexology. “It kind of takes your mind off your stomach,” she said. While Mathay gently pressed on her toes, Carlie sleepily closed her eyes.
So rather than simply a calming foot rub and some pleasant conversation with a caring individual, which would be just fine, the patient is subjected to quackery and is being used as part of the propaganda that helps it spread. She even admits that the process simply distracts her from her nausea. Distraction is a well-known phenomenon that science-based healthcare professionals employ daily in the care of ill patients.
Distraction, or rather altering the attentional state via passive or active methods, has been established as effective in modulating response to both acute and chronic subjective symptoms, particularly pain, in a variety of circumstances that don’t require deception. We know that active distraction is usually more effective than having a patient simply watch TV or listen to music, for example. So you could argue that this patient would have been better off with an electronic game to play. Better yet, Dana-Farber could use the $2 million to hire more Child Life practitioners who can assess each patient individually to find what mode of distraction would best suit their personality and abilities. This would be a lot more holistic than a foot massaging unitasker.
This anecdote, as sweet as it is, is just another example of two very common problems we regularly encounter. On one hand, stories like this are part of a bait-and-switch tactic commonly used by proponents of integrating unproven and implausible interventions with conventional medical care. To the uninitiated this probably seems like a good thing. Reflexology may just be a fancy name for a good old fashioned foot rub after all. It isn’t until almost the end of the article, after most readers will have moved on to something else, that the author provides a brief and inaccurate explanation: “Practitioners believe that pressing spots on the foot that correspond to organs, glands, and other parts of the body can promote deeper relaxation.” That may be the sanitized version Dana-Farber promotes, but it isn’t what reflexology proponents in the real world (or even other academic institutions) are claiming.
The other problem is the utter cluelessness that the media tends to demonstrate when it comes to pseudoscience in medicine. The author of this Globe article, Liz Kowalczyk, is a healthcare and medicine journalist and was a finalist for the Pulitzer in 2013 but she has offered up to the public a pile of credulous tripe. It contains an iota of token skepticism sandwiched between two emotional anecdotes and a barrage of pro-quackery clichés. Why not include one of the many easily-available cases where a child was directly or indirectly harmed by unproven therapies? Why not avoid worthless anecdotes altogether and do your job as a journalist? If Kowalczyk can’t get this stuff right, what chance does the public have to find accurate information?
They don’t need no stinkin’ evidence!
The article continues with a seemingly endless stream of fallacies and blatant misinformation:
A growing body of research supports acupuncture as a treatment for pain and nausea in oncology patients, but few high-quality studies exist on the effectiveness of reflexology and reiki.
It is true that the body of acupuncture research continues to grow, however this is a very poor synopsis of it. As regular readers of Science-Based Medicine know, the most accurate interpretation of the acupuncture literature, and one that takes into account basic science, prior plausibility, and the use of effective controls, is that acupuncture doesn’t work for any condition in any patient. It is theatrical placebo that evokes greater expectation of benefit, and thus greater subjective response, when the practitioner puts on a better performance. The imprimatur of one of the most highly-respected cancer centers in the world certainly adds to the impression of legitimacy and thus likely increases any expectation of benefit.
It’s also true that few high-quality studies have looked into reflexology and reiki. Dana-Farber offers them anyway though. The statement is misleading however, in that we already know enough to say with confidence that these nonsense therapies offer no objective and specific benefit, at best eliciting only subjective placebo responses similar to that of acupuncture or playing with a therapy dog. The dog at least exists, as opposed to mystical human energy fields or an undetectable connection between your foot and your spleen.
Then there is the best sentence in the entire article:
The investment by Dana-Farber, a leading cancer treatment center, underscores a growing willingness among mainstream medical institutions nationally to offer complementary therapies that appear to help patients — even without definitive proof.
There it is, right there in all its glory. The author lumps everything together into the category of “complementary therapies,” another common mistake made by reporters who don’t understand the topic they are covering and often a calculated strategy used by proponents looking to get their foot in the door with co-opted science-based therapies like exercise and relaxation. Exercise doesn’t just “appear to help patients.” We know it does based on decades of high quality research. Acupuncture and its ilk have only the appearance to efficacy and these mainstream medical institutions have an ethical duty to be honest with patients. When a Dana-Farber physician recommends reflexology because it seems to work, without explaining the lack of plausibility and supporting evidence, they are violating that patient’s autonomy, or parent’s authority, to make medical decisions based on accurate information.
Why are academic medical centers opening promoting quackery?
Why would a major academic cancer center offer therapies, like acupuncture and reiki, without solid proof of benefit? Why would they risk taking a hit to their credibility? While I don’t know what is in the hearts of hospital administrators with certainty, it is very likely the result of a combination of marketing aspirations and the work of a vocal minority of believers with money and influence. But those influences needed fertile ground to take root.
As we have discussed before numerous times, the vast majority of physicians working at these centers know that reflexology and reiki are baloney but just aren’t interested in this issue. They have patients to treat and cancer to cure, which are admirable endeavors. With the addition of these integrative medicine centers, they still have research to do and cancer patients to treat, some of which may now be more likely to take part in risky alternative therapies or to forego conventional treatment altogether. These huge numbers of physicians and other healthcare professionals that are uninterested in quackery infiltrating their institutions deserve the lion’s share of the blame for it.
Clearly there are physicians that believe in these interventions. The Globe article quotes Dr. Jennifer Ligibel, who is the director of the Zakim Center and a breast cancer specialist. I would love to eavesdrop on a conversation between her and David Gorski at the next ASCO conference. Ligibel provides a few examples of sloppy thinking and bogus rationalizations used by proponents of irregular medicine:
“Our cancer treatments have gotten better and patients are living longer than ever after diagnosis,” said Dr. Jennifer Ligibel, director of the Leonard P. Zakim Center for Integrative Therapies and a breast oncologist. “The flip side is our therapies have a lot of side effects. And traditional Western ways of trying to treat these side effects are pretty limited.”
Yes, science has helped many people avoid certain death from a cancer diagnosis and to live longer than doctors a generation or two removed would have dreamed possible, so let’s try something else? Of course science-based therapy has side effects. If it can alter physiology of the human body, it can alter the physiology of the human body, regardless of the intervention’s origins. In addition to demonstrating her bias and cultural ignorance by labeling science-based care as “Western,” she begs the very large question that alternative approaches are an improvement. If they were, the science would show it and we wouldn’t be having this discussion.
Many patients also are burdened with depression, and anxiety that the cancer will return.
This is undoubtedly true…so reiki? Perhaps providing your patients with counseling rather than nonsense would be a more effective intervention.
Ligibel said Dana-Farber will study different therapies and approaches — including whether 15-minute sessions during chemotherapy improve patients’ quality of life — in part to help guide other providers. “Without research it’s hard to know where resources should be devoted,” she said.
The OAM NCCAM NCCIH has spent billions of dollars of taxpayer money investigating alternative medicine and has failed to provide high quality evidence that any of it works. And the studies they’ve funded showing it doesn’t are consistently ignored. There are already thousands of poorly-designed and controlled studies with positive results for believers to cling too, so what possible benefit could come from a few more? Sadly this comes across as just a transparent justification. In reality, we already have research and the basic science knowledge enough to confidently divert resources away from such medical misadventures.
Speaking of transparent justifications:
Ligibel said more research is needed to sort this out. “I struggle with the mechanism of a lot of these therapies, but I’ve seen them work for people,” she said.
And:
Lorenzo Cohen, director of integrative medicine at MD Anderson said doctors don’t understand the biological mechanisms of these therapies, which is why there is debate. Still, he said, the risk of harm is nearly nonexistent, and if patients feel better “there is something to be said about that.”
There is debate because these therapies are blatant pseudoscience. And I wouldn’t exactly call it a debate. The existence of integrative medicine centers and believers within the medical profession doesn’t mean that there are two legitimate sides to this issue any more than the existence of the Discovery Institute means that there is a debate between evolutionary biologists and…irreducible complexionists?
We don’t understand the biological mechanism of acetaminophen, but we have clear evidence it reduces fever and has analgesic properties. We don’t understand the biological mechanism of IVIG in the treatment of Kawasaki disease, but it’s malpractice if you don’t give it because there is clear evidence that it substantially reduces the risk of serious injury to the coronary arteries. It doesn’t seem that they are “struggling with the mechanism of these therapies” as much as they are struggling to find something, anything to justify their use in the face of so much negative evidence and that they have already decided that these therapies are effective based on anecdotal experiences.
Conclusion: Fighting quackery in hospitals is hard
It’s 2016 and we continue to see quackery being integrated into our best academic centers, which I assume can now generate electricity from the spinning of the many medical pioneers who made them great centers of science and medical progress. Dana-Farber certainly won’t be the last to announce expansions such as the one written about in the featured Boston Globe article. Even Children’s Hospital of Philadelphia, home of Paul Offit, has caved and began offering acupuncture to children last month. It doesn’t look good for those of us struggling to push back.
I’m frequently at a loss when trying to come up with something positive to include in the conclusions to posts like this. Yes we should fight the good fight. We should try to reach out to others who are on the fence or who are skeptical and looking for like-minded folks and science-based information. Of course we should support organizations such as the Society for Science-Based Medicine and reach out to our government leaders. We should vote with our feet, when possible, and not support organizations that promote quackery with our business.
We should do all of these things as much as possible. Still, it is difficult to avoid a sense of helplessness. I am forced to focus on little accomplishments, such as when I discuss a concept such as this or one of the many we cover on SBM with a student and they get it. Every now and then one of them doesn’t just get it, but they are excited about it and they want to learn more. Maybe one day I’ll set someone on a path of skepticism that will result in meaningful change somewhere down the line. Sure it’s unlikely, but it’s a nice thought, and certainly a better one than what I’ve written about with the previous 2,600 or so words of this post.

The Integrative Oncology Scholars Program: Indoctrinating the next generation of “integrative oncology” believers
“Integrative oncology” involves “integrating” pseudoscience, mysticism, and quackery with science-based oncology and co-opting science-based lifestyle modalities as “alternative” in order to provide cover for the quackery. Unfortunately, my alma mater, funded by the National Cancer Institute, is running a course to indoctrinate 100 health care professionals in the ways of “integrative oncology.” The Trojan horse of “lifestyle interventions” and “nonpharmacologic treatments for pain” is at the gates. The quackery will leap out as soon as it’s in the fortress.
David Gorski on October 22, 2018
Link

Three weeks ago, I wrote about a whole “Special Focus” issue of the flagship journal for integrating quackery into medicine, the Journal of Alternative and Complementary Medicine (JACM). The issue was devoted to “integrative oncology,” which I view as being devoted to “integrating” mysticism, quackery, and pseudoscience into the clinical care of cancer patients while co-opting diet, exercise, and lifestyle interventions as somehow being “integrative” or “alternative” rather than part of conventional medicine, the better to provide cover for quackery like traditional Chinese medicine, energy medicine, and the like. Because the Special Focus issue was going to be available for free until October 24, I had planned on writing a follow-up post, but somehow (as is often the case) other topics intervened. Then, over the weekend, our very own Jann Bellamy sent me a PubMed link to an article from that issue touting something called the “Integrative Oncology Scholars Program”. I had mentioned that article in my previous loving deconstruction of the JACM integrative oncology Special Focus issue, but Jann’s email jolted me, making me realize that I really should have written more about this particular aspect, particularly given that it’s being spearheaded by my alma mater, both undergraduate and medical, the University of Michigan. In other words, it’s the perfect topic to discuss in more detail as a follow up to my previous post, and it’s still available for two more days to read for free online.
The article is, as is often the case for articles like this, credited to many authors, but the first (and corresponding) author is Suzanna Zick, a naturopath who is in charge of the Integrative Family Medicine program in the Department of Family Medicine at the University of Michigan, where she’s been teaching what I consider to be misinformation and retconned history about traditional Chinese medicine and hosting homeopaths for Family Medicine Grand Rounds, all while publishing dodgy acupressure papers. I also note that the Integrative Family Medicine program at U. of M. purports to provide “advanced training in holistic medicine, anthroposophic medicine, and acupuncture”. Anthroposophic medicine, as you might recall, was first invented by Rudolf Steiner, and it is loaded with mystical nonsense. Yet my alma mater has a program in it.
How did a naturopath find a faculty position in the family medicine department of what has traditionally been a bastion of science-based medicine? I have no idea, but it’s been a source of continual embarrassment to me ever since I discovered it. After all, U. of M. is my alma mater, and I still collaborated with U. of M. faculty as recently as 2017. It also doesn’t help that Zick is a player in the Society for Integrative Oncology (SIO), having been president of the organization a couple of years ago and having had integral (if you’ll excuse the term) involvement in drafting the SIO’s dubious guidelines for the integrative oncological care of breast cancer patients, an updated version of which, alas, was recently endorsed by the American Society of Clinical Oncology (ASCO).
So let’s take a look at what Zick et al have written, “Integrative Oncology Scholars Program: A Model for Integrative Oncology Education“.
The Integrative Oncology Scholars Program: Framing the frame
Basically, the Integrative Oncology Scholars Program is all about increasing the number of oncology professionals who buy into integrative oncology. (Note that I will quote fairly liberally, because after October 24, this article will go behind a paywall.) It all begins, as is usual for articles promoting “integrative medicine”, with framing integrative medicine as very, very popular, and therefore:
Despite this high level of use, communication about complementary and integrative medicine (CIM) use between oncology providers and patients is not ideal. Over half of oncology providers do not ask about CIM use3,4 and indicate the main reasons being a lack of knowledge about CIM approaches and not knowing what to do with the information once collected.3,5,6 This lack of communication can leave patients and their families with many unanswered questions, can result in negative (e.g., herb–drug) interactions and toxicities,7,8 and may prevent patients and survivors from receiving treatments that could help reduce cancer treatment side-effects and improve quality of life.9 Also, while the majority of CIM treatments are being delivered in the community by complementary providers, few oncology professionals and complementary providers communicate or are aware of the others’ practice. Oncology professionals rarely refer patients to complementary providers, with oncologists only referring for more information about complementary therapies 16% of the time, and nurses and social workers 13% and 36% of the time, respectively.4,10 One possible solution to the unsatisfactory interaction around CIM for both patients and providers (conventional and complementary) is education.
Of course, I’m all for education, as long as it’s based on science rather than promotion. Oncology professionals—heck, all physicians, nurses, physicians assistants, and anyone who gives medical advice to patients for a living—should have a working knowledge of “complementary and alternative medicine” (CAM) or “integrative medicine”. There’s the rub, though. I insist upon science-based education, which demonstrates that the vast majority of CAM doesn’t work and that which does work, such as exercise, science-based dietary modifications, and the like, is almost always already part of conventional medicine. (Low carb diet and weight loss as initial interventions for type II diabetes, anyone?)
It’s all about demand, though; that is, if you believe Zick et al. She and her co-authors are only doing this in response to overwhelming provider demand:
Oncology providers have expressed a desire to be more informed and to receive more education about oncology-specific CIM.6,11 Until recently, however, no oncology-specific CIM training has been available and the majority of educational opportunities have been designed for physicians (e.g., in the form of fellowships), despite the multidisciplinary and growing professional diversity of oncology teams.12 In response to this educational gap, we have designed the Integrative Oncology Scholars (IOS) Program.
See? We perceived a huge need for this education in “complementary and integrative medicine” (CIM). (I wish advocates of CAM, CIM, or whatever would make up their mind on what acronym they want to use.) So what will this program consist of?
The Integrative Oncology Scholars Program: The course
Now that the authors have established the desperate “need” for this education on integrating nonsense into oncology, how do they propose to provide for this need? The answer is simple. The authors have devised a program with the following goals:
The IOS Program is funded by a National Cancer Institute R25 grant. It has the joint goals of training 100 integrative oncology (IO) leaders over 4 years and facilitating partnerships between IO leaders and complementary practitioners within their communities. Eligible participants, who are designated as IOS, include a multidisciplinary selection of physicians, physician assistants, nurses, psychologists, social workers, physical or occupational therapists, and pharmacists, who are actively engaged in clinical oncology practice. IOS instructors are experts in the field of IO and/or adult education and reflect the multidisciplinary nature of the program with professions as diverse as patient advocates to oncology clinicians. Details on course instructors, program eligibility, and how to apply are available on the IOS Program website.*
An R25 grant from the NIH is, basically, an education grant whose purpose is “to support research education activities that: (a) Complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (b) Enhance the diversity of the biomedical, behavioral and clinical research workforce; (c) Help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; or (d) Foster a better understanding of biomedical, behavioral and clinical research and its implications.”
This particular R25 grant (R25 CA203651), entitled A short course for creating integrative oncology leaders, is, surprisingly, not a grant issued by the National Center for Complementary and Integrative Health (NCCIH), but rather from the National Cancer Institute. Not surprisingly, Suzanna Zick is the principal investigator. It’s not a huge grant, but it’s a decent chunk of change ($220,155 to $237,612 per year thus far). Its specific aims include:
     1.  Develop an interdisciplinary short-course in evidenced-based integrative oncology;
     2.  Train 100 integrative oncology leaders (25 participants per course x 4 courses = 100) via the short-course developed in aim #1;
     3.  Create partnerships between oncology leaders and complementary practitioners (who provide the majority of complementary oncology services) within their communities (~25 community-based complementary partners per year {one per oncology leader} for a total of 100 over 4 years)
     4.  Evaluate the impact of this short-course by measuring the process and the outcomes of the various educational activities over the course, and measuring the implementation and outcomes of the capstone projects initiated by participants at their home institutions after completion of the program;
     5.  Disseminate the findings through peer-reviewed journals, presentations at professional meetings, and through both conventional and integrative oncology networks and associations.
So, basically, the NCI has spent nearly a half million dollars (thus far) to support this educational endeavor in two years, with three more years to go in the grant. One might ask: Why wasn’t NCCIH involved? As I’ve mentioned before, unfortunately the NCI has a very large CAM program; indeed its yearly budget is nearly as large as that of the NCCIH. The program is called the Office of Cancer Complementary and Alternative Medicine, which has one of the most cringe-inducing (in context) acronyms ever: OCCAM. A decade ago, I once spoke with a representative of OCCAM at the American Association for Cancer Research (AACR) meeting, and his blather about “emperor” and “assistant” herbs was every bit as cringe inducing as the OCCAM acronym.
So basically, the Integrative Oncology Scholars Program involves two parts. First, there is an online eLearning component implemented using a Canvas website designed by Instructure, Inc., in Salt Lake City. Second, there are three in-person sessions at—groan!—the University of Michigan. You’ll just have to excuse me if I remain…skeptical…about the eLearning modules, given that an evaluation of the U. of M. Department of Family Medicine eLearning module on acupuncture shows that it teaches acupuncture and traditional Chinese medicine (TCM) with great credulity and totally buys into the retconned version of TCM originally promoted by Chairman Mao.
The article by Zick et al actually isn’t that detailed regarding the curriculum. It does list the components of what will be taught in the three in-person sessions at U. of M. Predictably, there’s a lot on natural products and “mind-body” interventions, but there are also modules on dietary interventions both science-based and dubious (e.g., ketogenic, alkaline, paleo, macrobiotic, etc.). There’s also modules on energy medicine and traditional Chinese medicine. As far as the web-based modules, there are additional modules on:
    • Diet – (1) Ketogenic Diets, (2) Calorie-restricted Diets and Fasting, (3) Anti-oxidant Supplementation During Cancer Treatment, and (4) Soy and Cancer
    • Whole Systems of Medicine – (1) Homeopathy, (2) Ayurveda, and (3) Naturopathy
    • Unique Pharmacological Treatments – (1) Vitamin D, (2) High Dose Vitamin C, and (3) Melatonin
    • Botanical Products – (1) Cannabis and Cannabinoids, and (2) Mistletoe.
Homeopathy is, of course, The One Quackery to Rule Them All. Naturopathy is basically a cornucopia of quackery, while Ayurveda and TCM are prescientific systems of medicine whose resemblance to anything science-based tends to be purely by coincidence (e.g., Artemisinin). Meanwhile, high dose vitamin C has consistently been shown to be, at best given the most generous interpretation of the existing evidence, a long run for a short slide.
In other words, what we see here is the typical “integrative medicine” approach: Co-opt some science-based diet and lifestyle modalities—such as exercise, various dietary interventions (often mixed with the more dubious, like the ketogenic diet), and mindfulness (which might be science-based)—and use them for cover for the quackery, such as homeopathy, naturopathy, high dose vitamin C, that is included with the modalities to be “integrated.”
As for the methods, besides eLearning, here’s how the in-person sessions will be organized:
As part of the TBL model we will employ a flipped classroom approach. In the flipped classroom approach scholars will read key materials, watch lectures, or complete modules before coming to class, and then engage in active educational strategies to maximize educational effectiveness during in-person class time.14 These strategies will include group discussion sessions, case studies, as well as demonstration and role-playing. Cancer patients, their families, advocates, and community-based complementary providers will be invited to be part of the curriculum to bring their experiences into the learning environment. Use of TBL and flipped classroom strategies improve short-term outcomes in health professions’ curricula,15 and out-perform traditional lecture-based continuing medical education in both short-term knowledge retention and daily practice behavior.16
So, in other words, they’re trying to be very, very effective in indoctrinating oncologists and other health care professionals into believing in integrative oncology and referring patients to integrative practitioners, including quacks like naturopaths.
Finally, let’s look at the faculty who are teaching the Integrative Oncology Scholars Program. Suzanna Zick, a naturopath, is of course the course director. Another naturopath, Heather Greenlee, will also be teaching. The first thing you’ll notice is a relative paucity of actual oncologists in the list. There’s a medical oncologist and a radiation oncologist, as well as a PA in gynecologic oncology. That’s it. There are, however, psychologists and a nurse. For instance:
Judith M. Fouladbakhsh, PhD, RN, AHN-BC, PHCNS-BC, CHTPDr. Judi Fouladbakhsh, Associate Professor at Oakland University, and former faculty of long standing at Wayne State University, College of Nursing, holds advanced clinical practice certifications in Community Health and Holistic Nursing, Healing Touch, Reflexology and Reiki. Dr. J has extensive experience in complementary and alternative (traditional) medicine, integrative oncology, pain management, public health and cancer nursing. Research interests include effects of yoga on breathing, mood, sleep and QOL of lung cancer patients funded by the NIH, and yoga therapy and qigong for pain management among breast cancer survivors. She also serves as faculty at the Beaumont Health System School of Yoga Therapy.
How depressing. She has apparently been faculty at my current medical school for a long time. Worse, she’s into healing touch and reiki, forms of “energy medicine” that rely on belief in the existence of a mystical magical “energy field” that healers can manipulate to healing effect. As I’ve said more times than I can remember, reiki, for instance, is nothing more than faith healing in which Eastern religious beliefs are substituted for Christian religious beliefs. Unfortunately, nonsense like reiki is available and promoted in far too many NCI-designated comprehensive cancer centers.
There’s also an acupuncture researcher:
Dr. Richard Harris, PhDRichard Harris is an Associate Professor in the Department of Anesthesiology and the Department of Internal Medicine at the University of Michigan. He received his Ph. D. in Molecular and Cell Biology from UC Berkeley in 1997. Dr. Harris is currently investigating mechanisms of acupuncture and acupressure in the treatment of chronic pain and fatigue conditions. His recent investigations have focused on the role of brain neurotransmitters in acupuncture analgesia and chronic pain.
Teaching focus areas: Pain; acupuncture/acupressure; traditional Chinese medicine; diet, exercise, and supplements in cancer prevention, cancer treatment and survivorship; GI disturbances
I perused Dr. Harris’ PubMed publication list (note that he is not this Richard Harris). There’s surprisingly little about acupuncture there, but what is there is pretty credulous, including a publication in JACM about how acupuncture “rewires” the brain with lasting effects and an article in the quack journal Medical Acupuncture about how cellular reorganization plays a vital role in acupuncture anesthesia. In other words, it’s quackademic medicine at its purest, and much of what will be taught to these “integrative oncology scholars” will either not be science based or will be a co-opted version of science based treatments framed as “integrative or alternative.” No big surprise there.
The Integrative Oncology Scholars Program: The goal
In the end, what is the goal of the Integrative Oncology Scholars Program? Clearly, it’s to increase the number of believers in integrative oncology in key locations, particularly academic medical centers (which, truth be told, are already hotbeds of pseudoscience). The investigators even have metrics that they want to look at for their “graduates” and their program:
To evaluate the IOS Program, we will use a mixed method approach employing tools developed from the University of Michigan Integrative Faculty Scholars Program in Integrative Healthcare and modified for the IOS Program. Overall, the IOS evaluation plan is composed of three elements: (1) evaluate overall IOS Program progress, (2) monitor individual IOS advancement, and (3) evaluate the IOS Program and make adjustments for subsequent cohorts, as needed.
We will also assess IOS progress toward nine goals focused on building IO research, clinical and educational impact: (1) writing applications for IO NIH funding, (2) authorship of IO publications, (3) presenting at IO-related conferences, (4) academic appointments to a faculty (or equivalent) position, (5) gaining employment in an IO team, (6) obtaining an IO leadership position, (7) individual IO-focused research grant support from NIH or other sources, (8) leadership as an IO “resource” person, and (9) improved IO clinical skills and knowledge as measured by a self-assessment tool.
The first cohort of 25 scholars is already well into the training, too:
The first cohort of 25 IOS has been accepted and will begin the program in August, 2018. The cohort is comprised of 10 physicians from radiation, medical, and surgical oncology as well as primary care, dermatology, and palliative care; 5 advanced practice nurses; 5 social workers; three physician assistants; 1 pharmacist; and 1 physical therapist. Several of the social workers and nurses coordinate cancer survivorship programs at their institutions. IOS come from 13 states and the District of Columbia and represent 23 U.S. healthcare systems, including comprehensive cancer centers (refer to Fig. 1).
It’s interesting to me that a minority of the first cohort are physicians and an even smaller minority appear to be from oncology-related specialties. Perhaps there is hope after all. On the other hand, this is only the first year. One can expect this program, if successful, to grow and metastasize to other institutions.
Now excuse me while I go and find a paper bag to put over my head, given that it’s my alma mater that’s leading this effort.

Apple Cider Vinegar
Steven Novella on February 19, 2025
Link
I just watched the new Netflix series, Apple Cider Vinegar, which tells the story of Belle Gibson, an Australian woman who launched a wellness business based largely on the false claim that she had survived “terminal brain cancer”. It is worth a watch, and overall I feel the writers (this is a fictionalized version, not a documentary) captured the industry of fake cancer cures and their victims very well. I have some quibbles, which I will get to, but in the end the telling serves the viewer well.
The series focuses mainly on three young women, including Gibson and two fictional characters facing serious cancer diagnoses. Together they represent different aspects of the wellness industry, and specifically the industry of dubious cancer treatments. David Gorski actually captured this spectrum quite well in his article, True believers, entrepreneurs, and scammers in alternative medicine. All are represented in this show.
Gibson is basically a sociopath, who is manipulative and deceptive. She falsely claimed she had brain cancer to obtain sympathy and then, seeing the power of that claim, parleyed that into a successful social media company. Eventually she launched The Whole Pantry app which had 200,000 downloads in the first month. Eventually her claims unraveled, mainly because of her financial misdeeds. It took a long time for anyone to challenge her false cancer claims.
Apple Cider Vinegar does a good job of showing how Gibson learned the language of wellness to sell her brand and, to exploit her customers, and to garner sympathy for herself. There are some lessons for the viewer from this character. First is that there are con artists out there – you cannot just assume that everyone is acting in good faith. No matter how sympathetic someone seems, they could be lying for profit.
But even more, the wellness industry is almost constructed for deception. The show points out that Gibson’s claims were hard to attack. Her personal medical records were protected, and any medical profession who knew her true story was bound by confidentiality. We see this all the time – health scammers, or just those who are misinterpreting their own medical story, hide behind confidentiality. We are left making general statements about what is probable, but cannot really know the medical truth unless it is made public.
The story is strengthened by the other characters. Milla Blake, who is fictional but based on real characters with very similar real-life stories, finds out she has a rare for of sarcoma. Her doctors recommend that her left arm be entirely amputated to save her life. She finds this advice unacceptable and opts for alternative treatment, a decision which greatly frustrates her doctors and her father, but her mother is on board.
The story of Blake is well done. She is simultaneously a very sympathetic character and an extremely frustrating and arrogant one. She is the true-believer, who comes to “wellness” out of fear and desperation, and then dives in completely. She gets coffee enemas five times a day and survives on “juicing”. This is all at the advice of a quack clinic which is not called Gerson Therapy, but which is very close. She also builds a successful wellness brand around her own journey.
The character is based upon the real person, Jess Ainscough’s. If I tell you how her story ends it is a huge spoiler, but you can probably guess. Ainscough eventually died of her cancer. Along the way her mother developed cancer, also treated it alternatively, and also died. This shows how the wellness industry makes people victims, and then turns those victims into purveyors of nonsense that cause further victims. It’s a pyramid scheme of death.
Blake’s journey also shows the viewer that there is a world of exploitation out there, ready to envelop and consume any who fall within its realm. There is fake research, dubious clinics, ready made conspiracy theories – an entire infrastructure supporting the world of alternative medicine.
The third main character, Lucy, is not a social media warrior, just a young women with breast cancer facing everything that entails. She highlights how absolutely terrifying a cancer diagnosis can be, and how difficult it is to navigate the world as someone battling cancer. Even those around her who want to be supporting don’t really know what she needs.
Lucy highlights how incredibly vulnerable people with potentially terminal cancer can be, and how easily exploited they are by the language, the false hope, the comforting lies, and well-meaning nonsense of the wellness industry.
Here come’s my main quibble with this show – all of the health care professionals are universally portrayed and cold and clinical. They have one note – frustration at the alternative claims harming their patients. This is a useful point to make, and I get for story telling purposes why the writers would do this, but it does not reflect reality, and is the one aspect of the show that I think plays into the wellness narrative.
Of course all doctors and nurses are people with their own quirks and personalities, but on the whole the people who work in oncology are extremely empathic. You have to be to survive in that specialty. I have dealt with many oncologists, and I find that they generally ooze sympathy, and have highly developed skills in dealing with patients facing a cancer diagnosis. They have to tell people something that they do not want to hear, and patients frequently will take their anger at the world and anger at their disease out on their caregivers, who just have to suck it up.
The doctors in this show lacked the temperament and the skills that are common in this field. At least showing one empathic oncologist, just for some balance, would have been nice. It also would be important for the story they are telling. People will fall for comforting lies, even with empathic doctors doing the best they can. The show falls for the simplistic narrative that cold and clinical doctors push patients into the arms of alternative medicine, as if CAM is not actively luring them away with lies.
Despite this caveat, I recommend the show. It’s a good watch, and the core of the story will leave the viewer with a good understanding of the pernicious dark underbelly of the wellness industry.
    • 

The metastasis hoax?
An anonymous blogger cites a virus denier who claims that our understanding of the mechanisms of cancer metastasis is a “hoax.” I cringe but cannot resist. Damn.
David Gorski on September 28, 2026
Link

This is one of those weeks where I thought I needed a break from writing about the hellscape into which, thanks to the current administration, federal medical, public health, and biomedical research programs are fast descending. One of the favorite rhetorical techniques of quacks, cranks, and conspiracy theorists is to point to the conventional understanding of a phenomenon and label it a “hoax.” They then try to back up their claim, and hilarity ensues, at least to people who actually know something about the topic about which they are pontificating so confidently. I, of course, am a cancer surgeon, scientist, and researcher, which is why I had that reaction when I came across a Substack article by an anonymous blogger whom we’ve encountered before. The blogger is Unbekoming (misspelling apparently intentional, for whatever reason), and the post is entitled What is Metastasis? In this post, the blogger references an incredibly long Substack by someone named Jamie Andrews entitled The Metastasis Hoax (with a subtitle, hilariously, of “The Oncogenesis Myth.”). The idea behind both is, of course, that “everything you think you know about cancer metastasis is wrong” (and “They” are covering it up). What attracted me to this offal wasn’t so much the delightful reek of woo, but the reference to an experiment that I hadn’t been aware of that was so beautifully misinterpreted that I couldn’t resist.
Unfortunately, Andrews’ article is behind a Substack paywall, and I was not willing to pay to subscribe. That might actually be fortunate, because in the part that I could read, Andrews brags that it “is a very long article topping 140 pages that has taken months of research.” Let’s just say that, even as verbose as I am and as long a time as I take to produce my weekly contributions to SBM, I wasn’t willing to read 140 pages of intellectual masturbation for a single blog post, which made me willing to gamble that Unbekoming’s summary was accurate enough to use as a basis to explain why the ideas about cancer being promoted are the purest bullshit, based on some cherry-picked studies that are, admittedly, rather interesting, although two of them are over 40 years old.
So let’s start out. Unbekoming informs us in an introductory paragraph:
This essay is built on the investigative research of Jamie Andrews, whose July 2026 piece “The Metastasis Hoax,” published at the Virology Controls Studies Project, assembled the primary evidence examined here. Andrews surfaced the Tarin shunt studies, the PulMiCC trial, the Padera angiogenic failure, and the Paget–Hart–Fidler line. He identified the metastatic cascade as a component of establishment oncology that has never been rigorously tested, and framed the woman with the shunt as the perfect control experiment medicine designed against itself. The credit for the research file belongs to him. What follows organizes his findings within the terrain framework developed in What Is Cancer and extends the containment reading into systemic containment. Readers interested in the full case, including Andrews’ broader dismantling of the somatic mutation theory and his examination of oncogenesis, should read the original piece here. His work is well worth following and supporting.
As I said, I pass. I’m not going to spend my good hard-earned money on this stuff. I also note that Andrews calls his Substack the Virology Controls Studies Project. I perused a number of his other posts on his Substack, and, consistent with the vibe of the name, it turns out that he’s one of those cranks who denies that viruses are real. For example, he refers to Ebola as a “hoax” (because of course he does), claiming that it’s due to “poisoning” and not a virus. Note, however, why Unbekoming is attracted to these ideas: Terrain theory. You remember terrain theory, right? It’s a hypothesis promoted by Antoine Béchamps that for a time competed with Louis Pasteur’s germ theory of disease in the mid-19th century, before Pasteur’s ideas won out based on evidence. The basic idea of terrain theory was that the microorganisms weren’t the cause of disease, but rather a manifestation of a “terrain” favorable to disease. There was, of course, a germ of truth in the idea in that it is now well-accepted that problems like malnutrition and poor general health can make one more susceptible to infection and serious complications from infection, but Béchamps, as you might recall, claimed that the microorganisms arose from the diseased tissue, not that they invaded it. I’m not going to go into a lot of detail here, because I’ve written about terrain theory many times, as it is very attractive to quacks and believers in alternative medicine, especially antivaxxers. Indeed, terrain theory underlies a whole lot of what the “make America healthy again” (MAHA) movement preaches.
Screenshot of the bio page on Jamie Andrews’ Substack. Note how he claims to be “falsifying virology.”
Yes, Jamie Andrews seems to be one of those “brave maverick” scientists who somehow has come to believe that he has discovered something that the entire worldwide scientific community cannot see and/or chooses to ignore. Never once does it occur to him that the reason he is not hailed with a Nobel Prize for falsifying virology is not because “They” don’t want you to know that virology is false, but rather because what he’s saying is nonsense tarted up with scientific language. Except that he’s not a scientist. He himself states that he has no formal scientific training but sells that as a strength, not a weakness, and he doesn’t do the experiments he describes himself. He appears to contract them out to contract research organizations (CROs), apparently not realizing that CROs just do what they are paid to do.
But I digress, although it is useful to know where someone who thinks he’s found major flaws in our understanding of cancer metastasis also thinks that he is successfully falsifying the entire field of virology. Instead, let’s look at what he says, admittedly filtered through the confident piffle published by Unbekoming.
What is metastasis?
Before I move on to the woo, it’s useful to briefly explain what cancer metastasis is (and isn’t) from a science-based perspective. In brief, cancer metastasis is the process by which cancer cells can spread beyond the primary tumor to implant in other organs and start growing secondary tumors, these secondary tumors being called metastases or metastatic deposits. The vast majority of patients with cancer do not die because of the growth of their primary tumor (although a minority do). Rather, they die from metastases, and in tumors arising from solid organs (e.g., colon, breast, etc.) metastatic disease beyond the immediate lymph nodes that drain the organ indicates incurability, which is why cancer with such metastases is usually considered stage 4, the highest stage on most cancer staging systems. There are occasional exceptions; for instance, colorectal cancer that has metastasized to the liver can sometimes be treated for long-term survival (“cure”) through the surgical extirpation of the liver metastases along with the primary tumor, but for the most part distant metastases (metastases beyond the regional lymph nodes) portend terminal disease.
Metastasis is complicated, as you might imagine, and can occur mainly by two methods, hematogenous (via the bloodstream) and lymphatic (through the lymph nodes). Breast cancer, my specialty, is notorious for being able to spread via both mechanisms, usually spreading first to the axillary lymph nodes (under the arm). I could get into all the varying models of breast cancer metastasis, dating back to Sir William Halsted, who hypothesized a very systematic, orderly model for how breast cancer spreads, first to the regional lymph nodes and then hematogenously to distant organs, and all the way up to Bernard Fisher, who proposed that breast cancer is metastatic at diagnosis, which is why surgery alone is often not enough to cure the patient. However, such a discussion is beyond the scope of this post. Suffice to say that hematogenous spread and lymphatic spread are the two main methods of cancer metastasis. Here’s a diagram summarizing hematogenous metastasis:
Schematic of the metastatic cascade for hematogenous metastasis. Obviously, this is quite simplified, as there’s a lot more going on than just this.
Here’s a similar diagram for lymphatic metastasis:
Schematic diagram for the stages of lymphatic metastasis.
Here’s the thing: While we by no means understand everything about cancer metastasis and the metastatic cascade, we do know the main steps and, in some cases, quite a lot about how each step comes about. There are thousands upon thousands of research and clinical studies on this phenomenon, the goal being to seek points where the process can be targeted and interrupted in order to treat the cancer. If you don’t believe me, here are a couple of good review articles:
     1.  Fares, J., Fares, M.Y., Khachfe, H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther 5, 28 (2020). https://doi.org/10.1038/s41392-020-0134-x.
     2.  Dai, X., Xi, M. & Li, J. Cancer metastasis: molecular mechanisms and therapeutic interventions. Mol Biomed 6, 20 (2025). https://doi.org/10.1186/s43556-025-00261-y
     3.  Lambert AW, Zhang Y, Weinberg RA. Cell-intrinsic and microenvironmental determinants of metastatic colonization. Nat Cell Biol. 2024 May;26(5):687-697. doi: 10.1038/s41556-024-01409-8. Epub 2024 May 7. doi: 10.1038/s41556-024-01458-z.
I can find more easily, but these are good ones to start with. The idea is that, even though the metastatic cascade is not yet well understood, we do know a hell of a lot about its general outline and steps, as well as a lot about certain specific aspects of it. Naturally, Unbekoming and Andrews want you to think that we know nothing and that everything we do know is wrong, because that’s how cranks work. Let’s dig in.
The woman with the shunt
Unbekoming is very much impressed with studies published in the early 1980s about a woman with liver cancer and a peritoneovenous shunt, which led to an autopsy series of patients with liver cancer and these sorts of shunts that failed to find a lot of distant metastatic disease in these patients, and she begins her “revelations” thusly:
A woman with advanced cancer lived twenty-seven months with a device pumping viable, clonogenic tumor cells continuously into her jugular vein. At autopsy: no established metastases in any organ.¹
The device is a peritoneovenous shunt. It was designed in the 1970s to relieve malignant ascites, the fluid buildup that accompanies late-stage cancer. Fluid drains from the peritoneal cavity through a subcutaneous catheter and returns to the venous circulation. In patients with cancer, that fluid contains large numbers of live tumor cells. The shunt runs those cells directly into the bloodstream, continuously, for as long as the device is in place.
If the metastatic cascade is a real biological process, this is the most efficient method ever devised for producing distant metastases. Live cancer cells enter the blood at rates that dwarf any biological shedding from a primary tumor. There is no need to explain intravasation (the cell’s supposed entry into a blood vessel); the shunt performs it mechanically. Every step of what medicine calls the cascade, after entry into the circulation, is available for study, in humans, over months.
Again, these two studies are over 40 years old and by only one scientist. That doesn’t necessarily invalidate them, but whenever I see such old studies being so selectively cited, I always wonder what the newer literature says. First, however, let’s look at the actual studies (1, 2). First, understand what this sort of shunt does. Patients with liver failure, from whatever cause, frequently develop ascites; that is, fluid in the abdomen, often several liters. A peritoneovenous shunt basically has one end open in the peritoneal cavity, where the fluid is accumulating, and the other end in a major blood vessel, usually the internal jugular vein, with a one-way valve to prevent backflow. This provides a route for the fluid in the abdomen to flow into the bloodstream, with relief of the ascites. There are also valves to prevent this. Here’s a schematic:
Peritoneovenous shunt. The shunt is triggered into action by the patient’s breathing. Upon inspiration, the diaphragm descends toward the abdominal cavity and causes a rise in fluid pressure in the thoracic superior vena cava. The difference in pressure, usually about 5 cm H2O, opens the shunt valve, allowing the flow of ascitic fluid into the large vein. The action of the shunt can be enhanced by the patient’s inspiring against pressure, as when using a blow bottle. (Source.)
There are lots of problems with these shunts, not the least of which is their tendency to get clogged with protein from the ascites, but they are effective for relieving ascites in patients with severe liver failure, whatever the cause.
But back to the experiment referenced by Unbekoming and Andrews:
D.M. Tarin and colleagues followed twenty-nine such patients and performed autopsies on fifteen. Findings were published in two 1984 papers, one in the British Medical Journal and one in Cancer Research.¹,² The results have never been meaningfully addressed by the field they undermine.
Fourteen patients in the BMJ report died from cancer. Eight had no hematogenous metastases at autopsy. In the six who did have secondary tumors, no debilitating large lesions could be attributed to the shunt. All fourteen died from the consequences of local abdominal tumor growth. The authors’ own summary: “peritoneovenous shunting does not result in the establishment of clinically important haematogenous metastases and… metastases do not necessarily develop even when large numbers of viable tumour cells regularly enter the blood.”²
One case is especially difficult to reconcile with the cascade model. A patient in the fourteen-person cohort had extensive hepatic and spinal metastases at the time of shunt insertion. Those tumors continued to grow. But despite months of viable cancer cells being infused directly into her jugular vein, “no secondary tumour deposits or even isolated tumour cells were found in the lungs or in any organ other than those colonised before the shunt was inserted.”²
Cells in blood. New tumors: none.
First off, contrary to what Unbekoming says, these papers were not “buried” or “ignored,” much less their results having failed to have been “meaningfully addressed by the field they undermine.” (Hint: The results did not undermine the field.) These two papers were, in fact, highly influential landmark studies that have been widely cited for over four decades.
Indeed, when I was searching for the links to these papers, that dratted unavoidable Google Gemini AI summary at the top of my search results helpfully informed me that the Cancer Research study was ” highly influential, classic study in cancer biology.” So I searched for the BMJ study, just to see what Gemini would say, and Gemini referred to it as a “classic study.” Far from being a forgotten and ignored set of clinical studies, the Tarin papers are considered landmark studies in the field precisely because they showed that there’s a lot more to the metastatic cascade than just cancer cells getting into the bloodstream, being carried along by the flow of blood, lodging in organs, and growing there. For one thing, the process is very inefficient, with a very tiny proportion of tumor cells able to dislodge from the primary tumor mass, extravasate into a blood vessel, survive being in the bloodstream, get out of the bloodstream, and set up shop in a distant organ. As this review article notes, these experiments provided powerful evidence for the “seed and soil” hypothesis of metastasis, in which metastasis is much more complicated than tumor cells spreading throughout the body in the bloodstream. They have to land in a suitable location that has the conditions necessary for them to spread, and those conditions tend to be specific to different kinds of tumor cells. Here, Unbekoming appears to be misrepresenting the cascade model as saying that tumor cells in the bloodstream are all that’s necessary for metastasis.
So how does Unbekoming interpret Tarin’s foundational observations in patients with shunts? If you thought that she’d latch onto terrain theory, you would be right:
The modern defense of the cascade points to circulating tumor cells. Liquid biopsies detect them, CTC [circulating tumor cell] counts correlate with disease progression, and the counts are used prognostically. The observation is real. The interpretation medicine places on it is not. Cells shed from primary tumors are a correlate of established cancer, indicating that the terrain in the primary site has already failed. They are a marker of what has already happened, not a mechanism of what happens next. The shunt data settles the direction of the arrow. Cells in the blood do not produce tumors at distant sites, regardless of concentration. The correlation between rising CTC counts and worsening disease tracks damage in the primary tumor, not seeding at other sites.
At least she admits that CTCs are real.
Note her interpretation, though. She takes this four-decade-old result and concludes that cells in the blood do not produce tumors at distant sites, ignoring all the evidence that they can and do, to conclude that the reason cells are being shed from the primary tumor is because the “terrain at the primary site has failed,” whatever that means, inverting the observation that increases in CTC count correlate with disease progression from meaning that more cells are getting out to potentially produce metastases to argue that more cells getting out is because the “terrain” in the organ of the primary site is somehow “failing.”
Now here’s the funny thing. Later in the post, Unbekoming mentions Stephen Paget‘s work in the late 19th century. Paget was a British surgeon, and let’s just say that, so great were his influence and discoveries that there are several diseases named after him, such as Paget’s disease of the nipple, which is a manifestation of pre-invasive breast cancer. He also popularized the “seed and soil” hypothesis, arguing that metastasis isn’t random, that tumor cells grow preferentially in certain organs because they have a favorable microenvironment. Unbekoming describes his work accurately enough, but then concludes, oddly:
Paget was right about what he saw. The metaphor he chose has misled the field ever since. Take away the seed and hold the soil, and the tumors still appear in the compromised tissues. It is soil all the way down.
That’s right. Unbekoming seems to be claiming that you don’t need a tumor cell (the seed) to lodge in a tissue (the soil) for a metastasis to form, which we know is total nonsense. This appears to be what is meant by the “metastatic cascade” being wrong. In reality, though, Paget was among the first physicians, along with Ernst Fuchs, to recognize that certain tumors have a predilection for certain tissues, the specific tissues varying depending upon the specific tumor type. It is not even controversial that metastases require tumor cells to travel to distant sites. What is contested are the mechanisms. Yet Andrews and Unbekoming are trying to
Resecting metastases (usually) does not work?
After having made that nonsensical argument, Unbekoming pivots to another question: Can resection of metastases result in cure? As I said in the introduction, for the vast majority of solid tumors (one rare exception being testicular cancer), distant metastasis portends incurable disease leading to eventual death. To that I would add that surgically resecting metastatic disease is usually futile, which is why it is not often done for most solid malignancies. I’ll elaborate a bit later, but first let’s see what Unbekoming says about the issue:
If cells reaching distant sites do not cause tumors at those sites, then surgically removing tumors at those sites should not affect survival. The only randomized trial ever conducted on the surgical practice tested this directly.
Pulmonary metastasectomy is the surgical removal of tumors that have appeared in the lung after treatment of a primary tumor elsewhere. It is a major operation performed hundreds of thousands of times annually worldwide. The justification for the procedure is that untreated five-year survival for patients with lung metastases is “less than five percent.” Cutting the tumors out, the argument runs, is life-saving.
That justification had never been tested against a control group. It rested on retrospective comparisons: patients selected for surgery had better outcomes than patients not selected for surgery. The selected patients were younger, had fewer metastases, and better overall health. Comparing their outcomes was like comparing marathon runners to hospital inpatients and concluding that running shoes extend life.
To cut to the chase, this particular study failed to find a significant difference in survival in patients who underwent metastasectomy of their lung lesions. (Remember, too, that lung metastases had to be the only known site of metastasis for patients to be considered for surgery.) This is, of course, a complicated question, and there were a lot of valid criticisms of this particular trial, including that it was underpowered, accruing less than 20% of its planned accrual goals, which is reflected in the very wide confidence intervals in the outcomes of the two groups. Worse, this accrual was prolonged over several years, and the patient population was heterogeneous, varying widely in tumor biology. As is the case all too often in medicine, this trial didn’t really answer the question, leading many surgeons to rely on the previous retrospective and prospective data that came from clinical practice as the best measure they have. Basically, there’s a large body of retrospective literature supporting the practice versus one underpowered negative randomized controlled trial (RCT). In other words, the question remains unsettled,
Unsurprisingly, Unbekoming treats the resistance to the findings of the RCT as evidence that surgeons are all biased and that old results are all the result of selection bias, stating:
The belief that untreated survival is less than five percent had produced a generation of surgeons willing to cut tumors out of the lungs of thousands of patients per year. When those patients were finally studied against a control group, they lived about as long either way, and slightly longer without the surgery.
Not quite. My view is that resection of pulmonary-only metastases from colorectal cancer probably does not meaningfully prolong survival, based on my reading of the literature, but you know what Unbekoming forgot to mention? There is a case where metastasis resection is very well supported, and that is for liver metastases from colorectal cancer. Like the case of pulmonary metastases, there are no randomized RCTs testing resection vs. no resection of liver metastases. Nor will there likely ever be, because the corpus of non-RCT evidence has become so accepted, much of it pointing in the direction of the efficacy of eliminating hepatic disease in prolonging survival. The most recent Cochrane Review on the subject notes that “up to 50% of patients with colorectal cancer develop metastases of which half are isolated to the liver and 10% to 25% are eligible for resection” and that “if all disease is removed these patients have a 30% to 50% chance of survival at five years,” which is far greater than no treatment. Ultimately:
The authors conclude that local ablative therapies might be useful for the management of liver metastases, but more research is required to further evaluate the effects of these treatment options and their potential role in increasing disease-free survival and in decreasing recurrence rates.
Again, the question isn’t fully answered, but in the case of liver-only metastases, the non-RCT data point much more strongly to a benefit of resecting the metastases, if all can be removed safely. There’s also indirect evidence from actual RCTs suggesting that removal of all cancer in the liver prolongs survival. For example, the COLLISION trial tested thermal ablation versus surgical resection and found that the 5-year overall survival was ~51% for ablation vs. ~58% for resection (not significantly different), with fewer adverse events for ablation. These are very high five-year survivals. Then there’s the TransMet Trial, which tested liver transplantation versus chemotherapy alone for unresectable liver-only metastatic disease, which showed striking results. Five-year survival was 73% in the transplant group plus chemo versus 9% with chemo alone, very strong evidence that removing metastatic disease can result in prolonged survival, even if this trial did include only a very highly selected group of patients. No wonder Unbekoming ignored it to pivot to another issue, angiogenesis.
The angiogenic failure?
When I saw that Unbekoming was going to discuss tumor angiogenesis, I chuckled, mainly because studying tumor angiogenesis was my thing for a long time, dating back to when its importance was first reported in animal models by Judah Folkman in the mid-1990s, leading to the popular press prematurely declaring it a way to make cancer into a manageable chronic disease, like diabetes or hypertension.
For those unfamiliar with tumor angiogenesis, its importance was first characterized decades ago, when it was noted that, without a blood supply, tumor cells could not grow beyond a diameter that allowed oxygen and nutrients to diffuse into the center of the tumor mass. Consequently, most solid tumors turn on something dubbed an “angiogenic switch,” in which they start secreting peptides that stimulate the ingrowth of new blood vessels, a process called angiogenesis. Of course, angiogenesis is a normal physiological process critical in embryogenesis, organogenesis, and, of course, wound healing; cancer just hijacks it to funnel nutrients, as well as the oxygen necessary to utilize them, to itself in order to grow.
Once again, Unbekoming cherry-picks an example to try to claim that the metastatic cascade is bogus, citing a drug called bevacizumab (trade name Avastin), which is an angiogenesis inhibitor. Basically, bevacizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), a key peptide secreted by normal tissues and tumors that is a powerful stimulator of angiogenesis. Now here’s the thing. It doesn’t always work, which, to Unbekoming, apparently means that the metastatic cascade is bogus. First, it is noted:
The theoretical basis of the drug is that tumors cannot grow beyond a few millimeters without recruiting new vessels to supply oxygen and nutrients. Cut off vessel growth in tumors that have already established at secondary sites, and further growth is prevented.
This is accurate enough, but this is not; at least the interpretation of the scientific observation is not:
Padera and colleagues at Massachusetts General Hospital tested it directly against lymph node metastases.⁴ They compared samples from patients treated with bevacizumab against samples from patients who received no anti-angiogenesis therapy. Their finding: “no difference in blood vessel density within the metastatic nodes.”⁴ The drug did nothing.
The reason it did nothing turned out to be structural. Lymph node metastases do not grow by recruiting new blood vessels. They use the pre-existing vasculature of the node. The angiogenic step is not part of what actually happens when a tumor appears in a lymph node. Padera’s conclusion: “since lymph node metastases do not require the development of new blood vessels, antiangiogenic therapy will not inhibit lymphatic metastasis.”⁴
The drug was designed around a theoretical requirement of the cascade model. That requirement is not real. The drug fails at the specific site where its mechanism was supposed to apply.
Bevacizumab remains in wide use in oncology. Its regulatory approvals are not being revisited. The theoretical model that produced it continues to guide drug design. Padera’s finding demonstrates that the model’s predictions do not hold, even in the presence of a drug specifically designed to test them.
WTF?
Here’s the study. Yes, it basically finds pretty much what is described above. A key paragraph in the introduction reads:
We and others have previously shown that antiangiogenic therapy did not stop the seeding or growth of lymph node metastases (9,17,18), but no mechanism of failure has been determined. Nonsprouting angiogenesis mechanisms to sustain tumor growth, such as vessel co-option and intussusception, have been implicated in the growth of lung, liver, and brain metastases (19) and are thought to play a role in resistance to antiangiogenic therapy (20). Based on these findings, we hypothesized that early growth of lymph node metastases is not dependent on sprouting angiogenesis.
In other words, there is more than one mechanism of angiogenesis. VEGF stimulates what is known as sprouting angiogenesis, which involves, as the name implies, new vessels sprouting out of old vessels towards the source of the angiogenic stimulus. It was also known that antiangiogenic therapy didn’t stop the seeding or growth of lymph node metastases, likely because of other mechanisms of angiogenesis. There are actually more mechanisms of angiogenesis than that; so, rather than describing them all, I’ll let a figure do the talking:
Angiogenesis is way more complicated than Unbekoming seems to understand!
Nope. The fact that bevacizumab didn’t work to inhibit the growth of lymph node metastases is not evidence against the metastatic cascade.
Enter the quacks
The funny thing about Unbekoming’s take on tumor metastasis and the metastatic cascade is that it doesn’t limit itself to just “conventional” oncologists and cancer scientists. It takes on quacks as well. For example, Unbekoming mentions the “metabolic dissidents,” which apparently means cranks who have adopted the idea of a metabolic origin for cancer as the be-all and end-all, rejecting “mutation theory.” Of course, I’ve written about tumor metabolism and treatments that target it many times in the past. An appreciation of aberrant metabolism in tumor cells dates back to Otto Warburg’s observations in the late 1920s, but really took off about 15-20 years ago. What I like to say is that mutation and aberrant metabolism are not mutually exclusive. In any case, Unbekoming writes:
The metabolic dissidents of the last two decades have done real work. Thomas Seyfried spent years dismantling the somatic mutation theory. Nasha Winters brought Warburg’s findings to a general audience. Jane McLelland made a serious case for repurposed metabolic drugs against her own diagnosis. Paul Marik built a rigorous protocol around mitochondrial biochemistry. Their contribution to a field captured by a false paradigm has been substantial.
All four inherited the metastatic cascade without examining it.
See the claim here? These supposedly brave mavericks “questioned” mutation theory. I’ve written about most of them, in particular Paul Marik, one of the doctors who made the pivot from a COVID-19 quack to a cancer quack disparaging chemotherapy to sell his bogus treatments. I’ve also written about Thomas Seyfried, who, while not completely full of crap, does massively oversell his ketogenic diet as a treatment for cancer. (No, it does not beat chemotherapy for nearly all cancers.) I’ve also written about Jane McClellan before. She appears to be a standard “starve the cancer”-sort of quack who more recently added “repurposed drugs”—cough, cough, ivermectin—to her armamentarium. (Repurposed drugs are a favorite of Paul Marik, too.) I haven’t written about Nasha Winters before, but she is a naturopath who is big into terrain theory and dismisses you close-minded oncologists out there who miss patterns “when health is reduced to isolated parts.”
Now here’s the hilarious thing. Even these brave maverick quacks are deluded enough to believe the metastatic cascade:
The pattern is the same in each case. These are thinkers who broke with the establishment on the causal question (genetics versus metabolism) but adopted the establishment’s mechanism for the downstream phenomenon (metastasis). They rejected the genetic story of tumor formation. They kept the establishment’s story of tumor spread.
Because of course they did. They’re not as brilliant as Andrews. They weren’t as “skeptical”:
A more consistent application of the same skepticism the metabolic dissidents applied to the genetic story would have caught the cascade. The genetic theory of cancer was mistaken about causation because it treated a downstream correlate as an upstream cause: present-day mutations in tumor cells were taken as the origin of the tumor rather than as its consequence. The cascade model of metastasis makes the same error at a different level. Cells in the blood are the consequence of terrain failure at the primary site, not the cause of terrain failure at other sites.
Or maybe, instead of being wrong about both a genetic origin for cancer and the metastatic cascade, these quacks are only wrong about one. Let’s just put it this way, Unbekoming says this:
That single autopsy report, replicated across the twenty-nine patients in the Tarin cohorts, is the falsification of the cascade model. It is the falsification that PulMiCC confirms at the level of the randomized trial and that Padera confirms at the level of drug design. Paget saw the shape of the answer in 1889. Hart and Fidler confirmed it experimentally in 1980. The field carried on describing metastasis as cellular travel because the alternative account required abandoning too much of the surrounding framework.
No, none of these “falsified” the cascade model. To write as much just shows that Unbekoming doesn’t understand nearly as much as they think they do about cancer. This does make for a good “alternative” cancer conspiracy theory, though. “They” won’t abandon the standard view of how metastasis happens because “the alternative account required abandoning too much of the surrounding framework.” Well, yes, but scientists have abandoned such frameworks before when the evidence demanded it. No one claims it’s easy, but nowhere does Unbekoming make a compelling argument that the conventional view held at present about the metastatic cascade is so disastrously wrong. Cherry-picked examples that ignore lots of other data and literally decades of experimentation won’t do it.
Cancer is not the true disease? Here we go again
All of this leads Andrews and his admirer Unbekoming to land on a common quack trope, that cancer is not the real disease, but rather a manifestation of the body’s defense against some “toxic” insult:
If cells reaching distant sites is not the cause of secondary tumors, what is?
Cancer, in the terrain framing, is a containment response. The primary tumor is the body walling off a region of tissue whose cellular machinery has failed and cannot be repaired while the causal insult persists. Structured water in the cytoplasm has broken down. This is the organized gel phase that runs cellular chemistry, and its collapse strips the cell of the medium in which its machinery operates. Zeta potential in the local capillary bed has collapsed alongside it. This is the electrical charge that keeps blood cells separated from each other and from vessel walls. Its loss produces capillary sludging that starves the surrounding cells of oxygen and forces them into fermentation. Respiration in the mitochondria of the affected cells has been overwhelmed. Cells have shifted into fermentation as a survival response. The body cannot restore the tissue while whatever damaged it continues to arrive, so it walls the region off. That is what medicine sees on the scan and calls a tumor.
Yes, it’s Robert O. Young all over again, claiming that the tumor is the body’s response to cells “spoiled by acid.” It’s the German New Medicine, which claims that tumors are a response to past trauma that causes a “Hamer body” that is walled off by the body as a defensive response. It’s Andreas Moritz all over again, claiming that cancer is a “survival mechanism” based on the “wisdom of the body.” As I wrote about a month and a half ago, according to this cancer quackery, the tumor is what is keeping you alive. The only difference here is that Andrews and Unbekoming extend the idea to metastases:
Paget’s seed-and-soil formulation is a hundred-and-thirty-seven-year-old approximation of something more direct. There are no seeds. There is only soil, in varying stages of failure, producing containment walls in the tissues whose terrain has collapsed. The word metastasis, as medicine uses it, describes a sequence of events that has not been observed to occur. What the word labels is a real phenomenon: additional tumors appear at additional sites over time. But the mechanism medicine assigns to the phenomenon is not the mechanism at work.
Andrews goes even further in his Substack article, claiming that cancer is “similar to a ‘virus’ in that it does not exist as specified by the mainstream medical view of what they are” and that “Cancer is a cellular imbalance mislabeled as a Genetic mutation that arises from a similar imbalance of the terrain of the whole,” pontificating in the part of his article not behind a paywall:
Once you fully realize the above information, you will understand that looking for a “cure” for Cancer is the wrong way of dealing with a case of imbalance. Certainly for cutting, burning and chemically poisoning ones self, which is the Allopathic way is never going to be beneficial to health. But more than that, to think you can take some sort of pill/chemical/ food stuff said to contain a chemical is also in my opinion not the way to make a change to a disease , that as we laid out above, is caused by environment, diet and lifestyle. The only way to deal with a disease caused by environment, diet and lifestyle is to… you guessed it… change your environment, diet and lifestyle. If you have been following along, the next bit should be an extension of logic in that these things, for the sake of balance, should be happening on a similar time frame as each other, a Ying to the Yang shall we put it: 3 decades of heavy drinking, smoking, processed food diets and pharma pill popping obviously cannot be undone by 3 months of cutting down on takeaways and quitting smoking whilst doing chemo (mustard gas).
This is the sort of idea that can sound plausible if (1) you don’t know very much about cancer and (2) don’t think about it very hard. After all, how would this model explain observations that the genome of metastatic tumor deposits and the accumulation of mutations in them can be mapped back to the primary tumor, showing how the tumor evolved into heterogeneity and that a subset of those cells spread to distant organs? We can literally trace where cells spread in animal models using labeled cells, and in human models we can use a variety of techniques to demonstrate the relationship of metastases to their primary tumors.
Also, treat cancer by changing your lifestyle? We already know that that doesn’t work. Even if everything Andrews writes is true, even by his own model, he’s talking nonsense pulled out of his nether regions. Remember that example of cancer being due to three decades of heavy drinking, smoking, and processed food diets not being able to be undone by three months of lifestyle changes and chemotherapy? The exact same “logic” applies to his idea that lifestyle changes can cure cancer. Under the “conventional” view of carcinogenesis and metastasis, cancer is a very late development. It’s the end stage of the process. Andrews seems to be claiming that some sort of terrain-targeted naturopathic quick fix can cure cancer, which is just as ridiculous a contention as his caricature of what modern cancer science and oncology currently understand as the nature of cancer. It’s serious woo, with no real applicability to treating and curing cancer. Even more amusing, no matter how much he tries to gussy it up as a radical new understanding of cancer, he’s really just dipping into 150-year-old terrain theory and tarting it up with all sorts of handwaving about tumor metabolism and microenvironment.
Contrary to nonsense like this being peddled by Anderson and Unbekoming, we now know a lot about how cancer originates, progresses, evades the immune system, and ultimately kills its host if left untreated. We know a lot about how it infiltrates blood vessels and lymph vessels, spreads via blood vessels and lymphatic vessels, lodges at distant sites, evades the immune system, and ultimately grows to kill the patient. Unfortunately, we do not know enough to come close to curing all cancers, and some cancers (e.g., pancreatic cancer) remain deadly and difficult to treat. We do, however, know enough that the death rate from cancer has been steadily declining for the last three and a half decades, having declined by approximately 34% since 1991. That’s what science can do.
What can Andrews and Unbekoming do? They can write reams and reams of plausible-sounding bullshit about cancer.
    • 

   What is the harm?

   The price of cancer quackery
David Gorski 
Link
I don’t have much to add to this one, as it’s a tragic tale. Shadowfax, a blogging ER doc, relates to us what happens when cancer patients rely on quackery like the Gerson protocol instead of scientific medicine:
This was a young woman, barely out of her teens, who presented with a tumor in her distal femur, by the knee. This was not a new diagnosis — it had first been noted in January or so, and diagnosed as a Primary B-Cell Lymphoma. By now, the tumor was absolutely huge, and she came to the ER in agonizing pain. Her physical exam was just amazing. The poor thing’s knee (or more precisely, the area just above the knee) was entirely consumed by this massive, hard, immobile mass about the size of a soccer ball. She could not move the knee; it was frozen in a mid-flexed position. She hadn’t been able to walk for months. The lower leg was swollen and red due to blood clots, and the worst of the pain she was having seemed due to compression of the nerves passing behind the knee. It was like something you see out of the third world, or historic medical textbooks. I have never seen its like before.
So we got her pain managed, of course, and I sat down to talk to her and her family.
Why had this tumor been allowed to grow so large and painful? If you’re a regular reader of SBM, I bet you know the answer. This patient had been relying on quackery (in this case, the Gerson protocol, immortalized in the quackery propaganda movie The Beautiful Truth):
In a less grave situation I might have laughed and asked “So how’s that working for ya?” As it was, the tears from her only partially-controlled pain took any humor out of the situation. She was very frustrated that the Gerson therapy wasn’t working yet, but she did not perceive this as a failure of the treatment. Her theory was that the severity of her uncontrolled pain was keeping her immune system suppressed and preventing it from working. If, she hoped, she could just get her pain under control, she would finally start to get better.
I spent a lot of time with this young lady. Listening as well as explaining. She was dead set against chemo, which to her mind was equated with the “toxins” which had caused her cancer in the first place. She wrote off the oncologists as pushing chemo “because that’s all they know how to do, and it never works.” She had, in fact, burnt all the bridges with the various oncologists who had treated her, and was now left with only a pain specialist and a primary care doctor trying to do what little they could for her. She was equally frustrated by doctors in general, who “won’t do anything to help me.”
I could see why she felt that way; when a patient refuses the only possible effective treatment, there is not really much we can do to help her.
All too true. The cliche goes that you can lead a horse to water but you can’t make him drink. This is true for every patient; we can’t force our therapies on a mentally competent adult patient. People have the right to make their own choices and to suffer the consequences when their choices are poor.
Just like this woman.
The person primarily at fault is the quack prescribing the treatment, taking advantage of this woman’s fear of chemotherapy. After relating how he arranged for this patient to see another oncologist, who was willing to try to help her despite her baggage and extreme distrust of “conventional” medicine, Shadowfax concludes:
Most woo is harmless — but that’s because most woo is directed at chronic, ill-defined, or otherwise incurable conditions. Think chronic fatigue or fibromyalgia. Wave a magnet at somebody, get them to do a lot of enemas and go on a special diet, and you get to write a book and go on Oprah and collect a lot of money. If the subjects of the “magical thinking medicine” think they are better from the intervention, then so much the better.
But the really pernicious thing about allowing fantasy medical theories and treatments into the mainstream is that when they gain enough credence among the masses, they will tend to be used in place of real medical treatments that work.
Exactly. What’s worse is that, the more woo infiltrates scientific medicine, as it is doing, the harder it is to tell woo from non-woo. Then we ostensibly “science-based” practitioners become the quacks who are only marginally better than the quack who indulges the delusions of a young woman with a potentially curable cancer and thereby leads her into a path of extreme suffering and likely death. I’ve seen it before myself.

Rejecting cancer treatment: What are the consequences?
There have been several studies of people who have refused scientific treatments for cancer. The results have not been good.
Scott Gavura on August 30, 2012
Link

One of the points I’ve tried to emphasize through my contributions to Science-Based Medicine is that every treatment decision requires an evaluation of risks and benefits. No treatment is without some sort of risk. And a decision to decline treatment has its own risks. One of the challenges that I confront regularly as a pharmacist is helping patients understand a medication’s expected long-term benefits against the risks and side effects of treatment. This dialogue is most challenging with symptomless conditions like high blood pressure, where patients face the prospect of immediate side effects against the potential for long-term benefit. One’s willingness to accept side effects is influenced, in part, by and understanding of, and belief in, the overall goals of therapy. Side effects from blood-pressure medications can be unpleasant. But weighed against the reduced risk of catastrophic events like strokes, drug therapy may be more acceptable. Willingness to accept these tradeoffs varies dramatically by disease, and are strongly influenced by patient-specific factors. In general, the more serious the illness, the greater the willingness to accept the risks of treatment.
As I’ve described before, consumers may have completely different risk perspectives when it comes to drug therapies and (so-called) complementary and alternative medicine (CAM). For some, there is a clear delineation between the two: drugs are artificial, harsh, and dangerous. Supplements, herbs and anything deemed “alternative”, however, are natural, safe, and effective. When we talk about drugs, we use scientific terms – discussing the probability of effectiveness or harm, and describing both. With CAM, no tentativeness or balance may be used. Specific treatment claims may not be backed up by any supporting evidence at all. On several occasions patients with serious medical conditions have told me that they are refusing all drug treatments, describing them as ineffective or too toxic. Many are attracted to the the simple promises of CAM, instead. Now I’m not arguing that drug treatment is always necessary for ever illness. For some conditions where lifestyle changes can obviate the need for drug treatments, declining treatment this may be a reasonable approach – it’s a kick in the pants to improve one’s lifestyle. Saying “no” may also be reasonable where the benefits from treatment are expected to be modest, yet the adverse effects from treatments are substantial. These scenarios are not uncommon in the palliative care setting. But in some circumstances, there’s a clear medical requirement for drug treatment – yet treatment is declined. This approach is particularly frustrating in situations where patients face very serious illnesses that are potentially curable. This week is the World Cancer Congress in Montreal and on Monday there were calls for patients to beware of fake cancer cures, ranging from laetrile, to coffee enemas, to juicing, and mistletoe. What are the consequences of using alternative treatments, instead of science-based care, for cancer? There are several studies and a recent publication that can help answer that question.
Who uses CAM instead of medicine?
Surveys suggest the vast majority of consumers with medical conditions use CAM in addition to, rather than as a substitute for medicine – that is, it is truly “complementary”. But there is a smaller population that uses CAM as a true “alternative” to medicine. A study by Nahin et al in 2010 looked at data from the 2002 National Healath Interview Survey (NHIS), which is described as a representative sample of Americans. It examined the group that did not use “conventional care” in the past 12 months – no health professionals, no emergency room visits, no surgery, and no nursing care of any kind. It asked about alternative medicine, which included acupuncture, ayurveda, biofeedback, chelation, chiropractic, energy healing/Reiki, hypnosis, massage, naturopathy, homeopathy, specialized diets, high-dose vitamins, yoga, tai chi, qui gong, and meditation. The survey found that 19.3% of adults did not access any “conventional” health care in the past 12 months. Of this group, over one third (38.4%) had some health need (of which 23.8% considered a serious condition). In the population that did not use conventional care, one-quarter (24.8%) used some form of alternative medicine. And 12% (approximately 4.6 million Americans) were estimated to be using alternative medicine, and not conventional medicine, to treat one or more health issues. Barriers to accessing health care were explored and users of alternative medicine had poorer health and had more barriers to care, with about 20% noting the decision to use alternative care was based on cost considerations of conventional care. There were several limitations worth noting: Most importantly, the types of conditions treated with “only CAM” were not collected. And as some users cited the costs of conventional care as a barrier, different insurance schemes might be expected to change utilization patterns. Finally, there is no assessment of outcomes. But this survey suggests that there is a small population that will preferentially treat a medical condition with CAM and not medicine.
So how would a decision to accept no treatment, or to only use alternative medicine, compare to “conventional” cancer care (chemotherapy, radiation, and surgery)? And what about delaying conventional cancer care to allow a trial of alternative medicine – does it have a measurable effect? Answering this question isn’t straightforward. In cancer research, new drugs are typically added to, or follow, established therapies, so all patients receive standard treatment options as part of their care. So we can’t ethically randomize patients to nothing, when established treatments exist. But we can answer this question in a different way: Patients that voluntarily opt out of cancer treatment can be followed, and compared to patients that do take cancer treatment. While it isn’t a prospective randomization, which would be the gold standard, it’s the best we can get. But even this approach is difficult. Most patients who decide to opt-out of cancer treatment, also opt-out of any follow-up evaluation. So tracking down patients, and their outcomes, is essential.
The effects of treatment refusals and delay, and the effectiveness of CAM as a substitute, has been evaluated in several groups of patients with breast cancer. Breast cancer is well studied, frequently diagnosed, and if detected early, potentially curable. Conventional treatment for early (localized) breast cancer is surgical resection of the tumor, followed by radiation and chemotherapy to reduce the risk of disease recurrence, by killing any residual cancer cells that remain. The overall effectiveness of conventional treatment is strongly influenced by the extent of the disease at diagnosis. When treated early in the disease course, the long-term outlook for for women with breast cancer can be excellent. However, once the cancer has spread to the lymph nodes, or metastasized to other part of the body, the outcomes are much worse. The treatment focus shifts from curative to palliative. (An old study of untreated breast cancer suggest the 5 year survival rates are 18% at 5 years and 3.6% at 10 years.) Given the potential for treatment cures, very few women elect to reject conventional treatment, or substitute CAM. But some do, which can inform us of the effectiveness of conventional care, as well as that of CAM. I found 5 studies which look at this question:
1. Patients’ Refusal of Surgery Strongly Impairs Breast Cancer Survival
This was a Swiss study by Verkooijen et al, published in 2005 in the Annals of Surgery that looked at 5339 patients under the age of 80 with non-metastatic breast cancer. It didn’t examine CAM, just the decision to refuse breast cancer surgery. It compared patients who refused breast cancer with those that those that accepted surgery. Only 1.3% of women (70) refused surgery. Of that group, 37 had no treatment, 25 had hormone-therapy only, and 8 had other types of treatments. So only a small percentage refused all treatment. In this study, the five-year survival of women that refused surgery was 72% versus 87% of women who had surgery. Adjusting for prognostic factors, the authors estimated that women that refused surgery had a 2.1-fold increased risk of death from breast cancer compared to conventional treatment. The survival curves make this clear:
The bottom line in this paper was that a decision to forgo surgery for breast cancer is associated with dramatically worse outcomes and survival.
2. Outcomes of breast cancer in patients who use alternative therapies as primary treatment
This was a medical chart review by Chang et al, published in the American Journal of Surgery in 2006. It examined breast cancer patients who refused conventional chemotherapy, or delay its initiation, in order to use CAM. The authors calculated each patient’s prognosis at the time of diagnosis. In total, 33 women were included. (Notably, patients who refused treatment and did not return for follow-up were excluded from the analysis, possibly biasing the results.) The results were grim:
    • Eleven patients initially refused surgery. Ten of these patients experienced progressive disease. Five ultimately had surgery. In the six others, the cancer had already metastasized, so surgery would have offered no benefit.
    • Three patients refused to allow sampling of lymph nodes to evaluate disease spread. One of these patients developed recurrent disease in the lymph nodes.
    • Ten patients refused local control (surgery/radiation) of the tumor site. Two patients developed recurrences in the same location, and two developed metastatic disease.
    • Nine patients refused chemotherapy, raising their estimated 10-year mortality from 17% to 25%
Consistent with the study above, the vast majority of breast cancer patients who refuse surgical intervention developed progressive disease. Even delaying surgery increased risks and overall mortality. Outcomes were better for patients that accepted surgery, but refused adjuvant treatments, like chemotherapy. However, even this strategy significantly raised 10-year mortality estimates.
3. Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes
This study from Han et al was published in the Annals of Surgical Oncology in 2011, and may include some of the patients in the Chang analysis. This was a retrospective chart review of breast cancer patients who refused or delayed conventional treatments. 61 patients were identified. On average patients had Stage 2 disease at diagnosis, which is highly treatable and potentially curable. In patients that omitted or delayed surgery (26 women) 96.2% had disease progression with 50% dying of the disease. At the time of diagnosis, the median tumor size was 2.0cm. Upon follow-up, the median-size was 7.8cm. (The authors include this photo of a tumor in a woman who elected to use diet and herbal treatments, rather than receive surgery.)
In patients that accepted surgery but rejected adjuvant therapy (chemotherapy/radiation), the initial 10-year relapse-free survival was estimated at 59.2%, which would have been 74.3% had the patients accepted these treatments. Actual outcomes were much worse than predicted. The actual observed relapse-free survival was only 13.8%. Some subsequently elected to take palliative chemotherapy and radiation to control their disease. From this study we can conclude that refusing or delaying conventional cancer care is associated with much worse outcomes.
4. Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer
This analysis, by Saquib et al, was a secondary analysis of the Women’s Healthy Eating and Living (WHEL) study. It looked at 2562 breast cancer survivors and surveyed for rejection of systemic treatment (i.e., chemotherapy) and use of CAM following surgical resection. All women had to be aged 18-70 and had operable Stage I-IIIa breast cancer. In this group, 177 women were identified who declined systemic treatment. 80% of this group used CAM. Compared to women that took chemotherapy, women that declined systemic treatment had a 90% greater risk of an additional breast cancer event, and the risk of death increased by 70%. CAM use had no effect on this finding. In addition, the lack of effect was consistent between “high supplement users” (>3 per day) and low supplement users. The authors concluded that women that decline systemic treatment are at greater risk for subsequent recurrence and death due to breast cancer. The use of CAM had no measurable effect on the recurrence of breast cancer or on the risk of subsequent death.
5. Outcome analysis of breast cancer patients who declined evidence-based treatment
Here is the recent paper I referred to above, which studied women with breast cancer in Northern Alberta who refused standard treatments. It was also a chart review with a matched pair analysis (age, disease stage, calendar year) that compared survival with those that received conventional cancer care. Between 1980 and 2006 they identified 185 women (1.2%) that refused cancer care following diagnosis by biopsy. (Notably, cancer care is an insured service in Alberta, so there should have been no financial barriers in accessing treatment.) Women older than 75 were excluded from the analysis because this population is generally not included in clinical trials and active treatment regimens. In addition, women that accepted surgery, but rejected chemotherapy/radiation were excluded from the analysis. To qualify, women had to have rejected all conventional care. The final population studied was 87 women, most of whom presented with early (Stage I or II) disease. Most were married, over the age of 50, and urban residents. In this group, the primary treatment was CAM in 58%, and was unknown in the remainder. Some women in this group eventually accepted cancer care, and the average delay was 20-30 weeks due to CAM use.
The results were grim. The 5 year overall survival was 43% for women that declined cancer care, and 86% for women that received conventional cancer care. For cancer-specific survival (i.e., those that died of breast cancer) survival was 46% vs. 85% in those that took cancer care. The survival curves are ugly:

The authors compared the “CAM” group to those where treatment plan (if any) was not known:

Note that the difference is only statistically significant in (a) where all-causes of death were included and not (b), cancer-specific causes. So does that mean CAM helps? Probably not. The two groups are not well defined, and the “unknown” group could include CAM users – it is not a comparison of CAM versus no treatment. And as the types of CAM used was not documented, this is a heterogeneous group. The key point this comparison illustrates is that CAM users did dramatically worse than women that took conventional cancer care. Even delaying surgery to allow for CAM first significantly decreased the effectiveness of subsequent conventional care. The authors conclude, correctly, that there is no evidence to support using CAM as primary cancer treatment.
Effectiveness evaluations
The data show that avoiding or delaying conventional cancer care is associated with negative outcomes, and CAM used does not seem to modify this risk. But have any specific CAM interventions shown any benefit? Probably the most comprehensive single review is a systematic review by Gerber et al, published in Breast Cancer Research and Treatment in 2006, which looked at CAM effectiveness for early breast cancer. It concludes:
There is no compelling evidence that any of the numerous complementary treatments available is sufficiently effective in breast cancer patients to justify its use. It should be the responsibility of those who claim efficacy for CAM to support these claims with acceptable evidence, rather than the responsibility of those who criticize CAM to prove its non-efficacy.
Based on the current evidence, there is nothing to suggest that any specific CAM treatment has any meaningful clinical effects.
Conclusion: Alternative medicine isn’t real medicine
Despite widespread claims, there is no evidence to support the use of any CAM treatment as a replacement for conventional cancer care. As the studies in breast cancer show, delaying treatment or substituting CAM for conventional cancer care dramatically worsens outcomes.The results of these studies will hopefully provide patients and health providers with a better understanding of the risks and consequences of CAM for cancer. CAM is no alternative to science-based cancer care.

References
1. Verkooijen HM, Fioretta GM, Rapiti E, Bonnefoi H, Vlastos G, Kurtz J, Schaefer P, Sappino AP, Schubert H, & Bouchardy C (2005). Patients’ refusal of surgery strongly impairs breast cancer survival. Annals of surgery, 242 (2), 276-80 PMID: 16041219
2. Chang EY, Glissmeyer M, Tonnes S, Hudson T, & Johnson N (2006). Outcomes of breast cancer in patients who use alternative therapies as primary treatment. American journal of surgery, 192 (4), 471-3 PMID: 16978951
3. Han E, Johnson N, DelaMelena T, Glissmeyer M, & Steinbock K (2011). Alternative therapy used as primary treatment for breast cancer negatively impacts outcomes. Annals of surgical oncology, 18 (4), 912-6 PMID: 21225354
4. Saquib J, Parker BA, Natarajan L, Madlensky L, Saquib N, Patterson RE, Newman VA, & Pierce JP (2012). Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer. Complementary therapies in medicine, 20 (5), 283-90 PMID: 22863642
5. Joseph K, Vrouwe S, Kamruzzaman A, Balbaid A, Fenton D, Berendt R, Yu E, & Tai P (2012). Outcome analysis of breast cancer patients who declined evidence-based treatment. World journal of surgical oncology, 10 (1) PMID: 22734852

Alternative medicine kills cancer patients
By definition, alternative medicine has not been shown to be effective or has been shown to be ineffective. Thus, alternative medicine is ineffective against cancer and can best be represented as either no treatment at all or potentially harmful treatment. It is thus not surprising that cancer patients who choose alternative medicine have a higher risk of dying from their cancer. A new study confirms this conclusion yet again.
David Gorski on August 14, 2017
Link

Alternative medicine, by definition, consists of medicine that either has not been shown to work or has been shown not to work. To paraphrase an old adage yet again, medicine that has been shown to work with an acceptable risk-benefit ceases to be “alternative” and becomes simply “medicine.”
Unlike the case for many conditions commonly treated with alternative medicine, whether or not a treatment works against cancer is determined by its impact on the hardest of “hard” endpoints: Survival. A patient either survives his cancer or he does not. Even the “softer” endpoints used to assess the effectiveness of cancer treatments tend to be much harder than for most other diseases, such as progression-free survival (the cancer either progresses after treatment or it does not) or recurrence-free survival (a cancer either recurs after treatment eliminates it, or it doesn’t). Yes, although there are lots of other aspects of cancer treatment to be assessed, such as quality of life and adverse reactions, at the very heart of evaluating any treatment for a specific cancer are the questions: Does the therapy save the lives of cancer patients? Does it prolong survival, and, if it does, by how much and at what cost?
One might reasonably predict that, for alternative medicine and any given cancer, the answer to both questions will be no. However, the question is much harder to study than one might guess if you don’t do cancer research yourself. For one thing, it is unethical to do a randomized, controlled clinical trial of a treatment with no evidence of benefit. So, except for very uncommon situations (e.g., the Gonzalez protocol, which was tested in a clinical trial against pancreatic cancer and failed miserably), we have to use other methods to investigate the effect of alternative medicine use on survival in cancer patients. Yes, anecdotes like that of Michaela Jakubczyk-Eckert, who died a horrible potentially preventable death from breast cancer because she chose the quackery of Ryke Geerd Hamer’s German New Medicine and stopped her neoadjuvant chemotherapy, which allowed the tumor to grow back bigger and deadlier than ever, are powerful and very likely representative of what happens, but this is science-based medicine. What are the actual numbers. Yes, I’ve seen at least a dozen women like Ms. Jakubczyk-Eckert through my career, but what is the effect of choosing alternative medicine beyond my clinical experience and in cancers that I personally do not treat?
Such were the thoughts going through my mind as I was made aware through social media of a study published online ahead of print in the Journal of the National Cancer Institute by Skyler et al, entitled “Use of Alternative Medicine for Cancer and Its Impact on Survival.” In it, Skyler B. Johnson, Henry S. Park, Cary P. Gross, James B. Yu, all from the Department of Therapeutic Radiation (basically radiation oncology) at Yale, seek to answer the question: What is the effect of choosing alternative medicine as the primary treatment for a potentially curable cancer on a cancer patient’s chance of surviving his or her disease?
The newest study showing that alternative medicine kills cancer patients
The latest study, by Skylar et al, is a good demonstration of how difficult it is to study alternative medicine use in cancer patients. I’ll show you why in a moment. First, however, the authors introduce why it is so important to study this:
Delay or refusal of conventional cancer treatment (CCT), when done in favor of alternative medicine (AM), may have serious survival implications for cancer patients (1–7). However, there is limited research evaluating the use and effectiveness of AM, partly due to data scarcity or patient hesitance to disclose nonmedical therapy to their providers (8,9). To address this knowledge gap, we used the four most prevalent cancers (breast, prostate, lung, and colorectal) in the United States (10) from the National Cancer Database (NCDB) between 2004 and 2013 to identify the factors associated with AM selection and compared survival outcomes between AM and CCT.
Yes, there is a paucity of studies evaluating the use of alternative medicine in cancer. (I will cite some of the other studies that exist after I discuss this one.) The reason is clear. It’s hard, and data are lacking. This brings me to the National Cancer Database.
There are two very large databases in the US that are commonly mined for cancer outcomes. One, of course, is the Surveillance, Epidemiology, and End Results (SEER) database, which is maintained by the National Cancer Institute. The program began in 1973 and consists of cancer registries all over the country that enter data regarding cancer outcomes in a standardized format, which includes patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. Mortality and patient survival are tracked, with the mortality data coming from the National Center for Health Statistics and population data coming periodically from the Census Bureau. As large as it is, though, because of many gaps in coverage SEER only reports cancer outcomes for 28% of the US population. Still, it is a large database that’s been around for 45 years. However, working with it in collaboration in the past, I’ve found that it has notable oddities and omissions. Often it is behind the times in tracking important variables, such as HER2 status in breast cancer, which SEER didn’t begin tracking until 2011 or so, even though HER2 status had been used for at least a decade before that.
That’s probably why the authors chose the National Cancer Database, which is a joint project of the American College of Surgeons and the American Cancer Society. It is a clinical oncology database sourced from hospital registry data collected by the more than 1,500 facilities accredited by the American College of Surgeons Commission on Cancer (CoC). Data cover more than 70% of newly diagnosed cancer cases nationwide and are used to develop quality improvement initiatives and set quality standards for cancer care in many hospitals across the US.
Now, imagine that you want to look at the effect of alternative medicine use on cancer mortality, and you had access to a large database like this. How would you go about doing it? There are a lot of things you have to consider. First, you would want to look at potentially curable cancers, because you want to find out if patients with curable cancers who choose alternative medicine die at a much higher rate than those who use conventional therapy. Thus, you have to exclude patients who had metastatic disease at the time of diagnosis. Another important thing you have to do is to choose cancers that have a reasonable rate of cure using conventional therapy. Choosing pancreatic cancer, for instance, wouldn’t make much sense, since the vast majority of pancreatic cancer patients, even those without metastatic disease at diagnosis, die of their disease. Even though we know from the Gonzalez trial that patients with pancreatic cancer still do much worse, dying faster and suffering more, than those treated with conventional medicine, such a difference would be unlikely to show up in a database study like this. So the authors chose four common cancers, nonmetastatic breast, prostate, lung, or colorectal cancer.
Similarly, how do you identify patients in the database who underwent alternative medicine treatment rather than conventional therapy? This is a question that is not as easy to answer as it sounds. For one thing, many databases don’t include that information. One statewide database with which I worked, for instance, didn’t even have a field for alternative medicine (or even “complementary and alternative medicine”), even though it had over 750 elements tracked for each patient. This is almost certainly the reason the SEER database was not used for this study.
Fortunately, the NCDB has data fields that can help:
Patients who underwent AM were identified as those coded as “other-unproven: cancer treatments administered by nonmedical personnel” and who also did not receive CCT, defined as chemotherapy, radiotherapy, surgery, and/or hormone therapy. Patients with metastatic disease at diagnosis, stage IV disease based on the American Joint Commission on Cancer (AJCC) staging system (11), receipt of upfront treatment with palliative intent, and unknown treatment status or clinical or demographic characteristics were excluded.
The authors identified only 280 patients who fit the criteria, and noted that patients in the alternative medicine group were likely to be younger, female, and have a lower Charlson-Deyo Comorbidity Score (CDCS, a measure of preexisting comorbidities or of how “sick” the patient is at the time of diagnosis). In multivariate analyses controlling for clinical and demographic factors, the authors found that patients undergoing alternative cancer treatments were more likely to have breast cancer, higher education, Intermountain West or Pacific regions of residence, stage 2 or 3 disease, and a lower CDCS. All of this jibes with the usual impression that patients who choose alternative cancer cures tend to be of higher socioeconomic status and education, as well as healthier than average.
So what were the results? Not surprisingly, the risk of death was higher for three out of the four cancers. Overall, the hazard ratio (HR) for death was 2.5 (95% confidence interval [CI] 1.88 to 3.27); 5.68 for breast cancer (CI 3.22 to 10.04); 2.17 for lung cancer (CI 1.42 to 3.32); and 4.57 for colorectal cancer (CI 1.66 to 12.61). The differences observed were not significant for prostate cancer, likely because the survival with conventional therapy was so high to begin with. Prostate cancer tends to have a long natural course, and in this study numbers were small and follow-up too short.
As the cliché goes, a picture is worth a thousand words. Here are the survival curves:

Obviously, this study has a lot of limitations. For one thing, the use of conventional medicine is likely to have been under-ascertained (i.e., undercounted or incompletely identified). After all, as I’ve discussed with other patients, some of those who choose alternative medicine to treat their cancer ultimately realize that it’s not working and come back to conventional medicine. Such patients could also have gone to different institutions that aren’t covered by the NCDB. However, if such a bias occurred, it would have tended to make the differences in survival between the alternative medicine group and the conventional treatment group smaller, not larger, meaning that if such a bias occurred in this study the harm caused by choosing alternative medicine is likely to be significantly worse than reported.
Other studies
Obviously, this study by Skyler et al is just one study, and the most recent. There are other studies showing similar results, but unfortunately they are relatively few. For example, the first study I remember encountering after I had started blogging about medicine and alternative medicine that addressed the question of the effect of alternative medicine on cancer survival was published in 2006 in the American Journal of Surgery by Chang et al. This study used a different methodology to study the effect of alternative medicine on breast cancer survival. Specifically, the authors did a chart review of patients who refused or delayed recommended treatment of their breast cancer to pursue alternative therapies and compared their survival to that expected in patients with disease of their type and stage.
Even eleven years later, this study remains interesting to me because it’s the first one that I can recall encountering that explicitly looked at the outcomes of patients who chose “alternative” therapies as their primary treatment. There are lots of studies out there looking at alternative medicine use in cancer patients, but these mainly look at patients who use it in addition to conventional therapy (i.e., as “complementary” therapy). This study does have one strength, too, compared to most such studies, in that the patient population comes from a community practice, not an academic medical center. Consequently, it can be viewed as more representative of the “real” world situation than many studies done in academic medical centers, where the patient population may be self-selected as people as either motivated enough to seek out tertiary care centers or sick enough that their community surgeons and oncologists refer them.
One thing that was also rather fascinating about the study was the variety of alternative therapies that the study population opted for, including coral calcium, coenzyme Q10, herbs, dietary therapy, high dose vitamins, mushrooms, chelation therapy, poison hemlock (I’m not kidding), and a variety of unspecified therapies. Because of the sheer variety of therapies used and the low number of patients using each individual therapy, it was not possible to “identify particular alternative modalities that were particularly ineffective,” as the authors put it.
Who says scientific papers don’t occasionally have sarcasm in them?
Basically, the study identified 47 breast cancer patients who opted for alternative therapy, but follow-up information was only available for 33. These were divided into patients who refused surgical treatment altogether; patients who delayed appropriate surgical treatment to pursue alternative treatments; patients who refused adequate sampling of the lymph nodes; patients who refused procedures to ensure adequate local control (additional surgery and/or radiation therapy); and patients who refused chemotherapy. I’m going to concentrate first on patients who refused or delayed surgery, for the simple reason that surgery is what is curative for breast cancer and differences in survival due to adjuvant therapy can be as low as the single digit percentages, depending upon the stage of the cancer.
Of patients who refused surgery, none of the six patients identified were Stage IV (metastatic disease) at initial diagnosis. However, five out of these six patients who returned to the surgeons doing the study had progressed to stage IV, with a median time of follow-up of 14 months, with one death within a year. That’s pretty amazing, given that two of these patients were Stage I upon initial presentation. There were also five patients identified who initially refused surgery in favor of alternative medicine, all of whom were Stage II or III. The median time between diagnosis and surgery was 37 months. All five demonstrated progression of their disease, with three progressing to Stage IV disease and one of these dying of metastatic disease. Thus, 10/11 patients who refused surgery experienced significant disease progression, with 8/11 of these progressing to stage IV disease, which is incurable, and 2/11 dying within the short time frame of the study.
Not surprisingly, patients who declined chemotherapy or hormonal therapy fared better because, as I’ve explained before, for operable breast cancer, the single most efficacious intervention is surgery, and it is not that uncommon for patients with even fairly large tumors to be “cured” with surgery alone. Indeed, the benefits of chemotherapy are fairly modest in many cases, particularly those with early stage disease. In a small number of patients, it was difficult to quantify the effect of choosing alternative medicine over conventional chemotherapy, but the authors were able to estimate that the relative risk of death in 10 years in those who refused chemotherapy was 1.54; i.e., a 54% higher chance of dying within 10 years compared to those treated with conventional medicine.
A few years later, there was followup study published in the Annals of Surgical Oncology examining the same question, this time with 61 patients to study and ten year follow-ups available. Again, a retrospective chart review was performed, with telephone interviews conducted when possible. Again, authors calculated an estimated expected 10-year survival rate and/or 10-year relapse rate of each patient if they used recommended therapy and compared it to what was actually observed in the alternative medicine group. For patients who delayed surgery, the prognosis at initial presentation was compared with the prognosis based upon return presentation.
The results were just as grim. As before, patients were divided into two groups, those who refused or delayed surgery (n=26) and those who refused adjuvant therapy, such as radiation and chemotherapy (n=35). In the group that refused surgery, 96.2% of patients experienced progression of their cancer, and 50% died of their disease. The mean stage at diagnosis in this group was II. The mean stage when patients in this group re-presented after primary treatment with alternative medicine was IV, which is, again, incurable. In the group refusing adjuvant therapy, progression occurred in 86.2% of those in the ASG, and 20% died of disease. Overall, in the surgery group, the expected mean 10-year survival calculated for those omitting surgery was 69.5%. In comparison the actual observed 10-year survival for these patients was 36.4% at a median follow-up of 33 months. For the patients who delayed surgery to undertake alternative treatments, the figures were 73.6% expected 10-year survival versus a 60% observed 10-year survival.
The authors also noted that, for the patients refusing adjuvant chemotherapy or hormonal therapy, the median tumor size at presentation was 2 cm and that the mean calculated 10-year relapse-free survival at initial presentation was 59.2%. Using a commonly utilized online tool to calculate the benefit of chemotherapy based on aggregated clinical trials, the authors noted that, had recommended adjuvant therapy been followed, relapse-free survival would have improved to 74.3%. However, the observed relapse-free survival was only 13.8%. They also noted that, although the patients’ intent was to avoid traditional therapy, ultimately, 6 patients in this group started endocrine therapy to control breast cancer recurrence, and 21 had salvage chemotherapy to attempt to control recurrent disease.
Here’s a summary of the patients who refused surgery (AWD = “alive with disease; NED = “no evaluable disease,” or basically no detectable disease):
You get the idea. This is far worse than what would be expected in patients undergoing standard treatment. As before, this study shows that refusing surgery results in the worst outcomes, which is something that has been known for a long time. For instance, this 2005 study utilizing data from the Geneva Cancer Registry. This study did not look at alternative treatments but rather at just the refusal of patients to undergo surgery for their breast cancer. The results were very similar to what the other studies I discussed showed:
Another study, this time published in the World Journal of Surgery in 2012 examined women in the Northern Alberta Health Region who declined recommended primary standard treatments and included 185 women who refused standard treatment, resulting in a median delay in instituting effective treatment of up to 101 months. The survival graphs look depressingly the same:
Both Scott Gavura and I discussed this study in detail when it was published. Of note, quoth the authors:
Our data showed that almost all the patients who initially refused treatment progressed to a higher stage on later presentation at the cancer center. The majority of the patients (57%) in our series initially chose CAM as the primary treatment instead of surgery. Those who had chosen CAM had disease progression with particularly poor disease-specific survival when compared to those who received standard treatment.
Finally, a recent study from Malaysia found a strong correlation between CAM use and delays in diagnosis and treatment in breast cancer patients, although this study also suggested that the reason many women use alternative medicine is because they don’t have good access to high quality medical care.
As an aside, I will note that one tendency in some of these studies that drives me up a wall is the authors’ tendency to refer to alternative medicine used as primary treatment for a cancer “CAM.” It is not CAM. CAM, by definition (you know, the “complementary” in “complementary and alternative medicine”) is not used as primary treatment for cancer or anything else. If an unproven or ineffective treatment “outside the mainstream” is being used to treat a cancer, it’s not CAM. It’s alternative medicine. I don’t like the term “CAM,” because it was designed as a means to slip unproven treatments into conventional medicine by adding them to conventional therapy when they are unnecessary, but it is the language we have.
Finally, compare the curves above to this curve, which I use frequently. This is from a famous study from 1962 by Bloom and Richardson that calculated the survival of patients with untreated breast cancer. It was carried out long before mammographic screening became the norm, which means that the cancers were detected by palpation and other clinical signs. The point is that survival in untreated breast cancer is longer than you might guess:
The authors compared their data with previous studies from the 1920s and 1930s and found that their curve lined up very closely with previous data on expected survival in a group of women, all comers, with untreated breast cancer. Basically, the median survival was 2.7 years. 18% of the patients survived five years; 3.6% survived 10 years; and 0.8% survived 15 years. Of note, it was 19 years before all 250 patients in the study were dead. Notice how the curves above for women choosing alternative medicine over conventional therapy get closer to resembling the curve from the Bloom-Richardson paper. The don’t quite get there because we’re in a different era, where breast cancers are usually discovered by mammography and were much smaller at diagnosis than in the patients in that paper.
But what about CAM?
I made a point of expressing annoyance over how some authors throw around the term “CAM” when they mean “alternative medicine.” This brings up a question. Does CAM use affect cancer survival? Again, there is a paucity of evidence. We might expect that it probably doesn’t, at least when used as the strict, “integrative medicine”-approved definition of unconventional therapies used in addition to conventional medicine is followed. Again, there aren’t a lot of studies, and most of those seek to demonstrate that a specific set of CAM involving “mind-body” or psychotherapeutic interventions actually improve survival in cancer patients. Unfortunately, they do not, as has been discussed here before.
Other studies have looked at CAM in cancer patients, with mixed and mostly unfavorable results. For example, a study from Norway found a modest negative effect of CAM use in cancers, with a higher death rate over the study period (79% versus 65%), with a hazard ratio for death of 1.30 that just missed statistical significance, leading the authors to conclude that the use of alternative medicine “seems to predict a shorter survival from cancer” and that “the effect appears predominantly in patients with a good performance status” (i.e., the healthiest patients). In addition, a Korean study of terminally ill cancer patients assessed the use of CAM on survival and health-related quality of life (HRQOL), finding that CAM did not provide a survival benefit but did negatively impact various measures that go into calculating HRQOL.
Finally, a large prospective trial known as the Health Eating, Activity, and Lifestyle (HEAL) Study examined 707 patients with stage I to IIIA breast cancer. No associations between CAM use and breast cancer-specific or total mortality were observed. Another study, a pooled analysis from 2012 of four studies conducted in Hawaii in 1994–2003 and linked to the Hawaii Tumor Registry to obtain long-term follow-up information, also found no overall link between CAM use and breast cancer mortality, but did find links between the use of energy medicine use and death as well as finding that Filipino women who used CAM were at a higher risk of death. Those results might have been spurious, but I note that the data did actually show a trend towards a correlation between overall CAM use and death that just didn’t reach statistical significance.
What’s probably most problematic about CAM is not so much that using it with conventional medicine harms patients. Rather, it’s the mindset that leads to strong associations between CAM use and, for instance, refusing adjuvant chemotherapy, as I have discussed in detail before and noted by way of citing a Malaysian study in which CAM use was associated with delays in diagnosis.
The bottom line: Alternative medicine kills cancer patients
There is a surprising paucity of evidence regarding whether the use of CAM in addition to conventional therapy has an adverse effect on cancer survival, but the evidence that we do have is very clear on at least one thing: CAM does not improve cancer survival. Less clear is whether CAM has an adverse effect on cancer survival. There the evidence is conflicting, but there is plenty of reason to be concerned about the use of CAM in cancer, given correlations between CAM use and delays in diagnosis and refusal of adjuvant chemotherapy.
Regardless of what you think of the phenomenon of “integrative” medicine or CAM, there is one thing that the existing medical literature, as thin as it is, indicates, and it’s that alternative medicine kills cancer patients. It is basically no different than refusing treatment altogether and much more expensive and troublesome. Given that there is no good evidence of specific anticancer effects from close to all (if not all) alternative medicines, there was never any reason to suspect that the answer would be otherwise. Moreover, as strongly suggested by the Gonzalez trial, alternative medicine use as a primary therapy for cancer often means that patients aren’t receiving effective, science-based supportive care for their cancers, resulting in inadequate (or nonexistent) relief of cancer-related symptoms and unnecessary suffering. Use of alternative medicine alone to treat cancer is likely to be a death sentence, or at least to cause delays that make ultimate cancer treatment with conventional medicine more difficult and less likely to be successful.

Risks of CAM Treatments for Cancer
Steven Novella on December 10, 2014
Link


“What’s the harm?” is an insidious idea when used as a justification for unscientific medical treatments. The argument is typically put forward with the assumption that direct physical harm is the only type of harm that can result from such treatments, so as long as they aren’t toxic there is no downside to trying them. Harm comes in many forms, however: delayed effective treatment, wasted time and energy, financial harm, the psychological harm of false hope, and the downstream effects of instilling unscientific beliefs regarding health care.
One other form of harm is physical but is not due to direct physical damage or toxicity. Rather, it is caused by CAM treatments interacting with proven therapies. A recent survey, presented at the Clinical Oncology Society of Australia annual scientific meeting, explored the potential for such interactions among oncology patients. Lead researcher Sally Brooks found that, in addition to vitamins and minerals, cancer patients were most interested in fish oil, turmeric, coenzyme Q10, milk thistle, green tea, ginger, lactobacillus, licorice, Astragalus and reishi mushrooms.
As I have written many times before, herbs are drugs, but many patients do not treat them as such because they are regulated and marketed as “supplements,” more like food than drugs. There are concerns that many vitamin and herbal products may interact with chemotherapy or radiation therapy in order to reduce effectiveness or even increase side effects.
The research on antioxidant supplementation, for example, raises some concerns, but is equivocal. Part of the effectiveness of chemotherapy comes from increasing reactive oxygen species (ROS) which cause damage to cells. ROS damage both cancerous and healthy cells, and so are part of the desired effects from chemotherapy, but also the side effects. It is therefore possible that antioxidants may decrease the side effects of chemotherapy, but also decrease the effects. The balance between efficacy and side effects is carefully managed in chemotherapy, and if patients are taking antioxidants (especially without telling their oncologist), this can affect that careful balance.
Systematic reviews to date have concluded that the evidence for the net effect of antioxidants in chemotherapy is mixed and of insufficient quality to come to any solid recommendations.
Other effects are also of concern. Turmeric, for example, may decrease the effectiveness of chemotherapy by interfering with the mechanisms by which chemotherapy induces cell-death in cancer cells. Turmeric also interferes with the cytochrome P450 system which is important for the metabolism of many drugs, including some chemotherapy agents, and therefore may increase side effects and toxicity.
Astragalus has effects on the immune system. While preliminary evidence suggests this may be helpful in cancer treatment, it may worsen auto-immune diseases and interact with immunosuppresive drugs.
Overall the evidence for any benefit from the commonly-taken herbal supplements as adjunctive care for any particular cancer is mixed and preliminary. At the same time these agents are drugs that can cause side effects and interact with chemotherapeutic agents, causing photosensitivity, interacting with metabolism and clearance, and perhaps reducing effectiveness. Some may actually prove useful as well, but the complexity of their effects requires careful study, which is often lacking.
Patients often do not disclose supplement use to their physicians, and therefore may not have an opportunity to receive specific advice on such use.
It is also important to recognize that studies involving carefully-standardized supplements are difficult to apply to the real world because the supplement industry is so poorly regulated. Many recent studies have found that supplements are often contaminated, have variable doses, and even contain product substitutions. It is very difficult, therefore, for patients to even know what they are getting.
While further research for each individual herbal product in specific doses for specific cancers and in combination with specific cancer treatments is required before we can make definitive statements about their safety and efficacy, there is also research into the net outcomes of those taking so-called CAM along with their cancer treatments.
What evidence we have is also preliminary, but not favorable. Some studies, for example, show that patients using CAM along with standard cancer treatments have a decreased survival. There are not randomized, and so conclusions regarding cause and effect are difficult, but such evidence does suggest caution.
Other studies find that quality of life, often touted as the main benefit for CAM, is also decreased in cancer patients using CAM.
Conclusion
Overall the evidence for the effectiveness, side effects, drug interactions, and net effects on survival and quality of life with herbs and other unconventional treatments for cancer is of poor quality, showing mixed and complex results. With herbs, since they often have active pharmacological effects, there is the potential for benefit, but also the potential for harm (as with any drug).
The claims made for such treatments often greatly exceed the evidence. Patients, therefore, are generally met with misleading information, suggesting efficacy where the evidence is thin, and downplaying the potential for harm and negative interactions. Because such treatments are promoted as “alternative” patients also are often reluctant to discuss such issues with their physicians, who may be in the best position to advise them on the potential risks and benefits.
As Brooks (the author of the recent survey) and others also point out, unconventional treatments may also present a financial burden at a time when patients are already under financial stress from their illness and perhaps reduced ability to work. They may also experience psychological stress from being pressured by well-meaning but misguided friends and family members pushing them to try unconventional treatments, at a time when they are vulnerable due to their illness.
The underlying source of all this unnecessary risk and stress for cancer and other patients is the basic notion of “complementary” or “alternative” medicine. The marketing of a subset of treatments as CAM creates an artificial double standard, one in which the rules of evidence are altered, informed consent is compromised by misinformation, product standards are lowered, and patients often do not feel comfortable discussing such treatments with their physicians.
Eliminating this double standard could be an effective first step in correcting such problems.

Naturopathy vs. patients: Patients lose
Over the weekend, there was a news story describing two cancer patients treated by naturopaths in New Zealand. Both died, one almost certainly unnecessarily, the other after enduring more suffering than she likely had to. These tragic cases and others reminded me of why it is so appalling that so many physicians are “integrating” naturopathy into “integrative medicine.” In reality, they are integrating quackery into medicine.
David Gorski on August 28, 2017
Link

We write frequently about naturopathy here because, of all the dubious pseudoscientific medical “disciplines” out there, naturopathy (along with chiropractic) has achieved the most “respectability.” Indeed, as I like to point out in my own specialty (breast cancer), the Society for Integrative Oncology (SIO) even admits naturopaths as members. Indeed, the immediate past president of SIO is a naturopath (and, depressingly, faculty at my medical alma mater, the University of Michigan), as was the SIO president in 2014. So entrenched are naturopaths in SIO that they have been prominent co-authors on SIO clinical guidelines papers, like this set of breast cancer guidelines, with two naturopaths as co-authors, one as first author. Basically, in academia at least, naturopaths have certainly surpassed chiropractors in terms of seeming respectability, even though they promote alternative medical treatments that, as I pointed out two weeks ago, kill cancer patients dead through lack of effective treatment.
I was reminded of this unfortunate infiltration of naturopaths when I saw a story yesterday from, of all places, New Zealand, “Naturopathy under microscope after cancer sufferers speak from under shadow of death.” It tells the story of two cancer patients who relied on naturopaths for treatment and didn’t live to regret it, at least not long. Consider this to be a sequel to my post from two weeks ago, only focusing on naturopaths.
An almost certainly preventable death
Naturopaths sell themselves to cancer patients as offering treatments that are “natural,” although I’ve always been puzzled how many treatments offered by naturopaths (like high dose intravenous vitamin C, “functional medicine, or various diagnostic tests like thermography) are any more “natural” than what “conventional medicine offers. What is really most attractive to patients is the claim that they can treat cancer without the toxicity associated with known effective treatments for cancer, such as radiation, surgery, and, most feared of all, chemotherapy. Unfortunately, when patients with highly treatable cancers believe these claims, the result can be fatal:
It is late July. An Auckland woman sits at her dining room table, frail, cosseted in a wool-knit beanie, brittle wisps of hair poking out.
She knows her time is running out. She doesn’t know it, but she will be dead in two weeks.
First, though, she wants to speak out to call for regulation of naturopaths after her bitter experience with alternative therapies.
“From my point of view the naturopath has used people like me as guinea pigs,” the Auckland woman told Stuff. “I don’t think naturopaths should try to heal cancer. I trusted in naturopathy, I don’t trust in it any more.”
This is the price patients with treatable cancers can end up paying for trusting naturopaths. This patient, who is not named in the story, didn’t even have cancer, but rather a premalignant condition known as ductal carcinoma in situ (DCIS). I’ve written about DCIS on multiple occasions , because it is a condition whose management is becoming less straightforward as we understand more about the biology of the disease. The reason is that not all DCIS progresses to life-threatening breast cancer in a woman’s lifetime; indeed, most probably do not, to the point where watchful waiting is being discussed as a viable treatment option for women with low grade, low risk DCIS. There is a clinical trial, the Low Risk DCIS (LORIS) trial, comparing outcomes between immediate surgery and active monitoring for low-risk DCIS. Close to 100% of women with DCIS women should survive their disease with treatment.
Here is this patient’s story. It began in 2013:
In July 2013 she had been diagnosed with ductal carcinoma in situ (DCIS), a pre-cancerous breast condition. Her oncologist told her she had a “50/50” likelihood of contracting breast cancer, and recommended an immediate double-mastectomy.
“I was shocked and scared of surgery, I’d never had surgery. Then you face one breast, both breasts, no breasts, you start looking for alternatives.”
Unaware some DCIS strains are more aggressive than others, she believed time was on her side and she could try alternative medicine.
We don’t have any information on the features of this woman’s DCIS that would allow me to estimate her risk. For instance, we don’t know from this story whether it was high or low grade, low grade being lower risk. We don’t know if it had high risk features, like comedo necrosis, which portends a high risk of progression to invasive cancer. I was also puzzled by the recommendation for immediate bilateral mastectomy. Mastectomy is usually not indicated for DCIS. Most DCIS lesions can be treated with breast conserving surgery (lumpectomy) followed by radiation. Mastectomy is reserved for cases of diffuse or extensive DCIS in which all the disease can’t be removed in by lumpectomy. Bilateral mastectomy is rarely indicated for DCIS, the main exception being when both breasts are involved with extensive DCIS, a very uncommon situation. In fairness, some women with extensive DCIS in one breast and DCIS in the other breast amenable to mastectomy will opt, not necessarily inappropriately, for bilateral mastectomy, but this is usually the woman’s choice, and this article states that the oncologist recommended bilateral mastectomy. Again, no reason for this recommendation is provided in this news story; so I don’t know whether this patient had any of the indications for a bilateral mastectomy in DCIS. I’d be willing to bet that she probably didn’t and that this recommendation was probably a recommendation for massive overtreatment.
I mention this because the aggressiveness of the recommended surgery almost certainly played a role in this Auckland woman’s disastrous decision. Whatever her reasons, though, this is how her story played out. The woman and her husband found a naturopath, whose name is never mentioned (much to my irritation), having heard stories about her alleged success rate and discovered that she was affiliated with Cape Town University. (Did they mean the University of Cape Town? I wondered.) The naturopath also advertised that she had an MDipNat.Herb from the South African College of Natural Medicines, which is apparently a degree in herbal medicine of some sort. This particular naturopath saw her and then followed up her treatments with Internet consultations:
The naturopath continued treating the Auckland woman over the internet using words such as “tumours” and “cancer”. “At this stage there is nothing to worry about,” she emailed.
Apart from a grueling regime of daily natural supplements, for a time the naturopath told her to simply apply ointment to her breasts.
The woman emailed the naturopath photos of her bruised breasts: “Hi, those green spots definitely little tumours,” the naturopath replied. “It looks like there is just the start of cancer, would most probably have developed into major pictures!!! … fantastic those come out”.
A week later the Auckland woman sent more pictures.
“Wow, girl this looks great,” the naturopath replied. “The top one looks at this stage there is nothing to worry about … you can just apply zambuck ointment to that to draw out the last anger and puss … do you have that, can I courier you some?”
Now here’s something I never figured out. Naturopaths contend that theirs is “natural medicine” that is much less toxic and causes many fewer side effects; sometimes it’s claimed that there will be no side effects. Yet their treatment regimens are often quite onerous. For example, read the description of this woman’s regimen, which got to the point where she had to get up earlier every morning just to “go through all my stuff.” She spent thousands on “myriad pills, drops, powders and ointments the naturopath advised her to take.” Then consider other alternative cancer treatments favored by naturopaths, like the Gerson protocol, which requires drinking thirteen organic juices (which have to be prepared fresh hourly) and well over a hundred supplement pills per day, as well as a basic organic whole food plant-based diet plus five coffee enemas per day. I kid you not.
In any case, none of her treatments worked, and in fact the woman became progressively fatigued to the point where she gave up less than a year later and gave the supplements back because she “didn’t believe in them any more.” Even so, instead of going back to real medicine, she went to another naturopath and didn’t finally undergo surgery until January 2016. One thing that bothers me about this story is that the timeline isn’t really very clear. As a cancer doctor, I really want to know when this patient was diagnosed with invasive cancer, as that would clarify my discussion a lot. However, I do know how the story ends, and it ends tragically:
Before dying, the woman confronted the naturopath by email about her treatment methods and unavailability.
And with days left to live, the Auckland woman asks one last time, “I don’t understand why there are no regulations?”
It’s late July. Pale, hunched, shuffling, months after her cancer had spread to her lymph nodes, the woman holds on.
“If we could make a difference there with regulation, that would help everyone – that would help the naturopath,” she says.
“I’m starting my chemotherapy, it’s quite exciting, the hope is it will shrink the existing cancer but it has spread, I don’t know how much hope there is.
“I don’t want to lose hope.”
It was not to be. This month, she passed away.
When the reporter, Simon Maude, contacts her one last time, instead of expressing regret, the naturopath makes it all about her:
And the naturopath? We give her a final phone call.
She’s closing her holistic health practice in September, she says.
“I’ve just had it. At the end of the day it’s a thankless job, I’ve given my life to people to try and help them, I’ve had enough”.
Selling ineffective supplements that fail to prevent what was almost certainly an eminently preventable death is a “thankless job.” I suppose so because this naturopath definitely doesn’t deserve anything resembling thanks. I did, of course, try to figure out who this naturopath is, and I think I did. Since I can’t be sure, I will not publish my speculation, however. Instead, I will move on to the second case.
Another way naturopaths harm cancer patients
The second patient, a 55-year-old woman named Jane Norcross-Wilkins, had breast cancer and treated by the same naturopath, but her case is quite different otherwise. She had breast cancer in 2001, but it recurred in 2011. By 2015 it was stage IV and incurable. As her husband, Mike Malcolm put it, she just wanted more time, with the rationale, “OK, if I can’t beat it, I can work with it and see how far I can go,” which is certainly not unreasonable and is the way many patients with terminal cancer think. It’s also the approach taken by real oncologists: To slow the progression of the cancer for as long as possible while also balancing the toxicities of therapy with the limited anticipated benefits and taking into account the patient’s values (e.g., to fight for as long as possible vs. to be as comfortable as possible for as long as possible). However, such decisions require a dispassionate assessment and communication of the actual prognosis versus the risks and toxicities of therapy. Naturopaths frequently short circuit that necessary discussion with false hope, as in the case of Norcross-Wilkins, who went to see this same naturopath in December 2015:
Upfront with the naturopath about Jane’s terminal cancer diagnosis, they listened as the naturopath held court. “She’s good at talking herself up, she highlighted how certain parts of the cancer process can be interrupted or changed with processes she used, stopped and reversed.
“You could listen to her all day, she’s very knowledgeable, she explains things in layman’s terms.”
Jane was put on a gruelling regime of expensive natural remedies. She discovered homeopathic melatonin sold to her for $50, retailed elsewhere for $12; vitamin C caplets sold for $140 retailed for $87 over the counter.
As with the first patient – not only was Norcross-Wilkins’ regimen expensive, it was brutal:
Mike explains: “It was like a detox, a purge, I’ve never seen anything like it, the amount of things she had to take. But the naturopath said ‘no, no Jane’s got to keep on doing it, it’s a little bit hard at the start but you’re killing the cancer, you’re giving the cancer an environment it can’t live in’.
“But Jane couldn’t live like that.”
As it became apparent that the woo wasn’t working, this happened, the naturopath became progressively more difficult to get a hold of, even after having promised at the beginning that Norcross-Wilkins could call her “any time.” Phone calls went unreturned, and e-mails were not answered for days. When Norcross-Wilkins was hospitalized for three weeks in January 2016 the naturopath didn’t inquire about her. The end result:
Angry emails sent to the naturopath ended with Jane and Mike dumping her late the following month.
A final March 2016 letter from Jane to the naturopath ended: “I strongly suggest you set up supervision for yourself and a highly experienced practitioner to ensure that you are working ethically … I also suggest you look into registering with a body such as the NZ Natural Health Council or the NZ Society of Naturopaths Inc.
“I do not wish to continue as your client,” Jane concluded.
The naturopath apologised profusely, and promised not to treat cancer sufferers any more. She refunded the cost of some of Jane’s medicine’s [sic].
Let’s just put it this way. Real oncologists don’t have the option, ethically, of avoiding their patients who aren’t doing well. In any event, Norcross-Wilkins married Malcolm in December 2016 and died on February 8, 2017.
Defenders of naturopaths and other quacks will frequently point to patients like Jane Norcross-Wilkins and ask, “What do they have to lose? Conventional medicine can’t save them.” The response is simple, if not easy. Patients like Norcross-Wilkins are going to die, but what naturopaths like this one rob them of are effective palliative care, so that they suffer more than they need to, both from their cancer progression and from the quack therapies they undergo; money that could go to their estate that instead is spent on ineffective nostrums; quality time with their families before their condition deteriorates too much; and a chance to put their affairs in order properly before the end.
The naturopath responds
There are usually at least two sides to every story, and this one is no exception. Unfortunately, the naturopath’s side of the story comes across as self-serving and very much covering her posterior:
“Cancer IS an exhausting disease,” the naturopath tells Stuff. “There’s no nice way to treat cancer, you show me a patient who is doing anything that is making them feel better.
“People think because [my treatment is natural] it should feel good. It’s not, there’s no easy way to treat cancer.”
Tumours, cancer – at this point shouldn’t the naturopath have stopped and suggested the woman go back to her oncologist?
“It’s not my place to refer them to a specialist,” she tells us. “I can’t do that because I’m a naturopath.”
That last bit strikes me a very intentionally legalistic justification. Let’s just put it this way. I don’t know the law in New Zealand, but whatever it says regarding regulating medical practice I’d be willing to bet that there’s nothing in it that forbids a naturopath from saying to a patient who is clearly not getting better, “I really think you should see an oncologist.”
Be that as it may, it turns out that naturopaths are not regulated in New Zealand. New Zealand Society of Naturopaths vice-president Sharon Erdrich is quoted as saying that New Zealand naturopaths want “tighter regulations.” This claim would seem to be belied by the fact reported that a non-regulated health profession can submit an application to the Ministry of Health to be regulated and the observation that the “ministry has not received an application from naturopaths to become regulated under the Health Practitioners Competence Assurance Act 2003.”
Beyond cancer and New Zealand
Of course, naturopaths are not just dangerous to cancer patients, as a recent story that I had thought about blogging about but somehow never got to shows. In this incident, which occurred two years ago, an Australian naturopath, using the rationale that a breastfeeding mother needed to “alkaline” her milk and “eliminate the toxins” from the baby’s body, recommended a 100% raw vegan diet:
An Australian naturopath who instructed a breastfeeding mother to stick to a “raw food” diet to cure her son’s eczema has admitted that her advice endangered the baby’s life.
Marilyn Bodnar, 61, was accused of directing the mother, a midwife who cannot be named for legal reasons, to abandon other medical advice and adhere to a strict diet of raw vegetables, fruit and seeds.
By the time the mother took the baby to hospital, he was limp, had sunken eyes and police believe he was just days from death.
According to court documents, Bodnar, from Sydney’s south-west, made the mother feel guilty for eating “rubbish” during her pregnancy and using steroid creams for the boy’s eczema.
When the baby developed a fever, this naturopath’s irresponsible advice went even beyond this. She advised the mother to drink nothing but water, saying, “You’re not allowed to drink anything if you want to see him better.” When the infant started vomiting, the naturopath went beyond even that and told the mother to continue, saying, “increased temperature meant increased vitality.” By the time the baby was taken to the hospital, he was badly emaciated and, at eight months, weighed only 6.39 kg, which placed him in the zero percentile for babies his age.
Nor is this the first time Bodnar endangered a life:
It can now be revealed that Bodnar — who boasts online of being able to help “parents and children’s health and infertility” — faced a manslaughter trial in 1988 over the death of a woman who was on a water only diet for 63 days.Bodnar was acquitted of the manslaughter of 42-year-old Narelle Niemann, who lost 35 per cent of her body weight while she was under Bodnar’s care.Prosecutors argued Bodnar failed to get professional help when her condition deteriorated, but the jury found her not guilty. She argued at trial she was helping Ms Niemann as a friend and not as a patient.
So Bodnar’s been at this sort of thing for nearly 30 years at least? One wonders why Australian authorities couldn’t stop her until now. Not that we in the US have anything to brag about on the score of stopping naturopathic quacks from endangering lives. For instance, four months ago, I wrote about the case of Jade Erick, a young woman with eczema who died of a hypersensitivity reaction when a naturopath named Kim Kelly treated her in his office with intravenous curcumin.
Another case that I’ve discussed here before involved a woman in Bowling Green named Fikreta Ibrisevic who sought the services of a local naturopath named Juan Sanchez Gonzalez to treat her rhabdomyosarcoma and was quoted in news reports as having told her and her husband Omer Ahmetovic that “chemotherapy is for losers” and that he could “guarantee” that Ibrisevic would be cancer-free with his treatments within three months. Predictably and tragically, Gonzalez’s quackery didn’t work. Ibrisevic also sought out the care of other naturopaths. Unfortunately, by the time Ibrisevic realized this and sought out conventional medical care it was too late for her. Although she accepted chemotherapy, the cancer was too advanced. She died of it on February 27, 2017. This case is compounded by further tragedy, as well. On a Friday evening after office hours four days after his wife’s death, the grieving husband allegedly walked into Gonzalez’s office and shot him dead.
There are no “good naturopaths”
I started this article by complaining about the SIO, which will no doubt consider my mentioning of the organization unfair in relationship to discussing these cases of naturopaths leading to the deaths of cancer patients. The reason is that most of the naturopaths I just discussed were not licensed and didn’t come from “approved” schools. To some extent, there might be a reasonable point there, but only in that naturopaths who join SIO are usually associated with academia, which (usually) keeps their worst impulses under control. Usually. Unfortunately, though, organizations like the SIO, as well as most integrative medicine physicians, turn a blind eye to the quackery inherent in naturopathy. To illustrate this, I like to relate an anecdote. (You can skip the next paragraph if you’ve heard it before, as I do repeat it from time to time.)
Back when I published my Perspective article, “Integrative oncology: Really the best of both worlds?” in Nature Reviews Medicine three years ago, the SIO immediately criticized me for spending so much of it discussing homeopathy, which its leadership properly rejected as being pseudoscience. There were two aspects of this complaint that amused me. First, homeopathy was a far smaller part of the first draft of the article, but reviewers forced me to add more. Second, even more amusing (or disappointing—or both) was that it was clear that the SIO had no clue how integral homeopathy is to naturopathy. I responded by pointing out that naturopathy schools include many hours of homeopathy in their curricula and that naturopaths are tested on homeopathy in the NPLEX, the licensing examination used by states that license naturopaths. I also couldn’t resist twisting the knife a little bit by pointing out that one of the authors of the SIO clinical guidelines for breast cancer was a naturopath who at the time had an open clinical trial of homeopathy listed on ClinicalTrials.gov. Basically, you can’t have naturopathy without homeopathy. To reject homeopathy as pseudoscience but still accept naturopaths as co-equal medical colleagues is inherently contradictory, because all naturopaths are trained in homeopathy and most of them use it.
Consider, for example, Kim Kelly, the “naturopathic physician” whose irresponsible use of an unproven treatment like IV curcumin for eczema killed Jade Erick. He graduated from Bastyr University, basically the Harvard or Yale of naturopathy schools, the crème de la crème of naturopathy schools. (Never mind that being the crème de la crème of quack schools is not a good thing.) Any naturopath who looked at his credentials would tell you that he is everything that a good, well-trained naturopath should be, and he is fully licensed by the State of California to practice naturopathy. Yet, as I discussed before, this upstanding naturopath offered a veritable cornucopia of quackery: biopuncture (an unholy union of homeopathy and acupuncture), naturopathic detoxing, hormonal balance treatment, intravenous nutrition, intravenous vitamin C, a dangerous modality like intravenous peroxide, and various “wellness programs.”
Let’s just put it this way. I’ve examined the practices of many naturopaths in my time. Outside the very privileged, cloistered, and protected ivory towers of medical academia, I’ve been unable to find any detectable difference between the level of quackery offered by the great unwashed unlicensed mass of naturopaths who didn’t graduate from schools like Bastyr and the elite group of naturopaths (elite only among naturopaths, that is) who did go to “accredited” naturopathy schools and are licensed. Yes, I acknowledge that I haven’t done a systematic study and my views might be affected by confirmation bias, but even if that’s true I’ve found a whole lot of what naturopaths would consider their crème de la crème offering a whole lot of quackery and discussing it in private forums, including some faculty of naturopathy schools and leaders of organized naturopathy, again the crème de la crème.
I tend to focus on cancer when I discuss the quackery in naturopathy because I’m a cancer surgeon. As a cancer doctor, I recognize that naturopaths are dangerous and harmful to cancer patients. No, strike that. They are dangerous and harmful to all patients.

Alternative cancer clinics, distrust of medicine, and MAHA
Yesterday’s New York Times featured an article about a man with terminal lung cancer who was enticed to chase cures that didn’t exist. He died before the pandemic. Will MAHA turbocharge this sort of quackery in the US?
David Gorski on October 5, 2026
Link

I’ve been writing about dubious cancer clinics that provide unproven (and disproven) cancer therapies, cash (or credit card) on the barrelhead, since the very beginning of this blog in 2008. These clinics tend not to be located in the US, preferring more—shall we say?—regulation-poor countries like Mexico or nations in Central America, Asia, and the former Soviet Union, or in certain European countries with a lax attitude towards clinics such as the Hallwang Private Oncology Clinic in Bavaria. That’s not to say that such clinics don’t exist in the US. After all, I’ve been writing about Stanislaw Burzynski and his antineoplaston quackery for well over 15 years now, and his clinic still functions in Houston, with Burzynski himself still quacking strong at age 83. Ever since the pandemic and the rise of the “make America healthy again” (MAHA) movement, I’ve paid less attention to such clinics than I used to do before 2020. So, when I came across a story in the New York Times Magazine this weekend by Trisha Thadani documenting how her father, Rajeev Thadani had been enticed by just such a clinic to treat his stage IV lung cancer, I saw an opportunity to revisit this subject. (Spoiler alert: Sadly, Mr. Thadani died of his disease.) I even approved of the title, something that is often not true as legacy media like the NYT is often too cautious to be too blunt: Dying Patients Are Inundated by Misinformation. My Dad Was One of Them, with the tagline: “Cancer patients are being persuaded to spend tens of thousands on unproven treatments by alternative-medicine clinics.”
Yes, they are. And they have been preyed upon this way for many decades. Indeed, as I read the very sad story of Rajeev Thadani, I kept thinking that the clinic where he went, Envita Medical Centers in Arizona, sounded very much like Hallwang Private Oncology Clinic in Bavaria, only that it was trying even harder to appear scientific in its approach, even though, right on its website, it answers the question of whether it does clinical trials thusly:
Envita has done clinical trials in the past but does not do clinical trials currently, due to several reasons. Dr. Dino Prato and Dr. John Oertle discuss how clinical trials are important for the discovery of a new drug, but at Envita Medical Centers and Center of Excellence, the focus is not on one single therapy, drug, or treatment. The world class integrative center for precision oncology aims to enhance treatment options for cancer patients by utilizing cutting-edge combination treatments, which include immunotherapy, proprietary interventional radiology procedures, genetically targeted chemo agents, and integrative adjuvants. We aim to provide a greater selection of treatments based on each patient’s genomics, as opposed to putting all our efforts and hopes into a single drug to produce a response to care.
In other words, no. Envita doesn’t do clinical trials. Instead, the doctors there “work towards providing a revolutionary treatment plan by going beyond the limitations of large sample clinical trials that have a rigid framework of who can or cannot qualify for them” and utilize “a multi-pronged precision oncology plan based on the n-of-1 clinical trial model, as well as our advanced algorithms which have been developed over the course of two decades in helping late-stage cancer patients respond to care. Our proprietary precision testing guides us to the most suitable agents for treating each patient’s cancer and its microenvironment to help with their holistic recovery.” Sure, whatever. Because some random clinic in Arizona has surpassed the greatest cancer centers in the world in developing these algorithms, which are so awesome that the doctors there don’t think they can do clinical trials because they just know they’re curing patients. This is, of course, my interpretation of what they are saying based on many years of hearing very similar claims, including Burzynski’s own touting of “personalized gene-targeted therapy” 15+ years ago.
And guess what? The clinic also states that it takes “advantage of the expanded right to try law to utilize the latest in conventional medicine, including drugs and therapies that are still in the clinical trial phase, and combine them with precision genomic chemotherapy, immunotherapy, and integrative agents,” doing exactly the sort of thing I was warning about all those years ago when right-to-try first reared its ugly head: Using it as a get-out-of-jail-free card to justify using whatever “experimental” therapies they want to profit from.
I’ll get back to these issues that facilitate the existence of clinics like Envita, and you’ll love their other justification for not doing clinical trials of their dendritic cell therapy. However, first let’s center this story on the victim, Rajeev Thadani, and his story told through his surviving daughter. The story, besides showing once again how these sorts of clinics exist and profit by charging desperate dying cancer patients tens or even hundreds of thousands of dollars for unproven treatments, plus a lot of “alternative medicine.”
Rajeev Thadani: Modern medicine vs. “holistic” care?
Reading the story of Rajeev Thadani depressed the hell out of me, because I’ve read so many similar stories and blogged on a number of them over the years. That’s why I’m going to quote directly the first few paragraphs of the story:
My mom was making lunch when she heard a thump come from the bedroom. She ran upstairs and found my dad face down on the carpet, blood seeping from a gash under his eye.
For days, he had been feeling lightheaded and fatigued since receiving a round of chemotherapy at Memorial Sloan Kettering Cancer Center. He was sitting on the edge of the bed when suddenly, he told my mom, everything went black. Thump. As my mom struggled to lift him from the ground, he vowed that he was done — done with Western doctors, who he said were “crooks” and “quacks”; done with “poisons” coursing through his body; done with sickening treatments he didn’t believe in.
“I’m going to die if I keep doing this,” he told her.
That evening, with a bruised eye and a stiff neck, my dad decided to book a flight from New Jersey to Arizona so he could check out a clinic he had found on the internet. On its website at the time, the clinic, Envita Medical Centers, said that its unique protocol had helped patients “outperform other renowned cancer centers for nearly two decades.” Its “proprietary” chemotherapy treatment was “so gentle,” it said, “that many patients report being able to hike and exercise” during care. My dad believed this outpatient clinic — which cost nearly $10,000 a week — could save him from the Stage 4 lung cancer ravaging his body.
How many times have I read variants of this sort of patient anecdote? I’ve lost track. Usually, they don’t start quite so dramatically, with a fall and a head injury leading the patient to decide to go down the alternative cancer cure path, but the beats are all there: a patient with a terminal cancer, tiredness and hopelessness undergoing conventional therapies for their disease, and the search for “alternatives” that leads to the patient finding the one clinic that gives him hope through patient testimonials. Also, the clinic charges huge sums of money for its treatments and doesn’t take health insurance. This narrative sounds just like the narratives I’ve encountered for cancer patients such as Pauline Gahan, a British woman who spent £300,000 at the Hallwang clinic to treat her metastatic cancer, or any of the many patients attracted to the Burzynski Clinic from the UK and US. It’s the business model of these clinics. They offer “hope” to patients who have cancers that are not treatable for cure using conventional therapies, cancers like stage IV lung cancer, although Burzynski did seem to specialize in terminal brain tumors.
They also often offer something that, I’ve admitted many times, conventional hospitals and clinics can lack: the human touch. In the US, the reason tends to be underpayment for services by third-party payers and our for-profit healthcare system; in countries with universal health insurance, it tends to be because of underinvestment in the healthcare system, as has been happening in Canada. Thadani describes it herself, and I have experienced it dealing with my parents and the medical system when both of them were experiencing declining health simultaneously in the months and years before they died. Her father was initially treated at Memorial Sloan-Kettering Cancer Center, arguably the premier cancer center in the US, if not the world, and this is what she described in an accompanying interview with Adam Kushner, editor of the NYT The Morning newsletter:
I texted a friend at the time: “The staff has been so rigid and unpleasant”; a doctor “made us feel like a burden”; “one nurse didn’t even look up from her computer!” Those moments really add up. But I have to give a disclaimer that my dad was a difficult patient. He went into his oncology appointments after spending hours researching alternatives. He did not want to be there and didn’t stay.
Who among us hasn’t experienced these little indignities, or even much worse, when dealing with the healthcare system? Now contrast that to how Thadani describes in the same interview what happened at Envita:
I was very skeptical, but I felt reassured as soon as we got there. During our first visit, a naturopathic medical doctor sat with us for nearly four hours to explain their unique treatment regimen. It seemed so promising that I started to think my dad would actually beat his disease. I was thrilled at how much better my dad looked during his first weeks at the clinic. He finally had hope, and that was having a real effect on his mood and energy.
Of course, stopping chemotherapy allows the adverse effects of the chemotherapy to wear off, and patients often feel better after that. Their cancer is still growing, though. It just hasn’t hit the point where it’s causing horrendous symptoms. Again, this is a very common feature of alternative cancer testimonials. Also, the practitioners at such clinics spend lots of time with patients, largely because they are able to because their payment doesn’t depend on what insurance companies or government payers like Medicare will reimburse them for. The contrast with conventional medical facilities is often just that jarring.
Moreover, Mr. Thadani was very much predisposed to distrust conventional medicine, as is documented in the story:
The modern medical system reminded him of all he learned to fear from his own father, an Indian homeopath, who worked at an alternative-medicine practice in Midtown Manhattan. Patients traveled from across the country to see my grandfather after finding him through televised interviews and a lecture series, where he disseminated his views that vaccines are dangerous and American children overmedicated. He also taught his audience about the healing power of homeopathy, an unproven alternative medical practice developed in the late 1700s.
It was this distrust that led Mr. Thadani to ignore evidence of early-stage cancer incidentally found on a CT scan done to screen for cardiac disease in early 2019. You can picture the sort of man Mr. Thadani was, as I see elements of my father’s behavior in him. According to the story, the only reason Mr. Thadani agreed to get the scan was because his wife had basically forced him to do it after having heard from a friend how he had undergone such a scan and been found to be at imminent risk for a heart attack. The results were:
The scan, which cost them each $750 out of pocket, revealed mostly healthy hearts but showed a concerning image in my dad’s lungs: “interstitial lung disease prominent in the lung apices” and “a nodule of ground glass lesion in the superior segment left lower lung,” according to the report. The doctor called five days later, on a Saturday morning, to implore my dad to get it checked out. “Don’t ignore this,” my mom remembers him saying. My dad smoked several Marlboro cigarettes a day for some 40 years, but with no symptoms at the time, he dismissed the results as unnecessary hysteria from a doctor.
Given that Mr. Thadani had been a smoker for decades before, albeit a light smoker who only smoked “several cigarettes a day,” you can see how such a finding would be very concerning. Several months later, Mr. Thadani developed a dry cough and, instead of following up on the concerning findings on his chest CT, went to his homeopath, who “initially suggested that he try rubbing castor oil under his arms and also take Carbo Vegetabilis, a remedy typically used for indigestion.” Mr. Thadani’s symptoms continued to progress until he was unable to make it all the way up a single flight of stairs without stopping to catch his breath. This finally pushed him to see a pulmonologist, who did a bronchoscopy and diagnosed multiple cancers in his lungs. His family managed to persuade him to go to MSKCC, although there’s an anecdote in the story about how his wife woke up in the middle of the night and found him not in his bed, but at the computer “looking for alternatives.”
Given this, it should perhaps not be surprising that, for all the effort Ms. Thadani, her mother, and her brother put into persuading Mr. Thadani not to fly to Arizona to be treated at Envita, he only made it through one round of chemotherapy, which led to him saying that he “felt so horrid that he vowed to never go back,” after the incident that started the story, in which he fell and split open his scalp.
From here on out, I’m going to try to be a lot more strategic quoting the news story, because you really should read it for yourself, but I will summarize Mr. Thadani’s story and course at Envita, first noting that Envita was not the first clinic that had interested him. He was first interested in a clinic in Florida, “whose treatment plan of ‘nontoxic’ alternatives cost $4,000 to $5,000 a week,” but didn’t go when he learned that the clinic’s lead doctor would have multiple complaints lodged against him beginning in 2021, ultimately losing his license in 2025. (Yikes! He must have been horrible, given how quack-friendly Florida was and how much more quack-friendly it’s been since the rise of MAHA!) Curiosity got the better of me, and I just had to do some Googling. The only physician offering alternative cancer treatments that I could find whose license was revoked in 2025 was Dr. Carlos M. Garcia of Utopia Wellness, whose license was revoked in March 2025 for using intravenous cesium to treat cancer, and I’m pretty sure that this is probably the doc and that Utopia Wellness was likely the clinic.
But back to Envita.
Envita: Bespoke concoctions of approved drugs and delivery systems plus quackery
According to the story, it was the anecdotes that led Mr. Thadani to want to go to Arizona to be treated at Envita, one anecdote in particular:
But it was Envita, based in Scottsdale, Ariz., that he was most taken with. On its website, the clinic said that it employed doctors “from a variety of disciplinary backgrounds,” which included those with standard medical licensing and naturopaths. In an email, a patient coordinator told my dad that the clinic was “strategically” located in Arizona because the state “has the largest scope of practice for integrative medicine.” The clinic also claimed to have helped “thousands” of patients from around the world.
My dad’s cousin happened to know a friend of a friend who went there for late-stage cancer, and my dad was able to call him. He told my father that before he went to Envita, he was emaciated from his cancer and sure he was going to die. But now, he said, he was golfing, boating and enjoying time with his children.
After that conversation, it was settled: My father knew that Arizona was where he needed to be.
Ah, the old “friend of a friend of a cousin” anecdote. It gets ’em every time. Whenever I hear stories like this, I can’t help but note that the actual patient is almost never identified, which, of course, makes it impossible to check out the anecdote in order to determine whether it’s a plausible inference that Envita helped the patient or not. So I looked at some of the testimonials that Envita includes on its website. Many appear to be of the sorts that I’ve described. For example, take this testimonial of a patient with stage IV colorectal cancer metastatic to the liver, whose metastases had been discovered within a month of surgery. The conventional oncology plan was for him to undergo a liver and gallbladder resection to remove the metastases, which is pretty standard when the metastases are resectable, followed by chemotherapy, which is, again, standard treatment. As I mentioned last week while discussing cancer metastases, such treatment can result in long-term survival 25-35% of the time. Now here’s the kicker:
However, with Envita’s advanced precision integrative oncology options, which combine the latest in conventional medicine with research-based natural therapies, Christian experienced exceptional results. “After the two months in Envita and such great results… the tumor in my liver had shrunk in half,” said Christian.
With a much smaller tumor to remove, the outcome of his scheduled surgery after pursuing care at Envita proved to be significantly different from what was expected. “We had to take out a lot less liver than we thought—less than 10 percent—did not have to take out the gallbladder, and with all the tests, I did not have to get the pump [for regional chemotherapy] … that’s radically life-changing,” added Christian, while explaining how he benefited from Envita’s precision-targeted care options.
Wow! Sounds fantastic, right? Here’s the thing. Neoadjuvant chemotherapy (chemotherapy given prior to surgery with the intent of shrinking the tumor to make an unresectable tumor resectable or to make the surgery to resect the tumor less extensive) is an accepted treatment for potentially resectable metastases from colorectal cancer. However, it is usually reserved for tumors that are borderline resectable. Reading between the lines, what Envita appears to have done is simply to give its proprietary concoction of chemotherapy, which it calls GTFC™ (Genetically Targeted Fractioned Chemotherapy), a “proprietary treatment utilizing not only low doses of targeted chemo agents, but it also enhances the impact on cancer cells by utilizing novel therapeutic windows induced by natural and integrative medicine” that delivers “targeted chemotherapy to the tumor by using a ‘Trojan Horse’ delivery mechanism.” A “Trojan horse” delivery system attaches the therapeutic drug to a vehicle that seems harmless to the body but delivers the drug to the cancer cells more specifically. Such vehicles can include antibodies, modified immune cells, nanoparticles, and viral vectors. Do we know how the drugs were delivered or what drugs were used? Of course not! The mixture is proprietary!
GTFC™ is, however, likely chemotherapy, possibly mixed with immunotherapy. Does it work better than conventional chemotherapy? We have no way of knowing because Envita didn’t publish any clinical trials testing GTFC™ versus standard-of-care chemotherapy to determine whether it is more efficacious and less toxic. Could it work? Possibly, but, again, even if it does work, we don’t know how it compares to standard-of-care. Its efficacy might have been similar to, lower than, or greater than conventional chemotherapy. We have no way of knowing. In any case, Christian is alive mainly because of conventional treatment, especially the surgery, but, as is the case in most alternative cancer cure testimonials, he attributes his good fortune to the “alternative” cancer therapies that he had chosen to pay tens or hundreds of thousands of dollars to undergo.
The same likely applies to Envita’s other “proprietary” concoctions, including PVM (Platelet Vesicle Medication) GTF™, whose delivery, if you believe Envita, “is designed to selectively affect the inflammatory microenvironment of tumors and cancer cells,” and Chemo Immuno Precision Injections (CIPI™), described as a “minimally invasive proprietary treatment for deactivating tumors by deploying anticancer agents directly at the tumor site” using interventional radiology. I can’t help but note that we’ve tried injecting therapeutic substances directly into tumors for literally decades, if not hundreds of years, and the track record is, in general, poor. How is Envita’s CIPI™ any different? It’s not, really, given its description as “customized immunotherapy treatments that are combined with adjuvant agents and deployed directly inside the tumors of concern.” Again, this sort of thing has been tried before with at best mixed success many, many times, which makes it incumbent upon Envita to prove that its protocol actually works.
Let’s take a look at a couple of tables Envita includes in its description, first for GTFC™:
I love the almost Quack Miranda warning at the bottom of the table! (It lacks the part about the treatment not being FDA-approved.)
And for CIPI™:
Yep. More weasel words at the end.
You can see how Mr. Thadani would have been impressed by such tables and such descriptions of the treatments offered at Envita! They sound so much better than what he had experienced undergoing just one round of the chemotherapy for stage IV lung cancer that had been recommended. Add to that testimonials, such as this one from a man with stage IV prostate cancer who was asymptomatic at the time of his diagnosis and whose cancer was only discovered by PSA testing who claims to have had his PSA return to normal under Envita care but does not say whether imaging studies show his cancer to have regressed after the CIPI™ treatments; a woman with stage IV breast cancer metastatic to bone who, if her cancer was estrogen receptor-positive (as 70% of breast cancer is) could potentially survive quite a few years under conventional treatment but attributes her doing so well to Envita; and a man with a cutaneous B-cell lymphoma that was clearly very indolent given that he had survived “decades” with it prior to Envita. One thing I noticed about these testimonials is that they all rely on tumor markers to say that the cancer had responded to treatment; I looked for descriptions of imaging studies and found almost nothing.
Then there was this testimonial of a woman with “stage 2 triple negative breast cancer.” The first thing to note is that stage 2 breast cancer is treatable for cure. In the case of the triple-negative variety, a stage 2 cancer would be treated first with neoadjuvant chemoimmunotherapy according to the KEYNOTE-522 protocol, followed by surgery and, if the breast is saved or there is found to be tumor in the axillary lymph nodes on the side of the cancer, radiation. With such treatment, one can expect a five-year recurrence-free survival in the 80% range. The neoadjuvant treatment produces a pathologic complete response rate (no tumor found in the surgery specimen) higher than 60%. This is all very standard. However, reading and watching the patient’s story, I found it hard to tell if she was being represented as metastatic. It’s not even clear whether she ever underwent surgery or how long she has survived since her diagnosis.
The mouse-over reveals a real Quack Miranda warning, complete with the mention that the treatment is not FDA-approved! No wonder, as in the video the patient describes “low dose chemotherapy” with “high dose supplements.”
Basically, all the testimonials, as described on the Envita website, are pretty useless for determining whether Envita’s claims of efficacy are true. There’s just not enough information provided.
So what did Mr. Thadani receive? I think it’s worth quoting again here, because it was a naturopathic quack who first went over the treatment plan and what it would cost:
The naturopath turned to a whiteboard behind him to explain Envita’s “proprietary” chemotherapy regimen ($2,315 per treatment), which included lowering my dad’s blood sugar with insulin and delivering low doses of chemotherapy into his body. The side effects would be minimal, he said, far less than what my father felt with standard chemotherapy. Envita would also send him to a clinic it operated in Mexico to receive a cell therapy ($125,000) that the naturopath said would help his body fight off whatever cancer cells remained.
While I was sitting in his office, a nagging thought emerged: What if Envita actually had the secret cure for my dad? Its treatment seemed sophisticated, thoughtful and promising. The naturopath said his own father was successfully treated at Envita — evidence of how much he trusted the protocol that he was recommending for mine.
Those are the things that I remember, at least. Now, looking through my dad’s medical records, I can also see that his treatment plan came with a battery of what Envita calls “supportive” therapies. Many of them had little to no clinical evidence supporting their use in cancer care. They included infusions of hydrogen peroxide ($215 per infusion); a therapy that included adding medical-grade ozone gas, a known toxin, to his blood (also $215 per infusion); and coffee enemas, which carry side effects such as rectal burns and severe infections. If the naturopath told us about these specific therapies with the risks clearly outlined, I didn’t hear it. By that point, my skepticism had largely fallen away, and I heard what I desperately wanted: that the clinic was safe and effective.
Here’s a hint about these clinics. If it sounds too good to be true, it is. These clinics do not have “secret cures” for cancers that conventional oncologists cannot treat for cure, but only palliation. Unfortunately:
It’s one thing for a doctor to inform you of all the clinical trials, the rigorous scientific evidence, the percentage chance of one therapy working over the other. But it’s another to be looked in the eye by another human and told that your suffering is real and that you will be OK, and to hear that there is, in fact, a secret cure, a magic bullet. Looking back on those desperate months with my father, I can see clearly how much he valued the feeling of his care above anything else.
This is precisely how these clinics lure their patients in.
Also, note the “supportive care.” As I’ve discussed many times right here on this very blog, coffee enemas are pure quackery associated with the Gerson therapy, and infusions of hydrogen peroxide are also not only unproven but disproven. However, the business model of clinics like Envita and Hallwang is to pitch “integrative care,” “the best of both worlds” that supposedly combines the best of cutting-edge medicine that’s so cutting-edge that nothing about its efficacy or safety has been published or even subjected to clinical trials, plus rank naturopathic quackery.
In fact, the cancer therapy is often quackery too. Did you notice that part about “lowering my dad’s blood sugar with insulin and delivering low doses of chemotherapy into his body”? That’s obviously a rebranded form of a cancer quackery known as insulin potentiation therapy, which is known not to work and is also potentially dangerous if a patient’s blood sugar is lowered too much. (Read this article on Quackwatch about IPT if you want the details. In fact, it makes me wonder whether the GTFC™ therapy being sold by Envita is nothing more than IPT in which the “low dose chemotherapy” is chosen in a make-it-up-as-you-go-along manner based on various genetic tests.
The overall cost is a familiar story too:
At this point, the costs were staggering: around $200,000 since moving to Arizona, a price that mostly included invoices from Envita. There were also scans and outside therapies the clinic recommended, like “colon hydrotherapy,” a treatment that supposedly cleansed toxins from his body (though there’s little scientific evidence to support it). This accounting does not include all the supplements he needed to take, which at one point was 14 different pills, twice a day.
His Envita medical records from this time detail his lethargy, his cough and his precipitous drop in weight. At certain points, the records show, Envita’s doctors referred my dad to the emergency room or to an outside pulmonologist when his symptoms got particularly bad. But there were also a few bits of good news that my dad clung to. In January, he was told that there were some signs of improvement in his lungs and that the lesions in his brain — which were being treated by an outside radiation oncologist — were disappearing.
Any positive news contrasted with the person we were seeing — a man suffering and shrinking, a husband and father wasting away. My mom, desperate to return to her support system in New Jersey and horrified by my dad’s rapid decline, suggested that they go back to Memorial Sloan Kettering — or, at the very least, call the oncologist for a second opinion. But my dad refused, saying that Envita’s treatments were just running their course.
Notice how Envita was falling back on conventional medical care to treat the brain metastases and was trying to send him to the emergency room because he was so obviously deteriorating. I note that, prior to this, according to the NYT article, Mr. Thadani had done pretty well for a few months. He felt reasonably well, and the environment at Envita when he went for his treatments was quite pleasant, with an attentive staff. Again, this is not an atypical story after a patient stops chemotherapy and his cancer has not yet progressed enough to worsen his symptoms. Ms. Thadani recounts how, when her father finally ended up in a nearby hospital in the ICU because his breathing and oxygen saturation had deteriorated so much, the ICU doctor asked where his cancer was being treated. When informed that it was Envita, he told them that he saw patients like her father “all the time” coming from Envita, concluding, “You wasted your money.”
I agree with Ms. Thadani that such a response from a doctor was quite callous and totally inappropriate. On the other hand, even Ms. Thadani became more understanding of that doctor when she did more investigating and found that Envita had a long history of investigations and complaints about “selling treatments ‘at a high cost to desperate subjects’ and administering unapproved drugs to vulnerable, end-state cancer patients.” She also learned that Envita was far from unique, noting that she had “found dozens of similar businesses around the country that provide cancer patients with costly, unproven treatments” and “spent months trying to figure out what kind of oversight exists for such clinics, only to discover a confusing patchwork of laws that vary from state to state.” From my perspective, that doctor’s response reminds me very much of a news report from Panorama on the Burzynski Clinic in which an interview with Dr. Jeanine Graf of the Texas Children’s Hospital, a pediatric intensive care unit doctor, detested Burzynski and took care of many of his patients who had deteriorated while being treated with his quackery.
At the risk of injecting myself too much into this story, which is really about how an alternative cancer clinic takes advantage of desperate patients, I can’t help but think that I wish she had discovered me and called me. I could have helped her so much with her story. At least, I like to think that I could have, and I wish I could have, given how much the story of her father moved me, being so similar to a number of stories that I had written about and analyzed over the years. My own self-absorption aside, one part really got to me. After noting that “it felt as if there were two options: treatment at any cost or death and how she “cannot remember a moment when the third option — acceptance — even crossed our minds,” she describes deciding to take her father off his ventilator and how he took much longer than expected to finally pass away, and how he kept wanting fenbendazole to save his life, apparently having discovered “turbo cancer” quack William Makis before his condition deteriorated, noting in the accompanying interview that her “dad spent some of his final conscious moments yelling at us to give him some.”
Moreover, this part of her story didn’t surprise me in the least:
Alternative treatment protocols like the one my dad received at Envita are often not covered by insurance and can cost families tens — if not hundreds — of thousands of dollars. My parents were able to shoulder the expense, but there are many whose decision to seek care drives them into serious debt. I came across hundreds of GoFundMe pages of people asking their communities for help and spoke to several families whose loved ones sold off assets or ran through their small savings to afford such treatments. Some claimed they were betrayed or misled by their clinics but felt their only recourse was to write a bad online review. (I would also later leave Envita a one-star review online.)
It’s just a fancier version of the Burzynski Clinic, and, yes, I’ve written a lot of stories about desperate families using GoFundMe and other such crowdsourced funding sites to pay for cancer quackery. It saddens me to see that the situation remains basically the same as when I first discovered it 20 years ago.
Will MAHA make things worse?
One point that Ms. Thadani makes that led me to start thinking about one of my “favorite” topics again is about the mistrust of the medical establishment that her father had been harboring before his cancer diagnosis:
As this unfolded in the fall of 2019, I dismissed my dad’s choices as an extreme reaction by someone who had long preferred natural remedies and didn’t like going to the doctor. But that was before the pandemic eroded trust in the medical system and the Make America Healthy Again movement elevated such skepticism into the federal government. Now I look back on my dad’s aversion to conventional medicine and realize it was more than just personal eccentricity; it was also an intimate preview of an ideology that was on the brink of going mainstream.
As my dad was, patients today are inundated with misinformation spread by alternative-medicine practitioners, social media influencers and public figures. They are willing to experiment with unproven therapies, often at great physical or financial risk, in part because they want more personalized and empathetic care — an antidote to the famously harsh aspects of traditional medicine.
This tension is nothing new. “Integrative medicine” frequently advertises itself by portraying conventional medicine as cold, bureaucratic, too scientific, and not caring about the individual patient, while wrapping itself in the human touch. Unfortunately, thanks to the manner in which we as a society choose to construct our medical system, there is more than a germ of truth in this. The deception, whether self-deception or intentional, comes when alternative and “integrative” medical practitioners try to claim that the only way to remedy this lack of the human touch is to “integrate” quackery into medicine.
Now that MAHA is firmly in control of the federal government and likely to remain so for at least the next couple of years, I fear that things will only get worse. For example, I long ago warned about how “right-to-try” laws, which give patients the “right to try” any experimental drug or therapeutic if it has passed the minimal safety bar of a phase I clinical trial, would eventually be turned into profit centers, as Envita openly admits how it’s using right-to-try as the basis for its combining experimental therapeutics that haven’t been FDA-approved yet with FDA-approved conventional therapies (although not necessarily FDA-approved for the combination given or the cancer being treated). It reminds me very much of clinics using 3-bromopyruvate a decade ago to treat cancer, even though it was not then FDA-approved.
Trisha Thadani describes a problem that is very old. As I like to say, there’s nothing new under the sun. She also describes how the “coldness” of our current system, combined with the distrust of the medical system that people with her father have harbored for a long time, can lead to the proliferation of alternative clinics such as Envita that satisfy people’s emotional needs to be treated seemingly as an individual, at least at first, but do so in service of a business model that sells unproven and disproven cancer treatments, along with rank quackery like coffee enemas and intravenous ozone in the guise of “supportive care.” MAHA has weaponized this distrust, and its ongoing project to chip away at laws and regulations that protect patients, even as poorly as they currently do, against alternative cancer clinics like this made it very likely that there will be many more Envitas forming and many more people like Rajeev Thadani being victimized, leading surviving daughters like Trisha Thadani to say:
Hope is a delicate thing in the face of a fatal disease: It can give a patient like my dad the will to keep going, but it can also blur easily into false expectations and questionable decisions. It’s a tricky balance that looks different for every patient and family. Instead of chasing an elusive cure, I wish my dad had taken more time to say goodbye and celebrate a life well lived.
Selling false hope is what these clinics do. It’s also what MAHA does, as long as it can profit.


The deadly false hope of German alternative cancer clinics
We at SBM have written about German cancer clinics that offer a combination of cancer quackery, some real medicine, plus unproven experimental therapies, all at a high cost, both financially and in false hope. Finally, an exposé of these clinics has been published. What these clinics are doing is even worse than even we had feared.
David Gorski on March 26, 2018
Link

When most people think of quack cancer clinics selling snake oil, they think of places like Tijuana and other cities in Mexico along the US border, locations that make them easily accessible to many Americans but free from the pesky regulations governing patient care in many developed countries and where, sometimes, American stem cell companies ship patients when they’re not eligible for US protocols or clinical trials. Sometimes, such clinics are located in countries like China, Argentina, Kazakhstan, or Latvia, where regulations governing what medical facilities can do are more lax. That’s not to say that we don’t have such clinics in the US (just read my posts about the Burzynski Clinic in Houston if you don’t believe me), but it’s harder for such clinics to continue to operate than in, for example, Mexico or Central America. There are also such clinics in Eastern Europe, such as the International Virotherapy Center in Latvia, which administers Rigvir, its unproven “oncolytic virotherapy,” and exports it to the quack cancer clinic Hope4Cancer in Mexico.
There is, however, another nation well known for its highly dubious cancer clinics. Indeed, one can argue that such clinics are a more vexing problem there than clinics in Mexico or former USSR member states because the nation has a reputation of being bastion of science and science-based medicine. I’m referring to Germany, of course, whose dubious cancer clinics I first became aware of when Farrah Fawcett traveled to a German cancer clinic to treat her recurrent anal cancer a decade ago. I’ve also taken note of such clinics on other occasions, such as when one clinic offered an unproven but legitimate experimental drug to patients outside the auspices of a clinical trial. I also noted how German cancer clinics market themselves to the whole European Union, drawing patients from many countries in Europe and also from the United Kingdom, where celebrities and GoFundMe campaigns promote them.
A year ago or more, a reporter in Germany called me about such clinics. I spoke with her for quite a while and then forgot about it, not having seen a story resulting from it. Although I did know a fair amount about what I viewed as the quackery being practiced at several German cancer clinics, I had no idea how much I had helped or not helped, given that my knowledge of German law and medical regulations was very thin indeed and that one of the reporter’s goals was to figure out how such clinics could continue to operate. Then, last week, I saw the story “The Last Resort” by Lindsay Gellman, with the tag line: Private clinics in Germany sell cancer patients hope — and mixed results — at exorbitant prices. The story had finally come out, and it even addressed a clinic I’ve discussed a couple of times before, the Hallwang Private Oncology Clinic. I also couldn’t help but note the appropriateness of the title, The Last Resort, given that these German cancer clinics look very much like spas in the Bavarian forest
The Last Resort: A typical Hallwang story
This story begins in the UK—Manchester, England, specifically. We meet Janet Colgan and her daughter Kate. The year was 2016, and the mother, 54-year-old Janet Colgan, is described as waking up from surgery for stomach cancer and soon thereafter telling her daughter, “Get me to Germany!” Colgan had been diagnosed with metastatic stomach cancer and given perhaps a year to live with palliative chemotherapy. The result was that Kate, who was 25 at the time, fitted the family car with a roof rack and piled luggage on it, arranged for her mother to be discharged from the NHS hospital against medical advice (AMA), and then drove with her mother, her then-fiancé Chad, and the couple’s infant daughter for 16 hours to a private treatment clinic on the outskirts of Dornstetten, a quiet medieval town in southern Germany. The clinic was Hallwang Clinic, which markets itself as a luxury spa that treats cancer, touting its “individualized treatments,”” pastoral setting in southern Germany’s Black Forest, and excellent meals.
Here’s what happened next:
The clinic’s online testimonials looked promising; so the Colgans inquired about treatment. After reviewing Janet’s medical records, a Hallwang Clinic doctor told the Colgans a cocktail of experimental drugs not widely available elsewhere could mean eventual remission for Janet. But the price would be staggering — more than $120,000. The clinic does not accept insurance and typically requires an 80% deposit before treatment can begin.
A chance at remission seemed worth a try — at any cost.
So in February 2017, Kate accompanied her mother to the Hallwang Clinic, where Janet stayed for several weeks and received treatments including immunotherapy vaccines, which are designed to help the body use its own defenses to fight specific cancer cells. Kate said she was given little information about these treatments and knew only that the staff called them “cancer vaccines.” The initial invoice totaled about $127,000. To cover it, Kate cashed out some of her home equity, liquidated both her parents’ pensions, took out a bank loan, and solicited donations on GoFundMe.
Doing a little Googling, I did find Kate Colgan’s appeals for funding. Here’s one on Facebook from last year:
The campaign, as we’ve seen with so many other campaigns, was aided and abetted by the UK media.
Here’s one on JustGiving. There, we learn a little more, specifically that the stomach cancer had spread not just to the lymph nodes (which would not necessarily have precluded resection, depending on the lymph node chains involved) but to the peritoneal lining of the abdominal organs (which did preclude resection and made her stage IV). Now, I note that the story in this fundraising appeal is a bit different than the news story. After the diagnosis of stomach cancer in September 2016, Colgan’s mother apparently did start to undergo palliative chemotherapy:
In an attempt to prolong her life, chemotherapy began, but it’s failing. The December scan showed the cancer has grown and spread.
Not only is the cancer resisting chemotherapy, she experiences agonising bone pain, permanent ringing in her ears, and when she eats is doubled up with stomach pain. I fear she won’t get the nutrition she needs to stay strong. Without help she will die.
With a background in clinical science, I began to research immunotherapy, an alternative to chemotherapy that is gradually gaining ground in cancer treatment. In simple terms immunotherapy stimulates your own immune system to work harder or smarter to attack cancer cells. There are cases where patients have gone into remission or been cured.
Sadly it’s not available on the NHS for stomach cancer. However it’s available at The Hallwang clinic in Germany but it isn’t cheap and whilst we’re working hard to fund as much ourselves, I need your help.
This is the stage in the story in The Last Resort where Lindsay Gellman met with Kate Colgan. By this point, her mother had relapsed:
According to Kate, after leaving the clinic in the early spring, Janet felt better at first, and was able to go about her daily life. But she soon developed infections and a partial bowel blockage that required surgery. Doctors at a local British hospital, Blackpool Victoria, agreed to operate on her, but were skeptical that she could make a full recovery. Their assessment distressed Janet, who insisted on a return trip to the Hallwang Clinic — where doctors had a more optimistic prognosis — once the surgery was complete.
Kate was posting videos like this:
Wow. She had five liters of fluid drained from her stomach. That’s a significant bowel obstruction. I also can’t help but note a couple of things. First, who lets a patient with carcinomatosis go to the cafeteria to eat when she comes in with peritonitis? That’s massive malpractice, in my not-so-humble opinion as a surgeon who used to deal with such problems routinely back before I subspecialized. Also, apparently the Hallwang doctors told her that her mother’s infection was not “cancer related” but was just “one of those things.” In reality, peritonitis is a not uncommon complication of peritoneal carcinomatosis (cancer growing on the membrane lining the organs in the abdomen). From a medical standpoint, the Blackpool surgeons were correct to be reluctant to operate on Colgan’s mother at this point. In the case of malignant bowel obstruction due to carcinomatosis, the chances of achieving prolonged postoperative palliation with acceptable surgery-related morbidity is only around one in three, although in carefully selected patients surgery can be appropriate. Yet, through it all, Kate Colgan credits Hallwang doctors with saving her mother’s life, when it sounds to me from her story (although I can’t be sure, not having all the information) very much as though they endangered it with gross incompetence.
Even so, I suspect that at some level Kate realized she was being taken advantage of:
Kate insisted she wasn’t naive. She said she was aware not only of the long odds of her mother’s recovery, but also of her own susceptibility to anyone offering hope.
“I am a desperate, desperate woman,” she said. When a family member has cancer, she went on, “You’re an easy target — you’re prey.”
Nevertheless, Kate told me she hoped to fund her mother’s continued treatment at the Hallwang Clinic “until she dies.” She drew a distinction between this plan and pursuing the palliative chemotherapy covered by the NHS, citing the Hallwang Clinic’s assessment that its immunotherapy vaccines might lead to Janet’s remission.
“They do perform miracles on people,” she said.
Except that there is no good evidence that the doctors at Hallwang do anything of the sort. The buzz generated when Leah Bracknell, a British television actress with lung cancer whose case I wrote about when announced she was soliciting online donations for stage-four lung cancer treatment there was never backed by solid evidence.
The Hallwang Private Oncology Clinic
In my previous writings about Hallwang, one of the things that frustrated me the most was how difficult it was to find out much about what goes on there. I learn from Gellman that I’m not the only one who has noticed the air of secrecy about the clinic. Since the clinic’s inception in 2009 as Privatklinik Dr. Ursula Jacob, the Hallwang Clinic has treated over 7,000 patients, while its website and other publications don’t mention any doctor names. Something I noticed every time I’ve written about the clinic is that it’s damned hard to find out who the clinic staff are.
Also:
Patients told me they are explicitly discouraged from speaking with media. Yet a handful of patient testimonials grace the clinic’s website and carefully curated social media accounts.
This air of secrecy has become a hallmark of the Hallwang Clinic, which in recent years has found a niche in selling hope to the seriously ill at astronomical prices. Patients, many of whom have been told by other physicians that they are too ill to benefit from further treatments, are drawn in by the prospect of a long-odds last resort: a menu of treatments not always supported by scientific evidence and hard to come by elsewhere. These range from so-called “alternative” therapies, like intravenous vitamin infusions, to the use of unapproved or experimental drugs.
A good rule of thumb: If a hospital or clinic discourages patients from talking to the press, that hospital or clinic has something to hide, perhaps something like this:
Sometimes the drugs the Hallwang Clinic offers can help extend a patient’s life. But based on conversations I had with more than two dozen current and former Hallwang Clinic patients, their family members, and former employees, as well as on medical and financial documents those patients and families shared with me, the Hallwang Clinic routinely couples unproven treatments with business practices that exploit the seriously ill. Patients and family members told me the clinic’s physicians sometimes pepper initial consultations with words like “remission” and pitch the drugs as potential cures. Treatment bills often reach six figures. In desperation, patients have sold homes, drained savings accounts, and launched crowdfunding campaigns, sometimes spending their last days and dollars with the clinic. Many die within months, often leaving behind families in dire financial straits.
This is exactly the harm that quack clinics like Hallwang do to cancer patients, the harm that infuriates me and drives me. Equally infuriating is the common claim by Hallwang in response to criticism:
When I contacted the Hallwang Clinic recently, its management declined to answer my specific questions. In an email reply, a Hallwang Clinic representative countered the bulk of my reporting.
“International scientists have acknowledged and confirmed exceptional treatment responses among our patients,” the representative wrote. “Needless to say, we are against any publication that spreads negative and derogative information about our specialized oncology clinic.”
One notes that these “international scientists” are seldom, if ever, named, nor is the science ever cited. If Hallwang were doing so well, it should be able to convince doubters like me by publishing its results in the peer-reviewed scientific literature. If its results are so striking and spectacular, it should be able to prove it in a public scientific forum where its results could be analyzed to see if they stand up to scrutiny. Oddly enough, Hallwang never does anything like this. This is not surprising, given that Hallwang offers a combination of conventional medicine, unproven experimental medicine, and rank quackery like homeopathy, ozone therapy, high dose vitamin C, and orthomolecular medicine.
As for “spreading negative and derogatory information about” Hallwang’s “specialized oncology clinic,” I can’t help but note how Hallwang spokespeople always try to paint criticism or stories about its practices as though they were whispered rumors without basis. I also point out that that publishing “negative and derogatory” information about clinic like Hallwang is a good thing if the information is well-sourced and backed up by science. Hallwang could refute it if it so chose, but it doesn’t because it almost certainly can’t. So instead its PR people lapse into PR-speak.
As Gellman notes, for many of the patients giving glowing testimonials for their treatment at Hallwang as having saved their lives against all odds, the gains, if gains they were, have been short-lived. For instance, Pauline Gahan, a woman with metastatic stomach cancer whose case I wrote about in October 2016 only lived to April 2017. Here’s another example:
The Hallwang Clinic’s website also features a lengthy first-person testimonial from British breast-cancer patient Kate Douglas, accompanied by a headshot. The clinic has also shared versions of Kate’s story on its Facebook page. The account details how, in September 2016, British doctors told Kate they had exhausted all options for treating her stage-three breast cancer, and that she should simply enjoy her remaining time with her young daughter.
Instead, the testimonial says, Kate sought treatment at the Hallwang Clinic.
“The medical team has since guided my treatment plan every step of the way and I have full confidence in them and as a result my tumor markers have dropped by over half,” the testimonial says. “I am fully reliant on fundraising through GoFundMe and so far I have been blessed.”
This testimonial, too, outlived its subject. Kate died last month, just days after her 40th birthday.
Hallwang’s answer to the question of why these testimonials are still featured on the Hallwang website is disingenuous in the extreme:
I asked Hallwang Clinic if its management had specific comments regarding Pauline’s and Kate’s testimonials and the continued use of these endorsements on its website. Part of the clinic’s reply alluded to these questions.
“Many of our patients are currently under a maintenance program for many years now,” the clinic’s statement said. The families of the two individuals about whom I’d asked, it continued, “are actually grateful for the Hallwang Clinic, which has helped both patients in a very difficult situation.”
Yes, but leaving such testimonials up and easily findable on search engines implies falsely that these two patients are still alive. Janet Colgan, it should be noted, is also dead. She died in October 2017, a little more than a year after her diagnosis. She survived only slightly longer than her NHS physicians had predicted, well within the uncertainty there always is around such estimates of remaining life.
Hallwang is not alone, or: Why do these clinics flourish in Germany?
Hallwang Clinic is not alone in Germany. There are many other similar clinics peddling variants of the same formula: Some conventional medicine, off-label uses of expensive drugs for indications for which their efficacy and safety have not been validated, the use of unproven experimental therapeutics (like 3-BP, which I wrote about), and rank quackery. Some throw in high-tech (and often either unproven, inappropriate, or oversold) treatments, much as the clinic that treated Farrah Fawcett did.
As I read about German cancer clinics using this sort of business model, my question was always less about the specific treatments sold—these days, the treatment du jour appears to be immunotherapy— and more about why. Why and how do these clinics continue to exist and profit in Germany? How is it that they can peddle unproven and quack treatments, charge upwards of six figures for them, and not face any sort of regulatory sanction? Gellman attempts to answer this question by first noting that Germany has a long history of embracing “unconventional” treatment methods, citing the example of The One Quackery To Rule Them All (homeopathy) and noting:
Yet German insurers typically reimburse patients for homeopathic treatments, and German law extends robust protections to certified nonmedical practitioners, or heilpraktikers, whose training in alternative healing methods like homeopathy permits them to treat patients with non-infectious diseases, such as cancer. The designation traces its roots to a 1935 statute implemented by the Nazi government in an attempt to regulate a growing group of natural healers. The original edict precluded the training of new heilpraktikers, a move intended to phase them out and push medical doctors to incorporate alternative treatments into their practices. Instead, after the war, the ban on heilpraktiker training was overturned.
Speaking with Eugen Brysch, CEO of the German patient-advocacy organization Deutsche Stiftung Patientenschutz, Gellman reports:
He explained that alternative treatments are now gaining popularity with licensed medical doctors, more of whom have begun to seek out such training as an add-on.
And increasingly, Brysch told me, experimental drugs are finding their way into alternative-treatment clinics, where they have been folded into an older menu of unproven cancer-treatment options, such as ozone therapy (in which the gas is pumped into the bloodstream) and whole-body hyperthermia (in which the patient’s body temperature is elevated to fever range for extended periods). In August 2016, three patients — two from the Netherlands and one from Belgium — died within days of one another at the Biological Cancer Center, a private clinic run by a heilpraktiker near Düsseldorf, in western Germany. They had been injected with the experimental cancer-treatment drug 3 Bromopyruvate, or 3-BP, according to a local prosecutor’s report. The incident briefly reignited debate over whether private clinics should be subject to stricter oversight.
Yep. As I pointed out, 3-BP is a legitimate experimental cancer drug. It just hasn’t been shown to be effective yet; it’s still in clinical trials.
Brysch also recounts that heilpraktikers have been growing in number and political clout and that the homeopathy lobby is also quite influential. Politicians in Germany are, understandably, reluctant to draw the ire of these lobbies and their patients.
Still, that might explain how heilpraktikers can continue to run quack cancer clinics in Germany in which conventional medicine is “integrated” with lots of quackery like homeopathy. It doesn’t explain how they can get away with using experimental drugs outside the auspices of clinical trials, something I had always wondered about. Gellman investigated and tries to explain:
Throughout Europe, drugs and vaccines intended for use in humans — even at private clinics — must comply with production standards set by the European Medicines Agency (EMA) and meet the quality-control criteria outlined in the international Good Manufacturing Practice (GMP) code. This code governs aspects of production ranging from safety to marketing, packaging, and labeling. Compliance can be cumbersome and often drives up manufacturing prices.
To circumvent these hurdles, some physicians offering peptide-based immunotherapy vaccines have an implicit arrangement with laboratories to skirt regulatory controls designed to protect patients. I contacted the University of Tübingen in southern Germany, which has a well-known Department of Immunology, and spoke with the department’s lead researcher, Dr. Hans-Georg Rammensee.
Rammensee confirmed that the university’s lab sometimes produces peptide vaccines for physicians at local private clinics. I asked him whether the lab adhered to GMP standards when filling these orders. He sounded agitated by the question, and warned me that the issue was “a gray area.” Yet he was willing to explain that, in what he called an increasingly common practice in Germany, a physician might place an order with a lab for a particular peptide sequence, designating it “for laboratory use” only — rather than for patient use. Since a request for a compound that won’t be administered to a human patient does not require GMP compliance, a lab can fill it quickly and cheaply, he said. The strategy allows for deniability on the part of labs, who sell the peptides to the clinics at cost. Some labs are aware of clinics’ intentions to administer them to patients as vaccines.
This is truly irresponsible, and, even worse, tells me that the markup on experimental cancer vaccines used by clinics like Hallwang is even more outrageous than it would first appear, given that, as Gellman reports, a laboratory can produce 30 mg of a given peptide, which is enough to yield about 100 vaccine doses, for roughly $570. She also reports that private clinics often go on to administer these laboratory-grade peptides to patients at inflated prices. Consider. There’s a reason why GMP is required and why only pharmaceutical-grade substances should be used as therapeutics. Laboratory-grade chemicals, peptides, and the like can have impurities that don’t affect their use in research purposes but could well be potentially dangerous in patients.
Big pharma and Hallwang: An unholy alliance
It’s even worse than that, though. Alternative medicine mavens often rant (sometimes appropriately sometimes exaggeratedly) about the depredations of big pharma. Here’s one that I bet they’ll never rant about:
The clinic’s parent company, Hallwang Clinic GmbH, is owned and operated in part by drugmakers who appear to have a vested interest in the treatments it sells — an arrangement that has raised red flags for potential collaborators. The company’s CEO, Albert Schmierer, a pharmacist by training, personally holds a roughly one-quarter ownership stake in the Hallwang Clinic, according to 2016 shareholder documents available through Moneyhouse.de, a German corporate-records database. Schmierer is also listed online as CEO and owner of Dr. Zinsser Pharmaceuticals, a medical-products company, and runs Rappen-Apotheke, a pharmacy that specializes in homeopathy and is located near the clinic, according to its website.
In the course of my reporting, I spoke with several physicians and practitioners who head private cancer-treatment clinics throughout Germany. Among them was Dr. Joachim Drevs, an oncologist who runs the private clinic Unifontis in the central German town of Sickte. He told me that in 2013, Hallwang Clinic management approached him about forging a collaborative relationship. During their preliminary conversations, Hallwang Clinic executives shared with him their drug-sourcing procedures, including that Schmierer’s pharmaceutical firm produces a significant portion of the treatments offered at the Hallwang Clinic. Drevs said he was distressed to learn of this arrangement.
“If the decisions are made by pharmacists — the owners of the treatments — it’s impossible to stay neutral” in determining the best course of care for a given patient, Drevs told me. He said he ended discussions with the Hallwang Clinic after a few weeks.
This is no different than Mike Adams, Joe Mercola, or Gary Null selling the very supplements that they tout on their websites and multimedia empires.
Gellman also spoke with several former employees, nearly all of whom were afraid to go on record because they had signed nondisclosure agreements. They told tales of highly unethical practices, such as barring patients from vetoing elements of proposed treatment plans, aggressively going after payment from a freshly grieving spouse, and revising costs upwards after treatments begin. She includes a story of a man who racked up $1.5 million in charges for the treatment of his wife, before realizing his mistake. Another woman, Lynn Wealleans, described her husband’s battle with late stage peritoneal cancer that ended up racking up $294,000 and said, “To me, they were just still making money” until her husband died.
Basically, Hallwang appears to take advantage of tumor biology as well. For instance, there’s the case of Claire Cunningham, who had been diagnosed with breast cancer in 2008 and for some reason didn’t undergo mastectomy until 2012. In 2016 she was diagnosed with metastatic disease to her liver, lungs, and bones. She went to Hallwang in November 2016 after having been hospitalized in England for seizures. Her story:
During her roughly six-week stay at the Hallwang Clinic, Claire said she received a mix of immunotherapy vaccines, vitamin treatments, dietary guidance, and physical therapy. She has since been able to return to work and was elated to learn that her tumors had shrunk dramatically.
“I am a miracle,” she told me.
Claire’s initial round of treatment cost more than $139,000, which she covered by tapping into her savings, mortgaging her home, selling her car, and launching a crowdfunding campaign. In fact, she told me that my call came as she and her staff were selling tickets to a Las Vegas–themed benefit, the proceeds of which would help fund her ongoing treatment.
Of course, it’s not entirely implausible that the treatments might have caused her tumors to shrink. However, her progress was short-lived:
Claire Cunningham, the West Yorkshire patient who felt she was improving last summer, now believes her time is running out. In a phone call earlier this month, she said that, despite having had subsequent treatment at the Hallwang Clinic and spending a total of more than $368,000 there over a several-month span, her cancer has lately returned to her lungs, and she now has at least 10 new tumors in her spine, which limit her mobility.
“I’m in a bad way,” she said.
Meanwhile, she added, more than a dozen fellow Hallwang Clinic patients have died since she began treatment there. And, while a few months ago she participated in the clinic’s promotional efforts — and her testimonial remains on its website — she’s now adamant that she would not return there, even if she could afford it.
A year and a half with metastatic disease before progression is not unreasonable, but breast cancer can have such a wide variation in aggressiveness and time to progression that it’s hard to make much of a comment one way or other. Certainly, we can’t really say whether Cunningham would have done any better with conventional therapy versus whatever combination of conventional and “dirty” experimental therapy offered at Hallwang or whether Hallwang helped her more than a conventional cancer hospital would have. We can say what’s more likely, and we can also say that she wouldn’t be near-bankrupt if she had gone with conventional therapy.
The business model of German cancer clinics
The business model of quack German cancer clinics like Hallwang, if Gellman’s reporting is to be believed, is based on exploiting frustration that patients with advanced cancer feel with conventional medicine, particularly when there is no further curative treatment to be offered. Indeed, in the case of Claire Cunningham’s testimonial back when she thought Hallwang was saving her life, Hallwang presented her dilemma as, “Hospice or Hallwang.”
Part and parcel of this business model is an utter lack of true informed consent. Not only are patients sold a glowing vision of a potential cure, but they aren’t even really told what it is they are getting, at least not in sufficient detail. When patients in a real cancer hospital go through the informed consent process, they are told exactly what drugs they will be getting, what the chances of success are estimated to be, what the expected side effects are, what the risks of adverse events are, and more. Gellman’s report indicates that Hallwang’s descriptions of the treatment are so vague as to be useless and that it massively overestimates of the probability of success.
A further part of the business model is to claim to be able to cure (or at least produce a remission) in clinical situations for which remission is incredibly unlikely if not nearly impossible. In the case of someone like Janet Colgan, with peritoneal carcinomatosis from stomach cancer, the chances of producing a remission are slim and none, but conventional medicine can palliate effectively and, in some cases, prolong life. Patients don’t want to hear that, though. They want cures, and thus, as Kate Colgan herself noted, are susceptible to overpromising of the sort many German cancer clinics engage in. Part and parcel of that business model is to discourage the patient from ever giving up, no matter how bad his or her situation becomes, no matter how much the cancer grows and spreads. This attitude delays decisions by patients to seek effective palliative care while draining their bank accounts and the bank accounts of their families and mandating that they spend the rest of their short existences chasing money from strangers on social media to pay for ever more treatment.
People will often say of a terminal illness: How could things get any worse? The lesson of Hallwang tells us. Things can get worse if you’re induced into chasing false hope. Things can get worse if you are enticed into eschewing effective palliative treatment and suffer more than is necessary—or even die prematurely from the treatment. Things can get worse if you drain your life’s savings, leave nothing behind for your family, and spend the rest of your life chasing ever more money. Things can get worse if your family joins you in draining their life’s savings to pay for your treatments. Things can always get worse, and quack cancer clinics virtually guarantee that they will.

   How not to win friends and influence people
David Gorski
Link
BLOGGER’S NOTE: The incident described in this post is true, although somewhat embellished to protect the names and identities of the innocent, if you know what I mean. This conversation occurred a few years ago at a large national cancer meeting.
The question caught me by surprise.
While attending a large national cancer meeting, I was having brunch with a friend, a colleague with whom I used to work when I was doing laboratory research, someone whom I hadn’t seen in a long time. She and her husband had brought along two of their oldest and dearest friends, whom they had known for decades, as well as another of my former coworkers from my old lab. We were idly chatting away and eating, when one of the occupational hazards of being a doctor presented itself. Tthe conversation drifted to medical topics. And then it came.
“What do you think of Dr. Gonzalez?”
Ah, hell.
Blindsided again! Why hadn’t I seen that one coming? As a doctor, I find that these sorts of questions hit me when I least expect them. I was half-tempted to play dumb and pretend that I didn’t know who Dr. Gonzalez is, but decided against that approach. It doesn’t work anyway. I knew feigning ignorance would only result in her telling me who Dr. Gonzalez is in excruciating detail. Instead, I asked a single question to make sure we were both on the same page and talking about the same Dr. Gonzalez, “Do you mean the Dr. Gonzalez in New York City, the one who uses ‘detoxification,’ diet, and enemas to treat cancer?”
“Yes, that’s him,” she replied.
No escape there. For those of you who aren’t aware of who he is, Dr. Nicholas Gonzalez is a physician in New York City who claims to be able to treat incurable cancers with a regimen that includes dietary manipulations, “detoxification” with coffee enemas, and the ingestion of pancreatic enzymes. I’ve discussed him before in the context of a patient who followed his regimen and paid a price and, indeed, who might even have been treated by Dr. Gonzalez himself back in the mid-1990s. My co-blogger Dr. Atwood has produced a series of blog posts (1, 2, 3, 4, 5, 6) that will tell you in exquisite and painful detail. Dr. Gonzalez’s methods are based on a regimen popularized by William Donald Kelley, D.D.S., whose regimen resembled that of Dr. Max Gerson (whom I’ve written about). Using this regimen, Dr. Gonzalez claims that he can produce long-term survival in patients with inoperable pancreatic cancer, for whom the median survival is usually less than six months. Never mind that his study only had 11 patients who could complete the regimen, had no control group, and, given the rigor of the regimen required, had the potential for serious selection bias (Gonzalez’s regimen can sometimes require as many as 150 pills per day). Based on this tiny uncontrolled study, somehow NCCAM saw fit to fund a $1.4 million clinical trial, for which my co-blogger Dr. Atwood has produced compelling evidence that the Gonzalez regimen did not work and, indeed, may have even produced worse results than conventional therapy. As I’ve said before, if I were to submit a grant proposal to the NIH with so little preliminary data, the study section would have a good laugh at my expense before filing my application in the cylindrical file. In fairness, I will give Dr. Gonzalez a modicum (but just that!) of credit for at least making an attempt to use science to look at his therapy, however dubious the supporting data. Too bad he apparently wasn’t intellectually honest enough to report the results when they almost certainly didn’t go his way.
I wasn’t in the mood, though. I had just wanted to hang out with some old friends and talk about science, old times, and other topics. Also, I knew that a debunking session would probably not be appreciated (they almost never are, particularly in what was supposed to be a light social situation), and I didn’t want to risk offending my friends by being too strident with their old friend. So I tried to discourage her. “You probably don’t want to know what I think,” I replied, with what I hoped was a self-deprecating smile and chuckle.
“No, I do,” she said.
Damn, she’s going to be persistent, I thought. Not in the mood for a confrontation, I became more insistent. “No, I really don’t think you do.”
“Please.” She leaned forward, expectantly.
“You’re probably not going to like it,” I gently warned her, feeling like Deep Thought preparing to reveal after seven million years of working on the problem that the answer to the Great Question of Life, the Universe, and Everything is 42. If she didn’t know what I was going to say now, I would no longer be responsible for what came next.
“Come on.”
OK, I warned you. “He’s a quack,” I blurted out, wincing inwardly at how it must have sounded coming out. “I see no evidence that his ‘therapies’ do anything for cancer patients.” Did you have to use the q-word? Why couldn’t you be more diplomatic? I rebuked myself. You know what you normally do in these cases. You normally say that the treatment is unproven, that there is no evidence that it does anything whatsoever to increase long-term survival in cancer patients, but that you doubt it does any harm. (Even if you don’t necessarily believe that inside for this particular therapy.) That’s how you defuse the situation, avoid unpleasantness, and even possibly educate the people asking about the questionable therapy. You don’t use the q-word!At least, you don’t use the q-word with well-intentioned people who just don’t know any better. Hard-core alt-med mavens, on the other hand, are another matter entirely.
She was silent for a moment. Silverware clinked, but no one spoke. Everyone, my friend included, was looking at me expectantly.
I began a discussion of why I held the opinion I did about Dr. Gonzalez. I was starting to explain that Gonzalez’s methods were based on out-dated, faulty, turn-of-the-century concepts of how cancer developed, how his concept that cancer is due to a deficiency in pancreatic enzymes is not only implausible but not supported by scientific evidence, how there was (at the time) no good randomized clinical study that shows his methods do anything for cancer patients, and how the only reason his methods hadn’t gone the way of Laetrile was because of aforementioned tiny study, which led to the NCCAM study, when my friend’s friend interrupted. “You know, my husband and I know one of Dr. Gonzalez’s patients.”
“Oh, really,” I said. So that was why she was so interested.
“Yes, he had melanoma. His doctors told him he should just go into hospice or go home to die. But he went to Dr. Gonzalez, and he’s been fine. That was 12 years ago.”
Ah, geez. The dreaded “the doctors sent me home to die” cliché of so many alternative medicine cancer cure testimonials–even worse, the testimonial told second-hand to a friend. You can’t effectively fight that one without risking serious unpleasantness, and I didn’t want things to get too unpleasant, in deference to my friends. I realized that there was no way I was going to convince these people that Gonzalez was using unproven–even harmful–methods with no evidence of efficacy. They believed he had saved their friend’s life when no other doctor could. I also realized that questioning them to see if I could figure out whether their friend really did have metastatic melanoma was probably pointless. I guessed that most likely their friend probably didn’t have stage IV melanoma and that surgery probably took care of the disease, as it does for the vast majority of melanoma patients who survive the cancer. (Lay people and even some physicians not familiar with melanoma frequently confuse “stage IV,” which does mean metastatic and, with few exceptions, incurable with Clark “level IV,” which does not, unless the melanoma is accompanied by distant metastases.) But people won’t believe that or hear it when you say that. Indeed, in my experience, lay people rarely have enough information to let an oncologist or cancer surgeon assess the true severity of their friend’s or relative’s illness.
So I did the only thing that was left to me. I explained that a single anecdote does not constitute evidence for general efficacy, using one of my favorite sayings, “The plural of ‘anecdote’ is not ‘data.’” I also explained that spontaneous remissions, although very rare, do occasionally occur for melanoma and that it was impossible to assess whether the Gonzalez treatment really worked or whether conventional surgery had taken care of the melanoma. (Remember, when patients undergo surgery and then decide to opt for alternative medicine for the remainder of their treatment, they almost always attribute their “cure” to the alternative medicine, and not to the surgery.) Finally, I pointed out that my skepticism was rooted in both the lack of evidence that Gonzalez’s therapy does any good and the flawed “model” of cancer upon which the Gonzalez therapy is based. I told them that it was being studied in a clinical trial but that I sincerely doubted that it would be shown to have much, if any, benefit. I also explained the concept of selection bias, and how the healthiest patients were the ones who could manage to go through Gonzalez’s rather rigorous regimen, which could include as many as 150 pills a day.
“Oh,” she said. “You know, I heard of another person that Dr. Gonzalez had turned down because he had had so much chemotherapy and other treatments before.”
“That doesn’t surprise me and only makes me think selection bias even more,” I replied.
Perhaps I had gotten through after all–maybe just a little. It also helped that everyone at the table except them were scientists involved in medical research. I got a little tactical air support from them.
The conversation moved on to other topics. I did see everyone again a couple of more times while in Anaheim, and, to my relief, the topic of Dr. Gonzalez never came up again.
But this encounter reminded me of a few things. First, credulity will hit you when you least expect it. Most people who believe in these things aren’t hardcore alt-med aficionados. They are regular people who just don’t have the background in science and critical thinking to assess claims of “unconventional” practitioners properly. Second, many of these people can be educated, but not by stridency or overly strong attacks on their favored practitioner. That’s why I winced when I let it blurt out that I thought Dr. Gonzalez was a quack, even though I do, in fact, believe that he is. That could have turned them off so completely that anything else I said would have been ignored. (Fortunately, it didn’t, but it could have.) It also reminded me when, out of the blue, a couple of my close relatives expressed to me the belief that Sylvia Browne could really communicate with the dead. Suffice it to say that I did not cover myself with glory in terms of communicating skepticism and critical thinking, even to my family. Indeed, I recall yelling and the liberal use of terms like “bullshit,” “con artist,” and “scammer,” among others. True, Sylvia Browne is all of those things and her claims to be able to speak with the dead are, in fact, bullshit, but using those terms probably did not change any minds.
Blogging is one thing; being blunt is often appropriate here because the modalities that we are talking about are often not just useless but actually harmful. Moreover, to engage the reader, we have to be at least somewhat entertaining to read, and it is entertaining to read a sarcastic deconstruction of quackery. Also, reading a blog post or an article is not the same as having someone call quackery to your face. Face-to-face encounters usually require a different, more diplomatic approach, which is, believe it or not, possible without compromising. I also believe that the same (usually) holds true for radio and television, where it is very easy for believers to paint the skeptic as angry and intolerant, just as creationists have been doing to defenders of evolution for years whenever one is tempted to accept invitations to debate creationists. Finally, if you’re a skeptic and a doctor, you have to be prepared at any moment to do your part for science- and evidence-based medicine and against quackery. And remember, don’t resort to bluntness until you’ve exhausted more diplomatic means of getting your message across–unless you’re dealing with a hardcore believer, of course, in which case diplomacy is probably pointless unless there are others around whom you don’t want to turn off. The old saying may point out that there is more than one way to skin a cat, but you have to know when to pick one way over another; i.e., diplomacy over all out war or vice versa.

   The Orange Man
David Gorski
Link
The first thing that struck me about him was that he was orange.
It was not a shade of orange I had ever ever encountered before in a patient. It was a yellowish orange, an almost artificial-looking color. At first I wondered if he was suffering from liver failure with jaundice, but this orange was just not the right shade of yellow for jaundice, and his sclerae were not yellow. I also considered whether he was suffering from renal failure, but the orange color of his skin didn’t quite match the rather coppery color that some patients suffering from longstanding renal failure necessitating dialysis sometimes acquire. I was puzzled. His chart said that he was being admitted for surgery for rectal cancer. So I sent the intern in to get the story, do the history and physical, and get him all plugged in for his bowel prep. Believe it or not, there was actually a time when it was not all that uncommon for patients to come into the hospital the night before major abdominal surgery in order to undergo a preoperative bowel prep, rather than being forced by their insurance companies to undergo the torture of drinking four liters of the purgative known as Go-Lytely–a misnomer, if ever there was one!–at home and spending the next several hours having to rush periodically to the toilet, waiting in vain for the liquid exploding out of their hind end to run clear.
Over twelve years ago, I was in my chief resident year in general surgery. I was doing a rotation as chief of one of the general surgery services back at the mothership (the main university hospital). This particular service was home to several colorectal surgeons, as well as the chief of the general surgery service. Consequently, we saw a lot of good, solid general surgery involving the colon, one of the organs that many general surgeons like to operate on the most. Naturally, a lot of this surgery was colorectal cancer, given how common this variety of cancer is. It was while I was doing this rotation that I first encountered the Orange Man, as I dubbed him in my mind (although I never called him that out, not even to the other residents, who might have found it amusing).
When rounding with my attending, the Orange Man’s surgeon, the one who had admitted him for the next day’s operation, I learned the sad tale of our patient. He was a man in his early 50′s, who had first seen my attending over a year before. He had suffered BRBPR (which, non-medical types, stands for “bright red blood per rectum”) and been referred to a gastroenterologist, who quite appropriately examined him and did a colonoscopy. This revealed a rather low-lying rectal cancer. He was next referred to my attending, who evaluated him, found that there was no evidence of metastasis of his tumor to the liver or elsewhere on CT scans, and recommended surgery. Although the tumor was relatively low in the rectum, the attending thought there was a very good chance he could do an anal sphincter-sparing procedure, known as a low anterior resection, possibly with either a very low anastomosis or a coloanal anastomosis. However, the patient would have to be prepared for the small possibility that it might require an abdominoperineal resection (APR) to remove the tumor. We generally try to avoid APRs whenever possible because APR involves taking not just the rectum, but the anus as well. It necessitates sewing the hole through which the anus once passed shut and leaving the patient with a permanent colostomy. APRs are sometimes necessary for very low-lying cancers, cancers that can’t be removed with an adequate margin of normal tissue between the tumor and the anus, or tumors low enough to be invading the anal sphincter mechanism itself.
Scary news indeed. I can only imagine the reaction of the Orange Man upon hearing the news. He was probably terrified. Certainly, I’d be scared if it were me. Certainly, I wouldn’t want to have a permanent colostomy if it wasn’t possible to get the tumor out with a clean margin and still save my anal sphincter. No one, and I mean no one, does. But, if it had been me, I’d still have undergone the surgery, because I know it would be my best shot at long-term survival. I’d take the small chance that it might be necessary to have a permanent colostomy. It also helps that I knew my attending was an excellent surgeon, and I would have trusted him to have the surgical judgment necessary to know the right thing to do.
The Orange Man, unfortunately, made a different choice. Convinced that he could find another way to avoid all that nasty, allopathic medicine, with its emphasis on “cutting and burning,” he sought “alternative” medical treatments. In his search, he somehow found his way to New York City, where he discovered a practitioner recommending a regimen that involved coffee enemas and megadoses of carrot juice. There he returned periodically for over a year, all the while purging himself with coffee enemas, consuming megadoses of carrot juice and vitamin supplements, and undertaking various other “alternative” treatments for a potentially curable cancer (and, I guess, trying to ignore the increasingly orange tint his skin was developing).
Coffee enemas? I couldn’t believe it. I had never heard of such a therapy before. Remember, this was 12 years ago, and I was a chief resident in general surgery. My interest in unscientific medicine and implausible medical claims was years in the future. At the time I wondered: What possible use could coffee enemas have against cancer? The only use for them I could imagine at the time was possibly as a more rapid (and highly disgusting) method of delivering caffeine directly into the bloodstream.
I didn’t know about it at the time, but now I can speculate that the “therapy” the Orange Man had chosen was very likely some variation of the Kelley/Gonzalez treatment, described so eloquently by my co-blogger Kimball Atwood. The inspiration for this “therapy,” first developed by Max Gerson, MD back in the 1940′s and 1950′s, after which a variant of a similar “detoxification” regimen was developed and practiced by William Kelley, DDS in the 1960′s, and still practiced today by Nicholas Gonzalez, MD, is a belief that all cancers come from a deficiency of pancreatic enzymes, which supposedly allows cancer cells to grow. According to the “concept” behind this, cancer grows and metastasizes because there is lack of cancer-digesting enzymes in the body. The solution is, supposedly, to get pancreatic enzymes to the place where cancer is growing in a concentration high enough to stop growth, but not so high as to cause too rapid production of “toxins” from tumor breakdown. Consequently, the treatment consists of “detoxification” with coffee enemas, which supposedly help flush the waste products of tumor cell breakdown out of the body; dietary manipulations; ingestion of pancreatic enzymes; and megadoses of supplements and vitamins, like carrot juice. The original Gerson diet required more than a gallon a day of juices made from fruits, vegetables, and raw calf’s liver, but, as I later learned, there are many variants to this sort of therapy, and none of them have any plausible basis in physiology, tumor biology, or pharmacology.
Looking back on the incident, I now wonder if the Orange Man was treated by Dr. Gonzalez himself, given that New York is where Gonzalez has practiced his brand of woo for many years.
The Orange Man was finally forced to return to my attending when it became clear even to him that the coffee enemas and megadose carrot juice therapy were not working. His rectal tumor had continued to bleed intermittently but with increasing frequency. It had continued to grow slowly and even started to interfere with his ability to defecate. Finally, it had began to produce the horrible sensation of tenesmus, which is the intractable sensation of having to move one’s bowels that rectal cancer patients sometimes get and which can at times be almost unbearable because it can never be relieved with actual defecation. Finally, the Orange Man had had enough.
Unfortunately, the cancer hadn’t yet had enough the Orange Man. By the time he returned to “conventional” doctors and surgeons, his tumor had grown considerably. It was now intermittently bulging out of his anus and may have been growing into his anal sphincter. Indeed, I examined him and was amazed at the size and firmness of this mass, which was easily reachable on rectal examination. Fortunately, CT scans showed that the tumor still did not appear to have metastasized to the liver or elsewhere. Fortunately for The Orange Man, the tumor still appeared to be operable. But he would require an APR and a permanent colostomy for the tumor to be excised with curative intent. So low and so large was the tumor that there was zero chance of sparing the anal sphincter and no chance that he would avoid a permanent colostomy. There was also a very high chance that the Orange Man would be left permanently impotent, as well.
The Orange Man was the first patient to teach me that alternative medicine that is ineffective is not harmless.
I still remember his operation. It was one of the last ones I did before I had to move on to another service. The Orange Man had a bulky rectal tumor that was very difficult to remove, along with numerous hard, suspicious lymph nodes in the mesentery, going all the way up to the root of the aorta. He clearly had node-positive disease, a negative prognostic factor. Also ominous was the observation that the tumor had clearly invaded all the way through the wall of the rectum, another negative prognostic factor. All I can remember thinking is: How on earth could this guy have chosen not to undergo surgery a year before, back when his tumor would have been much more easily removed, and he would have had a good chance of not needing an APR (with its attendant permanent colostomy), not to mention a much better shot at long-term survival? Why? What did the “alternative” medicine practitioner tell the Orange Man to convince him to forsake proven effective therapy? Did the practitioner promise him he could be “cured” without surgery, radiation, or chemotherapy, without pain? Did the practitioner scare him with horror stories of the complications from such therapies? Did he describe “conventional” therapy as “cutting,” “burning,” or “poisoning,” as so many such practitioners do? Dd he or she do a little of all of these?
I don’t know what ever happened to the Orange Man. I felt very sorry for him. He had clearly been taken in by a quack and was more likely than not to pay the ultimate price. And he knew it, too. A few days later, before the Orange Man was discharged, I had to move on to another service in another hospital. I never saw Orange Man again. Given the extent of his disease, there’s certainly less than a 50-50 chance that he is still alive today. If he is still alive, however, there is a 100% chance that he has a permanent colostomy that he very likely wouldn’t have required if he had simply undergone treatment according to known and effective regimens worked out through scientific medicine.
Alternative medicine that is ineffective is not harmless.
When I hear advocates of alternative therapies claim that their therapies are harmless, I think of the Orange Man. When I hear advocates of alternative therapies claim that their therapies are harmless, I also think of women like the one whom I discussed about a month ago or like Patti Davis, who underwent a breast biopsy and was told that she had breast cancer. Her cancer would have had a high probability of being cured (oncologists hate to use that word, but in this case it is not entirely inappropriate) with conventional therapy. However, instead she, like the Orange Man, opted for a variant of the Gerson therapy, driving to a clinic in Tijuana, undergoing “detoxification, and eating 7-8 pounds of carrots a week at one point. Her mother, who had had breast cancer at age 47 and survived 22 years after surgery, radiation, and chemotherapy, urged her daughter to finish her surgical therapy and a course of conventional therapy, to no avail. Mrs. Davis ultimately did return to conventional therapy when she felt a lump under her arm that had developed while she was undergoing the Gerson therapy and finally realized her mistake.
By then it was too late. She later died at the age of 39.
And she has company: Debbie Benson, who eschewed conventional therapies for a treatable cancer; Lucille Craven, who went so far as to hide her diagnosis from her husband for many months while she sought treatment from various “alternative” practitioners; and many others.
Alternative medicine that is ineffective is not harmless.
I think of the Orange Man and Patti Davis, when I read or hear advocates of “complementary and alternative medicine” (CAM) crowing about how the Gonzalez regimen was tested by an NIH-funded trial. What they forget are patients like those above and how the results of that clinical trial mysteriously have never been published, as Dr. Atwood pointed out. Although I support the rigorous testing of alternative medicine therapies in clinical trials to determine whether they have any efficacy, money is wasted when it is used to test implausible medical claims with no good preclinical or clinical evidence to support it. A prime example, the Gerson/Gonzalez therapy trial was funded on the basis of a single uncontrolled and poorly designed clinical study of 12 highly selected patients with pancreatic cancer. Dr. Atwood has ably described the many deficiencies in this preliminary study, the worst of which was the non-consecutive nature of the case series, which smelled strongly of cherry-picking of patients over three years. R01 grant applications for conventional medical therapies usually require considerable preliminary data from basic science, preclinical animal experiments, and often preliminary clinical trials if they are to have a shot at being recommended for funding. Where was the in vitro data to support the Gonzalez protocol, showing activity against pancreatic cancer cell lines? Where were the preclinical animal studies showing activity in models for pancreatic cancer (or any cancer)? Where were the animal studies that support the supposed mechanism by which the therapy is postulated to work? Not in the scientific literature or in the grant application, as far as I can tell. If I were to submit a grant application to the NCI for funding for a clinical trial based on so little data, the study section would deposit my application in the circular file; that is, if they didn’t pass out from laughing so hard first.
And don’t even get me started on the NIH Trial to Assess Chelation Therapy (TACT)!
Patients who choose implausible or unscientific treatments in preference to proven treatments who suffer, but they are not the only ones who suffer the consequences of their choice. It’s also their families and friends, who watch them die from potentially curable diseases (all too often draining their life’s savings along the way).It’s children who lose their parents and men and women who lose their spouses. Indeed, it’s all of us, who fund these ineffective treatments or end up paying more through taxes and insurance when a patient who might have been treated more effectively and inexpensively requires much more difficult and expensive treatment because of a delay caused by the pursuit of ineffective therapies and false hopes, who suffer as well.
Alternative medicine that is ineffective is not harmless.

When urgency to cure beats research ethics, bad things happen
David Gorski on August 26, 2013
Link
Editor’s note: Just for your edification, here’s a “bonus” post. True, you might have seen this recently elsewhere, but it’s so appropriate for SBM that I couldn’t resist sharing it with those of you who might not read the other source where this was published recently. 🙂
I’ve written a lot about Stanislaw Burzynski and what I consider to be his unethical use and abuse of clinical trials. Before that, I used to regularly write about Mark Geier and his unethical use and abuse of IRBs and clinical trials. Both doctors use their own IRBs stacked with their own cronies to rubberstamp scientifically and ethically dubious studies. Mark Geier got away with it for years. Stanislaw Burzynski got away with it for decades and, apparently, is still getting away with it to some extent. (His IRB is chaired by an old Baylor crony of his from the 1970s, and he has been cited for numerous problems with his IRBs.) I’d like to contrast how their unethical research, in which Mark Geier and his son David subjected autistic children to chemical castration with Lupron to decrease testosterone levels and allegedly make mercury easier to chelate (to them mercury was bound by testosterone, something that doesn’t happen under physiological conditions but requires organic solvents) and Stanislaw Burzynski administered an unproven cancer chemotherapy (antineoplastons) to hundreds of patients over the years and charged them for it, compares to a recent case in the news.
The case has been mentioned by PZ Myers. It happened that it involves the same sort of tumors that Stanislaw Burzynski claims to be able to cure, namely brain tumors. It happened at the University of California Davis (UC Davis) and involved two very prominent neurosurgeons there, a former head of the department Dr. J. Paul Muizelaar and Dr. Rudolph J. Schrot, who were found to have violated university’s faculty code of conduct with their experimental work. When you read this part of the story, you’ll shiver. At least, I did:
The procedure in question involved three patients described in documents only as Patients 1, 2 and 3 – two middle-aged women and one man who had a common enemy: glioblastoma.
For anyone unlucky enough to be diagnosed with the highly malignant brain tumor, the prognosis is dismal. Median survival is less than 15 months.
Muizelaar and Schrot called their novel approach “probiotic intracranial therapy,” or the introduction of live bowel bacteria, Enterobacter aerogenes, directly into their patients’ brains or bone flaps. The doctors theorized that an infection might stimulate the patients’ immune systems and prolong their lives.
The first patient lived about 5 1/2 weeks. The second survived another year, an outcome that buoyed the doctors and seemed to bolster their theory, they said.
The institutional trouble began in March 2011, when a newly diagnosed third patient developed sepsis, became unresponsive and died two weeks after being deliberately infected. The university’s first internal investigation soon followed.
As a cancer scientist and surgeon myself, my first thought here was: Who on earth thought this was a good idea? Let me put it this way. What Muizelaar and Schrot were doing was intentionally causing bacterial meningitis. In cancer patients! You know, patients whose immune systems are often compromised to begin with! To be honest, on the surface, Burzynski’s antineoplastons have more biological plausibility than this. Thirty years ago, I could say that they were at least drugs and therefore might have had some activity against cancer.
The concept that inducing an inflammatory reaction might help “prime” the immune system to counter cancer is not a new idea. In general, however, it’s not a good idea to use bacteria that could cause potentially life-threatening infections. The CNS is generally viewed to be an immune “privileged” site, meaning that the immune system doesn’t function the same way there as it does in the rest of the body. Immune privilege was first observed when it was noted that tissue grafts that would be rapidly rejected if grafted to the skin or other sites would survive a long time when grafted into the CNS. The original thought was that this meant the CNS was somehow cut off from the immune system by the blood-brain barrier, its lack of draining lymphatics, and the apparent inability of cells known as microglia to function as immune cells. However, recently this concept has been reevaluated in light of new data that show that the CNS is neither isolated nor passive in its interactions with the immune system, but that doesn’t change the observation that the immune system functions somewhat differently in the CNS. In any case, gut bacteria are in general not expected to be in the CNS, and bacterial meningitis can be really nasty. It’s also not that difficult to induce meningitis. Remember the outbreak of fungal meningitis from contaminated steroid injections last year?
Apparently, Muizelaar based his idea on an apparent observation in among neurosurgeons that postoperative infection was associated with better survival in patients with glioblastoma. However, the data supporting this particular association is, to put it kindly, mighty thin, a retrospective study. What Muizelaar apparently did was to place an enteric (gut) bacteria, Enterobacter aerogenes, into the open wound and bone flap after surgery in order to produce a wound infection. E. aerogenes tends not to be pathogenic except in patients who have compromised immunity, such as the elderly, infants, and, yes, cancer patients.
It’s instructive to read some of the PDFs included with the article, such as the report of the UC Davis investigation of Dr. Muizelaar and of Dr. Schrot. It reveals a bit of the complexity of doing investigations like this and, more importantly, why Drs. Muizelaar and Schrot went too far and how they gamed the system. He started with a consultation to the Bioethics Consultation Committee, which, after a lengthy debate, concludes that the practice “may be seen as consistent with the customs and practices of medicine.” However, the committee thought that the procedure required more oversight than it could provide, and suggested that the protocol should be reviewed by the IRB. So Dr. Schrot submitted a full application to the IRB in which he admitted that further preclinical work was needed but argued that in this patient the benefit/risk ratio was favorable. On what evidence? Who knows? I don’t have the IRB application. Dr. Schrot also discussed the procedure with the Center for Biologics Evaluation and Research at the FDA and was told that “animal studies will be necessary prior to entering into the clinic with your proposed therapy.” In addition, he was told that “these animal studies must show not only safety, but also establish a reasonable proof of concept in order for this investigational therapy to be introduced into patients.” In other words, the FDA told them to do the preliminary work first.
In the meantime, Drs. Muizelaar and Schrot submitted an NIH grant application for the animal studies. It was not well received by the study section, which characterized it as having “low translational impact with seriously flawed methodology and statistical analysis.” The summary statement concluded, “There is absolutely no feasibility evidence in support of this project” and comments that it has a “low translational impact since it is very unlikely that any IRB or the FDA will allow the introduction of Enterobacter aerogenes directly into patients.”
Here’s where things get interesting. The FDA had told Dr. Muizelaar that he and Dr. Schrot could proceed with their “innovative treatment” if the bacteria were available locally. No doubt this was because the FDA is a federal agency and doesn’t have jurisdiction if everything happens within one state. (It’s the same issue with Stanislaw Burzynski, actually.) If it was not available locally and had to go through the investigational new drug (IND) process, then more animal work was required, as the CBER stated. It turns out that a graduate student had some Enterobacter aerogenes from ATCC, and that’s what was used on these patients.
What follows then is wrangling between Dr. Muizelaar and the university. Dr. Muizelaar went to the Chief Medical Officer Al Siefkin and told him that the IRB had told Dr. Schot that the proposed procedure wouldn’t be considered research. In any case, both gave the impression that they were “shopping” for approval, and, although probably not lying, being a bit selective in what they told various parties involved in the approval process. As the news report notes:
Among the university’s findings, detailed in reports, email correspondence, interviews and regulatory documents:
A former top administrator said he believed the doctors went “shopping for approval” and were “doing all they could to get around” the formal approval process. A physician who served on the research oversight board said the surgeons seemed to be “gaming” the system to bypass any institutional rejection or skepticism of their plans.
Muizelaar and Schrot did not complete a study on rats before they began treating the three human patients, despite an FDA directive in 2008 that “animal studies will be necessary prior to entering into the clinic with your proposed therapy,” according to an email to Schrot from an FDA official. When asked by a compliance investigator why animal trials were not done first, Schrot allegedly responded that such testing would take “10 years … his entire career,” one internal review states. The investigator found Schrot’s “eagerness to proceed” to be concerning and his actions “reckless.”
One university investigator questioned whether the doctors ever would have been able to get federal approval of their concept. According to one report, Schrot’s grant application to the National Institutes of Health to study the bacterial treatment was rejected, with NIH commenting in 2009 that “(t)his is a very poorly developed scientific proposal that lacks feasibility.” The NIH thought it unlikely that university or federal regulators would allow the introduction of live bacteria directly into patients, the report states.
Ultimately, the procedures were done on three patients. Particularly disturbing is the consent forms that were drawn up, which basically said that there was no evidence that this would work but that the surgeons wanted to do it anyway. While technically that is accurate, one has to wonder how much coercion the patients might have felt and how free they felt they could say no. After all, they all had horrible diseases with a median survival of less than 15 months expected. As this editorial points out, patients also weren’t told everything:
Despite the absence of any FDA approval or IRB review, the neurosurgeons proposed their treatment, to Terri Bradley. The consent form she and her daughter signed appears straightforward. It made clear that the infection the surgeons were deliberately introducing into Bradley’s brain “may be totally ineffective.” It then laid out the many serious risks, including “further neurological deterioration … paralysis, coma or death.” The women were told the procedure did not have FDA approval.Faced with the alternatives presented and the near certainty of death, not surprisingly, the Bradleys signed.
Here’s what the Bradleys weren’t told. They were not told that the FDA hadn’t just failed to approve the procedure their physicians were pushing, federal officials had told the doctors specifically not to perform the procedure until they had conducted animal studies. The Bradleys were not told that the doctors had bypassed the university’s IRB process or that the IRB had previously told the doctors not to perform their “experimental” procedures on human patients.
In other words, the “informed consent” provided was every bit as much misinformed consent as what antivaccinationists and “health freedom” activists advocate for.
The end result was one patient living less than six weeks, another surviving two weeks, and the second patient, the “success story” living over a year. However, the family of that patient, Terri Bradley, didn’t view it as a “success.” Indeed, Mrs. Bradley required at least one operation to “clean out” her infected head wound and directly administer antibiotics. Indeed, her daughters reported that the infected wound had begun to smell bad. True, this patient did apparently have some tumor shrinkage. As I read about the tumor shrinkage, thoughts of Stanislaw Burzynski came to mind, as did the observation that three patients are too few to say anything and that one sees longer-than-expected survival in cancer patients with homeopathy (i.e., treatment with nothing but water). In any case, despite the doctors’ thinking that Ms. Bradley had benefited, she did not:
“Patient 2 did not experience significant functional benefit,” investigators concluded, “and upon her death … recurrences of the tumors and chronic infection of the brain were identified.”
Shockingly, even after this almost certainly treatment-related death, Drs. Muizelaar and Schrot convened an ad hoc ethics committee and presented them with a proposal to proceed with five additional patients. According to this report, the ad hoc committee concurred with the proposal and recommended continuing clinical activities with the understanding that they would develop an IRB-approved protocol as soon as possible.
In the end, this case demonstrates just how much oversight is needed on human subjects research and just how disturbing what “brave maverick doctors” like Stanislaw Burzynski, Mark Geier, and, yes, Drs. Muizelaar and Schrot do can be. The problem, of course, is that the line between research and trying something “innovative” (or truly innovative without the scare quotes) is not always clear, nor is the line between research and making a “last ditch” effort to save a patient’s life. It also speaks to the inherent conflict between the desire of a doctor to save lives and the need to do rigorous research in order to determine whether what the doctor does actually does save lives. As a physician, it’s very easy to develop a tunnel vision and believe that your latest idea is something that will work, that will save lives, if only those unimaginative clods would see what you see. Also, in the service of the goal of saving lives, it becomes progressively easier to justify cutting ethical corners, as Drs. Muizelaar and Schrot appear to have done. It’s very easy to start to view the system designed to protect human subjects as obstacles to be overcome rather than the patients’ advocate.
You know how they say that the road to hell is paved with good intentions? I can’t think of a better example in medicine than a case like this.

The sad saga of an Amish girl with a curable cancer whose parents are refusing chemotherapy in favor of “natural healing”
In Ohio, an Amish girl named Sarah Hershberger is refusing chemotherapy for her leukemia, and her parents are supporting her. Akron Children’s Hospital has instituted legal action to ensure that she receives life-saving treatment. As a motley crew of consisting of supporters of alternative medicine and anti-government libertarians are rallying to Sarah’s cause. Will this girl receive the life-saving treatment she needs?
David Gorski on November 4, 2013
Link
Over at my not-so-super secret other blog, one common type of story that I’ve blogged about has been that of the “chemotherapy refusenik.” It’s a topic I write about here not infrequently as well. People like Suzanne Somers and Chris Wark come to mind, mostly people who had effective surgical therapy for their cancers and then decided to forego adjuvant chemotherapy in favor of quackery. Not surprisingly, they attribute their having beaten cancer not to the surgery that saved them but to the woo du jour that they chose instead of chemotherapy, not understanding that such chemotherapy is not the cure; it only reduces the risk of recurrence after surgical extirpation of the tumor. What I haven’t discussed as much here as I have over there are cases of children with cancer whose parents refuse effective chemotherapy to treat their malignancy (other than Daniel Hauser). Because most childhood cancers are not treated with surgery, chemotherapy ± radiation therapy really is the primary therapeutic modality for most of them; so refusing it has a very high probability of resulting in the unnecessary death of a child. Generally pediatric cancers have an 80-90% five year survival, and recurrences after five years are rare, which, as I described recently, is an enormous improvement over 40 years ago.
Sadly, there have been many such cases, such as the aforementioned Daniel Hauser, Abraham Cherrix, Kate Wernecke, and Jacob Stieler. All of these are stories of children who were diagnosed with highly curable cancers who refused either chemotherapy or radiation therapy and were supported in that decision by their parents. Indeed, of these, Cherrix, Hauser, and Wernecke ran away with their parents to avoid chemotherapy. They all came back, but with different results. Hauser came back, started chemotherapy again, and is doing well. Cherrix ultimately came back, but the court made a deal with his parents that let him be treated by an “integrative medicine” doctors who treated him with low dose radiation and a bogus “immunotherapy.” As a result, several years later his tumor recurred, and he was last seen earlier this year asking for money for treatment. His battle in the courts in Virginia also inspired the passage of a supremely bad law that basically allows open season on teens for quackery. Wernecke disappeared when her parents refused radiation therapy after having undergone chemotherapy and took her for intravenous high dose vitamin C. In 2007, her cancer recurred, but the recurrence appeared to have been treated successfully. It’s not clear how much conventional therapy she had received, at least as of 2010, which was the last time I could find anything about her online.
The latest of these cases that has come to my attention is the case of a 10-year-old Amish girl from Medina County in Ohio named Sarah Hershberger, who developed T-cell lymphoblastic lymphoma, an aggressive form of lymphoma, underwent chemotherapy for a few weeks, and then decided she didn’t want it anymore. Her parents, convinced that the chemotherapy was killing her, instead of insisting that she undergo potentially curative therapy, which her doctors estimated to have an 85% chance of eliminating her cancer, refused to let undergo any further therapy. This led to a court case in which Akron Children’s Hospital (ACH) sued to obtain medical guardianship of the girl in order to make sure that she would undergo curative chemotherapy. The first ruling in the case in a Medina County court was for the parents. Then on appeal the 9th District Ohio Court of Appeals ordered Medina County Judge John Lohn to take another look at the case, ruling that he had failed to weigh adequately which course would best serve her interests — the decision of her parents to withhold treatment (at her request) or to appoint a limited guardian to make medical decisions, as proposed by Akron Children’s Hospital. Amazingly, Judge Lohn reiterated his previous ruling, finding that appointment of a guardian would interfere “with Sarah’s need and desire to be cared for by her loving parents” and stating that “the guardianship will not promote Sarah’s interests.” One month ago, Judge Lohn’s decision was reversed on appeal to the 9th District Ohio Court of Appeals, which caused everyone’s favorite quackery supporter to lose his mind in rage.
Since then the case has only gotten stranger, as hard as it is to believe. Indeed, it’s hard to know exactly what is going on, although discussing the case allows me to discuss a both the science and ethics of treating children with cancer using science-based modalities.
Whose rights matter here, anyway?
One of the most disturbing things about this case is the reaction of so many people to it. The predominant reaction was outrage that the hospital and state would attempt usurp parental rights, combined with undue credulity that “natural therapies” could cure patients. Indeed, on the hospital’s Facebook page, there are still people ranting about it, with posts like this:
You should all be ashamed of yourselves. You want people to vote on something in November? I can tell you that I won’t be voting for anything for your hospital. Was it worth it? Putting this family through all of this? Was it WORTH IT? You’ve ruined your public image. You’ve ruined the confidence of parents trusting you and bringing their children to your doctors and hospital. I can tell you that I am not the only person who feels this way about your hospital now. People are scared to death to bring their children to you now. People talk and they don’t trust your hospital any more.
Even today, a month after the ruling, ACH’s Facebook page is still deluged with posts by people claiming all sorts of evil intent on the part of the hospital, much of it based on two articles, one from a week ago, one from just the other day. The first is entitled Amish Girl Being Forced into Experimental Chemotherapy Taken Out of US and Recovers with Natural Treatment. The second is an interview with Isaac Keim, Sarah Hershberger’s grandfather, that appeared on the Chris Beat Cancer website over the weekend. (Yes, it’s that Chris.)
If this article is to be believed (and, as you will see below, it’s hard to know whether to believe it or not), sadly, but not entirely unexpectedly, the Hershbergers have apparently taken their daughter out of the country to avoid chemotherapy. The longer they do that, the more likely it is that their daughter will die a horrible death, and it will be her father Andy Hershberger’s fault. I realize that he has nothing but the best intentions and believes he is doing the best thing for his daughter, but he is wrong, so very wrong. If his decision is not reversed, his daughter will almost certainly pay a very unpleasant price. The author of the piece, David Michael, writes for a website called the Journal of Natural Food and Health. He’s also very obviously antivaccine and pro-quackery. Let’s take a look at what he claims:
Early in October 2013, the entire nation heard about how Sarah Hershberger, a 10-year old Ohio Amish girl with leukemia (now recovered), is being forced into a two-year unproven experimental chemotherapy study by Akron Children’s Hospital (ACH). It was just learned the parents, Andy and Anna Hershberger, took their significantly recovered daughter out of the United States before the court ruled that a hospital-affiliated, attorney-nurse, Maria Schimer, was made the medical guardian to make sure Sarah will get her treatments. Parents reported this week the child is fully recovered through natural treatments. Schimer is General Counsel (chief legal advisor) for Northeast Ohio Medical University (NEOMED), a close affiliate and business partner of the hospital. According to Andy, Ms. Schimer has never met Sarah or him and his wife and they were never told their child was being used in a research study—among other things.
Although they do not know it yet, the hospital now has a big problem they must deal with. Sarah is completely recovered, as of October 23, according to Andy. The hospital told them and the news media that Sarah would die in a few months without the treatment they recommend. Three doctors that have treated her with a natural, biochemical protocol using nutrition, supplements and plant extracts have declared Sarah cancer free based on cat scans and blood tests—confirmed three times.
Well, this is mighty convenient. Now that court has ruled that Sarah Hershberger has to undergo conventional treatment, suddenly the father claims that Sarah is cancer-free, thanks to the unnamed “nutritional therapies” to which he has subjected her. The three doctors who allegedly treated her with “natural therapies” are not identified, and no evidence that Sarah Hershberger is, in fact, cancer-free is presented. All of this puts the hospital at a profound disadvantage, because it can’t comment on Sarah Hershberger’s condition because of patient confidentiality laws. In contrast, Andy Hershberger can say whatever he wants and doesn’t have to produce any actual evidence. I’d love to know the names of the three doctors to see what sorts of treatments they recommend for cancer and what sorts of tests they order to determine if someone is “cancer-free.”
None of this should be construed to mean that I think Mr. Hershberger is lying. He is almost certainly telling the truth as he sees it, but he also clearly grossly misunderstands cancer treatments, specifically why pediatric oncologists do what they do. Unfortunately, quack apologists are taking advantage of Mr. Hershberger’s ignorance about cancer, an ignorance shared by most people. Most likely what happened is that the chemotherapy shrank Sarah’s tumors to the point where they are no longer detectable on CT scans. This is a common initial outcome after early rounds of chemotherapy. The problem with lymphoma is that, although it is fairly easy to put lymphoma into an apparent complete remission, making that remission permanent is difficult.
Unfortunately, it takes a lot more than just a round or two of chemotherapy, a lesson painfully learned by pioneering pediatric oncologists back in the 1960s and 1970s. For example, for the type of tumor that Sarah has, lymphoblastic lymphoma, the duration of one standard treatment is two years. For chemotherapy for lymphoma, there are at least three phases. The induction phase is designed to put the patient into remission. Consolidation chemotherapy is given to patients who have gone into remission and is designed to kill off any residual cancer cells that might be present, thus increasing the chance of complete cure. Maintenance chemotherapy is the ongoing, longer term use of chemotherapy to lower the risk of recurrence after a cancer has gone into remission. It’s basically lower-dose chemotherapy given for two to three years to help keep the cancer from returning. In Sarah Hershberger’s specific case, her oncologist, Dr. Prasad Bodas, testified that her chemotherapy would have five phases: induction (5 weeks), consolidation (seven weeks), interim maintenance (eight weeks), delayed intensification (six weeks), and maintenance (90 weeks), for a total duration of two years, three months.
At this point, it is quite possible that Sarah has no detectable cancer. If that’s the case, it’s the chemotherapy that she’s received thus far that almost certainly caused that result, not the herbs and vitamins her father has been giving her. If she is apparently tumor-free, it also means that failing to consolidation and maintenance chemotherapy greatly increases the chance that Sarah Hershberger’s lymphoma will relapse, a chance that is probably a near certainty if she only received her induction chemotherapy. Worse, relapsed cancer is always harder to treat. The first shot at treating cancer is always the best shot, with the best odds of eradicating the cancer. Letting cancer relapse through incomplete treatment breeds resistant tumor cells the same way that not finishing a complete course of antibiotics contributes to the development of resistant bacteria. It’s evolution in action.
The next part of Mr. Michael’s analysis is even more unbelievable:
The Hershberger family says they never were told the chemotherapy was part of a research project using experimental chemicals. They also said the hospital did not get their signature for the second phase of different chemicals and only Sarah was asked to “put her name on the line.” They claim they were not told of the serious side effects. They said Sarah’s confidential medical information was given to the news media violating federal privacy laws. After a significant improvement in killing the cancer, they saw that the chemo was starting to kill Sarah and decided to stop the treatment and employ a better option to stop the cancer altogether. This is when the hospital took legal action to keep Sarah in the treatment study.
One thing that you need to understand about pediatric cancer is that a very high percentage of patients with pediatric cancers are enrolled in clinical trials, well over 50%. Compare this to the 5% or so of adults with cancer who participate in clinical trials. This is a very good thing indeed for children and one of the reasons why survival rates for pediatric cancers have improved so much over the last four decades. So it would not be the least bit surprising if ACH had enrolled Sarah Hershberger in a clinical trial. In fact, I’d be disappointed in the hospital if its doctors didn’t at least offer her parents participation in a clinical trial.
The other thing you need to know is that clinical trials run by facilities that receive any federal funding or grants (as Akron Children’s Hospital surely does) are overseen by the Office of Human Research Protections (OHRP) Department of Health and Human Services, and children are considered a vulnerable population for which extra protections are mandated. I find it highly unlikely that Akron Children’s Hospital didn’t get the appropriate informed consent. However, I never completely dismiss the possibility that I could be wrong. So here’s what I propose. If Andy Hershberger really thinks that Akron Children’s Hospital failed to obtain proper informed consent for a clinical trial, then he has only to report it to the OHRP. If the drug in the study is a new drug, then he could report the issue to the FDA as well. In fact, I would very much urge him to do so if he thinks that he was not offered adequate informed consent for a clinical trial.
Next up, Michael accuses the hospital of being all about the money:
ACH will lose as much as $1,000,000 or more by not treating Sarah the full 110 weeks in this study and, according to our sources close to the case, has already billed $130,000 for the first five weeks. Add to this the various pediatric cancer research grants and other funds it is receiving directly or indirectly for this type of study. This is not counting the billings for treatments for the long-term side effects such as other cancers, kidney dysfunction, heart problems and nerve damage—all common for those that survive chemotherapy.
This is, of course, a misrepresentation of how clinical trials work. In clinical trials, the funding agency pays for all clinical trial-related treatments and tests that are not standard-of-care. The rest are billed regularly. Moreover, for the most part, hospitals do not make money off of clinical trials. The infrastructure to run them is hideously expensive, and funding agencies often don’t quite cover the full cost, particularly in these days of the sequester, which has hit NIH-funded clinical trials hard.
Ironically, Michael asks a question that should make all of people ranting about how greedy and evil Akron Children’s Hospital supposedly is wonder. Namely, “Why is the hospital going to all the time and expense, even with the risk of tarnishing their reputation, all to make sure their advice is taken as opposed to other available treatments widely known in Europe as well as clinics in the U.S.?” I’ve been asking the same question myself. It would have been so much easier for ACH to do nothing, to shrug its collective shoulder and let the Hershbergers do whatever they wanted with Sarah. It would have been far easier, far less trouble, and far less expensive. By any stretch of the imagination, it would have been the easy way out. But ACH didn’t take the easy way out. While conspiracy theorists might fantasize that this is because there is some amazing prize that makes all the bad publicity and harassment by the “health freedom” crowd worthwhile, the more likely conclusion is that ACH was willing to go through all this hassle because to make sure that Sarah Hershberger is treated according to science-based medicine.
I should also point out at this point that I have as yet been unable to find any corroborating evidence that the Hershberger family has, in fact, actually fled the country. Make no mistake, I searched a whole bunch of mainstream news sites, including the local news site for the Akron Beacon-Journal, and I found no stories of the Hershbergers fleeing the country last week, only reprints of the original story claiming that she fled and reports of a fundraiser to let her come back into the country. My guess is that she and her family are probably still in Medina County, but who knows?
In which we learn what likely caused the Hershbergers to reject chemotherapy
Over the weekend, as I alluded to above, I learned that Isaac Keim, Sarah Hershberger’s grandfather, gave an interview to Chris Wark of Chris Beat Cancer fame. (To reiterate, Chris did beat cancer, but it was the surgery, not his quackery, that cured him.) In any case, here is the telephone interview:
As you will see, the interview with Isaac Keim is enlightening in that he and Chris Wark inadvertently confirm that what I’ve written thus far is very likely spot on accurate in describing what probably happened.
We learn from Mr. Keim that the family first noticed something wrong when they found a lump on Sarah’s neck. So they took her to the doctor, and she ended up being referred to ACH. Ultimately she was diagnosed with a T-cell lymphoblastic lymphoma, and a workup revealed tumor in her neck, kidneys, and “in her body,” whatever Mr. Keim means by that, which seems to be elsewhere in her abdomen and chest. The Hershbergers were told that this is an aggressive tumor, but treatable with an 85% five year survival achievable with a 27 month course of chemotherapy consisting of five phases. All of this is consistent with what’s been reported and what I’ve just discussed.
Mr. Keim relates next that Sarah underwent the first phase of chemotherapy, which lasted 4-5 weeks and resulted in the lump on her neck nearly disappearing within a week. She also tolerated this first phase very well. It was at this point that the Hershbergers started to wonder why more chemotherapy was needed, given how good her response had been. Here’s where the story gets dicey. According to Mr. Keim, the doctors wanted to start the second phase but didn’t have the parents’ permission. Yet, according to him they just went ahead with the chemotherapy anyway. Clearly, there had to have been a breakdown in communication here, because, having worked in multiple hospitals over the years, I know that, if there’s one thing that major academic center hospitals are very, very compulsive about, particularly pediatric academic medical centers, it’s getting informed consent for almost everything, particularly now. Indeed, most such hospitals take it to an extreme, getting formal informed consent for tiny procedures like a punch biopsy of the skin. It stretches belief that ACH would subject a girl to further chemotherapy involving what sounded like intrathecal chemotherapy (chemotherapy injected by lumbar puncture into the central nervous system), requiring general anesthesia to administer and have a visiting nurse come out to administer chemotherapy at home, without having had the parents’ permission. At the very least, no anesthesiologist would put a child to sleep without the parents first signing permission, and no interventional radiologist would put a catheter into the spinal canal without permission. If it is really true that the hospital did all this without their consent, the parents would have a hell of a lawsuit that they could file, and I would urge them to file it.
In any case, from Mr. Keim’s account, it sounds as though the second phase was what caused Sarah to become really ill. He described her as feeling so weak that she wouldn’t get out of bed for a week and wouldn’t eat. At some point a nurse came to give the first of three weekly injections. She apparently was going to leave the remaining two injections at the Hershberger’s house and instructed them to keep them on ice. I found this to be rather odd, not the least of which because this was Amish territory and there was likely no refrigeration. True, the Hershbergers probably have an ice box, but if it’s so critical to keep a drug refrigerated, I doubt that a hospital would leave it in an Amish household where there might or might not be adequate ice to keep it cold enough long enough.
Whatever the case, if Mr. Keim’s account is accurate, that nurse then did something that arguably set the whole family off. She told the family to keep the syringes away from any children, which is certainly reasonable advice given that these were undoubtedly powerful chemotherapeutic agents, although I would wonder why the nurse would leave the drugs in a household where syringes of powerful chemotherapeutics would likely be placed next to food sitting in the icebox where children might be able to get at them. That wasn’t what set the family off, though. What set the family off was when the nurse also told the family that the chemotherapy in the syringes could cause cancer.
That’s when all hell broke loose. That’s when the Hershbergers decided to stop the chemotherapy.
At this point, Mr. Keim said that the Hershbergers were never told that cancer was a risk from chemotherapy, leading to an exchange with Mr. Wark castigating cancer doctors for not telling patients everything where Mr. Wark claims that most cancer patients aren’t told that chemotherapy can cause cancer. Again, this claim stretches credulity beyond the breaking point. If you’ve ever read the consent forms for chemotherapy regimens, you know that it’s right there in black and white, a statement that the chemotherapy can increase the risk of cancer years down the road. For childhood cancers, the risks are clearly listed as Dr. Bodas testified: infertility, an increased risk of cardiovascular disease, damage to various organs, an increased risk of contracting other cancers, and a “small but appreciable risk” of dying from the treatment itself. Yes, these are significant risks, but lymphoblastic lymphoma will kill without treatment; so these risks are not unreasonable weighed against the rewards. I’d be willing to bet that those risks are listed on the informed consent that the Hershbergers signed when induction therapy was begun, and I’d be doubly willing to bet that the oncologists who discussed chemotherapy with the parents mentioned those standard risks.
At this point, the Hershbergers went to ACH and brought Mr. Keim along to tell the doctors that they had decided to quit chemotherapy and go for “natural” healing. Sarah didn’t want any more, and they were convinced that the chemotherapy was killing her. To say that the session was contentious would be an understatement. The hospital must have been expecting trouble, because apparently within an hour it was able to mobilize a lawyer, “PR people,” doctors, and nurses. One thing that disturbed me to learn was that the hospital first referred the case to Medina County Job and Family Services in June, but that MCJFS refused to file neglect and dependency charges against the Hershbergers. This is confirmed in the second ruling that went in favor of the Hershbergers. All I can say here is that MCJFS completely dropped the ball here, and I agree with the doctor’s characterization of this decision as “child abuse.”
Much of the rest of the interview consists of attacks on ACH and Maria Schimer, the general counsel for the Northeast Ohio Medical University (NEOMED), the medical school with which ACH is affiliated and the person petitioning the court to be Sarah Hershberger’s medical guardian; conspiracy mongering, and unverifiable claims. For example, Wark and Keim claim that Schimer’s only qualification to be Sarah’s medical guardian is that she had been appointed guardian to people who had been on life support for over a year but had no guardians, all so that the hospital could “pull the plug,” characterizing her as a “witch” standing their ready to “pull the plug” by getting Sarah back on chemotherapy. Yes, they not-so-subtly implied that Ms. Schimer wants to kill Sarah. This is pure slander, as a reading of the actual opinion of the Ohio Appeals Court, Ninth Appellate District reveals. Yes, she was appointed ward of the court for people on life support in the 1990s, but she has also served as ward for “several medically compromised, developmentally disabled adolescents, who were unable to speak for themselves and had no family members to speak for them.”
The conspiracy mongering was of the standard variety, in which it was claimed that ACH was paid a million dollars by a medical company to win this case, echoing the accusations of David Michael’s article. The claim was bookended by Mr. Keim saying, “I have no proof of this but I have been told by several people” and then, “I don’t know this to be true, but I’ve heard that.” One wonders who those “several people” were, one does. One also wonders why Mr. Keim would repeat something that he himself does not know to be true. Could it be to poison the well? There’s no “could” about it. At the very least, it allowed our friend Mr. Wark to go off on a rant about tyranny and how “they” (whoever “they” are) don’t want parents to make decisions for their children and how “they” don’t want people to have “options” and “they” want to force therapy. No such rant would be complete without that old alt-med cancer trope that “it’s not about a cure, it’s about healing” and how “only the body can heal cancer.”
The unverifiable or very difficult to verify claims fly fast and furious, as well Mr. Keim claims that Sarah was taken to “one of the top cancer centers in the U.S.,” but doesn’t mention what that cancer center was. He claims that all her tests there show that she is free of cancer. He claims that county sheriffs have been out to the house but that they don’t want anything to do with this case unless they’re forced. (I actually believe that one; police generally don’t like the idea of taking children away from their parents.) He claims that a doctor in Cleveland took over her care but doesn’t know who that doctor is. One notes that Mr. Keim’s claims conflict with claims made earlier that Sarah Hershberger is being treated by three doctors and that she was on “experimental” chemotherapy in a clinical trial without her parents having been given informed consent.
Finally, Mr. Keim laments that he contacted several television stations to try to give the family’s side of the story but that they wouldn’t do it unless the Hershbergers appeared on camera, which they would not do because they are Amish. This, too, is hard to believe. No, it’s not hard to believe that television news producers wouldn’t present the family’s side of the story if the Hershbergers wouldn’t appear on camera. What’s hard to believe, given that this story has made international news, is that a newspaper wouldn’t eagerly interview the family if approached or that a radio station wouldn’t eagerly have the Hershbergers phone in, as Chris Wark had Isaac Keim phone in. No, what the Hershbergers likely wanted was an outlet sympathetic to their point of view that wouldn’t challenge them, and Isaac Keim got it in Chris Wark.
Here’s the final irony. At about 29:00 in the interview, Mr. Wark basically admits that my interpretation of events described above could well be correct. In other words, he admits that chemotherapy could well be what rendered Sarah Hershberger cancer-free, if cancer-free she is at the moment:
I do want to be fair about this. Leukemias and lymphomas and testicular cancers respond better to chemotherapy than most cancers do, and it is entirely possible that those few treatments she did got rid of her cancer…Even if that’s the case, if that is what got rid of her cancer—now typically chemotherapy only gets rid of it for a short time; it’s only a temporary solution; it doesn’t address the root cause of disease—the point is freedom. It’s about the freedom of choice, the freedom that a parent has to make decisions for their child, medical or otherwise…It’s a bigger fight about a parent’s right to choose what’s best for their child, what medical treatment is best for their child versus whether or not chemo is going to help her. And that decision belongs to the parents and belongs to Sarah.
This is what I’ve been saying all along, that to people like Chris Wark, parental rights trump all else. It doesn’t matter if the child is only 10 and thus too immature to make such a monumental decision. The life of the child apparently doesn’t matter to Wark, at least not in comparison to parental “rights” to choose quackery. He’s perfectly willing to sacrifice Sarah Hershberger on the altar of “health freedom” to the point that he’s willing to help raise money for the Hershbergers to fight for the right to let their daughter die using a Pledgie and a GoFundMe campaign.
In the meantime, Isaac Keim also revealed that the Hershbergers have been subpoenaed to appear in court on November 6. We’ll see what happens.

Flipping the Script In Action: The Nick Gundersen Case
The tragic consequences of a boy with leukemia and a mother who believed an alternative medicine documentary-maker over her son’s oncologist.
Braden MacBeth on March 1, 2019
Link
Back in October of last year, I wrote a review of the film Flipping the Script: Parents Fight Back by Jeff Witzeman. In the film, Witzeman argued that parents should have the right to refuse chemotherapy for their children, maintenance chemotherapy in particular. Witzeman argued that maintenance chemotherapy isn’t necessary because when the maintenance phase begins there are no cancer cells detectable on labs or scans. What he omits is that this is because our tests are not precise enough to detect any remaining cancer cells. Long-term maintenance chemotherapy has been proven to be very effective at preventing leukemia relapses, which are incredibly deadly, especially when they occur shortly after the cancer was put into remission.
Today, I want to talk about the tragic consequences that result when parents believe the dangerous ideas that Witzeman promotes in his films. I’ve been following a case in New York of a mother fighting for her right to refuse maintenance chemotherapy for her son for a few months now. On September 10th Candace Gundersen posted a fundraiser on GoFundMe titled “Help Nick Stay in Remission Safely”. According to her story on GoFundMe, Nick was diagnosed with acute myeloid leukemia (AML) on June 30th. However, she “challenged” the doctor on his diagnosis because she believed he had a different type of cancer called Mixed-Phenotype Acute Leukemia (MPAL). Gundersen has no medical training, nor any formal education that I can find. She works as a holistic wellness coach. I haven’t seen any evidence or statement from a reliable source that states Nick was diagnosed and treated by doctors for MPAL. It’s unlikely considering that MPAL is incredibly rare. MPAL only accounts for 2-3% of all acute leukemia cases, and it’s more common in adults.
Regardless, Gundersen wanted to delay treatment for her son’s leukemia because she believed Nick had MPAL and that they would be giving him the wrong treatment. She was told the first month of treatment would have been the same whether Nick had AML or MPAL. The hospital also told her that she could not delay treatment. If she refused to consent to letting them treat Nick, they would have to call Child Protective Services. She consented to treatment and claims that thirty days later, the doctors said that all signs pointed to Nick being in complete remission. He could leave the hospital. Unfortunately, on August 29th a test showed that the induction was a “complete failure” and that Nick would require further treatment.
Nick’s mother told the hospital that she wished to take Nick to a different hospital for treatment, and it was at this point the hospital contacted CPS stating that he was in imminent danger. On September 2nd, Nick was removed from his parents’ home and placed in the custody of Suffolk County Child Protective Services. Nick was taken to Cohen Children’s hospital again to be treated for his leukemia. Candace claims she tried for days to get Nick transferred to another hospital, and he was eventually transferred to Winthrop hospital. She claims that on October 9th, “Judge Whelan signed an order upon the agreement of all parties involved that we could move anywhere with Nick and treat him with doctors of our choosing.”. Nick’s leukemia was put into remission but he would need maintenance chemotherapy to keep the cancer in remission.
Candace Gundersen decided that she wanted to give Nick “natural, non-toxic cancer therapies” she had learned about from research online. She wanted to take him to a holistic clinic in Florida, so she secured housing and moved her son to Florida. Upon learning of this, CPS filed an emergency petition with the court to remove Nick from his parents’ custody. Nick was removed from his mother’s custody again, and has remained in the custody of Suffolk County CPS since. He was placed in the home of a family friend about a month later, following a hearing. Gundersen has been fighting Suffolk County CPS in court to regain custody of her son and the right to make medical decisions on his behalf since November.
Suffolk County CPS and Nick’s doctors did everything right
Candace Gundersen and her attorney claim that Nick’s doctors and CPS violated her and her son’s religious and constitutional rights. Parents have never had the right to refuse life-saving medical treatment for their children for religious reasons. This is well established in the 1944 Supreme Court Case, Sarah Prince v. Commonwealth of Massachusetts:
Parents may be free to become martyrs themselves. But it does not follow they are free, in identical circumstances, to make martyrs of their children before they have reached the age of full and legal discretion when they can make that choice for themselves.
Parents don’t have the legal right to place their children at risk because of their beliefs. AML is a very treatable form of cancer with a 75% 5-year survival rate if treated properly. If Nick’s mother refused further treatments against the advice of his doctors to pursue fake cancer treatments, the chances of the cancer relapsing and killing Nick would go up significantly. Doctors are legally required to file a CPS report if they have a reasonable suspicion that a child is being abused or maltreated. Nick fits the legal definition of a maltreated child under New York law, as his mother was not providing him with adequate medical care despite having the means to do so.
By her own admission, getting custody of her son back would be easy if she would agree to take her son for proper cancer treatment. In her most recent GoFundMe update post she states:
The condition of CPS returning him to me is for me to agree and consent to give him chemo, which will hurt Nick and our case long term and they know it, which is why they are making it impossible. I requested they put language into the agreement to accommodate the fact I do not believe this is in his best interest. I explained if I am mandated by a court to do so, I will comply with a court order but will not agree to give chemo voluntarily.
CPS has no interest in keeping a scared kid with a life-threatening illness from his mother. They just want to ensure that he is getting proper medical treatment.
About that doctor in Florida
Gundersen has stated in multiple interviews with news outlets that she just wants Nick to be treated at a clinic in Florida. What was so bad about the clinic and doctor that she wanted to transfer Nick’s care to that would cause CPS to file an emergency petition with the court? I had my suspicions, which were ultimately confirmed when Jeff Witzeman stated on his blog that she wanted to treat Nick at Utopia Wellness, run by Carlos Garcia. My first-ever post on SBM was a review of Cancer Can Be Killed, and Carlos Garcia was one of the “experts” Witzeman promoted in the film.
Carlos Garcia is an anesthesiologist, not an oncologist, and has some truly bizarre and dangerous ideas about cancer. In Cancer Can Be Killed, Garcia states that he believes that cancer is caused by dental issues, or vague emotional issues. For example, Garcia believes that being publicly embarrassed causes liver cancer. His clinic was raided by the Florida OIG-HHS for suspected fraudulent billing of Medicaid for chelation therapy. Garcia offered to testify in court for free that Nick would not need long-term chemotherapy. Fortunately, his testimony was likely ruled inadmissible as he was not a board-certified pediatric oncologist.
Witzeman’s unscrupulous activities
Witzeman has been talking about this for months on his films’ Facebook pages. Witzeman encouraged his fans to sign a petition advocating the firing of CPS administrative staff and Nick’s oncologist from their jobs. Witzeman even encouraged that fans of his films protest outside of the Suffolk County CPS office. Which they did:
I’m just in awe; they held signs in front of a CPS building, accusing the people who work there of being criminal predators. CPS is an organization that exists to protect children from neglect and abuse, they don’t go around stealing children from parents who make decisions they disagree with. The judge didn’t order a death sentence, he’s mandating a child get medical treatment for a condition that will kill him if it doesn’t get treated properly. I don’t know how anyone with a brain in their head would think protesting in front of a CPS building is something that is going to make people want to join their cause.
Jeff Witzeman is more than happy to give medical advice to anyone who asks him in his comment section and promote any quack doctor or radio show that will give him the time of day. People take his advice seriously too; Gundersen is clearly getting her medical information and taking direction from Witzeman. Gundersen even promotes Flipping the Script: Parents Fight Back in one of her updates on GoFundMe. Witzeman was the first person to donate to Nick Gundersen’s GoFundMe page.
This case shows the tragic consequences of parents taking medical advice from random people on social media, as well as the impact of bad documentaries on Amazon. A child suffering from leukemia is tragic, but Nick has to deal with all this nonsense on top of it all. He had to go through the first stages of treatment without the emotional support of his parents. Children parrot the beliefs of their parents, and Nick’s mother believes his doctors are trying to kill him. Consequently, that didn’t exactly lead to a trusting relationship between Nick and his doctors. After Nick was taken from his home, his oncologist wanted to install a port to begin to administer chemotherapy. According to his mother on GoFundMe, Nick locked himself in the bathroom in the hospital for an hour, claiming that his doctor couldn’t make him do anything he didn’t want to.
None of this should have happened; it didn’t have to be this way. Nick was diagnosed with a very treatable form of leukemia with a very high survival rate when treated properly. He probably would have been fine with treatment if his mother had been on-board with it too. But because she took medical advice from a filmmaker with no medical qualifications who gets paid to promote fake cancer treatments, she wanted to forego legitimate cancer treatments in favor of treatments that have been proven not to work. Nick’s doctors and CPS had to choose between letting a parent give her child fake cancer treatments that would astronomically increase his chances of relapsing and dying, or removing him from his mother’s home and forcing him into real cancer treatment that would give him a fighting chance.
Conclusion: The internet was a mistake
This whole case is depressing, and perfectly illustrates so many of the problems we’ve been talking about on SBM. Gundersen clearly gets her health information from Witzeman’s films, films that are so scientifically inaccurate a random computer science major from a university nobody has ever heard of can rip them apart. The fact that you can these films at no charge with Amazon Prime would make them seem like there’s some amount of legitimacy to them to a normal person. These films make it seem like cancer can be treated with simple diet changes or vitamin infusions, despite all of the evidence showing that isn’t true.
Social media and search engines have features that can cause them to distort reality; they show you what you want to see. Many search engines have a personalized search feature that prioritizes results based on your browsing history and search patterns. This is a great feature the majority of the time, but it can callow people to create a filter bubble that isolates them from information that conflicts with their viewpoints. Filter bubbles can prioritize results so that fringe, dubious sources of information appear first, making those sources seem more legitimate and popular than they actually are. They can also direct users to fringe social media echo chambers.
Social media echo chambers are incredibly common, and as this case demonstrates, they can be dangerous. Facebook groups are perfect for creating your own personal echo chamber where users can reinforce their beliefs with other people who think the exact same way as them without fear of dissent. When you search “chronic Lyme” on Facebook you will be presented with dozens of support groups that will tell you how to treat an illness that doesn’t exist. If you only get information from social media echo chambers that spread false information and fake news, your perception of reality can become very distorted, very quickly.
Candace Gundersen believes that her son’s doctors are trying to kill him because she has been presented fake information from a social media echo chamber. One month ago, she posted an update on her GoFundMe page stating she was absolutely outraged that Nick’s doctors were planning to give him the flu vaccine. The reason why she was upset was because of a news article that said that the First Lady banned the flu vaccine in the White House because she thought it was ineffective and dangerous. Here’s the scary part: I actually believed the First Lady banned the flu shot in the White House. It isn’t true, but I didn’t fact check it at first because I was biased toward believing that the Trump administration would do that. The entire article came from a fake news site. Similarly, Gundersen bought into it because it confirmed her existing belief that her son’s doctors were putting her son at risk. The flu shot is perfectly safe for cancer patients because the flu vaccine doesn’t contain a live virus. In fact, the flu shot is recommended for cancer patients because their immune systems are weakened and they are much more likely to be hospitalized or die if they catch the flu. PSA: Get the flu shot.
Social media also helps bankroll quackery, as Dr. Gorski has discussed in-detail in his posts over the past few months. Quack treatments are ludicrously expensive and aren’t covered by insurance, but through crowdfunding they’re financially accessible for just about anyone. Gundersen has raised over $35,000 on her GoFundMe page to pay for legal expenses and fake cancer treatments when she gets custody of her son again. Even if you don’t hide in an alternative medicine echo chamber, it’s hard not to be sympathetic to a mother who had their son taken away by CPS to be given chemotherapy involuntarily. That’s why it’s important to verify what your money is going towards when you donate to a crowdfunding campaign. If the campaign doesn’t specify where the person is being treated, and by whom; don’t donate to the campaign. This is a story of how social media and irresponsible documentaries drove a mother, who was already a hardcore alternative medicine believer, to pursue alternative treatments instead of real medicine. This was never a case of medical kidnapping; CPS and Nick’s doctors did everything in their legal power to act in his best interest.
All this talk of social media and crowdfunding encouraging people to seek out ineffective and potentially dangerous treatments for life-threatening illnesses can be a bit of a downer. In Dr. Gorski’s second article about GoFundMe fueling cancer quackery, his conclusion got me thinking a bit:
That’s where skeptics, either as part of skeptical organizations or on their own, could be most helpful. Steve Novella has frequently pointed out that one role of the skeptic is consumer protection, to educate consumers to avoid the fraud of psychics, pseudoscience, and, yes, quackery. Here’s a perfect example where we could help.
Quacks have a strong social media presence and once they get someone into their echo chamber, it’s very hard to pull them out. They need to look like they’re legitimate and popular. They seem to worry about how they’re perceived online more than any other type of business. Flipping the Script: Parents Fight Back and Cancer Can Be Killed currently sit at a 4.5/5 average star rating on Amazon. Just to put things in perspective, I looked up every popular film I could think of that was released in 2018. The only one I could find with ratings that high was Avengers: Infinity War. I don’t think a 4.5/5 average rating befits documentaries that claim you can regulate your body’s pH through diet.
People deserve to know that these films are not worth the bandwidth, and if you have an Amazon Prime membership, you can help. Let’s not stop there though, these films peddle dangerous advice to desperate people, and promote child neglect. The Amazon customer policy states “Amazon has the right to determine the appropriateness of listings on its site and remove any listing at any time”. I’m going to start a petition asking Amazon to remove both of these films from their video service because of the dangerous advice they give. I hope you all will sign it. Cancer quacks use social media to practice oncology without a license, and I think it’s about time we fight fire with fire for once. Let’s give Amazon’s video service some chemo..

Ontario fails to protect the life of a First Nations girl with cancer
David Gorski on November 17, 2014
Link

A few weeks ago, Steve Novella invited me on his podcast, The Skeptics’ Guide to the Universe, to discuss a cancer case that has been in the news for several months now. The case was about an 11-year-old girl with leukemia who is a member of Canada’s largest aboriginal community. Steve wrote about this case nearly a month ago. Basically, the girl’s parents are fighting for the right to use “natural healing” on their daughter after they had stopped her chemotherapy in August because of side effects. It is a profoundly disturbing case, just as all the other cases I’ve discussed in which children’s lives are sacrificed at the altar of belief in alternative medicine, but this one has a twist that I don’t recall having dealt with before: The girl’s status as part of the First Nations. Sadly, on Friday, Ontario Court Justice Gethin Edward has ruled that the parents can let their daughter die.
The First Nations consist of various Aboriginal peoples in Canada who are neither Inuit nor Métis. There are currently more than 630 recognized First Nations governments or bands in Canada, half of which are located in Ontario and British Columbia. This girl lives in Ontario, which is basically just next door to Detroit, just across the Detroit River. Unlike previous cases of minors who refuse chemotherapy or whose parents refuse chemotherapy for them that I’ve discussed, such as Sarah Hershberger, an Amish girl whose parents were taken to court by authorities in Medina County, Ohio at the behest of Akron General Hospital, where she had been treated because they stopped her chemotherapy for lymphoblastic lymphoma in favor of “natural healing,” or Daniel Hauser, a 13-year-old boy from Minnesota with Hodgkin’s lymphoma whose parents, in particular his mother, refused chemotherapy after starting his chemotherapy and suffering side effects, there’s very little information about this girl because of Canadian privacy laws. I do not know her name. I do not know anything about her case except that she has acute lymphoblastic leukemia, that she started treatment but her parents withdrew her because of side effects.
The Song Remains the Same: Parental rights trump children’s rights to health care
All these cases that I’ve written about over the years here and elsewhere, a depressing number that includes children such as Katie Wernecke, Abraham Cherrix, Daniel Hauser, Jeremy Fraser, Jacob Stieler, Sarah Hershberger, or others, follow a very similar script. It’s a script that on many an occasion has led me to quote Elton John sadly, “I’ve seen that movie, too.” Here’s the basic script:
     1.  A child is diagnosed with a treatable, curable pediatric cancer. (Note that most pediatric cancers are among the most curable cancers there are. Pediatric leukemias and lymphomas, for example, have gone from a virtually-zero survival rate 50 years ago to survival rates that approach 90% or even more. Truly, if there is a triumph of science based medicine, it is in pediatric cancers.)
     2.  The child begins chemotherapy, going through part of the recommended protocol, and suffers the expected side effects.
     3.  The parents, who quite naturally have a hard time watching their child suffer, hear about some quackery or other that promises to treat their child without the side effects of chemotherapy. If they are prone to belief in “natural healing” or alternative medicine, there is a good chance that they will stop their child’s chemotherapy and opt for the promise of the “natural healing” that claims to be a cure without the pain.
     4.  Doctors, alarmed at the likelihood that the child will die, report the child to the child protective service authorities, who intervene.
     5.  There is a court case. If the court case goes against the parents, frequently they flee with the child, as Daniel Hauser’s mother did, as did the parents of Katie Wernecke, Abraham Cherrix, and Sarah Hershberger, among others.
     6.  At this point, one of two things happens. Either the parents are persuaded or ordered to treat their child properly (as in the case of Daniel Hauser); they come to some sort of compromise that allows the child to get some treatment plus “alternative healing” (as in the case of Abraham Cherrix); or, a depressingly common outcome, they win the “right” to let their child die through medical neglect, as has just happened with this First Nations girl with lymphoma.
     7.  Through it all, quacks leap on these stories as examples of “fascism,” and “gunpoint medicine” in order to promote their world view of “health freedom” (otherwise known to skeptics as the freedom from pesky laws and regulations outlawing fraud and quackery), as happened in virtually all these cases, but most notably recently for the case of Sarah Hershberger.
How do these stories end? Sometimes they end with the death of the child. Sometimes the child lives (I’ll explain why a little later). Ofttimes it’s very difficult to find out what happened to the child, as I’ve found out to my frustration over the years. For instance, I have not been able to find out much about Sarah Hershberger since March, when Tracy Oppenheimer of Reason.com defended her medical neglect in the name of health freedom. (What are the deaths of some children with cancer compared to health freedom, eh?)
This First Nations case adds a different spin on the subject, but the script remains more or less the same. This time around, the parents have won the right to let their daughter die a horrible death from cancer based on Aboriginal rights.
Aboriginal children now have the right to refuse life-saving medical treatment in favour of traditional healing.
The Friday ruling has nothing to do with whether aboriginal medicine works.
Family court heard unequivocally in the case of a First Nations girl refusing chemotherapy that no child has survived acute lymphoblastic leukemia without treatment.
Instead, it’s about Canada’s Constitution protecting aboriginal rights.
Ontario Court Justice Gethin Edward has now expanded those rights to include traditional healing, saying “there is no question it forms an integral part.”
“This is monumental for our people all across the country,” said Six Nations Chief Ava Hill. “This is precedent-setting for us.”
No doubt this ruling is monumental and precedent-setting, but in a very bad way. So, in other words, our neighbor to the south (at least to me in southeast Michigan, which is the only place in the contiguous forty eight states where Canada is to the south) have declared that letting children die of cancer is an “integral” part of Aboriginal identity. I am not exaggerating. The court apparently didn’t even take into account whether the “natural healing” chosen by the girl’s family works. Ironically, it apparently didn’t even take into account whether the “healing” is actually traditional aboriginal medicine. (It isn’t.) Meanwhile, Six Nations Chief Ava Hill is exulting over the ruling, apparently unconcerned that it will result in the death of an 11 year old girl. As I’ve said many times before, a competent adult should have the right to choose any form of medicine he likes or even to choose no treatment at all, but children are different. They are not capable of understanding the implications of their decision, and this girl, at 11 years old, isn’t even in the gray area of the later teen years where an argument can sometimes be made for self-determination even though the child is a minor. They need and deserve protection from such outrageously bad choices on the part of the parents.
This case is a complete failure on the part of the province of Ontario and of Canada itself to protect the lives of its most vulnerable members, children, particularly children of a minority group. Even worse, it is an indictment of the First Nations, which, rather than seeking to protect one of the most vulnerable members of its community, a girl with a treatable, potentially curable cancer, instead glommed onto this case as a vehicle to promote its rights vis-a-vis the Canadian government. I don’t think it was cynically done; no doubt the leaders of this particular First Nations community and Six Nations Chief Ava Hill believe in their Aboriginal natural healing. On the other hand, it’s hard not to think that there was some opportunism given that the parents appear not to have even chosen to use Aboriginal “natural healing” techniques.
Instead, they are using the rankest quackery, which has nothing to do with aboriginal natural medicine, administered by Brian Clement in a “massage establishment” in Florida:
A Florida health resort licensed as a “massage establishment” is treating a young Ontario First Nations girl with leukemia using cold laser therapy, Vitamin C injections and a strict raw food diet, among other therapies.
The mother of the 11-year-old girl, who can not be identified because of a publication ban, says the resort’s director, Brian Clement, who goes by the title “Dr.,” told her leukemia is “not difficult to treat.”
Another First Nations girl, Makayla Sault, was also treated at Hippocrates Health Institute in West Palm Beach and is now critically ill after a relapse of her leukemia.
Somehow, I doubt that the traditional healing methods used by First Nations people have ever included cold laser therapy or vitamin C injections. Looking at Makayla Sault, you will see the future of this First Nations girl: Relapse. But what about Brian Clement? I’ve encountered him before this case but have never actually written about him for SBM. Let me tell you about him.
Who is Brian Clement, anyway?
In brief, he is, in my opinion, a quack. If you have any doubt, start by looking at what he is quoted as saying in this news story:
He’s been giving lectures in and around both girls’ communities in recent months, including one event attended by Makayla’s family this past May.
In a video obtained by CBC News, Clement says his institute teaches people to “heal themselves” from cancer by eating raw, organic vegetables and having a positive attitude.“We’ve had more people reverse cancer than any institute in the history of health care,” he says.
“So when McGill fails or Toronto hospital fails, they come to us. Stage four (cancer), and they reverse it.”
The mother of the girl whose identity is protected says she knew as soon as her daughter was diagnosed that she wanted to seek treatment at Hippocrates, a clinic she was familiar with through a relative, but didn’t have the money to go.
After securing financial support from family, she called Clement from the hospital waiting room on the 10th day of her daughter’s chemotherapy.
The story goes on to describe how the mother called Clement while her child was receiving chemotherapy and found how “confident” he sounded. As soon as he said he could help, the mother quit the chemotherapy for her daughter.
It’s all depressingly similar to a story I encountered about a year ago. It was the story of a young mother in Ireland who had been diagnosed with stage IV breast cancer and chosen the “alternative route.” She, like the anonymous young First Nations girl and Makayla Sault, found her way to the Hippocrates Health Institute. This young woman, Stephanie O’Halloran, was only 23 years old, an age range at which breast cancer is rare, but not unheard of. Here’s how she found out about the Hippocrates Center:
Declan said: “Ann’s sister in England heard about this treatment, which centres on a diet of raw vegetable, and she met the head of the clinic, Brian Clement, in Galway about two months ago.
“He told her he could help, but not to leave it too late.
“After the meeting we did a lot of soul searching and we prayed to the Lord.
“Stephanie is a very positive person and four weeks ago, she went to Florida where she spent 21 days starting on the programme. She came home at the weekend and is still very tired after the long flight. She feels much better.”
At the time, I had never heard of the Hippocrates Health Institute (HHI) or the doctor, Dr. Brian Clement before; so, as is my wont, I went to the source, the Hippocrates Health Institute website. It didn’t take long for me to figure out that its programs were a veritable cornucopia of nearly every quackery on the planet, including at least one I hadn’t realized that people did. Let’s just start with this list described in the HHI’s “Life Transformation Program“:
    • Superior nutrition through a diet of organically-grown, enzyme-rich, raw, life-giving foods
    • Detoxification
    • Wheatgrass therapies, green juice, juice fasting
    • Colonics, enemas, implants
    • Exercise, including cardio, strength training and stretching
    • Far infrared saunas, steam room
    • Ozone pools, including: dead sea salt, swimming, jacuzzi and cold plunge
    • Weekly massages
    • Bio-energy treatments
    • Med-spa & therapy services
Yes, indeed, there it is: enemas, “infrared saunas,” and all manner of other quack treatments. But what are “implants”? It turns out that wheatgrass “implants” are, in actuality, wheatgrass juice enemas:
When used as a rectal implant, reverses damage from inside the lower bowel. An implant is a small amount of juice held in the lower bowel for about 20 minutes. In the case of illness, wheatgrass implants stimulate a rapid cleansing of the lower bowel and draw out accumulations of debris.
It also seems that there’s nothing that wheatgrass can’t do. If the HHI is to be believed, wheatgrass can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many other things. Basically, boiling it all down, I found that HHI advocates raw vegan diets, wheatgrass (as part of the aforementioned raw vegan diets), and various other forms of quackery plus exercises as a cure for, well, almost everything. I’ve often said that one undeniable indication that a clinic is a quack clinic is whether it offers a certain treatment modality. The HHI offers this treatment modality. Can you guess which one? Yes, it’s the infamous “detox” footbath known as Aqua Chi.
All you need to know about this particularly ridiculous form of “detox” quackery has been written about before. Suffice to say, the “toxins” that such footbaths supposedly remove through the feet don’t exist, and the water would change color regardless of whether a customer has her feet in the water or not. Of course, detox footbaths aren’t all. Other quackery abounds, such as intravenous vitamin therapy, cranial electrotherapy stimulation, combination infrared waves plus oxygen, acupuncture, colon hydrotherapy (apparently with or without wheatgrass) and lymphatic drainage. There’s so much there, that the über-quack Joe Mercola featured Dr. Clement on his website last year:
There’s some serious, serious quackery in this interview, a transcript of which can be found here, if you can’t stand to watch a full hour plus of this stuff. For example, there are a lot of parts where Dr. Clements says stuff like this:
Photons come down in the secondary stage, they hit the earth. They transmute into different frequencies. Those frequencies are what create the physical body or the energetic body we really are. When you and I are talking and thinking and people are listening, that’s the energetic body. The physical body that you’re sitting watching us here now, that’s created by the microbial effect in the soil, which are still the protons but recycled or re-cached protons. It’s great stuff.
It’s great stuff if you are entertained by extravagant quackery, as I am. In the context of knowing that an 11-year-old First Nations girl is having her cancer treated by this quack, not so much. That’s why I stopped there, as I couldn’t take any more. Neither, apparently, could Katie Drummond, who wrote a scathing takedown of the “health program” offered at HHI, who reassures us that if you’re not into wheatgrass enemas, don’t worry about it. HHI offers them “in ‘Original’ and ‘Coffee’ varieties.” Imagine my relief. Unfortunately, that relief is rapidly eliminated by learning that HHI also offers quack modalities such as “live blood cell analysis.”
Anyway, let’s move on.
Perhaps the most unusual form of quackery offered at HHI is something called colorpuncture:
Based on modern biophysics and ancient Chinese medicine, color frequencies are applied to acupuncture points using a light pen and crystal rods. This promotes hormonal balance, detoxification, lymph flow and immune support while reducing headaches and sleeplessness. Working on cellular memory where the cause of disease resides, color puncture promotes healing from within. 50 minutes $120
All of this makes me sad. Very sad. It’s because I know that, however much I might laugh at the utter ridiculousness and lack of science behind Dr. Clement’s treatments and quackbabble, I know that patients like Stephanie O’Halloran, whose story depressed me to no end when I learned of it and depresses me even more now that I’ve followed up on her case and learned that she died a few months ago, fell for this. I know that Makayla Sault, who, unlike O’Halloran, had a highly treatable tumor, fell for this. I know that a little girl from First Nations, who also has a highly treatable tumor, is being subjected to this quackery. The only thing HHI can accomplish for any of these unfortunate cancer patients is to drain their parents’ bank accounts and drive them to seek many thousands of dollars to pay for Clement’s treatments, all while giving their parents false hope. Already, the First Nations girl’s family has paid Clement $18,000 and counting.
This is the “alternative healing” that the First Nations girl’s mother has chosen instead of effective chemotherapy. In essence, the parents and First Nations petitioned Ontario courts and Justice Gethin Edward acquiesced to letting First Nations parents have the right to let their children die through medical neglect. It might well be that Justice Edward’s ruling was legally correct and he had no real choice, but the end result will be the same: The death of a girl who otherwise would have a very good chance of living a long and productive life. Worse, his reasoning included this:
But Justice Gethin Edward of the Ontario Court of Justice suggested physicians essentially want to “impose our world view on First Nation culture.” The idea of a cancer treatment being judged on the basis of statistics that quantify patients’ five-year survival rate is “completely foreign” to aboriginal ways, he said.
“Even if we say there is not one child who has been cured of acute lymphoblastic leukemia by traditional methods, is that a reason to invoke child protection?” asked Justice Edward, noting that the girl’s mother believes she is doing what is best for her daughter.
“Are we to second guess her and say ‘You know what, we don’t care?’ … Maybe First Nations culture doesn’t require every child to be treated with chemotherapy and to survive for that culture to have value.”
Every parent who chooses quackery over effective medicine believes she is doing what’s best for her child. Every single one of them. The same is true of parents who thought that prayer could cure pneumonia or diabetes. That’s not a reason to deny such children protection. More disturbing, however, is Justice Edward’s last sentence, in which he seems to be shrugging his shoulders and saying, “So what if a few aboriginal children die anyway? It’s just their culture.” Or, as Steve aptly put it, using human sacrifice as a reductio ad absurdum of the judge’s argument: “Are we to second guess her and say ‘You know what, we don’t care?’ … Maybe First Nations culture doesn’t require every child to survive infancy without being sacrificed for that culture to have value.”
It’s understandable, given Canada’s history of riding roughshod over the wishes of First Nations families, such as the case of residential schools pointed out by Arthur Schafer, that the court would want to bend over backwards to respect the wishes of the parents. However, in doing so, Justice Edward utterly failed to take the best interests of the child into proper account.
How does this sort of thing happen?
Steve also correctly noted that the outcome of such legal battles often hinge on the reasons given by the parents for refusing chemotherapy. If, for example, they simply use medical opinions as a justification (i.e., they disagree with their doctors), the state is usually pretty quick and decisive in taking action. This is the sort of situation that ruled Daniel Hauser’s case, and ultimately Hauser underwent effective chemotherapy and lived. If, on the other hand, religion or culture is used as justification for choosing quackery over effective treatment, courts seem to be much less willing to step in and see that the child receive effective treatment. For instance, in 2009 Catherine and Herbert Schaible in the Philadelphia area to choose prayer over antibiotics for pneumonia for their first child. The child died. The Schaibles received ten years’ probation and had to promise, in essence, that their other children, who were not removed from their care, would receive modern medical care. In 2013, a second child, who was 8 months old at the time, died the same way. It took the second death of a child before the state actually took their children away and put them in jail. The same dynamic came into play in the case of Sarah Hershberger, where Medina County authorities were reluctant to be too harsh because they were Amish, and their culture valued “natural healing.” Clearly, the same dynamic has led to Justice Edward’s tragic decision with respect to this First Nations girl.
Also at play is an attitude that ascribes absolute rights to parents over their children. It’s a toxic attitude that is often mixed with a general distrust of government and medical authority that fails to acknowledge that children are separate beings with their own rights separate from the rights of the parents. Those rights include the right to not to suffer from medical neglect. As has been pointed out, parents don’t have the right to kill their children; they shouldn’t have the right to let them die through medical neglect, as the parents of this First Nations child are doing.
For all my railing against the medical system, what’s really critical here is understanding why parents make these choices. Having a child with cancer is a horrible, terrifying thing to go through. Having to watch a child suffer the complications of chemotherapy with the child not understanding why it’s necessary is even harder. It’s very understandable that parents with a tendency toward believing in natural medicine or with just a distrust of medical authorities in general would be tempted by the siren song of quacks claiming that they can cure the child without all the toxic side effects of chemotherapy. In particular, it’s often hard for parents to understand why, after tumors frequently shrink away to nothing after the first couple of courses of chemotherapy, more chemotherapy is needed.
Unfortunately, for most pediatric tumors it takes a lot more than just a round or two of chemotherapy, a lesson painfully learned by pioneering pediatric oncologists back in the 1960s and 1970s. For the type of tumor that, for example, Sarah Hershberger has, lymphoblastic lymphoma, the duration of one standard treatment is two years. For chemotherapy for lymphoma, there are at least three phases. The induction phase is designed to put the patient into remission. Consolidation chemotherapy is given to patients who have gone into remission and is designed to kill off any residual cancer cells that might be present, thus increasing the chance of complete cure. Maintenance chemotherapy is the ongoing, longer term use of chemotherapy to lower the risk of recurrence after a cancer has gone into remission. It’s basically lower-dose chemotherapy given for two to three years to help keep the cancer from returning. In Sarah Hershberger’s case, her oncologist recommended chemotherapy consisting of five phases: induction (5 weeks), consolidation (seven weeks), interim maintenance (eight weeks), delayed intensification (six weeks), and maintenance (90 weeks), for a total duration of two years, three months. In the case of this First Nations girl, who has lymphoblastic leukemia, the treatment would have involved at least three phases: remission induction, consolidation/intensification, and maintenance lasting a similar amount of time.
It’s thus understandable how parents, after seeing the tumor melt away during induction chemotherapy, wonder why all this additional chemotherapy is needed. It’s quite possible that after induction chemotherapy the First Nations girl had no detectable cancer. If that’s the case, it’s the chemotherapy that she’s received thus far that almost certainly caused that result, not any quackery to which Clement has been subjecting her. If the girl is apparently tumor-free, it also means that failing to consolidation and maintenance chemotherapy greatly increases the chance that her leukemia will relapse. Worse, relapsed cancer is always harder to treat. The first shot at treating cancer is always the best shot, with the best odds of eradicating the cancer. Letting cancer relapse through incomplete treatment breeds resistant tumor cells the same way that not finishing a complete course of antibiotics contributes to the development of resistant bacteria. It’s evolution in action.
Some children will be fortunate enough to have had their cancer eliminated completely after induction and will survive to become testimonials used in support of such parents’ actions, but they are the minority. Depending on when the chemotherapy is stopped relative to the complete recommended course, most will not be so lucky. Parents also often have a view that it is the chemotherapy that is the cause of the child’s suffering, believing that if they stopped the chemotherapy the suffering would stop, and even if the child dies it would not be as bad for her as the chemotherapy. Unfortunately, death from cancer is not pretty. It’s worse than chemotherapy. Stopping chemotherapy early might relieve suffering for a while, but only at the price of an ugly death later.
Somehow, there has to be a way to get such parents to see this, to teach them the very basics of cancer biology, why chemotherapy regimens for pediatric malignancies are as long as they are, and what the consequences of not finishing chemotherapy are. Remember, the parents are almost always only interested in what they believe to be best for their child, and they are suffering in a different way as they watch their child suffer the side effects of chemotherapy. When their child is crying that she can’t take it any more, when she’s vomiting and feeling very sick due to the chemotherapy, it’s very hard for parents to see that it’s worth this pain if the tumor is already gone. They need support systems to help them deal with this. Most pediatric cancer centers provide such support, but it isn’t always enough. Again, although my memory is by no means comprehensive, since I started paying attention to these cases ten years ago, I can’t recall a single case of parents who refused chemotherapy for their child until after the child had undergone at least a couple of cycles and suffered the expected side effects. I’m sure such parents probably exist, but they must be rare, because I’ve paid a lot of attention to these sorts of cases over the years, and I can’t recall one.
Finally, when faced with parents wanting to stop chemotherapy, oncologists have to be very careful not to come across as bullying, something I suspect that they sometimes do without realizing it when hearing a parent tell them she is going to stop chemotherapy. It’s understandable that physicians and nurses would react that way. Pediatric oncologists become pediatric oncologists because they want to save the lives of children with cancer, and nurses working on pediatric oncology wards work there for the same reason. It’s understandable that they react with alarm to such pronouncements by parents and might become angry or strident. After all, the child is their patient, not the parents, and the parents have just become an obstacle to saving the child’s life. When parents threaten to stop chemotherapy, it is often a cry for help; they’re telling doctors that they can’t handle seeing their child undergo chemotherapy any more. Sensitivity is required in working with them.
None of this, however, means that, if push comes to shove and the parents can’t be moved with all the understanding and empathy in the world, the interests of the child shouldn’t come first. The interests of the child must come first, and if parents can’t be persuaded to continue treatment of a highly curable tumor, then the state has a duty to step in. It’s a duty at which Ontario and Canada have failed in the case of this First Nations girl. It’s also a duty that First Nations authorities who supported the parents in filing suit have utterly failed to uphold.

An aboriginal girl dies of leukemia: Parental “rights” versus the right of a child to medical care
David Gorski on January 26, 2015
Link

One topic that keeps recurring and obligating me to write about it consists of critically analyzing stories of children with cancer whose parents, either on their own or at the behest of their child, stop or refuse chemotherapy or other treatment. It is, sadly, a topic that I’ve been discussing for nearly a decade now, starting first on my not-so-super-secret other blog and continuing both there and here. Indeed, the first post I wrote about this problem was in November 2005, a fact that depressed me when I went back through the archives to find it because so little has changed since that time.
I was painfully reminded of this last week when stories started circulating in the media about the death of Makayla Sault, an Ojibwe girl and member of the New Credit First Nation in Ontario:
The entire community of New Credit is in mourning today, following the news of the passing of 11 year old Makayla Sault.
The child suffered a stroke on Sunday morning and was unable to recover. Friends and family from across the province travelled to New Credit First Nation today to offer condolences, share tears and pay their respects.
Makayla, as you might recall, was an 11 year old aboriginal girl from Canada with lymphoblastic leukemia. She was one of two 11-year-old aboriginal girls last year who refused chemotherapy and have medical stories that are eerily similar. The other girl’s name is unknown (at least to me and most of the public), because of privacy concerns in her legal case, but she is referred to in court documents as “JJ” and is a Haudenosaunee girl from Six Nations of the Grand River First Nation, also in Ontario. I discussed her case extensively back in November and will be discussing her more here. The short version is that, like Makayla, JJ developed lymphoblastic leukemia, underwent a short course of chemotherapy, stopped the chemotherapy, and discovered a cancer quack by the name of Brian Clement, who promised JJ’s mother that he could cure her cancer. As a result, as is often the case in such situations, there was a legal battle, and Ontario Court Justice Gethin Edward ruled that the parents can let their daughter die. Of course, he didn’t put it in those words. Rather, the Justice Edward ruled that “traditional healing” is such an integral part of aboriginal rights that the parents’ “right” to treat their children with “traditional healing” trumps the right of the aboriginal child to live. I know, I know, I’m letting my bias show, but functionally and for all practical purposes, that’s what his ruling means.
When I come across a story like this, in which a child is being medically neglected and allowed to die, as Makayla Sault was and JJ is, I come at it from one unwavering viewpoint: The right of the child to receive proper medical care and thus to live trumps pretty much everything else. Religion doesn’t much matter to me. Nor does race, nationality, or culture, even that of the Amish or indigenous peoples. I am completely unapologetic about this stance, no matter how “intolerant” I’ve been called regarding this case and about other cases in which religion was the motivating factor behind the parents’ refusal to seek science-based treatment for their child. Competent adults with deadly diseases are free to choose to be treated, not to be treated, or to undergo quack treatment, but a child is not competent to make such a decision. Because of that, a child depends upon her parents to choose what is in her best interests.
None of this is to say that wide latitude shouldn’t be given to parents to choose their children’s health care. The state should never step in lightly. There are many gray areas, after all. However, when parental choice so mind-numbingly obviously conflicts with the best interests of the child and will inevitably lead to that child’s unpleasant death, as Makayla’s case so harshly demonstrated and JJ’s case will almost certainly demonstrate by the end of this year, then parental “rights” should cease to matter as well. Again, I make no apologies for this viewpoint, any more than I did when I lamented how a young Amish girl named Sarah Hershberger is similarly being allowed to die of a treatable cancer.
Now, another child who with proper medical treatment had a much better chance of surviving than dying has died because she and her parents chose quackery over effective treatment, and another is heading that way.
A tale of a preventable cancer death
It seems a long time ago, but it has only been a couple of months since I first discussed the case of Makayla Sault in the context of the story of JJ, a First Nations girl with cancer, whose fate was almost certainly sealed by Justice Edward’s ruling. Rather, as did Sault’s parents, JJ’s parents took her to Brian Clement, a Florida quack who isn’t even a physician but somehow has been treating patients with cancer at the Hippocrates Health Institute in West Palm Beach for many years now with his “Life Transformation Program” that includes a veritable cornucopia of quackery. Indeed, former staff of his are suing him for operating “a scam under Florida law” and practicing medicine without a license. Interestingly, approximately a third of Clement’s business appears to come from Canada. Why his quackery is particularly popular among Canadians is a mystery, but it is.
Clement seems to have a thing for treating everything with wheatgrass enemas. Wheatgrass, according to Clement, can increase red blood cell count, decrease blood pressure, cleanse the blood, organs and GI tract of “debris,” stimulate the thyroid gland, “restore alkalinity” to the blood, “detoxify” the blood, fight tumors and neutralize toxins, and many of the usual other things quacks like Clement claim. He even offers the infamous “detox footbath,” plus intravenous vitamin therapy, cranial electrotherapy stimulation, combination infrared waves plus oxygen, acupuncture, colon hydrotherapy (apparently with or without wheatgrass) and lymphatic drainage. There’s even a bit of quackery hilariously called colorpuncture, in which various colors are applied to acupuncture points.
You get the idea. Brian Clement’s clinic has nothing to do with Ongwehowe Onongwatri:yo (indigenous medicines) and everything to do with good, old-fashioned European-American quackery focused mainly on wheatgrass, a raw vegan diet, and “detoxification.”
Makayla Sault, as you might recall, preceded JJ in seeking treatment from Brian Clement. She was diagnosed with acute lymphoblastic leukemia last year and began a course of induction chemotherapy. In May, after eleven weeks of chemotherapy and alarmed at the side effects, she refused further treatment. Her reasons for stopping were explicitly religious, complete with a video in which she explained her reasons for stopping:
Then she reads her jarring words. “I am writing this letter to tell you that this chemo that I am on is killing my body and I cannot take it anymore.”
“I have asked my mom and dad to take me off the treatment because I don’t want to go this way anymore,” she said, describing how chemotherapy left her unable to walk and nauseous, with terrible sores and organ damage.
“I know that what I have can kill me but I don’t want to die in a hospital on chemo, weak and sick,” she said. “I wish that the doctors would listen to me because I live in this body and they don’t.”
And then a vision of Jesus:
In the video, she explains that she is at peace because of her faith. She said Jesus appeared to her in her hospital room, telling her not to be afraid.
He was wearing a robe and prayer shawl, with long straight hair, and was “beautiful,” she said. He showed his hands, with the stigmata marks. Two angels were beside him.
“I asked him ‘Can you heal me?’ and he said ‘You are already healed,'” she said. “He told me ‘Do not be afraid. You are my child.'”
In October, she filmed another video from a boat, saying, “I just want everybody to know that I’m alive and well and that I’m healed.”
The first video is here:
The video of Makayla on a boat is here:
It’s hard not to be moved seeing this video, knowing what happened to Makayla just a week ago. Like all children (and many adults), she is laboring under the delusion that death by cancer is better than suffering through chemotherapy. It’s not.
Both of Makayla’s parents are pastors at an evangelical church; so it is not surprising that she shared their Christian faith. They supported her decision, and although the decision was initially challenged by the Brant Children’s Aid Society (CAS), the CAS backed off and closed the case file because “we have to recognize the traditions and the community of First Nations people,” according to director Andy Koster, speaking last May. Koster also said:
“The more we looked at it we realized that this is a warm, loving family,” said Andy Koster, executive director of the Children’s Aid Society of Brant. “We don’t believe that bringing her into care, taking her away from that family — which is her support — and forcing chemotherapy, is going to be in any way emotionally sound for her, or psychologically or even spiritually.”
Nice job there, Mr. Koster. Letting such a child die of untreated leukemia isn’t emotionally sound for her, either, but that’s what the Brant CAS decided to do. No one said that forcing chemotherapy is a good thing; rather, it’s the lesser of two evils. Another child who very well might have been saved and lived to a ripe old age is dead, her whole life ahead of her having been thrown away pointlessly, because her family relied on quackery instead of effective medicine. Once more, a cancer quack has claimed a very salvageable life.
The saddest thing about this is that this outcome didn’t have to be. All reports indicate that Makayla’s tumor was a treatable variety. In fact, it was the same kind of cancer JJ’s, lymphoblastic leukemia, although it wasn’t as favorable a variety. Pediatric oncologists estimated that Makayla had a 70%-75% chance of surviving five years, because the cancer had the Philadelphia chromosome. Since recurrences after 5 years are almost nonexistent, that’s essentially a cure. So, yes, it’s quite possible that Makayla could have been treated with the very best drugs modern medicine has to throw at lymphoblastic leukemia and died anyway, roughly a one in three to one in four chance. However, by abandoning chemotherapy and choosing Clement’s quackery instead of her best shot at a cure, Makayla and her family reduced her chances of survival from a very good shot to zero shot. To be honest, after the descriptions of how her condition was deteriorating in November when I originally wrote my post about JJ, I’m a little surprised that she lasted a further two whole months.
Now Makayla’s parents have suffered one of the worst losses, if not the worst, a parent can endure. They are, no doubt, suffering intensely, as is Makayla’s entire family and community, over the loss of their beloved child. I do not blame either Makayla or them, at least not nearly as much as I blame Brian Clement for having duped them. Unfortunately, as is often the situation in these cases, the Sault family does not accept that the cancer killed Makayla. As is so frequently the case when a patient dies while treating her cancer with alternative medicine, they’re blaming the chemotherapy. In a statement, they said:
Makayla was on her way to wellness, bravely fighting toward holistic well-being after the harsh side effects that 12 weeks of chemotherapy inflicted on her body.
Chemotherapy did irreversible damage to her heart and major organs. This was the cause of the stroke.
We continue to support Makayla’s choice to leave chemotherapy. At this time we request privacy from the media while we mourn this tragic loss.
Yes, as happens so often in these cases, it’s not the quack’s fault that the child died. It’s the fault of those evil “Western” doctors and their poisonous chemotherapy. Always and forever. Unfortunately, a stroke is a known complication of leukemias due to either cancer-related coagulopathy or complications of treatment. It’s one way that patients with end stage leukemia die. True, one chemotherapy drug that might well have been used in the initial induction chemotherapy that Sault had can cause stroke, but not a delayed stroke several months after the therapy had been discontinued. As I pointed out in the comments of a story about Makayla’s death on Doubtful News and an oncologist has pointed out in an interview, intracranial hemorrhage due to leukemia is a not-uncommon terminal event when the bone marrow is taken over by the cancer and can’t make enough platelets and other blood products. Similarly, an ischemic stroke can occur due to (1) leukostasis, with high white blood cell counts (as can be caused by acute lymphocytic leukemia) causing sludging in the blood vessels of the brain or, less commonly; (2) direct infiltration of the brain with leukemia; or, even less commonly, particularly in children, (3) a red blood cell count so low that it causes lack of oxygen to the brain.
It’s thus far more likely that Makayla died of end stage leukemia, and that her stroke was the immediate terminal event, than it is that chemotherapy-related complications from many months ago resulted in a stroke. I have no doubt that Makayla’s family and people believe that the chemotherapy caused her stroke, but the likelihood that it did compared to the likelihood that progressive leukemia caused her stroke is infinitesimally small. From a medical and oncologic standpoint, it’s just not a convincing story, as much as they believe it. In a way, I can’t blame the Saults for believing that it was the chemotherapy that killed their daughter. I really can’t. It’s completely understandable. If they stopped believing that, then they would have no choice but to accept that it was the choice to abandon chemotherapy that doomed their daughter. That’s just not something that any parent is likely to be able to admit. In any case, once again, the “rights” of the parent trumped the right of the child to effective medical care.
It’s not (yet) too late for JJ
Makayla is now dead and buried. It is too late for her. Her family and community must deal with their horrible loss as best as they can. However, it might not be too late for JJ and other children elsewhere who are suffering from cancer but not receiving effective treatment. Fortunately, according to a press release from her family, she appears to be currently cancer-free. Not surprisingly, due to the usual misunderstanding that families who abandon chemotherapy for quackery for hematologic malignancies nearly always have, her family believes she is doing well because her latest tests have failed to find residual cancer:
The 11-year-old at the centre of a controversial ruling on aboriginal medicine tested negative for signs of cancer, her family says, months after she was pulled out of chemotherapy early in favour of natural therapies.
According to a published statement, the family credits the alternative treatment for the remission. But oncologists say it may be the result of the two weeks of chemotherapy the girl underwent at McMaster Children’s Hospital in August before her mother pulled her out.
Another story from Two Row Times reports:
Once we had the court ruling that upheld our right to use our traditional healthcare we sought out a oncologist [sic] who would work with our unique situation. I felt it necessary to have her closely monitored as we navigated through uncharted territory. Toronto Sick Kids agreed to fulfill that role. Of course we needed to hear the oncologist’s spiel about no child ever known to survive leukemia without chemo and they expect her to begin dying in mid January. I booked a biopsy for mid January. Its now 6 months following the diagnosis with only our choice of treatment. We received the biopsy results yesterday – NO VISIBLE CANCER!!!
An announcement was also posted on Facebook by Hippocrates graduate Jane Schweitzer describing the news.
Of course, JJ’s remission is far more likely to be the result of the chemotherapy that the girl underwent in August than it is to be due to Brian Clement’s quackery or whatever traditional healing methods they’ve also been using. I’ve explained this concept several times of late. For hematologic malignancies like this, there are several phases of chemotherapy, starting with the induction phase. The induction phase is designed to put the patient rapidly into remission. However, as pediatric oncologists (not to mention adult oncologists who treat hematologic malignancies) learned the hard way decades ago, it requires sustained courses of chemotherapy to prevent leukemias from rapidly recurring. Basically, it’s often easy to get a patient into remission, but keeping the patient in remission is much harder.
One good thing about this article is that the reporter interviewed some actual oncologists who explained this concept rather well:
“From my perspective, there’s lots that traditional healing can offer in terms of symptom management and support, but based on my scientific training I think it’s exceptionally unlikely that traditional medicine has cured her of her disease,” said pediatric hematologist and oncologist Dr. David Dix, a clinical professor at the University of British Columbia.
“It is quite possible that she went into remission after the first two weeks of chemotherapy,” he said. Dix said the likelihood of the cancer returning is “100 per cent” and that any return of the cancer will be more difficult to treat.
And, later in the article:
The typical course of treatment for lymphoblastic leukemia involves four weeks of intensive chemotherapy which puts “99.9 per cent” of people into remission, Dix said. That is normally followed by about six months of heavy chemotherapy, then about two years of maintenance chemotherapy.
“Achieving remission, even with a short duration of chemotherapy, is expected,” said Dr. Kirk Schultz, professor of pediatrics at the University of British Columbia. “The whole focus of chemotherapy in children with acute lymphoblastic leukemia is to get a curative outcome, that they cure the disease and it never comes back.”
And the conclusion of the article:
“Any pediatric oncologist would tell you that the likelihood of her disease recurring or relapsing is 100 per cent, that she’s at very high risk of recurrence for her disease,” said Dix. “When she does relapse it becomes more difficult then to get her back into remission. It’s very much better to get her back into chemotherapy as soon as possible.”
So what we have in JJ is, medically at least, a very similar story to that of Makayla Sault, just delayed. Her cancer will eventually recur, probably within the next year, and at that point it will be much more difficult to eradicate than it would have been if the girl had only undergone standard-of-care chemotherapy and completed the full course during her first pass It’s also been noted that there are significant differences between these cases. For instance, Makayla was much more bright and assertive than JJ apparently is, so much so that some believed her capable of making decisions about her own health care. Given her visions of Jesus as a rationale for stopping treatment, I’m a bit—shall we say?—skeptical that that was true. In contrast, Justice Edward found that JJ “lacked capacity to make such a life-and-death decision,” even as he ruled that the traditional medicine was so integral to aboriginal rights that JJ’s parents had the right to refuse chemotherapy for her.
It’s also important to note that right now it is not entirely clear exactly what treatments JJ is undergoing. For instance, this Two Row Times article states that since August she has “followed a strict protocol utilizing indigenous medicines, ceremonial healing and nutritional therapies – including consuming a 100% raw and sugar free vegan diet” and that she “has also pursued other nutritional and supplemental therapies under the wisdom and guidance of indigenous healers and advisors across North America.” Her mother in her statement wrote:
I believe our deep rooted faith in our medicine and ceremonial medicines, diet and exercise have been the reason for the biopsy results. I thank my Creator and all He set out on earth. I acknowledge our medicines. That they still fulfill their duties as our helpers, our healers. I acknowledge the spirit helpers that manifest themselves and their assistance in ways unknown to us still existing in the physical plane. I acknowledge my individual responsibility to look to Creation for what we need in all aspects of my family life. I acknowledge the individuals who still carry the ancient Haudenosaunee medicine knowledge. They choose to devote their lives from very early on to be a servant to the nation.I am eternally grateful to so many for the strength and support that, today has resulted in [my daughter’s] good health.
Yet, in an article published by CBC News, reporter Connie Walker describes an interview with JJ’s mother and a visit to the Hippocrates Health Institute by dryly noting:
There were two teas — one given to her by a healer in their community and another sent by someone she met on Facebook who says he is a medicine man from Saskatchewan.
The tea was likely the only indigenous medicine at Hippocrates.
As a First Nations person myself, I’m confident I can say that none of my ancestors abided by a strict raw vegan diet, or took high doses of vitamins intravenously or underwent cold laser technology. Regardless, her mother said Hippocrates was in line with her belief in natural medicine.
The entire story comes across to me as very consistent with Brian Clement being a particularly slick-talking con man and quack who didn’t like being questioned. Walker noted having viewed many of Clement’s videos in which he extolls the benefits of wheatgrass and attacks vaccines and “Western medicine” in general. One that stands out to me is this video of Clement being interviewed by Joe Mercola:
It’s chock full of pseudoscientific nonsense.
Walker reported further:
[JJ’s mother] spoke about the director, Brian Clement, with glowing adoration. “What struck me most,” she said, “was he was not afraid of cancer. Cancer didn’t shake him like it shook me.”
It was his words that convinced her to leave chemo. She said she called him from the waiting room at McMaster and he assured her that leukemia was “not difficult for them to deal with.”
It’s a claim he denied when we confronted him about it in Florida. He denied other allegations, too.
No, he was not practising medicine without a licence as some former employees of his alleged. Nor was he treating people battling cancer and other serious illnesses, he said. He was teaching them to heal themselves.
Can he give me the names of anyone he’s helped? I asked. “Get off my property!” he shouted.
Ah, yes. A classic 60 Minutes-like moment, the kind reporters love, when the target of their investigation gets ticked off and kicks them out of their office or off their property.
Sadly, the hard part will come when this girl’s leukemia, as is almost inevitable now, recurs. What will the parents do? Will they admit that the combination of “traditional” medicine and Brian Clement’s quackery didn’t work and finally let their daughter be treated with state-of-the-art chemotherapy? At this point, that is probably the best outcome that can be expected for JJ, because her mother is clearly never going to bring her back to have her leukemia treated correctly as long as the girl appears to be tumor-free, even though that would be the course of action that would maximize her daughter’s odds of survival. The problem, of course, is that this honeymoon period probably won’t last very long. The clock is ticking or the sands of the hourglass are running out. Pick your metaphor.
Unfortunately, I fear that when this girl’s cancer does recur, the parents will not change course. After all, this is what the girl’s mother has said:
In an interview with CBC News, her mother said, “This was not a frivolous decision I made. Before I took her off chemo, I made sure that I had a comprehensive health-care plan that I was very confident that was going to achieve ridding cancer of her body before I left the hospital. This is not something I think may work, this is something I know will work.”
Just as bad for JJ, it is doubtful that her mother will be able to admit that this “something” didn’t work, even after the leukemia recurs. Then we’ll have a second Makayla Sault, another dead aboriginal girl, with her family and community blaming the course of chemotherapy for her death, rather than the failure to complete her treatment for a very treatable leukemia.
The central conflict
How can such things happen? How can governments so routinely allow children to die due to medical neglect because that is what the parents choose, often based on religion, personal belief, or culture? If you want to know how bad it is, just consider the case of Herbert and Catherine Schaible, discussed by both Harriet Hall and myself. In 2009 the Schaibles chose prayer over antibiotics for pneumonia for their first child. The child died. The Schaibles received ten years’ probation and had to promise, in essence, that their other children who were not removed from their care would receive modern medical care. In 2013, a second child, who was 8 months old at the time, developed pneumonia and died the same way. It took the second death of a child before the state actually took their children away and put them in jail. As Steve Novella has pointed out, if parents only use medical opinions as a justification for choosing quackery or denying care, the state will usually intervene, as Ottawa is doing in the case of Marco Pedersen, whose son Aiden also has acute lymphoblastic leukemia, which Pedersen wants to treat with hemp oil. If, on the other hand, religion or culture is used as justification for choosing quackery over effective treatment, courts seem to be much less willing to step in and see that the child receives effective treatment.
This dynamic has definitely been at play in the two cases of the aboriginal girls. With Makayla Sault, both religion and her aboriginal culture led to the reluctance of authorities to intervene. With JJ, it’s primarily her culture. Indeed, her community and tribal elders fully supported the parents, as did Makayla Sault’s community and elders. In fact, when CAS was looking into Makayla’s case, New Credit Chief Bryan LaForme warned that hundreds of community members in the “Makayla Defence Force” would spring to action should the CAS attempt an apprehension. Emotion also ran high for JJ, as demonstrated by a Facebook post I cited in my previous post. I included the whole thing before, but for this post I will simply highlight a particularly-relevant part, so that you don’t have to go back. Accusing McMasters Children’s Hospital of trying to “undermine our way of life,” the Six Nations Elected Council stated:
The court affirmed that our use of traditional medicines was integral to our cultures, historically and today. The court recognized that our right to use our medicines is not subject to the approval of western medical practitioners.
And:
Forcing a First Nations child to undergo unwanted, mainstream, medical treatment is an affront to the dignity and autonomy of that child, our cultures, and our nations. Had our children been forced into treatment, it would have had a disastrous effect on their emotional, psychological, and spiritual well-being. Instead of being proud of their own traditions, they would learn that the laws, governance, teachings, and medicines of the Haudenosaunee and Anishinabe cultures were wrong and even dangerous. This is simply not true.
No, but Makayla Sault’s family learned that they were ineffective the hard way. Or they would have, if they had actually used traditional medicine instead of the quackery of a white man from Florida. Unfortunately, this view led JJ’s community hold fundraisers and provide JJ’s family with enough money to fly to Florida and pay the $18,000 that Clement charges.
Believe it or not, I understand, at least as much as a middle-aged citizen of an oppressor nation can, that aboriginal peoples have been treated horribly by the Canadian government, just as those in the US have been treated horribly by the US government. I know about, for instance, the Canadian residential schools, in which aboriginal children were forced to attend boarding schools away from their families and communities in order to assimilate them into the dominant Canadian culture. There, aboriginal children often suffered physical and sexual abuse. It’s not surprising that there still exists in Canadian aboriginal communities a great deal of distrust of the government and the medical system that facilitated such cultural imperialism, the same as the native peoples in my country very much distrust the government that drove them off their ancestral lands and onto reservations.
As simply as I view things, in which the life of the child is paramount, on the ground things are, sadly, often not that simple (although, I can’t help adding, they should be that simple). In the case of religion, because of the deference given religious beliefs governments are often very reluctant to intervene to stop religion-based medical neglect, as was the case with the Schaibles. Because of Canada’s abominable history with its native nations, Canada’s aboriginal peoples understandably tend to view even attempts to help two of their children through the lens of the residential schools and past oppression. Toxic attitudes common to many cultures, that of the US included, that ascribe absolute rights to parents over their children fuse with past grievances that led to current distrust and turn what should be a case of child welfare into a chance to assert aboriginal rights through the proxy of JJ’s case.
Unfortunately, among the tribes, few seem willing to speak up for these two girls’ right to the best shot at life medicine can give them. Thus, tribal authorities have done a grave disservice to aboriginal children in allowing their mistrust to lead to their using two innocent children as a weapon in their fight to obtain more autonomy. Meanwhile, Canadian authorities, aware of all these things, bend over backwards not to appear to be “undermining” the culture of the native peoples, even though they know it will cost the life of a child. In all of this, the rights of children as autonomous beings rather than the property of their parents or extensions of their parents’ cultural identity, are lost, possibly irretrievably.
How do we overcome this? Putting the child first, rather than religion, race, nationality, or culture, would be a way to start. If everyone involved could do that, just for a moment, for JJ there might be a chance to save her. Or maybe I’m just too naïve and JJ is doomed after all.

An update on the case of Sarah Hershberger: Parental rights trump the right of a child with cancer to live
Sarah Hershberger, an Amish girl with leukemia, is refusing chemotherapy, and her parents are supporting her. Unfortunately, it looks as though the State of Ohio will let this child die.
David Gorski on December 9, 2013
Link
Five weeks ago, when last I touched on the case of Sarah Hershberger, the now 11-year-old Amish girl from Medina County, Ohio near Akron with lymphoblastic lymphoma whose parents had taken her off of chemotherapy after only two rounds, reports had been coming out of the cancer quackery underground that Sarah’s parents, Andy and Anna Hershberger, had fled to avoid a court order that appointed a medical guardian for her to make sure that she received appropriate science-based therapy. At the time I was unable to confirm these stories in the mainstream press. However, over the last month there have been significant developments in this case and even over the last week; so I thought that now would be a good time to update SBM readers on developments in the case.
The Thanksgiving confirmation
One thing that I didn’t mention a month ago is that David Michael and others have been actively raising money to support the Hershbergers’ legal battles. Then, over the long Thanksgiving Day weekend news reports began to trickle out confirming what the “alternative” health sites had been reporting, namely that the Hershbergers had fled. These reports started with story from a local Medina newspaper, then spread to a northeast Ohio television stations, and then to national news sources (like Good Morning America and CNN) and international news outlets. The Medina Gazette first reported:
Neither the 10-year-old daughter who was ordered by a court to continue cancer treatments against her will nor the rest of her Amish family has been seen since at least last month.
Sarah Hershberger and her parents, Andy and Anna, were not at their Homer Township farm Oct. 30, when Medina County sheriff’s deputies accompanied county Job and Family Services officials on a welfare check.
County Sheriff Tom Miller said his office has no idea where the Hershbergers might be and is not actively searching for the family.
“It would take a court order for us to get involved,” Miller said, “and I’m not anticipating a court order.”
In October, an appellate court granted a request from Akron Children’s Hospital to appoint “limited guardianship” to registered nurse and attorney Maria Schimer granting Schimer the power to make medical decisions for the girl in place of her parents.
Clair Dickinson, an attorney representing Schimer, said he didn’t know the family’s whereabouts.
One point that needs to be addressed is that the parents and sources representing the parents keep claiming that Sarah is “doing much better” since being off chemotherapy and that her tumors have “shrunk” or even “disappeared” on “natural treatments.” However, no evidence is presented. We are not told what doctor is claiming that her tumors have shrunk, nor what tests were used to determine tumor burden. Given that Sarah appears to have been taken to an “alternative cancer clinic” somewhere, such claims are to be treated with a huge degree of skepticism, for obvious reasons. Many such clinics are known for using scientifically unproven tests or even outright quackery like “live blood cell analysis” to assess tumor burden. Even if Sarah has had a recent CT scan that shows no tumor or no progression of her tumor, that doesn’t mean she’s out of the woods. It can take a while for tumors to recur after a complete remission or to progress after a partial remission. If Sarah indeed had a complete remission due to her two rounds of chemotherapy—and, make no mistake, if Sarah is in complete remission it was the chemotherapy that caused it—she won’t be out of the woods until she reaches the five year mark. There’s a reason why the five year mark was chosen to measure survival of these tumors; recurrences are rare after that.
I also note that the reluctance of authorities to enforce the court order just goes to show how pervasive the attitude is that children are in essence the property of their parents, who can do anything they see fit with the child. Clearly, Medina law enforcement and court officials have been dragging their heels because they sympathize with the parents more than they care about a child who will very likely die within a year or two without effective science-based therapy for her cancer. (Yes, I’m talking to you, Medina County Sheriff Tom Miller.) I know that no one wants to take a child from a family, particularly a family that is likely viewed in its community as being full of fine, upstanding, God-fearing citizens. However, the girl has been without treatment since June, according to this account. We’re rapidly approaching six months.
So we now know that the Hershbergers fled over a month ago, as was first reported then in the “alternative” health press and now confirmed by mainstream media sources. Something else happened last week that has bearing on the case. Specifically, apparently the nurse who agreed to be the appointed medical guardian for Sarah, Maria Schimer, has resigned. According to a press release published on David Michael’s (also known as David Augenstein’s) Journal of Natural Food and Health website from the 1851 Center for Constitutional Law, which, as “health freedom” activists so frequently do, falsely and ignorantly downplays Sarah’s cancer, saying “Sarah’s mild form of cancer is a type that can and is being treated without chemotherapy.” Sarah’s cancer is not “mild.” It is aggressive, albeit curable with an intensive two year course of chemotherapy. If the cancer were “mild,” it wouldn’t require such aggressive treatment. In any case, this is the sound of the 1851 Center for Constitutional law crowing while either lying or being willfully ignorant (take your pick) about the seriousness of Sarah’s disease:
The 1851 Center for Constitutional Law today accepted the Resignation as Limited Guardian of a state official attempting to, on behalf of the State and Akron Children’s Hospital, force chemotherapy on ten-year-old Sarah Hershberger.
While the resignation still requires the signature of Probate Judge Kevin Dunn, Judge Dunn is expected to approve the resignation sometime next week, effectively ending the two-month stand-off with Sarah’s parents, Andy and Anna Hershberger, who, concerned that the chemotherapy was killing their daughter, sought the right to first try a less invasive alternative treatment that the hospital did not provide.
Andy and Anna, after the Court’s order, left the country to pursue an alternative treatment and prevent Sarah from being taken from them. The family reports that Sarah has responded well to the alternative treatment, the cancer is receding, and she is in excellent physical condition.
If the 1851 Center for Constitutional Law is correct and the parents now seem likely to prevail, Sarah Hershberger will almost certainly die, unless she happens to be one of the lucky minority of children whose tumor not only went into complete remission after two rounds of chemotherapy but doesn’t recur in a more resistant form, as most such cancers do. As I’ve pointed out, both here and at my not-so-super-secret other blog, oncologists don’t use a two year course of chemotherapy because they like to torture children. They use a two year course of chemotherapy because that’s what it takes to produce the 85% five year survival that is the current standard of care for lymphoblastic lymphoma. Its lofty claims of fighting for “parental rights” notwithstanding, the 1851 Center for Constitutional Law is in reality fighting to let Sarah Hershberger die a horrible death from cancer. Sure, it doesn’t see it that way, but medical science is quite clear that Sarah’s death will be the likely result of the actions of the 1851 Center for Constitutional Law. Already her chances of survival are fading. We just don’t know how much because we don’t know enough about her clinical situation.
Why Akron Children’s Hospital backed off and Maria Schimer bowed out
The hospital that treated Sarah Hershberger, Akron Children’s Hospital (ACH), strikes me an excellent children’s hospital. I had occasional dealings with patients who had been treated there back when I was doing my surgical residency in Cleveland. Moreover, the administration of ACH has earned my respect by its willingness to go to court to make sure that Sarah Hershberger has the best chance of surviving her cancer that science-based medicine can give her. The hospital has paid a price. Believers in alternative cancer therapies and parental rights activists regularly descend on any media report or blog post about Sarah Hershberger and castigate the hospital as being “fascist” or wanting to “poison” Sarah in order to make obscene profits by giving her chemotherapy. Its Facebook page is routinely home to the vilest slurs against the hospital, all based on the Hershberger case, such as:
So happy to see that you weren’t able to poison Sarah, and that she’s now healthy thanks to natural treatment in South America
As I write this, it’s actually not as bad on the ACH Facebook page as it was a month ago, when the news that the Hershberger’s family had fled started appearing in alt-health websites. The hospital, however, did also have to deal with Mike Adams, who harassed the hospital’s PR department and wrote about it for his audience:
These “heroes” of medicine are so moral, so ethical and so “in the right” that they won’t even reveal their names. They choose to hide behind anonymity, probably because at some level they realize their actions violate fundamental human rights and parental rights. These are crimes against families.
That’s what I told Akron Children’s Hospital public relations spokeswoman Lori Shuler, even encouraging her to “do something more meaningful with her life” than be a P.R. front woman for a destructive institution. Her answer to this? Literally, she screamed, “What an asshole!” and then slammed the phone down.
That is an on-the-record quote from Akron Children’s Hospital, by the way: “What an asshole!” This is the level of professionalism these people exhibit. They poison children for a living, then scream profanities at honest journalists trying to ask them intelligent questions about the names of the doctors involved in the lawsuit that’s forcing an innocent child to be poisoned with potentially deadly chemicals. For the record, I didn’t raise my voice at all. I was calmly asking questions and offering this person my view on the actions of their hospital.
Lori Shuler sounds as though she is a keen judge of character.
The charge that ACH is doing this because of the allegedly enormous profit it will receive from treating Sarah Hershberger is particularly ridiculous because it surely hasn’t been cheap for the hospital to pursue legal action through numerous appeals that now appear to be headed for the Ohio Supreme Court, to the point that it’s likely that the hospital, even if Sarah comes back and receives the rest of her therapy, will lose money on the case. The hospital has also endured accusations that it administered “experimental” chemotherapy without properly getting the Hershberger’s informed consent. The pressure that has been brought to bear on the hospital, both in terms of the expense of continuing the legal action and the PR nightmare it has endured over its decision to try to save the life of a girl whose parents, through a combination of religious beliefs, inability to bear watching their child suffer, and what definitely sounds like misunderstandings between Sarah’s oncologists and her parents, has made me wonder how much longer the hospital would continue. After all, ACH is being accused of conflicts of interest, of only wanting to “poison” Sarah Hershberger to make enormous profits, and of doing unauthorized research without informed consent. Any physician who’s ever worked for an NCI-designated comprehensive cancer center knows that these charges are almost certainly nonsense, borne of a combination of misunderstandings between the Hershbergers and ACH and “health freedom” activists taking advantage of them, but there comes a time when being unable to counter them publicly due to being involved in legal proceedings starts to wear on even an organization as committed to children’s health as ACH clearly is.
That’s why I wasn’t too surprised when news reports started percolating out that Ohio Amish Girl Won’t Be Forced to Have Chemo and Maria Schrimer had relinquished guardianship. I was wondering as long as a month ago how much longer ACH could keep this up, and, even more, how much longer Schimer could weather the incredible abuse that was being heaped on her for trying to do the right thing for Sarah. It’s not at all surprising that she decided:
“We don’t know where the little girl is,” said Dickinson, an attorney for Schimer. “We’ve kind of inferred that we’re not going to see her again, so it doesn’t make sense for this to continue.”
He said her family is saying she’s cancer-free as the result of natural treatments, including vitamins and herbs.
“If she is, that’s great,” Dickinson said.
“On the other hand, the undisputed medical testimony was that she would die in six months to a year without treatment.
“If she’s not cancer-free, it may be too late for chemotherapy to help her.”
And:
Dickinson said Schimer’s resignation isn’t final until Probate Judge Kevin W. Dunn accepts it. Once Dunn does, Dickinson said he plans to file a brief with the Ohio Supreme Court to say the case is moot.
“Maria’s purpose and the hospital’s purpose was to do anything we could to assist this little girl,” Dickinson said, “and we wish her well.”
It sure sounds to me as though ACH is washing its hands of the case. On the one hand, it saddens me greatly that ACH would make this decision, but on the other hand I really have a hard time blaming the ACH administration for doing so, given the expense, low likelihood of prevailing before the Ohio Supreme Court, and the continued distraction this one case has become to its mission. Most hospitals probably wouldn’t have fought as long and hard as ACH did to save the life of this child. Of course, I’d like to think that most county health authorities would not have declined to intervene, as was the case in Medina County.
So where are Sarah Hershberger and her family, anyway?
So where did Sarah Hershberger and her family flee six weeks ago, and what “alternative treatments” has she been receiving? Given my history of interest in cases like this, I was curious, and I figured that our readers would be interested in knowing as well. News reports seem to indicate that the Hershberger family fled to somewhere in Central America. I’ve also heard claims that the family fled to South America. David Michael reports that she is receiving these treatments:
Andy explained in general terms some of the treatment and nutritional supplements, including high doses of vitamin C and B17, oxygen therapy, detoxification methods, as well as the IV chelation to deliver some of these to Sarah’s bloodstream. He also explained how the doctors arrived at a cancer-free status. She is now on a special diet including lots of vegetables and raw foods and taking special natural supplements, as prescribed by the foreign doctors. Anna said they really needed to leave the area to escape the harassment, fear and pressure they had and have Sarah take biomedical therapy. Sarah only spoke a few words that included she is doing fine and feeling good and wants to come home. She is being schooled during the day while the mother also cares for the baby they needed to bring along. Sarah was very shy–this was likely to her first telephone call.
It would appear that Sarah is receiving a veritable cornucopia of quackery. For example, high dose vitamin C is ineffective against cancer, or so minimally effective as to be useless, while “vitamin B17” is nothing more than that old discredited warhorse of cancer quackery, laetrile. Chelation therapy for cancer is a form of quackery favored by practitioners like Dr. Rashid Buttar. “Detoxification” is a generic form of treatment favored by quacks, particularly naturopaths, as are “special diets.” From the description of Sarah’s treatments, I wonder if she is undergoing some sort of variant of the Gerson protocol, which involves a lot of supplements, often a vegan diet, and frequent coffee enemas to “detoxify.”
Naturally—ahem—I was curious which clinic among the many quack clinics that exist in Central America is treating Sarah. Remember, Costa Rica was where Dan Heckenlively took his autistic daughter for intrathecal injections of “stem cells.” I found a few, although most centers that come up on searches are, in fact, in Mexico. For example, there is Centro Harmony in Costa Rica; Ageless Wonders in Panama (which is a medical tourism service that hooks up foreigners with medical services, including mainly alternative medicine services); and several others, such as Robert B. Wickman in Ecuador. Unfortunately, it’s not clear at all where the Hershbergers took Sarah to be treated; it could also have been to one of the many alternative cancer treatment clinics in Mexico as well. I’m guessing that we’ll find out eventually. Now that there is no longer the threat of the law coming to bring Sarah home, there’s no reason not to reveal the clinic anymore, although it wouldn’t surprise me if David Michael and the Hershbergers keep it secret as long as they can. No doubt they don’t want nasty skeptics like me taking too close a look at what quack treatments these clinics offer.
Parental rights versus children’s rights
What is at the center of the Sarah Hershberger saga is more than just quackery versus science-based medicine, although that is part of it. It’s more than just about how difficult it is for parents like the Hershbergers, particularly if they have a tendency towards alternative medicine already, to bear watching their children suffer through cancer treatment. It’s also about more than just the perils and pitfalls of communicating with parents whose knowledge of science is not sophisticated and who misunderstand why it’s necessary to continue treatment for childhood cancers for longer than two years. Remember, from their standpoint, if the tumors have shrunk away to seemingly nothing after only two doses, it is not at all unreasonable to wonder why more toxic chemotherapy is necessary. The tumors are gone, right?
Since I first started blogging at my not-so-super-secret other blog back in 2004, I’ve covered a number of cases like that of Sarah Hershberger, such as Daniel Hauser, Abraham Cherrix, and Katie Wernecke. These stories are depressingly similar, as are the arguments that go on over them. First, a child develops cancer. That child starts chemotherapy and does well initially. Then, the child develops side effects. The parents react quite understandably, becoming alarmed at their child’s suffering. However, because of a tendency towards magical thinking they can’t seem to see the big picture. So they stop the chemotherapy and pursue quackery. Sometimes, thinking that their child’s tumor is gone because it is no longer detectable after a cycle or two (or three) of chemotherapy, they think their child doesn’t need any more chemotherapy. They don’t understand (or accept) the rationale for two years of chemotherapy. They don’t understand that by stopping therapy so early they are greatly increasing the chances that their child’s cancer will return.
Other aspects of these stories are maddeningly similar. Usually what happens next is that either the hospital or the state’s child protective services go to court to make sure that the child receives proper cancer care. What follows is then usually a court battle in which the parents and their allies (and, yes, they always find allies like the 1851 Center for Constitutional Law) portray the hospital and child protective services as fascistic tools of big government doing the will of big pharma to torture an innocent child for fun and profit. I only exaggerate a little. Actually, no, I am not exaggerating at all. In the uncommon case in which the court actually rules that the child must undergo treatment, it is not uncommon for the parents to flee with the child. We’ve seen it with Daniel Hauser; we’ve seen it with Abraham Cherrix and Katie Wernecke; and we now see it with Sarah Hershberger.
It is this demonization of medical professionals and case workers trying to do the right thing that reveals a very disturbing aspect of the American psyche, and that’s the attitude that children are property and parents’ rights trump the well-being of the child. If you go to the Akron Children’s Hospital Facebook page, you’ll find comments like this one by a man named John Strangis (whose YouTube channel is chock full of HIV/AIDS denialism and videos on chemtrails), who writes on the ACH Facebook page:
Looks like the family won and the girl recovered with NATURAL TREATMENTS regardless of your efforts to force her into something which went against the wishes of her parents.
Then someone by the name of Elect Sys writes:
The Lord has given parents custody of children–not the state or worse yet someone who has a conflict of interest with the parents such as Akron Hospital. Flee the place at all cost!
Here’s someone named Madison Treiber:
THIS HOSPITAL IS VIOLATING HUMAN RIGHTS!!!! They are forcefully administering chemotherapy to a child who does not wish to be treated with such a method. Her parents are being legally required to allow this treatment that they, nor their daughter support.
This hospital, in conjunction with the Ohio court, are violating human rights. They are legally mandating what this girl do her body! It is not their choice. What sort of a country do we live in if the courts can decide how we treat our ailments?? They are robbing this child and her family of their freedoms. There are so many other options in treating cancer, and everyone should be able to pursue the treatments THEY prefer, not be legally required to do what the state thinks is best.
Note how Ms. Treiber doesn’t seem to consider endangering the life of a child by withholding potentially life-saving treatment to be a violation of human rights. If you scroll back to the early part of October on the posts on the ACH Facebook page, which is around the time the ruling that Sarah Hershberger should undergo chemotherapy was handed down, you’ll find screed after screed after screed castigating ACH using similar arguments. They all boil down to outrage that any entity, be it the hospital, the courts, child protective services, or any other agency of the government, would dare to interfere with the parents’ absolute right (in their view) to care for their children the way that they see fit. It doesn’t matter that the parents are endangering Sarah Hershberger’s life by withholding the only treatment that can save her in favor of “natural healing” that can’t. While many commenters try to argue that this “natural healing” will work better than chemotherapy, more than a few of them seem to realize deep down that it won’t. They’ll qualify their statement by saying that the parent has the “right to choose” what is “best” for their child even if it’s clearly not, even as they express outrage that the state would try to intervene in the best interests of the child.
This belief that parental rights over their children are absolute and inviolate is not only common, but it takes some insidious forms, particularly when the abuse of children is based on religion. Given the strong tradition of religious freedom in this country that is inscribed in our very Constitution, it is understandable that people don’t want the government telling them how to practice their religion or interfering with their religion. However, as with all rights, the parents’ right to raise their children as they see fit has to be balanced with the rights of the child to life. When the exercise of a parents’ religion endangers the life of a child, the life of the child takes precedence—or should. It doesn’t always. It’s rare that parents who deny their children medical care suffer any penalty. (It does happen occasionally, but cases like this are rare.) Indeed, so much do government authorities bend over backward to respect parental rights that it is possible for parents who let one child die of pneumonia untreated because they believed Jesus would heal him retain custody of the rest of their children so that they could do it again and let a second child die.
We see this particular attitude among antivaccinationists as well. For instance, just the other day, the antivaccine crank blog Age of Autism published a little screed by someone named Dr. Karol Osborne entitled Concerns: UN Convention on Rights of Persons With Disabilities. Noting that the U.S. Senate has not yet ratified this treaty, Osborne is upset because this treaty would adopt a standard that is based on the “best interests of the child,” and she fears that such a standard might interfere with the ability of antivaccine parents to not vaccinate. She also fears (likely with more justification) that such a standard would make it far more difficult for antivaccine parents to subject their children to “autism biomed” quackery such as when Kent Heckenlively subjected his daughter to bogus “stem cell” treatments in Costa Rica or when parents risk the lives of their children by subjecting them to quackery like the Lupron protocol or chelation therapy.
If you read the actual text of the convention, however, it’s nowhere near as ominous as people like Osborne try to paint it. Article 5, for instance, states that “States Parties shall respect the responsibilities, rights and duties of parents or, where applicable, the members of the extended family or community as provided for by local custom, legal guardians or other persons legally responsible for the child, to provide, in a manner consistent with the evolving capacities of the child, appropriate direction and guidance in the exercise by the child of the rights recognized in the present Convention.” I will say that parts of the document strike me as a bit utopian, but not any horrific threat to parental authority.
I actually do understand to some extent how parents might take a dim view of too much government interference in how they raise their children, particularly if government views conflict with cultural views. I also recognize that there are gray areas, where it’s not clear whose vision of the best interests of the child should prevail. I am not talking about such gray areas. I’m referring to how an utter insistence the inviolability of parental rights leads to children being harmed, even dying. It’s an insistence that has led to a Proposed Parental Rights Amendment to the U.S. Constitution that would essentially neuter the government with respect to protecting children from parental medical neglect or mistreatment. No wonder antivaccinationists like it.
Cases like that of Sarah Hershberger are also directly attributable to the “health freedom” movement—or, as I like to refer to it, the freedom from pesky interference from laws and regulations designed to protect patients from quacks. I’ve said many times before that competent adults have the right to refuse any and all treatments and choose quackery if that is what they want to do. Acknowledging that right, however, is only part of what the “health freedom” movement is about. The other part is to free quacks from the shackles of having to abide by FDA and FTC regulations designed to protect consumers from false medical claims and allow them to claim anything they want.
Sometimes these goals entwine with various political movements, particularly libertarian or libertarian-leaning political movements. For example, in 2011, Ohio voters passed a “health freedom” amendment to its constitution. Obviously, this amendment was intended to shield Ohio from the individual mandate in the Affordable Care Act. However, in the Hershberger case, the 1851 Center for Constitutional Law is using it as an argument for why Sarah Hershberger should not be compelled to undergo chemotherapy, although how this amendment applies to a child whose parents are subjecting her to medical neglect—and, make no mistake, that is what the Hershbergers are doing, as well-intentioned as they are—is beyond me. (Perhaps Jann Bellamy will help me out here.)
“Health freedom” amendments and laws aside, this is about more than just antivaccinationists. This deference to parental rights over the health of the child plays out again and again and again in these chemotherapy “refusenik” stories. Daniel Hauser? His mother ran away with him. Fortunately, the story had a happy ending, with the Hausers ultimately accepting science-based treatment. Abraham Cherrix and Katie Wernecke? Their parents ran away with them, too. In particular, Cherrix’s story, which is still going on as he continues to battle recurrences of his lymphoma, even led to a horrible law in Virginia known as “Abraham’s law,” that states that the parents of a child at least 14 years old with a life-threatening disease or condition could refuse medically recommended treatment without the refusal being considered medical neglect, provided (1) the parents and child made the decision jointly, (2) the child is sufficiently mature to have an informed opinion on the treatment, (3) other treatments have been considered, and (4) they believe in good faith that their choice is in the child’s best interest. Unfortunately, this law essentially opened the door for a 14-year-old with a life-threatening illness to be given whatever quackery he or his parents choose, in place of treatment with proven efficacy.
Now it’s Sarah Hershberger’s turn. The fact is that no one wants to take a child away from her parents, and no hospital wants to, either, the rants about big pharma profiteering as a motive for crushing parental prerogatives notwithstanding. In the case of ACH, the easiest course of action would have been for the doctors there to shrug their shoulders and mourn the loss of another child to superstition after having done their best to persuade the parents of the disastrous outcome their decision would lead to. It didn’t. The hospital tried to stand up to defend the best interests of the child, the best interests of Sarah Hershberger. It failed. Unfortunately, now that the Ohio Supreme Court will likely moot the case because there is no longer anyone assigned to be her medical guardian (or even anyone petitioning to be her guardian), Sarah Hershberger is likely to die unnecessarily in a manner far worse than what she would suffer if her parents let the doctors treat her with chemotherapy as she needs.
Thanks, David Michael and the 1851 Center for Constitutional Law. Yours won’t be a victory for parental rights. It will be a major defeat for children and their right to effective medical treatment. Particularly disturbing is how Sarah’s impending demise doesn’t appear to matter much to them beyond making them feel obligated to downplay the seriousness of Sarah’s cancer. They care far more about “parental rights” than they do about Sarah’s life. I only hope that Andy and Anna Hershberger figure that out before it’s too late.

   Death by “alternative” medicine: Who’s to blame?
David Gorski 
Link
One of the more annoying duties I used to have several years ago at our cancer center was to “show the flag” at our various affiliates by attending their tumor boards. I say “annoying” not so much because the tumor boards themselves were onerous or even uninteresting but rather because traveling to them used to cut into my already limited time for research, given that these tumor boards were always scheduled on days on which I didn’t have to be in clinic or the operating room. In other words, they always took place on my research days.
One of our affiliates was a nearly an hour and a half drive away, and many of them were close to an hour away. When you add up travel time and the tumor board, that’s easily more than three hours eaten up, all too often right in the middle of the day. In actuality, though, several of the tumor boards themselves were quite good, one of which being the aforementioned one that required nearly a 90 minute drive to reach. (It helped that they served a really nice breakfast there, too, but they also have really stimulating discussion about various cancer cases.) One of the weird things about these tumor boards is that I was viewed as–and I quote–the “outside expert.” This was particularly disconcerting the first year I had the job. There I was, fresh out of fellowship, being looked up to as the “expert” by physicians, many of whom who may have been in practice for 10, 20, or even 30 years. Somehow I managed to muddle through without making too big a fool of myself. These days, years later, I almost even feel as though, for breast cancer at least, I am worthy of the appellation of “outside expert.” Experience does matter, I guess.
Maybe about three years ago, I found myself attending a tumor board at one of our affiliates that brought up issues that I do not see that often. It brought up a rather difficult issue, one that I hadn’t given as much thought to before as perhaps I should have or that I have in the years since I started blogging actively about so-called “alternative” medicine. I hadn’t been expecting anything out of the ordinary when I arrived at the hospital auditorium. As usual, I said hello to the oncologist who runs the tumor board, a private practice oncologist for whom I had considerable respect and with whom I have shared a few patients. There were some amusing technological difficulties with the computer projection of the radiological studies and pathology slides having to do with a problem moving between a Mac and a PC with the projector, and my attempt to apply my knowledge of the Macintosh in the service of helping them figure out the problem was in essence rebuffed. So, I sat down and let them figure it out on their own without my input, concentrating instead on the coffee and breakfast that was provided. (A common theme for morning tumor boards is food, in case you hadn’t guessed by now. Attendance rises in direct proportion to the quality and quantity of food.)
The first two cases presented were not particularly unusual, and we discussed them in a pretty standard fashion, but the last case presented was tragic in the extreme. If you’ve been a regular reader of this blog, you may have an idea of the general parameters, but this one shocked even me. The case involved a woman in her early 30′s, who presented to a surgeon with a small palpable breast mass. Her primary care doctor had appropriately ordered a mammogram and ultrasound, which the surgeon dutifully presented. The odd thing was that the films were from 2002. The surgeon presenting explained that this woman had presented over three years prior to him for the evaluation of this mass. On mammogram, there was a mass less than 1 cm in diameter, which was confirmed by ultrasound. The edges of the mass weren’t quite smooth enough to consider it very likely benign. Consequently, the mass fell into that gray areay that we in the biz call “indeterminate,” which is basically a code word for “we don’t know if it’s cancer or not and the imaging doesn’t look sufficiently ‘benign’ for us just to follow it.” To put it even more bluntly, it needed a biopsy. The surgeon described how he dutifully did an ultrasound-guided fine needle aspiration of the small nodule.
The results? Adenocarcinoma. Breast cancer. Not much of a surprise, given the appearance on ultrasound.
Here’s where things got interesting. Apparently, this woman was a die-hard believer in “alternative medicine.” And I do mean “die hard,” as she will quite likely die very hard for her beliefs, if she has not already in the interval between this tumor board and now. She absolutely refused any surgery or treatment for her cancer. It was explained to her that a less than 1 cm tumor with no evidence of spread to the lymph nodes carried a highly favorable prognosis, with upwards of 93% long term survival with proper surgery and radiation therapy combined with adjuvant chemotherapy and/or hormonal therapy. Here was a patient surgeons love, because we have a very high probability of curing her.
This woman would have none of it. She wanted to pursue “alternative” medicine. And pursue it she did, with a vengeance. For three years, she disappeared off the radar screen.
A few weeks prior to the tumor board, she had reappeared in this surgeon’s office. In the interim, she had tried Essiac tea, homeopathy, Hoxsey therapy, the Gerson treatment, and Reiki therapy, among others, all the while visiting various “healers.” The results? If you’ve been reading here, you can guess the result.
Her tumor had progressed.
Not only had the tumor progressed, but it had progressed a lot. When the surgeon saw her again, now more than three years after her diagnosis, her tumor had grown to 5-6 cm in size. It was now stuck to the chest wall, distorting her nipple, and ulcerating through the skin in a five centimeter area of bleeding, disgusting goo. Indeed, the surgeon even showed a picture of it. In addition, she had developed easily palpable axillary lymph nodes (the lymph nodes under the arm) on physical exam and complained of bone pain strongly suggestive of metastases to the bone. Even if she did not now have metatastic disease to the bone, her chances of cure had been vastly diminished, as she had clearly moved up from a highly curable clinical Stage I to a difficult to cure clinical stage IIIC. (If she had bone metastases, she was no longer curable at all.) This patient was in serious trouble. You would think that, finally–finally–she would have realized her mistake in not having gone with surgery and conventional medicine.
You would be mistaken.
The patient still steadfastly refused all surgery, chemotherapy, and radiation. Against all evidence that the course she had chosen thus far had not resulted in the elimination of her tumor that she expected, she nonetheless insisted on continuing with various alternative medicine treatments. Against all evidence to the contrary, she continued to refuse any form of “conventional medicine.” She still believed that her ” healer” could save her life, even though she now had a large, bleeding, stinking mass in her breast stuck to her chest wall that had three years ago been a pea-sized cancer that could have easily been excised with a small surgical procedure. She was well on her way to dying in the horrific way that so many women died of this disease 100 years ago. And the cost was more than just the growth of the tumor. The woman had three small children at the time of her diagnosis. Seeing what was happening to her, her husband had finally recently filed for divorce and custody of the children, basing his claim on the fact that, due to her progressing cancer, the poor woman would soon no longer be able to care for them properly and that she had rebuffed all of his attempts to persuade her to get proper medical treatment. He was right. Hearing this tragic case, I felt myself becoming simultaneously enraged and a little bit choked up. By presenting this case, the surgeon was in essence asking for advice, and none of us really had any words of wisdom to give him. He was up against religious or quasireligious fervor, and no amount of reality would change this woman’s mind in any way. He was desperate to help her but utterly helpless in the face of her beliefs. His only hope was that she had actually come to him again. Maybe he could finally reach her.
It was at this point the discussion took a second unexpected turn.
The medical oncologist who ran this particular tumor board stood up and addressed the attendees. She emphatically said that she viewed this case as a failure of the medical system. The medical system failed, she claimed, because it had been unable to reach this woman, because this woman had not gotten psychological help to help her to see the truly self-destructive course that she was taking. I had to disagree strongly and told her so.
The discussion became considerably more animated after that, with several doctors taking issue, including me.
How, I (and others) asked, could this be a failure of the medical system when the woman was given all the information necessary to make an informed choice and chose quackery? How, we asked, can this be a failure of the medical system when the woman continued in this course despite the fact that her primary care doctor, her surgeon, and her family begged her over and over and over again to reconsider? How, we asked, can this be a failure of the medical system when the tumor’s progression was obvious to even the most casual observer, given that it now was bleeding and eroding through the skin? We pointed out that the old cliché that you can take a horse to water but you can’t make him drink applies very well to this case. The woman had been given every opportunity. She had been brought right up to the water three years ago. It was not the system’s fault that she wouldn’t take the last step and take a drink. She had been (and was at the time of the tumor board) a competent adult. (I do not know if she still is, because I do not know if she is still alive.) Unlike minors, she is perfectly free to refuse treatment or to opt for whatever treatment she wishes, no matter how blatant the quackery. There are just some people for whom no amount of counseling or discussion will persuade. Respect for patient autonomy tells us that we must not force her to undergo the appropriate treatment, no matter how much it breaks our hearts to see a young woman with three young children throw her life way.
Faced with these objections, the oncologist changed her emphasis a little, and said that, had this been her patient, she would have viewed the failure to persuade her to see reason as a personal failure. I could see this point of view somewhat, but even so she seemed to be being a bit harsh on herself. On the one hand, I could respect her point of view, in which the inability to persuade a patient not to throw her life away would have been viewed as a profound professional and personal failure as a doctor. On the other hand, not everyone can be persuaded, no matter how good a physician is. If this woman had any mental illness that was leading her down this path, it couldn’t be discerned, unless one defines failure to face reality as a mental illness. If that were the case, a large proportion of the population would have to be hospitalized, given the rampant credulity and failure to face reality about so many issues that plagues our society. Indeed, refusing to face reality seems to be part of human nature. It’s just uncommon for it to be taken to such an extreme.
I used to be very reluctant to agree with a couple of my co-bloggers when they call alternative medicine “cult” medicine, but this woman demonstrated that maybe they know something I don’t. What else could explain her extreme inability to admit what was happening to her? What else could explain her inability to recognize or admit that all the quackery she had tried up until that point had failed utterly? What else could explain her intention to pursue even more of the same? I still think of her, two or three years later. These days, I wonder if she is still alive. Chances are, her faith in “alternative” medicine killed her sometime between that tumor board and now.
The discussion ended unresolved, although most of us weren’t able to think of anything further that could have been done in 2002, nor could we think of anything that could be done then, given that the patient was still refusing any sort of non-alternative therapy. Indeed, we were rather puzzled why she came back now if she were sure that she had no intention of accepting any sort of conventional therapy. Perhaps even she didn’t know, or perhaps her coming back was a cry for help, a manifestation of a realization that she didn’t want to face that her choice was clearly not working and her health was seriously deterioriating. Whatever the case, in situations like this, no matter how frustrated and powerless we feel, all we can do as doctors is to be there, ready to help and nonjudgmental as possible–and hope that when and if the patient comes back there is still something we can do.

   Death by “alternative” medicine: Who’s to blame? (Revisited)
David Gorski
Link
(NOTE: There is now an addendum to this post.)
(NOTE #2: The videos of Robert O. Young’s interview with Kim Tinkham have been removed, as I predicted in this post that they would be. Fortunately, I downloaded copies before he managed to do that. Part 6 appears to be still there–for now.)
(NOTE #3: It was announced on the Facebook page Caring for Kim that the subject of this post, Kim Tinkham, passed away on December 7, 2010 in the late afternoon. Although it was not revealed what kind of cancer she died of, Tinkham almost certainly died from metastatic breast cancer. Quackery appears to have claimed another victim.)
I hate stories like this. I really do. I hate them with a burning passion that makes it hard for me to see straight when I first find out about them.
In fact, you might even say that stories like this are a major part of the reason why I do what I do, both here and elsewhere. They’re a major part of the reason why I’ve recently branched out into public speaking, something that used to terrify me beyond belief but that lately I’ve become at least competent at–sometimes even not bad at all. Sadly, the story I’m about to tell is one I’ve told before, most recently at the Lorne Trottier Science Symposium, where I gave a talk on cancer cure “testimonials,” although at the time I gave the talk the story’s outcome, although predictable, was not yet known.
Now it is.
The woman to whom I refer is named Kim Tinkham, who was diagnosed with breast cancer over three and a half years ago. Regular readers may recall that Kim Tinkham achieved fame not long after that when she was featured on The Oprah Winfrey Show in an episode about The Secret, an episode I discussed posts entitled The Oprah-fication of Medicine and On the nature of “alternative” medicine cancer cure testimonials. I don’t want to discuss the utter nonsense that is The Secret in any detail here. However, for those unfamiliar with this particular bit of New Age woo, it’s important to point out that The Secret’s “Law of Attraction” takes the germ of a reasonable idea (namely that one’s attitudes and wishes influence whether one gets what one wants in life, something that’s been known for millennia) and goes off the deep end of woo by proclaiming that, in essence, you can get anything you want by wanting it badly enough and thinking positive thoughts. Basically “The Secret” is that you have the power to “attract” good to yourself by thinking happy thoughts (hence “the law of attraction,” which, according to Secret adherents always works). It’s an idea that resonates in so much of “alternative medicine,” such as German New Medicine or Biologie Totale. Of course, the implication of “Secret” thinking is that, if you don’t get what you want, it’s your fault, an idea that also resonates with so much “alternative” medicine, where a frequent excuse for failure is that the patient either didn’t follow the regimen closely enough or didn’t want it badly enough.
Basically, The Secret is what inspired Kim Tinkham to eschew all conventional therapy for her breast cancer and pursue “alternative” therapies, which is what she has done since 2007. Before I discuss her case in more detail, I’m going to cut to the chase, though.
This weekend, I learned that Kim Tinkham’s cancer has recurred and that she is dying. On Saturday, a reader of my other blog sent me an e-mail that informed me:
Our dear friend, Kim Tinkham, has been diagnosed with cancer. Kim’s friends and family have established a benefit account at Citibank to assist the Tinkhams with expenses during this difficult time.
The accompanying e-mail referred me to a website called Caring for Kim, which led me to related Twitter and Facebook pages. In addition, on the FaceBook page, there was a flyer:
I can’t tell you how much this depressed me. Granted, neither the website, the Twitter feed, nor the Facebook page confirmed the details of the story told by the person who e-mailed me. However, the nature of the comments on Facebook page did strongly suggest to me that it is true, as there are a number of supportive posts offering prayers of support and urging Tinkham to “keep up the fight” and be hopeful. At the very least, the Facebook page strongly suggested that something is very, very wrong with Tinkham’s health and that it has to do with her cancer coming back. Over the weekend, I have since confirmed, to the best of my ability, that the story related to me by my reader appears to be true. Kim Tinkham is dying of cancer. Most likely what has happened is that, after nearly four years of quack treatments, Tinkham’s breast cancer finally metastasized to what are, let’s face it, the most common sites to which breast cancer metastasizes, bone, liver, and lung. (One source told me that she had “cancer” in those sites but did not specify what kind.) The reports I’ve read suggest that Tinkham is not expected to live to see 2011.
And so it goes. Another quack appears to have claimed another victim.
Breast Cancer, The Secret, and Oprah
I first learned of Kim Tinkham from a testimonial that I read back in early 2008. Here is Kim’s story as related by her:
After a mammogram and a biopsy, Tinkham’s doctor told her that she has stage three breast cancer. That moment, she said, was one of the rare times in her life that she broke down and didn’t know what to do.
“My 50th birthday was a milestone. I started thinking, ‘What am I going to do for the next 50 years?’ I never, ever planned for this,” Tinkham said. “I’m not someone who breaks down. It was a scary time for me and it wasn’t a situation I wanted to deal with, but it wasn’t going to go away. I had that feeling of hopelessness and that feeling when you finally realize, ‘I’m not immortal.’”
Her doctors wanted to perform a partial mastectomy immediately, as well as remove her lymph nodes. She had 15 minutes to call her husband before going through more tests and discussing a combative plan.
This was very typical of breast cancer testimonials. There is the diagnosis. Then, the doctors seemingly pressure the patient into surgery, heedless of what she wants. Whether true or not, the woman perceives it to be this way. Be that as it may, when I first encountered it, this story gave me a fair amount of information, even as vague as it was, assuming that the information contained in it was true. Stage III breast cancer told me that at least one of two things must be true: Either the tumor must have been large (greater than 5 cm in diameter), and/or there must have been significant lymph node involvement. Also, from this story, we could reasonably conclude that, if Tinkham’s account was accurate, her tumor was stage IIIA, because stage IIIB and IIIC are by definition not operable; they require chemotherapy first to shrink them. Finally, we can assume that, whatever the status of her nodes, the primary tumor must not have been that much larger than 5 cm, because otherwise a partial mastectomy without preoperative chemotherapy to shrink the tumor would not have been possible.
The next step of the testimonial was the “courageous” decision to “go alternative”:
Hours and hours of research followed, and Tinkham realized that an alternative solution would be best for her.
“I knew, for me, the best route would be alternative. I don’t like surgery. I guess I don’t like the loss of control,” Tinkham said. “After thinking about it, there’s a quality of life that is involved. It’s not about just existing. For me, the quality wouldn’t be there if I had the surgery and went through the other things. I decided not to do it. That was a big step.”
In deciding to treat cancer without surgeries and chemotherapy, she had to tell her husband, Scott, son, Garrett, and her family and friends.
I really hate when this happens, because a woman who decides to forgo effective conventional therapy in favor of quackery is giving up her single best shot at surviving her cancer. This was not at that time a woman with metastatic disease that was incurable. Patients with stage IIIA cancer, although they don’t have the best prognosis in the world, are definitely eminently curable with conventional therapy. Unfortunately, Tinkham found one Robert O. Young, whom I’ve discussed here, at TAM7, and at the Trottier Symposium. Young is a proponent of the pseudoscientific idea that essentially all disease is due to “excess acidity” and can therefore be treated with alkalinization. In essence, “Dr.” Young peddles acid-base pseudoscience and the belief that cancer is a “liquid.” One reason that women with breast cancer who decide to opt for “alternative treatment” come to believe that their treatment cured them is because they have had a biopsy that completely excised the tumor. Remember, radiation and chemotherapy only decrease the chance of the tumor recurring after lumpectomy; the lumpectomy itself cures cancer in a significant proportion of cases. However, Tinkham did not undergo an exicisonal biopsy or lumpectomy, only Young’s unscientific and useless treatments. So, after “hyperalkalinizing” her body by changing her diet radically and imbibing all sorts of supplements, did Tinkham’s tumor shrink radically?
No:
She can still feel the tumor just underneath the surface of her skin, where it will probably remain for a while.
But she knows it’s harmless. Now, it’s simply her badge of honor – the reminder that she, Kim Tinkham, defeated cancer without any surgery, invasive procedures, radiation or chemotherapy.
The tumor was still there! Note also that no mention was made of whether the tumor had grown or shrunk. What was most likely going on was that Tinkham was (at the time) fortunate enough to have developed a relatively indolent, slow-growing tumor. So, if the tumor was still there and it was not obviously shrinking, how on earth could Young tell Tinkham that her tumor was gone? Here’s how:
A recent blood test proved that the stage three breast cancer diagnosed in February is absent from her body. But she really didn’t need a blood test to tell her that. Just hours after she had her blood taken for the test, and days before she knew the results, she was confident that her new lifestyle had allowed her body to fight the cancer.
There is no blood test that can tell a woman that she is breast cancer free. None. Moreover, even if she did have a blood test that told her she is tumor free, if the tumor is still there, she should pay attention to the tumor, not to any dubious “blood test” that a dubious practitioner represents to her as having any validity whatsoever in determining the status of her tumor.
How anyone could believe this testimonial is beyond me. Then I did a seearch on Tinkham’s name, and it became clear in accounts of how Oprah Winfrey had Tinkham on her show to discuss her decision to treat her breast cancer with “natural” methods that Tinkham really, really believes in The Secret. The same sort of wishful thinking that led her to fall for nonsense such as the “Law of Attraction” has led her to fall for the science-free nonsense that Young is telling her about her cancer.
Kim Tinkham 2010: Maybe the naysayers (like me) were wrong
After I first heard her testimonial in 2008, so often, I did some Googling about Kim Tinkham. I was happy to see that she actually did quite well for quite a long period of time. The reason I was happy for her was because, as long as the cancer had not metastasized, there was still a chance that Tinkham would see the light and seek out science-based treatment. There was still a chance that she could beat her cancer and live out her natural lifespan. Granted, the chance was probably decreasing by the month, but there was still a chance. By this summer, Tinkham had been alive with her breast cancer diagnosis for well over three years without any treatment other than Young’s acid-base woo. Unfortunately, this level of success also led Kim to believe that her cancer truly was gone, so much so that she started writing a book about her experience entitled Cancer Angel, which had been scheduled to be published this month. Something happened, though, and for some reason Tinkham didn’t get it published and instead uploaded 14 chapters to her blog in May.
In March, she also taped an interview with Robert O. Young and his wife:
In case Dr. Young tries to throw these down the memory hole, I have downloaded copies to my hard drive.
When I first saw these videos, I wondered if I could find out more about what was going on. One thing that Tinkham kept repeating again and again is that she was diagnosed with “stage III” breast cancer. In the video above, Young and his wife kept harping on that again and again. The three of them also complain again and again that there “weren’t any options.” My retort would be: Of course, there were options! Tinkham just didn’t like any of the options presented to her. If the tumor was Stage IIIA (which has been my working hypothesis since I first found out about Kim Tinkham’s story), then there was the option of surgery first. This would have included mastectomy and axillary lymph node dissection (i.e., modified radical mastectomy) or, in the case of a woman with–there’s no way to put this very delicately–very large breasts, it might also have been possible to do a lumpectomy with removal of the axillary lymph nodes. Afterward, chemotherapy and radiation would be indicated. Alternatively, if the tumor was too large to do a lumpectomy, breast conserving therapy might still have been possible if chemotherapy were given first to shrink the tumor. In all cases, if Tinkham’s tumor makes the estrogen receptor, then treatment would have been followed up with five years of Tamoxifen or an aromatase inhibitor, and if the tumor makes the HER2/neu oncogene, Herceptin would have been administered for a year.
Those, for the most part, are the choices, outside of unusual cases. All of these choices would have involved some combination of surgery, chemotherapy, and radiation therapy ± anti-estrogen therapy (Tamoxifen or aromatase inhibitors depending on whether Tinkham was postmenopausal yet) ± Herceptin. Tinkham rejected them. I can understand that she was afraid of them. None of these therapies are pleasant. It would probably have taken her around 6 months or so to get through all of them. She might have suffered complications; she would definitely have lost her hair. But these treatments work.
One thing I found interesting is how Young actually asked some reasonable questions at about the 4:00 mark. He asked if the tumor was aggressive, if it was hormone receptor positive (estrogen receptor positive, in other words). I’d ask the same questions, particularly whether the tumor is ER(+), because that would tell me the most. Some ER(+) tumors, after all, can be very indolent, even when they present fairly advanced. If her tumor were ER(-), I’d be a lot more worried that it was a fast-growing tumor. Then Tinkham said:
I remember them saying something about its being in situ, but, other than that…
If this was true, then Kim Tinkham by definition did not have stage III breast cancer. Ductal carcinoma in situ (DCIS) is by definition cancerous cells in the ducts that have not yet invaded into the breast tissue. By definition, DCIS is considered stage 0 cancer and has a close to 100% five year survival. If Tinkham really did have DCIS, then it’s not at all surprising that she’s still doing well three years later.
In retrospect, it’s obvious that Tinkham almost certainly had invasive cancer, although it is possible that her DCIS progressed to invasive cancer over three years. It also sounds as though her surgeons wanted to remove all the lymph nodes under the arm, which they would not have wanted to do if she didn’t have at least one positive lymph node. It is, of course, is quite possible that, given her lack of detail regarding what kind of cancer she had, Tinkham might well have been confusing the sentinel lymph node biopsy, in which one or a handful of lymph nodes were are removed for testing, with a complete axillary dissection, where all the lymph nodes under the arm are removed. Most stage III cancers require an axillary dissection, while tumors with clinically negative lymph nodes (i.e., lymph nodes that appear normal on physical examination, mammography, and ultrasound) are usually tested with sentinel lymph node biopsy. Sometimes for large DCIS, we do sentinel lymph node biopsies even though DCIS does not in general metastasize to the lymph nodes, because large DCIS lesions often harbor small foci of invasive breast cancer. You don’t want to miss evaluating the lymph nodes at the time of the original surgery, because if the surgery is a mastectomy you can’t go back later and do a sentinel lymph node biopsy. You have to go back and take all the nodes.
One thing about Tinkham’s testimonial as related in the videos that did resonate with me is that she felt rushed. Sometimes we surgeons do that, whether inadvertently or intentionally. Personally, I try very hard not to rush my patients. In most cases I tell them that they have time to decide, that there’s no huge rush, although I would hope they wouldn’t take more than a month to make up their minds. There are exceptions, of course. Nasty cancers that are ER(-)/PR(-)/HER2(-), so-called “triple negative” disease. These tumors tend to be aggressive and fast growing; so I don’t want to fart around. I want to get these women treated. But even for these women, except in uncommon cases, a week or two (or even three) probably won’t make a difference. If there’s one thing we physicians do that can drive cancer patients into the waiting arms of quacks, it’s to rush patients too much. True, there are cancers where delay really is fatal, but breast cancer is usually (but not always) a tumor for which the patient has the luxury of a fair amount of time to decide on a course of action.
Not surprisingly, Tinkham did what Jenny McCarthy did, and attended the University of Google. As she says in her testimonial, she Googled everything having to do with breast cancer, and she repeats how personal choice is the big thing for her. Another thing that resonated with me is that Tinkham kept asking doctors what caused her breast cancer, her criterion apparently being that if someone could tell her what caused her breast cancer she would listen to that person. The problem with this question is not the question but rather not accepting the answer, namely that science, while it does know a lot about what causes breast cancer, can’t (yet) really say what caused any individual patient’s cancer. That’s the honest answer, and that’s what I tell patients every week when I’m in clinic: I don’t know what caused your cancer. I do know the sorts of things that cause or predispose to cancer, but I don’t know what caused yours. I do, however, know how to treat your breast cancer, the odds of success, and the potential complications.
That’s honesty. It’s also humility in the face of biology that we only partially understand.
It’s also based on the realization that breast cancer has a highly variable biology from patient to patient. Because it’s important to understand the natural history of breast cancer, I’ll reference a classic study examining the natural history of untreated breast cancer. It was published in 1962 by H. J. G. Bloom, W. W. Richardson, and E. J. Harries, and examined data from Middlesex Hospital from 1805 to 1933 where 250 cases of untreated breast cancer were identified and studied. They calculated survival as the period of time from onset of symptoms to death. What they found was that 18% of the 250 patients survived five years; 3.6% survived 10 years; and 0.8% survived 15 years. Of note, it was 19 years before all patients were dead. Overall, the median survival was 2.7 years. A survival graph from this classic paper is below:
Fi1
I’ve discussed these issues in much more detail here.
In constrast to science-based practitioners, who are forced to be honest and admit the limits of their knowledge, it’s “practitioners” I consider to be quacks who “know” what causes cancer and lack the humility to admit the limits of their knowledge. Many of them focus on The One True Cause of Cancer, as Hulda Clark did when she declared a common liver fluke to be the cause of all cancer or when Robert O. Young declares that all cancer is caused by “excess acid,” which “spoils” cells and that the cancerous tumor is the body’s reaction to the cells “poisoned” by acid. In other words, such “practitioners” are always in error, biologically speaking, but never in doubt. In their arrogance of ignorance, they exude the confidence that patients like Kim Tinkham seem to need and flock to answers that are simple, neat, and completely wrong.
In fact, Kim Tinkham made it explicit by saying that Young and his wife had told her what causes cancer by saying “there is no such thing as cancer.” Again, remember that Young thinks that cancer is the body’s reaction to cells “poisoned” by too much acid, and he really does say that there is no such thing as cancer. He even goes on and on about how acid being “deposited into the fatty tissues” and thereby causing cancer. From a scientific standpoint, it’s a load of rubbish, pure pseudoscience without any good scientific evidence to back it up. But Young can assert his nonsense about tissue being due to acid “spoiling” tissues with utter sincerity. He looks completely convincing–if you don’t know anything about cancer biology, and most people don’t know much, if anything, about cancer biology. Give him a woman who is afraid, who wants concrete answers, and who has demonstrated that she is fairly clueless about breast cancer, and he can convince her that he has the answer and can cure her. The reason, it appears to me, is that Tinkham (and women like her) just want to believe that someone knows what’s wrong with them and how to fix it. Knowing how to fix it isn’t enough; they want an answer to the question, “Why me?”
Quacks are only too happy to provide that answer.
Unfortunately, we now know that the time Tinkham’s wasted “flushing herself out” with several liters a day and “alkalinizing” herself will soon cost her her life. At the time, I found it difficult to ascertain exactly what was going on with Tinkham and her cancer. I had no objective evidence and no objective tests. All I had were secondhand reports, none of which gave objective measurements of the tumor. We did know that Ms. Tinkham had undergone various useless tests. We did know that she was undergoing various other forms of quackery. We did know that her tumor was still there over three years after diagnosis, but we didn’t know whether it had grown or regressed. Most frustrating of all, we didn’t know how much longer Tinkham had before her luck ran out and her tumor started progressing.
Now we know.
Death by “alternative” medicine: Who is to blame?
Every indication I have been able to find indicates that Kim Tinkham has recently developed lung, liver, and bone metastases and is apparently in bad enough shape that she will soon die of her breast cancer. Her friends, family, and business associates have banded together to raise funds for her and her family, which makes me wonder if Tinkham has medical insurance. After all, if she has insurance, chances are that her final treatment, including, if necessary, hospice would be covered. Based on that suspicion alone, I’m tempted to donate to the fund myself, because I view Tinkham more as a victim of quackery than anything else. That does not mean that I absolve her of all responsibility for her decision. She is, after all, an adult. However, far more blame should go, in my opinion, to Robert O. Young, who claimed he could cure cancer when he can’t and offered Tinkham a false hope of cure without the pain and difficulty of undergoing surgery, chemotherapy, and radiation. It’s “practitioners” like Young who see a weakness or a need to believe in someone like Tinkham and then take full advantage of it. I can’t help but wonder if there are family members and friends who, having seen Tinkham’s choice in 2007, feared the arrival of this day. I wonder what they are going through. It must be truly horrible, particularly the guilt from wondering if they could have done something differently to persuade Tinkham not to take the course she took.
Then, let’s not forget Oprah Winfrey. Oprah Winfrey, after all, rewarded Tinkham’s decision to use The Secret as justification for rejecting science-based therapy and choosing quackery. While it is true that during her interview with Tinkham Oprah appeared distinctly uncomfortable that The Secret had lead Tinkham to reject effective therapy for her breast cancer:
This is part of the therapy that Tinkham is following.
Shockingly, Oprah actually sounds almost reasonable here. Almost. Clearly, she was disturbed enough by Tinkham’s e-mail to invite her on the show. Unfortunately, rather than have Dr. Oz (who, despite his tendencies towards woo in many areas, would be just as disturbed by a woman eschewing effective therapy for her cancer in favor of quackery) look into Tinkham’s case and possibly try to persuade her to accept therapy, Oprah’s first inclination was to get Tinkham on her show because interviewing her would be good television, even more so if the Mighty Oprah could persuade her to accept science-based medical treatment. Too bad the shock of being confronted by someone who used New Age woo that Oprah promoted instead of effective therapy didn’t keep her from later doing things like promoting faith healer John of God. How many Kim Tinkhams are out there who relied on, for instance, John of God instead of Robert O. Young for “healing” and are now dying of metastatic disease? More recently, nearly all mention of Tinkham on Oprah’s website appears to have been thrown down the proverbial memory hole. Search Oprah’s website for Tinkham’s name, and you’ll find nothing other than a couple of mentions in the community forums, such as So, what ever happened to Kim Tinkham? I wonder if Oprah knows what, in fact, has happened to Kim Tinkham. I wonder what she will say when she finds out, and I want her to find out as soon as possible. If there is still time and Tinkham is willing, perhaps Oprah would send a film crew out to Tinkham’s house to show her audience the result of Tinkham’s choice of eschewing science-based medicine in favor of pseudoscience.
The most depressing thing about Tinkham’s testimonial is that it did not have to be this way. It really didn’t. If Kim Tinkham did indeed have stage III cancer in 2007, she would have had (very roughly) a 50-50 chance of beating it if she had only accepted science-based treatment. Not fantastic odds, but way better than the odds she gave herself by not accepting treatment. By refusing science-based surgical and medical therapy, Tinkham reduced her chances to about as close to zero as you can get. Yes, it’s true, even if she had accepted aggressive science-based therapy, including surgery, chemotherapy, and radiation, that Tinkham would still have had a not inconsequential chance of ultimately finding herself in this situation, but refusing therapy guaranteed that, sooner or later, this is where she would come to. It should also not be forgotten that, as Peter Moran has pointed out for other cancer cure testmonials, it’s very common for the testimonials of people who ultimately died of their cancers to persist long beyond their deaths as “proof” that various cancer quackeries “work.” I expect to see the same thing happening with Kim Tinkham, particularly given that no mention is explicitly made on either Caring for Kim or its associated Facebook page.
Finally, I wonder what we as science-based practitioners can do to reduce the number of Kim Tinkhams being victimized in the future by dubious pratictioners. It’s too late for Tinkham, but it’s not too late for others. Ms. Tinkham has spoken over and over again about how she didn’t like the feeling of “being rushed” and how she wanted to “take control.” Doctors offered her options, but they were not options she liked. So she found others, ignoring that they have no science to support them and no evidence to suggest that they do anything to treat cancer. Even for an intelligent woman, the siren song of quackery can be strong. I’ve written about this question before in a post entitled Death by “alternative” medicine: Who’s to blame?, in which I asked: How much are we as a profession responsible when cancer patients seek out quackery rather than effective medicine? The comment thread still holds the record, I believe, for the longest comment thread in SBM history, with over 600 comments. I don’t know the answer, but I do know we need to do a better job at assuaging the fears of someone like Kim Tinkham.
Kim Tinkham has every appearance of being a lovely and vibrant woman who was only 50 years old when she was diagnosed with breast cancer. Potentially, she could have had another 30 or 40 years in front of her, but that’s all gone now. Even in spite of her bad decision, one must note that, after her diagnosis, Tinkham continued to run her own business, edited a local newsletter, and won the First Annual Civility Star Award. She did not have to die, but she is going to die soon. It didn’t have to be this way, but it is.
That is the price of quackery.
ADDENDUM:
In the wake of the revelation that Kim Tinkham is dying of metastatic breast cancer after having rejected conventional therapy for her disease in favor of Robert O. Young’s acid-base woo, Young’s response is now (possibly) known. In the comments after part 6 of Young’s interview with Kim Tinkham, a commenter by the ‘nym of inhisgrace7 reports:
I wanted to find out for myself the truth so I﻿ wrote to Dr. Young and here is his response:
Kim has always made her own decisions about cancer. Before I met her she had decided on her own that she did not want to have traditonal cancer treatments. I have had very little contact with her in the last few﻿ years.
Apparently Young had enough contact with Kim Tinkham to have taped an hour-long interview back in March 2010. For one thing, Kim has only had cancer for less than four years, and he’s been featuring her on his website all along ever since she was on Oprah Winfrey’s TV show–indeed right up to this very writing. Look for his videos and articles featuring Kim Tinkham to disappear down the memory hole, which is why I’ve downloaded web archives and copies of the six parts of the video all converted to QuickTime format. Young won’t erase the evidence so easily.
The rest of Young’s reported response as related by inhisgrace7 goes:
She called me a few weeks ago to tell me she had had breast surgery and her cancer was now in other parts of her body. She felt embarrassed to tell me this news because she had not been living an alkaline diet. Kim and their family are gratiful for the help I had given her over the years. She believes﻿ in the program, as well as the family for improving the﻿ quality and quantity of her life.
Despicable. That’s the only word to describe Robert O. Young. He’s despicable. Look at him try to backpedal, now that he’s faced with a woman whom he promised to cure and who is now dying.
As expected and as is typical of cancer quackery, the victim is being blamed for not adhering to the quack’s regimen, for not believing enough. Even worse, if this response truly came from Robert O. Young, he has just admitted that he’s been lying about Kim Tinkham on his website for at least a few weeks–ever since he got that phone call from her. After all, if this report truly came from him, Young has just admitted that he knew a few weeks ago that Kim Tinkham’s breast cancer had recurred and that she is dying of her disease. Yet he left the videos of her testimonial on his website and YouTube channel, not to mention his blog posts about how well Tinkham is doing. He didn’t even write addenda to update readers about Tinkham’s current condition. Rather, he left these glowing testimonials on the web in order to sell his woo. Look for those to disappear down the memory hole soon, too. Good thing I downloaded copies of Young’s webpage and his videos interviewing Tinkham, too.
Finally, inhisgrace7 reports that Young’s response finished thusly:
I received a beautiful letter from﻿ her son thanking me for all the help and sevice I gave to his mother. Thanks for your inquiry although the person who wrote you has no clue about what she is talking about – Kim has No regrets﻿ for the path she chose. All the best, Dr Young
I have to walk away from the computer now. I’m so angry that I might write something I’ll later regret.

Death from Cancer Quackery – Black Salve Edition
An Australian nurse dies of cancer while being treated by a cancer quack with a caustic substance known as black salve. How and why is this allowed to happen?
Steven Novella on May 23, 2018
Link

One of the frustrating, but also motivating, aspects of promoting science-based medicine is the window it provides into the human psyche. People really are largely driven by the narratives they use to understand the world. We are also vulnerable to other people implanting narratives in us through marketing and manipulation for their own (often nefarious) purposes.
For example, not a week goes by when I am not accused of being a shill for Big Pharma (despite there being zero reality to this claim). Many people just accept this “shill” narrative without really thinking about it, because it fits comfortably with the overall narrative they are being sold. The information and perspective we provide on SBM clashes with the “alternative medicine” narrative they have come to accept, and they can easily wipe away the resulting cognitive dissonance by playing the shill card. As a bonus they get the illusion of taking the moral high ground by falsely accusing us of being shills.
The power of this evolving alternative medicine narrative is even enough to motivate some people to forgo proven cancer treatments, and to rely on magic and toxic snake oil, even as they slowly and obviously die from their cancer. We feel compelled to document some of these cases here because it is a critically important part of why we do what we do. Far from being shills, we truly are motivated to simply protect people from the harms of relying on snake oil.
The death of Helen Lawson
This is a particularly upsetting story, as it shows how extreme these cases can be. It is an enlightening window into the power of desperation that facing a cancer diagnosis can create, and the false hope that misguided or uncaring gurus can sell.
Helen Lawson was a nurse, so you would think that she had enough medical expertise to at least recognize rank quackery, but not when it came to her own health. At 50 she was diagnosed with ovarian cancer, a serious and often terminal disease. She was scheduled for surgery to be followed by standard treatment, but at the last minute canceled the operation.
She had apparently fallen under the guile of a local cancer quack, Dennis Wayne Jensen, who claimed that he had successfully treated many cancers with something called black salve, including his own brain tumor, twice.
Lawson believed Jensen’s claims, and his assurances that he was curing her cancer. This convinced her to forgo standard treatment. Her significant other, Belinda Davies, reports that she begged and pleaded with Lawson to receive real treatment, but she would not listen.
Under Jensen’s ministrations, she became progressively more ill. The skin on her abdomen became bloated and started to break down from the black salve. Davies reports:
Literally above her pubic bone, all across her abdomen almost up to her rib cage, she was raw, mutilated bubbling flesh.
While she was obviously deteriorating, Jensen reassured her that she was being cured. Eventually toward the end, according to Davies, Jensen simply stopped returning her calls. On April 6th Lawson collapsed at home, she was rushed to the hospital and died later that night.
Black salve
Black salve is a common name given to a number of escharotic agents. These are caustic agents that are meant to kill cancer cells. They do indeed kill some cancers (although not all), but also kill healthy cells. It kills cancer like acid would, by indiscriminately eating away all tissue.
This alternative medicine snake oil is curious because it is meant to burn away the cancer, which is one of the standard CAM criticisms of mainstream cancer treatment (cut, burn, and poison). The CAM narrative is versatile, however – black salve is different because (wait for it) it’s “natural”.
Proponents play the “natural” card as if it were a magic wand. They then claim that black salve magically does not affect healthy cells, promotes healing, and leaves no scars behind. They make these claims not only without evidence, but in the face of obvious counter-evidence. Black salve simply burns away flesh, leaving scars and holes in its wake. You can see the disturbing evidence for yourself via this link.
There isn’t much published about black salve and other escharotic agents, but what is published is largely negative. A review, even in a friendly journal, reports:
Based upon an analysis of in vitro constituent cytotoxicity, in vivo post black salve histology, and experience with Mohs paste, black salve is likely to possess normal tissue toxicity with some cancer cell lines being relatively resistant to its effects.
That is some understatement – “normal tissue toxicity.”
Regulation
While we are not an overtly political blog, we do generally agree that there should be some quality control in health care. Most people agree with that basic sentiment, but it does depend greatly on how the question is asked. If you ask people – should untrained practitioners be allowed to practice medicine, giving untested and potentially harmful treatments to clients with serious medical disease? – most people would say no. But if you ask – should patients have the freedom to seek any treatment they wish? – the answer flips to yes, even if in practice these are the same thing.
But in the end, “health care freedom,” “right to try,” or “alternative medicine” are just different ways of eroding the standard of care and remove protections for patients.
This case is happening in Australia, which actually has been improving their protections in recent years. The Health Complaints Commissioner has started an investigation into Jensen and issued an interim order for him to stop practicing medicine while the investigation is ongoing.
Jensen’s response was completely predictable:
Jensen, however, insists black salve “works” and is not an approved mainstream treatment because pharmaceutical companies can’t make any money out of it.
“They don’t want black salve on the market because it cures cancer,” he said in an interview with Fairfax Media on Monday.
        ◦ They really don’t have many cards in their deck, and they just play them over and over – Big Pharma, all-natural, health care freedom.

The sad but unexpectedly hopeful cancer saga of Cassandra Callender
I’ve frequently discussed the stories of teenagers with cancer who either refuse chemotherapy or whose parents refuse chemotherapy for them. The case of Cassandra Callender is the same, yet different, from many of these unfortunate and sad sagas in that she was older when diagnosed with cancer and that she realized her mistake. I can now only hope that it’s not too late for science-based medicine to save her.
David Gorski on June 19, 2017
Link

As Sam Gamgee said at the very end of The Lord of the Rings, “Well, I’m back.”
I’m starting this post this way because some of you might not realize that I was on vacation the last couple of weeks. The post from two weeks ago was written before I left, and last week’s post was a reworking of a post from my not-so-super-secret other blog. This week, in order to ease myself back into the swing of things after a long flight home from Europe (and partially because the wifi was very slow on the flight), I thought I’d recount a case. It’s a case that I can’t believe I’ve never discussed in detail here on Science-Based Medicine before, but a search of the archives demonstrates conclusively that, although I’ve mentioned her name in passing while discussing the case of Sarah Hershberger, I’ve never really discussed the case of Cassandra Callender, and I really should have. Another reason is that right before I left two weeks ago on what for me is the longest vacation I’ve taken in many a year, I became aware of a development in her case that gave me hope.
The reason I mentioned Cassandra Callender in the context of discussing Sarah Hershberger is that, unfortunately, they both share something in common. Both are minors who refused chemotherapy for life-threatening cancers in favor of “natural” healing. There the similarities (mostly) end. Sarah Hershberger, for example, was only 12 years old when she was diagnosed and belonged to an Amish community in Ohio near Akron meaning that cultural issues played a heavy role in her parents’ decision to stop her chemotherapy prematurely. Callender, on the other hand, was 17 when she was diagnosed in 2015, thus making her case more complicated given how close she was to being an adult and able to make her own medical decisions. About a year ago, I thought Callender’s case, like so many of the cases of minors whose parents are chemotherapy refuseniks or who have enough of a “natural therapy” mindset that they don’t have the parenting wherewithal to tell chemo-averse teen that she needs it and is going to get it—period, end of conversation—and then enforce that decision, was hopeless. Now I don’t. The reason is simple. Just before I left on vacation, I became aware that Callender now has a GoFundMe page, and this is what it says:
This page has been set up to help raise money for Cassandra’s 2nd battle against Hodgkin’s lymphoma. In 2014 she was diagnosed and pronounced in remission after 6 months of chemotherapy in 2015. 9 months later in 2016 Cassandra had found out she relapsed with a mass in her left lung and surrounding neck/chest. She spent the whole year using alternative treatments/cannabis oils but unfortunately the cancer became more aggressive. In January of 2017 cassandra [sic] discovered that now both of her lungs are full of masses along with her surrounding lungs , chest , surrounding heart and neck. Cassandra now has to go through a very intensive 6-9 months of chemotherapy, again in hopes that things clear up. Her life expectancy doesn’t look well at the moment and it’s going to be quite the battle . She no longer has a normal breathing capacity and struggles with daily life functions that the sickness brings. She is unable to work, is now behind on bills and overall the financial struggle of going through this process yet again is taking a financial toll on her and her family . Any donations would be appreciated at this time . All donations will go directly to Cassandra. After going through this battle once already, Cassandra looks at life as everyday a gift especially when the next day is not promised.
She even includes a most excellent image illustrating her attitude towards cancer:

The basic story is all too common, but with a twist. The synopsis is that Callender was forced to undergo chemotherapy under court order when she was 17, but didn’t complete it after she turned 18. Instead, she fell in with cancer quack Ty Bollinger, who featured her case in an episode of his incredibly misleading, pseudoscience-packed, quackery-promoting video series, The Truth About Cancer. Unfortunately, she relapsed, after which she continued with alternative therapies for several months until the progression of her tumor disabused her of any notion that what she was doing was effective. Now, happily, she’s undergoing chemotherapy and has a fighting chance. Her story is worth telling in more detail, though, because it brings up many thorny issues, some ethical, and some involving how quacks exploit young people like her. It all began back in 2014.
A diagnosis, a refusal, and a court ruling
In September 2014, Cassandra Callender, then referred to as “Cassandra C” because she was 17 and still a minor, was diagnosed with Hodgkin’s lymphoma. Another thing that makes her case different from that of Sarah Hershberger is that she refused chemotherapy before having received a single dose. Remember that Hershberger underwent two cycles before deciding she couldn’t take it anymore and refusing further treatment. In November 2014, the Connecticut Department of Children and Families (DCF) petitioned the court for temporary custody and ordered Callender’s mother to cooperate with her daughter’s medical care. The court ruled in DCF’s favor, and Cassandra underwent two doses of chemotherapy. Then Cassandra ran away from home on November 18 and was missing for a week. She ultimately returned but then completely refused any further chemotherapy. There was another hearing on December 9, and the trial court ordered that Cassandra be removed from her home and remain in DCF’s care and custody. The court also authorized DCF to make all medical decisions on Cassandra’s behalf. So Cassandra and her mother appealed, and in early January 2015 that appeal was heard.
The court ruled:
The Connecticut Supreme Court ruled Thursday that the state may continue to force a teenager to undergo chemotherapy treatments that could save her life.
The court said that attorneys for the girl — who is 17 and therefore still a minor — failed to prove that she is mature enough to make her own medical decisions.
The teen, identified in court documents as “Cassandra C,” was diagnosed with Hodgkin’s lymphoma in September. Medical experts have testified that Cassandra has an 85% chance of survival if treated with chemotherapy. Without it, doctors say, she likely will die within two years.
And, indeed, Hodgkin’s lymphoma is very treatable, particularly in young adults and children. An 85% chance of long term survival is a typical number cited in these cases. At the time there seemed to be a bit of a disconnect between what Cassandra’s mother and her lawyer were saying:
After the court’s ruling Thursday, Fortin [Jackie Fortin, Cassandra’s mother] told reporters “she should be home with me, her family, her friends, going through a horrible thing with all this and she’s not, she’s been taken away.”
Fortin who was in court alongside her attorney Michael Taylor, also said “this is (my daughter’s) decision, not mine and she’s not making a decision to die.”
And what Cassandra herself was saying:
Cassandra told The Associated Press in an exclusive text interview from her hospital it disgusts her to have “such toxic harmful drugs” in her body and she’d like to explore alternative treatments. She said she understands “death is the outcome of refusing chemo” but believes in “the quality of my life, not the quantity.”
“Being forced into the surgery and chemo has traumatized me,” Cassandra wrote. “I do believe I am mature enough to make the decision to refuse the chemo, but it shouldn’t be about maturity, it should be a given human right to decide what you want and don’t want for your own body.”
There is a myth about cancer that I like to refer to as the myth of the “beautiful death.” Basically, it’s the idea that it’s the chemotherapy that makes the course of the disease so miserable and death from cancer so unpleasant. Although I have only my anecdotal experience here, this misconception appears most common among teenagers and young adults, who haven’t yet started to experience the physical decline of their bodies. Indeed, another such teen, Abraham Cherrix, expressed this myth rather eloquently when interviewed by the ever-irresponsible Sean Hannity. Unfortunately, as I’ve written before, with few exceptions, death from untreated cancer is anything but pleasant or painless.
I’m not a lawyer, but I do understand that Cassandra and her mother appealed based on the “mature minor” doctrine, which exists in many states including Connecticut, that allows minors deemed to be mature enough to make their own medical decisions, even if they conflict with their parents or, in this case, with the court. A good explanation of these issues can be found in this article, which explains that Cassandra and her mother’s case rested on three arguments:
    • Their constitutional rights were violated when Connecticut overrode their demands to cease treatment.
    • Cassandra and her mother also want Connecticut to acknowledge the mature minor doctrine, meaning that the court must decide if Cassandra is mature enough to make her own decisions before forcing her to receive medical care against her will.
    • Common law in Connecticut says a patient can’t be forced to receive care over knowing and informed objection.
The state countered that when all the medical experts agree that chemotherapy is needed to save the life of a minor, then the state has an obligation to step in and make sure that it is administered, just as it has an obligation to step in to stop abuse or neglect. In the end, the court sided with the state, noting a pattern of not going to treatment and bad faith, with promises to see doctors and seek second opinions made, but Cassandra nonetheless missing multiple doctor’s appointments. Also, the fact that Cassandra had run away after having promised under oath to be treated was taken as evidence of immaturity. (This latter one puzzled me; you don’t have to be immature to lie and plot, promising to do one thing and then doing another. Adults do this all the time.) The court also noted that Cassandra was very deferential to her mother and rarely spoke up for herself, in essence letting her mother do all the talking.
An ethical conundrum
Regular readers know that I very predictably come down—and come down very strongly—on the side of making sure that children in these situations obtain treatment. I take a back seat to no one in terms of being a fierce advocate of making sure that minors with cancer get the best chance of living to be happy, healthy adults, regardless of what their woo-prone parents or even they themselves want. Regular readers should also know that I’ve always said that competent adults should be able to choose whatever treatment they want or no treatment at all, even if it will result in their death. That’s why at the time I was very much torn about this case. The reason was simple. Cassandra was 17 and was going to be 18 in September 2015, eight months after the appeal. She was very close to being an adult legally. I have no problem—and never have had a problem—accepting that children are too immature to make such momentous decisions and that parents who refuse to treat children with cancer with appropriate therapy are guilty of medical neglect. Such certainty is easy for 10, 11, 12, 13, and even 14 year olds. Heck it’s easy for 15 and even 16 year olds. But as a child hits 17 and gets closer to being a legal adult, it becomes harder for me to be quite so certain.
Then there are practical matters. Let’s go back to a post I wrote about a similar case of a chemotherapy “refusenik,” in which I noted that, while it may be possible to physically restrain a teen in order to place permanent intravenous access and then, every so often, to give her chemotherapy, it would be very difficult, and there would be nothing to stop her from trying to rip the intravenous access out to prevent further doses, potentially hurting herself, unless she were kept under constant surveillance and possibly even put under anesthesia for her chemotherapy dose. In other words, she would in essence need to be imprisoned for therapy. Then there was the issue of radiation therapy, which requires the cooperation of the patient, who must lie still on the table and do so every day for 30-40 days, depending on the radiation therapy regimen. Sure, Cassandra could have been sedated for each session, but there’s nothing good about sedating someone five days a week for six weeks or so. As I pointed out before, oncologists have a real problem doing this, and for good reason.
In any case, part of the above was basically what happened to Cassandra, although fortunately anesthesia wasn’t necessary except for her port placement, for which a combination of local and IV sedation are routinely used. She was locked away in a hospital and is not allowed to see her mother more than once a week, and then only under supervision. DCF took away her cell phone, and the hospital removed her room’s land line. Fortunately, she was cooperative, but imagine if she hadn’t been.
Exploitation by quacks
Months passed with little or no information that I could glean about what was going on with Callender’s case. Ultimately, she was released from the hospital in April 2015, her cancer reportedly in remission. By August, she was willingly in the clutches of cancer quack Ty Bollinger. Presumably her mother was on board as well, because Cassandra was still 17 at the time; her 18th birthday a few weeks away.
Of course the cancer quackery brigade wanted to interview her, and they did! Also not surprisingly, Bollinger interviewed her for his quack website The Truth About Cancer under the predictably histrionic title “The Medical Kidnapping of Cassandra C (Finally The Truth Revealed) – The Truth About Cancer Exclusive Interview.” Also not surprisingly, the same video was hosted at NaturalNews.com:
It’s disturbing to view.
The first thing I learned from the video was that Cassandra’s diagnosis was delayed, perhaps because of an atypical presentation. She had had severe abdominal pain that was worked up, but, according to her, the doctors couldn’t figure out what was wrong with her. Then her primary care doctor felt a very enlarged lymph node “the size of a golf ball” and treated it with antibiotics. It didn’t go away. So what happened next sounded like a series of needle biopsies, which apparently didn’t provide enough tissue for diagnosis. Ultimately a surgical biopsy was performed, which, according to Cassandra, “looked like” Hodgkin’s lymphoma but that they weren’t sure.
As we already knew, Cassandra didn’t want chemotherapy. In the interview, she justified her decision based on the long term effects of chemotherapy:
I was reading into it. They were saying possible organ failures and difficulty doing physical activity the rest of my life, and I didn’t want that when I knew that there was homeopathic and natural ways of treating cancer.
Sadly, this is a very common rationale, fear of long term chemotherapy side effects. It’s not an unreasonable fear. However, when the alternative is death, the possibility of such long term side effects is not as unreasonable as it would be for a disease that was not so immediately life-threatening. It’s also a false equivalency. Sure, homeopathic treatments for cancer will be a hell of a lot less toxic. They also won’t do anything to treat the cancer. Cassandra would have felt much better for a while taking homeopathy than taking five months of chemotherapy; that is, until her cancer progressed.
There was also an ominous foreshadowing of what was to come in this video, as Cassandra revealed that her cancer might not have been completely eradicated. She referred to a PET scan she had in the month before that “didn’t look good” and how she was waiting for new scans. Not surprisingly, this led Bollinger and Cassandra—but particularly Bollinger—to express disgust that “they” forced Cassandra to undergo chemotherapy and yet there might be some cancer left. Well, as far as the chemotherapy goes, Bollinger needs to get over it. No treatment is 100% successful, and sometimes the first cycle doesn’t completely eradicate the disease. Cassandra related that a few months ago they thought she was in remission but in July her scan “wasn’t clear” and there was something that lit up. The doctors weren’t sure what it is. That, of course, is why chemotherapy for lymphoma requires so many cycles. We found out the hard way decades ago that just one cycle leaves the patient with an unacceptably high risk of recurrence. It takes multiple courses, including initiation, consolidation, and maintenance therapy, to reduce the risk of recurrence as much as possible.
One particularly despicable aspect of this video comes at the 19:20 mark, when Bollinger promised Cassandra that he could help her and show her ways to remain cancer-free, offering to help to get her to September 30 (her 18th birthday) without having to take chemotherapy. Indeed, she and Bollinger discussed how she could engage in a delaying action, pushing tests, appointments, and scans back as far as possible, so that there would be less time for her to receive any treatment again. Cassandra even noted that if it were only three weeks before her 18th birthday no judge would be likely to order her to undergo treatment when the treatment would stop in three weeks anyway. Basically, the two discussed how Cassandra could “run out the clock” and then go to Ty Bollinger, who will hook her up with practitioners who would “detox” her, give her laetrile and/or sodium bicarbonate and/or medical marijuana, put her on an alkaline diet, and subject her to whatever cancer quackery sounds most appealing.
Elsewhere, Bollinger stated that he thinks the “right” to choose natural healing is a fundamental human right, to which Cassandra responded:
I think it’s true. Either way I’m still doing something for my health. A lot of people in media have misinterpreted, saying that I wanted to die of cancer instead of treatment, but that’s not true. I simply didn’t want the chemotherapy, something that was less harmful to your body. Cancer is harmful enough to your body. Why would you want to add more to that?
Later, she said:
I never wanted to die. I wanted another way to live.
One notes that this directly contradicts what she said to AP News in the interview quoted above.
Cassandra also had a fundamental misunderstanding of chemotherapy and cancer:
Your statistics drop if you do chemo and then have to do it for a second time. I had an 85% survival and that won’t be the same if I have to do it a second time. And if they couldn’t cure me at 85, I don’t have any hope that they could do it for anything lower with chemotherapy.
Notice how she attributed the lower survival rate in patients who relapse after treatment to the second cycle of chemotherapy, rather than to having disease that was too resistant to be eradicated by the first course of chemotherapy. I can understand lacking faith that a second round of chemotherapy could cure her after the first one failed; that’s understandable even in patients who accept conventional therapy. In actuality, though, her relapse was an indication of bad disease with a bad prognosis. It’s not the chemotherapy that made it that way. It’s the fact that she had stage III-IV Hodgkin’s disease. Here Cassandra continued to demonstrate magical thinking at every level. She thought that there really is another effective way to eradicate her cancer “naturally” or with homeopathy. There isn’t. Would that there were! I mean, seriously. If there were such treatments, doctors would be falling all over themselves to use them, because we don’t like having to give patients drugs that cause severe toxicity and then dealing with that toxicity and watching our patients suffer.
Relapse and revelation
Eight months after her interview with Ty Bollinger, I learned that Callender’s cancer had relapsed:
A teenager who was forced by the courts to undergo chemotherapy for her cancer says a new mass has been found in her lungs.
Cassandra Callender, of Windsor Locks, disclosed the news Saturday on her Facebook page, posting an image of a CT scan dated Friday.
“This is the mass that is now inside of my lung,” she wrote. “I’ve known about this for a while, but it’s been hard going public with it. But this is why I fought so hard against chemotherapy. I am so sick of being treated like number and how everything is based off of statistics. I am a patient not a number.”
As bad as this news was, her life was still salvageable. To accomplish this would have required a difficult and arduous treatment, however. In general, the treatment of choice for relapsed or refractory Hodgkin’s lymphoma is salvage chemotherapy followed by autologous stem cell transplantation. In other words, the patient’s bone marrow is harvested for stem cells, after which the patient undergoes high-dose chemotherapy that wipes out her bone marrow and then has her bone marrow reconstituted by the harvested stem cells. It’s hard to predict the likelihood of success because I don’t know enough about Callender’s clinical situation, but salvage therapy of this type yields five year overall survival rates in the range of 40-60%.
That’s admittedly not great. It’s horrible indeed to be 18 years old and facing a future of high dose chemotherapy and a bone marrow transplant whose chance of letting her live five years is probably around 50-50 and of rendering her cancer-free for that time is around one in three, one in two at best. After she turned 18, Callender chose woo until sometime around March, which was when her GoFundMe page was posted. I’ll discuss more of what that woo entailed in a moment, but for now it suffices to know that the woo didn’t work and Callender’s disease is progressing alarmingly. Cannabis oils didn’t stop the cancer because cannabis does not cure cancer. Sadly, none of this is a surprise; untreated relapsed Hodgkin’s lymphoma is incredibly unlikely to go away, spontaneous remissions being quite rare, and that’s basically what would have had to have happened for Callender to get better: a spontaneous remission. At least she is finally getting potentially life-saving treatment again.
In actuality, this outcome is not uncommon among those who choose quackery instead of medicine. When it becomes mind-numbingly obvious even to them that the quackery isn’t stopping the relentless growth and spread of their cancer, they go back to the chemotherapy. Unfortunately, by then it is often too late, or they have to undergo a much more rigorous and unpleasant treatment with less chance of success than they had before. But at least now Callender has a real shot at surviving, and I truly hope that she does.
As sad and yet now hopeful her case is, it does illustrate one more thing, specifically the exploitation of young women like Callender and children whose parents also pursue alternative cures for cancer, which I address in the final section.
The exploitation of Cassandra Callender by Ty Bollinger and Hope4Cancer
It’s hard for me to imagine a person more vile and despicable than Ty Bollinger, with the possible exception of Mike Adams. What he did “for” Cassandra Callender was to lead her down a path of quackery that almost kept her from pursuing the salvage therapy that can still save her life, after having used her as a poster child for his quackery in his deceptive pseudodocumentary series The Truth About Cancer.
I strongly suspect that Callender’s choice to return to using conventional medicine in a last ditch effort to save her life explains a puzzling thing I noticed on Facebook while researching this post. In March 2016, about a month before Callender’s relapse made the news, Bollinger posted this on his “Truth About Cancer” Facebook page:
Here’s the interesting thing. The Vimeo link to the video above is dead. Similarly, the link to a similar earlier video from Callender from August 2016 that Ty Bollinger had posted to Facebook is also dead:
So Callender appeared, with Bollinger’s help, to have gone to Tony and Marcy Jimenez’s Hope 4 Cancer Institute in—where else?—Mexico. And, sadly, Hope4Cancer is quacky indeed. Just take a look at what it offers:
    • Poly MVA
    • Vitamin C
    • Immuno-Imagery
    • Full Spectrum Nutrition
    • Alkalinization
    • Coffee Enema
    • Juice Fasting
    • Near-Infra Red Sauna
    • Detox Routines
    • Biological Dentistry
    • Anti-Microbial Therapy
    • Oxygenation Methods
Rule of thumb: Any place that offers coffee enemas to treat cancer is a quack clinic par excellence.
Coffee enemas are such common quackery, though, that it’s hard for me to get too worked up about it being offered by Hope4Cancer. Rather, perhaps my favorite is this treatment, which is not like most of what I’ve seen before:
At Hope4Cancer Institute we require that the patients watch an Immuno-Imagery program, a health imaging video and audio series that promotes health from within. This unique self-imaging system combines the scientific discoveries of psychoneuroimmunology (the study of the interaction between the mind and the immune system) with the latest professional guided imagery and deep relaxation techniques of Emmett E. Miller, M.D., a nationally acclaimed physician specializing in Psychophysiological Medicine.
This comprehensive program contains time-lapse motion picture photography through a microscope of actual immune cells. It reveals captivating animation, coupled with an inspiring narration that describes just how the body defends itself. These images guide the patient through a visualization process that helps activate their immune system. The audio provides relaxation and visualization guidance with soothing music and calming sounds of nature. Dr. Miller comments, “IMMUNO-IMAGERY provides a crucial element in any program designed to support the healing process in a most beneficial way, providing clear, vivid images of healthy functioning immune cells doing exactly what you want them to do within your body.”
Yes, the Jimenezes sell their marks a bunch of videos of animations of how the immune system works with a soundtrack of soothing nature sounds as a method of showing patients how to tell their immune system to attack the cancer. Yeah, that’ll work. (That’s sarcasm, people.) I particularly like the woo babble (like Star Trek technobabble but with woo) about psychoneuroimmunology, proving once again that quacks can co-opt any scientific term in the service of selling stuff.
Then there’s this, which sounds scientific but really isn’t:
At Hope4Cancer Institute we have the technology and know-how to extract, from urine, the proteins that are produced by the cancer cells and develop a vaccine “Autologous Antigen Receptor Specific Oncogenic Target Acquisition” (AARSOTA). This vaccine is administered intramuscularly at specific intervals to promote an antigen-antibody response and provide immunological information to the antibodies. The immunological response enhances specific cancer fighting ability by the body’s defense system.
Tumor markers are measurable biochemicals that are associated with a malignancy. They are either produced by tumor cells (tumor-derived) or by the body in response to tumor cells (tumor-associated). They are typically substances that are released into the circulation and thus measured in the blood. There are a few exceptions to this, such as tissue-bound receptors that must be measured in a biopsy from the solid tumor or proteins that are secreted into the urine.
It all sounds pretty impressive; that is, if you don’t know anything about cancer. What amazed me even more is that the Jimenezes basically admit that what they are doing is complete BS:
As tumor cells grow and multiply, some of their substances can increase and leak into the bloodstream or other fluids. Depending upon the tumor marker, it can be measured in blood, urine, stool or tissue. Some widely used tumor markers include: AFP, beta-HCG, CA 15-3, CA 19-9, CA 27.29, CA 125, CEA, and PSA. Some tumor markers are associated with many types of cancer; others, with as few as one. Some tumor markers are always elevated in specific cancers; most are less predictable. However, no tumor marker is specific for cancer and most are found in low levels in healthy persons, or can be associated with non-neoplastic diseases as well as cancer. Also, no tumor marker test is free of false negatives or false positives.
If you know anything about cancer, you’ll quickly figure out that the above passage basically tells you that trying to make a vaccine out of all these tumor markers isolated from the urine is doomed to failure. In the slideshow that accompanies this woo babble, slide 6 shows a list of cancer vaccines in development by other companies without noting that the antigens being targeted are far more specific to the tumors being treated. The presentation also includes a slide about how whole cell extracts are good sources of cancer antigens, as though this justifies the approach of extracting them from urine. In particular, I note that not a single scientific paper or clinical trial is presented to justify the AARSOTA treatment.
I could go on—and maybe one day will. Let’s just say that the Hope4Cancer website is—shall we say?—a “target-rich” environment for a blogger like me. I’ve just presented enough to give you the idea of what sort of quacks exploited Callender and then dropped her when her recurrent cancer progressed while she was being treated at Hope4Cancer and especially after she decided to actually try to save her life with science-based oncologic treatment.
Discarding “inconvenient” testimonials, or: Heads I win, tails you lose
The case of Cassandra Callender saddens me but at the same time gives me hope. Certainly, there’s no doubt that she got a raw deal, first being diagnosed with cancer and then being on the wrong end of the 85% survival rate for Hodgkin’s lymphoma when her cancer relapsed. However, she still had a decent shot to salvage the situation. It would have been a hard and painful road. The high-dose chemotherapy and autologous stem cell rescue still had about a 50-50 chance of failing. But the flip side of that is it also had a 50-50 chance of succeeding. By choosing quackery, unfortunately Cassandra Callender unwittingly or not chose death, even as she later claimed she was choosing life. Her tumor progressed. Fortunately she appears to have realized her mistake, and I’m overjoyed that she’s finally fallen back on real medicine. I really do hope it’s not too late and that a bone marrow transplant can save her life. Unfortunately, delay is the enemy in cancer, and that’s what quackery did; it delayed the definitive treatment of her relapse by at least a year.
If Callender thinks that the quacks at Hope4Cancer and Ty Bollinger don’t know that, she should ask them why they’ve scrubbed the two videos about her “journey” at Hope4Cancer from Vimeo. (Certainly I couldn’t find them, either using the links in the Facebook posts—of which I’ve taken screenshots, by the way, in case Bollinger tries to flush them down the memory hole too) or through searching Google and Vimeo.
The reason is simple. While Cassandra looked healthy and vibrant and could say her relapsed Hodgkin’s lymphoma wasn’t progressing, here was an excellent testimonial that Bollinger and Hope4Cancer could use to sell their quackery. Once it became very clear that her cancer was progressing, despite all the cannabis oil and other quackery that the Jimenezes could throw at it, her testimonial became much less useful. Indeed, notice how the later one doesn’t say much about the state of her cancer but how she was continuing “to grow in beauty, wisdom, grace, love, and health,” whatever that means in the context of treating a life-threatening disease. Once she decided to undergo bone marrow transplantation to try to save her life, her testimonial then became utterly useless to them, particularly if, as I fervently hope, the treatment is successful and Cassandra survives to live a long, full life.
Unfortunately, as much as I hate to say it, if Callender dies of her disease relapse despite maximal therapy, her testimonial will become useful to Bollinger again. He and other quacks will point to her story and oh-so-sadly and piously say it was because poor, dear, deluded Cassandra was tempted by the evil cancer-chemo-pharma cartel and therefore didn’t stay the course with the Hope4Cancer treatment that she died. The chemotherapy, they will falsely claim, is what killed her, not the cancer. Then they’ll use that story to scare the other marks whose faith might be wavering.
That’s how cancer quacks operate.

Another cancer tragedy in the making
David Gorski on May 14, 2012
Link
I despise cancer quacks.
I know, I know. My saying that is probably akin to saying that the sun rises in the east, water is wet, and Donald Trump’s hair resembles nothing in nature. You know, brain-meltingly obvious statements. It’s true, though. I despise cancer quacks. It doesn’t much matter to me whether the quack is a true believer or a calculating con artist, the end result is the same: People with cancer throwing their one best chance to survive away chasing pixie dust and promises of “natural” cures without the toxicity that is the unfortunate byproduct of the surgery, radiation, and chemotherapy that are the mainstays of our current armamentarium against cancer. I’m a cancer surgeon. This I cannot abide, which is part of the reason I became active promoting science-based medicine, started my other blog, and then was so eager to join up when the opportunity to join this blog presented itself four years ago.
It’s hard to blame patients, too. After all, as I’ve described so many times before, curing cancer is hard. Very hard. Cancer is complicated. Incredibly complicated. Quacks make it sound easy and simple. They postulate One True Cause of Cancer, and, as a result, often what they represent as the One True Cure for All Cancer. Faced with a life-threatening disease and the possibility of chemotherapy, surgery, and/or radiation therapy, patients are understandably frightened and, if they don’t have a scientific background, susceptible to the blandishments of quacks. That’s what happened to a patient I wrote about long ago, and that’s what happened to Kim Tinkham.
It’s also what is happening right now to a woman named Danielle, and, worse, she’s falling victim to the same cancer quack. Worse still, from my point of view, she’s blogging it.
I came across Danielle’s blog because I happen to have a Google Alert for this particular cancer quack, and last week up popped a blog called New Life – A New Beginning. I knew it was going to be a problem when I saw the most recent post Good News!, which featured a credulous video promoting the Gerson Therapy. You might recall that the Gerson therapy was the basis of a movie called The Beautiful Truth that I reviewed a couple of years ago. At first I was going to ignore the blog, given that I’ve written about Gerson, and I would have had to watch several videos if I wanted to write about the most recent post on the blog, but something—curiosity, I don’t know what—compelled me to go to the beginning and read, and what I found was both frightening and, conveniently enough for purposes of this blog, a a perfect introduction to a particularly prevalent form of cancer quackery. Since the blog has only been in existence since January and much of what was posted thus far has been brief, including inspirational poems and prayers, it didn’t take me long to locate the key posts that discuss what Danielle, with the support of her husband Brad, has chosen in lieu of conventional therapy.
The diagnosis and the prognosis
In January, Danielle was diagnosed with breast cancer. In the U.S., this is all too frequent an occurrence, something that happens approximately 226,000 women every year, with close to 40,000 deaths. Danielle is from Canada (note the .ca in her blog and her mentions of going to the Cross Cancer Institute, which is in Edmonton. Ultimately, she decided to travel to southern California, but that’s getting ahead of the story. Let’s first just take a look at Danielle’s own description of her diagnosis in a post she calls (and I give her credit for cleverness here) more infearmation:
Today we met with our oncologist. The cancer is now considered Stage 3. They have not yet completed all the tests to see if it has attached to any other organs, which, if it has, would bring it to it’s final stage of 4.From the MRI results, there is a very large tumor with a large blood vessel feeding into it, along with a couple more tumors in my breast. Many lymph nodes are also full of cancer.
This is an aggressive, fast growing cancer, not run by hormones like most breast cancers are, but by a protein called HER2.
I will begin chemo treatments next week, on Thursday, the 2nd.
If all is clear in the rest of my body, the chemo will go on for 4 1/2 months and then my breast will be removed as well as many, if not all of the lymph nodes on that side. After surgery, I will undergo a month of radiation, five days a week. THEN, they are proposing putting me back on chemotherapy.
I tried to absorb all of the potential side effects that this chemo treatment will bring. I think I’ve gone numb.
As Chloe says every night, “I want my normal life back.”
Yes, I’ve heard this lament all too many times. Cancer patients do want their normal lives back, and that’s completely understandable. Before cancer, they could plan on living into their 70s, 80s, or even 90s; after cancer, it’s not clear that they’ll live even a couple of more years. Their lives have to be put on hold while they endure toxic and invasive treatments that might not even save their lives.
There’s no doubt, either, that Danielle has a nasty tumor. However, it is far from a hopeless situation. As she announced in a later post, there was no evidence on CT scans or bone scans that she had distant metastases (i.e., tumor that’s spread beyond the regional lymph nodes). However, as her husband Brad also characterized Danielle’s disease in a later post, she had stage IIIC disease, which tells me that she either has at least 10 axillary lymph nodes with cancer in them, tumor in the supraclavicular lymph nodes, or tumor in the internal mammary lymph node chain (just near the sternum). Because it’s not possible to know how many lymph nodes have cancer in them without removing them all to look, I presume that this means that Danielle has at least one enlarged supraclavicular node that was biopsied and found to have tumor, which is the most common reason for being staged at IIIC. However, she has no detectable metastases in organs like the lung, liver, bone, or brain. What that means is that Danielle is still potentially “curable” (oncologists don’t like to use that word, but it does convey the possibility of long-term survival and living out the rest of one’s natural life expectancy free from breast cancer), but just barely. In essence, she has cancer that is at the limits of modern science-based medicine to eliminate.
Moreover, it’s certainly true that a tumor that is estrogen receptor (ER) and progesterone receptor (PR) negative tends to have a worse prognosis than and ER/PR-postive tumor. However, in a perverse way, the fact that the tumor is HER2-positive is a good thing. It didn’t used to be. Back before Herceptin, HER2 positivity was viewed as a poor prognostic sign because it portended a more aggressive, less differentiated tumor. However, post-Herceptin, these patients do considerably better because of the efficacy of Herceptin at targeting the HER2 oncogene and shutting it down. We’re now developing other drugs to do the same thing because Herceptin, being a humanized monoclonal antibody against HER2, has to be given intravenously, while newer drugs such as lapatinib can be taken orally.
It also sounds to me as though the oncologists were recommending the appropriate therapy: Neoadjuvant chemotherapy (chemotherapy before surgery) to shrink the tumor, followed by surgery to remove residual tumor, followed by radiation therapy, and then a year of Herceptin (trastuzumab), a targeted therapy against the HER2 oncogene. As brutal as this regimen sounds, knowing what I know in general about patients with stage IIIC breast HER2-positive breast cancer, I can say with some confidence that her situation, although dire, is far from hopeless if she were to undergo the standard-of-care therapy recommended by her oncologists and surgeons. In fact, she might have as good as about a 50-50 chance of surviving five years and a slightly lower chance of surviving 10 years, although her chances are probably less than that. While these are not the greatest odds in the world, they are better than for a lot of cancers, and she can survive this thing. One thing that you need to know about ER-negative breast cancer, it’s that, unlike the case of ER-positive tumors, which, although they have a better overall prognosis than ER-negative tumors, have a nasty tendency to recur later than five—or even ten—years, for ER-negative tumors five year survival is actually a pretty good surrogate for long-term survival. The reason is that for ER-negative tumors late recurrence is a lot more uncommon. ER-negative tumors (particularly the so-called “triple negative” tumors, which have neither ER, PR, nor HER2), tend to recur early, within three years, if they’re going to recur at all, and the vast majority of deaths from triple-negative and ER-negative disease tend to occur before five years.
Just to give you an idea, I refer you to this table from the American Cancer Society, and then to two graphs. Data from the table are from patients diagnosed in 2001 and 2002. As you can see, the estimated survival for patients with stage IIIC cancer is 49%.
This agrees with graphs I generated by using Adjuvant Online. For those of you not familiar with Adjuvant Online, it’s a website that uses data from the medical literature to provide estimates of expected outcomes for various treatments of different cancers. It’s unfortunate that it doesn’t include HER2 status and the results of Herceptin therapy yet. AO is, unfortunately, a few years behind the times because in the estimation of its authors the long term data for Herceptin is not yet mature enough to incorporate into their models. No doubt that will be remedied in the future edition being worked on now. However, we can approximate Danielle’s case by combining facts (that her cancer is ER-negative) with some educated guesses (such as her age, which appears to be fairly young) and assuming that the tumor has the worst characteristics possible. So I assumed that Danielle is 40 years old, listed her tumor as ER-negative, and chose the worst grade for it. I then made some reasonable guesses about potential characteristics and produced a few graphs, which I’ve arranged from worst to best. I did this because I don’t know enough about Danielle’s situation to be more precise:
As you can see, the estimates of Danielle’s prognosis range from, at worst, around a 30% chance of surviving 10 years to nearly 50%. Because Danielle’s cancer is HER2-positive and could benefit from Herceptin, I’d tend not to be as pessimistic as the lowest estimate and place her chance of surviving 10 years somewhere between 40-50%. As I said before, these odds are anything but great. They are, for example, very different from the 90%-plus chance women with stage I breast cancer have of surviving their disease. But they are far from hopeless. More importantly, look at the green part of the graphs. They represent the chance of surviving ten years with surgery alone. The odds of surviving ten years with surgery alone ranges from 5% to around 19%. Without surgery, it’s virtually zero, and her chance of living even five years without treatment is quite low. And, make no mistake about it, no treatment is exactly what Danielle has chosen.
So why would a relatively young woman with everything to live for choose something that has no chance of saving her life over something that has perhaps a 40% chance of saving her life? Let’s find out.
Enter the quack
Somewhere, somehow, somewhen, Danielle, as is the case for so many breast cancer patients, went on the Internet. While the Internet can be a fantastic resource for information on cancer, it is also, unfortunately, also a fantastic resource for quacks to use to spread slick, seemingly reasonable propaganda for their pseudoscience for very little expense. For instance, on February 5, Danielle was very enamored of an article by someone named Gregory Delaney that’s been floating around the Internet entitled Curing Cancer with Baking Soda: What MD’s and Naturopaths Don’t Know. The article, as you can tell from its title, is a load of pseudoscience, indicating a complete lack of understanding of cancer. Delaney also rants against oncologists as “disciples of fraud” and claiming that the cancer is not the disease, but rather a manifestation of…something else. Instead of embracing the claim that cancer is a manifestation of buried emotional trauma (as do the German New Medicine and Biologie Totale), Delaney embraces the claim that cancer is not a disease but rather a “reaction of cells to various factors that will cause their death if they do not devolve to a lower, cancerous state.” His solution? Just what the title says: Cure cancer with baking soda!
Given that foreshadowing, it’s sadly unsurprising that, in Danielle’s case, the Internet apparently ultimately led her to one “Dr.” Robert O. Young. We’ve met Young before doing what he’s doing here, leading a woman named Kim Tinkham away from effective treatment and, in essence, to her ultimate death, but I’ve never discussed his beliefs other than briefly. I mean to remedy that situation now. Basically Young believes in “alkalinization” über alles as a cure for not just cancer but all disease, and that’s why he calls his variety of cancer quackery “pH Miracle Living.” Young even goes so far as to label his “understanding” of cancer as the “new biology,” which sounds way too much like the German New Medicine and Biologie Totale. But first, let’s hear about Danielle’s decision from her own keyboard:
Today I told the Doctors that I will not be using conventional methods to treat this, at this time.
I know it has been effective in saving so many lives, but this was MY decision.Given that I was told, due to the aggressive nature of this particular cancer, that these treatments may or may not cure this, they may only extend my life by a few months, the cancer may return, I would most likely suffer heart damage, the irreversible shut down of my hormones, the destruction of my immune system, the loss of my lymph nodes, my energy, my breasts (would likely remove the other as precautionary), my hair temporarily, and the list went on and on… I would head into surgery with no immune system and then when I’d recovered from that blow to my body, I would undergo rounds and rounds of radiation, and while healing from the trauma of that I would be put back on chemo therapy and my immune system again would be destroyed, and if I ever got sick while on these treatments it would be a life or death emergency.
We have discovered extensive, empirically founded research and proven results with many alternative treatments for cancer. There are no guarantees either way, so all I have is the information I have been given, the life I have been given, and the choice of how I live it, for me and for my family.
I am working with a microbiologist Doctor, whose knowledge and practice has resulted in phenomenal outcomes, to implement an intense protocol that will heal my blood.
I’m simplifying things quite a lot here. I realize this won’t make sense to many of you, but for me, this makes the MOST sense; at least, to have this treatment be my FIRST line of defense.
We will receive regular tests and monitor my progress.
I’d hate to be Danielle’s oncologist. What a moral dilemma he must have! As a doctor, you don’t want to abandon a patient, but on the other hand you can’t support this sort of pseudoscience.
Yes, this “microbiologist Doctor” whose practice has allegedly “resulted in phenomenal outcomes” is “Dr.” Robert O. Young. Young bills his treatments as “pH Miracle Living” and even goes so far as to label his “understanding” of cancer as the “new biology.” His “new biology,” however, is nothing more than a mish-mash of old quackery involving live blood cell analysis with his own special (and not so original) spin on “alkalinizing” the blood. For instance, here is what YOung thinks to be the cause of cancer:
Cancerous tissue, above all other consequences of choice, has countless secondary causes. But even for a cancerous condition there is only ONE PRIME ORIGIN and CAUSE. I have simply summarized this origin and cause of cancerous tissue in a few words. The prime origin and cause of cancerous tissue is the over-acidification of the tissues then the blood due to lifestyle and dietary choices. A cancerous tissue begins with our choices of what we eat, what we drink, what we think and how we live. Cancer is a liquid and this liquid is a toxic acidic waste product of metabolism or energy consumption.
All of which is so wrong that it’s not even wrong. But there’s more:
The following is a summary of understanding cancerous tissues:
Cancer is not a cell but a poisonous acidic liquid.
A cancer cell, is a cell that has been spoiled or poisoned by metabolic or gastrointestinal acids.
A tumor is the body’s protective mechanism to encapsulate spoiled or poisoned cells from excess acid that has not been properly eliminated through urination, perspiration, defecation or respiration.
The tumor is the body’s solution to protect healthy cells and tissues.
Cancer is a systemic acidic condition that settles at the weakest parts of the body – not a localized problem that metastases.
Metastases is localized acids spoiling other cells much like a rotten apple spoiling a bushel of healthy apples.
There is no such thing as a cancer cell. A cancer cell was once a healthy cell that has been spoiled by acid.
The tumor is not the problem but the solution to protect healthy cells and tissues from being spoiled from other rotting cells and tissues.
The only solution to the acidic liquids that poison body cells causing the effects that medical savants call cancer is to alkalize and energize the body.
In conclusion, the human body is alkaline by design and acidic by function! If we desire a healthy body we must maintain that alkaline design.
When I pointed out the similarity between the German New Medicine and Robert Young’s quackery, I wasn’t kidding. Both view the tumor as not being the actual disease but rather a “reaction” to something else. In the case of the German New Medicine, the tumor is supposedly a reaction to past emotional traumas; in the case of Young’s beliefs, it’s a reaction to “overacidification” of the tissues. To fight this “overacidification,” Young recommends a whole host of treatments, mostly dietary, and claims that they will cure cancer.
We get an idea of what this involves just by looking at some of of Danielle’s posts. First, let’s look at what Young told Danielle, as reported by her. The causes of Danielle’s breast cancer include, according to Young, rarely drinking water, not eating consistently, eating big meals, eating sugar, not taking deep breaths, being indoors too much, being under stress, being impatient and judgmental, not getting enough sleep, having a “clogged up digestive system” (remember the “toxins” and colon flushes), having blood “full of yeast,” and, of course, being exposed to all sorts of “toxins.” It’s a veritable cornucopia of nonsensical ideas about human physiology that have little or no (with an emphasis on “no”) grounding in science. In fact, one wonders how Young can keep all these causes straight and how he relates them all to “overacidification” of the blood, because apparently, according to him, virtually anything can cause overacidification of the blood.
If you look more closely at Young’s writings, it’s not hard to find that there is almost no form of quackery that he does not embrace. For instance, he is a germ theory denialist:
One must challenge everything in the modern construct of immunology and what is said to be the immune system. The basis of modern immunology is founded on Louis Pasteur, the fraud, impostor, deceiver and self promoter. There is a serious problem to where every word and part of the anatomy must be questioned to find their use and function because of the fraud of Louis Pasteur.
If you really want to see how far he’s willing to take it, look at Young’s explanation of what antibodies are. Not for Young is the standard explanation that antibodies are part of the immune system that bind to specific antigens and assist in the neutralization and elimination of invading microorganisms. Oh, no! Young knows what antibodies really are:
My final example is in defining the truth about antibodies and antigens. Antibodies are chemical clusters or alkaline buffers to a typical acidic condition properly referred to as antigens or enzymes. So called antibodies are released from healthy organ cells, such as the liver, in response to buffer and neutralize the acidity or liquid acid antigen that was first introduced. It must be noted that the word, antibody and antigen, are a Pasteurian dogma construct. The mind set being that an antibody or now even antibiotics, are defending or responding to bodies, microbes or invisible bodies or what I call phantom viruses, like Avian, SARS, or even HIV — even though HIV is not a virus but an alkaline antibody to buffer acid or antigens. The chemical response is actually due to an introduction, vector or antigen of a chemical nature, typically acidic, not a body, microbe or bacteria or yeast.
The above statement reveals such a fundamental misunderstanding of the biology of the immune system—indeed of biochemistry, given that Young apparently thinks that antigens are not really proteins and has no clue what their function is—that it boggles the mind. To him, the known function of antibodies is nothing but “Pasteurian dogma” (never mind that antibodies weren’t discovered until long after Pasteur’s discoveries), and their real function is to buffer acids with alkali, an idea that would certainly come as news to immunologists, biochemists, and physicians. Indeed, so much of a germ theory denialist is Young that when a young Brazilian model tragically died of bacterial sepsis, he blamed it on acid:
Ms. Bridi da Costa, at the young age of 20 died from systemic acidosis from the lack of proper alkaline treatment. Acidic drugs, such as antibiotics and metabolic acids ravaged her body which forced doctors to perform amputations of her extremities and extract part of her stomach as well as both kidneys. I strongly believe that Ms. Bridi da Costa would be alive, healthy and strong today, if, the prevailing 19th Century germ theory medical dogma and subsequent acidic treatment protocols of antibiotics would have been simply replaced with alkaline fluids of sodium, magnesium and potassium bicarbonate and alkaline water and foods.
And:
Body cells transform or breakdown to bacteria and yeast and then to mold as a result of excess tissue acidity and not from an infection from the atmosphere. Therefore, Germs DO NOT CAUSE DISEASE but are the result of excess tissue acidity not eliminated through urination, perspiration, respiration and/or defecation! Acid is the only CAUSE of dis-ease and disease, including sepsis!
Also, apparently viruses are not the cause of disease, but rather “molecular acids.”
I should have remembered: Young is a follower of Antoine Béchamp. He’s a germ theory denialist. Béchamp, as you may remember, was a contemporary of Louis Pasteur and proposed a competing hypothesis for the cause of infectious disease, which he dubbed the pleomorphic theory. The concept he championed was that bacteria do not cause disease but are rather a manifestation of disease. In other words, diseased tissues produce bacteria, arising from structures that Béchamp called microzymas, which to him referred to a class of enzyme. Béchamp postulated that microzymas are normally present in tissues and that their effects depended upon the cellular terrain. Of course, as we all know, ultimately Pasteur’s ideas won out based on evidence, experimentation, and clinical observation, relegating Béchamp to more or less a historical footnote. In fairness, it should be remembered that, 150 year ago, it wasn’t entirely clear who was correct, Pasteur or Béchamp. Given the technology and tools of the time, it was not a trivial matter to determine where bacteria arose, although it didn’t take long before experiments and methodology were developed that pretty much put Béchamp’s concepts to bed for good.
Except for people like Robert O. Young. His ideas incorporate Béchamp’s 150 year old ideas
I could go on and on and on. Truly, as Stephen Barrett put it, there’s so much pseudoscience and misinformation in Robert Young’s books and beliefs that it would easily take a book to refute them all. In the meantime, I thought it would be worthwhile to take a look at just what following Young’s regimen to treat cancer entails. Danielle, it turns out, provides the details in a post she entitles A Day in the LIFE. Truly, it’s a daunting list of “treatments,” including drinking mineral salts, drinking one liter of alkaline water, taking a “pile of supplements” (Danielle’s words, not mine), drinking another liter of water with chlorophyll and concentrated green vegie powder (what are we, plants, that we need chlorophyll?), eating a liquid meal, doing a colonic, drinking another liter of green water, checking her body’s pH, taking some more supplements, drinking a fourth liter of water, having another liquid meal, drinking a fifth liter, taking some more supplements, drinking a sixth liter of green water, sitting in an infrared sauna, taking a salt bath, dry brushing her skin, and—of course!—taking more supplements.
Wow. And Young complains that conventional medicine takes a lot of effort.
There is no science behind Young’s beliefs. He combines germ theory denialism, vitalism, and a complete misunderstanding of acid-base physiology into a toxic brew with which he entices his marks. Contrary to what patients like Danielle are told, there is no large, robust body of research supporting his approach. There is no evidence that what he does makes any difference whatsoever, while there is copious evidence that foregoing effective treatment greatly increases a cancer patient’s risk of death.
Why do cancer patients fall for this?
It’s not that difficult to understand why Robert O. Young’s message is so seductive to cancer patients. He offers hope where conventional oncologists and surgeons are ethically and professionally obligated to offer their best assessment of the patient’s prognosis and what results they can expect with science-based therapy. Quacks like Dr. Young are not constrained by the truth. It works, too, unfortunately. If you don’t believe me, look at this post by Brad, Danielle’s husband, in which he answers the criticisms of an anonymous commenter who had the temerity to point out that Dr. Young has no scientific credibility. Perhaps the most telling passage from that post is this:
We discovered that the prognosis for this type of cancer was pretty grim, no wonder the “Dr’s” were so tight lipped about the efficacy of their treatments. When talking with them, we received NO sense of reassurance, or confidence that their treatments would work to remove the cancer; they were confident about removing the tumor though (not to mention her breast and the majority of her lymph nodes on her left side). “But wait a second, what?!” – we assumed chemo, surgery, and radiation were a sure thing. No? Well… the research shows that, on average, a person lives 3-4 months longer when these treatments are used (if you’re able to survive the treatments of course). Three to four months longer, that’s statistically significant according to the research because she’s only expected to live 23 months without it, so 26-27 months is significant, statistically speaking – (“who cares about quality of life for the remaining MONTHS of your life, right?”).
What the doctors were CERTAIN about were the side effects. In fact, we heard about 3 hours worth of side-effects related to their proposed treatments. They said, “so, the cancer may grow resistant to the treatments we bombard it with. We can pretty much guarantee heart damage, with a side of intestinal destruction, and we know we can absolutely destroy your immune system and anything else your body could use to heal. And to top it off, you get to lose your hair, have no energy and walk around like a zombie. Don’t worry, as soon as you feel better we’ll make you feel terrible again… how about it?!” I was quite unimpressed when I knew more than the “oncologist” did (thank-you research) about the functional mechanisms of one of the drugs she was proposing to use. Ummm… awkward!
Somehow, if Brad’s posts are any indication, I doubt that he understood the functional mechanism of drugs better than the oncologists, particularly if he was repeating the same sort of misinformation and misunderstanding that Robert O. Young promotes. I’m also a bit confused. The discussion that Brad relates sounds very much as though the oncologists were assuming at the time that Danielle’s cancer was metastastic. When we as oncologic surgeons and oncologists discuss treatment options with potentially curable patients, we do not usually speak of median survival times. Far more often, we tend to talk about the odds of producing a five- or ten-year survival. In other words, we talk in terms of what the odds of a cure are with various treatment options. We usually don’t switch to “median survival discussion mode” until after it has become clear that long term survival is no longer possible, as in the case of stage IV disease.
Unfortunately, some patients, like Danielle and her husband, don’t see shades of gray. Rather than looking at probabilities, they see things in black and white. Cure or no cure:
And, if you have any empirical research to add to the already existing mountain of research we do have, please send that our way. Also, please let us know if you have access to a genuine crystal ball or a personal Mount Sinai, otherwise, it may be best to leave the predictive outcomes for God to decide. It may be difficult to accept the decision that Danielle has made in choosing life. I just want you to know, for as long as we have life, we stand beside you in hope and dignity of human life.
“Mountain of research”? More like the University of Google. As I’ve pointed out so many times before, it takes a significant amount of background knowledge to interpret the medical literature, and most people simply don’t have it, no matter how much they think they can just “pick it up as they go along.” Conventional oncologists, being science-based, are obligated to discuss their best estimates of what they can do for a patient and how likely their treatments are to result in cure. Young, on the other hand, is free to cater to fantasy and promise that he can cure diseases that conventional medicine can’t. In other words, he can say that he can cure patients like Danielle without toxicity. Whether he really believes it or is lying, I don’t know, but he can—and does—say things like this. For instance, Young claims that he knows about “natural inhibitors” of HER2 that will cure HER2-positive cancers, even though that there is no evidence that anything he recommends actually does anything of the sort.
Of course, Danielle can’t stay in California indefinitely; so she apparently didn’t. She headed back to Edmonton and has put together her own team of “alternative” medicine practitioners, including a naturopath who has her on on intravenous vitamin C & B12, as well as Mistletoe by injection. She also claims to be using an osteopathic doctor who’s making a cancer vaccine of some sort to help her. Now it’s true that anti-HER2 vaccines are a hot area of research, it’s a really hard thing to do. It takes a large and dedicated team of scientists and clinicians, a facility certified to make biologicals suitable for human use, and a lot of expertise and resources that I highly doubt this osteopath has; that is, unless he’s the principal investigator of a team working on such a vaccine at a major research institution. In other words, Danielle’s bringing Dr. Young’s quackery home with her and finding enablers to help her. Again, I have to wonder what her oncologist thinks. That’s a moral dilemma I’d hate to have to face: Keep following Danielle and ordering tests on her. Maybe the oncologist hopes that once it becomes clear that Dr. Young’s quackery is not working there will still be time to treat her and possibly save her.
I really hate seeing blogs like Danielle’s and stories like hers and others I’ve seen. They make me feel so helpless. I know, using science, reason, and logic, that Danielle has chosen a path that precludes her one and only chance of survival, science-based treatment, in favor of what I consider to be quackery. Her chances might not be that great with conventional therapy. I understand that. I understand, as much as it is possible to understand without actually having cancer myself, the sense of hopelessness she must have felt when she was told she had stage IIIC breast cancer. Unfortunately, her chances following Robert O. Young’s quackery are about as close to zero as I can imagine. Worse, even if conventional therapy can’t save Danielle’s life, it can provide good palliation, something Robert O. Young can’t do. There are few more unpleasant complications of breast cancer than a tumor that grows until it erodes through the skin and turns into a fungating, ulcerating, bleeding, stinking mass on a woman’s chest wall. I’ve written about this before, specifically the case of Michaela Jakubczyk-Eckert. (Note: The photos at the link are not for the weak of stomach.) Not only is Danielle foregoing her one and only shot at survival (and it’s a reasonable shot, too), but she’s giving up her chance for decent palliation and preventing the fate that Jakubczyk-Eckert suffered.
Danielle, I’m afraid, is another cancer tragedy in the making. I only hope that she realizes her error before it’s too late. Her latest report might sound as though things are going well, but it’s the calm before the storm. Even nasty tumors like Danielle’s sometimes go through periods where they don’t grow much or where they even shrink a little. Inevitably, they start growing again. Danielle’s already wasted over three months of time that she could have been using fighting her cancer with effective therapy. I hope there’s still time left for her.

   The case of chemotherapy refusenik Daniel Hauser
David Gorski
Link
I’ve written before about clinical trials as one place where “the rubber hits the road,” so to speak regarding the interface between science-based medicine and actual medical practice. Another critical place where an equal amount of rubber hits an equal amount of road is how the medical system and the law deal with the medical care of minors. In the vast majority of cases, parents take their children to physicians ostensibly practicing science-based medicine and, more or less, follow their advice. One of the more common areas where there is resistance to science-based medicine is, of course, the issue of vaccination, which I and other bloggers at SBM have written about extensively. Another issue, which has not yet been touched upon on this blog, is what to do about parents who refuse chemotherapy for their children with curable childhood cancers or children who refuse chemotherapy whose parents either agree with them or are unwilling to do the hard work of convincing their children that they must undergo therapy. Most often, the reason cited by such “chemotherapy refuseniks” is either religion or a desire to undergo “alternative” therapy rather than conventional therapy. One such case, a particularly high profile one, has been in the news over the last couple of weeks. In this post, I plan to discuss the case of Daniel Hauser, a 13-year-old boy from Minnesota with Hodgkin’s lymphoma who, after one round of chemotherapy, is currently refusing further therapy. This case ended up in court (as these cases often do) and led to a decision that is likely to satisfy no one (as these cases nearly always do).
Before I discuss Daniel’s case in more depth, however, let me make one thing clear. From my perspective, competent adults have the right to choose whatever treatment they wish–or to refuse treatment altogether–for virtually any condition. The sole exception that I can think of would be the case of a highly contagious infectious disease, where society has a right to prevent epidemics and, if necessary, quarantine someone who refuses treatment and refuses to avoid interaction with others. Note, however, that the right competent adults to choose whatever quackery they desire should in no way be construed to imply that quacks have any sort of “right” to provide them with quack treatments. The reason is that providing such treatments inherently involves making claims for them that are not supportable by science. In essence, selling such treatments involves fraud, even if the practitioner is a true believer and just as deluded about the efficacy of the woo he is selling as the person buying it is. Be that as it may, if a competent adult wants to refuse treatment and understands the consequences, then I will call him a fool if what he has is a potentially very curable disease like Hodgkin’s disease and chooses bogus (word choice intentional) alternative “cures” instead, but it’s his call.
However, from my perspective (and that of the law in most states) the key to such self-determination is that the person must be informed of and understand the consequences of his actions, and there are three components to this understanding. First, of course, is mental competence; i.e., no serious untreated mental illness that impairs a person’s ability to perceive reality can be present. Untreated schizophrenia, for example, can definitely interfere with a person’s ability to evaluate information. The second is the ability to understand the disease and what the consequences of treatment or doing nothing are. That is why adults with mental retardation severe enough to prevent them from understanding are in general not considered competent to make such decisions. Indeed, it is why parents are expected to act on the behalf of their normal children to make such decisions. Finally, there is informed consent. A person refusing treatment must be told the consequences of his refusal and acknowledge them. Whether he believes what he is told is another matter, but it is not up to physicians to force treatment on someone just because that person doesn’t believe what they tell him, as long as the first two conditions are met.
The conflict arises when a parent decides to pursue quackery for a life-threatening but potentially curable illness for a child or a child refuses therapy. It is on such occasions that society as represented by the state has a compelling interest in overriding the parent’s decision and making sure that the child gets the best science-based treatment available. It is also a situation when parental rights, rights of self-determination, and the legitimate interest of society in protecting children can all clash in a most chaotic and nasty manner. That is exactly what is at issue in the case of Daniel Hauser, as described in a news report of the testimony given in his case:
Daniel Hauser has what doctors consider one of the most curable types of cancer, Hodgkin’s lymphoma.
But the 13-year-old from Sleepy Eye, Minn. and his parents don’t want him to have chemotherapy and radiation, the standard treatments. For the past three months, they have ignored the advice of his cancer specialists and turned to natural therapies, such as herbs and vitamins, instead.
Daniel and his parents are justifying this decision using religion:
Daniel, one of eight children, has asserted that treatment would violate his religious beliefs. The teenager filed an affidavit saying that he is a medicine man and church elder in the Nemenhah, an American Indian religious organization that his parents joined 18 years ago (though they don’t claim to be Indians).
“I am opposed to chemotherapy because it is self-destructive and poisonous,” he told the court. “I want to live a virtuous life, in the eyes of my creator, not just a long life.” He also filed a “spiritual path declaration” that said: “I am a medicine man. Some times we teach, and some times we perform. Now, I am doing both. I will lead by example.”
Straight to the grave, I was afraid at the time I first read that report.
As mentioned in the news report, Daniel has Hodgkin’s disease, which is a form of lymphoma. In its early stages, it is highly treatable with chemotherapy and radiation. Whenever I see a case like his, I always try to figure out exactly what stage the child’s cancer is, so that I can get a better estimate of what his true chances of survival with treatment are. I found more information in a more detailed account of the beginning of the court hearing, which included an account of the testimony thus far. Specifically, Daniel has nodular sclerosing Hodgkin’s disease and a mass in the middle of his chest. He was diagnosed earlier this year after he suffered symptoms of fatigue and weight loss, the latter of which is important, because such symptoms are known as “B” symptoms and portend a poorer prognosis. In any case, according to this account, Daniel has stage 2B Hodgkin’s disease (more than one lymph node basin involved but on the same side of the diaphragm, plus B symptoms), which explains why chemotherapy is being recommended. Patients with stage 1 Hodgkin’s disease can be treated effectively with radiation therapy alone, but stages 2 and above generally require the addition of multimodality chemotherapy, usually a regimen abbreviated ABVD, which consists of Adriamycin, Bleomycin, Vincristine, and Dacarbazine. With such a regimen, a boy like Daniel could expect a chance of long term survival of around 85-90%, possibly higher. Without therapy, Hodgkin’s disease is almost always a death sentence.
In testimony, Daniel’s mother reported that this is how they are treating Daniel:
Olson asked how Daniel’s cancer was being treated. Colleen said they are treating it by “starving it, by not feeding it.” She said she found some information on the Internet and started giving Daniel high-PH water, many supplements and an organic diet that includes lots of greens and lightly-sauteed rice.
This brings up two observations. First, there is no doubt that dietary changes and “ionized water” (the latter of which is, by the way, the purest quackery and has no value against cancer whatsoever) will not make Daniel feel as sick as the chemotherapy did. Ditto the “high pH water,” which sounds very similar to Robert O. Young’s pH quackery. Of course, over time the lymphoma will do quite a good job of that until Daniel eventually dies. Chemotherapy is no walk in the park, but it’s nothing compared to death by untreated lymphoma, and at least the chemotherapy can save Daniel’s life. Many times, chemotherapy refuseniks, who feel good for the moment off of chemotherapy, labor under the delusion that, even if they die, at least they won’t be as sick as they would be if they took the chemotherapy. All too often, they learn to their dismay, just how much of a delusion that belief is, and then it’s too late.
One of the issues complicating this case is that it is being framed as a freedom of religion. Usually, such issues do not involve cancer. I’ve discussed such issues here before elsewhere, although rarely for cancer patients. For instance, there was the case of the child who relied on prayer instead of medicine for their daughter’s type I diabetes, leading her to die of untreated ketoacidosis. Christian Scientists believing in prayer over medicine and Jehovah’s Witnesses refusing blood transfusions on the basis of a highly tenuous intepretation of a single passage in Leviticus also come to mind as other examples. In this case, Daniel is claiming to be a medicine man and church elder in a cult of faux Native American wannabes called the Nemenhah, a group led by Philip “Cloudpiler” Landis (who really should be called “Woo-Piler”), a white man who claims to be a naturopath and Native American “healer” peddling “cures” for AIDS and cancer. Cloudpiler has also been involved in another case of a teen (Chad Jessop) who refused effective therapy for melanoma, opting instead for a caustic treatment known as black salve. Indeed, “Chief” Cloudpiler even commented on a blog criticizing the court hearing the case. In general, however, although the First Amendment guarantees freedom of religion, it is not an unlimited freedom, any more than parental rights over their children are unlimited. The state can and should step in to protect a child endangered by very clearly magical thinking. And, make no mistake, this is magical thinking, as this interview with Daniel’s mother shows:
“We believe in traditional methods. To strip that away would be stripping his soul right out of his body,” she said.
When Olson asked more questions, Colleen Hauser said she understands Bostrom’s point of view but does not agree that Daniel’s cancer will metastasize. She said she would give permission for chemotherapy treatments if it were a matter of life and death, but would not agree to routine treatments. She said the survival rate with traditional medicine is “one hundred percent.”
This is magical thinking that will kill Daniel if allowed to stand. Mrs. Hauser seems to think that right now Daniel’s life is not in danger. While it is true that his life is probably not in immediate danger at the moment, it is most definitely in a lot of danger, and the danger grows the longer treatment is delayed. For one thing, the reason that chemotherapy is “routine” right now for Daniel is because he is in a relatively early stage, and the tumor is not causing complications that are immediately life-threatening, such as superior vena cava syndrome or airway obstruction. In other words, chemotherapy is semi-urgent in that it shouldn’t be delayed weeks or months, but doesn’t have to be started tomorrow. There is some time to deliberate and formulate the best science-based treatment. However, waiting too long runs the risk of the tumor’s growing and further spreading. If it does that, then stage 2B Hodgkin’s lymphoma can turn into stage 3 and stage 4 disease, at which point the chances for remission and long term survival go way down. Either way, it is a matter of life and death that Daniel receive treatment expeditiously, especially because the best shot at curing lymphoma is the first shot. Failure to induce a complete remission or a relapse after a remission is a bad prognostic sign, and often a bone marrow transplant is required to salvage such patients.
Moreover, no medicine, not scientific medicine and certainly not “traditional” medicine can guarantee a “100% survival rate.” For any practitioner to make such a claim require lying. Indeed, if there’s any percentage survival rate that “traditional” medicine can guarantee for Hodgkin’s lymphoma, it’s much. much closer to 0% than it is to 100% (spontaneous remissions do rarely occur), while for conventional, science-based medicine the survival rate is much closer to 100% than it is to 0%. Yet, based on religious beliefs and faith in “alternative” and “natural” medicine, Daniel and his mother labor under the delusion that magic water (which, let’s face it, is what they’re offering) along with supplements will cure Daniel. Moreover, they have been given far more deference in court than that delusion warrants because they are based on religion, rather than just a belief in “alternative” cancer cures.
When there is no religious issue involved, cases like Daniel’s are often presented as issues of “health freedom,” parental rights, or the right of a minor to control his or her body. This brings to mind a case from three years ago, a youth by the name of Abraham Cherrix. Abraham was 15 years old when he, with the support of his parents, refused further chemotherapy after one round in favor of rank quackery known as the Hoxsey therapy. The initial decision of the judge in the case was similar to that in the Hauser case: That Abraham had to undergo chemotherapy. However, within a month, an agreement was struck in which Abraham could undergo therapy at a clinic in Mississippi where a radiation oncologist who provides a dubious “immunotherapy” in addition to standard radiation therapy, would treat him. Fortunately for Abraham, although his tumors were fairly advanced at the time, radiation therapy shrank the masses in his neck that might have obstructed his trachea, leading to the need for a tracheostomy, or his esophagus, and he did fairly well, puttering along with radiation therapy being used–Whac-A-Mole or “spot weld” style–to zap new tumors as they pop up. He may well be one of the lucky few for whom radiation therapy alone cures his non-localized Hodgkin’s disease. At least I hope he is, given that his case has stretched out to past his 18th birthday, and he now can legally do whatever he wishes. Cherrix was in an arguably gray area when it comes to having full adult rights with respect to choosing his treatment, and from his perspective he was fortunate enough that his tumor was indolent enough that it waited out the clock until he could do anything he wanted.
Although we can argue about where the line should be drawn as far as children being old enough to have sufficient judgment and understanding to decide matters of life and death for themselves, I would posit that 13 is too young and that Daniel Hauser clearly does not have the capacity to understand the consequences of his decision. Even so, does that mean that it would be right to use force to make him accept life-saving chemotherapy? This is where the particulars get very, very messy indeed:
Furthermore, Colleen Hauser said she won’t comply with a court order requiring chemotherapy, and Daniel is likely to physically resist the treatment.
“He said he would bite the doctor’s arm off,” she said. Daniel is one of eight children who lives on the family’s dairy farm outside Sleepy Eye.
Is there a judge who would order a child physically restrained in order to give him chemotherapy? Besides the horrible images it gives to opponents of science-based medicine who want the right to subject their children to their faith-based quackery without any government interference, there is a huge practical issue. While it may be possible to physically restrain a child like Daniel in order to place permanent intravenous access and then, every so often, to give him chemotherapy, it would be very difficult and traumatic. In addition, it would be potentially dangerous. There would be nothing to stop him from trying to rip the intravenous access out to prevent further doses, potentially hurting himself, unless he were kept under constant surveillance. In other words, Daniel would in essence need to be imprisoned in the hospital for the duration of his therapy.
Then there’s the issue of radiation. Radiation therapy, more than chemotherapy, requires the cooperation of the patient, who must lie still on the table and do so every weekday for 30-40 days, depending on the radiation therapy regimen.(I admit that I am not familiar with the common regimens used for Hodgkin’s disease.) If Daniel won’t cooperate for radiation, he will risk having the radiation beam hit structures that it’s not aimed at; i.e., miss the tumor and hit normal tissue. Yes, he could be sedated for each session, but there’s nothing good about sedating a child five days a week for however many weeks it takes to administer the full course of radiation. It wouldn’t be bad just for Daniel, either. Imagine the hit the morale at the hospital would take, with staff having to view such a spectacle day after day. In addition, you can bet that Colleen Hauser would make sure that the press knew every sordid detail and that the woo-o-sphere would spread it far and wide over the Internet, while even conventional news outlets would be likely to be far more sympathetic to Daniel than to the doctors carrying out the treatment and the judge who ordered it. Such an occurrence would be a disaster for Daniel, a disaster for the physicians and nurses treating him, and a disaster for science-based medicine.
Indeed, it might not even be ethical, and at the very least one of Daniel’s oncologists is very uncomfortable with the idea, as shown in this testimony:
Elbert asked if she would restrain Daniel. She answered that medication can be administered in different ways. She said she does see a need to restrain patients, but has never had to actually do it. She said she wouldn’t do something that would hurt a child.
She said the Mayo Clinic has teams of people who help patients with emotional issues and help children understand their treatments.
Elbert asked if Rodriguez had ever placed a patient under anesthesia and she replied she has never had to do it.
“I don’t know if you can ethically do that,” she said.
Rodriguez said children who are scared to be treated for cancer are common because of the treatment and because of changes in body image. She said it is normal for a 13 year-old to be scared of treatment. She said she has never had to sedate anyone for treatment.
Unfortunately, as he prepared to rule last Friday, the choices before the judge boiled down to:
     1.  Try to make Daniel and his family see reason. (Not likely.)
     2.  Force Daniel to undergo therapy. (Very ugly and problematic from an ethical standpoint, as I described above.)
     3.  Let Daniel die from medical neglect. (Horrible and wasteful.)
Not a very palatable choice. I most definitely did not envy Judge Rodenberg.
There’s still another wrinkle. Following the case over time, I became convinced that religion is probably not the driving force behind Daniel’s reluctance to undergo chemotherapy but rather a convenient excuse for justifying what he wanted to do anyway. What made me think that is the fact that Daniel’s mother allowed him to undergo one round of chemotherapy right after his diagnosis. It was only after Daniel had a rough time with the first round of chemotherapy that suddenly he started refusing to accept any more. Add to that this bit of personal history, and the story becomes more complex, as one of Daniel’s doctors testified:
Joyce said during his testimony that Daniel’s diagnosis was not the same as Daniel’s aunt’s, who died after having chemotherapy.
Apparently this happened when Daniel was only 5. And then there’s the testimony of Shiree Oliver guardian ad litem:
Oliver said she thinks Daniel’s fear is caused by his aunt’s death and said she would recommend he see a counselor.
Oliver said she doesn’t fully understand the Nemenhah’s religious beliefs and doesn’t believe Daniel Hauser fully understands his religious beliefs or has the capacity to make decisions on his medical care by himself.
Again, I would argue that such is true for the vast majority of 13-year-olds.
As I alluded to earlier in this post, one commonality between Abraham Cherrix and Daniel Hauser is that they both agreed to conventional treatment initially and only balked when they experienced how difficult chemotherapy can be. Certainly, I don’t minimize how bad chemotherapy for lymphoma can be. Despite advances over the last 30 years that have produced both treatments that are less toxic and better supportive and anti-emetic therapies, it’s still no walk in the park, and it’s even harder for a child to understand why enduring it is necessary. All the child knows is that he feels lousy, that the drugs are causing it, and that he feels better during the breaks between therapy. The parents, loving their child, see him suffering and complaining about it, but are unable to relieve it. They can only watch, hurting as they see their child hurt.
Is it any wonder that a child would do anything to make the awful feelings stop? Is it any wonder that some parents would latch on to any excuse they can find to make their child feel better while at the same time convincing themselves that they’re still treating the child’s cancer? Is it really that surprising that what some parents latch onto is a delusion, be it “alternative medicine” or religion? Is any more surprising that they would gravitate to a religious set of beliefs that seems to validate their rejection of conventional medicine and at the same time tell them that everything will be OK?
I don’t know about you, but I don’t think it’s surprising at all. Using religion to justify irrational choices to oneself is not limited to just medicine.
There’s also another factor at play here. It’s one that’s always puzzled me. For some reason, chemotherapy holds a particular horror for many people. Many operations are arguably as painful and difficult to recover from as chemotherapy; yet patients rarely refuse surgery for cancer, at least in my experience. Comparatively speaking, they often refuse chemotherapy, again at least in my experience. (Perhaps for a followup post I will have to find out if there are any studies that address these questions.)
Indeed, remember one of my earliest posts for SBM, when I wrote about cancer cure testimonials? I pointed out how, in many cases, the people making these testimonials accepted surgery for their tumors but rejected chemotherapy in favor of their favorite woo. Naturally, thereafter they almost always attribute their survival to the woo instead of the surgery. The reason such “testimonials” are convincing is because, for most solid tumors that haven’t metastasized, surgical extirpation is the primary therapy (exceptions include anal cancer and testicular cancer). For solid tumors successfully resected surgically, chemotherapy is then given in order to decrease the risk of recurrence. What that means is that it’s quite possible to be “cured” by surgery alone, particularly for common tumors like breast or colon cancer. Refusing chemotherapy may make cure less likely, but chemotherapy isn’t absolutely essential to a cure. Surgery is. The same is true of radiation as for chemotherapy. It reduces the risk of a tumor recurring in the location where it had been excised, but rarely is it curative on its own. Most people don’t understand that; so the testimonials for “alternative cancer cures” sound convincing: “I refused chemo and I’m still alive.” Of course, those who are no longer alive don’t give testimonials.
Unfortunately for Daniel, the primary treatment for Hodgkin’s lymphoma is not surgery. Indeed, surgery has a very limited role in Hodgkin’s lymphoma these days, mainly for diagnosis in the form of biopsies. Rather, the primary treatment for Hodgkin’s lymphoma consists of chemotherapy and radiation. Rejecting them is to reject any reasonable chance at cure.
Another aspect of the fear of chemotherapy may well be how much it is associated with death from cancer in people’s minds. As cancer patients get sicker and chemotherapy begins to fail, the cancer starts to take its toll. Dying cancer patients frequently take on the cachectic look of a starving concentration camp survivor as the cancer does its evil work. To the average person, it may well appear more as though it’s the chemotherapy that’s making the patient sicker more than it is the tumor. Then the patient dies, and the linkage between chemotherapy and a horrible, painful death is sealed in the mind of the family. It is an linkage that the “alternative” medicine cancer industry tries very hard to reinforce, as it offers “natural” medicines that supposedly cure cancer with no risk and no suffering. Would it were true! If it were, I would be all for using these “natural” therapies. But, sadly, whenever one looks at such claims more critically, they virtually always turn out to be without foundation or justification in science and clinical trials.
It’s not as if I’m oblivious to the fear of chemotherapy, either. Let’s face it. Chemotherapy is poison, and people are correctly afraid of poison. (Look for some woo-meister to quote-mine that sentence.) Chemotherapy poisons cancer cells, and the reason it can treat cancer is because it poisons the cancer cells more than it poisons normal cells. And radiation therapy does “burn.” It’s just that, the way it’s given, it’s more toxic to cancer cells than it is to the surrounding tissue, and that differential toxicity can be increased by administering it in numerous small fractions over several weeks. Be that as it may, older chemotherapy regimens could be very toxic indeed, and death due to immunosuppression and infection is a possible complication of even some of today’s chemotherapy regimens. What has to be considered is the risk of the chemotherapy versus the risk of death from cancer. In the case of metastatic cancer, the risk-benefit ratio to be considered is the risk of complications from the chemotherapy versus the relief of disabling symptoms due to the cancer and/or the prolongation (but not saving) of life. Either way, it’s a tradeoff, with death looming in the background and some degree of suffering unavoidable. Worse, scientific medicine can’t promise what patients and parents want most: That everything will be OK. All it can give is percentages, which do not satisfy. And we all know that chemotherapy doesn’t always work; patients all too often die of their cancer anyway.
Many, if not most, “alternative” cancer cures doesn’t acknowledge that tradeoff. They promise the cure of deadly diseases with no risks and no suffering. I ask again: Is it any wonder that fearful parents or patients might seek solace in such irrational belief systems that tell them their child will be cured of a fatal disease with no suffering if they follow a “natural” therapy? Remember, Daniel’s mother testified that she believed that the “alternative” therapies Daniel was pursuing will result in a “100%” chance of Daniel’s surviving.
The more I think about this case, the more it seems to me that the specter of Daniel’s aunt is probably driving things and that religion is merely a convenient excuse for a decision that was far more the result of fear of a second round of chemotherapy in the wake of a rough course with the first round. After all, Daniel’s mother agreed to let him undergo chemotherapy at first. What probably happened is that they both freaked out when they saw the complications, echoes of Daniel’s aunt running through their minds, and that this led to their refusal to let Daniel undergo any further chemotherapy. Add to that being a member of a fake religion run by a highly dubious “healer,” and claiming that their religion forbids chemotherapy is a convenient justification to do what they wanted to do anyway regardless of religion. Indeed, apparently one of the lawyers assigned to Daniel says he will no longer acknowledge religion as a justification for Daniel’s decision:
Discussion about that testimony was forbidden by the judge, but an attorney assigned by the court to represent Danny’s best interests emerged from the session with a different perspective.
The lawyer, Thomas Sinas, said he’ll no longer acknowledge “the genuineness of Danny Hauser’s religious beliefs” based on his closed-door testimony. Sinas offered to explain the change, but Judge Rodenberg told him not to.
Perhaps that change explains why Judge Rodenberg ruled the way he did:
MINNEAPOLIS – Daniel Hauser doesn’t think he’s sick, and he thinks chemotherapy will kill him. The 13-year-old with Hodgkin’s lymphoma told a judge he got so ill he couldn’t walk the one time he got the treatment.
“I’d fight it if I had to take it again,” Daniel said, according to a transcript of his court testimony. “I’d punch them and I’d kick them.”
[...]
Rodenberg found Daniel, who likes to do field work on the family farm, play baseball with his siblings and go sledding, has been “medically neglected” by his parents, Colleen and Anthony Hauser.
The judge wrote that Daniel has only a “rudimentary understanding at best of the risks and benefits of chemotherapy. … he does not believe he is ill currently. The fact is that he is very ill currently.”
The judge allowed Daniel to stay with his parents, noting they love him and acted in good faith. But he gave them until Tuesday to get an updated chest X-ray and select an oncologist.
If the tumor has not grown and if Daniel’s prognosis remains optimistic, then chemotherapy and possible radiation appear to be in Daniel’s best interest, Rodenberg wrote. The judge said he would not order chemotherapy if doctors find the cancer is too advanced.
If chemotherapy is ordered and the family refuses, the judge said, Daniel will be placed in temporary custody. It was unclear how the medicine would be administered if the boy fights it.
Calvin Johnson, an attorney for Daniel’s parents, said the family is considering an appeal. For now, he said, Daniel is following the order and will have X-rays Monday.
Judge Rodenberg’s reasoning:
In this case, Rodenberg said, the state’s interest in protecting the child overrides the constitutional right to freedom of religious expression and a parent’s right to direct a child’s upbringing.
Medical neglect, Rodenberg said, clearly took place on April 29, when the Hausers did not follow one doctor’s advice to return to an oncologist, and on May 7, when they disregarded their family doctor’s recommendation to get the tumor X-rayed. Up until then, Rodenberg wrote, the family was seeking second opinions and alternatives.
That is undoubtedly true. The record shows that Daniel’s mother clearly went doctor-shopping, looking for a physician who would recommend something other than chemotherapy. She found none, because there is no other effective therapy for Hodgkin’s disease other than radiation and chemotherapy. Every doctor she saw told her that the child needed chemotherapy to have a good chance of survival, mainly because he does. Refusing the advice of multiple doctors regarding the treatment of a life-threatening disease clearly constitutes medical neglect and child endangerment.
Moreover, to me this appears to be a reasonable ruling that could, if adequately supported, avoid the ethical landmines involved in forcing Daniel to undergo therapy. Rather than taking Daniel from his parents’ custody immediately, Judge Rodenberg has made a strong point of placing the entire onus on Daniel’s parents to live up to their responsibilities as parents and get Daniel the medical care he needs to survive. The judge has even left an “out” if the tumor is too advanced. Although it’s unlikely that Daniel’s mother (or even the judge) realizes it, such a finding is highly unlikely. The reason is that even stage IV Hodgkin’s disease–particularly if it isn’t a relapse after a full course of standard treatment, still has a reasonable shot at being “cured” with standard therapy. Consequently, I have a hard time imagining any pediatric oncologist who would not recommend therapy in such a case. The only situation that I can imagine where an oncologist might recommend no chemotherapy would be if the child was already moribund and at death’s door, which Daniel clearly is not. Finally, the judge points out that Daniel’s testimony reveals that Daniel is severely learning disabled and can’t read. It is clear that he lacks anything close to the ability to give or refuse to give informed consent, the latter of which, as I mentioned above, is a hallmark of deciding whether a patient is competent to make his own medical decisions. Judge Rodenberg even allowed the parents to continue with their woo, as long as Daniel receives conventional chemotherapy:
Minnesota laws require parents to provide children with “medically necessary care,” he wrote. He said the Hausers may continue with their natural remedies, but added that providing “complementary and alternative health care is not sufficient.”
All of this still leaves open the question of what will happen after Daniel gets his next set of staging studies to determine the extent of his disease. Although such studies are clearly necessary before oncologists can decide upon a chemotherapy regimen, the decision still smells a bit of punting, of playing for time, because agreeing to undergo another round of X-rays (probably CT scans of the chest, abdomen, pelvis, and brain) is relatively easy. After all, it’s just a set of diagnostic tests. What happens if Daniel, having undergone the scans, decides that he will still resist any further chemotherapy? If he continues to refuse and–worse–actively resists treatment, medical personnel will be left with the problems I discussed above regarding the practicality and ethics of using force to administer treatment to a 13-year-old boy who is large enough to put up considerable resistance. Seeing this possibility, I think that the judge was wise to place the onus for treatment squarely on the parents’ shoulders and to leave Daniel in their custody. My hope is that, with family counseling and the judge telling the parents to have Daniel undergo therapy, presumably leaving them some choice as to where he will receive chemotherapy and who will administer it, Daniel and his mother will come around.
If there’s one thing I’ve learned, however, from cases like that of Abraham Cherrix is that the judge’s ruling is not likely to be the last word, nor is the story over by any means. There could be an appeal. Other developments could occur. There might be a “compromise” like that of the case of Abraham Cherrix. Whatever happens, I will monitor the story and report updates as events warrant. In the meantime, I hope that eventually Daniel and his parents will see the light and get him the best medical treatment available for his disease.

Natural History
Mark Crislip on September 16, 2025
Link
It usually takes me several weeks to write these essays, in part because I am slow, and in part I have more to do in retirement than I ever did when working. But as this goes live, I am recovering from a new knee replacement. As I age I am having everything that fails and either be replaced or removed. Orchiectomy next? Or TMI? Anyhoo, I doubt I will be much in the mood to write for most of September, so a brief hodgepodge at the end of summer.
Critical Thinking is Tough.
I went to use the stove fan and it was dead. Crap. I do not use it often, but I remembered that we recently needed to replace the circuit breaker panel, as the system we had was noted to fail and burn down the house. I think the maker was Talking Heads. I wondered if the circuit breaker was off. I looked at panel and breaker appeared fine, but I flipped it on and off anyway. What do you know? The fan worked. I guessed, as if I know anything about circuit breakers, that maybe it had not been flipped completely to the on position.
A week later, I needed the fan again. It was dead. Crap. I flipped the circuit breaker few times, but this time nothing. It was Saturday, so I made a mental note to call the electrician on Monday.
However, the next day as I walked past the circuit breaker, I flipped the switch off and on and, what do you know, the fan worked. Must be a loose connection or a faulty breaker. So Monday I called the electrician.
She showed up and I told her the story. And? She first went to the stove. We keep the oils and vinegars on a lazy Susan under the stove and over time they had hit the cord to the fan and slowly wiggled out the plug, which was sitting half out. She pushed the plug in and everything was fine.
And I felt the idiot, And over the same weekend my wife had me look at the cable box, which wasn’t working. Because it was unplugged. First thing is to make sure the device is plugged in, I told her.
I will let you list the number and type of cognitive errors I made. Assuming causation and premature closure at a minimum.
Barbie had it easy. Critical thinking is not the default operating mode of the brain, and it annoys me no end with I forget to flip that mental circuit breaker.
Natural History
I have always practiced medicine when there are interventions that alters the course of diseases. Not always altered a lot, as in the beginning of the AIDS epidemic. And sometimes the course of diseases went the wrong direction, as was learned with antiarrhythmics.
But I have always been able to do something to treat diseases. So I rarely had the opportunity to see the natural, untreated, course of diseases. I knew historically what the natural history of some diseases were, such as Tb and syphilis, , but the opportunity was rare as a Coelacanth here in the great Pacific NW.
Disease progression is fascinating. How an infection twists and turns anatomy and physiology is interesting, but most of the time medical interventions modify those findings. And to witness the natural course of disease, people have to suffer and die, so never worth it.
The only people in the industrialized countries who get to see the natural history of disease are TCPM, homeopaths, NDs and other SCAM providers who victims, er, I mean patients rely solely upon them for their health care.
I have told the story before about how I became interested in SCAMs. It has been awhile, but us old folk relish any opportunity to repeat ourselves to captive audiences. Of course you can skip the next paragraph if you have read this one before.
It was early in my career that I was called to see a case of gangrene. What it turned out to be was a young woman who had a sarcoma of her leg that likely would have been cured with amputation. She opted instead to rely on a naturopath who, as I remember it, gave her alkaline therapy, The ‘treatment,’ being 100% useless, did nothing to the tumor, which had taken over her leg and, as big tumors can do, rotted, Quite the smell. But it wasn’t gangrene in the classic sense, just dead meat that putrefied, Nothing for me to do. She had fainted at home, which was why she was in the hospital, and when she woke up, she refused all care, wanting to return to the care of her ND. The rotting flesh was, you see, proof the ‘treatment’ was working. That night the tumor eroded into her femoral artery and she bled out and died.
Denial of massive tumors that went on to putrefy was not that uncommon, although that was the only case I ever saw while the patient was (six feet) under ND care.
But the ND did get to see the natural history of an untreated tumor. And sad to say that tradition of witnessing the natural history of untreated cancer continues, although not by an ND, but a forensic psychiatrist and the patient’s mother, an ex-nurse:
A University of Cambridge graduate who died after refusing chemotherapy was reportedly undergoing “five coffee enemas a day” under her mother’s supervision, according to her brother. Paloma Shemirani, 23, died at Royal Sussex County Hospital on July 24, 2024, having turned down treatment for non-Hodgkin lymphoma.
she also received
cancer treatment revolved largely around a strict diet and “lots of green juices”.
And so they got to watch the natural history of what should have been a curable non-Hogdkin’s lymphoma progress to death.
At an inquest into her death at Kent and Medway Coroner’s Court in Maidstone on Wednesday, pathologist Dr David Wright said Paloma had a large mass, as big as 17cm (6.7 in), in her chest.
“I looked at the tumour and you could see the bulk of it – growing in all directions,” he said.
The tumour had “distorted and displaced” veins and arteries and it caused “major compromise of vessels and airways”, Dr Wright added.
It was growing into the ribs and “replaced most of the upper lobe of the right lung,” he continued.
One of those cases that speaks for itself in its awfulness. Me? I am glad I rarely had to witness the natural history of disease and the inevitable death. I’ll leave that to the SCAM providers.
Uncertain Criteria
I received an email just yesterday from Castle Connelly informing me I was one of the 2025 US best doctors and would I like to purchase a plague? I think my spell checker meant plaque. What makes the designation so impressive is that I have been retired for 2 years and 9 months, also the last time I cut my hair. I am rocking the LBJ look. So either I am a better ID physician than all those who are actually in practice or their “rigorous research process” to identify top doctors isn’t. Probably the latter, even if I prefer the former. But I kind of want a plaque now.
Link to the photo.
    • 

A Review of Flipping The Script: Parents Fight Back
Jeff Witzeman has released a new documentary on cancer, Flipping the Script: Parents Fight Back. It is terrible and dangerous.
Braden MacBeth on October 30, 2018
Link

Jeff Witzeman released just released his newest film Flipping The Script: Parents Fight Back. I reviewed his last film Cancer Can Be Killed, which in retrospect, was a pretty tame film compared to this one. Flipping the Script argues that parents should have the right to refuse maintenance chemotherapy on behalf of their children while also expressing anti-vaccination views, promoting alternative medicine, and trying to sell you on ridiculous scientific and conspiracy theories. This film displays a critical lack of self-awareness and knowledge of science, medical ethics, literacy, and basic human decency.
The film opens with a recording of a phone call with a child’s oncologist who said that they will need to contact Child Protective Services if the parents do not take their child in for their maintenance chemotherapy treatments. Jeff Witzeman states that parents have called him asking “If cancer can be killed naturally, why is my child being forced into two to four years of chemotherapy when they’re already in remission?” My review of Cancer Can Be Killed covers Witzeman’s favorite “natural cancer treatments”, and how they’ve all been found to be ineffective. Flipping the Script, like Cancer Can Be Killed, relies entirely on testimonials of parents and experts with shady backgrounds.
All of the testimonials from parents follow the same format. First, their child is diagnosed with cancer, which was always leukemia or lymphoma, the most common and treatable types of cancer in children. Second, after undergoing the induction phase of chemotherapy, the child’s cancer was in remission but the child had terrible side effects. Then after learning that the cancer was no longer detectable on scans or tests, it came as a shock when their child’s oncologist wants their child to have maintenance chemotherapy treatments for more than a year. When they refused, the oncologists called CPS to report what they reasonably believed to be medical neglect. Without maintenance chemotherapy, the child would be at significant risk for having their cancer relapse. What follows varies and there’s no way to verify what actually happens with any of these stories. Some parents claim they were investigated by CPS and claim that nothing followed. Two parents fled to Mexico and lived there for years before returning to the US. Some parents claimed they walked into the hospital with a lawyer, said “no more chemo”, then took their child home.
Here’s the thing
Witzeman’s argument in the film is that parents should have the right to refuse chemotherapy on behalf of their children. The majority of the children featured in the film had acute lymphoblastic leukemia (ALL), which I will make the focus of the article to keep things simple. Acute lymphoblastic leukemia is the most common type of childhood cancer. When properly treated the average cure rate is somewhere around 90%. After being diagnosed, the first course of action is to begin the induction phase of chemotherapy, in which chemotherapy drugs are given in high doses intravenously or intrathecally for about a month, followed by a one week break. About 98% of children with ALL will go into remission (defined as having no leukemic cells in the blood, and less than 5% of leukemic cells in the bone marrow after) the induction phase. However, just because there are no cancer cells detectable on tests, doesn’t mean that they aren’t there. It just means that the tests are not precise enough to detect them. While it is possible to survive without relapsing, the chance of a relapse is much higher without maintenance therapy.
It’s very important that cancer relapses are prevented after the cancer is put into remission. Cancer cells are likely to be more resistant to chemotherapy if the relapse occurs shortly after initial remission. One study looked at the factors that influence survival after an ALL relapse; the numbers for early relapses aren’t pretty. If the relapse occurred less than 18 months after the initial diagnosis, the survival rates for the majority of relapse sites is below 15%. Relapses that occur later than 18 months, survival rates a bit more promising with the survival rates based on site of relapse being around 50% or higher – which is why oncologists are extremely concerned with preventing relapses in the first place
In order to prevent relapses after the initial induction phase, the consolidation phase is used to kill any remaining cancer cells that weren’t killed in the induction phase. The consolidation phase lasts for 1-2 months and consists of IV and intrathecal chemotherapy.
After the consolidation phase, the maintenance phase begins which is designed to prevent the cancer from relapsing. In this phase, lower doses of chemotherapy medications are given and the patient is monitored to ensure the cancer hasn’t relapsed. The recommended length of maintenance therapy for ALL is 2 years for girls, and 3 years for boys. When the maintenance phase beings, there are still no detectable cancerous cells in the blood or bone marrow. They may need to take daily chemotherapy drugs and receive IV or intrathecal chemotherapy every few weeks for years.
The research shows that it is very important that children receive these treatments to prevent their leukemia from relapsing. A study in 1997 measured the blood concentrations of methotrexate and mercaptopurine (common maintenance chemotherapy drugs) in cancer patients, and divided them into two groups. The group with blood concentrations of mE-MTX -6TGN greater than 818 mmol had a risk-free survival rate of 86%, people in the lower blood concentration group had a risk-free survival of 70%. One study published in the Journal of Clinical Oncology found that children with a medication compliance rate lower than 95%, had a 17% chance to relapse compared to only 5% with daily medication compliance of 95% or above. The study also concluded that 59% of all relapses could be attributed to medication non-adherence. So overall, maintenance chemotherapy is an important step in reducing the risk of a child’s cancer coming back. While it is possible to survive without a relapse after the induction and consolidation phases, the risk of a relapse is much higher and will be much more dangerous.
The consequences of chemotherapy refusal
If parents refuse maintenance or consolidation chemotherapy for their children, the results can be tragic. Friend of the blog Orac covered the case of Jeremy Fraser 10 years ago, Jeremy’s mother didn’t give him the daily oral chemotherapy prescribed by his doctors to prevent his cancer from relapsing. His cancer relapsed and he was given a 10% chance to live; he didn’t make it. Jeremy’s mother was convicted of reckless endangerment and spent 5 years in prison. Jeremy’s father had this to say to her in an interview: “If you ever get the chance to see that little boy again, pick him up. Just…. tell him you’re sorry”.
Cassandra Callender was forced into chemotherapy by the Connecticut Supreme Court, despite her, and her mother’s objections. Callender was diagnosed with Hodgkin’s Lymphoma and refused chemotherapy after running away from home. CPS petitioned the court and was granted temporary custody of Cassandra in addition to being authorized to make all medical decisions on her behalf. Unfortunately her cancer would relapse months later after she was able to make medical decisions for herself at which point she chose to pursue natural, alternative cancer treatments offered by the “Hope 4 Cancer Institute” including IV vitamin c, ozone therapy, laetrile (AKA vitamin B-17, which is basically cyanide), and hyperthermia. Unsurprisingly, the cancer progressed over the months she spent pursuing fake cancer treatments. She finally realized that the fake treatments weren’t working and decided to pursue chemotherapy, and fortunately the treatments were successful, resulting in a happy ending.
Parents are not allowed to neglect or abuse their children by law, which includes denying them necessary medical care. Children do not have the decision-making capacity to make medical decisions for themselves, therefore adults have to act in their best interest. The child’s best interest and parents’ wishes can conflict in some cases, and this film is a series of perfect examples. I think it is a reasonable assumption that it is in a child’s best interest to receive medical treatments that will significantly reduce the risk of their cancer relapsing. If parents refuse to consent to necessary medical care on behalf of their children and ensure that they receive that care, it is a healthcare provider’s ethical, and legal duty to contact the appropriate authorities. When CPS is contacted they have to investigate if there is any neglect going on and potentially remove children from their parents’ home, medically neglect can meet that criteria. In some cases, the state may take custody of parents’ children and force the child to receive chemotherapy, even if the child doesn’t want it. While that might sound bad, CPS is acting in the child’s best interest in these cases. Without treatment the child’s cancer has a significant chance of relapsing, which is life threatening. You don’t have the right to endanger your child’s life.
The bad science
Jen’s cancer theory
About midway through the film, one mother explains her theory of how leukemia works. There’s even this cute cartoon that plays like something you’d see on PBS:
After doing some research, Jen came up with this theory about leukemia. When a strong virus combined with toxins and stress hit the body, white blood cells rise up to meet it in order to fight off the onslaught. During this period if you were to measure the blast, or white blood cell count, you could call this extreme reaction leukemia. But as the virus, toxins and stress are removed; the white blood cell counts go back down. Now making it hard to even call it leukemia. This is the situation for many adults who just through nutrition and detox strategies are able to reverse their leukemia in just months.
The problems with this are:
No singular cause of leukemia has been identified. There are many risk factors for leukemia such as family history, blood disorders, and radiation. There is no evidence leukemia in any form is caused by any virus.
The blast count on a blood cell count panel does not measure the while blood cell count. We have a white blood cell count for that.
The blast cell count measures the presence of blast cells in the blood or bone marrow. Blast cells are not white blood cells; they are undifferentiated, primitive blood cells. In leukemia these mutated blast cells multiply in large numbers and will be present in high concentrations in the blood and bone marrow. There is no research I can find where adults of cured their leukemia using diet and “detox” strategies.
Nutrition and sugar
Nutrition is a rather large focus in Flipping the Script, many of the parents accuse doctors of having no nutrition training or claim that oncologists don’t care about their patient’s nutrition. All doctors receive at least some education on nutrition in medical school, and many will receive more training during their residency program after medical school. Many of the parents in the film firmly believe that sugar feeds cancer, and talk about how they forbid their child to eat food with sugar. While it is true that cancer cells get their fuel from sugar, so do all of the other cells in your body, not to mention many healthy foods including fruits and vegetables contain sugar, often in considerable amounts. There is no risk in eating sugar in normal amounts, however eating too much can lead to obesity.
Imposing a restrictive diet on your child while they’re receiving treatment for cancer can be dangerous. Research has shown that children who are underweight have a higher risk of relapse, and it is very important that people maintain a healthy body weight during and after treatment. Imposing a restrictive diet on a child that causes them to lose too much weight puts them at risk. One mother in the film talked about how frustrated she was when the hospital told her that the reason her child wasn’t gaining weight was because she fed her child an “all organic diet”. There’s no harm in feeding your kid an all “organic” diet (and no benefit). However, if the diet is so restrictive that the child is losing weight, then it would likely be a concern to the child’s doctors.
The Electrical Box of Doom
There are so many weird moments in Jeff Witzeman’s films. In Flipping the Script, Witzeman takes the time to explain what he thinks caused the child’s cancer. This explanation however just caught me totally off guard:
…and along with that had this electrical box sitting away from her bed every night. Unless you doubt that an electrical box could have an effect, the previous tenant in that same room became ill with TPP, which is also a blood disorder.
Thrombotic thrombocytopenic purpura is a very rare blood disorder, that is not like cancer in any way. It is incredibly rare, there are only about 4-5 cases per million people each year. There is no evidence that exposure to electromagnetic fields (EMF) causes TPP (or anything else). He backs up his claim that EMF exposure causes cancer with this page from the NIH. According to the NIH no consistent evidence has shown that exposure to EMFs cause cancer; Witzeman shows the NIH page that states exactly this on-screen. You can’t make this stuff up.
Vaccines and doctors in politics
Flipping the Script is also an anti-vaccine film. One of the parents says that a possible side effect listed on the vaccine information sheet was cancer. No vaccine I can find has cancer as a potential risk, and there is no evidence that vaccines cause cancer (not to mention the problems with relying on packaging inserts as if they were infallible). Some vaccines, such as the HPV vaccine, actually prevent diseases that can cause cancer.
Later in the film, Witzeman argues that parents’ rights have slowly been taken over by the government. To support this argument, he cites the passing of SB277 in California, which bans personal belief exemptions to vaccine requirements in schools. The bill was penned by Dr. Richard Pan, who is a practicing pediatrician and California State Senator. Witzeman then dropped this knowledge-bomb:
And yes, you heard me right. Doctors are now trying to get into politics with the express goal of taking away parents’ rights and enforcing millions of dollars in vaccines and forced treatments.
Doctors in politics, including Dr. Pan, did not get into politics did not get into politics with the express goal of taking away parents’ rights. They got into politics to serve their constituents; whether you agree with their policies is another topic entirely. Dr. Pan proposed SB277 in response to the “Mickey Mouse Measles” case in 2015, where measles – a disease declared to be largely eradicated in 2000 by the CDC – erupted in outbreak of 147 cases after a contagious person visited Disneyland in that year. This outbreak was due to vaccine refusals by parents with no legitimate reason to refuse the measles vaccine. The vaccine has been shown to be incredibly safe and effective at preventing measles, as well as mumps and rubella, with next to zero risks. These treatments aren’t even forced; children must receive the vaccine to enter primary or secondary school in California or must have a valid medical exemption. The option to homeschool your children is still available.
Witzeman tries to frame this as an issue of “adequate testing”‘. Vaccines have been proven to be safe and effective at preventing vaccine-preventable illnesses. Vaccines are tested extensively before they are brought to market. SB277 was necessary to help prevent the resurgence of one of the most contagious and deadly diseases in human history because parents wouldn’t vaccinate their children based on their irrational beliefs.
Conclusion: How dare you?
Flipping the Script is the vilest film on Amazon Prime, and gives unqualified, dangerous medical advice to parents. Maintenance chemotherapy is necessary for long periods of time to prevent the relapse of many cancers. If parents refuse they are putting their children at serious risk for a relapse and even death. Doctors are legally obligated to report medical neglect such as refusal of consent to lifesaving treatment on behalf of their children. This film blatantly accuses doctors of only using chemotherapy instead of some mythical “other” treatment because chemotherapy makes them a lot of money. Parents in the film laugh when asked “Do you ever think it’s all just about money?” One of the “experts” states “the overall survival rate for cancer has only improved 5% since the introduction of chemotherapy” – when in fact the death rates from cancer have been steadily falling for decades.
Witzeman has the audacity to conclude the film by stating that there is a “better way” to treat cancer and that cancer is “just a warning sign”. It’s not the pitiful “science”, or the despicable people held up as “experts” that frustrates me so much about this documentary; it’s the smugness and utter lack of self-awareness. I wanted to have fun with this review, it’s hard not to laugh at how ridiculous Jeff Witzeman’s films are. But there was a short segment in the film that broke me; it made me realize what this film stands for – what could happen if parents took this film’s advice. One mother had this to say in an interview:
It’s really interesting because you do see all the kids at St. Jude, but you don’t see the survivors. Where are they? Where are these people who have survived and lived on? You just don’t see them or hear much from them. Even Gunner commented when you go through St. Jude there’s this huge hall with all of the names of the kids who’ve died. They’re all over the walls, in the halls…. They have a few pictures, maybe six or eight pictures of survivors on one hall.
This quote has been on my mind for almost a week now, I have no idea why he chose to include it in the movie. I assume because in his warped worldview it somehow proves that children who get treated there don’t often survive. I imagine one reason they don’t put the names of survivors up in their halls is because fitting all the names would present a significant logistical issue when you have some of the best outcomes for pediatric cancer in the world. Patients treated at St. Jude for acute lymphoblastic leukemia have a 94% event-free survival rate. The other reason they don’t put the names of survivors in the halls is because the staff at St. Jude have the satisfaction of knowing those kids got to go home and live normal lives. You can find the stories of children who survived cancer because of the work of St. Jude everywhere. It’s easy. The staff at St. Jude put the names of children who died in their halls to pay their respects to the children they couldn’t save. They have integrity, humility, and tact; virtues Jeff Witzeman and his “experts” lack.
Jeff Witzman is so oblivious, ignorant, and uncouth that he states “in defense of St. Jude and every other children’s hospital, they’re just doing what they’ve been told to do. They’re just enforcing the protocol sent from on high”. Where does he think these treatment protocols come from? Unlike in naturopathy, doctors don’t just make up treatment protocols based on how trendy they sound, or how likely patients are to spend five figures on them. The doctors at St. Jude don’t have a jolly sit down with the Eli-Lilly C-suite every quarter to fill their bellies with caviar and fillet minion to get the latest “protocol from on high” that they will blindly use to treat children. They conduct and review research, and modify their practice to fit what the research shows is best. St. Jude plays a huge role in creating the “protocol from on high”, they had over 250 articles published in peer-reviewed, scientific journals last year.
In conclusion, I don’t think this film should be on Amazon Prime. It gives dangerous, unqualified medical advice to viewers who may be parents with children who have cancer. This film only exists to sell parents on medical fraud and magical thinking. It is completely devoid of critical thinking, scientific reasoning, and basic human decency. I couldn’t even recommend as a bad film; it’s just depressing. If any medical advice in the film were taken seriously, it would lead to tragedy.

   Chemotherapy versus death from cancer
David Gorski
Link
I’ve written before about the Daniel Hauser case, a 13 year old boy who last year refused chemotherapy for his Hodgkin’s lymphoma, necessitating the involvement of the legal system. Cases like that of Daniel Hauser reprsent supreme “teachable” moments that–fortunately–don’t come along that often. The antivaccine movement, for instance, will be with us always (or at least, I fear, as long as I still walk this earth and beyond), but cases like that of Daniel Hauser tend to pop up only once every couple of years or even less. As tragic as they are, they always bring up so many issues that I have a hard time leaving them alone.
This time around, I wanted to touch on an issue that has come up frequently in the discussions of this case, and that’s the issue of chemotherapy. Specifically, it’s the issue of how horrible chemotherapy can be. Again, make no mistake about it, chemotherapy can be rough. Very rough. But what is often forgotten is that it can also be life-saving, particularly in the case of hematologic malignancies, where it is the primary therapy. What is also often forgotten or intentionally ignored by promoters of unscientific medicine is that doctors don’t use chemotherapy because they have some perverted love of “torturing” patients, because they’re in the pockets of big pharma and looking for cash, or because they are too lazy to find another way. They do it because, at least right now, it’s the best therapy science-based medicine has to offer, and in the case of Hodgkin’s lymphoma, for example, it’s life-saving. You can be sure that if a less harsh way were found to achieve the same results, physicians would jump all over it. Indeed, a major focuse of oncology research these days is to find less brutal regimens and improve the quality of life of cancer patients while still giving them the best shot at survival.
Yes, chemotherapy can make you feel nauseated and make you throw up. It can make your hair fall out. It can temporarily depress the immune system. It can cause bleeding complications, such as GI bleeding. It can cause kidney damage. It can cause heart damage. It can cause lung damage. It can cause nerve damage. It can make you lose weight. It can even result in your death from complications. In short, it is not something to be used lightly. Unfortunately, the disease it’s meant to fight is a formidable foe indeed. It is your own cells, and all too often the difference between the toxicity of chemotherapy against the cancer and against normal cells is not that large.
But what does cancer do? How do cancer patients die? They suffer and die in protean ways. Cancer can do everything chemotherapy can do (with the exception of hair loss) and more. I’ve seen more patients than I care to know suffer and die from cancer. I’ve seen family members suffer and die from cancer, most recently my mother-in-law last year.
One of the most frequent claims of cancer patients who opt for quackery instead of chemotherapy and effective science-based therapies is that they want to remain healthy. Some, as Abraham Cherrix did, state that, even if they end up dying, they want to “die healthy.” It’s a dangerous delusion. There is nothing “healthy” about dying from cancer. Dying from cancer is anything but “healthy.” But it is perfectly natural, as natural (or even more so) than the herbal concoctions that so many alt-med believers put their faith into. But what does dying from untreated cancer mean? What happens? What does it involve?
Dying from untreated cancer can mean unrelenting pain that leaves you the choice of being drugged up with narcotics or being in agony.
Dying from untreated cancer can mean unrelenting vomiting from a bowel obstruction. It can mean having a nasogastric tube to drain your digestive juices and prevent you from throwing up. Alternatively, it can mean having to have a tube sticking out of your stomach to drain its fluids.
Dying from untreated cancer can mean bleeding because you don’t have enough platelets to clot. The bleeding can come in many forms. It can be bleeding into the brain, in essence a hemorrhagic stroke. It can mean bleeding from the rectum or vomiting blood incessantly. And, because so many transfusions are all too often necessary, immune reactions can chew up new platelets as fast as they’re infused. Yes, paradoxically, even when a cancer patient’s immune system is suppressed in late stage cancer, frequently it does work against the one thing you don’t want it to: Transfusions of blood products.
Dying from untreated cancer can mean horrific cachexia. Think Nazi concentration camp survivor. think starving Africans. Think famine. Think having cheeks so sunken that your face looks like the skull underlying it.
Dying from untreated cancer can mean your lungs progressively filling with fluid from tumor infiltration. Think choking on your own secretions. Think a progressive shortness of breath. Think an unrelenting feeling of suffocation but with no possibility of relief ever.
Dying from cancer can mean having your belly fill with ascites fluid due to a liver chock full of tumor.
Dying from cancer can mean a progressive decline in mental function due to brain metastases.
Dying from cancer can mean so many other horrific things happening to you that they are way to numerous to include a comprehensive list in a blog post, even a post by a blogger as regularly logorrheic as I am.
Modern medicine can alleviate many of the symptoms people with terminal cancer suffer, but all too often it can’t reverse the disease process. However, the relief of these symptoms requires that the patient actually accept treatment. Hospice can minimize such symptoms, often for significant periods of time. However, even with the very best hospice care, there is nothing “healthy” or pleasant about dying from cancer. It means a loss of control. It can mean being too weak to get up by yourself, to feed yourself, to go to the bathroom yourself, to bathe yourself, or do do much other than lie in your bed and wait for the end. Without such treatment, a patient who chooses quackery over effective curative or palliative therapy dooms himself to a painful and unpleasant death. He in effect dooms himself to the sorts of ends untreated cancer patients suffered hundreds of years ago, before there was effective therapy. It doesn’t have to be this way, but the seductive promise of a cure without pain, without hair falling out, without nausea lures cancer patients to havens of quackery in Tijuana or to flee from authorities trying to see that a child obtains potentially life-saving treatment, all because of a magnified fear of chemotherapy, all because of the propaganda that paints chemotherapy as “poison,” radiation as “burning,” and surgery as “slashing.”
Here’s the dirty little secret behind “alternative cancer cure” (ACC) promises. They are seductive because it is true that cancer patients who stop their chemotherapy will feel better than they did when undergoing chemotherapy. Of course they do, at least for a while! Often what happens, as in Daniel Hauser’s case, is that the tumor shrinks, and, once the chemotherapy course is done, the patient does feel better because the tumor is no longer causing B symptoms or compressing lungs and making him short of breath, and other symptoms are also relieved. It is also true that more chemotherapy will make the patient feel lousy again for a time. Unfortunately, in the case of Hodgkin’s lymphoma, the additional chemotherapy is necessary to maximize the chance of cure. Hodgkin’s disease frequently relapses without the additional courses of chemotherapy. Science and clinical trials have told us that. Daniel Hauser is living proof, an anecdote that is consistent with what science tells us.
In other words, the promise of ACCs is a lie. They promise that cancer patients will always feel the way they do after the first course of chemotherapy is over and they have recovered or the way they feel before the tumor has grown beyond what can be cured. They are either deluded or lying. That’s because cancer doesn’t give up. It’s like the Terminator. It can’t be bargained with. It can’t be reasoned with. It doesn’t feel pity, or remorse, or fear. And, if it is not treated, it absolutely will not stop, ever, until the patient is dead. And it rarely will be a pretty end. There’s a case to be made that it isn’t worth they symptoms to undergo chemotherapy when it has a very small chance of success. Such a judgment is up to the patient, based on his or her values and an accurate knowledge of the risks and benefits, which we as science-based physicians must provide them. However, all too often, by foregoing effective palliation, patients who choose ACCs condemn themselves to an end far more brutal than is necessary even if their cancer is terminal when diagnosed, and patients whose cancer is not terminal when diagnosed give up their one best shot at life.

   Complementary and alternative medicine in hospice care
Brennen McKenzie 
Link
A number of news outlets (e.g. Bloomberg Business Week, MSN.Com, US News, etc) have recently reported that use of complementary and alternative therapies (CAT) is widespread in hospice care facilities. This is based on a report from the Centers for Disease Control, Complementary and Alternative Therapies in Hospice: The National Home and Hospice Care Survey, Untied States, 2007. According to most news reports, about 42% of hospice care providers offer some kind of CAT.
I was initially inclined to find this a little worrisome. In my own field of veterinary medicine, advocates of alternative therapies are prominent among the organizers of the nascent hospice care movement. And while I am strongly supportive of better and more available veterinary hospice care, the involvement of CAM advocates raises the concern that animals at the end of their life might receive ineffective palliative care, or be denied the benefits of conventional treatments by some CAM providers, who often characterize “allopathic” treatments as “unnatural” and harmful.
In practice, I have seen this happen to patients with terminal diseases. I will never forget a Rottweiler dog I diagnosed with osteosarcoma, a very painful bone cancer, whose owner was convinced that homeopathy was adequate to control his pain and refused to use NSAIDs because of her conviction they were “toxic.” I have also seen my patients denied euthanasia even in the face of great suffering because so-called “animal communicators” claimed the pet was “not ready to leave” and had expressed a desire to remain with their owner as long as possible.
Perhaps these experiences have made me overly sensitive on this subject, but I saw these recent news reports and pictured people at the end of their lives being similarly denied effective palliative care or subjected to pointless therapies like homeopathy and “energy medicine,” or even more worrisome treatments like chiropractic or herbal remedies with real risks. However, a little digging into the details suggests that the headlines are a bit misleading, and these fears are probably unfounded.
As always, when trying to assess how popular alternative medical therapies are, the tricky issue arises of defining “alternative.” In this study, the authors referenced the MedlinePlus definition:
Complementary and alternative medicine (CAM) is the term for medical products and practices that are not part of standard care. Standard care is what medical doctors, doctors of osteopathy and allied health professionals, such as registered nurses and physical therapists, practice. Alternative medicine means treatments that you use instead of standard ones. Complementary medicine means nonstandard treatments that you use along with standard ones. Examples of CAM therapies are acupuncture, chiropractic and herbal medicines.
Personally, I prefer Dr. Novella’s definition:
CAM is a political/ideological entity, not a scientific one. It is an artificial category created for the purpose of promoting a diverse set of dubious, untested, or fraudulent health practices. It is an excellent example of the (successful) use of language as a propaganda tool.
In any case, in order to measure the popularity of something, one has to define it in some way, and in the past assessments of how popular or widespread CAM use is have created misleading impressions due to dodgy definitions. For example, the 2007 National Health Interview Survey (discussed in detail here) reported 30% of Americans to be regular CAM users. A closer look at the details of the survey, however, showed that very little of this self-reported usage involved the application of the usual dubious CAM approaches (e.g. acupuncture, chiropractic, homeopathy, various herbal traditions, etc) to treat specific medical problems. Much of this supposed CAM usage involved the non-medical application of massage, yoga, tai chi, prayer, and so on to provide psychological comfort or facilitate relaxation.
Of course, if one argues that massage, yoga, or even prayer are effective in reducing the objective signs or disease, or even bringing about a cure, then one could argue these are forms of alternative medicine. But such methods are mostly employed to provide comfort and help patients cope with their illness, and as such they can be valuable and legitimate interventions. This does not make them medical therapies, however, alternative or otherwise.
The hospice care survey suffers from the same kind of problematic definition for “complementary and alternative.” According to the report’s technical notes, providers of hospice care were asked first to choose all the services they offered from a list, and “Complementary and Alternative Medicine (CAM)” was one of the choices. Those that indicated they offered CAM were then asked to indicate “Which of these complementary and alternative medicine therapies does this agency use?”
Here is the list:
    • Acupuncture
    • Aromatherapy
    • Art therapy
    • Guided imagery or relaxation
    • Massage
    • Music therapy
    • Pet therapy
    • Supportive group therapy
    • Therapeutic touch (a westernized version of reiki)
    • TENS (Transcutaneous Electrical Nerve Stimulation)
    • Other
Personally, I see little on this list that I would classify as CAM. Acupuncture, certainly, along with therapeutic touch (like reiki) and aromatherapy. But most of the rest, unless specifically marketed as treatments for disease, seem more like benign, pleasurable activities designed to provide comfort, relaxation, and enjoyable stimulation. As a veterinarian, I work with a lot of pet therapy dogs, and I have yet to run across a handler of one who thought they were practicing alternative medicine! (Though I suppose there might be some such folks out there). And TENS is a perfectly conventional intervention, often somewhat disingenuously confused with acupuncture.
The most popular of the “true” CAM therapies offered was therapeutic touch, available at 48.3% of facilities. Aromatherapy was offered by 39.7% of hospice providers. I cannot even find a number for acupuncture in the report. And by far the most popular “alternative” therapies offered were massage (71.7%), group therapy (69%), music therapy (62.2%), and pet therapy (58.6%).
The report also indicates that only 8.6% of patients discharged from a hospice facility that offered CATs actually received one of these therapies. So even under such a loose definition of alternative, there is no evidence that large numbers of hospice patients are receiving alternative medical treatments.
It wouldn’t surprise me if we begin to see advocates of alternative medicine proclaiming that this report shows CAM is widely available, popular, and even indispensible in hospice care. The 2007 National Health Interview Survey results were frequently used this way to create the impression that CAM is becoming mainstream and that resistance to it is the province of extremists and ultimately futile. The details of both surveys, however, indicate that even with aggressive expansion of the definition of CAM to include conventional therapies such as TENS and non-medical interventions like pet therapy, CAM is not truly as popular ubiquitous as its proponents claim.
There is little objectionable from a science-based medicine perspective in most of the therapies hospice care providers are offering, according to this study. I enjoy a good massage, relaxing music, and the company of a friendly dog as much as anyone. And those elements that are truly nonsense, such as therapeutic touch and aromatherapy, are unlikely to do harm or replace appropriate conventional therapies, and they seem in any case not to be especially popular with patients even when they are available. So regardless of what PR use is made of this study, it does not suggest that human hospice care is becoming predominantly the domain of CAM providers, as I might have feared. I only hope the same will be true of veterinary hospice care as that becomes, hopefully, more commonplace.
